Les cookies nous permettent de vous proposer nos services plus facilement. En utilisant nos services, vous nous donnez expressément votre accord pour exploiter ces cookies.En savoir plus OK
Publications françaises #Covid19 référencées dans Pubmed
Source :https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-covid-publications-france/table/?sort=publication_date
| grant_agency | doi | publication_types | language | title | url | abstract | journal_issns | publication_date_week_end | source | mesh | journal_name | authors | keywords | publication_date | pmid | countries | grants | affiliations | cumulated_count |
| 10.2807/1560-7917.es.2020.25.6.2000082 | Journal Article | en | Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32046815 | Timely detection of novel coronavirus (2019-nCoV) infection cases is crucial to interrupt the spread of this virus. We assessed the required expertise and capacity for molecular detection of 2019-nCoV in specialised laboratories in 30 European Union/European Economic Area (EU/EEA) countries. Thirty-eight laboratories in 24 EU/EEA countries had diagnostic tests available by 29 January 2020. A coverage of all EU/EEA countries was expected by mid-February. Availability of primers/probes, positive controls and personnel were main implementation barriers. | 1560-7917 | 2020-02-16 01:00:00+01:00 | pubmed | Betacoronavirus;Clinical Laboratory Techniques__methods;Coronavirus__classification;Coronavirus Infections__diagnosis;Disease Outbreaks;European Union;Humans;Laboratories__standards;Pneumonia, Viral__genetics;RNA, Viral__genetics;Reference Standards;Reverse Transcriptase Polymerase Chain Reaction__methods;Sensitivity and Specificity;Sentinel Surveillance;Sequence Analysis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Chantal B E M Reusken;Eeva K Broberg;Bart Haagmans;Adam Meijer;Victor M Corman;Anna Papa;Remi Charrel;Christian Drosten;Marion Koopmans;Katrin Leitmeyer;On Behalf Of Evd-LabNet And Erli-Net | 2019-nCoV;coronavirus;emerging infections;laboratory;response;zoonoses | 2020-02-11 01:00:00+01:00 | 32046815 | FR;SE;UNK;GR;NL;DE | Viroscience department, Erasmus MC, Rotterdam, the Netherlands.;Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.;European Centre for Disease Prevention and Control, Solna, Sweden.;German Centre for Infection Research (DZIF), Berlin, Germany.;Charité - Universitätsmedizin Berlin Institute of Virology, Berlin, Germany.;Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.;Unité des Virus Emergents (Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.;The participating members of EVD-LabNet and ERLI-Net are acknowledged at the end of the article. | 7 | ||
| Editorial;Comment | en | Chloroquine for the 2019 novel coronavirus SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32070753 | 2020-02-16 01:00:00+01:00 | pubmed | Animals;Betacoronavirus;Chiroptera;Chloroquine;Coronavirus;Coronavirus Infections__drug therapy;Disease Outbreaks;Pneumonia;SARS Virus;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Philippe Colson;Jean-Marc Rolain;Didier Raoult | 2020-02-15 01:00:00+01:00 | 32070753 | FR | Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.;Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. Electronic address: didier.raoult@gmail.com. | 8 | |||||||
| 10.1016/j.joim.2020.02.005 | Journal Article;Research Support, Non-U.S. Gov't | en | In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. | https://www.ncbi.nlm.nih.gov/pubmed/32113846 | In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus (2019-nCoV), an ongoing novel coronavirus that causes pneumonia. | 2095-4964 | 2020-02-23 01:00:00+01:00 | pubmed | Coronavirus Infections__drug therapy;Drug Discovery;Drug Evaluation, Preclinical;Drugs, Chinese Herbal__pharmacology;Humans;Pneumonia, Viral__drug therapy;Respiratory Tract Infections__drug therapy;Virus Diseases__drug therapy;COVID-19 | Journal of Integrative Medicine | Deng-Hai Zhang;Kun-Lun Wu;Xue Zhang;Sheng-Qiong Deng;Bin Peng | 2019-nCoV;Chinese herbal;Drugs;Molecular docking;Natural compounds;Network pharmacology;Pneumonia;Wuhan coronavirus | 2020-02-20 01:00:00+01:00 | 32113846 | FR;CN | Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China. Electronic address: shanghai_zhang@hotmail.com.;Department of Traditional Chinese Medicine, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China.;Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China.;Department of Research Affair Management, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, China. | 10 | ||
| 10.2807/1560-7917.es.2020.25.6.2000094 | Case Reports;Journal Article | en | First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32070465 | A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) causing a cluster of respiratory infections (coronavirus disease 2019, COVID-19) in Wuhan, China, was identified on 7 January 2020. The epidemic quickly disseminated from Wuhan and as at 12 February 2020, 45,179 cases have been confirmed in 25 countries, including 1,116 deaths. Strengthened surveillance was implemented in France on 10 January 2020 in order to identify imported cases early and prevent secondary transmission. Three categories of risk exposure and follow-up procedure were defined for contacts. Three cases of COVID-19 were confirmed on 24 January, the first cases in Europe. Contact tracing was immediately initiated. Five contacts were evaluated as at low risk of exposure and 18 at moderate/high risk. As at 12 February 2020, two cases have been discharged and the third one remains symptomatic with a persistent cough, and no secondary transmission has been identified. Effective collaboration between all parties involved in the surveillance and response to emerging threats is required to detect imported cases early and to implement adequate control measures. | 1560-7917 | 2020-02-23 01:00:00+01:00 | pubmed | Adult;Betacoronavirus__isolation & purification;China__epidemiology;Contact Tracing;Coronavirus Infections__diagnosis;France__epidemiology;Humans;Infection Control;Male;Middle Aged;Pneumonia, Viral__diagnosis;Population Surveillance;Risk Assessment;Travel;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Sibylle Bernard Stoecklin;Patrick Rolland;Yassoungo Silue;Alexandra Mailles;Christine Campese;Anne Simondon;Matthieu Mechain;Laure Meurice;Mathieu Nguyen;Clément Bassi;Estelle Yamani;Sylvie Behillil;Sophie Ismael;Duc Nguyen;Denis Malvy;François Xavier Lescure;Scarlett Georges;Clément Lazarus;Anouk Tabaï;Morgane Stempfelet;Vincent Enouf;Bruno Coignard;Daniel Levy-Bruhl | COVID-19, SARS-CoV-2, 2019-nCov;France;Surveillance;contact tracing;containment;coronavirus | 2020-02-20 01:00:00+01:00 | 32070465 | FR;UNK | Santé publique France, Direction des maladies infectieuses, Saint-Maurice, France.;Santé publique France, Direction des régions, Saint-Maurice, France.;Santé publique France, Direction des régions, Cellule Régionale Ile-de-France, Paris, France.;Agence Régionale de Santé Ile-de-France, Paris, France.;Agence Régionale de Santé Nouvelle-Aquitaine, Bordeaux, France.;Santé publique France, Direction des régions, Cellule Régionale Nouvelle-Aquitaine, Bordeaux, France.;Centre National de Référence des virus des infections respiratoires, dont la grippe, Institut Pasteur, Paris, France.;AP-HP, Hôpital Bichat, Service des maladies infectieuses et tropicales, Paris, France.;Centre Hospitalier Universitaire de Bordeaux, Service des maladies infectieuses et tropicales, Bordeaux GeoSentinel Site, Bordeaux, France.;UMR 1219, Université de Bordeaux, Bordeaux, France.;Université de Paris, IAME, INSERM, Paris, France.;Direction Générale de la Santé, Ministère des solidarités et de la santé, Centre opérationnel de réception et de régulation des urgences sanitaires et sociales, Paris, France.;Santé publique France, Direction alerte et crise, Saint-Maurice, France.;The members of the investigation team are listed at the end of the article. | 13 | ||
| Editorial;Comment | en | Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future. | https://www.ncbi.nlm.nih.gov/pubmed/32119980 | 2020-03-01 01:00:00+01:00 | pubmed | Africa;Betacoronavirus;Coronavirus Infections;Disease Outbreaks;Emergencies;Epidemics;Humans;Pandemics;Pneumonia, Viral;Public Health;SARS Virus;World Health Organization;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nathan Kapata;Chikwe Ihekweazu;Francine Ntoumi;Tajudeen Raji;Pascalina Chanda-Kapata;Peter Mwaba;Victor Mukonka;Matthew Bates;John Tembo;Victor Corman;Sayoki Mfinanga;Danny Asogun;Linzy Elton;Liã Bárbara Arruda;Margaret J Thomason;Leonard Mboera;Alexei Yavlinsky;Najmul Haider;David Simons;Lara Hollmann;Swaib A Lule;Francisco Veas;Muzamil Mahdi Abdel Hamid;Osman Dar;Sarah Edwards;Francesco Vairo;Timothy D McHugh;Christian Drosten;Richard Kock;Giuseppe Ippolito;Alimuddin Zumla | 2020-02-28 01:00:00+01:00 | 32119980 | FR;ZM;NG;GB;ET;CG;IT;TZ;SD;DE | Zambia National Public Health Institute, Minsitry of Health, Lusaka, Zambia. Electronic address: nkapata@gmail.com.;Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria. Electronic address: chikwe.ihekweazu@ncdc.gov.ng.;University Marien NGouabi, Brazzaville, Congo, Institute for Tropical Medicine/University of Tübingen, Germany. Electronic address: fntoumi@fcrm-congo.com.;Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia. Electronic address: TajudeenR@africa-union.org.;Ministry of Health, Lusaka, Zambia. Electronic address: pascykapata@gmail.com.;Lusaka Apex Medical University, Lusaka, Zambia. Electronic address: pbmwaba2000@gmail.com.;National Public Health Institute, Ministry of Health, Lusaka, Zambia. Electronic address: vmukonka@gmail.com.;School of Life Sciences, University of Lincoln, Lincoln, United Kingdom. Electronic address: mbates@lincoln.ac.uk.;HerpeZ and UNZA-UCLMS Project, University Teaching Hospital, Lusaka, Zambia. Electronic address: john.tembo@gmail.com.;Charité - Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany, German Centre for Infection Research (DZIF), Berlin, Germany. Electronic address: victor.corman@charite.de.;National Institute of Medical Research, Dar es Salaam, Tanzania. Electronic address: gsmfinanga@yahoo.com.;Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria. Electronic address: asogun2001@yahoo.com.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom. Electronic address: linzy.elton@ucl.ac.uk.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom. Electronic address: l.arruda@ucl.ac.uk.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom. Electronic address: m.thomason@ucl.ac.uk.;SACIDS Foundation for One Health, Sokoine University of Agriculture, Morogoro, Tanzania. Electronic address: leonard.mboera@sacids.org.;Institute of Health Informatics, Faculty of Pop Health Sciences, UCL, London, United Kingdom. Electronic address: a.yavlinsky@ucl.ac.uk.;The Royal Veterinary College, University of London, Hatfield, Hertfordshire, United Kingdom. Electronic address: nhaider@rvc.ac.uk.;The Royal Veterinary College, University of London, Hatfield, Hertfordshire, United Kingdom. Electronic address: dsimons19@rvc.ac.uk.;Chatham House Centre on Global Health Security, Royal Institute of International Affairs, London, United Kingdom. Electronic address: LHollmann@chathamhouse.org.;Institute for Global Health, University College London, London, United Kingdom. Electronic address: swaiblule@gmail.com.;Faculty of Pharmacy, Montpellier University, IRD UMR5569, Montpellier, France. Electronic address: francisco.veas@ird.fr.;Dept of Parasitology and Medical Entomology, Institute of Endemic Diseases, University of Khartoum, Sudan. Electronic address: mahdi@iend.org.;Chatham House Centre on Global Health Security, Royal Institute of International Affairs, London, United Kingdom. Electronic address: Osman.Dar@phe.gov.uk.;Ethics and Governance, University College London, London, United Kingdom. Electronic address: sarah.edwards@ucl.ac.uk.;National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: francesco.vairo@inmi.it.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom. Electronic address: t.mchugh@ucl.ac.uk.;Charité - Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany, German Centre for Infection Research (DZIF), Berlin, Germany. Electronic address: christian.drosten@charite.de.;The Royal Veterinary College, University of London, Hatfield, Hertfordshire, United Kingdom. Electronic address: rkock@rvc.ac.uk.;National Institute for Infectious Diseases - Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.;Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom, Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk. | 14 | |||||||
| Letter | en | Coronavirus outbreak: the role of companies in preparedness and responses. | https://www.ncbi.nlm.nih.gov/pubmed/32119831 | 2020-03-01 01:00:00+01:00 | pubmed | Commerce;Coronavirus Infections__epidemiology;Disease Outbreaks__prevention & control;Global Health;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Professional Role;COVID-19 | Marc Fadel;Jérôme Salomon;Alexis Descatha | 2020-02-28 01:00:00+01:00 | 32119831 | FR | University of Angers, Centre Hospitalier Universitaire d'Angers, Université de Rennes, INSERM, School of Public Health, Institut de recherche en santé, environnement et travail-UMR_S1085, CAPTV-CDC, F49000 Angers, France, Paris Hospital (AP-HP) Occupational Health Unit, Poincaré University Hospital, Paris, France.;Versailles Saint Quentin-en-Yvelines University, INSERM, UMR 1181, Institut Pasteur, Paris, France, AP-HP, Department of Acute Medicine, CHU PIFO, Poincaré Hospital, Paris, France, General Director for Health, Ministry of Solidarities and Health, Paris, France.;University of Angers, Centre Hospitalier Universitaire d'Angers, Université de Rennes, INSERM, School of Public Health, Institut de recherche en santé, environnement et travail-UMR_S1085, CAPTV-CDC, F49000 Angers, France, Paris Hospital (AP-HP) Occupational Health Unit, Poincaré University Hospital, Paris, France. Electronic address: alexis.descatha@inserm.fr. | 15 | |||||||
| 10.2807/1560-7917.es.2020.25.8.2000171 | Journal Article | en | Letter to the editor: Plenty of coronaviruses but no SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32127122 | 1560-7917 | 2020-03-08 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus__classification;Coronavirus Infections__diagnosis;Humans;Pneumonia, Viral__diagnosis;Polymerase Chain Reaction;SARS Virus__classification;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Philippe Colson;Bernard La Scola;Vera Esteves-Vieira;Laetitia Ninove;Christine Zandotti;Marie-Thérèse Jimeno;Céline Gazin;Marielle Bedotto;Véronique Filosa;Audrey Giraud-Gatineau;Hervé Chaudet;Philippe Brouqui;Jean-Christophe Lagier;Didier Raoult | Coronavirus;France;SARS-CoV-2;respiratory infections | 2020-03-05 01:00:00+01:00 | 32127122 | FR | Aix-Marseille University, Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes Evolution Phylogeny and Infections (MEPHI), France.;Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille, France.;Unité des Virus Emergents (UVE), Aix-Marseille University, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.;Service de l'Information Médicale, Hôpital de la Timone, Marseille, France.;French Armed Forces Center for Epidemiology and Public Health (CESPA), Service de Santé des Armées (SSA), Marseille, France.;Aix-Marseille University, Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Vecteurs - Infections Tropicales et Méditerranéennes (VITROME), Marseille, France. | 17 | |||
| Letter | en | Guidelines for pregnant women with suspected SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32142639 | 2020-03-08 01:00:00+01:00 | pubmed | Algorithms;Betacoronavirus;Coronavirus Infections__diagnosis;Female;Humans;Pandemics;Pneumonia, Viral__diagnosis;Pregnancy;Pregnancy Complications, Infectious__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Guillaume Favre;Léo Pomar;Xiaolong Qi;Karin Nielsen-Saines;Didier Musso;David Baud | 2020-03-03 01:00:00+01:00 | 32142639 | FR;CN;CH;US | Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland.;CHESS Center, The First Hospital of Lanzhou University, Lanzhou, China.;Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.;Aix Marseille Université, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée infection, Marseille, France, Laboratoire Eurofins Labazur Guyane, French Guiana, France.;Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: david.baud@chuv.ch. | 27 | |||||||
| 10.1016/j.ijantimicag.2020.105933 | Editorial | en | Arguments in favour of remdesivir for treating SARS-CoV-2 infections. | https://www.ncbi.nlm.nih.gov/pubmed/32147516 | 0924-8579 | 2020-03-08 01:00:00+01:00 | pubmed | Adenosine Monophosphate__analogs & derivatives;Alanine__analogs & derivatives;Animals;Antiviral Agents__therapeutic use;Betacoronavirus__drug effects;Clinical Trials as Topic;Coronavirus Infections__drug therapy;DNA-Directed RNA Polymerases__antagonists & inhibitors;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Wen-Chien Ko;Jean-Marc Rolain;Nan-Yao Lee;Po-Lin Chen;Ching-Tai Huang;Ping-Ing Lee;Po-Ren Hsueh | Betacoronavirus;COVID-19;Coronavirus disease 2019;Remdesivir;SARS-CoV-2;Wuhan pneumonia | 2020-03-06 01:00:00+01:00 | 32147516 | FR;TW | Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, Center for Infection Control and Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.;Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance 7 Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 8 Marseille, France, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.;Department of Infectious Diseases, Chang Gung Memorial Hospital, Taoyuan, Taiwan.;Department of Pediatrics, National Taiwan University Children's Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.;Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hsporen@ntu.edu.tw. | 30 | |||
| 10.1684/vir.2020.0826 | Journal Article | en | Facing challenges with the novel coronavirus SARS-CoV-2 outbreak | https://www.ncbi.nlm.nih.gov/pubmed/32186279 | 2020-03-22 01:00:00+01:00 | pubmed | Betacoronavirus;China__epidemiology;Communicable Diseases, Emerging__epidemiology;Coronavirus Infections__epidemiology;Global Health__trends;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Sylvie van der Werf;Cécile Peltekian | 2020-03-19 01:00:00+01:00 | 32186279 | FR | National Reference Center for Respiratory Viruses, WHO National Influenza Center, Institut Pasteur, Paris, France, Molecular Genetics of RNA Viruses, UMR 3569 CNRS, University of Paris, Institut Pasteur, Paris, France.;Incentive Scientific Programs Department, Institut Pasteur, Paris, France. | 43 | ||||||
| NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NCI NIH HHS;NCI NIH HHS;NIGMS NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NCI NIH HHS | 10.1101/2020.03.22.002386 | Preprint | en | A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. | https://www.ncbi.nlm.nih.gov/pubmed/32511329 | An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption1,2. There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity- purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. | 2020-03-22 01:00:00+01:00 | pubmed | David E Gordon;Gwendolyn M Jang;Mehdi Bouhaddou;Jiewei Xu;Kirsten Obernier;Matthew J O'Meara;Jeffrey Z Guo;Danielle L Swaney;Tia A Tummino;Ruth Hüttenhain;Robyn M Kaake;Alicia L Richards;Beril Tutuncuoglu;Helene Foussard;Jyoti Batra;Kelsey Haas;Maya Modak;Minkyu Kim;Paige Haas;Benjamin J Polacco;Hannes Braberg;Jacqueline M Fabius;Manon Eckhardt;Margaret Soucheray;Melanie J Bennett;Merve Cakir;Michael J McGregor;Qiongyu Li;Zun Zar Chi Naing;Yuan Zhou;Shiming Peng;Ilsa T Kirby;James E Melnyk;John S Chorba;Kevin Lou;Shizhong A Dai;Wenqi Shen;Ying Shi;Ziyang Zhang;Inigo Barrio-Hernandez;Danish Memon;Claudia Hernandez-Armenta;Christopher J P Mathy;Tina Perica;Kala B Pilla;Sai J Ganesan;Daniel J Saltzberg;Rakesh Ramachandran;Xi Liu;Sara B Rosenthal;Lorenzo Calviello;Srivats Venkataramanan;Yizhu Lin;Stephanie A Wankowicz;Markus Bohn;Raphael Trenker;Janet M Young;Devin Cavero;Joe Hiatt;Theo Roth;Ujjwal Rathore;Advait Subramanian;Julia Noack;Mathieu Hubert;Ferdinand Roesch;Thomas Vallet;Björn Meyer;Kris M White;Lisa Miorin;David Agard;Michael Emerman;Davide Ruggero;Adolfo García-Sastre;Natalia Jura;Mark von Zastrow;Jack Taunton;Olivier Schwartz;Marco Vignuzzi;Christophe d'Enfert;Shaeri Mukherjee;Matt Jacobson;Harmit S Malik;Danica G Fujimori;Trey Ideker;Charles S Craik;Stephen Floor;James S Fraser;John Gross;Andrej Sali;Tanja Kortemme;Pedro Beltrao;Kevan Shokat;Brian K Shoichet;Nevan J Krogan | 2020-03-22 01:00:00+01:00 | 32511329 | FR;GB;US;UNK | [{"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI120694"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI135990"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI122747"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "R01 CA221969"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "R01 CA244550"}, {"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "R35 GM122481"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI135972"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "P01 AI063302"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "P50 AI150476"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI143292"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "F32 CA236347"}] | QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA.;University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA.;J. David Gladstone Institutes, San Francisco, CA 94158, USA.;University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA.;Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.;Department of Pharmaceutical Chemistry, University of California, San Francisco.;Howard Hughes Medical Institute.;European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.;Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco.;The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA.;Center for Computational Biology and Bioinformatics, Department of Medicine, University of California San Diego.;Department of Cell and Tissue Biology, University of California, San Francisco.;Biophysics Graduate Program, University of California, San Francisco.;Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, 94158, USA.;Division of Basic Sciences, Fred Hutchinson Cancer Research Center.;Medical Scientist Training Program, University of California, San Francisco, CA 94143, USA.;George William Hooper Foundation, Department of Microbiology and Immunology, UC San Francisco.;Virus and Immunity Unit, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France.;Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France.;Department for Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.;Biochemistry & Biophysics and Quantitative Biosciences Institute UCSF 600 16th St San Francisco, CA 94143.;Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98103.;Department of Urology, University of California, San Francisco, San Francisco, CA, USA.;Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA.;University of California San Francisco, Department of Psychiatry, San Francisco, CA, 94158, USA.;Direction Scientifique, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France.;Division of Genetics, Department of Medicine, University of California San Diego. | 45 | ||||
| 10.1016/j.ijantimicag.2020.105947 | Journal Article | en | SARS-CoV-2: fear versus data. | https://www.ncbi.nlm.nih.gov/pubmed/32201354 | SARS-CoV-2, the novel coronavirus from China, is spreading around the world, causing a huge reaction despite its current low incidence outside China and the Far East. Four common coronaviruses are in current circulation and cause millions of cases worldwide. This article compares the incidence and mortality rates of these four common coronaviruses with those of SARS-CoV-2 in Organisation for Economic Co-operation and Development countries. It is concluded that the problem of SARS-CoV-2 is probably being overestimated, as 2.6 million people die of respiratory infections each year compared with less than 4000 deaths for SARS-CoV-2 at the time of writing. | 0924-8579 | 2020-03-22 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__economics;Fear;Humans;Pandemics__economics;Pneumonia, Viral__economics;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Yanis Roussel;Audrey Giraud-Gatineau;Marie-Thérèse Jimeno;Jean-Marc Rolain;Christine Zandotti;Philippe Colson;Didier Raoult | COVID-19;Coronavirus;SARS-CoV-2 | 2020-03-19 01:00:00+01:00 | 32201354 | FR | Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France.;Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Service de Santé des Armées, Vecteurs - Infections Tropicales et Méditerranéennes, Marseille, France, Centre d'Epidémiologie et de Santé Publique des Armées, Marseille, France, Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Microbes Evolution Phylogénie et Infections, Marseille, France. Electronic address: didier.raoult@gmail.com. | 50 | ||
| 10.1016/s2468-1253(20)30082-0 | Journal Article | en | Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. | https://www.ncbi.nlm.nih.gov/pubmed/32192627 | 2468-1253 | 2020-03-22 01:00:00+01:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Fecal Microbiota Transplantation__methods;Feces__microbiology;Humans;Living Donors;Mass Screening__methods;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Gastroenterology & Hepatology | Gianluca Ianiro;Benjamin H Mullish;Colleen R Kelly;Harry Sokol;Zain Kassam;Siew C Ng;Monika Fischer;Jessica R Allegretti;Luca Masucci;Faming Zhang;Josbert Keller;Maurizio Sanguinetti;Samuel P Costello;Herbert Tilg;Antonio Gasbarrini;Giovanni Cammarota | 2020-03-17 01:00:00+01:00 | 32192627 | FR;CN;GB;US;HK;IT;AU;NL;AT | Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy. Electronic address: gianluca.ianiro@unicatt.it.;Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.;Division of Gastroenterology, Alpert Medical School of Brown University, Providence, RI, USA.;Service de Gastroenterologie, Hôpital Saint Antoine, Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Paris, France, French Group of Fecal Microbiota Transplantation, Paris, France, INRA, UMR1319 Micalis, AgroParisTech, Jouy-en-Josas, France.;Finch Therapeutics Group, Somerville, MA, USA.;Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.;Department of Medicine, Indiana University, Indianapolis, IN, USA.;Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.;Microbiology Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.;Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.;Department of Gastroenterology, Haaglanden Medical Center, The Hague, Netherlands, Netherlands Donor Feces Bank, Leiden University Medical Center, Leiden, Netherlands.;Department of Gastroenterology, The Queen Elizabeth Hospital, University of Adelaide, Adelaide, SA, Australia.;Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, and Metabolism, Innsbruck Medical University, Innsbruck, Austria.;Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy. | 51 | ||||
| 10.1128/mbio.00398-20 | Journal Article | en | Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32198163 | Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection. | 2150-7511 | 2020-03-22 01:00:00+01:00 | pubmed | Angiotensin II Type 2 Receptor Blockers__therapeutic use;Betacoronavirus;Coronavirus Infections__drug therapy;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors__therapeutic use;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__metabolism;Receptor, Angiotensin, Type 2__biosynthesis;Receptors, Virus__biosynthesis;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | mBio | David S Fedson;Steven M Opal;Ole Martin Rordam | COVID-19;endothelial dysfunction;generic drugs;host response treatment | 2020-03-20 01:00:00+01:00 | 32198163 | FR;NO;US | 57, chemin du Lavoir, Sergy Haut, France davidsfedson@gmail.com.;Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.;Fyordgata 59, Trondheim, Norway. | 55 | ||
| 10.1016/j.medmal.2020.03.004 | Editorial | en | Chloroquine and COVID-19, where do we stand? | https://www.ncbi.nlm.nih.gov/pubmed/32217166 | 0399-077X | 2020-03-29 01:00:00+01:00 | pubmed | Antiviral Agents__therapeutic use;Betacoronavirus;Chloroquine__adverse effects;Coronavirus Infections__drug therapy;Humans;Pandemics;Pneumonia, Viral__drug therapy;Treatment Failure;COVID-19;severe acute respiratory syndrome coronavirus 2 | Médecine et Maladies Infectieuses | M Lecuit | 2020-03-27 01:00:00+01:00 | 32217166 | FR | Institut Pasteur, Biology of Infection Unit, 75015 Paris, France, Inserm U1117, 75015 Paris, France, Université de Paris, Necker-Enfants Malades University Hospital, Division of Infectious Diseases and Tropical Medicine, Institut Imagine, APHP, 75006 Paris, France. Electronic address: marc.lecuit@pasteur.fr. | 63 | ||||
| Letter | fr | [SARS-CoV-2/COVID 19 Infection and Solid Cancers: Synthesis of Recommendations for Health Professionals]. | https://www.ncbi.nlm.nih.gov/pubmed/32229048 | 2020-03-29 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Health Personnel;Humans;Neoplasms__complications;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Thomas Grellety;Alain Ravaud;Anne Canivet;Gérard Ganem;Philippe Giraud;Rosine Guimbaud;Laure Kaluzinski;Ivan Krakowski;Didier Mayeur;Jean-Pierre Lotz;Benoit You | 2020-03-27 01:00:00+01:00 | 32229048 | FR | Service d'oncologie médicale, centre hospitalier de la Côte Basque, 13, avenue de l'Interne-Jacques-Loeb, 64100 Bayonne, France. Electronic address: tgrellety@ch-cotebasque.fr.;CHU de Bordeaux, service d'oncologie médicale, Bordeaux, France.;Centre Francois-Baclesse, service d'hygiène, Caen, France.;Clinique Victor Hugo-Centre Jean-Bernard, Le Mans, France.;Radiotherapy Department, hôpital Européen Georges-Pompidou, Société Française de Radiothérapie Oncologique, France.;CHU de Toulouse, oncologie médicale digestive, Toulouse, France.;Centre hospitalier public du Cotentin, service d'oncologie médicale, Cherbourg-en-Cotentin, France.;AFSOS, centre de lutte contre le cancer institut Bergonié, Bordeaux, France.;Centre Georges-François-Leclerc, service d'oncologie médicale, Dijon, France.;AP-HP, hôpital de Tenon, Paris, France.;Institut de cancérologie des hospices civils de Lyon (IC-HCL), service d'oncologie médicale, Lyon, France. | 65 | |||||||
| 10.1016/j.kint.2020.03.010 | Editorial | en | Kidney International and the COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32284224 | 0085-2538 | 2020-03-29 01:00:00+01:00 | pubmed | Kidney International | Brad H Rovin;Pierre Ronco | education;microbiology | 2020-03-26 01:00:00+01:00 | 32284224 | FR;US | Internal Medicine-Nephrology, The Ohio State University, Columbus, Ohio, USA. Electronic address: Brad.rovin@osumc.edu.;Sorbonne Université, Paris, France, Institut National de la Santé et de la Recherche Médicale (Inserm), Unité Mixte de Recherche S1155, Paris, France, Hôpital de jour - Néphrologie, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris, France. | 68 | ||||
| 10.1001/jama.2020.5110 | Journal Article | en | Toward Universal Deployable Guidelines for the Care of Patients With COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32215641 | 0098-7484 | 2020-03-29 01:00:00+01:00 | pubmed | JAMA | Francois Lamontagne;Derek C Angus | 2020-03-26 01:00:00+01:00 | 32215641 | FR;CA;US;UNK | Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.;Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.;Associate Editor. | 73 | |||||
| 10.1016/j.bulcan.2020.03.003 | Practice Guideline | fr | [Therapeutic options for genitourinary cancers during the epidemic period of COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32245603 | 0007-4551 | 2020-03-29 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Epidemics;Humans;Pandemics;Pneumonia, Viral__complications;Urogenital Neoplasms__therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Karim Fizazi | COVID-19;Cancers génito-urinaires;Genitourinary cancers | 2020-03-27 01:00:00+01:00 | 32245603 | FR | Institut Gustave-Roussy, département de médecine oncologique, 114, rue Édouard-Vaillant, 94800 Villejuif, France. Electronic address: Karim.Fizazi@gustaveroussy.fr.;Institut Gustave-Roussy, département de médecine oncologique, 114, rue Édouard-Vaillant, 94800 Villejuif, France. | 75 | |||
| 10.12890/2020_001641 | Journal Article | en | Anosmia and Dysgeusia in the Absence of Other Respiratory Diseases: Should COVID-19 Infection Be Considered? | https://www.ncbi.nlm.nih.gov/pubmed/32309267 | We describe two elderly patients evaluated at emergency departments for anosmia/dysgeusia in the absence of any other respiratory symptoms prior to or upon admission. In the current epidemiological context, clinical and biological work-up led to a diagnosis of COVID-19 infection. Unfortunately, one of the patients died during hospitalization, but the other recovered and was discharged. | 2020-04-05 02:00:00+02:00 | pubmed | Noel Lorenzo Villalba;Yasmine Maouche;Maria Belen Alonso Ortiz;Zaida Cordoba Sosa;Jean Baptiste Chahbazian;Aneska Syrovatkova;Pierre Pertoldi;Emmanuel Andres;Abrar-Ahmad Zulfiqar | 2019-nCoV;COVID-19;SARS-CoV-2;anosmia;dysgeusia | 2020-04-03 02:00:00+02:00 | 32309267 | FR;ES | Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, France.;Internal Medicine Department, Dr Negrin University Hospital, Gran Canaria, Spain.;Internal Medicine Department, Fuerteventura General Hospital, Fuerteventura, Spain. | 78 | |||||
| 10.1097/mej.0000000000000701 | Journal Article | en | European Society For Emergency Medicine position paper on emergency medical systems' response to COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32243317 | The 2019 novel coronavirus acute respiratory epidemic is creating a stressed situation in all the health systems of the affected countries. Emergency medical systems and specifically the emergency departments as the front line of the health systems are suffering from overload and severe working conditions, the risk of contagion and transmission of the health professionals adds a substantial burden to their daily work. Under the perspective of European Society For Emergency Medicine, the recommendations provided by the health authorities are reviewed focus on the emergency department's activity. | 0969-9546 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnosis;Emergency Medicine__standards;Emergency Service, Hospital__organization & administration;Humans;Infection Control;Pandemics;Patient Isolation;Personal Protective Equipment__supply & distribution;Pneumonia, Viral__diagnosis;Triage;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Emergency Medicine | Luis Garcia-Castrillo;Roberta Petrino;Robert Leach;Christoph Dodt;Wilhelm Behringer;Abdo Khoury;Marc Sabbe | 2020-04-04 02:00:00+02:00 | 32243317 | FR;IT;ES;BE;DE | Emergency Department, Hospital Marqués de Valdecilla, Santander, Spain.;Emergency Department, S. Andrea Hospital, Vercelli, Italy.;Department of Emergency Medicine, Centre Hospitalier de Wallonie picarde, Tournai, Belgium.;Emergency Department, Städtisches Klinikum München Bogenhausen, München.;Emergency Department, Center for Emergency Medicine, University Hospital Jena, Friedrich Schiller University, Am Klinikum 1, Jena, Germany.;Department of Emergency Medicine and Critical Care, Besançon University Hospital, Besançon, France.;Department of Emergency Medicine, University Hospitals Leuven, Leuven, Belgium. | 91 | |||
| 10.1016/s0262-4079(20)30683-7 | Journal Article | en | Tackling two crises at once. | https://www.ncbi.nlm.nih.gov/pubmed/32372791 | We can't lose sight of the climate emergency when dealing with the covid-19 pandemic, say Christiana Figueres and Tom Rivett-Carnac. | 0262-4079 | 2020-04-05 02:00:00+02:00 | pubmed | New Scientist | Christiana Figueres;Tom Rivett-Carnac | 2020-04-03 02:00:00+02:00 | 32372791 | FR | Christiana Figueres and Tom Rivett-Carnac played key roles in the Paris climate agreement. Their new book is The Future We Choose: Surviving the climate crisis. | 97 | ||||
| Letter | en | Will the Quality of Research Remain the Same During the COVID-19 Pandemic? | https://www.ncbi.nlm.nih.gov/pubmed/32240830 | 2020-04-05 02:00:00+02:00 | pubmed | Biomedical Research__standards;Coronavirus Infections__epidemiology;Humans;Pandemics;Peer Review, Research__standards;Pneumonia, Viral__epidemiology;COVID-19 | Laurent Peyrin-Biroulet | 2020-03-30 02:00:00+02:00 | 32240830 | FR | Inserm Nutrition - génétique et exposition aux risques environnementaux, Lorraine University, Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-les-Nancy, France. | 100 | |||||||
| Letter | en | COVID-19 therapeutic options for patients with kidney disease. | https://www.ncbi.nlm.nih.gov/pubmed/32317113 | 2020-04-05 02:00:00+02:00 | pubmed | Antiviral Agents__administration & dosage;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Dose-Response Relationship, Drug;Drug Dosage Calculations;Glomerular Filtration Rate__physiology;Humans;Kidney__drug effects;Off-Label Use;Pandemics;Pneumonia, Viral__drug therapy;Renal Elimination;Renal Insufficiency, Chronic__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Hassan Izzedine;Kenar D Jhaveri;Mark A Perazella | 2020-03-30 02:00:00+02:00 | 32317113 | FR;US | Department of Nephrology, Peupliers Private Hospital, Ramsay Générale de Santé, Paris, France. Electronic address: h.izzedine@ramsaygds.fr.;Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.;Yale University School of Medicine, New Haven, Connecticut, USA. | 104 | |||||||
| 10.1016/j.jchirv.2020.03.007 | English Abstract;Journal Article | fr | [Strategy for the practice of digestive and oncologic surgery in COVID-19 epidemic situation]. | https://www.ncbi.nlm.nih.gov/pubmed/32834885 | The COVID-19 pandemic is changing the organization of healthcare and has a direct impact on digestive surgery. Healthcare priorities and circuits are being modified. Emergency surgery is still a priority. Functional surgery is to be deferred. Laparoscopic surgery must follow strict rules so as not to expose healthcare professionals (HCPs) to added risk. The question looms large in cancer surgery - go ahead or defer? There is probably an added risk due to the pandemic that must be balanced against the risk incurred by deferring surgery. For each type of cancer - colon, pancreas, oesogastric, hepatocellular carcinoma - morbidity and mortality rates are stated and compared with the oncological risk incurred by deferring surgery and/or the tumour doubling time. Strategies can be proposed based on this comparison. For colonic cancers T1-2, N0, it is advisable to defer surgery. For advanced colonic lesions, it seems judicious to undertake neoadjuvant chemotherapy and then wait. For rectal cancers T3-4 and /or N+, chemoradiotherapy is indicated, short radiotherapy must be discussed (followed by a waiting period) to reduce time of exposure in the hospital and to prevent infections. Most complex surgery with high morbidity and mortality - oesogastric, hepatic or pancreatic - is most often best deferred. | 1878-786X | 2020-04-05 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | J-J Tuech;A Gangloff;F Di Fiore;P Michel;C Brigand;K Slim;M Pocard;L Schwarz | COVID-19;Cancer;Coronavirus;Digestive surgery;Surgical complications | 2020-03-31 02:00:00+02:00 | 32834885 | FR | Department of Digestive Surgery, Rouen University Hospital, 1, rue de Germont, 76031 Rouen cedex, France.;UMR 1245 Inserm, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, UNIROUEN, Rouen University Hospital, Normandie Université, 76000 Rouen, France.;Department of Digestive Oncology, Rouen University Hospital, 1, rue de Germont, 76031 Rouen cedex, France.;Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg University Hospital, 67200 Strasbourg, France.;Department of digestive surgery, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France.;UMR 1275 CAP Paris-Tech, université de Paris, 75010 Paris, France.;Service de chirurgie digestive et cancérologique, hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France. | 108 | |||
| 10.1016/j.reval.2020.03.003 | Journal Article | fr | [Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan]. | https://www.ncbi.nlm.nih.gov/pubmed/32292530 | 1877-0320 | 2020-04-05 02:00:00+02:00 | pubmed | Revue Française d'Allergologie | G Kanny | 2020-04-01 02:00:00+02:00 | 32292530 | FR | Médecine Interne, Immunologie Clinique et Allergologie, CHRU de Nancy, Laboratoire d'Hydrologie et Climatologie Médicales, Faculté de Médecine, 9 rue de la Forêt de Haye, 54505 Vandœuvre-lès-Nancy, France. | 119 | |||||
| 10.1016/j.encep.2020.03.001 | Journal Article;Review | fr | [Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review]. | https://www.ncbi.nlm.nih.gov/pubmed/32312567 | The lack of ressources and coordination to face the epidemic of coronavirus raises concerns for the health of patients with mental disorders in a country where we keep in memory the dramatic experience of famine in psychiatric hospitals during the Second World War. This article aims at proposing guidance to ensure mental health care during the SARS-CoV epidemy in France. | 0013-7006 | 2020-04-05 02:00:00+02:00 | pubmed | Aftercare;Age Factors;Aged, 80 and over;Antiviral Agents__pharmacokinetics;Betacoronavirus;Child;Cognition Disorders__epidemiology;Comorbidity;Continuity of Patient Care__organization & administration;Coronavirus Infections__epidemiology;Drug Interactions;France__epidemiology;Hospital Units__organization & administration;Hospitals, Psychiatric__organization & administration;Humans;Infection Control__methods;Mental Disorders__epidemiology;Mental Health Services__organization & administration;Pandemics;Patient Care Team;Patient Compliance;Pneumonia, Viral__epidemiology;Prisoners__psychology;Stress Disorders, Post-Traumatic__etiology;Stress, Psychological__etiology;Substance-Related Disorders__epidemiology;Suicide__prevention & control;Vulnerable Populations;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | A Chevance;D Gourion;N Hoertel;P-M Llorca;P Thomas;R Bocher;M-R Moro;V Laprévote;A Benyamina;P Fossati;M Masson;E Leaune;M Leboyer;R Gaillard | Coronavirus;Covid-19;Epidemy;France;Pandemy;Pandémie;Psychiatrie;Psychiatry;SARS-CoV-2;Santé mentale;Épidémie | 2020-04-02 02:00:00+02:00 | 32312567 | FR | Université de Paris, CRESS, Inserm, INRA, 75004 Paris, France. Electronic address: astrid.chevance@gmail.com.;HEC Paris (Jouy-en-Josas), Paris, France.;Centre ressource régional de psychiatrie du sujet âgé (CRRPSA), service de psychiatrie et d'addictologie de l'adulte et du sujet âgé, DMU psychiatrie et addictologie, Inserm U1266, institut de psychiatrie et neurosciences de Paris, centre université de Paris, AP-HP, Paris, France.;Université Clermont-Auvergne, CHU de Clermont-Ferrand, Clermont-Ferrand, France.;Laboratoire de sciences cognitives et sciences affectives (SCALab-PsyCHIC), université de Lille, CNRS UMR 9193, CHU de Lille, Lille, France.;CHU de Nantes, Nantes, France.;Université de Paris, collège national des universitaires de psychiatrie (CNUP), Inserm, CESP, Paris, France.;Pôle hospitalo-universitaire de psychiatrie d'adultes et d'addictologie du Grand-Nancy, centre psychothérapique de Nancy, Laxou, France, Faculté de médecine, université de Lorraine, Nancy, France.;Département de psychiatrie et d'addictologie, hôpital Paul-Brousse, AP-HP, 94800 Villejuif, France, Unité psychiatrie-comorbidités-addictions-unité de recherche, PSYCOMADD université Paris Sud, université Paris Saclay, AP-HP, Paris, France.;Service de psychiatrie adultes, Sorbonne université, groupe hospitalier Pitié-Salpêtrière, ICM, Inserm U1127, AP-HP, Paris, France.;SHU, GHU psychiatrie et neurosciences, Nightingale Hospitals-Paris, clinique du Château-de-Garches, Paris, France.;Centre hospitalier Le Vinatier, Bron, France, Université Lyon, Lyon, France.;Université Paris Est Créteil, Inserm, Fondation FondaMental, AP-HP, Paris, France.;Université de Paris, GHU psychiatrie et neurosciences, Paris, France. | 120 | ||
| Letter | en | Challenges with the management of older patients with cancer during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32273247 | 2020-04-05 02:00:00+02:00 | pubmed | Age Factors;Aged;Betacoronavirus;Coronavirus Infections__diagnosis;Humans;Incidence;Neoplasms__complications;Pandemics;Pneumonia, Viral__diagnosis;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Claire Falandry;Cynthia Filteau;Christine Ravot;Olivia Le Saux | 2020-04-02 02:00:00+02:00 | 32273247 | FR | Geriatric Unit, Lyon-Sud University Hospital, Lyon 1 University, France, CarMEN Laboratory of Lyon University INSERM U.1060/Université Lyon1/INRA U. 1397/INSA Lyon/Hospices Civils Lyon, France. Electronic address: claire.falandry@chu-lyon.fr.;Geriatric Unit, Lyon-Sud University Hospital, Lyon 1 University, France.;Centre de Recherche en Cancérologie de Lyon, UMR INSERM 1052 CNRS 5286, France. | 122 | |||||||
| 10.1016/j.bulcan.2020.03.008 | Practice Guideline | fr | [COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la Femme (SIFEM), the Société Française de Chirurgie Oncologique (SFCO), the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)]. | https://www.ncbi.nlm.nih.gov/pubmed/32278467 | 0007-4551 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus__classification;Breast Neoplasms__drug therapy;Carcinoma, Intraductal, Noninfiltrating__drug therapy;China__epidemiology;Coronavirus Infections__diagnosis;Female;France__epidemiology;Humans;Influenza, Human__complications;Italy__epidemiology;Neoplasms__epidemiology;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Societies, Medical__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Joseph Gligorov;Thomas Bachelot;Jean-Yves Pierga;Eric-Charles Antoine;Corinne Balleyguier;Emmanuel Barranger;Yazid Belkacemi;Hervé Bonnefoi;François-Clément Bidard;Luc Ceugnart;Jean-Marc Classe;Paul Cottu;Charles Coutant;Bruno Cutuli;Florence Dalenc;Emile Darai;Veronique Dieras;Nadine Dohollou;Sylvie Giacchetti;Anthony Goncalves;Anne-Claire Hardy-Bessard;Gilles Houvenaeghel;Jean-Philippe Jacquin;William Jacot;Christelle Levy;Carole Mathelin;Israel Nisand;Thierry Petit;Thierry Petit;Edouard Poncelet;Sofia Rivera;Roman Rouzier;Rémy Salmon;Florian Scotté;Jean-Philippe Spano;Catherine Uzan;Laurent Zelek;Marc Spielmann;Frédérique Penault-Llorca;Moise Namer;Suzette Delaloge | Breast cancer;Cancer du sein;Covid-19;Guidelines;Recommandation;SARS-CoV-2 | 2020-04-01 02:00:00+02:00 | 32278467 | FR | Institut Universitaire de Cancérologie, AP-HP, Sorbonne Université, Paris, France. Electronic address: joseph.gligorov@aphp.fr.;Centre Léon-Bérard, Lyon, France.;Institut Curie, Université Paris Centre, Paris, France.;Institut du sein Henri-Hartmann, Neuilly, France.;Institut Gustave-Roussy, Villejuif, France.;Centre Antoine-Lacassagne, Nice, France.;Université Paris Est Créteil, Hôpitaux Universitaires Henri-Mondor AP-HP, Créteil, France.;Institut Bergonié, Bordeaux, France.;Centre Oscar-Lambret, Lille, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;Centre Georges-François-Leclerc, Dijon, France.;Institut du Cancer Courlancy Reims, Reims, France.;Institut Claudius-Regaud, Toulouse, France.;Institut Universitaire de Cancérologie, AP-HP, Sorbonne Université, Paris, France.;Centre Eugène-Marquis, Rennes, France.;Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.;Hôpital Universitaire St.-Louis AP-HP, Paris, France.;Institut Paoli-Calmette, Marseille, France.;Centre Armoricain d'Oncologie CARIO, Plerin, France.;Institut de Cancérologie de la Loire, St.-Priest-en-Jarez, France.;Institut du Cancer, Montpellier, France.;Centre François-Baclesse, Caen, France.;Centre Hospitalo-Universitaire de Strasbourg, Strasbourg, France.;Centre Paul-Strauss, Strasbourg, France.;Centre Hospitalier de Valenciennes, Valenciennes, France.;Clinique Saint-Jean-de-Dieu, Paris, France.;Hôpital Universitaire Avicenne, Bobigny, France.;Institut Français du Sein, Paris, France.;Centre Jean-Perrin, Clermont-Ferrand, France.;RPC Nice-St.-Paul-de-Vence, Nice, France. | 126 | |||
| 10.1192/j.eurpsy.2020.35 | Editorial | en | The consequences of the COVID-19 pandemic on mental health and implications for clinical practice. | https://www.ncbi.nlm.nih.gov/pubmed/32234102 | 0924-9338,1778-3585 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__psychology;Humans;Mental Health;Pandemics;Pneumonia, Viral__psychology;Psychiatry__trends;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Psychiatry | Andrea Fiorillo;Philip Gorwood | 2020-04-01 02:00:00+02:00 | 32234102 | FR;IT;UNK | Department of Psychiatry, University of Campania "L. Vanvitelli", Naples, Italy.;Editor, European Psychiatry.;GHU Paris Psychiatrie et Neurosciences, CMME, Hôpital Sainte-Anne, 75014 Paris, France.;Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, 75014 Paris, France. | 127 | ||||
| 10.1016/j.eururo.2020.03.033 | Editorial | en | The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is "Safe Better than Sorry"? | https://www.ncbi.nlm.nih.gov/pubmed/32284245 | 0302-2838 | 2020-04-12 02:00:00+02:00 | pubmed | Anti-Inflammatory Agents, Non-Steroidal__therapeutic use;Betacoronavirus;Coronavirus Infections__complications;Humans;Pandemics;Pneumonia, Viral__complications;Treatment Outcome;Urologic Diseases__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Urology | Benjamin Pradère;Guillaume Ploussard;James W F Catto;Morgan Rouprêt;Vincent Misrai | 2020-04-10 02:00:00+02:00 | 32284245 | FR;GB;AT | Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria, Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France.;Department of Urology, Ramsay Santé, Clinique La Croix du Sud, Quint Fonsegrives, France.;Academic Urology Unit, University of Sheffield, Sheffield, UK.;Department of Urology, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.;Department of Urology, Clinique Pasteur, Toulouse, France. Electronic address: v.misrai@clinique-pasteur.com. | 139 | ||||
| 10.1016/j.tmaid.2020.101663 | Journal Article;Observational Study | en | Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. | https://www.ncbi.nlm.nih.gov/pubmed/32289548 | We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration. | 1477-8939 | 2020-04-12 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Azithromycin__therapeutic use;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Drug Therapy, Combination;Female;France;Humans;Hydroxychloroquine__therapeutic use;Male;Middle Aged;Nasopharynx__virology;Pandemics;Pilot Projects;Pneumonia, Viral__drug therapy;Viral Load;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Travel Medicine and Infectious Disease | Philippe Gautret;Jean-Christophe Lagier;Philippe Parola;Van Thuan Hoang;Line Meddeb;Jacques Sevestre;Morgane Mailhe;Barbara Doudier;Camille Aubry;Sophie Amrane;Piseth Seng;Marie Hocquart;Carole Eldin;Julie Finance;Vera Esteves Vieira;Hervé Tissot Tissot-Dupont;Stéphane Honoré;Andreas Stein;Matthieu Million;Philippe Colson;Bernard La Scola;Véronique Veit;Alexis Jacquier;Jean-Claude Deharo;Michel Drancourt;Pierre Edouard Fournier;Jean-Marc Rolain;Philippe Brouqui;Didier Raoult | Azithromycin;COVID-19;Culture;Hydroxychloroquine;PCR;SARS-CoV-2 | 2020-04-11 02:00:00+02:00 | 32289548 | FR;VN | IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France, Thai Binh University of Medicine and Pharmacy, Thai Binh, Viet Nam.;IHU-Méditerranée Infection, Marseille, France.;Assistance Publique de Marseille, Hôpital Nord, Explorations Fonctionnelles Respiratories, Aix Marseille Université, France.;Service de Pharmacie, Hôpital Timone, AP-HM, Marseille, France, Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.;Assistance Publique de Marseille, Médecine Interne, Unité de Médecine Aigue Polyvalente (UMAP), France.;Department of Radiology and Cardiovascular Imaging, Aix-Marseille Université, UMR 7339, CNRS, CRMBM-CEMEREM (Centre de Résonance Magnétique Biologique et Médicale-Centre d'Exploration Métaboliques par Résonance Magnétique), France.;Assistance Publique de Marseille, Hôpital Timone, Cardiologie, Rythomologie, Aix Marseille Université, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: didier.raoult@gmail.com. | 140 | ||
| Comparative Study;Letter | en | Collateral consequences of COVID-19 epidemic in Greater Paris. | https://www.ncbi.nlm.nih.gov/pubmed/32283116 | 2020-04-12 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Betacoronavirus;Cardiopulmonary Resuscitation__methods;Cohort Studies;Coronavirus Infections__epidemiology;Disease Outbreaks;Emergency Medical Services__organization & administration;Female;Heart Arrest__epidemiology;Humans;Intensive Care Units__statistics & numerical data;Male;Middle Aged;Outcome Assessment, Health Care;Pandemics;Paris;Pneumonia, Viral__epidemiology;Risk Assessment;Survival Analysis;COVID-19;severe acute respiratory syndrome coronavirus 2 | F Lapostolle;J M Agostinucci;A Alhéritière;T Petrovic;F Adnet | 2020-04-10 02:00:00+02:00 | 32283116 | FR | SAMU 93, hôpital Avicenne, APHP, 125, rue de Stalingrad, Université Paris 13, Bobigny, France. | 152 | |||||||
| 10.1093/eurheartj/ehaa282 | Journal Article | en | Denominator matters in estimating COVID-19 mortality rates. | https://www.ncbi.nlm.nih.gov/pubmed/32255475 | 0195-668X,1522-9645 | 2020-04-12 02:00:00+02:00 | pubmed | European Heart Journal | Bamba Gaye;Anouar Fanidi;Xavier Jouven | 2020-04-07 02:00:00+02:00 | 32255475 | FR;GB;UNK | The African Research Network.;Université de Paris, PARCC, INSERM, F-75015 Paris, France.;MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.;Cardiology Department, Georges-Pompidou European Hospital, Paris, France. | 156 | |||||
| 10.1007/s12204-020-2168-1 | Journal Article | en | CIRD-F: Spread and Influence of COVID-19 in China. | https://www.ncbi.nlm.nih.gov/pubmed/32288416 | The outbreak of coronavirus disease 2019 (COVID-19) has been spreading rapidly in China and the Chinese government took a series of policies to control the epidemic. Therefore, it will be helpful to predict the tendency of the epidemic and analyze the influence of official policies. Existing models for prediction, such as cabin models and individual-based models, are either oversimplified or too meticulous, and the influence of the epidemic was studied much more than that of official policies. To predict the epidemic tendency, we consider four groups of people, and establish a propagation dynamics model. We also create a negative feedback to quantify the public vigilance to the epidemic. We evaluate the tendency of epidemic in Hubei and China except Hubei separately to predict the situation of the whole country. Experiments show that the epidemic will terminate around 17 March 2020 and the final number of cumulative infections will be about 78 191 (prediction interval, 74 872 to 82 474). By changing the parameters of the model accordingly, we demonstrate the control effect of the policies of the government on the epidemic situation, which can reduce about 68% possible infections. At the same time, we use the capital asset pricing model with dummy variable to evaluate the effects of the epidemic and official policies on the revenue of multiple industries. | 1007-1172,1995-8188 | 2020-04-12 02:00:00+02:00 | pubmed | Journal of Shanghai Jiaotong University (Science) | Lingyun Zhou;Kaiwei Wu;Hanzhi Liu;Yuanning Gao;Xiaofeng Gao | capital asset pricing model;coronavirus disease 2019 (COVID-19);dummy variable;epidemic prediction model;negative feedback | 2020-04-07 02:00:00+02:00 | 32288416 | FR;CN | 1Antai College of Economics and Management, Shanghai Jiao Tong University, Shanghai, 200240 China.;2SJTU-ParisTech Elite Institute of Technology, Shanghai Jiao Tong University, Shanghai, 200240 China.;3School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, 200240 China. | 168 | |||
| Letter;Comment | en | Nutritional management in hospital setting during SARS-CoV-2 pandemic: a real-life experience. | https://www.ncbi.nlm.nih.gov/pubmed/32253375 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Intensive Care Units;Pandemics;Pneumonia, Viral;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Marco Cintoni;Emanuele Rinninella;Maria Giuseppina Annetta;Maria Cristina Mele | 2020-04-06 02:00:00+02:00 | 32253375 | FR;IT | Scuola di Specializzazione in Scienza dell'Alimentazione, Università di Roma Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. marco.cintoni@gmail.com.;UOC di Nutrizione Clinica, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy.;UOC di Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica, Dipartimento di Scienze dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy.;UOSA di Nutrizione Avanzata in Oncologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy. | 179 | |||||||
| 10.1016/j.accpm.2020.04.001 | Journal Article | en | SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria. | https://www.ncbi.nlm.nih.gov/pubmed/32278670 | Community transmission of SARS-CoV-2 was detected in Spain in February 2020, with 216% intensive care unit (ICU) capacity expanded in Vitoria by March 18th, 2020. | 2352-5568 | 2020-04-12 02:00:00+02:00 | pubmed | Anaesthesia Critical Care & Pain Medicine | Helena Barrasa;Jordi Rello;Sofia Tejada;Alejandro Martín;Goiatz Balziskueta;Cristina Vinuesa;Borja Fernández-Miret;Ana Villagra;Ana Vallejo;Ana San Sebastián;Sara Cabañes;Sebastián Iribarren;Fernando Fonseca;Javier Maynar | ARDS;COVID-19;Pneumonia;Procalcitonin | 2020-04-09 02:00:00+02:00 | 32278670 | FR;ES;PS | Critical Care Department, Hospital Universitario de Alava, Spain.;Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto Salud Carlos II, Madrid, Spain, Clinical Research in Pneumonia & Sepsis (CRIPS), Vall d'Hebron Institute of Research, Barcelona, Spain, Clinical Research, CHU Nîmes, University Montpellier - Nîmes, Nîmes, France.;Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto Salud Carlos II, Madrid, Spain, Clinical Research in Pneumonia & Sepsis (CRIPS), Vall d'Hebron Institute of Research, Barcelona, Spain. Electronic address: stmagraner@gmail.com. | 186 | |||
| Letter;Research Support, Non-U.S. Gov't | en | French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32278878 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnostic imaging;Disease Management;Disease Outbreaks;France__epidemiology;Humans;Pandemics;Pneumonia, Viral__diagnostic imaging;Sarcoma__diagnostic imaging;Time-to-Treatment__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | N Penel;S Bonvalot;V Minard;D Orbach;F Gouin;N Corradini;M Brahmi;P Marec-Bérard;S Briand;N Gaspar;C Llacer;S Carrère;A Dufresne;A Le Cesne;J Y Blay | 2020-04-09 02:00:00+02:00 | 32278878 | FR;UNK | Medical Oncology Department, Oscar Lambret Cancer Centre, Lille University, Lille, France.;Surgical Oncology Department, Institut Curie, Paris, France.;Department of Pediatric Oncology, Gustave Roussy Institute, Villejuif, France.;Department of Pediatric Oncology, Institut Curie, Paris, France.;Departments of Surgical Oncology.;Pediatric Oncology.;Medical Oncology, Centre Léon Bérard, Lyon, France.;Surgical Oncology Department, CHU Kremlin-Bicêtre, Paris, France.;Departments of Radiotherapy.;Department of Surgical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France.;Medical Oncology, Centre Léon Bérard, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr. | 191 | |||||||
| Letter | en | Intrapartum care of women with COVID-19: A practical approach. | https://www.ncbi.nlm.nih.gov/pubmed/32307204 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__therapy;Female;Humans;Pandemics;Pneumonia, Viral__therapy;Pregnancy;Pregnancy Complications, Infectious__therapy;Prenatal Care;COVID-19;severe acute respiratory syndrome coronavirus 2 | Joanna Sichitiu;David Desseauve | 2020-04-06 02:00:00+02:00 | 32307204 | FR;CH | Women-Mother-Child Department, Centre Hospitalier Universitaire Vaudois, Avenue Pierre-Decker 2, 1011, Lausanne, Switzerland. Electronic address: joanna.sichitiu@chuv.ch.;Women-Mother-Child Department, Centre Hospitalier Universitaire Vaudois, Avenue Pierre-Decker 2, 1011, Lausanne, Switzerland. | 195 | |||||||
| 10.1016/j.ajic.2020.04.011 | Journal Article;Review | en | Reducing antibiotic prescribing and addressing the global problem of antibiotic resistance by targeted hygiene in the home and everyday life settings: A position paper. | https://www.ncbi.nlm.nih.gov/pubmed/32311380 | Antimicrobial resistance (AMR) continues to threaten global health. Although global and national AMR action plans are in place, infection prevention and control is primarily discussed in the context of health care facilities with home and everyday life settings barely addressed. As seen with the recent global SARS-CoV-2 pandemic, everyday hygiene measures can play an important role in containing the threat from infectious microorganisms. This position paper has been developed following a meeting of global experts in London, 2019. It presents evidence that home and community settings are important for infection transmission and also the acquisition and spread of AMR. It also demonstrates that the targeted hygiene approach offers a framework for maximizing protection against colonization and infections, thereby reducing antibiotic prescribing and minimizing selection pressure for the development of antibiotic resistance. If combined with the provision of clean water and sanitation, targeted hygiene can reduce the circulation of resistant bacteria in homes and communities, regardless of a country's Human Development Index (overall social and economic development). Achieving a reduction of AMR strains in health care settings requires a mirrored reduction in the community. The authors call upon national and international policy makers, health agencies, and health care professionals to further recognize the importance of targeted hygiene in the home and everyday life settings for preventing and controlling infection, in a unified quest to tackle AMR. | 0196-6553 | 2020-04-19 02:00:00+02:00 | pubmed | American Journal of Infection Control | Jean-Yves Maillard;Sally F Bloomfield;Patrice Courvalin;Sabiha Y Essack;Sumanth Gandra;Charles P Gerba;Joseph R Rubino;Elizabeth A Scott | Antimicrobial resistance;COVID-19;Global health;Targeted hygiene | 2020-04-18 02:00:00+02:00 | 32311380 | FR;GB;ZA;US | Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK, International Scientific Forum on Home Hygiene, Somerset, UK. Electronic address: maillardj@cardiff.ac.uk.;London School of Hygiene and Tropical Medicine, London, UK.;Department of Microbiology, Institut Pasteur, Paris, France.;Antimicrobial Research Unit, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.;Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.;Departments of Soil, Water and Environmental Science and Environmental Health, University of Arizona, Tucson, AZ, USA.;Research & Development, Home Hygiene, Lysol/Harpic, Reckitt Benckiser LLC., One Philips Parkway, Montvale, NJ, USA.;College of Natural, Behavioral and Health Sciences, Simmons University, Boston, MA, USA. | 201 | |||
| 10.1530/eje-20-0386 | Editorial;Introductory Journal Article | en | Endocrinology in the time of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32302976 | 0804-4643,1479-683X | 2020-04-19 02:00:00+02:00 | pubmed | Coronavirus Infections;Delivery of Health Care;Endocrinology;Pandemics;Pneumonia, Viral;COVID-19 | European Journal of Endocrinology | Wiebke Arlt;Olaf M Dekkers;Juliane Léger;Robert K Semple | 2020-04-18 02:00:00+02:00 | 32302976 | FR;NL;GB | Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK.;Department of Clinical Epidemiology, Leids Universitair Medisch Centrum, Centrum voor Humane en Klinische Genetica, Leiden, the Netherlands.;Department of Paediatric Endocrinology and Diabetes, Head, Reference Center for Rare Endocrine Growth Diseases, Robert Debré University Hospital, Paris, France.;Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK. | 211 | ||||
| 10.1016/j.neurol.2020.03.002 | Editorial | en | Covid-19, the pandemic war: Implication for neurologists. | https://www.ncbi.nlm.nih.gov/pubmed/32303331 | 0035-3787 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Central Nervous System Diseases__complications;Coronavirus Infections__complications;Humans;Neurologists;Pandemics__prevention & control;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Revue Neurologique | J de Seze;C Lebrun-Frenay | 2020-04-19 02:00:00+02:00 | 32303331 | FR;US | MS Clinic, CHU Strasbourg, 1 Avenue Molière, 67200 Strasbourg, France.;MS Clinic, MS Unit research Nice Cote D'Azur University (UR2CA), Pasteur2 University Hospital, 30 Voie Romaine, 06002 Nice, France. Electronic address: lebrun-frenay.c@chu-nice.fr. | 213 | ||||
| Editorial;Comment | en | Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists. | https://www.ncbi.nlm.nih.gov/pubmed/32295769 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Humans;Italy;Oncologists;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Icro Meattini;Pierfrancesco Franco;Liliana Belgioia;Luca Boldrini;Angela Botticella;Maria Carmen De Santis;Giulia Marvaso;Giampaolo Montesi;Silvana Parisi;Luca Triggiani;Matteo Lambertini;Lorenzo Livi | COVID-19;clinical oncology;radiation therapy;recommendations;young oncologists | 2020-04-17 02:00:00+02:00 | 32295769 | FR;IT | Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Firenze, Italy icro.meattini@unifi.it.;Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.;Department of Oncology, Radiation Oncology, University of Turin, Torino, Italy.;Health Science Department (DISSAL), University of Genoa, Genova, Italy.;Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Roma, Italy.;Department of Radiation Oncology, Institut d'Oncologie Thoracique (IOT), Villejuif, France.;Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Division of Radiation Oncology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.;Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.;Radiation Oncology Unit, Santa Maria della Misericordia Hospital, Rovigo, Italy.;Radiation Oncology Unit - Department of Biomedical, Dental Science, and Morphological and Funcitional Images, University of Messina, Messina, Italy.;Department of Radiation Oncology, University of Brescia and Spedali Civili Hospital, Brescia, Italy.;Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genova, Italy.;Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Firenze, Italy. | 218 | ||||||
| Case Reports;Letter;Review | en | Urticarial eruption in COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32294273 | 2020-04-19 02:00:00+02:00 | pubmed | Adult;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Diagnosis, Differential;Female;Hospitalization;Humans;Italy;Pandemics;Pneumonia, Viral__diagnosis;Risk Assessment;Severe Acute Respiratory Syndrome__diagnosis;Urticaria__diagnosis;COVID-19;COVID-19 diagnostic testing | D Henry;M Ackerman;E Sancelme;A Finon;E Esteve | 2020-04-16 02:00:00+02:00 | 32294273 | FR | Department of Dermatology, CHR Orléans, Orléans, France. | 219 | |||||||
| 10.1093/cvr/cvaa097 | Journal Article;Research Support, Non-U.S. Gov't | en | Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32293003 | Systemic arterial hypertension (referred to as hypertension herein) is a major risk factor of mortality worldwide, and its importance is further emphasized in the context of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection referred to as COVID-19. Patients with severe COVID-19 infections commonly are older and have a history of hypertension. Almost 75% of patients who have died in the pandemic in Italy had hypertension. This raised multiple questions regarding a more severe course of COVID-19 in relation to hypertension itself as well as its treatment with renin-angiotensin system (RAS) blockers, e.g. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We provide a critical review on the relationship of hypertension, RAS, and risk of lung injury. We demonstrate lack of sound evidence that hypertension per se is an independent risk factor for COVID-19. Interestingly, ACEIs and ARBs may be associated with lower incidence and/or improved outcome in patients with lower respiratory tract infections. We also review in detail the molecular mechanisms linking the RAS to lung damage and the potential clinical impact of treatment with RAS blockers in patients with COVID-19 and a high cardiovascular and renal risk. This is related to the role of angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-2 entry into cells, and expression of ACE2 in the lung, cardiovascular system, kidney, and other tissues. In summary, a critical review of available evidence does not support a deleterious effect of RAS blockers in COVID-19 infections. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic. | 0008-6363,1755-3245 | 2020-04-19 02:00:00+02:00 | pubmed | Angiotensin II Type 1 Receptor Blockers__pharmacology;Angiotensin-Converting Enzyme Inhibitors__pharmacology;Betacoronavirus__pathogenicity;Coronavirus Infections__diagnosis;Humans;Lung Injury__complications;Pandemics;Pneumonia, Viral__diagnosis;Renin-Angiotensin System__drug effects;Respiratory Tract Infections__drug therapy;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cardiovascular Research | Reinhold Kreutz;Engi Abd El-Hady Algharably;Michel Azizi;Piotr Dobrowolski;Tomasz Guzik;Andrzej Januszewicz;Alexandre Persu;Aleksander Prejbisz;Thomas Günther Riemer;Ji-Guang Wang;Michel Burnier | Angiotensin;COVID-19;Cardiovascular;Hypertension;Lung | 2020-04-16 02:00:00+02:00 | 32293003 | FR;CN;GB;CH;PL;BE;DE | Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Germany.;Université Paris-Descartes, AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department and DMU CARTE, INSERM, CIC1418, Paris, France.;Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.;Institute of Cardiovascular & Medical Sciences BHF Glasgow Cardiovascular Research Centre, Glasgow, UK and Jagiellonian University, Collegium Medicum, Krakow, Poland.;Division of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.;The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.;Service of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. | 220 | ||
| 10.1016/j.jchirv.2020.04.009 | English Abstract;Journal Article | fr | [Management of the COVID-19 epidemic by public health establishments - Analysis by the Fédération hospitalière de France]. | https://www.ncbi.nlm.nih.gov/pubmed/32313587 | The objective of this article is to detail the measures taken in public institutions to cope with the COVID-19 epidemic. It details the initial strategy, organizational evolution towards "all-COVID", coordination between the various stakeholders and the strategy for maintaining continuity of care. The Quebec experience is also used as an example. Finally, an exit strategy must be anticipated at this phase of the epidemic. | 1878-786X | 2020-04-19 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | K Barro;A Malone;A Mokede;C Chevance | COVID-19;Coronavirus;Pandemic | 2020-04-18 02:00:00+02:00 | 32313587 | FR | CS 41402, pôle offre de soins, Fédération hospitalière de France, 1 bis, rue Cabanis, 75993 Paris cedex 14, France.;CS 41402, pôle prospective, Europe, International Fédération hospitalière de France, 1 bis, rue Cabanis, 75993 Paris cedex 14, France.;Pôle finance, Fédération hospitalière de France, 1 bis, rue Cabanis, 75993 Paris cedex 14, France. | 228 | |||
| Letter | fr | [Gynecological surgery during the COVID-19 pandemic: Take home messages]. | https://www.ncbi.nlm.nih.gov/pubmed/32311508 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Cross Infection__prevention & control;Elective Surgical Procedures;Emergency Treatment;Female;Genital Diseases, Female__surgery;Gynecologic Surgical Procedures__methods;Health Priorities;Humans;Intraoperative Care__methods;Laparoscopy__methods;Laparotomy__methods;Pandemics;Pneumonia, Viral__epidemiology;Postoperative Care__methods;Practice Guidelines as Topic;Preoperative Care__methods;Withholding Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2 | E Nohuz;G Dubernard;G Lamblin;K Lebail-Carval;P Chabert;G Chêne | COVID-19;Chirurgie gynécologique;Coronavirus;Cœlioscopie;Gynecological surgery;Laparoscopy;SARS-CoV-2 | 2020-04-18 02:00:00+02:00 | 32311508 | FR | Service de gynécologie-obstétrique, hôpital Femme-Mère-Enfant (HFME), hospices civils de Lyon, 59, boulevard Pinel, 69120 Lyon-Bron, France. Electronic address: erdogan.nohuz@chu-lyon.fr.;Service de gynécologie-obstétrique, hôpital de la Croix-Rousse, hospices civils de Lyon, 103, Grande Rue de la Croix-Rousse, 69004 Lyon, France.;Service de gynécologie-obstétrique, hôpital Femme-Mère-Enfant (HFME), hospices civils de Lyon, 59, boulevard Pinel, 69120 Lyon-Bron, France.;Service de gynécologie-obstétrique, hôpital Femme-Mère-Enfant (HFME), hospices civils de Lyon, 59, boulevard Pinel, 69120 Lyon-Bron, France, EMR 3738, université Claude-Bernard Lyon 1, 69000 Lyon, France. | 229 | ||||||
| Letter;Comment | en | Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. | https://www.ncbi.nlm.nih.gov/pubmed/32331979 | 2020-04-19 02:00:00+02:00 | pubmed | Azithromycin;Betacoronavirus;Cardiovascular Diseases;Chloroquine;Coronavirus Infections__drug therapy;Humans;Hydroxychloroquine;Pandemics;Pneumonia, Viral;Torsades de Pointes;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Christian Funck-Brentano;Joe-Elie Salem;Lee S Nguyen;Milou-Daniel Drici;Dan M Roden | Azithromycin;Azithromycine;Chloroquine;Hydroxychloroquine;Long QT syndrome;Syndrome du QT long;Torsade de Pointes | 2020-04-15 02:00:00+02:00 | 32331979 | FR;US | Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France. Electronic address: christian.funck-brentano@aphp.fr.;Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France.;Intensive Care Medicine department, Cochin University Hospital, AP-HP Centre, 75014 Paris, France.;Department of Pharmacology and Toxicology, PharmacoVigilance Centre, Hôpital de Cimiez, University of Nice Côte d'Azur Medical Centre, 06003, Nice, France.;Department of Medicine, Vanderbilt University Medical Centre, Nashville, TN, USA. | 231 | ||||||
| Case Reports;Letter | en | Immune Thrombocytopenic Purpura in a Patient with Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32294340 | 2020-04-19 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__complications;Female;Hashimoto Disease__complications;Humans;Hypertension__complications;Pandemics;Platelet Count;Pneumonia, Viral__complications;Purpura, Thrombocytopenic, Idiopathic__etiology;Subarachnoid Hemorrhage__etiology;Thyroiditis, Autoimmune__complications;COVID-19;Hypothyroidism, Autoimmune;severe acute respiratory syndrome coronavirus 2 | Abrar-Ahmad Zulfiqar;Noël Lorenzo-Villalba;Patrick Hassler;Emmanuel Andrès | 2020-04-15 02:00:00+02:00 | 32294340 | FR | Hôpitaux Universitaires de Strasbourg, Strasbourg, France abzulfiqar@gmail.com.;Centre Hospitalier de Haguenau, Haguenau, France.;Hôpitaux Universitaires de Strasbourg, Strasbourg, France. | 236 | |||||||
| Letter | en | Smell and taste dysfunction in patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32304629 | 2020-04-19 02:00:00+02:00 | pubmed | Michael S Xydakis;Puya Dehgani-Mobaraki;Eric H Holbrook;Urban W Geisthoff;Christian Bauer;Charlotte Hautefort;Philippe Herman;Geoffrey T Manley;Dina M Lyon;Claire Hopkins | 2020-04-15 02:00:00+02:00 | 32304629 | FR;GB;US;IT;DE | Department of Defense, United States Air Force Medical Corp, Wright-Patterson Air Force Base, OH 45433, USA. Electronic address: michael.xydakis@us.af.mil.;Associazione Naso Sano, Umbria Regional Registry of Volunteer Activities, Corciano, Italy.;Harvard University, Massachusetts Eye and Ear, Boston, MA, USA.;Philipps University Marburg, Marburg, Germany.;Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, INSERM U1141, Université of Paris, Paris, France.;University of California, San Francisco, CA, USA.;Air Force Research Lab, Wright-Patterson Air Force Base, OH 45433, USA.;Guy's and St Thomas' Hospital, London Bridge Hospital, London, UK. | 238 | ||||||||
| 10.1016/j.medin.2020.04.006 | Journal Article | en | Ethical recommendations for a difficult decision-making in intensive care units due to the exceptional situation of crisis by the COVID-19 pandemia: A rapid review & consensus of experts. | https://www.ncbi.nlm.nih.gov/pubmed/32402532 | In view of the exceptional public health situation caused by the COVID-19 pandemic, a consensus work has been promoted from the ethics group of the Spanish Society of Intensive, Critical Medicine and Coronary Units (SEMICYUC), with the objective of finding some answers from ethics to the crossroads between the increase of people with intensive care needs and the effective availability of means. In a very short period, the medical practice framework has been changed to a 'catastrophe medicine' scenario, with the consequent change in the decision-making parameters. In this context, the allocation of resources or the prioritization of treatment become crucial elements, and it is important to have an ethical reference framework to be able to make the necessary clinical decisions. For this, a process of narrative review of the evidence has been carried out, followed by a unsystematic consensus of experts, which has resulted in both the publication of a position paper and recommendations from SEMICYUC itself, and the consensus between 18 scientific societies and 5 institutes/chairs of bioethics and palliative care of a framework document of reference for general ethical recommendations in this context of crisis. | 0210-5691 | 2020-04-19 02:00:00+02:00 | pubmed | Medicina Intensiva | O Rubio;A Estella;L Cabre;I Saralegui-Reta;M C Martin;L Zapata;M Esquerda;R Ferrer;A Castellanos;J Trenado;J Amblas | Atención de crisis;Catastrophe;Catástrofe;Crisis care;Ethics;ICU;Pandemia;Pandemic;UCI;Ética | 2020-04-15 02:00:00+02:00 | 32402532 | FR;ES;PS | Cuidados Intensivos, Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Barcelona, España. Electronic address: orubio@althaia.cat.;Cuidados Intensivos, Hospital Universitario de Jerez, Jerez de la Frontera, Cádiz, España.;Cuidados Intensivos, Comité de Bioética de Cataluña, Catalunya, España.;Cuidados Intensivos, Hospital Universitario de Áraba, Osakidetza Araba, Vitoria-Gasteiz, España.;Servicio de Medicina Intensiva, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, España.;Cuidados Intensivos, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Instituto Borja de Bioética, Esplugues de Llobregat, Barcelona, España.;Servicio de Medicina Intensiva, Hospital Universitario Vall de Hebron, Barcelona, España.;Área de Medicina Crítica, Hospital Universitario y Politécnico La Fe, Valencia, España.;Servicio de Medicina Intensiva, Hospital Universitario Mútua de Terrassa, Terrassa, Barcelona, España.;Geriatría y Cuidados paliativos, Hospital Universitario de la Santa Creu de Vic, Central Catalonia Chronicity Research Group (C3RG), Universitat de Vic-UCC, Vic, Barcelona, España. | 244 | |||
| 10.1002/hed.26164 | Journal Article | en | COVID-19 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. | https://www.ncbi.nlm.nih.gov/pubmed/32270581 | The 2019 novel coronavirus disease (COVID-19) is a highly contagious zoonosis produced by SARS-CoV-2 that is spread human-to-human by respiratory secretions. It was declared by the WHO as a public health emergency. The most susceptible populations, needing mechanical ventilation, are the elderly and people with associated comorbidities. There is an important risk of contagion for anesthetists, dentists, head and neck surgeons, maxillofacial surgeons, ophthalmologists, and otolaryngologists. Health workers represent between 3.8% and 20% of the infected population; some 15% will develop severe complaints and among them, many will lose their lives. A large number of patients do not have overt signs and symptoms (fever/respiratory), yet pose a real risk to surgeons (who should know this fact and must therefore apply respiratory protective strategies for all patients they encounter). All interventions that have the potential to aerosolize aerodigestive secretions should be avoided or used only when mandatory. Health workers who are: pregnant, over 55 to 65 years of age, with a history of chronic diseases (uncontrolled hypertension, diabetes mellitus, chronic obstructive pulmonary diseases, and all clinical scenarios where immunosuppression is feasible, including that induced to treat chronic inflammatory conditions and organ transplants) should avoid the clinical attention of a potentially infected patient. Health care facilities should prioritize urgent and emergency visits and procedures until the present condition stabilizes; truly elective care should cease and discussed on a case-by-case basis for patients with cancer. For those who are working with COVID-19 infected patients' isolation is compulsory in the following settings: (a) unprotected close contact with COVID-19 pneumonia patients; (b) onset of fever, cough, shortness of breath, and other symptoms (gastrointestinal complaints, anosmia, and dysgeusia have been reported in a minority of cases). For any care or intervention in the upper aerodigestive tract region, irrespective of the setting and a confirmed diagnosis (eg, rhinoscopy or flexible laryngoscopy in the outpatient setting and tracheostomy or rigid endoscopy under anesthesia), it is strongly recommended that all health care personnel wear personal protective equipment such as N95, gown, cap, eye protection, and gloves. The procedures described are essential in trying to maintain safety of health care workers during COVID-19 pandemic. In particular, otolaryngologists, head and neck, and maxillofacial surgeons are per se exposed to the greatest risk of infection while caring for COVID-19 positive subjects, and their protection should be considered a priority in the present circumstances. | 1043-3074,1097-0347 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Otolaryngology;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Practice Patterns, Physicians';COVID-19;severe acute respiratory syndrome coronavirus 2 | Head & Neck | Luiz P Kowalski;Alvaro Sanabria;John A Ridge;Wai Tong Ng;Remco de Bree;Alessandra Rinaldo;Robert P Takes;Antti A Mäkitie;Andre L Carvalho;Carol R Bradford;Vinidh Paleri;Dana M Hartl;Vincent Vander Poorten;Iain J Nixon;Cesare Piazza;Peter D Lacy;Juan P Rodrigo;Orlando Guntinas-Lichius;William M Mendenhall;Anil D'Cruz;Anne W M Lee;Alfio Ferlito | COVID-19;contamination;head neck;otolaryngology;risk of contamination;surgery | 2020-04-15 02:00:00+02:00 | 32270581 | SE;FR;IE;CO;FI;CN;GB;US;HK;BR;IT;NL;ES;IN;BE;DE | Head and Neck Surgery Department, University of Sao Paulo Medical School, Sao Paulo, Brazil.;Department of Head and Neck Surgery and Otorhinolaryngology, A C Camargo Cancer Center, Sao Paulo, Brazil.;Department of Surgery, School of Medicine, Universidad de Antioquia, Centro de Excelencia en Cirugia de Cabeza y Cuello-CEXCA, Medellin, Colombia.;Head and Neck Surgery Section, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.;Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.;Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.;University of Udine School of Medicine, Udine, Italy.;Department of Otolaryngology-Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.;Department of Otorhinolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.;Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.;Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute and Karolinska Hospital, Stockholm, Sweden.;Screening Group, International Agency for Research in Cancer. IARC, Lyon, France.;Department of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.;Head and Neck Unit, The Royal Marsden Hospital, London, UK.;Department of Otolaryngology Head and Neck Surgery, Institut Gustave Roussy and University Paris-Sud, Villejuif Cedex, France.;Department of Oncology, Section Head and Neck Oncology, KU Leuven, Leuven, Belgium.;Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.;Department of Otolaryngology, Head and Neck Surgery, NHS Lothian, University of Edinburgh, Edinburgh, UK.;Department of Otorhinolaryngology, Maxillofacial, and Thyroid Surgery, Fondazione IRCCS, National Cancer Institute of Milan, University of Milan, Milan, Italy.;Department of Otolaryngology, Beaumont Hospital, Dublin, Ireland.;Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.;Department of Otorhinolaryngology, Institute of Phoniatry/Pedaudiology, Jena University Hospital, Jena, Germany.;Department of Radiation Oncology, University of Florida, Gainesville, Florida, USA.;Head Neck Services, Tata Memorial Hospital, Mumbai, Maharashtra, India.;Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.;International Head and Neck Scientific Group, Udine, Italy. | 247 | ||
| 10.7326/m20-1301 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review. | https://www.ncbi.nlm.nih.gov/pubmed/32282894 | Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase polymerase chain reaction-based assays performed in a laboratory on respiratory specimens are the reference standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging. Although excellent tools exist for the diagnosis of symptomatic patients in well-equipped laboratories, important gaps remain in screening asymptomatic persons in the incubation phase, as well as in the accurate determination of live viral shedding during convalescence to inform decisions to end isolation. Many affluent countries have encountered challenges in test delivery and specimen collection that have inhibited rapid increases in testing capacity. These challenges may be even greater in low-resource settings. Urgent clinical and public health needs currently drive an unprecedented global effort to increase testing capacity for SARS-CoV-2 infection. Here, the authors review the current array of tests for SARS-CoV-2, highlight gaps in current diagnostic capacity, and propose potential solutions. | 0003-4819,1539-3704 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Biomarkers__blood;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Humans;Pandemics;Pneumonia, Viral__diagnosis;Point-of-Care Testing;Radiography, Thoracic;Real-Time Polymerase Chain Reaction;Serologic Tests;Specimen Handling__methods;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Annals of Internal Medicine | Matthew P Cheng;Jesse Papenburg;Michaël Desjardins;Sanjat Kanjilal;Caroline Quach;Michael Libman;Sabine Dittrich;Cedric P Yansouni | Antibodies;Antigens;COVID-19;Cells;Infectious disease immunology;Nucleic acids;Prevention, policy, and public health;Pulmonary diseases;Research laboratories;Upper respiratory tract infections | 2020-04-13 02:00:00+02:00 | 32282894 | FR;CA;CH;GB;US | McGill University Health Centre and McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada (M.P.C.).;McGill Interdisciplinary Initiative in Infection and Immunity and Montreal Children's Hospital, Montreal, Quebec, Canada (J.P.).;Brigham and Women's Hospital, Boston, Massachusetts, and Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada (M.D.).;Brigham and Women's Hospital, Harvard Medical School, and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (S.K.).;CHU Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada (C.Q.).;McGill University Health Centre, McGill Interdisciplinary Initiative in Infection and Immunity, and McGill University, Montreal, Quebec, Canada (M.L., C.P.Y.).;Foundation of Innovative New Diagnostics, Malaria and Fever Program, Geneva, Switzerland, and University of Oxford, Oxford, United Kingdom (S.D.). | 257 | ||
| 10.1136/neurintsurg-2020-016137 | Journal Article;Review | en | European Society of Minimally Invasive Neurological Therapy (ESMINT) recommendations for optimal interventional neurovascular management in the COVID-19 era. | https://www.ncbi.nlm.nih.gov/pubmed/32303584 | 1759-8478,1759-8486 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Brain Ischemia__diagnosis;Coronavirus Infections__diagnosis;Disease Management;Europe__epidemiology;Health Personnel__standards;Humans;Nervous System Diseases__diagnosis;Pandemics;Personal Protective Equipment__standards;Pneumonia, Viral__diagnosis;Societies, Medical__standards;Stroke__diagnosis;Vascular Diseases__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of NeuroInterventional Surgery | Mohamed Aggour;Phil White;Zsolt Kulcsar;Jens Fiehler;Patrick Brouwer | infection | 2020-04-17 02:00:00+02:00 | 32303584 | SE;FR;CH;GB;NL;DE | Saint Etienne, Rhone-Alpes, France aggour.mohamed@gmail.com.;Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK.;Neuroradiology, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.;Neuroradiology, Zurich University Hospital, Zurich, Switzerland.;Department of Neuroradiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany.;Neuroradiology, Karolinska Universitetssjukhuset, Stockholm, Sweden.;University NeuroVascular Center - UNVC, LUMC Leiden / HMC The Hague, Netherlands. | 268 | |||
| Letter;Comment | en | PET imaging of COVID-19: the target and the number. | https://www.ncbi.nlm.nih.gov/pubmed/32303786 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Fluorodeoxyglucose F18;Pandemics;Pneumonia, Viral;Positron Emission Tomography Computed Tomography;COVID-19;severe acute respiratory syndrome coronavirus 2 | E Guedj;A Verger;S Cammilleri | 2020-04-17 02:00:00+02:00 | 32303786 | FR | Aix-Marseille Université, CNRS, Ecole Centrale Marseille, UMR 7249, Institut Fresnel, Marseille, France. eric.guedj@ap-hm.fr.;Department of Nuclear Medicine, Assistance Publique des Hôpitaux de Marseille, Timone University Hospital, Marseille, France. eric.guedj@ap-hm.fr.;CERIMED, Aix-Marseille Université, Marseille, France. eric.guedj@ap-hm.fr.;Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, F-54000, Nancy, France.;IADI, Université de Lorraine, INSERM U1254, F-54000, Nancy, France.;Aix-Marseille Université, CNRS, Ecole Centrale Marseille, UMR 7249, Institut Fresnel, Marseille, France.;Department of Nuclear Medicine, Assistance Publique des Hôpitaux de Marseille, Timone University Hospital, Marseille, France.;CERIMED, Aix-Marseille Université, Marseille, France. | 273 | |||||||
| 10.1016/j.jfo.2020.04.002 | Case Reports;Journal Article | en | Ocular manifestation as first sign of Coronavirus Disease 2019 (COVID-19): Interest of telemedicine during the pandemic context. | https://www.ncbi.nlm.nih.gov/pubmed/32334847 | We report here the case of a 27-year-old man who consulted by telemedicine during the Coronavirus disease 2019 (COVID-19) pandemic, due to foreign body sensation and left eye redness. Examination revealed unilateral eyelid edema and moderate conjunctival hyperemia. A few hours later, the patient experienced intense headache and developed fever, cough and severe dyspnea. A nasopharyngeal swab proved positive for SARS-CoV-2. This case demonstrates that conjunctivitis can be the inaugural manifestation of the COVID-19 infection. It illustrates the interest of telemedicine in ophthalmology during the COVID-19 pandemic, since moderate conjunctival hyperemia can be the first sign of a severe respiratory distress. | 0181-5512 | 2020-04-19 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Conjunctivitis, Viral__virology;Coronavirus Infections__diagnosis;Humans;Male;Ophthalmology;Pandemics;Pneumonia, Viral__diagnosis;Telemedicine;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | A Daruich;D Martin;D Bremond-Gignac | COVID-19;Conjonctivite;Conjunctivitis;Eye;Manifestation oculaire;Ocular;Ophtalmologie;Ophthalmology;SARS-CoV-2;SRAS-CoV-2;Telemedicine;Télémédecine | 2020-04-17 02:00:00+02:00 | 32334847 | FR;AR | Ophthalmology department, hôpital universitaire Necker-Enfants Malades, AP-HP université de Paris, 149, rue de Sèvres, 75015 Paris, France, INSERM, UMRS1138, Team 17, From physiopathology of ocular diseases to clinical development, université Sorbonne Paris Cité, Centre de recherche des cordeliers, 15, rue de l'école de médecine, Paris, France.;Instituto de ojos y oídos, avenida Belgrano 647, Resistencia, Chaco, Argentina.;Ophthalmology department, hôpital universitaire Necker-Enfants Malades, AP-HP université de Paris, 149, rue de Sèvres, 75015 Paris, France, INSERM, UMRS1138, Team 17, From physiopathology of ocular diseases to clinical development, université Sorbonne Paris Cité, Centre de recherche des cordeliers, 15, rue de l'école de médecine, Paris, France. Electronic address: dominique.bremond@aphp.fr. | 275 | ||
| 10.1055/a-1154-8768 | Editorial | en | COVID-19: How to select patients for endoscopy and how to reschedule the procedures? | https://www.ncbi.nlm.nih.gov/pubmed/32356849 | 2364-3722,2196-9736 | 2020-04-19 02:00:00+02:00 | pubmed | Endoscopy International Open | Thierry Ponchon;Stanislas Chaussade | 2020-04-17 02:00:00+02:00 | 32356849 | FR | Edouard Herriot Hospital - Hepatogastroenterology, Lyon, France.;Cochin Hospital - Gastroenterology, Paris, France. | 279 | |||||
| Journal Article;Comment | en | Mental health during the coronavirus disease 2019 (Covid-19) pandemic: more is still to be done. | https://www.ncbi.nlm.nih.gov/pubmed/32528618 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus;Coronavirus Infections;Humans;Mental Health;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Francky Teddy Endomba;Dominic Leandry Angong Wouna;Celestin Danwang | Mental health;novel coronavirus;pandemic;psychological support | 2020-04-16 02:00:00+02:00 | 32528618 | FR;BE;CM | Psychiatry Internship Program, University of Bourgogne, 21000 Dijon, France.;Bertoua Regional Hospital, Bertoua, Cameroon.;Epidemiology and Biostatistics Unit, Institute of Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium. | 281 | ||||||
| 10.1053/j.gastro.2020.04.032 | Journal Article | en | Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. | https://www.ncbi.nlm.nih.gov/pubmed/32305331 | 0016-5085 | 2020-04-19 02:00:00+02:00 | pubmed | Gastroenterology | Ferdinando D'Amico;Laurent Peyrin-Biroulet;Silvio Danese | 2020-04-16 02:00:00+02:00 | 32305331 | FR;IT | Department of Biomedical Sciences, Humanitas University, Milan, Italy, Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Biomedical Sciences, Humanitas University, IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center (IRCCS), Milan, Italy. | 287 | |||||
| 10.1016/j.cjca.2020.04.029 | Editorial;Research Support, Non-U.S. Gov't | en | A Focus on COVID-19: Fast and Accurate Information to Guide Management for Pandemic-Related Issues in Cardiac Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32343999 | 0828-282X | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Canada;Cardiovascular Diseases__epidemiology;Coronavirus Infections__epidemiology;Health Information Management;Hospital Rapid Response Team__organization & administration;Humans;Pandemics;Patient Care Management__methods;Pneumonia, Viral__epidemiology;Societies, Medical;Translational Medical Research;COVID-19;severe acute respiratory syndrome coronavirus 2 | Canadian Journal of Cardiology | Stanley Nattel;Michelle Graham;Andrew Krahn | 2020-04-25 02:00:00+02:00 | 32343999 | FR;CA;GB;US;DE | Department of Medicine, Montreal Heart Institute and Université de Montréal, and Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada, IHU Liryc and Fondation Bordeaux Université, Bordeaux, France, and Institute of Pharmacology, West German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Essen, Germany. Electronic address: stanley.nattel@icm-mhi.org.;Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.;Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. | 293 | ||||
| 10.1016/j.jaci.2020.04.026 | Editorial | en | Will environmental impacts of social distancing due to the pandemic caused by SARS-CoV-2 decrease allergic disease? | https://www.ncbi.nlm.nih.gov/pubmed/32348792 | 0091-6749 | 2020-04-26 02:00:00+02:00 | pubmed | Air Pollution__adverse effects;Betacoronavirus;Coronavirus Infections;Environment;Humans;Hypersensitivity__epidemiology;Pandemics__prevention & control;Pneumonia, Viral;Quarantine;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Allergy and Clinical Immunology | Valentin Navel;Frédéric Chiambaretta;Frédéric Dutheil | SARS-CoV-2 pandemic;air pollution;allergic diseases;coronavirus;quarantine | 2020-04-26 02:00:00+02:00 | 32348792 | FR | Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, Clermont-Ferrand, France. Electronic address: valentin.navel@hotmail.fr.;Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, Clermont-Ferrand, France. | 300 | |||
| 10.1016/j.jbspin.2020.03.011 | Editorial;Research Support, Non-U.S. Gov't | en | Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32321634 | 1297-319X | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Complement Activation;Coronavirus Infections__complications;Cytokines__metabolism;Fibromyalgia__virology;Humans;Inflammation__virology;Lung__immunology;Pandemics;Pneumonia, Viral__complications;Severe Acute Respiratory Syndrome__immunology;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Joint Bone Spine | Luca Quartuccio;Luca Semerano;Maurizio Benucci;Marie-Christophe Boissier;Salvatore De Vita | COVID-19;Coronavirus;Cytokine;IL-6;SARS | 2020-04-24 02:00:00+02:00 | 32321634 | FR;IT | Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy. Electronic address: luca.quartuccio@asufc.sanita.fvg.it.;Université Sorbonne Paris Nord, Li2P, Bobigny, France, Inserm U1125, Bobigny, France, Assistance Publique-Hôpitaux de Paris, GH HUPSSD, Rheumatology Department, Bobigny, France.;Rheumatology Unit, S. Giovanni di Dio Hospital, Florence, Italy.;Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy. | 301 | |||
| 10.1093/jtm/taaa063 | Journal Article | en | Pulmonary embolism in a returning traveller with COVID-19 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32330267 | 1195-1982,1708-8305 | 2020-04-26 02:00:00+02:00 | pubmed | Journal of Travel Medicine | Emilie Foch;Nathalie Allou;Thierry Vitry;Laurie Masse;Jérôme Allyn;Michel Andre;Nicolas Allou | COVID-19;D-dimer;SARS-CoV-2;acute pulmonary embolism;clotting;deep vein thrombosis;hypercoagulable;traveller;traveller's thrombosis | 2020-04-25 02:00:00+02:00 | 32330267 | FR | Pneumologie, Centre Hospitalier Universitaire Félix Guyon, Allée des Topazes, 97400 Saint Denis, France.;Radiologie, Centre Hospitalier Universitaire Félix Guyon, Allée des Topazes, 97400 Saint Denis, France.;Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Allée des Topazes, 97400 Saint Denis, France.;Département d'Informatique Clinique, Centre Hospitalier Universitaire Félix Guyon, Allée des Topazes, 97400 Saint Denis, France. | 303 | ||||
| Letter;Comment | en | Comment on 'Cutaneous manifestations in COVID-19: a first perspective' by Recalcati S. | https://www.ncbi.nlm.nih.gov/pubmed/32314436 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Skin Diseases__virology;COVID-19;severe acute respiratory syndrome coronavirus 2 | M Hedou;F Carsuzaa;E Chary;E Hainaut;F Cazenave-Roblot;M Masson Regnault | 2020-04-22 02:00:00+02:00 | 32314436 | FR | Dermatologie, Centre Hospitalo-Universitaire de Poitiers, Poitiers, France.;ORL, Chirurgie Cervico-Maxillo-Faciale et Audiophonologie, Centre Hospitalo-Universitaire de Poitiers, Poitiers, France.;Médecine interne et Maladie infectieuse, Centre Hospitalo-Universitaire de Poitiers, Poitiers, France.;Unité Inserm U1070, Faculté de Médecine et Pharmacie, Poitiers, France. | 308 | |||||||
| 10.1701/3347.33181 | Journal Article | it | [Post-Normal Pandemics: why CoViD-19 requires a new approach to science.] | https://www.ncbi.nlm.nih.gov/pubmed/32319440 | In addressing pandemics, science has never seemed more needed and useful, while at the same time limited and powerless. The existing contract between science and society is falling apart. A new covenant is urgently needed to navigate the days ahead. | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Science__trends;Social Conditions;COVID-19;severe acute respiratory syndrome coronavirus 2 | David Waltner-Toews;Annibale Biggeri;Bruna De Marchi;Silvio Funtowicz;Mario Giampietro;Martin O'Connor;Jerome R Ravetz;Andrea Saltelli;Jeroen P van der Sluijs | 2020-04-23 02:00:00+02:00 | 32319440 | FR;SE;CA;GB;IT;NL;ES | University of Guelph (Canada).;Università di Firenze (Italia).;Universitetet i Bergen (Norvegia).;Universitat Autònoma de Barcelona (Spagna) - Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona (Spagna).;L'Association ePLANETe Blue (Francia) - Université de Paris Saclay (Francia).;University of Oxford (Regno Unito).;Universitetet i Bergen (Norvegia) - Universitat Oberta de Catalunya (Spagna).;Universitetet i Bergen (Norvegia) - Universiteit Utrecht (Paesi Bassi). | 311 | |||||
| Letter;Comment | en | Does nasal screening for Staphylococcus aureus before surgery compromise health care professional safety in the COVID-19 era? | https://www.ncbi.nlm.nih.gov/pubmed/32448698 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;SARS Virus;Staphylococcal Infections;Staphylococcus aureus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nicolas Mayeur;Pierre Berthoumieu;Hélène Charbonneau | 2020-04-22 02:00:00+02:00 | 32448698 | FR | Department of Anesthesiology and Intensive Care Unit, Clinique Pasteur, Toulouse Cedex 03, France.;Department of Cardiothoracic and Vascular Surgery, Clinique Pasteur, Toulouse Cedex 03, France. | 322 | |||||||
| 10.1136/bmjgh-2020-002622 | Journal Article | en | COVID-19: time for paradigm shift in the nexus between local, national and global health. | https://www.ncbi.nlm.nih.gov/pubmed/32399261 | 2059-7908 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections__epidemiology;Disease Outbreaks__prevention & control;Global Health;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | BMJ Global Health | Elisabeth Paul;Garrett W Brown;Valery Ridde | health policy;health systems;prevention strategies;public health | 2020-04-20 02:00:00+02:00 | 32399261 | FR;BE;GB | School of Public Health, Université Libre de Bruxelles, Bruxelles, Belgium.;Tax Institute, Liege University, Liege, Belgium.;Global Health Theme, POLIS, University of Leeds, Leeds, West Yorkshire, UK.;CEPED (IRD-Universités de Paris), INSERM, Institut de recherche pour le developpement, Paris, France. | 340 | |||
| Letter;Comment | en | CORONA-steps for tracheotomy in COVID-19 patients: A staff-safe method for airway management. | https://www.ncbi.nlm.nih.gov/pubmed/32331964 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Tracheostomy;Tracheotomy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Pierre Haen;Jean-Baptiste Caruhel;Sophie Laversanne;Pierre-Yves Cordier | Airway management;Coronavirus disease 2019;Health-care worker;Safety;Tracheostomy | 2020-04-20 02:00:00+02:00 | 32331964 | FR | Department of Maxillofacial Surgery, Laveran Military Teaching Hospital, Laveran Boulevard, 13013 Marseille, France. Electronic address: pierre.haen@yahoo.fr.;Department of Head and Neck Surgery and Maxillofacial Surgery, Percy Military Teaching Hospital, 1 Lieutenant Raoul Batany Street, 92140 Clamart, France.;Department of Maxillofacial Surgery, Laveran Military Teaching Hospital, Laveran Boulevard, 13013 Marseille, France.;Intensive Care Unit, Laveran Military Teaching Hospital, Laveran Boulevard, 13013 Marseille, France. | 343 | ||||||
| 10.1016/j.jviscsurg.2020.04.013 | Journal Article;Review | en | Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups. | https://www.ncbi.nlm.nih.gov/pubmed/32387058 | The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care. | 1878-7886 | 2020-04-26 02:00:00+02:00 | pubmed | Coronavirus Infections;Health Priorities__organization & administration;Humans;Pandemics;Peritoneal Neoplasms__secondary;Pneumonia, Viral;COVID-19 | Journal of Visceral Surgery | O Glehen;V Kepenekian;O Bouché;L Gladieff;C Honore | Coronavirus;Covid-19;Peritoneal metastases;Primary peritoneal tumor | 2020-04-23 02:00:00+02:00 | 32387058 | FR | Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France, EA 3738, Université Lyon 1, Lyon, France. Electronic address: olivier.glehen@chu-lyon.fr.;Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France, EA 3738, Université Lyon 1, Lyon, France.;Service d'hépato-gastro-entérologie et cancérologie digestive, hôpital Robert-Debré, Reims, France.;Département d'oncologie médicale, institut universitaire du cancer de Toulouse, Toulouse, France.;Département de chirurgie, institut Gustave-Roussy, Villejuif, France. | 355 | ||
| 10.1017/s0033291720001336 | Journal Article | en | PTSD as the second tsunami of the SARS-Cov-2 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32326997 | Since the first cases, the coronavirus disease (COVID-19) rapidly spread around the world, with hundred-thousand cases and thousands of deaths. Post-traumatic stress disorder (PTSD) is a common consequence of major disasters. Exceptional epidemic situations also promoted PTSD in the past. Considering that humanity is undergoing the most severe pandemic since Spanish Influenza, the actual pandemic of COVID-19 is very likely to promote PTSD. Moreover, COVID-19 was renamed severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). With a poor understanding of viruses and spreading mechanisms, the evocation of SARS is generating a great anxiety contributing to promote PTSD. Quarantine of infected patients evolved to quarantine of 'infected' towns or popular districts, and then of entire countries. In the families of cases, the brutal death of family members involved a spread of fear and a loss of certainty, promoting PTSD. In the context of disaster medicine with a lack of human and technical resources, healthcare workers could also develop acute stress disorders, potentially degenerating into chronic PTSD. Globally, WHO estimates 30-50% of the population affected by a disaster suffered from diverse psychological distress. PTSD individuals are more at-risk of suicidal ideation, suicide attempt, and deaths by suicide - considering that healthcare workers are already at-risk occupations. We draw attention towards PTSD as a secondary effect of the SARS-Cov-2 pandemic, both for general population, patients, and healthcare workers. Healthcare policies need to take into account preventive strategy of PTSD, and the related risk of suicide, in forthcoming months. | 0033-2917,1469-8978 | 2020-04-26 02:00:00+02:00 | pubmed | Psychological Medicine | Frédéric Dutheil;Laurie Mondillon;Valentin Navel | 2020-04-24 02:00:00+02:00 | 32326997 | FR | Preventive and Occupational Medicine, Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Witty Fit, F-63000Clermont-Ferrand, France.;Physiological and Psychosocial Stress, Université Clermont Auvergne, CNRS, LaPSCo, F-63000Clermont-Ferrand, France.;Ophthalmology, Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, F-63000Clermont-Ferrand, France. | 358 | ||||
| 10.1016/j.eururo.2020.04.039 | Editorial | en | Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32349928 | Non-muscle-invasive bladder cancer patients with COVID-19 are more likely to develop acute respiratory distress syndrome. Thus, several adjustments to the use of intravesical instillations of bacillus Calmette-Guérin should be made during the current pandemic to limit the risk of contamination. | 0302-2838 | 2020-04-26 02:00:00+02:00 | pubmed | Adjuvants, Immunologic__administration & dosage;Administration, Intravesical;Aged;BCG Vaccine__administration & dosage;Betacoronavirus;Coronavirus Infections__complications;Disease Progression;Drug Administration Schedule;Female;Humans;Male;Neoplasm Invasiveness;Pandemics;Pneumonia, Viral__complications;Urinary Bladder Neoplasms__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Urology | Louis Lenfant;Thomas Seisen;Yohann Loriot;Morgan Rouprêt | 2020-04-24 02:00:00+02:00 | 32349928 | FR | Sorbonne University, GRC 5 Predictive onco-uro, APHP, Urology, Pitié-Salpétrière Hospital, 75013 Paris, France.;Department of Cancer Medicine, Gustave Roussy Institute, University Paris-Saclay, Villejuif, France.;Sorbonne University, GRC 5 Predictive onco-uro, APHP, Urology, Pitié-Salpétrière Hospital, 75013 Paris, France. Electronic address: morgan.roupret@aphp.fr. | 368 | |||
| Letter | en | Myositis as a manifestation of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32327427 | 2020-04-26 02:00:00+02:00 | pubmed | Maxime Beydon;Kevin Chevalier;Omar Al Tabaa;Sabrina Hamroun;Anne-Sophie Delettre;Marion Thomas;Julia Herrou;Elodie Riviere;Xavier Mariette | MRI;inflammation;polymyositis | 2020-04-23 02:00:00+02:00 | 32327427 | FR | Department of Rheumatology, Bicetre Hospital, Le Kremlin-Bicêtre, France.;Université Paris-Saclay, INSERM UMR1184, Le Kremlin Bicêtre, France.;Department of Rheumatology, Bicetre Hospital, Le Kremlin-Bicêtre, France xavier.mariette@aphp.fr. | 377 | |||||||
| 10.2217/fon-2020-0313 | Editorial | en | The impact of the coronavirus pandemic on the management of cancer patients in Lebanon: a single institutional experience. | https://www.ncbi.nlm.nih.gov/pubmed/32323581 | 1479-6694,1744-8301 | 2020-04-26 02:00:00+02:00 | pubmed | Coronavirus Infections__diagnosis;Hospitals, University;Humans;Infection Control__methods;Lebanon__epidemiology;Medical Oncology__organization & administration;Neoplasms__epidemiology;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Practice Guidelines as Topic;COVID-19 | Future Oncology | Clarisse Kattan;Hassan Badreddine;Elie Rassy;Hampig Raphael Kourie;Joseph Kattan | COVID-19;Lebanon;cancer patients;coronavirus;middle-income | 2020-04-23 02:00:00+02:00 | 32323581 | FR;LB | Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. | 378 | |||
| 10.1007/s12250-020-00223-4 | Published Erratum | en | Correction to: Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32328916 | The corrected legend is given below. | 1674-0769,1995-820X | 2020-04-26 02:00:00+02:00 | pubmed | Virologica Sinica | Renfei Lu;Xiuming Wu;Zhenzhou Wan;Yingxue Li;Lulu Zuo;Jianru Qin;Xia Jin;Chiyu Zhang | 2020-04-23 02:00:00+02:00 | 32328916 | FR;CN | Clinical Laboratory, Nantong Third Hospital Affiliated to Nantong University, Nantong, 226006, China.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China.;Medical Laboratory of Taizhou Fourth People's Hospital, Taizhou, 225300, China.;College of Life Sciences, Henan Normal University, Xinxiang, 453007, China.;Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China. zhangcy1999@ips.ac.cn. | 381 | ||||
| Letter;Comment | en | Analysis of incidence of thrombotic complications in the presence of competing risks. | https://www.ncbi.nlm.nih.gov/pubmed/32386984 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Critical Illness;Humans;Incidence;Intensive Care Units;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Sabine Mainbourg;Michel Cucherat;Jean-Christophe Lega | 2020-05-03 02:00:00+02:00 | 32386984 | FR | Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR 5558, F-69622 Villeurbanne, France, Département de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Département de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France, Département de pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France.;Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR 5558, F-69622 Villeurbanne, France, Département de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France, Groupe d'Etude Multidisciplinaire des Maladies Thrombotiques (GEMMAT), Hospices Civils de Lyon, Lyon, France. Electronic address: jean-christophe.lega@chu-lyon.fr. | 394 | |||||||
| 10.1016/j.annder.2020.04.006 | Editorial | fr | [After Covid-19: Towards a new dermatology?] | https://www.ncbi.nlm.nih.gov/pubmed/32418776 | 0151-9638 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Dermatology__trends;Humans;Life Change Events;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Annales de Dermatologie et de Vénéréologie | A Petit;L Martin;D Penso-Assathiany;S Consoli;P Assouly;C Velter;L Hefez;J-M Debarre;L Haddad | 2020-05-03 02:00:00+02:00 | 32418776 | FR | Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: antoine.petit@sls.aphp.fr.;Service de dermatologie, CHU, 49100 Angers, France.;Cabinet de dermatologie, 92130 Issy-les-Moulineaux, France.;Cabinet de psychanalyse, 75014 Paris, France.;Centre Sabouraud, 75010 Paris, France.;Cabinet de dermatologie, 75007 Paris, France.;Service de dermatologie, grand hôpital de l'Est Francilien, 77600 Jossigny, France.;Cabinet de dermatologie, Cholet, France, Laboratoire de recherche en droit, université Rennes 1, 35000 Rennes, France.;75017 Paris, France. | 398 | ||||
| Comparative Study;Letter;Research Support, Non-U.S. Gov't | en | Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32360743 | 2020-05-03 02:00:00+02:00 | pubmed | Antibodies, Viral__blood;Betacoronavirus;Coronavirus Infections__blood;Health Personnel;Humans;Neoplasms__blood;Pandemics;Pneumonia, Viral__blood;Retrospective Studies;COVID-19;severe acute respiratory syndrome coronavirus 2 | M L Solodky;C Galvez;B Russias;P Detourbet;V N'Guyen-Bonin;A-L Herr;P Zrounba;J-Y Blay | 2020-05-01 02:00:00+02:00 | 32360743 | FR | Centre Léon Bérard Cancer Center, Lyon, France.;Centre Léon Bérard Cancer Center, Lyon, France, Université Claude Bernard Lyon I, Lyon, France, Unicancer, Paris, France. Electronic address: jean-yves.blay@lyon.unicancer.fr. | 413 | |||||||
| 10.1016/j.eururo.2020.04.063 | Journal Article;Review | en | Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32414626 | The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the treatment of many urologic cancers. | 0302-2838 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Combined Modality Therapy__methods;Coronavirus Infections__complications;Disease Management;Humans;Pandemics;Pneumonia, Viral__complications;Risk Factors;Time-to-Treatment__organization & administration;Triage__organization & administration;Urogenital Neoplasms__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Urology | Christopher J D Wallis;Giacomo Novara;Laura Marandino;Axel Bex;Ashish M Kamat;R Jeffrey Karnes;Todd M Morgan;Nicolas Mottet;Silke Gillessen;Alberto Bossi;Morgan Roupret;Thomas Powles;Andrea Necchi;James W F Catto;Zachary Klaassen | Bladder cancer;Coronavirus;Coronavirus disease 2019;Delayed treatment;Kidney cancer;Penile cancer;Prostate cancer;Sstemic therapy;Surgery;Testicular cancer;Upper tract urothelial carcinoma | 2020-05-03 02:00:00+02:00 | 32414626 | FR;GE;CH;GB;US;IT | Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.;Department of Surgery, Oncology, and Gastroenterology-Urology Clinic, University of Padua, Padua, Italy.;Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science, London, UK.;Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.;Department of Urology, Mayo Clinic, Rochester, MN, USA.;Department of Urology, University of Michigan, Ann Arbor, MI, USA.;Department of Urology, University hospital Nord, St Etienne, France.;Department of Medical Oncology, Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland, Università della Svizzera Italiana, Lugano, Switzerland.;Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.;Urology, GRC n°5, PREDICTIVE ONCO-URO, AP-HP, Pitié Salpetriere Hospital, Sorbonne University, Paris, France, European Section of Onco Urology, EAU.;Barts Cancer Center, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.;Academic Urology Unit, University of Sheffield, Sheffield, UK. Electronic address: j.catto@sheffield.ac.uk.;Department of Surgery, Division of Urology, Augusta University-Medical College of Georgia, Augusta, GA, USA, Georgia Cancer Center, Augusta, GA, USA. Electronic address: zklaassen19@gmail.com. | 416 | ||
| 10.1016/j.encep.2020.04.010 | Journal Article | fr | [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]. | https://www.ncbi.nlm.nih.gov/pubmed/32387014 | The ongoing COVID-19 pandemic comprises a total of more than 2,350,000 cases and 160,000 deaths. The interest in anti-coronavirus drug development has been limited so far and effective methods to prevent or treat coronavirus infections in humans are still lacking. Urgent action is needed to fight this fatal coronavirus infection by reducing the number of infected people along with the infection contagiousness and severity. Since the beginning of the COVID-19 outbreak several weeks ago, we observe in GHU PARIS Psychiatrie & Neurosciences (Sainte-Anne hospital, Paris, France) a lower prevalence of symptomatic and severe forms of COVID-19 infections in psychiatric patients (∼4%) compared to health care professionals (∼14%). Similar observations have been noted in other psychiatric units in France and abroad. Our hypothesis is that psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments. Chlorpromazine (CPZ) is a phenothiazine derivative widely used in clinical routine in the treatment of acute and chronic psychoses. This first antipsychotic medication has been discovered in 1952 by Jean Delay and Pierre Deniker at Sainte-Anne hospital. In addition, to its antipsychotic effects, several in vitro studies have also demonstrated a CPZ antiviral activity via the inhibition of clathrin-mediated endocytosis. Recently, independent studies revealed that CPZ is an anti-MERS-CoV and an anti-SARS-CoV-1 drug. In comparison to other antiviral drugs, the main advantages of CPZ lie in its biodistribution: (i) preclinical and clinical studies have reported a high CPZ concentration in the lungs (20-200 times higher than in plasma), which is critical because of the respiratory tropism of SARS-CoV-2; (ii) CPZ is highly concentrated in saliva (30-100 times higher than in plasma) and could therefore reduce the contagiousness of COVID-19; (iii) CPZ can cross the blood-brain barrier and could therefore prevent the neurological forms of COVID-19. | 0013-7006 | 2020-05-03 02:00:00+02:00 | pubmed | Antiviral Agents__pharmacokinetics;Betacoronavirus;Biomarkers;Blood-Brain Barrier;Chlorpromazine__pharmacokinetics;Clinical Trials, Phase III as Topic__methods;Coronavirus Infections__drug therapy;Cytokines__blood;Dose-Response Relationship, Drug;Drug Repositioning;Endocytosis__drug effects;France__epidemiology;Humans;Lung__metabolism;Mental Disorders__drug therapy;Multicenter Studies as Topic__methods;Pandemics;Patient Selection;Pilot Projects;Pneumonia, Viral__drug therapy;Randomized Controlled Trials as Topic__methods;Research Design;Saliva__metabolism;Severity of Illness Index;Single-Blind Method;Tissue Distribution;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | M Plaze;D Attali;A-C Petit;M Blatzer;E Simon-Loriere;F Vinckier;A Cachia;F Chrétien;R Gaillard | COVID-19;Chlorpromazine;Clinical trial;Essai clinique;Repositionnement de molécules;Repurposing of drugs;SARS-CoV-2 | 2020-04-29 02:00:00+02:00 | 32387014 | FR | GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Université de Paris, Paris, France. Electronic address: m.plaze@ghu-paris.fr.;GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Université de Paris, Paris, France, Physics for medicine Paris, Inserm, ESPCI Paris, CNRS, PSL Research university, université Paris Diderot, Sorbonne Paris Cite, Paris, France.;GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Institut Pasteur, experimental neuropathology unit, Paris, France.;Institut Pasteur, experimental neuropathology unit, Paris, France.;Institut Pasteur, G5 evolutionary genomics of RNA viruses, Paris, France.;GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Université de Paris, Paris, France.;Université de Paris, Institut de Psychiatrie et Neurosciences de Paris, INSERM, Paris, France, Université de Paris, Laboratoire de Psychologie du développement et de l'Éducation de l'Enfant, CNRS, Paris, France.;Institut Pasteur, experimental neuropathology unit, Paris, France, GHU PARIS Psychiatrie et Neurosciences, site Sainte-Anne, service de Neuropathologie, Paris, France.;GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France, Université de Paris, Paris, France, Institut Pasteur, experimental neuropathology unit, Paris, France. | 420 | ||
| 10.1016/j.accpm.2020.04.010 | Journal Article;Review | en | Sedation for critically ill patients with COVID-19: Which specificities? One size does not fit all. | https://www.ncbi.nlm.nih.gov/pubmed/32360979 | 2352-5568 | 2020-05-03 02:00:00+02:00 | pubmed | Analgesics, Opioid__administration & dosage;Betacoronavirus;Coronavirus Infections__complications;Critical Illness;Deep Sedation__adverse effects;Delirium__chemically induced;Drug Therapy, Combination;Hemodynamics__drug effects;Humans;Hypnotics and Sedatives__administration & dosage;Lung Compliance__drug effects;Neuromuscular Blocking Agents__administration & dosage;Pain, Procedural__drug therapy;Pandemics;Pneumonia, Viral__complications;Propofol__administration & dosage;Respiration, Artificial__adverse effects;Respiratory Distress Syndrome, Adult__therapy;Unnecessary Procedures;Ventilator Weaning;Ventilator-Induced Lung Injury__prevention & control;COVID-19;severe acute respiratory syndrome coronavirus 2 | Anaesthesia Critical Care & Pain Medicine | Jean-François Payen;Gérald Chanques;Emmanuel Futier;Lionel Velly;Samir Jaber;Jean-Michel Constantin | COVID-19;Pain;Sedation;Ventilation | 2020-04-29 02:00:00+02:00 | 32360979 | FR | Department of Anaesthesia and Intensive Care, Grenoble-Alpes University Hospital, and Grenoble-Alpes University, Grenoble Institut des Neurosciences, INSERM U1216, 38000 Grenoble, France. Electronic address: jfpayen@univ-grenoble-alpes.fr.;Department of Anaesthesia and Intensive Care, University of Montpellier Saint-Éloi Hospital, and PhyMedExp, University of Montpellier, INSERM, CNRS, 34295 Montpellier cedex 5, France.;Department of Anaesthesia and Intensive Care, Estaing Hospital, and Université Clermont-Auvergne, CNRS, INSERM U-1103, 63000 Clermont-Ferrand, France.;Department of Anaesthesiology and Critical Care Medicine, Aix-Marseille University, AP-HM, University Hospital La Timone, Marseille, France.;Sorbonne University, GRC 29, AP-HP, DMU DREAM, and Department of Anaesthesiology and Critical Care, Pitié-Salpêtrière Hospital, Paris, France. | 427 | |||
| 10.1016/j.chest.2020.04.033 | Editorial | en | When the Game Changes: Guidance to Adjust Sarcoidosis Management During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32360495 | 0012-3692 | 2020-05-03 02:00:00+02:00 | pubmed | Chest | Nadera J Sweiss;Peter Korsten;Huzaefah J Syed;Aamer Syed;Robert P Baughman;Arthur M F Yee;Daniel A Culver;Teresa Sosenko;Arata Azuma;Francesco Bonella;Ulrich Costabel;Wonder P Drake;Marjolein Drent;Elyse E Lower;Dominique Israel-Biet;Remy L M Mostard;Hilario Nunes;Paola Rottoli;Paolo Spagnolo;Athol U Wells;Wim A Wuyts;Marc A Judson | SARS;coronavirus disease;diffuse lung disease;immunosuppressives;sarcoidosis;severe acute respiratory syndrome | 2020-04-29 02:00:00+02:00 | 32360495 | FR;JP;GB;US;IT;NL;BE;DE | Division of Rheumatology, University of Illinois at Chicago, Chicago, IL. Electronic address: nsweiss@uic.edu.;Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.;Department of Internal Medicine, VCU Health, Richmond, VA.;Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH.;Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY.;Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, OH.;Division of Rheumatology, University of Illinois at Chicago, Chicago, IL.;Nippon Medical School, Tokyo, Japan.;Center for Interstitial and Rare Lung Diseases, Department of Pneumology, Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany.;Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN.;Department of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands.;Hôpital Européen Georges Pompidou, Université de Paris, Paris, France.;Department of Respiratory Medicine, Zuyderland Medical Center, Heerlen/Sittard, The Netherlands.;Department of Pulmonology, Avicenne Hospital, Paris, France.;Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.;Respiratory Disease Unit, University of Padova, Padova, Italy.;Royal Brompton Hospital, London, England.;Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium.;Division of Pulmonary and Critical Care Medicine, Albany Medical College, Albany, NY. | 428 | ||||
| Letter | en | Type I IFN immunoprofiling in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32360285 | 2020-05-03 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections__blood;Female;Humans;Interferon Type I__blood;Male;Middle Aged;Pandemics;Pneumonia, Viral__blood;COVID-19;severe acute respiratory syndrome coronavirus 2 | Sophie Trouillet-Assant;Sebastien Viel;Alexandre Gaymard;Sylvie Pons;Jean-Christophe Richard;Magali Perret;Marine Villard;Karen Brengel-Pesce;Bruno Lina;Mehdi Mezidi;Laurent Bitker;Alexandre Belot | 2020-04-29 02:00:00+02:00 | 32360285 | FR | Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France, International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France. Electronic address: sophie.assant@chu-lyon.fr.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, Immunology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France, National Referee Centre for Rheumatic and AutoImmune and Systemic diseases in childrEn (RAISE), Lyon, France, Lyon Immunopathology Federation LIFE, Hospices Civils de Lyon, Lyon, France.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, Virology Department, Infective Agents Institute, National Reference Center for Respiratory Viruses, North Hospital Network, Lyon, France. Electronic address: alexandre.belot@chu-lyon.fr.;Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.;Lyon University, CREATIS, CNRS UMR5220, Inserm U1044, INSA, Lyon, France, Intensive Care Unit, Hospices Civils de Lyon, Lyon, France.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, Immunology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, Virology Department, Infective Agents Institute, National Reference Center for Respiratory Viruses, North Hospital Network, Lyon, France.;International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France, National Referee Centre for Rheumatic and AutoImmune and Systemic diseases in childrEn (RAISE), Lyon, France, Lyon Immunopathology Federation LIFE, Hospices Civils de Lyon, Lyon, France, Pediatric Nephrology, Rheumatology, Dermatology Unit, Hospices Civils de Lyon, Lyon, France. | 432 | |||||||
| Letter;Comment | en | No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. | https://www.ncbi.nlm.nih.gov/pubmed/32360995 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Non-alcoholic Fatty Liver Disease;Pandemics;Pneumonia, Viral;Retrospective Studies;COVID-19;severe acute respiratory syndrome coronavirus 2 | Louise Biquard;Dominique Valla;Pierre-Emmanuel Rautou | 2020-04-30 02:00:00+02:00 | 32360995 | FR | Université de Paris, Centre de recherche sur l'inflammation, Inserm, U1149, CNRS, ERL8252, Paris, France.;Université de Paris, Centre de recherche sur l'inflammation, Inserm, U1149, CNRS, ERL8252, Paris, France, Service d'Hépatologie, DMU Digest, Hôpital Beaujon, AP-HP, Clichy, France, Centre de Référence des Maladies Vasculaires du Foie, French Network for Rare Liver Diseases (FILFOIE), European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hôpital Beaujon, AP-HP, Clichy, France.;Université de Paris, Centre de recherche sur l'inflammation, Inserm, U1149, CNRS, ERL8252, Paris, France, Service d'Hépatologie, DMU Digest, Hôpital Beaujon, AP-HP, Clichy, France, Centre de Référence des Maladies Vasculaires du Foie, French Network for Rare Liver Diseases (FILFOIE), European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hôpital Beaujon, AP-HP, Clichy, France. Electronic address: pierre-emmanuel.rautou@inserm.fr. | 438 | |||||||
| 10.1016/j.acvd.2020.04.002 | Journal Article | en | One train may hide another: Acute cardiovascular diseases could be neglected because of the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32362433 | Coronavirus disease 2019 (COVID-19) is likely to have significant implications for the cardiovascular care of patients. In most countries, containment has already started (on 17 March 2020 in France), and self-quarantine and social distancing are reducing viral contamination and saving lives. However, these considerations may only be the tip of the iceberg; most resources are dedicated to the struggle against COVID-19, and this unprecedented situation may compromise the management of patients admitted with cardiovascular conditions. | 1875-2136 | 2020-05-03 02:00:00+02:00 | pubmed | Acute Disease;Cardiovascular Diseases__diagnosis;Coronavirus Infections__epidemiology;France__epidemiology;Health Care Rationing__statistics & numerical data;Heart Failure__epidemiology;Humans;Myocardial Infarction__epidemiology;Pandemics;Patient Admission__statistics & numerical data;Patient Care__standards;Pneumonia, Viral__epidemiology;COVID-19 | Archives of Cardiovascular Diseases | Fabien Huet;Cyril Prieur;Guillaume Schurtz;Edouard Gerbaud;Stéphane Manzo-Silberman;Gerald Vanzetto;Meyer Elbaz;Victoria Tea;Grégoire Mercier;Benoît Lattuca;Claire Duflos;François Roubille | Acute cardiac care;Acute coronary syndrome;COVID-19;Heart failure;Insuffisance cardiaque;Intensive care unit;Soins cardiaques aigus ,Unité de soins intensifs;Syndrome coronarien aigu | 2020-04-28 02:00:00+02:00 | 32362433 | FR | Department of Cardiology, Hôpital Universitaire de Montpellier, 34295 Montpellier, France, PhyMedExp, Université de Montpellier, Inserm U1046, CNRS UMR 9214, 34295 Montpellier, France.;Department of Cardiology, Hôpital Cardiologique Louis Pradel, 69500 Bron, France.;Department of Cardiology, Institut Coeur Poumons, Hôpital Cardiologique, 59000 Lille, France.;Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut Lévêque, 33604 Pessac, France, Bordeaux Cardio-Thoracic Research Centre, U1045, Bordeaux University, Hôpital Xavier Arnozan, 33600 Pessac, France.;Department of Cardiology, Hôpital Lariboisiere, 75010 Paris, France.;Department of Cardiology, Hôpital de Grenoble, 38700 La Tronche, France.;Department of Cardiology, Hôpital Rangueil, 31400 Toulouse, France.;Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Européen Georges-Pompidou, 75015 Paris, France.;CEPEL, Université de Montpellier, CNRS, 34090 Montpellier, France, Medico-Economic Research Unit, CHU de Montpellier, Université de Montpellier, 34295 Montpellier, France.;Department of Cardiology, CHU de Nimes, 30029 Nimes, France.;CEPEL, Université de Montpellier, CNRS, 34090 Montpellier, France, Clinical Research and Epidemiology Unit, CHU de Montpellier, Université de Montpellier, 34295 Montpellier, France.;Department of Cardiology, Hôpital Universitaire de Montpellier, 34295 Montpellier, France, PhyMedExp, Université de Montpellier, Inserm U1046, CNRS UMR 9214, 34295 Montpellier, France. Electronic address: francois.roubille@gmail.com. | 442 | ||
| 10.1016/j.radonc.2020.04.035 | Journal Article | en | A rapid review of evidence and recommendations from the SIOPE radiation oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises. | https://www.ncbi.nlm.nih.gov/pubmed/32342872 | To derive evidence-based recommendations for the optimal utilisation of resources during unexpected shortage of radiotherapy capacity. | 0167-8140 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Combined Modality Therapy;Coronavirus Infections__prevention & control;Guidelines as Topic;Humans;Neoplasms__radiotherapy;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Radiation Oncology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Radiotherapy and Oncology | Geert O Janssens;Henry C Mandeville;Beate Timmermann;John H Maduro;Claire Alapetite;Laetitia Padovani;Gail Horan;Yasmin Lassen-Ramshad;Karin Dieckmann;Christian Ruebe;Nicky Thorp;Lorenza Gandola;Thankamma Ajithkumar;Tom Boterberg | COVID-19;Coronavirus;Paediatric;Radiotherapy;Resources;Treatment | 2020-04-27 02:00:00+02:00 | 32342872 | FR;BE;GB;AT;IT;NL;DK;DE | Department of Radiation Oncology, University Medical Centre Utrecht, The Netherlands, Princess Maxima Centre for Paediatric Oncology, Utrecht, The Netherlands.;Department of Radiotherapy, The Royal Marsden Hospital, Sutton, United Kingdom, The Institute of Cancer Research, Sutton, United Kingdom.;Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ) and German Cancer Consortium (DKTK), Germany.;Princess Maxima Centre for Paediatric Oncology, Utrecht, The Netherlands, Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, The Netherlands.;Department of Radiation Oncology & Proton Center, Institut Curie, France.;Aix-Marseille University, Oncology Radiotherapy Department, CRCM Inserm, UMR1068, CNRS UMR7258, AMU UM105, Genome Instability and Carcinogenesis, APHM, France.;Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, United Kingdom.;Danish Centre for Particle Therapy, Aarhus, Denmark.;Department of Radiotherapy Medical University Vienna, Austria.;Strahlentherapie und Radioonkologie, Universitätsklinikum des Saarlandes, Homburg, Germany.;Department of Radiotherapy, The Clatterbridge Cancer Centre, Wirral, United Kingdom, The Proton Beam Therapy Centre, The Christie Hospital, Manchester, United Kingdom.;Pediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, United Kingdom. Electronic address: thankamma.ajithkumar@addenbrookes.nhs.uk.;Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium. | 444 | ||
| Case Reports;Letter | fr | [Acute respiratory distress syndrome secondary to SARS-CoV-2 infection in an infant]. | https://www.ncbi.nlm.nih.gov/pubmed/32471720 | 2020-05-03 02:00:00+02:00 | pubmed | Amoxicillin-Potassium Clavulanate Combination__therapeutic use;Anti-Bacterial Agents__administration & dosage;Azithromycin__administration & dosage;Betacoronavirus__isolation & purification;Chloroquine__administration & dosage;Combined Modality Therapy;Coronavirus Infections__complications;Fatal Outcome;Female;Humans;Infant;Morocco__ethnology;Multiple Organ Failure__etiology;Nasopharynx__virology;Pandemics;Pneumonia, Viral__complications;Respiration, Artificial;Respiratory Distress Syndrome, Adult__etiology;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | M Lahfaoui;M Azizi;M Elbakkaoui;R El Amrani;I Kamaoui;H Benhaddou | Child;Death;Décès;Nourrisson;SARS-CoV-2 | 2020-04-27 02:00:00+02:00 | 32471720 | FR;MA | Service de chirurgie pédiatrique, CHU Mohammed VI Oujda, Oujda, Maroc. Electronic address: simo88_6@hotmail.com.;Service de néonatologie, CHU Mohammed VI Oujda, Oujda, Maroc.;Service de Radiologie, CHU Mohammed VI Oujda, Oujda, Maroc.;Service de chirurgie pédiatrique, CHU Mohammed VI Oujda, Oujda, Maroc. | 459 | ||||||
| 10.1016/j.bulcan.2020.04.004 | Editorial | fr | [Impact of the COVID-19 epidemic on requests for initial care for breast cancer]. | https://www.ncbi.nlm.nih.gov/pubmed/32389352 | 0007-4551 | 2020-05-03 02:00:00+02:00 | pubmed | Age Factors;Betacoronavirus;Breast Neoplasms__diagnosis;Coronavirus Infections__diagnosis;Delayed Diagnosis;Delivery of Health Care__organization & administration;Female;France__epidemiology;Health Services Needs and Demand__statistics & numerical data;Humans;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Societies, Medical;Universal Precautions__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Delphine Héquet;Manuel Rodrigues;Anne Tardivon;Adriana Langer;Meryl Dahan;Roman Rouzier;Silvia Takanen;Yulia Kirova;François-Clément Bidard;Paul Cottu | 2020-04-30 02:00:00+02:00 | 32389352 | FR | Institut Curie, département d'oncologie chirurgicale, 35 rue Dailly, 92210 St Cloud, France, INSERM U900, institut Curie, St Cloud, France. Electronic address: delphine.hequet@curie.fr.;Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France, Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France, DNA repair and uveal melanoma (D.R.U.M.), Inserm U830, équipe labellisée par la Ligue nationale contre le cancer, 75005 Paris, France.;Institut Curie, département de radiologie, 26, rue d'Ulm, 75005 Paris, France.;Institut Curie, département de radiologie, 35, rue Dailly, 92210 St Cloud, France.;Institut Curie, département d'oncologie chirurgicale, 35 rue Dailly, 92210 St Cloud, France.;Institut Curie, département d'oncologie chirurgicale, 35 rue Dailly, 92210 St Cloud, France, INSERM U900, institut Curie, St Cloud, France.;Institut Curie, département de radiothérapie, 35 rue Dailly, 92210 St Cloud, France.;Institut Curie, département de radiothérapie, 26, rue d'Ulm, 75005 Paris, France.;Institut Curie, département d'oncologie médicale, 35 rue Dailly, 92210 St Cloud, France, Laboratory of Circulating Tumor Biomarkers, Inserm, institut Curie, UVSQ, Paris Saclay University, St Cloud, Paris, France.;Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France, Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France. | 470 | ||||
| 10.1016/j.canrad.2020.04.003 | Editorial | fr | [Low dose lung radiotherapy for COVID-19-related cytokine storm syndrome: Why not?] | https://www.ncbi.nlm.nih.gov/pubmed/32389579 | 1278-3218 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Cytokine Release Syndrome__etiology;Humans;Immunocompromised Host;Immunosuppression;Lung__radiation effects;Lung Diseases__radiotherapy;Lymphocyte Depletion;Pandemics;Pneumonia, Viral__complications;Radiotherapy Dosage;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cancer/Radiothérapie | J-M Cosset;É Deutsch;L Bazire;J-J Mazeron;C Chargari | 2020-05-01 02:00:00+02:00 | 32389579 | FR | Centre de radiothérapie Charlebourg, groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.;Département d'oncologie radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94600 Villejuif, France, Inserm, U1030 radiothérapie moléculaire et innovations thérapeutiques, 114, rue Édouard-Vaillant, 94805 Villejuif, France, Université Paris-Saclay, 114, rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: eric.deutsch@gustaveroussy.fr.;Centre Antoine-Béclère, 47, rue de la Colonie, 75013 Paris, France.;Département d'oncologie radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94600 Villejuif, France, Inserm, U1030 radiothérapie moléculaire et innovations thérapeutiques, 114, rue Édouard-Vaillant, 94805 Villejuif, France, Université Paris-Saclay, 114, rue Édouard-Vaillant, 94805 Villejuif, France, Service de santé des armées, école du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France, Institut de recherche biomédicale des armées, D19, 91220 Bretigny-sur-Orge, France. | 481 | ||||
| Letter;Comment | en | Our challenge is to adapt the organization of our system to the six stages of the epidemic to go beyond the COVID-19 crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32352560 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | J J Tuech;A Gangloff;L Schwarz | 2020-04-30 02:00:00+02:00 | 32352560 | FR | Department of Digestive Surgery, Rouen, France.;UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, Rouen, France.;Department of Digestive Oncology, Rouen University Hospital, Rouen, France. | 489 | |||||||
| Letter;Comment | en | Working from home in the time of COVID-19: how to best preserve occupational health? | https://www.ncbi.nlm.nih.gov/pubmed/32354748 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Musculoskeletal Diseases__epidemiology;Occupational Health;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Hanifa Bouziri;David R M Smith;Alexis Descatha;William Dab;Kevin Jean | musculoskeletal;occupational health practice;public health;stress | 2020-04-30 02:00:00+02:00 | 32354748 | FR | Laboratoire MESuRS, Conservatoire national des Arts et Métiers, Paris, France hanifa.bouziri@lecnam.net.;Laboratoire MESuRS, Conservatoire national des Arts et Métiers, Paris, France.;Laboratoire Épidémiologie et modélisation de l'Échappement aux Antibiotiques, Institut Pasteur, Paris, France.;Occupational Health Unit-UMS 011 U1168, Université de Versailles St-Quentin-Inserm APHP, Paris, France. | 490 | ||||||
| 10.1016/j.jfo.2020.04.014 | Practice Guideline | fr | [Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?] | https://www.ncbi.nlm.nih.gov/pubmed/32451138 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Antimalarials__administration & dosage;Betacoronavirus;Bone Density Conservation Agents__adverse effects;Contraindications, Drug;Coronavirus Infections__drug therapy;Humans;Hydroxychloroquine__administration & dosage;Obesity__complications;Pandemics;Pneumonia, Viral__drug therapy;Renal Insufficiency__complications;Retinal Diseases__chemically induced;Risk Factors;Tamoxifen__adverse effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | S Defoort-Dhellemmes | 2020-04-30 02:00:00+02:00 | 32451138 | FR | Cite Hospitalière, 2, avenue Oscar-Lambret, 59000 Lille, France. Electronic address: sabine.defoort@chru-lille.fr. | 493 | ||||
| 10.1016/j.anorl.2020.04.013 | Practice Guideline | en | COVID-19 and rhinology, from the consultation room to the operating theatre. | https://www.ncbi.nlm.nih.gov/pubmed/32387072 | The purpose of this article is to give rhinologists advice on how to adapt their standard practice during the COVID-19 pandemic. The main goal of these recommendations is to protect healthcare workers against COVID-19 while continuing to provide emergency care so as to prevent loss of chance for patients. We reviewed our recommendations concerning consultations, medical prescriptions and surgical activity in rhinology. | 1879-7296 | 2020-05-03 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | T Radulesco;B Verillaud;E Béquignon;J-F Papon;R Jankowski;L Le Taillandier De Gabory;P Dessi;A Coste;E Serrano;S Vergez;F Simon;V Couloigner;C Rumeau;J Michel | Allergic rhinitis;COVID-19;Coronavirus;Corticosteroids;Endonasal treatment;Endoscopy;Nasal cavity;Nasal lavages;Nasal spray;Nasopharynx;Otorhinolaryngology;Rhinology;SARS-CoV-2;Sinonasal polyposis;Sinus | 2020-04-30 02:00:00+02:00 | 32387072 | FR | Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, Assistance publique-Hôpitaux de Marseille, Marseille, France.;Department of otorhinolaryngology, head and neck surgery, Lariboisière university hospital, Assistance publique-Hôpitaux de Paris, Paris, France.;Department of otorhinolaryngology, head and neck surgery, Henri Mondor university hospitals, Créteil intercommunal hospital, Assistance publique-Hôpitaux de Paris, Créteil, France.;Department of otorhinolaryngology, head and neck surgery, Bicêtre university hospital, Assistance publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.;Department of otorhinolaryngology, head and neck surgery, Nancy university hospital, Nancy, France.;Department of otorhinolaryngology, head and neck surgery, Pellegrin university hospital, Bordeaux, France.;Department of otorhinolaryngology, head and neck surgery, Larrey university hospital, Toulouse, France.;Oncopole-1, university cancer Institute of Toulouse, Toulouse, France.;Paediatric ENT department, Necker-Enfants malades university hospital, Assistance publique-Hôpitaux de Paris, Paris, France.;Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, Assistance publique-Hôpitaux de Marseille, Marseille, France. Electronic address: justin.michel@ap-hm.fr. | 497 | |||
| 10.4193/rhin20.159 | Journal Article | en | Sniffing out the evidence; It's now time for public health bodies recognize the link between COVID-19 and smell and taste disturbance. | https://www.ncbi.nlm.nih.gov/pubmed/32352450 | Since the outbreak of the pandemic, anecdotal observations have been accumulating rapidly that sudden anosmia and dysgeusia are peculiar symptoms associated with the COVID-19 infection. Prof C. Hopkins, as President of British Rhinological Society, published a letter describing "the loss of sense of smell as a marker of COVID-19 infection" and proposed that adults presenting with anosmia but no other symptoms should self-isolate for seven days. The Hopkins team published the first case report and case series as well as other evidence that isolated sudden onset anosmia (ISOA), should be considered highly suspicious for SARS-CoV-2(1). Subsequently, a larger series of 2428 patients presenting with new onset anosmia during the COVID-19 pandemic has been reported, of whom 16% report loss of sense of smell as an isolated symptom. Only 51% reported the recognized symptoms of cough or fever. A major limitation of this series however, was a lack of access to testing to confirm the COVID-19 status of the patients(2); in the 80 who had been tested 74% were positive. In the same way, the American Academy of Otolaryngology-head and neck surgery (AA0-HNS) proposed "that anosmia could be added to the list of screening tools for possible COVID-19 infection. More, they warrant serious consideration for self-isolation and testing those patients". | 0300-0729 | 2020-05-03 02:00:00+02:00 | pubmed | Rhinology journal | J R Lechien;C Hopkins;S Saussez | 2020-04-30 02:00:00+02:00 | 32352450 | FR;BE;GB;UNK | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS).;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Guys and St Thomas NHS Foundation Trust, London, UK.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Universite Libre de Bruxelles, Brussels, Belgium. | 501 | ||||
| Letter | en | Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. | https://www.ncbi.nlm.nih.gov/pubmed/32354772 | 2020-05-03 02:00:00+02:00 | pubmed | Pierre-Marie Duret;Eden Sebbag;Auriane Mallick;Simon Gravier;Lionel Spielmann;Laurent Messer | antirheumatic agents;arthritis, infectious;biological therapy;spondylitis, ankylosing;tumour necrosis factor inhibitors | 2020-04-30 02:00:00+02:00 | 32354772 | FR | Department of Rheumatology, Hôpitaux Civils de Colmar, Colmar, Alsace, France pierremarie.duret@gmail.com.;Department of Rheumatology-Centre National de Référence des Maladies Systémiques Rares Est Sud-Ouest (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Department of Rheumatology, Hôpitaux Civils de Colmar, Colmar, Alsace, France.;Department of Infectious Diseases, Hopitaux Civils de Colmar, Colmar, Alsace, France. | 502 | |||||||
| 10.1016/j.jfo.2020.04.013 | Journal Article;Practice Guideline | fr | [Neuro-ophthalmologic emergencies during this COVID-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32471746 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Age Factors;Anisocoria__complications;Betacoronavirus;Coronavirus Infections__complications;Emergencies;Eye Diseases__diagnosis;Humans;Oculomotor Nerve Diseases__diagnosis;Pandemics;Papilledema__diagnosis;Pneumonia, Viral__complications;Referral and Consultation;Vision Disorders__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | S Defoort;C Lamirel;V Touitou;C Vignal | 2020-04-30 02:00:00+02:00 | 32471746 | FR | Cité Hospitalière, 2, avenue Oscar Lambret, 59000 Lille, France.;Fondation Ophtalmologique de Rothschild, 29, rue Manin, 75019 Paris, France.;Service d'ophtalmologie, CHU Pitié Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.;Fondation Ophtalmologique de Rothschild, 29, rue Manin, 75019 Paris, France. Electronic address: cvignal@fo-rothschild.fr. | 503 | ||||
| 10.1016/s2666-5247(20)30027-6 | Journal Article | en | Diagnosing COVID-19-associated pulmonary aspergillosis. | https://www.ncbi.nlm.nih.gov/pubmed/32835328 | 2666-5247 | 2020-05-10 02:00:00+02:00 | pubmed | The Lancet Microbe | Paul E Verweij;Jean-Pierre Gangneux;Matteo Bassetti;Roger J M Brüggemann;Oliver A Cornely;Philipp Koehler;Cornelia Lass-Flörl;Frank L van de Veerdonk;Arunaloke Chakrabarti;Martin Hoenigl | 2020-05-10 02:00:00+02:00 | 32835328 | FR;US;IT;NL;DE;IN;AT | Departments of Medical Microbiology, Radboud University Medical Centre, Nijmegen, Netherlands.;Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, Netherlands.;University of Rennes, Centre Hospitalier Universitaire (CHU) de Rennes, Inserm, EHESP, Institut de Recherche en Santé Environnement et Travail - UMR_S 1085, Rennes, France.;Clinica Malattie Infettive, Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere, Genoa, Italy.;Department of Health Sciences, University of Genoa, Genoa, Italy.;Department of Pharmacy, Radboud University Medical Centre, Nijmegen, Netherlands.;Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Faculty of Medicine, University of Cologne, Cologne, Germany.;Department I of Internal Medicine, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.;Excellence Center for Medical Mycology, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.;German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany.;Clinical Trials Centre Cologne, Cologne, Germany.;Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.;Dpeartment of Infectious Diseases, Radboud University Medical Centre, Nijmegen, Netherlands.;Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, CA, USA.;section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria. | 511 | |||||
| 10.1016/j.medmal.2020.05.001 | Journal Article | en | Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32387320 | No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. | 0399-077X | 2020-05-10 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized__therapeutic use;Betacoronavirus__drug effects;Case-Control Studies;Comorbidity;Coronavirus Infections__drug therapy;Critical Illness__epidemiology;Female;France__epidemiology;Humans;Intensive Care Units__statistics & numerical data;Male;Middle Aged;Mortality;Pandemics;Patient Admission__statistics & numerical data;Pneumonia, Viral__drug therapy;Retrospective Studies;Severity of Illness Index;Treatment Outcome;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Médecine et Maladies Infectieuses | T Klopfenstein;S Zayet;A Lohse;J-C Balblanc;J Badie;P-Y Royer;L Toko;C Mezher;N J Kadiane-Oussou;M Bossert;A-M Bozgan;A Charpentier;M-F Roux;R Contreras;I Mazurier;P Dussert;V Gendrin;T Conrozier | COVID-19;Intensive care unit;Mortality;SARS-CoV-2;Tocilizumab | 2020-05-06 02:00:00+02:00 | 32387320 | FR | Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: timothee.klopfenstein@hnfc.fr.;Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: souhail.zayet@gmail.com.;Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Intensive Care Unit Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Pharmacology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Biological Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. | 525 | ||
| 10.1016/j.encep.2020.05.001 | Journal Article;Review | fr | [Suicidal behavior in light of COVID-19 outbreak: Clinical challenges and treatment perspectives]. | https://www.ncbi.nlm.nih.gov/pubmed/32471707 | The COVID-19 pandemic affected today more than 3,000,000 worldwide, and more than half of humanity has been placed in quarantine. The scientific community and the political authorities fear an epidemic of suicide secondary to this crisis. The aim of this review is to analyze the impact of the COVID-19 pandemic on the dimensions of the suicidal process and its interaction with the various risk factors. We also propose innovative strategies to manage suicidal behavior in the context of pandemic. | 0013-7006 | 2020-05-10 02:00:00+02:00 | pubmed | Alcoholic Intoxication__psychology;Artificial Intelligence;Betacoronavirus__physiology;Coronavirus Infections__complications;Cost of Illness;Crisis Intervention__instrumentation;Economic Recession;France__epidemiology;Humans;Inflammation;Loneliness__psychology;Models, Neurological;Pandemics;Pneumonia, Viral__complications;Psychotherapy__methods;Psychotic Disorders__etiology;Quarantine__psychology;Renin-Angiotensin System__physiology;Severe Acute Respiratory Syndrome__epidemiology;Social Isolation__psychology;Stress, Psychological__etiology;Suicidal Ideation;Suicide__prevention & control;Suicide, Attempted__prevention & control;Telemedicine;Vulnerable Populations;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | I Conejero;S Berrouiguet;D Ducasse;M Leboyer;V Jardon;E Olié;P Courtet | COVID-19;Crise économique;Déconnexion sociale;Economic crisis;Prévention;Social disconnection;Suicidal behavior;Suicidal vulnerability;Suicide;Suicide prevention;Vulnérabilité suicidaire | 2020-05-08 02:00:00+02:00 | 32471707 | FR | Inserm, PSNREC, université Montpellier, CHU de Montpellier, Montpellier, France, Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital, CHU de Montpellier, Montpellier, France, FondaMental Foundation, Créteil, France.;CHU de Brest, université de Bretagne Occidentale, Brest, France.;Inserm, fondation FondaMental, université Paris Est Créteil, AP-HP, Paris, France.;Pôle de psychiatrie, médecine légale et médecine en milieu pénitentiaire, CHU de Lille, Lille, France.;Inserm, PSNREC, université Montpellier, CHU de Montpellier, Montpellier, France, Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital, CHU de Montpellier, Montpellier, France, FondaMental Foundation, Créteil, France. Electronic address: philippe.courtet@univ-montp1.fr. | 526 | ||
| 10.1016/j.tmaid.2020.101738 | Journal Article | en | Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. | https://www.ncbi.nlm.nih.gov/pubmed/32387409 | In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19. | 1477-8939 | 2020-05-10 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Antiviral Agents__administration & dosage;Azithromycin__administration & dosage;Betacoronavirus__genetics;Coronavirus Infections__drug therapy;Drug Therapy, Combination;Female;Follow-Up Studies;France;Humans;Hydroxychloroquine__administration & dosage;Male;Middle Aged;Pandemics;Pneumonia, Viral__drug therapy;Polymerase Chain Reaction;Retrospective Studies;Time Factors;Treatment Outcome;Viral Load;Young Adult;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Travel Medicine and Infectious Disease | Matthieu Million;Jean-Christophe Lagier;Philippe Gautret;Philippe Colson;Pierre-Edouard Fournier;Sophie Amrane;Marie Hocquart;Morgane Mailhe;Vera Esteves-Vieira;Barbara Doudier;Camille Aubry;Florian Correard;Audrey Giraud-Gatineau;Yanis Roussel;Cyril Berenger;Nadim Cassir;Piseth Seng;Christine Zandotti;Catherine Dhiver;Isabelle Ravaux;Christelle Tomei;Carole Eldin;Hervé Tissot-Dupont;Stéphane Honoré;Andreas Stein;Alexis Jacquier;Jean-Claude Deharo;Eric Chabrière;Anthony Levasseur;Florence Fenollar;Jean-Marc Rolain;Yolande Obadia;Philippe Brouqui;Michel Drancourt;Bernard La Scola;Philippe Parola;Didier Raoult | Azithromycin;COVID-19;Hydroxychloroquine;SARS-CoV-2 | 2020-05-05 02:00:00+02:00 | 32387409 | FR | IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ., IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France.;Aix Marseille Univ., Laboratoire de Pharmacie Clinique, Marseille, France, AP-HM, hôpital Timone, service Pharmacie, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ., IRD, AP-HM, SSA, VITROME, Marseille, France, Centre d'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille, France, AP-HM, Marseille, France.;Department of Radiology and Cardiovascular Imaging, Aix-Marseille Univ., UMR 7339, CNRS, CRMBM-CEMEREM (Centre de Résonance Magnétique Biologique et Médicale-Centre d'Exploration Métaboliques par Résonance Magnétique), Marseille, France.;AP-HM, Aix Marseille Univ., hôpital Timone, Cardiologie, Rythmologie, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France. Electronic address: didier.raoult@gmail.com. | 531 | ||
| 10.1016/j.meegid.2020.104351 | Journal Article | en | Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32387564 | SARS-CoV-2 is a SARS-like coronavirus of likely zoonotic origin first identified in December 2019 in Wuhan, the capital of China's Hubei province. The virus has since spread globally, resulting in the currently ongoing COVID-19 pandemic. The first whole genome sequence was published on January 5 2020, and thousands of genomes have been sequenced since this date. This resource allows unprecedented insights into the past demography of SARS-CoV-2 but also monitoring of how the virus is adapting to its novel human host, providing information to direct drug and vaccine design. We curated a dataset of 7666 public genome assemblies and analysed the emergence of genomic diversity over time. Our results are in line with previous estimates and point to all sequences sharing a common ancestor towards the end of 2019, supporting this as the period when SARS-CoV-2 jumped into its human host. Due to extensive transmission, the genetic diversity of the virus in several countries recapitulates a large fraction of its worldwide genetic diversity. We identify regions of the SARS-CoV-2 genome that have remained largely invariant to date, and others that have already accumulated diversity. By focusing on mutations which have emerged independently multiple times (homoplasies), we identify 198 filtered recurrent mutations in the SARS-CoV-2 genome. Nearly 80% of the recurrent mutations produced non-synonymous changes at the protein level, suggesting possible ongoing adaptation of SARS-CoV-2. Three sites in Orf1ab in the regions encoding Nsp6, Nsp11, Nsp13, and one in the Spike protein are characterised by a particularly large number of recurrent mutations (>15 events) which may signpost convergent evolution and are of particular interest in the context of adaptation of SARS-CoV-2 to the human host. We additionally provide an interactive user-friendly web-application to query the alignment of the 7666 SARS-CoV-2 genomes. | 1567-1348 | 2020-05-10 02:00:00+02:00 | pubmed | Adaptation, Physiological__genetics;Antiviral Agents;Betacoronavirus__genetics;Coronavirus Infections__prevention & control;Genetic Variation;Genome, Viral;Humans;Likelihood Functions;Mutation;Pandemics;Phylogeny;Pneumonia, Viral__virology;Viral Vaccines;COVID-19;severe acute respiratory syndrome coronavirus 2 | Infection, Genetics and Evolution | Lucy van Dorp;Mislav Acman;Damien Richard;Liam P Shaw;Charlotte E Ford;Louise Ormond;Christopher J Owen;Juanita Pang;Cedric C S Tan;Florencia A T Boshier;Arturo Torres Ortiz;François Balloux | Betacoronavirus;Homoplasies;Mutation;Phylogenetics | 2020-05-05 02:00:00+02:00 | 32387564 | FR;GB;US | UCL Genetics Institute, University College London, London WC1E 6BT, UK. Electronic address: lucy.dorp.12@ucl.ac.uk.;UCL Genetics Institute, University College London, London WC1E 6BT, UK.;Cirad, UMR PVBMT, F-97410, St Pierre, Réunion, France, Université de la Réunion, UMR PVBMT, F-97490, St Denis, Réunion, France.;Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.;UCL Genetics Institute, University College London, London WC1E 6BT, UK, Division of Infection and Immunity, University College London, London WC1E 6BT, UK.;Division of Infection and Immunity, University College London, London WC1E 6BT, UK.;UCL Genetics Institute, University College London, London WC1E 6BT, UK, Department of Infectious Disease, Imperial College, London W2 1NY, UK.;UCL Genetics Institute, University College London, London WC1E 6BT, UK. Electronic address: f.balloux@ucl.ac.uk. | 532 | ||
| 10.1016/s2213-2600(20)30221-6 | Journal Article | en | Airway management for COVID-19: a move towards universal videolaryngoscope? | https://www.ncbi.nlm.nih.gov/pubmed/32536367 | 2213-2600 | 2020-05-10 02:00:00+02:00 | pubmed | Airway Management__methods;Betacoronavirus;Coronavirus Infections__therapy;Humans;Intubation, Intratracheal__methods;Laryngoscopy__methods;Pandemics;Pneumonia, Viral__therapy;Video-Assisted Surgery__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Respiratory Medicine | Audrey De Jong;Emmanuel Pardo;Amélie Rolle;Sandra Bodin-Lario;Yvan Pouzeratte;Samir Jaber | 2020-05-05 02:00:00+02:00 | 32536367 | FR | Intensive Care Unit and Transplantation, Critical Care and Anesthesia Department, Hôpital Saint-Éloi, Montpellier University Hospital, PhyMed Exp INSERM U1046, 34090 Montpellier, France.;Intensive Care Unit, Critical Care and Anesthesia Department, Hôpital Saint-Antoine, APHP, Sorbonne Université, Paris, France.;Intensive Care Unit and Transplantation, Critical Care and Anesthesia Department, Hôpital Saint-Éloi, Montpellier University Hospital, PhyMed Exp INSERM U1046, 34090 Montpellier, France. Electronic address: s-jaber@chu-montpellier.fr. | 534 | ||||
| Letter | en | Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis. | https://www.ncbi.nlm.nih.gov/pubmed/32414510 | 2020-05-10 02:00:00+02:00 | pubmed | Aged;Blood Coagulation;Coronavirus Infections__blood;Extracorporeal Membrane Oxygenation__adverse effects;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__blood;Respiration, Artificial;Respiratory Distress Syndrome, Adult__etiology;Risk;Thrombosis__blood;COVID-19 | Christophe Beyls;Pierre Huette;Osama Abou-Arab;Pascal Berna;Yazine Mahjoub | COVID-19;acute respiratory distress syndrome;anticoagulation;extracorporeal membrane oxygenation;hypercoagulability;thrombosis | 2020-05-04 02:00:00+02:00 | 32414510 | FR | Amiens, France. Electronic address: beyls.christophe@chu-amiens.fr.;Amiens, France. | 536 | ||||||
| 10.1007/s00259-020-04834-7 | Journal Article | en | Tracheobronchitis signs observed on ventilation lung scintigraphy during the course of COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32378021 | 1619-7070,1619-7089 | 2020-05-10 02:00:00+02:00 | pubmed | European Journal of Nuclear Medicine and Molecular Imaging | Antoine Verger;Achraf Bahloul;Saifeddine Melki;Gilles Karcher;Laetitia Imbert;Pierre-Yves Marie | 2020-05-06 02:00:00+02:00 | 32378021 | FR | Department of Nuclear Medicine, CHRU-Nancy, Nancy, F-54000, France.;Nancyclotep Imaging Platform, CHRU-Nancy, Nancy, F-54000, France.;Inserm, IADI, Université de Lorraine, Nancy, F-54000, France.;Department of Nuclear Medicine, CHRU-Nancy, Nancy, F-54000, France. l.imbert@chru-nancy.fr.;Nancyclotep Imaging Platform, CHRU-Nancy, Nancy, F-54000, France. l.imbert@chru-nancy.fr.;Inserm, IADI, Université de Lorraine, Nancy, F-54000, France. l.imbert@chru-nancy.fr.;Inserm, DCAC, Université de Lorraine, Allée du Morvan, Vandœuvre-les-Nancy, F-54000, France. l.imbert@chru-nancy.fr. | 545 | |||||
| 10.1016/j.medin.2020.04.016 | Journal Article;Review | en | Ultrasound in the management of the critically ill patient with SARS-CoV-2 infection (COVID-19): narrative review. | https://www.ncbi.nlm.nih.gov/pubmed/32527471 | The clinical picture of SARS-CoV-2 infection (COVID-19) is characterized in its more severe form, by an acute respiratory failure which can worsen to pneumonia and acute respiratory distress syndrome (ARDS) and get complicated with thrombotic events and heart dysfunction. Therefore, admission to the Intensive Care Unit (ICU) is common. Ultrasound, which has become an everyday tool in the ICU, can be very useful during COVID-19 pandemic, since it provides the clinician with information which can be interpreted and integrated within a global assessment during the physical examination. A description of some of the potential applications of ultrasound is depicted in this document, in order to supply the physicians taking care of these patients with an adapted guide to the intensive care setting. Some of its applications since ICU admission include verification of the correct position of the endotracheal tube, contribution to safe cannulation of lines, and identification of complications and thrombotic events. Furthermore, pleural and lung ultrasound can be an alternative diagnostic test to assess the degree of involvement of the lung parenchyma by means of the evaluation of specific ultrasound patterns, identification of pleural effusions and barotrauma. Echocardiography provides information of heart involvement, detects cor pulmonale and shock states. | 0210-5691 | 2020-05-10 02:00:00+02:00 | pubmed | Medicina Intensiva | V Fraile Gutiérrez;J M Ayuela Azcárate;D Pérez-Torres;L Zapata;A Rodríguez Yakushev;A Ochagavía | COVID-19;Coronavirus;Critically ill;Echocardiography;Echography;Ecocardiografía;Ecografía;Paciente crítico;Ultrasonografía;Ultrasound | 2020-05-04 02:00:00+02:00 | 32527471 | FR;ES | Servicio de Medicina Intensiva, Hospital Universitario Río Hortega, Valladolid, España. Electronic address: vicky_uvi@yahoo.es.;Especialista en Medicina Intensiva, Burgos, España.;Servicio de Medicina Intensiva, Hospital Universitario Río Hortega, Valladolid, España.;Servicio de Medicina Intensiva, Hospital de la Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, Barcelona, España.;Servicio de Medicina Intensiva, Área de Críticos, Corporación Sanitaria Parc Taulí Sabadell, Barcelona, España. | 553 | |||
| Letter | en | A 5-point strategy for improved connection with relatives of critically ill patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32380024 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__psychology;Critical Illness__psychology;Family__psychology;Hospital-Patient Relations;Humans;Pandemics;Pneumonia, Viral__psychology;Visitors to Patients__psychology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Elie Azoulay;Nancy Kentish-Barnes | 2020-05-04 02:00:00+02:00 | 32380024 | FR | Médecine Intensive et Réanimation, Hôpital Saint-Louis AP-HP, Paris University, Paris 75010, France. Electronic address: elie.azoulay@aphp.fr.;Médecine Intensive et Réanimation, Hôpital Saint-Louis AP-HP, Paris University, Paris 75010, France. | 557 | |||||||
| 10.1016/j.ajog.2020.04.039 | Journal Article | en | Evidence for and against vertical transmission for severe acute respiratory syndrome coronavirus 2. | https://www.ncbi.nlm.nih.gov/pubmed/32376317 | COVID-19 can severely affect pregnant women Furthermore, issues regarding vertical transmission of severe acute respiratory syndrome coronavirus 2 are emerging. In patients and neonates who are showing symptoms of coronavirus disease 2019, real-time polymerase chain reaction of nasal and throat swabs, sputum, and feces is performed to detect the presence of severe acute respiratory syndrome coronavirus 2. In addition, real-time polymerase chain reaction of vaginal swabs, amniotic fluid, placenta, cord blood, neonatal blood, or breast milk for the detection of severe acute respiratory syndrome coronavirus 2 did not show substantial results. Viremia was present in 1% of adult patients who were showing symptoms of coronavirus disease 2019. Here, we reviewed 12 articles published between Feb. 10, 2020, and April 4, 2020, that reported on 68 deliveries and 71 neonates with maternal infection in the third trimester of pregnancy. To determine whether infection occurred congenitally or perinatally, perinatal exposure, mode of delivery, and time interval from delivery to the diagnosis of neonatal infection were considered. Neonates with severe acute respiratory syndrome coronavirus 2 infection are usually asymptomatic. In 4 cases, a diagnostic test for severe acute respiratory syndrome coronavirus 2 infection was performed within 48 hours of life. Furthermore, detection rates of real-time polymerase chain reaction and the interpretation of immunoglobulin M and immunoglobulin G antibodies levels in cord and neonatal blood were discussed in relation with the immaturity of the fetal and neonatal immune system. | 0002-9378 | 2020-05-10 02:00:00+02:00 | pubmed | Amniotic Fluid__virology;Betacoronavirus;Cesarean Section;Coronavirus Infections__diagnosis;Female;Humans;Infant, Newborn;Infectious Disease Transmission, Vertical;Pandemics;Placenta__virology;Pneumonia, Viral__diagnosis;Pregnancy;Pregnancy Complications, Infectious__virology;COVID-19;severe acute respiratory syndrome coronavirus 2 | American Journal of Obstetrics and Gynecology | Audrey Lamouroux;Tania Attie-Bitach;Jelena Martinovic;Marianne Leruez-Ville;Yves Ville | fetus;immunoglobulin G;immunoglobulin M;placenta;real-time polymerase chain reaction;severe acute respiratory syndrome coronavirus 2 | 2020-05-04 02:00:00+02:00 | 32376317 | FR | Department of Fetal Pathology and Genetics, Nimes and Montpellier University Hospitals, University of Montpellier, Montpellier, France.;Department of Embryology, Fetal Pathology, and Genetics, Imagine Institute, Necker-Enfants Malades Hospital, University of Paris, Paris, France.;Department of Fetal Pathology, Antoine-Béclère Hospital, Paris Saclay University, Clamart, France.;Departments of Medical Virology, Necker-Enfants Malades Hospital, University of Paris, Paris, France.;Obstetrics and Fetal Medicine, Necker-Enfants Malades Hospital, University of Paris, Paris, France. Electronic address: ville.yves@gmail.com. | 561 | ||
| 10.1016/j.jfo.2020.04.020 | Journal Article;Practice Guideline | fr | [COVID-19 recommendations for ophthalmologists]. | https://www.ncbi.nlm.nih.gov/pubmed/32466832 | 0181-5512 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__prevention & control;France;Humans;Ophthalmologists;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | 2020-05-04 02:00:00+02:00 | 32466832 | FR | 17, VLA d'Alésia, 75014 Paris, France. | 565 | |||||
| 10.1016/j.anorl.2020.04.014 | Practice Guideline | en | Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32482571 | This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections. | 1879-7296 | 2020-05-10 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | P Herman;C Vincent;C Parietti Winkler;N Loundon;V Couloigner;F Tankere;S Tringali;P Gallet;J-F Papon;M Montava;J-P Lavieille;A Charpiot;S Schmerber | Anosmia;Bell's palsy;COVID-19;Prednisone;SARS-CoV-2;Sudden hearing loss | 2020-05-04 02:00:00+02:00 | 32482571 | FR | Department of otorhinolaryngology, head and neck surgery, Lariboisière university hospital, AP-HP, Paris, France. Electronic address: philippe.herman099@gmail.com.;Department of otorhinolaryngology, head and neck surgery, Lille university hospital, Lille, France.;Department of otorhinolaryngology, head and neck surgery, Nancy university hospital, Nancy, France.;Department of otorhinolaryngology, head and neck surgery, Necker hospital for sick children, AP-HP, Paris, France.;Department of otorhinolaryngology, head and neck surgery, La Pitié-Salpêtrière university hospital, AP-HP, Paris, France.;Department of otorhinolaryngology, head and neck surgery, Lyon south university hospital, Lyon, France.;Department of otorhinolaryngology, head and neck surgery, Bicêtre university hospital, AP-HP, Le Kremlin Bicêtre, France.;Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, AP-HM, Marseille, France.;Department of otorhinolaryngology, head and neck surgery, Hautepierre university hospital, Strasbourg, France.;Department of otorhinolaryngology, head and neck surgery, CHU38 university hospital, Grenoble, France. | 566 | |||
| Letter | en | COVID-19 outcomes in patients with hematologic disease. | https://www.ncbi.nlm.nih.gov/pubmed/32376969 | 2020-05-10 02:00:00+02:00 | pubmed | Florent Malard;Alexis Genthon;Eolia Brissot;Zoe van de Wyngaert;Zora Marjanovic;Souhila Ikhlef;Anne Banet;Simona Lapusan;Simona Sestilli;Elise Corre;Annalisa Paviglianiti;Rosa Adaeva;Fella M 'Hammedi-Bouzina;Myriam Labopin;Ollivier Legrand;Rémy Dulery;Mohamad Mohty | 2020-05-06 02:00:00+02:00 | 32376969 | FR | Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France. florent.malard@inserm.fr.;Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France. | 573 | ||||||||
| 10.1016/j.micinf.2020.05.002 | Editorial | en | Could nasal nitric oxide help to mitigate the severity of COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32387333 | The nasal cavity and turbinates play important physiological functions by filtering, warming and humidifying inhaled air. Paranasal sinuses continually produce nitric oxide (NO), a reactive oxygen species that diffuses to the bronchi and lungs to produce bronchodilatory and vasodilatory effects. Studies indicate that NO may also help to reduce respiratory tract infection by inactivating viruses and inhibiting their replication in epithelial cells. In view of the pandemic caused by the novel coronavirus (SARS-CoV-2), clinical trials have been designed to examine the effects of inhaled nitric oxide in COVID-19 subjects. We discuss here additional lifestyle factors such as mouth breathing which may affect the antiviral response against SARS-CoV-2 by bypassing the filtering effect of the nose and by decreasing NO levels in the airways. Simple devices that promote nasal breathing during sleep may help prevent the common cold, suggesting potential benefits against coronavirus infection. In the absence of effective treatments against COVID-19, the alternative strategies proposed here should be considered and studied in more detail. | 1286-4579 | 2020-05-10 02:00:00+02:00 | pubmed | Administration, Intranasal;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Humans;Nitric Oxide__administration & dosage;Pandemics__prevention & control;Pneumonia, Viral__drug therapy;Viral Load__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Microbes and Infection | Jan Martel;Yun-Fei Ko;John D Young;David M Ojcius | Breathing;COVID-19;Coronavirus;Innate immunity;Nitric oxide | 2020-05-06 02:00:00+02:00 | 32387333 | FR;US;TW | Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan, Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.;Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan, Chang Gung Biotechnology Corporation, Taipei, Taiwan, Biochemical Engineering Research Center, Ming Chi University of Technology, New Taipei City, Taiwan.;Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan, Chang Gung Biotechnology Corporation, Taipei, Taiwan.;Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan, Chang Gung Immunology Consortium, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan, Department of Biomedical Sciences, University of the Pacific, Arthur Dugoni School of Dentistry, San Francisco, CA, USA, University of Paris, Paris, France. Electronic address: dojcius@pacific.edu. | 574 | ||
| NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS | 10.1101/2020.05.06.081695 | Preprint | en | Single-cell longitudinal analysis of SARS-CoV-2 infection in human bronchial epithelial cells. | https://www.ncbi.nlm.nih.gov/pubmed/32511382 | SARS-CoV-2, the causative agent of COVID-19, has resulted in more than 3,000,000 infections and 200,000 deaths. There are currently no approved drugs or vaccines for the treatment or prevention of COVID-19. Enhanced understanding of SARS-CoV-2 infection and pathogenesis is critical for the development of therapeutics. To reveal insight into viral replication, cell tropism, and host-viral interactions of SARS-CoV-2 we performed single-cell RNA sequencing of experimentally infected human bronchial epithelial cells (HBECs) in air-liquid interface cultures over a time-course. This revealed novel polyadenylated viral transcripts and highlighted ciliated cells as the major target of infection, which we confirmed by electron microscopy. Over the course of infection, cell tropism of SARS-CoV-2 expands to other epithelial cell types including basal and club cells. Infection induces cell intrinsic expression of type I and type III IFNs and IL6 but not IL1. This results in expression of interferon stimulated genes in both infected and bystander cells. Here, we have conducted an in-depth analysis of SARS-CoV-2 infection in HBECs and provide a detailed characterization of genes, cell types, and cell state changes associated with the infection. | 2020-05-10 02:00:00+02:00 | pubmed | Neal G Ravindra;Mia Madel Alfajaro;Victor Gasque;Jin Wei;Renata B Filler;Nicholas C Huston;Han Wan;Klara Szigeti-Buck;Bao Wang;Ruth R Montgomery;Stephanie C Eisenbarth;Adam Williams;Anna Marie Pyle;Akiko Iwasaki;Tamas L Horvath;Ellen F Foxman;David van Dijk;Craig B Wilen | 2020-05-07 02:00:00+02:00 | 32511382 | FR;US | [{"country": "United States", "agency": "NIAID NIH HHS", "grantid": "K08 AI119139"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "K08 AI128043"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI141609"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R21 AI133440"}] | Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.;Department of Computer Science, Yale University, New Haven, CT, USA.;Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.;Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.;Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Est, Lyon, France.;Département de Bioinformatique, Univ Evry, Université Paris-Saclay, Paris, France.;Department of Molecular Biophysics & Biochemistry, Yale School of Medicine, New Haven, CT, USA.;Department of Molecular, Cellular, and Developmental Biology, Yale School of Medicine, New Haven, CT, USA.;Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, USA.;Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA.;Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.;Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.;The Jackson Laboratory, Farmington, CT, USA.;Howard Hughes Medical Institute, Chevy Chase, MD, USA. | 577 | ||||
| Letter | en | COVID-19 and ethical considerations: Valuable decision-making tools from the leading medical societies in France. | https://www.ncbi.nlm.nih.gov/pubmed/32414630 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Comorbidity;Coronavirus Infections__epidemiology;Critical Care__ethics;Decision Making, Organizational;Decision Support Techniques;France__epidemiology;Health Priorities__ethics;Health Resources__ethics;Health Services Needs and Demand;Humans;Life Tables;Organ Dysfunction Scores;Pandemics;Personal Autonomy;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Resource Allocation__ethics;Societies, Medical;Treatment Refusal__ethics;Triage__ethics;COVID-19;severe acute respiratory syndrome coronavirus 2 | Antoine Lamblin;Sandrine de Montgolfier | 2020-05-07 02:00:00+02:00 | 32414630 | FR | Department of Civilian and Military Anaesthesia, Édouard-Herriot Hospital, Lyon University Hospital, 5, place d'Arsonval, 69003 Lyon, France, UMR ADéS 7268, Aix-Marseille University/EFS/CNRS, Espace éthique méditerranéen, University Hospital La Timone (adults), Marseille, France. Electronic address: antoine.lamblin@chu-lyon.fr.;IRIS Institut de recherche interdisciplinaire sur les enjeux sociaux, UMR 8156 CNRS - 997 Inserm - EHESS - UP13, 74, rue Marcel Cachin, 93017 Bobigny. | 578 | |||||||
| 10.1016/j.schres.2020.05.009 | Case Reports | en | Coronovirus infection as a novel delusional topic. | https://www.ncbi.nlm.nih.gov/pubmed/32404258 | Delusional topics tend to rapidly incorporate popular hot topical issues. Thus, the current coronavirus COVID-19 pandemic has rapidly reached delusional themes in patients with psychiatric disorders. Here we present the clinical case of a Spanish woman with bipolar disorder that included coronavirus infection in her delusional themes even faster than the real infection reached mainland Spain. | 0920-9964 | 2020-05-10 02:00:00+02:00 | pubmed | Schizophrenia Research | Santiago Ovejero;Enrique Baca-García;María Luisa Barrigón | COVID-19;Coronavirus;Delusional topics;Psychosis | 2020-05-08 02:00:00+02:00 | 32404258 | FR;ES;CL | Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain, Department of Psychiatry, Madrid Autonomous University, Madrid, Spain, Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, Spain, Department of Psychiatry, General Hospital of Villalba, Madrid, Spain, Department of Psychiatry, Infanta Elena University Hospital, Valdemoro, Spain, Universidad Catolica del Maule, Talca, Chile, Department of Psychiatry, Centre Hospitalier Universitaire de Nîmes, France.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain, Department of Psychiatry, Madrid Autonomous University, Madrid, Spain. Electronic address: luisa.barrigon@fjd.es. | 580 | |||
| Letter | en | COVID-19 Outbreak in France: Setup and Activities of a Mobile Extracorporeal Membrane Oxygenation Team During the First 3 Weeks. | https://www.ncbi.nlm.nih.gov/pubmed/32457006 | 2020-05-10 02:00:00+02:00 | pubmed | Guillaume Haye;Alex Fourdrain;Osama Abou-Arab;Pascal Berna;Yazine Mahjoub | 2020-05-08 02:00:00+02:00 | 32457006 | FR;UNK | Department of Anaesthesiology and Critical Care Medicine.;Department of Thoracic Surgery, Amiens Picardy University Hospital, Amiens, France. | 583 | ||||||||
| 10.1136/jech-2020-214297 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Importance of collecting data on socioeconomic determinants from the early stage of the COVID-19 outbreak onwards. | https://www.ncbi.nlm.nih.gov/pubmed/32385126 | Disadvantaged socioeconomic position (SEP) is widely associated with disease and mortality, and there is no reason to think this will not be the case for the newly emerged coronavirus disease 2019 (COVID-19) that has reached a pandemic level. Individuals with a more disadvantaged SEP are more likely to be affected by most of the known risk factors of COVID-19. SEP has been previously established as a potential determinant of infectious diseases in general. We hypothesise that SEP plays an important role in the COVID-19 pandemic either directly or indirectly via occupation, living conditions, health-related behaviours, presence of comorbidities and immune functioning. However, the influence of socioeconomic factors on COVID-19 transmission, severity and outcomes is not yet known and is subject to scrutiny and investigation. Here we briefly review the extent to which SEP has been considered as one of the potential risk factors of COVID-19. From 29 eligible studies that reported the characteristics of patients with COVID-19 and their potential risk factors, only one study reported the occupational position of patients with mild or severe disease. This brief overview of the literature highlights that important socioeconomic characteristics are being overlooked when data are collected. As COVID-19 spreads worldwide, it is crucial to collect and report data on socioeconomic determinants as well as race/ethnicity to identify high-risk populations. A systematic recording of socioeconomic characteristics of patients with COVID-19 will be beneficial to identify most vulnerable groups, to identify how SEP relates to COVID-19 and to develop equitable public health prevention measures, guidelines and interventions. | 0143-005X,1470-2738 | 2020-05-10 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Comorbidity;Coronavirus;Coronavirus Infections__epidemiology;Data Collection__methods;Disease Outbreaks__prevention & control;Female;Health Behavior;Humans;Male;Occupations;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Public Health;Risk Factors;Social Conditions;Social Determinants of Health;Socioeconomic Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Epidemiology and Community Health | Saman Khalatbari-Soltani;Robert C Cumming;Cyrille Delpierre;Michelle Kelly-Irving | Ageing;Cancer;Epidemiology;Health inequalities;Inequalities;Life course epidemiology;Longitudinal studies;Social epidemiology;Social inequalities;Stress | 2020-05-08 02:00:00+02:00 | 32385126 | FR;AU | Faculty of Medicine and Health, The University of Sydney School of Public Health, Sydney, Australia saman.khalatbarisoltani@sydney.edu.au.;ARC Centre of Excellence in Population Ageing Research (CEPAR), The University of Sydney, Sydney, Australia.;The University of Sydney School of Public Health, Sydney, Australia.;ARC Centre of Excellence in Population Ageing Research (CEPAR), The University of Sydney Faculty of Medicine and Health, Sydney, Australia.;LEASP, Université Toulouse III Paul Sabatier, Toulouse, France.;Umr 1027, Inserm, Toulouse, France.;IFERISS, Université de Toulouse, Toulouse, France. | 588 | ||
| 10.1016/j.resmer.2020.100758 | Editorial | en | Impact of the Covid-19 pandemic and lung transplantation program in France. | https://www.ncbi.nlm.nih.gov/pubmed/32474398 | 2590-0412 | 2020-05-10 02:00:00+02:00 | pubmed | Respiratory Medicine and Research | C Picard;J Le Pavec;A Tissot | COVID 19;Drug shortage;Lung Transplantation;SARS-CoV-2;Telemedicine | 2020-05-08 02:00:00+02:00 | 32474398 | FR | Respiratory medicine and lung transplantation group, Foch Hospital, 40, rue Worth, 92150 Suresnes, France.;Service de Transplantation, Chirurgie Thoracique et Vasculaire, Centre Chirugical Marie Lannelongue, Hôpital Marie Lannelongue, 133, avenue de la Résistance, 92350 Le Plessis-Robinson, France.;Service de Pneumologie et de Transplantation Pulmonaire, Centre Hospitalier Universitaire de Nantes, hôpital Nord Laennec, boulevard Jacques-Monod, 44093 Saint-Herblain, France. | 589 | ||||
| 10.1177/2048872620923639 | Journal Article | en | Covid-19: implications for prehospital, emergency and hospital care in patients with acute coronary syndromes. | https://www.ncbi.nlm.nih.gov/pubmed/32375487 | Hospitals play a critical role in providing communities with essential medical care during all types of disaster. Depending on their scope and nature, disasters can lead to a rapidly increasing service demand that can overwhelm the functional capacity and safety of hospitals and the healthcare system at large. Planning during the community outbreak of coronavirus disease 2019 (Covid-19) is critical for maintaining healthcare services during our response. This paper describes, besides general measures in times of a pandemic, also the necessary changes in the invasive diagnosis and treatment of patients presenting with different entities of acute coronary syndromes including structural adaptations (networks, spokes and hub centres) and therapeutic adjustments. | 2048-8726,2048-8734 | 2020-05-10 02:00:00+02:00 | pubmed | Acute Coronary Syndrome__diagnosis;Betacoronavirus__isolation & purification;Civil Defense__organization & administration;Coronavirus Infections__complications;Cross Infection__epidemiology;Delivery of Health Care__organization & administration;Disasters;Disease Outbreaks__statistics & numerical data;Emergencies__epidemiology;Emergency Service, Hospital__organization & administration;Facilities and Services Utilization__statistics & numerical data;Hospitals;Humans;Pandemics;Pneumonia, Viral__complications;Safety;Surge Capacity__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Heart Journal: Acute Cardiovascular Care | Kurt Huber;Patrick Goldstein | Covid-19;medical response actions;pandemic;preparedness | 2020-05-07 02:00:00+02:00 | 32375487 | FR;AT | 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Austria.;Medical School, Sigmund Freud University, Austria.;Lille University Hospital and SAMU59, France. | 601 | ||
| 10.1016/j.bulcan.2020.04.007 | Editorial | fr | [Clinical trials during pandemic crisis: How to ensure safety and maintain access to innovation]. | https://www.ncbi.nlm.nih.gov/pubmed/32414537 | 0007-4551 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Trials as Topic__legislation & jurisprudence;Communicable Disease Control__legislation & jurisprudence;Coronavirus Infections__prevention & control;Diffusion of Innovation;France;Government Agencies__organization & administration;Health Services Accessibility;Humans;Inventions;Pandemics__prevention & control;Patient Safety;Pneumonia, Viral__prevention & control;Practice Guidelines as Topic;Therapies, Investigational;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Stéphane Vignot;Olivier Le Blaye;Laurence Fluckiger;Sonia Errard;Benoît Marin;Elodie Chapel | 2020-05-07 02:00:00+02:00 | 32414537 | FR | Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), 143-147, boulevard Anatole France, 93285 Saint-Denis cedex, France. Electronic address: stephane.vignot@ansm.sante.fr.;Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), 143-147, boulevard Anatole France, 93285 Saint-Denis cedex, France.;Direction Générale de la Santé (DGS), 14, avenue Duquesne, 75350 Paris, France. | 604 | ||||
| Letter;Research Support, N.I.H., Extramural;Research Support, U.S. Gov't, Non-P.H.S.;Comment | en | Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable. | https://www.ncbi.nlm.nih.gov/pubmed/32381734 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Phylogeny;Pneumonia, Viral;SARS Virus;Selection Bias;COVID-19;severe acute respiratory syndrome coronavirus 2 | Carla Mavian;Sergei Kosakovsky Pond;Simone Marini;Brittany Rife Magalis;Anne-Mieke Vandamme;Simon Dellicour;Samuel V Scarpino;Charlotte Houldcroft;Julian Villabona-Arenas;Taylor K Paisie;Nídia S Trovão;Christina Boucher;Yun Zhang;Richard H Scheuermann;Olivier Gascuel;Tommy Tsan-Yuk Lam;Marc A Suchard;Ana Abecasis;Eduan Wilkinson;Tulio de Oliveira;Ana I Bento;Heiko A Schmidt;Darren Martin;James Hadfield;Nuno Faria;Nathan D Grubaugh;Richard A Neher;Guy Baele;Philippe Lemey;Tanja Stadler;Jan Albert;Keith A Crandall;Thomas Leitner;Alexandros Stamatakis;Mattia Prosperi;Marco Salemi | 2020-05-07 02:00:00+02:00 | 32381734 | FR;SE;PT;CN;GB;US;HK;CH;ZA;DE;BE;AT | Emerging Pathogens Institute, University of Florida, Gainesville, FL 32609, salemi@pathology.ufl.edu cmavian@ufl.edu m.prosperi@ufl.edu.;Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610.;Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, PA 19122.;Emerging Pathogens Institute, University of Florida, Gainesville, FL 32609.;Department of Epidemiology, University of Florida, Gainesville, FL 32610.;Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.;Center for Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, 1349-008 Lisboa, Portugal.;Spatial Epidemiology Laboratory, Université Libre de Bruxelles, 1050 Bruxelles, Belgium.;Network Science Institute, Northeastern University, Boston, MA 02115.;Department of Medicine, University of Cambridge, Cambridge CB2 3QG, United Kingdom.;Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, United Kingdom.;Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, United Kingdom.;Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD 20892.;Department of Computer & Information Science & Engineering, University of Florida, Gainesville, FL 32611.;Department of Informatics, Craig Venter Institute, La Jolla, CA 92037.;Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA 92037.;Department of Pathology, University of California San Diego, La Jolla, CA 92093.;Unité Bioinformatique Evolutive, Centre de Bioinformatique, Biostatistique et BiologieIntégrative (C3BI)-USR 3756 CNRS and Institut Pasteur, 75015 Paris, France.;State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong SAR, China.;Department of Biomathematics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.;Department of Biostatistics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.;Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095.;KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban 4041, South Africa.;Department of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN 47405.;Max F. Perutz Laboratories, Center for Integrative Bioinformatics Vienna (CIBIV), Medical University of Vienna, University of Vienna, 1030 Vienna, Austria.;Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.;Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.;Department of Zoology, University of Oxford, Oxford OX1 3PS, United Kingdom.;Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510.;Biozentrum, University of Basel, 4056 Basel, Switzerland.;Department of Biosystems Science and Engineering, Swiss Federal Institute of Technology, 4058 Basel, Switzerland.;Department of Microbiology Tumor and Cell Biology, Karolinska Institutet, 17177 Stockholm, Sweden.;Department of Biostatistics & Bioinformatics, Computational Biology Institute, Milken Institute School of Public Health, George Washington University, Washington, DC 20052.;Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545.;Computational Molecular Evolution Group, Heidelberg Institute for Theoretical Studies, 69118 Heidelberg, Germany.;Institute for Theoretical Informatics, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany. | 611 | |||||||
| 10.1038/s41433-020-0944-7 | Journal Article | en | Impact of the COVID-19 lockdown on basic science research in ophthalmology: the experience of a highly specialized research facility in France. | https://www.ncbi.nlm.nih.gov/pubmed/32382143 | 0950-222X,1476-5454 | 2020-05-10 02:00:00+02:00 | pubmed | Academies and Institutes__organization & administration;Betacoronavirus;Biomedical Research__organization & administration;Coronavirus Infections__prevention & control;France;Humans;Ophthalmology;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Workplace__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eye | Marco Nassisi;Isabelle Audo;Christina Zeitz;Juliette Varin;Juliette Wohlschlegel;Vasily Smirnov;Dominique Santiard-Baron;Serge Picaud;José-Alain Sahel | 2020-05-07 02:00:00+02:00 | 32382143 | FR;GB;US | Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France.;CHNO des Quinze-Vingts, DHU Sight Restore, INSERM-DGOS CIC1423, 28 rue de Charenton, F-75012, Paris, France.;Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France. isabelle.audo@inserm.fr.;CHNO des Quinze-Vingts, DHU Sight Restore, INSERM-DGOS CIC1423, 28 rue de Charenton, F-75012, Paris, France. isabelle.audo@inserm.fr.;Institute of Ophthalmology, University College of London, London, EC1V 9EL, UK. isabelle.audo@inserm.fr.;Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, F-75012, Paris, France. christina.zeitz@inserm.fr.;Fondation Ophtalmologique Adolphe de Rothschild, F-75019, Paris, France.;Department of Ophthalmology, University of Pittsburgh Medical School, Pittsburgh, PA, 15213, USA.;Académie des Sciences-Institut de France, F-75006, Paris, France. | 616 | ||||
| 10.1093/ajhp/zxaa146 | Journal Article | en | Clinical trials: Management of investigational products during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32406904 | 1079-2082,1535-2900 | 2020-05-17 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Clinical Trials as Topic;Coronavirus Infections__drug therapy;Documentation;Drugs, Investigational;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19 | American Journal of Health-System Pharmacy | Laurent Flet;Martine Tching-Sin;Adeline Chanat;Pauline Gendre;Annick Tibi | COVID-19;clinical trials;investigational drugs | 2020-05-15 02:00:00+02:00 | 32406904 | FR | Department of Pharmacy Nantes University Hospital Nantes, France.;Agence Générale des Equipements et Produits de Santé Hôpitaux de Paris, France. | 633 | |||
| 10.5588/ijtld.20.0176 | Journal Article | en | Monitoring the COVID-19 pandemic in sub-Saharan Africa: focusing on health facility admissions and deaths. | https://www.ncbi.nlm.nih.gov/pubmed/32398216 | 1027-3719 | 2020-05-17 02:00:00+02:00 | pubmed | Africa South of the Sahara__epidemiology;Betacoronavirus;Coronavirus Infections__epidemiology;Disease Notification__methods;Health Facilities;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | The International Journal of Tuberculosis and Lung Disease | A D Harries;L Martinez;J M Chakaya | 2020-05-14 02:00:00+02:00 | 32398216 | FR;KE;GB;US | International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.;Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, CA, USA.;International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Medicine, Therapeutics, Dermatology and Psychiatry, Kenyatta University, Nairobi, Kenya, <email></email>, Email: adharries@theunion.org. | 637 | ||||
| Letter | en | COVID-19: Act First, Think Later. | https://www.ncbi.nlm.nih.gov/pubmed/32400288 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Communicable Disease Control;Coronavirus Infections__epidemiology;Ethics, Medical;Global Health;Humans;Pandemics__ethics;Pneumonia, Viral__epidemiology;United States__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Henri-Corto Stoeklé;Christian Hervé | 2020-05-13 02:00:00+02:00 | 32400288 | FR;UNK | Foch Hospital.;Université de Paris.;International Academy of Medical Ethics and Public Health, Université de Paris. | 646 | |||||||
| 10.1038/s41409-020-0919-0 | Journal Article;Review | en | The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. | https://www.ncbi.nlm.nih.gov/pubmed/32404975 | The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients. These guidelines were developed by experts from the Infectious Diseases Working Party and have been endorsed by EBMT's scientific council and board. This work intends to provide guidelines for transplant centers, management of transplant candidates and recipients, and donor issues until the COVID-19 pandemic has passed. | 0268-3369,1476-5365 | 2020-05-17 02:00:00+02:00 | pubmed | Bone Marrow Transplantation | Per Ljungman;Malgorzata Mikulska;Rafael de la Camara;Grzegorz W Basak;Christian Chabannon;Selim Corbacioglu;Rafael Duarte;Harry Dolstra;Arjan C Lankester;Mohamad Mohty;Silvia Montoto;John Murray;Régis Peffault de Latour;John A Snowden;Ibrahim Yakoub-Agha;Bregje Verhoeven;Nicolaus Kröger;Jan Styczynski | 2020-05-13 02:00:00+02:00 | 32404975 | FR;SE;GB;IT;PL;NL;ES;DE | Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Per.Ljungman@ki.se.;Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. Per.Ljungman@ki.se.;Division of Infectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Genova, Italy.;Department of Hematology, Hospital de la Princesa, Madrid, Spain.;Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.;Institut Paoli Calmettes & Inserm CBT-1409, Centres d'Investigations Cliniques en Biothérapies, Marseille, France.;Pediatric Hematology, Oncology and Stem Cell Transplantation Department, University of Regensburg, Regensburg, Germany.;Servicio de Hematologia y Hemoterapia, Hospital Universitario Puerta de Hierro, Madrid, Spain.;Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.;Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Centre Leiden, Leiden, the Netherlands.;Department of Hematology, Hospital Saint Antoine, Paris, France.;St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.;The Christie NHS Foundation Trust, Manchester, UK.;BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.;Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.;CHU de Lille, Univ Lille, INSERM, U1285, Lille, France.;Foundation Hematon, Utrecht, the Netherlands.;Department of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.;Pediatric Hematology and Oncology, University Hospital, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland. | 652 | ||||
| Letter | en | Influence of the containment on the epidemiology of maxillo-facial emergencies during the COVID-19 pandemic. Why no more cellulites of odontogenic origin? | https://www.ncbi.nlm.nih.gov/pubmed/32405606 | 2020-05-17 02:00:00+02:00 | pubmed | J D Kün-Darbois;A Kahn;P Corre | Cellulitis;Coronavirus;Non-steroidal anti-inflammatory drugs | 2020-05-13 02:00:00+02:00 | 32405606 | FR | Department of oral and maxillo-facial surgery, Angers University Hospital, 4, rue Larrey, 49933 Angers cedex, France. Electronic address: daniel.kun-darbois@univ-angers.fr.;Department of oral and maxillo-facial surgery, Angers University Hospital, 4, rue Larrey, 49933 Angers cedex, France.;Department of oral and maxillo-facial surgery, Nantes University Hospital, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France. | 655 | |||||||
| 10.1016/j.clinph.2020.05.006 | Journal Article;Review | en | How to carry out and interpret EEG recordings in COVID-19 patients in ICU? | https://www.ncbi.nlm.nih.gov/pubmed/32405259 | There are questions and challenges regarding neurologic complications in COVID-19 patients. EEG is a safe and efficient tool for the evaluation of brain function, even in the context of COVID-19. However, EEG technologists should not be put in danger if obtaining an EEG does not significantly advance diagnosis or change management in the patient. Not every neurologic problem stems from a primary brain injury: confusion, impaired consciousness that evolves to stupor and coma, and headaches are frequent in hypercapnic/hypoxic encephalopathies. In patients with chronic pulmonary disorders, acute symptomatic seizures have been reported in acute respiratory failure in 6%. The clinician should be aware of the various EEG patterns in hypercapnic/hypoxic and anoxic (post-cardiac arrest syndrome) encephalopathies as well as encephalitides. In this emerging pandemic of infectious disease, reduced EEG montages using single-use subdermal EEG needle electrodes may be used in comatose patients. A full 10-20 EEG complement of electrodes with an ECG derivation remains the standard. Under COVID-19 conditions, an expedited study that adequately screens for generalized status epilepticus, most types of regional status epilepticus, encephalopathy or sleep may serve for most clinical questions, using simplified montages may limit the risk of infection to EEG technologists. We recommend noting whether the patient is undergoing or has been placed prone, as well as noting the body and head position during the EEG recording (supine versus prone) to avoid overinterpretation of respiratory, head movement, electrode, muscle or other artifacts. There is slight elevation of intracranial pressure in the prone position. In non-comatose patients, the hyperventilation procedure should be avoided. At present, non-specific EEG findings and abnormalities should not be considered as being specific for COVID-19 related encephalopathy. | 1388-2457 | 2020-05-17 02:00:00+02:00 | pubmed | Brain Diseases__diagnosis;Coronavirus Infections__complications;Critical Care__methods;Electroencephalography__instrumentation;Humans;Pandemics;Patient Positioning__methods;Pneumonia, Viral__complications;Practice Guidelines as Topic;COVID-19 | Clinical Neurophysiology | Philippe Gélisse;Andrea O Rossetti;Pierre Genton;Arielle Crespel;Peter W Kaplan | COVID-19;Coma;EEG;ICU;Prone position | 2020-05-13 02:00:00+02:00 | 32405259 | FR;CH;US | Epilepsy Unit, Hôpital Gui de Chauliac, Montpellier, France, Research Unit (URCMA: Unité de Recherche sur les Comportements et Mouvements Anormaux), INSERM, U661, Montpellier F-34000, France. Electronic address: p-gelisse@chu-montpellier.fr.;Department of Clinical Neuroscience, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.;Neurology Department, Hôpital Saint Charles, 13100 Aix en Provence, France.;Epilepsy Unit, Hôpital Gui de Chauliac, Montpellier, France, Research Unit (URCMA: Unité de Recherche sur les Comportements et Mouvements Anormaux), INSERM, U661, Montpellier F-34000, France.;Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. | 656 | ||
| Case Reports;Letter | en | Prone positioning and high-flow oxygen improved respiratory function in a 25-week pregnant woman with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32405137 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__physiopathology;Female;Humans;Lung__physiopathology;Oxygen Inhalation Therapy__methods;Pandemics;Patient Positioning__methods;Pneumonia, Viral__physiopathology;Pregnancy;Pregnancy Complications, Infectious__physiopathology;Prone Position;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Florence Vibert;Mathilda Kretz;Vincent Thuet;Florian Barthel;Fanny De Marcillac;Philippe Deruelle;Lise Lecointre | 2020-05-13 02:00:00+02:00 | 32405137 | FR | Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: florence.vibert@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: mathilda.kretz@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: vincent.thuet@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: florian.barthel@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: fanny.demarcillac@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: philippe.deruelle@chru-strasbourg.fr.;Hôpitaux universitaires de Strasbourg, 1 rue Molière, 67 200 Strasbourg, France. Electronic address: lise.lecointre@chru-strasbourg.fr. | 661 | |||||||
| 10.1016/j.accpm.2020.05.005 | Journal Article | en | Preliminary pragmatic lessons from the SARS-CoV-2 pandemic in France. | https://www.ncbi.nlm.nih.gov/pubmed/32405518 | The first wave of the SARS-CoV-2 pandemic required an unprecedented and historic increase in critical care capacity on a global scale in France. Authors and members from the ACUTE and REANIMATION committees of the French Society of Anaesthesia and Intensive Care (SFAR) wished to share experience and insights gained during the first weeks of this pandemic. These were summarised following the World Health Organization Response Checklist and detailed according to the subsequent subheadings: 1. Command and Control, 2. Communication, 3. Safety and Security, 4. Triage, 5. Surge Capacity, 6. Continuity of essential services, 7. Human resources, 8. Logistics and supply management, 9. Training/Preparation, 10. Psychological comfort for patients and next of kin, 11. Learning and 12. Post disaster recovery. These experience-based recommendations, consensual across all members from both committees of our national society, establish a practical framework for medical teams, either spared by the first wave of severe COVID patients or preparing for the second one. | 2352-5568 | 2020-05-17 02:00:00+02:00 | pubmed | Bed Conversion;Betacoronavirus;Checklist;Continuity of Patient Care__organization & administration;Coronavirus Infections__epidemiology;Disaster Planning__organization & administration;France__epidemiology;Health Personnel__education;Health Services Accessibility__organization & administration;Health Services Needs and Demand;Humans;Interdisciplinary Communication;Pandemics;Patient Safety;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Professional Staff Committees__organization & administration;Professional-Family Relations;Social Support;Triage__organization & administration;Workforce__organization & administration;World Health Organization;COVID-19;severe acute respiratory syndrome coronavirus 2 | Anaesthesia Critical Care & Pain Medicine | Tobias Gauss;Pierre Pasquier;Olivier Joannes-Boyau;Jean-Michel Constantin;Olivier Langeron;Pierre Bouzat;Julien Pottecher | Critical care;Pandemic;Recommendations;SARS-CoV-2;Surge capacity | 2020-05-13 02:00:00+02:00 | 32405518 | FR | Anesthésie-Réanimation, Hôpital Beaujon, DMU PARABOL AP-HP Nord, Université de Paris, Paris, France.;Percy Military Training Hospital, Clamart, France Val-de-Grâce French Military Medical Academy, Paris, France.;Service d'Anesthésie-Réanimation Sud, Centre Médico-Chirurgical Magellan, Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000 Bordeaux, France.;Réanimation Chirurgicale et Polyvalente, Département d'Anesthésie-Réanimation, Hôpital Universitaire Pitié-Salpêtrière, Paris, France.;Department of Anaesthesia and Intensive Care, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, France.;Grenoble Alps Trauma centre, Grenoble University Hospital, Grenoble Alps University, 38000 Grenoble, France.;Service d'Anesthésie-Réanimation & Médecine Péri-Opératoire, Hôpitaux Universitaires de Strasbourg-FMTS, Université de Strasbourg, Strasbourg, France. Electronic address: julien.pottecher@chru-strasbourg.fr. | 664 | ||
| 10.1016/j.annemergmed.2020.05.018 | Journal Article | en | Preparedness and response to Pediatric CoVID-19 in European Emergency Departments: a survey of the REPEM and PERUKI networks. | https://www.ncbi.nlm.nih.gov/pubmed/32419713 | We aimed to describe the variability and identify gaps in preparedness and response to the COVID-19 pandemic in European EDs caring for children. | 0196-0644 | 2020-05-17 02:00:00+02:00 | pubmed | Annals of Emergency Medicine | Silvia Bressan;Danilo Buonsenso;Ruth Farrugia;Niccolo' Parri;Rianne Oostenbrink;Luigi Titomanlio;Damian Roland;Ruud G Nijman;Ian Maconochie;Liviana Da Dalt;Santiago Mintegi | 2020-05-15 02:00:00+02:00 | 32419713 | FR;ES;GB;IT;NL;MT | Division of Pediatric Emergency Medicine, Department of Women's and Children's Health - University Hospital of Padova, Italy.;Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;Università Cattolica del Sacro Cuore, Roma, Italia.;Department of Child and Adolescent Health, Mater Dei Hospital, Msida, Malta.;Emergency Department & Trauma Center, Ospedale Pediatrico Meyer Firenze, Florence, Italy.;Department general Pediatrics, ErasmusMC - Sophia, Rotterdam, The Netherlands.;Pediatric Emergency Department, Hopital Universitaire Robert-Debre, Paris, France.;SAPPHIRE Group, Health Sciences, Leicester University, Leicester, UK.;Department of Pediatric Emergency Medicine, Division of Medicine, St. Mary's hospital - Imperial College NHS Healthcare Trust, London, London, London, UK.;Faculty of Medicine, Department of Infectious Diseases, Section of Pediatric Infectious Diseases, Imperial College London, UK.;Pediatric Emergency Department, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces. University of the Basque Country, UPV/EHU. Bilbao, Basque Country, Spain. | 667 | ||||
| Letter;Comment | fr | [Asthma and COVID-19: a risk population?] | https://www.ncbi.nlm.nih.gov/pubmed/32419737 | 2020-05-17 02:00:00+02:00 | pubmed | Animals;Asthma;Betacoronavirus;Chiroptera;Coronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | M Underner;G Peiffer;J Perriot;N Jaafari | Asthma;Asthme;COVID-19;Coronavirus 2019;Facteurs de risque;Risk factors;SARS-CoV-2 | 2020-05-15 02:00:00+02:00 | 32419737 | FR | Unité de recherche clinique, centre hospitalier Henri-Laborit, université de Poitiers, 370, avenue Jacques-Cœur, CS 10587, 86021 Poitiers, France. Electronic address: mike.underner@orange.fr.;Service de pneumologie, CHR de Metz-Thionville, 57038 Metz, France.;Dispensaire Emile-Roux, centre de tabacologie, 63100 Clermont-Ferrand, France.;Unité de recherche clinique, centre hospitalier Henri-Laborit, université de Poitiers, 370, avenue Jacques-Cœur, CS 10587, 86021 Poitiers, France. | 668 | ||||||
| 10.1016/j.dld.2020.03.031 | Journal Article;Practice Guideline | en | COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). | https://www.ncbi.nlm.nih.gov/pubmed/32418773 | Patients treated for malignancy are considered at risk of severe COVID-19. This exceptional pandemic has affected countries on every level, particularly health systems which are experiencing saturation. Like many countries, France is currently greatly exposed, and a complete reorganization of hospitals is ongoing. We propose here adaptations of diagnostic procedures, therapies and care strategies for patients treated for digestive cancer during the COVID-19 epidemic. | 1590-8658 | 2020-05-17 02:00:00+02:00 | pubmed | Antineoplastic Agents__therapeutic use;Betacoronavirus__isolation & purification;Comorbidity;Coronavirus Infections__epidemiology;Digestive System Surgical Procedures__methods;Disease Transmission, Infectious__prevention & control;France__epidemiology;Gastrointestinal Neoplasms__epidemiology;Humans;Infection Control__methods;Pandemics__prevention & control;Patient Care Management__methods;Pneumonia, Viral__epidemiology;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Digestive and Liver Disease | Frederic Di Fiore;Olivier Bouché;Come Lepage;David Sefrioui;Alice Gangloff;Lilian Schwarz;Jean Jacques Tuech;Thomas Aparicio;Thierry Lecomte;Camille Boulagnon-Rombi;Astrid Lièvre;Sylvain Manfredi;Jean Marc Phelip;Pierre Michel | COVID-19 infection;Chemotherapy;Digestive cancer;French Clinical Practice Guidelines;Surgery | 2020-05-14 02:00:00+02:00 | 32418773 | FR | Department of Hepatogastroenterology, Normandie Université, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, F 76000 Rouen, France. Electronic address: frederic.di-fiore@chu-rouen.fr.;Digestive Oncology, CHU Reims, University Reims Champagne Ardennes, France.;Hepato-Gastroenterology Department, University Hospital Le Bocage, EPICAD INSERM LNC-UMR 1231, Université de Bourgogne et Franche Comté, Dijon, France.;Department of Hepatogastroenterology, Normandie Université, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, F 76000 Rouen, France.;Department of Digestive Surgery, Normandie Université, UNIROUEN, Inserm U1245, IRON group, F 76000 Rouen, France.;Gastroenterology and Digestive Oncology, Saint Louis Hospital, APHP, Université de Paris, Paris, France.;Gastroenterology and Endoscopy Department, Trousseau Hospital, University F Rabelais Tours, France.;Pathology, CHU Reims, University Reims Champagne Ardennes, France.;Rennes 1 University, Rennes, France, Association pour le Dépistage des Cancers en Ille-et-Vilaine, ADECI35, Rennes, France, Department of Gastroenterology, CHU Pontchaillou, Rennes, France, INSERM UMR 1242, COSS "Chemistry, Oncogenesis, Stress Signaling", Rennes, France.;Department of Gastroenterology and Digestive Oncology, University Hospital of Saint Etienne, Saint Etienne, France.;Department of Hepatogastroenterology, Normandie Université, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, F 76000 Rouen, France. Electronic address: pierre.michel@chu-rouen.fr. | 677 | ||
| 10.1111/eje.12542 | Journal Article | en | COVID-19: The immediate response of european academic dental institutions and future implications for dental education. | https://www.ncbi.nlm.nih.gov/pubmed/32394605 | The COVID-19 pandemic has had an immediate and dramatic impact on dental education. The Association of Dental Education in Europe decided to carry out an investigation to assess the immediate response of European Academic Dental Institutions. An online survey was sent to both member and non-member dental schools to investigate the impact on non-clinical and clinical education, assessment and the well-being/pastoral care measures implemented. The preliminary findings and discussion are presented in this paper, for the responses collected between the 25 March and 5 April 2020. The survey at this time of publication is ongoing, and detailed results can be accessed https://adee.org/covid-19-european-dental-education%E2%80%99s-immediate-response. | 1396-5883,1600-0579 | 2020-05-17 02:00:00+02:00 | pubmed | European Journal of Dental Education | Barry Quinn;James Field;Ronald Gorter;Ilze Akota;Maria-Cristina Manzanares;Corrado Paganelli;Julia Davies;Jonathan Dixon;Gerber Gabor;Rui Amaral Mendes;Petra Hahn;Sibylle Vital;Judith O'Brien;Denis Murphy;Stéphanie Tubert-Jeannin | COVID-19;dental education;impact;public health;survey | 2020-05-11 02:00:00+02:00 | 32394605 | SE;FR;IE;LV;PT;GB;US;IT;NL;ES;HU;DE | King's College London, Faculty of Dentistry, Oral and Craniofacial Sciences, London, UK.;Cardiff University, Sheffield, UK.;Academisch Centrum Tandheelkunde Amsterdam, Amsterdam, Netherlands.;Riga Stradins University, Riga, Latvia.;University of Barcelona, Barcelona, Spain.;University of Brescia, Brescia, Italy.;Malmo University, Malmo, Sweden.;Semmelweis University, Budapest, Hungary.;Centre for Research in Higher Education Policies, University of Porto and Case Western Reserve University, Cleveland, OH, USA.;University of Freiburg, Freiburg, Germany.;University of Paris, Paris, France.;Dental Education in Europe, Dublin, Ireland.;University Clermont Auvergne, Clermont-Ferrand, France. | 691 | |||
| Letter | en | Cerebral venous thrombosis associated with COVID-19 infection: Causality or coincidence? | https://www.ncbi.nlm.nih.gov/pubmed/32437707 | 2020-05-17 02:00:00+02:00 | pubmed | Guillaume Poillon;Mickael Obadia;Mathilde Perrin;Julien Savatovsky;Augustin Lecler | 2020-05-11 02:00:00+02:00 | 32437707 | FR | Department of Neuroradiology, Adolphe de Rothschild Foundation Hospital, 29, rue Manin, 75019 Paris, France. Electronic address: gpoillon@for.paris.;Department of Neurology, Adolphe de Rothschild Foundation Hospital, Paris, France.;Neuro-Intensive Care Unit, Adolphe de Rothschild Foundation Hospital, Paris, France.;Department of Neuroradiology, Adolphe de Rothschild Foundation Hospital, 29, rue Manin, 75019 Paris, France. | 693 | ||||||||
| 10.1016/j.purol.2020.05.001 | Journal Article;Multicenter Study | fr | [Impact of the COVID-19 pandemic on surgical activity within academic urological departments in Paris]. | https://www.ncbi.nlm.nih.gov/pubmed/32430140 | As a result of the COVID-19 pandemic in France, all non-emergency surgical activity has been cancelled since March 12, 2020. In order to anticipate the reinstatement of delayed interventions, surgical activity reduction analysis is essential. The objective of this study was to evaluate the reduction of urological surgery in adult during the COVID-19 pandemic compared to 2019. | 1166-7087 | 2020-05-17 02:00:00+02:00 | pubmed | Adult;Coronavirus Infections__epidemiology;Hospitals__statistics & numerical data;Humans;Kidney Transplantation__statistics & numerical data;Pandemics;Paris__epidemiology;Pneumonia, Viral__epidemiology;Retrospective Studies;Urologic Surgical Procedures__statistics & numerical data;Urology__statistics & numerical data;COVID-19 | Progrès en Urologie | U Pinar;J Anract;I Duquesne;C Dariane;E Chartier-Kastler;O Cussenot;F Desgrandchamps;J-F Hermieu;J Irani;A de La Taille;A Méjean;P Mongiat-Artus;M Peyromaure;B Barrou;M Zerbib;M Rouprêt | COVID-19;Chirurgie;Coronavirus;Health care;Pandemic;Pandémie;Surgery;Urologie;Urology | 2020-05-11 02:00:00+02:00 | 32430140 | FR | GRC n(o) 5, PREDICTIVE ONCO-UROLOGY, hôpital Pitié-Salpêtrière, urologie, Sorbonne Université, AP-HP, 75013 Paris, France.;Servie d'urologie, hôpital Cochin, centre, université de Paris, AP-HP, 75014 Paris, France.;Service d'urologie, hôpital européen Georges-Pompidou, centre, université de Paris, AP-HP, 75015 Paris, France.;Service d'urologie et de transplantation rénale, Hôpital Pitié-Salpêtrière, Sorbonne Université, AP-HP, 75013 Paris, France.;GRC n(o) 5, PREDICTIVE ONCO-UROLOGY, hôpital Tenon, urologie, Sorbonne Université, AP-HP, 75020 Paris, France.;Service d'urologie, hôpital Saint-Louis, université de Paris, AP-HP, nord, 75010 Paris, France, CEA/SRHI, U976 HIPI, institut de recherche Saint-Louis, université de Paris, Paris, France.;Service d'urologie, hôpital Bichat, université de Paris, AP-HP, Nord, 75010 Paris, France.;Service d'urologie, hôpital Bicêtre, université Paris Saclay, AP-HP, 94270 Le Kremlin-Bicêtre, France.;Service d'urologie, hôpital Henri-Mondor, hôpitaux universitaires Henri-Mondor, AP-HP, 94010 Créteil, France.;Service d'urologie, hôpital Saint-Louis, université de Paris, AP-HP, nord, 75010 Paris, France.;Service d'urologie, centre, hôpital Cochin, université de Paris, AP-HP, 75014 Paris, France.;GRC n(o) 5, PREDICTIVE ONCO-UROLOGY, hôpital Pitié-Salpêtrière, urologie, Sorbonne Université, AP-HP, 75013 Paris, France. Electronic address: morgan.roupret@aphp.fr. | 699 | ||
| Letter | en | Prescribing COVID-19 treatments: what we should never forget. | https://www.ncbi.nlm.nih.gov/pubmed/32405110 | 2020-05-17 02:00:00+02:00 | pubmed | Adrenal Cortex Hormones__adverse effects;Anti-Inflammatory Agents__adverse effects;Antiviral Agents__adverse effects;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | S Tunesi;A Bourgarit | 2020-05-13 02:00:00+02:00 | 32405110 | FR | Sorbonne Paris-Nord University (Paris 13), Bobigny, France, Inserm, UMR 1135 CIMI, Paris, France, APHP, HUPSSD, Internal medicine department, Bondy, France. Electronic address: simonetunesi88@gmail.com.;Sorbonne Paris-Nord University (Paris 13), Bobigny, France, Inserm, UMR 1135 CIMI, Paris, France, APHP, HUPSSD, Internal medicine department, Bondy, France. | 717 | |||||||
| 10.3389/fmed.2020.00223 | Journal Article | en | COVID-19: The Conjunction of Events Leading to the Coronavirus Pandemic and Lessons to Learn for Future Threats. | https://www.ncbi.nlm.nih.gov/pubmed/32574324 | 2296-858X | 2020-05-17 02:00:00+02:00 | pubmed | Frontiers in Medicine | Roger Frutos;Marc Lopez Roig;Jordi Serra-Cobo;Christian A Devaux | COVID-19;SARS-CoV-2;dynamic;emerging diseases;preparedness | 2020-05-12 02:00:00+02:00 | 32574324 | FR;ES | Cirad, UMR 17, Intertryp, Montpellier, France.;IES, UMR 5214 Univ. Montpellier-CNRS, Montpellier, France.;Department of Evolutionary Biology, Ecology and Environmental Sciences, Biodiversity Research Institute, University of Barcelona, Barcelona, Spain.;IHU-Méditerranée Infection and CNRS, Marseille, France. | 718 | ||||
| 10.1111/ene.14316 | Journal Article | en | Impact of the COVID-19 outbreak on acute stroke pathways - insights from the Alsace region in France. | https://www.ncbi.nlm.nih.gov/pubmed/32399995 | To date, no study has attempted to quantify the impact of the COVID-19 outbreak on the incidence and treatment of acute stroke. | 1351-5101,1468-1331 | 2020-05-17 02:00:00+02:00 | pubmed | European Journal of Neurology | R Pop;V Quenardelle;A Hasiu;D Mihoc;F Sellal;M H Dugay;P A Lebedinsky;E Schluck;A LA Porta;S Courtois;R Gheoca;V Wolff;R Beaujeux | COVID-19;acute stroke pathway;stroke;thrombectomy;thrombolysis | 2020-05-12 02:00:00+02:00 | 32399995 | FR | Interventional Neuroradiology Department, Strasbourg University Hospitals, Strasbourg, France.;Institut de Chirurgie Minime Invasive Guidée par l'Image, Strasbourg, France.;Stroke Unit, Strasbourg University Hospitals, Strasbourg, France.;Neurology Department, Hôpitaux Civils de Colmar, Colmar, France.;Interventional Neuroradiology Department, Hôpitaux Civils de Colmar, Colmar, France.;Neurology Department, Mulhouse and South Alsace Region Hospital Group, Mulhouse, France. | 720 | |||
| Letter | en | Protecting the Prehospital Professional First Aid Teams from Airborne Viral Particles in the Case of Out-of-Hospital Pediatric Cardiac Arrest during the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32393400 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Coronavirus Infections__prevention & control;Emergency Medical Technicians;Female;First Aid;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Male;Out-of-Hospital Cardiac Arrest__therapy;Pandemics__prevention & control;Paris;Pneumonia, Viral__prevention & control;Virion;COVID-19;severe acute respiratory syndrome coronavirus 2 | Sabine Lemoine;Frederique Briche;Daniel Jost;Bertrand Prunet | 2020-05-12 02:00:00+02:00 | 32393400 | FR | Paris Fire Brigade, Medical Emergency Department, Paris, France. | 725 | |||||||
| 10.1111/bju.15071 | Journal Article;Review | en | COVID-19 and urology: a comprehensive review of the literature. | https://www.ncbi.nlm.nih.gov/pubmed/32249538 | To discuss the impact of COVID-19 on global health, particularly on urological practice and to review some of the available recommendations reported in the literature. | 1464-4096 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus__physiology;Coronavirus Infections__epidemiology;Elective Surgical Procedures;Global Health;Humans;Pandemics;Pneumonia, Viral__epidemiology;Triage;Urinary Tract__microbiology;Urologic Surgical Procedures;COVID-19;severe acute respiratory syndrome coronavirus 2 | BJU International | Stefano Puliatti;Ahmed Eissa;Radwa Eissa;Marco Amato;Elio Mazzone;Paolo Dell'Oglio;Maria Chiara Sighinolfi;Ahmed Zoeir;Salvatore Micali;Giampaolo Bianchi;Vipul Patel;Peter Wiklund;Rafael F Coelho;Jean-Christophe Bernhard;Prokar Dasgupta;Alexandre Mottrie;Bernardo Rocco | COVID-19;SARS-CoV-2;coronavirus;pandemic;urology | 2020-05-12 02:00:00+02:00 | 32249538 | SE;FR;GB;US;BR;IT;EG;BE | Urology Department, University of Modena and Reggio Emilia, Modena, Italy.;ORSI Academy, Melle, Belgium.;Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium.;Urology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.;Microbiology and Virology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.;Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.;Global Robotics Institute, Florida Hospital-Celebration Health Celebration, University of Central Florida School of Medicine, Orlando, FL, USA.;Department of Urology, Karolinska University Hospital, Stockholm, Sweden.;Department of urology, Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil.;Chirurgie Urologique, CHU de Bordeaux, France.;Department of Urology, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London, UK.;MRC Centre for Transplantation, King's College London, King's Health Partners, London, UK. | 726 | ||
| Letter | en | COVID-19, sweat, tears… and myopia? | https://www.ncbi.nlm.nih.gov/pubmed/32396988 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__prevention & control;Humans;Myopia__epidemiology;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Sweat__virology;Tears__virology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Valentin Navel;Steven Beze;Frédéric Dutheil | 2020-05-12 02:00:00+02:00 | 32396988 | FR | Translational Approach to Epithelial Injury and Repair, GReD, CNRS, INSERM, Université Clermont Auvergne, Clermont-Ferrand, France.;Ophthalmology, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.;Physiological and Psychosocial Stress, LaPSCo, CNRS, Université Clermont Auvergne, Clermont-Ferrand, France.;Preventive and Occupational Medicine, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Witty Fit, Clermont-Ferrand, France. | 727 | |||||||
| 10.5152/eurjrheum.2020.2062 | Journal Article | en | Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation. | https://www.ncbi.nlm.nih.gov/pubmed/32412405 | 2147-9720,2148-4279 | 2020-05-17 02:00:00+02:00 | pubmed | European Journal of Rheumatology | Pierre Miossec | 2020-05-11 02:00:00+02:00 | 32412405 | FR | Departments of Immunology and Rheumatology, University of Lyon, Lyon, France. | 729 | |||||
| Letter;Research Support, Non-U.S. Gov't;Comment | en | Organ procurement and transplantation during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32407668 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Tissue and Organ Procurement;COVID-19;severe acute respiratory syndrome coronavirus 2 | Alexandre Loupy;Olivier Aubert;Peter P Reese;Olivier Bastien;Florian Bayer;Christian Jacquelinet | 2020-05-11 02:00:00+02:00 | 32407668 | FR;US | Paris University, Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Paris, France, Department of Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: alexandre.loupy@inserm.fr.;Paris University, Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Paris, France, Department of Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Paris University, Paris Translational Research Center for Organ Transplantation, INSERM, UMR-S970, Paris, France, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.;Agence de la Biomédecine, Saint Denis la Plaine, France.;Agence de la Biomédecine, Saint Denis la Plaine, France, INSERM U1018, Center for Research in Epidemiology and Population Health, Université Paris Sud, Villejuif, France. | 731 | |||||||
| 10.1016/j.therap.2020.05.006 | Journal Article | en | Diabetes and COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32425249 | According to previous reports, diabetes seems to be a risk factor which worsens the serious clinical events caused by COVID-19. But is diabetes per se a risk factor that increases the probability of getting the virus? This paper will discuss this point. There are not many research data on antidiabetic drugs in this context. The potential influence of glucose-lowering agents on the severity of COVID-19 has not been described yet. Dipeptidylpeptidase-4 (DPP-4) is a cell surface protein ubiquitously expressed in many tissues and it is also a soluble molecule found in serum/plasma fluids. DPP-4 is involved in infection of cells by some viruses. This paper reviews data about the use of DPP-4 inhibitors and others diabetes drugs on COVID-19 patients. As such, no available evidence has yet suggested that glucose-lowering drugs - including those targeting DPP4-related pathways - produce any significant harm or benefit in the context of human infections. However, insulin must remain the first-choice agent in the management of critically ill-hospitalized patients, while it is recommended to suspend other agents in unstable patients. This paper provides related French and international recommendations for people with diabetes who got infected by COVID-19 and upholds that infections may alter glucose control and may require additional vigilance. | 0040-5957 | 2020-05-17 02:00:00+02:00 | pubmed | Therapies | Béatrice Bouhanick;Jean-Luc Cracowski;Jean-Luc Faillie | COVID-19;DPP-4 inhibitors;Diabetes;Diabetes drugs;Epidemiology;Recommendations | 2020-05-15 02:00:00+02:00 | 32425249 | FR | Service d'hypertension artérielle et thérapeutique PCVM, UMR 1027, université de Toulouse 3, CHU de Rangueil, 31059 Toulouse, France. Electronic address: duly-bouhanick.b@chu-toulouse.fr.;INSERM, HP2, centre régional de pharmacovigilance et centre d'investigation clinique de Grenoble, université de Grenoble-Alpes, 38000 Grenoble, France.;Département de pharmacologie médicale et toxicologie, centre régional de pharmacovigilance Occitanie-Est, université de Montpellier, CHU de Montpellier, 34295 Montpellier, France. | 735 | |||
| Medical Research Council | 10.1016/s2213-2600(20)30230-7 | Journal Article;Review | en | Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. | https://www.ncbi.nlm.nih.gov/pubmed/32422180 | Global health care is experiencing an unprecedented surge in the number of critically ill patients who require mechanical ventilation due to the COVID-19 pandemic. The requirement for relatively long periods of ventilation in those who survive means that many are considered for tracheostomy to free patients from ventilatory support and maximise scarce resources. COVID-19 provides unique challenges for tracheostomy care: health-care workers need to safely undertake tracheostomy procedures and manage patients afterwards, minimising risks of nosocomial transmission and compromises in the quality of care. Conflicting recommendations exist about case selection, the timing and performance of tracheostomy, and the subsequent management of patients. In response, we convened an international working group of individuals with relevant expertise in tracheostomy. We did a literature and internet search for reports of research pertaining to tracheostomy during the COVID-19 pandemic, supplemented by sources comprising statements and guidance on tracheostomy care. By synthesising early experiences from countries that have managed a surge in patient numbers, emerging virological data, and international, multidisciplinary expert opinion, we aim to provide consensus guidelines and recommendations on the conduct and management of tracheostomy during the COVID-19 pandemic. | 2213-2600 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__prevention & control;Critical Care__methods;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Internationality;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Practice Guidelines as Topic;Tracheostomy__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Respiratory Medicine | Brendan A McGrath;Michael J Brenner;Stephen J Warrillow;Vinciya Pandian;Asit Arora;Tanis S Cameron;José Manuel Añon;Gonzalo Hernández Martínez;Robert D Truog;Susan D Block;Grace C Y Lui;Christine McDonald;Christopher H Rassekh;Joshua Atkins;Li Qiang;Sébastien Vergez;Pavel Dulguerov;Johannes Zenk;Massimo Antonelli;Paolo Pelosi;Brian K Walsh;Erin Ward;You Shang;Stefano Gasparini;Abele Donati;Mervyn Singer;Peter J M Openshaw;Neil Tolley;Howard Markel;David J Feller-Kopman | 2020-05-15 02:00:00+02:00 | 32422180 | FR;CN;BO;GB;US;HK;CH;IT;AU;ES;DE | [{"country": "United Kingdom", "agency": "Medical Research Council", "grantid": "MR/T50256X/1"}] | Manchester University NHS Foundation Trust, Manchester, UK, Manchester Academic Critical Care, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK.;University of Michigan, Ann Arbor, USA.;Austin Health, Melbourne, VIC, Australia.;Johns Hopkins University, Baltimore, MD, USA.;Guy's and St Thomas' NHS Foundation Trust, London, UK.;La Paz-Carlos III University Hospital, IdiPAZ, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.;Virgen de la Salud Hospital, Health Service of Castilla-La Mancha, Toledo, Spain.;Center for Bioethics, Harvard Medical School, Boston, MA, USA, Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, MA, USA.;Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.;The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.;Austin Health, Institute for Breathing and Sleep (IBAS), Melbourne, VIC, Australia.;University of Pennsylvania, Philadelphia, PA, USA.;East Hospital of Shanghai, TongJi University, Shanghai, China.;University Hospital Rangueil-Larrey, Toulouse, France.;Hôpital de la Tour, Meyrin, Geneva University, Geneva, Switzerland.;Universitätsklinikum Augsburg Klinik für HNO-Heilkunde, Augsburg, Germany.;Dipartimento di Scienze dell' Emergenza Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.;Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy, Anesthesia and Intensive Care, San Martino Policlinico Hospital, Genoa, Italy.;Liberty University, Lynchburg, VA, USA.;Tracheostomy Team, Institute for Professionalism and Ethical Practice, Boston Children's Hospital, Boston, MA, USA.;Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Region - Azienda Ospedali Riuniti, Ancona, Italy.;University College London, London, UK.;National Heart and Lung Institute, Imperial College of London, London, UK.;Imperial College Healthcare NHS Trust, London, UK.;Johns Hopkins University, Baltimore, MD, USA. Electronic address: dfk@jhmi.edu. | 738 | |
| 10.1007/s10029-020-02212-8 | Journal Article | en | European Hernia Society (EHS) guidance for the management of adult patients with a hernia during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32415652 | 1265-4906,1248-9204 | 2020-05-17 02:00:00+02:00 | pubmed | Hernia | C Stabilini;B East;R Fortelny;J-F Gillion;R Lorenz;A Montgomery;S Morales-Conde;F Muysoms;M Pawlak;W Reinpold;M Simons;A C de Beaux | 2020-05-15 02:00:00+02:00 | 32415652 | FR;SE;GB;US;IT;NL;CZ;ES;DE;BE;AT | Department of Surgery, University of Genoa, Policlinico San Martino, Largo R. Benzi 8, 16132, Genoa, Italy. cesarestabil@hotmail.com.;3rd Department of Surgery at 1st Faculty of Medicine at Charles University, Motol University Hospital, Prague, Czech Republic.;2nd Faculty of Medicine, Charles University, Prague, Czech Republic.;Department of General, Visceral and Oncologic Surgery, Wilhelminenspital, Vienna, Austria.;Hôpital Privé d'Antony, 1 rue Velpeau, 92160, Antony, France.;Hernia Center, CHIRURGEN 3+, Berlin, Germany.;Department of Surgery, Lund University, Skåne University Hospital, Malmö, Sweden.;Unit of Innovation in Minimally Invasive Surgery, University Hospital Virgen del Rocio, University of Sevilla, Seville, Spain.;Unit of General and Digestive Surgery, Hospital Quironsalud Sagrado Corazón (Sevilla), Seville, Spain.;Department of Surgery, Maria Middelares Hospital, Ghent, Belgium.;Northern Devon Healthcare NHS Trust, Barnstaple, UK.;Department of Surgery, Wilhelmsburger Hospital Gross Sand, Academic Teaching Hospital of University Hamburg, Hamburg, Germany.;Department of Surgery, OLVG Hospital, Oosterpark 9, 1091 AC, Amsterdam, The Netherlands.;Department of General Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK. | 744 | |||||
| 10.1007/s00134-020-06088-1 | Journal Article | en | Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32415314 | 0342-4642,1432-1238 | 2020-05-17 02:00:00+02:00 | pubmed | Anticoagulants__therapeutic use;Betacoronavirus__physiology;Blood Coagulation Disorders__drug therapy;Coronavirus Infections__complications;Critical Illness;Cytokine Release Syndrome__etiology;Hemostasis__physiology;Humans;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Bérangère S Joly;Virginie Siguret;Agnès Veyradier | 2020-05-15 02:00:00+02:00 | 32415314 | FR | EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France.;UMR-S1140 Inserm, Innovative Therapeutics in Haemostasis, Université de Paris, Paris, France.;EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France. agnes.veyradier@aphp.fr. | 745 | ||||
| Letter;Comment | en | Transesophageal Echocardiography Remains Essential and Safe during Prone Ventilation for Hemodynamic Monitoring of Patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32561110 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Echocardiography;Echocardiography, Transesophageal;Hemodynamic Monitoring;Hemodynamics;Humans;Pandemics;Pneumonia, Viral;Respiration, Artificial;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bruno Evrard;Marine Goudelin;Philippe Vignon | 2020-05-20 02:00:00+02:00 | 32561110 | FR | Réanimation Polyvalente, CHU Dupuytren, Limoges, France.;Réanimation Polyvalente, CHU Dupuytren, Limoges, France, Inserm CIC 1435 and UMR 1092, CHU Dupuytren, Limoges, France, Faculté de Médecine, Université de Limoges, Limoges, France. | 749 | |||||||
| Case Reports;Letter | en | COVID-19 as a cause of immune thrombocytopenia. | https://www.ncbi.nlm.nih.gov/pubmed/32445664 | 2020-05-24 02:00:00+02:00 | pubmed | Adrenal Cortex Hormones__therapeutic use;Aged, 80 and over;Betacoronavirus__immunology;Coronavirus Infections__complications;Humans;Male;Pandemics;Pneumonia, Viral__complications;Prognosis;Purpura, Thrombocytopenic, Idiopathic__diagnosis;Seroconversion__physiology;Severity of Illness Index;Time-to-Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2 | S Humbert;J Razanamahery;C Payet-Revest;K Bouiller;C Chirouze | COVID-19;Immune thrombocytopenia;SARS-CoV-2 | 2020-05-20 02:00:00+02:00 | 32445664 | FR | Internal Medicine Department, Besancon University Hospital, Besançon, France. Electronic address: shumbert@chu-besancon.fr.;Internal Medicine Department, Besancon University Hospital, Besançon, France.;Infectious Diseases Department, Besancon University Hospital, Besançon, France. | 755 | ||||||
| 10.1159/000508512 | Journal Article;Multicenter Study | en | Urology in the Time of Coronavirus: Reduced Access to Urgent and Emergent Urological Care during the Coronavirus Disease 2019 Outbreak in Italy. | https://www.ncbi.nlm.nih.gov/pubmed/32434207 | The coronavirus disease 2019 (COVID-19) pandemic has put a substantial burden on the Italian healthcare system, resulting in the restructuring of hospitals to care for COVID-19 patients. However, this has likely impacted access to care for patients experiencing other conditions. We aimed to quantify the impact of COVID-19 on access to care for patients with urgent/emergent urological conditions throughout Italy. | 0042-1138,1423-0399 | 2020-05-24 02:00:00+02:00 | pubmed | Ambulatory Care;Betacoronavirus;Coronavirus Infections__epidemiology;Disease Outbreaks;Health Services Accessibility__trends;Hospitals__statistics & numerical data;Humans;Italy__epidemiology;Pandemics;Pneumonia, Viral__epidemiology;Regression Analysis;Surveys and Questionnaires;Urologic Diseases__epidemiology;Urology__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Urologia Internationalis | Angelo Porreca;Michele Colicchia;Daniele D'Agostino;Michele Amenta;Alfio Corsaro;Stefano Zaramella;Luisa Zegna;Fabrizio Gallo;Maurizio Schenone;Giorgio Bozzini;Alberto Calori;Antonio L Pastore;Yazan Al Salhi;Carmine Sciorio;Lorenzo Spirito;Virginia Varca;Carlo Marenghi;Francesco Greco;Vincenzo M Altieri;Paolo Verze;Ciro Barba;Alessandro Antonelli;Maria A Cerruto;Roberto Falabella;Silvana Di Bello;Costantino Leonardo;Antonio Tufano;Alessandro Volpe;Paolo Umari;Paolo Parma;Mattia Nidini;Giovannalberto Pini;Marco Borghesi;Carlo Terrone;Giovanni E Cacciamani;Maria C Sighinolfi;Gian Maria Busetto;Alexandra M Wennberg;Marinella Finocchiaro;Mario Falsaperla;Marco Oderda;Carlo Ceruti;Bernardo Rocco;Riccardo Schiavina;Lorenzo Bianchi;Andrea Mari;Fabrizio Di Maida;Orietta Dalpiaz;Antonio Celia;Marco Pirozzi;Pierluigi Bove;Valerio Iacovelli;Angelo Cafarelli;Luca Cindolo;Giovanni Ferrari;Lorenzo Gatti;Giacomo Pirola;Filippo Annino;Luigi Pucci;Daniele Romagnoli;Walter Artibani;Andrea Minervini | Coronavirus disease 2019;Italy;Outbreak;Urological care | 2020-05-20 02:00:00+02:00 | 32434207 | FR;IT;US;AT | Department of Urology, Policlinico Abano Terme, Abano Terme, Italy.;Department of Urology, Policlinico Abano Terme, Abano Terme, Italy, michelecolicchia@gmail.com.;Department of Urology, Ospedale Civile di Portogruaro, Portogruaro, Italy.;Department of Urology, Biella Hospital, Ponderano, Italy.;Department of Surgery, Division of Urology, San Paolo Hospital, Savona, Italy.;Department of Urology, ASST Valle Olona, Busto Arsizio, Italy.;Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Urology Unit, ICOT Hospital Latina, Rome, Italy.;Urology Unit, Manzoni Hospital, Lecco, Italy.;Hospital G. Salvini, ASST Rhodense Garbagnate Milanese, Milan, Italy.;Department of Urology, Humanitas Gavazzeni, Bergamo, Italy.;Department of Urology, Scuola Medica Salernitana, University of Salerno, Salerno, Italy.;Department of Urology, Azienda Ospedaliera Universitaria Integrata of Verona, University of Verona, Verona, Italy.;Department of Urology, Azienda Ospedaliera Regionale di Potenza, Potenza, Italy.;UO Pronto Soccorso, Accettazione, Medicina Urgenza, Azienda Ospedaliera Regionale di Potenza, Potenza, Italy.;Department of Urology, La Sapienza University of Rome, Rome, Italy.;Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.;Urology Department, ASST Mantova, Mantova, Italy.;Urologia Ospedale San Raffaele Turro, Milan, Italy.;Department of Urology, S. Martino Hospital, Department of Surgical and Diagnostic Sciences, University of Genoa, Genoa, Italy.;USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.;Urology Department, University of Modena and Reggio Emilia, Modena, Italy.;Department of Urology, Sapienza Rome University Policlinico Umberto I, Rome, Italy.;Department of Neurosciences (Padova Neuroscience Centre), Università degli Studi di Padova, Padova, Italy.;U.O.C. Urologia Ospedale Vittorio Emanuele, Catania, Italy.;Università di Torino, Città della Salute e della Scienza di Torino, Turin, Italy.;Department of Urology, University of Bologna, Bologna, Italy.;Department of Urology, University of Florence, Florence, Italy.;Department of Urology, Medical University of Graz, Graz, Austria.;Department of Urology, San Bassiano Hospital, Bassano del Grappa, Italy.;Urology Unit, San Carlo Di Nancy Hospital, GVM Care and Research, Rome, Italy.;Department of Urology, Casa di Cura Villa Igea, Ancona, Italy.;Department of Urology, Villa Stuart Casa di Cura, Rome, Italy.;Department of Urology, Hesperia Hospital, Modena, Italy.;Department of Urology, San Donato Hospital, USL Toscana Sudest, Arezzo, Italy.;Department of Urology, AORN A. Cardarelli, Naples, Italy. | 761 | ||
| 10.1016/j.therap.2020.05.009 | Journal Article | en | Drugs acting on renin angiotensin system and use in ill patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32553503 | Some concerns about the prescription of drugs acting on the renin-angiotensin system (angiotensin-converting enzyme 1 (ACE1) inhibitors, ACEi; angiotensin II type 1 receptor blockers, ARB) have emerged due to SARS COV2 and COVID-19 pandemic. These very legitimate questions are directly the consequence of the recent recognition of the fundamental role of ACE2 (angiotensin-converting enzyme 2) in COVID-19 infection. Indeed, SARS COV2 utilizes ACE2 as a membrane receptor to enter target cells. Consequently, the putative impact of drugs modulating the renin-angiotensin system on the risk of developing severe or fatal severe acute respiratory syndrome in case of COVID-19 infection emerged. As a membrane-bound enzyme (carboxypeptidase), ACE2 inactivates angiotensin II and therefore physiologically counters its effects. Due to a different structure compared with ACE1, ACE2 is insensitive to ACEIs. In vitro, both ARBs and ACEi appear able to upregulate ACE2 tissue expression and activity but these results were not confirmed in Humans. The exact impact of both ARBs and ACEis on COVID-19 infection is definitively known and preliminary results are even in favor of a protective role confers by these drugs. Due to the crucial role of ACE2, some groups support the hypothesis that a modulation of ACE2 expression could represent a valuable therapeutic target could confer protective properties against inflammatory tissue damage in COVID-19 infection. So, studies are currently ongoing to test the impact of elevated ACE2 membrane expression, administration of ARB and infusion of soluble ACE2. In summary, based on the currently available evidences and as recommended by several medical societies, ACEi or ARB should not be systematically discontinued because to date no safety signal was raised with the use of these drugs. | 0040-5957 | 2020-05-24 02:00:00+02:00 | pubmed | Therapies | Joachim Alexandre;Jean-Luc Cracowski;Vincent Richard;Béatrice Bouhanick | Arterial hypertension;Renin-angiotensin-aldosterone system | 2020-05-20 02:00:00+02:00 | 32553503 | FR | Service de pharmacologie, université de Caen-Normandie, UNICAEN, CHU de Caen Normandie, EA 4650, 14000 Caen, France. Electronic address: alexandre-j@chu-caen.fr.;University Grenoble Alpes, centre régional de pharmacovigilance de Grenoble, Inserm, HP2, 38000 Grenoble, France.;Service de pharmacologie, université de Rouen Normandie, UNIROUEN, CHU de Rouen Normandie, UMR Inserm U1096 EnVI, 76000 Rouen, France.;Service d'hypertension artérielle et thérapeutique PCVM, UMR 1027 université Toulouse 3, CHU Rangueil, 31000 Toulouse, France. | 764 | |||
| Letter;Comment | en | Surgical resection for liver cancer during the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32436017 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Liver Neoplasms;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Haitham Triki;Heithem Jeddou;Karim Boudjema | 2020-05-20 02:00:00+02:00 | 32436017 | FR | Department of Hepatobiliary and Digestive Surgery, Pontchaillou Hospital, Rennes 1 University, 35000, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou Hospital, Rennes 1 University, 35000, Rennes, France. karim.boudjema@chu-rennes.fr. | 765 | |||||||
| 10.1007/s12350-020-02197-y | Journal Article | en | Increased lung signal as a hint of COVID-19 infection on Tc-99m-sestamibi myocardial perfusion scintigraphy. | https://www.ncbi.nlm.nih.gov/pubmed/32436114 | 1071-3581,1532-6551 | 2020-05-24 02:00:00+02:00 | pubmed | Journal of Nuclear Cardiology | Pierre Delabie;Fabien Hyafil | 2020-05-20 02:00:00+02:00 | 32436114 | FR | Department of Nuclear Medicine, Centre Hospitalier Universitaire Bichat, Assistance Publique - Hôpitaux de Paris, Inserm, 1148, Université de Paris, Paris, France.;Department of Nuclear Medicine, Centre Hospitalier Universitaire Bichat, Assistance Publique - Hôpitaux de Paris, Inserm, 1148, Université de Paris, Paris, France. fabien.hyafil@aphp.fr. | 766 | |||||
| 10.1007/s12630-020-01704-6 | Journal Article | en | A proposed lung ultrasound and phenotypic algorithm for the care of COVID-19 patients with acute respiratory failure. | https://www.ncbi.nlm.nih.gov/pubmed/32440906 | Pulmonary complications are the most common clinical manifestations of coronavirus disease (COVID-19). From recent clinical observation, two phenotypes have emerged: a low elastance or L-type and a high elastance or H-type. Clinical presentation, pathophysiology, pulmonary mechanics, radiological and ultrasound findings of these two phenotypes are different. Consequently, the therapeutic approach also varies between the two. We propose a management algorithm that combines the respiratory rate and oxygenation index with bedside lung ultrasound examination and monitoring that could help determine earlier the requirement for intubation and other surveillance of COVID-19 patients with respiratory failure. | 0832-610X,1496-8975 | 2020-05-24 02:00:00+02:00 | pubmed | Canadian Journal of Anesthesia/Journal canadien d'anesthésie | André Y Denault;Stéphane Delisle;David Canty;Alistair Royse;Colin Royse;Ximena Cid Serra;Caroline E Gebhard;Étienne J Couture;Martin Girard;Yiorgos Alexandros Cavayas;Nicolas Peschanski;Stéphan Langevin;Paul Ouellet | COVID-19;and oxygenation index;lung ultrasound;respiratory failure;respiratory rate | 2020-05-21 02:00:00+02:00 | 32440906 | FR;CA;CH;US;AU | Division of Critical Care, Centre Hospitalier de l'Université Montréal, Montreal, QC, Canada. andre.denault@umontreal.ca.;Department of Anesthesiology and Critical Care Division, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, QC, Canada, H1T 1C8. andre.denault@umontreal.ca.;Département de médecine de famille et médecine d'urgence, Université de Montréal, Montreal, QC, Canada.;Collège Ellis, Trois-Rivières, QC, Canada.;Department of Surgery, University of Melbourne, Melbourne, Australia.;Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Melbourne, Australia.;Department of Medicine, Monash University, Melbourne, Australia.;Department of Anaesthesia and Perioperative Medicine, Monash Health, Melbourne, Australia.;Cardiothoracic Surgeon, Royal Melbourne Hospital, Melbourne, Australia.;Royal Melbourne Hospital, Melbourne, Australia.;Outcomes Research Consortium, Cleveland Clinic, Cleveland, USA.;Department of Intensive Care Medicine, University Hospital Basel, Basel, Switzerland.;Department of Anesthesiology and Department of Medicine, Division of Intensive Care Medicine, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC, Canada.;Université Laval, Quebec, QC, Canada.;Department of Anesthesiology and Division of Critical Care, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.;Division of Critical Care, Hôpital Sacré-Coeur de Montréal and Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.;Emergency Department, University of Rennes 1, Rennes, France.;Emergency Physician, University Hospital of Rennes, Rennes, France.;Department of Surgery, Sherbrooke University, Sherbrooke, QC, Canada.;Clinical Consultant, Vitalité Health Network, Edmundston, NB, Canada. | 774 | |||
| Letter;Research Support, Non-U.S. Gov't | en | Prevalence of obesity among adult inpatients with COVID-19 in France. | https://www.ncbi.nlm.nih.gov/pubmed/32437642 | 2020-05-24 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus;Coronavirus Infections__diagnosis;Female;France__epidemiology;Hospitalization__trends;Humans;Inpatients;Male;Middle Aged;Obesity__diagnosis;Pandemics;Pneumonia, Viral__diagnosis;Prevalence;Retrospective Studies;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cyrielle Caussy;François Pattou;Florent Wallet;Chantal Simon;Sarah Chalopin;Charlène Telliam;Daniel Mathieu;Fabien Subtil;Emilie Frobert;Maud Alligier;Dominique Delaunay;Philippe Vanhems;Martine Laville;Merce Jourdain;Emmanuel Disse | 2020-05-18 02:00:00+02:00 | 32437642 | FR | CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Hôpital Lyon Sud, Pierre-Bénite 69495, France, Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France, COVID-O-HCL Consortium, Hospices Civils de Lyon, Lyon, France. Electronic address: cyrielle.caussy@chu-lyon.fr.;Université Lille, Inserm Pasteur Lille, Inserm U1190 European Genomic Institute of Diabetes, CHU Lille, Lille, France.;Medical Intensive Care Unit, Hôpital Lyon Sud, Pierre-Bénite 69495, France, COVID-O-HCL Consortium, Hospices Civils de Lyon, Lyon, France.;CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Hôpital Lyon Sud, Pierre-Bénite 69495, France, Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France.;Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France.;Department of Intensive Care, CHU Lille, Lille, France.;Hospices Civils de Lyon, Service de Biostatistique, Lyon, France, Université Claude Bernard Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Villeurbanne, France.;Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Lyon, France, Equipe Virpath, Centre International de Recherche en Infectiologie, INSERM U1111 CNRS UMR 5308, ENS, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.;FCRIN/FORCE Network, Centre de Recherche en Nutrition Humaine Rhône-Alpes, Lyon, France.;Laboratoire des Pathogènes Emergents-Fondation Mérieux, Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale U1111, Université Claude Bernard Lyon 1, Lyon, France, Centre National de La Recherche Scientifique, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France, Service D'Hygiène, Epidémiologie et Prévention, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.;CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Hôpital Lyon Sud, Pierre-Bénite 69495, France, Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France, COVID-O-HCL Consortium, Hospices Civils de Lyon, Lyon, France, FCRIN/FORCE Network, Centre de Recherche en Nutrition Humaine Rhône-Alpes, Lyon, France.;CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Hôpital Lyon Sud, Pierre-Bénite 69495, France, Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite 69495, France, COVID-O-HCL Consortium, Hospices Civils de Lyon, Lyon, France. | 784 | |||||||
| 10.1016/j.jcv.2020.104447 | Journal Article;Review | en | Evidence and possible mechanisms of rare maternal-fetal transmission of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32425663 | While SARS-CoV-2 infection has spread rapidly worldwide, data remains scarce about the natural history of infection in pregnant women and the risk of mother-to-fetal transmission. Current data indicates that viral RNA levels in maternal blood are low and there is no evidence of placental infection with SARS-CoV-2. Published reports to date suggest that perinatal transmission of SARSCoV- 2 can occur but is rare. Among 179 newborns tested for SARS-CoV2 at birth from mothers with COVID-19, transmission was suspected in 8 cases, 5 with positive nasopharyngeal SARS-CoV-2 RT-PCR and 3 with SARS-CoV-2 IgM. However, these cases arise from maternal infection close to childbirth and there are no information about exposition during first or second trimester of pregnancy. Welldesigned prospective cohort studies with rigorous judgement criteria are needed to determine the incidence and risk factors for perinatal transmission of SARS-CoV-2. | 1386-6532 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus__physiology;Cohort Studies;Coronavirus Infections__transmission;Female;Humans;Incidence;Infant, Newborn;Infectious Disease Transmission, Vertical;Mothers;Nasopharynx__virology;Pandemics;Pneumonia, Viral__transmission;Pregnancy;Prospective Studies;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Clinical Virology | Charles Egloff;Christelle Vauloup-Fellous;Olivier Picone;Laurent Mandelbrot;Pierre Roques | COVID-19;Cellular tropism;Fetus;Maternal-infant infection;Newborn;Severe acute respiratory syndrome;Trans-placental passage | 2020-05-18 02:00:00+02:00 | 32425663 | FR | Service de gynécologie-obstétrique, Hôpital Louis Mourier, AP-HP, Université de PARIS, IAME INSERM U1137, Paris, France, IDMIT, CEA, IMVA INSERM U1184, Université Paris Saclay, Fontenay aux Roses, France. Electronic address: charles.egloff@cea.fr.;Service de Virologie, Hôpital Paul Brousse, AP-HP, Inserm U 1193, Université Paris Saclay, Villejuif, France.;Service de gynécologie-obstétrique, Hôpital Louis Mourier, AP-HP, Université de PARIS, IAME INSERM U1137, Paris, France.;IDMIT, CEA, IMVA INSERM U1184, Université Paris Saclay, Fontenay aux Roses, France. Electronic address: pierre.roques@cea.fr. | 786 | ||
| Letter | en | Teledermatology for COVID-19 cutaneous lesions: substitute or supplement? | https://www.ncbi.nlm.nih.gov/pubmed/32422693 | 2020-05-24 02:00:00+02:00 | pubmed | C Skayem;C Cassius;M Ben Kahla;C Fiani;L Frumholtz;M Mrad;A Petit;E Zuelgaray;M Bagot;J D Bouaziz;T A Duong | 2020-05-18 02:00:00+02:00 | 32422693 | FR | Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.;Faculty of Medicine, Paris Diderot University, Paris, France.;Dermatology Department, AP-HP, Paris University, Saint-Louis Hospital, Paris, France.;INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Université de Paris, Paris, France.;Chaire Avenir Santé numérique, Equipe 8 IMRB U955, INSERM, Université Paris Est Créteil, Créteil, France. | 787 | ||||||||
| 10.1016/j.surg.2020.05.006 | Journal Article | en | Surgical outcomes after systematic preoperative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) screening. | https://www.ncbi.nlm.nih.gov/pubmed/32425247 | 0039-6060 | 2020-05-24 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__diagnosis;Digestive System Surgical Procedures__adverse effects;Elective Surgical Procedures;Emergencies;Female;France__epidemiology;Hospital Units__organization & administration;Hospitals, University;Humans;Length of Stay__statistics & numerical data;Male;Mass Screening;Middle Aged;Operating Rooms__organization & administration;Pandemics;Pneumonia, Viral__diagnosis;Postoperative Complications;Preoperative Care;Retrospective Studies;COVID-19;severe acute respiratory syndrome coronavirus 2 | Surgery | Gilles Tilmans;Quentin Chenevas-Paule;Xavier Muller;Antoine Breton;Kayvan Mohkam;Christian Ducerf;Jean-Yves Mabrut;Mickaël Lesurtel | 2020-05-18 02:00:00+02:00 | 32425247 | FR | Department of Digestive Surgery and Liver Transplantation, Croix Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France.;Department of Digestive Surgery and Liver Transplantation, Croix Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France. Electronic address: mickael.lesurtel@chu-lyon.fr. | 788 | ||||
| 10.12688/f1000research.23843.1 | Journal Article | en | A snapshot of the ongoing clinical research on COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32518636 | The pandemic of coronavirus disease 2019 (COVID-19) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies. Currently, thousands of new COVID-19 patients are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the COVID-19 studies registered in ClinicalTrials.gov and report the extent to which they have incorporated features that are desirable for generating high-quality evidence. On April 28, 2020, a total of 945 studies on COVID-19 have been registered in ClinicalTrials.gov; 586 studies are interventional (62.0%), the most frequent allocation scheme is the parallel group assignment (437; 74.6%), they are open-label and the most common primary purpose is the research on treatment. Too many of the ongoing interventional studies have a small expected sample size and may not generate credible evidence at completion. This might lead to a delayed recognition of effective therapies that are urgently needed, and a waste of time and resources. In the COVID-19 pandemic era, it is crucial that the adoption of new diagnostic, preventive and therapeutic strategies is based upon evidence coming from well-designed, adequately powered and carefully conducted clinical trials. | 2046-1402 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Biomedical Research__trends;Clinical Trials as Topic;Coronavirus Infections__drug therapy;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | F1000Research | Daniele Piovani;Claudia Pansieri;Laurent Peyrin-Biroulet;Silvio Danese;Stefanos Bonovas | 2019 novel coronavirus;2019-nCoV;Covid-19;SARS-CoV-2;severe acute respiratory syndrome coronavirus 2 | 2020-05-18 02:00:00+02:00 | 32518636 | FR;IT | Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, 20090, Italy.;Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, 20089, Italy.;Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France. | 789 | ||
| 10.3390/jcm9051521 | Journal Article;Review | en | SARS-CoV-2 in Pregnancy: A Comprehensive Summary of Current Guidelines. | https://www.ncbi.nlm.nih.gov/pubmed/32443538 | Since the declaration of the global pandemic of COVID-19 by the World Health Organization on 11 March 2020, we have continued to see a steady rise in the number of patients infected by SARS-CoV-2. However, there is still very limited data on the course and outcomes of this serious infection in a vulnerable population of pregnant patients and their fetuses. International perinatal societies and institutions including SMFM, ACOG, RCOG, ISUOG, CDC, CNGOF, ISS/SIEOG, and CatSalut have released guidelines for the care of these patients. We aim to summarize these current guidelines in a comprehensive review for patients, healthcare workers, and healthcare institutions. We included 15 papers from 10 societies through a literature search of direct review of society's websites and their journal publications up till 20 April 2020. Recommendations specific to antepartum, intrapartum, and postpartum were abstracted from the publications and summarized into Tables. The summary of guidelines for the management of COVID-19 in pregnancy across different perinatal societies is fairly consistent, with some variation in the strength of recommendations. It is important to recognize that these guidelines are frequently updated, as we continue to learn more about the course and impact of COVID-19 in pregnancy. | 2077-0383 | 2020-05-24 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Kavita Narang;Eniola R Ibirogba;Amro Elrefaei;Ayssa Teles Abrao Trad;Regan Theiler;Roseli Nomura;Olivier Picone;Mark Kilby;Ramón Escuriet;Anna Suy;Elena Carreras;Gabriele Tonni;Rodrigo Ruano | COVID-19;SARS-CoV-2;coronavirus;guidelines;pandemic;perinatal;pregnancy;prevention;screening | 2020-05-18 02:00:00+02:00 | 32443538 | FR;GB;US;BR;IT;ES;PS | Maternal-Fetal Medicine Division, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.;Obstetrics Division, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.;Department of Obstetrics and Gynecology, Escola Paulista de Medicina - Universidade Federal de São Paulo, São Paulo 04021, Brazil.;Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), CNGOF, Service de Gynécologie-Obstétrique Colombes, Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Université de Paris, Inserm IAME-U1137, 75000 Paris, France.;Fetal Medicine Centre, Birmingham Women's and Children's Foundation Trust, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.;.Catalan Health Service, Government of Catalonia, Barcelona 080028, Spain.;Department of Obstetrics and Gynecology, Hospital Universitari Vall d'Hebron, 080028 Barcelona, Spain.;Prenatal Diagnostic Division, Department of Obstetrics and Gynecology, AUSL di Reggio Emilia Istituto di Ricerca a Carattere Clinico Scientifico, 42100 Reggio Emilia, Italy. | 792 | |||
| Letter | en | Encephalopathy in patients with COVID-19: 'Causality or coincidence?' | https://www.ncbi.nlm.nih.gov/pubmed/32427357 | The main tropism of the novel coronavirus disease 2019 (COVID-19) is respiratory. Increasing evidences show that SARS-CoV-2 is not always confined to the respiratory tract but can also invade the central nervous system (CNS) and induce neurological diseases. We report two cases illustrating this phenomenon. This article is protected by copyright. All rights reserved. | 2020-05-24 02:00:00+02:00 | pubmed | Souheil Zayet;Yousri Ben Abdallah;Pierre-Yves Royer;Lynda Toko-Tchiundzie;Vincent Gendrin;Timothee Klopfenstein | Coronavirus;Nervous system;SARS coronavirus | 2020-05-19 02:00:00+02:00 | 32427357 | FR | Nord Franche-Comté Hospital, Department of Infectious Diseases, Trevenans, 90400, France.;Nord Franche-Comté Hospital, Department of Pneumology, Trevenans, 90400, France. | 798 | ||||||
| 10.1016/j.amp.2020.05.002 | English Abstract;Journal Article | fr | [Jail incarceration, social sanitary confinement and ways of escape]. | https://www.ncbi.nlm.nih.gov/pubmed/32836295 | Jail incarceration and social confinement due to a sanitary stay-at-home law against the ongoing COVID-19 pandemic are compared to the introduction of dance workshops for imprisoned women charged with long sentences, then followed by an outside performance Soul Kitchen. The whole experience, organized by a famous contemporary choreographer Angelin Preljocaj, is filmed by Valérie Müller, producing Danser sa peine (To dance her sentence/her sorrow), nominated for an award. The sessions are planned: two hours and a half, 2 times a week, for four months, no technique required. A group of five women start with ordinary easy functional movements, gaining in innovative and expressive qualities, spatial perceptions, feelings and interpersonal interactions, lead by A. Preljocaj in a helpful and empathic mood. At the same time, he discovers the cooking authorization in their jail cell. The relevant results shift into a dynamic successful piece Soul Kitchen (2019) performed in town (Dance Festival in Montpellier, south of France) with dancing and cooking occurrences on stage. It makes sense, specially about self-esteem, body image and positive opinion from the audience. The women's physical and psychological states linked with a long lack of space and sensitivity… move to a better self-balance and feelings of well-being. In a similar state of mind, the French confined population - youth to elderly - try to find different and imaginative strategies at home as moving in a restrictive area, enjoying family cooking… through trainings provided by Internet, looking for reducing anxiety, depressive disorders and other social problems. A panel of situations goes from deleterious conflictual relationships, dramatic isolation, to funny and positive ones using creativeness to escape, facing the disruption of daily life. | 0003-4487 | 2020-05-24 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Jocelyne Vaysse;Antonella Poli | Art-therapy;Dance;Imaginary;Incarceration;Pandemic;Self-esteem;Socialization | 2020-05-19 02:00:00+02:00 | 32836295 | FR | 5, rue Foucault, 92110 Clichy, France.;7, rue de Thorigny, Paris, France. | 799 | |||
| 10.1177/1932296820929370 | Journal Article | en | Personal Experience With COVID-19 and Diabetes in the South of France: Technology Facilitates the Management of Diabetes in Disruptive Times. | https://www.ncbi.nlm.nih.gov/pubmed/32429701 | 1932-2968,1932-2968 | 2020-05-24 02:00:00+02:00 | pubmed | Blood Glucose__analysis;Blood Glucose Self-Monitoring;Coronavirus Infections__epidemiology;Diabetes Complications__prevention & control;Diabetes Mellitus__therapy;Diabetes Mellitus, Type 1__complications;France__epidemiology;Humans;Hypoglycemic Agents__therapeutic use;Insulin__therapeutic use;Insulin Infusion Systems;Pandemics;Pneumonia, Viral__epidemiology;Telemedicine__methods;COVID-19 | Journal of Diabetes Science and Technology | Eric Renard | COVID-19;continuous glucose monitoring;diabetes technology;insulin pump;telemedicine | 2020-05-19 02:00:00+02:00 | 32429701 | FR | Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital, France.;Institute of Functional Genomics, CNRS UMR 5203, INSERM U1191, University of Montpellier, France.;INSERM Clinical Investigation Centre 1411, Montpellier, France. | 805 | |||
| 10.3390/diagnostics10050319 | Journal Article | en | Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32438677 | The emergence of Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 made imperative the need for diagnostic tests that can identify the infection. Although Nucleic Acid Test (NAT) is considered to be the gold standard, serological tests based on antibodies could be very helpful. However, individual studies are usually inconclusive, thus, a comparison of different tests is needed. We performed a systematic review and meta-analysis in PubMed, medRxiv and bioRxiv. We used the bivariate method for meta-analysis of diagnostic tests pooling sensitivities and specificities. We evaluated IgM and IgG tests based on Enzyme-linked immunosorbent assay (ELISA), Chemiluminescence Enzyme Immunoassays (CLIA), Fluorescence Immunoassays (FIA), and the Lateral Flow Immunoassays (LFIA). We identified 38 studies containing data from 7848 individuals. Tests using the S antigen are more sensitive than N antigen-based tests. IgG tests perform better compared to IgM ones and show better sensitivity when the samples were taken longer after the onset of symptoms. Moreover, a combined IgG/IgM test seems to be a better choice in terms of sensitivity than measuring either antibody alone. All methods yield high specificity with some of them (ELISA and LFIA) reaching levels around 99%. ELISA- and CLIA-based methods perform better in terms of sensitivity (90%-94%) followed by LFIA and FIA with sensitivities ranging from 80% to 89%. ELISA tests could be a safer choice at this stage of the pandemic. LFIA tests are more attractive for large seroprevalence studies but show lower sensitivity, and this should be taken into account when designing and performing seroprevalence studies. | 2075-4418 | 2020-05-24 02:00:00+02:00 | pubmed | Diagnostics | Panagiota I Kontou;Georgia G Braliou;Niki L Dimou;Georgios Nikolopoulos;Pantelis G Bagos | COVID-19;ELISA;IgG;IgM;SARS-CoV-2;antibody test | 2020-05-19 02:00:00+02:00 | 32438677 | FR;GR;CY | Department of Computer Science and Biomedical Informatics, University of Thessaly, Papasiopoulou 2-4, 35131 Lamia, Greece.;International Agency for Research on Cancer, 69372 Lyon, France.;Medical School, University of Cyprus, 1678 Nicosia, Cyprus. | 807 | |||
| 10.12890/2020_001728 | Journal Article | en | Respiratory Distress in SARS-CoV-2 without Lung Damage: Phrenic Paralysis Should Be Considered in COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32523929 | We describe an overweight COVID-19 patient with respiratory distress preceded by anosmia/dysgeusia with no lung injury shown on CT, angio-CT or ventilation/perfusion scans. Orthopnoea and paradoxical abdominal respiration were identified. Phrenic paralysis, demonstrated by examination of patient breathing, and on x-ray while standing breathing in and out, explained the respiratory distress. This is a rare and previously undescribed neurological complication of COVID-19 infection caused by vagus nerve injury. | 2020-05-24 02:00:00+02:00 | pubmed | Francois Maurier;Benoit Godbert;Julie Perrin | COVID-19;neurotropism;phrenic paralysis;respiratory distress | 2020-05-21 02:00:00+02:00 | 32523929 | FR | Hôpitaux Privés de Metz, Metz, France. | 809 | |||||
| 10.1016/s0140-6736(20)31174-0 | Journal Article;Retracted Publication | en | Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? | https://www.ncbi.nlm.nih.gov/pubmed/32450109 | 0140-6736 | 2020-05-24 02:00:00+02:00 | pubmed | The Lancet | Christian Funck-Brentano;Joe-Elie Salem | 2020-05-22 02:00:00+02:00 | 32450109 | FR | AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France, INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France. Electronic address: christian.funck-brentano@aphp.fr.;AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France, INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France. | 812 | |||||
| 10.1016/j.anorl.2020.05.006 | Journal Article | en | How and why use the EasyBreath® surface snorkeling mask as a personal protective equipment during the COVID-19 pandemic? | https://www.ncbi.nlm.nih.gov/pubmed/32493648 | During the COVID-19 outbreak, personal protective equipment is widely used to limit infection of caregivers. Innovative solutions have been described to overcome supply shortage. The adaptation of the EasyBreath® surface snorkeling mask by the Prakash team has benefited from outstanding media coverage. We present four 3D-printed devices that we have modified from the initial innovative design in order to adapt to local constraints. We tested the mask during surgery. The modifications that we made provide better ergonomics, visibility and communication capacities, but that have no official approval for use and can therefore only be recommended in the absence of a validated alternative solution. 3D printing is a tool of prime importance in the production of devices for medical use in health crisis situations. | 1879-7296 | 2020-05-24 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | B Thierry;C Célérier;F Simon;C Lacroix;R-H Khonsari | 3D printing;COVID-19;Personal protective equipment;SARS-CoV-2;Tracheostomy | 2020-05-23 02:00:00+02:00 | 32493648 | FR | Pediatric ENT Department, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, 149, rue de Sèvres, 75015 Paris, France. Electronic address: briac.thierry@aphp.fr.;Pediatric ENT Department, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, 149, rue de Sèvres, 75015 Paris, France.;Department of Otorhinolaryngology, Head and Neck Surgery, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, Paris, France.;Department of Pediatric Maxillofacial and Plastic Surgery, Head and Neck Surgery, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, Paris, France. | 815 | |||
| 10.1016/j.therap.2020.05.010 | Journal Article | en | Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. | https://www.ncbi.nlm.nih.gov/pubmed/32473812 | Chloroquine and hydroxychloroquine are drugs that have shown in vitro activity on the replication of certain coronaviruses. In the context of the SARS-Cov-2 epidemic, the virus responsible for the novel coronavirus disease (COVID-19), these two drugs have been proposed as possible treatments. The results of the first clinical studies evaluating the effect of hydroxychloroquine do not support any efficacy of this drug in patients with COVID-19, due to major methodological weaknesses. Yet, these preliminary studies have aroused considerable media interest, raising fears of massive and uncontrolled use. In the absence of evidence of clinical benefits, the main risk is of exposing patients unnecessarily to the well-known adverse effects of hydroxychloroquine, with a possibly increased risk in the specific setting of COVID-19. In addition, widespread use outside of any recommendation risks compromising the completion of good quality clinical trials. The chloroquine hype, fueled by low-quality studies and media announcements, has yielded to the implementation of more than 150 studies worldwide. This represents a waste of resources and a loss of opportunity for other drugs to be properly evaluated. In the context of emergency, rigorous trials are more than ever needed in order to have, as soon as possible, reliable data on drugs that are possibly effective against the disease. Meanwhile, serious adverse drug reactions have been reported in patients with COVID-19 receiving hydroxychloroquine, justifying to limit its prescription, and to perform suitable cardiac and therapeutic drug monitoring. | 0040-5957 | 2020-05-24 02:00:00+02:00 | pubmed | Therapies | M Roustit;R Guilhaumou;M Molimard;M-D Drici;S Laporte;J-L Montastruc | COVID-19;Chloroquine;Coronavirus;Hydroxychloroquine;SARS-Cov-2 | 2020-05-23 02:00:00+02:00 | 32473812 | FR | Pharmacologie clinique, Université Grenoble Alpes, CHU de Grenoble, 38043 Grenoble, France. Electronic address: mroustit@chu-grenoble.fr.;Aix Marseille Université, hôpital de la Timone, institut de neuroscience des systèmes, 13005 Marseille, France.;Service de pharmacologie médicale, University Bordeaux, Inserm U1219, 33076 Bordeaux, France.;Pharmacovigilance - Department of Pharmacology, Pasteur Hospital, 06001 Nice, France.;Université Jean Monnet, Université de Lyon, et unité de recherche clinique, innovation, pharmacologie, CHU Saint-Etienne, 42055 Saint-Étienne, France.;Service de pharmacologie médicale et clinque, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, CIC INSERM 1436, faculté de Médecine, centre hospitalier universitaire de Toulouse, 31000 Toulouse, France. | 821 | |||
| 10.1016/j.resmer.2020.100769 | Practice Guideline | en | Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32563968 | The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels. | 2590-0412 | 2020-05-24 02:00:00+02:00 | pubmed | Respiratory Medicine and Research | N Girard;L Greillier;G Zalcman;J Cadranel;D Moro-Sibilot;J Mazières;C Audigier-Valette;J Bennouna;B Besse;A Cortot;S Couraud;M Duruisseaux;E Giroux-Leprieur;A-C Toffart;V Westeel;M Wislez | 2020-05-24 02:00:00+02:00 | 32563968 | FR | Department of Medical Oncology, Institut Curie, 75005 Paris, France. Electronic address: Nicolas.girard2@curie.fr.;Aix-Marseille Université, AP-HM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, 13915 Marseille, France.;Department of Thoracic Oncology, CIC 1425, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France.;Department of Thoracic Oncology, AP-HP, Hôpital Tenon, 75020 Paris, France.;Department of Pneumology, University Hospital of Grenoble, 38043 Grenoble, France.;Department of Pneumology, University Hospital of Toulouse, 31059 Toulouse, France.;Department of Pneumology, Hôpital Sainte-Musse, 83100 Toulon, France.;Department of Medical Oncology, University Hospital of Nantes, 44000 Nantes, France.;Department of Medical Oncology, Institut Gustave-Roussy, 94800 Villejuif, France.;Department of Pneumology, University Hospital of Lille, 59000 Lille, France.;Department of Pneumology and Thoracic Oncology, University Hospital of Lyon, 69002 Lyon, France.;Department of Thoracic Oncology, AP-HP, Hôpital Ambroise-Paré, 92100 Boulogne-Billancourt, France.;Department of Pneumology and Thoracic Oncology, University Hospital of Besançon, INSERM UMR 1098, Université de Franche-Comté, 25000 Besançon, France.;Department of Thoracic Oncology, AP-HP, Hôpital Cochin, Inserm UMR_S 1138, Université de Paris, 75014 Paris, France. | 824 | ||||
| Letter;Comment | en | Psychotic relapse from COVID-19 quarantine, a case report. | https://www.ncbi.nlm.nih.gov/pubmed/32516677 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Quarantine;Recurrence;COVID-19;severe acute respiratory syndrome coronavirus 2 | Sergio Sanchez-Alonso;Santiago Ovejero;Maria Luisa Barrigon;Enrique Baca-Garcia | 2020-05-22 02:00:00+02:00 | 32516677 | FR;ES;CL | Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain. Electronic address: serj.sad@gmail.com.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain, Department of Psychiatry, Madrid Autonomous University, Madrid, Spain.;Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain, Department of Psychiatry, Madrid Autonomous University, Madrid, Spain, Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, Spain, Department of Psychiatry, General Hospital of Villalba, Madrid, Spain, Department of Psychiatry, Infanta Elena University Hospital, Valdemoro, Spain, Universidad Católica del Maule, Talca, Chile, Department of Psychiatry. Centre Hospitalier Universitaire de Nîmes, Spain. | 826 | |||||||
| Case Reports;Letter | en | Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32356322 | 2020-05-24 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__epidemiology;Cytokines;Humans;Leukemia, Myelomonocytic, Chronic__genetics;Male;Myelodysplastic Syndromes__epidemiology;Myeloproliferative Disorders__epidemiology;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Mrinal M Patnaik;Terra Lasho;Eric Padron;Kristen McCullough;Aref Al-Kali;Ayalew Tefferi;Amer M Zeidan;Naseema Gangat;Michael Savona;David P Steensma;Eric Solary | 2020-05-22 02:00:00+02:00 | 32356322 | FR;US | Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.;Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.;Section of Hematology, Department of Internal Medicine , School of Medicine, Yale University and Yale Cancer Center, New Haven, Conneticut, USA.;Department of Internal Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.;Adult Leukemia Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusets, USA.;Department of Hematology, Institute Gustave Roussy, Paris, France. | 832 | |||||||
| Case Reports;Letter | en | Pay more attention to EEG in COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32482439 | 2020-05-24 02:00:00+02:00 | pubmed | Aged, 80 and over;Brain Diseases__diagnosis;Coronavirus Infections__complications;Electroencephalography__methods;Female;Humans;Pandemics;Pneumonia, Viral__complications;COVID-19 | M Flamand;A Perron;Y Buron;W Szurhaj | 2020-05-22 02:00:00+02:00 | 32482439 | FR | Department of Clinical Neurophysiology, Amiens University Medical Center, Amiens, France.;Department of Neurology, Amiens University Medical Center, Amiens, France.;Department of Clinical Neurophysiology, Amiens University Medical Center, Amiens, France. Electronic address: szurhaj.william@chu-amiens.fr. | 833 | |||||||
| 10.1002/hed.26278 | Journal Article;Review | en | Is the ultrasonic scalpel recommended in head and neck surgery during the COVID-19 pandemic? State-of-the-art review. | https://www.ncbi.nlm.nih.gov/pubmed/32441394 | Guidelines for ultrasonic devices use are imperative because infectious aerosols arising from airway procedures were a key etiologic factor in prior coronavirus outbreaks. This manuscript aims to summarize the available recommendations and the most relevant concepts about the use of ultrasonic scalpel during the SARS-CoV-2 pandemic. | 1043-3074,1097-0347 | 2020-05-24 02:00:00+02:00 | pubmed | Air Pollutants, Occupational__adverse effects;Betacoronavirus;Contraindications, Procedure;Coronavirus Infections__epidemiology;Humans;Infection Control;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Occupational Exposure__prevention & control;Otorhinolaryngologic Surgical Procedures__instrumentation;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Surgical Instruments;Ultrasonic Surgical Procedures__instrumentation;COVID-19;severe acute respiratory syndrome coronavirus 2 | Head & Neck | Miguel Mayo-Yánez;Christian Calvo-Henríquez;Jérôme R Lechien;Nicolas Fakhry;Tareck Ayad;Carlos M Chiesa-Estomba | SARS-CoV-2;aerosol;surgical smoke;ultrasonic scalpel;virus transmission | 2020-05-22 02:00:00+02:00 | 32441394 | FR;ES;BE;CA | Otorhinolaryngology-Head and Neck Surgery Department, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Galicia, Spain.;Clinical Research in Medicine, International Center for Doctorate and Advanced Studies (CIEDUS), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain.;Otorhinolaryngology-Head and Neck Surgery Department, Complexo Hospitalario Universitario Santiago de Compostela (CHUS), Santiago de Compostela, Galicia, Spain.;Human Anatomy & Experimental Oncology Department, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology , University of Mons (UMons), Mons, Belgium.;Otorhinolaryngology and Head and Neck Surgery Department, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Otolaryngology-Head and Neck Surgery Department, Universitary Hospital of la Conception Marseille, France.;Division of Otolaryngology-Head & Neck Surgery , Centre Hospitalier de l'Université de Montréal, Montreal, Canada.;Otorhinolaryngology-Head and Neck Surgery Department, Hospital Universitario Donostia, Donostia, Gipuzkoa, Spain. | 834 | ||
| 10.1016/j.encep.2020.05.012 | Journal Article | fr | [Coronavirus: Predictive brain and terror management]. | https://www.ncbi.nlm.nih.gov/pubmed/32517998 | Emerging infectious diseases like Covid-19 cause a major threat to global health. When confronted with new pathogens, individuals generate several beliefs about the epidemic phenomenon. Many studies have shown that individual protective behaviors largely depend on these beliefs. Due to the absence of treatment and vaccine against these emerging pathogens, the relation between these beliefs and these behaviors represents a crucial issue for public health policies. In the premises of the Covid-19 pandemic, several preliminary studies have highlighted a delay in the perception of risk by individuals, which potentially holds back the implementing of the necessary precautionary measures: people underestimated the risks associated with the virus, and therefore also the importance of complying with sanitary guidelines. During the peak of the pandemic, the salience of the threat and of the risk of mortality could then have transformed the way people generate their beliefs. This potentially leads to upheavals in the way they understand the world. Here, we propose to explore the evolution of beliefs and behaviors during the Covid-19 crisis, using the theory of predictive coding and the theory of terror management, two influential frameworks in cognitive science and in social psychology. | 0013-7006 | 2020-05-24 02:00:00+02:00 | pubmed | Adaptation, Psychological;Attitude to Health;Betacoronavirus;Brain__physiology;Communicable Disease Control;Coronavirus Infections__epidemiology;Culture;Denial, Psychological;Fear__psychology;Guideline Adherence;Guidelines as Topic;Health Behavior;Health Risk Behaviors;Humans;Hygiene;Models, Psychological;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Protective Devices;Risk Management;Risk Reduction Behavior;Universal Precautions;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | H Bottemanne;O Morlaàs;L Schmidt;P Fossati | Bayesian brain;Belief;Biais cognitif;Cerveau bayésie;Codage prédictif;Cognitive biases;Coronavirus;Covid-19;Croyance;Perceived risk;Perception du risque;Predictive coding;Terror management theory;Théorie de la gestion de la terreur | 2020-05-22 02:00:00+02:00 | 32517998 | FR | Control-Interoception-Attention team, Institut du cerveau et de la moelle épinière (ICM), UMR 7225/UMR_S 1127, Sorbonne University/CNRS/INSERM, Paris, France, Department for adult psychiatry, Pitié-Salpêtrière hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. Electronic address: hugo.bottemanne@gmail.com.;Control-Interoception-Attention team, Institut du cerveau et de la moelle épinière (ICM), UMR 7225/UMR_S 1127, Sorbonne University/CNRS/INSERM, Paris, France.;Control-Interoception-Attention team, Institut du cerveau et de la moelle épinière (ICM), UMR 7225/UMR_S 1127, Sorbonne University/CNRS/INSERM, Paris, France, Department for adult psychiatry, Pitié-Salpêtrière hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. | 844 | ||
| Letter;Comment | en | Sudden onset anosmia and dysgeusia in two patients: An early sign of SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32447056 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Centers for Disease Control and Prevention, U.S.;China;Coronavirus;Coronavirus Infections;Dysgeusia;Humans;Olfaction Disorders;Pandemics;Pneumonia, Viral;United States;COVID-19;severe acute respiratory syndrome coronavirus 2 | Ahmad Alamri;Constance Oriez;Florence Bouilloud;Olivier Dupuy;Adrien Ben Hamou | 2020-05-21 02:00:00+02:00 | 32447056 | FR | Paris Saint-Joseph hospital, 75014 Paris, France, Diabetology, endocrinology and nutrition department, 75014, Paris, France.;Paris Saint-Joseph hospital, 75014 Paris, France, Diabetology, endocrinology and nutrition department, 75014, Paris, France. Electronic address: abenhamou@hpsj.fr. | 848 | |||||||
| 10.1097/mpg.0000000000002729 | Journal Article | en | Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition. | https://www.ncbi.nlm.nih.gov/pubmed/32443020 | With the current coronavirus disease 2019 (COVID-19) pandemic, concerns have been raised about the risk to children with inflammatory bowel diseases (IBD). We aimed to collate global experience and provide provisional guidance for managing paediatric IBD (PIBD) in the era of COVID-19. | 0277-2116 | 2020-05-24 02:00:00+02:00 | pubmed | Adolescent;Adult;Betacoronavirus;Child;Consensus;Coronavirus Infections__chemically induced;Health Care Surveys;Humans;Immunologic Factors__adverse effects;Inflammatory Bowel Diseases__complications;Pandemics;Pneumonia, Viral__chemically induced;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Pediatric Gastroenterology & Nutrition | Dan Turner;Ying Huang;Javier Martín-de-Carpi;Marina Aloi;Gili Focht;Ben Kang;Ying Zhou;Cesar Sanchez;Michael D Kappelman;Holm H Uhlig;Gemma Pujol-Muncunill;Oren Ledder;Paolo Lionetti;Jorge Amil Dias;Frank M Ruemmele;Richard K Russell | 2020-05-23 02:00:00+02:00 | 32443020 | IL;FR;CN;PT;GB;US;IT;ES;KR | Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.;Department of Gastroenterology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.;Hospital Sant Joan de Déu, Barcelona, Spain.;Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy.;Kyungpook National University Children's Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.;Pediatric Gastrointestinal Unit H.G.U. Gregorio Maranon, Madrid, Spain.;Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, NC.;Translational Gastroenterology Unit, University of Oxford, Department of Paediatrics, John Radcliffe Hospital, University of Oxford, Biomedical Research Center Oxford, Oxford, UK.;Departement NEUROFARBA - University of Florence - Meyer children's Hospital - Florence, Florence, Italy.;Pediatric Gastroenterology, Centro Hospitalar Universitário S. João, Porto, Portugal.;Université Paris Descartes, Sorbonne Paris Cité, APHP, Hôpital Necker Enfants Malades, Paris, France.;Department of Paediatric Gastroenterology, The Royal Hospital for Sick Children, Edinburgh, UK. | 849 | |||
| 10.1136/esmoopen-2020-000793 | Journal Article;Practice Guideline;Review | en | ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. | https://www.ncbi.nlm.nih.gov/pubmed/32439716 | The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes.The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice.We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine.The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes. | 2059-7029 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Breast Neoplasms__diagnosis;Coronavirus Infections__epidemiology;Female;Health Priorities;Humans;Pandemics;Pneumonia, Viral__epidemiology;Public Health;Radiation Oncology__methods;Surgical Oncology__methods;Telemedicine__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | ESMO Open | Evandro de Azambuja;Dario Trapani;Sibylle Loibl;Suzette Delaloge;Elzbieta Senkus;Carmen Criscitiello;Philip Poortman;Michael Gnant;Serena Di Cosimo;Javier Cortes;Fatima Cardoso;Shani Paluch-Shimon;Giuseppe Curigliano | COVID-19;ESMO adapted recommendations;breast cancer | 2020-05-23 02:00:00+02:00 | 32439716 | FR;IL;PT;AT;IT;PL;ES;BE;PS;DE | Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Brussels, Belgium.;European Institute of Oncology (IEO) IRCCS, Milan, Italy.;GBG Forschungs GmbH, Neu-Isenburg, Germany.;Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France, France.;Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.;European Institute of Oncology IRCCS, Milan, Italy.;Iridium Kankernetwerk and University of Antwerp, Antwerp, Belgium.;Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.;Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona), Vall d'Hebron institute of Oncology (VHIO) (Barcelona), Barcelona, Madrid, Spain.;Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.;Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Jerusalem, Israel.;Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano, Italy giuseppe.curigliano@ieo.it. | 851 | ||
| 10.1007/s11523-020-00721-1 | Journal Article;Review | en | Impact of the COVID-19 Outbreak on the Management of Patients with Cancer. | https://www.ncbi.nlm.nih.gov/pubmed/32445083 | The coronavirus SARS-CoV-2 (COVID-19) outbreak is having a profound impact on the management of patients with cancer. In this review, we comprehensively investigate the various aspects of cancer care during the pandemic, taking advantage of data generated in Asia and Europe at the frontline of the COVID-19 pandemic spread. Cancer wards have been subjected to several modifications to protect patients and healthcare professionals from COVID-19 infection, while attempting to maintain cancer diagnosis, therapy, and research. In this setting, the management of COVID-19 infected patients with cancer is particularly challenging. We also discuss the direct and potential remote impacts of the global pandemic on the mortality of patients with cancer. As such, the indirect impact of the pandemic on the global economy and the potential consequences in terms of cancer mortality are discussed. As the infection is spreading worldwide, we are obtaining more knowledge on the COVID-19 pandemic consequences that are currently impacting and may continue to further challenge cancer care in several countries. | 1776-2596,1776-260X | 2020-05-24 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Betacoronavirus;Coronavirus Infections__diagnosis;Disease Outbreaks;Humans;Neoplasms__mortality;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Targeted Oncology | Eric Raymond;Catherine Thieblemont;Severine Alran;Sandrine Faivre | 2020-05-24 02:00:00+02:00 | 32445083 | FR | Department of Medical Oncology, Paris Saint-Joseph Hospital Group, 185 rue Raymond Losserand, 75014, Paris, France. eraymond@hpsj.fr.;Hemato-oncology, Saint-Louis Hospital, AP-HP, Paris 7 University, Paris, France.;Department of Gynecological and Mammary Surgery, Paris Saint-Joseph Hospital Group, Paris, France.;Medical Oncology, Saint-Louis Hospital, AP-HP, Paris 7 University, Paris, France. | 852 | |||
| 10.1016/j.jemep.2020.100528 | Journal Article | fr | [Historical setting of a dialogue between two pioneers of ethical reflection during the COVID-19 period]. | https://www.ncbi.nlm.nih.gov/pubmed/32835051 | 2352-5525 | 2020-05-24 02:00:00+02:00 | pubmed | Ethics, Medicine and Public Health | C Hervé | Assisted suicide;Covid-19;End of life;Ethical history;Religions;Sober medicine | 2020-05-21 02:00:00+02:00 | 32835051 | FR | Académie internationale éthique, médecine et politiques publiques (IAMEPH), université de Paris, 45, rue des Saints-Pères, 75006 Paris, France. | 858 | ||||
| 10.1016/j.nrl.2020.05.006 | Journal Article;Multicenter Study;Observational Study | en | Impact of the COVID-19 pandemic on headache management in Spain: an analysis of the current situation and future perspectives. | https://www.ncbi.nlm.nih.gov/pubmed/32561333 | The COVID-19 pandemic has had a great impact on healthcare systems. Spain, where headache is the main reason for outpatient neurology consultation, is one of the countries with the most reported cases of the disease. | 0213-4853 | 2020-05-24 02:00:00+02:00 | pubmed | Analgesics__therapeutic use;Antibodies, Monoclonal__therapeutic use;Betacoronavirus;Calcitonin Gene-Related Peptide Receptor Antagonists__therapeutic use;Coronavirus Infections;Cross-Sectional Studies;Disease Management;Emergency Medical Services__organization & administration;Forecasting;Headache__drug therapy;Health Care Surveys;Humans;Office Visits__statistics & numerical data;Pandemics;Patient Acceptance of Health Care;Personal Protective Equipment;Pneumonia, Viral;Referral and Consultation;Spain__epidemiology;Telemedicine__statistics & numerical data;Time-to-Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2 | Neurología | A López-Bravo;D García-Azorín;R Belvís;C González-Oria;G Latorre;S Santos-Lasaosa;Á L Guerrero-Peral | Asistencia sanitaria;COVID-19;Cefalea;Headache;Healthcare;Pandemia;Pandemic;Telemedicina;Telemedicine | 2020-05-21 02:00:00+02:00 | 32561333 | FR;ES;BG | Servicio de Neurología-Unidad de Tratamiento del Dolor, Hospital Reina Sofía, Navarra, España, Instituto de Investigación Sanitaria Aragón (IIS-A).;Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, España. Electronic address: davilink@hotmail.com.;Unidad de Cefaleas, Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Unidad de Cefaleas, Hospital Virgen del Rocío, Sevilla, España.;Unidad de Cefaleas, Servicio de Neurología, Hospital Universitario de Fuenlabrada, Fuenlabrada, España, Departamento de Medicina, Universidad Rey Juan Carlos, Madrid, España.;Instituto de Investigación Sanitaria Aragón (IIS-A), Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.;Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, España, Instituto de Investigación de Salamanca (IBSAL), Salamanca, España, Departamento de Medicina, Universidad de Valladolid, Valladolid, España. | 862 | ||
| Letter;Comment | en | Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32445671 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Sepsis;Ticagrelor;COVID-19;severe acute respiratory syndrome coronavirus 2 | Loukman Omarjee;Olivier Meilhac;Frédérique Perrot;Anne Janin;Guillaume Mahe | COVID-19;Neutrophil extracellular traps;P2Y12 inhibitor, Ticagrelor;Platelets – Neutrophils aggregates;Sepsis-induced coagulopathy;Vascular leakage | 2020-05-21 02:00:00+02:00 | 32445671 | FR;IN | Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France, Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France. Electronic address: loukman.omarjee@chu-rennes.fr.;Université de La Réunion, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France, CHU de La Réunion, Saint-Pierre F-97410, France.;Cellular and Molecular Biology Consultant, Rennes F-35033, France.;Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018, France.;Vascular Medicine Unit, Inserm, (Clinical Investigation Center 1414), Univ Rennes, CHU Rennes, Rennes F-35033, France. | 863 | ||||||
| 10.1530/eje-20-0445 | Journal Article;Review | en | ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism. | https://www.ncbi.nlm.nih.gov/pubmed/32438340 | This manuscript provides guidance on the management of thyroid dysfunction during the COVID-19 pandemic. Autoimmune thyroid diseases are not linked to increased risks of COVID-19. Uncontrolled thyrotoxicosis may result in more severe complications from SARS-CoV-2 infection, including thyroid storm. The management of patients with a new diagnosis of hyperthyroidism is best undertaken with a block-and-replace regimen due to limited biochemical testing availability. Antithyroid drug (ATD)-induced neutropenia may favour the progression of COVID-19 and symptoms of infection may be confused with SARS-CoV-2 infection. The withdrawal of ATDs and urgent measurement of neutrophils should be considered in case of flu-like manifestations occurring in the initial months of treatment. Urgent surgery or 131-I may be undertaken in selected cases of uncontrolled thyrotoxicosis. Patients with COVID-19 infection may present with conjunctivitis, which could cause diagnostic difficulties in patients with new or existing Graves' ophthalmopathy. Patients who are on replacement treatment with thyroid hormones should ensure they have sufficient supply of medication. The usual advice to increase dosage of levothyroxine during pregnancy should be adhered to. Many newly presenting and previously diagnosed patients with thyroid dysfunction can be managed through virtual telephone or video clinics supported by a dedicated nurse-led service, depending on available facilities. | 0804-4643,1479-683X | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnosis;Disease Management;Humans;Hyperthyroidism__diagnosis;Hypothyroidism__diagnosis;Pandemics;Pneumonia, Viral__diagnosis;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Endocrinology | Kristien Boelaert;W Edward Visser;Peter Nicholas Taylor;Carla Moran;Juliane Léger;Luca Persani | 2020-05-22 02:00:00+02:00 | 32438340 | FR;IE;GB;IT;NL | Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Academic Centre for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands.;Thyroid Research Group School of Medicine Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK.;Beacon Hospital, Sandyford, Dublin, Ireland.;Pediatric Endocrinology Diabetology Department, Reference Center for Growth and Development Endocrine Diseases, Université de Paris, Hopital Robert Debre, Paris, France.;Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.;Postgraduate School of Endocrinology and Metabolic Diseases, University of Milan, Milan, Italy.;Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, San Luca Hospital, Milan, Italy. | 871 | |||
| 10.1093/jac/dkaa213 | Journal Article | en | Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report. | https://www.ncbi.nlm.nih.gov/pubmed/32457980 | 0305-7453,1460-2091 | 2020-05-31 02:00:00+02:00 | pubmed | Journal of Antimicrobial Chemotherapy | Juliette Kauv;Minh P Lê;Marc Veyrier;Quentin Le Hingrat;Benoit Visseaux;Laurent Massias;Marie-Paule Chauveheid;Diane Descamps;Jade Ghosn;Gilles Peytavin | 2020-05-28 02:00:00+02:00 | 32457980 | FR | AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.;INSERM, UMRS-1144, Université de Paris, 75006 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Pharmacy Department, 75018 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Virology Department, 75018 Paris, France.;IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Internal Medicine Department, 75018 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Infectious Diseases Department, 75018 Paris, France. | 879 | |||||
| 10.1093/jac/dkaa191 | Journal Article | en | Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. | https://www.ncbi.nlm.nih.gov/pubmed/32473020 | Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. Thus, we propose a hydroxychloroquine sulphate dose regimen of 400 mg twice daily at Day 1 then 400 mg once daily from Day 2 to Day 10. We aim to evaluate this in the C-20-15 DisCoVeRy trial. | 0305-7453,1460-2091 | 2020-05-31 02:00:00+02:00 | pubmed | Journal of Antimicrobial Chemotherapy | Minh Patrick Lê;Nathan Peiffer-Smadja;Jeremie Guedj;Nadège Néant;France Mentré;Florence Ader;Yazdan Yazdanpanah;Gilles Peytavin | 2020-05-31 02:00:00+02:00 | 32473020 | FR | AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.;INSERM, UMRS-1144, Université de Paris, 75006 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.;IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.;Hospices Civils de Lyon, Department of Infectious Diseases, Croix-Rousse Hospital, 104 Grande-Rue de la Croix-Rousse, Lyon 69004, France.;Université Claude Bernard Lyon 1, Inserm, 1111, Centre International de Recherche en Infectiologie (CIRI) UCBL1, Lyon, France. | 885 | ||||
| 10.1097/rlu.0000000000003113 | Case Reports;Journal Article | en | FDG PET/CT in a Patient With Mantle Cell Lymphoma and COVID-19: Typical Findings. | https://www.ncbi.nlm.nih.gov/pubmed/32453077 | A 52-year-old woman with no medical history was admitted on March 18, 2020, presenting since 3 days asthenia, abdominal pain, and dry cough but no fever. Adenomegalies, splenomegaly, leukocytosis, and elevated LDH suggested mature lymphoproliferation. Considering the current health context, an RT-PCR testing for COVID-19 (coronavirus disease 2019) was performed and found to be positive. Early chest CT showed no sign of pulmonary infection but multiple adenomegalies. An F-FDG PET/CT performed 5 days later to assess the extent of the hemopathy revealed the apparition of FDG-avid bilateral ground glass and subpleural curvilinear opacities suggesting COVID-19-associated pneumopathy. | 0363-9762 | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Clinical Laboratory Techniques;Coronavirus Infections__complications;Female;Fluorodeoxyglucose F18;Humans;Lung__diagnostic imaging;Lymphoma, Mantle-Cell__complications;Middle Aged;Pandemics;Pneumonia, Viral__complications;Positron Emission Tomography Computed Tomography;Radiopharmaceuticals;COVID-19;COVID-19 diagnostic testing | Clinical Nuclear Medicine | Margot Playe;Justine Siavellis;Thorsten Braun;Michaël Soussan | 2020-05-27 02:00:00+02:00 | 32453077 | FR;UNK | From the Departments of Nuclear Medicine.;Hematology, Avicenne Hospital, Hopitaux universitaires Paris Seine Saint Denis, AP-HP, France.;UMR 1288, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Inserm, Institut Curie, France. | 886 | |||
| 10.1007/s10554-020-01892-8 | Journal Article;Review | en | Cardiac imaging procedures and the COVID-19 pandemic: recommendations of the European Society of Cardiovascular Radiology (ESCR). | https://www.ncbi.nlm.nih.gov/pubmed/32451877 | The severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2) pandemic currently constitutes a significant burden on worldwide health care systems, with important implications on many levels, including radiology departments. Given the established fundamental role of cardiovascular imaging in modern healthcare, and the specific value of cardiopulmonary radiology in COVID-19 patients, departmental organisation and imaging programs need to be restructured during the pandemic in order to provide access to modern cardiovascular services to both infected and non-infected patients while ensuring safety for healthcare professionals. The uninterrupted availability of cardiovascular radiology services remains, particularly during the current pandemic outbreak, crucial for the initial evaluation and further follow-up of patients with suspected or known cardiovascular diseases in order to avoid unnecessary complications. Suspected or established COVID-19 patients may also have concomitant cardiovascular symptoms and require further imaging investigations. This statement by the European Society of Cardiovascular Radiology (ESCR) provides information on measures for safety of healthcare professionals and recommendations for cardiovascular imaging during the pandemic in both non-infected and COVID-19 patients. | 1569-5794,1573-0743 | 2020-05-31 02:00:00+02:00 | pubmed | The International Journal of Cardiovascular Imaging | Dietrich Beitzke;Rodrigo Salgado;Marco Francone;Karl-Friedrich Kreitner;Luigi Natale;Jens Bremerich;Matthias Gutberlet;Ellie Mousseaux;Konstantin Nikolaou;Charles Peebles;Birgitta Velthuis;Rozemarijn Vliegenthart;Christian Loewe;Tilman Emrich;Natale Luigi;Gutberlet Matthias;Vliegenthart Rozemarijn;Nikolaou Konstantin;Francone Marco;Loewe Christian;Velthuis Brigitta;Salgado Rodrigo;Peebles Charles;Mousseaux Ellie | COVID-19;Cardiac magnetic resonance;Cardiovascular computed tomography;SARS-Cov-2;Safety | 2020-05-26 02:00:00+02:00 | 32451877 | FR;CH;AT;GB;US;IT;NL;BE;DE | Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Wien, Austria.;Department of Radiology, Antwerp University Hospital & Holy Heart Hospital, Antwerp/Lier, Belgium. rodrigo.salgado@uza.be.;Department of Radiological, Oncological and Pathological Sciences, Sapienza University, Policlinico Umberto I, Rome, Italy.;Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.;Department of Radiological and Haematological Sciences - Institute of Radiology, Catholic University of Rome, Fondazione Policlinico Universitario Gemelli - IRCCS, Rome, Italy.;Department of Radiology, University Hospital Basel, Basel, Switzerland.;Department of Radiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany.;Department of Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.;Department for Diagnostic and Interventional Radiology, University Hospital Tuebingen, Tuebingen, Germany.;Department of Cardiothoracic Radiology, University Hospital Southampton, Southampton, UK.;Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Radiology, University Medical Center Groningen, Groningen, The Netherlands.;Division of Cardiovascular Imaging, Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, SC, USA.;German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany. | 891 | |||
| 10.1016/j.revmed.2020.05.003 | Journal Article;Review | fr | [COVID-19: Pathogenesis of a multi-faceted disease]. | https://www.ncbi.nlm.nih.gov/pubmed/32507520 | SARS-CoV-2 infection, named COVID-19, can lead to a dysregulated immune response and abnormal coagulation responsible for a viral sepsis. In this review, we specify physiopathological mechanisms of each phase of COVID-19 - viral, immune and pro-thrombotic - notably because they involve different treatment. Finally, we specify the physiopathological mechanisms of organ injury. | 0248-8663 | 2020-05-31 02:00:00+02:00 | pubmed | Animals;Betacoronavirus__genetics;Coronavirus Infections__complications;Cytokines__metabolism;Humans;Immunization;Immunomodulation;Organ Specificity;Pandemics;Pneumonia, Viral__complications;Thrombosis__prevention & control;Viral Tropism;Virus Internalization;Virus Replication__physiology;Zoonoses__virology;COVID-19;severe acute respiratory syndrome coronavirus 2 | La Revue de Médecine Interne | V Bonny;A Maillard;C Mousseaux;L Plaçais;Q Richier | COVID-19;Immunity;Immunité;Pathogenesis;Physiopathologie;SARS-CoV-2;Thromboses;Thrombosis | 2020-05-27 02:00:00+02:00 | 32507520 | FR | Interne en DES de pneumologie, Sorbonne-université, France.;Interne en DES de maladies infectieuses, MSc, Université de Paris, France.;DES de néphrologie, MSc, Sorbonne-université, France.;Interne en DES de médecine interne, MSc, Sorbonne-université, France.;Interne en DES de médecine interne Paris, MSc, Université de Paris, France. Electronic address: quentin.richier@hotmail.fr. | 899 | ||
| ANR | 10.1007/s10456-020-09730-0 | Journal Article | en | Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32458111 | Coronavirus disease-2019 (COVID-19), a respiratory disease has been associated with ischemic complications, coagulation disorders, and an endotheliitis. | 0969-6970,1573-7209 | 2020-05-31 02:00:00+02:00 | pubmed | Angiogenesis | David M Smadja;Coralie L Guerin;Richard Chocron;Nader Yatim;Jeremy Boussier;Nicolas Gendron;Lina Khider;Jérôme Hadjadj;Guillaume Goudot;Benjamin Debuc;Philippe Juvin;Caroline Hauw-Berlemont;Jean-Loup Augy;Nicolas Peron;Emmanuel Messas;Benjamin Planquette;Olivier Sanchez;Bruno Charbit;Pascale Gaussem;Darragh Duffy;Benjamin Terrier;Tristan Mirault;Jean-Luc Diehl | Angiogenesis;Angiopoietin-2;Biomarker;COVID-19;E-selectin;Endothelial | 2020-05-27 02:00:00+02:00 | 32458111 | FR | [{"country": "", "agency": "ANR", "grantid": "SARCODO"}] | Université de Paris, Innovative Therapies in Haemostasis, INSERM, 75006, Paris, France. david.smadja@aphp.fr.;Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France. david.smadja@aphp.fr.;Université de Paris, Innovative Therapies in Haemostasis, INSERM, 75006, Paris, France.;Cytometry Department, Curie Institute, 75006, Paris, France.;Université de Paris, PARCC, INSERM, 75015, Paris, France.;Emergency Department, AP-HP, Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Laboratory of Dendritic Cell Immunobiology, Department of Immunology, Institut Pasteur, Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Université de Paris Imagine Institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR 1163, 75015, Paris, France.;Université de Paris, Plastic Surgery Department, Assistance Publique - Hôpitaux de Paris-Centre (APHP-CUP), 75015, Paris, France.;Université de Paris, Emergency Department, Assistance Publique - Hôpitaux de Paris-Centre (APHP-CUP), 75015, Paris, France.;Université de Paris, Intensive Care Unit, AH-HP, Georges Pompidou European Hospital, 75015, Paris, France.;Vascular Medicine Department, Assistance Publique - Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique - Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Institut Pasteur, Center for Translational Research, 75015, Paris, France.;Hematology Department, Assistance Publique - Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France.;Université de Paris, PARCC, INSERM U970, Paris, France.;Internal Medicine Department, AH-HP-Centre Université de Paris (CUP), 75014, Paris, France.;Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique - Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), 75015, Paris, France. | 907 | |
| Letter | en | Right-to-left interatrial shunt in COVID-19 patients with pulmonary embolism. | https://www.ncbi.nlm.nih.gov/pubmed/32492443 | 2020-05-31 02:00:00+02:00 | pubmed | Olivier Fabre;Olivier Rebet;Ilir Hysi | 2020-05-31 02:00:00+02:00 | 32492443 | FR | Department of Cardiac Surgery of Artois, Centre Hospitalier de Lens et Hôpital Privé de Bois Bernard, Ramsay Santé, France.;Department of Cardiac Surgery of Artois, Centre Hospitalier de Lens et Hôpital Privé de Bois Bernard, Ramsay Santé, France. Electronic address: ilirhysi@gmail.com. | 911 | ||||||||
| 10.1016/j.encep.2020.05.004 | Journal Article;Review | fr | [Responsiveness and sustainability of psychiatric care in France during COVID-19 epidemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32471705 | The sudden changes of healthcare system due to COVID-19 particularly affect the organization of psychiatry. The objective of this review is to examine the adaptations of psychiatric care in France during this pandemic. | 0013-7006 | 2020-05-31 02:00:00+02:00 | pubmed | Ambulatory Care__organization & administration;Bed Conversion;Betacoronavirus;Coronavirus Infections;France__epidemiology;Health Personnel__psychology;Health Services Accessibility;Hospital Restructuring;Hospitals, Psychiatric__organization & administration;Humans;Mental Disorders__epidemiology;Mental Health Services__organization & administration;Occupational Health;Pandemics;Patients' Rooms;Pneumonia, Viral;Psychotherapy__organization & administration;Social Change;Stress, Psychological__etiology;Telemedicine;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | R Bocher;C Jansen;P Gayet;P Gorwood;V Laprévote | COVID-19;Health system;Hospitalisation;Hospitalization;Organisation des soins;Psychiatrie;Psychiatry;SARS-COV-2 | 2020-05-26 02:00:00+02:00 | 32471705 | FR | Pôle hospitalo-universitaire de psychiatrie et d'addictologie, CHU de Nantes, 85, rue Saint-Jacques, 44093 Nantes cedex 01, France. Electronic address: rachel.bocher@chu-nantes.fr.;Centre psychothérapique de Nancy, pôle hospitalo-universitaire de psychiatrie d'adultes et d'addictologie, 54520 Laxou, France, Faculté de médecine de Nancy, université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.;Pôle hospitalo-universitaire de psychiatrie et d'addictologie, CHU de Nantes, 85, rue Saint-Jacques, 44093 Nantes cedex 01, France.;GHU Paris psychiatrie et neurosciences, CMME, hôpital Sainte-Anne, 75014 Paris, France, Université de Paris, institute of psychiatry and neuroscience of Paris (IPNP), Inserm U1266, 75014 Paris, France.;Centre psychothérapique de Nancy, pôle hospitalo-universitaire de psychiatrie d'adultes et d'addictologie, 54520 Laxou, France, Faculté de médecine de Nancy, université de Lorraine, 54500 Vandœuvre-lès-Nancy, France, Pôle de psychiatrie, fédération de médecine translationnelle de Strasbourg, institut national de la santé et de la recherche médicale U1114, université de Strasbourg, centre hospitalier régional universitaire de Strasbourg, Strasbourg, France. | 919 | ||
| 10.1016/j.jbusres.2020.05.026 | Journal Article | en | Managing uncertainty during a global pandemic: An international business perspective. | https://www.ncbi.nlm.nih.gov/pubmed/32501304 | Despite the perennial need to understand and manage uncertainty in international business, there is no comprehensive framework that incorporates different types of uncertainty, their antecedents and outcomes, and the different coping strategies used by managers and their outcomes. This makes it difficult for international business managers to understand the types of uncertainty in their businesses and develop appropriate strategies to deal with it effectively, especially during times such as the ongoing Covid-19 pandemic. This paper uses an extensive review of the international business literature to address the above research gap by identifying the different types of uncertainty, their antecedents and outcomes, the coping strategies used to mitigate their impact, and the consequences of these actions. The authors also use examples from the current Covid-19 crisis to assess the firms' responses and their consequences. The paper concludes with some implications for international business managers and directions for future research. | 0148-2963 | 2020-05-31 02:00:00+02:00 | pubmed | Journal of Business Research | Piyush Sharma;T Y Leung;Russel P J Kingshott;Nebojsa S Davcik;Silvio Cardinali | Covid-19;Globalization;International business;Risk;Trade;Uncertainty | 2020-05-25 02:00:00+02:00 | 32501304 | FR;GB;US;HK;IT;AU | School of Marketing, Curtin University, Bentley, WA 6102, Australia.;Lee Shau Kee School of Business & Administration, The Open University of Hong Kong.;EM Normandie Business School, Métis Lab, Oxford, UK.;Faculty of Economics "Giorgio Fuà", Università Politecnica delle Marche, Ancona, Italy. | 924 | |||
| Letter | en | Call for comments: climate and clean air responses to covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32458072 | 2020-05-31 02:00:00+02:00 | pubmed | Shardul Agrawala;Markus Amann;Graciela Binimelis de Raga;Nathan Borgford-Parnell;Michael Brauer;Harry Clark;Lisa Emberson;Andy Haines;Jiang Kejun;Nino Künzli;Johan Kuylenstierna;Rodolfo Lacy;Jian Liu;Yacob Mulugetta;Shonali Pachauri;V Ramanathan;A R Ravishankara;Drew Shindell;Supat Wongwangwatana | 2020-05-26 02:00:00+02:00 | 32458072 | FR;SE;CA;KE;NZ;CN;GB;US;CH;TH;MX;AT | Organization for Economic Co-operation and Development, Paris, France.;International Institute for Applied Systems Analysis, Laxenburg, Austria.;Universidad Nacional Autónoma de México, Mexico City, Mexico.;Climate and Clean Air Coalition, Paris, France. Nathan.borgford-parnell@un.org.;School of Population and Public Health, University of British Columbia, Vancouver, Canada.;New Zealand Agricultural Greenhouse Gas Research Centre, Palmerston North, New Zealand.;Stockholm Environment Institute, York, UK.;London School of Hygiene and Tropical Medicine, London, UK.;Energy Research Institute, National Development and Reform Commission, Beijing, China.;Swiss Tropical and Public Health Institute, Bern, Switzerland.;UN Environment Programme, Nairobi, Kenya.;Department of Science, Technology, Engineering and Public Policy, University College London, London, UK.;Scripps Institution of Oceanography, University of California San Diego, La Jolla, USA.;Department of Atmospheric Science, Colorado State University, Fort Collins, USA.;Nicholas School of the Environment, Duke University, Durham, USA.;Faculty of Public Health, Thammasat University, Bangkok, Thailand. | 930 | ||||||||
| Letter | en | Prone positioning combined with high-flow nasal or conventional oxygen therapy in severe Covid-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32456663 | 2020-05-31 02:00:00+02:00 | pubmed | Administration, Inhalation;Administration, Intranasal;Aged;Betacoronavirus;Coronavirus Infections__physiopathology;Humans;Male;Middle Aged;Oxygen Inhalation Therapy__methods;Pandemics;Pneumonia, Viral__physiopathology;Prone Position__physiology;Respiration, Artificial__methods;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cyrielle Despres;Yannick Brunin;Francis Berthier;Sebastien Pili-Floury;Guillaume Besch | 2020-05-26 02:00:00+02:00 | 32456663 | FR | Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, University of Franche-Comte, Besancon, France.;EA 3920, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besancon, France.;Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, University of Franche-Comte, Besancon, France. gbesch@chu-besancon.fr.;EA 3920, University of Franche-Comte, 3 bvd Alexander Fleming, 25000, Besancon, France. gbesch@chu-besancon.fr. | 932 | |||||||
| Letter | en | Non-COVID-19 emergencies: where have all the patients gone? | https://www.ncbi.nlm.nih.gov/pubmed/32458174 | • Early in the pandemic, numbers of patients undergoing non-COVID-19 emergent CTs dropped sharply but diagnostic yield did not increase, suggesting potentially undiagnosed emergencies in patients not seen in healthcare institutions. | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnostic imaging;Emergencies;Humans;Pandemics;Pneumonia, Viral__diagnostic imaging;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | Tom Boeken;Alice Le Berre;Anne Mebazaa;Isabelle Boulay-Coletta;Jérôme Hodel;Marc Zins | 2020-05-26 02:00:00+02:00 | 32458174 | FR | Department of Radiology, Groupe Hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France.;Department of Radiology, Groupe Hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France. mzins@hpsj.fr. | 934 | ||||||
| 10.1111/jth.14856 | Case Reports | en | COVID-19 and acute coagulopathy in pregnancy. | https://www.ncbi.nlm.nih.gov/pubmed/32302459 | We present a putative link between maternal COVID-19 infection in the peripartum period and rapid maternal deterioration with early organ dysfunction and coagulopathy. The current pandemic with SARS-CoV-2 has already resulted in high numbers of critically ill patients and deaths in the non-pregnant population, mainly due to respiratory failure. During viral outbreaks, pregnancy poses a uniquely increased risk to women due to changes to immune function, alongside physiological adaptive alterations, such as increased oxygen consumption and edema of the respiratory tract. The laboratory derangements may be reminiscent of HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome, and thus knowledge of the COVID-19 relationship is paramount for appropriate diagnosis and management. In addition to routine measurements of D-dimers, prothrombin time, and platelet count in all patients presenting with COVID-19 as per International Society on Thrombosis and Haemostasis (ISTH) guidance, monitoring of activated partial thromboplastin time (APTT) and fibrinogen levels should be considered in pregnancy, as highlighted in this report. These investigations in SARS-CoV-2-positive pregnant women are vital, as their derangement may signal a more severe COVID-19 infection, and may warrant pre-emptive admission and consideration of delivery to achieve maternal stabilization. | 1538-7933,1538-7836 | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Betacoronavirus__pathogenicity;Blood Coagulation;Blood Coagulation Tests;Clinical Laboratory Techniques;Coronavirus Infections__blood;Disseminated Intravascular Coagulation__blood;Female;Host-Pathogen Interactions;Humans;Pandemics;Pneumonia, Viral__blood;Pregnancy;Pregnancy Complications, Hematologic__blood;Pregnancy Complications, Infectious__blood;Pregnancy Trimester, Third__blood;Treatment Outcome;Young Adult;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Thrombosis and Haemostasis | Evangelia Vlachodimitropoulou Koumoutsea;Alexandre J Vivanti;Nadine Shehata;Alexandra Benachi;Agnes Le Gouez;Celine Desconclois;Wendy Whittle;John Snelgrove;Ann Kinga Malinowski | COVID-19;coagulopathy;disseminated intravascular coagulopathy;fibrinogen;pregnancy | 2020-05-26 02:00:00+02:00 | 32302459 | FR;CA | Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.;Division of Hematology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.;Department of Obstetrics and Gynecology, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, Clamart, France.;Anaesthesia and Critical Care Department, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, Clamart, France.;Biological Hematology, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, Clamart, France. | 935 | ||
| Letter;Comment | en | More on Neurologic Features in Severe SARS-CoV-2 Infection. Reply. | https://www.ncbi.nlm.nih.gov/pubmed/32453517 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Nervous System Diseases__virology;Pandemics;Pneumonia, Viral;Severe Acute Respiratory Syndrome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Julie Helms;Stéphane Kremer;Ferhat Meziani | 2020-05-26 02:00:00+02:00 | 32453517 | FR | Strasbourg University Hospital, Strasbourg, France.;University of Strasbourg, Strasbourg, France. | 942 | |||||||
| Letter | en | Perianesthetic concerns for the non-COVID-19 patients requiring surgery during the COVID-19 pandemic outbreak: An observational study. | https://www.ncbi.nlm.nih.gov/pubmed/32480207 | 2020-05-31 02:00:00+02:00 | pubmed | Gilles Boccara;David Cassagnol;Laurent Bargues;Thierry Guenoun;Benjamin Aubier;Ivan Goldstein;Stéphane Romano;Dan Longrois | Anesthesia;COVID-19;Non-COVID patient surgery | 2020-05-27 02:00:00+02:00 | 32480207 | FR;US | Anesthesia and Intensive Care Unit, American Hospital of Paris, Neuilly S/Seine, France. Electronic address: gilles.boccara@ahparis.org.;Well-Cornell Medical School, Presbyterian Hospital of New York, NYC, USA.;Anesthesia and Intensive Care Unit, American Hospital of Paris, Neuilly S/Seine, France.;Department of Surgery, American Hospital of Paris, Neuilly S/Seine, France.;University Hospital of Bichat, Paris 75018, France, Louis-Mourier, Colombes 92000, France. | 948 | |||||||
| 10.1212/nxi.0000000000000785 | Case Reports;Journal Article | en | Guillain-Barré syndrome related to SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32461235 | 2332-7812 | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Aged;Ageusia__etiology;Asthenia__etiology;Ataxia__etiology;Coronavirus Infections__complications;Diarrhea__etiology;Facial Paralysis__etiology;Female;Guillain-Barre Syndrome__cerebrospinal fluid;Humans;Immunoglobulins, Intravenous__therapeutic use;Immunologic Factors__therapeutic use;Male;Middle Aged;Myalgia__etiology;Neural Conduction;Olfaction Disorders__etiology;Pandemics;Paraparesis__etiology;Paresthesia__etiology;Pneumonia, Viral__complications;Quadriplegia__etiology;Reflex, Abnormal;Respiratory Insufficiency__etiology;COVID-19 | Neurology - Neuroimmunology Neuroinflammation | Kévin Bigaut;Martial Mallaret;Seyyid Baloglu;Benjamin Nemoz;Patrice Morand;Florent Baicry;Alexandre Godon;Paul Voulleminot;Laurent Kremer;Jean-Baptiste Chanson;Jérôme de Seze | 2020-05-27 02:00:00+02:00 | 32461235 | FR | From the Service de Neurologie (K.B., P.V., L.K., J.-B.C., J.S.), Hôpitaux Universitaires de Strasbourg, Service de Neurologie (M.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, Service de Neuroradiologie (S.B.), Hôpitaux Universitaires de Strasbourg, Institut de Biologie Structurale (IBS) (B.N., P.M.), Université de Grenoble Alpes, CEA, CNRS, Laboratoire de virologie (B.N., P.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, Service d'Accueil des Urgences (F.B.), Hôpitaux Universitaires de Strasbourg, and Service de Réanimation Polyvalente Chirurgicale (A.G.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, France. kevin.bigaut@chru-strasbourg.fr.;From the Service de Neurologie (K.B., P.V., L.K., J.-B.C., J.S.), Hôpitaux Universitaires de Strasbourg, Service de Neurologie (M.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, Service de Neuroradiologie (S.B.), Hôpitaux Universitaires de Strasbourg, Institut de Biologie Structurale (IBS) (B.N., P.M.), Université de Grenoble Alpes, CEA, CNRS, Laboratoire de virologie (B.N., P.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, Service d'Accueil des Urgences (F.B.), Hôpitaux Universitaires de Strasbourg, and Service de Réanimation Polyvalente Chirurgicale (A.G.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, France. | 949 | ||||
| 10.1055/s-0040-1713152 | Journal Article;Review | en | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. | https://www.ncbi.nlm.nih.gov/pubmed/32473596 | Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19. | 0340-6245,2567-689X | 2020-05-31 02:00:00+02:00 | pubmed | Animals;Anti-Inflammatory Agents__therapeutic use;Anticoagulants__therapeutic use;Antiviral Agents__therapeutic use;Betacoronavirus;Coronavirus Infections__complications;Fibrinolytic Agents__therapeutic use;Glycosaminoglycans__therapeutic use;Hemostasis;Humans;Inflammation__complications;Pandemics;Platelet Aggregation Inhibitors__therapeutic use;Pneumonia, Viral__complications;Thrombosis__complications;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Thrombosis and Haemostasis | Behnood Bikdeli;Mahesh V Madhavan;Aakriti Gupta;David Jimenez;John R Burton;Caroline Der Nigoghossian;Taylor Chuich;Shayan Nabavi Nouri;Isaac Dreyfus;Elissa Driggin;Sanjum Sethi;Kartik Sehgal;Saurav Chatterjee;Walter Ageno;Mohammad Madjid;Yutao Guo;Liang V Tang;Yu Hu;Laurent Bertoletti;Jay Giri;Mary Cushman;Isabelle Quéré;Evangelos P Dimakakos;C Michael Gibson;Giuseppe Lippi;Emmanuel J Favaloro;Jawed Fareed;Alfonso J Tafur;Dominic P Francese;Jaya Batra;Anna Falanga;Kevin J Clerkin;Nir Uriel;Ajay Kirtane;Claire McLintock;Beverley J Hunt;Alex C Spyropoulos;Geoffrey D Barnes;John W Eikelboom;Ido Weinberg;Sam Schulman;Marc Carrier;Gregory Piazza;Joshua A Beckman;Martin B Leon;Gregg W Stone;Stephan Rosenkranz;Samuel Z Goldhaber;Sahil A Parikh;Manuel Monreal;Harlan M Krumholz;Stavros V Konstantinides;Jeffrey I Weitz;Gregory Y H Lip | 2020-05-30 02:00:00+02:00 | 32473596 | IL;FR;RU;CA;NZ;CN;GR;GB;US;IT;AU;ES;DK;DE | New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States.;Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, United States.;Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States.;Respiratory Department, Hospital Ramón y Cajal, Madrid, Spain.;Medicine Department, Universidad de Alcalá (IRYCIS), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.;Harvard Medical School, Boston, Massachusetts, United States.;Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.;North Shore and Long Island Jewish University Hospitals, Queens, New York, United States.;Department of Medicine and Surgery, University of Insubria, Varese, Italy.;McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, United States.;Department of Cardiology, Chinese PLA General Hospital, Beijing, China.;Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.;Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Department of "Médecine Vasculaire et Thérapeutique," CIC 1408, INNOVTE, CHU de St-Etienne and INSERM UMR1059, Université Jean-Monnet, Saint-Etienne, France.;Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States.;Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, United States.;Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States.;Larner College of Medicine, University of Vermont, Burlington, Vermont, United States.;Department of Vascular Medicine, University of Montpellier, Montpellier CHU, InnoVTE F-CRIN Network, Montpellier, France.;Oncology Unit GPP, Sotiria General Hospital, Athens School of Medicine, Athens, Greece.;Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy.;Laboratory Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia.;Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia.;Loyola University Medical Center, Chicago, Illinois, United States.;Pritzker School of Medicine at the University of Chicago, Chicago, Illinois, United States.;Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, Illinois, United States.;Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, University of Milan Bicocca, Bergamo, Italy.;Auckland City Hospital, Auckland, New Zealand.;St Thomas' Hospital, London, United Kingdom.;The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, New York, United States.;Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, United States.;Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, United States.;Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.;Massachusetts General Hospital, Boston, Massachusetts, United States.;Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.;McMaster University, Hamilton, Ontario, Canada.;Thrombosis & Atherosclerosis Research Institute, Hamilton, Ontario, Canada.;The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.;Brigham and Women's Hospital, Boston, Massachusetts, United States.;Vanderbilt University School of Medicine, Nashville, Tennessee, United States.;The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.;Department of Cardiology, Cologne Cardiovascular Research Center (CCRC), Heart Center at the University of Cologne, University of Cologne, Cologne, Germany.;Department of Internal Medicine, Hospital Universitari Germans Trials I Pujol, Universidad Católica de Murcia, Barcelona, Spain.;Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut, United States.;Section of Cardiovascular Medicine, Department of Internal Medicie, Yale School of Medicine, New Haven, Connecticut, United States.;Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany.;Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark. | 963 | |||
| 10.1016/j.biochi.2020.05.013 | Journal Article | en | The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. | https://www.ncbi.nlm.nih.gov/pubmed/32485205 | The anti-malarial drug Chloroquine (CQ) and its derivative hydroxychloroquine have shown antiviral activities in vitro against many viruses, including coronaviruses, dengue virus and the biosafety level 4 Nipah and Hendra paramyxoviruses. The in vivo efficacy of CQ in the treatment of COVID-19 is currently a matter of debate. CQ is a lysosomotrophic compound that accumulates in lysosomes, as well as in food vacuoles of Plasmodium falciparum. In the treatment of malaria, CQ impairs the digestion and growth of the parasite by increasing the pH of the food vacuole. Similarly, it is assumed that the antiviral effects of CQ results from the increase of lysosome pH and the inhibition of acidic proteases involved in the maturation of virus fusion protein. CQ has however other effects, among which phospholipidosis, characterized by the accumulation of multivesicular bodies within the cell. The increase in phospholipid species particularly concerns bis(monoacylglycero)phosphate (BMP), a specific lipid of late endosomes involved in vesicular trafficking and pH-dependent vesicle budding. It was shown previously that drugs like progesterone, the cationic amphiphile U18666A and the phospholipase inhibitor methyl arachidonyl fluoro phosphonate (MAFP) induce the accumulation of BMP in THP-1 cells and decrease cell infection by human immunodeficiency virus. HIV viral particles were found to be retained into large endosomal-type vesicles, preventing virus spreading. Since BMP was also reported to favour virus entry through hijacking of the endocytic pathway, we propose here that BMP could play a dual role in viral infection, with its antiviral effects triggered by lysosomotropic drugs like CQ. | 0300-9084 | 2020-05-31 02:00:00+02:00 | pubmed | Biochimie | Frédéric Carrière;Sonia Longhi;Michel Record | 2020-05-30 02:00:00+02:00 | 32485205 | FR | Aix Marseille Univ, CNRS, BIP, UMR7281, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 9, France. Electronic address: carriere@imm.cnrs.fr.;Aix Marseille Univ, CNRS, AFMB, UMR7257, 163 Avenue de Luminy, 13288, Marseille cedex 09, France.;UMR INSERM 1037-CRCT (Cancer Research Center of Toulouse), University of Toulouse III Paul Sabatier, Team "Cholesterol Metabolism and Therapeutic Innovations,", 2 Avenue Hubert Curien, 31037, Toulouse cedex 1, France. Electronic address: michel.record@inserm.fr. | 965 | ||||
| 10.3390/pathogens9060430 | Journal Article;Review | en | SARS-CoV-2 Infection and the Liver. | https://www.ncbi.nlm.nih.gov/pubmed/32486188 | A novel strain of coronoviridae (SARS-CoV-2) was reported in Wuhan China in December 2019. Initially, infection presented with a broad spectrum of symptoms which typically included muscle aches, fever, dry cough, and shortness of breath. SARS-CoV-2 enters cells via ACE2 receptors which are abundant throughout the respiratory tract. However, there is evidence that these receptors are abundant throughout the body, and just as abundant in cholangiocytes as alveolar cells, posing the question of possible direct liver injury. While liver enzymes and function tests do seem to be deranged in some patients, it is questionable if the injury is due to direct viral damage, drug-induced liver injury, hypoxia, or microthromboses. Likely, the injury is multifactoral, and management of infected patients with pre-existing liver disease should be taken into consideration. Ultimately, a vaccine is needed to aid in reducing cases of SARS-CoV-2 and providing immunity to the general population. However, while considering the types of vaccines available, safety concerns, particularly of RNA- or DNA-based vaccines, need to be addressed. | 2076-0817 | 2020-05-31 02:00:00+02:00 | pubmed | Pathogens | Katie Morgan;Kay Samuel;Martin Vandeputte;Peter C Hayes;John N Plevris | COVID-19;SARS-CoV-2;drug induced liver injury;liver;microthromboses;viral damage | 2020-05-30 02:00:00+02:00 | 32486188 | FR;GB | The University of Edinburgh Hepatology Laboratory, Division of Heath Sciences, University of Edinburgh Medical School, Chancellor's Building, Edinburgh BioQuarter, 49 Little France Crescent, Edinburgh EH16 4SB, UK.;The Jack Copland Centre, Advanced Therapeutics, Scottish National Blood Transfusion Service, 52 Research Avenue North, Edinburgh EH14 4BE, UK. | 970 | |||
| Letter | en | Does spitting in public play a role in transmitting SARS-CoV-2? | https://www.ncbi.nlm.nih.gov/pubmed/32492484 | 2020-05-31 02:00:00+02:00 | pubmed | Philippe Gautret;Philippe Colson;Jean-Christophe Lagier;Philippe Parola;Didier Raoult | 2020-05-31 02:00:00+02:00 | 32492484 | FR | IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: philippe.gautret@club-internet.fr. | 974 | ||||||||
| Letter | en | Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32631576 | 2020-05-31 02:00:00+02:00 | pubmed | Charbel Skayem;Nakhle Ayoub | 2020-05-28 02:00:00+02:00 | 32631576 | FR;LB | Université de Paris, Faculté de Médecine, Paris, Assistance Publique des Hôpitaux de Paris (APHP), Paris, Hôpital Henri Mondor, Créteil, France. Electronic address: charbelskayem@hotmail.com.;Holy Spirit University of Kaslik, Lebanon, Centre Hospitalier Notre Dame des Secours (CHUNDS), Byblos, Lebanon. | 983 | ||||||||
| 10.3390/nu12061583 | Journal Article | en | Effects of COVID-19 Home Confinement on Eating Behaviour and Physical Activity: Results of the ECLB-COVID19 International Online Survey. | https://www.ncbi.nlm.nih.gov/pubmed/32481594 | Public health recommendations and governmental measures during the COVID-19 pandemic have resulted in numerous restrictions on daily living including social distancing, isolation and home confinement. While these measures are imperative to abate the spreading of COVID-19, the impact of these restrictions on health behaviours and lifestyles at home is undefined. Therefore, an international online survey was launched in April 2020, in seven languages, to elucidate the behavioural and lifestyle consequences of COVID-19 restrictions. This report presents the results from the first thousand responders on physical activity (PA) and nutrition behaviours. | 2072-6643 | 2020-05-31 02:00:00+02:00 | pubmed | Adolescent;Adult;Betacoronavirus;Coronavirus Infections__epidemiology;Exercise;Feeding Behavior;Female;Health Behavior;Humans;Male;Meals;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Snacks;Surveys and Questionnaires;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nutrients | Achraf Ammar;Michael Brach;Khaled Trabelsi;Hamdi Chtourou;Omar Boukhris;Liwa Masmoudi;Bassem Bouaziz;Ellen Bentlage;Daniella How;Mona Ahmed;Patrick Müller;Notger Müller;Asma Aloui;Omar Hammouda;Laisa Liane Paineiras-Domingos;Annemarie Braakman-Jansen;Christian Wrede;Sofia Bastoni;Carlos Soares Pernambuco;Leonardo Mataruna;Morteza Taheri;Khadijeh Irandoust;Aïmen Khacharem;Nicola L Bragazzi;Karim Chamari;Jordan M Glenn;Nicholas T Bott;Faiez Gargouri;Lotfi Chaari;Hadj Batatia;Gamal Mohamed Ali;Osama Abdelkarim;Mohamed Jarraya;Kais El Abed;Nizar Souissi;Lisette Van Gemert-Pijnen;Bryan L Riemann;Laurel Riemann;Wassim Moalla;Jonathan Gómez-Raja;Monique Epstein;Robbert Sanderman;Sebastian Vw Schulz;Achim Jerg;Ramzi Al-Horani;Taiysir Mansi;Mohamed Jmail;Fernando Barbosa;Fernando Ferreira-Santos;Boštjan Šimunič;Rado Pišot;Andrea Gaggioli;Stephen J Bailey;Jürgen M Steinacker;Tarak Driss;Anita Hoekelmann | COVID-19;nutrition;pandemic;physical activity;public health | 2020-05-28 02:00:00+02:00 | 32481594 | FR;CA;GE;SI;TN;JO;PT;GB;US;QA;BR;IT;NL;AE;IR;EG;ES;DE | Institute of Sport Science, Otto-von-Guericke University, 39106 Magdeburg, Germany.;Research Laboratory, Molecular Bases of Human Pathology, LR12ES17, Faculty of Medicine, University of Sfax, Sfax 3000, Tunisia.;Institute of Sport and Exercise Sciences, University of Münster, 48149 Münster, Germany.;High Institute of Sport and Physical Education of Sfax, University of Sfax, Sfax 3000, Tunisia.;Research Laboratory: Education, Motricity, Sport and Health, EM2S, LR19JS01, University of Sfax, Sfax 3000, Tunisia.;Research Unit: Physical Activity, Sport, and Health, UR18JS01, National Observatory of Sport, Tunis 1003, Tunisia.;Higher Institute of Computer Science and Multimedia of Sfax, University of Sfax, Sfax 3000, Tunisia.;Research Group Neuroprotection, German Center for Neurodegenerative Diseases (DZNE), Leipziger Str. 44, 39120 Magdeburg, Germany.;Medical Faculty, Department of Neurology, Otto-von-Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany.;High Institute of Sport and Physical Education, University of Gafsa, Gafsa 2112, Tunisia.;Laboratório de Vibrações Mecânicas e Práticas Integrativas, LAVIMPI-UERJ, Universidade do Estado do Rio de Janeiro, Rio de Janeiro RJ 20950-003, Brazil.;Faculdade Bezerra de Araújo, Rio de Janeiro Rj 23052-180, Brazil.;Department of Psychology, Health & Technology, University of Twente, 7522 Enschede, The Netherlands.;Department of Psychology, Università Cattolica del Sacro Cuore, 20123 Milano, Italy.;Laboratório de Fisiologia do Exercício, Estácio de Sá University, Rio de Janeiro 20261-063, Brazil.;College of Business Administration, American University in the Emirates, 503000-Dubai Academic City, Dubai, UAE.;Faculty of social science, Imam Khomeini International University, Qazvin 34148-96818, Iran.;UVHC, DeVisu, Valenciennes, LIRTES-EA 7313, Université Paris Est Créteil Val de Marne, 94000 Créteil, France.;Department of Health Sciences (DISSAL), Postgraduate School of Public Health, University of Genoa, 16132 Genoa, Italy.;Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, 4700 Keele Street, Toronto, ON M3J 1P3, Canada.;ASPETAR, Qatar Orthopaedic and Sports Medicine Hospital, Doha 29222, Qatar.;Laboratory "Sport Performance Optimization", (CNMSS), ISSEP Ksar-Said, Manouba University, Manouba 2010, Tunisia.;Exercise Science Research Center, Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville, AR 72701, USA.;Clinical Excellence Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.;Computer science department, University of Toulouse, IRIT-INP-ENSEEIHT (UMR 5505), BP 7122, Toulouse, France.;Faculty of Physical Education, Assiut University, Assiut 71515, Egypt.;Institute for Sports and Sports Science, Karlsruher Institut für Technologie, 76131 Karlsruher, Germany.;Department of Health Sciences and Kinesiology, Georgia Southern University, Statesboro, GA 30458, USA.;PharmD, BCBS, PharmIAD, Inc,Savannah, GA 30458, USA.;FundeSalud, Dept. of Health and Social Services, Government of Extremadura, 06800 Merida, Spain.;The E-Senior Association, 75020 Paris, France.;Department of Health Psychology, University Medical Center Groningen, University of Groningen, 9712 Groningen, The Netherlands.;Sports- and Rehabilitation Medicine, Ulm University Hospital, Leimgrubenweg 14, 89075 Ulm, Germany.;Department of Exercise Science, Yarmouk University, Irbid 21163, Jordan.;Faculty of Physical Education, The University of Jordan, Amman 11942, Jordan.;Digital Research Centre of Sfax, Sfax 3000, Tunisia.;Laboratory of Neuropsychophysiology, Faculty of Psychology and Education Sciences, University of Porto, 4200-135 Porto, Portugal.;Institute for Kinesiology Research, Science and Research Centre Koper, Garibaldijeva 1, 6000 Koper, Slovenia.;Applied Technology for Neuro-Psychology Lab, I.R.C.C.S. Istituto Auxologico Italiano, 20149 Milan, Italy.;School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough E11 3TU, UK.;Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology: Physical Activity, Health and Learning (LINP2-2APS), UFR STAPS, UPL, Paris Nanterre University, 92000 Nanterre, France. | 990 | ||
| 10.1016/j.ssci.2020.104854 | Journal Article | en | Prediction of CoVid-19 infection, transmission and recovery rates: A new analysis and global societal comparisons. | https://www.ncbi.nlm.nih.gov/pubmed/32518471 | We analyze the process of infection rate growth and decline for the recent global pandemic, applying a new method to the available global data. We describe and utilize an original approach based on statistical physics to predict the societal transmission timescale and the universal recovery trajectory resulting from the countermeasures implemented in entire societies. We compare the whole-society infection growth rates for many countries and local regions, to illustrate the common physical and mathematical basis for the viral spread and infection rate reduction, and validate the theory and resulting correlations. We show that methods traditionally considered for the numerical analysis and the control of individual virus transmission (e.g. ℜ0 scaling) represent one special case of the theory, and also compare our results to the available IHME computer model outcomes. We proceed to illustrate several interesting features of the different approaches to the mitigation of the pandemic, related to social isolation and "lockdown" tactics. Finally, we use presently available data from many countries to make actual predictions of the time needed for securing minimum infection rates in the future, highlighting the differences that emerge between isolated "islands" and mobile cities, and identifying the desired overall recovery trajectory. | 0925-7535 | 2020-05-31 02:00:00+02:00 | pubmed | Safety Science | Romney B Duffey;Enrico Zio | CoVid-19;Infection rate;Learning Theory;Pandemic risk;Universal Recovery Curve | 2020-05-28 02:00:00+02:00 | 32518471 | FR;IT;KR;US | Idaho Falls, ID, USA.;Centre de Recherche sur les Risques et les Crises (CRC), MINES ParisTech/PSL Université Paris, Sophia Antipolis, France.;Department of Energy, Politecnico di Milano, Milan, Italy.;Eminent Scholar at the Department of Nuclear Engineering, Kyung Hee University, Seoul, South Korea. | 991 | |||
| Letter;Comment | en | Cluster of chalazia in nurses using eye protection while caring for critically ill patients with COVID-19 in intensive care. | https://www.ncbi.nlm.nih.gov/pubmed/32467314 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Chalazion;Coronavirus;Coronavirus Infections;Critical Care;Critical Illness;Humans;Pandemics;Pneumonia, Viral;Telemedicine;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bruno Mégarbane;Ramin Tadayoni | PPE;hygiene / occupational hygiene;toxicology | 2020-05-28 02:00:00+02:00 | 32467314 | FR | Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology APHP, University of Paris, INSERM UMRS-1144, Paris, France bruno.megarbane@lrb.aphp.fr.;Department of Ophtalmology, Lariboisière Hospital, University of Paris, Paris, France. | 994 | ||||||
| 10.1038/s41385-020-0303-9 | Journal Article | en | Resistance of children to Covid-19. How? | https://www.ncbi.nlm.nih.gov/pubmed/32467603 | 1933-0219,1935-3456 | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Age Factors;Aged;Animals;Betacoronavirus__physiology;Child;Coronavirus Infections__epidemiology;Disease Susceptibility;Humans;Pandemics;Pneumonia, Viral__epidemiology;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | Mucosal Immunology | Alain Fischer | 2020-05-28 02:00:00+02:00 | 32467603 | FR | Collège de France, Paris, France. alain.fischer@aphp.fr.;Immunology and Pediatric Hematology Department, Assistance Publique-Hôpitaux de Paris, Paris, France. alain.fischer@aphp.fr.;INSERM UMR 1163, Institut Imagine, Paris, France. alain.fischer@aphp.fr. | 999 | ||||
| 10.1016/j.isci.2020.101212 | Journal Article | en | Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. | https://www.ncbi.nlm.nih.gov/pubmed/32512386 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19) has rapidly spread to the entire world within a few months. The origin of SARS-CoV-2 has been related to the lineage B Betacoronavirus SARS-CoV and SARS-related coronaviruses found in bats. Early characterizations of the SARS-CoV-2 genome revealed the existence of a distinct four amino acid insert within the spike (S) protein (underlined, SPRRAR↓S), at the S1/S2 site located at the interface between the S1 receptor binding subunit and the S2 fusion subunit. Notably, this insert appears to be a distinguishing feature among SARS-related sequences and introduces a potential cleavage site for the protease furin. Here, we investigate the potential role of this novel S1/S2 cleavage site and present direct biochemical evidence for proteolytic processing by a variety of proteases. We discuss these findings in the context of the origin of SARS-CoV-2, viral stability, and transmission. | 2589-0042 | 2020-05-31 02:00:00+02:00 | pubmed | iScience | Javier A Jaimes;Jean K Millet;Gary R Whittaker | Biochemistry;Virology | 2020-05-28 02:00:00+02:00 | 32512386 | FR;US | Department of Microbiology & Immunology, Cornell University, 930 Campus Road, Ithaca, NY 14853, USA.;Université Paris-Saclay, INRAE, UVSQ, Virologie et Immunologie Moléculaires, 78352 Jouy-en-Josas, France.;Department of Microbiology & Immunology, Cornell University, 930 Campus Road, Ithaca, NY 14853, USA, Master of Public Health Program, Cornell University, Ithaca, NY 14853, USA. Electronic address: grw7@cornell.edu. | 1000 | |||
| 10.1186/s13033-020-00371-w | Editorial | en | Mental health and psychosocial well-being during the COVID-19 pandemic: the invisible elephant in the room. | https://www.ncbi.nlm.nih.gov/pubmed/32514302 | The novel SARS-CoV-2 coronavirus pandemic has emerged as a truly formidable threat to humankind's existence. In the wake of the massively volatile global situation created by COVID-19, it is vital to recognize that the trauma it causes can affect people in different ways, at the individual and collective levels, resulting in mental health challenges for many. Although mental health problems account for about one-third of the world's disability among adults, these issues tend to be under-addressed and overlooked in society and are closely associated with deadly disease outbreaks. In large scale outbreaks, the mental health problems experienced are not limited to infected persons but also extend to involve frontline health workers and community members alike. While it is crucial to limit the spread of infections during an outbreak, previous experience suggests that mental and behavioural health interventions should be fully included in public health response strategies. | 1752-4458 | 2020-05-31 02:00:00+02:00 | pubmed | International Journal of Mental Health Systems | Akaninyene Otu;Carlo Handy Charles;Sanni Yaya | Covid-19;Health inequalities;Mental Health;Outbreak;Pandemic;Psychosocial well-being | 2020-05-28 02:00:00+02:00 | 32514302 | FR;CA;NG;GB;US;MQ | Department of Infection and Travel Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.;Department of Internal Medicine, College of Medical Sciences, University of Calabar, Calabar, Cross River State Nigeria.;Department of Sociology, McMaster University, Hamilton, ON Canada.;Geography at the Laboratoire Caribéen de Sciences Sociales du Centre National de la Recherche Scientifique, Université des Antilles, Schoelcher, Martinique, France.;School of International Development and Global Studies, University of Ottawa, Ottawa, ON Canada.;The George Institute for Global Health, The University of Oxford, Oxford, UK. | 1001 | |||
| Letter | en | Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics. | https://www.ncbi.nlm.nih.gov/pubmed/32501850 | 2020-06-07 02:00:00+02:00 | pubmed | Coronavirus__isolation & purification;Coronavirus Infections__epidemiology;Disease Susceptibility;Disease Transmission, Infectious;HIV Infections__complications;Humans;Incidence;Pandemics;Pneumonia, Viral__epidemiology;Risk Assessment;Severe Acute Respiratory Syndrome__epidemiology;COVID-19 | Nicolas Dauby | 2020-06-06 02:00:00+02:00 | 32501850 | FR;BE;UNK | Department of Infectious Diseases, Centre Hospitalier Universitaire (CHU) Saint-Pierre.;Centre for Environmental Health and Occupational Health, School of Public Health.;Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Brussels, Belgium. | 1008 | |||||||
| 10.1063/5.0008834 | Journal Article | en | Asymptotic estimates of SARS-CoV-2 infection counts and their sensitivity to stochastic perturbation. | https://www.ncbi.nlm.nih.gov/pubmed/32491888 | Despite the importance of having robust estimates of the time-asymptotic total number of infections, early estimates of COVID-19 show enormous fluctuations. Using COVID-19 data from different countries, we show that predictions are extremely sensitive to the reporting protocol and crucially depend on the last available data point before the maximum number of daily infections is reached. We propose a physical explanation for this sensitivity, using a susceptible-exposed-infected-recovered model, where the parameters are stochastically perturbed to simulate the difficulty in detecting patients, different confinement measures taken by different countries, as well as changes in the virus characteristics. Our results suggest that there are physical and statistical reasons to assign low confidence to statistical and dynamical fits, despite their apparently good statistical scores. These considerations are general and can be applied to other epidemics. | 1054-1500,1089-7682 | 2020-06-07 02:00:00+02:00 | pubmed | Asymptomatic Infections__epidemiology;Betacoronavirus;China;Coronavirus Infections__epidemiology;Global Health;Humans;Models, Statistical;Nonlinear Dynamics;Pandemics;Pneumonia, Viral__epidemiology;Stochastic Processes;COVID-19;severe acute respiratory syndrome coronavirus 2 | Chaos: An Interdisciplinary Journal of Nonlinear Science | Davide Faranda;Isaac Pérez Castillo;Oliver Hulme;Aglaé Jezequel;Jeroen S W Lamb;Yuzuru Sato;Erica L Thompson | 2020-06-04 02:00:00+02:00 | 32491888 | FR;GB | Laboratoire des Sciences du Climat et de l'Environnement, CEA Saclay l'Orme des Merisiers, UMR 8212 CEA-CNRS-UVSQ, Université Paris-Saclay and IPSL, 91191 Gif-sur-Yvette, France.;London Mathematical Laboratory, 8 Margravine Gardens, London W6 8RH, United Kingdom.;LMD/IPSL, ENS, PSL Université, École Polytechnique, Institut Polytechnique de Paris, Sorbonne Université, CNRS, 75005 Paris, France. | 1014 | |||
| 10.1038/s41577-020-0353-y | Journal Article;Published Erratum | en | Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. | https://www.ncbi.nlm.nih.gov/pubmed/32488203 | An amendment to this paper has been published and can be accessed via a link at the top of the paper. | 1474-1733,1474-1741 | 2020-06-07 02:00:00+02:00 | pubmed | Nature Reviews Immunology | Miriam Merad;Jerome C Martin | 2020-06-04 02:00:00+02:00 | 32488203 | FR;US | Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Université de Nantes, Inserm, CHU Nantes, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, Nantes, France. jerome.martin@univ-nantes.fr.;CHU Nantes, Laboratoire d'Immunologie, Center for Immuno Monitoring Nantes-Atlantique (CIMNA), Nantes, France. jerome.martin@univ-nantes.fr. | 1015 | ||||
| 10.1093/pubmed/fdaa075 | Journal Article | en | The substantial awareness role of web-based and social media platforms in developing countries during a pandemic scenario: the example of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32490518 | During the outbreak of coronavirus COVID-19, social media platforms have shown effectiveness in information dissemination. Delivering evidence-based medical knowledge and trustworthy recommendations is a difficult mission for classical entities, especially in a war-torn country with a fragile health system. In this context, the role of non-governmental scientific organizations was proven, filling the gap between original scientific sources and a non-English speaking population. | 1741-3842,1741-3850 | 2020-06-07 02:00:00+02:00 | pubmed | Journal of Public Health | Mohammad-Nasan Abdul-Baki;Yaseen Dhemesh;Lugien Alasadi;Tamim Alsuliman | 2020-06-04 02:00:00+02:00 | 32490518 | FR;SY | Faculty of Medicine, University of Hama, 0500 Hama, Syria.;Department of Gastroenterology and Hepatology, Faculty of Medicine, Damascus University, 0100 Damascus, Syria.;Hematology and Cell Therapy Department, Saint-Antoine Hospital, AP-HP Sorbonne University, 75012 Paris, France. | 1020 | ||||
| 10.1016/j.amp.2020.06.004 | English Abstract;Journal Article | fr | [Optimism and COVID-19: A resource to support people in confinement?] | https://www.ncbi.nlm.nih.gov/pubmed/32836302 | This text envisages looking at the psychological consequences of the health situation related to COVID-19 from the concept of optimism. Positive psychology has for several years been dealing with this concept, which is well known to the general public, but which has been the subject of major conceptual development in the field of science. It seems to us that the concept of optimism can be particularly useful in understanding and influencing the behaviour of our fellow citizens during the period of confinement that is currently imposed on everyone, in the same way that we must consider the consequences in the short, medium and long term, both economically and in terms of the moral and physical health of our fellow citizens, that is, after the period of confinement. Traditionally, being optimistic means being confident in the positive outcome of an event, whereas pessimism means expecting the worst. The uncertainty that this virus imposes on us and the new situations that it brings about, forces us to think the world in uncertain terms, which can be destabilizing. Understanding the contribution of the concept of optimism in the potential of the adaptive processes that each of us may or may not be able to mobilize to face and adapt to this unprecedented and unprecedented health crisis is essential. This will undoubtedly be a major challenge for the social sciences and psychology. This is why we believe that the concept of optimism can help to provide additional insights that will enable us to better grasp the rational (or non-rational) behaviours that we may face in the future, and in which we are already involved. | 0003-4487 | 2020-06-07 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Charles Martin-Krumm;Cyril Tarquinio;Camille Tarquinio | COVID-19;Containment;Health;Hope;Optimism | 2020-06-05 02:00:00+02:00 | 32836302 | FR | Laboratoire VCR, École de Psychologues Praticiens de l'Institut Catholique de Paris - Equipe d'accueil Religion, culture et société, Paris, France.;ChartUpon Nanterre Paris Ouest, Paris, France.;IRBA Brétigny, Brétigny, France.;ChartUpon EA 4004 Nanterre Paris Ouest, Nanterre, France. | 1025 | |||
| 10.1186/s13054-020-03013-2 | Editorial | en | The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32503590 | 1364-8535 | 2020-06-07 02:00:00+02:00 | pubmed | Coronavirus Infections__therapy;Humans;Pandemics;Pneumonia, Ventilator-Associated__diagnosis;Pneumonia, Viral__therapy;COVID-19 | Critical Care | Bruno François;Pierre-François Laterre;Charles-Edouard Luyt;Jean Chastre | 2020-06-05 02:00:00+02:00 | 32503590 | FR;BE | Intensive Care Unit and Inserm CIC1435 & UMR1092, CHU Dupuytren, Limoges, France. b.francois@unilim.fr.;Intensive Care Unit, St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.;Intensive Care Unit, Hôpital La Pitié-Salpétrière, APHP-Sorbonne Université, Paris, France. | 1034 | ||||
| 10.1111/tbed.13659 | Journal Article | en | First detection and genome sequencing of SARS-CoV-2 in an infected cat in France. | https://www.ncbi.nlm.nih.gov/pubmed/32500944 | After its first description in Wuhan (China), SARS-CoV-2 the agent of coronavirus disease 2019 (COVID-19) rapidly spread worldwide. Previous studies suggested that pets could be susceptible to SARS-CoV-2. Here, we investigated the putative infection by SARS-CoV-2 in 22 cats and 11 dogs from owners previously infected or suspected of being infected by SARS-CoV-2. For each animal, rectal, nasopharyngeal swabs and serum were taken. Swabs were submitted to RT-qPCR assays targeting 2 genes of SARS-CoV-2. All dogs were tested SARS-CoV-2 negative. One cat was tested positive by RT-qPCR on rectal swab. Nasopharyngeal swabs from this animal were tested negative. This cat showed mild respiratory and digestive signs. Serological analysis confirms the presence of antibodies against the SARS-CoV-2 in both serum samples taken 10 days apart. Genome sequence analysis revealed that the cat SARS-CoV-2 belongs to the phylogenetic clade A2a like most of the French human SARS-CoV-2. This study reports for the first time the natural infection of a cat in France (near Paris) probably through their owners. There is currently no evidence that cats can spread COVID-19 and owners should not abandon their pets or compromise their welfare. | 1865-1674,1865-1682 | 2020-06-07 02:00:00+02:00 | pubmed | Transboundary and Emerging Diseases | Corinne Sailleau;Marine Dumarest;Jessica Vanhomwegen;Manon Delaplace;Valerie Caro;Aurélia Kwasiborski;Véronique Hourdel;Patrick Chevaillier;Alix Barbarino;Loic Comtet;Philippe Pourquier;Bernard Klonjkowski;Jean-Claude Manuguerra;Stephan Zientara;Sophie Le Poder | ELISA;SARS-CoV-2;cats;luminex;next-generation sequencing;pets | 2020-06-05 02:00:00+02:00 | 32500944 | FR | UMR VIROLOGIE, INRAE, Ecole Nationale Vétérinaire d'Alfort, ANSES, Laboratoire de santé animale, Université Paris-Est, Maisons-Alfort, France.;Environment and Infectious Risk Unit, Laboratory for Urgent Response to Biological Threats, Institut Pasteur, Paris, France.;The OIE Collaborating Centre for Detection and Identification in Humans of Emerging Animal Pathogens, Institut Pasteur, Paris, France.;Clinique vétérinaire, Savigny sur Orge, France.;CHUVA, Ecole Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, France.;IDVET, Grabels, France. | 1037 | |||
| Letter;Comment | en | Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32512022 | 2020-06-07 02:00:00+02:00 | pubmed | Anti-Bacterial Agents;Betacoronavirus;Coinfection;Coronavirus Infections;Critical Illness;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Niccolò Buetti;Timothy Mazzuchelli;Elia Lo Priore;Carlo Balmelli;Michael Llamas;Micol Pallanza;Luigia Elzi;Vera Consonni;Pierpaolo Trimboli;Valentina Forni-Ogna;Enos Bernasconi | Antibiotics;COVID-19;Intensive care unit;SARS-CoV-2 | 2020-06-05 02:00:00+02:00 | 32512022 | FR;CH | Ente Ospedaliero Cantonale, Locarno Community Hospital, Locarno, Switzerland, INSERM IAME, U1137, Team DeSCID, Paris, France. Electronic address: niccolo.buetti@gmail.com.;Ente Ospedaliero Cantonale, Locarno Community Hospital, Locarno, Switzerland.;Ente Ospedialiero Cantonale, Infection Control Program, Ticino, Switzerland, Ente Ospedialiero Cantonale, Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland.;Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland, Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.;Ente Ospedialiero Cantonale, Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland. | 1039 | ||||||
| 10.1016/j.jhin.2020.06.003 | Journal Article | en | Preventing SARS-CoV-2 transmission in rehabilitation pools and therapeutic water environments. | https://www.ncbi.nlm.nih.gov/pubmed/32522671 | SARS-CoV-2 is mainly transmitted by respiratory droplets and contact with contaminated surfaces. It can be retrieved in faeces but there is no evidence of faecal-oral transmission, which is the main route of contamination in recreational waters. Standard cleaning and disinfecting procedures, microbiological control and health rules aim to prevent infectious risk regardless of the micro-organisms. In the context of progressive lockdown exit and hospital activities recovery, we assessed the risk of SARS-CoV-2 transmission in rehabilitation pools and therapeutic water environments in order to provide specific recommendations to control the spread of SARS-CoV-2 while ensuring essential rehabilitation care for patients. | 0195-6701 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus__growth & development;Coronavirus Infections__prevention & control;Guidelines as Topic;Humans;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Rehabilitation Centers__standards;Safety Management__standards;Swimming Pools__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Hospital Infection | S Romano-Bertrand;L-S Aho Glele;B Grandbastien;D Lepelletier | COVID-19;Coronavirus;Oral–faecal transmission;Viral pandemic;Waterborne infection | 2020-06-06 02:00:00+02:00 | 32522671 | FR;CH | HydroSciences Montpellier, IRD, CNRS, Montpellier University, Montpellier, France, Hospital Hygiene and Infection Control Team, University Hospital of Montpellier, Montpellier, France. Electronic address: sara.romano-bertrand@umontpellier.fr.;Department of Epidemiology and Infection Control, Dijon University Hospital, Dijon, France.;Department of Preventive Medicine, Infection Prevention and Control Team, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.;MiHAR Lab, EE 1701 S, Nantes University, Nantes, France, Department of Bacteriology and Infection Control, Nantes University Hospital, Nantes, France. | 1059 | ||
| 10.1093/ckj/sfaa099 | Journal Article | en | Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32695326 | Coronavirus disease 2019 (COVID-19)-associated acute kidney injury (AKI) frequency, severity and characterization in critically ill patients has not been reported. | 2048-8505,2048-8513 | 2020-06-07 02:00:00+02:00 | pubmed | Clinical Kidney Journal | Sébastien Rubin;Arthur Orieux;Renaud Prevel;Antoine Garric;Marie-Lise Bats;Sandrine Dabernat;Fabrice Camou;Olivier Guisset;Nahema Issa;Gaelle Mourissoux;Antoine Dewitte;Olivier Joannes-Boyau;Catherine Fleureau;Hadrien Rozé;Cédric Carrié;Laurent Petit;Benjamin Clouzeau;Charline Sazio;Hoang-Nam Bui;Odile Pillet;Claire Rigothier;Frederic Vargas;Christian Combe;Didier Gruson;Alexandre Boyer | COVID-19;acute interstitial nephritis;acute kidney injury;acute tubular injury;critically ill patients;renal replacement therapy | 2020-06-06 02:00:00+02:00 | 32695326 | FR | Service de Néphrologie, Transplantation, Dialyse et Aphérèses, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France.;Unité INSERM U1034, Université de Bordeaux, Bordeaux, France.;Service de Médecine Intensive Réanimation, Hôpital Pellegrin et Hôpital Saint André, CHU de Bordeaux, Bordeaux, France.;Service de Biochimie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France.;Service d'Anesthésie-Réanimation Sud, Centre Médico-Chirurgical Magellan, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France.;Service d'Anesthésie-Réanimation, Pellegrin CHU de Bordeaux, Bordeaux, France. | 1060 | |||
| 10.1016/j.therap.2020.06.002 | Editorial | en | Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32553502 | 0040-5957 | 2020-06-07 02:00:00+02:00 | pubmed | Therapies | Jean-Luc Cracowski;Mathieu Molimard;Vincent Richard | 2020-06-06 02:00:00+02:00 | 32553502 | FR | Université Grenoble Alpes, centre régional de pharmacovigilance et CIC1406, INSERM, HP2, 38000 Grenoble, France. Electronic address: jean-luc.cracowski@univ-grenoble-alpes.fr.;Service de pharmacologie médicale, University Bordeaux, INSERM U1219, 33076 Bordeaux, France.;Université de Rouen Normandie, UNIROUEN, CHU de Rouen Normandie, service de pharmacologie, UMR Inserm U1096 EnVI, 76000 Rouen, France. | 1061 | |||||
| 10.1016/j.ad.2020.05.004 | Case Reports | en | Managing Psoriasis Consultations During the COVID-19 Pandemic: Recommendations From the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (AEDV). | https://www.ncbi.nlm.nih.gov/pubmed/32522413 | 0001-7310 | 2020-06-07 02:00:00+02:00 | pubmed | Actas Dermo-Sifiliográficas | I Belinchón;L Puig;L Ferrándiz;P de la Cueva;J M Carrascosa | 2020-06-06 02:00:00+02:00 | 32522413 | FR;ES | Servicio de Dermatología, Hospital General Universitario de Alicante-ISABIAL-UMH, Alicante, España. Electronic address: belinchon_isa@gva.es.;Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Servicio de Dermatología, Hospital Universitario Virgen Macarena, Sevilla, España.;Servicio de Dermatología, Hospital Universitario Infanta Leonor, Madrid, España.;Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP, Barcelona, España. | 1065 | |||||
| Letter | en | A chilblain epidemic during the COVID-19 pandemic. A sign of natural resistance to SARS-CoV-2? | https://www.ncbi.nlm.nih.gov/pubmed/32534339 | 2020-06-07 02:00:00+02:00 | pubmed | Dan Lipsker | 2020-06-06 02:00:00+02:00 | 32534339 | FR | Clinique Dermatologique, Hôpitaux Universitaires, Strasbourg cedex, France, Faculté de Médecine, Université de Strasbourg, France. Electronic address: dan.lipsker@chru-strasbourg.fr. | 1066 | ||||||||
| Case Reports;Letter | en | Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab. | https://www.ncbi.nlm.nih.gov/pubmed/32505467 | 2020-06-07 02:00:00+02:00 | pubmed | Aged;Antibodies, Monoclonal, Humanized__therapeutic use;Betacoronavirus;Coronavirus Infections__complications;Cytokine Release Syndrome__drug therapy;Humans;Kidney Transplantation;Male;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gabriela Gautier-Vargas;Clement Baldacini;Ilies Benotmane;Nicolas Keller;Peggy Perrin;Bruno Moulin;Sophie Caillard | 2020-06-04 02:00:00+02:00 | 32505467 | FR | Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France, Institut national de la santé et de la recherche médical, immunorhumatologie moléculaire unité mixte de recherche-S 1109, Strasbourg, France. Electronic address: gabriela.gautier-vargas@chru-strasbourg.fr.;Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France.;Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France, Institut national de la santé et de la recherche médical, immunorhumatologie moléculaire unité mixte de recherche-S 1109, Strasbourg, France, Department of Virology, Strasbourg University Hospital, Strasbourg, France.;Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France, Institut national de la santé et de la recherche médical, immunorhumatologie moléculaire unité mixte de recherche-S 1109, Strasbourg, France. | 1077 | |||||||
| 10.1002/oby.22924 | Journal Article | en | COVID-19: A Lever for the Recognition of Obesity as a Disease? The French Experience. | https://www.ncbi.nlm.nih.gov/pubmed/32495493 | 1930-7381,1930-739X | 2020-06-07 02:00:00+02:00 | pubmed | Obesity | Karine Clément;Muriel Coupaye;Martine Laville;Jean-Michel Oppert;Olivier Ziegler | 2020-06-04 02:00:00+02:00 | 32495493 | FR | Assistance-Publique-Hôpitaux de Paris, Nutrition Department, Pitié-Salpêtrière hospital, Sorbonne University, Paris, France.;Sorbonne University, INSERM, Nutrition and obesity: systemic approaches (NutriOmics) research unit, F-CRIN/FORCE Network, Paris, France.;Assistance Publique Hôpitaux de Paris, Explorations Fonctionnelles Department, Obesity Reference Center, Louis Mourier Hospital, Université de Paris, Inserm UMR 1149, F-CRIN/FORCE Network, F-92000 , Colombes, France.;Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Centre de Recherche en Nutrition Humaine Rhône-Alpes, Univ-Lyon, CarMeN Laboratory, Université Claude Bernard Lyon1, F-CRIN/FORCE Network, Pierre Bénite, Lyon, France.;Specialized Obesity Center and Endocrinology, Diabetology, Nutrition dept, Brabois Hospital, CHRU of Nancy, F-CRIN/FORCE Network, Vandoeuvre-Les-Nancy, France. | 1078 | |||||
| Case Reports;Letter | en | Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32329915 | 2020-06-07 02:00:00+02:00 | pubmed | Acute Disease;Adult;Aged;Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Female;Fever__complications;Humans;Male;Pandemics;Pneumonia, Viral__complications;Urticaria__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | C van Damme;E Berlingin;S Saussez;O Accaputo | 2020-06-04 02:00:00+02:00 | 32329915 | FR;BE | Dermatology Department, Ambroise Paré University Hospital Center, Mons, Belgium.;Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine, Research Institute for Health Sciences and Technology, University of Mons (UMONS), Mons, Belgium. | 1081 | |||||||
| 10.1136/ijgc-2020-001617 | Journal Article | en | European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32487685 | 1048-891X,1525-1438 | 2020-06-07 02:00:00+02:00 | pubmed | International Journal of Gynecologic Cancer | Andrea Ciavattini;Giovanni Delli Carpini;Luca Giannella;Marc Arbyn;Maria Kyrgiou;Elmar A Joura;Jalid Sehouli;Xavier Carcopino;Charles W Redman;Pekka Nieminen;Maggie Cruickshank;Murat Gultekin | cervical cancer | 2020-06-02 02:00:00+02:00 | 32487685 | FR;FI;GB;US;IT;TR;DE;BE;AT | Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Faculty of Medicine, Università Politecnica delle Marche, Ancona, Italy.;Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.;Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Faculty of Medicine, Imperial College, London, W12 0NN, UK.;West London Gynaecological Cancer Centre, Queen Charlotte's and Chelsea, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, W12 0HS, UK.;Department of Gynecology and Gynecologic Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.;Department of Gynecology and Center for Oncological Surgery, Charité, University Medicine Berlin, Berlin, Germany.;Department of Obstetrics and Gynaecology, Hôpital Nord, APHM, Aix-Marseille University (AMU), Univ Avignon, CNRS, IRD, IMBE, UMR 7263, 13397, Marseille, France.;University Hospitals of North Midlands NHS Trust, Royal Stoke Hospital, Stoke-on-Trent, United Kingdom.;Department of Obstetrics and Gynaecology, Helsinki University Hospital and Helsinki University, Helsinki, Finland.;Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK.;Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Ankara, Turkey mrtgultekin@yahoo.com. | 1083 | ||||
| Letter | en | Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. | https://www.ncbi.nlm.nih.gov/pubmed/32487122 | 2020-06-07 02:00:00+02:00 | pubmed | Aged;Coronavirus Infections__epidemiology;Critical Illness;Female;France__epidemiology;Hemorrhage__epidemiology;Humans;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Retrospective Studies;Thrombosis__epidemiology;COVID-19 | Megan Fraissé;Elsa Logre;Olivier Pajot;Hervé Mentec;Gaëtan Plantefève;Damien Contou | ARDS;COVID-19;D-dimers;Intensive care;Pulmonary embolism;SARS-CoV-2;Thrombosis | 2020-06-02 02:00:00+02:00 | 32487122 | FR | Service de réanimation polyvalente, Centre Hospitalier Victor Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil, France.;Service de réanimation polyvalente, Centre Hospitalier Victor Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil, France. damien.contou@ch-argenteuil.fr. | 1085 | ||||||
| Letter;Comment | en | Turning a surgical unit into a COVID-19 facility: Governance counts. | https://www.ncbi.nlm.nih.gov/pubmed/32502703 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Michel Sfez;Alexandre Derichard;Marie-Laure Cittanova-Pansard | COVID-19;Governance;Surgery | 2020-06-02 02:00:00+02:00 | 32502703 | FR | Clinique Saint-Jean de Dieu, 2, Rue Rousselet, Paris, France. Electronic address: sfez_michel@yahoo.fr.;Clinique Saint-Jean de Dieu, 2, Rue Rousselet, Paris, France. Electronic address: alexandre.derichard@wanadoo.fr.;Clinique Saint-Jean de Dieu, 2, Rue Rousselet, Paris, France. Electronic address: mlcittanova@gmail.com. | 1091 | ||||||
| 10.1016/j.afjem.2020.05.012 | Editorial | en | Providing end-of-life care in the emergency department: Early experience from Médecins Sans Frontières during the Covid-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32837875 | 2211-419X | 2020-06-07 02:00:00+02:00 | pubmed | African Journal of Emergency Medicine | Anne-Marie Pegg;Miguel Palma;Cliff Roberson;Chibuzo Okonta;Marie-Hortense Nkokolo Massamba/Koudika;Natalie Roberts | 2020-06-01 02:00:00+02:00 | 32837875 | FR;CI;CA;US | Medical Department, Médecins Sans Frontières (MSF)-Operational Centre Paris (OCP), Paris, France.;Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada.;Medical Department, MSF-OCP, Paris, France.;School of Nursing, Columbia University, New York, NY, USA.;MSF-West and Central Africa, Abidjan, Cote d'Ivoire.;MSF-OCP, Paris, France.;Centre de réflexion sur l'action et les savoirs humanitaires (CRASH), MSF Foundation, Paris, France. | 1095 | |||||
| 10.3747/co.27.6685 | Consensus Development Conference;Journal Article | en | Consensus statement: summary of the Quebec Lung Cancer Network recommendations for prioritizing patients with thoracic cancers in the context of the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32669938 | The emergence of covid-19 has the potential to change the way in which the health care system can accommodate various patient populations and might affect patients with non-covid-19 problems. The Quebec Lung Cancer Network, which oversees thoracic oncology services in the province of Quebec under the direction of the Ministère de la Santé et des Services sociaux, convened to develop recommendations to deal with the potential disruption of services in thoracic oncology in the province of Quebec. The summary provided here has been adapted from the original document posted on the Programme québécois du cancer Web site at: https://www.msss.gouv.qc.ca/professionnels/documents/coronavirus-2019-ncov/PJ1_Recommandations_oncologie-thoracique-200415.pdf. | 1718-7729,1198-0052 | 2020-06-07 02:00:00+02:00 | pubmed | Administration, Oral;Antineoplastic Agents__administration & dosage;Betacoronavirus;Carcinoma, Non-Small-Cell Lung__diagnosis;Coronavirus Infections__epidemiology;Disease Management;Humans;Lung Neoplasms__diagnosis;Mediastinoscopy;Medical Oncology;Molecular Diagnostic Techniques;Neoplasm Staging;Pandemics;Pneumonia, Viral__epidemiology;Quebec__epidemiology;Radiosurgery;Radiotherapy;Small Cell Lung Carcinoma__diagnosis;Thoracic Surgical Procedures;Thoracoscopy;Triage;COVID-19;severe acute respiratory syndrome coronavirus 2 | Current Oncology | N Blais;M Bouchard;M Chinas;H Lizotte;M Morneau;J Spicer;S Martel | Thoracic cancer;covid-19;priorities | 2020-06-01 02:00:00+02:00 | 32669938 | FR;CA | Service d'hémato-oncologie, Département de médecine, Centre hospitalier de l'Université de Montréal, Montreal, QC.;Service de radio-oncologie, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC.;Programme québécois de cancérologie, Ministère de la Santé et des Services sociaux du Québec, Quebec City, QC.;Direction générale, Institut universitaire de cardiologie et pneumologie de Québec, Quebec City, QC.;Direction de l'offre de soins et services en cancérologie, Programme québécois de cancérologie, Ministère de la Santé et des Services sociaux du Québec, Quebec City, QC.;Division of Thoracic and Upper Gastrointestinal Surgery, Department of Surgery, McGill University, McGill University Health Centre, Montreal, QC.;Service de pneumologie, Institut universitaire de cardiologie et pneumologie de Québec, Quebec City, QC. | 1100 | ||
| Letter | en | Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32505756 | 2020-06-07 02:00:00+02:00 | pubmed | Marie-Reine Losser;Coline Lapoix;Matthieu Delannoy;Benoît Champigneulle;Didier Payen | Hypoxic pulmonary vasoconstriction;Prone position;SARS-CoV-2 | 2020-06-04 02:00:00+02:00 | 32505756 | FR | Département d'anesthésie réanimation Brabois Adulte, CHRU Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France, Inserm UMR 1116, équipe 2, faculté de médecine, Université de Lorraine, 9, avenue de la Forêt de Haye - CS 50184, 54505 Vandœuvre-lès-Nancy cedex, France. Electronic address: mr.losser@chru-nancy.fr.;Département d'anesthésie réanimation Brabois Adulte, CHRU Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France.;Pôle anesthésie réanimation, CHU de Grenoble-Alpes, 38000 Grenoble, France.;UMR Inserm 1160, UFR de médecine, Université Paris 7, Paris, France. | 1114 | |||||||
| 10.1007/s11125-020-09475-0 | Journal Article | en | COVID-19 causes unprecedented educational disruption: Is there a road towards a new normal? | https://www.ncbi.nlm.nih.gov/pubmed/32836420 | COVID-19 confronts the education system with a new and massive crisis. What should a "new normal" look like for future generations? How can countries use the innovativeness of the recovery period to "build back better"? This Viewpoint highlights the UNESCO-led Global Coalition for Education initiative, which is seeking solutions to support learners and teachers, as well as governments throughout the recovery process, with a principal focus on inclusion, equity, and gender equality. The Viewpoint also argues that the current crisis is an opportunity for stronger international collaboration, which might provide a better focus and deliver solutions, including digital tools. Resilience and adaptability will be crucial for the next generations to navigate through the present-and any future-pandemic. | 0033-1538,1573-9090 | 2020-06-07 02:00:00+02:00 | pubmed | PROSPECTS | Hans d'Orville | Digital learning tools;International cooperation;Learning crisis;Pandemic;School closures | 2020-06-03 02:00:00+02:00 | 32836420 | FR | Paris, France. | 1122 | |||
| 10.1111/ene.14373 | Editorial | en | How to support the quality of life of people living with cognitive disorders: a (k)new challenge in the post-COVID-19 world. | https://www.ncbi.nlm.nih.gov/pubmed/32492256 | 1351-5101,1468-1331 | 2020-06-07 02:00:00+02:00 | pubmed | European Journal of Neurology | Y Chen;C Chen | 2020-06-03 02:00:00+02:00 | 32492256 | FR;IE;SG | Global Brain Health Institute, TCD, Dublin, Ireland.;UMR-S1172, Degenerative and Vascular Cognitive Disorders, Inserm, CHU Lille, Lille Neurosciences and Cognition, Université de Lille, Lille, France.;Department of Pharmacology, Memory Aging and Cognition Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore. | 1124 | |||||
| 10.1111/liv.14557 | Journal Article | en | Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: Should we worry? | https://www.ncbi.nlm.nih.gov/pubmed/32495496 | While several studies from China have reported COVID-19-related liver injury, there are currently no data on liver dysfunction in hospitalized COVID-19 patients in Europe. The aim of this study was to describe the prevalence and predictive value of abnormal liver function in patients hospitalized with COVID-19. This was a retrospective cohort study of confirmed COVID-19 patients hospitalized in two referral hospitals in France. Clinical, biological and radiological data were collected and analysed. In all, 234 patients confirmed to have COVID-19 by RT-PCR were included. Liver function was abnormal in 66.6% of patients on admission. In multivariate logistic regression, abnormal liver test on admission were associated with in-hospital aggravation (OR = 4.1, 95% CI 1.5-10.8; P = .004) and mortality (OR 3.3; 95% CI = 1.04-10.5; P = .04). This study of liver tests in a European COVID-19 population confirms a high prevalence of abnormal liver tests on admission that are predictive of severe disease course and higher in-hospital mortality. | 1478-3223,1478-3231 | 2020-06-07 02:00:00+02:00 | pubmed | Liver International | Magdalena Meszaros;Lucy Meunier;David Morquin;Kada Klouche;Pierre Fesler;Emilie Malezieux;Alain Makinson;Vincent Le Moing;Jacques Reynes;Georges-Philippe Pageaux | Coronavirus disease 2019;SARS-CoV-2;abnormal liver tests;in-hospital aggravation;in-hospital mortality;prognosis | 2020-06-03 02:00:00+02:00 | 32495496 | FR | Department of Hepatology, Gastroenterology and Liver Transplantation, Montpellier University Hospital, University of Montpellier, Montpellier, France.;Department of Gastroenterology and Hepatology, Narbonne Hospital, Narbonne, France.;Department of Infectious Diseases, Montpellier University Hospital, University of Montpellier, Montpellier, France.;Department of Intensive Care Lapeyronie, Montpellier University Hospital, University of Montpellier, Montpellier, France.;Department of Internal Medicine Lapeyronie, Montpellier University Hospital, University of Montpellier, Montpellier, France. | 1130 | |||
| 10.1007/s00259-020-04910-y | Editorial | en | Impact of the COVID-19 crisis on imaging in oncological trials. | https://www.ncbi.nlm.nih.gov/pubmed/32533240 | 1619-7070,1619-7089 | 2020-06-14 02:00:00+02:00 | pubmed | Clinical Trials as Topic;Coronavirus Infections__complications;Humans;Incidental Findings;Neoplasms__diagnostic imaging;Pandemics;Patient Selection;Pneumonia__complications;Pneumonia, Viral__complications;Policy;COVID-19 | European Journal of Nuclear Medicine and Molecular Imaging | Christophe M Deroose;Frédéric E Lecouvet;Laurence Collette;Daniela E Oprea-Lager;Wolfgang G Kunz;Luc Bidaut;Joost J C Verhoeff;Caroline Caramella;Egesta Lopci;Bertrand Tombal;Lioe-Fee de Geus-Oei;Laure Fournier;Marion Smits;Nandita M deSouza | 2020-06-14 02:00:00+02:00 | 32533240 | FR;GB;IT;NL;BE;DE | European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium. christophe.deroose@uzleuven.be.;Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium. christophe.deroose@uzleuven.be.;Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. christophe.deroose@uzleuven.be.;European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium.;Department of Radiology, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.;European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.;Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers (VU University), Amsterdam, The Netherlands.;Department of Radiology, University Hospital, LMU Munich, Munich, Germany.;College of Science, University of Lincoln, Lincoln, UK.;Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.;Radiology Department, Hôpital Marie Lannelongue, Institut d'Oncologie Thoracique, Université Paris-Saclay, Le Plessis-Robinson, France.;Nuclear Medicine, Humanitas Clinical and Research Hospital - IRCCS, Rozzano, Milan, Italy.;Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.;Department of Radiology, AP-HP, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France.;Department of Radiology & Nuclear Medicine, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, The Netherlands.;Cancer Research UK Imaging Centre, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust-Sutton, Sutton, UK. | 1141 | ||||
| 10.1007/s40264-020-00953-0 | Editorial | en | Does Ibuprofen Worsen COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32529474 | 0114-5916,1179-1942 | 2020-06-14 02:00:00+02:00 | pubmed | Acute Disease__therapy;Anti-Inflammatory Agents, Non-Steroidal__pharmacology;Betacoronavirus__physiology;Coronavirus Infections__epidemiology;Humans;Ibuprofen__pharmacology;Pandemics__prevention & control;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__epidemiology;Risk Assessment;Up-Regulation__drug effects;Virus Internalization__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Drug Safety | Nicholas Moore;Bruce Carleton;Patrick Blin;Pauline Bosco-Levy;Cecile Droz | 2020-06-13 02:00:00+02:00 | 32529474 | FR;CA;GB;US | Bordeaux PharmacoEpi, INSEMR CIC 1401, Universityd of Bordeaux, 146 rue Leo Saignat, 33076, Bordeaux, France. Nicholas.moore@u-bordeaux.fr.;Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.;Bordeaux PharmacoEpi, INSEMR CIC 1401, Universityd of Bordeaux, 146 rue Leo Saignat, 33076, Bordeaux, France. | 1142 | ||||
| 10.1093/cid/ciaa746 | Journal Article | en | COVID-19 : Pacific Islands challenges. | https://www.ncbi.nlm.nih.gov/pubmed/32511697 | 1058-4838,1537-6591 | 2020-06-14 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Simon Poignant;Laure Baudouin;Marc Vinclair;Sandrine Mons | 2020-06-08 02:00:00+02:00 | 32511697 | FR | Département d'Anesthésie et Réanimation. Hôpital du Taaone, Centre Hospitalier de Polynésie Française, Pirae, Tahiti, French Polynesia. | 1144 | |||||
| 10.5455/jpma.16 | Journal Article | en | Endocrine vigilance in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32515380 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus responsible for a pandemic that emerged in December 2019. Heterogeneous clinical forms are described from asymptomatic to severe hypoxaemic acute respiratory syndrome with multisystem organ failure. The impact of this coronavirus disease 2019 on the endocrine glands remains unknown. However, the results of previous studies on viruses from the same family allow us to write proposals for patients followed for chronic endocrine diseases. Currently, if these subjects are infected with SARS-CoV-2, they must not stop their treatment. In some cases, hormone replacement doses have to be increased. In case of worsening clinical signs, hormonal biological monitoring must be done. This article will be helpful for improving the management of chronic endocrine diseases that could affect thyroid, adrenals, gonads and pituitary gland functions. Proposals could be applied in COVID-19 infected subjects or in those who have been in contact with COVID-19 infected people. | 0030-9982 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Chronic Disease;Coronavirus Infections__complications;Endocrine System Diseases__complications;Humans;Pandemics;Pneumonia, Viral__complications;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of the Pakistan Medical Association | Fritz-Line Velayoudom;Piyumi Sachindra Alwis Wijewickrama;H Ishara Ranathunga;Noel Somasundaram | COVID-19 , SARS-CoV-2, Endocrine glands, Endocrine vigilance. | 2020-06-10 02:00:00+02:00 | 32515380 | FR;LK;GP | Department of Diabetology-Endocrinology, University Hospital of Guadeloupe , Guadeloupe.;Diabetes and Endocrine Unit, National Hospital of Sri Lanka, Colombo, Sri Lanka.;Department of Endocrinology, National Hospital of Sri Lanka, Colombo, Sri Lanka. | 1151 | ||
| Journal Article;Review | en | Preparing for emerging respiratory pathogens such as SARS-CoV, MERS-CoV, and SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32532941 | Preparing for emerging respiratory pathogens is a fundamental requirement for enhancements of the safeguard in healthcare settings. We are facing an increasing pressure to be prepared more than before. Healthcare organizations should be ready to deal with such emerging infectious disease. Here, we share some points that are essential to be considered while we prepare our institutions to prevent the transmission of emerging respiratory pathogens such as MERS-CoV and the recently emerging pandemic of SARS-CoV-2, the causative agent of COVID-19. | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Civil Defense__methods;Clinical Laboratory Techniques;Communicable Diseases, Emerging__epidemiology;Coronavirus Infections__diagnosis;Guideline Adherence;Hospital Administration;Humans;Infection Control__organization & administration;Interdisciplinary Communication;Middle East Respiratory Syndrome Coronavirus;Pandemics__prevention & control;Patient Isolation;Personnel, Hospital__education;Pneumonia, Viral__diagnosis;Protective Devices;SARS Virus;Saudi Arabia;Severe Acute Respiratory Syndrome__epidemiology;Symptom Assessment;Triage;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Jaffar A Al-Tawfiq;Mohammed A Garout;Philippe Gautret | 2020-06-14 02:00:00+02:00 | 32532941 | FR;US;SA | Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.;Department of Community Medicine and Public Health, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.;Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France, IHU-Méditerranée Infection, Marseille, France. | 1153 | ||||||
| 10.1007/s00134-020-06153-9 | Journal Article;Review | en | Acute kidney injury in critically ill patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32533197 | Acute kidney injury (AKI) has been reported in up to 25% of critically-ill patients with SARS-CoV-2 infection, especially in those with underlying comorbidities. AKI is associated with high mortality rates in this setting, especially when renal replacement therapy is required. Several studies have highlighted changes in urinary sediment, including proteinuria and hematuria, and evidence of urinary SARS-CoV-2 excretion, suggesting the presence of a renal reservoir for the virus. The pathophysiology of COVID-19 associated AKI could be related to unspecific mechanisms but also to COVID-specific mechanisms such as direct cellular injury resulting from viral entry through the receptor (ACE2) which is highly expressed in the kidney, an imbalanced renin-angotensin-aldosteron system, pro-inflammatory cytokines elicited by the viral infection and thrombotic events. Non-specific mechanisms include haemodynamic alterations, right heart failure, high levels of PEEP in patients requiring mechanical ventilation, hypovolemia, administration of nephrotoxic drugs and nosocomial sepsis. To date, there is no specific treatment for COVID-19 induced AKI. A number of investigational agents are being explored for antiviral/immunomodulatory treatment of COVID-19 and their impact on AKI is still unknown. Indications, timing and modalities of renal replacement therapy currently rely on non-specific data focusing on patients with sepsis. Further studies focusing on AKI in COVID-19 patients are urgently warranted in order to predict the risk of AKI, to identify the exact mechanisms of renal injury and to suggest targeted interventions. | 0342-4642,1432-1238 | 2020-06-14 02:00:00+02:00 | pubmed | Acute Kidney Injury__drug therapy;Betacoronavirus__isolation & purification;Blood Coagulation Disorders__virology;Coronavirus Infections__complications;Creatinine__blood;Critical Illness;Hematuria__etiology;Humans;Kidney__physiopathology;Pandemics;Pneumonia, Viral__complications;Proteinuria__etiology;Renin-Angiotensin System__physiology;Urinalysis;Urine__chemistry;COVID-19;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Paul Gabarre;Guillaume Dumas;Thibault Dupont;Michael Darmon;Elie Azoulay;Lara Zafrani | Acute kidney injury;COVID-19;Intensive care unit;Renin–angiotensin–aldosterone system | 2020-06-12 02:00:00+02:00 | 32533197 | FR | Medical Intensive Care Unit, Hopital Saint-Louis, Assistance Publique des Hôpitaux de Paris, University of Paris, Paris, France.;Medical Intensive Care Unit, Hopital Saint-Louis, Assistance Publique des Hôpitaux de Paris, University of Paris, Paris, France. lara.zafrani@aphp.fr.;UMR 976, INSERM, Paris, France. lara.zafrani@aphp.fr. | 1157 | ||
| Letter;Comment | en | Severe Covid-19 disease: rather AVDS than ARDS? | https://www.ncbi.nlm.nih.gov/pubmed/32527297 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Respiratory Distress Syndrome, Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Yazine Mahjoub;Daniel Oscar Rodenstein;Vincent Jounieaux | 2020-06-11 02:00:00+02:00 | 32527297 | FR;BE | Cardiac Thoracic Vascular and Respiratory Intensive Care Unit, Amiens University Medical Centre, University Hospital Centre, Amiens, France. Mahjoub.Yazine@chu-amiens.fr.;Pneumology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Pneumology Department, Amiens University Medical Centre, Amiens, France. | 1162 | |||||||
| 10.1016/j.amp.2020.06.005 | English Abstract;Journal Article | fr | ["Crown protection" or protective tendencies of the Corona Covid-19 and its improbable encounters]. | https://www.ncbi.nlm.nih.gov/pubmed/32836304 | The title of our paper could be receipted (intellectually receipted) like a paradox or like choking item. In real life of our hospital activity is not at all true because in both clinical situations the symptomatology of infectious disease was protected about a long psychotic or pseudo psychotic episode. The most important for the psychiatric stabilization was strictly observance and repetition of consultations who created a secure feel, necessarily for construction after psychodramatic real story Covid-19. Our clinical case shows the possibility of our patients to relativize the gravity of the pandemic and his impact. The modalities of psychotropic treatment are very important in this specific pathologic case and our presentation could give us new ideas in psychiatry and immunology about protection by ay antibiotherapy in pre- and post-operatory. Unlikely encounter with a disease that leads to an episode of madness and psychological care after a severe episode of Covid-19. Psychological support is upset by this disease, like the rest. The clinic returns to its original meaning: at the patient's bed to understand this new disease and its protective and/or revealing effects. Clinical presentation of an unlikely encounter in the context of the Covid-19 epidemic. Encounter with both a severe form of this new disease and psychopathological expression in intensive care and post-reanimation units. Psychological support in a patient suffering from a delusional episode and identity disorders related to Covid-19. Psychological support is disrupted by this disease, as is the rest. The clinic returns to its original meaning: in the patient's bed to understand this new disease and its protective and/or revealing effects. The singular and psychoanalytic listening allows the patient to understand the process of constructing his episode of delusional appearance, like dreamlike construction. Adaptation and creation of a clinic requiring to be as close as possible to the patient to allow the psychological restructuring having been disorganized in connection with the disease but also with the hospital and family environment, strongly impacted by anxiety. | 0003-4487 | 2020-06-14 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Doina Diana Tesu Rollier;Paola Aburto | Covid-19;Depression;Pandemic;Psychosis;Psychotherapy;Specific therapeutic protocol;Trouble of comportment | 2020-06-11 02:00:00+02:00 | 32836304 | FR | 20, rue du Colonel-Dominé, 75013 Paris, France.;CHSF, Corbeil-Essonnes, France. | 1163 | |||
| 10.1038/s41575-020-0328-2 | Journal Article | en | COVID-19 and the liver-related deaths to come. | https://www.ncbi.nlm.nih.gov/pubmed/32528138 | 1759-5045,1759-5053 | 2020-06-14 02:00:00+02:00 | pubmed | Nature Reviews Gastroenterology & Hepatology | Jean-Michel Pawlotsky | 2020-06-11 02:00:00+02:00 | 32528138 | FR | Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France. jean-michel.pawlotsky@aphp.fr.;Viruses, Hepatology, Cancer research team, INSERM U955, Créteil, France. jean-michel.pawlotsky@aphp.fr. | 1173 | |||||
| 10.1177/1090198120935067 | Editorial | en | The COVID-19 Pandemic: Everything Old Is New Again in Public Health Education. | https://www.ncbi.nlm.nih.gov/pubmed/32517520 | 1090-1981,1552-6127 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Health Equity;Health Status Disparities;Healthcare Disparities__organization & administration;Humans;Pandemics;Pneumonia, Viral__epidemiology;Public Health__education;Social Determinants of Health__ethnology;Socioeconomic Factors;United States__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Health Education & Behavior | Jesus Ramirez-Valles;Eric Breton;David H Chae;Regine Haardörfer;Lisa M Kuhns | COVID-19;health behavior;health education;health equity;infectious disease | 2020-06-09 02:00:00+02:00 | 32517520 | FR;US | Health Equity Institute, San Francisco State University, San Francisco, CA, USA.;École des Hautes Études en Santé Publique, Rennes, France.;Auburn University, Auburn, AL, USA.;Emory University, Atlanta, GA, USA.;Northwestern University, Chicago, IL, USA. | 1174 | |||
| 10.1002/jmv.26172 | Journal Article | en | Dyspnea: The vanished warning symptom of COVID-19 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32530534 | 0146-6615,1096-9071 | 2020-06-14 02:00:00+02:00 | pubmed | Journal of Medical Virology | Gilles Allali;Christophe Marti;Olivier Grosgurin;Capucine Morélot-Panzini;Thomas Similowski;Dan Adler | 2020-06-12 02:00:00+02:00 | 32530534 | FR;CH;US | Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Department of Neurology, Division of Cognitive and Motor Aging, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York.;Division of General Internal Medicine, Geneva University Hospital, Geneva, Switzerland.;INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;AP-HP, Site Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Groupe Hospitalier Universitaire APHP-Sorbonne Université, Paris, France.;Division of Pulmonary Diseases, Geneva University Hospitals and Faculty of Medicine and University of Geneva, Geneva, Switzerland. | 1182 | |||||
| 10.1093/ecco-jcc/jjaa120 | Journal Article | en | Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD. | https://www.ncbi.nlm.nih.gov/pubmed/32520312 | The Coronavirus 2019 (COVID-19) pandemic has posed challenges in the routine care of patients with inflammatory bowel disease. One of the key challenges needing addressing is the quantification of the risks of immunosuppressive and biologic therapies in IBD patients during the pandemic. The similarities and differences between the previous coronavirus outbreaks and the pathobiology of the infections can give useful information in understanding the risks, and perhaps potential beneficial aspects of drugs used in IBD. Although clinical, immunological and pharmacological data from the experience with the previous coronavirus outbreaks cannot be automatically translated to predict the safety of IBD therapies during COVID-19 pandemic, the signals so far from these outbreaks on IBD patients who are on immunomodulators and biologics are reassuring to patients and clinicians alike. | 1873-9946,1876-4479 | 2020-06-14 02:00:00+02:00 | pubmed | Journal of Crohn's and Colitis | S Sebastian;H A Gonzalez;L Peyrin-Biroulet | 2020-06-10 02:00:00+02:00 | 32520312 | FR;GB | IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.;Hull York Medical School, Hull, UK.;Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-Les-Nancy, France.;Inserm U1256 NGERE, Lorraine University, Vandoeuvre-Les-Nancy, France. | 1190 | ||||
| Letter | en | Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis. | https://www.ncbi.nlm.nih.gov/pubmed/32540682 | 2020-06-14 02:00:00+02:00 | pubmed | Jean-Marie Vaugeois | 2020-06-10 02:00:00+02:00 | 32540682 | FR | Normandie University, université de Rouen, université de Caen, ABTE, Rouen 76000, France, Département de Pharmacie, UFR Santé, 22, boulevard Gambetta, 76183 Rouen cedex 1, France. Electronic address: jean-marie.vaugeois@univ-rouen.fr. | 1192 | ||||||||
| 10.12890/2020_001769 | Journal Article | en | Cutaneous Complications Secondary to Haemostasis Abnormalities in COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32665938 | We describe the case of a patient hospitalized for acute decompensated heart failure in a standard medical ward. During hospitalization, he was diagnosed with COVID-19 and transferred to a special unit. The clinical course was marked by worsening of the respiratory disease, the development of right parotiditis and thrombosis of the left internal jugular vein. Therapeutic anticoagulation was initiated and 2 days later, the minimal dermatoporosis lesions previously present in the upper extremities evolved to haemorrhagic bullae with intra-bullae blood clots and dissecting haematomas. Surgical management of the dissecting haematomas was difficult in the context of haemostasis abnormalities. The patient died 29 days after hospital admission. | 2020-06-14 02:00:00+02:00 | pubmed | Noel Lorenzo-Villalba;Yasmine Maouche;Aneska Syrovatkova;Felix Pham;Jean-Baptiste Chahbazian;Pierre Pertoldi;Emmanuel Andrès;Abrar-Ahmad Zulfiqar | COVID-19;coagulation abnormalities;dermatoporosis;dissecting haematoma | 2020-06-12 02:00:00+02:00 | 32665938 | FR | Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasboug, Strasbourg, France.;Service de Dermatologie, Hôpitaux Universitaires de Strasboug, Strasbourg, France. | 1199 | |||||
| 10.1016/j.ijantimicag.2020.106054 | Journal Article | en | Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. | https://www.ncbi.nlm.nih.gov/pubmed/32534188 | The emergence and rapid spread of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a potentially fatal disease, is swiftly leading to public health crises worldwide. The origin of SARS-CoV-2 infection was first reported in people exposed to a seafood market in Wuhan City, China in December 2019. It has been suggested that the infection is likely to be of zoonotic origin and transmitted to humans through a not-yet-known intermediary. As of 22 May 2020, the World Health Organization reported that there were approximately 4,995,996 confirmed cases and 327,821 deaths. SARS-CoV-2 is transmitted via inhalation or direct contact with droplets from infected people. It has an incubation period ranging from 2 to ≥14 days. The rate of spread of SARS-CoV-2 is greater than that for severe acute respiratory syndrome coronavirus and Middle East respiratory coronavirus. The symptoms are similar to influenza (i.e. breathlessness, sore throat and fatigue) and infected cases are isolated and treated. Infection is mild in most cases, but in elderly (>50 years) patients and those with cardiac and respiratory disorders, it may progress to pneumonia, acute respiratory distress syndrome and multi-organ failure. People with strong immunity or those who have developed herd immunity are asymptomatic. The fatality rate ranges from 3% to 4%. Recommended methods for diagnosis of COVID-19 are molecular tests (e.g. polymerase chain reaction) on respiratory secretions, chest scan and common laboratory diagnosis. Currently, treatment is essentially supportive, and the role of antiviral agents is yet to be established as a vaccine is not yet available. This review will focus on epidemiology, symptoms, transmission, pathogenesis, ongoing available treatments and future perspectives of SARS-CoV-2. | 0924-8579 | 2020-06-14 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Betacoronavirus__isolation & purification;Biomarkers__metabolism;Coronavirus Infections__drug therapy;Global Health;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Atul Sharma;Swapnil Tiwari;Manas Kanti Deb;Jean Louis Marty | Antiviral agents;Biosensor;Chloroquine;Coronavirus;SARS-CoV-2;Severe acute respiratory syndrome | 2020-06-10 02:00:00+02:00 | 32534188 | FR;IN;AU | School of Chemistry, Monash University, Clayton, VIC-3800, Melbourne, Australia. Electronic address: a.sharmard@gmail.com.;School of Studies in Chemistry, Pt. Ravishankar Shukla University, Raipur-492010, Chhattisgarh, India.;Biocapteurs-Analyses-Environnement, Universite de Perpignan Via Domitia, 52 Avenue Paul Alduy, Perpignan CEDEX 66860, France, Sensbiotech, 21rue de Nogarede, 66400 Ceret, France. | 1207 | ||
| 10.1371/journal.pntd.0008305 | Comparative Study;Evaluation Study;Journal Article;Research Support, Non-U.S. Gov't | en | Video as a public health knowledge transfer tool in Burkina Faso: A mixed evaluation comparing three narrative genres. | https://www.ncbi.nlm.nih.gov/pubmed/32520930 | The dengue virus is endemic in many low- and middle-income countries. In Burkina Faso, the proportion of fevers that could be due to dengue is growing. In 2013, a dengue epidemic spread there, followed by other seasonal outbreaks. Dengue is often confused with malaria, and health workers are not trained to distinguish between them. Three training videos using different narrative genres were tested with nursing students from two institutions in Ouagadougou: journalistic, dramatic and animated video. The study aimed to determine if video is an effective knowledge transfer tool, if narrative genre plays a role in knowledge acquisition, and which narrative elements are the most appreciated. | 1935-2735 | 2020-06-14 02:00:00+02:00 | pubmed | Audiovisual Aids;Burkina Faso;Dengue__diagnosis;Diagnostic Errors__prevention & control;Focus Groups;Health Personnel__education;Humans;Information Dissemination__methods;Inservice Training;Knowledge;Narration | PLOS Neglected Tropical Diseases | Catherine Hébert;Christian Dagenais;Esther Mc Sween-Cadieux;Valéry Ridde | 2020-06-10 02:00:00+02:00 | 32520930 | FR;CA | Department of Psychology, University of Montreal, Montreal, Quebec, Canada.;French Institute For Research on sustainable Development (IRD), CEPED (IRD-Université Paris Descartes), Universités Paris Sorbonne Cités, ERL INSERM SAGESUD, Paris, France. | 1210 | |||
| 10.1016/j.jemep.2020.100541 | Editorial | fr | [COVID-19, human dignity and psychological trauma for caregivers: An open letter to health authorities]. | https://www.ncbi.nlm.nih.gov/pubmed/32835058 | 2352-5525 | 2020-06-14 02:00:00+02:00 | pubmed | Ethics, Medicine and Public Health | P Charlier | 2020-06-12 02:00:00+02:00 | 32835058 | FR | Laboratoire Anthropologie Archéologie Biologie (LAAB), université Paris-Saclay (UVSQ), 2, avenue de la Source-de-la-Bièvre, 78180 Montigny-Le-Bretonneux, France.;Musée du quai Branly-Jacques-Chirac, 222, rue de l'Université, 75007 Paris, France. | 1215 | |||||
| 10.1016/j.jaccas.2020.06.003 | Case Reports | en | 4 Cases of Aortic Thrombosis in Patients With COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32835285 | Since the outbreak of the COVID-19 pandemic, increasing evidence suggests that infected patients present a high incidence of thrombotic complications. This report describes 4 cases of aortic thrombosis in patients admitted for COVID-19 infection between March 26 and April 12, 2020, in Mulhouse, France. (Level of Difficulty: Intermediate.). | 2666-0849 | 2020-06-14 02:00:00+02:00 | pubmed | JACC: Case Reports | Bastien Woehl;Bree Lawson;Lucas Jambert;Jonathan Tousch;Afif Ghassani;Amer Hamade | COVID-19;COVID-19, coronavirus-2019;CT, computed tomography;RT-PCR, reverse-transcriptase polymerase chain reaction;SARS-CoV-2;SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2;aorta;aortic thrombosis | 2020-06-08 02:00:00+02:00 | 32835285 | FR | Service de médecine vasculaire, Hôpital Emile Muller de Mulhouse, Groupe Hospitalier de la Région de Mulhouse et Sud-Alsace, Mulhouse, France.;Service de cardiologie, Hôpital Emile Muller de Mulhouse Groupe Hospitalier de la Région de Mulhouse et Sud-Alsace, Mulhouse, France.;Service de chirurgie vasculaire, Hôpital Emile Muller de Mulhouse Groupe Hospitalier de la Région de Mulhouse et Sud-Alsace, Mulhouse, France. | 1218 | |||
| Letter | en | Discrepancy in reports of COVID-19 onset of symptoms: are faulty data being collected? | https://www.ncbi.nlm.nih.gov/pubmed/32526276 | 2020-06-14 02:00:00+02:00 | pubmed | J Choucair;R Waked;G Saliba;F Haddad;E Haddad;J Makhoul | 2020-06-08 02:00:00+02:00 | 32526276 | FR;LB | Department of Infectious Diseases, Hotel Dieu de France, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.;Department of Infectious Diseases, Hotel Dieu de France, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. Electronic address: ramiwaked12@hotmail.com.;Department of Internal Medicine and Clinical Immunology, Hotel Dieu de France, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. | 1220 | ||||||||
| 10.12890/2020_001751 | Journal Article | en | Immune Thrombocytopenic Purpura in Patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32665935 | We described three COVID-19-infected patients with profound immune thrombocytopenia causing haemorrhagic mucocutaneous complications. We conclude that an immune mechanism was responsible as common causes were excluded. Since corticoids were considered harmful in the circumstances, the patients were successfully treated with intravenous immunoglobulins without later relapse. | 2020-06-14 02:00:00+02:00 | pubmed | Sabine Revuz;Nathalie Vernier;Leilah Saadi;Julien Campagne;Sophie Poussing;François Maurier | COVID-19;SARS-CoV-2;intravenous immunoglobulins;thrombocytopenia | 2020-06-09 02:00:00+02:00 | 32665935 | FR | Hôpitaux Privés de Metz, Metz, France. | 1222 | |||||
| 10.1016/j.jaccas.2020.06.002 | Case Reports | en | Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult. | https://www.ncbi.nlm.nih.gov/pubmed/32835271 | A 42-year-old man was admitted for an ST-segment elevation myocardial infarction revealing an acute thrombosis of the left anterior descending and right coronary arteries. Following this acute multivessel coronary occlusion in a young individual at low cardiovascular risk, he tested positive for severe acute respiratory syndrome-coronavirus-2 infection. (Level of Difficulty: Beginner.). | 2666-0849 | 2020-06-14 02:00:00+02:00 | pubmed | JACC: Case Reports | Sandra Zendjebil;Michel Zeitouni;Marc Batonga;Nathan El Bèze;Paul Guedeney;Jean-Philippe Collet;Rémi Choussat;Johanne Silvain;Gilles Montalescot | COVID-19, coronavirus-2019;SARS-CoV-2;SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2;STEMI, ST-segment elevation myocardial infarction;ULN, upper limit of normal value;acute coronary syndrome;arterial thrombosis;coronavirus disease-2019;myocardial infarction | 2020-06-09 02:00:00+02:00 | 32835271 | FR | ACTION (Allies in Cardiovascular Trials Initiatives and Organized Networks) Study Group, Sorbonne Université, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France. | 1224 | |||
| Letter | en | Neurological Involvement of COVID-19 Patients: Making the Most of MRI. | https://www.ncbi.nlm.nih.gov/pubmed/32515675 | 2020-06-14 02:00:00+02:00 | pubmed | Yvonne Purcell;Augustin Lecler;Edouard Saragoussi;Emilie Poiron;Guillaume Poillon;Julien Savatovsky | 2020-06-09 02:00:00+02:00 | 32515675 | FR | Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, 29 rue Manin, 75019, France. | 1225 | ||||||||
| 10.1002/anzf.1416 | Journal Article | en | Family Therapy and COVID-19: International Reflections during the Pandemic from Systemic Therapists across the Globe. | https://www.ncbi.nlm.nih.gov/pubmed/32836731 | The COVID-19 pandemic has convulsed human communities across the globe like no previous event in history. Family therapists, paradoxically, given the core of their work is with systems, are also experiencing upheaval in professional and personal lives, trying to work amidst a society in chaos. This paper offers a collection of reflections by systemic and family therapists from diverse cultures and contexts penned in the midst of the pandemic. The main intention in distilling these narratives is to preserve the 'cultural diversity' and 'ecological position' of the contributors, guided by phenomenology, cultural ecology, and systemic worldviews of 'experiencing.' The second intention is to 'unite' promoting solidarity in this isolating situation by bringing each story together, creating its own metaphor of a family: united, connected, stronger. As a cross-cultural family practitioner, with a strong mission for collaboration, the lead author acknowledges the importance of Context - the nation and location of the experience; Culture - the manner in which culture impacts on experience; Collaboration - enhancing partnership, enriching knowledge, and mapping the journey's direction; and Connectedness - combating isolation while enhancing unity. Since the key transmission of culture is through language, raw reflections were sought initially in the practitioners' own language, which were translated for an English-speaking readership. These narratives are honest and rich descriptions of the authors' lived experiences, diverse and distinctive. The contributors trust colleagues will find these reflections helpful, validating and acknowledging the challenges of this unique period in history. | 0814-723X,1467-8438 | 2020-06-14 02:00:00+02:00 | pubmed | Australian and New Zealand Journal of Family Therapy | Deisy Amorin-Woods;Peter Fraenkel;Andrea Mosconi;Martine Nisse;Susana Munoz | COVID‐19;collective trauma;cross‐cultural;cultural diversity;family therapy;intergenerational trauma;language | 2020-06-08 02:00:00+02:00 | 32836731 | FR;CL;US;IT;AU | Insight Counselling & Relationship Centre, Perth and Edith Cowan University Perth Australia.;Ackerman Institute for the Family New York USA.;Paduan Center of Family Therapy Padua Italy.;Center des Buttes-Chaumont Paris France.;Serbal Centro Desarrollos Sistémicos Santiago Chile. | 1232 | |||
| H2020 Research Infrastructures;H2020 Fast Track to Innovation;Agence Nationale de la Recherche;H2020 European Institute of Innovation and Technology | 10.3390/v12060624 | Journal Article;Research Support, Non-U.S. Gov't | en | Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples. | https://www.ncbi.nlm.nih.gov/pubmed/32521706 | Clinical samples collected in coronavirus disease 19 (COVID-19), patients are commonly manipulated in biosafety level 2 laboratories for molecular diagnostic purposes. Here, we tested French norm NF-EN-14476+A2 derived from European standard EN-14885 to assess the risk of manipulating infectious viruses prior to RNA extraction. SARS-CoV-2 cell-culture supernatant and nasopharyngeal samples (virus-spiked samples and clinical samples collected in COVID-19 patients) were used to measure the reduction of infectivity after 10 minute contact with lysis buffer containing various detergents and chaotropic agents. A total of thirteen protocols were evaluated. Two commercially available formulations showed the ability to reduce infectivity by at least 6 log 10, whereas others proved less effective. | 1999-4915 | 2020-06-14 02:00:00+02:00 | pubmed | Animals;Betacoronavirus__drug effects;Cell Culture Techniques__methods;Chlorocebus aethiops;Containment of Biohazards__methods;Coronavirus Infections__virology;Humans;Nasopharynx__virology;Pandemics;Pneumonia, Viral__virology;RNA, Viral__isolation & purification;Specimen Handling__methods;Vero Cells;Viral Load__methods;Virus Inactivation__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Viruses | Boris Pastorino;Franck Touret;Magali Gilles;Lea Luciani;Xavier de Lamballerie;Remi N Charrel | COVID-19;SARS-CoV-2;coronavirus;extraction buffer;inactivation;lysis buffer | 2020-06-08 02:00:00+02:00 | 32521706 | FR | [{"country": "International", "agency": "H2020 Research Infrastructures", "grantid": "871029"}, {"country": "International", "agency": "H2020 Fast Track to Innovation", "grantid": "101003544"}, {"country": "International", "agency": "Agence Nationale de la Recherche", "grantid": "PREPMedVet"}, {"country": "International", "agency": "H2020 European Institute of Innovation and Technology", "grantid": "823666"}] | Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), 13005 Marseille, France. | 1233 |
| Letter | en | A plea for the pathogenic role of immune complexes in severe Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32526273 | 2020-06-14 02:00:00+02:00 | pubmed | Antibodies, Viral__biosynthesis;Antigen-Antibody Complex__biosynthesis;Betacoronavirus__immunology;Blood Vessels__drug effects;Complement C3__antagonists & inhibitors;Complement Inactivating Agents__therapeutic use;Coronavirus Infections__complications;Cytokine Release Syndrome__complications;Humans;Immune Complex Diseases__complications;Immunity, Humoral__drug effects;Interleukin 1 Receptor Antagonist Protein__therapeutic use;Interleukin-6__antagonists & inhibitors;Pandemics;Pneumonia, Viral__complications;Receptors, Interleukin-1__antagonists & inhibitors;Severe Acute Respiratory Syndrome__complications;Severity of Illness Index;Vasculitis__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Dominique A Vuitton;Lucine Vuitton;Estelle Seillès;Pierre Galanaud | Complement;Covid-19;Immune complexes;Immunopathology;SARS-CoV2 | 2020-06-08 02:00:00+02:00 | 32526273 | FR | EA 3181, Université Bourgogne Franche-Comté, Besançon, France. Electronic address: dvuitton@univ-fcomte.fr.;Department of Acute and Chronic Diseases, Education, and Transplantation, Gastroenterology unit, University Hospital, Besançon, France.;Immuno-biology Laboratory, Établissement Français du Sang (EFS) Bourgogne Franche-Comté, Besançon, France, U1098, Inserm-EFS-Université Bourgogne Franche-Comté, Besançon, France.;U996, Inflammation, Microbiome and Immunosurveillance, Inserm, Université Paris-Saclay, Clamart, France. | 1235 | ||||||
| Letter | en | Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. | https://www.ncbi.nlm.nih.gov/pubmed/32514592 | 2020-06-14 02:00:00+02:00 | pubmed | Robin Jeannet;Thomas Daix;Rémy Formento;Jean Feuillard;Bruno François | 2020-06-08 02:00:00+02:00 | 32514592 | FR | UMR CNRS 7276, INSERM 1262, Faculty of Medicine, University of Limoges, 87000, Limoges, France.;Inserm CIC 1435 & UMR 1092, Dupuytren Teaching Hospital, 87000, Limoges, France.;Medical-Surgical Intensive Care Unit, Dupuytren Teaching Hospital, 87000, Limoges, France.;Laboratory of Hematology, Dupuytren Teaching Hospital, 87000, Limoges, France.;Inserm CIC 1435 & UMR 1092, Dupuytren Teaching Hospital, 87000, Limoges, France. b.francois@unilim.fr.;Medical-Surgical Intensive Care Unit, Dupuytren Teaching Hospital, 87000, Limoges, France. b.francois@unilim.fr.;Réanimation Polyvalente, CHU Dupuytren, 2 Avenue Martin-Luther King, 87042, Limoges, France. b.francois@unilim.fr. | 1242 | ||||||||
| Letter;Comment | en | COVID-19 and ABO blood group: another viewpoint. | https://www.ncbi.nlm.nih.gov/pubmed/32453863 | 2020-06-14 02:00:00+02:00 | pubmed | ABO Blood-Group System;Betacoronavirus;Blood Grouping and Crossmatching;Coronavirus Infections;Humans;Pandemics;Pneumonia;Pneumonia, Viral;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Christiane Gérard;Gianni Maggipinto;Jean-Marc Minon | COVID-19;antibodies;blood group serology | 2020-06-08 02:00:00+02:00 | 32453863 | FR;BE | Blood Transfusion service, Centre Hospitalier Universitaire, University of Liège, Liège, Belgium.;Department of Thrombosis-haemostasis and Transfusion, Centre Hospitalier Régional de la citadelle, Liège, Belgium. | 1243 | ||||||
| Letter | en | High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability? | https://www.ncbi.nlm.nih.gov/pubmed/32529774 | 2020-06-14 02:00:00+02:00 | pubmed | M Pineton de Chambrun;C Frere;M Miyara;Z Amoura;I Martin-Toutain;A Mathian;G Hekimian;A Combes | 2020-06-12 02:00:00+02:00 | 32529774 | FR | From the, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, Paris, France.;Service de Médecine Intensive-Réanimation, Institut de Cardiologie, Assistance Publique Hôpitaux de Paris (APHP), Hôpital La Pitié- Salpêtrière, Paris, France.;Service de Médecine Interne 2, Centre de Référence de Maladie Rare Lupus Systémique et Syndrome des Anticorps Antiphospholipides, Institut E3M, APHP, Hôpital La Pitié- Salpêtrière, Paris, France.;Service d'Hématologie Biologique, APHP, Hôpital La Pitié-Salpêtrière, Paris, France.;Laboratoire d'Immunochimie, APHP, Hôpital La Pitié-Salpêtrière, Paris, France. | 1247 | ||||||||
| Letter | en | Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32533322 | 2020-06-14 02:00:00+02:00 | pubmed | H Chaumont;A San-Galli;F Martino;C Couratier;G Joguet;M Carles;E Roze;A Lannuzel | 2020-06-12 02:00:00+02:00 | 32533322 | FR;GP | Centre Hospitalier Universitaire de la Guadeloupe, Service de Neurologie, 97139, Pointe-à-Pitre/Abymes, France. hugo.chaumont@chu-guadeloupe.fr.;Faculté de Médecine, Université Des Antilles, Pointe-à-Pitre, France. hugo.chaumont@chu-guadeloupe.fr.;Institut National de La Santé Et de La Recherche Médicale, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau Et de La Moelle épinière, ICM, Faculté de Médecine de Sorbonne Université, U 1127, Paris, France. hugo.chaumont@chu-guadeloupe.fr.;Centre Hospitalier Universitaire de la Guadeloupe, Service de Neurologie, 97139, Pointe-à-Pitre/Abymes, France.;Faculté de Médecine, Université Des Antilles, Pointe-à-Pitre, France.;Centre Hospitalier Universitaire de La Guadeloupe, Service de Réanimation, Pointe-à-Pitre/Abymes, France.;Laboratoire de Biologie de La Reproduction, Centre Hospitalier Universitaire de La Guadeloupe, Pointe-à-Pitre/Abymes, France.;Institut National de La Santé Et de La Recherche Médicale, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau Et de La Moelle épinière, ICM, Faculté de Médecine de Sorbonne Université, U 1127, Paris, France.;AP-HP, Hôpital de La Pitié-Salpêtrière, Département de Neurologie, Paris, France.;Centre D'investigation Clinique Antilles Guyane, Inserm CIC 1424, Pointe-à-Pitre, France. | 1248 | ||||||||
| Letter;Comment | en | Letter regarding "SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis". | https://www.ncbi.nlm.nih.gov/pubmed/32544410 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Peritoneal Dialysis;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Alexandre Candellier;Éric Goffin | 2020-06-13 02:00:00+02:00 | 32544410 | FR;BE | Department of Nephrology, Saint Luc University Clinics, Institute of Experimental and Clinical Research, Catholic University of Louvain, Brussels, Belgium, Division of Nephrology, Amiens-Picardie University Hospital Center, Amiens, France. Electronic address: alexandre.candellier@gmail.com.;Department of Nephrology, Saint Luc University Clinics, Institute of Experimental and Clinical Research, Catholic University of Louvain, Brussels, Belgium. | 1256 | |||||||
| Letter | en | In-ICU COVID-19 patients' characteristics for an estimation in post-ICU rehabilitation care requirement. | https://www.ncbi.nlm.nih.gov/pubmed/32544435 | 2020-06-14 02:00:00+02:00 | pubmed | Charlotte Poussardin;Walid Oulehri;Marie Eve Isner;Paul Michel Mertes;Olivier Collange | COVID-19;Post-resuscitation care;Rehabilitation | 2020-06-13 02:00:00+02:00 | 32544435 | FR | Pôle Anesthésie Réanimation Chirurgicale, service de Réanimation Chirurgicale, Hôpitaux Universitaires de Strasbourg NHC, 67000 Strasbourg, France, EA 3072, Institut de Physiologie, FMTS (Fédération de médecine translationnelle de Strasbourg), Faculté de Médecine de Strasbourg, Université de Strasbourg, Strasbourg, France.;Institut Universitaire de Réadaptation Clémenceau (IURC), Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.;Pôle Anesthésie Réanimation Chirurgicale, service de Réanimation Chirurgicale, Hôpitaux Universitaires de Strasbourg NHC, 67000 Strasbourg, France, EA 3072, Institut de Physiologie, FMTS (Fédération de médecine translationnelle de Strasbourg), Faculté de Médecine de Strasbourg, Université de Strasbourg, Strasbourg, France. Electronic address: olivier.collange@chru-strasbourg.fr. | 1257 | |||||||
| 10.1007/s40620-020-00784-3 | Editorial | en | The COVID-19 infection in dialysis: are home-based renal replacement therapies a way to improve patient management? | https://www.ncbi.nlm.nih.gov/pubmed/32542561 | 1121-8428,1724-6059 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Hemodialysis, Home;Humans;Pandemics;Peritoneal Dialysis;Pneumonia, Viral__epidemiology;Renal Dialysis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Nephrology | Mario Cozzolino;Giorgina Barbara Piccoli;Talat Alp Ikizler;Claudio Ronco | 2020-06-17 02:00:00+02:00 | 32542561 | FR;IT;US | Division of Nephrology and Dialysis, Department of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy. mario.cozzolino@unimi.it.;Centre Hospitalier Le Mans, France, Le Mans, France.;Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.;Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.;Department of Medicine, University of Padua, Padua, Italy.;Department of Nephrology, Dialysis and Kidney Transplant, International Renal Research Institute, San Bortolo Hospital, Vicenza, Italy. | 1277 | ||||
| 10.1097/rlu.0000000000003135 | Case Reports;Journal Article | en | Incidental Finding of COVID-19 Lung Infection in 18F-FDG PET/CT: What Should We Do? | https://www.ncbi.nlm.nih.gov/pubmed/32558722 | We report the case of an asymptomatic (no fever, no cough, no dyspnea) 80-year-old woman who had an F-FDG PET/CT scan for initial staging of Lieberkühnian adenocarcinoma located on anal canal. Chest analysis incidentally revealed bilateral diffuse patchy ground-glass opacity with mild increasing F-FDG uptake, consistent with incidental COVID-19 infection finding during the March 2020 pandemic. The infection was confirmed by reverse transcription-polymerase chain reaction. It led us to improve patient flow and to undertake broader measures to avoid patient clinical issues and potential disease spreading. | 2020-06-21 02:00:00+02:00 | pubmed | Aged, 80 and over;Betacoronavirus;Coronavirus Infections__diagnostic imaging;Female;Fluorodeoxyglucose F18;Humans;Incidental Findings;Pandemics;Pneumonia, Viral__diagnostic imaging;Positron Emission Tomography Computed Tomography;COVID-19;severe acute respiratory syndrome coronavirus 2 | Vincent Habouzit;Alicia Sanchez;Sabrina Dehbi;Nathalie Prevot;Pierre-Benoît Bonnefoy | 2020-06-20 02:00:00+02:00 | 32558722 | FR;UNK | From the Departments of Nuclear Medicine.;Radiology, CHU Saint-Etienne.;INSERM, U1059, Saint Etienne.;Université de Lyon, Lyon, France. | 1281 | |||||
| British Heart Foundation;Wellcome Trust;Medical Research Council | 10.1093/ehjci/jeaa178 | Journal Article;Research Support, Non-U.S. Gov't | en | Global evaluation of echocardiography in patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32556199 | To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography. | 2047-2404,2047-2412 | 2020-06-21 02:00:00+02:00 | pubmed | European Heart Journal - Cardiovascular Imaging | Marc R Dweck;Anda Bularga;Rebecca T Hahn;Rong Bing;Kuan Ken Lee;Andrew R Chapman;Audrey White;Giovanni Di Salvo;Leyla Elif Sade;Keith Pearce;David E Newby;Bogdan A Popescu;Erwan Donal;Bernard Cosyns;Thor Edvardsen;Nicholas L Mills;Kristina Haugaa | COVID-19;Echocardiography | 2020-06-20 02:00:00+02:00 | 32556199 | FR;NO;RO;GB;US;IT;TR;BE | [{"country": "United Kingdom", "agency": "British Heart Foundation"}, {"country": "United Kingdom", "agency": "Wellcome Trust"}, {"country": "United Kingdom", "agency": "Medical Research Council"}] | Centre for Cardiovascular Science, University of Edinburgh, UK.;Columbia University Irving Medical Center, NY, USA.;University Hospital Padua, Paediatric Cardiology, Padua, Italy.;Department of Cardiology, University of Baskent, Ankara, Turkey.;University Hospital South Manchester, Cardiology, Wythenshawe, Manchester, UK.;Department of Cardiology, University of Medicine and Pharmacy 'Carol Davila'-Euroecolab, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C. C. Iliescu', Bucharest, Romania.;University of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, Rennes, France.;Centrum voor Hart en Vaatziekten, Universitair Ziekenhuis Brussel, Vrij Universiteit van Brussel, Brussels, Belgium.;Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.;Faculty of Medicine, University of Oslo, Oslo, Norway.;Usher Institute, University of Edinburgh, UK. | 1282 | |
| 10.1016/s2468-1253(20)30155-2 | Journal Article | en | Converging pandemics: implications of COVID-19 for the viral hepatitis response in sub-Saharan Africa. | https://www.ncbi.nlm.nih.gov/pubmed/32553140 | 2468-1253 | 2020-06-21 02:00:00+02:00 | pubmed | Africa South of the Sahara__epidemiology;Betacoronavirus;Clinical Laboratory Techniques;Coinfection__diagnosis;Coronavirus Infections__diagnosis;Hepatitis, Viral, Human__diagnosis;Humans;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | The Lancet Gastroenterology & Hepatology | Neil Gupta;Hailemichael Desalegn;Ponsiano Ocama;Karine Lacombe;Richard Njouom;Mary Afihene;Lina Cunha;C Wendy Spearman;Mark W Sonderup;Fredrick Kateera | 2020-06-20 02:00:00+02:00 | 32553140 | FR;GH;UG;CM;US;MZ;ET;ZA;RW | Division of Global Health Equity, Brigham & Women's Hospital, Boston, MA 02115, USA, Partners In Health, Boston, MA, USA. Electronic address: ngupta5@bwh.harvard.edu.;Medicala Department, St Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.;Makerere University College of Health Sciences, Kampala, Uganda.;Department of Infectious and Tropical Diseases, Saint-Antoine Hospital, Paris, France, Institut Pierre Louis d'Épidémiologie et de Santé Publique, INSERM, Sorbonne Université, Paris, France.;Virology Department, Centre Pasteur of Cameroon, Yaounde, Cameroon.;Department of Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Komfo Anokye Teaching Hospital, Kumasi, Ghana.;Hospital Privado de Maputo, Hepato-Gastroenterology Division, Department of Medicine, Maputo, Mozambique.;Division of Hepatology, Department of Medicine, University of Cape Town, Cape Town, South Africa, Faculty of Health Sciences and Groote Schuur Hospital, Observatory, Cape Town, South Africa.;Clinical Programs Department, Partners in Health/Inshuti Mu Buzima, Kigali, Rwanda. | 1288 | ||||
| 10.1684/abc.2020.1563 | Historical Article;Journal Article | en | SFBC working group "Biochemical markers of COVID-19". | https://www.ncbi.nlm.nih.gov/pubmed/32540814 | The SARS-CoV-2 virus is responsible for an epidemic disease called COVID-19, which was initially evidenced in Wuhan, China, and spread very rapidly in China and around the world. In France, the first isolated case seems now to be reported in December 2019, stage 3 of the COVID-19 epidemic was triggered on March 14th, the start of the planned containment exit from May 11th. Healthcare services have faced a large influx of patients who may be beyond their capacity to receive and care, particularly in the Large-East and Ile-de-France regions. Some patients show an evolution of the disease never observed before with other coronaviruses and develop in a few days a very important inflammatory reaction, which can lead to death of patients. A working group of the French Society of Clinical Biology (SFBC) was set up with the objective of providing updated information on the current status of the biological prescriptions (focusing on biochemistry ones) and their evolution during the epidemic, and of analyzing the biological parameters associated with comorbidities and patient evolution in order to link biological results with medical events. The expanded working group covers all sectors of medical biology in France and extends to the French-speaking world: hospital sectors (CHU and CH, Army Training Hospitals) and the private sector opening a field of view on the biological situation in establishments for dependent elderly, social establishments and clinical medical institutions. The purpose of this article is the presentation of this working group and its immediate and future actions. | 0003-3898 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Biochemistry__organization & administration;Biomarkers__analysis;Clinical Laboratory Services__organization & administration;Community Networks__organization & administration;Coronavirus Infections__blood;Disease Outbreaks;France__epidemiology;History, 21st Century;Humans;Intersectoral Collaboration;Pandemics;Pneumonia, Viral__blood;Professional Practice__organization & administration;Societies, Scientific__organization & administration;Videoconferencing__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | Annales de Biologie Clinique | Marie-Christine Beauvieux;Annie M Bérard;Isabelle Aimone-Gastin;Françoise Barbé;Yann Barguil;Delphine Collin-Chavagnac;Hervé Delacour;Céline Delevallée;Valérie Nivet-Antoine;Katell Peoc'h;Carole Poupon;François Schmitt;Laurence Piéroni;Vincent Sapin | COVID-19;biological markers;medical biology | 2020-06-17 02:00:00+02:00 | 32540814 | FR | Service de biochimie, CHU de Bordeaux , RMSB, UMR5536 CNRS Université Bordeaux, France.;Service de biochimie, CHU de Bordeaux , Université Bordeaux, France.;Laboratoire de biochimie-biologie moléculaire-nutrition-métabolisme, CHU de Nancy , Université de Lorraine, Inserm UMR-S 1256, Faculté de médecine de Nancy, Vandoeuvre-lès-Nancy, France.;Laboratoire de biochimie-biologie moléculaire-nutrition-métabolisme, CHU de Nancy, France.;UF de biochimie-toxicologie, Centre hospitalier territorial de Nouméa, Nouvelle-Calédonie, France.;Service de biochimie et biologie moléculaire, Groupement hospitalier Sud, Hospices civils de Lyon, France.;Hôpital d'instruction des armées Bégin, Département des laboratoires, Saint-Mandé, France.;LBM Gen-Bio, Groupe Inovie, Clermont-Ferrand, France.;DMU BioPhyGen, Hôpital Necker-Enfants Malades, AP-HP Centre, Laboratoire de biochimie générale , UMRS1140, Faculté de pharmacie et Université de Paris, France.;HUPNVS, Hôpitaux Beaujon et Bichat, AP-HP Nord, Laboratoires de biochimie , Université de Paris, France.;Laboratoire de biologie médicale, Centre hospitalier de Gonesse, France.;Laboratoire de biologie médicale, Groupe hospitalier Bretagne Sud, Lorient, France.;Département de biochimie et hormonologie, CHU de Montpellier , DMU BioGeM, Hôpital Tenon, AP-HP Est, Département de biochimie, France.;Biochimie et génétique moléculaire, CHU Clermont-Ferrand , UMR CNRS 6293, Inserm 1103, Université Clermont Auvergne, France. | 1293 | ||
| 10.1007/s12630-020-01740-2 | Comparative Study;Journal Article;Systematic Review | en | High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. | https://www.ncbi.nlm.nih.gov/pubmed/32542464 | We conducted two World Health Organization-commissioned reviews to inform use of high-flow nasal cannula (HFNC) in patients with coronavirus disease (COVID-19). We synthesized the evidence regarding efficacy and safety (review 1), as well as risks of droplet dispersion, aerosol generation, and associated transmission (review 2) of viral products. | 0832-610X,1496-8975 | 2020-06-21 02:00:00+02:00 | pubmed | Aerosols;Cannula;Coronavirus Infections__complications;Humans;Oxygen Inhalation Therapy__methods;Pandemics;Pneumonia, Viral__complications;Randomized Controlled Trials as Topic;Respiratory Insufficiency__physiopathology;COVID-19 | Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Arnav Agarwal;John Basmaji;Fiona Muttalib;David Granton;Dipayan Chaudhuri;Devin Chetan;Malini Hu;Shannon M Fernando;Kimia Honarmand;Layla Bakaa;Sonia Brar;Bram Rochwerg;Neill K Adhikari;Francois Lamontagne;Srinivas Murthy;David S C Hui;Charles Gomersall;Samira Mubareka;Janet V Diaz;Karen E A Burns;Rachel Couban;Quazi Ibrahim;Gordon H Guyatt;Per O Vandvik | COVID-19;SARS-CoV-2;aerosols;high-flow nasal cannula;respiratory failure | 2020-06-15 02:00:00+02:00 | 32542464 | FR;NO;CA;CN;GB;US;HK;CH | Department of Medicine, University of Toronto, Toronto, ON, Canada.;Division of Critical Care, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.;Centre for Global Child Health, Hospital for Sick Children, Toronto, ON, Canada.;Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.;Department of Medicine, McMaster University, Hamilton, ON, Canada.;Department of Pediatrics, University of Toronto, Toronto, ON, Canada.;Division of Cardiology, Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada.;Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.;Department of Emergency Medicine, University of Ottawa, Ottawa, ON, Canada.;Schulich School of Medicine and Dentistry, Department of Medicine, Western University, London, ON, Canada.;Honours Life Sciences Program, Faculty of Science, McMaster University, Hamilton, ON, Canada.;School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, USA.;Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.;Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.;Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.;Université de Sherbrooke, Sherbrooke, Canada.;Centre de recherche du CHU de Sherbrooke, Sherbrooke, QC, Canada.;BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada.;Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China.;Stanley Ho, Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, China.;Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China.;Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.;Pacific Medical Center, San Francisco, CA, USA.;World Health Organization, Geneva, Switzerland.;Unity Health Toronto - St. Michael's Hospital, Toronto, ON, Canada.;University of Toronto, Toronto, ON, Canada.;Li Ka Shing Knowledge Institute, Toronto, ON, Canada.;Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, ON, Canada.;MAGIC Evidence Ecosystem Foundation, Oslo, Norway. per.vandvik@gmail.com. | 1294 | ||
| Letter | en | Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy. | https://www.ncbi.nlm.nih.gov/pubmed/32557889 | 2020-06-21 02:00:00+02:00 | pubmed | P Del Giudice;D Boudoumi;B Le Guen;M Reverte;J Gutnecht;J P Lacour;J P Kraemer;A Motard;M Roa | 2020-06-18 02:00:00+02:00 | 32557889 | FR | Infectiology-Dermatology Unit, Centre Hospitalier de Fréjus-Saint-Raphaël, Fréjus, France.;Pneumology Unit, Centre Hospitalier de Fréjus-Saint-Raphaël, Fréjus, France.;Dermatology Department, CHU Nice, Nice, France.;Biology Laboratory, Centre Hospitalier de Fréjus-Saint-Raphaël, Fréjus, France. | 1298 | ||||||||
| 10.1038/s41597-020-0524-5 | Journal Article;Research Support, N.I.H., Intramural | en | COVID-19 pandemic reveals the peril of ignoring metadata standards. | https://www.ncbi.nlm.nih.gov/pubmed/32561801 | 2052-4463 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Datasets as Topic;Genomics__standards;Humans;Metadata__standards;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Scientific Data | Lynn M Schriml;Maria Chuvochina;Neil Davies;Emiley A Eloe-Fadrosh;Robert D Finn;Philip Hugenholtz;Christopher I Hunter;Bonnie L Hurwitz;Nikos C Kyrpides;Folker Meyer;Ilene Karsch Mizrachi;Susanna-Assunta Sansone;Granger Sutton;Scott Tighe;Ramona Walls | 2020-06-19 02:00:00+02:00 | 32561801 | FR;GB;US;HK;AU | University of Maryland School of Medicine, Institute for Genome Sciences, Baltimore, MD, USA. lschriml@som.umaryland.edu.;Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Queensland, Australia.;Gump South Pacific Research Station, University of California Berkeley, Moorea, French Polynesia.;Department of Energy, Joint Genome Institute, Berkeley, California, 94598, USA.;European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, UK.;GigaScience, BGI-Hong Kong, NT, Hong Kong.;University of Arizona, Tucson, AZ, USA.;Argonne National Laboratory, Argonne, Illinois, USA.;National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, 20894, USA.;Oxford e-Research Centre, Department of Engineering Science, University of Oxford, Oxford, UK.;J. Craig Venter Institute, Rockville, Maryland, USA.;University of Vermont, Burlington, Vermont, USA. | 1309 | ||||
| 10.1159/000508560 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | The Role of Genetic Sex and Mitochondria in Response to COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32564017 | The difference between the female and male immune response to COVID-19 infection, and infections in general, is multifactorial. The well-known determiners of the immune response, such as X and Y chromosomes, sex hormones, and microbiota, are functionally interconnected and influence each other in shaping the organism's immunity. We focus our commentary on the interplay between the genetic sex and mitochondria and how this may affect a sex-dependent immune response in COVID-19 infection. Realizing the existence of these interactions may help in designing novel methods or fine-tuning the existing and routine therapies to fight COVID-19 and other infections. | 1018-2438,1423-0097 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__drug therapy;Female;Humans;Male;Melatonin__therapeutic use;Mitochondria__physiology;Pandemics;Pneumonia, Viral__drug therapy;Sex Characteristics;Sex Chromosomes__physiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Archives of Allergy and Immunology | Malgorzata Kloc;Rafik Mark Ghobrial;Jacek Z Kubiak | COVID-19;Immunity;Macrophages;Melatonin;SARS-CoV-2;X chromosome;Y chromosome | 2020-06-19 02:00:00+02:00 | 32564017 | FR;PL;US | The Houston Methodist Research Institute, Houston, Texas, USA, mkloc@houstonmethodist.org.;Department of Surgery, The Houston Methodist Hospital, Houston, Texas, USA, mkloc@houstonmethodist.org.;Department of Genetics, M.D. Anderson Cancer Center, The University of Texas, Houston, Texas, USA, mkloc@houstonmethodist.org.;The Houston Methodist Research Institute, Houston, Texas, USA.;Department of Surgery, The Houston Methodist Hospital, Houston, Texas, USA.;Laboratory of Regenerative Medicine and Cell Biology, Military Institute of Hygiene and Epidemiology (WIHE), Warsaw, Poland.;UnivRennes, UMR 6290, CNRS, Institute of Genetics and Development of Rennes, Cell Cycle Group, Faculty of Medicine, Rennes, France. | 1310 | ||
| Clinical Trial Protocol;Letter;Multicenter Study | en | Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial. | https://www.ncbi.nlm.nih.gov/pubmed/32560746 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for the treatment of cystic fibrosis, which cleaves extracellular DNA and may break up cell-free DNA, loosening sticky mucus in the distal airways and reducing NETs-induced toxicity on alveolar pneumocytes. The COVIDornase trial intends to define the impact of aerosolized intra-tracheal dornase alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs. | 2020-06-21 02:00:00+02:00 | pubmed | Adult;Aerosols;Betacoronavirus;Coronavirus Infections__complications;Deoxyribonuclease I__administration & dosage;Humans;Pandemics;Pneumonia, Viral__complications;Prospective Studies;Randomized Controlled Trials as Topic;Recombinant Proteins__administration & dosage;Respiratory Distress Syndrome, Adult__drug therapy;Trachea;COVID-19;severe acute respiratory syndrome coronavirus 2 | J P Desilles;C Gregoire;C Le Cossec;J Lambert;O Mophawe;M R Losser;F Lambiotte;S Le Tacon;M Cantier;N Engrand;P Trouiller;J Pottecher | ARDS;COVID-19;Dornase alfa;Lung damage;Neutrophil extracellular traps;Randomised controlled trial | 2020-06-19 02:00:00+02:00 | 32560746 | FR;US | Biological Resource Center, Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. jpdesilles@for.paris.;Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, Paris, France. jpdesilles@for.paris.;Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. jpdesilles@for.paris.;Intensive Care Department, Rothschild Foundation Hospital, Paris, France.;Clinical Research Unit, Rothschild Foundation Hospital, Paris, France.;CHRU Nancy, Pôle d'Anesthésie-Réanimation, 29 Avenue de Lattre de Tassigny, 54000, Nancy, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Valenciennes, Avenue Désandrouin, 59322, Valenciennes, France.;CHR Metz-Thionville-Site de Mercy, Service de Réanimation Polyvalente, 1 Allée du Château, 57350, Ars-Laquenexy, France.;Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Service d'Anesthésie-Réanimation Chirurgicale, 1 Avenue Molière, 67098, Strasbourg, France.;Université de Strasbourg, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), EA3072, Strasbourg, France. | 1311 | |||||
| 10.1007/s41885-020-00066-z | Journal Article | en | The Economic Cost of COVID Lockdowns: An Out-of-Equilibrium Analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32838118 | This paper estimates the cost of the lockdown of some sectors of the world economy in the wake of COVID-19. We develop a multi sector disequilibrium model with buyer-seller relations between agents located in different countries. The production network model allows us to study not only the direct cost of the lockdown but also indirect costs which emerge from the reductions in the availability of intermediate inputs. Agents determine the quantity of output and the proportions in which to combine inputs using prices that emerge from local interactions. The model is calibrated to the world economy using input-output data on 56 industries in 44 countries including all major economies. Within our model, the lockdowns are implemented as partial reductions in the output of some sectors using data on sectoral decomposition of capacity reductions. We use computational experiments to replicate the temporal sequence of the lockdowns implemented in different countries. World output falls by 7% at the early stage of the crisis when only China is under lockdown and by 23% at the peak of the crisis when many countries are under a lockdown. These direct impacts are amplified as the shock propagates through the world economy because of the buyer-seller relations. Supply-chain spillovers are capable of amplifying the direct impact by more than two folds. Naturally, the substitutability between intermediate inputs is a major determinant of the amplification. We also study the process of economic recovery following the end of the lockdowns. Price flexibility and minor technological adaptations help in reducing the time it takes for the economy to recover. The world economy takes about one quarter to move towards the new equilibrium in the optimistic and unlikely scenario of the end of all lockdowns. Recovery time is likely to be significantly greater if partial lockdowns persist. | 2511-1280,2511-1299 | 2020-06-21 02:00:00+02:00 | pubmed | Economics of Disasters and Climate Change | Antoine Mandel;Vipin Veetil | COVID-19;Disequilibrium dynamics;Lockdown;Multi market model;Production network | 2020-06-19 02:00:00+02:00 | 32838118 | FR;IN | Paris School of Economics, Université Panthéon-Sorbonne, Paris, France and Climate Finance Alpha, Paris, France.;Indian Instiute of Technology Madras, Chennai, India. | 1313 | |||
| 10.1016/j.cjco.2020.06.008 | Case Reports | en | Acute Myopericarditis in a Patient With Mild SARS-CoV-2 Respiratory Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32838254 | Herein is presented a case of a 71-year-old woman with mild SARS-CoV-2 respiratory infection who experienced acute myopericarditis diagnosed using clinical, biological, and electrocardiogram data and cardiac magnetic resonance imaging. The presented case highlights the risk of cardiac involvement, even in the absence of severe respiratory COVID-19 infection. The mechanisms involved in acute myocardial injury in SARS-CoV-2 infection are not well known and requires further studies to determine whether it is related to direct myocardial damage by the virus or to a systemic condition. | 2589-790X | 2020-06-21 02:00:00+02:00 | pubmed | CJC Open | Aissam Labani;Philippe Germain;Marie-Pierre Douchet;Mustapha Beghi;Jean Jacques Von Hunolstein;Floriane Zeyons;Catherine Roy;Soraya El Ghannudi | 2020-06-20 02:00:00+02:00 | 32838254 | FR | Radiology Cardiovascular Imaging, University Hospitals of Strasbourg, Strasbourg, France.;Cardiology, University Hospitals of Strasbourg, Strasbourg, France.;Biophysics and Nuclear Medicine, University Hospitals of Strasbourg, Strasbourg, France.;ICube, UMR 7357, University of Strasbourg/CNRS and FMTS, Faculty of Medicine, Strasbourg, France. | 1319 | ||||
| 10.1016/j.retram.2020.06.001 | Journal Article;Review | en | COVID-19 paraclinical diagnostic tools: Updates and future trends. | https://www.ncbi.nlm.nih.gov/pubmed/32576508 | COVID-19 is one of the most widely affecting pandemics. As for many respiratory viruses-caused diseases, diagnosis of COVID-19 relies on two main compartments: clinical and paraclinical diagnostic criteria. Rapid and accurate diagnosis is vital in such a pandemic. On one side, rapidity may enhance management effectiveness, while on the other, coupling efficiency and less costly procedures may permit more effective community-scale management. | 2452-3186 | 2020-06-21 02:00:00+02:00 | pubmed | Current Research in Translational Medicine | Tamim Alsuliman;Rand Sulaiman;Sawsan Ismail;Micha Srour;Ali Alrstom | COVID-19;CT;Diagnosis;Paraclinical;rRT-PCR | 2020-06-20 02:00:00+02:00 | 32576508 | FR;RU;SY | Service d'hématologie, hôpital Saint-Antoine, AP-HP Sorbonne Université, 75012, Paris, France. Electronic address: Dr.tameemsoliman@gmail.com.;Department of Genetics, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russian Federation.;Department of Pathology, Faculty of Medicine, Tishreen University, Lattakia, Syria.;Service maladie du sang, centre hospitalier universitaire de Lille, 59000, Lille, France.;Department of Infectious Diseases, Faculty of Medicine, Damascus University, Damascus, Syria. | 1320 | |||
| 10.1016/j.pharma.2020.05.004 | Journal Article | fr | [Ethics and biomedical research during the COVID-19 epidemic: Let's not confuse speed and precipitation!] | https://www.ncbi.nlm.nih.gov/pubmed/32569622 | 0003-4509 | 2020-06-21 02:00:00+02:00 | pubmed | Annales Pharmaceutiques Françaises | B Bertrand;B Bertrand;B Bertrand;P-M Bertrand | 2020-06-20 02:00:00+02:00 | 32569622 | FR | Service pharmacie, centre hospitalier de Grasse, chemin de Clavary, 06135 Grasse cedex, France, Comité de Protection des Personnes Sud Méditerranée V, Nice, France. Electronic address: ben.bertrand@ch-grasse.fr.;Pôle d'anesthésie réanimation, CHU Grenoble Alpes, Grenoble, France.;Service de chirurgie plastique et reconstructrice, hôpital de la Conception, Assistance publique-Hôpitaux de Marseille, Marseille, France, UMR1263, Inserm, Inra, AMU, laboratoire C2VN, France.;Service de médecine intensive et réanimation, centre hospitalier de Cannes, Cannes, France, Comité d'éthique du centre hospitalier de Cannes, Cannes, France. | 1321 | |||||
| Letter | en | COVID-19 transmission among gastrointestinal endoscopists. | https://www.ncbi.nlm.nih.gov/pubmed/32565017 | 2020-06-21 02:00:00+02:00 | pubmed | Maximilien Barret;Olivier Gronier;Stanislas Chaussade | 2020-06-18 02:00:00+02:00 | 32565017 | FR | Gastroenterology and Digestive Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, France.;Gastroenterology and Digestive Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris.;Gastroenterology and Digestive Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, France. Electronic address: stanislas.chaussade@aphp.fr. | 1324 | ||||||||
| 10.1093/cid/ciaa790 | Journal Article | en | Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32556265 | Knowledge on the epidemiological features and transmission patterns of COVID-19 is accumulating. Detailed line-list data with household settings can advance the understanding of COVID-19 transmission dynamics. | 1058-4838,1537-6591 | 2020-06-21 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Xiao-Ke Xu;Xiao-Fan Liu;Ye Wu;Sheikh Taslim Ali;Zhanwei Du;Paolo Bosetti;Eric H Y Lau;Benjamin J Cowling;Lin Wang | COVID-19;hazard of infection;serial interval;super-spreading event;transmission | 2020-06-18 02:00:00+02:00 | 32556265 | FR;CN;GB;US;HK | College of Information and Communication Engineering, Dalian Minzu University, Dalian, China.;Web Mining Lab, Department of Media and Communication, City University of Hong Kong, Hong Kong Special Administrative Region, China.;Computational Communication Research Center, Beijing Normal University, Zhuhai, China.;School of Journalism and Communication, Beijing Normal University, Beijing, China.;WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.;Department of Integrative Biology, University of Texas at Austin, Austin, Texas, USA.;Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, CNRS, Paris, France.;Department of Genetics, University of Cambridge, Cambridge, UK. | 1325 | |||
| 10.1016/j.jaci.2020.06.009 | Journal Article | en | Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. | https://www.ncbi.nlm.nih.gov/pubmed/32561389 | The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider. | 0091-6749 | 2020-06-21 02:00:00+02:00 | pubmed | Journal of Allergy and Clinical Immunology | Peter Valent;Cem Akin;Patrizia Bonadonna;Knut Brockow;Marek Niedoszytko;Boguslaw Nedoszytko;Joseph H Butterfield;Ivan Alvarez-Twose;Karl Sotlar;Juliana Schwaab;Mohamad Jawhar;Andreas Reiter;Mariana Castells;Wolfgang R Sperr;Hanneke C Kluin-Nelemans;Olivier Hermine;Jason Gotlib;Roberta Zanotti;Sigurd Broesby-Olsen;Hans-Peter Horny;Massimo Triggiani;Frank Siebenhaar;Alberto Orfao;Dean D Metcalfe;Michel Arock;Karin Hartmann | COVID-19;KIT D816V;Mast cells;SARS-CoV-2;coronavirus;mast cell activation syndrome;mastocytosis;tryptase | 2020-06-17 02:00:00+02:00 | 32561389 | FR;CH;US;AT;IT;PL;NL;ES;DK;DE | Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at.;Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich.;Allergy Unit, Verona University Hospital, Verona, Italy.;Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.;Department of Allergology, Medical University of Gdansk, Gdansk, Poland.;Department of Dermatology, Medical University of Gdansk, Gdansk, Poland.;Mayo Clinic, Division of Allergic Diseases, Rochester, Minn.;Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo, Spain.;Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria.;Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.;Brigham and Women's Hospital, Mastocytosis Center, Harvard Medical School, Boston, Mass.;Department of Internal Medicine I, Division of Haematology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.;Department of Haematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.;Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris, France.;Stanford Cancer Institute/Stanford University School of Medicine, Stanford, Calif.;Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.;Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.;Institute of Pathology, Ludwig-Maximilian-University, Munich, Germany.;Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.;Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.;Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC, CSIC/USAL), IBSAL, CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain.;Department of Dermatology & Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.;Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris, France.;Division of Allergy, Department of Dermatology, and Department of Biomedicine, University of Basel, Basel, Switzerland. | 1328 | |||
| Letter | en | Minimising COVID-19 exposure during tracheal intubation by using a transparent plastic box: A randomised prospective simulation study. | https://www.ncbi.nlm.nih.gov/pubmed/32562807 | 2020-06-21 02:00:00+02:00 | pubmed | Simon Clariot;Guillaume Dumain;Elisabeth Gauci;Olivier Langeron;Éric Levesque | Aerosol generating procedure;Airway management;Coronavirus;SARS-CoV-2;Simulation;Tracheal intubation | 2020-06-17 02:00:00+02:00 | 32562807 | FR | Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France, Université Paris Est Créteil, Faculté de Santé, 94010 Créteil, France. Electronic address: simon.clariot@aphp.fr.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France, Université Paris Est Créteil, Faculté de Santé, 94010 Créteil, France.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France, Université Paris Est Créteil, Faculté de Santé, 94010 Créteil, France, Experimental Neuropathology Unit, Institut Pasteur, 75015 Paris, France.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France, Université Paris Est Créteil, Faculté de Santé, 94010 Créteil, France, EA DYNAMYC Université Paris-Est Créteil (UPEC), École Nationale Vétérinaire d'Alfort (ENVA), Faculté de Santé de Créteil, 8, rue du Général Sarrail, 94010 Créteil, France. | 1333 | |||||||
| 10.1016/j.jbior.2020.100735 | Journal Article;Research Support, Non-U.S. Gov't | en | Thromboembolic events and Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32773098 | The novel Corona virus infection (Covid-19) first identified in China in December 2019 has rapidly progressed in pandemic leading to significant mortality and unprecedented challenge for healthcare systems. Although the clinical spectrum of Covid-19 is variable, acute respiratory failure and systemic coagulopathy are common in severe Covid-19 patients. Lung is an important target of the SARS-CoV-2 virus causing eventually acute respiratory distress syndrome associated to a thromboinflammatory state. The cytokinic storm, thromboinflammation and pulmonary tropism are the bedrock of tissue lesions responsible for acute respiratory failure and for prolonged infection that may lead to multiple organ failure and death. The thrombogenicity of this infectious disease is illustrated by the high frequency of thromboembolic events observed even in Covid-19 patients treated with anticoagulation. Increased D-Dimers, a biomarker reflecting activation of hemostasis and fibrinolysis, and low platelet count (thrombocytopenia) are associated with higher mortality in Covid-19 patients. In this review, we will summarize our current knowledge on the thromboembolic manifestations, the disturbed hemostatic parameters, and the thromboinflammatory conditions associated to Covid-19 and we will discuss the modalities of anticoagulant treatment or other potential antithrombotic options. | 2212-4926 | 2020-06-21 02:00:00+02:00 | pubmed | Advances in Biological Regulation | Agnès Ribes;Fanny Vardon-Bounes;Vincent Mémier;Michael Poette;Jonathan Au-Duong;Cédric Garcia;Vincent Minville;Pierre Sié;Alessandra Bura-Rivière;Sophie Voisin;Bernard Payrastre | Acute respiratory distress syndrome;Anticoagulants;Covid-19;Platelets;Thromboembolic events;Thromboinflammation | 2020-06-17 02:00:00+02:00 | 32773098 | FR | Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France, Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France.;Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France, Pôle Anesthésie-Réanimation, CHU de Toulouse, 31059, Toulouse, France.;Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France.;Pôle Anesthésie-Réanimation, CHU de Toulouse, 31059, Toulouse, France.;Service de Médecine Vasculaire, CHU de Toulouse, 31059, Toulouse, France.;Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France, Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France. Electronic address: bernard.payrastre@inserm.fr. | 1334 | |||
| 10.1016/j.etiqe.2020.06.001 | English Abstract;Journal Article | fr | [COVID-19: On the verge of madness]. | https://www.ncbi.nlm.nih.gov/pubmed/32837543 | Disorganizations due to the current coronavirus SARS-CoV-2 pandemic that have required a national quarantine from the 17th of march to the 11 of May 2020, mangle and question. In view of the situation's extreme traumatic character and of the pathological consequences observed, we are going to try to give meaning to an almost chaotic situation. Our shared production, coming out of two psychologists - one being in quarantine and the other one not - crossed diary trying to put the theory in favor of the clinic, has for aim to build a support structuring thought. In fact, the breaking of COVID-19's death anxiety creates hysterical looking defense mechanisms within the entire society. When the extreme and sudden situation that we are describing can be understood as a paradoxical injunction as much as a denial of the split, we will focus our analyzes on both societal and hospital realities, that seems to jeopardize humanity, dignity, solidarity, equity, justice and autonomy principles. Describing, trying to put into words and analyzing all movements concerning the current situation, could lead to giving meaning to a situation which seems already deprived. | 1765-4629 | 2020-06-21 02:00:00+02:00 | pubmed | Éthique & Santé | D Peyrat-Apicella;S Gautier | COVID-19;Cleavage;Extreme situation;Psychosis;Trauma | 2020-06-20 02:00:00+02:00 | 32837543 | FR | ATER, université Rouen-Normandie, 1, rue Thomas-Becket, 76130 Mont-Saint-Aignan, France.;Unité de soins palliatifs, centre des Massues, Croix-Rouge française, 92, rue Dr-Edmond-Locard, Lyon, France. | 1340 | |||
| 10.3390/biology9060132 | Journal Article | en | Unreported Cases for Age Dependent COVID-19 Outbreak in Japan. | https://www.ncbi.nlm.nih.gov/pubmed/32560572 | We investigate the age structured data for the COVID-19 outbreak in Japan. We consider a mathematical model for the epidemic with unreported infectious patient with and without age structure. In particular, we build a new mathematical model and a new computational method to fit the data by using age classes dependent exponential growth at the early stage of the epidemic. This allows to take into account differences in the response of patients to the disease according to their age. This model also allows for a heterogeneous response of the population to the social distancing measures taken by the local government. We fit this model to the observed data and obtain a snapshot of the effective transmissions occurring inside the population at different times, which indicates where and among whom the disease propagates after the start of public mitigation measures. | 2079-7737 | 2020-06-21 02:00:00+02:00 | pubmed | Biology | Quentin Griette;Pierre Magal;Ousmane Seydi | age-structured data;coronavirus;epidemic mathematical model;isolation;public closings;quarantine;reported and unreported cases | 2020-06-17 02:00:00+02:00 | 32560572 | FR;SN | Institute of Mathematics of Bordeaux (UMR 5251), University of Bordeaux, F-33400 Talence, France.;Département Tronc Commun, École Polytechnique de Thiès, Thiès BP A10, Senegal. | 1341 | |||
| 10.1111/bju.15149 | Journal Article | en | The dramatic COVID-19 outbreak in italy is responsible of a huge drop in urological surgical activity: A multicenter observational study. | https://www.ncbi.nlm.nih.gov/pubmed/32558053 | Italy is facing the COVID-19 outbreak with an abrupt reorganization of its national health-system, in order to augment care provision to symptomatic patients. The sudden shift of personnel and resources towards COVID-19 care has led to the reduction of surgery, with possible severe drawbacks. The aim of the study is to describe the trend in surgical volume in urology, in Italy. | 1464-4096 | 2020-06-21 02:00:00+02:00 | pubmed | BJU International | B Rocco;M C Sighinolfi;M Sandri;V Altieri;M Amenta;F Annino;A Antonelli;R Baio;R Bertolo;A Bocciardi;M Borghesi;P Bove;G Bozzini;G Cacciamani;A Calori;A Caffarelli;A Celia;A Cocci;A Corsaro;G Costa;C Ceruti;L Cindolo;S Crivellaro;O Dalpiaz;D D'Agostino;B Dall'Oglio;R Falabella;M Falsaperla;M Finocchiaro;F Gaboardi;A Galfano;F Gallo;F Greco;C Leonardo;R Nucciotti;M Oderda;V Pagliarulo;P Parma;L Pastore;G Pini;A Porreca;L Pucci;M Schenone;R Schiavina;C Sciorio;L Spirito;A Tafuri;C Terrone;P Umari;V Varca;D Veneziano;P Verze;A Volpe;S Micali;L Berti;S Zaramella;A Minervini | COVID-19 outbreak;trend of variation;urologic surgery | 2020-06-18 02:00:00+02:00 | 32558053 | FR;IT;US;AT | University of Modena and Reggio Emilia, Modena, Italy.;Data Methods and Systems Statistical Laboratory, University of Brescia, Brescia, Italy.;Urology Unito, Humanitas Gavazzeni, Bergamo, Italy.;Chief of the Urology Unit, Azienda ULSS n.4 Veneto Orientale, Portogruaro, VE), Italy.;Urology Unit, Ospedale San Donato, Arezzo, Italy.;Chief of the Urology Unit, Ospedale Maggiore Borgo Trento, Verona, Italy.;AOU San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy.;Urology Unit, Ospedale San Carlo di Nancy, Roma, Italy.;ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.;Urology Unit, Ospedale San Martino, Genova, Italy.;Urology Unit, ASST Valle Olona, Busto Arsizio, Italy.;USC, Institute of Urology and Catherine and Joseph Aresty Department of Urology, Los Angeles, US.;Urology Unit, Villa Igea, Ancona, Italy.;Urology Unit, Ospedale San Bassiano, Bassano del Grappa, Italy.;Urology Unit, Azienda Ospedaliero Universitaria Careggi Firenze, Italy.;Urology Unit, AULSS 4, Portogruaro, Italy.;Urology Unit, AOU Citta della Salute e della Scienza, Torino, Italy.;Urology Unit, Villa Stuart, Roma, Italy.;Urology Unit, Azienda Ospedaliero-Universitaria di Udine, Italy.;Medical University of Graz, Graz, Steiermark, AT, Austria.;Urology Unit, Policlinico Abano Terme, Abano Terme, Italy.;Urology Unit, ASST Mantova, Italy.;Urology Unit, San Carlo di Potenza, Potenza, Italy.;ARNAS Garibaldi Hospital, Catania, Italy.;Urology Unit, ARNAS Garibaldi Hospital, Catania, Italy.;Chief of the Urology Unit, San Raffaele Turro, Milan, Italy.;Chief of Endourology Sub-Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.;Urology Unit, Ospedale San Paolo di Savona, Italy.;Urology Unit, Humanitas Gavazzeni, Bergamo, Italy.;Urology Unit, Policlinico Umberto I, Rome, Italy.;Urology Unit, Azienda USL Toscana, Grosseto, Italy.;Urology Unit, Città della Salute e della Scienza Hospital, Torino, Italy.;Chief of the Urology Unit, Ospedale Vito Fazzi, Lecce, Italy.;Urology Unit, Ospedale San Carlo Poma, Mantova, Italy.;Urology Unit, Sapienza University, Rome, Italy.;Urology Unit, San Raffaele Turro, Milan, Italy.;Chief of the Urology Unit, Policlinico Abano Terme, Abano, Padova, Italy.;Urology Unit, Azienda Ospedaliera A. Cardarelli, Naples, Italy.;Urology Unit, Ospedale San Paolo, Savona, Italy.;Urology Unit, AOU Policlinico Sant'Orsola Malpighi, Bologna, Italy.;Urology Unit, ASST Ospedale Manzoni, Lecco, Italy.;Urology Unit, ASST Manzoni, Lecco, Italy.;Urology Unit, Azienda Ospedaliera Universitaria Integrata di Verona - Ospedale Maggiore Borgo Trento, Verona, Italy.;Ospedale IRRCS Policlinico San Martino Genova, Italy.;Urology Unit, Maggiore della Carità Hospital, Novara, Italy.;ASAT Rhodense Ospedale Guido Salvini di Garbagnate, Garbagnate, Italy.;Urology Unit, AO Bianchi Melacrino Morelli, Calabria, Italy.;Urology Unit, AOU San Giovanni di Rio e Ruggi d'Aragona, Salerno, Italy.;Urology Unit, Ospedale Maggiore della Carita, Novara, Italy.;Urology Unit, Ospedale degli Infermi, Biella, Italy.;Azienda Ospedaliero Universitaria Careggi, Firenze, Italy. | 1353 | |||
| 10.1093/chemse/bjaa041 | Journal Article | en | More than smell - COVID-19 is associated with severe impairment of smell, taste, and chemesthesis. | https://www.ncbi.nlm.nih.gov/pubmed/32564071 | Recent anecdotal and scientific reports have provided evidence of a link between COVID-19 and chemosensory impairments such as anosmia. However, these reports have downplayed or failed to distinguish potential effects on taste, ignored chemesthesis, and generally lacked quantitative measurements. Here, we report the development, implementation and initial results of a multi-lingual, international questionnaire to assess self-reported quantity and quality of perception in three distinct chemosensory modalities (smell, taste, and chemesthesis) before and during COVID-19. In the first 11 days after questionnaire launch, 4039 participants (2913 women, 1118 men, 8 other, ages 19-79) reported a COVID-19 diagnosis either via laboratory tests or clinical assessment. Importantly, smell, taste and chemesthetic function were each significantly reduced compared to their status before the disease. Difference scores (maximum possible change ±100) revealed a mean reduction of smell (-79.7 ± 28.7, mean ± SD), taste (-69.0 ± 32.6), and chemesthetic (-37.3 ± 36.2) function during COVID-19. Qualitative changes in olfactory ability (parosmia and phantosmia) were relatively rare and correlated with smell loss. Importantly, perceived nasal obstruction did not account for smell loss. Furthermore, chemosensory impairments were similar between participants in the laboratory test and clinical assessment groups. These results show that COVID-19-associated chemosensory impairment is not limited to smell, but also affects taste and chemesthesis. The multimodal impact of COVID-19 and lack of perceived nasal obstruction suggest that SARS-CoV-2 infection may disrupt sensory-neural mechanisms. | 0379-864X,1464-3553 | 2020-06-21 02:00:00+02:00 | pubmed | Chemical Senses | Valentina Parma;Kathrin Ohla;Maria G Veldhuizen;Masha Y Niv;Christine E Kelly;Alyssa J Bakke;Keiland W Cooper;Cédric Bouysset;Nicola Pirastu;Michele Dibattista;Rishemjit Kaur;Marco Tullio Liuzza;Marta Y Pepino;Veronika Schöpf;Veronica Pereda-Loth;Shannon B Olsson;Richard C Gerkin;Paloma Rohlfs Domínguez;Javier Albayay;Michael C Farruggia;Surabhi Bhutani;Alexander W Fjaeldstad;Ritesh Kumar;Anna Menini;Moustafa Bensafi;Mari Sandell;Iordanis Konstantinidis;Antonella Di Pizio;Federica Genovese;Lina Öztürk;Thierry Thomas-Danguin;Johannes Frasnelli;Sanne Boesveldt;Özlem Saatci;Luis R Saraiva;Cailu Lin;Jérôme Golebiowski;Liang- Dar Hwang;Mehmet Hakan Ozdener;Maria Dolors Guàrdia;Christophe Laudamiel;Marina Ritchie;Jan Havlícek;Denis Pierron;Eugeni Roura;Marta Navarro;Alissa A Nolden;Juyun Lim;K L Whitcroft;Lauren R Colquitt;Camille Ferdenzi;Evelyn V Brindha;Aytug Altundag;Alberto Macchi;Alexia Nunez-Parra;Zara M Patel;Sébastien Fiorucci;Carl M Philpott;Barry C Smith;Johan N Lundström;Carla Mucignat;Jane K Parker;Mirjam van den Brink;Michael Schmuker;Florian Ph S Fischmeister;Thomas Heinbockel;Vonnie D C Shields;Farhoud Faraji;Enrique Santamaría;William E A Fredborg;Gabriella Morini;Jonas K Olofsson;Maryam Jalessi;Noam Karni;Anna D'Errico;Rafieh Alizadeh;Robert Pellegrino;Pablo Meyer;Caroline Huart;Ben Chen;Graciela M Soler;Mohammed K Alwashahi;Antje Welge-Lüssen;Jessica Freiherr;Jasper H B de Groot;Hadar Klein;Masako Okamoto;Preet Bano Singh;Julien W Hsieh;Danielle R Reed;Thomas Hummel;Steven D Munger;John E Hayes | 2020-06-20 02:00:00+02:00 | 32564071 | IL;CA;UNK;JP;AR;CL;NL;BE;DK;FR;CN;GB;US;CH;IT;IR;DE;AT;SE;NO;FI;AU | Department of Psychology, Temple University.;Institute of Neuroscience and Medicine (INM-3), Research Center Jülich.;Department of Anatomy, School of Medicine, Mersin University.;Institute of Biochemistry, Food Science and Nutrition, The Hebrew University of Jerusalem.;AbScent.;Department of Food Science, The Pennsylvania State University.;Interdepartmental Neuroscience Program, University of California Irvine.;Institut de Chimie de Nice, Université Côte d'Azur.;Centre for Global Health Research, Usher Institute, The University of Edinburgh.;Department of Basic Medical Sciences, Neuroscience and Sensory Organs, Università degli Studi di Bari A. Moro.;V1-B, CSIR-Central Scientific Instruments Organisation.;Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro.;Food Science and Human Nutrition, University of Illinois at Urbana Champaign.;Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna.;GSBMS - Medecine Evolutive UMR5288, Université de Toulouse.;National Centre for Biological Sciences, National Centre for Biological Sciences, Tata Institute of Fundamental Research.;School of Life Sciences, Arizona State University.;Department of Psychology and Anthropology, University of Extremadura.;Department of General Psychology, University of Padova.;Psychiatry, Yale University School of Medicine.;Exercise and Nutritional Sciences, San Diego State University.;Department of Otolaryngology, Hospital Unit West, Aarhus University.;Biocomputation Group, University of Hertfordshire.;Neuroscience Area, SISSA, International School for Advanced Studies.;Neuropop Team, Lyon Neuroscience Research Center, CNRS UMR5292 - INSERM U1028 - University Lyon 1.;Department of Food and Nutrition, Functional Foods Forum, University of Helsinki, University of Turku.;Academic ORL Department, Aristotle University.;Section In-silico Biology and Machine Learning, Leibniz-Institute for Food Systems Biology at the Technical University of Munich.;Monell Chemical Senses Center.;Mersin University.;CSGA-Centre for Taste and Feeding Behavior, INRAE.;Anatomy, Université du Québec à Trois-Rivières.;Division of Human Nutrition and Health, Wageningen University.;Otorhinolaryngology, Medical Science University.;Translational Medicine Division, Sidra Medicine.;The University of Queensland Diamantina Institute, The University of Queensland.;Food Technology, IRTA.;DreamAir Llc.;Neurobiology and Behavior, University of California, Irvine.;Department of Zoology, Charles University.;Médecine Evolutive UMR5288, Université de Toulouse-CNRS.;Centre for Nutrition and Food Sciences, The University of Queensland.;Department of Food Science, University of Massachusetts.;Food Science and Technology, Oregon State University.;Ear Institute, UCL.;Lyon Neuroscience Research Center, Lyon Neuroscience Research Center, CNRS UMR5292 - INSERM U1028 - University Lyon 1.;EEE, Karunya University.;Otorhinolaryngology Department, Biruni University.;ENT Department, Italian Academy Of Rhinology - Assi Sette Llaghi Varese.;Department of Biology, Universidad de Chile.;Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine.;Institut de Chimie de Nice, UMR CNRS 7272, Université Côte d'Azur.;The Norfolk Smell & Taste Clinic, University of East Anglia.;Institute of Philosophy, University of London.;Department of Clinical Neuroscience, Karolinska Institutet.;Department of Molecular Medicine, University of Padova.;Department of Food and Nutritional Sciences, University of Reading.;Laboratory of Behavioural Gastronomy, Maastricht University.;Department of Computer Science, University of Hertfordshire.;Institute of Psychology, University of Graz.;Department of Anatomy, Howard University College of Medicine.;Biological Sciences Department, Fisher College of Science and Mathematics, Towson University.;Otolaryngology-Head and Neck Surgery, University of California San Diego Health.;Clinical Neuroproteomics Unit, Navarrabiomed-IDISNA.;Department of Psychology, Stockholm University.;University of Gastronomic Sciences.;Skull Base Research Center, The Five Senses Institute, Iran University of Medical Sciences.;Internal Medicine Department, Hadassah Medical Center.;Neurobiology, Goethe Universität Frankfurt.;ENT and Head and Neck Research Center and Department, Hazrat Rasoul Hospital, the Five Senses Institute, Iran University of Medical Sciences.;Food Science Department, University of Tennessee.;Health Care and Life Sciences, IBM T.J. Watson Research Center.;Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels University.;Psychiatry, Guangzhou Medical University.;Otorhinolaringology, Buenos Aires University and GEOG (Grupo de Estudio de Olfato y Gusto).;Surgery Department, ENT Division, Sultan Qaboos University.;Department of Otorhinolaryngology, University Hospital Basel, Basel.;Department of Psychiatry and Psychotherapy, FAU Erlangen.;Psychology, Utrecht University.;Department of Applied Biological Chemistry, The University of Tokyo.;Department of Oral Surgery and Oral Medicine, Faculty of Dentistry, University of Oslo.;Rhinology- Olfactology Unit, ENT Department, Geneva University Hospitals.;Department of Otorhinolaryngology, TU Dresden.;Center for Smell and Taste, University of Florida.;Department of Pharmacology and Therapeutics, University of Florida. | 1356 | ||||
| 10.1016/j.micinf.2020.06.005 | Journal Article | en | Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). | https://www.ncbi.nlm.nih.gov/pubmed/32574789 | COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: "Death" and "Recovery". Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O2) requirements 10.4 l/min. At baseline, all patients had multiple biological abnormalities (lymphopenia, increased CRP, ferritin, fibrinogen, D-dimer and liver enzymes). 24 patients (70.5%) recovered after TCZ therapy and 10 died (29.5%). Deceased subjects differed from patients in whom treatment was effective with regard to more pronounced lymphopenia (0.6 vs 1.0 G/l; p = 0.037), lower platelet number (156 vs 314 G/l; p = 0.0001), lower fibrinogen serum level (0.6 vs 1.0 G/l; p = 0.03), higher aspartate-amino-transferase (108 vs 57 UI/l; p = 0.05) and greater O2 requirements (11 vs 8 l/min; p = 0.003). | 1286-4579 | 2020-06-21 02:00:00+02:00 | pubmed | Microbes and Infection | Anne Lohse;Timothée Klopfenstein;Jean-Charles Balblanc;Pierre-Yves Royer;Marie Bossert;Vincent Gendrin;Aline Charpentier;Ana-Maria Bozgan;Julio Badie;Charlotte Bourgoin;Remy Contreras;Isabelle Mazurier;Thierry Conrozier;Souheil Zayet | Acute respiratory distress syndrome;Biomarkers;COVID-19;Predictive factors;SARS-CoV-2;Tocilizumab | 2020-06-20 02:00:00+02:00 | 32574789 | FR | Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France.;Department of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France.;Intensive Care Unit, Nord Franche-Comté Hospital, Belfort, France, Clinical Research Unit, Nord Franche-Comté Hospital, Belfort, France.;Clinical Research Unit, Nord Franche-Comté Hospital, Belfort, France.;Department of Pharmacology, Nord Franche-Comté Hospital, Belfort, France.;Department of Biology, Nord Franche-Comté Hospital, Belfort, France.;Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France, Clinical Research Unit, Nord Franche-Comté Hospital, Belfort, France.;Department of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France. Electronic address: souhail.zayet@gmail.com. | 1357 | |||
| Letter | en | COVID-19 heath crisis: less colorectal resections and yet no more peritonitis or bowel obstruction as a collateral effect? | https://www.ncbi.nlm.nih.gov/pubmed/32542838 | 2020-06-21 02:00:00+02:00 | pubmed | M K Collard;J H Lefèvre;F Batteux;Y Parc | 2020-06-16 02:00:00+02:00 | 32542838 | FR | Digestive Surgery Department, Saint-Antoine Hospital, APHP, Sorbonne University, Paris, France.;Department of Strategy and Transformation, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. | 1360 | ||||||||
| 10.1016/j.ygyno.2020.06.486 | Journal Article | en | Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations. | https://www.ncbi.nlm.nih.gov/pubmed/32563593 | To develop expert consensus recommendations regarding radiation therapy for gynecologic malignancies during the COVID-19 pandemic. | 0090-8258 | 2020-06-21 02:00:00+02:00 | pubmed | Gynecologic Oncology | Christen R Elledge;Sushil Beriwal;Cyrus Chargari;Supriya Chopra;Beth A Erickson;David K Gaffney;Anuja Jhingran;Ann H Klopp;William Small;Catheryn M Yashar;Akila N Viswanathan | 2020-06-15 02:00:00+02:00 | 32563593 | FR;IN;US | Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.;Department of Radiation Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA.;Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Department of Radiation Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Kharghar, Navi Mumbai, India.;Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.;Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.;Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Department of Radiation Oncology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.;Department of Radiation Oncology, University of California San Diego, San Diego, CA, USA.;Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: anv@jhu.edu. | 1365 | ||||
| 10.1016/j.ajog.2020.06.022 | Journal Article | en | Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. | https://www.ncbi.nlm.nih.gov/pubmed/32553908 | Despite the mainly reassuring outcomes for pregnant women with coronavirus disease 2019 reported by previous case series with small sample sizes, some recent reports of severe maternal morbidity requiring intubation and of maternal deaths show the need for additional data about the impact of coronavirus disease 2019 on pregnancy outcomes. | 0002-9378 | 2020-06-21 02:00:00+02:00 | pubmed | American Journal of Obstetrics and Gynecology | Loïc Sentilhes;Fanny De Marcillac;Charlotte Jouffrieau;Pierre Kuhn;Vincent Thuet;Yves Hansmann;Yvon Ruch;Samira Fafi-Kremer;Philippe Deruelle | COVID-19 pneumonia;extracorporeal membrane oxygenation;intubation;maternal and neonatal outcomes;maternal morbidity;pregnancy;preterm birth;respiratory failure | 2020-06-15 02:00:00+02:00 | 32553908 | FR | Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France. Electronic address: loicsentilhes@hotmail.com.;Department of Obstetrics and Gynecology, Strasbourg University Hospitals, Strasbourg, France.;Department of Neonatology, Strasbourg University Hospital, Strasbourg, France.;Department of Anesthesiology, Strasbourg University Hospitals, Strasbourg, France.;Department of Infectious and Tropical Diseases, Strasbourg University Hospitals, Strasbourg, France.;Virology Laboratory, Strasbourg University Hospitals, Strasbourg, France. | 1367 | |||
| 10.18176/jiaci.0625 | Journal Article;Review | en | Upper and Lower Airways Functional Examination in Asthma and Respiratory Allergic Deseases. Considerations in the SARS-CoV-2 Post-Pandemic Situation. | https://www.ncbi.nlm.nih.gov/pubmed/32540791 | Airway examination techniques are procedures that can potentially transmit infectious diseases to both patients and healthcare professionals who perform them, by various mechanisms. The pandemic situation due to the COVID-19 disease has practically halted most of the activity of the clinics and laboratories of pulmonary and nasal function, with clear recommendations in this regard. Being already in the early stages after the peak of the pandemic, we still do not know for sure what its consequences will be in the short or long term, since there are important gaps in the knowledge of aspects as fundamental as the transmission mechanisms of the virus, its pathophysiology and immune response or its diagnosis. In this review we will examine the different examination techniques available on the assessment of patients suffering from respiratory allergy, asthma and associated diseases, int the postpandemic momentum, highlighting their possible advantages and disadvantages. For this reason, we wanted to focus on exploring the entire upper and lower airways, from the perspective of the safety of both the healthcare professionals and patients and their specific characteristics. And at the same time we will approach the analysis of the intrinsic value that these interventions provide from the point of view of both diagnosis and management of these patients. The changing situation of this disease may cause some modifications of the assertions presented in this review in the future.While this guidance seeks to ensure a consistent wide approach, some differences in operational details may be applied due to local regulations. | 1018-9068 | 2020-06-21 02:00:00+02:00 | pubmed | Journal of Investigational Allergology and Clinical Immunology | J M Olaguibel;I Alobid;M Alvarez Puebla;A Crespo-Lessmann;J Domínguez Ortega;F García-Rio;A Izquierdo-Domínguez;J Mullol;V Plaza;S Quirce;M J Rojas-Lechuga;M Valvere-Monge;J Sastre | Allergic rhinitis;Asthma;Bronchaill challenge;Inflammatory biomarkers;Lung function tests;Upper airways examination | 2020-06-16 02:00:00+02:00 | 32540791 | FR;ES;BO | Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Spain.;CIBER de Enfermedades Respiratorias (CIBERES), Spain.;Unidad Alergo-Rino, Centro Médico Teknon, Barcelona, Catalonia, Spain.;Unitat de Rinologia & Clínica de l'Olfacte, Servei d'Oto-rino-laringologia, Hospital Clinic Barcelona, Immunoalèrgia Respiratòria Clínica i Experimental, IDIBAPS, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain.;Department of Allergy, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.;Department of Respiratry Medicine, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain. Departamento de Medicina, Facultad de Medicina, Universidad Autónoma de Madrid, Spain.;Department of Allergy, Consorci Sanitari de Terrassa, Clínica Diagonal, Barcelona, Catalonia, Spain.;Department of Allergy, Fundación Jiménez Díaz, Madrid, Spain. | 1368 | |||
| 10.1111/bjh.16943 | Journal Article | en | Rapid screening of COVID-19 patients using white blood cell scattergrams, a study on 381 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32542672 | Complementary tools are warranted to increase the sensitivity of the initial testing for COVID-19. We identified a specific 'sandglass' aspect on the white blood cell scattergram of COVID-19 patients reflecting the presence of circulating plasmacytoid lymphocytes. Patients were dichotomized as COVID-19-positive or -negative based on reverse transcriptase polymerase chain reaction (RT-PCR) and chest computed tomography (CT) scan results. Sensitivity and specificity of the 'sandglass' aspect were 85·9% and 83·5% respectively. The positive predictive value was 94·3%. Our findings provide a non-invasive and simple tool to quickly categorize symptomatic patients as either COVID-19-probable or -improbable especially when RT-PCR and/or chest CT are not rapidly available. | 0007-1048,1365-2141 | 2020-06-21 02:00:00+02:00 | pubmed | British Journal of Haematology | Jennifer Osman;Jérome Lambert;Marie Templé;Floriane Devaux;Rémy Favre;Claire Flaujac;Delphine Bridoux;Stéphanie Marque-Juillet;Fabrice Bruneel;François Mignon;Ernesto Diaz-Flores;Véronique Hentgen;Alix Greder-Belan;Reza Azarian;Mehrsa Koukabi;Philippe Rousselot;Victoria Raggueneau;Benjamin Manéglier | COVID-19;SARS-Cov-2;coronavirus;plasmacytoid lymphocytes;white blood cells scattergram | 2020-06-15 02:00:00+02:00 | 32542672 | FR;US;DE | Department of Hematobiology, CH Versailles, Le Chesnay, France.;Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.;INSERM UMR1153 ECSTRRA Team, Paris, France.;Department of Virology, CH de Versailles, Le Chesnay, France.;Department of Critical Care, CH de Versailles, Le Chesnay, France.;Department of Radiology, CH de Versailles, Le Chesnay, France.;Department of Pediatrics, Benioff Children's Hospital, Helen Diller Comprehensive cancer center, UCSF, San Francisco, CA, USA.;Department of Pediatrics, CH de Versailles, Le Chesnay, France.;Department of Internal Medecine and Infectious Diseases, CH de Versailles, Le Chesnay, France.;Department of Pneumology, CH de Versailles, Le Chesnay, France.;Emergency department, CH de Versailles, Le Chesnay, France.;Department of Hematology and Oncology, CH de Versailles, Le Chesnay, France.;UMR1184, University of Versailles Saint-Quentin-en-Yvelines and Paris Saclay, Versailles, France.;Department of Pharmacology, CH Versailles, Le Chesnay, France. | 1374 | |||
| 10.1099/jgv.0.001452 | Journal Article | en | Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection. | https://www.ncbi.nlm.nih.gov/pubmed/32538738 | We constructed complex models of SARS-CoV-2 spike protein binding to pangolin or human ACE2, the receptor for virus transmission, and estimated the binding free energy changes using molecular dynamics simulation. SARS-CoV-2 can bind to both pangolin and human ACE2, but has a significantly lower binding affinity for pangolin ACE2 due to the increased binding free energy (9.5 kcal mol-1). Human ACE2 is among the most polymorphous genes, for which we identified 317 missense single-nucleotide variations (SNVs) from the dbSNP database. Three SNVs, E329G (rs143936283), M82I (rs267606406) and K26R (rs4646116), had a significant reduction in binding free energy, which indicated higher binding affinity than wild-type ACE2 and greater susceptibility to SARS-CoV-2 infection for people with them. Three other SNVs, D355N (rs961360700), E37K (rs146676783) and I21T (rs1244687367), had a significant increase in binding free energy, which indicated lower binding affinity and reduced susceptibility to SARS-CoV-2 infection. | 0022-1317,1465-2099 | 2020-06-21 02:00:00+02:00 | pubmed | Journal of General Virology | Jingfang Wang;Xintian Xu;Xinbo Zhou;Ping Chen;Huiying Liang;Xuan Li;Wu Zhong;Pei Hao | ACE2 variants;SARS-CoV-2;coronavirus;molecular dynamic simulation;pangolin;susceptibility | 2020-06-15 02:00:00+02:00 | 32538738 | FR;CN | Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai 200031, PR China.;University of Chinese Academy of Sciences, Beijing 100039, PR China.;National Engineering Research Center For the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, PR China.;The Joint Program in Infection and Immunity, a. Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China, and b. Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, PR China.;Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Chinese Academy of Sciences, Shanghai 200032, PR China. | 1381 | |||
| 10.1093/cid/ciaa768 | Journal Article | en | Corticosteroids in patients with COVID-19: what about the control group? | https://www.ncbi.nlm.nih.gov/pubmed/32548616 | 1058-4838,1537-6591 | 2020-06-21 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Tomasz Chroboczek;Marie Lacoste;Chloe Wackenheim;Thibaut Challan-Belval;Benjamin Amar;Thomas Boisson;Jason Hubac;Dominique Leduc;Colleen Masse;Victor Dechaene;Laetitia Touhiri-Maximin;Sandrine Megessier;Camille Lassale | 2020-06-16 02:00:00+02:00 | 32548616 | GB;FR;ES | Service de maladies infectieuses et tropicales, Centre Hospitalier Alpes Léman, France.;Service de médecine Interne, Centre Hospitalier Alpes Léman, France.;Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.;Department of Epidemiology and Public Health, University College London, London, United Kingdom. | 1395 | |||||
| 10.1186/s13054-020-03062-7 | Journal Article;Review | en | The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32546188 | In severe SARS-CoV-2 infections, emerging data including recent histopathological studies have emphasized the crucial role of endothelial cells (ECs) in vascular dysfunction, immunothrombosis, and inflammation.Histopathological studies have evidenced direct viral infection of ECs, endotheliitis with diffuse endothelial inflammation, and micro- and macrovascular thrombosis both in the venous and arterial circulations. Venous thrombotic events, particularly pulmonary embolism, with elevated D-dimer and coagulation activation are highly prevalent in COVID-19 patients. The pro-inflammatory cytokine storm, with elevated levels of interleukin-6 (IL-6), IL-2 receptor, and tumor necrosis factor-α, could also participate in endothelial dysfunction and leukocyte recruitment in the microvasculature. COVID-19-induced endotheliitis may explain the systemic impaired microcirculatory function in different organs in COVID-19 patients. Ongoing trials directly and indirectly target COVID-19-related endothelial dysfunctions: i.e., a virus-cell entry using recombinant angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS-2) blockade, coagulation activation, and immunomodulatory therapies, such as anti-IL-6 strategies. Studies focusing on endothelial dysfunction in COVID-19 patients are warranted as to decipher their precise role in severe SARS-CoV-2 infection and organ dysfunction and to identify targets for further interventions. | 1364-8535 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Capillary Permeability__physiology;Coronavirus Infections__diagnosis;Endothelium, Vascular__metabolism;Humans;Pandemics;Pneumonia, Viral__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Critical Care | Stéphanie Pons;Sofiane Fodil;Elie Azoulay;Lara Zafrani | COVID-19;Cytokines;Endothelial cells;Endothelial dysfunction;SARS-CoV-2;Thrombosis | 2020-06-16 02:00:00+02:00 | 32546188 | FR | INSERM U976, Human Immunology, Pathophysiology and Immunotherapy, Saint-Louis Teaching Hospital, Paris University, Paris, France.;Anesthesia and Critical Care Department, Avicenne Teaching Hospital, Assistance Publique des Hôpitaux de Paris, Bobigny, France.;Department of Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Assistance Publique des Hôpitaux de Paris, 1, Avenue Claude Vellefaux, 75010, Paris, France.;INSERM U976, Human Immunology, Pathophysiology and Immunotherapy, Saint-Louis Teaching Hospital, Paris University, Paris, France. lara.zafrani@aphp.fr.;Department of Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Assistance Publique des Hôpitaux de Paris, 1, Avenue Claude Vellefaux, 75010, Paris, France. lara.zafrani@aphp.fr. | 1399 | ||
| Letter;Comment | en | Liver injury without liver failure in COVID-19 patients: how to explain, in some cases, elevated ammonia without hepatic decompensation. | https://www.ncbi.nlm.nih.gov/pubmed/32546201 | 2020-06-21 02:00:00+02:00 | pubmed | Ammonia;Betacoronavirus;Coronavirus Infections;Critical Illness;Humans;Liver Failure;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Patrick M Honore;Leonel Barreto Gutierrez;Luc Kugener;Sebastien Redant;Rachid Attou;Andrea Gallerani;David De Bels | 2020-06-16 02:00:00+02:00 | 32546201 | FR;BE | ICU Department, Centre Hospitalier Universitaire Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. Patrick.Honore@CHU-Brugmann.be.;ICU Department, Centre Hospitalier Universitaire Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. | 1401 | |||||||
| 10.24875/ric.20000113 | Journal Article | en | DISPERSION OF A NEW CORONAVIRUS SARS-COV-2 BY AIRLINES IN 2020: TEMPORAL ESTIMATES OF THE OUTBREAK IN MEXICO. | https://www.ncbi.nlm.nih.gov/pubmed/32584328 | On January 23, 2020, China imposed a quarantine on the city of Wuhan to contain the SARS-CoV-2 outbreak. Regardless of this measure, the new infection has spread to several countries around the world. | 0034-8376 | 2020-06-28 02:00:00+02:00 | pubmed | Air Travel;Betacoronavirus;China__epidemiology;Coronavirus Infections__epidemiology;Disease Outbreaks__prevention & control;Geography, Medical;Humans;Mexico__epidemiology;Models, Theoretical;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Time Factors;Travel-Related Illness;Urban Health;COVID-19;severe acute respiratory syndrome coronavirus 2 | Revista de investigaci n Cl nica | Gustavo Cruz-Pacheco;José F Bustamante-Castañeda;Jean G Caputo;María E Jiménez-Corona;Samuel Ponce-de-León-Rosales | COVID-19;Coronavirus;Outbreak;SARS-CoV-2 | 2020-06-26 02:00:00+02:00 | 32584328 | FR;MX | Department of Mathematics and Mechanics, Instituto de Investigaciones en Matemáticas Aplicadas y en Sistemas (IIMAS), National University of Mexico (UNAM), Mexico City, Mexico.;Graduate Program in Mathematical Sciences, UNAM, Mexico City, Mexico.;Laboratory of Mathematics, Institut National des Sciences Appliquées de Rouen Normandie, Saint-Etienne du Rouvray, France.;Department of Epidemiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.;Division of Graduate Studies and Research, Facultad de Odontología, UNAM, Mexico City, Mexico.;Programa Universitario de Investigación en Salud, UNAM, Mexico City, Mexico. | 1412 | ||
| Letter;Comment | en | Gustatory dysfunctions in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32577904 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Renin-Angiotensin System;Taste;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jerome R Lechien;Julien W Hsieh;Tareck Ayad;Nicolas Fakhry;Stephane Hans;Carlos M Chiesa-Estomba;Sven Saussez | Anosmia;COVID-19;Coronavirus;Dear editor;Dysgeusia;Gustatory;Hyposmia;Loss;Smell;Taste | 2020-06-23 02:00:00+02:00 | 32577904 | FR;CA;CH;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France. Jerome.Lechien@umons.ac.be.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium. Jerome.Lechien@umons.ac.be.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France. Jerome.Lechien@umons.ac.be.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. Jerome.Lechien@umons.ac.be.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France.;Rhinology-Olfactology Unit, Department of Otorhinolaryngology, Head and Neck Surgery, Geneva University Hospitals (HUG), Geneva, Switzerland.;Department of Otolaryngology-Head and Neck Surgery, CHU de Montreal, Montreal, Canada.;Department of Otolaryngology-Head and Neck Surgery, APHM, Aix-Marseille Univ, Hopital La Conception, Marseille, France.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. | 1427 | ||||||
| Journal Article | en | Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. | https://www.ncbi.nlm.nih.gov/pubmed/32573419 | Acute respiratory distress syndrome (ARDS) related to SARS-CoV-2 is likely due to a cytokine storm characterised by a major release of pro-inflammatory cytokines, including interleukin-6 (IL-6). Blocking excessive IL-6 production might be the key to the COVID-19-ARDS treatment. Beneficial effects of IL-6 blockade using a humanised anti-IL-6 receptor antibody, tocilizumab (TCZ) were previously reported in patients with COVID-19 related ARDS. The aim of the study was to study the variation over time of several biomarkers, demonstrated to be predictors of poor prognostic, in subjects successfully treated with TCZ for severe COVID-19. | 2020-06-28 02:00:00+02:00 | pubmed | Antibodies, Monoclonal, Humanized__therapeutic use;Betacoronavirus;Biomarkers__analysis;Coronavirus Infections__drug therapy;Humans;Pandemics;Pneumonia, Viral__drug therapy;Receptors, Interleukin-6__antagonists & inhibitors;Retrospective Studies;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Thierry Conrozier;Anne Lohse;Jean-Charles Balblanc;Pascale Dussert;Pierre-Yves Royer;Marie Bossert;Ana-Maria Bozgan;Vincent Gendrin;Aline Charpentier;Lynda Toko;Julio Badie;Chaouki Mezher;Marie-Françoise Roux;Ndri Juliette Kadiane-Oussou;Rémy Contreras;Julie Kessler;Isabelle Mazurier;Timothée Klopfenstein;Souheil Zayet | 2020-06-23 02:00:00+02:00 | 32573419 | FR | Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France. thierry.conrozier@hnfc.fr.;Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France.;Department of Biology, Nord Franche-Comté Hospital, Belfort, France.;Department of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France.;Intensive Care Unit, Nord Franche-Comté Hospital, Belfort, France.;Pharmacy, Nord Franche-Comté Hospital, Belfort, France. | 1428 | ||||||
| 10.1128/aac.00819-20 | Journal Article;Research Support, Non-U.S. Gov't | en | Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. | https://www.ncbi.nlm.nih.gov/pubmed/32366720 | Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC50s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects. | 0066-4804,1098-6596 | 2020-06-28 02:00:00+02:00 | pubmed | Animals;Anti-Inflammatory Agents__pharmacology;Antiviral Agents__pharmacology;Betacoronavirus__drug effects;Cell Line;Chlorocebus aethiops;Coronavirus Infections__drug therapy;Drug Evaluation, Preclinical__methods;Drug Repositioning;Humans;Niclosamide__pharmacology;Pandemics;Pneumonia, Viral__drug therapy;Pregnenediones__pharmacology;Vero Cells;COVID-19;severe acute respiratory syndrome coronavirus 2 | Antimicrobial Agents and Chemotherapy | Sangeun Jeon;Meehyun Ko;Jihye Lee;Inhee Choi;Soo Young Byun;Soonju Park;David Shum;Seungtaek Kim | COVID-19;FDA-approved drug;SARS-CoV-2 | 2020-06-23 02:00:00+02:00 | 32366720 | FR;KR | Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.;Medicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea.;Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea.;Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea seungtaek.kim@ip-korea.org. | 1429 | ||
| Case Reports;Letter | en | COVID-19 associated encephalopathy: Is there a specific EEG pattern? | https://www.ncbi.nlm.nih.gov/pubmed/32615526 | 2020-06-28 02:00:00+02:00 | pubmed | Adult;Brain Diseases__diagnosis;Brain Waves;Coronavirus Infections__complications;Humans;Male;Pandemics;Pneumonia, Viral__complications;COVID-19 | Geoffroy Vellieux;Anny Rouvel-Tallec;Pierre Jaquet;Alexandra Grinea;Romain Sonneville;Marie-Pia d'Ortho | 2020-06-24 02:00:00+02:00 | 32615526 | FR | Université de Paris, NeuroDiderot, Inserm, F-75019 Paris, France, Neurophysiologie clinique, Service de Physiologie - Explorations Fonctionnelles, AP-HP, Hôpital Bichat-Claude Bernard, F-75018 Paris, France. Electronic address: geoffroy.vellieux@aphp.fr.;Université de Paris, NeuroDiderot, Inserm, F-75019 Paris, France, Neurophysiologie clinique, Service de Physiologie - Explorations Fonctionnelles, AP-HP, Hôpital Bichat-Claude Bernard, F-75018 Paris, France.;Médecine intensive-réanimation, AP-HP, Bichat-Claude Bernard Hospital, F-75018 Paris, France.;Médecine intensive-réanimation, AP-HP, Bichat-Claude Bernard Hospital, F-75018 Paris, France, Université de Paris, INSERM UMR1148, Team 6, F-75018 Paris, France. | 1430 | |||||||
| 10.1007/s15010-020-01467-8 | Journal Article | en | Utility of CT scan in patients with initial negative PCR for SARS-CoV2: a report of three cases. | https://www.ncbi.nlm.nih.gov/pubmed/32583171 | PCR-based viral RNA to confirm the diagnosis of SARS-CoV-2 infection has a sensitivity of around 70%. We report three cases of patients with negative initial PCR and CT scan lesions that led us to suspect COVID-19, but which one(s) are really COVID-19? | 0300-8126,1439-0973 | 2020-06-28 02:00:00+02:00 | pubmed | Infection | Kevin Bouiller;Sébastien Humbert;Camille Payet-Revest;Anne-Sophie Brunel;Adrien Mareshal;Quentin Lepiller;Franck Grillet;Catherine Chirouze | COVID-19;CT scan;Coronavirus;Mycoplasma pneumoniae;SARS-CoV2 | 2020-06-24 02:00:00+02:00 | 32583171 | FR | Infectious and Tropical Disease Department, University Hospital Besancon (CHRU Besancon), 3 Boulevard Alexandre Fleming, 25030, Besançon, France. kbouiller@chu-besancon.fr.;UMR CNRS 6249, Chrono Environnement, University of Burgundy Franche-Comté, Besançon, France. kbouiller@chu-besancon.fr.;Internal Medicine Department, University Hospital Besancon, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Infectious and Tropical Disease Department, University Hospital Besancon (CHRU Besancon), 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Dermatology Department, University Hospital Besancon, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Laboratory of Virology, University Hospital Besancon, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Radiology Department, University Hospital Besancon, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.;Infectious and Tropical Disease Department, University Hospital Besancon (CHRU Besancon), 3 Boulevard Alexandre Fleming, 25030, Besançon, France. cchirouze@chu-besancon.fr.;UMR CNRS 6249, Chrono Environnement, University of Burgundy Franche-Comté, Besançon, France. cchirouze@chu-besancon.fr. | 1433 | |||
| Letter | en | Implementation of a non-invasive oxygenation support strategy during the COVID-19 pandemic in an ephemeral Respiratory Intermediate Care Unit. | https://www.ncbi.nlm.nih.gov/pubmed/32651097 | 2020-06-28 02:00:00+02:00 | pubmed | Tsipora N Guenancia;Anne Rosa;Charles Damoisel;Frédéric J Mercier;Bénédicte Jeannin | 2020-06-24 02:00:00+02:00 | 32651097 | FR | Département d'anesthésie-réanimation, hôpital Antoine-Béclère, université Paris-Saclay, AP-HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France. Electronic address: tguenancia@gmail.com.;Département d'anesthésie-réanimation, hôpital Antoine-Béclère, université Paris-Saclay, AP-HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France.;Réanimation polyvalente, hôpital Antoine-Béclère, université Paris-Saclay, AP-HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France. | 1440 | ||||||||
| 10.3390/biology9060135 | Journal Article | en | On a Coupled Time-Dependent SIR Models Fitting with New York and New-Jersey States COVID-19 Data. | https://www.ncbi.nlm.nih.gov/pubmed/32599867 | This article describes a simple Susceptible Infected Recovered (SIR) model fitting with COVID-19 data for the month of March 2020 in New York (NY) state. The model is a classical SIR, but is non-autonomous; the rate of susceptible people becoming infected is adjusted over time in order to fit the available data. The death rate is also secondarily adjusted. Our fitting is made under the assumption that due to limiting number of tests, a large part of the infected population has not been tested positive. In the last part, we extend the model to take into account the daily fluxes between New Jersey (NJ) and NY states and fit the data for both states. Our simple model fits the available data, and illustrates typical dynamics of the disease: exponential increase, apex and decrease. The model highlights a decrease in the transmission rate over the period which gives a quantitative illustration about how lockdown policies reduce the spread of the pandemic. The coupled model with NY and NJ states shows a wave in NJ following the NY wave, illustrating the mechanism of spread from one attractive hot spot to its neighbor. | 2079-7737 | 2020-06-28 02:00:00+02:00 | pubmed | Biology | Benjamin Ambrosio;M A Aziz-Alaoui | COVID-19;Network;New Jersey;New York;SIR models | 2020-06-24 02:00:00+02:00 | 32599867 | FR | UNIHAVRE, LMAH, FR-CNRS-3335, ISCN, Normandie University, 76600 Le Havre, France. | 1447 | |||
| 10.1038/s41559-020-1237-z | Journal Article | en | COVID-19 lockdown allows researchers to quantify the effects of human activity on wildlife. | https://www.ncbi.nlm.nih.gov/pubmed/32572222 | 2397-334X | 2020-06-28 02:00:00+02:00 | pubmed | Nature Ecology & Evolution | Christian Rutz;Matthias-Claudio Loretto;Amanda E Bates;Sarah C Davidson;Carlos M Duarte;Walter Jetz;Mark Johnson;Akiko Kato;Roland Kays;Thomas Mueller;Richard B Primack;Yan Ropert-Coudert;Marlee A Tucker;Martin Wikelski;Francesca Cagnacci | 2020-06-22 02:00:00+02:00 | 32572222 | FR;CA;SA;GB;US;IT;NL;DK;DE | Centre for Biological Diversity, School of Biology, University of St Andrews, St Andrews, UK. christian.rutz@st-andrews.ac.uk.;Radcliffe Institute for Advanced Study, Harvard University, Cambridge, MA, USA. christian.rutz@st-andrews.ac.uk.;Department of Migration, Max Planck Institute of Animal Behavior, Radolfzell, Germany.;Department of Biology, University of Konstanz, Konstanz, Germany.;Department of Ocean Sciences, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.;Centre for the Advanced Study of Collective Behaviour, University of Konstanz, Konstanz, Germany.;Red Sea Research Center and Computational Biosciences Research Center, King Abdullah University of Science and Technology, Thuwal, Kingdom of Saudi Arabia.;Ecology and Evolutionary Biology Department, Yale University, New Haven, CT, USA.;Center for Biodiversity and Global Change, Yale University, New Haven, CT, USA.;Sea Mammal Research Unit, University of St Andrews, St Andrews, UK.;Department of Biology, Aarhus University, Aarhus, Denmark.;Centre d'Etudes Biologiques de Chizé, La Rochelle Université - CNRS, UMR 7372, Villiers en Bois, France.;North Carolina Museum of Natural Sciences, Biodiversity Lab, Raleigh, NC, USA.;Fisheries, Wildlife, and Conservation Biology Program, College of Natural Resources, North Carolina State University, Raleigh, NC, USA.;Senckenberg Biodiversity and Climate Research Centre, Senckenberg Gesellschaft für Naturforschung, Frankfurt (Main), Germany.;Department of Biological Sciences, Goethe University, Frankfurt (Main), Germany.;Biology Department, Boston University, Boston, MA, USA.;Department of Environmental Science, Institute for Water and Wetland Research, Radboud University, Nijmegen, The Netherlands.;Department of Biodiversity and Molecular Ecology, Research and Innovation Centre, Fondazione Edmund Mach, Trento, Italy. | 1452 | |||||
| 10.1016/j.jcv.2020.104521 | Evaluation Study;Journal Article;Research Support, Non-U.S. Gov't | en | Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. | https://www.ncbi.nlm.nih.gov/pubmed/32623350 | Knowledge of the COVID-19 epidemic extent and the level of herd immunity is urgently needed to help manage this pandemic. | 1386-6532 | 2020-06-28 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Antibodies, Viral__blood;Antigens, Viral__immunology;Betacoronavirus__immunology;Coronavirus Infections__diagnosis;Female;Humans;Immunoglobulin G__blood;Male;Middle Aged;Middle East Respiratory Syndrome Coronavirus__immunology;Nucleocapsid Proteins__immunology;Pandemics;Pneumonia, Viral__diagnosis;ROC Curve;SARS Virus__immunology;Sensitivity and Specificity;Serologic Tests__methods;Severe Acute Respiratory Syndrome__diagnosis;Spike Glycoprotein, Coronavirus__immunology;Time Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Clinical Virology | Ahidjo Ayouba;Guillaume Thaurignac;David Morquin;Edouard Tuaillon;Raisa Raulino;Antoine Nkuba;Audrey Lacroix;Nicole Vidal;Vincent Foulongne;Vincent Le Moing;Jacques Reynes;Eric Delaporte;Martine Peeters | COVID-19;Luminex;SARS;SARS-CoV2;Serology | 2020-06-22 02:00:00+02:00 | 32623350 | FR | Recherches Translationnelles sur le VIH et Maladies Infectieuses/INSERM U1175, Institut de Recherche pour le Développement et Université de Montpellier, France. Electronic address: ahidjo.ayouba@ird.fr.;Recherches Translationnelles sur le VIH et Maladies Infectieuses/INSERM U1175, Institut de Recherche pour le Développement et Université de Montpellier, France.;Recherches Translationnelles sur le VIH et Maladies Infectieuses/INSERM U1175, Institut de Recherche pour le Développement et Université de Montpellier, France, Département de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, CHU Montpellier, Montpellier, France.;Département de bacteriologie-virologie, CHU de Montpellier, 34295 Montpellier, France. | 1454 | ||
| Letter | en | SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32572527 | 2020-06-28 02:00:00+02:00 | pubmed | Slim Fourati;Sophie Hue;Jean-Michel Pawlotsky;Armand Mekontso-Dessap;Nicolas de Prost | 2020-06-22 02:00:00+02:00 | 32572527 | FR | Virology Unit, Département de prévention, diagnostic et traitement des infections, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP), Créteil, France.;INSERM U955, Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France.;INSERM U955 Team « Virus Hepatology Cancer », Créteil, France.;Département Immunologie-Hématologie, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP), Créteil, France.;INSERM U955 Team 16, Créteil, France.;Vaccine Research Institute (VRI), Faculté de Médecine, Université Paris Est Créteil, 94010, Créteil, France.;Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP), Créteil, France.;Groupe de Recherche Clinique CARMAS, Université Paris Est-Créteil, Créteil, France.;INSERM U955, Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France. nicolas.de-prost@aphp.fr.;Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP), Créteil, France. nicolas.de-prost@aphp.fr.;Groupe de Recherche Clinique CARMAS, Université Paris Est-Créteil, Créteil, France. nicolas.de-prost@aphp.fr.;Service de Médecine Intensive Réanimation, Hôpital Henri Mondor, Créteil, France. nicolas.de-prost@aphp.fr. | 1455 | ||||||||
| Letter | en | Impact of COVID-19 pandemic on emergency department services acuity and possible collateral damage. | https://www.ncbi.nlm.nih.gov/pubmed/32585231 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Emergency Service, Hospital__organization & administration;Humans;Infection Control__organization & administration;Out-of-Hospital Cardiac Arrest__epidemiology;Pandemics;Pneumonia, Viral__epidemiology;Prevalence;Retrospective Studies;Severity of Illness Index;Taiwan__epidemiology;Triage;Workload;COVID-19;severe acute respiratory syndrome coronavirus 2 | Chih-Wei Sung;Tsung-Chien Lu;Cheng-Chung Fang;Chien-Hua Huang;Wen-Jone Chen;Shyr-Chyr Chen;Chu-Lin Tsai | 2020-06-22 02:00:00+02:00 | 32585231 | FR;TW | Department of Emergency Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.;Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan, College of Medicine, National Taiwan University, Taipei, Taiwan.;Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: chulintsai@ntu.edu.tw. | 1462 | |||||||
| 10.1016/j.scitotenv.2020.140426 | Journal Article | en | Impact of lockdown measures to combat Covid-19 on air quality over western Europe. | https://www.ncbi.nlm.nih.gov/pubmed/32593893 | Recent studies based on observations have shown the impact of lockdown measures taken in various European countries to contain the Covid-19 pandemic on air quality. However, these studies are often limited to compare situations without and with lockdown measures, which correspond to different time periods and then under different meteorological conditions. We propose a modelling study with the WRF-CHIMERE modelling suite for March 2020, an approach allowing to compare atmospheric composition with and without lockdown measures without the biases of meteorological conditions. This study shows that the lockdown effect on atmospheric composition, in particular through massive traffic reductions, has been important for several short-lived atmospheric trace species, with a large reduction in NO2 concentrations, a lower reduction in Particulate Matter (PM) concentrations and a mitigated effect on ozone concentrations due to non-linear chemical effects. | 0048-9697 | 2020-06-28 02:00:00+02:00 | pubmed | Science of The Total Environment | Laurent Menut;Bertrand Bessagnet;Guillaume Siour;Sylvain Mailler;Romain Pennel;Arineh Cholakian | CHIMERE;COVID-19;Chemistry-transport modelling;Emissions scenario;Lockdown | 2020-06-23 02:00:00+02:00 | 32593893 | FR | Laboratoire de Météorologie Dynamique (LMD), Ecole Polytechnique, IPSL Research University, Ecole Normale Supérieure, Université Paris-Saclay, Sorbonne Universités, UPMC Univ Paris 06, CNRS, Route de Saclay, 91128 Palaiseau, France. Electronic address: menut@lmd.polytechnique.fr.;Laboratoire de Météorologie Dynamique (LMD), Ecole Polytechnique, IPSL Research University, Ecole Normale Supérieure, Université Paris-Saclay, Sorbonne Universités, UPMC Univ Paris 06, CNRS, Route de Saclay, 91128 Palaiseau, France, Now at Citepa, Technical Reference Center for Air Pollution and Climate Change, 42, rue de Paradis, 75010 Paris, France.;Laboratoire Interuniversitaire des Systèmes Atmosphériques (LISA), UMR CNRS 7583, Université Paris Est Créteil et Université de Paris, Institut Pierre Simon Laplace, Créteil, France.;Laboratoire de Météorologie Dynamique (LMD), Ecole Polytechnique, IPSL Research University, Ecole Normale Supérieure, Université Paris-Saclay, Sorbonne Universités, UPMC Univ Paris 06, CNRS, Route de Saclay, 91128 Palaiseau, France. | 1469 | |||
| 10.1016/j.ctrv.2020.102063 | Journal Article;Review | en | Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). | https://www.ncbi.nlm.nih.gov/pubmed/32623296 | The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19. | 0305-7372 | 2020-06-28 02:00:00+02:00 | pubmed | Antineoplastic Agents__administration & dosage;Betacoronavirus__isolation & purification;Clinical Trials as Topic__methods;Coronavirus Infections__drug therapy;Humans;Medical Oncology__methods;Neoplasms__drug therapy;Pandemics;Pharmacy__methods;Pneumonia, Viral__drug therapy;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cancer Treatment Reviews | Florian Slimano;Amandine Baudouin;Jérémie Zerbit;Anne Toulemonde-Deldicque;Audrey Thomas-Schoemann;Régine Chevrier;Mikaël Daouphars;Isabelle Madelaine;Bertrand Pourroy;Jean-François Tournamille;Alain Astier;Florence Ranchon;Jean-Louis Cazin;Christophe Bardin;Catherine Rioufol | COVID-19;Clinical trials;Drug safety;Drug-drug interactions;Drug-related problems;Herb-Drug interactions;Immune depression | 2020-06-23 02:00:00+02:00 | 32623296 | FR;US | Department of Pharmacy, CHU Reims, France, Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims, France. Electronic address: florianslimano@gmail.com.;Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France. Electronic address: amandine.baudouin@chu-lyon.fr.;Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: jeremiezerbit@gmail.com.;Institut of Pharmacy, CHU Lille, 59000 Lille, France. Electronic address: anne.deldicque@gmail.com.;Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France, UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris, France. Electronic address: schoemann.audrey@gmail.com.;Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand, France. Electronic address: regine.chevrier@clermont.unicancer.fr.;Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen, France. Electronic address: mikael.daouphars@chb.unicancer.fr.;Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France. Electronic address: isabelle.madelaine@aphp.fr.;Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: bertrand.pourroy@ap-hm.fr.;Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours, France. Electronic address: jf.tournamille@sfpo.com.;Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil, France. Electronic address: prof.astier@gmail.com.;Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France, EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: florence.ranchon@chu-lyon.fr.;Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France, Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille, France. Electronic address: jean-louis.cazin@univ-lille.fr.;Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: christophe.bardin@aphp.fr.;Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France, EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: catherine.rioufol@chu-lyon.fr. | 1475 | ||
| 10.1016/j.retram.2020.06.003 | Journal Article;Review | en | CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. | https://www.ncbi.nlm.nih.gov/pubmed/32620465 | The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic. | 2452-3186 | 2020-06-28 02:00:00+02:00 | pubmed | Current Research in Translational Medicine | Yongxian Hu;Elaine Tan Su Yin;Yingying Yang;Hengwei Wu;Guoqing Wei;Junwei Su;Qu Cui;Aiyun Jin;Li Yang;Shan Fu;Jianfeng Zhou;Lugui Qiu;Xi Zhang;Aibin Liang;Hongmei Jing;Yuhua Li;Didier Blaise;Mohamad Mohty;Arnon Nagler;He Huang | COVID-19;Chimeric antigen receptor T-cells;Cytokine release syndrome;Immunocompromised;Relapsed/refractory hematological malignancies | 2020-06-28 02:00:00+02:00 | 32620465 | FR;CN;IL | Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: huyongxian2000@aliyun.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: elainetansuyin@outlook.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: yangyingying15@zju.edu.cn.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: 457166156@qq.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: weiguoqing2000@sina.com.;State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: zjusujunwei@zju.edu.cn.;Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: cncuiqu@hotmail.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: ayjin2007@aliyun.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: yanglizju@163.com.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: fushan0817@163.com.;Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: jfzhou@tjh.tjmu.edu.cn.;State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China. Electronic address: qiulg@ihcams.ac.cn.;Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China. Electronic address: zhangxxi@sina.com.;Department of Hematology, Shanghai Tongji Hospital, Shanghai, China. Electronic address: lab7182@tongji.edu.cn.;Department of Hematology, Peking University Third Hospital, Beijing, China. Electronic address: drjinghm@163.com.;Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China. Electronic address: liyuhua2011gz@163.com.;Transplant and Cellular Immunotherapy Programs, Department of Hematology, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France. Electronic address: BLAISED@ipc.unicancer.fr.;Sorbonne University, Department of Hematology, Hôpital Saint Antoine, Paris, France, INSERM UMRs 938, EBMT Paris Study Office/CEREST-TC, Paris, France. Electronic address: mohamad.mohty@inserm.fr.;Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel. Electronic address: Arnon.Nagler@sheba.health.gov.il.;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: huanghe@zju.edu.cn. | 1479 | |||
| 10.1212/nxi.0000000000000823 | Case Reports;Journal Article | en | COVID-19-associated ophthalmoparesis and hypothalamic involvement. | https://www.ncbi.nlm.nih.gov/pubmed/32587102 | 2332-7812 | 2020-06-28 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections__complications;Female;Humans;Hypothalamus__diagnostic imaging;Middle Aged;Ophthalmoplegia__diagnostic imaging;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Neurology - Neuroimmunology Neuroinflammation | Elba Pascual-Goñi;Juan Fortea;Alejandro Martínez-Domeño;Nuria Rabella;Mario Tecame;Cristina Gómez-Oliva;Luis Querol;Beatriz Gómez-Ansón | 2020-06-25 02:00:00+02:00 | 32587102 | FR;ES | From the Department of Neurology (E.P.-G., J.F., A.M.-D., L.Q.), Neuroradiology Unit (M.T., B.G.-A.), Radiology Department, Microbiology Department (N.R.), and Gastroenterology Department (C.G.-O.), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain.;From the Department of Neurology (E.P.-G., J.F., A.M.-D., L.Q.), Neuroradiology Unit (M.T., B.G.-A.), Radiology Department, Microbiology Department (N.R.), and Gastroenterology Department (C.G.-O.), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain. lquerol@santpau.cat. | 1496 | ||||
| Letter | en | Short-term acceptability by patients and psychiatrists of the turn to psychiatric teleconsultation in the context of the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32511825 | 2020-06-28 02:00:00+02:00 | pubmed | Adult;Attitude of Health Personnel;Coronavirus Infections;France;Humans;Mental Disorders__therapy;Mentally Ill Persons;Pandemics;Patient Acceptance of Health Care__statistics & numerical data;Pneumonia, Viral;Psychiatry__statistics & numerical data;Remote Consultation__organization & administration;COVID-19 | Romain Colle;Abd El Kader Ait Tayeb;Delphine de Larminat;Line Commery;Bruno Boniface;Pierre-Alexandre Lasica;Florence Gressier;Rima Mecifi;Samuel Rotenberg;Adrien Rigal;Sarah Zitoun;Antonia Mezzacappa;Cerasella Nicolicea;Edouard Chaneac;Severine Martin;Walid Choucha;Patrick Hardy;Elisabeth Schouman-Claeys;Emmanuelle Corruble | 2020-06-28 02:00:00+02:00 | 32511825 | FR | Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.;Faculté de Médecine Paris-Saclay, Equipe MOODS, INSERM, CESP, Université Paris-Saclay, Le Kremlin Bicêtre, France.;Direction de l'Organisation Médicale et des Relations avec les Universités, Assistance Publique-Hôpitaux de Paris, Paris, France. | 1505 | |||||||
| 10.1016/j.amp.2020.06.014 | Journal Article | fr | [The Covid-19 pandemic: Media overdose, fear and soon antonomasia? A squared pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32836307 | 0003-4487 | 2020-06-28 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Anne-Frédérique Naviaux;Pascal Janne;Maximilien Gourdin | 2020-06-28 02:00:00+02:00 | 32836307 | FR;IE;BE;GB | Health Service Executive (HSE) Summerhill Community Mental Health Service, W35 KC58 Summerhill, Wexford, Ireland.;Faculty of Medicine, Université catholique de Louvain, avenue Emmanuel Mounier 50, B-1200 Woluwé-Saint-Lambert, Belgique.;Université catholique de Louvain , CHU UCL Namur, avenue Dr. G. Thérasse, B. 5530 Yvoir, Belgique.;Faculty of Psychology, Université catholique de Louvain, place Cardinal Mercier 10, 1348 Ottignies-Louvain-la-Neuve, Belgique. | 1507 | |||||
| 10.1016/j.therap.2020.06.013 | Journal Article | en | Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. | https://www.ncbi.nlm.nih.gov/pubmed/32665090 | Since December 2019, the COVID-19 pandemic has become a major public health problem. To date, there is no evidence of a higher incidence of COVID in patients with autoimmune rheumatic diseases and we support the approach of maintaining chronic rheumatological treatments. However, once infected there is a small but significant increased risk of mortality. Among the different treatments, NSAIDs are associated with higher rates of complications, but data for other drugs are conflicting or incomplete. The use of certain drugs for autoimmune inflammatory rheumatisms appears to be a potentially interesting options for the treatment. The rationale for their use is based on the immune system runaway and the secretion of pro-inflammatory cytokines (Il1, IL6, TNFα) in severe forms of the disease. Notably, patients on chloroquine or hydroxychloroquine as a treatment for their autoimmune rheumatic disease are not protected from COVID-19. | 0040-5957 | 2020-06-28 02:00:00+02:00 | pubmed | Therapies | Lucile Grange;Philippe Guilpain;Marie-Elise Truchetet;Jean-Luc Cracowski | Dexamethasone;Hydroxychloroquine;Pharmacology;Rheumatoid arthritis;Rheumatology | 2020-06-27 02:00:00+02:00 | 32665090 | FR | University Saint-Étienne, 42000 Saint-Étienne, France.;Montpellier's school of medicine, university Montpellier, 34967 Montpellier, France, Department of internal medicine - multi-organ diseases, local referral center for autoimmune diseases, Saint-Éloi university hospital, 34295 Montpellier, France, IRMB, Inserm U1183, CHU Montpellier, Saint-Éloi university hospital, university Montpellier, 34090 Montpellier, France.;Univ. Bordeaux, CHU Bordeaux, 33000 Bordeaux, France.;Univ. Grenoble Alpes, INSERM, HP2, 38000 Grenoble, France. Electronic address: Jean-Luc.Cracowski@univ-grenoble-alpes.fr. | 1518 | |||
| Case Reports;Letter | en | SARS-CoV-2-associated cold agglutinin disease: a report of two cases. | https://www.ncbi.nlm.nih.gov/pubmed/32591877 | 2020-06-28 02:00:00+02:00 | pubmed | Adult;Anemia, Hemolytic, Autoimmune__blood;Betacoronavirus;Coronavirus Infections__blood;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__blood;COVID-19;severe acute respiratory syndrome coronavirus 2 | Tessa Huscenot;Joris Galland;Margot Ouvrat;Mathias Rossignol;Stéphane Mouly;Damien Sène | 2020-06-26 02:00:00+02:00 | 32591877 | FR | Department of Internal Medicine, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, University of Paris, 2 rue Ambroise Paré, 75010, Paris, France.;Department of Intensive Care, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, University of Paris, Paris, France.;Department of Internal Medicine, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, University of Paris, 2 rue Ambroise Paré, 75010, Paris, France. damin.sene@aphp.fr. | 1522 | |||||||
| 10.1016/j.acvd.2020.06.001 | Comparative Study;Journal Article;Multicenter Study | en | Worrying decrease in hospital admissions for myocardial infarction during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32636131 | How coronavirus 2019 (COVID-19) is affecting management of myocardial infarction is a matter of concern, as medical resources have been massively reorientated and the population has been in lockdown since 17 March 2020 in France. | 1875-2136 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Coronavirus Infections__diagnosis;France__epidemiology;Humans;Incidence;Non-ST Elevated Myocardial Infarction__diagnosis;Pandemics;Patient Admission__trends;Pneumonia, Viral__diagnosis;Prognosis;ST Elevation Myocardial Infarction__diagnosis;Time Factors;Virulence;COVID-19;severe acute respiratory syndrome coronavirus 2 | Archives of Cardiovascular Diseases | Pierre Lantelme;Sandrine Couray Targe;Pierre Metral;Thomas Bochaton;Sylvain Ranc;Maggie Le Bourhis Zaimi;Andre Le Coanet;Pierre-Yves Courand;Brahim Harbaoui | Acute coronary syndrome;COVID-19;Infarctus du myocarde;Myocardial infarction | 2020-06-25 02:00:00+02:00 | 32636131 | FR | University of Lyon, CREATIS UMR5220, INSERM U1044, INSA-15 Lyon, France, Cardiology Department, Hôpital Croix-Rousse and Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France. Electronic address: pierre.lantelme@chu-lyon.fr.;Department of Medical Information, Hospices Civils de Lyon, Lyon, France.;Department of Medical Information, Saint-Joseph Hospital, Lyon, France.;Cardiology Department, Hôpital Louis-Pradel, Lyon, France.;Cardiology Department, Saint-Joseph Hospital, Lyon, France.;University of Lyon, CREATIS UMR5220, INSERM U1044, INSA-15 Lyon, France, Cardiology Department, Hôpital Croix-Rousse and Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France. | 1526 | ||
| 10.1136/bjophthalmol-2020-316776 | Journal Article | en | Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32586933 | Immunomodulatory therapy (IMT) is often considered for systemic treatment of non-infectious uveitis (NIU). During the evolving coronavirus disease-2019 (COVID-19) pandemic, given the concerns related to IMT and the increased risk of infections, an urgent need for guidance on the management of IMT in patients with uveitis has emerged. | 0007-1161,1468-2079 | 2020-06-28 02:00:00+02:00 | pubmed | British Journal of Ophthalmology | Rupesh Agrawal;Ilaria Testi;Cecilia S Lee;Edmund Tsui;Marian Blazes;Jennifer E Thorne;Annabelle A Okada;Justine R Smith;Peter J McCluskey;John H Kempen;Christoph Tappeiner;Manisha Agarwal;Bahram Bodaghi;Quan Dong Nguyen;Vishali Gupta;Marc D De Smet;Manfred Zierhut;Carlos Pavesio | Choroid;Ciliary body;Conjunctiva;Cornea;Drugs;Epidemiology;Imaging;Immunology;Infection;Inflammation;Iris;Macula;Retina;Telemedicine;Treatment lasers;Treatment medical;Vitreous | 2020-06-25 02:00:00+02:00 | 32586933 | FR;SG;JP;GB;US;CH;ET;AU;IN;BE;DE | National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore rupesh_agrawal@ttsh.com.sg c.pavesio@nhs.net ndquan@stanford.edu.;Singapore Eye Research Institute, Singapore, Singapore.;School of Material Science and Engineering, Nanyang Technological University, Singapore, Singapore.;Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.;Department of Ophthalmology, University of Washington, Seattle, USA.;UCLA Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, USA.;Wilmer Eye Institute, Johns Hopkins University School of Medicine, USA, Baltimore.;Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, New South Wales, Japan.;Flinders University College of Medicine and Public Health, Adelaide, Australia.;Department of Ophthalmology, Director Save Sight Institute, The University of Sydney, Sydney, Pennsylvania, Australia.;Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, USA.;Eye Unit, MyungSung Christian Medical Center, MCM General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia.;Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.;Shroff Eye Centre, New Delhi, India.;Department of Ophthalmology,, Sorbonne University, Paris, France.;Byers Eye Institute, Stanford Medical School, Stanford, USA.;Advanced Eye Centre, Postgraduate Institute of Medical Education (PGIMER), Chandigarh, India.;Department of Ophthalmology ZNA Middelheim, Antwerp, Belgium.;Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany. | 1527 | |||
| 10.1016/j.jhin.2020.06.028 | Journal Article | en | Dynamic of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk health care workers and hospital staff. | https://www.ncbi.nlm.nih.gov/pubmed/32593608 | Staff members from Covid-19 highly exposed units were invited to participate in a six month study of SARS-CoV-2 carriage and seroprevalence. The results of Day 1 and Day 15 visits show that 41 SARS-CoV-2 infections were confirmed by RT-PCR and/or serology in 326 participants (overall infection rate=12.6%). Having co-morbidity or symptoms at the time of collection was a risk factor for infection but not working as a physician/nurse. This universal screening in high-risk units irrespective of symptoms allowed asymptomatic and potentially contagious infected workers to be self-isolated during 7 days. | 0195-6701 | 2020-06-28 02:00:00+02:00 | pubmed | Journal of Hospital Infection | Charlotte Martin;Isabel Montesinos;Nicolas Dauby;Christine Gilles;Hafid Dahma;Sigi Van Den Wijngaert;Stéphane De Wit;Marc Delforge;Nathan Clumeck;Olivier Vandenberg | 2020-06-25 02:00:00+02:00 | 32593608 | FR;BE;GB | Department of Infectious Diseases, CHU Saint-Pierre - Université Libre de Bruxelles (ULB), Brussels, Belgium.;LHUB-ULB, Microbiology, Brussels, Belgium.;Department of Infectious Diseases, CHU Saint-Pierre - Université Libre de Bruxelles (ULB), Brussels, Belgium, Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Brussels, Belgium, Environmental Health Research Centre, Public Health School, Université Libre de Bruxelles (ULB), Brussels, Belgium.;Gynecology-Obstetric Department, CHU Saint-Pierre - Université Libre de Bruxelles (ULB), Brussels, Belgium.;LHUB-ULB, Microbiology, Brussels, Belgium, University College London. | 1530 | ||||
| Letter | en | No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France". | https://www.ncbi.nlm.nih.gov/pubmed/32629139 | 2020-07-05 02:00:00+02:00 | pubmed | David Lebeaux;Matthieu Revest | 2020-07-03 02:00:00+02:00 | 32629139 | FR | Service de Microbiologie, Unité Mobile d'Infectiologie, AP-HP, Hôpital Européen Georges Pompidou, Université de Paris, France. 20 rue Leblanc, 75015, PARIS, France. Electronic address: david.lebeaux@aphp.fr.;Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 2 rue Henri Le Guilloux, 35033, Rennes Cedex, France. | 1534 | ||||||||
| 10.1002/lary.28957 | Journal Article | en | Evolution of Olfactory Disorders in COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32617990 | A high frequency and a strong association of olfactory/gustatory impairment with COVID-19 were reported. Its spontaneous evolution remains unknown. The aim of this study was to investigate the spontaneous evolution of olfactory disorders in COVID-19 patients. | 0023-852X,1531-4995 | 2020-07-05 02:00:00+02:00 | pubmed | The Laryngoscope | Victor Gorzkowski;Sibylle Bevilacqua;Alexandre Charmillon;Roger Jankowski;Patrice Gallet;Cécile Rumeau;Duc Trung Nguyen | Olfactory disorders, olfactory dysfunction, COVID-19, olfactory recovery, anosmia | 2020-07-02 02:00:00+02:00 | 32617990 | FR | ENT - Head and Neck Surgery Department, Université de Lorraine, CHRU-Nancy, Nancy, France.;Infectious Disease Department, Université de Lorraine, CHRU-Nancy, Nancy, France.;Université de Lorraine, Inserm, NGERE, Nancy, France.;Université de Lorraine, DevAH, Nancy, France.;Université de Lorraine, Inserm, IADI, Nancy, France. | 1542 | |||
| 10.1093/cid/ciaa677 | Journal Article | en | Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France. | https://www.ncbi.nlm.nih.gov/pubmed/32623470 | In patients with severe COVID-19, data are scarce and conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease outcomes. In patients with severe COVID-19, we assessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart, and liver dysfunctions and the severity of the inflammatory reaction as evaluated by biomarkers kinetics, and their association with disease outcomes. | 1058-4838,1537-6591 | 2020-07-05 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Abderrahim Oussalah;Stanislas Gleye;Isabelle Clerc Urmes;Elodie Laugel;Jonas Callet;Françoise Barbé;Sophie Orlowski;Catherine Malaplate;Isabelle Aimone-Gastin;Beatrice Maatem Caillierez;Marc Merten;Elise Jeannesson;Raphaël Kormann;Jean-Luc Olivier;Rosa-Maria Rodriguez-Guéant;Farès Namour;Sybille Bevilacqua;Marie-Reine Losser;Bruno Levy;Antoine Kimmoun;Sébastien Gibot;Nathalie Thilly;Luc Frimat;Evelyne Schvoerer;Jean-Louis Guéant | SARS-CoV-2;acute kidney injury;angiotensin receptor blocker;angiotensin-converting enzyme inhibitor;severe COVID-19 | 2020-07-05 02:00:00+02:00 | 32623470 | FR | Department of Molecular Medicine, Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, University Hospital of Nancy, Nancy, France.;University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, Nancy, France.;Department of Methodology, Promotion, and Investigation, University Hospital of Nancy, University of Lorraine, Nancy, France.;Department of Virology, University Hospital of Nancy, Nancy, France, Laboratory of Physical Chemistry and Microbiology for the Environment, LCPME UMR 7564 CNRS-UL, Villers-les-Nancy, France.;Department of Nephrology, University Hospital of Nancy, Nancy, France.;Department of Infectious Diseases, University Hospital of Nancy, Nancy, France.;Department of Anesthesiology and Intensive Care Medicine, University Hospital of Nancy, Vandoeuvre-Lès-Nancy, France.;Medical Intensive Care Unit, University Hospital of Nancy, Brabois Hospital, Nancy, France. | 1544 | |||
| 10.1016/j.ejogrb.2020.06.049 | Journal Article | en | Fetal heart rate changes on the cardiotocograph trace secondary to maternal COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32645644 | To determine the cardiotocograph (CTG) changes in women with symptomatic COVID-19 infection. | 0301-2115 | 2020-07-05 02:00:00+02:00 | pubmed | European Journal of Obstetrics & Gynecology and Reproductive Biology | Anna Gracia-Perez-Bonfils;Oscar Martinez-Perez;Elisa Llurba;Edwin Chandraharan | COVID-19;CTG;Cardiotocograph;Cytokine storm;Physiological CTG interpretation;ZigZag pattern | 2020-07-02 02:00:00+02:00 | 32645644 | FR;ES;GB | Hospital General de l'Hospitalet, Barcelona, Spain, Autonomous University of Barcelona, Spain. Electronic address: gracia.anna@gmail.com.;Obs Simulation Unit, Spain, Puerta de Hierro-Majadahonda University Hospital, Universidad Autónoma de Madrid, Spain, Universidad Católica de Murcia, Spain.;Sant Pau University Hospital, Barcelona, Spain.;Global Academy of Medical Education & Training, London, United Kingdom. | 1557 | |||
| 10.1007/s00330-020-07035-w | Journal Article | en | COVID-19 impact assessment on the French radiological centers: a nationwide survey. | https://www.ncbi.nlm.nih.gov/pubmed/32621241 | To determine the impact of the COVID-19 on the CT activities in French radiological centers during the epidemic peak. | 0938-7994,1432-1084 | 2020-07-05 02:00:00+02:00 | pubmed | European Radiology | Guillaume Herpe;Mathieu Naudin;Mathieu Léderlin;Farida Enikeeva;Olivier Boumendil;Lucie Cassagnes;Madeleine Cavet;Kathia Chaumoitre;Philippe Feuerstein;Isabelle Fitton;Violaine Flory;Cornelia Anna Freitag;Jean Yves Gaubert;Jules Gregory;Hubert Nivet;Mickaël Ohana;Isabelle Petit;Nicolas Sans;Mathilde Wagner;Rémy Guillevin;Pierre-Jean Saulnier;Jean-Michel Bartoli;Jean Pierre Tasu;Jean-Paul Beregi | COVID-19;Prospective;Radiology;Surveys and questionnaires;Tomography;X-Ray computed | 2020-07-03 02:00:00+02:00 | 32621241 | FR | University Hospital Centre Poitiers, Radiology, 2 rue de la milétrie, 86000, Poitiers, Vienne, France. guillaume.herpe@chu-poitiers.fr.;Université de Poitiers Laboratoire de Mathématiques et Applications, Dactim Mis Team, 86073, Chasseneuil, Nouvelle-Aquitaine, France. guillaume.herpe@chu-poitiers.fr.;Université de Poitiers Laboratoire de Mathématiques et Applications, Dactim Mis Team, 86073, Chasseneuil, Nouvelle-Aquitaine, France.;University Hospital of Rennes, Radiology, Rennes, Ille-et-Vilaine, France.;TELEDIAG, 69009, Lyon, France.;CHU Clermont-Ferrand, Service de Radiologie B, 63003, Clermont-Ferrand, France.;CTM groupe, 34967, Montpellier, Occitanie, France.;APHM, Radiology, 13015, Marseille, PACA, France.;Groupe Hospitalier de la Region de Mulhouse et Sud Alsace, Radiology, 68051, Mulhouse, Grand Est, France.;European Hospital Group Georges-Pompidou, Radiology, 75908, Paris, Ile-de-France, France.;Centre Hospitalier Universitaire de Nice Hôpital Pasteur, Radiology, 06189, Nice, Alpes Maritimes, France.;CHU Nimes, 30029, Nimes, Gard, France.;CHU Timone, Radiology, 13385, Marseille, BDR, France.;APHP Hopital Beaujon, Paris, France.;Imadis téléradiologie, 69002, Lyon, Rhône, France.;Nouvel Hôpital Civil, Radiology, 67000, Strasbourg, Alsace, France.;CHRU de Nancy, RADIOLOGY, 54500, Nancy, Grand Est, France.;CHU Purpan, Service central d'imagerie médicale, 31059, Toulouse, Haute-Garonne, France.;Sorbonne Université, Radiology, 75013, Paris, Île-de-France, France.;University Hospital Poitiers, Radiology, Poitiers, France.;CHU Poitiers, Clinical Investigation Center CIC1402, 86021, Poitiers, Vienne, France.;La Timone Hospital, Radiology, Marseille, BDR, France.;CHU de Poitiers, Service de Radiologie, Poitiers, France.;University Hospital Center of Nîmes, Radiology, Nîmes, Gard, France. | 1559 | |||
| 10.3389/fimmu.2020.01409 | Journal Article;Review | en | Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. | https://www.ncbi.nlm.nih.gov/pubmed/32714335 | As the world is severely affected by COVID-19 pandemic, the use of chloroquine and hydroxychloroquine in prevention or for the treatment of patients is allowed in multiple countries but remained at the center of much controversy in recent days. This review describes the properties of chloroquine and hydroxychloroquine, and highlights not only their anti-viral effects but also their important immune-modulatory properties and their well-known use in autoimmune diseases, including systemic lupus and arthritis. Chloroquine appears to inhibit in vitro SARS virus' replication and to interfere with SARS-CoV2 receptor (ACE2). Chloroquine and hydroxychloroquine impede lysosomal activity and autophagy, leading to a decrease of antigen processing and presentation. They are also known to interfere with endosomal Toll-like receptors signaling and cytosolic sensors of nucleic acids, which result in a decreased cellular activation and thereby a lower type I interferons and inflammatory cytokine secretion. Given the antiviral and anti-inflammatory properties of chloroquine and hydroxychloroquine, there is a rational to use them against SARS-CoV2 infection. However, the anti-interferon properties of these molecules might be detrimental, and impaired host immune responses against the virus. This duality could explain the discrepancy with the recently published studies on CQ/HCQ treatment efficacy in COVID-19 patients. Moreover, although these treatments could be an interesting potential strategy to limit progression toward uncontrolled inflammation, they do not appear per se sufficiently potent to control the whole inflammatory process in COVID-19, and more targeted and/or potent therapies should be required at least in add-on. | 1664-3224 | 2020-07-05 02:00:00+02:00 | pubmed | Antigen Presentation;Antiviral Agents__therapeutic use;Betacoronavirus__physiology;Coronavirus Infections__drug therapy;Humans;Hydroxychloroquine__therapeutic use;Lysosomes__immunology;Pandemics;Peptidyl-Dipeptidase A__immunology;Pneumonia, Viral__drug therapy;Toll-Like Receptors__immunology;Virus Replication__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Frontiers in Immunology | Vincent Gies;Nassima Bekaddour;Yannick Dieudonné;Aurélien Guffroy;Quentin Frenger;Frédéric Gros;Mathieu Paul Rodero;Jean-Philippe Herbeuval;Anne-Sophie Korganow | COVID-19;RIG-I;SARS-CoV2;STING;TLR;chloroquine;hydroxychloroquine;interferon | 2020-07-02 02:00:00+02:00 | 32714335 | FR | Université de Strasbourg, INSERM UMR - S1109, Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiencies, Strasbourg, France.;Université de Strasbourg, Faculty of Pharmacy, Illkirch, France.;Université de Paris, CNRS UMR-8601, Paris, France.;Team Chemistry & Biology, Modeling & Immunology for Therapy, CBMIT, Paris, France.;Université de Strasbourg, Faculty of Medicine, Strasbourg, France.;Université de Strasbourg, Faculty of Life Sciences, Strasbourg, France. | 1561 | ||
| Letter | en | Shortage of sedatives and neuromuscular blockers during COVID-19 pandemic: The result of an overstocking procedure in French hospitals? | https://www.ncbi.nlm.nih.gov/pubmed/32654910 | 2020-07-05 02:00:00+02:00 | pubmed | Déborah Montmeat;Claudine Gard;Mathieu Raux;Jean-Michel Constantin;Patrick Tilleul | 2020-06-30 02:00:00+02:00 | 32654910 | FR | DMU ESPRIT, pharmacy, Pitié-Salpêtrière hospital, AP-HP, Paris, France.;Sorbonne University, GRC 29, AP-HP, DMU DREAM, Department of Anaesthesiology and Critical Care, Pitié-Salpêtrière Hospital, Paris, France.;Sorbonne University, GRC 29, AP-HP, DMU DREAM, Department of Anaesthesiology and Critical Care, Pitié-Salpêtrière Hospital, Paris, France. Electronic address: jean-michel.constantin@aphp.fr.;DMU ESPRIT, pharmacy, faculté de pharmacie de Paris, Pitié-Salpêtrière hospital, AP-HP, Paris, France. | 1565 | ||||||||
| Letter | en | Letter to the Editor: COVID-19-Related Liver Injury and Clinical Outcomes: Does It Really Exist? | https://www.ncbi.nlm.nih.gov/pubmed/32619043 | We read with interest the study by Lei and colleagues on the association between markers of liver injury and mortality in coronavirus disease 2019 (COVID-19) in China. The authors have painstakingly collated data from a large number of COVID-19 patients from multiple centers across Wuhan. They found that an increase in aspartate aminotransferase (AST) and its dynamicity correlated with COVID-19-related liver injury and patient outcomes. They concluded that the dynamic patterns of liver injury indicators, represented by AST, correspond with COVID-19-related liver injury. | 2020-07-05 02:00:00+02:00 | pubmed | Cyriac Abby Philips;Rizwan Ahamed;Philip Augustine | 2020-07-03 02:00:00+02:00 | 32619043 | FR;IN | The Liver Unit and Monarch Liver Lab, Cochin Gastroenterology Group, Ernakulam Medical Center Hospital, Kochi, Kerala, India.;Gastroenterology and Advanced GI Endoscopy, Cochin Gastroenterology Group, Ernakulam Medical Center Hospital, Kochi, Kerala, India. | 1574 | |||||||
| 10.1016/j.chaos.2020.110077 | Journal Article | en | Spreading of infections on random graphs: A percolation-type model for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32834619 | We introduce an epidemic spreading model on a network using concepts from percolation theory. The model is motivated by discussing the standard SIR model, with extensions to describe effects of lockdowns within a population. The underlying ideas and behaviour of the lattice model, implemented using the same lockdown scheme as for the SIR scheme, are discussed in detail and illustrated with extensive simulations. A comparison between both models is presented for the case of COVID-19 data from the USA. Both fits to the empirical data are very good, but some differences emerge between the two approaches which indicate the usefulness of having an alternative approach to the widespread SIR model. | 0960-0779 | 2020-07-05 02:00:00+02:00 | pubmed | Chaos, Solitons & Fractals | Fabrizio Croccolo;H Eduardo Roman | Critical percolation;Monte Carlo simulations;Random graphs;SIR Model | 2020-07-03 02:00:00+02:00 | 32834619 | FR;IT | Universite de Pau et des Pays de l'Adour, E2S UPPA, CNRS, TOTAL, LFCR UMR5150, Anglet, France.;Department of Physics, University of Milano-Bicocca, Piazza delle Scienze 3, Milan 20126, Italy. | 1578 | |||
| 10.1016/j.accpm.2020.05.016 | Journal Article | en | Ultrasound findings in patients with COVID-19 pneumonia in early and late stages: Two case-reports. | https://www.ncbi.nlm.nih.gov/pubmed/32654908 | 2352-5568 | 2020-07-05 02:00:00+02:00 | pubmed | Anaesthesia Critical Care & Pain Medicine | Laurent Zieleskiewicz;Gary Duclos;Ophélie Dransart-Rayé;Nicolas Nowobilski;Belaid Bouhemad | 2020-07-03 02:00:00+02:00 | 32654908 | FR | Department of Anaesthesia and Intensive Care Medicine, University Hospital of Marseille, Aix-Marseille University, Marseille, France, C2VN Inra Inserm, Faculty of medicine, Aix- Marseille University, Marseille, France.;Department of Anaesthesia and Intensive Care Medicine, University Hospital of Marseille, Aix-Marseille University, Marseille, France.;Department of Anaesthesiology and Intensive Care, University Hospital of Dijon, Dijon, France.;Department of Anaesthesiology and Intensive Care, University Hospital of Dijon, Dijon, France, Lipness Team, Inserm Research Centre LNC-UMR1231 and LabEx LipSTIC, Université Bourgogne Franche-Comté, Dijon, France. Electronic address: belaid_bouhemad@hotmail.com. | 1584 | |||||
| 10.1016/j.biocon.2020.108693 | Journal Article;Review | en | The Fox and the Crow. A need to update pest control strategies. | https://www.ncbi.nlm.nih.gov/pubmed/32834058 | The recent discovery that cats and mustelids can be infected by SARS-CoV-2 may raise the question of monitoring domestic, feral and wild populations of such animals, as an adjunct to the elimination of COVID-19 in humans. Emergency solutions might consider large scale control of these animals in the wild. However, looking at science recently published on native vertebrate pest control reveals first that usual controls do not succeed in reducing animal numbers and associated damages, second that controlling can be counter-productive in increasing the infectious risks for humans and livestock. The examples of red fox and corvids are detailed in a European context, illustrating the urgent need for an ethical evaluation of ecological and economic costs and benefits of pest control strategies. A complete scientific evaluation process must be implemented and up-dated regularly, to be organized in four major steps, once the aim of the control strategy has been defined: (1) evaluating damages/risks caused by the animals, to be balanced with the ecosystem services they may provide, also in terms of economic costs; (2) unravelling spatial and temporal population dynamics of target animals to identify, if any, optimal control scenarios - which could be done within an adaptive management framework; (3) estimating the economic costs of implementing those optimal control scenarios, to be compared to the economic costs of damages/diseases; (4) finally evaluating how the control strategy reached its aims. A modern fable of the Fox and the Crow should deliver a timely moral for an ethical, ecological and economical appraisal of pest control strategies in Europe. | 0006-3207 | 2020-07-05 02:00:00+02:00 | pubmed | Biological Conservation | Frédéric Jiguet | 2020-07-03 02:00:00+02:00 | 32834058 | FR | UMR7204 Centre d'Ecologie et des Sciences de la Conservation, MNHN-CNRS-SU, CP135, 43 Rue Buffon, 75005 Paris, France. | 1586 | ||||
| 10.1017/s0033291720002500 | Journal Article | en | COVID-19 lockdown and mental health: why we must look into oncology units. | https://www.ncbi.nlm.nih.gov/pubmed/32616099 | 0033-2917,1469-8978 | 2020-07-05 02:00:00+02:00 | pubmed | Psychological Medicine | Carolyne Croizier;Jean-Baptiste Bouillon-Minois;Jacques-Olivier Bay;Frédéric Dutheil | 2020-07-03 02:00:00+02:00 | 32616099 | FR | Service thérapie cellulaire et hématologie clinique, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.;CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, Emergency Medicine, Clermont Auvergne University, Clermont-Ferrand, France.;CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, Occupational and Environmental Medicine, WittyFit, Clermont Auvergne University, Clermont-Ferrand, Auvergne-Rhône-Alpes, France. | 1587 | |||||
| Letter | en | COVID-19 on cruise ships: preventive quarantine or abandonment of patients? | https://www.ncbi.nlm.nih.gov/pubmed/32604459 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__prevention & control;Humans;Naval Medicine__methods;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Quarantine__ethics;Ships;COVID-19;severe acute respiratory syndrome coronavirus 2 | Richard Pougnet;Laurence Pougnet;Jean-Dominique Dewitte;David Lucas;Brice Loddé | COVID-19;pandemics;quarantine | 2020-07-01 02:00:00+02:00 | 32604459 | FR | French Society for Maritime Medicine, Faculty of Medicine and Health Sciences, University of Western Brittany, Brest, France. richard.pougnet@live.fr.;Centre for Professional and Environmental Pathologies, Morvan Teaching Hospital (CHRU), Brest, France. richard.pougnet@live.fr.;Laboratory for Studies and Research in Sociology (LABERS), EA 3149, University of Western Brittany, Brest, France. richard.pougnet@live.fr.;French Society for Maritime Medicine, Faculty of Medicine and Health Sciences, University of Western Brittany, Brest, France.;Clermont-Tonnerre Military Teaching Hospital, rue du Colonel Fontferrier, 29200 Brest, France.;Centre for Professional and Environmental Pathologies, Morvan Teaching Hospital (CHRU), Brest, France.;Laboratory for Studies and Research in Sociology (LABERS), EA 3149, University of Western Brittany, Brest, France. | 1592 | ||||||
| Letter | en | Investigation of a family outbreak of COVID-19 using systematic rapid diagnostic tests raises new questions about transmission. | https://www.ncbi.nlm.nih.gov/pubmed/32610107 | 2020-07-05 02:00:00+02:00 | pubmed | Thierry Prazuck;Susanna Giaché;Camelia Gubavu;Mathilda Colin;Vincent Rzepecki;Aymeric Sève;Gilles Pialoux;Laurent Hocqueloux | Children;Couples;Covid-19;Family cluster;Rapid diagnostic test;Sars-cov-2;Transmission | 2020-06-29 02:00:00+02:00 | 32610107 | FR | Department of Infectious Diseases, Centre Hospitalier Régional d'Orléans, Orléans, France.;Department of Infectious Diseases, Hôpital Tenon, Sorbonne University, Paris, France.;Department of Infectious Diseases, Centre Hospitalier Régional d'Orléans, Orléans, France. Electronic address: laurent.hocqueloux@chr-orleans.fr. | 1604 | |||||||
| 10.1111/jth.14980 | Journal Article | en | Lupus anticoagulant is frequent in patients with Covid-19: Response to Reply. | https://www.ncbi.nlm.nih.gov/pubmed/32608109 | We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid-19 patients (1). Different authors had confirmed these results (2). Connell and colleagues had discussed, in the Journal, technical points concerning LAC as well as anti-phospholipids (aPL) auto-antibodies detection (3). | 1538-7933,1538-7836 | 2020-07-05 02:00:00+02:00 | pubmed | Journal of Thrombosis and Haemostasis | Inès Harzallah;Agathe Debliquis;Bernard Drénou | 2020-06-30 02:00:00+02:00 | 32608109 | FR | Groupe Hospitalier de la région Mulhouse Sud Alsace, Laboratoire d'Hématologie, 20 rue Dr Laënnec, 68070, Mulhouse, cedex, France. | 1615 | ||||
| 10.1016/j.ejvs.2020.07.003 | Journal Article | en | Acute Aortic Thrombosis Revealing a COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32800476 | 1078-5884 | 2020-07-12 02:00:00+02:00 | pubmed | European Journal of Vascular and Endovascular Surgery | Raphaël Coscas;Marc Coggia | 2020-07-07 02:00:00+02:00 | 32800476 | FR | Department of Vascular Surgery, Ambroise Paré University Hospital, Boulogne-Billancourt, France, UMR 1018, Inserm-Paris11 - CESP, Versailles Saint-Quentin-en-Yvelines University, Paris-Saclay University, Paul Brousse Hospital, Villejuif, France. Electronic address: rcoscas@gmail.com.;Department of Vascular Surgery, Ambroise Paré University Hospital, Boulogne-Billancourt, France. | 1624 | |||||
| 10.1684/abc.2020.1576 | Journal Article | en | Interactive pedagogical tools could be helpful for medical education continuity during COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32627731 | Training and education are essential for medical students. During the COVID-19 outbreak, numerous schools and universities have had to close. Ensuring pedagogical continuity requires alternatives to the traditional classroom, especially in medical education. Usual distance learning tools such as videos and downloadable handouts are not sufficient to promote efficient teaching. Distance learning requires self-motivation and does not give you direct access to your instructor. Some students fear the loss of human contact with an instructor - like asking questions during and after class - which promotes learning, understanding and communication. Moreover, classical distance learning methods do not offer immediate feedback that can help students in their understanding of the lecture. In this context, interactive pedagogic tools (IPT) could be useful for medical education continuity and for maintaining human contact necessary in pedagogy. We briefly evaluated interactive pedagogic tool compared to traditionnal distancial tools on medical students. This study showed the importance to have direct contact with a teacher and feedback during a lecture and to not exclusively perform distance learning without direct interaction and feedback. Hence, in the present context, we encourage teacher to use this type of tools to maintain direct interaction with students - which is essential in pedagogy - and ensure a qualitative pedagogical continuity. | 0003-3898 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Laboratory Services__organization & administration;Computer-Assisted Instruction__methods;Coronavirus Infections__epidemiology;Disease Outbreaks;Education, Distance__methods;Education, Medical, Continuing__methods;Humans;Internet__organization & administration;Learning;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Problem-Based Learning__methods;Simulation Training__methods;Software;Students, Medical__psychology;Video Recording__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Annales de Biologie Clinique | Guillaume Grzych;Susanna Schraen-Maschke | active distance learning;audience response system;medical education continuity;online interactive pedagogy tools | 2020-07-07 02:00:00+02:00 | 32627731 | FR | University of Lille, Faculty of pharmaceutical and biological sciences, Lille, France, CHU Lille, Laboratory of biochemistry, biology and pathology center, Lille, France, Inserm, UMR-1011-European genomic institute for diabetes, Institut Pasteur de Lille, Université de Lille, France.;CHU Lille, Laboratory of biochemistry, biology and pathology center, Lille, France, University of Lille, Faculty of medicine, Lille, France, Inserm, UMR 1172, JPArc, Faculté de médecine, Université de Lille, France. | 1627 | ||
| 10.1136/bcr-2020-236815 | Case Reports;Journal Article | en | Acute immune thrombocytopaenic purpura in a patient with COVID-19 and decompensated cirrhosis. | https://www.ncbi.nlm.nih.gov/pubmed/32641442 | We report on a patient with coronavirus disease 2019 (COVID-19) and decompensated cirrhosis who experienced a favourable outcome of severe immune thrombocytopaenic purpura (ITP) after administration of intravenous immunoglobulin and high-dose dexamethasone. The present case suggests that it is reasonable to evoke ITP in case of profound thrombocytopaenia in a patient with COVID-19. | 1757-790X | 2020-07-12 02:00:00+02:00 | pubmed | Adult;Betacoronavirus__isolation & purification;Comorbidity;Coronavirus Infections__diagnosis;Glucocorticoids__administration & dosage;Humans;Hypoxia__diagnosis;Immunoglobulins, Intravenous__administration & dosage;Immunologic Factors__administration & dosage;Liver Cirrhosis, Alcoholic__diagnosis;Male;Obesity__diagnosis;Oxygen Inhalation Therapy__methods;Pandemics;Pneumonia, Viral__diagnosis;Purpura, Thrombocytopenic, Idiopathic__diagnosis;Radiography, Thoracic__methods;Tomography, X-Ray Computed__methods;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | BMJ Case Reports | Florent Artru;Lorenzo Alberio;Darius Moradpour;Grégoire Stalder | haematology (incl blood transfusion);infectious diseases | 2020-07-07 02:00:00+02:00 | 32641442 | FR;CH | Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland gregoire.stalder@chuv.ch. | 1628 | ||
| H2020 Research Infrastructures;H2020 European Institute of Innovation and Technology;Agence Nationale de la Recherche;H2020 European Institute of Innovation and Technology;Institut National de la Santé et de la Recherche Médicale | 10.3390/v12070735 | Journal Article;Research Support, Non-U.S. Gov't | en | Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics? | https://www.ncbi.nlm.nih.gov/pubmed/32646015 | Standard precautions to minimize the risk of SARS-CoV-2 transmission implies that infected cell cultures and clinical specimens may undergo some sort of inactivation to reduce or abolish infectivity. We evaluated three heat inactivation protocols (56 °C-30 min, 60 °C-60 min and 92 °C-15 min) on SARS-CoV-2 using (i) infected cell culture supernatant, (ii) virus-spiked human sera (iii) and nasopharyngeal samples according to the recommendations of the European norm NF EN 14476-A2. Regardless of the protocol and the type of samples, a 4 Log10 TCID50 reduction was observed. However, samples containing viral loads > 6 Log10 TCID50 were still infectious after 56 °C-30 min and 60 °C-60 min, although infectivity was < 10 TCID50. The protocols 56 °C-30 min and 60 °C-60 min had little influence on the RNA copies detection, whereas 92 °C-15 min drastically reduced the limit of detection, which suggests that this protocol should be avoided for inactivation ahead of molecular diagnostics. Lastly, 56 °C-30 min treatment of serum specimens had a negligible influence on the results of IgG detection using a commercial ELISA test, whereas a drastic decrease in neutralizing titers was observed. | 1999-4915 | 2020-07-12 02:00:00+02:00 | pubmed | Antibodies, Neutralizing__immunology;Betacoronavirus__immunology;Containment of Biohazards__methods;Coronavirus Infections__diagnosis;Enzyme-Linked Immunosorbent Assay;Hot Temperature;Humans;Neutralization Tests;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Serologic Tests__methods;Virus Inactivation;COVID-19;severe acute respiratory syndrome coronavirus 2 | Viruses | Boris Pastorino;Franck Touret;Magali Gilles;Xavier de Lamballerie;Remi N Charrel | COVID-19;ELISA;SARS-CoV-2;coronavirus;heat inactivation;neutralization;serology;virus neutralization test | 2020-07-07 02:00:00+02:00 | 32646015 | FR | [{"country": "International", "agency": "H2020 Research Infrastructures", "grantid": "871029"}, {"country": "International", "agency": "H2020 European Institute of Innovation and Technology", "grantid": "101003544"}, {"country": "International", "agency": "Agence Nationale de la Recherche", "grantid": "PREPMedVet"}, {"country": "International", "agency": "H2020 European Institute of Innovation and Technology", "grantid": "IMI2 VHFMODRAD 823666"}, {"country": "International", "agency": "Institut National de la Santé et de la Recherche Médicale", "grantid": "REACTing"}] | Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Aix-Marseille University, 13005 Marseille, France. | 1631 |
| 10.1111/jdv.16593 | Journal Article | en | Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. | https://www.ncbi.nlm.nih.gov/pubmed/32416629 | 0926-9959,1468-3083 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Humans;Lymphoma, T-Cell, Cutaneous__complications;Pandemics;Pneumonia, Viral__complications;Practice Guidelines as Topic;Skin Neoplasms__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of the European Academy of Dermatology and Venereology | E Papadavid;J Scaribrick;P Ortiz Romero;P Guaglino;M Vermeer;R Knobler;R Stadler;M Bagot | 2020-07-07 02:00:00+02:00 | 32416629 | FR;GR;GB;US;IT;NL;ES;DE;AT | 2nd Dermatology Department, National and Kapodistrian University of Athens, Athens, Greece.;University Hospital Birmingham, Birmingham, UK.;Dermatology Department, University 12 of Octubre, Madrid, Spain.;Department of Dermatology, University of Turin, Turin, Italy.;University of Leiden, Leiden, Netherlands.;Department of Dermatology, Medical University of Vienna, Vienna, Austria.;Department of Dermatology, Venerology, Allergology und Phlebology, Johannes Wesling Klinikum Minden, Minden, Germany.;University of Paris, Hospital Saint-Louis, Paris, France. | 1632 | ||||
| Letter;Research Support, Non-U.S. Gov't;Comment | en | Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32639219 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Estrone__analogs & derivatives;Fibrinolysin;Humans;Leukocyte Elastase;Pandemics;Pneumonia, Viral;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Alain R Thierry | COVID;elastase;neutrophil extracellular traps;plasmin;treatment | 2020-07-09 02:00:00+02:00 | 32639219 | FR;US | Research Institute of Cancerology of Montpellier, National Institute of Health and Medical Research, INSERM U1194, IRCM, ICM, Montpellier University, Montpellier, France. | 1634 | ||||||
| 10.1016/s0140-6736(20)31528-2 | Journal Article;Retraction of Publication | en | Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32653079 | 0140-6736 | 2020-07-12 02:00:00+02:00 | pubmed | The Lancet | Christian Funck-Brentano;Lee S Nguyen;Joe-Elie Salem | 2020-07-09 02:00:00+02:00 | 32653079 | FR | AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France, INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France. Electronic address: christian.funck-brentano@aphp.fr.;AP-HP, Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Pharmacology and Clinical Investigation Centre, Paris 75013, France, INSERM, CIC-1901 and UMR-S 1166, Sorbonne Université, Faculty of Medicine, Paris, France. | 1635 | |||||
| Letter | en | Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? | https://www.ncbi.nlm.nih.gov/pubmed/32663703 | 2020-07-12 02:00:00+02:00 | pubmed | Virginie Siguret;Sebastian Voicu;Marie Neuwirth;Maxime Delrue;Etienne Gayat;Alain Stépanian;Bruno Mégarbane | Anti-β2-glycoprotein-I;Anticardiolipin;COVID-19;Lupus anticoagulant;Thrombosis | 2020-07-08 02:00:00+02:00 | 32663703 | FR | Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France, INSERM UMRS 1140, Paris University, Paris, France. Electronic address: virginie.siguret@aphp.fr.;Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris University, Paris, France, INSERM UMRS 1144, Paris University, Paris, France.;Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France, INSERM UMRS 1140, Paris University, Paris, France.;Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France, EA 3518, Paris University, Paris, France.;Department of Anesthesiology and Critical Care, Lariboisière Hospital, Paris University, Paris, France. | 1647 | |||||||
| 10.1111/bju.15164 | Journal Article | en | Urology surgical activity and COVID-19: risk assessment at the epidemic peak: a Parisian multicentre experience. | https://www.ncbi.nlm.nih.gov/pubmed/32640121 | 1464-4096 | 2020-07-12 02:00:00+02:00 | pubmed | BJU International | Alexandre Ingels;Steeven Bibas;Maher Abdessater;Thomas Tabourin;Morgan Roupret;Emmanuel Chartier-Kastler;Gwendolyn Barker;Nouha Tobbal;Steeve Doizi;Olivier Cussenot;Doriane Prost;Francois Desgrandchamps;Idir Ouzaid;Paul Rollin;Jean-Francois Hermieu;Francois Audenet;Mickael Userovici;Arnaud Mejean;Julien Anract;Sabine Roux;Michael Peyromaure;Nicolas Couteau;Cédric Lebacle;Jacques Irani;Dimitri Vordos;René Yiou;Andras Hoznek;Cecile M Champy;Jose Batista Da Costa;Alexandre de la Taille | 2020-07-08 02:00:00+02:00 | 32640121 | FR | Department of Urology, UPEC - Henri Mondor Hospital, AP-HP, Creteil, France.;Department of Urology, AP-HP, Pitié-Salpétrière Hospital, Sorbonne Université, Paris.;Department of Urology, AP-HP, Tenon Hospital, Sorbonne Université, Paris, France.;Department of Urology, AP-HP, Saint-Louis Hospital, Paris, France.;Department of Urology, AP-HP, Bichat Hospital, Paris, France.;Department of Urology, AP-HP, HEGP Hospital, Paris, France.;Department of Urology, AP-HP, Cochin Hospital, Paris, France.;Department of Urology, AP-HP, Kremlin-Bicêtre Hospital, Le Kremlin-Bicêtre, France. | 1648 | |||||
| 10.1371/journal.pone.0235597 | Journal Article | en | Exploring the future of land use and food security: A new set of global scenarios. | https://www.ncbi.nlm.nih.gov/pubmed/32639991 | Facing a growing and more affluent world population, changing climate and finite natural resources, world food systems will have to change in the future. The aim of the Agrimonde-Terra foresight study was to build global scenarios linking land use and food security, with special attention paid to overlooked aspects such as nutrition and health, in order to help explore the possible future of the global food system. In this article, we seek to highlight how the resulting set of scenarios contributes to the debate on land use and food security and enlarges the range of possible futures for the global food system. We highlight four main contributions. Combining a scenario building method based on morphological analysis and quantitative simulations with a tractable and simple biomass balance model, the proposed approach improves transparency and coherence between scenario narratives and quantitative assessment. Agrimonde-Terra's scenarios comprise a wide range of alternative diets, with contrasting underlying nutritional and health issues, which accompany contrasting urbanization and rural transformation processes, both dimensions that are lacking in other sets of global scenarios. Agrimonde-Terra's scenarios share some similarities with existing sets of global scenarios, notably the SSPs, but are usually less optimistic regarding agricultural land expansion up to 2050. Results suggest that changing global diets toward healthier patterns could also help to limit the expansion in agricultural land area. Agrimonde-Terra's scenarios enlarge the scope of possible futures by proposing two pathways that are uncommon in other sets of global scenarios. The first proposes to explore possible reconnection of the food industry and regional production within supranational regional blocs. The second means that we should consider that a 'perfect storm', induced by climate change and an ecological crisis combined with social and economic crises, is still possible. Both scenarios should be part of the debate as the current context of the COVID-19 pandemic shows. | 1932-6203 | 2020-07-12 02:00:00+02:00 | pubmed | Agriculture;Computer Simulation;Conservation of Natural Resources;Coronavirus Infections__economics;Diet;Food Quality;Food Supply;Global Health;Humans;Pandemics__economics;Pneumonia, Viral__economics;Urbanization;COVID-19 | PLOS ONE | Olivier Mora;Chantal Le Mouël;Marie de Lattre-Gasquet;Catherine Donnars;Patrice Dumas;Olivier Réchauchère;Thierry Brunelle;Stéphane Manceron;Elodie Marajo-Petitzon;Clémence Moreau;Marc Barzman;Agneta Forslund;Pauline Marty | 2020-07-08 02:00:00+02:00 | 32639991 | FR | DEPE, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), Paris, France.;Agrocampus-Ouest, SMART-LERECO, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), Rennes, France.;Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), ART-DEV, Montpellier, France.;ART-DEV, Université de Montpellier, CIRAD, CNRS, Université de Montpellier 3, Montpellier, France.;Université de Perpignan Via Domitia, Montpellier, France.;Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), CIRED, Montpellier, France.;Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), CIRED, Nogent-sur-Marne, France.;Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), Paris, France.;Département EcoSocio, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), Rennes, France. | 1654 | |||
| 10.1111/tesg.12451 | Journal Article | en | Discourse and Strategic Use of the Military in France and Europe in the COVID-19 Crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32834143 | In March 2020, the French President called to war against the COVID-19 which was followed by the launch of a military operation called Operation Resilience. This use of martial rhetoric initiated an effective mobilisation consisting in logistical assistance to the health sector. While armies are increasingly used to deal with environmental disasters, aside from their traditional role, this paper postulates that the geography of the French and international military engagement can be used to analyse both the institutional strategy of crisis management and the message governments send to their population. Military involvement differs in terms of missions given and of the amount of troops mobilised. It first questions the use of the military in the name of national resilience in the political discourse and the way it displays a symbolic message to the population, before analysing the role of armies in the crisis through the spatiality of their interventions. | 0040-747X,1467-9663 | 2020-07-12 02:00:00+02:00 | pubmed | Tijdschrift voor economische en sociale geografie | Florian Opillard;Angélique Palle;Léa Michelis | COVID‐19;Europe;France;military;resilience | 2020-07-09 02:00:00+02:00 | 32834143 | FR | Institute for Strategic Research (IRSEM, Paris) / IHEAL-CREDA Paris France.;Institute for Strategic Research (IRSEM, Paris) / UMR Prodig Paris France.;Rennes 1 University / IRSEM Paris France. | 1655 | |||
| 10.1016/j.banm.2020.07.004 | Journal Article | en | COVID-19 epidemic phases: Criteria, challenges and issues for the future. | https://www.ncbi.nlm.nih.gov/pubmed/32836261 | 0001-4079 | 2020-07-12 02:00:00+02:00 | pubmed | Bulletin de l'Académie Nationale de Médecine | A Migus;P Netter;C Boitard;B Clement;J-F Allilaire;R Ardaillou;P Berche;B Charpentier;P Debre;F Galibert;B Nordlinger | 2020-07-09 02:00:00+02:00 | 32836261 | FR | Académie nationale de médecine, 16, rue Bonaparte, 75006 Paris, France. | 1660 | |||||
| 10.1016/j.frl.2020.101690 | Journal Article | en | COVID-19 and the march 2020 stock market crash. Evidence from S&P1500. | https://www.ncbi.nlm.nih.gov/pubmed/32837377 | This paper investigates the US stock market performance during the crash of March 2020 triggered by COVID-19. We find that natural gas, food, healthcare, and software stocks earn high positive returns, whereas equity values in petroleum, real estate, entertainment, and hospitality sectors fall dramatically. Moreover, loser stocks exhibit extreme asymmetric volatility that correlates negatively with stock returns. Firms react in a variety of different ways to the COVID-19 revenue shock. The analysis of the 8K and DEF14A filings of poorest performers reveals departures of senior executives, remuneration cuts, and (most surprisingly) newly approved cash bonuses and salary increases. | 1544-6123 | 2020-07-12 02:00:00+02:00 | pubmed | Finance Research Letters | Mieszko Mazur;Man Dang;Miguel Vega | 2020-07-09 02:00:00+02:00 | 32837377 | FR;VN | IESEG School of Management (LEM-CNRS 9221), Parvis de la Défense, 92800 Puteaux, France.;The University of Da Nang, University of Economics, 71 Ngu Hanh Son Street, Danang City 550000, Vietnam. | 1662 | ||||
| 10.1259/bjr.20200515 | Journal Article | en | Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32584604 | During the first two decades of the 21st century, there have been three coronavirus infection outbreaks raising global health concerns by severe acute respiratory syndrome coronavirus (SARS-CoV), the Middle East respiratory syndrome coronavirus (MERS-CoV), and the SARS-CoV-2. Although the reported imaging findings of coronavirus infection are variable and non-specific, the most common initial chest radiograph (CXR) and CT findings are ground-glass opacities and consolidation with peripheral predominance and eventually spread to involve both lungs as the disease progresses. These findings can be explained by the immune pathogenesis of coronavirus infection causing diffuse alveolar damage. Although it is insensitive in mild or early coronavirus infection, the CXR remains as the first-line and the most commonly used imaging modality. That is because it is rapid and easily accessible and helpful for monitoring patient progress during treatment. CT is more sensitive to detect early parenchymal lung abnormalities and disease progression, and can provide an alternative diagnosis. In this pictorial review, various coronavirus infection cases are presented to provide imaging spectrums of coronavirus infection and present differences in imaging among them or from other viral infections, and to discuss the role of imaging in viral infection outbreaks. | 0007-1285,1748-880X | 2020-07-12 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus;Coronavirus Infections__diagnostic imaging;Diagnosis, Differential;Female;Humans;Male;Middle Aged;Middle East Respiratory Syndrome Coronavirus;Pandemics;Pneumonia, Viral__diagnostic imaging;Radiography;SARS Virus;Severe Acute Respiratory Syndrome__diagnostic imaging;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | The British Journal of Radiology | Tomas Franquet;Yeon Joo Jeong;Hiu Yin Sonia Lam;Ho Yuen Frank Wong;Yeun-Chung Chang;Myung Jin Chung;Kyung Soo Lee | 2020-07-06 02:00:00+02:00 | 32584604 | FR;CN;GB;TW;HK;ES;KR | Department of Radiology, Hospital de Sant Pau. Universidad Autónoma de Barcelona, Barcelona, Spain.;Department of Radiology and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.;Department of Radiology, Queen Mary Hospital, Hong Kong, China.;Department of Medical Imaging, National Taiwan University Hospital and Department of Radiology, National Taiwan University College of Medicine, Taipei, Taiwan.;Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine (SKKU-SOM), Seoul, Korea. | 1663 | |||
| 10.1002/hpm.3015 | Journal Article | en | Principalism in public health decision making in the context of the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32648280 | The COVID-19 pandemic lead scientists and governmental authorities to issue clinical and public health recommendations based on progressively emerging evidence and expert opinions and many of these fast-tracked to peer-reviewed publications. Concerns were raised on scientific quality and generalizability of this emerging evidence. | 0749-6753,1099-1751 | 2020-07-12 02:00:00+02:00 | pubmed | The International Journal of Health Planning and Management | Paulo Ferrinho;Mohsin Sidat;Gisela Leiras;Fernando Passos Cupertino de Barros;Horácio Arruda | COVID-19;principalism;public health decision making | 2020-07-10 02:00:00+02:00 | 32648280 | FR;CA;PT;MZ;BR | Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal.;Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique.;European Network of Medical Residents in Public Health (EuroNet MRPH), Paris, France.;Conselho Nacional dos Secretários de Saude-CONASS, Faculdade de Medicina da Universidade Federal de Goiás, Núcleo de Estudos em Saúde Pública da Universidade de Brasília, Brasilia, Brazil.;Directeur national de santé publique et sous-ministre adjoint, Ministère de la Santé et des Services sociaux, Quebec, Canada. | 1671 | |||
| 10.1038/s41433-020-1080-0 | Journal Article | en | Transforming ophthalmic education into virtual learning during COVID-19 pandemic: a global perspective. | https://www.ncbi.nlm.nih.gov/pubmed/32651545 | The coronavirus disease 2019 (COVID-19) pandemic has imposed measures of social distancing and barriers in delivery of "in person" education. Institutions, involved in training the next generation of ophthalmologists, are using alternative teaching methods to maintain the standard of education. | 0950-222X,1476-5454 | 2020-07-12 02:00:00+02:00 | pubmed | Eye | Irini Chatziralli;Camila V Ventura;Sara Touhami;Rhianon Reynolds;Marco Nassisi;Tamir Weinberg;Kaivon Pakzad-Vaezi;Denis Anaya;Mushawiahti Mustapha;Adam Plant;Miner Yuan;Anat Loewenstein | 2020-07-10 02:00:00+02:00 | 32651545 | FR;IL;MY;CA;CO;CN;GR;GB;US;BR;IT;AU | 2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece. eirchat@yahoo.gr.;Department of Ophthalmology, Altino Ventura Foundation, Recife, Brazil.;Department of Ophthalmology, HOPE Eye Hospital, Recife, Brazil.;Department of Ophthalmology, Reference Center in Rare diseases, DHU Sight Restore, Hôpital Pitié Salpêtrière, Sorbonne Université, Paris, France.;Department of Ophthalmology, Aneurin Bevan University Health Board, Wales, UK.;Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.;Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France.;Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel.;Hadassah School of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.;Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.;Department of Retina and Vitreous, Clínica de Oftalmología de Cali, Cali, Colombia.;Department of Ophthalmology, National University of Malaysia, Kuala Lumpur, Malaysia.;Westmead and Central (Save Sight Institute) Clinical Schools, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, NSW, Australia.;State Key Laboratory of Ophthalmology, Retina Division, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.;Division of Ophthalmology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.;Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. | 1678 | ||||
| Letter;Comment | en | Delayed acute bronchiolitis in infants hospitalized for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32779885 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus;Bronchiolitis;Child;Coronavirus Infections;Humans;Infant;Internationality;Pandemics;Pneumonia, Viral;Respiratory Syncytial Virus Infections;COVID-19;severe acute respiratory syndrome coronavirus 2 | Emilie Grimaud;Marie Challiol;Camille Guilbaud;Céline Delestrain;Fouad Madhi;Julien Ngo;Ralph Epaud;Elodie Nattes | Covid‐19;bronchiolitis;neurologic symptoms | 2020-07-10 02:00:00+02:00 | 32779885 | FR | Department of general pediatrics, Centre Hospitalier Intercommunal de Créteil, Créteil, France.;INSERM, IMRB, Univ Paris Est Creteil, Team GEIC2O, Creteil, France.;Centre of Rare Lung Diseasees (RESPIRARE®), Créteil, France. | 1679 | ||||||
| 10.1590/0034-7167-2020-0247 | Journal Article | po | In defense of the Unified Health System in the context of SARS-CoV-2 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32667577 | To discuss the political and structural conditions for establishing the Unified Health System (UHS - Sistema Único de Saúde, SUS) in coping with the SARS-CoV-2 pandemic. | 1984-0446,0034-7167 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Brazil;Coronavirus Infections__diagnosis;Humans;Organizational Objectives;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Societies, Medical__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | Revista Brasileira de Enfermagem | Janieiry Lima de Araújo;Kalyane Kelly Duarte de Oliveira;Rodrigo Jácob Moreira de Freitas | 2020-07-10 02:00:00+02:00 | 32667577 | FR;BR | Universidade do Estado do Rio Grande do Norte, Pau dos Ferros, Rio Grande do Norte, Brazil. | 1684 | |||
| 10.1007/s00428-020-02886-6 | Journal Article;Review | en | Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. | https://www.ncbi.nlm.nih.gov/pubmed/32642842 | Since its initial recognition in December 2019, Coronavirus disease 19 (COVID-19) has quickly spread to a pandemic infectious disease. The causative agent has been recognized as a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily affecting the respiratory tract. To date, no vaccines are available nor any specific treatment. To limit the number of infections, strict directives have been issued by governments that have been translated into equally rigorous guidelines notably for post-mortem examinations by international and national scientific societies. The recommendations for biosafety control required during specimen collection and handling have strongly limited the practice of autopsies of the COVID-19 patients to a few adequate laboratories. A full pathological examination has always been considered an important tool to better understand the pathophysiology of diseases, especially when the knowledge of an emerging disorder is limited and the impact on the healthcare system is significant. The first evidence of diffuse alveolar damage in the context of an acute respiratory distress syndrome has now been joined by the latest findings that report a more complex scenario in COVID-19, including a vascular involvement and a wide spectrum of associated pathologies. Ancillary tools such as electron microscopy and molecular biology used on autoptic tissue samples from autopsy are also significantly contributing to confirm and/or identify new aspects useful for a deeper knowledge of the pathogenetic mechanisms. This article will review and summarize the pathological findings described in COVID-19 until now, chiefly focusing on the respiratory tract, highlighting the importance of autopsy towards a better knowledge of this disease. | 0945-6317,1432-2307 | 2020-07-12 02:00:00+02:00 | pubmed | Virchows Archiv | Fiorella Calabrese;Federica Pezzuto;Francesco Fortarezza;Paul Hofman;Izidor Kern;Angel Panizo;Jan von der Thüsen;Sergei Timofeev;Gregor Gorkiewicz;Francesca Lunardi | Autopsy;COVID-19;Lung;Pandemic;SARS-CoV-2 | 2020-07-09 02:00:00+02:00 | 32642842 | FR;RU;SI;IT;NL;ES;AT | Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, Via A. Gabelli 61, 35121, Padova, Italy. fiorella.calabrese@unipd.it.;Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova Medical School, Via A. Gabelli 61, 35121, Padova, Italy.;Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank BB-0033-00025, University Côte d'Azur, Nice, France.;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.;Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain.;Department of Pathology, Erasmus MC, Rotterdam, The Netherlands.;Moscow City Hospital #40, Moscow, Russia.;Institute of Pathology, Medical University of Graz, Graz, Austria. | 1687 | |||
| 10.1183/23120541.00182-2020 | Journal Article | en | COVID-19 necrotising pneumonia and extracorporeal membrane oxygenation: a challenge for anticoagulation. | https://www.ncbi.nlm.nih.gov/pubmed/32665949 | ECMO and curative anticoagulation may be associated with severe bleeding events in #COVID19 pneumonia. ECMO and high levels of anticoagulation must be considered with caution in the most severe patients with #SARS-CoV-2 necrotising pneumonia. https://bit.ly/3clhu31. | 2312-0541 | 2020-07-12 02:00:00+02:00 | pubmed | ERJ Open Research | Suzanne Goursaud;Martin Mombrun;Damien du Cheyron | 2020-07-06 02:00:00+02:00 | 32665949 | FR | Dept of Medical Intensive Care, Caen University Hospital, Caen, France.;Normandie Univ., UNICAEN, INSERM, U1237, PhIND "Physiopathology and imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, Caen, France. | 1697 | ||||
| 10.1016/j.yebeh.2020.107262 | Journal Article;Review | en | Bridging the healthcare gap: Building the case for epilepsy virtual clinics in the current healthcare environment. | https://www.ncbi.nlm.nih.gov/pubmed/32645620 | Access to quality healthcare remains a challenge that is complicated by mounting pressures to control costs, and now, as we witness, the unprecedented strain placed on our healthcare delivery systems due to the COVID-19 pandemic. Challenges in healthcare access have driven a need for innovative approaches ensuring connectivity to health providers. Telehealth services and virtual clinics offer accessible disease management pathways for patients living in health resource limited areas or, as in the case of the COVID-19 pandemic, where there may be potential barriers to existing healthcare resources. Those suffering with serious chronic disorders often cannot be seen by a healthcare specialist due to their limited availability, or the lack of a specialist within a reasonable proximity. Epilepsy represents such a disorder where most of the world's population lacks the availability of necessary specialists. Virtual clinics allow for specialist care and an ability to perform necessary ambulatory electroencephalogram (EEG) monitoring by placing the technologies directly in patients' homes or at local clinics near the patients' homes. By moving the diagnostic process out of the hospital or epilepsy center, it becomes possible to overcome growing gaps in neurology services. Virtual clinics have the potential to expand access to high-quality, cost-effective care for the patient. The virtual clinic remotely connects those in need of medical support with specialists anywhere in the world, at any time of the day. | 1525-5050 | 2020-07-12 02:00:00+02:00 | pubmed | Epilepsy & Behavior | Bruce Lavin;Cassie Dormond;Morris H Scantlebury;Pierre-Yves Frouin;Martin J Brodie | Epilepsy;Telemedicine;Virtual clinic | 2020-07-06 02:00:00+02:00 | 32645620 | FR;CA;GE;CH;US;GB | BioSerenity, Inc, Atlanta Georgia, Serenity Medical Services, Paris, France. Electronic address: Bruce.lavin@bioserenity.com.;High Lantern Group, Geneva, Switzerland.;Departments of Pediatrics and Clinical Neurosciences, Cumming School of Medicine, Alberta Children's Hospital Research Institute, Hotchkiss Brain Institute, University of Calgary, Canada.;BioSerenity, Inc, Atlanta Georgia, Serenity Medical Services, Paris, France.;Epilepsy Unit, University of Glasgow, Glasgow, Scotland, UK. | 1701 | |||
| 10.1089/lap.2020.0535 | Journal Article | en | Image-Guided Surgical e-Learning in the Post-COVID-19 Pandemic Era: What Is Next? | https://www.ncbi.nlm.nih.gov/pubmed/32628558 | The current unprecedented coronavirus 2019 (COVID-19) crisis has accelerated and enhanced e-learning solutions. During the so-called transition phase, efforts were made to reorganize surgical services, reschedule elective surgical procedures, surgical research, academic education, and careers to optimize results. The intention to switch to e-learning medical education is not a new concern. However, the current crisis triggered an alarm to accelerate the transition. Efforts to consider e-learning as a teaching and training method for medical education have proven to be efficient. For image-guided therapies, the challenge requires more effort since surgical skills training is combined with image interpretation training, thus the challenge is to cover quality educational content with a balanced combination of blended courses (online/onsite). Several e-resources are currently available in the surgical scenario; however, further efforts to enhance the current system are required by accelerating the creation of new learning solutions to optimize complex surgical education needs in the current disrupted environment. | 1092-6429,1557-9034 | 2020-07-12 02:00:00+02:00 | pubmed | Journal of Laparoendoscopic & Advanced Surgical Techniques | Alain García Vazquez;Juan M Verde;Francesca Dal Mas;Mariano Palermo;Lorenzo Cobianchi;Jacques Marescaux;Benoit Gallix;Bernard Dallemagne;Silvana Perretta;Mariano E Gimenez | e-learning;online training;surgical education;surgical learning;training | 2020-07-06 02:00:00+02:00 | 32628558 | FR;AR;GB;IT | Department of Image-Guided Liver Interventions, IHU-Strasbourg, Institute of Image-Guided Surgery, Strasbourg, France.;Department of Minimally-Invasive Surgery, IRCAD, Research Institute Against Cancer of the Digestive System, Strasbourg, France.;Department of Strategy and Enterprise, Lincoln International Business School, University of Lincoln, Lincoln, United Kingdom.;Department of Percutaneous Surgery, DAICIM Foundation, Teaching, Research, Assistance in Minimally Invasive Surgery, Buenos Aires, Argentina.;Department of Clinic, Diagnostic, and Pediatric Science, University of Pavia, Pavia, Italy. | 1704 | |||
| 10.1136/esmoopen-2020-000852 | Journal Article | en | Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. | https://www.ncbi.nlm.nih.gov/pubmed/32669298 | The coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) infection. Immune checkpoint inhibitor (ICI) containing regimens are standard of care in the majority of metastatic clear cell renal cell carcinoma (mccRCC) patients. It remains unclear whether therapies should be modified in response to the COVID-19 pandemic. | 2059-7029 | 2020-07-19 02:00:00+02:00 | pubmed | Antineoplastic Agents__therapeutic use;Betacoronavirus;Carcinoma, Renal Cell__drug therapy;Clinical Decision-Making;Coronavirus Infections__epidemiology;Humans;Immunologic Factors__therapeutic use;Kidney Neoplasms__drug therapy;Medical Oncology__statistics & numerical data;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Practice Patterns, Physicians'__statistics & numerical data;Protein Kinase Inhibitors__therapeutic use;Urology__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | ESMO Open | Stefanie Aeppli;Eric Innocents Eboulet;Tim Eisen;Bernard Escudier;Stefanie Fischer;James Larkin;Viktor Gruenwald;David McDermott;Jan Oldenburg;Aurelius Omlin;Camillo Porta;Brian Rini;Manuela Schmidinger;Cora Sternberg;Christian Rothermundt | COVID-19;decision criteria;pandemic;renal cell carcinoma;treatment pattern | 2020-07-17 02:00:00+02:00 | 32669298 | FR;IL;NO;GB;CH;US;AT;IT;DE | Medical Oncology and Haematology, Kantonsspital St Gallen, Sankt Gallen, Switzerland.;Coordinating Center, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.;Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, UK.;Department Medical Oncology, Gustave Roussy, Villejuif, Île-de-France, France.;Medical Oncology, Royal Marsden Hospital NHS Trust, London, London, UK.;Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, University Hospital Essen, Essen, Germany.;Kidney Cancer Program, Dana-Farber/Harvard Cancer Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.;Division of Medicine an Laboratory Sciences, Akershus University Hospital, Lorenskog, Norway.;Biomedical Sciences and Human Oncology, Università degli Studi di Bari Aldo Moro, Bari, Italy.;Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Medicine I, Clinical Division of Oncology, Vienna, Austria.;Medical Oncology, Weill Cornell Medicine, New York, New York, USA.;Medical Oncology and Haematology, Kantonsspital St Gallen, Sankt Gallen, Switzerland christian.rothermundt@kssg.ch. | 1723 | ||
| 10.1186/s13613-020-00716-1 | Journal Article | en | Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesis-generating study. | https://www.ncbi.nlm.nih.gov/pubmed/32676824 | COVID-19 ARDS could differ from typical forms of the syndrome. | 2110-5820 | 2020-07-19 02:00:00+02:00 | pubmed | Annals of Intensive Care | J-L Diehl;N Peron;R Chocron;B Debuc;E Guerot;C Hauw-Berlemont;B Hermann;J L Augy;R Younan;A Novara;J Langlais;L Khider;N Gendron;G Goudot;J-F Fagon;T Mirault;D M Smadja | ARDS;COVID-19;Physiological dead-space;Ventilatory ratio | 2020-07-16 02:00:00+02:00 | 32676824 | FR | Université de Paris, Innovative Therapies in Haemostasis, INSERM, 75006, Paris, France. jean-luc.diehl@aphp.fr.;Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, 20 Rue Leblanc, 75015, Paris, France. jean-luc.diehl@aphp.fr.;Intensive Care Unit, AH-HP, Georges Pompidou European Hospital, Université de Paris, 75015, Paris, France.;Université de Paris, PARCC, INSERM, 75015, Paris, France.;Emergency Department, AP-HP, Georges Pompidou European Hospital, 75015, Paris, France.;Plastic Surgery Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, 75015, Paris, France.;Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, 75015, Paris, France.;Université de Paris, Innovative Therapies in Haemostasis, INSERM, 75006, Paris, France.;Hematology Department and Biosurgical Research Lab (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, 75015, Paris, France.;Vascular Medicine Department, AP-HP, Georges Pompidou European Hospital, 75015, Paris, France. | 1736 | |||
| 10.1016/j.jaad.2020.07.048 | Journal Article | en | Lack of association between chilblains outbreak and SARS-CoV-2: histological and serological findings from a new immunoassay. | https://www.ncbi.nlm.nih.gov/pubmed/32682889 | 0190-9622 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of the American Academy of Dermatology | Vivien Hébert;Anne-Bénédicte Duval-Modeste;Pascal Joly;Véronique Lemée;Lucie Cellier;Fabienne Jouen;Benoit Veber;Laurent Drouot;Olivier Boyer | 2020-07-16 02:00:00+02:00 | 32682889 | FR | Normandie Univ, UNIROUEN, Inserm, U1234, FOCIS Center of Excellence PAn'THER, Rouen University Hospital, Department of Dermatology, Rouen, France. Electronic address: Vivien.Hebert@chu-rouen.fr.;Normandie Univ, UNIROUEN, Inserm, U1234, FOCIS Center of Excellence PAn'THER, Rouen University Hospital, Department of Dermatology, Rouen, France.;Department of Virology, Rouen University Hospital, Rouen, France.;Department of Patholohy, Rouen University Hospital, Rouen, France.;Normandie Univ, UNIROUEN, Inserm, U1234, FOCIS Center of Excellence PAn'THER, Rouen University Hospital, Département of Immunology and Biotherapy, Rouen, France.;Department of Reanimation, Rouen University Hospital, Rouen, France. | 1740 | |||||
| Letter | en | Necrotic acral lesions and lung failure in a fatal case of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32671827 | 2020-07-19 02:00:00+02:00 | pubmed | Antonella Tammaro;Camilla Chello;Alvise Sernicola;Francesca Magri;Ganiyat Adenike Ralitsa Adebanjo;Francesca Romana Parisella;Alessandra Scarabello;Aldo Pezzuto;Sergio Ramirez-Estrada;Jordi Rello | 2020-07-16 02:00:00+02:00 | 32671827 | FR;IT;AU;ES;PS | NESMOS Department, Department of Dermatology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.;Queensland University, Brisbane, Australia.;Dermatology Unit, National Institute for Infectious Diseases 'Lazzaro Spallanzani'-IRCCS, Rome, Italy.;Cardiovascular-Respiratory Science Department, Sant'Andrea Hospital-Sapienza University of Rome, Rome, Italy.;Critical Care Unit, Clìnica Corachan, Barcelona, Spain.;Clinical Research/Epidemiology in Pneumonia & Sepsis (CRIPS), Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.;Centro de Investigaciòn Biomedica en Red de Enfermedades Respirorias (CIBERES), Instituto Salud Carlos III, Madrid, Spain.;Clinical Research, CHU, Université Montepellier-Nimes, Nimes, France. | 1741 | ||||||||
| 10.1111/ene.14440 | Journal Article | en | Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32677329 | Post-viral olfactory dysfunction is well established and has been shown to be a key symptom of COVID-19 with more than 66% of European and US patients reporting some degree of loss of smell. Persistent olfactory dysfunction appears to be commonplace and will drive the demand for general practitioner, otolaryngology or neurology consultation in the next few months - evidence regarding recovery will be essential in counselling our patients. | 1351-5101,1468-1331 | 2020-07-19 02:00:00+02:00 | pubmed | European Journal of Neurology | C M Chiesa-Estomba;J R Lechien;T Radulesco;J Michel;L J Sowerby;C Hopkins;S Saussez | COVID-19;anosmia;coronavirus;olfaction;recovery;smell | 2020-07-16 02:00:00+02:00 | 32677329 | FR;CA;GB;ES;BE | COVID-19 Task Force of the Young Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.;Department of Otorhinolaryngology - Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otolaryngology - Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Oto-Rhino-Laryngology Head and Neck Surgery, Aix Marseille Univ, APHM, IUSTI, La Conception University Hospital, Marseille, France.;Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.;King's College, London, UK.;Department of Head and Neck Surgery, EpiCURA Hospital, Hornu, Belgium. | 1742 | |||
| Letter;Comment | en | Pulmonary Vascular Pathology in Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32678531 | 2020-07-19 02:00:00+02:00 | pubmed | Fanny Burel-Vandenbos;Nathalie Cardot-Leccia;Thierry Passeron | 2020-07-17 02:00:00+02:00 | 32678531 | FR | University Hospital of Nice, Nice, France burel-vandenbos.f@chu-nice.fr. | 1747 | ||||||||
| Letter | en | Response to letter: COVID-19 and macular edema-a necessary blindness? | https://www.ncbi.nlm.nih.gov/pubmed/32683486 | 2020-07-19 02:00:00+02:00 | pubmed | Jean-François Korobelnik | 2020-07-18 02:00:00+02:00 | 32683486 | FR | Service d'ophtalmologie, CHU Bordeaux, Bordeaux, France. jean-francois.korobelnik@chu-bordeaux.fr.;Inserm, Bordeaux Population Health Research Center, team LEHA, Université de Bordeaux, UMR 1219, F-33000, Bordeaux, France. jean-francois.korobelnik@chu-bordeaux.fr. | 1748 | ||||||||
| Letter | en | COVID-19: What type of cytokine storm are we dealing with? | https://www.ncbi.nlm.nih.gov/pubmed/32681651 | 2020-07-19 02:00:00+02:00 | pubmed | Guillaume Monneret;Ihsane Benlyamani;Morgane Gossez;Jesus F Bermejo-Martin;Marta Martín-Fernandez;Pierre Sesques;Florent Wallet;Fabienne Venet | 2020-07-18 02:00:00+02:00 | 32681651 | FR;ES | EA 7426 "Pathophysiology of Injury-Induced Immunosuppression (PI3)," Claude Bernard Lyon 1 University Hospices Civils de Lyon-bioMérieux, Lyon, France.;Immunology Department, Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.;Biomedical research Department, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.;Biomedical research Department, Hospital Universitario Río Hortega de Valladolid, Valladolid, Spain.;Medical Intensive Care Unit, Hospices Civils de Lyon, Lyon Sud Teaching Hospital, Lyon, France.;Department of Hematology, Hospices Civils de Lyon, Lyon Sud Teaching Hospital, Lyon, France. | 1769 | ||||||||
| 10.1038/s41591-020-1001-6 | Journal Article | en | A stochastic agent-based model of the SARS-CoV-2 epidemic in France. | https://www.ncbi.nlm.nih.gov/pubmed/32665655 | Many European countries have responded to the COVID-19 pandemic by implementing nationwide protection measures and lockdowns1. However, the epidemic could rebound when such measures are relaxed, possibly leading to a requirement for a second or more, repeated lockdowns2. Here, we present results of a stochastic agent-based microsimulation model of the COVID-19 epidemic in France. We examined the potential impact of post-lockdown measures, including physical distancing, mask-wearing and shielding individuals who are the most vulnerable to severe COVID-19 infection, on cumulative disease incidence and mortality, and on intensive care unit (ICU)-bed occupancy. While lockdown is effective in containing the viral spread, once lifted, regardless of duration, it would be unlikely to prevent a rebound. Both physical distancing and mask-wearing, although effective in slowing the epidemic and in reducing mortality, would also be ineffective in ultimately preventing ICUs from becoming overwhelmed and a subsequent second lockdown. However, these measures coupled with the shielding of vulnerable people would be associated with better outcomes, including lower mortality and maintaining an adequate ICU capacity to prevent a second lockdown. Benefits would nonetheless be markedly reduced if most people do not adhere to these measures, or if they are not maintained for a sufficiently long period. | 1078-8956,1546-170X | 2020-07-19 02:00:00+02:00 | pubmed | Nature Medicine | Nicolas Hoertel;Martin Blachier;Carlos Blanco;Mark Olfson;Marc Massetti;Marina Sánchez Rico;Frédéric Limosin;Henri Leleu | 2020-07-14 02:00:00+02:00 | 32665655 | FR;ES;US | AP-HP.Centre, DMU Psychiatrie et Addictologie, Corentin Celton Hospital, Issy-les-Moulineaux, France. nico.hoertel@yahoo.fr.;INSERM U1266, Paris, France. nico.hoertel@yahoo.fr.;Paris University, Paris, France. nico.hoertel@yahoo.fr.;Public Health Expertise, Paris, France.;National Institute on Drug Abuse, Bethesda, MD, USA.;Columbia University/New York State Psychiatric Institute, New York, NY, USA.;AP-HP.Centre, DMU Psychiatrie et Addictologie, Corentin Celton Hospital, Issy-les-Moulineaux, France.;Universidad Complutense de Madrid, Campus de Somosaguas, Pozuelo de Alarcon, Spain.;INSERM U1266, Paris, France.;Paris University, Paris, France. | 1773 | ||||
| 10.1093/jtm/taaa114 | Journal Article | en | COVID-19 and dengue co-infection in a returning traveller. | https://www.ncbi.nlm.nih.gov/pubmed/32657339 | In march 2020, a pandemic of respiratory infection due to the SARS-CoV2 is underway, dengue fever epidemics are at the same time present in many regions of the inter-equatorial zone. We report the first cases of covid19-dengue co-infection, which occurred in Mayotte, a French island in the Indian Ocean. | 1195-1982,1708-8305 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Travel Medicine | Loïc Epelboin;Renaud Blondé;Mathieu Nacher;Patrice Combe;Louis Collet | COVID-19;France;Mayotte, coinfection;Western Europe;coronavirus;pandemic, dengue fever;severe acute respiratory syndrome coronavirus 2;tropical diseases | 2020-07-13 02:00:00+02:00 | 32657339 | FR;YT | Unité de Maladies Infectieuses et Tropicales, Centre Hospitalier Andrée Rosemon, F-97300 Cayenne, French Guiana.;Ecosystèmes Amazoniens et Pathologie Tropicale, EA3593, Université de Guyane, F97300-Cayenne, French Guiana.;Intensive Care Unit, Centre Hospitalier de Mayotte, F-97600 Mamoudzou, Mayotte, France.;Centre d'Investigation Clinique, CIC INSERM 1424, Centre Hospitalier de Cayenne, 97300 Cayenne, French Guiana.;Medical Biology Laboratory, Centre Hospitalier de Mayotte, F-97600 Mamoudzou, Mayotte, France. | 1791 | |||
| 10.1017/dmp.2020.234 | Journal Article | en | Adaptation of Coronavirus Disease (COVID-19) Protocols to a Parisian Maternity Unit During the 2020 Pandemic: A Managerial Perspective. | https://www.ncbi.nlm.nih.gov/pubmed/32660662 | The coronavirus disease (COVID-19) pandemic overwhelmed health services in France during March 2020 and, to cope, service delivery was reduced in most disciplines. However, as this was impossible for Obstetrics, the COVID-19 infection had to be added to existing clinical care pathways at the children's hospital, Hôpital Necker-Enfants Malades. This was further complicated by an increasing number of pregnancies affected by infection, in addition to scientific uncertainty about the virus. Procedures based on scientific recommendations from French and international authorities were adapted to maternity care and regularly updated as the situation progressed. Weekly medical manager team meetings covered the evolving clinical situation, and an initial evaluation revealed that our procedures worked well. However, it was necessary to adapt the policy as the epidemic progressed rapidly. Shortly after March 16, traffic control bundling was implemented in anticipation of a dramatic increase in pregnant women affected by infection and to better protect the staff. By April 18, with the peak of the COVID-19 epidemic receding, protocols were again readjusted to meet new service delivery requirements. Although a full debrief is yet to occur, from an operational level perspective, staff response was more than satisfactory. While preventing another epidemic may be impossible, this experience will improve our resilience in the future. | 1935-7893,1938-744X | 2020-07-19 02:00:00+02:00 | pubmed | Disaster Medicine and Public Health Preparedness | Ali Ghanchi | COVID-19 pandemic;Paris;infection prevention and control policies;midwifery unit management;traffic control bundling | 2020-07-14 02:00:00+02:00 | 32660662 | FR | Université de Paris, CRESS, INSERM, INRA, Paris, and Service d'Obstétrique, Maternité, chirurgie médecine et imagerie fœtales, APHP, Hôpital Necker Enfants Malades, Paris. | 1805 | |||
| 10.1016/j.jhin.2020.07.005 | Journal Article | en | Nosocomial transmission prevention of SARS-Cov-2 using a preoperative chest CT: a monocentric study during the outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32681858 | 0195-6701 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Hospital Infection | J Touati;G Rico;P Habert;M Gérault;J-Y Gaubert;C Chagnaud;A Varoquaux | 2020-07-15 02:00:00+02:00 | 32681858 | FR;GB;US | Department of Radiology, La Conception University Hospital, APHM, 147 boulevard Baille, 13005 Marseille, France. Electronic address: Julian.TOUATI@ap-hm.fr.;Department of Radiology, La Conception University Hospital, APHM, 147 boulevard Baille, 13005 Marseille, France.;Department of Radiology, La Conception University Hospital, APHM, 147 boulevard Baille, 13005 Marseille, France, Aix-Marseille University, LIIE, 27 boulevard Jean Moulin, 13005 Marseille, France.;Dept. of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 54-317, Cambridge, MA 02139-4307.;Department of Radiology, La Conception University Hospital, APHM, 147 boulevard Baille, 13005 Marseille, France, Aix-Marseille University, CRMBM-CEMEREM (UMR73-39) 27 boulevard Jean Moulin 13005 Marseille, France. | 1806 | |||||
| 10.1136/annrheumdis-2020-218146 | Journal Article | en | Response to: 'Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India' by Goyal et al. | https://www.ncbi.nlm.nih.gov/pubmed/32669304 | 0003-4967,1468-2060 | 2020-07-19 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Alexis Mathian;Zahir Amoura | hydroxychloroquine;lupus erythematosus, systemic;therapeutics | 2020-07-15 02:00:00+02:00 | 32669304 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 1809 | ||||
| the French Agricultural Research Centre for International Development (CIRAD);the French General Directorate for Food (DGAL);French National Research Agency under the Investments for the Future Program;H2020 "Monitoring outbreak events for disease surveillance in a data science context" (MOOD);SONGES Project FEDER and Occitanie | 10.1111/tbed.13738 | Journal Article | en | Monitoring online media reports for early detection of unknown diseases: Insight from a retrospective study of COVID-19 emergence. | https://www.ncbi.nlm.nih.gov/pubmed/32683774 | Event-based surveillance (EBS) systems monitor a broad range of information sources to detect early signals of disease emergence, including new and unknown diseases. In December 2019, a newly identified coronavirus emerged in Wuhan (China), causing a global coronavirus disease (COVID-19) pandemic. A retrospective study was conducted to evaluate the capacity of three event-based surveillance (EBS) systems (ProMED, HealthMap and PADI-web) to detect early COVID-19 emergence signals. We focused on changes in online news vocabulary over the period before/after the identification of COVID-19, while also assessing its contagiousness and pandemic potential. ProMED was the timeliest EBS, detecting signals one day before the official notification. At this early stage, the specific vocabulary used was related to 'pneumonia symptoms' and 'mystery illness'. Once COVID-19 was identified, the vocabulary changed to virus family and specific COVID-19 acronyms. Our results suggest that the three EBS systems are complementary regarding data sources, and all require timeliness improvements. EBS methods should be adapted to the different stages of disease emergence to enhance early detection of future unknown disease outbreaks. | 1865-1674,1865-1682 | 2020-07-19 02:00:00+02:00 | pubmed | Transboundary and Emerging Diseases | Sarah Valentin;Alizé Mercier;Renaud Lancelot;Mathieu Roche;Elena Arsevska | COVID-19;PADI-web;emerging disease;epidemic intelligence;one Health;online news | 2020-07-19 02:00:00+02:00 | 32683774 | FR | [{"country": "", "agency": "the French Agricultural Research Centre for International Development (CIRAD)"}, {"country": "", "agency": "the French General Directorate for Food (DGAL)"}, {"country": "", "agency": "French National Research Agency under the Investments for the Future Program", "grantid": "ANR-16-CONV-0004"}, {"country": "", "agency": "H2020 \"Monitoring outbreak events for disease surveillance in a data science context\" (MOOD)", "grantid": "874850"}, {"country": "", "agency": "SONGES Project FEDER and Occitanie"}] | UMR TETIS, CIRAD, Montpellier, France.;TETIS, AgroParisTech, CIRAD, CNRS, INRAE, Univ Montpellier, Montpellier, France.;UMR ASTRE, CIRAD, Montpellier, France.;ASTRE, CIRAD, INRAE, Univ Montpellier, Montpellier, France. | 1819 | |
| 10.1002/dmrr.3388 | Journal Article | en | Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. | https://www.ncbi.nlm.nih.gov/pubmed/32683744 | Coronavirus disease 2019 (COVID-19) is a rapidly progressing pandemic, with four million confirmed cases and 280 000 deaths at the time of writing. Some studies have suggested that diabetes is associated with a greater risk of developing severe forms of COVID-19. The primary objective of the present study was to compare the clinical features and outcomes in hospitalized COVID-19 patients with vs without diabetes. | 1520-7552,1520-7560 | 2020-07-19 02:00:00+02:00 | pubmed | Diabetes/Metabolism Research and Reviews | Abdallah Al-Salameh;Jean-Philippe Lanoix;Youssef Bennis;Claire Andrejak;Etienne Brochot;Guillaume Deschasse;Hervé Dupont;Vincent Goeb;Maité Jaureguy;Sylvie Lion;Julien Maizel;Julien Moyet;Benoit Vaysse;Rachel Desailloud;Olivier Ganry;Jean-Luc Schmit;Jean-Daniel Lalau | acute respiratory distress syndrome;coronavirus disease 2019 (COVID-19);diabetes;intensive care;mortality;outcome | 2020-07-19 02:00:00+02:00 | 32683744 | FR | Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, Amiens, France.;PériTox = UMR_I 01, University of Picardy Jules Verne, Amiens, France.;Department of Infectious Diseases, Amiens University Hospital, Amiens, France.;Laboratory of Clinical Pharmacology, Amiens University Hospital, Amiens, France.;Department of Pulmonary diseases, Amiens University Hospital, Amiens, France.;Laboratory of Virology, Amiens University Hospital, Amiens, France.;Department of Geriatrics, Amiens University Hospital, Amiens, France.;Surgical Intensive Care Unit, Amiens University Hospital, Amiens, France.;Department of Rheumatology, Amiens University Hospital, Amiens, France.;Department of Nephrology, Amiens University Hospital, Amiens, France.;Department of Orthopaedics and Traumatology, Amiens University Hospital, Amiens, France.;Medical Intensive Care Unit, Amiens University Hospital, Amiens, France.;Department of Medical Informatics, Amiens University Hospital, Amiens, France.;Department of Epidemiology, Amiens University Hospital, Amiens, France. | 1823 | |||
| 10.1016/j.cmi.2020.07.028 | Journal Article | en | Post-COVID-19 chronic symptoms: a postinfectious entity? | https://www.ncbi.nlm.nih.gov/pubmed/32712242 | 1198-743X | 2020-07-26 02:00:00+02:00 | pubmed | Clinical Microbiology and Infection | Benjamin Davido;Sophie Seang;Roland Tubiana;Pierre de Truchis | COVID-19;Chronic symptoms;Dysautonomia | 2020-07-23 02:00:00+02:00 | 32712242 | FR | Maladies Infectieuses, Hôpital Universitaire Raymond-Poincaré, APHP, Garches, France. Electronic address: benjamin.davido@aphp.fr.;Maladies Infectieuses, Hôpital Universitaire Pitié Salpêtrière, APHP, Paris, France.;Maladies Infectieuses, Hôpital Universitaire Raymond-Poincaré, APHP, Garches, France. | 1837 | ||||
| 10.1007/s00259-020-04965-x | Editorial | en | COVID-19 and the brain: impact on nuclear medicine in neurology. | https://www.ncbi.nlm.nih.gov/pubmed/32700058 | 1619-7070,1619-7089 | 2020-07-26 02:00:00+02:00 | pubmed | European Journal of Nuclear Medicine and Molecular Imaging | Silvia Morbelli;Ozgul Ekmekcioglu;Henryk Barthel;Nathalie L Albert;Ronald Boellaard;Diego Cecchin;Eric Guedj;Adriaan A Lammertsma;Ian Law;Ivan Penuelas;Franck Semah;Tatjana Traub-Weidinger;Elsmarieke van de Giessen;Andrea Varrone;Valentina Garibotto | 2020-07-23 02:00:00+02:00 | 32700058 | FR;SE;CH;AT;IT;NL;TR;ES;DK;DE | IRCCS Ospedale Policlinico San Martino, Genoa, Italy. silviadaniela.morbelli@hsanmartino.it.;Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Department of Health Sciences(DISSAL), University of Genoa, Genoa, Italy. silviadaniela.morbelli@hsanmartino.it.;Department of Nuclear Medicine, Sisli Etfal Education and Research Hospital, Istanbul, Turkey.;Department of Nuclear Medicine, Leipzig University, Leipzig, Germany.;Department of Nuclear Medicine, Ludwig Maximilians-University of Munich, Munich, Germany.;Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, De Boelelaan, 1117, Amsterdam, Netherlands.;Nuclear Medicine Unit, Department of Medicine - DIMED, University of Padua, Padua, Italy.;APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix Marseille Univ, Marseille, France.;Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.;Department of Nuclear Medicine, Clinica Universidad de Navarra, IdiSNA, University of Navarra, Pamplona, Spain.;Nuclear Medicine Department, University Hospital, Lille, France.;Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.;Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, Meibergdreef 9, Amsterdam, The Netherlands.;Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.;NIMTLab, Faculty of Medicine, Geneva University, Geneva, Switzerland.;Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland. | 1843 | |||||
| 10.1016/j.jaip.2020.07.016 | Journal Article | en | Managing Food Allergy in Schools During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32711118 | In the wake of the COVID-19 pandemic and massive disruptions to daily life in the spring of 2020, in May 2020, the Centers for Disease Control (CDC) released guidance recommendations for schools regarding how to have students attend while adhering to principles of how to reduce the risk of contracting SARS-CoV-2. As part of physical distancing measures, the CDC is recommending that schools who traditionally have had students eat in a cafeteria or common large space instead have children eat their lunch or other meals in the classroom at already physically distanced desks. This has sparked concern for the safety of food-allergic children attending school, and some question of how the new CDC recommendations can coexist with recommendations in the 2013 CDC Voluntary Guidelines on Managing Food Allergy in Schools as well as accommodations that students may be afforded through disability law that may have previously prohibited eating in the classroom. This expert consensus explores the issues related to evidence-based management of food allergy at school, the issues of managing the health of children attending school that are acutely posed by the constraints of an infectious pandemic, and how to harmonize these needs so that all children can attend school with minimal risk from both an infectious and allergic standpoint. | 2213-2198 | 2020-07-26 02:00:00+02:00 | pubmed | The Journal of Allergy and Clinical Immunology: In Practice | Matthew Greenhawt;Marcus Shaker;David R Stukus;David M Fleischer;Jonathan Hourihane;Mimi L K Tang;Elissa M Abrams;Julie Wang;Theresa A Bingemann;Edmond S Chan;Jay Lieberman;Hugh A Sampson;S Allan Bock;Michael C Young;Susan Waserman;Douglas P Mack | Allergen bans;Americans with Disabilities Act;Anaphylaxis;CDC;COVID-19;Epinephrine;Food allergy;Hand washing;Rehabilitation Act of 1973;SARS-CoV-2;Schools;Social distancing;Stock epinephrine | 2020-07-23 02:00:00+02:00 | 32711118 | IE;FR;CA;LB;GB;US;AU | Department of Pediatrics, Section of Allergy/Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo. Electronic address: Matthew.Greenhawt@childrenscolorado.org.;Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, NH, Department of Pediatrics, Dartmouth Children's Hospital, Dartmouth Geisel School of Medicine, Hanover, NH.;Department of Pediatrics, Division of Allergy and Immunology, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.;Department of Pediatrics, Section of Allergy/Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo.;Department of Paediatrics, Royal College of Surgeons, Dublin, Ireland.;Department of Allergy and Immunology, The Royal Children's Hospital Melbourne, Murdoch Children's Research Institute, University of Melbourne, Parkville, Victoria, Australia.;Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, The University of Manitoba, Winnipeg, Manitoba, Canada.;Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.;University of Rochester Division of Allergy, Immunology and Rheumatology, Rochester, NY.;BC Children's Hospital, Division of Allergy & Immunology, The University of British Columbia, Vancouver, British Columbia, Canada.;Division of Allergy and Immunology, The University of Tennessee, Memphis, TN.;Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, DBV Technologies, Montrouge, France.;Deptartment of Pediatrics, University of Colorado School of Medicine (Emeritus), Aurora, Colo.;Division of Allergy & Immunology, Children's Hospital Boston, Harvard Medical School, Boston, Mass.;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada.;Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada, Halton Pediatric Allergy, Burlington, Ontario, Canada. | 1845 | |||
| 10.1177/2054358120944298 | Journal Article | en | COVID-19 Outbreak in a Hemodialysis Center: A Retrospective Monocentric Case Series. | https://www.ncbi.nlm.nih.gov/pubmed/32782814 | The rapid worldwide spread of COVID-19 has posed a serious threat to patients treated with kidney replacement therapy (KRT). Moreover, the impact of the disease on hemodialysis centers, the patients, and the health care workers is still not completely understood. | 2054-3581,2054-3581 | 2020-07-26 02:00:00+02:00 | pubmed | Canadian Journal of Kidney Health and Disease | Lionel Mazzoleni;Chadi Ghafari;Fabienne Mestrez;Roxana Sava;Elena Bivoleanu;Philippe Delmotte;France Laurent;Thomas Roland;Camelia Rossi;Stéphane Carlier | COVID-19;SARS-CoV2;end-stage kidney disease;hemodialysis;hemodialysis center;mortality | 2020-07-24 02:00:00+02:00 | 32782814 | FR;BE | Department of Nephrology, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Belgium.;Department of Cardiology, Université de Mons, Belgium.;Department of Endocrinology, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Belgium.;Department of Cardiology, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Belgium.;Department of Infectious Disease, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Belgium. | 1848 | |||
| 10.1093/eurheartj/ehaa588 | Journal Article | en | Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32710612 | 0195-668X,1522-9645 | 2020-07-26 02:00:00+02:00 | pubmed | European Heart Journal | Marc Bonnet;Anne Champagnac;Pierre Lantelme;Brahim Harbaoui | 2020-07-25 02:00:00+02:00 | 32710612 | FR | Cardiology Department, Hôpital Croix-Rousse and Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Histopathology Department, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, France. | 1861 | |||||
| 10.1016/j.ejogrb.2020.07.025 | Journal Article;Review | en | Sars-CoV-2 in pregnancy: Why is it better than expected? | https://www.ncbi.nlm.nih.gov/pubmed/32739606 | Since the outbreak of Coronavirus disease in December 2019, information specific to pregnancy remains limited and controversial. Based on data from previous reports, it has been noticed that contrary to prior pandemics such as SARS, MERS and H1N1 and although pregnancy is usually considered as a condition of high susceptibility to viral infections, new SARS-CoV2 infection seems to have a more benign clinical course when affecting pregnant women. We speculate that during pregnancy the physiological "silencing" of the Th1 pro-inflammatory response may blunt the cytokines storm which is thought to play a key-role in the pathogenesis of the severe complications of Covid-19. | 0301-2115 | 2020-07-26 02:00:00+02:00 | pubmed | European Journal of Obstetrics & Gynecology and Reproductive Biology | Tullio Ghi;Elvira di Pasquo;Arsene Mekinian;Leonardo Calza;Tiziana Frusca | Immunology;Inflammation;Pregnancy;Sars-CoV-2 | 2020-07-24 02:00:00+02:00 | 32739606 | FR;IT | Department of Obstetrics and Gynecology, University of Parma, Parma, Italy. Electronic address: tullio.ghi@unipr.it.;Department of Obstetrics and Gynecology, University of Parma, Parma, Italy.;Department of Internal Medicine, Referral Center for Autoimmune Diseases, Saint Antoine Hospital, Sorbonne University, Paris, France.;Unit of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy. | 1862 | |||
| Letter | en | Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2? | https://www.ncbi.nlm.nih.gov/pubmed/32773341 | 2020-07-26 02:00:00+02:00 | pubmed | B Nobile;M Durand;P Courtet;P Van de Perre;N Nagot;J P Molès;E Olié | Chlorpromazine;Clathrin-mediated endocytosis;SARS-CoV-2;Sedative medication;Viral replication | 2020-07-25 02:00:00+02:00 | 32773341 | FR | Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France, PSNREC, Univ Montpellier, INSERM, CHU de Montpellier, Montpellier, France. Electronic address: benedicte.nobile@gmail.com.;Pathogenesis and Control of Chronic Infection, INSERM, EFS, Université de Montpellier, Montpellier, France.;Department of Emergency Psychiatry and Acute Care, CHU Montpellier, France, PSNREC, Univ Montpellier, INSERM, CHU de Montpellier, Montpellier, France, FondaMental Foundation, France.;Pathogenesis and Control of Chronic Infection, INSERM, EFS, Université de Montpellier, Montpellier, France, Department of Medical Information, CHU Montpellier, France. | 1867 | |||||||
| 10.1001/jamapediatrics.2020.2141 | Journal Article | en | Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From the Mother to the Infant. | https://www.ncbi.nlm.nih.gov/pubmed/32687548 | 2168-6203 | 2020-07-26 02:00:00+02:00 | pubmed | JAMA Pediatrics | Sergio Verd;Jaume Ponce-Taylor;Gemma Ginovart | 2020-07-20 02:00:00+02:00 | 32687548 | FR;ES | Pediatric Division, Department of Primary Care, Balearic Health Authority, La Vileta Surgery, Palma de Mallorca, Spain.;Balearic Institute of Medical Research (IdISBa), Palma de Mallorca, Spain.;Division of Accidents & Emergency, Department of Primary Care, Balearic Health Authority, La Vileta Surgery, Palma de Mallorca, Spain.;Neonatal Unit, Department of Pediatrics. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. | 1879 | |||||
| 10.1080/1744666x.2020.1791086 | Journal Article | en | Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32615046 | Routine medical and ophthalmic care is being drastically curtailed in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Uveitis patients require particular attention because of their theoretical risk of viral infection, in the context of therapeutic immunosuppression. | 1744-666X,1744-8409 | 2020-07-26 02:00:00+02:00 | pubmed | Expert Review of Clinical Immunology | Dinu Stanescu-Segall;Thomas Sales de Gauzy;Rhianon Reynolds;Livia Faes;Dominika Pohlmann;Kaivon Pakzad-Vaezi;Daniel Ting;David Saadoun;Jayakrishna Ambati;Anat Loewenstein;Bahram Bodaghi;Marc D de Smet;Sara Touhami | SARS-CoV-2;Uveitis;biologics;coronavirus;corticosteroid;immunosuppression;immunosuppressive therapy;intravitreous injection;management | 2020-07-21 02:00:00+02:00 | 32615046 | FR;SG;IL;CA;CH;GB;US;NL;DE | Department of Ophthalmology, IHU FOReSIGHT, Sorbonne University-APHP , Paris, France.;Department of Ophthalmology, Aneurin Bevan University Health Board , Newport, UK.;Department of Ophthalmology, Cantonal Hospital Lucerne , Lucerne, Switzerland.;Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health , Berlin, Germany.;Department of Ophthalmology and Visual Sciences, University of British Columbia , Vancouver, Canada.;Singapore National Eye Center , Singapore, Singapore.;Department of Internal Medicine, Pitié Salpétrière University Hospital, Sorbonne University-APHP , Paris, France.;Center for Advanced Vision Science, Department of Ophthalmology, Department of Pathology, Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine , Charlottesville, VA, USA.;Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv, Israel.;Department of Ophthalmology, University of Leiden, the Netherlands, MIOS - Retina and Ocular Inflammation Center , Lausanne, Switzerland. | 1891 | |||
| 10.3324/haematol.2020.265066 | Journal Article | en | ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults. | https://www.ncbi.nlm.nih.gov/pubmed/32703796 | 0390-6078,1592-8721 | 2020-07-26 02:00:00+02:00 | pubmed | Haematologica | Laurys Boudin;Frédéric Janvier;Olivier Bylicki;Fabien Dutasta | ABO;Blood group;Covid 19;SARS-CoV-2 | 2020-07-23 02:00:00+02:00 | 32703796 | FR | Department of Oncology and Haematology, HIA Sainte-Anne, Toulon, France, laurys84@hotmail.com.;Biology Unit, HIA Sainte-Anne, Toulon, France.;Respiratory Disease Unit, HIA Sainte-Anne, Toulon, France.;Department of Internal Medicine, HIA Sainte-Anne, Toulon, France. | 1892 | ||||
| 10.1038/s41586-020-2558-4 | Journal Article | en | Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. | https://www.ncbi.nlm.nih.gov/pubmed/32698191 | COVID-19 has rapidly become a pandemic for which no antiviral drug or vaccine is yet available2-4. Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals worldwide but definitive evidence for HCQ efficacy in treatment of COVID-19 is still missing6,7,17,18. We evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (VeroE6) but not in a model of reconstituted human airway epithelium. In macaques, we tested different treatment strategies in comparison to placebo, before and after peak viral load, alone or in combination with azithromycin (AZTH). Neither HCQ nor HCQ+AZTH showed a significant effect on the viral load levels in any of the tested compartments. When the drug was used as a pre-exposure prophylaxis (PrEP), HCQ did not confer protection against acquisition of infection. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral treatment for COVID-19 in humans. | 0028-0836,1476-4687 | 2020-07-26 02:00:00+02:00 | pubmed | Nature | Pauline Maisonnasse;Jérémie Guedj;Vanessa Contreras;Sylvie Behillil;Caroline Solas;Romain Marlin;Thibaut Naninck;Andres Pizzorno;Julien Lemaitre;Antonio Gonçalves;Nidhal Kahlaoui;Olivier Terrier;Raphael Ho Tsong Fang;Vincent Enouf;Nathalie Dereuddre-Bosquet;Angela Brisebarre;Franck Touret;Catherine Chapon;Bruno Hoen;Bruno Lina;Manuel Rosa Calatrava;Sylvie van der Werf;Xavier de Lamballerie;Roger Le Grand | 2020-07-22 02:00:00+02:00 | 32698191 | FR | Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.;Université de Paris, INSERM, IAME, F-75018, Paris, France.;Unité de Génétique Moléculaire des Virus à ARN, GMVR: Institut Pasteur, UMR CNRS 3569, Université de Paris, Paris, France.;Centre National de Référence des Virus des infections respiratoires (dont la grippe), Institut Pasteur, Paris, France.;Aix-Marseille Univ, APHM, Unité des Virus Emergents (UVE) IRD 190, INSERM 1207, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, 13005, Marseille, France.;CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.;Plate-forme de microbiologie mutualisée (P2M), Pasteur International Bioresources Network (PIBnet), Institut Pasteur, Paris, France.;Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, 13005, Marseille, France.;Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.;Laboratoire de Virologie, Centre National de Référence des Virus des infections respiratoires (dont la grippe), Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69004, Lyon, France.;Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France. roger.le-grand@cea.fr. | 1905 | ||||
| 10.1007/s00264-020-04712-9 | Journal Article | en | Evaluation of containment measures' effect on orthopaedic trauma surgery during the COVID-19 pandemic: a retrospective comparison between 2019 and 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32696333 | There is no available information about the effect of containment measures on trauma surgery activity. The aim of this study was to analyse and report the containment measures' impact on trauma surgery activity during the COVID-19 pandemic in order to quickly react and adjust in case of a new sanitary crisis and containment. | 0341-2695,1432-5195 | 2020-07-26 02:00:00+02:00 | pubmed | International Orthopaedics | Thibault Druel;Quentin Andeol;Frédéric Rongieras;Antoine Bertani;Maxence Bordes;Agathe Alvernhe | COVID-19;Containment measures;Pandemic;Traumatology | 2020-07-21 02:00:00+02:00 | 32696333 | FR | Department of Orthopaedic and Traumatology, Edouard Herriot Hospital, 5 place d'Arsonval, 69003, Lyon, France.;Claude Bernard University, Lyon, France.;Department of Orthopaedic and Traumatology, Desgenettes Military Hospital, Lyon, France.;Department of Orthopaedic and Traumatology, Edouard Herriot Hospital, 5 place d'Arsonval, 69003, Lyon, France. agathe.alvernhe@chu-lyon.fr.;Claude Bernard University, Lyon, France. agathe.alvernhe@chu-lyon.fr.;Department of Orthopaedic and Traumatology, Desgenettes Military Hospital, Lyon, France. agathe.alvernhe@chu-lyon.fr. | 1909 | |||
| 10.1136/annrheumdis-2020-218173 | Journal Article | en | Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh et al. | https://www.ncbi.nlm.nih.gov/pubmed/32737109 | 0003-4967,1468-2060 | 2020-08-02 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Alexis Mathian;Zahir Amoura | autoimmune diseases;hydroxychloroquine;lupus erythematosus;systemic | 2020-07-31 02:00:00+02:00 | 32737109 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 1917 | ||||
| 10.1183/13993003.01875-2020 | Journal Article | en | Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. | https://www.ncbi.nlm.nih.gov/pubmed/32732333 | Viral respiratory infections are the main causes of asthma exacerbation. The susceptibility of asthmatics to develop an exacerbation when they present with severe pneumonia due to SARS-CoV-2 infection is unknown. The objective of this study was to investigate the characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who required hospitalisation during the spring 2020 outbreak in Paris, France. | 0903-1936,1399-3003 | 2020-08-02 02:00:00+02:00 | pubmed | European Respiratory Journal | Antoine Beurnier;Etienne-Marie Jutant;Mitja Jevnikar;Athénaïs Boucly;Jérémie Pichon;Mariana Preda;Marie Frank;Jérémy Laurent;Christian Richard;Xavier Monnet;Jacques Duranteau;Anatole Harrois;Marie-Camille Chaumais;Marie-France Bellin;Nicolas Noël;Sophie Bulifon;Xavier Jaïs;Florence Parent;Andrei Seferian;Laurent Savale;Olivier Sitbon;David Montani;Marc Humbert | 2020-07-30 02:00:00+02:00 | 32732333 | FR | Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Le Kremlin-Bicêtre, France.;AP-HP, Service de physiologie et d'explorations fonctionnelles respiratoires (CRISALIS/F-CRIN network), Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Département d'information médicale, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service de médecine intensive-réanimation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Département d'anesthésie et réanimation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service de pharmacie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service d'imagerie médicale, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;AP-HP, Service de médecine interne, Hôpital Bicêtre, Le Kremlin-Bicêtre, France. | 1919 | ||||
| 10.1007/s00415-020-10108-x | Journal Article | en | Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. | https://www.ncbi.nlm.nih.gov/pubmed/32734353 | Evidence of immune-mediated neurological syndromes associated with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is limited. We therefore investigated clinical, serological and CSF features of coronavirus disease 2019 (COVID-19) patients with neurological manifestations. | 0340-5354,1432-1459 | 2020-08-02 02:00:00+02:00 | pubmed | Journal of Neurology | Antoine Guilmot;Sofia Maldonado Slootjes;Amina Sellimi;Maroussia Bronchain;Bernard Hanseeuw;Leila Belkhir;Jean Cyr Yombi;Julien De Greef;Lucie Pothen;Halil Yildiz;Thierry Duprez;Catherine Fillée;Ahalieyah Anantharajah;Antoine Capes;Philippe Hantson;Philippe Jacquerye;Jean-Marc Raymackers;Frederic London;Souraya El Sankari;Adrian Ivanoiu;Pietro Maggi;Vincent van Pesch | Anti-GD1b;Cerebrospinal fluid;Encephalitis;SARS-CoV-2 | 2020-07-30 02:00:00+02:00 | 32734353 | FR;BE;GB | Department of Neurology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Hippocrate 10, 1200, Brussels, Belgium.;Department of Internal Medicine, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Radiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Biology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Intensive Care, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Neurology, Clinique Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium.;Department of Neurology, CHU UCL Namur Site Godinne, Yvoir, Belgium.;Department of Neurology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Hippocrate 10, 1200, Brussels, Belgium. vincent.vanpesch@uclouvain.be. | 1923 | |||
| 10.1002/alr.22677 | Journal Article | en | International registry of otolaryngologist-head and neck surgeons with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32735062 | It has become clear that healthcare workers are at high risk, and otolaryngology has been theorized to be among the highest risk specialties for coronavirus disease 2019 (COVID-19). The purpose of this study was to detail the international impact of COVID-19 among otolaryngologists, and to identify instructional cases. | 2042-6976,2042-6984 | 2020-08-02 02:00:00+02:00 | pubmed | International Forum of Allergy & Rhinology | Leigh J Sowerby;Kate Stephenson;Alexander Dickie;Federico A Di Lella;Niall Jefferson;Hannah North;R Daniele De Siati;Rebecca Maunsell;Michael Herzog;Raghu Nandhan;Marilena Trozzi;Puya Dehgani-Mobaraki;Antoine Melkane;Claudio Callejas;Harald Miljeteig;Diane Smit;Daniel Dibildox Reynoso;Joao Eloi Moura;Ann Hermansson;Shazia Peer;Lisa Burnell;Nicolas Fakhry;Carlos Chiesa-Estomba;Özlem Önerci Çelebi;Sergei Karpischenko;Steven Sobol;Zoukaa Sargi;Zara M Patel | COVID-19;aerosol generating procedures (AGPs);coronavirus;morbidity;mortality;otolaryngology;personal protective equipment (PPE);physicians | 2020-07-31 02:00:00+02:00 | 32735062 | CA;PT;BR;AR;CL;NL;MX;BE;FR;RU;GB;US;IT;DE;SE;NO;LB;AU;TR;ZA;ES;IN | Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada.;Department of Paediatric Otolaryngology, Birmingham Children's Hospital, Birmingham, UK.;Department of Otorhinolaryngology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.;Department of Otolaryngology-Head and Neck Surgery, John Hunter Adult and Children's' Hospitals, Newcastle, NSW, Australia.;Department of Otolaryngology-Head and Neck Surgery, Children's Hospital Westmead and Westmead Hospital, Sydney, NSW, Australia.;Department of Otorhinolaryngology, Saint-Luc University Hospital, University of Louvain, Brussels, Belgium.;Department of Otorhinolaryngology, State University of Campinas (UNICAMP), Campinas, Brazil.;Department of Otorhinolaryngology-Head and Neck Surgery, Carl-Thiem-Klinikum, Cottbus, Germany.;Department of Otorhinolaryngology - Head and Neck Surgery, Madras ENT Research Foundation, Chennai, India.;Airway Surgery Unit, Pediatric Surgery Department, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.;Association "Naso Sano" Onlus, Umbria Regional Registry of Volunteer Activities, Department of Otorhinolaryngology and Head and Neck Surgery, Gubbio-Gualdo Tadino Hospital, Perugia, Italy.;Department of Otolaryngology-Head and Neck Surgery, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon.;Department of Otolaryngology, Pontificia Universidad Católica de Chile, Santiago, Chile.;Norwegian Society of Otorhinolaryngology-Head and Neck Surgery, Nesttun, Norway.;University Medical Center Utrecht, Utrecht, Netherlands.;Department of Otolaryngology Hospital Medica Sur, Mexico, Mexico.;Department of Otorhinolaryngology, Coimbra Hospital and University Centre, Coimbra, Portugal.;Department of Otolaryngology, Lund University, Lund, Sweden.;Division of Otorhinolaryngology, University of Cape Town, Cape Town, South Africa.;ENT Morningside, Morningside Mediclinic, Sandton, Johannesburg, South Africa.;Department of Otolaryngology-Head and Neck Surgery, Hôpitaux Universitaires de Marseille Conception, Assistance Publique-Hôpitaux de Marseille (APHM), Aix-Marseille University, Marseille, France.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario de Donostia, San Sebastian, Spain.;Department of Otolaryngology-Head and Neck Surgery, Istanbul Training and Research Hospital, Istanbul, Turkey.;Department of Otolaryngology, Saint Petersburg Research Institute of Ear, Throat, Nose and Speech, First Pavlov State Medical University, Saint Petersburg, Russia.;Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA.;Department of Otolaryngology, University of Miami, Miami, FL.;Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, CA. | 1941 | |||
| 10.5001/omj.2020.81 | Editorial | en | Lessons to Learn from COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32802418 | 1999-768X,2070-5204 | 2020-08-02 02:00:00+02:00 | pubmed | Oman Medical Journal | Khaled Moustafa | 2020-07-31 02:00:00+02:00 | 32802418 | FR | Editor of Arabic Science Archive, Paris, France. | 1952 | |||||
| 10.2340/00015555-3610 | Journal Article | en | Impact of the COVID-19 Pandemic on Chronic Inflammatory Dermatoses: Mixed Messages Regarding the Dermatologist's Point of View and the Patient's Concerns. | https://www.ncbi.nlm.nih.gov/pubmed/32735023 | 1651-2057 | 2020-08-02 02:00:00+02:00 | pubmed | Acta Dermato Venereologica | Anne-Claire Fougerousse;François Maccari;Ziad Reguiai;Edouard Begon;Valérie Pallure;Charles Taïeb;Céline Girard;Laure Mery-Bossard | COVID-19;dermatologists;impact;patients;chronic inflammatory dermatoses | 2020-07-31 02:00:00+02:00 | 32735023 | FR | Department of Dermatology, Military Teaching Hospital Bégin, 69 avenue de Paris, FR-94160 Saint Mandé, France. E-mail: ac.fougerousse@gmail.com. | 1957 | ||||
| Instituto de Salud Carlos III | 10.1186/s12916-020-01693-9 | Journal Article;Research Support, Non-U.S. Gov't | en | "The post-COVID era": challenges in the treatment of substance use disorder (SUD) after the pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32731868 | Citizens affected by substance use disorders are high-risk populations for both SARS-CoV-2 infection and COVID-19-related mortality. Relevant vulnerabilities to COVID-19 in people who suffer substance use disorders are described in previous communications. The COVID-19 pandemic offers a unique opportunity to reshape and update addiction treatment networks. | 1741-7015 | 2020-08-02 02:00:00+02:00 | pubmed | Betacoronavirus;Comorbidity;Coronavirus Infections__complications;Humans;Pandemics;Pneumonia, Viral__complications;Quality of Life;Severe Acute Respiratory Syndrome__epidemiology;Substance-Related Disorders__epidemiology;Telemedicine__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | BMC Medicine | Hugo López-Pelayo;Henri-Jean Aubin;Colin Drummond;Geert Dom;Francisco Pascual;Jürgen Rehm;Richard Saitz;Emanuele Scafato;Antoni Gual | Addictions;COVID-19;Harm-reduction;Stigma;Substance use disorder;Telemedicine | 2020-07-31 02:00:00+02:00 | 32731868 | FR;RU;CA;GB;US;IT;ES;BE;DE | [{"country": "International", "agency": "Instituto de Salud Carlos III", "grantid": "JR19/00025"}] | Grup Recerca Addiccions Clínic (GRAC-GRE), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic Barcelona, Rosselló 149, 08036, Barcelona, Spain. hlopez@clinic.cat.;Socidrogalcohol (Spanish Society of Drug and Alcohol Specialists), Barcelona, Spain. hlopez@clinic.cat.;Département de psychiatrie et d'addictologie, Université Paris-Saclay, Route de l'Orme aux Merisiers - RD 128 91190 Saint-Aubin, Paris, France.;Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM 1018, Paris, France.;Groupe Hospitalo-Universitaire AP-HP, Paris, France.;Addiction Psychiatry, Addictions Department, National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College, 16 De Crespigny Park, Camberwell, London, SE5 8AF, UK.;European Federation of Addiction Societies (EUFAS), 16 De Crespigny Park, Camberwell, London, SE5 8AF, UK.;Antwerp University (UA, CAPRI), Antwerp, Belgium.;Belgian Professional Psychiatry Association, Antwerp, Belgium.;European Federation of Addiction Societies (EUFAS), Antwerp, Belgium.;European Psychiatric Association (EPA), Prinsstraat 13, 2000, Antwerp, Belgium.;SOCIDROGALCOHOL, Barcelona, Spain.;CAARFE, Valencia, Spain.;Departamento de Biología Aplicada, Alicante, Spain.;UCA, Alcoy, Alicante, Spain.;Institute for Mental Health Policy Research & Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.;Dalla Lana School of Public Health and Department of Psychiatry, University of Toronto (UofT), 155 College St., Toronto, Canada.;Epidemiological Research Unit, Technische Universität Dresden, Klinische Psychologie and Psychotherapie, Dresden, Germany.;Department of International Health Projects, Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.;Department of Community Health Sciences (CHS), Boston University School of Public Health, 715 Albany St, Boston, MA, 02118, USA.;Medicine, Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Boston University School of Medicine, Boston, MA, 02118, USA.;Grayken Center on Addiction, Boston Medical Center, Boston, MA, 02118, USA.;WHO Collaborating Centre on Research and Health-Osservatorio Nazionale Alcol, Promotion on Alcohol and Alcohol-related Health, Problems (ITA-79), Istituto Superiore di Sanità, Rome, Italy.;Società Italiana di Alcologia - SIA, EUFAS Istituto Superiore di Sanità, Rome, Italy.;Grup Recerca Addiccions Clínic (GRAC-GRE), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic Barcelona, Rosselló 149, 08036, Barcelona, Spain.;International Network on Brief Interventions for Alcohol and Other Drugs (INEBRIA), Barcelona, Spain. | 1959 |
| 10.1136/bmj.m2924 | Journal Article;Practice Guideline | en | Remdesivir for severe covid-19: a clinical practice guideline. | https://www.ncbi.nlm.nih.gov/pubmed/32732352 | What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020. | 1756-1833 | 2020-08-02 02:00:00+02:00 | pubmed | Adenosine Monophosphate__analogs & derivatives;Alanine__analogs & derivatives;Antiviral Agents__therapeutic use;Betacoronavirus__isolation & purification;Coronavirus Infections__diagnosis;Guideline Adherence;Humans;Length of Stay__statistics & numerical data;Network Meta-Analysis;Pandemics;Pneumonia, Viral__diagnosis;Randomized Controlled Trials as Topic;Respiration, Artificial__statistics & numerical data;Severity of Illness Index;Time Factors;Treatment Outcome;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | BMJ | Bram Rochwerg;Arnav Agarwal;Linan Zeng;Yee-Sin Leo;John Adabie Appiah;Thomas Agoritsas;Jessica Bartoszko;Romina Brignardello-Petersen;Begum Ergan;Long Ge;Heike Geduld;Hayley B Gershengorn;Hela Manai;Minhua Huang;François Lamontagne;Seema Kanda;Leticia Kawano-Dourado;Linda Kurian;Arthur Kwizera;Srinivas Murthy;Nida Qadir;Reed Siemieniuk;Maria Asuncion Silvestre;Per Olav Vandvik;Zhikang Ye;Dena Zeraatkar;Gordon Guyatt | 2020-07-30 02:00:00+02:00 | 32732352 | FR;SG;NO;CA;GH;UNK;TN;CN;UG;CH;US;GB;BR;TR;ZA;PH | Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada rochwerg@mcmaster.ca.;Department of Medicine, McMaster University, Hamilton, Ontario Canada.;Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.;Department of Medicine, University of Toronto, Toronto, Ontario, Canada.;Pharmacy Department-Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.;National Center for Infectious Diseases, Singapore.;Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.;Division of General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland.;Not panel member, systematic review team and resource for guideline panel.;Department of Pulmonary and Critical Care, Dokuz Eylul University, School of Medicine, Izmir, Turkey.;Evidence Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.;Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China.;Division of Emergency Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.;Division of Pulmonary, Critical Care and Sleep Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA.;Division of Critical Care Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.;Emergency Medical Services, Faculty of Medicine, Tunis, Tunisia.;Guangdong Kuaiwen Information Technology Co. LTD, Guangzhou, Guangdong, China.;Department of Medicine, Centre de recherche du CHU de Sherbrooke, Sherbrooke, Quebec, Canada.;McMaster University (alumnus).;Pulmonary Division, Heart Institute (InCor)- HCFMUSP, Medical School, University of Sao Paulo, São Paulo, Brazil.;Research Institute, Hospital do Coração (HCor), São Paulo, Brazil.;Division of Hospital Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.;Department of Anaesthesia and Critical Care, College of Health Sciences, Makerere University, Kampala, Uganda.;Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.;Not panel member, resource for methodology and content support.;Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.;Kalusugan ng Mag-Ina (Health of Mother and Child), Inc., Quezon City, Philippines.;Asia-Pacific Center for Evidence-Based Healthcare, Manila, Philippines.;Department of Health Economics and Health Management, Institute for Health and Society, University of Oslo, Oslo, Norway. | 1965 | |||
| 10.1371/journal.ppat.1008737 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Interplay between SARS-CoV-2 and the type I interferon response. | https://www.ncbi.nlm.nih.gov/pubmed/32726355 | The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the current COVID-19 pandemic. An unbalanced immune response, characterized by a weak production of type I interferons (IFN-Is) and an exacerbated release of proinflammatory cytokines, contributes to the severe forms of the disease. SARS-CoV-2 is genetically related to SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS-CoV), which caused outbreaks in 2003 and 2013, respectively. Although IFN treatment gave some encouraging results against SARS-CoV and MERS-CoV in animal models, its potential as a therapeutic against COVID-19 awaits validation. Here, we describe our current knowledge of the complex interplay between SARS-CoV-2 infection and the IFN system, highlighting some of the gaps that need to be filled for a better understanding of the underlying molecular mechanisms. In addition to the conserved IFN evasion strategies that are likely shared with SARS-CoV and MERS-CoV, novel counteraction mechanisms are being discovered in SARS-CoV-2-infected cells. Since the last coronavirus epidemic, we have made considerable progress in understanding the IFN-I response, including its spatiotemporal regulation and the prominent role of plasmacytoid dendritic cells (pDCs), which are the main IFN-I-producing cells. While awaiting the results of the many clinical trials that are evaluating the efficacy of IFN-I alone or in combination with antiviral molecules, we discuss the potential benefits of a well-timed IFN-I treatment and propose strategies to boost pDC-mediated IFN responses during the early stages of viral infection. | 1553-7374 | 2020-08-02 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Dendritic Cells__drug effects;Humans;Immunity, Innate__drug effects;Interferon Type I__therapeutic use;Pandemics;Pneumonia, Viral__drug therapy;Prognosis;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | PLOS Pathogens | Margarida Sa Ribero;Nolwenn Jouvenet;Marlène Dreux;Sébastien Nisole | 2020-07-29 02:00:00+02:00 | 32726355 | FR | CIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, École Normale Supérieure de Lyon, Univ Lyon, Lyon, France.;Institut Pasteur, CNRS UMR3569, Paris, France.;IRIM, CNRS UMR9004, Université de Montpellier, Montpellier, France. | 1966 | |||
| 10.3390/ma13153339 | Journal Article;Review | en | 3D Printing to Support the Shortage in Personal Protective Equipment Caused by COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32727050 | Currently, the emergence of a novel human coronavirus disease, named COVID-19, has become a great global public health concern causing severe respiratory tract infections in humans. Yet, there is no specific vaccine or treatment for this COVID-19 where anti-disease measures rely on preventing or slowing the transmission of infection from one person to another. In particularly, there is a growing effort to prevent or reduce transmission to frontline healthcare professionals. However, it is becoming an increasingly international concern respecting the shortage in the supply chain of critical single-use personal protective equipment (PPE). To that scope, we aim in the present work to provide a comprehensive overview of the latest 3D printing efforts against COVID-19, including professional additive manufacturing (AM) providers, makers and designers in the 3D printing community. Through this review paper, the response to several questions and inquiries regarding the following issues are addressed: technical factors connected with AM processes; recommendations for testing and characterizing medical devices that additively manufactured; AM materials that can be used for medical devices; biological concerns of final 3D printed medical parts, comprising biocompatibility, cleaning and sterility; and limitations of AM technology. | 1996-1944 | 2020-08-02 02:00:00+02:00 | pubmed | Materials | Mostapha Tarfaoui;Mourad Nachtane;Ibrahim Goda;Yumna Qureshi;Hamza Benyahia | COVID-19;additive manufacturing/3D printing;material biocompatibility;medical devices;novel coronavirus;personal protective equipment;technical considerations | 2020-07-27 02:00:00+02:00 | 32727050 | FR | ENSTA Bretagne, IRDL-UMR CNRS 6027, F-29200 Brest, France.;Arts et Metiers Institute of Technology, University of Bordeaux, CNRS, Bordeaux INP, INRAE, I2M Bordeaux, F-33400 Talence, France. | 1973 | |||
| Letter | en | Are clinical outcomes worse for pregnant women ≥ 20 weeks' gestation infected with COVID-19? A multicenter case-control study with propensity score matching. | https://www.ncbi.nlm.nih.gov/pubmed/32730899 | 2020-08-02 02:00:00+02:00 | pubmed | Dominique A Badr;Jérémie Mattern;Andrew Carlin;Anne-Gaël Cordier;Evelyne Maillart;Larissa El Hachem;Hanane El Kenz;Marc Andronikof;David De Bels;Charles Damoisel;Thierry Preseau;Dorothée Vignes;Mieke M Cannie;Christelle Vauloup-Fellous;Jean-François Fils;Alexandra Benachi;Jacques C Jani;Alexandre J Vivanti | COVID-19;Diabetes;Endotracheal intubation;High-risk pregnancy;Hypertension;Intensive care unit;Pregnancy;Propensity score matching;Respiratory failure;SARS-CoV-2 | 2020-07-27 02:00:00+02:00 | 32730899 | FR;BE | Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Obstetrics and Gynecology, Antoine Béclère Hospital, Paris Saclay University, AP-HP, Clamart, France.;Division of Obstetrics and Gynecology, Bicêtre Hospital, Paris Saclay University, AP-HP, Le Kremlin-Bicêtre, France.;Department of Infectious Diseases, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Obstetrics and Gynecology, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France.;Department of Transfusion and Blood Bank, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Emergency, Antoine Béclère Hospital, Paris Saclay University, AP-HP, Clamart, France.;Department of Intensive Care, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Critical Care, Antoine Béclère Hospital, Paris Saclay University, AP-HP, Clamart, France.;Department of Emergency, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Internal Medicine and Immunology, Antoine Béclère Hospital, Paris Saclay University, AP-HP, Clamart, France.;Department of Radiology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium.;Division of Virology, Paul Brousse Hospital, Paris Saclay University, AP-HP, Villejuif, France.;Ars Statistica, Nivelles, Belgium.;Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: jackjani@hotmail.com. | 1977 | |||||||
| 10.1016/j.ohx.2020.e00129 | Journal Article | en | Conversion of self-contained breathing apparatus mask to open source powered air-purifying particulate respirator for fire fighter COVID-19 response. | https://www.ncbi.nlm.nih.gov/pubmed/32835140 | To assist firefighters and other first responders to use their existing equipment for respiration during the COVID-19 pandemic without using single-use, low-supply, masks, this study outlines an open source kit to convert a 3M-manufactured Scott Safety self-contained breathing apparatus (SCBA) into a powered air-purifying particulate respirator (PAPR). The open source PAPR can be fabricated with a low-cost 3-D printer and widely available components for less than $150, replacing commercial conversion kits saving 85% or full-fledged proprietary PAPRs saving over 90%. The parametric designs allow for adaptation to other core components and can be custom fit specifically to fire-fighter equipment, including their suspenders. The open source PAPR has controllable air flow and its design enables breathing even if the fan is disconnected or if the battery dies. The open source PAPR was tested for air flow as a function of battery life and was found to meet NIOSH air flow requirements for 4 h, which is 300% over expected regular use. | 2468-0672 | 2020-08-02 02:00:00+02:00 | pubmed | HardwareX | Benjamin R Hubbard;Joshua M Pearce | 3-D printing;Additive manufacturing;COVID-19;Medical hardware;Open hardware;PAPR;Personal protective equipment;Powered Air-Purifying Respirator;RepRap;Safety equipment | 2020-07-27 02:00:00+02:00 | 32835140 | FI;FR;US | Department of Mechanical Engineering-Engineering Mechanics, Michigan Technological University, Houghton, MI 49931, USA.;Department of Materials Science & Engineering, Michigan Technological University, USA.;Department of Electrical & Computer Engineering, Michigan Technological University, USA.;Équipe de Recherche sur les Processus Innovatifs (ERPI), Université de Lorraine, France.;School of Electrical Engineering, Aalto University, Finland. | 1984 | |||
| 10.1016/j.ejps.2020.105495 | Journal Article | en | Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages. | https://www.ncbi.nlm.nih.gov/pubmed/32730844 | In December 2019, a new coronavirus was identified in the Hubei province of central china and named SARS-CoV-2. This new virus induces COVID-19, a severe respiratory disease with high death rate. A putative target to interfere with the virus is the host transmembrane serine protease family member II (TMPRSS2). This enzyme is critical for the entry of coronaviruses into human cells by cleaving and activating the spike protein (S) of SARS-CoV-2. Repositioning approved, investigational and experimental drugs on the serine protease domain of TMPRSS2 could thus be valuable. There is no experimental structure for TMPRSS2 but it is possible to develop quality structural models for the serine protease domain using comparative modeling strategies as such domains are highly structurally conserved. Beside the TMPRSS2 catalytic site, we predicted on our structural models a main exosite that could be important for the binding of protein partners and/or substrates. To block the catalytic site or the exosite of TMPRSS2 we used structure-based virtual screening computations and two different collections of approved, investigational and experimental drugs. We propose a list of 156 molecules that could bind to the catalytic site and 100 compounds that may interact with the exosite. These small molecules should now be tested in vitro to gain novel insights over the roles of TMPRSS2 or as starting point for the development of second generation analogs. | 0928-0987 | 2020-08-02 02:00:00+02:00 | pubmed | European Journal of Pharmaceutical Sciences | Natesh Singh;Etienne Decroly;Abdel-Majid Khatib;Bruno O Villoutreix | COVID-19;Drug repositioning;Drug repurposing;Homology modeling;SARS-CoV2;Structural bioinformatics;Virtual screening | 2020-07-28 02:00:00+02:00 | 32730844 | FR | Univ. Lille, INSERM, Institut Pasteur de Lille, U1177, F-59000 Lille, France.;Aix Marseille Univ. CNRS, AFMB UMR 7257, Marseille, France.;Univ. Bordeaux, Allée Geoffroy St Hilaire, 33615 Pessac, France, INSERM, LAMC, UMR 1029, Allée Geoffroy St Hilaire, 33615 Pessac, France.;Univ. Lille, INSERM, Institut Pasteur de Lille, U1177, F-59000 Lille, France. Electronic address: bruno.villoutreix@inserm.fr. | 1989 | |||
| 10.1093/ecco-jcc/jjaa150 | Journal Article | en | Care of the Patient with IBD Requiring Hospitalization During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32722757 | The management of IBD has been highly impacted in the context of the COVID-19 pandemic, with restriction of hospitalizations and unprecedented redeployment of healthcare resources. Hospital admissions of IBD patients should be limited to reduce the risks of coronavirus transmission. However, delaying hospitalization of IBD patients with severe or complicated disease may increase the risk of poor outcomes. Delaying surgery in some cases may increase the risk of disease progression, post-operative morbidity and disease complications. IBD patients who are infected with SARS-CoV-2 may have a higher risk of poor outcomes than the general population, potentially related to concomitant medications, especially corticosteroids. There is no evidence today that IBD patients with COVID-19 have worse outcomes if they receive immunosuppressant medications including thiopurines, biologics and novel small molecules. This article summarizes recommendations by the international membership of IOIBD regarding hospitalizations of IBD patients, either for active or complicated IBD or severe COVID-19, and for management of IBD patients according to SARS-CoV-2 infectious status. | 1873-9946,1876-4479 | 2020-08-02 02:00:00+02:00 | pubmed | Journal of Crohn's and Colitis | Matthieu Allez;Phillip Fleshner;Richard Gearry;Peter L Lakatos;David T Rubin | 2020-07-29 02:00:00+02:00 | 32722757 | FR;CA;NZ;US;HU | Hôpital Saint-Louis, Department of Gastroenterology, APHP, Université de Paris, France.;Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.;Department of Medicine, University of Otago, Christchurch, New Zealand.;McGill University, Division of Gastroenterology Department of Medicine, Montreal, Canada and Semmelweis University, 1st Department of Medicine, Budapest, Hungary.;University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA. | 1993 | ||||
| Letter | en | Surgery and COVID-19: Balancing the nosocomial risk a french academic center experience during the epidemic peak. | https://www.ncbi.nlm.nih.gov/pubmed/32725815 | 2020-08-02 02:00:00+02:00 | pubmed | A Ingels;S Bibas;J B Da Costa;A Attias;F Brunetti;N De Angelis;P Desgranges;C-H Flouzat-Lachaniette;T Folliguet;T Ivanov;O Langeron;L Lelde;E Levesque;P L Corvoisier;C Marmorat;F Melendugno;J-P Meningaud;F Mesli;W Paillusson;S Palfi;L Pedre;D Somacale;C M Champy;A de la Taille | 2020-07-29 02:00:00+02:00 | 32725815 | FR | Department of Urology, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Anesthesiology and Intensive Care, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Visceral surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Vascular surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Orthopedic surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Cardiac surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;INSERM, CIC 1430 - Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Reconstructive surgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Gastroenterology, Hôpital Henri Mondor - APHP, UPEC, Créteil, France.;Department of Neurosurgery, Hôpital Henri Mondor - APHP, UPEC, Créteil, France. | 1994 | ||||||||
| 10.1038/s41577-020-0407-1 | Journal Article | en | Tissue damage from neutrophil-induced oxidative stress in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32728221 | 1474-1733,1474-1741 | 2020-08-02 02:00:00+02:00 | pubmed | Nature Reviews Immunology | Mireille Laforge;Carole Elbim;Corinne Frère;Miryana Hémadi;Charbel Massaad;Philippe Nuss;Jean-Jacques Benoliel;Chrystel Becker | 2020-07-29 02:00:00+02:00 | 32728221 | FR | CNRS, INSERM UMRS 1124, Faculté des sciences fondamentales et biomédicales, Université de Paris, Paris, France.;Centre de Recherche Saint-Antoine, INSERM UMRS 938, Sorbonne Université, Paris, France.;Institute of Cardiometabolism and Nutrition (ICAN), GRC 27 GRECO, INSERM 1166, Sorbonne Université, Paris, France.;Université de Paris, CNRS-UMR 7086, Interfaces, Traitements, Organisation et DYnamique des Systèmes (ITODYS), Paris, France.;Service de psychiatrie et de psychologie médicale, Sorbonne Université, Hôpital Saint-Antoine, AP-HP, Paris, France.;Service de biochimie endocrinienne et oncologie, Hôpital Pitié-Salpêtrière AP-HP, Sorbonne Université, Paris, France.;CNRS, INSERM UMRS 1124, Faculté des sciences fondamentales et biomédicales, Université de Paris, Paris, France. christel.becker@parisdescartes.fr. | 2003 | |||||
| 10.1002/ddr.21732 | Journal Article;Review | en | Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32761647 | The severe acute respiratory syndrome coronavirus-2 (SARS-COV-2), a novel coronavirus responsible for the recent infectious pandemic, is known to downregulate angiotensin-converting enzyme-2 (ACE2). Most current investigations focused on SARS-COV-2-related effects on the renin-angiotensin system and especially the resultant increase in angiotensin II, neglecting its effects on the kinin-kallikrein system. SARS-COV-2-induced ACE2 inhibition leads to the augmentation of bradykinin 1-receptor effects, as ACE2 inactivates des-Arg9-bradykinin, a bradykinin metabolite. SARS-COV-2 also decreases bradykinin 2-receptor effects as it affects bradykinin synthesis by inhibiting cathepsin L, a kininogenase present at the site of infection and involved in bradykinin production. The physiologies of both the renin-angiotensin and kinin-kallikrein system are functionally related suggesting that any intervention aiming to treat SARS-COV-2-infected patients by triggering one system but ignoring the other may not be adequately effective. Interestingly, the snake-derived bradykinin-potentiating peptide (BPP-10c) acts on both systems. BPP-10c strongly decreases angiotensin II by inhibiting ACE, increasing bradykinin-related effects on the bradykinin 2-receptor and increasing nitric oxide-mediated effects. Based on a narrative review of the literature, we suggest that BPP-10c could be an optimally effective option to consider when aiming at developing an anti-SARS-COV-2 drug. | 0272-4391,1098-2299 | 2020-08-09 02:00:00+02:00 | pubmed | Drug Development Research | Ahmed S Gouda;Bruno Mégarbane | COVID-19;kinin-kallikrein system;snake-derived bradykinin-potentiating peptide | 2020-08-05 02:00:00+02:00 | 32761647 | FR;EG | National Egyptian Center for Toxicological Researches, Faculty of Medicine, University of Cairo, Cairo, Egypt.;Department of Medical and Toxicological Critical Care, Lariboisière Hospital, University of Paris, INSERM UMRS-1144, Paris, France. | 2014 | |||
| 10.1021/acs.jproteome.0c00535 | Journal Article | en | Proteotyping SARS-CoV-2 Virus from Nasopharyngeal Swabs: A Proof-of-Concept Focused on a 3 Min Mass Spectrometry Window. | https://www.ncbi.nlm.nih.gov/pubmed/32697082 | Rapid but yet sensitive, specific, and high-throughput detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical samples is key to diagnose infected people and to better control the spread of the virus. Alternative methodologies to PCR and immunodiagnostics that would not require specific reagents are worthy to investigate not only for fighting the COVID-19 pandemic but also to detect other emergent pathogenic threats. Here, we propose the use of tandem mass spectrometry to detect SARS-CoV-2 marker peptides in nasopharyngeal swabs. We documented that the signal from the microbiota present in such samples is low and can be overlooked when interpreting shotgun proteomic data acquired on a restricted window of the peptidome landscape. In this proof-of-concept study, simili nasopharyngeal swabs spiked with different quantities of purified SARS-CoV-2 viral material were used to develop a nanoLC-MS/MS acquisition method, which was then successfully applied on COVID-19 clinical samples. We argue that peptides ADETQALPQR and GFYAQGSR from the nucleocapsid protein are of utmost interest as their signal is intense and their elution can be obtained within a 3 min window in the tested conditions. These results pave the way for the development of time-efficient viral diagnostic tests based on mass spectrometry. | 1535-3893,1535-3907 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Proteome Research | Duarte Gouveia;Guylaine Miotello;Fabrice Gallais;Jean-Charles Gaillard;Stéphanie Debroas;Laurent Bellanger;Jean-Philippe Lavigne;Albert Sotto;Lucia Grenga;Olivier Pible;Jean Armengaud | COVID-19;SARS-CoV-2;mass spectrometry;peptides;proteomics;viral protein detection, nasopharyngeal swab | 2020-08-05 02:00:00+02:00 | 32697082 | FR | INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Université Paris Saclay, CEA, 30200 Bagnols-sur-Cèze, France.;U1047, Institut National de la Santé et de la Recherche Médicale, Université Montpellier, Montpellier, France.;VBMI, INSERM U1047, Université de Montpellier, Service de Microbiologie et Hygiène Hospitalière, CHU Nîmes, Nîmes, France.;VBMI, INSERM U1047, Université de Montpellier, Service des Maladies Infectieuses et Tropicales, CHU Nîmes, Nîmes, France. | 2016 | |||
| Letter | en | COVID-19: Time to exonerate the pangolin from the transmission of SARS-CoV-2 to humans. | https://www.ncbi.nlm.nih.gov/pubmed/32768565 | The emergence of COVID-19 has triggered many works aiming at identifying the animal intermediate potentially involved in the transmission of SARS-CoV-2 to humans. The presence of SARS-CoV-2-related viruses in Malayan pangolins, in silico analysis of the ACE2 receptor polymorphism and sequence similarities between the Receptor Binding Domain (RBD) of the spike proteins of pangolin and human Sarbecoviruses led to the proposal of pangolin as intermediary. However, the binding affinity of the pangolin ACE2 receptor for SARS-CoV-2 RBD was later on reported to be low. Here, we provide evidence that the pangolin is not the intermediate animal at the origin of the human pandemic. Moreover, data available do not fit with the spillover model currently proposed for zoonotic emergence which is thus unlikely to account for this outbreak. We propose a different model to explain how SARS-CoV-2 related coronaviruses could have circulated in different species, including humans, before the emergence of COVID-19. | 2020-08-09 02:00:00+02:00 | pubmed | Roger Frutos;Jordi Serra-Cobo;Tianmu Chen;Christian A Devaux | COVID-19;Coronavirus;Pangolin;SARS-CoV-2;Zoonosis;Zoonotic model | 2020-08-05 02:00:00+02:00 | 32768565 | FR;CN;ES | Cirad, UMR 17, Intertryp, Montpellier, France, IES, UMR 5214 Univ. Montpellier-CNRS, Montpellier, France. Electronic address: roger.frutos@cirad.fr.;Department of Evolutionary Biology, Ecology and Environmental Sciences, University of Barcelona, Biodiversity Research Institute, Barcelona, Spain.;State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, PR China.;IHU-Méditerranée Infection and CNRS, Marseille, France. | 2019 | ||||||
| Letter | en | EMS dispatch center activity during the COVID-19 containment. | https://www.ncbi.nlm.nih.gov/pubmed/32826107 | 2020-08-09 02:00:00+02:00 | pubmed | Yann Penverne;Joel Jenvrin;Emmanuel Montassier | Activity;COVID-19;Calls;EMS dispatch center | 2020-08-05 02:00:00+02:00 | 32826107 | FR | Department of Emergency Medicine & SAMU44, CHU de Nantes, 44000 Nantes, France.;Department of Emergency Medicine & SAMU44, CHU de Nantes, 44000 Nantes, France, MiHAR lab, University of Nantes, France. Electronic address: emmanuel.montassier@chu-nantes.fr. | 2023 | |||||||
| 10.1111/all.14549 | Journal Article;Review | en | Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32762135 | Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage were associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin converting enzyme 2 (ACE2). As a result of SARS-Cov-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT1 R) axis associated with oxidative stress. This leads to insulin resistanceas well as lung and endothelial damage, two severe outcomes of COVID-19. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is the most potent antioxidant in humans and can block the AT1 R axis. Cabbage contains precursors of sulforaphane, the most active natural activator of Nrf2. Fermented vegetables contain many lactobacilli, which are also potent Nrf2 activators. Three examples are given: Kimchi in Korea, westernized foods and the slum paradox. It is proposed that fermented cabbage is a proof-of-concept of dietary manipulations that may enhance Nrf2-associated antioxidant effects helpful in mitigating COVID-19 severity. | 0105-4538,1398-9995 | 2020-08-09 02:00:00+02:00 | pubmed | Allergy | Jean Bousquet;Josep M Anto;Wienczyslawa Czarlewski;Tari Haahtela;Susana C Fonseca;Guido Iaccarino;Hubert Blain;Alain Vidal;Aziz Sheikh;Cezmi A Akdis;Torsten Zuberbier | Angiotensin converting enzyme 2;COVID-19;Lactobacillus;cabbage;diet;fermented vegetable;kimchi;sulforaphane | 2020-08-06 02:00:00+02:00 | 32762135 | FR;FI;PT;CH;GB;IT;ES;DE | Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.;MACVIA-France and CHU, Montpellier, France.;ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.;IMIM (Hospital del Mar Research Institute), Barcelona, Spain.;Universitat Pompeu Fabra (UPF), Barcelona, Spain.;CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.;MASK-air, Montpellier, France.;Medical Consulting Czarlewski, Levallois, France.;Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Finland.;GreenUPorto - Sustainable Agrifood Production Research Centre, DGAOT, Faculty of Sciences, University of Porto, Campus de Vairão, Porto, Portugal.;Federico II University, Department of Advanced Biomedical Sciences, Napoli, Italy.;Department of Geriatrics, Montpellier University hospital and MUSE, Montpellier, France.;World Business Council for Sustainable Development (WBCSD), Maison de la Paix, Geneva, Switzerland & AgroParisTech - Paris Institute of Technology for Life, Food and Environmental Sciences, Paris, France.;Usher Institute, University of Edinburgh, Scotland, UK.;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland. | 2027 | |||
| 10.1016/j.ijid.2020.08.012 | Journal Article | en | New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France. | https://www.ncbi.nlm.nih.gov/pubmed/32771635 | New loss of smell or taste was not included as common symptoms of COVID-19 until March 2020 when the pandemic started in Western countries. We want to describe the prevalence and features of anosmia and dysgeusia in COVID-19 patients. | 1201-9712 | 2020-08-09 02:00:00+02:00 | pubmed | International Journal of Infectious Diseases | Timothée Klopfenstein;Hajer Zahra;N'dri Juliette Kadiane-Oussou;Quentin Lepiller;Pierre-Yves Royer;Lynda Toko;Vincent Gendrin;Souheil Zayet | Anosmia;Clinical features;Coronavirus disease 2019;Dysgeusia;Symptoms | 2020-08-06 02:00:00+02:00 | 32771635 | FR | Infectious Disease Department, Nord Franche-Comté Hospital, France. Electronic address: timothee.klopfenstein@hnfc.fr.;Diabetology Department, Nord Franche-Comté Hospital, France.;Infectious Disease Department, Nord Franche-Comté Hospital, France.;Virology Department, Centre-Hospitalier Universitaire de Besançon, France.;Infectious Disease Department, Nord Franche-Comté Hospital, France. Electronic address: souhail.zayet@gmail.com. | 2038 | |||
| Letter;Comment | en | Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. | https://www.ncbi.nlm.nih.gov/pubmed/32554533 | 2020-08-09 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Patient Discharge;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Justine Frija-Masson;Marie-Pierre Debray;Marie Gilbert;François-Xavier Lescure;Florence Travert;Raphaël Borie;Antoine Khalil;Bruno Crestani;Marie-Pia d'Ortho;Catherine Bancal | 2020-08-06 02:00:00+02:00 | 32554533 | FR | Physiologie-Explorations Fonctionnelles, FHU APOLLO, Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France justine.frija@aphp.fr.;Université de Paris, Inserm U 1141, Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service de radiologie, Paris, France.;Université de Paris, Inserm U 1152, Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service de maladies infectieuses et tropicales, Paris, France.;Université de Paris, Inserm U 1137, Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service d'endocrinologie, Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service de pneumologie, Paris, France.;Physiologie-Explorations Fonctionnelles, FHU APOLLO, Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France. | 2041 | |||||||
| 10.1016/j.clinre.2020.07.012 | Journal Article | en | Drastic decrease of urgent endoscopies outside regular working hours during the Covid-19 pandemic in the paris area. | https://www.ncbi.nlm.nih.gov/pubmed/32788129 | The coronavirus 2019 (COVID-19) pandemic has significantly affected medical care. We surmise that the number of urgent endoscopies outside regular working hours in the Paris area decreased as a result. The objective of this study was to describe the observed number of acts during the 2020 mandatory period of home isolation, compared to the values in prior years and the expected value for 2020. | 2210-7401 | 2020-08-09 02:00:00+02:00 | pubmed | Clinics and Research in Hepatology and Gastroenterology | Aymeric Becq;Benedicte Jais;Clémence Fron;Hugo Rotkopf;Guillaume Perrod;Marika Rudler;Dominique Thabut;Abdellah Hedjoudje;Maxime Palazzo;Aurélien Amiot;Iradj Sobhani;Xavier Dray;Marine Camus | COVID-19 pandemic;Endoscopy outside regular working hours;Urgent endoscopy | 2020-08-04 02:00:00+02:00 | 32788129 | FR | Sorbonne Université, Endoscopy Unit, AP-HP, Hôpital Saint-Antoine, 75012 Paris, France. Electronic address: aymeric.becq@aphp.fr.;Endoscopy Unit, AP-HP, Hôpital Beaujon, 92110 Clichy, France.;Sorbonne Université, Endoscopy Unit, AP-HP, Hôpital Pitié Salpêtrière, 75013 Paris, France.;Paris 12 Université, APH-HP, Hôpital Henri Mondor, 94010 Créteil, France.;Gastroenterology Department, AP-HP, Hôpital Européen Georges Pompidou, Assistance, 75015 Paris, France.;Sorbonne Université, Endoscopy Unit, AP-HP, Hôpital Saint-Antoine, 75012 Paris, France. | 2050 | |||
| 10.1515/jpm-2020-0280 | Journal Article;Review | en | COVID-19, neutrophil extracellular traps and vascular complications in obstetric practice. | https://www.ncbi.nlm.nih.gov/pubmed/32739908 | An issue of the novel coronavirus infection spreading is currently in the first place among others in the list of the international medical community. Due to lack of information, conflicting research findings, multicomponent effect of the virus on the body host, as well as various consequences that the virus triggers in the body, now every medical specialty does study the viral attack pathogenesis. Recent months showed that vascular complications are the most severe in the Coronavirus Disease 2019 (COVID-19) and are the main cause of death in the patients. The mechanisms of vascular complications are complex and affect both the hemostatic system and immune responses, "inflammatory storm", disorders of the renin-angiotensin-aldosterone system, endotheliopathy, etc. Due to the leading role of vascular complications in the viral infection pathogenesis, several groups of patients are at extra risk, including pregnant women, patients with a burdened obstetric history, with hereditary thrombophilia and antiphospholipid syndrome, and patients after in vitro fertilization (IVF). In this category of pregnant women, use of low-molecular-weight heparins (LMWH) is particularly important for both prevention of vascular and obstetric complications, and for pathogenetic therapy of COVID-19. | 1619-3997,0300-5577 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Perinatal Medicine | Alexander Makatsariya;Ekaterina Slukhanchuk;Viktoriya Bitsadze;Jamilya Khizroeva;Maria Tretyakova;Valentina Tsibizova;Andrey Dobryakov;Ismail Elalamy;Jean C Gris | COVID-19;extracellular neutrophil traps;neutrophil extracellular traps (NETs);thrombophilia;vascular complications | 2020-08-03 02:00:00+02:00 | 32739908 | FR;RU | Department of Obstetrics and Gynecology, I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.;Gynecological Unit of Petrovsky National Research Center of Surgery, Moscow, Russia.;Department of Gynecology, «Medical Center» LLC, Moscow, Russia.;Department of Functional and Ultrasound Diagnostics, Almazov National Medical Research Centre, Saint Petersburg, Russia.;Pathologo-Anatomical Department of City Clinical Hospital, Bakhrushin Brothers Hospital, Moscow, Russia.;Hematology Department of Thrombosis Center, Tenon University Hospital, Medicine Sorbonne University, Paris, France.;Hematology Department of Montpellier University, Montpellier, France. | 2051 | |||
| 10.1111/ene.14466 | Journal Article | en | Large vessel stroke in six patients following SARS-CoV-2 infection: a retrospective case study series of acute thrombotic complications on stable underlying atherosclerotic disease. | https://www.ncbi.nlm.nih.gov/pubmed/32761999 | Ischemic stroke has been described in association with COVID-19. Several pathophysiological mechanisms have been suggested i.e prothrombotic state, cardiac injury etc. We sought to assess the potential association between ischemic stroke associated with SARS-CoV-2 infection and underlying atherosclerotic lesions. | 1351-5101,1468-1331 | 2020-08-09 02:00:00+02:00 | pubmed | European Journal of Neurology | Bertrand Lapergue;Aïcha Lyoubi;Elena Meseguer;Ioan Avram;Christian Denier;Laura Venditti;Arturo Consoli;Alexis Guedon;Emmanuel Houdart;David Weisenburger-Lile;Michel Piotin;Benjamin Maier;Mikael Obadia;Thomas De Broucker | atherosclerotic disease;cardiovascular disease;covid;intravascular clotting;ischemic stroke;large vessel occlusion | 2020-08-06 02:00:00+02:00 | 32761999 | FR | Neurovascular Unit Interventional Neuroradiology Department, Foch Hospital, Suresnes, France.;Neurovascular Unit, Saint Denis Hospital, France.;Neurovascular Unit, Bichat University Hospital, Paris, France.;Neurovascular Unit, Interventional Neuroradiology Department, Kremlin-Bicetre University Hospital, France.;Neurovascular Unit, Interventional Neuroradiology Department, Lariboisiere University Hospital Paris, France.;Interventional Neuroradiology Department Rothschild Fundation, Paris, France. | 2058 | |||
| 10.1007/s12603-020-1416-2 | Journal Article;Review | en | COVID-19, Virology and Geroscience: A Perspective. | https://www.ncbi.nlm.nih.gov/pubmed/32744561 | A new coronavirus, called SARS-CoV-2, was identified in Wuhan, China, in December 2019. The SARS-CoV-2 spread very rapidly, causing a global pandemic, Coronavirus Disease 2019 (COVID-19). Older adults have higher peak of viral load and, especially those with comorbidities, had higher COVID-19-related fatality rates than younger adults. In this Perspective paper, we summarize current knowledge about SARS-CoV-2 and aging, in order to understand why older people are more affected by COVID-19. We discuss about the possibility that the so-called "immunosenescence" and "inflammaging" processes, already present in a fraction of frail older adults, could allow the immune escape of SARS-CoV-2 leading to COVID-19 serious complications. Finally, we propose to use geroscience approaches to the field of COVID-19. | 1279-7707,1760-4788 | 2020-08-09 02:00:00+02:00 | pubmed | Aged;Aging__immunology;Betacoronavirus;Coronavirus Infections__epidemiology;Geriatrics;Humans;Inflammation__immunology;Pandemics;Pneumonia, Viral__epidemiology;Virology;COVID-19;severe acute respiratory syndrome coronavirus 2 | The journal of nutrition, health & aging | C Vellas;P Delobel;P de Souto Barreto;J Izopet | COVID-19;SARS-CoV-2;aging;coronavirus;frailty;geroscience;prevention | 2020-08-04 02:00:00+02:00 | 32744561 | FR | Camille Vellas, INSERM UMR1043 - CNRS UMR5282 Centre de Physiopathologie Toulouse-Purpan (CPTP), Toulouse, France, vellas.camille@gmail.com. | 2062 | ||
| 10.1080/21645515.2020.1787068 | Journal Article | en | Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. | https://www.ncbi.nlm.nih.gov/pubmed/32755425 | The current Coronavirus Disease 2019 (COVID-19) pandemic is causing great alarm around the world. The pathogen for COVID-19 - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - is the seventh known coronavirus to cause pneumonia in humans. While much remains unknown about SARS-CoV-2, physicians and researchers have begun to publish relevant findings, and much evidence is available on coronaviruses previously circulating in human and animal populations. In this review, we situate COVID-19 in its context as a transboundary viral disease, and provide a comprehensive discussion focused on the discovery, spread, virology, pathogenesis, and clinical features of this disease, its causative coronaviral pathogen, and approaches to combating the disease through immunotherapies and other treatments and vaccine development. An epidemiological survey revealed a potentially large number of asymptomatic SARS-CoV-2 carriers within the population, which may hamper efforts against COVID-19. Finally, we emphasize that vaccines against SARS-CoV-2, which may be developed by 2021, will be essential for prevention of COVID-19. | 2164-5515,2164-554X | 2020-08-09 02:00:00+02:00 | pubmed | Human Vaccines & Immunotherapeutics | Sayeh Ezzikouri;Jalal Nourlil;Soumaya Benjelloun;Michinori Kohara;Kyoko Tsukiyama-Kohara | Human coronavirus;origin;pathogenesis;public health;respiratory viruses;sars-CoV-2 | 2020-08-05 02:00:00+02:00 | 32755425 | FR;JP;MA | Virology Unit¸ Viral Hepatitis Laboratory, Institut Pasteur Du Maroc , Casablanca, Morocco.;Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University , Kagoshima, Japan.;Medical Virology and BSL3 Laboratory, Institut Pasteur Du Maroc , Casablanca, Morocco.;Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science , Tokyo, Japan. | 2065 | |||
| 10.1007/s00464-020-07835-7 | Journal Article | en | Surgical challenges and research priorities in the era of the COVID-19 pandemic: EAES membership survey. | https://www.ncbi.nlm.nih.gov/pubmed/32749615 | Healthcare systems and general surgeons are being challenged by the current pandemic. The European Association for Endoscopic Surgery (EAES) aimed to evaluate surgeons' experiences and perspectives, to identify gaps in knowledge, to record shortcomings in resources and to register research priorities. | 0930-2794,1432-2218 | 2020-08-09 02:00:00+02:00 | pubmed | Surgical Endoscopy | Marco Milone;Francesco Maria Carrano;Emina Letić;Andreas Shamiyeh;Antonello Forgione;Bang Wool Eom;Beat P Müller-Stich;Carmen Balagué Ponz;Christos Kontovounisios;Daniel Preda;Dejan Ignjatovic;Elisa Cassinotti;Eugenia Yiannakopoulou;George Theodoropoulos;Gil Faria;Luca Morelli;Marguerite Gorter-Stam;Sheraz Markar;Thanjakumar Arulampalam;Therese Velthoven;Stavros A Antoniou;Nader K Francis | COVID-19;Laparoscopy;Pandemic;Surgical challenges | 2020-08-04 02:00:00+02:00 | 32749615 | FR;CY;NO;PT;BA;GR;GB;US;RO;IT;NL;ES;DE;KR;AT | Department of Clinical Medicine and Surgery, University of Naples "Federico II", via pansini 5, Naples, Italy.;Department of Applied Medical-Surgical Sciences, University of Rome "Tor Vergata", Rome, Italy.;Humanitas Clinical and Research Center - IRCCS, via Manzoni 56, Rozzano, Milan, Italy.;Department of General Surgery, Faculty of Medicine, University of Sarajevo, Čekaluša 90, 71000, Sarajevo, Bosnia and Herzegovina.;Ludwig Boltzmann Institute for Operative Laparoscopy and 2nd Surgical Department, Academic Teaching Hospital of Linz, Krankenhausstrasse 9, 4020, Linz, Austria.;Department of Surgical Oncology and Minimally Invasive Surgery, AIMS Academy, Niguarda Hospital, Milan, Italy.;Center for Gastric Cancer, National Cancer Center, Research Institute and Hospital, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do, Republic of Korea.;Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.;Service of General & Digestive Surgery, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK.;1st Clinic of Surgery, Craiova Emergency Clinical County Hospital, Craiova, Romania.;Department of Digestive Surgery, Akershus University Hospital, Oslo, Norway.;Maggiore Policlinico Hospital, Fondazione IRCCS Cà Granda, Milan, Italy.;Department of Biomedical Sciences, Faculty of Health Sciences, University of West Attica, Athens, Greece.;First Department of Propaedeutic Surgery, Hippocration Hospital, Medical School of Athens University, 11527, Athens, Greece.;CINTESIS-Center for Research in Health Technologies and Information Systems, 4200-450, Porto, Portugal.;General Surgery, Hospital de Pedro Hispano, Unidade Local de Saúde de Matosinhos, 4464-513, Senhora da Hora, Portugal.;Department of Traslational Research and of New Surgical and Medical Technologies, Azienda Ospedaliero-Universitaria Pisana/University of Pisa, Pisa, Italy.;Department of Surgery, VU University Medical Center, Amsterdam, The Netherlands.;Division of Surgery, Department of Surgery & Cancer, St Mary's Hospital - Imperial College Healthcare NHS Trust, London, UK.;Department of General Surgery, Colchester General Hospital, Colchester, UK.;European Association for Endoscopic Surgery, Rome, Italy.;Department of Surgery, European University of Cyprus, Nicosia, Cyprus.;Griffin Institute (Northwick Park Institute of Medical Research), Northwick Park Hospital, Harrow, HA1 3UJ, UK. nader.francis@ydh.nhs.uk.;Yeovil District Hospital, Somerset, BA21 4AT, UK. nader.francis@ydh.nhs.uk. | 2066 | |||
| 10.1007/s10640-020-00478-1 | Journal Article | en | Suggestions for a Covid-19 Post-Pandemic Research Agenda in Environmental Economics. | https://www.ncbi.nlm.nih.gov/pubmed/32836846 | In this article we draw upon early lessons from the 2020 Covid-19 crisis and discuss how these may relate to a future research agenda in environmental economics. In particular, we describe how the events surrounding the Covid-19 crisis may inform environmental research related to globalization and cooperation, the green transition, pricing carbon externalities, as well as the role of uncertainty and timing of policy inventions. We also discuss the implications for future empirical research in this area. | 0924-6460,1573-1502 | 2020-08-09 02:00:00+02:00 | pubmed | Environmental and Resource Economics | Robert J R Elliott;Ingmar Schumacher;Cees Withagen | Cooperation;Covid-19;Environmental economics;Globalization;Green stimulus;Green transition;Research agenda | 2020-08-04 02:00:00+02:00 | 32836846 | FR;NL;GB | Department of Economics, Birmingham University, Birmingham, United Kingdom.;IPAG Business School, 183 Bvd St Germain, 75006 Paris, France.;Department of Spatial Economics Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. | 2072 | |||
| Editorial;Comment | en | To immunosuppress: whom, when and how? That is the question with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32753413 | 2020-08-09 02:00:00+02:00 | pubmed | Kevin L Winthrop;Xavier Mariette | arthritis;biological therapy;glucocorticoids;rheumatoid | 2020-08-04 02:00:00+02:00 | 32753413 | FR;US | Divisions of Infectious Diseases and Public Health, Oregon Health and Sciences University, Portland, Oregon, USA winthrop@ohsu.edu.;Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, Le Kremlin Bicêtre, France.;Université Paris-Sud, Center for Immunology of Viral Infections and Autoimmune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM) UMR 1184, Université Paris-Saclay, Le Kremlin Bicêtre, France. | 2076 | |||||||
| 10.1007/s10640-020-00473-6 | Journal Article | en | Impacts of the COVID-19 Pandemic on the Global Agricultural Markets. | https://www.ncbi.nlm.nih.gov/pubmed/32836856 | This paper analyses the impacts on global agricultural markets of the demand shock caused by the COVID-19 pandemic and the first wave of lockdown measures imposed by the governments in the first semester of 2020 to contain it. Specifically, we perform a scenario-based analysis on the IMF economic growth forecasts for 2020 and 2021 using a global multi-commodity agricultural market model. According to our results, the sharp decline in economic growth causes a decrease in international meat prices by 7-18% in 2020 and dairy products by 4-7% compared to a business as usual situation. Following the slowdown of the economy, biofuel prices fall strongly in 2020, followed by their main feedstocks, maize and oilseeds. Although the income losses and local supply chain disruptions associated with the pandemic undoubtedly has led to an increase in food insecurity in many developing countries, global food consumption is largely unaffected due to the inelastic demand of most agricultural commodities and the short duration of the shock. From an environmental viewpoint, the COVID-19 impacts point to a modest reduction of direct greenhouse gases from agriculture of about 1% or 50 million tonnes of carbon dioxide equivalents in 2020 and 2021. | 0924-6460,1573-1502 | 2020-08-09 02:00:00+02:00 | pubmed | Environmental and Resource Economics | Christian Elleby;Ignacio Pérez Domínguez;Marcel Adenauer;Giampiero Genovese | Aglink-Cosimo;Agricultural markets;Biofuel markets;COVID-19;GDP shock | 2020-08-04 02:00:00+02:00 | 32836856 | FR;ES | European Commission, Joint Research Centre, Seville, Spain.;Agro-Food Trade and Markets Division, OECD, Paris, France. | 2077 | |||
| 10.1007/s10640-020-00488-z | Journal Article | en | Assessing Short-Term and Long-Term Economic and Environmental Effects of the COVID-19 Crisis in France. | https://www.ncbi.nlm.nih.gov/pubmed/32836852 | In response to the COVID-19 health crisis, the French government has imposed drastic lockdown measures for a period of 55 days. This paper provides a quantitative assessment of the economic and environmental impacts of these measures in the short and long term. We use a Computable General Equilibrium model designed to assess environmental and energy policies impacts at the macroeconomic and sectoral levels. We find that the lockdown has led to a significant decrease in economic output of 5% of GDP, but a positive environmental impact with a 6.6% reduction in CO2 emissions in 2020. Both decreases are temporary: economic and environmental indicators return to their baseline trajectory after a few years. CO2 emissions even end up significantly higher after the COVID-19 crisis when we account for persistently low oil prices. We then investigate whether implementing carbon pricing can still yield positive macroeconomic dividends in the post-COVID recovery. We find that implementing ambitious carbon pricing speeds up economic recovery while significantly reducing CO2 emissions. By maintaining high fossil fuel prices, carbon taxation reduces the imports of fossil energy and stimulates energy efficiency investments while the full redistribution of tax proceeds does not hamper the recovery. | 0924-6460,1573-1502 | 2020-08-09 02:00:00+02:00 | pubmed | Environmental and Resource Economics | Paul Malliet;Frédéric Reynès;Gissela Landa;Meriem Hamdi-Cherif;Aurélien Saussay | CO2 emissions;Carbon tax;Macroeconomic modeling;Neo-Keynesian CGE model;Post-COVID economy | 2020-08-04 02:00:00+02:00 | 32836852 | GB;FR;NL | OFCE - French Economic Observatory, Paris, France.;NEO - Netherlands Economic Observatory, Rotterdam, The Netherlands.;TNO - Netherlands Organization for Applied Scientific Research, The Hague, The Netherlands.;LSE - London School of Economics, London, UK. | 2082 | |||
| 10.1139/cjm-2020-0373 | Journal Article | en | Keeping the Microbiology Lab Alive: Essential Microbiology Lab Skill Development in the Wake of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32758098 | NA. | 0008-4166,1480-3275 | 2020-08-09 02:00:00+02:00 | pubmed | Canadian Journal of Microbiology | Tanya C Noel;Joseph E Rubin;Yanelis Acebo Guerrero;Maria C Davis;Heather Dietz;Josie Libertucci;Nicole Sukdeo | 2020-08-06 02:00:00+02:00 | 32758098 | FR;CA;GB;US | University of Windsor, 8637, Integrative Biology, Windsor, Ontario, Canada , Tanya.Noel@uwindsor.ca.;University of Saskatchewan College of Veterinary Medicine, 70399, Veterinary Microbiology, Saskatoon, Saskatchewan, Canada , jer298@mail.usask.ca.;Integrated DNA Technologies Inc, 10865, Coralville, Iowa, United States , yaceboguerrero@idtdna.com.;University of Regina Department of Biology, 98642, Regina, Saskatchewan, Canada , maria.davis@uregina.ca.;University of Regina Department of Biology, 98642, Regina, Saskatchewan, Canada , Heather.Dietz@uregina.ca.;McMaster University, 3710, Hamilton, Ontario, Canada , libertj@mcmaster.ca.;College of New Caledonia, 6726, Biology, Prince George, British Columbia, Canada , sukdeon1@cnc.bc.ca. | 2085 | ||||
| 10.1684/epd.2020.1175 | Journal Article | en | Did the COVID-19 pandemic silence the needs of people with epilepsy? | https://www.ncbi.nlm.nih.gov/pubmed/32759092 | The COVID-19 pandemic shook European healthcare systems, with unavoidable gaps in the management of patients with chronic diseases. We describe the impact of the pandemic on epilepsy care in three tertiary epilepsy centres from Spain and Italy, the most affected European countries. The three epilepsy centres, members of the European EpiCARE network, manage more than 5,700 people with epilepsy. In Bologna and Barcelona, the hospitals housing the epilepsy centres were fully converted into COVID-19 units. We describe the reorganization of the clinics and report on the frequency of SARS-CoV-2 in people with epilepsy as well as the frequency of seizures in patients admitted to the COVID units. Finally, we elaborate on critical issues regarding the second phase of the pandemic. The activities related to epilepsy care were reduced to less than 10% and were deprioritized. Discharges were expedited and elective epilepsy surgeries, including vagal nerve stimulator implantations, cancelled. Hospitalizations and EEG examinations were limited to emergencies. The outpatient visits for new patients were postponed, and follow-up visits mostly managed by telehealth. Antiseizure medication weaning plans and changes in vagal nerve stimulator settings were halted. Among the 5,700 people with epilepsy managed in our centres, only 14 tested positive for SARS-CoV-2, without obvious impact on their epilepsy. None of the 2,122 patients admitted to COVID units experienced seizures among the early symptoms. Epilepsy care was negatively impacted by the pandemic, irrespective of COVID-19 epidemiology or conversion of the hospital into a COVID-19 centre. The pandemic did not silence the needs of people with epilepsy, and this must be considered in the planning of the second phase. | 2020-08-09 02:00:00+02:00 | pubmed | Tiziana Granata;Francesca Bisulli;Alexis Arzimanoglou;Rodrigo Rocamora | COVID-19;SARS-CoV-2;chronic disease;epilepsy;pandemic | 2020-08-06 02:00:00+02:00 | 32759092 | FR;IT;ES | Epilepsy Unit, Department of Pediatric Neuroscience. Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy. Member of ERN EpiCARE.;IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. Member of ERN EpiCARE, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.;Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology in Children, University Hospitals of Lyon (HCL), Coordinator of the ERN EpiCARE and of the Brain Dynamics and Cognition Team (DYCOG),INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, Lyon, France, Research Coordinator, Epilepsy Unit, San Juan de Dios Children's Hospital, Member of the ERN EpiCARE and Universitat de Barcelona, Barcelona, Spain.;Epilepsy Monitoring Unit, Department of Neurology, Hospital del Mar, Barcelona, Spain. Member of ERN EpiCARE, Hospital del Mar Medical Research Institute (IMIM) Barcelona, Spain. | 2087 | |||||
| Letter | en | Letter to the Editors: Statins and COVID-19: Efficacy Still to Be Proven. | https://www.ncbi.nlm.nih.gov/pubmed/32767854 | We read with interest the article by Bloom et al reporting liver biochemistry-associated trends, etiologies, and outcomes in 60 patients with coronavirus disease 2019 (COVID-19). The authors reported that 69% of the patients had abnormal liver function tests (LFTs) on admission and 93% during their hospital stay, with an aspartate aminotransferase (AST) predominance. These results are similar to our own experience of 234 patients admitted with COVID-19 according to World Health Organization (WHO) diagnostic guidelines. | 2020-08-09 02:00:00+02:00 | pubmed | Lucy Meunier;Magdalena Meszaros;Georges-Philippe Pageaux | 2020-08-07 02:00:00+02:00 | 32767854 | FR | Department of Hepatology and Liver Transplantation, Centre Hospitalier Universitaire Montpellier, Montpellier, France. | 2089 | |||||||
| 10.1093/geront/gnaa104 | Journal Article | en | Changes in Subjective Age During COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32766780 | To examine change in subjective age with the emergence of coronavirus disease 2019 (COVID-19). Two competing hypotheses were tested: (a) people felt increasingly older due to the stress generated by the pandemic; (b) people felt increasingly younger due to psychological distancing from older age, a vulnerability to COVID-19. | 0016-9013,1758-5341 | 2020-08-09 02:00:00+02:00 | pubmed | The Gerontologist | Antonio Terracciano;Yannick Stephan;Damaris Aschwanden;Ji Hyun Lee;Amanda A Sesker;Jason E Strickhouser;Martina Luchetti;Angelina R Sutin | Age identity;Coronavirus;Longitudinal;Multilevel Modeling;SARS-CoV-2 | 2020-08-07 02:00:00+02:00 | 32766780 | FR;US | Department of Geriatrics, Florida State University College of Medicine, Tallahassee, Florida.;Euromov, University of Montpellier, Montpellier, France.;Department of Behavioral Sciences and Social Medicine, Florida State University College of Medicine, Tallahassee, Florida. | 2090 | |||
| National Research Foundation of Korea;National Research Foundation of Korea | 10.1002/jmv.26397 | Journal Article | en | Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. | https://www.ncbi.nlm.nih.gov/pubmed/32767684 | Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM). | 0146-6615,1096-9071 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Medical Virology | Meehyun Ko;Sangeun Jeon;Wang-Shick Ryu;Seungtaek Kim | COVID-19;FDA-approved drug;SARS-CoV-2;drug repositioning | 2020-08-07 02:00:00+02:00 | 32767684 | FR;KR | [{"country": "", "agency": "National Research Foundation of Korea", "grantid": "NRF-2017M3A9G6068245"}, {"country": "", "agency": "National Research Foundation of Korea", "grantid": "NRF-2020M3E9A1041756"}] | Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, Korea.;CEO Office, Institut Pasteur Korea, Seongnam, Korea. | 2109 | |
| 10.1016/j.jelectrocard.2020.08.007 | Journal Article;Review | en | Value of electrocardiography in coronavirus disease 2019 (COVID-19). | https://www.ncbi.nlm.nih.gov/pubmed/32805546 | In December 2019, reports of an unknown pneumonia not responsive to traditional treatments arose in Wuhan, China. The pathogen was subsequently identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known to be responsible for the coronavirus disease-2019 (COVID-19) illness, and public health emergency of international concern was declared by the World Health Organization. There is increasing awareness of the cardiovascular manifestations of COVID-19 disease, and the adverse impact of cardiovascular involvement on its prognosis. In this setting, the electrocardiogram (ECG) is one of the leading tools to assess the extent of cardiac involvement in COVID-19 patients, due to its wide disponibility, low cost, and the possibility of remote evaluation. In this article, we review the role of the ECG in the identification of cardiac involvement in COVID-19, highlighting relevant clinical implications. | 0022-0736 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Electrocardiology | Sohaib Haseeb;Enes Elvin Gul;Göksel Çinier;George Bazoukis;Jesus Alvarez-Garcia;Sebastian Garcia-Zamora;Sharen Lee;Cynthia Yeung;Tong Liu;Gary Tse;Adrian Baranchuk | Arrhythmia;COVID-19;Electrocardiogram;Pandemics;QT interval;SARS-CoV-2 | 2020-08-06 02:00:00+02:00 | 32805546 | FR;AR;CA;SA;CN;GR;GB;US;AU;TR;ES | College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.;Division of Cardiac Electrophysiology, Madinah Cardiac Centre, Madinah, Saudi Arabia.;Department of Cardiology, Dr Siyami Ersek Hospital Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.;Second Department of Cardiology, Evangelismos General Hospital of Athens, Athens, Greece.;Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, USA, Cardiology Department, Hospital de la Santa Creu i Sant Pau, CIBERCV, Barcelona, Spain.;South American Center of Excellence for Cardiovascular Health (CESCAS), Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.;Laboratory of Cardiovascular Physiology, Chinese University Shenzhen Research Institute, PR China.;Heart Rhythm Service, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada.;Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, PR China.;Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, PR China. Electronic address: gary.tse@doctors.org.uk.;Heart Rhythm Service, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada. Electronic address: Adrian.Baranchuk@kingstonhsc.ca. | 2110 | |||
| 10.1016/j.jhep.2020.07.042 | Journal Article | en | Impact of COVID-19 on global hepatitis C elimination efforts. | https://www.ncbi.nlm.nih.gov/pubmed/32777322 | COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. | 0168-8278 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Hepatology | Sarah Blach;Loreta A Kondili;Alessio Aghemo;Zongzhen Cai;Ellen Dugan;Chris Estes;Ivane Gamkrelidze;Siya Ma;Jean Michel Pawlotsky;Devin Razavi-Shearer;Homie Razavi;Imam Waked;Stefan Zeuzem;Antonio Craxi | COVID-19;hepatitis C;mathematical modeling;viral hepatitis elimination | 2020-08-07 02:00:00+02:00 | 32777322 | FR;US;IT;EG;DE | Center for Disease Analysis Foundation, Lafayette, Colorado, United States. Electronic address: sblach@cdafound.org.;National Center for Global Health- Istituto Superiore di Sanità Rome Italy.;Internal Medicine and Hepatology Division, Humanitas Clinical and Research Center - IRCCS, Rozzano (Mi) - Italy, Humanitas University, Department of Biomedical Sciences, Milan, Italy.;Center for Disease Analysis Foundation, Lafayette, Colorado, United States.;National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, 94010 Créteil, France, INSERM U955, 94010 Créteil, France.;National Liver Institute, Menoufia University, Egypt.;Internal Medicine Department, Goethe University Hospital, Frankfurt, Germany.;Gastroenterology and Hepatology Unit, Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy. | 2115 | |||
| 10.1016/j.amcp.2020.08.003 | Journal Article;Review | fr | [Arterial and venous thrombosis in patients with COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32837203 | 1261-694X | 2020-08-09 02:00:00+02:00 | pubmed | Archives des Maladies du Coeur et des Vaisseaux - Pratique | S Zuily;V Dufrost;D Wahl | 2020-08-07 02:00:00+02:00 | 32837203 | FR | Université de Lorraine, Inserm DCAC UMR_S 1116 et Service de médecine vasculaire et centre de compétences régional maladies rares vasculaires, maladies autoimmunes et systémiques, syndrome de Marfan et apparentés, CHRU de Nancy, Institut Lorrain Louis-Mathieu, rue du Morvan, 54511 Vandoeuvre-lès-Nancy Cedex, France. | 2116 | |||||
| 10.1016/s2665-9913(20)30272-1 | Journal Article | en | Anakinra for severe forms of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32838318 | 2665-9913 | 2020-08-09 02:00:00+02:00 | pubmed | The Lancet Rheumatology | Laine Marc;Bonello Laurent | 2020-08-07 02:00:00+02:00 | 32838318 | FR | Department of Cardiology, Assistance Publique des Hôpitaux de Marseille, Hôpital Nord, Marseille 13015, France.;Centre for CardioVascular and Nutrition research and Faculté de Médecine de Marseille, Aix-Marseille University, Marseille, France. | 2117 | |||||
| 10.1016/j.ijantimicag.2020.106136 | Journal Article | en | Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results. | https://www.ncbi.nlm.nih.gov/pubmed/32777263 | During the Covid-19 pandemic, a large number of intensive care unit (ICU) patients received hydroxychloroquine. The primary objective of our study was to assess the effects of hydroxychloroquine according to its plasma concentration in ICU patients. To this purpose, a single-center retrospective study was performed from March to April 2020 in an ICU of a university hospital. All patients admitted to our ICU with a confirmed Covid-19 pneumonia and treated by hydroxychloroquine were included. We compared 17 patients in whom the hydroxychloroquine plasma concentration was in the therapeutic target (on-target) and 12 patients in whom the plasma concentration was below the target (off-target). The follow-up of patients was 15 days. No association was found between hydroxychloroquine plasma concentration and viral load evolution (p = 0.77). There was no significant difference between the two groups for the duration of mechanical ventilation, length of ICU stay, in-hospital mortality, and 15-days mortality. This finding suggests that hydroxychloroquine administration for Covid-19 patients hospitalized in ICU is not associated with improved outcomes. These results need confirmation by larger multicenter studies. | 0924-8579 | 2020-08-09 02:00:00+02:00 | pubmed | International Journal of Antimicrobial Agents | Alexandre Lopez;Gary Duclos;Bruno Pastene;Karine Bezulier;Romain Guilhaumou;Caroline Solas;Laurent Zieleskiewicz;Marc Leone | Covid-19 pneumonia;Hydroxychloroquine;Intensive care unit | 2020-08-07 02:00:00+02:00 | 32777263 | FR | Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015, France. Electronic address: alexandre.lopez@ap-hm.fr.;Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015, France.;Service de Pharmacologie Clinique et Pharmacovigilance, APHM, Institut de neurosciences des systèmes, Inserm UMR 1106, Université d'Aix-Marseille, France.;Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, 13005 Marseille, France.;Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Department of Anesthesiology and Intensive Care, Hôpital Nord, Marseille, 13015, France, Center for Cardiovascular and Nutrition Research (C2VN) Aix Marseille Université, INSERM, INRA, Marseille, 13005, France. | 2118 | |||
| Letter | en | Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32769152 | 2020-08-09 02:00:00+02:00 | pubmed | Augustin Lecler;Delphine Villeneuve;Catherine Vignal;Thomas Sené | giant cell arteritis;glucocorticoids;health services research | 2020-08-07 02:00:00+02:00 | 32769152 | FR | Neuroradiology, The Fondation Adolphe de Rothschild Hospital, Paris, France alecler@for.paris.;Internal Medicine, The Fondation Adolphe de Rothschild Hospital, Paris, France.;Ophthalmology, The Fondation Adolphe de Rothschild Hospital, Paris, France. | 2124 | |||||||
| 10.1016/j.jhin.2020.08.009 | Journal Article | en | Wearing of face masks by healthcare workers during covid-19 lockdown: what did the public observe through the French media? | https://www.ncbi.nlm.nih.gov/pubmed/32798641 | Wearing a face mask is a major issue in the fight against Covid-19 pandemic spreading. The French general population widely started to wear this individual protection equipment usually dedicated to healthcare workers, without being educated to its correct use. People base their behavior on what they see in the media. However, we observed that masks wearing of healthcare workers published in the media during the pandemic was only conform on 70.8% of the photographs collected on some of the main French information websites. Health authorities should communicate widely about the good practices for mask wearing in general population. | 0195-6701 | 2020-08-16 02:00:00+02:00 | pubmed | Journal of Hospital Infection | Jérémy Picard;Gwenael Cornec;Raoul Baron;Philippe Saliou | COVID-19 pandemic;filtering face piece (FFP) mask;media;surgical mask | 2020-08-13 02:00:00+02:00 | 32798641 | FR | Infection control unit, Brest Teaching Hospital, F-29200 Brest, France.;Infection control unit, Brest Teaching Hospital, F-29200 Brest, France, University of Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France. Electronic address: philippe.saliou@chu-brest.fr. | 2133 | |||
| 10.1016/s2213-2600(20)30328-3 | Journal Article | en | Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. | https://www.ncbi.nlm.nih.gov/pubmed/32798468 | Patients with COVID-19 who develop severe acute respiratory distress syndrome (ARDS) can have symptoms that rapidly evolve to profound hypoxaemia and death. The efficacy of extracorporeal membrane oxygenation (ECMO) for patients with severe ARDS in the context of COVID-19 is unclear. We aimed to establish the clinical characteristics and outcomes of patients with respiratory failure and COVID-19 treated with ECMO. | 2213-2600 | 2020-08-16 02:00:00+02:00 | pubmed | The Lancet Respiratory Medicine | Matthieu Schmidt;David Hajage;Guillaume Lebreton;Antoine Monsel;Guillaume Voiriot;David Levy;Elodie Baron;Alexandra Beurton;Juliette Chommeloux;Paris Meng;Safaa Nemlaghi;Pierre Bay;Pascal Leprince;Alexandre Demoule;Bertrand Guidet;Jean Michel Constantin;Muriel Fartoukh;Martin Dres;Alain Combes | 2020-08-13 02:00:00+02:00 | 32798468 | FR | Sorbonne University, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France, Service de médecine intensive-réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Département de Santé Publique, Centre de Pharmacoépidémiologie, Paris, France.;Sorbonne University, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France, Service de chirurgie cardiaque, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;Multidisciplinary Intensive Care Unit, Department of Anaesthesiology and Critical Care, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France, Biotherapy and Inflammation-Immunopathology-Biotherapy Department, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France, Sorbonne University, INSERM, UMR-S 959, Immunology-Immunopathology-Immunotherapy, Paris, France.;Assistance Publique-Hôpitaux de Paris Sorbonne University, Hôpital Tenon, Service de Médecine intensive Réanimation, Paris, France, INSERM Institut Mondor de Recherche Biomédicale, Team GEIC20, Créteil, France.;Service de médecine intensive-réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;Multidisciplinary Intensive Care Unit, Department of Anaesthesiology and Critical Care, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France, Sorbonne University, INSERM, UMR-S 959, Immunology-Immunopathology-Immunotherapy, Paris, France.;Service de Pneumologie, Médecine intensive, Réanimation, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;Assistance Publique-Hôpitaux de Paris Sorbonne University, Hôpital Tenon, Service de Médecine intensive Réanimation, Paris, France.;Service de Pneumologie, Médecine intensive, Réanimation, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France, Sorbonne University, INSERM, UMRS1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France.;Assistance Publique-Hôpitaux de Paris Sorbonne University Saint Antoine Hospital, Service de médecine intensive-réanimation, Paris, France.;GRC 29, DMU DREAM, Department of Anaesthesiology and Critical Care, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.;Sorbonne University, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France, Service de médecine intensive-réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France. Electronic address: alain.combes@aphp.fr. | 2135 | ||||
| Letter | en | Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations. | https://www.ncbi.nlm.nih.gov/pubmed/32790951 | We read with much interest the recent observational study of Nougier et al., which aimed at studying thrombin generation (TG) and fibrinolysis profiles of COVID-19 patients admitted to an intensive care unit (ICU) or to an internal medicine ward and receiving various schemes of prophylactic heparin.[1] They reported that thrombin potential remained within normal range despite heparin and that fibrinolysis was decreased in relation with increased plasminogen activator inhibitor 1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) antigen plasma levels. Using the rotational thromboelastometry (ROTEM) delta device with EXTEM reagents and the addition of 0.625µg/mL tPA (referred to as 'TEM-tPA'), they reported decreased clot lysis in COVID-19 patients, which was more pronounced in patients who presented a thrombotic event, compared to event-free patients. | 2020-08-16 02:00:00+02:00 | pubmed | Michael Hardy;Jonathan Douxfils;Marion Bareille;Sarah Lessire;Isabelle Gouin-Thibault;Pierre Fontana;Thomas Lecompte;François Mullier | Blood coagulation tests;COVID-19;Factor Xa;Heparin;Thrombelastography | 2020-08-13 02:00:00+02:00 | 32790951 | FR;BE;GB;CH | Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NARILIS, Hematology Laboratory, Yvoir, Belgium.;Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), NARILIS, Anesthesiology Department, Yvoir, Belgium.;Université de Namur, Département Pharmacie, Namur Thrombosis and Hemostasis Center (NTHC), NARILIS, Namur, Belgium.;Qualiblood s.a, Namur, Belgium.;INSERM, CIC 1414 (Centre d'Investigation Clinique de Rennes), Université de Rennes, CHU de Rennes, Département d'Hématologie Biologique, Rennes, France.;Département de Médecine, Hôpitaux Universitaires de Genève, service d'angiologie et d'hémostase et Faculté de Médecine, Geneva Platelet Group (GpG), Université de Genève, Geneva, Switzerland. | 2137 | ||||||
| 10.1164/rccm.202007-2670le | Journal Article | en | Reply to : Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19 Related Acute Respiratory Distress Syndrome: Worth the Effort! | https://www.ncbi.nlm.nih.gov/pubmed/32795240 | 1073-449X,1535-4970 | 2020-08-16 02:00:00+02:00 | pubmed | American Journal of Respiratory and Critical Care Medicine | Alexandra Monnier;Pierre-Emmanuel Falcoz;Julie Helms;Ferhat Meziani | 2020-08-14 02:00:00+02:00 | 32795240 | FR | Hôpitaux universitaires de Strasbourg, 36604, Médecine Intensive-Réanimation, Strasbourg, France.;Hopitaux universitaires de Strasbourg, 36604, Department of Thoracic Surgery, Strasbourg, France.;Hôpitaux universitaires de Strasbourg, 36604, intensive care, Strasbourg, France.;Hôpitaux universitaires de Strabourg, réanimation médicale, Strasbourg, France, ferhat.Meziani@chru-strasbourg.fr. | 2143 | |||||
| 10.1080/07853890.2020.1803499 | Journal Article | en | A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area. | https://www.ncbi.nlm.nih.gov/pubmed/32723107 | To identify predictive factors of unfavourable outcome among patients hospitalized for COVID-19. | 0785-3890,1365-2060 | 2020-08-16 02:00:00+02:00 | pubmed | Annals of Medicine | Yann Nguyen;Félix Corre;Vasco Honsel;Sonja Curac;Virginie Zarrouk;Catherine Paugam Burtz;Emmanuel Weiss;Jean-Denis Moyer;Tobias Gauss;Jules Grégory;Frédéric Bert;Catherine Trichet;Katell Peoc'h;Valérie Vilgrain;Vinciane Rebours;Bruno Fantin;Adrien Galy | COVID-19;nomogram;risk factors | 2020-08-14 02:00:00+02:00 | 32723107 | FR | Departement of Internal Medicine, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.;Centre for Research in Epidemiology and Population Health, INSERM U1018, Villejuif, France.;Emergency Department, AP-HP.Nord, Beaujon Hospital, Clichy, France.;Department of Anaesthesiology and Intensive Care, AP-HP.Nord, Beaujon Hospital, DMU PARABOL, University of Paris, Clichy, France.;Department of Radiology, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.;Laboratory of Microbiology, AP-HP.Nord, Beaujon Hospital, Clichy, France.;Laboratory of Hematology and Hemostasis, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.;Laboratory of Biochemistry, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.;Departement of Pancreatology, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France. | 2148 | |||
| 10.1002/uog.22178 | Journal Article | en | Anatomical and timely assessment of protein expression of angiotensin-converting enzyme 2, SARS-CoV-2 specific receptor, in fetal and placental tissues: new insight for perinatal counseling. | https://www.ncbi.nlm.nih.gov/pubmed/32798244 | Infection with SARS-CoV2 does not spare pregnant women and the possibility of vertical transmission which might lead to fetal damages is pending. | 0960-7692,1469-0705 | 2020-08-16 02:00:00+02:00 | pubmed | Ultrasound in Obstetrics & Gynecology | V Faure-Bardon;P Isnard;N Roux;M Leruez-Ville;T Molina;B Bessieres;Y Ville | ACE-2;fetal organs;placenta;protein expression;sars-CoV-2;vertical transmission | 2020-08-15 02:00:00+02:00 | 32798244 | FR | EA 73-28, Université de Paris, Paris, France.;AP-HP, Department of Obstetrics and Fetal Medicine, Hospital Necker-Enfants Malades, Paris, France.;AP-HP, Department of Histology, Embryology and Cytogenetics, Hospital Necker-E.M, Paris, France.;Institut National de la Santé et de la Recherche Médicale (INSERM), U1151, CNRS UMR 8253, Hospital Necker-E.M, Department of Growth and Signaling, Université de Paris, Paris, France.;AP- HP, Virology Laboratory, Hospital Necker-E.M, Paris, France. | 2153 | |||
| Letter | en | Fatal Covid-19 vasoplegic shock in a recipient few hours before double lung transplantation in high emergency. | https://www.ncbi.nlm.nih.gov/pubmed/32785961 | SARS-Cov2 outbreak has deeply impacted French lung transplant programs by the decreased number of lung donors, the scarcity of intensive care unit (ICU) beds and most importantly, the assumed worse prognosis of Covid-19 in recipients during perioperative period. Despite no evidence has been published to suggest that lung transplant recipients were at high-risk of acquiring the virus or developing severe Covid-19, immunosuppression may worsen the prognosis of such infection in patient transplanted for end-staged lung diseases. | 2020-08-16 02:00:00+02:00 | pubmed | Olaf Mercier;Florent Laverdure;Laura Filaire;Hervé Mal;Vincent Bunel;Delphine Deblauwe;Lidwine Wemeau;Gaëlle Dauriat;Elie Fadel;André Vincentelli | 2020-08-12 02:00:00+02:00 | 32785961 | FR | Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, France, INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France.;Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, France.;Assistance Publique-Hôpitaux de Paris, Centre Hospitalier Universitaire Bichat-Claude Bernard, Service de Pneumologie B et Transplantation Pulmonaire, Paris, France.;Intensive care Unit, CHU Lille, Lille, France.;Department of Respirology, CHU Lille, Lille, France.;Department of Cardiac Surgery, CHU Lille, Lille, France. | 2158 | |||||||
| 10.1136/bcr-2020-237511 | Case Reports;Journal Article | en | Successful continuation of pregnancy in a patient with COVID-19-related ARDS. | https://www.ncbi.nlm.nih.gov/pubmed/32788159 | A 33-year-old pregnant woman was hospitalised with fever, cough, myalgia and dyspnoea at 23.5 weeks of gestation (WG). Development of acute respiratory distress syndrome (ARDS) mandated invasive mechanical ventilation. A nasopharyngeal swab proved positive for severe acute respiratory syndrome coronavirus 2 by reverse transcription-PCR. The patient developed hypertension and biological disorders suggesting pre-eclampsia and HELLP (haemolysis, elevated liver enzyme levels and low platelet levels) syndrome. Pre-eclampsia was subsequently ruled out by a low ratio of serum soluble fms-like tyrosine kinase-1 to placental growth factor. Given the severity of ARDS, delivery by caesarean section was contemplated. Because the ratio was normal and the patient's respiratory condition stabilised, delivery was postponed. She recovered after 10 days of mechanical ventilation. She spontaneously delivered a healthy boy at 33.4 WG. Clinical and laboratory manifestations of COVID-19 infection can mimic HELLP syndrome. Fetal extraction should not be systematic in the absence of fetal distress or intractable maternal disease. Successful evolution was the result of a multidisciplinary teamwork. | 1757-790X | 2020-08-16 02:00:00+02:00 | pubmed | Adult;Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Female;Humans;Live Birth;Pandemics;Pneumonia, Viral__complications;Pregnancy;Pregnancy Complications, Infectious__diagnostic imaging;Radiography, Thoracic;Respiration, Artificial;Respiratory Distress Syndrome, Adult__diagnostic imaging;COVID-19;severe acute respiratory syndrome coronavirus 2 | BMJ Case Reports | Laura Federici;Olivier Picone;Didier Dreyfuss;Jeanne Sibiude | adult intensive care;mechanical ventilation;obstetrics and gynaecology;pneumonia (infectious disease) | 2020-08-11 02:00:00+02:00 | 32788159 | FR | Service de médecine intensive reanimation, Hôpital Louis-Mourier, Colombes, France laura.federici85@gmail.com.;Service de gynécologie-obstétrique, Hôpital Louis-Mourier, Colombes, Île-de-France, France.;IAME-U11337, INSERM, Paris, Île-de-France, France.;Service de médecine intensive reanimation, Hôpital Louis-Mourier, Colombes, France.;Unit UMR S-1155 Common and Rare Kidney Disease, INSERM, Paris, Île-de-France, France. | 2165 | ||
| 10.1136/bmjsrh-2020-200709 | Editorial | en | The impact of COVID-19 on contraception and abortion care policy and practice: experiences from selected countries. | https://www.ncbi.nlm.nih.gov/pubmed/32788180 | 2515-1991,2515-2009 | 2020-08-16 02:00:00+02:00 | pubmed | BMJ Sexual & Reproductive Health | Deborah J Bateson;Patricia A Lohr;Wendy V Norman;Caroline Moreau;Kristina Gemzell-Danielsson;Paul D Blumenthal;Lesley Hoggart;Hang-Wun Raymond Li;Abigail R A Aiken;Kirsten I Black | abortion;family planning services;health services accessibility;induced;long-acting reversible contraception;reproductive health services | 2020-08-11 02:00:00+02:00 | 32788180 | FR;SE;CA;GB;US;HK;AU | Family Planning New South Wales, Sydney, New South Wales, Australia deborahb@fpnsw.org.au.;Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.;British Pregnancy Advisory Service (BPAS), Stratford upon Avon, UK.;Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada.;Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.;Population Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.;CESP Centre for Research in Epidemiology and Population Health, INSERM (Institut National de la Santé et de la Recherche Medicale), Villejuif, France.;Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.;Karolinska University Hospital, Stockholm, Sweden.;Stanford University School of Medicine, Stanford, California, USA.;Faculty of Wellbeing, Education and Language Studies, The Open University, Milton Keynes, UK.;Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, Hong Kong.;LBJ School of Public Affairs, The University of Texas at Austin, Austin, Texas, USA.;Women's Health, Neonatology and Paediatrics, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. | 2167 | ||||
| NIAMS NIH HHS;NIAMS NIH HHS;NIAMS NIH HHS;NIAMS NIH HHS | 10.1080/1744666x.2020.1792778 | Journal Article | en | Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32620062 | Several months into the COVID-19 pandemic, safe and effective treatments against this global health disaster have yet to be identified. Clinical research trials around the world are underway testing a wide array of possible medications. In particular, the off-label use of hydroxychloroquine for COVID-19 prophylaxis and treatment has created many unprecedented challenges for the scientific community and the public. | 1744-666X,1744-8409 | 2020-08-16 02:00:00+02:00 | pubmed | Expert Review of Clinical Immunology | Sebastian E Sattui;Jean W Liew;Elizabeth R Graef;Ariella Coler-Reilly;Francis Berenbaum;Alí Duarte-García;Carly Harrison;Maximilian F Konig;Peter Korsten;Michael S Putman;Philip C Robinson;Emily Sirotich;Manuel F Ugarte-Gil;Kate Webb;Kristen J Young;Alfred H J Kim;Jeffrey A Sparks | Hydroxychloroquine;SARS-CoV-2;antimalarials;chloroquine;coronavirus disease 2019 | 2020-08-11 02:00:00+02:00 | 32620062 | FR;IL;CA;GB;US;AU;ZA;PE;DE | [{"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "K23 AR069688"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "L30 AR066953"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "R03 AR075886"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "T32 AR048522"}] | Division of Rheumatology, Department of Medicine, Hospital for Special Surgery , New York, NY, USA.;Division of Rheumatology, Department of Medicine, University of Washington , Seattle, WA, USA.;Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, USA.;Division of Rheumatology, Department of Medicine, Washington University School of Medicine , St. Louis, MO, USA.;Department of Rheumatology, Sorbonne University, INSERM CRSA, AP-HP , Paris, France.;Division of Rheumatology, Mayo Clinic , Rochester, MN, USA.;LupusChat , New York, NY, USA.;Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine , Baltimore, MD, USA.;Department of Nephrology and Rheumatology, University Medical Center Göttingen , Göttingen, Germany.;Department of Medicine, Northwestern University , Chicago, IL, USA.;University of Queensland Faculty of Medicine , Brisbane, Australia.;Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON, Canada.;Canadian Arthritis Patient Alliance , Toronto, ON, Canada.;School of Medicine, Universidad Científica Del Sur and Hospital Nacional Guillermo Almenara Irigoyen , EsSalud, Lima, Peru.;Department of Paediatric Rheumatology, University of Cape Town , Cape Town, South Africa.;Francis Crick Institute , London, UK.;Division of Rheumatic Diseases, UT Southwestern Medical Center , Dallas, TX, USA.;Division of Rheumatology, Department of Medicine, Washington University School of Medicine , Saint Louis, MO, USA.;Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School , Boston, MA, USA. | 2168 | |
| 10.1093/trstmh/traa066 | Journal Article | en | Testing wastewater to detect severe acute respiratory syndrome coronavirus 2 in communities. | https://www.ncbi.nlm.nih.gov/pubmed/32780856 | Research groups around the world are starting to analyse whether wastewater surveillance is a useful tool to monitor the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in communities. Reported studies from the Netherlands, USA, Australia and France have demonstrated that SARS-CoV-2 can be detected and quantified in wastewater, allowing the total number of community infections to be estimated as well as monitoring whether the virus has returned to a community after elimination. Further work is required to improve the quantification of virus, to better detect the virus at low levels and to ensure wastewater samples are representative of the community under surveillance. | 0035-9203,1878-3503 | 2020-08-16 02:00:00+02:00 | pubmed | Transactions of the Royal Society of Tropical Medicine and Hygiene | Anthony D Harries;Selma Dar Berger;Srinath Satyanarayana;Pruthu Thekkur;Ajay M V Kumar | COVID-19;SARS-CoV-2;sewerage;surveillance;wastewater | 2020-08-11 02:00:00+02:00 | 32780856 | FR;IN;GB | International Union Against Tuberculosis and Lung Disease, Paris, France.;London School of Hygiene and Tropical Medicine, Keppel Street, London, UK.;International Union Against Tuberculosis and Lung Disease, South-east Asia Office, C-6 Qutub Institutional Area, New Delhi 110016, India.;Yenepoya Medical College, Yenepoya (Deemed to be University), University Road, Deralakatte, Mangalore 575018, India. | 2170 | |||
| 10.1021/acs.jcim.0c00545 | Journal Article | en | Fast Rescoring Protocols to Improve the Performance of Structure-Based Virtual Screening Performed on Protein-Protein Interfaces. | https://www.ncbi.nlm.nih.gov/pubmed/32786511 | Protein-protein interactions (PPIs) are attractive targets for drug design because of their essential role in numerous cellular processes and disease pathways. However, in general, PPIs display exposed binding pockets at the interface, and as such, have been largely unexploited for therapeutic interventions with low-molecular weight compounds. Here, we used docking and various rescoring strategies in an attempt to recover PPI inhibitors from a set of active and inactive molecules for 11 targets collected in ChEMBL and PubChem. Our focus is on the screening power of the various developed protocols and on using fast approaches so as to be able to apply such a strategy to the screening of ultralarge libraries in the future. First, we docked compounds into each target using the fast "pscreen" mode of the structure-based virtual screening (VS) package Surflex. Subsequently, the docking poses were postprocessed to derive a set of 3D topological descriptors: (i) shape similarity and (ii) interaction fingerprint similarity with a co-crystallized inhibitor, (iii) solvent-accessible surface area, and (iv) extent of deviation from the geometric center of a reference inhibitor. The derivatized descriptors, together with descriptor-scaled scoring functions, were utilized to investigate possible impacts on VS performance metrics. Moreover, four standalone scoring functions, RF-Score-VS (machine-learning), DLIGAND2 (knowledge-based), Vinardo (empirical), and X-SCORE (empirical), were employed to rescore the PPI compounds. Collectively, the results indicate that the topological scoring algorithms could be valuable both at a global level, with up to 79% increase in areas under the receiver operating characteristic curve for some targets, and in early stages, with up to a 4-fold increase in enrichment factors at 1% of the screened collections. Outstandingly, DLIGAND2 emerged as the best scoring function on this data set, outperforming all rescoring techniques in terms of VS metrics. The described methodology could help in the rational design of small-molecule PPI inhibitors and has direct applications in many therapeutic areas, including cancer, CNS, and infectious diseases such as COVID-19. | 1549-9596,1549-960X | 2020-08-16 02:00:00+02:00 | pubmed | Journal of Chemical Information and Modeling | Natesh Singh;Ludovic Chaput;Bruno O Villoutreix | 2020-08-11 02:00:00+02:00 | 32786511 | FR | Université de Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, F-59000 Lille, France. | 2171 | ||||
| 10.1007/s00345-020-03402-w | Journal Article | en | Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32776243 | The current COVID-19 pandemic is transforming our urologic practice and most urologic societies recommend to defer any surgical treatment for prostate cancer (PCa) patients. It is unclear whether a delay between diagnosis and surgical management (i.e., surgical delay) may have a detrimental effect on oncologic outcomes of PCa patients. The aim of the study was to assess the impact of surgical delay on oncologic outcomes. | 0724-4983,1433-8726 | 2020-08-16 02:00:00+02:00 | pubmed | World Journal of Urology | Romain Diamand;Guillaume Ploussard;Mathieu Roumiguié;Marco Oderda;Daniel Benamran;Gaelle Fiard;Alexandre Peltier;Giuseppe Simone;Julien Van Damme;Bernard Malavaud;Christophe Iselin;Jean-Luc Descotes;Jean-Baptiste Roche;Thierry Quackels;Thierry Roumeguère;Simone Albisinni | Biochemical recurrence;COVID-19;Delay;Oncologic outcomes;Prostate cancer | 2020-08-10 02:00:00+02:00 | 32776243 | FR;IT;BE;CH | Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium. romain.diamand@erasme.ulb.ac.be.;Urology Department, La Croix du Sud Hospital, Quint Fonsegrives, France.;Urology Department, CHU Toulouse, Toulouse, France.;Urology Department, Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.;Urology Department, Hôpitaux Universitaires de Genève, Geneva, Switzerland.;Urology Department, CHU de Grenoble, Grenoble, France.;Grenoble Alpes University, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France.;Urology Department, Jules Bordet Institute, Brussels, Belgium.;Urology Department, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.;Urology Department, University Clinics Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Urology Department, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;Urology Department, Clinique Saint-Augustin, Bordeaux, France.;Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium. | 2194 | |||
| 10.1051/medsci/2020123 | English Abstract;Journal Article | fr | [Tracing the origins of SARS-COV-2 in coronavirus phylogenies]. | https://www.ncbi.nlm.nih.gov/pubmed/32773024 | SARS-CoV-2 is a new human coronavirus (CoV), which emerged in People's Republic of China at the end of 2019 and is responsible for the global Covid-19 pandemic that caused more than 540 000 deaths in six months. Understanding the origin of this virus is an important issue and it is necessary to determine the mechanisms of its dissemination in order to be able to contain new epidemics. Based on phylogenetic inferences, sequence analysis and structure-function relationships of coronavirus proteins, informed by the knowledge currently available, we discuss the different scenarios evoked to account for the origin - natural or synthetic - of the virus. On the basis of currently available data, it is impossible to determine whether SARS-CoV-2 is the result of a natural zoonotic emergence or an accidental escape from experimental strains. Regardless of its origin, the study of the evolution of the molecular mechanisms involved in the emergence of this pandemic virus is essential to develop therapeutic and vaccine strategies. | 0767-0974,1958-5381 | 2020-08-16 02:00:00+02:00 | pubmed | médecine/sciences | Erwan Sallard;José Halloy;Didier Casane;Jacques van Helden;Étienne Decroly | 2020-08-10 02:00:00+02:00 | 32773024 | FR | École Normale Supérieure de Paris, 45 rue d'Ulm, 75005 Paris, France.;Université de Paris, CNRS, LIED UMR 8236, 85 bd Saint-Germain, 75006 Paris, France.;Université Paris-Saclay, CNRS, IRD, UMR Évolution, Génomes, Comportement et Écologie, 91198, Gif-sur-Yvette, France - Université de Paris, UFR Sciences du Vivant, F-75013 Paris, France.;CNRS, Institut Français de Bioinformatique, IFB-core, UMS 3601, Évry, France - Aix-Marseille Univ, Inserm, laboratoire Theory and approaches of genome complexity (TAGC), Marseille, France.;AFMB, CNRS, Aix-Marseille Univ, UMR 7257, Case 925, 163 avenue de Luminy, 13288 Marseille Cedex 09, France. | 2199 | ||||
| 10.15252/emmm.202013038 | Journal Article | en | Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes. | https://www.ncbi.nlm.nih.gov/pubmed/32816392 | Early in the COVID-19 pandemic, type 2 diabetes (T2D) was marked as a risk-factor for severe disease and mortality. Inflammation is central to the aetiology of both conditions where variations in immune responses can mitigate or aggravate disease course. Identifying at-risk groups based on immuno-inflammatory signatures is valuable in directing personalised care and developing potential targets for precision therapy. This observational study characterised immunophenotypic variation associated with COVID-19 severity in T2D. Broad-spectrum immunophenotyping quantified 15 leukocyte populations in peripheral circulation from a cohort of 45 hospitalised COVID-19 patients with and without T2D. Lymphocytopenia and specific loss of cytotoxic CD8+ lymphocytes was associated with severe COVID-19 and requirement for intensive care in both non-diabetic and T2D patients. A morphological anomaly of increased monocyte size and monocytopenia restricted to classical CD14Hi CD16- monocytes were specifically associated with severe COVID-19 in patients with T2D requiring intensive care. Increased expression of inflammatory markers reminiscent of the type-1 interferon pathway (IL6, IL8, CCL2, INFB1) underlaid the immunophenotype associated with T2D. These immunophenotypic and hyperinflammatory changes may contribute to increased voracity of COVID-19 in T2D. These findings allow precise identification of T2D patients with severe COVID-19 as well as provide evidence that the type-1 interferon pathway may be an actionable therapeutic target for future studies. | 1757-4676,1757-4684 | 2020-08-23 02:00:00+02:00 | pubmed | EMBO Molecular Medicine | Fawaz Alzaid;Jean-Baptiste Julla;Marc Diedisheim;Charline Potier;Louis Potier;Gilberto Velho;Bénédicte Gaborit;Philippe Manivet;Stéphane Germain;Tiphaine Vidal-Trecan;Ronan Roussel;Jean-Pierre Riveline;Elise Dalmas;Nicolas Venteclef;Jean-François Gautier | COVID-19;SARS-CoV-2;inflammation;monocyte;type 2 diabetes | 2020-08-20 02:00:00+02:00 | 32816392 | FR | Cordeliers Research Centre, INSERM, IMMEDIAB Laboratory, Sorbonne Université, Université de Paris, F-75006, Paris, France.;Department of Diabetes, Clinical Investigation Centre (CIC-9504), Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.;Department of diabetology, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France.;Department of Diabetology, Endocrinology and Nutrition, Bichat Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.;Aix Marseille University, INSERM, INRA, C2VN, Marseille, Metabolic Diseases and Nutrition Department, Assistance Publique Hôpitaux de Marseille, France. Endocrinology, France.;Centre de Ressources Biologique « biobank Lariboisière », BB-0033-00064. APHP. Nord, Université de Paris, Paris Diderot. Hôpital Lariboisière, Paris 10, France.;Center for Interdisciplinary Research in Biology (CIRB), College de France - Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Paris Sciences et Lettres (PSL) Research University, Paris, France. | 2202 | |||
| 10.1002/oby.23014 | Journal Article | en | Obesity doubles mortality in patients hospitalized for SARS-CoV-2 in Paris hospitals, France: a cohort study on 5795 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32815621 | Preliminary data from different cohorts of small sample size or with short follow-up indicate poorer prognosis in people with obesity compared to other patients. This study aims to precisely describe the strength of association between obesity in patients hospitalised with Covid-19 and mortality and clarify the risk according to usual cardiometabolic risk factors in a large cohort. | 2020-08-23 02:00:00+02:00 | pubmed | Sébastien Czernichow;Nathanael Beeker;Claire Rives-Lange;Emmanuel Guerot;Jean-Luc Diehl;Sandrine Katsahian;Jean-Sébastien Hulot;Tigran Poghosyan;Claire Carette;Anne Sophie Jannot | Metabolically Benign;Obesity;SARS-CoV-2;body mass index;mortality determinants;obesity | 2020-08-20 02:00:00+02:00 | 32815621 | FR | Université de Paris, F-75015, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Nutrition, Centre Spécialisé Obésité, Hôpital Européen Georges Pompidou, Paris, France.;INSERM, UMR1153, Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Unité de Recherche clinique, Hôpital Cochin, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Médecine Intensive Réanimation, Hôpital Européen Georges Pompidou, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Service d'informatique médicale, biostatistiques et santé publique, Hôpital Européen Georges Pompidou, Paris, France.;INSERM, Cordeliers Research Center, Information sciences to support personalized medicine, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges-Pompidou, CIC1418 and DMU CARTE, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Chirurgie Digestive, Oncologique et Bariatrique, Hôpital Européen Georges Pompidou, Paris, France. | 2206 | |||||
| 10.1183/13993003.01104-2020 | Journal Article;Research Support, Non-U.S. Gov't | en | Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study. | https://www.ncbi.nlm.nih.gov/pubmed/32616597 | The outbreak of coronavirus disease 2019 (COVID-19) has globally strained medical resources and caused significant mortality. | 0903-1936,1399-3003 | 2020-08-23 02:00:00+02:00 | pubmed | European Respiratory Journal | Guangyao Wu;Pei Yang;Yuanliang Xie;Henry C Woodruff;Xiangang Rao;Julien Guiot;Anne-Noelle Frix;Renaud Louis;Michel Moutschen;Jiawei Li;Jing Li;Chenggong Yan;Dan Du;Shengchao Zhao;Yi Ding;Bin Liu;Wenwu Sun;Fabrizio Albarello;Alessandra D'Abramo;Vincenzo Schininà;Emanuele Nicastri;Mariaelena Occhipinti;Giovanni Barisione;Emanuela Barisione;Iva Halilaj;Pierre Lovinfosse;Xiang Wang;Jianlin Wu;Philippe Lambin | 2020-08-20 02:00:00+02:00 | 32616597 | FR;UNK;CN;IT;NL;BE | The D-Lab, Dept of Precision Medicine, GROW - School for Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands g.wu@maastrichtuniversity.nl.;Guangyao Wu and Pei Yang are joint first authors.;Guangyao Wu and Xiang Wang are co-corresponding authors.;Dept of Radiology, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, China.;The D-Lab, Dept of Precision Medicine, GROW - School for Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands.;Dept of Radiology and Nuclear Medicine, GROW- School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands.;Dept of Ultrasound, The Central Hospital of Huangshi, Huangshi, China.;Dept of Respiratory Medicine, CHU of Liège, Liège, Belgium.;Dept of Infectiology, CHU of Liège, Liège, Belgium.;Dept of Radiology, China Resources Wuhan Iron and Steel Hospital, Wuhan, China.;Dept of Radiology, The Central Hospital of Shaoyang, Shaoyang, China.;Dept of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.;Dept of Intensive Care Unit, The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, China.;National Institute for Infectious Diseases - IRCCS, Rome, Italy.;Dept of Biomedical, Clinical and Experimental Sciences "Mario Serio", University of Florence, Florence, Italy.;Unit of Respiratory Pathophysiology, Respiratory Diseases and Allergy Clinic, Dept of Internal Medicine and Medical Specialties, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.;Unit of Interventional Pulmonology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.;Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liège, Liège, Belgium.;Dept of Radiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China. | 2208 | ||||
| 10.2214/ajr.20.23546 | Journal Article | en | Could Spectral CT Have a Potential Benefit in Coronavirus Disease (COVID-19)? | https://www.ncbi.nlm.nih.gov/pubmed/32822225 | OBJECTIVE. The purpose of this study is to evaluate the potential benefit of spectral imaging, notably electron density imaging, in patients with suspected or confirmed coronavirus disease (COVID-19), by retrospectively reviewing the cases of four patients who each underwent two chest CT scans for confirmed COVID-19. CONCLUSION. The use of spectral CT with electron density imaging could improve the assessment of lung lesion extent in patients with early-stage COVID-19. | 0361-803X,1546-3141 | 2020-08-23 02:00:00+02:00 | pubmed | American Journal of Roentgenology | Beatrice Daoud;Julien Cazejust;Sebastian Tavolaro;Sebastien Durand;Romain Pommier;Adel Hamrouni;Gregoire Bornet | COVID-19;DECT;SARS-CoV-2;coronavirus;electron density;ground-glass opacities;spectral CT | 2020-08-21 02:00:00+02:00 | 32822225 | FR;US | Department of Radiology, Antony's Private Hospital, 25 Ave de la Providence, 92160 Antony, France. | 2217 | |||
| Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund (HMRF) | 10.1038/s41590-020-0773-7 | Journal Article | en | ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32807944 | The SARS-CoV-2 virus emerged in December 2019 and has caused a worldwide pandemic due to the lack of any pre-existing immunity. Accurate serology testing is urgently needed to help diagnose infection, determine past exposure of populations and assess the response to a future vaccine. The landscape of antibody responses to SARS-CoV-2 is unknown. In this study, we utilized the luciferase immunoprecipitation system to assess the antibody responses to 15 different SARS-CoV-2 antigens in patients with COVID-19. We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses. ORF8 and ORF3b antibodies, taken together as a cluster of points, identified 96.5% of COVID-19 samples at early and late time points of disease with 99.5% specificity. Our findings could be used to develop second-generation diagnostic tests to improve serological assays for COVID-19 and are important in understanding pathogenicity. | 1529-2908,1529-2916 | 2020-08-23 02:00:00+02:00 | pubmed | Nature Immunology | Asmaa Hachim;Niloufar Kavian;Carolyn A Cohen;Alex W H Chin;Daniel K W Chu;Chris K P Mok;Owen T Y Tsang;Yiu Cheong Yeung;Ranawaka A P M Perera;Leo L M Poon;J S Malik Peiris;Sophie A Valkenburg | 2020-08-17 02:00:00+02:00 | 32807944 | FR;CN;GB;HK | [{"country": "", "agency": "Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund (HMRF)", "grantid": "COVID190115"}] | HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.;HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. niloufar@hku.hk.;Faculté de Médecine Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire Cochin, Service d'Immunologie Biologique, Paris, France. niloufar@hku.hk.;Institut Cochin, INSERM U1016, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. niloufar@hku.hk.;Division of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.;Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Hong Kong SAR, China.;HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. sophiev@hku.hk. | 2231 | ||
| Letter | en | COVID-19 and its psychological consequences: Beware of the respiratory subtype of panic disorder. | https://www.ncbi.nlm.nih.gov/pubmed/32818605 | 2020-08-23 02:00:00+02:00 | pubmed | Hervé Javelot;Luisa Weiner;Coraline Hingray;Rafael C Freire;Antonio E Nardi | 2020-08-18 02:00:00+02:00 | 32818605 | FR;CA;BR | Établissement Public De Santé Alsace Nord, Brumath, France, Laboratoire De Toxicologie Et Pharmacologie Neuro Cardiovasculaire, Université De Strasbourg, Strasbourg, France. Electronic address: herve.javelot@ch-epsan.fr.;Clinique De Psychiatrie, CHU De Strasbourg, France, Laboratoire De Psychologie Des Cognitions, Université De Strasbourg, Strasbourg, France.;Pôle Hospitalo-Universitaire De Psychiatrie d'Adultes Du Grand Nancy, Centre Psychothérapique De Nancy, Laxou, France, CHU De Nancy, Département De Neurologie, Nancy, France.;Laboratory of Panic and Respiration, Institute of Psychiatry, Federal University of Rio De Janeiro, Rio De Janeiro, Brazil.;Department of Psychiatry and Centre for Neuroscience Studies, Queen's University, Kingston, Canada. | 2236 | ||||||||
| 10.1111/ijlh.13312 | Journal Article | en | Interest of the cellular population data analysis as an aid in the early diagnosis of SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32812365 | Coronavirus disease 2019 (COVID-19) is characterized by a high contagiousness requiring isolation measures. At this time, diagnosis is based on the positivity of specific RT-PCR and/or chest computed tomography scan, which are time-consuming and may delay diagnosis. Complete blood count (CBC) can potentially contribute to the diagnosis of COVID-19. We studied whether the analysis of cellular population data (CPD), provided as part of CBC-Diff analysis by the DxH 800 analyzers (Beckman Coulter), can help to identify SARS-CoV-2 infection. | 2020-08-23 02:00:00+02:00 | pubmed | Marc Vasse;Marie-Christine Ballester;Degnile Ayaka;Dmitry Sukhachev;Frédérique Delcominette;Florence Habarou;Emilie Jolly;Elena Sukhacheva;Tiffany Pascreau;Éric Farfour | DxH800 analyzer;SARS-CoV-2 diagnosis;cellular population data | 2020-08-19 02:00:00+02:00 | 32812365 | FR;RU;CH | Biology Department, Foch Hospital& UMR-S 1176, Suresnes and Kremlin-Bicêtre, France.;Emergency Unit, Foch Hospital, Suresnes, France.;Biology Department, Foch Hospital, Suresnes, France.;LabTech Ltd, Saint-Petersburg, Russia.;Beckman Coulter Eurocenter, Nyon, Switzerland. | 2248 | |||||
| Fonds De La Recherche Scientifique - FNRS;Fonds De La Recherche Scientifique - FNRS | 10.3390/mps3030059 | Journal Article | en | SARS-CoV-2 Detection for Diagnosis Purposes in the Setting of a Molecular Biology Research Lab. | https://www.ncbi.nlm.nih.gov/pubmed/32824827 | The emergence of the SARS-CoV-2 virus and the exponential growth of COVID-19 cases have created a major crisis for public health systems. The critical identification of contagious asymptomatic carriers requires the isolation of viral nucleic acids, reverse transcription, and amplification by PCR. However, the shortage of specific proprietary reagents or the lack of automated platforms have seriously hampered diagnostic throughput in many countries. Here, we provide a procedure for SARS-CoV-2 detection for diagnostic purposes from clinical samples in the setting of a basic research molecular biology lab. The procedure details the necessary steps for daily analysis of up to 500 clinical samples with a team composed of 12 experienced researchers. The protocol has been designed to rely on widely available reagents and devices, to cope with heterogeneous clinical specimens, to guarantee nucleic acid extraction from very scarce biological material, and to minimize the rate of false-negative results. | 2409-9279 | 2020-08-23 02:00:00+02:00 | pubmed | Methods and Protocols | Damien Coupeau;Nicolas Burton;Noémie Lejeune;Suzanne Loret;Astrid Petit;Srdan Pejakovic;Florian Poulain;Laura Bonil;Gabrielle Trozzi;Laetitia Wiggers;Kévin Willemart;Emmanuel André;Lies Laenen;Lize Cuypers;Marc Van Ranst;Pierre Bogaerts;Benoît Muylkens;Nicolas Albert Gillet | COVID-19;RTqPCR;SARS-CoV-2;diagnosis | 2020-08-18 02:00:00+02:00 | 32824827 | FR;BE;GB | [{"country": "", "agency": "Fonds De La Recherche Scientifique - FNRS", "grantid": "34972507"}, {"country": "", "agency": "Fonds De La Recherche Scientifique - FNRS", "grantid": "31454280"}] | Namur Research Institute for Life Sciences (NARILIS), Integrated Veterinary Research Unit (URVI), University of Namur, 61 rue de Bruxelles, 5000 Namur, Belgium.;KU Leuven, Laboratory of Clinical Bacteriology and Mycology, campus Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.;Department of Laboratory Medicine, National Reference Center for Respiratory Pathogens, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.;CHU UCL NAMUR, Laboratory of microbiology and molecular biology, Site Godinne, 5530 Yvoir, Belgium. | 2251 | |
| 10.1164/rccm.202006-2521le | Journal Article | en | On Happy Hypoxia and on Sadly Ignored "Acute Vascular Distress Syndrome" in COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32813543 | 1073-449X,1535-4970 | 2020-08-23 02:00:00+02:00 | pubmed | American Journal of Respiratory and Critical Care Medicine | Vincent Jounieaux;Daniel Oscar Rodenstein;Yazine Mahjoub | SARS-CoV-2;enhanced contrast echocardiography;intrapulmonary shunt | 2020-08-19 02:00:00+02:00 | 32813543 | FR;BE | University Hospital Centre Amiens-Picardie, 36673, PNEUMOLOGY, Amiens, France, jounieaux.vincent@chu-amiens.fr.;Cliniques universitaires Saint-Luc, 70492, Pneumology Department, Bruxelles, Belgium.;University Hospital Centre Amiens-Picardie, 36673, Department of Anesthesia and Critical Care., Amiens, France. | 2253 | ||||
| 10.1101/2020.03.02.968818 | Preprint | en | Rapid metagenomic characterization of a case of imported COVID-19 in Cambodia. | https://www.ncbi.nlm.nih.gov/pubmed/32511296 | Rapid production and publication of pathogen genome sequences during emerging disease outbreaks provide crucial public health information. In resource-limited settings, especially near an outbreak epicenter, conventional deep sequencing or bioinformatics are often challenging. Here we successfully used metagenomic next generation sequencing on an iSeq100 Illumina platform paired with an open-source bioinformatics pipeline to quickly characterize Cambodia's first case of COVID-2019. | 2020-03-08 01:00:00+01:00 | pubmed | Jessica E Manning;Jennifer A Bohl;Sreyngim Lay;Sophana Chea;Ly Sovann;Yi Sengdoeurn;Seng Heng;Chan Vuthy;Katrina Kalantar;Vida Ahyong;Michelle Tan;Jonathan Sheu;Cristina M Tato;Joseph L DeRisi;Laurence Baril;Veasna Duong;Philippe Dussart;Erik A Karlsson | COVID-19;SARS-CoV-2;coronavirus;sequencing;unbiased metagenomics | 2020-03-05 01:00:00+01:00 | 32511296 | FR;KH;US | Laboratory of Malaria and Vector Research, US National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.;Cambodian Center for Disease Control, Ministry of Health, Phnom Penh, Cambodia.;Chan Zuckerberg Initiative, Redwood City, California, USA.;Chan Zuckerberg Biohub, San Francisco, California, USA.;Institut Pasteur du Cambodge, Phnom Penh, Cambodia.;Virology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia. | 25 | |||||
| World Health Organization | 10.2807/1560-7917.es.2020.25.9.2000178 | Journal Article | en | First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32156327 | In the WHO European Region, COVID-19 surveillance was implemented 27 January 2020. We detail the first European cases. As at 21 February, nine European countries reported 47 cases. Among 38 cases studied, 21 were linked to two clusters in Germany and France, 14 were infected in China. Median case age was 42 years; 25 were male. Late detection of the clusters' index cases delayed isolation of further local cases. As at 5 March, there were 4,250 cases. | 1560-7917 | 2020-03-15 01:00:00+01:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus__genetics;Child;Child, Preschool;China__epidemiology;Coronavirus Infections__diagnosis;Europe__epidemiology;Female;Hospitalization;Humans;Male;Middle Aged;Pneumonia, Viral__diagnosis;Population Surveillance;Real-Time Polymerase Chain Reaction;Risk Factors;Travel;Viral Envelope Proteins__analysis;World Health Organization;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Gianfranco Spiteri;James Fielding;Michaela Diercke;Christine Campese;Vincent Enouf;Alexandre Gaymard;Antonino Bella;Paola Sognamiglio;Maria José Sierra Moros;Antonio Nicolau Riutort;Yulia V Demina;Romain Mahieu;Markku Broas;Malin Bengnér;Silke Buda;Julia Schilling;Laurent Filleul;Agnès Lepoutre;Christine Saura;Alexandra Mailles;Daniel Levy-Bruhl;Bruno Coignard;Sibylle Bernard-Stoecklin;Sylvie Behillil;Sylvie van der Werf;Martine Valette;Bruno Lina;Flavia Riccardo;Emanuele Nicastri;Inmaculada Casas;Amparo Larrauri;Magdalena Salom Castell;Francisco Pozo;Rinat A Maksyutov;Charlotte Martin;Marc Van Ranst;Nathalie Bossuyt;Lotta Siira;Jussi Sane;Karin Tegmark-Wisell;Maria Palmérus;Eeva K Broberg;Julien Beauté;Pernille Jorgensen;Nick Bundle;Dmitriy Pereyaslov;Cornelia Adlhoch;Jukka Pukkila;Richard Pebody;Sonja Olsen;Bruno Christian Ciancio | COVID-19;Novel coronavirus;SARS;SARS-COV-2;coronavirus disease 2019 | 2020-03-12 01:00:00+01:00 | 32156327 | FR;SE;RU;BE;UNK;FI;IT;ES;DK;DE | [{"country": "International", "agency": "World Health Organization", "grantid": "001"}] | European Centre for Disease Prevention and Control, Stockholm, Sweden.;World Health Organisation Regional Office for Europe, Copenhagen, Denmark.;Robert Koch Institute, Berlin, Germany.;Santé Publique France - Direction des maladies infectieuses, Saint-Maurice, France.;Centre national de référence Virus des infections respiratoires, dont la grippe, Institut Pasteur, Paris, France.;Centre national de référence Virus des infections respiratoires, dont la grippe, Hospices civils de Lyon, Lyon, France.;Istituto Superiore di Sanita, Rome, Italy.;Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy.;Coordination Centre for Health Alerts and Emergencies. Spanish Ministry of Health, Madrid, Spain.;Servicio de Epidemiología, Dirección General de Salut Pública, Islas Baleares, Spain.;Federal Service for Surveillance on Consumer Rights Protection and Human Well-being (Rospotrebnadzor), Moscow, Russia.;Department of Infectious Disease Prevention and Control, Common Community Commission, Brussels-Capital Region, Brussels, Belgium.;Chief Physician, Infection control unit, Lapland Hospital District, Rovaniemi, Finland.;County Medical Officer, Jönköping Region, Jönköping, Sweden.;Santé publique France - Direction des régions, Cellule régionale Nouvelle Aquitaine, Bordeaux, France.;Santé publique France - Direction des régions, Cellule régionale Ile-de-France, Paris, France.;Santé publique France - Direction des régions, Cellule régionale Auvergne-Rhône-Alpes, Lyon, France.;National Centre for Microbiology, WHO-National Influenza Centre, Institute of Health Carlos III. Madrid, Spain.;National Centre of Epidemiology, CIBERESP, Institute of Health Carlos III. Madrid, Spain.;Dirección General de Salut Pública, Islas Baleares, Spain.;State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Moscow, Russia.;St. Pierre Hospital, Brussels, Belgium.;Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute, KU Leuven - University of Leuven, Leuven, Belgium.;Epidemiology of infectious diseases, Sciensano, Brussels, Belgium.;Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.;Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.;Public Health Agency of Sweden, Solna, Sweden.;Jönköping Region, Jönköping, Sweden.;These authors have contributed equally to the manuscript. | 31 |
| 10.1016/j.tmaid.2020.101624 | Journal Article | en | Testing the repatriated for SARS-Cov2: Should laboratory-based quarantine replace traditional quarantine? | https://www.ncbi.nlm.nih.gov/pubmed/32179125 | An ongoing epidemic of respiratory diseases caused by a novel coronavirus (COVID 2019, SARS-CoV2) started in Wuhan, Hubei, in China at the end of December 2019. The French government decided to repatriate the 337 French nationals living in Wuhan and place them in quarantine in their home country. We decided to test them all for SARS-Cov2 twice in order to reduce anxiety among the population and decision-makers. | 1477-8939 | 2020-03-15 01:00:00+01:00 | pubmed | Adolescent;Adult;Aged;Betacoronavirus;Child;Child, Preschool;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Female;France;Humans;Infant;Infant, Newborn;Male;Middle Aged;Nose;Pandemics;Pharynx;Pneumonia, Viral__diagnosis;Quarantine;RNA, Viral__isolation & purification;Real-Time Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Sputum;Travel;Young Adult;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Travel Medicine and Infectious Disease | Jean Christophe Lagier;Philippe Colson;Hervé Tissot Dupont;Jérôme Salomon;Barbara Doudier;Camille Aubry;Frédérique Gouriet;Sophie Baron;Pierre Dudouet;Rémi Flores;Lucie Ailhaud;Philippe Gautret;Philippe Parola;Bernard La Scola;Didier Raoult;Philippe Brouqui | Anxiety;COVID-19;Coronavirus;Early;Quarantine;Rapid testing | 2020-03-14 01:00:00+01:00 | 32179125 | FR | Aix Marseille Univ, IRD, AP-HM, MEPHI, IHU Méditerranée Infection, Marseille, France. Electronic address: jean-christophe.lagier@univ-amu.fr.;Aix Marseille Univ, IRD, AP-HM, MEPHI, IHU Méditerranée Infection, Marseille, France.;Ministry of Health, Paris, France.;Aix-Marseille Univ, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée Infection, Marseille, France. | 32 | ||
| NIAID NIH HHS;NIGMS NIH HHS | 10.1016/j.cell.2020.02.058 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't | en | Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. | https://www.ncbi.nlm.nih.gov/pubmed/32155444 | The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination. | 0092-8674 | 2020-03-15 01:00:00+01:00 | pubmed | Amino Acid Sequence;Antibodies, Neutralizing__metabolism;Antigens, Viral__chemistry;Betacoronavirus__chemistry;Cell Line;Cryoelectron Microscopy;Humans;Models, Molecular;Peptidyl-Dipeptidase A__metabolism;Receptors, Virus__chemistry;SARS Virus__metabolism;Spike Glycoprotein, Coronavirus__chemistry;Virus Internalization__drug effects;severe acute respiratory syndrome coronavirus 2 | Cell | Alexandra C Walls;Young-Jun Park;M Alejandra Tortorici;Abigail Wall;Andrew T McGuire;David Veesler | SARS-CoV;SARS-CoV-2;antibodies;coronavirus;cryo-EM;neutralizing antibodies;spike glycoprotein;viral receptor | 2020-03-09 01:00:00+01:00 | 32155444 | FR;US | [{"country": "United States", "agency": "NIAID NIH HHS", "grantid": "HHSN272201700059C"}, {"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "R01 GM120553"}] | Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.;Department of Biochemistry, University of Washington, Seattle, WA 98195, USA, Institute Pasteur & CNRS UMR 3569, Unité de Virologie Structurale, Paris 75015, France.;Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA.;Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA, Department of Global Health, University of Washington, Seattle, WA 98195, USA.;Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Electronic address: dveesler@uw.edu. | 34 |
| 10.1016/j.ijantimicag.2020.105938 | Journal Article | en | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32171740 | Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle. | 0924-8579 | 2020-03-15 01:00:00+01:00 | pubmed | Antiviral Agents__pharmacology;Betacoronavirus__drug effects;Chloroquine__pharmacology;Coronavirus Infections__drug therapy;Drug Evaluation, Preclinical;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Christian A Devaux;Jean-Marc Rolain;Philippe Colson;Didier Raoult | COVID-19;Chloroquine;Coronavirus;SARS-CoV-2 | 2020-03-12 01:00:00+01:00 | 32171740 | FR | Aix-Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France, CNRS, Marseille, France, IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. Electronic address: christian.devaux@mediterranee-infection.com.;Aix-Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France, IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. | 39 | ||
| Preprint | en | SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways. | https://www.ncbi.nlm.nih.gov/pubmed/32550242 | The SARS-CoV-2 coronavirus, the etiologic agent responsible for COVID-19 coronavirus disease, is a global threat. To better understand viral tropism, we assessed the RNA expression of the coronavirus receptor, ACE2, as well as the viral S protein priming protease TMPRSS2 thought to govern viral entry in single-cell RNA-sequencing (scRNA-seq) datasets from healthy individuals generated by the Human Cell Atlas consortium. We found that ACE2, as well as the protease TMPRSS2, are differentially expressed in respiratory and gut epithelial cells. In-depth analysis of epithelial cells in the respiratory tree reveals that nasal epithelial cells, specifically goblet/secretory cells and ciliated cells, display the highest ACE2 expression of all the epithelial cells analyzed. The skewed expression of viral receptors/entry-associated proteins towards the upper airway may be correlated with enhanced transmissivity. Finally, we showed that many of the top genes associated with ACE2 airway epithelial expression are innate immune-associated, antiviral genes, highly enriched in the nasal epithelial cells. This association with immune pathways might have clinical implications for the course of infection and viral pathology, and highlights the specific significance of nasal epithelia in viral infection. Our findings underscore the importance of the availability of the Human Cell Atlas as a reference dataset. In this instance, analysis of the compendium of data points to a particularly relevant role for nasal goblet and ciliated cells as early viral targets and potential reservoirs of SARS-CoV-2 infection. This, in turn, serves as a biological framework for dissecting viral transmission and developing clinical strategies for prevention and therapy. | 2020-03-15 01:00:00+01:00 | pubmed | Waradon Sungnak;Ni Huang;Christophe Bécavin;Marijn Berg | 2020-03-13 01:00:00+01:00 | 32550242 | FR;NL;GB | Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.;Université Côte d'Azur, CNRS, IPMC, Sophia-Antipolis 06560, France.;Department of Pathology and Medical Biology, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, Netherlands.;Groningen Research Institute for Asthma and COPD, University Medical Centre Groningen, University of Groningen, 9713 AV Groningen, Netherlands. | 40 | |||||||
| 10.1101/2020.02.19.20025452 | Preprint | en | The serial interval of COVID-19 from publicly reported confirmed cases. | https://www.ncbi.nlm.nih.gov/pubmed/32511454 | We estimate the distribution of serial intervals for 468 confirmed cases of COVID-19 reported in 93 Chinese cities by February 8, 2020. The mean and standard deviation are 3.96 (95% CI 3.53-4.39) and 4.75 (95% CI 4.46-5.07) days, respectively, with 12.6% of reports indicating pre-symptomatic transmission. | 2020-03-22 01:00:00+01:00 | pubmed | Zhanwei Du;Xiaoke Xu;Ye Wu;Lin Wang;Benjamin J Cowling;Lauren Ancel Meyers | Wuhan;coronavirus;epidemiology;serial interval | 2020-03-20 01:00:00+01:00 | 32511454 | FR;CN;US;HK;MX | The University of Texas at Austin, Austin, Texas 78712, The United States of America.;Dalian Minzu University, Dalian 116600, China.;Computational Communication Research Center, Beijing Normal University, Zhuhai, 519087, China.;School of Journalism and Communication, Beijing Normal University, Beijing, 100875, China.;Institut Pasteur, 28 rue du Dr Roux, Paris 75015, France.;The University of Hong Kong, Hong Kong SAR, China.;Santa Fe Institute, Santa Fe, New Mexico, The United States of America. | 46 | |||||
| Letter;Comment | en | COVID-19 in pregnant women - Authors' reply. | https://www.ncbi.nlm.nih.gov/pubmed/32197096 | 2020-03-22 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections;Female;Humans;Pandemics;Pneumonia, Viral;Pregnancy;COVID-19;severe acute respiratory syndrome coronavirus 2 | David Baud;Eric Giannoni;Léo Pomar;Xiaolong Qi;Karin Nielsen-Saines;Didier Musso;Guillaume Favre | 2020-03-17 01:00:00+01:00 | 32197096 | FR;CN;CH;US | Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: david.baud@chuv.ch.;Clinic of Neonatology, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.;Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland.;CHESS Center, The First Hospital of Lanzhou University, Lanzhou, China.;Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.;Aix Marseille Université, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée infection, Marseille, France, Laboratoire Eurofins Labazur Guyane, French Guiana, France. | 52 | |||||||
| 10.1016/j.tmaid.2020.101632 | Journal Article | en | Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot. | https://www.ncbi.nlm.nih.gov/pubmed/32205269 | Rapid virological diagnosis is needed to limit the length of isolation for suspected COVID-19 cases. | 1477-8939 | 2020-03-22 01:00:00+01:00 | pubmed | Travel Medicine and Infectious Disease | Sophie Amrane;Hervé Tissot-Dupont;Barbara Doudier;Carole Eldin;Marie Hocquart;Morgane Mailhe;Pierre Dudouet;Etienne Ormières;Lucie Ailhaud;Philippe Parola;Jean-Christophe Lagier;Philippe Brouqui;Christine Zandotti;Laetitia Ninove;Léa Luciani;Céline Boschi;Bernard La Scola;Didier Raoult;Matthieu Million;Philippe Colson;Philippe Gautret | COVID-19;Coronaviruses;Epidemic;Influenza;SARS-CoV-2;Travel | 2020-03-20 01:00:00+01:00 | 32205269 | FR | IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix-Marseille Univ, APHM, Unité des Virus Émergents (UVE), IRD 190 - Inserm 1207, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France. Electronic address: philippe.gautret@ap-hm.fr. | 56 | |||
| Editorial;Comment | en | The challenge of emergency medicine facing the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32205709 | 2020-03-29 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections;Disease Outbreaks;Emergency Medicine;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Yonathan Freund | 2020-03-25 01:00:00+01:00 | 32205709 | FR | Sorbonne University, Emergency Department, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, Paris, France. | 60 | |||||||
| 10.1016/s1473-3099(20)30200-0 | Journal Article;Observational Study;Research Support, Non-U.S. Gov't | en | Clinical and virological data of the first cases of COVID-19 in Europe: a case series. | https://www.ncbi.nlm.nih.gov/pubmed/32224310 | On Dec 31, 2019, China reported a cluster of cases of pneumonia in people at Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the relevant features of the first cases in Europe of confirmed infection, named coronavirus disease 2019 (COVID-19), with the first patient diagnosed with the disease on Jan 24, 2020. | 1473-3099 | 2020-03-29 01:00:00+01:00 | pubmed | Adult;Aged, 80 and over;Betacoronavirus__isolation & purification;Blood__virology;China;Coronavirus Infections__diagnosis;Feces__virology;Female;France__epidemiology;Humans;Male;Middle Aged;Nasopharynx__virology;Pandemics;Pneumonia, Viral__diagnosis;RNA, Viral__isolation & purification;Travel;Urine__virology;Viral Load;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Infectious Diseases | Francois-Xavier Lescure;Lila Bouadma;Duc Nguyen;Marion Parisey;Paul-Henri Wicky;Sylvie Behillil;Alexandre Gaymard;Maude Bouscambert-Duchamp;Flora Donati;Quentin Le Hingrat;Vincent Enouf;Nadhira Houhou-Fidouh;Martine Valette;Alexandra Mailles;Jean-Christophe Lucet;France Mentre;Xavier Duval;Diane Descamps;Denis Malvy;Jean-François Timsit;Bruno Lina;Sylvie van-der-Werf;Yazdan Yazdanpanah | 2020-03-27 01:00:00+01:00 | 32224310 | FR | Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Department of Infectious Diseases and Tropical Medicine, University Hospital of Bordeaux, Bordeaux, France, INSERM U1219, University of Bordeaux, Bordeaux, France.;Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.;National Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses, CNRS-UMR 3569, The Institut Pasteur, Paris, France.;National Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France, Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS-UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France.;Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;National Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses, CNRS-UMR 3569, The Institut Pasteur, Paris, France, Mutualized Platform of Microbiology, Pasteur International Bioresources Network, The Institut Pasteur, Paris, France.;Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.;Santé Publique France, Saint Maurice, France.;Infection Control Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Department of Epidemiology, Biostatistics and Clinical Research, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Center for Clinical Investigation, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France. Electronic address: yazdan.yazdanpanah@aphp.fr. | 74 | |||
| 10.1111/jsr.13052 | Journal Article;Review | en | Dealing with sleep problems during home confinement due to the COVID-19 outbreak: Practical recommendations from a task force of the European CBT-I Academy. | https://www.ncbi.nlm.nih.gov/pubmed/32246787 | In the current global home confinement situation due to the COVID-19 outbreak, most individuals are exposed to an unprecedented stressful situation of unknown duration. This may not only increase daytime stress, anxiety and depression levels, but also disrupt sleep. Importantly, because of the fundamental role that sleep plays in emotion regulation, sleep disturbance can have direct consequences upon next day emotional functioning. In this paper, we summarize what is known about the stress-sleep link and confinement as well as effective insomnia treatment. We discuss those effects of the current home confinement situation that can disrupt sleep but also those that could benefit sleep quality. We suggest adaptions of cognitive behavioural therapy elements that are feasible to implement for those facing changed work schedules and requirements, those with health anxiety and those handling childcare and home-schooling, whilst also recognizing the general limitations imposed on physical exercise and social interaction. Managing sleep problems as best as possible during home confinement can limit stress and possibly prevent disruptions of social relationships. | 0962-1105,1365-2869 | 2020-04-05 02:00:00+02:00 | pubmed | Journal of Sleep Research | Ellemarije Altena;Chiara Baglioni;Colin A Espie;Jason Ellis;Dimitri Gavriloff;Brigitte Holzinger;Angelika Schlarb;Lukas Frase;Susanna Jernelöv;Dieter Riemann | COVID-19;home confinement;sleep problems;stress | 2020-04-04 02:00:00+02:00 | 32246787 | FR;SE;GB;IT;DE;AT | UMR 5287, Institut de Neurosciences Intégratives et Cognitives d'Aquitaine, Neuroimagerie et Cognition Humaine, CNRS, Université de Bordeaux, Bordeaux, France.;Department of Psychiatry and Psychotherapy, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.;Department of Human Sciences, University of Rome 'G. Marconi' - Telematic, Italy.;Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.;Northumbria Centre for Sleep Research, Northumbria University, Newcastle, UK.;Institut für Bewusstseins- und Traumforschung, Vienna, Austria.;Department of Psychology, University of Bielefeld, Bielefeld, Germany.;Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden.;Stockholm Health Care Services, Stockholm County Council, Huddinge Hospital, Stockholm, Sweden.;Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. | 77 | |||
| Letter | fr | [Clozapine prescription in the wake of the coronavirus (SARS CoV-2) outbreak: What measures? Why?] | https://www.ncbi.nlm.nih.gov/pubmed/32317164 | 2020-04-05 02:00:00+02:00 | pubmed | Agammaglobulinemia__chemically induced;Antipsychotic Agents__adverse effects;Betacoronavirus;Clozapine__adverse effects;Contraindications, Drug;Coronavirus Infections__complications;Drug Monitoring;Drug Prescriptions;Humans;Pandemics;Parkinson Disease__complications;Pneumonia, Aspiration__chemically induced;Pneumonia, Viral__complications;Psychotic Disorders__drug therapy;Schizophrenia__complications;Sialorrhea__chemically induced;COVID-19;severe acute respiratory syndrome coronavirus 2 | A Ben Dhia;S Hamzaoui;F Mouaffak | 2020-04-03 02:00:00+02:00 | 32317164 | FR | Pôle 93G04 de Psychiatrie d'Adultes, EPS Ville Evrard. 5 rue du Dr Delafontaine 93200, Saint Denis, France.;Pôle 93G04 de Psychiatrie d'Adultes, EPS Ville Evrard. 5 rue du Dr Delafontaine 93200, Saint Denis, France. Electronic address: f.mouaffak@epsve.fr. | 81 | |||||||
| Letter | en | An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32246784 | 2020-04-05 02:00:00+02:00 | pubmed | Serge Nataf | 2020-04-04 02:00:00+02:00 | 32246784 | FR | Bank of Tissues and Cells, Hôpital Edouard Herriot, Lyon University Hospital, Lyon, France.;CarMeN Laboratory, INSERM 1060, INRA 1397, INSA, Oullins, France.;Department of Cytology/Histology, Lyon-Est School of Medicine, University Claude Bernard Lyon-1, Lyon, France. | 84 | ||||||||
| Letter;Review | en | European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis. | https://www.ncbi.nlm.nih.gov/pubmed/32223003 | 2020-04-05 02:00:00+02:00 | pubmed | Advisory Committees;Comorbidity;Coronavirus Infections__epidemiology;Dermatitis, Atopic__drug therapy;Europe;Female;Humans;Immunocompromised Host__drug effects;Immunosuppressive Agents__therapeutic use;Male;Pandemics;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Risk Assessment;Severe Acute Respiratory Syndrome__epidemiology;Treatment Outcome;COVID-19 | A Wollenberg;C Flohr;D Simon;M J Cork;J P Thyssen;T Bieber;M S de Bruin-Weller;S Weidinger;M Deleuran;A Taieb;C Paul;M Trzeciak;T Werfel;J Seneschal;S Barbarot;U Darsow;A Torrelo;J-F Stalder;Å Svensson;D Hijnen;C Gelmetti;Z Szalai;U Gieler;L De Raeve;B Kunz;P Spuls;L B von Kobyletzki;R Fölster-Holst;P V Chernyshov;S Christen-Zaech;A Heratizadeh;J Ring;C Vestergaard | 2020-03-31 02:00:00+02:00 | 32223003 | FR;SE;BE;UA;CH;GB;US;PL;IT;NL;ES;HU;DK;DE | Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany.;Department of Dermatology I, München Klinik Thalkirchner Strasse, Munich, Germany.;St John's Institute of Dermatology, King's College London and Guy's & St Thomas' NHS Foundation Trust, London, UK.;Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.;Sheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.;Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark.;Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, Denmark.;Department of Dermatology and Allergy, Christine Kühne-Center for Allergy Research and Education, University Hospital of Bonn, Bonn, Germany.;National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.;Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.;University of Bordeaux, Bordeaux, France.;Department of Dermatology, Toulouse University, Toulouse, France.;Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.;Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.;Department of Adult and Pediatric Dermatology, CHU Bordeaux, University of Bordeaux, Bordeaux, France.;Department of Dermatology, CHU, Nantes, France.;Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.;Department of Dermatology, Hospital Infantil Niño Jesús, Madrid, Spain.;Department of Dermatology, Nantes Université, CHU Nantes, UMR 1280 PhAN, INRAE, F-4400, Nantes, France.;Department of Dermatology, Skane University Hospital, Malmö, Sweden.;Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Pathophysiology and Transplantation, Foundation IRCCS, Cà Granda Ospedale Maggiore Policlinico, Foundation IRCCS, Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.;Department of Dermatology, Heim Pál National Children's Institute, Budapest, Hungary.;Department of Dermatology, University of Gießen and Marburg GmbH, Gießen, Germany.;Department of Dermatology, Universitair Ziekenhuis Brussel (UZB), Free University of Brussels (VUB), Brussels, Belgium.;Dermatologicum, Hamburg, Germany.;Department of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.;University Healthcare Research Center, Faculty of Medicine, Lund University, Lund, Sweden.;Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.;Department of Dermatology and Venereology, National Medical University, Kiev, Ukraine.;Pediatric Dermatology Unit, Departments of Dermatology and Pediatrics, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.;Christine-Kühne Center for Allergy Research and Education (CK-Care), Davos, Switzerland. | 85 | |||||||
| 10.1213/ane.0000000000004844 | Journal Article;Review | en | Essential Role of Patient Blood Management in a Pandemic: A Call for Action. | https://www.ncbi.nlm.nih.gov/pubmed/32243296 | The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic. Global health care now faces unprecedented challenges with widespread and rapid human-to-human transmission of SARS-CoV-2 and high morbidity and mortality with COVID-19 worldwide. Across the world, medical care is hampered by a critical shortage of not only hand sanitizers, personal protective equipment, ventilators, and hospital beds, but also impediments to the blood supply. Blood donation centers in many areas around the globe have mostly closed. Donors, practicing social distancing, some either with illness or undergoing self-quarantine, are quickly diminishing. Drastic public health initiatives have focused on containment and "flattening the curve" while invaluable resources are being depleted. In some countries, the point has been reached at which the demand for such resources, including donor blood, outstrips the supply. Questions as to the safety of blood persist. Although it does not appear very likely that the virus can be transmitted through allogeneic blood transfusion, this still remains to be fully determined. As options dwindle, we must enact regional and national shortage plans worldwide and more vitally disseminate the knowledge of and immediately implement patient blood management (PBM). PBM is an evidence-based bundle of care to optimize medical and surgical patient outcomes by clinically managing and preserving a patient's own blood. This multinational and diverse group of authors issue this "Call to Action" underscoring "The Essential Role of Patient Blood Management in the Management of Pandemics" and urging all stakeholders and providers to implement the practical and commonsense principles of PBM and its multiprofessional and multimodality approaches. | 0003-2999 | 2020-04-05 02:00:00+02:00 | pubmed | Blood Banks__organization & administration;Blood Donors;Blood Transfusion;Coronavirus Infections__therapy;Evidence-Based Medicine;Humans;Pandemics;Pneumonia, Viral__therapy;COVID-19 | Anesthesia & Analgesia | Aryeh Shander;Susan M Goobie;Matthew A Warner;Matti Aapro;Elvira Bisbe;Angel A Perez-Calatayud;Jeannie Callum;Melissa M Cushing;Wayne B Dyer;Jochen Erhard;David Faraoni;Shannon Farmer;Tatyana Fedorova;Steven M Frank;Bernd Froessler;Hans Gombotz;Irwin Gross;Nicole R Guinn;Thorsten Haas;Jeffrey Hamdorf;James P Isbister;Mazyar Javidroozi;Hongwen Ji;Young-Woo Kim;Daryl J Kor;Johann Kurz;Sigismond Lasocki;Michael F Leahy;Cheuk-Kwong Lee;Jeong Jae Lee;Vernon Louw;Jens Meier;Anna Mezzacasa;Manuel Munoz;Sherri Ozawa;Marco Pavesi;Nina Shander;Donat R Spahn;Bruce D Spiess;Jackie Thomson;Kevin Trentino;Christoph Zenger;Axel Hofmann | 2020-04-04 02:00:00+02:00 | 32243296 | FR;JE;RU;CA;CN;CH;US;AT;HK;IT;AU;ZA;ES;MX;KR;DE | From the Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Health, Englewood, New Jersey.;Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.;Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.;Cancer Center Clinique Genolier, Genolier, Switzerland.;Department of Anesthesiology, Perioperative Medicine Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.;Department of Critical Care, Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico.;Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.;Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, New York.;Australian Red Cross Lifeblood and Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.;Department of Surgery, Evangelisches Klinikum Niederrhein, Duisburg, Germany.;Department of Anesthesiology and Pain Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.;Medical School, Division of Surgery, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Western Australia, Australia.;School of Health Sciences and Graduate Studies, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia.;Institute of Anesthesiology, Resuscitation and Transfusiology of the National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Acad. V. I. Kulakov, Ministry of Health of the Russian Federation, Moscow, Russia.;Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.;Department of Anesthesia, Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia.;Discipline of Acute Care Medicine, University of Adelaide, Adelaide, South Australia, Australia.;Department of Anesthesiology and Intensive Care, General Hospital Linz, Linz, Austria.;Northern Light Health, Brewer, Maine.;Accumen, Inc, San Diego, California.;Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina.;Department of Anesthesiology, University Children's Hospital Zurich, Zurich, Switzerland.;Medical School, The University of Western Australia, Western Australia Patient Blood Management Group, Perth, Western Australia, Australia.;Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.;Department of Anesthesiology and Transfusion Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.;Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy and Center for Gastric Cancer, National Cancer Center, Ilsandong-gu, Goyang, Korea.;Austrian Federal Ministry of Health, Vienna, Austria.;Department Applied Sciences, University of Applied Sciences, Vienna, Austria.;Département Anesthésie-Réanimation, Anesthésie Samu Urgences Réanimation, CHU Angers, Angers, France.;Department of Haematology, PathWest Laboratory Medicine, University of Western Australia, Royal Perth Hospital, Perth, Western Australia, Australia.;Hong Kong Red Cross Blood Transfusion Service, Hong Kong Special Administrative Region, China.;Department of Obstetrics and Gynecology, Soonchunhyang University Hospital, Seoul, Korea.;Division Clinical Haematology, Department of Medicine, University of Cape Town, Cape Town, South Africa.;Clinic of Anesthesiology and Intensive Care Medicine, Johannes Kepler University Linz, Linz, Austria.;Vifor Pharma, Glattbrugg, Switzerland.;Department of Surgical Sciences, Biochemistry and Immunology, School of Medicine, University of Málaga, Málaga, Spain.;Patient Blood Management, Englewood Health, Englewood, New Jersey.;Department of Anesthesiology and Intensive Care, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Donato, San Donato Milanese, Milan, Italy.;Jerry M. Wallace School of Osteopathic Medicine, Campbell University, Buies Creek, North Carolina.;Institute of Anesthesiology, University of Zurich, University Hospital of Zurich, Zurich, Switzerland.;Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida.;South African National Blood Service, Johannesburg, South Africa.;Medical School, The University of Western Australia, Perth, Western Australia, Australia.;Data and Digital Innovation, East Metropolitan Health Service, Perth, Western Australia, Australia.;Center for Health Law and Management, University of Bern, Bern, Switzerland.;Institute of Anesthesiology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.;Medical School, The University of Western Australia, Crawley, Western Australia, Australia.;School of Health Sciences and Graduate Studies, Curtin University, Perth, Western Australia, Australia. | 90 | |||
| 10.1016/j.jfo.2020.03.001 | Editorial | fr | [Hand hygiene and facemasks against COVID-19: Should we consider alternate strategies?] | https://www.ncbi.nlm.nih.gov/pubmed/32278505 | 0181-5512 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus__physiology;Coronavirus Infections__prevention & control;Equipment Design;Equipment Reuse;Hand Hygiene;Health Personnel;Humans;Masks__classification;Occupational Diseases__prevention & control;Pandemics__prevention & control;Personal Protective Equipment__supply & distribution;Pneumonia, Viral__prevention & control;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | I Cochereau;C Lamirel | 2020-03-31 02:00:00+02:00 | 32278505 | FR | Hôpital Fondation Rothschild, 29, rue Manin, 75019, Paris, France, Hôpital Bichat-Claude Bernard, 46, rue Henri Huchard, 75018 Paris, France. Electronic address: icochereau@for.paris.;Hôpital Fondation Rothschild, 29, rue Manin, 75019, Paris, France. | 98 | ||||
| Clinical Trial;Letter | en | No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32240719 | 2020-04-05 02:00:00+02:00 | pubmed | Adult;Aged;Antiviral Agents__therapeutic use;Azithromycin__therapeutic use;Betacoronavirus__isolation & purification;Coronavirus Infections__therapy;Drug Therapy, Combination__standards;Female;Humans;Hydroxychloroquine__therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Viral__therapy;Treatment Outcome;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | J M Molina;C Delaugerre;J Le Goff;B Mela-Lima;D Ponscarme;L Goldwirt;N de Castro | 2020-03-30 02:00:00+02:00 | 32240719 | FR | Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France, U944 INSERM, université de Paris, 75000 Paris, France. Electronic address: jean-michel.molina@aphp.fr.;Université de Paris, 75000 Paris, France, Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.;Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France.;Pharmacology Department, AP-HP, Saint-Louis Hospital, 75010 Paris, France. | 102 | |||||||
| 10.1016/j.acvd.2020.03.009 | Journal Article | en | COVID-19 in patients with cardiovascular diseases. | https://www.ncbi.nlm.nih.gov/pubmed/32245656 | 1875-2136 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Cardiovascular Diseases__complications;Coronavirus Infections__complications;Humans;Pandemics;Peptidyl-Dipeptidase A;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Archives of Cardiovascular Diseases | Jean-Sébastien Hulot | Acute cardiac injury;COVID-19;COVID19;Cardiopathie;Heart failure;Hypertension;Myocardium;Risque cardiovasculaire | 2020-03-31 02:00:00+02:00 | 32245656 | FR | Université de Paris, Inserm, PARCC, 75015 Paris, France, CIC1418 and DMU CARTE, hôpital européen Georges-Pompidou, AP-HP, 56, rue Leblanc, 75015 Paris, France. Electronic address: jean-sebastien.hulot@aphp.fr. | 113 | |||
| 10.1111/vox.12926 | Journal Article;Review | en | Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? | https://www.ncbi.nlm.nih.gov/pubmed/32240545 | Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality. | 0042-9007,1423-0410 | 2020-04-05 02:00:00+02:00 | pubmed | Vox Sanguinis | Pierre Tiberghien;Xavier de Lamballerie;Pascal Morel;Pierre Gallian;Karine Lacombe;Yazdan Yazdanpanah | COVID-19;antibody;convalescent plasma;infectious disease;plasma | 2020-04-02 02:00:00+02:00 | 32240545 | FR | Etablissement Français du Sang, La Plaine-St Denis, France.;UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France.;IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.;Sorbonne Université Inserm IPLESP Hôpital St Antoine AP-HP, Paris, France.;REACTing Inserm, Paris, France.;AP-HP Hôpital Bichat, Paris, France. | 121 | |||
| Letter;Comment | en | Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32239445 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Reverse Transcription;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Renfei Lu;Xiuming Wu;Zhenzhou Wan;Yingxue Li;Lulu Zuo;Jianru Qin;Xia Jin;Chiyu Zhang | 2020-04-01 02:00:00+02:00 | 32239445 | FR;CN | Clinical Laboratory, Nantong Third Hospital Affiliated to Nantong University, Nantong, 226006, China.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China.;Medical Laboratory of Taizhou Fourth People's Hospital, Taizhou, 225300, China.;College of Life Sciences, Henan Normal University, Xinxiang, 453007, China.;Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai, 201508, China.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China. zhangcy1999@ips.ac.cn. | 124 | |||||||
| Case Reports;Letter | en | Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. | https://www.ncbi.nlm.nih.gov/pubmed/32247642 | 2020-04-05 02:00:00+02:00 | pubmed | Adult;Antibodies, Monoclonal, Humanized__therapeutic use;Autoantibodies__therapeutic use;Betacoronavirus;Coronavirus Infections__complications;Humans;Male;Pandemics;Pneumonia, Viral__complications;Receptors, Interleukin-6__antagonists & inhibitors;Respiratory Insufficiency__diagnostic imaging;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | J-M Michot;L Albiges;N Chaput;V Saada;F Pommeret;F Griscelli;C Balleyguier;B Besse;A Marabelle;F Netzer;M Merad;C Robert;F Barlesi;B Gachot;A Stoclin | 2020-04-02 02:00:00+02:00 | 32247642 | FR;UNK | Department of Therapeutic Innovation and Early Testing. Electronic address: jean-marie.michot@gustaveroussy.fr.;Medical Oncology, University Paris Saclay, Gustave Roussy.;Molecular Analysis, modélisation et imagerie de la Maladie cancéreuse, Laboratoire d'Immunomonitoring en Oncologie, Gustave Roussy, INSERM, CNRS.;Department of Biology, University Paris Saclay, Gustave Roussy.;Department of Medical Imaging.;Department of Therapeutic Innovation and Early Testing.;Department of Pharmacy, Villejuif, France.;Intensive Care Department, Université Paris-Saclay, Gustave Roussy Villejuif, France. | 125 | |||||||
| 10.1016/j.ijantimicag.2020.105980 | Editorial | en | Chloroquine as a prophylactic agent against COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32294495 | 0924-8579 | 2020-04-12 02:00:00+02:00 | pubmed | Animals;Antimalarials__therapeutic use;Antiviral Agents__therapeutic use;Azithromycin__therapeutic use;Betacoronavirus__drug effects;Chlorocebus aethiops;Chloroquine__therapeutic use;Coronavirus Infections__drug therapy;Drug Therapy, Combination;Humans;Hydroxychloroquine__therapeutic use;Pandemics__prevention & control;Pneumonia, Viral__drug therapy;Pre-Exposure Prophylaxis__methods;Vero Cells;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Mathieu Gendrot;Emilie Javelle;Axelle Clerc;Hélène Savini;Bruno Pradines | 2020-04-12 02:00:00+02:00 | 32294495 | FR | Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France, Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France.;Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France, Service des Maladies Infectieuses, Hôpital d'Instruction des Armées Laveran, Marseille, France.;Service des Maladies Infectieuses, Hôpital d'Instruction des Armées Laveran, Marseille, France.;Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, Service des Maladies Infectieuses, Hôpital d'Instruction des Armées Laveran, Marseille, France.;Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France, Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France, Centre National de Référence du Paludisme, Marseille, France. Electronic address: bruno.pradines@gmail.com. | 142 | ||||
| Letter;Comment | en | Surgery and the COVID-19 epidemic: Some additional precautions. Re: "Strategy for the practice of digestive and oncological surgery during the COVID-19 epidemic". | https://www.ncbi.nlm.nih.gov/pubmed/32305341 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | M Canis;N Bourdel;R Botchorishvili | 2020-04-08 02:00:00+02:00 | 32305341 | FR | Department of Gynecologic Surgery, CHU d'Estaing, 1, place Lucie et Raymond-Aubrac, 63000 Clermont-Ferrand, France. Electronic address: mcanis@chu-clermontferrand.fr.;Department of Gynecologic Surgery, CHU d'Estaing, 1, place Lucie et Raymond-Aubrac, 63000 Clermont-Ferrand, France. | 160 | |||||||
| 10.1007/s12204-020-2167-2 | Journal Article | en | Prediction of COVID-19 Outbreak in China and Optimal Return Date for University Students Based on Propagation Dynamics. | https://www.ncbi.nlm.nih.gov/pubmed/32288415 | On 12 December 2019, a novel coronavirus disease, named COVID-19, began to spread around the world from Wuhan, China. It is useful and urgent to consider the future trend of this outbreak. We establish the 4+1 penta-group model to predict the development of the COVID-19 outbreak. In this model, we use the collected data to calibrate the parameters, and let the recovery rate and mortality change according to the actual situation. Furthermore, we propose the BAT model, which is composed of three parts: simulation of the return rush (Back), analytic hierarchy process (AHP) method, and technique for order preference by similarity to an ideal solution (TOPSIS) method, to figure out the best return date for university students. We also discuss the impacts of some factors that may occur in the future, such as secondary infection, emergence of effective drugs, and population flow from Korea to China. | 1007-1172,1995-8188 | 2020-04-12 02:00:00+02:00 | pubmed | Journal of Shanghai Jiaotong University (Science) | Ganyu Huang;Qiaoyi Pan;Shuangying Zhao;Yucen Gao;Xiaofeng Gao | analytic hierarchy process (AHP);epidemic dynamics model, nonlinear least squares;technique for order preference by similarity to an ideal solution (TOPSIS) | 2020-04-07 02:00:00+02:00 | 32288415 | FR;CN | 1SJTU-ParisTech Elite Institute of Technology, Shanghai Jiao Tong University, Shanghai, 200240 China.;2School of Mechanical Engineering, Shanghai Jiao Tong University, Shanghai, 200240 China.;3School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, 200240 China. | 161 | |||
| 10.1093/eurheartj/ehaa278 | Journal Article | en | Strategies to control COVID-19 and future pandemics in Africa and around the globe. | https://www.ncbi.nlm.nih.gov/pubmed/32255477 | 0195-668X,1522-9645 | 2020-04-12 02:00:00+02:00 | pubmed | European Heart Journal | Anouar Fanidi;Xavier Jouven;Bamba Gaye | 2020-04-07 02:00:00+02:00 | 32255477 | FR;GB;UNK | The African Research Network.;MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, UK.;Université de Paris, PARCC, INSERM, F-75015 Paris, France.;Cardiology Department, Georges-Pompidou European Hospital, Paris, France. | 162 | |||||
| 10.1016/j.ancard.2020.04.001 | Journal Article;Review | fr | [COVID-19 pandemia: Impact on the cariovascular system. Data of 1st April 2020]. | https://www.ncbi.nlm.nih.gov/pubmed/32303363 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells with angiotensin receptors, leading to pneumonia linked to COVID-19. The virus has a double impact on the cardiovascular system, the infection will be more intense if the host has cardiovascular co-morbidities and the virus can cause life-threatening cardiovascular lesions. Therapies associated with COVID-19 may have adverse cardiovascular effects. Therefore, special attention should be given to cardiovascular protection during COVID-19 infection. | 0003-3928 | 2020-04-12 02:00:00+02:00 | pubmed | Antimalarials__adverse effects;Antiviral Agents__adverse effects;Azithromycin__adverse effects;Betacoronavirus__immunology;Cardiomyopathies__virology;Cardiovascular Diseases__complications;Cerebrovascular Disorders__complications;Chloroquine__adverse effects;Comorbidity;Coronary Disease__complications;Coronavirus Infections__complications;Drug Interactions;Drug Therapy, Combination__adverse effects;Female;Humans;Hydroxychloroquine__adverse effects;Hydroxymethylglutaryl-CoA Reductase Inhibitors__adverse effects;Male;Methylprednisolone__adverse effects;Pandemics__prevention & control;Pneumonia, Viral__complications;Risk Factors;Virus Internalization__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Annales de Cardiologie et d'Angéiologie | B El Boussadani;C Benajiba;A Aajal;A Ait Brik;O Ammour;J El Hangouch;O Oussama;B Oussama;N Tahiri;Z Raissuni | COVID-19;Cardiac impact;Gestion des thérapeutiques;Impact cardiaque;Therapeutics management | 2020-04-07 02:00:00+02:00 | 32303363 | FR;MA | Service de cardiologie, centre hospitalier universitaire Tanger Tétouan Al Hoceima, faculté de médecine et de pharmacie de Tanger, université Abdelmalek Essadi, Tanger, Maroc.;Service de cardiologie, centre hospitalier universitaire Tanger Tétouan Al Hoceima, faculté de médecine et de pharmacie de Tanger, université Abdelmalek Essadi, Tanger, Maroc. Electronic address: zainab.raissouni@hotmail.com. | 165 | ||
| 10.1148/radiol.2020201365 | Journal Article;Practice Guideline | en | The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. | https://www.ncbi.nlm.nih.gov/pubmed/32255413 | With more than 900 000 confirmed cases worldwide and nearly 50 000 deaths during the first 3 months of 2020, the coronavirus disease 2019 (COVID-19) pandemic has emerged as an unprecedented health care crisis. The spread of COVID-19 has been heterogeneous, resulting in some regions having sporadic transmission and relatively few hospitalized patients with COVID-19 and others having community transmission that has led to overwhelming numbers of severe cases. For these regions, health care delivery has been disrupted and compromised by critical resource constraints in diagnostic testing, hospital beds, ventilators, and health care workers who have fallen ill to the virus exacerbated by shortages of personal protective equipment. Although mild cases mimic common upper respiratory viral infections, respiratory dysfunction becomes the principal source of morbidity and mortality as the disease advances. Thoracic imaging with chest radiography and CT are key tools for pulmonary disease diagnosis and management, but their role in the management of COVID-19 has not been considered within the multivariable context of the severity of respiratory disease, pretest probability, risk factors for disease progression, and critical resource constraints. To address this deficit, a multidisciplinary panel comprised principally of radiologists and pulmonologists from 10 countries with experience managing patients with COVID-19 across a spectrum of health care environments evaluated the utility of imaging within three scenarios representing varying risk factors, community conditions, and resource constraints. Fourteen key questions, corresponding to 11 decision points within the three scenarios and three additional clinical situations, were rated by the panel based on the anticipated value of the information that thoracic imaging would be expected to provide. The results were aggregated, resulting in five main and three additional recommendations intended to guide medical practitioners in the use of chest radiography and CT in the management of COVID-19. | 0033-8419,1527-1315 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Consensus;Coronavirus Infections__diagnostic imaging;Disease Progression;Global Health;Guideline Adherence;Humans;Pandemics;Personal Protective Equipment;Pneumonia, Viral__diagnostic imaging;Radiography, Thoracic__instrumentation;Severity of Illness Index;Societies, Medical;Triage;Video Recording;COVID-19;severe acute respiratory syndrome coronavirus 2 | Radiology | Geoffrey D Rubin;Christopher J Ryerson;Linda B Haramati;Nicola Sverzellati;Jeffrey P Kanne;Suhail Raoof;Neil W Schluger;Annalisa Volpi;Jae-Joon Yim;Ian B K Martin;Deverick J Anderson;Christina Kong;Talissa Altes;Andrew Bush;Sujal R Desai;Onathan Goldin;Jin Mo Goo;Marc Humbert;Yoshikazu Inoue;Hans-Ulrich Kauczor;Fengming Luo;Peter J Mazzone;Mathias Prokop;Martine Remy-Jardin;Luca Richeldi;Cornelia M Schaefer-Prokop;Noriyuki Tomiyama;Athol U Wells;Ann N Leung | 2020-04-07 02:00:00+02:00 | 32255413 | FR;CA;CN;JP;GB;US;IT;NL;KR;DE | From the Department of Radiology, Duke University School of Medicine, Box 3808, Durham, NC 27705 (G.D.R.), Department of Medicine, University of British Columbia, Vancouver, Canada (C.J.R.), Department of Radiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (L.B.H.), Department of Scienze Radiologiche, Department of Medicine and Surgery, University of Parma, Parma, Italy (N.S.), Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wis (J.P.K.), Division of Pulmonary, Critical Care & Sleep Medicine, Lenox Hill Hospital, New York, NY (S.R.), Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Irving Medical Center, New York, NY (N.W.S.), 1st Anesthesia and Intensive Care Unit, University Hospital of Parma, Parma, Italy (A.V.), Division of Pulmonary and Critical Medicine, Seoul National University College of Medicine, Seoul, South Korea (J.J.Y.), Department of Emergency Medicine, The Medical College of Wisconsin School of Medicine, Milwaukee, Wis (I.B.K.M.), Director, Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University Medical Center, Durham, NC (D.J.A.), Medical Director of Pathology and Clinical Laboratory Medicine, Stanford University Medical Center, Stanford, Calif (C.K.), Department of Radiology, University of Missouri, Columbia, Mo (T.A.), Department of Paediatrics and Paediatric Respirology, Royal Brompton Hospital, London, England (A.B.), Department of Radiology, Royal Brompton & Harefield NHS Foundation Trust, London, England (S.R.D.), National Heart and Lung Institute, Imperial College, London, England (S.R.D.), Department of Radiology, David Geffen School of Medline at University of California Los Angeles, Los Angeles, Calif (J.G.), Department of Radiology, Seoul National University College of Medicine, Seoul, South Korea (J.M.G.), Department of Respiratory and Intensive Care Medicine, Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France (M.H.), Department of Pathology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan (Y.I.), Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany (H.U.K.), Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Sichuan, China (F.L.), Respiratory Institute, Cleveland Clinic, Cleveland,Ohio (P.J.M.), Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands (M.P.), Department of Thoracic Imaging-Hospital Calmette, University Centre of Lille, Lille, France (M.R.J.), Divisionof Pulmonary Medicine, Università Cattolica del Sacro Cuore, Rome, Italy (L.R.), Department of Radiology and Nuclear Medicine, Meander Medical Centre, Amersfoort, the Netherlands (C.M.S.P.), Department of Radiology, Osaka University Graduate School of Medicine, Osaka, Japan (N.T.), Department of Pulmonary Medicine, Royal Brompton Hospital, London, England (A.U.W.), and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (A.N.L.). | 166 | |||
| Letter | fr | [Smoking and coronavirus disease 2019 (COVID-19)]. | https://www.ncbi.nlm.nih.gov/pubmed/32331829 | 2020-04-12 02:00:00+02:00 | pubmed | Adult;Age Factors;Aged;Aged, 80 and over;Betacoronavirus__physiology;China__epidemiology;Comorbidity;Coronavirus Infections__complications;Female;Hospitalization__statistics & numerical data;Humans;Male;Middle Aged;Pandemics;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__complications;Prevalence;Risk Factors;Severity of Illness Index;Smoking__epidemiology;Tobacco Use Disorder__complications;Up-Regulation;COVID-19;severe acute respiratory syndrome coronavirus 2 | M Underner;G Peiffer;J Perriot;N Jaafari | COVID-19;Coronavirus 2019;Facteurs de risque;Risk factors;SARS-CoV-2;Smoking;Tabagisme | 2020-04-08 02:00:00+02:00 | 32331829 | FR | Unité de recherche clinique, centre hospitalier Henri-Laborit, université de Poitiers, 370, avenue Jacques-Cœur, CS 10587, 86021 Poitiers cedex, France. Electronic address: mike.underner@orange.fr.;Service de pneumologie, CHR de Metz-Thionville, 57038 Metz, France.;Dispensaire Emile-Roux, centre de tabacologie, 63100 Clermont-Ferrand, France.;Unité de recherche clinique, centre hospitalier Henri-Laborit, université de Poitiers, 370, avenue Jacques-Cœur, CS 10587, 86021 Poitiers cedex, France. | 170 | ||||||
| 10.18332/tid/120005 | Journal Article | en | COVID-19 outbreak impact in Spain: A role for tobacco smoking? | https://www.ncbi.nlm.nih.gov/pubmed/32336968 | 1617-9625 | 2020-04-12 02:00:00+02:00 | pubmed | Tobacco Induced Diseases | Javier C Vázquez;Diego Redolar-Ripoll | COVID-19;coronavirus;sex differences;smoking;tobacco | 2020-04-06 02:00:00+02:00 | 32336968 | FR;ES | NutriNeuro, Bordeaux Neurocampus, Bordeaux, France.;Cognitive NeuroLab, Faculty of Health Sciences, Universitat Oberta de Catalunya, Barcelona, Spain. | 177 | ||||
| 10.1016/j.cgh.2020.04.001 | Journal Article;Systematic Review | en | Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. | https://www.ncbi.nlm.nih.gov/pubmed/32278065 | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19) pandemic is a worldwide emergency. An increasing number of diarrhea cases is reported. Here we investigate the epidemiology, clinical presentation, molecular mechanisms, management, and prevention of SARS-CoV-2 associated diarrhea. We searched on PubMed, EMBASE, and Web of Science up to March 2020 to identify studies documenting diarrhea and mechanism of intestinal inflammation in patients with confirmed diagnosis of SARS-CoV-2 infection. Clinical studies show an incidence rate of diarrhea ranging from 2% to 50% of cases. It may precede or trail respiratory symptoms. A pooled analysis revealed an overall percentage of diarrhea onset of 10.4%. SARS-CoV uses the angiotensin-converting enzyme 2 (ACE2) and the serine protease TMPRSS2 for S protein priming. ACE2 and TMPRSS2 are not only expressed in lung, but also in the small intestinal epithelia. ACE2 is expressed furthermore in the upper esophagus, liver, and colon. SARS-CoV-2 binding affinity to ACE2 is significantly higher (10-20 times) compared with SARS-CoV. Several reports indicate viral RNA shedding in stool detectable longer time period than in nasopharyngeal swabs. Current treatment is supportive, but several options appear promising and are the subject of investigation. Diarrhea is a frequent presenting symptom in patients infected with SARS-CoV-2. Increasing evidence indicates possible fecal oral transmission, indicating the need for a rapid and effective modification of the screening and diagnostic algorithms. The optimal methods to prevent, manage, and treat diarrhea in COVID-19 infected patients are subjects of intensive research. | 1542-3565 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Child;Coronavirus Infections__complications;Diarrhea__epidemiology;Disease Management;Disease Transmission, Infectious__prevention & control;Feces__virology;Humans;Incidence;Infection Control__methods;Pandemics;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__complications;Serine Endopeptidases__metabolism;Spike Glycoprotein, Coronavirus__metabolism;Virus Attachment;Virus Internalization;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Gastroenterology and Hepatology | Ferdinando D'Amico;Daniel C Baumgart;Silvio Danese;Laurent Peyrin-Biroulet | ACE2;Angiotensin-Converting Enzyme 2;COVID-19;Diarrhea;Epidemiology;SARS-CoV-2;TMPRSS2 | 2020-04-08 02:00:00+02:00 | 32278065 | FR;IT;CA | Department of Biomedical Sciences, Humanitas University, Milan, Italy, Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.;Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada.;Department of Biomedical Sciences, Humanitas University, Milan, Italy, IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, IRCCS, Milan, Italy.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com. | 178 | ||
| 10.1016/j.mycmed.2020.100971 | Editorial | en | Invasive fungal diseases during COVID-19: We should be prepared. | https://www.ncbi.nlm.nih.gov/pubmed/32307254 | 1156-5233 | 2020-04-12 02:00:00+02:00 | pubmed | Coronavirus Infections__complications;Humans;Incidence;Intensive Care Units;Mycoses__complications;Pandemics;Pneumonia, Viral__complications;Risk Factors;COVID-19 | Journal de Mycologie Médicale | J-P Gangneux;M-E Bougnoux;E Dannaoui;M Cornet;J R Zahar | Covid Aspergillus;Covid Pneumocystis;Covid aspergillosis;Covid fungal;Covid mucorales;Covid pneumocystosis | 2020-04-06 02:00:00+02:00 | 32307254 | FR | Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé environnement et Travail) - UMR_S 1085, CHU Rennes, 2, rue Henri Le Guilloux, 35033 Rennes, France. Electronic address: jean-pierre.gangneux@univ-rennes1.fr.;Service de microbiologie clinique, unité de parasitologie-mycologie, hôpital Necker-Enfants-Malades, AP-HP, Centre - université de Paris, France, Unité biologie et pathogénicité fongiques - Institut Pasteur, Paris, France.;Service de microbiologie, unité de parasitologie - mycologie, hôpital européen Georges-Pompidou, Centre - université de Paris, AP-HP, France.;Service de parasitologie - mycologie, CHU de Grenoble, TIMC-IMAG TheREX, université Grenoble-Alpes, France.;Unité de prévention du risque infectieux, groupe hospitalier Paris Seine-Saint-Denis, hôpital Avicenne, UFR SMBH, université Paris 13, France. | 180 | |||
| 10.1016/j.hansur.2020.04.001 | Journal Article | en | COVID-19: Initial experience of an international group of hand surgeons. | https://www.ncbi.nlm.nih.gov/pubmed/32278932 | The emergence of the COVID-19 pandemic has severely affected medical treatment protocols throughout the world. While the pandemic does not affect hand surgeons at first glance, they have a role to play. The purpose of this study was to describe the different measures that have been put in place in response to the COVID-19 pandemic by hand surgeons throughout the world. The survey comprised 47 surgeons working in 34 countries who responded to an online questionnaire. We found that the protocols varied in terms of visitors, health professionals in the operating room, patient waiting areas, wards and emergency rooms. Based on these preliminary findings, an international consensus on hand surgery practices for the current viral pandemic, and future ones, needs to be built rapidly. | 2468-1229 | 2020-04-12 02:00:00+02:00 | pubmed | Coronavirus Infections__prevention & control;Hand__surgery;Health Care Surveys;Humans;Internationality;Internet;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Practice Patterns, Physicians'__organization & administration;Professional Practice__organization & administration;COVID-19 | Hand Surgery and Rehabilitation | F Ducournau;M Arianni;S Awwad;E-M Baur;J-Y Beaulieu;M Bouloudhnine;M Caloia;K Chagar;Z Chen;A Y Chin;E C Chow;T Cobb;Y David;P J Delgado;M Woon Man Fok;R French;I Golubev;J R Haugstvedt;S Ichihara;R A Jorquera;S C J J Koo;J Y Lee;Y K Lee;Y J Lee;B Liu;T Kaleli;G R Mantovani;C Mathoulin;J C Messina;C Muccioli;S Nazerani;C Y Ng;M C Obdeijn;L Van Overstraeten;T O H Prasetyono;M Ross;J T Shih;N Smith;F A Suarez R;P-T Chan;H Tiemdjo;A Wahegaonkar;M C Wells;W-Y Wong;F Wu;X F Yang;D Yanni;J Yao;P A Liverneaux | COVID-19;Chirurgie de la main;Coronavirus;Covid_19;Epidemic;Hand Surgery;Pandemic;Pandémie;Épidémie | 2020-04-09 02:00:00+02:00 | 32278932 | IL;ID;CA;JP;TW;BR;AR;CL;CM;NL;MA;BE;FR;RU;CO;TN;CN;CH;US;HK;GB;IT;IR;KR;DE;SG;NO;SA;AU;TR;ZA;ES;IN | Icube CNRS 7357, department of hand surgery, hôpital de Hautepierre, university hospital of Strasbourg, FMTS, university of Strasbourg, 1, avenue Molière, 67200 Strasbourg cedex, France.;Department of Surgery, RSUD Pasar Minggu Hospital, Jl. TB Simatupang No.1, RT.1/RW.5, Ragunan, Kec. Ps. Minggu, Kota Jakarta Selatan, Daerah Khusus Ibukota Jakarta 12550, Indonesia.;National Guard Hospital Medina, Ad Dar, Medina, Saudi Arabia.;Practice of Plastic and Hand Surgery, James-Loeb-Straße 13, 82418 Murnau am Staffelsee, Germany.;Hôpitaux universitaire de Genève, département de chirurgie, rue Gabrielle-Perret-Gentil 4, 1205 Genève, Switzerland.;Les Cliniques El Manar, 2092 rue Habib Echatti, Tunis, Tunisia.;Department of Orthopaedic Surgery, Facultad de Ciencias Biomedicas, Universidad Austral, Hospital Universitario Austral, Pilar, Buenos Aires, Argentina.;Pôle de chirurgie orthopédique, hôpital Militaire d'Instruction Mohamed V, Hay Riad, Rabat, Morocco.;Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 328 Qi'an Ave, Xinzhou, Wuhan, Hubei, China.;Department of Hand and Reconstructive Microsurgery, Singapore General Hospital, Academia Building, Outram Rd, Singapour 169608, Singapore.;Department of Orthopaedics and Traumatology, United Christian Hospital, 130 Hip Wo St, Kwun Tong, Hong Kong.;Orthopedic Specialists, P.C., 4622 Progress Drive Suite C, Davenport, IA 52807, USA.;Hand surgery unit and microsurgery, Hospital Kaplan medical center, Derech Pasternak, Rehovot, Israel.;Hand Surgery and Microsurgery Department, University Hospital HM Monteprincipe, CEU San Pablo University, Calle de Julián Romea 23, 28003 Madrid, Spain.;Department of Orthopaedics and Traumatology 5/F, Professorial Block, Queen Mary Hospital, The University of Hong Kong, Queen Mary Hospital Main Block, Pok Fu Lam Rd, Pok Fu Lam, Hong Kong.;The Specialist Referral Clinic, 555W 12th Ave #121, Vancouver, BC V5Z 3X7, Canada.;N. Priorov Research Institute of Trauma Surgery and Orthopaedics, 10 Moscow Ulitsa Priorova, Russia.;Division of Handsurgery, Department of Orthopedics, Østfold Hospital, Per Gynts vei 78, 1535 Moss, Norway.;Department of Hand Surgery, Juntendo University Urayasu Hospital, 2 Chome-1-1 Tomioka, Urayasu, Chiba 279-0021, Japan.;Department of Hand Surgery and Microsurgery, Clínica Indisa, Andrés Bello University, Av. Sta. María 1810, Santiago, Providencia, Región Metropolitana, Chile.;Department of Orthoapedics and Traumatology, Alice Ho Miu Ling Nethersole Hospital, 11 Chuen On Road, Tai Po, NT, Hong Kong.;Department of Orthopedic Surgery, The Catholic University of Korea, Eunpyeong St. Mary's Hospital, 1021 Tongil-ro, Eunpyeong-gu, 03312 Seoul, Korea.;Department of Orthopedic Surgery, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, 567 Baekje-daero, Geumam 1(il)-dong, Deokjin-gu, Jeonju-si, Jeollabuk-do, Republic of Korea.;Department of Orthopaedic Surgery, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Republic of Korea.;Department of Hand Surgery, Beijing Ji Shui Tan Hospital, the 4th Clinical College of Peking University, 31 Xinjiekou E Rd, Beijing Xicheng District, China.;Uludag University, Faculty of Medicine, Department of Orthopaedics, Hand Surgery Clinic, Özlüce, Görükle Kampüsü, 16059 Nilüfer/Bursa, Turkey.;Department of Hand Surgery, Sao Paolo Hand center, Ben Portuguesa Hospital, R. Maestro Cardim 769, Bela Vista, São Paulo, SP, 01323-001, Brazil.;International Wrist Center, clinique Bizet, Institut de la main, 23, rue Georges-Bizet, 75116 Paris, France.;Gaetano Pini- CTO Orthopaedic Institute, First Orthopaedic Clinic University of Milan, Piazza Cardinale Andrea Ferrari 1, 20122 Milano MI, Italy.;Department of Hand and Reconstructive Microsurgery, Mehr General Hospital, W Zartosht St, District 6, Tehran, Tehran Province, IR, Iran.;Upper Limb Unit, Wrightington Hospital, Appley Bridge, Wigan, UK.;Department of Plastic, Reconstructive and Hand surgery, Amsterdam University Medical Centers, AMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.;Hôpital Erasme, ULB, route de Lennik 808, 1070 Bruxelles, Belgium, Hand and foot surgery unit, Rue Pierre Caille 9, 7500 Tournai, Belgium.;Division of Plastic Surgery, Department of Surgery, Cipto Mangunkusumo Hospital/Faculty of Medicine Universitas Indonesia, Jl. Pangeran Diponegoro No.71, RW.5, Kenari, Kec. Senen, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta 10430, Indonesia.;Brisbane Hand and Upper Limb Research Institute, Brisbane Private Hospital, 259 Wickham Terrace, Brisbane City QLD 4000, Australia.;Department of Orthopaedic Surgery, Armed Forces Taoyuan General Hospital, No. 168, Zhongxing Road, Longtan District, Taoyuan City, Taiwan.;Southern Highlands Private Hospital, St Jude Specialist Centre, 21 St Jude St, Bowral NSW 2576, Australia.;Universidad Militar Nueva Granada, Bogota, Colombia/Private clinic Centro de Cirugia Minimamente Invasiva CECIMIN, 76, Autopista Nte. #104, Bogotá, Colombia.;Department of Orthopaedics and Traumatology, Tuen Mun Hospital, Block H, Tsing Chung Koon Rd, Tuen Mun, Hong Kong.;Centre de chirurgie de la main et des paralysies de Douala, Bonamoussadi, Douala, Cameroon.;Dept of Upper Limb, Hand and Microvascular Reconstructive Surgery, Brachial Plexus and Peripheral Nerve Surgery, Sancheti Institute for Orthopaedics and Rehabilitation, Jehangir Hospital, 32, Sasoon Road Opposite Railway Station, Central Excise Colony, Sangamvadi, Pune, Maharashtra 411001, India, The Hand Surgery Clinics, 81/A/11 Giridarshan Society, Behind NEXA Showroom, Baner Road, Pune, Maharashtra 411007, India.;Orthopaedic hand surgeon, Mediclinic Panorama, Panorama, Rothschild Blvd, Panorama, Cape Town, 7500, South Africa.;Department of Orthopaedics and Traumatology, the Chinese University of Hong Kong, Central Ave, Hong Kong.;Dept of Orthopaedics, University Hospitals Birmingham, Bordesley Green East, Bordesley Green E, Birmingham B9 5SS, UK.;Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiang'an District, Wuhan, Hubei, China.;KIMS Hospital, Newnham Ct Way, Weavering, Maidstone ME14 5FT, Kent, UK.;Robert A. Chase Hand and Upper Limb Center, Stanford University Medical Center, 450 Broadway, Redwood City, CA 94063, USA.;Icube CNRS 7357, department of hand surgery, hôpital de Hautepierre, university hospital of Strasbourg, FMTS, university of Strasbourg, 1, avenue Molière, 67200 Strasbourg cedex, France. Electronic address: Philippe.liverneaux@chru-strasbourg.fr. | 183 | ||
| 10.1016/j.annonc.2020.04.002 | Editorial;Research Support, Non-U.S. Gov't | en | Testing for COVID-19 in lung cancer patients. | https://www.ncbi.nlm.nih.gov/pubmed/32278879 | 0923-7534 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Humans;Lung Neoplasms__diagnosis;Pandemics;Pneumonia, Viral__diagnosis;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Annals of Oncology | A Passaro;S Peters;T S K Mok;I Attili;T Mitsudomi;F de Marinis | 2020-04-09 02:00:00+02:00 | 32278879 | FR;CN;JP;CH;HK;IT | Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: antonio.passaro@ieo.it.;Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.;Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, China.;Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.;Thoracic Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan. | 184 | ||||
| 10.1016/j.bulcan.2020.03.010 | Journal Article;Practice Guideline | fr | [French Society for Surgical Oncology (SFCO) guidelines for the management of surgical oncology in the pandemic context of COVID 19]. | https://www.ncbi.nlm.nih.gov/pubmed/32307107 | 0007-4551 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Comorbidity;Coronavirus Infections__complications;France__epidemiology;Humans;Immunocompromised Host;Neoplasms__psychology;Pandemics;Pneumonia, Viral__complications;Preoperative Care__standards;Societies, Medical__standards;Surgical Oncology__standards;Surgical Procedures, Operative__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Jean-Marc Classe;Gilles Dolivet;Serge Evrard;Gwenael Ferron;Fabrice Lécuru;Lea Leufflen;Michel Rivoire;Olivia Sgarbura | 2020-04-06 02:00:00+02:00 | 32307107 | FR | Université de Nantes, institut de cancérologie de l'Ouest, département de chirurgie oncologique, boulevard du Professeur-J.-Monod, 44805 Saint-Herblain, France. Electronic address: Jean-Marc.Classe@ico.unicancer.fr.;Institut de cancérologie de Lorraine, département de chirurgie oncologique, UMR 7039 CRAN CNRS Nancy, Nancy, France.;Université de Bordeaux, institut Bergonié, département de chirurgie oncologique, 229, cours de l'Argonne, 33076 Bordeaux, France.;Institut universitaire du cancer de Toulouse (IUCT)-Oncopole, institut Claudius-Regaud, département de chirurgie oncologique, Inserm CRCT19, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.;Université de Paris, institut Curie, faculté de médecine, service de chirurgie sérologique, gynécologique et plastie, 26, rue d'Ilm, 75005 Paris, France.;Institut de cancérologie de Lorraine, département de chirurgie oncologique, Nancy, France.;Université Claude-Bernard, département de chirurgie carcinologique, centre Léon-Bérard, unité Inserm U1032, 28, rue Laennec, Lyon, France.;Université de Montpellier, institut de cancérologie de Montpellier (ICM), département de chirurgie oncologique, Montpellier, France. | 190 | ||||
| 10.1016/s2213-2600(20)30170-3 | Journal Article | en | Challenges in lung cancer therapy during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32278368 | 2213-2600 | 2020-04-12 02:00:00+02:00 | pubmed | Antineoplastic Agents__adverse effects;Betacoronavirus;Coronavirus Infections__complications;Drug-Related Side Effects and Adverse Reactions__virology;Humans;Lung Neoplasms__drug therapy;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Respiratory Medicine | Luana Calabrò;Solange Peters;Jean-Charles Soria;Anna Maria Di Giacomo;Fabrice Barlesi;Alessia Covre;Maresa Altomonte;Virginia Vegni;Cesare Gridelli;Martin Reck;Naiyer Rizvi;Michele Maio | 2020-04-09 02:00:00+02:00 | 32278368 | FR;CH;US;IT;DE | Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100 Siena, Italy.;Centre Hospitalier Universitaire Vaudois, Oncology Department, Lausanne University, Lausanne, Switzerland.;Gustave Roussy Cancer Campus, Villejuif, France, Université Paris-Saclay, Orsay, France.;Gustave Roussy Cancer Campus, Villejuif, France, Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.;Radiology Unit, Rugani Hospital, Siena, Italy.;Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.;LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.;Division of Hematology/Oncology, Department of Medicine, Columbia University, New York, NY, USA.;Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, 53100 Siena, Italy, NIBIT Foundation Onlus, Siena, Italy. Electronic address: mmaiocro@gmail.com. | 198 | ||||
| 10.1016/j.retram.2020.04.002 | Editorial | en | Hydroxychloroquine in Covid-19: Does the end justify the means? | https://www.ncbi.nlm.nih.gov/pubmed/32340837 | 2452-3186 | 2020-04-19 02:00:00+02:00 | pubmed | Current Research in Translational Medicine | Ibrahim Yakoub-Agha | 2020-04-18 02:00:00+02:00 | 32340837 | FR | CHU de Lille, univ Lille, INSERM U1286, 59000 Lille, France. Electronic address: Ibrahim.yakoubagha@chru-lille.fr. | 216 | |||||
| 10.2807/1560-7917.es.2020.25.14.2000326 | Journal Article | en | Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France, March 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32290901 | Several French regions where coronavirus disease (COVID-19) has been reported currently show a renewed increase in ILI cases in the general practice-based Sentinelles network. We computed the number of excess cases by region from 24 February to 8 March 2020 and found a correlation with the number of reported COVID-19 cases so far. The data suggest larger circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the French population than apparent from confirmed cases. | 1560-7917 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections__epidemiology;Disease Outbreaks;France__epidemiology;Humans;Influenza, Human__epidemiology;Pandemics;Pneumonia, Viral__epidemiology;Sentinel Surveillance;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Pierre-Yves Boëlle;Cécile Souty;Titouan Launay;Caroline Guerrisi;Clément Turbelin;Sylvie Behillil;Vincent Enouf;Chiara Poletto;Bruno Lina;Sylvie van der Werf;Daniel Lévy-Bruhl;Vittoria Colizza;Thomas Hanslik;Thierry Blanchon | COVID-19;Surveillance Sentinel Network, influenza-like illness | 2020-04-16 02:00:00+02:00 | 32290901 | FR | Sorbonne Université, Institut Pierre Louis d'Epidemiologie et de Santé Publique, Paris, France.;Institut Pasteur, Centre Coordonnateur du Centre National de Référence des virus des infections respiratoires (dont la grippe), Paris, France.;INSERM, Institut Pierre Louis d'Epidemiologie et de Santé Publique, Paris, France.;Université de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Lyon, France.;Laboratoire de Virologie, Hospices Civils de Lyon, Institut des Agents Infectieux (IAI), Centre National de Référence des virus respiratoires (dont la grippe), Centre de Biologie et de Pathologie Nord, Groupement Hospitalier Nord, Lyon, France.;Université Paris Diderot, Sorbonne Paris Cité, Unité de Génétique Moléculaire des Virus à ARN, Paris, France.;UMR CNRS 3569, Paris, France.;Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Paris, France.;Santé Publique France, Saint Maurice, France. | 221 | ||
| 10.1097/ta.0000000000002727 | Journal Article | en | Laparoscopy at all costs? Not now during COVID-19 outbreak and not for acute care surgery and emergency colorectal surgery: A practical algorithm from a hub tertiary teaching hospital in Northern Lombardy, Italy. | https://www.ncbi.nlm.nih.gov/pubmed/32282750 | 2163-0763,2163-0755 | 2020-04-19 02:00:00+02:00 | pubmed | Algorithms;Betacoronavirus;Coronavirus Infections__complications;Digestive System Surgical Procedures;Humans;Italy;Laparoscopy;Pandemics;Patient Selection;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Trauma and Acute Care Surgery | Salomone Di Saverio;Mansoor Khan;Francesco Pata;Giuseppe Ietto;Belinda De Simone;Elia Zani;Giulio Carcano | 2020-04-14 02:00:00+02:00 | 32282750 | FR;IT;GB | From the Department of General Surgery (S.D.S., G.I., E.Z., G.C.), University of Insubria, University Hospital of Varese, ASST Sette Laghi, Regione Lombardia, Italy, Digestive Diseases Department (M.K.), Brighton and Sussex University Hospitals, Brighton, United Kingdom, General Surgery Unit (F.P.), Nicola Giannettasio Hospital, Corigliano-Rossano, Italy, and Département de Chirurgie Viscérale (Bariatrique & Métabolique, Oncologique, et d'Urgence)(B.D.S.), Centre Hospitalier Poissy/Saint-Germain, France. | 223 | ||||
| Letter | fr | [Early EMDR defusing in a COVID-19 testing center]. | https://www.ncbi.nlm.nih.gov/pubmed/32362503 | 2020-04-19 02:00:00+02:00 | pubmed | Attitude to Health;Betacoronavirus;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Early Diagnosis;Eye Movement Desensitization Reprocessing;Humans;Outpatients__psychology;Pandemics;Pneumonia, Viral__diagnosis;Social Isolation;Social Stigma;Stress Disorders, Post-Traumatic__diagnosis;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | M Thépaut;S Ferracci;I Dormois;F Haour;N Cazenave | 2020-04-18 02:00:00+02:00 | 32362503 | FR | Université Rennes 1, 35000 Rennes, France. Electronic address: covividness@gmail.com.;Groupement hospitalier Brocéliande Atlantique, service des urgences, 56000 Vannes, France.;Groupement hospitalier Brocéliande Atlantique, établissement public de santé mentale du Morbihan, référente départementale de la CUMP 56, 56890 Saint-Avé, France.;Inserm, France.;Centre d'étude et de recherche en psychopathologie et psychologie et psychologie de la santé (EA 7411), université de Toulouse Jean-Jaurès, 31000 Toulouse, France. | 227 | |||||||
| 10.1016/j.anorl.2020.04.009 | Editorial | en | Ethical questions related to Covid-19 and ENT practice. | https://www.ncbi.nlm.nih.gov/pubmed/32312621 | 1879-7296 | 2020-04-19 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Disease Management;France;Humans;Otolaryngologists__ethics;Pandemics__ethics;Pneumonia, Viral__epidemiology;COVID-19 | European Annals of Otorhinolaryngology, Head and Neck Diseases | F Simon | 2020-04-15 02:00:00+02:00 | 32312621 | FR | Service d'ORL et chirurgie cervico-faciale pédiatrique, hôpital Necker-enfants malades, AP-HP, 149, rue de Sèvres, 75015 Paris, France. Electronic address: f.simon@aphp.fr. | 230 | ||||
| Case Reports;Letter | en | Fulminant myocarditis due to COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32345547 | 2020-04-19 02:00:00+02:00 | pubmed | Acute Disease;Betacoronavirus;Coronavirus Infections__complications;Echocardiography;Electrocardiography;Female;Humans;Middle Aged;Myocarditis__diagnosis;Pandemics;Pneumonia, Viral__complications;Radiography, Thoracic;Stroke Volume__physiology;Ventricular Function, Left__physiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Ángela Irabien-Ortiz;José Carreras-Mora;Alessandro Sionis;Julia Pàmies;José Montiel;Manel Tauron | 2020-04-15 02:00:00+02:00 | 32345547 | FR;ES | Servicio de Cirugía Cardiovascular, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Electronic address: angelairabien@hotmail.com.;Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Servicio de Cirugía Cardiovascular, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. | 233 | |||||||
| 10.1161/circulationaha.120.047549 | Journal Article;Research Support, Non-U.S. Gov't | en | The Science Underlying COVID-19: Implications for the Cardiovascular System. | https://www.ncbi.nlm.nih.gov/pubmed/32293910 | The coronavirus disease 2019 (COVID-19) pandemic has affected health and economy worldwide on an unprecedented scale. Patients have diverse clinical outcomes, but those with preexisting cardiovascular disease, hypertension, and related conditions incur disproportionately worse outcome. The high infectivity of severe acute respiratory syndrome coronavirus 2 is in part related to new mutations in the receptor binding domain, and acquisition of a furin cleavage site in the S-spike protein. The continued viral shedding in the asymptomatic and presymptomatic individuals enhances its community transmission. The virus uses the angiotensin converting enzyme 2 receptor for internalization, aided by transmembrane protease serine 2 protease. The tissue localization of the receptors correlates with COVID-19 presenting symptoms and organ dysfunction. Virus-induced angiotensin converting enzyme 2 downregulation may attenuate its function, diminish its anti-inflammatory role, and heighten angiotensin II effects in the predisposed patients. Lymphopenia occurs early and is prognostic, potentially associated with reduction of the CD4+ and some CD8+ T cells. This leads to imbalance of the innate/acquired immune response, delayed viral clearance, and hyperstimulated macrophages and neutrophils. Appropriate type I interferon pathway activation is critical for virus attenuation and balanced immune response. Persistent immune activation in predisposed patients, such as elderly adults and those with cardiovascular risk, can lead to hemophagocytosis-like syndrome, with uncontrolled amplification of cytokine production, leading to multiorgan failure and death. In addition to the airways and lungs, the cardiovascular system is often involved in COVID-19 early, reflected in the release of highly sensitive troponin and natriuretic peptides, which are all extremely prognostic, in particular, in those showing continued rise, along with cytokines such as interleukin-6. Inflammation in the vascular system can result in diffuse microangiopathy with thrombosis. Inflammation in the myocardium can result in myocarditis, heart failure, cardiac arrhythmias, acute coronary syndrome, rapid deterioration, and sudden death. Aggressive support based on early prognostic indicators with expectant management can potentially improve recovery. Appropriate treatment for heart failure, arrhythmias, acute coronary syndrome, and thrombosis remain important. Specific evidence-based treatment strategies for COVID-19 will emerge with ongoing global collaboration on multiple approaches being evaluated. To protect the wider population, antibody testing and effective vaccine will be needed to make COVID-19 history. | 0009-7322,1524-4539 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Blood Coagulation;CD4-Positive T-Lymphocytes__cytology;CD8-Positive T-Lymphocytes__cytology;Cardiovascular Diseases__complications;Cardiovascular System__metabolism;Coronavirus Infections__immunology;Female;Humans;Immunity, Innate;Interleukin-6__metabolism;Lymphopenia__etiology;Male;Pandemics;Peptidyl-Dipeptidase A__metabolism;Phenotype;Pneumonia, Viral__immunology;Prognosis;Serine Endopeptidases__metabolism;Survival Rate;COVID-19;severe acute respiratory syndrome coronavirus 2 | Circulation | Peter P Liu;Alice Blet;David Smyth;Hongliang Li | angiotensin converting enzyme 2;heart failure;human coronavirus;inflammation;myocarditis;severe acute respiratory syndrome;vasculitis | 2020-04-15 02:00:00+02:00 | 32293910 | FR;CN;CA | University of Ottawa Heart Institute (P.P.L., A.B., D.S.), University of Ottawa, Ontario, Canada.;Departments of Medicine and Cellular & Molecular Medicine (P.P.L., D.S.), University of Ottawa, Ontario, Canada.;Department of Anesthesiology, Critical Care and Burn Center, Lariboisière - Saint-Louis Hospitals, DMU Parabol, AP-HP Nord, University of Paris, France (A.B.).;Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris, France (A.B.).;Department of Cardiology, Renmin Hospital (H.L.), Wuhan University, China.;Medical Science Research Center, Zhongnan Hospital (H.L.), Wuhan University, China.;Basic Medical School (H.L.), Wuhan University, China. | 234 | ||
| Letter;Comment | en | COVID-19 may induce Guillain-Barré syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32334841 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Guillain-Barre Syndrome;Humans;Pandemics;Pneumonia, Viral;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | J-P Camdessanche;J Morel;B Pozzetto;S Paul;Y Tholance;E Botelho-Nevers | 2020-04-15 02:00:00+02:00 | 32334841 | FR | Department of Neurology, University Hospital of Saint-Étienne, Saint-Étienne, France. Electronic address: j.philippe.camdessanche@chu-st-etienne.fr.;Department of Anesthesiology and Intensive Care Medicine, University Hospital of Saint-Étienne, Saint-Étienne, France.;Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Étienne, Saint-Étienne, France.;Department of Immunology, University Hospital of Saint-Étienne, Saint-Étienne, France.;Laboratory of Biochemistry, University Hospital of Saint-Étienne, Saint-Étienne, France.;Infectious Diseases Department, University Hospital of Saint-Étienne, Saint-Étienne, France. | 237 | |||||||
| Letter;Comment | en | Taking care of older patients with cancer in the context of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32302533 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Neoplasms;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Loïc Mourey;Claire Falandry;Laure de Decker;Rabia Boulahssass;Elisabeth Carola;Leila Bengrine Lefevre;Tristan Cudennec;Etienne Brain;Eléna Paillaud;Pierre Soubeyran | 2020-04-14 02:00:00+02:00 | 32302533 | FR | Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.;Geriatrics Unit, Lyon Sud University Hospital, Hospices Civils de Lyon and Lyon University, Pierre-Bénite, France.;Médecine Aiguë Gériatrique, Université de Nantes, Vice-Présidente de la Société Francophone d'Oncogériatrie, CHU Nantes, Saint Herblain, France.;Geriatric Coordination Unit for Geriatric Oncology, Centre Hospitalier Universitaire de Nice, Nice, France.;Pôle d'Oncologie Médicale, Groupe Hospitalier Public du Sud de l'Oise, Creil, France.;Department of Medical Oncology, Centre Georges-Francois Leclerc, Dijon, France.;Service de Médecine Gériatrique du Pr Teillet AP-HP, Université Paris Saclay Hôpitaux Antoine-Béclère, Boulogne-Billancourt, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Geriatric Oncology Unit, APHP, Hôpital Européen Georges Pompidou, Paris, France, Clinical Epidemiology and Ageing Unit, Université Paris-Est, Créteil, France.;Department of Medical Oncology, Institut Bergonié, Université de Bordeaux, Inserm U1218, 33076 Bordeaux Cedex, France. Electronic address: p.soubeyran@bordeaux.unicancer.fr. | 248 | |||||||
| 10.1016/j.ijrobp.2020.04.016 | Journal Article | en | Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. | https://www.ncbi.nlm.nih.gov/pubmed/32302681 | Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff. | 0360-3016 | 2020-04-19 02:00:00+02:00 | pubmed | Consensus;Coronavirus Infections__epidemiology;Head and Neck Neoplasms__radiotherapy;Humans;Medical Oncology;Pandemics;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Societies, Medical;COVID-19 | International Journal of Radiation Oncology*Biology*Physics | David J Thomson;David Palma;Matthias Guckenberger;Panagiotis Balermpas;Jonathan J Beitler;Pierre Blanchard;David Brizel;Wilfred Budach;Jimmy Caudell;June Corry;Renzo Corvo;Mererid Evans;Adam S Garden;Jordi Giralt;Vincent Gregoire;Paul M Harari;Kevin Harrington;Ying J Hitchcock;Jorgen Johansen;Johannes Kaanders;Shlomo Koyfman;J A Langendijk;Quynh-Thu Le;Nancy Lee;Danielle Margalit;Michelle Mierzwa;Sandro Porceddu;Yoke Lim Soong;Ying Sun;Juliette Thariat;John Waldron;Sue S Yom | 2020-04-14 02:00:00+02:00 | 32302681 | FR;SG;CA;GE;CN;GB;US;CH;IT;AU;NL;ES;DK;PS;DE | Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, and the Division of Cancer Sciences, The University of Manchester, UK.;Division of Radiation Oncology, Western University, London, Canada.;Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.;Department of Radiation Oncology, Emory University, Atlanta, Georgia.;Department of Radiation Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Radiation Oncology, Duke Cancer Institute, Durham, North Carolina.;Department of Radiation Oncology, University Hospital Düsseldorf, Germany.;Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida.;Department Radiation Oncology Genesiscare, St Vincent's Hospital, Melbourne, Australia.;Department of Radiation Oncology, Ospedale Policlinico San Martino and University, Genoa, Italy.;Department of Clinical Oncology, Velindre University NHS Trust, Cardiff, Wales, UK.;Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.;Department of Radiation Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.;Department of Radiation Oncology, Centre Leon Berard, Lyon, France.;Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.;Division of Radiotherapy and Imaging, Institute for Cancer Research, London, UK.;Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah.;Department of Oncology, Odense University Hospital, Department of Oncology, Denmark.;Department of Radiation Oncology, Radboudumc, Nijmegen, The Netherlands.;Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio.;Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.;Department of Radiation Oncology, Stanford University, Palo Alto, California.;Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.;Department of Radiation Oncology, Dana-Farber/Brigham & Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.;Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.;Department of Radiation Oncology, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia.;Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.;Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, PR China.;Department of Radiation Oncology, Centre François Baclesse, University of Normandy, Caen, France.;Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.;Department of Radiation Oncology, University of California San Francisco, San Francisco, California. Electronic address: sue.yom@ucsf.edu. | 250 | |||
| 10.12688/f1000research.23275.2 | Journal Article | en | Gilles de la Tourette Syndrome: advice in the times of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32411359 | The novel coronavirus disease (COVID-19) was identified as the cause of an outbreak of respiratory disease in China at the end of 2019. It then spread with enormous rapidity and by mid-March 2020 was declared a world pandemic. Gilles de la Tourette Syndrome (GTS) is a childhood-onset neurodevelopmental disorder with a worldwide prevalence of about 1% of the population. The clinical symptoms include multiple motor and one or more phonic (vocal) tics. Germane to this communication is that 85% of patients with GTS have associated psychiatric co-morbidities, many of which are being exacerbated in the current global health crisis. In addition, several symptoms of GTS may mimic COVID-19, such as a dry cough and sniffing (phonic tics), while other symptoms such as spitting, inappropriate touching of others and "non-obscene socially inappropriate symptoms" can potentially get patients with GTS into trouble with the law. We suggest that a clear explanation of the COVID-19 illness and GTS is important to enable colleagues of various specialities who tend to patients with GTS. It is important to acknowledge at the outset that the information available on the COVID-19 pandemic changes daily, including cases infected, deaths reported, and how various national health systems are planning and or coping or not. It is fair to say that having read the current medical and lay press we conclude that it is not easy to reassure our patients with absolute certainty. However, notwithstanding that, we hope our documentation is of some assistance. | 2046-1402 | 2020-04-19 02:00:00+02:00 | pubmed | Adolescent;Aged;Aged, 80 and over;Betacoronavirus;Child;Coronavirus Infections__complications;Humans;Pandemics;Pneumonia, Viral__complications;Tourette Syndrome__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | F1000Research | Mary M Robertson;Valsamma Eapen;Renata Rizzo;Jeremy S Stern;Andreas Hartmann | ADHD;COVID-19;Gilles de la Tourette syndrome;OCD;anxiety;confinement;tics | 2020-04-14 02:00:00+02:00 | 32411359 | FR;IT;AU;GB | Department of Psychiatry, University College of London, London, W1T-7NF, UK.;University of New South Wales and Academic Unit of Child Psychiatry, Liverpool Hospital and Ingham Institute, Sydney, NSW 2170, Australia.;Section of Child and Adolescent Neuropsychiatry, University of Catania, Catania, Italy.;Department of Neurology, St George's University of London, London, SW17 0QQ, UK.;Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière, Paris, 75013, France. | 251 | ||
| 10.1016/j.jchirv.2020.04.007 | English Abstract;Journal Article | fr | [SARS-CoV-2 infection may result in appendicular syndrome: Chest CT scan before appendectomy]. | https://www.ncbi.nlm.nih.gov/pubmed/32296473 | The initial clinical presentation of coronavirus disease 2019 may be appendicular syndrome. An abdominal CT scan ruled out a diagnosis of appendicitis and a chest CT scan yielded a diagnosis of SARS-CoV-2 infection. CT scan is required before considering emergency surgery for acute appendicitis. | 1878-786X | 2020-04-19 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | K Pautrat;N Chergui | Appendicitis;COVID-19;Coronavirus disease 2019;TDM | 2020-04-15 02:00:00+02:00 | 32296473 | FR | Service de chirurgie viscérale, cancérologique et endocrinienne, groupe hospitalier Saint-Louis Lariboisière, AP-HP, 75010 Paris, France.;Service d'imagerie ostéo-articulaire, hôpital Lariboisière, AP-HP, 2, rue Ambroise-Paré, 75010 Paris, France. | 259 | |||
| NIAMS NIH HHS;NIAMS NIH HHS;NIAMS NIH HHS | 10.1016/s2665-9913(20)30095-3 | Journal Article | en | Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. | https://www.ncbi.nlm.nih.gov/pubmed/32309814 | 2665-9913 | 2020-04-19 02:00:00+02:00 | pubmed | The Lancet Rheumatology | Milena A Gianfrancesco;Kimme L Hyrich;Laure Gossec;Anja Strangfeld;Loreto Carmona;Elsa F Mateus;Paul Sufka;Rebecca Grainger;Zachary Wallace;Suleman Bhana;Emily Sirotich;Jean Liew;Jonathan S Hausmann;Wendy Costello;Philip Robinson;Pedro M Machado;Jinoos Yazdany | 2020-04-16 02:00:00+02:00 | 32309814 | FR;IL;IE;CA;NZ;PT;GB;US;CH;AU;ES;DE | [{"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "F32 AR070585"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "K24 AR074534"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "P30 AR070155"}] | Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, 94143 CA, USA.;Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.;National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.;Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris France.;Rheumatology Department, Pitié-Salpêtrière hospital, AP-HP, Paris, France.;Epidemiology Unit, German Rheumatism Research Center (DRFZ Berlin), Berlin, Germany.;Instituto de Salud Musculoesquelética, Madrid, Madrid, Spain.;Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.;EULAR Standing Committee of PARE (People with Arthritis Rheumatism in Europe), Zurich, Switzerland.;Healthpartners, St. Paul, MN, USA.;Department of Medicine, University of Otago, Dunedin, Otago, New Zealand.;Massachusetts General Hospital and Program in Rheumatology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.;Crystal Run Health, Middletown, NY, USA.;Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.;Canadian Arthritis Patient Alliance, Toronto, ON, Canada.;Division of Rheumatology, University of Washington, Seattle, WA, USA.;Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.;Irish Children's Arthritis Network (iCAN), Tipperary, Ireland.;University of Queensland Faculty of Medicine, Brisbane, QLD, Australia.;Centre for Rheumatology and Department of Neuromuscular Diseases, University College London, London, UK.;Department of Rheumatology and Queen Square Centre for Neuromuscular Diseases, University College London Hospitals NHS Foundation Trust, London, UK.;Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK. | 261 | |||
| Letter;Comment | en | Blood transfusion strategies and ECMO during the COVID-19 pandemic - Authors' reply. | https://www.ncbi.nlm.nih.gov/pubmed/32305077 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Blood Transfusion;Communicable Diseases, Emerging;Coronavirus Infections;Extracorporeal Membrane Oxygenation;Humans;Pandemics;Pneumonia, Viral;Respiratory Distress Syndrome, Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Kollengode Ramanathan;Graeme MacLaren;Alain Combes;Daniel Brodie;Kiran Shekar | 2020-04-16 02:00:00+02:00 | 32305077 | FR;SG;AU;US | Cardiothoracic Intensive Care Unit, National University Hospital, National University of Singapore, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Bond University, Robina, QLD, Australia.;Cardiothoracic Intensive Care Unit, National University Hospital, National University of Singapore, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Paediatric Intensive Care Unit, The Royal Children's Hospital, University of Melbourne, Melbourne, VIC, Australia.;Institute of Cardiometabolism and Nutrition, University of Paris, Paris, France, Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.;Columbia University College of Physicians and Surgeons, New York, NY, USA, Centre for Acute Respiratory Failure, New York-Presbyterian Hospital, New York, NY, USA.;Bond University, Robina, QLD, Australia, University of Queensland, Brisbane, QLD, Australia, Adult Intensive Care Services, The Prince Charles Hospital, Metro North Hospital and Health Service, Brisbane, QLD 4032, Australia, Critical Care Research Group, Centre of Research Excellence for Advanced Cardio-respiratory Therapies Improving OrgaN Support, Brisbane, QLD, Australia. Electronic address: kiran.shekar@health.qld.gov.au. | 263 | |||||||
| Letter | en | Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India. | https://www.ncbi.nlm.nih.gov/pubmed/32299795 | 2020-04-19 02:00:00+02:00 | pubmed | Latika Gupta;Durga Prasanna Misra;Vishwesh Agarwal;Suma Balan;Vikas Agarwal | antirheumatic agents;autoimmune diseases;biological therapy;communicable diseases, imported;glucocorticoids | 2020-04-16 02:00:00+02:00 | 32299795 | FR;IN | Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP, India.;Mahatma Gandhi Mission's Medical College, Navi Mumbai, Maharashtra, India.;Department of Paediatric Rheumatology, Amrita Institute of Medical Sciences and Research Centre, Cochin, Kerala, India.;Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP, India vikasagr@yahoo.com. | 265 | |||||||
| 10.1038/s41591-020-0874-8 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Caring for patients with cancer in the COVID-19 era. | https://www.ncbi.nlm.nih.gov/pubmed/32405058 | The current COVID-19 pandemic challenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced immune-related complications without compromising cancer outcomes. Since COVID-19 is a novel disease, guidance by scientific evidence is often unavailable, and impactful decisions are inevitably made on the basis of expert opinions. Here we report how the seven comprehensive cancer centers of Cancer Core Europe have organized their healthcare systems at an unprecedented scale and pace to make their operations 'pandemic proof'. We identify and discuss many commonalities, but also important local differences, and pinpoint critical research priorities to enable evidence-based remodeling of cancer care during the COVID-19 pandemic. Also, we discuss how the current situation offers a unique window of opportunity for assessing the effects of de-escalating anticancer regimens, which may fast-forward the development of more-refined and less-toxic treatments. By sharing our joint experiences, we offer a roadmap for proceeding and aim to mobilize the global research community to generate the data that are critically needed to offer the best possible care to patients. | 1078-8956,1546-170X | 2020-04-19 02:00:00+02:00 | pubmed | Ambulatory Care__statistics & numerical data;Betacoronavirus;Coronavirus Infections__complications;Delivery of Health Care;Humans;Neoplasms__complications;Pandemics__prevention & control;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nature Medicine | Joris van de Haar;Louisa R Hoes;Charlotte E Coles;Kenneth Seamon;Stefan Fröhling;Dirk Jäger;Franco Valenza;Filippo de Braud;Luigi De Petris;Jonas Bergh;Ingemar Ernberg;Benjamin Besse;Fabrice Barlesi;Elena Garralda;Alejandro Piris-Giménez;Michael Baumann;Giovanni Apolone;Jean Charles Soria;Josep Tabernero;Carlos Caldas;Emile E Voest | 2020-04-16 02:00:00+02:00 | 32405058 | SE;FR;GB;IT;NL;ES;PS;DE | Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Cancer Research UK Cambridge Cancer Center, Cambridge, UK.;German Cancer Consortium, Heidelberg, Germany.;Division of Translational Medical Oncology, National Center for Tumor Diseases Heidelberg and German Cancer Research Center, Heidelberg, Germany.;Department of Medical Oncology, National Center for Tumor Diseases Heidelberg and Heidelberg University Hospital, Heidelberg, Germany.;Università Statale di Milano, Milan, Italy.;Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.;Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.;Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.;Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.;Gustave Roussy Cancer Campus, Villejuif, France.;Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.;Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.;German Cancer Research Center, Heidelberg, Germany.;Cancer Research UK Cambridge Cancer Center, Cambridge, UK. carlos.caldas@cruk.cam.ac.uk.;Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Center, University of Cambridge, Cambridge, UK. carlos.caldas@cruk.cam.ac.uk.;Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.;Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl. | 282 | |||
| 10.1016/j.jacc.2020.04.029 | Journal Article;Review | en | COVID-19 and Disruptive Modifications to Cardiac Critical Care Delivery: JACC Review Topic of the Week. | https://www.ncbi.nlm.nih.gov/pubmed/32305402 | The COVID-19 pandemic has presented a major unanticipated stress on the workforce, organizational structure, systems of care, and critical resource supplies. To ensure provider safety, to maximize efficiency, and to optimize patient outcomes, health systems need to be agile. Critical care cardiologists may be uniquely positioned to treat the numerous respiratory and cardiovascular complications of the SARS-CoV-2 and support clinicians without critical care training who may be suddenly asked to care for critically ill patients. This review draws upon the experiences of colleagues from heavily impacted regions of the United States and Europe, as well as lessons learned from military mass casualty medicine. This review offers pragmatic suggestions on how to implement scalable models for critical care delivery, cultivate educational tools for team training, and embrace technologies (e.g., telemedicine) to enable effective collaboration despite social distancing imperatives. | 0735-1097 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Cardiology Service, Hospital__organization & administration;Civil Defense__methods;Coronavirus Infections__epidemiology;Critical Care__methods;Delivery of Health Care__methods;Humans;Organizational Innovation;Organizational Objectives;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of the American College of Cardiology | Jason N Katz;Shashank S Sinha;Carlos L Alviar;David M Dudzinski;Ann Gage;Samuel B Brusca;M Casey Flanagan;Timothy Welch;Bram J Geller;P Elliott Miller;Sergio Leonardi;Erin A Bohula;Susanna Price;Sunit-Preet Chaudhry;Thomas S Metkus;Connor G O'Brien;Alessandro Sionis;Christopher F Barnett;Jacob C Jentzer;Michael A Solomon;David A Morrow;Sean van Diepen | cardiac critical care;crisis;pandemic | 2020-04-16 02:00:00+02:00 | 32305402 | FR;CA;GB;US;IT;ES | Division of Cardiology, Duke University, Durham, North Carolina. Electronic address: jason.katz@duke.edu.;Inova Heart and Vascular Institute, Inova Fairfax Medical Center, Falls Church, Virginia. Electronic address: https://twitter.com/ShashankSinhaMD.;Leon H. Charney Division of Cardiology, New York University Langone Medical Center NYU Langone Medical Center, New York, New York.;Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts.;Division of Cardiology, Cleveland Clinic, Cleveland, Ohio.;Critical Care Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland.;Inova Heart and Vascular Institute, Inova Fairfax Medical Center, Falls Church, Virginia.;Inova Heart and Vascular Institute, Inova Fairfax Medical Center, Falls Church, Virginia, Virginia Heart, Falls Church, Virginia.;Division of Cardiology, Maine Medical Center, Portland, Maine.;Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut.;Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology-Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy.;TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.;Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital, London, United Kingdom.;Department of Cardiology, St. Vincent Hospital, Indianapolis, Indiana.;Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.;Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, California.;Intensive Cardiac Care Unit, Cardiology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute IIB-SantPaul, Universidad Autonoma de Barcelona, Barcelona, Spain.;Department of Cardiology, Medstar Washington Hospital Center, Washington, DC.;Department of Cardiovascular Medicine and Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.;Critical Care Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland, Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.;Department of Critical Care and Division of Cardiology, Department of Medicine, University of Alberta Hospital, Alberta, Canada. Electronic address: https://twitter.com/seanvandiepen. | 283 | ||
| Letter;Comment | en | COVID-19: Thoughts and comments from a tertiary liver transplant center in France. | https://www.ncbi.nlm.nih.gov/pubmed/32282972 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;France;Humans;Liver Transplantation;Pandemics;Pneumonia, Viral;Tissue and Organ Procurement;COVID-19;severe acute respiratory syndrome coronavirus 2 | Stylianos Tzedakis;Heithem Jeddou;Pauline Houssel-Debry;Laurent Sulpice;Karim Boudjema | clinical decision-making;clinical research/practice;editorial/personal viewpoint;ethics;guidelines;infection and infectious agents - viral;liver transplantation/hepatology;organ procurement and allocation;organ procurement organization | 2020-04-26 02:00:00+02:00 | 32282972 | FR | Department of Hepatobiliary and Digestive Surgery, University Hospital Pontchaillou, Rennes 1 University, Rennes, France.;Department of Gastroenterology and Hepatology, University Hospital Pontchaillou, Rennes 1 University, Rennes, France. | 291 | ||||||
| 10.1007/s13167-020-00207-0 | Journal Article | en | Covid-19 pandemic by the "real-time" monitoring: the Tunisian case and lessons for global epidemics in the context of 3PM strategies. | https://www.ncbi.nlm.nih.gov/pubmed/32341719 | Covid-19 is neither the first nor the last viral epidemic which societies around the world are, were and will be affected by. Which lessons should be taken from the current pandemic situation? The Covid-19 disease is still not well characterised, and many research teams all over the world are working on prediction of the epidemic scenario, protective measures to populations and sub-populations, therapeutic and vaccination issues, amongst others. Contextually, countries with currently low numbers of Covid-19-infected individuals such as Tunisia are intended to take lessons from those countries which already reached the exponential phase of the infection distribution as well as from those which have the exponential phase behind them and record a minor number of new cases such as China. To this end, in Tunisia, the pandemic wave has started with a significant delay compared with Europe, the main economic partner of the country. In this paper, we do analyse the current pandemic situation in this country by studying the infection evolution and considering potential protective strategies to prevent a pandemic scenario. The model is predictive based on a large number of undetected Covid-19 cases that is particularly true for some country regions such as Sfax. Infection distribution and mortality rate analysis demonstrate a highly heterogeneous picture over the country. Qualitative and quantitative comparative analysis leads to a conclusion that the reliable "real-time" monitoring based on the randomised laboratory tests is the optimal predictive strategy to create the most effective evidence-based preventive measures. In contrast, lack of tests may lead to incorrect political decisions causing either unnecessary over-protection of the population that is risky for a long-term economic recession, or under-protection of the population leading to a post-containment pandemic rebound. Recommendations are provided in the context of advanced predictive, preventive and personalised (3P) medical approach. | 1878-5077,1878-5085 | 2020-04-26 02:00:00+02:00 | pubmed | EPMA Journal | Lotfi Chaari;Olga Golubnitschaja | Anti-body;Anti-gene;Bottle-neck;Comorbidities;Covid-19;Depression;Economy;Epidemics;Ethics;Home isolation;Individual outcomes;Infection;Laboratory medicine;Multi-professional expertise;Pandemic;Policymaking;Population screening;Predictive preventive personalised (3P) medicine;Psychotic attitude;Related mortality;SARS-CoV-2;Salami-tactic;Strategy;Suicide;Suppressed immune defence;Targeted protective measures;Test;Titanic;Triage;Violence;“Real-time” monitoring | 2020-04-25 02:00:00+02:00 | 32341719 | FR;DE | 1University of Toulouse, IRIT - INP-ENSEEIHT (UMR 5505), 2 rue Charles Camichel, BP 7122 Toulouse Cedex 7, France.;2Predictive, Preventive and Personalised (3P) Medicine, Department of Radiation Oncology, Friedrich-Wilhelms-University Bonn, Bonn, Germany. | 296 | |||
| 10.1016/j.micpath.2020.104228 | Journal Article | en | In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. | https://www.ncbi.nlm.nih.gov/pubmed/32344177 | Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung. | 0882-4010 | 2020-04-26 02:00:00+02:00 | pubmed | Animals;Antiviral Agents__pharmacology;Azithromycin__pharmacology;Betacoronavirus__drug effects;Cell Line;Chlorocebus aethiops;Coronavirus Infections__drug therapy;Drug Repositioning;Drug Synergism;Drug Therapy, Combination__methods;Humans;Hydroxychloroquine__pharmacology;Pandemics;Pneumonia, Viral__drug therapy;Vero Cells;Virus Replication__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Microbial Pathogenesis | Julien Andreani;Marion Le Bideau;Isabelle Duflot;Priscilla Jardot;Clara Rolland;Manon Boxberger;Nathalie Wurtz;Jean-Marc Rolain;Philippe Colson;Bernard La Scola;Didier Raoult | 2019-nCoV;Azithromycin;COVID-19;Hydroxychloroquine;SARS-CoV-2;Vero E6 | 2020-04-25 02:00:00+02:00 | 32344177 | FR | IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: bernard.la-scola@univ-amu.fr.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: didier.raoult@gmail.com. | 297 | ||
| 10.1016/j.jormas.2020.03.012 | Practice Guideline | fr | [Practitioners specialized in oral health and coronavirus disease 2019: Professional guidelines from the French society of stomatology, maxillofacial surgery and oral surgery, to form a common front against the infectious risk]. | https://www.ncbi.nlm.nih.gov/pubmed/32307086 | 2468-7855 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Humans;Oral Health;Oral Medicine;Oral Surgical Procedures;Pandemics;Pneumonia, Viral;Surgery, Oral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Stomatology, Oral and Maxillofacial Surgery | 2020-04-21 02:00:00+02:00 | 32307086 | FR | Service de Chirurgie Maxillo-Faciale et Stomatologie, Hôpital Roger Salengro, CHRU Lille, Lille, France. | 307 | |||||
| 10.24272/j.issn.2095-8137.2020.031 | Editorial | en | Zoonotic origins of human coronavirus 2019 (HCoV-19 / SARS-CoV-2): why is this work important? | https://www.ncbi.nlm.nih.gov/pubmed/32314559 | The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by infection with human coronavirus 2019 (HCoV-19 / SARS-CoV-2 / 2019-nCoV), is a global threat to the human population. Here, we briefly summarize the available data for the zoonotic origins of HCoV-19, with reference to the other two epidemics of highly virulent coronaviruses, SARS-CoV and MERS-CoV, which cause severe pneumonia in humans. We propose to intensify future efforts for tracing the origins of HCoV-19, which is a very important scientific question for the control and prevention of the pandemic. | 2095-8137 | 2020-04-26 02:00:00+02:00 | pubmed | Animals;Betacoronavirus__physiology;Coronavirus Infections__transmission;Disease Reservoirs;Humans;Pandemics;Pneumonia, Viral__transmission;Zoonoses;COVID-19;severe acute respiratory syndrome coronavirus 2 | Zoological Research | Gary Wong;Yu-Hai Bi;Qi-Hui Wang;Xin-Wen Chen;Zhi-Gang Zhang;Yong-Gang Yao | Bat;HCoV-19 / SARS-CoV-2;Natural Reservoir;Pangolin;Susceptibility;Zoonotic origins | 2020-04-22 02:00:00+02:00 | 32314559 | FR;CN;CA | CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China. E-mail: garyckwong@ips.ac.cn.;Department of Microbiology-Infectiology and Immunology, Laval University, Quebec G1V 4G2, Canada.;CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing 100101, China. E-mail: beeyh@im.ac.cn.;CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing 100101, China. E-mail: wangqihui@im.ac.cn.;State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, China. E-mail: chenxw@wh.iov.cn.;State key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, School of Life Sciences, Yunnan University, Kunming, Yunnan 650091, China. E-mail: zhangzhigang@ynu.edu.cn.;Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China. E-mail: yaoyg@mail.kiz.ac.cn.;Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan 650204, China.;KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China. | 309 | ||
| 10.1016/j.encep.2020.04.007 | Journal Article;Review | fr | [Psychopathological consequences of confinement]. | https://www.ncbi.nlm.nih.gov/pubmed/32370983 | The psychological effects of isolation have already been described in the literature (polar expeditions, submarines, prison). Nevertheless, the scale of confinement implemented during the COVID-19 pandemic is unprecedented. In addition to reviewing the published studies, we need to anticipate the psychological problems that could arise during or at a distance from confinement. We have gone beyond the COVID-19 literature in order to examine the implications of the known consequences of confinement, like boredom, social isolation, stress, or sleep deprivation. Anxiety, post-traumatic stress disorder, depression, suicidal or addictive behaviours, domestic violence are described effects of confinement, but the mechanisms of emergence of these disorders and their interrelationships remain to be studied. For example, what are the mechanisms of emergence of post-traumatic stress disorders in the context of confinement? We also remind the reader of points of vigilance to be kept in mind with regard to eating disorders and hallucinations. Hallucinations are curiously ignored in the literature on confinement, whereas a vast literature links social isolation and hallucinations. Due to the broad psychopathological consequences, we have to look for these various symptoms to manage them. We quickly summarize the diagnostic and therapeutic approaches already in place, such as telemedicine, which is undergoing rapid development during the COVID-19 crisis. | 0013-7006 | 2020-04-26 02:00:00+02:00 | pubmed | Adult;Anxiety Disorders__etiology;Behavior, Addictive__etiology;Betacoronavirus;Boredom;Child;Child Abuse;Coronavirus Infections__psychology;Delivery of Health Care;Depression__etiology;Domestic Violence__psychology;Feeding and Eating Disorders__etiology;France;Hallucinations__etiology;Health Services Accessibility;Humans;Mental Health Services__organization & administration;Pandemics;Patient Isolation__psychology;Pneumonia, Viral__psychology;Sleep Wake Disorders__etiology;Social Isolation__psychology;Stress Disorders, Post-Traumatic__etiology;Suicide__psychology;Telemedicine;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | A Mengin;M C Allé;J Rolling;F Ligier;C Schroder;L Lalanne;F Berna;R Jardri;G Vaiva;P A Geoffroy;P Brunault;F Thibaut;A Chevance;A Giersch | Anxiety;Anxiété;Confinement;Depression;Dépression;Hallucinations;PTSD;TSPT | 2020-04-22 02:00:00+02:00 | 32370983 | FR;DK | Inserm U1114, pôle de psychiatrie des hôpitaux universitaires de Strasbourg, centre régional psychotraumatisme Grand Est, Strasbourg, France.;Inserm U1114, pôle de psychiatrie des hôpitaux universitaires de Strasbourg, université de Strasbourg, 1, place de l'Hôpital, 67091 Strasbourg, France, Center on Autobiographical Memory Research, Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Danemark.;Service de psychiatrie de l'enfant et de l'adolescent, CNRS UPR 3212, institut des neurosciences cellulaires et intégratives, hôpitaux universitaires de Strasbourg, centre régional psychotraumatisme Grand Est, Strasbourg, France.;Pôle universitaire de psychiatrie de l'enfant et de l'adolescent, centre psychothérapique de Nancy - EA 4360 APEMAC, université de Lorraine, Nancy, France.;Fondation Fondamental, Créteil, France, Service de psychiatrie de l'enfant et de l'adolescent, CNRS UPR 3212, institut des neurosciences cellulaires et intégratives, hôpitaux universitaires de Strasbourg, Strasbourg, France.;Inserm U1114, service d'addictologie, pôle de psychiatrie des hôpitaux universitaires de Strasbourg, Strasbourg, France.;Inserm U1114, pôle de psychiatrie des hôpitaux universitaires de Strasbourg, université de Strasbourg, 1, place de l'Hôpital, 67091 Strasbourg, France, Fondation Fondamental, Créteil, France.;Dir. Plasticity & SubjectivitY (PSY) team, Lille Neuroscience & Cognition Centre (LiNC), Inserm U-1172, université de Lille, Lille, France.;U1172 Inserm, centre hospitalier universitaire de Lille, Centre National de Ressources et Résilience (Cn2r) pour les Psychotraumatisme, Lille, France.;NeuroDiderot, Inserm, université de Paris, 75019 Paris, France, Department of Psychiatry and Addictive Medicine, University Hospital Bichat-Claude-Bernard, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.;CHRU de Tours, Équipe de liaison et de soins en addictologie, UMR 1253, iBrain, Université de Tours, INSERM, Université de Tours, QualiPsy EE 1901, Tours, France.;International Association of Women's Mental Health (President), Université de Paris, CHU Cochin, Inserm U1266, institut de psychiatrie et neurosciences de Paris, Paris, France.;Inserm U1153, CRESS, Inra, service hospitalo-universitaire de psychiatrie, centre hospitalier Sainte-Anne, université Paris Descartes, Paris, France.;Inserm U1114, pôle de psychiatrie des hôpitaux universitaires de Strasbourg, université de Strasbourg, 1, place de l'Hôpital, 67091 Strasbourg, France, Fondation Fondamental, Créteil, France. Electronic address: giersch@unistra.fr. | 320 | ||
| Letter | fr | [SARS-CoV-2 and cancer in France: Resident in oncology on the front line. Testimony of residents in oncology in two French clusters: Grand-Est and Île-de-France]. | https://www.ncbi.nlm.nih.gov/pubmed/32387062 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Disease Progression;France__epidemiology;Health Resources__organization & administration;Humans;Internship and Residency__organization & administration;Medical Oncology__organization & administration;Neoplasms__complications;Pandemics;Personal Autonomy;Pneumonia, Viral__complications;Practice Guidelines as Topic;Risk;COVID-19;severe acute respiratory syndrome coronavirus 2 | Matthieu Delaye;Natacha Naoun;Léah Mailly-Giacchetti | 2020-04-24 02:00:00+02:00 | 32387062 | FR;US | AERIO , Association pour l'Enseignement et le Recherche des Internes en Oncologie, 149 avenue du Maine, 75014 Paris. Electronic address: mdelaye@sfr.fr.;AERIO , Association pour l'Enseignement et le Recherche des Internes en Oncologie, 149 avenue du Maine, 75014 Paris. | 321 | |||||||
| Letter | en | Could ferritin help the screening for COVID-19 in hemodialysis patients? | https://www.ncbi.nlm.nih.gov/pubmed/32471636 | 2020-04-26 02:00:00+02:00 | pubmed | Coronavirus Infections__blood;Female;Ferritins__blood;Humans;Kidney Failure, Chronic__blood;Mass Screening;Pandemics;Pneumonia, Viral__blood;COVID-19 | Stanislas Bataille;Nathalie Pedinielli;Jean-Philippe Bergounioux | 2020-04-22 02:00:00+02:00 | 32471636 | FR | Phocean Nephrology Institute, Clinique Bouchard, Elsan, Marseille, France, Aix Marseille University, INSERM, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Marseille, France. Electronic address: stanislas.bataille@ap-hm.fr.;Phocean Nephrology Institute, Clinique Bouchard, Elsan, Marseille, France.;Laboratoire Cerballiance Provence, Marseille, France. | 323 | |||||||
| 10.1016/j.encep.2020.04.003 | Journal Article | fr | [Real-life data and Covid-19: The third avenue of reseach]. | https://www.ncbi.nlm.nih.gov/pubmed/32362504 | The analysis of real-life data from hospital information systems could make possible to decide on the efficacy and safety of Covid-19 treatments by avoiding the pitfalls of preliminary studies and randomized clinical trials. The different drugs tested in current clinical trials are already widely prescribed to patients by doctors in hospitals, and can therefore be immediately analysed according to validated methodological standards. | 0013-7006 | 2020-04-26 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Betacoronavirus;Coronavirus Infections__drug therapy;Drug Repositioning;Drugs, Investigational__therapeutic use;Evidence-Based Medicine;France__epidemiology;Hospital Information Systems__statistics & numerical data;Hospital Records__statistics & numerical data;Humans;Hydroxychloroquine__therapeutic use;Pandemics;Pneumonia, Viral__drug therapy;Randomized Controlled Trials as Topic__statistics & numerical data;Research Design;Retrospective Studies;Software;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | L Boyer;P Auquier;G Fond | Covid;Evidence;Infection;Method;Méthode;Preuve;Psychiatrie;Psychiatry;Public health;Santé publique;Traitement;Treatment | 2020-04-22 02:00:00+02:00 | 32362504 | FR | EA 3279, Secteur Timone, centre d'études et de recherches sur les services de santé et qualité de vie (CEReSS), faculté de médecine, Aix-Marseille Université Marseille, 27, boulevard Jean-Moulin, 13005 Marseille, France.;EA 3279, Secteur Timone, centre d'études et de recherches sur les services de santé et qualité de vie (CEReSS), faculté de médecine, Aix-Marseille Université Marseille, 27, boulevard Jean-Moulin, 13005 Marseille, France. Electronic address: guillaume.fond@ap-hm.fr. | 324 | ||
| Bayer Consumer Care AG, Switzerland | Letter;Comment | en | Communicating with patients with nAMD and their families during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32322965 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Bevacizumab;Coronavirus Infections;Humans;Intravitreal Injections;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean-François Korobelnik;Anat Loewenstein | 2020-04-22 02:00:00+02:00 | 32322965 | FR;IL | [{"country": "International", "agency": "Bayer Consumer Care AG, Switzerland", "grantid": "N/A"}] | Service d'ophtalmologie, CHU Bordeaux, Bordeaux, France. jean-francois.korobelnik@chu-bordeaux.fr.;Inserm, Bordeaux Population Health Research Center, team LEHA, Université de Bordeaux, UMR 1219, F-33000, Bordeaux, France. jean-francois.korobelnik@chu-bordeaux.fr.;Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. | 326 | |||||
| 10.1016/j.encep.2020.04.004 | Journal Article | fr | [Evolution of electro-convulsive therapy activity in France since the beginning of the COVID-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32370981 | The recent COVID-19 pandemic has led to major organisational changes in health care settings, especially in psychiatric hospitals. We conducted a national online survey to assess the evolution of electroconvulsive therapy (ECT) in the different centres practicing this treatment. 65 responses from all over France were analysed. More than 90 % of the centres practising ECT experienced a decrease in their activity. Half of the centres experienced a total cessation of activity and 25 % of the centres experienced a decrease of more than half of their usual activity. Post-pandemic COVID-19 psychiatric care is expected to be difficult. It is essential not to add to this difficulty the complications, often serious, that will be associated with delaying or stopping the practice of ECT. It will also be necessary to remain vigilant with regard to the specific neuropsychiatric consequences that will follow the pandemic. | 0013-7006 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Bipolar Disorder__therapy;Communicable Disease Control;Continuity of Patient Care;Coronavirus Infections;Delivery of Health Care;Depressive Disorder__therapy;Electroconvulsive Therapy__statistics & numerical data;France;Hospitals, Psychiatric__organization & administration;Humans;Pandemics;Pneumonia, Viral;Procedures and Techniques Utilization;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | A Amad;M Magnat;C Quilès;A Yrondi;A Sauvaget;S Bulteau;M Plaze;M Rotharmel;M Polosan;D Lévy-Chavagnat;N Jaafari;G Vaiva;P Thomas | Accès aux soins;COVID-19;Complications;Electroconvulsive therapy;Epidemiology;Health care access;Pandémie;Électro-convulsivo-thérapie;Épidémiologie | 2020-04-22 02:00:00+02:00 | 32370981 | FR | Université de Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, 59000 Lille, France. Electronic address: ali.amad@chru-lille.fr.;Université de Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, 59000 Lille, France.;Centre hospitalier Charles-Perrens, 33000 Bordeaux, France.;Service de Psychiatrie et de Psychologie Médicale, Centre Expert Dépression Résistante FondaMental, CHU de Toulouse, Hôpital Purpan,ToNIC Toulouse NeuroImaging Center, Université de Toulouse, INSERM, UPS, Toulouse, France.;Nantes Université, CHU Nantes,Movement, Interactions, Performance (MIP), EA 4334, University of Nantes, Nantes, France.;Université de Paris, 75005 Paris, France, Service Hospitalo-Universitaire, GHU Paris Psychiatrie & Neurosciences, 75014 Paris, France.;Service Hospitalo-Universitaire-Unité START, Centre Hospitalier du Rouvray, Sotteville-lès-Rouen, France.;Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, GIN, 38000 Grenoble, France.;Unité de recherche clinique, université de Poitiers, centre hospitalier Henri-Laborit, 370, avenue Jacques-Cœur, CS10587, 86021 Poitiers cedex, France. | 327 | ||
| 10.1212/wnl.0000000000009632 | Consensus Development Conference;Journal Article | en | Keeping people with epilepsy safe during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32327490 | To provide information on the effect of the coronavirus disease of 2019 (COVID-19) pandemic on people with epilepsy and provide consensus recommendations on how to provide the best possible care for people with epilepsy while avoiding visits to urgent care facilities and hospitalizations during the novel coronavirus pandemic. | 0028-3878,1526-632X | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Epilepsy__complications;Humans;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Neurology | Jacqueline A French;Martin J Brodie;Roberto Caraballo;Orrin Devinsky;Ding Ding;Lara Jehi;Nathalie Jette;Andres Kanner;Avani C Modi;Charles R Newton;Archana A Patel;Page B Pennell;Emilio Perucca;Josemir W Sander;Ingrid E Scheffer;Gagandeep Singh;Emma Williams;Jo Wilmshurst;J Helen Cross | 2020-04-23 02:00:00+02:00 | 32327490 | FR;AR;KE;CN;GB;US;IT;AU;NL;ZA;IN | From the Department Neurology (J.A.F.), NYU Grossman School of Medicine New York University, NY, Epilepsy Unit (M.J.B.), International Bureau for Epilepsy, Scottish Epilepsy Initiative, Glasgow, Scotland, Neurology (R.C.), Hospital J P Garrahan, Buenos Aires, AR, Department Neurology (O.D.), NYU Grossman School of Medicine, NY, Institute of Neurology (D.D.), Huashan Hospital, Fudan University, Shanghai, China, Cleveland Clinic Epilepsy Center (L.J.), Cleveland, OH, Department of Neurology (N.J.), Icahn School of Medicine at Mount Sinai, New York, NY, Division of Epilepsy (A.K.), Department of Neurology, Miller School of Medicine, University of Miami, FL, Cincinnati Children's Hospital Medical Center (A.C.M.), School of Medicine, University of Cincinnati, OH, KEMRI-Wellcome Programme (C.R.N.), Kilifi, Kenya and Department of Psychiatry (C.R.N.), University of Oxford, United Kingdom, Division of Epilepsy and Clinical Neurophysiology (A.A.P.), Department of Neurology, Harvard Medical School, Boston Children's Hospital, MA, Harvard Medical School (P.B.P.), Brigham and Women's Hospital, Boston, MA, Department of Internal Medicine and Therapeutics (E.P.), University of Pavia and IRCCS Mondino Foundation, Member of the ERN EpiCARE, Pavia, Italy, UCL Queen Square Institute of Neurology (J.W.S.), London, United Kingdom and Stichting Epilepsie Instelligen Nederland (SEIN) (J.W.S.), Heemstede, Netherlands, University of Melbourne (I.E.S.), Austin and Royal Children's Hospitals, Florey and Murdoch Children's Research Institutes, Melbourne, Australia, Dayanand Medical College (G.S.), Ludhiana, India, Matthew's Friends-Ketogenic Dietary Therapies (E.W.), London, United Kingdom, Department of Paediatric Neurology (J.W.), Red Cross War Memorial Children's Hospital, Neuroscience Institute, Cape Town, South Africa, and UCL NIHR BRC Great Ormond Street Institute of Child Health (J.H.C.), Great Ormond Street Hospital for Children, London, United Kingdom and Member of the ERN EpiCARE (J.H.C.), Young Epilepsy, Lingfield, United Kingdom. Jacqueline.french@nyulangone.org.;From the Department Neurology (J.A.F.), NYU Grossman School of Medicine New York University, NY, Epilepsy Unit (M.J.B.), International Bureau for Epilepsy, Scottish Epilepsy Initiative, Glasgow, Scotland, Neurology (R.C.), Hospital J P Garrahan, Buenos Aires, AR, Department Neurology (O.D.), NYU Grossman School of Medicine, NY, Institute of Neurology (D.D.), Huashan Hospital, Fudan University, Shanghai, China, Cleveland Clinic Epilepsy Center (L.J.), Cleveland, OH, Department of Neurology (N.J.), Icahn School of Medicine at Mount Sinai, New York, NY, Division of Epilepsy (A.K.), Department of Neurology, Miller School of Medicine, University of Miami, FL, Cincinnati Children's Hospital Medical Center (A.C.M.), School of Medicine, University of Cincinnati, OH, KEMRI-Wellcome Programme (C.R.N.), Kilifi, Kenya and Department of Psychiatry (C.R.N.), University of Oxford, United Kingdom, Division of Epilepsy and Clinical Neurophysiology (A.A.P.), Department of Neurology, Harvard Medical School, Boston Children's Hospital, MA, Harvard Medical School (P.B.P.), Brigham and Women's Hospital, Boston, MA, Department of Internal Medicine and Therapeutics (E.P.), University of Pavia and IRCCS Mondino Foundation, Member of the ERN EpiCARE, Pavia, Italy, UCL Queen Square Institute of Neurology (J.W.S.), London, United Kingdom and Stichting Epilepsie Instelligen Nederland (SEIN) (J.W.S.), Heemstede, Netherlands, University of Melbourne (I.E.S.), Austin and Royal Children's Hospitals, Florey and Murdoch Children's Research Institutes, Melbourne, Australia, Dayanand Medical College (G.S.), Ludhiana, India, Matthew's Friends-Ketogenic Dietary Therapies (E.W.), London, United Kingdom, Department of Paediatric Neurology (J.W.), Red Cross War Memorial Children's Hospital, Neuroscience Institute, Cape Town, South Africa, and UCL NIHR BRC Great Ormond Street Institute of Child Health (J.H.C.), Great Ormond Street Hospital for Children, London, United Kingdom and Member of the ERN EpiCARE (J.H.C.), Young Epilepsy, Lingfield, United Kingdom. | 351 | |||
| 10.1016/j.eururo.2020.04.031 | Editorial | en | Widespread Postponement of Functional Urology Cases During the COVID-19 Pandemic: Rationale, Potential Pitfalls, and Future Consequences. | https://www.ncbi.nlm.nih.gov/pubmed/32349933 | 0302-2838 | 2020-04-26 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__complications;Disease Management;Disease Transmission, Infectious__prevention & control;Female;Humans;Male;Pandemics;Pneumonia, Viral__complications;Telemedicine__methods;Urologic Neoplasms__complications;Urology__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Urology | Véronique Phé;Gilles Karsenty;Grégoire Robert;Xavier Gamé;Jean-Nicolas Cornu | 2020-04-23 02:00:00+02:00 | 32349933 | FR | Department of Urology, La Pitié-Salpêtrière Academic Hospital, Sorbonne Université, Paris, France, Department of Urology, La Conception Hospital, Aix-Marseille Université, Marseille, France. Electronic address: phe.veronique@gmail.com.;Department of Urology, La Conception Hospital, Aix-Marseille Université, Marseille, France.;Department of Urology, CHU Bordeaux, University of Bordeaux, Bordeaux, France.;Department of Urology, CHU Rangueil, Université Paul Sabatier Toulouse III, Toulouse, France.;Department of Urology, Rouen University Hospital, Rouen, France. | 352 | ||||
| 10.1148/radiol.2020201544 | Journal Article | en | Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography. | https://www.ncbi.nlm.nih.gov/pubmed/32324103 | Online supplemental material is available for this article. | 0033-8419,1527-1315 | 2020-04-26 02:00:00+02:00 | pubmed | Radiology | Franck Grillet;Julien Behr;Paul Calame;Sébastien Aubry;Eric Delabrousse | 2020-04-23 02:00:00+02:00 | 32324103 | FR | From the Department of Radiology. Centre Hospitalier Universitaire de Besançon, Boulevard Fleming, 25030 Besançon, France (F.G., J.B., P.C., S.A., E.D.), and Nanomedecine Laboratory, INSERM EA4662, University of Franche-Comte, 25000 Besançon, France (S.A., E.D.). | 357 | ||||
| 10.1016/j.oraloncology.2020.104734 | Editorial | en | Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32353793 | 1368-8375 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Coronavirus Infections__complications;Emergencies;Global Burden of Disease;Head and Neck Neoplasms__complications;Humans;Infection Control__standards;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Infectious Disease Transmission, Professional-to-Patient__prevention & control;Medical Oncology__standards;National Health Programs__standards;Pandemics__prevention & control;Pneumonia, Viral__complications;Practice Guidelines as Topic;Risk Factors;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Oral Oncology | Aline Lauda Freitas Chaves;Ana Ferreira Castro;Gustavo Nader Marta;Gilberto Castro Junior;Robert L Ferris;Raúl Eduardo Giglio;Wojciech Golusinski;Philippe Gorphe;Sefik Hosal;C René Leemans;Nicolas Magné;Hisham Mehanna;Ricard Mesía;Eduardo Netto;Amanda Psyrri;Assuntina G Sacco;Jatin Shah;Christian Simon;Jan B Vermorken;Luiz Paulo Kowalski | 2020-04-24 02:00:00+02:00 | 32353793 | FR;AR;PT;GR;GB;US;CH;BR;PL;TR;NL;ES;BE | DOM Oncologia, Brazilian Group of Head and Neck Cancer/Latin American Cooperative Group - Head and Neck, Divinópolis, Brazil. Electronic address: aline@domoncologia.com.br.;Lenitudes Medical Center & Research, Chair of Portuguese Group of Head and Neck Cancer - GECCP, Portugal. Electronic address: ana.castro@lenitudes.pt.;Department of Radiation Oncology, Hospital Sírio-Libanês, São Paulo, Brazil, Division of Radiation Oncology, Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, Brazil, Brazilian Group of Head and Neck Cancer/Latin American Cooperative Group - Head and Neck, Brazil. Electronic address: gustavo.marta@hc.fm.usp.br.;Brazilian Group of Head and Neck Cancer/Latin American Cooperative Group - Head and Neck, Brazil, Department of Clinical Oncology, Hospital Sírio-Libanês, São Paulo, Brazil, Division of Clinical Oncology, Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, Brazil. Electronic address: gilberto.castro@usp.br.;UPMC Hillman Cancer Center, Hillman Professor of Oncology, University of Pittsburgh School of Medicine, USA. Electronic address: ferrrl@upmc.edu.;Unidad Funcional de Tumore de Cabeza y Cuello, Instituto de Oncología Ángel H. Roffo, Universidad de Buenos Aires, Argentina.;Chair of the Department of Head and Neck Surgery, Poznan University of Medical Sciences, The Greater Poland Cancer Centre, Poznan, European Head and Neck Society, Polish Head and Neck Society, Poland. Electronic address: wgolus@ump.edu.pl.;Chief of Head and Neck Surgery Service, Head and Neck Oncology Department, Institute Gustave Roussy, Villejuif - Cancer Campus Grand-Paris, Intergroupe National ORL, GORTEC-GETTEC-GERCOR-Unicancer H&N-REFCOR, France. Electronic address: Philippe.GORPHE@gustaveroussy.fr.;Department of Otolaryngology-Head & Neck Surgery Atilim University Faculty of Medicine, Ankara, Turkey. Electronic address: shosal@ada.net.tr.;Department of Otolaryngology, European Head and Neck Surgery, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam University Medical Centre's, VU University, Amsterdam, the Netherlands. Electronic address: cr.leemans@amsterdamumc.nl.;Chef du Département de Radiothérapie, Directeur de la Recherche et de l'Innovation, Coordonnateur Régional du DES d'Oncologie, Institut de Cancérologie Lucien Neuwirth, Saint-Priest en Jarez, France. Electronic address: nicolas.magne@icloire.fr.;Institute of Head & Neck Studies and Education (InHANSE), University of Birmingham, UK. Electronic address: h.mehanna@bham.ac.uk.;Medical Oncology Department. Catalan Institut of Oncology, Badalona. B-ARGO group, IGTP, Badalona, Spain. Electronic address: rmesia@iconcologia.net.;Radiation Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal. Electronic address: enetto@ipolisboa.min-saude.pt.;National Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. Electronic address: dpsyrri@med.uoa.gr.;Department of Medicine, Division of Hematology-Oncology, University of California San Diego Health, Moores Cancer Center, La Jolla, CA, USA. Electronic address: agsacco@health.ucsd.edu.;Head and Neck Service, Memorial Sloan Kettering Cancer Center, International Federation of Head and Neck Oncologic Societies, New York, NY 10065, USA. Electronic address: shahj@mskcc.org.;Service d'Oto-rhino-laryngologie - chirurgie cervico-faciale, CHUV, UNIL, Lausanne, Switzerland. Electronic address: Christian.Simon@chuv.ch.;Department of Medical Oncology, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp University Hospital, Edegem, Belgium. Electronic address: JanB.Vermorken@uza.be.;Brazilian Group of Head and Neck Cancer/Latin American Cooperative Group - Head and Neck, Brazil, Head and Neck Surgery Department, University of São Paulo Medical School, Sao Paulo, Brazil, Head and Neck Surgery and Otorhinolaryngology Department, A C Camargo Cancer Center, Sao Paulo, Brazil. Electronic address: lp_kowalski@uol.com.br. | 360 | ||||
| Letter | en | Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. | https://www.ncbi.nlm.nih.gov/pubmed/32330083 | 2020-04-26 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Female;Fibrinolytic Agents__therapeutic use;Humans;Intensive Care Units;Length of Stay;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Prevalence;Prognosis;Pulmonary Embolism__complications;Risk Factors;Tertiary Care Centers;COVID-19;severe acute respiratory syndrome coronavirus 2 | Julien Poissy;Julien Goutay;Morgan Caplan;Erika Parmentier;Thibault Duburcq;Fanny Lassalle;Emmanuelle Jeanpierre;Antoine Rauch;Julien Labreuche;Sophie Susen | COVID-19;D-dimer;body mass index;factor VIII;pulmonary embolism;thrombosis;von Willebrand factor | 2020-04-24 02:00:00+02:00 | 32330083 | FR | Université de Lille, Inserm U1285, CHU Lille, Pôle de réanimation, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, France (J.P.).;CHU Lille, Pôle de réanimation, France (J.G., M.C., E.P., T.D.).;Université de Lille, Inserm, CHU Lille, Department of Hematology and Transfusion, Pôle de Biologie Pathologie Génétique, Institut Pasteur de Lille, UMR1011-EGID, France (F.L., E.J., A.R., S.S.).;Université de Lille, CHU Lille, ULR 2694-METRICS: Évaluation des technologies de santé et des pratiques médicales, France (J.L.). | 365 | ||||||
| 10.1016/j.anorl.2020.04.011 | Practice Guideline | en | Guidelines of clinical practice for the management of swallowing disorders and recent dysphonia in the context of the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32332004 | Procedures putting healthcare workers in close contact with the airway are particularly at risk of contamination by the SARS-Cov-2 virus, especially when exposed to sputum, coughing, or a tracheostomy. In the current pandemic phase, all patients should be considered as potentially infected. Thus, the level of precaution recommended for the caregivers depends more on the type of procedure than on the patient's proved or suspected COVID-19 status. Procedures that are particularly at high risk of contamination are clinical and flexible endoscopic pharyngo-laryngological evaluation, and probably also video fluoroscopic swallowing exams. Voice rehabilitation should not be considered urgent at this time. Therefore, recommendations presented here mainly concern the management of swallowing disorders, which can sometimes be dangerous for the patient, and recent dysphonia. In cases where they are considered possible and useful, teleconsultations should be preferred to face-to-face assessments or rehabilitation sessions. The latter must be maintained only in few selected situations, after team discussions or in accordance with the guidelines provided by health authorities. | 1879-7296 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Deglutition Disorders__diagnosis;Dysphonia__diagnosis;Humans;Infection Control__methods;Otolaryngology__methods;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Annals of Otorhinolaryngology, Head and Neck Diseases | A Mattei;B Amy de la Bretèque;S Crestani;L Crevier-Buchman;C Galant;S Hans;A Julien-Laferrière;A Lagier;C Lobryeau;F Marmouset;D Robert;V Woisard;A Giovanni | COVID;COVID-19;Coronavirus;Laryngology;Phoniatrics;Rehabilitation;SARS-CoV-2;Swallowing | 2020-04-20 02:00:00+02:00 | 32332004 | FR;BE | Service d'ORL et chirurgie cervico-faciale, CHU La Conception, Assistance publique-Hôpitaux de Marseille, Marseille, France, Aix Marseille University, CNRS, LPL, Aix-en-Provence, France. Electronic address: alexia.mattei@ap-hm.fr.;Aix Marseille University, CNRS, LPL, Aix-en-Provence, France, Service d'ORL et chirurgie cervico-faciale, CHU Gui-de-Chauliac, Montpellier, France.;Unité voix et déglutition, service d'ORL et chirurgie cervico-faciale, CHU de Toulouse, hôpital Larrey, TSA 30030, 31059 Toulouse cedex 09, France.;Service d'ORL et chirurgie cervico-faciale, Assistance publique-Hôpitaux de Paris, Hôpital Foch, UFR Simone-Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Service d'ORL et chirurgie cervico-faciale, CHU La Conception, Assistance publique-Hôpitaux de Marseille, Marseille, France, Aix Marseille University, CNRS, LPL, Aix-en-Provence, France.;Service d'ORL et chirurgie cervico-faciale, CHU de Liège, Liège, Belgium.;14, rue Lejemptel, 94300 Vincennes, France.;Service d'ORL et chirurgie cervico-faciale, hôpital Clocheville, CHRU de Tours, Tours, France. | 367 | ||
| 10.1016/j.acvd.2020.04.003 | Journal Article | en | Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32354666 | 1875-2136 | 2020-04-26 02:00:00+02:00 | pubmed | Algorithms;Antiviral Agents__adverse effects;Arrhythmias, Cardiac__chemically induced;Betacoronavirus;Cardiovascular Agents__adverse effects;Coronavirus Infections__complications;Electrocardiography;Heart Diseases__diagnosis;Humans;Pandemics;Pneumonia, Viral__complications;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Archives of Cardiovascular Diseases | Frederic Sacher;Laurent Fauchier;Serge Boveda;Christian de Chillou;Pascal Defaye;Jean Claude Deharo;Estelle Gandjbakhch;Vincent Probst;Ariel Cohen;Christophe Leclercq | COVID-19;Covid-19;ECG;Hydroxychloroquine;Long QT;QT long médicamenteux;QT prolonging drugs;SARS-CoV-2;Torsades de pointe | 2020-04-24 02:00:00+02:00 | 32354666 | FR | IHU LIRYC, Bordeaux University Hospital, University Bordeaux, 33604 Bordeaux, France. Electronic address: frederic.sacher@chu-bordeaux.fr.;Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, EA7505, Université de Tours, France.;Cardiology, Cardiac Arrhythmias Management Department, Clinique Pasteur, 45, avenue de Lombez, 31076 Toulouse, France.;Department of Cardiology, University Hospital Nancy, Inserm-IADI, U947, rue du Morvan, 54511 Vandœuvre lès-Nancy, France.;Arrhythmia Department, Cardiology, University Hospital of Grenoble Alpes, 38043 Grenoble, France.;Service de Cardiologie, CHU La Timone, 13005 Marseille, France.;Sorbonne Universités, UPMC University Paris 06, Inserm 1166, AP-HP, Pitié-Salpêtrière University Hospital, Institute of Cardiology, Centre de Référence des Maladies Cardiaques Héréditaires, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.;L'Institut du Thorax, Cardiologic Department and Reference Center for Hereditary Arrhythmic Diseases Inserm 1087, boulevard Monod, Nantes, France.;Hôpital Saint Antoine, APHP, 75012 Paris, France.;Université de Rennes I, CICIT 804, CHU Pontchaillou, Rennes, France. | 369 | |||
| Letter;Comment | en | Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32328726 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Critical Illness;Humans;Lung Injury;Pandemics;Phenotype;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Marie-Christine Copin;Erika Parmentier;Thibault Duburcq;Julien Poissy;Daniel Mathieu | 2020-04-23 02:00:00+02:00 | 32328726 | FR | Institut de Pathologie, CHU Lille, Univ. Lille, Avenue Oscar Lambret, 59000, Lille, France.;Pôle de reanimation, CHU Lille, Univ. Lille, Avenue Oscar Lambret, 59000, Lille, France.;Inserm U1285, CHU Lille, Pôle de réanimation, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, Univ. Lille, 59000, Lille, France. julien_poissy@hotmail.fr. | 371 | |||||||
| Y.A.R. has received speaker/consultancy honoraria from CSL Behring, LFB, Grifols, BPL, Octapharma, and Kedrion, has received educational sponsorships from LFB, CSL Behring and Baxter and has obtained research grants from CSL Behring and LFB;H.S.G. has received research grants from Prinses Beatrix Spierfonds (W.OR14.08 and W.OR17-21), and received speaker fee/travel grants from Shire/Baxalta.S.A. has received speaker/consultancy honoraria from LFB, Alnylam, Akcea, Pfizer, Pharnext, Sanofi, and Biogen, has received educational sponsorships from LFB, and has obtained research grants from and LFB and Pfizer. H.P.H. received fees for serving on steering committees and advisory boards from CSL Behring, LFB, Octapharma, Roche, UCB | 10.1002/mus.26896 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32311114 | Since March 2020, the COVID-19 pandemic has led to the need to re-think the delivery of services to patients with chronic dysimmune neuropathies. Telephone/video consultations have become widespread but have compounded concerns about objective evaluation. Therapeutic decisions need, more than ever before, to be considered in the best interests of both patients, and society, while not denying function-preserving/restoring treatment. Immunoglobulin therapy and plasma exchange, for those treated outside of the home, expose patients to the hazards of hospital or outpatient infusion centers. Steroid therapy initiation and continuation pose increased infectious risk. Immunosuppressant therapy similarly becomes highly problematic, with the risks of treatment continuation enhanced by uncertainties regarding duration of the pandemic. The required processes necessitate considerable time and effort especially as resources and staff are re-deployed to face the pandemic, but are essential for protecting this group of patients and as an integral part of wider public health actions. | 0148-639X,1097-4598 | 2020-04-26 02:00:00+02:00 | pubmed | Autoimmune Diseases of the Nervous System__complications;Betacoronavirus;Coronavirus Infections__complications;Disease Management;Humans;Pandemics;Pneumonia, Viral__complications;Polyneuropathies__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Muscle & Nerve | Yusuf A Rajabally;H Stephan Goedee;Shahram Attarian;Hans-Peter Hartung | COVID-19;chronic inflammatory demyelinating polyneuropathy;dysimmune;multifocal motor neuropathy;pandemic;paraproteinemic neuropathy | 2020-04-24 02:00:00+02:00 | 32311114 | FR;NL;GB;DE | [{"country": "International", "agency": "Y.A.R. has received speaker/consultancy honoraria from CSL Behring, LFB, Grifols, BPL, Octapharma, and Kedrion, has received educational sponsorships from LFB, CSL Behring and Baxter and has obtained research grants from CSL Behring and LFB"}, {"country": "International", "agency": "H.S.G. has received research grants from Prinses Beatrix Spierfonds (W.OR14.08 and W.OR17-21), and received speaker fee/travel grants from Shire/Baxalta.S.A. has received speaker/consultancy honoraria from LFB, Alnylam, Akcea, Pfizer, Pharnext, Sanofi, and Biogen, has received educational sponsorships from LFB, and has obtained research grants from and LFB and Pfizer. H.P.H. received fees for serving on steering committees and advisory boards from CSL Behring, LFB, Octapharma, Roche, UCB"}] | Inflammatory Neuropathy Clinic, University Hospitals Birmingham, Birmingham, United Kingdom.;Aston Medical School, Aston University, Birmingham, United Kingdom.;Brain Center Rudolf Magnus, Department of Neurology and Neurosurgery, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.;Reference Centre for Neuromuscular Diseases and ALS, Centre Hospitalier Universitaire La Timone, 264 rue Saint-Pierre, 13385, Marseille, France.;Aix-Marseille University, Inserm, GMGF, Marseille, France.;Department of Neurology, Medical Faculty and Center of Neurology and Neuropsychiatry, LVR Klinikum, Heinrich-Heine University, Düsseldorf, Germany. | 372 |
| 10.2217/fon-2020-0312 | Editorial | en | What the oncologist needs to know about COVID-19 infection in cancer patients. | https://www.ncbi.nlm.nih.gov/pubmed/32323577 | 1479-6694,1744-8301 | 2020-04-26 02:00:00+02:00 | pubmed | Antineoplastic Agents__therapeutic use;Antiviral Agents__therapeutic use;Clinical Decision-Making;Coronavirus Infections__diagnosis;Disease Progression;Humans;Medical Oncology__trends;Neoplasms__drug therapy;Oncologists;Pandemics;Pneumonia, Viral__diagnosis;Vulnerable Populations;COVID-19 | Future Oncology | Elie Rassy;Rita-Maria Khoury-Abboud;Nathalie Ibrahim;Clarisse Kattan;Tarek Assi;Joseph Kattan | COVID-19;chemotherapy;coronavirus;immune checkpoint inhibitors;oncologist;oncology;review | 2020-04-23 02:00:00+02:00 | 32323577 | FR;LB | Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Lebanon. | 373 | |||
| 10.1016/j.purol.2020.04.015 | Journal Article | en | COVID19 pandemic impacts on anxiety of French urologist in training: Outcomes from a national survey. | https://www.ncbi.nlm.nih.gov/pubmed/32376208 | The COVID-19 outbreak in France is disturbing our health system. Urologists in training who are already known to have burnout, are in the front line to face this disease. The aim of our study was to assess the psychological impact of COVID-19 pandemic on young French urologists in training. | 1166-7087 | 2020-04-26 02:00:00+02:00 | pubmed | Adult;Anxiety__epidemiology;Coronavirus Infections__epidemiology;Female;France__epidemiology;Humans;Internship and Residency;Male;Medical Staff, Hospital__psychology;Pandemics;Pneumonia, Viral__epidemiology;Risk Factors;Surveys and Questionnaires;Urologists__psychology;Urology__education;COVID-19 | Progrès en Urologie | M Abdessater;M Rouprêt;V Misrai;X Matillon;B Gondran-Tellier;L Freton;M Vallée;I Dominique;M Felber;Z-E Khene;E Fortier;F Lannes;C Michiels;T Grevez;N Szabla;J Boustany;F Bardet;K Kaulanjan;E Seizilles de Mazancourt;G Ploussard;U Pinar;B Pradere | Anxiety;Anxiété;COVID19;Enquête;Internes;Residents;Survey;Urologie;Urology;Virus SARS-Cov2 | 2020-04-23 02:00:00+02:00 | 32376208 | FR;AT;GP | Sorbonne Université, GRC n(o) 5, Predictive onco-urology, AP-HP, Hôpital Pitié-Salpêtrière, Urology, 75013 Paris, France.;Sorbonne Université, GRC n(o) 5, Predictive onco-urology, AP-HP, Hôpital Pitié-Salpêtrière, Urology, 75013 Paris, France. Electronic address: morgan.roupret@aphp.fr.;Clinique Pasteur, 31300 Toulouse, France.;Department of Urology and Transplantation, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.;Department of Urology, La Conception University Hospital, Assistance-Publique Marseille, Marseille, France.;Department of Urology, University Hospital of Rennes, Rennes, France.;Department of Urology, Poitiers University Hospital, Poitiers, France.;Department of Urology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Department of Urology, Montpellier University Hospital, Montpellier, France.;Department of Urology, Bordeaux University Hospital, Bordeaux, France.;Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France.;Department of Urology and Transplantation, Caen University Hospital, Caen, France.;Department of Urology and Renal Transplantation, Henri Mondor University Hospital, Créteil, France.;Department of Urology, Dijon University Hospital, Dijon, France.;Department of Urology, CHU Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe.;Department of Urology, Ramsay Santé, Clinique La Croix du Sud, Quint Fonsegrives, France.;Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France, Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. | 383 | ||
| 10.3389/fcvm.2020.00071 | Journal Article | en | COVID and the Renin-Angiotensin System: Are Hypertension or Its Treatments Deleterious? | https://www.ncbi.nlm.nih.gov/pubmed/32391384 | 2297-055X | 2020-04-26 02:00:00+02:00 | pubmed | Frontiers in Cardiovascular Medicine | Florian Zores;Mathieu E Rebeaud | 2019-nCoV;ACE2;COVID-19;SARS-CoV-2;angiotensin;renin | 2020-04-23 02:00:00+02:00 | 32391384 | FR;CH | Groupe Médical Spécialisé, Strasbourg, France.;DBMV, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland. | 387 | ||||
| 10.1007/s10072-020-04442-1 | Journal Article | en | Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. | https://www.ncbi.nlm.nih.gov/pubmed/32363506 | Because of COVID-19 outbreak, regular clinical services for Parkinson's disease (PD) patients have been suddenly suspended, causing worries, confusion and unexpected needs in such frail population. Here, we reviewed the messages spontaneously sent by patients to an Italian PD clinic during the first two weeks of COVID-19 lockdown (9-21 March 2020), in order to highlight their main needs and then outline appropriate strategies of care for this critical period. One hundred sixty-two messages were analysed. Forty-six percent queried about clinical services; 28% communicated an acute clinical worsening for which a therapeutic change was done in 52% of cases; 17% (those patients with younger age and milder disease) asked about the relationship between PD and COVID-19; 8% informed about an intercurrent event. Our analysis suggests that PD patients' needs during COVID-19 emergency include appropriate and complete information, a timely update on changes in clinical services, and the continuity of care, even in a remote mode. By addressing these issues, acute clinical worsening, complications and subsequent therapeutic changes could be prevented. In this perspective, telecommunication systems and virtual medicine should be implemented. | 1590-1874,1590-3478 | 2020-05-03 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections__diagnosis;Emergency Service, Hospital__trends;Female;Health Services Needs and Demand__trends;Humans;Italy;Male;Middle Aged;Pandemics;Parkinson Disease__diagnosis;Pneumonia, Viral__diagnosis;Self Report;Telemedicine__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Neurological Sciences | Tommaso Schirinzi;Rocco Cerroni;Giulia Di Lazzaro;Claudio Liguori;Simona Scalise;Roberta Bovenzi;Matteo Conti;Elena Garasto;Nicola Biagio Mercuri;Mariangela Pierantozzi;Antonio Pisani;Alessandro Stefani | COVID-19;Coronavirus;Neurological diseases;Parkinson’s disease;Telemedicine | 2020-05-03 02:00:00+02:00 | 32363506 | FR;IT | Department of Systems Medicine, University of Roma Tor Vergata, Via Montpellier, 00133, Rome, Italy. t.schirinzi@yahoo.com.;Department of Systems Medicine, University of Roma Tor Vergata, Via Montpellier, 00133, Rome, Italy.;IRCCS Fondazione Santa Lucia, Rome, Italy. | 400 | ||
| 10.1007/s12603-020-1364-x | Journal Article | en | Editorial: A COVID-19 Support Platform for Long Term Care Facilities. | https://www.ncbi.nlm.nih.gov/pubmed/32346680 | 1279-7707,1760-4788 | 2020-05-03 02:00:00+02:00 | pubmed | The journal of nutrition, health & aging | Y Rolland;A Benetos;H Villars;H Braun;H Blain | 2020-04-30 02:00:00+02:00 | 32346680 | FR | Professeur Yves Rolland, Gerontople de Toulouse, 20 rue du Pont Saint Pierre, 31 059 Toulouse, France, Tel: 05 61 77 64 45, E-Mail : rolland.y@chu-toulouse.fr. | 401 | |||||
| 10.1016/j.bulcan.2020.03.005 | Editorial | fr | [Freedom, equality, fraternity facing the COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32334673 | 0007-4551 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Delivery of Health Care;France;Freedom;Humans;Interprofessional Relations;Pandemics;Pneumonia, Viral__epidemiology;Social Conditions;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Jacques-Olivier Bay;Gilles L'Allemain | 2020-04-27 02:00:00+02:00 | 32334673 | FR | Site Estaing, université d'Auvergne, CHU de Clermont-Ferrand, service de thérapie cellulaire et d'hématologie clinique adulte, EA7453 CHELTER, 63000 Clermont-Ferrand, France. Electronic address: jobay@chu-clermontferrand.fr.;Université Côte-d'Azur, institut de biologie Valrose, CNRS, Inserm, 06108 Nice cedex 2, France. | 409 | ||||
| 10.1016/j.bulcan.2020.03.004 | Editorial | fr | [Covid-19, the Société française du cancer (SFC) and the BulletinduCancer]. | https://www.ncbi.nlm.nih.gov/pubmed/32334674 | 0007-4551 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;France;Humans;Medical Oncology;Pandemics;Periodicals as Topic;Pneumonia, Viral;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Manuel Rodrigues | 2020-04-27 02:00:00+02:00 | 32334674 | FR | Institut Curie, PSL research university, département d'oncologie médicale, 75005 Paris, France. Electronic address: manuel.rodrigues@curie.fr. | 411 | ||||
| Case Reports;Letter | en | First case of COVID-19 in a kidney transplant recipient treated with belatacept. | https://www.ncbi.nlm.nih.gov/pubmed/32282977 | 2020-05-03 02:00:00+02:00 | pubmed | Abatacept__administration & dosage;Coronavirus Infections__complications;Cyclosporine__administration & dosage;Humans;Immunosuppression__adverse effects;Immunosuppressive Agents__administration & dosage;Kidney Failure, Chronic__complications;Kidney Transplantation;Lung__diagnostic imaging;Male;Middle Aged;Mycophenolic Acid__administration & dosage;Pandemics;Pneumonia, Viral__complications;Prednisone__administration & dosage;Radiography, Thoracic;Tomography, X-Ray Computed;Treatment Outcome;COVID-19 | David Marx;Bruno Moulin;Samira Fafi-Kremer;Ilies Benotmane;Gabriela Gautier;Peggy Perrin;Sophie Caillard | clinical research/practice;immunosuppressant;immunosuppression/immune modulation;infection and infectious agents-viral;infectious disease;kidney transplantation/nephrology | 2020-04-28 02:00:00+02:00 | 32282977 | FR | Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France.;Department of Virology, Strasbourg University Hospital, Strasbourg, France. | 418 | ||||||
| 10.1016/j.radcr.2020.04.055 | Case Reports | en | Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32351657 | As coronavirus pandemic continue to spread over the world, we have to be aware of potential complications on hospitalized patients. We report a case of a 79-year-old woman with COVID-19 pneumonia complicated by combined arterial and venous thrombosis of upper mesenteric vessels. As unenhanced chest CT scan plays a key role in managing the COVID-19 pandemic, we should pay attention to indirect signs of thrombosis. | 1930-0433 | 2020-05-03 02:00:00+02:00 | pubmed | Radiology Case Reports | Olivier de Barry;Ahmed Mekki;Caroline Diffre;Martin Seror;Mostafa El Hajjam;Robert-Yves Carlier | COVID-19;CT scan;Severe acute respiratory syndrome coronavirus 2;Thrombosis;coronavirus | 2020-04-29 02:00:00+02:00 | 32351657 | FR | DMU Smart Imaging, Medical Imaging Department, Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay, Ambroise Paré Teaching Hospital, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France.;DMU Smart Imaging, Medical Imaging department, Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay, Raymond Poincaré Teaching Hospital, Garches, France.;UMR 1179 End-icap, Université Versailles Saint-Quentin-en-Yvelines/Paris-Saclay, Versailles, France. | 425 | |||
| NHLBI NIH HHS;NCI NIH HHS | 10.1161/jaha.120.017013 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't;Research Support, U.S. Gov't, Non-P.H.S.;Review | en | Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the JAHA Editors. | https://www.ncbi.nlm.nih.gov/pubmed/32347144 | Coronavirus Disease 2019 (COVID-19) has infected more than 3.0 million people worldwide and killed more than 200,000 as of April 27, 2020. In this White Paper, we address the cardiovascular co-morbidities of COVID-19 infection; the diagnosis and treatment of standard cardiovascular conditions during the pandemic; and the diagnosis and treatment of the cardiovascular consequences of COVID-19 infection. In addition, we will also address various issues related to the safety of healthcare workers and the ethical issues related to patient care in this pandemic. | 2047-9980 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Cardiovascular Diseases__epidemiology;Comorbidity;Coronavirus Infections__epidemiology;Global Health;Humans;Incidence;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of the American Heart Association | Ajay K Gupta;Hani Jneid;Daniel Addison;Hossein Ardehali;Amelia K Boehme;Sanket Borgaonkar;Romain Boulestreau;Kevin Clerkin;Nicolas Delarche;Holli A DeVon;Isabella M Grumbach;Jose Gutierrez;Daniel A Jones;Vikas Kapil;Carmela Maniero;Amgad Mentias;Pamela S Miller;Sher May Ng;Jai D Parekh;Reynaldo H Sanchez;Konrad Teodor Sawicki;Anneline S J M Te Riele;Carol Ann Remme;Barry London | COVID‐19;SARS‐CoV‐2;cardiovascular disease;cardiovascular risk factors;coronavirus disease 2019;management;treatment | 2020-04-29 02:00:00+02:00 | 32347144 | FR;NL;GB;US | [{"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "R01 HL108932"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "K12 CA133250"}] | William Harvey Research Institute Barts and the London School of Medicine and Dentistry Queen Mary University of London United Kingdom.;Barts BP Centre of Excellence Barts Heart Centre London United Kingdom.;Royal London and St Bartholomew's Hospital Barts Health NHS Trust London United Kingdom.;Division of Cardiology Baylor College of Medicine Houston TX.;Division of Cardiovascular Medicine Department of Medicine The Ohio State University Columbus OH.;Feinberg Cardiovascular and Renal Research Institute Northwestern University Chicago IL.;Department of Neurology Vagelos College of Physicians and Surgeons Columbia University New York NY.;Department of Epidemiology Mailman School of Public Health Columbia University New York NY.;Department of Cardiology Pau Hospital Pau France.;Division of Cardiology Department of Medicine Vagelos College of Physicians and Surgeons Columbia University New York NY.;University of California, Los Angeles, School of Nursing Los Angeles CA.;Division of Cardiovascular Medicine Department of Medicine University of Iowa Carver College of Medicine Iowa City IA.;Division of Cardiology Department of Internal Medicine University of Iowa Iowa City IA.;Center for Nursing Excellence UCLA Health Los Angeles CA.;Division of Heart and Lungs Department of Cardiology University Medical Center Utrecht Utrecht the Netherlands.;Department of Clinical and Experimental Cardiology Heart Centre Amsterdam UMC Location Academic Medical Center Amsterdam the Netherlands. | 426 |
| 10.1089/hs.2020.0043 | Journal Article;Review | en | Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks. | https://www.ncbi.nlm.nih.gov/pubmed/32348165 | The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines. | 2326-5094,2326-5108 | 2020-05-03 02:00:00+02:00 | pubmed | Communicable Disease Control__organization & administration;Communicable Diseases, Emerging__epidemiology;Coronavirus Infections__epidemiology;Drug Approval;Drug Development;Drug Industry__organization & administration;Female;Global Health;Humans;Influenza Vaccines__administration & dosage;Male;Needs Assessment;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Public Health;Security Measures;Technology, Pharmaceutical__organization & administration;COVID-19 | Health Security | John Billington;Isabelle Deschamps;Stanley C Erck;Julie L Gerberding;Emmanuel Hanon;Sabrina Ivol;John W Shiver;Julia A Spencer;Johan Van Hoof | COVID-19;Epidemic management/response;Infectious diseases;SARS-CoV-2;Vaccine development | 2020-04-29 02:00:00+02:00 | 32348165 | FR;BE;NL;US | John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D, both at GSK Vaccines, Wavre, Belgium.;Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs, and John W. Shiver, PhD, is Senior Vice President R&D, both with Sanofi Pasteur, Lyon, France.;Stanley C. Erck, MBA, is President and Chief Executive Officer, Novavax, Gaithersburg, MD.;Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health, and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy, both with Merck & Co., Inc., Kenilworth, NJ.;Sabrina Ivol is Senior Specialist, Policy, and Johan Van Hoof, MD, is Managing Director, both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands. | 430 | ||
| 10.1016/j.jviscsurg.2020.04.018 | Journal Article;Practice Guideline;Review | en | Endocrine surgery during and after the COVID-19 epidemic: Expert guidelines from AFCE. | https://www.ncbi.nlm.nih.gov/pubmed/32448761 | The COVID-19 pandemic commands a major reorganisation of the entire French healthcare system. In France, general rules have been issued nationally and implemented by each healthcare centre, both public and private, throughout France. Guidelines drafted by an expert group led by the French-speaking Association of Endocrine Surgery (AFCE) propose specific surgical management principles for thyroid, parathyroid, endocrine pancreas and adrenal surgery during and after the COVID-19 epidemic. | 1878-7886 | 2020-05-03 02:00:00+02:00 | pubmed | Coronavirus Infections;Decision Trees;Endocrine Surgical Procedures;Endocrine System Diseases__surgery;Humans;Pandemics;Pneumonia, Viral;COVID-19 | Journal of Visceral Surgery | G Baud;L Brunaud;J-C Lifante;C Tresallet;F Sebag;J-P Bizard;M Mathonnet;F Menegaux;R Caiazzo;E Mirallié;F Pattou | Adrenal;COVID-19;Coronavirus;Endocrine surgery;Neuroendocrine tumour;Parathyroid;Thyroid | 2020-04-30 02:00:00+02:00 | 32448761 | FR | Chirurgie générale et endocrinienne, CHU de Lille, 59000 Lille, France.;Chirurgie viscérale, métabolique et cancérologique (CVMC), CHRU de Nancy, 54511 Vandœuvre-lès-Nancy, France.;Chirurgie digestive, oncologique et endocrinienne, CHU de Lyon, 69310 Pierre-Bénite, France.;Chirurgie viscérale et digestive, AP-HP, hôpital Avicenne, 93000 Bobigny, France.;Chirurgie générale et endocrinienne, AP-HM, La Conception, 13005 Marseille, France.;Chirurgie endocrinienne et viscérale, hôpital privé Arras-les-Bonnettes, 62000 Arras, France.;Chirurgie digestive et endocrinienne, CHU de Limoges, 87000 Limoges, France.;Chirurgie générale digestive et endocrinienne, AP-HP, hôpital Pitié-Salpêtrière, Sorbonne université, 75013 Paris, France.;Chirurgie cancérologique, digestive et endocrinienne (CCDE), CHU de Nantes, 44093 Nantes, France.;Chirurgie générale et endocrinienne, CHU de Lille, 59000 Lille, France. Electronic address: fpattou@univ-lille2.fr. | 435 | ||
| Letter | en | The Imperative of Early Treatment for Children With COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32358228 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Coronavirus Infections__therapy;Humans;Pandemics;Pneumonia, Viral__therapy;Time-to-Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2 | Narcisse Elenga | 2020-04-30 02:00:00+02:00 | 32358228 | FR | Pediatric Medicine and Surgery, Centre Hospitalier Andrée Rosemon, Rue des flamboyants, BP 6006, 97306, Cayenne Cedex, French Guiana. elengafr@yahoo.fr. | 440 | |||||||
| 10.1080/17843286.2020.1761162 | Journal Article | en | COVID-19 pandemic: overview of protective-ventilation strategy in ARDS patients. | https://www.ncbi.nlm.nih.gov/pubmed/32340583 | Objectives: In the context of COVID-19 pandemic, the aim of this manuscript is to provide a standard of care of patients with ARDS for non-emergency medicine trained physicians who are not customary with mechanical ventilation.Methods: We conducted a systematic review of the literature to investigate the best practice recommendations regarding the mechanical ventilation of patients with ARDS.Conclusion: We summarized the principal strategies for lung-protective ventilation of patients with ARDS. This focus is particularly addressed to physicians who are not experienced in the invasive respiratory management of ARDS patients. Nevertheless, it remains fundamental to acknowledge that new insights concerning this quickly spreading illness become available on a regular base. | 1784-3286,2295-3337 | 2020-05-03 02:00:00+02:00 | pubmed | Acta Clinica Belgica | Julien Higny;Frédéric Feye;Frédéric Forêt | COVID-19;SARS-CoV-2;acute respiratory distress syndrome;mechanical ventilation;protective ventilation | 2020-04-27 02:00:00+02:00 | 32340583 | FR;BE;GB | Department of Cardiovascular Disease, CHU UCL Namur, Yvoir, Belgium.;Department of Emergency Medicine, Provincial Director of COVID-19 Health Services, CHU UCL Namur, Dinant, Belgium.;Department of Intensive Care Medicine, CHU UCL Namur, Dinant, Belgium. | 445 | |||
| 10.1016/j.kint.2020.04.022 | Case Reports | en | Tubuloreticular inclusions in COVID-19-related collapsing glomerulopathy. | https://www.ncbi.nlm.nih.gov/pubmed/32471641 | 0085-2538 | 2020-05-03 02:00:00+02:00 | pubmed | Aged;Coronavirus Infections__complications;Humans;Inclusion Bodies__ultrastructure;Kidney Diseases__pathology;Kidney Glomerulus__ultrastructure;Male;Pandemics;Pneumonia, Viral__complications;COVID-19 | Kidney International | François Gaillard;Sophie Ismael;Aurélie Sannier;Hassan Tarhini;Thomas Volpe;Clarisse Greze;Marie Christine Verpont;Ilyass Zouhry;Christophe Rioux;François-Xavier Lescure;David Buob;Eric Daugas | 2020-04-27 02:00:00+02:00 | 32471641 | FR | Department of Nephrology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Université de Paris, Centre de recherche sur l'inflammation, INSERM UMR1149, CNRS EL8252, Laboratoire d'Excellence Inflamex, Université de Paris, Paris, France. Electronic address: gaillard.f@protonmail.com.;Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.;Service d'Anatomie et Cytologie Pathologiques, Assistance Publique - hôpitaux de Paris, hôpital Bichat, Université de Paris, INSERM UMR1148, F-75018, Paris, France.;Department of Nephrology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Université de Paris, Centre de recherche sur l'inflammation, INSERM UMR1149, CNRS EL8252, Laboratoire d'Excellence Inflamex, Université de Paris, Paris, France.;Institut National de la Santé Et de la Recherche Médicale, UMRS 1155, plateforme d'imagerie et de cytométrie, Hôpital Tenon, Paris, France, Sorbonne Université, UMRS 1155, F-75020, Paris, France.;Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Service d'Anatomie et Cytologie Pathologiques, INSERM, UMRS 1155, Hôpital Tenon, Paris, France. | 446 | ||||
| 10.1016/j.jviscsurg.2020.04.016 | Journal Article | en | Nosocomial infection with SARS-Cov-2 within Departments of Digestive Surgery. | https://www.ncbi.nlm.nih.gov/pubmed/32381426 | The COVID-19 pandemic imposed a drastic reduction in surgical activity in order to respond to the influx of hospital patients and to protect uninfected patients by avoiding hospitalization. However, little is known about the risk of infection during hospitalization or its consequences. The aim of this work was to report a series of patients hospitalized on digestive surgery services who developed a nosocomial infection with SARS-Cov-2 virus. | 1878-7886 | 2020-05-03 02:00:00+02:00 | pubmed | Adult;Aged;Coronavirus Infections__epidemiology;Cross Infection__epidemiology;Digestive System Surgical Procedures;Female;Hospital Departments;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Retrospective Studies;COVID-19 | Journal of Visceral Surgery | M Luong-Nguyen;H Hermand;S Abdalla;N Cabrit;C Hobeika;A Brouquet;D Goéré;A Sauvanet | COVID-19;Digestive surgery;Nosocomial transmission;SARS-cov-2 | 2020-04-27 02:00:00+02:00 | 32381426 | FR | Digestive, Oncologic and endocrine Surgery Department, Saint Louis Hospital, APHP, Paris University, 1, rue Claude Vellefaux, 75010 Paris, France.;Digestive Surgery, Bicêtre Hospital, APHP, Paris Sud University, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France.;Hepatic and Pancreatic Surgery, Beaujon Hospital, AP-HP, Paris University, 100, boulevard du Général Leclerc, 92110 Clichy, France.;Hepatic and Pancreatic Surgery, Beaujon Hospital, AP-HP, Paris University, 100, boulevard du Général Leclerc, 92110 Clichy, France. Electronic address: alain.sauvanet@aphp.fr. | 448 | ||
| 10.1007/s10096-020-03913-9 | Journal Article | en | Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. | https://www.ncbi.nlm.nih.gov/pubmed/32342252 | In a preliminary clinical study, we observed that the combination of hydroxychloroquine and azithromycin was effective against SARS-CoV-2 by shortening the duration of viral load in Covid-19 patients. It is of paramount importance to define when a treated patient can be considered as no longer contagious. Correlation between successful isolation of virus in cell culture and Ct value of quantitative RT-PCR targeting E gene suggests that patients with Ct above 33-34 using our RT-PCR system are not contagious and thus can be discharged from hospital care or strict confinement for non-hospitalized patients. | 0934-9723,1435-4373 | 2020-05-03 02:00:00+02:00 | pubmed | Animals;Betacoronavirus__isolation & purification;Chlorocebus aethiops;Coronavirus Infections__diagnosis;France;Humans;Pandemics;Patient Discharge;Pneumonia, Viral__diagnosis;RNA, Viral__analysis;Reverse Transcriptase Polymerase Chain Reaction;Specimen Handling__standards;Vero Cells;Viral Load;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Clinical Microbiology & Infectious Diseases | Bernard La Scola;Marion Le Bideau;Julien Andreani;Van Thuan Hoang;Clio Grimaldier;Philippe Colson;Philippe Gautret;Didier Raoult | Co-culture;Correlation;Covid-19;RT-PCR;SARS-CoV2;Viral load | 2020-04-27 02:00:00+02:00 | 32342252 | FR;VN | 1IHU-Méditerranée Infection, Marseille, France.;Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.;Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;4Thai Binh University of Medicine and Pharmacy, Thai Binh, Viet Nam. | 450 | ||
| Letter | en | Vascular skin symptoms in COVID-19: a french observational study. | https://www.ncbi.nlm.nih.gov/pubmed/32339344 | Coronavirus 19 (COVID-19) was declared as a pandemic viral infection by the World Health organization on March 11th 2020. Usual clinical manifestations of COVID-19 infection include fever, fatigue, myalgia, headache, diarrhea, dry cough, dyspnea that may lead to acute respiratory distress syndrome and death (1). Skin symptoms of COVID-19 have been poorly described but may include erythematous rash, urticaria and chicken pox like lesions (2-7). Angiotensin-converting enzyme 2 (ACE2) is a cellular receptor for COVID-19. | 2020-05-03 02:00:00+02:00 | pubmed | J D Bouaziz;T Duong;M Jachiet;C Velter;P Lestang;C Cassius;A Arsouze;E Domergue Than Trong;M Bagot;E Begon;L Sulimovic;M Rybojad | COVID-19;chilblain;livedo;purpura;thrombosis;vasculitis | 2020-04-27 02:00:00+02:00 | 32339344 | FR;UNK | Dermatology Department, Paris University, Saint-Louis Hospital, Paris, France.;Dermatology Department, Henri Mondor hospital, Créteil, France.;On behalf of the SNDV (syndicat national des dermatologues-vénéréologues)/Corona group.;Dermatology Department, Renée Dubos hospital, Pontoise, France.;President of the SNDV (syndicat national des dermatologues-vénéréologues). | 452 | ||||||
| NHLBI NIH HHS;NHLBI NIH HHS;NHLBI NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NHLBI NIH HHS;NIDA NIH HHS;NIAID NIH HHS;NIGMS NIH HHS;NHLBI NIH HHS;NHLBI NIH HHS;NIAID NIH HHS;NIGMS NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS | 10.1016/j.cell.2020.04.035 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't | en | SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. | https://www.ncbi.nlm.nih.gov/pubmed/32413319 | There is pressing urgency to understand the pathogenesis of the severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2), which causes the disease COVID-19. SARS-CoV-2 spike (S) protein binds angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine protease 2 (TMPRSS2), promotes cellular entry. The cell subsets targeted by SARS-CoV-2 in host tissues and the factors that regulate ACE2 expression remain unknown. Here, we leverage human, non-human primate, and mouse single-cell RNA-sequencing (scRNA-seq) datasets across health and disease to uncover putative targets of SARS-CoV-2 among tissue-resident cell subsets. We identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and nasal goblet secretory cells. Strikingly, we discovered that ACE2 is a human interferon-stimulated gene (ISG) in vitro using airway epithelial cells and extend our findings to in vivo viral infections. Our data suggest that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection. | 0092-8674 | 2020-05-03 02:00:00+02:00 | pubmed | Adolescent;Alveolar Epithelial Cells__immunology;Animals;Betacoronavirus__physiology;Cell Line;Cells, Cultured;Child;Coronavirus Infections__virology;Enterocytes__immunology;Goblet Cells__immunology;HIV Infections__immunology;Humans;Influenza, Human__immunology;Interferon Type I__immunology;Lung__cytology;Macaca mulatta;Mice;Mycobacterium tuberculosis;Nasal Mucosa__cytology;Pandemics;Peptidyl-Dipeptidase A__genetics;Pneumonia, Viral__virology;Receptors, Virus__genetics;Serine Endopeptidases__metabolism;Single-Cell Analysis;Tuberculosis__immunology;Up-Regulation;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cell | Carly G K Ziegler;Samuel J Allon;Sarah K Nyquist;Ian M Mbano;Vincent N Miao;Constantine N Tzouanas;Yuming Cao;Ashraf S Yousif;Julia Bals;Blake M Hauser;Jared Feldman;Christoph Muus;Marc H Wadsworth;Samuel W Kazer;Travis K Hughes;Benjamin Doran;G James Gatter;Marko Vukovic;Faith Taliaferro;Benjamin E Mead;Zhiru Guo;Jennifer P Wang;Delphine Gras;Magali Plaisant;Meshal Ansari;Ilias Angelidis;Heiko Adler;Jennifer M S Sucre;Chase J Taylor;Brian Lin;Avinash Waghray;Vanessa Mitsialis;Daniel F Dwyer;Kathleen M Buchheit;Joshua A Boyce;Nora A Barrett;Tanya M Laidlaw;Shaina L Carroll;Lucrezia Colonna;Victor Tkachev;Christopher W Peterson;Alison Yu;Hengqi Betty Zheng;Hannah P Gideon;Caylin G Winchell;Philana Ling Lin;Colin D Bingle;Scott B Snapper;Jonathan A Kropski;Fabian J Theis;Herbert B Schiller;Laure-Emmanuelle Zaragosi;Pascal Barbry;Alasdair Leslie;Hans-Peter Kiem;JoAnne L Flynn;Sarah M Fortune;Bonnie Berger;Robert W Finberg;Leslie S Kean;Manuel Garber;Aaron G Schmidt;Daniel Lingwood;Alex K Shalek;Jose Ordovas-Montanes | ACE2;COVID-19;ISG;SARS-CoV-2;human;influenza;interferon;mouse;non-human primate;scRNA-seq | 2020-04-27 02:00:00+02:00 | 32413319 | FR;GB;US;ZA;DE | [{"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "R01 HL128241"}, {"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "R01 HL095791"}, {"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "R01 HL117945"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "K23 AI139352"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R33 AI116184"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI095219"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI078908"}, {"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "K23 HL111113"}, {"country": "United States", "agency": "NIDA NIH HHS", "grantid": "DP2 DA042422"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "UM1 AI126623"}, {"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "R01 GM081871"}, {"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "U19 HL129902"}, {"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "R01 HL136209"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R37 AI052353"}, {"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "T32 GM007753"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI051731"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI124378"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U24 AI118672"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI136041"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "UM1 AI126617"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R56 AI139053"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI137057"}] | Program in Health Sciences & Technology, Harvard Medical School & Massachusetts Institute of Technology, Boston, MA 02115, USA, Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Harvard Graduate Program in Biophysics, Harvard University, Cambridge, MA 02138, USA.;Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.;Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Program in Computational & Systems Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Computer Science & Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.;Africa Health Research Institute, Durban, South Africa, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.;Program in Health Sciences & Technology, Harvard Medical School & Massachusetts Institute of Technology, Boston, MA 02115, USA, Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.;University of Massachusetts Medical School, Worcester, MA 01655, USA.;Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.;Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA.;Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA, Program in Virology, Harvard Medical School, Boston, MA 02115, USA.;Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, John A. Paulson School of Engineering & Applied Sciences, Harvard University, Cambridge, MA 02138, USA.;Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.;Program in Health Sciences & Technology, Harvard Medical School & Massachusetts Institute of Technology, Boston, MA 02115, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.;Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA.;Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.;Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA.;Aix-Marseille University, INSERM, INRA, C2VN, Marseille, France.;Université Côte d'Azur, CNRS, IPMC, Sophia-Antipolis, France.;Comprehensive Pneumology Center & Institute of Lung Biology and Disease, Helmholtz Zentrum München, Munich, Germany, German Center for Lung Research, Munich, Germany, Institute of Computational Biology, Helmholtz Zentrum München, Munich, Germany.;Comprehensive Pneumology Center & Institute of Lung Biology and Disease, Helmholtz Zentrum München, Munich, Germany, German Center for Lung Research, Munich, Germany.;German Center for Lung Research, Munich, Germany, Research Unit Lung Repair and Regeneration, Helmholtz Zentrum München, Munich, Germany.;Division of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.;Divison of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.;Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.;Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA, Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA 02115, USA.;Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.;University of California, Berkeley, CA 94720, USA.;University of Washington, Seattle, WA 98195, USA.;Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA, Dana Farber Cancer Institute, Boston, MA 02115, USA, Harvard Medical School, Boston, MA 02115, USA.;Stem Cell & Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA, Department of Medicine, University of Washington, Seattle, WA 98195, USA.;Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA, Division of Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA 98145, USA.;University of Washington, Seattle, WA 98195, USA, Division of Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA 98145, USA.;Department of Microbiology & Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA, Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.;Department of Microbiology & Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA, Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.;Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.;Department of Infection, Immunity & Cardiovascular Disease, The Medical School and The Florey Institute for Host Pathogen Interactions, University of Sheffield, Sheffield, S10 2TN, UK.;Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA, Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN 37240, USA, Department of Veterans Affairs Medical Center, Nashville, TN 37212, USA.;Institute of Computational Biology, Helmholtz Zentrum München, Munich, Germany.;Africa Health Research Institute, Durban, South Africa, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa, Department of Infection & Immunity, University College London, London, UK.;Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.;Computer Science & Artificial Intelligence Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Department of Mathematics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.;Program in Health Sciences & Technology, Harvard Medical School & Massachusetts Institute of Technology, Boston, MA 02115, USA, Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Harvard Graduate Program in Biophysics, Harvard University, Cambridge, MA 02138, USA, Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Program in Computational & Systems Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Program in Immunology, Harvard Medical School, Boston, MA 02115, USA, Harvard Medical School, Boston, MA 02115, USA, Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: shalek@mit.edu.;Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA, Program in Immunology, Harvard Medical School, Boston, MA 02115, USA, Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA 02115, USA, Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: jose.ordovas-montanes@childrens.harvard.edu. | 454 |
| 10.1016/j.jdmv.2020.04.008 | Journal Article;Practice Guideline | en | Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32571561 | 2542-4513 | 2020-05-03 02:00:00+02:00 | pubmed | Ambulatory Care__standards;Betacoronavirus__pathogenicity;Coronavirus Infections__diagnosis;Humans;Pandemics;Pneumonia, Viral__diagnosis;Prognosis;Risk Assessment;Risk Factors;Venous Thromboembolism__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | JMV-Journal de Médecine Vasculaire | L Khider;S Soudet;D Laneelle;G Boge;A Bura-Rivière;J Constans;M Dadon;H Desmurs-Clavel;A Diard;A Elias;J Emmerich;J-P Galanaud;P Giordana;S Gracia;A Hamade;C Jurus;C Le Hello;A Long;U Michon-Pasturel;T Mirault;G Miserey;A Perez-Martin;G Pernod;I Quere;M Sprynger;D Stephan;D Wahl;S Zuily;G Mahe;M A Sevestre | 2020-04-27 02:00:00+02:00 | 32571561 | FR;BE;CA | Vascular Medicine department, Georges-Pompidou European Hospital, Paris University, AP-HP, 75015 Paris, France.;Vascular Medicine department, University Hospital Amiens Picardie, 80000 Amiens, France.;Vascular Medicine department, University Hospital of Caen-Normandie, 14000 Caen, France.;Vascular Medicine unit, Department of Internal Medicine, Montpellier University Hospital, 34000 Montpellier cedex 5, France.;Vascular Medicine department, CHU of Rangueil, 31059 Toulouse cedex 9, France.;Vascular Medicine department, Saint-André Hospital, 33075 Bordeaux cedex, France.;Vascular Medicine department, Paris Saint-Joseph Hospital Group, 75014 Paris, France.;Internal Medicine department, Hospital Edouard-Herriot, 69003 Lyon, France.;Vascular Medicine office, 33550 Langoiran, France.;Vascular Medicine department, Sainte-Musse Hospital Center, 83100 Toulon, France.;Vascular Medicine department, Paris Saint-Joseph Hospital Group, 75014 Paris, France, Paris Descartes University, Paris, France.;Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, M4N 3M5 Toronto, ON, Canada.;Vascular Medicine office, 06000 Nice, France.;Vascular Medicine office, 17138 Puilboreau, France.;Vascular Medicine unit, Emile-Muller Hospital, 68070 Mulhouse cedex 01, France.;Vascular Medicine department, Tonkin Clinic, 69100 Villeurbanne, France.;Vascular Medicine department, University Hospital of Saint-Étienne, 42000 Saint-Étienne, France.;Vascular Medicine department, Edouard-Herriot Hospital, 69003 Lyon, France.;Vascular Medicine office, 78120 Rambouillet, France.;Vascular Medicine department, University hospital of Nîmes, 30000 Nîmes, France.;Vascular Medicine department, Grenoble-Alpes University Hospital, 38000 Grenoble, France.;Department of Cardiology, University Hospital of Liège, 4000 Liège, Belgium.;Hypertension and Vascular Medicine department, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.;Vascular Medicine Division and Regional Competence Centre for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, 54000 Nancy, France.;Vascular Medicine departement, University hospital of Rennes, 35000 Rennes, France.;Vascular Medicine department, University Hospital Amiens Picardie, 80000 Amiens, France. Electronic address: sevestre.marie-antoinette@chu-amiens.fr. | 456 | ||||
| 10.1016/j.clinre.2020.04.002 | Editorial | en | Diarrhea: An underestimated symptom in Coronavirus disease 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32371006 | In a retrospective study in the Nord Franche-Comté hospital conducted between March 1st and March 17th 2020, and compared to the review of Li et al., diarrhea was a main symptom in patients with COVID-19. Out of the 114 patients, 55 (48%) had diarrhea; it was the fifth most common symptom. In the group of patients with diarrhea, the median age was 56 years (±18) and 32 (58%) were female. Only 2 patients (3.6%) had a past history of inflammatory bowel disease. Fifty-six percent of patients (n=30/54) were hospitalised. Diarrhea appeared 4.5 days (±1.8) after the onset of the first other symptoms in COVID-19. Of the 55 patients with diarrhea, 29 (52.7%) had at least one simultaneous gastrointestinal (GI) symptom other than diarrhea. Twenty-five patients (45.5%) had nausea, 19 patients (34.5%) had abdominal pain and 9 (16.3%) had vomiting. Myalgia, sore throat, sneezing and the other GI symptoms were statistically more frequent in the group with diarrhea than in the group without diarrhea (P<0.05). | 2210-7401 | 2020-05-03 02:00:00+02:00 | pubmed | Abdominal Pain__epidemiology;Betacoronavirus;Coronavirus Infections__complications;Diarrhea__epidemiology;Female;Gastrointestinal Diseases__epidemiology;Humans;Male;Middle Aged;Myalgia__epidemiology;Nausea__epidemiology;Pandemics;Pneumonia, Viral__complications;Retrospective Studies;Sex Distribution;Symptom Assessment;Vomiting__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinics and Research in Hepatology and Gastroenterology | Timothée Klopfenstein;N'dri Juliette Kadiane-Oussou;Pierre-Yves Royer;Lynda Toko;Vincent Gendrin;Souheil Zayet | 2020-04-27 02:00:00+02:00 | 32371006 | FR | Infectious Diseases Department, Nord Franche-Comté Hospital, site de Belfort, 90016 Belfort, France. Electronic address: timothee.klopfenstein@hnfc.fr.;Infectious Diseases Department, Nord Franche-Comté Hospital, site de Belfort, 90016 Belfort, France. Electronic address: kadianeoussou14@gmail.com.;Infectious Diseases Department, Nord Franche-Comté Hospital, site de Belfort, 90016 Belfort, France. Electronic address: pierre-yves.royer@hnfc.fr.;Infectious Diseases Department, Nord Franche-Comté Hospital, site de Belfort, 90016 Belfort, France. Electronic address: lynda.toko@hnfc.fr.;Infectious Diseases Department, Nord Franche-Comté Hospital, site de Belfort, 90016 Belfort, France. Electronic address: vincent.gendrin@hnfc.fr.;Infectious Diseases Department, Nord Franche-Comté Hospital, site de Belfort, 90016 Belfort, France. Electronic address: souhail.zayet@gmail.com. | 457 | |||
| 10.7861/clinmed.2020-0150 | Journal Article | en | COVID-19 patients presenting with afebrile acute abdominal pain. | https://www.ncbi.nlm.nih.gov/pubmed/32341078 | With the surge in COVID-19 cases worldwide, the medical community should be aware of atypical clinical presentations to help with correct diagnosis, to take the proper measures to place the patient in isolation and to avoid healthcare professionals being infected by coronavirus (SARS-CoV-2). | 1470-2118,1473-4893 | 2020-05-03 02:00:00+02:00 | pubmed | Clinical Medicine | Gérald Gahide;Julien Frandon;Jean-François Vendrell | COVID-19;abdominal pain;afebrile;atypical presentation;computed tomography | 2020-04-27 02:00:00+02:00 | 32341078 | FR;CA | Imagerie Medicale, Centre Hospitalier Universitaire de Sherbrooke, Quebec, Canada geraldgahide@hotmail.com.;Imagerie Medicale, Centre Hospitalier Universitaire de Nîmes, France. | 458 | |||
| 10.1016/j.eururo.2020.04.042 | Editorial | en | The Impact of COVID-19 on European Health Care and Urology Trainees. | https://www.ncbi.nlm.nih.gov/pubmed/32376133 | The COVID-19 pandemic has had rapid and inevitable effects on health care systems and the training and work plans of urology residents. Smart learning is a valuable strategy for maintaining the learning curve of residents. | 0302-2838 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Delivery of Health Care__organization & administration;Education, Medical, Graduate__methods;Europe;Faculty, Medical;Humans;Internship and Residency__methods;Pandemics;Pneumonia, Viral__epidemiology;Surveys and Questionnaires;Urology__education;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Urology | Karl H Pang;Diego M Carrion;Juan Gomez Rivas;Guglielmo Mantica;Angelika Mattigk;Benjamin Pradere;Francesco Esperto | 2020-04-27 02:00:00+02:00 | 32376133 | FR;BO;GB;IT;ES;DE | Academic Urology Unit, University of Sheffield, Sheffield, UK. Electronic address: karlpang@doctors.org.uk.;Department of Urology, La Paz University Hospital, Madrid, Spain.;Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy.;Department of Urology, Ulm University Medical Centre, Ulm, Germany.;Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France.;Department of Urology, Campus Biomedico, University of Rome, Rome, Italy. | 460 | |||
| Letter | en | Is the use of laparoscopy in a COVID-19 epidemic free of risk? | https://www.ncbi.nlm.nih.gov/pubmed/32343368 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__prevention & control;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Laparoscopy;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Risk;COVID-19;severe acute respiratory syndrome coronavirus 2 | L Schwarz;J J Tuech | 2020-04-28 02:00:00+02:00 | 32343368 | FR | Department of Digestive Surgery Rouen University Hospital, Rouen, France.;UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie University, Rouen, France. | 463 | |||||||
| 10.1002/ccd.28948 | Case Reports | en | Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients. | https://www.ncbi.nlm.nih.gov/pubmed/32352633 | Important health resources are dedicated worldwide to the management of COVID-19. This new disease, due to its large diffusion, may significantly hamper the prognosis of other pathologies, such as ST-segment elevation myocardial infarction (STEMI) because of (a) a possible direct negative impact and (b) shortage of first response medical resources and increased delays to reperfusion. We report the case of a 68-year-old man admitted for anterior STEMI and asymptomatic COVID-19. Due to extended transportation delays to a cathlab, he received intravenous fibrinolytic therapy, which failed. Reperfusion was achieved with rescue coronary angioplasty, but the patient experienced two episodes of acute stent thrombosis at 2- and 36-hr following admission and despite optimal medical therapy. He finally died because of cardiogenic shock. This raises concerns about a possible increase in platelet aggregability associated with COVID-19 leading to an increased risk of stent thrombosis, particularly in the context of STEMI. This pleads for the promotion of primary coronary angioplasty as the first-choice revascularization technique in this population and the use of new generation P2Y12 inhibitors. In addition, the use of GPIIb/IIIa inhibitors may be considered in every STEMI patient with COVID-19 to prevent the risk of acute stent thrombosis. | 1522-1946,1522-726X | 2020-05-03 02:00:00+02:00 | pubmed | Catheterization and Cardiovascular Interventions | Thibaud Lacour;Carl Semaan;Thibaud Genet;Fabrice Ivanes | acute myocardial infarction;antithrombotic treatment;viral infection | 2020-04-30 02:00:00+02:00 | 32352633 | FR | Centre Hospitalier Régional Universitaire de Tours, Service de Cardiologie, Tours, France.;Faculté de Médecine, Université de Tours, Tours, France. | 475 | |||
| NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NHLBI NIH HHS;NIH HHS;NIGMS NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NCI NIH HHS;Howard Hughes Medical Institute;NIAID NIH HHS | 10.1038/s41586-020-2286-9 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't;Research Support, U.S. Gov't, Non-P.H.S. | en | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. | https://www.ncbi.nlm.nih.gov/pubmed/32353859 | A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that physically associated with each of the SARS-CoV-2 proteins using affinity-purification mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors. Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19. | 0028-0836,1476-4687 | 2020-05-03 02:00:00+02:00 | pubmed | Animals;Antiviral Agents__classification;Betacoronavirus__drug effects;Chlorocebus aethiops;Cloning, Molecular;Coronavirus Infections__drug therapy;Drug Evaluation, Preclinical;Drug Repositioning;HEK293 Cells;Host-Pathogen Interactions__drug effects;Humans;Immunity, Innate;Mass Spectrometry;Molecular Targeted Therapy;Pandemics;Pneumonia, Viral__drug therapy;Protein Binding;Protein Biosynthesis__drug effects;Protein Domains;Protein Interaction Mapping;Protein Interaction Maps;Receptors, sigma__metabolism;SKP Cullin F-Box Protein Ligases__metabolism;Vero Cells;Viral Proteins__genetics;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Nature | David E Gordon;Gwendolyn M Jang;Mehdi Bouhaddou;Jiewei Xu;Kirsten Obernier;Kris M White;Matthew J O'Meara;Veronica V Rezelj;Jeffrey Z Guo;Danielle L Swaney;Tia A Tummino;Ruth Hüttenhain;Robyn M Kaake;Alicia L Richards;Beril Tutuncuoglu;Helene Foussard;Jyoti Batra;Kelsey Haas;Maya Modak;Minkyu Kim;Paige Haas;Benjamin J Polacco;Hannes Braberg;Jacqueline M Fabius;Manon Eckhardt;Margaret Soucheray;Melanie J Bennett;Merve Cakir;Michael J McGregor;Qiongyu Li;Bjoern Meyer;Ferdinand Roesch;Thomas Vallet;Alice Mac Kain;Lisa Miorin;Elena Moreno;Zun Zar Chi Naing;Yuan Zhou;Shiming Peng;Ying Shi;Ziyang Zhang;Wenqi Shen;Ilsa T Kirby;James E Melnyk;John S Chorba;Kevin Lou;Shizhong A Dai;Inigo Barrio-Hernandez;Danish Memon;Claudia Hernandez-Armenta;Jiankun Lyu;Christopher J P Mathy;Tina Perica;Kala Bharath Pilla;Sai J Ganesan;Daniel J Saltzberg;Ramachandran Rakesh;Xi Liu;Sara B Rosenthal;Lorenzo Calviello;Srivats Venkataramanan;Jose Liboy-Lugo;Yizhu Lin;Xi-Ping Huang;YongFeng Liu;Stephanie A Wankowicz;Markus Bohn;Maliheh Safari;Fatima S Ugur;Cassandra Koh;Nastaran Sadat Savar;Quang Dinh Tran;Djoshkun Shengjuler;Sabrina J Fletcher;Michael C O'Neal;Yiming Cai;Jason C J Chang;David J Broadhurst;Saker Klippsten;Phillip P Sharp;Nicole A Wenzell;Duygu Kuzuoglu-Ozturk;Hao-Yuan Wang;Raphael Trenker;Janet M Young;Devin A Cavero;Joseph Hiatt;Theodore L Roth;Ujjwal Rathore;Advait Subramanian;Julia Noack;Mathieu Hubert;Robert M Stroud;Alan D Frankel;Oren S Rosenberg;Kliment A Verba;David A Agard;Melanie Ott;Michael Emerman;Natalia Jura;Mark von Zastrow;Eric Verdin;Alan Ashworth;Olivier Schwartz;Christophe d'Enfert;Shaeri Mukherjee;Matt Jacobson;Harmit S Malik;Danica G Fujimori;Trey Ideker;Charles S Craik;Stephen N Floor;James S Fraser;John D Gross;Andrej Sali;Bryan L Roth;Davide Ruggero;Jack Taunton;Tanja Kortemme;Pedro Beltrao;Marco Vignuzzi;Adolfo García-Sastre;Kevan M Shokat;Brian K Shoichet;Nevan J Krogan | 2020-04-30 02:00:00+02:00 | 32353859 | FR;GB;US | [{"country": "United States", "agency": "NIH HHS", "grantid": "1R01CA244550"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "HHSN272201400008C"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI120694"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI122747"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "F32 CA239333"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "R01 CA221969"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "R01 CA244550"}, {"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "K08 HL124068"}, {"country": "United States", "agency": "NIH HHS", "grantid": "1F32CA236347-01"}, {"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "R35 GM122481"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI135972"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "P01 AI063302"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "P50 AI150476"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI143292"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "F32 CA236347"}, {"country": "United States", "agency": "Howard Hughes Medical Institute"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI135990"}] | QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.;Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA.;J. David Gladstone Institutes, San Francisco, CA, USA.;Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.;Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.;Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.;Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.;Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA.;European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.;Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.;The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA.;Center for Computational Biology and Bioinformatics, Department of Medicine, University of California San Diego, San Diego, CA, USA.;Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA.;Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.;Biophysics Graduate Program, University of California San Francisco, San Francisco, CA, USA.;Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.;Zoic Labs, Culver City, CA, USA.;Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.;Department of Urology, University of California San Francisco, San Francisco, CA, USA.;Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.;Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.;George William Hooper Foundation, Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.;Medical Scientist Training Program, University of California San Francisco, San Francisco, CA, USA.;Virus and Immunity Unit, Institut Pasteur, Paris, France.;Department of Medicine, University of California San Francisco, San Francisco, CA, USA.;Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.;Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA.;Buck Institute for Research on Aging, Novato, CA, USA.;Direction Scientifique, Institut Pasteur, Paris, France.;Division of Genetics, Department of Medicine, University of California San Diego, San Diego, CA, USA.;Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France. marco.vignuzzi@pasteur.fr.;Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.;Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.;Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.;The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.;QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.;Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.;Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.;Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.;QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. shoichet@cgl.ucsf.edu.;Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. shoichet@cgl.ucsf.edu.;Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA. shoichet@cgl.ucsf.edu.;QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. nevan.krogan@ucsf.edu.;Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.;J. David Gladstone Institutes, San Francisco, CA, USA. nevan.krogan@ucsf.edu.;Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.;Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. nevan.krogan@ucsf.edu. | 476 | |
| 10.1016/j.bulcan.2020.04.003 | Practice Guideline | en | COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE). | https://www.ncbi.nlm.nih.gov/pubmed/32387061 | Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. They may have to evolve according to the rapid evolution of knowledge on COVID-19. | 0007-4551 | 2020-05-03 02:00:00+02:00 | pubmed | Adolescent;Antineoplastic Combined Chemotherapy Protocols__administration & dosage;Antiviral Agents__pharmacokinetics;Child;Clinical Laboratory Techniques;Combined Modality Therapy;Comorbidity;Coronavirus Infections__diagnosis;Disease Management;Down Syndrome__epidemiology;Drug Interactions;Febrile Neutropenia__chemically induced;Female;Granulocyte Colony-Stimulating Factor__therapeutic use;Hematopoietic Stem Cell Transplantation__adverse effects;Humans;Immunocompromised Host;Male;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma__drug therapy;Recurrence;Remission Induction;Risk;Risk Assessment;Salvage Therapy;Symptom Assessment;COVID-19;COVID-19 diagnostic testing | Bulletin du Cancer | André Baruchel;Yves Bertrand;Nicolas Boissel;Benoit Brethon;Stéphane Ducassou;Virginie Gandemer;Carine Halfon-Domenech;Thierry Leblanc;Guy Leverger;Gérard Michel;Arnaud Petit;Anne-France Ray-Lunven;Pierre-Simon Rohrlich;Pascale Schneider;Nicolas Sirvent;Marion Strullu | Acute lymphoblastic leukemia-children-adolescents;COVID-19;SARS-CoV-2 | 2020-04-30 02:00:00+02:00 | 32387061 | FR | Hôpital Universitaire Robert-Debré AP-HP, Université de Paris, service d'hémato-immunologie pédiatrique, Paris, France. Electronic address: andre.baruchel@aphp.fr.;CHU de Lyon, institut d'hémato-oncologie pédiatrique, Lyon, France.;Hôpital Saint-Louis, AP-HP, Université de Paris, unité adolescents et jeunes adultes, Paris, France.;Hôpital Universitaire Robert-Debré AP-HP, Université de Paris, service d'hémato-immunologie pédiatrique, Paris, France.;Groupe hospitalier Pellegrin, unité d'hémato-oncologie pédiatrique, Bordeaux, France.;CHU de Rennes, service d'hémato-oncologie pédiatrique, Rennes, France.;Hôpital Armand-Trousseau AP-HP, Sorbonne université, service d'hémato-oncologie pédiatrique, Paris, France.;CHU la Timone, service d'hématologie pédiatrique, Marseille, France.;CHU l'Archet, service d'hémato-oncologie pédiatrique, Nice, France.;CHU Charles-Nicolle, service d'hématologie pédiatrique, Rouen, France.;CHU Arnaud-de-Villeneuve, service d'hématologie et oncologie pédiatrique, Montpellier, France. | 477 | ||
| 10.1001/jamanetworkopen.2020.10478 | Journal Article | en | Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). | https://www.ncbi.nlm.nih.gov/pubmed/32469410 | 2574-3805 | 2020-05-03 02:00:00+02:00 | pubmed | Aged;Anticoagulants__therapeutic use;Betacoronavirus;Comorbidity;Coronavirus Infections__diagnosis;Critical Illness__epidemiology;Female;France;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;Venous Thrombosis__diagnosis;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | JAMA Network Open | Julien Nahum;Tristan Morichau-Beauchant;Fabrice Daviaud;Perrine Echegut;Jérôme Fichet;Jean-Michel Maillet;Stéphane Thierry | 2020-05-01 02:00:00+02:00 | 32469410 | FR | Intensive Care Unit, Centre Cardiologique du Nord, Saint-Denis, France.;Ultrasound and Vascular Lab, Centre Cardiologique du Nord, Saint-Denis, France. | 480 | ||||
| 10.1016/j.jhin.2020.04.041 | Journal Article | en | COVID-19-associated shortage of alcohol-based hand rubs, face masks, medical gloves, and gowns: proposal for a risk-adapted approach to ensure patient and healthcare worker safety. | https://www.ncbi.nlm.nih.gov/pubmed/32360355 | The coronavirus disease 2019 (COVID-19) pandemic has caused a huge demand for alcohol-based hand rubs, medical gloves, face masks, and gowns in healthcare and from the public. More and more hospitals face a serious shortage of these articles. We propose a risk-adapted approach to ensure adequate patient and healthcare worker safety for as long as possible. | 0195-6701 | 2020-05-03 02:00:00+02:00 | pubmed | Journal of Hospital Infection | G Kampf;S Scheithauer;S Lemmen;P Saliou;M Suchomel | Alcohol-based hand rubs;Coronavirus;Face masks;Medical gloves | 2020-04-30 02:00:00+02:00 | 32360355 | FR;AT;DE | University Medicine Greifswald, Institute for Hygiene and Environmental Medicine, Ferdinand-Sauerbruch-Strasse, Greifswald, Germany.;Institute of Infection Control and Infectious Diseases, University Medical Center, Georg August University, Göttingen, Germany.;University Hospital Aachen, Department of Infection Control and Infectious Diseases, Aachen, Germany.;University Brest, Inserm, EFS, UMR 1078, GGB, Infection Control Unit, Brest, France.;Institute of Hygiene and Applied Immunology, Medical University, Vienna, Austria. | 488 | |||
| 10.1016/j.jfo.2020.04.012 | Journal Article;Practice Guideline | fr | [How to approach follow-up of uveitis patients during the Covid-19 pandemic?] | https://www.ncbi.nlm.nih.gov/pubmed/32386902 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Ambulatory Care__methods;Antiviral Agents__therapeutic use;Betacoronavirus;Coronavirus Infections__diagnosis;Hospitalization;Humans;Immunosuppressive Agents__administration & dosage;Intravitreal Injections;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Recurrence;Scleritis__drug therapy;Steroids__administration & dosage;Telemedicine;Uveitis__diagnosis;Uveitis, Anterior__drug therapy;Withholding Treatment__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | S Touhami;D Saadoun;L Kodjikian;B Bodaghi | 2020-04-30 02:00:00+02:00 | 32386902 | FR | Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.;Service de médecine interne, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.;Service d'ophtalmologie, CHU Croix-Rousse, 103, grande rue de la Croix-Rousse, 69004 Lyon, France. Electronic address: kodjikian.laurent@wanadoo.fr. | 491 | ||||
| 10.1308/rcsann.2020.0097 | Journal Article;Review | en | Emergency surgery during the COVID-19 pandemic: what you need to know for practice. | https://www.ncbi.nlm.nih.gov/pubmed/32352836 | Several articles have been published about the reorganisation of surgical activity during the COVID-19 pandemic but few, if any, have focused on the impact that this has had on emergency and trauma surgery. Our aim was to review the most current data on COVID-19 to provide essential suggestions on how to manage the acute abdomen during the pandemic. | 0035-8843,1478-7083 | 2020-05-03 02:00:00+02:00 | pubmed | Abdomen, Acute__complications;Aerosols__adverse effects;Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Humans;Infection Control__methods;Laparoscopy__adverse effects;Operating Rooms__organization & administration;Pandemics__prevention & control;Pneumonia, Viral__complications;Pneumoperitoneum, Artificial__adverse effects;Professional Practice__organization & administration;Surgical Procedures, Operative__adverse effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Annals of The Royal College of Surgeons of England | B De Simone;E Chouillard;S Di Saverio;L Pagani;M Sartelli;W L Biffl;F Coccolini;A Pieri;M Khan;G Borzellino;F C Campanile;L Ansaloni;F Catena | 2019-nCoV;Acute abdomen;COVID-19;Coronavirus;Emergency surgery;Laparoscopy;Non-operative management;Open surgery;SARS-CoV-2 | 2020-04-30 02:00:00+02:00 | 32352836 | FR;IT;GB;US | Centre Hospitalier Intercommunal Poissy/Saint-Germain-en-Laye, France.;University of Insubria, Varese, Italy.;Bolzano Central Hospital, Italy.;Macerata Hospital, Italy.;Scripps Memorial Hospital, La Jolla, CA, US.;University Hospital of Pisa, Italy.;Brighton and Sussex University Hospitals NHS Trust, UK.;San Giovanni Decollato-Andosilla Hospital, Civita Castellana, Italy.;University Hospital of Verona, Italy.;Bufalini Hospital, Cesena, Italy.;University Hospital of Parma, Italy. | 492 | ||
| 10.1093/ageing/afaa097 | Journal Article | en | Ageism and COVID-19: what does our society's response say about us? | https://www.ncbi.nlm.nih.gov/pubmed/32377666 | The goal of this commentary is to highlight the ageism that has emerged during the COVID-19 pandemic. Over 20 international researchers in the field of ageing have contributed to this document. This commentary discusses how older people are misrepresented and undervalued in the current public discourse surrounding the pandemic. It points to issues in documenting the deaths of older adults, the lack of preparation for such a crisis in long-term care homes, how some 'protective' policies can be considered patronising and how the initial perception of the public was that the virus was really an older adult problem. This commentary also calls attention to important intergenerational solidarity that has occurred during this crisis to ensure support and social-inclusion of older adults, even at a distance. Our hope is that with this commentary we can contribute to the discourse on older adults during this pandemic and diminish the ageist attitudes that have circulated. | 0002-0729,1468-2834 | 2020-05-10 02:00:00+02:00 | pubmed | Age and Ageing | Sarah Fraser;Martine Lagacé;Bienvenu Bongué;Ndatté Ndeye;Jessica Guyot;Lauren Bechard;Linda Garcia;Vanessa Taler;Stéphane Adam;Marie Beaulieu;Caroline D Bergeron;Valérian Boudjemadi;Donatienne Desmette;Anna Rosa Donizzetti;Sophie Éthier;Suzanne Garon;Margaret Gillis;Mélanie Levasseur;Monique Lortie-Lussier;Patrik Marier;Annie Robitaille;Kim Sawchuk;Constance Lafontaine;Francine Tougas | COVID-19;ageism;long-term care homes;older people;public discourse | 2020-05-08 02:00:00+02:00 | 32377666 | FR;BE;CA;IT | Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario KIN6N5, Canada.;Department of Communication, Faculty of Arts, University of Ottawa, Desmarais Building, Ottawa, Ontario KIN6N5, Canada.;Université Jean-Monnet, France.;Department of Kinesiology, University of Waterloo, Ontario, Canada.;Life Institute, University of Ottawa, Ottawa, Ontario, Canada.;School of Psychology, University of Ottawa, Ottawa, Ontario, Canada.;Psychology of Aging Unit, University of Liège, Belgium.;School of Social Work, University of Sherbrooke.;National Public Health Institute of Quebec.;Faculty of Psychology, University of Strasbourg, France.;Faculté des sciences économiques, sociales, politiques et de communication, Université Catholique de Louvain, Belgium.;Social Psychology Department of Humanities, University of Naples "Federico II", Italy.;School of Social Work & Criminology, Laval University, Québec, Canada.;School of Social Work, University of Sherbrooke, Québec, Canada.;International Longevity Centre, Canada.;School of Readaptation, University of Sherbrooke, Québec, Canada.;Centre de Recherche et d'Expertise en Gérontologie Sociale (CREGÉS), Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Ouest de l'Île de Montréal, Centre Affilié Universitaire, Québec, Canada.;Concordia University, Montreal, Canada. | 516 | |||
| 10.1016/s2665-9913(20)30124-7 | Journal Article | en | Initial data from the COVID-19 Global Rheumatology Alliance provider registries. | https://www.ncbi.nlm.nih.gov/pubmed/32377641 | 2665-9913 | 2020-05-10 02:00:00+02:00 | pubmed | The Lancet Rheumatology | Anthony Vanjak | 2020-05-05 02:00:00+02:00 | 32377641 | FR | Assistance Publique-Hôpitaux de Paris, 75004 Paris, France. | 533 | |||||
| 10.1016/j.cell.2020.05.006 | Evaluation Study;Journal Article | en | Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32479746 | Viruses are a constant threat to global health as highlighted by the current COVID-19 pandemic. Currently, lack of data underlying how the human host interacts with viruses, including the SARS-CoV-2 virus, limits effective therapeutic intervention. We introduce Viral-Track, a computational method that globally scans unmapped single-cell RNA sequencing (scRNA-seq) data for the presence of viral RNA, enabling transcriptional cell sorting of infected versus bystander cells. We demonstrate the sensitivity and specificity of Viral-Track to systematically detect viruses from multiple models of infection, including hepatitis B virus, in an unsupervised manner. Applying Viral-Track to bronchoalveloar-lavage samples from severe and mild COVID-19 patients reveals a dramatic impact of the virus on the immune system of severe patients compared to mild cases. Viral-Track detects an unexpected co-infection of the human metapneumovirus, present mainly in monocytes perturbed in type-I interferon (IFN)-signaling. Viral-Track provides a robust technology for dissecting the mechanisms of viral-infection and pathology. | 0092-8674 | 2020-05-10 02:00:00+02:00 | pubmed | Animals;Betacoronavirus__isolation & purification;Coinfection__immunology;Coronavirus Infections__immunology;Host-Pathogen Interactions;Humans;Interferons__immunology;Lung__pathology;Pandemics;Pneumonia, Viral__immunology;Sensitivity and Specificity;Sequence Analysis, RNA;Severity of Illness Index;Single-Cell Analysis;Software;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cell | Pierre Bost;Amir Giladi;Yang Liu;Yanis Bendjelal;Gang Xu;Eyal David;Ronnie Blecher-Gonen;Merav Cohen;Chiara Medaglia;Hanjie Li;Aleksandra Deczkowska;Shuye Zhang;Benno Schwikowski;Zheng Zhang;Ido Amit | COVID-19;Viral-Track;single-cell RNA-seq;virus host interactions | 2020-05-08 02:00:00+02:00 | 32479746 | FR;CN;IL | Department of Immunology, Weizmann Institute of Science, Rehovot, Israel, Systems Biology Group, Department of Computational Biology and USR 3756, Institut Pasteur and CNRS, Paris 75015, France, Sorbonne Universite, Complexite du vivant, Paris 75005, France.;Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.;Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China.;Systems Biology Group, Department of Computational Biology and USR 3756, Institut Pasteur and CNRS, Paris 75015, France.;Shanghai Public Health Clinical Center and Institute of Biomedical Sciences, Fudan University, Shanghai 201508, China.;Systems Biology Group, Department of Computational Biology and USR 3756, Institut Pasteur and CNRS, Paris 75015, France. Electronic address: benno@pasteur.fr.;Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China. Electronic address: zhangzheng1975@aliyun.com.;Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. Electronic address: ido.amit@weizmann.ac.il. | 538 | ||
| Buddhist Tzu Chi Medical Foundation | Letter;Comment | en | Can computed tomography be a primary tool for COVID-19 detection? Evidence appraisal through meta-analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32375883 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus;Coronavirus Infections;Pandemics;Pneumonia, Viral;Reverse Transcriptase Polymerase Chain Reaction;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | Edward Pei-Chuan Huang;Chih-Wei Sung;Chi-Hsin Chen;Cheng-Yi Fan;Pei-Chun Lai;Yen-Ta Huang | COVID-19;Computed tomography;Likelihood ratio;Meta-analysis;Sensitivity;Specificity | 2020-05-06 02:00:00+02:00 | 32375883 | FR;TW | [{"country": "International", "agency": "Buddhist Tzu Chi Medical Foundation", "grantid": "TCF-MP 108-01-02"}] | Department of Emergency Medicine, National Taiwan University Medical College and Hospital, Taipei, Taiwan.;Department of Emergency Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.;Department of Medicine Education, National Taiwan University Hospital, Taipei, Taiwan.;Evidence-based Medicine Center, Department of Medical Education, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Sec. 3, Chung-Yang Rd, Hualien, 970, Taiwan. debbie0613.lai@gmail.com.;Department of Pediatrics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Sec. 3, Chung-Yang Rd, Hualien, 970, Taiwan. debbie0613.lai@gmail.com.;School of Medicine, Tzu Chi University, Hualien, Taiwan. debbie0613.lai@gmail.com.;Division of Experimental Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Sec. 3, Chung-Yang Rd, Hualien, 970, Taiwan. uncleda.haung@gmail.com.;Surgical Intensive Care Unit, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Sec. 3, Chung-Yang Rd, Hualien, 970, Taiwan. uncleda.haung@gmail.com.;Department of Pharmacology, Tzu Chi University, Hualien, Taiwan. uncleda.haung@gmail.com. | 542 | ||||
| 10.1016/j.eclinm.2020.100358 | Journal Article | en | Pandemic-related excess mortality (COVID-19), public health measures and funerary rituals. | https://www.ncbi.nlm.nih.gov/pubmed/32377635 | 2589-5370 | 2020-05-10 02:00:00+02:00 | pubmed | EClinicalMedicine | Eric Crubézy;Norbert Telmon | 2020-05-05 02:00:00+02:00 | 32377635 | FR | UMR 5288, CNRS Université Toulouse 3, 37 allées Jules Guesde, 31 000 Toulouse, France.;Service de Médecine Légale, CHU de Rangueil, 1 Avenue du Professeur Jean Poulhès, 31 400 Toulouse, France. | 547 | |||||
| 10.1016/j.purol.2020.04.021 | Journal Article;Review | fr | [Recommendations of the Urolithiasis Committee of the French Urology Association for the management and the treatment of the stone formers patients during the COVID-19 pandemic crisis]. | https://www.ncbi.nlm.nih.gov/pubmed/32389492 | For the first time, faced with a crisis with an exceptional magnitude due to the COVID-19 pandemic responsible for saturation of emergency services and intensive care units, the urolithiasis committee of the French Urology Association designed the recommendations for care and treatment of stone-forming patients and their treatment during crisis. | 1166-7087 | 2020-05-10 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;France__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Urolithiasis__therapy;Urology__methods;COVID-19 | Progrès en Urologie | C Almeras;E Denis;P Meria;V Estrade;G Raynal;A Hoznek;B Malval;S Dominique;S Bart;J R Gautier;N Abid | Calcul;Coronavirus;Covid-19;Crise sanitaire;Heath crisis;Lithiase;Pandemic;Pandémie;Recommandations;Recommendations;Stone;Traitement;Treatment;Urinaire;Urinary;Urolithiasis | 2020-05-04 02:00:00+02:00 | 32389492 | FR;UNK | Urologie, Uro. Sud, RGDS Clinique La Croix du Sud, 52 bis, chemin de Ribaute, 31130 Quint Fonsegrives. Electronic address: c_almeras@yahoo.fr.;Urologie, Centre hospitalier Saint Joseph Saint Luc, Lyon.;Urologie, Hôpital Saint Louis, Paris.;Urologie, Centre hospitalier d'Angoulême, France.;Urologie, Clinique médico- chirurgicale Gaston Métivet, Saint-Maur-des-Fossés.;Urologie, Hôpital Henri Mondor, Créteil.;Urologie, Clinique Saint Hilaire, Rouen.;Urologie, Cabinet d'Urologie Paris Opéra, Paris.;Urologie, Centre Hospitalier René Dubos, Pontoise.;Urologie, Uro. Sud, RGDS Clinique La Croix du Sud, 52 bis, chemin de Ribaute, 31130 Quint Fonsegrives.;Urologie, Hospices civils de Lyon, Lyon. | 551 | ||
| 10.1016/j.jfo.2020.04.019 | Journal Article;Practice Guideline | fr | [How to approach intravitreal injections during this COVID-19 pandemic ?] | https://www.ncbi.nlm.nih.gov/pubmed/32451137 | 0181-5512 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Diabetic Retinopathy__diagnostic imaging;Emergencies;Humans;Intravitreal Injections__methods;Macular Degeneration__drug therapy;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Retinal Degeneration__drug therapy;Retinal Neovascularization__drug therapy;Tomography, Optical Coherence;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | L Kodjikian | 2020-05-04 02:00:00+02:00 | 32451137 | FR | Service d'ophtalmologie, CHU Croix-Rousse, 103, grande rue de la Croix-Rousse, 69004 Lyon, France. Electronic address: kodjikian.laurent@wanadoo.fr. | 554 | ||||
| Editorial;Comment | fr | [A special edition of the Journal of Visceral Surgery on COVID-19: What problems, dangers and solutions have been identified?] | https://www.ncbi.nlm.nih.gov/pubmed/32374298 | 2020-05-10 02:00:00+02:00 | pubmed | M Pocard | 2020-05-04 02:00:00+02:00 | 32374298 | FR | UMR 1275 CAP Paris-Tech, université de Paris, 75010 Paris, France.;Service de chirurgie digestive et cancérologique, hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France. | 563 | ||||||||
| Letter | en | Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France. | https://www.ncbi.nlm.nih.gov/pubmed/32380219 | 2020-05-10 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus__isolation & purification;Chilblains__diagnosis;Child;Child, Preschool;Coronavirus Infections__complications;Female;France__epidemiology;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Retrospective Studies;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Adèle de Masson;Jean-David Bouaziz;Luc Sulimovic;Charles Cassius;Marie Jachiet;Marius-Anton Ionescu;Michel Rybojad;Martine Bagot;Tu-Anh Duong | 2020-05-04 02:00:00+02:00 | 32380219 | FR | Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, Human Immunology, Pathophysiology and Immunotherapy, Institut National de la Santé et de la Recherche Médicale U976, Université de Paris, Paris.;Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, French National Union of Dermatologists-Venereologists (SNDV).;Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris.;Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, Human Immunology, Pathophysiology and Immunotherapy, Institut National de la Santé et de la Recherche Médicale U976, Université de Paris, Paris. Electronic address: martine.bagot@aphp.fr.;Department of Dermatology, Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Chaire Avenir Santé numérique, Equipe 8 Institut Mondor de Recherche Biomédicale, Human Immunology, Pathophysiology and Immunotherapy, Université Paris Est Créteil, Créteil, France. | 570 | |||||||
| Letter | en | Acute ischemic stroke complicating common carotid artery thrombosis during a severe COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32389423 | 2020-05-10 02:00:00+02:00 | pubmed | Alain Viguier;Louis Delamarre;Julien Duplantier;Jean-Marc Olivot;Fabrice Bonneville | 2020-05-04 02:00:00+02:00 | 32389423 | FR | Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, Toulouse NeuroImaging Center, Université de Toulouse, Inserm U1214, UPS, France. Electronic address: viguier.a@chu-toulouse.fr.;Department of Anesthesiology and Critical Care, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Department of Neuroradiology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, Toulouse NeuroImaging Center, Université de Toulouse, Inserm U1214, UPS, France.;Toulouse NeuroImaging Center, Université de Toulouse, Inserm U1214, UPS, France, Department of Neuroradiology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. | 571 | ||||||||
| 10.1016/j.bulcan.2020.04.006 | Practice Guideline | fr | [Breast cancer screening and diagnosis at the end of the COVID-19 confinement period, practical aspects and prioritization rules: recommendations of 6 French health professionals societies]. | https://www.ncbi.nlm.nih.gov/pubmed/32416925 | 0007-4551 | 2020-05-10 02:00:00+02:00 | pubmed | Age Factors;Betacoronavirus;Breast Neoplasms__diagnostic imaging;Coronavirus Infections__diagnosis;Delivery of Health Care__organization & administration;Female;France__epidemiology;Health Priorities__organization & administration;Humans;Hygiene;Mass Screening__organization & administration;Pandemics__prevention & control;Personal Space;Pneumonia, Viral__diagnosis;Quarantine__methods;Risk;Social Isolation;Societies, Medical;Symptom Assessment__methods;Time Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Luc Ceugnart;Suzette Delaloge;Corinne Balleyguier;Michel Deghaye;Lucie Veron;Aldis Kaufmanis;Audrey Mailliez;Edouard Poncelet;Gregory Lenczner;Laurent Verzaux;Joseph Gligorov;Isabelle Thomassin-Naggara | Breast;COVID-19;Diagnosis;Diagnostic;Dépistage;Screening;Sein | 2020-05-07 02:00:00+02:00 | 32416925 | FR | Département d'imagerie médicale, centre Oscar-Lambret, Lille, France.;Département de médecine oncologique et prévention des cancers, Gustave-Roussy, Villejuif, France. Electronic address: suzette.delaloge@gustaveroussy.fr.;Département d'imagerie, Gustave-Roussy, Villejuif, France.;Centre régional de coordination des dépistages des cancers d'Ile de France, Paris, France.;Département de médecine oncologique et prévention des cancers, Gustave-Roussy, Villejuif, France.;Département d'oncologie médicale et génétique, centre Oscar-Lambret, Lille, France.;Service d'imagerie de la femme, centre hospitalier de Valenciennes, Valenciennes, France.;Radiologie Paris-Ouest, Levallois-Perret, France.;Service de radiologie clinique Les Ormeaux, Le Havre, France.;Département d'oncologie médicale, hôpital Tenon, Paris, France.;Département d'Imagerie médicale, hôpital Tenon, Paris, France. | 575 | |||
| 10.1016/j.jns.2020.116884 | Journal Article;Review | en | The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. | https://www.ncbi.nlm.nih.gov/pubmed/32464367 | A comprehensive review of the neurological disorders reported during the current COVID-19 pandemic demonstrates that infection with SARS-CoV-2 affects the central nervous system (CNS), the peripheral nervous system (PNS) and the muscle. CNS manifestations include: headache and decreased responsiveness considered initial indicators of potential neurological involvement; anosmia, hyposmia, hypogeusia, and dysgeusia are frequent early symptoms of coronavirus infection. Respiratory failure, the lethal manifestation of COVID-19, responsible for 264,679 deaths worldwide, is probably neurogenic in origin and may result from the viral invasion of cranial nerve I, progressing into rhinencephalon and brainstem respiratory centers. Cerebrovascular disease, in particular large-vessel ischemic strokes, and less frequently cerebral venous thrombosis, intracerebral hemorrhage and subarachnoid hemorrhage, usually occur as part of a thrombotic state induced by viral attachment to ACE2 receptors in endothelium causing widespread endotheliitis, coagulopathy, arterial and venous thromboses. Acute hemorrhagic necrotizing encephalopathy is associated to the cytokine storm. A frontal hypoperfusion syndrome has been identified. There are isolated reports of seizures, encephalopathy, meningitis, encephalitis, and myelitis. The neurological diseases affecting the PNS and muscle in COVID-19 are less frequent and include Guillain-Barré syndrome; Miller Fisher syndrome; polyneuritis cranialis; and rare instances of viral myopathy with rhabdomyolysis. The main conclusion of this review is the pressing need to define the neurology of COVID-19, its frequency, manifestations, neuropathology and pathogenesis. On behalf of the World Federation of Neurology we invite national and regional neurological associations to create local databases to report cases with neurological manifestations observed during the on-going pandemic. International neuroepidemiological collaboration may help define the natural history of this worldwide problem. | 0022-510X | 2020-05-10 02:00:00+02:00 | pubmed | Adult;Animals;Betacoronavirus;Cerebrovascular Disorders__etiology;Communicable Diseases, Emerging__epidemiology;Coronaviridae__pathogenicity;Coronavirus Infections__complications;Cytokine Release Syndrome__etiology;Endothelium, Vascular__pathology;Humans;Models, Animal;Nervous System Diseases__etiology;Neuromuscular Diseases__etiology;Organ Specificity;Pandemics;Peptidyl-Dipeptidase A__physiology;Pneumonia, Viral__complications;Registries;Thrombophilia__etiology;Viral Tropism;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of the Neurological Sciences | Gustavo C Román;Peter S Spencer;Jacques Reis;Alain Buguet;Mostafa El Alaoui Faris;Sarosh M Katrak;Miguel Láinez;Marco Tulio Medina;Chandrashekhar Meshram;Hidehiro Mizusawa;Serefnur Öztürk;Mohammad Wasay | COVID-19 neurological complications;Coronavirus disease 2019;Coronaviruses;Endotheliitis;Environmental neurology, MERS;MERS-CoV;Neuroepidemiology;Neuropathology;Pandemic;SARS;SARS-CoV-1;SARS-CoV-2;Viral neurotropism;Zoonosis | 2020-05-07 02:00:00+02:00 | 32464367 | FR;HN;JP;GB;US;TR;MA;ES;IN;PK | Environmental Neurology Specialty Group of the World Federation of Neurology (ENSG-WFN), London, UK, Department of Neurology, Neurological Institute, Houston Methodist Hospital, 6560 Fannin Street, Suite 802, Houston, TX 77030, USA. Electronic address: gcroman@houstonmethodist.org.;Department of Neurology, School of Medicine, Oregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, OR 97239, USA.;Université de Strasbourg, 67000 Strasbourg, France and Association RISE, 67205 Oberhausbergen, France.;General (r) French Army Health Services, Malaria Research Unit, UMR 5246 CNRS, Claude-Bernard Lyon-1 University, 69622 Villeurbanne, France.;World Congress of Neurology, Marrakesh WCN2011, Moroccan Foundation Against Neurological Disease, Neurology, Mohammed V University of Rabat, Rabat, Morocco.;Neurology Department, Jaslok Hospital & Research Center, Professor Emeritus GMC and Sir JJ Group of Hospitals, Mumbai, India.;Spanish Neurological Society, Department of Neurology, University Clinic Hospital, Catholic University of Valencia, 46010, Valencia, Spain.;Latin America, WFN, Pan American Federation of Neurological Societies (PAFNS), Neurology and Epileptology, Faculty of Medical Sciences, National Autonomous University of Honduras, Tegucigalpa, Honduras.;Indian Academy of Neurology. Nagpur, India.;World Congress of Neurology, Kyoto WCN2017, National Center of Neurology and Psychiatry (NCNP), Japan, Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo, Japan.;Turkish Neurological Society, Department of Neurology, Selcuk University Faculty of Medicine, Konya, Turkey.;Pakistan International Neuroscience Society, Neurology, Aga Khan University, Karachi, Pakistan. | 576 | ||
| INRAE | 10.3390/biology9050097 | Journal Article | en | Using Early Data to Estimate the Actual Infection Fatality Ratio from COVID-19 in France. | https://www.ncbi.nlm.nih.gov/pubmed/32397286 | The number of screening tests carried out in France and the methodology used to target the patients tested do not allow for a direct computation of the actual number of cases and the infection fatality ratio (IFR). The main objective of this work is to estimate the actual number of people infected with COVID-19 and to deduce the IFR during the observation window in France. We develop a `mechanistic-statistical' approach coupling a SIR epidemiological model describing the unobserved epidemiological dynamics, a probabilistic model describing the data acquisition process and a statistical inference method. The actual number of infected cases in France is probably higher than the observations: we find here a factor ×8 (95%-CI: 5-12) which leads to an IFR in France of 0.5% (95%-CI: 0.3-0.8) based on hospital death counting data. Adjusting for the number of deaths in nursing homes, we obtain an IFR of 0.8% (95%-CI: 0.45-1.25). This IFR is consistent with previous findings in China (0.66%) and in the UK (0.9%) and lower than the value previously computed on the Diamond Princess cruse ship data (1.3%). | 2079-7737 | 2020-05-10 02:00:00+02:00 | pubmed | Biology | Lionel Roques;Etienne K Klein;Julien Papaïx;Antoine Sar;Samuel Soubeyrand | Bayesian inference;COVID-19;SIR model;case fatality rate;infection fatality ratio;mechanistic-statistical model | 2020-05-08 02:00:00+02:00 | 32397286 | FR;CH | [{"country": "", "agency": "INRAE", "grantid": "MEDIA"}] | INRAE, BioSP, 84914 Avignon, France.;Medicentre Moutier, 2740 Moutier, Switzerland. | 581 | |
| 10.1016/j.therap.2020.05.003 | Journal Article | en | Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32418728 | Non-steroidal anti-inflammatory drugs (NSAIDs) have an optional prescription status that has resulted in frequent use, in particular for the symptomatic treatment of fever and non-rheumatic pain. In 2019, a multi-source analysis of complementary pharmacological data showed that using NSAIDs in these indications (potentially indicative of an underlying infection) increases the risk of a severe bacterial complication, in particular in the case of lung infections. First, the clinical observations of the French Pharmacovigilance Network showed that severe bacterial infections can occur even after a short NSAID treatment, and even if the NSAID is associated with an antibiotic. Second, pharmacoepidemiological studies, some of which minimized the protopathic bias, all converged and confirmed the risk. Third, experimental in vitro and in vivo animal studies suggest several biological mechanisms, which strengthens a causal link beyond the well-known risk of delaying the care of the infection (immunomodulatory effects, effects on S. pyogenes infections, and reduced antibiotics efficacy). Therefore, in case of infection, symptomatic treatment with NSAIDs for non-severe symptoms (fever, pain, or myalgia) is not to be recommended, given a range of clinical and scientific arguments supporting an increased risk of severe bacterial complication. Besides, the existence of a safer drug alternative, with paracetamol at recommended doses, makes this recommendation of precaution and common sense even more legitimate. In 2020, such recommendation is more topical than ever with the emergence of COVID-19, especially since it results in fever, headaches, muscular pain, and cough, and is further complicated with pneumopathy, and given experimental data suggesting a link between ibuprofen and the level of expression of angiotensin-converting enzyme 2. | 0040-5957 | 2020-05-10 02:00:00+02:00 | pubmed | Therapies | Joëlle Micallef;Thomas Soeiro;Annie-Pierre Jonville-Béra | Anti-inflammatory agents, non-steroidal;COVID-19;Infections;Pharmacoepidemiology;Pharmacovigilance;Respiratory tract infections;Superinfection | 2020-05-07 02:00:00+02:00 | 32418728 | FR | Aix-Marseille université, Inserm, UMR 1106, Assistance publique-Hôpitaux de Marseille, service de pharmacologie clinique, centre régional de pharmacovigilance, 264, rue Saint-Pierre, 13005 Marseille, France. Electronic address: joelle.micallef@ap-hm.fr.;Aix-Marseille université, Inserm, UMR 1106, Assistance publique-Hôpitaux de Marseille, service de pharmacologie clinique, centre régional de pharmacovigilance, 264, rue Saint-Pierre, 13005 Marseille, France.;Centre hospitalier régional universitaire de Tours, service de pharmacosurveillance, centre régional de pharmacovigilance, 37000 Tours, France. | 584 | |||
| 10.1017/s0950268820000990 | Journal Article;Research Support, Non-U.S. Gov't | en | Chaos theory applied to the outbreak of COVID-19: an ancillary approach to decision making in pandemic context. | https://www.ncbi.nlm.nih.gov/pubmed/32381148 | While predicting the course of an epidemic is difficult, predicting the course of a pandemic from an emerging virus is even more so. The validity of most predictive models relies on numerous parameters, involving biological and social characteristics often unknown or highly uncertain. Data of the COVID-19 epidemics in China, Japan, South Korea and Italy were used to build up deterministic models without strong assumptions. These models were then applied to other countries to identify the closest scenarios in order to foresee their coming behaviour. The models enabled to predict situations that were confirmed little by little, proving that these tools can be efficient and useful for decision making in a quickly evolving operational context. | 0950-2688,1469-4409 | 2020-05-10 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Decision Making;Disease Outbreaks;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Psychological Theory;COVID-19 | Epidemiology and Infection | S Mangiarotti;M Peyre;Y Zhang;M Huc;F Roger;Y Kerr | Coronavirus;epidemics;infectious disease control;mathematical modelling;pandemic | 2020-05-08 02:00:00+02:00 | 32381148 | FR | Centre d'Etudes Spatiales de la Biosphère., CESBIO/OMP, UMR UPS-CNES-CNRS-IRD-INRA, 18, Av. Edouard Belin, 31401Toulouse Cedex 9, France.;Animal Santé Territoires Risques Ecosystèmes, ASTRE/CIRAD, UMR CIRAD-INRAE-University of Montpellier (I-MUSE), 34398Montpellier, France. | 586 | ||
| Letter | en | Firearms or SARS-Cov-2: what is the most lethal? | https://www.ncbi.nlm.nih.gov/pubmed/32422439 | 2020-05-10 02:00:00+02:00 | pubmed | F Dutheil;J S Baker;V Navel | 2020-05-08 02:00:00+02:00 | 32422439 | FR;HK | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, F-63000, Clermont-Ferrand, France. Electronic address: fdutheil@chu-clermontferrand.fr.;Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong.;Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, F-63000, Clermont-Ferrand, France. | 591 | ||||||||
| 10.31616/asj.2020.0197 | Journal Article | en | Spine Surgical Procedures during Coronavirus Disease 2019 Pandemic: Is It Still Possible to Take Care of Patients? Results of an Observational Study in the First Month of Confinement. | https://www.ncbi.nlm.nih.gov/pubmed/32380582 | Observational study. | 1976-1902,1976-7846 | 2020-05-10 02:00:00+02:00 | pubmed | Asian Spine Journal | Mikael Meyer;Solène Prost;Kaissar Farah;Jean-Baptiste Denis;Henry Dufour;Benjamin Blondel;Stéphane Fuentes | COVID-19;Organizations;Spine;Surgery | 2020-05-08 02:00:00+02:00 | 32380582 | FR | Unité de Chirurgie Rachidienne, Aix-Marseille Université, APHM, CNRS, ISM, CHU Timone, Marseille, France. | 592 | |||
| 10.1016/j.jvb.2020.103436 | Editorial | en | Unemployment in the time of COVID-19: A research agenda. | https://www.ncbi.nlm.nih.gov/pubmed/32390656 | This essay represents the collective vision of a group of scholars in vocational psychology who have sought to develop a research agenda in response to the massive global unemployment crisis that has been evoked by the COVID-19 pandemic. The research agenda includes exploring how this unemployment crisis may differ from previous unemployment periods; examining the nature of the grief evoked by the parallel loss of work and loss of life; recognizing and addressing the privilege of scholars; examining the inequality that underlies the disproportionate impact of the crisis on poor and working class communities; developing a framework for evidence-based interventions for unemployed individuals; and examining the work-family interface and unemployment among youth. | 0001-8791 | 2020-05-10 02:00:00+02:00 | pubmed | Journal of Vocational Behavior | David L Blustein;Ryan Duffy;Joaquim A Ferreira;Valerie Cohen-Scali;Rachel Gali Cinamon;Blake A Allan | COVID-19;Inequality;Precarious work;Unemployment;Unemployment interventions;Work-family interface;Youth unemployment | 2020-05-08 02:00:00+02:00 | 32390656 | FR;PT;US;IL | Boston College, United States of America.;University of Florida, United States of America.;University of Coimbra, Portugal.;Conservatoire National des Arts et Métiers, France.;University of Tel Aviv, Israel.;Purdue University, United States of America. | 595 | |||
| Letter | en | Stroke Health Care Use and COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32381538 | 2020-05-10 02:00:00+02:00 | pubmed | I Derraz | 2020-05-07 02:00:00+02:00 | 32381538 | FR | Department of Diagnostic and Interventional NeuroradiologyGui de Chauliac Hospital, Montpellier University Medical CenterMontpellier, France. | 597 | ||||||||
| Letter | en | Three alternative ways to screen for hyperglycaemia in pregnancy during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32387699 | 2020-05-10 02:00:00+02:00 | pubmed | A Vambergue;S Jacqueminet;M-F Lamotte;F Lamiche-Lorenzini;C Brunet;P Deruelle;C Vayssière;E Cosson | COVID 19 pandemic;Gestational diabetes;Hyperglycemia in pregnancy | 2020-05-06 02:00:00+02:00 | 32387699 | FR | Endocrinology, Diabetology, Metabolism and Nutrition Department, Lille University Hospital, European Genomics Institute for Diabetes, University of Lille, France, Francophone Society of Diabetes (SFD), France. Electronic address: anne.vambergue@chru-lille.fr.;Diabetology Department, Cardiometabolism and Nutrition Institute (ICAN), AP-HP6, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, 75013 Paris, France, Francophone Society of Diabetes (SFD), France.;Nutrition, Endocrinology, Metabolic Diseases, Department ENDO, Assistance Publique Hôpitaux de Marseille (AP-HM), France, Francophone Society of Diabetes (SFD), France.;CH Jura Sud, Lons-Le-Saunier, France, Francophone Society of Diabetes (SFD), France.;Endocrinology Diseases Department, CHU Montpellier, France, Francophone Society of Diabetes (SFD), France.;Department of Obstetrics and Gynecology, University Hospital of Strasbourg, France, French National College of Obstetricians and Gynecologists (CNGOF), France.;Department of Obstetrics and Gynecology, Paule de Viguier Hospital, CHU Toulouse, France, UMR 1027 Inserm, Team SPHERE, Toulouse III University, Toulouse, France, French National College of Obstetricians and Gynecologists (CNGOF), France.;AP-HP, Avicenne Hospital, Paris 13 University, Sorbonne Paris Cité, Department of Endocrinology-Diabetology-Nutrition, CRNH-IdF, CINFO, UMR U557 Inserm/U11125 INRAE/CNAM/Université Paris13, Unité de Recherche Epidémiologique Nutritionnelle, Bobigny, France, Francophone Society of Diabetes (SFD), France. | 599 | |||||||
| Letter;Comment | en | Correspondence-COVID-19: Initial experience of hand surgeons in Northern Italy. | https://www.ncbi.nlm.nih.gov/pubmed/32387693 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Italy;Pandemics;Pneumonia, Viral;Surgeons;COVID-19;severe acute respiratory syndrome coronavirus 2 | F Ducournau;S Gouzou;S Facca;P A Liverneaux | 2020-05-07 02:00:00+02:00 | 32387693 | FR | Department of Hand Surgery, Strasbourg University Hospitals, FMTS, 1, avenue Molière, 67200 Strasbourg, France.;Department of Hand Surgery, Strasbourg University Hospitals, FMTS, 1, avenue Molière, 67200 Strasbourg, France, Cube CNRS UMR7357, Strasbourg University, 2-4, rue Boussingault, 67000 Strasbourg, France.;Department of Hand Surgery, Strasbourg University Hospitals, FMTS, 1, avenue Molière, 67200 Strasbourg, France, Cube CNRS UMR7357, Strasbourg University, 2-4, rue Boussingault, 67000 Strasbourg, France. Electronic address: Philippe.liverneaux@chru-strasbourg.fr. | 602 | |||||||
| Letter | en | Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32380930 | 2020-05-10 02:00:00+02:00 | pubmed | Issam Khneisser;Chantal Farra | 2020-05-07 02:00:00+02:00 | 32380930 | FR;LB | Medical Genetics Unit, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.;Department of Medical Genetics, Hotel Dieu de France, Beirut, Lebanon. | 603 | ||||||||
| Letter | en | Inflammatory bowel disease and the SARS-CoV-2 pandemic: more speed, less haste. | https://www.ncbi.nlm.nih.gov/pubmed/32389663 | 2020-05-10 02:00:00+02:00 | pubmed | C Gower-Rousseau;M Fumery;B Pariente | Inflammatory Bowel disease;coronarovirus 2 (SARS-CoV-2);epidemiology;methodology | 2020-05-07 02:00:00+02:00 | 32389663 | FR | Public Health, Epidemiology and Medico-economic Unit, Epimad Registry, Lille University Hospital, France, Institute for Translational Research in Inflammation INFINITE - U1286 Inserm, Université de Lille, CHU de Lille, France. Electronic address: Corinne.gower@chru-lille.fr.;Gastroenterology Unit, Epimad Registry, Amiens University Hospital, France, PERITOX - UMR-I 01 Unité mixte INERIS Périnatalité & Risques Toxiques, Université Jules Verne Picardie, CHU d'Amiens, France.;Institute for Translational Research in Inflammation INFINITE - U1286 Inserm, Université de Lille, CHU de Lille, France, Gastroenterology Unit, Epimad Registry, Lille University Hospital, France. | 605 | |||||||
| Letter | en | Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32383343 | 2020-05-10 02:00:00+02:00 | pubmed | R Bernard-Valnet;B Pizzarotti;A Anichini;Y Demars;E Russo;M Schmidhauser;J Cerutti-Sola;A O Rossetti;R Du Pasquier | COVID-19;SARS-CoV-2;encephalitis;meningitis | 2020-05-07 02:00:00+02:00 | 32383343 | FR;CH | Department of Clinical Neurosciences, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Lausanne, Switzerland.;Service of Internal Medicine, Department of Medicine, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Lausanne, Switzerland. | 614 | |||||||
| Letter | en | COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients? | https://www.ncbi.nlm.nih.gov/pubmed/32350872 | 2020-05-10 02:00:00+02:00 | pubmed | Azithromycin__administration & dosage;Chloroquine__administration & dosage;Coronavirus Infections__drug therapy;Drug Therapy, Combination;Humans;Hydroxychloroquine__administration & dosage;Long QT Syndrome__chemically induced;Mental Disorders__complications;Pandemics;Pneumonia, Viral__drug therapy;Risk Factors;COVID-19 | Hervé Javelot;Wissam El-Hage;Guillaume Meyer;Guillaume Becker;Bruno Michel;Coraline Hingray | COVID-19;QT prolongation;azithromycin;hydroxychloroquine | 2020-05-07 02:00:00+02:00 | 32350872 | FR | Clinical Pharmacy Service, EPSAN, Brumath, France.;Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France.;UMR 1253, iBrain, Université de Tours, CHRU de Tours, INSERM, Tours, France.;CentreExpert Dépression Résistante, Fondation FondaMental, Tours, France.;Clinical Pharmacy Service, CHU, Strasbourg, France.;Pôle Hospitalo-Universitaire de Psychiatrie d'Adultes du Grand Nancy, Centre Psychothérapique de Nancy, Laxou, France.;CHU de Nancy, Département de Neurologie, Nancy, France. | 617 | ||||||
| Agence Nationale de la Recherche (ANR);Service de Coopération et d'Action Culturelle (SCAC) de l'Ambassade de France au Cameroun | 10.1007/s11033-020-05511-6 | Journal Article | en | Development and characterization of 20 polymorphic microsatellite markers for the white-bellied pangolin Phataginus tricuspis (Mammalia, Pholidota). | https://www.ncbi.nlm.nih.gov/pubmed/32419053 | Pangolins, or scaly anteaters, have recently been flagshiped as one of the most illegally traded mammals, and as a corollary, as potential intermediate hosts at the origin of the COVID-19 pandemic. In order to improve the traceability of their trade, we developed 20 polymorphic microsatellite loci for the white-bellied pangolin (Phataginus tricuspis), the species most frequently found on African bushmeat markets. We genotyped 24 white-bellied pangolins from the Douala market, Cameroon, originating from the Ebo forest c. 75 km north-east of Douala. The number of alleles per locus ranged from 4 to 12 (mean = 6.95), and mean observed and expected heterozygosities were 0.592 (0.208-0.875) and 0.671 (0.469-0.836), respectively. Genetic diversity was higher than that cross-estimated from microsatellite loci developed for other species of pangolins. Two loci deviated from Hardy-Weinberg equilibrium and two loci showed linkage disequilibrium. Genetic variance (PCoA) was increased with the addition of 13 pangolins of unknown origin, possibly suggesting that the Douala market is fed from differentiated source populations of white-bellied pangolins. Each of the 37 individuals had a unique multilocus genotype. The unbiased probability of identity (uPI) and the probability of identity among siblings (PIsibs) were both very low (uPI = 8.443 e-21; PIsibs = 1.011 e-07). Only five microsatellite loci were needed to reach the conservative value of PIsibs < 0.01, overall indicating a powerful discriminating power of our combined loci. These 20 newly developed microsatellite loci might prove useful in tracing the local-to-global trade of the white-bellied pangolin, and will hopefully contribute to the DNA-assisted implementation of future conservation strategies at reasonable costs. | 0301-4851,1573-4978 | 2020-05-17 02:00:00+02:00 | pubmed | Alleles;Animals;Betacoronavirus__pathogenicity;Cameroon__epidemiology;Coronavirus Infections__epidemiology;Disease Reservoirs__virology;Eutheria__genetics;Female;Genetic Loci;Genetic Markers;Genotype;Humans;Linkage Disequilibrium;Male;Microsatellite Repeats;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Zoonoses__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Molecular Biology Reports | Samantha Aguillon;Alain Din Dipita;Emilie Lecompte;Alain Didier Missoup;Maurice Tindo;Philippe Gaubert | Bushmeat;Cameroon;Illegal wildlife trade;Microsatellite loci;Pangolins;Phataginus tricuspis | 2020-05-17 02:00:00+02:00 | 32419053 | FR;CM | [{"country": "", "agency": "Agence Nationale de la Recherche (ANR)", "grantid": "ANR-17-CE02-0001"}, {"country": "", "agency": "Service de Coopération et d'Action Culturelle (SCAC) de l'Ambassade de France au Cameroun", "grantid": "939537G"}] | Laboratoire Evolution et Diversité Biologique (EDB), CNRS/UPS/IRD, Université Toulouse III Paul Sabatier - Bâtiment 4R1, 118 route de Narbonne, 31062, Toulouse Cedex 9, France.;Unité de Zoologie, Laboratoire de Biologie et Physiologie des Organismes Animaux, Faculté des Sciences, Université de Douala, BP 24157, Douala, Cameroon.;Laboratoire Evolution et Diversité Biologique (EDB), CNRS/UPS/IRD, Université Toulouse III Paul Sabatier - Bâtiment 4R1, 118 route de Narbonne, 31062, Toulouse Cedex 9, France. philippe.gaubert@univ-tlse3.fr. | 631 |
| Letter | en | New diseases and old threats: lessons from tuberculosis for the COVID-19 response. | https://www.ncbi.nlm.nih.gov/pubmed/32398212 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Communicable Disease Control;Contact Tracing;Coronavirus;Coronavirus Infections__epidemiology;Delivery of Health Care;Disease Outbreaks__prevention & control;Humans;Infection Control;Pandemics;Pneumonia, Viral__epidemiology;Triage;Tuberculosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | M Dara;G Sotgiu;M R Reichler;C-Y Chiang;C B E Chee;G B Migliori | 2020-05-14 02:00:00+02:00 | 32398212 | FR;SG;US;IT;DK | World Health Organization Regional Office for Europe - Tuberculosis, HIV and Viral Hepatitis Programme, Copenhagen, Denmark.;Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.;Independent Consultant, Atlanta, GA, USA.;International Union Against Tuberculosis and Lung Disease, Paris, France.;Respiratory Medicine, Tan Tock Seng Hospital, Singapore.;Maugeri Care and Research Institute, WHO Collaborating Center, Tradate, Italy, <email></email>, Email: daram@who.int. | 636 | |||||||
| 10.2174/1871526520666200518073329 | Editorial | en | Counter-regulatory 'Renin-Angiotensin' System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected patients. | https://www.ncbi.nlm.nih.gov/pubmed/32418532 | SARS-CoV-2 / COVID-19 and the 'Renin-Angiotensin' System The ubiquitous 'Renin-Angiotensin' system (RAS), also referred to as 'Renin-Angiotensin-Aldosterone' system, plays a crucial physiological role in humans as being a key regulator of renal, cardiovascular and innate immune functions [1, 2]. It appears to work in tandem with vitamin D, a secosteroid pro-hormone which reportedly acts as a negative regulatory factor of the RAS [3-6]. A dysfunction (e.g. over-reactivity) of RAS, together with hypovitaminosis D, is likely associated with some of the various renal, cardiac, vascular and immune outcomes that might be observed in COVID-19 patients, including the cytokine storm (i.e. unopposed hyperactive immune reaction generating both pro-inflammatory and anti-inflammatory cytokines) and consequent lethal acute respiratory distress syndrome [1, 7]. Recently, SARS-CoV-2 [8, 9], the causative agent of COVID-19, has been described to interfere with the RAS [2] by interacting -via its spike (S) glycoprotein- with the metallopeptidase Angiotensin-Converting Enzyme 2 (ACE2) receptor [9, 10] that is expressed at the surface of epithelial cells from blood vessels, lung, kidney (renal tubules), intestine, and heart, as well as on cerebral neurons and immune monocytes/macrophages [11-13]. The main SARS-CoV-2-related COVID-19 symptoms/diseases reported hitherto are hypertension, atherosclerosis, thrombosis (coagulopathy), diarrhea, glaucoma, anosmia, ageusia, skin lesions (dermatitis), autoimmune inflammation of the central nervous system, and damages to various organs such as the lung, heart, kidney, and testicle [1, 2, 14]. All these diffuse COVID-19 disorders are likely linked to an over-reaction of RAS in SARS-CoV-2-infected persons. Such a RAS imbalance would be also favored by hypovitaminosis D [2-7, 11]. Since RAS appears to be central in COVID-19 symptoms/diseases, selective targeting of key component(s) of this system might be appropriate to treat RAS-dependent disorders. COVID-19 Disorders: 'Renin-Angiotensin' System (RAS) & Counter-regulatory RAS In the RAS pathway [1, 15], Renin (kidney) cleaves Angiotensinogen (liver) to give Angiotensin I (i.e. peptide DRVYIHPFHL). The latter is cleaved by the Angiotensin-Converting Enzyme (ACE) to produce Angiotensin II (i.e. peptide DRVYIHPF), which is the substrate of ACE2 (SARS-CoV-2 receptor) and key player of the RAS. The cellular targets of Angiotensin II are the vasoconstrictor type 1 (AT1R) and vasodilatator type 2 (AT2R) Angiotensin II receptors (AT1R is expressed at the surface of monocytes/macrophages and T-cells indicating that RAS acts on innate immunity in host). When cleaved by ACE2, Angiotensin II gives Angiotensin 1-7 (i.e. peptide DRVYIHP), targeting the vasodilatator proto-oncogene Mas receptor (MasR). Angiotensin 1-7 can be further transformed to Alamandine (i.e. peptide ARVYIHP) by an aspartate decarboxylase. Alamandine would bind to the vasodilatator Mas-related G protein-coupled receptor member D (MRGD) thus promoting most of the Angiotensin 1-7-like effects. Angiotensin II can produce Angiotensin A (i.e. peptide ARVYIHPF) via an aspartate decarboxylase, and Alamandine via an additional ACE2 cleavage. ACE2 can also cleave Angiotensin I to form Angiotensin 1-9 (i.e. peptide DRVYIHPFH), which targets AT2R. In the RAS pathway were finally evidenced the related Angiotensin III (i.e. peptide RVYIHPF) and Angiotensin IV (i.e. peptide VYIHPF) variants targeting the AT1R and vasodilatator AT4R, respectively. From the known molecular functioning of the RAS, Angiotensins I and II (aside Angiotensin III) are playing central roles in the activity of RAS and associated pathologies, including COVID-19 [2, 10]. Interestingly, it appears that a 'counter-regulatory' RAS does exist to modulate system homeostasis; it relies on Angiotensin 1-7, Angiotensin 1-9, Alamandine, Angiotensin A, and Angiotensin IV, which are targeting the MasR, AT2R, MRGD, ACE2 and AT4R vasodilatator receptors, respectively. These peptides were found to exhibit cardioprotective, vasoactive (anti-hypertensive), anti-hypertrophic and/or anti-inflammatory potentials [15]. Such naturally-produced molecules of the RAS are expected to counteract the SARS-CoV-2-induced over-activation of RAS and reverse, to some extent, the associated COVID-19 diseases. CONCLUDING REMARKS A recent report suggests that RAS inhibitors may act on the severity of viral infection and mortality of COVID-19 patients [14]. Whether or not RAS blockers would be beneficial to COVID-19 cases is still controversial. The RAS inhibitors likely prevent the cytokine storm as RAS is reported to control the release of pro-inflammatory cytokines [1, 7]. It appears that COVID-19 disorders of SARS-CoV-2-infected humans depend on the RAS over-reacted by the (ACE2-dependent) viral infection and vitamin D deficiency. The track for a possible COVID-19 treatment would be to target RAS using specific candidate chemotherapeutic drugs. The proposed molecules are (so far) ACE inhibitors (to prevent the production of Angiotensin II from Angiotensin I), and blockers/antagonists of AT1R such as Losartan and derivatives. Recombinant ACE2 (under clinical trials) is also considered as a decoy for the recognition and competitive binding to the spike (S) glycoprotein of SARS-CoV-2 [9, 10]. We support the use of natural candidate peptide drugs that belong to the 'counter-regulatory' RAS, i.e. Angiotensin 1-7, Angiotensin 1-9, Alamandine, Angiotensin A and/or Angiotensin IV to treat COVID-19 disorders. The targeted receptors would thus be MasR, AT2R, MRGD, ACE2 and AT4R. The authors wish to thank Bonabes De Rougé MD for fruitful discussions. | 1871-5265 | 2020-05-17 02:00:00+02:00 | pubmed | Infectious Disorders - Drug Targets | Cédric Annweiler;Zhijian Cao;Yingliang Wu;Emmanuelle Faucon;Stéphanie Mouhat;Hervé Kovacic;Jean-Marc Sabatier | 2020-05-17 02:00:00+02:00 | 32418532 | FR;CN | Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers. France.;State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072. China.;EFFE, 252 Bd Grignan, 83000 Toulon. France.;Université Aix-Marseille, Institut de Neuro-physiopathologie (INP), UMR 7051, Faculté de Pharmacie, 27 Bd Jean Moulin, 13385 Marseille Cedex. France. | 639 | ||||
| 10.1016/j.eclinm.2020.100382 | Journal Article | en | Can we operate our patients without fear during the period of COVID-19 infection? | https://www.ncbi.nlm.nih.gov/pubmed/32426708 | 2589-5370 | 2020-05-17 02:00:00+02:00 | pubmed | EClinicalMedicine | Jean-Jacques Tuech;Lilian Schwarz | 2020-05-17 02:00:00+02:00 | 32426708 | FR | Rouen University Hospital, Department of Digestive Surgery, 1 rue de Germont, F-76031, Rouen cedex, France.;Normandie Univ, UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, F-76000, Rouen, France. | 641 | |||||
| 10.1016/s2468-1253(20)30151-5 | Journal Article | en | Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. | https://www.ncbi.nlm.nih.gov/pubmed/32411920 | 2468-1253 | 2020-05-17 02:00:00+02:00 | pubmed | Attitude to Health;Betacoronavirus;Coronavirus Infections__epidemiology;Global Health;Health Services Accessibility;Health Surveys;Humans;Inflammatory Bowel Diseases__psychology;Pandemics__prevention & control;Physician-Patient Relations;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Gastroenterology & Hepatology | Ferdinando D'Amico;Jean-François Rahier;Salvo Leone;Laurent Peyrin-Biroulet;Silvio Danese | 2020-05-13 02:00:00+02:00 | 32411920 | FR;IT;BE | Department of Biomedical Sciences, Humanitas University, Milan, Italy, Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Gastroenterology, Université Catholique de Louvain, Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Yvoir, Belgium.;European Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Biomedical Sciences, Humanitas University, Milan, Italy, Inflammatory Bowel Disease Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy. Electronic address: sdanese@hotmail.com. | 648 | ||||
| 10.1093/intqhc/mzaa050 | Journal Article | en | COVID-19: Patient Safety and Quality Improvement Skills to Deploy during the Surge. | https://www.ncbi.nlm.nih.gov/pubmed/32400870 | 1353-4505,1464-3677 | 2020-05-17 02:00:00+02:00 | pubmed | International Journal for Quality in Health Care | Anthony Staines;René Amalberti;Donald M Berwick;Jeffrey Braithwaite;Peter Lachman;Charles A Vincent | COVID-19;Pandemic;Patient Safety;Quality Improvement | 2020-05-13 02:00:00+02:00 | 32400870 | FR;IE;CH;US;GB;AU | Hospital Federation of Vaud, Prilly, Switzerland - IFROSS Institute, University of Lyon 3, France.;Public Foundation for Industrial Safety Culture-FONCSI, Toulouse, France.;Institute for Healthcare Improvement, Boston, USA.;Australian Institute of Health Innovation, Macquarie University, Australia.;International Society for Quality in Healthcare, Dublin, Ireland.;University of Oxford, Experimental Psychology, United Kingdom. | 649 | ||||
| 10.1080/15265161.2020.1764135 | Editorial | en | Medically Vulnerable Clinicians and Unnecessary Risk During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32400303 | 1526-5161,1536-0075 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics__ethics;Physicians;Pneumonia, Viral__epidemiology;Practice Patterns, Physicians'__ethics;Risk;United States__epidemiology;Work Engagement;COVID-19;severe acute respiratory syndrome coronavirus 2 | The American Journal of Bioethics | Annie Janvier;John D Lantos | 2020-05-13 02:00:00+02:00 | 32400303 | FR;CA;US | Université de Montréal.;CHU Sainte-Justine.;Children's Mercy Kansas City. | 660 | ||||
| 10.1093/cid/ciaa587 | Journal Article | en | SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir. | https://www.ncbi.nlm.nih.gov/pubmed/32409832 | December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called COVID-19, caused by a newly identified coronavirus, SARS-CoV-2. No therapeutic option is available to treat this infection that has already killed more than 235,000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a non-immunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached Phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the lifecycle of many coronaviruses, including SARS-CoV and MERS-CoV, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at-risk of severe forms of SARS-CoV-2 infection. | 1058-4838,1537-6591 | 2020-05-17 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Jean-Michel Pawlotsky | 2020-05-15 02:00:00+02:00 | 32409832 | FR | Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.;INSERM U955, Créteil, France. | 666 | ||||
| 10.1016/j.anorl.2020.05.007 | Practice Guideline | en | Best practice recommendations: ENT consultations during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32419879 | These best practice recommendations for ENT consultations during the COVID-19 pandemic have been drawn up because ENT examinations and treatments are at risk of contamination by the SARS-Cov-2 virus in certain instances. Thus, ENT specialists are among the professionals who are most exposed to this infection. During the pandemic, insofar as an asymptomatic patient may be infected and contagious, the same precautions must be employed whether the patient is ill with, suspected of having, or without any clinical evidence of COVID-19 infection. According to the scientific data available, the examinations and procedures potentially exposing to projections/aerosolizations of organic material of human origin are considered to be at risk of staff contamination. For ENT examinations and procedures without exposure to such projections/aerosolizations, the professional is advised to a long sleeve clean outfit, a surgical mask and gloves in case of contact with the patient's mucosa. ENT examinations and procedures with exposure to these projections/aerosolizations require the so-called "airborne", "contact", and "droplets" additional precautions: FFP2/N95 respiratory protection device, eye protection, disposable headwear and long sleeve overgown. | 1879-7296 | 2020-05-17 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | E Lescanne;N van der Mee-Marquet;J-M Juvanon;A Abbas;N Morel;J-M Klein;M Hanau;V Couloigner | COVID-19 pandemic;FFP2/N95 Mask;Otolaryngology;Personal protective equipment (PPE);SARS-CoV-2 | 2020-05-15 02:00:00+02:00 | 32419879 | FR | Department of Otorhinolaryngology, Head and Neck Surgery, Tours University Hospital, Tours, France. Electronic address: lescanne@univ-tours.fr.;Support Centre for the Prevention of Healthcare-associated Infections (CPias Centre Val de Loire), Tours University Hospital, Tours, France.;ENT practice, Nemours, France.;ENT practice, Paris, France.;ENT practice, Echirolles, France.;French National Professional ENT Council (CNPORL), Paris, France.;ENT practice, Amiens, France.;Department of Otorhinolaryngology, Head and Neck Surgery, hôpital Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Paris, France. | 673 | |||
| Letter;Comment | en | High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. | https://www.ncbi.nlm.nih.gov/pubmed/32299867 | 2020-05-17 02:00:00+02:00 | pubmed | Aerosols;Betacoronavirus;Cannula;Coronavirus Infections;Critical Illness;Cross-Over Studies;Humans;Oxygen;Pandemics;Pneumonia;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jie Li;James B Fink;Stephan Ehrmann | 2020-05-14 02:00:00+02:00 | 32299867 | FR;US | Dept of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University Medical Center, Chicago, IL, USA Jie_Li@rush.edu.;Dept of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University Medical Center, Chicago, IL, USA.;CHRU Tours, Médecine Intensive Réanimation, CIC INSERM 1415, CRICS-TriggerSep network, Tours France, and INSERM, Centre d'étude des pathologies respiratoires, U1100, Université de Tours, Tours, France. | 679 | |||||||
| 10.1016/j.rmr.2020.05.001 | Journal Article;Practice Guideline | fr | [Guide for follow-up of patients with SARS-CoV-2 pneumonia. Management proposals developed by the French-language Respiratory Medicine Society. Version of 10 May 2020]. | https://www.ncbi.nlm.nih.gov/pubmed/32410773 | The French-language Respiratory Medicine Society (SPLF) proposes a guide for the follow-up of patients who have presented with SARS-CoV-2 pneumonia. The proposals are based on known data from previous epidemics, on acute lesions observed in SARS-CoV-2 patients and on expert opinion. This guide proposes a follow-up based on three categories of patients: (1) patients managed outside hospital for possible or proven SARS-CoV-2 infection, referred by their physician for persistent dyspnoea; (2) patients hospitalized for SARS-CoV-2 pneumonia in a medical unit; (3) patients hospitalized for SARS-CoV-2 pneumonia in an intensive care unit. The subsequent follow-up will have to be adapted to the initial assessment. This guide emphasises the possibility of others causes of dyspnoea (cardiac, thromboembolic, hyperventilation syndrome…). These proposals may evolve over time as more knowledge becomes available. | 0761-8425 | 2020-05-17 02:00:00+02:00 | pubmed | Aftercare__methods;Ambulatory Care__methods;Cardiovascular Diseases__prevention & control;Coronavirus Infections__complications;Critical Care__methods;Diagnostic Techniques, Respiratory System__standards;Disease Management;Emergency Medical Services__methods;Health Priorities;Hospitalization;Humans;Inpatients;Outpatients;Pandemics;Pneumonia, Viral__complications;Respiratory Therapy__methods;Symptom Assessment__methods;Thromboembolism__prevention & control;Thrombophilia__drug therapy;COVID-19 | Revue des Maladies Respiratoires | C Andrejak;F-X Blanc;F Costes;B Crestani;D Debieuvre;T Perez;B Philippe;L Plantier;F Schlemmer;L Sesé;B Stach;Y Uzunhan;C Zanetti;M Zysman;C Raherison;B Maitre | COVID;CT scan;Fibrose;Fibrosis;Follow-up;Plethysmography;Pléthysmographie;Scanner;Suivi | 2020-05-14 02:00:00+02:00 | 32410773 | FR | Service de pneumologie, UR 4294 AGIR, université Picardie Jules-Verne, CHU Amiens-Picardie, rond point Christian-Chabrol, 80054 Amiens, France. Electronic address: andrejak.claire@chu-amiens.fr.;Service de pneumologie, l'institut du thorax, université de Nantes, CHU de Nantes, 44093 Nantes, France.;Service de médecine du sport et explorations fonctionnelles, INRAE, UNH, université Clermont Auvergne, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.;Inserm 1152, service de pneumologie, hôpital Bichat, université de Paris, 75108 Paris, France.;Service de pneumologie, groupe hospitalier de la région Mulhouse Sud-Alsace, hôpital Émile-Muller, Mulhouse, France.;Service d'explorations fonctionnelles respiratoires, clinique des maladies respiratoires, CHU de Lille, 59000 Lille, France.;Service de pneumologie, centre hospitalier René-Dubos, 95300 Pontoise, France.;CEPR, Inserm UMR1100, service de pneumologie et explorations fonctionnelles respiratoires, université de Tours, CHRU de Tours, 37000 Tours, France.;Unité de pneumologie, hôpitaux universitaires Henri-Mondor, université Paris Est Créteil, Assistance publique-Hôpitaux de Paris, 94000 Créteil, France.;Service de physiologie, hôpital Avicenne, Assistance publique-Hôpitaux de Paris, 93000 Bobigny, France.;Cabinet médical Saint-Michel, 59300 Valenciennes, France.;Inserm U1272, service de pneumologie, laboratoire « hypoxie et poumon », hôpital Avicenne, université Paris Nord, Bobigny, France.;Cabinet médical, 20, avenue Raoul-Briquet, 62300 Lens, France.;Inserm 1045 équipe 2, service des maladies respiratoires, CHU de Bordeaux, 33000 Bordeaux, France.;U1219 Epicene, service des maladies respiratoires, université de Bordeaux, CHU de Bordeaux, Bordeaux, France. | 684 | ||
| 10.1016/j.encep.2020.05.003 | Journal Article | fr | [The effects of quarantine for SARS-CoV-2 on sleep: An online survey]. | https://www.ncbi.nlm.nih.gov/pubmed/32475692 | Explore the evolution of sleep during the SARS-CoV-2 quarantine period and define associated factors. | 0013-7006 | 2020-05-17 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections__complications;Dyssomnias__drug therapy;Exercise;Family;Female;France__epidemiology;Habits;Health Surveys;Housing;Humans;Light;Male;Middle Aged;Online Systems;Pandemics__prevention & control;Pneumonia, Viral__complications;Quarantine;Sleep__physiology;Sleep Aids, Pharmaceutical;Sleep Deprivation;Sleep Disorders, Circadian Rhythm__drug therapy;Sleep Latency;Sleep Wake Disorders__drug therapy;Social Isolation__psychology;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | S Hartley;C Colas des Francs;F Aussert;C Martinot;S Dagneaux;V Londe;L Waldron;S Royant-Parola | COVID 19;Confinement;Habitudes de sommeil;Quarantine;Sleep;Sleep habits;Social jet-lag;Sommeil;« Jet-lag » social | 2020-05-11 02:00:00+02:00 | 32475692 | FR | Réseau Morphée, 2, Grande rue, 92380 Garches, France, Unité du sommeil, EA 4047, université de Versailles Saint-Quentin en Yvelines, hôpital Raymond-Poincaré, AP-HP, 92380 Garches, France. Electronic address: sarah.hartley@reseau-morphee.fr.;Réseau Morphée, 2, Grande rue, 92380 Garches, France.;Réseau Morphée, 2, Grande rue, 92380 Garches, France, Centre des explorations multifonctionnelles, hôpital Antoine-Béclère, AP-HP, Clamart, France. | 692 | ||
| Case Reports;Letter | en | Post SARS-CoV-2 Guillain-Barré syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32422529 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Guillain-Barre Syndrome__diagnosis;Humans;Male;Middle Aged;Neural Conduction__physiology;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Souraya Arnaud;Clara Budowski;Sophie Ng Wing Tin;Bertrand Degos | 2020-05-11 02:00:00+02:00 | 32422529 | FR | Service de Neurologie, APHP, Hôpital Avicenne, Hôpitaux Universitaires de Paris - Seine Saint Denis, Sorbonne Paris Nord, Bobigny, France.;Service de Physiologie, Explorations Fonctionnelles et Médecine du Sport, APHP, Hôpital Avicenne, Hôpitaux Universitaires de Paris - Seine Saint Denis, Sorbonne Paris Nord, Bobigny, France, Inserm UMR 1272, Université Sorbonne Paris Nord, Bobigny, France.;Service de Neurologie, APHP, Hôpital Avicenne, Hôpitaux Universitaires de Paris - Seine Saint Denis, Sorbonne Paris Nord, Bobigny, France, Dynamics and Pathophysiology of Neuronal Networks Team, Center for Interdisciplinary Research in Biology, Collège de France, CNRS UMR7241/INSERM U1050, MemoLife Labex, 75005 Paris, France. Electronic address: bertrand.degos@aphp.fr. | 697 | |||||||
| 10.1016/j.endinu.2020.04.001 | Journal Article | en | Consequences of COVID-19 on people with diabetes. | https://www.ncbi.nlm.nih.gov/pubmed/32475769 | 2530-0164 | 2020-05-17 02:00:00+02:00 | pubmed | Antimalarials__therapeutic use;Betacoronavirus;Coronavirus Infections__complications;Diabetes Complications__complications;Health Services Accessibility;Hospitalization;Humans;Hydroxychloroquine__therapeutic use;Hyperglycemia__complications;Hypoglycemic Agents__therapeutic use;Pandemics;Pneumonia, Viral__complications;Prognosis;Risk;COVID-19;severe acute respiratory syndrome coronavirus 2 | Endocrinología, Diabetes y Nutrición | Virginia Bellido;Antonio Pérez | 2020-05-11 02:00:00+02:00 | 32475769 | FR;ES | Servicio de Endocrinología y Nutrición, Hospital Universitario Cruces, Biocruces, Universidad del País Vasco, Vizcaya, España. Electronic address: virginiabellido@gmail.com.;Servicio de Endocrinología y Nutrición, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Universitat Autònoma de Barcelona. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, España. Electronic address: aperez@santpau.cat. | 704 | ||||
| Editorial;Comment | en | Coronavirus Disease (COVID)-19: World Health Organization Definitions and Coding to Support the Allergy Community and Health Professionals. | https://www.ncbi.nlm.nih.gov/pubmed/32418622 | 2020-05-17 02:00:00+02:00 | pubmed | Anaphylaxis;Betacoronavirus;Brazil;Coronavirus;Coronavirus Infections;Humans;International Classification of Diseases;Pandemics;Pneumonia, Viral;World Health Organization;COVID-19;severe acute respiratory syndrome coronavirus 2 | Luciana K Tanno;Thomas Casale;Pascal Demoly | 2020-05-11 02:00:00+02:00 | 32418622 | FR;US;BR | Hospital Sírio-Libanês, Sao Paulo, Brazil, Division of Allergy, Département de Pneumologie et Addictologie, University Hospital of Montpellier, Montpellier, France, Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, Paris, France, WHO Collaborating Centre on Scientific Classification Support, Montpellier, France. Electronic address: luciana.tanno@gmail.com.;Morsani College of Medicine, University of South Florida, Tampa, Fla.;Division of Allergy, Département de Pneumologie et Addictologie, University Hospital of Montpellier, Montpellier, France, Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, Paris, France, WHO Collaborating Centre on Scientific Classification Support, Montpellier, France. | 705 | |||||||
| 10.1016/j.dib.2020.105698 | Journal Article | en | Dataset for country profile and mobility analysis in the assessment of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32405515 | Understanding the COVID-19 pandemic is a multidisciplinary effort that requires a significant number of variables. This dataset comprises (i) sociodemographic characteristics, compiled from 35 datasets obtained at UN Data; (ii) mobility metrics that can assist the analysis of social distancing, from Google Community Mobility Reports and; (iii) daily counts of cases and deaths by COVID-19, from the European Centre for Disease Prevention and Control and the Johns Hopkins University Center for Systems Science and Engineering. This unified dataset ranges from February 15, 2020 to May 7, 2020, a total of 83 days, and is provided as a collection of time series for 131 countries with 192 variables. The pipeline to preprocess and generate the dataset, along with the dataset itself, are versioned with the Data Version Control tool (DVC) and are thus easily reproducible. | 2352-3409 | 2020-05-17 02:00:00+02:00 | pubmed | Data in Brief | Marcel da Câmara Ribeiro-Dantas;Gisliany Alves;Rafael B Gomes;Leonardo C T Bezerra;Luciana Lima;Ivanovitch Silva | COVID-19;Health Informatics;Mobility;Pandemic;Social Distancing;Sociodemographic data | 2020-05-13 02:00:00+02:00 | 32405515 | FR;BR | Institut Curie, Paris, France.;Ecole Doctorale Informatique, Télécomunications et Electronique, Paris, France.;Federal University of Rio Grande do Norte, Natal, Brazil. | 712 | |||
| Letter | en | Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32405269 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Cytokine Release Syndrome__etiology;Cytokines__antagonists & inhibitors;Disease Progression;Gene Expression Regulation;Humans;Immunity, Innate__drug effects;Immunologic Factors__therapeutic use;Molecular Targeted Therapy__methods;Pandemics;Pneumonia, Viral__drug therapy;Sirolimus__therapeutic use;T-Lymphocytes__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Loukman Omarjee;Anne Janin;Frédérique Perrot;Bruno Laviolle;Olivier Meilhac;Guillaume Mahe | 2020-05-13 02:00:00+02:00 | 32405269 | FR;IN | Inserm, NuMeCan Institute (UMR INSERM 1241), Rennes F-35033, France, Univ Rennes, CHU Rennes, INSERM, CIC1414, Clinical Immunology and Vascular Medicine, Rennes F-35033, France. Electronic address: loukman.omarjee@chu-rennes.fr.;Inserm, (U942), Paris Diderot University, Sorbonne Paris Cité, Paris F-75018, France.;Cellular and Molecular Biology Consultant, Rennes F-35033, France.;Inserm, Clinical Investigation Center 1414, Univ Rennes, CHU Rennes, Rennes F-35033, France.;Reunion Island University, INSERM U1188, Diabetes atherothrombosis Réunion Indian Ocean (DéTROI), CYROI Plateform, Sainte-Clotilde F-97490, France, CHU de La Réunion, Saint-Pierre F- 97448, France. | 715 | |||||||
| 10.1016/j.mehy.2020.109827 | Journal Article | en | COVID-19: beta-thalassemia subjects immunised? | https://www.ncbi.nlm.nih.gov/pubmed/32447232 | The novel coronavirus pneumonia (COVID-19) is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a novel virus of the coronavirus family, SARSCoV-2. A recent PRE-print study has showed a heme attack on the 1-beta chain of hemoglobin by COVID19. Beta-thalassemia results of a default in the hemoglobin beta-chain synthesis. 1,5% global population are heterozygotes for this disease. In this study, by a multiple linear regression, we have analyzed the evolution of COVID-19 infection in three Italian regions (Puglia, Sardinia, Sicilia) with different beta-thalassemic prevalences, in order to search a link. The results have showed that betathalassemic heterozygote population prevalence is correlated to immunity against COVID-19, by a regression. This paper is only for academic discussion, the hypotheses and conclusions needs to be confirmed by further research. | 0306-9877 | 2020-05-17 02:00:00+02:00 | pubmed | Medical Hypotheses | Edouard Lansiaux;Philippe Pierre Pébaÿ;Jean-Laurent Picard;Joachim Son-Forget | Beta thalassemia;Correlation;Favipiravir;Heme;Immunization;Italy;Novel coronavirus;Regression;Respiratory distress;Sardinia;Statistics | 2020-05-12 02:00:00+02:00 | 32447232 | FR;US | Henry Warembourg Medicine School, Lille University, 59000 Lille, France. Electronic address: edouard.lansiaux.etu@univ-lille.fr.;NexGen Analytics, 82801 Sheridan, WY, United States.;Conservatoire National des Arts et Métiers, 75141 Paris, France.;Assemblée Nationale, 75355 Paris, France. | 722 | |||
| 10.1186/s13613-020-00675-7 | Journal Article | en | Recruitability and effect of PEEP in SARS-Cov-2-associated acute respiratory distress syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32399901 | A large proportion of patients with a SARS-Cov-2-associated respiratory failure develop an acute respiratory distress syndrome (ARDS). It has been recently suggested that SARS-Cov-2-associated ARDS may differ from usual non-SARS-Cov-2-associated ARDS by higher respiratory system compliance (CRS), lower potential for recruitment with positive end-expiratory pressure (PEEP) contrasting with severe shunt fraction. The purpose of the study was to systematically assess respiratory mechanics and recruitability in SARS-Cov-2-associated ARDS. | 2110-5820 | 2020-05-17 02:00:00+02:00 | pubmed | Annals of Intensive Care | François M Beloncle;Bertrand Pavlovsky;Christophe Desprez;Nicolas Fage;Pierre-Yves Olivier;Pierre Asfar;Jean-Christophe Richard;Alain Mercat | Acute respiratory distress syndrome;Covid-19;Mechanical ventilation;Positive end-expiratory pressure;Recruitability;Respiratory failure;Respiratory mechanics;SARS-Cov-2 | 2020-05-12 02:00:00+02:00 | 32399901 | FR | Département de Médecine Intensive-Réanimation, CHU d'Angers, Université d'Angers, 4 rue Larrey, 49933, Angers Cedex 9, France. francois.beloncle@univ-angers.fr.;Département de Médecine Intensive-Réanimation, CHU d'Angers, Université d'Angers, 4 rue Larrey, 49933, Angers Cedex 9, France.;INSERM, UMR 955, Créteil, France. | 724 | |||
| 10.1016/j.ajem.2020.05.018 | Journal Article;Systematic Review | en | Management of acute ischemic stroke in patients with COVID-19 infection: Insights from an international panel. | https://www.ncbi.nlm.nih.gov/pubmed/32444298 | To present guidance for clinicians caring for adult patients with acuteischemic stroke with confirmed or suspected COVID-19 infection. | 0735-6757 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Brain Ischemia__diagnostic imaging;Coronavirus Infections__complications;Disease Management;Humans;Infection Control;Pandemics;Pneumonia, Viral__complications;Stroke__diagnostic imaging;COVID-19;severe acute respiratory syndrome coronavirus 2 | The American Journal of Emergency Medicine | Adnan I Qureshi;Foad Abd-Allah;Fahmi Al-Senani;Emrah Aytac;Afshin Borhani-Haghighi;Alfonso Ciccone;Camilo R Gomez;Erdem Gurkas;Chung Y Hsu;Vishal Jani;Liqun Jiao;Adam Kobayashi;Jun Lee;Jahanzeb Liaqat;Mikael Mazighi;Rajsrinivas Parthasarathy;Muhammad Shah Miran;Thorsten Steiner;Kazunori Toyoda;Marc Ribo;Fernando Gongora-Rivera;Jamary Oliveira-Filho;Guven Uzun;Yongjun Wang | Acute stroke;COVID-19;Corona virus;Ischemic stroke;Mechanical thrombectomy;Thrombolysis | 2020-05-11 02:00:00+02:00 | 32444298 | FR;MX;SA;CN;PS;JP;US;TW;BR;IT;PL;IR;EG;TR;ES;IN;KR;PK;DE | Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USA.;Department of Neurology, Kasralainy school of Medicine, Cairo University, Cairo, Egypt.;Department of Neurology, National Neurosciences Institute, King Fahad Medical City, Riyadh,Kingdom of Saudi Arabia.;Zeenat Qureshi Stroke Institute,Department of Neurology, University of FIRAT, Elazig Turkey.;Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.;Department of Neurosciences, Hospital Carlo Poma, ASST di Mantova, Mantua, Italy.;Department of Neurology, University of Missouri, MO, USA.;Stroke Center, Department of Neurology, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey.;Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan.;Department of Neurology, Creighton University Medical Center/CHI Health, Omaha, NE, USA. Electronic address: vbjani@yahoo.com.;Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.;Department of Neurology and Interventional Stroke Treatment Centre, Kazimierz Pulaski University of Technology and Humanities, Radom, Poland.;Department of Neurology, Yeungnam University School of Medicine, Daegu, Korea.;Department of Neurology, Pak-Emirates Military Hospital, Rwp, Pakistan.;Department of Interventional Neuroradiology, Rothschild Foundation Hospital, University of Paris, Laboratory of Vascular Translational Sciences, Paris, France.;Stroke & Neurointervention Artemis Hospitals, Gurugram, Haryana 122001, India.;Michigan State University, Hurley Medical Center, Flint, MI, USA.;Department of Neurology, Klinikum Frankfurt Ho¨chst, Frankfurt and Heidelberg University Hospital, Heidelberg, Germany.;Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.;Department of Neurology, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Spain.;Servicio de Neurología, Hospital Universitario José Eleuterio González de la Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México, Instituto de Neurología y Neurocirugía, Hospital Zambrano Hellion, Tecnológico de Monterrey, San Pedro, Nuevo León, México.;Department of Biomorphology, Federal University of Bahia, Salvador, Brazil.;Beverly Hills Pain Institute and Neurology, Beverly Hills, CA, USA.;Tiantan Comprehensive Stroke Center, Beijing Tiantan Hospital, Capital Medical University Beijing, China. | 730 | ||
| NCATS NIH HHS;NIAMS NIH HHS;NHLBI NIH HHS;NCATS NIH HHS | 10.1016/j.jcyt.2020.05.002 | Journal Article | en | International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. | https://www.ncbi.nlm.nih.gov/pubmed/32425691 | The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight. | 1465-3249 | 2020-05-17 02:00:00+02:00 | pubmed | Cytotherapy | Verena Börger;Daniel J Weiss;Johnathon D Anderson;Francesc E Borràs;Benedetta Bussolati;David R F Carter;Massimo Dominici;Juan M Falcón-Pérez;Mario Gimona;Andrew F Hill;Andrew M Hoffman;Dominique de Kleijn;Bruce L Levine;Rebecca Lim;Jan Lötvall;S Alex Mitsialis;Marta Monguió-Tortajada;Maurizio Muraca;Rienk Nieuwland;Anna Nowocin;Lorraine O'Driscoll;Luis A Ortiz;Donald G Phinney;Ilona Reischl;Eva Rohde;Ralf Sanzenbacher;Clotilde Théry;Wei Seong Toh;Kenneth W Witwer;Sai Kiang Lim;Bernd Giebel | 2020-05-16 02:00:00+02:00 | 32425691 | SE;IE;FR;SG;GB;US;AT;IT;AU;NL;ES;DE | [{"country": "United States", "agency": "NCATS NIH HHS", "grantid": "KL2 TR001859"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "R21 AR076861"}, {"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "T32 HL086350"}, {"country": "United States", "agency": "NCATS NIH HHS", "grantid": "UL1 TR001860"}] | Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.;Department of Medicine, University of Vermont, Burlington, Vermont, USA.;Department of Otolaryngology, Stem Cell Program, University of California, Davis, Davis, California, USA.;REMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, and Nephrology Service, Germans Trias i Pujol University Hospital, Badalona, Spain.;Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.;Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK.;Department of Medical and Surgical Sciences of Children and Adults, University Hospital of Modena, Modena, Italy.;Exosomes Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain, Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain, IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.;GMP Unit and EV-TT Transfer Center, Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.;La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Australia.;School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.;Department of Vascular Surgery, University Medical Center Utrecht and Netherlands Heart Institute, Utrecht, the Netherlands.;Center for Cellular Immunotherapies at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.;Department of Obstetrics and Gynaecology, Hudson Institute of Medical Research, Monash University and The Ritchie Centre, Melbourne, Australia.;Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.;Department of Pediatrics, Harvard Medical School and Boston Children's Hospital, Boston, Massachusetts, USA.;ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, and Cardiology Service, Germans Trias i Pujol University Hospital, Badalona, Spain.;Department of Women's and Children's Health, University of Padua, Padua, Italy.;Laboratory of Experimental Clinical Chemistry, Department of Clinical Chemistry and Vesicle Observation Center, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.;Biotherapeutics, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare Products Regulatory Agency, Hertfordshire, UK.;School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.;Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.;Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida, USA.;Federal Office for Safety in Health Care (BASG) and Austrian Agency for Health and Food Safety (AGES), Institute Surveillance, Vienna, Austria.;Department of Transfusion Medicine, University Hospital, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria, GMP Unit, Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.;Section Tissue Engineering and Cell Therapeutics, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.;Institut Curie/INSERM U932/PSL Research University, Paris, France.;Faculty of Dentistry, National University of Singapore, Singapore.;Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: kwitwer1@jhmi.edu.;Institute of Molecular and Cellular Biology, Agency for Science, Technology and Research, Singapore. Electronic address: Lim_Sai_Kiang@imcb.a-star.edu.sg.;Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Electronic address: bernd.giebel@uk-essen.de. | 733 | ||
| Letter | en | COVID-19 symptoms masking inaugural ketoacidosis of type 1 diabetes. | https://www.ncbi.nlm.nih.gov/pubmed/32447100 | 2020-05-24 02:00:00+02:00 | pubmed | L Potier;J B Julla;R Roussel;P Boudou;D C Gauthier;C Ketfi;J F Gautier | 2020-05-21 02:00:00+02:00 | 32447100 | FR | Bichat Hospital, AP-HP, Université de Paris, Paris, France. Electronic address: louis.potier@gmail.com.;Lariboisière Hospital, AP-HP, Université de Paris, Paris, France.;Bichat Hospital, AP-HP, Université de Paris, Paris, France.;Saint-Louis Hospital, AP-HP, Université de Paris, Paris, France. | 754 | ||||||||
| 10.1016/j.pulmoe.2020.05.003 | Journal Article | en | COVID-19 and asthma: To have or not to have T2 inflammation makes a difference? | https://www.ncbi.nlm.nih.gov/pubmed/32466999 | 2531-0437 | 2020-05-24 02:00:00+02:00 | pubmed | Pulmonology | M Morais-Almeida;J Bousquet | Allergy;Asthma;COVID-19;Risk factors;SARS-CoV-2;T2 inflammation | 2020-05-19 02:00:00+02:00 | 32466999 | FR;PT;DE | Allergy Centre, CUF Descobertas, Lisbon and Portuguese Association of Asthmatics (APA), Portugal. Electronic address: mmoraisalmeida@netcabo.pt.;Hospital Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany, MACVIA-France, Montpellier, France. | 777 | ||||
| 10.1111/1469-8676.12795 | Journal Article | en | Overlapping values: religious and scientific conflicts during the COVID-19 crisis in Brazil. | https://www.ncbi.nlm.nih.gov/pubmed/32836932 | 0964-0282,1469-8676 | 2020-05-24 02:00:00+02:00 | pubmed | Social Anthropology | Giovanna Capponi | 2020-05-18 02:00:00+02:00 | 32836932 | FR | Département de la recherche et de l'enseignement Musée du Quai Branly 75343 Paris cedex 07 France. | 780 | |||||
| 10.1016/j.bulcan.2020.05.001 | English Abstract;Journal Article | fr | [COVID-19 impact on the cancer care structuration: Example of the multidisciplinary team meeting dedicated to oncology in Occitanie]. | https://www.ncbi.nlm.nih.gov/pubmed/32425210 | This work examines the impact of the SARS-CoV2 epidemic and the organizational recommendations that have been issued since March 16 on tumor boards (TB) activity. The tumor board activity was measured from tumor board sheets extracted from the oncologic electronic file between January 7, 2019 and April 24, 2020. The pre-containment activity was compared to the activity of the containment periods but also to the equivalent periods in 2019. The number of meetings held, the average number of files reviewed per meeting including first presentations and the average number of physicians' attendance were the evaluation criteria. The study covered 191 TB that held 3943 multidisciplinary team meetings (MTM) and reviewed 72,070 files (including 30,127 first submissions). There was a moderate decrease of 8 % in the number of meetings after March 16, 2020. The number of files examined decreased by 23 % in the following month and even more by 33 % in the third period. The physicians' number who attended MTM also decreased by 25 %. The negative impact was higher in the Mediterranean part of the region. This first study of tumor board activity, covering a large region but little affected by the pandemic, shows that its impact on the participation to the MTM has been moderate. In addition, tumor boards have followed the recommendations for optimizing quorum. However, the decrease in average MTM activity, particularly for first submissions, suggests a potential delay in patient management. Complementary qualitative and quantitative works are warranted to estimate the real impact on carcinologic outcomes. | 0007-4551 | 2020-05-24 02:00:00+02:00 | pubmed | Bulletin du Cancer | Pascale Grosclaude;David Azria;Rosine Guimbaud;Séverine Thibault;Laetitia Daubisse-Marliac;Guillaume Cartron;Marie-José Renaudie;Pierre-Adrien Dalbies;Jean-Pierre Delord;Eric Bauvin | Cancérologie;Multidisciplinary team meeting;Oncology;Quality of Care;Qualité de la prise en charge;Réunion de concertation pluridisciplinaire;SARS-CoV2;Tumor board | 2020-05-18 02:00:00+02:00 | 32425210 | FR | Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France, UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France. Electronic address: pascale.grosclaude@inserm.fr.;Institut du cancer de Montpellier, fédération universitaire d'oncologie radiothérapie d'Occitanie Méditerranée, département d'oncologie radiothérapie, 298, avenue des Apothicaires, Montpellier cedex 05, France, Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.;Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France, Oncologie médicale digestive, CHU de Toulouse 31400 Toulouse, France.;Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.;Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France, UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France, Centre de coordination en cancérologie, CHU de Toulouse, 31000 Toulouse, France.;Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France, Fédération d'Hématologie Universitaire Montpellier-Nïmes, Département d'hématologie clinique, CHU de Montpellier, 34090 Montpellier, France.;Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France, URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier, France.;Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France, Institut universitaire du cancer de Toulouse, Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.;UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France, Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France. | 782 | |||
| 10.1007/s10460-020-10051-7 | Journal Article | en | Post COVID 19 and food pathways to sustainable transformation. | https://www.ncbi.nlm.nih.gov/pubmed/32427212 | 0889-048X,1572-8366 | 2020-05-24 02:00:00+02:00 | pubmed | Agriculture and Human Values | Alison Blay-Palmer;Rachel Carey;Elodie Valette;Matthew R Sanderson | 2020-05-18 02:00:00+02:00 | 32427212 | AU;FR;CA;US | 1Wilfrid Laurier University, Waterloo, Canada.;2School of Agriculture and Food, University of Melbourne, Melbourne, Australia.;3CIRAD, UMR ART-DEV, Univ Montpellier, Montpellier, France.;4Sociology, Anthropology, and Social Work, Kansas State University, Manhattan, KS USA. | 785 | |||||
| 10.1007/s00134-020-06079-2 | Case Reports;Journal Article | en | Systemic arterial thrombosis and acute mesenteric ischemia in a patient with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32424482 | 0342-4642,1432-1238 | 2020-05-24 02:00:00+02:00 | pubmed | Aorta, Thoracic__diagnostic imaging;Aortic Diseases__diagnostic imaging;Betacoronavirus;Coronavirus Infections__complications;Humans;Intestine, Small__blood supply;Mesenteric Arteries__diagnostic imaging;Mesenteric Ischemia__etiology;Middle Aged;Pandemics;Pneumonia, Viral__complications;Stroke__etiology;Thrombosis__etiology;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Eya Azouz;Sisi Yang;Laurence Monnier-Cholley;Lionel Arrivé | 2020-05-18 02:00:00+02:00 | 32424482 | FR | Hopital Saint-Antoine, Paris, France.;Hopital Saint-Antoine, Paris, France. laurence.monnier-cholley@aphp.fr. | 795 | ||||
| 10.1111/1462-2920.15053 | Journal Article | en | SARS-CoV-2 variants: Relevance for symptom granularity, epidemiology, immunity (herd, vaccines), virus origin and containment? | https://www.ncbi.nlm.nih.gov/pubmed/32367648 | The origin of the SARS-CoV-2 virus remains enigmatic. It is likely to be a continuum resulting from inevitable mutations and recombination events. These genetic changes keep developing in the present epidemic. Mutations tending to deplete the genome in its cytosine content will progressively lead to attenuation as a consequence of Muller's ratchet, but this is counteracted by recombination when different mutants co-infect the same host, in particular, in clusters of infection. Monitoring as a function of time the genome sequences in closely related cases is critical to anticipate the future of SARS-CoV-2 and hence of COVID-19. | 1462-2912,1462-2920 | 2020-05-24 02:00:00+02:00 | pubmed | Base Sequence;Betacoronavirus__genetics;Coronavirus Infections__epidemiology;Evolution, Molecular;Genes, Viral__genetics;Humans;Mutation;Pandemics;Pneumonia, Viral__epidemiology;Recombination, Genetic;Viral Vaccines__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Environmental Microbiology | Antoine Danchin;Kenneth Timmis | 2020-05-19 02:00:00+02:00 | 32367648 | FR;CN;DE;HK | Kodikos Labs, 24 rue Jean Baldassini, Lyon 69007, France.;Institut Cochin, Paris 75013, France.;School of Biomedical Sciences, Li Kashing Faculty of Medicine, University of Hong Kong, 21 Sassoon Road, SAR Hong Kong, China.;Institute of Microbiology, Technical University of Braunschweig, Braunschweig, Germany. | 797 | |||
| 10.1016/j.onehlt.2020.100141 | Editorial | en | Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32562480 | In the absence of a vaccine the medical and scientific community is looking intensely at utilizing a pre or post exposure drug that could decrease viremia. The search for a medication that could reduce risk of serious disease, and ideally of any manifestation of disease from SARS-CoV2, and of asymptomatic shedding of SARS-CoV2 is of urgent interest. Repurposing existing pharmaceuticals is among the approaches to achieve these ends. We performed a systematic review of all interventional studies registered in ClinicalTrials.gov with a focus on one repurposed drug, Hydroxychloroquine (HCQ). The detailed analysis of these studies, some of them already recruiting, provide an overall picture of HCQ use as a COVID-19 prophylaxis around the world. Among the included studies, all but three were randomized and parallel and most of them (74%, 23/31) were double-blinded to quadruple-blinded studies. We found a great diversity in dosing and nearly all the possible scientifically reasonable regimens are under evaluation. This diversity offers benefits as well as challenges. Importantly, the final analysis of these trials should be done through an extensive reading of the results in regard to the clinical design, it will be crucial to carefully read and evaluate the results of each study in regards to the clinical design rather than quickly glancing a 140 characters-based social media message announcing the failure or success of a drug against a disease. | 2352-7714 | 2020-05-24 02:00:00+02:00 | pubmed | One Health | Anne-Lise Bienvenu;Aileen M Marty;Malcolm K Jones;Stephane Picot | COVID-19;Hydroxychloroquine;Post-exposure prophylaxis;Pre-exposure prophylaxis;SARS-CoV2;clinicaltrials.gov | 2020-05-19 02:00:00+02:00 | 32562480 | FR;AU;US | Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, Lyon, France.;Univ Lyon, Malaria Research Unit, ICBMS, UMR 5246 CNRS INSA CPE, F-69100, Lyon, France.;Translational Medicine, HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami, Florida.;School of Veterinary Science, The University of Queensland, Brisbane, Qld, Australia.;Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France. | 800 | |||
| 10.1183/13993003.01028-2020 | Comparative Study;Journal Article | en | Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. | https://www.ncbi.nlm.nih.gov/pubmed/32341111 | Patients with COVID-19 present a broad spectrum of clinical presentation. Whereas hypoxaemia is the marker of severity, different strategies of management should be customised to five specific individual phenotypes. Many intubated patients present with phenotype 4, characterised by pulmonary hypoxic vasoconstriction, being associated with severe hypoxaemia with "normal" (>40 mL·cmH2O-1) lung compliance and likely representing pulmonary microvascular thrombosis. Phenotype 5 is often associated with high plasma procalcitonin and has low pulmonary compliance, Which is a result of co-infection or acute lung injury after noninvasive ventilation. Identifying these clinical phenotypes and applying a personalised approach would benefit the optimisation of therapies and improve outcomes. | 0903-1936,1399-3003 | 2020-05-24 02:00:00+02:00 | pubmed | Acute Lung Injury__physiopathology;Betacoronavirus__genetics;Biomarkers__blood;Biomedical Research;Coronavirus Infections__genetics;Disease Management;Female;Humans;Hypoxia__diagnosis;Lung Compliance__genetics;Male;Pandemics;Phenotype;Pneumonia, Viral__genetics;Procalcitonin__metabolism;SARS Virus__genetics;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Respiratory Journal | Jordi Rello;Enrico Storti;Mirko Belliato;Ricardo Serrano | 2020-05-21 02:00:00+02:00 | 32341111 | FR;ES;IT;PS | Centro de Investigación Biomedica en Red (CIBERES), Instituto de Salud Carlos III, Madrid, Spain jrello@crips.es.;CRIPS, Vall d'Hebron Institute of Research, Barcelona, Spain.;Clinical Research, CHU Nîmes, Université Montpellier-Nîmes, Nîmes, France.;Anesthesia and ICU Dept, Hospitale de Lodi, Lodi, Italy.;UOC Anestesia e Rianimazione 1, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.;Critical Care Dept, Hospital de Hellin, Albacete, Spain. | 802 | |||
| Letter | en | The outbreak of COVID-19 in Mulhouse : Hospital crisis management and deployment of military hospital during the outbreak of COVID-19 in Mulhouse, France. | https://www.ncbi.nlm.nih.gov/pubmed/32430597 | 2020-05-24 02:00:00+02:00 | pubmed | Khaldoun Kuteifan;Pierre Pasquier;Christian Meyer;Jacques Escarment;Odile Theissen | 2020-05-19 02:00:00+02:00 | 32430597 | FR | Service de Réanimation Médicale GHRMSA, Hôpital Emile Muller, Mulhouse, France. kuteifank@ghrmsa.fr.;Département d'anesthésie-réanimation, Hôpital d'instruction des armées, Clamart, France.;Ecole du Val-de-Grâce, Paris, France.;Elément Militaire de Réanimation du Service de Santé des Armées, Mulhouse, France.;Service de Réanimation Chirurgicale, GHRMSA, Hôpital Emile Muller, Mulhouse, France.;Service d'Anesthésie, GHRMSA, Hôpital Emile Muller, Mulhouse, France. | 803 | ||||||||
| 10.1016/j.lfs.2020.117836 | Journal Article;Review | en | Coronaviruses pandemics: Can neutralizing antibodies help? | https://www.ncbi.nlm.nih.gov/pubmed/32450171 | For the first time in Homo sapiens history, possibly, most of human activities is stopped by coronavirus disease 2019 (COVID-19). Nearly eight billion people of this world are facing a great challenge, maybe not "to be or not to be" yet, but unpredictable. What happens to other major pandemics in the past, and how human beings went through these hurdles? The human body is equipped with the immune system that can recognize, respond and fight against pathogens such as viruses. Following the innate response, immune system processes the adaptive response by which each pathogen is encoded and recorded in memory system. The humoral reaction containing cytokines and antibodies is expected to activate when the pathogens come back. Exploiting this nature of body protection, neutralizing antibodies have been investigated. Learning from past, in parallel to SARS-CoV-2, other coronaviruses SARS-CoV and MERS-CoV who caused previous pandemics, are recalled in this review. We here propose insights of origin and characteristics and perspective for the future of antibodies development. | 0024-3205 | 2020-05-24 02:00:00+02:00 | pubmed | Antibodies, Neutralizing__immunology;Betacoronavirus__immunology;Coronavirus Infections__immunology;Humans;Pandemics__prevention & control;Pneumonia, Viral__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Life Sciences | Phuoc-Bao-Viet Tong;Li-Yun Lin;Tuan Hiep Tran | Antibodies;COVID-19;MERS-CoV;SARS-CoV;SARS-CoV-2 | 2020-05-22 02:00:00+02:00 | 32450171 | FR;VN;US | INSERM U1109, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.;Faculty of Pharmacy, PHENIKAA University, Yen Nghia, Ha Dong, Hanoi 12116, Viet Nam, PHENIKAA Research and Technology Institute (PRATI), A&A Green Phoenix Group JSC, No.167 Hoang Ngan, Trung Hoa, Cau Giay, Hanoi 11313, Viet Nam. Electronic address: hiep.trantuan@phenikaa-uni.edu.vn. | 811 | ||
| 10.1016/j.amsu.2020.05.025 | Journal Article | en | Orthopedic healthcare in the time of COVID-19: Experience of the orthopedic surgery department at Mustapha Bacha Hospital, Algeria. | https://www.ncbi.nlm.nih.gov/pubmed/32483487 | In response to the global health emergency, which has been raised to its highest level as a consequence of the coronavirus disease 2019 (COVID-19), urgent and aggressive actions were taken by health institutions across the world to stop the spread of the disease while ensuring continuity of vital care. This article outlines the urgent measures put in place by the orthopedic surgery department at Mustapha Bacha Hospital in response to the COVID-19 pandemic. | 2049-0801 | 2020-05-24 02:00:00+02:00 | pubmed | Annals of Medicine and Surgery | Nadhir Meraghni;Riad Benkaidali;Mohamed Derradji;Zoubir Kara | COVID-19;Orthopedic surgery;Pandemic | 2020-05-23 02:00:00+02:00 | 32483487 | FR;DZ | Department of Orthopedic Surgery. Centre Hospitalier Universitaire Mustapha Bacha, Algiers, Algeria. | 813 | |||
| 10.1016/j.ebiom.2020.102801 | Journal Article | en | COVID-19 as a STING disorder with delayed over-secretion of interferon-beta. | https://www.ncbi.nlm.nih.gov/pubmed/32454408 | 2352-3964 | 2020-05-24 02:00:00+02:00 | pubmed | Animals;Betacoronavirus__isolation & purification;Chiroptera__virology;Coronavirus Infections__metabolism;Humans;Interferon Regulatory Factor-3__metabolism;Interferon-beta__metabolism;Membrane Proteins__metabolism;NF-kappa B__metabolism;Pandemics;Pneumonia, Viral__metabolism;Risk;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | EBioMedicine | Jean-Marie Berthelot;Frédéric Lioté | 2020-05-23 02:00:00+02:00 | 32454408 | FR | Rheumatology Department, Nantes University Hospital, Hôtel-Dieu, Place Alexis-Ricordeau, 44093, Nantes Cedex 01, France. Electronic address: jeanmarie.berthelot@chu-nantes.fr.;Rheumatology Department & Inserm UMR 1132 (centre Viggo Petersen), Hôpital Lariboisière, 2 rue Ambroise Paré, F-75010 Paris, Université de Paris, UFR de Médecine, F-75010 Paris, France. | 814 | ||||
| 10.1007/s00345-020-03262-4 | Published Erratum | en | Correction to: COVID-19 outbreak situation and its psychological impact among surgeons in training in France. | https://www.ncbi.nlm.nih.gov/pubmed/32447441 | In the original publication of the article, the first and last name of the first author were interchanged. The correct name of the author should be as given below. | 0724-4983,1433-8726 | 2020-05-24 02:00:00+02:00 | pubmed | World Journal of Urology | Maher Abdessater;Morgan Rouprêt;Vincent Misrai;Ugo Pinar;Xavier Matillon;Bastien Gondran-Tellier;Lucas Freton;Maxime Vallée;Inès Dominique;Margaux Felber;Zine-Eddine Khene;Edouard Fortier;François Lannes;Clément Michiels;Tristan Grevez;Nicolas Szabla;Florian Bardet;Kevin Kaulanjan;Emilien Seizilles de Mazancourt;Guillaume Ploussard;Benjamin Pradere | 2020-05-23 02:00:00+02:00 | 32447441 | FR;AT;GP | Sorbonne Université, GRC n°5, Predictive Onco-Urology, Ap-Hp, Hôpital Pitié-Salpêtrière, Urology, 75013, Paris, France.;Sorbonne Université, GRC n°5, Predictive Onco-Urology, Ap-Hp, Hôpital Pitié-Salpêtrière, Urology, 75013, Paris, France. morgan.roupret@aphp.fr.;Clinique Pasteur, 31300, Toulouse, France.;Department of Urology and Transplantation, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.;Department of Urology, La Conception University Hospital, Assistance-Publique Marseille, Marseille, France.;Department of Urology, University Hospital of Rennes, Rennes, France.;Department of Urology, Poitiers University Hospital, Poitiers, France.;Department of Urology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Department of Urology, Montpellier University Hospital, Montpellier, France.;Department of Urology, Bordeaux University Hospital, Bordeaux, France.;Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France.;Department of Urology and Transplantation, Caen University Hospital, Caen, France.;Department of Urology, Dijon University Hospital, Dijon, France.;Department of Urology, CHU Pointe à Pitre, Guadeloupe, France.;Department of Urology, Ramsay Santé, Clinique la Croix du Sud, Quint Fonsegrives, France.;Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. | 817 | ||||
| Letter;Comment | en | Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32350860 | 2020-05-24 02:00:00+02:00 | pubmed | Amides;Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Pyrazines;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Philippine Eloy;Caroline Solas;Franck Touret;France Mentré;Denis Malvy;Xavier de Lamballerie;Jérémie Guedj | 2020-05-21 02:00:00+02:00 | 32350860 | FR | Département d'Epidémiologie, Biostatistiques et Recherche Clinique, Hôpital Bichat-Claude Bernard, AP-HP.Nord Université de Paris, Paris, France.;Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-EC 1425, Hôpital Bichat-Claude Bernard, Paris, France.;APHM, Unité des Virus Émergents (UVE: IRD 190-Inserm 1207-IHU Méditerranée Infection), Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Aix Marseille University, Marseille, France.;Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.;IAME, Inserm, University of Paris, Paris, France.;Department for Infectious and Tropical Diseases, University Hospital Center of Bordeaux, Bordeaux, France.;Inserm 1219, University of Bordeaux, Bordeaux, France. | 847 | |||||||
| Letter | en | Anosmia Is a Key Symptom of COVID-19 Infection and Should Be Used as a Diagnostic Tool. | https://www.ncbi.nlm.nih.gov/pubmed/32436441 | Based on observations described in our letter, we can draw the following conclusions: (1) anosmia must imperatively be added to the list of specific symptoms of COVID-19 infection, (2) anosmia can serve as a free and specific diagnostic tool for developing countries currently affected by the pandemic, (3) the mechanisms of COVID-19 anosmia seem not to directly involve nasal obstruction but rather seem to be related to damage the olfactory neuroepithelium. | 2020-05-24 02:00:00+02:00 | pubmed | Jerome R Lechien;Maria Rosaria Barillari;Lionel Jouffe;Sven Saussez | COVID-19;anosmia;diagnostic;neuroepithelium | 2020-05-21 02:00:00+02:00 | 32436441 | FR;IT;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Otorhino-laryngological Societies (YO-IFOS), Paris, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Mental and Physical Health and Preventive Medicine, University of L. Vanvitelli, Naples, Italy.;BayesiaLab, Changé, France.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. | 857 | ||||||
| 10.1684/pnv.2020.0864 | Journal Article;Review | en | COVID-19 and cardiovascular diseases: viewpoint for older patients. | https://www.ncbi.nlm.nih.gov/pubmed/32420884 | The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The link between cardiovascular disease and COVID-19 appears to be twofold. First, some reports of data indicate that certain groups of patients are more at risk of COVID-19. This includes patients with cardiovascular risk factors or pre-existing cardiovascular conditions and older patients. In addition, these patients incur disproportionately worse outcome. Second, SARS-CoV2 infection can be complicated by life-threatening cardiovascular acute diseases. Despite the rapid evolution of data on this pandemic, this review aims to highlight the cardiovascular considerations related to COVID-19 whether as comorbidities including concerns and uncertainty regarding the effect of renin-angiotensin-aldosterone system (RAAS) inhibitors on angiotensin conversion enzyme 2 or related to acute cardiovascular complications. | 2020-05-24 02:00:00+02:00 | pubmed | Cardiovascular Agents__adverse effects;Cardiovascular Diseases__complications;Coronavirus Infections__complications;Humans;Pandemics;Pneumonia, Viral__complications;Renin-Angiotensin System__drug effects;Treatment Outcome;COVID-19 | Anne-Sophie Boureau;Laure de Decker;Gilles Berrut;Olivier Hanon | COVID-19;cardiovascular diseases;myocardial injury;older patients | 2020-05-19 02:00:00+02:00 | 32420884 | FR | Pôle de gérontologie clinique, CHU de Nantes, Nantes, France, Université de Nantes, CHU Nantes, CNRS, Inserm, Institut du thorax, Nantes, France.;Pôle de gérontologie clinique, CHU de Nantes, Nantes, France.;Service de gériatrie, Hôpital Broca, Hôpitaux universitaires Paris Centre, EA-4468 Université Paris-Descartes, Paris, France. | 859 | ||||
| 10.1093/jac/dkaa195 | Journal Article | en | Lopinavir pharmacokinetics in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32443151 | 0305-7453,1460-2091 | 2020-05-24 02:00:00+02:00 | pubmed | Journal of Antimicrobial Chemotherapy | Matthieu Gregoire;Paul Le Turnier;Benjamin J Gaborit;Gwenaelle Veyrac;Raphaël Lecomte;David Boutoille;Emmanuel Canet;Berthe-Marie Imbert;Ronan Bellouard;François Raffi | 2020-05-23 02:00:00+02:00 | 32443151 | FR | Clinical Pharmacology Laboratory Department, Nantes University Hospital, Nantes, France.;UMR INSERM 1235, The enteric nervous system in gut and brain disorders, University of Nantes, Nantes, France.;Department of Infectious Diseases, Hotel-Dieu Hospital - INSERM CIC 1413, Nantes University Hospital, Nantes, France.;Department of Pharmacovigilance, Nantes University Hospital, Nantes, France.;Intensive Care Unit, Nantes University Hospital, Nantes, France.;Virology Department, Nantes University Hospital, Nantes, France. | 860 | |||||
| 10.1016/j.critrevonc.2020.102991 | Journal Article;Systematic Review | en | COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. | https://www.ncbi.nlm.nih.gov/pubmed/32544802 | It is reasonable to think that cancer patients undergoing chemotherapy, targeted therapy or immunotherapy could have a more aggressive course if positive for Coronavirus disease CoV-2 (COVID- 19). | 1040-8428 | 2020-05-24 02:00:00+02:00 | pubmed | Antineoplastic Agents__therapeutic use;Betacoronavirus;Coronavirus Infections__drug therapy;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Critical Reviews in Oncology/Hematology | Giuseppe Di Lorenzo;Rossella Di Trolio;Zisis Kozlakidis;Giuseppina Busto;Concetta Ingenito;Luciana Buonerba;Claudia Ferrara;Annamaria Libroia;Gianluca Ragone;Concetta Dello Ioio;Beatrice Savastano;Mario Polverino;Ferdinando De Falco;Simona Iaccarino;Emilio Leo | Antiviral therapy;Cancer;Coronavirus disease SARS-CoV-2 (COVID-19);Drug-interactions;Management | 2020-05-21 02:00:00+02:00 | 32544802 | FR;IT | Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy, Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, 86100 Campobasso, Italy. Electronic address: direttoreuocpagani@gmail.com.;Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Via Mariano Semmola, Naples, Italy.;International Agency for Research on Cancer, World Health Organization, 150 cours Albert Thomas, 69372 Lyon, France.;Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. | 866 | ||
| Letter | fr | https://www.ncbi.nlm.nih.gov/pubmed/32446986 | 2020-05-24 02:00:00+02:00 | pubmed | R Amarsy;G R Pean de Ponfilly;H A Benmansour;H Jacquier;E E Cambau;B Mégarbane | COVID-19;Hospital-acquired infection;Serratia marcescens | 2020-05-21 02:00:00+02:00 | 32446986 | FR | Infection Prevention and Control Team, Lariboisière Hospital, University of Paris, Inserm IAME UMRS-1137, Paris, France.;Laboratory of Microbiology, Lariboisière Hospital, University of Paris, Inserm IAME UMRS-1137, Paris, France.;Department of Medical and Toxicological Critical Care, Lariboisière Hospital, University of Paris, Inserm UMRS-1144, Paris, France. Electronic address: bruno-megarbane@wanadoo.fr. | 870 | ||||||||
| 10.1016/j.anorl.2020.05.015 | Journal Article | en | The influenza virus, SARS-CoV-2, and the airways: Clarification for the otorhinolaryngologist. | https://www.ncbi.nlm.nih.gov/pubmed/32507410 | The influenza virus and SARS-CoV-2 cause trivial upper and severe lower respiratory infections (Influenza virus 290,000 to 650,000 deaths/year). These viruses come into contact with the airways either by direct projection, by secondary inhalation of airborne droplets, or by handling (fomites). The objective of this article is to clarify the mechanisms of production and penetration of droplets of secretions emitted during all expiratory phenomena likely to transport these viruses and come into contact with the respiratory mucosa. The droplets>5μm follow the laws of ballistics, those<5μm follow Brownian motion and remain suspended in the air. The aerosols of droplets are very heterogeneous whether the subject is healthy or sick. During an infectious period, not all droplets contain viral RNA. If these RNAs are detectable around patients, on surfaces, and in the ambient air at variable distances according to the studies (from 0.5m to beyond the patient's room), this is without prejudice to the infectious nature (viability) of the virus and the minimum infectious dose. There is a time lag between the patient's infectious period and that of RNA detection for both viruses. Subsequently, the inhaled particles must meet the laws of fluid dynamics (filtration) to settle in the respiratory tree. All of this partly explains the contagiousness and the clinical expression of these two viruses from the olfactory cleft to the alveoli. | 1879-7296 | 2020-05-31 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | L de Gabory;A Alharbi;M Kérimian;M-E Lafon | Airborne particle;COVID-19;Influenza virus;Respiratory infection;SARS-CoV-2 | 2020-05-31 02:00:00+02:00 | 32507410 | FR | Department of ENT and Head & Neck Surgery, Bordeaux University Hospital, France, University Bordeaux, 33000 Bordeaux, France. Electronic address: ludovic.de-gabory@chu-bordeaux.fr.;Department of ENT and Head & Neck Surgery, Bordeaux University Hospital, France.;Department of Virology and Biological Monitoring Unit, Bordeaux University Hospital, France. | 873 | |||
| 10.1136/bmjgh-2020-002699 | Journal Article | en | The relatively young and rural population may limit the spread and severity of COVID-19 in Africa: a modelling study. | https://www.ncbi.nlm.nih.gov/pubmed/32451367 | A novel coronavirus disease 2019 (COVID-19) has spread to all regions of the world. There is great uncertainty regarding how countries' characteristics will affect the spread of the epidemic; to date, there are few studies that attempt to predict the spread of the epidemic in African countries. In this paper, we investigate the role of demographic patterns, urbanisation and comorbidities on the possible trajectories of COVID-19 in Ghana, Kenya and Senegal. | 2059-7908 | 2020-05-31 02:00:00+02:00 | pubmed | Africa__epidemiology;Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Rural Population;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | BMJ Global Health | Binta Zahra Diop;Marieme Ngom;Clémence Pougué Biyong;John N Pougué Biyong | epidemiology;health policy | 2020-05-27 02:00:00+02:00 | 32451367 | FR;GB;US | Economics, University of Oxford, Oxford, UK bintazahra.diop@economics.ox.ac.uk.;Mathematics and Computer Science, Argonne National Laboratory, Lemont, Illinois, USA.;Economics, Université Paris 1 Panthéon-Sorbonne, Paris, Île-de-France, France.;Mathematics, University of Oxford, Oxford, UK. | 877 | ||
| Letter | en | Loss of Smell and Taste in 2013 European Patients With Mild to Moderate COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32449883 | 2020-05-31 02:00:00+02:00 | pubmed | Jerome R Lechien;Carlos M Chiesa-Estomba;Stephane Hans;Maria Rosaria Barillari;Lionel Jouffe;Sven Saussez | COVID-19;Charts;Dyspnea;Fevers;Myalgia;Neurodegenerative diseases;Smell;Surgery;Surveys;Taste | 2020-05-26 02:00:00+02:00 | 32449883 | FR;IT;BE;ES | Centre Hospitalier Universitaire Saint-Pierre (CHU de Bruxelles), Université Libre de Bruxelles, Brussels, Belgium (J.R.L.).;Hospital Universitario Donostia, San Sebastian, Spain (C.M.C.).;Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France (S.H.).;University of Campania Luigi Vanvitelli, Naples, Italy (M.R.B.).;Bayesia, Changé, France (L.J.).;University of Mons, Mons, Belgium (S.S.). | 893 | |||||||
| Letter | en | Telemedicine in nursing homes during the COVID-19 outbreak: A star is born (again). | https://www.ncbi.nlm.nih.gov/pubmed/32462676 | 2020-05-31 02:00:00+02:00 | pubmed | Asia__epidemiology;Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Nursing Homes;Pandemics;Pneumonia, Viral__epidemiology;Telemedicine__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clément Cormi;Jan Chrusciel;David Laplanche;Moustapha Dramé;Stéphane Sanchez | Covid-19;geriatrics;nursing homes;outbreak;telemedicine | 2020-05-27 02:00:00+02:00 | 32462676 | FR;MQ | Pôle Territorial Santé Publique et Performance des Hôpitaux Champagne Sud, France.;Unité de Soutien Méthodologique à la Recherche, CHU Martinique, Martinique, France.;Fondation Korian pour le Bien Vieillir, Paris, France. | 894 | ||||||
| NIGMS NIH HHS | Letter | en | 'All In': a pragmatic framework for COVID-19 testing and action on a global scale. | https://www.ncbi.nlm.nih.gov/pubmed/32375201 | Current demand for SARS-CoV-2 testing is straining material resource and labor capacity around the globe. As a result, the public health and clinical community are hindered in their ability to monitor and contain the spread of COVID-19. Despite broad consensus that more testing is needed, pragmatic guidance toward realizing this objective has been limited. This paper addresses this limitation by proposing a novel and geographically agnostic framework (the 4Ps framework) to guide multidisciplinary, scalable, resource-efficient, and achievable efforts toward enhanced testing capacity. The 4Ps (Prioritize, Propagate, Partition, and Provide) are described in terms of specific opportunities to enhance the volume, diversity, characterization, and implementation of SARS-CoV-2 testing to benefit public health. Coordinated deployment of the strategic and tactical recommendations described in this framework has the potential to rapidly expand available testing capacity, improve public health decision-making in response to the COVID-19 pandemic, and/or to be applied in future emergent disease outbreaks. | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus__genetics;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Global Health;Humans;Pandemics;Pneumonia, Viral__diagnosis;RNA, Viral__analysis;Reverse Transcriptase Polymerase Chain Reaction;Strategic Planning;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Syril D Pettit;Keith R Jerome;David Rouquié;Bernard Mari;Pascal Barbry;Yasunari Kanda;Mineo Matsumoto;Susan Hester;Leah Wehmas;Jason W Botten;Emily A Bruce | 2020-05-27 02:00:00+02:00 | 32375201 | FR;JP;US | [{"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "P30 GM118228"}] | Health and Environmental Sciences Institute, Washington, DC, USA.;Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.;SAS Bayer Crop Science, Sophia Antipolis, France.;Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne, France.;National Institute of Health Sciences, Kanagawa, Japan.;Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.;Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC, USA.;Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA. | 896 | ||||
| 10.1016/j.amp.2020.05.006 | Journal Article | en | South Africa: Challenges and successes of the COVID-19 lockdown. | https://www.ncbi.nlm.nih.gov/pubmed/32836300 | At the beginning of March 2020, South Africa (59 million inhabitants) was hit by the pandemic of COVID-19 and soon became the most affected country in Africa by the SARS-CoV-2 virus. From one single case on March 5th, the number of cases increased rapidly, forcing the South-African Government to swiftly react and place the country under strict lockdown for six weeks. The strategy of the South African Government bore fruits with a contained spread of the virus. If the number of positive cases at the end of the lockdown reached 5647, the number of fatal casualties was limited to 103 deaths. The lockdown was overall well respected, even if serious problems of food supply soon occurred in informal settlements, leading to riots and confrontation with security forces. Indeed, populations were obedient, but not being able to practice sport or outdoors activities appeared heavy. The constant fear of the poorest not to have enough money to pay rent and buy food (even if the Government organised food parcels' distributions), and to find less and less work was echoed by the fear of losing jobs among those more privileged. Despite the risk of an economic crisis, the South African Government has continued on the reasonable path of containing the pandemic with ending the lockdown at a slow pace, in five phases. | 0003-4487 | 2020-05-31 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Nancy Stiegler;Jean-Pierre Bouchard | COVID-19;Contagion;Coronavirus;Deconfinement;Epidemic;Infectious illness;Lockdown;Pandemic;SARS-CoV-2;South Africa;Violence | 2020-05-27 02:00:00+02:00 | 32836300 | FR;ZA | Statistic and Population Studies Department, Faculty of Natural Sciences, University of the Western Cape, Robert-Sobukwe road, Bellville, 7535, South Africa.;Institut Psycho-Judiciaire et de Psychopathologie (IPJP)/Institute of Forensic Psychology and Psychopathology, Cadillac hospital centre, 10, avenue Joseph-Caussil, 33410 Cadillac, France.;Unit for Difficult Patients, Cadillac hospital centre, 10, avenue Joseph-Caussil, 33410 Cadillac, France. | 897 | |||
| Letter | en | Is the paradigm of community pharmacy practice expected to shift due to COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32565052 | 2020-05-31 02:00:00+02:00 | pubmed | Muhammad Faisal Nadeem;Soumya Samanta;Fatima Mustafa | 2020-05-27 02:00:00+02:00 | 32565052 | FR;CA;PK | The University of Strasbourg, Alsace, France, Institute of Pharmaceutical Science, University of Veterinary and Animal Sciences, Pakistan. Electronic address: faisal.nadeem@uvas.edu.pk.;Alberta Health Services, Canada. Electronic address: soumyasamanta@gmail.com.;Ziauddin University, Karachi, Pakistan. Electronic address: rph.fatimamustafa@gmail.com. | 898 | ||||||||
| 10.1111/jth.14869 | Journal Article;Multicenter Study | en | High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32320517 | Coagulopathy is a common abnormality in patients with COVID-19. However, the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe COVID-19 patients. | 1538-7933,1538-7836 | 2020-05-31 02:00:00+02:00 | pubmed | Aged;Anticoagulants__therapeutic use;Betacoronavirus__pathogenicity;Blood Coagulation__drug effects;Coronavirus Infections__blood;Female;France__epidemiology;Host-Parasite Interactions;Humans;Incidence;Male;Middle Aged;Pandemics;Pneumonia, Viral__blood;Pulmonary Embolism__blood;Retrospective Studies;Risk Factors;Severity of Illness Index;Treatment Outcome;Venous Thromboembolism__blood;Venous Thrombosis__blood;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Thrombosis and Haemostasis | Jean-François Llitjos;Maxime Leclerc;Camille Chochois;Jean-Michel Monsallier;Michel Ramakers;Malika Auvray;Karim Merouani | COVID-19;SARS-CoV-2;anticoagulation;critical care;pulmonary embolism;venous thromboembolism | 2020-05-27 02:00:00+02:00 | 32320517 | FR | Institut Cochin, 3i Department, Team "Pulmonary & Systemic Immune Responses During Acute and Chronic Bacterial Infections", Paris, France.;Service de Réanimation, Soins Continus, Centre Hospitalier Mémorial France Etats-Unis, Saint-Lô, France.;Service de Réanimation, Centre Hospitalier Intercommunal Alençon Mamers, Alençon, France. | 901 | ||
| 10.2217/fon-2020-0414 | Editorial | en | Hematopoietic stem cell transplantation dilemma during the COVID-19 era. | https://www.ncbi.nlm.nih.gov/pubmed/32458703 | 1479-6694,1744-8301 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus__immunology;Coronavirus Infections__epidemiology;Donor Selection__standards;Graft Rejection__immunology;Hematopoietic Stem Cell Transplantation__adverse effects;Humans;Immunocompromised Host;Infection Control__standards;Neoplasms__immunology;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Transplantation Conditioning__adverse effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Future Oncology | Ramy Samaha;Joseph Kattan | COVID-19;coronavirus;hematology;hematopoietic stem cell transplantation;oncologist;oncology | 2020-05-27 02:00:00+02:00 | 32458703 | FR;LB | Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. | 909 | |||
| Letter | en | Autoimmune haemolytic anaemia associated with COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32374906 | 2020-05-31 02:00:00+02:00 | pubmed | Aged;Anemia, Hemolytic, Autoimmune__epidemiology;Betacoronavirus;Coronavirus Infections__complications;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gregory Lazarian;Anne Quinquenel;Mathieu Bellal;Justine Siavellis;Caroline Jacquy;Daniel Re;Fatiha Merabet;Arsene Mekinian;Thorsten Braun;Gandhi Damaj;Alain Delmer;Florence Cymbalista | B-cell lymphoproliferative disorder;COVID-19;autoimmune hemolytic anemia | 2020-05-27 02:00:00+02:00 | 32374906 | FR;BE | Hôpital Avicenne, Assistance Publique - Hôpitaux de Paris, Université Paris 13, Bobigny, France.;CHU de Reims, Hôpital Robert-Debré, Université Reims Champagne-Ardenne, Reims, France.;Centre Hospitalier Régional Universitaire, Caen, France.;CHU Ambroise Paré, Mons, Belgique.;Hôpital Général d'Antibes, Antibes, France.;Hôpital de Versailles, Université Versailles - Saint Quentin, Le Chesnay, France.;Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris, Paris, France. | 916 | ||||||
| 10.1007/s40520-020-01601-4 | Journal Article;Review | en | The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing. | https://www.ncbi.nlm.nih.gov/pubmed/32458356 | The early stages of the COVID-19 pandemic have focused on containing SARS-CoV-2 infection and identifying treatment strategies. While controlling this communicable disease is of utmost importance, the long-term effect on individuals with non-communicable diseases (NCD) is significant. Although certain NCDs appear to increase the severity of COVID-19 and mortality risk, SARS-CoV-2 infection in survivors with NCDs may also affect the progression of their pre-existing clinical conditions. Infection containment measures will have substantial short- and long-term consequences; social distancing and quarantine restrictions will reduce physical activity and increase other unhealthy lifestyles, thus increasing NCD risk factors and worsening clinical symptoms. Vitamin D levels might decrease and there might be a rise in mental health disorders. Many countries have made changes to routine management of NCD patients, e.g., cancelling non-urgent outpatient visits, which will have important implications for NCD management, diagnosis of new-onset NCDs, medication adherence, and NCD progression. We may have opportunities to learn from this unprecedented crisis on how to leverage healthcare technologies and improve procedures to optimize healthcare service provision. This article discusses how the COVID-19 outbreak and related infection control measures could hit the most frail individuals, worsening the condition of NCD patients, while further jeopardizing the sustainability of the healthcare systems. We suggest ways to define an integrated strategy that could involve both public institutional entities and the private sector to safeguard frail individuals and mitigate the impact of the outbreak. | 1720-8319 | 2020-05-31 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Chronic Disease__epidemiology;Coronavirus Infections__complications;Delivery of Health Care;Disease Outbreaks;Disease Progression;Europe__epidemiology;Frail Elderly__psychology;Frailty__complications;Healthy Aging;Humans;Infection Control;Loneliness;Noncommunicable Diseases__epidemiology;Pandemics__prevention & control;Pneumonia, Viral__complications;Prevalence;Quarantine;COVID-19;severe acute respiratory syndrome coronavirus 2 | Aging Clinical and Experimental Research | Katie Palmer;Alessandro Monaco;Miia Kivipelto;Graziano Onder;Stefania Maggi;Jean-Pierre Michel;Rita Prieto;Georgia Sykara;Shaantanu Donde | COVID-19;Chronic diseases;Coronavirus;Elderly;Frailty;NCD;SARS-coV-2 | 2020-05-26 02:00:00+02:00 | 32458356 | FR;SE;MC;FI;GR;GB;CH;IT;ES | Oliba, Rome, Italy.;Catholic University of the Sacred Heart, Rome, Italy.;HEC, 1, Rue de la Liberation Jouy en Josas, Paris, France. alessandro.monaco@hec.edu.;Division of Clinical Geriatrics, Department of NVS, Center for Alzheimer Research, Karolinska Institutet, Karolinska University Hospital, Theme Aging, Stockholm, Sweden.;Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.;Ageing and Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, UK.;Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy.;CNR-Neuroscience Institute, Aging Branch, Padua, Italy.;Department of Geriatrics and Rehabilitation, Medical University of Geneva, Geneva, Switzerland.;Pfizer GEP SLU, Upjohn, Madrid, Spain.;Medical Affairs, Upjohn Hellas Ltd (Division of Pfizer), Athens, Greece.;Upjohn (Division of Pfizer), Surrey, UK. | 931 | ||
| 10.1016/j.jemep.2020.100530 | Editorial | fr | [Signatures of the COVID-19 pandemic and the ethical tensions of our modernity]. | https://www.ncbi.nlm.nih.gov/pubmed/32835052 | 2352-5525 | 2020-05-31 02:00:00+02:00 | pubmed | Ethics, Medicine and Public Health | C Hervé;H-C Stoeklé | 2020-05-26 02:00:00+02:00 | 32835052 | FR | Hôpital Foch, Suresnes, France.;Université de Paris, Paris, France.;Académie internationale d'éthique, médecine et politique publique, université de Paris, Paris, France. | 940 | |||||
| 10.1016/j.resmer.2020.100768 | Practice Guideline | en | Respiratory support in patients with COVID-19 (outside intensive care unit). A position paper of the Respiratory Support and Chronic Care Group of the French Society of Respiratory Diseases. | https://www.ncbi.nlm.nih.gov/pubmed/32707480 | With first cases noted towards the end of 2019 in China, COVID-19 infection was rapidly become a devastating pandemic. Even if most patients present with a mild to moderate form of the disease, the estimated prevalence of COVID-19-related severe acute respiratory failure (ARF) is 15-20% and 2-12% needed intubation and mechanical ventilation. In addition to mechanical ventilation some other techniques of respiratory support could be used in some forms of COVID-19 related ARF. This position paper of the Respiratory Support and Chronic Care Group of the French Society of Respiratory Diseases is intended to help respiratory clinicians involved in care of COVID-19 pandemic in the rational use of non-invasive techniques such as oxygen therapy, CPAP, non-invasive ventilation and high flow oxygen therapy in managing patients outside intensive care unit (ICU). The aims are: (1) to focus both on the place of each technique and in describing practical tips (types of devices and circuit assemblies) aimed to limit the risk of caregivers when using those techniques at high risk spreading of viral particles; (2) to propose a step-by-step strategy to manage ARF outside ICU. | 2590-0412 | 2020-05-31 02:00:00+02:00 | pubmed | Respiratory Medicine and Research | C Rabec;J Gonzalez-Bermejo | Acute respiratory failure;COVID-19;High flow oxygen therapy;Non invasive ventilation;Oxygen | 2020-05-27 02:00:00+02:00 | 32707480 | FR | Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalier Universitaire de Dijon, 14, rue Gaffarel, 21000 Dijon, France. Electronic address: claudio.rabec@chu-dijon.fr.;Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S, Sorbonne Université, INSERM UMRS 1158 Neurophysiologie respiratoire, expérimentale et clinique, Groupe Hospitalier Universitaire AP-HP Sorbonne Université, AP-HP site Pitié-Salpêtrière, Paris, France. | 947 | |||
| NIAMS NIH HHS;NIAMS NIH HHS | 10.1136/annrheumdis-2020-217871 | Journal Article | en | Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. | https://www.ncbi.nlm.nih.gov/pubmed/32471903 | COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease. | 0003-4967,1468-2060 | 2020-05-31 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Anti-Inflammatory Agents, Non-Steroidal__therapeutic use;Antimalarials__therapeutic use;Antirheumatic Agents__therapeutic use;Arthritis, Psoriatic__complications;Arthritis, Rheumatoid__complications;Betacoronavirus;Biological Products__therapeutic use;Coronavirus Infections__complications;Female;Glucocorticoids__therapeutic use;Hospitalization__statistics & numerical data;Humans;Janus Kinase Inhibitors__therapeutic use;Lupus Erythematosus, Systemic__complications;Male;Middle Aged;Multivariate Analysis;Pandemics;Pneumonia, Viral__complications;Prednisone__therapeutic use;Protective Factors;Registries;Rheumatic Diseases__complications;Risk Factors;Severity of Illness Index;Spondylarthropathies__complications;Tumor Necrosis Factor Inhibitors__therapeutic use;Vasculitis__complications;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Annals of the Rheumatic Diseases | Milena Gianfrancesco;Kimme L Hyrich;Sarah Al-Adely;Loreto Carmona;Maria I Danila;Laure Gossec;Zara Izadi;Lindsay Jacobsohn;Patricia Katz;Saskia Lawson-Tovey;Elsa F Mateus;Stephanie Rush;Gabriela Schmajuk;Julia Simard;Anja Strangfeld;Laura Trupin;Katherine D Wysham;Suleman Bhana;Wendy Costello;Rebecca Grainger;Jonathan S Hausmann;Jean W Liew;Emily Sirotich;Paul Sufka;Zachary S Wallace;Jinoos Yazdany;Pedro M Machado;Philip C Robinson | arthritis, rheumatoid;hydroxychloroquine;lupus erythematosus, systemic;methotrexate;tumor necrosis factor inhibitors | 2020-05-29 02:00:00+02:00 | 32471903 | FR;IE;CA;NZ;PT;GB;US;AU;ES;DE | [{"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "K01 AR075085"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "P30 AR070155"}] | Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.;Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.;National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.;Instituto de Salud Musculoesquelética, Madrid, Spain.;Division of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.;Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.;APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France.;Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK.;Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.;Health Research & Policy, Division of Epidemiology and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California, USA.;Forschungsbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.;University of Washington, Seattle, Washington, USA.;Crystal Run Healthcare, Middletown, New York, USA.;Irish Children's Arthritis Network (iCAN), Tipperary, Ireland.;Department of Medicine, University of Otago, Wellington, New Zealand.;Boston Children's Hospital, Boston, Massachusetts, USA.;Harvard Medical School, Boston, Massachusetts, USA.;Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.;Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.;Healthpartners, St Paul, Minnesota, USA.;Massachusetts General Hospital, Boston, Massachusetts, USA.;Centre for Rheumatology & Department of Neuromuscular Diseases, University College London (UCL), London, UK.;University College London Hospitals (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), London, UK.;Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK.;Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia philip.robinson@uq.edu.au.;Metro North Hospital & Health Service, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia. | 954 |
| Journal Article;Comment | en | Why not use the Easybreath snorkeling mask to prevent COVID-19 transmission during endoscopy procedures when FFP2 are lacking? | https://www.ncbi.nlm.nih.gov/pubmed/32483789 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Endoscopy;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jérôme Rivory;Éric Beaugendre;Claire Yvon;Fréderic Ploteau;Bertrand Condat;Florian Rostain;Mathieu Pioche | 2020-05-29 02:00:00+02:00 | 32483789 | FR | Department of Endoscopy and Gastroenterology, French Polynesia Hospital, Papeete, French Polynesia.;Department of Endoscopy and Gastroenterology, Pavillon L, Edouard Herriot Hospital, Lyon, France.;Inserm U1032 LabTau, Lyon, France. | 958 | |||||||
| 10.1016/j.retram.2020.05.004 | Journal Article;Review | en | A review of potential treatments to date in COVID-19 patients according to the stage of the disease. | https://www.ncbi.nlm.nih.gov/pubmed/32540367 | Since the end of 2019, the COVID-19 pandemic has affected millions of people worldwide. With the rapid spread of this virus, an immense burden has fallen upon both healthcare and economic systems. As a consequence, there is an unprecedented urgency for researchers and scientific committees from all over the world to find an effective treatment and vaccine. | 2452-3186 | 2020-05-31 02:00:00+02:00 | pubmed | Current Research in Translational Medicine | Tamim Alsuliman;Lugien Alasadi;Banan Alkharat;Micha Srour;Ali Alrstom | COVID-19;Pathophysiology;Treatment | 2020-05-30 02:00:00+02:00 | 32540367 | FR;SY | Service d'Hématologie, hôpital Saint-Antoine, AP-HP, Sorbonne Université, 75012, Paris, France. Electronic address: dr.tameem.soliman@gmail.com.;Department of Gastroenterology and Hepatology, Damascus University, Faculty of Medicine, Damascus, Syria. Electronic address: lugienalasadi@gmail.com.;Department of Infectious Diseases, Damascus University, Faculty of Medicine, Damascus, Syria. Electronic address: Banankharat88@hotmail.com.;Service maladie du sang, centre hospitalier universitaire de Lille, 59000, Lille, France. Electronic address: micha.srour@chru-lille.fr.;Department of Infectious Diseases, Damascus University, Faculty of Medicine, Damascus, Syria. Electronic address: Ali.alrstom@spu.edu.sy. | 960 | |||
| 10.1007/s11739-020-02379-z | Journal Article | en | Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. | https://www.ncbi.nlm.nih.gov/pubmed/32474850 | Clinical features of COVID-19 have been mostly described in hospitalized patients with and without ICU admission. Yet, up to 80% of patients are managed in an outpatient setting. This population is poorly documented. In France, health authorities recommend outpatient management of patients presenting mild-to-moderate COVID-19 symptoms. The aim of this study was to describe their clinical characteristics. The study took place in an emergency medical dispatching center located in the Greater Paris region. Patients included in this survey met confirmed COVID-19 infection criteria according to the WHO definition. We investigated clinical features and classified symptoms as general, digestive, ear-nose-throat, thoracic symptoms, and eye disease. Patients were included between March 24 and April 6 2020. 1487 patients included: 700 (47%) males and 752 (51%) females, with a median age of 44 (32-57) years. In addition to dry cough and fever reported in more than 90% of cases, the most common symptoms were general symptoms: body aches/myalgia (N = 845; 57%), headache (N = 824; 55%), and asthenia (N = 886; 60%); shortness of breath (N = 479; 32%) and ear-nose-throat symptoms such as anosmia (N = 415; 28%) and ageusia (N = 422; 28%). Chest pain was reported in 320 (21%) cases and hemoptysis in 41 (3%) cases. The main difference between male and female patients was an increased prevalence of ear-nose-throat symptoms as well as diarrhea, chest pains, and headaches in female patients. General symptoms and ear-nose-throat symptoms were predominant in COVID-19 patients presenting mild-to-moderate symptoms. Shortness of breath and chest pain were remarkably frequent. | 1828-0447,1970-9366 | 2020-05-31 02:00:00+02:00 | pubmed | Internal and Emergency Medicine | Frédéric Lapostolle;Elodie Schneider;Isabelle Vianu;Guillaume Dollet;Bastien Roche;Julia Berdah;Julie Michel;Laurent Goix;Erick Chanzy;Tomislav Petrovic;Frédéric Adnet | COVID-19;Clinical feature;Epidemic;Out-patient | 2020-05-30 02:00:00+02:00 | 32474850 | FR | SAMU 93-UF Recherche-Enseignement-Qualité, Université Paris 13, Sorbonne Paris Cité, Inserm U942, Hôpital Avicenne, 125, rue de Stalingrad, 93009, Bobigny, France. frederic.lapostolle@aphp.fr.;SAMU 93-UF Recherche-Enseignement-Qualité, Université Paris 13, Sorbonne Paris Cité, Inserm U942, Hôpital Avicenne, 125, rue de Stalingrad, 93009, Bobigny, France. | 968 | |||
| 10.1111/ajt.16082 | Journal Article | en | Strategies for liver transplantation during the SARS-CoV-2 outbreak: Preliminary experience from a single center in France. | https://www.ncbi.nlm.nih.gov/pubmed/32476233 | Liver transplantation (LT) during the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is challenging given the urgent need to reallocate resources to other areas of patient care. Available guidelines recommend reorganizing transplant care, but data on clinical experience in the context of SARS-CoV-2 pandemic are scarce. Thus, we report strategies and preliminary results in LT during the peak of the SARS-CoV-2 pandemic from a single center in France. Our strategy to reorganize the transplant program included 4 main steps: optimization of available resources, especially intensive care unit capacity; multidisciplinary risk stratification of LT candidates on the waiting list; implementation of a systematic SARS-CoV-2 screening strategy prior to transplantation; and definition of optimal recipient-donor matching. After implementation of these 4 steps, we performed 10 successful LTs during the peak of the pandemic with a short median intensive care unit stay (2.5 days), benchmark posttransplant morbidity, and no occurrence of SARS-CoV-2 infection during follow-up. From this preliminary experience we conclude that efforts in resource planning, optimal recipient selection, and organ allocation strategy are key to maintain a safe LT activity. Transplant centers should be ready to readapt their practices as the pandemic evolves. | 1600-6135,1600-6143 | 2020-05-31 02:00:00+02:00 | pubmed | American Journal of Transplantation | Xavier Muller;Gilles Tilmans;Quentin Chenevas-Paule;Fanny Lebossé;Teresa Antonini;Domitille Poinsot;Agnès Rode;Céline Guichon;Zoé Schmitt;Christian Ducerf;Kayvan Mohkam;Mickaël Lesurtel;Jean-Yves Mabrut | cancer/malignancy/neoplasia;clinical decision-making;clinical research/practice;diagnostic techniques and imaging;infection and infectious agents - viral;liver transplantation/hepatology;organ procurement and allocation;risk assessment/risk stratification | 2020-05-31 02:00:00+02:00 | 32476233 | FR | Department of Digestive Surgery and Transplantation, University Hospital Croix Rousse, Hospices Civils de Lyon, University of Lyon I, Lyon, France.;Department of Hepatology, University Hospital Croix Rousse, Hospices Civils de Lyon, University of Lyon I, Lyon, France.;Department of Radiology, University Hospital Croix Rousse, Hospices Civils de Lyon, University of Lyon I, Lyon, France.;Department of Intensive Care, University Hospital Croix Rousse, Hospices Civils de Lyon, University of Lyon I, Lyon, France.;Clinical Research Center of Lyon, INSERM Unit 1052, Lyon, France. | 971 | |||
| Letter | en | The association between laryngopharyngeal reflux and COVID-19 is still not demonstrated. | https://www.ncbi.nlm.nih.gov/pubmed/32462666 | 2020-05-31 02:00:00+02:00 | pubmed | Jerome R Lechien;Emmanuel Bartaire;Francois Bobin;Stephane Hans;Sven Saussez | 2020-05-28 02:00:00+02:00 | 32462666 | FR;BE | Research Committee, COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.;Research Committee, Reflux Study Group of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otolaryngology-Head & Neck Surgery, School of Medicine, Foch Hospital, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology and Head and Neck Surgery, Faculté Libre de Médecine de Lille, GHICL Saint-Vincent-de-Paul Hospital, Lille, France.;Department of Otolaryngology-Head and Neck Surgery, Polyclinique de Poitiers, Poitiers, France. | 981 | ||||||||
| Letter;Comment | en | SARS-CoV-2 as a protective factor for cardiovascular mortality? | https://www.ncbi.nlm.nih.gov/pubmed/32527466 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Cardiovascular Diseases;Coronavirus Infections;Healthy Lifestyle;Humans;Inflammation;Pandemics;Pneumonia, Viral;Protective Factors;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Frédéric Dutheil;Marion Trousselard;Valentin Navel | 2020-05-28 02:00:00+02:00 | 32527466 | FR | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, F-63000, Clermont-Ferrand, France. Electronic address: fdutheil@chu-clermontferrand.fr.;French Armed Forces Biomedical Research Institute-IRBA, Neurophysiology of Stress, Neuroscience and Operational Constraint Department, F-91000, Brétigny-sur-Orge, France.;Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, F-63000, Clermont-Ferrand, France. | 984 | |||||||
| 10.3389/fimmu.2020.01229 | Journal Article;Review | en | Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets? | https://www.ncbi.nlm.nih.gov/pubmed/32574272 | COVID-19 is caused by the Severe Acute Respiratory Syndrome (SARS) coronavirus (Cov)-2, an enveloped virus with a positive-polarity, single-stranded RNA genome. The initial outbreak of the pandemic began in December 2019, and it is affecting the human health of the global community. In common with previous pandemics (Influenza H1N1 and SARS-CoV) and the epidemics of Middle east respiratory syndrome (MERS)-CoV, CoVs target bronchial and alveolar epithelial cells. Virus protein ligands (e.g., haemagglutinin or trimeric spike glycoprotein for Influenza and CoV, respectively) interact with cellular receptors, such as (depending on the virus) either sialic acids, Dipeptidyl peptidase 4 (DPP4), or angiotensin-converting enzyme 2 (ACE2). Host proteases, e.g., cathepsins, furin, or members of the type II transmembrane serine proteases (TTSP) family, such as Transmembrane protease serine 2 (TMPRSS2), are involved in virus entry by proteolytically activating virus ligands. Also involved are Toll Like Receptor (TLR) family members, which upregulate anti-viral and pro-inflammatory mediators [interleukin (IL)-6 and IL-8 and type I and type III Interferons among others], through the activation of Nuclear Factor (NF)-kB. When these events (virus cellular entry and innate immune responses) are uncontrolled, a deleterious systemic response is sometimes encountered in infected patients, leading to the well-described "cytokine storm" and an ensuing multiple organ failure promoted by a downregulation of dendritic cell, macrophage, and T-cell function. We aim to describe how the lung and systemic host innate immune responses affect survival either positively, through downregulating initial viral load, or negatively, by triggering uncontrolled inflammation. An emphasis will be put on host cellular signaling pathways and proteases involved with a view on tackling these therapeutically. | 1664-3224 | 2020-05-31 02:00:00+02:00 | pubmed | Animals;Antiviral Agents__therapeutic use;Betacoronavirus__immunology;Coronavirus Infections__drug therapy;Drug Delivery Systems;Epithelial Cells__virology;Humans;Immunity, Innate;Lung__immunology;Mice;Myeloid Cells__virology;Pandemics;Pneumonia, Viral__drug therapy;Receptors, Cell Surface__metabolism;Receptors, Virus__metabolism;Serine Proteases__metabolism;Signal Transduction;Virus Internalization;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Frontiers in Immunology | Jean-Michel Sallenave;Loïc Guillot | COVID-19;SARS-CoV-2;coronavirus;lung innate immunity;protease | 2020-05-28 02:00:00+02:00 | 32574272 | FR | INSERM UMR1152, Laboratoire d'Excellence Inflamex, Faculté de Médecine, Hôpital Bichat, Université de Paris, Paris, France.;Sorbonne Université, INSERM UMR S 938, Centre de Recherche Saint-Antoine (CRSA), Paris, France. | 985 | ||
| 10.1016/j.meegid.2020.104384 | Journal Article;Review | en | SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective. | https://www.ncbi.nlm.nih.gov/pubmed/32473976 | In less than five months, COVID-19 has spread from a small focus in Wuhan, China, to more than 5 million people in almost every country in the world, dominating the concern of most governments and public health systems. The social and political distresses caused by this epidemic will certainly impact our world for a long time to come. Here, we synthesize lessons from a range of scientific perspectives rooted in epidemiology, virology, genetics, ecology and evolutionary biology so as to provide perspective on how this pandemic started, how it is developing, and how best we can stop it. | 1567-1348 | 2020-05-31 02:00:00+02:00 | pubmed | Infection, Genetics and Evolution | Manuela Sironi;Seyed E Hasnain;Benjamin Rosenthal;Tung Phan;Fabio Luciani;Marie-Anne Shaw;M Anice Sallum;Marzieh Ezzaty Mirhashemi;Serge Morand;Fernando González-Candelas | Coevolution;Coronavirus;Host susceptibility;Immune system;Pandemics;Phylodynamics | 2020-05-29 02:00:00+02:00 | 32473976 | FR;GB;US;BR;IT;AU;ES;IN | Bioinformatics Unit, Scientific Institute IRCCS E. MEDEA, Bosisio Parini (LC), Italy. Electronic address: manu.sir@gmail.com.;JH Institute of Molecular Medicine, Jamia Hamdard, Tughlakabad, New Delhi, India. Electronic address: seyedhasnain@gmail.com.;Animal Parasitic Disease Laboratory, Agricultural Research Service, United States Department of Agriculture, Beltsville, MD, USA. Electronic address: benjamin.rosenthal@ars.usda.gov.;Division of Clinical Microbiology, University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: phantg@upmc.edu.;University of New South Wales, Sydney, 2052, New South Wales, Australia. Electronic address: luciani@unsw.edu.anu.;Leeds Institute of Medical Research at St James's, School of Medicine, University of Leeds, Leeds, United Kingdom. Electronic address: genmas@leeds.ac.uk.;Departamento de Epidemiologia, Faculdade de Saúde Pública, Universidade de São Paulo, São Paulo, Brazil. Electronic address: masallum@usp.br.;University of Massachusetts Medical School, Worcester, MA 01655-0112, USA. Electronic address: Marzieh.Mirhashemi@umassmed.edu.;Institute of Evolution Science of Montpellier, Case Courier 064, F-34095 Montpellier, France. Electronic address: serge.morand@univ-montp2.fr.;Joint Research Unit Infection and Public Health FISABIO-University of Valencia, Institute for Integrative Systems Biology (I2SysBio) and CIBER in Epidemiology and Public Health, Valencia, Spain. Electronic address: fernando.gonzalez@uv.es. | 986 | |||
| 10.1007/s10096-020-03930-8 | Journal Article | en | The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis? | https://www.ncbi.nlm.nih.gov/pubmed/32462501 | Several commercial assays for SARS-CoV-2 RT-PCR are available but few of them were assessed. We evaluate the Allplex 2019-nCoV (Seegene) assay using 41 nasopharyngeal samples. The rates of agreement were 92.7% and 100% with the GeneFinder COVID-19 plus (Elitech) and the diagnosis of the infectious disease specialist respectively. Four samples display a Ct < 22.0 for the E and RdRp genes while the N gene was not detected, suggesting a variability of the viral sequence. There was no cross-reactivity with other respiratory viruses. The Allplex 2019-nCoV appears as a reliable method, but additional evaluations using more samples are needed. RT-PCR assays should probably include at least 2 viral targets. | 0934-9723,1435-4373 | 2020-05-31 02:00:00+02:00 | pubmed | European Journal of Clinical Microbiology & Infectious Diseases | Eric Farfour;Philippe Lesprit;Benoit Visseaux;Tiffany Pascreau;Emilie Jolly;Nadira Houhou;Laurence Mazaux;Marianne Asso-Bonnet;Marc Vasse | Allplex 2019-nCoV (Seegene);COVID-19;Nasopharyngeal swab;RT-PCR;SARS-CoV-2;Sensitivity | 2020-05-28 02:00:00+02:00 | 32462501 | FR | Service de biologie Clinique, Hôpital Foch, Suresnes, France. e.farfour@hopital-foch.org.;Service de biologie Clinique, Hôpital Foch, Suresnes, France.;Service de virologie, Hôpital Bichat, Saint-Ouen, France. | 988 | |||
| Case Reports;Letter | en | Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32462329 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Female;Humans;Middle Aged;Pandemics;Pneumonia, Viral__complications;Purpura, Thrombotic Thrombocytopenic__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nil Albiol;Rahinatu Awol;Rodrigo Martino | 2020-05-28 02:00:00+02:00 | 32462329 | FR;ES | Hematology Department, Hospital de la Santa Creu i Sant Pau, Carrer del Mas Casanovas, 90, 08041, Barcelona, Spain. nalbiol@santpau.cat.;Hematology Department, Hospital de la Santa Creu i Sant Pau, Carrer del Mas Casanovas, 90, 08041, Barcelona, Spain. | 989 | |||||||
| 10.1016/j.chest.2020.05.551 | Editorial | en | Key Highlights From the Canadian Thoracic Society Position Statement on the Optimization of Asthma Management During the Coronavirus Disease 2019 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32473948 | 0012-3692 | 2020-05-31 02:00:00+02:00 | pubmed | Chest | Christopher Licskai;Connie L Yang;Francine M Ducharme;Dhenuka Radhakrishnan;Delanya Podgers;Clare Ramsey;Tania Samanta;Andréanne Côté;Masoud Mahdavian;M Diane Lougheed | COVID-19;Canadian Thoracic Society;asthma | 2020-05-28 02:00:00+02:00 | 32473948 | FR;CA;GB;US | Department of Medicine, Western University, London, ON, Canada. Electronic address: chris.licskai@sjhc.london.on.ca.;Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.;Department of Pediatrics and the Department of Social and Preventive Medicine, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, QC, Canada.;Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.;Kingston Health Sciences Centre-Kingston General Hospital, Kingston, ON, Canada.;Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.;Department of Pediatrics, North York General Hospital, University of Toronto, Toronto, ON, Canada.;Department of Pulmonary Medicine and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Québec, QC, Canada.;Department of Medicine, Royal Victoria Regional Health Centre, Barrie, ON, Canada.;Department of Medicine, Queen's University, Kingston, ON, Canada. | 993 | ||||
| Letter;Comment | en | Uncertainties on the prognostic value of D-dimers in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32344457 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Fibrin Fibrinogen Degradation Products;Hospital Mortality;Humans;Pandemics;Pneumonia, Viral;Prognosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean-Christophe Gris;Isabelle Quéré;Antonia Pérez-Martin;Jean-Yves Lefrant;Albert Sotto | 2020-05-28 02:00:00+02:00 | 32344457 | FR;RU | Department of Haematology, Nîmes University Hospital, Nîmes, France.;University of Montpellier, Montpellier, France.;I.M. Sechenov First Moscow State Medical University, Moscow, Russia.;Department of Vascular Medicine, Montpellier University Hospital, Montpellier, France.;Department of Vascular Investigations and Vascular Medicine, Nîmes University Hospital, Nîmes, France.;Department of Intensive Care, Nîmes University Hospital, Nîmes, France.;Department of Infectious and Tropical Diseases, Nîmes University Hospital, Nîmes, France. | 1004 | |||||||
| 10.1016/j.etiqe.2020.05.003 | English Abstract;Journal Article | fr | [What's the covid's name?] | https://www.ncbi.nlm.nih.gov/pubmed/32837542 | The massive irruption of Covid-19 expression in the hospital environment as well as in our lives has brought to light a strange analogy between the expansion of a virus and viral dissemination, too, in a way of speaking and naming for action. This article proposes to question the impact of the expression Covid-19 on the language of caregivers. It proposes to discuss the ethical dimension of a care of care words when a way of speaking imposes itself on them. It also questions the epistemological and ethical pluralism involving medicine between science, clinical and politics. | 1765-4629 | 2020-05-31 02:00:00+02:00 | pubmed | Éthique & Santé | J-P Pierron | Acronym;Covid-19;Ethics;Language | 2020-05-28 02:00:00+02:00 | 32837542 | FR | UMR LIR3S, laboratoire interdisciplinaire de recherches soin sensibilités et sociétés, université de Bourgogne, boulevard Gabriel, 21000 Dijon, France. | 1005 | |||
| 10.1093/eurheartj/ehaa461 | Consensus Development Conference;Journal Article;Practice Guideline | en | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). | https://www.ncbi.nlm.nih.gov/pubmed/32498081 | The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, consequently, for the trials themselves. Patients with heart failure may be at greater risk of infection with COVID-19 and the consequences might also be more serious, but they are also at risk of adverse outcomes if their clinical care is compromised. As physicians and clinical trialists, it is our responsibility to ensure safe and effective care is delivered to trial participants without affecting the integrity of the trial. The social contract with our patients demands no less. Many regulatory authorities from different world regions have issued guidance statements regarding the conduct of clinical trials during this COVID-19 crisis. However, international trials may benefit from expert guidance from a global panel of experts to supplement local advice and regulations, thereby enhancing the safety of participants and the integrity of the trial. Accordingly, the Heart Failure Association of the European Society of Cardiology on 21 and 22 March 2020 conducted web-based meetings with expert clinical trialists in Europe, North America, South America, Australia, and Asia. The main objectives of this Expert Position Paper are to highlight the challenges that this pandemic poses for the conduct of clinical trials in heart failure and to offer advice on how they might be overcome, with some practical examples. While this panel of experts are focused on heart failure clinical trials, these discussions and recommendations may apply to clinical trials in other therapeutic areas. | 0195-668X,1522-9645 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Trials as Topic__ethics;Coronavirus Infections;Europe;Heart Failure__complications;Humans;Informed Consent__ethics;Pandemics;Patient Safety;Patient Selection__ethics;Pneumonia, Viral;Research Design__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Heart Journal | Stefan D Anker;Javed Butler;Muhammad Shahzeb Khan;William T Abraham;Johann Bauersachs;Edimar Bocchi;Biykem Bozkurt;Eugene Braunwald;Vijay K Chopra;John G Cleland;Justin Ezekowitz;Gerasimos Filippatos;Tim Friede;Adrian F Hernandez;Carolyn S P Lam;JoAnn Lindenfeld;John J V McMurray;Mandeep Mehra;Marco Metra;Milton Packer;Burkert Pieske;Stuart J Pocock;Piotr Ponikowski;Giuseppe M C Rosano;John R Teerlink;Hiroyuki Tsutsui;Dirk J Van Veldhuisen;Subodh Verma;Adriaan A Voors;Janet Wittes;Faiez Zannad;Jian Zhang;Petar Seferovic;Andrew J S Coats | COVID-19;Clinical trials;Coronavirus;Heart failure | 2020-06-05 02:00:00+02:00 | 32498081 | FR;SG;CA;CN;GR;JP;GB;US;BR;IT;PL;NL;RS;IN;DE | Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Germany.;Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.;Department of Medicine, Cook County Hospital, Chicago, IL, USA.;Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA.;Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.;Division of Cardiology, Sâo Paulo University Medical School, São Paulo, Brazil.;Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX, USA.;Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.;Department of Cardiology, Max Super Speciality Hospital, Saket, New Delhi, India.;Robertson Centre for Biostatistics & Clinical Trials, University of Glasgow, Lanarkshire, UK.;Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.;National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.;Department of Medical Statistics, University Medical Center Goettingen, and German Centre for Cardiovascular Research (DZHK), partner site Goettingen, Goettingen, Germany.;Division of Cardiology, Duke University Medical Center, Durham, NC, USA.;National Heart Centre Singapore, Duke-National University of Singapore, Singapore.;Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.;Vanderbilt Heart and Vascular Institute, Nashville, TN, USA.;BHF Cardiovascular Research Center, University of Glasgow, Glasgow, UK.;Heart and Vascular Center, Brigham and Women's Hospital, Boston, MA, USA.;Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.;Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.;Department of Internal Medicine and Cardiology, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Department of Internal Medicine and Cardiology, German Heart Center Berlin, and German Centre for Cardiovascular Research (DZHK), Partner site Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.;London School of Hygiene and Tropical Medicine, London, UK.;Department of Heart Disease, University Hospital, Medical University, Wrocław, Poland.;IRCCS San Raffaele Pisana, Rome, Italy.;St George's Medical School, London, UK.;Section of Cardiology, San Francisco Veterans Affairs Medical Center, School of Medicine, University of California, San Francisco, San Francisco, CA, USA.;Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.;Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Canada.;Statistics Collaborative, Inc., Washington, DC, USA.;Centre d'Investigation Clinique-Plurithématique INSERM CIC-P 1433, and INSERM U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.;Heart Failure Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China.;University of Belgrade Faculty of Medicine, Serbian Academy of Sciences and Arts, Belgrade, Serbia.;San Raffaele Pisana Scientific Institute, Rome, Italy. | 1010 | ||
| Letter;Comment | en | The association between D-dimers in COVID-19 patients and mortality remains beset of uncertainties. | https://www.ncbi.nlm.nih.gov/pubmed/32495985 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Fibrin Fibrinogen Degradation Products;Humans;Lupus Coagulation Inhibitor;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean-Christophe Gris;Paul Loubet;Claire Roger;Eva Cochery-Nouvellon;Jean-Marc Mauboussin;Laurent Muller;Sylvie Bouvier;Didier Laureillard;Saber Davide Barbar;Érick Mercier;Jean-Yves Lefrant;Albert Sotto | 2020-06-05 02:00:00+02:00 | 32495985 | FR;RU | Department of Haematology, CHU Nîmes, University Montpellier, Nîmes, France.;Research Laboratory EA 2992, Montpellier University, Nîmes, France.;Faculty of Pharmaceutical and Biological Sciences, Montpellier University, Nîmes, France.;I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.;Department of Infectious and Tropical Diseases, CHU Nîmes, University Montpellier, Nîmes, France.;Department of Anaesthesiology, Critical Care and Emergency Medicine, CHU Nîmes, University Montpellier, Nîmes, France. | 1011 | |||||||
| 10.1080/22221751.2020.1766382 | Journal Article | en | Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. | https://www.ncbi.nlm.nih.gov/pubmed/32476607 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide since it was confirmed as the causative agent of COVID-19. Molecular diagnosis of the disease is typically performed via nucleic acid-based detection of the virus from swabs, sputum or bronchoalveolar lavage fluid (BALF). However, the positive rate from the commonly used specimens (swabs or sputum) was less than 75%. Immunological assays for SARS-CoV-2 are needed to accurately diagnose COVID-19. Sera were collected from patients or healthy people in a local hospital in Xiangyang, Hubei Province, China. The SARS-CoV-2 specific IgM antibodies were then detected using a SARS-CoV-2 IgM colloidal gold immunochromatographic assay (GICA). Results were analysed in combination with sera collection date and clinical information. The GICA was found to be positive with the detected 82.2% (37/45) of RT-qPCR confirmed COVID-19 cases, as well as 32.0% (8/25) of clinically confirmed, RT-qPCR negative patients (4-14 days after symptom onset). Investigation of IgM-negative, RT-qPCR-positive COVID-19 patients showed that half of them developed severe disease. The GICA was found to be a useful test to complement existing PCR-based assays for confirmation of COVID-19, and a delayed specific IgM antibody response was observed among COVID-19 patients with severe progression. | 2222-1751 | 2020-06-07 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Antibodies, Viral__blood;Antibody Formation;Betacoronavirus;Child;China;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Disease Progression;Female;Humans;Immunoassay;Immunoglobulin M__blood;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;Real-Time Polymerase Chain Reaction;Young Adult;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Emerging Microbes & Infections | Liang Shen;Chunhua Wang;Jianzhong Zhao;Xiaoyong Tang;Ying Shen;Mingqing Lu;Zhe Ding;Canping Huang;Ji Zhang;Shichao Li;Jiaming Lan;Gary Wong;Yufang Zhu | COVID-19;GICA;IgM antibody;delayed;severity | 2020-06-02 02:00:00+02:00 | 32476607 | FR;CN;CA | Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, People's Republic of China.;CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People's Republic of China.;Department of Microbiology-Infectiology and Immunology, Laval University, Quebec City, Canada. | 1017 | ||
| 10.21873/invivo.11956 | Comparative Study;Journal Article | en | Endoplasmic Reticulum Stress Markers in SARS-COV-2 Infection and Pneumonia: Case-Control Study. | https://www.ncbi.nlm.nih.gov/pubmed/32503824 | A novel human coronavirus, named SARS-COV-2, has recently caused thousands of deaths all around the world. Endoplasmic reticulum (ER) stress plays an important role in the development of diseases. | 0258-851X,1791-7549 | 2020-06-07 02:00:00+02:00 | pubmed | Biomarkers;Case-Control Studies;Coronavirus Infections__blood;Endoplasmic Reticulum Stress;Enzyme-Linked Immunosorbent Assay;Female;Heat-Shock Proteins__blood;Humans;Male;Pandemics;Pneumonia__blood;Pneumonia, Viral__blood;Transcription Factor CHOP__blood;eIF-2 Kinase__blood;COVID-19 | In Vivo | Aylin Köseler;Ramazan Sabirli;Tarik Gören;Ibrahim Türkçüer;Özgür Kurt | Endoplasmic reticulum stress;GRP78;SARS-COV-2;pneumonia | 2020-06-07 02:00:00+02:00 | 32503824 | FR;TR | Department of Biophysics, Pamukkale University Faculty of Medicine, Denizli, Turkey akoseler@pau.edu.tr.;Department of Emergency Medicine, Kafkas University Faculty of Medicine, Kars, Turkey.;Department of Emergency Medicine, Pamukkale University Faculty of Medicine, Denizli, Turkey.;Department of Microbiology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey. | 1019 | ||
| 10.1016/j.surg.2020.05.033 | Journal Article;Multicenter Study | en | Is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present intraperitoneally in patients with coronavirus disease 2019 (COVID-19) infection undergoing emergency operations? | https://www.ncbi.nlm.nih.gov/pubmed/32591139 | 0039-6060 | 2020-06-07 02:00:00+02:00 | pubmed | Adult;Aged;Ascitic Fluid__virology;Betacoronavirus__genetics;Cohort Studies;Coronavirus Infections__diagnosis;Digestive System Diseases__surgery;Digestive System Surgical Procedures;Emergencies;Female;Humans;Intraoperative Period;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;RNA, Viral__genetics;Reverse Transcriptase Polymerase Chain Reaction;COVID-19;severe acute respiratory syndrome coronavirus 2 | Surgery | Barbara Seeliger;Guillaume Philouze;Ilies Benotmane;Didier Mutter;Patrick Pessaux | 2020-06-05 02:00:00+02:00 | 32591139 | FR | IHU-Strasbourg, Institute of Image-Guided Surgery, Strasbourg, France, IRCAD, Research Institute against Digestive Cancer, Strasbourg, France, Department of General, Digestive, and Endocrine Surgery, University Hospital of Strasbourg, Strasbourg, France. Electronic address: barbara.seeliger@ihu-strasbourg.eu.;Department of General, Digestive, and Endocrine Surgery, University Hospital of Strasbourg, Strasbourg, France.;Department of Virology, University Hospital of Strasbourg, Strasbourg, France.;IHU-Strasbourg, Institute of Image-Guided Surgery, Strasbourg, France, IRCAD, Research Institute against Digestive Cancer, Strasbourg, France, Department of General, Digestive, and Endocrine Surgery, University Hospital of Strasbourg, Strasbourg, France. | 1024 | ||||
| 10.1016/j.rmr.2020.06.002 | Practice Guideline | fr | [Lung function testing under COVID-19: A position paper]. | https://www.ncbi.nlm.nih.gov/pubmed/32600900 | 0761-8425 | 2020-06-07 02:00:00+02:00 | pubmed | Revue des Maladies Respiratoires | L Plantier;F Costes | 2020-06-05 02:00:00+02:00 | 32600900 | FR | Service de pneumologie et explorations fonctionnelles respiratoires, CHRU de Tours, hôpital Bretonneau, 2, boulevard Tonnellé, 37044 Tours cedex 9, France, CEPR/Inserm UMR1100, université de Tours, Tours, France. Electronic address: laurent.plantier@univ-tours.fr.;Service de médecine du sport et explorations fonctionnelles, CHU de Clermont-Ferrand, Clermont-Ferrand, France, INRAE, UNH, Université Clermont-Auvergne, Clermont-Ferrand, France. | 1032 | |||||
| 10.1016/j.amp.2020.06.002 | English Abstract;Journal Article | fr | [Phone sessions in Covid-19 environment: The frame and his limits]. | https://www.ncbi.nlm.nih.gov/pubmed/32836301 | To deal with the Covid 19 pandemic, health protection measures require changes to our clinical practices. Faced up with the unprecedented nature of this situation, the liberal psychotherapist is led to rethink some aspects of the framework of his practice in order to preserve the thread of the transferential relationship. The authors develop a clinical reflection on the clinical setting in a pandemic period by exploring in particular the dynamics of telephone sessions. For telephone interviews, the question of the sound envelope is central, in particular regarding the psychic function of silence. We choose to illustrate our point with short vignettes than by relying on long-term clinical cases, more likely to represent the variety of new clinical situations encountered and the questions that accompany them. This article introduces his point by recounting the plague epidemic in ancient Greece to show the impact of the environment on humans and its collective fantasy implications. Being faced up with death, contamination, the invisible enemy brings out a palpable concern. It is indeed quite remarkable that these same reactions and concerns in front of death caused by the pandemic match whith what is related by Thucydides who survived the plague, which affected Athens during the Peloponnesian War. In another context, Winnicott highlights the place and importance of the therapeutic environment. It is both a question of adjusting the framework according to the context while maintaining certain intangible aspects representing the permanence of the link and its framework. A framework cannot exist without being kept, which is equivalent to thinking of the framework above all as an internal framework, questioning the clinician about what he values and what he makes sense in his practice. In the current context, these questions arise from the perspective of a certain flexibility, depending on the human context (child, adolescent, consultations, etc.) or external context (crisis linked to a virus, etc.) showing that it is more than never question of exercising on a case-by-case basis, taking into account changes in the environment. The initial observation during this period of confinement concerns the fact that some patients contact a therapist for the first time by telephone and wish to initiate psychotherapy (during this period) when they explain that such an initiative was not possible. despite the difficulties already encountered in the past. But there is also the opposite case: patients who have no intention of continuing the work already started during this time. Thus, faced up with the injunction of confinement, they show themselves in the psychic impossibility of following the treatment by other means such as, for example, telephone sessions. In this perspective, the silence on the phone takes on a different tone; silence reveals itself to be a source of greater anxiety than in presence: the presence of bodies, of its movements perceptible as imperceptible, of a gesture that carries or accompanies the senses, breathing, the visual context of the office and of its "decor", represent as many essential elements in the usual capacity of the frame; in the absence of these basic sensory elements, silence can be experienced as a void, or even a gap in the bond, opening Pandora's box of paranoid fantasies acting unconsciously. If silence is representative of the whole framework, it promotes in this context the partialization of the clinician's body reduced to one ear and not to a whole body. Here, it is the change of framework that mobilizes the difference, established by Mr. Klein, between the partial and total object; this circumstance neo-framework could therefore call for regressive movements, undoing the silence of its symbolic function when the bodies are present. | 0003-4487 | 2020-06-07 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Florian Houssier;Angélique Christaki;Xanthie Vlachopoulou | Covid-19;Environment;Frame;Pandemic;Phone;Silence;Transfer | 2020-06-05 02:00:00+02:00 | 32836301 | FR | Psychogenèse et psychopathologie (UTRPP-EA 4430), université Paris 13, Villetaneuse, Sorbonne-Paris-Nord, France.;Université Sorbonne-Paris-Nord, France.;Laboratoire de psychologie clinique, psychopathologie, psychanalyse (PCPP, EA 4056), université Paris-Descartes, Sorbonne-Paris-Cité, France. | 1040 | |||
| 10.1016/j.banm.2020.05.109 | Editorial | fr | [Confined but mobilized, the National Academy of Medicine at the time of Covid-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32834022 | 0001-4079 | 2020-06-07 02:00:00+02:00 | pubmed | Bulletin de l'Académie Nationale de Médecine | P Berche;J Brugère-Picoux;Y Buisson;A-C Crémieux;G Dubois;D Houssin;D Kerouedan;C Rouzioux | 2020-06-04 02:00:00+02:00 | 32834022 | FR | Académie nationale de médecine, 16, rue Bonaparte, 75006 Paris. | 1041 | |||||
| Editorial;Comment | en | Adaptive neurology in COVID-19 times. | https://www.ncbi.nlm.nih.gov/pubmed/32513552 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Italy;Neurology;Pandemics;Parkinsonian Disorders;Pneumonia, Viral;Telemedicine;COVID-19;severe acute respiratory syndrome coronavirus 2 | Elena Moro;Hubert H Fernandez | 2020-06-04 02:00:00+02:00 | 32513552 | FR;US | Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble Institute of Neurosciences, Grenoble, France. Electronic address: emoro@chu-grenoble.fr.;Department of Neurology, Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. | 1044 | |||||||
| 10.1007/s00264-020-04651-5 | Journal Article | en | Thoracic computerised tomography scans in one hundred eighteen orthopaedic patients during the COVID-19 pandemic: identification of chest lesions; added values; help in managing patients; burden on the computerised tomography scan department. | https://www.ncbi.nlm.nih.gov/pubmed/32506142 | Based on the recent literature, chest computed tomography (CT) examination could aid for management of patients during COVID-19 pandemic. However, the role of chest CT in management of COVID-19 patients is not exactly the same for medical or surgical specialties. In orthopaedic or trauma emergency, abdomen, pelvis, cervical, dorsal, and lumbar spine CT are performed to investigate patients; the result is a thoracic CT scan incorporating usually the thorax; however, information about lung parenchyma can be obtained on this thorax CT, and manifestations of COVID-19 can be diagnosed. The objective of our study was to evaluate this role in orthopedic patients to familiarize orthopaedists with the value and limits of thoracic CT in orthopaedic surgery. | 0341-2695,1432-5195 | 2020-06-07 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections;Female;Humans;Male;Middle Aged;Orthopedics__methods;Pandemics;Pneumonia, Viral;Radiography, Thoracic;Thorax__diagnostic imaging;Tomography, X-Ray Computed__methods;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Orthopaedics | Jacques Hernigou;François Cornil;Alexandre Poignard;Said El Bouchaibi;Jean Mani;Jean François Naouri;Patrick Younes;Philippe Hernigou | COVID-19;Chest CT scan;Coronavirus;Orthopaedic patients and COVID-19;PCR test;Pandemic COVID-19;Thoracic CT scan;Trauma patients and COVID-19 | 2020-06-07 02:00:00+02:00 | 32506142 | FR;BE | Orthopedic Department, EpiCURA baudour Hornu Hospital, Mons, Belgium.;Imaging Department, EpiCURA baudour Hornu Hospital, Mons, Belgium.;Orthopedic Department, Clinique Geoffroy Saint Hilaire, 75005, Paris, France.;Imaging Department, Clinique Geoffroy Saint Hilaire, 75005, Paris, France.;Orthopedic Department, Clinique Geoffroy Saint Hilaire, 75005, Paris, France. philippe.hernigou@wanadoo.fr.;Hospital Henri Mondor, University Paris, Paris, France. philippe.hernigou@wanadoo.fr. | 1056 | ||
| 10.1016/j.jaip.2020.05.046 | Journal Article | en | Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32525093 | 2213-2198 | 2020-06-07 02:00:00+02:00 | pubmed | The Journal of Allergy and Clinical Immunology: In Practice | Jérémie Delaleu;Benjamin Deniau;Maxime Battistella;Adèle de Masson;Benoit Bensaid;Marie Jachiet;Ingrid Lazaridou;Martine Bagot;Jean-David Bouaziz | 2020-06-07 02:00:00+02:00 | 32525093 | FR | Dermatology Department, APHP, Saint Louis Hospital, Paris, France, INSERM U976, Department of Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France, Université de Paris, Paris, France.;Université de Paris, Paris, France, Department of Anaesthesia and Intensive Care Medicine, APHP, Saint Louis Hospital, Paris, France, INSERM U942, "Cardiovascular Markers in Stresses COndiTions", Paris, France.;INSERM U976, Department of Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France, Université de Paris, Paris, France, Laboratory of Pathology, APHP, Saint Louis Hospital, Paris, France.;Department of Allergy and Clinical Immunology, Drug Allergy Unit-CCR2A, CHU Lyon-Sud, Pierre Benite, France.;Dermatology Department, APHP, Saint Louis Hospital, Paris, France.;Dermatology Department, APHP, Saint Louis Hospital, Paris, France, INSERM U976, Department of Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France, Université de Paris, Paris, France. Electronic address: jean-david.bouaziz@aphp.fr. | 1057 | |||||
| Letter;Comment | en | Ethical considerations of thoracic transplant and circulatory support during the COVID-19 pandemic: A closer look at pulmonary vascular disease. | https://www.ncbi.nlm.nih.gov/pubmed/32576419 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Lung Transplantation;Pandemics;Pneumonia, Viral;Vascular Diseases;COVID-19;severe acute respiratory syndrome coronavirus 2 | Elisa A Bradley;Athénaïs Boucly;Raymond L Benza | 2020-06-06 02:00:00+02:00 | 32576419 | FR;US | Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio. Electronic address: elisa.bradley@osumc.edu.;Faculté de Medecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France, Assistance publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France.;Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio. | 1067 | |||||||
| 10.1111/ene.14382 | Journal Article | en | A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details. | https://www.ncbi.nlm.nih.gov/pubmed/32503088 | We systematically reviewed available evidence for reports of neurological signs and symptoms in patients with COVID-19 to identify cases with severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection or immune-mediated reaction in the nervous system. | 1351-5101,1468-1331 | 2020-06-07 02:00:00+02:00 | pubmed | European Journal of Neurology | M Romoli;I Jelcic;R Bernard-Valnet;D García Azorín;L Mancinelli;T Akhvlediani;S Monaco;P Taba;J Sellner | COVID-19;SARS-CoV-2;cerebrospinal fluid;encephalitis;neuroinvasion;neurological complications | 2020-06-05 02:00:00+02:00 | 32503088 | FR;GE;CH;US;IT;DE;ES;EE;AT | Neurology Unit, Maurizio Bufalini Hospital, Cesena, Italy.;Neurology Clinic, University of Perugia - S. Maria della Misericordia Hospital, Perugia, Italy.;Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital of Zurich, Zurich, Switzerland.;Department of Clinical Neurosciences, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Lausanne, Switzerland.;Department of Neurology, Hospital Clinico de Valladolid, Valladolid, Spain.;American MD Program, Faculty of Medicine, Tbilisi State Medical University, Tblisi, Georgia.;Department of Neuroscience, Biomedicine and Movement Sciences, University Hospital of Verona, Verona, Italy.;Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.;Neurology Clinic, Tartu University Hospital, Tartu, Estonia.;Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.;Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.;Department of Neurology, Klinikum rechts der Isar, Technische Universität München, München, Germany. | 1074 | |||
| 10.3389/fmed.2020.00274 | Journal Article | en | Impact of Lockdown on the Epidemic Dynamics of COVID-19 in France. | https://www.ncbi.nlm.nih.gov/pubmed/32582739 | The COVID-19 epidemic was reported in the Hubei province in China in December 2019 and then spread around the world reaching the pandemic stage at the beginning of March 2020. Since then, several countries went into lockdown. Using a mechanistic-statistical formalism, we estimate the effect of the lockdown in France on the contact rate and the effective reproduction number R e of the COVID-19. We obtain a reduction by a factor 7 (R e = 0.47, 95%-CI: 0.45-0.50), compared to the estimates carried out in France at the early stage of the epidemic. We also estimate the fraction of the population that would be infected by the beginning of May, at the official date at which the lockdown should be relaxed. We find a fraction of 3.7% (95%-CI: 3.0-4.8%) of the total French population, without taking into account the number of recovered individuals before April 1st, which is not known. This proportion is seemingly too low to reach herd immunity. Thus, even if the lockdown strongly mitigated the first epidemic wave, keeping a low value of R e is crucial to avoid an uncontrolled second wave (initiated with much more infectious cases than the first wave) and to hence avoid the saturation of hospital facilities. | 2296-858X | 2020-06-07 02:00:00+02:00 | pubmed | Frontiers in Medicine | Lionel Roques;Etienne K Klein;Julien Papaïx;Antoine Sar;Samuel Soubeyrand | Bayesian inference;COVID-19;SARS-CoV-2;SIR model;effective reproduction number;herd immunity;lockdown;mechanistic-statistical model | 2020-06-05 02:00:00+02:00 | 32582739 | FR;CH | INRAE, BioSP, Avignon, France.;Medicentre Moutier, Moutier, Switzerland. | 1075 | |||
| Letter | en | COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. | https://www.ncbi.nlm.nih.gov/pubmed/32505228 | 2020-06-07 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus;Child;Coronavirus Infections__diagnosis;Europe;Female;Humans;Immunocompromised Host;Liver Transplantation;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;Preliminary Data;Registries;Risk Factors;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Luca S Belli;Christophe Duvoux;Vincent Karam;Rene Adam;Valentin Cuervas-Mons;Luisa Pasulo;Carmelo Loinaz;Federica Invernizzi;Damiano Patrono;Sherrie Bhoori;Olga Ciccarelli;Maria Cristina Morelli;Lluis Castells;Victor Lopez-Lopez;Sara Conti;Costantino Fondevila;Wojchiech Polak | 2020-06-04 02:00:00+02:00 | 32505228 | FR;IT;NL;ES;BE;PS | Department of Hepatology and Gastroenterology, Niguarda Hospital, Milan 20162, Italy. Electronic address: luca.belli@ospedaleniguarda.it.;Department of Hepatology and Liver Transplant Unit, Henri Mondor Hospital, Paris-Est University, Paris, France.;Centre Hépatobiliaire, Université Paris-Sud, Hôpital Paul Brousse, Paris, France.;Departimento de Medicina, Hospital Universitario Puerta de Hierro, Madrid, Spain.;Division of Gastroenterology and Hepatology, Papa Giovanni XXIII Hospital, Bergamo, Italy.;Chirugía General, Doce de Octubre Universidad Complutense de Madrid, Madrid, Spain.;Division of Gastroenterology and Hepatology, University of Milan, Milan, Italy.;Liver Transplant Unit, University of Turin, Turin, Italy.;Department of Surgery and Oncology, Istituto Nazionale Tumori, Milan, Italy.;Starzl Abdominal Transplant Unit, Université Catholique de Louvain, Brussels, Belgium.;Liver and Multi-organ Transplantation, University of Bologna, Bologna, Italy.;Liver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.;Department of General and Transplantation Surgery, University Hospital Virgen de la Arrixaca, Murcia, Spain.;Research Centre on Public Health, University of Milan-Bicocca, Monza, Italy.;Department of Surgery, University of Barcelona Villaroel, Barcelona, Spain.;Department of Surgery, Erasmus MC-University, Rotterdam, Netherlands. | 1080 | |||||||
| 10.1007/s00264-020-04654-2 | Journal Article | en | Impact of the COronaVIrus Disease 2019 lockdown on hand and upper limb emergencies: experience of a referred university trauma hand centre in Paris, France. | https://www.ncbi.nlm.nih.gov/pubmed/32488564 | The lockdown imposed in France to cope with the COronaVIrus Disease 2019 (COVID-19) outbreak has led to major changes in the lifestyle of French citizens. The aim of our study was to study its impact on activity related to emergencies in hand and upper limb trauma in comparison to the same reference period in 2019. | 0341-2695,1432-5195 | 2020-06-07 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections;Emergencies;Female;France;Hand Injuries__surgery;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral;Trauma Centers;Universities;Upper Extremity__injuries;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Orthopaedics | Rémy Pichard;Luc Kopel;Quentin Lejeune;Rafik Masmoudi;Emmanuel H Masmejean | COVID-19;FESUM;Hand infection;Hand trauma;Lockdown | 2020-06-02 02:00:00+02:00 | 32488564 | FR | Hand, Upper Limb and Peripheral Nerve Surgery, Georges-Pompidou European Hospital (HEGP), 20 rue Leblanc, 75015, Paris, France. rem.pichard@gmail.com.;University of Paris, Paris, France. rem.pichard@gmail.com.;Hand, Upper Limb and Peripheral Nerve Surgery, Georges-Pompidou European Hospital (HEGP), 20 rue Leblanc, 75015, Paris, France.;Emergency Unit, Georges-Pompidou European Hospital (HEGP), Paris, France.;University of Paris, Paris, France.;Clinique Blomet, Research Unit, Paris, France. | 1086 | ||
| Letter | en | No antibody response in acral cutaneous manifestations associated with COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32488946 | 2020-06-07 02:00:00+02:00 | pubmed | R Mahieu;L Tillard;H Le Guillou-Guillemette;E Vinatier;P Jeannin;A Croué;Y Le Corre;Y-M Vandamme | 2020-06-02 02:00:00+02:00 | 32488946 | FR | Infectious Diseases and Tropical Medicine, LUNAM Université, University Hospital of Angers, Angers, France.;Université d'Angers, INSERM, CRCINA, Angers, France.;Virology Department, University Hospital of Angers, HIFIH Laboratory EA 3859, LUNAM, Angers, France.;Immunology Department, University Hospital of Angers, Angers, France.;Pathology Department, University Hospital of Angers, Angers, France.;Dermatology Department, LUNAM Université, University Hospital of Angers, Angers, France. | 1090 | ||||||||
| Interdisciplinary Graduate School for the blue planet;French Government | Letter | en | Conservation needs to evolve to survive in the post-pandemic world. | https://www.ncbi.nlm.nih.gov/pubmed/32479657 | The conservation of biodiversity-and the vital ecosystem services it generates-is one of the greatest challenges humanity faces, yet the field faces drastic funding cuts as society realigns its priorities in the face of the COVID-19 pandemic. Here, we argue that diverting attention from conservation would, however, increase the risk of further global health crises because the emergence of novel infectious diseases is partially driven by global environmental change. As the discrepancy between conservation needs and society's willingness to pay for them grows, conservation will have to evolve to stay relevant in the age global change-induced human infectious disease. | 2020-06-07 02:00:00+02:00 | pubmed | Javid Kavousi;Forough Goudarzi;Mohammad Izadi;Charlie J Gardner | 2020-06-01 02:00:00+02:00 | 32479657 | GB;FR;IR | [{"country": "", "agency": "Interdisciplinary Graduate School for the blue planet", "grantid": "ANR-17-EURE-0015"}, {"country": "", "agency": "French Government"}] | Univ Brest, CNRS, IRD, Ifremer, LEMAR, Plouzane, France.;Department of Natural Resources, Isfahan University of Technology, Isfahan, Iran.;Department of Fisheries, Faculty of Natural Resources, University of Tehran, Karaj, Iran.;Durrell Institute of Conservation and Ecology, University of Kent, Canterbury, UK. | 1094 | |||||
| NIA NIH HHS;NIA NIH HHS | 10.1016/j.bbi.2020.05.074 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't | en | Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. | https://www.ncbi.nlm.nih.gov/pubmed/32497776 | Differentials in COVID-19 hospitalisations and mortality according to ethnicity have been reported but their origin is uncertain. We examined the role of socioeconomic, mental health, and pro-inflammatory factors in a community-based sample. | 0889-1591 | 2020-06-07 02:00:00+02:00 | pubmed | African Continental Ancestry Group__statistics & numerical data;Aged;Asian Continental Ancestry Group__statistics & numerical data;Betacoronavirus;Body Mass Index;C-Reactive Protein__immunology;Cohort Studies;Comorbidity;Coronavirus Infections__ethnology;Diabetes Mellitus__epidemiology;England__epidemiology;European Continental Ancestry Group__statistics & numerical data;Female;Forced Expiratory Volume;Glycated Hemoglobin A__metabolism;Health Status;Healthcare Disparities__ethnology;Hospitalization__statistics & numerical data;Humans;Inflammation;Male;Mental Health;Middle Aged;Pandemics;Patient Health Questionnaire;Pneumonia, Viral__ethnology;Socioeconomic Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Brain, Behavior, and Immunity | Camille Lassale;Bamba Gaye;Mark Hamer;Catharine R Gale;G David Batty | COVID-19;Ethnicity;Inflammatory factors | 2020-06-01 02:00:00+02:00 | 32497776 | FR;ES;GB | [{"country": "United States", "agency": "NIA NIH HHS", "grantid": "R56 AG052519"}, {"country": "United States", "agency": "NIA NIH HHS", "grantid": "R01 AG052519"}] | Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain, CIBER of Pathophysiology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain, Department of Epidemiology and Public Health, University College London, UK. Electronic address: classale@imim.es.;Integrative Epidemiology of Cardiovascular Diseases, Paris Cardiovascular Research Center-INSERM U970 (PARCC), France.;Division of Surgery and Interventional Sciences, Faculty Medical Sciences, University College London, London, UK.;MRC Lifecourse Epidemiology Unit, University of Southampton, UK, Lothian Birth Cohorts, Department of Psychology, University of Edinburgh, UK.;Department of Epidemiology and Public Health, University College London, UK. | 1103 |
| 10.1016/j.cnsns.2020.105372 | Journal Article | en | On the uncertainty of real-time predictions of epidemic growths: A COVID-19 case study for China and Italy. | https://www.ncbi.nlm.nih.gov/pubmed/32834701 | While COVID-19 is rapidly propagating around the globe, the need for providing real-time forecasts of the epidemics pushes fits of dynamical and statistical models to available data beyond their capabilities. Here we focus on statistical predictions of COVID-19 infections performed by fitting asymptotic distributions to actual data. By taking as a case-study the epidemic evolution of total COVID-19 infections in Chinese provinces and Italian regions, we find that predictions are characterized by large uncertainties at the early stages of the epidemic growth. Those uncertainties significantly reduce after the epidemics peak is reached. Differences in the uncertainty of the forecasts at a regional level can be used to highlight the delay in the spread of the virus. Our results warn that long term extrapolation of epidemics counts must be handled with extreme care as they crucially depend not only on the quality of data, but also on the stage of the epidemics, due to the intrinsically non-linear nature of the underlying dynamics. These results suggest that real-time epidemiological projections should include wide uncertainty ranges and urge for the needs of compiling high-quality datasets of infections counts, including asymptomatic patients. | 1007-5704 | 2020-06-07 02:00:00+02:00 | pubmed | Communications in Nonlinear Science and Numerical Simulation | Tommaso Alberti;Davide Faranda | COVID-19;Epidemic model;Logistic model;National vs. regional diffusion | 2020-06-01 02:00:00+02:00 | 32834701 | FR;IT;GB | INAF - Istituto di Astrofisica e Planetologia Spaziali, via del Fosso del Cavaliere 100, Roma 00133, Italy.;Laboratoire des Sciences du Climat et de l'Environnement, 5 CEA Saclay l'Orme des Merisiers, UMR 8212 CEA-CNRS-UVSQ, 6 Université Paris-Saclay & IPSL, Gif-sur-Yvette 91191, France.;London Mathematical Laboratory, 8 Margravine Gardens, London W6 8RH, UK.;LMD/IPSL, Ecole Normale Superieure, 9 PSL research University, Paris, France. | 1104 | |||
| 10.1002/eat.23318 | Journal Article | en | The impact of the COVID-19 pandemic on eating disorder risk and symptoms. | https://www.ncbi.nlm.nih.gov/pubmed/32476175 | The current COVID-19 pandemic has created a global context likely to increase eating disorder (ED) risk and symptoms, decrease factors that protect against EDs, and exacerbate barriers to care. Three pathways exist by which this pandemic may exacerbate ED risk. One, the disruptions to daily routines and constraints to outdoor activities may increase weight and shape concerns, and negatively impact eating, exercise, and sleeping patterns, which may in turn increase ED risk and symptoms. Relatedly, the pandemic and accompanying social restrictions may deprive individuals of social support and adaptive coping strategies, thereby potentially elevating ED risk and symptoms by removing protective factors. Two, increased exposure to ED-specific or anxiety-provoking media, as well as increased reliance on video conferencing, may increase ED risk and symptoms. Three, fears of contagion may increase ED symptoms specifically related to health concerns, or by the pursuit of restrictive diets focused on increasing immunity. In addition, elevated rates of stress and negative affect due to the pandemic and social isolation may also contribute to increasing risk. Evaluating and assessing these factors are key to better understanding the impact of the pandemic on ED risk and recovery and to inform resource dissemination and targets. | 0276-3478,1098-108X | 2020-06-07 02:00:00+02:00 | pubmed | Adaptation, Psychological;Betacoronavirus;Coronavirus Infections__prevention & control;Exercise__psychology;Fear;Feeding Behavior__psychology;Feeding and Eating Disorders__psychology;Female;Humans;Male;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Quarantine__psychology;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Eating Disorders | Rachel F Rodgers;Caterina Lombardo;Silvia Cerolini;Debra L Franko;Mika Omori;Matthew Fuller-Tyszkiewicz;Jake Linardon;Philippe Courtet;Sebastien Guillaume | COVID-19;access to care;body image;eating disorders;media;risk and protective factors | 2020-06-01 02:00:00+02:00 | 32476175 | FR;JP;US;IT;AU | APPEAR, Department of Applied Psychology, Northeastern University, Boston, Massachusetts, USA.;Department of Psychiatric Emergency & Acute Care , Lapeyronie Hospital, CHRU Montpellier, Montpellier, France.;Department of Psychology, Sapienza University of Rome, Rome, Italy.;Department of Psychology, Ochanomizu University, Tokyo, Japan.;School of Psychology, Deakin University, Melbourne, Victoria, Australia. | 1105 | ||
| 10.4269/ajtmh.20-0540 | Journal Article | en | Erroneous Communication Messages on COVID-19 in Africa. | https://www.ncbi.nlm.nih.gov/pubmed/32500850 | Adherence of the population to COVID-19 prevention recommendations is crucial to control the epidemic. However, a study of communication messages around COVID-19 in 15 West African countries showed a number of unfounded messages, as well as a lack of communication on critical information to understand the prevention measures being promoted. Incidents of violence that have taken place recently suggest that general mistrust and hostility could grow, similar to the events that occurred during the previous Ebola epidemics. It is therefore urgent to review and revise the COVID-19 communication messages currently used in sub-Saharan Africa. | 0002-9637,1476-1645 | 2020-06-07 02:00:00+02:00 | pubmed | Africa;Animals;Betacoronavirus;Coronavirus Infections__epidemiology;Health Communication__standards;Health Education__standards;Health Literacy;Humans;Pandemics;Pneumonia, Viral__epidemiology;Public Health;Trust;COVID-19;severe acute respiratory syndrome coronavirus 2 | The American Journal of Tropical Medicine and Hygiene | Bernard Seytre | 2020-06-03 02:00:00+02:00 | 32500850 | FR | bnscommunication, Paris, France. | 1118 | |||
| 10.1186/s13690-020-00432-z | Journal Article | en | How to deal with COVID-19 epidemic-related lockdown physical inactivity and sedentary increase in youth? Adaptation of Anses' benchmarks. | https://www.ncbi.nlm.nih.gov/pubmed/32514348 | Faced with the spread of the SARS-CoV-2 virus, regulatory measures aiming to prevent interpersonal contaminations have been undertaken and among these, lockdown. Due to strong restrictions out-of-home movements, we hypothesize that overall physical activity will decrease and sedentary behavior increase. This could result in highest exposure to the well-known risk related to insufficient physical activity. To mitigate physical inactivity and sedentary behaviors health-related risks related to children and adolescents lockdown and school closure, Anses (French Agency for Food, Environmental and Occupational Health & Safety) has adapted, within the first days of the public authorities' prescription, its former benchmarks. This paper supports and comments Anses' Opinion by raising the questions of whether, why, and how to deal with short- or medium-term lockdown-related physical inactivity and sedentary behavior increases. Short-term and unknown long term-impacts on mental health and well-being, physical fitness and eating behaviors clearly appearing for children and adolescents as being the main issues of concern are highlighted. Targeting the compensations of the physical inactivity increase, the types, frequencies and durations of physical activity, are adapted to restricted environment. Sedentary behavior limitation and frequent interruptions becomes a priority. Overall, considering children and adolescents, the emerging risk justifies proposing specific adaptations and type of activities in order to ensure maintaining health underpinned, at least partly, by physiological equilibrium and physical fitness and avoid the installation of new unhealthy habits or routines that young people could keep after lockdown. | 2049-3258 | 2020-06-07 02:00:00+02:00 | pubmed | Archives of Public Health | Irène Margaritis;Sabine Houdart;Youssef El Ouadrhiri;Xavier Bigard;Anne Vuillemin;Pascale Duché | Adolescents;Behaviors;COVID-19;Children;Physical activity;Screens;Sedentary lifestyle | 2020-06-03 02:00:00+02:00 | 32514348 | FR;CH | French Agency for Food, Environmental and Occupational Health & Safety (Anses), Nutrition Risk Assessment Unit, 14 rue Pierre et Marie Curie, 94701 Maisons-Alfort, Cedex France.;International Cycling Union (UCI), Allée Ferdi Kübler 12, 1860 Aigle, Switzerland.;Université Côte d'Azur, Laboratoire Motricité Humaine Expertise Sport Santé (LAMHESS), 261 Boulevard du Mercantour, BP 3259, 06205 Nice, Cedex 3 France.;Université de Toulon, Unité de recherche Impact de l'activité physique sur la santé (IAPS), CS 60584, 83041 Toulon, Cedex 9 France. | 1121 | |||
| Letter;Comment | en | First case of acute pancreatitis related to SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32492174 | 2020-06-07 02:00:00+02:00 | pubmed | Acute Disease;Betacoronavirus;Coronavirus Infections;Humans;Pancreatitis;Pandemics;Pneumonia, Viral;Severe Acute Respiratory Syndrome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Y Miao;O Lidove;W Mauhin | 2020-06-03 02:00:00+02:00 | 32492174 | FR | Internal Medicine Department, Diaconesses Croix Saint Simon Hospital, Paris, France. | 1123 | |||||||
| 10.1136/bmj.m2094 | Journal Article;Observational Study | en | Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. | https://www.ncbi.nlm.nih.gov/pubmed/32493739 | To describe the characteristics of children and adolescents affected by an outbreak of Kawasaki-like multisystem inflammatory syndrome and to evaluate a potential temporal association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. | 1756-1833 | 2020-06-07 02:00:00+02:00 | pubmed | Adolescent;Adrenal Cortex Hormones__therapeutic use;Antibodies, Viral__blood;Betacoronavirus__genetics;Child;Child, Preschool;Coronavirus Infections__complications;Female;Humans;Immunoglobulins, Intravenous__therapeutic use;Male;Nasopharynx__virology;Pandemics;Paris;Pneumonia, Viral__complications;Prospective Studies;RNA, Viral__genetics;Systemic Inflammatory Response Syndrome__drug therapy;COVID-19;pediatric multisystem inflammatory disease, COVID-19 related;severe acute respiratory syndrome coronavirus 2 | BMJ | Julie Toubiana;Clément Poirault;Alice Corsia;Fanny Bajolle;Jacques Fourgeaud;François Angoulvant;Agathe Debray;Romain Basmaci;Elodie Salvador;Sandra Biscardi;Pierre Frange;Martin Chalumeau;Jean-Laurent Casanova;Jérémie F Cohen;Slimane Allali | 2020-06-03 02:00:00+02:00 | 32493739 | FR;US | Department of General Paediatrics and Paediatric Infectious Diseases, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, 149 rue de Sèvres, 75015 Paris, France.;Institut Pasteur, Biodiversity and Epidemiology of Bacterial Pathogens, Paris, France.;Paediatric Intensive Care Unit, Necker-Enfants Malades University Hospital, AP-HP, Université de Paris. Paris, France.;M3C-Necker-Enfants Malades University Hospital, Université de Paris, Paris, France.;Virology Laboratory, Necker-Enfants Malades University Hospital, AP-HP, Université de Paris, Paris, France.;Pediatric Emergency Department, Necker-Enfants Malades University Hospital, AP-HP, INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université de Paris, Paris, France.;Pediatric and Emergency Unit, Louis Mourier Hospital, Université de Paris, Paris, France.;Pediatric Emergency Unit, Hôpital Intercommunal, Créteil, France.;Department of Clinical Microbiology, Necker-Enfants Malades University Hospital, AP-HP, EHU 7328 PACT, Imagine Institute, Université de Paris, Paris, France.;Department of General Paediatrics and Paediatric Infectious Diseases, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, 149 rue de Sèvres, 75015 Paris, France martin.chalumeau@aphp.fr.;Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Centre of Research in Epidemiology and Statistics, INSERM, Université de Paris, Paris, France.;Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Imagine Institute, Pediatric Hematology and Immunology Unit, Necker-Enfants Malades Hospital, AP-HP, Université de Paris, Paris, France.;St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller Unversity, Howard Hughes Medical Institute, New York, NY, USA. | 1126 | |||
| Journal Article;Research Support, Non-U.S. Gov't;Comment | en | Comparison of the Clinical Features of SARS-CoV-2, Other Coronavirus and Influenza Infections in Infants Less Than 1-Year-Old. | https://www.ncbi.nlm.nih.gov/pubmed/32525645 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Coronavirus;Coronavirus Infections;Humans;Infant;Influenza, Human;Pandemics;Pneumonia, Viral;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Philippe Vanhems;Hubert Endtz;Cédric Dananché;Florence Komurian-Pradel;Valentina Sanchez Picot | 2020-06-12 02:00:00+02:00 | 32525645 | FR;NL | Hospices Civils de Lyon et Centre International de Recherche en Infectiologue, Lyon, France Emerging Pathogens Laboratory, Mérieux Foundation, Lyon, France and Medische Microbiologie en Infectieziekten (MMIZ), Erasmus MC, Rotterdam, The Netherlands Hospices Civils de Lyon et Centre International de Recherche en Infectiologue, Lyon, France Emerging Pathogens Laboratory, Mérieux Foundation, Lyon, France. | 1135 | |||||||
| 10.1038/s41591-020-0960-y | Journal Article | en | Socio-demographic and epidemiological consideration of Africa's COVID-19 response: what is the possible pandemic course? | https://www.ncbi.nlm.nih.gov/pubmed/32528153 | 1078-8956,1546-170X | 2020-06-14 02:00:00+02:00 | pubmed | Africa__epidemiology;Betacoronavirus;Climate;Community Networks__organization & administration;Comorbidity;Coronavirus Infections__epidemiology;Demography;Humans;Mortality;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Socioeconomic Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nature Medicine | Bamba Gaye;Stéphanie Khoury;Crystal W Cene;Samuel Kingue;Roland N'Guetta;Camille Lassale;Dadhi Baldé;Ibrahima Bara Diop;Jennifer Beam Dowd;Melinda C Mills;Xavier Jouven | 2020-06-13 02:00:00+02:00 | 32528153 | FR;CI;GH;SN;CM;US;GN;GB;ES | The African Research Network, Kumasi, Ghana. bamba.gaye@inserm.fr.;Université de Paris, Integrative Epidemiology of Cardiovascular Diseases, Paris Cardiovascular Research Center-INSERM U970, Paris, France. bamba.gaye@inserm.fr.;The African Research Network, Kumasi, Ghana.;Université de Paris, Integrative Epidemiology of Cardiovascular Diseases, Paris Cardiovascular Research Center-INSERM U970, Paris, France.;Department of Medicine, Division of General Internal Medicine, University of North Carolina at Chapel Hill, Chapel Hill School of Medicine, Chapel Hill, NC, USA.;Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.;University of Yaoundé, Ministry of Public Health, Yaoundé, Cameroon.;Institute of Cardiology of Abidjan, Abidjan, Côte d'Ivoire.;CIBER of Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Madrid, Spain.;Department of Cardiology, University Hospital of Conakry, Conakry, Guinea.;Cardiology Department, University Hospital of Fann, Dakar, Senegal.;Leverhulme Centre for Demographic Science, Nuffield College, University of Oxford, Oxford, UK.;Cardiology Department, Georges-Pompidou European Hospital, Paris, France. | 1139 | ||||
| 10.1007/s40264-020-00954-z | Editorial | en | Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same. | https://www.ncbi.nlm.nih.gov/pubmed/32514859 | 0114-5916,1179-1942 | 2020-06-14 02:00:00+02:00 | pubmed | Antiviral Agents__administration & dosage;Betacoronavirus__isolation & purification;Chemical and Drug Induced Liver Injury__blood;Coronavirus Infections__blood;Humans;Liver Function Tests__methods;Medicine, Traditional__adverse effects;Pandemics;Pharmacovigilance;Pneumonia, Viral__blood;Risk Assessment;Risk Factors;Severity of Illness Index;Symptom Assessment__methods;Withholding Treatment;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Drug Safety | Alexandre Olry;Lucy Meunier;Bénédicte Délire;Dominique Larrey;Yves Horsmans;Hervé Le Louët | 2020-06-10 02:00:00+02:00 | 32514859 | FR;BE;GB | Pharmacovigilance Department, Henri Mondor University Hospital (APHP), 51 Avenue du Maréchal de Lattre de Tassigny, Créteil, 94010, Paris, France. alexandre.olry@aphp.fr.;Liver Unit, Saint-Eloi Hospital, INSERM 1183, Montpellier School of Medicine, Montpellier, France.;Department of Hepatogastroenterology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCL), Brussels, Belgium.;CIOMS, Head of Vigilance Department, Henri Mondor University Hospital (APHP), Paris, France. | 1148 | ||||
| 10.1038/s41409-020-0965-7 | Published Erratum | en | Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. | https://www.ncbi.nlm.nih.gov/pubmed/32514158 | An amendment to this paper has been published and can be accessed via a link at the top of the paper. | 0268-3369,1476-5365 | 2020-06-14 02:00:00+02:00 | pubmed | Bone Marrow Transplantation | Per Ljungman;Malgorzata Mikulska;Rafael de la Camara;Grzegorz W Basak;Christian Chabannon;Selim Corbacioglu;Rafael Duarte;Harry Dolstra;Arjan C Lankester;Mohamad Mohty;Silvia Montoto;John Murray;Régis Peffault de Latour;John A Snowden;Ibrahim Yakoub-Agha;Bregje Verhoeven;Nicolaus Kröger;Jan Styczynski | 2020-06-08 02:00:00+02:00 | 32514158 | FR;SE;GB;IT;PL;NL;ES;DE | Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. Per.Ljungman@ki.se.;Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. Per.Ljungman@ki.se.;Division of Infectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Genova, Italy.;Department of Hematology, Hospital de la Princesa, Madrid, Spain.;Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.;Institut Paoli Calmettes & Inserm CBT-1409, Centres d'Investigations Cliniques en Biothérapies, Marseille, France.;Pediatric Hematology, Oncology and Stem Cell Transplantation Department, University of Regensburg, Regensburg, Germany.;Servicio de Hematologia y Hemoterapia, Hospital Universitario Puerta de Hierro, Madrid, Spain.;Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.;Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Centre, Leiden, The Netherlands.;Department of Hematology, Hospital Saint Antoine, Paris, France.;St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.;The Christie NHS Foundation Trust, Manchester, UK.;BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.;Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.;CHU de Lille, Univ Lille, INSERM, U1285, Lille, France.;Foundation Hematon, Utrecht, The Netherlands.;Department of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.;Pediatric Hematology and Oncology, University Hospital, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland. | 1152 | ||||
| 10.1136/annrheumdis-2020-217988 | Journal Article | en | Response to: 'Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak' by Holubar et al. | https://www.ncbi.nlm.nih.gov/pubmed/32513651 | 0003-4967,1468-2060 | 2020-06-14 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Alexis Mathian;Zahir Amoura | hydroxychloroquine;lupus erythematosus, systemic;therapeutics | 2020-06-08 02:00:00+02:00 | 32513651 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 1156 | ||||
| 10.1016/j.reuma.2020.05.006 | Journal Article | en | COVID-19: Overview of Rheumatology Fellows. | https://www.ncbi.nlm.nih.gov/pubmed/32565030 | SARS-CoV-2 infection has spread worldwide since it originated in December 2019, in Wuhan, China. The pandemic has largely demonstrated the resilience of the world's health systems and is the greatest health emergency since World War II. There is no single therapeutic approach to the treatment of COVID-19 and the associated immune disorder. The lack of randomised clinical trials (RCTs) has led different countries to tackle the disease based on case series, or from results of observational studies with off-label drugs. We as rheumatologists in general, and specifically rheumatology fellows, have been on the front line of the pandemic, modifying our activities and altering our training itinerary. We have attended patients, we have learned about the management of the disease and from our previous experience with drugs for arthritis and giant cell arteritis, we have used these drugs to treat COVID-19. | 1699-258X | 2020-06-14 02:00:00+02:00 | pubmed | Reumatología Clínica | Andrea Garcia-Guillén;Sicylle Jeria;David Lobo-Prat;Luís Sainz | Biological agents;Biológicos;COVID-19;Coronavirus;Pandemia;Pandemic;Resident;Residente;Reumatólogos;Rheumatologists | 2020-06-11 02:00:00+02:00 | 32565030 | FR;ES | Servei de Reumatologia. Hospital de la Santa Creu i Sant Pau, Barcelona, España. Electronic address: agarciagui@santpau.cat.;Servei de Reumatologia. Hospital de la Santa Creu i Sant Pau, Barcelona, España. | 1160 | |||
| Letter | en | Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future? | https://www.ncbi.nlm.nih.gov/pubmed/32525607 | 2020-06-14 02:00:00+02:00 | pubmed | Marta Scorsetti;Karyn A Goodman;Jinsil Seong;Mauro Loi;Florence Huguet;Laura A Dawson | 2020-06-11 02:00:00+02:00 | 32525607 | FR;CA;GB;US;IT;KR | Humanitas Clinical and Research Center - IRCCS, Department of Radiotherapy and Radiosurgery, Milan, Italy, Department of Biomedical Sciences, Humanitas University, Milan, Italy.;Department of Radiation Oncology, The Mount Sinai Hospital, New York, New York, USA.;Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Republic of Korea.;Humanitas Clinical and Research Center - IRCCS, Department of Radiotherapy and Radiosurgery, Milan, Italy.;Department of Radiation Oncology, Hôpital Tenon, AP-HP Sorbonne Université, Paris, France.;Department of Radiation Oncology, University of Toronto, Toronto, Canada, Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Canada. | 1161 | ||||||||
| 10.1038/s41409-020-0970-x | Journal Article;Review | en | Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. | https://www.ncbi.nlm.nih.gov/pubmed/32528122 | 0268-3369,1476-5365 | 2020-06-14 02:00:00+02:00 | pubmed | Bone Marrow Transplantation | Eolia Brissot;Myriam Labopin;Frédéric Baron;Ali Bazarbachi;Gesine Bug;Fabio Ciceri;Jordi Esteve;Sebastian Giebel;Maria H Gilleece;Norbert-Claude Gorin;Francesco Lanza;Zinaida Peric;Annalisa Ruggeri;Jaime Sanz;Bipin N Savani;Christoph Schmid;Roni Shouval;Alexandros Spyridonidis;Jurjen Versluis;Arnon Nagler;Mohamad Mohty | 2020-06-11 02:00:00+02:00 | 32528122 | FR;IL;LB;GR;GB;HR;US;IT;PL;NL;ES;BE;DE | Saint-Antoine Hospital, Sorbonne University, AP-HP, INSERM UMRs 938, Paris, France. eolia.brissot@aphp.fr.;Saint-Antoine Hospital, Sorbonne University, AP-HP, INSERM UMRs 938, Paris, France.;Department of Hematology, University of Liège, Liège, Belgium.;Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.;University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.;Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.;Università Vita-Salute San Raffaele, Milan, Italy.;Hematology Department, Hospital Clinic, Barcelona, Spain.;Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice, Poland.;Yorkshire Blood and Marrow Transplant Programme, Haematology Department, St James's Institute of Oncology, Leeds, UK.;European Society for Blood and Marrow Transplantation, Hopital Saint-Antoine, Paris, France.;Hematology Unit, Romagna Transplant Network, Ravenna, Italy.;Bone Marrow Transplant Unit, University Hospital Center Rebro, Zagreb, Croatia.;University Hospital La Fe, Valencia, Spain.;Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, USA.;Klinikum Augsburg, II Medizinische Klinik, Augsburg, Germany.;Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;BMT Unit, University Hospital of Patras, Patras, Greece.;Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.;Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel. | 1167 | |||||
| 10.1016/s1470-2045(20)30334-x | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. | https://www.ncbi.nlm.nih.gov/pubmed/32534633 | The speed and scale of the global COVID-19 pandemic has resulted in unprecedented pressures on health services worldwide, requiring new methods of service delivery during the health crisis. In the setting of severe resource constraint and high risk of infection to patients and clinicians, there is an urgent need to identify consensus statements on head and neck surgical oncology practice. We completed a modified Delphi consensus process of three rounds with 40 international experts in head and neck cancer surgical, radiation, and medical oncology, representing 35 international professional societies and national clinical trial groups. Endorsed by 39 societies and professional bodies, these consensus practice recommendations aim to decrease inconsistency of practice, reduce uncertainty in care, and provide reassurance for clinicians worldwide for head and neck surgical oncology in the context of the COVID-19 pandemic and in the setting of acute severe resource constraint and high risk of infection to patients and staff. | 1470-2045 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Consensus;Coronavirus Infections__epidemiology;Head and Neck Neoplasms__diagnosis;Health Care Rationing;Humans;International Cooperation;Occupational Health;Pandemics__prevention & control;Patient Safety;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Surgical Oncology__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Oncology | Hisham Mehanna;John C Hardman;Jared A Shenson;Ahmad K Abou-Foul;Michael C Topf;Mohammad AlFalasi;Jason Y K Chan;Pankaj Chaturvedi;Velda Ling Yu Chow;Andreas Dietz;Johannes J Fagan;Christian Godballe;Wojciech Golusiński;Akihiro Homma;Sefik Hosal;N Gopalakrishna Iyer;Cyrus Kerawala;Yoon Woo Koh;Anna Konney;Luiz P Kowalski;Dennis Kraus;Moni A Kuriakose;Efthymios Kyrodimos;Stephen Y Lai;C Rene Leemans;Paul Lennon;Lisa Licitra;Pei-Jen Lou;Bernard Lyons;Haitham Mirghani;Anthonny C Nichols;Vinidh Paleri;Benedict J Panizza;Pablo Parente Arias;Mihir R Patel;Cesare Piazza;Danny Rischin;Alvaro Sanabria;Robert P Takes;David J Thomson;Ravindra Uppaluri;Yu Wang;Sue S Yom;Yi-Ming Zhu;Sandro V Porceddu;John R de Almeida;Chrisian Simon;F Christopher Holsinger | 2020-06-11 02:00:00+02:00 | 32534633 | CA;JP;TW;BR;AE;GH;NL;DK;FR;CO;CN;GR;GB;US;HK;CH;PL;IT;KR;DE;IE;SG;AU;TR;ZA;ES;IN | Institute for Head and Neck Studies and Education, University of Birmingham, Birmingham, UK. Electronic address: h.mehanna@bham.ac.uk.;Head and Neck Unit, The Royal Marsden National Health Service Foundation Trust, London, UK.;Division of Head and Neck Surgery, Department of Otolaryngology, Stanford University, Palo Alto, CA, USA.;Department of Otolaryngology and Head and Neck Surgery, Walsall Manor Hospital, Walsall, UK.;Department of Otolaryngology, United Arab Emirates University, Alain, United Arab Emirates.;Department of Otorhinolaryngology and Head and Neck Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China.;Department of Otorhinolaryngology and Head and Neck Surgery, Tata Memorial Hospital, Mumbai, India.;Department of Surgery, The University of Hong Kong, Hong Kong Special Administrative Region, China.;Department of Ear, Nose and Throat Surgery, University of Leipzig, Leipzig, Germany.;Division of Otolaryngology, University of Cape Town, Cape Town, South Africa.;Department of Otorhinolaryngology-Head and Neck Surgery, Odense University Hospital and University of Southern Denmark, Odense, Denmark.;Department of Head and Neck Surgery, Poznan University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland.;Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.;Department of Otolaryngology-Head and Neck Surgery, Atilim University Faculty of Medicine, Ankara, Turkey.;Department of Head and Neck Surgery, National Cancer Centre and Singapore General Hospital, Singapore.;Department of Otorhinolaryngology, Yonsei University, Seoul, South Korea.;Department of Otolaryngology, Komfo Anokye Teaching Hospital, Kwame Nkrumah University of Science and Technology, School of Medical Science, Kumasi, Ghana.;Department of Head and Neck Surgery, University of Sao Paulo Medical School, Sao Paulo, Brazil, Department of Head and Neck Surgery and Otorhinolaryngology, A C Camargo Cancer Center, Sao Paulo, Brazil.;Department of Otolaryngology-Head and Neck Surgery, Zucker School of Medicine, Northwell Health Cancer Institute, New York, NY, USA.;Department of Otolaryngology-Head and Neck Surgery, Cochin Cancer Research Centre, Cochin, India.;First Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece.;Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Department of Otolaryngology and Head and Neck Surgery, Amsterdam University Medical Centre, Cancer Center Amsterdam, VU University, Amsterdam, Netherlands.;Department of Otolaryngology and Head and Neck Surgery, St James's Hospital and The Royal Victoria Eye and Ear Hospital, Dublin, Ireland.;Foundation IRCCS, Division of Medical Oncology, National Institute of Cancer of Milan, University of Milan, Milan, Italy.;Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.;Department of Otolaryngology Head and Neck Surgery, St Vincent's Hospital, Melbourne, VIC, Australia.;Department of Otolaryngology and Head and Neck Surgery, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France.;Department of Otolaryngology-Head and Neck Surgery and Department of Oncology, University of Western Ontario, London, ON, Canada.;Department of Otolaryngology-Head and Neck Surgery, Princess Alexandra Hospital and Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.;Department of Otolaryngology and Head and Neck Surgery, Hospital Universitario Lucus Augusti, Lugo, Spain.;Department of Otolaryngology and Head and Neck Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.;Department of Otorhinolaryngology, Maxillofacial and Thyroid Surgery, National Institute of Cancer of Milan, University of Milan, Milan, Italy.;Department of Medical Oncology, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.;Department of Surgery, School of Medicine, Universidad de Antioquia-Hospital Universitario San Vicente Fundación, Medellin, Colombia, CEXCA Centro de Excelencia en Enfermedades de Cabeza y Cuello, Medellin, Colombia.;Department of Otolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, Netherlands.;Department of Clinical Oncology, The Christie National Health Service Foundation Trust, Manchester, UK, Division of Cancer Sciences, University of Manchester, Manchester, UK.;Division of Otolaryngology-Head and Neck Surgery, Dana-Farber and Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.;Department of Head and Neck Surgery, Fudan University, Shanghai Cancer Center, Shanghai, China.;Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.;Department of Head and Neck Surgery, National Cancer Center-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.;Department of Cancer Services, Princess Alexandra Hospital and Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.;Department of Otolaryngology-Head and Neck Surgery and Department of Surgical Oncology, University Health Network, Toronto, ON, Canada, Department of Otolaryngology-Head and Neck Surgery, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada.;Department of Otolaryngology and Head and Neck Surgery, Lausanne University Hospital, Lausanne, Switzerland. | 1168 | |||
| Letter | en | Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32533198 | 2020-06-14 02:00:00+02:00 | pubmed | Nathalie Cardot-Leccia;Thomas Hubiche;Jean Dellamonica;Fanny Burel-Vandenbos;Thierry Passeron | 2020-06-12 02:00:00+02:00 | 32533198 | FR;US | Department of Pathology, Université Côte D'Azur. CHU Nice, Nice, France.;Department of Dermatology, Université Côte D'Azur. CHU Nice, Nice, France.;Medical Intensive Care Unit, Université Côte D'Azur. UPR 01, UR2CA, CHU Nice, Nice, France.;Department of Dermatology, Université Côte D'Azur. CHU Nice, Nice, France. passeron@unice.fr.;Université Côte D'Azur. INSERM. U1065, C3M, Nice, France. passeron@unice.fr. | 1177 | ||||||||
| 10.1093/ehjcvp/pvaa062 | Journal Article | en | Association between renin-angiotensin system inhibitors and COVID-19 complications. | https://www.ncbi.nlm.nih.gov/pubmed/32531040 | To describe the characteristics of patients hospitalized with COVID-19 (including their long-term at-home medication use), and compare them with regard to the course of the disease. To assess the association between renin-angiotensin system inhibitors (RASIs) and disease progression and critical outcomes. | 2055-6837,2055-6845 | 2020-06-14 02:00:00+02:00 | pubmed | European Heart Journal - Cardiovascular Pharmacotherapy | Sophie Liabeuf;Julien Moragny;Youssef Bennis;Benjamin Batteux;Etienne Brochot;Jean Luc Schmit;Jean-Philippe Lanoix;Claire Andrejak;Olivier Ganry;Michel Slama;Julien Maizel;Yazine Mahjoub;Kamel Masmoudi;Valérie Gras-Champel | Associated factors;COVID-19;Critical outcomes;Renin–angiotensin system inhibitors | 2020-06-12 02:00:00+02:00 | 32531040 | FR | Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France.;MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France.;Department of Virology, Amiens University Medical Center, Amiens, France.;EA 4294, Jules Verne University of Picardie, Amiens, France.;Infectious Diseases Department, University Hospital, Amiens, France.;Department of Pneumology, University Hospital of Amiens-Picardie, Amiens, France.;Epidemiology and Public Health Service, Amiens University Hospital, Amiens, France.;Intensive Care Department and BoReal study group, Amiens University Hospital, Amiens, France.;Department of Anesthesiology and Critical Care Medicine, Amiens University Medical Center, Amiens, France. | 1178 | |||
| 10.1016/j.ejmech.2020.112557 | Journal Article | en | Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase. | https://www.ncbi.nlm.nih.gov/pubmed/32563813 | The spreading of new viruses is known to provoke global human health threat. The current COVID-19 pandemic caused by the recently emerged coronavirus SARS-CoV-2 is one significant and unfortunate example of what the world will have to face in the future with emerging viruses in absence of appropriate treatment. The discovery of potent and specific antiviral inhibitors and/or vaccines to fight these massive outbreaks is an urgent research priority. Enzymes involved in the capping pathway of viruses and more specifically RNA N7- or 2'O-methyltransferases (MTases) are now admitted as potential targets for antiviral chemotherapy. We designed bisubstrate inhibitors by mimicking the transition state of the 2'-O-methylation of the cap RNA in order to block viral 2'-O MTases. This work resulted in the synthesis of 16 adenine dinucleosides with both adenosines connected by various nitrogen-containing linkers. Unexpectedly, all the bisubstrate compounds were barely active against 2'-O MTases of several flaviviruses or SARS-CoV but surprisingly, seven of them showed efficient and specific inhibition against SARS-CoV N7-MTase (nsp14) in the micromolar to submicromolar range. The most active nsp14 inhibitor identified is as potent as but particularly more specific than the broad-spectrum MTase inhibitor, sinefungin. Molecular docking suggests that the inhibitor binds to a pocket formed by the S-adenosyl methionine (SAM) and cap RNA binding sites, conserved among SARS-CoV nsp14. These dinucleoside SAM analogs will serve as starting points for the development of next inhibitors for SARS-CoV-2 nsp14 N7-MTase. | 0223-5234 | 2020-06-14 02:00:00+02:00 | pubmed | Adenine__chemistry;Betacoronavirus__isolation & purification;Coronavirus Infections__drug therapy;Exoribonucleases__antagonists & inhibitors;Humans;Methylation;Methyltransferases__antagonists & inhibitors;Molecular Docking Simulation;Nucleosides__chemistry;Pandemics;Pneumonia, Viral__drug therapy;RNA Caps__chemistry;RNA, Viral__genetics;S-Adenosylmethionine__analogs & derivatives;Viral Nonstructural Proteins__antagonists & inhibitors;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Medicinal Chemistry | Rostom Ahmed-Belkacem;Priscila Sutto-Ortiz;Mathis Guiraud;Bruno Canard;Jean-Jacques Vasseur;Etienne Decroly;Françoise Debart | Bisubstrate;Coronavirus;Inhibitor;Nucleoside;RNA methyltransferase;SAM analogs | 2020-06-12 02:00:00+02:00 | 32563813 | FR | IBMM, CNRS, University of Montpellier, ENSCM, Montpellier, France.;AFMB, CNRS, Aix-Marseille University, UMR 7257, 163 Avenue de Luminy, Marseille, France.;AFMB, CNRS, Aix-Marseille University, UMR 7257, 163 Avenue de Luminy, Marseille, France. Electronic address: etienne.decroly@afmb.univ-mrs.fr.;IBMM, CNRS, University of Montpellier, ENSCM, Montpellier, France. Electronic address: francoise.debart@umontpellier.fr. | 1179 | ||
| 10.2196/19855 | Journal Article | en | Epidemiological Observations on the Association Between Anosmia and COVID-19 Infection: Analysis of Data From a Self-Assessment Web Application. | https://www.ncbi.nlm.nih.gov/pubmed/32496206 | We developed a self-assessment and participatory surveillance web application for coronavirus disease (COVID-19), which was launched in France in March 2020. | 1438-8871 | 2020-06-14 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus__pathogenicity;Coronavirus Infections__epidemiology;Disease Outbreaks;France__epidemiology;Humans;Middle Aged;Olfaction Disorders__epidemiology;Pandemics;Pneumonia, Viral__epidemiology;Self-Assessment;Surveys and Questionnaires;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Medical Internet Research | Fabrice Denis;Simon Galmiche;Aurélien Dinh;Arnaud Fontanet;Arnaud Scherpereel;Francois Benezit;François-Xavier Lescure | COVID-19;anosmia;epidemiological surveillance;epidemiology;outbreak;self-assessment;surveillance;symptoms;web application | 2020-06-11 02:00:00+02:00 | 32496206 | FR | Inter-regional Cancer Institut Jean Bernard, Le Mans, France.;Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.;Service de maladies infectieuses et tropicales, Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris, Garches, France.;Service de pneumologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France.;Service de maladies infectieuses et réanimation médicale, Centre Hospitalier Universitaire de Rennes Pointchaillou, Rennes, France.;Infectious and Tropical Diseases Department, Bichat-Claude Bernard University Hospital and University of Paris, Assistance Publique - Hôpitaux de Paris, Paris, France.;Team DesCID, Infection, Antimicrobials, Modelling, Evolution - U1137, French Institute for Health and Medical Research, Institut national de la santé et de la recherche médicale, Paris, France. | 1184 | ||
| 10.1016/j.hpb.2020.05.012 | Journal Article | en | Delivery of hepato-pancreato-biliary surgery during the COVID-19 pandemic: an European-African Hepato-Pancreato-Biliary Association (E-AHPBA) cross-sectional survey. | https://www.ncbi.nlm.nih.gov/pubmed/32565039 | The extent of the COVID-19 pandemic and the resulting response has varied globally. The European and African Hepato-Pancreato-Biliary Association (E-AHPBA), the premier representative body for practicing HPB surgeons in Europe and Africa, conducted this survey to assess the impact of COVID-19 on HPB surgery. | 1365-182X | 2020-06-14 02:00:00+02:00 | pubmed | HPB | Anita Balakrishnan;Mickael Lesurtel;Ajith K Siriwardena;Stefan Heinrich;Alejandro Serrablo;Marc G H Besselink;Mert Erkan;Bodil Andersson;Wojciech G Polak;Andrea Laurenzi;Stefan W M Olde Damink;Frederik Berrevoet;Isabella Frigerio;Jose M Ramia;Thomas K Gallagher;Susanne Warner;Shailesh V Shrikhande;Rene Adam;Martin D Smith;Kevin C Conlon | 2020-06-10 02:00:00+02:00 | 32565039 | FR;SE;IE;GB;US;IT;NL;TR;ZA;ES;IN;BE;DE | Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, United Kingdom. Electronic address: ab2031@cam.ac.uk.;Department of Digestive Surgery and Liver Transplantation, University Hospital Croix Rousse, Hospices Civils de Lyon, University of Lyon 1, 69317, Lyon, France.;Department of Surgery, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, United Kingdom.;Department of General, Visceral and Transplant Surgery, Universitätsmedizin Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany.;Department of Surgery, Miguel Servet University Hospital, Paseo Isabel la Catolica, 50009, Zaragoza, Spain.;Department of Surgery, Amsterdam UMC, G4.146-1, Meibergdreef 9, 1105, Amsterdam, the Netherlands.;Department of Surgery, Koc University School of Medicine and Research Center for Translational Medicine, Davutpasa Caddesi No:4, 34010, Instanbul, Turkey.;Department of Clinical Sciences Lund, Surgery, Lund University and Skane University Hospital, 22100, Lund, Sweden.;Department of Surgery, Erasmus MC University Medical Center, Dr. Molewaterplein 40, 3016 GD, Rotterdam, the Netherlands.;Division of General Surgery and Transplantation, S. Orsola-Malpighi Hospital, University of Bologna, via G Masserenti 9, 40138, Bologna, Italy.;Department of Surgery, Maastricht University Medical Center and NUTRIM School of Nutrition and Translational Research in Metabolism, Maastrict University, 6200 MD, Maastricht, the Netherlands, Department of General Visceral and Transplantation Surgery, RWTH University Hospital Aachen, Aachen, Germany.;Department of General and HPB Surgery and Liver Transplantation, University Hospital Gent, Corneel Heymanslaan 10, 9000, Gent, Belgium.;Department of General and Vascular Surgery, Pederzoli Hospital, Via Monte Baldo 24, 37019, Peschiera del Garda, Verona, Italy.;Department of Surgery, Hospital Universitario de Guadalajara, 19002, Guadalajara, Spain.;Department of Surgery, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.;Department of Surgery, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA.;Department of Gastrointestinal and HPB Surgery, Tata Memorial Centre, Ernest Borges Marg, Parel, Mumbai, 400012, India.;APHP Hopital Universitaire Paul Brousse, Universite Paris-Saclay, F-94804, Villejuif, France.;Department of Surgery, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Braamfontein, 2000, Johannesburg, South Africa.;Department of Surgery, Trinity College Dublin, Ireland and St Vincent's University Hospital, Elm Park, Dublin 4, Ireland. | 1188 | ||||
| Letter | en | COVID reverse transcriptase PCR in private laboratories: From theory to reality. | https://www.ncbi.nlm.nih.gov/pubmed/32531329 | 2020-06-14 02:00:00+02:00 | pubmed | M Autissier;G Guiraud;Y Lévy | COVID-19;Reverse transcriptase PCR | 2020-06-10 02:00:00+02:00 | 32531329 | FR;US | Université Claude Bernard Lyon 1, faculté de médecine Lyon est, collège universitaire de médecine générale, 8, avenue Rockefeller, 69008 Lyon, France. Electronic address: marianne.autissier@wanadoo.fr.;Laboratoire Dynabio: Le Loup Pendu, 545, avenue Victor-Hugo, 69140 Rillieux-la-Pape, France.;Université Claude Bernard Lyon 1, faculté de médecine Lyon est, collège universitaire de médecine générale, 8, avenue Rockefeller, 69008 Lyon, France. | 1198 | |||||||
| 10.1016/j.midw.2020.102779 | Editorial | en | The impact of the coronavirus (COVID-19) pandemic on maternity care in Europe. | https://www.ncbi.nlm.nih.gov/pubmed/32600862 | 0266-6138 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Birth Setting__nursing;Coronavirus Infections__epidemiology;Critical Pathways__trends;Europe__epidemiology;Female;Humans;Infection Control__methods;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Infectious Disease Transmission, Vertical__prevention & control;Maternal Health Services__organization & administration;Midwifery__methods;Organizational Innovation;Pandemics__prevention & control;Perinatal Care__methods;Pneumonia, Viral__epidemiology;Pregnancy;Pregnancy Complications, Infectious__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Midwifery | Kirstie Coxon;Cristina Fernandez Turienzo;Liselotte Kweekel;Bahareh Goodarzi;Lia Brigante;Agnes Simon;Miriam Morlans Lanau | 2020-06-10 02:00:00+02:00 | 32600862 | FR;NL;GB;ES | Department of Midwifery, Faculty of Health, Social Care and Education, Kingston University and St.George's, University of London, 6th Floor, Hunter Wing, Cranmer Terrace, London, SW17 0RE, UK. Electronic address: k.coxon@sgul.kingston.ac.uk.;Department of Women's and Children's Health, Faculty of Life Sciences and Medicine, King's College London, London, UK.;Royal Dutch Organisation of Midwives KNOV Utrecht, Netherlands.;Department of Midwifery Science, AVAG, Amsterdam Public Health research institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.;French College of Midwves, Paris, France.;Midwife, Hospital Universitario Infanta Leonor, Madrid, Spain. | 1202 | ||||
| Letter | en | Patient flow in the largest French psychiatric emergency centre in the context of the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32593065 | To date, we have no French data about the psychiatric consequences of the Covid-19 pandemic and the confinement. In the largest French psychiatric emergency centre, we compared the average number of consultations per day during the confinement with the same period preceding the confinement and with the same periods of previous years, and we observed a significant drop in attendance. Our team had to adapt promptly to these changes in public mental health services, and we set up a telephone hotline dedicated to psychiatric patients and their families, in order to prevent a secondary psychiatric crisis. | 2020-06-14 02:00:00+02:00 | pubmed | Alexandra Pham-Scottez;Jérôme Silva;David Barruel;Valérie Dauriac-Le Masson;Liova Yon;Anne-Kristelle Trebalag;Raphaël Gourevitch | Covid-19;Psychiatric emergency centre;Psychological crisis intervention | 2020-06-08 02:00:00+02:00 | 32593065 | FR | Centre Psychiatrique d'Orientation et d'Accueil (CPOA), GHU Paris Psychiatrie et Neurosciences, 1 rue Cabanis, 75014 Paris, France. Electronic address: a.pham@ghu-paris.fr.;Centre Psychiatrique d'Orientation et d'Accueil (CPOA), GHU Paris Psychiatrie et Neurosciences, 1 rue Cabanis, 75014 Paris, France, Département d'Information Médicale (DIM), GHU Paris Psychiatrie et Neurosciences, 1 rue Cabanis, 75014 Paris, France.;Service de Psychiatrie de l'Adolescent et du Jeune Adulte, Institut Mutualiste Montsouris, 42 boulevard Jourdan, 75014 Paris, France.;Centre Psychiatrique d'Orientation et d'Accueil (CPOA), GHU Paris Psychiatrie et Neurosciences, 1 rue Cabanis, 75014 Paris, France. | 1221 | ||||||
| Letter | en | Self-Reported Loss of Smell and Taste in SARS-CoV-2 Patients: Primary Care Data to Guide Future Early Detection Strategies. | https://www.ncbi.nlm.nih.gov/pubmed/32519322 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnosis;Critical Pathways;Cross-Sectional Studies;Dysgeusia__diagnosis;Female;France__epidemiology;Humans;Male;Middle Aged;Olfaction Disorders__diagnosis;Pandemics;Pneumonia, Viral__diagnosis;Primary Health Care__methods;Reproducibility of Results;Self Report__statistics & numerical data;Symptom Assessment;COVID-19;severe acute respiratory syndrome coronavirus 2 | Benoit Tudrej;Paul Sebo;Julie Lourdaux;Clara Cuzin;Martin Floquet;Dagmar M Haller;Hubert Maisonneuve | 2020-06-09 02:00:00+02:00 | 32519322 | FR;CH | University College of General Medicine, University Claude Bernard Lyon 1, Lyon, France. dr.tudrej@gmail.com.;Mermoz Primary Health Centre, 99 Avenue Jean Mermoz, 69008, Lyon, France. dr.tudrej@gmail.com.;Primary Care Unit, Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Cerballiance Rhône-Alpes Laboratory, Lyon, France.;University College of General Medicine, University Claude Bernard Lyon 1, Lyon, France.;Mermoz Primary Health Centre, 99 Avenue Jean Mermoz, 69008, Lyon, France. | 1223 | |||||||
| 10.1017/s1049023x20000783 | Case Reports;Journal Article | en | Feedback to Prepare EMS Teams to Manage Infected Patients with COVID-19: A Case Series. | https://www.ncbi.nlm.nih.gov/pubmed/32507122 | Coronavirus Disease 2019 (COVID-19), a new respiratory disease, is spreading globally. In France, Emergency Medical Service (EMS) teams are mobile medicalized resuscitation teams composed of emergency physician, nurse or anesthesiologist nurse, ambulance driver, and resident. Four types of clinical cases are presented here because they have led these EMS teams to change practices in their management of patients suspected of COVID-19 infection: cardiac arrest, hypoxia on an acute pneumonia, acute chronic obstructive pulmonary disease (COPD) exacerbation with respiratory and hemodynamic disorders, and upper function disorders in a patient in a long-term care facility. The last case raised the question of COVID-19 cases with atypical forms in elderly subjects. Providers were contaminated during the management of these patients. These cases highlighted the need to review the way these EMS teams are responding to the COVID-19 pandemic, in view of heightening potential for early identification of suspicious cases, and of reinforcing the application of staff protection equipment to limit risk of contamination. | 1049-023X,1945-1938 | 2020-06-14 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__diagnosis;Disaster Planning;Emergency Medical Services__organization & administration;Emergency Treatment__standards;Female;France__epidemiology;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Male;Pandemics;Personal Protective Equipment;Planning Techniques;Pneumonia, Viral__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Prehospital and Disaster Medicine | Daniel Aiham Ghazali;Amina Ouersighni;Matthieu Gay;Virginie Audebault;Thomas Pavlovsky;Enrique Casalino | COVID-19;EMS;emergency;personnel protection equipment;providers’ contamination | 2020-06-08 02:00:00+02:00 | 32507122 | FR | Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Universitaire Paris Nord Val de Seine, EMS of Beaujon Academic Hospital, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Universitaire Paris Nord Val de Seine, Emergency Department of Bichat Academic Hospital, Paris, France.;Infection Antimicrobials Modelling Evolution (IAME) Research Center, UMR 1137 - INSERM, University of Paris Diderot, Paris, France. | 1230 | ||
| Letter | en | The use of Google Trends for acral symptoms during COVID-19 outbreak in France. | https://www.ncbi.nlm.nih.gov/pubmed/32358813 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Disease Outbreaks;France__epidemiology;Humans;Internet__trends;Pandemics;Pneumonia, Viral__complications;Skin Diseases__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | N Kluger;J N Scrivener | 2020-06-08 02:00:00+02:00 | 32358813 | FI;FR | Departments of Dermatology, Allergology and Venereology, Helsinki University Hospital, Helsinki, Finland.;Clinique Dermatologique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. | 1237 | |||||||
| Letter | en | European Task Force on Contact Dermatitis statement on coronavirus disease-19 (COVID-19) outbreak and the risk of adverse cutaneous reactions. | https://www.ncbi.nlm.nih.gov/pubmed/32356382 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Dermatitis, Contact__complications;Disease Outbreaks;Europe__epidemiology;Humans;Pandemics;Pneumonia, Viral__complications;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | A Balato;F Ayala;M Bruze;M-N Crepy;M Gonçalo;J Johansen;S M John;P Pigatto;A Raimondo;T Rustemeyer;M-L A Schuttelaar;C Svedman;O Aerts;W Uter;M Wilkinson;A Gimenez-Arnau | 2020-06-08 02:00:00+02:00 | 32356382 | FR;SE;BE;PT;GB;IT;NL;ES;DK;DE | Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.;Professor Emeritus of Dermatology, University of Naples Federico II, Naples, Italy.;Department of Occupational and Environmental Dermatology, Skåne University Hospital, Lund University, Malmö, Sweden.;Department of Occupational and Environmental Diseases, Hotel-Dieu Hospital, Paris, France.;Department of Dermatology, Cochin Hospital, Paris Descartes University, Paris, France.;Clinic of Dermatology, University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.;Department of Dermatology and Allergy, National Allergy Research Centre, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.;Department of Dermatology, Environmental Medicine, Health Theory, University of Osnabrueck, Osnabrueck, Germany.;Institute for Interdisciplinary Dermatological Prevention and Rehabilitation (iDerm) at the University of Osnabrueck, Osnabrueck, Germany.;Rehabilitation (iDerm) at the University of Osnabrueck, Osnabrueck, Germany.;Department of Biomedical, Surgical and Dental Sciences, Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, University of Milan, Milan, Italy.;Department of Medicine, Surgery and Dentistry, 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy.;Department of Dermatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.;Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.;University Hospital Antwerp (UZA) and University of Antwerp, Antwerp, Belgium.;Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander University Erlangen/Nürnberg, Erlangen, Germany.;Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.;Department of Dermatology, Hospital del Mar. IMIM, Universitat Autònoma Barcelona, Barcelona, Spain. | 1238 | |||||||
| 10.1016/j.jhin.2020.06.018 | Journal Article | en | Sustainabilit of SARS-CoV-2 in aerosols: should we worry about airborne transmission? | https://www.ncbi.nlm.nih.gov/pubmed/32540460 | 0195-6701 | 2020-06-14 02:00:00+02:00 | pubmed | Journal of Hospital Infection | S Romano-Bertrand;L-S Aho-Glele;B Grandbastien;J-F Gehanno;D Lepelletier | COVID-19;FFP2 mask;N95 mask;Personal protective equipment;Respiratory droplets | 2020-06-12 02:00:00+02:00 | 32540460 | FR;CH | HydroSciences Montpellier, IRD, CNRS, Montpellier University, Montpellier, France, Hospital Hygiene and Infection Control Team, University Hospital of Montpellier, Montpellier, France. Electronic address: sara.romano-bertrand@umontpellier.fr.;Department of Epidemiology and Infection Control, Dijon University Hospital, Dijon, France.;Service de Médecine Préventive Hospitalière Hygiène, Prévention et Contrôle de l'Infection (HPCI), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Evaluation and Public Health Department, Rouen University Hospital, Rouen, France.;MiHAR Lab, EE 1701 S, Nantes University, Nantes, France, Bacteriology and Infection Control Department, University Hospital, Nantes, France. | 1251 | ||||
| 10.1016/j.euf.2020.05.023 | Journal Article;Review | en | Management of Female and Functional Urology Patients During the COVID Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32540267 | Coronavirus disease 19 (COVID-19) has changed standard urology practice around the world. The situation is affecting not only uro-oncological patients but also patients with benign and disabling conditions who are suffering delays in medical attention that impact their quality of life. | 2405-4569 | 2020-06-14 02:00:00+02:00 | pubmed | Ambulatory Care;Betacoronavirus;Coronavirus Infections__epidemiology;Cystitis, Interstitial__diagnosis;Disease Management;Female;Humans;Lower Urinary Tract Symptoms__diagnosis;Male;Pandemics__prevention & control;Personal Protective Equipment;Pneumonia, Viral__epidemiology;Telemedicine;Urinary Incontinence__diagnosis;Urinary Retention__diagnosis;Urinary Tract Infections__diagnosis;Urologic Diseases__diagnosis;Urologic Surgical Procedures;Urology__methods;Vesicovaginal Fistula__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Urology Focus | Luis López-Fando;Paulina Bueno;David Carracedo;Marcio Averbeck;David M Castro-Díaz;Emmanuel Chartier-Kastler;Francisco Cruz;Roger Dmochowski;Enrico Finazzi-Agrò;Sakineh Hajebrahimi;John Heesakkers;George Kasyan;Tufan Tarcan;Benoit Peyronnet;Mauricio Plata;Bárbara Padilla-Fernández;Frank Van Der Aa;Salvador Arlandis;Hashim Hashim | COVID-19;Female urology;Functional urology;Neurourology;Prioritization;Telehealth | 2020-06-12 02:00:00+02:00 | 32540267 | FR;RU;CO;PT;GB;US;BR;IT;IR;NL;TR;ES;BE | Bladder Section, Urology Department, Hospital Ramón y Cajal, Madrid, Spain.;Bristol Urological Institute, Southmead Hospital, Bristol, UK.;Functional, Female and Urodynamic Section, Urology Department, Hospital Rey Juan Carlos, Madrid, Spain.;Videourodynamics Unit, Neuro-Urology Department, Moinhos de Vento Hospital, Porto Alegre, Brazil.;Urology Department, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain, Department of Surgery, Universidad de La Laguna, Tenerife, Spain.;Medical School, Sorbonne Université, Academic Hospital Pitié-Salpêtrière, Paris, France.;Hospital São João and Faculty of Medicine of Porto, Porto, Portugal.;Vanderbilt University Medical Center, Nashville, TN, USA.;Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy.;Research Center for Evidence Based Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.;Department of Urology, Radboudumc, Nijmegen, The Netherlands.;Urology Department, Moscow State University of Medicine and Dentistry, Spasokukotsky Moscow City Hospital, Moscow, Russia.;Department of Urology, Marmara University School of Medicine and Department of Urology, Koç University School of Medicine, Istanbul, Turkey.;Department of Urology, University of Rennes, Rennes, France.;Department of Urology, Fundación Santa Fe de Bogotá, Universidad de los Andes School of Medicine, Bogotá, Colombia.;Urology Department, University Hospitals Leuven, KU Leuven, Leuven, Belgium.;Functional and Reconstructive Urology Section, Urology Department, La Fe University and Polytechnic Hospital, Valencia, Spain. Electronic address: arlandis_sal@gva.es. | 1252 | ||
| 10.3390/ijerph17124205 | Journal Article | en | A Taxonomy Proposal for the Assessment of the Changes in Soundscape Resulting from the COVID-19 Lockdown. | https://www.ncbi.nlm.nih.gov/pubmed/32545587 | Many countries around the world have chosen lockdown and restrictions on people's mobility as the main strategies to combat the COVID-19 pandemic. These actions have significantly affected environmental noise and modified urban soundscapes, opening up an unprecedented opportunity for research in the field. In order to enable these investigations to be carried out in a more harmonized and consistent manner, this paper makes a proposal for a set of indicators that will enable to address the challenge from a number of different approaches. It proposes a minimum set of basic energetic indicators, and the taxonomy that will allow their communication and reporting. In addition, an extended set of descriptors is outlined which better enables the application of more novel approaches to the evaluation of the effect of this new soundscape on people's subjective perception. | 1660-4601 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Noise;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Environmental Research and Public Health | César Asensio;Pierre Aumond;Arnaud Can;Luis Gascó;Peter Lercher;Jean-Marc Wunderli;Catherine Lavandier;Guillermo de Arcas;Carlos Ribeiro;Patricio Muñoz;Gaetano Licitra | COVID-19;descriptors;indicators;lockdown;metrics;noise;sound;soundscape | 2020-06-12 02:00:00+02:00 | 32545587 | FR;CH;IT;ES;AT | Instrumentation and Applied Acoustics Research group (I2A2), Universidad Politécnica de Madrid, 28031 Madrid, Spain.;UMRAE, Univ Gustave Eiffel, IFSTTAR, CEREMA, 44340 Bouguenais, France.;Institute for Highway Engineering and Transport Planning, Graz University of Technology, 8010 Graz, Austria.;Empa, Swiss Federal Laboratories for Material Science and Technology, Laboratory for Acoustics/Noise Control, 8600 Dübendorf, Switzerland.;ETIS Laboratory, UMR 8051, CY Cergy Paris University, ENSEA, CNRS, F-95302 Cergy-Pontoise Cedex, France.;Bruitparif, 93200 Saint-Denis, France.;Acoucite, Observatoire de l'environnement sonore de la Métropole de Lyon, 69007 Lyon, France.;Environmental Protection Agency of Tuscany Region, Pisa Department, 56127 Pisa, Italy. | 1254 | ||
| 10.1016/j.anorl.2020.06.007 | Journal Article | en | Impact of the first month of Covid-19 lockdown on oncologic surgical activity in the Ile de France region university hospital otorhinolaryngology departments. | https://www.ncbi.nlm.nih.gov/pubmed/32565242 | To evaluate the impact of the first month of lockdown related to the Covid-19 epidemic on the oncologic surgical activity in the Ile de France region university hospital otorhinolaryngology departments. | 1879-7296 | 2020-06-14 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | O Laccourreye;H Mirghani;D Evrard;P Bonnefont;L Brugel;F Tankere;A Coste;B Barry;B Baujat;S Atallah;R Kania | Cancer;Covid-19;Otorhinolaryngology | 2020-06-13 02:00:00+02:00 | 32565242 | FR | Service d'ORL et de Chirurgie Cervico-Faciale, Université Paris Centre, HEGP, AP-HP, 20-40, rue Leblanc, 75015 Paris, France. Electronic address: ollivier.laccourreye@aphp.fr.;Service d'ORL et de Chirurgie Cervico-Faciale, Université Paris Centre, HEGP, AP-HP, 20-40, rue Leblanc, 75015 Paris, France.;Service d'ORL et de Chirurgie Cervico-Faciale, Université Paris Centre, Hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France.;Service d'ORL et de Chirurgie Cervico-Faciale, Université Paris Nord, Hôpital La Pitié-Salpétrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.;Service d'ORL et de Chirurgie Cervico-Faciale, Université Paris Est, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94000 Créteil, France.;Service d'ORL et de Chirurgie Cervico-Faciale, Université Paris Sorbonne, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.;Service d'ORL et de Chirurgie Cervico-Faciale, Université Paris Nord, AP-HP, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France. | 1262 | |||
| 10.1016/j.clim.2020.108510 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Development of child immunity in the context of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32544611 | Children, because of having an immature immune system, are usually more prone than the adults to the microbial infections and have more severe symptoms, which is especially true for the newborns, and very young children. However, the review of clinical data from the current COVID-19 pandemic indicates otherwise. We discuss here what are the main features and components of children's immune system, the role of maternal transmission of immunity, and what are the possible explanations for the seemingly lower infection rate and severity of COVI-19 in children. | 1521-6616 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Age Factors;Betacoronavirus__immunology;Child;Child, Preschool;Coronavirus Infections__epidemiology;Cytokines__immunology;Disease Resistance;Female;Humans;Immune System__virology;Incidence;Infant;Infant, Newborn;Milk, Human__immunology;Pandemics;Placenta__immunology;Pneumonia, Viral__epidemiology;Pregnancy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Immunology | Małgorzata Kloc;Rafik M Ghobrial;Ernest Kuchar;Sławomir Lewicki;Jacek Z Kubiak | COVID-19;Child immunity;Immune system development;Macrophages | 2020-06-13 02:00:00+02:00 | 32544611 | FR;PL;US | The Houston Methodist Research Institute, Houston, TX, USA, The Houston Methodist Hospital, Department of Surgery, Houston, TX, USA, The University of Texas, M.D. Anderson Cancer Center, Department of Genetics, Houston, TX, USA. Electronic address: mkloc@houstonmethodist.org.;The Houston Methodist Research Institute, Houston, TX, USA, The Houston Methodist Hospital, Department of Surgery, Houston, TX, USA.;Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, Poland.;Department of Regenerative Medicine and Cell Biology, Military Institute of Hygiene and Epidemiology (WIHE), Warsaw, Poland.;Department of Regenerative Medicine and Cell Biology, Military Institute of Hygiene and Epidemiology (WIHE), Warsaw, Poland, UnivRennes, UMR 6290, CNRS, Institute of Genetics and Development of Rennes, Cell Cycle Group, Faculty of Medicine, Rennes, France. Electronic address: jacek.kubiak@univ-rennes1.fr. | 1263 | ||
| 10.1111/all.14439 | Journal Article;Review | en | Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19. | https://www.ncbi.nlm.nih.gov/pubmed/32511784 | Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease. | 0105-4538,1398-9995 | 2020-06-14 02:00:00+02:00 | pubmed | Allergy | Aslı Gelincik;Knut Brockow;Gülfem E Çelik;Inmaculada Doña;Cristobalina Mayorga;Antonino Romano;Özge Soyer;Marina Atanaskovic-Markovic;Annick Barbaud;Maria Jose Torres | COVID-19;SARS-CoV-2;desensitization;drug hypersensitivity reactions | 2020-06-08 02:00:00+02:00 | 32511784 | FR;GB;IT;TR;RS;ES;DE | Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.;Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.;Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.;Allergy Unit, Hospital Regional Universitario de Málaga-ARADyAL, Málaga, Spain.;Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA-ARADyAL, Málaga, Spain.;Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA-ARADyAL, Malaga, Spain.;IRCCS Oasi Maria S.S., Troina, Italy.;Fondazione Mediterranea G.B. Morgagni, Catania, Italy.;Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara, Turkey.;Faculty of Medicine, University Children's Hospital, University of Belgrade, Belgrade, Serbia.;Department of Dermatology and Allergology, Tenon Hospital (AP-HP), Sorbonne Universities, Pierre et Marie Curie University, Paris, France.;Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Sorbonne Université, Paris, France.;Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-BIONAND-ARADyAL, Malaga, Spain. | 1269 | |||
| 10.1590/s1677-5538.ibju.2020.s106 | Journal Article;Review | en | Clinical and Surgical Assistance in Prostate Cancer during the COVID-19 Pandemic: Implementation of assistance protocols. | https://www.ncbi.nlm.nih.gov/pubmed/32549073 | Propose an approach of prostate cancer (PCa) patients during COVID-19 pandemic. | 1677-6119,1677-5538 | 2020-06-21 02:00:00+02:00 | pubmed | Androgen Antagonists__therapeutic use;Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Male;Pandemics;Pneumonia, Viral__epidemiology;Prostatic Neoplasms__surgery;Urology__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | International braz j urol | Lara Rodriguez Sanchez;Xavier Cathelineau;Alexis M Alva Pinto;Ángel Borque-Fernando;Maria Jesús Gil;Chi-Hang Yee;Rafael Sanchez-Salas | COVID-19 [Supplementary Concept];Pandemics;Prostate cancer, familial [Supplementary Concept] | 2020-06-18 02:00:00+02:00 | 32549073 | FR;CN;HK;ES;PE | Department of Urology, L'Institut Mutualiste Montsouris, Université Paris-Descartes, Paris, France.;Department of Urology, Hospital Universitario Miguel Servet, Zaragoza, Spain.;Department of Urology, Clínica Oncosalud, Lima, Peru.;IIS-Aragon, Zaragoza, Spain.;Department of Surgery, S.H. Ho Urology Centre,The Chinese University of Hong Kong, Hong Kong. | 1280 | ||
| 10.1684/vir.2020.0842 | Journal Article | en | A scenario to safely ease the covid-19 lockdown while allowing economic recovery. | https://www.ncbi.nlm.nih.gov/pubmed/32540825 | If they work as expected, the strict containment measures enforced to stop the French Covid-19 epidemic will leave a large proportion of the population "naive" about the SARS-CoV-2 virus. In these conditions, how can we prevent the epidemic from rebounding, at a time when this restrictive policy will soon become untenable economically and socially? Based on the figures, now well known, of the lethality of covid-19 according to age classes, I suggest that a gradual release of the containment be instituted, which will keep retirees in isolation (the 65+ age class), whose risk is maximal and the impact on economic production the lowest. This scenario might be applicable to most European countries that enforce mandatory retirement ages for most of workers. | 2020-06-21 02:00:00+02:00 | pubmed | Age Factors;Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections__economics;France__epidemiology;Humans;Pandemics__economics;Pneumonia, Viral__economics;Public Policy__economics;Quarantine__economics;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean-Michel Claverie | Covid-19;age-dependent lethality;economic recovery;lockdown termination | 2020-06-17 02:00:00+02:00 | 32540825 | FR | Emeritus Professor of Medicine, Aix-Marseille Université/APHM Genomic & Structural Information Laboratory (UMR 7256) Mediterranean Institute of Microbiology (FR 3479), Marseille, France Member of the board of directors of the French society of virology until March 30, 2020. | 1283 | ||||
| NCI NIH HHS;NCI NIH HHS | 10.1016/s2352-3026(20)30205-2 | Journal Article;Review | en | Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. | https://www.ncbi.nlm.nih.gov/pubmed/32563283 | The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts. | 2352-3026 | 2020-06-21 02:00:00+02:00 | pubmed | Adult;Betacoronavirus__pathogenicity;Coronavirus Infections__complications;Disease Management;Expert Testimony;Humans;Infection Control__standards;Leukemia__therapy;Myeloproliferative Disorders__therapy;Pandemics;Pneumonia, Viral__complications;Practice Guidelines as Topic__standards;Resource Allocation;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Haematology | Amer M Zeidan;Prajwal C Boddu;Mrinal M Patnaik;Jan Philipp Bewersdorf;Maximilian Stahl;Raajit K Rampal;Rory Shallis;David P Steensma;Michael R Savona;Mikkael A Sekeres;Gail J Roboz;Daniel J DeAngelo;Andre C Schuh;Eric Padron;Joshua F Zeidner;Roland B Walter;Francesco Onida;Amir Fathi;Amy DeZern;Gabriela Hobbs;Eytan M Stein;Paresh Vyas;Andrew H Wei;David T Bowen;Pau Montesinos;Elizabeth A Griffiths;Amit K Verma;Alla Keyzner;Michal Bar-Natan;Shyamala C Navada;Marina Kremyanskaya;Aaron D Goldberg;Aref Al-Kali;Mark L Heaney;Aziz Nazha;Huda Salman;Selina Luger;Keith W Pratz;Heiko Konig;Rami Komrokji;Michael Deininger;Blanca Xicoy Cirici;Vijaya Raj Bhatt;Lewis R Silverman;Harry P Erba;Pierre Fenaux;Uwe Platzbecker;Valeria Santini;Eunice S Wang;Martin S Tallman;Richard M Stone;John Mascarenhas | 2020-06-18 02:00:00+02:00 | 32563283 | FR;CA;GB;US;IT;AU;ES;DE | [{"country": "United States", "agency": "NCI NIH HHS", "grantid": "K12 CA087723"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "P30 CA016359"}] | Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA, Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu.;Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA, Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.;Department of Hematology, Mayo Clinic, Rochester, MN, USA.;Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Department of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA.;Department of Hematology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.;Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.;Department of Hematology and Oncology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.;Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.;Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.;Division of Hematology and Oncology, Lineberger Comprehensive Care Center, University of North Carolina, Chapel Hill, NC, USA.;Division of Hematology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.;Department of Hematology, IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.;Department of Hematology, Centre for Leukemia, Massachusetts General Hospital, Boston, MA, USA.;Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.;MRC Molecular Haematology Unit, BRC Oxford Department of Haematology, University of Oxford, Oxford, UK.;Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia.;Department of Haematology, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK.;Department of Haematology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, CIBERONC, Instituto Carlos III, University of Valencia, Madrid, Spain.;Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.;Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.;Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Hematology, Herbert Irving Comprehensive Care Centre, Columbia University, New York, NY, USA.;Department of Hematology, Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH, USA.;Department of Internal Medicine, Stony Brook University Cancer Center, Stony Brook, NY, USA.;Department of Medicine, Hematology and Oncology Division, University of Pennsylvania, Philadelphia, PA, USA.;Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, Indiana University, Indianapolis, IN, USA.;Huntsman Cancer Institute, Department of Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.;Clinical Haematology Department, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.;Fred and Pamela Buffett Cancer Center, Department of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.;Duke Cancer Institute, Department of Medicine, Division of Hematologic Malignancies and Cellular Therapies, Durham, NC, USA.;Department of Hematology, Hôpital St Louis, Assistance Publique-Hôpitaux de Paris, Paris, France, Department of Haematology, Paris University, Paris, France.;Department of Medicine, Division of Translational Hematology, Leipzig University Hospital, Leipzig, Germany.;Department of Medicine, University of Florence Medical School, Florence, Italy. | 1299 | |
| 10.1186/s13054-020-03000-7 | Journal Article;Review | en | Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. | https://www.ncbi.nlm.nih.gov/pubmed/32560658 | COVID-19 is an infection induced by the SARS-CoV-2 coronavirus, and severe forms can lead to acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) management. Severe forms are associated with coagulation changes, mainly characterized by an increase in D-dimer and fibrinogen levels, with a higher risk of thrombosis, particularly pulmonary embolism. The impact of obesity in severe COVID-19 has also been highlighted.In this context, standard doses of low molecular weight heparin (LMWH) may be inadequate in ICU patients, with obesity, major inflammation, and hypercoagulability. We therefore urgently developed proposals on the prevention of thromboembolism and monitoring of hemostasis in hospitalized patients with COVID-19.Four levels of thromboembolic risk were defined according to the severity of COVID-19 reflected by oxygen requirement and treatment, the body mass index, and other risk factors. Monitoring of hemostasis (including fibrinogen and D-dimer levels) every 48 h is proposed. Standard doses of LMWH (e.g., enoxaparin 4000 IU/24 h SC) are proposed in case of intermediate thrombotic risk (BMI < 30 kg/m2, no other risk factors and no ARDS). In all obese patients (high thrombotic risk), adjusted prophylaxis with intermediate doses of LMWH (e.g., enoxaparin 4000 IU/12 h SC or 6000 IU/12 h SC if weight > 120 kg), or unfractionated heparin (UFH) if renal insufficiency (200 IU/kg/24 h, IV), is proposed. The thrombotic risk was defined as very high in obese patients with ARDS and added risk factors for thromboembolism, and also in case of extracorporeal membrane oxygenation (ECMO), unexplained catheter thrombosis, dialysis filter thrombosis, or marked inflammatory syndrome and/or hypercoagulability (e.g., fibrinogen > 8 g/l and/or D-dimers > 3 μg/ml). In ICU patients, it is sometimes difficult to confirm a diagnosis of thrombosis, and curative anticoagulant treatment may also be discussed on a probabilistic basis. In all these situations, therapeutic doses of LMWH, or UFH in case of renal insufficiency with monitoring of anti-Xa activity, are proposed.In conclusion, intensification of heparin treatment should be considered in the context of COVID-19 on the basis of clinical and biological criteria of severity, especially in severely ill ventilated patients, for whom the diagnosis of pulmonary embolism cannot be easily confirmed. | 1364-8535 | 2020-06-21 02:00:00+02:00 | pubmed | Coronavirus Infections__physiopathology;Hemostasis__physiology;Hospitalization;Humans;Monitoring, Physiologic;Pandemics;Pneumonia, Viral__physiopathology;Risk;Thrombosis__prevention & control;COVID-19 | Critical Care | Sophie Susen;Charles Ambroise Tacquard;Alexandre Godon;Alexandre Mansour;Delphine Garrigue;Philippe Nguyen;Anne Godier;Sophie Testa;Jerrold H Levy;Pierre Albaladejo;Yves Gruel | Anticoagulant;COVID-19;Coagulation;Heparin;Obesity;Thrombosis | 2020-06-19 02:00:00+02:00 | 32560658 | FR;IT;US | Department of Hematology and Transfusion, Lille University Hospital, Lille, France. Sophie.SUSEN@CHRU-LILLE.FR.;Department of Hemostasis and Transfusion, CHU Lille, Lille, France. Sophie.SUSEN@CHRU-LILLE.FR.;Department of Anesthesia and Intensive Care, Strasbourg University Hospital, Strasbourg, France.;Department of Anesthesiology and Critical Care, Grenoble Alpes University Hospital, La Tronche, France.;Department of Anesthesiology and Critical Care Medicine, Rennes University Hospital, Rennes, France.;Department of Hematology and Transfusion, Lille University Hospital, Lille, France.;Department of Hematology Laboratory, Reims University Hospital, Reims, France.;Department of Anesthesia and Intensive Care, HEGP-AP-HP, Paris, France.;AO Istituti Ospitalieri, Cremona, Italy.;Duke University Hospital, Durham, NC, USA.;Department of Hematology-Hemostasis, Tours University Hospital, CHRU Tours, Tours, France. yves.gruel@univ-tours.fr. | 1305 | ||
| Letter | en | Fulminant myocarditis and COVID-19. Response. | https://www.ncbi.nlm.nih.gov/pubmed/32653344 | 2020-06-21 02:00:00+02:00 | pubmed | Ángela Irabien-Ortiz;José Carreras-Mora;Alessandro Sionis;Manel Tauron | 2020-06-19 02:00:00+02:00 | 32653344 | FR;ES | Servicio de Cirugía Cardiovascular, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Electronic address: angelairabien@hotmail.com.;Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Servicio de Cirugía Cardiovascular, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. | 1308 | ||||||||
| 10.1016/j.ensci.2020.100248 | Journal Article | en | Acute hypothermia in Covid 19: A case report. | https://www.ncbi.nlm.nih.gov/pubmed/32671233 | 2405-6502 | 2020-06-21 02:00:00+02:00 | pubmed | eNeurologicalSci | Nicolas Allard;Ari Maruani;Corina Cret;Alain Ameri | 2020-06-20 02:00:00+02:00 | 32671233 | FR | Department of Neurology, GHEF Meaux, 6-8, rue Saint-Fiacre, 77100 Meaux, France. | 1318 | |||||
| 10.3174/ajnr.a6642 | Case Reports;Journal Article | en | Atypical Deep Cerebral Vein Thrombosis with Hemorrhagic Venous Infarction in a Patient Positive for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32554423 | There is growing evidence that Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has a neurotropic and neuroinvasive potential. In particular, neurologic complications associated with the infection by SARS-CoV-2 include strokes that may result from a dysregulated inflammatory response to the infection. We report an atypical deep cerebral vein thrombosis complicated with hemorrhagic venous infarction in a patient positive for SARS-CoV-2 with no risk factors for thrombosis. | 0195-6108,1936-959X | 2020-06-21 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__complications;Humans;Intracranial Hemorrhages__diagnostic imaging;Intracranial Thrombosis__diagnostic imaging;Magnetic Resonance Imaging;Male;Multimodal Imaging;Pandemics;Pneumonia, Viral__complications;Tomography, X-Ray Computed;Venous Thrombosis__diagnostic imaging;COVID-19;severe acute respiratory syndrome coronavirus 2 | American Journal of Neuroradiology | L Chougar;B Mathon;N Weiss;V Degos;N Shor | 2020-06-18 02:00:00+02:00 | 32554423 | FR;UNK | From the Service de Neuroradiologie (L.C., N.S.) chougar.lydia@gmail.com.;Service de Neurochirurgie (B.M.).;Anesthesia, Critical Care and Perioperative Medicine (V.D.).;Médecine Intensive Réanimation Neurologique (N.W.), Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.;Institut du Cerveau et de la Moelle épinière (L.C., B.M.), National Institute for Health and Medical Research U 1127, Centre National de la Recherche Scientifique, Une Unité Mixte de Recherche, 7225, Sorbonne Université, Pierre and Marie Curie University, Une Unité Mixte de Recherche S 1127, Centre National de la Recherche Scientifique, Une Unité Mixte de Recherche 7225, Paris, France.;Sorbonne Université (L.C., B.M., N.W., V.D., N.S.), Paris, France.;From the Service de Neuroradiologie (L.C., N.S.). | 1345 | |||
| Letter | en | Delayed pulmonary abscess following COVID-19 pneumonia: A case report. | https://www.ncbi.nlm.nih.gov/pubmed/32623310 | 2020-06-21 02:00:00+02:00 | pubmed | B Renaud-Picard;F Gallais;M Riou;A Zouzou;M Porzio;R Kessler | COVID-19;Pneumonia;Pulmonary abscess | 2020-06-18 02:00:00+02:00 | 32623310 | FR | Department of respirology and Strasbourg Lung Transplant Program, Nouvel hôpital civil, University Hospital of Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France. Electronic address: benjamin.renaudpicard@chru-strasbourg.fr.;Laboratory of Virology, University Hospital of Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France.;Department of respirology and Strasbourg Lung Transplant Program, Nouvel hôpital civil, University Hospital of Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France. | 1350 | |||||||
| 10.1016/j.acvd.2020.05.003 | Editorial | en | Nuclear cardiology in the COVID-19 pandemic era. | https://www.ncbi.nlm.nih.gov/pubmed/32605783 | 1875-2136 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Clinical Decision-Making;Coronavirus Infections__diagnosis;Cross Infection__diagnosis;Heart Diseases__diagnostic imaging;Host-Pathogen Interactions;Humans;Infection Control;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Infectious Disease Transmission, Professional-to-Patient__prevention & control;Nuclear Medicine;Occupational Exposure__adverse effects;Occupational Health;Pandemics__prevention & control;Patient Safety;Patient Selection;Pneumonia, Viral__diagnosis;Risk Assessment;Risk Factors;Triage;Virulence;COVID-19;severe acute respiratory syndrome coronavirus 2 | Archives of Cardiovascular Diseases | Jonathan Vigne;Alain Manrique;Audrey Mouet;Simon Le Hello;Denis Agostini | Biological protection;COVID-19;Cardiologie nucléaire;Médecine nucléaire;Nuclear cardiology;Nuclear medicine;Protection biologique | 2020-06-18 02:00:00+02:00 | 32605783 | FR | Department of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000 Caen, France, Department of Pharmacy, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000 Caen, France, Normandie Université, UNICAEN, INSERM U1237, PhIND, Institut Blood and Brain @ Caen-Normandie, Centre Cyceron, Caen 14000, France. Electronic address: vigne-jo@chu-caen.fr.;Department of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000 Caen, France, Normandie Université, UNICAEN, EA 4650, Caen, France.;Department of Hospital Hygiene, CHU de Caen Normandie, Caen 14033, France.;Department of Hospital Hygiene, CHU de Caen Normandie, Caen 14033, France, Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Normandie Université, UNICAEN, UNIROUEN, GRAM 2.0, 14000 Caen, France. | 1354 | |||
| 10.3390/jcm9061871 | Journal Article | en | Performance Assessment of SARS-CoV-2 PCR Assays Developed by WHO Referral Laboratories. | https://www.ncbi.nlm.nih.gov/pubmed/32560044 | A reliable diagnostic assay is crucial to early detect new COVID-19 cases and limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. Since the onset of the COVID-19 pandemic, the World Health Organization has published several diagnostic molecular approaches developed by referral laboratories, including Charité (Germany), HKU (Hong Kong), China CDC (China), US CDC (United States), and Institut Pasteur, Paris (France). We aimed to compare the sensitivity and specificity of these different RT-PCR assays using SARS-CoV-2 cell culture supernatants and clinical respiratory samples. Overall, the different RT-PCR assays performed well for SARS-CoV-2 detection and were all specific except the N Charité (Germany), and N2 US CDC (United States) assays. RdRp Institut Pasteur (IP2, IP4), N China CDC, and N1 US CDC were found to be the most sensitive assays. The data presented herein are of prime importance to facilitate the equipment choice of diagnostic laboratories, as well as for the development of marketed tests. | 2077-0383 | 2020-06-21 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Sibyle Etievant;Antonin Bal;Vanessa Escuret;Karen Brengel-Pesce;Maude Bouscambert;Valérie Cheynet;Laurence Generenaz;Guy Oriol;Gregory Destras;Geneviève Billaud;Laurence Josset;Emilie Frobert;Florence Morfin;Alexandre Gaymard | COVID-19;RT-PCR;SARS-CoV-2;diagnostics;sensitivity | 2020-06-16 02:00:00+02:00 | 32560044 | FR | Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004 Lyon, France.;Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004 Lyon, France.;Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Centre Hospitalier Lyon Sud, 69310 Pierre-Bénite, France.;Université de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France. | 1361 | |||
| 10.3389/fpubh.2020.00294 | Journal Article | en | Living With COVID-19: A Systemic and Multi-Criteria Approach to Enact Evidence-Based Health Policy. | https://www.ncbi.nlm.nih.gov/pubmed/32612973 | The lifting of COVID-19 (coronavirus disease 2019) lockdown requires, in the short and medium terms, a holistic and evidence-based approach to population health management based on combining risk factors and bio-economic outcomes, including actors' behaviors. This dynamic and global approach to health control is necessary to deal with the new paradigm of living with an infectious disease, which disrupts our individual freedom and behaviors. The challenge for policymakers consists of defining methods of lockdown-lifting and follow-up (middle-term rules) that best meet the needs for resumption of economic activity, societal wellbeing, and containment of the outbreak. There is no simple and ready-to-use way to do this since it means considering several competing objectives at the same time and continuously adapting the strategy and rules, ideally at local scale. We propose a framework for creating a precision evidence-based health policy that simultaneously considers public health, economic, and societal dimensions while accounting for constraints and uncertainty. It is based on the four following principles: integrating multiple and heterogeneous information, accepting navigation with uncertainty, adjusting the strategy dynamically with feedback mechanisms, and managing clusters through a multi-scalar conception. The evidence-based policy intervention for COVID-19 obtained includes scientific background via epidemiological modeling and bio-economic modeling. A set of quantitative and qualitative indicators are used as feedback to precisely monitor the societal-economic-epidemiological dynamics, allowing tightening or loosening of measures before epidemic damage (re-)occurs. Altogether, this allows an evidence-based policy that steers the strategy with precision and avoids any political shock. | 2296-2565 | 2020-06-21 02:00:00+02:00 | pubmed | Frontiers in Public Health | Didier Raboisson;Guillaume Lhermie | COVID-19;evidence-based policy;population medicine;social-ecological system (SES);systemic approach | 2020-06-16 02:00:00+02:00 | 32612973 | FR | IHAP, University of Toulouse, INRA, ENVT, Toulouse, France. | 1362 | |||
| 10.4193/rhin20.199 | Journal Article | en | Acute smell and taste loss in outpatients: all infected with SARS-CoV-2? | https://www.ncbi.nlm.nih.gov/pubmed/32542238 | During SARS-CoV-2 pandemic, our region (Alsace, East of France) became a Covid-19 cluster quite early in Europe. Loss of smell and taste was quickly flagged by the Ears-Nose and Throat scientific community as a potential warning signs of SARS-CoV-2 infection (1). Many patients and medical/paramedical workers with mild to moderate form of SARS-CoV-2 infection complained about their loss of sense of smell and taste to our ENT department. The aim of our study was to compare the characteristics of loss of smell and taste between patients with a clinical diagnosis of SARS-CoV-2 infection to patients with a RT-PCR diagnosis. | 0300-0729 | 2020-06-21 02:00:00+02:00 | pubmed | Rhinology journal | M Renaud;A Leon;G Trau;L Fath;S Ciftci;Y Bensimon;A Venkatasamy;C Debry | 2020-06-15 02:00:00+02:00 | 32542238 | FR | Department of Otolaryngology, Head and Neck Surgery, University Hospital of Strasbourg, France.;Department of Radiology 1, University Hospital of Strasbourg, France.;INSERM Unit 1121, Strasbourg, France. | 1370 | ||||
| Case Reports;Letter | en | Cutaneous lesions in a patient with COVID-19: are they related? | https://www.ncbi.nlm.nih.gov/pubmed/32353170 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus__genetics;Biopsy;Chilblains__diagnosis;Clinical Laboratory Techniques;Coronavirus Infections__complications;Diagnosis, Differential;Female;Humans;Middle Aged;Nasopharynx__virology;Pandemics;Pneumonia, Viral__complications;Polymerase Chain Reaction;RNA, Viral;Skin__immunology;Urticaria__diagnosis;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | B Ahouach;S Harent;A Ullmer;P Martres;E Bégon;L Blum;O Tess;C Bachmeyer | 2020-06-15 02:00:00+02:00 | 32353170 | FR | Unité de dermatologie, Hôpital René Dubos, Pontoise, France.;Unité d'infectiologie, Hôpital René Dubos, Pontoise, France.;Unité de médecine interne, Hôpital René Dubos, Pontoise, France.;Laboratoire de microbiologie, Hôpital René Dubos, Pontoise, France.;Service d'anatomopathologie, Hôpital René Dubos, Pontoise, France.;Service de médecine interne, Hôpital Tenon (AP-HP), Paris, France. | 1375 | |||||||
| Agence Nationale de la Recherche | 10.1002/pmic.202000107 | Journal Article;Research Support, Non-U.S. Gov't | en | Shortlisting SARS-CoV-2 Peptides for Targeted Studies from Experimental Data-Dependent Acquisition Tandem Mass Spectrometry Data. | https://www.ncbi.nlm.nih.gov/pubmed/32462744 | Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial tool for fighting the COVID-19 pandemic. This dataset brief presents the exploration of a shotgun proteomics dataset acquired on SARS-CoV-2 infected Vero cells. Proteins from inactivated virus samples were extracted, digested with trypsin, and the resulting peptides were identified by data-dependent acquisition tandem mass spectrometry. The 101 peptides reporting for six viral proteins were specifically analyzed in terms of their analytical characteristics, species specificity and conservation, and their proneness to structural modifications. Based on these results, a shortlist of 14 peptides from the N, S, and M main structural proteins that could be used for targeted mass-spectrometry method development and diagnostic of the new SARS-CoV-2 is proposed and the best candidates are commented. | 1615-9853,1615-9861 | 2020-06-21 02:00:00+02:00 | pubmed | Amino Acid Sequence;Animals;Betacoronavirus__chemistry;Chlorocebus aethiops;Coronavirus Infections__diagnosis;Humans;Pandemics;Peptides__analysis;Pneumonia, Viral__diagnosis;Proteomics;Tandem Mass Spectrometry;Vero Cells;Viral Proteins__analysis;Viral Structural Proteins__analysis;COVID-19;severe acute respiratory syndrome coronavirus 2 | PROTEOMICS | Duarte Gouveia;Lucia Grenga;Jean-Charles Gaillard;Fabrice Gallais;Laurent Bellanger;Olivier Pible;Jean Armengaud | COVID-19;SARS-CoV-2;mass spectrometry;peptides;proteomics;viral protein detection | 2020-06-21 02:00:00+02:00 | 32462744 | FR | [{"country": "International", "agency": "Agence Nationale de la Recherche", "grantid": "ANR-17-CE18-0023-01"}] | Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Bagnols-sur-Cèze, 30200, France. | 1386 |
| Letter;Review | en | Left ventricular dysfunction in COVID-19: A diagnostic issue. | https://www.ncbi.nlm.nih.gov/pubmed/32562808 | 2020-06-21 02:00:00+02:00 | pubmed | Azithromycin__administration & dosage;Betacoronavirus__isolation & purification;Biomarkers;Coronavirus Infections__complications;Cytokine Release Syndrome__etiology;Diagnosis, Differential;Drug Therapy, Combination;Humans;Hydroxychloroquine__administration & dosage;Hypoxia__etiology;Long QT Syndrome__chemically induced;Myocardial Infarction__diagnosis;Myocarditis__etiology;Pandemics;Pericarditis__etiology;Pneumonia, Viral__complications;Systemic Inflammatory Response Syndrome__etiology;Tachycardia, Ventricular__etiology;Thrombophilia__blood;Ventricular Dysfunction, Left__diagnosis;Ventricular Fibrillation__etiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Matthias Jacquet-Lagrèze;Zakaria Riad;Elisabeth Hugon-Vallet;Arnaud Ferraris;Jean-Luc Fellahi | COVID-19;Myocarditis;Type 2 myocardial infarction | 2020-06-17 02:00:00+02:00 | 32562808 | FR;US | Département d'Anesthésie Réanimation, Centre Hospitalier Louis Pradel, Hospices Civils de Lyon, 59, boulevard Pinel, 69500 Bron, France, Université Claude-Bernard, Lyon 1, Campus Lyon Santé Est, 8, avenue Rockefeller, 69008 Lyon, France, Laboratoire CARMEN, UMR inserm unité 1060, Lyon, France. Electronic address: matthias.jl@gmail.com.;Département d'Anesthésie Réanimation, Centre Hospitalier Louis Pradel, Hospices Civils de Lyon, 59, boulevard Pinel, 69500 Bron, France, Université Claude-Bernard, Lyon 1, Campus Lyon Santé Est, 8, avenue Rockefeller, 69008 Lyon, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Louis Pradel, Hospices Civils de Lyon, 59, boulevard Pinel, 69500 Bron, France, Université Claude-Bernard, Lyon 1, Campus Lyon Santé Est, 8, avenue Rockefeller, 69008 Lyon, France, Laboratoire CARMEN, UMR inserm unité 1060, Lyon, France. | 1388 | ||||||
| 10.1111/joim.13089 | Journal Article | en | Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32352202 | The clinical presentation of European patients with mild-to-moderate COVID-19 infection is still unknown. | 0954-6820,1365-2796 | 2020-06-21 02:00:00+02:00 | pubmed | Journal of Internal Medicine | Jerome R Lechien;Carlos M Chiesa-Estomba;Sammy Place;Yves Van Laethem;Pierre Cabaraux;Quentin Mat;Kathy Huet;Jan Plzak;Mihaela Horoi;Stéphane Hans;Maria Rosaria Barillari;Giovanni Cammaroto;Nicolas Fakhry;Delphine Martiny;Tareck Ayad;Lionel Jouffe;Claire Hopkins;Sven Saussez | COVID-19;Europe;clinical;coronavirus;epidemiological;medicine;patients;symptoms | 2020-06-17 02:00:00+02:00 | 32352202 | FR;CA;GB;IT;CZ;ES;BE;AT | From, COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Department of Otorhinolaryngology-Head & Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Internal Medicine, Infectiology, EpiCURA Hospital, Baudour, Belgium.;Department of Internal Medicine, Infectiology, CHU Saint-Pierre, Brussels, Belgium.;Department of Medicine, Neurology, CHU de Charleroi, Charleroi, Belgium.;Department of Statistics, Language Sciences, University of Mons, Mons, Belgium.;Department of Otolaryngology - Head & Neck Surgery, 1st Faculty of Medicine, University Hospital Motol, Prague, Czech Republic.;Confederation of European Otorhinolaryngology-Head & Neck Surgery, Vienna, Austria.;Department of Mental and Physical Health and Preventive Medicine, University of L. Vanvitelli, Naples, Italy.;Department of Otolaryngology-Head & Neck Surgery, Morgagni Pierantoni Hospital, Forli, Italy.;Department of Otorhinolaryngology- Head & Neck Surgery, APHM, Aix Marseille University, La Conception University Hospital, Marseille, France.;Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles, Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Faculté de Médecine et Pharmacie, Université de Mons (UMONS), Mons, Belgium.;Division of Otolaryngology-Head & Neck Surgery, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.;BayesiaLab, Changé, France.;Guy's and St Thomas NHS Foundation Trust, London, UK.;British Rhinological Society (President), London, UK.;Department of Otolaryngology-Head & Neck Surgery, EpiCURA Hospital, Hornu, Belgium. | 1389 | |||
| Letter | en | A Call to Ensure Access to Human Milk for Vulnerable Infants During the COVID-19 Epidemic. | https://www.ncbi.nlm.nih.gov/pubmed/32799595 | 2020-06-21 02:00:00+02:00 | pubmed | Virginie Rigourd;Alexandre Lapillonne | 2020-06-17 02:00:00+02:00 | 32799595 | FR | 37072Neonatal Department, APHP Necker Enfants Malades Hospital, Paris, France.;37072Human Milk Bank Ile de France, APHP Necker Enfants Malades Hospital, Paris, France.;EHU 7328 PACT, Paris Descartes University, Paris, France. | 1394 | ||||||||
| 10.3390/molecules25122784 | Journal Article;Systematic Review | en | Quinoxaline Derivatives as Antiviral Agents: A Systematic Review. | https://www.ncbi.nlm.nih.gov/pubmed/32560203 | In recent decades, several viruses have jumped from animals to humans, triggering sizable outbreaks. The current unprecedent outbreak SARS-COV-2 is prompting a search for new cost-effective therapies to combat this deadly pathogen. Suitably functionalized polysubstituted quinoxalines show very interesting biological properties (antiviral, anticancer, and antileishmanial), ensuring them a bright future in medicinal chemistry. | 1420-3049 | 2020-06-21 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;DNA Viruses__drug effects;Humans;Pandemics;Pneumonia, Viral__drug therapy;Quinoxalines__chemistry;Structure-Activity Relationship;COVID-19;severe acute respiratory syndrome coronavirus 2 | Molecules | Marc Montana;Vincent Montero;Omar Khoumeri;Patrice Vanelle | SAR;antiviral;biological applications;chemistry;quinoxaline | 2020-06-16 02:00:00+02:00 | 32560203 | FR | Laboratoire de Pharmaco-Chimie Radicalaire, Institut de Chimie Radicalaire ICR, Aix Marseille Univ, CNRS, UMR 7273, 13005 Marseille, France.;Oncopharma, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France.;Service central de la qualité et de l'information pharmaceutiques (SCQIP), Assistance Publique-Hôpitaux de Marseille (AP-HM), 13005 Marseille, France. | 1396 | ||
| 10.24875/ric.20000131 | Journal Article | en | CLINICAL DECISION MAKING IN OLDER ADULTS WITH COVID-19 IN DEVELOPING COUNTRIES: LOOKING BEYOND CHRONOLOGICAL AGE. | https://www.ncbi.nlm.nih.gov/pubmed/32584321 | The coronavirus disease 2019 (COVID-19) has been declared a global pandemic. Older adults have been found as a vulnerable group for developing severe forms of disease and increased mortality. | 0034-8376 | 2020-06-28 02:00:00+02:00 | pubmed | Activities of Daily Living;Aged;Aged, 80 and over;Betacoronavirus;Clinical Decision-Making;Coronavirus Infections__economics;Developing Countries__economics;Emergency Service, Hospital__economics;Female;Frail Elderly;Geriatric Assessment__methods;Humans;Male;Pandemics__economics;Patient Preference;Pneumonia, Viral__economics;Prognosis;Resource Allocation__ethics;Triage;Vulnerable Populations;COVID-19;severe acute respiratory syndrome coronavirus 2 | Revista de investigaci n Cl nica | Carolina Gómez-Moreno;Virgilio Hernández-Ruiz;Thierry Hernández-Gilsoul;José A Avila-Funes | COVID-19;Emergency care;Ethics;Frailty;Resource-allocation | 2020-06-26 02:00:00+02:00 | 32584321 | FR;MX | Department of Emergency and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.;Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.;Department of Centre de Recherche INSERM, Bordeaux, France. | 1411 | ||
| Letter;Comment | en | Impact of COVID-19 on pediatric clinical research in France. | https://www.ncbi.nlm.nih.gov/pubmed/32575064 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Coronavirus Infections__epidemiology;France;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Florence Flamein;Frederic Gottrand;Maya Laxmi Patel;Régis Hankard | 2020-06-24 02:00:00+02:00 | 32575064 | FR | Pediatrician, French Clinical Research Infrastructure Network (F-CRIN) - PEDSTART, Centre Hospitalier Universitaire de Lille, University of Lille, Lille, France.;Professor of pediatrics, French Clinical Research Infrastructure Network (F-CRIN) - PEDSTART, Centre Hospitalier Universitaire de Lille, University of Lille, Lille, France.;Project manager, French Clinical Research Infrastructure Network (F-CRIN) - PEDSTART, University of Tours, Institut National de la Santé et de la Recherche Médicale, Tours, France.;Professor of pediatrics, French Clinical Research Infrastructure Network (F-CRIN) - PEDSTART, University of Tours, Institut National de la Santé et de la Recherche Médicale, Tours, France. | 1413 | |||||||
| Editorial;Comment | en | Skin and COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32571556 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Skin;COVID-19;severe acute respiratory syndrome coronavirus 2 | T Klejtman | 2020-06-24 02:00:00+02:00 | 32571556 | FR | Department of dermatology, Cochin Hospital, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France, Paris Descartes University, Paris, France. Electronic address: tiffany.klejtman@aphp.fr. | 1416 | |||||||
| 10.1007/s10877-020-00550-7 | Editorial | en | COVID-19: Pulse oximeters in the spotlight. | https://www.ncbi.nlm.nih.gov/pubmed/32578070 | From home to intensive care units, innovations in pulse oximetry are susceptible to improve the monitoring and management of patients developing acute respiratory failure, and particularly those with the coronavirus disease 2019 (COVID-19). They include self-monitoring of oxygen saturation (SpO2) from home, continuous wireless SpO2 monitoring on hospital wards, and the integration of SpO2 as the input variable for closed-loop oxygen administration systems. The analysis of the pulse oximetry waveform may help to quantify respiratory efforts and prevent intubation delays. Tracking changes in the peripheral perfusion index during a preload-modifying maneuver may be useful to predict preload responsiveness and rationalize fluid therapy. | 1387-1307,1573-2614 | 2020-06-28 02:00:00+02:00 | pubmed | Journal of Clinical Monitoring and Computing | Frederic Michard;Kirk Shelley;Erwan L'Her | 2020-06-23 02:00:00+02:00 | 32578070 | FR;CH;US | MiCo, Chemin de Chapallaz 4, Denens, Switzerland. frederic.michard@bluewin.ch.;Professor Emeritus, Department of Anesthesiology, Yale University, New Haven, CT, USA.;Intensive Care Medicine, University Hospital of Brest, La Cavale Blanche, Brest, France. | 1423 | ||||
| Letter | en | Severe acute respiratory syndrome Coronavirus 2 infection in cancer population: Are patient-related symptoms helpful to track a harmful invisible? | https://www.ncbi.nlm.nih.gov/pubmed/32574373 | 2020-06-28 02:00:00+02:00 | pubmed | Sandra Assoun;Marc-Antoine Benderra;Jean-Pierre Lotz;Sandrine Richard;Joseph Gligorov | 2020-06-23 02:00:00+02:00 | 32574373 | FR | Medicine Faculty, University Hospital Tenon, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Institut Universitaire de Cancérologie, Paris, France. | 1425 | ||||||||
| 10.1016/j.pharmthera.2020.107618 | Journal Article;Review | en | Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? | https://www.ncbi.nlm.nih.gov/pubmed/32592716 | Safe and efficient drugs to combat the current COVID-19 pandemic are urgently needed. In this context, we have analyzed the anti-coronavirus potential of the natural product glycyrrhizic acid (GLR), a drug used to treat liver diseases (including viral hepatitis) and specific cutaneous inflammation (such as atopic dermatitis) in some countries. The properties of GLR and its primary active metabolite glycyrrhetinic acid are presented and discussed. GLR has shown activities against different viruses, including SARS-associated Human and animal coronaviruses. GLR is a non-hemolytic saponin and a potent immuno-active anti-inflammatory agent which displays both cytoplasmic and membrane effects. At the membrane level, GLR induces cholesterol-dependent disorganization of lipid rafts which are important for the entry of coronavirus into cells. At the intracellular and circulating levels, GLR can trap the high mobility group box 1 protein and thus blocks the alarmin functions of HMGB1. We used molecular docking to characterize further and discuss both the cholesterol- and HMG box-binding functions of GLR. The membrane and cytoplasmic effects of GLR, coupled with its long-established medical use as a relatively safe drug, make GLR a good candidate to be tested against the SARS-CoV-2 coronavirus, alone and in combination with other drugs. The rational supporting combinations with (hydroxy)chloroquine and tenofovir (two drugs active against SARS-CoV-2) is also discussed. Based on this analysis, we conclude that GLR should be further considered and rapidly evaluated for the treatment of patients with COVID-19. | 0163-7258 | 2020-06-28 02:00:00+02:00 | pubmed | Pharmacology & Therapeutics | Christian Bailly;Gérard Vergoten | COVID-19;Cholesterol;Coronavirus;Glycyrrhizin;HMGB1;Natural product | 2020-06-24 02:00:00+02:00 | 32592716 | FR | OncoWitan, Lille, Wasquehal 59290, France. Electronic address: christian.bailly@oncowitan.com.;University of Lille, Inserm, U995 - LIRIC - Lille Inflammation Research International Center, ICPAL, 3 rue du Professeur Laguesse, BP-83, F-59006 Lille, France. | 1431 | |||
| 10.1159/000509434 | News | en | Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy. | https://www.ncbi.nlm.nih.gov/pubmed/32570240 | To date, the clinical characteristics of coronavirus disease 19 (COVID-19)-infected urologic cancer patients are unknown. | 0030-2414,1423-0232 | 2020-06-28 02:00:00+02:00 | pubmed | Oncology | Giuseppe Di Lorenzo;Luciana Buonerba;Concetta Ingenito;Felice Crocetto;Carlo Buonerba;Annamaria Libroia;Antonella Sciarra;Gianluca Ragone;Roberto Sanseverino;Simona Iaccarino;Giorgio Napodano;Ciro Imbimbo;Emilio Leo;Zisis Kozlakidis;Sabino De Placido | Comorbidities;Coronavirus disease SARS-CoV-2;Drug interaction;Hormonal therapy;Prostate cancer | 2020-06-22 02:00:00+02:00 | 32570240 | FR;IT | Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy, direttoreuocpagani@gmail.com.;Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy, direttoreuocpagani@gmail.com.;Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy.;Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.;Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.;Urology Division, Umberto I Hospital, Nocera Inferiore, Italy.;International Agency for Research on Cancer, World Health Organization, Lyon, France. | 1457 | |||
| 10.1016/j.tifs.2020.06.006 | Journal Article | en | The role of food science and technology in humanitarian response. | https://www.ncbi.nlm.nih.gov/pubmed/32836824 | In humanitarian contexts, ensuring access to safe, nutritious, good quality and culturally appropriate food in the right quantity at the right time and place during an emergency or a protracted crisis is an enormous challenge, which is likely to increase given uncertainties such as climate change, global political and economic instability and emerging pandemics like COVID-19. Several international organizations and non-government organizations have well established systems to respond to food security emergencies. However, the role of food science and technology in humanitarian response is not well understood and is seldom considered in humanitarian circles. | 0924-2244 | 2020-06-28 02:00:00+02:00 | pubmed | Trends in Food Science & Technology | Dominique Bounie;Jayashree Arcot;Martin Cole;Florence Egal;Pablo Juliano;Carla Mejia;Donna Rosa;Jay Sellahewa | Food policies;Food science and technology;Food security;Humanitarian food aid;Local food systems;Resilience | 2020-06-23 02:00:00+02:00 | 32836824 | FR;US;TH;IT;AU | GBA Department/Institut Charles Violette, Polytech Lille, University of Lille, 59655, Villeneuve d'Ascq Cedex, France.;Food and Health Cluster, School of Chemical Engineering, UNSW Sydney, NSW, 2052, Australia.;School of Agriculture, Food and Wine, University of Adelaide, Glen Osmond, SA, 5064, Australia.;Independent Expert, Sustainable Food Systems, Rome, Italy.;CSIRO Agriculture and Food, Werribee, VIC, 3030, Australia.;World Food Programme, Lumpini, Pathumwan, 10330, Bangkok, Thailand.;EFour Enterprises LLC, Miami, FL, USA.;CSIRO Agriculture and Food, North Ryde, NSW, 2154, Australia. | 1463 | |||
| NIH HHS | 10.1016/j.vetmic.2020.108777 | Journal Article;Review | en | Coronaviruses in cats and other companion animals: Where does SARS-CoV-2/COVID-19 fit? | https://www.ncbi.nlm.nih.gov/pubmed/32768223 | Coronaviruses (CoVs) cause disease in a range of agricultural and companion animal species, and can be important causes of zoonotic infections. In humans, several coronaviruses circulate seasonally. Recently, a novel zoonotic CoV named SARS-CoV-2 emerged from a bat reservoir, resulting in the COVID-19 pandemic. With a focus on felines, we review here the evidence for SARS-CoV-2 infection in cats, ferrets and dogs, describe the relationship between SARS-CoV-2 and the natural coronaviruses known to infect these species, and provide a rationale for the relative susceptibility of these species to SARS-CoV-2 through comparative analysis of the ACE-2 receptor. | 0378-1135 | 2020-06-28 02:00:00+02:00 | pubmed | Animals;Betacoronavirus;Cat Diseases__virology;Cats__virology;Coronavirus Infections__veterinary;Dog Diseases__virology;Dogs__virology;Evolution, Molecular;Ferrets__virology;Humans;Pandemics__veterinary;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__veterinary;Receptors, Virus__genetics;Zoonoses__transmission;COVID-19;severe acute respiratory syndrome coronavirus 2 | Veterinary Microbiology | Alison E Stout;Nicole M André;Javier A Jaimes;Jean K Millet;Gary R Whittaker | ACE-2;Coronavirus;Feline coronavirus;SARS-CoV-2 | 2020-06-23 02:00:00+02:00 | 32768223 | FR;US | [{"country": "United States", "agency": "NIH HHS", "grantid": "T32 OD011000"}] | Department of Microbiology & Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, United States.;Université Paris-Saclay, INRAE, UVSQ, Virologie et Immunologie Moléculaires, 78352, Jouy-en-Josas, France.;Department of Microbiology & Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, United States, Master of Public Health Program, Cornell University, Ithaca, NY, 14853, United States, Cornell Feline Health Center, Ithaca, NY, 14853, United States. Electronic address: grw7@cornell.edu. | 1464 |
| Letter | en | The "Big Five" Lung Diseases in CoViD-19 Pandemic - a Google Trends analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32636165 | 2020-06-28 02:00:00+02:00 | pubmed | M T Barbosa;M Morais-Almeida;C S Sousa;J Bousquet | 2020-06-23 02:00:00+02:00 | 32636165 | FR;PT;DE | Pulmonology Department, Hospital Centre of Barreiro-Montijo, Barreiro, Portugal, Allergy Centre, CUF Descobertas Hospital, Lisboa, Portugal. Electronic address: migueltrbarbosa@gmail.com.;Allergy Centre, CUF Descobertas Hospital, Lisboa, Portugal.;Allergy Centre, CUF Descobertas Hospital, Lisboa, Portugal, Pulmonology Department, Central Hospital of Funchal, Portugal.;Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany and MACVIA-France, Montpellier, France. | 1465 | ||||||||
| Editorial;Comment | en | Chloroquine and COVID-19: A western medical and scientific drift? | https://www.ncbi.nlm.nih.gov/pubmed/32600860 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Chloroquine;Coronavirus Infections__drug therapy;Humans;Hydroxychloroquine;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Matthieu Million;Yanis Roussel;Didier Raoult | 2020-06-23 02:00:00+02:00 | 32600860 | FR | IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France. | 1473 | |||||||
| 10.1128/aac.00876-20 | Journal Article;Research Support, Non-U.S. Gov't | en | Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). | https://www.ncbi.nlm.nih.gov/pubmed/32376613 | Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC50) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection. | 0066-4804,1098-6596 | 2020-06-28 02:00:00+02:00 | pubmed | Animals;Antiviral Agents__pharmacology;Betacoronavirus__drug effects;Cell Line;Chlorocebus aethiops;Coronavirus Infections__drug therapy;Cyclophilins__antagonists & inhibitors;Cyclosporine__pharmacology;Humans;Pandemics;Pneumonia, Viral__drug therapy;Vero Cells;Virus Replication__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Antimicrobial Agents and Chemotherapy | Laurent Softic;Rozenn Brillet;François Berry;Nazim Ahnou;Quentin Nevers;Margot Morin-Dewaele;Sabah Hamadat;Patrice Bruscella;Slim Fourati;Jean-Michel Pawlotsky;Abdelhakim Ahmed-Belkacem | SARS-CoV-2;alisporivir;antiviral;cyclophilin | 2020-06-23 02:00:00+02:00 | 32376613 | FR | Research Team "Viruses, Hepatology, Cancer," Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France.;Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.;Research Team "Viruses, Hepatology, Cancer," Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France jean-michel.pawlotsky@aphp.fr. | 1474 | ||
| 10.3389/fmed.2020.00372 | Journal Article | en | Randomized Controlled Study Evaluating Efficiency of Low Intensity Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID Protocol. | https://www.ncbi.nlm.nih.gov/pubmed/32671084 | The severe respiratory distress syndrome linked to the new coronavirus disease (COVID-19) includes unbearable dyspneic suffering which contributes to the deterioration of the prognosis of patients in intensive care unit (ICU). Patients are put on mechanical ventilation to reduce respiratory suffering and preserve life. Despite this mechanical ventilation, most patients continue to suffer from dyspnea. Dyspnea is a major source of suffering in intensive care and one of the main factors that affect the prognosis of patients. The development of innovative methods for its management, especially non-drug management is more than necessary. In recent years, numerous studies have shown that transcranial direct current stimulation (tDCS) could modulate the perception of acute or chronic pain. In the other hand, it has been shown that the brain zones activated during pain and dyspnea are close and/or superimposed, suggesting that brain structures involved in the integration of aversive emotional component are shared by these two complex sensory experiences. Therefore, it can be hypothesized that stimulation by tDCS with regard to the areas which, in the case of pain have activated one or more of these brain structures, may also have an effect on dyspnea. In addition, our team recently demonstrated that the application of tDCS on the primary cortical motor area can modulate the excitability of the respiratory neurological pathways. Indeed, tDCS in anodal or cathodal modality reduced the excitability of the diaphragmatic cortico-spinal pathways in healthy subjects. We therefore hypothesized that tDCS could relieve dyspnea in COVID-19 patients under mechanical ventilation in ICU. This study was designed to evaluate effects of two modalities of tDCS (anodal and cathodal) vs. placebo, on the relief of dyspnea in COVID-19 patients requiring mechanical ventilation in ICU. Trial Registration: This protocol is derived from the tDCS-DYSP-REA project registered on ClinicalTrials.gov NCT03640455. It will however be registered under its own NCT number. | 2296-858X | 2020-06-28 02:00:00+02:00 | pubmed | Frontiers in Medicine | Eric Azabou;Guillaume Bao;Nicholas Heming;Rania Bounab;Pierre Moine;Sylvain Chevallier;Sylvie Chevret;Matthieu Resche-Rigon;Shidaps Siami;Tarek Sharshar;Frederic Lofaso;Djillali Annane | COVID-19;ICU;acute respiratory distress syndrome (ARDS);brain;dyspnea relief;mechanical ventilation;neuromodulation;tDCS | 2020-06-26 02:00:00+02:00 | 32671084 | FR | Clinical Neurophysiology and Neuromodulation Unit, Departments of Physiology and Critical Care Medicine, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Inserm UMR 1173, Infection and Inflammation (2I), University of Versailles Saint-Quentin en Yvelines (UVSQ), Paris-Saclay University, Paris, France.;General Intensive Care Unit-Assistance Publique Hôpitaux de Paris, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Inserm UMR 1173, Infection and Inflammation (2I), University of Versailles Saint-Quentin en Yvelines (UVSQ), Paris-Saclay University, Paris, France.;Versailles Engineering Systems Laboratory (LISV), University of Versailles Saint-Quentin en Yvelines (UVSQ), Paris-Saclay University, Velizy, France.;Service de Biostatistique et Information Médicale, AP-HP Hôpital Saint Louis, Paris, France.;Inserm U1153 CRESS, Epidemiology and Clinical Statistics for Tumor, Respiratory, and Resuscitation Assessments (ECSTRRA) Team, Paris, France.;Université Paris 7 Diderot, Sorbonne Paris Cité, Paris, France.;Critical Care Medicine Unit, CH Etampes-Dourdan, Etampes, France.;Department of Neuro-Intensive Care Medicine, Sainte-Anne Hospital, Paris-Descartes University, Paris, France.;Laboratory of Human Histopathology and Animal Models, Institut Pasteur, Paris, France. | 1484 | |||
| 10.1016/j.ejca.2020.06.017 | Journal Article | en | Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? | https://www.ncbi.nlm.nih.gov/pubmed/32619884 | A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic. | 0959-8049 | 2020-06-28 02:00:00+02:00 | pubmed | Antibodies, Monoclonal, Humanized__adverse effects;Antigens, CD20;Betacoronavirus;Coronavirus Infections__prevention & control;Drug Interactions;Humans;Immunologic Factors__adverse effects;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Rituximab__adverse effects;Treatment Outcome;Viral Vaccines__therapeutic use;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Cancer | Roch Houot;Ronald Levy;Guillaume Cartron;Philippe Armand | Anti-CD20 antibody;COVID-19;Rituximab;SARS-CoV-2;Vaccine | 2020-06-25 02:00:00+02:00 | 32619884 | FR;US | Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, Rennes, France, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: roch.houot@chu-rennes.fr.;Department of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA.;Department of Hematology, CHU Montpellier University Hospitality, University of Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, Montpellier, France.;Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. | 1488 | ||
| 10.1016/j.alter.2020.06.015 | Journal Article | fr | [COVID-19: disabilities, loss of autonomy and human assistance. Difficulties and tensions in practices barrieries and personal protective equipment]. | https://www.ncbi.nlm.nih.gov/pubmed/32834874 | 1875-0672 | 2020-06-28 02:00:00+02:00 | pubmed | Alter | Cyril Desjeux | 2020-06-25 02:00:00+02:00 | 32834874 | FR | Handéo services, Paris, France. | 1492 | |||||
| Letter | en | Will an obesity pandemic replace the coronavirus disease-2019 (COVID-19) pandemic? | https://www.ncbi.nlm.nih.gov/pubmed/32758883 | 2020-06-28 02:00:00+02:00 | pubmed | Abdelaziz Ghanemi;Mayumi Yoshioka;Jonny St-Amand | Coronavirus disease-2019 (COVID-19);Obesity | 2020-06-25 02:00:00+02:00 | 32758883 | FR;CA;US | Functional Genomics Laboratory, Endocrinology and Nephrology Axis, CHU de Québec-Université Laval Research Center, Québec, Québec G1V 4G2, Canada, Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec, Québec G1V 0A6, Canada.;Functional Genomics Laboratory, Endocrinology and Nephrology Axis, CHU de Québec-Université Laval Research Center, Québec, Québec G1V 4G2, Canada.;Functional Genomics Laboratory, Endocrinology and Nephrology Axis, CHU de Québec-Université Laval Research Center, Québec, Québec G1V 4G2, Canada, Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec, Québec G1V 0A6, Canada. Electronic address: jonny.st-amand@crchudequebec.ulaval.ca. | 1493 | |||||||
| 10.1016/j.amp.2020.06.008 | English Abstract;Journal Article | fr | [PSYCOVID-19, psychological support device in the fields of mental health, somatic and medico-social]. | https://www.ncbi.nlm.nih.gov/pubmed/32836306 | In December 2019 the World Health Organization (WHO) recorded the first cases of an infectious disease that appeared in China in November of the same year. Generated by the new coronavirus SARS-CoV2, it is quickly named COVID-19 for COronaVirus Infectious Disease 2019. The spread of this unknown disease will soon have worldwide consequences: the contagiousness of the virus is extremely high and potentially lethal. In France, the population initially reacted with disbelief until the disease reached Europe and the first cases appeared on French territory, at the end of January. A few weeks later, on 16 March 2020, President Macron declared the country "at war" against COVID-19. The next day the population was placed in lockdown. At the present time, the country's activity is at a standstill. Schools, businesses and shops are closed. The French citizens are astounded. They suddenly have to face fear: fear of falling ill or that a close relative may fall ill, fear of being locked up and experiencing restrictions of liberties, fear of economic precariousness. And, above all, fear of uncertainty. In order to prevent the mental consequences of this crisis, psychological support units have been created with urgency at national scale. These units are intended to support the healthcare professionals as well as the patients and more broadly, the general population. The unit responsible for the department of Gironde has been set up quickly, over the weekend of March 21, 2020. The COVIDPSY33 listening unit has thus been created in Bordeaux by the Charles Perrens Hospital with support from the Agence Régionale de Santé Nouvelle-Aquitaine (ARS). Simultaneously, the PSYCOVID-19 unit was created. This additional unit works in collaboration with the COVIDPSY33 platform and offers psychological assistance to the general population and caregivers in the sectors of Bordeaux Rive Droite, Bordeaux Gare, Rives de Garonne, Rives d'Arcins and Sud Gironde. It thus covers an area equivalent to approximately half of Gironde, the largest department in metropolitan France. In the present interview, Samantha Al Joboory and Florence Monello, psychiatrist and psychologist coordinating PSYCOD-19, present this psychological support unit. | 0003-4487 | 2020-06-28 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Samantha Al Joboory;Florence Monello;Jean-Pierre Bouchard | Coronavirus;Covid-19;Crisis unit;Epidemic;PSYCOVID-19;Pandemic;Psychological support;SARS-CoV2 | 2020-06-25 02:00:00+02:00 | 32836306 | FR | Centre d'Accueil SPÉcialisé dans le Repérage et le Traitement des Traumatismes psychiques (Caspertt), centre hospitalier de Cadillac, 31 rue des Cavaillès, 33310 Lormont, France.;Institut psycho-judiciaire et de psychopathologie (IPJP), institute of forensic psychology and psychopathology, centre hospitalier de Cadillac, 10, avenue Joseph-Caussil, 33410 Cadillac, France.;Centre de recherche inserm/U1219, université de Bordeaux, ISPED, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France.;Maison d'Ella, 381, boulevard du Président-Wilson, 33200 Bordeaux, France.;Centre hospitalier de Cadillac, 89, rue Cazeaux-Cazalet, 33410 Cadillac, France.;Unité pour malades difficiles (UMD), pôle de psychiatrie médico-légale (PPML), centre hospitalier de Cadillac, 10, avenue Joseph-Caussil, 33410 Cadillac, France. | 1498 | |||
| 10.1111/bjhp.12449 | Journal Article | en | Looking out for myself: Exploring the relationship between conspiracy mentality, perceived personal risk, and COVID-19 prevention measures. | https://www.ncbi.nlm.nih.gov/pubmed/32583540 | This research examined how conspiracy mentality may affect compliance with preventive health measures necessary to fight the COVID-19 pandemic, and the underlying motivations to comply. | 1359-107X,2044-8287 | 2020-06-28 02:00:00+02:00 | pubmed | British Journal of Health Psychology | Gaëlle Marinthe;Genavee Brown;Sylvain Delouvée;Daniel Jolley | COVID-19;conspiracy mentality;motivation;perceived risk;preventive health behaviours | 2020-06-25 02:00:00+02:00 | 32583540 | FR;GB | Laboratoire de Psychologie: Cognition, Comportement, Communication, University of Rennes 2, France.;Institut de Recherche Médias, Cultures, Communication et Numérique, Université Sorbonne Nouvelle Paris 3, France.;Department of Psychology, Northumbria University, Newcastle upon Tyne, UK. | 1501 | |||
| 10.1016/j.cell.2020.06.035 | Journal Article;Research Support, Non-U.S. Gov't | en | A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. | https://www.ncbi.nlm.nih.gov/pubmed/32645327 | Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coronavirus (CoV) infections. The CoV spike receptor-binding domain (RBD) is an attractive vaccine target but is undermined by limited immunogenicity. We describe a dimeric form of MERS-CoV RBD that overcomes this limitation. The RBD-dimer significantly increased neutralizing antibody (NAb) titers compared to conventional monomeric form and protected mice against MERS-CoV infection. Crystal structure showed RBD-dimer fully exposed dual receptor-binding motifs, the major target for NAbs. Structure-guided design further yielded a stable version of RBD-dimer as a tandem repeat single-chain (RBD-sc-dimer) which retained the vaccine potency. We generalized this strategy to design vaccines against COVID-19 and SARS, achieving 10- to 100-fold enhancement of NAb titers. RBD-sc-dimers in pilot scale production yielded high yields, supporting their scalability for further clinical development. The framework of immunogen design can be universally applied to other beta-CoV vaccines to counter emerging threats. | 0092-8674 | 2020-06-28 02:00:00+02:00 | pubmed | Cell | Lianpan Dai;Tianyi Zheng;Kun Xu;Yuxuan Han;Lili Xu;Enqi Huang;Yaling An;Yingjie Cheng;Shihua Li;Mei Liu;Mi Yang;Yan Li;Huijun Cheng;Yuan Yuan;Wei Zhang;Changwen Ke;Gary Wong;Jianxun Qi;Chuan Qin;Jinghua Yan;George F Gao | COVID-19;MERS;MERS-CoV;SARS;SARS-CoV;SARS-CoV-2;betacoronavirus;coronavirus;receptor-binding domain (RBD);vaccine | 2020-06-28 02:00:00+02:00 | 32645327 | FR;CN;CA | Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China, Savaid Medical School, University of Chinese Academy of Sciences, Beijing 101408, China, Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Tropical Medicine and Laboratory Medicine, The First Affiliated Hospital, Hainan Medical University, Hainan 571199, China. Electronic address: dailp@biols.ac.cn.;Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China, Savaid Medical School, University of Chinese Academy of Sciences, Beijing 101408, China.;Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Tropical Medicine and Laboratory Medicine, The First Affiliated Hospital, Hainan Medical University, Hainan 571199, China.;Savaid Medical School, University of Chinese Academy of Sciences, Beijing 101408, China.;Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100032, China.;Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Anhui 230088, China.;Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China.;CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.;CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.;Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.;Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China, Department of Microbiology-Infectiology and Immunology, Laval University, Quebec City, QC G1V 4G2, Canada.;Savaid Medical School, University of Chinese Academy of Sciences, Beijing 101408, China, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.;Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100032, China. Electronic address: qinchuan@pumc.edu.cn.;CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China, CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China. Electronic address: yanjh@im.ac.cn.;Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China, Savaid Medical School, University of Chinese Academy of Sciences, Beijing 101408, China, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China. Electronic address: gaof@im.ac.cn. | 1511 | |||
| Letter | en | Health equity and COVID-19: global perspectives. | https://www.ncbi.nlm.nih.gov/pubmed/32586388 | The COVID-19 is disproportionally affecting the poor, minorities and a broad range of vulnerable populations, due to its inequitable spread in areas of dense population and limited mitigation capacity due to high prevalence of chronic conditions or poor access to high quality public health and medical care. Moreover, the collateral effects of the pandemic due to the global economic downturn, and social isolation and movement restriction measures, are unequally affecting those in the lowest power strata of societies. To address the challenges to health equity and describe some of the approaches taken by governments and local organizations, we have compiled 13 country case studies from various regions around the world: China, Brazil, Thailand, Sub Saharan Africa, Nicaragua, Armenia, India, Guatemala, United States of America (USA), Israel, Australia, Colombia, and Belgium. This compilation is by no-means representative or all inclusive, and we encourage researchers to continue advancing global knowledge on COVID-19 health equity related issues, through rigorous research and generation of a strong evidence base of new empirical studies in this field. | 2020-06-28 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Global Health__statistics & numerical data;Health Equity;Health Status Disparities;Humans;Pandemics;Pneumonia, Viral__epidemiology;Socioeconomic Factors;COVID-19 | Efrat Shadmi;Yingyao Chen;Inês Dourado;Inbal Faran-Perach;John Furler;Peter Hangoma;Piya Hanvoravongchai;Claudia Obando;Varduhi Petrosyan;Krishna D Rao;Ana Lorena Ruano;Leiyu Shi;Luis Eugenio de Souza;Sivan Spitzer-Shohat;Elizabeth Sturgiss;Rapeepong Suphanchaimat;Manuela Villar Uribe;Sara Willems | Covid-19;Health equity;Humanitarian crisis;Pandemic | 2020-06-26 02:00:00+02:00 | 32586388 | IL;FR;NO;SE;GT;ZM;CN;TH;AM;US;BR;AU;BE | The Cheryl Spencer Department of Nursing, Faculty of Social Welfare and Health Sciences, University of Haifa, 31905, Mount Carmel, Israel. eshadmi@univ.haifa.ac.il.;School of Public Health, Fudan University, Shanghai, PR China.;Health Collective Institute, Federal University of Bahia, Salvador, Brazil.;The Cheryl Spencer Department of Nursing, Faculty of Social Welfare and Health Sciences, University of Haifa, 31905, Mount Carmel, Israel.;The mobile clinic for minimizing prostitution damages, Ministry of Health, Haifa, Israel.;"Ve'ahavta" clinic, for refugees and non-citizenship people, Nesher, Israel.;Department of General Practice, Faculty of Medicine, Dentistry and Health Science, The University of Melbourne, Melbourne, Australia.;Department of Health Policy and Management, School of Public Health, University of Zambia, Lusaka, Zambia.;Chr. Michelsen Institute, Bergen, Norway.;Bergen Centre for Ethics in Priority Setting (BCEP), University of Bergen, Bergen, Norway.;Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.;National Health Foundation, Bangkok, Thailand.;The Equity Initiative, CMB Foundation, Bangkok, Thailand.;Department of Clinical, Umeå University, Umeå, Sweden.;Gerald and Patricia Turpanjian School of Public Health, American University of Armenia, Yerevan, Armenia.;Department of International Health, Johns Hopkins University, Baltimore, USA.;Center for the Study of Equity and Governance in Health Systems, CEGSS, Guatemala City, Guatemala.;Center for International Health, University of Bergen, Bergen, Norway.;Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.;The Azrieli Faculty of Medicine, Bar-Ilan University, Zefat, Israel.;Department of General Practice, Monash University, Melbourne, Australia.;International Health Policy Program, Ministry of Public Health, Nonthaburi, Thailand.;Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.;Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.;Faculty of Medicine and Health Sciences, Department of Public Health and Primary Care, Ghent University, Ghent, Belgium. | 1513 | |||||
| 10.1016/j.jstrokecerebrovasdis.2020.105095 | Case Reports | en | Bilateral posterior cerebral artery territory infarction in a SARS-Cov-2 infected patient: discussion about an unusual case. | https://www.ncbi.nlm.nih.gov/pubmed/32807489 | In time of SARS-Cov2 pandemic, neurologists need to be vigilant for cerebrovascular complications of Covid-19. We present a case of bilateral occipito-temporal infarction revealed by a sudden cortical blindness with haemorrhagic transformation after intravenous thrombolysis in a diabetic patient infected by Covid-19. Differential diagnoses are discussed in front of this unusual presentation and evolution. | 1052-3057 | 2020-06-28 02:00:00+02:00 | pubmed | Adenosine Monophosphate__analogs & derivatives;Alanine__analogs & derivatives;Antiviral Agents__therapeutic use;Betacoronavirus__pathogenicity;Coronavirus Infections__complications;Diagnosis, Differential;Fatal Outcome;Host-Pathogen Interactions;Humans;Infarction, Posterior Cerebral Artery__complications;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Predictive Value of Tests;Risk Factors;Thrombolytic Therapy;Treatment Outcome;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Journal of Stroke and Cerebrovascular Diseases | Claire Bonardel;Mathieu Bonnerot;Marie Ludwig;Wilfried Vadot;Gaspard Beaune;Bruno Chanzy;Lucie Cornut;Hélène Baysson;Magali Farines;Isabelle Combes;Gabriel Macheda;Fabrice Bing | COVID-19;Infarction;MR perfusion;SARS-Cov2;Visual loss | 2020-06-28 02:00:00+02:00 | 32807489 | FR | Imaging Unit, Annecy Hospital, Metz-Tessy, France. Electronic address: cbonardel@chu-grenoble.fr.;Neurology Unit, Annecy Hospital. Electronic address: mbonnerot@ch-annecygenevois.fr.;Imaging Unit, Annecy Hospital, Metz-Tessy, France. Electronic address: mludwig@ch-annecygenevois.fr.;Neurology Unit, Annecy Hospital. Electronic address: wvadot@ch-annecygenevois.fr.;Biology Department, Annecy Hospital. Electronic address: gbeaune@ch-annecygenevois.fr.;Biology Department, Annecy Hospital. Electronic address: bchanzy@ch-annecygenevois.fr.;Imaging Unit, Annecy Hospital, Metz-Tessy, France. Electronic address: lcornut@ch-annecygenevois.fr.;Delegation to Clinical Research and Innovation, Annecy Hospital. Electronic address: hbaysson@ch-annecygenevois.fr.;Delegation to Clinical Research and Innovation, Annecy Hospital. Electronic address: mfarines@ch-annecygenevois.fr.;Delegation to Clinical Research and Innovation, Annecy Hospital. Electronic address: icombes@ch-annecygenevois.fr.;Infectiology Unit, Annecy Hospital. Electronic address: gmacheda@ch-annecygenevois.fr.;Imaging Unit, Annecy Hospital, Metz-Tessy, France. Electronic address: fabricebing@yahoo.fr. | 1514 | ||
| 10.1016/j.jaip.2020.06.032 | Journal Article | en | SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. | https://www.ncbi.nlm.nih.gov/pubmed/32603901 | Viral infections are known to exacerbate asthma in adults. Previous studies have found few patients with asthma among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases. However, the relationship between SARS-CoV-2 infection and severe asthma exacerbation is not known. | 2213-2198 | 2020-06-28 02:00:00+02:00 | pubmed | The Journal of Allergy and Clinical Immunology: In Practice | Manon Grandbastien;Anays Piotin;Julien Godet;Ines Abessolo-Amougou;Carole Ederlé;Irina Enache;Philippe Fraisse;Thi Cam Tu Hoang;Loic Kassegne;Aissam Labani;Pierre Leyendecker;Louise Manien;Christophe Marcot;Guillaume Pamart;Benjamin Renaud-Picard;Marianne Riou;Virginie Doyen;Romain Kessler;Samira Fafi-Kremer;Carine Metz-Favre;Naji Khayath;Frédéric de Blay | Asthma;COVID-19;Coronavirus;Europe;Exacerbation;France;SARS-CoV-2;SARS-CoV-2 pneumonia | 2020-06-27 02:00:00+02:00 | 32603901 | FR;BE | Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France.;Public Health Department, Strasbourg University Hospital, Strasbourg, France.;Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France, Public Health Department, Strasbourg University Hospital, Strasbourg, France, EA 3070 Federation of Translational Medicine, FHU Homicare, University of Strasbourg, Strasbourg, France.;Department of Radiology B, Strasbourg University Hospital, Strasbourg, France.;Clinic of Immuno-Allergology, Brugmann Hospital, ULB, Brussels, Belgium.;Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France, Public Health Department, Strasbourg University Hospital, Strasbourg, France, EA 3070 Federation of Translational Medicine, FHU Homicare, University of Strasbourg, Strasbourg, France, Department of Radiology B, Strasbourg University Hospital, Strasbourg, France, Clinic of Immuno-Allergology, Brugmann Hospital, ULB, Brussels, Belgium, INSERM-UNISTRA, UMR 1260 "Regenerative NanoMedecine," University of Strasbourg, Strasbourg, France.;Department of Virology, Strasbourg University Hospital, INSERM U748, University of Strasbourg, Strasbourg, France.;Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France, Public Health Department, Strasbourg University Hospital, Strasbourg, France, EA 3070 Federation of Translational Medicine, FHU Homicare, University of Strasbourg, Strasbourg, France. Electronic address: frederic.deblay@chru-strasbourg.fr. | 1517 | |||
| 10.1016/j.transci.2020.102858 | Journal Article | en | Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials? | https://www.ncbi.nlm.nih.gov/pubmed/32631501 | 1473-0502 | 2020-06-28 02:00:00+02:00 | pubmed | Transfusion and Apheresis Science | Olivier Garraud | COVID-19;Plasma therapy;clinkical trial;immunotherapy | 2020-06-27 02:00:00+02:00 | 32631501 | FR | Faculty of Medicine, EA3064, University of Lyon, Saint-Etienne, France, The National Institute for Blood Transfusion (INTS), Paris, France, Palliative Care Unit, the Ruffec general hospital, Ruffec, France. Electronic address: olivier.garraud@univ-st-etienne.fr. | 1520 | ||||
| 10.1007/s12291-020-00906-5 | Journal Article;Review | en | COVID-19: Current Trends in Invitro Diagnostics. | https://www.ncbi.nlm.nih.gov/pubmed/32641875 | The novel coronavirus SARS-CoV-2 is the seventh known species of coronavirus, infectious to human beings. The pandemic COVID-19 spread all over the world with an unprecedented spreading rate after its first appearance in Wuhan, China. As a novel viral disease there in no antiviral treatment or vaccine for the COVID-19. At present, the early detection and the quarantine of infected patients are the ways to stop the spreading of the disease. This review will discuss about the current invitro diagnostic methods used worldwide for the early and accurate diagnosis of COVID-19. Currently the nucleic acid based polymerase chain reaction is used as the reliable diagnostic platform and antigen/antibody detection immunoassays are playing the role of screening tests for early detection and prognosis in COVID-19 treatment. | 0970-1915,0974-0422 | 2020-06-28 02:00:00+02:00 | pubmed | Indian Journal of Clinical Biochemistry | R Arun Krishnan;Rhema Elizabeth Thomas;Ajaikumar Sukumaran;Jofy K Paul;D M Vasudevan | CLIA;ELISA;Lateral flow immunoassay;Loop mediated isothermal amplification;Reverse transcriptase PCR;SARS-CoV-2 | 2020-06-27 02:00:00+02:00 | 32641875 | FR;IN | R&D Reagent Department, Agappe Diagnostics Limited, Cochin, Kerala India. | 1521 | |||
| NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NIGMS NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS;NCI NIH HHS;European Research Council | 10.1016/j.cell.2020.06.034 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't;Research Support, U.S. Gov't, Non-P.H.S. | en | The Global Phosphorylation Landscape of SARS-CoV-2 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32645325 | The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies. Here we present a quantitative mass spectrometry-based phosphoproteomics survey of SARS-CoV-2 infection in Vero E6 cells, revealing dramatic rewiring of phosphorylation on host and viral proteins. SARS-CoV-2 infection promoted casein kinase II (CK2) and p38 MAPK activation, production of diverse cytokines, and shutdown of mitotic kinases, resulting in cell cycle arrest. Infection also stimulated a marked induction of CK2-containing filopodial protrusions possessing budding viral particles. Eighty-seven drugs and compounds were identified by mapping global phosphorylation profiles to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies. | 0092-8674 | 2020-06-28 02:00:00+02:00 | pubmed | Cell | Mehdi Bouhaddou;Danish Memon;Bjoern Meyer;Kris M White;Veronica V Rezelj;Miguel Correa Marrero;Benjamin J Polacco;James E Melnyk;Svenja Ulferts;Robyn M Kaake;Jyoti Batra;Alicia L Richards;Erica Stevenson;David E Gordon;Ajda Rojc;Kirsten Obernier;Jacqueline M Fabius;Margaret Soucheray;Lisa Miorin;Elena Moreno;Cassandra Koh;Quang Dinh Tran;Alexandra Hardy;Rémy Robinot;Thomas Vallet;Benjamin E Nilsson-Payant;Claudia Hernandez-Armenta;Alistair Dunham;Sebastian Weigang;Julian Knerr;Maya Modak;Diego Quintero;Yuan Zhou;Aurelien Dugourd;Alberto Valdeolivas;Trupti Patil;Qiongyu Li;Ruth Hüttenhain;Merve Cakir;Monita Muralidharan;Minkyu Kim;Gwendolyn Jang;Beril Tutuncuoglu;Joseph Hiatt;Jeffrey Z Guo;Jiewei Xu;Sophia Bouhaddou;Christopher J P Mathy;Anna Gaulton;Emma J Manners;Eloy Félix;Ying Shi;Marisa Goff;Jean K Lim;Timothy McBride;Michael C O'Neal;Yiming Cai;Jason C J Chang;David J Broadhurst;Saker Klippsten;Emmie De Wit;Andrew R Leach;Tanja Kortemme;Brian Shoichet;Melanie Ott;Julio Saez-Rodriguez;Benjamin R tenOever;R Dyche Mullins;Elizabeth R Fischer;Georg Kochs;Robert Grosse;Adolfo García-Sastre;Marco Vignuzzi;Jeffery R Johnson;Kevan M Shokat;Danielle L Swaney;Pedro Beltrao;Nevan J Krogan | AXL;CDK;MAPK;PIKFYVE;SARS-CoV-2;antiviral;casein kinase II;mass spectrometry;p38;phosphoproteomics | 2020-06-28 02:00:00+02:00 | 32645325 | FR;GB;US;DE | [{"country": "United States", "agency": "NIAID NIH HHS", "grantid": "HHSN272201400008C"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI120694"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI135990"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI122747"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "F32 CA239333"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "R01 CA221969"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "R01 CA244550"}, {"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "R01 GM133981"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI118610"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI135972"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "P50 AI150476"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI143292"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "F32 CA236347"}, {"country": "International", "agency": "European Research Council"}] | QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA, Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA, J. David Gladstone Institutes, San Francisco, CA 94158, USA, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.;European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.;Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 75724 Paris, Cedex 15, France.;Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.;QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA, Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA, Howard Hughes Medical Institute.;Institute for Clinical and Experimental Pharmacology and Toxicology, University of Freiburg, Freiburg 79104, Germany.;Virus & Immunity Unit, Department of Virology, CNRS UMR 3569, Institut Pasteur, 75724 Paris, Cedex 15, France, Vaccine Research Institute, 94000 Creteil, France.;Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.;Institute of Virology, Medical Center - University of Freiburg, Freiburg 79104, Germany.;Institute for Computational Biomedicine, Bioquant, Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Heidelberg 69120, Germany.;QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA.;QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA, Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA, Department of Bioengineering & Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94158, USA.;Zoic Labs, Culver City, CA 90232, USA.;NIH/NIAID/Rocky Mountain Laboratories, Hamilton, MT 59840, USA.;QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA, Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA.;J. David Gladstone Institutes, San Francisco, CA 94158, USA.;QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA, Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.;Vaccine Research Institute, 94000 Creteil, France, Faculty of Medicine, University of Freiburg, Freiburg 79008, Germany.;Howard Hughes Medical Institute, Faculty of Medicine, University of Freiburg, Freiburg 79008, Germany, Centre for Integrative Biological Signalling Studies (CIBSS), Freiburg 79104, Germany. Electronic address: robert.grosse@pharmakol.uni-freiburg.de.;Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. Electronic address: adolfo.garcia-sastre@mssm.edu.;Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 75724 Paris, Cedex 15, France. Electronic address: marco.vignuzzi@pasteur.fr.;Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: jeffrey.johnson@mssm.edu.;QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA, Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA, Howard Hughes Medical Institute. Electronic address: kevan.shokat@ucsf.edu.;QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA, Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA, J. David Gladstone Institutes, San Francisco, CA 94158, USA, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: danielle.swaney@ucsf.edu.;QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA, European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK. Electronic address: pbeltrao@ebi.ac.uk.;QBI COVID-19 Research Group (QCRG), San Francisco, CA 94158, USA, Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA, J. David Gladstone Institutes, San Francisco, CA 94158, USA, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA, Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: nevan.krogan@ucsf.edu. | 1524 | |
| Letter | en | Mental health of medical professionals during the COVID-19 pandemic in Togo. | https://www.ncbi.nlm.nih.gov/pubmed/32621390 | 2020-07-05 02:00:00+02:00 | pubmed | Kossi Blewussi Kounou;Koffi Mawuse Guédénon;Ayoko Akouavi Dogbe Foli;Eric Gnassounou-Akpa | 2020-07-03 02:00:00+02:00 | 32621390 | FR;TG | University of Lomé, Research Team in Psychology, Orientation and Development, Lomé, Togo.;Center of Psychotraumatology and Brief Therapies - Training and Research, Lomé, Togo.;University of Lomé, Sylvanus Olympio University Hospital, Pediatrics Unit, Lomé, Togo.;Toulouse - Jean Jaurès University, Socialization Psychology Laboratory - Development and Work, Toulouse, France.;Medico-Social Center of Adidogome, Lomé, Togo. | 1533 | ||||||||
| 10.1097/meg.0000000000001824 | Journal Article | en | COVID-19: an emergent cause of liver injury? | https://www.ncbi.nlm.nih.gov/pubmed/32639418 | 0954-691X | 2020-07-05 02:00:00+02:00 | pubmed | European Journal of Gastroenterology & Hepatology | Jean-François Cadranel;Noémi Reboux;Jean-Baptiste Nousbaum | 2020-07-03 02:00:00+02:00 | 32639418 | FR | Service d'Hépato-Gastroentérologie, Centre Hospitalier Laennec, Creil.;Service d'Hépato-Gastroentérologie, CHU La Cavale Blanche, Brest, France. | 1537 | |||||
| 10.1016/j.medcle.2020.05.003 | Journal Article | en | Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence. | https://www.ncbi.nlm.nih.gov/pubmed/32835102 | 2387-0206 | 2020-07-05 02:00:00+02:00 | pubmed | Medicina Clínica (English Edition) | Ernesto Cairoli;Gerard Espinosa | 2020-07-04 02:00:00+02:00 | 32835102 | FR;UY;ES | Unidad de Enfermedades Autoinmunes Sistémicas, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.;Laboratorio de Inmunorregulación e Inflamación, Institut Pasteur de Montevideo, Montevideo, Uruguay.;Servicio de Enfermedades Autoinmunes, Institut d'Investigacions August Pi i Sunyer, Universitat de Barcelona, Hospital Clinic, Barcelona, Spain. | 1539 | |||||
| Letter | en | Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? | https://www.ncbi.nlm.nih.gov/pubmed/32619697 | For the first 3 months of COVID-19 pandemic, COVID-19 was expected to be an immunizing non-relapsing disease. We report a national case series of 11 virologically-confirmed COVID-19 patients having experienced a second clinically- and virologically-confirmed acute COVID-19 episode. According to the clinical history, we discuss either re-infection or reactivation hypothesis. Larger studies including further virological, immunological and epidemiologic data are needed to understand the mechanisms of these recurrences. | 2020-07-05 02:00:00+02:00 | pubmed | Dominique Batisse;Nicolas Benech;Elisabeth Botelho-Nevers;Kevin Bouiller;Rocco Collarino;Anne Conrad;Laure Gallay;Francois Goehringer;Marie Gousseff;Dr Cédric Joseph;Adrien Lemaignen;François-Xavier Lescure;Bruno Levy;Matthieu Mahevas;Pauline Penot;Bruno Pozzetto;Dominique Salmon;Dorsaf Slama;Nicolas Vignier;Benjamin Wyplosz | 2020-06-30 02:00:00+02:00 | 32619697 | FR | Department of Infectious Diseases and Immunology, Cochin-Hôtel-Dieu Hospital, Publique -Hôpitaux de Paris (APHP), University of Paris. 1, place parvis Notre Dame, 75014 Paris.;Service de Maladies Infectieuses et Tropicales, Hôpital de La Croix-Rousse, Hospices Civils, de Lyon, 103, Grande rue de La Croix-Rousse, 69004 Lyon. Electronic address: nicolas.benech@chu-lyon.fr.;Infectious Diseases Department, University Hospital of Saint-Etienne, 42055 cedex 02 Saint-Etienne, GIMAP (EA 3064), University of Saint-Etienne, University of Lyon, Faculty of Medicine of Saint-Etienne, 42023 cedex 02 Saint-Etienne. Electronic address: elisabeth.botelho-nevers@chu-st-etienne.fr.;Department of infectious disease, University Hospital of Besançon, F-25000 Besançon, France, UMR-CNRS 6249 Chrono-environnement, Université Bourgogne Franche-Comté, 25000 Besançon. Electronic address: kbouiller@chu-besancon.fr.;Service des Maladies infectieuses et tropicales, Assistance publique- hôpitaux de Paris, Centre hospitalier universitaire Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre. Electronic address: rocco.collarino@aphp.fr.;Service de Maladies Infectieuses et Tropicales, Hôpital de La Croix-Rousse, Hospices Civils, de Lyon, 103, Grande rue de La Croix-Rousse, 69004 Lyon. Electronic address: anne.conrad@chu-lyon.fr.;Service Médecine Interne, Pr Hot, INMG CNRS UMR5310 INSERM U1217, Place d'arsonvaal, 69003 Lyon. Electronic address: laure.gallay@chu-lyon.fr.;Service de Maladies Infectieuses et Tropicales, Centre Régional Universitaire de Nancy, Hôpitaux de Brabois, Rue du Morvan, 54511 Vandoeuvre Lés Nancy. Electronic address: f.goehringer@chru-nancy.fr.;Service de Medecine interne, Maladies Infectieuses, hematologie, Centre Hospitalier Bretagne Atlantique, 20, boulevard Maurice Guillaudot, 56000 Vannes. Electronic address: marie.gousseff@ch-bretagne-atlantique.fr.;Service des Maladies Infectieuses et Tropicales, CHU Amiens-Picardie, Place Victor Pauchet 80054 Amiens. Electronic address: joseph.cedric@chu-amiens.fr.;Service de Médecine Interne et Maladies Infectieuses, CHRU de Tours, Hôpital Bretonneau, Université de Tours, 2, Boulevard Tonnellé, 37000 Tours. Electronic address: adrien.lemaignen@univ-tours.fr.;1-AP-HP, Infectious and Tropical Diseases Department, Bichat-Claude Bernard University, Hospital, Paris, France, 2 - University of Paris, French Institute for Health and Medical Research (INSERM), IAME, U1137, Team DesCID, Paris, France. 46 rue Henri Huchard, 75018 paris. Electronic address: xavier.lescure@aphp.fr.;Service de Médecine Intensive et Reanimation Brabois, CHRU Nancy, Pôle Cardio-Médico-Chirurgical, Vandoeuvre-les-Nancy, INSERM U1116, Faculté de Médecine, Vandoeuvre-les-Nancy, and Université de Lorraine. Electronic address: blevy5463@gmail.com.;Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France. IMRB - U955 - INSERM Equipe n°2 "Transfusion et maladies du globule rouge" EFS Île-de-France, Hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil. Electronic address: matthieu.mahevas@aphp.fr.;Hôpital intercommunal André Grégoire, groupement hospitalier Grand Paris Nord Est, 56, boulevard de la Boissière, 93100 Montreuil. Electronic address: pauline.penot@ght-gpne.fr.;GIMAP (EA 3064), University of Saint-Etienne, University of Lyon, Faculty of Medicine of Saint-Etienne, 42023 cedex 02 Saint-Etienne. Electronic address: bruno.pozzetto@chu-st-etienne.fr.;Department of Infectious Diseases and Immunology, Cochin-Hôtel-Dieu Hospital, Assistance, Publique -Hôpitaux de Paris (APHP), University of Paris. 1, place parvis Notre Dame, 75014 Paris. Electronic address: Dominique.salmon@aphp.fr.;Department of Infectious Diseases and Immunology, Cochin-Hôtel-Dieu Hospital, Assistance, Publique -Hôpitaux de Paris (APHP), University of Paris. 1, place parvis Notre Dame, 75014 Paris. Electronic address: dorssaf.slama@gmail.com.;Groupe hospitalier Sud Ile de France & INSERM, Institut Pierre Louis d'Épidémiologie et de, Santé Publique (IPLESP), Sorbonne Université, Paris, France, 270 avenue Marc Jacquet, 77 000 Melun. Electronic address: dr.vignier@gmail.com.;Service des Maladies infectieuses et tropicales, Assistance publique- hôpitaux de Paris, Centre hospitalier universitaire Bicêtre, 78 rue du général Leclerc, 94270 Le Kremlin-Bicêtre. Electronic address: Benjamin.wyplosz@aphp.fr. | 1555 | |||||||
| NIGMS NIH HHS | 10.1001/jamanetworkopen.2020.16485 | Journal Article;Research Support, N.I.H., Extramural | en | Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19). | https://www.ncbi.nlm.nih.gov/pubmed/32697322 | 2574-3805 | 2020-07-05 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Betacoronavirus__immunology;Case-Control Studies;Coronavirus Infections__epidemiology;Cytokines__immunology;Female;Humans;Immunotherapy__methods;Interleukin-7__administration & dosage;Lymphocyte Count__methods;Lymphopenia__etiology;Male;Middle Aged;Outcome Assessment, Health Care;Pandemics;Pneumonia, Viral__epidemiology;Randomized Controlled Trials as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | JAMA Network Open | Pierre Francois Laterre;Bruno François;Christine Collienne;Philippe Hantson;Robin Jeannet;Kenneth E Remy;Richard S Hotchkiss | 2020-07-01 02:00:00+02:00 | 32697322 | FR;BE;US | [{"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "R35 GM126928"}] | Department of Critical Care Medicine, Saint Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.;Intensive Care Unit Department and Inserm Centre Investigation Clinique 1435 and Unité Mixte de Recherche 1092, University Hospital of Limoges, Limoges, France.;Department of Intensive Care Medicine and Anaesthesiology, University Hospital of Limoges, Limoges, France.;Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.;Department of Anesthesiology and Critical Care Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri.;Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri.;Department of Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri. | 1558 | ||
| Clinical Trial Protocol;Letter | en | Comparison of two methods to clear the airways of critically ill children and adults with COVID-19 infection: a structured summary of a study protocol for a pilot randomized controlled trial. | https://www.ncbi.nlm.nih.gov/pubmed/32620174 | As there is no treatment for COVID-19 with a proven mortality benefit at this moment in the pandemic, supportive management including mechanical ventilation is the core management in an intensive care unit (ICU). It is a challenge to provide consistent care in this situation, highly demanding and leading to potential staff shortages in ICU. We need to reduce unnecessary exposure of healthcare workers to the virus. This study aims to examine the impact of care using a non-invasive oscillating device (NIOD) for chest physiotherapy in the care of mechanically ventilated patients with COVID-19. In particular, we aim to explore if a NIOD performed by non-specialized personnel is not inferior to the standard chest physiotherapy (CPT) undertaken by physiotherapists caring for patients with COVID-19. | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Coronavirus Infections__diagnosis;Critical Illness;Equivalence Trials as Topic;Host-Pathogen Interactions;Humans;Lung__physiopathology;Multicenter Studies as Topic;Pandemics;Physical Therapy Modalities__adverse effects;Pilot Projects;Pneumonia, Viral__diagnosis;Prospective Studies;Quebec;Respiration, Artificial;Time Factors;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Atsushi Kawaguchi;Gabrielle Bernier;Jacques Lacroix;Saly El Salti;Matthew P Cheng;Todd C Lee;Kosar Khwaja;Philippe Jouvet | COVID-19;Chest physiotherapy;Intensive care;Oscillation;Protocol;Randomized controlled trial | 2020-07-03 02:00:00+02:00 | 32620174 | FR;CA;US | Department of Pediatrics, University of Montreal, CHU Sainte-Justine, 3175 Chemin de Côte Sainte Catherine, Quebec, QB, H3T 1C5, Canada.;Department of Pediatrics, Children's Hospital Eastern Ontario, University of Ottawa, Ottawa, Canada.;School of Medicine, University of Montreal, Quebec, Canada.;Divisions of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Quebec, Canada.;McGill Interdisciplinary Initiative in Infection and Immunity, Quebec, Canada.;Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Quebec, Canada.;Réseau de Recherche en Santé Respiratoire du Québec, Quebec, Canada.;Department of Pediatrics, University of Montreal, CHU Sainte-Justine, 3175 Chemin de Côte Sainte Catherine, Quebec, QB, H3T 1C5, Canada. philippe.jouvet@umontreal.ca. | 1575 | |||||
| 10.1016/j.jaad.2020.06.1018 | Journal Article | en | New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus. | https://www.ncbi.nlm.nih.gov/pubmed/32622895 | 0190-9622 | 2020-07-05 02:00:00+02:00 | pubmed | Journal of the American Academy of Dermatology | Gilles Battesti;Jihane El Khalifa;Nour Abdelhedi;Valentine Ferre;Fabrice Bouscarat;Catherine Picard-Dahan;Florence Brunet-Possenti;Gilles Collin;Justine Lavaud;Patrick Le Bozec;Marion Rousselot;Amélie Tournier;Coralie Lheure;Anne Couvelard;Salima Hacein-Bey-Abina;Amine M Abina;Charlotte Charpentier;Sabine Mignot;Pascale Nicaise;Diane Descamps;Lydia Deschamps;Vincent Descamps | 2020-07-03 02:00:00+02:00 | 32622895 | FR | Department of Pathology, Bichat Hospital, Paris, France.;Department of Dermatology, Bichat Hospital, Paris, France.;Department of Virology, Bichat Hospital, Paris, France.;Unité des Technologies Chimiques et Biologiques Pour la Santé, Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UTCBS CNRS UMR) 8258, Institut National de la Santé et de la Recherche Médicale (INSERM) U1267, Faculté de Pharmacie de Paris, Université de Paris, Paris, France, Clinical Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Hôpital Kremlin-Bicêtre, Assistance Publique-Hôpitaux de Paris, Le-Kremlin-Bicêtre, France.;Unité des Technologies Chimiques et Biologiques Pour la Santé, Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UTCBS CNRS UMR) 8258, Institut National de la Santé et de la Recherche Médicale (INSERM) U1267, Faculté de Pharmacie de Paris, Université de Paris, Paris, France, Cerba Healthcare, Cerballiance-Ile-de-France Ouest, Hôpital Privé de l'Ouest Parisien, Trappes, France.;Department of Immunology, Bichat Hospital, Paris, France.;Department of Dermatology, Bichat Hospital, Paris, France. Electronic address: vincent.descamps@aphp.fr. | 1577 | |||||
| 10.1016/j.celrep.2020.107915 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32649864 | Coronaviruses cause several human diseases, including severe acute respiratory syndrome. The global coronavirus disease 2019 (COVID-19) pandemic has become a huge threat to humans. Intensive research on the pathogenic mechanisms used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is urgently needed-notably to identify potential drug targets. Clinical studies of patients with COVID-19 have shown that gastrointestinal disorders appear to precede or follow the respiratory symptoms. Here, we review gastrointestinal disorders in patients with COVID-19, suggest hypothetical mechanisms leading to gut symptoms, and discuss the potential consequences of gastrointestinal disorders on the outcome of the disease. Lastly, we discuss the role of the gut microbiota during respiratory viral infections and suggest that targeting gut dysbiosis may help to control the pathogenesis of COVID-19. | 2211-1247 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus__physiology;Coronavirus Infections__pathology;Dysbiosis__drug therapy;Gastrointestinal Diseases__pathology;Gastrointestinal Microbiome__physiology;Gastrointestinal Tract__microbiology;Humans;Pandemics;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__pathology;Severe Acute Respiratory Syndrome__pathology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cell Reports | François Trottein;Harry Sokol | COVID-19;SARS-CoV-2;disease outcomes;gastrointestinal symptoms;gut microbiota;microbial dysbiosis | 2020-07-03 02:00:00+02:00 | 32649864 | FR | Centre d'Infection et d'Immunité de Lille, INSERM U1019, CNRS UMR 9017, University of Lille, CHU Lille-Institut Pasteur de Lille, 59000 Lille, France. Electronic address: francois.trottein@pasteur-lille.fr.;Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, 75012 Paris, France, INRA, UMR1319 Micalis & AgroParisTech, 78350 Jouy en Josas, France, Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, 75012 Paris, France. | 1585 | ||
| Letter | en | COVID-19 studies registration worldwide for prospective studies with a specific focus on the fast-tracking of French ethic procedures. | https://www.ncbi.nlm.nih.gov/pubmed/32651096 | 2020-07-05 02:00:00+02:00 | pubmed | Téa Gremi;Éric Ginesy;Didier Payen;Jean-Yves Lefrant;Benoît Marin | 2020-06-30 02:00:00+02:00 | 32651096 | FR | EA 2992 IMAGINE, pôle anesthésie-réanimation douleur urgence, CHU de Nîmes, université Montpellier, Nîmes, France. Electronic address: gremi.tea@gmail.com.;Inspection générale des affaires sociales, Paris, France.;UMR Inserm 1160, UFR de médecine de l'université Paris 7, Paris, France.;EA 2992 IMAGINE, pôle anesthésie-réanimation douleur urgence, CHU de Nîmes, université Montpellier, Nîmes, France.;Direction générale de la santé, ministère des Solidarités et de la Santé, Paris, France. | 1589 | ||||||||
| Algerian Ministry of Higher Education and Scientific Research | 10.3390/nano10071271 | Journal Article | en | Magneto-Optical Nanostructures for Viral Sensing. | https://www.ncbi.nlm.nih.gov/pubmed/32610549 | The eradication of viral infections is an ongoing challenge in the medical field, as currently evidenced with the newly emerged Coronavirus disease 2019 (COVID-19) associated with severe respiratory distress. As treatments are often not available, early detection of an eventual infection and its level becomes of outmost importance. Nanomaterials and nanotechnological approaches are increasingly used in the field of viral sensing to address issues related to signal-to-noise ratio, limiting the sensitivity of the sensor. Superparamagnetic nanoparticles (MPs) present one of the most exciting prospects for magnetic bead-based viral aggregation assays and their integration into different biosensing strategies as they can be easily separated from a complex matrix containing the virus through the application of an external magnetic field. Despite the enormous potential of MPs as capture/pre-concentrating elements, they are not ideal with regard of being active elements in sensing applications as they are not the sensor element itself. Even though engineering of magneto-plasmonic nanostructures as promising hybrid materials directly applicable for sensing due to their plasmonic properties are often used in sensing, to our surprise, the literature of magneto-plasmonic nanostructures for viral sensing is limited to some examples. Considering the wide interest this topic is evoking at present, the different approaches will be discussed in more detail and put into wider perspectives for sensing of viral disease markers. | 2079-4991 | 2020-07-05 02:00:00+02:00 | pubmed | Nanomaterials | Sabine Szunerits;Tamazouzt Nait Saada;Dalila Meziane;Rabah Boukherroub | magnetic nanoparticles;plasmonic;sensing;virus | 2020-06-29 02:00:00+02:00 | 32610549 | FR;DZ | [{"country": "", "agency": "Algerian Ministry of Higher Education and Scientific Research", "grantid": "PROFAS B+ 2018 grant."}] | Institut d'Electronique, de Microélectronique et de Nanotechnologie (IEMN-UMR CNRS 8520), University Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France.;Laboratory of Applied Chemistry and Chemical Engineering (LCAGC), Université Mouloud Mammeri de Tizi-Ouzou, Tizi-Ouzou 15000, Algeria. | 1610 | |
| 10.1007/s11239-020-02201-9 | Journal Article | en | Impact of Coronavirus Disease 2019 outbreak on acute coronary syndrome admissions: four weeks to reverse the trend. | https://www.ncbi.nlm.nih.gov/pubmed/32601849 | Data whether the COVID-19 outbreak impacts the acute coronary syndromes (ACS) admissions and the time required to reverse the downward curve are scarce. We included all consecutive patients referred for an ACS who underwent PCI from February 17, 2020 to April 26, 2020 in a high-volume PCI coronary care unit. We compared the number of ACS patients in 2020 to the same period in 2018 and 2019. Predictors of adverse outcome in ST-elevation myocardial infarction (STEMI) patients were recorded: symptom-onset-to-first medical contact (FMC), and FMC-to-sheath insertion times. During the studied period (calendar weeks 8-17, 2018-2020), 144 ACS patients were included. In 2020, we observed two distinct phases in the ACS admissions: a first significant fall, with a relative reduction of 73%, from the week of lockdown (week 12) to 3 weeks later and then an increase of ACS. Median symptom-onset-to-FMC time was significantly higher in 2020 than in the two previous years (600 min [298-632] versus 121 min [55-291], p < 0.001). Median FMC-to-sheath insertion did not differ significantly (93 min [81-131] in 2020 versus 90 min [67-137] in 2018-2019, p = 0.57). The main findings are (1) a pattern of a U-curve in ACS admissions, with a first decrease in ACS admissions and a return to "normality" 4 weeks after; (2) a significant increase in the total ischemic time exclusively due to an increase in the symptom-onset-to-first-medical-contact time. | 0929-5305,1573-742X | 2020-07-05 02:00:00+02:00 | pubmed | Journal of Thrombosis and Thrombolysis | Marie Hauguel-Moreau;Rémy Pillière;Giulio Prati;Sébastien Beaune;Thomas Loeb;Simon Lannou;Sophie Mallet;Hazrije Mustafic;Céline Bégué;Olivier Dubourg;Nicolas Mansencal | Acute coronary syndrome;COVID-19;ST-elevation myocardial infarction | 2020-06-29 02:00:00+02:00 | 32601849 | FR | Department of Cardiology, Ambroise Paré Hospital (AP-HP), ACTION Study Group, Université de Versailles-Saint Quentin, Boulogne, France. marie.hauguel@aphp.fr.;INSERM U-1018, CESP, Épidémiologie clinique, Villejuif, France. marie.hauguel@aphp.fr.;Department of Cardiology, Ambroise Paré Hospital (AP-HP), ACTION Study Group, Université de Versailles-Saint Quentin, Boulogne, France.;Department of Emergency Medicine, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France.;Service D'Aide Médicale D'Urgence (SAMU), Raymond Poincaré Hospital, APHP, Garches, France.;INSERM U-1018, CESP, Épidémiologie clinique, Villejuif, France. | 1616 | |||
| European Society of Gynaecologic Oncology;Horizon 2020 Framework Programme;Stichting Tegen Kanker;International Agency for Research on Cancer (IARC) | 10.1002/ijc.33189 | Journal Article | en | The European response to the WHO call to eliminate cervical cancer as a public health problem. | https://www.ncbi.nlm.nih.gov/pubmed/32638362 | The age-standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women-years) in 2018. Human papillomavirus (HPV) vaccine coverage is low in countries with the highest incidence and screening performance is heterogeneous among European countries. A broad group of delegates of scientific professional societies and cancer organisations endorse the principles of the WHO call to eliminate cervical cancer as a public health problem, also in Europe. All European nations should, by 2030, reach at least 90% HPV vaccine coverage among girls by the age of 15 years and also boys, if cost-effective; they should introduce organised population-based HPV-based screening and achieve 70% of screening coverage in the target age group, providing also HPV testing on self-samples for nonscreened or underscreened women; and to manage 90% of screen-positive women. To guide member states, a group of scientific professional societies and cancer organisations engage to assist in the rollout of a series of concerted evidence-based actions. European health authorities are requested to mandate a group of experts to develop the third edition of European Guidelines for Quality Assurance of Cervical Cancer prevention based on integrated HPV vaccination and screening and to monitor the progress towards the elimination goal. The occurrence of the COVID-19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. In the immediate postepidemic phase, health professionals should focus on high-risk women and adhere to cost-effective policies including self-sampling. | 0020-7136,1097-0215 | 2020-07-12 02:00:00+02:00 | pubmed | International Journal of Cancer | Marc Arbyn;Murat Gultekin;Philippe Morice;Pekka Nieminen;Maggie Cruickshank;Philip Poortmans;Daniel Kelly;Mario Poljak;Christine Bergeron;David Ritchie;Dietmar Schmidt;Maria Kyrgiou;Ann Van den Bruel;Laia Bruni;Partha Basu;Freddie Bray;Elisabete Weiderpass | COVID-19;Europe;HPV vaccination;WHO;cervical cancer screening;elimination of cervical cancer | 2020-07-07 02:00:00+02:00 | 32638362 | FR;SI;FI;GB;TR;ES;BE;DE | [{"country": "", "agency": "European Society of Gynaecologic Oncology", "grantid": "2019"}, {"country": "", "agency": "Horizon 2020 Framework Programme", "grantid": "847845"}, {"country": "", "agency": "Stichting Tegen Kanker", "grantid": "IHUVAC"}, {"country": "", "agency": "International Agency for Research on Cancer (IARC)"}] | Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.;Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.;Department of Gynecologic Surgery, Gustave Roussy Institute, Villejuif, France.;Department of Obstetrics and Gynaecology, University of Helsinki and University Hospital of Helsinki, Finland.;Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK.;European Cancer Organisation, Brussels, Belgium.;School of Healthcare Sciences, Cardiff University, UK.;Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;Laboratoire Cerba, Cergy Pontoise, France.;Association of European Cancer Leagues, Brussels, Belgium.;MVZ of Pathology, Cytology and Molecular Diagnostics, Trier, University of Kiel, Germany.;Department of Gut, Metabolism and Reproduction & Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, UK.;West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust, London, UK.;Academic Centre for General Practice, University of Leuven, Belgium.;Cancer Epidemiology Research Program, Catalan Institute of Oncology - IDIBELL, Barcelona, Spain.;International Agency for Research on Cancer, Lyon, France. | 1626 | |
| 10.1016/j.jinf.2020.07.005 | Journal Article | en | Self-reported loss of smell without nasal obstruction to identify COVID-19. The multicenter Coranosmia cohort study. | https://www.ncbi.nlm.nih.gov/pubmed/32650110 | To determine the frequency of SARS-CoV-2 positive samples in a subset of patients consulting for primarily isolated acute (<7 days) loss of smell and to assess the diagnostic accuracy of olfactory/gustatory dysfunction for COVID-19 diagnosis in the overall population tested for COVID-19 in the same period. | 0163-4453 | 2020-07-12 02:00:00+02:00 | pubmed | Journal of Infection | Dominique Salmon Ceron;Sophie Bartier;Charlotte Hautefort;Yann Nguyen;Jérôme Nevoux;Anne-Laure Hamel;Yohan Camhi;Florence Canouï-Poitrine;Benjamin Verillaud;Dorsaf Slama;Stephanie Haim-Boukobza;Elise Sourdeau;Delphine Cantin;Alain Corré;Agnes Bryn;Nicolas Etienne;Flore Rozenberg;Richard Layese;Jean-François Papon;Emilie Bequignon | Anosmia;COVID-19;Dysguageusia;Loss of smell;Positive predictive value;SARS-CoV-2;Viral load | 2020-07-07 02:00:00+02:00 | 32650110 | FR | Department of Infectious Diseases and Immunology, Hotel Dieu Hospital, Paris Public Hospitals (APHP), 1 Place du Parvis de Notre-Dame, Paris 75004, France, University of Paris, School of Medicine, Paris 75005, France. Electronic address: dominique.salmon@aphp.fr.;Department of Oto-rhino-laryngology, Head and Neck Surgery, Intercommunal Hospital of Créteil, Créteil 94000, France, University Paris-Est Créteil (UPEC), School of Medicine, Créteil 94000, France, INSERM U955, IMRB- CEpiA team, 94000 Créteil, France Paris Public Hospitals Henri Mondor Hospital (APHP), Créteil 94000, France, Department of Oto-rhino-laryngology, Henri Mondor Hospital of Créteil, Paris Public Hospitals, Créteil 94000, France, Centre National de la Recherche Scientifique CNRS, ERL 7000, Créteil 94000, France.;Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals, Lariboisière Hospital (APHP), Paris 75010, France, University Paris Diderot, School of Medicine, Paris 75010, France.;Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals, AP-HP Sorbonne University Hospital Pitié Salpêtrière Hospital (AP-HP), Paris 75006, France, Sorbonne University, Paris 75013, France.;Groupe Hospitalier Paris-Saclay, Hôpital Bicêtre, Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals. Le Kremlin-Bicêtre 94270, France, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre F-94275, France.;Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals, AP-HP Sorbonne University Hospital Pitié Salpêtrière Hospital (AP-HP), Paris 75006, France.;University Paris-Est Créteil (UPEC), School of Medicine, Créteil 94000, France, INSERM U955, IMRB- CEpiA team, 94000 Créteil, France Paris Public Hospitals Henri Mondor Hospital (APHP), Créteil 94000, France, Clinical Research Unit: (URC-Mondor), Department of Public Health, Henri Mondor Hospital Paris Public Hospitals (AP-HP), Créteil 94000, France.;Department of Infectious Diseases and Immunology, Hotel Dieu Hospital, Paris Public Hospitals (APHP), 1 Place du Parvis de Notre-Dame, Paris 75004, France.;Cerba Laboratory, Saint-Ouen L'Aumône, France.;Emergency Department, Hotel Dieu Hospital, Paris Public Hospitals (APHP), Paris 75004, France.;Department of Oto-rhino-laryngology Head and Neck Surgery, Hopital Rothschild Foundation, Paris, France.;University of Paris, School of Medicine, Paris 75005, France, General Medical Practioner, Paris, France.;University of Paris, School of Medicine, Paris 75005, France, Virology Department, Cochin Hospital, Paris Public Hospitals (APHP), Paris 75004, France.;INSERM U955, IMRB- CEpiA team, 94000 Créteil, France Paris Public Hospitals Henri Mondor Hospital (APHP), Créteil 94000, France, Centre National de la Recherche Scientifique CNRS, ERL 7000, Créteil 94000, France, Groupe Hospitalier Paris-Saclay, Hôpital Bicêtre, Department of Oto-rhino-laryngology Head and Neck Surgery, Paris Public Hospitals. Le Kremlin-Bicêtre 94270, France, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre F-94275, France. | 1629 | |||
| 10.1111/jgs.16728 | Journal Article | en | Recurrence or Relapse of COVID-19 in Older Patients: A Description of Three Cases. | https://www.ncbi.nlm.nih.gov/pubmed/32638347 | COVID-19 has infected millions of people worldwide, particularly in older adults. The first cases of possible reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported in April 2020 among older adults. | 0002-8614,1532-5415 | 2020-07-12 02:00:00+02:00 | pubmed | Journal of the American Geriatrics Society | Ludovic Lafaie;Thomas Célarier;Luc Goethals;Bruno Pozzetto;Sylvain Grange;Etienne Ojardias;Cédric Annweiler;Elisabeth Botelho-Nevers | COVID-19;recurrence;severe acute respiratory syndrome coronavirus 2 | 2020-07-07 02:00:00+02:00 | 32638347 | FR;CA;GB | Department of Clinical Gerontology, University Hospital of Saint-Etienne, Saint-Etienne, France.;Chaire Santé des Ainés, University of Jean Monnet, Saint-Etienne, France.;Gérontopôle Auvergne-Rhône-Alpes, Saint-Etienne, France.;Autonomic Nervous System Research Laboratory, University of Jean Monnet, Saint-Etienne, France.;Groupe Immunité des Muqueuses et Agents Pathogènes-EA3064, University Hospital of Saint-Etienne, Saint-Etienne, France.;Department of Radiology, University Hospital of Saint Etienne, Saint-Priest-en-Jarez, France.;Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France.;UPRES EA 4638, University of Angers, Angers, France.;Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.;Infectious Diseases Department, University Hospital of Saint-Etienne, Saint-Etienne, France. | 1630 | |||
| 10.1055/s-0040-1713637 | Journal Article | en | Fibrinolysis Resistance: A Potential Mechanism Underlying COVID-19 Coagulopathy. | https://www.ncbi.nlm.nih.gov/pubmed/32645725 | 0340-6245,2567-689X | 2020-07-12 02:00:00+02:00 | pubmed | Thrombosis and Haemostasis | Emmanuel Weiss;Olivier Roux;Jean-Denis Moyer;Catherine Paugam-Burtz;Larbi Boudaoud;Nadine Ajzenberg;Dorothée Faille;Emmanuelle de Raucourt | 2020-07-09 02:00:00+02:00 | 32645725 | FR;ES | Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP.Nord, Paris, France.;Inserm UMR_S1149, Inserm et Université de Paris, Paris, France.;EASL CLIF Consortium, European Foundation for the Study of Chronic Liver Failure, EF CLIF, Barcelona, Spain.;Hepatology & Liver Intensive Care Unit, Hôpital Beaujon, Paris, France.;Service Hématologie Biologique, Hôpital Beaujon, Paris, France.;Laboratoire d'hématologie, APHP, Hôpital Bichat, Paris, France.;UMR_S1148, Inserm et Université de Paris, Paris, France. | 1636 | |||||
| 10.1016/j.eclinm.2020.100449 | Journal Article | en | Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. | https://www.ncbi.nlm.nih.gov/pubmed/32838231 | Coronavirus disease 2019 (COVID-19) is associated with a high disease burden with 10% of confirmed cases progressing towards critical illness. Nevertheless, the disease course and predictors of mortality in critically ill patients are poorly understood. | 2589-5370 | 2020-07-12 02:00:00+02:00 | pubmed | EClinicalMedicine | Pedro David Wendel Garcia;Thierry Fumeaux;Philippe Guerci;Dorothea Monika Heuberger;Jonathan Montomoli;Ferran Roche-Campo;Reto Andreas Schuepbach;Matthias Peter Hilty | Acute respiratory distress syndrome;COVID-19;Coronavirus;Pandemic;Public health | 2020-07-06 02:00:00+02:00 | 32838231 | FR;NL;CH;ES | The RISC-19-ICU registry board, University of Zurich, Zurich, Switzerland.;Institute of Intensive Care Medicine, University Hospital of Zurich, Rämistrasse 100, Zurich 8091, Switzerland.;Soins intensifs, Groupement Hospitalier de l'Ouest Lémanique - Hopital de Nyon, Nyon, Switzerland.;Department of Anesthesiology and Critical care Medicine, University Hospital of Nancy, France.;Department of Intensive Care Medicine, Erasmus medical Center, Rotterdam, Netherlands.;Servei de Medicina intensiva, Hospital Verge de la Cinta, Tortosa, Tarragona, Spain. | 1639 | |||
| 10.3390/jcm9072158 | Journal Article;Review | en | Obesity and COVID-19: Oro-Naso-Sensory Perception. | https://www.ncbi.nlm.nih.gov/pubmed/32650509 | Through a recent upsurge of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, the clinical assessment of most of the coronavirus disease 19 (COVID-19) patients clearly presents a health condition with the loss of oro-naso-sensory (ONS) perception, responsible for the detection of flavor and savor. These changes include anosmia and dysgeusia. In some cases, these clinical manifestations appear even before the general flu-like symptoms, e.g., sore throat, thoracic oppression and fever. There is no direct report available on the loss of these chemical senses in obese COVID-19 patients. Interestingly, obesity has been shown to be associated with low ONS cues. These alterations in obese subjects are due to obesity-induced altered expression of olfacto-taste receptors. Besides, obesity may further aggravate the SARS-CoV-2 infection, as this pathology is associated with a high degree of inflammation/immunosuppression and reduced protection against viral infections. Hence, obesity represents a great risk factor for SARS-CoV-2 infection, as it may hide the viral-associated altered ONS symptoms, thus leading to a high mortality rate in these subjects. | 2077-0383 | 2020-07-12 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Amira Sayed Khan;Aziz Hichami;Naim Akhtar Khan | COVID-19;SARS-CoV-2;obesity;smell;taste | 2020-07-08 02:00:00+02:00 | 32650509 | FR | Centre de Recherche Inserm, U1231 INSERM/UB/AgroSup, Team-Physiologie de la Nutrition & Toxicologie, Université de Bourgogne Franche-Comté (UBFC), Faculté des Sciences de la Vie, 6 Boulevard Gabriel, 21000 Dijon, France. | 1645 | |||
| 10.1055/a-1213-5761 | Journal Article | en | ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: An update on guidance during the post-lockdown phase and selected results from a membership survey. | https://www.ncbi.nlm.nih.gov/pubmed/32643767 | N/A. | 0013-726X,1438-8812 | 2020-07-12 02:00:00+02:00 | pubmed | Endoscopy | Ian Gralnek;Cesare Hassan;Ulrike Beilenhoff;Giulio Antonelli;Alanna Ebigbo;Maria Pellisé;Marianna Arvanitakis;Pradeep Bhandari;Raf Bisschops;Jeanin van Hooft;Michal Kaminski;Konstantinos Triantafyllou;George Webster;Andrei Voiosu;Heiko Pohl;Irene Dunkley;Björn Fehrke;Mario Gazic;Tatjana Gjergek;Siiri Maasen;Wendy Jo Waagenes;Marjon de Pater;Thierry Ponchon;Peter D Siersema;Helmut Messmann;Mário Dinis-Ribeiro | 2020-07-08 02:00:00+02:00 | 32643767 | IL;IE;FR;SI;PT;GR;GB;US;RO;CH;HR;IT;PL;NL;DK;ES;EE;BE;DE | Ha'Emek Medical Center, Gastroenterology, Haifa, Israel.;Nuovo Regina Marg Hospitalherita, Gastroenterology, Rome, Italy.;ESGENA, Endoscopy, Ulm, Germany.;Azienda Ospedaliera Sant'Andrea, Sapienza University of Rome, Digestive and Liver Disease Unit, Roma, Italy.;Universitätsklinikum Augsburg, Gastroenterology, Augsburg, Germany.;Hospital Clínic Barcelona, Gastroenterology, Barcelona, Spain.;Erasme University Hospital, Gastroenterology, Brussels, Belgium.;Portsmouth Hosp NHS Trust, Gastroenterology, Portsmouth, United Kingdom of Great Britain and Northern Ireland.;University Hospital Gasthuisberg, Gastroenterology, Leuven, Belgium.;Leiden University Medical Center, Gastroenterology and Hepatology LUMC, Leiden, Netherlands.;Medical Center for Postgraduate Education and the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Gastroenterology and Hepatology, Warsaw, Poland.;Attikon University General Hospital, Hepatogastroenterology Unit, 2nd Department of Internal Medicine, Haidari, Greece.;University College London Hospitals, Gastroenterology, London, United Kingdom of Great Britain and Northern Ireland.;Colentina Clinical Hospital, Gastroenterology Department, Bucharest, Romania.;Carol Davila University of Medicine and Pharmacy, Internal Medicine Department, Bucharest, Romania.;VA Medical Center, Section of Gastroenterology, Vermont, United States.;North West Anglia NHS Foundation Trust, Gastroenterology, Peterborough, United Kingdom of Great Britain and Northern Ireland.;Inselspital Universitatsspital Bern, Pneumological Endoscopy unit, Bern, Switzerland.;General Hospital Opća bolnica Bjelovar, Endoscopy Unit, Bjelovar, Croatia.;University Medical Centre Ljubljana Division of Internal Medicine, Division of Internal Medicine, Ljubljana, Slovenia.;Tallinn Health Care College, Gastroenterology Dep., Tallinn, Estonia.;Hvidovre Hospital, Gastrounit, Hvidovre, Denmark.;Academic Medical Centre Amsterdam, Dept of Gastroenterology, Amsterdam, Netherlands.;Edouard Herriot, hepatogastroenterology, LYON, France.;Radboud University Medical Center, Dept. of Gastroenterology and Hepatology, Nijmegen, Netherlands.;Klinikum Augsburg, III. Med. Klinik, Augsburg, Germany.;Porto Faculty of Medicine, Biostatistics and Medical Informatics, Porto, Portugal.;Instituto Português de Oncologia, Gastrenterologia, Porto, Portugal. | 1650 | ||||
| 10.1016/j.worlddev.2020.105071 | Journal Article | en | Covid-19 outbreak and the need for rice self-sufficiency in West Africa. | https://www.ncbi.nlm.nih.gov/pubmed/32834379 | In the decade since the 2008 global food crisis, West African countries have made efforts to raise domestic rice production and to make the region self-sufficient. Today, West Africa produces nearly two-thirds of Africa's rice. The region's rice import dependency has fallen from nearly half of local consumption in 2010 to about 30%. In spite of this improvement, the region remains the world's second largest rice importer. The situation of Benin, Burkina Fasso, Gambia and Niger remains challenging with rice import dependency still exceeding 70%. Production in some countries has fallen even below the 2010 level due to civil strife, climatic changes and macroeconomic difficulties. Countries of the region, on average, allocate less than 5% of their budget to agriculture, less than half the share committed in the Maputo Agreement. The Covid-19 outbreak and corresponding preventive lockdowns have posed a new challenge as food supply chains were stretched; production, transportation and consumption fell sharply; and household income was affected. In addition, closure of frontiers and temporary trade disruption in major Asian rice exporters has led to increase in rice prices in the international market. In late April, rice futures rose to reach a level not surpassed since 2011. This threatens to further aggravate an already fragile food security situation in the region. The crisis again points to the need for greater efforts at the national and international level to achieve food security. West African countries will need to enhance public spending on agriculture with a greater focus on measures aimed at improving rice productivity. | 0305-750X | 2020-07-12 02:00:00+02:00 | pubmed | World Development | Charlotte Fontan Sers;Mazhar Mughal | Covid-19;Food security;Rice;West Africa | 2020-07-09 02:00:00+02:00 | 32834379 | FR | Pau Business School, France. | 1658 | |||
| Letter | en | Impact of initial respiratory compliance in ventilated patients with acute respiratory distress syndrome related to COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32646470 | 2020-07-12 02:00:00+02:00 | pubmed | Adult;Coronavirus Infections__complications;Female;Humans;Lung Compliance;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Respiration, Artificial;Respiratory Distress Syndrome, Adult__therapy;Treatment Outcome;COVID-19 | Florent Laverdure;Amélie Delaporte;Astrid Bouteau;Thibaut Genty;François Decailliot;François Stéphan | Acute respiratory distress syndrome;COVID-19;Invasive mechanical ventilation;Positive end-expiratory pressure;Prone positioning;Respiratory compliance | 2020-07-09 02:00:00+02:00 | 32646470 | FR | Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Paris, France. f.laverdure@hml.fr.;Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Paris, France.;Pediatric Intensive Care Unit, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Paris, France. | 1661 | ||||||
| 10.3390/jof6030105 | Journal Article | en | Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience. | https://www.ncbi.nlm.nih.gov/pubmed/32664423 | (1) Background: The diagnosis of invasive aspergillosis (IA) in an intensive care unit (ICU)remains a challenge and the COVID-19 epidemic makes it even harder. Here, we evaluatedAspergillus PCR input to help classifying IA in SARS-CoV-2-infected patients. (2) Methods: 45COVID-19 patients were prospectively monitored twice weekly for Aspergillus markers and anti-Aspergillus serology. We evaluated the concordance between (Ι) Aspergillus PCR and culture inrespiratory samples, and (ΙΙ) blood PCR and serum galactomannan. Patients were classified asputative/proven/colonized using AspICU algorithm and two other methods. (3) Results: Theconcordance of techniques applied on respiratory and blood samples was moderate (kappa = 0.58and kappa = 0.63, respectively), with a higher sensitivity of PCR. According to AspICU, 9/45 patientswere classified as putative IA. When incorporating PCR results, 15 were putative IA because theymet all criteria, probably with a lack of specificity in the context of COVID-19. Using a modifiedAspICU algorithm, eight patients were classified as colonized and seven as putative IA. (4)Conclusion: An appreciation of the fungal burden using PCR and Aspergillus serology was addedto propose a modified AspICU algorithm. This proof of concept seemed relevant, as it was inagreement with the outcome of patients, but will need validation in larger cohorts. | 2309-608X | 2020-07-12 02:00:00+02:00 | pubmed | Journal of Fungi | Jean-Pierre Gangneux;Florian Reizine;Hélène Guegan;Kieran Pinceaux;Pierre Le Balch;Emilie Prat;Romain Pelletier;Sorya Belaz;Mathieu Le Souhaitier;Yves Le Tulzo;Philippe Seguin;Mathieu Lederlin;Jean-Marc Tadié;Florence Robert-Gangneux | Aspergillus;COVID-19;ICU;PCR;Sars-CoV-2;classification;galactomannan;invasive aspergillosis;probable;putative | 2020-07-10 02:00:00+02:00 | 32664423 | FR | Service de Parasitologie-Mycologie, CHU Rennes, F-35033 Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Univ Rennes, CHU Rennes, Inserm, EHESP, F-35000 Rennes, France.;Maladies Infectieuses et Réanimation Médicale, CHU Rennes, F-35033 Rennes, France.;Service de Réanimation Chirurgicale, CHU Rennes, F-35033 Rennes, France.;Service d'Imagerie Médicale, CHU Rennes, F-35033 Rennes, France. | 1669 | |||
| 10.1016/j.pratan.2020.07.005 | English Abstract;Journal Article;Review | fr | [Obstetric anaesthesia during the COVID-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32837210 | Pregnant women and parturients have also been concerned by the COVID-19 pandemic. However, they are not especially at risk for severe forms of the disease prone to induce prematurity but without transmission to the fœtus. Obstetrical management of parturients have changed with an extensive use of teleconsultation and a limitation of relatives in the delivery room and in the ward. The choice of the mode of delivery remains determined by obstetrical reasons, and use of regional anaesthesia remains recommended for labour and caesarean section provided there is not haemostasis disorders. The pandemic issue has not change management of fever and hypertension. The post-partum period is more impacted due to an increased risk of thromboembolic events justifying an extended use of anticoagulants. On the other hand, the use of non-steroidal anti-inflammatory drugs is restricted. The key point was cooperation between obstetricians, anaesthesiologists, intensivists and pediatrician. | 1279-7960 | 2020-07-12 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Nithiya Ung;Marie Pierre Bonnet | Anticoagulation;COVID-19;Obstetrical anaesthesia;Pregnancy;Regional anaesthesia;SARS-CoV-2 | 2020-07-10 02:00:00+02:00 | 32837210 | FR | DMU DREAM, service d'anesthésie réanimation, hôpital Armand-Trousseau, Sorbonne université, AP-HP, 26, avenue du Dr Arnold-Netter, 75012 Paris, France.;Inserm, INRA, Center of Research in Epidemiology and statistics/CRESS/Obstetrical Pediatric and perinatal epidemiology Research Team (EPOPé), université de Paris, 75004 Paris, France. | 1673 | |||
| Letter | en | COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. | https://www.ncbi.nlm.nih.gov/pubmed/32651243 | 2020-07-12 02:00:00+02:00 | pubmed | Louis Delamarre;Cédric Gollion;Gaspard Grouteau;David Rousset;Guillaume Jimena;Jérôme Roustan;François Gaussiat;Etienne Aldigé;Charlène Gaffard;Julien Duplantier;Charlotte Martin;Olivier Fourcade;Chloé Bost;Françoise Fortenfant;Pierre Delobel;Guillaume Martin-Blondel;Jérémie Pariente;Fabrice Bonneville;Thomas Geeraerts | autoimmune encephalitis;intensive care;neuropathology, virology;steroids | 2020-07-10 02:00:00+02:00 | 32651243 | FR | Anesthesiology and Intensive Care, Centre Hospitalier Universitaire de Toulouse, Toulouse, France delamarre.l@chu-toulouse.fr.;Neurology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Infectious and Tropical Diseases, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Anesthesiology and Intensive Care, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Intensive Care, Centre Hospitalier de Montauban, Montauban, Midi-Pyrénées, France.;Neuroradiology, Centre Hospitalier Universitaire de Toulouse, Toulouse, Midi-Pyrénées, France.;Immunology, Centre Hospitalier Universitaire de Toulouse, Toulouse, Midi-Pyrénées, France.;INSERM U1043-CNRS UMR 5282, Centre de Physiopathologie de Toulouse Purpan, Toulouse, Midi-Pyrénées, France. | 1677 | |||||||
| 10.1016/j.pratan.2020.06.001 | Journal Article;Review | fr | [April 220, emergency and INtensive care in Mulhouse, France: In the heart of the COVID-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32837208 | 1279-7960 | 2020-07-12 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Gaétan Dangelser | 2020-07-10 02:00:00+02:00 | 32837208 | FR | Réanimation chirurgicale, hôpital Emile-Muller, 20, avenue du Dr René-Laennec, 68100 Mulhouse, France. | 1682 | |||||
| 10.1016/j.pratan.2020.07.002 | English Abstract;Journal Article;Review | fr | [Nutritional support for critically ill patients suffering from SARS-CoV-2 infection]. | https://www.ncbi.nlm.nih.gov/pubmed/32837212 | Patients with severe cases of COVID-19 are at high nutritional risk during their ICU stay. Prolonged immobilization associated with an exacerbated systemic inflammatory response is a major provider of ICU-acquired muscle weakness. Early enteral nutrition is recommended to gradually reach the energy target of 25 kcal/kg/day and protein target of 1.3 g/kg/day around D4. The occurrence of a Refeeding syndrome should be closely monitored. In case of feeding intolerance refractory to a prokinetic treatment, complementary or total parenteral nutrition is advised, favouring new generation mixed lipid emulsions (containing fish oil) and regular monitoring of triglyceridemia. Nutrition care of critically ill patients should be carried out with limited procedures that may pose a risk of contamination for the healthcare staff. | 1279-7960 | 2020-07-12 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Emmanuel Pardo | COVID-19;Fish oil;Nutrition;Refeeding syndrome | 2020-07-10 02:00:00+02:00 | 32837212 | FR | Service d'anesthésie-réanimation, hôpital Saint-Antoine, AP-HP, Paris, France.;Sorbonne universités, UPMC Université Paris 06, Paris, France. | 1683 | |||
| 10.1093/ehjcvp/pvaa083 | Journal Article | en | Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19 in critically ill elderly patients. | https://www.ncbi.nlm.nih.gov/pubmed/32645153 | 2055-6837,2055-6845 | 2020-07-12 02:00:00+02:00 | pubmed | European Heart Journal - Cardiovascular Pharmacotherapy | Christian Jung;Raphael Romano Bruno;Bernhard Wernly;Michael Joannidis;Sandra Oeyen;Tilemachos Zafeiridis;Brian Marsh;Finn H Andersen;Rui Moreno;Ana Margarida Fernandes;Antonio Artigas;Bernardo Bollen Pinto;Joerg Schefold;Georg Wolff;Malte Kelm;Dylan W De Lange;Bertrand Guidet;Hans Flaatten;Jesper Fjølner | 2020-07-09 02:00:00+02:00 | 32645153 | IE;FR;NO;SE;PT;GR;CH;NL;DK;ES;DE;BE;AT | Heinrich-Heine-University Duesseldorf, Medical Faculty, Department of Cardiology, Pulmonology and Vascular Medicine, Düsseldorf, Germany.;Department of Cardiology, Paracelsus Medical University, Salzburg, Austria.;Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria.;Department of Intensive Care 1K12IC Ghent University Hospital, Ghent, Belgium.;Intensive Care Unit General Hospital of Larissa, Larissa, Greece.;Mater Misericordiae University Hospital, Dublin, Ireland.;Dep. Of Anaesthesia and Intensive Care, Ålesund Hospital, Ålesund, Norway. Dep. of Circulation and medical imaging, Norwegian university of Science and Technology, Trondheim, Norway.;Unidade de Cuidados Intensivos Neurocríticos e Trauma. Hospital de São José, Centro Hospitalar Universitário de Lisboa Central, Faculdade de Ciências Médicas de Lisboa, Nova Médical School, Lisbon, Portugal.;Department of Intensive Care Medecine, CIBER Enfermedades Respiratorias, Corporacion Sanitaria Universitaria Parc Tauli, Autonomous University of Barcelona, Sabadell, Spain.;Department of Acute Medicine, Geneva University Hospitals, Geneva, Switzerland.;Department of Intensive Care Medicine, Inselspital, Universitätsspital, University of Bern, Bern, Switzerland.;Department of Intensive Care Medicine, University Medical Center, University Utrecht, the Netherlands.;Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, Paris, F-75012, France.;Department of Clinical Medecine,University of Bergen, Department of Anaestesia and Intensive Care, Haukeland University Hospital , Bergen, Norway.;Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark. | 1690 | |||||
| Letter | en | Social inequalities and collateral damages of the COVID-19 pandemic: when basic needs challenge mental health care. | https://www.ncbi.nlm.nih.gov/pubmed/32651593 | 2020-07-12 02:00:00+02:00 | pubmed | Jude Mary Cénat;Rose Darly Dalexis;Cyrille Kossigan Kokou-Kpolou;Joana N Mukunzi;Cécile Rousseau | 2020-07-10 02:00:00+02:00 | 32651593 | FR;CA;US | School of Psychology (Clinical), University of Ottawa, 136 Jean-Jacques-Lussier, 4085, Vanier Hall, Ottawa, ON, K1N 6N5, Canada. jcenat@uottawa.ca.;School of Industrial Relations, University of Montreal, Quebec, Canada.;Department of Psychology, University of Picardy Jules Verne, Amiens, France.;School of Psychology (Clinical), University of Ottawa, 136 Jean-Jacques-Lussier, 4085, Vanier Hall, Ottawa, ON, K1N 6N5, Canada.;Division of Social and Transcultural Psychiatry, McGill University, Montreal, Canada. | 1693 | ||||||||
| 10.1111/bjd.19377 | Journal Article | en | Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing. | https://www.ncbi.nlm.nih.gov/pubmed/32628270 | Acral lesions, mainly chilblains, are the most frequently reported cutaneous lesions associated with COVID-19. In more than 80% of patients tested, nasopharyngeal swabs were negative on reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 when performed, and serology was generally not performed. | 0007-0963,1365-2133 | 2020-07-12 02:00:00+02:00 | pubmed | British Journal of Dermatology | L Le Cleach;L Dousset;H Assier;S Fourati;S Barbarot;C Boulard;C Bourseau Quetier;L Cambon;C Cazanave;A Colin;E Kostrzewa;C Lesort;A Levy Roy;F Lombart;J Marco-Bonnet;J-B Monfort;M Samimi;M Tardieu;P Wolkenstein;E Sbidian;M Beylot-Barry | 2020-07-06 02:00:00+02:00 | 32628270 | FR | Dermatology Department, Hôpital Henri Mondor, Créteil, France.;EA 7379 EpiDermE, UPEC, Créteil, France.;Dermatology Department, University Hospital Bordeaux, Bordeaux, France.;Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.;Department of Dermatology, Nantes Université, CHU Nantes, UMR 1280 PhAN, INRAE, F-44000, Nantes, France.;Le Havre Hospital, Department of Dermatology, 76600, Le Havre, France.;Private Practice, rue Jules Ferry, Blanquefort, France.;Private Practice, rue de la Balance, Toulouse, France.;Infectious Diseases, University Hospital Bordeaux, Bordeaux, France.;Dermatology Department, Hôpital Robert Boulin, Libourne, France.;Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.;Private Practice, Avenue du Général de Gaulle, 13410, Lambesc, France.;Dermatology, Amiens University Hospital Centre, Amiens, France.;Private practice, Avenue Pierre Brossolette 92120, Montrouge, France.;Sorbonne Université, Paris, France.;Dermatology and Allergology Department, AP-HP, Hôpital Tenon, F-75020, Paris, France.;Dermatology Department, University Hospital of Tours, ISP1282 INRA-University of Tours, Tours, France.;Dermatology Department, Centre Hospitalier Universitaire Grenoble Alpes, 38700, La Tronche, France.;French Society of Dermatology, Paris, France. | 1696 | ||||
| 10.1016/j.ygeno.2020.07.003 | Journal Article | en | Comparative genomic signature representations of the emerging COVID-19 coronavirus and other coronaviruses: High identity and possible recombination between Bat and Pangolin coronaviruses. | https://www.ncbi.nlm.nih.gov/pubmed/32645523 | Coronaviruses are responsible on respiratory diseases in animal and human. The combination of numerical encoding techniques and digital signal processing methods are becoming increasingly important in handling large genomic data. In this paper, we propose to analyze the SARS-CoV-2 genomic signature using the combination of different nucleotide representations and signal processing tools in the aim to identify its genetic origin. The sequence of SARS-CoV-2 was compared with 21 relevant sequences including bat, yak and pangolin coronavirus sequences. In addition, we developed a new algorithm to locate the nucleotide modifications. The results show that the Bat and Pangolin coronaviruses were the most related to SARS-CoV-2 with 96% and 86% of identity all along the genome. Within the S gene sequence, the Pangolin sequence presents local highest nucleotide identity. Those findings suggest genesis of SARS-Cov-2 through evolution from bat and pangolin strains. This study offers new ways to automatically characterize viruses. | 0888-7543 | 2020-07-12 02:00:00+02:00 | pubmed | Genomics | Rabeb Touati;Sondes Haddad-Boubaker;Imen Ferchichi;Imen Messaoudi;Afef Elloumi Ouesleti;Henda Triki;Zied Lachiri;Maher Kharrat | Bat;COVID19;Genome signature;Pangolin;SARS-CoV-2;Yak | 2020-07-06 02:00:00+02:00 | 32645523 | FR;TN | University of Tunis El Manar, LR99ES10 Human Genetics Laboratory, Faculty of Medicine of Tunis, Tunisia, University of Tunis El Manar, SITI Laboratory, National School of Engineers of Tunis, BP 37, le Belvédère, 1002 Tunis, Tunisie. Electronic address: Rabeb.touati.enit@gmail.com.;University of Tunis El Manar, Laboratory of Clinical Virology, WHO Regional Reference Laboratory for Poliomyelitis and Measles for EMRO region, Institut Pasteur de Tunis, 13 place Pasteur, BP74 1002 le Belvédère, Tunis, Tunisie.;University of Tunis El Manar, LR99ES10 Human Genetics Laboratory, Faculty of Medicine of Tunis, Tunisia.;University of Carthage, Higher Institute of Information Technologies and Communications, Industrial Computing Department, Tunisia, University of Tunis El Manar, SITI Laboratory, National School of Engineers of Tunis, BP 37, le Belvédère, 1002 Tunis, Tunisie.;University of Carthage, National School of Engineers of Carthage, Electrical Engineering Department, Tunisia, University of Tunis El Manar, SITI Laboratory, National School of Engineers of Tunis, BP 37, le Belvédère, 1002 Tunis, Tunisie.;University of Tunis El Manar, SITI Laboratory, National School of Engineers of Tunis, BP 37, le Belvédère, 1002 Tunis, Tunisie. | 1699 | |||
| 10.1186/s13054-020-03117-9 | Comparative Study;Journal Article | en | Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32653015 | The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide. To date, no specific treatment has convincingly demonstrated its efficacy. Hydroxychloroquine and lopinavir/ritonavir have potential interest, but virological and clinical data are scarce, especially in critically ill patients. | 1364-8535 | 2020-07-12 02:00:00+02:00 | pubmed | Aged;Coronavirus Infections__drug therapy;Critical Illness;Drug Combinations;Female;Humans;Hydroxychloroquine__therapeutic use;Lopinavir__therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Viral__drug therapy;Retrospective Studies;Ritonavir__therapeutic use;Standard of Care;Treatment Outcome;COVID-19 | Critical Care | Marie Lecronier;Alexandra Beurton;Sonia Burrel;Luc Haudebourg;Robin Deleris;Julien Le Marec;Sara Virolle;Safaa Nemlaghi;Côme Bureau;Pierre Mora;Martin De Sarcus;Olivier Clovet;Baptiste Duceau;Paul Henri Grisot;Marie Hélène Pari;Jérémy Arzoine;Ulrich Clarac;David Boutolleau;Mathieu Raux;Julie Delemazure;Morgane Faure;Maxens Decavele;Elise Morawiec;Julien Mayaux;Alexandre Demoule;Martin Dres | Hydroxychloroquine;Intensive care unit;Lopinavir/ritonavir;SARS-CoV-2;Standard of care | 2020-07-11 02:00:00+02:00 | 32653015 | FR | AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France. marie.lecronier@aphp.fr.;AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France.;Sorbonne Université, INSERM, UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France.;Sorbonne Université, INSERM UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Team 3 THERAVIR, Paris, France.;AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Centre National de Référence Herpès virus, Paris, France.;AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'anesthésie réanimation, Paris, France.;AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), Paris, France. martin.dres@aphp.fr.;Sorbonne Université, INSERM, UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France. martin.dres@aphp.fr. | 1712 | ||
| Letter | en | COVID-19: How the Paris area faced the massive influx of critical patients. | https://www.ncbi.nlm.nih.gov/pubmed/32727708 | 2020-07-12 02:00:00+02:00 | pubmed | Arnaud Foucrier;Romain Hellmann;Aurélien Rousseau | 2020-07-11 02:00:00+02:00 | 32727708 | FR | Medical Doctor, Anesthésie-Réanimation, Hôpital Beaujon, DMU PARABOL, AP-HP Nord, traumabase.eu, Paris, France, CEO's medical advisor for critical care at Regional Health Agency (Agence régionale de santé Ile-de-France), 75019 Paris, France. Electronic address: arnaud.foucrier@aphp.fr.;Medical Doctor, CEO's medical advisor for emergency care at Regional Health Agency (Agence régionale de santé Ile-de-France), 75019 Paris, France.;CEO of Regional Health Agency (Agence régionale de santé Ile-de-France), 75019 Paris, France. | 1714 | ||||||||
| 10.1007/s00134-020-06141-z | Journal Article | en | Emerging pharmacological therapies for ARDS: COVID-19 and beyond. | https://www.ncbi.nlm.nih.gov/pubmed/32654006 | ARDS, first described in 1967, is the commonest form of acute severe hypoxemic respiratory failure. Despite considerable advances in our knowledge regarding the pathophysiology of ARDS, insights into the biologic mechanisms of lung injury and repair, and advances in supportive care, particularly ventilatory management, there remains no effective pharmacological therapy for this syndrome. Hospital mortality at 40% remains unacceptably high underlining the need to continue to develop and test therapies for this devastating clinical condition. The purpose of the review is to critically appraise the current status of promising emerging pharmacological therapies for patients with ARDS and potential impact of these and other emerging therapies for COVID-19-induced ARDS. We focus on drugs that: (1) modulate the immune response, both via pleiotropic mechanisms and via specific pathway blockade effects, (2) modify epithelial and channel function, (3) target endothelial and vascular dysfunction, (4) have anticoagulant effects, and (5) enhance ARDS resolution. We also critically assess drugs that demonstrate potential in emerging reports from clinical studies in patients with COVID-19-induced ARDS. Several therapies show promise in earlier and later phase clinical testing, while a growing pipeline of therapies is in preclinical testing. The history of unsuccessful clinical trials of promising therapies underlines the challenges to successful translation. Given this, attention has been focused on the potential to identify biologically homogenous subtypes within ARDS, to enable us to target more specific therapies 'precision medicines.' It is hoped that the substantial number of studies globally investigating potential therapies for COVID-19 will lead to the rapid identification of effective therapies to reduce the mortality and morbidity of this devastating form of ARDS. | 0342-4642,1432-1238 | 2020-07-12 02:00:00+02:00 | pubmed | Intensive Care Medicine | Shahd Horie;Bairbre McNicholas;Emanuele Rezoagli;Tài Pham;Ger Curley;Danny McAuley;Cecilia O'Kane;Alistair Nichol;Claudia Dos Santos;Patricia R M Rocco;Giacomo Bellani;John G Laffey | Acute respiratory distress syndrome;Acute respiratory failure;Coronavirus;Mesenchymal stromal cells;Pharmacologic therapy | 2020-07-11 02:00:00+02:00 | 32654006 | FR;IE;CA;NZ;GB;BR;IT;AU | Lung Biology Group, Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, Biomedical Sciences Building, National University of Ireland, Galway, Ireland.;Department of Anaesthesia and Intensive Care Medicine, Galway University Hospitals, Galway, Ireland.;Department of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy.;Department of Emergency and Intensive Care, San Gerardo Hospital, Monza, Italy.;Service de médecine Intensive-Réanimation, AP-HP, Hôpital de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France.;Department of Anaesthesiology, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland.;Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.;Department of Intensive Care Medicine, Royal Victoria Hospital, Belfast, Northern Ireland, UK.;Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland.;Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.;Intensive Care Unit, Alfred Hospital, Melbourne, Australia.;Keenan Research Centre and Interdepartmental Division of Critical Care, University of Toronto, Toronto, ON, Canada.;Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.;Lung Biology Group, Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, Biomedical Sciences Building, National University of Ireland, Galway, Ireland. john.laffey@nuigalway.ie.;Department of Anaesthesia and Intensive Care Medicine, Galway University Hospitals, Galway, Ireland. john.laffey@nuigalway.ie. | 1715 | |||
| 10.1080/09546634.2020.1794290 | Editorial | en | International Collaboration. | https://www.ncbi.nlm.nih.gov/pubmed/32646257 | 0954-6634,1471-1753 | 2020-07-12 02:00:00+02:00 | pubmed | Journal of Dermatological Treatment | Mitchel P Goldman;Dedee F Murrell;Nawaf Al-Mutairi;Monika Arenbergerova;Brigitte Dréno;Marwan Alhaddad;Sami N Al-Suwaidan;Alireza Firooz;Peter Cm van de Kerkhof;Steven R Feldman | COVID-19;SARS-CoV2;collaboration;medical care;research | 2020-07-10 02:00:00+02:00 | 32646257 | FR;KW;SA;US;AU;IR;NL;CZ | Volunteer Clinical Professor of Dermatology, University of California, San Diego, Medical Director, West Dermatology, Cosmetic Laser Dermatology, A West Dermatology Company, Goldman, Butterwick, Groff, Fabi, Wu & Boen, San Diego, California.;Department of Dermatology, St George Hospital, Faculty of Medicine, University of New South Wales, Sydney, Australia.;Department of Dermatology, Farwaniya Hospital, Kuwait University, Kuwait.;Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.;Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, France.;Slocum Dickson Medical Group, New Hartford, New York.;Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.;Center for Research & Training in Skin Diseases & Leprosy, Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran.;Department of Dermatology, University of Nijmegen, The Netherlands.;Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina. | 1720 | ||||
| Letter | en | Strengthening the global effort on COVID-19 research. | https://www.ncbi.nlm.nih.gov/pubmed/32682490 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus;Biomedical Research__economics;Coronavirus Infections__epidemiology;Health Policy;Health Priorities;Humans;Information Dissemination;International Cooperation;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Research Support as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Alice Norton;Jeffrey Mphahlele;Yazdan Yazdanpanah;Peter Piot;Marta Tufet Bayona | 2020-07-16 02:00:00+02:00 | 32682490 | FR;GB;ZA | UK Collaborative on Development Research, London NW1 2BE, UK.;South African Medical Research Council, Pretoria, South Africa.;Research and Action Targeting emerging Infectious Diseases (REACTing) Task Force, Inserm, Paris, France.;London School of Hygiene & Tropical Medicine, London, UK.;UK Collaborative on Development Research, London NW1 2BE, UK. Electronic address: m.tufet@ukcdr.org.uk. | 1726 | |||||||
| NCI NIH HHS | 10.1016/j.jgo.2020.07.008 | Journal Article;Review | en | Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. | https://www.ncbi.nlm.nih.gov/pubmed/32709495 | The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer in older adults. The International Society of Geriatric Oncology (SIOG) formed a panel of experts to develop consensus recommendations on the implications of the pandemic on several aspects of cancer care in this age group including geriatric assessment (GA), surgery, radiotherapy, systemic treatment, palliative care and research. Age and cancer diagnosis are significant predictors of adverse outcomes of the COVID-19 infection. In this setting, GA is particularly valuable to drive decision-making. GA may aid estimating physiologic reserve and adaptive capability, assessing risk-benefits of either providing or temporarily withholding treatments, and determining patient preferences to help inform treatment decisions. In a resource-constrained setting, geriatric screening tools may be administered remotely to identify patients requiring comprehensive GA. Tele-health is also crucial to ensure adequate continuity of care and minimize the risk of infection exposure. In general, therapeutic decisions should favor the most effective and least invasive approach with the lowest risk of adverse outcomes. In selected cases, this might require deferring or omitting surgery, radiotherapy or systemic treatments especially where benefits are marginal and alternative safe therapeutic options are available. Ongoing research is necessary to expand knowledge of the management of cancer in older adults. However, the pandemic presents a significant barrier and efforts should be made to ensure equitable access to clinical trials and prospective data collection to elucidate the outcomes of COVID-19 in this population. | 1879-4068 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Geriatric Oncology | Nicolò Matteo Luca Battisti;Anna Rachelle Mislang;Lisa Cooper;Anita O'Donovan;Riccardo A Audisio;Kwok-Leung Cheung;Regina Gironés Sarrió;Reinhard Stauder;Enrique Soto-Perez-de-Celis;Michael Jaklitsch;Grant R Williams;Shane O'Hanlon;Mahmood Alam;Clarito Cairo;Giuseppe Colloca;Luiz Antonio Gil;Schroder Sattar;Kumud Kantilal;Chiara Russo;Stuart M Lichtman;Etienne Brain;Ravindran Kanesvaran;Hans Wildiers | COVID-19;Competing risks;Geriatric oncology;Older patients;Recommendations;SARS-CoV-2 | 2020-07-16 02:00:00+02:00 | 32709495 | SE;IE;FR;PH;CA;SG;GB;US;BR;IT;AU;ES;MX;BE;AT | [{"country": "United States", "agency": "NCI NIH HHS", "grantid": "K08 CA234225"}] | Breast Unit, Department of Medicine Department, The Royal Marsden NHS Foundation Trust, Breast Cancer Research Division, The Institute of Cancer Research, London, UK. Electronic address: nicolo.battisti@rmh.nhs.uk.;Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, SA, Australia. Electronic address: Anna.Mislang@sa.gov.au.;Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: lcooper5@bwh.harvard.edu.;Discipline of Radiation Therapy, Trinity College, Dublin, Ireland. Electronic address: Anita.ODonovan@tcd.ie.;Department of surgery, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Electronic address: raudisio@doctors.org.uk.;School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby, UK. Electronic address: kl.cheung@nottingham.ac.uk.;Department of Medical Oncology, Hospital Universitari i Politècnic La FE, Valencia, Spain.;Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria. Electronic address: reinhard.stauder@i-med.ac.at.;Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Electronic address: enrique.sotop@incmnsz.mx.;Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: mjaklitsch@bwh.harvard.edu.;Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA. Electronic address: grwilliams@uabmc.edu.;University College Dublin, St Vincent's University Hospital, Dublin, Ireland. Electronic address: shaneohanlon@svhg.ie.;Pfizer Oncology, Asia Pacific Region, Australia. Electronic address: Mahmood.Alam2@pfizer.com.;National Integrated Cancer Control Program, Department of Health, Manila, Philippines.;Policlinico A. Gemelli, Rome, Italy.;Geriatric Division, São Paulo University, São Paulo, Brazil.;College of Nursing, University of Saskatchewan, Regina, Canada. Electronic address: schroder.sattar@usask.ca.;School of Pharmacy, University of East Anglia, Norwich, UK. Electronic address: k.kantilal@uea.ac.uk.;Department of Medical Oncology, Centre Léon Bérard, Regional Comprehensive Cancer Centre, Claude-Bernard Lyon-1 University, Lyon, France. Electronic address: Chiara.RUSSO@lyon.unicancer.fr.;Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: LichtmaS@mskcc.org.;Department of Medical Oncology, Institut Curie/Saint-Cloud, Paris, France. Electronic address: Etienne.brain@curie.fr.;Department of Medical Oncology, National Cancer Centre Singapore, Singapore. Electronic address: ravindran.kanesvaran@singhealth.com.sg.;Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be. | 1727 | |
| 10.1016/j.radcr.2020.07.035 | Case Reports | en | 18-FDG PSEUDOTUMORAL LESION WITH QUICK FLOWERING TO A TYPICAL LUNG CT COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32788946 | As coronavirus pandemic continues to spread over the world, physicians have to be aware of atypical features of COVID-19 pneumonia. We report the case of a 78-year-old man presenting with pseudo-tumoral focal lesion of the left lung which switched shortly to severe and diffuse COVID-19 induced pneumonia. Nuclear medicine physicians and radiologists should be careful of some misleading hypermetabolic aspects mostly in asymptomatic patients. | 1930-0433 | 2020-07-19 02:00:00+02:00 | pubmed | Radiology Case Reports | Olivier de Barry;Dominique Cabral;Jean Emmanuel Kahn;François Vidal;Robert-Yves Carlier;Mostafa El Hajjam | COVID-19;Coronavirus;Early bronchiectasis;PET-CT;Pseudo-tumoral | 2020-07-16 02:00:00+02:00 | 32788946 | FR | DMU Smart Imaging, Medical Imaging department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay. Ambroise Paré Teaching Hospital, 92100 Boulogne-Billancourt, France.;DMU Smart Imaging, Medical Imaging department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay. Raymond Poincaré Teaching Hospital, 92380 Garches, France.;Internal medicine department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay. Ambroise Paré Teaching Hospital, 92100 Boulogne-Billancourt, France.;Rheumatology department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay. Ambroise Paré Teaching Hospital, 92100 Boulogne-Billancourt, France. | 1729 | |||
| 10.1093/cid/ciaa1007 | Journal Article | en | Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32672790 | Excess soluble fms-like tyrosine kinase 1 (sFlt-1), a soluble inhibitor of the vascular endothelial growth factor pathway, has been demonstrated to promote endothelial dysfunction. Here we demonstrate that sFlt-1 plasma levels correlate with respiratory symptoms severity, expression of endothelial dysfunction biomarker and incidence of organ failure in COVID-19 patients. | 1058-4838,1537-6591 | 2020-07-19 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Vincent Dupont;Lukshe Kanagaratnam;Antoine Goury;Gaël Poitevin;Mathieu Bard;Gauthier Julien;Michel Bonnivard;Vanessa Champenois;Violaine Noel;Bruno Mourvillier;Philippe Nguyen | COVID-19;critical care;endothelial dysfunction;sFlt-1 | 2020-07-16 02:00:00+02:00 | 32672790 | FR | Medical intensive care unit, University hospital of Reims, France.;University of Reims Champagne Ardenne, France.;Clinical Research Unit, University hospital of Reims, France.;Department of Internal Medicine, Clinical Immunology and Infectious Diseases, University Hospital of Reims, France. | 1730 | |||
| 10.1016/j.jaad.2020.06.1023 | Journal Article | en | Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-consensus: Recommendations by an international panel of experts. | https://www.ncbi.nlm.nih.gov/pubmed/32682031 | 0190-9622 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of the American Academy of Dermatology | Dedee F Murrell;Anne W Lucky;Julio C Salas-Alanis;David T Woodley;Francis Palisson;Ken Natsuga;Milos Nikolic;Mae Ramirez-Quizon;Amy S Paller;Irene Lara-Corrales;Mohammadreza Amir Barzegar;Eli Sprecher;Cristina Has;Martin Laimer;Anna L Bruckner;Asli Bilgic;Arti Nanda;Diana Purvis;Alain Hovnanian;Slobodna Murat-Sušić;Johannes Bauer;Johannes S Kern;Christine Bodemer;Linda K Martin;Jemima Mellerio;Cezary Kowaleski;Susan J Robertson;Leena Bruckner-Tuderman;Elena Pope;M Peter Marinkovich;Jean Y Tang;John Su;Jouni Uitto;Lawrence F Eichenfield;Joyce Teng;Mark Jean Aan Koh;Sang Eun Lee;Phuong Khuu;Heather I Rishel;Mette Sommerlund;Karen Wiss;Chao-Kai Hsu;Tor Wo Chiu;Anna E Martinez | 2020-07-16 02:00:00+02:00 | 32682031 | IL;CA;NZ;JP;TW;KW;CL;HR;PH;MX;DK;FR;CN;GB;US;HK;PL;IR;RS;KR;AT;DE;SG;AU;TR | Department of Dermatology, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: d.murrell@unsw.edu.au.;Cincinnati Children's Epidermolysis Bullosa Center, Cincinnati Children's Hospital, Cincinnati, Ohio.;DebRA (Dystrophic Epidermolysis Bullosa Research Association) Mexico, Monterrey, Mexico.;Department of Dermatology, University of Southern California, Los Angeles, California.;Dystrophic Epidermolysis Bullosa Research Association DebRA (Dystrophic Epidermolysis Bullosa Research Association) Chile, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.;Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.;Deptartment of Dermatovenereology, University of Belgrade School of Medicine, Belgrade, Serbia.;Department of Dermatology, University of the Philippines, Philippines General Hospital, Manila, Philippines.;Departments of Dermatology and Pediatrics, Children's Hospital, Northwestern University, Chicago, Illinois.;Section of Dermatology, Hospital for Sick Children, Toronto, Ontario, Canada.;Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.;Department of Dermatology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany.;EB Haus, Department of Dermatology, Paracelsus University, Salzburg, Austria.;Pediatric Dermatology Department, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado.;Department of Dermatology, Akdeniz University, Antalya, Turkey.;Pediatric Dermatology Unit, As'ad Al-Hamad Dermatology Center, Kuwait.;Department of Dermatology, Starship Children's Health, Auckland, New Zealand.;Department of Genetics, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1163, Laboratory of Genetic Skin Diseases, Paris, France, Institut des Maladies Génétiques (IMAGINE), University of Paris, Paris, France.;Department of Dermatovenereology, University Hospital Centre, Zagreb, Croatia.;Dermatology Department, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, The University of Melbourne, Parkville, Victoria, Australia.;Department of Dermatology, Necker Enfants Malades Hospital, University of Paris, Paris, France, Reference Centre for Genodermatoses and Rare Skin Diseases (MAGEC), Paris, France.;Department of Dermatology, Sydney Children's Hospital, University of New South Wales Faculty of Medicine, Sydney, New South Wales, Australia.;Adult Epidermolysis Bullosa Service, St John's Institute of Dermatology, St Thomas' Hospital, London, United Kingdom.;Department of Dermatology and Immunodermatology, University of Warsaw, Warsaw, Poland.;Dermatology Department, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, Department of Dermatology, The Royal Children's Hospital, Melbourne, Victoria, Australia.;Department of Dermatology, Stanford University Medical Center, Palo Alto, California.;The University of Melbourne, Parkville, Victoria, Australia, Monash University, Eastern Health, Melbourne, Victoria, Australia.;Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, Sidney Kimmel Medical College, Philadelphia, Pennsylvania.;Departments of Dermatology and Pediatrics, University of California, San Diego, California, Department of Pediatric Dermatology, Rady Children's Hospital, San Diego, California.;Dermatology Service, KK Women's & Children's Hospital, Singapore.;Department of Dermatology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.;Rishel Pediatric Dermatology, PC, Rishel Enterprises, LLC, San Francisco, California.;Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.;Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts.;Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.;Chinese University of Hong Kong, Hong Kong, China.;Paediatric Dermatology Department, Great Ormond Street National Health Service Foundation Trust, London, United Kingdom. | 1732 | |||||
| 10.1097/qad.0000000000002639 | Journal Article | en | COVID-19 attack rate in HIV-infected patients and in PrEP users. | https://www.ncbi.nlm.nih.gov/pubmed/32694421 | 0269-9370 | 2020-07-19 02:00:00+02:00 | pubmed | AIDS | Caroline Charre;Vinca Icard;Pierre Pradat;Corinne Brochier;Bruno Lina;Christian Chidiac;Laurent Cotte | 2020-07-17 02:00:00+02:00 | 32694421 | FR | Laboratoire de Virologie, Institut de Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.;Universite[Combining Acute Accent] Claude Bernard, Lyon, France.;INSERM U1052-CRCL (centre de recherche en cancérologie), Lyon, France.;Centre de Recherche Clinique (CRC), Hospices Civils de Lyon, Lyon, France.;Service des maladies infectieuses et tropicales, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France. | 1733 | |||||
| Journal Article;Comment | en | France's COVID-19 response: balancing conflicting public health traditions. | https://www.ncbi.nlm.nih.gov/pubmed/32682489 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;France;Global Health;Humans;Pandemics;Pneumonia, Viral;Public Health;Universal Health Insurance;COVID-19;severe acute respiratory syndrome coronavirus 2 | Laëtitia Atlani-Duault;Franck Chauvin;Yazdan Yazdanpanah;Bruno Lina;Daniel Benamouzig;Lila Bouadma;Pierre Louis Druais;Aymeril Hoang;Marie-Aleth Grard;Denis Malvy;Jean-François Delfraissy | 2020-07-16 02:00:00+02:00 | 32682489 | FR | CEPEP, IRD, University of Paris, INSERM ERL 1244, 75006 Paris, France, Institut COVID19 Ad Memoriam, Paris, France, WHO Collaborative Center for Research on Health and Humanitarian Policies and Practices, IRD, University of Paris, Paris, France. Electronic address: laetitia.atlani-duault@ird.fr.;French High Council of Public Health, Paris, France, Institut PRESAGE, Jean Monnet University-Saint-Etienne University Hospital, Saint Etienne, France.;REACTting, INSERM, Paris, France, University of Paris, Assistance Publique-Hôpitaux de Paris, Infectious and Tropical Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France.;University of Lyon, Virpath Team, CIRI, INSERM U1111, CNRS UMR5308, ENS, UCBL, Lyon, France, Virology Laboratory of the HCL & French National Reference Centre for Respiratory Viruses, Infectious Agent Institute, Croix-Rousse Hospital, Lyon, France.;Sciences Po, Centre de Sociologie des Organisations, CNRS, Paris, France.;Medical and Infectious Diseases Intensive Care Unit, Bichat-Claude Bernard University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Infections Antimicrobials Modelling Evolution (IAME-UMR1137), University of Paris, INSERM, Paris, France.;Haute Autorité de Santé, Saint Denis, France.;Modus Operandi International Institute, Paris, France.;ATD Quart Monde, Paris, France.;Department for Infectious and Tropical Diseases, University Hospital Center of Bordeaux and INSERM 1219, University of Bordeaux, Bordeaux, France.;National Ethical Consultative Committee for Life Sciences and Health, Paris, France. | 1737 | |||||||
| 10.1016/j.reval.2020.07.001 | Journal Article | fr | [The allergist facing the COVID-19 pandemic: what impact and what precautions should be taken?] | https://www.ncbi.nlm.nih.gov/pubmed/32837662 | 1877-0320 | 2020-07-19 02:00:00+02:00 | pubmed | Revue Française d'Allergologie | J F Fontaine;E Fromentin;S Lefevre;P Demoly | 2020-07-16 02:00:00+02:00 | 32837662 | FR | Cabinet d'Allergologie, 113 rue de Vesle, Reims, France, et Service de Pneumologie et Allergologie, CHU de Reims, Reims, France.;Cabinet d'Allergologie, 32 place Sébastopol, Lille, France.;Institut Régional d'Allergologie, CHR Metz-Thionville, Metz, France.;Département de pneumologie, unité d'exploration des allergies, Hôpital Arnaud de Villeneuve, Hôpital universitaire de Montpellier, Univ Montpellier, et UMR-S 1136 INSERM-Sorbonne Université, Equipe EPAR - IPLESP, Paris, France. | 1738 | |||||
| 10.1016/j.recesp.2020.06.015 | Journal Article | sp | [Fulminant myocarditis and COVID-19. Response]. | https://www.ncbi.nlm.nih.gov/pubmed/32836665 | 0300-8932 | 2020-07-19 02:00:00+02:00 | pubmed | Revista Española de Cardiología | Ángela Irabien-Ortiz;José Carreras-Mora;Alessandro Sionis;Manel Tauron | 2020-07-16 02:00:00+02:00 | 32836665 | FR;ES | Servicio de Cirugía Cardiovascular, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. | 1743 | |||||
| 10.1177/1740774520939938 | Journal Article | en | Endpoints for randomized controlled clinical trials for COVID-19 treatments. | https://www.ncbi.nlm.nih.gov/pubmed/32674594 | Endpoint choice for randomized controlled trials of treatments for novel coronavirus-induced disease (COVID-19) is complex. Trials must start rapidly to identify treatments that can be used as part of the outbreak response, in the midst of considerable uncertainty and limited information. COVID-19 presentation is heterogeneous, ranging from mild disease that improves within days to critical disease that can last weeks to over a month and can end in death. While improvement in mortality would provide unquestionable evidence about the clinical significance of a treatment, sample sizes for a study evaluating mortality are large and may be impractical, particularly given a multitude of putative therapies to evaluate. Furthermore, patient states in between "cure" and "death" represent meaningful distinctions. Clinical severity scores have been proposed as an alternative. However, the appropriate summary measure for severity scores has been the subject of debate, particularly given the variable time course of COVID-19. Outcomes measured at fixed time points, such as a comparison of severity scores between treatment and control at day 14, may risk missing the time of clinical benefit. An endpoint such as time to improvement (or recovery) avoids the timing problem. However, some have argued that power losses will result from reducing the ordinal scale to a binary state of "recovered" versus "not recovered." | 1740-7745,1740-7753 | 2020-07-19 02:00:00+02:00 | pubmed | Clinical Trials | Lori E Dodd;Dean Follmann;Jing Wang;Franz Koenig;Lisa L Korn;Christian Schoergenhofer;Michael Proschan;Sally Hunsberger;Tyler Bonnett;Mat Makowski;Drifa Belhadi;Yeming Wang;Bin Cao;France Mentre;Thomas Jaki | COVID-19;WHO ordinal scale;censoring;clinical trials;endpoints;log-rank test;proportional odds model | 2020-07-16 02:00:00+02:00 | 32674594 | FR;CN;JP;GB;US;AT | Biostatistics Research Branch, National Institute Allergy and Infectious Diseases, Bethesda, MD, USA.;Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.;Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.;Department of Medicine (Rheumatology, Allergy, and Immunology Section) and Department of Immunobiology, Yale University, New Haven, CT, USA.;Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.;The Emmes Company, LLC, Rockville, MD, USA.;Université de Paris, IAME, Inserm, Paris, France.;AP-HP, Hôpital Bichat, DEBRC, Paris, France.;Center of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, National Clinical Research Center for Respiratory Diseases, Beijing, China.;China-Japan Friendship Hospital, Department of Respiratory Medicine, Capital Medical University, Beijing, China.;Department of Mathematics and Statistics, Lancaster University, Lancaster, UK.;MRC Biostatistics Unit, University of Cambridge, Cambridge, UK. | 1744 | |||
| 10.1016/j.scitotenv.2020.141053 | Journal Article | en | Environmental side effects of the injudicious use of antimicrobials in the era of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32702547 | Use of antimicrobials in the treatment and prevention of COVID-19, caused by novel coronavirus SARS-CoV-2, is on the rise. The increased use of antimicrobials can have serious consequences on the environment. Antibiotics have had a reasonable role in bacterial co-infections with regards to the management of COVID-19. However, recent evidences suggest that there has been injudicious prescription of antimicrobials. Moreover, a large number of people are self-medicating with antibiotics in a misguided attempt to protect themselves from the virus. This practice is especially prevalent in developing communities. Although common soaps are effective at inactivating enveloped viruses, such as the SARS-CoV-2, use of antibacterial products bearing biocides has increased during this pandemic. Current wastewater treatment techniques are unable to offer complete elimination of antibacterial biocides. These compounds can then accumulate in different environmental compartments thus, disrupting the functioning of native microbes. These microbes are involved in the biogeochemical cycling of elements and environmental remediation. In addition, the presence of antimicrobial elements in the environment can stimulate antimicrobial resistance. Concrete actions are needed to address this issue. Development of an antimicrobial policy specific for COVID-19 is urgently needed. Investments into improving wastewater infrastructure as well as public awareness is crucial. Moreover, global monitoring programs and multidisciplinary collaborations are required to understand the environmental impact of this pandemics. | 0048-9697 | 2020-07-19 02:00:00+02:00 | pubmed | Science of The Total Environment | Muhammad Usman;Muhammad Farooq;Khalil Hanna | Antibacterial soaps;Antibiotics in environment;Antimicrobial resistance (AMR);COVID-19;Wastewater contamination | 2020-07-18 02:00:00+02:00 | 32702547 | FR;OM;PK | PEIE Research Chair for the Development of Industrial Estates and Free Zones, Center for Environmental Studies and Research, Sultan Qaboos University, Al-Khoud 123, Muscat, Oman. Electronic address: muhammad.usman@squ.edu.om.;Department of Clinical Sciences, College of Veterinary and Animal Sciences, University of Veterinary and Animal Sciences, Jhang, Lahore, Pakistan. Electronic address: muhammad.farooq@uvas.edu.pk.;Univ Rennes, Ecole Nationale Supérieure de Chimie de Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes) - UMR 6226, F-35000 Rennes, France, Institut Universitaire de France (IUF), MESRI, 1 rue Descartes, 75231 Paris, France.. Electronic address: khalil.hanna@ensc-rennes.fr. | 1750 | |||
| Letter | en | Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. | https://www.ncbi.nlm.nih.gov/pubmed/32678953 | 2020-07-19 02:00:00+02:00 | pubmed | Matthieu Mahévas;Guillaume Moulis;Emmanuel Andres;Etienne Riviere;Margaux Garzaro;Etienne Crickx;Vivien Guillotin;Marion Malphettes;Lionel Galicier;Nicolas Noel;Luc Darnige;Louis Terriou;Claire Guerveno;Mateo Sanchis-Borja;Thomas Moulinet;Benoit Meunier;Mikael Ebbo;Marc Michel;Bertrand Godeau | COVID-19;ITP;Treatment | 2020-07-17 02:00:00+02:00 | 32678953 | FR;US | Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France.;Department of Internal Medicine, Toulouse University Hospital (CHU de Toulouse), Toulouse, France.;CIC 1436, Toulouse University Hospital (CHU de Toulouse), Toulouse, France.;UMR 1027 Inserm, University of Toulouse, Toulouse, France.;Department of Internal Medicine, University Hospital of Strasbourg, Research Team EA, 3072 "Mitochondrie, Stress oxydant et Protection musculaire", University of Strasbourg, Strasbourg, France.;Department of Internal Medicine, Bordeaux University Hospital (CHU de Bordeaux), Bordeaux, France.;Inserm U1034-University of Bordeaux, Bordeaux, France.;Department of Clinical Immunology, Saint Louis University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.;Department of internal medicine, Kremlin-Bicêtre, Assistance Publique Hôpitaux de Paris, Paris, France.;Inserm UMR-S 1140, Service d'Hématologie Biologique, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France.;Department of Internal Medicine and Immunology, Claude-Huriez University Hospital, Université Lille Nord de France, Lille, France.;Department of Internal Medicine, Albi Hospital, Albi, France.;Department of pneumology, Hôpital européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.;Department of internal medicine, Nancy University Hospital (CHU de Nancy), University of Lorraine, Vandoeuvre-lès-Nancy, France.;Department of internal medicine, Hôpital la Timone, Assistance Publique Hôpitaux de Marseille, Aix Marseille Université, Marseille, France. | 1752 | |||||||
| 10.1016/j.amcp.2020.07.005 | Journal Article;Review | fr | [Children and COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32837200 | 1261-694X | 2020-07-19 02:00:00+02:00 | pubmed | Archives des Maladies du Coeur et des Vaisseaux - Pratique | J-C Mercier;A Maroni;I Melki;U Meinzer;J Gaschignard;C Beyler;A Santos | 2020-07-17 02:00:00+02:00 | 32837200 | FR | Université de Paris, plateforme COVIDOM AP-HP, ARS Île-de-France, Millénaire 2, 35, rue de la Gare, 75019 Paris, France.;Service de réanimation pédiatrique, groupe hospitalier universitaire, hôpital universitaire Robert-Debré, AP-HP Nord, boulevard Serrurier, 75019 Paris, France.;Service de pédiatrie générale, groupe hospitalier universitaire, hôpital universitaire Robert-Debré, AP-HP Nord, boulevard Serrurier, 75019 Paris, France.;Service de cardiologie pédiatrique, groupe hospitalier universitaire, hôpital universitaire Robert-Debré, AP-HP Nord, boulevard Serrurier, 75019 Paris, France.;Service des urgences pédiatriques, groupe hospitalier universitaire, hôpital universitaire Robert-Debré, AP-HP Nord, boulevard Serrurier, 75019 Paris, France. | 1753 | |||||
| 10.1016/s1473-3099(20)30517-x | Journal Article;Review | en | Serology testing in the COVID-19 pandemic response. | https://www.ncbi.nlm.nih.gov/pubmed/32687805 | The collapse of global cooperation and a failure of international solidarity have led to many low-income and middle-income countries being denied access to molecular diagnostics in the COVID-19 pandemic response. Yet the scarcity of knowledge on the dynamics of the immune response to infection has led to hesitation on recommending the use of rapid immunodiagnostic tests, even though rapid serology tests are commercially available and scalable. On the basis of our knowledge and understanding of viral infectivity and host response, we urge countries without the capacity to do molecular testing at scale to research the use of serology tests to triage symptomatic patients in community settings, to test contacts of confirmed cases, and in situational analysis and surveillance. The WHO R&D Blue Print expert group identified eight priorities for research and development, of which the highest is to mobilise research on rapid point-of-care diagnostics for use at the community level. This research should inform control programmes of the required performance and utility of rapid serology tests, which, when applied specifically for appropriate public health measures to then be put in place, can make a huge difference. | 1473-3099 | 2020-07-19 02:00:00+02:00 | pubmed | The Lancet Infectious Diseases | Rosanna W Peeling;Catherine J Wedderburn;Patricia J Garcia;Debrah Boeras;Noah Fongwen;John Nkengasong;Amadou Sall;Amilcar Tanuri;David L Heymann | 2020-07-17 02:00:00+02:00 | 32687805 | FR;SN;GB;US;ET;BR;ZA;PE | Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: rosanna.peeling@lshtm.ac.uk.;Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK, Neuroscience Institute and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.;Universidad Peruana Cayetano Heredia, Lima, Peru.;Global Health Impact Group, Atlanta, GA, USA.;Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.;Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.;Institut Pasteur Dakar, Dakar, Senegal.;Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. | 1754 | ||||
| Letter | en | Neuro-Urology during the COVID-19 pandemic: Triage and priority of treatments. | https://www.ncbi.nlm.nih.gov/pubmed/32678457 | 2020-07-19 02:00:00+02:00 | pubmed | Stefania Musco;Giulio Del Popolo;Marcello Lamartina;Achim Herms;Julien Renard;Alberto Manassero;Emmanuel Chartier-Kastler;David Castro-Diaz;Marco Soligo | 2020-07-17 02:00:00+02:00 | 32678457 | FR;IT;ES;CH | Department of Neuro-Urology, Azienda Ospedaliera-Universitaria Careggi, Firenze, Italy.;Urology Unit, Casa di Cura Candela, Palermo, Italy.;Department of Urology, SüdtirolerSanitätsbetrieb Azienda Sanitaria dell' Alto Adige Azienda Sanitera de Sudtirol, Brixen/Bressanone, Italy.;Division of Urology, Geneva University Hospital, Geneva, Switzerland.;Department of Neurourology, CTO - Unità Spinale, Città della Salute e della Scienza di Torino, Torino, Italy.;Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.;Department of Urology, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain, Tenerife, Spain.;Department of Obstetrics and Gynecology, Buzzi Hospital, ASST FBF Sacco, University of Milan, Milan, Italy. | 1755 | ||||||||
| 10.1148/radiol.2020202422 | Journal Article | en | Retrospective Observational Study of Brain Magnetic Resonance Imaging Findings in Patients with Acute SARS-CoV-2 Infection and Neurological Manifestations. | https://www.ncbi.nlm.nih.gov/pubmed/32677875 | Background This study provides a detailed imaging assessment in a large series of COVID-19 patients with neurological manifestations. Purpose To review the MRI findings associated with acute neurological manifestations in COVID-19 patients. Methods This was a cross-sectional study conducted between March 23 and May 7, 2020 at the Pitié-Salpêtrière University Hospital, a reference center for COVID-19 in the Paris area. Inclusion criteria were: adult patients diagnosed with SARS-CoV-2 infection, presenting with acute neurological manifestations and referred for a brain MRI examination. Patients were excluded if they had a previous history of neurological disease. The characteristics and the frequency of different MRI features were investigated. The findings were analyzed separately in patients in intensive care units (ICU) and other departments (non-ICU). Results During the inclusion period, 1176 consecutive patients were hospitalized for suspected COVID-19. Out of 308 patients with acute neurological symptoms, 73 patients met the inclusion criteria (23.7%) and were included: 35 ICU patients (47.9%) and 38 non-ICU patients (52.1%). The mean age was 58.5 ± 15.6 years, with a male predominance (65.8% vs. 34.2%). Forty-three patients presented pathological MRI findings 2-4 weeks after symptom onset (58.9%), including 17 with acute ischemic infarct (23.3%), 1 with a deep venous thrombosis (1.4%), 8 with multiple microhemorrhages (11.3%), 22 with perfusion abnormalities (47.7%), 3 with restricted diffusion foci within the corpus callosum consistent with cytotoxic lesions of the corpus callosum (CLOCC, 4.1%). Multifocal white matter enhancing lesions were seen in 4 ICU patients (5%). Basal ganglia abnormalities were seen in 4 other patients (5%). The cerebrospinal fluid (CSF) analysis was negative for SARS-CoV-2 in all tested patients (n=39). Conclusion In addition to cerebrovascular lesions, perfusion abnormalities, CLOCC and ICU-related complications, we identified two patterns including white matter enhancing lesions and basal ganglia abnormalities that could be related to SARS-CoV-2 infection. | 0033-8419,1527-1315 | 2020-07-19 02:00:00+02:00 | pubmed | Radiology | Lydia Chougar;Natalia Shor;Nicolas Weiss;Damien Galanaud;Delphine Leclercq;Bertrand Mathon;Samia Belkacem;Sebastian Stroër;Sonia Burrel;David Boutolleau;Alexandre Demoule;Charlotte Rosso;Cécile Delorme;Danielle Seilhean;Didier Dormont;Elise Morawiec;Mathieu Raux;Sophie Demeret;Sophie Gerber;Stéphanie Trunet;Thomas Similowski;Vincent Degos;Pierre Rufat;Jean-Christophe Corvol;Stéphane Lehéricy;Nadya Pyatigorskaya | COVID-19;SARS-CoV-2;brain MRI;imaging patterns;neurological manifestations | 2020-07-17 02:00:00+02:00 | 32677875 | FR;GB | Sorbonne Université, Inserm, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, F-75013, Paris, France (L.C., D.G., B.M., C.R., D.D., J.C., S.L., N.P.), Sorbonne Université, 75013, Paris, France (L.C., N.S., N.W., D.G., B.M., S.B., D.B., A.D., C.R., D.S., D.D., E.M., M.R., T.S., V.D., J.C., S.L., N.P.), ICM, "Movement Investigations and Therapeutics" Team (MOV'IT), Paris, France (L.C., S.L., N.P.), ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France (L.C., D.G., S.L., N.P.), Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neuroradiologie, Paris, France (L.C., N.S., D.G., D.L., S.B., S.S., D.D., S.G., S.T., S.L., N.P.), Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN) (N.W., S.D.), Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation Neurologique, Paris, France (N.W.), Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de neurochirurgie, Paris, France (B.M.), Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de virologie, Centre d'Investigation Clinique Neurosciences, Paris, France (S.B., D.B.), CNR Herpèsvirus (laboratoire associé HSV), SU-INSERM UMR_S 1136 Team 3 THERAVIR IPLESP (S.B., D.B.), Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation, Paris, France (A.D., E.M., T.S.), Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Urgences Cérébro-Vasculaires, Paris, France (C.R.), ICM, stroke network, STAR team, Paris, France (C.R.), Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neurologie, Centre d'Investigation Clinique Neurosciences, Paris, France (C.D., J.C.), Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France (D.S.), ICM, INRIA, ARAMIS project-team, Paris, France (D.D., M.R., M.R.), Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Anesthesia, Critical Care and Peri-Operative Medicine, Paris, France (M.R., V.D.), Clinical Research Group ARPE, Sorbonne University, Paris, France (V.D.), INSERM UMR 1141, Paris France (V.D.), Assistance Publique Hôpitaux de Paris, DMU ESPRIT, Paris, France(P.R.). | 1756 | |||
| 10.1016/j.amcp.2020.07.004 | Journal Article;Review | fr | [Are renin-angiotensin system inhibitors protective or deleterious in patients with COVID-19?] | https://www.ncbi.nlm.nih.gov/pubmed/32837199 | 1261-694X | 2020-07-19 02:00:00+02:00 | pubmed | Archives des Maladies du Coeur et des Vaisseaux - Pratique | J-B de Fréminville;M Azizi | 2020-07-17 02:00:00+02:00 | 32837199 | FR | Université de Paris, 75006 Paris, France.;AP-HP, Service d'Hypertension artérielle, DMU CARTE, hôpital européen Georges-Pompidou, 75015 Paris, France. | 1759 | |||||
| 10.1016/j.amcp.2020.07.003 | Journal Article;Review | fr | [Myocarditis and COVID-19, myth or fact?] | https://www.ncbi.nlm.nih.gov/pubmed/32837198 | 1261-694X | 2020-07-19 02:00:00+02:00 | pubmed | Archives des Maladies du Coeur et des Vaisseaux - Pratique | L Filippetti;C Selton-Suty;O Huttin;N Pace;P-Y Marie;Y Juillière | 2020-07-17 02:00:00+02:00 | 32837198 | FR | Département de cardiologie, institut Lorrain du cœur et des vaisseaux, CHU Nancy-Brabois, rue du Morvan, 54500 Vandœuvre-les-Nancy, France. | 1760 | |||||
| 10.1212/wnl.0000000000010112 | Journal Article | en | Neurologic and neuroimaging findings in COVID-19 patients: A retrospective multicenter study. | https://www.ncbi.nlm.nih.gov/pubmed/32680942 | To describe neuroimaging findings and to report the epidemiological and clinical characteristics of COVID-19 patients with neurological manifestations. | 0028-3878,1526-632X | 2020-07-19 02:00:00+02:00 | pubmed | Neurology | Stéphane Kremer;François Lersy;Mathieu Anheim;Hamid Merdji;Maleka Schenck;Hélène Oesterlé;Federico Bolognini;Julien Messie;Marie-Cécile Henri-Feugeas;Antoine Khalil;Augustin Gaudemer;Sophie Carré;Manel Alleg;Claire Lecocq;Emmanuelle Schmitt;René Anxionnat;François Zhu;Lavinia Jager;Patrick Nesser;Yannick Talla Mba;Ghazi Hmeydia;Joseph Benzakoun;Catherine Oppenheim;Jean-Christophe Ferré;Adel Maamar;Béatrice Carsin-Nicol;Pierre-Olivier Comby;Frédéric Ricolfi;Pierre Thouant;Claire Boutet;Xavier Fabre;Géraud Forestier;Isaure de Beaurepaire;Grégoire Bornet;Hubert Desal;Grégoire Boulouis;Jérome Berge;Apolline Kazémi;Nadya Pyatigorskaya;Augustin Lecler;Suzana Saleme;Myriam Edjlali-Goujon;Basile Kerleroux;Jean Marc Constans;Pierre-Emmanuel Zorn;Muriel Mathieu;Seyyid Baloglu;François-Daniel Ardellier;Thibault Willaume;Jean Christophe Brisset;Sophie Caillard;Olivier Collange;Michel Mertes;Francis Schneider;Samira Fafi-Kremer;Mickael Ohana;Ferhat Meziani;Nicolas Meyer;Julie Helms;François Cotton | 2020-07-17 02:00:00+02:00 | 32680942 | FR;US | Hôpitaux Universitaires de Strasbourg, Service d'imagerie 2, Hôpital de Hautepierre, Strasbourg, France stephane.kremer@chru-strasbourg.fr.;Engineering science, computer science and imaging laboratory (ICube), UMR 7357, University of Strasbourg-CNRS, Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Service d'imagerie 2, Hôpital de Hautepierre, Strasbourg, France.;Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.;Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.;Hôpitaux universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, Strasbourg, France.;INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France.;Médecine Intensive-Réanimation, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, France.;Service de Neuroradiologie, Hôpitaux Civils de Colmar, Colmar, France.;Service d'Imagerie, Unité de Neuroradiologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Bichat Claude Bernard, Paris, France.;Université Paris Diderot, Paris, France.;Service de Neurologie, Centre Hospitalier de Haguenau, Haguenau, France.;Service de Radiologie, Centre Hospitalier de Haguenau, Haguenau, France.;Service de Neuroradiologie, Hôpital Central, CHU de Nancy, Nancy, France.;CHIC Unisanté, Hôpital Marie Madeleine, Forbach, France.;Neuroimaging Department, GHU Paris Psychiatrie et Neurosciences, Hôpital Sainte-Anne, Université de Paris, INSERM U1266, F-75014 Paris, France.;CHU Rennes, Department of Neuroradiology, Rennes, France.;CHU Rennes, Medical intensive care unit, Rennes, France.;Department of Neuroradiology, University Hospital of Dijon, Hôpital François Mitterrand, Dijon, France.;Service de Radiologie, CHU de Saint-Etienne, Saint-Etienne, France.;Service de Réanimation, CH de Roanne, Roanne, France.;Service de Neuroradiologie, CHU de Limoges, Limoges, France.;Radiology Department, Hôpital Privé d'Antony, Antony, France.;Department of Diagnostic and Interventional Neuroradiology, University Hospital, Nantes, France.;Neuroradiology department - CHU de Bordeaux, Bordeaux, France.;Service de Neuroradiologie, CHU de Lille, Lille, France.;Assistance Publique Hôpitaux de Paris, Service de Neuroradiologie, Hôpital Pitié-Salpêtrière, Paris, France Sorbonne Université, Univ Paris 06, UMR S 1127, CNRS UMR 7225, ICM, F-75013, Paris, France.;Service de Neuroradiologie Diagnostique, Foundation A.Rothschild Hospital, Paris, France.;EA CHIMERE 7516, Université de Picardie Jules Verne, Amiens, France , Service de NeuroRadiologie, pôle Imagerie Médicale, Centre Hospitalo-Universitaire d'Amiens, Amiens, France.;Hôpitaux Universitaires de Strasbourg, UCIEC, Pôle d'Imagerie, Strasbourg, France.;Observatoire Français de la Sclérose en Plaques, Lyon, France.;Nephrology and Transplantation department, Hôpitaux Universitaires de Strasbourg. Inserm UMR S1109, LabEx Transplantex, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.;Hôpitaux universitaires de Strasbourg, Service d'Anesthésie-Réanimation, Nouvel Hôpital Civil, Strasbourg, France.;Hôpitaux universitaires de Strasbourg, Laboratoire de Virologie Médicale, Strasbourg, France.;Immuno-Rhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France.;Radiology Department, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.;CHU de Strasbourg, Service de Santé Publique, GMRC, F-67091 Strasbourg, France.;MRI center, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Université Lyon 1, CREATIS-LRMN, CNRS/UMR/5220-INSERM U630, Villeurbanne, France. | 1767 | ||||
| 10.1128/aem.01244-20 | Journal Article | en | Modelling the inactivation of viruses from the Coronaviridae family in response to temperature and relative humidity in suspensions or surfaces. | https://www.ncbi.nlm.nih.gov/pubmed/32680860 | Temperature and relative humidity are major factors determining virus inactivation in the environment. This article reviews inactivation data of coronaviruses on surfaces and in liquids from published studies and develops secondary models to predict coronaviruses inactivation as a function of temperature and relative humidity. A total of 102 D-values (time to obtain a log10 reduction of virus infectivity), including values for SARS-CoV-2, were collected from 26 published studies. The values obtained from the different coronaviruses and studies were found to be generally consistent. Five different models were fitted to the global dataset of D-values. The most appropriate model considered temperature and relative humidity. A spreadsheet predicting the inactivation of coronaviruses and the associated uncertainty is presented and can be used to predict virus inactivation for untested temperatures, time points or any coronavirus strains belonging to Alphacoronavirus and Betacoronavirus genera.Importance: The prediction of the persistence of SARS-CoV-2 on fomites is essential to investigate the importance of contact transmission. This study collects available information on inactivation kinetics of coronaviruses in both solid and liquid fomites and creates a mathematical model for the impact of temperature and relative humidity on virus persistence. The predictions of the model can support more robust decision-making and could be useful in various public health contexts. Having a calculator for the natural clearance of SARS-CoV-2 depending on temperature and relative humidity could be a valuable operational tool for public authorities. | 0099-2240,1098-5336 | 2020-07-19 02:00:00+02:00 | pubmed | Applied and Environmental Microbiology | Laurent Guillier;Sandra Martin-Latil;Estelle Chaix;Anne Thébault;Nicole Pavio;Sophie Le Poder;Christophe Batéjat;Fabrice Biot;Lionel Koch;Don Schaffner;Moez Sanaa | 2020-07-17 02:00:00+02:00 | 32680860 | FR;US | Risk Assessment Department, French Agency for Food, Environmental and Occupational Health & Safety, 14, rue Pierre et Marie Curie, Maisons-Alfort, France laurent.guillier@anses.fr.;Laboratory for food safety French Agency for Food, Environmental and Occupational Health & Safety, University of Paris-EST, Maisons-Alfort, France.;Risk Assessment Department, French Agency for Food, Environmental and Occupational Health & Safety, 14, rue Pierre et Marie Curie, Maisons-Alfort, France.;UMR Virologie 1161, ENVA, INRAE, Anses, Maisons-Alfort, France.;Environment and Infectious Risks Unit, Laboratory for Urgent Response to Biological Threats (CIBU), Institut Pasteur, Paris, France.;Bacteriology Unit, French Armed Forces Biomedical Research Institute (IRBA), Brétigny-sur-Orge, France.;Department of Food Science, Rutgers University, New Brunswick, NJ, USA. | 1768 | ||||
| 10.4088/pcc.20com02709 | Journal Article | en | The COVID-19 Pandemic: Do Not Turn the Health Crisis Into a Humanity Crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32678524 | 2155-7780 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Family;Funeral Rites;Humans;Palliative Care;Pandemics__prevention & control;Patient Isolation;Pneumonia, Viral__epidemiology;Telephone;Terminal Care;Videoconferencing;Visitors to Patients;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Primary Care Companion For CNS Disorders | Sélim Benjamin Guessoum;Marie Rose Moro;Jasmina Mallet | 2020-07-16 02:00:00+02:00 | 32678524 | FR | Maison de Solenn, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 97 Blvd Port-Royal, Paris, France 75014. selim.guessoum@gmail.com.;AP-HP Greater Paris University Hospitals, University Hospital Cochin, Paris, France.;University of Paris, PCPP, Paris, France.;University Paris-Saclay, UVSQ, INSERM, CESP, Villejuif, France.;AP-HP Greater Paris University Hospitals, University Hospital Louis Mourier, University of Paris, Paris, France.;INSERM UMR1266, Institute of Psychiatry and Neurosciences of Paris, Paris, France. | 1770 | ||||
| 10.3390/ijerph17145026 | Journal Article;Meta-Analysis;Systematic Review | en | Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32668763 | (1) Background: The global threat of Coronavirus disease 2019 (COVID-19) continues. The diversity of clinical characteristics and progress are reported in many countries as the duration of the pandemic is prolonged. We aimed to perform a novel systematic review and meta-analysis focusing on findings about correlations between clinical characteristics and laboratory features of patients with COVID-19. (2) Methods: We analyzed cases of COVID-19 in different countries by searching PubMed, Embase, Web of Science databases and Google Scholar, from the early stage of the outbreak to late March. Clinical characteristics, laboratory findings, and treatment strategies were retrospectively reviewed for the analysis. (3) Results: Thirty-seven (n = 5196 participants) COVID-19-related studies were eligible for this systematic review and meta-analysis. Fever, cough and fatigue/myalgia were the most common symptoms of COVID-19, followed by some gastrointestinal symptoms which are also reported frequently. Laboratory markers of inflammation and infection including C-reactive protein (CRP) (65% (95% confidence interval (CI) 56-81%)) were elevated, while lymphocyte counts were decreased (63% (95% CI 47-78%)). Meta-analysis of treatment approaches indicated that three modalities of treatment were predominantly used in the majority of patients with a similar prevalence, including antiviral agents (79%), antibiotics (78%), and oxygen therapy (77%). Age was negatively correlated with number of lymphocytes, but positively correlated with dyspnea, number of white blood cells, neutrophils, and D-dimer. Chills had been proved to be positively correlated with chest tightness, lung abnormalities on computed tomography (CT) scans, neutrophil/lymphocyte/platelets count, D-dimer and CRP, cough was positively correlated with sputum production, and pulmonary abnormalities were positively correlated with CRP. White blood cell (WBC) count was also positively correlated with platelet counts, dyspnea, and neutrophil counts with the respective correlations of 0.668, 0.728, and 0.696. (4) Conclusions: This paper is the first systematic review and meta-analysis to reveal the relationship between various variables of clinical characteristics, symptoms and laboratory results with the largest number of papers and patients until now. In elderly patients, laboratory and clinical characteristics indicate a more severe disease course. Moreover, treatments such as antiviral agents, antibiotics, and oxygen therapy which are used in over three quarters of patients are also analyzed. The results will provide "evidence-based hope" on how to manage this unanticipated and overwhelming pandemic. | 1660-4601 | 2020-07-19 02:00:00+02:00 | pubmed | Age Factors;Betacoronavirus;C-Reactive Protein__analysis;Chills__virology;Coronavirus Infections__diagnosis;Cough__virology;Dyspnea__virology;Fibrin Fibrinogen Degradation Products__analysis;Humans;Inflammation__virology;Leukocyte Count;Lymphocyte Count;Pandemics;Platelet Count;Pneumonia, Viral__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Environmental Research and Public Health | Ramy Abou Ghayda;Jinhee Lee;Jun Young Lee;Da Kyung Kim;Keum Hwa Lee;Sung Hwi Hong;Young Joo Han;Jae Seok Kim;Jae Won Yang;Andreas Kronbichler;Lee Smith;Ai Koyanagi;Louis Jacob;Jae Il Shin | COVID-19;clinical characteristics;correlation;laboratory findings;treatment | 2020-07-13 02:00:00+02:00 | 32668763 | FR;GB;US;ES;KR;AT | Division of Urology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.;Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.;Department of Psychiatry, Yonsei University Wonju College of Medicine, Ilsan-ro 20, Wonju 26426, Korea.;Department of Nephrology, Yonsei University Wonju College of Medicine, Ilsan-ro 20, Wonju 26426, Korea.;Yonsei University Wonju College of Medicine, Ilsan-ro 20, Wonju 26426, Korea.;Department of Pediatrics, Yonsei University College of Medicine, Yonsei-ro 50, Seodaemun-gu, Seoul 03722, Korea.;Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, Korea.;Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck 6020, Austria.;The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge CB1 1PT, UK.;Parc Sanitari Sant Joan de Déu/CIBERSAM, Universitat de Barcelona, Fundació Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain.;ICREA, Pg, Lluis Companys 23, 08010 Barcelona, Spain.;Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le-Bretonneux, France. | 1779 | ||
| 10.1002/ejhf.1915 | Journal Article;Review | en | Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. | https://www.ncbi.nlm.nih.gov/pubmed/32463543 | The coronavirus disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID-19. Moreover, evaluating and treating HF patients with comorbid COVID-19 represents a formidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID-19. Since these issues pose serious new challenges for clinicians worldwide, HF specialists must develop a structured approach to the care of patients with COVID-19 and be included early in the care of these patients. Therefore, the Heart Failure Association of the European Society of Cardiology and the Chinese Heart Failure Association & National Heart Failure Committee conducted web-based meetings to discuss these unique clinical challenges and reach a consensus opinion to help providers worldwide deliver better patient care. The main objective of this position paper is to outline the management of HF patients with concomitant COVID-19 based on the available data and personal experiences of physicians from Asia, Europe and the United States. | 1388-9842,1879-0844 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus;Cardiology;China;Comorbidity;Coronavirus Infections__epidemiology;Disease Management;Europe;Heart Failure__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Heart Failure | Yuhui Zhang;Andrew J S Coats;Zhe Zheng;Marianna Adamo;Giuseppe Ambrosio;Stefan D Anker;Javed Butler;Dingli Xu;Jingyuan Mao;Muhammad Shahzeb Khan;Ling Bai;Alexandre Mebazaa;Piotr Ponikowski;Qizhu Tang;Frank Ruschitzka;Petar Seferovic;Carsten Tschöpe;Shuyang Zhang;Chuanyu Gao;Shenghua Zhou;Michele Senni;Jian Zhang;Marco Metra | COVID-19;Coronavirus;Diagnosis;Heart failure;Management;SARS-CoV-2 | 2020-07-13 02:00:00+02:00 | 32463543 | FR;CN;CH;US;IT;PL;RS;DE | Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.;Department of Cardiology, IRCCS San Raffaele Pisana, Rome, Italy.;Department of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.;Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.;Division of Cardiology, University of Perugia School of Medicine, Perugia, Italy.;Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.;Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.;Key Laboratory for Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China.;First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.;Department of Medicine, Cook County Hospital, Chicago, IL, USA.;Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.;Université de Paris, Paris, France, U942 Inserm - MASCOT and Department of Anaesthesia and Critical Care, University Hospitals Saint Louis-Lariboisière, APHP, Paris, France.;Center for Heart Diseases, University Hospital, Medical University, Wroclaw, Poland.;Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan, China.;University Heart Centre, University Hospital Zurich, Zurich, Switzerland.;Clinic of Endocrinology, Diabetes and Metabolic Diseases, Belgrade University Medical Center, Belgrade, Serbia.;Department of Cardiology, Campus Virchow Klinikum, Charite - Universitaetsmedizin Berlin, Berlin, Germany.;Department of Cardiology, Peking Union Medical College & Chinese Academy of Medical Science, Peking Union Medical College Hospital, Beijing, China.;Department of Cardiology, Henan Provincial People's Hospital, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China.;Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China.;Cardiology Division, Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy. | 1785 | ||
| 10.1007/s40618-020-01350-1 | Journal Article;Review | en | Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32661947 | The COVID-19 pandemic, caused by the SARS-CoV-2, represents an unprecedented challenge for healthcare. COVID-19 features a state of hyperinflammation resulting in a "cytokine storm", which leads to severe complications, such as the development of micro-thrombosis and disseminated intravascular coagulation (DIC). Despite isolation measures, the number of affected patients is growing daily: as of June 12th, over 7.5 million cases have been confirmed worldwide, with more than 420,000 global deaths. Over 3.5 million patients have recovered from COVID-19; although this number is increasing by the day, great attention should be directed towards the possible long-term outcomes of the disease. Despite being a trivial matter for patients in intensive care units (ICUs), erectile dysfunction (ED) is a likely consequence of COVID-19 for survivors, and considering the high transmissibility of the infection and the higher contagion rates among elderly men, a worrying phenomenon for a large part of affected patients. | 1720-8386 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Endocrinological Investigation | A Sansone;D Mollaioli;G Ciocca;E Limoncin;E Colonnello;W Vena;E A Jannini | COVID-19;Cardiovascular health;Erectile dysfunction;Male hypogonadism;SARS-CoV-2;Sexual dysfunction | 2020-07-13 02:00:00+02:00 | 32661947 | FR;IT | Chair of Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, 00133, Rome, Italy.;Department of Dynamic and Clinical Psychology, "Sapienza" University of Rome, Rome, Italy.;Endocrinology, Diabetology and Andrology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, MI, Italy.;Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy.;Chair of Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, 00133, Rome, Italy. eajannini@gmail.com. | 1787 | |||
| Letter | en | Extension of COVID-19 pulmonary parenchyma lesions based on real-life visual assessment on initial chest CT is an independent predictor of poor patient outcome. | https://www.ncbi.nlm.nih.gov/pubmed/32657190 | 2020-07-19 02:00:00+02:00 | pubmed | Jules Grégory;Lucas Raynaud;Adrien Galy;Félix Corre;Jean Charles Bijot;Yann Nguyen;Valérie Vilgrain | 2020-07-13 02:00:00+02:00 | 32657190 | FR | Department of Radiology, Assistance Publique des Hôpitaux de Paris Nord, Beaujon Hospital, University of Paris, Clichy, France.;Department of Internal Medicine, Beaujon Hospital, Paris Nord Val de Seine Hospitals, Assistance Publique des Hôpitaux de Paris, University of Paris, Clichy, France.;Centre for Research on Inflammation, Laboratory of Imaging Biomarkers, INSERM U1149, Paris, France. | 1792 | ||||||||
| 10.1177/0883073820940189 | Journal Article | en | Care Delivery for Children With Epilepsy During the COVID-19 Pandemic: An International Survey of Clinicians. | https://www.ncbi.nlm.nih.gov/pubmed/32666891 | To evaluate the effect of the COVID-19 pandemic on global access to care and practice patterns for children with epilepsy. | 0883-0738,1708-8283 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Child Neurology | Elaine C Wirrell;Zachary M Grinspan;Kelly G Knupp;Yuwu Jiang;Biju Hammeed;John R Mytinger;Anup D Patel;Rima Nabbout;Nicola Specchio;J Helen Cross;Renée A Shellhaas | epilepsy;epilepsy surgery;infantile spasms;telemedicine | 2020-07-15 02:00:00+02:00 | 32666891 | FR;UNK;CN;GB;US;IT | Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester, MN, USA.;These are co-first authors of this article.;Departments of Population Sciences and Pediatrics, Weill Cornell Medicine, New York, NY, USA.;Department of Pediatrics and Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.;Department of Pediatrics, Peking University First Hospital, Beijing, China.;Paediatric Neurosciences, Great Ormond Street Children's Hospital, London, United Kingdom.;Department of Pediatrics, Division of Pediatric Neurology, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.;Centre de Reference Epilepsies Rares, Department of Pediatric Neurology, Necker Enfants Malades Hospital, Imagine Institute, Paris Descartes University, Paris, France.;Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesu' Children's Hospital, IRCCS, Rome, Italy and Member of European Reference Network EpiCARE.;Developmental Neurosciences, UCL NIHR BRC Great Ormond Street Institute of Child Health, London, WC1 N 1EH, & and Member of European Reference Network EpiCARE.;Department of Pediatrics (Pediatric Neurology), Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. | 1798 | |||
| 10.1016/j.jvs.2020.06.112 | Journal Article | en | Managing central venous access during a health care crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32682063 | During the COVID-19 pandemic, central venous access line teams were implemented at many hospitals throughout the world to provide access for critically ill patients. The objective of this study was to describe the structure, practice patterns, and outcomes of these vascular access teams during the COVID-19 pandemic. | 0741-5214 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Vascular Surgery | Tristen T Chun;Dejah R Judelson;David Rigberg;Peter F Lawrence;Robert Cuff;Sherene Shalhub;Max Wohlauer;Christopher J Abularrage;Papapetrou Anastasios;Shipra Arya;Bernadette Aulivola;Melissa Baldwin;Donald Baril;Carlos F Bechara;William E Beckerman;Christian-Alexander Behrendt;Filippo Benedetto;Lisa F Bennett;Kristofer M Charlton-Ouw;Amit Chawla;Matthew C Chia;Sungsin Cho;Andrew M T L Choong;Elizabeth L Chou;Anastasiadou Christiana;Raphael Coscas;Giovanni De Caridi;Sharif Ellozy;Yana Etkin;Peter Faries;Adrian T Fung;Andrew Gonzalez;Claire L Griffin;London Guidry;Nalaka Gunawansa;Gary Gwertzman;Daniel K Han;Caitlin W Hicks;Carlos A Hinojosa;York Hsiang;Nicole Ilonzo;Lalithapriya Jayakumar;Jin Hyun Joh;Adam P Johnson;Loay S Kabbani;Melissa R Keller;Manar Khashram;Issam Koleilat;Bernard Krueger;Akshay Kumar;Cheong Jun Lee;Alice Lee;Mark M Levy;C Taylor Lewis;Benjamin Lind;Gabriel Lopez-Pena;Jahan Mohebali;Robert G Molnar;Nicholas J Morrissey;Raghu L Motaganahalli;Nicolas J Mouawad;Daniel H Newton;Jun Jie Ng;Leigh Ann O'Banion;John Phair;Zoran Rancic;Ajit Rao;Hunter M Ray;Aksim G Rivera;Limael Rodriguez;Clifford M Sales;Garrett Salzman;Mark Sarfati;Ajay Savlania;Andres Schanzer;Mel J Sharafuddin;Malachi Sheahan;Sammy Siada;Jeffrey J Siracuse;Brigitte K Smith;Matthew Smith;Ina Soh;Rebecca Sorber;Varuna Sundaram;Scott Sundick;Tadaki M Tomita;Bradley Trinidad;Shirling Tsai;Ageliki G Vouyouka;Gregory G Westin;Michael S Williams;Sherry M Wren;Jane K Yang;Jeniann Yi;Wei Zhou;Saqib Zia;Karen Woo | Central line teams;Central venous access;Iatrogenic injuries | 2020-07-15 02:00:00+02:00 | 32682063 | FR;SG;JE;CA;LK;UNK;NZ;GR;GB;US;CH;IT;IN;MX;KR;DE | Division of Vascular Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, Calif.;Division of Vascular and Endovascular Surgery, Department of Surgery, University of Massachusetts Medical School, Worcester, Mass.;Division of Vascular Surgery, Department of Surgery, Spectrum Health/Michigan State University, Grand Rapids, Mich.;Division of Vascular Surgery, Department of Surgery, University of Washington, Seattle, Wash.;Division of Vascular Surgery, Department of Surgery, University of Colorado School of Medicine, Aurora, Colo.;Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, Md.;Department of Vascular Surgery, General Hospital of Athens KAT, Athens, Greece.;Department of Surgery Stanford University School of Medicine, Palo Alto, Calif.;Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Loyola University Medical Center, Maywood, Ill.;Division of Vascular Surgery, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY.;Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Rutgers Robert Wood Johnson, New Brunswick, NJ.;Department of Vascular Medicine, Research Group GermanVasc, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Division of Vascular Surgery, University of Messina, Messina, Italy.;Rose Medical Center, HealthOne, Denver, Colo.;Department of Cardiothoracic and Vascular Surgery, McGovern Medical School at University of Texas Health Science Center at Houston, Houston, Tex.;Division of Vascular Surgery, Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, La.;Division of Vascular Surgery, Department of Surgery, Northwestern University, Chicago, Ill.;Division of Vascular Surgery, Department of Surgery, Kyung Hee University School of Medicine, Seoul, South Korea.;Division of Vascular and Endovascular Surgery, National University Heart Centre, Singapore.;Division of Vascular Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Mass.;Vascular Surgery Department, Ambroise Paré University Hospital, AP-HP, Boulogne-Billancourt, Paris, France.;Division of Vascular and Endovascular Surgery, Department of Surgery, Weill Cornell Medicine, New York, NY.;Division of Vascular and Endovascular Surgery, Department of Surgery, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.;Division of Vascular Surgery, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.;Division of Vascular Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, Ind.;Vascular Division, Department of Surgery, University of Utah, Salt Lake City, Utah.;Department of Vascular and Transplant Surgery, National Institute of Nephrology Dialysis and Transplantation, Colombo, Sri Lanka.;Division of Vascular and Endovascular Surgery, Department of Surgery, Universidad Nacional Autónoma de México, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.;Vascular and Endovascular Division, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex.;Department of Vascular Surgery, Columbia University Valegos College of Physicians and Surgeons, New York, NY.;Vascular Division, Department of Surgery, Wayne State University, Detroit, Mich.;Department of Surgery, Michigan State University, East Lansing, Mich.;Department of Surgery, University of Auckland, Auckland, New Zealand.;Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.;Institute of Anesthesiology, Intensive Care Unit for Cardiovascular Surgery and Department of Vascular Surgery, University Hospital Zurich, Faculty of Medicine, University of Zurich, Zurich, Switzerland.;Department of Cardiovascular and Thoracic Surgery, Medanta Hospital, Gurgaon, India.;Division of Vascular Surgery, Department of Surgery, NorthShore University Health System, Evanston, Ill.;Vascular Division, Department of Surgery, Virginia Commonwealth University, Richmond, Va.;Department of Surgery, Michigan State University, East Lansing, Mich, Vascular and Endovascular Surgery, McLaren Health System, Bay City, Mich.;Vascular Division, Department of Surgery, University of California San Francisco at Fresno, Fresno, Calif.;The Cardiovascular Care Group, Westfield, NJ.;Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Department of Vascular Surgery, University of Iowa Healthcare, Iowa City, Iowa.;Department of Surgery, Boston University School of Medicine, Boston, Mass.;Division of Vascular and Endovascular Surgery, Mayo Clinic, Phoenix, Ariz.;Vascular Division, Department of Surgery, University of Arizona, Tucson, Ariz.;Vascular Division, Department of Surgery, VA North Texas Health Care Systems, Dallas, Tex.;Vascular and Endovascular Division, Department of Surgery, St. Louis University School of Medicine, St. Louis, Mo.;Vascular Division, Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ.;Division of Vascular Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, Calif. Electronic address: kwoo@mednet.ucla.edu. | 1807 | |||
| 10.1016/j.antiviral.2020.104878 | Journal Article | en | In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32679055 | In response to the current pandemic caused by the novel SARS-CoV-2, identifying and validating effective therapeutic strategies is more than ever necessary. We evaluated the in vitro antiviral activities of a shortlist of compounds, known for their cellular broad-spectrum activities, together with drugs that are currently under evaluation in clinical trials for COVID-19 patients. We report the antiviral effect of remdesivir, lopinavir, chloroquine, umifenovir, berberine and cyclosporine A in Vero E6 cells model of SARS-CoV-2 infection, with estimated 50% inhibitory concentrations of 0.99, 5.2, 1.38, 3.5, 10.6 and 3 μM, respectively. Virus-directed plus host-directed drug combinations were also investigated. We report a strong antagonism between remdesivir and berberine, in contrast with remdesivir/diltiazem, for which we describe high levels of synergy, with mean Loewe synergy scores of 12 and peak values above 50. Combination of host-directed drugs with direct acting antivirals underscore further validation in more physiological models, yet they open up interesting avenues for the treatment of COVID-19. | 0166-3542 | 2020-07-19 02:00:00+02:00 | pubmed | Antiviral Research | Andrés Pizzorno;Blandine Padey;Julia Dubois;Thomas Julien;Aurélien Traversier;Victoria Dulière;Pauline Brun;Bruno Lina;Manuel Rosa-Calatrava;Olivier Terrier | COVID-19;antivirals;berberine;diltiazem;drug combination;remdesivir | 2020-07-14 02:00:00+02:00 | 32679055 | FR | CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France, Signia Therapeutics SAS, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France, VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France, Laboratoire de Virologie, Centre National de Référence des Virus Influenza Sud, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France, VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France. Electronic address: manuel.rosa-calatrava@univ-lyon1.fr.;CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France. Electronic address: olivier.terrier@univ-lyon1.fr. | 1810 | |||
| Letter | en | Is computed tomography really the future of biology for diagnosing COVID-19 infection? | https://www.ncbi.nlm.nih.gov/pubmed/32675170 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Humans;Nasopharynx__virology;Pandemics;Pneumonia, Viral__diagnostic imaging;Tomography, X-Ray Computed;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Jean-François Vendrell;Jean-Pierre Vendrell;Gérald Gahide | 2020-07-18 02:00:00+02:00 | 32675170 | FR | Centre Hospitalier Universitaire de Nîmes, Nîmes, France. | 1824 | |||||||
| 10.1038/s41586-020-2577-1 | Journal Article | en | Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. | https://www.ncbi.nlm.nih.gov/pubmed/32707573 | The emergence of the novel SARS coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19)1. The development of a vaccine is likely to require at least 12-18 months, and the typical timeline for approval of a novel antiviral therapeutic can exceed 10 years. Thus, repurposing of known drugs could significantly accelerate the deployment of novel therapies for COVID-19. Towards this end, we profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules. We report the identification of 100 molecules that inhibit viral replication, including 21 known drugs that exhibit dose response relationships. Of these, thirteen were found to harbor effective concentrations likely commensurate with achievable therapeutic doses in patients, including the PIKfyve kinase inhibitor apilimod2-4, and the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334. Notably, MDL-28170, ONO 5334, and apilimod were found to antagonize viral replication in human iPSC-derived pneumocyte-like cells, and the PIKfyve inhibitor also demonstrated antiviral efficacy in a primary human lung explant model. Since most of the molecules identified in this study have already advanced into the clinic, the known pharmacological and human safety profiles of these compounds will enable accelerated preclinical and clinical evaluation of these drugs for the treatment of COVID-19. | 0028-0836,1476-4687 | 2020-07-26 02:00:00+02:00 | pubmed | Nature | Laura Riva;Shuofeng Yuan;Xin Yin;Laura Martin-Sancho;Naoko Matsunaga;Lars Pache;Sebastian Burgstaller-Muehlbacher;Paul D De Jesus;Peter Teriete;Mitchell V Hull;Max W Chang;Jasper Fuk-Woo Chan;Jianli Cao;Vincent Kwok-Man Poon;Kristina M Herbert;Kuoyuan Cheng;Tu-Trinh H Nguyen;Andrey Rubanov;Yuan Pu;Courtney Nguyen;Angela Choi;Raveen Rathnasinghe;Michael Schotsaert;Lisa Miorin;Marion Dejosez;Thomas P Zwaka;Ko-Yung Sit;Luis Martinez-Sobrido;Wen-Chun Liu;Kris M White;Mackenzie E Chapman;Emma K Lendy;Richard J Glynne;Randy Albrecht;Eytan Ruppin;Andrew D Mesecar;Jeffrey R Johnson;Christopher Benner;Ren Sun;Peter G Schultz;Andrew I Su;Adolfo García-Sastre;Arnab K Chatterjee;Kwok-Yung Yuen;Sumit K Chanda | 2020-07-24 02:00:00+02:00 | 32707573 | FR;CN;US;HK;AT | Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA.;State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, Hong Kong, China.;Center for Integrative Bioinformatics Vienna, Max Perutz Laboratories, University of Vienna and Medical University of Vienna, Vienna, Austria.;Calibr at Scripps Research, La Jolla, CA, 92037, USA.;Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.;Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, 20892, USA.;Biological Sciences Graduate Program, University of Maryland, College Park, MD, 20742, USA.;Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.;Global Health and Emerging pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.;Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.;Huffington Foundation Center for Cell-based Research in Parkinson's Disease, Department for Cell, Regenerative and Developmental Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, Hong Kong, China.;Texas Biomedical Research Institute, San Antonio, TX, USA.;Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.;Department of Biochemistry, Purdue University, West Lafayette, IN, USA.;Inception Therapeutics, 6175 Nancy Ridge Dr, San Diego, 92121, USA.;Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.;Department of Integrative, Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.;Department of Medicine - Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.;The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.;Calibr at Scripps Research, La Jolla, CA, 92037, USA. achatterjee@scripps.edu.;State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, Hong Kong, China. kyyuen@hku.hk.;Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA. schanda@sbpdiscovery.org. | 1831 | ||||
| 10.1016/j.pratan.2020.07.006 | Editorial | fr | [Regional anesthesia during the COVID-19 epidemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32837215 | 1279-7960 | 2020-07-26 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Sébastien Bloc | 2020-07-24 02:00:00+02:00 | 32837215 | FR | Clinique Drouot Sport, 21, rue Rémusat, 75016 Paris, France. | 1832 | |||||
| 10.1016/j.eclinm.2020.100473 | Journal Article | en | SARS-CoV-2 and human reproduction: An open question. | https://www.ncbi.nlm.nih.gov/pubmed/32734175 | 2589-5370 | 2020-07-26 02:00:00+02:00 | pubmed | EClinicalMedicine | Frida Entezami;Marise Samama;Nathalie Dejucq-Rainsford;Louis Bujan | 2020-07-24 02:00:00+02:00 | 32734175 | FR;BR | American Hospital of Paris, IVF Department, 63 boulevard Victor Hugo, 92200 Neuilly sur Seine, France.;Inserm U1203, Human Early Embryonic Development and Pluripotency, Montpellier, France.;Department of Gynecology, Federal University of São Paulo, Brazil.;GERA Institute of Reproductive Medicine, São Paulo, Brazil.;Inserm, EHESP, Irset - UMR_S1085, University Rennes, France.;Research Group on Human Fertility EA 3694, University Paul Sabatier Toulouse III and CECOS, Hôpital Paule de Viguier CHU de Toulouse, Toulouse, France. | 1833 | |||||
| 10.1126/science.abd2161 | Journal Article | en | Evolution and epidemic spread of SARS-CoV-2 in Brazil. | https://www.ncbi.nlm.nih.gov/pubmed/32703910 | Brazil currently has one of the fastest growing SARS-CoV-2 epidemics in the world. Owing to limited available data, assessments of the impact of non-pharmaceutical interventions (NPIs) on virus spread remain challenging. Using a mobility-driven transmission model, we show that NPIs reduced the reproduction number from >3 to 1-1.6 in São Paulo and Rio de Janeiro. Sequencing of 427 new genomes and analysis of a geographically representative genomic dataset identified >100 international virus introductions in Brazil. We estimate that most (76%) of the Brazilian strains fell in three clades that were introduced from Europe between 22 February11 March 2020. During the early epidemic phase, we found that SARS-CoV-2 spread mostly locally and within-state borders. After this period, despite sharp decreases in air travel, we estimated multiple exportations from large urban centers that coincided with a 25% increase in average travelled distances in national flights. This study sheds new light on the epidemic transmission and evolutionary trajectories of SARS-CoV-2 lineages in Brazil, and provide evidence that current interventions remain insufficient to keep virus transmission under control in the country. | 0036-8075,1095-9203 | 2020-07-26 02:00:00+02:00 | pubmed | Science | Darlan S Candido;Ingra M Claro;Jaqueline G de Jesus;William M Souza;Filipe R R Moreira;Simon Dellicour;Thomas A Mellan;Louis du Plessis;Rafael H M Pereira;Flavia C S Sales;Erika R Manuli;Julien Thézé;Luiz Almeida;Mariane T Menezes;Carolina M Voloch;Marcilio J Fumagalli;Thaís M Coletti;Camila A M da Silva;Mariana S Ramundo;Mariene R Amorim;Henrique H Hoeltgebaum;Swapnil Mishra;Mandev S Gill;Luiz M Carvalho;Lewis F Buss;Carlos A Prete;Jordan Ashworth;Helder I Nakaya;Pedro S Peixoto;Oliver J Brady;Samuel M Nicholls;Amilcar Tanuri;Átila D Rossi;Carlos K V Braga;Alexandra L Gerber;Ana Paula de C Guimarães;Nelson Gaburo;Cecila Salete Alencar;Alessandro C S Ferreira;Cristiano X Lima;José Eduardo Levi;Celso Granato;Giulia M Ferreira;Ronaldo S Francisco;Fabiana Granja;Marcia T Garcia;Maria Luiza Moretti;Mauricio W Perroud;Terezinha M P P Castiñeiras;Carolina S Lazari;Sarah C Hill;Andreza Aruska de Souza Santos;Camila L Simeoni;Julia Forato;Andrei C Sposito;Angelica Z Schreiber;Magnun N N Santos;Camila Zolini de Sá;Renan P Souza;Luciana C Resende-Moreira;Mauro M Teixeira;Josy Hubner;Patricia A F Leme;Rennan G Moreira;Maurício L Nogueira;Neil M Ferguson;Silvia F Costa;José Luiz Proenca-Modena;Ana Tereza R Vasconcelos;Samir Bhatt;Philippe Lemey;Chieh-Hsi Wu;Andrew Rambaut;Nick J Loman;Renato S Aguiar;Oliver G Pybus;Ester C Sabino;Nuno Rodrigues Faria | 2020-07-23 02:00:00+02:00 | 32703910 | FR;BR;BE;GB | Department of Zoology, University of Oxford, Oxford, UK.;Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.;Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.;Centro de Pesquisa em Virologia, Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, Brazil.;Departamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.;Spatial Epidemiology Lab, Université Libre de Bruxelles, Brussels, Belgium.;Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.;MRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College London, London, UK.;Institute for Applied Economic Research, Brasília, Brazil.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, Saint-Genès-Champanelle, France.;Laboratório de Bioinformática, Laboratório Nacional de Computação Científica, Petrópolis, Brazil.;Departamento de Genética, Evolução, Microbiologia e Imunologia, Instituto de Biologia and Experimental Medicine Research Cluster (EMRC), Universidade Estadual de Campinas, Campinas, Brazil.;Department of Mathematics, Imperial College London, London, UK.;Escola de Matemática Aplicada (EMAp), Fundação Getúlio Vargas, Rio de Janeiro, Brazil.;Department of Electronic Systems Engineering, University of São Paulo, São Paulo, Brazil.;Usher Institute, University of Edinburgh, Edinburgh, UK.;Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.;Departamento de Matemática Aplicada, Instituto de Matemática e Estatística, Universidade de São Paulo, São Paulo, Brazil.;Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.;Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK.;Institute for Microbiology and Infection, University of Birmingham, Birmingham, UK.;DB Diagnósticos do Brasil, São Paulo, Brazil.;LIM 03 Laboratório de Medicina Laboratorial, Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.;Instituto Hermes Pardini, Belo Horizonte, Brazil.;Departamento de Cirurgia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.;Simile Instituto de Imunologia Aplicada Ltda, Belo Horizonte, Brazil.;Laboratório DASA, São Paulo, Brazil.;Laboratório Fleury, São Paulo, Brazil.;Laboratório de Virologia, Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia, Brazil.;Centro de Estudos da Biodiversidade, Universidade Federal de Roraima, Boa Vista, Brazil.;Divisão de Doenças Infecciosas, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, Brazil.;Hospital Estadual Sumaré, Universidade Estadual de Campinas, Campinas, Brazil.;Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.;Divisão de Laboratório Central do Hospital das Clínicas, da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.;Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, UK.;University of Oxford, Latin American Centre, Oxford School of Global and Area Studies, Oxford, UK.;Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, Brazil.;Departamento de Patologia Clínica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, Brazil.;Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.;Departamento de Botânica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.;Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.;Departamento de Biologia Celular, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.;Centro de Saúde da Comunidade, Universidade Estadual de Campinas, Campinas, Brazil.;Centro de Laboratórios Multiusuários, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.;Laboratório de Pesquisas em Virologia, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil.;Mathematical Sciences, University of Southampton, Southampton, UK.;Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK.;Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. sabinoec@usp.br nuno.faria@zoo.ox.ac.uk.;Department of Zoology, University of Oxford, Oxford, UK. sabinoec@usp.br nuno.faria@zoo.ox.ac.uk. | 1838 | ||||
| 10.1186/s13613-020-00717-0 | Journal Article;Review | en | SARS-CoV-2 post-infective myocarditis: the tip of COVID-19 immune complications? | https://www.ncbi.nlm.nih.gov/pubmed/32705368 | Recent paediatric cases of acute myocarditis following a SARS-CoV-2 infection have raised the possibility of post-infective complications of COVID-19. This short editorial is reviewing current understanding of this new complication, its pathophysiology, diagnosis and therapeutic strategy. | 2110-5820 | 2020-07-26 02:00:00+02:00 | pubmed | Annals of Intensive Care | Pierre Tissières;Jean-Louis Teboul | COVID-19;Kawasaki disease;MIS-C;Myocarditis;Post-infective complications;SARS-CoV-2 | 2020-07-23 02:00:00+02:00 | 32705368 | FR | Pediatric Intensive Care, AP-HP Paris Saclay University, 78, Rue du Général Leclerc, 94275, Le Kremlin-Bicêtre, France. pierre.tissieres@aphp.fr.;Institute of Integrative Biology of the Cell, CNRS, CEA, Univ. Paris Saclay, Gif-sur-Yvette, France. pierre.tissieres@aphp.fr.;Medical Intensive Care, AP-HP Paris Saclay University, Bicêtre Hospital, Le Kremlin-Bicêtre, France. | 1840 | |||
| 10.1128/jcm.00630-20 | Evaluation Study;Journal Article | en | Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection. | https://www.ncbi.nlm.nih.gov/pubmed/32341142 | In the race to contain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), efficient detection and triage of infected patients must rely on rapid and reliable testing. In this work, we performed the first evaluation of the QIAstat-Dx respiratory SARS-CoV-2 panel (QIAstat-SARS) for SARS-CoV-2 detection. This assay is the first rapid multiplex PCR (mPCR) assay, including SARS-CoV-2 detection, and is fully compatible with a non-PCR-trained laboratory or point-of-care (PoC) testing. This evaluation was performed using 69 primary clinical samples (66 nasopharyngeal swabs [NPS], 1 bronchoalveolar lavage fluid sample [BAL], 1 tracheal aspirate sample, and 1 bronchial aspirate sample) comparing SARS-CoV-2 detection with the currently WHO-recommended reverse transcription-PCR (RT-PCR) (WHO-RT-PCR) workflow. Additionally, a comparative limit of detection (LoD) assessment was performed for QIAstat-SARS and WHO-RT-PCR using a quantified clinical sample. Compatibility of sample pretreatment for viral neutralization or viscous samples with the QIAstat-SARS system were also tested. The QIAstat-Dx respiratory SARS-CoV-2 panel demonstrated a sensitivity comparable to that of the WHO-recommended assay with a limit of detection at 1,000 copies/ml. The overall percent agreement between QIAstat-Dx SARS and WHO-RT-PCR on 69 clinical samples was 97% with a sensitivity of 100% (40/40) and specificity at 93% (27/29). No cross-reaction was encountered for any other respiratory viruses or bacteria included in the panel. The QIAstat-SARS rapid multiplex PCR panel provides a highly sensitive, robust, and accurate assay for rapid detection of SARS-CoV-2. This assay allows rapid decisions even in non-PCR-trained laboratory or point-of-care testing, allowing innovative organization. | 0095-1137,1098-660X | 2020-07-26 02:00:00+02:00 | pubmed | Betacoronavirus__genetics;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Humans;Multiplex Polymerase Chain Reaction__methods;Pandemics;Pneumonia, Viral__diagnosis;Respiratory System__virology;Sensitivity and Specificity;Time Factors;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Clinical Microbiology | Benoit Visseaux;Quentin Le Hingrat;Gilles Collin;Donia Bouzid;Samuel Lebourgeois;Diane Le Pluart;Laurène Deconinck;François-Xavier Lescure;Jean-Christophe Lucet;Lila Bouadma;Jean-François Timsit;Diane Descamps;Yazdan Yazdanpanah;Enrique Casalino;Nadhira Houhou-Fidouh | COVID-19;SARS-CoV-2;diagnostics;mPCR;rapid tests | 2020-07-23 02:00:00+02:00 | 32341142 | FR | Université de Paris, Assistance Publique - Hôpitaux de Paris, Service de Virologie, Hôpital Bichat, Paris, France benoit.visseaux@aphp.fr.;UMR 1137-IAME, Decision Sciences in Infectious Diseases Control and Care (DeSCID), INSERM, Université de Paris, Paris, France.;Université de Paris, Assistance Publique - Hôpitaux de Paris, Service de Virologie, Hôpital Bichat, Paris, France.;Université de Paris, Assistance Publique - Hôpitaux de Paris, Service d'Accueil des Urgences, Hôpital Bichat, Paris, France.;Université de Paris, Service de Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, Assistance Publique - Hôpitaux de Paris, Paris, France.;Université de Paris, Unité d'Hygiène et de Lutte contre les Infections Nosocomiales, Hôpital Bichat Claude Bernard, Assistance Publique - Hôpitaux de Paris, Paris, France.;Université de Paris, Réanimation Médicale et Infectieuse, Hôpital Bichat Claude Bernard, Assistance Publique - Hôpitaux de Paris, Paris, France. | 1842 | ||
| 10.1097/mou.0000000000000808 | Journal Article;Review | en | Secretion of severe acute respiratory syndrome coronavirus 2 in urine. | https://www.ncbi.nlm.nih.gov/pubmed/32701726 | Despite the plethora of publications discussing the severe respiratory coronavirus 2 (SARS-CoV-2), evidence of viral secretion in urine is sparse. | 0963-0643 | 2020-07-26 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__urine;Humans;Pandemics;Pneumonia, Viral__urine;Virus Shedding;COVID-19;severe acute respiratory syndrome coronavirus 2 | Current Opinion in Urology | Stephan Brönimann;Katharina Rebhan;Ursula Lemberger;Vincent Misrai;Shahrokh F Shariat;Benjamin Pradere | 2020-07-24 02:00:00+02:00 | 32701726 | FR;RU;JO;US;NL;CZ;AT | Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.;Department of Urology, Clinique Pasteur, Toulouse, France.;Departments of Urology, Weill Cornell Medical College, New York, New York.;Department of Urology, University of Texas Southwestern, Dallas, Texas, USA.;Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.;Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.;Department of Urology, University of Jordan, Amman, Jordan.;European Association of Urology Research Foundation, Arnhem, the Netherlands.;Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.;Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France. | 1853 | |||
| 10.1016/j.jcrc.2020.07.020 | Journal Article | en | Meta-trial of awake prone positioning with nasal high flow therapy: Invitation to join a pandemic collaborative research effort. | https://www.ncbi.nlm.nih.gov/pubmed/32799184 | 0883-9441 | 2020-07-26 02:00:00+02:00 | pubmed | Journal of Critical Care | Jie Li;Ivan Pavlov;John G Laffey;Oriol Roca;Sara Mirza;Yonatan Perez;Bairbre McNicholas;David Cosgrave;David Vines;Elsa Tavernier;Stephan Ehrmann | Acute respiratory distress syndrome;COVID-19 [MeSH];Meta-analysis [MeSH];Pandemics [MeSH];Research design [MeSH] | 2020-07-24 02:00:00+02:00 | 32799184 | IE;FR;CA;US;ES;PS | Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University Medical Center, Chicago, IL, United States of America.;Department of Emergency Medicine, Hôpital de Verdun, Montréal, Québec, Canada.;Anaesthesia and Intensive Care Medicine, School of Medicine, National University of Ireland Galway, Ireland, Department of Anaesthesia, University Hospital Galway, Saolta Hospital Group, Ireland.;Servei de Medicina Intensiva, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron, Barcelona, Spain, Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Ciber Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.;Division of Pulmonary and Critical care, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States of America.;CHRU Tours, Médecine Intensive Réanimation, CIC INSERM 1415, REVA and CRICS-TriggerSEP Research Networks, Tours, France.;Universities of Tours and Nantes, INSERM 1246-SPHERE, Tours, France, Clinical Investigation Center, INSERM 1415, CHRU Tours, Tours, France.;CHRU Tours, Médecine Intensive Réanimation, CIC INSERM 1415, REVA and CRICS-TriggerSEP Research Networks, Tours, France, INSERM, Centre d'étude des Pathologies Respiratoires, U1100, Université de Tours, Tours, France. Electronic address: stephanehrmann@gmail.com. | 1857 | ||||
| 10.1093/sleep/zsaa125 | Journal Article | en | Poor sleep associated with overuse of media during the COVID-19 lockdown. | https://www.ncbi.nlm.nih.gov/pubmed/32710627 | 0161-8105,1550-9109 | 2020-07-26 02:00:00+02:00 | pubmed | Sleep | Damien Léger;François Beck;Lisa Fressard;Pierre Verger;Patrick Peretti-Watel | 2020-07-25 02:00:00+02:00 | 32710627 | FR | Université de Paris, EA 7330 VIFASOM (Vigilance Fatigue Sommeil et Santé Publique), Paris, France.;APHP, Hôtel-Dieu, Centre du Sommeil et de la Vigilance, Consultation de pathologie professionnelle Sommeil Vigilance et Travail, Paris, France.;CESP (Centre de recherche en Épidémiologie et Santé des Populations), Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm U1018, Villejuif, France.;Southeastern Health Regional Observatory (ORS Paca), Marseille, France.;AMU, UMR Vitrome, IHU Méditerrannée, IRD, Marseille, France. | 1858 | |||||
| 10.1016/s1473-3099(20)30458-8 | Journal Article;Review | en | Monitoring approaches for health-care workers during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32711692 | Health-care workers are crucial to any health-care system. During the ongoing COVID-19 pandemic, health-care workers are at a substantially increased risk of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and could come to considerable harm as a result. Depending on the phase of the pandemic, patients with COVID-19 might not be the main source of SARS-CoV-2 infection and health-care workers could be exposed to atypical patients, infected family members, contacts, and colleagues, or live in communities of active transmission. Clear strategies to support and appropriately manage exposed and infected health-care workers are essential to ensure effective staff management and to engender trust in the workplace. These management strategies should focus on risk stratification, suitable clinical monitoring, low-threshold access to diagnostics, and decision making about removal from and return to work. Policy makers need to support health-care facilities in interpreting guidance during a pandemic that will probably be characterised by fluctuating local incidence of SARS-CoV-2 to mitigate the impact of this pandemic on their workforce. | 1473-3099 | 2020-07-26 02:00:00+02:00 | pubmed | The Lancet Infectious Diseases | Julia A Bielicki;Xavier Duval;Nina Gobat;Herman Goossens;Marion Koopmans;Evelina Tacconelli;Sylvie van der Werf | 2020-07-23 02:00:00+02:00 | 32711692 | FR;CH;GB;IT;NL;BE | Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's University of London, London, UK, Paediatric Infectious Diseases and Infection Prevention and Control, University of Basel Children's Hospital, Basel, Switzerland. Electronic address: julia.bielicki@ukbb.ch.;Center for Clinical Investigation, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France, INSERM, Infections Antimicrobials Modelling Evolution, University of Paris, Paris, France.;Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.;Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium.;Erasmus MC, Rotterdam, Netherlands.;Division of Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.;Department of Virology, University of Paris, Paris, France, National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France. | 1868 | ||||
| 10.1126/science.abd2438 | Journal Article | en | Global quieting of high-frequency seismic noise due to COVID-19 pandemic lockdown measures. | https://www.ncbi.nlm.nih.gov/pubmed/32703907 | Human activity causes vibrations that propagate into the ground as high-frequency seismic waves. Measures to mitigate the COVID-19 pandemic caused widespread changes in human activity, leading to a months-long reduction in seismic noise of up to 50%. The 2020 seismic noise quiet period is the longest and most prominent global anthropogenic seismic noise reduction on record. While the reduction is strongest at surface seismometers in populated areas, this seismic quiescence extends for many kilometers radially and hundreds of meters in depth. This provides an opportunity to detect subtle signals from subsurface seismic sources that would have been concealed in noisier times and to benchmark sources of anthropogenic noise. A strong correlation between seismic noise and independent measurements of human mobility suggests that seismology provides an absolute, real-time estimate of population dynamics. | 0036-8075,1095-9203 | 2020-07-26 02:00:00+02:00 | pubmed | Science | Thomas Lecocq;Stephen P Hicks;Koen Van Noten;Kasper van Wijk;Paula Koelemeijer;Raphael S M De Plaen;Frédérick Massin;Gregor Hillers;Robert E Anthony;Maria-Theresia Apoloner;Mario Arroyo-Solórzano;Jelle D Assink;Pinar Büyükakpınar;Andrea Cannata;Flavio Cannavo;Sebastian Carrasco;Corentin Caudron;Esteban J Chaves;David G Cornwell;David Craig;Olivier F C den Ouden;Jordi Diaz;Stefanie Donner;Christos P Evangelidis;Läslo Evers;Benoit Fauville;Gonzalo A Fernandez;Dimitrios Giannopoulos;Steven J Gibbons;Társilo Girona;Bogdan Grecu;Marc Grunberg;György Hetényi;Anna Horleston;Adolfo Inza;Jessica C E Irving;Mohammadreza Jamalreyhani;Alan Kafka;Mathijs R Koymans;Celeste R Labedz;Eric Larose;Nathaniel J Lindsey;Mika McKinnon;Tobias Megies;Meghan S Miller;William Minarik;Louis Moresi;Víctor H Márquez-Ramírez;Martin Möllhoff;Ian M Nesbitt;Shankho Niyogi;Javier Ojeda;Adrien Oth;Simon Proud;Jay Pulli;Lise Retailleau;Annukka E Rintamäki;Claudio Satriano;Martha K Savage;Shahar Shani-Kadmiel;Reinoud Sleeman;Efthimios Sokos;Klaus Stammler;Alexander E Stott;Shiba Subedi;Mathilde B Sørensen;Taka'aki Taira;Mar Tapia;Fatih Turhan;Ben van der Pluijm;Mark Vanstone;Jerome Vergne;Tommi A T Vuorinen;Tristram Warren;Joachim Wassermann;Han Xiao | 2020-07-23 02:00:00+02:00 | 32703907 | CR;CA;NZ;CL;NL;MX;BE;FR;GR;GB;CH;US;RO;IT;IR;LU;AT;DE;IE;SE;NO;FI;BO;AU;TR;ES;PE | Seismology-Gravimetry, Royal Observatory of Belgium, Avenue circulaire 3, 1180 Brussels, Belgium. thomas.lecocq@seismology.be.;Department of Earth Science and Engineering, Imperial College London, London, UK.;Seismology-Gravimetry, Royal Observatory of Belgium, Avenue circulaire 3, 1180 Brussels, Belgium.;Department of Physics, University of Auckland, New Zealand.;Department of Earth Sciences, Royal Holloway University of London, Egham, UK.;Centro de Geociencias, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico.;Swiss Seismological Service, ETH Zurich, Sonneggstrasse 5, CH-8092, Zurich, Switzerland.;Institute of Seismology, University of Helsinki, Helsinki, Finland.;U.S. Geological Survey - Albuquerque Seismological Laboratory, New Mexico, USA.;Zentralanstalt für Meteorologie und Geodynamik (ZAMG), Vienna, Austria.;Escuela Centroamericana de Geología, Universidad de Costa Rica, San José, Costa Rica.;R&D Seismology and Acoustics, Royal Netherlands Meteorological Institute (KNMI), Utrechtseweg 297, 3731 GA De Bilt, Netherlands.;Kandilli Observatory and Earthquake Research Institute, Boğaziçi University, Istanbul, Turkey.;GFZ German Research Centre for Geosciences, Potsdam, Germany.;Dipartimento di Scienze Biologiche, Geologiche e Ambientali, Università Degli Studi di Catania, Catania, Italy.;Istituto Nazionale di Geofisica e Vulcanologia, Osservatorio Etneo, Catania, Italy.;Bensberg Observatory, University of Cologne, Cologne, Germany.;Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, IRD, IFSTTAR, ISTerre, 38000 Grenoble, France.;Volcanological and Seismological Observatory of Costa Rica at Universidad Nacional (OVSICORI-UNA), Costa Rica.;Department of Geology & Geophysics, School of Geosciences, University of Aberdeen, King's College, Aberdeen, AB24 3UE, UK.;Dublin Institute for Advanced Studies, Geophysics Section, 5 Merrion Square, D02 Y006 Dublin, Ireland.;Dept. of Geoscience and Engineering, Delft University of Technology, Stevinweg 1, 2628 CN Delft, Netherlands.;Geosciences Barcelona, CSIC, Barcelona, Spain.;Federal Institute for Geosciences and Natural Resources (BGR), Hannover, Germany.;Institute of Geodynamics, National Observatory of Athens, Greece.;Noise Department, Brussels Environment, Brussels-Capital Region, Belgium.;Observatorio San Calixto, Bolivia.;Seismotech S.A., Athens, Greece.;Hellenic Mediterranean University, Dept. of Environmental & Natural Resources Engineering, Laboratory of Geophysics & Seismology, Chania, Greece.;Norges Geotekniske Institutt, Sognsveien 72, 0855 Oslo, Norway.;Geophysical Institute, University of Alaska Fairbanks, Alaska 99775, USA.;National Institute for Earth Physics, Calugareni 12, Magurele, Romania.;Réseau National de Surveillance Sismique (RENASS), Université de Strasbourg, CNRS, EOST UMS830, 5 rue René Descartes, F-67084 Strasbourg Cedex, France.;Institute of Earth Sciences, Faculty of Geosciences and Environment, University of Lausanne, Lausanne, Switzerland.;School of Earth Sciences, University of Bristol, Queen's Road, Bristol, BS8 1RJ, UK.;Instituto Geofisico del Peru, Lima, Peru.;Department of Geosciences, Princeton University, NJ, USA.;Institute of Geophysics, University of Tehran, Iran.;Weston Observatory, Department of Earth and Environmental Sciences, Boston College, Weston, MA, USA.;Seismological Laboratory, California Institute of Technology, Pasadena, CA, USA.;Geophysics Department, Stanford University, Stanford, CA, USA.;SETI Institute, Mountain View, CA, USA.;Faculty of Science, Department of Earth, Ocean and Atmospheric Sciences, University of British Columbia, Canada.;Ludwig-Maximilians-Universität München, Munich, Germany.;Research School of Earth Sciences, Australian National University, Canberra, ACT Australia.;Department of Earth and Planetary Sciences, McGill University, Montréal, QC, Canada.;GEOTOP Research Centre, Montréal, QC, Canada.;University of California, Riverside, USA.;Departamento de Geofísica, Universidad de Chile, Santiago, Chile.;European Center for Geodynamics and Seismology, 19, rue Josy Welter, L-7256 Walferdange, Grand Duchy of Luxembourg.;National Centre for Earth Observation, Department of Physics, University of Oxford, UK.;Raytheon BBN Technologies, Arlington, VA, USA.;Université de Paris, Institut de physique du globe de Paris, CNRS, F-75005 Paris, France.;Observatoire Volcanologique du Piton de la Fournaise, Institut de physique du globe de Paris, F-97418 La Plaine des Cafres, France.;School of Geography, Environment and Earth Sciences, Victoria University of Wellington, New Zealand.;Department of Geology, University of Patras, Patras, 26504 Rio, Greece.;Department of Electrical and Electronic Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.;Department of Earth Science, University of Bergen, Bergen, Norway.;Berkeley Seismological Laboratory, University of California Berkeley, Berkeley, USA.;Laboratori d'Estudis Geofísics Eduard Fontserè, Institut d'Estudis Catalans (LEGEF-IEC), Barcelona, Spain.;Department of Earth and Environmental Sciences, University of Michigan-Ann Arbor, MI, USA.;Geology Department, Truro School, Trennick Lane, Truro, Cornwall, TR1 1TH, UK.;Institut de Physique du Globe de Strasbourg , UMR 7516, Université de Strasbourg/EOST, CNRS , 5 rue René Descartes, F-67084 Strasbourg Cedex, France.;Department of Physics, University of Oxford, UK.;Department of Earth Science and Earth Research Institute, University of California, Santa Barbara, CA, USA. | 1869 | ||||
| 10.3324/haematol.2020.260117 | Journal Article | en | Complement C5 inhibition in patients with COVID-19 - a promising target? | https://www.ncbi.nlm.nih.gov/pubmed/32703791 | 0390-6078,1592-8721 | 2020-07-26 02:00:00+02:00 | pubmed | Haematologica | Regis Peffault de Latour;Anne Bergeron;Etienne Lengline;Thibault Dupont;Armance Marchal;Lionel Galicier;Nathalie de Castro;Louise Bondeelle;Michael Darmon;Clairelyne Dupin;Guillaume Dumas;Pierre Leguen;Isabelle Madelaine;Sylvie Chevret;Jean-Michel Molina;Elie Azoulay;Veronique Fremeaux-Bacchi | Cell Therapy and Immunotherapy;Infectious Disorders;complement | 2020-07-23 02:00:00+02:00 | 32703791 | FR;US;UNK | Saint Louis Hospital, regis.peffaultdelatour@aphp.fr.;Saint-Louis Hospital.;HEGP Hospital.;Saint Louis Hospital.;Saint-Louis University Hospital. | 1870 | ||||
| 10.1371/journal.pone.0236312 | Journal Article | en | Lung ultrasound score to monitor COVID-19 pneumonia progression in patients with ARDS. | https://www.ncbi.nlm.nih.gov/pubmed/32692769 | COVID-19 pneumonia typically begins with subpleural ground glass opacities with progressive extension on computerized tomography studies. Lung ultrasound is well suited to this interstitial, subpleural involvement, and it is now broadly used in intensive care units (ICUs). The extension and severity of lung infiltrates can be described numerically with a reproducible and validated lung ultrasound score (LUSS). We hypothesized that LUSS might be useful as a tool to non-invasively monitor the evolution of COVID-19 pneumonia at the bedside. LUSS monitoring was rapidly implemented in the management of our COVID-19 patients with RT-PCR-documented COVID-19. The LUSS was evaluated repeatedly at the bedside. We present a graphic description of the course of LUSS during COVID-19 in 10 consecutive patients admitted in our intensive care unit with moderate to severe ARDS between March 15 and 30th. LUSS appeared to be closely related to the disease progression. In successfully extubated patients, LUSS decreased and was lower than at the time of intubation. LUSS increased inexorably in a patient who died from refractory hypoxemia. LUSS helped with the diagnosis of ventilator-associated pneumonia (VAP), showing an increased score and the presence of new lung consolidations in all 5 patients with VAPs. There was also a good agreement between CT-scans and LUSS as for the presence of lung consolidations. In conclusion, our early experience suggests that LUSS monitoring accurately reflect disease progression and indicates potential usefulness for the management of COVID-19 patients with ARDS. It might help with early VAP diagnosis, mechanical ventilation weaning management, and potentially reduce the need for X-ray and CT exams. LUSS evaluation is easy to use and readily available in ICUs throughout the world, and might be a safe, cheap and simple tool to optimize critically ill COVID-19 patients care during the pandemic. | 1932-6203 | 2020-07-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Disease Progression;Female;France;Humans;Intensive Care Units;Lung__diagnostic imaging;Male;Middle Aged;Pandemics;Pneumonia, Ventilator-Associated__diagnostic imaging;Pneumonia, Viral__complications;Respiratory Distress Syndrome, Adult__virology;Tomography, X-Ray Computed;Ultrasonography;COVID-19;severe acute respiratory syndrome coronavirus 2 | PLOS ONE | Auguste Dargent;Emeric Chatelain;Louis Kreitmann;Jean-Pierre Quenot;Martin Cour;Laurent Argaud | 2020-07-21 02:00:00+02:00 | 32692769 | FR | Service de Médecine Intensive-Réanimation Médicale, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;Faculté de médecine Lyon-Est, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.;Médecine Intensive Réanimation, CHU Dijon, Dijon, France.;Université Bourgogne Franche-Comté, LNC, Dijon, France.;INSERM, LNC UMR1231, Dijon, France.;FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France. | 1873 | |||
| Agence Nationale de la Recherche | 10.3390/cancers12071992 | Journal Article | en | Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32708264 | Advanced age or preexisting comorbidities have been characterized as risk factors for severe coronavirus disease 2019 (COVID-19) cases requiring hospitalization and intensive care. In recent years, clonal hematopoiesis (CH) of indeterminate potential (CHIP) has emerged as a risk factor for chronic inflammatory background and subsequent aging-associated diseases. The purpose of this study was to identify biological factors (particularly leukocyte subtypes and inflammatory markers) associated with a risk of clinical deterioration (i.e., orotracheal intubation (OTI)) and to determine whether CH was likely to influence clinical and biological behavior in patients with severe COVID-19 requiring hospitalization. Here, we describe clinical and biological features, including the screening of CHIP mutants in a well-annotated cohort of 122 hospitalized patients with a laboratory-confirmed diagnosis of COVID-19 (55% requiring OTI). We showed that elevated white blood cell counts, especially neutrophils and high C-reactive protein (CRP) levels at admission, were associated with an increased requirement of OTI. We noticed a high prevalence of CH (25%, 38%, 56%, and 82% of patients aged <60 years, 60-70 years, 70-80 years, and >80 years) compared to a retrospective cohort of patients free of hematological malignancy explored with the same pipelines (10%, 21%, 37%, and 44%). However, the existence of CH did not significantly impact clinical outcome, including OTI or death, and did not correlate with other laboratory findings. | 2072-6694 | 2020-07-26 02:00:00+02:00 | pubmed | Cancers | Nicolas Duployez;Jordane Demonchy;Céline Berthon;Julien Goutay;Morgan Caplan;Anne-Sophie Moreau;Anne Bignon;Alice Marceau-Renaut;Delphine Garrigue;Imelda Raczkiewicz;Sandrine Geffroy;Maxime Bucci;Kazali Alidjinou;Julie Demaret;Myriam Labalette;Thierry Brousseau;Annabelle Dupont;Antoine Rauch;Julien Poissy;Sophie Susen;Claude Preudhomme;Bruno Quesnel | CHIP;COVID-19;DNMT3A;SARS-CoV-2;TET2;clonal hematopoiesis;sequencing | 2020-07-21 02:00:00+02:00 | 32708264 | FR | [{"country": "", "agency": "Agence Nationale de la Recherche", "grantid": "I-SITE ULNE/ANR-16-IDEX-0004 ULNE"}] | UMR 9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France.;Department of Hematology, CHU Lille, F-59000 Lille, France.;Department of Intensive Care, CHU Lille, F-59000 Lille, France.;Department of Anesthesia and Critical Care, CHU Lille, F-59000 Lille, France.;Department of Emergency, CHU Lille, F-59000 Lille, France.;Department of Virology, CHU Lille, F-59000 Lille, France.;Department of Immunology, CHU Lille, F-59000 Lille, France.;Department of Biochemistry, CHU Lille, F-59000 Lille, France.;UMR1011-EGID, Pasteur Institute of Lille, University Lille, Inserm, CHU Lille, F-59000 Lille, France.;Department of Hemostasis, CHU Lille, F-59000 Lille, France. | 1874 | |
| 10.3389/fimmu.2020.01714 | Journal Article;Research Support, Non-U.S. Gov't | en | COVID-19: Underlying Adipokine Storm and Angiotensin 1-7 Umbrella. | https://www.ncbi.nlm.nih.gov/pubmed/32793244 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus leading to a global health outbreak. Despite the high mortality rates from SARS-CoV-1 and Middle-East respiratory syndrome (MERS)-CoV infections, which both sparked the interest of the scientific community, the underlying physiopathology of the SARS-CoV-2 infection, remains partially unclear. SARS-CoV-2 shares similar features with SARS-CoV-1, notably the use of the angiotensin conversion enzyme 2 (ACE2) as a receptor to enter the host cells. However, some features of the SARS-CoV-2 pandemic are unique. In this work, we focus on the association between obesity, metabolic syndrome, and type 2 diabetes on the one hand, and the severity of COVID-19 infection on the other, as it seems greater in these patients. We discuss how adipocyte dysfunction leads to a specific immune environment that predisposes obese patients to respiratory failure during COVID-19. We also hypothesize that an ACE2-cleaved protein, angiotensin 1-7, has a beneficial action on immune deregulation and that its low expression during the SARS-CoV-2 infection could explain the severity of infection. This introduces angiotensin 1-7 as a potential candidate of interest in therapeutic research on CoV infections. | 1664-3224 | 2020-07-26 02:00:00+02:00 | pubmed | Adipokines__blood;Angiotensin I__immunology;Betacoronavirus__immunology;Coronavirus Infections__pathology;Diabetes Mellitus, Type 2__immunology;Humans;Metabolic Syndrome__immunology;Obesity__immunology;Pandemics;Peptide Fragments__immunology;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__pathology;Severe Acute Respiratory Syndrome__pathology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Frontiers in Immunology | Geoffroy Méry;Olivier Epaulard;Anne-Laure Borel;Bertrand Toussaint;Audrey Le Gouellec | ACE2;SARS-CoV;adipocyte;coronavirus;inflammation;metabolic syndrome;obesity | 2020-07-21 02:00:00+02:00 | 32793244 | FR | Service Hospitalier Universitaire de Pneumologie Physiologie, CHU Grenoble-Alpes, La Tronche, France.;Service de Maladies Infectieuses et Tropicales, CHU Grenoble-Alpes, La Tronche, France.;Groupe de Recherche en Infectiologie Clinique, Université Grenoble Alpes, La Tronche, France.;UMR 5075-Institut de Biologie Structurale, Grenoble, France.;Service de Nutrition, Pole DIGIDUNE, CHU Grenoble-Alpes, La Tronche, France.;Hypoxia PathoPhysiology Laboratory, INSERM U1042, University Grenoble Alpes, La Tronche, France.;Laboratoire TIMC-TheREx UMR 5525 CNRS-Université Grenoble Alpes, La Tronche, France.;Service de Biochimie Biologie Moléculaire Toxicologie Environnementale, UM Biochimie des Enzymes et des Protéines, Institut de Biologie et Pathologie, C.H.U. Grenoble-Alpes, La Tronche, France. | 1877 | ||
| 10.1126/science.abc9004 | Journal Article | en | Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions. | https://www.ncbi.nlm.nih.gov/pubmed/32694200 | Studies of novel coronavirus disease (COVID-19) have reported varying estimates of epidemiological parameters including serial interval distributions, i.e., the time between illness onset in successive cases in a transmission chain, and reproduction numbers. By compiling a line-list database of transmission pairs in mainland China, we show that mean serial intervals of COVID-19 have shortened substantially from 7.8 days to 2.6 days within a month (January 9 to February 13, 2020). This change is driven by enhanced non-pharmaceutical interventions, in particular case isolation. We also show that using real-time estimation of serial intervals allowing for variation over time, provides more accurate estimates of reproduction numbers than using conventionally fixed serial interval distributions. These findings could improve assessment of transmission dynamics, forecasting future incidence, and estimating the impact of control measures. | 0036-8075,1095-9203 | 2020-07-26 02:00:00+02:00 | pubmed | Science | Sheikh Taslim Ali;Lin Wang;Eric H Y Lau;Xiao-Ke Xu;Zhanwei Du;Ye Wu;Gabriel M Leung;Benjamin J Cowling | 2020-07-21 02:00:00+02:00 | 32694200 | FR;CN;GB;US;HK | WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.;Department of Genetics, University of Cambridge, Cambridge CB2 3EH, UK.;Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris 75015, France.;College of Information and Communication Engineering, Dalian Minzu University, Dalian 116600, China.;Department of Integrative Biology, University of Texas at Austin, Austin, TX 78705, USA.;School of Journalism and Communication, Beijing Normal University, Beijing 100875, China.;Computational Communication Research Center, Beijing Normal University, Zhuhai 519087, China.;WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China. bcowling@hku.hk. | 1878 | ||||
| 10.1164/rccm.202005-1945le | Journal Article | en | Fungal Infection During COVID-19: Does Aspergillus Mean Secondary Invasive Aspergillosis? | https://www.ncbi.nlm.nih.gov/pubmed/32687389 | 1073-449X,1535-4970 | 2020-07-26 02:00:00+02:00 | pubmed | American Journal of Respiratory and Critical Care Medicine | Arnaud Fekkar;Corentin Poignon;Marion Blaize;Alexandre Lampros | Aspergillus fumigatus;SARS-CoV-2;broncho-alveolar lavage;galactomannan;intensive care unit | 2020-07-20 02:00:00+02:00 | 32687389 | FR | Hôpital de La Pitié-Salpêtrière, Parasitology Mycology, Paris, France, arnaud.fekkar@aphp.fr.;Hôpital de La Pitié-Salpêtrière, Parasitology Mycology, Paris, France. | 1882 | ||||
| 10.1093/aje/kwaa151 | Journal Article | en | RE: EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED-UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS. | https://www.ncbi.nlm.nih.gov/pubmed/32685975 | 0002-9262,1476-6256 | 2020-07-26 02:00:00+02:00 | pubmed | American Journal of Epidemiology | Nathan Peiffer-Smadja;Dominique Costagliola | 2020-07-20 02:00:00+02:00 | 32685975 | FR | Université de Paris, INSERM, IAME, AP-HP, Service de maladies Infectieuses et tropicales, Hôpital Bichat Claude Bernard, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France. | 1884 | |||||
| 10.1007/s42399-020-00417-7 | Journal Article;Review | en | Coronavirus Disease 2019 (COVID-19) as a Multi-Systemic Disease and its Impact in Low- and Middle-Income Countries (LMICs). | https://www.ncbi.nlm.nih.gov/pubmed/32838173 | Currently, the coronavirus disease 2019 (COVID-19) is the priority of the global health agenda. Since the first case was reported in Wuhan, China, this infection has continued to spread and has been considered as a pandemic by the World Health Organization (WHO) within 3 months of its outbreak. Several studies have been done to better understand the pathogenesis and clinical aspects of the disease. It appears that COVID-19 affects almost all body organs due to the direct effect of the virus and its induced widespread inflammatory response. This multi-systemic aspect of the disease has to be inculcated in COVID-19 management by health providers to improve patient outcomes. This strategy could help curb the burden of the disease especially in low- and middle-income countries (LMICs) like most African countries where the pandemic is at an "embryonic" stage. | 2523-8973 | 2020-07-26 02:00:00+02:00 | pubmed | SN Comprehensive Clinical Medicine | Mazou Ngou Temgoua;Francky Teddy Endomba;Jan René Nkeck;Gabin Ulrich Kenfack;Joel Noutakdie Tochie;Mickael Essouma | Coronavirus disease 2019;Low- and middle-income countries;Multi-systemic disease;Therapeutical implication | 2020-07-20 02:00:00+02:00 | 32838173 | FR;CM | Department of Internal Medicine and Specialities, Faculty of Medicine and Biomedical Sciences, University of Yaounde, Yaoundé, Cameroon.;Psychiatry Internship Program, University of Bourgogne, 21000 Dijon, France.;Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine and Biomedical Sciences, University of Yaounde, Yaoundé, Cameroon. | 1885 | |||
| 10.1128/jcm.01233-20 | Comparative Study;Evaluation Study;Journal Article;Research Support, Non-U.S. Gov't | en | Evaluation of the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech. | https://www.ncbi.nlm.nih.gov/pubmed/32518071 | While the coronavirus disease 2019 (COVID-19) pandemic has peaked in many countries already, the current challenge is to assess population immunity on a large scale. Many serological tests are available and require urgent independent validation. Here, we report performance characteristics of Orient Gene Biotech COVID-19 IgG/IgM Rapid Test Cassette (OG) and compare it to Abbott SARS-CoV-2 IgG immunoassay (ASIA). Patients (n = 102) with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase PCR (RT-PCR) were tested. The patients were asymptomatic (n = 2) or had mild (n = 37) or severe symptoms requiring hospitalization in a medical unit (n = 35) or intensive care unit (n = 28). Specificity was evaluated for 42 patients with previous viral and parasitic diseases as well as a high level of rheumatic factor. The sensitivity of OG was 95.8% (95% confidence interval [CI95%], 89.6 to 98.8) for samples collected ≥10 days after the onset of symptoms, which was equivalent to the sensitivity of ASIA of 90.5% (CI95%, 82.8 to 95.6). OG uncovered six false-negative results of ASIA, of which two had only IgM with OG. Specificity was 100% (CI95%, 93.4 to 100) with both tests on samples, including patients infected with endemic coronavirus. Overall, OG performance characteristics indicate that the test is suitable for routine use in clinical laboratories, and its performance is equivalent to that of immunoassay. Testing OG on a larger asymptomatic population may be needed to confirm these results. | 0095-1137,1098-660X | 2020-07-26 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Antibodies, Viral__blood;Betacoronavirus__immunology;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Female;Humans;Immunoglobulin G__blood;Immunoglobulin M__blood;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;Point-of-Care Testing;Sensitivity and Specificity;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Clinical Microbiology | Sarah Dellière;Maud Salmona;Marine Minier;Audrey Gabassi;Alexandre Alanio;Jérôme Le Goff;Constance Delaugerre;Marie-Laure Chaix | COVID-19;lateral flow assay;rapid test | 2020-07-23 02:00:00+02:00 | 32518071 | FR | Université de Paris, Département des Agents Infectieux, Service de Parasitologie-Mycologie, Hôpital Saint-Louis, Paris, France sarah.delliere@aphp.fr.;Université de Paris, Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Paris, France.;INSERM UMR 976, Université de Paris, Paris, France.;Université de Paris, Département des Agents Infectieux, Service de Parasitologie-Mycologie, Hôpital Saint-Louis, Paris, France.;INSERM UMR 944, Université de Paris, Paris, France. | 1888 | ||
| 10.1007/s11239-020-02231-3 | Journal Article;Review | en | Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32696172 | A common and potent consideration has recently entered the landscape of the novel coronavirus disease of 2019 (COVID-19): venous thromboembolism (VTE). COVID-19 has been associated to a distinctive related coagulopathy that shows unique characteristics. The research community has risen to the challenges posed by this « evolving COVID-19 coagulopathy » and has made unprecedented efforts to promptly address its distinct characteristics. In such difficult time, both national and international societies of thrombosis and hemostasis released prompt and timely responses to guide recognition and management of COVID-19-related coagulopathy. However, latest guidelines released by the international Society on Thrombosis and Haemostasis (ISTH) on May 27, 2020, followed the American College of Chest Physicians (CHEST) on June 2, 2020 showed some discrepancies regarding thromboprophylaxis use. In this forum article, we would like to offer an updated focus on thromboprophylaxis with current incidence of VTE in ICU and non-ICU patients according to recent published studies; highlight the main differences regarding ISTH and CHEST guidelines; summarize and describe which are the key ongoing RCTs testing different anticoagulation strategies in patients with COVID-19; and finally set a proposal for COVID-19 coagulopathy specific risk factors and dedicated trials. | 0929-5305,1573-742X | 2020-07-26 02:00:00+02:00 | pubmed | Journal of Thrombosis and Thrombolysis | Benjamin Marchandot;Antonin Trimaille;Anais Curtiaud;Kensuke Matsushita;Laurence Jesel;Olivier Morel | COVID-19;Coronavirus;Guidelines;Thromboprophylaxis;Venous thromboembolism | 2020-07-21 02:00:00+02:00 | 32696172 | FR;US | Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, 1 place de l'Hôpital, 67000, Strasbourg, France.;INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, 67000, Strasbourg, France.;Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, 1 place de l'Hôpital, 67000, Strasbourg, France. olivier.morel@chru-strasbourg.fr.;INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, 67000, Strasbourg, France. olivier.morel@chru-strasbourg.fr. | 1889 | |||
| 10.1007/s10311-020-01054-1 | Editorial | en | Unprotected mothers and infants breastfeeding in public amenities during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32837483 | 1610-3653,1610-3661 | 2020-07-26 02:00:00+02:00 | pubmed | Environmental Chemistry Letters | Xue Wang;Jie Han;Eric Lichtfouse | 2020-07-21 02:00:00+02:00 | 32837483 | FR;CN | Department of Environmental Science and Engineering, Xi'an Jiaotong University, Xi'an, 710049 Shaanxi People's Republic of China.;Aix-Marseille University, CNRS, IRD, INRAE, Coll France, CEREGE, 13100 Aix en Provence, France.;State Key Laboratory of Multiphase Flow in Power Engineering, Xi'an Jiaotong University, Xi'an, 710049 Shaanxi People's Republic of China. | 1890 | |||||
| 10.1177/0145561320940117 | Editorial | en | MRI of Patients Infected With COVID-19 Revealed Cervical Lymphadenopathy. | https://www.ncbi.nlm.nih.gov/pubmed/32703030 | 0145-5613,1942-7522 | 2020-07-26 02:00:00+02:00 | pubmed | Ear, Nose & Throat Journal | Lea Distinguin;Amine Ammar;Jerome R Lechien;Annaelle Chetrit;Younes Chekkoury Idrissi;Marta Circiu;Sven Saussez;Najete Berradja;Myriam Edjlali;Robert Carlier;Stephane Hans | 2020-07-23 02:00:00+02:00 | 32703030 | FR;BE | Department of Otolaryngology-Head Neck Surgery, Foch Hospital, Paris Saclay University, Paris, France.;Department of Radiology, APHP, Hôpitaux R. Poincaré-Ambroise Paré, DMU Smart Imaging, GH Université Paris-Saclay, U 1179 UVSQ/Paris-Saclay, Paris, France.;Department of Anatomy, University of Mons (UMons), Mons, Belgium.;Department of Otolaryngology-Head Neck Surgery, CHU de Bruxelles (Saint-Pierre), Université Libre de Bruxelles, Brussels, Belgium.;Department of Neuroradiology, Centre Hospitalier Sainte-Anne, Paris, France. | 1896 | |||||
| 10.1007/s12250-020-00265-8 | Journal Article | en | Mild Cytokine Elevation, Moderate CD4+ T Cell Response and Abundant Antibody Production in Children with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32699972 | Children with Coronavirus Disease 2019 (COVID-19) were reported to show milder symptoms and better prognosis than their adult counterparts, but the difference of immune response against SARS-CoV-2 between children and adults hasn't been reported. Therefore we initiated this study to figure out the features of immune response in children with COVID-19. Sera and whole blood cells from 19 children with COVID-19 during different phases after disease onset were collected. The cytokine concentrations, SARS-CoV-2 S-RBD or N-specific antibodies and T cell immune responses were detected respectively. In children with COVID-19, only 3 of 12 cytokines were increased in acute sera, including interferon (IFN)-γ-induced protein 10 (IP10), interleukin (IL)-10 and IL-16. We observed an increase in T helper (Th)-2 cells and a suppression in regulatory T cells (Treg) in patients during acute phase, but no significant response was found in the IFN-γ-producing or tumor necrosis factor (TNF)-α-producing CD8+ T cells in patients. S-RBD and N IgM showed an early induction, while S-RBD and N IgG were prominently induced later in convalescent phase. Potent S-RBD IgA response was observed but N IgA seemed to be inconspicuous. Children with COVID-19 displayed an immunophenotype that is less inflammatory than adults, including unremarkable cytokine elevation, moderate CD4+ T cell response and inactive CD8+ T cell response, but their humoral immunity against SARS-CoV-2 were as strong as adults. Our finding presented immunological characteristics of children with COVID-19 and might give some clues as to why children develop less severe disease than adults. | 1674-0769,1995-820X | 2020-07-26 02:00:00+02:00 | pubmed | Virologica Sinica | Ran Jia;Xiangshi Wang;Pengcheng Liu;Xiaozhen Liang;Yanling Ge;He Tian;Hailing Chang;Hao Zhou;Mei Zeng;Jin Xu | Antibody dynamics;COVID-19;Cytokine;SARS-CoV-2;T cell immune response | 2020-07-22 02:00:00+02:00 | 32699972 | FR;CN | Department of Clinical Laboratory, Children's Hospital of Fudan University, Shanghai, 201102, China.;Department of Infectious Diseases, Children's Hospital of Fudan University, Shanghai, 201102, China.;Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.;Shanghai Kehua Bio-Engineering Co., Ltd., Shanghai 200233, China.;Department of Clinical Laboratory, Children's Hospital of Fudan University, Shanghai, 201102, China. jinxu_125@163.com. | 1903 | |||
| 10.1073/pnas.2009017117 | Journal Article | en | Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32699149 | Around the tenth day after diagnosis, ∼20% of patients with coronavirus disease 2019 (COVID-19)-associated pneumonia evolve toward severe oxygen dependence (stage 2b) and acute respiratory distress syndrome (stage 3) associated with systemic inflammation often termed a "cytokine storm." Because interleukin-1 (IL-1) blocks the production of IL-6 and other proinflammatory cytokines, we treated COVID-19 patients early in the disease with the IL-1 receptor antagonist, anakinra. We retrospectively compared 22 patients from three different centers in France with stages 2b and 3 COVID-19-associated pneumonia presenting with acute severe respiratory failure and systemic inflammation who received either standard-of-care treatment alone (10 patients) or combined with intravenous anakinra (12 patients). Treatment started at 300 mg⋅d-1 for 5 d, then tapered with lower dosing over 3 d. Both populations were comparable for age, comorbidities, clinical stage, and elevated biomarkers of systemic inflammation. All of the patients treated with anakinra improved clinically (P < 0.01), with no deaths, significant decreases in oxygen requirements (P < 0.05), and more days without invasive mechanical ventilation (P < 0.06), compared with the control group. The effect of anakinra was rapid, as judged by significant decrease of fever and C-reactive protein at day 3. A mean total dose of 1,950 mg was infused with no adverse side effects or bacterial infection. We conclude that early blockade of the IL-1 receptor is therapeutic in acute hyperinflammatory respiratory failure in COVID-19 patients. | 0027-8424,1091-6490 | 2020-07-26 02:00:00+02:00 | pubmed | Proceedings of the National Academy of Sciences | Raphaël Cauchois;Marie Koubi;David Delarbre;Cécile Manet;Julien Carvelli;Valery Benjamin Blasco;Rodolphe Jean;Louis Fouche;Charleric Bornet;Vanessa Pauly;Karin Mazodier;Vincent Pestre;Pierre-André Jarrot;Charles A Dinarello;Gilles Kaplanski | COVID-19;anakinra;interleukin-1;pneumonia | 2020-07-22 02:00:00+02:00 | 32699149 | FR;US | Division of Clinical Immunology, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France.;Division of Internal Medicine, L'hôpital d'Instruction des Armées Sainte Anne, 83000 Toulon, France.;Division of Internal Medicine, Centre Hospitalier Henri Duffaut, 84000 Avignon, France.;Réanimation des Urgences, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France.;Réanimation Polyvalente des Pathologies du Foie, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France.;Réanimation des Brûlés, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France.;Pharmacy, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France.;Department of Medical Information, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France.;Department of Medicine, University of Colorado, Aurora, CO 80045 cdinare333@aol.com gilles.kaplanski@ap-hm.fr.;Division of Clinical Immunology, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France, cdinare333@aol.com gilles.kaplanski@ap-hm.fr. | 1904 | |||
| Amiens University Hospital | 10.1111/bcp.14489 | Journal Article | en | Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32692462 | It is not known whether the adverse events (AEs) associated with the administration of lopinavir and ritonavir (LPV/r) in the treatment of COVID-19 are concentration-dependent. In a retrospective study of 65 patients treated with LPV/r and therapeutic drug monitoring (TDM) for severe forms of COVID-19 (median age: 67; males: 41 [63.1%]), 33 (50.8%) displayed a grade ≥2 increase in plasma levels of hepatobiliary markers, lipase and/or triglycerides. A causal relationship between LPV/r and the AE was suspected in 9 of the 65 patients (13.8%). At 400 mg b.i.d., the plasma trough concentrations of LPV/r were high and showed marked interindividual variability (median [interquartile range]: 16,600 [11,430-20,842] ng/ml for lopinavir and 501 [247-891] ng/ml for ritonavir). The trough lopinavir concentration was negatively correlated with body mass index, while the trough ritonavir concentration was positively correlated with age and negatively correlated with prothrombin activity. However, the occurrence of abnormal laboratory values was not associated with higher trough plasma concentrations of LPV/r. Further studies will be needed to determine the value of TDM in LPV/r-treated patients with COVID-19. | 0306-5251,1365-2125 | 2020-07-26 02:00:00+02:00 | pubmed | British Journal of Clinical Pharmacology | Benjamin Batteux;Sandra Bodeau;Valérie Gras-Champel;Sophie Liabeuf;Jean-Philippe Lanoix;Jean-Luc Schmit;Claire Andréjak;Yoann Zerbib;Guillaume Haye;Kamel Masmoudi;Anne-Sophie Lemaire-Hurtel;Youssef Bennis | adverse drug reactions;antiretroviral drug;hepatotoxicity;pharmacovigilance;therapeutic drug monitoring | 2020-07-21 02:00:00+02:00 | 32692462 | FR | [{"country": "", "agency": "Amiens University Hospital"}] | Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France.;MP3CV laboratory, EA 7517, Jules Verne University of Picardie, Amiens, France.;Department of Clinical Research, Amiens University Hospital, Amiens, France.;Department of Infectious Diseases, Amiens University Hospital, Amiens, France.;AGIR, EA 4294, Jules Verne University of Picardie, Amiens, France.;Department of Pulmonology, Amiens University Hospital, Amiens, France.;Department of Intensive Care and BoReal study group, Amiens University Hospital, Amiens, France.;Department of Anaesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France. | 1908 | |
| 10.1093/ageing/afaa092 | Journal Article | en | COVID-19 outbreak: organisation of a geriatric assessment and coordination unit. A French example. | https://www.ncbi.nlm.nih.gov/pubmed/32725209 | Older people are particularly affected by the COVID-19 outbreak because of their vulnerability as well as the complexity of health organisations, particularly in the often-compartmentalised interactions between community, hospital and nursing home actors. In this endemic situation, with massive flows of patients requiring holistic management including specific and intensive care, the appropriate assessment of each patient's level of care and the organisation of specific networks is essential. To that end, we propose here a territorial organisation of health care, favouring communication between all actors. This organisation of care is based on three key points: To use the basis of territorial organisation of health by facilitating the link between hospital settings and geriatric sectors at the regional level.To connect private, medico-social and hospital actors through a dedicated centralised unit for evaluation, geriatric coordination of care and decision support. A geriatrician coordinates this multidisciplinary unit. It includes an emergency room doctor, a supervisor from the medical regulation centre (Centre 15), an infectious disease physician, a medical hygienist and a palliative care specialist.To organise an ad hoc follow-up channel, including the necessary resources for the different levels of care required, according to the resources of the territorial network, and the creation of a specific COVID geriatric palliative care service. This organisation meets the urgent health needs of all stakeholders, facilitating its deployment and allows the sustainable implementation of a coordinated geriatric management dynamic between the stakeholders on the territory. | 0002-0729,1468-2834 | 2020-08-02 02:00:00+02:00 | pubmed | Aged;Betacoronavirus__isolation & purification;Community Networks__organization & administration;Coronavirus Infections__epidemiology;France__epidemiology;Geriatric Assessment__methods;Health Care Rationing__trends;Health Services for the Aged__ethics;Humans;Organizational Innovation;Palliative Care__methods;Pandemics__prevention & control;Patient Care Management__ethics;Pneumonia, Viral__epidemiology;Regional Medical Programs__organization & administration;Semantic Web;Stakeholder Participation;COVID-19;severe acute respiratory syndrome coronavirus 2 | Age and Ageing | Séverine Koeberle;Thomas Tannou;Kévin Bouiller;Nicolas Becoulet;Justin Outrey;Catherine Chirouze;Régis Aubry | COVID-19;decision-making;ethics;geriatrics;healthcare organisation;older people;palliative care | 2020-07-30 02:00:00+02:00 | 32725209 | FR;CA | Geriatrics Department, CHU, Besançon, France.;"Ethics and Medical Progress" reseach team, INSERM CIC 1431, CHU Besançon, France.;EA 481 Neurosciences, Université de Franche-comté, Besançon, France.;Research Centre, Geriatric University Institute of Montreal (IUGM), Montréal, Qc, Canada.;Infectious Disease Department, CHU de Besançon, Besançon, France.;Palliative Care Department, CHU de Besançon, Besançon, France.;Emergency Department, CHU de Besançon, Besançon, France.;Laboratoire Chrono-environnement - UMR 6249 CNRS-UFC, Besançon, France. | 1913 | ||
| Letter;Comment | en | Impact of COVID-19 lockdown on adherence to continuous positive airway pressure by obstructive sleep apnoea patients. | https://www.ncbi.nlm.nih.gov/pubmed/32430426 | 2020-08-02 02:00:00+02:00 | pubmed | Betacoronavirus;Continuous Positive Airway Pressure;Coronavirus Infections;Data Analysis;Humans;Pandemics;Pneumonia, Viral;Sleep Apnea, Obstructive;COVID-19;severe acute respiratory syndrome coronavirus 2 | David Attias;Jean Louis Pepin;Atul Pathak | 2020-07-30 02:00:00+02:00 | 32430426 | FR;MC | Dept of Pulmonary and Sleep Medicine, Clinique Pasteur, Toulouse, France.;HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France.;Dept of Cardiovascular Medicine, Princess Grace Hospital, Monaco, Monaco atul.pathak@chpg.mc. | 1921 | |||||||
| World Health Organization | 10.1148/radiol.2020203173 | Journal Article | en | Use of Chest Imaging in the Diagnosis and Management of COVID-19: A WHO Rapid Advice Guide. | https://www.ncbi.nlm.nih.gov/pubmed/32729811 | The World Health Organization (WHO) undertook the development of a rapid guide on the use of chest imaging in the diagnosis and management of COVID-19. The rapid guide was developed over two months using standard WHO processes, except for the use of 'rapid reviews' and online meetings of the panel. The evidence review was supplemented by a survey of stakeholders regarding their views on the acceptability, feasibility, impact on equity and resource use of the relevant chest imaging modalities (chest radiography, chest CT and lung ultrasound). The guideline development group had broad expertise and country representation. The rapid guide includes three diagnosis recommendations and four management recommendations. The recommendations cover patients with suspected or confirmed COVID-19 with different levels of disease severity, throughout the care pathway from outpatient facility or hospital entry, to home discharge. All recommendations are conditional and are based on low certainty evidence (n=2), very low certainty evidence (n=2), or expert opinion (n=3). The remarks accompanying the recommendations suggest which patients are likely to benefit from chest imaging and what factors should be considered when choosing the specific imaging modality. The guidance also offers considerations about implementation, monitoring and evaluation, and identifies research needs. | 0033-8419,1527-1315 | 2020-08-02 02:00:00+02:00 | pubmed | Radiology | Elie A Akl;Ivana Blazic;Sally Yaacoub;Guy Frija;Roger Chou;John Adabie Appiah;Mansoor Fatehi;Nicola Flor;Eveline Hitti;Hussain Jafri;Zheng-Yu Jin;Hans Ulrich Kauczor;Michael Kawooya;Ella Annabelle Kazerooni;Jane P Ko;Rami Mahfouz;Valdair Muglia;Rose Nyabanda;Marcelo Sanchez;Priya B Shete;Marina Ulla;Chuansheng Zheng;Emilie van Deventer;Maria Del Rosario Perez | 2020-07-30 02:00:00+02:00 | 32729811 | FR;AR;KE;GH;CN;LB;UG;CH;US;GB;BR;IT;IR;RS;ES;PK;DE | [{"country": "International", "agency": "World Health Organization", "grantid": "001"}] | From the Department of Internal Medicine, American University of Beirut Beirut, Lebanon (E.A.K.), Clinical Hospital Centre, Zemun, Belgrade, Serbia (I.B.), Clinical Research Institute (CRI), American University of Beirut Beirut, Lebanon (S.Y.), Paris Descartes University Paris, France (G.F.), Oregon Health & Science University Portland, OR (R.C.), Komfo Anokye Teaching Hospital, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana (J.A.A.), Department of Imaging Informatics, Virtual University of Medical Sciences, Tehran, Iran (M.F.), L. Sacco, University Hospital Milan, Italy (N.F.), Department of Emergency Medicine, American University of Beirut Beirut, Lebanon (E.H.), WHO Patients for Patient Safety Program Advisory Group, Fatima Jinnah Medical University Lahore, Pakistan (H.J.), Department of Radiology PUMC Hospital Beijing Beijing, China (Z.Y.J.), Department of Diagnostic and Interventional Radiology, Translational Pneumology, Heidelberg University Hospital, Translational lung Research Center Heidelberg member of the German Center of Lung Research, Heidelberg, Germany (H.U.K.), Ernest Cook Ultrasound Research and Education Institute Kampala, Uganda (M.K.), Departments of Radiology & Internal Medicine, University of Michigan / Michigan Medicine Ann Arbor, Michigan, USA (E.A.K.), Department of Radiology, NYU Langone Health New York, NY 10016 (J.P.K.), Department of Pathology and Laboratory Medicine, American University of Beirut Beirut, Lebanon (R.M.), Imaging, Radiation Therapy and Oncohematology Department Ribeirao Preto, Sao Paulo, Brazil (V.M.), Radiology Department. Kenyatta National Hospital Nairobi, Kenya (R.N.), Radiology Department.CDI.Hospital Clinic. University of Barcelona Barcelona, Spain (M.S.), Division of Pulmonary and Critical Care Medicine, University of California San Francisco San Francisco, CA, USA (P.B.S.), Imaging Department, Hospital Italiano de Buenos Aires. Buenos Aires, Argentina. (M.U.), Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, China (C.Z.), World Health Organization, Department of Environment, Climate Change and Health (ECH), Radiation and Health Unit Geneva, Switzerland (E.V.D.), World Health Organization, Department of Environment, Climate Change and Health (ECH), Radiation and Health Unit Geneva, Switzerland (M.D.R.P.). | 1924 | ||
| 10.1007/s10072-020-04632-x | Journal Article | en | Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32734396 | The relationship between dyspnea and COVID-19 is unknown. In COVID-19 patients, the higher prevalence of neurological symptoms and the lack of dyspnea may suggest common underlying pathogenetic mechanisms. The aim of this preliminary study is to address whether there is a lack of dyspnea in COVID-19 patients and if there is a relationship between neurological symptoms and the perception of dyspnea. | 1590-1874,1590-3478 | 2020-08-02 02:00:00+02:00 | pubmed | Neurological Sciences | Josuel Ora;Claudio Liguori;Ermanno Puxeddu;Angelo Coppola;Matteo Matino;Mariangela Pierantozzi;Nicola Biagio Mercuri;Paola Rogliani | COVID-19;Dyspnea;arterial blood gas;dyspnea descriptors | 2020-07-30 02:00:00+02:00 | 32734396 | FR;IT | Respiratory Medicine Unit, University Hospital Policlinico Tor Vergata, Rome, Italy.;Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.;Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.;Experimental Neurology, IRCCS Santa Lucia Foundation, Rome, Italy.;Respiratory Medicine Unit, University Hospital Policlinico Tor Vergata, Rome, Italy. paola.rogliani@uniroma2.it.;Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. paola.rogliani@uniroma2.it. | 1934 | |||
| Letter | en | Magnetic resonance imaging of COVID-19 anosmic patients reveals abnormalities of the olfactory bulb: Preliminary prospective study. | https://www.ncbi.nlm.nih.gov/pubmed/32739489 | 2020-08-02 02:00:00+02:00 | pubmed | Annaelle Chetrit;Jerome R Lechien;Amine Ammar;Younes Chekkoury-Idrissi;Lea Distinguin;Marta Circiu;Sven Saussez;Marie-Christine Ballester;Marc Vasse;Najete Berradja;Stephane Hans;Robert Carlier;Myriam Edjlali | Anosmia;COVID-19;Coronavirus;Imaging;MRI;Olfaction;Olfactory;Smell | 2020-07-30 02:00:00+02:00 | 32739489 | FR;BE | Department of Radiology, APHP, Hôpitaux R. Poincaré-Ambroise Paré, DMU Smart Imaging, GH Université Paris-Saclay, U 1179 UVSQ/Paris-Saclay, Paris, France.;Department of Otolaryngology-Head & Neck Surgery, Hopital Foch, Paris Saclay University, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France, Department of Otolaryngology-Head & Neck Surgery, CHU Saint-Pierre (CHU de Bruxelles), Université Libre de Bruxelles, Brussels, Belgium, Department of Human Anatomy and Experimental Oncology, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium. Electronic address: Jerome.Lechien@umons.ac.be.;Department of Otolaryngology-Head & Neck Surgery, Hopital Foch, Paris Saclay University, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otolaryngology-Head & Neck Surgery, CHU Saint-Pierre (CHU de Bruxelles), Université Libre de Bruxelles, Brussels, Belgium, Department of Human Anatomy and Experimental Oncology, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Emergency, Hopital Foch, Paris Saclay University, Paris, France.;Department of Biology, Hopital Foch, Paris Saclay University, Paris, France.;Department of Radiology, APHP, Hôpitaux R. Poincaré-Ambroise Paré, DMU Smart Imaging, GH Université Paris-Saclay, U 1179 UVSQ/Paris-Saclay, Paris, France, Department of Neuroradiology, Université Paris-Descartes-Sorbonne-Paris-Cité, IMABRAIN-INSERM-UMR1266, DHU-Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France. | 1935 | |||||||
| Editorial;Comment | en | Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? | https://www.ncbi.nlm.nih.gov/pubmed/32554538 | 2020-08-02 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Endothelial Cells;Humans;Intensive Care Units;Pandemics;Pneumonia, Viral__epidemiology;Venous Thromboembolism;COVID-19;severe acute respiratory syndrome coronavirus 2 | Alice Huertas;David Montani;Laurent Savale;Jérémie Pichon;Ly Tu;Florence Parent;Christophe Guignabert;Marc Humbert | 2020-07-30 02:00:00+02:00 | 32554538 | FR | Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France alice.huertas@inserm.fr.;INSERM UMR_S 999 «Pulmonary Hypertension: Pathophysiology and Novel Therapies», Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France. | 1937 | |||||||
| 10.1212/wnl.0000000000010537 | Journal Article | en | Critical illness-associated cerebral microbleeds in COVID-19 acute respiratory distress syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32727834 | 0028-3878,1526-632X | 2020-08-02 02:00:00+02:00 | pubmed | Neurology | Octave Cannac;Laurent Martinez-Almoyna;Sami Hraiech | 2020-07-29 02:00:00+02:00 | 32727834 | FR | From the Assistance Publique-Hôpitaux de Marseille (O.C., S.H.), Hôpital Nord, Médecine Intensive Réanimation, Aix-Marseille Université (O.C., S.H.), Faculté de médecine, Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, and Assistance Publique-Hôpitaux de Marseille (L.M.-A.), Hôpital Nord, Pôle de Neurosciences Cliniques, Service de Neurochirurgie, Marseille, France.;From the Assistance Publique-Hôpitaux de Marseille (O.C., S.H.), Hôpital Nord, Médecine Intensive Réanimation, Aix-Marseille Université (O.C., S.H.), Faculté de médecine, Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, and Assistance Publique-Hôpitaux de Marseille (L.M.-A.), Hôpital Nord, Pôle de Neurosciences Cliniques, Service de Neurochirurgie, Marseille, France. laurent.martinez-almoyna@ap-hm.fr. | 1939 | |||||
| 10.1016/j.ejogrb.2020.07.050 | Journal Article | en | First follow-up of art pregnancies in the context of the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32805629 | The aims of this study were to follow up the monitoring, health and anxiety from women who became pregnant after an embryo transfer or a intrauterine insemination during the COVID-19 epidemic in France STUDY DESIGN: This is a single centre, retrospective study from December 2019 to March 2020 based on a phone call interview using a specific questionnaire sheet specially developed for this study. Questionnaires from 104 pregnant women were completed and descriptive data are then analyzed. | 0301-2115 | 2020-08-02 02:00:00+02:00 | pubmed | European Journal of Obstetrics & Gynecology and Reproductive Biology | Anne Mayeur;Olivier Binois;Vanessa Gallot;Laetitia Hesters;Alexandra Benoit;Anne Oppenheimer;Marion Presse;Faycal Zeghari;Jonas BenguigUi;Michael Grynberg;Nelly Frydman;Charlotte Sonigo | ART Pregnancies;COVID-19;Follow-up;SARS-CoV-2 | 2020-07-31 02:00:00+02:00 | 32805629 | FR | Reproductive Biology Unit CECOS, Paris-Saclay University, Antoine Béclère Hospital, APHP, Clamart 92140, France. Electronic address: anne.mayeur@aphp.fr.;Reproductive Biology Unit CECOS, Paris-Saclay University, Antoine Béclère Hospital, APHP, Clamart 92140, France.;Reproductive Biology Unit CECOS, Paris-Saclay University, Antoine Béclère Hospital, APHP, Clamart 92140, France, Department of Reproductive Medicine and Fertility Preservation, Paris-Saclay University, Antoine Béclère Hospital, APHP, Clamart 92140, France.;Department of Reproductive Medicine and Fertility Preservation, Paris-Saclay University, Antoine Béclère Hospital, APHP, Clamart 92140, France. | 1940 | |||
| 10.1016/j.ijantimicag.2020.106129 | Journal Article | en | Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time. | https://www.ncbi.nlm.nih.gov/pubmed/32755653 | Interest of anti-infective agents in COVD-19 showed discrepant results. However, there is no evaluation about the impact in changes of practices on the prognosis over time. | 0924-8579 | 2020-08-02 02:00:00+02:00 | pubmed | International Journal of Antimicrobial Agents | Benjamin Davido;Ghilas Boussaid;Isabelle Vaugier;Thibaud Lansaman;Frédérique Bouchand;Christine Lawrence;Jean-Claude Alvarez;Pierre Moine;Véronique Perronne;Frédéric Barbot;Azzam Saleh-Mghir;Christian Perronne;Djillali Annane;Pierre De Truchis | Covid-19;azithromycin;hydroxychloroquine;pneumonia | 2020-08-02 02:00:00+02:00 | 32755653 | FR | Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France. Electronic address: benjamin.davido@aphp.fr.;Université Paris-Saclay, UVSQ, Erphan, 78000, Versailles, France.;Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.;Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.;Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.;EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.;Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.;Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France.;Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France. | 1942 | |||
| 10.1016/j.nmni.2020.100714 | Journal Article | en | Nullane salus extra ecclesiam. | https://www.ncbi.nlm.nih.gov/pubmed/32834899 | Randomized clinical trials are not relevant for infectious disease outbreaks due to a new pathogen, for which public health decisions have to be made urgently. An approach based on group comparisons, in silico, may provide valuable results in a reasonably short period of time for a negligible amount of money. | 2052-2975 | 2020-08-02 02:00:00+02:00 | pubmed | New Microbes and New Infections | P Gautret;D Raoult | COVID-19;Chloroquine derivatives;SARS-CoV-2;clinical trials;in silico comparison | 2020-08-01 02:00:00+02:00 | 32834899 | FR | IHU-Méditerranée Infection, Marseille, France.;Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;Aix Marseille Université, IRD, AP-HM, MEPHI, Marseille, France. | 1947 | |||
| 10.7717/peerj.9642 | Journal Article | en | Air quality improvement during triple-lockdown in the coastal city of Kannur, Kerala to combat Covid-19 transmission. | https://www.ncbi.nlm.nih.gov/pubmed/32821548 | The novel SARS-CoV-2 coronavirus that emerged in the city of Wuhan, China, last year has since become the COVID-19 pandemic across all continents. To restrict the spread of the virus pandemic, the Government of India imposed a lockdown from 25 March 2020. In India, Kannur district was identified as the first "hotspot" of virus transmission and a "triple-lockdown" was implemented for a span of twenty days from 20 April 2020. This article highlights the variations of surface O3, NO, NO2, CO, SO2, NH3, VOC's, PM10, PM2.5 and meteorological parameters at the time of pre-lockdown, lockdown and triple-lockdown days at Kannur town in south India using ground-based analyzers. From pre-lockdown days to triple-lockdown days, surface O3 concentration was found to increase by 22% in this VOC limited environment. NO and NO2 concentrations were decreased by 61% and 71% respectively. The concentration of PM10 and PM2.5 were observed to decline significantly by 61% and 53% respectively. Reduction in PM10 during lockdown and triple-lockdown days enhanced the intensity of solar radiation reaching the lower troposphere, and increased air temperature and reduced the relative humidity. Owing to this, surface O3 production over Kannur was found to have increased during triple-lockdown days. The concentration of CO (67%), VOCs (61%), SO2 (62%) and NH3 (16%) were found to decrease significantly from pre-lockdown days to triple-lockdown days. The air quality index revealed that the air quality at the observational site was clean during the lockdown. | 2167-8359 | 2020-08-02 02:00:00+02:00 | pubmed | PeerJ | C T Resmi;T Nishanth;M K Satheesh Kumar;M G Manoj;M Balachandramohan;K T Valsaraj | Air pollutants;Air quality;COVID-19;Kannur;Lockdown | 2020-07-31 02:00:00+02:00 | 32821548 | FR;IN;US | Department of Physics, Erode Arts and Science College, Erode, Tamil Nadu, India.;Department of Physics, Sree Krishna College Guruvayur, Thrissur, Kerala, India.;Department of Atomic and Molecular Physics, Manipal Academy of Higher Education, Manipal, Karnataka, India.;Advanced Centre for Atmospheric Radar Research, Cochin University of Science and Technology, Cochin, Kerala, India.;Cain Department of Chemical Engineering, Louisiana State University, Baton Rouge, LA, USA. | 1955 | |||
| 10.1634/theoncologist.2020-0420 | Journal Article | en | Management of germ cell tumors during the outbreak of the novel coronavirus disease-19 pandemic: a survey of international expertise centers. | https://www.ncbi.nlm.nih.gov/pubmed/32735386 | The coronavirus disease 2019 (COVID-19) pandemic has become a public health emergency, affecting frail populations including cancer patients. This poses the question as to whether cancer treatments can be postponed or modified without compromising their efficacy, especially for highly curable cancers such as germ cell tumors (GCTs). | 1083-7159,1549-490X | 2020-08-02 02:00:00+02:00 | pubmed | The Oncologist | Lucia Nappi;Margaret Ottaviano;Pasquale Rescigno;Marianna Tortora;Giuseppe L Banna;Giulia Baciarello;Umberto Basso;Christina Canil;Alessia Cavo;Maria Cossu Rocca;Piotr Czaykowski;Ugo De Giorgi;Xavier Garcia Del Muro;Marilena Di Napoli;Giuseppe Fornarini;Jourik A Gietema;Daniel Y C Heng;Sebastien J Hotte;Christian Kollmannsberger;Marco Maruzzo;Carlo Messina;Franco Morelli;Sasja Mulder;Craig Nichols;Franco Nolè;Christoph Oing;Teodoro Sava;Simona Secondino;Giuseppe Simone;Denis Soulieres;Bruno Vincenzi;Paolo A Zucali;Sabino De Placido;Giovannella Palmieri | COVID-19;cancer;curable tumors;expert centers;germ cell tumors;pandemic testicular | 2020-07-31 02:00:00+02:00 | 32735386 | FR;CA;GB;US;IT;NL;ES;DE | British Columbia Cancer Agency - Vancouver Cancer Center, Vancouver, BC, Canada.;Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.;Ospedale del Mare, Naples, Italy.;University of Naples "Federico II", Department of Clinical Medicine and Surgery, CRCTR Regional Rare Tumors Reference Center, Naples, Italy.;The Royal Marsden NHS Foundation Trust, London, UK.;The Institute of Cancer Research, London, UK.;Portsmouth Hospitals NHS Trust, UK.;Gustave Roussy, Université Paris-Saclay, Oncology Medicine Department, Villejuif, France.;Oncology Unit, Oncology Department, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy.;The Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, ON, Canada.;Villa Scassi Hospital, Genoa, Italy.;IEO, European Institute of Oncology, IRCCS, Milan, Italy.;Cancer Care Manitoba, University of Manitoba, Winnipeg, MB, Canada.;Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.;Catalan Institute of Oncology, Barcelona, Spain.;National Institute of Tumors "G. Pascale", Naples, Italy.;IRCCS Ospedale Policlinico San Martino, Genoa, Italy.;University Medical Center Groningen, Groningen, The Netherlands.;Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.;Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada.;Santa Chiara Hospital, Trento, Italy.;IRCCS Casa Sollievo della sofferenza, San Giovanni Rotondo, Italy.;Radboud University Medical Center, Nijmegen, The Netherlands.;Testicular Cancer Commons, and SWOG Group Chair's Office, Portland, OR, USA.;University Medical Center Eppendorf, Hamburg, Germany.;Oncologia AUSLSS6 EUGANEA, Padua, Italy.;Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.;IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.;Center Hospitalier de l'Université de Montréal, Montreal, QC, Canada.;University Campus Bio-Medico, Rome, Italy.;Humanitas Clinical and Research Center, IRCCS, Rozzano (Milan), Italy. | 1956 | |||
| 10.1038/s41586-020-2600-6 | Journal Article | en | Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. | https://www.ncbi.nlm.nih.gov/pubmed/32726800 | Coronavirus disease 2019 (COVID-19) is a new pandemic disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1. The C5a anaphylatoxin and its receptor C5aR1 (CD88) play a key role in the initiation and maintenance of several inflammatory responses, by recruiting and activating neutrophils and monocytes in the lungs1. We provide a longitudinal analysis of immune responses, including immune cell phenotyping and assessments of the soluble factors present in the blood and broncho-alveolar lavage fluid (BALF) of patients at various stages of COVID-19 severity: paucisymptomatic, pneumonia and acute respiratory distress syndrome (ARDS). We report an increase in soluble C5a levels proportional to COVID-19 severity and high levels of C5aR1 expression in blood and pulmonary myeloid cells, supporting a role for the C5a-C5aR1 axis in the pathophysiology of ARDS. Anti-C5aR1 therapeutic monoclonal antibodies (mAbs) prevented C5a-mediated human myeloid cell recruitment and activation, and inhibited acute lung injury (ALI) in human C5aR1 knockin mice. These results suggest that C5a-C5aR1 axis blockade might be used as a means of limiting myeloid cell infiltration in damaged organs and preventing the excessive lung inflammation and endothelialitis associated with ARDS in COVID-19 patients. | 0028-0836,1476-4687 | 2020-08-02 02:00:00+02:00 | pubmed | Nature | Julien Carvelli;Olivier Demaria;Frédéric Vély;Luciana Batista;Nassima Chouaki Benmansour;Joanna Fares;Sabrina Carpentier;Marie-Laure Thibult;Ariane Morel;Romain Remark;Pascale André;Agnès Represa;Christelle Piperoglou;Pierre Yves Cordier;Erwan Le Dault;Christophe Guervilly;Pierre Simeone;Marc Gainnier;Yannis Morel;Mikael Ebbo;Nicolas Schleinitz;Eric Vivier | 2020-07-29 02:00:00+02:00 | 32726800 | FR | Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Réanimation des Urgences, Marseille, France.;Aix Marseille Univ, Marseille, France.;Innate Pharma, Marseille, France.;Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.;Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Immunology, Marseille Immunopole, Marseille, France.;Hôpital d'Instruction des Armées Laveran, Marseille, France.;Assistance Publique des Hôpitaux de Marseille, Marseille, France.;Assistance Publique des Hôpitaux de Marseille, Hôpital Nord, Réanimation des Détresses Respiratoires et Infections Sévères, Aix-Marseille Université, Marseille, France.;Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Réanimation Polyvalente, Aix-Marseille Université, Marseille, France.;Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Internal Medicine, Marseille, France.;Innate Pharma, Marseille, France. vivier@ciml.univ-mrs.fr.;Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France. vivier@ciml.univ-mrs.fr.;Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Immunology, Marseille Immunopole, Marseille, France. vivier@ciml.univ-mrs.fr. | 1964 | ||||
| Letter | en | Cross-reactions between rheumatoid factor and IgM SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32778426 | 2020-08-02 02:00:00+02:00 | pubmed | Marta Vinyé Bausà;Rosa Bausà Peris;Hèctor Corominas | 2020-07-28 02:00:00+02:00 | 32778426 | FR;ES | Universitat Autònoma de Barcelona (UAB), Barcelona, España.;Servei de Salut Laboral, Hospital Universitari de la Sant creu i Sant Pau, Barcelona, España.;Universitat Autònoma de Barcelona (UAB), Barcelona, España, Servei de Reumatologia, Hospital Universitari de la Sant creu i Sant Pau, Barcelona, España. Electronic address: vancor@yahoo.com. | 1968 | ||||||||
| 10.1016/j.frl.2020.101703 | Journal Article | en | The bubble contagion effect of COVID-19 outbreak: Evidence from crude oil and gold markets. | https://www.ncbi.nlm.nih.gov/pubmed/32837382 | This paper examines the causal relationship between crude oil and gold spot prices to assess how the economic impact of COVID-19 has affected them. We analyze West Texas Light crude oil (WTI) and gold prices from January 4, 2010, to May 4, 2020. We detect common periods of mild explosivity in WTI and gold markets. More importantly, we find a bilateral contagion effect of bubbles in oil and gold markets during the recent COVID-19 outbreak. | 1544-6123 | 2020-08-02 02:00:00+02:00 | pubmed | Finance Research Letters | Cheima Gharib;Salma Mefteh-Wali;Sami Ben Jabeur | COVID-19;Contagion;Explosive process;Gold;Recursive rolling window;Time-varying Granger causality;WTI | 2020-07-28 02:00:00+02:00 | 32837382 | FR;TN | Quantitative Analysis Research Group (QUARG), ESCT School of Business, University of Manouba, Tunisia.;ESSCA School of Management, 1 rue Lakanal, 49003, Angers, France.;ESDES Business School of UCLyon, 10, place des archives, 69002, Lyon, France. | 1969 | |||
| Letter | en | Answer to the Letter to the Editor of Akbari KK et al. concerning "The short-term impact of COVID-19 pandemic on spine surgeons: a cross-sectional global study" by Khattab MF, et al. (Eur Spine J; [2020]: doi:10.1007/s00586-020-06517-1). | https://www.ncbi.nlm.nih.gov/pubmed/32728803 | 2020-08-02 02:00:00+02:00 | pubmed | Anouar Bourghli;Mohamed Fawzy Khattab;Tareq M A Kannan;Ibrahim Obeid | 2020-07-29 02:00:00+02:00 | 32728803 | FR;EG;SA;JO | Orthopedic and Spinal Surgery Department, Kingdom Hospital, Riyadh, Saudi Arabia.;Orthopedic Surgery Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.;Spine Unit, Jordan University Hospital, University of Jordan, Amman, Jordan.;Spine Surgery Unit, ELSAN Group Jean Villar Private Hospital, 33000, Bruges-Bordeaux, France. ibrahim.obeid@gmail.com. | 1980 | ||||||||
| Letter | en | Posterior reversible encephalopathy syndrome associated with SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32718920 | 2020-08-02 02:00:00+02:00 | pubmed | Abdenour Djellaoui;Lilia Seddik;Laurent Cleret De Langavant;Samuel Cattan;Anne Catherine Bachoud-Lévi;Hassan Hosseini | hypertensive encepha;infectious diseases | 2020-07-27 02:00:00+02:00 | 32718920 | FR | Neurology, Henri Mondor University Hospitals, APHP, Créteil, France abdenour.djellaoui@aphp.fr.;Neurology, Henri Mondor University Hospitals, APHP, Créteil, France. | 1983 | |||||||
| 10.1016/j.virusres.2020.198093 | Editorial | en | 100 days of solitude: The spring of COVID-19 through the eyes of 15 young virologists of the INITIATE program. | https://www.ncbi.nlm.nih.gov/pubmed/32730780 | 0168-1702 | 2020-08-02 02:00:00+02:00 | pubmed | Virus Research | Zsofia Keszei;Xavier Martinez Vendrell;Maria Soultsioti;Pau Ribo Molina;Lorenz Wirth;Hauke Weiss;Magdalini Alexandridi;Chiara Aloise;Balasubramanian Susma;Coralie Guy;Adriana Loverre;Sonia Marquez Martinez;Julija Mazej;Alix Spahn;Mihai Sularea;John Hiscott;Bernadette van den Hoogen | 2020-07-28 02:00:00+02:00 | 32730780 | SE;IE;FR;NO;IT;NL;BE;AT | CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.;Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands.;AstraZeneca, Gothenburg, Sweden.;School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland.;Istituto Pasteur Italia Cenci Bolognetti Foundation, Rome, Italy.;Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.;Stimunity, Paris, France.;Janssen Vaccines & Prevention B.V., Leiden, the Netherlands.;Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, 7006 Trondheim, Norway.;Istituto Pasteur Italia Cenci Bolognetti Foundation, Rome, Italy. Electronic address: john.hiscott@istitutopasteur.it.;Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands. Electronic address: b.vandenhoogen@erasmusmc.nl. | 1990 | |||||
| 10.1016/j.ebiom.2020.102887 | Journal Article;Review | en | The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). | https://www.ncbi.nlm.nih.gov/pubmed/32736307 | The pathogenesis of coronavirus disease 2019 (COVID-19) may be envisaged as the dynamic interaction between four vicious feedback loops chained or happening at once. These are the viral loop, the hyperinflammatory loop, the non-canonical renin-angiotensin system (RAS) axis loop, and the hypercoagulation loop. Severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 lights the wick by infecting alveolar epithelial cells (AECs) and downregulating the angiotensin converting enzyme-2 (ACE2)/angiotensin (Ang-1-7)/Mas1R axis. The viral feedback loop includes evading the host's innate response, uncontrolled viral replication, and turning on a hyperactive adaptative immune response. The inflammatory loop is composed of the exuberant inflammatory response feeding back until exploding in an actual cytokine storm. Downregulation of the ACE2/Ang-(1-7)/Mas1R axis leaves the lung without a critical defense mechanism and turns the scale to the inflammatory side of the RAS. The coagulation loop is a hypercoagulable state caused by the interplay between inflammation and coagulation in an endless feedback loop. The result is a hyperinflammatory and hypercoagulable state producing acute immune-mediated lung injury and eventually, adult respiratory distress syndrome. | 2352-3964 | 2020-08-02 02:00:00+02:00 | pubmed | EBioMedicine | Pere Domingo;Isabel Mur;Virginia Pomar;Héctor Corominas;Jordi Casademont;Natividad de Benito | ACE2;Acute lung injury;Adult distress respiratory syndrome;COVID-19;Hypercoagulability;Hyperinflammatory state;RAS;SARS-CoV-2 | 2020-07-29 02:00:00+02:00 | 32736307 | FR;ES | Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Av. Sant Antoni Mª Claret, 167, 08025 Barcelona, Spain. Electronic address: pdomingo@santpau.cat.;Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Av. Sant Antoni Mª Claret, 167, 08025 Barcelona, Spain.;Departments of Rheumatology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Internal Medicine, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. | 1995 | |||
| Letter | en | Euglycaemic ketoacidosis during gestational diabetes with concomitant COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32738403 | 2020-08-02 02:00:00+02:00 | pubmed | Sarra Smati;Pascale Mahot;Alexandre Bourdiol;Stéphane Ploteau;Samy Hadjadj;Bertand Cariou | 2020-07-29 02:00:00+02:00 | 32738403 | FR | Département d'Endocrinologie, Diabétologie et Nutrition, l'Institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France.;Réanimation Chirurgicale et des Brûlés, Département d'Anesthésie-Réanimation, CHU de Nantes, Nantes, France.;Laboratoire d'Anatomie - Faculté de Médecine, Service de Gynécologie-Obstétrique, Centre Fédératif de Pelvi-Périnéologie, CHU de Nantes, Nantes, France.;Département d'Endocrinologie, Diabétologie et Nutrition, l'Institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France. Electronic address: bertrand.cariou@univ-nantes.fr. | 2000 | ||||||||
| Letter | en | The comeback of vaginal surgery during and after the COVID-19 pandemic: a new paradigm. | https://www.ncbi.nlm.nih.gov/pubmed/32728868 | 2020-08-02 02:00:00+02:00 | pubmed | Gautier Chene;Emanuele Cerruto;Erdogan Nohuz | 2020-07-29 02:00:00+02:00 | 32728868 | FR | Department of Gynecology and Obstetrics, Hôpital Femme Mère Enfant, HFME, 59 boulevard Pinel, Hospices civils de Lyon, 69000, Lyon, France. chenegautier@yahoo.fr.;Université Claude Bernard Lyon 1, EMR 3738, 69000, Lyon, France. chenegautier@yahoo.fr.;Department of Gynecology and Obstetrics, Hôpital Femme Mère Enfant, HFME, 59 boulevard Pinel, Hospices civils de Lyon, 69000, Lyon, France. | 2002 | ||||||||
| 10.1038/s41559-020-1275-6 | Journal Article;Review | en | Conserving Africa's wildlife and wildlands through the COVID-19 crisis and beyond. | https://www.ncbi.nlm.nih.gov/pubmed/32728187 | The SARS-CoV-2 virus and COVID-19 illness are driving a global crisis. Governments have responded by restricting human movement, which has reduced economic activity. These changes may benefit biodiversity conservation in some ways, but in Africa, we contend that the net conservation impacts of COVID-19 will be strongly negative. Here, we describe how the crisis creates a perfect storm of reduced funding, restrictions on the operations of conservation agencies, and elevated human threats to nature. We identify the immediate steps necessary to address these challenges and support ongoing conservation efforts. We then highlight systemic flaws in contemporary conservation and identify opportunities to restructure for greater resilience. Finally, we emphasize the critical importance of conserving habitat and regulating unsafe wildlife trade practices to reduce the risk of future pandemics. | 2397-334X | 2020-08-02 02:00:00+02:00 | pubmed | Nature Ecology & Evolution | Peter Lindsey;James Allan;Peadar Brehony;Amy Dickman;Ashley Robson;Colleen Begg;Hasita Bhammar;Lisa Blanken;Thomas Breuer;Kathleen Fitzgerald;Michael Flyman;Patience Gandiwa;Nicia Giva;Dickson Kaelo;Simon Nampindo;Nyambe Nyambe;Kurt Steiner;Andrew Parker;Dilys Roe;Paul Thomson;Morgan Trimble;Alexandre Caron;Peter Tyrrell | 2020-07-29 02:00:00+02:00 | 32728187 | BW;FR;KE;UG;GB;US;MZ;AU;NL;ZA;ZW;DE | Mammal Research Institute, Department of Zoology and Entomology, University of Pretoria, Pretoria, South Africa. peter@wildnet.org.;Environmental Futures Research Institute, Griffith University, Nathan, Queensland, Australia. peter@wildnet.org.;Wildlife Conservation Network, San Francisco, CA, USA. peter@wildnet.org.;Institute for Biodiversity and Ecosystem Dynamics (IBED), University of Amsterdam, Amsterdam, The Netherlands.;Department of Geography, University of Cambridge, Cambridge, UK.;University of Oxford, Tubney, UK.;Institute for Communities and Wildlife in Africa, Department of Biological Science, University of Cape Town, Cape Town, South Africa.;TRT Conservation Foundation, Rondebosch, South Africa.;World Bank, Washington, DC, USA.;Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH, Eschborn, Germany.;WWF Germany, Berlin, Germany.;Conservation Capital, Nairobi, Kenya.;Department of Wildlife and National Parks, Gaborone, Botswana.;International Conservation Affairs Department, Parks and Wildlife Management Authority, Harare, Zimbabwe.;Faculty of Agronomy and Forestry Engineering, Universidade Eduardo Mondlane, Maputo, Mozambique.;Kenya Wildlife Conservancies Association, Nairobi, Kenya.;Wildlife Conservation Society, Uganda Country Programme, Kampala, Uganda.;Kavango Zambezi Transfrontier Conservation Area Secretariat, Kasane, Botswana.;Independent consultant, Johannesburg, South Africa.;Conserve Africa, Johannesburg, South Africa.;International Institute for Environment and Development (IIED), London, UK.;IUCN Sustainable Use and Livelihoods Specialist Group (SULi), London, UK.;Wildlife Conservation Network, San Francisco, CA, USA.;Independent consultant, Cape Town, South Africa.;ASTRE, Uni Montpellier, CIRAD, INRA, Montpellier, France.;Faculdade de Veterinaria, Universidade Eduardo Mondlane, Maputo, Mozambique.;South Rift Association of Landowners, Nairobi, Kenya.;Department of Geography and Environmental Studies, University of Nairobi, Nairobi, Kenya. | 2005 | ||||
| 10.1111/head.13923 | Journal Article | en | High Prevalence of Headaches During Covid-19 Infection: A Retrospective Cohort Study. | https://www.ncbi.nlm.nih.gov/pubmed/32757419 | To document the prevalence of new headaches in patients with Covid-19 infection and the potential association with other neuro-sensorial symptoms (anosmia and ageusia). The persistence of these symptoms 1 month after recovery was also documented. | 0017-8748,1526-4610 | 2020-08-09 02:00:00+02:00 | pubmed | Headache: The Journal of Head and Face Pain | Louis Poncet-Megemont;Pauline Paris;Amélie Tronchere;Jean-Pascal Salazard;Bruno Pereira;Radhouane Dallel;Claire Aumeran;Jean Beytout;Christine Jacomet;Henri Laurichesse;Olivier Lesens;Natacha Mrozek;Magali Vidal;Xavier Moisset | Covid-19;SARS-CoV-2;ageusia;anosmia;headache | 2020-08-05 02:00:00+02:00 | 32757419 | FR | CHU Clermont-Ferrand, Inserm, Neuro-Dol, CNRS 6023 Laboratoire Microorganismes: Génome Environnement (LMGE), Université Clermont Auvergne, Clermont-Ferrand, France. | 2010 | |||
| 10.1136/bmjmilitary-2020-001569 | Journal Article | en | How do we fight COVID-19? Military medical actions in the war against the COVID-19 pandemic in France. | https://www.ncbi.nlm.nih.gov/pubmed/32759228 | 'We are at war', French President Emmanuel Macron said in an address to the nation on 16 March 2020. As part of this national effort, the French Military Medical Service (FMMS) is committed to the fight against COVID-19. This original report aimed to describe and detail actions that the FMMS has carried out in the nationwide fight against the COVID-19 pandemic in France, as well as overseas. Experts in the field reported major actions conducted by the FMMS during the COVID-19 pandemic in France. In just few weeks, the FMMS developed ad hoc medical capabilities to support national health authorities. It additionally developed adaptive, collective en route care via aeromedical and naval units and deployed a military intensive care field hospital. A COVID-19 crisis cell coordinated the French Armed Forces health management. The French Military Centre for Epidemiology and Public Health provided all information needed to guide the decision-making process. Medical centres of the French Armed Forces organised the primary care for military patients, with the widespread use of telemedicine. The Paris Fire Brigade and the Marseille Navy Fire Battalion emergency departments ensured prehospital management of patients with COVID-19. The eight French military training hospitals cooperated with civilian regional health agencies. The French military medical supply chain supported all military medical treatment facilities in France as well as overseas, coping with a growing shortage of medical equipment. The French Armed Forces Biomedical Research Institute performed diagnostics, engaged in multiple research projects, updated the review of the scientific literature on COVID-19 daily and provided expert recommendations on biosafety. Finally, even students of the French military medical academy volunteered to participate in the fight against the COVID-19 pandemic. In conclusion, in an unprecedented medical crisis, the FMMS engaged multiple innovative and adaptive actions, which are still ongoing, in the fight against COVID-19. The collaboration between military and civilian healthcare systems reinforced the shared objective to achieve the goal of 'saving the greatest number'. | 2633-3767,2633-3775 | 2020-08-09 02:00:00+02:00 | pubmed | BMJ Military Health | Pierre Pasquier;A Luft;J Gillard;M Boutonnet;C Vallet;J-M Pontier;S Duron-Martinaud;A Dia;L Puyeo;F Debrus;B Prunet;S Beaume;G de Saint Maurice;E Meaudre;C Ficko;A Merens;G Raharisson;B Conte;F Dorandeu;F Canini;R Michel;S Ausset;J Escarment | COVID-19;Coronavirus;France;military;public health | 2020-08-05 02:00:00+02:00 | 32759228 | FR | Percy Military Training Hospital, French Military Health Service, Clamart, France pasquier9606@me.com.;Ecole du Val-de-Grâce French Military Medical Academy, Paris, France.;Direction Centrale du Service de Santé des Armées, Paris, France.;Percy Military Training Hospital, French Military Health Service, Clamart, France.;Service Médical de la Force d'Action Navale, French Military Health Service, Toulon, France.;Cephismer, Centre d'Expertise Plongée pour la Marine Nationale, French Military Health Service, Toulon, France.;Centre d'épidémiologie et de Santé Publique des Armées, French Military Health Service, Marseille, France.;Direction de la Médecine des forces, French Military Health Service, Tours, France.;Emergency Department, Brigade de Sapeurs-Pompiers de Paris, Paris, France.;Bataillon des Marins-Pompiers de Marseille, French Military Health Service, Marseille, France.;Legouest Military Training Hospital, French Military Health Service, Metz, France.;Sainte-Anne Military Training Hospital, French Military Health Service, Toulon, France.;Bégin Military Training Hospital, French Military Health Service, Saint-Mandé, France.;Direction des approvisionnements en produits de santé des armées, French Military Health Service, Orléans, France.;Institut de Recherche Biomédicale des Armées, French Military Health Service, Brétigny-sur-Orge, France.;Écoles Militaires de Santé, French Military Health Service, Lyon-Bron, France.;French Military Health Service, Paris, France. | 2013 | |||
| Letter | en | Testing strategies for the control of COVID-19 in nursing homes: Universal or targeted screening? | https://www.ncbi.nlm.nih.gov/pubmed/32768449 | 2020-08-09 02:00:00+02:00 | pubmed | Gabriel Birgand;Karine Blanckaert;Colin Deschanvres;Adrien Vaudron;Pascaline Loury;Lisa King | 2020-08-05 02:00:00+02:00 | 32768449 | FR;GB | Regional center for infection control (CPias), University Hospital of Nantes, Nantes, France, NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London, Hammersmith Campus, Du Cane Road, London, UK. Electronic address: gabriel.birgand@chu-nantes.fr.;NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London, Hammersmith Campus, Du Cane Road, London, UK.;Santé Publique France (SpFrance), the French National Public Health Agency, Pays de la Loire regional office, Nantes, France. | 2018 | ||||||||
| Université de Franche-Comté | 10.1186/s13148-020-00912-7 | Journal Article;Review;Research Support, Non-U.S. Gov't | en | Management of epigenomic networks entailed in coronavirus infections and COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32758273 | Coronaviruses (CoVs) are highly diverse single-stranded RNA viruses owing to their susceptibility to numerous genomic mutations and recombination. Such viruses involve human and animal pathogens including the etiologic agents of acute respiratory tract illnesses: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and the highly morbific SARS-CoV-2. Coronavirus disease 2019 (COVID-19), an emerging disease with a quick rise in infected cases and deaths, was recently identified causing a worldwide pandemic. COVID-19 disease outcomes were found to increase in elderly and patients with a compromised immune system. Evidences indicated that the main culprit behind COVID-19 deaths is the cytokine storm, which is illustrated by an uncontrolled over-production of soluble markers of inflammation. The regulation process of coronavirus pathogenesis through molecular mechanism comprise virus-host interactions linked to viral entry, replication and transcription, escape, and immune system control. Recognizing coronavirus infections and COVID-19 through epigenetics lens will lead to potential alteration in gene expression thus limiting coronavirus infections. Focusing on epigenetic therapies reaching clinical trials, clinically approved epigenetic-targeted agents, and combination therapy of antivirals and epigenetic drugs is currently considered an effective and valuable approach for viral replication and inflammatory overdrive control. | 1868-7075,1868-7083 | 2020-08-09 02:00:00+02:00 | pubmed | Clinical Epigenetics | Ranim El Baba;Georges Herbein | COVID-19;Coronavirus;Epigenetic;Inflammation;MERS-CoV;SARS-CoV;SARS-CoV-2 | 2020-08-05 02:00:00+02:00 | 32758273 | FR;LB | [{"country": "International", "agency": "Université de Franche-Comté", "grantid": "CR3300"}] | Department Pathogens & Inflammation-EPILAB, UPRES EA4266, University of Franche-Comté and University of Bourgogne Franche-Comté, F-25030, Besançon, France.;Université Libanaise, Beirut, Lebanon.;Department Pathogens & Inflammation-EPILAB, UPRES EA4266, University of Franche-Comté and University of Bourgogne Franche-Comté, F-25030, Besançon, France. georges.herbein@univ-fcomte.fr.;Department of Virology, CHRU Besancon, F-25030, Besançon, France. georges.herbein@univ-fcomte.fr. | 2020 | |
| 10.1016/j.jpsychores.2020.110214 | Journal Article | en | Role and importance of consultation-liaison psychiatry during the Covid-19 epidemic. | https://www.ncbi.nlm.nih.gov/pubmed/32798833 | 0022-3999 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Psychosomatic Research | Mathilde Horn;Benoit Granon;Guillaume Vaiva;Thomas Fovet;Ali Amad | Consultation-liaison psychiatry;Covid-19;Mental health | 2020-08-05 02:00:00+02:00 | 32798833 | FR | Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000, Lille, France. Electronic address: horn.mathilde@gmail.com.;Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000, Lille, France.;Centre National de Ressources et Résilience pour les Psychotraumatisme Lille Paris (CN2R), F-59000 LILLE, France. | 2024 | ||||
| 10.1164/rccm.202005-2007le | Journal Article | en | High Flow Nasal Canula in Critically Ill Severe COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32758000 | 1073-449X,1535-4970 | 2020-08-09 02:00:00+02:00 | pubmed | American Journal of Respiratory and Critical Care Medicine | Alexandre Demoule;Antoine Vieillard Baron;Michael Darmon;Alexandra Beurton;Guillaume Géri;Guillaume Voiriot;Thibault Dupont;Lara Zafrani;Lola Girodias;Vincent Labbé;Martin Dres;Muriel Fartoukh;Elie Azoulay | COVID-19;acute respiratory failure;high flow nasal canula;intubation;treatment | 2020-08-06 02:00:00+02:00 | 32758000 | FR | Groupe Hospitalier Pitié Salpêtrière, Assistance Publique Hopitaux de Paris, Service de Pneumologie et Réanimation Médicale, Paris, France, alexandre.demoule@aphp.fr.;Ambroise Paré University Hosptial, AP-HP, Boulogne-Billancourt, France.;Hôpital Saint Louis Paris - APHP, France, Paris, France.;Groupe Hospitalier Pitié Salpêtrière, Assistance Publique Hopitaux de Paris, Service de Pneumologie et Réanimation Médicale, Paris, France.;Hopital Cochin, 26935, Paris, France.;Hopital Tenon, 55705, Réanimation médico-chirurgicale, Paris, France.;Medical Intensive Care Unit, Hôpital Saint-Louis, ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistics Sorbonne Paris Cité, CRESS), INSERM, Université Paris Diderot Sorbonne, Paris, France, Paris, France.;APHP - Tenon University Hospital, Medico-Surgical Intensive Care Unit, Paris, France.;APHP, 26930, Pneumology and ICU, Paris, France.;Assistance Publique Hopitaux de Paris. Sorbonne Université, Hôpital Tenon, Médecine intensive Réanimatio, Paris, France.;St Louis Hospital, Paris, Paris, France. | 2029 | ||||
| 10.1016/j.anorl.2020.05.014 | Journal Article | en | Viruses and viral epidemics in the metabolic theory of evolution. | https://www.ncbi.nlm.nih.gov/pubmed/32773332 | Viruses, including the SARS-CoV-2 virus responsible for the current COVID-19 epidemic, are a key to the understanding of life and evolution. Cells may have arisen from aqueous sequestration inside a lipid envelope studded with chromophores capable of capturing solar photons. Nitrogen incorporation in the primordial cell chemistry allowed synthesis of amino acids and nucleic acids, a prelude to RNA and subsequently DNA. Metagenomics provides access to nucleoprotein sediments synthesised by a googol of metabolically differentiated cells that have marked the evolution of life. Replication of a virus, a nucleoprotein particle, occurs passively in competent cells. Viruses are only identified in the context of the epidemic that they induce as a result of transmission from one host to another. By breaking down the viral particle, the host cell appears to resurrect the metabolic function of the nucleic acid, which synthesises its components without any form of control. Viral products undergo self-assembly and are exported by either exocytosis or cytolysis. In the absence of cells, viruses appear to be inert. However, intracellular contamination of a virus does not always result in replication: the viral genome can disappear, remain latent, wake up, remain embedded in the cellular genome, become an oncogene or induce auto-immunity. The presence of endogenous retroviruses in eukaryotic cells raises the question of their possible role in evolution. | 1879-7296 | 2020-08-09 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | R Jankowski | COVID-19;Cell;Infection;Prokaryotes;Protists | 2020-08-06 02:00:00+02:00 | 32773332 | FR | ORL et Chirurgie Cervico-Faciale, Hôpital de Brabois, CHRU de Nancy, Université de Lorraine, Bâtiment Louis-Mathieu, 54500 Vandoeuvre-les-Nancy, France, EA 3450 DevAH-Développement, Adaptation et Handicap, Régulations Cardio-Respiratoires et de la Motricité, Faculté de Médecine, Université de Lorraine, 54505, Vandoeuvre-les-Nancy, France, UMR_S 1256 INSERM, Nutrition, génétique et expositions aux risques environnementaux, Faculté de Médecine, 9, avenue de la Forêt-de-Haye, 54500 Vandœuvre-lès-Nancy, France. Electronic address: r.jankowski@chru-nancy.fr. | 2030 | |||
| 10.1093/jamia/ocaa203 | Journal Article | en | A citizen science initiative for open data and visualization of COVID-19 outbreak in Kerala, India. | https://www.ncbi.nlm.nih.gov/pubmed/32761211 | India reported its first COVID-19 case in the state of Kerala and an outbreak initiated subsequently. The Department of Health Services, Government of Kerala, initially released daily updates through daily textual bulletins for public awareness to control the spread of the disease. However, this unstructured data limits upstream applications, such as visualization, and analysis, thus demanding refinement to generate open and reusable datasets. | 1067-5027,1527-974X | 2020-08-09 02:00:00+02:00 | pubmed | Journal of the American Medical Informatics Association | Jijo Pulickiyil Ulahannan;Nikhil Narayanan;Nishad Thalhath;Prem Prabhakaran;Sreekanth Chaliyeduth;Sooraj P Suresh;Musfir Mohammed;E Rajeevan;Sindhu Joseph;Akhil Balakrishnan;Jeevan Uthaman;Manoj Karingamadathil;Sunil Thonikkuzhiyil Thomas;Unnikrishnan Sureshkumar;Shabeesh Balan;Neetha Nanoth Vellichirammal | COVID-19;India;Kerala;Open data;Visualization | 2020-08-06 02:00:00+02:00 | 32761211 | FR;JP;US;PL;IN;KR | Department of Physics, Government College Kasaragod, Kannur University, Kerala, India.;Open Data Researcher, Bengaluru, India.;School of Library, Information and Media Studies., University of Tsukuba, Japan.;Department of Advanced Materials and Chemical Engineering, Hannam University, Daejeon, South Korea.;Centre for Cognitive and Brain Sciences, Indian Institute of Technology Gandhinagar, Gujarat, India.;Department of Humanities and Social Sciences, National Institute of Technology Tiruchirappalli, Tamil Nadu, India.;Embedded Analytics, ML and Data Sciences, Experion Technologies, TechnoPark, Thiruvananthapuram, India.;Department of Philosophy, Government Brennen College, Kannur University, Kerala, India.;Department of Travel and Tourism Management, Govinda Pai Memorial Government College, Kannur University, Kerala, India.;Crowcon - A Halma Company, ITPB, Whitefield, Bengaluru, India.;Department of Marine Geophysics, Cochin University of Science and Technology, Kochi, Kerala, India.;Swathanthra Malayalam Computing, Thrissur, Kerala, India.;Department of Electronics, College of Engineering Attingal, APJ Abdul Kalam Technical University, Thiruvananthapuram, Kerala, India.;Astronomical Observatory of the Jagiellonian University, Kraków, Małopolska, Poland.;Laboratory for Molecular Psychiatry, RIKEN Center for Brain Science, Wakoshi, Saitama, Japan.;Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska, USA. | 2032 | |||
| Letter | en | Is hypoxemia explained by intracardiac or intrapulmonary shunt in COVID-19-related acute respiratory distress syndrome? | https://www.ncbi.nlm.nih.gov/pubmed/32761524 | Hypoxemia is the main feature of COVID-19-related acute respiratory distress syndrome (C-ARDS), but its underlying mechanisms are debated, especially in patients with low respiratory system elastance (Ers). We assessed 60 critically ill patients hospitalized in our intensive care unit for C-ARDS. We used contrast transthoracic echocardiography to assess patent foramen ovale (PFO) shunt and transpulmonary bubble transit (TPBT). The median Ers was 32 cmH2O/L. PFO shunt was detected in six (10%) patients and TPBT in 12 (20%) patients. PFO shunt and TPBT were similar in patients with higher or lower Ers. In conclusion, PFO and TPBT do not seem to be the main drivers of hypoxemia in C-ARDS, especially in patients with lower Ers. | 2020-08-09 02:00:00+02:00 | pubmed | Paul Masi;François Bagate;Thomas d'Humières;Lara Al-Assaad;Laure Abou Chakra;Genevieve Derumeaux;Armand Mekontso Dessap | 2020-08-06 02:00:00+02:00 | 32761524 | FR | Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, 51, avenue du Maréchal de Lattre de Tassigny, 94010, Créteil Cedex, France. paul.masi@aphp.fr.;Groupe de recherche clinique CARMAS, Faculté de Santé, Université Paris Est Créteil, 94010, Créteil, France. paul.masi@aphp.fr.;Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, 51, avenue du Maréchal de Lattre de Tassigny, 94010, Créteil Cedex, France.;Groupe de recherche clinique CARMAS, Faculté de Santé, Université Paris Est Créteil, 94010, Créteil, France.;Service de Physiologie, AP-HP, Hôpitaux Universitaires Henri Mondor, 94010, Créteil, France.;INSERM U955, Université Paris-Est, Créteil, France. | 2034 | |||||||
| 10.1016/j.dib.2020.106121 | Journal Article | en | Quantitative proteomic dataset from oro- and naso-pharyngeal swabs used for COVID-19 diagnosis: Detection of viral proteins and host's biological processes altered by the infection. | https://www.ncbi.nlm.nih.gov/pubmed/32835036 | Since January 2020, the world is facing the COVID-19 pandemic caused by SARS-CoV-2. In a big effort to cope with this outbreak, two Uruguayan institutions, Institut Pasteur de Montevideo and Universidad de la República, have developed and implemented a diagnosis pipeline based on qRT-PCR using entirely local resources. In this context, we performed comparative quantitative proteomic analysis from oro- and naso-pharyngeal swabs used for diagnosis. Tryptic peptides obtained from five positive and five negative samples were analysed by nano-LC-MS/MS using a Q-Exactive Plus mass spectrometer. Data analysis was performed using PatternLab for Proteomics software. From all SARS-CoV-2 positive swabs we were able to detect peptides of the SARS-CoV-2 nucleoprotein that encapsulates and protect the RNA genome. Additionally, we detected an average of 1100 human proteins from each sample. The most abundant proteins exclusively detected in positive swabs were "Guanylate-binding protein 1", "Tapasin" and "HLA class II histocompatibility antigen DR beta chain". The biological processes overrepresented in infected host cells were "SRP-dependent cotranslational protein targeting to membrane", "nuclear-transcribed mRNA catabolic process, nonsense-mediated decay", "viral transcription" and "translational initiation". Data is available via ProteomeXchange with identifier PXD020394. We expect that this data can contribute to the future development of mass spectrometry based approaches for COVID-19 diagnosis. Also, we share this preliminary proteomic characterization concerning the host response to infection for its reuse in basic investigation. | 2352-3409 | 2020-08-09 02:00:00+02:00 | pubmed | Data in Brief | Bernardina Rivera;Alejandro Leyva;María Magdalena Portela;Gonzalo Moratorio;Pilar Moreno;Rosario Durán;Analía Lima | COVID-19;Nucleoprotein;Quantitative proteomics;SARS-CoV-2;Shotgun proteomics | 2020-08-05 02:00:00+02:00 | 32835036 | FR;UY | Unidad de Bioquímica y Proteómica Analíticas, Institut Pasteur de Montevideo & Instituto de Investigaciones Biológicas Clemente Estable, Mataojo 2020, CP 11400 Montevideo, Uruguay.;Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay.;Laboratorio de Inmunovirología, Institut Pasteur de Montevideo, Uruguay.;Laboratorio de Virología Molecular, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay. | 2045 | |||
| 10.1002/jha2.74 | Journal Article | en | Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes. | https://www.ncbi.nlm.nih.gov/pubmed/32838401 | 2688-6146,2688-6146 | 2020-08-09 02:00:00+02:00 | pubmed | eJHaem | Marie-Agnès Azerad;Firas Bayoudh;Thierry Weber;Jean-Marc Minon;Olivier Ketelslegers;Marie Hoyoux;Xueying Ren;Olivier Kaye;Nils De Marneffe;Vincent Fraipont;Catherine Masset;Anne Sophie Bouillon;Aurélie Jaspers;Malek Tebache;Guillaume D'Hoen;Anousha Habibi;André Efira;Jecko Thachil;Hans Deckmyn;Yves Beguin | 2020-08-04 02:00:00+02:00 | 32838401 | FR;BE;GB | Department of Haematology CHU of Liège at site CHR Citadelle Liège Belgium.;Thierry Weber Head of pneumology department CHR Citadelle Liège Belgium.;Head of Department of Laboratory Medicine Thrombosis-haemostasis and Transfusion unit CHR Citadelle Liège Belgium.;Department of Laboratory Medicine, Hemopathology Unit CHR Citadelle Liège Belgium.;Department of Paediatrics CHU of Liège at site CHR Citadelle Liège Belgium.;Department of Internal Medicine CHR Citadelle Liège Belgium.;Department of Rheumatology CHR Citadelle Liège Belgium.;Department of Cardiology CHR Citadelle Liège Belgium.;Head of Intensive Care Unit CHR Citadelle Liège Belgium.;Department of Nephrology and dialysis CHR Citadelle Liège Belgium.;Department of Radiology CHR Citadelle Liège Belgium.;Medical Direction Scientific Committee for COVID -19 at CHR Citadelle Liège Belgium.;Unité des Maladies Génétiques du Globule Rouge, APHP, Hôpitaux Universitaires Henri-Mondor, UPEC, Institut Mondor de recherche biomedicale (IMRB) Institut National de la Santé et de la Recherche Medicale (INSERM) U955 DHU A-TVB Créteil France.;Department of Haematology CHU Brugmann Bruxelles Belgium.;Department of Haematology Manchester Royal Infirmary Manchester UK.;Laboratory for Thrombosis Research KU Leuven Campus Kulak Kortrijk Kortrijk Belgium.;Department of Haematology, CHU of Liège and GIGA I3 University of Liège Liège Belgium. | 2048 | |||||
| 10.1016/j.resmer.2020.100778 | Editorial | en | Nebulization: A potential source of SARS-CoV-2 transmission. | https://www.ncbi.nlm.nih.gov/pubmed/32763845 | 2590-0412 | 2020-08-09 02:00:00+02:00 | pubmed | Respiratory Medicine and Research | G Reychler;L Vecellio;J C Dubus | Antifungal drugs;Azoles;Mucorales;Nebulization;Polyenes;Prophylaxis | 2020-08-04 02:00:00+02:00 | 32763845 | FR;BE | Service de Pneumologie, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Bruxelles, Belgique. Electronic address: gregory.reychler@uclouvain.be.;CEPR-INSERM U1100, Université de Tours, Faculté de Médecine, 37032 Tours cedex, France.;Pneumologie Pédiatrique, CHU Timone-Enfants, et Aix-Marseille Université, IRD, MEPHI, IHU Méditerranée-Infection, 13385 Marseille Cedex 5, France. | 2055 | ||||
| 10.1684/abc.2020.1572 | Historical Article;Journal Article | en | Point-of-care testing: place of France in the world National survey in healthcare establisments in 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32753365 | The point-of-care tests (POCT) are subject to accreditation. A national inventory survey provides a synthesis of knowledge. The survey distributed 31 questions in 2019. 147 responses were received (75% biologists, 49% CHU, 42% CHG). Only 20.41% are accredited ISO22870, the majority for <50% of the medical departments; 70% say they are going there at the end of 2019 or in 2020. The maps are unknown for 32% (EBMD) and 82% (TROD). Visibility is poor with: medical establishment committee (40%), IT department (31%). Connection is necessary for 87-95% depending on the criterion (QC, authorizations, etc.) and 66% of answers highlight that less than 50% of connexion is effective. The major advantage is the delay of the result (62.5%), then the relationship with the health teams (33.3%). The disadvantages: difficulty of the quality approach (45%), cost of tests (34.3%). Human resource requirements are identified for technicians (82%) and biologists (76%). The multiplicity of sites, devices and operators means that it is difficult to set up and maintain. Biology outside the laboratories, under biological responsibility, must meet a rigorous imperative quality approach. | 0003-3898 | 2020-08-09 02:00:00+02:00 | pubmed | Accreditation;Clinical Laboratory Services__standards;Clinical Laboratory Techniques__standards;Coronavirus Infections__diagnosis;France__epidemiology;Global Health__standards;History, 21st Century;Humans;Internationality;Laboratories__standards;Laboratory Proficiency Testing__standards;Pandemics;Pneumonia, Viral__diagnosis;Point-of-Care Systems__standards;Point-of-Care Testing__organization & administration;Quality Assurance, Health Care__organization & administration;Surveys and Questionnaires;COVID-19;COVID-19 diagnostic testing | Annales de Biologie Clinique | Marie-Christine Beauvieux;Erika Bost;Gladys Castaing-Mouhica;Catherine Terral;Nathalie Berthon;Isabelle Martinel;Emmanuelle Chauzit | ARS;AS;Agence régionale de santé;CLIA;CME;COVID-19;CQ;Clinical laboratory improvement amendements;Cofrac;Comité français d’accréditation;Comité médical d’établissement;DIV;DM;EBMD;GHT;Groupement hospitalier de territoire;IDE;ISO 22 870;PBP;PCR;POCT;RAQ;SF;TDR;TROD;accreditation;aide-soignant;contrôle de qualité;diagnostic in vitro;dispositifs médicaux;examens de biologie médicale délocalisée;infirmier diplômé d’Etat;polymerase chain reaction;pôle de biologie et pathologie;responsable assurance qualité;sage-femme;survey in France;test de diagnostic rapide;test rapide d’orientation diagnostique | 2020-08-06 02:00:00+02:00 | 32753365 | FR | Cellule de biologie délocalisée, CHU de Bordeaux, Bordeaux, France, Résonance magnétique des systèmes biologiques, UM5536 CNRS Université Bordeaux, Bordeaux, France.;Cellule de biologie délocalisée, CHU de Bordeaux, Bordeaux, France.;Cellule qualité, Pôle de biologie et pathologie, CHU de Bordeaux, Bordeaux, France. | 2059 | ||
| 10.1007/s12571-020-01093-0 | Journal Article | en | Mapping disruption and resilience mechanisms in food systems. | https://www.ncbi.nlm.nih.gov/pubmed/32837660 | This opinion article results from a collective analysis by the Editorial Board of Food Security. It is motivated by the ongoing covid-19 global epidemic, but expands to a broader view on the crises that disrupt food systems and threaten food security, locally to globally. Beyond the public health crisis it is causing, the current global pandemic is impacting food systems, locally and globally. Crises such as the present one can, and do, affect the stability of food production. One of the worst fears is the impacts that crises could have on the potential to produce food, that is, on the primary production of food itself, for example, if material and non-material infrastructure on which agriculture depends were to be damaged, weakened, or fall in disarray. Looking beyond the present, and not minimising its importance, the covid-19 crisis may turn out to be the trigger for overdue fundamental transformations of agriculture and the global food system. This is because the global food system does not work well today: the number of hungry people in the world has increased substantially, with the World Food Programme warning of the possibility of a "hunger pandemic". Food also must be nutritious, yet unhealthy diets are a leading cause of death. Deepening crises impoverish the poorest, disrupt food systems, and expand "food deserts". A focus on healthy diets for all is all the more relevant when everyone's immune system must react to infection during a global pandemic. There is also accumulating and compelling evidence that the global food system is pushing the Earth system beyond the boundaries of sustainability. In the past twenty years, the growing demand for food has increasingly been met through the destruction of Earth's natural environment, and much less through progress in agricultural productivity generated by scientific research, as was the case during the two previous decades. There is an urgent need to reduce the environmental footprint of the global food system: if its performances are not improved rapidly, the food system could itself be one main cause for food crises in the near future. The article concludes with a series of recommendations intended for policy makers and science leaders to improve the resilience of the food system, global to local, and in the short, medium and long term. | 1876-4517,1876-4525 | 2020-08-09 02:00:00+02:00 | pubmed | Food Security | Serge Savary;Sonia Akter;Conny Almekinders;Jody Harris;Lise Korsten;Reimund Rötter;Stephen Waddington;Derrill Watson | Global food security;crises;earth system;environmental footprint;spatial scales;system resilience;time characteristics | 2020-08-04 02:00:00+02:00 | 32837660 | FR;SG;TH;US;NL;ZA;MX;DE | UMR AGIR (AGroécologie, Innovations et teRritoires), INRAE, Institut National Polytechnique de Toulouse, INP-EI Purpan, Université de Toulouse, Castanet Tolosan, France.;Lee Kuan Yew School of Public Policy, The National University of Singapore, Singapore, Singapore.;Knowledge, Technology and Innovation, Social Sciences, Wageningen University, Hollandseweg 1, 6706 KN Wageningen, The Netherlands.;World Vegetable Center, Tainan, Thailand.;Department of Plant and Soil Sciences, Centre of Excellence Food Security, University of Pretoria, Pretoria, 0002 South Africa.;TROPAGS, Department of Crop Sciences, University of Göttingen, Grisebachstr. 6, 37077 Göttingen, Germany.;Apartado Postal 552, Centro, CP 62001 Cuernavaca, Morelos Mexico.;Department of Accounting, Finance, and Economics, Tarleton State University, Stephenville, TX 76401 USA. | 2070 | |||
| 10.1136/annrheumdis-2020-218145 | Journal Article | en | Response to: 'Presence of anti-phospholipid antibodies in COVID-19: a case series study' by Amezcua-Guerra et al. | https://www.ncbi.nlm.nih.gov/pubmed/32753427 | 0003-4967,1468-2060 | 2020-08-09 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Alexis Mathian;Marc Pineton De Chambrun;Alain Combes;Zahir Amoura | antibodies;anticardiolipin;antiphospholipid;antiphospholipid syndrome;hydroxychloroquine;lupus erythematosus;systemic | 2020-08-04 02:00:00+02:00 | 32753427 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Institut de Cardiométabolisme et Nutrition (ICAN), Service de Médecine Intensive-Réanimation, Inserm UMRS1166, Paris, France.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 2073 | ||||
| 10.1097/qad.0000000000002651 | Journal Article | en | HIV infection and COVID-19: risk factors for severe disease. | https://www.ncbi.nlm.nih.gov/pubmed/32773476 | : We performed an observational prospective monocentric study in patients living with HIV (PLWH) diagnosed with COVID-19. Fity four PLWH developed COVID-19 with respectively 14 severe (25.9%) and 5 critical cases (9.3%). By multivariate analysis, age, male gender, ethnic origin from Sub Saharan Africa, and metabolic disorder, were associated with severe or critical forms of COVID-19. Prior CD4 T cell counts did not differ between groups. No protective effect of a particular antiretroviral class was observed. | 0269-9370 | 2020-08-09 02:00:00+02:00 | pubmed | AIDS | Nicolas Etienne;Marina Karmochkine;Laurence Slama;Juliette Pavie;Dominique Batisse;Rafael Usubillaga;Valerie-Anne Letembet;Patricia Brazille;Etienne Canouï;Dorsaf Slama;Hassan Joumaa;Florence Canoui-Poitrine;Lauriane Segaux;Laurence Weiss;Jean-Paul Viard;Dominique Salmon | 2020-08-07 02:00:00+02:00 | 32773476 | FR | Department of Immunology and Infectious Diseases, Cochin and Hôtel-Dieu Hospitals, Assistance Publique -Hôpitaux de Paris (APHP). Centre - Université de Paris, Paris, France.;University of Paris School of Medicine, Paris, France.;Antimicrobial Stewardship Team, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.;Department of Pneumology, Cochin-Hôtel-Dieu Hospital, Assistance Publique -Hôpitaux de Paris (APHP), Paris, France.;Clinical Research Unit, Department of Public Health, Henri Mondor Hospital, AP-HP, Créteil, France.;University Paris-Est Créteil (UPEC) School of Medicine, Créteil, France.;INSERM U955, IMRB- CEpiA team, Henri Mondor Hospital, APHP, créteil, France. | 2092 | ||||
| 10.1016/j.jhin.2020.08.001 | Journal Article | en | SARS-CoV-2 infection: Advocacy for training and social distancing in healthcare settings. | https://www.ncbi.nlm.nih.gov/pubmed/32781200 | We report the observed SARS-Cov-2 infection rate in healthcare workers (HCWs) according to the ward dedicated or not to care of COVID-19 patients. This rate was significantly higher among HCWs working in units not dedicated to COVID-19 patients (OR=2.3, P=0.005), illustrating the need for strengthening social distancing measures and training. | 0195-6701 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Hospital Infection | Amandine Gagneux-Brunon;Carole Pelissier;Julie Gagnaire;Sylvie Pillet;Bruno Pozzetto;Elisabeth Botelho-Nevers;Philippe Berthelot | COVID-19;healthcare worker;prevention;social distance;training | 2020-08-08 02:00:00+02:00 | 32781200 | FR | Infection Control Unit, Infectious Diseases Department, University Hospital of Saint-Etienne, France, GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Université Jean Monnet Saint-Etienne, France, Institut Presage Université de Lyon, Université Jean Monnet France.;Occupational Health Unit, University Hospital of Saint-Etienne, France.;Infection Control Unit, Infectious Diseases Department, University Hospital of Saint-Etienne, France, Institut Presage Université de Lyon, Université Jean Monnet France.;GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Université Jean Monnet Saint-Etienne, France, Service des Agents Infectieux et Hygiène, University Hospital of Saint-Etienne, France.;Infection Control Unit, Infectious Diseases Department, University Hospital of Saint-Etienne, France, GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), University of Lyon, Université Jean Monnet Saint-Etienne, France, Institut Presage Université de Lyon, Université Jean Monnet France, Service des Agents Infectieux et Hygiène, University Hospital of Saint-Etienne, France. Electronic address: philippe.berthelot@chu-st-etienne.fr. | 2099 | |||
| NIA NIH HHS | 10.1371/journal.pone.0237056 | Journal Article;Research Support, N.I.H., Extramural | en | Change in five-factor model personality traits during the acute phase of the coronavirus pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32760108 | The rapid spread of the coronavirus and the strategies to slow it have disrupted just about every aspect of our lives. Such disruption may be reflected in changes in psychological function. The present study used a pre-posttest design to test whether Five Factor Model personality traits changed with the coronavirus outbreak in the United States. Participants (N = 2,137) were tested in early February 2020 and again during the President's 15 Days to Slow the Spread guidelines. In contrast to the preregistered hypotheses, Neuroticism decreased across these six weeks, particularly the facets of Anxiety and Depression, and Conscientiousness did not change. Interestingly, there was some evidence that the rapid changes in the social context had changed the meaning of an item. Specifically, an item about going to work despite being sick was a good indicator of conscientiousness before COVID-19, but the interpretation of it changed with the pandemic. In sum, the unexpected small decline in Neuroticism suggests that, during the acute phase of the coronavirus outbreak, feelings of anxiety and distress may be attributed more to the pandemic than to one's personality. | 1932-6203 | 2020-08-09 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Anxiety__pathology;Betacoronavirus__isolation & purification;Consciousness;Coronavirus Infections__epidemiology;Depression__pathology;Female;Humans;Internet;Male;Middle Aged;Neuroticism;Pandemics;Pneumonia, Viral__epidemiology;Surveys and Questionnaires;United States__epidemiology;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | PLOS ONE | Angelina R Sutin;Martina Luchetti;Damaris Aschwanden;Ji Hyun Lee;Amanda A Sesker;Jason E Strickhouser;Yannick Stephan;Antonio Terracciano | 2020-08-06 02:00:00+02:00 | 32760108 | FR;US | [{"country": "United States", "agency": "NIA NIH HHS", "grantid": "R01 AG053297"}] | Department of Behavioral Sciences and Social Medicine, Florida State University College of Medicine, Tallahassee, Florida, United States of America.;Department of Geriatrics, Florida State University College of Medicine, Tallahassee, Florida, United States of America.;Euromov, University of Montpellier, Montpellier, France. | 2104 | |
| 10.1016/j.anorl.2020.08.006 | Journal Article | en | Impact of the COVID-19 epidemic on ENT surgical volume. | https://www.ncbi.nlm.nih.gov/pubmed/32807696 | The purpose of this study was to assess the impact of the COVID-19 pandemic on the surgical volume of three ENT departments in Ile-de-France, a region severely affected by the epidemic. | 1879-7296 | 2020-08-09 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | R Hervochon;S Atallah;S Levivien;N Teissier;B Baujat;F Tankere | COVID-19;ENT surgery;Surgical volume | 2020-08-07 02:00:00+02:00 | 32807696 | FR | Service d'ORL, GHU Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France. Electronic address: remihervochon@gmail.com.;Service d'ORL, CHU Tenon, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.;Service d'ORL, CHU Robert Debré, Assistance Publique-Hôpitaux de Paris, Université Diderot, Paris, France.;Service d'ORL, GHU Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France. | 2112 | |||
| Letter | en | Impact of the COVID-19 lockdown on the management and control of patients with GCA. | https://www.ncbi.nlm.nih.gov/pubmed/32769157 | 2020-08-09 02:00:00+02:00 | pubmed | Roman Praliaud;Helene Greigert;Maxime Samson;Marianne Zeller;Mathieu Boulin;Philip Bielefeld;André Ramon;Yves Cottin;Bernard Bonnotte | giant cell arteritis;outcome and process assessment, health care;polymyalgia rheumatica | 2020-08-07 02:00:00+02:00 | 32769157 | FR | Department of Internal Medicine and Clinical Immunology, University Hospital Centre Dijon, Dijon, France.;INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, Dijon, France.;Department of Cardiology, University Hospital Centre Dijon, Dijon, France.;Department of Pharmacy, University Hospital Centre Dijon, Dijon, France.;Department of Rheumatology, University Hospital Centre Dijon, Dijon, France.;Department of Internal Medicine and Clinical Immunology, University Hospital Centre Dijon, Dijon, France bernard.bonnotte@chu-dijon.fr. | 2119 | |||||||
| 10.3390/v12080861 | Journal Article;Review | en | Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? | https://www.ncbi.nlm.nih.gov/pubmed/32784685 | Seven years after the Middle East respiratory syndrome (MERS) outbreak, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) made its first appearance in a food market in Wuhan, China, drawing an entirely new course to our lives. As the virus belongs to the same genus of MERS and SARS, researchers have been trying to draw lessons from previous outbreaks to find a potential cure. Although there were five Phase I human vaccine trials against SARS and MERS, the lack of data in humans provided us with limited benchmarks that could help us design a new vaccine for Coronavirus disease 2019 (COVID-19). In this review, we showcase the similarities in structures of virus components between SARS-CoV, MERS-CoV, and SARS-CoV-2 in areas relevant to vaccine design. Using the ClinicalTrials.gov and World Health Organization (WHO) databases, we shed light on the 16 current approved clinical trials worldwide in search for a COVID-19 vaccine. The different vaccine platforms being tested are Bacillus Calmette-Guérin (BCG) vaccines, DNA and RNA-based vaccines, inactivated vaccines, protein subunits, and viral vectors. By thoroughly analyzing different trials and platforms, we also discuss the advantages and disadvantages of using each type of vaccine and how they can contribute to the design of an adequate vaccine for COVID-19. Studying past efforts invested in conducting vaccine trials for MERS and SARS will provide vital insights regarding the best approach to designing an effective vaccine against COVID-19. | 1999-4915 | 2020-08-09 02:00:00+02:00 | pubmed | Viruses | Jawad Al-Kassmy;Jannie Pedersen;Gary Kobinger | COVID-19;MERS;SARS;clinical trials;coronavirus;vaccine | 2020-08-07 02:00:00+02:00 | 32784685 | FR;CA;US | Department of Experimental Surgery, McGill University, Montreal General Hospital 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada.;Axe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1V 4G2, Canada.;Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.;Department of Medical Microbiology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.;Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4238, USA. | 2120 | |||
| 10.1016/j.ijheh.2020.113600 | Journal Article | en | Surfaces and equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the emergency department at a university hospital. | https://www.ncbi.nlm.nih.gov/pubmed/32799101 | Environmental contamination by patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through respiratory droplets suggests that surfaces and equipment could be a medium of transmission. We aimed to assess the surface and equipment contamination by SARS-COV-2 of an emergency department (ED) during the coronavirus infectious disease-2019 (COVID-19) outbreak. | 1438-4639 | 2020-08-09 02:00:00+02:00 | pubmed | International Journal of Hygiene and Environmental Health | Olivier Peyrony;Sami Ellouze;Jean-Paul Fontaine;Micheline Thegat-Le Cam;Maud Salmona;Linda Feghoul;Nadia Mahjoub;Séverine Mercier-Delarue;Audrey Gabassi;Constance Delaugerre;Jérôme Le Goff | COVID-19;Contamination;Emergency department;Equipment;SARS-CoV-2;Surfaces | 2020-08-07 02:00:00+02:00 | 32799101 | FR | Emergency Department, Saint-Louis Hospital, AP-HP, Paris, France. Electronic address: olivier.peyrony@aphp.fr.;Emergency Department, Saint-Louis Hospital, AP-HP, Paris, France. Electronic address: sami.ellouze@aphp.fr.;Emergency Department, Saint-Louis Hospital, AP-HP, Paris, France. Electronic address: jean-paul.fontaine@aphp.fr.;Infection Control Team, Saint-Louis Hospital, AP-HP, Paris, France. Electronic address: micheline.thegat@aphp.fr.;Université de Paris, Virology Department, Saint-Louis Hospital, AP-HP, INSERM U976, Paris, France. Electronic address: maud.salmona@aphp.fr.;Université de Paris, Virology Department, Saint-Louis Hospital, AP-HP, INSERM U944, Paris, France. Electronic address: linda.feghoul@aphp.fr.;Virology Department, Saint-Louis Hospital, AP-HP, Paris, France. Electronic address: nadia.mahjoub@aphp.fr.;Virology Department, Saint-Louis Hospital, AP-HP, Paris, France. Electronic address: severine.mercier-delarue@aphp.fr.;Virology Department, Saint-Louis Hospital, AP-HP, Paris, France. Electronic address: audrey.gabassi@aphp.fr.;Université de Paris, Virology Department, Saint-Louis Hospital, AP-HP, INSERM U944, Paris, France. Electronic address: constance.delaugerre@aphp.fr.;Université de Paris, Virology Department, Saint-Louis Hospital, AP-HP, INSERM U976, Paris, France. Electronic address: jerome.le-goff@aphp.fr. | 2121 | |||
| 10.2196/20773 | Journal Article | en | Natural Language Processing for Rapid Response to Emergent Diseases: Case Study of Calcium Channel Blockers and Hypertension in the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32759101 | A novel disease poses special challenges for informatics solutions. Biomedical informatics relies for the most part on structured data, which require a preexisting data or knowledge model; however, novel diseases do not have preexisting knowledge models. In an emergent epidemic, language processing can enable rapid conversion of unstructured text to a novel knowledge model. However, although this idea has often been suggested, no opportunity has arisen to actually test it in real time. The current coronavirus disease (COVID-19) pandemic presents such an opportunity. | 1438-8871 | 2020-08-16 02:00:00+02:00 | pubmed | Betacoronavirus;Calcium Channel Blockers__therapeutic use;Coronavirus Infections__complications;Data Mining;Electronic Health Records;Humans;Hypertension__complications;Natural Language Processing;Pandemics;Pneumonia, Viral__complications;Time Factors;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Journal of Medical Internet Research | Antoine Neuraz;Ivan Lerner;William Digan;Nicolas Paris;Rosy Tsopra;Alice Rogier;David Baudoin;Kevin Bretonnel Cohen;Anita Burgun;Nicolas Garcelon;Bastien Rance | COVID-19;electronic health records;emergent disease;informatics;medication information;natural language processing;public health;response | 2020-08-14 02:00:00+02:00 | 32759101 | FR;US;UNK | Department of Biomedical Informatics, Necker-Enfant Malades Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.;Centre de Recherche des Cordeliers, INSERM UMRS 1138 Team 22, Université de Paris, Paris, France.;LIMSI, CNRS, Université Paris Saclay, Orsay, France.;Department of Biomedical Informatics, Georges Pompidou European Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.;DSI WIND, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.;School of Medicine, University of Colorado, Denver, CO, United States.;Institut Imagine, INSERM U1163, Université Paris Descartes, Université de Paris, Paris, France.;Please see acknowledgements for list of collaborators, . | 2126 | ||
| Letter;Comment | en | Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study. | https://www.ncbi.nlm.nih.gov/pubmed/32430410 | 2020-08-16 02:00:00+02:00 | pubmed | Mathilde Oranger;Jésus Gonzalez-Bermejo;Philippine Dacosta-Noble;Claudia Llontop;Antoine Guerder;Valery Trosini-Desert;Morgane Faure;Mathieu Raux;Maxens Decavele;Alexandre Demoule;Capucine Morélot-Panzini;Thomas Similowski | 2020-08-13 02:00:00+02:00 | 32430410 | FR;UNK | AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Paris, France.;M. Oranger and J. Gonzalez-Bermejo contributed equally and are both first authors.;Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France.;AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Département d'Anesthésie et Réanimation, Paris, France.;C. Morélot-Panzini and T. Similowski contributed equally and are both last authors.;AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Paris, France thomas.similowski@upmc.fr. | 2134 | ||||||||
| Letter | en | Switch in use of midazolam for cancer patients during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32791947 | 2020-08-16 02:00:00+02:00 | pubmed | Guillaume Marliot;Nicolas Penel;Vincent Gamblin | 2020-08-14 02:00:00+02:00 | 32791947 | FR | Pharmacy Department, Centre Oscar Lambret, Lille, France.;Medical Oncology Department, Centre Oscar Lambret, Lille, France.;Medical School, Lille University, Lille, France.;Palliative Care Unit, Centre Oscar Lambret, Lille, France. | 2136 | ||||||||
| 10.3174/ajnr.a6750 | Journal Article | en | Stroke Thrombectomy in Patients with COVID-19: Initial Experience in 13 Cases. | https://www.ncbi.nlm.nih.gov/pubmed/32816767 | We performed a retrospective review in both comprehensive stroke units of a region affected early by the coronavirus disease 2019 (COVID-19) pandemic, between March 1 and April 26, 2020, including patients with COVID-19 who underwent mechanical thrombectomy for ischemic stroke. We identified 13 cases, representing 38.2% of 34 thrombectomies performed during this period. We observed increased mortality and a high incidence of thrombotic complications during hospitalization. Given the high rate of infected patients, systematic use of full personal protection measures seems justified. | 0195-6108,1936-959X | 2020-08-16 02:00:00+02:00 | pubmed | American Journal of Neuroradiology | R Pop;A Hasiu;F Bolognini;D Mihoc;V Quenardelle;R Gheoca;E Schluck;S Courtois;M Delaitre;M Musacchio;J Pottecher;T-N Chamaraux-Tran;F Sellal;V Wolff;P A Lebedinsky;R Beaujeux | 2020-08-13 02:00:00+02:00 | 32816767 | FR;UNK | From the Interventional Neuroradiology Department (R.P., A.H., D.M., R.B.) pop.raoul@gmail.com.;Institut de Chirurgie Minime Invasive Guidée par l'Image (R.P., R.B.), Strasbourg, France.;From the Interventional Neuroradiology Department (R.P., A.H., D.M., R.B.).;Diagnostic and Interventional Neuroradiology Department (F.B., M.D., M.M., P.A.L.).;Stroke Unit (V.Q., R.G., V.W.).;Neurology Department (E.S., S.C.), Emile Muller Hospital, Mulhouse, France.;Department of Anesthesia (J.P., T.-N.C.-T.), Strasbourg University Hospitals, Strasbourg, France.;Neurology Department (F.S.), Hôpitaux Civils de Colmar, Colmar, France. | 2138 | ||||
| 10.1093/ibd/izaa202 | Journal Article | en | Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. | https://www.ncbi.nlm.nih.gov/pubmed/32793973 | Persons with inflammatory bowel disease (IBD) may be particularly vulnerable to COVID-19 either because of their underlying disease or its management. Guidance has been presented on the management of persons with IBD in the time of this pandemic by different groups. We aimed to determine how gastroenterologists around the world were approaching the management of IBD. | 1078-0998,1536-4844 | 2020-08-16 02:00:00+02:00 | pubmed | Inflammatory Bowel Diseases | Charles N Bernstein;Siew C Ng;Rupa Banerjee;Flavio Steinwurz;Bo Shen;Franck Carbonnel;Saeed Hamid;Ajit Sood;Jesus K Yamamoto-Furusho;Anne Griffiths;Eric I Benchimol;Simon Travis;Susana Lopes;David T Rubin;Gilaad G Kaplan;David Armstrong;Richard Gearry | COVID-9;immunomodulatory therapy;inflammatory bowel disease;management;pandemic | 2020-08-14 02:00:00+02:00 | 32793973 | FR;CA;NZ;CN;PT;GB;US;HK;BR;MX;IN;PK | University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.;Department of Medicine and Therapeutics, Institute of Digestive Disease, LK Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, China.;Asian Institute of Gastroenterology, Hyderabad, India.;Hospital Israelita Albert Einstein, Sao Paulo, Brazil.;Columbia University Irving Medical Center, New York, NY, USA.;Service de Gastroentérologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris Saclay, Le Kremlin-Bicêtre, France.;Aga Khan University, Karachi, Pakistan.;Dayanand Medical College and Hospital, Ludhiana, India.;National Institute of Medical Sciences and Nutrition, Mexico City, Mexico.;Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.;Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada.;Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.;Centro Hospitalar e Universitário São João, Porto, Portugal.;University of Chicago, Chicago, Illinois, USA.;University of Calgary, Calgary, Alberta, Canada.;McMaster University Medical Centre, Hamilton, Ontario, Canada.;Department of Medicine, University of Otago, Christchurch, New Zealand. | 2140 | |||
| Letter | en | Medical features of COVID-19 and influenza infection: A comparative study in Paris, France. | https://www.ncbi.nlm.nih.gov/pubmed/32798533 | 2020-08-16 02:00:00+02:00 | pubmed | Hélène Faury;Camille Courboulès;Mathilde Payen;Aude Jary;Pierre Hausfater;CharlesEdouard Luyt;Martin Dres;Valérie Pourcher;Basma Abdi;Marc Wirden;Vincent Calvez;Anne-Geneviève Marcelin;David Boutolleau;Sonia Burrel | COVID-19;Influenza;References: 10;Risk factors;Severe clinical forms | 2020-08-14 02:00:00+02:00 | 32798533 | FR | AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France.;Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France.;AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service d'Accueil des Urgences and Sorbonne Universités GRC-14 BIOSFAST et INSERM UMR-S 1166, Paris, France.;AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Institut de Cardiologie and Sorbonne Université, INSERM, UMRS_1166-ICAN Institut de Cardiométabolisme et Nutrition, Paris, France.;AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive et Réanimation, Paris, France, Sorbonne Université, INSERM, UMRS1158 Neurophysiologie respiratoire expérimentale et clinique - Réanimation, Paris, France.;Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses, Paris, France.;Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France. Electronic address: sonia.burrel@aphp.fr. | 2146 | |||||||
| Letter | en | COVID-19 pandemic more than a century after the Spanish flu. | https://www.ncbi.nlm.nih.gov/pubmed/32795410 | 2020-08-16 02:00:00+02:00 | pubmed | Emilie Javelle;Didier Raoult | 2020-08-11 02:00:00+02:00 | 32795410 | FR | Laveran Military Teaching Hospital, Marseille, France, IHU-Méditerranée Infection, 13005 Marseille, France, Aix-Marseille Université, IRD, AP-HM, SSA, MEPHI, and VITROME, Marseille, France. Electronic address: emilie.javelle@gmail.com.;IHU-Méditerranée Infection, 13005 Marseille, France, Aix-Marseille Université, IRD, AP-HM, SSA, MEPHI, and VITROME, Marseille, France. | 2157 | ||||||||
| 10.5664/jcsm.8742 | Journal Article | en | Long-term effects of treatment for chronic nightmares: is imagery rehearsal therapy robust in the COVID-19 pandemic? | https://www.ncbi.nlm.nih.gov/pubmed/32780012 | 1550-9389,1550-9397 | 2020-08-16 02:00:00+02:00 | pubmed | Journal of Clinical Sleep Medicine | Caroline Sierro;Wendy Leslie;Benjamin Putois | 2020-08-11 02:00:00+02:00 | 32780012 | GB;FR;CH | Swiss Distance Learning University, Brig, Switzerland.;Clinical Health Psychology, University of Ulster, Ulster, United Kingdom.;Lyon Neuroscience Research Center, CNRS UMR 5292, INSERM U1028, Lyon 1 University, France. | 2162 | |||||
| 10.1103/physreve.102.010401 | Journal Article | en | Self-isolation or borders closing: What prevents the spread of the epidemic better? | https://www.ncbi.nlm.nih.gov/pubmed/32794949 | Pandemic propagation of COVID-19 motivated us to discuss the impact of the human network clustering on epidemic spreading. Today, there are two clustering mechanisms which prevent of uncontrolled disease propagation in a connected network: an "internal" clustering, which mimics self-isolation (SI) in local naturally arranged communities, and an "external" clustering, which looks like a sharp frontiers closing (FC) between cities and countries, and which does not care about the natural connections of network agents. SI networks are "evolutionarily grown" under the condition of maximization of small cliques in the entire network, while FC networks are instantly created. Running the standard SIR model on clustered SI and FC networks, we demonstrate that the evolutionary grown clustered network prevents the spread of an epidemic better than the instantly clustered network with similar parameters. We find that SI networks have the scale-free property for the degree distribution P(k)∼k^{η}, with a small critical exponent -2<η<-1. We argue that the scale-free behavior emerges as a result of the randomness in the initial degree distributions. | 2470-0045,2470-0053 | 2020-08-16 02:00:00+02:00 | pubmed | Physical Review E | O Valba;V Avetisov;A Gorsky;S Nechaev | 2020-08-16 02:00:00+02:00 | 32794949 | FR;RU | Department of Applied Mathematics, National Research University Higher School of Economics, 101000 Moscow, Russia.;Federal Research Center of Chemical Physics RAS, 119991 Moscow, Russia.;Institute of Information Transmission Problems RAS, 127051 Moscow, Russia.;Moscow Institute of Physics and Technology, Dolgoprudny 141700, Russia.;Interdisciplinary Scientific Center Poncelet, CNRS UMI 2615, 119002 Moscow, Russia.;P.N. Lebedev Physical Institute RAS, 119991 Moscow, Russia. | 2163 | ||||
| 10.1182/blood.2020006228 | Journal Article | en | Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient. | https://www.ncbi.nlm.nih.gov/pubmed/32790855 | 0006-4971,1528-0020 | 2020-08-16 02:00:00+02:00 | pubmed | Blood | Gregoire Stalder;Lorenzo Alberio | 2020-08-14 02:00:00+02:00 | 32790855 | FR | Centre Hospitalier Universitaire Vaudois. | 2164 | |||||
| 10.1016/j.ohx.2020.e00131 | Journal Article | en | Partially RepRapable automated open source bag valve mask-based ventilator. | https://www.ncbi.nlm.nih.gov/pubmed/32835141 | This study describes the development of a simple and easy-to-build portable automated bag valve mask (BVM) compression system, which, during acute shortages and supply chain disruptions can serve as a temporary emergency ventilator. The resuscitation system is based on the Arduino controller with a real-time operating system installed on a largely RepRap 3-D printable parametric component-based structure. The cost of the materials for the system is under $170, which makes it affordable for replication by makers around the world. The device provides a controlled breathing mode with tidal volumes from 100 to 800 mL, breathing rates from 5 to 40 breaths/minute, and inspiratory-to-expiratory ratio from 1:1 to 1:4. The system is designed for reliability and scalability of measurement circuits through the use of the serial peripheral interface and has the ability to connect additional hardware due to the object-oriented algorithmic approach. Experimental results after testing on an artificial lung for peak inspiratory pressure (PIP), respiratory rate (RR), positive end-expiratory pressure (PEEP), tidal volume, proximal pressure, and lung pressure demonstrate repeatability and accuracy exceeding human capabilities in BVM-based manual ventilation. Future work is necessary to further develop and test the system to make it acceptable for deployment outside of emergencies such as with COVID-19 pandemic in clinical environments, however, the nature of the design is such that desired features are relatively easy to add using protocols and parametric design files provided. | 2468-0672 | 2020-08-16 02:00:00+02:00 | pubmed | HardwareX | Aliaksei Petsiuk;Nagendra G Tanikella;Samantha Dertinger;Adam Pringle;Shane Oberloier;Joshua M Pearce | 3-D printing;COVID-19;Coronavirus;Coronavirus pandemic;Embedded systems;Influenza pandemic;Medical hardware;Open hardware;Open source;Open source medical hardware;Pandemic;Pandemic ventilator;Real-time operating system;RepRap;Single-limb;Ventilation;Ventilator | 2020-08-11 02:00:00+02:00 | 32835141 | FI;FR;US | Department of Electrical & Computer Engineering, Michigan Technological University, USA.;Department of Materials Science & Engineering, Michigan Technological University, USA.;Biomedical Engineering, Michigan Technological University, USA.;Équipe de Recherche sur les Processus Innovatifs (ERPI) , Université de Lorraine, France.;School of Electrical Engineering, Aalto University, Finland. | 2166 | |||
| 10.1016/j.ijid.2020.08.024 | Journal Article | en | Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32798660 | No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. | 1201-9712 | 2020-08-16 02:00:00+02:00 | pubmed | International Journal of Infectious Diseases | Timothée Klopfenstein;Souheil Zayet;Anne Lohse;Phillippe Selles;Hajer Zahra;N'dri Juliette Kadiane-Oussou;Lynda Toko;Pierre-Yves Royer;Jean-Charles Balblanc;Vincent Gendrin;Thierry Conrozier | COVID-19;Mortality;SARS-CoV-2;TOCILIZUMAB;invasive mechanical ventilation | 2020-08-12 02:00:00+02:00 | 32798660 | FR | Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: timothee.klopfenstein@hnfc.fr.;Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: souhail.zayet@gmail.com.;Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Medical Information Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Diabetology and Endocrinology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. | 2177 | |||
| National Science Foundation | 10.1007/s00894-020-04472-8 | Journal Article | en | Computational analysis of complement inhibitor compstatin using molecular dynamics. | https://www.ncbi.nlm.nih.gov/pubmed/32789582 | The complement system plays a major role in human immunity, but its abnormal activation can have severe pathological impacts. By mimicking a natural mechanism of complement regulation, the small peptide compstatin has proven to be a very promising complement inhibitor. Over the years, several compstatin analogs have been created, with improved inhibitory potency. A recent analog is being developed as a candidate drug against several pathological conditions, including COVID-19. However, the reasons behind its higher potency and increased binding affinity to complement proteins are not fully clear. This computational study highlights the mechanistic properties of several compstatin analogs, thus complementing previous experimental studies. We perform molecular dynamics simulations involving six analogs alone in solution and two complexes with compstatin bound to complement component 3. These simulations reveal that all the analogs we consider, except the original compstatin, naturally adopt a pre-bound conformation in solution. Interestingly, this set of analogs adopting a pre-bound conformation includes analogs that were not known to benefit from this behavior. We also show that the most recent compstatin analog (among those we consider) forms a stronger hydrogen bond network with its complement receptor than an earlier analog. | 1610-2940,0948-5023 | 2020-08-16 02:00:00+02:00 | pubmed | Antiviral Agents__chemistry;Complement C3__antagonists & inhibitors;Coronavirus Infections__drug therapy;Humans;Hydrogen Bonding;Molecular Dynamics Simulation;Pandemics;Peptides, Cyclic__chemistry;Pneumonia, Viral__drug therapy;Structure-Activity Relationship;COVID-19 | Journal of Molecular Modeling | Didier Devaurs;Dinler A Antunes;Lydia E Kavraki | Complement inhibition;Complement system;Compstatin;Molecular dynamics | 2020-08-12 02:00:00+02:00 | 32789582 | FR;US | [{"country": "", "agency": "National Science Foundation", "grantid": "CCF 1423304"}] | University of Grenoble Alpes, CNRS, Inria, Grenoble INP, LJK, 38000, Grenoble, France.;Department of Computer Science, Rice University, 6100 Main St, Houston, TX, 77005, USA.;Department of Computer Science, Rice University, 6100 Main St, Houston, TX, 77005, USA. kavraki@rice.edu. | 2182 |
| 10.3390/biology9080220 | Journal Article | en | Mathematical Parameters of the COVID-19 Epidemic in Brazil and Evaluation of the Impact of Different Public Health Measures. | https://www.ncbi.nlm.nih.gov/pubmed/32806613 | A SIRU-type epidemic model is employed for the prediction of the COVID-19 epidemy evolution in Brazil, and analyze the influence of public health measures on simulating the control of this infectious disease. The proposed model allows for a time variable functional form of both the transmission rate and the fraction of asymptomatic infectious individuals that become reported symptomatic individuals, to reflect public health interventions, towards the epidemy control. An exponential analytical behavior for the accumulated reported cases evolution is assumed at the onset of the epidemy, for explicitly estimating initial conditions, while a Bayesian inference approach is adopted for the estimation of parameters by employing the direct problem model with the data from the first phase of the epidemy evolution, represented by the time series for the reported cases of infected individuals. The evolution of the COVID-19 epidemy in China is considered for validation purposes, by taking the first part of the dataset of accumulated reported infectious individuals to estimate the related parameters, and retaining the rest of the evolution data for direct comparison with the predicted results. Then, the available data on reported cases in Brazil from 15 February until 29 March, is used for estimating parameters and then predicting the first phase of the epidemy evolution from these initial conditions. The data for the reported cases in Brazil from 30 March until 23 April are reserved for validation of the model. Then, public health interventions are simulated, aimed at evaluating the effects on the disease spreading, by acting on both the transmission rate and the fraction of the total number of the symptomatic infectious individuals, considering time variable exponential behaviors for these two parameters. This first constructed model provides fairly accurate predictions up to day 65 below 5% relative deviation, when the data starts detaching from the theoretical curve. From the simulated public health intervention measures through five different scenarios, it was observed that a combination of careful control of the social distancing relaxation and improved sanitary habits, together with more intensive testing for isolation of symptomatic cases, is essential to achieve the overall control of the disease and avoid a second more strict social distancing intervention. Finally, the full dataset available by the completion of the present work is employed in redefining the model to yield updated epidemy evolution estimates. | 2079-7737 | 2020-08-16 02:00:00+02:00 | pubmed | Biology | Renato M Cotta;Carolina P Naveira-Cotta;Pierre Magal | Bayesian inference;Brazil;COVID-19;MCMC;SIRU model;epidemics modeling | 2020-08-12 02:00:00+02:00 | 32806613 | FR;BR | General Directorate of Nuclear and Technological Development, DGDNTM, Brazilian Navy, Ilha das Cobras, Centro, Rio de Janeiro, RJ CEP 20091-000, Brazil.;Laboratory of Nano & Microfluidics and Microsystems, LabMEMS, Mechanical Engineering Department, POLI & COPPE, UFRJ, Federal University of Rio de Janeiro, Cidade Universitária, Rio de Janeiro, RJ CEP 21945-970, Brazil.;Institut de Mathématiques de Bordeaux, Université de Bordeaux, 351, COURS de la Libération, 33400 Talence, France. | 2186 | |||
| 10.1089/jamp.2020.1615 | Journal Article | en | Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. | https://www.ncbi.nlm.nih.gov/pubmed/32783675 | National and international guidelines recommend droplet/airborne transmission and contact precautions for those caring for coronavirus disease 2019 (COVID-19) patients in ambulatory and acute care settings. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, an acute respiratory infectious agent, is primarily transmitted between people through respiratory droplets and contact routes. A recognized key to transmission of COVID-19, and droplet infections generally, is the dispersion of bioaerosols from the patient. Increased risk of transmission has been associated with aerosol generating procedures that include endotracheal intubation, bronchoscopy, open suctioning, administration of nebulized treatment, manual ventilation before intubation, turning the patient to the prone position, disconnecting the patient from the ventilator, noninvasive positive-pressure ventilation, tracheostomy, and cardiopulmonary resuscitation. The knowledge that COVID-19 subjects can be asymptomatic and still shed virus, producing infectious droplets during breathing, suggests that health care workers (HCWs) should assume every patient is potentially infectious during this pandemic. Taking actions to reduce risk of transmission to HCWs is, therefore, a vital consideration for safe delivery of all medical aerosols. Guidelines for use of personal protective equipment (glove, gowns, masks, shield, and/or powered air purifying respiratory) during high-risk procedures are essential and should be considered for use with lower risk procedures such as administration of uncontaminated medical aerosols. Bioaerosols generated by infected patients are a major source of transmission for SARS CoV-2, and other infectious agents. In contrast, therapeutic aerosols do not add to the risk of disease transmission unless contaminated by patients or HCWs. | 1941-2711,1941-2703 | 2020-08-16 02:00:00+02:00 | pubmed | Journal of Aerosol Medicine and Pulmonary Drug Delivery | James B Fink;Stephan Ehrmann;Jie Li;Patricia Dailey;Paul McKiernan;Chantal Darquenne;Andrew R Martin;Barbara Rothen-Rutishauser;Philip J Kuehl;Sabine Häussermann;Ronan MacLoughlin;Gerald C Smaldone;Bernhard Muellinger;Timothy E Corcoran;Rajiv Dhand | COVID-19;aerosol generating procedures;bioaerosol dispersion;filters;medical aerosol;risk factors | 2020-08-12 02:00:00+02:00 | 32783675 | FR;IE;CA;CH;US;MX;DE | Aerogen Pharma Corp., San Mateo, California, USA.;Division of Respiratory Care, Department of Cardiopulmonary Sciences, Rush University Medical Center, Chicago, Illinois, USA.;CHRU Tours, Médecine Intensive Réanimation, CIC INSERM 1415, CRICS-TriggerSep Research Network, Tours, France.;INSERM, Centre d'étude des Pathologies Respiratoires, U1100, Université de Tours, Tours, France.;Aerogen Limited, Galway, Ireland.;Department of Medicine, University of California, San Diego, California, USA.;Mechanical Engineering, University of Alberta, Edmonton, Canada.;Adolphe Merkle Institute, University of Fribourg, Fribourg, Switzerland.;Lovelace Biomedical, Albuquerque, New Mexico, USA.;VisionHealth GmbH, Garching Forschungszentrum, Germany.;School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons, Dublin, Ireland.;School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland.;Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, State University of New York at Stony Brook, Stony Brook, New York, USA.;Vectura GmbH, Gauting, Germany.;Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.;Department of Medicine, Graduate School of Medicine, University of Tennessee Health Science Center, Knoxville, Tennessee, USA. | 2190 | |||
| 10.1111/ajt.16251 | Journal Article | en | In-depth virological assessment of kidney transplant recipients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32777130 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread widely, causing coronavirus disease 2019 (COVID-19) and significant mortality. However, data on viral loads and antibody kinetics in immunocompromised populations are lacking. We aimed to determine nasopharyngeal and plasma viral loads via RT-PCR and SARS-CoV-2 serology via ELISA and study their association with severe forms of COVID-19 and death in kidney transplant recipients. In this study we examined hospitalized kidney transplant recipients with non-severe (n = 21) and severe (n =19) COVID-19. SARS-CoV-2 nasopharyngeal and plasma viral load and serological response were evaluated based on outcomes and disease severity. Ten recipients (25%) displayed persistent viral shedding 30 days after symptom onset. The SARS-CoV-2 viral load of the upper respiratory tract was not associated with severe COVID-19, whereas the plasma viral load was associated with COVID-19 severity (p=0.010) and mortality (p=0.010). All patients harbored antibodies the second week after symptom onset that persisted for two months. We conclude that plasma viral load is associated with COVID-19 morbidity and mortality, whereas nasopharyngeal viral load is not. SARS-CoV-2 shedding is prolonged in kidney transplant recipients and the humoral response to SARS-CoV-2 does not show significant impairment in this series of transplant recipients. | 1600-6135,1600-6143 | 2020-08-16 02:00:00+02:00 | pubmed | American Journal of Transplantation | Ilies Benotmane;Gabriela Gautier Vargas;Marie-Josée Wendling;Peggy Perrin;Aurélie Velay;Xavier Bassand;Dimitri Bedo;Clement Baldacini;Mylene Sagnard;Dogan Bozman;Margaux Della Chiesa;Morgane Solis;Floriane Gallais;Noëlle Cognard;Jerome Olagne;Héloïse Delagreverie;Louise Gontard;Baptiste Panaget;David Marx;Francoise Heibel;Laura Braun;Bruno Moulin;Sophie Caillard;Samira Fafi-Kremer | 2020-08-10 02:00:00+02:00 | 32777130 | FR | Department of Nephrology and Transplantation, University Hospital, Strasbourg, France.;Department of Virology, Strasbourg University Hospital, Strasbourg, France.;INSERM U1109, LabEx TRANSPLANTEX, Strasbourg, France. | 2193 | ||||
| 10.1007/s40261-020-00963-x | Journal Article;Review | en | Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32779119 | During the ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more attention should be paid to the balance of risks and benefits associated with proton pump inhibitors for the following reasons. One of the main functions of gastric juice is to inactivate swallowed microorganisms, thereby inhibiting infectious agents from reaching the intestine. Studies have documented that proton pump inhibitors are a risk factor for rotavirus, influenza virus, norovirus, and Middle East respiratory syndrome coronavirus infections, and are associated with an increased risk of acute gastroenteritis during periods of highest circulation of enteric viruses. In light of the evidence for gastrointestinal infection implying a fecal-oral transmission of SARS-CoV-2 and given the magnitude of the SARS-CoV-2/coronavirus disease 2019 pandemic, associated with the widespread misuse of proton pump inhibitors, this suggests that we should not rule out the hypothesis that patients treated with proton pump inhibitors may be more at risk of being infected by SARS-CoV-2. | 1173-2563,1179-1918 | 2020-08-16 02:00:00+02:00 | pubmed | Clinical Drug Investigation | Bruno Charpiat;Nathalie Bleyzac;Michel Tod | 2020-08-10 02:00:00+02:00 | 32779119 | FR | Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France. bruno.charpiat@chu-lyon.fr.;Service Pharmacie, Hôpital de La Croix-Rousse, Groupement Hospitalier Nord, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France.;EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins Cedex, France. | 2198 | ||||
| 10.1136/bjsports-2020-103091 | Journal Article | en | Infectious Diseases Outbreak Management Tool for endurance mass participation sporting events: an international effort to counteract the COVID-19 spread in the endurance sport setting. | https://www.ncbi.nlm.nih.gov/pubmed/32819919 | 0306-3674,1473-0480 | 2020-08-23 02:00:00+02:00 | pubmed | British Journal of Sports Medicine | Paolo Emilio Adami;John Cianca;Brian McCloskey;Wayne Derman;Juergen Michael Steinacker;Francis O'Connor;Sergio Migliorini;Richard Budgett;Fumihiro Yamasawa;Inggard Lereim;Xavier Bigard;Chris Troyanos;Frederic Garrandes;Stephane Bermon | cross-country skiing;cycling;rowing;running;triathlon | 2020-08-20 02:00:00+02:00 | 32819919 | FR;MC;NO;JP;CH;GB;US;IT;ZA;DE | Health and Science, World Athletics, Monaco paoloemilio.adami@worldathletics.org.;Sport, Human and Health sciences, HUniversità degli Studi di Roma 'Foro Italico', Roma, Lazio, Italy.;International Institute for Race Medicine, Plymouth, Massachusetts, USA.;Human Performance Center, Houston, Texas, USA.;Centre on Global Health Security, Chatham House, London, UK.;Co-chair WHO Expert Group on COVID-19 and Mass Gatherings, World Health Organization, Geneva, Switzerland.;Institute of Sports and Exercise Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Tygerberg, South Africa.;International Olympic Committee Research Centre, Cape Town, South Africa.;International Paralympic Committee, Bonn, Germany.;Sport- und Rehabilitationsmedizin, Universitat Ulm, Ulm, Germany.;Sports Medicine Commission, World Rowing Federation, Lausanne, Switzerland.;Consortium for Health and Military Performance (CHAMP), Military and Emergency Medicine, Uniformed Services University, Bethesda, Maryland, USA.;Medical Committee, International Triathlon Union, ITU, Lausanne, Switzerland.;International Olympic Committee, Lausanne, Switzerland.;Health and Science, World Athletics, Monaco.;Marubeni Health Promotion Center, Tokyo, Japan.;Neuroscience Department, Norwegian University of Science and Technology, Trondheim, Norway.;Medical Committee, International Ski Federation, Oberhofen/Thunersee, Switzerland.;Val-de-Grace Medical School, Paris, France.;Medical Department, International Cycling Union, Aigle, Switzerland.;LAMHESS, Université Côte d'Azur, Nice, France. | 2204 | ||||
| Letter;Comment | en | On tuberculosis and COVID-19 co-infection. | https://www.ncbi.nlm.nih.gov/pubmed/32586888 | 2020-08-23 02:00:00+02:00 | pubmed | Marina Tadolini;José-María García-García;François-Xavier Blanc;Sergey Borisov;Delia Goletti;Ilaria Motta;Luigi Ruffo Codecasa;Simon Tiberi;Giovanni Sotgiu;Giovanni Battista Migliori | 2020-08-20 02:00:00+02:00 | 32586888 | FR;RU;GB;IT;ES | Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.;Tuberculosis Research Programme (PII-TB), SEPAR, Barcelona, Spain.;Centre Hospitalier Universitaire, Nantes, France.;Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation.;Translational Research Unit, National Institute for Infectious Diseases "L. Spallanzani", IRCCS, Rome, Italy.;Dipartimento di Scienze Mediche, Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italia.;TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy.;Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.;Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.;Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.;Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy giovannibattista.migliori@icsmaugeri.it. | 2207 | ||||||||
| 10.1136/annrheumdis-2020-218644 | Journal Article | en | Response to: 'Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?' by Yamashita et al. | https://www.ncbi.nlm.nih.gov/pubmed/32826274 | 0003-4967,1468-2060 | 2020-08-23 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Marie Pouletty;Glory Dingulu;Naim Ouldali;Olivier Corseri;Camille Ducrocq;Ulrich Meinzer;Albert Faye;Caroline Galeotti;Isabelle Melki | autoimmune diseases;cytokines;inflammation | 2020-08-21 02:00:00+02:00 | 32826274 | FR | General Paediatrics, Department of Infectious Disease and Internal Medicine, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Robert Debré University Hospital, AP-HP, Paris, France.;Université de Paris, UFR de Médecine Paris Nord, 75010 Paris, France.;INSERM UMR 1123, ECEVE, Paris, France.;Center for Research on Inflammation, UMR1149, INSERM, Paris, France.;Biology and Genetics of Bacterial Cell Wall Unit, Pasteur Institute, Paris, France.;Department of Pediatric Rheumatology, Reference centre for Autoinflammatory diseases and amyloidosis (CEREMAIA), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France.;General Paediatrics, Department of Infectious Disease and Internal Medicine, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Robert Debré University Hospital, AP-HP, Paris, France isabelle.melki@aphp.fr.;Paediatric Hematology-Immunology and Rheumatology Department, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France, Necker-Enfants-Malades University Hospital, AP-HP, Paris, France.;Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris, France. | 2213 | ||||
| 10.1016/j.ijid.2020.08.049 | Journal Article | en | Clusters of COVID-19 associated with Purim celebration in the Jewish community in Marseille, France, March 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32829043 | We investigated possible COVID-19 epidemic clusters and their common sources of exposure that led to a sudden increase in the incidence of COVID-19 in the Jewish community of Marseille between March 15 and March 20, 2020. | 1201-9712 | 2020-08-23 02:00:00+02:00 | pubmed | International Journal of Infectious Diseases | Sarah Aherfi;Philippe Gautret;Hervé Chaudet;Didier Raoult;Bernard La Scola | COVID-19;Jewish community;Purim;attack rate;children | 2020-08-20 02:00:00+02:00 | 32829043 | FR | Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France, MEPHI, Institut de Recherche pour le Développement (IRD), Aix-Marseille Université, Marseille, France, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France. Electronic address: sarah.aherfi@ap-hm.fr.;Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France, VITROME, Institut de Recherche pour le Développement (IRD), Aix-Marseille Université, Marseille, France.;Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.;Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France, MEPHI, Institut de Recherche pour le Développement (IRD), Aix-Marseille Université, Marseille, France, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France. | 2214 | |||
| 10.1007/s10875-020-00839-x | Journal Article | en | Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32829467 | We report a longitudinal analysis of the immune response associated with a fatal case of COVID-19 in Europe. This patient exhibited a rapid evolution towards multiorgan failure. SARS-CoV-2 was detected in multiple nasopharyngeal, blood, and pleural samples, despite antiviral and immunomodulator treatment. Clinical evolution in the blood was marked by an increase (2-3-fold) in differentiated effector T cells expressing exhaustion (PD-1) and senescence (CD57) markers, an expansion of antibody-secreting cells, a 15-fold increase in γδ T cell and proliferating NK-cell populations, and the total disappearance of monocytes, suggesting lung trafficking. In the serum, waves of a pro-inflammatory cytokine storm, Th1 and Th2 activation, and markers of T cell exhaustion, apoptosis, cell cytotoxicity, and endothelial activation were observed until the fatal outcome. This case underscores the need for well-designed studies to investigate complementary approaches to control viral replication, the source of the hyperinflammatory status, and immunomodulation to target the pathophysiological response. The investigation was conducted as part of an overall French clinical cohort assessing patients with COVID-19 and registered in clinicaltrials.gov under the following number: NCT04262921. | 0271-9142,1573-2592 | 2020-08-23 02:00:00+02:00 | pubmed | Journal of Clinical Immunology | Lila Bouadma;Aurélie Wiedemann;Juliette Patrier;Mathieu Surénaud;Paul-Henri Wicky;Emile Foucat;Jean-Luc Diehl;Boris P Hejblum;Fabrice Sinnah;Etienne de Montmollin;Christine Lacabaratz;Rodolphe Thiébaut;J F Timsit;Yves Lévy | COVID-19;T cells;cytokines;immune dysfunction | 2020-08-22 02:00:00+02:00 | 32829467 | FR | APHP- Hôpital Bichat - Médecine Intensive et Réanimation des Maladies Infectieuses, Paris, France.;UMR 1137 - IAME Team 5 - DeSCID: Decision Sciences in Infectious Diseases, Control and Care, Inserm/Univ Paris Diderot, Sorbonne Paris Cité, Paris, France.;Vaccine Research Institute, Faculté de Médecine, INSERM U955, Université Paris-Est Créteil, Créteil, France.;APHP, Hôpital Georges Pompidou, Médecine Intensive Reanimation, Paris, France.;Univ. Bordeaux, Department of Public Health, Inserm Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, Vaccine Research Institute (VRI), Créteil, France.;CHU Bordeaux, Bordeaux, France.;Vaccine Research Institute, Faculté de Médecine, INSERM U955, Université Paris-Est Créteil, Créteil, France. yves.levy@aphp.fr.;Assistance Publique-Hôpitaux de Paris, Service Immunologie Clinique, Groupe Henri-Mondor Albert-Chenevier, Créteil, France. yves.levy@aphp.fr. | 2222 | |||
| Wellcome Trust;European Union: EU- LACANET | 10.1111/zph.12759 | Journal Article | en | Perception of health risks in Lao market vendors. | https://www.ncbi.nlm.nih.gov/pubmed/32812389 | Wet markets are a critical part of South-East Asian culture and economy. However, their role in circulation and transmission of both endemic and emerging disease is a source of concern in a region considered a hotspot of disease emergence. In the Lao People's Democratic Republic (Lao PDR, Laos), live and dead wild animals are frequently found in wet markets, despite legislation against the bushmeat trade. This is generally considered to increase the risk of disease transmission and emergence, although whether or not wildlife vendors themselves have indeed increased incidence of zoonotic disease has rarely been assessed. In preparation for a future longitudinal study of market vendors investigating vendors' exposure to zoonotic pathogens, we conducted a pilot survey of Lao market vendors of wildlife meat, livestock meat and vegetables, to identify demographic characteristics and potential control groups within markets. We also investigated baseline risk perception for infectious diseases among market vendors and assessed the association between risk perception and risk mitigation behaviours. The surveys conducted with 177 vendors revealed similar age, sex, ethnic background and geographical origin between vendor types, but differences in professional background and work history for livestock meat vendors. The perception of disease risk was very low across all vendors, as was the reported use of personal protective equipment, and the two appeared unrelated. Personal risk discounting and assumptions about transmission routes may explain this lack of association. This information will help inform the development of future research, risk communication and risk mitigation policy, especially in the light of the COVID-19 pandemic. | 2020-08-23 02:00:00+02:00 | pubmed | Chanfong Philavong;Mathieu Pruvot;Daniel Reinharz;Mayfong Mayxay;Kongsy Khammavong;Phonesavanh Milavong;Sayapeth Rattanavong;Paul F Horwood;Philippe Dussart;Bounlom Douangngeun;Watthana Theppangna;Amanda E Fine;Matthew T Robinson;Paul N Newton | Laos;bushmeat;food;health risk;markets;one health;risk perception;wildlife;zoonoses | 2020-08-19 02:00:00+02:00 | 32812389 | FR;CA;LA;GB;US;AU;KH | [{"country": "United Kingdom", "agency": "Wellcome Trust"}, {"country": "", "agency": "European Union: EU- LACANET", "grantid": "DCIASIE/2013/315-151"}] | Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR.;Ministry of Health, Vientiane, Lao PDR.;Institut de la Francophonie pour la Médecine Tropicale, Vientiane, Lao PDR.;Wildlife Conservation Society, Health Program, Bronx, NY, USA.;Département de Médecine Sociale et Préventive, Université Laval, Québec City, QC, Canada.;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.;Institute of Research and Education Development, University of Health Sciences, Vientiane, Lao PDR.;Wildlife Conservation Society, Lao PDR Program, Vientiane, Lao PDR.;College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Australia.;Virology Unit, Institut Pasteur du Cambodge, Institut Pasteur International Network, Phnom Penh, Cambodia.;Department of Livestock and Fisheries, National Animal Health Laboratory, Ministry of Agriculture, Vientiane, Lao PDR. | 2227 | |||
| 10.1126/scitranslmed.abc3103 | Journal Article | en | A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. | https://www.ncbi.nlm.nih.gov/pubmed/32817357 | It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti-SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals prior to the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the Luciferase Immunoprecipitation System (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the C-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti-SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly-symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region. | 1946-6234,1946-6242 | 2020-08-23 02:00:00+02:00 | pubmed | Science Translational Medicine | Ludivine Grzelak;Sarah Temmam;Cyril Planchais;Caroline Demeret;Laura Tondeur;Christèle Huon;Florence Guivel-Benhassine;Isabelle Staropoli;Maxime Chazal;Jeremy Dufloo;Delphine Planas;Julian Buchrieser;Maaran Michael Rajah;Remy Robinot;Françoise Porrot;Mélanie Albert;Kuang-Yu Chen;Bernadette Crescenzo-Chaigne;Flora Donati;François Anna;Philippe Souque;Marion Gransagne;Jacques Bellalou;Mireille Nowakowski;Marija Backovic;Lila Bouadma;Lucie Le Fevre;Quentin Le Hingrat;Diane Descamps;Annabelle Pourbaix;Cédric Laouénan;Jade Ghosn;Yazdan Yazdanpanah;Camille Besombes;Nathalie Jolly;Sandrine Pellerin-Fernandes;Olivia Cheny;Marie-Noëlle Ungeheuer;Guillaume Mellon;Pascal Morel;Simon Rolland;Felix A Rey;Sylvie Behillil;Vincent Enouf;Audrey Lemaitre;Marie-Aude Créach;Stephane Petres;Nicolas Escriou;Pierre Charneau;Arnaud Fontanet;Bruno Hoen;Timothée Bruel;Marc Eloit;Hugo Mouquet;Olivier Schwartz;Sylvie van der Werf | 2020-08-17 02:00:00+02:00 | 32817357 | FR;UNK | Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France, CNRS UMR 3569, Paris, France, Vaccine Research Institute, Creteil, France.;Université de Paris, Sorbonne Paris Cité, Paris, France.;Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France.;Laboratory of Humoral Immunology, Department of Immunology, Institut Pasteur, INSERM U1222, Paris, France.;Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur CNRS UMR 3569, Université de Paris, Paris, France.;Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France.;Department of Virology, Institut Pasteur, Paris, France.;National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.;RNA Biology of Influenza Virus, Department of Virology, Institut Pasteur, Paris, France.;Pasteur-TheraVectys joined unit.;Molecular Virology & Vaccinology Unit, Department of Virology, Institut Pasteur, Paris, France.;Innovation lab: Vaccines, Institut Pasteur, Paris, France.;Plate-Forme Technologique Production et Purification de Protéines Recombinantes, Institut Pasteur, Paris, France.;Structural Virology Unit, Department of Virology, Institut Pasteur, Paris, France, CNRS UMR 3569, Paris, France.;Université of Paris, INSERM UMR 1137 IAME, Paris, France.;Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, France.;Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, France.;Department of Infectious diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, France.;Department of Epidemiology, Biostatistics and Clinical Research, Assistance Publique-Hôpitaux de Paris, Bichat Claude Bernard University Hospital, INSERM CIC-EC 1425, Paris, France.;Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France.;Unité Coordination du Risque Epidémique et Biologique, AP-HP, Hôpital Necker, Paris, France.;Etablissement Français du Sang (EFS), Paris, France.;Service de maladies infectieuses, hôpital universitaire Cavale Blanche, Brest, France , CIC 1417, CIC de vaccinologie Cochin-Pasteur, AP-HP, Hôpital Cochin, Paris, France.;Direction alerte et crises, réserve sanitaire, Santé publique France, Saint-Maurice, France.;Centre d'épidémiologie et de santé publique des armées, Marseille, and Direction Générale de la Santé, Paris, France.;PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France.;Direction de la recherche médicale, Institut Pasteur, Paris, France.;Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France. marc.eloit@pasteur.fr schwartz@pasteur.fr.;National Veterinary School of Alfort, Maisons-Alfort, France.;Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France, CNRS UMR 3569, Paris, France, Vaccine Research Institute, Creteil, France. marc.eloit@pasteur.fr schwartz@pasteur.fr. | 2228 | ||||
| 10.1016/j.rehab.2020.08.001 | Journal Article | en | Emerging health challenges for children with physical disabilities and their parents during the COVID-19 pandemic: the ECHO French survey. | https://www.ncbi.nlm.nih.gov/pubmed/32818674 | The daily lives of children with physical disabilities and their families have been significantly affected by the COVID-19 pandemic. The children face health risks, especially mental, behavioral, social and physical risks. | 1877-0657 | 2020-08-23 02:00:00+02:00 | pubmed | Annals of Physical and Rehabilitation Medicine | Marine Cacioppo;Sandra Bouvier;Rodolphe Bailly;Laetitia Houx;Mathieu Lempereur;Johanne Mensah-Gourmel;Christèle Kandalaft;Roxane Varengue;Alain Chatelin;Jacky Vagnoni;Carole Vuillerot;Vincent Gautheron;Mickael Dinomais;Elea Dheilly;Sylvain Brochard;Christelle Pons | COVID-19;children with physical disabilities;lockdown;rehabilitation;wellbeing | 2020-08-17 02:00:00+02:00 | 32818674 | FR | Fondation Ildys, Brest, France, Service de Médecine Physique et de Réadaptation, CHRU Brest, Brest, France, Laboratoire de Traitement de l'information Médicale (LaTIM), Inserm U1101, Université Bretagne Occidentale, France. Electronic address: marine.cacioppo@ildys.org.;Laboratoire de Traitement de l'information Médicale (LaTIM), Inserm U1101, Université Bretagne Occidentale, France, CHRU Brest, Brest, France.;Fondation Ildys, Brest, France, Laboratoire de Traitement de l'information Médicale (LaTIM), Inserm U1101, Université Bretagne Occidentale, France.;Fondation Ildys, Brest, France, Service de Médecine Physique et de Réadaptation, CHRU Brest, Brest, France, Laboratoire de Traitement de l'information Médicale (LaTIM), Inserm U1101, Université Bretagne Occidentale, France.;Service de Médecine Physique et de Réadaptation, CHRU Brest, Brest, France, Laboratoire de Traitement de l'information Médicale (LaTIM), Inserm U1101, Université Bretagne Occidentale, France.;Fondation Ildys, Brest, France.;Expert parent, Paris, France.;Département de neurologie pédiatrique, CHU Angers, Angers, France.;Fondation Paralysie Cérébrale, France.;Fédération Française des Associations d'Infirmes Moteurs Cérébraux, France.;Service de Médecine Physique et de Réadaptation Pédiatrique, Hôpital Mère-Enfant, hospices civils de Lyon, 69500, Bron, France, Institut Neuromyogène CNRS UMR 5310 INSERM U1217, Université de Lyon, Lyon, France.;Service de Médecine Physique et de Réadaptation Pédiatrique, CHU Saint-Etienne, Saint-Etienne, France, Université de Lyon, UJM Saint-Etienne, Laboratoire Interuniversitaire de biologie de la motricité, EA7424, 42023, Saint-Etienne, France.;Service de Médecine Physique et de Réadaptation, CHU Angers -Les Capucins, Angers, France, Laboratoire Angevin de recherche en ingénierie des systèmes (LARIS) EA7315, Université d'Angers, Angers, France. | 2230 | |||
| 10.4037/ccn2020799 | Journal Article | en | A California Hospital's Response to COVID-19: From a Ripple to a Tsunami Warning. | https://www.ncbi.nlm.nih.gov/pubmed/32803240 | The outbreak of coronavirus disease 2019 (COVID-19) rippled across the world from Wuhan, China, to the shores of the United States within a few months. Hospitals and intensive care units were suddenly faced with a "tsunami" warning requiring instantaneous implementation and escalation of disaster plans. | 0279-5442,1940-8250 | 2020-08-23 02:00:00+02:00 | pubmed | Critical Care Nurse | Mary Kay Bader;Annabelle Braun;Cherie Fox;Lauren Dwinell;Jennifer Cord;Marne Andersen;Bryan Noakes;Daniel Ponticiello | 2020-08-17 02:00:00+02:00 | 32803240 | FR;US;UNK | Mary Kay Bader is a neuro/critical care clinical nurse specialist, Mission Hospital, Mission Viejo, California. She is the President of the Neurocritical Care Society.;Annabelle Braun is Executive Director of Critical Care and Emergency Services, Mission Hospital.;Cherie Fox is Executive Director of Acute Care Services, Mission Hospital. She is Hospital Incident Command Structure incident commander and operations chief for Mission Hospital.;Lauren Dwinell was the Executive Director, Patient Flow Operations, Mission Hospital at the time this article was written.;Jennifer Cord is Chief Nursing Officer, Mission Hospital.;Marne Andersen is Nurse Manager, cardiac intensive care unit, Mission Hospital.;Bryan Noakes is Nurse Manager, surgical intensive care unit, Mission Hospital.;Daniel Ponticiello is Medical Director, Critical Care Services, Mission Hospital. | 2233 | ||||
| Letter | en | Cytotoxic lesion of the corpus callosum as presenting neuroradiological manifestation of COVID-2019 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32809155 | 2020-08-23 02:00:00+02:00 | pubmed | Géraud Forestier;Isaure de Beaurepaire;Grégoire Bornet;Grégoire Boulouis | 2020-08-18 02:00:00+02:00 | 32809155 | FR;US | Neuroradiology Department, University Hospital of Limoges, Dupuytren, 2 avenue Martin Luther King, 87042, Limoges Cedex, France. geraudforestier@gmail.com.;Radiology Department, Hôpital Privé d'Antony, 25 Avenue de la Providence, 92160, Antony, France.;Neuroradiology Department, INSERM U1266, Université de Paris, Sainte-Anne Hospital, Paris, France. | 2239 | ||||||||
| 10.1038/s42003-020-01190-y | Journal Article;Research Support, Non-U.S. Gov't | en | Network pharmacology suggests biochemical rationale for treating COVID-19 symptoms with a Traditional Chinese Medicine. | https://www.ncbi.nlm.nih.gov/pubmed/32811894 | Chinese herbal formulas including the lung-cleaning and toxicity-excluding (LCTE) soup have played an important role in treating the ongoing COVID-19 pandemic (caused by SARS-CoV-2) in China. Applying LCTE outside of China may prove challenging due to the unfamiliar rationale behind its application in terms of Traditional Chinese Medicine. To overcome this barrier, a biochemical understanding of the clinical effects of LCTE is needed. Here, we explore the chemical compounds present in the reported LCTE ingredients and the proteins targeted by these compounds via a network pharmacology analysis. Our results indicate that LCTE contains compounds with the potential to directly inhibit SARS-CoV-2 and inflammation, and that the compound targets proteins highly related to COVID-19's main symptoms. We predict the general effect of LCTE is to affect the pathways involved in viral and other microbial infections, inflammation/cytokine response, and lung diseases. Our work provides a biochemical basis for using LCTE to treat COVID-19 and its main symptoms. | 2399-3642 | 2020-08-23 02:00:00+02:00 | pubmed | Communications Biology | Deng-Hai Zhang;Xue Zhang;Bin Peng;Sheng-Qiong Deng;Yu-Fang Wang;Lin Yang;Kai-Zheng Zhang;Chang-Quan Ling;Kun-Lun Wu | 2020-08-18 02:00:00+02:00 | 32811894 | FR;CN | Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, 200135, Shanghai, China. shanghai_zhang@hotmail.com.;Post-graduate Training Base in Shanghai Gongli, Post-Graduate College, Ningxia Medical University, 750004, Yinchuan, Ningxia Province, China. shanghai_zhang@hotmail.com.;Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, 200135, Shanghai, China.;Department of Research Affair Management, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, 200135, Shanghai, China.;Post-graduate Training Base in Shanghai Gongli, Post-Graduate College, Ningxia Medical University, 750004, Yinchuan, Ningxia Province, China.;The State Key Laboratory of Bioreactor Engineering, New World Institute of Biotechnology, East China University of Science and Technology, 200237, Shanghai, China.;The Traditional Chinese Medicines of Changhai Hospital, Secondary Military Medical University, 200433, Shanghai, China.;Department of Traditional Chinese Medicine, Shanghai Pudong Gongli Hospital, China, Secondary Military Medical University, 200135, Shanghai, China. | 2240 | ||||
| 10.1038/s41419-020-02842-x | Journal Article;Research Support, Non-U.S. Gov't | en | On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32814759 | The current epidemic of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) calls for the development of inhibitors of viral replication. Here, we performed a bioinformatic analysis of published and purported SARS-CoV-2 antivirals including imatinib mesylate that we found to suppress SARS-CoV-2 replication on Vero E6 cells and that, according to the published literature on other coronaviruses is likely to act on-target, as a tyrosine kinase inhibitor. We identified a cluster of SARS-CoV-2 antivirals with characteristics of lysosomotropic agents, meaning that they are lipophilic weak bases capable of penetrating into cells. These agents include cepharentine, chloroquine, chlorpromazine, clemastine, cloperastine, emetine, hydroxychloroquine, haloperidol, ML240, PB28, ponatinib, siramesine, and zotatifin (eFT226) all of which are likely to inhibit SARS-CoV-2 replication by non-specific (off-target) effects, meaning that they probably do not act on their 'official' pharmacological targets, but rather interfere with viral replication through non-specific effects on acidophilic organelles including autophagosomes, endosomes, and lysosomes. Imatinib mesylate did not fall into this cluster. In conclusion, we propose a tentative classification of SARS-CoV-2 antivirals into specific (on-target) versus non-specific (off-target) agents based on their physicochemical characteristics. | 2041-4889 | 2020-08-23 02:00:00+02:00 | pubmed | Cell Death & Disease | Allan Sauvat;Fabiola Ciccosanti;Francesca Colavita;Martina Di Rienzo;Concetta Castilletti;Maria Rosaria Capobianchi;Oliver Kepp;Laurence Zitvogel;Gian Maria Fimia;Mauro Piacentini;Guido Kroemer | 2020-08-19 02:00:00+02:00 | 32814759 | SE;FR;IT;CN | Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France.;Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France.;Department of Epidemiology, Preclinical Research, and Advanced Diagnostics, National Institute for Infectious Diseases 'L. Spallanzani' IRCCS, Rome, Italy.;Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.;INSERM U1015, Villejuif, France.;Center of Clinical Investigations in Biotherapies of Cancer (CICBT), 1428, Villejuif, France.;Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France.;Université Paris Sud, Paris Saclay, Faculty of Medicine, Kremlin Bicêtre, France.;Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.;Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.;Department of Epidemiology, Preclinical Research, and Advanced Diagnostics, National Institute for Infectious Diseases 'L. Spallanzani' IRCCS, Rome, Italy. mauro.piacentini@uniroma2.it.;Department of Biology, University of Rome 'Tor Vergata', Rome, Italy. mauro.piacentini@uniroma2.it.;Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France. kroemer@orange.fr.;Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France. kroemer@orange.fr.;Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China. kroemer@orange.fr.;Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. kroemer@orange.fr.;Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. kroemer@orange.fr. | 2246 | ||||
| 10.1017/s0950268820001831 | Journal Article | en | COVID-19: Relationship between atmospheric temperature and daily new cases growth rate. | https://www.ncbi.nlm.nih.gov/pubmed/32811577 | 0950-2688,1469-4409 | 2020-08-23 02:00:00+02:00 | pubmed | Epidemiology and Infection | A Rouen;J Adda;O Roy;E Rogers;P Levy | 2020-08-19 02:00:00+02:00 | 32811577 | FR | Département de Génétique Médicale, unité INSERM U933, Hôpital Armand-Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France.;Département de Cardiologie, CHU Montpellier, Montpellier, France.;Synlab Paris, Synlab France, Paris, France.;Institut Pierre-Louis de Santé Publique (INSERM UMR S 1136, EPAR Team), Sorbonne Université, Departement de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, 75020Paris, France. | 2249 | |||||
| 10.3390/biology9080235 | Journal Article | en | ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32824830 | The coronavirus pandemic raging worldwide since December 2019 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which invades human cells via the angiotensin-converting enzyme 2 (ACE2) receptor. Although it has already been identified in many organs, ACE2 expression remains largely unknown in the head and neck (HN) sphere. Thus, this study aims to investigate its protein expression in several sites of the upper aerodigestive tract in order to highlight potential routes of infection. We compared ACE2 immunohistochemical expression between 70 paraffin-embedded specimens with two different antibodies and reported the quantified expression in each histological location. Surprisingly, we obtained different results depending on the antibody, an absence of labeling having been observed with a monoclonal antibody raised against the extracellular domain, whereas the polyclonal, against the cytoplasmic part of the protein, revealed enriched ACE2 expression, particularly in sinuses, vocal cords, salivary glands and oral cavity epithelial cells. The interpretation of these discordant results has brought several exciting lines of reflection. In conclusion, this study provides possible routes of entry for the SARS-CoV-2 in HN region and, above all, has led us to encourage caution when studying the ACE2 expression which is currently at the center of all attention. | 2079-7737 | 2020-08-23 02:00:00+02:00 | pubmed | Biology | Géraldine Descamps;Laurine Verset;Anne Trelcat;Claire Hopkins;Jérome R Lechien;Fabrice Journe;Sven Saussez | ACE2;SARS-CoV-2;head and neck;immunohistochemistry;protein | 2020-08-18 02:00:00+02:00 | 32824830 | FR;BE;GB | Department of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMONS), Avenue du Champ de Mars 6, 7000 Mons, Belgium.;Department of Pathology, Institute Jules Bordet, Université Libre de Bruxelles, Rue Héger-Bordet 1, 1000 Brussels, Belgium.;Guy's and St Thomas' Hospitals, Westminster Bridge Road, London SE1 9RT, UK.;British Rhinological Society (President), 35-43 Lincoln's Inn Fields, London WC2A 3PE, UK.;Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), 40 Rue Worth, Suresnes, 92150 Paris, France.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, Université Libre de Bruxelles, Rue aux Laines 105, 1000 Brussels, Belgium.;Department of Oncology and Experimental Surgery, Institute Jules Bordet (IJB), Université Libre de Bruxelles (ULB), Rue Heger-Bordet 1, 1000 Brussels, Belgium. | 2254 | |||
| 10.1136/annrheumdis-2020-218147 | Journal Article | en | Rheumatic diseases and COVID-19: a cohort of 17 patients under DMARDs. Response to: 'Comment on: Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina et al. | https://www.ncbi.nlm.nih.gov/pubmed/32816687 | 0003-4967,1468-2060 | 2020-08-23 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Pierre-Marie Duret;Lionel Spielmann;Laurent Messer | ankylosing;antirheumatic agents;arthritis;biological therapy;infectious;rheumatoid;spondylitis | 2020-08-18 02:00:00+02:00 | 32816687 | FR | Service de Rhumatologie, Hôpitaux Civils de Colmar, Colmar, Alsace, France pierremarie.duret@gmail.com.;Service de Rhumatologie, Hôpitaux Civils de Colmar, Colmar, Alsace, France. | 2256 | ||||
| 10.1016/j.dib.2020.106178 | Journal Article | en | COVID-19: A scholarly production dataset report for research analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32837978 | COVID-2019 has been recognized as a global threat, and several studies are being conducted in order to contribute to the fight and prevention of this pandemic. This work presents a scholarly production dataset focused on COVID-19, providing an overview of scientific research activities, making it possible to identify countries, scientists and research groups most active in this task force to combat the coronavirus disease. The dataset is composed of 40,212 records of articles' metadata collected from Scopus, PubMed, arXiv and bioRxiv databases from January 2019 to July 2020. Those data were extracted by using the techniques of Python Web Scraping and preprocessed with Pandas Data Wrangling. In addition, the pipeline to preprocess and generate the dataset are versioned with the Data Version Control tool (DVC) and are thus easily reproducible and auditable. | 2352-3409 | 2020-08-23 02:00:00+02:00 | pubmed | Data in Brief | Breno Santana Santos;Ivanovitch Silva;Marcel da Câmara Ribeiro-Dantas;Gisliany Alves;Patricia Takako Endo;Luciana Lima | Bibliometrics;COVID-19;Data Science;Pandemic;SARS-CoV-2;Scientometrics | 2020-08-19 02:00:00+02:00 | 32837978 | FR;BR | Universidade Federal do Rio Grande do Norte (UFRN), Rio Grande do Norte, Brazil.;Núcleo de Pesquisa e Prática em Inteligência Competitiva (NUPIC), Universidade Federal de Sergipe (UFS), Itabaiana/SE, Brazil.;Institut Curie (UMR168), Sorbonne Université (EDITE), Paris, France.;Universidade de Pernambuco (UPE), Pernambuco, Brazil. | 2258 | |||
| 10.1016/j.xcrm.2020.100059 | Journal Article | en | Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. | https://www.ncbi.nlm.nih.gov/pubmed/32835306 | In the current COVID-19 pandemic context, proposing and validating effective treatments represents a major challenge. However, the scarcity of biologically relevant pre-clinical models of SARS-CoV-2 infection imposes a significant barrier for scientific and medical progress, including the rapid transition of potentially effective treatments to the clinical setting. We use reconstituted human airway epithelia to isolate and then characterize the viral infection kinetics, tissue-level remodeling of the cellular ultrastructure, and transcriptional early immune signatures induced by SARS-CoV-2 in a physiologically relevant model. Our results emphasize distinctive transcriptional immune signatures between nasal and bronchial HAE, both in terms of kinetics and intensity, hence suggesting putative intrinsic differences in the early response to SARS-CoV-2 infection. Most important, we provide evidence in human-derived tissues on the antiviral efficacy of remdesivir monotherapy and explore the potential of the remdesivir-diltiazem combination as an option worthy of further investigation to respond to the still-unmet COVID-19 medical need. | 2666-3791 | 2020-08-30 02:00:00+02:00 | pubmed | Cell Reports Medicine | Andrés Pizzorno;Blandine Padey;Thomas Julien;Sophie Trouillet-Assant;Aurélien Traversier;Elisabeth Errazuriz-Cerda;Julien Fouret;Julia Dubois;Alexandre Gaymard;François-Xavier Lescure;Victoria Dulière;Pauline Brun;Samuel Constant;Julien Poissy;Bruno Lina;Yazdan Yazdanpanah;Olivier Terrier;Manuel Rosa-Calatrava | COVID-19;SARS-CoV-2;cell ultrastructure remodeling;coronavirus;diltiazem;drug combination;innate immune response;remdesivir;repurposing | 2020-08-25 02:00:00+02:00 | 32835306 | FR;CH | CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Université de Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France.;Signia Therapeutics SAS, Lyon, France.;VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.;Laboratoire Commun de Recherche HCL-bioMérieux, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.;Centre d'Imagerie Quantitative Lyon-Est (CIQLE), Université Claude Bernard Lyon 1, Lyon, France.;Laboratoire de Virologie, Centre National de Référence des Virus Influenza Sud, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.;AP-HP, Infectious and Tropical Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France.;University of Paris, French Institute for Health and Medical Research (INSERM), IAME U1137, Team DesCID, Paris, France.;Epithelix Sàrl, Geneva, Switzerland.;Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France. | 2261 | |||
| 10.1007/s00134-020-05967-x | Journal Article | en | Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists. | https://www.ncbi.nlm.nih.gov/pubmed/32103284 | 0342-4642,1432-1238 | 2020-03-01 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections__epidemiology;Critical Care;Decision Making;Humans;Intensive Care Units;Pandemics;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Lila Bouadma;Francois-Xavier Lescure;Jean-Christophe Lucet;Yazdan Yazdanpanah;Jean-Francois Timsit | 2020-02-26 01:00:00+01:00 | 32103284 | FR | AP-HP, Bichat Claude Bernard Hospital, Medial and infectious diseases ICU (MI2), 75018, Paris, France.;Université de Paris, IAME, INSERM, 75018, Paris, France.;AP-HP, Hôpital Bichat, Infectious Diseases, 75018, Paris, France.;AP-HP, Hôpital Bichat, Infection Control Unit, 75018, Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Medial and infectious diseases ICU (MI2), 75018, Paris, France. Jean-Francois.timsit@aphp.fr.;Université de Paris, IAME, INSERM, 75018, Paris, France. Jean-Francois.timsit@aphp.fr. | 16 | ||||
| 10.1093/jtm/taaa031 | Editorial | en | The pandemic of social media panic travels faster than the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32125413 | 1195-1982,1708-8305 | 2020-03-08 01:00:00+01:00 | pubmed | Betacoronavirus;Communication;Coronavirus Infections__epidemiology;Fear;Humans;Information Dissemination;Pandemics;Pneumonia, Viral__epidemiology;Racism;Social Media;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Travel Medicine | Anneliese Depoux;Sam Martin;Emilie Karafillakis;Raman Preet;Annelies Wilder-Smith;Heidi Larson | 2020-03-04 01:00:00+01:00 | 32125413 | SE;FR;GB | Centre Virchow-Villerme, Paris, France.;London School of Hygiene and Tropical Medicine, London, UK.;Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden. | 20 | ||||
| 10.1016/j.antiviral.2020.104762 | Journal Article;Review | en | Of chloroquine and COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32147496 | Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research. | 0166-3542 | 2020-03-08 01:00:00+01:00 | pubmed | Antiviral Agents__adverse effects;Betacoronavirus__drug effects;China;Chloroquine__adverse effects;Clinical Trials as Topic__standards;Coronavirus Infections__drug therapy;Humans;Hydroxychloroquine__adverse effects;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Antiviral Research | Franck Touret;Xavier de Lamballerie | 2019-nCoV;Antiviral;COVID-19;Chloroquine;SARS-CoV-2 | 2020-03-05 01:00:00+01:00 | 32147496 | FR | Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, 13005, Marseille, France. Electronic address: franck.touret@univ-amu.fr.;Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, 13005, Marseille, France. Electronic address: xavier.de-lamballerie@univ-amu.fr. | 26 | ||
| 10.15698/cst2020.04.216 | Editorial | en | Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. | https://www.ncbi.nlm.nih.gov/pubmed/32292881 | Coronaviruses (CoVs) are a large family of enveloped, positive-strand RNA viruses. Four human CoVs (HCoVs), the non-severe acute respiratory syndrome (SARS)-like HCoVs (namely HCoV 229E, NL63, OC43, and HKU1), are globally endemic and account for a substantial fraction of upper respiratory tract infections. Non-SARS-like CoV can occasionally produce severe diseases in frail subjects but do not cause any major (fatal) epidemics. In contrast, SARS like CoVs (namely SARS-CoV and Middle-East respiratory syndrome coronavirus, MERS-CoV) can cause intense short-lived fatal outbreaks. The current epidemic caused by the highly contagious SARS-CoV-2 and its rapid spread globally is of major concern. There is scanty knowledge on the actual pandemic potential of this new SARS-like virus. It might be speculated that SARS-CoV-2 epidemic is grossly underdiagnosed and that the infection is silently spreading across the globe with two consequences: (i) clusters of severe infections among frail subjects could haphazardly occur linked to unrecognized index cases; (ii) the current epidemic could naturally fall into a low-level endemic phase when a significant number of subjects will have developed immunity. Understanding the role of paucisymptomatic subjects and stratifying patients according to the risk of developing severe clinical presentations is pivotal for implementing reasonable measures to contain the infection and to reduce its mortality. Whilst the future evolution of this epidemic remains unpredictable, classic public health strategies must follow rational patterns. The emergence of yet another global epidemic underscores the permanent challenges that infectious diseases pose and underscores the need for global cooperation and preparedness, even during inter-epidemic periods. | 2523-0204 | 2020-03-08 01:00:00+01:00 | pubmed | Cell Stress | Didier Raoult;Alimuddin Zumla;Franco Locatelli;Giuseppe Ippolito;Guido Kroemer | COVID-19;Coronavirus;MERS-CoV;SARS-CoV;epidemiology;immunology;sARS-CoV-2 | 2020-03-02 01:00:00+01:00 | 32292881 | FR;SE;CN;GB;US;IT | Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France, IHU Méditerranée Infection, Marseille, France.;Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK.;The National Institute of Health Research Biomedical Research Centre at UCL Hospitals, London, UK.;Department of Pediatric Hematology and Oncology IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.;National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.;Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.;Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.;Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.;Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.;Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. | 29 | |||
| 10.14336/ad.2020.0228 | Journal Article | en | Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32257537 | A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11bmid regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-α was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2- and TMPRSS2- which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition. | 2152-5250 | 2020-03-15 01:00:00+01:00 | pubmed | Aging and disease | Zikuan Leng;Rongjia Zhu;Wei Hou;Yingmei Feng;Yanlei Yang;Qin Han;Guangliang Shan;Fanyan Meng;Dongshu Du;Shihua Wang;Junfen Fan;Wenjing Wang;Luchan Deng;Hongbo Shi;Hongjun Li;Zhongjie Hu;Fengchun Zhang;Jinming Gao;Hongjian Liu;Xiaoxia Li;Yangyang Zhao;Kan Yin;Xijing He;Zhengchao Gao;Yibin Wang;Bo Yang;Ronghua Jin;Ilia Stambler;Lee Wei Lim;Huanxing Su;Alexey Moskalev;Antonio Cano;Sasanka Chakrabarti;Kyung-Jin Min;Georgina Ellison-Hughes;Calogero Caruso;Kunlin Jin;Robert Chunhua Zhao | ACE2 negative;COVID-19;cell transplantation;function recovery;immunomodulation;mesenchymal stem cells | 2020-03-09 01:00:00+01:00 | 32257537 | FR;IL;RU;CN;GB;US;HK;IT;ES;IN;KR | 1School of Life Sciences, Shanghai University, Shanghai, China.;5Department of Orthopaedics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.;2Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.;3Beijing YouAn Hospital, Capital Medical University, Beijing, China.;4Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.;6Institute of Stem Cell and Regeneration Medicine, School of Basic Medicine, Qingdao University, Shandong, China.;7Department of Orthopaedics, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.;8Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.;9The Executive Committee on Anti-aging and Disease Prevention in the framework of Science and Technology, Pharmacology and Medicine Themes under an Interactive Atlas along the Silk Roads, UNESCO, Paris, France.;10International Society on Aging and Disease, Fort Worth, Texas, USA.;11The Geriatric Medical Center "Shmuel Harofe", Beer Yaakov, affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.;12School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.;13Institute of Chinese Medical Science, University of Macau, Taipa, Macau, China.;14Institute of Biology, Komi Science Center of Russian Academy of Sciences, Syktyvkar, Russia.;15Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain.;16Maharishi Markandeshwar Deemed University, Mullana-Ambala, India.;17Department of Biological Sciences, Inha University, Incheon, South Korea.;18Faculty of Life Sciences & Medicine, King's College London, London, UK.;19Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy.;20University of North Texas Health Science Center, Fort Worth, TX76107, USA. | 41 | |||
| 10.1016/j.chaos.2020.109761 | Journal Article | en | Analysis and forecast of COVID-19 spreading in China, Italy and France. | https://www.ncbi.nlm.nih.gov/pubmed/32308258 | In this note we analyze the temporal dynamics of the coronavirus disease 2019 outbreak in China, Italy and France in the time window 22 / 01 - 15 / 03 / 2020 . A first analysis of simple day-lag maps points to some universality in the epidemic spreading, suggesting that simple mean-field models can be meaningfully used to gather a quantitative picture of the epidemic spreading, and notably the height and time of the peak of confirmed infected individuals. The analysis of the same data within a simple susceptible-infected-recovered-deaths model indicates that the kinetic parameter that describes the rate of recovery seems to be the same, irrespective of the country, while the infection and death rates appear to be more variable. The model places the peak in Italy around March 21st 2020, with a peak number of infected individuals of about 26000 (not including recovered and dead) and a number of deaths at the end of the epidemics of about 18,000. Since the confirmed cases are believed to be between 10 and 20% of the real number of individuals who eventually get infected, the apparent mortality rate of COVID-19 falls between 4% and 8% in Italy, while it appears substantially lower, between 1% and 3% in China. Based on our calculations, we estimate that 2500 ventilation units should represent a fair figure for the peak requirement to be considered by health authorities in Italy for their strategic planning. Finally, a simulation of the effects of drastic containment measures on the outbreak in Italy indicates that a reduction of the infection rate indeed causes a quench of the epidemic peak. However, it is also seen that the infection rate needs to be cut down drastically and quickly to observe an appreciable decrease of the epidemic peak and mortality rate. This appears only possible through a concerted and disciplined, albeit painful, effort of the population as a whole. | 0960-0779 | 2020-03-22 01:00:00+01:00 | pubmed | Chaos, Solitons & Fractals | Duccio Fanelli;Francesco Piazza | Covid-19;epidemic spreading;non linear fitting;population model | 2020-03-21 01:00:00+01:00 | 32308258 | FR;IT | Dipartimento di Fisica e Astronomia, Universitá di Firenze, INFN and CSDC, Via Sansone 1, Sesto Fiorentino 50019, Firenze, Italy.;Centre de Biophysique Moléculaire (CBM), CNRS-UPR 4301, Rue C. Sadron, Orléans 45071, France.;Université d'Orléans, Chéteau de la Source, Orléans Cedex 45071, France. | 44 | |||
| 10.1016/j.ijantimicag.2020.105949 | Clinical Trial;Journal Article | en | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. | https://www.ncbi.nlm.nih.gov/pubmed/32205204 | Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the effect of hydroxychloroquine on respiratory viral loads. | 0924-8579 | 2020-03-22 01:00:00+01:00 | pubmed | Adult;Azithromycin__administration & dosage;Betacoronavirus;Coronavirus Infections__drug therapy;Drug Therapy, Combination;Female;Humans;Hydroxychloroquine__administration & dosage;Male;Middle Aged;Pandemics;Pneumonia, Viral__drug therapy;Polymerase Chain Reaction;Viral Load;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Philippe Gautret;Jean-Christophe Lagier;Philippe Parola;Van Thuan Hoang;Line Meddeb;Morgane Mailhe;Barbara Doudier;Johan Courjon;Valérie Giordanengo;Vera Esteves Vieira;Hervé Tissot Dupont;Stéphane Honoré;Philippe Colson;Eric Chabrière;Bernard La Scola;Jean-Marc Rolain;Philippe Brouqui;Didier Raoult | 2019-nCoV;Azithromycin;COVID-19;Clinical trial;Hydroxychloroquine;SARS-CoV-2 | 2020-03-20 01:00:00+01:00 | 32205204 | FR;VN | IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France, Thai Binh University of Medicine and Pharmacy, Thai Binh, Viet Nam.;IHU-Méditerranée Infection, Marseille, France.;Infectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France, Université Côte d'Azur, Nice, France, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Virulence Microbienne et Signalisation Inflammatoire, INSERM, Nice, France.;Department of Virology, Biological and Pathological Center, Centre Hospitalier Universitaire de Nice, 06200 Nice, France.;Service Pharmacie, Hôpital Timone, AP-HM, Marseille, France, Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: Didier.raoult@gmail.com. | 48 | ||
| NIGMS NIH HHS | 10.1126/science.abb4218 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't | en | The effect of human mobility and control measures on the COVID-19 epidemic in China. | https://www.ncbi.nlm.nih.gov/pubmed/32213647 | The ongoing coronavirus disease 2019 (COVID-19) outbreak expanded rapidly throughout China. Major behavioral, clinical, and state interventions were undertaken to mitigate the epidemic and prevent the persistence of the virus in human populations in China and worldwide. It remains unclear how these unprecedented interventions, including travel restrictions, affected COVID-19 spread in China. We used real-time mobility data from Wuhan and detailed case data including travel history to elucidate the role of case importation in transmission in cities across China and to ascertain the impact of control measures. Early on, the spatial distribution of COVID-19 cases in China was explained well by human mobility data. After the implementation of control measures, this correlation dropped and growth rates became negative in most locations, although shifts in the demographics of reported cases were still indicative of local chains of transmission outside of Wuhan. This study shows that the drastic control measures implemented in China substantially mitigated the spread of COVID-19. | 0036-8075,1095-9203 | 2020-03-29 01:00:00+01:00 | pubmed | Age Distribution;Betacoronavirus;China;Coronavirus Infections__epidemiology;Epidemiological Monitoring;Humans;Linear Models;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Sex Distribution;Spatial Analysis;Travel__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | Science | Moritz U G Kraemer;Chia-Hung Yang;Bernardo Gutierrez;Chieh-Hsi Wu;Brennan Klein;David M Pigott;Louis du Plessis;Nuno R Faria;Ruoran Li;William P Hanage;John S Brownstein;Maylis Layan;Alessandro Vespignani;Huaiyu Tian;Christopher Dye;Oliver G Pybus;Samuel V Scarpino | 2020-03-25 01:00:00+01:00 | 32213647 | FR;CN;GB;US;IT;EC | [{"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "U54 GM088558"}] | Department of Zoology, University of Oxford, Oxford, UK. s.scarpino@northeastern.edu oliver.pybus@zoo.ox.ac.uk moritz.kraemer@zoo.ox.ac.uk.;Harvard Medical School, Harvard University, Boston, MA, USA.;Boston Children's Hospital, Boston, MA, USA.;Network Science Institute, Northeastern University, Boston, MA, USA.;Department of Zoology, University of Oxford, Oxford, UK.;School of Biological and Environmental Sciences, Universidad San Francisco de Quito USFQ, Quito, Ecuador.;Mathematical Sciences, University of Southampton, Southampton, UK.;Institute for Health Metrics and Evaluation, Department of Health Metrics, University of Washington, Seattle, WA, USA.;Harvard T.H. Chan School of Public Health, Boston, MA, USA.;Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France.;Sorbonne Université, Paris, France.;ISI Foundation, Turin, Italy.;State Key Laboratory of Remote Sensing Science, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China.;Department of Pathobiology and Population Sciences, The Royal Veterinary College, London, UK.;Network Science Institute, Northeastern University, Boston, MA, USA. s.scarpino@northeastern.edu oliver.pybus@zoo.ox.ac.uk moritz.kraemer@zoo.ox.ac.uk. | 72 | |
| Journal Article;Comment | en | From China: hope and lessons for COVID-19 control. | https://www.ncbi.nlm.nih.gov/pubmed/32251637 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Andrew S Azman;Francisco J Luquero | 2020-04-03 02:00:00+02:00 | 32251637 | FR;CH;US | Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA, Médecins Sans Frontières, Geneva, Switzerland. Electronic address: azman@jhu.edu.;Epicentre, Paris, France. | 82 | |||||||
| 10.1016/j.clon.2020.03.006 | Editorial | en | International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32241520 | 0936-6555 | 2020-04-05 02:00:00+02:00 | pubmed | Clinical Oncology | C E Coles;C Aristei;J Bliss;L Boersma;A M Brunt;S Chatterjee;G Hanna;R Jagsi;O Kaidar Person;A Kirby;I Mjaaland;I Meattini;A M Luis;G N Marta;B Offersen;P Poortmans;S Rivera | 2020-04-04 02:00:00+02:00 | 32241520 | IL;FR;NO;GB;US;BR;IT;AU;NL;ES;IN;DK | Oncology Department, University of Cambridge, UK. Electronic address: c.coles@editorialoffice.co.uk.;University of Perugia, Italy, Perugia General Hospital Sant'Andrea delle Fratte, Italy.;The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK.;Department of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.;University Hospitals of North Midlands & Keele University, Stoke-on-Trent, UK.;Tata Medical Center, Kolkata, India.;Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia.;Department of Radiation Oncology, Center for Bioethics and Social Sciences in Medicine, University of Michigan, USA.;Breast Radiation Unit, Sheba Tel Ha'shomer, Ramat Gan, Israel.;Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK.;Department of Hematology and Oncology, Stavanger University Hospital, Norway.;Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy, Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.;University Hospital HM Sanchinarro, Madrid, Spain.;Department of Radiation Oncology, Hospital Sírio-Libanês, São Paulo, Brazil, Division of Radiation Oncology, Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, Brazil.;Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark.;Paris Sciences et Lettres University, Paris, France.;Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France, Molecular Radiotherapy and Innovative Therapeutics, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France. | 92 | |||||
| 10.1093/ntr/ntaa059 | Journal Article | en | COVID-19 and Smoking. | https://www.ncbi.nlm.nih.gov/pubmed/32242236 | 1469-994X | 2020-04-05 02:00:00+02:00 | pubmed | Nicotine & Tobacco Research | Ivan Berlin;Daniel Thomas;Anne-Laurence Le Faou;Jacques Cornuz | 2020-04-04 02:00:00+02:00 | 32242236 | FR;CH | Département de pharmacologie, Hôpital Pitié-Salpêtrière, Paris, France.;Centre Universitaire de Médecine Générale et Santé Publique, UNISANTE, Université de Lausanne, Lausanne, Switzerland.;Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France.;Centre ambulatoire d'addictologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Centre, Fédération Hospitalo-Universitaire Network of Research in Substance Use Disorder, Université de Paris, Paris, France. | 94 | |||||
| 10.1007/s00268-020-05501-6 | Editorial | en | We Asked the Experts: Covid-19 Outbreak: Is There Still a Place for Scheduled Surgery? "Reflection from Pathophysiological Data". | https://www.ncbi.nlm.nih.gov/pubmed/32246185 | 0364-2313,1432-2323 | 2020-04-05 02:00:00+02:00 | pubmed | World Journal of Surgery | Emmanuel Besnier;Jean-Jacques Tuech;Lilian Schwarz | 2020-04-05 02:00:00+02:00 | 32246185 | FR | Normandie Univ, UNIROUEN, Inserm U1096, FHU- REMOD-VHF, 76000, Rouen, France. emmanuel.besnier@chu-rouen.fr.;Department of Anesthesiology and Critical Care, Hôpital Charles Nicolle, Rouen University Hospital, 1 Rue de Germont, 76031, Rouen Cedex, France. emmanuel.besnier@chu-rouen.fr.;Department of Digestive Surgery, Rouen University Hospital, 1 Rue de Germont, 76031, Rouen Cedex, France.;Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, 76000, Rouen, France. | 95 | |||||
| Letter | en | Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. | https://www.ncbi.nlm.nih.gov/pubmed/32237918 | 2020-04-05 02:00:00+02:00 | pubmed | Bruno Mégarbane | 2020-04-02 02:00:00+02:00 | 32237918 | FR | Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology APHP, Paris-Diderot University, Paris, France. | 99 | ||||||||
| 10.1016/j.purol.2020.03.009 | Journal Article;Practice Guideline | fr | [Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32224294 | The French population is facing the COVID-19 pandemic and the health system have been reoriented in emergency for the care of patients with coronavirus. The management of cancers of the urinary and male genital tracts must be adapted to this context. | 1166-7087 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Decision Making;Disease Management;Epidemics;Humans;Infection Control;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Male;Pandemics;Pneumonia, Viral__epidemiology;Societies, Medical;Urogenital Neoplasms__surgery;Urologists;COVID-19;severe acute respiratory syndrome coronavirus 2 | Progrès en Urologie | A Méjean;M Rouprêt;F Rozet;K Bensalah;T Murez;X Game;X Rebillard;R Mallet;A Faix;P Mongiat-Artus;G Fournier;Y Neuzillet | Bladder cancer;COVID-19;Cancer de la prostate;Cancer de la vessie;Cancer du penis;Cancer du rein;Cancer du testicule;Kidney cancer;Penile cancer;Prostate cancer;Testicular cancer | 2020-03-30 02:00:00+02:00 | 32224294 | FR | Comité de cancérologie de l'Association française d'urologie, 11, rue Viète, 75017 Paris, France.;Bureau du Conseil d'administration d'Association française d'urologie, 11, rue Viète, 75017 Paris, France.;Bureau du Conseil d'administration d'Association française d'urologie, 11, rue Viète, 75017 Paris, France. Electronic address: yneuzillet@afu.fr. | 101 | ||
| 10.12688/f1000research.22942.2 | Journal Article;Review | en | A review of open source ventilators for COVID-19 and future pandemics. | https://www.ncbi.nlm.nih.gov/pubmed/32411358 | Coronavirus Disease 2019 (COVID-19) threatens to overwhelm our medical infrastructure at the regional level causing spikes in mortality rates because of shortages of critical equipment, like ventilators. Fortunately, with the recent development and widespread deployment of small-scale manufacturing technologies like RepRap-class 3-D printers and open source microcontrollers, mass distributed manufacturing of ventilators has the potential to overcome medical supply shortages. In this study, after providing a background on ventilators, the academic literature is reviewed to find the existing and already openly-published, vetted designs for ventilators systems. These articles are analyzed to determine if the designs are open source both in spirit (license) as well as practical details (e.g. possessing accessible design source files, bill of materials, assembly instructions, wiring diagrams, firmware and software as well as operation and calibration instructions). Next, the existing Internet and gray literature are reviewed for open source ventilator projects and designs. The results of this review found that the tested and peer-reviewed systems lacked complete documentation and the open systems that were documented were either at the very early stages of design (sometimes without even a prototype) and were essentially only basically tested (if at all). With the considerably larger motivation of an ongoing pandemic, it is assumed these projects will garner greater attention and resources to make significant progress to reach a functional and easily-replicated system. There is a large amount of future work needed to move open source ventilators up to the level considered scientific-grade equipment, and even further work needed to reach medical-grade hardware. Future work is needed to achieve the potential of this approach by developing policies, updating regulations, and securing funding mechanisms for the development and testing of open source ventilators for both the current COVID19 pandemic as well as for future pandemics and for everyday use in low-resource settings. | 2046-1402 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | F1000Research | Joshua M Pearce | COVID-19;influenza pandemic;medical hardware;open hardware;open source;pandemic;ventilation;ventilator | 2020-03-30 02:00:00+02:00 | 32411358 | FI;FR;US | Department of Materials Science & Engineering and Department of Electrical & Computer Engineering, Michigan Technological University, Houghton, MI, 49931, USA.;Équipe de Recherche sur les Processus Innovatifs (ERPI), Université de Lorraine, Nancy, France.;School of Electrical Engineering, Aalto University, Helsinki, Finland. | 103 | ||
| 10.1016/j.canrad.2020.03.007 | Editorial | fr | [Covid-19 epidemic: guidelines issued by the French society of oncology radiotherapy (SFRO) for oncology radiotherapy professionals]. | https://www.ncbi.nlm.nih.gov/pubmed/32299663 | 1278-3218 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;France__epidemiology;Humans;Infection Control;Neoplasms__radiotherapy;Pandemics;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Radiotherapy__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cancer/Radiothérapie | P Giraud;E Monpetit;A Lisbona;C Chargari;V Marchesi;A Dieudonné | 2020-03-31 02:00:00+02:00 | 32299663 | FR | Président de la SFRO, Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. Electronic address: philippe.giraud@aphp.fr.;Président du SNRO, Centre Saint-Yves-radiothérapie, 11, rue du Docteur-Audic, 56000 Vannes, France.;Service de physique médicale, Institut de cancérologie de l'Ouest, 44805 Saint-Herblain, France.;Département de radiothérapie, Gustave-Roussy Cancer Campus, Villejuif, 94800, France.;Institut de cancérologie de Lorraine -centre Alexis-Vautrin, 6, avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Président de la SFPM, service de médecine nucléaire, hôpital Beaujon, 100, boulevard du Général-Leclerc, 92110 Clichy, France.;Centre Antoine-Béclère, 47, rue de la Colonie, 75013 Paris, France.;Syndicat national des radiothérapeutes oncologues, 168A, rue de Grenelle, 75007 Paris, France. | 110 | ||||
| 10.1016/j.tmaid.2020.101658 | Editorial | en | Repurposing antimalarials and other drugs for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32247925 | 1477-8939 | 2020-04-05 02:00:00+02:00 | pubmed | Adenosine Monophosphate__analogs & derivatives;Alanine__analogs & derivatives;Antimalarials__therapeutic use;Antiviral Agents__therapeutic use;Betacoronavirus;Coronavirus Infections__drug therapy;Drug Repositioning;Humans;Hydroxychloroquine__therapeutic use;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Travel Medicine and Infectious Disease | Patricia Schlagenhauf;Martin P Grobusch;Julian D Maier;Philippe Gautret | 2020-04-02 02:00:00+02:00 | 32247925 | FR;NL;CH | University of Zurich Centre for Travel Medicine, WHO Collaborating for Travellers' Health, Department of Public and Global Health, Institute for Epidemiology, Biostatistics and Prevention, Hirschengraben 84, 8001, Zurich, Switzerland. Electronic address: patricia.schlagenhauf@uzh.ch.;Center of Tropical Medicine and Travel Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.;University of Zurich Centre for Travel Medicine, WHO Collaborating for Travellers' Health, Department of Public and Global Health, Institute for Epidemiology, Biostatistics and Prevention, Hirschengraben 84, 8001, Zurich, Switzerland.;Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée Infection, Marseille, France. | 117 | ||||
| Letter;Comment | en | Probable aircraft transmission of Covid-19 in-flight from the Central African Republic to France. | https://www.ncbi.nlm.nih.gov/pubmed/32247016 | 2020-04-05 02:00:00+02:00 | pubmed | Aircraft;Betacoronavirus;Central African Republic;Coronavirus Infections;France;Humans;Pandemics;Pneumonia, Viral;Referral and Consultation;COVID-19;severe acute respiratory syndrome coronavirus 2 | Carole Eldin;Jean-Christophe Lagier;Morgane Mailhe;Philippe Gautret | 2020-04-01 02:00:00+02:00 | 32247016 | FR | IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France. Electronic address: philippe.gautret@ap-hm.fr. | 129 | |||||||
| Letter | fr | [French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak]. | https://www.ncbi.nlm.nih.gov/pubmed/32265035 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Disease Outbreaks;Humans;Pandemics;Pneumonia, Viral__epidemiology;Sarcoma__therapy;Soft Tissue Neoplasms__therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nicolas Penel;Sylvie Bonvalot;Véronique Minard;Daniel Orbach;François Gouin;Nadège Corradini;Mehdi Brahmi;Perrine Marec-Berard;Sylvain Briand;Nathalie Gaspar;Carmen Llacer;Sébastien Carrere;Armelle Dufresne;Axel Le Cesne;Jean-Yves Blay | COVID-19;Management;Prise en charge;Sarcoma;Sarcome | 2020-04-01 02:00:00+02:00 | 32265035 | FR | Lille University, Oscar Lambret Cancer Center, Medical Oncology Department, 3, rue Frederic-Combemale, 59000 Lille, France. Electronic address: n-penel@o-lambret.fr.;Institut Curie, Surgical Oncology Department, Paris, France.;Gustave Roussy Institute, Department of Pediatric Oncology, Villejuif, France.;Institut Curie, Department of Pediatric Oncology, Paris, France.;Centre Léon-Bérard, Surgical Oncology Departement, Lyon, France.;Institut d'hématologie et d'oncologie pédiatrique, Department of Pediatric Oncology, Lyon, France.;Centre Léon-Bérard, Medical Oncology Department, Lyon, France.;CHU Kremlin-Bicêtre, Surgical Oncology Department, Paris, France.;Institut du cancer de Montpellier, Radiotherapy department, Montpellier, France.;Institut du cancer de Montpellier, Surgical Oncology Department, Montpellier, France.;Gustave Roussy Institute, Medical Oncology Department, Villejuif, France. | 130 | ||||||
| Letter;Comment | en | Re: "Strategy for the practice of digestive and oncological surgery during the COVID-19 epidemic". | https://www.ncbi.nlm.nih.gov/pubmed/32327325 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | P Pessaux | 2020-04-10 02:00:00+02:00 | 32327325 | FR | Hepato-biliairy and pancreatic surgery unit, digestive and endocrine surgery department, nouvel hôpital civil, Strasbourg University Hospital, 1, place de l'Hôpital, 67100 Strasbourg, France. Electronic address: patrick.pessaux@chru-strasbourg.fr. | 136 | |||||||
| Journal Article | fr | [Coronavirus and COVID-19 : focus on a galopping pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32267109 | The international community is currently facing a pandemic of acute respiratory syndrome caused by a new coronavirus, SARS-CoV-2. This syndrome has been named COVID-19 for CoronaVIrus Disease 2019 by the World Health Organization. The starting point of the epidemic is the city of Wuhan (China), where the virus is said to have been transmitted from animals to humans before inter-human transmission. This is the third epidemic caused by a coronavirus after those of severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS) started in 2012. COVID-19 has rapidly spread to China and is currently spreading all over the world. The infection mainly affects patients over 40 years of age and mortality is increased in the presence of comorbidities. Children are pauci- or asymptomatic. The diagnosis is most often based on the detection of the viral genome in the nasopharynx by molecular biology methods. In the absence of specific anti-viral molecules, treatment is currently mainly symptomatic. It is clear that the COVID-19 pandemic is more difficult to control than what the first data suggested. The key strategy to SARS-CoV-2 is to limit its transmission. Preventive measures are mainly based on the application of adequate hand hygiene measures and disinfection of the environment, as well as measures of social distance aimed at limiting contacts in the population and protecting populations at risk. | 2020-04-12 02:00:00+02:00 | pubmed | Adult;Age Factors;Aged;Animals;Asymptomatic Diseases;Betacoronavirus__genetics;Child;China__epidemiology;Clinical Laboratory Techniques;Coronavirus;Coronavirus Infections__diagnosis;Hand Disinfection;Humans;Infection Control__methods;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;Zoonoses;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | E Davenne;J B Giot;P Huynen | COVID 19;Pandemia;SARS;2;CoV;Coronavirus | 2020-04-09 02:00:00+02:00 | 32267109 | FR;BE | Faculté de Médecine, Liège Université, Belgique.;Service des Maladies Infectieuses, CHU Liège, Belgique.;Service de Microbiologie Clinique, CHU Liège, Belgique. | 145 | |||||
| 10.1053/j.jvca.2020.03.059 | Journal Article;Review | en | Thoracic Anesthesia of Patients With Suspected or Confirmed 2019 Novel Coronavirus Infection: Preliminary Recommendations for Airway Management by the European Association of Cardiothoracic Anaesthesiology Thoracic Subspecialty Committee. | https://www.ncbi.nlm.nih.gov/pubmed/32414544 | The novel coronavirus has caused a pandemic around the world. Management of patients with suspected or confirmed coronavirus infection who have to undergo thoracic surgery will be a challenge for the anesthesiologists. The thoracic subspecialty committee of European Association of Cardiothoracic Anaesthesiology (EACTA) has conducted a survey of opinion in order to create recommendations for the anesthetic approach to these challenging patients. It should be emphasized that both the management of the infected patient with COVID-19 and the self-protection of the anesthesia team constitute a complicated challenge. The text focuses therefore on both important topics. | 1053-0770 | 2020-04-12 02:00:00+02:00 | pubmed | Advisory Committees__standards;Airway Management__methods;Anesthesia, Cardiac Procedures__methods;Anesthesiology__methods;Betacoronavirus;Coronavirus Infections__diagnosis;Europe__epidemiology;Humans;Pandemics;Pneumonia, Viral__diagnosis;Practice Guidelines as Topic__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Cardiothoracic and Vascular Anesthesia | Mert Şentürk;Mohamed R El Tahan;Laszlo L Szegedi;Nandor Marczin;Waheedullah Karzai;Ben Shelley;Federico Piccioni;Manuel Granell Gil;Steffen Rex;Massimiliano Sorbello;Johan Bence;Edmond Cohen;Guido Di Gregorio;Izumi Kawagoe;Mojca Drnovšek Globokar;Maria-José Jimenez;Marc-Joseph Licker;Jo Mourisse;Chirojit Mukherjee;Ricard Navarro;Vojislava Neskovic;Balazs Paloczi;Gianluca Paternoster;Paolo Pelosi;Ahmed Salaheldeen;Radu Stoica;Carmen Unzueta;Caroline Vanpeteghem;Tamas Vegh;Patrick Wouters;Davud Yapici;Fabio Guarracino | COVID-19;coronavirus;lung separation;personal protective equipment;thoracic anesthesia | 2020-04-11 02:00:00+02:00 | 32414544 | FR;RS;SI;SA;JP;GB;US;CH;RO;IT;TR;EG;NL;ES;HU;BE;DE | Department of Anaesthesiology & Intensive care of Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey. Electronic address: senturkm@istanbul.edu.tr.;Department of Anaesthesia, Intensive Care and Pain Medicine, College of Medicine, Mansoura University, Mansoura, Egypt.;Department of Anesthesiology, CUB Hôpital Erasme, ULB Université Libre de Bruxelles, Brussels, Belgium.;Department of Surgery & Cancer, Section of Anaesthetics, Imperial College London, London, UK, Harefield Hospital, Royal Brompton & Harefield NHS Foundation Trust, Harefield, UK, Department of Anesthesia and Intensive Care, Semmelweis University, Budapest, Hungary.;Zentralklinik Bad Berka GmbH, Bad Berka, Germany.;Golden Jubilee National Hospital/West of Scotland Heart and Lung Centre, University of Glasgow Academic Unit of Anesthesia, Pain, and Critical Care, Glasgow, Scotland.;Anesthesia and Intensive Care Unit, Department of Critical and Supportive Care, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;University General Hospital of Valencia, Valencia, Spain.;Department of Anesthesiology, University Hospitals Leuven, Leuven, Belgium, Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Leuven, Belgium.;Anesthesia and Intensive Care, AOU Policlinico Vittorio Emanuele San Marco, Catania, Italy.;Department of Anesthesia, Glenfield Hospital Leicester, Leicester, England, UK.;Icahn School of Medicine at Mount Sinai, New York, NY.;Anesthesia and Critical Care, Azienda Ospedaliera Università di Padova, Padova, Italy.;Department of Anesthesiology and Pain Medicine, Juntendo University, Tokyo, Japan.;Department of Anesthesiology, Ljubjljana University Medical Centre Ljubljana, Ljubljana, Slovenia.;Department of Anesthesiology, Clinic Barcelona, Barcelona, Spain.;Anesthesia, Pharmacology and Intensive Care, University Hospital Geneva, Geneva, Switzerland.;Department of Anesthesia, Pain, and Palliative Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.;Department of Anesthesia and Intensive Care, Helios Clinic for Cardiac Surgery, Karlsruhe, Germany.;Department of Anesthesiology and Critical Care, Hospital Clinic Barcelona, Barcelona, Spain.;Military Medical Academy Belgrade, Belgrade, Serbia.;Department of Anesthesiology and Intensive Care, University of Debrecen, Debrecen, Hungary.;Division of Cardiac Resuscitation, Cardiovascular Anesthesia and Intensive Care, San Carlo Hospital, Potenza, Italy.;Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate, Università degli Studi di Genova, Genoa, Italy.;Department of Anesthesia, King Fahd Hospital of the Imam Abdulrahman Bin Faisal University, Al Khobar, Saudi Arabia.;Department of Thoracic Anesthesia, Institute of Pulmonology "Marius Nasta," Bucharest, Romania.;Department of Anesthesiology, Hospital de la Santa Creu i San Pau, Barcelona, Spain.;Department of Anesthesiology, Universitair Ziekenhuis Gent, Ghent, Belgium.;Anesthesia and Perioperative Medicine, Ghent University, Ghent, Belgium.;Mersin University School of Medicine, Mersin, Turkey.;Department of Anesthesia and Critical Care Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. | 151 | ||
| Letter | en | Ecosystem approaches to the risk for schizophrenia. | https://www.ncbi.nlm.nih.gov/pubmed/32299718 | 2020-04-12 02:00:00+02:00 | pubmed | Adult;Child;Child Development;Coronavirus Infections;Ecosystem;Female;Humans;Pandemics;Pneumonia, Viral;Pregnancy;Prenatal Exposure Delayed Effects;Schizophrenia__etiology;Social Environment;COVID-19 | Vincent Paquin;Mélanie Lemire;Suzanne King | COVID-19;Child development;Ecosystem;Epidemiology;Policy;Schizophrenia | 2020-04-10 02:00:00+02:00 | 32299718 | FR;CA;US | Department of Psychiatry, McGill University, 1033 Avenue des Pins, Montréal, Québec H3A 1A1, Canada, Douglas Hospital Research Centre, 6875 LaSalle Blvd., Verdun, Québec H4H 1R3, Canada, Axe Santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec, Université Laval, 1050 Chemin Ste-Foy, Québec City, Québec G1S 4L8, Canada. Electronic address: Vincent.Paquin2@mail.mcgill.ca.;Axe Santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec, Université Laval, 1050 Chemin Ste-Foy, Québec City, Québec G1S 4L8, Canada, Département de médecine sociale et préventive, Université Laval, 1050 avenue de la Médecine, Québec City, Québec G1V 0A6, Canada.. Electronic address: Melanie.Lemire@crchudequebec.ulaval.ca.;Department of Psychiatry, McGill University, 1033 Avenue des Pins, Montréal, Québec H3A 1A1, Canada, Douglas Hospital Research Centre, 6875 LaSalle Blvd., Verdun, Québec H4H 1R3, Canada. Electronic address: Suzanne.King@mcgill.ca. | 154 | ||||||
| 10.1016/j.chest.2020.04.003 | Practice Guideline | en | The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner Society. | https://www.ncbi.nlm.nih.gov/pubmed/32275978 | With more than 900,000 confirmed cases worldwide and nearly 50,000 deaths during the first 3 months of 2020, the coronavirus disease 2019 (COVID-19) pandemic has emerged as an unprecedented health care crisis. The spread of COVID-19 has been heterogeneous, resulting in some regions having sporadic transmission and relatively few hospitalized patients with COVID-19 and others having community transmission that has led to overwhelming numbers of severe cases. For these regions, health care delivery has been disrupted and compromised by critical resource constraints in diagnostic testing, hospital beds, ventilators, and health care workers who have fallen ill to the virus exacerbated by shortages of personal protective equipment. Although mild cases mimic common upper respiratory viral infections, respiratory dysfunction becomes the principal source of morbidity and mortality as the disease advances. Thoracic imaging with chest radiography and CT are key tools for pulmonary disease diagnosis and management, but their role in the management of COVID-19 has not been considered within the multivariable context of the severity of respiratory disease, pretest probability, risk factors for disease progression, and critical resource constraints. To address this deficit, a multidisciplinary panel comprised principally of radiologists and pulmonologists from 10 countries with experience managing patients with COVID-19 across a spectrum of health care environments evaluated the utility of imaging within three scenarios representing varying risk factors, community conditions, and resource constraints. Fourteen key questions, corresponding to 11 decision points within the three scenarios and three additional clinical situations, were rated by the panel based on the anticipated value of the information that thoracic imaging would be expected to provide. The results were aggregated, resulting in five main and three additional recommendations intended to guide medical practitioners in the use of chest radiography and CT in the management of COVID-19. | 0012-3692 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__diagnosis;Diagnosis, Differential;Disease Progression;Early Diagnosis;Humans;International Cooperation;Lung__diagnostic imaging;Pandemics;Patient Care Management__methods;Pneumonia, Viral__diagnosis;Radiography, Thoracic__methods;Respiratory Tract Diseases__diagnosis;Tomography, X-Ray Computed__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Chest | Geoffrey D Rubin;Christopher J Ryerson;Linda B Haramati;Nicola Sverzellati;Jeffrey P Kanne;Suhail Raoof;Neil W Schluger;Annalisa Volpi;Jae-Joon Yim;Ian B K Martin;Deverick J Anderson;Christina Kong;Talissa Altes;Andrew Bush;Sujal R Desai;Jonathan Goldin;Jin Mo Goo;Marc Humbert;Yoshikazu Inoue;Hans-Ulrich Kauczor;Fengming Luo;Peter J Mazzone;Mathias Prokop;Martine Remy-Jardin;Luca Richeldi;Cornelia M Schaefer-Prokop;Noriyuki Tomiyama;Athol U Wells;Ann N Leung | 2020-04-07 02:00:00+02:00 | 32275978 | FR;CA;CN;JP;GB;US;IT;NL;KR;DE | Department of Radiology, Duke University School of Medicine, Durham, NC. Electronic address: grubin@duke.edu.;Department of Medicine, University of British Columbia, Vancouver, BC, Canada.;Department of Radiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.;Department of Scienze Radiologiche, Department of Medicine and Surgery, University of Parma, Parma, Italy.;Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI.;Division of Pulmonary, Critical Care & Sleep Medicine, Lenox Hill Hospital, New York, NY.;Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Irving Medical Center, New York, NY.;1st Anesthesia and Intensive Care Unit, University Hospital of Parma, Parma, Italy.;Division of Pulmonary and Critical Medicine, Seoul National University College of Medicine, Seoul, South Korea.;Department of Emergency Medicine, The Medical College of Wisconsin School of Medicine, Milwaukee, WI.;Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University Medical Center, Durham, NC.;Department of Pathology and Clinical Laboratory Medicine, Stanford University Medical Center, Stanford, CA.;Department of Radiology, University of Missouri, Columbia, MO.;Department of Paediatrics and Paediatric Respirology, Royal Brompton Hospital, London, England.;Department of Radiology, Royal Brompton & Harefield NHS Foundation Trust, London, England, National Heart and Lung Institute, Imperial College, London, England.;Department of Radiology, David Geffen School of Medline at University of California Los Angeles, Los Angeles, CA.;Department of Radiology, Seoul National University College of Medicine, Seoul, South Korea.;Department of Respiratory and Intensive Care Medicine, Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;Department of Pathology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.;Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.;Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Sichuan, China.;Respiratory Institute, Cleveland Clinic, Cleveland, OH.;Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.;Department of Thoracic Imaging-Hospital Calmette, University Centre of Lille, Lille, France.;Division of Pulmonary Medicine, Università Cattolica del Sacro Cuore, Rome, Italy.;Department of Radiology and Nuclear Medicine, Meander Medical Centre, Amersfoort, The Netherlands.;Department of Radiology, Osaka University Graduate School of Medicine, Osaka, Japan.;Department of Pulmonary Medicine, Royal Brompton Hospital, London, England.;Department of Radiology, Stanford University School of Medicine, Stanford, CA. | 155 | |||
| 10.1016/j.jchirv.2020.04.002 | Journal Article | fr | [Surgery and the COVID-19 epidemic: Some additional precautions. Re: "Strategy for the practice of digestive and oncological surgery during the COVID-19 epidemic"]. | https://www.ncbi.nlm.nih.gov/pubmed/32292532 | 1878-786X | 2020-04-12 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | M Canis;N Bourdel;R Botchorishvili | 2020-04-08 02:00:00+02:00 | 32292532 | FR | Department of Gynecologic Surgery, CHU d'Estaing, 1, place Lucie-et-Raymond-Aubrac, 63000 Clermont-Ferrand, France. | 159 | |||||
| 10.1093/cid/ciaa394 | Journal Article | en | Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32255489 | Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting on various concentrations PK studies are therefore needed to define the optimal dosing regimen. | 1058-4838,1537-6591 | 2020-04-12 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Sophie Perinel;Manon Launay;Élisabeth Botelho-Nevers;Éric Diconne;Aurore Louf-Durier;Raphaël Lachand;Martin Murgier;Dominique Page;Régine Vermesch;Guillaume Thierry;Xavier Delavenne | 2020-04-07 02:00:00+02:00 | 32255489 | FR | Service de Médecine Intensive et Réanimation, CHU de Saint-Etienne, France.;INSERM U1059, Dysfonctions Vasculaires et de L'Hémostase, Université de Lyon, Saint-Etienne, France.;Laboratoire de Pharmacologie - Toxicologie - Gaz du Sang, CHU de Saint-Etienne.;Infectious Diseases Department, CHU de Saint-Etienne, France. | 164 | ||||
| Letter | en | A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19-positive patients with cancer. | https://www.ncbi.nlm.nih.gov/pubmed/32294611 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Humans;Internet__instrumentation;Neoplasms__complications;Pandemics;Patient Reported Outcome Measures;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Florian Scotté;Etienne Minvielle;Olivier Mir;Fabrice André;Fabrice Barlesi;Jean-Charles Soria | 2020-04-07 02:00:00+02:00 | 32294611 | FR | Gustave Roussy Cancer Institute, 114 rue Edouard Vaillant, 94800 Villejuif, France. Electronic address: flscotte@gmail.com.;Gustave Roussy Cancer Institute, 114 rue Edouard Vaillant, 94800 Villejuif, France. | 167 | |||||||
| Journal Article;Comment | en | Spontaneous Coronary Artery Dissection in a Patient With COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32553344 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Pierre-Yves Courand;Brahim Harbaoui;Marc Bonnet;Pierre Lantelme | COVID-19;OCT;spontaneous coronary artery dissection | 2020-04-08 02:00:00+02:00 | 32553344 | FR | University of Lyon, CREATIS UMR5220, INSERM U1044, INSA-15, Lyon, France, Cardiology Department, Hôpital Croix-Rousse, Hospices Civils de Lyon, Lyon, France, Cardiology Department, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France. Electronic address: pycourand@hotmail.com.;University of Lyon, CREATIS UMR5220, INSERM U1044, INSA-15, Lyon, France, Cardiology Department, Hôpital Croix-Rousse, Hospices Civils de Lyon, Lyon, France, Cardiology Department, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Cardiology Department, Hôpital Croix-Rousse, Hospices Civils de Lyon, Lyon, France, Cardiology Department, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France. | 169 | ||||||
| Editorial;Comment | en | The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32266838 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Italy;Medical Oncology;Neoplasms;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nizar Bitar;Joseph Kattan;Hampig Raphael Kourie;Deborah Mukherji;Nagi El Saghir | COVID-19;cancer patients;lebanon;oncology staff;recommendations | 2020-04-08 02:00:00+02:00 | 32266838 | FR;LB | Lebanese Society of Medical Oncology (LSMO), Beirut, Lebanon.;Hematology-Oncology Department, Hôtel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.;Department of Internal Medicine, Division of Hematology-Oncology, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon. | 173 | ||||||
| 10.1016/j.envpol.2020.114466 | Journal Article | en | COVID-19 as a factor influencing air pollution? | https://www.ncbi.nlm.nih.gov/pubmed/32283458 | 0269-7491 | 2020-04-12 02:00:00+02:00 | pubmed | Air Pollution;Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Environmental Pollution | Frédéric Dutheil;Julien S Baker;Valentin Navel | Air pollutants;Epidemy;Mortality;Public health;Sars virus | 2020-04-09 02:00:00+02:00 | 32283458 | FR;HK | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, F-63000, Clermont-Ferrand, France. Electronic address: fdutheil@chu-clermontferrand.fr.;Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong.;Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, F-63000, Clermont-Ferrand, France. | 182 | |||
| 10.1016/j.anorl.2020.04.006 | Practice Guideline | en | French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32307265 | Tracheostomy post-tracheostomy care are regarded as at high risk for contamination of health care professionals with the new coronavirus (SARS-CoV-2). Considering the rapid spread of the infection, all patients in France must be considered as potentially infected by the virus. Nevertheless, patients without clinical or radiological (CT scan) markers of COVID-19, and with negative nasopharyngeal sample within 24h of surgery, are at low risk of being infected. Instructions for personal protection include specific wound dressings and decontamination of all material used. The operating room should be ventilated after each tracheostomy and the pressure of the room should be neutral or negative. Percutaneous tracheostomy is to be preferred over surgical cervicotomy in order to reduce aerosolization and to avoid moving patients from the intensive care unit to the operating room. Ventilation must be optimized during the procedure, to limit patient oxygen desaturation. Drug assisted neuromuscular blockage is advised to reduce coughing during tracheostomy tube insertion. An experienced team is mandatory to secure and accelerate the procedure as well as to reduce risk of contamination. | 1879-7296 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Consensus;Coronavirus Infections__diagnosis;France__epidemiology;Humans;Infection Control__methods;Intubation, Intratracheal__instrumentation;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Postoperative Care__methods;Tracheostomy__methods;Ventilation__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Annals of Otorhinolaryngology, Head and Neck Diseases | P Schultz;J-B Morvan;N Fakhry;S Morinière;S Vergez;C Lacroix;S Bartier;B Barry;E Babin;V Couloigner;I Atallah | COVID-19;Care;Pandemic;Percutaneous;SARS-Cov-2;Tracheostomy | 2020-04-09 02:00:00+02:00 | 32307265 | FR | Service d'ORL et de chirurgie cervico-faciale, hôpital de Hautepierre, avenue Molière, 67098 Strasbourg, France. Electronic address: philippe.schultz@chru-strasbourg.fr.;Service d'ORL et de chirurgie cervico-faciale, hôpital d'instruction des armées Saint-Anne, 2, boulevard Sainte-Anne, 83000 Toulon, France.;Service d'ORL et de chirurgie cervico-faciale, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France.;Service d'ORL et de chirurgie cervico-faciale, CHRU Bretonneau-Tours, 2, boulevard Tonnellé, 37044 Tours, France.;Service d'ORL et de chirurgie cervico-faciale, CHU Rangueil-Larrey, 24, chemin de Pourvourville, 31400 Toulouse, France, Service de chirurgie, Institut universitaire du cancer de Toulouse, 1, avenue Irène Joliot-Curie, 31100 Toulouse, France.;Service d'ORL et de chirurgie cervico-faciale, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France.;Service d'ORL et de chirurgie cervico-faciale, centre hospitalier intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.;Service d'ORL et de chirurgie cervico-faciale, hôpital Bichat-Claude-Bernard, 46, rue Henri-Huchard, 75018 Paris, France.;Service d'ORL et de chirurgie cervico-faciale, CHU Caen Normandie, avenue Côte de Nacre, 14000 Caen, France.;Service d'ORL et de chirurgie cervico-faciale pédiatriques, hôpital Necker-Enfants-Malades, Assistance publique-Hôpitaux de Paris, 149, rue de Sèvres, 75743 Paris, France.;Service d'ORL et de chirurgie cervico-faciale, CHU Grenoble Alpes, boulevard de la Chantourne, 38700 La Tronche, France. | 185 | ||
| Editorial;Comment | en | Early experience with COVID-19 in kidney transplantation. | https://www.ncbi.nlm.nih.gov/pubmed/32354635 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Kidney Transplantation;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | P Toby Coates;Germaine Wong;Tilman Drueke;Brad Rovin;Pierre Ronco | COVID-19;education;kidney transplantation;transplantation | 2020-04-09 02:00:00+02:00 | 32354635 | FR;AU;US | Renal and Transplantation Services, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Electronic address: Toby.Coates@sa.gov.au.;School of Public Health, University of Sydney, Sydney, New South Wales, Australia.;Hopital Paul Brousse, Bat 15/16, Inserm U-1018, Team 5, CESP, Villejuif Cedex, France.;Internal Medicine-Nephrology, The Ohio State University, Columbus, Ohio, USA.;Institut National de la Santé et de la Recherche Médicale (Inserm), Unité Mixte de Recherche S1155, Hôpital Tenon, Paris, France. | 189 | ||||||
| 10.1007/s00405-020-05965-1 | Journal Article;Multicenter Study | en | Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. | https://www.ncbi.nlm.nih.gov/pubmed/32253535 | To investigate the occurrence of olfactory and gustatory dysfunctions in patients with laboratory-confirmed COVID-19 infection. | 0937-4477,1434-4726 | 2020-04-12 02:00:00+02:00 | pubmed | Adult;Ageusia__epidemiology;Betacoronavirus;Coronavirus__isolation & purification;Coronavirus Infections__complications;Cough__epidemiology;Europe__epidemiology;Female;Humans;Male;Middle Aged;Myalgia__epidemiology;Nutrition Surveys;Olfaction Disorders__epidemiology;Pandemics;Pneumonia, Viral__complications;Prevalence;Smell;Taste;Taste Disorders;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Archives of Oto-Rhino-Laryngology | Jerome R Lechien;Carlos M Chiesa-Estomba;Daniele R De Siati;Mihaela Horoi;Serge D Le Bon;Alexandra Rodriguez;Didier Dequanter;Serge Blecic;Fahd El Afia;Lea Distinguin;Younes Chekkoury-Idrissi;Stéphane Hans;Irene Lopez Delgado;Christian Calvo-Henriquez;Philippe Lavigne;Chiara Falanga;Maria Rosaria Barillari;Giovanni Cammaroto;Mohamad Khalife;Pierre Leich;Christel Souchay;Camelia Rossi;Fabrice Journe;Julien Hsieh;Myriam Edjlali;Robert Carlier;Laurence Ris;Andrea Lovato;Cosimo De Filippis;Frederique Coppee;Nicolas Fakhry;Tareck Ayad;Sven Saussez | Anosmia;COVID;COVID-19;Coronavirus;Dysgeusia;ENT;Gustatory;Hyposmia;Infection;Loss;Olfaction;Olfactory;SARS-CoV-2;Smell;Taste | 2020-04-06 02:00:00+02:00 | 32253535 | FR;CA;CH;IT;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France. Jerome.Lechien@umons.ac.be.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium. Jerome.Lechien@umons.ac.be.;Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France. Jerome.Lechien@umons.ac.be.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. Jerome.Lechien@umons.ac.be.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Department of Neurology, EpiCURA Hospital, Ath, Belgium.;Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Quironsalud Valencia, Valencia, Spain.;Department of Otolaryngology-Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;Division of Otolaryngology-Head and Neck Surgery, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.;Division of Phoniatrics and Audiology, Department of Mental and Physical Health and Preventive Medicine, University of L. Vanvitelli, Naples, Italy.;Department of Otolaryngology-Head and Neck Surgery, Morgagni Pierantoni Hospital, Forli, Italy.;Department of Otolaryngology-Head and Neck Surgery, EpiCURA Hospital, Baudour, Belgium.;Department of Otolaryngology-Head and Neck Surgery, CHU Ambroise Paré, Mons, Belgium.;Division of Infectious Disease, CHU Ambroise-Paré, Mons, Belgium.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Rhinology-Olfactology Unit, Department of Otorhinolaryngology, Head and Neck Surgery, Geneva University Hospitals (HUG), Geneva, Switzerland.;Department of Neuroradiology, Université Paris-Descartes-Sorbonne-Paris-Cité, IMABRAIN-INSERM-UMR1266, DHU-Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France.;Department of Radiology, APHP, Hôpitaux R. Poincaré-Ambroise Paré, DMU Smart Imaging, GH Université Paris-Saclay, U 1179 UVSQ/Paris-Saclay, Paris, France.;Department of Neurosciences, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Neuroscience, Audiology Unit, Padova University, Treviso, Italy.;Department of Metabolic and Molecular Biochemistry, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otorhinolaryngology-Head and Neck Surgery, APHM, Aix Marseille University, La Conception University Hospital, Marseille, France. | 196 | ||
| 10.1016/j.gofs.2020.04.008 | Editorial | fr | [Breast cancer management during the COVID 19 pandemic: The CNGOF takes action]. | https://www.ncbi.nlm.nih.gov/pubmed/32320812 | 2468-7189 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Breast Neoplasms__complications;Comorbidity;Coronavirus Infections__complications;Disease Management;Female;France__epidemiology;Humans;Neoplasms__complications;Pandemics__prevention & control;Pneumonia, Viral__complications;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gynécologie Obstétrique Fertilité & Sénologie | C Mathelin;I Nisand | Breast cancer;CNGOF;Cancer du sein;Covid-19 | 2020-04-19 02:00:00+02:00 | 32320812 | FR | Pôle de Gynécologie-Obstétrique-Sénologie, CHRU, Hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67091 Strasbourg cedex, France, IGBMC, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Biologie du Cancer, 1, rue Laurent-Fries, 67400 Illkirch-Graffenstaden, France. Electronic address: carole.mathelin.x@gmail.com.;Pôle de Gynécologie-Obstétrique-Sénologie, CHRU, Hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67091 Strasbourg cedex, France, 91, boulevard de Sébastopol, 75002 Paris, France. | 199 | |||
| NIAID NIH HHS | 10.1016/j.jmb.2020.04.009 | Journal Article;Research Support, N.I.H., Extramural | en | Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop. | https://www.ncbi.nlm.nih.gov/pubmed/32320687 | The 2019 novel coronavirus (2019-nCoV/SARS-CoV-2) originally arose as part of a major outbreak of respiratory disease centered on Hubei province, China. It is now a global pandemic and is a major public health concern. Taxonomically, SARS-CoV-2 was shown to be a Betacoronavirus (lineage B) closely related to SARS-CoV and SARS-related bat coronaviruses, and it has been reported to share a common receptor with SARS-CoV (ACE-2). Subsequently, betacoronaviruses from pangolins were identified as close relatives to SARS-CoV-2. Here, we perform structural modeling of the SARS-CoV-2 spike glycoprotein. Our data provide support for the similar receptor utilization between SARS-CoV-2 and SARS-CoV, despite a relatively low amino acid similarity in the receptor binding module. Compared to SARS-CoV and all other coronaviruses in Betacoronavirus lineage B, we identify an extended structural loop containing basic amino acids at the interface of the receptor binding (S1) and fusion (S2) domains. We suggest this loop confers fusion activation and entry properties more in line with betacoronaviruses in lineages A and C, and be a key component in the evolution of SARS-CoV-2 with this structural loop affecting virus stability and transmission. | 0022-2836 | 2020-04-19 02:00:00+02:00 | pubmed | Amino Acid Sequence;Animals;Betacoronavirus__chemistry;Chiroptera__virology;Coronavirus Infections__veterinary;Eutheria;Humans;Models, Molecular;Pandemics;Phylogeny;Pneumonia, Viral__virology;Proteolysis;SARS Virus__chemistry;Sequence Alignment;Spike Glycoprotein, Coronavirus__chemistry;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Molecular Biology | Javier A Jaimes;Nicole M André;Joshua S Chappie;Jean K Millet;Gary R Whittaker | COVID-19;SARS-CoV-2;cleavage sites;coronavirus;spike protein | 2020-04-19 02:00:00+02:00 | 32320687 | FR;US | [{"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI135270"}] | Department of Microbiology & Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.;Department of Molecular Medicine, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.;Université Paris-Saclay, INRAE, UVSQ, Virologie et Immunologie Moléculaires, 78350 Jouy-en-Josas, France. Electronic address: jean.millet@inrae.fr.;Department of Microbiology & Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA, Master of Public Health Program, Cornell University, Ithaca, NY 14853, USA. Electronic address: grw7@cornell.edu. | 200 |
| Letter | en | The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician's view. | https://www.ncbi.nlm.nih.gov/pubmed/32315802 | 2020-04-19 02:00:00+02:00 | pubmed | Stefano Carda;Marco Invernizzi;Ganesh Bavikatte;Djamel Bensmaïl;Francesca Bianchi;Thierry Deltombe;Nathalie Draulans;Alberto Esquenazi;Gerard E Francisco;Raphaël Gross;Luis Jorge Jacinto;Susana Moraleda Pérez;Michael W O'Dell;Rajiv Reebye;Monica Verduzco-Gutierrez;Jörg Wissel;Franco Molteni | 2020-04-18 02:00:00+02:00 | 32315802 | FR;CA;PT;BO;GB;CH;US;IT;NL;ES;BE;DE | Service of Neuropsychology and Neurorehabilitation, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland. Electronic address: stefano.carda@chuv.ch.;University of Eastern Piedmont, Department of Health Sciences, 28100 Novara, Italy.;Neurorehabilitation Medicine, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ United Kingdom.;Physical and Rehabilitation Medicine Department, R.-Pointcaré Hospital, AP-HP Université Paris-Saclay, Team INSERM 1179, UFR de Santé Simone-Veil, Université de Versailles Saint-Quentin, Paris, France.;Neurophysiology Unit, IRCCS San Raffaele Scientific Institute Milan, Italy.;Service de Médecine Physique & Réadaptation, CHU UCL Namur site Godinne, 5530 Yvoir, Belgium.;Libra Revalidatie & Audiologie, Eindhoven, The Netherlands.;Department of Physical Medicine & Rehabilitation, MossRehab Gait and Motion Analysis Lab, Elkins Park, PA, USA.;Department of Physical Medicine & Rehabilitation, UTHealth McGovern Medical School, and TIRR Memorial Hermann Hospital, Houston, TX, USA.;Service de MPR Neurologique, CHU de Nantes, Hôpital Saint-Jacques, 44093 Nantes cedex, France, EA 43334 laboratoire Motricité, Interactions, Performance-UFR STAPS Nantes, 44300 Nantes, France.;Serviço de Reabilitação de Adultos 3, Centro de Medicina de Reabilitação de Alcoitão, Alcabideche, Portugal.;Physical Medicine & Rehabilitation Department, La Paz University Hopital, Madrid, Spain.;New York Presbyterian Hospital, Weill-Cornell Medical Centre, New York, NY, USA.;Division of Physical Medicine & Rehabilitation, University of British Columbia, Vancouver, BC, Canada.;Department of Rehabilitation Medicine, Joe-R.-and-Teresa-Lozano Long School of Medicine, UT Health San Antonio, San Antonio, TX, USA.;Neurological Rehabilitation & Physical Therapy, Department of Neurology with Stroke Unit, Vivantes Hospital Spandau, 13585 Berlin, Germany.;Valduce Hospital, Villa Beretta Rehabilitation Centre, Costamasnaga (LC), Italy. | 202 | ||||||||
| National Science and Technology Major Project of China;Natural Science Research Project of Nantong Science and Technology Bureau | 10.3390/ijms21082826 | Journal Article | en | A Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32325642 | COVID-19 has become a major global public health burden, currently causing a rapidly growing number of infections and significant morbidity and mortality around the world. Early detection with fast and sensitive assays and timely intervention are crucial for interrupting the spread of the COVID-19 virus (SARS-CoV-2). Using a mismatch-tolerant amplification technique, we developed a simple, rapid, sensitive and visual reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for SARS-CoV-2 detection based on its N gene. The assay has a high specificity and sensitivity, and robust reproducibility, and its results can be monitored using a real-time PCR machine or visualized via colorimetric change from red to yellow. The limit of detection (LOD) of the assay is 118.6 copies of SARS-CoV-2 RNA per 25 μL reaction. The reaction can be completed within 30 min for real-time fluorescence monitoring, or 40 min for visual detection when the template input is more than 200 copies per 25 μL reaction. To evaluate the viability of the assay, a comparison between the RT-LAMP and a commercial RT-qPCR assay was made using 56 clinical samples. The SARS-CoV-2 RT-LAMP assay showed perfect agreement in detection with the RT-qPCR assay. The newly-developed SARS-CoV-2 RT-LAMP assay is a simple and rapid method for COVID-19 surveillance. | 1422-0067 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus__genetics;Biological Assay;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Humans;Nucleic Acid Amplification Techniques;Pandemics;Pneumonia, Viral__diagnosis;Reverse Transcriptase Polymerase Chain Reaction;Reverse Transcription;Sensitivity and Specificity;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | International Journal of Molecular Sciences | Renfei Lu;Xiuming Wu;Zhenzhou Wan;Yingxue Li;Xia Jin;Chiyu Zhang | COVID-19;LAMP;POCT;SARS-CoV-2;pneumonia | 2020-04-18 02:00:00+02:00 | 32325642 | FR;CN | [{"country": "", "agency": "National Science and Technology Major Project of China", "grantid": "2019YFC1200603 and 2017ZX10103009-002"}, {"country": "", "agency": "Natural Science Research Project of Nantong Science and Technology Bureau", "grantid": "MS12019048"}] | Clinical Laboratory, Nantong Third Hospital Affiliated to Nantong University, Nantong 226006, China.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.;Medical Laboratory of Taizhou Fourth People's Hospital, Taizhou 225300 China.;Shanghai Public Health Clinical Center, Fudan University, Jinshan District, Shanghai 201508, China. | 208 |
| NCI NIH HHS;NICHD NIH HHS | 10.1084/jem.20200652 | Journal Article;Research Support, N.I.H., Extramural | en | Targeting potential drivers of COVID-19: Neutrophil extracellular traps. | https://www.ncbi.nlm.nih.gov/pubmed/32302401 | Coronavirus disease 2019 (COVID-19) is a novel, viral-induced respiratory disease that in ∼10-15% of patients progresses to acute respiratory distress syndrome (ARDS) triggered by a cytokine storm. In this Perspective, autopsy results and literature are presented supporting the hypothesis that a little known yet powerful function of neutrophils-the ability to form neutrophil extracellular traps (NETs)-may contribute to organ damage and mortality in COVID-19. We show lung infiltration of neutrophils in an autopsy specimen from a patient who succumbed to COVID-19. We discuss prior reports linking aberrant NET formation to pulmonary diseases, thrombosis, mucous secretions in the airways, and cytokine production. If our hypothesis is correct, targeting NETs directly and/or indirectly with existing drugs may reduce the clinical severity of COVID-19. | 0022-1007,1540-9538 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Cytokines__metabolism;Extracellular Traps;Humans;Lung Diseases__etiology;Neutrophils__pathology;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Experimental Medicine | Betsy J Barnes;Jose M Adrover;Amelia Baxter-Stoltzfus;Alain Borczuk;Jonathan Cools-Lartigue;James M Crawford;Juliane Daßler-Plenker;Philippe Guerci;Caroline Huynh;Jason S Knight;Massimo Loda;Mark R Looney;Florencia McAllister;Roni Rayes;Stephane Renaud;Simon Rousseau;Steven Salvatore;Robert E Schwartz;Jonathan D Spicer;Christian C Yost;Andrew Weber;Yu Zuo;Mikala Egeblad | 2020-04-18 02:00:00+02:00 | 32302401 | FR;CA;US | [{"country": "United States", "agency": "NCI NIH HHS", "grantid": "P30 CA045508"}, {"country": "United States", "agency": "NICHD NIH HHS", "grantid": "R01 HD093826"}] | Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, The Feinstein Institutes for Medical Research & Departments of Molecular Medicine and Pediatrics, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.;Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.;Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.;Division of Thoracic and Upper GI Surgery, Department of Surgery, Montreal, Canada.;Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, East Garden City, NY.;Centre Hospitalier Universitaire de Nancy, Nancy, France.;Goodman Cancer Research Centre, McGill University, Montreal, Canada.;Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.;Department of Medicine, University of California, San Francisco, San Francisco, CA.;Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX.;Department of Medicine, McGill University & The Research Institute of the McGill University Health Centre, Montreal, Canada.;Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY.;Department of Pediatrics, Program in Molecular Medicine, University of Utah School of Medicine, Salt Lake City, UT.;Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Northwell Health, Manhasset, NY. | 215 | |
| 10.5435/jaaos-d-20-00360 | Journal Article;Review | en | Orthopaedic Surgical Selection and Inpatient Paradigms During the Coronavirus (COVID-19) Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32304401 | The novel coronavirus pandemic, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed an immense strain on healthcare systems across the entire world. Consequently, multiple federal and state governments have placed restrictions on hospitals such as limiting "elective surgery" and recommending social or physical distancing. We review the literature on several areas that have been affected including surgical selection, inpatient care, and physician well-being. These areas affecting inpatient paradigms include surgical priority, physical or social distancing, file sharing for online clinical communications, and physician wellness. During this crisis, it is important that orthopaedic departments place an emphasis on personnel safety and slowing the spread of the virus so that the department can still maintain vital functions. Physical distancing and emerging technologies such as inpatient telemedicine and online file sharing applications can enable orthopaedic programs to still function while attempting to protect medical staff and patients from the novel coronavirus spread. This literature review sought to provide evidence-based guidance to orthopaedic departments during an unprecedented time. Orthopaedic surgeons should follow the Centers for Disease Control and Prevention guidelines, wear personal protective equipment (PPE) when appropriate, have teams created using physical distancing, understand the department's policy on elective surgery, and engage in routines which enhance physician wellness. | 1067-151X,1940-5480 | 2020-04-19 02:00:00+02:00 | pubmed | Communicable Disease Control__organization & administration;Coronavirus Infections__epidemiology;Elective Surgical Procedures__methods;Female;Humans;Inpatients__statistics & numerical data;Male;Occupational Health;Orthopedic Procedures__statistics & numerical data;Pandemics__prevention & control;Patient Isolation__methods;Patient Safety;Patient Selection;Personal Protective Equipment__statistics & numerical data;Pneumonia, Viral;Program Development;Program Evaluation;Safety Management__organization & administration;United States;COVID-19 | Journal of the American Academy of Orthopaedic Surgeons | Patrick A Massey;Kaylan McClary;Andrew S Zhang;Felix H Savoie;R Shane Barton | 2020-04-19 02:00:00+02:00 | 32304401 | FR;US | From the Department of Orthopaedic Surgery, Louisiana State University Health, Shreveport, LA (Dr. Massey, Dr. McClary, Dr. Zhang, and Dr. Barton), and the Department of Orthopaedic Surgery, Tulane Medical Center, New Orleans, LA (Dr. Savoie). | 226 | |||
| 10.3390/jcm9041126 | Editorial | en | COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression. | https://www.ncbi.nlm.nih.gov/pubmed/32326426 | Considered to be a major portal of entry for infectious agents, the oral cavity is directly associated with the evolutionary process of SARS-CoV-2 in its inhalation of ambient particles in the air and in expectorations. Some new generations of mouth rinses currently on the market have ingredients that could contribute to lower the SARS-CoV-2 viral load, and thus facilitate the fight against oral transmission. If chlorhexidine, a usual component of mouth rinse, is not efficient to kill SARS-CoV-2, the use of a mouth rinses and/or with local nasal applications that contain β-cyclodextrins combined with flavonoids agents, such as Citrox, could provide valuable adjunctive treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS-CoV-2 carriage. We urge national agencies and authorities to start clinical trials to evaluate the preventive effects of βCD-Citrox therapeutic oral biofilm rinses in reducing the viral load of the infection and possibly disease progression. | 2077-0383 | 2020-04-19 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Florence Carrouel;Maria Pia Conte;Julian Fisher;Lucio Souza Gonçalves;Claude Dussart;Juan Carlos Llodra;Denis Bourgeois | 2019-nCoV;COVID-19;Citrox;SARS-CoV-2;microbiome;mouthrinse;oral cavity;viral load;β-cyclodextrins | 2020-04-15 02:00:00+02:00 | 32326426 | FR;US;BR;IT;ES | University Lyon 1, Laboratory "Health Systemic Process", EA4129, 69008 Lyon, France.;Sapienza University of Rome, Department of Public Health and Infectious Diseases, 00185 Rome, Italy.;THEnet, Training for Health Equity Network, New York, NY 10023, USA.;Estacio de Sá University, Faculty of Dentistry, Rio de Janeiro 22640-102, Brazil.;Lyon Public Hospices, Central Pharmacy, EA4129, 69002 Lyon, France.;University of Granada, Department of Preventive and Community Dentistry, 18010 Granada, Spain. | 239 | |||
| 10.1055/a-1149-9872 | Journal Article | en | Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic era. The views of a panel of worldwide international experts. | https://www.ncbi.nlm.nih.gov/pubmed/32294795 | 0172-4614,1438-8782 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Ultrasonography;COVID-19;severe acute respiratory syndrome coronavirus 2 | Ultraschall in der Medizin - European Journal of Ultrasound | Fabio Piscaglia;Federico Stefanini;Vito Cantisani;Paul S Sidhu;Richard Barr;Annalisa Berzigotti;Maria Cristina Chammas;Jean-Michel Correas;Christoph Frank Dietrich;Steven Feinstein;Pintong Huang;Christian Jenssen;Yuko Kono;Masatoshi Kudo;Ping Liang;Andrej Lyshchik;Christian Nolsøe;Xyaoyan Xie;Francesco Tovoli | 2020-04-15 02:00:00+02:00 | 32294795 | FR;CN;JP;CH;GB;US;BR;IT;DK;DE | COVID-19 Unit & Unit of Internal Medicine, Azienda Ospedaliero Universitaria S.Orsola Malpighi, Bologna, Italy.;Radiological, Anatomo-pathological and Oncologic Sciences Department, Policlinico Umberto I, University La Sapienza, Rome, Italy.;Department of Radiology, King's College London. King's College Hospital, London, UK.;Radiology, Northeastern Ohio Medical University, USA.;Hepatology, University Clinic for visceral surgery and medicine, Inselspital, University of Bern, Switzerland.;Ultrasound Division of Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil.;Department of Adult Radiology, Paris University & Necker University Hospital, Paris, France.;Kliniken Hirslanden Beau Site, Salem und Permanence, Bern, Switerzeland.;Rush Universty Medical Center, Chicago, USA.;Department of Ultrasound in Medicine,the Second Affiliated Hospital of Zhejiang University School of Medicine, China.;Department of Internal Medicine, Krankenhaus Märkisch-Oderland, Strausberg, and Brandenburg Institute for Clinical Ultrasound (BICUS), Medical University Brandenburg, Neuruppin, Germany.;Department of Medicine, Radiology, University of California, San Diego, USA.;Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan.;Interventional Ultrasound Department, Chinese PLA General Hospital, Beijing, China.;Radiology Unity, Thomas Jefferson University Hospital, Philadelphia, USA.;Centre for Surgical Ultrasound, Dep of Surgery, Zealand University Hospital, Køge, Copenhagen Denmark.;Institute of Diagnostic and Interventional Ultrasound The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. | 242 | ||||
| Letter | en | Neurologic Features in Severe SARS-CoV-2 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32294339 | 2020-04-19 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus__genetics;Brain__diagnostic imaging;Brain Diseases__etiology;Confusion__etiology;Coronavirus Infections__complications;Humans;Magnetic Resonance Imaging;Middle Aged;Pandemics;Pneumonia, Viral__complications;Respiratory Distress Syndrome, Adult__complications;Reverse Transcriptase Polymerase Chain Reaction;Stroke__etiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Julie Helms;Stéphane Kremer;Hamid Merdji;Raphaël Clere-Jehl;Malika Schenck;Christine Kummerlen;Olivier Collange;Clotilde Boulay;Samira Fafi-Kremer;Mickaël Ohana;Mathieu Anheim;Ferhat Meziani | 2020-04-15 02:00:00+02:00 | 32294339 | FR | Strasbourg University Hospital, Strasbourg, France.;University of Strasbourg, Strasbourg, France. | 243 | |||||||
| Journal Article;Comment | en | Blockade of SARS-CoV-2 infection by recombinant soluble ACE2. | https://www.ncbi.nlm.nih.gov/pubmed/32354636 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Peptidyl-Dipeptidase A;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Francois Alhenc-Gelas;Tilman B Drueke | ACE2;COVID-19;renin-angiotensin system;viral infection | 2020-04-14 02:00:00+02:00 | 32354636 | FR | U1138-Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, Paris Université, Sorbonne Université, Paris, France.;U1018, Centre de recherche en Épidémiologie et Santé des Populations (CESP), Institut National de la Santé et de la Recherche Médicale, Paris-Sud Université and Versailles Saint-Quentin-en-Yvelines Université, Paris-Ile-de-France-Ouest Université, Villejuif, France. Electronic address: tilman.drueke@inserm.fr. | 249 | ||||||
| Journal Article;Comment | en | Keep Socially (but Not Physically) Connected and Carry on: Preventing Suicide in the Age of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32297718 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Quarantine;Suicide;COVID-19;severe acute respiratory syndrome coronavirus 2 | Philippe Courtet;Emilie Olié;Christophe Debien;Guillaume Vaiva | 2020-04-14 02:00:00+02:00 | 32297718 | FR | Université Montpellier, CHRU Montpellier, Montpellier, France 34090. philippe.courtet@univ-montp1.fr.;Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital, CHU Montpellier, Montpellier, France;PSNREC, Univ Montpellier, INSERM, CHU de Montpellier, Montpellier, France;FondaMental Foundation, Créteil, France;Department of Psychiatry, University Hospital of Lille, Lille, France;Centre National de Ressources et Résilience, Lille, France | 252 | |||||||
| 10.1016/j.radonc.2020.04.010 | Journal Article;Research Support, Non-U.S. Gov't | en | Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32342878 | As of April 6, 2020, there are over 1,200,000 reported cases and 70,000 deaths worldwide due to COVID-19, the disease caused by the SARS-CoV-2 virus, and these numbers rise exponentially by the day [1]. According to the Centers for Disease Control (CDC), the most effective means of minimizing the spread of the virus is through reducing interactions between individuals [2]. We performed a review of the literature, as well as national and international treatment guidelines, seeking data in support of the RADS principle (Remote visits, Avoid radiation, Defer radiation, Shorten radiation) [3] as it applies to gastrointestinal cancers. The purpose of the present work is to guide radiation oncologists managing patients with gastrointestinal cancers during the COVID-19 crisis in order to maintain the safety of our patients, while minimizing the impact of the pandemic on cancer outcomes. | 0167-8140 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Gastrointestinal Neoplasms__radiotherapy;Guidelines as Topic;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Radiotherapy and Oncology | Leila T Tchelebi;Karin Haustermans;Marta Scorsetti;Ali Hosni;Florence Huguet;Maria A Hawkins;Laura A Dawson;Karyn A Goodman | COVID-19;Gastrointestinal neoplasms;Pandemic;Radiation oncology | 2020-04-13 02:00:00+02:00 | 32342878 | FR;CA;GB;US;IT;BE | Department of Radiation Oncology, Penn State College of Medicine, Hershey, USA. Electronic address: ltchelebi@pennstatehealth.psu.edu.;Department of Radiation Oncology, Particle Therapy Interuniversity Center Leuven, Belgium.;Humanitas Clinical and Research Center - IRCCS, Department of Radiotherapy and Radiosurgery, Milan, Italy, Department of Biomedical Sciences, Humanitas University, Milan, Italy.;Department of Radiation Oncology, University of Toronto, Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Canada.;Department of Radiation Oncology, Hôpital Tenon, AP-HP.Sorbonne Université, Paris, France.;Medical Physics and Biomedical Engineering, University College London, University College London Hospitals NHS Foundation Trust, London, UK.;Department of Biomedical Sciences, Humanitas University, Milan, Italy.;Department of Radiation Oncology, The Mount Sinai Hospital, New York, USA. | 255 | ||
| 10.1016/j.jbo.2020.100291 | Journal Article | en | Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic: GEMO position paper. | https://www.ncbi.nlm.nih.gov/pubmed/32292693 | The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic. All indications and treatment modalities must be re-discussed. This is particularly the case for radiotherapy of bone metastases for which it is possible to reduce the number of sessions, the frequency of transport and the complexity of treatments. These changes will have to be discussed according to the organization of each radiotherapy department and the health situation, while medical teams must remain vigilant about the risks of complications of bone metastases, particularly spinal metastases. In this short piece, the members of the GEMO (the European Study Group of Bone Metastases) offer a number of recommendations to achieve the above objectives, both in general and in relation to five of the most common situations on radiation therapy for bone metastases. | 2212-1374 | 2020-04-19 02:00:00+02:00 | pubmed | Journal of Bone Oncology | Sébastien Thureau;Jean Christophe Faivre;Richard Assaker;Emmanuel Biver;Cyrille B Confavreux;Françoise Debiais;Martine Duterque-Coquillaud;Francesco Giammarile;Dominique Heymann;Frédéric E Lecouvet;Laetitia Morardet;Frederic Paycha;Jean-Jacques Body;Marie-Hélène Vieillard | 2020-04-13 02:00:00+02:00 | 32292693 | FR;BE;CH | Radiation department, Center Henri Becquerel, Quantif-Litis EA 4108, University of Rouen, Rouen, France.;Radiation department, Institut de Cancérologie de Lorraine - Alexis-Vautrin, Vandœuvre-lès-Nancy, France.;University Department of neurosurgery, Lille University Hospital, Lille, France.;Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.;INSERM UMR 1033 - University of Lyon, Bone Metastasis Expert Center (CEMOS) Cancer Institute of Hospices Civils de Lyon, Rheumatology Department, Centre Hospitalier Lyon Sud, Pierre Bénite, F- 69310 France.;Rheumatology department, CHU Poitiers, Poitiers, France.;CNRS UMR9020, INSERM UMR1277, University of Lille, Institut Pasteur de Lille, CHU Lille, France.;Nuclear Medecine LUMEN, Centre Leon Berard, Lyon, France.;Institut de Cancérologie de l'Ouest, University of Nantes, Inserm, CRCINA, Saint-Herblain, France.;Institut du Cancer Roi Albert 2, Cliniques Universitaires Saint-Luc, Service de Radiologie et d'Imagerie Médicale, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.;Oncology Department, Pitié Salpêtrière Hospital, Paris, France.;Nuclear Medicine Department, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Medicine, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.;University department of Rheumatology, Lille University hospital, Oscar Lambret Center, CNRS UMR9020, INSERM UMR1277, University of Lille, Institut Pasteur, Lille. | 256 | ||||
| 10.1016/j.jviscsurg.2020.04.011 | Journal Article | en | Management of the COVID-19 epidemic by public health establishments-Analysis by the Fédération Hospitalière de France. | https://www.ncbi.nlm.nih.gov/pubmed/32417194 | The objective of this article is to detail the measures taken in public institutions to cope with the COVID-19 epidemic. It details the initial strategy, organizational evolution towards "all-COVID", coordination between the various stakeholders and the strategy for maintaining continuity of care. The Quebec experience is also used as an example. Finally, an exit strategy must be anticipated at this phase of the epidemic. | 1878-7886 | 2020-04-19 02:00:00+02:00 | pubmed | Continuity of Patient Care;Coronavirus Infections__therapy;France;Hospitals, Public__organization & administration;Humans;Pandemics;Pneumonia, Viral__therapy;Practice Guidelines as Topic;Public Health;Quality of Health Care;Quebec;Societies, Hospital;COVID-19 | Journal of Visceral Surgery | K Barro;A Malone;A Mokede;C Chevance | COVID-19;Coronavirus;Pandemic | 2020-04-18 02:00:00+02:00 | 32417194 | FR | Pôle offre de soins - Fédération hospitalière de France, 1 bis, rue Cabanis, CS 41402, 75993 Paris cedex 14, France.;Pôle prospective, Europe, International Fédération hospitalière de France, 1 bis, rue Cabanis - CS 41402, 75993 Paris cedex 14, France.;Pôle finance Fédération hospitalière de France, 1 bis, rue Cabanis - CS 41402, 75993 Paris cedex 14, France. Electronic address: c.chevance@fhf.fr. | 260 | ||
| 10.1016/j.canrad.2020.04.002 | Journal Article | fr | [Management of a radiotherapy center during the COVID-19 outbreak: The experience of the Mulhouse hospital centre (France)]. | https://www.ncbi.nlm.nih.gov/pubmed/32334905 | The COVID-19 outbreak grows exponentially in our country. Despite most of patients develops benign symptoms, cancer patients are at risk of a severe form of the disease. Radiotherapy centres are a potential contamination place due to the number of patients treated and staff present. Their organization during the outbreak period aims to ensure continuity of care while limiting the risk of death from COVID-19. In the radiotherapy department of Mulhouse hospital (France), we pointed five points out: protection of medical and paramedical staff, protection of patients undergoing treatment, detection of patients suspected of being infected by SARS-CoV-2 and their management, reorganization of the patient circuit and measures regarding the quality management. This reflection, which began at the beginning of the outbreak in our city, allows us to preserve the access to radiotherapy treatments by anticipating the risk of spreading the virus. Through biweekly meetings, we continue to adapt to the epidemic in our department, considering our material resources. The ability to perform diagnostic tests in all suspect patients would also allow us to refine our procedures. | 1278-3218 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Cancer Care Facilities__organization & administration;Clinical Protocols;Continuity of Patient Care__organization & administration;Coronavirus Infections__diagnosis;France__epidemiology;Health Services Accessibility__organization & administration;Humans;Neoplasms__radiotherapy;Occupational Diseases__prevention & control;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Quality of Health Care__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cancer/Radiothérapie | T Ohnleiter;L Piot;A Rogenmuser;M Noirclerc;R Hamlaoui;A Grandgirard | COVID-19;Department;Epidemic;Organisation;Organization;Patient;Radiotherapy;Radiothérapie;Service;Épidémie | 2020-04-17 02:00:00+02:00 | 32334905 | FR | Service de radiothérapie, hôpital Émile-Muller, 20, avenue du Dr-René-Laennec, 68100 Mulhouse, France. Electronic address: thomas.ohnleiter@ghrmsa.fr.;Unité de physique médicale, hôpital Émile-Muller, 20, avenue du Dr-René-Laennec, 68100 Mulhouse, France.;Centre de coordination en cancérologie, hôpital Émile-Muller, 20, avenue du Dr-René-Laennec, 68100 Mulhouse, France.;Service de radiothérapie, hôpital Émile-Muller, 20, avenue du Dr-René-Laennec, 68100 Mulhouse, France. | 266 | ||
| 10.1016/j.medmal.2020.04.006 | Journal Article;Observational Study | en | Features of anosmia in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32305563 | Medical publications about anosmia with COVID-19 are scarce. We aimed to describe the prevalence and features of anosmia in COVID-19 patients. | 0399-077X | 2020-04-19 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus__physiology;Cohort Studies;Comorbidity;Coronavirus Infections__complications;Female;France__epidemiology;Humans;Male;Middle Aged;Olfaction Disorders__epidemiology;Oxygen Inhalation Therapy;Pandemics;Pneumonia__epidemiology;Pneumonia, Viral__complications;Prevalence;Respiratory Function Tests;Retrospective Studies;Severity of Illness Index;Time Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Médecine et Maladies Infectieuses | T Klopfenstein;N J Kadiane-Oussou;L Toko;P-Y Royer;Q Lepiller;V Gendrin;S Zayet | Anosmia;COVID-19;Dysgeusia | 2020-04-17 02:00:00+02:00 | 32305563 | FR | Infectious Diseases Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: timothee.klopfenstein@hnfc.fr.;Infectious Diseases Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.;Virology Department, Centre-Hospitalier Universitaire de Besançon, 25000 Besançon, France.;Infectious Diseases Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: souhail.zayet@gmail.com. | 269 | ||
| 10.1016/j.jfo.2020.04.003 | Editorial | fr | [COVID-19: The day after]. | https://www.ncbi.nlm.nih.gov/pubmed/32340758 | 0181-5512 | 2020-04-19 02:00:00+02:00 | pubmed | Animals;Artificial Intelligence__trends;Betacoronavirus;Camelus__virology;China__epidemiology;Coronavirus Infections__epidemiology;Disease Vectors;Ebolavirus;Eutheria__virology;Forecasting;Hand Disinfection;Humans;Hygiene;Life Change Events;Masks;Middle East Respiratory Syndrome Coronavirus;Models, Economic;Ophthalmologists;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Politics;SARS Virus;Telemedicine__trends;Viverridae__virology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | C Baudouin | 2020-04-17 02:00:00+02:00 | 32340758 | FR | CHNO des Quinze-Vingts, 28, rue De-Charenton, 75012 Paris, France. Electronic address: cbaudouin@15-20.fr. | 272 | ||||
| NHLBI NIH HHS | 10.1016/j.jacc.2020.04.031 | Journal Article;Research Support, N.I.H., Extramural;Review | en | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. | https://www.ncbi.nlm.nih.gov/pubmed/32311448 | Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic. | 0735-1097 | 2020-04-19 02:00:00+02:00 | pubmed | Anticoagulants__pharmacology;Betacoronavirus__isolation & purification;Coronavirus Infections__blood;Fibrinolytic Agents__pharmacology;Humans;Pandemics;Platelet Aggregation Inhibitors__pharmacology;Pneumonia, Viral__blood;Thromboembolism__drug therapy;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of the American College of Cardiology | Behnood Bikdeli;Mahesh V Madhavan;David Jimenez;Taylor Chuich;Isaac Dreyfus;Elissa Driggin;Caroline Der Nigoghossian;Walter Ageno;Mohammad Madjid;Yutao Guo;Liang V Tang;Yu Hu;Jay Giri;Mary Cushman;Isabelle Quéré;Evangelos P Dimakakos;C Michael Gibson;Giuseppe Lippi;Emmanuel J Favaloro;Jawed Fareed;Joseph A Caprini;Alfonso J Tafur;John R Burton;Dominic P Francese;Elizabeth Y Wang;Anna Falanga;Claire McLintock;Beverley J Hunt;Alex C Spyropoulos;Geoffrey D Barnes;John W Eikelboom;Ido Weinberg;Sam Schulman;Marc Carrier;Gregory Piazza;Joshua A Beckman;P Gabriel Steg;Gregg W Stone;Stephan Rosenkranz;Samuel Z Goldhaber;Sahil A Parikh;Manuel Monreal;Harlan M Krumholz;Stavros V Konstantinides;Jeffrey I Weitz;Gregory Y H Lip | COVID-19;SARS-CoV-2;anticoagulant;antiplatelet;antithrombotic therapy;thrombosis | 2020-04-17 02:00:00+02:00 | 32311448 | FR;IL;RU;CA;NZ;CN;GR;GB;US;IT;AU;ES;DK;DE | [{"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "T32 HL007854"}] | NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, Clinical Trials Center, Cardiovascular Research Foundation, New York, New York. Electronic address: bb2813@cumc.columbia.edu.;NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, Clinical Trials Center, Cardiovascular Research Foundation, New York, New York. Electronic address: mvm2122@cumc.columbia.edu.;Respiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (Instituto de Ramón y Cajal de Investigación Sanitaria), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.;NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.;Department of Medicine and Surgery, University of Insubria, Varese, Italy.;McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas.;Department of Cardiology, Chinese PLA General Hospital, Beijing, China.;Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.;University of Vermont Medical Center, Burlington, Vermont.;Department of Vascular Medicine, University of Montpellier, Centre Hospitalier Universitaire Montpellier, InnoVTE F-CRIN Network, Montpellier, France.;Oncology Unit GPP, Sotiria General Hospital Athens School of Medicine, Athens, Greece.;Harvard Medical School, Boston, Massachusetts, Beth Israel Deaconess Medical Center, Boston, Massachusetts.;Laboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy.;Haematology Laboratory, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia, Sydney Centres for Thrombosis and Haemostasis, Westmead, New South Wales, Australia.;Loyola University Medical Center, Chicago, Illinois.;Pritzker School of Medicine, University of Chicago, Chicago, Illinois.;Pritzker School of Medicine, University of Chicago, Chicago, Illinois, Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, Illinois.;Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.;Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, University of Milan Bicocca, Bergamo, Italy.;Auckland City Hospital, Auckland, New Zealand.;St Thomas' Hospital, London, United Kingdom.;Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, New York.;Center for Bioethics and Social Science in Medicine, University of Michigan, Ann Arbor, Michigan, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan.;Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.;Harvard Medical School, Boston, Massachusetts, Massachusetts General Hospital, Boston, Massachusetts.;Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, McMaster University, Hamilton, Ontario, Canada, Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.;Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.;Harvard Medical School, Boston, Massachusetts, Brigham and Women's Hospital, Boston, Massachusetts.;Vanderbilt University School of Medicine, Nashville, Tennessee.;INSERM U1148, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, FACT (French Alliance for Cardiovascular Trials), Paris, France, Université Paris, Paris, France, Royal Brompton Hospital, Imperial College London, London, United Kingdom.;Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.;Cologne Cardiovascular Research Center, Heart Center, Department of Cardiology, University of Cologne, Cologne, Germany.;NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.;Department of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Católica San Antonio de Murcia, Barcelona, Spain.;Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.;Center for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany.;McMaster University, Hamilton, Ontario, Canada, Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.;Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom, Aalborg University, Aalborg, Denmark. | 276 |
| 10.1055/a-1155-6229 | Journal Article;Practice Guideline | en | ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32303090 | We are currently living in the throes of the COVID-19 pandemic that imposes a significant stress on health care providers and facilities. Europe is severely affected with an exponential increase in incident infections and deaths. The clinical manifestations of COVID-19 can be subtle, encompassing a broad spectrum from asymptomatic mild disease to severe respiratory illness. Health care professionals in endoscopy units are at increased risk of infection from COVID-19. Infection prevention and control has been shown to be dramatically effective in assuring the safety of both health care professionals and patients. The European Society of Gastrointestinal Endoscopy (www.esge.com) and the European Society of Gastroenterology and Endoscopy Nurses and Associates (www.esgena.org) are joining forces to provide guidance during this pandemic to help assure the highest level of endoscopy care and protection against COVID-19 for both patients and endoscopy unit personnel. This guidance is based upon the best available evidence regarding assessment of risk during the current status of the pandemic and a consensus on which procedures to perform and the priorities on resumption. We appreciate the gaps in knowledge and evidence, especially on the proper strategy(ies) for the resumption of normal endoscopy practice during the upcoming phases and end of the pandemic and therefore a list of potential research questions is presented. New evidence may result in an updated statement. | 0013-726X,1438-8812 | 2020-04-19 02:00:00+02:00 | pubmed | Coronavirus Infections__prevention & control;Endoscopy, Gastrointestinal__methods;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Infectious Disease Transmission, Professional-to-Patient__prevention & control;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Risk Management__methods;COVID-19 | Endoscopy | Ian M Gralnek;Cesare Hassan;Ulrike Beilenhoff;Giulio Antonelli;Alanna Ebigbo;Maria Pellisè;Marianna Arvanitakis;Pradeep Bhandari;Raf Bisschops;Jeanin E Van Hooft;Michal F Kaminski;Konstantinos Triantafyllou;George Webster;Heiko Pohl;Irene Dunkley;Björn Fehrke;Mario Gazic;Tatjana Gjergek;Siiri Maasen;Wendy Waagenes;Marjon de Pater;Thierry Ponchon;Peter D Siersema;Helmut Messmann;Mario Dinis-Ribeiro | 2020-04-17 02:00:00+02:00 | 32303090 | IL;FR;SI;PT;GR;GB;US;CH;HR;IT;PL;NL;DK;ES;EE;BE;DE | Institute of Gastroenterology and Hepatology, Emek Medical Center, Afula, Israel & Rappaport Faculty of Medicine Technion Israel Institute of Technology, Haifa, Israel.;Nuovo Regina Margherita Hospital, Rome, Italy.;Ulm, Germany.;III. Medizinische Klinik Universitätsklinikum Augsburg, Augsburg, Germany.;Department of Gastroenterology, Hospital Clinic de Barcelona. Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS). Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Universitat de Barcelona, Barcelona, Spain.;Department of Gastroenterology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.;Portsmouth Hospital NHS Trust, Gastroenterology, Portsmouth, United Kingdom.;Department of Gastroenterology and Hepatology,Catholic University of Leuven (KUL), TARGID, University, Hospitals Leuven, Leuven, Belgium.;Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands.;Department of Cancer Prevention and Department of Oncological Gastroenterology,The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.;Hepatogastroenterology Unit, 2nd Department of Internal Medicine - Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.;Department of Gastroenterology, University College London Hospitals, London, United Kingdom.;Dartmouth Geisel School of Medicine, Hanover NH, VA Medical Center, Section of Gastroenterology, White River Junction, VT., USA.;North West Anglia NHS Foundation Trust, Hinchingbrooke, United Kingdom.;Inselspital, Bern, Switzerland.;General hospital, Bjelovar, Croatia.;University Medical Centre, Ljubljana, Slovenia.;Tallinn Healthcare College, Tallin,Estonia.;Hvidovre Hospital, Copenhagen, Denmark.;Amsterdam UMC location AMC, Amsterdam, The Netherlands.;Gastroenterology Division, Edouard Herriot Hospital Lyon, France.;Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.;Gastroenterology Department, Portuguese Oncology Institute of Porto, Portugal. | 278 | |||
| Case Reports;Letter | en | COVID-19: before stopping specific infection prevention and control measures, be sure to exclude the diagnosis. | https://www.ncbi.nlm.nih.gov/pubmed/32343984 | 2020-04-26 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections__diagnosis;Cross Infection__prevention & control;Disinfection__standards;Female;France;Humans;Male;Middle Aged;Occupational Exposure__prevention & control;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | E Farfour;M-C Ballester;M Lecuru;A Verrat;E Imhaus;F Mellot;F Karnycheff;M Vasse;C Cerf;P Lesprit | 2020-04-25 02:00:00+02:00 | 32343984 | FR | Service de Biologie Clinique, Hôpital Foch, Suresnes, France. Electronic address: e.farfour@hopital-foch.org.;Service des Urgences, Hôpital Foch, Suresnes, France.;Service de Biologie Clinique, Hôpital Foch, Suresnes, France.;Service d'imagerie Médicale, Hôpital Foch, Suresnes, France.;Service de Réanimation Polyvalente, Hôpital Foch, Suresnes, France. | 299 | |||||||
| 10.1097/aog.0000000000003926 | Journal Article | en | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32332320 | 0029-7844 | 2020-04-26 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections__transmission;Female;Humans;Infant, Newborn;Infectious Disease Transmission, Vertical__statistics & numerical data;Pandemics;Pneumonia, Viral__transmission;Pregnancy;Pregnancy Complications, Infectious__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Obstetrics & Gynecology | Xiaolin Hu;Jinzhi Gao;Xiaoping Luo;Ling Feng;Weiyong Liu;Juan Chen;Alexandra Benachi;Daniele De Luca;Ling Chen | 2020-04-26 02:00:00+02:00 | 32332320 | FR;CN | Departments of Pediatrics, Obstetrics and Gynecology, and Clinical Laboratory, Tongji Hospital, and the Department of Biochemistry and Molecular Biology, Basic Medicine School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, and the Divisions of Obstetrics and Gynecology and Pediatrics and Neonatal Critical Care, "A. Béclère" Medical Centre, Paris Saclay University Hospitals APHP and Paris Saclay University, Paris, France. | 302 | ||||
| 10.1111/all.14336 | Journal Article | en | Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. | https://www.ncbi.nlm.nih.gov/pubmed/32329930 | 0105-4538,1398-9995 | 2020-04-26 02:00:00+02:00 | pubmed | Allergists__psychology;Asthma__complications;Betacoronavirus__genetics;CD8-Positive T-Lymphocytes__immunology;Coronavirus Infections__complications;Eosinophils__immunology;Humans;Immunoglobulin E__metabolism;Immunoglobulin M__metabolism;Infection Control__methods;Pandemics__prevention & control;Pneumonia, Viral__complications;Rhinitis, Allergic__complications;Sublingual Immunotherapy__methods;Th2 Cells__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Allergy | Ludger Klimek;Marek Jutel;Cezmi Akdis;Jean Bousquet;Mübeccel Akdis;Claus Bachert;Ioana Agache;Ignacio Ansotegui;Anna Bedbrook;Sinthia Bosnic-Anticevich;Giorgio W Canonica;Tomas Chivato;Alvaro A Cruz;Wienia Czarlewski;Stefano Del Giacco;Hui Du;Joao A Fonseca;Yadong Gao;Tari Haahtela;Karin Hoffmann-Sommergruber;Juan-Carlos Ivancevich;Nikolai Khaltaev;Edward F Knol;Piotr Kuna;Desiree Larenas-Linnemann;Erik Melen;Joaquim Mullol;Robert Naclerio;Ken Ohta;Yoshitaka Okamoto;Liam O'Mahony;Gabrielle L Onorato;Nikos G Papadopoulos;Ruby Pawankar;Oliver Pfaar;Boleslaw Samolinski;Jurgen Schwarze;Sanna Toppila-Salmi;Mohamed H Shamji;Maria Teresa Ventura;Arunas Valiulis;Arzu Yorgancioglu;Paolo Matricardi;Torsten Zuberbier | allergy treatment;immunotherapy clinical;immunotherapy vaccines and mechanisms | 2020-04-25 02:00:00+02:00 | 32329930 | LT;PT;JP;BR;AR;NL;MX;BE;FR;CN;CH;RO;US;GB;PL;IT;AT;DE;SE;IE;FI;AU;TR;ES | Center for Rhinology and Allergology, Wiesbaden, Germany.;Department of Clinical Immunology, Wrocław Medical University, ALL-MED Medical Research Institute, Wrocław, Poland.;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.;Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany.;University Hospital Montpellier, Montpellier, France.;MACVIA-France, Montpellier, France.;Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium.;Transylvania University Brasov, Brasov, Romania.;Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain.;Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia.;Personalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Center IRCCS, Rozzano, MI, Italy.;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.;School of Medicine, University CEU San Pablo, Madrid, Spain.;ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil.;WHO GARD Planning Group, Bahia, Brazil.;Medical Consulting Czarlewski, Levallois, and MASK-air, Montpellier, France.;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital "Duilio Casula", University of Cagliari, Cagliari, Italy.;Department of Respiratory Medicine, Wuhan Children's Hospital, Tongji Medical College, Huazhong, China.;University of Science and Technology, Wuhan, China.;Center for Research in Health Technologies and Information Systems- CINTESIS, Universidade do Porto, Porto, Portugal.;Allergy Unit, Instituto CUF Porto e Hospital CUF Porto, Porto, Portugal.;Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.;Faculdade de Medicina da Universidade do Porto, Porto, Portugal.;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.;GARD Chairman, Geneva, Switzerland.;Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.;Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.;Institute of Environmental Medicine, Karolinska Institutet and Sachs' Children's Hospital, Stockholm, Sweden.;Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain.;Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.;Johns Hopkins School of Medicine, Baltimore, MD, USA.;National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.;Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.;Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital,, University of Manchester, Manchester, UK.;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Marburg, Germany.;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany.;Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.;Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.;Vilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, Lithuania.;European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.;Department of Pulmonology, Celal Bayar University, Manisa, Turkey.;Charité - Universitätsmedizin Berlin, Berlin, Germany.;Department of Dermatology and Allergy, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Berlin, Germany.;Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.;Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China. | 304 | |||
| 10.1016/j.jormas.2020.03.011 | Practice Guideline | en | Practitioners specialized in oral health and coronavirus disease 2019: Professional guidelines from the French society of stomatology, maxillofacial surgery and oral surgery, to form a common front against the infectious risk. | https://www.ncbi.nlm.nih.gov/pubmed/32307085 | Medical as well as non-medical practitioners specialized in oral health are at high risk of infection with the Coronavirus-19 (Covid-19) because of the proximity with potentially infected biological fluids. This risk is permanent, especially during examination, care and transfer of patients. Regarding the pandemic progression of Covid-19, efficient protocols of prevention are urgently needed. Based on our experience and on the recently reported guidelines from the French National Agency for Public Health (ARS, March 5, 2020), the French Society of Hospital Hygiene (SFHH, March 4, 2020) and the Department of Infectious Risk Prevention of the Hospitals of Paris-Public Assistance (APHP, March 6, 2020), we provide several recommendations for practitioners specialized in oral health, to protect themselves from nosocomial infections, especially Covid-19. | 2468-7855 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Disease Outbreaks;Humans;Oral Health;Oral Medicine;Oral Surgical Procedures;Pandemics;Pneumonia, Viral;Surgery, Oral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Stomatology, Oral and Maxillofacial Surgery | Coronavirus;Covid-19;Guidelines;Oral;Recommendations;SARS-Cov-2 | 2020-04-21 02:00:00+02:00 | 32307085 | FR | Department of Maxillofacial Surgery and Stomatology, Roger Salengro Hospital, Lille University Hospital, Lille, France. | 305 | |||
| Letter;Comment | en | SARS-CoV2 infection and primary school closure. | https://www.ncbi.nlm.nih.gov/pubmed/32317053 | 2020-04-26 02:00:00+02:00 | pubmed | Child;Coronavirus Infections;Humans;Pneumonia, Viral;Schools;Severe Acute Respiratory Syndrome | Philippe Vanhems | SARS-CoV-2 School closure Transmission Children Control Social contacts | 2020-04-23 02:00:00+02:00 | 32317053 | FR | Hospices Civils de Lyon, Lyon 1 University and International Center for Research in Infectiology (CIRI), Lyon, France. | 312 | ||||||
| Letter | en | Mediastinal lymphadenopathy in patients with severe COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32330440 | 2020-04-26 02:00:00+02:00 | pubmed | Xavier Valette;Damien du Cheyron;Suzanne Goursaud | 2020-04-21 02:00:00+02:00 | 32330440 | FR | Department of Medical Intensive Care, CHU de Caen Normandie, 14000 Caen, France. Electronic address: valette-x@chu-caen.fr.;Department of Medical Intensive Care, CHU de Caen Normandie, 14000 Caen, France. | 334 | ||||||||
| 10.1016/j.ando.2020.04.005 | Journal Article;Review | en | Renin-angiotensin-aldosterone system and COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32370986 | With the multiplication of COVID-19 severe acute respiratory syndrome cases due to SARS-COV2, some concerns about angiotensin-converting enzyme 1 (ACE1) inhibitors (ACEi) and angiotensin II type 1 receptor blockers (ARB) have emerged. Since the ACE2 (angiotensin-converting enzyme 2) enzyme is the receptor that allows SARS COV2 entry into cells, the fear was that pre-existing treatment with ACEi or ARB might increase the risk of developing severe or fatal severe acute respiratory syndrome in case of COVID-19 infection. The present article discusses these concerns. ACE2 is a membrane-bound enzyme (carboxypeptidase) that contributes to the inactivation of angiotensin II and therefore physiologically counters angiotensin II effects. ACEis do not inhibit ACE2. Although ARBs have been shown to up-regulate ACE2 tissue expression in experimental animals, evidence was not always consistent in human studies. Moreover, to date there is no evidence that ACEi or ARB administration facilitates SARS-COV2 cell entry by increasing ACE2 tissue expression in either animal or human studies. Finally, some studies support the hypothesis that elevated ACE2 membrane expression and tissue activity by administration of ARB and/or infusion of soluble ACE2 could confer protective properties against inflammatory tissue damage in COVID-19 infection. In summary, based on the currently available evidence and as advocated by many medical societies, ACEi or ARB should not be discontinued because of concerns with COVID-19 infection, except when the hemodynamic situation is precarious and case-by-case adjustment is required. | 0003-4266 | 2020-04-26 02:00:00+02:00 | pubmed | Aldosterone__metabolism;Angiotensin II Type 1 Receptor Blockers__therapeutic use;Angiotensin-Converting Enzyme Inhibitors__therapeutic use;Betacoronavirus__metabolism;Blood Pressure__physiology;Comorbidity;Coronavirus Infections__epidemiology;Humans;Hypertension__drug therapy;Pandemics;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Renin-Angiotensin System__physiology;Severity of Illness Index;Withholding Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2 | Annales d'Endocrinologie | Joachim Alexandre;Jean-Luc Cracowski;Vincent Richard;Béatrice Bouhanick | Arterial hypertension;COVID-19;Hypertension artérielle;Renin-angiotensin-aldosterone system;Système rénine-angiotensine-aldostérone | 2020-04-21 02:00:00+02:00 | 32370986 | FR | Service de pharmacologie, université de Caen-Normandie, UNICAEN, CHU de Caen-Normandie, EA 4650, 14000 Caen, France. Electronic address: alexandre-j@chu-caen.fr.;Université de Grenoble-Alpes, centre régional de pharmacovigilance de Grenoble, INSERM, HP2, 38000 Grenoble, France.;Service de pharmacologie, université de Rouen-Normandie, UNIROUEN, CHU de Rouen-Normandie, UMR Inserm U1096 EnVI, 76000 Rouen, France.;Service d'hypertension artérielle et thérapeutique PCVM, CHU de Rangueil, UMR 1027 université Toulouse 3, 1, avenue J.-Poulhes 31059 Toulouse cedex 9, France. | 335 | ||
| 10.1016/j.purol.2020.04.007 | Journal Article;Review | fr | [French Association of Urology. COVID-19: Recommendations for functional urology]. | https://www.ncbi.nlm.nih.gov/pubmed/32418734 | The management of urology patient is currently disrupted by the COVID-19 epidemic. In the field of functional urology, there are clinical situations with a high risk of complication if management is delayed and a great heterogeneity of advisable reprogramming times after cancellation. A prioritization of functional urology procedures is necessary to adapt management during the COVID-19 crisis and to better organize post-epidemic recovery. | 1166-7087 | 2020-04-26 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Female;France__epidemiology;Humans;Male;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Urologic Diseases__therapy;Urologic Surgical Procedures__methods;Urology__organization & administration;COVID-19 | Progrès en Urologie | F Michel;S Gaillet;J N Cornu;G Robert;X Game;V Phé;G Karsenty | Benign prostatic hyperplasia;COVID-19;Functional urology;Hyperactivité vésicale;Hyperplasie bénigne de la prostate;Incontinence urinaire;Male LUTS;Neurogenic bladder;Overactive bladder;Pelvic organ prolapse;Prolapsus des organes pelviens;Urinary incontinence;Urologie fonctionnelle;Vessie neurologique | 2020-04-20 02:00:00+02:00 | 32418734 | FR | Service d'urologie et transplantation rénale, hôpital de la Conception, Aix-Marseille université, AP-HM, 147, boulevard Baille, 13005 Marseille, France.;Service d'urologie, CHU de Rouen Charles-Nicolle, Rouen, France.;Service d'urologie, andrologie et transplantation rénale, hôpital Pellegrin Tripode, université de Bordeaux, CHU de Bordeaux, Bordeaux, France.;Département d'urologie, transplantation rénale et andrologie, université Paul Sabatier, CHU Rangueil, Toulouse, France.;Service d'urologie, hôpital universitaire La Pitié-Salpêtrière, Sorbonne université, AP-HP, Paris, France.;Service d'urologie et transplantation rénale, hôpital de la Conception, Aix-Marseille université, AP-HM, 147, boulevard Baille, 13005 Marseille, France. Electronic address: Gilles.karsenty@ap-hm.fr. | 337 | ||
| Letter | en | Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32312768 | 2020-04-26 02:00:00+02:00 | pubmed | Philippe Guilpain;Clément Le Bihan;Vincent Foulongne;Patrice Taourel;Nathalie Pansu;Alexandre Thibault Jacques Maria;Boris Jung;Romaric Larcher;Kada Klouche;Vincent Le Moing | communicable diseases, imported;granulomatosis with polyangiitis;hydroxychloroquine;rituximab;systemic vasculitis | 2020-04-20 02:00:00+02:00 | 32312768 | FR | Internal Medicine: Multi-Organic Diseases, Local Referral Center for systemic autoimmune diseases, Saint Eloi Hospital, Univ Montpellier, Medical School, Montpellier University Hospital, Montpellier cedex 5, France a-maria@chu-montpellier.fr.fr p-guilpain@chu-montpellier.fr.;Univ Montpellier, IRMB, Univ Montpellier, INSERM, Montpellier, France.;Tropical and Infectious Diseases, Saint Eloi Hospital, Univ Montpellier, Medical School, Montpellier University Hospital, Montpellier cedex 5, France.;Pathogenesis and Control of Chronic Infections, Inserm, Universite Montpellier 1 Faculte de Medecine Montpellier-Nimes, Montpellier, Languedoc-Roussillon, France.;Osteoarticular Medical Imaging Section, Department of Medical Imaging, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France.;Department of Intensive Care Medicine, Lapeyronie Hospital, Univ Montpellier, Medical School, Montpellier University Hospital, Montpellier, France.;Inserm, CNRS, PhyMedExp, Univ Montpellier, Montpellier, France. | 338 | |||||||
| 10.1016/j.neurol.2020.04.004 | Practice Guideline | en | Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. | https://www.ncbi.nlm.nih.gov/pubmed/32354651 | In France, the epidemic phase of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in February 2020 and resulted in the implementation of emergency measures and a degradation in the organization of neuromuscular reference centers. In this special context, the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS) has established guidance in an attempt to homogenize the management of neuromuscular (NM) patients within the French territory. Hospitalization should be reserved for emergencies, the conduct of treatments that cannot be postponed, check-ups for which the diagnostic delay may result in a loss of survival chance, and cardiorespiratory assessments for which the delay could be detrimental to the patient. A national strategy was adopted during a period of 1 to 2months concerning treatments usually administered in hospitalization. NM patients treated with steroid/immunosuppressants for a dysimmune pathology should continue all of their treatments in the absence of any manifestations suggestive of COVID-19. A frequently asked questions (FAQ) sheet has been compiled and updated on the FILNEMUS website. Various support systems for self-rehabilitation and guided exercises have been also provided on the website. In the context of NM diseases, particular attention must be paid to two experimental COVID-19 treatments, hydroxycholoroquine and azithromycin: risk of exacerbation of myasthenia gravis and QT prolongation in patients with pre-existing cardiac involvement. The unfavorable emergency context related to COVID-19 may specially affect the potential for intensive care admission (ICU) for people with NMD. In order to preserve the fairest medical decision, a multidisciplinary working group has listed the neuromuscular diseases with a good prognosis, usually eligible for resuscitation admission in ICU and, for other NM conditions, the positive criteria suggesting a good prognosis. Adaptation of the use of noninvasive ventilation (NIV) make it possible to limit nebulization and continue using NIV in ventilator-dependent patients. | 0035-3787 | 2020-04-26 02:00:00+02:00 | pubmed | Angiotensin Receptor Antagonists__therapeutic use;Angiotensin-Converting Enzyme Inhibitors__therapeutic use;Anti-Bacterial Agents__therapeutic use;Antimalarials__therapeutic use;Azithromycin__therapeutic use;Betacoronavirus;Cardiorespiratory Fitness;Coronavirus Infections__drug therapy;Emergency Treatment;France__epidemiology;Glycogen Storage Disease Type II__therapy;Hospitalization;Humans;Hydroxychloroquine__therapeutic use;Immune System Diseases__therapy;Immunoglobulins, Intravenous__therapeutic use;Immunosuppressive Agents__therapeutic use;Muscular Atrophy, Spinal__drug therapy;Neuromuscular Diseases__therapy;Oligonucleotides__therapeutic use;Pandemics;Physical Therapy Modalities;Pneumonia, Viral__drug therapy;Prognosis;RNA, Small Interfering__therapeutic use;Steroids__therapeutic use;Withholding Treatment;alpha-Glucosidases__therapeutic use;COVID-19;severe acute respiratory syndrome coronavirus 2 | Revue Neurologique | G Solé;E Salort-Campana;Y Pereon;T Stojkovic;K Wahbi;P Cintas;D Adams;P Laforet;V Tiffreau;I Desguerre;L I Pisella;A Molon;S Attarian | COVID-19;Guidelines;Management;Neuromuscular;Treatment | 2020-04-20 02:00:00+02:00 | 32354651 | FR | Reference Center for Neuromuscular Disorders AOC, Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Pellegrin University Hospital), place Amélie-Raba-Léon, 33076 Bordeaux, France.;Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France, Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille, France.;CHU Nantes, Reference Center for Neuromuscular Disorders AOC, Hôtel-Dieu, Nantes, France.;Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris, France.;AP-HP, Cochin Hospital, Cardiology Department, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Île-de-France, Paris-Descartes, Sorbonne Paris Cité University, 75006 Paris, France, INSERM Unit 970, Paris Cardiovascular Research Centre (PARCC), Paris, France.;Reference Center of Neuromuscular Disorders AOC, Toulouse, University Hospitals, 31000 Toulouse, France.;Department of Neurology, CHU Bicetre, Hôpitaux Universitaires Paris Sud, Paris, France.;Nord/Est/Île-de-France Neuromuscular Reference Center, Neurology Department, Raymond-Poincaré Teaching Hospital, AP-HP, Garches, France, INSERM U1179, END-ICAP, Versailles-Saint-Quentin-en-Yvelines University, Université Paris Saclay, Montigny-le-Bretonneux, France.;Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Hôpital Pierre-Swynghedauw, CHU de Lille, EA 7369 URePSSS, 59000 Lille, France.;Reference Center of Neuromuscular Disorders Nord/Est/Île-de-France, Pediatric Neurology Department, Necker-Enfants-Malades Hospital, AP-HP, Paris, France.;Filnemus, AP-HM, Marseille, France.;Reference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 13385 Marseille, France, Medical Genetics, Aix-Marseille Université, Inserm UMR_1251, 13005 Marseille, France. Electronic address: Shahram.ATTARIAN@ap-hm.fr. | 339 | ||
| Letter | en | Treating neovascular age-related macular degeneration in the era of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32318805 | 2020-04-26 02:00:00+02:00 | pubmed | Aged;Angiogenesis Inhibitors__administration & dosage;Betacoronavirus;Comorbidity;Coronavirus Infections__epidemiology;Disease Management;Disease Transmission, Infectious__prevention & control;Humans;Intravitreal Injections;Pandemics;Pneumonia, Viral__epidemiology;Wet Macular Degeneration__drug therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Fares Antaki;Ali Dirani | 2020-04-21 02:00:00+02:00 | 32318805 | FR;CA | Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.;Department of Ophthalmology, Centre Universitaire d'Ophtalmologie, Hôpital du Saint-Sacrement, CHU de Québec - Université Laval, Québec, Canada. drdirani@gmail.com. | 345 | |||||||
| 10.5152/ejbh.2020.200420 | Editorial | en | Breast Cancer Management during the COVID 19 Pandemic: French Guidelines. | https://www.ncbi.nlm.nih.gov/pubmed/32656513 | 2587-0831 | 2020-04-26 02:00:00+02:00 | pubmed | European Journal of Breast Health | Emile Daraï;Carole Mathelin;Joseph Gligorov | 2020-04-21 02:00:00+02:00 | 32656513 | FR | Department of Gynaecology, Obstetrics and Human Reproductive Medicine, TENON Hospital, Paris, France.;Department of Surgery, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.;Executive Director of Institut Universitaire de Cancérologie AP-HP, Sorbonne Université, Paris, France. | 349 | |||||
| 10.1016/j.jclinepi.2020.04.016 | Journal Article;Review | en | COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. | https://www.ncbi.nlm.nih.gov/pubmed/32330521 | Prior epidemics of high-mortality human coronaviruses, such as the acute respiratory syndrome coronavirus (SARS-CoV or SARS-1) in 2003, have driven the characterization of compounds that could be possibly active against the currently emerging novel coronavirus SARS-CoV-2 (COVID-19). Presently, no approved treatment or prophylaxis is available for COVID-19. We comment on the existing COVID-19 research methodologies in general and the published reporting. Given the media attention and claims of effectiveness, we chose chloroquine and hydroxychloroquine, in combination with azithromycin, as an area of COVID-19 research to examine. | 0895-4356 | 2020-04-26 02:00:00+02:00 | pubmed | Biomedical Research__methods;Chloroquine__therapeutic use;Coronavirus Infections__drug therapy;Humans;Hydroxychloroquine__therapeutic use;Observational Studies as Topic;Pandemics;Pneumonia, Viral__drug therapy;Randomized Controlled Trials as Topic;Research Design__standards;COVID-19 | Journal of Clinical Epidemiology | Paul Elias Alexander;Victoria Borg Debono;Manoj J Mammen;Alfonso Iorio;Komal Aryal;Dianna Deng;Eva Brocard;Waleed Alhazzani | Bias;COVID-19;Chloroquine;Clinical trial;Coronavirus;Hydroxychloroquine | 2020-04-21 02:00:00+02:00 | 32330521 | FR;CA;GB;US | Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, GUIDE Research Methods Group, McMaster University, Hamilton, Ontario, Canada. Electronic address: alexap@mcmaster.ca.;Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, Department of Anesthesia, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.;Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.;Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.;Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.;Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.;Graduate Student (International Intern), France.;Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada, GUIDE Research Methods Group, McMaster University, Hamilton, Ontario, Canada, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada. | 350 | ||
| 10.1016/j.jviscsurg.2020.04.014 | Journal Article;Review | en | Antibiotics alone as an alternative to appendectomy for uncomplicated acute appendicitis in adults: Changes in treatment modalities related to the COVID-19 health crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32362368 | The massive inflow of patients with COVID-19 requiring urgent care has overloaded hospitals in France and impacts the management of other patients. Deferring hospitalization and non-urgent surgeries has become a priority for surgeons today in order to relieve the health care system. It is obviously not simple to reduce emergency surgery without altering the quality of care or leading to a loss of chance for the patient. Acute appendicitis is a very specific situation and the prevalence of this disease leads us to reconsider this particular disease in the context of the COVID-19 crisis. Indeed, while the currently recommended treatment for uncomplicated acute appendicitis is surgical appendectomy, the non-surgical alternative of medical management by antibiotic therapy alone has been widely evaluated by high-quality studies in the literature. Insofar as the main limitation of exclusively medical treatment of uncomplicated acute appendicitis is the risk of recurrent appendicitis, this treatment option represents an alternative of choice to reduce the intra-hospital overload in this context of health crisis. The aim of this work is therefore to provide physicians and surgeons with a practical guide based on a review of the literature on the medical treatment of uncomplicated acute appendicitis in adults, to offer this alternative treatment to the right patients and under good conditions, especially when access to the operating room is limited or impossible. | 1878-7886 | 2020-04-26 02:00:00+02:00 | pubmed | Acute Disease;Adult;Algorithms;Ambulatory Care;Anti-Bacterial Agents__therapeutic use;Appendectomy;Appendicitis__drug therapy;Coronavirus Infections;Humans;Pandemics;Patient Selection;Pneumonia, Viral;COVID-19 | Journal of Visceral Surgery | M Collard;Z Lakkis;J Loriau;D Mege;C Sabbagh;J H Lefevre;L Maggiori | Acute appendicitis;Antibiotic therapy;Appendectomy;COVID-19;Coronavirus | 2020-04-24 02:00:00+02:00 | 32362368 | FR | Digestive Surgery Department, Sorbonne University, Saint-Antoine Hospital, AP-HP, 75012 Paris, France.;Department of Digestive Surgical Oncology, Liver Transplantation Unit, University Hospital of Besançon, 2, boulevard Alexander Fleming, 25000, Besançon, France.;Department of Visceral Surgery, Groupe Hospitalier Paris Saint Joseph, 75014, Paris, France.;Department of Digestive Surgery, Assistance Publique Hôpitaux de Marseille, Timone University Hospital, Marseille, France.;Digestive surgery department, CHU Amiens-Picardie, 80000 Amiens, France, Research Unit SSPC (simplification des soins des patients chirurgicaux complexes), université de Picardie Jules Verne, 80025 Amiens, France.;Department of Colorectal surgery, Beaujon Hospital, Paris University, AP-HP, 92110, Clichy, France. Electronic address: leon.maggiori@aphp.fr. | 356 | ||
| Letter | en | The Impact of COVID-19 Outbreak on Uro-oncological Practice Across Europe: Which Burden of Activity Are We Facing Ahead? | https://www.ncbi.nlm.nih.gov/pubmed/32349934 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Delivery of Health Care;Europe;Humans;Medical Oncology__organization & administration;Pandemics;Pneumonia, Viral__complications;Urologic Neoplasms__complications;Urology__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | Marco Oderda;Morgan Roupret;Giancarlo Marra;Axel S Merseburger;Gianluca Oderda;Marco Falcone;Carlo Ceruti;Shahrokh F Shariat;Paolo Gontero | 2020-04-24 02:00:00+02:00 | 32349934 | FR;CH;IT;DE;AT | Division of Urology, Molinette Hospital-Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.;Urology Department, GRC n°5, PREDICTIVE ONCO-URO, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne University, Paris, France.;Urologic Clinic, University Clinic Schleswig-Holstein, Campus Lübeck, Germany.;Credit Suisse AG, Zurich, Switzerland.;Department of Urology, Medical University of Vienna, Vienna, Austria.;Division of Urology, Molinette Hospital-Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy. Electronic address: paolo.gontero@unito.it. | 359 | |||||||
| 10.3389/fmed.2020.00184 | Journal Article | en | SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment. | https://www.ncbi.nlm.nih.gov/pubmed/32391371 | 2296-858X | 2020-04-26 02:00:00+02:00 | pubmed | Frontiers in Medicine | Mathieu E Rebeaud;Florian Zores | 2019-nCoV;COVID-19;SARS-CoV-2;antiviral;chloroquine | 2020-04-24 02:00:00+02:00 | 32391371 | FR;CH | DBMV, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.;Groupe médical spécialisé, Strasbourg, France. | 364 | ||||
| Letter | en | COVID-19 outbreak situation and its psychological impact among surgeons in training in France. | https://www.ncbi.nlm.nih.gov/pubmed/32333109 | 2020-04-26 02:00:00+02:00 | pubmed | Maher Abdessater;Morgan Rouprêt;Vincent Misrai;Ugo Pinar;Xavier Matillon;Bastien Gondran-Tellier;Lucas Freton;Maxime Vallée;Inès Dominique;Margaux Felber;Zine-Eddine Khene;Edouard Fortier;François Lannes;Clément Michiels;Tristan Grevez;Nicolas Szabla;Florian Bardet;Kevin Kaulanjan;Emilien Seizilles de Mazancourt;Guillaume Ploussard;Benjamin Pradere | 2020-04-24 02:00:00+02:00 | 32333109 | FR;AT;GP | Sorbonne Université, GRC n°5, Predictive Onco-Urology, Ap-Hp, Hôpital Pitié-Salpêtrière, Urology, 75013, Paris, France.;Sorbonne Université, GRC n°5, Predictive Onco-Urology, Ap-Hp, Hôpital Pitié-Salpêtrière, Urology, 75013, Paris, France. morgan.roupret@aphp.fr.;Clinique Pasteur, 31300, Toulouse, France.;Department of Urology and Transplantation, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.;Department of Urology, La Conception University Hospital, Assistance-Publique Marseille, Marseille, France.;Department of Urology, University Hospital of Rennes, Rennes, France.;Department of Urology, Poitiers University Hospital, Poitiers, France.;Department of Urology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Department of Urology, Montpellier University Hospital, Montpellier, France.;Department of Urology, Bordeaux University Hospital, Bordeaux, France.;Department of Urology, CHRU Tours, Francois Rabelais University, Tours, France.;Department of Urology and Transplantation, Caen University Hospital, Caen, France.;Department of Urology, Dijon University Hospital, Dijon, France.;Department of Urology, CHU Pointe à Pitre, Guadeloupe, France.;Department of Urology, Ramsay Santé, Clinique la Croix du Sud, Quint Fonsegrives, France.;Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. | 366 | ||||||||
| 10.1016/s2213-8587(20)30152-2 | Journal Article;Review | en | Practical recommendations for the management of diabetes in patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32334646 | Diabetes is one of the most important comorbidities linked to the severity of all three known human pathogenic coronavirus infections, including severe acute respiratory syndrome coronavirus 2. Patients with diabetes have an increased risk of severe complications including Adult Respiratory Distress Syndrome and multi-organ failure. Depending on the global region, 20-50% of patients in the coronavirus disease 2019 (COVID-19) pandemic had diabetes. Given the importance of the link between COVID-19 and diabetes, we have formed an international panel of experts in the field of diabetes and endocrinology to provide some guidance and practical recommendations for the management of diabetes during the pandemic. We aim to briefly provide insight into potential mechanistic links between the novel coronavirus infection and diabetes, present practical management recommendations, and elaborate on the differential needs of several patient groups. | 2213-8587 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Comorbidity;Contraindications, Drug;Coronavirus Infections__physiopathology;Diabetes Mellitus, Type 1__drug therapy;Diabetes Mellitus, Type 2__drug therapy;Humans;Hypoglycemic Agents__administration & dosage;Multiple Organ Failure__chemically induced;Pandemics;Pneumonia, Viral__physiopathology;Practice Guidelines as Topic;Respiratory Distress Syndrome, Adult__chemically induced;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Diabetes & Endocrinology | Stefan R Bornstein;Francesco Rubino;Kamlesh Khunti;Geltrude Mingrone;David Hopkins;Andreas L Birkenfeld;Bernhard Boehm;Stephanie Amiel;Richard Ig Holt;Jay S Skyler;J Hans DeVries;Eric Renard;Robert H Eckel;Paul Zimmet;Kurt George Alberti;Josep Vidal;Bruno Geloneze;Juliana C Chan;Linong Ji;Barbara Ludwig | 2020-04-23 02:00:00+02:00 | 32334646 | FR;SG;CN;CH;GB;US;HK;BR;IT;AU;NL;ES;DE | Department of Medicine III, University Hospital Carl Gustav Carus, Dresden, Germany, Paul Langerhans Institute Dresden of the Helmholtz Center Munich, University Hospital Carl Gustav Carus, Dresden, Germany, Department of Diabetes, School of Life Course Science and Medicine, King's College London, London, UK, Department of Endocrinology and Diabetology, University Hospital Zurich, Zurich, Switzerland, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany, German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany. Electronic address: Stefan.Bornstein@uniklinikum-dresden.de.;Department of Diabetes, School of Life Course Science and Medicine, King's College London, London, UK, Bariatric and Metabolic Surgery, King's College Hospital, London, UK.;Diabetes Research Centre, University of Leicester, Leicester, UK.;Department of Diabetes, School of Life Course Science and Medicine, King's College London, London, UK, Fondazione Policlinico Universitario Agostino Gemelli Istituto Di Ricovero e Cura a Carattere Scientifico, Rome, Italy, Department of Internal Medicine, Università Cattolica del Sacro Cuore, Rome, Italy.;Department of Diabetes, School of Life Course Science and Medicine, King's College London, London, UK, Institute of Diabetes Endocrinology and Obesity, King's Health Partners, London, UK.;Department of Diabetes, School of Life Course Science and Medicine, King's College London, London, UK, German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany, Department of Diabetology, Endocrinology and Nephrology, University Hospital Tübingen, Tübingen, Germany, Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich at the University of Tübingen, Tübingen, Germany.;Department of Endocrinology, Tan Tock Seng Hospital, Singapore, Singapore, Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore.;Department of Diabetes, School of Life Course Science and Medicine, King's College London, London, UK.;Human Development and Health, Faculty of Medicine, University of Southampton, UK.;Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA.;Department of Endocrinology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands, Profil Institute for Metabolic Research, Neuss, Germany.;Montpellier University Hospital and Institute of Functional Genomics, Centre national de la recherche scientifique, INSERM, University of Montpellier, Montpellier, France.;Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.;Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.;Division of Diabetes, Endocrinology and Metabolism, Imperial College, London, UK.;Centro de Investigación Biomédica en Red en Diabetes y Enfermedades Metabólicas Asociadas, Barcelona, Spain.;Obesity and Comorbities Research Center, Laboratory of Investigation in Metabolism and Diabetes/Gastrocentro, Universidade de Campinas, Campinas, São Paulo, Brazil.;Department of Medicine and Therapeutics, Hong Kong Institute of Diabetes and Obesity and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Special Administrative Region, China.;Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Center, Beijing, China.;Department of Medicine III, University Hospital Carl Gustav Carus, Dresden, Germany, Paul Langerhans Institute Dresden of the Helmholtz Center Munich, University Hospital Carl Gustav Carus, Dresden, Germany, Department of Endocrinology and Diabetology, University Hospital Zurich, Zurich, Switzerland, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany, Deutsche Forschungsgemeinschaft-Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany, German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany. | 380 | |||
| NHLBI NIH HHS;NHLBI NIH HHS;Rosetrees Trust;British Heart Foundation;NHLBI NIH HHS;Newton Fund | 10.1038/s41591-020-0868-6 | Journal Article | en | SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. | https://www.ncbi.nlm.nih.gov/pubmed/32327758 | We investigated SARS-CoV-2 potential tropism by surveying expression of viral entry-associated genes in single-cell RNA-sequencing data from multiple tissues from healthy human donors. We co-detected these transcripts in specific respiratory, corneal and intestinal epithelial cells, potentially explaining the high efficiency of SARS-CoV-2 transmission. These genes are co-expressed in nasal epithelial cells with genes involved in innate immunity, highlighting the cells' potential role in initial viral infection, spread and clearance. The study offers a useful resource for further lines of inquiry with valuable clinical samples from COVID-19 patients and we provide our data in a comprehensive, open and user-friendly fashion at www.covid19cellatlas.org. | 1078-8956,1546-170X | 2020-04-26 02:00:00+02:00 | pubmed | Nature Medicine | Waradon Sungnak;Ni Huang;Christophe Bécavin;Marijn Berg;Rachel Queen;Monika Litvinukova;Carlos Talavera-López;Henrike Maatz;Daniel Reichart;Fotios Sampaziotis;Kaylee B Worlock;Masahiro Yoshida;Josephine L Barnes | 2020-04-23 02:00:00+02:00 | 32327758 | FR;GB;US;NL;DE | [{"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "K08 HL130595"}, {"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "R01 HL145372"}, {"country": "International", "agency": "Rosetrees Trust", "grantid": "M899"}, {"country": "United Kingdom", "agency": "British Heart Foundation", "grantid": "PG/16/47/32156"}, {"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "R01 HL146557"}, {"country": "International", "agency": "Newton Fund", "grantid": "G2987"}] | Wellcome Sanger Institute, Cambridge, UK. ws4@sanger.ac.uk.;Wellcome Sanger Institute, Cambridge, UK.;Université Côte d'Azur, CNRS, IPMC, Sophia-Antipolis, France.;Department of Pathology and Medical Biology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.;Groningen Research Institute for Asthma and COPD, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.;Bioinformatics Core Facility, Newcastle University Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK.;Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.;Department of Genetics, Harvard Medical School, Boston, MA, USA.;Wellcome and MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.;Department of Medicine, Addenbrookes Hospital, Cambridge, UK.;Cambridge Liver Unit, Cambridge University Hospitals, Cambridge, UK.;UCL Respiratory, Division of Medicine, University College London, London, UK. | 382 | ||
| Letter | en | Early experience in Paris with the impact of the COVID-19 pandemic on vascular surgery. | https://www.ncbi.nlm.nih.gov/pubmed/32335307 | 2020-04-26 02:00:00+02:00 | pubmed | Arteries__surgery;Betacoronavirus__pathogenicity;Blood Coagulation__physiology;Coronavirus Infections__complications;Emergencies;Hospital Restructuring__standards;Humans;Infection Control__standards;Intensive Care Units__organization & administration;Myocardial Infarction__therapy;Operating Rooms__organization & administration;Pandemics;Paris__epidemiology;Pneumonia, Viral__complications;Referral and Consultation__statistics & numerical data;Resuscitation__instrumentation;Stroke__therapy;Telemedicine__organization & administration;Thrombosis__etiology;Vascular Surgical Procedures__standards;Ventilators, Mechanical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Iannis Ben Abdallah | 2020-04-23 02:00:00+02:00 | 32335307 | FR | Paris Association of Vascular Surgeons, Assistance Publique-Hôpitaux de Paris, Paris, France. | 385 | |||||||
| 10.1016/j.ijantimicag.2020.106006 | Journal Article | en | SARS-CoV-2 was already spreading in France in late December 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32371096 | The COVID-19 epidemic is believed to have started in late January 2020 in France. Here we report a case of a patient hospitalised in December 2019 in an intensive care unit in a hospital in the north of Paris for haemoptysis with no aetiological diagnosis. RT-PCR was performed retrospectively on the stored respiratory sample and confirmed the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Based on this result, it appears that the COVID-19 epidemic started much earlier in France. | 0924-8579 | 2020-05-03 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Female;France__epidemiology;Humans;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Retrospective Studies;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | A Deslandes;V Berti;Y Tandjaoui-Lambotte;Chakib Alloui;E Carbonnelle;J R Zahar;S Brichler;Yves Cohen | COVID-19;Coronavirus disease 2019;France;Intensive care unit;SARS-CoV-2 | 2020-05-03 02:00:00+02:00 | 32371096 | FR | Université Paris 13, Sorbonne Paris Cité, France, and Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du Risque Infectieux, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, France.;Réanimation polyvalente, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, France, INSERM U1272 Hypoxie et Poumon, Bobigny, France.;Université Paris 13, Sorbonne Paris Cité, France, and Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du Risque Infectieux, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, France, IAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France.;Université Paris 13, Sorbonne Paris Cité, France, and Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du Risque Infectieux, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, France, IAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France. Electronic address: jrzahar@gmail.com.;Réanimation polyvalente, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, France, INSERM, U942, F-75010, Paris, France. | 397 | ||
| 10.1007/s00167-020-06033-1 | Journal Article;Multicenter Study | en | Disruption of joint arthroplasty services in Europe during the COVID-19 pandemic: an online survey within the European Hip Society (EHS) and the European Knee Associates (EKA). | https://www.ncbi.nlm.nih.gov/pubmed/32361927 | The aim of the present study was to evaluate the impact of the coronavirus (COVID-19) pandemic on joint arthroplasty service in Europe by conducting an online survey of arthroplasty surgeons. | 0942-2056,1433-7347 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Delivery of Health Care__statistics & numerical data;Elective Surgical Procedures__statistics & numerical data;Europe__epidemiology;Health Care Surveys;Humans;Internet;Male;Orthopedic Procedures__statistics & numerical data;Pandemics;Pneumonia, Viral__epidemiology;Prospective Studies;COVID-19;severe acute respiratory syndrome coronavirus 2 | Knee Surgery, Sports Traumatology, Arthroscopy | M Thaler;Ismail Khosravi;M T Hirschmann;N P Kort;L Zagra;J A Epinette;M C Liebensteiner | COVID-19;Coronavirus disease 2019;Disruption;Health care;Orthopaedic surgery;Pandemic;SARS-CoV-2;Severe acute respiratory syndrome coronavirus 2;Total joint arthroplasty | 2020-05-02 02:00:00+02:00 | 32361927 | FR;CH;IT;NL;AT | Department of Orthopaedic Surgery, Medical University of Innsbruck, Innrain 52, 6020, Innsbruck, Austria.;Department of Orthopaedic Surgery, Medical University of Innsbruck, Innrain 52, 6020, Innsbruck, Austria. ismail.khosravi@tirol-kliniken.at.;Department of Orthopaedic Surgery and Traumatology, Kantonsspital Baselland, (Bruderholz, Liestal, Laufen), 4101, Bruderholz, Switzerland.;University of Basel, Basel, Switzerland.;CortoClinics, Schijndel, The Netherlands.;Hip Department, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.;Center of Research and Documentation of Arthroplasty, Houdain, France. | 399 | ||
| 10.1097/dcr.0000000000001718 | Journal Article | en | International Organization for the Study of IBD Recommendations for Surgery in Patients With IBD During the Coronavirus Disease 2019 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32355056 | 0012-3706 | 2020-05-03 02:00:00+02:00 | pubmed | Abscess__surgery;Asymptomatic Infections;Betacoronavirus;Clinical Laboratory Techniques;Colitis, Ulcerative__surgery;Colorectal Surgery;Coronavirus Infections__diagnosis;Crohn Disease__surgery;Digestive System Surgical Procedures__methods;Disease Management;Emergencies;False Negative Reactions;Humans;Infection Control;Intestinal Obstruction__surgery;Intestinal Perforation__surgery;Operating Rooms;Pandemics;Patient Care Team;Pneumonia, Viral__diagnosis;Polymerase Chain Reaction;Practice Guidelines as Topic;Preoperative Care;Sensitivity and Specificity;Time Factors;Ventilation;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Diseases of the Colon & Rectum | Feza H Remzi;Yves Panis;Antonino Spinelli;Paulo G Kotze;Gerassimos Mantzaris;Johan D Söderholm;André d'Hoore;Willem A Bemelman;Takayuki Yamamoto;John H Pemberton;Emmanuel Tiret;Tom Øresland;Phillip Fleshner | 2020-05-02 02:00:00+02:00 | 32355056 | FR;SE;NO;GR;JP;US;BR;IT;NL;BE | Department of Surgery, New York University Langone Medical Center, New York, New York.;Department of Colorectal Surgery, Beaujon Hospital (APHP) Clichy and University of Paris, France.;Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy.;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.;Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, Brazil.;Department of Gastroenterology, Evangelismos General Hospital, Athens, Greece.;Department of Surgery, Linköping University, Linköping, Sweden.;Department of Surgery, University Hospital Leuven, Leuven, Belgium.;Department of Surgery, University of Amsterdam, Amsterdam, the Netherlands.;Department of Gastroenterology, Yokkaichi Hazu Medical Center, Yokkaichi, Japan.;Division of Colon and Rectal Surgery, Mayo Clinic Rochester, Rochester, Minnesota.;Department of General and Digestive Surgery, Paris VI University, Paris, France.;Department of Digestive Surgery, Akershus University Hospital, Lorenskog, Norway.;Division of Colon and Rectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California. | 404 | ||||
| 10.1093/ehjci/jeaa107 | Case Reports;Journal Article;Review | en | Myocarditis revealing COVID-19 infection in a young patient. | https://www.ncbi.nlm.nih.gov/pubmed/32338706 | 2047-2404,2047-2412 | 2020-05-03 02:00:00+02:00 | pubmed | Adult;Coronavirus Infections__complications;DNA, Viral__analysis;Follow-Up Studies;France;Humans;Magnetic Resonance Imaging, Cine__methods;Male;Myocarditis__complications;Pandemics;Pneumonia, Viral__complications;Polymerase Chain Reaction__methods;Radiography, Thoracic__methods;Risk Assessment;Severity of Illness Index;COVID-19 | European Heart Journal - Cardiovascular Imaging | Jean-François Paul;Pierre Charles;Clémence Richaud;Christophe Caussin;Christelle Diakov | 2020-04-28 02:00:00+02:00 | 32338706 | FR | Institut Mutualiste Montsouris, Paris, France. | 408 | ||||
| 10.1093/neuros/nyaa157 | Journal Article | en | Letter: The Risk of COVID-19 Infection During Neurosurgical Procedures: A Review of Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2) Modes of Transmission and Proposed Neurosurgery-Specific Measures for Mitigation. | https://www.ncbi.nlm.nih.gov/pubmed/32335684 | 0148-396X,1524-4040 | 2020-05-03 02:00:00+02:00 | pubmed | Neurosurgery | Christian Iorio-Morin;Mojgan Hodaie;Can Sarica;Nicolas Dea;Harrison J Westwick;Sean D Christie;Patrick J McDonald;Moujahed Labidi;Jean-Pierre Farmer;Simon Brisebois;Frédérick D'Aragon;Alex Carignan;David Fortin | 2020-04-27 02:00:00+02:00 | 32335684 | FR;CA;GB;US | Division of Neurosurgery Department of Surgery Université de Sherbrooke Centre hospitalier universitaire de Sherbrooke Sherbrooke, Québec, Canada.;Division of Neurosurgery Department of Surgery University of Toronto University Health Network - TWH Toronto, Ontario, Canada.;Division of Neurosurgery Department of Surgery University of British Columbia Blusson Spinal Cord Center Vancouver, British Columbia, Canada.;CIUSSS du Nord de l'Ile de Montréal Hôpital de Sacré-Coeur de Montréal Montréal, Québec, Canada.;Division of Neurosurgery Department of Surgery Dalhousie University Halifax, Nova Scotia, Canada.;Division of Neurosurgery Department of Surgery University of British Columbia BC Children's Hospital Vancouver, British Columbia, Canada.;Division of Neurosurgery Department of Surgery Centre hospitalier de l'Université de Montréal Montréal, Québec, Canada.;Division of Neurosurgery Department of Pediatric Surgery McGill University The Montreal Children's Hospital Montréal, Québec, Canada.;Division of Otolaryngology-Head & Neck Surgery Department of Surgery Université de Sherbrooke Sherbrooke, Québec, Canada.;Department of Anesthesiology Université de Sherbrooke Sherbrooke, Québec, Canada.;Department of Microbiology and Infectious Diseases Université de Sherbrooke Sherbrooke, Québec, Canada. | 412 | |||||
| 10.1016/j.jfo.2020.04.017 | Journal Article;Practice Guideline | fr | [How to approach follow-up of glaucoma patients during COVID-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32386725 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Disease Progression;Disinfection;Emergencies;Glaucoma__diagnosis;Gonioscopy;Humans;Intraocular Pressure;Pandemics;Personal Protective Equipment;Pneumonia, Viral__epidemiology;Tonometry, Ocular__adverse effects;Visual Field Tests;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | J-M Giraud;J-R Fenolland | 2020-05-01 02:00:00+02:00 | 32386725 | FR | Hôpital d'Instruction des Armées Bégin, Centre du Glaucome, 69, avenue de Paris, 94160 Saint-Mandé, France. Electronic address: giraud777@hotmail.fr.;Hôpital d'Instruction des Armées Bégin, Centre du Glaucome, 69, avenue de Paris, 94160 Saint-Mandé, France. | 415 | ||||
| 10.1016/j.resmer.2020.100759 | Editorial | en | Venous thromboembolism and COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32474397 | 2590-0412 | 2020-05-03 02:00:00+02:00 | pubmed | Respiratory Medicine and Research | L Bertoletti;F Couturaud;D Montani;F Parent;O Sanchez | COVID-19;Coronavirus disease;Pulmonary embolism;SARS-CoV-2;Venous thromboembolic disease | 2020-04-28 02:00:00+02:00 | 32474397 | FR | Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalo-Universitaire de Saint-Etienne, INSERM CIC 1408 and UMR 1059, FCRIN-INNOVTE, Université Jean Monnet, Saint-Étienne, France.;Département de Médecine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Université de Bretagne-Occidentale, EA 3878, CIC INSERM 1412, FCRIN-INNOVTE, Brest, France.;Department of Respiratory and Intensive Care Medicine, Université Paris-Saclay, Assistance publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le Plessis-Robinson, France.;Service de Pneumologie et de Soins Intensifs, Hôpital Européen Georges-Pompidou, AP-HP, Université de Paris, INSERM UMR S 1140, FCRIN-INNOVTE, Paris, France. | 419 | ||||
| Letter | en | Preliminary observations of anaesthesia ventilators use for prolonged mechanical ventilation in intensive care unit patients during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32360978 | 2020-05-03 02:00:00+02:00 | pubmed | Aged;Anesthesia, Inhalation__instrumentation;Betacoronavirus;Blood Gas Analysis;Coronavirus Infections__complications;Equipment Design;Equivalence Trials as Topic;Feasibility Studies;Female;Health Services Needs and Demand;Humans;Hypoxia__etiology;Intensive Care Units;Male;Middle Aged;Nurse Anesthetists;Pandemics;Patient Selection;Pneumonia, Viral__complications;Respiration, Artificial__instrumentation;Retrospective Studies;Time-to-Treatment;Ventilators, Mechanical__classification;COVID-19;severe acute respiratory syndrome coronavirus 2 | Aurélie Gouel-Cheron;Camille Couffignal;Yoann Elmaleh;Elie Kantor;Philippe Montravers | Anaesthesia;Mechanical ventilators | 2020-04-29 02:00:00+02:00 | 32360978 | FR;US | Anaesthesiology and Critical Care Medicine Department, DMU PARABOLE, Bichat-Claude-Bernard hospital, HUPNVS, AP-HP, Paris, France, Paris University, Paris, France, Antibody in Therapy and Pathology, Pasteur Institute, UMR 1222 INSERM, Paris, France, Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: aurelie.gouel@aphp.fr.;Clinical Research, Biostatistics and Epidemiology Department, Bichat hospital, AP-HP, Paris University, 75018 Paris, France, INSERM CIC-EC 1425, Bichat hospital, AP-HP, Paris University, 75018 Paris, France.;Anaesthesiology and Critical Care Medicine Department, DMU PARABOLE, Bichat-Claude-Bernard hospital, HUPNVS, AP-HP, Paris, France.;Anaesthesiology and Critical Care Medicine Department, DMU PARABOLE, Bichat-Claude-Bernard hospital, HUPNVS, AP-HP, Paris, France, Paris University, Paris, France.;Anaesthesiology and Critical Care Medicine Department, DMU PARABOLE, Bichat-Claude-Bernard hospital, HUPNVS, AP-HP, Paris, France, Paris University, Paris, France, INSERM UMR 1152, Paris University, Paris, France. | 424 | ||||||
| 10.1159/000507898 | Journal Article | en | Performing Bronchoscopy in Times of the COVID-19 Pandemic: Practice Statement from an International Expert Panel. | https://www.ncbi.nlm.nih.gov/pubmed/32344422 | These recommendations for physicians who perform bronchoscopy will help to protect those patients (un)-affected by the current COVID-19 pandemic, minimize the risk of transmission, and maintain clinical care for all patients. | 0025-7931,1423-0356 | 2020-05-03 02:00:00+02:00 | pubmed | Bronchoscopes;Bronchoscopy__methods;Coronavirus Infections__diagnosis;Equipment Reuse;Expert Testimony;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Intensive Care Units;International Cooperation;Masks;Pandemics;Personal Protective Equipment;Pneumonia, Viral__diagnosis;Practice Guidelines as Topic;COVID-19 | Respiration | Fengming Luo;Kaid Darwiche;Suveer Singh;Alfonso Torrego;Daniel P Steinfort;Stefano Gasparini;Dan Liu;Wei Zhang;Sebastian Fernandez-Bussy;Felix J F Herth;Pallav L Shah | Bronchoscopy;COVID-19;Interventional pneumology | 2020-04-28 02:00:00+02:00 | 32344422 | FR;CN;GB;US;IT;AU;ES;DE | Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.;Department of Interventional Pneumology, Ruhrlandklinik, University Medicine Essen, Essen, Germany.;Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom.;National Heart and Lung Institute, Imperial College, London, United Kingdom.;Chelsea and Westminster Hospital, London, United Kingdom.;Respiratory Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain.;Department Respiratory Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia.;Department Medicine, University of Melbourne, Parkville, Victoria, Australia.;Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Region Azienda Ospedali Riuniti, Ancona, Italy.;Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.;Division of Pulmonary and Critical Care, Mayo Clinic Florida, Jacksonville, Florida, USA.;Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany, felix.herth@med.uni-heidelberg.de.;Translational Lung Research Center Heidelberg, Heidelberg, Germany, felix.herth@med.uni-heidelberg.de. | 439 | ||
| 10.1016/s2352-3026(20)30124-1 | Journal Article | en | Management of patients with multiple myeloma during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32353254 | 2352-3026 | 2020-05-03 02:00:00+02:00 | pubmed | Antineoplastic Agents, Alkylating__therapeutic use;Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Disease Management;Hematopoietic Stem Cell Transplantation;Humans;Melphalan__therapeutic use;Multiple Myeloma__complications;Outpatients;Pandemics;Pneumonia, Viral__complications;Risk Factors;Steroids__therapeutic use;Transplantation, Autologous;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Haematology | Florent Malard;Mohamad Mohty | 2020-04-27 02:00:00+02:00 | 32353254 | FR | Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, 75012, France. Electronic address: florent.malard@inserm.fr.;Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, 75012, France. | 451 | ||||
| 10.1016/j.idm.2020.03.003 | Journal Article | en | A COVID-19 epidemic model with latency period. | https://www.ncbi.nlm.nih.gov/pubmed/32346664 | At the beginning of a COVID-19 infection, there is a period of time known as the exposed or latency period, before an infected person is capable of transmitting the infection to another person. We develop two differential equations models to account for this period. The first is a model that incorporates infected persons in the exposed class, before transmission is possible. The second is a model that incorporates a time delay in infected persons, before transmission is possible. We apply both models to the COVID-19 epidemic in China. We estimate the epidemiological parameters in the models, such as the transmission rate and the basic reproductive number, using data of reported cases. We thus evaluate the role of the exposed or latency period in the dynamics of a COVID-19 epidemic. | 2468-0427 | 2020-05-03 02:00:00+02:00 | pubmed | Infectious Disease Modelling | Z Liu;P Magal;O Seydi;G Webb | Corona virus;Epidemic mathematical model;Isolation;Public closings;Quarantine;Reported and unreported cases | 2020-04-28 02:00:00+02:00 | 32346664 | FR;CN;SN;US | School of Mathematical Sciences, Beijing Normal University, Beijing, 100875, People's Republic of China.;Univ. Bordeaux, France CNRS, IMB, UMR 5251, F-33400, Talence, France.;Département Tronc Commun, École Polytechnique de Thiés, Senegal.;Mathematics Department, Vanderbilt University, Nashville, TN, USA. | 462 | |||
| NIGMS NIH HHS | 10.1016/s2213-2600(20)30217-4 | Journal Article | en | Immunotherapies for COVID-19: lessons learned from sepsis. | https://www.ncbi.nlm.nih.gov/pubmed/32444269 | 2213-2600 | 2020-05-03 02:00:00+02:00 | pubmed | The Lancet Respiratory Medicine | Kenneth E Remy;Scott C Brakenridge;Bruno Francois;Thomas Daix;Clifford S Deutschman;Guillaume Monneret;Robin Jeannet;Pierre-Francois Laterre;Richard S Hotchkiss;Lyle L Moldawer | 2020-04-28 02:00:00+02:00 | 32444269 | FR;BE;US | [{"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "K08 GM129763"}] | Departments of Pediatrics and Internal Medicine, Washington University School of Medicine, St Louis, MO, USA.;Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610-0108, USA.;INSERM CIC-1435, Dupuytren University Hospital, Limoges, France, Intensive Care Unit, Dupuytren University Hospital, Limoges, France, INSERM UMR-1092, Université Limoges, Limoges, France.;Cohen Children's Medical Center, Northwell Health, Feinstein Institute for Medical Research, Zucker-Hofstra School of Medicine, Manhasset, NY, USA.;Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;INSERM CIC-1435, Dupuytren University Hospital, Limoges, France, UMR CNRS-7276 INSERM-1262, Limoges University, Limoges, France.;Department of Critical Care Medicine, St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.;Departments of Anesthesiology, Medicine, and Surgery, Washington University School of Medicine, St Louis, MO 63110-1093, USA. Electronic address: richardshotchkiss@wustl.edu.;Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610-0108, USA. Electronic address: lyle.moldawer@surgery.ufl.edu. | 464 | |||
| Editorial | en | Summary of the coronavirus disease 2019 (COVID-19) update from the 2020 Conference on Retroviruses and Opportunistic Infections, 8-11 March 2020, Boston, USA. | https://www.ncbi.nlm.nih.gov/pubmed/32405428 | 2020-05-03 02:00:00+02:00 | pubmed | Christina K Psomas;Sabine Kinloch | 2020-04-30 02:00:00+02:00 | 32405428 | FR;GB | European Hospital, Marseille, France.;Royal Free Hospital NHS Trust and University College London, UK. | 465 | ||||||||
| 10.1016/j.eclinm.2020.100370 | Journal Article | en | Serosurveys and convalescent plasma in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32632410 | 2589-5370 | 2020-05-03 02:00:00+02:00 | pubmed | EClinicalMedicine | Cristina Pérez-Cameo;Juan Marín-Lahoz | 2020-05-01 02:00:00+02:00 | 32632410 | FR;ES;PS | Emergency Department, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron 119-129, 08035 Barcelona (SPAIN).;Neurology Department and Emergency Department, Hospital de la Santa Creu I Sant Pau, C/ Mas Casanovas 90, 08041 Barcelona (SPAIN). | 469 | |||||
| 10.1016/j.jfo.2020.04.009 | Journal Article;Practice Guideline | fr | [Recommendations on personal protective measures in ophthalmology (French Ophthalmology Society and National Council of Professionals in Ophthalmology) during this COVID-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32402411 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Disinfection__methods;France__epidemiology;Humans;Ophthalmologists;Ophthalmology__organization & administration;Pandemics__prevention & control;Personal Protective Equipment;Physicians' Offices__organization & administration;Pneumonia, Viral__epidemiology;Risk Factors;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | 2020-04-30 02:00:00+02:00 | 32402411 | FR | 17, VLA d'Alésia, 75014 Paris, France. | 471 | |||||
| Letter | en | Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32413699 | 2020-05-03 02:00:00+02:00 | pubmed | Rami Bou Khalil | COVID-19;Coronavirus;Lithium;Rapamycin;mTOR | 2020-05-01 02:00:00+02:00 | 32413699 | FR;LB | Department of psychiatry, Hotel Dieu de France- Beirut- Lebanon, Saint Joseph University, Beirut, Lebanon. Electronic address: rami.boukhalil@usj.edu.lb. | 479 | |||||||
| 10.1016/j.soard.2020.04.032 | Editorial | en | The quintuple penalty of obese patients in the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32418769 | 1550-7289 | 2020-05-03 02:00:00+02:00 | pubmed | Surgery for Obesity and Related Diseases | Karem Slim;Yves Boirie | 2020-05-01 02:00:00+02:00 | 32418769 | FR | Department of Digestive Surgery, CHU Clermont-Ferrand, Clermont-Ferrand, France, Francophone Group for Enhanced Recovery After Surgery, Beaumont, France.;Department of Nutrition, CHU Clermont-Ferrand, Clermont-Ferrand, France. | 482 | |||||
| 10.12688/f1000research.23496.2 | Journal Article | en | SARS-CoV-2 epidemic in India: epidemiological features and in silico analysis of the effect of interventions. | https://www.ncbi.nlm.nih.gov/pubmed/32528664 | Background: After SARS-CoV-2 set foot in India, the Government took a number of steps to limit the spread of the virus in the country. This included restricted testing, isolation, contact tracing and quarantine, and enforcement of a nation-wide lockdown starting 25 March 2020. The objectives of this study were to i) describe the age, gender distribution, and mortality among COVID-19 patients identified till 14 April 2020 and predict the range of contact rate; and ii) predict the number of COVID-19 infections after 40 days of lockdown. Methods: We used a cross-sectional descriptive design for the first objective and a susceptible-infected-removed model for in silico predictions. We collected data from government-controlled and crowdsourced websites. Results: Studying age and gender parameters of 1161 Indian COVID-19 patients, the median age was 38 years (IQR, 27-52) with 20-39 year-old males being the most affected group. The number of affected patients were 854 (73.6%) men and 307 (26.4%) women. If the current contact rate continues (0.25-27), India may have 110460 to 220575 infected persons at the end of 40 days lockdown. Conclusion: The disease is majorly affecting a younger age group in India. Interventions have been helpful in preventing the worst-case scenario in India but will be unable to prevent the spike in the number of cases. | 2046-1402 | 2020-05-03 02:00:00+02:00 | pubmed | Adult;Age Distribution;Betacoronavirus;Communicable Disease Control;Coronavirus Infections__epidemiology;Cross-Sectional Studies;Female;Humans;India__epidemiology;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Sex Distribution;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | F1000Research | Archisman Mazumder;Mehak Arora;Vishwesh Bharadiya;Parul Berry;Mudit Agarwal;Priyamadhaba Behera;Hemant Deepak Shewade;Ayush Lohiya;Mohak Gupta;Aditi Rao;Giridara Gopal Parameswaran | COVID-19;Coronavirus;India;SIR model | 2020-04-30 02:00:00+02:00 | 32528664 | FR;IN | All India Institute of Medical Sciences, New Delhi, Delhi, India.;All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India.;Operational Research, The Union South-East Asia Office, New Delhi, Delhi, India.;Centre For Operational Research, International Union Against Tuberculosis and Lung Disease (The Union), Paris, France.;Super Specialty Cancer Institute & Hospital, Lucknow, India. | 485 | ||
| 10.1111/andr.12809 | Journal Article | en | SARS-CoV-2 pandemic and repercussions for male infertility patients: A proposal for the individualized provision of andrological services. | https://www.ncbi.nlm.nih.gov/pubmed/32357288 | The prolonged lockdown of health facilities providing non-urgent gamete cryopreservation-as currently recommended by many reproductive medicine entities and regulatory authorities due to the SARS-CoV-2 pandemic will be detrimental for subgroups of male infertility patients. We believe the existing recommendations should be promptly modified and propose that the same permissive approach for sperm banking granted for men with cancer is expanded to other groups of vulnerable patients. These groups include infertility patients (eg, azoospermic and cryptozoospermic) undergoing medical or surgical treatment to improve sperm quantity and quality, as well as males of reproductive age affected by inflammatory and systemic auto-immune diseases who are about to start treatment with gonadotoxic drugs or who are under remission. In both scenarios, the "fertility window" may be transitory; postponing diagnostic semen analysis and sperm banking in these men could compromise the prospects of biological parenthood. Moreover, we provide recommendations on how to continue the provision of andrological services in a considered manner and a safe environment. Our opinion is timely and relevant given the fact that fertility services are currently rated as of low priority in most countries. | 2047-2919,2047-2927 | 2020-05-03 02:00:00+02:00 | pubmed | Andrology | Sandro C Esteves;Francesco Lombardo;Nicolás Garrido;Juan Alvarez;Armand Zini;Giovanni M Colpi;Jackson Kirkman-Brown;Sheena E M Lewis;Lars Björndahl;Ahmad Majzoub;Chak-Lam Cho;Pedro Vendeira;Jorge Hallak;Edouard Amar;Marcello Cocuzza;Fabiola C Bento;Rita C Figueira;Romualdo Sciorio;Rita J Laursen;Ahmad M Metwalley;Sunil K Jindal;Sijo Parekattil;Ranjith Ramasamy;Carlo Alviggi;Peter Humaidan;John L Yovich;Ashok Agarwal | SARS-CoV-2;azoospermia;male infertility;opinion;semen analysis;sperm banking;systemic auto-immune diseases | 2020-05-01 02:00:00+02:00 | 32357288 | SE;FR;CA;SA;CN;PT;CH;GB;US;QA;BR;IT;HK;AU;EG;ES;IN;DK | ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil.;Department of Surgery (Division of Urology), University of Campinas (UNICAMP), Campinas, Brazil.;Faculty of Health, Aarhus University, Aarhus, Denmark.;Department of Medical Physiopathology, University of Rome "La Sapienza", Rome, Italy.;IVI Foundation, Health Research Institute La Fe, Valencia, Spain.;Centro ANDROGEN, La Coruña, Spain.;Division of Urology, Department of Surgery, St. Mary's Hospital, McGill University, Montreal, QC, Canada.;Andrology Service, Procrea Swiss Fertility Center, Lugano, Switzerland.;Andrology and IVF Department, San Carlo Cinic, Paderno Dugnano/Milano, Italy.;Centre for Human Reproductive Science, IMSR, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Birmingham Women's Fertility Centre, Birmingham Women's & Children's NHS Foundation Trust, Birmingham, UK.;Queens University Belfast, Belfast, UK.;Examenlab Ltd., Belfast, UK.;ANOVA, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.;Department of Urology, Hamad Medical Corporation, Doha, Qatar.;Weill Cornell Medicine-Qatar, Doha, Qatar.;Department of Surgery, Union Hospital, Hong Kong, Hong Kong.;S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong.;Urology/Andrology Unit, Saúde Atlântica, Clínica do Dragão, Porto, Portugal.;Androscience, Science and Innovation Center in Andrology and High-Complex Clinical and Andrology Laboratory, São Paulo, Brazil.;Division of Urology, University of São Paulo, São Paulo, Brazil.;Men's Health Study Group, Institute for Advanced Studies, University of São Paulo, São Paulo, Brazil.;Reproductive Toxicology Unit, Department of Pathology, University of São Paulo, São Paulo, Brazil.;Cabinet D'Andrologie Victor Hugo, American Hospital of Paris Reproductive Center, Paris, France.;Human Reproduction Center, Division of Urology, University of São Paulo, São Paulo, Brazil.;Edinburgh Assisted Conception Programme, EFREC, Royal Infirmary of Edinburgh, Edinburgh, UK.;Fertility Clinic Skive, Skive Regional Hospital, Skive, Denmark.;IVF Laboratory, Al Saad Specialist Hospitals, Jeddah, Saudi Arabia.;Reproductive Medicine and Genetic Unit, GEBRI, Sadat City, Egypt.;Division of Reproductive Medicine and Andrology, Jindal Hospital, Meerut, India.;PUR Clinic and University of Central Florida, Clermont, FL, USA.;Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA.;Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico II, Naples, Italy.;PIVET Medical Centre, Perth, WA, Australia.;Curtin University, Perth, WA, Australia.;Cairns Fertility Centre, Cairns, QLD, Australia.;Andrology Center, Department of Urology, Cleveland Clinic, Cleveland, OH, USA. | 486 | |||
| 10.1016/j.jchirv.2020.04.014 | English Abstract;Journal Article;Review | fr | [Antibiotics alone as an alternative to appendectomy for uncomplicated acute appendicitis in adults: Changes in treatment modalities related to the COVID-19 health crisis]. | https://www.ncbi.nlm.nih.gov/pubmed/32355509 | The massive inflow of patients with COVID-19 requiring urgent care has overloaded hospitals in France and impacts the management of other patients. Deferring hospitalization and non-urgent surgeries has become a priority for surgeons today in order to relieve the health care system. It is obviously not simple to reduce emergency surgery without altering the quality of care or leading to a loss of chance for the patient. Acute appendicitis is a very specific situation and the prevalence of this disease leads us to reconsider this particular disease in the context of the COVID-19 crisis. Indeed, while the currently recommended treatment for uncomplicated acute appendicitis is surgical appendectomy, the non-surgical alternative of medical management by antibiotic therapy alone has been widely evaluated by high-quality studies in the literature. Insofar as the main limitation of exclusively medical treatment of uncomplicated acute appendicitis is the risk of recurrent appendicitis, this treatment option represents an alternative of choice to reduce the intra-hospital overload in this context of health crisis. The aim of this work is therefore to provide physicians and surgeons with a practical guide based on a review of the literature on the medical treatment of uncomplicated acute appendicitis in adults, to offer this alternative treatment to the right patients and under good conditions, especially when access to the operating room is limited or impossible. | 1878-786X | 2020-05-03 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | M Collard;Z Lakkis;J Loriau;D Mege;C Sabbagh;J H Lefevre;L Maggiori | Acute appendicitis;Antibiotic therapy;Appendectomy;COVID-19;Coronavirus | 2020-04-30 02:00:00+02:00 | 32355509 | FR | Service de chirurgie digestive, Sorbonne université, hôpital Saint-Antoine, AP-HP, 75012, Paris, France.;Service de chirurgie digestive et oncologique , et de transplantation hépatique, CHU de Besançon, 2, boulevard Alexander-Fleming, 25000, Besançon, France.;Service de chirurgie viscérale, groupe hospitalier Paris Saint-Joseph, 75014, Paris, France.;Service de chirurgie digestive, assistance publique hôpitaux de Marseille, hôpital de la Timone, CHU de Marseille, France.;Service de chirurgie digestive, CHU Amiens-Picardie, 8000 Amiens, France.;Unité de recherche SSPC (simplification des soins des patients chirurgicaux complexes), université de Picardie Jules-Verne, 80025 Amiens, France.;Service de chirurgie colorectale, hôpital Beaujon, université de Paris, AP-HP, 92110 Clichy, France. | 487 | |||
| 10.1016/j.xcrm.2020.100016 | Journal Article;Review | en | Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32562483 | Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as of May 8, 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and development of acute respiratory distress syndrome. In view of uncertainty associated with immunosuppressive treatments, such as corticosteroids and their possible secondary effects, including risks of secondary infections, we suggest immunotherapies as an adjunct therapy in severe COVID-19 cases. Such immunotherapies based on inflammatory cytokine neutralization, immunomodulation, and passive viral neutralization not only reduce inflammation, inflammation-associated lung damage, or viral load but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation, both of which are limited resources. | 2666-3791 | 2020-05-03 02:00:00+02:00 | pubmed | Cell Reports Medicine | Srinivasa Reddy Bonam;Srini V Kaveri;Anavaj Sakuntabhai;Laurent Gilardin;Jagadeesh Bayry | COVID-19;IVIG;SARS-CoV-2;convalescent plasma;cytokine storm syndrome;cytokines;hyperimmune globulin;immunotherapy;inflammation;monoclonal antibody;passive immunotherapy | 2020-04-30 02:00:00+02:00 | 32562483 | FR | Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe - Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Université de Paris, Paris 75006, France.;Unité de Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur, CNRS UMR2000 Génomique Évolutive, Modélisation et Santé, Institut Pasteur, Paris 75015, France.;Hôpital Bégin, Saint Mandé 94160, France. | 494 | |||
| 10.1016/j.jfo.2020.04.011 | Journal Article;Practice Guideline | fr | [How to approach management of surgical vitreoretinal disease during the SARS-CoV-2 Covid-19 pandemic?] | https://www.ncbi.nlm.nih.gov/pubmed/32386901 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Emergencies;Eye Diseases__surgery;Humans;Ophthalmologic Surgical Procedures__classification;Pandemics;Pneumonia, Viral__epidemiology;Retinal Diseases__surgery;Vitreous Body__surgery;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | C Arndt;M-N Delyfer;L Kodjikian;N Leveziel;C Zech | 2020-04-30 02:00:00+02:00 | 32386901 | FR | Société Française d'Ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France.;Société Française d'Ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France. Electronic address: kodjikian.laurent@wanadoo.fr. | 498 | ||||
| Letter | en | Role of doctors in epidemics: historical perspectives and implications for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32390080 | 2020-05-10 02:00:00+02:00 | pubmed | Donatella Lippi;Raffaella Bianucci;Simon Donell | 2020-05-10 02:00:00+02:00 | 32390080 | FR;IT;GB | Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.;Warwick Medical School, Biomedical Sciences, University of Warwick, Coventry, UK. raffaella.bianucci@unito.it.;Legal Medicine Section, Department of Public Health and Paediatric Sciences, University of Turin, Corso Galileo Galilei 22, 10126, Turin, Italy. raffaella.bianucci@unito.it.;UMR 7268, Laboratoire d'Anthropologie Bio-culturelle, Droit, Etique & Santé (Adés), Faculté de Médecine de Marseille, Marseille, France. raffaella.bianucci@unito.it.;Norwich Medical School, University of East Anglia, Norwich, UK. | 506 | ||||||||
| Case Reports;Letter | en | COVID-19 in lung-transplanted and cystic fibrosis patients: Be careful. | https://www.ncbi.nlm.nih.gov/pubmed/32402680 | 2020-05-10 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections__complications;Cystic Fibrosis__surgery;Humans;Lung Transplantation;Male;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eric Farfour;Clément Picard;Laurence Beaumont;Philippe Lesprit;Marie-Christine Ballester;Felix Ackermann;Richard Galliot;Sylvie Colin de Verdiere;Charles Cerf;Marc Vasse | 2020-05-10 02:00:00+02:00 | 32402680 | FR | Service de biologie Clinique, Hôpital Foch, Suresnes, France. Electronic address: ericf6598@yahoo.fr.;Service de pneumologie et transplantation pulmonaire, Hôpital Foch, Suresnes, France.;Service de biologie Clinique, Hôpital Foch, Suresnes, France.;Service des urgences, Hôpital Foch, Suresnes, France.;Service de médecine interne, Hôpital Foch, Suresnes, France.;Service de réanimation médicale, Hôpital Foch, Suresnes, France.;Service de pneumologie et transplantation pulmonaire, Hôpital Foch, Suresnes, France, Université Versailles-Saint Quentin en Yvelines, France. | 507 | |||||||
| Letter | en | Possible consequences of the COVID-19 pandemic on the use of biospecimens from cancer biobanks for research in academia and bioindustry. | https://www.ncbi.nlm.nih.gov/pubmed/32382152 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Biological Specimen Banks__trends;Biomedical Research__trends;Coronavirus Infections__complications;Humans;Neoplasms__complications;Pandemics__prevention & control;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Paul Hofman;Pascal Puchois;Patrick Brest;Hicham Lahlou;Daniel Simeon-Dubach | 2020-05-09 02:00:00+02:00 | 32382152 | FR;CA;CH | Université Côte d'Azur, CHU de Nice, Laboratory of Clinical and Experimental Pathology, Biobank (BB-0033-00025), FHU-OncoAge, Nice, France. hofman.p@chu-nice.fr.;Université Côte d'Azur, Institute of Research on Cancer and Ageing of Nice, CNRS, INSERM, Centre Antoine Lacassagne, FHU-OncoAge, Nice, France. hofman.p@chu-nice.fr.;Trans-Hit, Biomarkers, Montreal, Canada.;Université Côte d'Azur, Institute of Research on Cancer and Ageing of Nice, CNRS, INSERM, Centre Antoine Lacassagne, FHU-OncoAge, Nice, France.;Medservice, Biobanking Consulting & Services, Walchwil, Switzerland. | 513 | |||||||
| Letter | en | Impact of COVID-19 pandemic on SLE: beyond the risk of infection. | https://www.ncbi.nlm.nih.gov/pubmed/32376774 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Humans;Lupus Erythematosus, Systemic__diagnosis;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Alice Horisberger;Laura Moi;Camillo Ribi;Denis Comte | antirheumatic agents;interferon type I;lupus erythematosus, systemic | 2020-05-08 02:00:00+02:00 | 32376774 | FR;CH | Service of Immunology and Allergy, Departement de medecine, Centre hospitalier universitaire vaudois, Lausanne, Switzerland.;Service of Immunology and Allergy, Departement de medecine, Centre hospitalier universitaire vaudois, Lausanne, Switzerland denis.comte@chuv.ch. | 515 | ||||||
| Letter | en | Re: Reflections on the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32374144 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Practice Guidelines as Topic;Robotic Surgical Procedures__standards;Urologic Surgical Procedures__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | Riccardo Bertolo;Chiara Cipriani;Matteo Vittori;Pierluigi Bove | 2020-05-07 02:00:00+02:00 | 32374144 | FR;IT | Department of Urology, San Carlo di Nancy Hospital, Rome, Italy.;Department of Surgery, Urology Unit, Tor Vergata University of Rome, Rome, Italy. | 518 | |||||||
| Journal Article;Review | en | How the COVID-19 Overcomes the Battle? An Approach to Virus Structure. | https://www.ncbi.nlm.nih.gov/pubmed/32361692 | Coronaviruses primarily cause zoonotic infections, however in the past few decades several interspecies transmissions have occurred, the last one by SARS-CoV-2, causing COVID-19 pandemic, posing serious threat to global health. The SARS-CoV-2 spike (S) protein plays an important role in viral attachment, fusion and entry. However, other structural and non-structural SARS-CoV-2 proteins are potential influencers in virus pathogenicity. Among these proteins; Orf3, Orf8, and Orf10 show the least homology to SARSCoV proteins and therefore should be further studied for their abilities to modulate antiviral and inflammatory responses. Here, we discuss how SARS-COV-2 interacts with our immune system. | 2020-05-10 02:00:00+02:00 | pubmed | Animals;Betacoronavirus__genetics;Coronavirus Infections__immunology;Gene Order;Genome, Viral__genetics;Humans;Immune System__virology;Pandemics;Pneumonia, Viral__immunology;SARS Virus__genetics;Spike Glycoprotein, Coronavirus__genetics;Viral Proteins__genetics;Viral Structures__genetics;Virus Internalization;COVID-19;severe acute respiratory syndrome coronavirus 2 | Doryaneh Ahmadpour;Pedram Ahmadpoor | 2020-05-04 02:00:00+02:00 | 32361692 | FR | Department of Nephrology, Dialysis and Apheresis, Nimes University Hospital Center, Nimes, France. pedram.ahmadpoor@chu-nimes.fr. | 521 | ||||||
| Letter;Personal Narrative | en | Staying in a Burning House: Perks and Perils of a Hotline in the Times of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32277475 | 2020-05-10 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Betacoronavirus;Comorbidity;Coronavirus Infections__psychology;Disease Transmission, Infectious__prevention & control;Female;Geriatrics__methods;Hotlines__methods;Humans;Male;Mexico;Pandemics;Pneumonia, Viral__psychology;Public Assistance;Telemedicine__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Ana Patricia Navarrete-Reyes;José Alberto Avila-Funes | 2020-05-05 02:00:00+02:00 | 32277475 | FR;MX | Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico.;Centre de Recherche Inserm, U897, University Victor Segalen Bordeaux 2, Bordeaux, France. | 530 | |||||||
| 10.1016/j.arcped.2020.05.004 | Case Reports;Journal Article | en | Child with liver transplant recovers from COVID-19 infection. A case report. | https://www.ncbi.nlm.nih.gov/pubmed/32402433 | We present the case of a 55-month-old girl who recovered from coronavirus disease 2019 (COVID-19) infection 5 months after undergoing liver transplantation; she had a co-infection with Epstein-Barr virus (EBV). To the best of our knowledge, this is the first case report of a COVID-19 infection in a pediatric patient with liver transplantation. Additionally, this is also the first report of confirmed co-infection between COVID-19 and EBV. On the basis of this case, we suggest that liver transplantation is not associated with COVID-19 symptom severity and development. Moreover, COVID-19 and EBV co-infections do not seem to aggravate the clinical outcome. | 0929-693X | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Child, Preschool;Coinfection__diagnosis;Coronavirus Infections__diagnosis;Epstein-Barr Virus Infections__diagnosis;Female;Humans;Liver Transplantation;Pandemics;Pneumonia, Viral__diagnosis;Postoperative Complications__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Archives de Pédiatrie | Aurélie Morand;Bertrand Roquelaure;Philippe Colson;Sophie Amrane;Emmanuelle Bosdure;Didier Raoult;Jean-Christophe Lagier;Alexandre Fabre | Biliary atresia;COVID-19;Children;Liver graft | 2020-05-06 02:00:00+02:00 | 32402433 | FR | Department of Infant Medicine and Specialized Pediatrics, Aix Marseille University, La Timone Children Hospital, AP-HM, 278, rue Saint-Pierre, 13005 Marseille, France, Aix Marseille University, IRD, AP-HM, MEPHI, 13005 Marseille, France. Electronic address: aurelie.morand@ap-hm.fr.;Department of Pediatric Gastroenterology and Hepatology, Multidisciplinary pediatric, Aix Marseille University, La Timone Children Hospital, AP-HM, 13005 Marseille, France.;Aix Marseille University, IRD, AP-HM, MEPHI, 13005 Marseille, France, IHU-Méditerranée Infection, 13005 Marseille, France.;Department of Infant Medicine and Specialized Pediatrics, Aix Marseille University, La Timone Children Hospital, AP-HM, 278, rue Saint-Pierre, 13005 Marseille, France.;Department of Pediatric Gastroenterology and Hepatology, Multidisciplinary pediatric, Aix Marseille University, La Timone Children Hospital, AP-HM, 13005 Marseille, France, Inserm, MMG, Aix Marseille Univ, 13005 Marseille, France. | 544 | ||
| High Performance Computing (HPC) Center of the Strasbourg University;State Research Funding for FSBSI "Chumakov FSC R&D IBP RAS" | 10.1002/minf.202000080 | Journal Article | en | A Chemographic Audit of anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL). | https://www.ncbi.nlm.nih.gov/pubmed/32363750 | Discovery of drugs against newly emerged pathogenic agents like the SARS-CoV-2 coronavirus (CoV) must be based on previous research against related species. Scientists need to get acquainted with and develop a global oversight over so-far tested molecules. Chemography (herein used Generative Topographic Mapping, in particular) places structures on a human-readable 2D map (obtained by dimensionality reduction of the chemical space of molecular descriptors) and is thus well suited for such an audit. The goal is to map medicinal chemistry efforts so far targeted against CoVs. This includes comparing libraries tested against various virus species/genera, predicting their polypharmacological profiles and highlighting often encountered chemotypes. Maps are challenged to provide predictive activity landscapes against viral proteins. Definition of "anti-CoV" map zones led to selection of therein residing 380 potential anti-CoV agents, out of a vast pool of 800 M organic compounds. | 1868-1743,1868-1751 | 2020-05-10 02:00:00+02:00 | pubmed | Molecular Informatics | Dragos Horvath;Alexey Orlov;Dmitry I Osolodkin;Aydar A Ishmukhametov;Gilles Marcou;Alexandre Varnek | Antivirals;Generative Topographic Mapping;SARS;Structure-Activity Relationships;chemography;coronavirus | 2020-05-04 02:00:00+02:00 | 32363750 | FR;RU | [{"country": "", "agency": "High Performance Computing (HPC) Center of the Strasbourg University"}, {"country": "", "agency": "State Research Funding for FSBSI \"Chumakov FSC R&D IBP RAS\"", "grantid": "0837-2019-0002"}] | Chemoinformatics Laboratory, UMR 7140 CNRS/University of Strasbourg, 4, rue Blaise Pascal, 67000, Strasbourg.;FSBSI "Chumakov FSC R&D IBP RAS", Poselok Instituta Poliomielita 8 bd. 1, Poselenie Moskovsky, Moscow, 108819, Russia.;Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Trubetskaya ul. 8, Moscow, 119991, Russia. | 549 | |
| Case Reports;Comparative Study;Letter | en | Ultrasound findings in patients with COVID-19 pneumonia in early and late stages: Two case-reports. | https://www.ncbi.nlm.nih.gov/pubmed/32417024 | 2020-05-10 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__complications;Disease Progression;Female;Humans;Lung__diagnostic imaging;Male;Pandemics;Pneumonia, Viral__complications;Respiration, Artificial;Respiratory Distress Syndrome, Adult__diagnostic imaging;Tomography, X-Ray Computed;Ultrasonography;COVID-19;severe acute respiratory syndrome coronavirus 2 | Laurent Zieleskiewicz;Gary Duclos;Ophélie Dransart-Rayé;Nicolas Nowobilski;Belaid Bouhemad | 2020-05-04 02:00:00+02:00 | 32417024 | FR | Department of Anaesthesia and Intensive Care Medicine, University Hospital of Marseille, Aix-Marseille University, Marseille, France, Faculty of medicine, C2VN Inra INSERM, Aix-Marseille University, Marseille, France.;Department of Anaesthesia and Intensive Care Medicine, University Hospital of Marseille, Aix-Marseille University, Marseille, France.;Department of Anaesthesiology and Intensive Care, University Hospital of Dijon, Dijon, France.;Department of Anaesthesiology and Intensive Care, University Hospital of Dijon, Dijon, France, Lipness Team, INSERM Research Centre LNC-UMR1231 and LabEx LipSTIC, Université Bourgogne Franche-Comté, Dijon, France. Electronic address: belaid_bouhemad@hotmail.com. | 555 | |||||||
| Letter | en | Limited effectiveness of systematic screening by nasopharyngeal RT-PCR of medicalized nursing home staff after a first case of COVID-19 in a resident. | https://www.ncbi.nlm.nih.gov/pubmed/32376476 | 2020-05-10 02:00:00+02:00 | pubmed | R Guery;C Delaye;N Brule;V Nael;L Castain;F Raffi;L De Decker | COVID-19;Health worker;Medicalized nursing home | 2020-05-04 02:00:00+02:00 | 32376476 | FR | Service de Maladies Infectieuses et Tropicales, CIC UIC 1413 inserm, CHU de Nantes, 44093 Nantes, France. Electronic address: romain.guery@yahoo.fr.;Service de Maladies Infectieuses et Tropicales, CIC UIC 1413 inserm, CHU de Nantes, 44093 Nantes, France.;Service de Santé au Travail, CHU de Nantes, Nantes, France.;Service de Virologie, CHU de Nantes, Nantes, France.;Service de Médecine Aigue Gériatrique, CHU Nantes, Nantes, France. | 556 | |||||||
| 10.1016/j.encep.2020.04.006 | Journal Article;Review | fr | [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32376004 | The 2019-20 coronavirus pandemic (SARS-CoV-2; severe acute respiratory syndrome coronavirus 2) has dramatic consequences on populations in terms of morbidity and mortality and in social terms, the general confinement of almost half of the world's population being a situation unprecedented in history, which is difficult today to measure the impact at the individual and collective levels. More specifically, it affects people with various risk factors, which are more frequent in patients suffering from psychiatric disorders. Psychiatrists need to know: (i) how to identify, the risks associated with the prescription of psychotropic drugs and which can prove to be counterproductive in their association with COVID-19 (coronavirus disease 2019), (ii) how to assess in terms of benefit/risk ratio, the implication of any hasty and brutal modification on psychotropic drugs that can induce confusion for a differential diagnosis with the evolution of COVID-19. We carried out a review of the literature aimed at assessing the specific benefit/risk ratio of psychotropic treatments in patients suffering from COVID-19. Clinically, symptoms suggestive of COVID-19 (fever, cough, dyspnea, digestive signs) can be caused by various psychotropic drugs and require vigilance to avoid false negatives and false positives. In infected patients, psychotropic drugs should be used with caution, especially in the elderly, considering the pulmonary risk. Lithium and Clozapine, which are the reference drugs in bipolar disorder and resistant schizophrenia, warrant specific attention. For these two treatments the possibility of a reduction in the dosage - in case of minimal infectious signs and in a situation, which does not allow rapid control - should ideally be considered taking into account the clinical response (even biological; plasma concentrations) observed in the face of previous dose reductions. Tobacco is well identified for its effects as an inducer of CYP1A2 enzyme. In a COVID+ patient, the consequences of an abrupt cessation of smoking, particularly related with the appearance of respiratory symptoms (cough, dyspnea), must therefore be anticipated for patients receiving psychotropics metabolized by CYP1A2. Plasma concentrations of these drugs are expected to decrease and can be related to an increase risk of relapse. The symptomatic treatments used in COVID-19 have frequent interactions with the most used psychotropics. If there is no curative treatment for infection to SARS-CoV-2, the interactions of the various molecules currently tested with several classes of psychotropic drugs (antidepressants, antipsychotics) are important to consider because of the risk of changes in cardiac conduction. Specific knowledge on COVID-19 remains poor today, but we must recommend rigor in this context in the use of psychotropic drugs, to avoid adding, in patients suffering from psychiatric disorders, potentially vulnerable in the epidemic context, an iatrogenic risk or loss of efficiency. | 0013-7006 | 2020-05-10 02:00:00+02:00 | pubmed | Age Factors;Antiviral Agents__adverse effects;Betacoronavirus;Biotransformation;Cardiovascular Diseases__chemically induced;Comorbidity;Continuity of Patient Care;Coronavirus Infections__drug therapy;Cytochrome P-450 CYP1A2__metabolism;Drug Interactions;Fever__chemically induced;France__epidemiology;Gastrointestinal Diseases__chemically induced;Humans;Mental Disorders__chemically induced;Pandemics;Pharmaceutical Preparations__supply & distribution;Pneumonia, Viral__drug therapy;Psychotropic Drugs__administration & dosage;Respiration Disorders__chemically induced;Risk Assessment;Smoking Cessation;Symptom Assessment;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | H Javelot;P-M Llorca;D Drapier;E Fakra;C Hingray;G Meyer;S Dizet;A Egron;C Straczek;M Roser;M Masson;R Gaillard;P Fossati;E Haffen | COVID-19;Drug interactions;Intéractions médicamenteuses;Psychotropes;Psychotropics | 2020-05-04 02:00:00+02:00 | 32376004 | FR | Établissement Public de Santé Alsace Nord, Brumath, France, Laboratoire de toxicologie et pharmacologie neuro-cardiovasculaire, université de Strasbourg, Strasbourg, France. Electronic address: herve.javelot@ch-epsan.fr.;CHU de Clermont-Ferrand, Clermont-Ferrand, France, Université Clermont Auvergne, Clermont-Ferrand, France.;Pôle hospitalo-universitaire de psychiatrie adulte, centre hospitalier Guillaume-Régnier, Rennes, France, EA 4712, comportements et noyaux gris centraux, université de Rennes 1, Rennes, France.;Pôle universitaire de psychiatrie, CHU de Saint-Étienne, Saint-Étienne, France.;Pôle hospitalo-universitaire de psychiatrie d'adultes du Grand Nancy, centre psychothérapique de Nancy, Laxou, France, Département de neurologie, CHU de Nancy, Nancy, France.;Service de pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France, Service de pharmacie, CHU de Strasbourg, Strasbourg, France.;Service de pharmacie, CHS de Sevrey, Chalon-sur-Saône, France.;Service de pharmacie, centre hospitalier de Cadillac, Cadillac, France.;Département de pharmacie, CHU Henri-Mondor, Créteil, France, Institut Mondor de recherche biomédical, Inserm U955, équipe 15 neuropsychiatrie translationnelle, Créteil, France.;Institut Mondor de recherche biomédical, Inserm U955, équipe 15 neuropsychiatrie translationnelle, Créteil, France, Service de psychiatrie sectorisée, hôpital Albert-Chenevier, Créteil, France.;Nightingale Hospitals-Paris, clinique du Château de Garches, Garches, France, SHU, GHU psychiatrie et neurosciences, Paris, France.;GHU psychiatrie et neurosciences, université de Paris, Paris, France, Sous-section 49-03, Conseil national des universités (CNU), Paris, France.;Inserm U1127, service de psychiatrie adultes, ICM, groupe hospitalier Pitié-Salpêtrière, Sorbonne université, AP-HP, Paris, France.;CIC-1431 Inserm, service de psychiatrie, CHU de Besançon, Besançon, France, Laboratoire de neurosciences, université de Franche-Comté, Besançon, France. | 559 | ||
| 10.1177/1359105320925149 | Editorial | en | Human needs in COVID-19 isolation. | https://www.ncbi.nlm.nih.gov/pubmed/32375564 | To reduce the spread of COVID-19, the World Health Organization and the majority of governments have recommended that the entire human population should 'stay-at-home'. A significant proportion of the population live alone or are vulnerable to mental health problems yet, in the vast majority of cases, individuals in social isolation have no access to mental healthcare. The only resource is people themselves using self-help, self-medication and self-care. During prolonged COVID-19 isolation, an in-built system of homeostasis can help rebalance activity, thought and feeling. Increased physical activity enables a reset of physical and mental well-being. During periods of lockdown, it is recommended that exercise should be as vigorously promoted as social distancing itself. | 1359-1053,1461-7277 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Communicable Disease Control;Coronavirus Infections__epidemiology;Exercise;Health Services Needs and Demand;Humans;Mental Health;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Quarantine;Self Care;Social Isolation;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Health Psychology | Thiago Matias;Fabio H Dominski;David F Marks | COVID-19 pandemic;communicable diseases;exercise;mental health;needs;psychological homeostasis;self-esteem | 2020-05-06 02:00:00+02:00 | 32375564 | FR;BR | UFSC, Brazil.;UDESC, Brazil.;Independent Researcher, France. | 572 | ||
| 10.1111/anae.15095 | Journal Article;Review | en | Patient blood management during the COVID-19 pandemic: a narrative review. | https://www.ncbi.nlm.nih.gov/pubmed/32339260 | As COVID-19 disease escalates globally, optimising patient outcome during this catastrophic healthcare crisis is the number one priority. The principles of patient blood management are fundamental strategies to improve patient outcomes and should be given high priority in this crisis situation. The aim of this expert review is to provide clinicians and healthcare authorities with information regarding how to apply established principles of patient blood management during the COVID-19 pandemic. In particular, this review considers the impact of the COVID-19 pandemic on blood supply and specifies important aspects of donor management. We discuss how preventative and control measures implemented during the COVID-19 crisis could affect the prevalence of anaemia, and highlight issues regarding the diagnosis and treatment of anaemia in patients requiring elective or emergency surgery. In addition, we review aspects related to patient blood management of critically ill patients with known or suspected COVID-19, and discuss important alterations of the coagulation system in patients hospitalised due to COVID-19. Finally, we address special considerations pertaining to supply-demand and cost-benefit issues of patient blood management during the COVID-19 pandemic. | 0003-2409,1365-2044 | 2020-05-10 02:00:00+02:00 | pubmed | Anemia__complications;Betacoronavirus;Blood Coagulation Disorders__diagnosis;Blood Donors__supply & distribution;Coronavirus Infections__complications;Elective Surgical Procedures;Emergencies;Humans;Operative Blood Salvage;Pandemics__prevention & control;Pneumonia, Viral__complications;Preoperative Care__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Anaesthesia | D M Baron;M Franchini;S M Goobie;M Javidroozi;A A Klein;S Lasocki;G M Liumbruno;M Muñoz;A Shander;D R Spahn;K Zacharowski;P Meybohm | COVID-19;anaemia;coagulation;coronavirus;patient blood management | 2020-05-06 02:00:00+02:00 | 32339260 | FR;JE;GB;US;CH;IT;ES;DE;AT | Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Austria.;Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy.;Italian National Blood Centre, Rome, Italy.;Department of Anesthesiology, Critical Care and Pain Medicine, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.;Department of Anesthesiology and Critical Care Medicine, Englewood Hospital and Medical Center, New Jersey, NJ, USA.;Department of Anaesthesia and Intensive Care, Royal Papworth Hospital, Cambridge, UK.;Département Anesthésie Réanimation, CHU Angers, Université d'Angers, France.;Peri-operative Transfusion Medicine, Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, University of Málaga, Spain.;Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Health, NJ, USA.;UF College of Medicine, Gainesville, FL, USA.;Icahn School of Medicine at Mount, Sinai New York, New York, NY, USA.;Rutgers University, Newark, NJ, USA.;Institute of Anesthesiology and Head Anesthesiology, Intensive Care Medicine and OR Facilities, University of Zurich and University Hospital Zurich, Switzerland.;Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.;Department of Anesthesiology, University Hospital Würzburg, Germany. | 579 | ||
| 10.3892/ol.2020.11599 | Journal Article;Review | en | Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients. | https://www.ncbi.nlm.nih.gov/pubmed/32565968 | COVID-19 has caused unprecedented societal turmoil, triggering a rapid, still ongoing, transformation of healthcare provision on a global level. In this new landscape, it is highly important to acknowledge the challenges this pandemic poses on the care of the particularly vulnerable cancer patients and the subsequent psychosocial impact on them. We have outlined our clinical experience in managing patients with gastrointestinal, hematological, gynaecological, dermatological, neurological, thyroid, lung and paediatric cancers in the COVID-19 era and have reviewed the emerging literature around barriers to care of oncology patients and how this crisis affects them. Moreover, evolving treatment strategies and novel ways of addressing the needs of oncology patients in the new context of the pandemic are discussed. | 1792-1074,1792-1082 | 2020-05-10 02:00:00+02:00 | pubmed | Oncology Letters | Konstantinos Tsamakis;Maria Gavriatopoulou;Dimitrios Schizas;Athina Stravodimou;Aikaterini Mougkou;Dimitrios Tsiptsios;Vasileios Sioulas;Eleftherios Spartalis;Athanasios D Sioulas;Charalampos Tsamakis;Nikolaos Charalampakis;Christoph Mueller;Donna Arya;Paul Zarogoulidis;Demetrios A Spandidos;Meletios A Dimopoulos;Charalabos Papageorgiou;Emmanouil Rizos | COVID-19;SARS-Cov-2;cancer;care;challenges;oncology;pandemic;patients;psychosocial impact;telemedicine | 2020-05-08 02:00:00+02:00 | 32565968 | SE;FR;GR;CH;GB;US | Second Department of Psychiatry, University of Athens, 'ATTIKON' University Hospital, 12462 Athens, Greece.;King's College London, Institute of Psychiatry, Psychology and Neuroscience, London SE5 8AF, UK.;Department of Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.;First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.;Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital, CH-1011 Lausanne, Switzerland.;Paediatric Infectious Diseases Dept, Karolinska University Hospital, 171 77 Stockholm, Sweden.;Department of Neurophysiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland SR47TP, UK.;Department of Gynaecologic Oncology MITERA Hospital, 15123 Athens, Greece.;2nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens School of Medicine, 11527 Athens, Greece.;Gastroenterology Department, Hygeia Hospital, 15123 Athens, Greece.;Department of Dermatology, Luton and Dunstable University Hospital, Bedfordshire Hospitals NHS Foundation Trust, Luton LU4 0DZ, UK.;Department of Medical Oncology, Metaxa Cancer Hospital, Pireas, 18537 Athens, Greece.;South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK.;Thornford Park, Elysium Healthcare, Berkshire RG19 8ET, UK.;3rd Department of Surgery, 'AHEPA' University Hospital, Aristotle University of Thessaloniki, Medical School, 54621 Thessaloniki, Greece.;Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece.;Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, 11527 Athens, Greece.;First Department of Psychiatry, University of Athens, 'EGINITION' Hospital, 11528 Athens, Greece. | 582 | |||
| Letter | en | Should RT-PCR be considered a gold standard in the diagnosis of COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32383182 | 2020-05-10 02:00:00+02:00 | pubmed | Moustapha Dramé;Maturin Tabue Teguo;Emeline Proye;Fanny Hequet;Maxime Hentzien;Lukshe Kanagaratnam;Lidvine Godaert | COVID-19;RT-PCR;diagnosis;gold standard;serology | 2020-05-08 02:00:00+02:00 | 32383182 | FR;MQ;GP | Department of Clinical Research and Innovation, University Hospital of Martinique, Fort-de-France, Martinique, France.;Department of Geriatrics, University Hospital of Guadeloupe, Pointe-à-Pitre, Guadeloupe.;Department of Geriatrics, General Hospital of Valenciennes, Valenciennes, France.;Department of Infectious Diseases, University Hospital of Reims, Reims, France.;Department of Clinical Research and Public Health, University Hospital of Reims, Reims, France. | 585 | |||||||
| Letter | en | Rapid worsening in Parkinson's disease may hide COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32414669 | 2020-05-10 02:00:00+02:00 | pubmed | Elodie Hainque;David Grabli | COVID-19;Parkinson's disease;Prognosis | 2020-05-08 02:00:00+02:00 | 32414669 | FR | Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Institut du Cerveau et de la Moëlle épinière, F-75013, Paris, France. Electronic address: elodie.hainque@aphp.fr.;Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Institut du Cerveau et de la Moëlle épinière, F-75013, Paris, France. Electronic address: david.grabli@aphp.fr. | 593 | |||||||
| 10.3389/fped.2020.00259 | Systematic Review | en | Management of COVID-19-Positive Pediatric Patients Undergoing Minimally Invasive Surgical Procedures: Systematic Review and Recommendations of the Board of European Society of Pediatric Endoscopic Surgeons. | https://www.ncbi.nlm.nih.gov/pubmed/32550670 | Introduction: Hospital response to the COVID-19 outbreak has involved the cancellation of elective, deferrable surgeries throughout Europe in order to ensure capacity for emergent surgery and a selection of elective but non-deferrable surgeries. The purpose of this document is to propose technical strategies to assist the pediatric surgeons to minimize the potential aerosolization of viral particles in COVID-19 patients undergoing urgent or emergent surgical treatment using laparoscopic approaches, based on the currently available literature. The situation and recommendations are subject to change with emerging information. Materials and Methods: The Scientific Committee and the Board of the European Society of Pediatric Endoscopic Surgeons gathered together in order to address the issue of minimally invasive surgery during this COVID-19 pandemic. A systematic search through PubMed, Embase, and World Wide Web of the terms "COVID-19," "Coronavirus," and "SARS-CoV-2" matched with "pneumoperitoneum," "laparoscopy," "thoracoscopy," "retroperitoneoscopy," and "surgery" was performed. Non-English language papers were excluded. A PRISMA report was performed. Criticalities were identified and a consensus was achieved over a number of key aspects. Results: We identified 121 documents. A total of 11 full-text documents were assessed to address all concerns related to the adoption of minimally invasive surgery. All aspect of pediatric minimally invasive surgery, including elective surgery, urgent surgery, laparoscopy, thoracoscopy, retroperitoneoscopy, and pneumoperitoneum creation and maintainance were extensively addressed through systematic review. A consensus regarding urgent laparoscopic procedures, setting and operation techniques was obtained within the Committee and the Board. Conclusions: The ESPES proposes the following recommendations in case minimally invasive surgery is needed in a COVID-19 positive pediatric patients: (1) consider conservative treatment whenever safely possible, (2) dedicate a theater, columns and reusable laparoscopic instrumentation to COVID-19 pediatric patients, (3) prefer disposable instrumentation and cables, (4) use low CO2 insufflation pressures, (5) use low power electrocautery, (6) prefer closed-systems CO2 insufflation and desufflation systems, and (7) avoid leaks through ports. These recommendations are subject to change with emerging information and might be amended in the near future. | 2296-2360 | 2020-05-10 02:00:00+02:00 | pubmed | Frontiers in Pediatrics | Alessio Pini Prato;Andrea Conforti;Markus Almstrom;Wim Van Gemert;Maria G Scuderi;Naziha Khen-Dunlop;Isabela Draghici;Mario Mendoza-Sagaon;Carlos Giné Prades;Fabio Chiarenza;Henri Steyaert | COVID 19;minimally invasive surgeries (MIS);outbreak;pediatrics;pneumoperitoneum;safety | 2020-05-07 02:00:00+02:00 | 32550670 | FR;SE;RO;CH;IT;NL;ES;BE;PS | The Children Hospital, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.;Department of Medical and Surgical Neonatology, Ospedale Pediatrico Bambino Gesù, Rome, Italy.;Department of Pediatric Surgery, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.;Department of Pediatric Surgery, University Medical Center Maastricht, Maastricht, Netherlands.;Unit of Pediatric Surgery, Department GF Ingrassia, Hospital Policlinico, University of Catania, Catania, Italy.;University Hospital Necker-Enfants Malades, Paris, France.;Department of Pediatric Surgery, Maria Sklodowska Curie Hospital for Children, Bucharest, Romania.;Department of Pediatric Surgery, Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland.;Digestive Pediatric Surgery, University Hospital Vall d'Hebron, Barcelona, Spain.;Division of Pediatric Surgery, San Bortolo Hospital, Vicenza, Italy.;Department of Pediatric Surgery, Queen Fabiola Children's Hospital, University of Brussels, Brussels, Belgium. | 598 | |||
| 10.1016/j.jinf.2020.04.033 | Journal Article | en | Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays. | https://www.ncbi.nlm.nih.gov/pubmed/32389784 | In order to fight the SARS-CoV-2 pandemic infection, there is a growing need and demand for diagnostic tools that are complementary and different from the RT-PCR currently in use. Multiple serological tests are or will be very soon available but need to be evaluated and validated. We have thus tested 4 immunochromatographic tests for the detection of antibodies to SARS-CoV-2. In addition, we assessed the kinetics of antibody appearance using these assays in 22 patients after they were tested positive by RT-PCR. We observed great heterogeneity in antibody detection post-symptom onset. The median antibody detection time was between 8 and 10 days according to the manufacturers. All the tests showed a sensitivity of 60 to 80% on day 10 and 100% on day 15. In addition, a single cross-reaction was observed with other human coronavirus infections. Thus, immunochromatographic tests for the detection of anti-SARS-CoV-2 antibodies may have their place for the diagnostic panel of COVID-19. | 0163-4453 | 2020-05-10 02:00:00+02:00 | pubmed | Antibodies, Viral__analysis;Betacoronavirus__immunology;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Humans;Immunoassay__methods;Pandemics;Pneumonia, Viral__diagnosis;Real-Time Polymerase Chain Reaction;Sensitivity and Specificity;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Infection | Baptiste Demey;Nagib Daher;Catherine François;Jean-Philippe Lanoix;Gilles Duverlie;Sandrine Castelain;Etienne Brochot | Antibody;COVID-19;Lateral flow assay;SARS-CoV-2 | 2020-05-07 02:00:00+02:00 | 32389784 | FR | Department of Virology, Amiens University Medical Center, Amiens, France, AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France.;Department of Gynecology-Obstetrics, University Hospital, Amiens.;AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France, Infectious Diseases Department, University Hospital, Amiens.;Department of Virology, Amiens University Medical Center, Amiens, France, AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France. Electronic address: etienne.brochot@u-picardie.fr. | 610 | ||
| Letter;Comment | en | A hybrid approach to tracheostomy in COVID-19 patients ensuring staff safety. | https://www.ncbi.nlm.nih.gov/pubmed/32418207 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Tracheostomy;COVID-19;severe acute respiratory syndrome coronavirus 2 | L Tanaka;M Alexandru;S Jbyeh;C Desbrosses;Z Bouzit;G Cheisson;J F Papon;J Nevoux | 2020-05-17 02:00:00+02:00 | 32418207 | FR | Department of Otolaryngology - Head and Neck Surgery, Centre Hospitalier Universitaire de Bicêtre, Assistance Publique-Hôpitaux de Paris, Paris, France.;Faculty of Medicine, University of Paris-Saclay, Paris, France.;Inserm, Pasteur Institute, Paris, France. | 628 | |||||||
| Letter | en | Tackling the threat of COVID-19 in Africa: an urgent need for practical planning. | https://www.ncbi.nlm.nih.gov/pubmed/32398210 | 2020-05-17 02:00:00+02:00 | pubmed | Africa;Betacoronavirus;Coronavirus Infections;Health Planning;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | C-Y Chiang;A El Sony | 2020-05-14 02:00:00+02:00 | 32398210 | FR;SD;TW | International Union Against Tuberculosis and Lung Disease, Paris, France, Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.;The Epidemiological Laboratory for Research and Public Health (WHO Collaborating Center), Khartoum, Sudan, Africa Representative for the Global Alliance Against Chronic Respiratory Diseases, <email></email>, Email: cychiang@theunion.org. | 629 | |||||||
| 10.1007/s12311-020-01139-1 | Journal Article;Practice Guideline;Review | en | Management of Patients with Cerebellar Ataxia During the COVID-19 Pandemic: Current Concerns and Future Implications. | https://www.ncbi.nlm.nih.gov/pubmed/32405955 | The current worldwide severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that causes coronavirus disease 2019 (COVID-19) has brought some medical systems to the brink of collapse. This crisis is also negatively impacting the care of patients with non-COVID-19 conditions, including those with cerebellar ataxia (CA). Older patients with CA and those with immune-mediated ataxias on immunosuppressive medication are potentially at high risk of developing serious complications of the infection, although it is also possible that immunosuppressive agents may provide a defense against cytokine storm. This has implications for even greater attention to preventing contracting the disease through physical distancing and/or isolation. The CA patient population is also at higher risk because of the neurological complexities of their underlying disorder and the comorbid medical illnesses that often accompany the genetic ataxias. As the disruption of social patterns and healthcare delivery in response to the crisis continues, interruption of rehabilitation, speech and language therapy, and face-to-face consultations threatens to have a negative impact on the course and well-being of CA patients. Mental and physical health is also potentially at greater risk because the prevailing uncertainty and anxiety may be superimposed upon cerebellum-specific neuropsychological challenges. We identify and review some of the short- and long-term consequences of this global pandemic for the community of ataxia patients and their families and for the clinical and academic neurologists/ataxiologists caring for these patients. This includes the recognition that telemedicine has emerged as a principle means of caregiver-patient contact and that neurological manifestations of COVID-19 including those specific to cerebellar neurobiology are increasingly recognized and will require close surveillance and monitoring. This COVID-19 Cerebellum Task Force consensus provides some guidance on how we may approach this uncertain time and consider preparing for the new realities we face in CA patient care once this acute crisis has passed. | 1473-4222,1473-4230 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Cerebellar Ataxia__epidemiology;Comorbidity;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Cerebellum | Mario Manto;Nicolas Dupre;Marios Hadjivassiliou;Elan D Louis;Hiroshi Mitoma;Marco Molinari;Aasef G Shaikh;Bing-Wen Soong;Michael Strupp;Frank Van Overwalle;Jeremy D Schmahmann | COVID-19;Cerebellar ataxia;Cerebellum;SARS-CoV-2 | 2020-05-15 02:00:00+02:00 | 32405955 | FR;CA;JP;GB;US;TW;IT;BE;DE | Unité des Ataxies Cérébelleuses, Service de Neurologie, CHU-Charleroi, 6000, Charleroi, Belgium. mmanto@ulb.ac.be.;CHU-Charleroi and Service des Neurosciences, University of Mons, 7000, Mons, Belgium. mmanto@ulb.ac.be.;Department of Medicine, Faculty of Medicine, Université Laval & Neuroscience Axis, CHU de Québec-Université Laval, Quebec City, QC, Canada.;Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.;Department of Neurology and Neurotherapeutics, University of Texas Southwestern, Dallas, TX, USA.;Department of Medical Education, Tokyo Medical University, Tokyo, Japan.;IRCCS Fondazione S. Lucia, Rome, Italy.;Department of Neurology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland VA Medical Center, Cleveland, OH, USA.;Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan.;Department of Neurology, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.;Department of Neurology, Taipei Veterans General Hospital, and Brain Research Center, National Yang-Ming University, Taipei, Taiwan.;Department of Neurology, Ludwig Maximilians University, Munich, Germany.;Brain, Body and Cognition Lab, Faculty of Psychology, Vrije Universiteit Brussel, Brussels, Belgium.;Ataxia Center, Cognitive Behavioral Neurology Unit, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. | 632 | ||
| 10.1016/j.neuchi.2020.05.001 | Editorial | en | How SARS-CoV-2 is forcing us to reconsider and reorganize our daily neurosurgical practice. | https://www.ncbi.nlm.nih.gov/pubmed/32405094 | 0028-3770 | 2020-05-17 02:00:00+02:00 | pubmed | Neurochirurgie | S Chibbaro;M Ganau;J Todeschi;F Proust;H Cebula | 2020-05-13 02:00:00+02:00 | 32405094 | FR | Department of Neurosurgery, Strasbourg University Hospital, 1, avenue Molière, 67098 Strasbourg, France. Electronic address: salvatore.chibbaro@chru-strasbourg.fr.;Department of Neurosurgery, Strasbourg University Hospital, 1, avenue Molière, 67098 Strasbourg, France. | 644 | |||||
| Howard Hughes Medical Institute | 10.1016/j.cell.2020.05.016 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't | en | A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32405102 | SARS-CoV-2 infection displays immense inter-individual clinical variability, ranging from silent infection to lethal disease. The role of human genetics in determining clinical response to the virus remains unclear. Studies of outliers-individuals remaining uninfected despite viral exposure and healthy young patients with life-threatening disease-present a unique opportunity to reveal human genetic determinants of infection and disease. | 0092-8674 | 2020-05-17 02:00:00+02:00 | pubmed | Age Factors;Betacoronavirus__physiology;Coronavirus Infections__epidemiology;Disease Resistance;Genetic Association Studies;Genetic Diseases, Inborn__immunology;Genetic Predisposition to Disease;Genetic Variation;Genome, Human;Host-Pathogen Interactions;Humans;Infections__genetics;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cell | Jean-Laurent Casanova;Helen C Su | 2020-05-13 02:00:00+02:00 | 32405102 | FR;US | [{"country": "United States", "agency": "Howard Hughes Medical Institute"}] | St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller Unversity, New York, NY, USA, Howard Hughes Medical Institute, New York, NY, USA, Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France, University of Paris, Imagine Institute, Paris, France, Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, AP-HP, Paris, France. Electronic address: casanova@rockefeller.edu.;Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. | 645 | |
| 10.1016/j.cca.2020.05.019 | Journal Article | en | Decreased T cell populations contribute to the increased severity of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32405080 | We observe changes of the main lymphocyte subsets (CD16+CD56、CD19、CD3、CD4、and CD8) in COVID-19-infected patients and explore whether the changes are associated with disease severity. | 0009-8981 | 2020-05-17 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Betacoronavirus__pathogenicity;Biomarkers__analysis;CD3 Complex__genetics;CD4 Antigens__genetics;CD8 Antigens__genetics;Cardiovascular Diseases__diagnosis;Cohort Studies;Comorbidity;Coronavirus Infections__diagnosis;Diabetes Mellitus__diagnosis;Female;Gene Expression;Humans;Immunophenotyping;Lung Diseases__diagnosis;Male;Middle Aged;Pandemics;Patient Selection;Pneumonia, Viral__diagnosis;Prognosis;Severity of Illness Index;Survival Analysis;T-Lymphocyte Subsets__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinica Chimica Acta | Rui Liu;Ying Wang;Jie Li;Huan Han;Zunen Xia;Fang Liu;Kailang Wu;Lan Yang;Xinghui Liu;Chengliang Zhu | CD3(+) T cells;CD4(+) T cells;CD8(+) T cells;COVID-19;Lymphocyte subsets | 2020-05-13 02:00:00+02:00 | 32405080 | FR;CN | Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, PR China.;Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, Secondary Military Medical University, Shanghai 200135, PR China.;Postgraduate training base in Shanghai Gongli Hospital, Ningxia medical university, Pudong New Area, Shanghai200135, PR China.;State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, PR China, Wuhan Institute of Biotechnology, Wuhan, Hubei 430075, PR China.;State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, PR China.;Department of Clinical Laboratory, Shanghai Gongli Hospital, the Second Military Medical University, Pudong New Area, Shanghai200135, PR China.;Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, PR China. Electronic address: xinchengzhu@163.com. | 650 | ||
| 10.1016/j.amjmed.2020.03.057 | Case Reports | en | SARS-CoV-2 Induces Acute and Refractory Relapse of Systemic Capillary Leak Syndrome (Clarkson's Disease). | https://www.ncbi.nlm.nih.gov/pubmed/32405072 | 0002-9343 | 2020-05-17 02:00:00+02:00 | pubmed | The American Journal of Medicine | Marc Pineton de Chambrun;Fleur Cohen-Aubart;Dirk W Donker;Pierre-Louis Cariou;Charles-Edouard Luyt;Alain Combes;Zahir Amoura | 2020-05-13 02:00:00+02:00 | 32405072 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Service de Médecine Intensive-Réanimation, Hôpital La Pitié-Salpêtrière, Paris, France, Sorbonne Université, APHP, Institut E3M, Service de Médecine Interne 2, Centre de Référence National Lupus Systémique et SAPL et Autres Maladies Auto-immunes et Systémiques Rares, Hôpital de la Pitié-Salpêtrière, Paris, France, Sorbonne Universite, INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, (ICAN) Paris, France. Electronic address: marc.dechambrun@gmail.com.;Sorbonne Université, APHP, Institut E3M, Service de Médecine Interne 2, Centre de Référence National Lupus Systémique et SAPL et Autres Maladies Auto-immunes et Systémiques Rares, Hôpital de la Pitié-Salpêtrière, Paris, France.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Service de Médecine Intensive-Réanimation, Hôpital La Pitié-Salpêtrière, Paris, France.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Service de Médecine Intensive-Réanimation, Hôpital La Pitié-Salpêtrière, Paris, France, Sorbonne Universite, INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, (ICAN) Paris, France. | 659 | |||||
| 10.3389/fpubh.2020.00185 | Journal Article | en | Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy? | https://www.ncbi.nlm.nih.gov/pubmed/32574289 | 2296-2565 | 2020-05-17 02:00:00+02:00 | pubmed | Frontiers in Public Health | Aurélien Mary;Lucie Hénaut;Jean-Luc Schmit;Jean-Philippe Lanoix;Michel Brazier | COVID-19;SARS-CoV-2;azithromycin;hydroxychloroquine;type I interferon | 2020-05-15 02:00:00+02:00 | 32574289 | FR | Clinical Critical Care Pharmacy Department, Amiens-Picardie University Hospital, Amiens, France.;UR UPJV 7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France.;Infectious Diseases Department, Amiens-Picardie University Hospital, Amiens, France.;AGIR UR UPJV 4294, CURS, University of Picardie Jules Verne, Amiens, France.;Department of Biochemistry, Amiens-Picardie University Hospital, Amiens, France. | 669 | ||||
| Letter | en | AMD Management During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32410325 | 2020-05-17 02:00:00+02:00 | pubmed | Donato Colantuono;Alexandra Miere;Oudy Semoun;Francesca Amoroso;Eric H Souied | 2020-05-15 02:00:00+02:00 | 32410325 | FR | Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France.;Laboratory of Images, Signals and Intelligent Systems (LISSI, EA N ° 3956), University Paris-Est Créteil, Créteil, France. | 674 | ||||||||
| 10.1016/j.maturitas.2020.05.009 | Journal Article;Review | en | Are we equal in adversity? Does Covid-19 affect women and men differently? | https://www.ncbi.nlm.nih.gov/pubmed/32425315 | This article examines whether women are less prone than men to Covid-19 infections and their complications. | 0378-5122 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Comorbidity;Coronavirus Infections__diagnosis;Databases, Factual;Female;Humans;Intensive Care Units;Male;Pandemics;Pneumonia, Viral__diagnosis;Public Health;Public Health Informatics;Sex Factors;Viral Vaccines;COVID-19;severe acute respiratory syndrome coronavirus 2 | Maturitas | Serge Rozenberg;Jean Vandromme;Charlotte Martin | Complications;Covid-19;Fatality rate;Gender difference;Sex difference | 2020-05-15 02:00:00+02:00 | 32425315 | FR;BE | Department of Gynaecology-Obstetrics, CHU St Pierre, Université Libre de Bruxelles, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: serge_rozenberg@stpierre-bru.be.;Department of Gynaecology-Obstetrics, CHU St Pierre, Université Libre de Bruxelles, Vrije Universiteit Brussel, Brussels, Belgium.;Department of Infectious diseases, CHU St Pierre. Université Libre de Bruxelles, Brussels, Belgium. | 676 | ||
| 10.1136/bmj.m1844 | Journal Article;Observational Study | en | Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. | https://www.ncbi.nlm.nih.gov/pubmed/32409486 | To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. | 1756-1833 | 2020-05-17 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Antiviral Agents__therapeutic use;Coronavirus Infections__drug therapy;Female;Humans;Hydroxychloroquine__therapeutic use;Male;Middle Aged;Oxygen Inhalation Therapy;Pandemics;Pneumonia, Viral__drug therapy;Young Adult;COVID-19 | BMJ | Matthieu Mahévas;Viet-Thi Tran;Mathilde Roumier;Amélie Chabrol;Romain Paule;Constance Guillaud;Elena Fois;Raphael Lepeule;Tali-Anne Szwebel;François-Xavier Lescure;Frédéric Schlemmer;Marie Matignon;Mehdi Khellaf;Etienne Crickx;Benjamin Terrier;Caroline Morbieu;Paul Legendre;Julien Dang;Yoland Schoindre;Jean-Michel Pawlotsky;Marc Michel;Elodie Perrodeau;Nicolas Carlier;Nicolas Roche;Victoire de Lastours;Clément Ourghanlian;Solen Kerneis;Philippe Ménager;Luc Mouthon;Etienne Audureau;Philippe Ravaud;Bertrand Godeau;Sébastien Gallien;Nathalie Costedoat-Chalumeau | 2020-05-14 02:00:00+02:00 | 32409486 | FR | Department of Internal Medicine, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France matthieu.mahevas@gmail.com.;Centre for Clinical Epidemiology, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Centre of Research in Epidemiology and Statistics, Paris, France.;Department of Internal Medicine, Foch Hospital, Suresnes, France.;Department of Infectious Diseases, Sud Francilien Hospital, Corbeil-Essonnes, France.;Department of Internal Medicine, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France.;Transversal Infections Treatment Unit, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.;Department of Internal Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France.;Department of Infectious Diseases, Hôpital Bichat Hospital, Paris, France.;Pulmonology Unit, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.;Department of Nephrology, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.;Department of Virology, Bacteriology-Hygiene, and Mycology-Parasitology Centre, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Pulmonology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France.;Department of Internal Medicine, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France.;Pharmacy, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.;Mobile Infectious Disease Team, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France.;Pulmonology Unit, Sud Francilien Hospital, Corbeil-Essonnes, France.;Clinical Epidemiology and Aging Team, Mondor Institute for Biomedical Research (INSERM U955), Public Health Services, Henri-Mondor Hosptial, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.;Department of Infectious Diseases, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Pari, Paris-Est Créteil University, Créteil, France. | 681 | |||
| 10.1016/j.bbrc.2020.05.028 | Journal Article;Research Support, Non-U.S. Gov't | en | Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism. | https://www.ncbi.nlm.nih.gov/pubmed/32410735 | The spread of COVID-19 caused by the SARS-CoV-2 outbreak has been growing since its first identification in December 2019. The publishing of the first SARS-CoV-2 genome made a valuable source of data to study the details about its phylogeny, evolution, and interaction with the host. Protein-protein binding assays have confirmed that Angiotensin-converting enzyme 2 (ACE2) is more likely to be the cell receptor through which the virus invades the host cell. In the present work, we provide an insight into the interaction of the viral spike Receptor Binding Domain (RBD) from different coronavirus isolates with host ACE2 protein. By calculating the binding energy score between RBD and ACE2, we highlighted the putative jump in the affinity from a progenitor form of SARS-CoV-2 to the current virus responsible for COVID-19 outbreak. Our result was consistent with previously reported phylogenetic analysis and corroborates the opinion that the interface segment of the spike protein RBD might be acquired by SARS-CoV-2 via a complex evolutionary process rather than a progressive accumulation of mutations. We also highlighted the relevance of Q493 and P499 amino acid residues of SARS-CoV-2 RBD for binding to human ACE2 and maintaining the stability of the interface. Moreover, we show from the structural analysis that it is unlikely for the interface residues to be the result of genetic engineering. Finally, we studied the impact of eight different variants located at the interaction surface of ACE2, on the complex formation with SARS-CoV-2 RBD. We found that none of them is likely to disrupt the interaction with the viral RBD of SARS-CoV-2. | 0006-291X | 2020-05-17 02:00:00+02:00 | pubmed | Amino Acid Sequence;Betacoronavirus__chemistry;Binding Sites;Coronavirus Infections;Humans;Molecular Docking Simulation;Pandemics;Peptidyl-Dipeptidase A__chemistry;Phylogeny;Pneumonia, Viral;Protein Domains;Protein Structure, Tertiary;Spike Glycoprotein, Coronavirus__chemistry;COVID-19;severe acute respiratory syndrome coronavirus 2 | Biochemical and Biophysical Research Communications | Houcemeddine Othman;Zied Bouslama;Jean-Tristan Brandenburg;Jorge da Rocha;Yosr Hamdi;Kais Ghedira;Najet Srairi-Abid;Scott Hazelhurst | ACE2;COVID-19;Homology-based protein-protein docking;Variants;Viral spike receptor binding domain | 2020-05-14 02:00:00+02:00 | 32410735 | FR;AU;ZA;TN | Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: houcemoo@gmail.com.;Laboratory of Veterinary Epidemiology and Microbiology LR16IPT03, Institut Pasteur of Tunis. University of Tunis El Manar, Tunis, Tunisia.;Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.;Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis, Tunisia.;Laboratory of Bioinformatics, Biomathematics and Biostatistics, LR16IPT09, Pasteur Institute of Tunis, University Tunis El Manar, Tunis, Tunisia.;Université de Tunis El Manar, Institut Pasteur de Tunis, LR11IPT08 Venins et Biomolécules Thérapeutiques, 1002, Tunis, Tunisia.;Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, School of Electrical and Information Engineering, University of the Witwatersrand, Johannesburg, South Africa. | 685 | ||
| 10.1016/j.anorl.2020.05.001 | Practice Guideline | en | Treatment of sleep apnea by ENT specialists during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32417164 | The treatment of sleep disorders has been strongly impacted by the COVID-19 pandemic. When the lockdown is over, resumption of usual patient care will require precautions to limit the risk of contamination for patients and caregivers. In this document, the French Association of Otorhinolaryngology and Sleep disorders (AFSORL) and the French Society of Otorhinolaryngology (SFORL) put forward a summary of the measures for continuing the treatment of sleep apnoea syndrome in these new practice conditions. Emphasis is placed on teleconsultation, methods of nocturnal sleep studies, the conditions for treatment by continuous positive airway pressure (CPAP) ventilation, and the postponement of more invasive treatments. | 1879-7296 | 2020-05-17 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | P-L Bastier;N Aisenberg;F Durand;P Lestang;D Abedipour;O Gallet de Santerre;V Couloigner;E Bequignon | COVID-19;CPAP (Continuous Positive Airway Pressure);Coronavirus;Hygiene;Mandibular advancement device (MAD);OSAS (Obstructive Sleep Apnea Syndrome);Organisation of treatment;Otorhinolaryngology;Polygraph;SARS-CoV-2;Sleep apnoea;Sleep disorders;Sleep endoscopy | 2020-05-11 02:00:00+02:00 | 32417164 | FR | Department of ENT and Maxillofacial Surgery, Maison de Santé Protestante de Bordeaux-Bagatelle, Talence, France.;Medical practice, Les Pavillons-sous-bois, France, Department of Sleep Medicine, Hôpital Hôtel-Dieu, Assistance publique - Hôpitaux de Paris, Paris, France.;Medical practice, Levallois Perret, France.;Medical practice, La Rochelle, France.;Charcot Clinic, Sainte-Foy-les-Lyon, France, Department of ENT, Head and Neck Surgery, E. Herriot University Hospital, Lyon, France.;Beau Soleil Clinic, Montpellier, France.;Paediatric ENT Department, Necker - Enfants Malades University Hospital, Assistance publique-Hôpitaux de Paris, Paris, France.;Department of ENT, Head and Neck Surgery, Créteil Intercommunal Hospital and Henri Mondor University Hospital, Assistance publique - Hôpitaux de Paris, Créteil, France. Electronic address: emilie.bequignon@gmail.com. | 689 | |||
| Letter;Comment | en | Lupus anticoagulant is frequent in patients with Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32324958 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Humans;Lupus Coagulation Inhibitor;Pandemics;Pneumonia;Pneumonia, Viral;Prognosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Inès Harzallah;Agathe Debliquis;Bernard Drénou | 2020-05-11 02:00:00+02:00 | 32324958 | FR | Laboratoire d'Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse, France.;Département d'Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse, France. | 690 | |||||||
| Letter | en | Chilblains and COVID19 infection: Causality or coincidence? How to proceed? | https://www.ncbi.nlm.nih.gov/pubmed/32571563 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Chilblains__diagnosis;Coronavirus Infections__diagnosis;France__epidemiology;Humans;Pandemics;Pneumonia, Viral__diagnosis;Prognosis;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | M A Pistorius;S Blaise;C Le Hello;S Barbarot;B Dréno | COVID19;Chilblains | 2020-05-11 02:00:00+02:00 | 32571563 | FR | Department of Vascular Medicine, Nantes University Hospital, 44000 Nantes, France. Electronic address: marc.pistorius@chu-nantes.fr.;Department of Vascular Medicine, Grenoble University Hospital, University Grenoble Alpes, 38000 Grenoble, France.;Department of Therapeutic and Vascular Medicine, Saint-Etienne University Hospital, inserm, U1059 Sainbiose, University de Lyon, Saint-Etienne, 42000 Saint-Etienne, France.;Department of Dermatology, Nantes University Hospital, 44000 Nantes, France. | 700 | ||||||
| 10.1016/j.gofs.2020.05.004 | Journal Article | fr | [Gynecologic surgery in the era of COVID-19 - Recommendations for deconfinement]. | https://www.ncbi.nlm.nih.gov/pubmed/32430141 | 2468-7189 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnosis;Female;Gynecologic Surgical Procedures;Humans;Laparoscopy__adverse effects;Laparotomy__adverse effects;Operating Rooms__organization & administration;Pandemics__prevention & control;Personal Protective Equipment__standards;Pneumonia, Viral__diagnosis;Practice Guidelines as Topic;Remote Consultation;Ventilation__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gynécologie Obstétrique Fertilité & Sénologie | M Canis;P Descamps;G Dubernard;J-P Estrade;P Mourtialon;H Fernandez | COVID;Chirurgie gynécologique;Deconfinement;Déconfinement;Gynecologic surgery | 2020-05-11 02:00:00+02:00 | 32430141 | FR | Département gynécologie obstétrique, CHU d'Estaing, 63000 Clermont-Ferrand, France.;Département gynécologie obstétrique, CHU d'Angers, 49100 Angers, France.;Département gynécologie obstétrique, CHU de la Croix Rousse, 69000 Lyon, France.;Département gynécologie obstétrique, clinique Bouchard Groupe Elsan, 13006 Marseille, France.;Provence gynécologie, maison médicale de Provence, 13100 Aix-en-Provence, France.;Service gynécologie obstétrique, GHU-Sud, CHU de Bicêtre, AP-HP, 78, rue du Général Leclerc, 94270 Le-Kremlin-Bicêtre, France. Electronic address: herve.fernandez@aphp.fr. | 702 | |||
| 10.1093/cid/ciaa558 | Journal Article | en | Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics. | https://www.ncbi.nlm.nih.gov/pubmed/32392332 | Different dosage regimens of hydroxychloroquine are used to manage COVID-19 patients, without information on the pharmacokinetics in this population.Blood samples (n=101) were collected from 57 COVID-19 patients for 7 days and concentrations were compared with simulated kinetic profiles.Hydroxychloroquine exposure is low and cannot be predicted by other populations. | 1058-4838,1537-6591 | 2020-05-17 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | G Martin-Blondel;S Ruiz;M Murris;S Faguer;V Duhalde;F Eyvrard;J Izopet;J M Mansuy;Y Rolland;K Delavigne;R Guimbaud;G Pugnet;J M Conil;B Georges;P Delobel;V Minville;S Silva Sifontes;D Concordet;P Gandia | COVID-19;dosage regimens;drug monitoring;hydroxychloroquine;population pharmacokinetic modelling | 2020-05-11 02:00:00+02:00 | 32392332 | FR | CHU de Toulouse, Service des Maladies Infectieuses, avenue de Grande-Bretagne, Toulouse cedex , France.;CHU de Toulouse, Pôle d'Anesthésie-Réanimation, 1 avenue du Professeur Jean Poulhès - TSA Toulouse cedex 9, France.;CRCM, CHU Toulouse, Hôpital Larrey, Service de Pneumologie, 20 chemin de Pourvourville, TSA Toulouse Cedex 9, France.;CHU de Toulouse, Pôle de Néphrologie et Transplantation d'Organes, 1 avenue du Professeur Jean Poulhès - TSA Toulouse cedex 9.;CHU de Toulouse, Pôle Pharmacie, 1 avenue du Professeur Jean Poulhès - TSA Toulouse cedex 9, France.;CHU de Toulouse, Laboratoire de Virologie, Institut Fédératif de Biologie, avenue de Grande-Bretagne, Toulouse cedex 9, France.;CHU de Toulouse, Pôle de Gériatrie, avenue de Grande-Bretagne, Toulouse cedex 9, France.;IUCT-Oncopole, Service d'Hématologie, avenue Irene Joliot-Curie -Toulouse Cedex 9, France.;CHU de Toulouse, Pôle des Maladies de l'Appareil Digestif, 1 avenue du Professeur Jean Poulhès - TSA Toulouse cedex 9, France.;CHU de Toulouse, Service de Médecine Interne, avenue de Grande-Bretagne, Toulouse cedex 9, France.;CHU de Toulouse, Pôle d'Anesthésie-Réanimation, 330 avenue de Grande-Bretagne, Toulouse cedex 9, France.;INTHERES, Université de Toulouse, INRA, ENVT, 23 Chemin des Capelles, BP, Toulouse Cedex 3, France.;CHU de Toulouse, Laboratoire de Pharmacocinétique et Toxicologie Clinique, Institut Fédératif de Biologie, avenue de Grande-Bretagne, Toulouse cedex 9, France. | 708 | |||
| Letter | en | "MoRPHEE" fighting COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32423608 | 2020-05-17 02:00:00+02:00 | pubmed | Aircraft;Betacoronavirus;Coronavirus Infections__complications;Emergency Medical Dispatch;Emergency Medical Service Communication Systems__organization & administration;France__epidemiology;Humans;Intensive Care Units__organization & administration;Military Health Services__statistics & numerical data;Mobile Health Units__organization & administration;Pandemics;Patient Care Team;Pneumonia, Viral__complications;Respiratory Distress Syndrome, Adult__etiology;Respiratory Therapy__methods;Time Factors;Transportation of Patients__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Mathieu Boutonnet;Jean Turc;Henri-Louis Dupre;Raphaël Paris;Violaine Muller | 2020-05-11 02:00:00+02:00 | 32423608 | FR | Military Teaching Hospital Percy, Intensive Care Unit Anaesthesiology Department, Clamart, France. Electronic address: mathieuboutonnet@hotmail.com.;Military Teaching Hospital Desgenettes, Intensive Care Unit Anaesthesiology Department, Lyon, France.;Military Teaching Hospital Saint-Anne, Intensive Care Unit Anaesthesiology Department, Toulon, France.;Military Teaching Hospital Laveran, Intensive Care Unit Anaesthesiology Department, Marseille, France.;Military Teaching Hospital Percy, Intensive Care Unit Anaesthesiology Department, Clamart, France. | 711 | |||||||
| This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. | 10.1002/ajh.25833 | Case Reports;Journal Article | en | Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. | https://www.ncbi.nlm.nih.gov/pubmed/32282956 | 0361-8609,1096-8652 | 2020-05-17 02:00:00+02:00 | pubmed | Acute Chest Syndrome__diagnostic imaging;Anemia, Sickle Cell__complications;Antibodies, Monoclonal, Humanized__therapeutic use;Betacoronavirus;Combined Modality Therapy;Coronavirus Infections__complications;Drug Therapy, Combination;Humans;Hydroxychloroquine__therapeutic use;Male;Middle Aged;Oxygen Inhalation Therapy;Pandemics;Pneumonia, Viral__complications;Tomography, X-Ray Computed;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | American Journal of Hematology | Gonzalo De Luna;Anoosha Habibi;Jean-François Deux;Martin Colard;Anne-Laure Pham Hung d'Alexandry d'Orengiani;Frédéric Schlemmer;Nizar Joher;Christian Kassasseya;Jean Michel Pawlotsky;Clément Ourghanlian;Marc Michel;Armand Mekontso-Dessap;Pablo Bartolucci | 2020-05-12 02:00:00+02:00 | 32282956 | FR | [{"country": "International", "agency": "This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors."}] | Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital- UPEC, AP-HP, Créteil, France.;Department of Radiology, Henri Mondor Hospital/AP-HP, Créteil, France.;MCGRE, APHP, CHU Henri Mondor, Créteil, France.;Service de Pneumologie, DHU A-TVB, APHP, CHU Henri Mondor, Créteil, France.;Nephrology and Renal Transplantation Department, Institut Francilien de Recherche en Néphrologie et Transplantation (IFRNT), Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Créteil, France.;Emergency Department, APHP, CHU Henri Mondor, Créteil, France.;National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.;AP-HP, Hôpital Henri Mondor, Créteil, France.;Department of Internal Medicine, National Referral Center for Adult Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Paris, France.;Department of Intensive Care, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Paris, France. | 723 | ||
| Letter | en | Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France. | https://www.ncbi.nlm.nih.gov/pubmed/32425250 | 2020-05-17 02:00:00+02:00 | pubmed | François Montastruc;Charles Romano;Jean-Louis Montastruc;Stein Silva;Thierry Seguin;Vincent Minville;Bernard Georges;Béatrice Riu-Poulenc;Olivier Fourcade | Angiotensin II receptor blockers;Angiotensin converting enzyme inhibitors;COVID-19;Drugs;Non-steroidal anti-inflammatory drugs;Renin-angiotensin-aldosterone system | 2020-05-15 02:00:00+02:00 | 32425250 | FR | Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, 31000 Toulouse, France, Inserm, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul-Sabatier, 31000 Toulouse, France. Electronic address: francois.montastruc@univ-tlse3.fr.;Anestesia and Critical Care Medicine Department, Intensive Care Unit, Toulouse University Hospital, 31000 Toulouse, France.;Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, 31000 Toulouse, France, Inserm, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul-Sabatier, 31000 Toulouse, France. | 737 | |||||||
| NIA NIH HHS | 10.1016/s0140-6736(20)31104-1 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't;Research Support, U.S. Gov't, Non-P.H.S. | en | Voluntary collective isolation as a best response to COVID-19 for indigenous populations? A case study and protocol from the Bolivian Amazon. | https://www.ncbi.nlm.nih.gov/pubmed/32422124 | Indigenous communities worldwide share common features that make them especially vulnerable to the complications of and mortality from COVID-19. They also possess resilient attributes that can be leveraged to promote prevention efforts. How can indigenous communities best mitigate potential devastating effects of COVID-19? In Bolivia, where nearly half of all citizens claim indigenous origins, no specific guidelines have been outlined for indigenous communities inhabiting native communal territories. In this Public Health article, we describe collaborative efforts, as anthropologists, physicians, tribal leaders, and local officials, to develop and implement a multiphase COVID-19 prevention and containment plan focused on voluntary collective isolation and contact-tracing among Tsimane forager-horticulturalists in the Bolivian Amazon. Phase 1 involves education, outreach, and preparation, and phase 2 focuses on containment, patient management, and quarantine. Features of this plan might be exported and adapted to local circumstances elsewhere to prevent widespread mortality in indigenous communities. | 0140-6736 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Bolivia;Communicable Disease Control__methods;Contact Tracing;Coronavirus Infections__prevention & control;Humans;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Population Groups;Social Isolation;Vulnerable Populations;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet | Hillard S Kaplan;Benjamin C Trumble;Jonathan Stieglitz;Roberta Mendez Mamany;Maguin Gutierrez Cayuba;Leonardina Maito Moye;Sarah Alami;Thomas Kraft;Raul Quispe Gutierrez;Juan Copajira Adrian;Randall C Thompson;Gregory S Thomas;David E Michalik;Daniel Eid Rodriguez;Michael D Gurven | 2020-05-15 02:00:00+02:00 | 32422124 | FR;BO;US | [{"country": "United States", "agency": "NIA NIH HHS", "grantid": "RF1 AG054442"}] | Economic Science Institute, Chapman University, Orange, CA, USA, Tsimane Health and Life History Project, San Borja, Bolivia. Electronic address: hkaplan@chapman.edu.;Tsimane Health and Life History Project, San Borja, Bolivia, School of Human Evolution and Social Change, Center for Evolution and Medicine, Arizona State University, Tempe, AZ, USA.;Tsimane Health and Life History Project, San Borja, Bolivia, Institute for Advanced Study in Toulouse, Toulouse, France.;Economic Science Institute, Chapman University, Orange, CA, USA, Tsimane Health and Life History Project, San Borja, Bolivia.;Gran Consejo Tsimane, San Borja, Bolivia.;Asemblea Legislativa Departamental, Trinidad, Bolivia.;Tsimane Health and Life History Project, San Borja, Bolivia, Department of Anthropology, University of California, Santa Barbara CA, USA.;Tsimane Health and Life History Project, San Borja, Bolivia.;Saint Luke's Mid America Heart Institute, Kansas City, MO, USA, University of Missouri-Kansas City, Kansas City, MO, USA.;MemorialCare, Southern California, USA, Division of Cardiology, University of California, Irvine, CA, USA.;Miller Children's and Women's Hospital Long Beach, CA, USA, Division of Pediatric Infectious Diseases, University of California, Irvine, CA, USA.;Tsimane Health and Life History Project, San Borja, Bolivia, Institute of Biomedical Research, Faculty of Medicine, San Simon University, Cochabamba, Bolivia.;Tsimane Health and Life History Project, San Borja, Bolivia, Department of Anthropology, University of California, Santa Barbara CA, USA. Electronic address: gurven@anth.ucsb.edu. | 741 | |
| 10.1001/jama.2020.8255 | Journal Article | en | Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure. | https://www.ncbi.nlm.nih.gov/pubmed/32412581 | 0098-7484 | 2020-05-17 02:00:00+02:00 | pubmed | JAMA | Xavier Elharrar;Youssef Trigui;Anne-Marie Dols;François Touchon;Stéphanie Martinez;Eloi Prud'homme;Laurent Papazian | 2020-05-15 02:00:00+02:00 | 32412581 | FR | Service des Maladies Respiratoires, Centre Hospitalier d'Aix-en-Provence, Aix-en-Provence, France.;Faculté de médecine, Université Grenoble Alpes, Grenoble, France.;Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Marseille, Marseille, France.;Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, Marseille, France. | 742 | |||||
| Letter;Comment | en | Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure. | https://www.ncbi.nlm.nih.gov/pubmed/32414417 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Humans;Pandemics;Plasma Exchange;Pneumonia, Viral;Shock, Septic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Patrick M Honore;Aude Mugisha;Luc Kugener;Sebastien Redant;Rachid Attou;Andrea Gallerani;David De Bels | 2020-05-15 02:00:00+02:00 | 32414417 | FR;BE | ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. Patrick.Honore@CHU-Brugmann.be.;ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. | 743 | |||||||
| NCATS NIH HHS | 10.1016/j.ccell.2020.05.008 | Journal Article;Research Support, N.I.H., Extramural | en | TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. | https://www.ncbi.nlm.nih.gov/pubmed/32425702 | Prior publications on small subsets of cancer patients infected with SARS CoV-2 have shown an increased risk of mortality compared to the general population. Furthermore, patients with thoracic malignancies are thought to be at particularly high risk given their older age, smoking habits, and pre-existing cardio-pulmonary comorbidities. For this reason, physicians around the world have formed TERAVOLT, a global consortium dedicated to understanding the impact of COVID-19 on patients with thoracic malignancies. | 1535-6108 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Global Burden of Disease;Humans;International Cooperation;Intersectoral Collaboration;Medical Oncology__organization & administration;Pandemics;Pneumonia, Viral__complications;Practice Guidelines as Topic;Registries;Thoracic Neoplasms__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cancer Cell | Jennifer G Whisenant;Annalisa Trama;Valter Torri;Alessandro De Toma;Giuseppe Viscardi;Alessio Cortellini;Olivier Michielin;Fabrice Barlesi;Anne-Marie C Dingemans;Jan Van Meerbeeck;Vera Pancaldi;Ross A Soo;Natasha B Leighl;Solange Peters;Heather Wakelee;Marina Chiara Garassino;Leora Horn | 2020-05-16 02:00:00+02:00 | 32425702 | FR;SG;CA;CH;US;GB;IT;NL;ES;BE | [{"country": "United States", "agency": "NCATS NIH HHS", "grantid": "UL1 TR000445"}] | Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.;Department of Research, Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Laboratory of Clinical Research, Methodology Oncology Department "Mario Negri" Institute of Pharmacological Researches, IRCCS, Milan, Italy.;Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Department of Biotechnology and Applied Clinical Science, University of L'Aquila, L'Aquila, Italy.;Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.;Gustave Roussy Cancer Center, Villejuif, France, Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.;Department of Pulmonology, Erasmus University Medical Center, Rotterdam, University Maastricht, Maastricht, the Netherlands.;Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital, Edegem, Belgium.;Univeristy Paul Sabatier, Toulouse, Inserm, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France, Barcelona Supercomputing Center, Barcelona.;National University Cancer Institute, Singapore.;Princess Margaret Cancer Centre, Toronto, Canada.;Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.;Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: marina.garassino@istitutotumori.mi.it.;Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN, USA, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: leora.horn@vumc.org. | 746 | |
| Letter;Comment | en | Protecting patients with IBD during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32442545 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus Infections;Humans;Inflammatory Bowel Diseases;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gionata Fiorino;Laurent Peyrin-Biroulet;Silvio Danese | 2020-05-20 02:00:00+02:00 | 32442545 | FR;IT | IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan 20089, Italy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.;Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-les-Nancy, France, Inserm U1256 NGERE, Lorrraine University, Vandoeuvre-les-Nancy, France.;IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan 20089, Italy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. Electronic address: silvio.danese@hunimed.eu. | 748 | |||||||
| Letter;Comment | en | Children are protected against SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32454427 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Child;China;Cohort Studies;Coronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Chloé Dimeglio;Jean-Michel Mansuy;Sandrine Charpentier;Isabelle Claudet;Jacques Izopet | 2020-05-20 02:00:00+02:00 | 32454427 | FR | UMR Inserm, U1043, UMR CNRS, U5282, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, 31300, France, CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France. Electronic address: dimeglio.c@chu-toulouse.fr.;CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France.;CHU Toulouse, Emergency Department, Toulouse, 31300, France, UMR 1027, Inserm, Paul Sabatier University, Toulouse, France.;UMR 1027, Inserm, Paul Sabatier University, Toulouse, France, CHU Toulouse, Pediatric Emergency Unit, Children Hospital, Toulouse, France.;UMR Inserm, U1043, UMR CNRS, U5282, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, 31300, France, CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France. | 750 | |||||||
| 10.23736/s1973-9087.20.06317-0 | Journal Article | en | COVID-19 pandemic. What should PRM specialists do? A clinician's perspective. | https://www.ncbi.nlm.nih.gov/pubmed/32434314 | COVID-19 pandemic is rapidly spreading all over the world, creating the risk for an healthcare collapse. While acute care and intensive care units are the main pillars of the early response to the disease, rehabilitative medicine should play an important part in allowing COVID-19 survivors to reduce disability and optimize the function of acute hospital setting. | 2020-05-24 02:00:00+02:00 | pubmed | Stefano Carda;Marco Invernizzi;Ganesh Bavikatte;Djamel Bensmaïl;Francesca Bianchi;Thierry Deltombe;Nathalie Draulans;Alberto Esquenazi;Gerard E Francisco;Raphaël Gross;Luis J Jacinto;Susana Moraleda Pérez;Michael W O'dell;Rajiv Reebye;Monica Verduzco-Gutierrez;Jörg Wissel;Franco Molteni | 2020-05-19 02:00:00+02:00 | 32434314 | FR;CA;PT;BO;GB;CH;US;IT;NL;ES;BE;DE | Department of Clinical Neurosciences, Service of Neuropsychology and Neurorehabilitation, Lausanne University Hospital (CHUV), Lausanne, Switzerland - Stefano.carda@chuv.ch.;Department of Health Sciences, University of Eastern Piedmont, Novara, Italy.;Neurorehabilitation Medicine, The Walton Centre NHS Foundation Trust, Liverpool, UK.;Physical and Rehabilitation Medicine Department, R. Pointcaré Hospital, AP-HP Université Paris- Saclay, Team INSERM 1179, UFR de Santé Simone Veil, Université de Versailles Saint-Quentin, Versailles, France.;Neurophysiology Unit, IRCCS San Raffaele Scientific Institut, e Milan, Italy.;Service de Médecine Physique &, Réadaptation, CHU UCL Namur Site Godinne, Yvoir, Belgium.;Libra Revalidatie &, Audiologie, Eindhoven, the Netherlands.;Department of Physical Medicine &, Rehabilitation, MossRehab Gait and Motion Analysis Lab, Elkins Park, PA, USA.;Department of Physical Medicine &, Rehabilitation, UTHealth McGovern Medical School, and TIRR Memorial Hermann Hospital, Houston, TX, USA.;Service de MPR Neurologique, CHU Nantes Hôpital Saint Jacques, Nantes cedex, France.;EA 43334 Laboratoire Motricité, Interactions, Performance, UFR STAPS Nantes, France.;Serviço de Reabilitação de Adultos 3, Centro de Medicina de Reabilitação de Alcoitão, Alcabideche, Portugal.;Physical Medicine &, Rehabilitation Department, La Paz University Hospital, Madrid, Spain.;New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA.;Division of Physical Medicine &, Rehabilitation, University of British Columbia, Vancouver, BC, Canada.;UT Health Science Center San Antonio Department of Rehabilitation Medicine, San Antonio, TX, USA.;Neurological Rehabilitation &, Physical Therapy, Department of Neurology with Stroke Unit, Vivantes Hospital Spandau, Berlin, Germany.;Valduce Hospital, Villa Beretta Rehabilitation Center, Costamasnaga, Lecco, Italy. | 756 | ||||||
| 10.3390/jcm9051536 | Journal Article;Review | en | Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32438763 | Anemia is a frequent manifestation in patients with chronic inflammatory bowel disease (IBD) and requires tight monitoring and adequate supplementary therapy. Intravenous iron is the first-line treatment in subjects with moderate-severe anemia, active disease, or oral iron intolerance. On the other hand, oral iron is recommended in patients with mild anemia and inactive disease. However, during the current coronavirus pandemic, hospital activities have significantly changed, and all non-essential procedures, including non-urgent iron infusions, have been rescheduled. Oral iron, including both the traditional formulations with ferrous iron and the new ferric iron complexes, could constitute a valid alternative for anemia treatment. For this reason, we conducted a literature review, to summarize the scientific evidence on oral iron therapy in IBD patients with anemia. | 2077-0383 | 2020-05-24 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Ferdinando D'Amico;Laurent Peyrin-Biroulet;Silvio Danese | COVID-19;anemia;inflammatory bowel disease;iron deficiency;oral iron | 2020-05-19 02:00:00+02:00 | 32438763 | FR;IT | Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele, Milan, Italy.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 54500 Vandoeuvre-lès-Nancy, France.;IBD center, Department of Gastroenterology, Humanitas Clinical and Research Center, IRCCS, 20089 Rozzano, Milan, Italy. | 758 | |||
| 10.1111/apa.15334 | Journal Article | en | Paediatric ethical issues during the COVID-19 pandemic are not just about ventilator triage. | https://www.ncbi.nlm.nih.gov/pubmed/32364256 | 0803-5253,1651-2227 | 2020-05-24 02:00:00+02:00 | pubmed | Child;Coronavirus Infections__epidemiology;Health Care Rationing__ethics;Humans;Infant;Infant, Newborn;Pandemics;Pediatrics__ethics;Pneumonia, Viral__epidemiology;Triage__ethics;Ventilators, Mechanical__supply & distribution;COVID-19 | Acta Paediatrica | Marlyse F Haward;Gregory P Moore;John Lantos;Annie Janvier | 2020-05-20 02:00:00+02:00 | 32364256 | FR;CA;US | Division of Neonatology, Department of Pediatrics, Children's Hospital at Montefiore, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.;Division of Neonatology, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.;Division of Newborn Care, Department of Obstetrics and Gynecology, The Ottawa Hospital General Campus, University of Ottawa, Ottawa, ON, Canada.;Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.;Department of Pediatrics, Bureau de l'Éthique Clinique, Université de Montréal, Montréal, QC, Canada.;Division of Neonatology, Research Center, Clinical Ethics Unit, Palliative Care Unit, Unité de recherche en éthique clinique et partenariat famille, CHU Sainte-Justine, Montréal, QC, Canada. | 759 | ||||
| 10.1016/j.agsy.2020.102873 | Editorial | en | Editorial: Impacts of COVID-19 on agricultural and food systems worldwide and on progress to the sustainable development goals. | https://www.ncbi.nlm.nih.gov/pubmed/32501358 | 0308-521X | 2020-05-24 02:00:00+02:00 | pubmed | Agricultural Systems | Emma C Stephens;Guillaume Martin;Mark van Wijk;Jagadish Timsina;Val Snow | 2020-05-20 02:00:00+02:00 | 32501358 | FR;CA;NZ;AU;EC | Agriculture and Agri-Food Canada, Lethbridge Research and Development Centre, Lethbridge, Alberta, Canada.;INRAE-AGIR, F-31320 Auzeville, France.;International Livestock Research Institute, Quito, Ecuador.;Institute for Study and Development Worldwide, Sydney, Australia.;AgResearch - Lincoln Research Centre, PB 4749, Christchurch 8140, New Zealand. | 760 | |||||
| 10.1007/s10928-020-09690-4 | Journal Article | en | Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32435882 | To face SARS-CoV-2 pandemic various attempts are made to identify potential effective treatments by repurposing available drugs. Among them, indomethacin, an anti-inflammatory drug, was shown to have potent in-vitro antiviral properties on human SARS-CoV-1, canine CCoV, and more recently on human SARS-CoV-2 at low micromolar range. Our objective was to show that indomethacin could be considered as a promising candidate for the treatment of SARS-CoV-2 and to provide criteria for comparing benefits of alternative dosage regimens using a model-based approach. A multi-stage model-based approach was developed to characterize % of recovery and viral load in CCoV-infected dogs, to estimate the PK of indomethacin in dog and human using published data after administration of immediate (IR) and sustained-release (SR) formulations, and to estimate the expected antiviral activity as a function of different assumptions on the effective exposure in human. Different dosage regimens were evaluated for IR formulation (25 mg and 50 mg three-times-a-day, and 25 mg four-times-a-day), and SR formulation (75 mg once and twice-a-day). The best performing dosing regimens were: 50 mg three-times-a-day for the IR formulation, and 75 mg twice-a-day for the SR formulation. The treatment with the SR formulation at the dose of 75 mg twice-a-day is expected to achieve a complete response in three days for the treatment in patients infected by the SARS-CoV-2 coronavirus. These results suggest that indomethacin could be considered as a promising candidate for the treatment of SARS-CoV-2 whose potential therapeutic effect need to be further assessed in a prospective clinical trial. | 1567-567X,1573-8744 | 2020-05-24 02:00:00+02:00 | pubmed | Animals;Antiviral Agents__administration & dosage;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Delayed-Action Preparations__administration & dosage;Dogs;Drug Dosage Calculations;Humans;Indomethacin__administration & dosage;Models, Biological;Pandemics;Pneumonia, Viral__drug therapy;Viral Load__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Pharmacokinetics and Pharmacodynamics | Roberto Gomeni;Tianhong Xu;Xuejuan Gao;Françoise Bressolle-Gomeni | Clinical dose;Indomethacin;Model-based;SARS-CoV-2;Translational model | 2020-05-20 02:00:00+02:00 | 32435882 | FR;CN | Pharmacometrica, Lieu-Dit Longcol, 12270, La Fouillade, France. roberto.gomeni@pharmacometrica.com.;BaylorOracle Inc., Hangzhou, China.;Pharmacometrica, Lieu-Dit Longcol, 12270, La Fouillade, France. | 762 | ||
| 10.1002/jcph.1646 | Journal Article | en | Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes? | https://www.ncbi.nlm.nih.gov/pubmed/32434282 | 0091-2700,1552-4604 | 2020-05-24 02:00:00+02:00 | pubmed | Anti-Bacterial Agents__administration & dosage;Azithromycin__therapeutic use;Betacoronavirus;Coronavirus Infections__drug therapy;Drug Therapy, Combination;Enzyme Inhibitors__administration & dosage;Humans;Hydroxychloroquine__administration & dosage;Pandemics;Pneumonia, Viral__drug therapy;Risk Assessment;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Journal of Clinical Pharmacology | Bruno Mégarbane;Jean-Michel Scherrmann | COVID-19;azithromycin;hydroxychloroquine;risk/benefit;toxicity | 2020-05-20 02:00:00+02:00 | 32434282 | FR | Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology APHP, University of Paris, INSERM UMRS-1144, Paris, France.;Faculty of Pharmacy, University of Paris, INSERM UMRS-1144, Paris, France. | 763 | |||
| 10.1016/j.mayocp.2020.05.005 | Journal Article | en | Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32753141 | Among candidate drugs to treat coronavirus disease 2019 (COVID-19), the combination of hydroxychloroquine (HCQ) and azithromycin (AZ) has received intense worldwide attention. Even as the efficacy of this combination is under evaluation, clinicians have begun to use it largely. As these medications are known to prolong the QT interval, we analyzed serial electrocardiograms recorded in patients hospitalized for COVID-19 pneumonia and treated with HCQ + AZ. Fifty consecutive patients received the combination of HCQ (600 mg/d for 10 days) and AZ (500 mg/d on day 1 and 250 mg/d from day 2 to day 5). Twelve-lead electrocardiograms were recorded before treatment, at day 3, at day 5, and at discharge. The median age of patients was 68 years (interquartile range, 53-81 years); 28 (56%) were men. The main comorbidities were hypertension (36%; n=18) and diabetes (16%; n=8). The mean corrected QT (QTc) interval was 408 ms at baseline and increased up to 437 ms at day 3 and to 456 ms at day 5. Thirty-eight patients (76%) presented short-term modifications of the QTc duration (>30 ms). Treatment discontinuation was decided in 6 patients (12%), leading to QTc normalization in 5 of them. No deaths and no cardiac arrhythmic events were observed in this cohort. Our report confirms that a short duration treatment with HCQ + AZ modifies the QTc interval. The treatment had to be discontinued for QTc modifications in 12% of patients. Nevertheless, in inpatients hospitalized for COVID-19, we did not observe any clinically relevant consequences of these transitory modifications. In conclusion, when patients are treated with HCQ + AZ, cardiac monitoring should be regularly performed and hospital settings allow monitoring under in safe conditions. | 0025-6196 | 2020-05-24 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Antiviral Agents__adverse effects;Arrhythmias, Cardiac__chemically induced;Azithromycin__adverse effects;Betacoronavirus;Coronavirus Infections__drug therapy;Drug Administration Schedule;Drug Therapy, Combination;Electrocardiography;Female;Humans;Hydroxychloroquine__adverse effects;Male;Middle Aged;Pandemics;Pneumonia, Viral__drug therapy;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Mayo Clinic Proceedings | Olivier Voisin;Erwan le Lorc'h;Annabelle Mahé;Philippe Azria;Marie-Françoise Borie;Sidonie Hubert;Elodie Ménage;Jean-Christophe Guillerm;Jean-Jacques Mourad | 2020-05-20 02:00:00+02:00 | 32753141 | FR | Department of Internal Medicine, Groupe hospitalier Paris Saint-Joseph, Paris, France.;Department of Internal Medicine, Groupe hospitalier Paris Saint-Joseph, Paris, France. Electronic address: jjmourad@hpsj.fr. | 769 | |||
| 10.1016/s0140-6736(20)31191-0 | Journal Article | en | Attacks against health-care personnel must stop, especially as the world fights COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32445692 | 0140-6736 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Health Personnel;Humans;Pandemics;Pneumonia, Viral;Workplace Violence__prevention & control;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet | Donna McKay;Michele Heisler;Ranit Mishori;Howard Catton;Otmar Kloiber | 2020-05-20 02:00:00+02:00 | 32445692 | FR;CH;US | Physicians for Human Rights, New York, NY 10018, USA. Electronic address: dmckay@phr.org.;Physicians for Human Rights, New York, NY 10018, USA.;International Council of Nurses, Geneva, Switzerland.;World Medical Association, Ferney-Voltaire, France. | 772 | ||||
| NIGMS NIH HHS;NIAID NIH HHS;NIAID NIH HHS | 10.1038/s41586-020-2349-y | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't;Research Support, U.S. Gov't, Non-P.H.S. | en | Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. | https://www.ncbi.nlm.nih.gov/pubmed/32422645 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease. | 0028-0836,1476-4687 | 2020-05-24 02:00:00+02:00 | pubmed | Animals;Antibodies, Monoclonal__chemistry;Antibodies, Neutralizing__chemistry;Antibodies, Viral__chemistry;Antibody-Dependent Cell Cytotoxicity__drug effects;B-Lymphocytes__immunology;Betacoronavirus__chemistry;Chlorocebus aethiops;Coronavirus Infections__immunology;Cross Reactions__drug effects;Cryoelectron Microscopy;Epitopes, B-Lymphocyte__chemistry;HEK293 Cells;Humans;Immune Evasion__immunology;Immunoglobulin Fab Fragments__chemistry;Immunologic Memory__immunology;Killer Cells, Natural__drug effects;Models, Molecular;Neutralization Tests;Pandemics__prevention & control;Peptidyl-Dipeptidase A__chemistry;Pneumonia, Viral__immunology;SARS Virus__chemistry;Severe Acute Respiratory Syndrome__immunology;Spike Glycoprotein, Coronavirus__chemistry;Vero Cells;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nature | Dora Pinto;Young-Jun Park;Martina Beltramello;Alexandra C Walls;M Alejandra Tortorici;Siro Bianchi;Stefano Jaconi;Katja Culap;Fabrizia Zatta;Anna De Marco;Alessia Peter;Barbara Guarino;Roberto Spreafico;Elisabetta Cameroni;James Brett Case;Rita E Chen;Colin Havenar-Daughton;Gyorgy Snell;Amalio Telenti;Herbert W Virgin;Antonio Lanzavecchia;Michael S Diamond;Katja Fink;David Veesler;Davide Corti | 2020-05-18 02:00:00+02:00 | 32422645 | FR;CH;US | [{"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "R01 GM120553"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "HHSN272201700059C"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "75N93019C00062"}] | Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.;Department of Biochemistry, University of Washington, Seattle, WA, USA.;Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.;Vir Biotechnology, San Francisco, CA, USA.;Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.;Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.;Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.;Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.;Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.;Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio. | 791 | |
| Letter | en | Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32432518 | 2020-05-24 02:00:00+02:00 | pubmed | Stanislas Faguer;Arnaud Del Bello;Florence Abravanel;Marie-Laure Nicolau-Travers;Nassim Kamar | 2020-05-18 02:00:00+02:00 | 32432518 | FR | University Hospital of Toulouse, Toulouse, France (S.F., A.D., F.A., M.N., N.K.). | 793 | ||||||||
| 10.1016/j.amp.2020.05.005 | English Abstract;Journal Article | fr | [Institutional Psychotherapy during confinement situation: Adaptation of the therapeutic setting in a day hospital. Towards a virtual mental institution]. | https://www.ncbi.nlm.nih.gov/pubmed/32836297 | Within the context of the SARS-Cov-2 virus epidemic, the Ambulatory Care Unit of the Toulouse University Hospital Center, offering institutional psychotherapeutic care to people with severe and/or disabling psychiatric pathologies, closed its doors to patients on the 16th of March 2020. This article aims to document the necessary adjustments to the care setting during this extraordinary period. As it was, the team had to tell patients to stay at home and to respect rules of social distancing. An inescapable paradox when our work consists precisely in de-confining, connecting, being in contact with each other. Face-to-face meetings, group workshops, the array of our mediations were suspended; the challenge for us was to bring to light what is irreducible or essential in the institutional psychotherapeutic care for psychoses, what must remain active through the confinement. These modifications of the psychotherapeutic setting will be described in terms of constructing a virtual mental institution, based on a setting twisted by the distance but not abolished, telephone consultations opening up to a speculative but not disembodied psychopathological imaginary, and finally a blog as a quasi-materialization of a virtual space. This experience led the team of the Ambulatory Care Unit to radicalize the institution to keep it in its simplest apparatus: a virtual tree structure of the mental institution. The prior interactions between caregivers and patients have been translated (and thus re-created) virtually. As to respect their singular aspects, as well as their fundamental belonging to the collective that supports our institution. This virtual mental institution can therefore maintain the framework that structures our institutional care project, and can link the before and what will be the after of the confinement. For this study, we have conducted an "on-the-spot" analysis of the concrete arrangements of our therapeutic setting from an interdisciplinary perspective: phenomenological, systemic and psychodynamic. | 0003-4487 | 2020-05-24 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Hélène de Brouwer;Karine Faure;Tudi Gozé | Confinement;Covid-19;Institutional psychotherapy;Teleconsultation;Therapeutic setting | 2020-05-19 02:00:00+02:00 | 32836297 | FR | Service de psychiatrie, psychothérapies et art-thérapie, centre hospitalier universitaire de Toulouse, Toulouse, France.;Équipe de recherche sur les rationalités philosophiques et les savoirs (EA 3015), université de Toulouse Jean-Jaurès, Toulouse, France. | 801 | |||
| 10.1007/s10530-020-02287-5 | Journal Article | en | International tracking of the COVID-19 invasion: an amazing example of a globalized scientific coordination effort. | https://www.ncbi.nlm.nih.gov/pubmed/32837264 | It is extraordinary to witness the spread of COVID-19 almost in real-time. This tight monitoring of the invasion of a new virus is a situation that most other invasion scientists could only dream of. Especially spatiotemporal spread data of the early phases of an invasion would be extremely useful in order to understand and predict the human-mediated spread of species around the globe. So far, invasive species that directly affect human health, such as the Sars-Cov-2 virus causing COVID-19, have been treated differently from invasive species affecting environmental health. Despite progresses in constructing large checklists of invasive species, these records often enter the databases only decades after the establishment of the organism in a country. This is inadequate to understand ongoing spread dynamics and estimate current invasion risks. Yet, national services often possess extremely useful information about early detections and interceptions of species at air and maritime ports, which could greatly improve predictions and help set management priorities. Considering the massive impacts of invasive species, it is time to move on to such a collaborative way of handling invasion data. Invasive insects, birds, mammals, fungi, and other species are the result of globalization and call for a globalized response, exactly like the COVID-19 pandemic. | 1387-3547,1573-1464 | 2020-05-24 02:00:00+02:00 | pubmed | Biological Invasions | Cleo Bertelsmeier;Sébastien Ollier | Biosecurity;COVID-19;Infectious disease;Interceptions;International policy;Invasions;Port of entry | 2020-05-19 02:00:00+02:00 | 32837264 | FR;CH | Department of Ecology and Evolution, University of Lausanne, Le Biophore, 1015 Lausanne, Switzerland.;Department of Ecology, Systematics and Evolution, University Paris-Saclay, Bâtiment 362, rue du Doyen André Guinier, 91405 Orsay, France. | 806 | |||
| 10.1016/j.rbmo.2020.05.006 | Journal Article | en | Managing the IVF laboratory during a pandemic: international perspectives from laboratory managers. | https://www.ncbi.nlm.nih.gov/pubmed/32622702 | Fertility societies worldwide responded to the COVID-19 pandemic by recommending that fertility clinics close, or sharply reduce, the clinical operation, leading to a shift in the management of IVF laboratories in three phases: shutdown preparation; maintenance during shutdown; and restart. Each of these phases carries distinct risks that need identification and mitigation, forcing laboratory managers to rethink and adapt their procedures in response to the pandemic. The sudden and unprecedented nature of the pandemic forced laboratory managers from around the world to base decisions on opinion and experience when evidence-based response options were unavailable. These perspectives on pandemic response were presented during a virtual international symposium on COVID-19, held on 3 April 2020, and organized by the London Laboratory Managers' Group. Laboratory managers from seven different countries at different stages of the pandemic (China, Italy, Spain, France, UK, Brazil and Australia) presented their personal experiences to a select audience of experienced laboratory managers from 19 different countries. The intention of this paper is to collect the learnings and considerations from this group of laboratory managers who collaborated to share personal experiences to contribute to the debate surrounding what constitutes good IVF laboratory practice in extraordinary circumstances, such as the COVID-19 pandemic. | 1472-6483 | 2020-05-24 02:00:00+02:00 | pubmed | Australia__epidemiology;Betacoronavirus;Brazil__epidemiology;China__epidemiology;Coronavirus Infections__epidemiology;Female;Fertility Clinics__organization & administration;Fertilization in Vitro__methods;France__epidemiology;Humans;Internationality;Italy__epidemiology;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Spain__epidemiology;Standard of Care;United Kingdom__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Reproductive BioMedicine Online | Cristina Hickman;Shaun Rogers;Guoning Huang;Steven MacArthur;Marcos Meseguer;Daniela Nogueira;Rafael Portela;Laura Rienzi;Timothy Sharp;Hong Ye | 2020-05-21 02:00:00+02:00 | 32622702 | FR;CN;GB;US;BR;IT;AU;ES | Apricity, 30 Rue Fortuny, Paris 75017, France, Institute of Reproduction and Developmental Biology, Imperial College London, London, UK, TMRW Life Sciences, 250 Hudson St. Suite 701, New York, NY, USA. Electronic address: cristina@apricity.life.;GENNET City Fertility, 16 St John Street, London EC1M 4NT, UK.;Chongqing Key Laboratory of Human Embryo Engineering, Chongqing Reproductive and Genetics Institute, Chongqing Health Center for Women and Children, Chongqing 400013, China.;Genea, Level 2 321 Kent Street, Sydney, NSW 2000, Australia.;IVIRMA, Plaça de la Policia Local, 3, Valencia 46015, Spain.;INOVIE Fertilité, Labosud Garonne-Clinique Croix du Sud, 52 Chemin de Ribaute, Toulouse 31130, France.;Genesis, Av. Ibirapuera, 2315 - 8° andar - Indianópolis, São Paulo - SP, Brazil Sao Paulo 04029-200, Brazil.;GENERA Centers for Reproductive Medicine, Rome, Italy.;TMRW Life Sciences, 250 Hudson St. Suite 701, New York, NY, USA. | 808 | |||
| 10.1016/j.idcr.2020.e00836 | Journal Article | en | First description of SARS-CoV-2 in ascites. | https://www.ncbi.nlm.nih.gov/pubmed/32483526 | 2214-2509 | 2020-05-24 02:00:00+02:00 | pubmed | IDCases | Aurélien Culver;Charlotte Arbelot;Carole Bechis;Nadim Cassir;Marc Leone | 2020-05-21 02:00:00+02:00 | 32483526 | FR | Service d'Anesthésie et de Réanimation, Hôpital Nord, Marseille, France.;Aix Marseille University, IRD, AP-HM, MEPHI, University Hospital Institute-Méditerranée Infection (IHU), Marseille, France. | 810 | |||||
| 10.1016/j.frl.2020.101604 | Journal Article | en | Financial contagion during COVID-19 crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32837363 | This study examines how financial contagion occurs through financial and nonfinancial firms between China and G7 countries during the COVID-19 period. The empirical results show that listed firms across these countries, financial and non-financial firms alike, experience significant increase in conditional correlations between their stock returns. However, the magnitude of increase in these correlations is considerably higher for financial firms during the COVID-19 outbreak, indicating the importance of their role in financial contagion transmission. They also show that optimal hedge ratios increase significantly in most cases, implying higher hedging costs during the COVID-19 period. | 1544-6123 | 2020-05-24 02:00:00+02:00 | pubmed | Finance Research Letters | Md Akhtaruzzaman;Sabri Boubaker;Ahmet Sensoy | COVID–19;financial contagion;financial firms;hedge ratios;nonfinancial firms;spillover index | 2020-05-23 02:00:00+02:00 | 32837363 | FR;VN;BD;AU;TR | Australian Catholic University, Sydney, Australia.;Visiting Research Fellow, UCB Capital Management Ltd, Bangladesh.;EM Normandie Business School, Métis Lab, France.;International School, Vietnam National University, Hanoi, Vietnam.;Bilkent University, Faculty of Business Administration, Ankara, Turkey. | 818 | |||
| 10.1016/j.encep.2020.05.009 | Case Reports;Journal Article | fr | [Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate]. | https://www.ncbi.nlm.nih.gov/pubmed/32475694 | 0013-7006 | 2020-05-24 02:00:00+02:00 | pubmed | Anticonvulsants__administration & dosage;Antipsychotic Agents__administration & dosage;Betacoronavirus;Clozapine__administration & dosage;Coronavirus Infections__complications;Delayed-Action Preparations;Drug Resistance;Drug Therapy, Combination;Humans;Immunologic Factors__administration & dosage;Lithium Carbonate__administration & dosage;Male;Middle Aged;Paliperidone Palmitate__administration & dosage;Pandemics;Pneumonia, Viral__complications;Psychotic Disorders__drug therapy;Sialorrhea__chemically induced;Treatment Outcome;Valproic Acid__administration & dosage;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | N Bouaziz;H Ben Rejeb;S Ateb;T Fourati;F Chammas;D Baha;R Rosetti;K Kalalou;G Saba;R Benadhira;D Januel | 2020-05-21 02:00:00+02:00 | 32475694 | FR | Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France. Electronic address: bouaziznoomane@gmail.com.;Unité de recherche clinique, pôle 93G03, EPS de Ville Evrard, 202, avenue Jean-Jaurès, 93330 Neuilly-sur-Marne, France. | 827 | ||||
| 10.1038/s41375-020-0876-z | Journal Article;Review | en | Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). | https://www.ncbi.nlm.nih.gov/pubmed/32444866 | Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-19 infection and associated complications due to their immunocompromised state, the older age and comorbidities. The European Myeloma Network has provided an expert consensus statement in order to guide therapeutic decisions in the era of the COVID-19 pandemic. Patient education for personal hygiene and social distancing measures, along with treatment individualization, telemedicine and continuous surveillance for early diagnosis of COVID-19 are essential. In countries or local communities where COVID-19 infection is widely spread, MM patients should have a PCR test of nasopharyngeal swab for SARS-CoV-2 before hospital admission, starting a new treatment line, cell apheresis or ASCT in order to avoid ward or community spread and infections. Oral agent-based regimens should be considered, especially for the elderly and frail patients with standard risk disease, whereas de-intensified regimens for dexamethasone, bortezomib, carfilzomib and daratumumab should be used based on patient risk and response. Treatment initiation should not be postponed for patients with end organ damage, myeloma emergencies and aggressive relapses. Autologous (and especially allogeneic) transplantation should be delayed and extended induction should be administered, especially in standard risk patients and those with adequate MM response to induction. Watchful waiting should be considered for standard risk relapsed patients with low tumor burden, and slow biochemical relapses. The conduction of clinical trials should continue with appropriate adaptations to the current circumstances. Patients with MM and symptomatic COVID-19 disease should interrupt anti-myeloma treatment until recovery. For patients with positive PCR test for SARS-CoV-2, but with no symptoms for COVID-19, a 14-day quarantine should be considered if myeloma-related events allow the delay of treatment. The need for surveillance for drug interactions due to polypharmacy is highlighted. The participation in international COVID-19 cancer registries is greatly encouraged. | 0887-6924,1476-5551 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Disease Management;Europe__epidemiology;Humans;Infection Control__methods;Multiple Myeloma__therapy;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic__standards;Telemedicine;Time-to-Treatment__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | Leukemia | Evangelos Terpos;Monika Engelhardt;Gordon Cook;Francesca Gay;Maria-Victoria Mateos;Ioannis Ntanasis-Stathopoulos;Niels W C J van de Donk;Hervé Avet-Loiseau;Roman Hajek;Annette Juul Vangsted;Heinz Ludwig;Sonja Zweegman;Philippe Moreau;Hermann Einsele;Mario Boccadoro;Jesus San Miguel;Meletios A Dimopoulos;Pieter Sonneveld | 2020-05-22 02:00:00+02:00 | 32444866 | FR;GR;GB;AT;IT;NL;CZ;ES;DK;DE | Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. eterpos@med.uoa.gr.;Faculty of Freiburg, Hematology and Oncology Department, Interdisciplinary Cancer Center (ITZ) and Comprehensive Cancer Center Freiburg (CCCF), University of Freiburg, Freiburg, Germany.;Leeds Cancer Centre, Leeds Teaching Hospitals National Health Service Trust and University of Leeds, Leeds, UK.;Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.;Cancer Research Unit, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.;Institute of Cancer Molecular and Cellular Biology (USAL-CSIC), Centre for Cancer Research (IBMCC), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.;Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.;Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.;Genomics of Myeloma Laboratory, L'Institut Universitaire du Cancer Oncopole, Toulouse, France.;Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.;Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.;Wilhelminen Cancer Research Institute, c/o Department of Medical Oncology, Hematology and Palliative Care, Wilhelminenspital Wien, Austria.;Department of Hematology, University Hospital Hotel-Dieu, Nantes, France.;Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.;Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain.;Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. | 835 | |||
| 10.3390/ijerph17103650 | Journal Article;Review | en | Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel. | https://www.ncbi.nlm.nih.gov/pubmed/32455961 | COVID-19 is a highly infectious respiratory disease which leads to several clinical conditions related to the dysfunction of the respiratory system along with other physical and psychological complaints. Severely affected patients are referred to intensive care units (ICUs), limiting their possibilities for physical exercise. Whole body vibration (WBV) exercise is a non-invasive, physical therapy, that has been suggested as part of the procedures involved with pulmonary rehabilitation, even in ICU settings. Therefore, in the current review, the World Association of Vibration Exercise Experts (WAVEX) reviewed the potential of WBV exercise as a useful and safe intervention for the management of infected individuals with COVID-19 by mitigating the inactivity-related declines in physical condition and reducing the time in ICU. Recommendations regarding the reduction of fatigue and the risk of dyspnea, the improvement of the inflammatory and redox status favoring cellular homeostasis and the overall improvement in the quality of life are provided. Finally, practical applications for the use of this paradigm leading to a better prognosis in bed bound and ICU-bound subjects is proposed. | 1660-4601 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__physiopathology;Exercise;Fatigue;Humans;Intensive Care Units;Pandemics;Physical Therapy Modalities;Pneumonia, Viral__physiopathology;Quality of Life;Vibration;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Environmental Research and Public Health | Borja Sañudo;Adérito Seixas;Rainer Gloeckl;Jörn Rittweger;Rainer Rawer;Redha Taiar;Eddy A van der Zee;Marieke J G van Heuvelen;Ana Cristina Lacerda;Alessandro Sartorio;Michael Bemben;Darryl Cochrane;Trentham Furness;Danúbia de Sá-Caputo;Mario Bernardo-Filho | COVID-19;SARS-CoV-2;coronavirus;whole body vibration exercise | 2020-05-22 02:00:00+02:00 | 32455961 | FR;NZ;PT;US;BR;IT;AU;NL;ES;DE | Departamento de Educación Física y Deporte, Universidad de Sevilla, 41013, Seville, Spain.;Escola Superior de Saúde, Universidade Fernando Pessoa, 4200-253 Porto, Portugal.;Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, 83471 Schoenau am Koenigssee, Germany.;Department of Pulmonary Rehabilitation, Philipps-University of Marburg, German Center for Lung Research (DZL), 35037 Marburg, Germany.;Institute of Aerospace Medicine, German Aerospace Center (DLR), 51147 Cologne, Germany.;Department of Pediatrics and Adolescent Medicine, University of Cologne, D50931 Cologne, Germany.;Head of Research & Development Department, Novotec Medical GmbH & Galileo Training, 75172 Pforzheim, Germany.;Université de Reims Champagne Ardenne, 51100 Grand Est, France.;Molecular Neurobiology, Groningen Institute for Evolutionary Life Sciences (GELIFES), University of Groningen, 9747 AG Groningen, The Netherlands.;Department of Human Movement Sciences, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.;Faculdade de Ciências Biológicas e da Saúde, Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM), Diamantina 39100-000, MG, Brazil.;Istituto Auxologico Italiano, IRCCS, Experimental Laboratory for Auxo-endocrinological Research & Division of Metabolic Diseases, 20145 Milan, Italy.;Department of Health and Exercise Science, University of Oklahoma, Norman, OK 73019, USA.;School of Sport, Exercise and Nutrition, Massey University, Private Bag 11 222, Palmerston North 4442, New Zealand.;Faculty of Health Sciences, Australian Catholic University, Fitzroy, VIC 3065, Australia.;Laboratório de Vibrações Mecânicas, Policlínica Piquet Carneiro, Instituto de Biología Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20950-003, Brazil.;Faculdade Bezerra de Araújo, Rio de Janeiro 23052-180, Brazil. | 838 | ||
| Letter | en | Letter to the Editor about the Beltrán-Corbellini et al. publication: 'Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study' (Eur J Neurol 2020. doi: 10.1111/ene.14273). | https://www.ncbi.nlm.nih.gov/pubmed/32443166 | 2020-05-24 02:00:00+02:00 | pubmed | J R Lechien;C Hopkins;S Saussez | Covid-19;anosmia;letter | 2020-05-22 02:00:00+02:00 | 32443166 | FR;BE;GB | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons, Mons, Belgium.;Department of Surgery, School of Medicine, UFR Simone Veil, Foch Hospital, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Guy's and St Thomas NHS Foundation Trust, London, UK. | 842 | |||||||
| Letter | en | Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system? | https://www.ncbi.nlm.nih.gov/pubmed/32439915 | 2020-05-24 02:00:00+02:00 | pubmed | Animals;Betacoronavirus;Coronavirus Infections__enzymology;Humans;Pandemics;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__enzymology;Renin-Angiotensin System;COVID-19;severe acute respiratory syndrome coronavirus 2 | François Silhol;Gabrielle Sarlon;Jean-Claude Deharo;Bernard Vaïsse | 2020-05-22 02:00:00+02:00 | 32439915 | FR | Cardiology Department, HTA and Vascular Medicine University Hospital Timone, Marseille, France. francois.silhol@ap-hm.fr.;Cardiology Department, HTA and Vascular Medicine University Hospital Timone, Marseille, France. | 843 | |||||||
| 10.1016/j.diabet.2020.05.008 | Journal Article | en | Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports. | https://www.ncbi.nlm.nih.gov/pubmed/32447101 | Diabetes mellitus is challenging in the context of the COVID-19 pandemic. The prevalence of diabetes patients hospitalized in intensive care units for COVID-19 is two- to threefold higher, and the mortality rate at least double, than that of non-diabetes patients. As the population with diabetes is highly heterogeneous, it is of major interest to determine the risk factors of progression to a more serious life-threatening COVID-19 infection. This brief review discusses the main findings of CORONADO, a prospective observational study in France that specifically addressed this issue as well as related observations from other countries, mainly China and the US. Some prognostic factors beyond old age have been identified: for example, an increased body mass index is a major risk factor for requiring respiratory assistance. Indeed, obesity combines several risk factors, including impaired respiratory mechanics, the presence of other comorbidities and inappropriate inflammatory responses, partly due to ectopic fat deposits. While previous diabetic microvascular (renal) and macrovascular complications also increase risk of death, the quality of past glucose control had no independent influence on hospitalized diabetes patient outcomes, but whether the quality of glucose control might modulate risk of COVID-19 in non-hospitalized diabetes patients is still unknown. In addition, no negative signs regarding the use of RAAS blockers and DPP-4 inhibitors and outcomes of COVID-19 could be identified. Hyperglycaemia at the time of hospital admission is associated with poor outcomes, but it may simply be considered a marker of severity of the infection. Thus, the impact of glucose control during hospitalization on outcomes related to COVID-19, which was not investigated in the CORONADO study, is certainly deserving of specific investigation. | 1262-3636 | 2020-05-24 02:00:00+02:00 | pubmed | Diabetes & Metabolism | A J Scheen;M Marre;C Thivolet | Diabetic complications;Glucose control;Mechanical ventilation;Mortality;Obesity;SARS-CoV-2 | 2020-05-21 02:00:00+02:00 | 32447101 | FR;BE | Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, University of Liège, Liège, Belgium. Electronic address: andre.scheen@chuliege.be.;UMR_S 1138, Metabolic Inflammation in Diabetes and its Complications, Cordeliers Research Centre, 75006 PARIS, France, President of the FFRD and the Clinique Ambroise Paré, 92200 Neuilly-sur-Seine, France.;President of the SFD and DIAB-eCARE, Centre for Diabetes, Hospices Civils de Lyon, University of Lyon, Lyon, France. | 854 | |||
| Editorial;Comment | en | Is Universal Testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Needed on All Labor and Delivery Units? | https://www.ncbi.nlm.nih.gov/pubmed/32433452 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Pregnancy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Torri D Metz | 2020-05-21 02:00:00+02:00 | 32433452 | FR;US | Published online ahead-of-print May 19, 2020. Dr. Metz is from University of Utah Health, Salt Lake City, Utah, email: torri.metz@hsc.utah.edu. | 855 | |||||||
| Journal Article | en | Insights in Public Health: COVID-19 Special Column: The Crisis of Non-Communicable Diseases in the Pacific and the Coronavirus Disease 2019 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32432219 | Globally, coronavirus disease 2019 (COVID-19) is threatening human health and changing the way people live. With the increasing evidence showing comorbidities of COVID-19 and non-communicable diseases (NCDs), the Pacific region, where approximately 75% of deaths are due to NCDs, is significantly vulnerable during this crisis unless urgent action is taken. Whilst enforcing the critical mitigation measures of the COVID-19 pandemic in the Pacific, it is also paramount to incorporate and strengthen NCD prevention and control measures to safeguard people with NCDs and the general population; keep people healthy and minimise the impact of COVID-19. To sustain wellbeing of health, social relationships, and the economy in the Pacific, it is a critical time for all governments, development partners and civil societies to show regional solidarity in the fight against emerging COVID-19 health crisis and existing Pacific NCDs crisis through a whole of government and whole of society approach. | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pacific Islands;Pandemics;Pneumonia, Viral__epidemiology;Public Health;COVID-19;severe acute respiratory syndrome coronavirus 2 | Si Thu Win Tin;Paula Vivili;Elisiva Na'ati;Solene Bertrand;Ilisapeci Kubuabola | Pacific;coronavirus disease 2019;health crisis;non-communicable diseases | 2020-05-21 02:00:00+02:00 | 32432219 | FR;FJ | Public Health Division, Pacific Community (SPC), Noumea, New Caledonia (PV, SB).;Public Health Division, Pacific Community (SPC), Suva, Fiji (STWT, EN, IK). | 856 | |||||
| 10.1007/s11239-020-02146-z | Journal Article;Multicenter Study | en | Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. | https://www.ncbi.nlm.nih.gov/pubmed/32451823 | Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p < 0.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level < 1.0 µg/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level ≥ 1.0 µg/ml and ≥ 3 µg/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0 μg/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies. | 0929-5305,1573-742X | 2020-05-31 02:00:00+02:00 | pubmed | Aged;Anticoagulants__therapeutic use;Coronavirus Infections__complications;Enoxaparin__therapeutic use;Female;Fibrin Fibrinogen Degradation Products__metabolism;France__epidemiology;Humans;Incidence;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Retrospective Studies;Venous Thromboembolism__blood;COVID-19 | Journal of Thrombosis and Thrombolysis | Mathieu Artifoni;Gwenvael Danic;Giovanni Gautier;Pascal Gicquel;David Boutoille;François Raffi;Antoine Néel;Raphaël Lecomte | COVID-19;D-dimer;Pulmonary embolism;Venous thromboembolism | 2020-05-27 02:00:00+02:00 | 32451823 | FR | Service de Médecine Interne, CHU de Nantes, 44093, Nantes, France.;Service de Médecine Polyvalente, CH de Châteaubriant, 44110, Châteaubriant, France.;Service de Maladies Infectieuses et Tropicales, CHU de Nantes, 44093, Nantes, France.;CIC UIC 1413 INSERM, CHU de Nantes, 44093, Nantes, France.;Faculté de Médecine, Université de Nantes, 44093, Nantes, France.;Service de Maladies Infectieuses et Tropicales, CHU de Nantes, 44093, Nantes, France. raphael.lecomte@chu-nantes.fr.;CIC UIC 1413 INSERM, CHU de Nantes, 44093, Nantes, France. raphael.lecomte@chu-nantes.fr. | 876 | ||
| 10.1111/jth.14929 | Journal Article;Practice Guideline | en | Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32459046 | 1538-7933,1538-7836 | 2020-05-31 02:00:00+02:00 | pubmed | Aftercare;Anticoagulants__administration & dosage;Betacoronavirus;Biomarkers;Clinical Laboratory Techniques;Coronavirus Infections__blood;Critical Care;Cytokine Release Syndrome__blood;Diagnostic Techniques, Cardiovascular;Disease Management;Drug Administration Schedule;Fibrin Fibrinogen Degradation Products__analysis;Hemorrhage__chemically induced;Humans;Inpatients;Mass Screening;Pandemics;Pneumonia, Viral__blood;Point-of-Care Testing;Pulmonary Edema__blood;Sensitivity and Specificity;Thrombophilia__blood;Venous Thromboembolism__diagnosis;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Thrombosis and Haemostasis | Alex C Spyropoulos;Jerrold H Levy;Walter Ageno;Jean Marie Connors;Beverley J Hunt;Toshiaki Iba;Marcel Levi;Charles Marc Samama;Jecko Thachil;Dimitrios Giannis;James D Douketis | SARS-CoV-2;anticoagulant;antithrombotic therapy;coronavirus disease 2019;hospitalization | 2020-05-28 02:00:00+02:00 | 32459046 | FR;CA;JP;GB;US;IT | Feinstein Institutes for Medical Research and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY, USA.;Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, USA.;Department of Medicine and Surgery, University of Insubria, Varese, Italy.;Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.;Thrombosis and Haemophilia Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.;Department of Emergency and Disaster Medicine, Juntendo University, Tokyo, Japan.;Department of Medicine and Cardiometabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London, UK.;Department of Anaesthesia, Intensive Care and Perioperative Medicine GHU AP-HP. Centre-Université de Paris-Cochin Hospital, Paris, France.;Department of Haematology, Manchester University Hospitals, Manchester, UK.;Feinstein Institutes for Medical Research, Manhasset, NY, USA.;Department of Medicine, McMaster University, Hamilton, ON, Canada. | 878 | |||
| Journal Article;Review | fr | [Obesity and risk of severe COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32462841 | Obesity represents a higher risk of severe COVID-19 infection, which may lead to the requirement of a mechanical ventilation in intensive care units and premature death. The underlying mechanisms are multiple: alteration of the respiratory performance, presence of comorbidities such as diabetes, hypertension or obstructive sleep apnea, finally inadequate and excessive immunological responses, possibly aggravated by ectopic intrathoracic fat depots. Thus, COVID-19 may challenge the so-called « obesity paradox » commonly reported by intensivists in patients with acute respiratory distress syndrome. These findings require reinforced preventive and curative measures among obese patients to limit the risk of progression towards an unfavorable outcome in case of COVID-19. | 2020-05-31 02:00:00+02:00 | pubmed | Coronavirus Infections__complications;Disease Progression;Disease Susceptibility;Humans;Obesity__complications;Pandemics__prevention & control;Pneumonia, Viral__complications;Respiratory Distress Syndrome, Adult__complications;COVID-19 | André J Scheen | 2020-05-29 02:00:00+02:00 | 32462841 | FR;BE | Service de diabétologie, nutrition et maladies métaboliques, Département de médecine, CHU Liège, Liège Université, 4000 Liège, Belgique. | 881 | ||||||
| 10.14283/jpad.2020.17 | Editorial | en | Viewpoint: Impact of the Covid-19 Outbreak on the Clinical and Research Activities of Memory Clinics: An Alzheimer's Disease Center Facing the Covid-19 Crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32463074 | 2020-05-31 02:00:00+02:00 | pubmed | Alzheimer Disease__epidemiology;Betacoronavirus;Biomedical Research__organization & administration;Comorbidity;Coronavirus Infections__epidemiology;France__epidemiology;Hospitals, Special__organization & administration;Humans;Long-Term Care__organization & administration;Pandemics__statistics & numerical data;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | P J Ousset;B Vellas | 2020-05-29 02:00:00+02:00 | 32463074 | FR | Pierre Jean Ousset, Toulouse Alzheimer's Disease Research and Clinical Center, UMR INSERM 1027, Gerontopole, Toulouse University Hospital, France, ousset.pj@chu-toulouse.fr. | 882 | ||||||
| 10.1093/ehjqcco/qcaa046 | Journal Article;Research Support, Non-U.S. Gov't | en | Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology. | https://www.ncbi.nlm.nih.gov/pubmed/32467968 | The COVID-19 pandemic required a significant redeployment of worldwide healthcare resources. Fear of infection, national lockdowns and altered healthcare priorities have the potential to impact utilisation of healthcare resources for non-communicable diseases. To survey health professionals' views of the impact of the COVID-19 pandemic on the rate and timing of admission of patients with ST-elevation myocardial infarction (STEMI), the European Society of Cardiology (ESC) administered an internet-based questionnaire to cardiologists and cardiovascular nurses across 6 continents. | 2058-5225,2058-1742 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Emergency Service, Hospital__statistics & numerical data;Facilities and Services Utilization;Health Care Surveys;Hospitalization__statistics & numerical data;Humans;Pandemics;Pneumonia, Viral__epidemiology;ST Elevation Myocardial Infarction__diagnosis;Time-to-Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Heart Journal - Quality of Care and Clinical Outcomes | Guilherme Pessoa-Amorim;Christian F Camm;Parag Gajendragadkar;Giovanni Luigi De Maria;Celine Arsac;Cecile Laroche;José Luis Zamorano;Franz Weidinger;Stephan Achenbach;Aldo P Maggioni;Chris P Gale;Athena Poppas;Barbara Casadei | COVID-19;European Society of Cardiology;ST-elevation myocardial infarction | 2020-05-30 02:00:00+02:00 | 32467968 | FR;GB;AT;US;IT;ES;DE | Nuffield Department of Population Health, University of Oxford, Oxford, UK.;NIHR Oxford Biomedical Research Centre, UK.;Division of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK.;British Heart Foundation Centre of Research Excellence, Oxford, UK.;Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK.;EURObservational Research Programme, ESC, Sophia Antipolis, France.;Department of Cardiology, Hospital Universitario Ramon y Cajal, Madrid, Spain.;KA Rudolfstiftung, Vienna, Austria.;Department of Cardiology, University of Erlangen-Nürnberg, Erlangen, Germany.;ANMCO Research Center, Florence, Italy.;Leeds Institute for Data Analytics, University of Leeds, UK.;Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK.;Department of Cardiology, Leeds Teaching Hospitals NHS Trust, UK.;Division of Cardiology, Lifespan Cardiovascular Institute, Rhode Island, Miriam and Newport Hospitals, Brown University, 208 Collyer St, Providence, RI 02904, USA. | 883 | ||
| 10.1080/10641955.2020.1769645 | Journal Article;Systematic Review | en | Complications and outcomes of SARS-CoV-2 in pregnancy: where and what is the evidence? | https://www.ncbi.nlm.nih.gov/pubmed/32456489 | To add to the growing evidence on SARS-CoV-2 infection during pregnancy, so as to better inform clinical decision making and optimize patient outcomes. | 1064-1955,1525-6065 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Cesarean Section__statistics & numerical data;Coronavirus Infections__complications;Female;Humans;Pandemics;Pneumonia, Viral__complications;Pregnancy;Pregnancy Complications, Infectious__diagnosis;Prognosis;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | Hypertension in Pregnancy | Ayssa Teles Abrao Trad;Eniola R Ibirogba;Amro Elrefaei;Kavita Narang;Gabriele Tonni;Olivier Picone;Anna Suy;Elena Carreras Moratonas;Mark D Kilby;Rodrigo Ruano | SARS-CoV-2;perinatal;pregnancy;vertical transmission | 2020-05-26 02:00:00+02:00 | 32456489 | FR;GB;US;IT;ES;PS | Maternal-Fetal Medicine Division, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine , Rochester, MN, USA.;Prenatal Diagnostic Unit, Department of Obstetrics and Gynaecology, AUSL Istituto Di Ricerca a Carattere Clinico Scientifico (IRCCS) Di Reggio Emilia , Reggio Emilia, Italy.;Service de Gynécologie-obstétrique Colombes, Assistance publique-hôpitaux de Paris, hôpitaux Louis Mourier, Université de Paris , Colombes, France.;Department of Obstetrics and Gynecology, Hospital Universitari Vall d'Hebron , Barcelona, Spain.;Fetal Medicine Centre, Birmingham Women's and Children's Foundation NHS Trust , Birmingham, UK.;College of Medical & Dental Sciences, University of Birmingham , Birmingham, UK. | 902 | ||
| Letter;Comment | en | Nursing Activities Score is increased in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32712068 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | P Reper;M A Bombart;I Leonard;B Payen;O Darquennes;S Labrique | 2020-05-27 02:00:00+02:00 | 32712068 | FR;BE;GB | Critical Care Department, CHU UCL Namur, Yvoir, Belgium, Critical Care Department, CHR Haute Senne, Soignies, Belgium.;Critical Care Department, CHR Haute Senne, Soignies, Belgium. | 903 | |||||||
| Letter | en | Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32473230 | 2020-05-31 02:00:00+02:00 | pubmed | Elise Klement-Frutos;Sonia Burrel;Gilles Peytavin;Stéphane Marot;Minh P Lê;Nagisa Godefroy;Vincent Calvez;Anne-Geneviève Marcelin;Eric Caumes;Valérie Pourcher;David Boutolleau | Covid-19;Lopinavir;Protease inhibitor;Sars-cov-2;Virology;pharmacology | 2020-05-27 02:00:00+02:00 | 32473230 | FR | Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris, France. Electronic address: elisemarie.klement@aphp.fr.;Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France. Electronic address: sonia.burrel@aphp.fr.;Assistance Publique - Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Pharmacologie-Toxicologie, DMU Biologie et Génomique Médicale (BioGeM), IAME INSERM UMR-S 1137, Paris, France. Electronic address: gilles.peytavin@aphp.fr.;Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France. Electronic address: stephanesylvain.marot@aphp.fr.;Assistance Publique - Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Pharmacologie-Toxicologie, DMU Biologie et Génomique Médicale (BioGeM), INSERM UMR-S 1144, Paris, France. Electronic address: minh.le@aphp.fr.;Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris, France. Electronic address: nagisa.godefroy@aphp.fr.;Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France. Electronic address: vincent.calvez@aphp.fr.;Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France. Electronic address: anne-genevieve@aphp.fr.;Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris, France. Electronic address: eric.caumes@aphp.fr.;Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris, France. Electronic address: valerie.martinez@aphp.fr.;Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France. Electronic address: david.boutolleau@aphp.fr. | 906 | |||||||
| Editorial;Comment | en | Cardiology practice in the COVID-19 era. | https://www.ncbi.nlm.nih.gov/pubmed/32460532 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Cardiology;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean-Jacques Monsuez | 2020-05-27 02:00:00+02:00 | 32460532 | FR | Cardiology, Hôpital René Muret, France. | 908 | |||||||
| Case Reports;Letter | en | SARS-CoV-2 infection presenting as a febrile rash. | https://www.ncbi.nlm.nih.gov/pubmed/32330336 | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Exanthema__complications;Fever__complications;Humans;Male;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | F Amatore;N Macagno;M Mailhe;B Demarez;C Gaudy-Marqueste;J J Grob;D Raoult;P Brouqui;M A Richard | 2020-05-27 02:00:00+02:00 | 32330336 | FR | Department of Dermatology, Timone Hospital, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.;Department of Pathology, Timone Hospital, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.;IHU-Méditerranée Infection, Marseille, France.;IRD, APHM, MEPHI, Aix-Marseille University, Marseille, France.;CEReSS-EA 3279, Research Centrer in Health Services and Quality of Life Aix Marseille University, Dermatology Department, Universitary Hospital Timone, Assistance Publique Hôpitaux de Marseille, Marseille, France. | 912 | |||||||
| Letter | sp | [The alteration of smell and taste in COVID-19 patients. A diagnostic resource in primary care]. | https://www.ncbi.nlm.nih.gov/pubmed/32620292 | 2020-05-31 02:00:00+02:00 | pubmed | Carlos M Chiesa-Estomba;Jerome R Lechien;Sven Saussez | 2020-05-27 02:00:00+02:00 | 32620292 | FR;ES;BE | Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Servicio de Otorrinolaringología, Cirugía de Cabeza y Cuello, Hospital Universitario Donostia, Donostia, Gipuzkoa, España. Electronic address: chiesaestomba86@gmail.com.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Bélgica, Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), París, Francia, Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Bruselas, Bélgica.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Bélgica, Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Bruselas, Bélgica. | 914 | ||||||||
| 10.1111/btp.12802 | Editorial | en | Tropical biology and conservation in the time of the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32536692 | 0006-3606,1744-7429 | 2020-05-31 02:00:00+02:00 | pubmed | Biotropica | Jennifer S Powers;Emilio M Bruna;Ahimsa Campos-Arceiz;Patricia Delamonica Sampaio;Saara J DeWalt;Lúcia G Lohmann;Rakan A Zahawi | 2020-05-25 02:00:00+02:00 | 32536692 | FR;CN;MM;US;BR | Departments of Ecology, Evolution & Behavior and Plant & Microbial Biology University of Minnesota Saint Paul MN USA.;Department of Wildlife Ecology and Conservation University of Florida Gainesville FL USA.;Center for Latin American Studies University of Florida Gainesville FL USA.;Southeast Asia Biodiversity Research Institute Chinese Academy of Sciences Nay Pyi Taw Myanmar.;Xishuangbanna Tropical Botanical Garden Chinese Academy of Sciences Menglun China.;Tropical Conservation and Development Program Center for Latin American Studies University of Florida Gainesville FL USA.;Department of Biological Sciences Clemson University Clemson SC USA.;Departamento de Botânica Instituto de Biociências Universidade de São Paulo São Paulo Brazil.;Lyon Arboretum University of Hawai'i at Mānoa Honolulu HI USA. | 923 | |||||
| 10.1007/s10669-020-09776-x | Journal Article | en | Bouncing forward: a resilience approach to dealing with COVID-19 and future systemic shocks. | https://www.ncbi.nlm.nih.gov/pubmed/32837818 | Policy questions are often framed in popular discussion as situations where pulling the right levers will get the economy and society back on track after shocks and crises. This approach ignores how systems interact and how their systemic properties shape socioeconomic outcomes, leading to an over-emphasis on a limited set of characteristics, notably efficiency. We argue that this emphasis on efficiency in the operation, management and outcomes of various economic and social systems is not a conscious collective choice, but rather the response of the whole system to the incentives that individual components face. This has brought much of the world to rely upon complex, nested, and interconnected systems to deliver goods and services around the globe. While this approach has many benefits, the Covid-19 crisis shows how it has also reduced the resilience of key systems to shocks, and allowed failures to cascade from one system to others. This paper reviews the impact of COVID-19 on socioeconomic systems, discusses the notion of resilience, and provides specific recommendations on both integrating resilience analytics for recovery from the current crisis as well as on building resilient infrastructure to address future systemic challenges. | 2194-5403,2194-5411 | 2020-05-31 02:00:00+02:00 | pubmed | Environment Systems and Decisions | William Hynes;Benjamin Trump;Patrick Love;Igor Linkov | Coronavirus;Covid-19;Economic impact;OECD;Resilience;Risk | 2020-05-25 02:00:00+02:00 | 32837818 | FR;US | New Approaches to Economic Challenges Unit, Office of the Secretary General, OECD, 2 rue Andre Pascal, 75775 Paris, France.;University of Michigan, Ann Arbor, MI USA.;Carnegie Mellon University, Pittsburgh, PA USA. | 927 | |||
| Letter | en | Obesity and COVID-19: ACE 2, the Missing Tile. | https://www.ncbi.nlm.nih.gov/pubmed/32451913 | 2020-05-31 02:00:00+02:00 | pubmed | Antonio Iannelli;Guillaume Favre;Sébastien Frey;Vincent Esnault;Jean Gugenheim;Samir Bouam;Luigi Schiavo;Albert Tran;Marco Alifano | 2020-05-25 02:00:00+02:00 | 32451913 | FR;IT | University of Côte d'Azur, Nice, France. iannelli.a@chu-nice.fr.;Digestive Surgery and Liver Transplantation Unit, University Hospital of Nice, Archet 2 Hospital, Nice, France. iannelli.a@chu-nice.fr.;Inserm, U1065, Team 8 "Hepatic complications of obesity and alcohol", Nice, France. iannelli.a@chu-nice.fr.;Service de Chirurgie Digestive et Centre de Transplantation Hépatique, Hôpital Archet, 151 Route Saint Antoine de Ginestière, BP 3079, Nice Cedex 3, France. iannelli.a@chu-nice.fr.;University of Côte d'Azur, Nice, France.;Nephrology Department, University Hospital of Nice, Pasteur Hospital, Nice, France.;UMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, France.;Digestive Surgery and Liver Transplantation Unit, University Hospital of Nice, Archet 2 Hospital, Nice, France.;Inserm, U1065, Team 8 "Hepatic complications of obesity and alcohol", Nice, France.;Department of Medical Information, University Hospital of Paris, Cochin Hospital, APHP Centre, Paris, France.;Department of Medicine, Surgery, and Dentistry, "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.;Hepatology Unit, University Hospital of Nice, Archet 2 Hospital, Nice, France.;Thoracic Surgery Department, University Hospital of Paris, Cochin Hospital, APHP Centre, Paris, France.;Inserm, U1138 Team «Cancer, Immune Control, and Escape», Cordeliers Research Center, Paris, France. | 929 | ||||||||
| Letter;Comment | en | Insomnia during COVID-19 pandemic and lockdown: Prevalence, severity, and associated risk factors in French population. | https://www.ncbi.nlm.nih.gov/pubmed/32563951 | In response to Voitsidis et al. (2020) published in Psychiatry Research addressing the paucity of research on insomnia during a pandemic, we obtained data from an online cross-sectional survey by documenting the prevalence of clinical insomnia and its contributing factors in a French general public sample. Participants (N = 556) completed the Insomnia Severity Index, UCLA Loneliness scale, and provided information on sociodemographics, antecedents of mental and physical health conditions, and COVID-19-related stressful life events. In our sample, 19.1% met the diagnostic criteria of clinical insomnia, which was twice lower than that reported in the study by Voitsidis et al., but close to those found among Chinese and Italian populations. We confirmed COVID-19-related worries and loneliness to be the major contributing factors to clinical insomnia, in addition to education status, being infected by the virus and pre-existing mental health illness. These findings underscore that sleep-related problems should be an important component of mental health interventions during pandemics. | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Cross-Sectional Studies;Greece;Humans;Italy;Pandemics;Pneumonia, Viral;Prevalence;Risk Factors;Sleep Initiation and Maintenance Disorders;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cyrille Kossigan Kokou-Kpolou;Olga Megalakaki;Dimitra Laimou;Marina Kousouri | 2020-05-26 02:00:00+02:00 | 32563951 | FR | University of Picardy Jules Verne, Centre de Recherche en Psychologie: Cognition, Psychisme, Organisations (CRP-CPO), Amiens, France. Electronic address: kkkcyrille@yahoo.fr.;University of Picardy Jules Verne, Centre de Recherche en Psychologie: Cognition, Psychisme, Organisations (CRP-CPO), Amiens, France, Sigmund Freud University, Paris, France.;University of Picardy Jules Verne, Centre de Recherche en Psychologie: Cognition, Psychisme, Organisations (CRP-CPO), Amiens, France, University of Paris Descartes, Sorbonne Paris Cité LPCP, Boulogne-Billancourt, Paris, France.;Sigmund Freud University, Paris, France, Roger Prevot General Psychiatric Hospital, France. | 933 | ||||||
| 10.1159/000508125 | Journal Article;Review | en | Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation. | https://www.ncbi.nlm.nih.gov/pubmed/32454500 | Critically ill COVID-19 patients are generally admitted to the ICU for respiratory insufficiency which can evolve into a multiple-organ dysfunction syndrome requiring extracorporeal organ support. Ongoing advances in technology and science and progress in information technology support the development of integrated multi-organ support platforms for personalized treatment according to the changing needs of the patient. Based on pathophysiological derangements observed in COVID-19 patients, a rationale emerges for sequential extracorporeal therapies designed to remove inflammatory mediators and support different organ systems. In the absence of vaccines or direct therapy for COVID-19, extracorporeal therapies could represent an option to prevent organ failure and improve survival. The enormous demand in care for COVID-19 patients requires an immediate response from the scientific community. Thus, a detailed review of the available technology is provided by experts followed by a series of recommendation based on current experience and opinions, while waiting for generation of robust evidence from trials. | 0253-5068,1421-9735 | 2020-05-31 02:00:00+02:00 | pubmed | Blood Purification | Claudio Ronco;Sean M Bagshaw;Rinaldo Bellomo;William R Clark;Faeq Husain-Syed;John A Kellum;Zaccaria Ricci;Thomas Rimmelé;Thiago Reis;Marlies Ostermann | Continuous renal replacement therapies;Cytokine removal;Extracorporeal organ support;Hemoadsorption;Hemoperfusion | 2020-05-26 02:00:00+02:00 | 32454500 | FR;CA;GB;US;BR;IT;AU;DE | Department of Nephrology, University of Padova, Padova, Italy.;International Renal Research Institute (IRRIV), San Bortolo Hospital, Vicenza, Italy.;Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.;Centre for Integrated Critical Care, The University of Melbourne, Melbourne, Victoria, Australia.;Department of Intensive Care, Austin Hospital, Melbourne, Victoria, Australia.;Davidson School of Chemical Engineering, Purdue University, West Lafayette, Indiana, USA.;Department of Internal Medicine II, Division of Nephrology, Pulmonology and Critical Care Medicine, University Hospital Giessen and Marburg, Giessen, Germany.;Department of Critical Care Medicine, Center for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.;Center for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.;Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.;Anesthesiology and Critical Care Medicine, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.;EA 7426 "Pathophysiology of Injury-induced Immunosuppression", Pi3, Hospices Civils de Lyon - BioMérieux - Claude Bernard University Lyon, Lyon, France.;Department of Nephrology, Clinica de Doenças Renais de Brasilia, Brasilia, Brazil.;Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, London, United Kingdom.;Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, London, United Kingdom, Marlies.Ostermann@gstt.nhs.uk. | 941 | |||
| Letter | en | A call from the European Academy of Neurology on COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32470415 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Europe;Humans;Nervous System Diseases__virology;Pandemics;Pneumonia, Viral__complications;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Elena Moro;Gunther Deuschl;Marianne de Visser;Dafin Muresanu;Riccardo Soffietti;Anthony Marson;Marie Vidailhet;David B Vodusek;Claudio L A Bassetti | 2020-05-26 02:00:00+02:00 | 32470415 | FR;SI;RO;GB;CH;IT;NL;DE | Division of Neurology, CHU de Grenoble, Grenoble Alpes University, Grenoble, France.;Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.;Department of Neurology, Academic Medical Centre Amsterdam, Amsterdam, Netherlands.;Department of Neurology, Spitalul Clinic Judetean Cluj, Cluj Napoca, Romania.;Department of Neuro-Oncology, University and City of Health and Science Hospital, Torino, Italy.;Unit of Neuroscience Research, Department of Neurological Science, University of Liverpool, Liverpool, UK.;Fédération de Neurologie, Groupe Hospitalier de la Pitié Salpêtrière, Service de Neurologie, Paris, France.;Division of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.;Department of Neurology, University of Bern, Inselspital, Bern, Switzerland. Electronic address: claudio.bassetti@insel.ch. | 943 | |||||||
| 10.1161/strokeaha.120.030574 | Journal Article | en | Treatment of Acute Ischemic Stroke due to Large Vessel Occlusion With COVID-19: Experience From Paris. | https://www.ncbi.nlm.nih.gov/pubmed/32466736 | Higher rates of strokes have been observed in patients with coronavirus disease 2019 (COVID-19), but data regarding the outcomes of COVID-19 patients suffering from acute ischemic stroke due to large vessel occlusion (LVO) are lacking. We report our initial experience in the treatment of acute ischemic stroke with LVO in patients with COVID-19. | 0039-2499,1524-4628 | 2020-05-31 02:00:00+02:00 | pubmed | Aged;Arterial Occlusive Diseases__complications;Blood Coagulation Disorders__etiology;Brain__diagnostic imaging;Brain Ischemia__diagnostic imaging;Cerebral Arteries;Cerebral Veins;Coronavirus Infections__complications;Female;Hospital Mortality;Humans;Male;Middle Aged;Pandemics;Plasminogen Activators__therapeutic use;Pneumonia, Viral__complications;Stroke__diagnostic imaging;Thrombectomy;Thrombolytic Therapy;Time-to-Treatment;Tissue Plasminogen Activator__therapeutic use;Treatment Outcome;COVID-19 | Stroke | Simon Escalard;Benjamin Maïer;Hocine Redjem;François Delvoye;Solène Hébert;Stanislas Smajda;Gabriele Ciccio;Jean-Philippe Desilles;Mikael Mazighi;Raphael Blanc;Michel Piotin | COVID-19;coagulation disorder;outbreak;stroke;thrombectomy | 2020-05-29 02:00:00+02:00 | 32466736 | FR | From the Interventional Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. | 950 | ||
| 10.1177/0145561320929169 | Journal Article | en | Psychophysical Olfactory Tests and Detection of COVID-19 in Patients With Sudden Onset Olfactory Dysfunction: A Prospective Study. | https://www.ncbi.nlm.nih.gov/pubmed/32469246 | To investigate the coronavirus disease 2019 (COVID-19) status of patients with initial sudden olfactory anosmia (ISOA) through nasopharyngeal swabs for reverse transcription-polymerase chain reaction (RT-PCR) analysis and to explore their olfactory dysfunctions with psychophysical olfactory evaluation. | 0145-5613,1942-7522 | 2020-05-31 02:00:00+02:00 | pubmed | Ear, Nose & Throat Journal | Jerome R Lechien;Pierre Cabaraux;Carlos M Chiesa-Estomba;Mohamad Khalife;Jan Plzak;Stéphane Hans;Delphine Martiny;Christian Calvo-Henriquez;Maria R Barillari;Claire Hopkins;Sven Saussez | COVID-19;RT-PCR;anosmia;olfactory dysfunction;psychophysical olfactory evaluation | 2020-05-29 02:00:00+02:00 | 32469246 | FR;GB;IT;CZ;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Department of Medicine, Neurology, CHU de Charleroi, Charleroi, Belgium.;Department of Otorhinolaryngology-Head & Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Head and Neck Surgery, EpiCURA Hospital, Hornu, Belgium.;Department of Otolaryngology-Head & Neck Surgery, 1st Faculty of Medicine, University Hospital Motol, Prague, Czech Republic.;Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium.;Faculté de Médecine et Pharmacie, Université de Mons (UMONS), Mons, Belgium.;Department of Otolaryngology-Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;Division of Phoniatrics and Audiology, Department of Mental and Physical Health and Preventive Medicine, University of Naples SUN, Naples, Italy.;Guy's and St Thomas NHS Foundation Trust, London, United Kingdom.;British Rhinological Society (President), London, United Kingdom. | 956 | |||
| 10.1016/j.mehy.2020.109907 | Journal Article | en | Periodontal pockets: A potential reservoir for SARS-CoV-2? | https://www.ncbi.nlm.nih.gov/pubmed/32504927 | Periodontal pockets are the major clinical manifestation of Periodontitis, a chronic inflammatory oral disease affecting the teeth-supporting tissues and has high prevalence in the adult population. Periodontal pockets are ideal environments for subgingival bacterial biofilms, that interact with the supragingival oral cavity, mucosal tissues of the pocket and a peripheral circulatory system. Periodontal pockets have been found to harbor viral species such as the Herpes simplex viruses' family. Recently, the SARS-CoV-2 has gained major interest of the scientific/medical community as it caused a global pandemic (Covid-19) and paralyzed the globe with high figures of infected people worldwide. This virus behavior is still partially understood, and by analyzing some of its features we hypothesized that periodontal pocket could be a favorable anatomical niche for the virus and thus acting as a reservoir for SARS-CoV-2. | 0306-9877 | 2020-05-31 02:00:00+02:00 | pubmed | Medical Hypotheses | Zahi Badran;Alexis Gaudin;Xavier Struillou;Gilles Amador;Assem Soueidan | 2020-05-30 02:00:00+02:00 | 32504927 | FR;CA | Department of Periodontology (Rmes U1229, UIC 11), Faculty of Dental Surgery, University of Nantes (CHU de Nantes), Nantes, France, Faculty of Dentistry, McGill University, Montreal, Canada.;Department of Endodontics (Rmes U1229, UIC 11), Faculty of Dental Surgery, University of Nantes (CHU de Nantes), Nantes, France.;Department of Periodontology (Rmes U1229, UIC 11), Faculty of Dental Surgery, University of Nantes (CHU de Nantes), Nantes, France.;Department of Dental Public Health (UPRES EA 3826, UIC 11), Faculty of Dental Surgery, University of Nantes (CHU de Nantes), Nantes, France.;Department of Periodontology (Rmes U1229, UIC 11), Faculty of Dental Surgery, University of Nantes (CHU de Nantes), Nantes, France. Electronic address: assem.soueidan@univ-nantes.fr. | 961 | ||||
| 10.1136/annrheumdis-2020-217910 | Journal Article | en | Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace et al. | https://www.ncbi.nlm.nih.gov/pubmed/32475832 | 0003-4967,1468-2060 | 2020-05-31 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Alexis Mathian;Zahir Amoura | hydroxychloroquine;lupus erythematosus, systemic;therapeutics | 2020-05-31 02:00:00+02:00 | 32475832 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 972 | ||||
| Letter;Comment | en | Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32474039 | The CURB-65 is a severity score to predict mortality secondary to community acquired pneumonia and is widely used to identify patients who can be managed as outpatients. However, whether CURB-65 can be applicable to COVID-19 patients for the decision of outpatient treatment is still unknown. | 2020-05-31 02:00:00+02:00 | pubmed | Ambulatory Care;Betacoronavirus;Community-Acquired Infections;Coronavirus;Coronavirus Infections;Humans;Outpatients;Pandemics;Pneumonia;Pneumonia, Viral;Retrospective Studies;Severity of Illness Index;United Kingdom;COVID-19;severe acute respiratory syndrome coronavirus 2 | Yann Nguyen;Félix Corre;Vasco Honsel;Sonja Curac;Virginie Zarrouk;Bruno Fantin;Adrien Galy | COVID-19;CURB-65;Outpatient care;Risk factor | 2020-05-29 02:00:00+02:00 | 32474039 | FR | Departement of Internal Medicine, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France, Center for Epidemiology and Population Health, INSERM U1018, Villejuif, France. Electronic address: yann.nguyen2@aphp.fr.;Departement of Internal Medicine, AP-HP.Nord, Beaujon Hospital, University of Paris, Clichy, France.;Department of Emergency, AP-HP.Nord, Beaujon Hospital, Clichy, France. | 977 | |||||
| Letter | en | Admission chest CT score predicts 5-day outcome in patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32468085 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Humans;Lung__diagnostic imaging;Pandemics;Pneumonia, Viral__diagnosis;Prognosis;Radiography, Thoracic;Reverse Transcriptase Polymerase Chain Reaction;Tomography, X-Ray Computed;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Elyas Mahdjoub;Waqaas Mohammad;Thomas Lefevre;Marie-Pierre Debray;Antoine Khalil | 2020-05-28 02:00:00+02:00 | 32468085 | FR | Radiology Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France. elyas.mahdjoub@aphp.fr.;Paris University, Paris, France. elyas.mahdjoub@aphp.fr.;Hôpital Bichat-Claude-Bernard, 46 Rue Henri Huchard, 75018, Paris, France. elyas.mahdjoub@aphp.fr.;Radiology Department, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.;Hôpital Bichat-Claude-Bernard, 46 Rue Henri Huchard, 75018, Paris, France.;Paris University, Paris, France. | 995 | |||||||
| Letter | en | Frequency of lupus anticoagulant in Covid-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32470207 | We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid-19 patients (Harzallah et al.1 ). Bowles et al.2 and Helms et al.3 have confirmed these results in new publications. Tang4 has reported discordant data. He has found that very few tested covid-19 patients had positive LAC in a small series (n=12). Bowles et al. have found that LAC were positive in 91% of patients (n=34) with high activated partial thromboplastin time (aPTT). | 2020-05-31 02:00:00+02:00 | pubmed | Inès Harzallah;Agathe Debliquis;Bernard Drénou | 2020-05-29 02:00:00+02:00 | 32470207 | FR | Groupe Hospitalier de la région Mulhouse Sud Alsace, Laboratoire d'Hématologie, 20 rue Dr Laënnec, 68070, Mulhouse, cedex, France. | 998 | |||||||
| Letter | en | Clinical phenotypes of critically ill COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32468086 | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Age Factors;Aged;Betacoronavirus__isolation & purification;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Critical Illness;Female;Hospital Mortality;Humans;Intensive Care Units;Intubation, Intratracheal;Male;Middle Aged;Pandemics;Phenotype;Pneumonia, Viral__mortality;Proportional Hazards Models;Respiration, Artificial;Risk Factors;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Elie Azoulay;Lara Zafrani;Adrien Mirouse;Etienne Lengliné;Michael Darmon;Sylvie Chevret | 2020-05-28 02:00:00+02:00 | 32468086 | FR | Médecine Intensive Et Réanimation, APHP, Hôpital Saint-Louis, Paris University, 1 avenue Claude Vellefaux, 75010, Paris, France. elie.azoulay@aphp.fr.;Médecine Intensive Et Réanimation, APHP, Hôpital Saint-Louis, Paris University, 1 avenue Claude Vellefaux, 75010, Paris, France. | 1002 | |||||||
| 10.5414/alx02147e | Journal Article | en | Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA GroupA in cooperation with the Austrian ARIA GroupB, the Swiss ARIA GroupC, German Society for Applied Allergology (AEDA)D, German Society for Allergology and Clinical Immunology (DGAKI)E, Society for Pediatric Allergology (GPA)F in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHCG and the European Academy of Allergy and Clinical Immunology (EAACI)H. | https://www.ncbi.nlm.nih.gov/pubmed/32568272 | No abstract available. | 2512-8957 | 2020-05-31 02:00:00+02:00 | pubmed | Allergologie select | Ludger Klimek;Oliver Pfaar;Margitta Worm;Karl-Christian Bergmann;Thomas Bieber;Roland Buhl;Jeroen Buters;Ulf Darsow;Thomas Keil;Jörg Kleine-Tebbe;Susanne Lau;Marcus Maurer;Hans Merk;Ralph Mösges;Joachim Saloga;Petra Staubach;Petra Stute;Klaus Rabe;Uta Rabe;Claus Vogelmeier;Tilo Biedermann;Kirsten Jung;Wolfgang Schlenter;Johannes Ring;Adam Chaker;Wolfgang Wehrmann;Sven Becker;Norbert Mülleneisen;Katja Nemat;Wofgang Czech;Holger Wrede;Randolf Brehler;Thomas Fuchs;Peter-Valentin Tomazic;Werner Aberer;Antje Fink-Wagner;Friedrich Horak;Stefan Wöhrl;Verena Niederberger-Leppin;Isabella Pali-Schöll;Wolfgang Pohl;Regina Roller-Wirnsberger;Otto Spranger;Rudolf Valenta;Mübecell Akdis;Cezmi Akdis;Karin Hoffmann-Sommergruber;Marek Jutel;Paolo Matricardi;FranÇois Spertin;Nikolai Khaltaev;Jean-Pierre Michel;Laurent Nicod;Peter Schmid-Grendelmeier;Eckard Hamelmann;Thilo Jakob;Thomas Werfel;Martin Wagenmann;Christian Taube;Michael Gerstlauer;Christian Vogelberg;Jean Bousquet;Torsten Zuberbier | Allergen immunotherapy;COVID-19;SCIT;SLIT;antiviral immunity | 2020-05-28 02:00:00+02:00 | 32568272 | FR;UNK;CH;DE;BE;AT | German ARIA Group.;German Society for Applied Allergology (AEDA).;German Society for Allergology and Clinical Immunology (DGAKI).;AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHC.;Zentrum für Rhinologie und Allergologie, Wiesbaden.;European Academy of Allergy and Clinical Immunology (EAACI).;Sektion Rhinologie und Allergologie, Klinik für Hals-, Nasen-und Ohrenheilkunde, Universitätsklinikum Gießen und Marburg, Philipps-Universität Marburg.;Comprehensive Allergy Centre Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité - Universitätsmedizin Berlin.;Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Bonn.;III. Medizinische Klinik und Poliklinik Hämatologie, Internistische Onkologie und Pneumologie, Universitätsmedizin Mainz.;Zentrum Allergie und Umwelt (ZAUM) Technische Universität und Helmholtz Zentrum München.;Klinik und Poliklinik für Dermatologie und Allergologie der Technischen Universität München.;Institut für klinische Epidemiologie und Biometrie, Julius-Maximilian-Universität, Würzburg.;Allergie- und Asthma-Zentrum Westend, Berlin.;Klinik für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin, Charité - Universitätsmedizin Berlin.;Dermatologische Allergologie, Allergie-Centrum-Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité - Universitätsmedizin Berlin.;Abteilung Dermatologie & Allergologie, RWTH Aachen Universität.;Medizinische Fakultät der Universität zu Köln.;CRI - Clinical Research International Ltd., Hamburg.;ClinCompetence Cologne GmbH, Köln.;Hautklinik, Universitätsmedizin, Johannes Gutenberg-Universität, Mainz.;Europäische Vereinigung für Vitalität und Aktives Altern, Leipzig.;Abteilung für Pneumologie, LungenClinic Grosshansdorf.;Klinik für Allergologie, Johanniter-Krankenhaus im Fläming Treuenbrietzen GmbH, Treuenbrietzen.;Klinik für Innere Medizin Schwerpunkt Pneumologie, Philipps-Universität Marburg.;Einheit für Klinische Allergologie (EKA), Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg.;Praxis für Dermatologie, Immunologie und Allergologie, Erfurt.;Ärzteverband Deutscher Allergologen, Dreieich.;Haut- und Laserzentrum an der Oper, München.;Academia: München.;HNO-Klinik des Klinikums rechts der Isar, Technische Universität München.;Zentrum Allergie und Umwelt München (ZAUM), Helmholtz Zentrum München.;Praxis für Dermatologie und Allergologie, Münster.;Klinik für Hals-, Nasen- und Ohrenheilkunde, Universität Tübingen.;Asthma und Allergiezentrum Leverkusen.;Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Dresden.;Praxis für Kinderpenumologie/Allergologie am Kinderzentrum Dresden (Kid), Dresden.;Klinik für Dermatologie, Universität Freiburg.;Hals-, Nasenund Ohrenarzt, Nordrhein-Westfalen.;Klinik für Allergologie, Berufsdermatologie und Umweltmedizin, Universitätsklinikum Münster.;Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum, Georg-August-Universität, Göttingen.;Austrian ARIA Group.;Klinische Abteilung für Allgemeine HNO, Medizinische Universität Graz, Österreich.;Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Graz, Österreich.;Global Allergy and Airways Patient Platform GAAPP, Wien, Österreich.;Praxis für Hals-, Nasen- und Ohrenkrankheiten, Wien, Österreich.;Floridsdorfer Allergiezentrum, Wien, Österreich.;Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Medizinische Universität Wien, Österreich.;Institut für Komparative Medizin, Interdisziplinäres Messerli Forschungsinstitut, Veterinärmedizinische Universität Wien und Medizinische Universität Wien, Österreich.;Institut für Pathophysiologie und Allergieforschung, Medizinische Universität Wien, Österreich.;Abteilung für Atmungs- und Lungenkrankheiten, Krankenhaus Hietzing, Wien, Österreich.;Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Österreich.;Institut für Pathophysiologie, Medizinische Universität Wien, Österreich.;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Schweiz.;Department of Clinical Immunology, Medizinische Universität Breslau, Polen.;Charité - Universitätsmedizin Berlin.;Swiss ARIA Group.;Division of Allergy and Immunology, Centre Hospitalier Universitaire Vaudois, Lausanne, Schweiz.;GARD Chairman, Genf, Schweiz.;Department of Rehabilitation and Geriatrics, University of Geneva, Genf, Schweiz.;Clinique Cecil, Hirslanden Gruppe, Lausanne, Schweiz.;Abteilung Pneumologie, Centre hospitalier universitaire vaudois, Lausanne, Schweiz.;Allergiestation, Dermatologische Klinik, Universitätsspital Zürich, Schweiz.;Kinderzentrum Bethel, Evangelisches Klinikum Bethel, Universitätsmedizin OWL der Universität Bielefeld.;Klinik für Dermatologie, Allergologie, Universitätsklinikum Gießen, UKGM, Justus-Liebig-Universität Gießen.;Klinik fürDermatologie, Allergologie und Venerologie Medizinische Hochschule Hannover, 59HNO-Klinik, Universitätsklinikum Düsseldorf.;Klinik für Pneumologie, Ruhrlandklinik, Universitätsmedizin Essen.;MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, Frankreich.;Society for Pediatric Allergology (GPA).;Klinik für Kinderpneumologie und Allergologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden.;INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif.;Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, Frankreich.;Euforea, Brussels, Belgien.;Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin.;Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin.;Abteilung für Kinderpneumologie und Allergologie, Medizinische Universität Augsburg. | 1006 | |||
| 10.1016/j.bulcan.2020.04.008 | Editorial | fr | [COVID-19 and cancers. Summary of French guidelines from medical societies and their evolution]. | https://www.ncbi.nlm.nih.gov/pubmed/32475396 | 0007-4551 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;France__epidemiology;Humans;Neoplasms__therapy;Palliative Care;Pandemics;Pneumonia, Viral__complications;Practice Guidelines as Topic;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Manuel Rodrigues | 2020-06-02 02:00:00+02:00 | 32475396 | FR | Institut Curie, PSL research university, département d'oncologie médicale, 75005 Paris, France. Electronic address: manuel.rodrigues@curie.fr. | 1013 | ||||
| Letter;Observational Study | en | Respiratory Mechanics of COVID-19- versus Non-COVID-19-associated Acute Respiratory Distress Syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32479162 | 2020-06-07 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Case-Control Studies;Coronavirus Infections__complications;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Respiratory Distress Syndrome, Adult__physiopathology;Respiratory Mechanics__physiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Anne-Fleur Haudebourg;François Perier;Samuel Tuffet;Nicolas de Prost;Keyvan Razazi;Armand Mekontso Dessap;Guillaume Carteaux | 2020-06-02 02:00:00+02:00 | 32479162 | FR | CHU Henri MondorCréteil, France.;Université Paris Est-CréteilCréteil, Franceand.;Institut Mondor de Recherche Biomédicale INSERM 955Créteil, France. | 1018 | |||||||
| 10.1016/j.jaccas.2020.05.060 | Case Reports | en | SARS-CoV-2 Fulminant Myocarditis. | https://www.ncbi.nlm.nih.gov/pubmed/32835276 | An 18-year-old male without prior medical history developed fulminant myocarditis concomitant to severe COVID-19 pneumonia, which was confirmed using serial cardiac magnetic resonance. This may have important diagnostic, monitoring, and pathogenic implications. (Level of Difficulty: Intermediate.). | 2666-0849 | 2020-06-07 02:00:00+02:00 | pubmed | JACC: Case Reports | Jérôme Garot;Julien Amour;Théo Pezel;Firas Dermoch;Kamel Messadaa;Marie-Louise Felten;Valérie Raymond;Eric Baubillier;Francesca Sanguineti;Philippe Garot | COVID-19, coronavirus disease-2019;EF, ejection fraction;EGE, early gadolinium enhancement;LGE, late gadolinium enhancement;LV, left ventricle;LVEF, left ventricular ejection fraction;SARS-CoV-19, severe acute respiratory syndrome-coronavirus-2019;cardiac magnetic resonance;coronavirus disease 2019;myocarditis | 2020-06-05 02:00:00+02:00 | 32835276 | FR | Cardiovascular Magnetic Resonance Laboratory, Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Ramsay Santé, Massy, France.;Covid-19-Intensive Care Unit #2, Hôpital Privé Jacques Cartier, Ramsay Santé, Massy, France. | 1022 | |||
| Letter | en | Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. | https://www.ncbi.nlm.nih.gov/pubmed/32503857 | 2020-06-07 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal, Humanized__therapeutic use;Antirheumatic Agents__therapeutic use;Arthritis, Rheumatoid__complications;Betacoronavirus;Coronavirus Infections__complications;Female;Glucocorticoids__therapeutic use;Hospitalization__statistics & numerical data;Humans;Hydroxychloroquine__therapeutic use;Intensive Care Units;Interleukin 1 Receptor Antagonist Protein__therapeutic use;Janus Kinase Inhibitors__therapeutic use;Male;Methotrexate__therapeutic use;Middle Aged;Pandemics;Pneumonia, Viral__complications;Rheumatic Diseases__complications;Rituximab__therapeutic use;Spain;Spondylarthropathies__complications;Tumor Necrosis Factor Inhibitors__therapeutic use;COVID-19;severe acute respiratory syndrome coronavirus 2 | Carlos Sanchez-Piedra;Cesar Diaz-Torne;Javier Manero;José M Pego-Reigosa;Íñigo Rúa-Figueroa;Miguel A Gonzalez-Gay;Juan Gomez-Reino;Jose M Alvaro-Gracia | arthritis, rheumatoid;autoimmune diseases;autoimmunity;lupus erythematosus, systemic;spondylitis, ankylosing | 2020-06-05 02:00:00+02:00 | 32503857 | FR;ES | Research Unit, Sociedad Española de Reumatologia, Madrid, Madrid, Spain.;Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain.;Rheumatology, Complejo Hospitalario de Vigo Hospital Xeral, Vigo, Galicia, Spain.;Rheumatology, Hospital Universitario Insulsar Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain.;Rheumatology, Hospital Universitario Marqués de Valdecilla Servicio de Medicina Interna, Santander, Cantabria, Spain.;Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.;Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain jalvarogracia@gmail.com. | 1027 | ||||||
| 10.1016/j.jclinepi.2020.05.030 | Journal Article | en | Using GRADE in situations of emergencies and urgencies: Certainty in evidence and recommendations matters during the COVID-19 pandemic, now more than ever and no matter what. | https://www.ncbi.nlm.nih.gov/pubmed/32512187 | 0895-4356 | 2020-06-07 02:00:00+02:00 | pubmed | Journal of Clinical Epidemiology | Holger J Schünemann;Nancy Santesso;Gunn E Vist;Carlos Cuello;Tamara Lotfi;Signe Flottorp;Marina Davoli;Reem Mustafa;Joerg J Meerpohl;Pablo Alonso-Coello;Elie A Akl | GRADE;guidelines;pandemics;recommendations;systematic reviews | 2020-06-05 02:00:00+02:00 | 32512187 | FR;NO;CA;LB;US;IT;ES;DE | World Health Organization Collaborating Center for Infectious Diseases, Research Methods and Recommendations, Michael G. DeGroote Cochrane Canada & McMaster GRADE Centres, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, Department of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: schuneh@mcmaster.ca.;World Health Organization Collaborating Center for Infectious Diseases, Research Methods and Recommendations, Michael G. DeGroote Cochrane Canada & McMaster GRADE Centres, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.;Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway.;Department of Epidemiology Lazio Region, Via Cristoforo Colombo 112, 00147.;Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.;Institute for Evidence in Medicine, Medical Center and Faculty of Medicine & Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.;Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau-CIBERESP), Barcelona 08025, Spain.;American University of Beirut Medical Center, P.O.Box 11-0236 / CRI (E15), Riad-El-Solh, Beirut 1107 2020, Lebanon. | 1030 | ||||
| Letter | en | Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. | https://www.ncbi.nlm.nih.gov/pubmed/32503849 | 2020-06-07 02:00:00+02:00 | pubmed | Jérôme Avouac;Paolo Airó;Nicolas Carlier;Marco Matucci-Cerinic;Yannick Allanore | inflammation;rituximab;scleroderma;systemic | 2020-06-05 02:00:00+02:00 | 32503849 | FR;IT | Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France javouac@me.com.;Department of Rheumatology and Clinical Immunology Service, Spedali Civili di Brescia, Brescia, Italy.;Université de Paris, Service de Pneumologie, Hôpital Cochin, AP-HP.CUP, Paris, France.;Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.;Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France. | 1031 | |||||||
| Medical Research Council | 10.1136/annrheumdis-2020-217877 | Journal Article;Practice Guideline | en | EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32503854 | The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a 'living document' and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available. | 0003-4967,1468-2060 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Europe;Glucocorticoids__therapeutic use;Humans;Immunosuppressive Agents__therapeutic use;Musculoskeletal Diseases__therapy;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Rheumatic Diseases__therapy;Rheumatology;Societies, Medical;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Annals of the Rheumatic Diseases | Robert Bm Landewé;Pedro M Machado;Féline Kroon;Hans Wj Bijlsma;Gerd R Burmester;Loreto Carmona;Bernard Combe;Massimo Galli;Laure Gossec;Annamaria Iagnocco;John D Isaacs;Xavier Mariette;Iain McInnes;Ulf Mueller-Ladner;Peter Openshaw;Josef S Smolen;Tanja A Stamm;Dieter Wiek;Hendrik Schulze-Koops | antirheumatic agents;epidemiology;health services research;patient care team;quality indicators, health care | 2020-06-05 02:00:00+02:00 | 32503854 | FR;GB;AT;IT;NL;ES;DE | [{"country": "United Kingdom", "agency": "Medical Research Council", "grantid": "MR/T50256X/1"}] | Amsterdam Rheumatology Center, AMC, Amsterdam, The Netherlands landewe@rlandewe.nl.;Rheumatology, Zuyderland MC, Heerlen, The Netherlands.;Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.;Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.;Rheumatology, UMCUtrecht, Utrecht, The Netherlands.;Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany.;Depratment of Rheumatology, Instituto de Salud Musculoesquelética, Madrid, Spain.;Immunorhumatologie, CHU Lapeyronie, Montpellier, France.;Department of infectious diseases, Universita degli Studi di Milano, Milano, Lombardia, Italy.;Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.;APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France.;Scienze Cliniche e Biologiche, Università degli Studi di Torino, Torino, Italy.;Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, Institute of Cellular Medicine, Newcastle upon Tyne, UK.;Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Le Kremlin Bicêtre, France.;3Université Paris-Sud, Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM) UMR 1184, Université Paris-Saclay, Le Kremlin Bicêtre, France.;Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.;Rheumatology and Clinical Immunology, Giessen University, Bad Nauheim, Germany.;National Heart & Lung Institute, Imperial College London Faculty of Medicine, London, London, UK.;Department of Rheumatology, Medical University of Vienna, Wien, Austria.;Section for Outcomes Research, Medical University of Vienna, Vienna, Austria.;Deutsche Rheuma-Liga, Bonn, Germany.;Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig Maximilian University of Munich, Munich, Germany. | 1036 |
| Letter | en | Decrease in surgical activity in the COVID-19 pandemic: an economic crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32506419 | 2020-06-07 02:00:00+02:00 | pubmed | Y Farid;M Schettino;A K Kapila;M Hamdi;N Cuylits;P Wauthy;S Ortiz | 2020-06-07 02:00:00+02:00 | 32506419 | FR;BE | Department of Plastic and Reconstructive Surgery, CHU Brugmann, Brussels, Belgium. | 1053 | ||||||||
| 10.1007/s10272-020-0890-4 | Journal Article | en | How the COVID-19 Pandemic Is Reshaping the Trade Landscape and What to Do About It. | https://www.ncbi.nlm.nih.gov/pubmed/32536707 | The COVID-19 pandemic carries heavy threats, and preserving stable and coordinated international trade relations will be essential to avoid catastrophic disorders or conflicts. | 0020-5346,1613-964X | 2020-06-07 02:00:00+02:00 | pubmed | Intereconomics | Sébastien Jean | 2020-06-07 02:00:00+02:00 | 32536707 | FR | d'informations internationales (CEPII), Centre d'études prospectives et, 20, av. de Ségur, 75007 Paris, France. | 1054 | ||||
| 10.1016/j.encep.2020.05.011 | Journal Article | fr | [How do children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) experience lockdown during the COVID-19 outbreak?] | https://www.ncbi.nlm.nih.gov/pubmed/32522407 | During the COVID-19 pandemic, the French government has decided a general lockdown. This unprecedented situation has raised concerns about children's and adolescent's mental health. Children and adolescents diagnosed with attention deficit hyperactivity disorder (ADHD) may find this context of restrained activity particularly tricky. The objectives of our study are to gather information about the well-being and global life conditions of children and adolescents with ADHD during the COVID-19 outbreak in France. | 0013-7006 | 2020-06-07 02:00:00+02:00 | pubmed | Adaptation, Psychological;Adolescent;Attention Deficit Disorder with Hyperactivity__psychology;Attitude;Betacoronavirus;Boredom;Child;Coronavirus Infections;Education;Family Relations;Female;France;Housing;Humans;Leisure Activities;Male;Pandemics;Parent-Child Relations;Parents__psychology;Pneumonia, Viral;Psychology, Adolescent;Psychology, Child;Self Concept;Sleep Wake Disorders__epidemiology;Social Isolation__psychology;Surveys and Questionnaires;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | E Bobo;L Lin;E Acquaviva;H Caci;N Franc;L Gamon;M-C Picot;F Pupier;M Speranza;B Falissard;D Purper-Ouakil | ADHD;Bien-être;Children;Confinement;Enfants;Famille;Family;Lockdown;School;TDAH;Well-being;École | 2020-06-07 02:00:00+02:00 | 32522407 | FR | Service de médecine psychologique de l'enfant et de l'adolescent 1 (MPEA1), CHU de Montpellier-Hôpital Saint-Eloi, 80 avenue Augustin-Fliche, 34295 Montpellier cedex 5, France.;Département d'informatique médicale, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France.;Service de psychopathologie de l'enfant et de l'adolescent, CHU de Robert-Debré, 48, boulevard Sérurier, 75019 Paris, France.;CHU Lenval, 57, avenue de la Californie, 06200 Nice, France.;CHU de Versailles, 177, rue de Versailles, 78157 Le-Chesnay cedex, France, CESP INSERM 1018 centre de recherche en épidemiologie et santé des populations, équipe psychiatrie, développement et trajectoires/TDAH et émotions, Montpellier, France.;CESP INSERM 1018 centre de recherche en épidemiologie et santé des populations, équipe psychiatrie, développement et trajectoires/TDAH et émotions, Montpellier, France.;Service de médecine psychologique de l'enfant et de l'adolescent 1 (MPEA1), CHU de Montpellier-Hôpital Saint-Eloi, 80 avenue Augustin-Fliche, 34295 Montpellier cedex 5, France, CESP INSERM 1018 centre de recherche en épidemiologie et santé des populations, équipe psychiatrie, développement et trajectoires/TDAH et émotions, Montpellier, France. Electronic address: d-purper_ouakil@chu-montpellier.fr. | 1058 | ||
| 10.1136/annrheumdis-2020-217955 | Journal Article | en | Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al. | https://www.ncbi.nlm.nih.gov/pubmed/32503848 | 0003-4967,1468-2060 | 2020-06-07 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Philippe Guilpain;Clément Le Bihan;Vincent Foulongne;Patrice Taourel;Nathalie Pansu;Alexandre Thibault Jacques Maria;Boris Jung;Romaric Larcher;Kada Klouche;Vincent Le Moing | B-Lymphocytes;autoantibodies;rituximab | 2020-06-05 02:00:00+02:00 | 32503848 | FR | Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, Universite Montpellier, Medical School, Montpellier Cedex 5, France.;IRMB, Universite Montpellier, INSERM, Montpellier, France.;Tropical and Infectious Diseases, Hôpital Saint Eloi, CHRU de Montpellier, Montpellier Cedex 5, Hérault, France.;Pathogenesis and Control of Chronic Infections, Inserm, Universite Montpellier 1 Faculte de Medecine Montpellier-Nimes, Montpellier, Languedoc-Roussillon, France.;Osteoarticular Medical Imaging Section, Department of Medical Imaging, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France.;Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, Universite Montpellier, Medical School, Montpellier Cedex 5, France alexandremaria@hotmail.fr.;Department of Intensive Care Medicine, Lapeyronie University Hospital, and PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France.;Lapeyronie University Hospital, and PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France. | 1069 | ||||
| 10.1016/j.accpm.2020.05.012 | Practice Guideline | en | Guidelines: Anaesthesia in the context of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32512197 | The world is currently facing an unprecedented healthcare crisis caused by the COVID-19 pandemic. The objective of these guidelines is to produce a framework to facilitate the partial and gradual resumption of intervention activity in the context of the COVID-19 pandemic. | 2352-5568 | 2020-06-07 02:00:00+02:00 | pubmed | Adult;Airway Management;Analgesia__adverse effects;Anesthesia__adverse effects;Betacoronavirus;Child;Clinical Laboratory Techniques;Comorbidity;Coronavirus Infections__diagnosis;Critical Pathways;Cross Infection__prevention & control;Disinfection;Elective Surgical Procedures;Equipment Contamination__prevention & control;Health Services Accessibility;Humans;Infection Control__methods;Informed Consent;Occupational Diseases__prevention & control;Operating Rooms__standards;Pandemics__prevention & control;Patient Isolation;Personal Protective Equipment__supply & distribution;Pneumonia, Viral__prevention & control;Preoperative Care;Professional Staff Committees;Risk;Symptom Assessment;Universal Precautions;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Anaesthesia Critical Care & Pain Medicine | Lionel Velly;Etienne Gayat;Hervé Quintard;Emmanuel Weiss;Audrey De Jong;Philippe Cuvillon;Gérard Audibert;Julien Amour;Marc Beaussier;Matthieu Biais;Sébastien Bloc;Marie Pierre Bonnet;Pierre Bouzat;Gilles Brezac;Claire Dahyot-Fizelier;Souhayl Dahmani;Mathilde de Queiroz;Sophie Di Maria;Claude Ecoffey;Emmanuel Futier;Thomas Geeraerts;Haithem Jaber;Laurent Heyer;Rim Hoteit;Olivier Joannes-Boyau;Delphine Kern;Olivier Langeron;Sigismond Lasocki;Yoan Launey;Frederic le Saché;Anne Claire Lukaszewicz;Axel Maurice-Szamburski;Nicolas Mayeur;Fabrice Michel;Vincent Minville;Sébastien Mirek;Philippe Montravers;Estelle Morau;Laurent Muller;Jane Muret;Karine Nouette-Gaulain;Jean Christophe Orban;Gilles Orliaguet;Pierre François Perrigault;Florence Plantet;Julien Pottecher;Christophe Quesnel;Vanessa Reubrecht;Bertrand Rozec;Benoit Tavernier;Benoit Veber;Francis Veyckmans;Hélène Charbonneau;Isabelle Constant;Denis Frasca;Marc-Olivier Fischer;Catherine Huraux;Alice Blet;Marc Garnier | Airway management;COVID-19;Infection prevention and control;Personal protective equipment;SARS-CoV-2;Viruses | 2020-06-05 02:00:00+02:00 | 32512197 | FR;CA | Aix-Marseille University, AP-HM, Department of Anaesthesiology and Critical Care Medicine, University Hospital Timone, 13005 Marseille, France, Aix-Marseille University, CNRS, Institut Neuroscience Timone, UMR7289, Marseille, France. Electronic address: lionel.velly@ap-hm.fr.;Department of Anaesthesiology and Critical Care, Lariboisière Hospital, DMU Parabol, AP-HP Nord, University of Paris, Paris, France, Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris, Paris, France.;Intensive Care Unit, Centre Hospitalier Universitaire de Nice, Pasteur 2 Hospital, Nice, France.;Department of Anaesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP Nord, Paris, France, Inserm UMR_S1149, Inserm, Université de Paris, Paris, France.;Department of Anaesthesia and Intensive Care unit, Regional University Hospital of Montpellier, St-Éloi Hospital, Montpellier, France, PhyMedExp, University of Montpellier, Inserm U1046, CNRS UMR, 9214, Montpellier, France.;Department of Anaesthesiology, Beaujon Hospital, CHU Carémeau, Nîmes, France.;Department of Anaesthesia and Intensive Care, Lorraine University, Nancy University Hospital, 54000 Nancy, France.;Cardiovascular and Thoracic Surgery Department, Hôpital Privé Jacques-Cartier, 91300 Massy, France.;Département d'Anesthésie, Institut Mutualiste Montsouris, 75014 Paris, France.;Department of Anaesthesiology and Critical Care, Pellegrin Hospital, CHU de Bordeaux, Bordeaux, France, Inserm UMR-S 1034, Biology of Cardiovascular Diseases, Bordeaux University, Bordeaux, France.;CMC Ambroise-Paré, Département d'anesthésie, 92200 Neuilly-sur-Seine, France.;Department of Anaesthesiology and Critical Care, Armand-Trousseau University Hospital, Assistance publique-Hôpitaux de Paris, Paris, France, Centre for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Université de Paris, Obstetrical Perinatal and Paediatric Epidemiology Research Team (EPOPé), Inserm INRA, Paris, France, Department of Anaesthesiology and Critical Care, Cochin-Port Royal University Hospital, Assistance publique-Hôpitaux de Paris, Paris, France.;Department of Anaesthesiology and Intensive Care Medicine, Grenoble University Hospital, 38000 Grenoble, France.;Anaesthesiology, Lenval Children's Hospital, 06200 Nice, France.;Anaesthesia and Intensive Care, University Hospital of Poitiers, Poitiers, France, Inserm UMR1070, Pharmacology of Anti-infective Agents, University of Poitiers, Poitiers, France.;Department of Anaesthesia and Intensive Care, Robert-Debré University Hospital, AP-HP, DHU PROTECT, Inserm U1141, Paris, France.;Department of Paediatric Anaesthesia and Intensive Care, Femme-Mère-Enfant Hospital, Lyon, France.;Department of Anaesthesiology and Critical Care, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.;Department of Anaesthesia and Intensive Care, CHU de Rennes, Inserm UMR 991, CIC 1414, Rennes 1 University, Rennes, France.;Department of Anaesthesiology and Critical Care, Estaing Hospital, CHU de Clermont-Ferrand, Clermont-Ferrand, France, Université Clermont Auvergne, CNRS, Inserm U-1103, Clermont-Ferrand, France.;Pôle Anesthésie-Réanimation, Inserm, UMR 1214, Toulouse Neuroimaging Centre (ToNIC), université Toulouse 3 - Paul-Sabatier, CHU de Toulouse, 31059 Toulouse, France.;Departments of Anaesthesia and Intensive Care, Caen University Hospital, Caen, France.;Intensive Care Unit, Department of Anaesthesiology and Intensive Care Medicine, Croix-Rousse Hospital, Lyon, France.;Department of Anaesthesia and Intensive Care unit, Regional University Hospital of Montpellier, St-Éloi Hospital, Montpellier, France.;Service d'Anesthésie-Réanimation Sud, Centre Médico-Chirurgical Magellan, Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000 Bordeaux, France.;Departments of Anaesthesia and Intensive Care, Children Hospital, University Hospital of Toulouse, Toulouse, France.;Department of Anaesthesiology and Critical Care Medicine, Henri-Mondor University Hospital, University Paris-Est Créteil (UPEC), Assistance publique-Hôpitaux de Paris, Paris, France.;Department of Anaesthesiology and Critical Care Medicine, UBL Université d'Angers, CHU d'Angers, Angers, France.;Department of Anaesthesiology and Critical Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Anaesthesiology and Intensive Care, DMU DREAM, AP-HP, 6 Sorbonne Université, Paris, France, Clinique Remusat, 75016 Paris, France, Clinique Jouvenet, 75016 Paris, France.;University of Lyon, EA 7426: Pathophysiology of Injury-Induced Immunosuppression (PI3), Lyon, France, Department of Anaesthesiology and Critical Care, Neurological hospital, Hospices Civils de Lyon, Lyon, France.;Department of Anaesthesia, Clinique Monticelli-Velodrome, GDS, 13008 Marseille, France.;Anaesthesiology and intensive care medicine, Clinique Pasteur, 31076 Toulouse, France.;Department of Paediatric Intensive Care Unit, Assistance publique-Hôpitaux de Marseille, La Timone Hospital, Marseille, France.;Department of Anaesthesiology and Intensive Care, Toulouse University Hospital, 31432 Toulouse, France, Inserm, U1048, Université Paul-Sabatier, Institute of Metabolic and Cardiovascular Diseases, I2MC, 31432 Toulouse, France.;Department of Anaesthesiology and Intensive Care, Dijon University Hospital, 21079 Dijon, France, U-SEEM, Healthcare Simulation Centre of University Hospital of Dijon, 21079 Dijon, France.;Department of Anaesthesiology and Critical Care, CHU Bichat-Claude-Bernard, DMU Parabol, AP-HP Nord, University of Paris, Paris, France, Inserm UMR-S 1152, Epidemiology and Physiopathology of Respiratory Diseases, University of Paris, Paris, France.;Department of Anaesthesiology and Critical Care Medicine, Hôpital Universitaire Arnaud-de-Villeneuve, Montpellier, France.;Department of Anaesthesiology and Intensive Care, Pain and Emergency Medicine, Nîmes-Caremeau University Hospital, Université Montpellier, place du Professeur-Robert-Debré, 30029 Nîmes cedex 9, France, Physiology Department, EA 2992, Faculty of Medicine, Université Montpellier, Montpellier-Nimes University, Nîmes, France.;Institut Curie PSL Research University, 75005 Paris, France.;Department of Anaesthesiology, Intensive Care and Pain, Institut Curie, 75005 Paris, France.;Department of Anaesthesiology and Intensive Care Medicine, Nice University Hospital, Nice, France.;Surgical Paediatric Intensive Care Unit, Universitary Hospital Necker-Enfants-Malades, Paris, France, EA08 Pharmacologie et Évaluation des Thérapeutiques chez l'Enfant et la Femme Enceinte, Paris Descartes University (Paris V), Paris, France.;Department of Anaesthesia and Critical Care Medicine, Montpellier University, Gui-de-Chauliac Hospital, Montpellier, France.;Service d'Anesthésie-Réanimation, Clinique Générale, 4, chemin de la Tour-la-Reine, Annecy, France.;Department of Anaesthesiology and Critical Care, Les Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg, France, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.;Inserm UMR-S 1152, Epidemiology and Physiopathology of Respiratory Diseases, University of Paris, Paris, France, Department of Anaesthesiology and Critical Care, Tenon Hospital, DMU DREAM, AP-HP, 6 Sorbonne Université School of Medicine, Paris, France.;Anesthésie-Réanimation, CHU Nantes, Hôpital Laennec, 1, boulevard Jacques-Monod, 44093 Nantes cedex, France.;Department of Anaesthesiology and Critical Care, CHU de Lille, Pôle d'Anesthésie-Réanimation, 59000 Lille, France.;Department of Anaesthesiology and Critical Care, Université de Rouen Normandie, Rouen, France.;Department of Paediatric Anaesthesia, Jeanne-de-Flandre Hospital, University Hospitals of Lille, Lille, France.;Anaesthesiology Department, Hôpital Armand-Trousseau, Sorbonne Université, Assistance publique-Hôpitaux de Paris, DMU DREAM, Sorbonne Université, Paris, France.;Department of Anaesthesiology and Critical Care, Poitiers University, CHU de Poitiers, Poitiers, France.;Department of Anaesthesiology and Critical Care, Normandie Université, UNICAEN, CHU de Caen Normandie, 14000 Caen, France.;Department of Anaesthesiology, Clinique des Cèdres, 38130 Échirolles, France.;Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris, Paris, France, Department of Anaesthesiology, Critical Care and Burn Centre, Lariboisière-Saint-Louis Hospitals, DMU Parabol, AP-HP Nord, University of Paris, Paris, France, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.;Inserm UMR-S 1152, Epidemiology and Physiopathology of Respiratory Diseases, University of Paris, Paris, France, Department of Anaesthesiology and Critical Care, Saint-Antoine Hospital, DMU DREAM, AP-HP, 6 Sorbonne Université, Paris, France, Sorbonne Université School of Medicine, Paris, France. | 1076 | ||
| 10.1016/j.encep.2020.05.008 | Journal Article | fr | [Recommendations for a gradual and controlled resumption of electroconvulsive therapy in France during the period of lifting of the containment and of the COVID-19 pandemic linked to SARS-CoV-2]. | https://www.ncbi.nlm.nih.gov/pubmed/32507557 | The COVID-19 pandemic has had major consequences for the organization of care. In France and around the world, centers practicing electroconvulsive therapy (ECT) have seen their activity decrease, or even stop for many reasons. In this context, maintaining or resuming this essential therapeutic activity for many patients suffering from psychiatric disorders requires material, human and logistical adaptations that should be supervised. The objective of this collective and national work is to offer simple recommendations that can be applied immediately by any healthcare establishment, public or private, practicing ECT. They are the result of feedback from multiprofessional and inter-establishment experiences. Declined in three stages, these recommendations are accompanied by a practical sheet which describes in detail the necessary conditions and prerequisites for any resumption of ECT activity. | 0013-7006 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Communicable Disease Control__legislation & jurisprudence;Coronavirus Infections__prevention & control;Electroconvulsive Therapy__methods;France;Hospitals, Private;Hospitals, Public;Humans;Nursing Homes;Pandemics__prevention & control;Patient Safety;Patient Selection;Pneumonia, Viral__prevention & control;Practice Guidelines as Topic;Procedures and Techniques Utilization;Protective Devices;Social Isolation;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | A Sauvaget;R Dumont;N Bukowski;O Bonnot;R Auffret;E Poulet;D Szekely;C Quiles;A Yrondi;M Plaze;W de Carvalho;A Amad;S Bulteau | Accessibility;Accès;COVID-19;Electroconvulsive therapy;Guidelines;Recommandations;Électroconvulsivothérapie | 2020-06-04 02:00:00+02:00 | 32507557 | FR;MC | French Society for Biological Psychiatry and Neuropsychopharmacology, STEP Section (Stimulation transcrânienne en psychiatrie), Saint-Germain-en-Laye, France, Nantes Université, CHU Nantes, Movement, Interactions, Performance (MIP), EA 4334, University of Nantes, Nantes, France. Electronic address: anne.sauvaget@chu-nantes.fr.;CHU de Nantes, Department of Anesthesiology and Critical Care Medicine, Hôtel-Dieu-PTMC, Nantes, France.;CHU Nantes, Department of Addictology and Psychiatry, Nantes, France.;Child and Adolescent Psychiatry Department, CHU and University of Nantes, Nantes, France.;French Society for Biological Psychiatry and Neuropsychopharmacology, STEP Section (Stimulation transcrânienne en psychiatrie), Saint-Germain-en-Laye, France, Centre hospitalier Le Vinatier, Bron, France, Université de Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, 69000 Lyon, France, University Lyon 1, 69000 Villeurbanne, France, Department of Emergency Psychiatry, hospices civils de Lyon, University Hospital Edouard-Herriot, Lyon, France.;French Society for Biological Psychiatry and Neuropsychopharmacology, STEP Section (Stimulation transcrânienne en psychiatrie), Saint-Germain-en-Laye, France, Department of psychiatry, centre hospitalier Princesse-Grace, 98000 Monaco, France.;Centre hospitalier Charles-Perrens, 33000 Bordeaux, France.;French Society for Biological Psychiatry and Neuropsychopharmacology, STEP Section (Stimulation transcrânienne en psychiatrie), Saint-Germain-en-Laye, France, Service de psychiatrie et de psychologie médicale, centre expert dépression résistante fondamental, CHU de Toulouse, Toulouse, France, Inserm, UPS, ToNIC Toulouse NeuroImaging Center, hôpital Purpan, université de Toulouse, Toulouse, France.;French Society for Biological Psychiatry and Neuropsychopharmacology, STEP Section (Stimulation transcrânienne en psychiatrie), Saint-Germain-en-Laye, France, Université de Paris, 75005 Paris, France, Service hospitalo-universitaire, GHU de Paris psychiatrie & neurosciences, 75014 Paris, France.;Pôle ECT - groupe SINOUÉ, clinique BELLEVUE, 92190 Meudon, France.;Inserm, U1172 - LilNCog - Lille Neuroscience & Cognition, CHU de Lille, université de Lille, 59000 Lille, France.;French Society for Biological Psychiatry and Neuropsychopharmacology, STEP Section (Stimulation transcrânienne en psychiatrie), Saint-Germain-en-Laye, France, CHU Nantes, Department of Addictology and Psychiatry, Nantes, France, Inserm-U1246 SPHERE University of Nantes and University of Tours, Nantes, France. | 1079 | ||
| 10.1016/j.cjca.2020.05.033 | Editorial | en | Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence. | https://www.ncbi.nlm.nih.gov/pubmed/32502522 | 0828-282X | 2020-06-07 02:00:00+02:00 | pubmed | Canadian Journal of Cardiology | Ricky D Turgeon;Shelley Zieroth;David Bewick;Chi-Ming Chow;Brian Clarke;Simone Cowan;Christopher B Fordyce;Anne Fournier;Kenneth Gin;Anil Gupta;Sean Hardiman;Simon Jackson;Benny Lau;Howard Leong-Poi;Samer Mansour;Ariane Marelli;Ata Rehman Quraishi;Idan Roifman;Marc Ruel;John Sapp;Gurmeet Singh;Gary Small;Sean Virani;David A Wood;Andrew Krahn | 2020-06-02 02:00:00+02:00 | 32502522 | FR;CA;GB;US | Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: ricky.turgeon@gmail.com.;University of Manitoba, Winnipeg, Manitoba, Canada.;New Brunswick Heart Centre, Saint John, New Brunswick, Canada.;Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.;Libin Cardiovascular Institute, Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada.;Centre for Cardiovascular Innovation, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.;Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, Québec, Canada.;Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada.;Cardiac Services British Columbia, Provincial Health Services Authority, Vancouver, British Columbia, Canada.;Queen Elizabeth II Health Sciences Center, Division of Cardiology, Dalhousie University, Halifax, Nova Scotia, Canada.;Department of Medicine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.;McGill University Health Center, Department of Medicine, McGill University, Montréal, Québec, Canada.;Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;University of Ottawa Heart Institute, Ottawa, Ontario, Canada.;Mazankowski Alberta Hearth Institute, Division of Cardiac Surgery, Departments of Critical Care Medicine and Surgery, University of Alberta, Edmonton, Alberta, Canada. | 1087 | |||||
| Letter | en | Androgenic hormones and the excess male mortality observed in COVID-19 patients: new convergent data. | https://www.ncbi.nlm.nih.gov/pubmed/32488360 | 2020-06-07 02:00:00+02:00 | pubmed | Pierre-Jean Lamy;Xavier Rébillard;Francis Vacherot;Alexandre de la Taille | Androgens;Excess mortality;Male;SARS-CoV-2;TMPRSS2 | 2020-06-02 02:00:00+02:00 | 32488360 | FR | Institut d'Analyse Génomique, IMAGENOME, Labosud-Inovie, Montpellier, France. Pierre-Jean.Lamy@labosud.fr.;Service d'urologie Clinique BeauSoleil, Montpellier, France.;Univ Paris Est Creteil, TRePCa, 94010, Creteil, France.;AP-HP, Hopital Henri Mondor, Service Urology, 94010, Creteil, France. | 1089 | |||||||
| 10.1097/sle.0000000000000811 | Journal Article | en | Cost-Effective Filtrating Suction to Evacuate Surgical Smoke in Laparoscopic and Robotic Surgery During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32487856 | The wide and fast spread of COVID-19 around the world has led to a dramatic increase in the need for protection products both for carers and for populations. Surgical team protection includes a systematic screening of patients, wearing protection devices by all the operating staff, and adequate management of aerosols. The risk of aerosol dispersal is particularly high during laparoscopic and robotic surgeries due to the interaction between circulating CO2 and surgical smoke that may contain small viral particles. To decrease the risk of virus transmission, many recommendations have been implemented including the use of integrated insufflation devices comprising smoke evacuation and filtration mode. Such devices are lacking in many centers around the world and to overcome this urgent unmet need, we designed a cost-effective filtrating suction as a more readily available alternative. | 1530-4515 | 2020-06-07 02:00:00+02:00 | pubmed | Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | Adil Ouzzane;Pierre Colin | 2020-06-01 02:00:00+02:00 | 32487856 | FR;UNK | Institut d'Urologie d'Auxerre, Polyclinique Sainte-Marguerite, Auxerre.;Institut de Cancérologie de Bourgogne, Dijon.;Service d'Urologie, Hôpital Privé la Louvière, Lille, France. | 1092 | ||||
| USAID;USAID | 10.1007/s00705-020-04683-7 | Journal Article | en | Coronavirus surveillance of wildlife in the Lao People's Democratic Republic detects viral RNA in rodents. | https://www.ncbi.nlm.nih.gov/pubmed/32488616 | Coronaviruses can become zoonotic, as in the case of COVID-19, and hunting, sale, and consumption of wild animals in Southeast Asia increases the risk for such incidents. We sampled and tested rodents (851) and other mammals and found betacoronavirus RNA in 12 rodents. The sequences belong to two separate genetic clusters and are closely related to those of known rodent coronaviruses detected in the region and distantly related to those of human coronaviruses OC43 and HKU1. Considering the close human-wildlife contact with many species in and beyond the region, a better understanding of virus diversity is urgently needed for the mitigation of future risks. | 0304-8608,1432-8798 | 2020-06-07 02:00:00+02:00 | pubmed | Animals;Animals, Wild__virology;Betacoronavirus__genetics;Chiroptera__virology;Coronavirus Infections__veterinary;Coronavirus OC43, Human__genetics;Humans;Laos__epidemiology;Pandemics__veterinary;Pneumonia, Viral__veterinary;RNA, Viral__genetics;Rodentia__virology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Archives of Virology | David J McIver;Soubanh Silithammavong;Watthana Theppangna;Amethyst Gillis;Bounlom Douangngeun;Kongsy Khammavong;Sinpakone Singhalath;Veasna Duong;Philippe Buchy;Sarah H Olson;Lucy Keatts;Amanda E Fine;Zoe Greatorex;Martin Gilbert;Matthew LeBreton;Karen Saylors;Damien O Joly;Edward M Rubin;Christian E Lange | 2020-06-01 02:00:00+02:00 | 32488616 | FR;CA;LA;CN;CM;US;GB;KH | [{"country": "", "agency": "USAID", "grantid": "GHN-A-OO-09-00010-00"}, {"country": "", "agency": "USAID", "grantid": "AID-OAA-A-14-00102"}] | Metabiota Inc., Nanaimo, BC, Canada.;Wildlife Conservation Society, Laos Program, Vientiane, Lao PDR.;Metabiota Inc., San Francisco, CA, USA.;Department of Livestock and Fisheries, National Animal Health Laboratory, Vientiane, Lao PDR.;Development Alternatives, Inc., Washington, DC, USA.;Institut Pasteur du Cambodge, Virology Unit, Phnom Penh, Cambodia.;GlaxoSmithKline Vaccines R&D, Greater China and Intercontinental, Shanghai, China.;Wildlife Conservation Society, Health Program, Bronx, NY, USA.;Mosaic, Yaoundé, Cameroon.;Labyrinth Global Health, Inc., St. Petersburg, FL, USA.;British Columbia Ministry of Environment and Climate Change Strategy, Victoria, BC, Canada.;Metabiota Inc., Nanaimo, BC, Canada. clange_virology@gmx.de. | 1096 | |
| 10.1186/s13613-020-00690-8 | Journal Article | en | Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. | https://www.ncbi.nlm.nih.gov/pubmed/32488505 | A recent increase in children admitted with hypotensive shock and fever in the context of the COVID-19 outbreak requires an urgent characterization and assessment of the involvement of SARS-CoV-2 infection. This is a case series performed at 4 academic tertiary care centers in Paris of all the children admitted to the pediatric intensive care unit (PICU) with shock, fever and suspected SARS-CoV-2 infection between April 15th and April 27th, 2020. | 2110-5820 | 2020-06-07 02:00:00+02:00 | pubmed | Annals of Intensive Care | Marion Grimaud;Julie Starck;Michael Levy;Clémence Marais;Judith Chareyre;Diala Khraiche;Marianne Leruez-Ville;Pierre Quartier;Pierre Louis Léger;Guillaume Geslain;Nada Semaan;Florence Moulin;Matthieu Bendavid;Sandrine Jean;Géraldine Poncelet;Sylvain Renolleau;Mehdi Oualha | Acute myocarditis;Children;Multisystem inflammatory syndrome;SARS-CoV-2;Shock | 2020-06-01 02:00:00+02:00 | 32488505 | FR | Pediatric Intensive Care Unit, Necker-Enfants-Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Pediatric and Neonatal Intensive Care Unit, Armand-Trousseau University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Pediatric Intensive Care Unit, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France.;Pediatric and Neonatal Intensive Care Unit, Kremlin-Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;M3C-Necker, Congenital and Pediatric Cardiology, Necker-Enfants-Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Laboratoire de Virologie, Paris University, EA 7328, Paris, France.;Paediatric Hematology-Immunology and Rheumatology Unit, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, IMAGINE Institute, Université de Paris, Paris, France.;Pediatric and Neonatal Intensive Care unit, Armand-Trousseau University Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France.;Pediatric Intensive Care Unit, Necker-Enfants-Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, EA7323, 75006, Paris, France.;Pediatric Intensive Care Unit, Necker-Enfants-Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, EA7323, 75006, Paris, France. mehdi.oualha@aphp.fr. | 1098 | |||
| 10.1136/jclinpath-2020-206789 | Journal Article | en | Cellular pathology in the COVID-19 era: a European perspective on maintaining quality and safety. | https://www.ncbi.nlm.nih.gov/pubmed/32482888 | COVID-19 is a zoonotic viral infection that originated in Wuhan, China, in late 2019. WHO classified the resulting pandemic as a 'global health emergency' due to its virulence and propensity to cause acute respiratory distress syndrome. The COVID-19 pandemic has had a major impact on diagnostic laboratories, particularly those handling cell and tissue specimens. This development carries serious implications for laboratory practice in that safety of personnel has to be balanced against high-quality analysis and timely reporting of results. The aim of this article is to present some recommendations for the handling of such specimens in the preanalytical, analytical and postanalytical phases of laboratory testing and analysis in an era of high COVID-19 prevalence, such as that seen, for example, in the UK, Spain, Italy and France. | 0021-9746,1472-4146 | 2020-06-07 02:00:00+02:00 | pubmed | Journal of Clinical Pathology | John R Gosney;Paul Hofman;Giancarlo Troncone;Fernando Lopez-Rios | decontamination;laboratory personnel;safety | 2020-06-01 02:00:00+02:00 | 32482888 | FR;IT;ES;GB | Cellular Pathology, Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK J.Gosney@liverpoolft.nhs.uk.;Pathology, INSERM, Nice, France.;Public Health, University of Naplese Federico II, Napoli, Italy.;Pathology-Targeted therapies laboratory, HM Hospitales, Madrid, Spain. | 1101 | |||
| Letter | en | Feasibility of tocilizumab in ICU patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32484915 | 2020-06-07 02:00:00+02:00 | pubmed | Nahéma Issa;Margot Dumery;Olivier Guisset;Gaelle Mourissoux;Fabrice Bonnet;Fabrice Camou | 2020-06-02 02:00:00+02:00 | 32484915 | FR | Medical Intensive Care and Infectious Diseases Unit, Saint-Andre Hospital, Bordeaux, France.;Internal medicine and Infectious Diseases Unit, Saint-Andre Hospital, Bordeaux, France. | 1106 | ||||||||
| Letter | en | Potential pitfalls of routine SARS-CoV-2 serology for mass screening. | https://www.ncbi.nlm.nih.gov/pubmed/32484942 | 2020-06-07 02:00:00+02:00 | pubmed | Laurent Bélec;Hélène Péré;Ralph-Sydney Mboumba Bouassa;David Veyer;Mohammad-Ali Jenabian | 2020-06-02 02:00:00+02:00 | 32484942 | FR;CA | Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Université de Paris, Paris, France.;Département des Sciences Biologiques, Centre de Recherche CERMO-FC, Université du Québec Montréal (UQAM), Montréal, Québec, Canada. | 1108 | ||||||||
| 10.1377/hlthaff.2020.00652 | Evaluation Study;Journal Article | en | Incarceration And Its Disseminations: COVID-19 Pandemic Lessons From Chicago's Cook County Jail. | https://www.ncbi.nlm.nih.gov/pubmed/32496864 | Jails and prisons are major sites of novel coronavirus (SARS-CoV-2) infection. Many jurisdictions in the United States have therefore accelerated the release of low-risk offenders. Early release, however, does not address how arrest and pretrial detention practices may be contributing to disease spread. Using data from Cook County Jail-one of the largest known nodes of SARS-CoV-2 spread in the United States-in Chicago, Illinois, we analyzed the relationship between jailing practices and community infections at the ZIP code level. We found that jail-community cycling was a significant predictor of cases of coronavirus disease 2019 (COVID-19), accounting for 55 percent of the variance in case rates across ZIP codes in Chicago and 37 percent of the variance in all of Illinois. Jail-community cycling far exceeds race, poverty, public transit use, and population density as a predictor of variance. The data suggest that cycling people through Cook County Jail alone is associated with 15.7 percent of all documented COVID-19 cases in Illinois and 15.9 percent of all documented cases in Chicago as of April 19, 2020. Our findings support arguments for reduced reliance on incarceration and for related justice reforms both as emergency measures during the present pandemic and as sustained structural changes vital for future pandemic preparedness and public health. | 0278-2715,1544-5208 | 2020-06-07 02:00:00+02:00 | pubmed | Chicago;Communicable Disease Control__organization & administration;Coronavirus Infections__epidemiology;Female;Humans;Illinois;Infectious Disease Transmission, Vertical__prevention & control;Male;Pandemics__statistics & numerical data;Pneumonia, Viral__epidemiology;Prisoners__statistics & numerical data;Prisons__organization & administration;Public Health;Vulnerable Populations;COVID-19 | Health Affairs | Eric Reinhart;Daniel L Chen | Access and use;Bundled charges;Coronavirus;Covid-19;Diseases;Ethics;Health policy;Jail-involved population;Pandemics;Public health;Social determinants of health;Socioeconomic determinants of health;health disparities;prison health care | 2020-06-04 02:00:00+02:00 | 32496864 | FR;GB;US | Eric Reinhart (reinhar@fas.harvard.edu) is a PhD candidate in the Department of Anthropology, Harvard University, in Cambridge, Massachusetts, and an MD candidate at the University of Chicago Pritzker School of Medicine, in Chicago, Illinois. He is also a candidate in adult psychoanalysis at the Chicago Center for Psychoanalysis.;Daniel L. Chen is a director of research at the Centre National de la Recherche Scientifique (CNRS), in Paris, France, a professor at the Toulouse School of Economics and Université de Toulouse Faculty of Law, in Toulouse, France, and lead principal investigator of the DE JURE (Data and Evidence for Justice Reform) Program at the World Bank in Washington, D.C. | 1111 | ||
| Letter | en | Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32505755 | 2020-06-07 02:00:00+02:00 | pubmed | Michael Cardinale;Pierre Esnault;Jean Cotte;Pierre J Cungi;Philippe Goutorbe | Acute respiratory distress syndrome;Almitrine Bismesylate;COVID-19;Inhaled nitric oxide | 2020-06-04 02:00:00+02:00 | 32505755 | FR | Intensive Care Unit, Sainte Anne Military Teaching Hospital, Toulon, France. Electronic address: mickaelcardinale@hotmail.fr.;Intensive Care Unit, Sainte Anne Military Teaching Hospital, Toulon, France. | 1112 | |||||||
| 10.1016/j.cjca.2020.06.002 | Journal Article | en | Guiding Cardiac Care During the COVID-19 Pandemic: How Ethics Shapes Our Health System Response. | https://www.ncbi.nlm.nih.gov/pubmed/32505633 | The COVID-19 pandemic has raised ethical questions for the cardiovascular leader and practitioner. Attention has been redirected from a system that focuses on individual patient benefit toward one that focuses on protecting society as a whole. Challenging resource allocation questions highlight the need for a clearly articulated ethics framework that integrates principled decision making into how different cardiovascular care services are prioritized. A practical application of the principles of harm minimisation, fairness, proportionality, respect, reciprocity, flexibility, and procedural justice is provided, and a model for prioritisation of the restoration of cardiovascular services is outlined. The prioritisation model may be used to determine how and when cardiovascular services should be continued or restored. There should be a focus on an iterative and responsive approach to broader health care system needs, such as other disease groups and local outbreaks. | 0828-282X | 2020-06-07 02:00:00+02:00 | pubmed | Canadian Journal of Cardiology | Alice Virani;Gurmeet Singh;David Bewick;Chi-Ming Chow;Brian Clarke;Simone Cowan;Christopher B Fordyce;Anne Fournier;Kenneth Gin;Anil Gupta;Sean Hardiman;Simon Jackson;Yoan Lamarche;Benny Lau;Jean-François Légaré;Howard Leong-Poi;Samer Mansour;Ariane Marelli;Ata Quraishi;Idan Roifman;Marc Ruel;John Sapp;Gary Small;Ricky Turgeon;David A Wood;Shelley Zieroth;Sean Virani;Andrew D Krahn | 2020-06-04 02:00:00+02:00 | 32505633 | FR;CA;GB;US | Department of Medical Genetics, University of British Columbia, British Columbia, Canada. Electronic address: alice.virani@phsa.ca.;Mazankowski Alberta Hearth Institute, Division of Cardiac Surgery, Departments of Critical Care Medicine and Surgery, University of Alberta, Edmonton, Alberta, Canada.;New Brunswick Heart Centre, Saint John, New Brunswick, Canada.;Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.;Libin Cardiovascular Institute, Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada.;Centre for Cardiovascular Innovation, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.;Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, Québec, Canada.;Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada.;Cardiac Services BC, Provincial Health Services Authority, Vancouver, British Columbia, Canada.;QEII Health Sciences Center, Division of Cardiology, Dalhousie University Halifax, Halifax, Nova Scotia, Canada.;Department of Surgery, Montréal Heart Institute, Université de Montréal, Montréal, Québec, Canada.;Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.;Department of Medicine, McGill University Health Center, McGill University, Montréal, Québec, Canada.;Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;University of Ottawa Heart Institute, Ottawa, Ontario, Canada.;Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.;University of Manitoba, Winnipeg, Manitoba, Canada. | 1113 | ||||
| 10.1016/j.jvoice.2020.05.012 | Journal Article | en | Features of Mild-to-Moderate COVID-19 Patients With Dysphonia. | https://www.ncbi.nlm.nih.gov/pubmed/32600873 | To explore the prevalence of dysphonia in European patients with mild-to-moderate COVID-19 and the clinical features of dysphonic patients. | 0892-1997 | 2020-06-07 02:00:00+02:00 | pubmed | Journal of Voice | Jerome R Lechien;Carlos M Chiesa-Estomba;Pierre Cabaraux;Quentin Mat;Kathy Huet;Bernard Harmegnies;Mihaela Horoi;Serge D Le Bon;Alexandra Rodriguez;Didier Dequanter;Stéphane Hans;Lise Crevier-Buchman;Baptiste Hochet;Lea Distinguin;Younes Chekkoury-Idrissi;Marta Circiu;Fahd El Afia;Maria Rosaria Barillari;Giovanni Cammaroto;Nicolas Fakhry;Justin Michel;Thomas Radulesco;Delphine Martiny;Philippe Lavigne;Lionel Jouffe;Géraldine Descamps;Fabrice Journe;Eleonora M C Trecca;Julien Hsieh;Irene Lopez Delgado;Christian Calvo-Henriquez;Sebastien Vergez;Mohamad Khalife;Gabriele Molteni;Giuditta Mannelli;Giovanna Cantarella;Manuel Tucciarone;Christel Souchay;Pierre Leich;Tareck Ayad;Sven Saussez | Clinical;Coronavirus;Covid-19;Dysphonia;ENT;Findings;Symptoms;Voice | 2020-06-04 02:00:00+02:00 | 32600873 | FR;CA;CH;US;IT;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: Jerome.Lechien@umons.ac.be.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otorhinolaryngology-Head & Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Neurology, CHU de Charleroi, Charleroi, Belgium.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otolaryngology-Head & Neck Surgery, CHU de Charleroi, Charleroi, Belgium.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Language Sciences, Faculty of Psychology, University of Mons, Belgium.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Mental and Physical Health and Preventive Medicine, University of L. Vanvitelli, Naples, Italy.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otolaryngology-Head & Neck Surgery, Morgagni Pierantoni Hospital, Forli, Italy.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otorhinolaryngology- Head & Neck Surgery, APHM, Aix Marseille University, La Conception University Hospital, Marseille, France.;Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium, Faculté de Médecine et Pharmacie, Université de Mons (UMONS), Mons, Belgium.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Division of Otolaryngology-Head & Neck Surgery, Centre Hospitalier de l'Université de Montréal, Montreal, Québec, Canada.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Bayesia, Changé, France.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otolaryngology- Head and Neck Surgery, University Hospital of Foggia, Foggia, Italy.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Rhinology-Olfactology Unit, Department of Otorhinolaryngology, Head and Neck Surgery, Geneva University Hospitals (HUG), Geneva, Switzerland.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otorhinolaryngology-Head & Neck Surgery, Hospital Quironsalud Valencia, Spain.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of otolaryngology-Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otorhinolaryngology-Head & Neck Surgery, CHU Rangueil-Larrey, Institut Universitaire du Cancer de Toulouse, Toulouse, France.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otorhinolaryngology-Head & Neck Surgery, EpiCURA Hospital, Baudour, Belgium.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Division of Otolaryngology-Head and Neck Surgery, University Hospital of Verona, Verona, Italy.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Head and Neck Oncology and Robotic Surgery, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.;Department of Otolaryngology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS)., Department of Otolaryngology-Head & Neck Surgery, Hospital Universitario de Jerez, Jerez, Spain.;Department of Otolaryngology-Head & Neck Surgery, CHU Ambroise Paré, Mons, Belgium.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium, Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium, Department of Otorhinolaryngology-Head & Neck Surgery, EpiCURA Hospital, Baudour, Belgium. | 1115 | |||
| 10.1016/j.ijid.2020.05.110 | Journal Article;Review | en | Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? | https://www.ncbi.nlm.nih.gov/pubmed/32497811 | The coronavirus 2 (SARS-CoV-2) pandemic is viciously spreading through the continents with rapidly increasing mortality rates. Current management of COVID-19 is based on the premise that respiratory failure is the leading cause of mortality. However, mounting evidence links accelerated pathogenesis in gravely ill COVID-19 patients to a hyper-inflammatory state involving a cytokine storm. Several components of the heightened inflammatory state were addressed as therapeutic targets. Another key component of the heightened inflammatory state is hyper-ferritinemia which reportedly identifies patients with increased mortality risk. In spite of its strong association with mortality, it is not yet clear if hyper-ferritinemia in COVID-19 patients is merely a systemic marker of disease progression, or a key modulator in disease pathogenesis. Here we address implications of a possible role for hyper-ferritinemia, and altered iron homeostasis in COVID-19 pathogenesis, and potential therapeutic targets in this regard. | 1201-9712 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__mortality;Cytokine Release Syndrome__virology;Ferroptosis;Hepcidins__physiology;Humans;Inflammation;Iron__blood;Iron Overload__virology;Mitochondria__pathology;Oxidative Stress;Pandemics;Pneumonia, Viral__mortality;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Infectious Diseases | Marvin Edeas;Jumana Saleh;Carole Peyssonnaux | Ferroptosis;Hyper-ferritinemia;Hypercoagulability;Iron homeostasis;Mitochondria;Oxidative stress | 2020-06-02 02:00:00+02:00 | 32497811 | FR;OM | Université de Paris, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France, Laboratory of Excellence GR-Ex, Paris, France. Electronic address: marvin.edeas@inserm.fr.;College of Medicine, Sultan Qaboos University, Oman.;Université de Paris, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France, Laboratory of Excellence GR-Ex, Paris, France. | 1117 | ||
| 10.1016/j.jinf.2020.05.077 | Evaluation Study;Journal Article | en | Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients. | https://www.ncbi.nlm.nih.gov/pubmed/32504735 | SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests. | 0163-4453 | 2020-06-07 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Antibodies, Viral__blood;Betacoronavirus__immunology;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Enzyme-Linked Immunosorbent Assay;Female;Hospitalization__statistics & numerical data;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;Point-of-Care Systems;Reagent Kits, Diagnostic;Sensitivity and Specificity;Seroconversion;Serologic Tests;Young Adult;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Infection | E Tuaillon;K Bolloré;A Pisoni;S Debiesse;C Renault;S Marie;S Groc;C Niels;N Pansu;A M Dupuy;D Morquin;V Foulongne;A Bourdin;V Le Moing;P Van de Perre | COVID-19;ELISA;SARS-CoV-2 antibodies;point of care tests | 2020-06-03 02:00:00+02:00 | 32504735 | FR | Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, CHU Montpellier, Montpellier, France. Electronic address: e-tuaillon@chu-montpellier.fr.;Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France.;Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, CHU Montpellier, Montpellier, France.;Montpellier University Hospital, Montpellier, France. | 1120 | ||
| 10.1111/ene.14375 | Journal Article;Review | en | Stroke care during the COVID-19 pandemic: experience from three large European countries. | https://www.ncbi.nlm.nih.gov/pubmed/32492764 | In order to cope with the exponentially increasing number of patients infected with SARS-CoV-2, European countries made enormous efforts to reorganize medical assistance and several diseases, including stroke, were particularly impacted. We report the experience of stroke neurologists from three European countries (Italy, France and Germany) that faced the pandemic at diverse time points and with different approaches, depending on their resources and healthcare system organization. Pre-hospital and in-hospital acute stroke pathways were reorganized to prioritize COVID-19 management and, in severely affected regions of Italy and France, stroke care was centralized to a limited number of centers, whereas the remaining stroke units were dedicated to patients with COVID-19. Access to acute stroke diagnostics and time-dependent therapies was limited or delayed because of reduced capacities of emergency services due to the burden of patients with COVID-19. A marked reduction in the number of patients presenting with transient ischaemic attack and stroke was noted in the emergency departments of all three countries. Although we only have preliminary data, these conditions may have affected stroke outcome. These indirect effects of the COVID-19 pandemic could negate the efforts of stroke neurologists over the last few years to improve outcome and reduce mortality of stroke patients. Although the SARS-CoV-2 infection rate is slowing down in Europe, the effects of ending lockdown in the next months are unpredictable. It is important for the European and world stroke community to share what has been learned so far to be plan strategies to ensure stroke care in the future and upcoming challenging times. | 1351-5101,1468-1331 | 2020-06-07 02:00:00+02:00 | pubmed | European Journal of Neurology | A Bersano;M Kraemer;E Touzé;R Weber;S Alamowitch;I Sibon;L Pantoni | COVID-19;Europe;care;emergency;outbreak;pathways;stroke | 2020-06-03 02:00:00+02:00 | 32492764 | FR;IT;DE | Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.;Department of Neurology, Alfried Krupp Krankenhaus Essen, Essen.;University Clinic of Duesseldorf, Heinrich Heine University, Duesseldorf, Germany.;Université Caen Normandie, Inserm U1237, CHU Caen Normandie, Service de Neurologie, GIP Cyceron, Caen, 14000, France.;Faculty of Medicine, Ruhr-University Bochum, Bochum, Germany.;Department of Neurology, Inserm, UMRS 938, Hôpital St-Antoine, AP-HP, Sorbonne Université, Paris.;Stroke Unit, Department of Neurology, CHU Bordeaux, Bordeaux University, Bordeaux, France.;Stroke and Dementia Laboratory, 'Luigi Sacco' Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. | 1129 | |||
| 10.1093/cid/ciaa710 | Journal Article | en | COVID-19 pandemic: Impact caused by school closure and national lockdown on pediatric visits and admissions for viral and non-viral infections, a time series analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32492117 | A time series analysis of 871,543 pediatric emergency visits revealed that the COVID-19 lockdown and school closure were associated with a significant decrease in infectious diseases disseminated through airborne or fecal-oral transmissions: common cold, gastro-enteritis, bronchiolitis, acute otitis. No change was found for urinary tract infections. | 1058-4838,1537-6591 | 2020-06-07 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | François Angoulvant;Naïm Ouldali;David Dawei Yang;Mathilde Filser;Vincent Gajdos;Alexis Rybak;Romain Guedj;Valérie Soussan-Banini;Romain Basmaci;Alain Lefevre-Utile;Dominique Brun-Ney;Laure Beaujouan;David Skurnik | covid-19;emergency;epidemic;lockdown;pediatric | 2020-06-03 02:00:00+02:00 | 32492117 | FR;US | Assistance Publique - Hôpitaux de Paris, Pediatric Emergency Department, Necker-Enfants Malades University Hospital, Université de Paris, Paris, France.;INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Sorbonne Université, Université de Paris, Paris, France.;Assistance Publique-Hôpitaux de Paris, Department of general pediatrics, pediatric infectious disease and internal medicine, Robert Debré university hospital, Université de Paris, Paris, France.;Assistance Publique-Hôpitaux de Paris, Clinical epidemiology unit, Robert Debré university hospital, ECEVE INSERM UMR 1123, Université de Paris, Paris, France.;ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France.;Assistance Publique-Hôpitaux de Paris, Department of Clinical Microbiology, Necker-Enfants Malades University Hospital, Université de Paris, Paris, France.;Assistance Publique - Hôpitaux de Paris, Pediatric Department, Antoine Béclère University hospital, Université de Paris Saclay, Clamart, France.;Centre for Research in Epidemiology and Population Health, INSERM UMR1018, Villejuif, France.;Assistance Publique - Hôpitaux de Paris, Pediatric Emergency Department, Robert Debré university hospital, Université de Paris, Paris, France.;Assistance Publique - Hôpitaux de Paris, Pediatric Emergency Department, Armand Trousseau University Hospital, Sorbonne Université, Paris, France.;Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS), Inserm UMR1153, Université de Paris, Paris, France.;Assistance Publique - Hôpitaux de Paris, Service de Pédiatrie, Hôpital Ambroise Paré, Boulogne Billancourt, France.;Assistance Publique - Hôpitaux de Paris, Service de Pédiatrie-Urgences, Hôpital Louis-Mourier, Université de Paris, Colombes, France.;IAME, INSERM UMR1137, Université de Paris, Paris, France.;Assistance Publique-Hôpitaux de Paris - General Pediatric and Pediatric Emergency Departement, Jean Verdier Hospital, Bondy, France.;INSERM U976 - Human systems immunology and inflammatory networks , Saint Louis Research Institute, Université de Paris,France.;Assistance Publique-Hôpitaux de Paris, Strategy and Transformation Management Department - Emergencies and Intensive Cares, Paris, France.;Assistance Publique-Hôpitaux de Paris, Patient Quality Medical Organisation Departement - Health Crisis Management, Paris France.;INSERM U1151-Equipe 11, Institut Necker-Enfants Malades, Université de Paris, Paris, France.;Division of Infectious Diseases, Harvard Medical School, Boston, Massachusetts, United States of America. | 1132 | |||
| 10.2807/1560-7917.es.2020.25.22.2000956 | Journal Article | en | High impact of COVID-19 in long-term care facilities, suggestion for monitoring in the EU/EEA, May 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32524949 | Residents in long-term care facilities (LTCF) are a vulnerable population group. Coronavirus disease (COVID-19)-related deaths in LTCF residents represent 30-60% of all COVID-19 deaths in many European countries. This situation demands that countries implement local and national testing, infection prevention and control, and monitoring programmes for COVID-19 in LTCF in order to identify clusters early, decrease the spread within and between facilities and reduce the size and severity of outbreaks. | 1560-7917 | 2020-06-14 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Betacoronavirus;Coronavirus__isolation & purification;Coronavirus Infections__diagnosis;Disease Outbreaks;Europe__epidemiology;Female;Humans;Long-Term Care;Male;Nursing Homes;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Vulnerable Populations;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Kostas Danis;Laure Fonteneau;Scarlett Georges;Côme Daniau;Sibylle Bernard-Stoecklin;Lisa Domegan;Joan O'Donnell;Siri Helene Hauge;Sara Dequeker;Eline Vandael;Johan Van der Heyden;Françoise Renard;Natalia Bustos Sierra;Enrico Ricchizzi;Birgitta Schweickert;Nicole Schmidt;Muna Abu Sin;Tim Eckmanns;José-Artur Paiva;Elke Schneider | COVID-19;EU/EEA;long-term care facilities;surveillance | 2020-06-12 02:00:00+02:00 | 32524949 | SE;FR;NO;IE;PT;IT;ES;BE;DE | Santé Publique France (SpFrance), the French National Public Health Agency, St Maurice, France.;Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.;European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.;Norwegian Institute of Public Health, Oslo, Norway.;Sciensano, Brussels, Belgium.;Regional Health and Social Agency - Emilia Romagna, Bologna, Italy.;Robert Koch-Institute, Berlin, Germany.;Directorate General of Health, Lisbon, Portugal.;European Agency for Safety and Health at Work, Bilbao, Spain. | 1138 | ||
| 10.1136/bmjgh-2020-002913 | Journal Article | en | Ethnic and racial disparities in COVID-19-related deaths: counting the trees, hiding the forest. | https://www.ncbi.nlm.nih.gov/pubmed/32513864 | 2059-7908 | 2020-06-14 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Health Status Disparities;Healthcare Disparities;Humans;Minority Groups;Pandemics;Pneumonia, Viral__epidemiology;Race Factors;United States__epidemiology;COVID-19 | BMJ Global Health | Sanni Yaya;Helena Yeboah;Carlo Handy Charles;Akaninyene Otu;Ronald Labonte | COVID-19;epidemiology;health disparities;health policy;health systems;public health | 2020-06-10 02:00:00+02:00 | 32513864 | FR;CA;NG;GB;US;MQ | School of International Development and Global Studies, University of Ottawa, Ottawa, Ontario, Canada sanni.yaya@uottawa.ca.;The George Institute for Global Health, University of Oxford, Oxford, United States.;School of International Development and Global Studies, University of Ottawa, Ottawa, Ontario, Canada.;Department of Sociology, McMaster University, Hamilton, Ontario, Canada.;Geography at the Laboratoire Caribéen de Sciences Sociales du Centre National de la Recherche Scientifique, Université des Antilles, Schoelcher, Martinique.;Department of Infection and Travel Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.;Department of Internal Medicine, College of Medical Sciences, University of Calabar, Calabar, Cross River State, Nigeria.;School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. | 1150 | |||
| 10.1097/rlu.0000000000003144 | Case Reports;Journal Article | en | Incidental Discovery of a COVID-19 Infection on a Reevaluation FDG PET/CT in a Patient Treated for Hodgkin Lymphoma. | https://www.ncbi.nlm.nih.gov/pubmed/32520506 | We report the results of F-FDG PET/CT in an asymptomatic case of COVID-19 infection. A 27-year-old woman underwent FDG PET/CT for revaluation of a stage IIIE B Hodgkin lymphoma after the fourth cycle of chemotherapy. It showed intense avid FDG subpleural mixed ground-glass and consolidative lesions, especially in the left lung. Because of this morpho-metabolic aspect and the epidemic context, a viral pneumopathy was suspected. The patient who was initially asymptomatic was admitted for fever 28 hours after the PET/CT. The nasopharyngeal swab was positive for COVID-19, and the outcome was favorable. | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections__complications;Female;Fluorodeoxyglucose F18;Hodgkin Disease__complications;Humans;Neoplasm Staging;Pandemics;Pneumonia, Viral__complications;Positron Emission Tomography Computed Tomography;COVID-19;severe acute respiratory syndrome coronavirus 2 | Celestine Simand;Caroline Bund;Blandine Guffroy;Vitaliy Chaban;Raoul Herbrecht | 2020-06-11 02:00:00+02:00 | 32520506 | FR;UNK | From the Institut de Cancérologie Strasbourg, Europe (ICANS).;Departments of Hematology.;Biophysics and Nuclear Medicine, University Hospital of Strasbourg.;ICube, Université de Strasbourg/CNRS, UMR 7357.;Université de Strasbourg, Inserm UMR S1113/IRFAC.;Intermediate Care Unit, Institut de Cancérologie Strasbourg, Europe (ICANS), Strasbourg, France. | 1154 | |||||
| Letter | en | Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32513650 | 2020-06-14 02:00:00+02:00 | pubmed | Jan Holubar;Moglie Le Quintrec;Hind Letaief;Jean Luc Faillie;Yves-Marie Pers;Christian Jorgensen | epidemiology;hydroxychloroquine;lupus erythematosus, systemic | 2020-06-08 02:00:00+02:00 | 32513650 | FR | Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHRU Lapeyronie, Montpellier, France j.holubar11@gmail.com.;Nephrology Unit, CHRU Lapeyronie, Montpellier, France.;Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHRU Lapeyronie, Montpellier, France.;Medical Pharmacology and Toxicology Unit, CHRU Lapeyronie, Montpellier, France. | 1155 | |||||||
| 10.1016/s2666-5247(20)30066-5 | Journal Article | en | Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32835345 | 2666-5247 | 2020-06-14 02:00:00+02:00 | pubmed | The Lancet Microbe | Grégory Destras;Antonin Bal;Vanessa Escuret;Florence Morfin;Bruno Lina;Laurence Josset | 2020-06-11 02:00:00+02:00 | 32835345 | FR | Laboratoire de Virologie, Centre National de Référence France-Sud des Virus des Infections Respiratoires, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004 Lyon, France.;Université de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Lyon, France. | 1172 | |||||
| 10.1111/all.14453 | Journal Article | en | COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper. | https://www.ncbi.nlm.nih.gov/pubmed/32531110 | The Coronavirus disease 2019 (COVID-19) has evolved as a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-)2. Allergists and other health care providers (HCPs) in the field of allergies and associated airway diseases are in the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. | 0105-4538,1398-9995 | 2020-06-14 02:00:00+02:00 | pubmed | Allergy | O Pfaar;L Klimek;M Jutel;C A Akdis;J Bousquet;H Breiteneder;S Chinthrajah;Z Diamant;T Eiwegger;W J Fokkens;H W Fritsch;K C Nadeau;R E O'Hehir;L O'Mahony;W Rief;V Sampath;M Schedlowski;M Torres;C Traidl-Hoffmann;D Y Wang;L Zhang;M Bonini;R Brehler;H A Brough;T Chivato;S Del Giacco;S Dramburg;R Gawlik;A Gelincik;K Hoffmann-Sommergruber;V Hox;E Knol;A Lauerma;P M Matricardi;C G Mortz;M Ollert;O Palomares;C Riggioni;J Schwarze;I Skypala;S Untersmayr;J Walusiak-Skorupa;I Ansotegui;C Bachert;A Bedbrook;S Bosnic-Anticevich;L Brussino;G W Canonica;V Cardona;P Carreiro-Martins;A A Cruz;W Czarlewski;J A Fonseca;M Gotua;T Haatela;J C Ivancevich;P Kuna;V Kvedariene;D Larenas-Linnemann;A Latiff;M Morais-Almeida;J Mullol;R Naclerio;K Ohta;Y Okamoto;G L Onorato;N G Papadopoulos;V Patella;F S Regateiro;B Samolinski;C Suppli Ulrik;S Toppila-Salmi;A Valiulis;M T Ventura;A Yorgancioglu;T Zuberbier;I Agache | COVID-19;SARS-CoV-2;allergen immunotherapy (AIT);allergy clinic;anaphylaxis;asthma;clinical trials;position paper;psychological COVID | 2020-06-12 02:00:00+02:00 | 32531110 | LT;CA;PT;JP;BR;CZ;AR;GE;NL;MX;DK;BE;PS;FR;CN;GR;CH;US;GB;RO;PL;IT;LU;DE;AT;SE;IE;SG;MY;FI;AU;TR;ES | Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.;Center for Rhinology and Allergology, Wiesbaden, Germany.;Department of Clinical Immunology, Wrocław Medical University, ALL-MED Medical Research Institute, Wrocław, Poland.;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.;Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.;University Hospital Montpellier, Montpellier, France.;MACVIA-France, Montpellier, France.;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.;Stanford University School of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, United States of America.;Dept of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.;Dept Clin Pharm & Pharmacol, Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.;Translational Medicine Program, Peter Gilgan Centre for Research and Learning, Hospital for Sick Children, Toronto, Ontario, Canada.;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Departments of Paediatrics and Immunology, University of Toronto, Toronto, ON, Canada.;Department of Immunology, University of Toronto, Toronto, ON, Canada.;Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands.;Department of Information-Technology (IT), University Hospital Marburg, Marburg, Germany.;Allergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, VIC, Australia.;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University and Alfred Health, Melbourne, VIC, Australia.;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.;Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg, Germany.;Institute of Medical Psychology and Behavioral Immunobiology, University Clinic Essen, Essen, Germany.;Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.;Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München, Augsburg, Germany.;Outpatient Clinic for environmental medicine, University Hospital, Augsburg, Germany.;Department of Otolaryngology, National University of Singapore, Singapore, Singapore.;Department of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing Tongren Hospital, Beijing, China.;Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.;National Heart and Lung Institute (NHLI), Imperial College London, UK.;University Hospital Münster, Department of Allergology, Occupational Dermatology and Environmental Medicine, Münster, Germany.;Children's Allergy Service, Evelina Children's Hospital, Guy's and St, Thomas' Hospital NHS Foundation Trust, London, UK.;Paediatric Allergy Group, Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK.;School of Medicine, University CEU San Pablo, Madrid, Spain.;Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.;Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité Universitaetsmedizin, Berlin, Germany.;Dpt. of Internal Medicine, Allergology, Clinical Immunology Medical, University of Silesia, Katowice, Poland.;Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.;Department of Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.;Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Dermatology and Allergology, University of Helsinki, and Helsinki University Hospital Inflammation Centre, Helsinki, Finland.;Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense, Denmark.;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.;Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain.;Institut de Recerca Sant Joan de Déu, Barcelona, Spain.;Centre for Inflammation Research and Child Life and Heath, the University of Edinburgh, Edinburgh, UK.;Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, UK.;Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Erandio, Spain.;Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium.;Sun Yat-sen University, International Airway Research Center, First Affiliated Hospital, Guangzou, China.;Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden.;Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia.;Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino & Mauriziano Hospital, Torino, Italy.;Personalized Medicine Asthma & Allergy Clinic-Humanitas University & Research Hospital, IRCCS-Milano, Milano, Italy.;Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL research network, Barcelona, Spain.;Serviço de Imunoalergologia, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.;NOVA Medical School/Comprehensive Health Research Center (CHRC), Universidade Nova de Lisboa, Lisbon, Portugal.;ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and GARD/WHO Executive Committee, Bahia, Brazil.;Medical Consulting Czarlewski, Levallois-Perret, France.;CINTESIS, Center for Research in Health Technologies and Information Systems, Faculdade de Medicina da Universidade do Porto, and MEDIDA, Lda, Porto, Portugal.;Center of Allergy and Immunology, Tbilisi, Georgia and David Tvildiani Medical, University in Tbilisi, Tbilisi, Georgia.;Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.;Institute of Clinical medicine, Clinic of Chest diseases and Allergology, faculty of Medicine, Vilnius University, Vilnius, Lithuania.;Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.;Allergy & Immunology Centre, Pantai Hospital, Kuala Lumpur, Malaisia.;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.;Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic - Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.;Johns Hopkins School of Medicine, Baltimore, Maryland, USA.;National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.;Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.;Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.;Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital "P&A Kyriakou, University of Athens, Athens, Greece.;Allergy and Respiratory Diseases, Department of Internal Medicine, IRCCS San Martino-IST-Univesity of Genoa, Genoa, Italy.;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra and Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.;Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.;Dept of Respiratory Medicine, Hvidovre Hospital, Hvidovre and Institute of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.;Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.;Vilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, Lithuania.;Interdisciplinary Department of Medicine, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy.;Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey.;Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health,, Comprehensive Allergy Center, Department of Dermatology and Allergy, a member of GA2LEN, Berlin, Germany.;Transylvania University, Brasov, Romania.;Theramed Medical Center, Brasov, Romania. | 1175 | |||
| 10.1016/j.cub.2020.06.031 | Journal Article;Research Support, Non-U.S. Gov't | en | On the evolutionary epidemiology of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32750338 | There is no doubt that the novel coronavirus SARS-CoV-2 that causes COVID-19 is mutating and thus has the potential to adapt during the current pandemic. Whether this evolution will lead to changes in the transmission, the duration, or the severity of the disease is not clear. This has led to considerable scientific and media debate, from raising alarms about evolutionary change to dismissing it. Here we review what little is currently known about the evolution of SARS-CoV-2 and extend existing evolutionary theory to consider how selection might be acting upon the virus during the COVID-19 pandemic. Although there is currently no definitive evidence that SARS-CoV-2 is undergoing further adaptation, continued evidence-based analysis of evolutionary change is important so that public health measures can be adjusted in response to substantive changes in the infectivity or severity of COVID-19. | 0960-9822 | 2020-06-14 02:00:00+02:00 | pubmed | Adaptation, Biological__genetics;Animals;Asymptomatic Infections;Betacoronavirus__genetics;Biological Evolution;Coronavirus Infections__epidemiology;Genetic Pleiotropy;Genetic Variation;Humans;Mutation;Pandemics;Pneumonia, Viral__epidemiology;Population Growth;Selection, Genetic;Social Distance;Zoonoses;COVID-19;severe acute respiratory syndrome coronavirus 2 | Current Biology | Troy Day;Sylvain Gandon;Sébastien Lion;Sarah P Otto | 2020-06-11 02:00:00+02:00 | 32750338 | FR;CA;GB;US | Department of Mathematics and Statistics, Department of Biology, Queen's University, Kingston, ON K7L 3N6, Canada. Electronic address: day@queensu.ca.;CEFE, CNRS, University of Montpellier, Paul Valéry University of Montpellier, EPHE, IRD, 34293 Montpellier Cedex 5, France. Electronic address: sylvain.gandon@cefe.cnrs.fr.;CEFE, CNRS, University of Montpellier, Paul Valéry University of Montpellier, EPHE, IRD, 34293 Montpellier Cedex 5, France. Electronic address: sebastien.lion@cefe.cnrs.fr.;Department of Zoology and Biodiversity Research Centre, University of British Columbia, Vancouver, BC V6T 1Z4, Canada. Electronic address: otto@zoology.ubc.ca. | 1185 | |||
| Comparative Study;Evaluation Study;Letter | en | The use of exoskeletons to help with prone positioning in the intensive care unit during COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32531399 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Allied Health Personnel;Back Injuries__etiology;Betacoronavirus;Biomechanical Phenomena;Coronavirus Infections__complications;Cumulative Trauma Disorders__etiology;Equipment Design;Exoskeleton Device;Hospitals, University__organization & administration;Humans;Intensive Care Units;Lumbosacral Region__physiology;Male;Manikins;Moving and Lifting Patients__adverse effects;Occupational Diseases__etiology;Pandemics;Patient Positioning;Pilot Projects;Pneumonia, Viral__complications;Prone Position;Respiratory Distress Syndrome, Adult__etiology;Stress, Mechanical;Weight-Bearing;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nicla Settembre;Pauline Maurice;Jean Paysant;Jean Theurel;Laurent Claudon;Antoine Kimmoun;Bruno Levy;Hind Hani;Bruno Chenuel;Serena Ivaldi | COVID-19;Ergonomy;Exoskeleton;Intensive care unit;Prone position;Simulation | 2020-06-10 02:00:00+02:00 | 32531399 | FR | CHRU-Nancy, Inserm 1116, Virtual Hospital of Lorraine, University of Lorraine, 1, rue du Morvan, 54500 Nancy, France. Electronic address: nicla.settembre@univ-lorraine.fr.;University of Lorraine, CNRS, Inria, LORIA, 54000 Nancy, France.;CHRU-Nancy, Department of Rehabilitation Medicine, EA DevAH, University of Lorraine, 54000 Nancy, France.;Working Life Department, French National Research and Safety Institute for the Prevention of Occupational Accidents and Diseases (INRS), 54500 Vandœuvre-lès-Nancy, France.;Medical Intensive Care Unit Brabois, Nancy University Hospital, INSERM U1116, University of Lorraine, 54000 Nancy, France.;Virtual Hospital of Lorraine, CUESim, University of Lorraine, 54000 Nancy, France.;CHRU-Nancy, University of Lorraine, University Centre of Sports Medicine and Adapted Physical Activity, Pulmonary Function and Exercise Testing Department, EA DevAH, Department of Medical Physiology, 54000 Nancy, France. | 1189 | ||||||
| Letter | en | Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use? | https://www.ncbi.nlm.nih.gov/pubmed/32610172 | 2020-06-14 02:00:00+02:00 | pubmed | Amides__adverse effects;Antibodies, Monoclonal, Humanized__adverse effects;Antineoplastic Agents__adverse effects;Antineoplastic Agents, Hormonal__adverse effects;Antineoplastic Agents, Immunological__adverse effects;Antiviral Agents__adverse effects;Betacoronavirus;Chemical and Drug Induced Liver Injury__etiology;Coronavirus Infections__complications;Cytochrome P-450 Enzyme System__metabolism;Drug Combinations;Drug Interactions;Histone Deacetylase Inhibitors__adverse effects;Humans;Hydroxychloroquine__adverse effects;Immunosuppression__adverse effects;Kidney Diseases__chemically induced;Long QT Syndrome__chemically induced;Lopinavir__adverse effects;Neoplasms__complications;Pandemics;Pneumonia, Viral__complications;Poly(ADP-ribose) Polymerase Inhibitors__adverse effects;Proteasome Inhibitors__adverse effects;Protein Kinase Inhibitors__adverse effects;Pyrazines__adverse effects;Ritonavir__adverse effects;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Paul Gougis;Charlotte Fenioux;Christian Funck-Brentano;Marianne Veyri;Joseph Gligorov;Caroline Solas;Jean-Philippe Spano | Anticancer drugs;Antiviral interactions;COVID-19;Drug interactions;Drug-induced long QT syndrome | 2020-06-10 02:00:00+02:00 | 32610172 | FR | Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France, Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Oncology, F-75013 Paris, France, Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France. Electronic address: paul.gougis@aphp.fr.;Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France, Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France.;Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP(2) Galilée, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France.;Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Oncology, F-75013 Paris, France, Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, équipe Theravir, France.;Institut Universitaire de Cancérologie. AP-HP Sorbonne Université, Paris, France, Sorbonne Université, INSERM U-938, CLIP(2) Galilée, Assistance-Publique - Hôpitaux de Paris, Tenon Hospital, Medical Oncology Department, Paris, France.;Aix Marseille Univ, APHM, INSERM 1207, IRD 190, UVE, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, F-13005 Marseille, France. | 1191 | ||||||
| European Genomic Institute for Diabetes;European Commission;Foundation Coeur et Arteres | 10.1002/oby.22831 | Journal Article;Research Support, Non-U.S. Gov't | en | High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. | https://www.ncbi.nlm.nih.gov/pubmed/32271993 | The COVID-19 pandemic is rapidly spreading worldwide, notably in Europe and North America where obesity is highly prevalent. The relation between obesity and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has not been fully documented. | 1930-7381,1930-739X | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus;Body Mass Index;Coronavirus Infections__complications;Female;France__epidemiology;Hospitalization__statistics & numerical data;Humans;Male;Middle Aged;Obesity__epidemiology;Pandemics;Pneumonia, Viral__complications;Prevalence;Respiration, Artificial__statistics & numerical data;Retrospective Studies;Risk Factors;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Obesity | Arthur Simonnet;Mikael Chetboun;Julien Poissy;Violeta Raverdy;Jerome Noulette;Alain Duhamel;Julien Labreuche;Daniel Mathieu;Francois Pattou;Merce Jourdain | 2020-06-10 02:00:00+02:00 | 32271993 | FR | [{"country": "International", "agency": "European Genomic Institute for Diabetes", "grantid": "ANR-10-LABX-46"}, {"country": "International", "agency": "European Commission", "grantid": "FEDER 12003944"}, {"country": "International", "agency": "Foundation Coeur et Arteres", "grantid": "FCA R15112EE"}] | Department of Intensive Care, Centre Hospitalier Universitaire Lille, Lille, France.;University of Lille, Inserm, Centre Hospitalier Universitaire Lille, Lille Pasteur Institute, U1190, European Genomic Institute for Diabetes, Lille, France.;Centre Hospitalier Universitaire Lille, U2694 METRICS, University of Lille, Lille, France.;Integrated Center for Obesity, Centre Hospitalier Universitaire Lille, Lille, France. | 1193 | |
| 10.1097/shk.0000000000001565 | Journal Article | en | SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. | https://www.ncbi.nlm.nih.gov/pubmed/32433217 | Approximately 3 billion people around the world have gone into some form of social separation to mitigate the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The uncontrolled influx of patients in need of emergency care has rapidly brought several national health systems to near-collapse with deadly consequences to those afflicted by Coronavirus Disease 2019 (COVID-19) and other critical diseases associated with COVID-19. Solid scientific evidence regarding SARS-CoV-2/COVID-19 remains scarce; there is an urgent need to expand our understanding of the SARS-CoV-2 pathophysiology to facilitate precise and targeted treatments. The capacity for rapid information dissemination has emerged as a double-edged sword; the existing gap of high-quality data is frequently filled by anecdotal reports, contradictory statements, and misinformation. This review addresses several important aspects unique to the SARS-CoV-2/COVID-19 pandemic highlighting the most relevant knowledge gaps and existing windows-of-opportunity. Specifically, focus is given on SARS-CoV-2 immunopathogenesis in the context of experimental therapies and preclinical evidence and their applicability in supporting efficacious clinical trial planning. The review discusses the existing challenges of SARS-CoV-2 diagnostics and the potential application of translational technology for epidemiological predictions, patient monitoring, and treatment decision-making in COVID-19. Furthermore, solutions for enhancing international strategies in translational research, cooperative networks, and regulatory partnerships are contemplated. | 1073-2322 | 2020-06-14 02:00:00+02:00 | pubmed | Shock | Marcin F Osuchowski;Federico Aletti;Jean-Marc Cavaillon;Stefanie B Flohé;Evangelos J Giamarellos-Bourboulis;Markus Huber-Lang;Borna Relja;Tomasz Skirecki;Andrea Szabó;Marc Maegele | 2020-06-10 02:00:00+02:00 | 32433217 | FR;GR;US;AT;PL;HU;DE | Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Vienna, Austria.;Department of Bioengineering, University of California San Diego, La Jolla, California.;National Research Agency, Paris, France.;Department of Trauma, Hand, and Reconstructive Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany.;4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.;Institute of Clinical and Experimental Trauma-Immunology, University Hospital Ulm, Ulm University, Ulm, Germany.;Experimental Radiology, Department of Radiology and Nuclear Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany.;Laboratory of Flow Cytometry, Centre of Postgraduate Medical Education, Warsaw, Poland.;Institute of Surgical Research, University of Szeged, Szeged, Hungary.;Department of Trauma and Orthopaedic Surgery, Cologne-Merheim Medical Center (CMMC), University of Witten/Herdecke, Cologne-Merheim Campus, Cologne, Germany.;Institute for Research in Operative Medicine (IFOM), University of Witten/Herdecke, Cologne-Merheim Campus, Cologne, Germany. | 1200 | ||||
| 10.1016/j.jfo.2020.05.005 | Journal Article | en | Teleconsultation in primary ophthalmic emergencies during the COVID-19 lockdown in Paris: Experience with 500 patients in March and April 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32564983 | This prospective observational cohort study is based on the first 500 patients who requested emergency teleconsultation during the initial days of the COVID-19 lockdown in Paris, France between 20 March and 10 April 2020. It is the first study to assess the utility of emergency teleophthalmology with a simple smartphone application or web browser and a webcam to manage emergency eye care in a population with sudden restricted access to ophthalmologists. In this study, every patient who asked for an ophthalmic emergency consultation in a single specialized center in Paris ('SOS Œil') first had to undergo a teleconsultation appointment to evaluate the indication for a physical consultation to preserve lockdown. Under medical advice only, a physical appointment was given within a day (if necessary). The aim of the study was to describe the population and diagnoses and evaluate the main judgment criteria, defined as the 'ability of teleconsultation to properly indicate a physical consultation for fair diagnosis and treatment in eye emergencies'. This organization has permitted physicians and patients to preserve social distancing while avoiding 3 or 4 physical consultations per person. Notably, 27% of teleconsultations were followed by a physical appointment. There was a mean 4.12-day delay between symptom apparition and consultation, and less than 1 day for traumas, superficial corneal foreign body and neuro-ophthalmological emergencies. There was a 96% sensitivity and 95% specificity to properly evaluate the indication of a physical consultation and only 1.0% misdiagnoses that lead to delayed care. Hence, teleconsultation maintained satisfactory healthcare access to patients with severe ophthalmological disorders while preserving social distancing and sanitary precautions. Therefore, teleconsultation may be seriously considered as a way to efficiently regulate ophthalmic emergencies, especially for patients with limited access to a specialist. | 0181-5512 | 2020-06-14 02:00:00+02:00 | pubmed | Journal Français d'Ophtalmologie | H Bourdon;R Jaillant;A Ballino;P El Kaim;L Debillon;S Bodin;L N'Kosi | COVID-19;Confinement;Distanciation sociale;Emergency ophthalmology;Lockdown;Social distancing;Teleophthalmology;Téléophtalmologie;Urgences ophtalmologiques | 2020-06-10 02:00:00+02:00 | 32564983 | FR | Department of Ophthalmology III, CHNO des Quinze-Vingts, IHU FOReSIGHT, 28, rue de Charenton, 75012 Paris, France, OphtalmoPôle Cochin, 8, rue Méchain, 75014 Paris, France. Electronic address: bourdonhugo@gmail.com.;Centre Ophtalmologique Paris 17 - SOS Œil, 33-35, rue de Chazelles, 75017 Paris, France.;Department of Ophthalmology III, CHNO des Quinze-Vingts, IHU FOReSIGHT, 28, rue de Charenton, 75012 Paris, France.;OphtalmoPôle Cochin, 8, rue Méchain, 75014 Paris, France. | 1204 | |||
| 10.1136/medethics-2020-106489 | Journal Article | en | The good, the bad and the ugly: pandemic priority decisions and triage. | https://www.ncbi.nlm.nih.gov/pubmed/32522814 | In this analysis we discuss the change in criteria for triage of patients during three different phases of a pandemic like COVID-19, seen from the critical care point of view. Availability of critical care beds has become a hot topic, and in many countries, we have seen a huge increase in the provision of temporary intensive care bed capacity. However, there is a limit where the hospitals may run out of resources to provide critical care, which is heavily dependent on trained staff, just-in-time supply chains for clinical consumables and drugs and advanced equipment. In the first (good) phase, we can still do clinical prioritisation and decision-making as usual, based on the need for intensive care and prognostication: what are the odds for a good result with regard to survival and quality of life. In the next (bad phase), the resources are mostly available, but the system is stressed by many patients arriving over a short time period and auxiliary beds in different places in the hospital being used. We may have to abandon admittance of patients with doubtful prognosis. In the last (ugly) phase, usual medical triage and priority setting may not be sufficient to decrease inflow and there may not be enough intensive care unit beds available. In this phase different criteria must be applied using a utilitarian approach for triage. We argue that this is an important transition where society, and not physicians, must provide guidance to support triage that is no longer based on medical priorities alone. | 0306-6800,1473-4257 | 2020-06-14 02:00:00+02:00 | pubmed | Journal of Medical Ethics | Hans Flaatten;Vernon Van Heerden;Christian Jung;Michael Beil;Susannah Leaver;Andrew Rhodes;Bertrand Guidet;Dylan W deLange | allocation of health care resources;anaesthetics / anesthesiology;clinical ethics;epidemiology;health care for specific diseases/groups | 2020-06-10 02:00:00+02:00 | 32522814 | SE;IL;NO;FR;GB;NL;DE | Department of Anaesthesia, Haukeland Universitetssjukehus, Bergen, Norway hans.flaatten@uib.no.;Intensive Care and Department of Clinical Medicine, Haukeland Universitetssjukehus, Bergen, Norway.;General Intensive Care Unit, Hadassah Medical Center, Jerusalem, Jerusalem, Israel.;Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine-University, Düsseldorf, Germany.;Intensive Care and Respiratory Medicine, St George's University Hospitals NHS Foundation Trust, London, London, UK.;St George's University Hospitals NHS Foundation Trust, London, London, UK.;Assistance Publique, Hôpitaux de Paris, Hôpital Saint‑Antoine, Service de Réanimation Médicale, Paris 75012, France.;Department of Intensive Care Medicine, University Medical Center, University of Utrecht, Utrecht, Netherlands. | 1208 | |||
| Letter | en | SARS-CoV-2 pandemic and emergency medicine: The worst is yet to come. | https://www.ncbi.nlm.nih.gov/pubmed/32593460 | 2020-06-14 02:00:00+02:00 | pubmed | Jean-Baptiste Bouillon-Minois;Jeannot Schmidt;Frédéric Dutheil | 2020-06-10 02:00:00+02:00 | 32593460 | FR | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Emergency Medicine, F-63000 Clermont-Ferrand, France. Electronic address: jbb.bouillon@gmail.com.;Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Emergency Medicine, F-63000 Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Occupational and Environmental Medicine, WittyFit, F-63000 Clermont-Ferrand, France. | 1209 | ||||||||
| 10.1177/1756286420932036 | Journal Article;Review | en | Neurological manifestations and implications of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32565914 | The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China and rapidly spread worldwide, with a vast majority of confirmed cases presenting with respiratory symptoms. Potential neurological manifestations and their pathophysiological mechanisms have not been thoroughly established. In this narrative review, we sought to present the neurological manifestations associated with coronavirus disease 2019 (COVID-19). Case reports, case series, editorials, reviews, case-control and cohort studies were evaluated, and relevant information was abstracted. Various reports of neurological manifestations of previous coronavirus epidemics provide a roadmap regarding potential neurological complications of COVID-19, due to many shared characteristics between these viruses and SARS-CoV-2. Studies from the current pandemic are accumulating and report COVID-19 patients presenting with dizziness, headache, myalgias, hypogeusia and hyposmia, but also with more serious manifestations including polyneuropathy, myositis, cerebrovascular diseases, encephalitis and encephalopathy. However, discrimination between causal relationship and incidental comorbidity is often difficult. Severe COVID-19 shares common risk factors with cerebrovascular diseases, and it is currently unclear whether the infection per se represents an independent stroke risk factor. Regardless of any direct or indirect neurological manifestations, the COVID-19 pandemic has a huge impact on the management of neurological patients, whether infected or not. In particular, the majority of stroke services worldwide have been negatively influenced in terms of care delivery and fear to access healthcare services. The effect on healthcare quality in the field of other neurological diseases is additionally evaluated. | 1756-2864,1756-2864 | 2020-06-14 02:00:00+02:00 | pubmed | Therapeutic Advances in Neurological Disorders | Georgios Tsivgoulis;Lina Palaiodimou;Aristeidis H Katsanos;Valeria Caso;Martin Köhrmann;Carlos Molina;Charlotte Cordonnier;Urs Fischer;Peter Kelly;Vijay K Sharma;Amanda C Chan;Ramin Zand;Amrou Sarraj;Peter D Schellinger;Konstantinos I Voumvourakis;Nikolaos Grigoriadis;Andrei V Alexandrov;Sotirios Tsiodras | COVID-19;SARS-CoV-2;cerebrovascular diseases;healthcare impact;neurological manifestations | 2020-06-09 02:00:00+02:00 | 32565914 | FR;IE;SG;MK;GR;CH;US;IT;ES;PS;DE | Second Department of Neurology, National & Kapodistrian University of Athens, School of Medicine, Rimini 1, Chaidari, Athens 12462, Greece.;Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Athens, Greece.;Stroke Unit, University of Perugia - Santa Maria della Misericordia Hospital, Perugia, Italy.;Department of Neurology, University of Essen, Essen, Germany.;Department of Neurology, Stroke Unit, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.;Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Univ. Lille, Lille, France.;Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.;HRB Stroke Clinical Trials Network Ireland and Stroke Service/Department of Neurology, Mater University Hospital/University College, Dublin, Ireland.;Department of Medicine, Division of Neurology, National University Hospital, Singapore.;Department of Neurology, Neuroscience Institute, Geisinger Health System, Danville, PA, USA.;Department of Neurology, The University of Texas at Houston, Houston, TX, USA.;Department of Neurology and Neurogeriatry, Johannes Wesling Medical Center Minden, University Clinic RUB, Minden, Germany.;Second Department of Neurology, "AHEPA" University Hospital, Aristotelion University of Thessaloniki, Thessaloniki, Macedonia, Greece.;Department of Neurology, The University of Tennessee Health Science Center, Memphis, TN, USA.;4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. | 1227 | |||
| Letter | en | Prehospital pulse oximetry: a red flag for early detection of silent hypoxemia in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32513249 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Aged;Coronavirus Infections__therapy;Early Diagnosis;Emergency Medical Services;Humans;Hypoxia__diagnosis;Middle Aged;Oximetry;Pandemics;Pneumonia, Viral__therapy;Retrospective Studies;COVID-19 | Romain Jouffroy;Daniel Jost;Bertrand Prunet | 2020-06-08 02:00:00+02:00 | 32513249 | FR | Paris Fire Brigade, Emergency Medicine Department, 1 Place Jules Renard, 75017, Paris, France.;Paris Fire Brigade, Emergency Medicine Department, 1 Place Jules Renard, 75017, Paris, France. Daniel.jost@pompiersparis.fr. | 1231 | |||||||
| Letter | en | Isolated post SARS-CoV-2 diplopia. | https://www.ncbi.nlm.nih.gov/pubmed/32533321 | 2020-06-14 02:00:00+02:00 | pubmed | Alice Faucher;Pierre-Antoine Rey;Elise Aguadisch;Bertrand Degos | 2020-06-12 02:00:00+02:00 | 32533321 | FR | Service de Neurologie, APHP, Hôpital Avicenne, Hôpitaux Universitaires de Paris-Seine Saint Denis, Sorbonne Paris Nord, Bobigny, France.;Service d'Ophtalmologie, APHP, Hôpital Avicenne, Hôpitaux Universitaires de Paris-Seine Saint Denis, Sorbonne Paris Nord, Bobigny, France.;Urgences-SAMU 93, APHP, Hôpital Avicenne, Hôpitaux Universitaires de Paris-Seine Saint Denis, Sorbonne Paris Nord, Bobigny, France.;Service de Neurologie, APHP, Hôpital Avicenne, Hôpitaux Universitaires de Paris-Seine Saint Denis, Sorbonne Paris Nord, Bobigny, France. bertrand.degos@aphp.fr.;Dynamics and Pathophysiology of Neuronal Networks Team, Center for Interdisciplinary Research in Biology, UMR7241/INSERM U1050, MemoLife Labex, Collège de France, CNRS, 75005, Paris, France. bertrand.degos@aphp.fr. | 1255 | ||||||||
| 10.1007/s10311-020-01028-3 | Journal Article | en | Unexpected rise of ozone in urban and rural areas, and sulfur dioxide in rural areas during the coronavirus city lockdown in Hangzhou, China: implications for air quality. | https://www.ncbi.nlm.nih.gov/pubmed/32837481 | The outbreak of coronavirus named COVID-19, initially identified in Wuhan, China in December 2019, has spread rapidly at the global scale. Most countries have rapidly stopped almost all activities including industry, services and transportation of goods and people, thus decreasing air pollution in an unprecedented way, and providing a unique opportunity to study air pollutants. While satellite data have provided visual evidence for the global reduction in air pollution such as nitrogen dioxide (NO2) worldwide, precise and quantitative information is missing at the local scale. Here we studied changes in particulate matter (PM2.5, PM10), carbon monoxide (CO), NO2, sulfur dioxide (SO2) and ozone (O3) at 10 urban sites in Hangzhou, a city of 7.03 million inhabitants, and at 1 rural site, before city lockdown, January 1-23, during city lockdown, January 24-February 15, and during resumption, February 16-28, in 2020. Results show that city lockdown induced a sharp decrease in PM2.5, PM10, CO, and NO2 concentrations at both urban and rural sites. The NO2 decrease is explained by reduction in traffic emissions in the urban areas, and by lower regional transport in rural areas during lockdown, as expected. SO2 concentrations decreased from 6.3 to 5.3 μg m-3 in the city, but increased surprisingly from 4.7 to 5.8 μg m-3 at the rural site: this increase is attributed both to higher coal consumption for heating and emissions from traditional fireworks of the Spring Eve and Lantern Festivals during lockdown. Unexpectedly, O3 concentrations increased by 145% from 24.6 to 60.6 μg m-3 in the urban area, and from 42.0 to 62.9 μg m-3 in the rural area during the lockdown. This finding is explained by the weakening of chemical titration of O3 by NO due to reductions of NOx fresh emissions during the non-photochemical reaction period from 20:00 PM to 9:00 AM (local time). During the lockdown, compared to the same period in 2019, the daily average concentrations in the city decreased by 42.7% for PM2.5, 47.9% for PM10, 28.6% for SO2, 22.3% for CO and 58.4% for NO2, which is obviously explained by the absence of city activities. Overall, we observed not only the expected reduction in some atmospheric pollutants (PM, SO2, CO, NO2), but also unexpected increases in SO2 in the rural areas and of ozone (O3) in both urban and rural areas, the latter being paradoxically due to the reduction in nitrogen oxide levels. In other words, the city lockdown has improved air quality by reducing PM2.5, PM10, CO, and NO2, but has also decreased air quality by augmenting O3 and SO2. | 1610-3653,1610-3661 | 2020-06-14 02:00:00+02:00 | pubmed | Environmental Chemistry Letters | Liqiang Wang;Mengying Li;Shaocai Yu;Xue Chen;Zhen Li;Yibo Zhang;Linhui Jiang;Yan Xia;Jiali Li;Weiping Liu;Pengfei Li;Eric Lichtfouse;Daniel Rosenfeld;John H Seinfeld | Air quality;CO;COVID-19;Coronavirus;Emission reductions;Hangzhou;Lockdown;NO2;O3;PM10;PM2.5;SO2 | 2020-06-12 02:00:00+02:00 | 32837481 | FR;CN;US;IL | Key Laboratory of Environmental Remediation and Ecological Health, Ministry of Education, Research Center for Air Pollution and Health, College of Environmental and Resource Sciences, Zhejiang University, Hangzhou, 310058 Zhejiang People's Republic of China.;Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125 USA.;College of Science and Technology, Hebei Agricultural University, Baoding, 071000 Hebei People's Republic of China.;Aix-Marseille Univ, CNRS, Coll France, CNRS, INRA, IRD, CEREGE, Avenue Louis Philibert, 13100 Aix En Provence, France.;State Key Laboratory of Multiphase Flow in Power Engineering, Xi'an Jiaotong University, Xi'an, 710049 Shaanxi People's Republic of China.;Institute of Earth Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel. | 1258 | |||
| 10.1016/j.jcrc.2020.06.005 | Journal Article | en | Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey. | https://www.ncbi.nlm.nih.gov/pubmed/32570052 | To survey healthcare workers (HCW) on availability and use of personal protective equipment (PPE) caring for COVID-19 patients in the intensive care unit (ICU). | 0883-9441 | 2020-06-14 02:00:00+02:00 | pubmed | Journal of Critical Care | Alexis Tabah;Mahesh Ramanan;Kevin B Laupland;Niccolò Buetti;Andrea Cortegiani;Johannes Mellinghoff;Andrew Conway Morris;Luigi Camporota;Nathalie Zappella;Muhammed Elhadi;Pedro Povoa;Karin Amrein;Gabriela Vidal;Lennie Derde;Matteo Bassetti;Guy Francois;Nathalie Ssi Yan Kai;Jan J De Waele | COVID-19;Health care workers;Intensive care;Personal protective equipment;Safety | 2020-06-13 02:00:00+02:00 | 32570052 | FR;AR;PT;GB;IT;LY;AU;NL;BE;AT | Intensive Care Unit, Faculty of Medicine, Redcliffe Hospital, University of Queensland, 4019, Redcliffe, Brisbane, Queensland 4029, Australia. Electronic address: a.tabah@uq.edu.au.;Intensive Care Units, Caboolture and Prince Charles Hospitals, School of Medicine, University of Queensland, The George Institute for Global Health, University of New South Wales, Sydney, Queensland, Australia.;Department of Intensive Care Services, Royal Brisbane and Women's Hospital, Queensland University of Technology, Brisbane, Queensland, Australia.;INSERM IAME, U1137, Team DesCID, Paris, France.;Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.) Section of Anesthesia, Analgesia, Intensive Care and Emergency Policlinico Paolo Giaccone University of Palermo Palermo, Italy.;Faculty of Health and Social Care Education, Kingston & St George's University of London, UK.;Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.;Centre for Human & Applied Physiological Sciences (CHAPS) and School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, Department of Critical Care, Guy's and St Thomas' NHS Foundation Trust, London, UK.;Anesthesiology and Critical Care Medicine Department, DMU PARABOL, Bichat - Claude Bernard Hospital, HUPNVS, AP-HP, Paris, France.;Faculty of Medicine, University of Tripoli, Libya.;Sao Francisco Xavier Hospital, CHLO, NOVA Medical School, CHRC, New University of Lisbon, Lisbon, Portugal.;Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.;Servicio de Terapia Intensiva, Hospital Interzonal de Agudos San Martin de La Plata, La Plata, Buenos Aires, Argentina.;Intensive Care Center, University Medical Center Utrecht, Utrecht, the Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.;Infectious Diseases Clinic, Department of Health Sciences, University of Genoa, Genoa and Hospital Policlinico San Martino-IRCCS, Genoa, Italy.;Division of Scientific Affairs, Research, European Society of Intensive Care Medicine, Brussels, Belgium.;Brisbane, Australia.;Department of Critical Care Medicine, Ghent University Hospital, Gent, Belgium. | 1260 | |||
| 10.1002/rth2.12396 | Journal Article | en | The underrecognized prothrombotic vascular disease of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32685906 | 2475-0379,2475-0379 | 2020-06-14 02:00:00+02:00 | pubmed | Research and Practice in Thrombosis and Haemostasis | Kevin P Cohoon;Guillaume Mahé;Alex C Spyropoulos | 2020-06-14 02:00:00+02:00 | 32685906 | FR;US | 1Division of Cardiovascular Medicine Department of Medicine Froedtert and Medical College of Wisconsin Milwaukee Wisconsin USA.;Unité de Médecine Vasculaire CHU de Rennes Rennes France.;Inserm CIC 1414 CHU Rennes Université de Rennes Rennes France.;Institute for Health Innovations and Outcomes Research Feinstein Institutes for Medical Research and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Manhasset New York USA. | 1267 | |||||
| NHMRC Senior Research Fellowship;Consejo Superior de Investigaciones Científicas;Instituto de Salud Carlos III | 10.1111/all.14449 | Journal Article;Review | en | A compendium answering 150 questions on COVID-19 and SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32535955 | In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease. | 0105-4538,1398-9995 | 2020-06-14 02:00:00+02:00 | pubmed | Allergy | Carmen Riggioni;Pasquale Comberiati;Mattia Giovannini;Ioana Agache;Mübeccel Akdis;Magna Alves-Correia;Josep M Antó;Alessandra Arcolaci;Ahmet Kursat Azkur;Dilek Azkur;Burcin Beken;Cristina Boccabella;Jean Bousquet;Heimo Breiteneder;Daniela Carvalho;Leticia De Las Vecillas;Zuzana Diamant;Ibon Eguiluz-Gracia;Thomas Eiwegger;Stefanie Eyerich;Wytske Fokkens;Ya-Dong Gao;Farah Hannachi;Sebastian L Johnston;Marek Jutel;Aspasia Karavelia;Ludger Klimek;Beatriz Moya;Kari C Nadeau;Robyn O'Hehir;Liam O'Mahony;Oliver Pfaar;Marek Sanak;Jürgen Schwarze;Milena Sokolowska;María J Torres;Willem van de Veen;Menno C van Zelm;De Yun Wang;Luo Zhang;Rodrigo Jiménez-Saiz;Cezmi A Akdis | COVID-19;SARS-CoV-2;allergy;coronavirus disease 2019;severe acute respiratory syndrome-related coronavirus 2 | 2020-06-14 02:00:00+02:00 | 32535955 | CA;PT;CZ;NL;FR;RU;CN;GR;CH;RO;GB;US;IT;PL;LU;AT;DE;SE;IE;SG;AU;TR;ES | [{"country": "", "agency": "NHMRC Senior Research Fellowship", "grantid": "GNT1117687"}, {"country": "", "agency": "Consejo Superior de Investigaciones Científicas", "grantid": "IJCI-2016-27619"}, {"country": "", "agency": "Instituto de Salud Carlos III", "grantid": "JR19/0029"}] | Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain.;Institut de Recerca Sant Joan de Déu, Barcelona, Spain.;Section of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.;Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.;Allergy Unit, Department of Pediatrics, Meyer Children's University Hospital, Florence, Italy.;Faculty of Medicine, Transylvania University, Brasov, Romania.;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.;Allergy Unit, CUF Porto Hospital & Institute, Oporto, Portugal.;Faculty of Medicine, Center for Health Technology and Services Research (CINTESIS), University of Porto, Oporto, Portugal.;ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.;IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.;Universitat Pompeu Fabra (UPF), Barcelona, Spain.;CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.;Allergy Unit & Asthma Center, Borgo Roma Hospital, University of Verona and General Hospital, Verona, Italy.;Department of Virology, Faculty of Veterinary Medicine, University of Kirikkale, Kirikkale, Turkey.;Division of Pediatric Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, University of Kirikkale, Kirikkale, Turkey.;Department of Pediatric Allergy and Immunology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.;Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario "A Gemelli" - IRCCS, University of the Sacred Heart, Rome, Italy.;Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.;Department of Dermatology and Allergy, Comprehensive Allergy Center, Berlin Institute of Health, Berlin, Germany.;MACVIA-France, Montpellier, France.;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.;Public Health Research Center, NOVA University of Lisbon, Lisboa, Portugal.;Department of Allergy, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.;Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.;Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.;Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.;Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, RETICS ARADyAL, BIONAND, Malaga, Spain.;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Toronto, ON, Canada.;Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.;Department of Immunology, University of Toronto, Toronto, ON, Canada.;ZAUM - Center of Allergy and Environment, Technical University and Helmholtz Center Munich, Munich, Germany.;Department of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Immuno-Allergology Unit, Hospital Centre of Luxembourg, Luxembourg, Luxembourg.;National Heart and Lung Institute, Imperial College London, London, UK.;Department of Clinical Immunology, University of Wroclaw, Wroclaw, Poland.;ALL-MED" Medical Research Institute, Wroclaw, Poland.;ENT Department, General Hospital of Chania, Greece, Greece.;Center for Rhinology and Allergology, Wiesbaden, Germany.;Allergy Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.;Division of Pulmonary and Critical Care Medicine, Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, CA, USA.;Department of Immunology and Pathology, Monash University, Melbourne, Vic., Australia.;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University and The Alfred Hospital, Melbourne, Vic., Australia.;Department of Medicine and School of Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.;Department of Medicine, Jagiellonian University Medical College, Krakow, Poland.;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.;Christine Kühne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.;Department of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing Tongren Hospital, Beijing, China.;Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC, Madrid, Spain.;McMaster Immunology Research Centre (MIRC), Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.;Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain. | 1268 | |
| 10.1016/j.ejca.2020.05.015 | Journal Article;Review | en | A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. | https://www.ncbi.nlm.nih.gov/pubmed/32580130 | Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low- and middle-income countries (LMICs). In this review, we aimed to summarize these international guidelines in accordance with cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumour criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints. | 0959-8049 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Coronavirus Infections__epidemiology;Developing Countries__economics;Global Burden of Disease;Humans;Infection Control__economics;Medical Oncology__economics;Neoplasms__diagnosis;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Poverty;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Cancer | Yazid Belkacemi;Noemie Grellier;Sahar Ghith;Kamel Debbi;Gabriele Coraggio;Adda Bounedjar;Redouane Samlali;Pauletta G Tsoutsou;Mahmut Ozsahin;Marie-Pierre Chauvet;Sedat Turkan;Hamouda Boussen;Abraham Kuten;Dusanka Tesanovic;Hassan Errihani;Farouk Benna;Kamel Bouzid;Ahmed Idbaih;Karima Mokhtari;Lazar Popovic;Jean-Philippe Spano;Jean-Pierre Lotz;Aziz Cherif;Hahn To;Vladimir Kovcin;Oliver Arsovski;Semir Beslija;Radan Dzodic;Ivan Markovic;Suzana Vasovic;Liljana Stamatovic;Davorin Radosavljevic;Sinisa Radulovic;Damir Vrbanec;Souha Sahraoui;Nino Vasev;Igor Stojkovski;Milan Risteski;Salvador Villà Freixa;Marco Krengli;Nina Radosevic;Giorgio Mustacchi;Mladen Filipovic;Khaldoun Kerrou;Alphonse G Taghian;Vladimir Todorovic;Fady Geara;Joseph Gligorov | AROME;COVID-19;Cancer;Guidelines;Health care;LMICs;Recommendations;TRONE | 2020-06-08 02:00:00+02:00 | 32580130 | FR;IL;DZ;MK;TN;BA;LB;CH;HR;US;IT;ME;TR;MA;RS;ES | Department of Radiation Oncology and Henri Mondor Breast Center, APHP, INSERM Unit 955 Team 21, University of Paris-Est Creteil (UPEC), France. Electronic address: yazid.belkacemi@aphp.fr.;Department of Radiation Oncology and Henri Mondor Breast Center, APHP, INSERM Unit 955 Team 21, University of Paris-Est Creteil (UPEC), France.;Department of Medical Oncology, Université Blida 1. Laboratoire de Cancérologie, Faculté de Médecine, Blida, Algeria.;Department of Radiation Oncology, Clinique du Littoral, Casablanca, Morocco.;Department of Radiation Oncology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.;Department of Radiation Oncology, Lausanne University Medical Center and University of Lausanne, Lausanne, Switzerland.;Department of Surgery, Oscar Lambret Comprehensive Cancer Center, Unicancer, Lille, France.;Department of Radiation Oncology, University of Cerrahpasa, Istanbul, Turkey.;Department of Medical Oncology, University Hospital Abderrahman Mami, Ariana, Tunisia.;Department of Radiation Oncology, University of Haifa, Haifa, Israel.;Department of Radiation Oncology, Oncology Institute of Vojvodina, Faculty of Medicine Novi Sad, University of Novi Sad, Serbia.;Department of Medical Oncology, University of Rabat, Rabat, Morocco.;Department of Radiation Oncology, University of Tunis, Tunis, Tunisia.;Department of Medical Oncology, Pierre et Marie Curie, Comprehensive Cancer Center University of Algiers, Algiers, Algeria.;Department of Neuro-Oncology, Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie AP-HP. Sorbonne University, Paris, France.;Department of Neuropathologie, Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie AP-HP. Sorbonne University, Paris, France.;Department of Medical Oncology, University of Novi Sad, Novi Sad, Serbia.;Department of Medical Oncology, Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie AP-HP. Sorbonne University, Paris, France.;Department of Medical Oncology, Tenon Hospital, Institut Universitaire de Cancérologie AP-HP. Sorbonne University, Paris, France.;Department of Medical Oncology, Oncomed, Belgrade, Serbia.;Department of Radiation Oncology, International Medical Center AFFIDEA, Banja Luka, Bosnia and Hercegovina.;Department of Medical Oncology, Clinical Center of Sarajevo, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.;Department of Surgery, Oncology and Radiology Institute of Serbia, Belgrade, Serbia.;Department of Medical Oncology, Oncology and Radiology Institute of Serbia, Belgrade, Serbia.;Department of Molecular Oncology, Oncology and Radiology Institute of Serbia, Belgrade, Serbia.;School of Medicine, Juraj Dobrila University of Pula, Radiochirurgia Special Oncology Hospital, Croatia.;Ibn Roshd Anti-cancer Center, University of Casablanca, Morocco.;University Clinic of Radiotherapy and Oncology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, North Macedonia.;Institut Català d'Oncologia, Cap de Servei Oncologia Radioteràpica Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain.;Division of Radiation Oncology, University Hospital "Maggiore della Carità", Novara, Italy.;Department of Pathology and Molecular Pathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France.;Medical Oncology, University of Trieste, Italy.;Department of Radiology, Poliklinika Filipovic, Podgorica, Montenegro.;Department of Nuclear Medicine, Tenon Hospital. Sorbonne University, Paris, France.;Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.;Clinic for Oncology and Radiotherapy, Clinical Center of Montenegro and University of Montenegro, Podgorica, Montenegro.;Department of Radiation Oncology, American University of Beirut, Beirut, Lebanon. | 1271 | ||
| Letter | en | The Right Ventricle in COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32624188 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__physiopathology;Echocardiography;Humans;Pandemics;Pneumonia, Viral__physiopathology;Ventricular Dysfunction, Right__diagnostic imaging;COVID-19;severe acute respiratory syndrome coronavirus 2 | Abdallah Fayssoil;Hazrije Mustafic;Nicolas Mansencal | 2020-06-09 02:00:00+02:00 | 32624188 | FR | Department of Cardiology, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Versailles-Saint Quentin (UVSQ), Boulogne-Billancourt, France, Department of Cardiology, Ambroise Paré Hospital, AP-HP, Centre de référence des cardiomyopathies et des troubles du rythme cardiaque héréditaires ou rares, UVSQ, Boulogne-Billancourt, France. Electronic address: abdallah.fayssoil@aphp.fr.;Department of Cardiology, Ambroise Paré Hospital, AP-HP, Centre de référence des cardiomyopathies et des troubles du rythme cardiaque héréditaires ou rares, UVSQ, Boulogne-Billancourt, France, INSERM U-1018, CESP, Epidémiologie Clinique, UVSQ, Université de Paris Saclay, Villejuif, France. | 1273 | |||||||
| 10.1042/cs20200531 | Journal Article;Research Support, Non-U.S. Gov't | en | SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure. | https://www.ncbi.nlm.nih.gov/pubmed/32543703 | We demonstrate that the general clinical conditions, risk factors and numerous pathological and biological features of COVID-19 are analogous with various disorders caused by the uncontrolled formation of neutrophil extracellular traps and their by-products. Given the rapid evolution of this disease's symptoms and its lethality, we hypothesize that SARS-CoV2 evades innate immune response causing COVID-19 progresses under just such an amplifier loop, leading to a massive, uncontrolled inflammation process. This work allows us to propose new strategies for treating the pandemic. | 0143-5221,1470-8736 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus__physiology;Coronavirus Infections__complications;Deoxyribonuclease I__therapeutic use;Extracellular Traps__physiology;Host-Pathogen Interactions__immunology;Humans;Immunity, Innate;Multiple Organ Failure__immunology;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Science | Alain R Thierry;Benoit Roch | COVID19;Neutrophil;Traps;circulating DNA;pathogenesis | 2020-06-17 02:00:00+02:00 | 32543703 | FR | Research Institute of Cancerology of Montpellier, INSERM U1194, IRCM, ICM, Université de Montpellier, Montpellier, F-34298, France.;Respiratory Medicine, University Hospital of Montpellier, Montpellier Université, Montpellier, France. | 1276 | ||
| 10.1684/pnv.2020.0869 | Journal Article | en | Ethics, care and ageing during the Covid-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32554346 | At the beginning of the Covid-19 epidemic, National forum for ethical reflection on Alzheimer's disease and neurodegenerative diseases conducted a national survey to identify the difficulties encountered by professionals working in the field of old age and autonomy, families and volunteers, and the initiatives they have implemented. Seven major difficulties were identified: the isolation induced by the prohibition of visits, the lack of protective equipment and tests, the difficulties of people with cognitive difficulties in understanding measures to avoid the spread of the epidemic, the sustainability of overwork for professionals, the concern of the families of residents, complex situations at home and difficulties in accessing care. Four initiatives are being implemented: information and training for teams, compensation for interrupted visits, consultations and exchanges between professionals, actions to benefit people living at home. The Covid-19 epidemic hit the elderly sector at a very special moment in its history, several years of effort by the sector to reinvent itself around strong values. They have been a resource during this period of crisis. An ambitious law on old age and autonomy therefore appears to be a necessity. | 2020-06-21 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Aging;Clinical Laboratory Techniques__statistics & numerical data;Cognition Disorders__complications;Coronavirus Infections__diagnosis;Family;Female;France__epidemiology;Geriatrics__ethics;Health Services Accessibility;Humans;Male;Pandemics;Patient Education as Topic;Patient Isolation__psychology;Personal Autonomy;Personal Protective Equipment;Pneumonia, Viral__epidemiology;Surveys and Questionnaires;COVID-19;COVID-19 diagnostic testing | Fabrice Gzil;Anne-Caroline Clause-Verdreau;Pierre-Emmanuel Brugeron;Emmanuel Hirsch | care;elderly;ethics;long term care | 2020-06-20 02:00:00+02:00 | 32554346 | FR | Espace de réflexion éthique de la région Île-de-France, France. | 1289 | ||||
| 10.1016/s2352-3026(20)30204-0 | Journal Article | en | Prognosis of patients with sickle cell disease and COVID-19: a French experience. | https://www.ncbi.nlm.nih.gov/pubmed/32563282 | 2352-3026 | 2020-06-21 02:00:00+02:00 | pubmed | The Lancet Haematology | Jean-Benoît Arlet;Gonzalo de Luna;Djamal Khimoud;Marie-Hélène Odièvre;Mariane de Montalembert;Laure Joseph;Christelle Chantalat-Auger;Edouard Flamarion;Pablo Bartolucci;François Lionnet;Sebastien Monnier;Cécile Guillaumat;Aline Santin | 2020-06-18 02:00:00+02:00 | 32563282 | FR | French Sickle Cell Referral Centre, Department of Internal Medicine, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France. Electronic address: jean-benoit.arlet@aphp.fr.;French Sickle Cell Referral Centre, Mondor Hospital, AP-HP, Creteil, France.;French Sickle Cell Referral Centre, Department of Internal Medicine, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France.;Department of Paediatrics, Hôpital Armand Trousseau, APHP, Paris, France.;French Sickle Cell Referral Centre, Necker-Enfants malades Hospital, AP-HP, Paris, France.;French Sickle Cell Referral Centre, Bicètre Hospital, AP-HP, Paris, France.;Internal Medicine Department, Tenon Hospital, APHP, Paris, France.;Internal medicine Department, Centre Hospitalier de Versailles, Versailles, France.;Department of Paediatrics, Hôpital du Sud Francilien, Corbeil-Essonnes, France. | 1301 | |||||
| 10.1007/s00259-020-04919-3 | Journal Article | en | 18F-Fluorocholine uptake matching CT lesions in the lungs of a patient clinically cured from COVID-19 syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32561970 | 1619-7070,1619-7089 | 2020-06-21 02:00:00+02:00 | pubmed | European Journal of Nuclear Medicine and Molecular Imaging | Léa Turpin;Quentin Pouliot;Jules Zhang;Martine Glikman;Florie Gomez;Jean-Noël Talbot;Françoise Montravers | 2020-06-19 02:00:00+02:00 | 32561970 | FR | Service de Médecine Nucléaire, Hôpital Tenon, AP-HP, et Sorbonne Université, Paris, France. lea.turpin@aphp.fr.;Service de Médecine Nucléaire, Hôpital Tenon, AP-HP, et Sorbonne Université, Paris, France.;Cabinet de consultation de médecine générale, Pantin, France.;Service d'urologie, Hôpital Tenon, AP-HP, et Sorbonne Université, Paris, France. | 1303 | |||||
| 10.1016/j.ekir.2020.05.031 | Journal Article | en | Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD? | https://www.ncbi.nlm.nih.gov/pubmed/32775845 | 2468-0249 | 2020-06-21 02:00:00+02:00 | pubmed | Kidney International Reports | Marion Delafosse;Camille Saint-Jaques;Camille Petit-Hoang;Hélène François;Julie Peltier;Laurence Nicolet;Charles Verney;Martin Viguier;Emmanuel Letavernier;Karine Dahan | 2020-06-17 02:00:00+02:00 | 32775845 | FR | UMRS 1155, Sorbonne Université INSERM, Paris, France.;Physiology Unit, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.;Intensive Care Nephrology and Transplantation Department, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.;Nephrology Unit, Clinique Edouard Rist, Paris, France.;Department of Infectious Diseases Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.;Nephrology Unit, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.;ANDRA, B Braun Nephrology Center, Paris, France. | 1332 | |||||
| 10.1016/j.frl.2020.101657 | Journal Article | en | Price reaction, volatility timing and funds' performance during Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32837369 | In this paper we assess the price reaction, performance and volatility timing of European investment funds during the outbreak of Covid-19. We analyze the time period between January and June 2020 and demonstrate that while most of the investment funds exhibit stressed performance, social entrepreneurship funds endured resilience. This performance remained robust during the various stages of evolution of this contagion. The social funds also demonstrated volatility timing that was absent for most of their counterparts. We attribute the overall stability of these funds to their niche investments in social enterprises that specialize in providing innovative solutions for social issues. | 1544-6123 | 2020-06-21 02:00:00+02:00 | pubmed | Finance Research Letters | Nawazish Mirza;Bushra Naqvi;Birjees Rahat;Syed Kumail Abbas Rizvi | Covid-19;Price reaction;Volatility timing | 2020-06-18 02:00:00+02:00 | 32837369 | FR;PK | La Rochelle Business School - Excelia Group, La Rochelle, France.;Lahore University of Management Sciences, Lahore, Pakistan.;Lahore School of Economics, Lahore, Pakistan. | 1351 | |||
| 10.1093/ofid/ofaa249 | Journal Article | en | Coronavirus Disease 2019: Associated Multiple Organ Damage. | https://www.ncbi.nlm.nih.gov/pubmed/32661498 | A 56-year-old man presented a particularly severe and multisystemic case of coronavirus disease 2019 (COVID-19). In addition to the common lung and quite common pulmonary embolism and kidney injuries, he presented ocular and intestinal injuries that, to our knowledge, have not been described in COVID-19 patients. Although it is difficult to make pathophysiological hypotheses about a single case, the multiplicity of injured organs argues for a systemic response to pulmonary infection. A better understanding of physiopathology should feed the discussion about therapeutic options in this type of multifocal damage related to severe acute respiratory syndrome coronavirus 2. | 2328-8957 | 2020-06-21 02:00:00+02:00 | pubmed | Open Forum Infectious Diseases | Olivier Collange;Charles Tacquard;Xavier Delabranche;Ian Leonard-Lorant;Mickaël Ohana;Mihaela Onea;Mathieu Anheim;Morgane Solis;Arnaud Sauer;Seyyid Baloglu;Patrick Pessaux;Patrick Ohlmann;Charlotte Kaeuffer;Walid Oulehri;Stephane Kremer;Paul Michel Mertes | COVID-19;SARS-CoV-2;brain magnetic resonance imaging;microthrombi;severe acute respiratory syndrome | 2020-06-21 02:00:00+02:00 | 32661498 | FR | Service d'Anesthésie-Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Service de Radiologie, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Département de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Service Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Laboratoire de Virologie Médicale, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Service d'Ophtalmologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Service d'Imagerie 2, Hôpital de Hautepierre, Strasbourg, France.;Service Chirurgie Digestive et Endocrinienne, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Service de Cardiologie, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Service de Maladies Infectieuses, Nouvel Hopital Civil, Hopitaux Universitaires de Strasbourg, Strasbourg, France. | 1358 | |||
| 10.1148/radiol.2020202222 | Journal Article | en | Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study. | https://www.ncbi.nlm.nih.gov/pubmed/32544034 | Background Brain MRI parenchymal signal abnormalities have been in association with SARS-CoV-2. Purpose Describe the neuroimaging findings (excluding ischemic infarcts) in patients with severe COVID-19 infection. Methods This was a retrospective study of patients evaluated from March 23th, 2020 to April 27th, 2020 at 16 hospitals. Inclusion criteria were: (i) positive nasopharyngeal or lower respiratory tract reverse transcriptase-polymerase chain reaction assays; (ii) severe COVID infection defined as requirement for hospitalization and oxygen therapy; (iii) neurologic manifestations; (iv) abnormal brain MRI. Exclusion criteria were patients with missing or non-contributory data regarding brain MRI or a brain MRI showing ischemic infarcts, cerebral venous thrombosis, or chronic lesions unrelated to the current event. Categorical data were compared using Fisher exact test. Quantitative data were compared using Student's t-test or Wilcoxon test. A p-value lower than 0.05 was considered significant. Results Thirty men (81%) and 7 women (19%) met inclusion criteria, with a mean age of 61+/- 12 years (range: 8-78). The most common neurologic manifestations were alteration of consciousness (27/37, 73%), pathological wakefulness when the sedation was stopped (15/37, 41%), confusion (12/37, 32%), and agitation (7/37, 19%). The most frequent MRI findings were: signal abnormalities located in the medial temporal lobe in 16/37 (43%, 95% CI 27-59%) patients, non-confluent multifocal white matter hyperintense lesions on FLAIR and diffusion sequences, with variable enhancement, with associated hemorrhagic lesions in 11/37 patients (30%, 95% CI 15-45%), and extensive and isolated white matter microhemorrhages in 9/37 patients (24%, 95% CI 10-38%). A majority of patients (20/37, 54%) had intracerebral hemorrhagic lesions with a more severe clinical presentation: higher admission rate in intensive care units, 20/20 patients, 100% versus 12/17 patients, 71%, p=0.01; development of the acute respiratory distress syndrome in 20/20 patients, 100% versus 11/17 patients, 65%, p=0.005. Only one patient was positive for SARS-CoV-2 RNA in the cerebrospinal fluid. Conclusion Patients with severe COVID-19 and without ischemic infarcts had a wide range of neurologic manifestations that were be associated with abnormal brain MRIs. Eight distinctive neuroradiological patterns were described. | 0033-8419,1527-1315 | 2020-06-21 02:00:00+02:00 | pubmed | Radiology | Stéphane Kremer;François Lersy;Jérome de Sèze;Jean-Christophe Ferré;Adel Maamar;Béatrice Carsin-Nicol;Olivier Collange;Fabrice Bonneville;Gilles Adam;Guillaume Martin-Blondel;Marie Rafiq;Thomas Geeraerts;Louis Delamarre;Sylvie Grand;Alexandre Krainik;Sophie Caillard;Jean Marc Constans;Serge Metanbou;Adrien Heintz;Julie Helms;Maleka Schenck;Nicolas Lefèbvre;Claire Boutet;Xavier Fabre;Géraud Forestier;Isaure de Beaurepaire;Grégoire Bornet;Audrey Lacalm;Hélène Oesterlé;Federico Bolognini;Julien Messie;Ghazi Hmeydia;Joseph Benzakoun;Catherine Oppenheim;Blanche Bapst;Imen Megdiche;Marie-Cécile Henri-Feugeas;Antoine Khalil;Augustin Gaudemer;Lavinia Jager;Patrick Nesser;Yannick Talla Mba;Céline Hemmert;Philippe Feuerstein;Nathan Sebag;Sophie Carré;Manel Alleg;Claire Lecocq;Emmanuelle Schmitt;René Anxionnat;François Zhu;Pierre-Olivier Comby;Frédéric Ricolfi;Pierre Thouant;Hubert Desal;Grégoire Boulouis;Jérome Berge;Apolline Kazémi;Nadya Pyatigorskaya;Augustin Lecler;Suzana Saleme;Myriam Edjlali-Goujon;Basile Kerleroux;Pierre-Emmanuel Zorn;Muriel Mathieu;Seyyid Baloglu;François-Daniel Ardellier;Thibault Willaume;Jean Christophe Brisset;Clotilde Boulay;Véronique Mutschler;Yves Hansmann;Paul-Michel Mertes;Francis Schneider;Samira Fafi-Kremer;Mickael Ohana;Ferhat Meziani;Jean-Stéphane David;Nicolas Meyer;Mathieu Anheim;François Cotton | 2020-06-16 02:00:00+02:00 | 32544034 | FR;GB;US | Hôpitaux Universitaires de Strasbourg, Service d'imagerie 2, Hôpital de Hautepierre, Strasbourg, France (S.K., F.L., S.B., F.D.A., T.W.), Engineering science, computer science and imaging laboratory (ICube), Integrative Multimodal Imaging in Healthcare, UMR 7357, University of Strasbourg-CNRS, Strasbourg, France (S.K.,), Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France (J.S., C.B., V.M., M.A.), CHU Rennes, Department of Neuroradiology, Rennes, France (J.C.F., B.C.N.), Service de maladies infectieuses et réanimation médicale. CHU Rennes, France (A.M.), Hôpitaux universitaires de Strasbourg, Service d'Anesthésie-Réanimation, Nouvel Hôpital Civil, Strasbourg, France (O.C., P.M.M.), Service de Neuroradiologie, CHU Toulouse, Toulouse, France (F.B., G.A.), Department of infectious and tropical diseases, Toulouse University Hospital, Toulouse, France (G.M.B.), Department of Neurology, Toulouse University Hospital, Toulouse, France (M.R.), Department of Anesthesia and Critical Care, Toulouse University Hospital University Toulouse 3-Paul Sabatier, Toulouse, France (T.G., L.D.), Service de neuroradiologie diagnostique et interventionnelle, Centre Hospitalier Universitaire des Alpes, Grenoble, France (S.G., A.K.), Nephrology and Transplantation department, Hôpitaux Universitaires de Strasbourg. Inserm UMR S1109, LabEx Transplantex, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France (S.C.), EA CHIMERE 7516, Université de Picardie Jules Verne, Amiens, France, Service de NeuroRadiologie, pôle Imagerie Médicale, Centre Hospitalo-Universitaire d'Amiens, Amiens, France (J.M.C., A.H.), Service de Neuro Radiologie, pôle Imagerie Médicale, Centre Hospitalo-Universitaire d'Amiens, Amiens, France (S.M.), Hôpitaux universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, Strasbourg, France (J.H., F.M.), Immuno-Rhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France (J.H.), Hôpitaux universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Hautepierre, Strasbourg, France (M.S., F.C.), Service de Maladies infectieuses, NHC, CHU de Strasbourg, Strasbourg, France (N.L., Y.H.), Service de Radiologie, CHU de Saint-Etienne, Saint-Etienne, France (C.B.), Service de Réanimation, CH de Roanne, Roanne, France (X.F.), University Hospital of Limoges, Neuroradiology Department, Limoges, France (G.F., S.S.), Radiology Department, Hôpital Privé d'Antony, Antony, France (I.B., G.B.), Service d'imagerie Pédiatrique et Fœtale, Hôpital Femme Mère Enfant, HCL, Lyon, France (A.L.), Service de Neuroradiologie, Hôpitaux Civils de Colmar, Colmar, France (H.O., F.B., J.M.), INSERM U1266, Service d'imagerie morphologique et fonctionnelle, GHU Psychiatrie et Neurosciences, site Sainte-Anne, Paris, France (G.H., J.B., C.O., G.B., M.E.G., B.K.), service de Neuroradiologie, CHU Henri Mondor, Créteil, France (B.B., I.M.), Neuroradiology Unit, Department of Radiology, Assistance Publique-Hôpitaux de Paris (APHP), Bichat University Hospital, Paris, France (M.H.F., A.G.), Department of Radiology, Assistance Publique-Hôpitaux de Paris (APHP), Denis Diderot University and Medical School, Bichat University Hospital, Paris, France (A.K.), CHIC Unisanté, Hôpital Marie Madeleine, Forbach, France (L.J., P.N., Y.T.M.), service de Radiologie 1, GHR Mulhouse Sud Alsace, Hôpital Mère Enfants, Mulhouse, France (C.H., P.F., N.S.), Service de Neurologie, Centre Hospitalier de Haguenau, Haguenau, France (S.C., C.L.), Service de Radiologie, Centre Hospitalier de Haguenau, Haguenau, France (M.A.), Service de Neuroradiologie, Hôpital Central, CHU de Nancy, Nancy, France (E.S., R.A., F.Z.), Department of Neuroradiology, University Hospital of Dijon, Hôpital François Mitterrand, Dijon, France (P.C., F.R., P.T.), Department of Diagnostic and Interventional Neuroradiology, University Hospital, Nantes, France (H.D.), Neuroradiology department - CHU de Bordeaux, Bordeaux, France (J.B.), Service de Neuroradiologie, CHU de Lille, Lille, France (A.K.), Assistance Publique Hôpitaux de Paris, Service de Neuroradiologie, Hôpital Pitié-Salpêtrière, Paris, France Sorbonne Université, Univ Paris 06, UMR S 1127, CNRS UMR 7225, ICM, F-75013, Paris, France (N.P.), Neuroradiology department, Fondation A.Rothschild Hospital, Paris, France (A.L.), Hôpitaux Universitaires de Strasbourg, UCIEC, Pôle d'Imagerie, Strasbourg, France (P.E.Z., M.M.), Observatoire Français de la Sclérose en Plaques, Lyon, France (J.C.B.), Hôpitaux universitaires de Strasbourg, Laboratoire de Virologie Médicale, Strasbourg, France (S.F.K.), Radiology Department, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France (M.O.), INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France (F.M.), Department of Anaesthesia and Intensive Care, Lyon-Sud Hospital, Hospices Civils de Lyon, F-69495 Pierre Benite, University Claude Bernard Lyon 1, Lyon, France (J.S.D.), CHU de Strasbourg, Service de Santé Publique, GMRC, F-67091 Strasbourg, France (N.M.), Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRSUMR7104/Université de Strasbourg, Illkirch, France (M.A.), MRI center, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France (F.C.), Université Lyon 1, CREATIS-LRMN, CNRS/UMR/5220-INSERM U630, Villeurbanne, France (F.C.). | 1359 | ||||
| 10.1200/op.20.00295 | Journal Article | en | Providing Oncology Pharmacy Services During the Coronavirus Pandemic: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique [SFPO]) Guidelines. | https://www.ncbi.nlm.nih.gov/pubmed/32539650 | Patients with cancer are at higher risk for contracting the COVID-19 infection and are more likely to have higher morbidity and mortality. This is a big challenge for oncology teams that have to treat patients to avoid contamination by SARS-CoV-2. The aim of the current work is to present oncology pharmacy practice guidelines during the COVID-19 pandemic to secure the pharmaceutical care of patients with cancer. | 2688-1527,2688-1535 | 2020-06-21 02:00:00+02:00 | pubmed | JCO Oncology Practice | Bertrand Pourroy;Jean Francois Tournamille;Christophe Bardin;Florian Slimano;Régine Chevrier;Catherine Rioufol;Isabelle Madelaine | 2020-06-15 02:00:00+02:00 | 32539650 | FR;US | Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique-Hôpitaux de Marseille, Marseille, France.;French Society for Oncology Pharmacy, Paris, France.;Pharmacy Department, Cochin University Teaching Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Pharmacy, Centre Hospitalier Universitaire Reims, and Faculty of Pharmacy, EA7506, Université de Reims Champagne-Ardenne, Reims, France.;Pharmacy Department, Jean Perrin Cancer Center, Clermont Ferrand, France.;Oncology Clinical Pharmacy Unit, Lyon Sud University Teaching Hospital. Hospices Civils de Lyon, Pierre-Bénite, and EMR3738, Lyon University, Lyon, France.;Pharmacy Department, Saint Louis University Teaching Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. | 1366 | ||||
| 10.1007/s11023-020-09527-6 | Journal Article | en | Analysing the Combined Health, Social and Economic Impacts of the Corovanvirus Pandemic Using Agent-Based Social Simulation. | https://www.ncbi.nlm.nih.gov/pubmed/32836870 | During the COVID-19 crisis there have been many difficult decisions governments and other decision makers had to make. E.g. do we go for a total lock down or keep schools open? How many people and which people should be tested? Although there are many good models from e.g. epidemiologists on the spread of the virus under certain conditions, these models do not directly translate into the interventions that can be taken by government. Neither can these models contribute to understand the economic and/or social consequences of the interventions. However, effective and sustainable solutions need to take into account this combination of factors. In this paper, we propose an agent-based social simulation tool, ASSOCC, that supports decision makers understand possible consequences of policy interventions, but exploring the combined social, health and economic consequences of these interventions. | 0924-6495,1572-8641 | 2020-06-21 02:00:00+02:00 | pubmed | Minds and Machines | Frank Dignum;Virginia Dignum;Paul Davidsson;Amineh Ghorbani;Mijke van der Hurk;Maarten Jensen;Christian Kammler;Fabian Lorig;Luis Gustavo Ludescher;Alexander Melchior;René Mellema;Cezara Pastrav;Loïs Vanhee;Harko Verhagen | 2020-06-15 02:00:00+02:00 | 32836870 | FR;SE;NL | Umeå University, Umeå, Sweden.;Malmö University, Malmö, Sweden.;TU Delft, Delft, Netherlands.;Utrecht University, Utrecht, Netherlands.;University of Caen, Caen, France.;Stockholm University, Stockholm, Sweden. | 1373 | ||||
| Letter | en | Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32557535 | Thrombocytopenia (defined by platelet count <150 x 109 /L) has been observed in up to 36% of patients with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for Coronavirus disease 2019 (COVID-19; Guan et al, 2020). In this setting, thrombocytopenia is usually mild, caused by platelet activation and consumption (Thachil, 2020; Pavord et al, 2020). In a recent paper published in the British Journal of Haematology, Jiang et al. conducted a meta-analysis of 31 studies involving 7613 participants and found a significant association between thrombocytopenia and severe COVID-19 hospitalized patients or poor outcome in this setting (Jiang et al, 2020). However, other clinical, biological and radiological factors strongly impact COVID-19 outcome. Whether thrombocytopenia is independently associated to poor outcome in this population is unknown. This study was aimed at addressing this question. | 2020-06-21 02:00:00+02:00 | pubmed | Julien Maquet;Margaux Lafaurie;Agnès Sommet;Guillaume Moulis;Muriel Alvarez;Jacques Amar;Michel Attal;Laurent Balardy;Frédéric Balen;Odile Beyne-Rauzy;Ourdia Bouali;Fanny Bounes;Christophe Bureau;Louis Buscail;Lionel Calviere;Sandrine Charpentier;François Chollet;Isabelle Claudet;Arnaud Constantin;Alexa Debard;Karen Delavigne;Pierre Delobel;Julien Delrieu;Alain Didier;Marie Faruch;Olivier Fourcade;Bernard Georges;Etienne Grunenwald;Sophie Guyonnet;Hélène Hanaire;Christophe Hein;Nassim Kamar;Olivier Lairez;Pierre Mansat;Guillaume Martin-Blondel;Vincent Minville;Jérémie Pariente;Carle Paul;Pierre Payoux;Grégory Pugnet;Marie-Léa Piel-Julian;Christian Recher;Yves Rolland;Adeline Ruyssen-Witrand;Jean Sabatier;Laurent Sailler;Jean-Pierre Salles;Nicolas Sans;Marion Secher;Annick Sevely;Stein Silva;Claire Thalamas;Olivier Toulza | COVID-2019;SARS-CoV-2;intensive care unit;mortality;thrombocytopenia | 2020-06-17 02:00:00+02:00 | 32557535 | FR | Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Centre d'investigation clinique 1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;UMR 1027, INSERM-Université de Toulouse, Toulouse, France.;Service de Pharmacologie Médicale, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. | 1390 | ||||||
| Letter | en | International collaboration and rapid harmonization across dermatologic COVID-19 registries. | https://www.ncbi.nlm.nih.gov/pubmed/32562840 | 2020-06-21 02:00:00+02:00 | pubmed | Esther E Freeman;Devon E McMahon;George J Hruza;Alan D Irvine;Phyllis I Spuls;Catherine H Smith;Satveer K Mahil;Leslie Castelo-Soccio;Kelly M Cordoro;Irene Lara-Corrales;Haley B Naik;Raed Alhusayen;John R Ingram;Steven R Feldman;Esther A Balogh;Michael D Kappelman;Dmitri Wall;Nekma Meah;Rodney Sinclair;Marie Beylot-Barry;Matthew Fitzgerald;Lars E French;Henry W Lim;Christopher E M Griffiths;Carsten Flohr | 2020-06-17 02:00:00+02:00 | 32562840 | IE;FR;CA;GB;US;AU;NL;DE | Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: efreeman@mgh.harvard.edu.;Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.;Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri.;Clinical Medicine, Trinity College Dublin, Dublin, Ireland.;Department of Dermatology, Public Health and Epidemiology, Immunity and Infections, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, the Netherlands.;St John's Institute of Dermatology, King's College London and Guy's & St Thomas' National Health Service Foundation Trust, London, United Kingdom.;Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.;Department of Dermatology, University of California, San Francisco, San Francisco, California.;Section of Pediatric Dermatology, Hospital for Sick Children, Toronto, Ontario, Canada.;Sunnybrook Research Institute, Dermatology Division, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.;Division of Infection and Immunity, Department of Dermatology & Academic Wound Healing, Cardiff University, Cardiff, United Kingdom.;Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.;Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.;Hair Restoration Blackrock, Dublin, Ireland, National and International Skin Registry Solutions (NISR), Charles Institute of Dermatology, Dublin, Ireland.;Sinclair Dermatology, East Melbourne, Victoria, Australia.;French Society of Dermatology and Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France.;American Academy of Dermatology, Rosemont, Illinois.;Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany.;Department of Dermatology, Henry Ford Health System, Detroit, Michigan.;Dermatology Centre, Salford Royal Hospital, National Institute for Health Research, Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom.;Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, King's College London and Guy's & St Thomas' National Health Service Foundation Trust, London, United Kingdom. | 1391 | ||||||||
| Letter | en | Diabetes care during the acute phase of infection in ICU patients with specific attention to COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32620420 | 2020-06-21 02:00:00+02:00 | pubmed | Acute Disease;Betacoronavirus;Blood Glucose__analysis;Contraindications, Drug;Coronavirus Infections__complications;Critical Care__methods;Diabetes Mellitus, Type 1__complications;Diabetes Mellitus, Type 2__complications;Diabetic Ketoacidosis__drug therapy;Drug Administration Routes;Glycated Hemoglobin A__analysis;Humans;Hypoglycemic Agents__administration & dosage;Insulin__administration & dosage;Insulin Resistance;Intensive Care Units;Pandemics;Parenteral Nutrition;Pneumonia, Viral__complications;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bogdan Catargi;Gaëlle Cheisson;Igor Tauveron;Sophie Jacqueminet;Dan Benhamou | 2020-06-17 02:00:00+02:00 | 32620420 | FR | French Society for the study of Diabetes (SFD), 75009 Paris, France.;French Society of Anaesthesia and Intensive Care (SFAR), 75016 Paris, France.;French Society of Anaesthesia and Intensive Care (SFAR), 75016 Paris, France. Electronic address: dan.benhamou@aphp.fr. | 1392 | |||||||
| Letter | en | Overcoming fragmentation of health research in Europe: lessons from COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32559417 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Europe;Health Policy;Health Services Research__organization & administration;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Karin R Sipido;Fernando Antoñanzas;Julio Celis;Laurent Degos;Richard Frackowiak;Valentin Fuster;Detlev Ganten;Steffen Gay;Hans Hofstraat;Stephen T Holgate;Gabriel Krestin;Michael Manns;Francoise Meunier;Wolfgang Oertel;Susanna Palkonen;Dainius Pavalkis;Helga Rübsamen-Schaeff;Ulf Smith;Bente Merete Stallknecht;Tomáš Zima | 2020-06-16 02:00:00+02:00 | 32559417 | FR;SE;CH;US;GB;NL;DK;CZ;ES;BE;KZ;DE | Department of Cardiovascular Sciences, KU Leuven, 3000 Leuven, Belgium. Electronic address: karin.sipido@kuleuven.be.;Department of Economics, University of La Rioja, Logroño, Spain.;Danish Cancer Society Research Center, Copenhagen, Denmark.;Department of Hematology, University of Paris Diderot, Paris, France.;Faculté des sciences du vivant, Ecole Polytechnique Fédérale de Lausanne, Geneva, Switzerland.;Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain, Mount Sinai Medical Hospital, New York, NY, USA.;Max Planck Institute of Molecular Plant Physiology, Potsdam, Germany.;Center of Experimental Rheumatology, University Hospital of Zurich, Zurich, Switzerland.;Philips Research, Eindhoven, Netherlands.;Faculty of Medicine, Clinical and Experimental Sciences, University of Southamptom, Southampton, UK.;Department of Radiology, Erasmus Medical Centre, Rotterdam, Netherlands.;Hannover Medical School, Hannover, Germany.;Federation of European Academies of Medicine, Brussels, Belgium.;Department of Neurology, Philipps University Marburg, M-rburg, Germany.;Patient Access Partnership, Brussels, Belgium.;Astana Medical University, Astana, Kazakhstan.;AiCuris, Wuppertal, Germany.;Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Göteborg University, Gothenberg, Sweden.;Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.;Charles University, Prague, Czech Republic. | 1393 | |||||||
| 10.1007/s10479-020-03685-7 | Journal Article | en | Impacts of epidemic outbreaks on supply chains: mapping a research agenda amid the COVID-19 pandemic through a structured literature review. | https://www.ncbi.nlm.nih.gov/pubmed/32836615 | The coronavirus (COVID-19) outbreak shows that pandemics and epidemics can seriously wreak havoc on supply chains (SC) around the globe. Humanitarian logistics literature has extensively studied epidemic impacts; however, there exists a research gap in understanding of pandemic impacts in commercial SCs. To progress in this direction, we present a systematic analysis of the impacts of epidemic outbreaks on SCs guided by a structured literature review that collated a unique set of publications. The literature review findings suggest that influenza was the most visible epidemic outbreak reported, and that optimization of resource allocation and distribution emerged as the most popular topic. The streamlining of the literature helps us to reveal several new research tensions and novel categorizations/classifications. Most centrally, we propose a framework for operations and supply chain management at the times of COVID-19 pandemic spanning six perspectives, i.e., adaptation, digitalization, preparedness, recovery, ripple effect, and sustainability. Utilizing the outcomes of our analysis, we tease out a series of open research questions that would not be observed otherwise. Our study also emphasizes the need and offers directions to advance the literature on the impacts of the epidemic outbreaks on SCs framing a research agenda for scholars and practitioners working on this emerging research stream. | 0254-5330,1572-9338 | 2020-06-21 02:00:00+02:00 | pubmed | Annals of Operations Research | Maciel M Queiroz;Dmitry Ivanov;Alexandre Dolgui;Samuel Fosso Wamba | Adaptation;COVID-19;Digitalization;Epidemic outbreaks;Influenza;Pandemic;Preparedness;Recovery;Resilience;Ripple effect;Structured literature review;Supply chain;Sustainability | 2020-06-16 02:00:00+02:00 | 32836615 | FR;BR;DE | Postgraduate Program in Business Administration, Paulista University - UNIP, São Paulo, 04026-002 Brazil.;Supply Chain and Operations Management, Berlin School of Economics and Law, 10825 Berlin, Germany.;LS2N - CNRS, IMT Atlantique, La Chantrerie, 4 rue Alfred Kastler, 44307 Nantes, France.;Information, Operations and Management Sciences, TBS Business School, 1 Place Alphonse Jourdain, 31068 Toulouse, France. | 1397 | |||
| 10.24875/ric.20000157 | Journal Article;Review | en | OLFACTORY DISORDERS IN SARS-COV-2 INFECTION: CONSIDERATIONS IN AGING. | https://www.ncbi.nlm.nih.gov/pubmed/32584324 | 0034-8376 | 2020-06-28 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Aging__physiology;Coronavirus Infections__complications;Humans;Olfaction Disorders__epidemiology;Pandemics;Pneumonia, Viral__complications;COVID-19 | Revista de investigaci n Cl nica | Alberto J Mimenza-Alvarado;José A Avila-Funes;Sara G Aguilar-Navarro | 2020-06-26 02:00:00+02:00 | 32584324 | FR;MX | Department of Geriatric Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.;University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France. | 1408 | ||||
| 10.1038/s41477-020-0691-6 | Consensus Development Conference;Journal Article | en | Reshaping the future of ethnobiology research after the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32572213 | 2055-0278 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus__physiology;Biology__trends;Coronavirus Infections__epidemiology;Ethnic Groups;Ethnology__trends;Global Health;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nature Plants | Ina Vandebroek;Andrea Pieroni;John Richard Stepp;Natalia Hanazaki;Ana Ladio;Rômulo Romeu Nóbrega Alves;David Picking;Rupika Delgoda;Alfred Maroyi;Tinde van Andel;Cassandra L Quave;Narel Y Paniagua-Zambrana;Rainer W Bussmann;Guillaume Odonne;Arshad Mehmood Abbasi;Ulysses Paulino Albuquerque;Janelle Baker;Susan Kutz;Shrabya Timsina;Masayoshi Shigeta;Tacyana Pereira Ribeiro Oliveira;Julio A Hurrell;Patricia M Arenas;Jeremias P Puentes;Jean Hugé;Yeter Yeşil;Laurent Jean Pierre;Temesgen Magule Olango;Farid Dahdouh-Guebas | 2020-06-24 02:00:00+02:00 | 32572213 | FR;AR;CA;GE;CL;BO;JP;US;BR;IT;PK;ET;NL;ZA;TR;LC;BE;JM | Institute of Economic Botany, The New York Botanical Garden, The Bronx, NY, USA. ivandebroek@nybg.org.;University of Gastronomic Sciences, Pollenzo, Italy.;University of Florida, Gainesville, FL, USA.;Universidade Federal de Santa Catarina, Florianopolis, Brazil.;Universidad Nacional del Comahue-CONICET, INIBIOMA, Bariloche, Argentina.;Universidade Estadual da Paraíba, Campina Grande, Brazil.;The University of the West Indies, Mona Campus, Kingston, Jamaica.;University of Fort Hare, Medicinal Plants and Economic Development (MPED) Research Centre, Alice, South Africa.;Naturalis Biodiversity Center, Leiden, the Netherlands.;Department of Dermatology, School of Medicine, Emory University, Atlanta, GA, USA.;Herbario Nacionál de Bolivia, Universidad Mayor de San Andrés, La Paz, Bolivia.;Department of Ethnobotany, Institute of Botany and Bakuriani Alpine Botanical Garden, Ilia State University, Tbilisi, Georgia.;LEEISA (Laboratoire Ecologie, Evolution, Interactions des Systèmes Amazoniens), CNRS, Université de Guyane, IFREMER, Cayenne, French Guiana.;Department of Environmental Sciences, COMSATS University Islamabad, Abbottabad Campus, Pakistan.;Laboratory of Ecology and Evolution of Social-Ecological Systems, Universidade Federal de Pernambuco, Recife, Brazil.;Athabasca University, Athabasca, Alberta, Canada.;Department of Ecosystem and Public Health, Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, Canada.;The Forest School at the Yale School of the Environment, New Haven, CT, USA.;Graduate School of Asian and African Area Studies, Kyoto University, Kyoto, Japan.;Universidade Estadual da Paraíba, João Pessoa, Brazil.;Laboratorio de Etnobotánica y Botánica Aplicada (LEBA), CONICET, Universidad Nacional de La Plata, La Plata, Argentina.;Open University of the Netherlands, Heerlen, the Netherlands.;Department of Pharmaceutical Botany, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.;Saint Lucia Archaeological and Historical Society (SLAHS), Castries, Saint Lucia.;School of Plant and Horticultural Science, Hawassa University, Hawassa, Ethiopia.;Department of (Organism) Biology, Systems Ecology and Resource Management, Free University of Brussels ULB-VUB, Brussels, Belgium. | 1414 | ||||
| 10.3233/jad-200604 | Journal Article;Research Support, Non-U.S. Gov't | en | The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32568211 | Neuropsychiatric symptoms, such as depression, anxiety, apathy, agitation, and hallucinations, are frequent in Alzheimer's disease (AD) and their prevalence tends to increase with external stressors. | 1387-2877,1875-8908 | 2020-06-28 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Alzheimer Disease__epidemiology;Betacoronavirus;Cohort Studies;Coronavirus Infections__epidemiology;Female;Humans;Male;Mental Disorders__epidemiology;Mental Status and Dementia Tests;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Quarantine__psychology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Alzheimer's Disease | Claire Boutoleau-Bretonnière;Hélene Pouclet-Courtemanche;Aurelie Gillet;Amelie Bernard;Anne Laure Deruet;Ines Gouraud;Aurelien Mazoue;Estelle Lamy;Laetitia Rocher;Dimitrios Kapogiannis;Mohamad El Haj | Alzheimer’s disease;COVID-19;confinement;neuropsychiatric symptoms | 2020-06-23 02:00:00+02:00 | 32568211 | FR;US | CHU Nantes, Inserm CIC04, Nantes, France.;CHU Nantes, Départementde Neurologie, Centre Mémoire de Ressources et Recherche, Nantes, France.;Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA.;Nantes Université, Univ Angers, Laboratoire de Psychologie des Pays de la Loire (LPPL - EA 4638), Nantes, France.;Unité de Gériatrie, Centre Hospitalier de Tourcoing, Tourcoing, France.;Institut Universitaire de France, Paris, France. | 1417 | ||
| 10.1016/s0038-0814(20)30062-1 | Journal Article | fr | [From one epidemic to the next: how can the learned experience serve to alleviate the psychosocial impact of Covid-19 confinement?] | https://www.ncbi.nlm.nih.gov/pubmed/32563514 | The confinement of the population for an indefinite period within the framework of the national French prevention strategy of Covid-19 has a negative psychosocial impact already documented in other countries. In the past, several epidemics have built different strategies of prevention. It is urgent to consider how strategies used in other epidemics might be useful and helpful to manage the quarantine used to prevent the epidemics of COVID-19. | 0038-0814 | 2020-06-28 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Epidemics__prevention & control;France__epidemiology;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Quarantine__psychology;COVID-19 | Soins | Catherine Tourette-Turgis;Maryline Rébillon | COVID-19;Covid-19;confinement;epidemics;impact psychosocial;prevention;prévention;psychosocial impact;tay at home order;épidémie | 2020-06-22 02:00:00+02:00 | 32563514 | FR | Professeur des universités à la Sorbonne Université, chercheur au Conservatoire national des arts et métiers, fondatrice de l'Université des patients-Sorbonne Université des patients Sorbonne Université, faculté de médecine, bâtiment de stomatologie, 91 boulevard de l'hôpital, 75013 Paris, France, Professeur associé en ingénierie de la formation à Sorbonne Université Université des patients Sorbonne Université, faculté de médecine, bâtiment de stomatologie, 91 boulevard de l'hôpital, 75013 Paris, France. Electronic address: tourette-turgis@sorbonne-universite.fr.;Professeur des universités à la Sorbonne Université, chercheur au Conservatoire national des arts et métiers, fondatrice de l'Université des patients-Sorbonne Université des patients Sorbonne Université, faculté de médecine, bâtiment de stomatologie, 91 boulevard de l'hôpital, 75013 Paris, France, Professeur associé en ingénierie de la formation à Sorbonne Université Université des patients Sorbonne Université, faculté de médecine, bâtiment de stomatologie, 91 boulevard de l'hôpital, 75013 Paris, France. | 1419 | ||
| 10.1080/22221751.2020.1785336 | Journal Article;Review | en | Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway? | https://www.ncbi.nlm.nih.gov/pubmed/32574107 | We previously made the hypothesis that STING contributes to COVID-19. The present review detail new arguments for over-activation of STING pathways in COVID-19, following the description of hyper-coagulability and Kawasaki-like diseases in children. Indeed, Kawasaki disease is induced by overreaction of innate cells following exposition to various viruses, including herpes viruses which trigger STING. It predisposes to diffuse vasculitis and aneurysms, whereas STING is over-expressed in arterial aneurisms. The redness at the inoculation site of bacillus Calmette-Guérin, a specific feature of Kawasaki disease, is reproduced by activation of the STING pathway, which is inhibited upstream by aspirin, intravenous immunoglobulins, and Vitamin-D. SARS-CoV2 binding to ACE2 can lead to excessive angiotensin II signaling, which activates the STING pathway in mice. Over-activation of the STING-pathway promotes hyper-coagulability through release of interferon-β and tissue factor by monocytes-macrophages. Aspirin and dipyridamole, besides their anti-platelet activity, also reduce tissue factor procoagulant activity, and aspirin inhibits the STING pathway upstream of STING. Aspirin and dipyridamole may be used, in combination with drugs blocking downstream the activation of the STING pathway, like inhibitors of IL-6R and JAK/STAT pathways. The risk of bleeding should be low as bleeding has not been reported in severe COVID-19 patients. | 2222-1751 | 2020-06-28 02:00:00+02:00 | pubmed | Angiotensin II__metabolism;Animals;Aspirin__therapeutic use;Blood Coagulation Disorders__drug therapy;Coronavirus Infections__complications;Dipyridamole__therapeutic use;Humans;Immunoglobulins, Intravenous__therapeutic use;Interferons__metabolism;Membrane Proteins__metabolism;Mice;Mucocutaneous Lymph Node Syndrome__etiology;Pandemics;Platelet Aggregation Inhibitors__therapeutic use;Pneumonia, Viral__complications;Signal Transduction;Thrombosis__drug therapy;COVID-19 | Emerging Microbes & Infections | Jean-Marie Berthelot;Ludovic Drouet;Frédéric Lioté | ACE2;COVID-19;Kawasaki disease;STING;aspirin;coagulopathy;thrombosis;tissue factor | 2020-06-24 02:00:00+02:00 | 32574107 | FR | Rheumatology Department, Nantes University Hospital, Nantes, France.;CREATIF (centre de référence et d'éducation aux antithrombotiques d'Île-de-France).;Service de cardiologie, hôpital Lariboisière, Paris, France.;Rheumatology Department, centre Viggo Petersen, Paris, France.;Hôpital Lariboisière, Paris, France.;Université de Paris, Paris, France. | 1420 | ||
| 10.3390/biology9060134 | Journal Article | en | A Brief Theory of Epidemic Kinetics. | https://www.ncbi.nlm.nih.gov/pubmed/32580293 | In the context of the COVID-19 epidemic, and on the basis of the Theory of Dynamical Systems, we propose a simple theoretical approach for the expansion of contagious diseases, with a particular focus on viral respiratory tracts. The infection develops through contacts between contagious and exposed people, with a rate proportional to the number of contagious and of non-immune individuals, to contact duration and turnover, inversely proportional to the efficiency of protection measures, and balanced by the average individual recovery response. The obvious initial exponential increase is readily hindered by the growing recovery rate, and also by the size reduction of the exposed population. The system converges towards a stable attractor whose value is expressed in terms of the "reproductive rate" R0, depending on contamination and recovery factors. Various properties of the attractor are examined, and particularly its relations with R0. Decreasing this ratio below a critical value leads to a tipping threshold beyond which the epidemic is over. By contrast, significant values of the above ratio may bring the system through a bifurcating hierarchy of stable cycles up to a chaotic behaviour. | 2079-7737 | 2020-06-28 02:00:00+02:00 | pubmed | Biology | François Louchet | COVID-19;attractor;chaos;contamination kinetics;critical state;dynamical systems;epidemic;herd immunity;reproductive rate;stable cycle | 2020-06-22 02:00:00+02:00 | 32580293 | FR | Grenoble Institute of Technology and Laboratoire de Glaciologie et de Geophysique de l'Environnement, CNRS, Grenoble University (Retired), 38410 St Martin d'Uriage, France. | 1422 | |||
| Letter | en | Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. | https://www.ncbi.nlm.nih.gov/pubmed/32589076 | 2020-06-28 02:00:00+02:00 | pubmed | Administration, Inhalation;Aerosols;Betacoronavirus;Coronavirus Infections__drug therapy;Decision Making;Humans;Pandemics;Pneumonia, Viral__drug therapy;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jolyon P Mitchell;Ariel Berlinski;Sebastian Canisius;David Cipolla;Myrna B Dolovich;Igor Gonda;Guenther Hochhaus;Nani Kadrichu;Svetlana Lyapustina;Heidi M Mansour;Chantal Darquenne;Andy R Clark;Michael Newhouse;Stephan Ehrmann;Robert Humphries;Homer Boushey | 2020-06-23 02:00:00+02:00 | 32589076 | FR;JE;CA;GB;US;DE | Jolyon Mitchell Inhaler Consultancy Services, Inc., London, Ontario, Canada.;Pulmonology Division, Department of Pediatrics, University of Arkansas for Medical Sciences, College of Medicine, Little Rock, Arkansas, USA.;ACLiRA Consulting GmbH, Ebsdorfergrund, Germany.;Insmed, Inc., Bridgewater, New Jersey, USA.;Department of Medicine, McMaster University, Hamilton, Ontario, Canada.;Respidex LLC, Dennis, Massachusetts, USA.;College of Pharmacy, University of Florida, Gainesville, Florida, USA.;Inspired-Pulmonary Solutions LLC, San Carlos, California, USA.;Faegre Drinker Biddle & Reath LLP, Washington, District of Columbia, USA.;College of Pharmacy, College of Medicine and The University of Arizona-Tucson, Tucson, Arizona, USA.;Department of Medicine, UCSD, La Jolla, California, USA.;Aerogen Pharma Corporation, San Mateo, California, USA.;St. Joseph's Hospital Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.;Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada.;Centre Hospitalier Régional et Universitaire de Tours, Médecine Intensive Réanimation, Tours, France.;VisionRealisation, Shepshed, Leicestershire, United Kingdom.;School of Medicine, Universtiy of California San Francisco, San Francisco, California, USA. | 1426 | |||||||
| 10.3892/mco.2020.2075 | Journal Article | en | [Comment] Ethical and practical considerations on cancer recommendations during COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32754319 | National and international authorities and societies have recently published important cancer treatment recommendations in order to propose extra measures that should be taken during the COVID-19 pandemic, such as prioritisation of intend-to-cure treatments and younger patients, omission of non-urgent cases, and reduction of personnel present. These measures raise important ethical considerations, since they prioritise protection of Health Systems and Professionals without seemingly taking cancer patient feelings of stress into consideration. This could lead to an erosion of the physician-patient relationship, which is considered the core element of medical ethics. Moreover, they raise practical concerns about the continuous education of Health Professionals, the status of reference centres and the evaluation of the hitherto cancer treatments. | 2049-9450,2049-9469 | 2020-06-28 02:00:00+02:00 | pubmed | Molecular and Clinical Oncology | Christos Melidis;Miltiadis Vantsos | COVID-19;cancer treatment;ethical considerations;pandemic | 2020-06-24 02:00:00+02:00 | 32754319 | FR;GR | Radiation Therapy Department, 20200 Bastia, France.;Faculty of Theology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. | 1435 | |||
| 10.1017/cem.2020.434 | Journal Article | en | Aeromedical evacuations during the COVID-19 pandemic: practical considerations for patient transport. | https://www.ncbi.nlm.nih.gov/pubmed/32576326 | 1481-8035,1481-8043 | 2020-06-28 02:00:00+02:00 | pubmed | CJEM | Francois Lemay;Abel Vanderschuren;Judith Alain | COVID-19;aeromedical;transport | 2020-06-24 02:00:00+02:00 | 32576326 | FR;CA | Département d'anesthésiologie, CHU de Québec Université Laval, Hôtel-Dieu de Québec, Québec, QC.;Service d'évacuations aéromédicales du Québec, CHU de Québec Université Laval, Québec, QC.;Département de médecine, CHU de Québec Université Laval, Québec, QC.;Département de médecine d'urgence. CHU de Québec Université Laval, Québec, QC. | 1438 | ||||
| 10.1590/0037-8682-0271-2020 | Journal Article;Technical Report | en | #StayHome: Monitoring and benchmarking social isolation trends in Caruaru and the Região Metropolitana do Recife during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32609249 | This technical report presents information related to the Social Isolation Index (SII) of the city of Caruaru, Pernambuco, Brazil. The data was provided by In Loco, a technology startup that has collected the movement of around 60 million Brazilians through cell phone location. | 1678-9849,0037-8682 | 2020-06-28 02:00:00+02:00 | pubmed | Benchmarking;Brazil__epidemiology;Cell Phone;Cities__epidemiology;Coronavirus Infections__epidemiology;Decision Making;Geographic Information Systems;Humans;Pandemics__prevention & control;Personal Space;Pneumonia, Viral__epidemiology;Population Surveillance__methods;Social Isolation;Software;Time Factors;COVID-19 | Revista da Sociedade Brasileira de Medicina Tropical | Patricia Takako Endo;Ivanovitch Silva;Luciana Lima;Leonardo Bezerra;Rafael Gomes;Marcel Ribeiro-Dantas;Gisliany Alves;Kayo Henrique de Carvalho Monteiro;Theo Lynn;Vanderson de Souza Sampaio | 2020-06-24 02:00:00+02:00 | 32609249 | FR;BR;IE | Universidade de Pernambuco, Recife, PE, Brasil.;Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil.;Institut Curie, France.;Dublin City University, Ireland.;Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, AM, Brasil.;Fundação de Vigilância em Saúde do Amazonas, Manaus, AM, Brasil. | 1441 | |||
| 10.1007/s00405-020-06131-3 | Journal Article | en | Ethyl alcohol threshold test: a fast, reliable and affordable olfactory Assessment tool for COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32583183 | COVID-19 patients may present mild symptoms. The identification of paucisymptomatic patients is paramount in order to interrupt the transmission chain of the virus. Olfactory loss could be one of those early symptoms which might help in the diagnosis of COVID-19 patients. In this study, we aim to develop and validate a fast, inexpensive, reliable and easy-to-perform olfactory test for the screening of suspected COVID-19 patients. | 0937-4477,1434-4726 | 2020-06-28 02:00:00+02:00 | pubmed | European Archives of Oto-Rhino-Laryngology | Christian Calvo-Henriquez;Byron Maldonado-Alvarado;Carlos Chiesa-Estomba;Irene Rivero-Fernández;Marta Sanz-Rodriguez;Ithzel María Villarreal;Miguel Rodriguez-Iglesias;Franklin Mariño-Sánchez;Alejandro Rivero-de-Aguilar;Jerome R Lechien;Gabriel Martínez-Capoccioni;Sven Saussez;Robson Capasso;Petros D Karkos;Valentin Schriever;Carlos Martin-Martin;Isam Alobid;Alfonso Santamaría-Gadea;Claudio Fragola;Miguel Mayo-Yáñez;Hugo Pérez-Freixo;Elisabeth Ninchritz-Becerra;María Soriano-Reixach;Elisabeth Mondragon-Rezola;Maria Del Mar Martínez Ruiz-Coello;Raimundo Andrés Navarro;Alfredo García-Fernández;Álvaro Marchan-López | COVID-19;Olfaction;Olfactory impairment;SARS-CoV-2;Sniff test | 2020-06-24 02:00:00+02:00 | 32583183 | FR;GR;US;ES;BE;DE | Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS) Study Group, Paris, France. christian.ezequiel.calvo.henriquez@sergas.es.;Department of Otolaryngology, Service of Otolaryngology, Hospital Complex of Santiago de Compostela, Travesía de Choupana, s/n. 15706, Santiago de Compostela, Spain. christian.ezequiel.calvo.henriquez@sergas.es.;Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS) Study Group, Paris, France.;Department of Otolaryngology, Service of Otolaryngology, Hospital Complex of Santiago de Compostela, Travesía de Choupana, s/n. 15706, Santiago de Compostela, Spain.;Department of Otolaryngology, Donostia University Hospital, San Sebastian, Spain.;Department of Otolaryngology, Hospital 12 de Octubre, Madrid, Spain.;Department of Otolaryngology, University Hospital of Fuenlabrada, Madrid, Spain.;College of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.;Rhinology and Skull Base Surgery Unit, Otorhinolaryngology Department, Ramon y Cajal University Hospital, Madrid, Spain.;Department of Neurology, General Hospital of La Palma, Canary Islands, La Palma, Spain.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otolaryngology-Head and Neck Surgery, Stanford Hospital and Clinics, Stanford, CA, USA.;1st Department of Otolaryngology-Head Neck Surgery, AHEPA University Hospital, Thessaloniki, Greece.;Abteilung Neuropädiatrie, Klinik Und Poliklinik für Kinder-Und Jugendmedizin, Medizinische Fakultät Carl Gustav Carus, Technische Universität, Dresden, Germany.;Skull Base Unite, Department of Otolaryngology, IDIBAPS, Ciberes, Hospital Clinic, Barcelona, Spain.;Department of Otolaryngology, University Hospital of La Coruña, La Coruña, Spain.;Service of Preventive Medicine and Public Health, Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;Department of Neurology, Donostia University Hospital, San Sebastian, Spain. | 1442 | |||
| 10.1080/15548627.2020.1779467 | Journal Article | en | Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. | https://www.ncbi.nlm.nih.gov/pubmed/32522067 | During the last week of December 2019, Wuhan (China) was confronted with the first case of respiratory tract disease 2019 (coronavirus disease 2019, COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to the rapid outbreak of the transmission (~3.64 million positive cases and high mortality as of 5 May 2020), the world is looking for immediate and better therapeutic options. Still, much information is not known, including origin of the disease, complete genomic characterization, mechanism of transmission dynamics, extent of spread, possible genetic predisposition, clinical and biological diagnosis, complete details of disease-induced pathogenicity, and possible therapeutic options. Although several known drugs are already under clinical evaluation with many in repositioning strategies, much attention has been paid to the aminoquinoline derivates, chloroquine (CQ) and hydroxychloroquine (HCQ). These molecules are known regulators of endosomes/lysosomes, which are subcellular organelles central to autophagy processes. By elevating the pH of acidic endosomes/lysosomes, CQ/HCQ inhibit the autophagic process. In this short perspective, we discuss the roles of CQ/HCQ in the treatment of COVID-19 patients and propose new ways of possible treatment for SARS-CoV-2 infection based on the molecules that selectivity target autophagy.Abbreviation: ACE2: angiotensin I converting enzyme 2; CoV: coronavirus; CQ: chloroquine; ER: endoplasmic reticulum; HCQ: hydroxychloroquine; MERS-CoV: Middle East respiratory syndrome coronavirus; SARS-CoV: severe acute respiratory syndrome coronavirus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2. | 1554-8627,1554-8635 | 2020-06-28 02:00:00+02:00 | pubmed | Autophagy | Srinivasa Reddy Bonam;Sylviane Muller;Jagadeesh Bayry;Daniel J Klionsky | Autophagy;COVID-19;SARS-CoV-2;coronavirus;cytokine storm syndrome | 2020-06-24 02:00:00+02:00 | 32522067 | FR;US | Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe- Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Université De Paris , Paris, France.;CNRS and Strasbourg University Unit Biotechnology and Cell signalling / Laboratory of excellence Medalis , Strasbourg, France.;Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg University , Strasbourg, France.;Chair of Therapeutic Immunology, University of Strasbourg Institute for Advanced Study (USIAS) , Strasbourg, France.;Life Sciences Institute and Department of Molecular, Cellular and Developmental Biology, University of Michigan , Ann Arbor, MI, USA. | 1444 | |||
| 10.1097/cce.0000000000000166 | Journal Article | en | Factors Associated With Pulmonary Embolism Among Coronavirus Disease 2019 Acute Respiratory Distress Syndrome: A Multicenter Study Among 375 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32766562 | Risk factors associated with pulmonary embolism in coronavirus disease 2019 acute respiratory distress syndrome patients deserve to be better known. We therefore performed a post hoc analysis from the COronaVirus-Associated DIsease Study (COVADIS) project, a multicenter observational study gathering 21 ICUs from France (n = 12) and Belgium (n = 9). Three-hundred seventy-five consecutive patients with moderate-to-severe acute respiratory distress syndrome and positive coronavirus disease 2019 were included in the study. At day 28, 15% were diagnosed with pulmonary embolism. Known risk factors for pulmonary embolism including cancer, obesity, diabetes, hypertension, and coronary artery disease were not associated with pulmonary embolism. In the multivariate analysis, younger age (< 65 yr) (odds ratio, 2.14; 1.17-4.03), time between onset of symptoms and antiviral administration greater than or equal to 7 days (odds ratio, 2.39; 1.27-4.73), and use of neuromuscular blockers greater than or equal to 7 days (odds ratio, 1.89; 1.05-3.43) were independently associated with pulmonary embolism. These new findings reinforce the need for prospective studies that will determine the predictors of pulmonary embolism among patients with severe coronavirus disease 2019. | 2639-8028 | 2020-06-28 02:00:00+02:00 | pubmed | Critical Care Explorations | Thibaud Soumagne;Jean-Baptiste Lascarrou;Sami Hraiech;Geoffroy Horlait;Julien Higny;Alain d'Hondt;David Grimaldi;Stéphane Gaudry;Romain Courcelle;Giuseppe Carbutti;Gauthier Blonz;Nadia Aissaoui;Christophe Vinsonneau;Benoit Vandenbunder;Julien Textoris;Piotr Szychowiak;Nicolas Serck;Bertrand Sauneuf;Michael Piagnerelli;Andre Ly;François Lejeune;Laurent Lefebvre;Gaël Piton | acute respiratory distress syndrome;coronavirus disease 2019;critically ill;pulmonary embolism;severe acute respiratory syndrome coronavirus 2;thrombotic complications | 2020-06-25 02:00:00+02:00 | 32766562 | FR;BE | Service de Réanimation Médicale, CHU Besançon, Besançon, France.;CRICS-TriggerSEP research network, Tours, France, and Medecine Intensive Reanimation, CHU Nantes, Nantes, France.;Médecine Intensive Réanimation, Assistance Publique - Hôpitaux de Marseille, Marseille, France, and Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix- Faculté de médecine, Marseille Université, Marseille, France.;Unité de soins intensifs, CHU Dinant Godinne, site Godinne, Namur, Belgium.;Unité de soins intensifs, CHU Dinant Godinne, site Dinant, Dinant, Belgium.;Unité de soins intensifs, CHU Ambroise Paré, Mons, Belgium.;Soins Intensifs, Hôpital Erasme, ULB, Bruxelles, Belgium.;Réanimation médico-chirurgicale CHU Avicennes, Université Sorbonne Paris Nord, Bobigny, France.;Unité de soins intensifs, Centres Hospitaliers de Jolimont, La Louvière, Belgium.;Unité de soins intensifs, CHR Mons-Hainaut, Mons, Belgium.;Medecine Intensive Reanimation, District Hospital Center, Boulevard Stephane Moreau, La Roche Sur Yon, France.;Medecine Intensive Reanimation, Hôpital Européen Georges Pompidou, Paris centre U 970 PARCC, Paris, France.;CRICS-TriggerSEP research network, Tours, France, and Service de Médecine Intensive Réanimation Unité de Sevrage Ventilatoire et Réhabilitation Centre Hospitalier de Bethune, Beuvry, France.;Groupe des anesthésistes réanimateurs, Hôpital Privé d'Antony, Antony, France.;Service de réanimation, Hospices Civils de Lyon, Lyon, France, and Laboratoire Commun de Recherche bioMérieux-Hospices Civils de Lyon-Université de Lyon 1, Lyon, France.;CRICS-TriggerSEP research network, Tours, France, and Médecine Intensive Réanimation, CHRU Tours, Tours, France, and INSERM CIC 1415, CHRU Tours, Tours, France.;Unité de soins intensifs, Clinique Saint Pierre, Ottignies, Belgium.;Réanimation - Médecine Intensive, Centre Hospitalier Public du Cotentin, Cherbourg-en-Cotentin, France.;Intensive Care, CHU-Charleroi, Marie Curie, Université Libre de Bruxelles, chaussée de Bruxelles, Charleroi, Belgium.;Service d'anesthésie-réanimation chirurgicale Unité de réanimation chirurgicale polyvalente Hôpitaux Universitaires Henri Mondor, Créteil, France.;Unité de soins intensifs, Clinique Notre Dame de Grâce, Gosselies, Belgium.;Réanimation polyvalente Centre Hospitalier du pays d'Aix, Aix en Provence, France. | 1446 | |||
| Letter | en | COVID-19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH). | https://www.ncbi.nlm.nih.gov/pubmed/32573924 | 2020-06-28 02:00:00+02:00 | pubmed | Marta González Vicent;Antonio Pérez Martinez;María Trabazo Del Castillo;Blanca Molina;Luisa Sisini;Georgina Morón;Miguel Ángel Díaz | 2020-06-23 02:00:00+02:00 | 32573924 | FR;ES;BO | Stem Cell Transplant Unit, Hospital Universitario Niño Jesús, Madrid, Spain.;Pediatric Hematology Oncology Unit, Hospital Universitario la Paz, Madrid, Spain.;Pediatric Hematology Oncology Unit, Hospital Sant Pau, Barcelona, Spain. | 1448 | ||||||||
| 10.18632/aging.103583 | Journal Article | en | ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32576712 | To assess factors associated with one-month mortality among older inpatients with Covid-19. | 1945-4589 | 2020-06-28 02:00:00+02:00 | pubmed | Activities of Daily Living;Aged;Aged, 80 and over;Aging;Anticoagulants__blood;Betacoronavirus;Biomarkers__blood;Coronavirus Infections__mortality;Female;Fibrin Fibrinogen Degradation Products__metabolism;Humans;Inpatients;L-Lactate Dehydrogenase__blood;Male;Pandemics;Pneumonia, Viral__mortality;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Aging | Guilhem Bousquet;Géraldine Falgarone;David Deutsch;Sophie Derolez;Marilucy Lopez-Sublet;François-Xavier Goudot;Khadaoudj Amari;Yurdagul Uzunhan;Olivier Bouchaud;Frédéric Pamoukdjian | COVID-19;anticoagulation;geriatric assessment;mortality;predictive biomarkers | 2020-06-23 02:00:00+02:00 | 32576712 | FR | AP-HP Hôpital Avicenne, Oncologie Médicale, Bobigny 93000, France.;Université Sorbonne Paris Nord, INSERM, U942, Cardiovascular Markers in Stressed Conditions, MASCOT, Bobigny 93000, France.;AP-HP Hôpital Avicenne, Unité de Médecine Ambulatoire (UMA), Bobigny 93000, France.;Université Sorbonne Paris Nord, Villetaneuse 93430, France.;AP-HP Hôpital Avicenne, Gastroentérologie et Oncologie Digestive, Bobigny 93000, France.;AP-HP Hôpital Avicenne, Rhumatologie, Bobigny 93000, France.;AP-HP Hôpital Avicenne, Médecine Interne, ESH Hypertension Excellence Centre, Bobigny 93000, France.;AP-HP Hôpital Avicenne, Cardiologie, Bobigny 93000, France.;APHP Hôpital Avicenne, Service de Médecine Gériatrique, Bobigny 93000, France.;AP-HP Hôpital Avicenne, Pneumologie, Bobigny 93000, France.;Université Sorbonne Paris Nord, INSERM, U1272, Hypoxia and Lung, Bobigny 93000, France.;AP-HP Hôpital Avicenne, Infectious Diseases, Bobigny 93000, France.;EA 3412, Laboratoire Educations et Pratiques de Santé, Bobigny 93000, France. | 1449 | ||
| 10.1136/gutjnl-2020-321923 | Journal Article | en | COVID-19 in an international European liver transplant recipient cohort. | https://www.ncbi.nlm.nih.gov/pubmed/32571972 | Knowledge on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in liver transplant recipients is lacking, particularly in terms of severity of the disease. The aim of this study was to describe the demographic, baseline clinical characteristics and early outcomes of a European cohort of liver transplant recipients with SARS-CoV-2 infection. | 0017-5749,1468-3288 | 2020-06-28 02:00:00+02:00 | pubmed | Gut | Chiara Becchetti;Marco Fabrizio Zambelli;Luisa Pasulo;Maria Francesca Donato;Federica Invernizzi;Olivier Detry;Géraldine Dahlqvist;Olga Ciccarelli;Maria Cristina Morelli;Montserrat Fraga;Gianluca Svegliati-Baroni;Hans van Vlierberghe;Minneke J Coenraad;Mario Cristobal Romero;Andrea de Gottardi;Pierluigi Toniutto;Luca Del Prete;Claudia Abbati;Didier Samuel;Jacques Pirenne;Frederik Nevens;Jean-François Dufour | chronic liver disease;infectious disease;orthotopic liver transplantation | 2020-06-22 02:00:00+02:00 | 32571972 | FR;CH;US;IT;NL;ES;BE | University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern, Bern, Switzerland.;Department of Surgery, General Surgery and Abdominal Transplant Unit, "Papa Giovanni XXIII" Hospital, Bergamo, Bergamo, Lombardia, Italy.;Gastroenterology and Transplant Hepatology, "Papa Giovanni XXIII" Hospital, Bergamo, Bergamo, Lombardia, Italy.;Transplant Hepatology Unit, Division of Gastroenterology and Hepatology, IRCSS Foundation Ca' Granda, Maggiore Hospital Policlinico, CRC "A.M. and A. Migliavacca" Center of Liver Disease, Milan, Italy.;Department of Abdominal Surgery and Transplantation, Central University Hospital of Liege, Liege, Belgium.;Hepatogastroenterology Unit, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.;Department of Abdominal Surgery and Transplantation, Cliniques universitaires Saint-Luc, Bruxelles, Belgium.;Department of Organ Failures and Transplantation, Universita degli Studi di Bologna Azienda Ospedaliera di Bologna Policlinico Sant'Orsola-Malpighi, Bologna, Emilia-Romagna, Italy.;Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.;Liver Injury and Transplant Unit, AOU Ospedali Riuniti di Ancona, Ancona, Marche, Italy.;Department of Clinical and Molecular Sciences and Obesity Center, Polytechnic University of Marche, Ancona, Marche, Italy.;Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.;Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands.;Department of Hepatology, General University hospital Gregorio Maranon, Madrid, Spain.;Gastroenterology and Hepatology, Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Lugano, Switzerland.;Hepatology and Liver Transplant Unit, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Friuli-Venezia Giulia, Italy.;Centre Hépato-Biliaire, Paris-Saclay University, Inserm research unit, Hôpital Paul Brousse, Villejuif, France.;Abdominal Transplant Surgery, KU Leuven Hospital, Leuven, Flanders, Belgium.;Hepatology, KU Leuven Hospital, Leuven, Flanders, Belgium.;University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern, Bern, Switzerland jean-francois.dufour@dbmr.unibe.ch.;Hepatology, Depertment of Biomedical Research, University of Bern, Bern, Switzerland. | 1460 | |||
| 10.1016/j.mehy.2020.110023 | Journal Article | en | Why is SARS-CoV-2 infection more severe in obese men? The gut lymphatics - Lung axis hypothesis. | https://www.ncbi.nlm.nih.gov/pubmed/32593832 | Consistent observations report increased severity of SARS-CoV-2 infection in overweight men with cardiovascular factors. As the visceral fat possesses an intense immune activity, is involved in metabolic syndrome and is at the crossroad between the intestines, the systemic circulation and the lung, we hypothesized that it plays a major role in severe forms of SARS-CoV-2 infection. SARS-CoV2 presents the ability to infect epithelial cells of the respiratory tract as well as the intestinal tract. Several factors may increase intestinal permeability including direct enterocyte damage by SARS-CoV2, systemic inflammatory response syndrome (SIRS) and epithelial ischemia secondary to SARS-CoV2- associated endothelial dysfunction. This increase permeability further leads to translocation of microbial components such as MAMPs (microbial-associated molecular pattern), triggering an inflammatory immune response by TLR-expressing cells of the mesentery fat (mostly macrophages and adipocytes). The pro-inflammatory cytokines produced by the mesentery fat mediates systemic inflammation and aggravate acute respiratory distress syndrome (ARDS) through the mesenteric lymph drainage. | 0306-9877 | 2020-06-28 02:00:00+02:00 | pubmed | Medical Hypotheses | Mathieu Uzzan;Olivier Corcos;Jerome C Martin;Xavier Treton;Yoram Bouhnik | 2020-06-23 02:00:00+02:00 | 32593832 | FR | Department of Gastroenterology, IBD and Nutritional Support, CHU Paris Nord-Val de Seine, Beaujon Hospital, Clichy, France. Electronic address: mathieu.uzzan@aphp.fr.;Department of Gastroenterology, IBD and Nutritional Support, CHU Paris Nord-Val de Seine, Beaujon Hospital, Clichy, France.;Université de Nantes, Inserm, CHU Nantes, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France, CHU Nantes, Laboratoire d'Immunologie, Center for Immuno Monitoring Nantes-Atlantique (CIMNA), F-44000 Nantes, France. | 1470 | ||||
| 10.1017/s1751731120001639 | Journal Article | en | Opinion paper: Severe Acute Respiratory Syndrome Coronavirus 2 and domestic animals: what relation? | https://www.ncbi.nlm.nih.gov/pubmed/32638677 | 1751-7311,1751-732X | 2020-06-28 02:00:00+02:00 | pubmed | animal | E Khamisse;C Dunoyer;M Ar Gouilh;P Brown;F Meurens;G Meyer;E Monchatre-Leroy;N Pavio;G Simon;S Le Poder | 2020-06-23 02:00:00+02:00 | 32638677 | FR | Direction de l'évaluation des risques, ANSES, 94700Maisons-Alfort, France.;Groupe de Recherche sur l'Adaptation Microbienne, Normandie Université, 14000Caen, France.;Service de Virologie, CHU de Caen, 14000Caen, France.;Laboratoire de Ploufragan-Plouzané-Niort, ANSES, 22440Ploufragan, France.;BIOEPAR, Oniris, INRAE, 44307Nantes, France.;ENVT, INRAE, 31076Toulouse, France.;Laboratoire de la rage et de la faune sauvage, ANSES, 54220Malzéville, France.;UMR Virologie, ENVA, INRAE, ANSES Laboratoire de santé animale, 94700Maisons-Alfort, France. | 1471 | |||||
| 10.1007/s00134-020-06091-6 | Consensus Development Conference;Journal Article | en | Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. | https://www.ncbi.nlm.nih.gov/pubmed/32572532 | Invasive pulmonary aspergillosis is increasingly reported in patients with influenza admitted to the intensive care unit (ICU). Classification of patients with influenza-associated pulmonary aspergillosis (IAPA) using the current definitions for invasive fungal diseases has proven difficult, and our aim was to develop case definitions for IAPA that can facilitate clinical studies. | 0342-4642,1432-1238 | 2020-06-28 02:00:00+02:00 | pubmed | Antifungal Agents__therapeutic use;Aspergillus__isolation & purification;Betacoronavirus;Bronchoalveolar Lavage Fluid__chemistry;Coronavirus Infections__complications;Humans;Influenza, Human__complications;Intensive Care Units;Mannans__analysis;Pandemics;Pneumonia, Viral__complications;Pulmonary Aspergillosis__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Paul E Verweij;Bart J A Rijnders;Roger J M Brüggemann;Elie Azoulay;Matteo Bassetti;Stijn Blot;Thierry Calandra;Cornelius J Clancy;Oliver A Cornely;Tom Chiller;Pieter Depuydt;Daniele Roberto Giacobbe;Nico A F Janssen;Bart-Jan Kullberg;Katrien Lagrou;Cornelia Lass-Flörl;Russell E Lewis;Peter Wei-Lun Liu;Olivier Lortholary;Johan Maertens;Ignacio Martin-Loeches;M Hong Nguyen;Thomas F Patterson;Thomas R Rogers;Jeroen A Schouten;Isabel Spriet;Lore Vanderbeke;Joost Wauters;Frank L van de Veerdonk | COVID-19;ICU;Influenza;Invasive aspergillosis;Viral pneumonia | 2020-06-22 02:00:00+02:00 | 32572532 | FR;IE;CH;US;AT;TW;IT;AU;NL;ES;BE;DE | Department of Medical Microbiology, Radboud University Medical Center, PO box 9101, 6500 HB, Nijmegen, The Netherlands. paul.verweij@radboudumc.nl.;Centre of Expertise in Mycology Radboudumc/CWZ, Radboudumc Center for Infectious Diseases (RCI), Nijmegen, The Netherlands. paul.verweij@radboudumc.nl.;Department of Internal Medicine and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.;Centre of Expertise in Mycology Radboudumc/CWZ, Radboudumc Center for Infectious Diseases (RCI), Nijmegen, The Netherlands.;Department of Pharmacy and Radboud Institute of Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.;Medical Intensive Care Unit, Saint-Louis Hospital, APHP, Paris, France.;Clinica Malattie Infettive, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy.;Department of Health Sciences, DISSAL, University of Genoa, Genoa, Italy.;Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.;Burns, Trauma, and Critical Care Research Centre, Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.;Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.;Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA.;Infectious Diseases Section, VA Pittsburgh Healthcare System, Pittsburgh, USA.;Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.;Department of Internal Medicine, ECMM Center of Excellence for Medical Mycology, German Centre for Infection Research, Partner Site Bonn-Cologne (DZIF), University of Cologne, Cologne, Germany.;Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.;Centers for Disease Control and Prevention, Atlanta, GA, 30329, USA.;Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium.;Department of Health Sciences, University of Genoa, Genoa, Italy.;Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.;Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.;Department of Laboratory Medicine and National Reference Centre for Mycosis, University Hospitals Leuven, Leuven, Belgium.;Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.;Infectious Diseases Hospital, S'Orsola-Malpighi, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.;Department of Emergency and Critical Care Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei, Taiwan.;School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.;Necker - Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, AP-HP, Paris University, Paris, France.;Molecular Mycology Unit National Reference Center for Invasive Mycoses and Antifungals, CNRS, UMR 2000, Institut Pasteur, Paris, France.;Department of Hematology, University Hospitals Leuven, Leuven, Belgium.;Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, Dublin, Ireland.;Hospital Clinic, IDIBAPS, Universidad de Barcelona, Ciberes, Barcelona, Spain.;Department of Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.;South Texas Veterans Health Care Center, San Antonio, TX, USA.;Department of Clinical Microbiology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.;Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.;Scientific Center for Quality of Healthcare (IQ Healthcare), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.;Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.;Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium. | 1476 | ||
| Letter | en | Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. | https://www.ncbi.nlm.nih.gov/pubmed/32586918 | 2020-06-28 02:00:00+02:00 | pubmed | Arielle Mendel;Sasha Bernatsky;Anca Askanase;Sang-Cheol Bae;Ann Elaine Clarke;Nathalie Costedoat-Chalumeau;Dafna D Gladman;Caroline Gordon;John Hanly;Søren Jacobsen;Ken Kalunian;Anselm Mak;Marta Mosca;Bernardo A Pons-Estel;Guillermo Ruiz-Irastorza;Murray Urowitz;Évelyne Vinet | epidemiology;hydroxychloroquine;lupus erythematosus;systemic | 2020-06-25 02:00:00+02:00 | 32586918 | FR;SG;AR;CA;GB;US;IT;DK;ES;KR | Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada arielle.mendel@mail.mcgill.ca.;Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada.;Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.;Division of Rheumatology, Columbia University Irving Medical Center, New York, New York, USA.;Division of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seongdong-gu, Republic of Korea.;Division of Rheumatology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.;Centre de Référence Maladies Auto-immunes et Systémiques Rares, Service de Médecine Interne, Hôpital Cochin, Paris, France.;Lupus Program, Centre for Prognosis Studies in the Rheumatic Disease and Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.;Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.;Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.;Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.;Copenhagen Lupus and Vasculitis Clinic, Section 4242, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.;Division of Rheumatology, University of California San Diego School of Medicine, La Jolla, California, USA.;Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.;Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.;Regional Center for Autoimmune and Rheumatic Diseases of Rosario, Sanatorio Parque, Rosario, Argentina.;Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain. | 1477 | |||||||
| Letter | en | ARIA-EAACI statement on Asthma and COVID-19 (June 2, 2020). | https://www.ncbi.nlm.nih.gov/pubmed/32588922 | 2020-06-28 02:00:00+02:00 | pubmed | Jean Bousquet;Marek Jutel;Cezmi A Akdis;Ludger Klimek;Oliver Pfaar;Kari C Nadeau;Thomas Eiwegger;Anna Bedbrook;Ignacio J Ansotegui;Josep M Anto;Claus Bachert;Eric D Bateman;Kazi S Bennoor;Emilia Camelia Berghea;Karl-Christian Bergmann;Hubert Blain;Mateo Bonini;Sinthia Bosnic-Anticevich;Louis-Philippe Boulet;Luisa Brussino;Roland Buhl;Paulo Camargos;G Walter Canonica;Victoria Cardona;Thomas Casale;Sharon Chinthrajah;Mübeccel Akdis;Tomas Chivato;George Christoff;Alvaro A Cruz;Wienczyslawa Czarlewski;Stefano Del Giacco;Hui Du;Yehia El-Gamal;Wytske J Fokkens;Joao A Fonseca;Yadong Gao;Mina Gaga;Bilun Gemicioglu;Maia Gotua;Tari Haahtela;David Halpin;Eckard Hamelmann;Karin Hoffmann-Sommergruber;Marc Humbert;Nataliya Ilina;Juan-Carlos Ivancevich;Guy Joos;Musa Khaitov;Bruce Kirenga;Edward F Knol;Fanny W Ko;Seppo Koskinen;Marek L Kowalski;Helga Kraxner;Dmitri Kudlay;Piotr Kuna;Maciej Kupczyk;Violeta Kvedariene;Amir H Abdul Latiff;Lan T Le;Michael Levin;Desiree Larenas-Linnemann;Renaud Louis;Mohammad R Masjedi;Erik Melén;Florin Mihaltan;Branislava Milenkovic;Yousser Mohammad;Mario Morais-Almeida;Joaquim Mullol;Leyla Namazova;Hugo Neffen;Elisabete Nunes;Paul O'Byrne;Robyn O'Hehir;Liam O'Mahony;Ken Ohta;Yoshitaka Okamoto;Gabrielle L Onorato;Petr Panzner;Nikos G Papadopoulos;Gianni Passalacqua;Vincenzo Patella;Ruby Pawankar;Nhân Pham-Thi;Bernard Pigearias;Todor A Popov;Francesca Puggioni;Frederico S Regateiro;Giovanni Rolla;Menachem Rottem;Boleslaw Samolinski;Joaquin Sastre;Jurgen Schwarze;Aziz Sheikh;Nicola Scichilone;Manuel Soto-Quiros;Milan Sova;Stefania Nicola;Rafael Stelmach;Charlotte Suppli-Ulrik;Luis Taborda-Barata;Teresa To;Peter-Valentin Tomazic;Sanna Toppila-Salmi;Ioanna Tsiligianni;Omar Usmani;Arunas Valiulis;Maria Teresa Ventura;Giovanni Viegi;Theodor Vontetsianos;De Yun Wang;Sian Williams;Gary Wk Wong;Arzu Yorgancioglu;Mario Zernotti;Mihaela Zidarn;Torsten Zuberbier;Ioana Agache | 2020-06-26 02:00:00+02:00 | 32588922 | CR;LT;IL;CA;SI;PT;JP;BR;CZ;AR;GE;UG;VN;BG;NL;UA;MX;BE;PS;DK;FR;RU;CN;GR;CH;US;RO;GB;HK;PL;IT;IR;EG;RS;HU;DE;AT;SE;MY;IE;SY;SG;FI;MZ;BD;AU;TR;ZA;ES | Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.;University Hospital Montpellier, Montpellier, France.;MACVIA-France, Montpellier, France.;Department of Clinical Immunology, Wrocław Medical University and ALL-MED Medical Research Institute, Wroclaw, Poland.;Akdis M. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.;Center for Rhinology and Allergology, Wiesbaden, Germany.;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.;Stanford University School of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, USA.;The Hospital for Sick Children, Department of Paediatrics, Division of Clinical Immunology and Allergy, Food allergy and Anaphylaxis Program, The University of Toronto, Toronto, Ontario, Canada.;Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Erandio, Spain.;ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.;IMIM (Hospital del Mar Research Institute), Barcelona, Spain.;Universitat Pompeu Fabra (UPF), Barcelona, Spain.;CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.;Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium.;Sun Yat-sen University, International Airway Research Center, First Affiliated Hospital Guangzou, Guangzou, China.;Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden.;Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden.;Department of Medicine, University of Cape Town, Cape Town, South Africa.;Dept of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.;Allergology and Clinical Immunology, Carol Davila University of Medicine and Pharmacy, Bucharest and Clinical Emergency Hospital for Children MS Curie, Bucharest, Romania.;Department of Geriatrics, Montpellier University Hospital, Montpellier, France.;EA 2991, Euromov, University Montpellier, Montpellier, France.;Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.;National Heart and Lung Institute, Royal Brompton Hospital & Imperial College , London, UK.;Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia.;Quebec Heart and Lung Institute, Laval University, Québec City, Quebec, Canada.;Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino & Mauriziano Hospital, Torino, Italy.;Dept of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany.;Federal University of Minas Gerais, Medical School, Department of Pediatrics, Belo Horizonte, Brazil.;Personalized Medicine Asthma & Allergy Clinic-Humanitas University & Research Hospital, IRCCS-Milano, Milano, Italy.;Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL research network, Barcelona, Spain.;Division of Allergy/immunology, University of South Florida, Tampa, Fla, USA.;School of Medicine, University CEU San Pablo, Madrid, Spain.;Medical University - Sofia, Faculty of Public Health, Sofia, Sofia, Bulgaria.;Fundação ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Brazil.;Medical Consulting Czarlewski, Levallois, France.;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital "Duilio Casula", University of Cagliari, Cagliari, Italy.;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.;Pediatric Allergy and Immunology Unit, Children's hospital, Ain Shams University, Cairo, Egypt.;Department of Otorhinolaryngology, Academic Medical Centers, AMC, Amsterdam, The Netherland, and EUFOREA, Brussels, Belgium.;Center for research in health technologies and information systems, CINTESIS, Universidade do Porto, Porto, Portugal.;Allergy Unit, Instituto CUF Porto e Hospital CUF Porto, Porto, Portugal.;Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.;Faculdade de Medicina da Universidade do Porto, Porto, Portugal.;7th Resp. Med. Dept and Asthma Center, Athens Chest Hospital, Athens, Greece.;Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.;Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia.;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.;University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.;Klinik für Kinder- und Jugendmedizin, Kinderzentrum Bethel, Evangelisches Klinikum Bethel EvKB, University Bielefeld, Bielefeld, Germany.;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.;Université Paris-Sud, Service de Pneumologie, Hôpital Bicêtre, Inserm UMR_S999, Le Kremlin Bicêtre, France.;Vinnytsa National Medical University by Mykola Pyrogov, Vinnytsa, Ukraine.;IServicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.;Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.;Makerere University Lung Institute, Kampala, Uganda.;Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.;Finnish Institute for Health and Welfare, Helsinki, Finland.;Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland.;Semmelweis University, Department of Otorhinolaryngology, Head and Neck Surgery, Szigony u. 36, Budapest, Hungary.;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.;Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University and Institute of Clinical medicine, Clinic of Chest diseases and Allergology, faculty of Medicine, Vilnius University, Vilnius, Lithuania.;Allergy & Immunology Centre, Pantai Hospital, Kuala Lumpur, Malaysia.;University of Medicine and Pharmacy, Hochiminh City, Vietnam.;Division Paediatric Allergology, University of Cape Town, Cape Town, South Africa.;Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.;Department of Pulmonary Medicine, CHU Sart-Tilman, GIGA I3 research group, Liege, Belgium.;Tobacco Control Research Centre, Iranian Anti Tobacco Association, Tehran, Iran.;Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.;National Institute of Pneumology M Nasta, Bucharest, Romania.;Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia.;National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia and Syrian Private University-Damascus, Latakia, Syria.;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.;Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.;Scientific Centre of Children's Health under the MoH, Moscow, Russia.;Director of Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina Center for Allergy and Immunology, Santa Fe, Argentina.;Serviço de Pneumologia Hospital Central and Faculdade de Medicina Dr Eduardo Mondelane, Maputo, Mozambique.;Division of Respirology, Department of Medicine, McMaster University, Hamilton, and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada.;Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University, and Alfred Health, Melbourne, Victoria, Australia.;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.;National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.;Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.;Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic.;Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.;Allergy and Respiratory Diseases, Ospedale Policlino San Martino -University of Genoa, Genoa, Italy.;Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, "Santa Maria della Speranza" Hospital, Battipaglia, Salerno, Italy.;Department of Pediatrics, Nippon Medical School, Tokyo, Japan.;Ecole polytechnique, Ecole polytechnique Institut Polytechnique de Paris, Palaiseau, France.;Société de Pneumologie de Langue Française, Espace francophone de Pneumologie, Paris, France.;University Hospital 'Sv Ivan Rilski'", Sofia, Bulgaria.;Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, and ICBR - Coimbra Institute for Clinical and Biomedical Research, CIBB, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.;Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, and Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.;Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.;Fundacion Jimenez Diaz, CIBERES, Faculty of Medicine, Autonoma University of Madrid, Madrid, Spain.;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, United Kingdom.;The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.;PROMISE Department, University of Palermo, Palermo, Italy.;Department of Pediatrics, Hospital Nacional de Niños, San José, Costa Rica.;Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic.;Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.;Department of Respiratory Medicine, Hvidovre Hospital & University of Copenhagen, Copenhagen, Denmark.;Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal.;Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilhã, Portugal.;The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.;Dept of General ORL, H&NS, Medical University of Graz, ENT-University Hospital Graz, Graz, Austria.;Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece.;International Primary Care Respiratory Group, International Primary Care Respiratory Group, (IPCRG), Aberdeen, Scotland.;National Heart and Lung Institute (NHLI), Imperial College London & Royal Brompton Hospital, Airways Disease Section, London, UK.;Vilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, Lithuania.;European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.;University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy.;Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, and CNR Institute for Biomedical Research and Innovation, Palermo, Italy.;Sotiria Hospital, Athens, Greece.;Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.;International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland.;Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Shatin, Hong Kong, China.;Celal Bayar University, Department of Pulmonology, Manisa, Turkey.;Universidad Católica de Córdoba, Universidad Nacional de Villa Maria, Argentina.;University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.;Transylvania University Brasov, Brasov, Romania. | 1480 | ||||||||
| 10.1016/j.jormas.2020.06.010 | Journal Article | en | 3D-printed contact-free devices designed and dispatched against the COVID-19 pandemic: The 3D COVID initiative. | https://www.ncbi.nlm.nih.gov/pubmed/32599093 | Direct contact with devices such as elevator buttons, beepers, telephones, computer mice and keyboards can contribute to spread viral diseases. Here, we report our experience in designing, producing and dispatching three 3D-printed objected intending to lower the risks of COVID-19 contamination by limiting direct contacts: (1) fixed hand-free door openers, (2) door hooks and (3) button pushers. These devices were produced in industrial quantities and made available for free for Greater Paris University Hospitals and various state institutions as part of the 3D COVID project. In this short technical note, we describe the sequential organisation of the design and production and highlight the advantages of additive manufacturing in dealing with specific aspects of sanitary crises. | 2468-7855 | 2020-06-28 02:00:00+02:00 | pubmed | Journal of Stomatology, Oral and Maxillofacial Surgery | P-M François;X Bonnet;J Kosior;J Adam;R H Khonsari | COVID-19;Contamination;Door opener;Infection control;Pandemic;Virus | 2020-06-26 02:00:00+02:00 | 32599093 | FR | Bone3D, Paris, France.;Institut de biomécanique humaine George-Charpak, Arts et Métiers, Paris, France.;Service de chirurgie maxillo-faciale et chirurgie plastique, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Centre de Références Maladies Rares Fentes et Malformations Faciales MAFACE, Centre de Références Maladies Rares Craniosténoses et Malformations Craniofaciales CRANIOST, Filière Maladies Rares TeteCou, Université de Paris, Paris, France. Electronic address: roman.khonsari@aphp.fr. | 1481 | |||
| 10.1016/j.alter.2020.06.006 | English Abstract;Journal Article | fr | [In student residences during lockdown, disabled students coping with distance learning are left on the sidelines]. | https://www.ncbi.nlm.nih.gov/pubmed/32834872 | The health crisis due to the outbreak of Coronavirus since the beginning of 2020 has strongly exposed the effect of decades of public service cuts in France, especially in the fields of education or health. Although the French President has recently declared that the living conditions of people with disabilities were a "national priority", this issue has not been addressed by public authorities while managing the current crisis. This article analyses and helps to understand the situation of young people with disabilities living in student residences in lockdown for about two months, an issue that has been overlooked. The case study is based on a series of interviews with Joseph, a blind Master's student, and some of his relatives. It looks back on Joseph's experience and academic career, his living conditions in lockdown, his difficulties in coping with distance learning, as well as the resources and support he gets to be able to live and get through. | 1875-0672 | 2020-06-28 02:00:00+02:00 | pubmed | Alter | Étienne Douat | Containment;Covid 19;Disability;Student;University | 2020-06-25 02:00:00+02:00 | 32834872 | FR | GRESCO, université de Poitiers, 8, plan Saint-Simplicien, Poitiers, France. | 1494 | |||
| Comparative Study;Letter | en | To compare the incomparable: COVID-19 pneumonia and high-altitude disease. | https://www.ncbi.nlm.nih.gov/pubmed/32398299 | 2020-06-28 02:00:00+02:00 | pubmed | Altitude Sickness__complications;Betacoronavirus;Coronavirus Infections__complications;Humans;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Giacomo Strapazzon;Matthias P Hilty;Pierre Bouzat;Lorenza Pratali;Hermann Brugger;Simon Rauch | 2020-06-25 02:00:00+02:00 | 32398299 | FR;CH;US;IT;AT | Institute of Mountain Emergency Medicine, Eurac Research, Bolzano, Italy giacomo.strapazzon@eurac.edu.;Dept of Anaesthesiology and Critical Care Medicine, Medical University of Innsbruck, Innsbruck, Austria.;Intensive Care Unit, University Hospital of Zurich, Zurich, Switzerland.;Dept Anaesthesia and Critical Care, University Hospital of Grenoble, Grenoble, France.;Institute of Clinical Physiology, National Council of Research - CNR, Pisa, Italy.;Institute of Mountain Emergency Medicine, Eurac Research, Bolzano, Italy.;Dept of Anesthesia and Intensive Care Medicine, "F. Tappeiner" Hospital, Merano, Italy. | 1495 | |||||||
| 10.1016/s2665-9913(20)30176-4 | Journal Article | en | Anakinra for patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32835234 | 2665-9913 | 2020-06-28 02:00:00+02:00 | pubmed | The Lancet Rheumatology | Xavier Valette;Damien du Cheyron | 2020-06-25 02:00:00+02:00 | 32835234 | FR | Department of Medical Intensive Care, CHU de Caen Normandie, Caen 14000, France. | 1500 | |||||
| 10.1016/j.glt.2020.06.003 | Journal Article | en | Predictors of COVID-19 voluntary compliance behaviors: An international investigation. | https://www.ncbi.nlm.nih.gov/pubmed/32835202 | With a large international sample (n = 8317), the present study examined which beliefs and attitudes about COVID-19 predict 1) following government recommendations, 2) taking health precautions (including mask wearing, social distancing, handwashing, and staying at home), and 3) encouraging others to take health precautions. The results demonstrate the importance of believing that taking health precautions will be effective for avoiding COVID-19 and generally prioritizing one's health. These beliefs continued to be important predictors of health behaviors after controlling for demographic and personality variables. In contrast, we found that perceiving oneself as vulnerable to COVID-19, the perceived severity of catching COVID-19, and trust in government were of relatively little importance. We also found that women were somewhat more likely to engage in these health behaviors than men, but that age was generally unrelated to voluntary compliance behaviors. These findings may suggest avenues and dead ends for behavioral interventions during COVID-19 and beyond. | 2589-7918 | 2020-06-28 02:00:00+02:00 | pubmed | Global Transitions | Cory Clark;Andrés Davila;Maxime Regis;Sascha Kraus | COVID-19;Government trust;Health behavior;Rule compliance | 2020-06-26 02:00:00+02:00 | 32835202 | FR;GB;US | Heterodox Academy, New York, USA.;ESCE International Business School, INSEEC U Research Center & Praditus SAS, Paris, France.;Université Panthéon Assas Paris II, LARGEPA & Praditus SAS, Paris, France.;Durham University, Durham University Business School, United Kingdom. | 1502 | |||
| 10.1007/s10479-020-03692-8 | Journal Article | en | Long term optimal investment with regime switching: inflation, information and short sales. | https://www.ncbi.nlm.nih.gov/pubmed/32836616 | Financial models are based on the standard assumptions of frictionless markets, complete information, no transaction costs and no taxes and borrowing and short selling without restrictions. Short-selling bans around the world after the global financial crisis and in several exchanges during the COVID 19 period, become more and more important. This paper bridges the gap by providing for the first time in the literature a model that accounting explicitly and simultaneously for inflation, information costs and short sales in the portfolio performance with regime switching. Our model can be used by portfolio managers to assess the impact of these market imperfections on portfolio decisions. | 0254-5330,1572-9338 | 2020-06-28 02:00:00+02:00 | pubmed | Annals of Operations Research | Mondher Bellalah;Akeb Hakim;Kehan Si;Detao Zhang | Inflation rate;Information costs;Regime switching;Short selling costs | 2020-06-28 02:00:00+02:00 | 32836616 | FR;CN | Cy Cergy Paris University, Cergy, France.;ISC Paris Business School, Paris, France.;School of Mathematics, Shandong University, Jinan, 250100 People's Republic of China.;School of Economics, Shandong University, Jinan, 250100 People's Republic of China. | 1504 | |||
| Letter | en | COVID-19 Lockdown induced acral dermatosis in children. | https://www.ncbi.nlm.nih.gov/pubmed/32594634 | Recently, several case series of cutaneous acral manifestations in patients with suspected or confirmed coronavirus disease 2019 (COVID-19) have been reported. A majority of these acral manifestations have a pseudo-chilblain pattern with erythema and oedema and sometimes vesicles. | 2020-06-28 02:00:00+02:00 | pubmed | Nathalie Bodak;Christine Chiaverini;Sebastien Barbarot | COVID-19;frictional dermatosis | 2020-06-28 02:00:00+02:00 | 32594634 | FR | Consultant dermatologist, Private Office, Paris, France.;Department of Dermatology, CHU Nice, Nice, France.;Nantes Université, Department of Dermatology, CHU Nantes, UMR, INRA, 1280 PhAN, F-44000, Nantes, France. | 1506 | ||||||
| French National Agency for Research (ANR);French the National Research Institute for Sustainable Development (IRD);France Fundation (Fondation de France) | 10.1111/jsr.13119 | Journal Article | en | Covid-19 health crisis and lockdown associated with high level of sleep complaints and hypnotic uptake at the population level. | https://www.ncbi.nlm.nih.gov/pubmed/32596936 | The Covid-19 pandemic has disrupted the habits of billions of people around the world. Lockdown at home is mandatory, forcing many families, each member with their own sleep-wake habits, to spend 24 hr a day together, continuously. Sleep is crucial for maintaining immune systems and contributes deeply to physical and psychological health. To assess sleep problems and use of sleeping pills, we conducted a cross-sectional study of a representative sample of the general population in France. The self-reported sleep complaint items, which covered the previous 8 days, have been used in the 2017 French Health Barometer Survey, a cross-sectional survey on various public health issues. After 2 weeks of confinement, 74% of the participants (1,005 subjects) reported trouble sleeping compared with a prevalence rate of 49% in the last general population survey. Women reported more sleeping problems than men, with greater frequency or severity: 31% vs. 16%. Unusually, young people (aged 18-34 years) reported sleep problems slightly more frequently than elderly people (79% vs. 72% among those aged 35 or older), with 60% of the younger group reporting that these problems increased with confinement (vs. 51% of their elders). Finally, 16% of participants reported they had taken sleeping pills during the last 12 months, and 41% of them reported using these drugs since the lockdown started. These results suggest that the COVID crisis is associated with severe sleep disorders among the French population, especially young people. | 0962-1105,1365-2869 | 2020-06-28 02:00:00+02:00 | pubmed | Journal of Sleep Research | Francois Beck;Damien Léger;Lisa Fressard;Patrick Peretti-Watel;Pierre Verger | COVID-19;epidemiology;hypnotics;sleep;sleep problems;young adults | 2020-06-28 02:00:00+02:00 | 32596936 | FR | [{"country": "", "agency": "French National Agency for Research (ANR)"}, {"country": "", "agency": "French the National Research Institute for Sustainable Development (IRD)"}, {"country": "", "agency": "France Fundation (Fondation de France)"}] | CESP (Centre de recherche en Épidémiologie et Santé des Populations), Université Paris-Saclay, UVSQ, Université de Paris-Sud, Villejuif, France.;Université de Paris, VIFASOM (EA 7330, Vigilance Fatigue Sommeil et Santé Publique), Paris, France.;APHP, Hôtel Dieu, Centre du Sommeil et de la Vigilance, Consultation de pathologie professionnelle Sommeil Vigilance et Travail, Centre de référence hypersomnies rares, Paris, France.;Southeastern Health Regional Observatory (ORS Paca), Marseille, France.;UMR Vitrome, AMU, IHU Méditerrannée, IRD, Marseille, France. | 1515 | |
| 10.1016/j.ejogrb.2020.06.064 | Journal Article | en | Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic! | https://www.ncbi.nlm.nih.gov/pubmed/32650189 | EMA decided that with ulipristal acetate (UPA) treatment for uterine fibroids, should be discontinued due to the associated risk of hepatic failure, We analyzed whether the risk of recurrent symptoms due to fibroids may lead to an increased risk of Covid -19 infection and death, that would exceed the former risk of hepatic failure and transplantation. | 0301-2115 | 2020-06-28 02:00:00+02:00 | pubmed | European Journal of Obstetrics & Gynecology and Reproductive Biology | Serge Rozenberg;Perrine Revercez;Maxime Fastrez;Jean Vandromme;Dario Bucella | Covid-19;Fibroids;Markov model;Ulipristal acetate;Uterine leiomyoma | 2020-06-27 02:00:00+02:00 | 32650189 | FR;BE | Department of Gynaecology-Obstetrics, CHU St Pierre. Université Libre De Bruxelles, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: serge_rozenberg@stpierre-bru.be.;Department of Gynaecology-Obstetrics, CHU St Pierre. Université Libre De Bruxelles, Vrije Universiteit Brussel, Brussels, Belgium. | 1519 | |||
| 10.1111/bjh.16898 | Journal Article;Review | en | Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32480420 | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) is primarily manifested as a respiratory tract infection, but may affect and cause complications in multiple organ systems (cardiovascular, gastrointestinal, kidneys, haematopoietic and immune systems), while no proven specific therapy exists. The challenges associated with COVID-19 are even greater for patients with light chain (AL) amyloidosis, a rare multisystemic disease affecting the heart, kidneys, liver, gastrointestinal and nervous system. Patients with AL amyloidosis may need to receive chemotherapy, which probably increases infection risk. Management of COVID-19 may be particularly challenging in patients with AL amyloidosis, who often present with cardiac dysfunction, nephrotic syndrome, neuropathy, low blood pressure and gastrointestinal symptoms. In addition, patients with AL amyloidosis may be more susceptible to toxicities of drugs used to manage COVID-19. Access to health care may be difficult or limited, diagnosis of AL amyloidosis may be delayed with detrimental consequences and treatment administration may need modification. Both patients and treating physicians need to adapt in a new reality. | 0007-1048,1365-2141 | 2020-07-05 02:00:00+02:00 | pubmed | Antiviral Agents__adverse effects;Betacoronavirus;Coronavirus Infections__complications;Health Services Accessibility;Humans;Immunoglobulin Light-chain Amyloidosis__complications;Immunologic Factors__adverse effects;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | British Journal of Haematology | Efstathios Kastritis;Ashutosh Wechalekar;Stefan Schönland;Vaishali Sanchorawala;Giampaolo Merlini;Giovanni Palladini;Monique Minnema;Murielle Roussel;Arnaud Jaccard;Ute Hegenbart;Shaji Kumar;Maria T Cibeira;Joan Blade;Meletios A Dimopoulos | COVID-19;amyloidosis;hydroxychloroquine;remdesivir;tocilizumab | 2020-07-04 02:00:00+02:00 | 32480420 | FR;GR;GB;US;IT;NL;ES;DE | Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.;National Amyloidosis Centre, London, UK.;Medical Department V, Amyloidosis Centre, University Hospital Heidelberg, Heidelberg, Germany.;Amyloidosis Center, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA.;Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo", University of Pavia, Pavia, Italy.;Department of Hematology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.;Clinical Hematology, IUC Oncopole/CHU Toulouse, Toulouse, France.;CHU Poitiers, Poitiers, France.;Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.;Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain. | 1541 | ||
| Letter | en | Rethinking the post-COVID-19 pandemic hospital: more ICU beds or smart monitoring on the wards? | https://www.ncbi.nlm.nih.gov/pubmed/32613430 | 2020-07-05 02:00:00+02:00 | pubmed | Frederic Michard;Bernd Saugel;Benoit Vallet | 2020-07-01 02:00:00+02:00 | 32613430 | FR;CH;US;DE | MiCo (michardconsulting.com), Denens, Switzerland. frederic.michard@bluewin.ch.;Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Outcomes Research Consortium, Cleveland, OH, USA.;EA2694 University of Lille and School of Public Affairs at SciencesPo, Paris, France. | 1547 | ||||||||
| 10.1038/s41423-020-0493-9 | Journal Article | en | Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32612152 | 1672-7681,2042-0226 | 2020-07-05 02:00:00+02:00 | pubmed | Cellular & Molecular Immunology | Olivier Demaria;Julien Carvelli;Luciana Batista;Marie-Laure Thibult;Ariane Morel;Pascale André;Yannis Morel;Frederic Vély;Eric Vivier | 2020-07-01 02:00:00+02:00 | 32612152 | FR | Innate Pharma, 117 avenue de Luminy, Marseille, 13009, France. olivier.demaria@innate-pharma.fr.;Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Réanimation des Urgences, Marseille, 13005, France.;Innate Pharma, 117 avenue de Luminy, Marseille, 13009, France.;Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, 13009, France.;Assistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Immunology, Marseille Immunopole, Marseille, 13005, France. | 1550 | |||||
| Letter;Comment | en | In Reference to Anosmia and Ageusia: Common Findings in COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32603479 | 2020-07-05 02:00:00+02:00 | pubmed | Ageusia;Betacoronavirus;Coronavirus Infections;Humans;Olfaction Disorders;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jerome R Lechien;Carlos M Chiesa-Estomba;Nicolas Fakhry;Tareck Ayad;Sven Saussez | Coronavirus, covid-19, anosmia, olfaction, olfactory, gustatory, smell, taste, loss, SARS-CoV-2, ACE2, infection | 2020-06-30 02:00:00+02:00 | 32603479 | FR;BE;ES;CA | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Marseille, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Department of Otorhinolaryngology-Head & Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Otorhinolaryngology- Head & Neck Surgery, APHM, Aix Marseille University, La Conception University Hospital, Marseille, France.;Division of Otolaryngology-Head & Neck Surgery, Centre Hospitalier de l'Université de Montréal, Montreal, Québec, Canada. | 1553 | ||||||
| 10.1002/rth2.12376 | Journal Article | en | Venous thromboembolism in critically Ill patients with COVID-19: Results of a screening study for deep vein thrombosis. | https://www.ncbi.nlm.nih.gov/pubmed/32685893 | The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and coronavirus disease 2019 (COVID-19), has caused more than 3.9 million cases worldwide. Currently, there is great interest to assess venous thrombosis prevalence, diagnosis, prevention, and management in patients with COVID-19. | 2475-0379,2475-0379 | 2020-07-05 02:00:00+02:00 | pubmed | Research and Practice in Thrombosis and Haemostasis | Alban Longchamp;Justine Longchamp;Sara Manzocchi-Besson;Livia Whiting;Claude Haller;Séverin Jeanneret;Manoelle Godio;Juan Jose Garcia Martinez;Thierry Bonjour;Mary Caillat;Guillaume Maitre;Julian Matthias Thaler;Rémy Pantet;Viviane Donner;Alexis Dumoulin;Stéphane Emonet;Gilbert Greub;Raymond Friolet;Helia Robert-Ebadi;Marc Righini;Bienvenido Sanchez;Julie Delaloye | COVID‐19;SARS virus;pulmonary embolism;ultrasonography;venous thrombosis | 2020-06-30 02:00:00+02:00 | 32685893 | FR;CH | Department of Intensive Care Medicine Centre Hospitalier du Valais Romand de l'Hôpital du Valais (site de Sion) Sion Switzerland.;Department of Vascular Surgery Centre Hospitalier du Valais Romand de l'Hôpital du Valais (site de Sion) Sion Switzerland.;Department of Vascular Surgery Centre Hospitalier Universitaire Vaudois and University of Lausanne Lausanne Switzerland.;Division of Angiology and Haemostasis Faculty of Medicine Geneva University Hospitals Geneva Switzerland.;Department of Infectious Diseases Institut Central des Hôpitaux Hôpital du Valais Sion Switzerland.;Department of Infectious Diseases Institute of Microbiology Centre Hospitalier Universitaire Vaudois Lausanne Switzerland. | 1554 | |||
| 10.1016/j.jhepr.2020.100141 | Editorial | en | Quality and reproducibility during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32691022 | 2589-5559 | 2020-07-05 02:00:00+02:00 | pubmed | JHEP Reports | Thierry Gustot | 2020-07-03 02:00:00+02:00 | 32691022 | FR;BE;ES | Dept. Gastroenterology and Hepato-Pancreatology, C.U.B. Erasme Hospital, Brussels, Belgium.;Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.;Inserm Unité 1149, Centre de Recherche sur l'inflammation (CRI), Paris, France.;UMR S_1149, Université Paris Diderot, Paris, France.;The EASL-CLIF Consortium, European Foundation-CLIF, Barcelona, Spain. | 1560 | |||||
| 10.1016/s2352-4642(20)30175-9 | Journal Article | en | Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32622376 | Kawasaki disease is an acute febrile systemic childhood vasculitis, which is suspected to be triggered by respiratory viral infections. We aimed to examine whether the ongoing COVID-19 epidemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with an increase in the incidence of Kawasaki disease. | 2352-4642 | 2020-07-05 02:00:00+02:00 | pubmed | The Lancet Child & Adolescent Health | Naim Ouldali;Marie Pouletty;Patricia Mariani;Constance Beyler;Audrey Blachier;Stephane Bonacorsi;Kostas Danis;Maryline Chomton;Laure Maurice;Fleur Le Bourgeois;Marion Caseris;Jean Gaschignard;Julie Poline;Robert Cohen;Luigi Titomanlio;Albert Faye;Isabelle Melki;Ulrich Meinzer | 2020-07-02 02:00:00+02:00 | 32622376 | FR | Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic Diseases in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Université de Paris, INSERM UMR 1123, ECEVE, Paris, France, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France, Université de Paris, UFR de Médecine Paris Nord, Paris, France.;Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic Diseases in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Université de Paris, UFR de Médecine Paris Nord, Paris, France.;Université de Paris, UFR de Médecine Paris Nord, Paris, France, Department of Microbiology, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Pediatric Cardiology, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Medical Information, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Université de Paris, UFR de Médecine Paris Nord, Paris, France, Department of Microbiology, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Université de Paris, IAME, INSERM UMR1137, Paris, France.;Santé Publique France, Saint Maurice, France.;Paediatric Intensive Care Unit, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic Diseases in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Department of Microbiology, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic Diseases in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Université de Paris, UFR de Médecine Paris Nord, Paris, France, Université de Paris, IAME, INSERM UMR1137, Paris, France.;Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic Diseases in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Center for Research on Inflammation, INSERM, UMR1149, Paris, France.;Université de Paris, UFR de Médecine Paris Nord, Paris, France.;Université de Paris, UFR de Médecine Paris Nord, Paris, France, Department of Paediatric Emergency Care, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic Diseases in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Université de Paris, INSERM UMR 1123, ECEVE, Paris, France, Université de Paris, UFR de Médecine Paris Nord, Paris, France.;Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic Diseases in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris, France, Paediatric Haematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, National Referee Centre for Rheumatic, Autoimmune and Systemic Diseases in Children, Paris, France.;Department of General Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases, National Referee Centre for Rheumatic, Autoimmune and Systemic Diseases in Children, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, Université de Paris, UFR de Médecine Paris Nord, Paris, France, Center for Research on Inflammation, INSERM, UMR1149, Paris, France, Biology and Genetics of Bacterial Cell Wall Unit, Pasteur Institute, Paris, France. Electronic address: ulrich.meinzer@aphp.fr. | 1562 | ||||
| Letter | en | Potential of regulatory T cell-based therapies in the management of severe COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32616599 | 2020-07-05 02:00:00+02:00 | pubmed | Emmanuel Stephen-Victor;Mrinmoy Das;Anupama Karnam;Bruno Pitard;Jean-François Gautier;Jagadeesh Bayry | 2020-07-02 02:00:00+02:00 | 32616599 | FR;US | Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.;Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France.;Université de Nantes, CNRS ERL6001, Inserm 1232, CRCINA, Nantes, France.;Service de Diabétologie, Endocrinologie, Nutrition, Centre Universitaire du Diabète et de ses Complications, Hôpital Lariboisière, Université Paris-Diderot Paris-7, Paris, France. | 1563 | ||||||||
| 10.1136/annrheumdis-2020-218069 | Journal Article | en | Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß et al. | https://www.ncbi.nlm.nih.gov/pubmed/32616603 | 0003-4967,1468-2060 | 2020-07-05 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Alexis Mathian;Zahir Amoura | hydroxychloroquine;lupus erythematosus, systemic;therapeutics | 2020-07-02 02:00:00+02:00 | 32616603 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@psl.aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 1564 | ||||
| 10.1016/j.mmcr.2020.06.006 | Case Reports | en | Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU - A case report. | https://www.ncbi.nlm.nih.gov/pubmed/32837880 | Although invasive pulmonary aspergillosis (IPA) is typically described in immunocompromised host, patient with severe influenzae can develop IPA. Similarly, patients with severe COVID-19 complicated with IPA are increasingly reported. Here, we describe a case of invasive aspergillosis with triazole-resistant A. fumigatus (TR34/L98H mutation) in a 56-year-old patient with COVID-19 in intensive care unit. This report highlights the need to define the available tools for diagnosis of invasive aspergillosis in severe COVID-19 patients. | 2211-7539 | 2020-07-05 02:00:00+02:00 | pubmed | Medical Mycology Case Reports | Théo Ghelfenstein-Ferreira;Anastasia Saade;Alexandre Alanio;Stéphane Bretagne;Raffael Araujo de Castro;Samia Hamane;Elie Azoulay;Swann Bredin;Sarah Dellière | Aspergillosis;COVID-19;Coronavirus;ICU;SARS-CoV2;Triazole-resistance | 2020-07-02 02:00:00+02:00 | 32837880 | FR | Laboratoire de Parasitologie - Mycologie, Hôpital Saint-Louis (AP-HP), Université de Paris, France.;Médecine Intensive et Réanimation, Hôpital Saint-Louis (AP-HP), Université de Paris, France.;Unité de Mycologie Moléculaire, Institut Pasteur, CNRS URA 3012, Centre National de Référence des Mycoses Invasives et des Antifongiques, URA, 3012, Paris, France. | 1566 | |||
| 10.1097/prs.0000000000007266 | Journal Article | en | Reconstructive Microsurgery Emergency in a Patient with Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32639424 | 0032-1052 | 2020-07-05 02:00:00+02:00 | pubmed | Plastic & Reconstructive Surgery | Martin Lhuaire;Ignacio Garrido;Victoire Cladière-Nassif;Valérie Dumaine;Laurent Lantieri | 2020-07-02 02:00:00+02:00 | 32639424 | FR | Department of Plastic, Reconstructive and Aesthetic Surgery, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France.;Department of Anatomy, UFR Biomédicale des Saints-Pères, Université de Paris, Paris, France.;Department of Orthopedics, Oncologic and Traumatologic Surgery, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Université de Paris, Paris, France. | 1568 | |||||
| 10.1111/fcp.12588 | Editorial | en | Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. | https://www.ncbi.nlm.nih.gov/pubmed/32615022 | 0767-3981,1472-8206 | 2020-07-05 02:00:00+02:00 | pubmed | Fundamental & Clinical Pharmacology | Nicolas Venisse | 2020-07-02 02:00:00+02:00 | 32615022 | FR | INSERM CIC1402, University Hospital of Poitiers, University of Poitiers, Poitiers Cedex, 86021, France.;Biology-Pharmacy-Public Health Department, University Hospital of Poitiers, 2 Rue de la Milétrie, Poitiers Cedex, 86021, France. | 1570 | |||||
| 10.1183/13993003.01727-2020 | Journal Article | en | Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members# of ESCMID Study Group for Mycobacterial Infections (ESGMYC). | https://www.ncbi.nlm.nih.gov/pubmed/32586885 | Major epidemics including some that qualify as pandemics, such as Severe Acute Respiratory Syndrome (SARS), Middle-Eastern Respiratory Syndrome (MERS), Human Immunodeficiency Virus, pandemic H1N1/09 and most recently COVID-19 affect the lung. Tuberculosis (TB) remains the top infectious disease killer but apart from the TB-HIV syndemic, little is known regarding the interaction of viral epidemics and pandemics with TB. The aim of this consensus-based document is to describe the effects of the viral infections resulting in epidemics and pandemics that affect the lung (MERS, SARS, HIV, influenza A (H1N1)pdm/09 and COVID-19) and their interactions with TB. A search of the scientific literature was performed. A writing committee of international experts including the European Centre for Disease Prevention and Control Public Health Emergency (ECDC PHE) team, the World Association for Infectious Diseases and Immunological Disorders (WAidid), the Global Tuberculosis Network (GTN) and members of ESCMID Study Group for Mycobacterial Infections (ESGMYC) was established. Consensus was achieved after multiple rounds of revisions between the writing committee and a larger expert group. A Delphi process involving the core group of authors, excluding the ECDC PHE team identified the areas requiring review/consensus, followed by a second round to refine the definitive consensus elements. The epidemiology, immunology of these viral infections and their interactions with TB are discussed with implications on diagnosis, treatment and prevention of airborne infections (infection control, viral containment and workplace safety). This consensus document represents a rapid and comprehensive summary on what is known on the topic. | 0903-1936,1399-3003 | 2020-07-05 02:00:00+02:00 | pubmed | European Respiratory Journal | Catherine Wei Min Ong;Giovanni Battista Migliori;Mario Raviglione;Gavin MacGregor-Skinner;Giovanni Sotgiu;Jan-Willem Alffenaar;Simon Tiberi;Cornelia Adlhoch;Tonino Alonzi;Sophia Archuleta;Sergio Brusin;Emmanuelle Cambau;Maria Rosaria Capobianchi;Concetta Castilletti;Rosella Centis;Daniela M Cirillo;Lia D'Ambrosio;Giovanni Delogu;Susanna M R Esposito;Jose Figueroa;Jon S Friedland;Benjamin Ho Choon Heng;Giuseppe Ippolito;Mateja Jankovic;Hannah Yejin Kim;Senia Rosales Klintz;Csaba Ködmön;Eleonora Lalle;Yee Sin Leo;Chi-Chiu Leung;Anne-Grete Märtson;Mario Melazzini;Saeid Najafi Fard;Pasi Penttinen;Linda Petrone;Elisa Petruccioli;Emanuele Pontali;Laura Saderi;Miguel Santin;Antonio Spanevello;Reinout van Crevel;Marieke J van der Werf;Dina Visca;Miguel Viveiros;Jean Pierre Zellweger;Alimuddin Zumla;Delia Goletti | 2020-07-02 02:00:00+02:00 | 32586885 | SE;SG;FR;CN;PT;CH;US;GB;HR;HK;IT;AU;NL;ES | Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.;Institute for Health Innovation & Technology (iHealthtech), National University of Singapore, Singapore.;Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.;Centre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy.;Global Studies Institute, University of Geneva, Geneva, Switzerland.;Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.;Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.;University of Sydney, Sydney Pharmacy School, Sydney, New South Wales, Australia.;Westmead Hospital, Sydney, Australia.;Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.;Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.;Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.;Public Health Emergency Team, European Centre for Disease Prevention and Control, Stockholm, Sweden.;Translational Research Unit, Epidemiology and Preclinical Research Department, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.;APHP-Lariboisiere, Bacteriologie, Laboratory Associated to the National Reference Center for Mycobacteria, IAME UMR1137, INSERM, University of Paris, Paris, France.;Laboratory of Virology, Epidemiology and Preclinical Research Department, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.;Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.;Public Health Consulting Group, Lugano, Switzerland.;Università Cattolica Sacro Cuore, Roma, Italy.;Mater Olbia Hospital, Olbia, Italy.;Pediatric Clinic, Pietro Barilla Children's Hospital, University of Parma, Parma, Italy.;National Health Service (NHS), London, UK.;St George's, University of London, London, UK.;Tuberculosis Control Unit, Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.;Scientific Direction, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.;University of Zagreb, School of Medicine, Clinic for Respiratory Diseases, University Hospital Center Zagreb, Zagreb, Croatia.;National Centre for Infectious Diseases, Singapore.;Hong Kong Tuberculosis, Chest and Heart Diseases Association, Wanchai, Hong Kong, China.;University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands.;Scientific Direction, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.;Department of Infectious Diseases, Galliera Hospital, Genova, Italy.;Department of Infectious Diseases, Bellvitge University Hospital-Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.;Department of Clinical Science, University of Barcelona, L'Hospitalet de Llobregat, Spain.;Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy.;Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, Varese-Como, Italy.;Radboudumc Center for Infectious Diseases, Radboud Institute for Health Sciences, Radboudumc, Nijmegen, the Netherlands.;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.;Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, NOVA University of Lisbon, Lisbon, Portugal.;TB Competence Centre, Swiss Lung Association, Berne, Switzerland.;Department of Infection, Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK. | 1571 | ||||
| 10.1021/acs.jpclett.0c01097 | Journal Article | en | Role of RNA Guanine Quadruplexes in Favoring the Dimerization of SARS Unique Domain in Coronaviruses. | https://www.ncbi.nlm.nih.gov/pubmed/32536162 | Coronaviruses may produce severe acute respiratory syndrome (SARS). As a matter of fact, a new SARS-type virus, SARS-CoV-2, is responsible for the global pandemic in 2020 with unprecedented sanitary and economic consequences for most countries. In the present contribution we study, by all-atom equilibrium and enhanced sampling molecular dynamics simulations, the interaction between the SARS Unique Domain and RNA guanine quadruplexes, a process involved in eluding the defensive response of the host thus favoring viral infection of human cells. Our results evidence two stable binding modes involving an interaction site spanning either the protein dimer interface or only one monomer. The free energy profile unequivocally points to the dimer mode as the thermodynamically favored one. The effect of these binding modes in stabilizing the protein dimer was also assessed, being related to its biological role in assisting the SARS viruses to bypass the host protective response. This work also constitutes a first step in the possible rational design of efficient therapeutic agents aiming at perturbing the interaction between SARS Unique Domain and guanine quadruplexes, hence enhancing the host defenses against the virus. | 1948-7185,1948-7185 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus__chemistry;Coronavirus Infections__virology;Dimerization;G-Quadruplexes__drug effects;Humans;Models, Molecular;Molecular Dynamics Simulation;Pandemics;Pneumonia, Viral__virology;Protein Binding;RNA, Viral__chemistry;Spike Glycoprotein, Coronavirus__chemistry;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Journal of Physical Chemistry Letters | Cécilia Hognon;Tom Miclot;Cristina Garcı A-Iriepa;Antonio Francés-Monerris;Stephanie Grandemange;Alessio Terenzi;Marco Marazzi;Giampaolo Barone;Antonio Monari | 2020-07-02 02:00:00+02:00 | 32536162 | FR;IT;ES | Université de Lorraine and CNRS, LPCT UMR 7019, F-54000 Nancy, France.;Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, Università degli Studi di Palermo, Viale delle Scienze, 90128 Palermo, Italy.;Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering, Universidad de Alcalá, Ctra. Madrid-Barcelona, Km 33,600, 28871 Alcalá de Henares, Madrid, Spain.;Chemical Research Institute "Andrés M. del Río" (IQAR), Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain.;Departament de Química Física, Universitat de València, 46100 Burjassot, Spain.;Université de Lorraine and CNRS, CRAN UMR 7039, F-54000 Nancy, France. | 1572 | |||
| 10.1016/j.mehy.2020.110063 | Published Erratum | en | Corrigendum to "COVID-19-related Complications and Decompression Illness Share Main Features. Could the SARS-CoV2-related complications rely on blood foaming?" [Med Hypothesis 144 (2020) 109918]. | https://www.ncbi.nlm.nih.gov/pubmed/32688183 | 0306-9877 | 2020-07-05 02:00:00+02:00 | pubmed | Medical Hypotheses | Pierre A Denis | 2020-07-03 02:00:00+02:00 | 32688183 | FR | Occupational Medicine, Mutualité Sociale Agricole (M.S.A.), 12 rue de Paimpont 22025 Saint-Brieuc Cedex, France. | 1579 | |||||
| 10.1136/gutjnl-2020-321829 | Journal Article;Practice Guideline | en | Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32620549 | The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of Clostridioides difficile infection. In the time of the pandemic, FMT centres and stool banks are required to adopt a workflow that continues to ensure reliable patient access to FMT while maintaining safety and quality of procedures. In this position paper, based on the best available evidence, worldwide FMT experts provide guidance on issues relating to the impact of COVID-19 on FMT, including patient selection, donor recruitment and selection, stool manufacturing, FMT procedures, patient follow-up and research activities. | 0017-5749,1468-3288 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus;Change Management;Clostridium Infections__microbiology;Coronavirus Infections__epidemiology;Donor Selection;Fecal Microbiota Transplantation__methods;Gastroenterology__organization & administration;Gastrointestinal Microbiome;Humans;Infection Control__methods;Pandemics__prevention & control;Patient Selection;Pneumonia, Viral__epidemiology;Risk Adjustment__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gut | Gianluca Ianiro;Benjamin H Mullish;Colleen R Kelly;Zain Kassam;Ed J Kuijper;Siew C Ng;Tariq H Iqbal;Jessica R Allegretti;Stefano Bibbò;Harry Sokol;Faming Zhang;Monika Fischer;Samuel Paul Costello;Josbert J Keller;Luca Masucci;Joffrey van Prehn;Gianluca Quaranta;Mohammed Nabil Quraishi;Jonathan Segal;Dina Kao;Reetta Satokari;Maurizio Sanguinetti;Herbert Tilg;Antonio Gasbarrini;Giovanni Cammarota | colonic microflora;diarrhoeal disease | 2020-07-03 02:00:00+02:00 | 32620549 | FR;CA;FI;CN;GB;US;HK;IT;AU;NL;AT | Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.;Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.;Division of Gastroenterology, Alpert Medical School of Brown University, Providence, Rhode Island, USA.;Finch Therapeutics Group, Somerville, Massachusetts, USA.;Center for Microbiota Analysis and Therapy, Department of Medical Microbiology, Leiden University Medical Centre, Leiden, The Netherlands.;Netherlands Donor Feces Bank, Leiden University Medical Center, Leiden, The Netherlands.;Center for Gut Microbiota Research, Institute of Digestive Disease, Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, Hong Kong.;Microbiome Treatment Centre, University of Birmingham, Birmingham, UK.;Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.;Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.;Service de Gastroenterologie, French Group of Fecal Microbiota Transplantation, Hôpital Saint Antoine, Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Paris, France.;INRA, UMR1319 Micalis, AgroParisTech, Jouy-en-Josas, France.;Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.;Department of Medicine, Indiana University, Indianapolis, Indiana, USA.;Department of Gastroenterology, The Queen Elizabeth Hospital, University of Adelaide, Woodville, South Australia, Australia.;Department of Gastroenterology, Haaglanden Medical Center, The Hague, The Netherlands.;Institute of Microbiology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.;Department of Gastroenterology, St Mark's Hospital, Harrow, UK.;Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.;Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.;Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Innsbruck Medical University, Innsbruck, Austria.;Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy giovanni.cammarota@unicatt.it. | 1588 | ||
| 10.1089/pop.2020.0141 | Journal Article | en | Facing the COVID-19 Pandemic in France: From Managerialism to Business Logistics. | https://www.ncbi.nlm.nih.gov/pubmed/32603240 | 1942-7891,1942-7905 | 2020-07-05 02:00:00+02:00 | pubmed | Population Health Management | Gilles Paché | COVID-19 pandemic;France;health system;logistics;population health | 2020-06-30 02:00:00+02:00 | 32603240 | FR | CRET-LOG, Aix-Marseille University, Aix-en-Provence, France. | 1591 | ||||
| 10.1097/mat.0000000000001193 | Journal Article | en | Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: A Consensus Document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers. | https://www.ncbi.nlm.nih.gov/pubmed/32604322 | Disclaimer: The Extracorporeal Life Support Organization (ELSO) Coronavirus Disease 2019 (COVID-19) Guidelines have been developed to assist existing extracorporeal membrane oxygenation (ECMO) centers to prepare and plan provision of ECMO during the ongoing pandemic. The recommendations have been put together by a team of interdisciplinary ECMO providers from around the world. Recommendations are based on available evidence, existing best practice guidelines, ethical principles, and expert opinion. This is a living document and will be regularly updated when new information becomes available. ELSO is not liable for the accuracy or completeness of the information in this document. These guidelines are not meant to replace sound clinical judgment or specialist consultation but rather to strengthen provision and clinical management of ECMO specifically, in the context of the COVID-19 pandemic. | 1058-2916 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus;Consensus;Coronavirus Infections__therapy;Extracorporeal Membrane Oxygenation;Humans;Pandemics;Pneumonia, Viral__therapy;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | ASAIO Journal | Kiran Shekar;Jenelle Badulak;Giles Peek;Udo Boeken;Heidi J Dalton;Lovkesh Arora;Bishoy Zakhary;Kollengode Ramanathan;Joanne Starr;Bindu Akkanti;M Velia Antonini;Mark T Ogino;Lakshmi Raman;Nicholas Barret;Daniel Brodie;Alain Combes;Roberto Lorusso;Graeme MacLaren;Thomas Müller;Matthew Paden;Vincent Pellegrino | 2020-07-01 02:00:00+02:00 | 32604322 | FR;SG;GE;GB;US;IT;AU;NL;DE | From Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia.;University of Washington, Seattle, Washington.;University of Florida, Shands Hospital for Children, Gainesville, Florida.;Department of Cardiac Surgery, University Hospital, Duesseldorf, Germany.;INOVA Fairfax Medical Center, Falls Church, Virginia.;University of Iowa Hospital & Clinics, Iowa City, Iowa.;Oregon Health and Science University, Portland, Oregon.;National University Hospital, Singapore.;CHOC Children's Hospital, Orange, California.;UT McGovern Medical School, Houston, Texas.;1st Intensive Care Unit, University Hospital of Parma, Parma, Italy.;Department of Paediatrics, Division of Neonatology, Nemours Alfred I duPont Hospital for Children, Wilmington, Delaware.;Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.;University of Texas Southwestern Medical Center, Dallas, Texas.;St. Thomas Hospital, London, United Kingdom.;Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York.;Assitance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.;Maastricht University Medical Centre, Maastricht, The Netherlands.;University Hospital Regensburg, Regensburg, Germany.;Department of Pediatrics, Emory University, Atlanta, Georgia.;The Alfred, Melbourne, Victoria, Australia. | 1593 | |||
| 10.1016/s1293-8505(20)30149-4 | Journal Article | fr | [Covid-19: health care workers between heroism and ostracism]. | https://www.ncbi.nlm.nih.gov/pubmed/32600593 | Originating in China in November 2019, the wave of infection caused by the new coronavirus Sars-CoV-2 is sweeping across the planet through human contact and fast, global, mass travel. Health professionals on every level are fighting relentlessly against Covid-19, this deadly, invisible yet real enemy. The public, increasingly worried, expect them to protect it against the disease and death. Perceived by most people as a line of defence against the pandemic, health professionals are supported and treated as heroes. Some people howeverfear tthat they may be possible contamination agents. | 1293-8505 | 2020-07-05 02:00:00+02:00 | pubmed | Attitude to Health;China__epidemiology;Coronavirus Infections__epidemiology;Courage;Health Personnel;Humans;Infectious Disease Transmission, Professional-to-Patient;Pandemics;Pneumonia, Viral__epidemiology;COVID-19 | La Revue de l'Infirmière | Jean-Pierre Bouchard | Covid-19;Sars-CoV-2;contagion;coronavirus;infectious disease;maladie infectieuse;pandemic;pandémie | 2020-07-01 02:00:00+02:00 | 32600593 | FR | Institut psycho-judiciaire et de psychopathologie (IPJP), Institute of Forensic Psychology and Psychopathology, centre hospitalier de Cadillac, 10, avenue Joseph-Caussil, 33410 Cadillac, France, Unité pour malades difficiles, pôle de psychiatrie médico-légale, centre hospitalier de Cadillac, 10, avenue Joseph-Caussil, 33410 Cadillac, France. Electronic address: jean_pierre_bouchard@yahoo.fr. | 1595 | ||
| 10.1136/rmdopen-2020-001333 | Journal Article;Review | en | Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32611651 | A few weeks after the peak of the global 2019 novel coronavirus disease pandemic, cases of shock, multisystem inflammation and severe myocarditis have occurred in children and adolescents, generating some concerns and above all many questions. An almost immediate association raised with shock syndrome related to Kawasaki disease (KD). However, in light of bo/th experience and literature have taught us about severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, and what already known on the epidemiology of KD, we suggest here the hypothesis of a new 'post-viral' systemic inflammatory disease related to excessive adaptive immune response rather than a form of KD caused by SARS-COV-2. We discuss analogies and differences between the two forms. | 2056-5933 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Child;Coronavirus Infections__diagnosis;Diagnosis, Differential;Disease Management;Humans;Mucocutaneous Lymph Node Syndrome__diagnosis;Pandemics;Pneumonia, Viral__diagnosis;Systemic Vasculitis__immunology;Terminology as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | RMD Open | Isabelle Koné-Paut;Rolando Cimaz | Arthritis;Behcet Syndrome;Juvenile;Systemic vasculitis | 2020-07-03 02:00:00+02:00 | 32611651 | FR;IT | Service De Rhumatologie Pédiatrique, Centre De Référence Des Maladies Auto-Inflammatoires et de l'amylose inflammatoire, Hospital Bicetre, APHP and University of Paris Sud Saclay, Le Kremlin-Bicetre, France isabelle.kone-paut@aphp.fr.;Department of Clinical Sciences and Community Health, University of Milan, and ASST G. Pini, Milan, Italy. | 1596 | ||
| Editorial;Comment | en | Uncertainty upon uncertainty: supportive Care for Cancer and COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32613372 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus Infections;Humans;Neoplasms;Pandemics;Pneumonia, Viral;Uncertainty;COVID-19;severe acute respiratory syndrome coronavirus 2 | Annie M Young;Fredrick D Ashbury;Lidia Schapira;Florian Scotté;Carla I Ripamonti;Ian N Olver | 2020-07-03 02:00:00+02:00 | 32613372 | FR;CA;GB;US;IT;AU | Warwick Medical School, University of Warwick, Coventry, England, UK. annie.young@warwick.ac.uk.;VieCure, Denver, CO, USA.;Department of Oncology, University of Calgary, Calgary, Canada.;Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.;Stanford University School of Medicine, California, USA.;Interdisciplinary Cancer Course Department, Gustave Roussy Cancer, Center, Villejuif, France.;Department of Oncology and Haematology, Fondazione IRCCS, Istituto, Nazionale dei Tumori, Milan, Italy.;Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia. | 1598 | |||||||
| Letter | en | Excess out-of-hospital deaths during the COVID-19 outbreak: evidence of pulmonary embolism as a main determinant. | https://www.ncbi.nlm.nih.gov/pubmed/32463538 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Disease Outbreaks;Global Health;Humans;Pandemics;Pneumonia, Viral__complications;Pulmonary Embolism__etiology;Survival Rate__trends;COVID-19;severe acute respiratory syndrome coronavirus 2 | Joseph Benzakoun;Ghazi Hmeydia;Tania Delabarde;Lilia Hamza;Jean-François Meder;Bertrand Ludes;Alexandre Mebazaa | 2020-06-29 02:00:00+02:00 | 32463538 | FR | Service d'Imagerie Morphologique et Fonctionnelle, GHU Paris, Centre Hospitalier Sainte-Anne, Paris, France.;INSERM UMR 1266, Institut de Psychiatrie et Neurosciences de Paris, Paris, France.;Université de Paris, Paris, France.;Université de Paris, BABEL, CNRS, Paris, France.;Institut Médico-Légal de Paris, Paris, France.;Pôle Universitaire d'Imagerie Post-Mortem, Université Paris Descartes, Paris, France.;Department of Anesthesiology and Critical Care Medicine, AP-HP, Saint Louis Lariboisière University Hospitals, FHU PROMICE, Paris, France.;INSERM UMR-S 942, Paris, France. | 1600 | |||||||
| 10.1016/j.jcv.2020.104520 | Evaluation Study;Journal Article;Research Support, Non-U.S. Gov't | en | Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection. | https://www.ncbi.nlm.nih.gov/pubmed/32652476 | The use of efficient, reliable and sensitive PCR assays is a cornerstone in the race to contain the SARS-CoV-2 pandemic. In this work we performed an independent evaluation of the RealStar® SARS-CoV-2 RT-PCR Kit Researh Use Only (Altona) for SARS-CoV-2 detection. | 1386-6532 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Humans;Limit of Detection;Molecular Diagnostic Techniques__methods;Pandemics;Pneumonia, Viral__diagnosis;Reverse Transcriptase Polymerase Chain Reaction__methods;Sensitivity and Specificity;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Clinical Virology | Benoit Visseaux;Quentin Le Hingrat;Gilles Collin;Valentine Ferré;Alexandre Storto;Houria Ichou;Donia Bouzid;Nora Poey;Etienne de Montmollin;Diane Descamps;Nadhira Houhou-Fidouh | COVID-19;RT-PCR;SARS-CoV-2;Sensitivity | 2020-06-29 02:00:00+02:00 | 32652476 | FR | Université de Paris, Assistance Publique - Hôpitaux de Paris, Service de virologie, Hôpital Bichat, Paris, France, UMR 1137-IAME, DeSCID: Decision SCiences in Infectious Diseases Control and Care, INSERM, Université de Paris, Paris, France. Electronic address: benoit.visseaux@aphp.fr.;Université de Paris, Assistance Publique - Hôpitaux de Paris, Service de virologie, Hôpital Bichat, Paris, France, UMR 1137-IAME, DeSCID: Decision SCiences in Infectious Diseases Control and Care, INSERM, Université de Paris, Paris, France.;Université de Paris, Assistance Publique - Hôpitaux de Paris, Service de virologie, Hôpital Bichat, Paris, France.;UMR 1137-IAME, DeSCID: Decision SCiences in Infectious Diseases Control and Care, INSERM, Université de Paris, Paris, France, Université de Paris, Assistance Publique - Hôpitaux de Paris, Service d'Accueil des Urgences, Hôpital Bichat, Paris, France.;Université de Paris, Assistance Publique - Hôpitaux de Paris, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat, Paris, France.;Université de Paris, Assistance Publique - Hôpitaux de Paris, Réanimation Médicale et Infectieuses, Hôpital Bichat, Paris, France. | 1601 | ||
| Letter | en | First case of persistent pancytopenia associated with SARS-CoV-2 bone marrow infiltration in an immunocompromised patient. | https://www.ncbi.nlm.nih.gov/pubmed/32615155 | 2020-07-05 02:00:00+02:00 | pubmed | N Issa;F Lacassin;F Camou | 2020-06-29 02:00:00+02:00 | 32615155 | FR | Medical Intensive Care and Infectious Diseases Unit, Saint-Andre Hospital, CHU Bordeaux, Bordeaux, France. Electronic address: nahema.issa@chu-bordeaux.fr.;Infectious Disease Department, Mont de Marsan Hospital, Mont de Marsan, France.;Medical Intensive Care and Infectious Diseases Unit, Saint-Andre Hospital, CHU Bordeaux, Bordeaux, France. | 1606 | ||||||||
| 10.1016/j.ijid.2020.06.093 | Case Reports | en | Case report study of the first five COVID-19 patients treated with remdesivir in France. | https://www.ncbi.nlm.nih.gov/pubmed/32619764 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the virus responsible for the coronavirus disease 2019 (COVID-19) outbreak worldwide. Data on treatment are scare and parallels have been made between SARS-CoV-2 and other coronaviruses. Remdesivir is a broad-spectrum antiviral with efficient in vitro activity against SARS-CoV-2. Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial. The aim of this study was to describe the clinical outcomes and virological monitoring of the first five COVID-19 patients admitted to the intensive care unit of Bichat-Claude Bernard University Hospital, Paris, France, for severe pneumonia related to SARS-CoV-2 and treated with remdesivir. Quantitative reverse transcription PCR was used to monitor SARS-CoV-2 in blood plasma and the lower and upper respiratory tract. Among the five patients treated, two needed mechanical ventilation and one needed high-flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load in the upper respiratory tract was observed in most cases, but two patients died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted before the initialy planned duration in four patients, two because of alanine aminotransferase elevations (3 to 5 normal range) and two because of renal failure requiring renal replacement. This case series of five COVID-19 patients requiring intensive care unit treatment for respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients. | 1201-9712 | 2020-07-05 02:00:00+02:00 | pubmed | International Journal of Infectious Diseases | Marie Dubert;Benoit Visseaux;Valentina Isernia;Lila Bouadma;Laurène Deconinck;Juliette Patrier;Paul-Henri Wicky;Diane Le Pluart;Laura Kramer;Christophe Rioux;Quentin Le Hingrat;Nadhira Houhou-Fidouh;Yazdan Yazdanpanah;Jade Ghosn;Francois-Xavier Lescure | Antiviral therapy;Case reports;Remdesivir;SARS-CoV-2 viral load;Viral pneumonia | 2020-06-30 02:00:00+02:00 | 32619764 | FR | AP-HP. Nord, Infectious and Tropical Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France. Electronic address: marie.dubert@aphp.fr.;AP-HP. Nord, Virology Department, Bichat-Claude Bernard University Hospital, Paris, France, University of Paris, French Institute for Health and Medical Research (INSERM), IAME, U1137, Team DesCID, Paris, France.;AP-HP. Nord, Infectious and Tropical Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France.;University of Paris, French Institute for Health and Medical Research (INSERM), IAME, U1137, Team DesCID, Paris, France, AP-HP. Nord, Medical and Infectious Diseases Intensive Care Unit, Bichat-Claude Bernard University Hospital, Paris, France.;AP-HP. Nord, Pharmacy Unit, Bichat-Claude Bernard University Hospital, Paris, France.;AP-HP. Nord, Virology Department, Bichat-Claude Bernard University Hospital, Paris, France.;AP-HP. Nord, Infectious and Tropical Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France, University of Paris, French Institute for Health and Medical Research (INSERM), IAME, U1137, Team DesCID, Paris, France. | 1612 | |||
| World Health Organization | 10.2807/1560-7917.es.2020.25.26.2001214 | Journal Article | en | Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32643601 | A remarkable excess mortality has coincided with the COVID-19 pandemic in Europe. We present preliminary pooled estimates of all-cause mortality for 24 European countries/federal states participating in the European monitoring of excess mortality for public health action (EuroMOMO) network, for the period March-April 2020. Excess mortality particularly affected ≥ 65 year olds (91% of all excess deaths), but also 45-64 (8%) and 15-44 year olds (1%). No excess mortality was observed in 0-14 year olds. | 1560-7917 | 2020-07-12 02:00:00+02:00 | pubmed | Adolescent;Adult;Age Distribution;Aged;Aged, 80 and over;Betacoronavirus;Cause of Death__trends;Child;Child, Preschool;Coronavirus__isolation & purification;Coronavirus Infections__diagnosis;Disease Outbreaks;Europe__epidemiology;Female;Humans;Infant;Infant, Newborn;Influenza, Human__diagnosis;Male;Middle Aged;Mortality__trends;Pandemics;Pneumonia, Viral__diagnosis;Population Surveillance;Preliminary Data;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Lasse S Vestergaard;Jens Nielsen;Lukas Richter;Daniela Schmid;Natalia Bustos;Toon Braeye;Gleb Denissov;Tatjana Veideman;Oskari Luomala;Teemu Möttönen;Anne Fouillet;Céline Caserio-Schönemann;Matthias An der Heiden;Helmut Uphoff;Theodore Lytras;Kassiani Gkolfinopoulou;Anna Paldy;Lisa Domegan;Joan O'Donnell;Francesca De' Donato;Fiammetta Noccioli;Patrick Hoffmann;Telma Velez;Kathleen England;Liselotte van Asten;Richard A White;Ragnhild Tønnessen;Susana P da Silva;Ana P Rodrigues;Amparo Larrauri;Concepción Delgado-Sanz;Ahmed Farah;Ilias Galanis;Christoph Junker;Damir Perisa;Mary Sinnathamby;Nick Andrews;Mark O'Doherty;Diogo Fp Marquess;Sharon Kennedy;Sonja J Olsen;Richard Pebody;Tyra G Krause;Kåre Mølbak | All-cause mortality;Covid-19 pandemic;EuroMOMO;Europe | 2020-07-10 02:00:00+02:00 | 32643601 | UNK;PT;EE;NL;MT;DK;BE;FR;GR;CH;GB;IT;HU;LU;DE;AT;SE;IE;NO;FI;ES | [{"country": "International", "agency": "World Health Organization", "grantid": "001"}] | Statens Serum Institut, Copenhagen, Denmark.;Austrian Agency for Health and Food Safety, Vienna, Austria.;Sciensano, Brussels, Belgium.;National Institute for Health Development, Tallinn, Estonia.;Finnish National Institute for Health and Welfare, Helsinki, Finland.;French Public Health Agency (Santé Publique France), Saint-Maurice, France.;Robert Koch Institute, Berlin, Germany.;Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen, Dillenburg, Germany.;National Public Health Organization, Athens, Greece.;National Public Health Institute, Budapest, Hungary.;European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.;Health Service Executive - Health Protection Surveillance Centre, Dublin, Ireland.;Dipartimento Epidemiologia del S.S.R., Lazio - ASL Roma 1, Rome, Italy.;Health Directorate Luxembourg - Division de l'inspection sanitaire, Luxembourg.;Directorate for Health Information and Research, Ministry for Health, Malta.;National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.;Norwegian Institute of Public Health, Oslo, Norway.;Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.;National Centre of Epidemiology, CIBER Epidemiología y Salud Pública (CIBERESP), Carlos III Health Institute, Madrid, Spain.;Public Health Agency of Sweden, Stockholm, Sweden.;Federal Statistical Office, Neuchâtel, Switzerland.;Federal Office of Public Health, Bern, Switzerland.;Public Health England, Colindale, United Kingdom.;Public Health Agency, Northern Ireland, United Kingdom.;Public Health Scotland, Glasgow, United Kingdom.;World Health Organization, Regional Office for Europe, Copenhagen, Denmark.;The members of the ECDC Public Health Emergency Team for COVID-19 are listed below.;Department of Veterinary and Animal Science, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark. | 1619 |
| 10.2807/1560-7917.es.2020.25.26.2001200 | Journal Article;Research Support, Non-U.S. Gov't | en | Introductions and early spread of SARS-CoV-2 in France, 24 January to 23 March 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32643599 | Following SARS-CoV-2 emergence in China, a specific surveillance was implemented in France. Phylogenetic analysis of sequences retrieved through this surveillance suggests that detected initial introductions, involving non-clade G viruses, did not seed local transmission. Nevertheless, identification of clade G variants subsequently circulating in the country, with the earliest from a patient who neither travelled to risk areas nor had contact with travellers, suggests that SARS-CoV-2 might have been present before the first recorded local cases. | 1560-7917 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus__classification;Coronavirus Infections__diagnosis;Disease Outbreaks__prevention & control;France__epidemiology;Genome, Viral__genetics;Humans;Pandemics__prevention & control;Phylogeny;Pneumonia, Viral__diagnosis;RNA, Viral__genetics;Reverse Transcriptase Polymerase Chain Reaction;Sentinel Surveillance;Sequence Analysis;Viral Proteins__genetics;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Fabiana Gámbaro;Sylvie Behillil;Artem Baidaliuk;Flora Donati;Mélanie Albert;Andreea Alexandru;Maud Vanpeene;Méline Bizard;Angela Brisebarre;Marion Barbet;Fawzi Derrar;Sylvie van der Werf;Vincent Enouf;Etienne Simon-Loriere | SARS-CoV-2;outbreak surveillance;phylogeny;virus genomics | 2020-07-10 02:00:00+02:00 | 32643599 | FR;DZ;UNK | These authors contributed equally.;Université de Paris, Paris, France.;Evolutionary genomics of RNA viruses, Institut Pasteur, Paris, France.;Molecular Genetics of RNA Viruses, CNRS - UMR 3569, University of Paris, Institut Pasteur, Paris, France.;National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.;Mutualized Platform of Microbiology, Pasteur International Bioresources Network, Institut Pasteur, Paris, France.;National Influenza Centre, Viral Respiratory Laboratory, Algiers, Algeria.;These authors co-supervised this work. | 1621 | ||
| 10.1684/vir.2020.0838 | Journal Article;Review | en | Mother to Child SARS-CoV-2 Transmission: Fact or Fantasy. | https://www.ncbi.nlm.nih.gov/pubmed/32648549 | The emerging coronavirus called SARS-CoV-2 has spread rapidly around the world. Responsible for severe pneumonitis (Covid-19), there are also doubts concerning a possible mother-to-fetal transmission of this virus. Current data are patchy and obtained from small groups of patients. They tend to support the idea that the mother-to-fetal transmission of SARS-CoV-2 is very rare, but the period between infection and childbirth was often very short and may not allow sufficient replication to consider transplacental passage. Here, we reviewed the existing virological data and those remaining to explore. Thus, the natural history of SARS-CoV-2 infection in pregnant women and the risk of transmission in utero is not yet fully understood and defined. Four months from the emergence of this virus, it is therefore reasonable to wait for the results of specific studies on larger cohorts which, to be conclusive, must meet the best scientific criteria. | 1267-8694,1950-6961 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus__physiology;Coronavirus Infections__transmission;Female;Fetal Diseases__virology;Humans;Infant, Newborn;Infectious Disease Transmission, Vertical;Pandemics;Placenta__virology;Pneumonia, Viral__transmission;Pregnancy;Pregnancy Complications, Infectious;Viral Load;Viral Tropism;COVID-19;severe acute respiratory syndrome coronavirus 2 | Virologie | Chales Egloff;Olivier Picone;Christelle Vauloup-Fellous;Pierre Roques | cellular tropism;fetus;maternal-infant infection;newborn;severe acute respiratory syndrome;trans-placental passage | 2020-07-11 02:00:00+02:00 | 32648549 | FR | Service de gynécologie-obstétrique, Hôpital Louis Mourier, AP-HP, Université de Paris, IAME Inserm U1137, Paris, France, IDMIT, CEA, Université Paris-Saclay, IMVA Inserm U1184, Fontenay-aux-Roses, France.;Service de gynécologie-obstétrique, Hôpital Louis Mourier, AP-HP, Université de Paris, IAME Inserm U1137, Paris, France.;Service de Virologie, Hôpital Paul Brousse, AP-HP, Université Paris Saclay, Inserm U1193, Villejuif, France.;IDMIT, CEA, Université Paris-Saclay, IMVA Inserm U1184, Fontenay-aux-Roses, France. | 1622 | ||
| 10.1038/s41390-020-1050-z | Journal Article;Review | en | European consensus recommendations for neonatal and paediatric retrievals of positive or suspected COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32634819 | The 2020 novel coronavirus (SARS-Cov-2) pandemic necessitates tailored recommendations addressing specific procedures for neonatal and paediatric transport of suspected or positive COVID-19 patients. The aim of this consensus statement is to define guidelines for safe clinical care for children needing inter-facility transport while making sure that the clinical teams involved are sufficiently protected from SARS-CoV-2. | 0031-3998,1530-0447 | 2020-07-12 02:00:00+02:00 | pubmed | Pediatric Research | Ulrich Terheggen;Christian Heiring;Mattias Kjellberg;Fredrik Hegardt;Martin Kneyber;Maurizio Gente;Charles C Roehr;Gilles Jourdain;Pierre Tissieres;Padmanabhan Ramnarayan;Morten Breindahl;Johannes van den Berg | 2020-07-07 02:00:00+02:00 | 32634819 | SE;FR;GB;IT;NL;AE;DK | Department of Critical Care, Paediatric and Cardiac Intensive Care Unit, Al Jalila Children's Hospital, Dubai, United Arab Emirates. terheggen@gmx.org.;Department of Neonatal and Paediatric Intensive Care, Rigshospitalet, the National University Hospital in Denmark, Copenhagen, Denmark.;Department of Neonatal Intensive Care, Uppsala University Children's Hospital, Uppsala, Sweden.;Department of Pediatrics, Neonatal Intensive Care Unit, Umeå University Hospital, Umeå, Sweden.;Department of Paediatrics, Division of Paediatric Critical Care Medicine, Beatrix Children's Hospital, University, Medical Center Groningen, University of Groningen, Groningen, The Netherlands.;Critical Care, Anaesthesiology, Peri-Operative & Emergency Medicine (CAPE), University of Groningen, Groningen, The Netherlands.;Maternal Infant Department, Policlinico Umberto I, Sapienza University of Roma, Roma, Italy.;National Perinatal Epidemiology Unit Clinical Trials Unit, Department of Population Health, Medical Sciences Division, University of Oxford, Oxford, UK.;Newborn Services, Women's Centre, John Radcliffe Hospital, Oxford University Hospitals, NHS Foundation Trust, Oxford, UK.;Division of Pediatrics, Neonatal Critical Care and Transportation, Medical Center "A.Béclère", Paris Saclay University Hospitals, APHP, Paris, France.;Pediatric Intensive Care Unit, Bicêtre University Hospital, AP-HP, Paris Saclay University, Le Kremlin-Bicêtre, France.;Integrative Biology of the Cell, CNRS, CEA, Paris South University, Paris Saclay University, Gif-sur-Yvette, France.;Children's Acute Transport Service (CATS), Great Ormond Street Hospital, London, UK.;Paediatric Intensive Care Unit, St Mary's Hospital, London, UK.;Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden. | 1625 | ||||
| 10.1016/j.gfs.2020.100405 | Journal Article | en | Policy options for mitigating impacts of COVID-19 on domestic rice value chains and food security in West Africa. | https://www.ncbi.nlm.nih.gov/pubmed/32834953 | Rice plays a strategic role in food security in West Africa. However, the region increasingly relies on rice imports due to a growing and structural deficit, and domestic value chains face constraints in technology, finance and coordination. As a result, West Africa is very vulnerable to international and local trade disruptions, such as the ones currently inflicted by the COVID-19 pandemic. We build on evidence of the current state of domestic rice value chain upgrading in West Africa to anticipate the impacts of the COVID-19 pandemic on rice value chains' resilience and their capacity to sustain food security in the region. Several policy options are proposed to help West African governments mitigate the impacts of the COVID-19 crisis on food security. | 2211-9124 | 2020-07-12 02:00:00+02:00 | pubmed | Global Food Security | Aminou Arouna;Guillaume Soullier;Patricio Mendez Del Villar;Matty Demont | Food policy;Food security;Foodborne zoonotic pathogens;Impact;Trade disruption;West Africa | 2020-07-08 02:00:00+02:00 | 32834953 | FR;PH;CI | Africa Rice Center (AfricaRice), 01 BP 2551, Bouake 01, Cote d'Ivoire.;CIRAD, UMR ART-DEV, F-34398, Montpellier, France.;ART-DEV, Univ Montpellier, CIRAD, CNRS, Univ Montpellier 3, Univ Perpignan Via Domitia, Montpellier, France.;CIRAD, UMR TETIS, F-34398, Montpellier, France.;TETIS, Univ Montpellier, AgroParisTech, CIRAD, CNRS, INRAE, Montpellier, France.;International Rice Research Institute (IRRI), Los Baños, Laguna, Philippines. | 1649 | |||
| 10.1161/circimaging.120.010907 | Case Reports;Journal Article | en | Myopericarditis, Rhabdomyolysis, and Acute Hepatic Injury: Sole Expression of a SARS-CoV-2 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32635747 | 1941-9651,1942-0080 | 2020-07-12 02:00:00+02:00 | pubmed | Acute Lung Injury__diagnosis;Adult;Betacoronavirus;Coronavirus Infections__complications;Diagnosis, Differential;Electrocardiography;Follow-Up Studies;Humans;Magnetic Resonance Imaging;Male;Pandemics;Pericarditis__diagnosis;Pneumonia, Viral__complications;Rhabdomyolysis__diagnosis;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | Circulation: Cardiovascular Imaging | Frédéric Legrand;Caroline Chong-Nguyen;Nachwan Ghanem | COVID-19;creatinine;diuretics;hyperkalemia;pericardial effusion | 2020-07-08 02:00:00+02:00 | 32635747 | FR | Department of Cardiology, Simone Veil hospital, Eaubonne, France (F.L., N.G.).;Department of Cardiology, Bichat Hospital, Paris, France (C.C.-N.). | 1652 | |||
| 10.1016/j.jpurol.2020.07.002 | Journal Article | en | The impact of COVID-19 on research. | https://www.ncbi.nlm.nih.gov/pubmed/32713792 | 1477-5131 | 2020-07-12 02:00:00+02:00 | pubmed | Journal of Pediatric Urology | L Harper;N Kalfa;G M A Beckers;M Kaefer;A J Nieuwhof-Leppink;Magdalena Fossum;K W Herbst;D Bagli | Covid-19;Pandemic;Pediatric urology;Research | 2020-07-09 02:00:00+02:00 | 32713792 | SE;FR;CA;US;NL;DK | Department of Pediatric Urology and Pediatric Surgery, Hopital Pellegrin-Enfants, CHU Bordeaux, France. Electronic address: harper_luke@hotmail.com.;Service de chirurgie et urologie pédiatrique, hôpital Lapeyronie, CHU de Montpellier et Université de Montpellier, France. Electronic address: nicolaskalfa@gmail.com.;Department of Urology, Section of Pediatric Urology, AmsterdamUMC, Location VUmc, Amsterdam, the Netherlands. Electronic address: gma.beckers@amsterdamumc.nl.;Indiana University, 702 Barnhill Drive, Suite 4230, Indianapolis, IN, USA. Electronic address: mkaefer@iupui.edu.;Department of Medical Psychology and Social Work, Urology, Wilhelmina Children's Hospital, University Medical Center Utrecht, PO box 85090, 3508 AB, Utrecht, the Netherlands. Electronic address: A.Nieuwhof-Leppink@umcutrecht.nl.;Department of Pediatric Surgery, Copenhagen University Hospital Rigshospitalet, DK-2100, Denmark, Department of Women's and Children's Health, Bioclinicum, Floor 10, Karolinska Institutet, SE-171 76, Stockholm, Sweden. Electronic address: magdalena.fossum@ki.se.;Division of Urology, Department of Research, Connecticut Children's Medical Center, Hartford, CT, USA. Electronic address: kherbst@connecticutchildrens.org.;Hospital for Sick Chidlren, Univeristy of Toronto, Canada. Electronic address: darius.bagli@sickkids.ca. | 1659 | ||||
| 10.1177/1077801220935194 | Journal Article | en | Coronavirus and Quarantine: Catalysts of Domestic Violence. | https://www.ncbi.nlm.nih.gov/pubmed/32627703 | The pandemic of COVID-19 has resulted in quarantines imposed all around the world; these and other restrictions could produce an increase in domestic violence. | 1077-8012,1552-8448 | 2020-07-12 02:00:00+02:00 | pubmed | Violence Against Women | Jean-Baptiste Bouillon-Minois;Maëlys Clinchamps;Frédéric Dutheil | COVID-19;SARS-CoV-2;domestic violence;pandemic;quarantine | 2020-07-06 02:00:00+02:00 | 32627703 | FR | University Hospital of Clermont-Ferrand, France. | 1665 | |||
| 10.1016/j.pratan.2020.07.004 | English Abstract;Journal Article;Review | fr | [Acute renal failure during COVID-19 epidemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32837207 | Renal impairment is a common complication in patients hospitalized in intensive care unit for acute respiratory distress syndrome (ARDS) due to COVID-19 infection. However, the prevalence of SARS-CoV-2 kidney injury is difficult to estimate worldwide. Several pathophysiological mechanisms are involved, including decreased renal perfusion related to mechanical ventilation, sepsis and cytokines release, as well as direct virus toxicity on proximal tubular cells and podocytes, mediated by angiotensin 2 conversion receptors (ACE 2) and TMPRSS proteases. More than 20 % of ICU COVID-19 patients require extra renal replacement therapy (ERT) for acute renal failure that is made difficult by the hypercoagulable state of these patients, responsible for filter thrombosis. | 1279-7960 | 2020-07-12 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Lucie Darriverre;Fabienne Fieux;Christophe de la Jonquière | Acute kidney injury;Acute respiratory distress syndrome;COVID-19 pandemic;Renal replacement therapy | 2020-07-10 02:00:00+02:00 | 32837207 | FR | Service d'anesthésie réanimation, hôpital Saint-Antoine, AP-HP, Paris, France. | 1676 | |||
| Letter | en | No added value of the modified NEWS score to predict clinical deterioration in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32659455 | 2020-07-12 02:00:00+02:00 | pubmed | Maxime Volff;David Tonon;Jeremy Bourenne;Pierre Simeone;Lionel Velly | ARDS;COVID-19;Intensive care Unit;News Score | 2020-07-10 02:00:00+02:00 | 32659455 | FR | Aix Marseille University, AP-HM, Department of Anaesthesiology and Critical Care Medicine, University Hospital Timone, Marseille, France.;Aix Marseille University, AP-HM, Emergency and Critical Care Medicine, University Hospital Timone, Marseille, France. Electronic address: jeremy.bourenne@ap-hm.fr.;Aix Marseille University, AP-HM, Department of Anaesthesiology and Critical Care Medicine, University Hospital Timone, Marseille, France, CNRS, Institut des neurosciences de la Timone, UMR 7289, Marseille, France. | 1680 | |||||||
| Letter | en | Impact of the Prevalence on the Predictive Positive Value of Chest CT in the Diagnosis of Coronavirus Disease (COVID-19). | https://www.ncbi.nlm.nih.gov/pubmed/32755172 | 2020-07-12 02:00:00+02:00 | pubmed | Guillaume Herpe;Jean-Pierre Tasu | 2020-07-09 02:00:00+02:00 | 32755172 | FR | University Hospital of Poitiers, Poitiers, France herpeguillaume@gmail.com.;University Hospital of Poitiers, Poitiers, France. | 1688 | ||||||||
| 10.1016/j.jbior.2020.100744 | Editorial | en | Foreword for the special issue advances in COVID-19: Biology and clinic. | https://www.ncbi.nlm.nih.gov/pubmed/32773104 | 2212-4926 | 2020-07-12 02:00:00+02:00 | pubmed | Advances in Biological Regulation | James A McCubrey;Shaw M Akula;Bernard Payrastre | 2020-07-09 02:00:00+02:00 | 32773104 | FR;US | Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858, USA. Electronic address: mccubreyj@ecu.edu.;Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858, USA. Electronic address: akulas@ecu.edu.;Inserm U1048, Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France and Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France. Electronic address: bernard.payrastre@inserm.fr. | 1689 | |||||
| Letter | en | Rapid onset honeycombing fibrosis in spontaneously breathing patient with Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32631838 | 2020-07-12 02:00:00+02:00 | pubmed | Margot Combet;Arthur Pavot;Laurent Savale;Marc Humbert;Xavier Monnet | 2020-07-06 02:00:00+02:00 | 32631838 | FR | AP-HP, Service de médecine intensive-réanimation, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.;AP-HP, Service de pneumologie et soins intensifs respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le Plessis-Robinson, France. | 1692 | ||||||||
| 10.1007/s00134-020-06155-7 | Editorial | en | Critical care journals during the COVID-19 pandemic: challenges and responsibilities. | https://www.ncbi.nlm.nih.gov/pubmed/32632505 | 0342-4642,1432-1238 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus;Biomedical Research__ethics;Coronavirus Infections__epidemiology;Critical Care;Editorial Policies;Humans;Pandemics;Peer Review, Research;Periodicals as Topic;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Giuseppe Citerio;Jan Bakker;Laurent Brochard;Timothy G Buchman;Samir Jaber;Peter J Mazzone;Jean-Louis Teboul;Jean-Louis Vincent;Elie Azoulay | 2020-07-06 02:00:00+02:00 | 32632505 | FR;CA;GE;CL;US;IT;NL;BE | Editor in Chief, Intensive Care Medicine. Editor in Chief, Intensive Care Medicine Experimental, School of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy. giuseppe.citerio@unimib.it.;Editor in Chief, Journal of Critical Care, NYU School of Medicine, Columbia University College of Physicians & Surgeons, New York, USA.;Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.;Pontificia Universidad Católica de Chile, Santiago, Chile.;Deputy Editor, American Journal of Respiratory and Critical Care Medicine, Keenan Research Centre, St Michael's Hospital and Interdepartmental Division of Critical Care Medicine , University of Toronto, Toronto, ON, Canada.;Editor in Chief, Critical Care Medicine, Emory Critical Care Center, Emory University, Atlanta, Georgia.;Deputy Editor, Intensive Care Medicine, Département Anesthésie et Réanimation B (DAR B), Centre Hospitalier Universitaire (CHU) de Montpellier, Hôpital Saint-Éloi, and INSERM U-1046, Montpellier, France.;Editor in Chief, Chest, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.;Editor in Chief, Annals of Intensive Care, Service de Médecine Intensive-Réanimation, Hôpital Bicêtre, AP-HP Université Paris-Saclay, Le Kremlin-Bicêtre, France.;Editor in Chief, Critical Care, Department of Intensive Care , Erasme University Hospital, Université Libre de Bruxelles, Bruxelles, Belgium.;Past Editor in Chief, Intensive Care Medicine, Médecine Intensive Et Réanimation, APHP, Hôpital Saint-Louis, Paris University, Paris, France. | 1700 | ||||
| 10.1016/j.jcv.2020.104541 | Evaluation Study;Journal Article | en | Evaluation of the Aptima™ transcription-mediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens. | https://www.ncbi.nlm.nih.gov/pubmed/32659713 | The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which appeared in late 2019, has been limited by isolating infected individuals. However, identifying such individuals requires accurate diagnostic tools. | 1386-6532 | 2020-07-12 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Betacoronavirus__genetics;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Female;Humans;Male;Middle Aged;Molecular Diagnostic Techniques__methods;Nucleic Acid Amplification Techniques__methods;Pandemics;Pneumonia, Viral__diagnosis;Prospective Studies;Retrospective Studies;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Clinical Virology | Pauline Trémeaux;Sébastien Lhomme;Florence Abravanel;Stéphanie Raymond;Catherine Mengelle;Jean-Michel Mansuy;Jacques Izopet | COVID-19;Coronavirus;Hologic® Panther System;SARS-CoV-2 | 2020-07-06 02:00:00+02:00 | 32659713 | FR | Department of Virology, CHU Purpan, Toulouse, France. Electronic address: tremeaux.p@chu-toulouse.fr.;Department of Virology, CHU Purpan, Toulouse, France, INSERM UMR1043/CNRS UMR5282, Center for Pathophysiology of Toulouse Purpan, France, Toulouse III University Paul Sabatier, Toulouse, France.;Department of Virology, CHU Purpan, Toulouse, France. | 1702 | ||
| 10.1684/vir.2020.0843 | Editorial;Review | en | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease? | https://www.ncbi.nlm.nih.gov/pubmed/32648548 | 1267-8694,1950-6961 | 2020-07-12 02:00:00+02:00 | pubmed | Anti-Inflammatory Agents__therapeutic use;Antiviral Agents__therapeutic use;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Cytokines__antagonists & inhibitors;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Virologie | Sébastien Nisole;Aure Saulnier;Anne Gatignol | 2020-07-11 02:00:00+02:00 | 32648548 | FR;CA;UNK | Institut de recherche en infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS, Montpellier, France.;À titre personnel.;Laboratoire des interactions Virus-Cellule, Institut Lady Davis de recherches médicales , Département de médecine, Département de microbiologie et immunologie, Université McGill, Montréal, Québec, Canada. | 1706 | ||||
| 10.1111/tid.13410 | Journal Article | en | Discordant courses of COVID-19 in a cohabiting couple of lung transplant recipients. | https://www.ncbi.nlm.nih.gov/pubmed/32654244 | COVID-19 is a novel infectious disease caused by SARS-CoV-2 that emerged in late 2019 and which is now a pandemic. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 due to their chronic use of immunosuppressive drugs (ISDs) and to their associated conditions. Scarce data are available on the optimized management of ISDs in these patients and on its impact on presentation, clinical course, viral shedding, and outcome. We report here two cases of COVID-19 in a cohabiting couple of lung transplant recipients for cystic fibrosis, who had different ISDs management and who developed discordant courses of their disease. Our findings suggest that the degree of their immunosuppression might be a reason for their different course and that ISDs might prove partially protective. | 1398-2273,1399-3062 | 2020-07-12 02:00:00+02:00 | pubmed | Transplant Infectious Disease | Nadine Desmazes-Dufeu;Bérengère Coltey;Lyria Amari;Marion Gouitaa;Camille Touzery;Martine Reynaud-Gaubert;Pascal Chanez;Nadim Cassir | COVID-19;SARS-CoV-2;cystic fibrosis;immunosuppression;lung transplant;viral pneumonia | 2020-07-12 02:00:00+02:00 | 32654244 | FR | Service de Pneumologie, Équipe de Transplantation Pulmonaire, Hôpital Nord, Assistance Publique Hôpitaux de Marseille (APHM), Marseille, France.;Clinique des Bronches, Allergie et Sommeil/APHM, Marseille C2VN Center INSERM INRAE UMR1062, Aix-Marseille Université, Marseille, France.;Service de Radiologie, Hôpital Nord, APHM, Marseille, France.;Microbes, Evolution, Phylogeny and Infection (MEΦI), Aix-Marseille Université UM63, Institut de Recherche pour le Développement IRD 198, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France. | 1711 | |||
| Letter | fr | https://www.ncbi.nlm.nih.gov/pubmed/32829912 | 2020-07-12 02:00:00+02:00 | pubmed | Nicholas Moore | COVID-19;Ibuprofen;SARS-CoV2 | 2020-07-11 02:00:00+02:00 | 32829912 | FR | Bordeaux PharmacoEpi, Inserm CIC1401, université de Bordeaux, 146, rue Léao Saignat, 33076 Bordeaux cedex, France. Electronic address: nicholas.moore@u-bordeaux.fr. | 1713 | ||||||||
| World Health Organization | 10.1007/s10461-020-02969-0 | Journal Article | en | Economic, Mental Health, HIV Prevention and HIV Treatment Impacts of COVID-19 and the COVID-19 Response on a Global Sample of Cisgender Gay Men and Other Men Who Have Sex with Men. | https://www.ncbi.nlm.nih.gov/pubmed/32654021 | There is an urgent need to measure the impacts of COVID-19 among gay men and other men who have sex with men (MSM). We conducted a cross-sectional survey with a global sample of gay men and other MSM (n = 2732) from April 16, 2020 to May 4, 2020, through a social networking app. We characterized the economic, mental health, HIV prevention and HIV treatment impacts of COVID-19 and the COVID-19 response, and examined whether sub-groups of our study population are disproportionately impacted by COVID-19. Many gay men and other MSM not only reported economic and mental health consequences, but also interruptions to HIV prevention and testing, and HIV care and treatment services. These consequences were significantly greater among people living with HIV, racial/ethnic minorities, immigrants, sex workers, and socio-economically disadvantaged groups. These findings highlight the urgent need to mitigate the negative impacts of COVID-19 among gay men and other MSM. | 1090-7165,1573-3254 | 2020-07-12 02:00:00+02:00 | pubmed | AIDS and Behavior | Glenn-Milo Santos;Benjamin Ackerman;Amrita Rao;Sara Wallach;George Ayala;Erik Lamontage;Alex Garner;Ian W Holloway;Sonya Arreola;Vince Silenzio;Susanne Strömdahl;Louis Yu;Carol Strong;Tyler Adamson;Anna Yakusik;Tran Thu Doan;Poyao Huang;Damiano Cerasuolo;Amie Bishop;Teymur Noori;Anastasia Pharris;Max Aung;Masoud Dara;Ssu Yu Chung;Marguerite Hanley;Stefan Baral;Chris Beyrer;Sean Howell | AIDS;COVID-19;Economic impact;Gay;HIV;Men who have sex with men;Mental health | 2020-07-11 02:00:00+02:00 | 32654021 | SE;FR;CH;TW;US;DK | [{"country": "International", "agency": "World Health Organization", "grantid": "001"}] | Community Health Systems Department, University of California San Francisco, San Francisco, CA, USA. Glenn-Milo.Santos@ucsf.edu.;Center of Public Health Research, San Francisco Department of Public Health, San Francisco, CA, USA. Glenn-Milo.Santos@ucsf.edu.;Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.;Center for Public Health and Human Rights, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.;MPact Global Action for Gay Men's Health and Rights, Oakland, CA, USA.;Joint United Nations Programme On HIV and AIDS, Geneva, Switzerland.;Aix-Marseille University, CNRS, EHESS, Centrale Marseille, AMSE, Chemin du Château Lafarge, 13290, Les Milles, France.;, Hornet, Los Angeles, CA, USA.;Luskin School of Public Affairs, University of California Los Angeles, Los Angeles, CA, USA.;Rutgers School of Public Health, Piscataway, NJ, USA.;Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.;Section of Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.;Department of Mathematics, Computer Science, and Statistics, Gustavus Adolphus College, Saint Peter, MN, USA.;Department of Public Health, National Cheng Kung University, Tainan City, Taiwan.;Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.;Department of Communication, University of California San Diego, San Diego, CA, USA.;University Hospital of Caen, Caen, France.;OutRight Action International, New York, NY, USA.;European Centre for Disease Prevention and Control, Solna, Sweden.;WHO Regional Office for Europe, Copenhagen, Denmark.;LGBT Foundation, San Francisco, CA, USA.;Tech4HIV, San Francisco, CA, USA. | 1717 | |
| Case Reports;Letter | en | COVID-19-associated acute cerebral venous thrombosis: clinical, CT, MRI and EEG features. | https://www.ncbi.nlm.nih.gov/pubmed/32653019 | 2020-07-12 02:00:00+02:00 | pubmed | Cerebral Veins__diagnostic imaging;Coronavirus Infections__complications;Critical Care;Electroencephalography;Female;Humans;Magnetic Resonance Imaging;Middle Aged;Pandemics;Pneumonia, Viral__complications;Tomography, X-Ray Computed;Venous Thrombosis__diagnosis;COVID-19 | Fabian Roy-Gash;Marine DE Mesmay;Jean-Michel Devys;Hervé Vespignani;Raphaël Blanc;Nicolas Engrand | COVID-19;Cerebral venous thrombosis;Diagnostic imaging;Electroencephalography;Intracerebral hematoma;Pandemics;SARS-CoV-2 | 2020-07-11 02:00:00+02:00 | 32653019 | FR | Neuro-Intensive Care Unit, Fondation Ophtalmologique Adolphe de Rothschild, 29 rue Manin, 75019, Paris, France. froygash@for.paris.;Neuro-Intensive Care Unit, Fondation Ophtalmologique Adolphe de Rothschild, 29 rue Manin, 75019, Paris, France.;Serenity Medical Services-NeuroPhy, ICM-iPEPS, 47-85 Boulevard de l'Hôpital, 75013, Paris, France.;Department of Interventional Neuro-Radiology, Fondation Rothschild, 29 rue Manin, 75019, Paris, France. | 1718 | ||||||
| 10.1684/vir.2020.0849 | Journal Article | en | Persistence of infectious SARS-CoV-2 on inert surfaces and hand-mediated transmission. | https://www.ncbi.nlm.nih.gov/pubmed/32648550 | 1267-8694,1950-6961 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Communicable Disease Control;Coronavirus Infections__prevention & control;Disinfection;Fomites__virology;Hand__virology;Hand Disinfection;Humans;Masks;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Quarantine;COVID-19;severe acute respiratory syndrome coronavirus 2 | Virologie | Denis Gerlier;Sandra Martin-Latil | 2020-07-11 02:00:00+02:00 | 32648550 | FR | Centre international de recherche en infectiologie, CIRI, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Université Cl. Bernard Lyon 1, ENS de Lyon, Lyon, France.;Université Paris-Est, Anses, Laboratory for Food Safety, 14 rue Pierre et Marie Curie, F-94701 Maisons-Alfort cedex, France. | 1721 | ||||
| 10.1002/jmv.26309 | Journal Article | en | Encephalitic syndrome and anosmia in COVID-19: do these clinical presentations really reflect SARS-CoV-2 neurotropism? A theory based on the review of 25 COVID-19 cases. | https://www.ncbi.nlm.nih.gov/pubmed/32672843 | Since the discovery of COVID-19, a disease caused by the new coronavirus SARS-CoV-2, the pathology showed different faces. There is an increasing number of cases described as (meningo)encephalitis although evidence often lacks. Anosmia, another atypical form of COVID-19, has been considered as testimony of the potential of neuroinvasiveness of SARS-CoV-2, though this hypothesis remains highly speculative. We did a review of the cases reported as brain injury caused by SARS-CoV-2. Over 98 papers found, 21 were analyzed. Only four publications provided evidence of the presence of SARS-CoV-2 within the CNS. When facing acute neurological abnormalities during an infectious episode it is often difficult to disentangle neurological symptoms induced by the brain infection and those due to the impact of host immune response on the CNS. Cytokines release can disturb neural cells functioning and can have in the most severe cases vascular and cytotoxic effects. An inappropriate immune response can lead to the production of auto-antibodies directed toward CNS components. In the case of proven SARS-CoV-2 brain invasion, the main hypothesis found in the literature focus on a neural pathway, especially the direct route via the nasal cavity, although the virus is likely to reach the CNS using other routes. Our ability to come up with hypotheses about the mechanisms by which the virus might interact with the CNS may help to keep in mind that all neurological symptoms observed during COVID-19 do not always rely on CNS viral invasion. This article is protected by copyright. All rights reserved. | 0146-6615,1096-9071 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Medical Virology | Lydia Pouga | COVID-19;SARS-CoV-2;anosmia;central nervous system;encephalitis;meningitis | 2020-07-16 02:00:00+02:00 | 32672843 | FR | Service de Maladies infectieuses et tropicales, Hôpital Necker, AP-HP, 149 Rue de Sèvres, 75015, Paris, France. | 1725 | |||
| 10.1001/jamaoto.2020.1591 | Journal Article | en | Olfactory Loss of Function as a Possible Symptom of COVID-19-Reply. | https://www.ncbi.nlm.nih.gov/pubmed/32672801 | 2168-6181 | 2020-07-19 02:00:00+02:00 | pubmed | JAMA Otolaryngology–Head & Neck Surgery | Michael Eliezer;Corinne Eloit;Charlotte Hautefort | 2020-07-16 02:00:00+02:00 | 32672801 | FR | Department of Neuroradiology, Lariboisière University Hospital, Paris, France.;Department of Head and Neck Surgery, Lariboisière University Hospital, Paris, France. | 1728 | |||||
| Letter;Comment | en | Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. | https://www.ncbi.nlm.nih.gov/pubmed/32593180 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Fatal Outcome;Humans;Lymphocyte Depletion;Pandemics;Pneumonia, Viral;Rituximab;Viremia;COVID-19;severe acute respiratory syndrome coronavirus 2 | Evangéline Clark;Philippe Guilpain;Ionut Laurentiu Filip;Nathalie Pansu;Clément Le Bihan;Guillaume Cartron;Emmanuelle Tchernonog;Camille Roubille;David Morquin;Alain Makinson;Edouard Tuaillon;Vincent Le Moing | 2020-07-16 02:00:00+02:00 | 32593180 | FR | CHU Montpellier, University of Montpellier I, Montpellier, France.;Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, Montpellier University, Medical School, Montpellier, France.;IRMB, Universite Montpellier, INSERM, Montpellier, France.;Tropical and Infectious Diseases, University Hospital, Montpellier, France.;Department of Clinical Hematology, Montpellier University Hospital, Montpellier, France.;Institut de Génétique Moléculaire de Montpellier, CNRS 5535, Montpellier, France.;Internal medecine: CHU de Montpellier, hôpital Lapeyronie, Montpellier, France.;INSERM U1175/IRD UMI 233, IRD, Montpellier, France.;Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, Montpellier, France. | 1731 | |||||||
| 10.1016/s2215-0366(20)30307-2 | Journal Article;Review | en | How mental health care should change as a consequence of the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32682460 | The unpredictability and uncertainty of the COVID-19 pandemic; the associated lockdowns, physical distancing, and other containment strategies; and the resulting economic breakdown could increase the risk of mental health problems and exacerbate health inequalities. Preliminary findings suggest adverse mental health effects in previously healthy people and especially in people with pre-existing mental health disorders. Despite the heterogeneity of worldwide health systems, efforts have been made to adapt the delivery of mental health care to the demands of COVID-19. Mental health concerns have been addressed via the public mental health response and by adapting mental health services, mostly focusing on infection control, modifying access to diagnosis and treatment, ensuring continuity of care for mental health service users, and paying attention to new cases of mental ill health and populations at high risk of mental health problems. Sustainable adaptations of delivery systems for mental health care should be developed by experts, clinicians, and service users, and should be specifically designed to mitigate disparities in health-care provision. Thorough and continuous assessment of health and service-use outcomes in mental health clinical practice will be crucial for defining which practices should be further developed and which discontinued. For this Position Paper, an international group of clinicians, mental health experts, and users of mental health services has come together to reflect on the challenges for mental health that COVID-19 poses. The interconnectedness of the world made society vulnerable to this infection, but it also provides the infrastructure to address previous system failings by disseminating good practices that can result in sustained, efficient, and equitable delivery of mental health-care delivery. Thus, the COVID-19 pandemic could be an opportunity to improve mental health services. | 2215-0366 | 2020-07-19 02:00:00+02:00 | pubmed | The Lancet Psychiatry | Carmen Moreno;Til Wykes;Silvana Galderisi;Merete Nordentoft;Nicolas Crossley;Nev Jones;Mary Cannon;Christoph U Correll;Louise Byrne;Sarah Carr;Eric Y H Chen;Philip Gorwood;Sonia Johnson;Hilkka Kärkkäinen;John H Krystal;Jimmy Lee;Jeffrey Lieberman;Carlos López-Jaramillo;Miia Männikkö;Michael R Phillips;Hiroyuki Uchida;Eduard Vieta;Antonio Vita;Celso Arango | 2020-07-16 02:00:00+02:00 | 32682460 | IE;FR;BE;SG;CO;CL;CN;JP;GB;US;HK;IT;AU;ES;DK;DE | Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain. Electronic address: cmoreno@hggm.es.;Institute of Psychiatry, Psychology and Neuroscience, Department of Psychology, King's College London, London, UK, South London and Maudsley NHS Foundation Trust, London, UK.;University of Campania "Luigi Vanvitelli", Naples, Italy.;CORE-Copenhagen Research Center for Mental Health, Mental Health Services in the Capital Region, Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.;Department of Psychiatry, Pontificia Universidad Católica de Chile, Santiago, Chile.;Department of Psychiatry, University of South Florida, Tampa, FL, USA.;Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland.;Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA, Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA, Department of Child and Adolescent Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany.;School of Management, College of Business, RMIT University, Melbourne, VIC, Australia, Program for Recovery and Community Health, School of Medicine, Yale, New Haven, CT, USA, School of Medicine, Yale, New Haven, CT, USA.;School of Social Policy and Institute for Mental Health, University of Birmingham, Birmingham, UK.;Department of Psychiatry and State Key Laboratory on Cognitive and Brain Sciences, University of Hong Kong, Hong Kong Special Administrative Region, China.;Institute of Psychiatry and Neuroscience of Paris, University of Paris, INSERM U1266, Paris, France, GHU Paris Psychiatrie et Neurosciences, CMME, Hôpital Sainte-Anne, Paris, France.;Division of Psychiatry (National Insitute for Health Research Mental Health Policy Research Unit), University College London, London, UK.;Global Alliance of Mental Illness Advocacy Networks-Europe, Brussels, Belgium.;Department of Psychiatry, School of Medicine, Yale, New Haven, CT, USA, Yale New Haven Hospital, New Haven, CT, USA.;North Region and Department of Psychosis, Institute of Mental Health, Singapore, Neuroscience and Mental Health, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.;Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA.;Department of Psychiatry, School of Medicine, University of Antioquia, Medellín, Colombia.;EUFAMI, Leuven, Belgium.;Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.;Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.;Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.;Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Department of Mental Health and Addiction Services, Spedali Civili Hospital, Brescia, Italy.;Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain. | 1734 | ||||
| 10.1016/j.ekir.2020.07.016 | Journal Article | en | COVID-19 in Patients on Maintenance Dialysis in the Paris Region. | https://www.ncbi.nlm.nih.gov/pubmed/32838082 | Coronavirus disease 2019 (COVID-19) represents a serious threat to patients on maintenance dialysis. The clinical setting, mortality rate, and prognostic factors in these patients have not been well established. | 2468-0249 | 2020-07-19 02:00:00+02:00 | pubmed | Kidney International Reports | Sarah Tortonese;Ivan Scriabine;Louis Anjou;Christopher Loens;Arthur Michon;Mohammed Benabdelhak;Sarah Ouali;Gabriel Morin;Marwa Laifi;Hélène Dobosziewicz;Matthieu Guillet;Manon Dekeyser;Liem Binh Luong Nguyen;Anne Grünenwald;Julien Dang;Geoffroy Desbuissons;Laurent Becquemont;Renaud Snanoudj;Christophe Legendre;Hadia Hebibi;Edouard Lefèvre;Séverine Beaudreuil;Mohamad Zaidan | COVID-19;coronavirus;hemodialysis;kidney;peritoneal dialysis | 2020-07-18 02:00:00+02:00 | 32838082 | FR | Service de Néphrologie, Dialyse et Transplantation, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), Le Kremlin Bicêtre, France.;Université Paris Saclay, Université Paris-Sud, UVSQ, Villejuif, France.;Unité d'épidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France.;Centre d'Investigation Clinique (CIC) Cochin Pasteur, Université de Paris, Hôpital Cochin, Paris, France.;Centre de recherche en Epidémiologie et Santé des Populations (CESP), INSERM, Villejuif, France.;Service de Néphrologie-Dialyse, Nephrocare, Villejuif, France.;Service de Néphrologie-Dialyse, Hôpital de Thiais, Thiais, France.;Institut national de la santé et de la recherche médicale U1163, Institut des Maladies Génétiques, Hôpital Necker-Enfants malades, Paris, France. | 1749 | |||
| 10.1016/j.ijsu.2020.07.023 | Journal Article | en | Surgical activity during the Covid-19 pandemic: Results for 112 patients in a French tertiary care center, a quality improvement study. | https://www.ncbi.nlm.nih.gov/pubmed/32693151 | After the emergence of Covid-19 in China, Hubei Province, the epidemic quickly spread to Europe. France was quickly hit and our institution was one of the first French university to receive patients infected with Sars-COV2. The predicted massive influx of patients motivated the cancellation of all elective surgical procedures planned to free hospitalization beds and to free intensive care beds. Nevertheless, we should properly select patients who will be canceled to avoid life-threatening. The retained surgical indications are surgical emergencies, oncologic surgery, and organ transplantation. | 1743-9191 | 2020-07-19 02:00:00+02:00 | pubmed | International Journal of Surgery | P Philouze;M Cortet;D Quattrone;P Céruse;F Aubrun;G Dubernard;J Y Mabrut;M C Delignette;K Mohkam | Surgery anesthesiology Covid19 | 2020-07-18 02:00:00+02:00 | 32693151 | FR;US | Head and Neck Department, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon 1 University 103 Grande Rue de La Croix-Rousse, 69004, Lyon, France. Electronic address: pierre.philouze@chu-lyon.fr.;Gynecology and Obstetrics Department, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon 1 University 103 Grande Rue de La Croix-Rousse, 69004, Lyon, France. Electronic address: marion.cortet@chu-lyon.fr.;Department of Anesthesiology and Critical Care, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon 1 University 103 Grande Rue de La Croix-Rousse, 69004, Lyon, France. Electronic address: diego.quattrone@chu-lyon.fr.;Head and Neck Department, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon 1 University 103 Grande Rue de La Croix-Rousse, 69004, Lyon, France. Electronic address: philippe.ceruse@chu-lyon.fr.;Department of Anesthesiology and Critical Care, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon 1 University 103 Grande Rue de La Croix-Rousse, 69004, Lyon, France. Electronic address: frederic.aubrun@chu-lyon.fr.;Gynecology and Obstetrics Department, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon 1 University 103 Grande Rue de La Croix-Rousse, 69004, Lyon, France. Electronic address: gil.dubernard@chu-lyon.fr.;Department of General Surgery and Liver Transplantation, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon 1 University, INSERM Unit 1052 / CNRS 5286 103 Grande Rue de La Croix-Rousse, 69004, Lyon, France. Electronic address: jean-yves.mabrut@chu-lyon.fr.;Department of Anesthesiology and Critical Care, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon 1 University 103 Grande Rue de La Croix-Rousse, 69004, Lyon, France. Electronic address: marie-charlotte.delignette@chu-lyon.fr.;Department of General Surgery and Liver Transplantation, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon 1 University, INSERM Unit 1052 / CNRS 5286 103 Grande Rue de La Croix-Rousse, 69004, Lyon, France. Electronic address: kayvan.mohkam@chu-lyon.fr. | 1751 | |||
| 10.1007/s00423-020-01932-w | Journal Article | en | The wave of "opinion articles" in the coverage of COVID-19 in surgical literature. | https://www.ncbi.nlm.nih.gov/pubmed/32676739 | The COVID-19 pandemic is having a deep impact on our surgical practice and scientific publishing output. | 1435-2443,1435-2451 | 2020-07-19 02:00:00+02:00 | pubmed | Langenbeck's Archives of Surgery | Karem Slim;Catherine Mattevi;Flora Badon;Camille Lecomte;Marie Selvy | Covid-19;Journals;Original article;Surgery | 2020-07-17 02:00:00+02:00 | 32676739 | FR | Department of Digestive Surgery, University Hospital CHU Clermont-Ferrand, Place Lucie Aubrac, 63003, Clermont-Ferrand, France. kslim@chu-clermontferrand.fr.;Francophone Group for Enhanced Recovery After Surgery, Beaumont, France. kslim@chu-clermontferrand.fr.;Department of Digestive Surgery, University Hospital CHU Clermont-Ferrand, Place Lucie Aubrac, 63003, Clermont-Ferrand, France. | 1762 | |||
| 10.1038/s41597-020-00589-w | Journal Article;Published Erratum | en | Author Correction: COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms. | https://www.ncbi.nlm.nih.gov/pubmed/32678106 | An amendment to this paper has been published and can be accessed via a link at the top of the paper. | 2052-4463 | 2020-07-19 02:00:00+02:00 | pubmed | Scientific Data | Marek Ostaszewski;Alexander Mazein;Marc E Gillespie;Inna Kuperstein;Anna Niarakis;Henning Hermjakob;Alexander R Pico;Egon L Willighagen;Chris T Evelo;Jan Hasenauer;Falk Schreiber;Andreas Dräger;Emek Demir;Olaf Wolkenhauer;Laura I Furlong;Emmanuel Barillot;Joaquin Dopazo;Aurelio Orta-Resendiz;Francesco Messina;Alfonso Valencia;Akira Funahashi;Hiroaki Kitano;Charles Auffray;Rudi Balling;Reinhard Schneider | 2020-07-17 02:00:00+02:00 | 32678106 | FR;CA;JP;GB;US;IT;AU;NL;ZA;ES;LU;DE | Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.;European Institute for Systems Biology and Medicine (EISBM), Vourles, France.;Ontario Institute for Cancer Research, Toronto, Canada.;College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.;Institut Curie, PSL Research University, Mines Paris Tech, Inserm, Paris, France.;Department of Biology, Univ. Évry, University of Paris-Saclay, Genopole, 91025, Évry, France.;European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, UK.;Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, United States.;Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands.;Maastricht Centre for Systems Biology, Maastricht University, Maastricht, The Netherlands.;Helmholtz Zentrum München, Institute of Computational Biology, Neuherberg, Germany.;Center for Mathematics, Technische Universität München, Garching, Germany.;Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany.;University of Konstanz, Department of Computer and Information Science, Konstanz, Germany.;Monash University, Faculty of Information Technology, Melbourne, Australia.;Computational Systems Biology of Infection and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tübingen, 72076, Tübingen, Germany.;Department of Computer Science, University of Tübingen, 72076, Tübingen, Germany.;German Center for Infection Research (DZIF), partner site, Tübingen, Germany.;Department of Molecular and Medical Genetics, School of Medicine, Oregon Health & Science University, Portland, USA.;Department of Systems Biology & Bioinformatics, University of Rostock, Rostock, Germany.;Stellenbosch Institute of Advanced Study (STIAS), Wallenberg Research Centre at Stellenbosch University, 7602, Stellenbosch, South Africa.;Research Programme on Biomedical informatics, Hospital del Mar Medical Research Institute, Department of experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain.;Clinical Bioinformatics Area, Fundación Progreso y Salud. Hosp. Virgen del Rocío, Sevilla, Spain.;Bioinformatics in Rare Diseases. Centro de Investigación Biomédica en Red de Enfermedades Raras, Fundación Progreso y Salud, Hosp. Virgen del Rocío, Sevilla, Spain.;INB-ELIXIR-es, FPS, Hospital Virgen del Rocío, Sevilla, 42013, Spain.;Institute of Biomedicine of Seville (IBIS), Hospital Virgen del Rocio, 41013, Sevilla, Spain.;HIV, Inflammation and Persistence Unit, Virology Department, Institut Pasteur, Paris, France.;Bio Sorbonne Paris Cité, Université de Paris, Paris, France.;Dipartimento di Epidemiologia Ricerca Pre-Clinica e Diagnostica Avanzata, National Institute for Infectious Diseases "Lazzaro Spallanzani" i.R.c.c.S., Rome, Italy.;COVID 19 INMI Network Medicine for IDs Study Group, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy.;Barcelona Supercomputing Center (BSC), Barcelona, Spain.;Institucio Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain.;Department of Biosciences and Informatics, Keio University, Yokohama, Kanagawa, Japan.;The Systems Biology Institute, Shinagawa, Tokyo, Japan.;Okinawa Institute of Science and Technology Graduate University, Kunigami, Okinawa, Japan.;Sony Computer Science Laboratories, inc., Tokyo, Japan.;Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg. reinhard.schneider@uni.lu. | 1764 | ||||
| 10.1371/journal.pmed.1003193 | Journal Article;Research Support, Non-U.S. Gov't | en | Tracing and analysis of 288 early SARS-CoV-2 infections outside China: A modeling study. | https://www.ncbi.nlm.nih.gov/pubmed/32678827 | In the early months of 2020, a novel coronavirus disease (COVID-19) spread rapidly from China across multiple countries worldwide. As of March 17, 2020, COVID-19 was officially declared a pandemic by the World Health Organization. We collected data on COVID-19 cases outside China during the early phase of the pandemic and used them to predict trends in importations and quantify the proportion of undetected imported cases. | 1549-1676 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus;China__epidemiology;Communicable Disease Control__methods;Coronavirus Infections__epidemiology;Humans;Models, Theoretical;Pandemics;Pneumonia, Viral__epidemiology;Travel;COVID-19;severe acute respiratory syndrome coronavirus 2 | PLOS Medicine | Francesco Pinotti;Laura Di Domenico;Ernesto Ortega;Marco Mancastroppa;Giulia Pullano;Eugenio Valdano;Pierre-Yves Boëlle;Chiara Poletto;Vittoria Colizza | 2020-07-17 02:00:00+02:00 | 32678827 | FR;CU;IT;US | INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.;Facultad de Física, Universidad de la Habana, Cuba.;Dipartimento di Scienze Matematiche, Fisiche e Informatiche, Università degli Studi di Parma, Parco Area delle Scienze, Parma, Italy.;INFN, Gruppo Collegato di Parma, Parco Area delle Scienze, Parma, Italy.;Sociology and Economics of Networks and Services lab at Orange Experience Design Lab (SENSE/XDLab) Chatillion, Paris, France.;Center for Biomedical Modeling, The Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, United States of America. | 1766 | |||
| 10.3390/ijerph17145074 | Journal Article | en | Subjective Overload and Psychological Distress among Dentists during COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32674416 | Psychological distress during the COVID-19 pandemic is not solely limited to SARS-CoV-2 infection. It may also be related to social, cultural, and environmental factors, which may act as additional stressors. The aim of the current study was to explore the association between psychological distress and subjective overload among dentists in different countries, and whether it is associated with COVID-19-related factors. A cross-sectional survey was conducted among 1302 dentists from China, India, Israel, Italy, and the UK, who filled out demographics data, COVID-19-related factor questions, subjective overload, and psychological distress scales. Our findings showed that the positive association between subjective overload and psychological distress was different among countries, suggesting higher rate of intensity in Italy compared to China, India, and Israel (the UK was near significance with China and Israel). The interaction variable of the subjective overload × psychological distress was significantly associated with a particular country, with those individuals reporting fear of contracting COVID-19 from patients, fear of their families contracting COVID-19, and receiving enough professional knowledge regarding COVID-19. Given the above, dentists were found to have elevated levels of subjective overload and psychological distress, which differed among the countries, presumably due to certain background issues such as social, cultural, and environmental factors. | 1660-4601 | 2020-07-19 02:00:00+02:00 | pubmed | Adult;Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Cross-Sectional Studies;Dentists__psychology;Fear;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Psychological Distress;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Environmental Research and Public Health | Eitan Mijiritsky;Yaira Hamama-Raz;Feng Liu;Abhay N Datarkar;Luca Mangani;Julian Caplan;Anna Shacham;Roni Kolerman;Ori Mijiritsky;Menachem Ben-Ezra;Maayan Shacham | COVID-19;occupational dentistry;psychological distress;psychosocial factors;stress;subjective overload | 2020-07-14 02:00:00+02:00 | 32674416 | FR;IL;CN;GB;IT;IN | Department of Otolaryngology, Head and Neck and Maxillofacial Surgery, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv 6139001, Israel.;The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.;School of Social Work, Ariel University, Ariel 40700, Israel.;Department of Stomatology, Peking University, Beijing 100034, China.;Department of Oral & Maxillofacial Surgery, Govermental Dental College and Hospital Nagpur Maharashtra, Maharashtra 440003, India.;Department of Chemical and Technological Sciences, University of Roma "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.;Private Practice, Aviva Dentistry Ltd., St Albans AL1 3EN, Hertfordshire, UK.;Lev Hasharon Medical Center, Netanya 42100, Israel.;Department of Periodontology and Dental Implantology, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.;Department of Psychology, Tel Aviv-Yafo Academic College, Tel Aviv 6818543, Israel. | 1772 | ||
| 10.1111/iej.13368 | Journal Article | en | Continuing endodontic education and COVID-19: before, during and after? | https://www.ncbi.nlm.nih.gov/pubmed/32779736 | 0143-2885,1365-2591 | 2020-07-19 02:00:00+02:00 | pubmed | International Endodontic Journal | A Galibourg;O A Peters;F Diemer;K Nasr;D Maret | 2020-07-13 02:00:00+02:00 | 32779736 | FR;AU | Faculté de Chirurgie Dentaire, Centre Hospitalier Universitaire, Université Paul Sabatier, Toulouse, France.;Laboratoire Anthropologie Moléculaire et Imagerie de Synthèse, Université Paul Sabatier, Toulouse, France.;Department of Endodontics, School of Dentistry, University of Queensland, Brisbane, QLD, Australia.;Institut Clément Ader (laboratoire), Toulouse, France. | 1775 | |||||
| 10.1186/s12610-020-00106-4 | Journal Article | en | COVID-19 and andrology: Recommendations of the French-speaking society of andrology (Société d'Andrologie de langue Française SALF). | https://www.ncbi.nlm.nih.gov/pubmed/32685170 | SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) metamorphosed our medical practice. In early June 2020, more than 6,400,000 COVID-19 (coronavirus-19 disease) cases were diagnosed across the world and more than 380,000 deaths were linked to COVID-19. Many medical symptoms of COVID-19 were reported. We will focus, here, on potential impacts of COVID-19 on men's andrological health. Our society (French-speaking society of andrology, SALF) also emitted some recommendations in the andrological management of men infected by SARS-CoV-2. First, considering the fever and the potential presence of SARS-CoV2 in semen, SALF recommends waiting for 3 months (duration of one spermatogenesis cycle and epididymal transit) before re-starting ART in the case of men diagnosed COVID-19 positive. Whatever the nature of testosterone and COVID-19 relationships, we recommend an andrological examination, sperm parameters, and hormonal evaluation at the time of the COVID-19 is diagnosed, and several months later. Furthermore, we are concerned by the potential morbid-mortality of the COVID-19, which mainly affects men. This "andrological bias", if proven, must be reduced by specific andrological diagnosis, therapeutic and prophylactic measures. Research in this direction must be substantiated and financially supported over the next few months (years). | 2051-4190 | 2020-07-19 02:00:00+02:00 | pubmed | Basic and Clinical Andrology | S Hamdi;M Bendayan;E Huyghe;J-C Soufir;E Amar;R El Osta;I Plotton;C Delalande;J Perrin;C Leroy;A Bouker;H Pons;H Lejeune;G Robin;F Boitrelle | Andrological care;Assisted reproductive technologies;Covid-19;Fever;Male;Orchitis;SARS-CoV-2;Semen;Testis;Testosterone | 2020-07-13 02:00:00+02:00 | 32685170 | FR | Société d'Andrologie de langue Française (SALF), http://www.salf.fr.;Université de Toulouse, UPS, Groupe de Recherche en Fertilité Humaine (EA 3694, Human Fertility Research Group), 330 avenue de Grande Bretagne, 31059 Toulouse, France.;Unité d'Andrologie, Groupe d'activité de médecine de la reproduction, Hôpital Paule de Viguier, CHU Toulouse, 330 avenue de Grande Bretagne, 31059 Toulouse, France.;Service de biologie de la reproduction-Préservation de la fertilité- Andrologie, Hôpital de Poissy Saint Germain en Laye, 78300 Poissy, France.;Université Paris-Saclay, UVSQ, INRAE, BREED, 78350 Jouy-en-Josas, France.;École Nationale Vétérinaire d'Alfort, BREED, 94700 Maisons-Alfort, France.;Service d'AMP et Préservation de la Fertilité, Hôpital Jeanne de Flandre, CHU de Lille, 59037 Lille cedex, France.;Service d'Andrologie, Hôpital Claude Huriez, CHU de Lille, 59037 Lille cedex, France.;Lille University, EA4308 "Gametogenesis and gamete quality", 59120 Loos, France. | 1777 | |||
| 10.1016/j.pratan.2020.07.007 | English Abstract;Journal Article;Review | fr | https://www.ncbi.nlm.nih.gov/pubmed/32837214 | Coagulation disorders are commonly reported in patients suffering from COVID-19 pneumonia. These are associated to an increase incidence of thrombotic disorders associated with an increase mortality rate. D-Dimers concentrations > 3 μg/L, fibrinogen > 8 g/L and decreased platelets count are associated with an increased thrombotic risk. These biological markers have to be closely monitored during ICU stay. The diagnosis of pulmonary embolism could be difficult in this setting. However, it has to be evoked in case of worsening hypoxemia unexplained by other reason and/or right ventricular failure. The thrombotic risk can be scored to adapt the thromboprophylactic treatment, impaired renal function and overweight making it even more difficult. | 1279-7960 | 2020-07-19 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Léa Satre Buisson | COVID-19 pandemic;Hemostasis disorders;Hypercoagulability;Pulmonary embolism;SARS-CoV2 | 2020-07-13 02:00:00+02:00 | 32837214 | FR | Service d'anesthésie-réanimation, hôpital Saint-Antoine, DMU DREAM, hôpitaux Sorbonne université, Assistance publique-Hôpitaux de Paris, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France. | 1780 | ||||
| Letter | en | Late miscarriage as a presenting manifestation of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32690331 | 2020-07-19 02:00:00+02:00 | pubmed | R Hachem;G A Markou;C Veluppillai;C Poncelet | 2020-07-13 02:00:00+02:00 | 32690331 | FR | Department of Obstetrics and Gynaecology, René Dubos Hospital, Cergy-Pontoise cedex, France. Electronic address: ramihachem@hotmail.com.;Department of Obstetrics and Gynaecology, René Dubos Hospital, Cergy-Pontoise cedex, France.;Department of Obstetrics and Gynaecology, René Dubos Hospital, Cergy-Pontoise cedex, France, Université Paris 13, Bobigny, France. | 1784 | ||||||||
| 10.1016/j.molstruc.2020.128918 | Journal Article | en | Crystal structure, chemical reactivity, kinetic and thermodynamic studies of new ligand derived from 4-hydroxycoumarin: Interaction with SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32834114 | Currently, Covid-19 pandemic infects staggering number of people around the globe and causes a high rate of mortality. In order to fight this disease, a new coumarin derivative ligand (4-[(pyridin-3-ylmethyl) amino]-2H-chromen-2-one) (LTA) has been synthesized and characterized by single-crystal X-ray diffraction, NMR, ATR, UV-Visible and cyclic voltammetry. Chemical reactivity, kinetic and thermodynamic studies were investigated using DFT method. The possible binding mode between LTA and Main protease (Mpro) of SARS-CoV-2 and their reactivity were studied using molecular docking simulation. Single crystal X-ray diffraction showed that LTA crystallizes in a monoclinic system with P2 1 space group. The reactivity descriptors such as nucleophilic index confirm that LTA is more nucleophile, inducing complexation with binding species like biomolecules. The kinetic and thermodynamic parameters showed that the mechanism of crystal formation is moderately exothermic. The binding energy of the SARS-CoV-2/Mpro-LTA complex and the calculated inhibition constant using docking simulation showed that the active LTA molecule has the ability to inhibit SARS-CoV-2. | 0022-2860 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Molecular Structure | Chafia Ait-Ramdane-Terbouche;Hasnia Abdeldjebar;Achour Terbouche;Houria Lakhdari;Khaldoun Bachari;Thierry Roisnel;Didier Hauchard | Chemical reactivity;Coumarin derivative;Crystal structure;Interaction SARS-CoV-2/Mpro-LTA;Thermodynamic properties | 2020-07-16 02:00:00+02:00 | 32834114 | FR;DZ | Centre de Recherche Scientifique et Technique en Analyses Physico-chimiques(CRAPC), BP384, Bou-Ismail, RP 42004, Tipasa, Algeria.;Univ Rennes CNRS ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226 F-35000 Rennes France.;Univ Rennes Ecole Nationale Supérieure de Chimie de Rennes CNRS ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226 F-35000 Rennes France. | 1793 | |||
| 10.1016/j.antiviral.2020.104880 | Journal Article | en | Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. | https://www.ncbi.nlm.nih.gov/pubmed/32679056 | We investigated the distribution of antibodies neutralizing SARS-CoV-2 according to age, sex or blood group in French blood donors. In 464 samples collected before the emergence of SARS-CoV-2 (2017 and 2018), our virus neutralization assay had a 100% specificity. It was used to test 998 samples collected from blood donors during the last week of March or the first week of April 2020. As expected at this stage of the outbreak, the prevalence was low (2.7%) and, importantly, criteria for blood donation imply that the vast majority of seropositives had asymptomatic or pauci-symptomatic SARS-CoV-2 infections. Seroprevalence values did not differ significantly among age groups (but were slightly higher in donors <30yo and ≥60yo), and between males and females (2.82% vs 2.69%), unlike what has been observed regarding hospitalizations admission to ICU and death rates in France. By contrast, we observed that the proportion of seropositives was significantly lower in group O donors (1.32% vs 3.86% in other donors, p=0.014). We conclude that virus infection seems to occur with a similar incidence in men and women among French blood donors, but that blood group O persons are less at risk of being infected and not only of suffering from severe clinical presentations, as previously suggested. | 0166-3542 | 2020-07-19 02:00:00+02:00 | pubmed | Antiviral Research | Pierre Gallian;Boris Pastorino;Pascal Morel;Jacques Chiaroni;Laetitia Ninove;Xavier de Lamballerie | COVID-19;SARS-CoV-2;blood donors;blood groups;seroneutralisation | 2020-07-14 02:00:00+02:00 | 32679056 | FR | Unité des Virus Émergents, (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207-IHU Méditerranée Infection), Marseille, France, Établissement Français Du Sang, La Plaine, St Denis, France.;Unité des Virus Émergents, (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207-IHU Méditerranée Infection), Marseille, France.;Établissement Français Du Sang, La Plaine, St Denis, France.;Établissement Français Du Sang, Provence Alpes Côte D'Azur et Corse, Marseille, France, «Biologie des Groupes Sanguins», Aix Marseille Univ-CNRS-EFS-ADÉS, Marseille, France.;Unité des Virus Émergents, (UVE: Aix-Marseille Univ-IRD 190-INSERM 1207-IHU Méditerranée Infection), Marseille, France. Electronic address: xavier.de-lamballerie@univ-amu.fr. | 1795 | |||
| 10.1111/jth.15016 | Journal Article | en | Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. | https://www.ncbi.nlm.nih.gov/pubmed/32668058 | Thirty percent of Covid-19 patients admitted to intensive care units present with thrombotic complications despite thromboprophylaxis. Bed rest, obesity, hypoxia, coagulopathy, and acute excessive inflammation are potential mechanisms reported by previous studies. Better understanding of the underlying mechanisms leading to thrombosis is crucial for developing more appropriate prophylaxis and treatment strategies. | 1538-7933,1538-7836 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Thrombosis and Haemostasis | Christophe Nougier;Remi Benoit;Marie Simon;Helene Desmurs-Clavel;Guillaume Marcotte;Laurent Argaud;Jean Stephane David;Aurelie Bonnet;Claude Negrier;Yesim Dargaud | Covid-19;TAFI;fibrinolysis;plasminogen activator inhibitor 1;thrombin generation;tissue plasminogen activator | 2020-07-15 02:00:00+02:00 | 32668058 | FR | Laboratoire d'Hematologie, Groupement Hospitalier Est, Hospices Civils de Lyon, France.;Service de Medecine Intensive Reanimation, Hopital Edouard Herriot, Lyon, France.;GEMMAT, Groupe d'Etude Multidisciplinaire en Maladies Thrombotiques, Lyon, France.;Service de Medecine Interne, Hopital Edouard Herriot, Lyon, France.;Service de Reanimation Chirurgicale, Hopital Edouard Herriot, Lyon, France.;Service de Medecine Intensive Reanimation, Centre Hospitalier Lyon Sud, Lyon, France.;Service de réanimation chirurgicale, Hopital de la Croix Rousse, Lyon, France.;EA4609, Universite Claude Bernard Lyon 1, Lyon, France. | 1800 | |||
| 10.1093/cid/ciaa977 | Journal Article | en | Comparing dynamics and determinants of SARS-CoV-2 transmissions among health care workers of adult and pediatric settings in central Paris. | https://www.ncbi.nlm.nih.gov/pubmed/32663849 | Health-care workers (HCW) have paid a heavy toll to the coronavirus disease-19 (COVID-19) outbreak. Routes of transmission remain to be fully understood. | 1058-4838,1537-6591 | 2020-07-19 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Adrien Contejean;Jérémie Leporrier;Etienne Canouï;Fanny Alby-Laurent;Emmanuel Lafont;Lauren Beaudeau;Perrine Parize;Fabienne Lecieux;Agnès Greffet;Gérard Chéron;Rémy Gauzit;Jacques Fourgeaud;Anne-Sophie L'Honneur;Jean-Marc Tréluyer;Caroline Charlier;Anne Casetta;Pierre Frange;Marianne Leruez-Ville;Flore Rozenberg;Olivier Lortholary;Solen Kernéis | COVID-19;Determinants;Dynamics;Health Care Workers;SARS-CoV-2 | 2020-07-15 02:00:00+02:00 | 32663849 | FR | Université de Paris, Faculté de Médecine, Paris, France.;Equipe Mobile d'Infectiologie, AP-HP, Hôpital Cochin, Paris, France.;Service de maladies infectieuses et tropicales, AP-HP, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France.;Service de santé au travail, AP-HP, Hôpital Cochin, Paris, France.;Service de santé au travail, AP-HP, Hôpital Necker-Enfants malades, Paris, France.;Service d'urgences pédiatriques, AP-HP, Hôpital Necker-Enfants malades, Paris, France.;Laboratoire de virologie, AP-HP, Hôpital Necker-Enfants malades, Paris, France.;EHU 7328 PACT, Institut Imagine, Université de Paris, Faculté de Médecine, Paris, France.;Département de virologie, AP-HP, Hôpital Cochin, Paris, France.;Département de soins intensifs pédiatriques, AP-HP, Hôpital Necker-Enfants malades, Paris, France.;Pharmacology and Drug Evaluation in Children and Pregnant Women EA, Université de Paris, Faculté de Médecine, Paris, France.;Département de pharmacologie clinique AP-HP, Hôpital Cochin, Paris, France.;Equipe opérationnelle d'hygiène hospitalière, AP-HP, Hôpital Cochin, Paris, France.;Laboratoire de microbiologie clinique, AP-HP, Hôpital Necker-Enfants malades, Paris, France.;Institut Pasteur, Molecular Mycology Unit, National Reference Centre for Invasive Mycoses and Antifungals, CNRS UMR, Paris, France.;Epidemiology and modelling of bacterial escape to antimicrobials (EMEA), Institut Pasteur , Paris, France. | 1803 | |||
| 10.1007/s10096-020-03989-3 | Journal Article | en | A mobile DNA laboratory for forensic science adapted to coronavirus SARS-CoV-2 diagnosis. | https://www.ncbi.nlm.nih.gov/pubmed/32666482 | The Forensic Science Institute of the French "Gendarmerie Nationale" (IRCGN™) developed in 2015 an ISO 17025 certified mobile DNA laboratory for genetic analyses. This Mobil'DNA laboratory is a fully autonomous and adaptable mobile laboratory to perform genetic analyses in the context of crime scenes, terrorism attacks or disasters. To support the hospital task force in Paris during the peak of the COVID-19 epidemic, we adapted this mobile genetic laboratory to perform high-throughput molecular screening for coronavirus SARS-CoV-2 by real-time PCR. We describe the adaptation of this Mobil'DNA lab to assist in Coronavirus SARS-CoV-2 diagnosis. | 0934-9723,1435-4373 | 2020-07-19 02:00:00+02:00 | pubmed | European Journal of Clinical Microbiology & Infectious Diseases | Patrick Touron;Christian Siatka;Amaury Pussiau;Sébastien Follot;Thibaud Fritz;Mikaël Petit;Noussair Latifa;Jean-Louis Herrmann;Martin Rottman;Antoinette Lemoine;Sylvain Hubac | 2020-07-14 02:00:00+02:00 | 32666482 | FR | PJGN, 5 Boulevard de l'Hautil, 95000, Cergy, France.;IRCGN, 5 Boulevard de l'Hautil, 95000, Cergy, France.;Université de Nîmes, 7 Place Gabriel Péri, 30000, Nîmes, France.;Ecole de l'ADN, 19 grand rue, Muséum d'Histoire Naturelle, 30000, Nîmes, France.;Assistance Publique-Hôpitaux de Paris INSERM U1173, UFR Simone Veil, Versailles-Saint-Quentin University, 78180, Saint-Quentin en Yvelines, France.;Département Médical Universitaire de Biologie-Génétique-Pharmacie, AP-HP, Université Paris Saclay, 78 rue du Général Leclerc, 94270, Le Kremlin-Bicêtre, France.;IRCGN, 5 Boulevard de l'Hautil, 95000, Cergy, France. sylvain.hubac@gendarmerie.interieur.gouv.fr.;Ecole de l'ADN, 19 grand rue, Muséum d'Histoire Naturelle, 30000, Nîmes, France. sylvain.hubac@gendarmerie.interieur.gouv.fr. | 1811 | ||||
| 10.1038/s41467-020-17436-6 | Case Reports;Journal Article | en | Transplacental transmission of SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32665677 | SARS-CoV-2 outbreak is the first pandemic of the century. SARS-CoV-2 infection is transmitted through droplets; other transmission routes are hypothesized but not confirmed. So far, it is unclear whether and how SARS-CoV-2 can be transmitted from the mother to the fetus. We demonstrate the transplacental transmission of SARS-CoV-2 in a neonate born to a mother infected in the last trimester and presenting with neurological compromise. The transmission is confirmed by comprehensive virological and pathological investigations. In detail, SARS-CoV-2 causes: (1) maternal viremia, (2) placental infection demonstrated by immunohistochemistry and very high viral load; placental inflammation, as shown by histological examination and immunohistochemistry, and (3) neonatal viremia following placental infection. The neonate is studied clinically, through imaging, and followed up. The neonate presented with neurological manifestations, similar to those described in adult patients. | 2041-1723 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnosis;Female;Humans;Infant, Newborn;Infectious Disease Transmission, Vertical;Male;Maternal-Fetal Exchange__physiology;Mothers;Pandemics;Placenta__pathology;Pneumonia, Viral__diagnosis;Pregnancy;Pregnancy Complications, Infectious__virology;Vasculitis, Central Nervous System__virology;Viral Load;Viremia__transmission;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nature Communications | Alexandre J Vivanti;Christelle Vauloup-Fellous;Sophie Prevot;Veronique Zupan;Cecile Suffee;Jeremy Do Cao;Alexandra Benachi;Daniele De Luca | 2020-07-14 02:00:00+02:00 | 32665677 | FR | Division of Obstetrics and Gynecology, Antoine Béclère Hospital, Paris Saclay University Hospitals, APHP 157 rue de la Porte de Trivaux, 92140, Clamart, France.;Division of Virology, Paul Brousse Hospital, Paris Saclay University Hospitals, APHP 12 Avenue Paul Vaillant Couturier, 94800, Villejuif, France.;Division of Pathology, Bicetre Hospital, Paris Saclay University Hospitals, APHP, Le Kremlin-Bicêtre, France.;Division of Pediatrics and Neonatal Critical Care, Antoine Béclère Hospital, Paris Saclay University Hospitals, APHP 157 rue de la Porte de Trivaux, 92140, Clamart, France.;Division of Radiology, Antoine Béclère Hospital, Paris Saclay University Hospitals, APHP 157 rue de la Porte de Trivaux, 92140, Clamart, France.;Division of General Pediatrics, Antoine Béclère Hospital, Paris Saclay University Hospitals, APHP 157 rue de la Porte de Trivaux, 92140, Clamart, France.;Division of Pediatrics and Neonatal Critical Care, Antoine Béclère Hospital, Paris Saclay University Hospitals, APHP 157 rue de la Porte de Trivaux, 92140, Clamart, France. dm.deluca@icloud.com.;Physiopathology and Therapeutic Innovation Unit-INSERM U999, Paris Saclay University, 63 Rue Gabriel Péri, 94270, Le Kremlin-Bicêtre, France. dm.deluca@icloud.com. | 1812 | |||
| Letter | en | Ischemic cerebrovascular diseases in patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32732014 | 2020-07-19 02:00:00+02:00 | pubmed | S El Aoud;C Morin;B Boutin;H Chouchane;D Sorial;P Rondeau;L Thomas | 2020-07-19 02:00:00+02:00 | 32732014 | FR | Department of internal medicine, Saint-Camille Hospital, 94360 Bry-Sur-Marne, France. Electronic address: elaoudsahar@gmail.com.;Department of internal medicine, Saint-Camille Hospital, 94360 Bry-Sur-Marne, France. | 1818 | ||||||||
| 10.1016/j.ajic.2020.07.006 | Journal Article | en | Developing and Implementing an Infection Prevention and Control Program for a COVID-19 Alternative Care Site in Philadelphia, PA. | https://www.ncbi.nlm.nih.gov/pubmed/32697947 | On March 27, 2020, the city of Philadelphia was given permission by Temple University to convert the Liacouras Center gymnasium to an alternate care site (ACS) to treat low-acuity COVID-19 patients. ACS's, especially those created to specifically care for infectious patients, require a robust infection prevention and control (IPC) program. | 0196-6553 | 2020-07-19 02:00:00+02:00 | pubmed | American Journal of Infection Control | Silpa N Tadavarthy;KerriAnn Finnegan;Gretchen Bernatowicz;Elisha Lowe;Susan E Coffin;MaryLou Manning | alternate care site;coronavirus;infection prevention | 2020-07-19 02:00:00+02:00 | 32697947 | FR;GB;US | Lewis Katz School of Medicine, Temple University, 3500 N Broad St, Philadelphia, PA 19140. Electronic address: tug31996@temple.edu.;Lewis Katz School of Medicine, Temple University, 3500 N Broad St, Philadelphia, PA 19140. Electronic address: kerriann.finnegan@temple.edu.;Villanova University, Student Health Center, 800 Lancaster Ave, Villanova, PA 19085. Electronic address: Gkkb23@gmail.com.;Medical Science Liaison, bioMerieux, Durham, NC. Electronic address: lowe.elisha@gmail.com.;Medical Director, Healthcare Associated Infections &Antimicrobial Resistance Program, Philadelphia Department of Public Health, 1101 Market St, Philadelphia, PA 19107. Electronic address: COFFIN@email.chop.edu.;Professor, Thomas Jefferson University, College of Nursing, 901 Walnut St, Philadelphia, PA. Electronic address: marylouman@gmail.com. | 1821 | |||
| 10.1007/s00405-020-06236-9 | Journal Article;Review | en | Sinus and anterior skull base surgery during the COVID-19 pandemic: systematic review, synthesis and YO-IFOS position. | https://www.ncbi.nlm.nih.gov/pubmed/32710178 | The COVID-19 pandemic has caused significant confusion about healthcare providers' and patients' pandemic-specific risks related to surgery. The aim of this systematic review is to summarize recommendations for sinus and anterior skull base surgery during the COVID-19 pandemic. | 0937-4477,1434-4726 | 2020-07-26 02:00:00+02:00 | pubmed | European Archives of Oto-Rhino-Laryngology | Thomas Radulesco;Jerome R Lechien;Leigh J Sowerby;Sven Saussez;Carlos Chiesa-Estomba;Zoukaa Sargi;Philippe Lavigne;Christian Calvo-Henriquez;Chwee Ming Lim;Napadon Tangjaturonrasme;Patravoot Vatanasapt;Puya Dehgani-Mobaraki;Nicolas Fakhry;Tareck Ayad;Justin Michel | Coronavirus infections;Health planning guidelines;Nose diseases;Operative procedures | 2020-07-24 02:00:00+02:00 | 32710178 | FR;SG;CA;GB;US;TH;IT;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Marseille, France. thomas.radulesco@ap-hm.fr.;Department of Oto-Rhino-Laryngology and Head and Neck Surgery, APHM, La Conception University Hospital, 13385, Marseille Cedex, France. thomas.radulesco@ap-hm.fr.;Aix-Marseille University, IUSTI, 13013, Marseille, France. thomas.radulesco@ap-hm.fr.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Marseille, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada.;Department of Otorhinolaryngology, Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, USA.;Division of Otolaryngology-Head and Neck Surgery, Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada.;Department of Otolaryngology, Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;Department of Otorhinolaryngology Head and Neck Surgery, Duke-NUS Medical School, Singapore General Hospital, Singapore, Singapore.;Department of Otolaryngology Head of Division of Head and Neck Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.;Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.;Department of Otolaryngology Head and Surgery, Gubbio-Gualdo Tadino Hospital, USL Umbria 1, Gubbio, Italy.;Association "Naso Sano" Onlus, Umbria Regional Registry of Volunteer Activities, Corciano, Italy.;Department of Oto-Rhino-Laryngology and Head and Neck Surgery, APHM, La Conception University Hospital, 13385, Marseille Cedex, France.;Aix-Marseille University, IUSTI, 13013, Marseille, France. | 1829 | |||
| 10.2967/jnumed.120.249821 | Journal Article | en | Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32709733 | Introduction: The coronavirus disease 2019 (COVID-19) pandemic has placed significant challenges on health care systems worldwide, whether in the preparation, response, or recovery phase of the pandemic. This has been primarily managed by dramatically reducing in- and outpatient services for other diseases and implementing infection prevention and control (IPC) measures. The impact of the pandemic on nuclear medicine departments and their services has not yet been established. The aim of this online survey was to evaluate the impact of COVID-19 on nuclear medicine departments. Materials and Methods: A web-based questionnaire, made available from April 16 to May 3, 2020, was designed to determine the impact of the pandemic on in- and out-patient nuclear medicine departments; including the number of procedures, employee health, availability of radiotracers and other essential supplies, and availability of personal protective equipment (PPE). The survey also enquired about operational aspects and types of facilities, as well as other challenges. Results: A total of 434 responses from 72 countries were registered and analysed. Respondents reported an average decline of 54% in diagnostic procedures. Positron emission tomography / computed tomography (PET/CT) scans decreased by an average of 36%, while sentinel lymph-node procedures decreased by 45%, lung scans by 56%, bone scans by 60%, myocardial studies by 66%, and thyroid studies by 67%. Out of all participating centres, 81% perform radionuclide therapies, and they reported a reduction of 45% on average in the last four weeks, ranging from over 76% in Latin America and South East Asia to 16% in South Korea and Singapore. Survey results showed that 52% of participating sites limited their 99mTc/99Mo generator purchases and 12% of them temporarily cancelled orders. Insufficient supplies of essential materials (radioisotopes, generators, and kits) were reported, especially for 99mTc/99Mo generators and 131I, particularly in Africa, Asia, and Latin America. Conclusion: Both diagnostic and therapeutic nuclear medicine procedures declined precipitously with countries worldwide being affected by the pandemic to a similar degree. Countries that were in the post-peak phase of the pandemic when they responded to the survey, such as South Korea and Singapore reported a less pronounced impact on nuclear medicine services however, the overall results of the survey showed that nuclear medicine services worldwide had been significantly impacted. In relation to staff health, 15% of respondents experienced COVID-19 infections within their own departments. | 0161-5505,2159-662X | 2020-07-26 02:00:00+02:00 | pubmed | Journal of Nuclear Medicine | Lutz S Freudenberg;Diana Paez;Francesco Giammarile;Juliano Julio Cerci;Moshe Modiselle;Thomas N B Pascual;Noura El-Haj;Pilar Orellana;Ignasi Carrio;Stefano Fanti;Cristina Sebastiao Matushita;Yaroslav Pynda;Ken Herrmann | COVID-19;Other;PET/CT;Radionuclide Therapy;SPECT;global impact;nuclear medicine;survey | 2020-07-24 02:00:00+02:00 | 32709733 | FR;PT;BR;IT;ZA;ES;DE;PH;AT | ZRN Rheinland, Germany.;Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Austria.;QUANTA Diagnostico e Terapia, Brazil.;KVNR Nuclear and Molecular Medicine, South Africa.;Philippine Nuclear Research Institute, Philippines.;Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency n of Human Health, International Atomic Energy Agency, Austria.;Hospital de la Santa Creu i Sant Pau, Spain.;Department of Oncology, Division of Nuclear Medicine, University of Bologna, Italy.;Instituto do Cérebro do Rio Grande do Sul, Porto Alegre, Brazil, Brazil.;University Hospital Essen, Germany. | 1830 | |||
| 10.1016/s1473-3099(20)30461-8 | Journal Article;Review | en | Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential. | https://www.ncbi.nlm.nih.gov/pubmed/32717208 | Outbreaks of infectious diseases are occurring with increasing frequency and unpredictability. The rapid development and deployment of diagnostics that can accurately and quickly identify pathogens as part of epidemic preparedness is needed now for the COVID-19 pandemic. WHO has developed a global research and innovation forum to facilitate, accelerate, and deepen research collaboration among countries and funders. Great progress has been made in the past decade, but access to specimens remains a major barrier for the development and evaluation of needed quality diagnostics. We present a sustainable model for a global network of country-owned biobanks with standardised methods for collection, characterisation, and archiving of specimens and pathogens to facilitate and accelerate diagnostics development and evaluation for COVID-19 and other diseases of epidemic potential. The biobanking network should be run on the guiding principles of transparency, equitable access, ethics, and respect for national laws that support country ownership and sustainability. Adapting the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits, sharing of specimens from national biobanks can be rewarded through mechanisms such as equitable access to diagnostics at negotiated prices. Such networks should be prepared for any pathogen of epidemic potential. | 1473-3099 | 2020-07-26 02:00:00+02:00 | pubmed | The Lancet Infectious Diseases | Rosanna W Peeling;Debrah Boeras;Annelies Wilder-Smith;Amadou Sall;John Nkengasong | 2020-07-24 02:00:00+02:00 | 32717208 | FR;SN;GB;US;ET | Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: rosanna.peeling@lshtm.ac.uk.;Global Health Impact Group, Atlanta, GA, USA.;Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.;Institut Pasteur de Dakar, Dakar, Senegal.;Africa Centres for Disease Control and Prevention, Ethiopia. | 1835 | ||||
| Journal Article;Multicenter Study;Observational Study | en | Analysis of clinical characteristics and outcomes in patients with COVID-19 based on a series of 1000 patients treated in Spanish emergency departments. | https://www.ncbi.nlm.nih.gov/pubmed/32692000 | To describe the clinical characteristics of patients with coronavirus disease 2019 (COVID-19) treated in hospital emergency departments (EDs) in Spain, and to assess associations between characteristics and outcomes. | 2020-07-26 02:00:00+02:00 | pubmed | Adolescent;Adult;Age Distribution;Age Factors;Aged;Aged, 80 and over;Betacoronavirus;Cardiovascular Diseases__epidemiology;Child;Child, Preschool;Comorbidity;Coronavirus Infections__diagnosis;Emergency Service, Hospital__statistics & numerical data;Female;Hospital Mortality;Humans;Infant;Infant, Newborn;Intubation, Intratracheal__statistics & numerical data;Logistic Models;Male;Middle Aged;Neoplasms__epidemiology;Obesity__complications;Odds Ratio;Pandemics;Pneumonia, Viral__diagnosis;Prognosis;Prospective Studies;Respiration Disorders__epidemiology;Respiration, Artificial__statistics & numerical data;Sex Distribution;Spain__epidemiology;Symptom Assessment;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Adriana Gil-Rodrigo;Òscar Miró;Pascual Piñera;Guillermo Burillo-Putze;Sònia Jiménez;Alfonso Martín;Francisco Javier Martín-Sánchez;Javier Jacob;Josep María Guardiola;Eric Jorge García-Lamberechts;Begoña Espinosa;Enrique Martín Mojarro;Matilde González Tejera;Leticia Serrano;Carmen Agüera;Ester Soy;Lluís Llauger;María Ángeles Juan;Anna Palau;Carmen Del Arco;Belén Rodríguez Miranda;María Teresa Maza Vera;Alejandro Martín Quirós;Laura Tejada de Los Santos;Noemí Ruiz de Lobera;Marta Iglesias Vela;Raquel Torres Garate;Aitor Alquézar-Arbé;Juan González Del Castillo;Pere Llorens | COVID-19;Características clínicas;Clinical characteristics;Comorbidity;Comorbilidades;Coronavirus disease 2019 (COVID-19);Emergency health services;SARS-CoV-2;Servicios de urgencias;Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | 2020-07-22 02:00:00+02:00 | 32692000 | FR;ES;BG;BO | Servicio de Urgencias, Hospital General Universitario de Alicante, Universidad Miguel Hernández, Elche, Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), España.;Servicio de Urgencias, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, España.;Servicio de Urgencias, Hospital General Universitario Reina Sofía, Murcia, España.;Servicio de Urgencias, Hospital Universitario de Canarias, Tenerife, España.;Servicio de Urgencias, Hospital Universitario Severo Ochoa, Leganés, Madrid, España.;Servicio de Urgencias, Hospital Clínico San Carlos, IDISSC, Universidad Complutense, Madrid, España.;Servicio de Urgencias, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.;Servicio de Urgencias, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Servicio de Urgencias, Hospital Santa Tecla, Tarragona, España.;Servicio de Urgencias, Hospital General de Elche, Alicante, España.;Servicio de Urgencias, Hospital Politécnico La Fe, Valencia, España.;Servicio de Urgencias, Hospital Costa del Sol, Marbella, Málaga, España.;Servicio de Urgencias, Hospital Universitari Doctor Josep Trueta, Girona, España.;Servicio de Urgencias, Hospital Universitari de Vic, Barcelona, España.;Servicio de Urgencias, Hospital Doctor Peset, Valencia, España.;Servicio de Urgencias, Hospital Universitari Joan XXIII, Tarragona, España.;Servicio de Urgencias, Hospital La Princesa, Madrid, España.;Servicio de Urgencias, Hospital Rey Juan Carlos, Madrid, España.;Servicio de Urgencias, Complejo Hospitalario Universitario de Vigo. Hospital Álvaro Cunqueiro de Vigo, Pontevedra, España.;Servcio de Urgencias, Hospital Universitario La Paz, Madrid, España.;Servicio de Urgencias, Complejo Asistencial de Soria, España.;Servicio de Urgencias, Hospital San Pedro, Logroño, España.;Servicio de Urgencias, Hospital de León, España. | 1851 | |||||
| 10.1016/j.cmi.2020.07.030 | Journal Article | en | CT lung lesions as predictors of early death or ICU admission in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32717417 | The main objective of this study was to investigate the prognostic value of early systematic chest computed tomography (CT) with quantification of lung lesions in coronavirus disease 2019 (COVID-19) patients. | 1198-743X | 2020-07-26 02:00:00+02:00 | pubmed | Clinical Microbiology and Infection | Yvon Ruch;Charlotte Kaeuffer;Mickael Ohana;Aissam Labani;Thibaut Fabacher;Pascal Bilbault;Sabrina Kepka;Morgane Solis;Valentin Greigert;Nicolas Lefebvre;Yves Hansmann;François Danion | COVID-19;Computed tomography;Coronavirus;Ground-glass opacities;Visual quantification | 2020-07-24 02:00:00+02:00 | 32717417 | FR | Department of Infectious Disease, Strasbourg University Hospital, Strasbourg, France. Electronic address: yvon.ruch@chru-strasbourg.fr.;Department of Infectious Disease, Strasbourg University Hospital, Strasbourg, France.;Department of Radiology, Strasbourg University Hospital, Strasbourg, France.;Department of Biostatistics, Strasbourg University Hospital, Strasbourg, France.;Department of Emergency Medicine, Strasbourg University Hospital, Strasbourg, France.;Department of Virology, Strasbourg University Hospital, Strasbourg, France. | 1866 | |||
| 10.3389/fimmu.2020.01841 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32793246 | Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a betacoronavirus, and is associated with cytokine storm inflammation and lung injury, leading to respiratory distress. The transmission of the virus is mediated by human contact. To control and prevent the spread of this virus, the majority of people worldwide are facing quarantine; patients are being subjected to non-specific treatments under isolation. To prevent and stop the COVID-19 pandemic, several clinical trials are in the pipeline. The current clinical trials either target the intracellular replication and spread of the virus or the cytokine storm inflammation seen in COVID-19 cases during the later stages of the disease. Since both targeting strategies are different, the window drug administration plays a crucial role in the efficacy of the treatment. Here, we review the mechanism underlying SARS-CoV-2 cell infection and potential future therapeutic approaches. | 1664-3224 | 2020-07-26 02:00:00+02:00 | pubmed | Anti-Inflammatory Agents__therapeutic use;Antibodies, Viral__therapeutic use;Anticoagulants__therapeutic use;Antiviral Agents__therapeutic use;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Cytokine Release Syndrome__drug therapy;Humans;Pandemics__prevention & control;Pneumonia, Viral__drug therapy;Quarantine__methods;Respiratory Insufficiency__therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Frontiers in Immunology | Abdelouaheb Benani;Sanae Ben Mkaddem | COVID-19;SARS-CoV-2;cytokine treatment;immune therapy;monoclonal antibody;respiratory distress | 2020-07-21 02:00:00+02:00 | 32793246 | FR;MA | Unité de Biologie Moléculaire, Institut Pasteur du Maroc, Casablanca, Morocco.;U978 Institut National de la Santé et de la Recherche Médicale, Bobigny, France.;UFR SMBH, Université Sorbonne Paris Nord, Bobigny, France. | 1871 | ||
| Clinical Trial Protocol;Letter;Multicenter Study | en | Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial. | https://www.ncbi.nlm.nih.gov/pubmed/32690074 | To assess the efficacy of local intranasal treatment with budesonide (nasal irrigation), in addition to olfactory rehabilitation, in the management of loss of smell in COVID-19 patients without signs of severity and with persistent hyposmia 30 days after the onset of symptoms. To search for an association between the presence of an obstruction on MRI and the severity of olfactory loss, at inclusion and after 30 days of treatment. | 2020-07-26 02:00:00+02:00 | pubmed | Betacoronavirus;Budesonide__administration & dosage;Coronavirus Infections__complications;Humans;Olfaction Disorders__drug therapy;Pandemics;Pneumonia, Viral__complications;Randomized Controlled Trials as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Mary Daval;Alain Corré;Clement Palpacuer;Juliette Housset;Guillaume Poillon;Michael Eliezer;Benjamin Verillaud;Dorsaf Slama;Denis Ayache;Philippe Herman;Clement Jourdaine;Camille Hervé;Wissame El Bakkouri;Dominique Salmon;Charlotte Hautefort | COVID-19;MRI;Randomised controlled trial;budesonide;corticosteroid;dysgeusia;hyposmia;nasal irrigation;rotocol | 2020-07-20 02:00:00+02:00 | 32690074 | FR | Hopital Fondation Adolphe de Rothschild, Paris, France. mdaval@for.paris.;Hopital Fondation Adolphe de Rothschild, Paris, France.;Hopital Lariboisiere, Paris, France.;Hotel Dieu Hospital, Paris, France. | 1880 | |||||
| 10.1007/s12571-020-01087-y | Journal Article | en | COVID-19 and Pacific food system resilience: opportunities to build a robust response. | https://www.ncbi.nlm.nih.gov/pubmed/32837656 | The unfolding COVID-19 pandemic has exposed the vulnerability of the Pacific food system to externalities and has had far-reaching impacts, despite the small number of COVID-19 cases recorded thus far. Measures adopted to mitigate risk from the pandemic have had severe impacts on tourism, remittances, and international trade, among other aspects of the political economy of the region, and are thus impacting on food systems, food security and livelihoods. Of particular concern will be the interplay between loss of incomes and the availability and affordability of local and imported foods. In this paper, we examine some of the key pathways of impact on food systems, and identify opportunities to strengthen Pacific food systems during these challenging times. The great diversity among Pacific Island Countries and Territories in their economies, societies, and agricultural potential will be an important guide to planning interventions and developing scenarios of alternative futures. Bolstering regional production and intraregional trade in a currently import-dependent region could strengthen the regional economy, and provide the health benefits of consuming locally produced and harvested fresh foods - as well as decreasing reliance on global supply chains. However, significant production, processing, and storage challenges remain and would need to be consistently overcome to influence a move away from shelf-stable foods, particularly during periods when human movement is restricted and during post-disaster recovery. | 1876-4517,1876-4525 | 2020-07-26 02:00:00+02:00 | pubmed | Food Security | Penny Farrell;Anne Marie Thow;Jillian Tutuo Wate;Nichol Nonga;Penina Vatucawaqa;Tom Brewer;Michael K Sharp;Anna Farmery;Helen Trevena;Erica Reeve;Hampus Eriksson;Itziar Gonzalez;Georgina Mulcahy;Jacob G Eurich;Neil L Andrew | COVID-19, pandemic;Food security;Food systems;Pacific;Policy | 2020-07-20 02:00:00+02:00 | 32837656 | FJ;FR;US;SB;AU | Menzies Centre for Health Policy, Level 2, Charles Perkins Centre (D17), Sydney School of Public Health, The University of Sydney, Sydney, NSW 2006 Australia.;WorldFish, Honiara, Solomon Islands.;Food and Agriculture Organization of the United Nations (FAO), Honiara, Solomon Islands.;Food and Agriculture Organization of the United Nations (FAO), Suva, Fiji.;Australian National Centre for Ocean Resources and Security, University of Wollongong, Wollongong, Australia.;Pacific Community, Noumea, New Caledonia.;Global Obesity Centre, Institute for Health Transformation, Faculty of Health, Deakin University, Geelong, Australia.;Marine Science Institute, University of California Santa Barbara, Santa Barbara, CA USA.;Department of Ecology, Evolution and Marine Biology, University of California, Santa Barbara, Santa Barbara, CA USA. | 1887 | |||
| Letter | fr | [Is SARS-CoV-2 also attacking the French language?] | https://www.ncbi.nlm.nih.gov/pubmed/32768268 | 2020-07-26 02:00:00+02:00 | pubmed | E Andrès;P Pessaux | Covid-19;SARS-CoV-2;Sémiologie | 2020-07-22 02:00:00+02:00 | 32768268 | FR | Service de Médecine Interne, Diabète et Maladies métaboliques, Hôpitaux Universitaires de Strasbourg, 67084, France. Electronic address: emmanuel.andres@chu-strasbourg.fr.;Service de Chirurgie Digestive, Hôpitaux Universitaires de Strasbourg, France. | 1897 | |||||||
| 10.1111/bcp.14486 | Journal Article | en | Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32693436 | We hypothesized that viral kinetic modelling could be helpful to prioritize rational drug combinations for COVID-19. The aim of this research was to use a viral cell cycle model of SARS-CoV-2 to explore the potential impact drugs, or combinations of drugs, that act at different stages in the viral life cycle might have on various metrics of infection outcome relevant in the early stages of COVID-19 disease. | 0306-5251,1365-2125 | 2020-07-26 02:00:00+02:00 | pubmed | British Journal of Clinical Pharmacology | Michael G Dodds;Rajesh Krishna;Antonio Goncalves;Craig R Rayner | COVID-19;combination therapy;modelling;repurposing;viral cell cycle | 2020-07-21 02:00:00+02:00 | 32693436 | FR;AU;US | Certara, USA Inc., Princeton, NJ.;Université de Paris, IAME, INSERM, Paris, France.;Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia. | 1899 | |||
| Letter | en | Monitoring of high-flow nasal cannula for SARS-CoV-2 severe pneumonia: less is more, better look at respiratory rate. | https://www.ncbi.nlm.nih.gov/pubmed/32737522 | 2020-08-02 02:00:00+02:00 | pubmed | Damien Blez;Anne Soulier;Francis Bonnet;Etienne Gayat;Marc Garnier | 2020-07-31 02:00:00+02:00 | 32737522 | FR | GRC 29, APHP.6, DMU DREAM, Anesthesiology and Critical Care Department, Saint-Antoine Hospital, Sorbonne University, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.;APHP.7, DMU PARABOL, Anesthesiology and Intensive Care Department, Lariboisière Hospital, Paris University, Paris, France.;GRC 29, APHP.6, DMU DREAM, Anesthesiology and Critical Care Department, Saint-Antoine Hospital, Sorbonne University, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. marc.garnier@aphp.fr. | 1916 | ||||||||
| 10.3390/pathogens9080627 | Journal Article | en | Objective Olfactory Findings in Hospitalized Severe COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32752123 | We investigate the prevalence of the self-reported and objective sudden loss of smell (SLS) in patients with severe coronavirus disease 2019 (COVID-19). | 2076-0817 | 2020-08-02 02:00:00+02:00 | pubmed | Pathogens | Jerome R Lechien;Morgane Ducarme;Sammy Place;Carlos M Chiesa-Estomba;Mohamad Khalife;Giacomo De Riu;Luigi Angelo Vaira;Christophe de Terwangne;Shahram Machayekhi;Arnaud Marchant;Fabrice Journe;Sven Saussez | COVID-19;anosmia;coronavirus;olfactory;severe;smell | 2020-07-31 02:00:00+02:00 | 32752123 | FR;IT;BE;ES | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), F92150 Paris, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), B7000 Mons, Belgium.;Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), F92150 Paris, France.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, B1000 Brussels, Belgium.;Department of Surgery, EpiCURA Hospital, B7000 Hornu, Belgium.;Department of Internal Medicine, EpiCURA Hospital, B7000 Baudour, Belgium.;Department of Otorhinolaryngology-Head & Neck Surgery, Hospital Universitario Donostia, 00685 San Sebastian, Spain.;Department of Otolaryngology-Head & Neck Surgery, EpiCURA Hospital, B7000 Baudour, Belgium.;Maxillofacial Surgery Unit, University Hospital of Sassari, 07100 Sassari, Italy.;Department of Intensive Care, EpiCURA Hospital, B7000 Hornu, Belgium.;Institute for Medical Immunology, Université libre de Bruxelles, B1000 Brussels, Belgium. | 1918 | |||
| 10.1016/j.ohx.2020.e00130 | Journal Article | en | Open source high-temperature RepRap for 3-D printing heat-sterilizable PPE and other applications. | https://www.ncbi.nlm.nih.gov/pubmed/32838090 | Thermal sterilization is generally avoided for 3-D printed components because of the relatively low deformation temperatures for common thermoplastics used for material extrusion-based additive manufacturing. 3-D printing materials required for high-temperature heat sterilizable components for COVID-19 and other applications demands 3-D printers with heated beds, hot ends that can reach higher temperatures than polytetrafluoroethylene (PTFE) hot ends and heated chambers to avoid part warping and delamination. There are several high temperature printers on the market, but their high costs make them inaccessible for full home-based distributed manufacturing required during pandemic lockdowns. To allow for all these requirements to be met for under $1,000, the Cerberus - an open source three-headed self-replicating rapid prototyper (RepRap) was designed and tested with the following capabilities: i) 200°C-capable heated bed, ii) 500°C-capable hot end, iii) isolated heated chamber with 1kW space heater core and iv) mains voltage chamber and bed heating for rapid start. The Cereberus successfully prints polyetherketoneketone (PEKK) and polyetherimide (PEI, ULTEM) with tensile strengths of 77.5 and 80.5 MPa, respectively. As a case study, open source face masks were 3-D printed in PEKK and shown not to warp upon widely home-accessible oven-based sterilization. | 2468-0672 | 2020-08-02 02:00:00+02:00 | pubmed | HardwareX | Noah G Skrzypczak;Nagendra G Tanikella;Joshua M Pearce | 3-D printing;COVID-19;RepRap;ULTEM;additive manufacturing;high temperature 3-D printing;medical hardware;open hardware;open source;open source medical hardware;polycarbonate | 2020-07-30 02:00:00+02:00 | 32838090 | FI;FR;US | Mechanical Engineering - Engineering Mechanics, Michigan Technological University, USA.;Department of Materials Science & Engineering, Michigan Technological University, USA.;Department of Electrical & Computer Engineering, Michigan Technological University, USA.;Équipe de Recherche sur les Processus Innovatifs (ERPI), Université de Lorraine, France.;School of Electrical Engineering, Aalto University, Finland. | 1925 | |||
| 10.1136/bmj.m2980 | Comparative Study;Journal Article;Research Support, Non-U.S. Gov't;Systematic Review | en | Drug treatments for covid-19: living systematic review and network meta-analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32732190 | To compare the effects of treatments for coronavirus disease 2019 (covid-19). | 1756-1833 | 2020-08-02 02:00:00+02:00 | pubmed | Adenosine Monophosphate__analogs & derivatives;Alanine__analogs & derivatives;Antiviral Agents__therapeutic use;Betacoronavirus__isolation & purification;Centers for Disease Control and Prevention, U.S.__statistics & numerical data;China__epidemiology;Coronavirus Infections__diagnosis;Databases, Factual__statistics & numerical data;Drug Combinations;Evidence-Based Medicine__methods;Glucocorticoids__therapeutic use;Humans;Hydroxychloroquine__therapeutic use;Lopinavir__therapeutic use;Network Meta-Analysis;Pandemics;Pneumonia, Viral__diagnosis;Randomized Controlled Trials as Topic;Respiration, Artificial__statistics & numerical data;Ritonavir__therapeutic use;Severity of Illness Index;Standard of Care;Treatment Outcome;United States__epidemiology;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | BMJ | Reed Ac Siemieniuk;Jessica J Bartoszko;Long Ge;Dena Zeraatkar;Ariel Izcovich;Hector Pardo-Hernandez;Bram Rochwerg;Francois Lamontagne;Mi Ah Han;Elena Kum;Qin Liu;Arnav Agarwal;Thomas Agoritsas;Paul Alexander;Derek K Chu;Rachel Couban;Andrea Darzi;Tahira Devji;Bo Fang;Carmen Fang;Signe Agnes Flottorp;Farid Foroutan;Diane Heels-Ansdell;Kimia Honarmand;Liangying Hou;Xiaorong Hou;Quazi Ibrahim;Mark Loeb;Maura Marcucci;Shelley L McLeod;Sharhzad Motaghi;Srinivas Murthy;Reem A Mustafa;John D Neary;Anila Qasim;Gabriel Rada;Irbaz Bin Riaz;Behnam Sadeghirad;Nigar Sekercioglu;Lulu Sheng;Charlotte Switzer;Britta Tendal;Lehana Thabane;George Tomlinson;Tari Turner;Per O Vandvik;Robin Wm Vernooij;Andrés Viteri-García;Ying Wang;Liang Yao;Zhikang Ye;Gordon H Guyatt;Romina Brignardello-Petersen | 2020-07-30 02:00:00+02:00 | 32732190 | FR;AR;NO;CA;UNK;CN;CL;CH;US;GB;AU;NL;EC;ES;KR | Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada reed.siemieniuk@medportal.ca.;Joint first authors.;Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada.;Evidence Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, Gansu, China.;Servicio de Clinica Médica del Hospital Alemán, Buenos Aires, Argentina.;Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain.;CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.;Department of Medicine, McMaster University, Hamilton, ON, Canada.;Department of Medicine and Centre de recherche du CHU de Sherbrooke, Sherbrooke, Quebec, Canada.;Department of Preventive Medicine, College of Medicine, Chosun University, Gwangju, Republic of Korea.;Cochrane China Network Affiliate, Chongqing Medical University, Chongqing, China.;School of Public Health and Management, Chongqing Medical University, Chongqing, China.;Department of Medicine, University of Toronto, Toronto, ON, Canada.;Division of General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland.;Department of Anesthesia, McMaster University, Hamilton, ON, Canada.;William Osler Health Network, Toronto, ON, Canada.;Norwegian Institute of Public Health, Oslo, Norway.;Institute of Health and Society, University of Oslo, Oslo, Norway.;Ted Rogers Center for Heart Research, Toronto General Hospital, ON, Canada.;College of Medical Informatics, Chongqing Medical University, Chongqing, China.;Schwartz/Reisman Emergency Medicine Institute, Sinai Health, Toronto, ON, Canada.;Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.;Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.;Department of Medicine, University of Kansas Medical Center, Kansas City, MO, USA.;Epistemonikos Foundation, Santiago, Chile.;UC Evidence Center, Cochrane Chile Associated Center, Pontificia Universidad Católica de Chile, Santiago, Chile.;Hematology and Oncology, Mayo Clinic Rochester, Rochester, MN, USA.;School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia.;Department of Medicine, University Health Network, Toronto, ON, Canada.;Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, Netherlands.;Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.;Centro de Investigación de Salud Pública y Epidemiología Clínica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador. | 1926 | |||
| Letter | en | Pulmonary embolism in patients with COVID-19 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32398297 | 2020-08-02 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Contrast Media;Coronavirus Infections__complications;Critical Care;Female;Fibrin Fibrinogen Degradation Products__analysis;Humans;Incidence;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Pulmonary Embolism__complications;Retrospective Studies;Tomography, X-Ray Computed;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Florian Bompard;Hippolyte Monnier;Ines Saab;Mickael Tordjman;Hendy Abdoul;Laure Fournier;Olivier Sanchez;Christine Lorut;Guillaume Chassagnon;Marie-Pierre Revel | 2020-07-30 02:00:00+02:00 | 32398297 | FR | Dept of Radiology, Cochin Hospital, AP-HP Centre, Paris, France.;Dept of Radiology, Hôpital Européen Georges-Pompidou, AP-HP Centre, Paris, France.;Université de Paris, Descartes-Paris 5, Paris, France.;Unité de Recherche Clinique Centre d'Investigation Clinique, Paris Descartes Necker/Cochin, Hôpital Tarnier, Paris, France.;Dept of Pulmonology and Intensive Care, Hôpital Européen Georges-Pompidou, AP-HP Centre, Paris, France.;Dept of Pulmonology, Cochin Hospital, AP-HP Centre, Paris, France.;Dept of Radiology, Cochin Hospital, AP-HP Centre, Paris, France marie-pierre.revel@aphp.fr. | 1930 | |||||||
| 10.1080/00015385.2020.1796035 | Journal Article | en | Impact of COVID-19-related public containment measures on the ST elevation myocardial infarction epidemic in Belgium: a nationwide, serial, cross-sectional study. | https://www.ncbi.nlm.nih.gov/pubmed/32727305 | The current study assessed the impact of COVID-19-related public containment measures (i.e. lockdown) on the ST elevation myocardial infarction (STEMI) epidemic in Belgium. | 0001-5385,0373-7934 | 2020-08-02 02:00:00+02:00 | pubmed | Acta Cardiologica | Marc J Claeys;Jean-François Argacha;Philippe Collart;Marc Carlier;Olivier Van Caenegem;Peter R Sinnaeve;Walter Desmet;Philippe Dubois;Francis Stammen;Sofie Gevaert;Suzanne Pourbaix;Patrick Coussement;Christophe Beauloye;Patrick Evrard;Olivier Brasseur;Frans Fierens;Patrick Marechal;Dan Schelfaut;Vincent Floré;Claude Hanet | COVID-19;PCI;STEMI;containment;mortality;pollution | 2020-07-30 02:00:00+02:00 | 32727305 | FR;BE | Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium.;Department of Cardiology, University Hospital Brussels, Brussels, Belgium.;Centre de recherche en Epidémiologie, Biostatistiques et Recherche Clinique, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium.;Department of Cardiology, GHDC, Charleroi, Belgium.;Division of Cardiovascular Intensive Care, Cliniques universitaires Saint Luc, Brussels, Belgium.;Department of Cardiology, University Hospital Leuven, Leuven, Belgium.;Department of Cardiology, CHU, Charleroi, Belgium.;Department of Cardiology, Hospital Roeselare, Roeselare, Belgium.;Department of Cardiology, Ghent University Hospital, Ghent, Belgium.;Department of Cardiology, CHR Citadelle Liège, Liège, Belgium.;Department of Cardiology, Hospital Sint-Jan Brugge, Brugge, Belgium.;Division of Cardiology and Pole of Cardiovascular Research, Institut de Recherche Experimentale et Clinique, Cliniques universitaires Saint Luc, Brussels, Belgium.;Department of Intensive Care, Belgium Catholic University Hospital Mont-Godinne, Brussels, Belgium.;Laboratory of Environmental Research, Brussels Environment, Brussels, Belgium.;Belgian Interregional Environment Agency, Brussels, Belgium.;Department of Cardiology, University hospital of Liege, Liège, Belgium.;Department of Cardiology, OLV Aalst, Aalst, Belgium.;Department of Cardiology, Hospital Maria Middelares, Ghent, Belgium.;Department of Cardiology, Catholic University Hospital Mont-Godinne, Brussels, Belgium. | 1931 | |||
| 10.1016/j.radcr.2020.07.071 | Case Reports | en | Use of chest CT-scan images to differentiate between SARS-CoV-2 infection and fat embolism: a clinical case. | https://www.ncbi.nlm.nih.gov/pubmed/32837669 | The authors present the case of a young man victim of a traffic accident during the SARS-CoV-2 confinement, having presented a fracture of the femoral shaft that was soon complicated by respiratory failure with oxygen desaturation. In this pandemic context, Covid-19 RT-PCR tests were carried out but returned negative. The CT images could suggest either a fatty embolism, a SARS-CoV-2 infection or both. The patient's condition improved significantly after going into intensive care and only symptomatic treatment. This case demonstrates the difficulty of differential interpretation of CT images between fatty embolism and SARS-CoV-2 infection. | 1930-0433 | 2020-08-02 02:00:00+02:00 | pubmed | Radiology Case Reports | Penance Agbelele;François Vanmaris;Mario Sanguina;Bachar Zerkly;Az-Eddine Djebara;Pierre Girard | SARS-CoV-2;Thoracic CT-scan;differential diagnosis;fat embolism | 2020-07-30 02:00:00+02:00 | 32837669 | FR | Orthopedic Surgery and Traumatology Department, South Oise Hospital Group, 60100, Creil, France.;Medical Imaging Department, South Oise Hospital Group, 60100, Creil, France.;Orthopedic Surgery and Traumatology Department, University Hospital of Amiens-Picardy, 80480, Salouel, France. | 1933 | |||
| 10.1016/j.diabet.2020.07.006 | Journal Article | en | Metformin and COVID-19: From cellular mechanisms to reduced mortality. | https://www.ncbi.nlm.nih.gov/pubmed/32750451 | Type 2 diabetes mellitus (T2DM) is associated with both poorer clinical outcomes during the COVID-19 pandemic and an increased risk of death in such hospitalized patients. While the role of glucose control has been emphasized to improve the prognosis, the impact of different glucose-lowering agents remains largely unknown. Metformin remains the first-line pharmacological choice for the management of hyperglycaemia in T2DM. Because metformin exerts various effects beyond its glucose-lowering action, among which are anti-inflammatory effects, it may be speculated that this biguanide might positively influence the prognosis of patients with T2DM hospitalized for COVID-19. The present concise review summarizes the available data from observational retrospective studies that have shown a reduction in mortality in metformin users compared with non-users, and briefly discusses the potential underlying mechanisms that might perhaps explain this favourable impact. However, given the potential confounders inherently found in observational studies, caution is required before drawing any firm conclusions in the absence of randomized controlled trials. | 1262-3636 | 2020-08-02 02:00:00+02:00 | pubmed | Diabetes & Metabolism | A J Scheen | Inflammation;Meta-analysis;Metformin;Mortality;SARS-CoV-2;Type 2 diabetes | 2020-08-01 02:00:00+02:00 | 32750451 | FR;BE | Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, and Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium. Electronic address: andre.scheen@chuliege.be. | 1948 | |||
| 10.1016/j.jcv.2020.104573 | Journal Article | en | Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32769025 | RT-PCR testing is crucial in the diagnostic of SARS-CoV-2 infection. The use of reliable and comparable PCR assays is a cornerstone to allow use of different PCR assays depending on the local equipment. In this work, we provide a comparison of the Cobas® (Roche) and the RealStar® assay (Altona). | 1386-6532 | 2020-08-02 02:00:00+02:00 | pubmed | Journal of Clinical Virology | Marc Wirden;Linda Feghoul;Mélanie Bertine;Marie-Laure Nere;Quentin Le Hingrat;Basma Abdi;David Boutolleau;Valentine Marie Ferre;Aude Jary;Constance Delaugerre;Anne-Genevieve Marcelin;Diane Descamps;Jérôme Legoff;Benoit Visseaux;Marie-Laure Chaix | Altona;COVID-19;Cobas 6800;RT-PCR;SARS-CoV-2 | 2020-07-31 02:00:00+02:00 | 32769025 | FR | Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France.;Université de Paris, Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Paris, France, INSERM UMR 976, Université de Paris, Paris, France.;Université de Paris, Assistance Publique - Hôpitaux de Paris, Service de virologie, Hôpital Bichat, Paris, France, UMR 1137-IAME, DeSCID: Decision SCiences in Infectious Diseases control and care, INSERM, Université de Paris, Paris, France.;Université de Paris, Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Paris, France.;Université de Paris, Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Paris, France, INSERM UMR 944, Université de Paris, Paris, France.;Université de Paris, Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Paris, France, INSERM UMR 944, Université de Paris, Paris, France. Electronic address: marie-laure.chaix@aphp.fr. | 1960 | |||
| Letter | en | Helping nursing homes to manage the COVID-19 crisis: an illustrative example from France. | https://www.ncbi.nlm.nih.gov/pubmed/32722843 | 2020-08-02 02:00:00+02:00 | pubmed | Amal Aïdoud;Pierre Poupin;Wassim Gana;Jacques-Alexis Nkodo;Camille Debacq;Sophie Dubnitskiy-Robin;Bertrand Fougère | Crisis management;Decision support, clinical;Healthcare quality improvement;Infection control;Medical homes | 2020-07-28 02:00:00+02:00 | 32722843 | FR | Division of Geriatric Medicine, Tours University Hospital, Tours, France.;Education, Ethics, Health (EA 7505), Tours University, Tours, France. | 1970 | |||||||
| 10.1007/s40262-020-00924-9 | Journal Article;Review | en | Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. | https://www.ncbi.nlm.nih.gov/pubmed/32725382 | There is an urgent need to identify optimal antiviral therapies for COVID-19 caused by SARS-CoV-2. We have conducted a rapid and comprehensive review of relevant pharmacological evidence, focusing on (1) the pharmacokinetics (PK) of potential antiviral therapies; (2) coronavirus-specific pharmacodynamics (PD); (3) PK and PD interactions between proposed combination therapies; (4) pharmacology of major supportive therapies; and (5) anticipated drug-drug interactions (DDIs). We found promising in vitro evidence for remdesivir, (hydroxy)chloroquine and favipiravir against SARS-CoV-2; potential clinical benefit in SARS-CoV-2 with remdesivir, the combination of lopinavir/ritonavir (LPV/r) plus ribavirin; and strong evidence for LPV/r plus ribavirin against Middle East Respiratory Syndrome (MERS) for post-exposure prophylaxis in healthcare workers. Despite these emerging data, robust controlled clinical trials assessing patient-centred outcomes remain imperative and clinical data have already reduced expectations with regard to some drugs. Any therapy should be used with caution in the light of potential drug interactions and the uncertainty of optimal doses for treating mild versus serious infections. | 0312-5963,1179-1926 | 2020-08-02 02:00:00+02:00 | pubmed | Clinical Pharmacokinetics | Markus Zeitlinger;Birgit C P Koch;Roger Bruggemann;Pieter De Cock;Timothy Felton;Maya Hites;Jennifer Le;Sonia Luque;Alasdair P MacGowan;Deborah J E Marriott;Anouk E Muller;Kristina Nadrah;David L Paterson;Joseph F Standing;João P Telles;Michael Wölfl-Duchek;Michael Thy;Jason A Roberts | 2020-07-28 02:00:00+02:00 | 32725382 | FR;SI;GB;US;BR;AU;NL;ES;BE;AT | Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. markus.zeitlinger@meduniwien.ac.at.;Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands.;Radboud University Medical Center, Nijmegen, The Netherlands.;Department of Pharmacy 2, Heymans Institute of Pharmacology, Ghent University Hospital, Ghent University, Ghent, Belgium.;Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.;Intensive Care Unit, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.;Clinic of Infectious Diseases, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.;Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA.;Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain.;Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar D'Investigacions Mèdiques (IMIM), Barcelona, Spain.;Bristol Centre for Antimicrobial Research and Evaluation, Infection Sciences, Severn Pathology Partnership, North Bristol NHS Trust, Southmead Hospital, Westbury-On-Trym, Bristol, UK.;St. Vincent's Hospital, Darlinghurst, NSW, Australia.;University of New South Wales, Sydney, NSW, Australia.;HaaglandenMC, The Hague and ErasmusMC, Rotterdam, The Netherlands.;Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.;Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.;Infection, Inflammation and Immunity, Great Ormond Street Institute of Child Health, University College London, London, UK.;Department of Pharmacy, Great Ormond Street Hospital for Children, London, UK.;Department of Infectious Diseases, AC Camargo Cancer Center, São Paulo, SP, Brazil.;Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.;Infectious Diseases Department and Intensive Care Unit, Hospital Bichat, Paris, France.;EA7323, Evaluation of Perinatal and Paediatric Therapeutics and Pharmacology, University Paris Descartes, Paris, France.;University of Queensland Centre for Clinical Research, Faculty of Medicine and Centre for Translational Anti-Infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia. j.roberts2@uq.edu.au.;Department of Pharmacy, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. j.roberts2@uq.edu.au.;Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. j.roberts2@uq.edu.au.;Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France. j.roberts2@uq.edu.au.;The University of Queensland Centre for Clinical Research, The University of Queensland, Royal Brisbane and Women's Hospital, Butterfield St, Herston, QLD, 4029, Australia. j.roberts2@uq.edu.au. | 1987 | ||||
| Letter | en | SARS-CoV-2 Tackles the Tobacco Industry: Comment on "Tobacco Industry Interference Index: Implementation of the World Health Organization's Framework Convention on Tobacco Control Article 5.3 in India". | https://www.ncbi.nlm.nih.gov/pubmed/32723082 | 2020-08-02 02:00:00+02:00 | pubmed | Frédéric Dutheil;Hijrah Nasir;Valentin Navel | 2020-07-29 02:00:00+02:00 | 32723082 | FR | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Clermont-Ferrand, France.;Université Clermont Auvergne, Economic Development, Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, Clermont-Ferrand, France. | 1991 | ||||||||
| 10.1016/j.annonc.2020.07.010 | Practice Guideline | en | Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus. | https://www.ncbi.nlm.nih.gov/pubmed/32745693 | We established an international consortium to discuss clinical evidence and to provide expert advice on statements related to cancer management during COVID-19 pandemics. The steering committee prepared ten working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology, statements have been discussed and voted upon. When consensus could not be reached, the panel revised statements in order to develop consensual clinical guidance. The expert panel agreed on 28 statements that can be used to overcome many of the clinical and technical areas of uncertainty ranging from diagnosis to therapeutic planning. | 0923-7534 | 2020-08-02 02:00:00+02:00 | pubmed | Annals of Oncology | G Curigliano;S Banerjee;A Cervantes;M Garassino;P Garrido;N Girard;J Haanen;K Jordan;F Lordick;J P Machiels;O Michielin;S Peters;J Tabernero;J Y Douillard;G Pentheroudakis | 2020-07-29 02:00:00+02:00 | 32745693 | FR;GR;GB;CH;IT;NL;ES;BE;PS;DE | Department of Medicine, Division of Early Drug Development, European Institute of Oncology, Milan, Italy. Electronic address: clinicalguidelines@esmo.org.;Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Division of Clinical Studies, The Institute of Cancer Research, London UK.;Department of Medical Oncology, Biomedical Research Institute, INCLIVA, University of Valencia, Valencia, Spain, Hematology and Medical Oncology, CIBERONC Instituto de Salud Carlos III, Madrid, Spain.;Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Medical Oncology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain.;Thoracic Oncology, Université de Lyon, Université Claude Bernard Lyon, Lyon, France, Thoracic Surgery, Département Oncologie Médicale, Institut Curie, Paris, France.;Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.;Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.;Department of Hematology and Medical Oncology, University Cancer Center Leipzig, University Leipzig, Leipzig, Germany.;Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.;Department of Oncology, University Hospital Lausanne, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, Lausanne, Switzerland.;Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.;Department of Medical Oncology, Centre René Gauducheau, Nantes, France.;Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece. | 1992 | ||||
| Letter | en | Protecting healthcare providers from COVID-19 through a large simulation training programme. | https://www.ncbi.nlm.nih.gov/pubmed/32828493 | 2020-08-09 02:00:00+02:00 | pubmed | Clément Buléon;Rebecca D Minehart;Marc-Olivier Fischer | COVID-19;Peyton's approach;airway management;crisis management;preparedness;simulation;training | 2020-08-05 02:00:00+02:00 | 32828493 | FR;US | Department of Anaesthesiology, Intensive Care and Perioperative Medicine, Caen Normandy University Hospital, Caen, France, Medical School, University of Caen Normandy, Caen, France. Electronic address: buleon-c@chu-caen.fr.;Department of Anaesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA, Harvard Medical School, Boston, MA, USA.;Department of Anaesthesiology, Intensive Care and Perioperative Medicine, Caen Normandy University Hospital, Caen, France, Medical School, University of Caen Normandy, Caen, France. | 2015 | |||||||
| Letter | en | Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers. | https://www.ncbi.nlm.nih.gov/pubmed/32781366 | 2020-08-09 02:00:00+02:00 | pubmed | Marion Migueres;Catherine Mengelle;Chloé Dimeglio;Alain Didier;Muriel Alvarez;Pierre Delobel;Jean-Michel Mansuy;Jacques Izopet | 2020-08-05 02:00:00+02:00 | 32781366 | FR | Department of Virology, CHU Purpan, Toulouse, France, INSERM UMR1043/CNRS UMR5282, Center for Pathophysiology of Toulouse Purpan, France, Toulouse III University Paul Sabatier, Toulouse, France. Electronic address: migueres.m@chu-toulouse.fr.;Department of Virology, CHU Purpan, Toulouse, France.;Department of Virology, CHU Purpan, Toulouse, France, INSERM UMR1043/CNRS UMR5282, Center for Pathophysiology of Toulouse Purpan, France, Toulouse III University Paul Sabatier, Toulouse, France.;Department of Pulmonology, CHU Toulouse, France.;Department of Tropical and Infectious Diseases, CHU Toulouse, France.;INSERM UMR1043/CNRS UMR5282, Center for Pathophysiology of Toulouse Purpan, France, Toulouse III University Paul Sabatier, Toulouse, France, Department of Tropical and Infectious Diseases, CHU Toulouse, France. | 2017 | ||||||||
| 10.1371/journal.pone.0237296 | Journal Article;Research Support, Non-U.S. Gov't | en | COVID-19-related perceptions, context and attitudes of adults with chronic conditions: Results from a cross-sectional survey nested in the ComPaRe e-cohort. | https://www.ncbi.nlm.nih.gov/pubmed/32760127 | To avoid a surge of demand on the healthcare system due to the COVID-19 pandemic, we must reduce transmission to individuals with chronic conditions who are at risk of severe illness with COVID-19. We aimed at understanding the perceptions, context and attitudes of individuals with chronic conditions during the COVID-19 pandemic to clarify their potential risk of infection. | 1932-6203 | 2020-08-09 02:00:00+02:00 | pubmed | Adult;Aged;Asthma__complications;Betacoronavirus__isolation & purification;Chronic Disease;Coronavirus Infections__pathology;Cross-Sectional Studies;Diabetes Complications__pathology;Female;France;Health Knowledge, Attitudes, Practice;Humans;Male;Middle Aged;Neoplasms__complications;Pandemics;Pneumonia, Viral__pathology;Risk;Severity of Illness Index;Surveys and Questionnaires;COVID-19;severe acute respiratory syndrome coronavirus 2 | PLOS ONE | Viet-Thi Tran;Philippe Ravaud | 2020-08-06 02:00:00+02:00 | 32760127 | FR;US | Université de Paris, CRESS, INSERM, INRA, Paris, France.;Centre d'Epidémiologie Clinique, AP-HP, Hôpital Hôtel-Dieu, Paris, France.;Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York, United States of America. | 2033 | |||
| 10.1007/s00414-020-02390-1 | Journal Article | en | Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations. | https://www.ncbi.nlm.nih.gov/pubmed/32767018 | A 75-year-old man presented to a French hospital with a 4-day fever after returning from a coronavirus disease-19 (COVID-19) cluster region. A reverse-transcription polymerase chain reaction test was positive for severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) using a nasopharyngeal swab sample. After he returned home and a telephone follow-up, he was found deceased 9 days after first showing symptoms. Whole-body, non-enhanced, post-mortem computed tomography (PMCT) and a forensic autopsy were performed approximately 48 h after death, with sanitary precautions. The PMCT showed bilateral and diffuse crazy-paving lung opacities, with bilateral pleural effusions. Post-mortem virology studies detected the presence of SARS-CoV-2 (B.1 lineage) in the nasopharynx, plasma, lung biopsies, pleural effusion and faeces confirming the persistence of viral ribonucleic acid 48 h after death. Microscopic examination showed that severe lung damage was responsible for his death. The main abnormality was diffuse alveolar damage, associated with different stages of inflammation and fibrosis. This case is one of the first to describe complete post-mortem data for a COVID-19 death and highlights the ability of PMCT to detect severe involvement of the lungs before autopsy in an apparently natural death. The present pathology results are concordant with previously reported findings and reinforce the disease pathogenesis hypothesis of combined viral replication with an inappropriate immune response. | 0937-9827,1437-1596 | 2020-08-09 02:00:00+02:00 | pubmed | International Journal of Legal Medicine | Mathilde Ducloyer;Benjamin Gaborit;Claire Toquet;Louise Castain;Antonin Bal;Pierre Paul Arrigoni;Raphaël Lecomte;Renaud Clement;Christine Sagan | Autopsy;COVID-19;Pathology;Post-mortem;Post-mortem computed tomography;SARS-CoV-2 coronavirus | 2020-08-06 02:00:00+02:00 | 32767018 | FR | Forensic Medicine Department, University Hospital, 30 Boulevard Jean Monnet, Nantes, 44000, France. Mathilde.ducloyer@chu-nantes.fr.;Department of Radiology, University Hospital, Nantes, France. Mathilde.ducloyer@chu-nantes.fr.;Department of Infectious Diseases, University Hospital, Nantes, France.;Department of Pathology, University Hospital, Nantes, France.;Virology Department, University Hospital, Nantes, France.;Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, 44000, Nantes, France.;Virology Department, Hospices Civils de Lyon, Groupement Hospitalier Nord, Institut des Agents Infectieux (IAI), Lyon, France.;University of Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Lyon, France.;Department of Radiology, University Hospital, Nantes, France.;Forensic Medicine Department, University Hospital, 30 Boulevard Jean Monnet, Nantes, 44000, France. | 2040 | |||
| Letter | en | Was child abuse underdetected during the COVID-19 lockdown? | https://www.ncbi.nlm.nih.gov/pubmed/32807622 | 2020-08-09 02:00:00+02:00 | pubmed | F Caron;M-C Plancq;P Tourneux;R Gouron;C Klein | COVID-19;Child abuse;Lockdown | 2020-08-06 02:00:00+02:00 | 32807622 | FR | Service d'orthopédie pédiatrique, Groupe hospitalier Sud, CHU d'Amiens-Picardie, 80054 Amiens cedex 1, France.;Médecine néonatale et réanimation pédiatrique, pôle femme-couple-enfant, Groupe hospitalier Sud, 80054 Amiens cedex 1, France.;Service d'orthopédie pédiatrique, Groupe hospitalier Sud, CHU d'Amiens-Picardie, 80054 Amiens cedex 1, France. Electronic address: celinekleinfr@yahoo.fr. | 2046 | |||||||
| 10.1016/j.cell.2020.08.002 | Journal Article | en | Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32810439 | Blood myeloid cells are known to be dysregulated in coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2. It is unknown whether the innate myeloid response differs with disease severity and whether markers of innate immunity discriminate high-risk patients. Thus, we performed high-dimensional flow cytometry and single-cell RNA sequencing of COVID-19 patient peripheral blood cells and detected disappearance of non-classical CD14LowCD16High monocytes, accumulation of HLA-DRLow classical monocytes (Human Leukocyte Antigen - DR isotype), and release of massive amounts of calprotectin (S100A8/S100A9) in severe cases. Immature CD10LowCD101-CXCR4+/- neutrophils with an immunosuppressive profile accumulated in the blood and lungs, suggesting emergency myelopoiesis. Finally, we show that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe form of COVID-19, suggesting a predictive value that deserves prospective evaluation. | 0092-8674 | 2020-08-09 02:00:00+02:00 | pubmed | Cell | Aymeric Silvin;Nicolas Chapuis;Garett Dunsmore;Anne-Gaëlle Goubet;Agathe Dubuisson;Lisa Derosa;Carole Almire;Clémence Hénon;Olivier Kosmider;Nathalie Droin;Philippe Rameau;Cyril Catelain;Alexia Alfaro;Charles Dussiau;Chloé Friedrich;Elise Sourdeau;Nathalie Marin;Tali-Anne Szwebel;Delphine Cantin;Luc Mouthon;Didier Borderie;Marc Deloger;Delphine Bredel;Severine Mouraud;Damien Drubay;Muriel Andrieu;Anne-Sophie Lhonneur;Véronique Saada;Annabelle Stoclin;Christophe Willekens;Fanny Pommeret;Frank Griscelli;Lai Guan Ng;Zheng Zhang;Pierre Bost;Ido Amit;Fabrice Barlesi;Aurélien Marabelle;Frédéric Pène;Bertrand Gachot;Fabrice André;Laurence Zitvogel;Florent Ginhoux;Michaela Fontenay;Eric Solary | COVID-19;S100A8;S100A9;SARS-CoV-2;calprotectin;emergency myelopoiesis;monocyte subsets;neutrophils;type I interferon | 2020-08-05 02:00:00+02:00 | 32810439 | FR;SG;IL;CN;US | INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France.;Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France, Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France.;INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France, Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France.;Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France.;INSERM U981, Gustave Roussy Cancer Campus, Villejuif 94800, France.;INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France, INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France.;INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France.;Service des Urgences, AP-HP, Hôpital Hôtel-Dieu, Paris 75014, France.;Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, Paris 75014, France.;Service de Médecine Interne, AP-HP, Hôpital Cochin, Paris 75014, France.;Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France, Service de Médecine Interne, AP-HP, Hôpital Cochin, Paris 75014, France.;Service de Diagnostic Biologique Automatisé, AP-HP, Hôpital Cochin, Paris 75014, France.;INSERM U1018, Gustave Roussy Cancer Campus, Villejuif 94800, France.;Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France.;Laboratoire de Virologie, AP-HP, Hôpital Cochin, Paris 75014, France.;Département de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif 94800, France.;Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France.;INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France, Département d'Hématologie, Gustave Roussy Cancer Campus, Villejuif 94800, France.;Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France.;Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France, Département de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif 94800, France.;Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos Building #3-4, Biopolis, Singapore 138648, Singapore.;Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China.;Systems Biology Group, Department of Computational Biology and USR 3756, Institut Pasteur and CNRS, Paris 75015, France, Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.;Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.;INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France, Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy Cancer Campus, Villejuif 94800, France.;Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France, Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, Paris 75014, France.;Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France, INSERM U981, Gustave Roussy Cancer Campus, Villejuif 94800, France, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France.;INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France, Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, Villejuif 94800, France.;Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos Building #3-4, Biopolis, Singapore 138648, Singapore, Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China, Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore. Electronic address: florent_ginhoux@immunol.a-star.edu.sg.;Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France, Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France. Electronic address: michaela.fontenay@aphp.fr.;INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France, Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France. Electronic address: eric.solary@gustaveroussy.fr. | 2047 | |||
| H2020 Research Infrastructures;Institut National de la Santé et de la Recherche Médicale | 10.1038/s41598-020-70143-6 | Journal Article;Research Support, Non-U.S. Gov't | en | In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. | https://www.ncbi.nlm.nih.gov/pubmed/32753646 | A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2 < EC50 ≤ 20 µM. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection. | 2045-2322 | 2020-08-09 02:00:00+02:00 | pubmed | Animals;Antiviral Agents__chemistry;Betacoronavirus__isolation & purification;Caco-2 Cells;Cell Survival__drug effects;Chlorocebus aethiops;Coronavirus Infections__pathology;Drug Approval;Drug Evaluation, Preclinical;Drug Repositioning;Humans;Pandemics;Pneumonia, Viral__pathology;Small Molecule Libraries__chemistry;Vero Cells;Virus Replication__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Scientific Reports | Franck Touret;Magali Gilles;Karine Barral;Antoine Nougairède;Jacques van Helden;Etienne Decroly;Xavier de Lamballerie;Bruno Coutard | 2020-08-04 02:00:00+02:00 | 32753646 | FR | [{"country": "International", "agency": "H2020 Research Infrastructures", "grantid": "871029"}, {"country": "International", "agency": "Institut National de la Santé et de la Recherche Médicale", "grantid": "REACTing"}] | Unité Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), 13005, Marseille, France. franck.touret@univ-amu.fr.;Unité Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), 13005, Marseille, France.;Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France.;Institut Français de Bioinformatique (IFB), UMS 3601-CNRS, Université Paris-Saclay, Orsay, France.;Aix-Marseille Univ, INSERM, Lab. Theory and Approaches of Genome Complexity (TAGC), Marseille, France.;AFMB UMR 7257, Aix-Marseille Université, CNRS, Marseille, France.;Unité Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), 13005, Marseille, France. bruno.coutard@univ-amu.fr. | 2049 | |
| Letter | en | Immunosuppression in a lung transplant recipient with COVID-19? Lessons from an early case. | https://www.ncbi.nlm.nih.gov/pubmed/32801101 | 2020-08-09 02:00:00+02:00 | pubmed | J Raëth;A Tomio;A Eugene;A Mouffak;M Durand;R Hamidfar;C Pison;H Pluchart;A L Mounayar | Immunosuppressants;Lung transplantation;Protease inhibitors;SARS-CoV-2;Therapeutic drug monitoring | 2020-08-03 02:00:00+02:00 | 32801101 | FR | Pôle thorax et vaisseaux, service hospitalier universitaire pneumologie, CHU Grenoble Alpes, Grenoble, France, Université Grenoble Alpes, Grenoble, France.;Université Grenoble Alpes, Grenoble, France, Pôle pharmacie, CHU Grenoble Alpes, Grenoble, France.;Université Grenoble Alpes, Grenoble, France, Centre régional de pharmacovigilance, centre hospitalier universitaire Grenoble-Alpes, 38000 Grenoble, France.;Pôle anesthésie réanimation, CHU Grenoble Alpes, Grenoble, France.;Pôle thorax et vaisseaux, service hospitalier universitaire pneumologie, CHU Grenoble Alpes, Grenoble, France.;Pôle thorax et vaisseaux, service hospitalier universitaire pneumologie, CHU Grenoble Alpes, Grenoble, France, Université Grenoble Alpes, Grenoble, France. Electronic address: cpison@chu-grenoble.fr.;Université Grenoble Alpes, Grenoble, France, Pôle pharmacie, CHU Grenoble Alpes, Grenoble, France, TIMC-IMAG UMR5525/ThEMAS, CNRS, université Grenoble Alpes, Grenoble, France.;Pôle urgence médecine aiguë, service des maladies infectieuses et tropicales, CHU Grenoble Alpes, Grenoble, France. | 2052 | |||||||
| 10.1007/s40487-020-00124-2 | Journal Article | en | Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months. | https://www.ncbi.nlm.nih.gov/pubmed/32749634 | The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future. | 2366-1070,2366-1089 | 2020-08-09 02:00:00+02:00 | pubmed | Oncology and Therapy | Begoña de Las Heras;Kamal S Saini;Frances Boyle;Felipe Ades;Evandro de Azambuja;Ivana Bozovic-Spasojevic;Marco Romano;Marta Capelan;Rajeev Prasad;Pugazhenthi Pattu;Christophe Massard;Chia Portera;Monika Lamba Saini;Brajendra Prasad Singh;Ramachandran Venkitaraman;Richard McNally;Manuela Leone;Enrique Grande;Sudeep Gupta | COVID-19;Cancer;Coronavirus;Immuno-oncology;Malignancy;Mortality;Pandemic;Risk;SARS-CoV-2;Therapy | 2020-08-04 02:00:00+02:00 | 32749634 | FR;GB;US;BR;AU;RS;ES;IN;BE;PS | Covance Inc., Princeton, NJ, USA.;Madrid Medical Doctors Association, Madrid, Spain.;Covance Inc., Princeton, NJ, USA. kamalveer.saini@covance.com.;East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK. kamalveer.saini@covance.com.;Mater Hospital, Sydney, Australia.;Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.;Institut Jules Bordet, Brussels, Belgium.;Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.;Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.;Vall d'Hebron University Hospital, Barcelona, Spain.;Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK.;East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK.;Gustave Roussy, Université Paris-Saclay, Villejuif, France.;HistoGeneX, Antwerp, Belgium.;Max Smart Super Speciality Hospital, Saket, New Delhi, India.;MD Anderson Cancer Center Madrid, Madrid, Spain.;Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. | 2067 | |||
| 10.1136/annrheumdis-2020-218683 | Journal Article | en | Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al. | https://www.ncbi.nlm.nih.gov/pubmed/32759257 | 0003-4967,1468-2060 | 2020-08-09 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Manuel Francisco Ugarte-Gil;Maximilian F Konig;Peter Korsten;Francis Berenbaum;Alfred Hyoungju Kim;Jeffrey A Sparks | arthritis;hydroxychloroquine;lupus erythematosus;rheumatoid;systemic | 2020-08-05 02:00:00+02:00 | 32759257 | FR;PE;US;DE | Department of Rheumatology, Universidad Cientifica del Sur, Lima, Peru.;Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.;Department of Nephrology and Rheumatology, University Medical Center Göttingen, Gottingen, Germany.;Rheumatology, Sorbonne Université, Paris, France.;Medicine/Rheumatology, Washington University in Saint Louis School of Medicine, St. Louis, Missouri, USA jsparks@bwh.harvard.edu akim@wustl.edu.;Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA jsparks@bwh.harvard.edu akim@wustl.edu. | 2068 | ||||
| 10.1016/j.crad.2020.07.019 | Journal Article;Review | en | Thromboembolic complications of COVID-19: the combined effect of a pro-coagulant pattern and an endothelial thrombo-inflammatory syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32829885 | Coronavirus disease 2019 (COVID-19) is a newly emerging human infectious disease that has quickly become a worldwide threat to health, mainly causing severe acute respiratory syndrome. In addition to the widely described respiratory syndrome, COVID-19 may cause life-treating complications directly or indirectly related to this infection. Among these, thrombotic complications have emerged as an important issue in patients with COVID-19 infection, particularly in patients in intensive care units. Thrombotic complications due to COVID-19 are likely to occur due to a pro-coagulant pattern encountered in some of these patients or to a progressive endothelial thrombo-inflammatory syndrome causing microvascular disease. In the present authors' experience, from five different hospitals in Italy and the UK, imaging has proved its utility in identifying these COVID-19-related thrombotic complications, with translational clinical relevance. The aim of this review is to illustrate thromboembolic complications directly or indirectly related to COVID-19 disease. Specifically, this review will show complications related to thromboembolism due to a pro-coagulant pattern from those likely related to an endothelial thrombo-inflammatory syndrome. | 0009-9260 | 2020-08-09 02:00:00+02:00 | pubmed | Clinical Radiology | F Vernuccio;F P Lombardo;R Cannella;F Panzuto;D Giambelluca;M Arzanauskaite;M Midiri;P Cabassa | 2020-08-04 02:00:00+02:00 | 32829885 | GB;FR;IT;ES | Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University Hospital of Palermo, Via del Vespro 129, 90127, Palermo, Italy, University Paris Diderot, Sorbonne Paris Cité, Paris, France, I.R.C.C.S. Centro Neurolesi Bonino Pulejo, Contrada Casazza, SS113, 98124, Messina, Italy, Section of Radiology - BiND, University Hospital "Paolo Giaccone", Via del Vespro 129, 90127, Palermo, Italy. Electronic address: federicavernuccio@gmail.com.;Department of Radiology, ASST Valtellina ed Alto Lario, Ospedale "E. Morelli", Via Zubiani 33, 23035, Sondalo (SO), Italy.;Section of Radiology - BiND, University Hospital "Paolo Giaccone", Via del Vespro 129, 90127, Palermo, Italy.;Department of Radiology, ASST Lariana, Ospedale "S.Anna", Via Ravona, 20, 22042, San Fermo della Battaglia (CO), Italy.;Department of Radiology, ASST Franciacorta, Azienda Ospedaliera M.Mellini, Viale Mazzini 4, 25032, Chiari (BS), Italy.;Radiology and Imaging Department, Liverpool Heart and Chest Hospital, Liverpool, UK, Cardiovascular Program ICCC, IR, HSCiSP, IIB-Sant Pau, Barcelona, Spain. | 2069 | ||||
| 10.1136/bmjmilitary-2020-001547 | Journal Article | en | Military gas mask to protect surgeons when performing tracheotomies on patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32753542 | 2633-3767,2633-3775 | 2020-08-09 02:00:00+02:00 | pubmed | BMJ Military Health | Jean-Baptiste Caruhel;N Sigaux;A Crambert;N Donat;G Boddaert;P Haen;C Hoffmann | adult intensive & critical care;head & neck surgery;respiratory infections;risk management | 2020-08-04 02:00:00+02:00 | 32753542 | FR | Maxillo-facial, Head and Neck Surgery Department, Hopital d'Instruction des Armees Percy, Clamart, France docteur.caruhel@gmail.com.;Maxillo-Facial Surgery Department, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.;Maxillo-facial, Head and Neck Surgery Department, Hopital d'Instruction des Armees Percy, Clamart, France.;Intensive Care Unit and Burn Center, Hopital d'Instruction des Armees Percy, Clamart, Île-de-France, France.;Department of Thoracic and Vascular Surgery, Hopital d'Instruction des Armees Percy, Clamart, Île-de-France, France.;Maxillo-Facial Surgery Department, Hopital d'Instruction des Armees Laveran, Marseille, Provence-Alpes-Côte d'Azur, France. | 2075 | ||||
| Letter;Comment | en | Compared to NIPPV, HFNC is more dangerous regarding aerosol dispersion and contamination of healthcare personnel: we are not sure. | https://www.ncbi.nlm.nih.gov/pubmed/32753062 | 2020-08-09 02:00:00+02:00 | pubmed | Aerosols;Betacoronavirus;Cannula;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Positive-Pressure Respiration;COVID-19;severe acute respiratory syndrome coronavirus 2 | Patrick M Honore;Leonel Barreto Gutierrez;Luc Kugener;Sebastien Redant;Rachid Attou;Andrea Gallerani;David De Bels | 2020-08-04 02:00:00+02:00 | 32753062 | FR;BE | ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. Patrick.Honore@CHU-Brugmann.be.;ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. | 2083 | |||||||
| 10.1200/go.20.00300 | Journal Article | en | Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. | https://www.ncbi.nlm.nih.gov/pubmed/32755479 | To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic. | 2687-8941 | 2020-08-09 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus__pathogenicity;Clinical Decision-Making;Coronavirus Infections__epidemiology;Female;Humans;Infection Control__methods;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Infectious Disease Transmission, Professional-to-Patient__prevention & control;Male;Medical Oncology__methods;Middle Aged;Neoplasms__diagnosis;Oncologists__statistics & numerical data;Pandemics__prevention & control;Personal Protective Equipment__standards;Pneumonia, Viral__epidemiology;Practice Patterns, Physicians'__standards;Surveys and Questionnaires__statistics & numerical data;Telemedicine__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | JCO Global Oncology | Yüksel Ürün;Syed A Hussain;Ziad Bakouny;Daniel Castellano;Saadettin Kılıçkap;Gilberto Morgan;Rana R Mckay;Kevin Pels;Andrew Schmidt;Deborah B Doroshow;Fábio Schütz;Laurence Albiges;Gilberto Lopes;James W F Catto;Solange Peters;Toni K Choueiri | 2020-08-07 02:00:00+02:00 | 32755479 | SE;FR;GB;US;CH;BR;TR;ES | Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.;Ankara University Cancer Research Institute, Ankara, Turkey.;Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.;Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.;Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.;Hacettepe University Cancer Institute, Ankara, Turkey.;Department of Medical and Radiation Oncology, Skåne University Hospital, Lund, Sweden.;Moores Cancer Center, University of California San Diego, La Jolla, CA.;Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.;Clinical Oncology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.;Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland. | 2086 | |||
| 10.1093/cid/ciaa1181 | Journal Article | en | Posterior oropharyngeal salivafor the detection of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32770241 | 1058-4838,1537-6591 | 2020-08-09 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Marie Pierre Otto;Chrystelle Darles;Elodie Valero;Patrick Benner;Fabien Dutasta;Frédéric Janvier | 2020-08-08 02:00:00+02:00 | 32770241 | FR | Microbiology and infection control unit, Military Instruction Hospital Sainte Anne, Toulon, France.;Emergency unit, Military Instruction Hospital Sainte Anne, Toulon, France.;Internal medecine unit, Military Instruction Hospital Sainte Anne, Toulon, France.;School of Val-de-Grâce, Paris, France. | 2093 | |||||
| 10.1186/s13054-020-03200-1 | Journal Article | en | Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. | https://www.ncbi.nlm.nih.gov/pubmed/32771053 | Neurotropism of SARS-CoV-2 and its neurological manifestations have now been confirmed. We aimed at describing delirium and neurological symptoms of COVID-19 in ICU patients. | 1364-8535 | 2020-08-09 02:00:00+02:00 | pubmed | Aged;Brain Diseases__epidemiology;Cohort Studies;Coronavirus Infections__epidemiology;Delirium__epidemiology;Female;Humans;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Severity of Illness Index;COVID-19 | Critical Care | Julie Helms;Stéphane Kremer;Hamid Merdji;Malika Schenck;François Severac;Raphaël Clere-Jehl;Antoine Studer;Mirjana Radosavljevic;Christine Kummerlen;Alexandra Monnier;Clotilde Boulay;Samira Fafi-Kremer;Vincent Castelain;Mickaël Ohana;Mathieu Anheim;Francis Schneider;Ferhat Meziani | COVID-19;Delirium;Encephalopathy;ICU;MRI | 2020-08-08 02:00:00+02:00 | 32771053 | FR;US | Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, 1, place de l'Hôpital, F-67091, Strasbourg, Cedex, France.;ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Service d'imagerie 2, Hôpital de Hautepierre, Strasbourg, France.;Engineering Science, Computer Science and Imaging Laboratory (ICube), Integrative Multimodal Imaging in Healthcare, UMR 7357, University of Strasbourg-CNRS, Strasbourg, France.;INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive-Réanimation, Hautepierre, Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Groupe Méthodes en Recherche Clinique (GMRC), Hôpital Civil, Strasbourg, France.;Laboratoire d'immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.;Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Laboratoire de Virologie Médicale, Strasbourg, France.;Radiology Department, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, 1, place de l'Hôpital, F-67091, Strasbourg, Cedex, France. ferhat.meziani@chru-strasbourg.fr.;INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France. ferhat.meziani@chru-strasbourg.fr. | 2095 | ||
| 10.1016/j.onehlt.2020.100157 | Journal Article | en | Post-lockdown detection of SARS-CoV-2 RNA in the wastewater of Montpellier, France. | https://www.ncbi.nlm.nih.gov/pubmed/32835069 | The evolution of the COVID-19 pandemic can be monitored through the detection of SARS-CoV-2 RNA in sewage. Here, we measured the amount of SARS-CoV-2 RNA at the inflow point of the main waste water treatment plant (WWTP) of Montpellier, France. We collected samples 4 days before the end of lockdown and up to 70 days post-lockdown. We detected increased amounts of SARS-CoV-2 RNA at the WWTP from mid-June on, whereas the number of new COVID-19 cases in the area started increasing a couple of weeks later. Future epidemiologic investigations shall explain such asynchronous finding. | 2352-7714 | 2020-08-09 02:00:00+02:00 | pubmed | One Health | Julie Trottier;Regis Darques;Nassim Ait Mouheb;Emma Partiot;William Bakhache;Maika S Deffieu;Raphael Gaudin | COVID-19;Health Surveillance;PCR;Virus | 2020-08-09 02:00:00+02:00 | 32835069 | FR | CNRS, ART-Dev, Site Saint-Charles, Rue du Professeur Henri Serre, 34090 Montpellier, France.;Université de Montpellier, 163 Rue Auguste Broussonnet, 34090 Montpellier, France.;INRAE, UMR G-eau, 361 Rue Jean-François Breton, 34196 Montpellier Cedex 5, France.;CNRS, Institut de Recherche en Infectiologie de Montpellier (IRIM), 1919 Route de Mende, 34293 Montpellier, France. | 2102 | |||
| 10.1016/s2665-9913(20)30274-5 | Journal Article | en | Anakinra for severe forms of COVID-19 - Authors' reply. | https://www.ncbi.nlm.nih.gov/pubmed/32838321 | 2665-9913 | 2020-08-09 02:00:00+02:00 | pubmed | The Lancet Rheumatology | Gilles Hayem;Thomas Huet;Stéphane Jouveshomme;Hélène Beaussier;Gilles Chatellier;Jean-Jacques Mourad | 2020-08-07 02:00:00+02:00 | 32838321 | FR | Rheumatology Department, Hôpital Paris Saint-Joseph, Paris 75014, France.;Pulmonology Department, Hôpital Paris Saint-Joseph, Paris 75014, France.;Clinical Research Centre, Hôpital Paris Saint-Joseph, Paris 75014, France.;Assistance Publique, Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Université de Paris, Paris, France.;Internal Medicine Department, Hôpital Paris Saint-Joseph, Paris 75014, France. | 2123 | |||||
| 10.1007/s10531-020-02021-6 | Editorial | en | Biodiversity loss, emerging pathogens and human health risks. | https://www.ncbi.nlm.nih.gov/pubmed/32836920 | Outbreaks of emerging infectious diseases are occurring with increasing frequency and consequences, including wildlife diseases and zoonoses. Those have potentially long-lasting effects on human and wildlife populations, with inevitable direct and indirect effects on ecosystems. The intensifying emergence of infectious pathogens has many underlying reasons, all driven by the growing anthropogenic impact on nature. Intensifying pathogen emergence can be attributed to climate change, biodiversity loss, habitat degradation, and an increasing rate of wildlife-human contacts. All of these are caused by synergies between persisting intense poverty and a growing human population. Improved global management of the human-driven biological degradation and international dispersal processes that exacerbate those pandemic threats are now long overdue. It is vital that we act decisively in the aftermath of the COVID-19 crisis to radically change how we collectively manage the planet as a whole. | 0960-3115,1572-9710 | 2020-08-16 02:00:00+02:00 | pubmed | Biodiversity and Conservation | Dirk S Schmeller;Franck Courchamp;Gerry Killeen | Covid-19;Disease pyramid;Ecosystem health;Pandemics;Zoonoses | 2020-08-13 02:00:00+02:00 | 32836920 | FR;IE | ECOLAB, Université de Toulouse, CNRS, INPT, UPS, Toulouse, France.;Université Paris-Saclay, CNRS, AgroParisTech, Ecologie Systématique Evolution, 91405 Orsay, France.;School of Biological, Earth & Environmental Sciences, and Environmental Research Institute, University College Cork, Cork, Republic of Ireland. | 2132 | |||
| 10.1097/ccm.0000000000004584 | Journal Article | en | International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32804789 | There are over 4,000 trials conducted in people with coronavirus disease 2019. However, the variability of outcomes and the omission of patient-centered outcomes may diminish the impact of these trials on decision-making. The aim of this study was to generate a consensus-based, prioritized list of outcomes for coronavirus disease 2019 trials. | 0090-3493 | 2020-08-16 02:00:00+02:00 | pubmed | Critical Care Medicine | Nicole Evangelidis;Allison Tong;Martin Howell;Armando Teixeira-Pinto;Julian H Elliott;Luciano Cesar Azevedo;Andrew Bersten;Lilia Cervantes;Derek P Chew;Sally Crowe;Ivor S Douglas;Ella Flemyng;Peter Horby;Jaehee Lee;Eduardo Lorca;Deena Lynch;John C Marshall;Anne McKenzie;Sangeeta Mehta;Mervyn Mer;Andrew Conway Morris;Saad Nseir;Pedro Povoa;Mark Reid;Yasser Sakr;Ning Shen;Alan R Smyth;Tom Snelling;Giovanni F M Strippoli;Antoni Torres;Tari Turner;Steve Webb;Paula R Williamson;Laila Woc-Colburn;Junhua Zhang;Amanda Baumgart;Sebastian Cabrera;Yeoungjee Cho;Tess Cooper;Chandana Guha;Emma Liu;Andrea Matus Gonzalez;Charlie McLeod;Patrizia Natale;Valeria Saglimbene;Andrea K Viecelli;Jonathan C Craig | 2020-08-14 02:00:00+02:00 | 32804789 | FR;CA;CL;PT;CN;GB;US;BR;IT;AU;ZA;DK;ES;KR;DE | Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.;Centre for Kidney Research, The Children's Hospital at Westmead, NSW, Australia.;Cochrane Australia, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.;Department of Critical Care Medicine, Hospital Sirio-Libanes, São Paulo, Brazil.;College of Medicine and Public Health, Flinders University, Adelaide, Australia.;Department of Medicine, Denver Health, Denver, CO.;Crowe Associates Ltd, Oxon, United Kingdom.;Department of Medicine, Pulmonary Sciences and Critical Care, Denver Health and University of Colorado Anschutz, School of Medicine, Denver, CO.;Editorial and Methods Department, Cochrane, London, United Kingdom.;Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.;Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.;Department of Internal Medicine, Faculty of Medicine, University of Chile, Santiago, Chile.;Jonze Society, Brisbane, Australia.;Department of Surgery, University of Toronto, Toronto, ON, Canada.;Telethon Kids Institute, Perth, Australia.;Department of Medicine and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.;Divisions of Critical Care and Pulmonology, Department of Medicine, Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.;Department of Medicine, University of Cambridge, Cambridge, United Kingdom.;Critical Care Centre, CHU Lille, and Lille University, F-59000 Lille, France.;Nova Medical School, CHRC, New University of Lisbon, Polyvalent Intensive Care Unit, Sao Francisco Xavier Hospital, CHLO, Lisbon, Portugal. Center for Clinical Epidemiology and Research Unit of Clinical Epidemiology, OUH Odense University Hospital, Denmark.;Department of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany.;Department of Respiratory Medicine, Peking University Third Hospital, Beijing, China.;Evidence Based Child Health Group, University of Nottingham, Nottingham, United Kingdom.;Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.;Department of Pulmonology Hospital Clinic. University of Barcelona, CIBERES, IDIBAPS, ICREA, Barcelona, Spain.;Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.;Section of Infectious Diseases Department of Medicine, National School of Tropical Medicine Baylor College of Medicine, Houston, TX.;Evidence-based Medicine center, Tianjin University of Traditional Chinese Medicine, Tianjin, China.;Faculty of Medicine, University of Queensland, Brisbane, Australia.;Department of Infectious Diseases, Perth Children's Hospital, Perth, Australia. | 2144 | ||||
| 10.1007/s42399-020-00451-5 | Journal Article | en | Analysing the Covid-19 Cases in Kerala: a Visual Exploratory Data Analysis Approach. | https://www.ncbi.nlm.nih.gov/pubmed/32838189 | To analyse the Covid-19 cases and effective measures taken by the Kerala government in India to fight against the pandemic. To conduct an exploratory analysis of the model put forward by Kerala. Data were collected from various sources. Three phases were identified for analysis: first phase starting from January 30 to March 9, 2020; second phase starting from March 10 to May 8 and the last phase from May 9 to May 31, 2020. Data analysis was carried out in MATLAB software. The steps taken by the Kerala government ensured the virus to be contained in the affected persons itself. Community spread was reduced by the implementation of contact tracing and home quarantine. Welfare measures taken during the lockdown helped the people to adjust to the changes. The abstinence of community spread still stands strong. Apart from tackling the Covid-19 virus, Kerala with a series of welfare measures made the life of Kerala citizens comfortable. The model raised by Kerala for fighting against Covid-19 can be considered as a benchmark for how the public health department can be utilised properly. | 2523-8973 | 2020-08-16 02:00:00+02:00 | pubmed | SN Comprehensive Clinical Medicine | Jayesh S;Shilpa Sreedharan | Analysis;Coronavirus;Covid-19;Data;Exploratory analysis;Kerala;Virus | 2020-08-14 02:00:00+02:00 | 32838189 | FR;IN | Department of Mechanical Engineering, School of Engineering, Cochin University of Science and Technology, Kochi, Kerala 682022 India.;Wellness Solutions, Kochi, Kerala 682304 India. | 2147 | |||
| Letter | en | COVID-19 in a pediatric patient with Glanzmann thrombasthenia. | https://www.ncbi.nlm.nih.gov/pubmed/32798297 | 2020-08-16 02:00:00+02:00 | pubmed | Laurent Sattler;Olivier Feugeas;Claire Hager;Lélia Grunebaum;Dominique Desprez | 2020-08-15 02:00:00+02:00 | 32798297 | FR | Laboratoire d'Hématologie, Unité Hémostase, Hôpitaux universitaires de Strasbourg, Strasbourg, France.;Centre de Ressource et Compétence des Maladies Hémorragiques Constitutionnelles, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Service de Néonatologie, Hôpitaux universitaires de Strasbourg, Strasbourg, France. | 2152 | ||||||||
| 10.1097/rlu.0000000000003255 | Journal Article | en | Images of COVID-19 Infection Cases in Asymptomatic or Paucisymptomatic Patients With Neoplastic Diseases on 18F-FDG PET/CT. | https://www.ncbi.nlm.nih.gov/pubmed/32804760 | We describe the results of F-FDG PET/CT of 3 patients referred to our institution during the single day of Monday, March 23, 2020, for an initial assessment of cancer extension or for the therapeutic evaluation of chemotherapy of neoplastic pathology, with no obvious infectious or respiratory symptoms at the time of examination. A retrospective review of the recent clinical history of patients in association with the typical pulmonary images on CT scan suggested the diagnosis of COVID-19. The characteristic aspects of COVID-19 infection should be recognized on F-FDG PET/CT, even if patients are asymptomatic or minimally symptomatic. | 2020-08-16 02:00:00+02:00 | pubmed | Jean-François Grellier;David Lussato;Mohamed Guernou;Mathieu Queneau;Gérald Bonardel | 2020-08-15 02:00:00+02:00 | 32804760 | FR | From the Department of Nuclear Medicine, Centre Cardiologique du Nord, Saint-Denis, France. | 2155 | ||||||
| 10.1038/s41577-020-00425-7 | Published Erratum | en | Author Correction: Tissue damage from neutrophil-induced oxidative stress in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32778830 | An amendment to this paper has been published and can be accessed via a link at the top of the paper. | 1474-1733,1474-1741 | 2020-08-16 02:00:00+02:00 | pubmed | Nature Reviews Immunology | Mireille Laforge;Carole Elbim;Corinne Frère;Miryana Hémadi;Charbel Massaad;Philippe Nuss;Jean- Jacques Benoliel;Chrystel Becker | 2020-08-10 02:00:00+02:00 | 32778830 | FR | CNRS, INSERM UMRS 1124, Faculté des sciences fondamentales et biomédicales, Université de Paris, Paris, France.;Centre de Recherche Saint-Antoine, INSERM UMRS 938, Sorbonne Université, Paris, France.;Institute of Cardiometabolism and Nutrition (ICAN), GRC 27 GRECO, INSERM 1166, Sorbonne Université, Paris, France.;Université de Paris, CNRS-UMR 7086, Interfaces, Traitements, Organisation et DYnamique des Systèmes (ITODYS), Paris, France.;Service de psychiatrie et de psychologie médicale, Sorbonne Université, Hôpital Saint-Antoine, AP-HP, Paris, France.;Service de biochimie endocrinienne et oncologie, Hôpital Pitié-Salpêtrière AP-HP, Sorbonne Université, Paris, France.;CNRS, INSERM UMRS 1124, Faculté des sciences fondamentales et biomédicales, Université de Paris, Paris, France. christel.becker@parisdescartes.fr. | 2159 | ||||
| 10.1007/s00405-020-06278-z | Published Erratum | en | Correction to: Sinus and anterior skull base surgery during the COVID-19 pandemic: systematic review, synthesis and YO-IFOS position. | https://www.ncbi.nlm.nih.gov/pubmed/32776196 | In the original publication of the article, one of the author's first and family name was published incorrectly. | 0937-4477,1434-4726 | 2020-08-16 02:00:00+02:00 | pubmed | European Archives of Oto-Rhino-Laryngology | Thomas Radulesco;Jerome R Lechien;Leigh J Sowerby;Sven Saussez;Carlos Chiesa-Estomba;Zoukaa Sargi;Philippe Lavigne;Christian Calvo-Henriquez;Chwee Ming Lim;Napadon Tangjaturonrasme;Patravoot Vatanasapt;Puya Dehgani-Mobaraki;Nicolas Fakhry;Tareck Ayad;Justin Michel | 2020-08-10 02:00:00+02:00 | 32776196 | FR;SG;CA;GB;US;TH;IT;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Marseille, France. thomas.radulesco@ap-hm.fr.;Department of Oto-Rhino-Laryngology and Head and Neck Surgery, APHM, La Conception University Hospital, 13385, Marseille Cedex, France. thomas.radulesco@ap-hm.fr.;Aix-Marseille University, IUSTI, 13013, Marseille, France. thomas.radulesco@ap-hm.fr.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Marseille, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada.;Department of Otorhinolaryngology, Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL, USA.;Division of Otolaryngology-Head and Neck Surgery, Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada.;Department of Otolaryngology, Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;Department of Otorhinolaryngology Head and Neck Surgery, Duke-NUS Medical School, Singapore General Hospital, Singapore, Singapore.;Department of Otolaryngology Head of Division of Head and Neck Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.;Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.;Department of Otolaryngology Head and Surgery, Gubbio-Gualdo Tadino Hospital, USL Umbria 1, Gubbio, Italy.;Association "Naso Sano" Onlus, Umbria Regional Registry of Volunteer Activities, Corciano, Italy.;Department of Oto-Rhino-Laryngology and Head and Neck Surgery, APHM, La Conception University Hospital, 13385, Marseille Cedex, France.;Aix-Marseille University, IUSTI, 13013, Marseille, France. | 2161 | ||||
| Letter | en | Impact of COVID-19 on dental education: How could pre-clinical training be done at home? | https://www.ncbi.nlm.nih.gov/pubmed/32799343 | 2020-08-16 02:00:00+02:00 | pubmed | Antoine Galibourg;Delphine Maret;Paul Monsarrat;Karim Nasr | 2020-08-16 02:00:00+02:00 | 32799343 | FR | Dental Faculty, Department of Oral Rehabilitation, Paul Sabatier University, Toulouse University Hospital, Toulouse, France.;Laboratoire Anthropologie Moléculaire et Imagerie de Synthèse, Université Paul Sabatier, Toulouse, France.;Toulouse Institute of Artificial Intelligence ANITI, Toulouse, France.;STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, ENVT, Inserm, UPS, France. | 2173 | ||||||||
| 10.1111/jdv.16772 | Journal Article | en | Recommendations for skin cancer consultation and surgery during COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32789960 | 0926-9959,1468-3083 | 2020-08-16 02:00:00+02:00 | pubmed | Journal of the European Academy of Dermatology and Venereology | L Brochez;J F Baurain;V Del Marmol;A Nikkels;V Kruse;F Sales;M Stas;A Van Laethem;M Garmyn | 2020-08-12 02:00:00+02:00 | 32789960 | FR;BE;GB | Dermatology, University Hospital Gent, Ghent, Belgium.;Centre du Cancer, Cu Saint-Luc/UCL, Brussels, Belgium.;Dermatology, Hôspital Erasme, Université Libre de Bruxelles, Brussels, Belgium.;Dermatology, CHU du Sart Tilman, University of Liège, Liège, Belgium.;Oncology, University Hospital Gent, Ghent, Belgium.;Surgery, Bordet Institute, Brussels, Belgium.;Oncological Surgery, University Hospital Leuven, Leuven, Belgium.;Dermatology, University Hospital Leuven, Leuven, Belgium. | 2188 | |||||
| 10.1016/s2589-7500(20)30196-5 | Journal Article | en | Applications of predictive modelling early in the COVID-19 epidemic. | https://www.ncbi.nlm.nih.gov/pubmed/32838252 | 2589-7500 | 2020-08-16 02:00:00+02:00 | pubmed | The Lancet Digital Health | Chiara Poletto;Samuel V Scarpino;Erik M Volz | 2020-08-10 02:00:00+02:00 | 32838252 | FR;GB;US | Pierre Louis Institute of Epidemiology and Public Health, INSERM, Paris, France.;Network Science Institute, Northeastern University, Boston, MA, USA.;MRC Centre for Global Infectious Disease Analysis and Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, UK. | 2196 | |||||
| 10.1016/j.ajic.2020.08.005 | Journal Article | en | 3D-printed protected face shields for healthcare workers in Covid-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32791260 | The coronavirus pandemic resulted in a shortage of protective equipment. To meet the request of eye-protecting devices, an interdisciplinary consortium involving practitioners, researchers, engineers and technicians developed and manufactured thousands of inexpensive 3D-printed face shields, inside hospital setting. This action lead to the concept of "concurrent, agile and rapid engineering". | 0196-6553 | 2020-08-16 02:00:00+02:00 | pubmed | American Journal of Infection Control | Vincent Lemarteleur;Vincent Fouquet;Stéphane Le Goff;Laurent Tapie;Pascal Morenton;Aurélie Benoit;Elsa Vennat;Bruno Zamansky;Thomas Guilbert;Arnaud Depil-Duval;Anne-Laure Gaultier;Bertrand Tavitian;Patrick Plaisance;Pierre-Louis Tharaux;Pierre-François Ceccaldi;Jean-Pierre Attal;Elisabeth Dursun | COVID-19;face shield;protective equipment | 2020-08-10 02:00:00+02:00 | 32791260 | FR | Center of simulation iLumens Paris Diderot-Paris Nord, Faculty of Health, University of Paris, Paris, France.;Innovative Dental Materials and Interfaces Research Unit (UR4462), Universities of Paris and Sorbonne Paris Nord, Faculty of Health, University of Paris, Paris, France.;CentraleSupélec, University of Paris-Saclay, Gif-sur-Yvette, France.;Innovative Dental Materials and Interfaces Research Unit (UR4462), Universities of Paris and Sorbonne Paris Nord, Faculty of Health, University of Paris, Paris, France, CentraleSupélec, University of Paris-Saclay, Gif-sur-Yvette, France.;Institut Cochin, Inserm (U1016), CNRS (UMR 8104), University of Paris, Paris, France.;Department of Emergency Medicine, Lariboisière Hospital.;Department of Radiology, Georges Pompidou European Hospital (AP-HP), Paris, France.;Department of Radiology, Georges Pompidou European Hospital (AP-HP), Paris, France, Paris Cardiovascular Centre (PARCC), Inserm, University of Paris, France.;Department of Emergency Medicine, Lariboisière Hospital, University of Paris, Paris, France.;Paris Cardiovascular Centre (PARCC), Inserm, University of Paris, France.;Center of simulation iLumens Paris Diderot-Paris Nord, Faculty of Health, University of Paris, Paris, France, Service of Gynecology and Obstetrics, Beaujon teaching hospital (AP-HP), Clichy, France.;Innovative Dental Materials and Interfaces Research Unit (UR4462), Universities of Paris and Sorbonne Paris Nord, Faculty of Health, University of Paris, Paris, France, University of Paris, Charles Foix Hospital (AP-HP), Paris, France.;Innovative Dental Materials and Interfaces Research Unit (UR4462), Universities of Paris and Sorbonne Paris Nord, Faculty of Health, University of Paris, Paris, France, Henri Mondor Hospital (AP-HP), Paris, France. Electronic address: elisabeth.dursun@parisdescartes.fr. | 2197 | |||
| Letter | en | Hydroxychloroquine at usual doses as an option for Covid-19 treatment. | https://www.ncbi.nlm.nih.gov/pubmed/32835721 | 2020-08-23 02:00:00+02:00 | pubmed | Lionel Carbillon;Amelie Benbara;Jeremy Boujenah | 2020-08-21 02:00:00+02:00 | 32835721 | FR | Universite Paris 13. Electronic address: lionel.carbillon@aphp.fr.;Assistance Publique - Hopitaux de Paris. | 2218 | ||||||||
| Letter | en | IFSO Endoscopy Committee Position Statement on the Practice of Bariatric Endoscopy During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32827093 | 2020-08-23 02:00:00+02:00 | pubmed | Gianfranco Donatelli;Fabrizio Cereatti;Jean-Loup Dumont | 2020-08-22 02:00:00+02:00 | 32827093 | FR;IT | Unité d'Endoscopie Interventionnelle, Ramsay Santé, Hôpital Privé des Peupliers, 8 Place de l'Abbé G. Hénocque, 75013, Paris, France. donatelligianfranco@gmail.com.;Unité d'Endoscopie Interventionnelle, Ramsay Santé, Hôpital Privé des Peupliers, 8 Place de l'Abbé G. Hénocque, 75013, Paris, France.;Gastroenterologia ed Endoscopia Digestiva ASST Cremona, Cremona, Italy. | 2221 | ||||||||
| 10.1007/s00167-020-06212-0 | Journal Article | en | Recommendations for resuming elective hip and knee arthroplasty in the setting of the SARS-CoV-2 pandemic: the European Hip Society and European Knee Associates Survey of Members. | https://www.ncbi.nlm.nih.gov/pubmed/32809121 | The COVID-19 pandemic has disrupted the health care system around the entire globe. A consensus is needed about resuming total hip and knee procedures. The European Hip Society (EHS) and the European Knee Association (EKA) formed a panel of experts that have produced a consensus statement on how the safe re-introduction of elective hip and knee arthroplasty should be undertaken. | 0942-2056,1433-7347 | 2020-08-23 02:00:00+02:00 | pubmed | Knee Surgery, Sports Traumatology, Arthroscopy | N P Kort;E Gómez Barrena;M Bédard;S Donell;J-A Epinette;B Gomberg;M T Hirschmann;P Indelli;Ismail Khosravi;T Karachalios;M C Liebensteiner;B Stuyts;R Tandogan;B Violante;L Zagra;M Thaler | COVID-19;Hip;Knee;Primary arthroplasty;Recommendations;Survey | 2020-08-18 02:00:00+02:00 | 32809121 | FR;CA;GR;BO;GB;US;CH;IT;NL;TR;ES;BE;AT | CortoClinics, Schijndel, The Netherlands.;Dept of Orthopaedic Surgery and Traumatology, Hospital La Paz, Universidad Autónoma de Madrid, Madrid, Spain.;Département de Chirurgie Orthopédique, CHU de Québec-Université Laval, Quebec City, QC, Canada.;Norwich Medical School, University of East Anglia, Norwich, UK. s.donell@uea.ac.uk.;Center for Research and Documentation in Arthroplasty, Lille, France.;OA Centers for Orthopaedics, Portland, ME, USA.;Department of Orthopaedic Surgery and Traumatology, Kantonsspital Baselland, (Bruderholz, Liestal, Laufen), 4101, Bruderholz, Switzerland.;University of Basel, Basel, Switzerland.;Department of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, USA.;International Committee American Academy Hip and Knee Surgeons (AAHKS), Rosemont, IL, USA.;Department of Orthopaedic Surgery, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.;Orthopaedic Department, School of Health Sciences, Faculty of Medicine, University General Hospital of Larissa, University of Thessalia, Thessalia, Greece.;Department of Orthopedic Surgery and Traumatology, GZA Hospitals, Antwerp, Belgium.;Ortoklinik and Cankaya Orthopedics, Ankara, Turkey.;Orthopaedic Department, Istituto Clinico Sant'Ambrogio IRCCS Galeazzi, Milan, Italy.;Hip Department IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. | 2244 | |||
| 10.1007/s11071-020-05862-6 | Journal Article | en | Generalized logistic growth modeling of the COVID-19 outbreak: comparing the dynamics in the 29 provinces in China and in the rest of the world. | https://www.ncbi.nlm.nih.gov/pubmed/32836822 | Started in Wuhan, China, the COVID-19 has been spreading all over the world. We calibrate the logistic growth model, the generalized logistic growth model, the generalized Richards model and the generalized growth model to the reported number of infected cases for the whole of China, 29 provinces in China, and 33 countries and regions that have been or are undergoing major outbreaks. We dissect the development of the epidemics in China and the impact of the drastic control measures both at the aggregate level and within each province. We quantitatively document four phases of the outbreak in China with a detailed analysis on the heterogeneous situations across provinces. The extreme containment measures implemented by China were very effective with some instructive variations across provinces. Borrowing from the experience of China, we made scenario projections on the development of the outbreak in other countries. We identified that outbreaks in 14 countries (mostly in western Europe) have ended, while resurgences of cases have been identified in several among them. The modeling results clearly show longer after-peak trajectories in western countries, in contrast to most provinces in China where the after-peak trajectory is characterized by a much faster decay. We identified three groups of countries in different level of outbreak progress, and provide informative implications for the current global pandemic. | 0924-090X,1573-269X | 2020-08-23 02:00:00+02:00 | pubmed | Nonlinear Dynamics | Ke Wu;Didier Darcet;Qian Wang;Didier Sornette | Epidemic modeling;Logistic growing;Novel coronavirus (COVID-19);Prediction | 2020-08-19 02:00:00+02:00 | 32836822 | FR;CN;CH | Institute of Risk Analysis, Prediction and Management (Risks-X), Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology (SUSTech), Shenzhen, China.;Department of Management, Technology and Economics (D-MTEC), Chair of Entrepreneurial Risks, ETH Zurich, Zurich, Switzerland.;Gavekal Intelligence Software, Nice, France.;Department of Banking and Finance, University of Zurich, Zurich, Switzerland. | 2247 | |||
| 10.1007/s11239-020-02246-w | Journal Article | en | High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards. | https://www.ncbi.nlm.nih.gov/pubmed/32812199 | Coronavirus disease 2019 (COVID-19) is associated with coagulation activation and high incidence of venous thromboembolism (VTE) in severe patients despite routine thromboprophylaxis. Conflicting results exist regarding the epidemiology of VTE for unselected anticoagulated COVID-19 patients hospitalized in general wards. The aim of this study was to evaluate the prevalence of asymptomatic deep venous thrombosis (DVT) in unselected patients with COVID-19 recently hospitalized in general wards. We performed a systematic complete doppler ultrasound (CDU) at a median 4 days after admission in 42 consecutive COVID-19 patients hospitalized in general wards of our university hospital, irrespective of D-Dimer level, and retrospectively collected clinical, biological and outcome data from electronic charts. Thromboprophylaxis was systematically applied following a French national proposal. In our population, the prevalence of asymptomatic DVT was 19% (8/42 patients), with distal thrombosis in 7/8 cases and bilateral DVT in 4/8 cases. Symptomatic pulmonary embolism was detected in 4 (9.5%) patients, associated to DVT in one case. Compared to patients without DVT, patients with DVT were older and experienced poorer outcomes. In conclusion, prevalence of asymptomatic DVT is high in the first days of hospitalization of unselected COVID-19 patients in general wards and may be related to poor prognosis. Individualized assessment of thromboprophylaxis and early systematic screening for DVT is warranted in this context. | 0929-5305,1573-742X | 2020-08-23 02:00:00+02:00 | pubmed | Journal of Thrombosis and Thrombolysis | Sylvain Le Jeune;Jaehyo Suhl;Ruben Benainous;François Minvielle;Christine Purser;Farid Foudi;Ursula Warzocha;Robin Dhote | Anticoagulation;COVID-19;General wards;SARS-CoV-2;Venous thromboembolism | 2020-08-18 02:00:00+02:00 | 32812199 | FR | Service de Médecine Interne, Centre Hospitalo-Universitaire Avicenne, Assistance Publique-Hôpitaux de Paris, 125 rue de Stalingrad, 93000, Bobigny, France. sylvain.le-jeune@aphp.fr.;Service de Médecine Interne, Centre Hospitalo-Universitaire Avicenne, Assistance Publique-Hôpitaux de Paris, 125 rue de Stalingrad, 93000, Bobigny, France.;Service des Explorations Fonctionnelles, Centre Hospitalo-Universitaire Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France. | 2257 | |||
| Letter | en | Usefulness and safety of a dedicated team to prone patients with severe ARDS due to COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32811555 | 2020-08-23 02:00:00+02:00 | pubmed | Antoine Kimmoun;Bruno Levy;Bruno Chenuel | 2020-08-18 02:00:00+02:00 | 32811555 | FR | CHRU-Nancy, INSERM U1116, Médecine Intensive et Réanimation Brabois, Université de Lorraine, F-54000, Nancy, France.;CHRU-Nancy, INSERM U1116, Médecine Intensive et Réanimation Brabois, Université de Lorraine, F-54000, Nancy, France. blevy5463@gmail.com.;CHRU-Nancy, Centre Universitaire de Médecine du Sport et Activité Physique Adaptée, Explorations Fonctionnelles Respiratoires, EA DevAH, Département de Physiologie, Université de Lorraine, F-54000, Nancy, France. | 2259 | ||||||||
| Letter;Comment | en | 2019-nCoV epidemic: what about pregnancies? | https://www.ncbi.nlm.nih.gov/pubmed/32035511 | 2020-02-09 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Epidemics;Female;Humans;Middle East Respiratory Syndrome Coronavirus;Pandemics;Pneumonia, Viral__epidemiology;Pregnancy;Pregnancy Complications, Infectious__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Guillaume Favre;Léo Pomar;Didier Musso;David Baud | 2020-02-06 01:00:00+01:00 | 32035511 | FR;CH | Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland.;Laboratoire Eurofins Labazur Guyane, French Guiana, Aix Marseille Université, IRD, AP-HM, SSA, VITROME, IHU-Méditerranée infection, Marseille, France.;Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: david.baud@chuv.ch. | 4 | |||||||
| 10.2807/1560-7917.es.2020.25.4.2000057 | Journal Article | en | Novel coronavirus (2019-nCoV) early-stage importation risk to Europe, January 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32019667 | As at 27 January 2020, 42 novel coronavirus (2019-nCoV) cases were confirmed outside China. We estimate the risk of case importation to Europe from affected areas in China via air travel. We consider travel restrictions in place, three reported cases in France, one in Germany. Estimated risk in Europe remains high. The United Kingdom, Germany and France are at highest risk. Importation from Beijing and Shanghai would lead to higher and widespread risk for Europe. | 1560-7917 | 2020-02-09 01:00:00+01:00 | pubmed | Air Travel;Betacoronavirus;China__epidemiology;Coronavirus Infections__epidemiology;Disease Outbreaks;Europe__epidemiology;Humans;Models, Theoretical;Pneumonia, Viral__epidemiology;Public Policy;Risk Assessment;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Giulia Pullano;Francesco Pinotti;Eugenio Valdano;Pierre-Yves Boëlle;Chiara Poletto;Vittoria Colizza | 2019-nCoV;Europe;importation risk;travel ban | 2020-02-06 01:00:00+01:00 | 32019667 | FR;US | INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France.;Center for Biomedical Modeling, The Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, United States. | 5 | ||
| 10.1016/j.antiviral.2020.104742 | Journal Article;Research Support, Non-U.S. Gov't | en | The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. | https://www.ncbi.nlm.nih.gov/pubmed/32057769 | In 2019, a new coronavirus (2019-nCoV) infecting Humans has emerged in Wuhan, China. Its genome has been sequenced and the genomic information promptly released. Despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs, we identified a peculiar furin-like cleavage site in the Spike protein of the 2019-nCoV, lacking in the other SARS-like CoVs. In this article, we discuss the possible functional consequences of this cleavage site in the viral cycle, pathogenicity and its potential implication in the development of antivirals. | 0166-3542 | 2020-02-16 01:00:00+01:00 | pubmed | Amino Acid Sequence;Betacoronavirus__chemistry;Furin__chemistry;Genome, Viral;Protein Conformation;Spike Glycoprotein, Coronavirus__chemistry;severe acute respiratory syndrome coronavirus 2 | Antiviral Research | B Coutard;C Valle;X de Lamballerie;B Canard;N G Seidah;E Decroly | 2019-nCoV;Antivirals;Furin;Maturation protease;SARS-CoV;Spike protein | 2020-02-10 01:00:00+01:00 | 32057769 | FR;CA | Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207 - IHU Méditerranée Infection), Marseille, France.;Aix Marseille Université, CNRS, AFMB UMR 7257, Marseille, France.;Laboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM, Affiliated to the University of Montreal), 110 Pine Ave West, Montreal, QC, H2W1R7, Canada.;Aix Marseille Université, CNRS, AFMB UMR 7257, Marseille, France. Electronic address: etienne.decroly@afmb.univ-mrs.fr. | 6 | ||
| 10.1016/j.accpm.2020.02.002 | Editorial | en | COVID-19: A critical care perspective informed by lessons learnt from other viral epidemics. | https://www.ncbi.nlm.nih.gov/pubmed/32088344 | 2352-5568 | 2020-02-23 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnosis;Critical Care;Disease Progression;Epidemics;Humans;Pandemics;Pneumonia, Viral__diagnosis;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Anaesthesia Critical Care & Pain Medicine | Lowell Ling;Gavin M Joynt;Jeff Lipman;Jean-Michel Constantin;Olivier Joannes-Boyau | Infection control;Outbreak;SARS-CoV-2 | 2020-02-20 01:00:00+01:00 | 32088344 | FR;CN;AU;HK | Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China.;Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: gavinmjoynt@cuhk.edu.hk.;Intensive Care Services, Royal Brisbane and Women's Hospital, The University of Queensland Centre for Clinical Research, Brisbane, Australia, Nîmes University Hospital, University of Montpellier, Nîmes, France.;Medecine Sorbonne-Université, DMU DREAM, AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France, GRC ARPE, Medecine Sorbonne-Université, Paris, France.;Service d'Anesthésie-Réanimation Sud, Centre Médico-Chirurgical Magellan, Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000, Bordeaux, France. | 11 | |||
| 10.1016/s0140-6736(20)30411-6 | Journal Article | en | Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. | https://www.ncbi.nlm.nih.gov/pubmed/32087820 | The novel coronavirus disease 2019 (COVID-19) epidemic has spread from China to 25 countries. Local cycles of transmission have already occurred in 12 countries after case importation. In Africa, Egypt has so far confirmed one case. The management and control of COVID-19 importations heavily rely on a country's health capacity. Here we evaluate the preparedness and vulnerability of African countries against their risk of importation of COVID-19. | 0140-6736 | 2020-02-23 01:00:00+01:00 | pubmed | Africa__epidemiology;China__epidemiology;Civil Defense;Coronavirus Infections__epidemiology;Epidemics__prevention & control;Health Planning;Health Resources;Humans;Models, Theoretical;Pneumonia, Viral__epidemiology;Population Surveillance;Risk Assessment;Travel;Vulnerable Populations;COVID-19 | The Lancet | Marius Gilbert;Giulia Pullano;Francesco Pinotti;Eugenio Valdano;Chiara Poletto;Pierre-Yves Boëlle;Eric D'Ortenzio;Yazdan Yazdanpanah;Serge Paul Eholie;Mathias Altmann;Bernardo Gutierrez;Moritz U G Kraemer;Vittoria Colizza | 2020-02-20 01:00:00+01:00 | 32087820 | FR;CI;GB;US;BE | Spatial Epidemiology Laboratory, Université Libre de Bruxelles, Brussels, Belgium, Fonds National de la Recherche Scientifiques, Brussels, Belgium.;INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, Sociology and Economics of Networks and Services Laboratory at Orange Experience Design Laboratory Chatillion, Paris, France.;INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.;Center for Biomedical Modeling, The Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California Los Angeles, LA, USA.;Infection, Antimicrobials, Modelling, Evolution, INSERM, Université de Paris, Paris, France, Bichat Claude Bernard Hospital, Assistance publique-Hôpitaux de Paris, Paris, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d'Ivoire, Département de Dermatologie-Infectiologie, Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouet-Boigny, Abidjan, Côte d'Ivoire.;IDLIC-Maladies Infectieuses Dans Les Pays à Ressources Limitées, INSERM U1219, Bordeaux, France, Bordeaux Population Health, University of Bordeaux, Bordeaux, France.;Department of Zoology, University of Oxford, Oxford, UK.;Department of Zoology, University of Oxford, Oxford, UK, Harvard Medical School, Harvard University, Boston, MA, USA, Computational Epidemiology Group, Boston Children's Hospital, Boston, MA, USA.;INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France. Electronic address: vittoria.colizza@inserm.fr. | 12 | |||
| Journal Article;Comment | en | Authors' response: Plenty of coronaviruses but no SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32127125 | 2020-03-08 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__virology;Middle East Respiratory Syndrome Coronavirus;Pandemics;Phylogeny;Pneumonia, Viral__virology;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Chantal B Reusken;Bart Haagmans;Adam Meijer;Victor M Corman;Anna Papa;Remi Charrel;Christian Drosten;Marion Koopmans | Coronavirus;SARS-CoV-2;respiratory infections | 2020-03-05 01:00:00+01:00 | 32127125 | FR;GR;NL;DE | Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.;Viroscience department, Erasmus MC, Rotterdam, the Netherlands.;Charité - Universitätsmedizin Berlin Institute of Virology, Berlin, Germany and German Centre for Infection Research (DZIF), Berlin, Germany.;Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.;Unité des Virus Emergents (Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France. | 18 | ||||||
| 10.3390/biology9030050 | Journal Article | en | Understanding Unreported Cases in the COVID-19 Epidemic Outbreak in Wuhan, China, and the Importance of Major Public Health Interventions. | https://www.ncbi.nlm.nih.gov/pubmed/32182724 | We develop a mathematical model to provide epidemic predictions for the COVID-19 epidemic in Wuhan, China. We use reported case data up to 31 January 2020 from the Chinese Center for Disease Control and Prevention and the Wuhan Municipal Health Commission to parameterize the model. From the parameterized model, we identify the number of unreported cases. We then use the model to project the epidemic forward with varying levels of public health interventions. The model predictions emphasize the importance of major public health interventions in controlling COVID-19 epidemics. | 2079-7737 | 2020-03-08 01:00:00+01:00 | pubmed | Biology | Zhihua Liu;Pierre Magal;Ousmane Seydi;Glenn Webb | corona virus;epidemic mathematical model;isolation;public closings;quarantine;reported and unreported cases | 2020-03-08 01:00:00+01:00 | 32182724 | FR;CN;SN;US | School of Mathematical Sciences, Beijing Normal University, Beijing 100875, China.;Université de Bordeaux, IMB, UMR 5251, F-33400 Talence, France.;CNRS, IMB, UMR 5251, F-33400 Talence, France.;Département Tronc Commun, École Polytechnique de Thiés, Thies 21001, Senegal.;Mathematics Department, Vanderbilt University, Nashville, TN 37212, USA. | 19 | |||
| Editorial;Comment | en | Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32145363 | 2020-03-08 01:00:00+01:00 | pubmed | Adenosine Monophosphate__analogs & derivatives;Alanine__analogs & derivatives;Betacoronavirus;Chloroquine;Coronavirus;Coronavirus Infections;Hydroxychloroquine;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Philippe Colson;Jean-Marc Rolain;Jean-Christophe Lagier;Philippe Brouqui;Didier Raoult | 2020-03-04 01:00:00+01:00 | 32145363 | FR | Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.;Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin, 13005 Marseille, France, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. Electronic address: didier.raoult@gmail.com. | 22 | |||||||
| Editorial;Comment | en | Coronavirus Disease 2019 (COVID-19): A critical care perspective beyond China. | https://www.ncbi.nlm.nih.gov/pubmed/32142972 | 2020-03-08 01:00:00+01:00 | pubmed | Betacoronavirus;China;Coronavirus;Coronavirus Infections;Critical Care;Critical Illness;Humans;Pandemics;Pneumonia, Viral;Retrospective Studies;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jordi Rello;Sofia Tejada;Caroline Userovici;Kostoula Arvaniti;Jérôme Pugin;Grant Waterer | Coronavirus;Influenza;Intensive care medicine;Mechanical ventilation;Outbreak;Pneumonia;SARS-COV-2 | 2020-03-03 01:00:00+01:00 | 32142972 | FR;GR;CH;AU;ES;PS | Centro de Investigación Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto Salud Carlos III, Madrid, Spain, Clinical Research/Epidemiology in Pneumonia and Sepsis (CRIPS), Vall d'Hebron Institut of Research (VHIR), Barcelona, Spain, Anaesthesiology and Critical Care Division, CHU Nîmes, University Montpellier-Nîmes, Nîmes, France. Electronic address: jrello@crips.es.;Centro de Investigación Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto Salud Carlos III, Madrid, Spain, Clinical Research/Epidemiology in Pneumonia and Sepsis (CRIPS), Vall d'Hebron Institut of Research (VHIR), Barcelona, Spain.;Département Anesthésie Réanimation, Hôpital Pitié-Salpêtrière, Paris, France, Junior Group of the French Society of Anaesthesia and Intensive Care Medicine (SFAR), Paris, France.;Critical Care Department, General Hospital Papageorgiou, Thessaloniki, Greece.;Division of Intensive Care, University Hospitals of Geneva, Geneva, Switzerland.;School of Medicine, University of Western Australia, Perth, Australia. | 28 | ||||||
| 10.1016/j.ijantimicag.2020.105944 | Editorial | en | Teicoplanin: an alternative drug for the treatment of COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32179150 | In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells. This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus. | 0924-8579 | 2020-03-15 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__drug therapy;Drug Repositioning;Humans;Pandemics;Pneumonia, Viral__drug therapy;Teicoplanin__therapeutic use;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Sophie Alexandra Baron;Christian Devaux;Philippe Colson;Didier Raoult;Jean-Marc Rolain | COVID-19;Drug repurposing;SARS-CoV-2;Teicoplanin | 2020-03-13 01:00:00+01:00 | 32179150 | FR | Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.;Aix-Marseille Université, IRD, APHM, VITROME, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.;Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France, IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.;Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France, IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France. Electronic address: jean-marc.rolain@univ-amu.fr. | 33 | ||
| Letter;Comment | en | Novel Coronavirus (COVID-19) Epidemic: What Are the Risks for Older Patients? | https://www.ncbi.nlm.nih.gov/pubmed/32162679 | 2020-03-15 01:00:00+01:00 | pubmed | Betacoronavirus;China;Coronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Antoine Garnier-Crussard;Emmanuel Forestier;Thomas Gilbert;Pierre Krolak-Salmon | 2020-03-12 01:00:00+01:00 | 32162679 | FR | Institut du Vieillissement I-Vie, Hospices Civils de Lyon, Lyon, France.;Centre Mémoire Ressource et Recherche de Lyon, Hospices Civils de Lyon, Lyon, France.;Service de Maladies Infectieuses, Centre Hospitalier Métropole Savoie, Chambéry, France.;Health Services and Performance Research (HESPER EA7425), Lyon, France.;Centre de Recherche Clinique CRC-VCF (Vieillissement-Cerveau-Fragilité), Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France. | 36 | |||||||
| 10.1093/ndt/gfaa069 | Journal Article | en | Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. | https://www.ncbi.nlm.nih.gov/pubmed/32196116 | COVID-19, a disease caused by a novel coronavirus, is a major global human threat that has turned into a pandemic. This novel coronavirus has specifically high morbidity in the elderly and in comorbid populations. Uraemic patients on dialysis combine an intrinsic fragility and a very frequent burden of comorbidities with a specific setting in which many patients are repeatedly treated in the same area (haemodialysis centres). Moreover, if infected, the intensity of dialysis requiring specialized resources and staff is further complicated by requirements for isolation, control and prevention, putting healthcare systems under exceptional additional strain. Therefore, all measures to slow if not to eradicate the pandemic and to control unmanageably high incidence rates must be taken very seriously. The aim of the present review of the European Dialysis (EUDIAL) Working Group of ERA-EDTA is to provide recommendations for the prevention, mitigation and containment in haemodialysis centres of the emerging COVID-19 pandemic. The management of patients on dialysis affected by COVID-19 must be carried out according to strict protocols to minimize the risk for other patients and personnel taking care of these patients. Measures of prevention, protection, screening, isolation and distribution have been shown to be efficient in similar settings. They are essential in the management of the pandemic and should be taken in the early stages of the disease. | 0931-0509,1460-2385 | 2020-03-22 01:00:00+01:00 | pubmed | Betacoronavirus;Caregivers;Coronavirus Infections__epidemiology;Equipment Contamination;Hospitals, Isolation;Humans;Pandemics__prevention & control;Patient Care Team;Pneumonia, Viral__epidemiology;Renal Dialysis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nephrology Dialysis Transplantation | Carlo Basile;Christian Combe;Francesco Pizzarelli;Adrian Covic;Andrew Davenport;Mehmet Kanbay;Dimitrios Kirmizis;Daniel Schneditz;Frank van der Sande;Sandip Mitra | COVID-19;coronavirus;end-stage kidney disease;haemodialysis;pandemic | 2020-03-21 01:00:00+01:00 | 32196116 | FR;GB;RO;IT;TR;NL;AT | Division of Nephrology, Miulli General Hospital, Acquaviva delle Fonti, Italy.;Associazione Nefrologica Gabriella Sebastio, Martina Franca, Italy.;Service de Néphrologie Transplantation Dialyse Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Nephrology Unit, SM Annunziata Hospital, Florence, Italy.;Nephrology Clinic, Dialysis and Renal Transplant Center - 'C.I. Parhon' University Hospital, Iasi, Romania.;'Grigore T. Popa' University of Medicine, Iasi, Romania.;UCL Centre for Nephrology, Royal Free Hospital, Division of Medicine, University College, London, UK.;Division of Nephrology, Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.;Department of Nephrology, Colchester General Hospital, Colchester, UK.;Otto Loewi Research Center, Medical University of Graz, Graz, Austria.;Division of Nephrology, Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands.;Manchester Academy of Health Sciences Centre, Manchester University Hospitals Foundation Trust and University of Manchester, Manchester, UK. | 42 | ||
| 10.1016/s0140-6736(20)30673-5 | Journal Article | en | COVID-19: towards controlling of a pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32197103 | 0140-6736 | 2020-03-22 01:00:00+01:00 | pubmed | Age Factors;Aneurysm, Infected;Betacoronavirus__genetics;Civil Defense;Comorbidity;Contact Tracing;Coronavirus Infections__mortality;Developing Countries;Financial Support;Humans;Pandemics__prevention & control;Patient Isolation;Pneumonia, Viral__mortality;Population Surveillance;Quarantine;Risk Assessment;World Health Organization;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet | Juliet Bedford;Delia Enria;Johan Giesecke;David L Heymann;Chikwe Ihekweazu;Gary Kobinger;H Clifford Lane;Ziad Memish;Myoung-Don Oh;Amadou Alpha Sall;Anne Schuchat;Kumnuan Ungchusak;Lothar H Wieler | 2020-03-17 01:00:00+01:00 | 32197103 | SE;AR;FR;CA;SA;NG;SN;GB;US;TH;KR;DE | Anthrologica, Oxfordshire, UK.;Instituto Nacional de Enfermedades Virales Humanas (INEVH) "Julio Maiztegui" and CCWHO-OPS on Viral Haemorrhagic Fevers and Arboviruses, Buenos Aires, Argentina.;Karolinska Institute, Stockholm, Sweden.;Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK. Electronic address: david.heymann@lshtm.ac.uk.;Nigeria Centre for Disease Control, Abuja, Nigeria.;Infectious Disease Research Centre, Université Laval, Faculty of Medicine, Québec City, Canada.;National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.;Research and Innovation Center, King Saud Medical City, Ministry of Health, Riyadh, Saudi Arabia.;J W Lee Center for Global Medicine, SNU College of Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.;Institut Pasteur de Dakar, Dakar, Senegal.;Centers for Disease Control and Prevention, Atlanta, GA, USA.;Ministry of Health, Department of Diseases Control, Bangkok, Thailand.;Robert Koch Institute, Berlin, Germany. | 53 | ||||
| 10.1016/s0140-6736(20)30561-4 | Journal Article | en | Preparedness is essential for malaria-endemic regions during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32192582 | 0140-6736 | 2020-03-22 01:00:00+01:00 | pubmed | Coronavirus Infections__epidemiology;Endemic Diseases;Humans;Malaria__epidemiology;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;COVID-19 | The Lancet | Jigang Wang;Chengchao Xu;Yin Kwan Wong;Yingke He;Ayôla A Adegnika;Peter G Kremsner;Selidji T Agnandji;Amadou A Sall;Zhen Liang;Chen Qiu;Fu Long Liao;Tingliang Jiang;Sanjeev Krishna;Youyou Tu | 2020-03-17 01:00:00+01:00 | 32192582 | FR;SG;CN;SN;GA;GB;DE | ShenZhen People's Hospital, ShenZhen, China, Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China, Central People's Hospital of Zhanjiang, Zhanjiang, Guangdong, China.;ShenZhen People's Hospital, ShenZhen, China, Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.;Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China, Department of Anaesthesiology, Singapore General Hospital, Singapore.;Department of Anaesthesiology, Singapore General Hospital, Singapore.;Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany, Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.;Institut Pasteur de Dakar, Dakar, Senegal.;ShenZhen People's Hospital, ShenZhen, China.;Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.;Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany, Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon, Centre for Diagnostics and Antimicrobial Resistance, Institute for Infection Immunity, St George's University of London, London, UK, St George's University Hospitals NHS Foundation Trust, London, UK.;Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: yytu@icmm.ac.cn. | 54 | ||||
| 10.1007/s00038-020-01362-x | Editorial | en | ASPHER statement on the novel coronavirus disease (COVID-19) outbreak emergency. | https://www.ncbi.nlm.nih.gov/pubmed/32227250 | 1661-8556,1661-8564 | 2020-03-29 01:00:00+01:00 | pubmed | International Journal of Public Health | John Middleton;Jose M Martin-Moreno;Henrique Barros;Laurent Chambaud;Carlo Signorelli | 2020-03-29 01:00:00+01:00 | 32227250 | FR;PT;IT;ES;BE | Association of Schools of Public Health in the European Region - ASPHER, Brussels, Belgium. john.middleton@aspher.org.;ASPHER Honours Committee, University of Valencia, Valencia, Spain.;Institute of Public Health, University of Porto, Porto, Portugal.;EHESP School of Public Health, Rennes, France.;School of Public Health, Vita-Salute San Raffaele University, Milan, Italy. | 57 | |||||
| Editorial;Comment | en | Hospitals as health factories and the coronavirus epidemic. | https://www.ncbi.nlm.nih.gov/pubmed/32200489 | 2020-03-29 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__prevention & control;Disease Transmission, Infectious__prevention & control;Economics, Hospital;Hospital Administration;Hospitals__standards;Humans;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;COVID-19;severe acute respiratory syndrome coronavirus 2 | Giorgina Barbara Piccoli | Dialysis;Hospital architecture;Hospital wards;SARS-CoV-2 infection | 2020-03-23 01:00:00+01:00 | 32200489 | FR;IT | Nephrologie, Centre Hospitalier Le Mans, Avenue Roubillard 196, 72000, Le Mans, France. gbpiccoli@yahoo.it.;Dipartimento Di Scienze Cliniche E Biologiche, Università Di Torino, Turin, Italy. gbpiccoli@yahoo.it. | 59 | ||||||
| 10.1016/j.jns.2020.116803 | Journal Article;Practice Guideline | en | Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32247193 | 0022-510X | 2020-03-29 01:00:00+01:00 | pubmed | Betacoronavirus;Clinical Trials as Topic;Coronavirus Infections__complications;Disease Management;Disease Susceptibility;Humans;Immunoglobulins, Intravenous__therapeutic use;Immunologic Factors__therapeutic use;Immunosuppressive Agents__therapeutic use;Immunotherapy;Lambert-Eaton Myasthenic Syndrome__complications;Myasthenia Gravis__complications;Pandemics;Plasma Exchange;Pneumonia, Viral__complications;Vaccines;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Journal of the Neurological Sciences | Saiju Jacob;Srikanth Muppidi;Amanda Guidon;Jeffrey Guptill;Michael Hehir;James F Howard;Isabel Illa;Renato Mantegazza;Hiroyuki Murai;Kimiaki Utsugisawa;John Vissing;Heinz Wiendl;Richard J Nowak | 2020-03-25 01:00:00+01:00 | 32247193 | FR;JP;GB;US;IT;ES;DK;DE | Department of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH, United Kingdom. Electronic address: saiju.jacob@uhb.nhs.uk.;Department of Neurology, Stanford Neuroscience Health Center, Palo Alto, CA 94304, USA. Electronic address: muppidis@stanford.edu.;Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.;Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.;Department of Neurology, University of Vermont Medical Center, Burlington, VT 05401, USA.;Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7025, USA.;Catedràtica Neurologia U.A.B., Unitat Patologia Neuromuscular, Servei Neurologia, Hospital Santa Creu i Sant Pau, C/ Pare Claret 167, Barcelona 08025, Spain.;Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milano, Italy.;Department of Neurology, School of Medicine, International University of Health and Welfare, Narita, Japan.;Department of Neurology, Hanamaki General Hospital, Japan.;Department of Neurology, 2082 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.;Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany.;Department of Neurology, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: richard.nowak@yale.edu. | 66 | ||||
| 10.1038/s41597-020-0448-0 | Dataset;Journal Article;Research Support, Non-U.S. Gov't | en | Epidemiological data from the COVID-19 outbreak, real-time case information. | https://www.ncbi.nlm.nih.gov/pubmed/32210236 | Cases of a novel coronavirus were first reported in Wuhan, Hubei province, China, in December 2019 and have since spread across the world. Epidemiological studies have indicated human-to-human transmission in China and elsewhere. To aid the analysis and tracking of the COVID-19 epidemic we collected and curated individual-level data from national, provincial, and municipal health reports, as well as additional information from online reports. All data are geo-coded and, where available, include symptoms, key dates (date of onset, admission, and confirmation), and travel history. The generation of detailed, real-time, and robust data for emerging disease outbreaks is important and can help to generate robust evidence that will support and inform public health decision making. | 2052-4463 | 2020-03-29 01:00:00+01:00 | pubmed | Betacoronavirus;China;Coronavirus Infections__epidemiology;Epidemics;Geographic Mapping;Geography;Humans;Pandemics;Pneumonia, Viral__epidemiology;Public Health;COVID-19;severe acute respiratory syndrome coronavirus 2 | Scientific Data | Bo Xu;Bernardo Gutierrez;Sumiko Mekaru;Kara Sewalk;Lauren Goodwin;Alyssa Loskill;Emily L Cohn;Yulin Hswen;Sarah C Hill;Maria M Cobo;Alexander E Zarebski;Sabrina Li;Chieh-Hsi Wu;Erin Hulland;Julia D Morgan;Lin Wang;Katelynn O'Brien;Samuel V Scarpino;John S Brownstein;Oliver G Pybus;David M Pigott;Moritz U G Kraemer | 2020-03-24 01:00:00+01:00 | 32210236 | FR;CN;GB;US;EC | Ministry of Education Key Laboratory for Earth System Modeling, Department of Earth System Science, Tsinghua University, Beijing, China.;Department of Zoology, University of Oxford, Oxford, United Kingdom.;School of Biological and Environmental Sciences, Universidad San Francisco de Quito USFQ, Quito, Ecuador.;Computational Epidemiology Lab, Boston Children's Hospital, Boston, United States.;Booz Allen Hamilton, Westborough Massachusetts, United States.;School of Public Health, Boston University, Boston, United States.;Department of Paediatrics, University of Oxford, Oxford, United Kingdom.;Department of Zoology, University of Oxford, Oxford, United Kingdom. alexander.zarebski@zoo.ox.ac.uk.;School of Geography and the Environment, University of Oxford, Oxford, United Kingdom.;Mathematical Sciences, University of Southampton, Southampton, United Kingdom.;Department of Health Metrics Sciences, University of Washington, Seattle, United States.;Institute for Health Metrics and Evaluation, University of Washington, Seattle, United States.;Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France.;Department of Genetics, University of Cambridge, Cambridge, United Kingdom.;Network Science Institute, Northeastern University, Boston, United States.;Department of Pediatrics, Harvard Medical School, Boston, United States.;Department of Health Metrics Sciences, University of Washington, Seattle, United States. pigottdm@uw.edu.;Institute for Health Metrics and Evaluation, University of Washington, Seattle, United States. pigottdm@uw.edu.;Department of Zoology, University of Oxford, Oxford, United Kingdom. moritz.kraemer@zoo.ox.ac.uk.;Computational Epidemiology Lab, Boston Children's Hospital, Boston, United States. moritz.kraemer@zoo.ox.ac.uk.;Department of Pediatrics, Harvard Medical School, Boston, United States. moritz.kraemer@zoo.ox.ac.uk. | 70 | |||
| 10.1016/j.ijantimicag.2020.105960 | Journal Article | en | Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32251731 | The recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) is responsible for a worldwide pandemic. Given the global health emergency, drug repositioning is the most reliable option to design an efficient therapy for infected patients without delay. The first step of the viral replication cycle [i.e. attachment to the surface of respiratory cells, mediated by the spike (S) viral protein] offers several potential therapeutic targets. The S protein uses the angiotension-converting enzyme-2 (ACE-2) receptor for entry, but also sialic acids linked to host cell surface gangliosides. Using a combination of structural and molecular modelling approaches, this study showed that chloroquine (CLQ), one of the drugs currently under investigation for SARS-CoV-2 treatment, binds sialic acids and gangliosides with high affinity. A new type of ganglioside-binding domain at the tip of the N-terminal domain of the SARS-CoV-2 S protein was identified. This domain (111-158), which is fully conserved among clinical isolates worldwide, may improve attachment of the virus to lipid rafts and facilitate contact with the ACE-2 receptor. This study showed that, in the presence of CLQ [or its more active derivative, hydroxychloroquine (CLQ-OH)], the viral S protein is no longer able to bind gangliosides. The identification of this new mechanism of action of CLQ and CLQ-OH supports the use of these repositioned drugs to cure patients infected with SARS-CoV-2. The in-silico approaches used in this study might also be used to assess the efficiency of a broad range of repositioned and/or innovative drug candidates before clinical evaluation. | 0924-8579 | 2020-04-05 02:00:00+02:00 | pubmed | Amino Acid Sequence;Betacoronavirus__chemistry;Chloroquine__chemistry;Coronavirus Infections__drug therapy;Humans;Hydroxychloroquine__chemistry;Models, Molecular;Molecular Targeted Therapy;Pandemics;Pneumonia, Viral__drug therapy;Protein Structure, Quaternary;Protein Structure, Tertiary;Sequence Analysis, Protein;Spike Glycoprotein, Coronavirus__chemistry;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Jacques Fantini;Coralie Di Scala;Henri Chahinian;Nouara Yahi | Chloroquine;Coronavirus;Ganglioside;Pandemic;SARS-CoV-2;Spike | 2020-04-03 02:00:00+02:00 | 32251731 | FR | INSERM UMR_S 1072, Marseille, France, Department of Biology, Aix-Marseille Université, Marseille, France. Electronic address: jacques.fantini@univ-amu.fr.;INMED, INSERM U1249, Parc Scientifique de Luminy, Marseille, France.;INSERM UMR_S 1072, Marseille, France, Department of Biology, Aix-Marseille Université, Marseille, France. | 79 | ||
| 10.1016/j.diii.2020.03.014 | Journal Article;Review | en | COVID-19 pneumonia: A review of typical CT findings and differential diagnosis. | https://www.ncbi.nlm.nih.gov/pubmed/32291197 | The standard of reference for confirming COVID-19 relies on microbiological tests such as real-time polymerase chain reaction (RT-PCR) or sequencing. However, these tests might not be available in an emergency setting. Computed tomography (CT) can be used as an important complement for the diagnosis of COVID-19 pneumonia in the current epidemic context. In this review, we present the typical CT features of COVID-19 pneumonia and discuss the main differential diagnosis. | 2211-5684 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnosis;Diagnosis, Differential;Emergency Service, Hospital;Humans;Pandemics;Pneumonia, Viral__diagnosis;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | Diagnostic and Interventional Imaging | C Hani;N H Trieu;I Saab;S Dangeard;S Bennani;G Chassagnon;M-P Revel | COVID-19 pneumonia;Cryptogenic Organizing Pneumonia;Pneumonia;Tomography;X-Ray Computed | 2020-04-03 02:00:00+02:00 | 32291197 | FR | Department of Radiology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France.;Department of Radiology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France, Université de Paris, Descartes-Paris 5, 75006 Paris, France.;Department of Radiology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France, Université de Paris, Descartes-Paris 5, 75006 Paris, France. Electronic address: marie-pierre.revel@aphp.fr. | 80 | ||
| Letter;Comment | en | Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32231328 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Cardiovascular System;Coronavirus Infections;Humans;Pandemics;Peptidyl-Dipeptidase A;Pneumonia, Viral;Renin-Angiotensin System__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean-Jacques Mourad;Bernard I Levy | 2020-04-02 02:00:00+02:00 | 32231328 | FR | ESH Excellence Centre, Internal Medicine, Groupe hospitalier Paris Saint-Joseph, Paris, France. jjmourad@hpsj.fr.;InsermU970, PARRC, Hôpital Lariboisière, Paris, France. | 88 | |||||||
| 10.1097/mej.0000000000000704 | Journal Article | en | COVID-19: response plan for International Medical Assistance companies. | https://www.ncbi.nlm.nih.gov/pubmed/32229768 | 0969-9546 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;International Agencies;Pandemics;Pneumonia, Viral__epidemiology;Travel;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Emergency Medicine | François-Xavier Duchateau;Geoffrey Ramin;Anne Lepetit | 2020-04-02 02:00:00+02:00 | 32229768 | AU;FR;BE | Allianz Partners Medical Global Competency Center Europe Brussels, Brussels, Belgium.;Allianz Partners Group Medical Operations, Paris, France.;Allianz Partners Medical Global Competency Center Asia Pacific, Brisbane, Australia. | 89 | ||||
| 10.1093/ehjci/jeaa072 | Journal Article;Practice Guideline | en | COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel. | https://www.ncbi.nlm.nih.gov/pubmed/32242891 | 2047-2404,2047-2412 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__diagnostic imaging;Echocardiography__methods;Echocardiography, Transesophageal__methods;Heart Diseases__diagnostic imaging;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Pandemics__prevention & control;Pneumonia, Viral__diagnostic imaging;Ultrasonography, Prenatal__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Heart Journal - Cardiovascular Imaging | Helge Skulstad;Bernard Cosyns;Bogdan A Popescu;Maurizio Galderisi;Giovanni Di Salvo;Erwan Donal;Steffen Petersen;Alessia Gimelli;Kristina H Haugaa;Denisa Muraru;Ana G Almeida;Jeanette Schulz-Menger;Marc R Dweck;Gianluca Pontone;Leyla Elif Sade;Bernhard Gerber;Pal Maurovich-Horvat;Tara Bharucha;Matteo Cameli;Julien Magne;Mark Westwood;Gerald Maurer;Thor Edvardsen | 2020-04-04 02:00:00+02:00 | 32242891 | FR;NO;PT;RO;GB;AT;IT;TR;HU;BE;DE | Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.;Faculty of Medicine, University of Oslo, Oslo, Norway.;Centrum voor Hart en Vaatziekten (CHVZ), Universitair Ziekenhuis Brussel, Vrij Universiteit van Brussel, Brussels, Belgium.;Department of Cardiology, University of Medicine and Pharmacy 'Carol Davila'-Euroecolab, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C. C. Iliescu', Bucharest, Romania.;Department of Advanced Biomedical Sciences, Federico II University Hospital, Naples, Italy.;University Hospital Padua, Paediatric Cardiology, Padua, Italy.;University of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, Rennes, France.;William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK.;Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.;Fondazione Toscana G. Monasterio, Pisa, Italy.;Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.;Cardiology, University Hospital Santa Maria /CHLN, CCUL, Faculty of Medicine of Lisbon University, Lisbon, Portugal.;Charité Medical Faculty of the Humboldt University Berlin, ECRC, Berlin, Germany.;DZHK, Partner site, Berlin, Germany.;Helios Clinics Berlin-Buch, Cardiology, Berlin, Germany.;Centre for Cardiovascular Science, University of Edinburgh, UK.;Department of Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Milan, Italy.;Department of Cardiology, University of Baskent, Ankara, Turkey.;Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc, Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.;Medical Imaging Centre, Semmelweis University, Budapest, Hungary.;Department of Congenital Cardiology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.;Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.;CHU Limoges, Hôpital Dupuytren, Service Cardiologie, Limoges, France.;INSERM U1094, Univ. Limoges, CHU Limoges, IRD, U1094, GEIST, 2, Limoges, France.;Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. | 93 | ||||
| Letter | en | SARS-CoV-2 Infection in a Pediatric Department in Milan: A Logistic Rather Than a Clinical Emergency. | https://www.ncbi.nlm.nih.gov/pubmed/32221165 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Child, Hospitalized;Coronavirus Infections__diagnosis;Humans;Italy;Pandemics;Parents;Patient Isolation;Pediatrics__organization & administration;Pneumonia, Viral__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Giovanna Chidini;Cristina Villa;Edoardo Calderini;Paola Marchisio;Daniele De Luca | 2020-03-30 02:00:00+02:00 | 32221165 | FR;IT;US | Department of Anesthesia and Intensive Care, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Pediatric Intensive Care Unit, Milan, Italy Department of Anesthesia and Intensive Care, Fondazione IRCCS Cà Granda Ospedale, Maggiore Policlinico Fondazione IRCCS Cà Granda Ospedale Maggiore, Policlinico, Milan, Italy Pédiatrie et Réanimation Néonatale - Pediatrics and Neonatal Critical Care, Hôpital Antoine Béclère - "A. Béclère" Medical center - GHU Paris Saclay, APHP. | 96 | |||||||
| NIAMS NIH HHS;NIAMS NIH HHS | 10.7326/m20-1223 | Editorial | en | A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32227189 | 0003-4819,1539-3704 | 2020-04-05 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Azithromycin__therapeutic use;Betacoronavirus;Clinical Trials as Topic__standards;Confounding Factors, Epidemiologic;Coronavirus Infections__drug therapy;Humans;Hydroxychloroquine__therapeutic use;Information Dissemination;Mass Media;Pandemics;Pneumonia, Viral__drug therapy;Research Design__standards;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Annals of Internal Medicine | Alfred H J Kim;Jeffrey A Sparks;Jean W Liew;Michael S Putman;Francis Berenbaum;Alí Duarte-García;Elizabeth R Graef;Peter Korsten;Sebastian E Sattui;Emily Sirotich;Manuel F Ugarte-Gil;Kate Webb;Rebecca Grainger | Antimalarials;Biomarkers;COVID-19;Chloroquine;Intensive care units;Metastasis;Polymerase chain reaction;Post-exposure prophylaxis;Safety;Viral load | 2020-03-30 02:00:00+02:00 | 32227189 | FR;IL;CA;NZ;GB;US;ZA;PE;DE | [{"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "L30 AR072421"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "P30 AR073752"}] | Washington University School of Medicine, St. Louis, Missouri (A.H.K.).;Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (J.A.S.).;University of Washington, Seattle, Washington (J.W.L.).;Northwestern Medicine, Chicago, Illinois (M.S.P.).;Sorbonne University, Inserm CRSA, AP-HP Saint-Antoine Hospital, Paris, France (F.B.).;Mayo Clinic, Rochester, Minnesota (A.D.).;Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (E.R.G.).;University Medical Center Göttingen, Göttingen, Germany (P.K.).;Hospital for Special Surgery, New York, New York (S.E.S.).;McMaster University, Hamilton, and Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada (E.S.).;School of Medicine, Universidad Científica del Sur and Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru (M.F.U.).;University of Cape Town, Cape Town, South Africa, and the Francis Crick Institute, London, United Kingdom (K.W.).;University of Otago, Wellington, New Zealand (R.G.). | 105 | |
| 10.1503/jpn.200061 | Journal Article | en | Consensus statement on the use of clozapine during the COVID-19 pandemic | https://www.ncbi.nlm.nih.gov/pubmed/32242646 | 1180-4882 | 2020-04-05 02:00:00+02:00 | pubmed | Journal of Psychiatry and Neuroscience | Dan Siskind;William G. Honer;Scott Clark;Christoph U. Correll;Alkomiet Hasan;Oliver Howes;John M. Kane;Deanna L. Kelly;Robert Laitman;Jimmy Lee;James H. MacCabe;Nick Myles;Jimmi Nielsen;Peter F. Schulte;David Taylor;Helene Verdoux;Amanda Wheeler;Oliver Freudenreich | 2020-04-03 02:00:00+02:00 | 32242646 | FR;SG;CA;GB;US;AU;NL;DK;DE | From the Metro South Addiction and Mental Health Service, Brisbane, Australia (Siskind), the University of Queensland, School of Clinical Medicine, Brisbane, Australia (Siskind, Myles), the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Honer), the University of Adelaide, School of Medicine, Adelaide, Australia (Clark, Kane), the The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA (Correll, Kane), the Zucker School of Medicine at Hofstra/ Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA (Correll), Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany (Correll), the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Augsburg, Augsburg, Germany (Hassan), the Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK (Howes, MacCabe), the MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK (Howes), the Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK (Howes), the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA (Kelly), the Bronx Westchester Medical Group, New York, NY, USA (Laitman), the North Region & Department of Psychosis, Institute of Mental Health, Singapore (Lee), the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Lee), the Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen (Nielsen), the Mental Health Service Noord-Holland- Noord, Alkmaar, The Netherlands (Schulte), the South London and Maudsley NHS Foundation Trust, Pharmacy Department, Maudsley Hospital, London, UK (Taylor), the University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France (Verdoux), the Menzies Health Institute Queensland, Griffith University, Brisbane, Australia (Wheeler), the MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA (Freudenreich), and the Harvard Medical School, Boston, MA, USA (Freudenreich) | 107 | |||||
| 10.1016/j.amp.2020.03.001 | Journal Article | fr | [Medico-psychological aspects relating to the coronavirus epidemic (Covid-19): The contribution of the theory of signal detection and the concept of place of control]. | https://www.ncbi.nlm.nih.gov/pubmed/32518421 | 0003-4487 | 2020-04-05 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Anne-Frédérique Naviaux;Pascal Janne;Maximilien Gourdin | Comportement;Coronavirus;Covid-19;Health locus of control;Pandemic;Signal detection theory | 2020-03-31 02:00:00+02:00 | 32518421 | FR;BE;GB;UNK | Health Service Executive (HSE) Summerhill Community Mental Health Service, Summerhill, Wexford, Y35 KC58, Irlande.;Faculty of Medicine, Université catholique de Louvain, avenue Emmanuel-Mounier 50, 1200 Woluwé-Saint-Lambert, Belgique.;Université catholique de Louvain, CHU UCL Namur, avenue Dr-G.-Thérasse, 5530 Yvoir, Belgique.;Faculty of Psychology, Université catholique de Louvain, place Cardinal-Mercier 10, 1348 Ottignies-Louvain-la-Neuve, Belgique. | 109 | ||||
| 10.1016/j.jviscsurg.2020.03.008 | Journal Article | en | Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic. | https://www.ncbi.nlm.nih.gov/pubmed/32249098 | The Covid-19 pandemic is changing the organization of healthcare and has a direct impact on digestive surgery. Healthcare priorities and circuits are being modified. Emergency surgery is still a priority. Functional surgery is to be deferred. Laparoscopic surgery must follow strict rules so as not to expose healthcare professionals (HCPs) to added risk. The question looms large in cancer surgery-go ahead or defer? There is probably an added risk due to the pandemic that must be balanced against the risk incurred by deferring surgery. For each type of cancer-colon, pancreas, oesogastric, hepatocellular carcinoma-morbidity and mortality rates are stated and compared with the oncological risk incurred by deferring surgery and/or the tumour doubling time. Strategies can be proposed based on this comparison. For colonic cancers T1-2, N0, it is advisable to defer surgery. For advanced colonic lesions, it seems judicious to undertake neoadjuvant chemotherapy and then wait. For rectal cancers T3-4 and/or N+, chemoradiotherapy is indicated, short radiotherapy must be discussed (followed by a waiting period) to reduce time of exposure in the hospital and to prevent infections. Most complex surgery with high morbidity and mortality-oesogastric, hepatic or pancreatic-is most often best deferred. | 1878-7886 | 2020-04-05 02:00:00+02:00 | pubmed | Coronavirus Infections;Digestive System Diseases__surgery;Digestive System Neoplasms__surgery;Health Services Needs and Demand;Humans;Laparoscopy;Pandemics;Pneumonia, Viral;Postoperative Care;Practice Guidelines as Topic;Time-to-Treatment;COVID-19 | Journal of Visceral Surgery | J-J Tuech;A Gangloff;F Di Fiore;P Michel;C Brigand;K Slim;M Pocard;L Schwarz | Cancer;Coronavirus;Covid-19;Digestive surgery;Surgical complications | 2020-03-31 02:00:00+02:00 | 32249098 | FR | Rouen University Hospital, Department of Digestive Surgery, 1, rue de Germont, 76031 Rouen cedex, France, Normandie University, UNIROUEN, UMR 1245 Inserm, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, 76000 Rouen, France. Electronic address: jean-jacques.tuech@chu-rouen.fr.;Rouen University Hospital, Department of Digestive Oncology, 1, rue de Germont, 76031 Rouen cedex, France.;Normandie University, UNIROUEN, UMR 1245 Inserm, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, 76000 Rouen, France, Rouen University Hospital, Department of Digestive Oncology, 1, rue de Germont, 76031 Rouen cedex, France.;Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg University Hospital, 67200 Strasbourg, France.;Department of digestive surgery, CHU Clermont-Ferrand, 63003 Clermont-Ferrand, France.;Université de Paris, UMR 1275 CAP Paris-Tech, 75010 Paris, France, Service de chirurgie digestive et cancérologique Hôpital Lariboisière, 2, rue Ambroise Paré, 75010 Paris, France.;Rouen University Hospital, Department of Digestive Surgery, 1, rue de Germont, 76031 Rouen cedex, France, Normandie University, UNIROUEN, UMR 1245 Inserm, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, 76000 Rouen, France. | 111 | ||
| 10.1016/j.tracli.2020.03.005 | Editorial | en | COVID-19: Is a paradigm change to be expected in health care and transfusion medicine? | https://www.ncbi.nlm.nih.gov/pubmed/32280061 | 1246-7820 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Blood Donors;Blood Transfusion__standards;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Transfusion Clinique et Biologique | O Garraud | 2020-03-31 02:00:00+02:00 | 32280061 | FR | Faculty of medicine, university of Lyon, Saint-Étienne, France, Palliative care, the Ruffec hospital, Ruffec, France. Electronic address: Olivier.garraud@univ-st-etienne.fr. | 115 | ||||
| Letter;Comment | en | International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32342861 | 2020-04-05 02:00:00+02:00 | pubmed | C A M Marijnen;F P Peters;C Rödel;K Bujko;K Haustermans;E Fokas;R Glynne-Jones;V Valentini;K-L G Spindler;M G Guren;Philippe Maingon;F A Calvo;O Pares;B Glimelius;D Sebag-Montefiore | COVID 19;Radiotherapy;Rectal cancer | 2020-04-02 02:00:00+02:00 | 32342861 | FR;SE;NO;PT;GB;PL;IT;NL;DK;ES;BE;DE | Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands, Department of Radiation Oncology, Leiden University Medical Center, the Netherlands.;Department of Radiotherapy and Oncology, University of Frankfurt, Germany.;Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.;Department of Radiation Oncology, University Hospitals Leuven, Belgium.;Department of Radiotherapy, Mount Vernon Centre for Cancer Treatment, Northwood, London, United Kingdom.;Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica S. Cuore, Rome, Italy.;Department of Oncology, Aarhus University Hospital, Denmark.;Department of Oncology, Oslo University Hospital, Norway.;Department of Oncology, Sorbonne University, Paris, France.;Department of Radiotherapy, Universidad de Navarra, Madrid, Spain.;Department of Radiotherapy, Champalimaud Foundation, Lisbon, Portugal.;Department of Immunology, Genetics and Pathology, Uppsala University, Sweden.;Department of Radiotherapy, Leeds Cancer Centre, University of Leeds, UK. | 123 | |||||||
| Letter;Comment | en | Comment on "Epidemiological and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China" by Ren et al. | https://www.ncbi.nlm.nih.gov/pubmed/32299650 | 2020-04-12 02:00:00+02:00 | pubmed | China;Coronavirus;Disease Outbreaks;Heart Transplantation;Surveys and Questionnaires | Pierre Ambrosi | 2020-04-11 02:00:00+02:00 | 32299650 | FR | Cardiac Transplant Unit, La Timone Hospital, Marseille, France, Laboratory of Therapeutics, Aix-Marseille University, Marseille, France. Electronic address: pierre.ambrosi@ap-hm.fr. | 131 | |||||||
| 10.1016/j.chest.2020.03.062 | Editorial | en | The Indirect Benefit on Respiratory Health From the World's Effort to Reduce Transmission of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32283062 | 0012-3692 | 2020-04-12 02:00:00+02:00 | pubmed | Chest | Frédéric Dutheil;Valentin Navel;Maëlys Clinchamps | air pollution;coronavirus;respiratory disease | 2020-04-10 02:00:00+02:00 | 32283062 | FR | University Clermont Auvergne, CNRS, LaPSCo, Clermont-Ferrand, France, Physiological and Psychosocial Stress and Witty Fit, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ferrand, France, Occupational and Environmental Medicine, Ferrand, France. Electronic address: fdutheil@chu-clermontferrand.fr.;University Clermont Auvergne, CNRS, LaPSCo, Clermont-Ferrand, France, Translational Approach to Epithelial Injury and Repair, Ferrand, France, NSERM, GReD, Translational Approach to Epithelial Injury and Repair, Ferrand, France.;Occupational and Environmental Medicine, Ferrand, France. | 132 | ||||
| Journal Article | fr | [COVID-19 andcardiovascular diseases]. | https://www.ncbi.nlm.nih.gov/pubmed/32267110 | COVID-2019 disease mainly affects the respiratory tract and can progress in severe cases to pneumonia, acute respiratory distress syndrome and multi-organ failure. Patients with prior cardiovascular disease are at higher risk of developing an infection and progressing to a severe form of the disease. Also, due to the growing number of infected cases, it is clear that, in addition to the typical respiratory symptoms caused by the infection, some patients suffer from cardiovascular damage. This condition can, in fact, cause significant myocardial damage, which worsens the disease and affects the prognosis. Based on the results of currently published research, it seems important to discuss the manifestations and characteristics of myocardial damage induced by COVID-19 and its impact on patient prognosis. | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Cardiovascular Diseases__complications;Comorbidity;Coronavirus Infections__complications;Humans;Myocardium__pathology;Pandemics;Pneumonia, Viral__complications;Prognosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | G Haeck;A Ancion;P Marechal;C Oury;P Lancellotti | Cardiovascular disease;Myocardial injury;2019;COVID | 2020-04-09 02:00:00+02:00 | 32267110 | FR;BE | Service de Cardiologie, CHU Liège, Belgique.;GIGA Cardiovascular Sciences, ULiège, Belgique.;Service de Cardiologie, CHU Liège, GIGA Cardiovascular Sciences, Liège, Belgique. | 143 | |||||
| 10.1016/j.arcped.2020.03.001 | Editorial | en | COVID-19 virus and children: What do we know? | https://www.ncbi.nlm.nih.gov/pubmed/32253003 | 0929-693X | 2020-04-12 02:00:00+02:00 | pubmed | Adolescent;Asymptomatic Diseases;Betacoronavirus__pathogenicity;Child;Child, Preschool;Coronavirus Infections__complications;Family Health;Female;Humans;Immunocompromised Host;Incidence;Infant;Infant, Newborn;Infection Control;Pandemics;Pneumonia, Viral__complications;Pregnancy;Pregnancy Complications, Infectious;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | Archives de Pédiatrie | A Morand;A Fabre;P Minodier;A Boutin;N Vanel;E Bosdure;P E Fournier | 2020-04-08 02:00:00+02:00 | 32253003 | FR | Service de médecine infantile et pédiatrie spécialisée, CHU Timone, AP-HM, 13385 Marseille cedex 05, France, UMR MEPHI, IRD, IHU-méditerranée-infection, Aix-Marseille university, AP-HM, 13385 Marseille cedex 05, France. Electronic address: aurelie.morand@ap-hm.fr.;Service de pédiatrie multidisciplinaire, CHU Timone, AP-HM, 13385 Marseille cedex 05, France, UMR_S 910, Inserm, faculté de médecine, AMU, 13385 Marseille cedex 05, France.;Service d'urgences pédiatriques, CHU Nord, AP-HM, 13015 Marseille, France.;Service d'urgences pédiatriques, CHU Timone, AP-HM, 13385 Marseille cedex 05, France.;Service de réanimation pédiatrique et de soins continus, CHU Timone, AP-HM, 13385 Marseille cedex 05, France.;Service de médecine infantile et pédiatrie spécialisée, CHU Timone, AP-HM, 13385 Marseille cedex 05, France.;UMR VITROME, service de santé des armées, IRD, IHU-méditerranée-infection, Aix-Marseille university, AP-HM, 13385 Marseille cedex 05, France. | 146 | ||||
| 10.1007/s40291-020-00460-z | Journal Article;Review | en | Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution. | https://www.ncbi.nlm.nih.gov/pubmed/32248387 | This opinion article discusses the increasing attention paid to the role of activating damage-associated molecular patterns (DAMPs) in initiation of inflammatory diseases and suppressing/inhibiting DAMPs (SAMPs) in resolution of inflammatory diseases and, consequently, to the future roles of these novel biomarkers as therapeutic targets and therapeutics. Since controlled production of DAMPs and SAMPs is needed to achieve full homeostatic restoration and repair from tissue injury, only their pathological, not their homeostatic, concentrations should be therapeutically tackled. Therefore, distinct caveats are proposed regarding choosing DAMPs and SAMPs for therapeutic purposes. For example, we discuss the need to a priori identify and define a context-dependent "homeostatic DAMP:SAMP ratio" in each case and a "homeostatic window" of DAMP and SAMP concentrations to guarantee a safe treatment modality to patients. Finally, a few clinical examples of how DAMPs and SAMPs might be used as therapeutic targets or therapeutics in the future are discussed, including inhibition of DAMPs in hyperinflammatory processes (e.g., systemic inflammatory response syndrome, as currently observed in Covid-19), administration of SAMPs in chronic inflammatory diseases, inhibition of SAMPs in hyperresolving processes (e.g., compensatory anti-inflammatory response syndrome), and administration/induction of DAMPs in vaccination procedures and anti-cancer therapy. | 1177-1062,1179-2000 | 2020-04-12 02:00:00+02:00 | pubmed | Biomarkers__blood;Cell-Free Nucleic Acids__blood;Chronic Disease;Coronavirus Infections__drug therapy;HMGB1 Protein__blood;Homeostasis;Humans;Immunity, Innate__drug effects;Inflammation__drug therapy;Molecular Targeted Therapy__methods;Pathogen-Associated Molecular Pattern Molecules__metabolism;S100 Proteins__blood;Vaccination;COVID-19 drug treatment | Molecular Diagnosis & Therapy | Walter Gottlieb Land | 2020-04-06 02:00:00+02:00 | 32248387 | FR;DE | Molecular ImmunoRheumatology, INSERM UMR_S1109, Laboratory of Excellence Transplantex, University of Strasbourg, Strasbourg, France. land.w.damps@gmail.com.;German Academy for Transplantation Medicine, Munich, Germany. land.w.damps@gmail.com. | 147 | |||
| 10.1016/j.antiviral.2020.104793 | Journal Article | en | Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. | https://www.ncbi.nlm.nih.gov/pubmed/32283108 | The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation. To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogues (NAs), with over 25 approved for the treatment of several medically important viral diseases. However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals. Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes. We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision. Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogues. Additionally, we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir. This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN. | 0166-3542 | 2020-04-12 02:00:00+02:00 | pubmed | Adenosine Monophosphate__analogs & derivatives;Alanine__analogs & derivatives;Antimetabolites__chemistry;Antiviral Agents__chemistry;Betacoronavirus__chemistry;Catalytic Domain;Coronavirus Infections__drug therapy;Drug Resistance, Viral;Exoribonucleases__chemistry;Humans;Models, Molecular;Mutation;Pandemics;Pneumonia, Viral__drug therapy;Protein Conformation;RNA Replicase__chemistry;RNA, Viral__chemistry;Structure-Activity Relationship;Viral Nonstructural Proteins__chemistry;COVID-19;severe acute respiratory syndrome coronavirus 2 | Antiviral Research | Ashleigh Shannon;Nhung Thi-Tuyet Le;Barbara Selisko;Cecilia Eydoux;Karine Alvarez;Jean-Claude Guillemot;Etienne Decroly;Olve Peersen;Francois Ferron;Bruno Canard | COVID-19;Coronavirus;Exonuclease;Mutation;Nucleotide analogue;RNA-Dependent RNA polymerase;Remdesivir;Resistance | 2020-04-10 02:00:00+02:00 | 32283108 | FR;US | Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.;Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO, USA, Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France.;Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France. Electronic address: francois.ferron@afmb.univ-mrs.fr.;Aix-Marseille Université, CNRS UMR 7257, Architecture et Fonction des Macromolécules Biologiques, 163 Avenue de Luminy, 13288, Marseille, France. Electronic address: bruno.canard@afmb.univ-mrs.fr. | 150 | ||
| 10.1007/s10096-020-03869-w | Journal Article | en | Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32270412 | 0934-9723,1435-4373 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus__genetics;Coronavirus Infections__diagnosis;France__epidemiology;Genome, Viral__genetics;Humans;Microbiological Techniques;Microscopy, Electron;Nasopharynx__virology;Pandemics;Pneumonia, Viral__diagnosis;RNA, Viral__genetics;Time Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Clinical Microbiology & Infectious Diseases | Philippe Colson;Jean-Christophe Lagier;Jean-Pierre Baudoin;Jacques Bou Khalil;Bernard La Scola;Didier Raoult | 2020-04-08 02:00:00+02:00 | 32270412 | FR | IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille, France.;Microbes Evolution Phylogeny and Infections (MEPHI), Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Aix-Marseille University, 27 Boulevard Jean Moulin, 13005, Marseille, France.;IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille, France. didier.raoult@gmail.com.;Microbes Evolution Phylogeny and Infections (MEPHI), Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Aix-Marseille University, 27 Boulevard Jean Moulin, 13005, Marseille, France. didier.raoult@gmail.com. | 157 | ||||
| 10.1016/j.antiviral.2020.104791 | Journal Article | en | Type 1 interferons as a potential treatment against COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32275914 | Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19. | 0166-3542 | 2020-04-12 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Betacoronavirus__isolation & purification;Coronavirus Infections__drug therapy;Humans;Interferon Type I__therapeutic use;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Antiviral Research | Erwan Sallard;François-Xavier Lescure;Yazdan Yazdanpanah;France Mentre;Nathan Peiffer-Smadja | COVID-19;Interferon;SARS-CoV-2 | 2020-04-07 02:00:00+02:00 | 32275914 | FR | École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.;Université de Paris, IAME, INSERM, F-75018, Paris, France, Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.;Université de Paris, IAME, INSERM, F-75018, Paris, France.;Université de Paris, IAME, INSERM, F-75018, Paris, France, Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr. | 163 | ||
| 10.1016/j.medmal.2020.04.003 | Editorial | en | A few thoughts and evidence on the COViD-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32278064 | 0399-077X | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Fear;Health Personnel;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Médecine et Maladies Infectieuses | J P Stahl | 2020-04-08 02:00:00+02:00 | 32278064 | FR | Infectious diseases, CHU Grenoble, 38043 Grenoble, France. Electronic address: JPStahl@chu-grenoble.fr. | 171 | ||||
| 10.1016/j.clim.2020.108409 | Journal Article;Review | en | Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32276137 | It is an ugly fact that a significant amount of the world's population will contract SARS-CoV-II infection with the current spreading. While a specific treatment is not yet coming soon, individual risk assessment and management strategies are crucial. The individual preventive and protective measures drive the personal risk of getting the disease. Among the virus-contracted hosts, their different metabolic status, as determined by their diet, nutrition, age, sex, medical conditions, lifestyle, and environmental factors, govern the personal fate toward different clinical severity of COVID-19, from asymptomatic, mild, moderate, to death. The careful individual assessment for the possible dietary, nutritional, medical, lifestyle, and environmental risks, together with the proper relevant risk management strategies, is the sensible way to deal with the pandemic of SARS-CoV-II. | 1521-6616 | 2020-04-12 02:00:00+02:00 | pubmed | Age Factors;Antiviral Agents__therapeutic use;Betacoronavirus__drug effects;Communicable Disease Control;Coronavirus Infections__epidemiology;Diet__methods;Female;Gastrointestinal Microbiome__immunology;Humans;Hygiene__education;Immunization, Passive__methods;Life Style;Male;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Precision Medicine__methods;Risk Management__methods;Severity of Illness Index;Sex Factors;Smoking__physiopathology;COVID-19;COVID-19 serotherapy;severe acute respiratory syndrome coronavirus 2 | Clinical Immunology | Amin Gasmi;Sadaf Noor;Torsak Tippairote;Maryam Dadar;Alain Menzel;Geir Bjørklund | Antiviral medication;COVID-19;Diet;Herbs;Lifestyle;Nutrition;SARS-CoV-II;Smoking | 2020-04-07 02:00:00+02:00 | 32276137 | FR;NO;TH;IR;LU;PK | Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.;Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University Multan, Pakistan.;Nutritional and Environmental Medicine Department, BBH Hospital, Bangkok, Thailand, Faculty of Medicine, Ramathibodi Hospital and Institute of Nutrition, Mahidol University, Bangkok, Thailand.;Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.;Laboratoires Réunis, Junglinster, Luxembourg.;Council for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway. Electronic address: bjorklund@conem.org. | 174 | ||
| 10.1017/dmp.2020.82 | Journal Article | en | Adaptation of the National Plan for the Prevention and Fight Against Pandemic Influenza to the 2020 COVID-19 Epidemic in France. | https://www.ncbi.nlm.nih.gov/pubmed/32252845 | On Tuesday, March 17, 2020, at noon, France became the third European country to impose a nationwide containment policy in the fight against epidemic coronavirus disease 2019 (COVID-19) viral infection. Announcing that the country was at "war," President Macron called upon all to play a role in mitigating against further development of contagion. This extreme measure never seen before during peace time was the result of adapting not only the French Pandemic Influenza Plan (PIP) being applied to the national context but also real-time clinical, epidemiological, and scientific information about the evolution of COVID-19 infection in the country. The situation was further complicated by local municipal elections and political agendas by populist opinions. Despite mass communication about the importance of individual behavioral attitudes to counter disease propagation, few heeded government advice. Consequently, the situation rapidly deteriorated with increasing number of cases that started to overwhelm health services. As a result, decisive and immediate action was taken by the State for the national public health interest. This report from the field details the timely events that contributed to this extreme policy decision taken by France. A policy decision that other Western democracies have since applied as the pandemic disseminated across the globe. | 1935-7893,1938-744X | 2020-04-12 02:00:00+02:00 | pubmed | Disaster Medicine and Public Health Preparedness | Ali Ghanchi | COVID-19;France;emergency planning;health crisis management;pandemic influenza plan;public health emergency of international concern | 2020-04-07 02:00:00+02:00 | 32252845 | FR | Université de Paris. Center of research in Epidemiology and Statistics (CRESS), INSERM, INRA, F-75004, Paris, France and Necker Enfants Malades Hospital. Service d'Obstétrique - Maternité, chirurgie médecine et imagerie fœtales. Assistance publique - Hôpitaux de Paris (AP-HP), Paris, France. | 175 | |||
| 10.1016/j.jviscsurg.2020.04.001 | Editorial | en | Urgent digestive surgery, a collateral victim of the COVID-19 crisis? | https://www.ncbi.nlm.nih.gov/pubmed/32335008 | 1878-7886 | 2020-04-12 02:00:00+02:00 | pubmed | Coronavirus Infections;Digestive System Diseases__surgery;Digestive System Surgical Procedures;Emergency Treatment;Humans;Pandemics;Pneumonia, Viral;Quarantine;COVID-19 | Journal of Visceral Surgery | K Slim;J Veziant | Appendicitis;COVID-19 epidemic;Cholecystitis;Emergency;Surgery | 2020-04-06 02:00:00+02:00 | 32335008 | FR | Department of Digestive Surgery, Clermont-Ferrand Teaching Hospital, Clermont-Ferrand, France. Electronic address: kslim@chu-clermontferrand.fr.;Department of Digestive Surgery, Clermont-Ferrand Teaching Hospital, Clermont-Ferrand, France. | 192 | |||
| 10.1016/j.cmi.2020.04.002 | Journal Article | en | Challenges and issues about organizing a hospital to respond to the COVID-19 outbreak: experience from a French reference centre. | https://www.ncbi.nlm.nih.gov/pubmed/32278082 | 1198-743X | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Disease Outbreaks;France__epidemiology;Hospital Administration__standards;Hospitals;Humans;Pandemics__statistics & numerical data;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Microbiology and Infection | N Peiffer-Smadja;J-C Lucet;G Bendjelloul;L Bouadma;S Gerard;C Choquet;S Jacques;A Khalil;P Maisani;E Casalino;D Descamps;J-F Timsit;Y Yazdanpanah;F-X Lescure | COVID-19;Emerging infectious diseases;Health systems;Infection prevention and control;Preparedness;Resilience | 2020-04-08 02:00:00+02:00 | 32278082 | FR | AP-HP, Hôpital Bichat, Infectious Diseases, F-75018, Paris, France, Université de Paris, IAME, INSERM, F-75018, Paris, France.;Université de Paris, IAME, INSERM, F-75018, Paris, France, AP-HP, Hôpital Bichat, Infection Control, F-75018, Paris, France.;AP-HP, Hôpital Bichat, Infection Control, F-75018, Paris, France.;Université de Paris, IAME, INSERM, F-75018, Paris, France, AP-HP, Hôpital Bichat, Medical and Infectious Diseases ICU, F-75018, Paris, France.;AP-HP, Hôpital Bichat, Infectious Diseases, F-75018, Paris, France.;AP-HP, Hôpital Bichat, Emergency Department, F-75018, Paris, France.;AP-HP, Hôpital Bichat, Medical and Infectious Diseases ICU, F-75018, Paris, France.;AP-HP, Hôpital Bichat, Radiology, F-75018, Paris, France.;AP-HP, Hôpital Bichat, Direction, F-75018, Paris, France.;AP-HP, Hôpital Bichat, Virology, F-75018, Paris, France.;AP-HP, Hôpital Bichat, Infectious Diseases, F-75018, Paris, France, Université de Paris, IAME, INSERM, F-75018, Paris, France. Electronic address: xavier.lescure@aphp.fr. | 197 | |||
| 10.1016/j.anorl.2020.04.010 | Practice Guideline | en | COVID-19 and ENT Pediatric otolaryngology during the COVID-19 pandemic. Guidelines of the French Association of Pediatric Otorhinolaryngology (AFOP) and French Society of Otorhinolaryngology (SFORL). | https://www.ncbi.nlm.nih.gov/pubmed/32312676 | Joint guidelines of the French Pediatric Otolaryngology Society (AFOP) and of the French Society of otorhinolaryngology-head and neck surgery (SFORL) on the management of paediatric otolaryngology patients in the context of the COVID-19 pandemic. | 1879-7296 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Child;Coronavirus Infections__epidemiology;France__epidemiology;Humans;Infection Control__methods;Otolaryngology__methods;Pandemics__prevention & control;Pediatrics__methods;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Annals of Otorhinolaryngology, Head and Neck Diseases | N Leboulanger;T Sagardoy;M Akkari;S Ayari-Khalfallah;C Celerier;P Fayoux;R Luscan;A-L Mansbach;E Moreddu;S Pondaven;F Simon;N Teissier;B Thierry;A Fanous;E Lescanne;R Nicollas;V Couloigner | COVID-19;Coronavirus;ENT;Otolaryngology;Paediatric;Pandemic;SARS-CoV-2 | 2020-04-18 02:00:00+02:00 | 32312676 | FR;BE;CA | Service d'ORL pédiatrique et de chirurgie cervico-faciale, hôpital Necker-enfants malades, Assistance publique-Hôpitaux de Paris, université de Paris, Paris, France. Electronic address: nicolas.leboulanger@aphp.fr.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, hôpital Pellegrin, université de Bordeaux, Bordeaux, France.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, hôpital Gui-de-Chauliac, CHU de Montpellier, université de Montpellier, Montpellier, France.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, hôpital femme, mère, enfant, hospices civils de Lyon, université Claude-Bernard-Lyon 1, Lyon, France.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, hôpital Necker-enfants malades, Assistance publique-Hôpitaux de Paris, université de Paris, Paris, France.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, hôpital Jeanne-de-Flandre, CHRU de Lille, Lille, France.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, hôpital universitaire des enfants Reine-Fabiola (HUDERF), Bruxelles, Belgium.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, hôpital La Timone, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, Marseille, France.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, CHU de Tours, université de Tours, Tours, France.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, hôpital Robert-Debré, Assistance publique-Hôpitaux de Paris, université de Paris, NeuroDiderot, Inserm, 75019, Paris, France.;Service d'ORL pédiatrique et de chirurgie cervico-faciale, université McGill, Montréal, Québec, Canada. | 203 | ||
| Letter | en | Preliminary therapeutic drug monitoring data of β-lactams in critically ill patients with SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32315803 | 2020-04-19 02:00:00+02:00 | pubmed | Aged;Anti-Bacterial Agents__adverse effects;Antibiotic Prophylaxis__adverse effects;Betacoronavirus;Cefepime__adverse effects;Coinfection__prevention & control;Confusion__chemically induced;Coronavirus Infections__complications;Critical Illness__therapy;Cross Infection__prevention & control;Deep Sedation;Delirium__chemically induced;Drug Monitoring;Female;Humans;Hypnotics and Sedatives__therapeutic use;Male;Middle Aged;Pandemics;Pneumonia, Ventilator-Associated__prevention & control;Pneumonia, Viral__complications;Respiration, Artificial__adverse effects;Sepsis__prevention & control;beta-Lactams__adverse effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Emmanuel Novy;Julien Scala-Bertola;Claire Roger;Philippe Guerci | COVID-19;Therapeutic drug monitoring;β lactam | 2020-04-18 02:00:00+02:00 | 32315803 | FR | Department of anaesthesiology and intensive care medicine, university hospital of Nancy, 54511 Vandœuvre-lès-Nancy, France, University of Lorraine, 54000 Nancy, France. Electronic address: e.novy@chru-nancy.fr.;Department of clinical pharmacology and toxicology, 54000 Nancy, France, University of Lorraine, 54000 Nancy, France.;Department of anaesthesiology and intensive care, pain and emergency medicine, Nîmes-Caremeau university hospital, 30029 Nîmes cedex 9, France, EA 2992 dysfonctions des interfaces vasculaires, university of Montpellier-Nîmes, 30908 Nîmes cedex 2, France.;Department of anaesthesiology and intensive care medicine, university hospital of Nancy, 54511 Vandœuvre-lès-Nancy, France, University of Lorraine, 54000 Nancy, France. | 205 | ||||||
| 10.1016/j.diii.2020.04.004 | Evaluation Study;Journal Article | en | 3D-printed face protective shield in interventional radiology: Evaluation of an immediate solution in the era of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32354631 | The purpose of this study was to report the clinical evaluation of a 3D-printed protective face shield designed to protect interventional radiologists from droplet transmission of the SARS-Cov-2. | 2211-5684 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Equipment Design__methods;Equipment Reuse;Humans;Masks;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Printing, Three-Dimensional;Prospective Studies;Radiography, Interventional__instrumentation;Time Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Diagnostic and Interventional Imaging | M Sapoval;A L Gaultier;C Del Giudice;O Pellerin;N Kassis-Chikhani;V Lemarteleur;V Fouquet;L Tapie;P Morenton;B Tavitian;J P Attal | COVID-19;Interventional radiology;Protective face shield;Three-dimensional printing | 2020-04-18 02:00:00+02:00 | 32354631 | FR | Université de Paris, PARCC, Inserm, 75015 Paris, France, Department of Vascular and Oncological Interventional Radiology, AP-HP, Hôpital Européen Georges Pompidou, 75015 Paris, France. Electronic address: marc.sapoval2@aphp.fr.;Université de Paris, PARCC, Inserm, 75015 Paris, France, Department of Radiology, AP-HP, Hôpital Européen Georges Pompidou, 75015 Paris, France.;Université de Paris, PARCC, Inserm, 75015 Paris, France, Department of Vascular and Oncological Interventional Radiology, AP-HP, Hôpital Européen Georges Pompidou, 75015 Paris, France.;Medical Hygien Department, AP-HP, Hôpital Européen Georges Pompidou, 75015 Paris, France.;Université de Paris, Centre de Simulation Ilumens, 75006 Paris, France.;Unité de Recherches Biomatériaux Innovants et Interfaces (URB2i - EA 4462), Université de Paris, Paris, France, Hopital Louis-Mourier, 92700 Colombes, France.;Unité de Recherches Biomatériaux Innovants et Interfaces (URB2i - EA 4462), Université Sorbonne Paris Nord, 93430 Villetaneuse, France.;CentraleSupelec, Université Paris-Saclay, 91192 Gif-sur-Yvette, France.;Unité de Recherches Biomatériaux Innovants et Interfaces (URB2i - EA 4462), Université de Paris, Hôpital Charles Foix, 94200 Ivry-sur-Seine, France. | 206 | ||
| 10.1007/s00204-020-02744-z | Editorial | en | Electronic cigarette and vaping should be discouraged during the new coronavirus SARS-CoV-2 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32303807 | 0340-5761,1432-0738 | 2020-04-19 02:00:00+02:00 | pubmed | Aerosols;Betacoronavirus;Coronavirus Infections;Humans;Lung Injury__etiology;Pandemics;Pneumonia, Viral;Vaping__adverse effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Archives of Toxicology | Emilie Javelle | COVID-19;Coronavirus;Lung injuries;SARS-CoV-2;Vaping;e-cigarettes | 2020-04-18 02:00:00+02:00 | 32303807 | FR | Laveran Military Hospital, Aix Marseille University, IRD, AP-HM, SSA, VITROME, Marseille, France. emilie.javelle@gmail.com. | 210 | |||
| 10.1097/ftd.0000000000000761 | Journal Article;Review | en | Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. | https://www.ncbi.nlm.nih.gov/pubmed/32304488 | COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs (ISDs). It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals. | 0163-4356 | 2020-04-19 02:00:00+02:00 | pubmed | Adenosine Monophosphate__analogs & derivatives;Alanine__analogs & derivatives;Antibodies, Monoclonal, Humanized;Antiviral Agents__adverse effects;Betacoronavirus;Coronavirus Infections__drug therapy;Drug Interactions;Drug Monitoring;Glucocorticoids;Humans;Hydroxychloroquine;Immunosuppressive Agents__adverse effects;Pandemics;Pneumonia, Viral__drug therapy;Protease Inhibitors;Transplant Recipients;COVID-19;severe acute respiratory syndrome coronavirus 2 | Therapeutic Drug Monitoring | Laure Elens;Loralie J Langman;Dennis A Hesselink;Stein Bergan;Dirk Jan A R Moes;Mariadelfina Molinaro;Raman Venkataramanan;Florian Lemaitre | 2020-04-19 02:00:00+02:00 | 32304488 | FR;NO;US;IT;NL;BE | Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Institut de Recherche Expérimentale et Clinique (IREC), Louvain Center for Toxicology and Applied Pharmacology (LTAP), Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota.;Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.;Rotterdam Transplant Group.;Department of Pharmacology, Oslo University Hospital, Oslo, Norway.;Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.;Clinical and Experimental Pharmacokinetics Lab, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.;School of Pharmacy and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sante[Combining Acute Accent], environnement et travail)-UMR_S 1085, Rennes, France.;INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, France. | 212 | |||
| 10.1093/eurheartj/ehaa301 | Journal Article;Research Support, Non-U.S. Gov't | en | Call to action for the cardiovascular side of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32282026 | 0195-668X,1522-9645 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Cardiovascular Diseases__virology;Coronavirus Infections__complications;European Union;Humans;Interdisciplinary Research;International Cooperation;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Heart Journal | Costanza Emanueli;Lina Badimon;Fabio Martelli;Ines Potočnjak;Irina Carpusca;Emma L Robinson;Yvan Devaux | 2020-04-14 02:00:00+02:00 | 32282026 | FR;GB;HR;IT;NL;ES;LU | National Heart and Lung Institute, Imperial College London, London, UK.;Cardiovascular Program (ICCC)-IR, Hospital de la Santa Creu i Sant Pau, CIBERCV, Barcelona, Spain.;Molecular Cardiology Laboratory, Policlinico San Donato IRCCS, San Donato Milanese, Milan, Italy.;Institute for clinical medical research and education, University Hospital Centre Sisters of Charity, Zagreb, Croatia.;Cardiovascular Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg.;Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands. | 225 | ||||
| Letter | en | Impact of COVID-19 on people with cystic fibrosis. | https://www.ncbi.nlm.nih.gov/pubmed/32304639 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Cystic Fibrosis__epidemiology;Europe__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Carla Colombo;Pierre-Régis Burgel;Silvia Gartner;Silke van Koningsbruggen-Rietschel;Lutz Naehrlich;Isabelle Sermet-Gaudelus;Kevin W Southern | 2020-04-15 02:00:00+02:00 | 32304639 | FR;GB;US;IT;ES;PS;DE | Cystic Fibrosis Regional Reference Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Department of Pathophysiology and Transplantation, 20122 Milan, Italy. Electronic address: carla.colombo@unimi.it.;Respiratory Medicine and National Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Institut Cochin, INSERM U1016, Paris, France.;Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.;Cystic Fibrosis Centre, Children's Hospital, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.;Department of Pediatrics, Justus-Liebig-University, Giessen, Germany.;INSERM U1151, Institut Necker Enfants Malades, National Cystic Fibrosis Reference Center (paediatric site), Hôpital Necker Enfants Malades, Assistance Publique Hôpitaux de Paris Paris, ERN-Lung, Université de Paris, France.;Department of Women's and Children's Health, University of Liverpool, Institute in the Park, Alder Hey Children's Hospital, Liverpool, UK. | 240 | |||||||
| 10.1016/j.banm.2020.04.007 | Editorial | fr | [Return of ancestral fears with coronavirus, Covid-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32296245 | 0001-4079 | 2020-04-19 02:00:00+02:00 | pubmed | Bulletin de l'Académie Nationale de Médecine | Jacques Battin | 2020-04-15 02:00:00+02:00 | 32296245 | FR | Académie nationale de médecine, 16 rue Bonaparte, 75006 Paris, France. | 241 | |||||
| 10.3390/diseases8020009 | Journal Article;Review | en | From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation. | https://www.ncbi.nlm.nih.gov/pubmed/32326509 | Fecal Microbiota Transplantation (FMT) is suggested as an efficacious therapeutic strategy for restoring intestinal microbial balance, and thus for treating disease associated with alteration of gut microbiota. FMT consists of the administration of fresh or frozen fecal microorganisms from a healthy donor into the intestinal tract of diseased patients. At this time, in according to healthcare authorities, FMT is mainly used to treat recurrent Clostridium difficile. Despite the existence of a few existing stool banks worldwide and many studies of the FMT, there is no standard method for producing material for FMT, and there are a multitude of factors that can vary between the institutions. The main constraints for the therapeutic uses of FMT are safety concerns and acceptability. Technical and logistical issues arise when establishing such a non-standardized treatment into clinical practice with safety and proper governance. In this context, our manuscript describes a process of donor safety screening for FMT compiling clinical and biological examinations, questionnaires and interviews of donors. The potential risk of transmission of SARS-CoV-2 virus by the use of fecal microbiota for transplantation must be taken urgently into consideration. We discuss a standardized procedure of collection, preparation and cryopreservation of fecal samples through to the administration of material to patients, and explore the risks and limits of this method of FMT. The future success of medicine employing microbiota transplantation will be tightly related to its modulation and manipulation to combat dysbiosis. To achieve this goal, standard and strict methods need to be established before performing any type of FMT. | 2079-9721 | 2020-04-19 02:00:00+02:00 | pubmed | Diseases | Carole Nicco;Armelle Paule;Peter Konturek;Marvin Edeas | COVID-19;FMT;cryoconservation;fecal microbiota transplantation;fecal samples;gut microbiota;stool banks | 2020-04-15 02:00:00+02:00 | 32326509 | FR;DE | Cochin Institute, INSERM U1016, University Paris Descartes, Development, Reproduction and Cancer, Cochin Hospital, 75014 Paris, France.;International Society of Microbiota, 75002 Paris, France.;Teaching Hospital of the University of Jena, Thuringia-Clinic Saalfeld, 07318 Saalfeld, Germany. | 245 | |||
| 10.1016/j.jviscsurg.2020.04.007 | Case Reports;Journal Article | en | SARS-CoV-2 infection may result in appendicular syndrome: Chest CT scan before appendectomy. | https://www.ncbi.nlm.nih.gov/pubmed/32387057 | The initial clinical presentation of coronavirus disease 2019 may be appendicular syndrome. An abdominal CT scan ruled out a diagnosis of appendicitis and a chest CT scan yielded a diagnosis of SARS-CoV-2 infection. CT scan is required before considering emergency surgery for acute appendicitis. | 1878-7886 | 2020-04-19 02:00:00+02:00 | pubmed | Acute Disease;Appendectomy;Appendicitis__diagnostic imaging;Coronavirus Infections__diagnostic imaging;Diagnosis, Differential;Female;Humans;Middle Aged;Pandemics;Pneumonia, Viral__diagnostic imaging;Preoperative Period;Radiography, Thoracic__methods;Syndrome;Tomography, X-Ray Computed;COVID-19 | Journal of Visceral Surgery | K Pautrat;N Chergui | Appendicitis;COVID-19;Coronavirus Disease 2019;TDM | 2020-04-15 02:00:00+02:00 | 32387057 | FR | Service de chirurgie viscérale, cancérologique et endocrinienne, groupe hospitalier Saint-Louis Lariboisière, AP-HP, 75010 Paris, France. Electronic address: karine.pautrat@aphp.fr.;Service d'imagerie ostéo-articulaire, hôpital Lariboisière, AP-HP, 2, rue Ambroise-Paré, 75010 Paris, France. | 246 | ||
| 10.2217/imt-2020-0077 | Editorial | en | Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection? | https://www.ncbi.nlm.nih.gov/pubmed/32290754 | The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents. | 1750-743X,1750-7448 | 2020-04-19 02:00:00+02:00 | pubmed | Antineoplastic Agents, Immunological__adverse effects;Cell Cycle Checkpoints__drug effects;Coronavirus Infections__complications;Disease Progression;Humans;Neoplasms__drug therapy;Pandemics;Pneumonia, Viral__complications;COVID-19 | Immunotherapy | Joseph Kattan;Clarisse Kattan;Tarek Assi | COVID-19;cancer;checkpoints inhibitors;coronavirus;immune therapy;immunosuppression | 2020-04-14 02:00:00+02:00 | 32290754 | FR;LB | Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. | 253 | ||
| 10.1111/obr.13034 | Editorial | en | Risk of COVID-19 for patients with obesity. | https://www.ncbi.nlm.nih.gov/pubmed/32281287 | 1467-7881,1467-789X | 2020-04-19 02:00:00+02:00 | pubmed | Coronavirus Infections__complications;Humans;Obesity__complications;Pandemics;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__complications;Renin-Angiotensin System__physiology;COVID-19 | Obesity Reviews | Radwan Kassir | BMI;COVID-19;adipose;human angiotensin converting enzyme 2;obesity | 2020-04-13 02:00:00+02:00 | 32281287 | FR | Department of Bariatric Surgery, CHU Felix Guyon, Réunion, France. | 254 | |||
| Case Reports;Letter | en | Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32334995 | 2020-04-19 02:00:00+02:00 | pubmed | Aged;Aorta;Coronavirus Infections__complications;Fibrin Fibrinogen Degradation Products;Humans;Male;Pandemics;Pneumonia, Viral__complications;Pulmonary Embolism__complications;Real-Time Polymerase Chain Reaction;Thrombosis__complications;Tomography Scanners, X-Ray Computed;COVID-19 | A Le Berre;V Marteau;J Emmerich;M Zins | Acute arterial thrombosis;COVID-19 pneumonia;Computed tomography angiography;Disseminated intravascular coagulation;Pulmonary embolism | 2020-04-16 02:00:00+02:00 | 32334995 | FR | Department of Radiology, Fondation Hôpital Saint-Joseph, 75014 Paris, France. Electronic address: alice.leberre@ymail.com.;Department of Radiology, Fondation Hôpital Saint-Joseph, 75014 Paris, France.;Department of Vascular Medicine, Fondation Hôpital Saint-Joseph, 75014 Paris, France. | 264 | ||||||
| 10.1016/j.jdmv.2020.04.004 | Editorial | en | Ten key points that vascular doctors learned very quickly about COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32402423 | 2542-4513 | 2020-04-19 02:00:00+02:00 | pubmed | Biomarkers__analysis;Comorbidity;Coronavirus Infections__diagnosis;Ethics, Clinical;Humans;Interdisciplinary Communication;Learning Curve;Medicine__standards;Oxygen__analysis;Oxygen Inhalation Therapy;Pandemics__ethics;Patient Care__ethics;Pneumonia, Viral__diagnosis;Prognosis;Specialties, Surgical__ethics;Tomography, X-Ray Computed;Vascular Diseases__surgery;COVID-19 | JMV-Journal de Médecine Vasculaire | Pascal Priollet;Alexandra Yannoutsos;Jean-Jacques Mourad | 2020-04-17 02:00:00+02:00 | 32402423 | FR | Vascular Medicine, Paris Saint-Joseph Hospital Group, 185, rue Raymond Losserand, 75014 Paris, France. Electronic address: ppriollet@hpsj.fr.;Vascular Medicine, Paris Saint-Joseph Hospital Group, Paris, France. Electronic address: ayannoutsos@hpsj.fr.;ESH excellence Centre, Internal Medicine, Paris Saint-Joseph Hospital Group, Paris, France. Electronic address: jjmourad@hpsj.fr. | 267 | ||||
| 10.1136/gpsych-2019-100183 | Journal Article | en | Clozapine is strongly associated with the risk of pneumonia and inflammation. | https://www.ncbi.nlm.nih.gov/pubmed/32420521 | Clinicians need to remember that (1) systemic inflammations can increase clozapine level; (2) clozapine, by itself, can cause inflammation, particularly during titration that is too rapid for that patient; (3) clozapine may increase the risk of infection; and (4) more specifically, clozapine may be particularly strongly associated with the risk of pneumonia. Pneumonia appears to be associated with high mortality in clozapine patients around the world. Clinicians who are alert to the risk of pneumonia in clozapine patients may significantly decrease mortality in clozapine patients. There is no data on COVID-19 infections in clozapine patients, but based on what we know about clozapine pharmacology, we can hypothesise that clozapine, possibly by impairing immunological mechanisms, may increase the risk of pneumonia in infected patients. More importantly, once fever and/or pneumonia develops, the clozapine dose should be cut in half to decrease the risk of clozapine intoxication. If there is any doubt that in spite of halving the dose there are still signs of clozapine intoxication, completely stopping clozapine may be indicated. Once the signs of inflammation and fever have disappeared, the clozapine dose can be increased to the prior dosage level. | 2517-729X | 2020-04-19 02:00:00+02:00 | pubmed | General Psychiatry | Jose de Leon;Can-Jun Ruan;Hélène Verdoux;Chuanyue Wang | psychopharmacology;schizophrenia | 2020-04-16 02:00:00+02:00 | 32420521 | FR;CN;US | University of Kentucky Mental Health Research Center, Eastern State Hospital, Lexington, Kentucky, USA.;Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing, China.;Inserm, Bordeaux Population Health Research Center, University of Bordeaux Faculty of Medical Sciences, Bordeaux, Aquitaine, France. | 270 | |||
| 10.1016/j.gofs.2020.04.009 | Editorial | fr | [Breast cancer management during the COVID 19 pandemic: the CNGOF takes action]. | https://www.ncbi.nlm.nih.gov/pubmed/32315805 | 2468-7189 | 2020-04-19 02:00:00+02:00 | pubmed | Gynécologie Obstétrique Fertilité & Sénologie | Carole Mathelin;Israel Nisand | Breast cancer;CNGOF;Cancer du sein;Covid-19 | 2020-04-18 02:00:00+02:00 | 32315805 | FR | Pôle de Gynécologie-Obstétrique-Sénologie. CHRU. Hôpitaux Universitaires de Strasbourg, 1 place de l'Hôpital, 67091, Strasbourg Cedex, France, IGBMC, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Biologie du Cancer, 1, rue Laurent Fries, 67400, Illkirch-Graffenstaden, France. Electronic address: carole.mathelin.x@gmail.com.;Pôle de Gynécologie-Obstétrique-Sénologie. CHRU. Hôpitaux Universitaires de Strasbourg, 1 place de l'Hôpital, 67091, Strasbourg Cedex, France, Président du CNGOF, 91 Boulevard de Sébastopol, 75002, Paris, France. | 284 | ||||
| 10.1016/j.athoracsur.2020.04.005 | Case Reports | en | Severe Acute Proximal Pulmonary Embolism and COVID-19: A Word of Caution. | https://www.ncbi.nlm.nih.gov/pubmed/32305287 | Acute pulmonary embolism is an uncharacteristic presentation in patients with COVID-19. Here we describe the case of a young woman presenting with severe pulmonary embolism, without any associated symptoms of infections. A clot in a patent foramen ovale was noted. Despite emergency surgical embolectomy, her clinical conditions continued to deteriorate. She was put on extracorporeal life support and tested positive for COVID-19. She died of multiorgan failure on day 10. COVID-19 may have a thrombogenic effect and it may need to be considered in cases of pulmonary embolism and in absence of any obvious risk factor. | 0003-4975 | 2020-04-19 02:00:00+02:00 | pubmed | The Annals of Thoracic Surgery | Olivier Fabre;Olivier Rebet;Ionut Carjaliu;Mihai Radutoiu;Laurence Gautier;Ilir Hysi | 2020-04-16 02:00:00+02:00 | 32305287 | FR | Departement of Cardiac Surgery of Artois, Centre Hospitalier de Lens et Hôpital Privé de Bois Bernard, Ramsay Santé, France.;Departement of Cardiac Surgery of Artois, Centre Hospitalier de Lens et Hôpital Privé de Bois Bernard, Ramsay Santé, France. Electronic address: ilirhysi@gmail.com. | 285 | ||||
| 10.1016/j.ando.2020.04.006 | Editorial;Introductory Journal Article | en | Covid-19: The challenges facing endocrinology. | https://www.ncbi.nlm.nih.gov/pubmed/32381288 | 0003-4266 | 2020-04-26 02:00:00+02:00 | pubmed | Adult;Age Factors;Aged;Angiotensin-Converting Enzyme Inhibitors__therapeutic use;Betacoronavirus__physiology;Child;Comorbidity;Coronavirus Infections__epidemiology;Diabetes Mellitus__epidemiology;Endocrinology__methods;Female;Gonadal Steroid Hormones__blood;Humans;Hypertension__drug therapy;Male;Middle Aged;Mortality;Pandemics;Pneumonia, Viral__epidemiology;Sex Factors;Telemedicine__trends;Withholding Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2 | Annales d'Endocrinologie | Michel Pugeat;Olivier Chabre;Marie-Christine Van Tyghem | 2020-04-25 02:00:00+02:00 | 32381288 | FR | Hospices Civils de Lyon, Fédération d'Endocrinologie, Groupement Hospitalier Est, 69677 Bron, France, Université de Lyon, CarMen Laboratory, INSERM U1060, INRA U1397, INSA Lyon, Université Claude Bernard Lyon 1, 69600, Oullins, France. Electronic address: michel.pugeat@chu-lyon.fr.;Service d'Endocrinologie, Diabétologie, Nutrition, CHU de Grenoble, Hôpital Albert-Michallon, 38043 Grenoble cedex 9, France. Electronic address: OlivierChabre@chu-grenoble.fr.;Endocrinology, Diabetology, Metabolism Department, Lille University Hospital, 59000 Lille, France. Electronic address: mc-vantyghem@chru-lille.fr. | 290 | ||||
| 10.1016/j.diii.2020.04.008 | Editorial | en | COVID-19 pandemic: A stress test for interventional radiology. | https://www.ncbi.nlm.nih.gov/pubmed/32359930 | 2211-5684 | 2020-04-26 02:00:00+02:00 | pubmed | Algorithms;Allied Health Personnel__supply & distribution;Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Radiology, Interventional;COVID-19;severe acute respiratory syndrome coronavirus 2 | Diagnostic and Interventional Imaging | M Barral;A Dohan;C Marcelin;T Carteret;O Zurlinden;J-B Pialat;A Kastler;F H Cornelis | COVID-19;Interventional oncology;Interventional radiology | 2020-04-25 02:00:00+02:00 | 32359930 | FR | Sorbonne Université, Department of Interventional Radiology and Oncology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, 75020 Paris, France.;Université de Paris, Department of Radiology, Hopital Cochin, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France.;Department of Radiology, CHU Bordeaux, Pellegrin Hospital, 33076 Bordeaux, France.;Department of Radiology, Nouvelle Clinique Bordeaux Tondu, 33272 Floirac, France.;Department of Radiology, Centre Hospitalier Gaston Bourret, 98835 Dumbéa Sur Mer, Nouvelle-Calédonie.;Department of Radiology, Hospices Civils de Lyon, Groupement Hospitalier Sud, 69310 Pierre-Bénite, France.;Department of Radiology, CHU Grenoble, boulevard de la Chantourne, 38700 La Tronche, France.;Sorbonne Université, Department of Interventional Radiology and Oncology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, 75020 Paris, France. Electronic address: francois.cornelis@aphp.fr. | 294 | |||
| Letter | en | Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. | https://www.ncbi.nlm.nih.gov/pubmed/32330340 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Female;Humans;Male;Pandemics;Pneumonia, Viral__complications;Rome__epidemiology;Skin Diseases__complications;Spain__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | A Tammaro;G A R Adebanjo;F R Parisella;A Pezzuto;J Rello | 2020-04-25 02:00:00+02:00 | 32330340 | FR;IT;AU;ES;PS | NESMOS Dermatology Department, Sapienza University of Rome, Rome, Italy.;University of Queensland, Brisbane, Qld, Australia.;Cardiovascular-Respiratory Science Department, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.;Centro de Investigación Biomedica en Red de Enfermedades Respirorias (CIBERES), Instituto Salud Carlos III, Madrid, Spain.;Clinical Research/Epidemiology in Pneumonia and Sepsis (CRIPS), Vall d'Hebron Institut of Research (VHIR), Barcelona, Spain.;Clinical Research, CHU Nîmes, Université Montpellier-Nimes, Nîmes, France. | 314 | |||||||
| 10.1016/j.clinre.2020.04.001 | Journal Article;Practice Guideline;Review | en | Suggestions for the care of patients with liver disease during the Coronavirus 2019 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32360055 | This document, written by the French Association for the Study of the Liver (AFEF) board, aims to provide information to physicians involved in the care of patients with liver disease during the Coronavirus disease (COVID-19) epidemic. These are not based on a systematic review of the literature and a rigorous evaluation using the GRADE method. These are recommendations based on feedback from China available in the form of original articles or letters - for which the scientific evidence is often modest - and the rules put forward by American (1) and European (Boettler et al, 2020) hepatology societies, the French National Digestive Cancer Thesaurus (Di Fiore et al., 2020) and the Francophone Transplantation Society (4). These suggestions require adjustment according to the geographical particularities of the epidemic, available standard procedures and access to local resources. This document will be updated as regularly as possible according to the evolution of our knowledge and characteristics on the epidemic. | 2210-7401 | 2020-04-26 02:00:00+02:00 | pubmed | Ambulatory Care__organization & administration;Betacoronavirus;Coronavirus Infections__epidemiology;Employment;France;Hepatocytes__metabolism;Hospitalization;Humans;Length of Stay;Liver__enzymology;Liver Diseases__classification;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Receptors, Virus__metabolism;Societies, Medical;Time Factors;Transplant Recipients;Universal Precautions;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinics and Research in Hepatology and Gastroenterology | Nathalie Ganne-Carrié;Hélène Fontaine;Jérôme Dumortier;Jérôme Boursier;Christophe Bureau;Vincent Leroy;Marc Bourlière | COVID-19;Cholangiocytes;Chronic liver disease;SARS-CoV-2 | 2020-04-22 02:00:00+02:00 | 32360055 | FR | Hôpitaux Universitaires Paris Seine Saint-Denis, site Jean Verdier Liver Unit, avenue du 14 juillet, 93140 Bondy, France. | 319 | ||
| 10.3390/diagnostics10040243 | Guideline | en | ISIDOG Recommendations Concerning COVID-19 and Pregnancy. | https://www.ncbi.nlm.nih.gov/pubmed/32338645 | Providing guidelines to health care workers during a period of rapidly evolving viral pandemic infections is not an easy task, but it is extremely necessary in order to coordinate appropriate action so that all patients will get the best possible care given the circumstances they are in. With these International Society of Infectious Disease in Obstetrics and Gynecology (ISIDOG) guidelines we aim to provide detailed information on how to diagnose and manage pregnant women living in a pandemic of COVID-19. Pregnant women need to be considered as a high-risk population for COVID-19 infection, and if suspected or proven to be infected with the virus, they require special care in order to improve their survival rate and the well-being of their babies. Both protection of healthcare workers in such specific care situations and maximal protection of mother and child are envisioned. | 2075-4418 | 2020-04-26 02:00:00+02:00 | pubmed | Diagnostics | Francesca Donders;Risa Lonnée-Hoffmann;Aristotelis Tsiakalos;Werner Mendling;José Martinez de Oliveira;Philippe Judlin;Fengxia Xue;Gilbert G G Donders;Isidog Covid-Guideline Workgroup | COVID-19;coronavirus;maternal complications;obstetric complications;pandemic;pregnancy outcome;review | 2020-04-22 02:00:00+02:00 | 32338645 | FR;NO;PT;GR;CN;BE;DE | Femicare VZW Clinical Research for Women, 3300 Tienen, Belgium.;Department Gynecology, Hospital St Olav, 7010 Trondheim, Norway.;Department Ob/Gyn, LETO Obstetrician Gynecological & Surgical Center, 11525 Athens, Greece.;German Center for Infections in Gynecology and Obstetrics, 42283 Wuppertal, Germany.;Department OB/Gyn, University Interior Beira, 6200 Covilha, Portugal.;Department OB/Gyn, CHU De Nancy-Université de Lorraine, 54000 Nancy, France.;Department OB/Gyn, Tianjin Medical University General Hospital, Tianjin 30000, China.;Department Ob/Gyn, University Hospital Antwerp, 2650 Ekeren, Belgium. | 325 | |||
| 10.1016/j.encep.2020.04.008 | Journal Article | fr | [Health professionals facing the coronavirus disease 2019 (COVID-19) pandemic: What are the mental health risks?] | https://www.ncbi.nlm.nih.gov/pubmed/32370984 | The coronavirus disease 2019 (COVID-19) pandemic has caused major sanitary crisis worldwide. Half of the world has been placed in quarantine. In France, this large-scale health crisis urgently triggered the restructuring and reorganization of health service delivery to support emergency services, medical intensive care units and continuing care units. Health professionals mobilized all their resources to provide emergency aid in a general climate of uncertainty. Concerns about the mental health, psychological adjustment, and recovery of health care workers treating and caring for patients with COVID-19 are now arising. The goal of the present article is to provide up-to-date information on potential mental health risks associated with exposure of health professionals to the COVID-19 pandemic. | 0013-7006 | 2020-04-26 02:00:00+02:00 | pubmed | Adaptation, Psychological;Anxiety__etiology;Attitude of Health Personnel;Behavior, Addictive__etiology;Betacoronavirus;Burnout, Professional__etiology;Coronavirus Infections;Delivery of Health Care;Depression__etiology;France__epidemiology;Health Personnel__psychology;Health Workforce;Helplessness, Learned;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Influenza Pandemic, 1918-1919;Occupational Diseases__etiology;Pandemics;Pneumonia, Viral;Protective Devices__supply & distribution;Resilience, Psychological;Risk Factors;Severe Acute Respiratory Syndrome__epidemiology;Social Support;Stress Disorders, Post-Traumatic;Suicide__psychology;Uncertainty;Work Schedule Tolerance__psychology;Workload;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | W El-Hage;C Hingray;C Lemogne;A Yrondi;P Brunault;T Bienvenu;B Etain;C Paquet;B Gohier;D Bennabi;P Birmes;A Sauvaget;E Fakra;N Prieto;S Bulteau;P Vidailhet;V Camus;M Leboyer;M-O Krebs;B Aouizerate | Anxiety;Anxiété;COVID-19;Depression;Dépression;Health personnel;Mental health;Post-traumatic stress disorder;Professionnels de santé;Santé mentale;Trouble de stress post-traumatique | 2020-04-22 02:00:00+02:00 | 32370984 | FR | Pôle de psychiatrie et d'addictiologie, CHRU de Tours, Tours, France, Inserm, UMR 1253, iBrain, université de Tours, Tours, France. Electronic address: wissam.el-hage@univ-tours.fr.;Pôle hospitalo-universitaire de psychiatrie d'adultes du Grand Nancy, centre psychothérapique de Nancy, Laxou, France.;Inserm, UMR S1266, université de Paris, institut de psychiatrie et neurosciences de Paris, Paris, France, Service de psychiatrie et d'addictologie de l'adulte et du sujet âgé, centre-université de Paris, hôpital européen Georges-Pompidou, AP-HP, Paris, France.;Inserm, UPS, service de psychiatrie et de psychologie médicale de l'adulte, centre expert dépression résistante FondaMental, ToNIC Toulouse NeuroImaging Center, université de Toulouse, hôpital Purpan, CHU de Toulouse, Toulouse, France.;Pôle de psychiatrie et d'addictiologie, CHRU de Tours, Tours, France, QualiPsy EE 1901, qualité de vie et santé psychologique, département de psychologie, université de Tours, Tours, France.;Pôle de psychiatrie générale et universitaire, centre de référence régional des pathologies anxieuses et de la dépression, université de Bordeaux, CH Charles-Perrens, Bordeaux, France, Neurocentre Magendie, Inserm U1215, Bordeaux, France.;Inserm, UMRS 1144, université de Paris, Paris, France, DMU Neurosciences, centre expert troubles bipolaires FondaMental, hôpital Fernand-Widal, AP-HP Nord, Paris, France.;Inserm, UMRS 1144, université de Paris, Paris, France, DMU Neurosciences, centre de neurologie cognitive, hôpital Lariboisière, AP-HP Nord, Paris, France.;UPRES, EA 4638, département de psychiatrie et d'addictologie, université d'Angers, CHU d'Angers, Angers, France.;Service de psychiatrie de l'adulte, centre expert dépression résistante FondaMental, université Bourgogne Franche-Comté, CHU de Besançon, Besançon, France.;Inserm, UPS, Toulouse NeuroImaging Center, université de Toulouse, Toulouse, France.;EA 4334, Movement Interactions Performance (MIP), université de Nantes, CHU de Nantes, Nantes, France.;Inserm U1028, CNRS UMR 5292, pôle universitaire de psychiatrie, équipe PsyR2, centre de recherche en neurosciences de Lyon, université St-Étienne-Lyon 1, CHU Saint-Étienne, Saint-Étienne, France.;Service de médecine légale, centre régional de psychotraumatologie Auvergne Rhône-Alpes, groupement hospitalier Édouard-Herriot, hospices civils de Lyon, Lyon, France.;Inserm, U1246, SPHERE, université de Nantes et université de Tours, Nantes, France.;Inserm, U1114, centre régional de psychotraumatologie Grand-Est, université de Strasbourg, Strasbourg, France.;Pôle de psychiatrie et d'addictiologie, CHRU de Tours, Tours, France, Inserm, UMR 1253, iBrain, université de Tours, Tours, France.;DMU IMPACT, département médico-universitaire de psychaitrie et d'addictologie, hôpital H. Mondor, AP-HP, Créteil, France, Fondation Fondamental, Créteil, France, UPEC, Inserm, université Paris Est Créteil, U955, équipe 15 Neuro-Psychiatrie translationnelle, Créteil, France.;UMR 1266, Inserm, IPNP, CNRS, université Paris Descartes, GDR 3557-Institut de Psychiatrie, Paris, France, Service hospitalo-universitaire, GHU Paris Sainte-Anne, Paris, France.;Pôle de psychiatrie générale et universitaire, centre de référence régional des pathologies anxieuses et de la dépression, université de Bordeaux, CH Charles-Perrens, Bordeaux, France. | 328 | ||
| 10.1016/j.encep.2020.04.009 | Journal Article;Review | fr | [Challenges for psychotropics in the context of the SARS-Cov-2 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32360037 | French recommendations have been proposed for psychotropics use and possible adaptations during the SARS-CoV-2 epidemic. Between uncertainties linked to the lack of data and speculations about possible benefits of psychotropics against the coronavirus, we propose here elements allowing to base the pharmacotherapeutic decisions potentially useful in Covid+ patients with psychiatric disorders. | 0013-7006 | 2020-04-26 02:00:00+02:00 | pubmed | Anti-Anxiety Agents__adverse effects;Antiviral Agents__adverse effects;Betacoronavirus__drug effects;Comorbidity;Coronavirus Infections__drug therapy;Drug Repositioning;Dyspnea__chemically induced;Humans;Hypnotics and Sedatives__adverse effects;Mental Disorders__drug therapy;Pandemics;Pneumonia, Viral__drug therapy;Psychotropic Drugs__adverse effects;Respiration__drug effects;Risk Assessment;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | H Javelot;P-M Llorca;G Meyer;P Fossati;E Haffen | COVID-19;Psychotropes;Psychotropics;Recommandations;Recommendations;SARS-Cov-2 | 2020-04-23 02:00:00+02:00 | 32360037 | FR | Établissement Public de Santé Alsace Nord, Brumath, France, Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France. Electronic address: herve.javelot@ch-epsan.fr.;CHU Clermont-Ferrand, EA 7280, Université Clermont Auvergne, France.;Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France, Service Pharmacie, CHU de Strasbourg, Strasbourg, France.;Service de psychiatrie adultes, APHP, Sorbonne université, Groupe Hospitalier Pitié Salpêtrière, ICM, Inserm U1127, Paris, France.;Service de psychiatrie, CIC-1431 Inserm, CHU de Besançon, Laboratoire de Neurosciences, Université de Franche-Comté, Besançon, France. | 330 | ||
| 10.1016/s2214-109x(20)30206-0 | Journal Article | en | A call for action for COVID-19 surveillance and research during pregnancy. | https://www.ncbi.nlm.nih.gov/pubmed/32333854 | 2214-109X | 2020-04-26 02:00:00+02:00 | pubmed | Biomedical Research__organization & administration;Coronavirus Infections__epidemiology;Female;Humans;Pandemics;Pneumonia, Viral__epidemiology;Population Surveillance;Pregnancy;COVID-19 | The Lancet Global Health | Pierre Buekens;Jackeline Alger;Gérard Bréart;Maria Luisa Cafferata;Emily Harville;Giselle Tomasso | 2020-04-22 02:00:00+02:00 | 32333854 | FR;AR;HN;US;UY | Department of Epidemiology, Tulane School of Public Health and Tropical Medicine, New Orleans, LA 70112, USA. Electronic address: pbuekens@tulane.edu.;Departamento de Laboratorio Clínico, Hospital Escuela and Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal, Tegucigalpa, Honduras.;Institut National de la Santé et de la Recherche Médicale U1153, Paris, France, Paris University, Paris, France.;Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.;Department of Epidemiology, Tulane School of Public Health and Tropical Medicine, New Orleans, LA 70112, USA.;Unidad de Investigación Clínica y Epidemiológica, Montevideo, Uruguay. | 332 | ||||
| 10.1016/j.encep.2020.04.005 | Journal Article;Review | en | Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review. | https://www.ncbi.nlm.nih.gov/pubmed/32370982 | The lack of resources and coordination to face the coronavirus epidemic raises concerns for the health of patients with mental disorders in a country where we still have memories of the dramatic experience of famine in psychiatric hospitals during the Second World War. This article aims to propose guidance to ensure mental health care during the SARS-CoV epidemic in France. | 0013-7006 | 2020-04-26 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections__epidemiology;Epidemics;France__epidemiology;Hospitals, Psychiatric__organization & administration;Humans;Mental Disorders__epidemiology;Mental Health;Pandemics;Pneumonia, Viral__epidemiology;Psychotic Disorders__epidemiology;Quarantine__psychology;Risk Factors;Stress Disorders, Post-Traumatic__epidemiology;Suicide__prevention & control;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | A Chevance;D Gourion;N Hoertel;P-M Llorca;P Thomas;R Bocher;M-R Moro;V Laprévote;A Benyamina;P Fossati;M Masson;E Leaune;M Leboyer;R Gaillard | Coronavirus;Covid-19;Epidemic;France;Pandemic;Psychiatry;SARS-CoV-2 | 2020-04-22 02:00:00+02:00 | 32370982 | FR | Université de Paris, CRESS, Inserm, INRA, 75004 Paris, France. Electronic address: astrid.chevance@gmail.com.;Psychiatre libéral, HEC, Paris (Jouy-en-Josas), France.;Centre ressource régional de psychiatrie du sujet âgé (CRRPSA), Service de psychiatrie et d'addictologie de l'adulte et du sujet âgé, DMU psychiatrie et addictologie, AP-HP, Centre-Université de Paris, Inserm U1266, Institut de psychiatrie et neurosciences de Paris, France.;CHU Clermont-Ferrand, Clermont-Ferrand, France, Université Clermont Auvergne, Clermont-Ferrand, France.;CHU Lille, Université de Lille, CNRS UMR 9193, laboratoire de sciences cognitives et sciences affectives (SCALab-PsyCHIC), Lille, France.;CHU de Nantes, Nantes, France.;Université de Paris, Présidente du Collège National des Universitaires de Psychiatrie (CNUP), Inserm, CESP, Paris, France.;Pôle hospitalo-universitaire de psychiatrie d'adultes et d'addictologie du Grand-Nancy, Centre Psychothérapique de Nancy, Faculté de Médecine, Université de Lorraine, Nancy, France.;AP-HP, Hôpital Paul Brousse, Département de Psychiatrie et d'Addictologie, Unité Psychiatrie-Comorbidités-Addictions-Unité de Recherche, PSYCOMADD Université Paris Sud - AP-HP, Université Paris Saclay, 94800 Villejuif, France.;Service de psychiatrie adultes, APHP, Sorbonne université, Groupe Hospitalier pitié Salpêtrière, ICM, Inserm U1127, Paris, France.;Nightingale Hospitals-Paris, Clinique du Château de Garches, SHU, GHU Psychiatrie et neurosciences, Paris, France.;Centre Hospitalier Le Vinatier, Université Lyon, Bron, Lyon, France.;AP-HP, Université Paris Est Créteil, Inserm, Fondation FondaMental, Paris, France.;Université de Paris, GHU Psychiatrie et neurosciences, Président de la sous-section 49-03 du Conseil National des Universités (CNU), Paris, France. | 333 | ||
| 10.1016/j.jfo.2020.04.005 | Editorial | fr | [Healthcare in the context of Covid-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32340757 | 0181-5512 | 2020-04-26 02:00:00+02:00 | pubmed | Coronavirus Infections;Delivery of Health Care;Humans;Ophthalmology;Pandemics;Pneumonia, Viral;Quarantine;COVID-19 | Journal Français d'Ophtalmologie | L Kodjikian | 2020-04-20 02:00:00+02:00 | 32340757 | FR | Hôpital de la Croix-Rousse, 103, Grande Rue de la Croix-Rousse, 69004 Lyon, France. Electronic address: laurent.kodjikian@chu-lyon.fr. | 336 | ||||
| 10.1016/j.jchirv.2020.04.008 | English Abstract;Journal Article;Review | fr | [Risks of viral contamination in healthcare professionals during laparoscopy in the Covid-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32322313 | The Covid-19 pandemic has markedly changed our practices. This article analyses the risks of contamination among healthcare professionals (HCPs) during laparoscopic surgery on patients with Covid-19. Harmful effects of aerosols from a pneumoperitoneum with the virus present have not yet been quantified. Measures for the protection of HCPs are an extrapolation of those taken during other epidemics. They must still be mandatory to minimise the risk of viral contamination. Protection measures include personal protection equipment for HCPs, adaptation of surgical technique (method for obtaining pneumoperitoneum, filters, preferred intracorporeal anastomosis, precautions during the exsufflation of the pneumoperitoneum), and organisation of the operating room. | 1878-786X | 2020-04-26 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | J Veziant;N Bourdel;K Slim | Laparoscopy;SARS-CoV-2;Viral contamination;Virus | 2020-04-21 02:00:00+02:00 | 32322313 | FR | Service de chirurgie digestive, CHU de Clermont-Ferrand, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand, France.;Service de gynécologie, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France. | 346 | |||
| Case Reports;Letter | en | Unilateral conjunctivitis as first presentation of Coronavirus Disease 2019 (COVID-19): A telemedicine diagnosis. | https://www.ncbi.nlm.nih.gov/pubmed/32327279 | 2020-04-26 02:00:00+02:00 | pubmed | Adult;Betacoronavirus__genetics;Clinical Laboratory Techniques__methods;Conjunctivitis__diagnosis;Coronavirus Infections__diagnosis;Humans;Male;Pandemics;Pneumonia, Viral__diagnosis;Reverse Transcriptase Polymerase Chain Reaction;Telemedicine__methods;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | A Daruich;D Martin;D Bremond-Gignac | 2020-04-21 02:00:00+02:00 | 32327279 | FR;AR | Hôpital Universitaire Necker Enfants Malades, APHP Ophthalmology Department, Université de Paris, 149, rue de Sèvres, 75015 Paris, France, Inserm, UMRS1138, Team 17, From physiopathology of ocular diseases to clinical development, Université Sorbonne Paris Cité, Centre de Recherche des Cordeliers, 15, rue de l'Ecole de Médecine, 75006 Paris, France.;Instituto de ojos y oídos, Avenida Belgrano 647, Resistencia, Chaco, Argentina.;Hôpital Universitaire Necker Enfants Malades, APHP Ophthalmology Department, Université de Paris, 149, rue de Sèvres, 75015 Paris, France, Inserm, UMRS1138, Team 17, From physiopathology of ocular diseases to clinical development, Université Sorbonne Paris Cité, Centre de Recherche des Cordeliers, 15, rue de l'Ecole de Médecine, 75006 Paris, France. Electronic address: dominique.bremond@aphp.fr. | 347 | |||||||
| 2020-KYGG-01-05;2016YFC0905600;2016YFC0901104;2018-I2M-1-003;81570049;81970058 | 10.1055/s-0040-1710019 | Journal Article;Review | en | Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. | https://www.ncbi.nlm.nih.gov/pubmed/32316065 | Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months, causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation abnormalities, which may occur in almost all of the severe and critical ill COVID-19 cases. Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has been frequently reported in COVID-19 cases, but its management is still challenging due to the complexity between antithrombotic therapy and coagulation disorders. Based on frontline practical experience and comprehensive literature review, here a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of VTE associated with COVID-19. This statement aims for clinicians treating COVID-19 and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. With limited experience on COVID19-associated VTE, this expert consensus statement should be helpful for clinicians worldwide with specific suggestions. | 0340-6245,2567-689X | 2020-04-26 02:00:00+02:00 | pubmed | Anticoagulants__therapeutic use;Betacoronavirus;Blood Coagulation Disorders__drug therapy;China__epidemiology;Consensus;Coronavirus Infections__blood;Critical Illness;Europe__epidemiology;Fibrin Fibrinogen Degradation Products__analysis;Hemorrhage__prevention & control;Humans;Pandemics;Pneumonia, Viral__blood;Pulmonary Embolism__complications;Registries;Risk Assessment;Risk Factors;Treatment Outcome;Venous Thromboembolism__complications;Venous Thrombosis__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Thrombosis and Haemostasis | Zhenguo Zhai;Chenghong Li;Yaolong Chen;Grigorios Gerotziafas;Zhenlu Zhang;Jun Wan;Peng Liu;Ismaïl Elalamy;Chen Wang | 2020-04-21 02:00:00+02:00 | 32316065 | FR;CN;RU;JP | [{"country": "", "agency": "2020-KYGG-01-05", "grantid": "Chinese Academy of Engineering emergency research and cultivation project for COVID-19"}, {"country": "", "agency": "2016YFC0905600", "grantid": "National Key Research and Development Program of China"}, {"country": "", "agency": "2016YFC0901104", "grantid": "National Key Research and Development Program of China"}, {"country": "", "agency": "2018-I2M-1-003", "grantid": "CAMS Innovation Fund for Medical Sciences"}, {"country": "", "agency": "81570049", "grantid": "National Natural Science Foundation of China"}, {"country": "", "agency": "81970058", "grantid": "National Natural Science Foundation of China"}] | Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.;Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.;National Clinical Research Center for Respiratory Diseases, Beijing, China.;Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Jianghan University, Wuhan, China.;Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.;Hematology and Thrombosis Center, Tenon University Hospital, INSERM UMRS 938, Sorbonne University, Paris, France.;Department of Clinical Laboratory, Wuhan Asia Heart Hospital, Wuhan, China.;Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Beijing, China.;Department of Obstetrics and Gynaecology, the First I.M. Sechenov Moscow State Medical University, Moscow, Russia.;Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. | 348 | |
| 10.1002/ca.23601 | Journal Article | en | Daily medical education for confined students during coronavirus disease 2019 pandemic: A simple videoconference solution. | https://www.ncbi.nlm.nih.gov/pubmed/32253771 | The outbreak of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 infection has recently spread globally and is now a pandemic. As a result, university hospitals have had to take unprecedented measures of containment, including asking nonessential staff to stay at home. Medical students practicing in the surgical departments find themselves idle, as nonurgent surgical activity has been canceled, until further notice. Likewise, universities are closed and medical training for students is likely to suffer if teachers do not implement urgent measures to provide continuing education. Thus, we sought to set up a daily medical education procedure for surgical students confined to their homes. We report a simple and free teaching method intended to compensate for the disappearance of daily lessons performed in the surgery department using the Google Hangouts application. This video conference method can be applied to clinical as well as anatomy lessons. | 0897-3806,1098-2353 | 2020-04-26 02:00:00+02:00 | pubmed | Anatomy__education;Betacoronavirus;Coronavirus Infections__prevention & control;Education, Distance__methods;Education, Medical__methods;General Surgery__education;Humans;Infection Control__methods;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Surgery Department, Hospital;Teaching__trends;Videoconferencing__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Anatomy | David Moszkowicz;Henri Duboc;Caroline Dubertret;Damien Roux;Frédéric Bretagnol | COVID-19 pandemic;anatomical learning;anatomy;medical education | 2020-04-22 02:00:00+02:00 | 32253771 | FR | Department of Digestive Surgery, Louis-Mourier Hospital, DMU ESPRIT, GHU AP-HP, Nord, University of Paris, Paris, France.;Department of Gastroenterology, Louis-Mourier Hospital, DMU ESPRIT, GHU AP-HP, Nord, University of Paris, Paris, France.;Department of Psychiatry, Louis-Mourier Hospital, DMU ESPRIT, GHU AP-HP, Nord, University of Paris, Paris, France.;Intensive Care Unit, Louis-Mourier Hospital, DMU ESPRIT, GHU AP-HP, Nord, University of Paris, Paris, France. | 353 | ||
| 10.1016/j.diii.2020.04.005 | Journal Article;Review | en | Interventional oncology at the time of COVID-19 pandemic: Problems and solutions. | https://www.ncbi.nlm.nih.gov/pubmed/32360351 | The COVID-19 pandemic has deeply impacted the activity of interventional oncology in hospitals and cancer centers. In this review based on official recommendations of different international societies, but also on local solutions found in different expert large-volume centers, we discuss the changes that need to be done for the organization, safety, and patient management in interventional oncology. A literature review of potential solutions in a context of scarce anesthesiologic resources, limited staff and limited access to hospital beds are proposed and discussed based on the literature data. | 2211-5684 | 2020-04-26 02:00:00+02:00 | pubmed | Aerosols;Age Factors;Anesthesia, General;Anesthesiology__statistics & numerical data;Betacoronavirus;Biopsy__adverse effects;Cancer Care Facilities__organization & administration;Carcinoma, Hepatocellular__therapy;Carcinoma, Renal Cell__therapy;Chemoembolization, Therapeutic__methods;Clinical Laboratory Techniques__methods;Colonic Neoplasms__pathology;Coronavirus Infections__complications;Databases, Factual;Health Personnel__statistics & numerical data;Health Resources__organization & administration;Hospital Bed Capacity__statistics & numerical data;Hospitalization__statistics & numerical data;Humans;Hyperthermia, Induced__methods;Kidney Neoplasms__therapy;Liver Neoplasms__therapy;Lung Neoplasms__secondary;Neoplasms__complications;Palliative Care__methods;Pandemics;Pneumonia, Viral__complications;Triage;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Diagnostic and Interventional Imaging | A Denys;B Guiu;P Chevallier;A Digklia;E de Kerviler;T de Baere | COVID-19;Interventional radiology;Kidney cancer;Liver cancer;Lung cancer | 2020-04-23 02:00:00+02:00 | 32360351 | FR;CH | Department of Radiology, CHUV UNIL, rue du Bugnon 46, 1011 Lausanne, Switzerland. Electronic address: Alban.Denys@chuv.ch.;Department of Radiology, Hôpital Saint ELOI, CHU Montpellier, 34000 Montpellier, France.;Department of Radiology, Hôpital ARCHET 2, CHU Nice, 06000 Nice, France.;Department of Oncology, CHUV UNIL, 1011 Lausanne, Switzerland.;Department of Radiology, Assistance Publique-Hopitaux de Paris, Hôpital Saint-Louis, 75010 Paris, France, Université de Paris, 75006 Paris, France.;Department of Interventional Radiology, Institut Gustave Roussy, 94800 Villejuif, France. | 354 | ||
| 10.1016/j.jchirv.2020.04.012 | English Abstract;Journal Article | fr | [Nosocomial infection with SARS-Cov-2 within departments of digestive surgery]. | https://www.ncbi.nlm.nih.gov/pubmed/32341721 | The COVID-19 pandemic imposed a drastic reduction in surgical activity in order to respond to the influx of hospital patients and to protect uninfected patients by avoiding hospitalization. However, little is known about the risk of infection during hospitalization or its consequences. The aim of this work was to report a series of patients hospitalized on digestive surgery services who developed a nosocomial infection with SARS-Cov-2 virus. | 1878-786X | 2020-04-26 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | M Luong-Nguyen;H Hermand;S Abdalla;N Cabrit;C Hobeika;A Brouquet;D Goéré;A Sauvanet | COVID-19;Digestive surgery;Nosocomial transmission;SARS-cov-2 | 2020-04-24 02:00:00+02:00 | 32341721 | FR | Chirurgie digestive, oncologique et endocrinienne, hôpital Saint Louis, AP-HP, université de Paris, 1, rue Claude Vellefaux, 75010 Paris, France.;Chirurgie digestive, hôpital de Bicêtre, AP-HP, université Paris Sud, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France.;Chirurgie hépatique et pancréatique, hôpital Beaujon, AP-HP, université de Paris, 100, boulevard du Général Leclerc, 92110 Clichy, France. | 361 | |||
| 10.1016/j.jviscsurg.2020.04.017 | Journal Article;Review | en | What do surgeons need to know about the digestive disorders and paraclinical abnormalities induced by COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32360205 | The symptoms associated with COVID-19 are mainly characterized by a triad composed of fever, dry cough and dyspnea. However, digestive symptoms have also been reported. At first considered as infrequent, they in fact seem to affect more than half of patients. The symptoms mainly include anorexia, diarrhea, nausea and/or vomiting and abdominal pain. Even though prognosis is associated with lung injury, digestive symptoms seem significantly more frequent in patients presenting with severe COVID-19 infection. Digestive presentations, which may be isolated or which can precede pulmonary symptoms, have indeed been reported, with diarrhea as a leading clinical sign. The main biological abnormalities that can suggest COVID-19 infection at an early stage are lymphopenia, elevated CRP and heightened ASAT transaminases. Thoraco-abdominal scan seems useful as a means of on the one hand ruling out digestive pathology not connected with coronavirus and on the other hand searching for pulmonary images consistent with COVID-19 infection. No data exist on the value of digestive endoscopy in cases of persistent digestive symptoms. Moreover, the endoscopists may themselves be at significant risk of contamination. Fecal-oral transmission of the infection is possible, especially insofar as viral shedding in stools seems frequent and of longer duration than at the ENT level, including in patients with negative throat swab and without digestive symptoms. In some doubtful cases, virologic assessment of stool samples can yield definitive diagnosis. In the event of prolonged viral shedding in stools, a patient's persistent contagiousness is conceivable but not conclusively established. Upcoming serology should enable identification of the patients having been infected by the COVID-19 epidemic, particularly among previously undetected pauci-symptomatic members of a health care staff. Resumption of medico-surgical activity should be the object of a dedicated strategy preceding deconfinement. | 1878-7886 | 2020-04-26 02:00:00+02:00 | pubmed | Coronavirus Infections__complications;Digestive System Diseases__etiology;Digestive System Surgical Procedures;Humans;Pandemics;Pneumonia, Viral__complications;COVID-19 | Journal of Visceral Surgery | J-M Gornet;M L Tran Minh;F Leleu;D Hassid | COVID-19;Diarrhea;Digestive disorders | 2020-04-24 02:00:00+02:00 | 32360205 | FR | Paris University, Department of Gastroenterology, AP-HP Hôpital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France. Electronic address: jean-marc.gornet@aphp.fr.;Paris University, Department of Gastroenterology, AP-HP Hôpital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France.;Paris University, Department of Radiology, AP-HP Hôpital Saint Louis, Paris, France. | 362 | ||
| 10.1016/j.jchirv.2020.04.011 | English Abstract;Journal Article;Review | fr | [Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups]. | https://www.ncbi.nlm.nih.gov/pubmed/32328206 | The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care. | 1878-786X | 2020-04-26 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | O Glehen;V Kepenekian;O Bouché;L Gladieff;C Honore | Coronavirus;Covid-19;Peritoneal metastases;Primary peritoneal tumor | 2020-04-23 02:00:00+02:00 | 32328206 | FR | Service de chirurgie digestive et endocrinienne, hôpital Lyon Sud - Hospices Civils de Lyon, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite, France.;EA 3738, Université Lyon 1, Lyon, France.;Service d'hépato-gastro-entérologie et cancérologie digestive, hôpital Robert-Debré, Reims, France.;Département d'oncologie médicale, institut universitaire du cancer de Toulouse, Toulouse, France.;Département de chirurgie, institut Gustave-Roussy, Villejuif, France. | 384 | |||
| 10.1016/j.transci.2020.102804 | Journal Article | en | Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients? | https://www.ncbi.nlm.nih.gov/pubmed/32387238 | Covid-19 is characterized by weak symptoms in most affected patients whilst severe clinical complications, with frequent fatal issues, occur in others. Disease severity is associated with age and comorbidities. Understanding of viral infectious mechanisms, and antibody immune response, can help to better control disease progression. SARS-CoV-2 has a major impact on the Renin Angiotensin Aldosterone System (RAAS), through its binding to the membrane cellular glycoprotein, Angiotensin Converting Enzyme-2 (ACE-2), then infecting cells for replication. This report hypothesizes the possible implication of an autoimmune response, induced by generation of allo- or autoantibodies to ACE-2, or to its complexes with viral spike protein. This could contribute to some delayed severe complications occurring in affected patients. We also propose a strategy for investigating this eventuality. | 1473-0502 | 2020-05-03 02:00:00+02:00 | pubmed | Antibodies, Viral__immunology;Antibody Specificity;Autoantibodies__immunology;Autoimmunity;Betacoronavirus__immunology;Blood Coagulation;Coronavirus Infections__blood;Cytokine Release Syndrome__etiology;Disease Progression;Disseminated Intravascular Coagulation__etiology;Humans;Isoantibodies__immunology;Pandemics;Peptidyl-Dipeptidase A__blood;Pneumonia, Viral__blood;Renin-Angiotensin System__physiology;Serine Endopeptidases__physiology;Severity of Illness Index;Spike Glycoprotein, Coronavirus__immunology;Thrombophilia__blood;Time Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Transfusion and Apheresis Science | Jean Amiral;Anne Marie Vissac;Jerard Seghatchian | ACE-2;Angiotensin II;Autoantibodies;Covid-19;Disease severity;Hemostasis;Spike protein S | 2020-05-03 02:00:00+02:00 | 32387238 | FR;GB | SH/Scientific-Hemostasis, Scientific Director and Consultant in Hemostasis and Thrombosis Diagnostics, Franconville, France. Electronic address: jean.amiral@scientific-hemostasis.com.;Hyphen BioMed, Neuville sur Oise, France.;International Consultancy in Strategic Safety Improvements of Blood-Derived Bioproducts and Suppliers Quality Audit / Inspection, London, UK. Electronic address: jseghatchian@btopenworld.com. | 389 | ||
| Letter | en | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Related Deaths in French Long-Term Care Facilities: The "Confinement Disease" Is Probably More Deleterious Than the Coronavirus Disease-2019 (COVID-19) Itself. | https://www.ncbi.nlm.nih.gov/pubmed/32507530 | 2020-05-03 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__mortality;Disease Outbreaks;France__epidemiology;Humans;Long-Term Care;Pandemics;Pneumonia, Viral__mortality;Severe Acute Respiratory Syndrome__mortality;COVID-19;severe acute respiratory syndrome coronavirus 2 | Sylvain Diamantis;Coralie Noel;Paul Tarteret;Nicolas Vignier;Sébastien Gallien | 2020-05-03 02:00:00+02:00 | 32507530 | FR | Hôpital Marc Jacquet, Melun, France.;Hôpital Henri-Mondor, Université Paris Est Créteil, Créteil, France. | 390 | |||||||
| Letter | en | Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32370951 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Cardiology__methods;Child;Child, Preschool;Coronary Aneurysm__prevention & control;Coronavirus Infections__epidemiology;Delayed Diagnosis;Fever__diagnosis;Health Services Accessibility;Humans;Immunoglobulins, Intravenous__therapeutic use;Infant;Infant, Newborn;Missed Diagnosis;Mucocutaneous Lymph Node Syndrome__diagnosis;Pandemics;Patient Acceptance of Health Care;Pediatrics__methods;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Ashraf S Harahsheh;Nagib Dahdah;Jane W Newburger;Michael A Portman;Maryam Piram;Robert Tulloh;Brian W McCrindle;Sarah D de Ferranti;Rolando Cimaz;Dongngan T Truong;Jane C Burns | COVID-19;Kawasaki disease;bayesian thinking;pediatric cardiology | 2020-05-03 02:00:00+02:00 | 32370951 | FR;CA;GB;US;IT | Division of Pediatric Cardiology, Department of Pediatrics, Children's National Hospital, The George Washington University School of Medicine, Washington, District of Columbia.;Division of Pediatric Cardiology, Department of Pediatrics, CHU Sainte Justine, University of Montreal, Montreal, Quebec, Canada.;Department of Cardiology, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.;Seattle Children's Hospital, University of Washington, Seattle, Washington.;Division of Pediatric Dermatology, Department of Pediatrics, CHU Sainte Justine, University of Montreal, Montreal, Quebec, Canada, CEREMAIA, Université Paris Saclay, Le Kremlin Bicêtre, France.;University of Bristol, Bristol, United Kingdom.;The Hospital for Sick Children, Toronto, Ontario, Canada.;University of Milano, Milano, Italy.;University of Utah, Primary Children's Hospital, Salt Lake City, Utah.;Department of Pediatrics, Rady Children's Hospital, University of California San Diego, San Diego, California. | 391 | ||||||
| Journal Article;Comment | en | The importance of naturally attenuated SARS-CoV-2in the fight against COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32342578 | The current SARS-CoV-2 pandemic is wreaking havoc throughout the world and has rapidly become a global health emergency. A central question concerning COVID-19 is why some individuals become sick and others not. Many have pointed already at variation in risk factors between individuals. However, the variable outcome of SARS-CoV-2 infections may, at least in part, be due also to differences between the viral subspecies with which individuals are infected. A more pertinent question is how we are to overcome the current pandemic. A vaccine against SARS-CoV-2 would offer significant relief, although vaccine developers have warned that design, testing and production of vaccines may take a year if not longer. Vaccines are based on a handful of different designs (i), but the earliest vaccines were based on the live, attenuated virus. As has been the case for other viruses during earlier pandemics, SARS-CoV-2 will mutate and may naturally attenuate over time (ii). What makes the current pandemic unique is that, thanks to state-of-the-art nucleic acid sequencing technologies, we can follow in detail how SARS-CoV-2 evolves while it spreads. We argue that knowledge of naturally emerging attenuated SARS-CoV-2 variants across the globe should be of key interest in our fight against the pandemic. | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Disease Outbreaks;Humans;Pandemics;Pneumonia, Viral;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean Armengaud;Agnès Delaunay-Moisan;Jean-Yves Thuret;Eelco van Anken;Diego Acosta-Alvear;Tomás Aragón;Carolina Arias;Marc Blondel;Ineke Braakman;Jean-François Collet;René Courcol;Antoine Danchin;Jean-François Deleuze;Jean-Philippe Lavigne;Sophie Lucas;Thomas Michiels;Edward R B Moore;Jonathon Nixon-Abell;Ramon Rossello-Mora;Zheng-Li Shi;Antonio G Siccardi;Roberto Sitia;Daniel Tillett;Kenneth N Timmis;Michel B Toledano;Peter van der Sluijs;Elisa Vicenzi | 2020-04-29 02:00:00+02:00 | 32342578 | FR;SE;CN;GB;US;IT;AU;NL;ES;BE;DE | Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Bagnols-sur-Cèze, 30200, France.;Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, 91198, France.;Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Via Olgettina 58, Milan, 20132, Italy.;Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA.;Center for Applied Medical Research, Department of Gene Therapy and Regulation of Gene Expression, University of Navarra, 55 Pio XII Street, Pamplona, 31008, Spain.;Institut National de la Santé et de la Recherche Médicale UMR1078, 22 Avenue Camille Desmoulins, Brest, F-29200, France.;Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé, 22 Avenue Camille Desmoulins, Brest, F-29200, France.;Etablissement Français du Sang (EFS) Bretagne, Brest, F-29200, France.;CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, 22 Avenue Camille Desmoulins, Brest, F-29200, France.;Cellular Protein Chemistry, Bijvoet Centre for Biomolecular Science, Science for Life, Utrecht University, The Netherlands.;de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.;WELBIO, Wallonia, Belgium.;Expertise France, 73 Avenue de Vaugirard, Paris, 75006, France.;Stellate Therapeutics/Kodikos, Institut Cochin, Paris, 75014, France.;Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, Evry, 91057, France.;U1047, Institut National de la Santé et de la Recherche Médicale, Université Montpellier, Montpellier, France.;Service de Microbiologie et Hygiène Hospitalière, CHU Nîmes, Nîmes, France.;Department of Infectious Diseases, Institute for Biomedicine, Sahlgrenska Academy of the University of Gothenburg, Gothenburg, SE-41346, Sweden.;Department of Clinical Microbiology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, SE-41346, Sweden.;Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, CB2 0XY, UK.;Marine Microbiology Group, Department of Animal and Bacterial Diversity, IMEDEA (CSIC-UIB), Esporles, Balearic Islands, 07190, Spain.;CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.;Nucleics Pty Ltd, 29 John Street, Woollahra, New South Wales, 2025, Australia.;Institute of Microbiology, Technical University Braunschweig, Braunschweig, Germany.;Viral Pathogenesis and Biosafety Unit, San Raffaele Scientific Institute, Via Olgettina 58, Milan, 20132, Italy. | 407 | ||||||
| AF03 British Heart Foundation Translational;Wellcome Trust | 10.1111/bph.15094 | Journal Article;Review | en | A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. | https://www.ncbi.nlm.nih.gov/pubmed/32358833 | In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide. | 0007-1188,1476-5381 | 2020-05-03 02:00:00+02:00 | pubmed | British Journal of Pharmacology | Steve P H Alexander;Jane F Armstrong;Anthony P Davenport;Jamie A Davies;Elena Faccenda;Simon D Harding;Francesca Levi-Schaffer;Janet J Maguire;Adam J Pawson;Christopher Southan;Michael Spedding | 2020-05-01 02:00:00+02:00 | 32358833 | SE;IL;FR;GB;US | [{"country": "", "agency": "AF03 British Heart Foundation Translational", "grantid": "Award Ref TG/18/4/33770"}, {"country": "United Kingdom", "agency": "Wellcome Trust", "grantid": "107715/Z/15/Z"}] | Chair, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), School of Life Sciences, University of Nottingham, Nottingham, UK.;Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.;Executive Committee, NC-IUPHAR, University of Cambridge, Cambridge, UK.;Principal Investigator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.;Database Developer, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.;First Vice-President and Chair of Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR), Hebrew University of Jerusalem, Jerusalem, Israel.;University of Cambridge, Cambridge, UK.;Senior Curator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.;Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.;TW2Informatics Ltd, Gothenburg, Sweden.;Secretary-General, International Union of Basic and Clinical Pharmacology (IUPHAR) and Spedding Research Solutions SAS, Le Vesinet, France. | 417 | ||
| 10.1136/annrheumdis-2020-217407 | Journal Article;Practice Guideline | en | Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. | https://www.ncbi.nlm.nih.gov/pubmed/32349982 | Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients. | 2020-05-03 02:00:00+02:00 | pubmed | Antibodies, Monoclonal, Humanized__therapeutic use;Betacoronavirus;Coronavirus Infections__drug therapy;Humans;Immunosuppressive Agents__administration & dosage;Lung Diseases, Interstitial__immunology;Pandemics;Pneumonia, Viral__drug therapy;Respiratory Distress Syndrome, Adult__drug therapy;Scleroderma, Systemic__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Marco Matucci-Cerinic;Cosimo Bruni;Yannick Allanore;Massimo Clementi;Lorenzo Dagna;Nemanja S Damjanov;Amato de Paulis;Christopher P Denton;Oliver Distler;David Fox;Daniel E Furst;Dinesh Khanna;Thomas Krieg;Masataka Kuwana;Eun Bong Lee;Mengtao Li;Shiv Pillai;Yukai Wang;Xiaofeng Zeng;Gloria Taliani | autoimmune diseases;hydroxychloroquine;scleroderma;systemic | 2020-04-29 02:00:00+02:00 | 32349982 | FR;CN;JP;CH;GB;US;IT;RS;KR;DE | Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy marco.matuccicerinic@unifi.it.;Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy.;Rheumatology Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.;Unit of Microbiology and Virology, San Raffaele Hospital, Milano, Lombardia, Italy.;Unit of Microbiology and Virology, Università Vita Salute San Raffaele, Milano, Lombardia, Italy.;Vita-Salute San Raffaele University, Milan, Italy.;Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.;Rheumatology department, University of Belgrade School of Medicine, Belgrade, Serbia.;Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.;Department of Rheumatology, Royal Free Hospital, University College London, London, UK.;Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.;Rheumatology department, University of Michigan, Ann Arbor, Michigan, USA.;Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA.;University of Washington, Seattle, Washington DC, USA.;Translational Matrix Biology, Medical Faculty, Cologne, Germany.;Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.;Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.;Rheumatology & Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.;Ragon Institute, Massachusetts General Hospital, Cambridge, Massachusetts, USA.;Rheumatology department, Shantou Central Hospital, Shantou, Guangdong, China.;Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.;Infectious Diseases Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Roma, Lazio, Italy. | 423 | ||||
| 10.3389/fcimb.2020.00181 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives. | https://www.ncbi.nlm.nih.gov/pubmed/32411619 | The availability of pathogen-specific treatment options for respiratory tract infections (RTIs) increased the need for rapid diagnostic tests. Besides, retrospective studies, improved lab-based detection methods and the intensified search for new viruses since the beginning of the twenty-first century led to the discovery of several novel respiratory viruses. Among them are human bocavirus (HBoV), human coronaviruses (HCoV-HKU1, -NL63), human metapneumovirus (HMPV), rhinovirus type C (RV-C), and human polyomaviruses (KIPyV, WUPyV). Additionally, new viruses like SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV), novel strains of influenza virus A and B, and (most recently) SARS coronavirus 2 (SARS-CoV-2) have emerged. Although clinical presentation may be similar among different viruses, associated symptoms may range from a mild cold to a severe respiratory illness, and thus require a fast and reliable diagnosis. The increasing number of commercially available rapid point-of-care tests (POCTs) for respiratory viruses illustrates both the need for this kind of tests but also the problem, i.e., that the majority of such assays has significant limitations. In this review, we summarize recently published characteristics of POCTs and discuss their implications for the treatment of RTIs. The second key aspect of this work is a description of new and innovative diagnostic techniques, ranging from biosensors to novel portable and current lab-based nucleic acid amplification methods with the potential future use in point-of-care settings. While prototypes for some methods already exist, other ideas are still experimental, but all of them give an outlook of what can be expected as the next generation of POCTs. | 2235-2988 | 2020-05-03 02:00:00+02:00 | pubmed | Biosensing Techniques__methods;Communicable Diseases, Emerging__diagnosis;DNA Viruses__isolation & purification;Humans;Point-of-Care Testing;Polymerase Chain Reaction__methods;RNA Viruses__isolation & purification;Respiratory Tract Infections__diagnosis | Frontiers in Cellular and Infection Microbiology | Philipp P Nelson;Barbara A Rath;Paraskevi C Fragkou;Emmanouil Antalis;Sotirios Tsiodras;Chrysanthi Skevaki | POCT;bedside testing;biosensors;commercial point-of-care tests;innovative approaches;virus diagnostics | 2020-04-29 02:00:00+02:00 | 32411619 | FR;GR;CH;DE;AT | Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, German Center for Lung Research (DZL) Marburg, Marburg, Germany.;Vienna Vaccine Safety Initiative - Pediatric Infectious Diseases and Vaccines, Berlin, Germany.;UMR Chrono-Environnement, Université Bourgogne Franche-Comté, Besançon, France.;ESCMID Study Group for Respiratory Viruses (ESGREV), Basel, Switzerland.;4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. | 431 | ||
| 10.1002/hed.26222 | Journal Article;Review | en | Health workers' safety during tracheostomy in COVID-19 patients: Homemade protective screen. | https://www.ncbi.nlm.nih.gov/pubmed/32347991 | As an aerosol and droplets generating procedure, tracheostomy increases contamination risks for health workers in the coronavirus disease context. To preserve the health care system capacity and to limit virus cross-transmission, protecting caregivers against coronavirus infection is of critical importance. We report the use of external fixator equipment to set up a physical interface between the patient's neck and the caregiver performing a tracheostomy in COVID-19 patients. Once the metal frame set in place, it is wrapped with a single-use clear and sterile cover for surgical C-arm. This installation is simple, easy, and fast to achieve and can be carried out with inexpensive material available in every hospital. This physical interface is an additional safety measure that prevents the direct projection of secretions or droplets. It should, of course, only be considered as a complement to strict compliance with barrier precautions and personal protective equipment. | 1043-3074,1097-0347 | 2020-05-03 02:00:00+02:00 | pubmed | China;Coronavirus Infections__epidemiology;Equipment Design;Female;Health Personnel__statistics & numerical data;Humans;Infection Control__methods;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Male;Occupational Health;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Protective Devices__statistics & numerical data;Tracheostomy__instrumentation;COVID-19 | Head & Neck | Pierre-Yves Cordier;Bruno De La Villeon;Edouard Martin;Yvain Goudard;Pierre Haen | COVID-19;caregivers;safety;tracheostomy;transmission | 2020-04-29 02:00:00+02:00 | 32347991 | FR | Intensive Care Unit, Laveran Military Teaching Hospital, Marseille, France.;Visceral Surgery Unit, Laveran Military Teaching Hospital, Marseille, France.;Maxillofacial Surgery Unit, Laveran Military Teaching Hospital, Marseille, France. | 433 | ||
| 10.1001/jamacardio.2020.1787 | Journal Article | en | Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. | https://www.ncbi.nlm.nih.gov/pubmed/32356858 | 2380-6583 | 2020-05-03 02:00:00+02:00 | pubmed | JAMA Cardiology | Francis Bessière;Hugo Roccia;Antoine Delinière;Rome Charrière;Philippe Chevalier;Laurent Argaud;Martin Cour | 2020-05-01 02:00:00+02:00 | 32356858 | FR | Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Service d'électrophysiologie et de Stimulation Cardiaque, Université de Lyon, Lyon, France.;Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Centre de Référence National des Troubles du Rythme Cardiaque d'origine Héréditaire, Lyon, France.;Hospices Civils de Lyon, Hôpital Edouard Herriot, Médecine Intensive - Réanimation, Lyon, France.;Centre Hospitalier de Valence, Service de Maladies Infectieuses, Valence, France. | 437 | |||||
| Letter;Comment | en | Atypical presentation of COVID-19 in young infants. | https://www.ncbi.nlm.nih.gov/pubmed/32353326 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Coronavirus;Coronavirus Infections;Humans;Infant;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nadia Nathan;Blandine Prevost;Harriet Corvol | 2020-04-27 02:00:00+02:00 | 32353326 | FR | Paediatric Pulmonology Department and Reference Centre For Rare Lung Disease RespiRare, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75012, France.;Paediatric Pulmonology Department and Reference Centre For Rare Lung Disease RespiRare, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75012, France, Sorbonne Université, Centre de Recherche Saint Antoine, Paris, France. Electronic address: harriet.corvol@aphp.fr. | 447 | |||||||
| Letter;Comment | en | Spinal anesthesia for Cesarean delivery in women with COVID-19 infection: questions regarding the cause of hypotension. | https://www.ncbi.nlm.nih.gov/pubmed/32342348 | 2020-05-03 02:00:00+02:00 | pubmed | Anesthesia, Spinal;Anesthetics;Betacoronavirus;Coronavirus Infections;Female;Humans;Hypotension;Pandemics;Pneumonia, Viral;Pregnancy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Dan Benhamou;Hawa Keita Meyer;Estelle Morau;Dominique Chassard;Frédéric J Mercier | 2020-04-27 02:00:00+02:00 | 32342348 | FR | Service D'Anesthésie Réanimation Médecine Péri Opératoire, AP-HP, Université Paris Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France. dan.benhamou@aphp.fr.;Service D'Anesthésie-Réanimation pédiatrique Et obstétricale, Hôpital Universitaire Necker Enfants Malades - APHP, Université Paris Descartes, Paris, France.;Département Anesthésie Réanimation, CHU Nimes, Nimes, France.;Département D'Anesthésie Réanimation, Hôpital Femme-Mère-Enfant, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France.;Département D'Anesthésie, Université Paris Saclay, Hôpital Antoine Béclère, Clamart, France. | 455 | |||||||
| 10.1016/j.jfo.2020.04.016 | Journal Article;Practice Guideline | fr | [How to approach management of ocular surface disease during COVID-19 pandemic?] | https://www.ncbi.nlm.nih.gov/pubmed/32402410 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Acute Disease;Animals;Betacoronavirus;Conjunctivitis__diagnosis;Conjunctivitis, Allergic__diagnosis;Contact Lenses;Cornea__surgery;Coronavirus Infections__diagnosis;Dry Eye Syndromes__diagnosis;Eye Diseases__diagnosis;Humans;Keratitis__diagnosis;Keratoconjunctivitis, Infectious__diagnosis;Pandemics;Pneumonia, Viral__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | M Labetoulle;S Doan;A Rousseau | 2020-04-30 02:00:00+02:00 | 32402410 | FR | Service d'ophtalmologie, hôpital de Bicêtre, 78, avenue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France, IDMIT Infrastructure, CEA, Université Paris Sacaly, Inserm U1184, 18, route du Panorama, 92265 Fontenay-aux-Roses cedex, France. Electronic address: marc.labetoulle@aphp.fr.;Service d'ophtalmologie, hôpital de Bicêtre, 78, avenue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France, Hôpital Fondation Adolphe de Rothschild, 29, rue Manin, 75019 Paris, France.;Service d'ophtalmologie, hôpital de Bicêtre, 78, avenue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France, IDMIT Infrastructure, CEA, Université Paris Sacaly, Inserm U1184, 18, route du Panorama, 92265 Fontenay-aux-Roses cedex, France. | 466 | ||||
| Letter | en | French ICUs fight back: An example of regional ICU organisation to tackle the SARS-CoV-2 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32360980 | 2020-05-03 02:00:00+02:00 | pubmed | Anesthesiology__organization & administration;Bed Conversion;Betacoronavirus;Coronavirus Infections__epidemiology;Emergency Medical Service Communication Systems__organization & administration;Extracorporeal Membrane Oxygenation;France__epidemiology;Hospital Bed Capacity;Hospital Communication Systems__organization & administration;Hospital Planning__organization & administration;Hospitals, University__organization & administration;Hotlines;Humans;Intensive Care Units__organization & administration;Medicine__organization & administration;Mobile Applications;Mobile Health Units__organization & administration;Pandemics;Patient Transfer__organization & administration;Pneumonia, Viral__epidemiology;Software;COVID-19;severe acute respiratory syndrome coronavirus 2 | Benjamin Terrasi;Emilien Arnaud;Mathieu Guilbart;Patricia Besserve;Yazine Mahjoub | COVID-19 app;ICU organisation;Outbreak;Picardy;SARS-CoV-2 | 2020-04-30 02:00:00+02:00 | 32360980 | FR | Department of anaesthesia and critical care, Amiens University Hospital, 80054 Amiens, France.;Emergency department, Amiens University Hospital, 80054 Amiens, France.;Department of anaesthesia and critical care, Amiens University Hospital, 80054 Amiens, France. Electronic address: mahjoub.yazine@chu-amiens.fr. | 467 | ||||||
| 10.1016/j.jamda.2020.04.022 | Editorial | en | The Importance of Physical Activity to Care for Frail Older Adults During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32513558 | 1525-8610 | 2020-05-03 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__epidemiology;Exercise;Frail Elderly;Healthy Aging;Humans;Nursing Homes;Pandemics;Pneumonia, Viral__epidemiology;Quarantine;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of the American Medical Directors Association | Mylene Aubertin-Leheudre;Yves Rolland | 2020-04-30 02:00:00+02:00 | 32513558 | FR;CA;US | Centre de recherche, Institut universitaire de gériatrie de Montréal (IUGM), CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, Canada, Département des Sciences de l'activité physique, Faculté des sciences, Université du Québec à Montréal, Montreal, Canada. Electronic address: aubertin-leheudre.mylene@uqam.ca.;Gerontopole of Toulouse, University Hospital of Toulouse (CHU-Toulouse), Toulouse, France, UMR INSERM 1027, University of Toulouse III, Toulouse, France. | 474 | ||||
| 10.1016/j.jfo.2020.04.015 | Practice Guideline | fr | [Management of ocular cancer during COVID-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32389526 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Child;Choroid Neoplasms__secondary;Conjunctival Neoplasms__diagnostic imaging;Coronavirus Infections__epidemiology;Eye Neoplasms__diagnosis;Humans;Melanoma__therapy;Nevus__diagnostic imaging;Pandemics;Pneumonia, Viral__epidemiology;Retinoblastoma__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | N Cassoux | 2020-04-30 02:00:00+02:00 | 32389526 | FR | Département Ophtalmologie, Institut Curie, Oncologie Chirurgicale, 26, rue d'ULM, 750005 Paris, France. Electronic address: nathalie.cassoux@curie.fr. | 478 | ||||
| 10.1016/j.cgh.2020.04.071 | Journal Article | en | Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. | https://www.ncbi.nlm.nih.gov/pubmed/32360811 | The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics may increase the risk of COVID-19 infection. IOIBD has put in place an international registry, SECURE-IBD, for tracking all the cases with IBDs infected by COVID-19 (SECURE-IBD registry: http://www.covidibd.org). It will describe the outcomes of infected patients and the association between IBD-related medications and these outcomes. | 1542-3565 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;France__epidemiology;Humans;Immunocompromised Host;Incidence;Inflammatory Bowel Diseases__complications;Italy__epidemiology;Pandemics;Pneumonia, Viral__epidemiology;Registries__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Gastroenterology and Hepatology | Mariangela Allocca;Gionata Fiorino;Camille Zallot;Federica Furfaro;Daniela Gilardi;Simona Radice;Silvio Danese;Laurent Peyrin-Biroulet | 2020-04-30 02:00:00+02:00 | 32360811 | FR;IT | Humanitas Clinical and Research Center, Istituto di ricovero e cura a carattere scientifico, Rozzano, Milan, Italy, Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy. Electronic address: mariangela.allocca@humanitas.it.;Humanitas Clinical and Research Center, Istituto di ricovero e cura a carattere scientifico, Rozzano, Milan, Italy, Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy.;Department of Gastroenterology, Inserm U1256 Nutrition - génétique et exposition aux risques environnementaux, Nancy University Hospital, Lorraine University, Vandoeuvre-les-Nancy, France.;Humanitas Clinical and Research Center, Istituto di ricovero e cura a carattere scientifico, Rozzano, Milan, Italy. | 483 | |||
| 10.1016/j.jchirv.2020.04.015 | English Abstract;Journal Article;Review | fr | [Endocrine surgery during and after the COVID-19 epidemic: Guidelines from AFCE]. | https://www.ncbi.nlm.nih.gov/pubmed/32355510 | The COVID-19 pandemic commands a major reorganization of the entire French healthcare system. In France, general rules have been issued nationally and implemented by each healthcare center, both public and private, throughout France. Guidelines drafted by an expert group led by the French-speaking Association of Endocrine Surgery (AFCE) propose specific surgical management principles for thyroid, parathyroid, endocrine pancreas and adrenal surgery during and after the COVID-19 epidemic. | 1878-786X | 2020-05-03 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | G Baud;L Brunaud;J C Lifante;C Tresallet;F Sebag;J P Bizard;M Mathonnet;F Menegaux;R Caiazzo;É Mirallié;F Pattou | Adrenal;COVID-19;Coronavirus;Endocrine surgery;Neuroendocrine tumor;Parathyroid;Thyroid | 2020-04-30 02:00:00+02:00 | 32355510 | FR | Chirurgie générale et endocrinienne, CHU de Lille, 59000 Lille, France.;Chirurgie viscérale, métabolique et cancérologique (CVMC), CHRU de Nancy, 54511 Vandœuvre-lès-Nancy, France.;Chirurgie digestive, oncologique et endocrinienne, CHU de Lyon, 69310 Pierre-Bénite, France.;Chirurgie digestive, bariatrique et endocrinienne, AP-HP, Hôpital Avicenne, université Sorbonne Paris Nord, 93000 Bobigny, France.;Chirurgie générale et endocrinienne, AP-HM, La Conception, 13005 Marseille, France.;Chirurgie endocrinienne et viscérale, hôpital privé Arras-lès-Bonnettes, 62000 Arras, France.;Chirurgie digestive et endocrinienne, CHU de Limoges, 87000 Limoges, France.;Chirurgie générale digestive et endocrinienne, Sorbonne université, hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France.;Chirurgie cancérologique, digestive et endocrinienne (CCDE), CHU de Nantes, 44093 Nantes, France. | 484 | |||
| 10.1016/j.jbspin.2020.04.006 | Editorial | en | How and why are rheumatologists relevant to COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32451147 | 1297-319X | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Competence;Clinical Trials as Topic;Coronavirus Infections__epidemiology;Global Health;Humans;Pandemics;Pneumonia, Viral__epidemiology;Rheumatologists__standards;Rheumatology;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Joint Bone Spine | Renaud Felten;Emmanuel Chatelus;Laurent Arnaud | COVID-19;Clinical trials;Rheumatology;Therapeutics | 2020-04-30 02:00:00+02:00 | 32451147 | FR | Service de rhumatologie, CHU de Strasbourg, Strasbourg, France. Electronic address: renaud.felten@chru-strasbourg.fr.;Service de rhumatologie, CHU de Strasbourg, Strasbourg, France, Centre national de références des maladies systémiques et auto-immunes rares Est Sud-Ouest (RESO), université de Strasbourg, Strasbourg, France. | 495 | |||
| Letter | en | Intravesical therapy for bladder cancer in the pandemic of Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32356225 | 2020-05-03 02:00:00+02:00 | pubmed | Jeremy Y C Teoh;Morgan Roupret;Shahrokh F Shariat;Thomas Herrmann | 2020-04-30 02:00:00+02:00 | 32356225 | FR;RU;CN;CH;US;HK;CZ;DE;AT | Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.;Sorbonne University, GRC n°5, Predicitive onco-uro, AP-HP, Hôpital Pitié-Salpêtrière, 75013, Paris, France.;Department of Urology, Medical University of Vienna, Vienna, Austria.;Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.;Department of Urology, Weill Cornell Medical College, New York, NY, USA.;Department of Urology, University of Texas Southwestern, Dallas, TX, USA.;Department of Urology, Charles University, Prague, Czech Republic.;Department of Urology, Spital Thurgau AG, Frauenfeld, Switzerland. thomas.herrmann@stgag.ch.;Department of Urology, Hanover Medical School (MHH), Hannover, Germany. thomas.herrmann@stgag.ch. | 496 | ||||||||
| 10.3390/jcm9051407 | Journal Article;Review | en | Impact of COVID-19 on the Cardiovascular System: A Review. | https://www.ncbi.nlm.nih.gov/pubmed/32397558 | The recent outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has been declared a public health emergency of international concern. COVID-19 may present as acute respiratory distress syndrome in severe cases, and patients with pre-existing cardiovascular comorbidities are reported to be the most vulnerable. Notably, acute myocardial injury, determined by elevated high-sensitivity troponin levels, is commonly observed in severe cases, and is strongly associated with mortality. Therefore, understanding the effects of COVID-19 on the cardiovascular system is essential for providing comprehensive medical care for critically ill patients. In this review, we summarize the rapidly evolving data and highlight the cardiovascular considerations related to COVID-19. | 2077-0383 | 2020-05-10 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Kensuke Matsushita;Benjamin Marchandot;Laurence Jesel;Patrick Ohlmann;Olivier Morel | COVID-19;cardiovascular disease;myocardial injury | 2020-05-09 02:00:00+02:00 | 32397558 | FR | Université de Strasbourg, Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, 67091 Strasbourg, France.;UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Université de Strasbourg, F-67401 Illkirch, France. | 509 | |||
| Letter | en | Balancing the Covid-19-motivated vascular access guidelines and patient-centred care of pre-dialysis candidates. | https://www.ncbi.nlm.nih.gov/pubmed/32390495 | The recommendations recently proposed by the European and American Vascular Societies in this new 'Covid-19' era regarding the triage of various vascular operations into urgent, emergent and programmed based on the nature of their pathology aim at reserving health care expenses and hospital staff towards managing the current unexpected worldwide pandemic to the highest possible degree. The suggestion for implementation of these changes into real-world practice, however, does not come without a cost. In particular, the recommendation for deferral of access creation in pre-dialysis patients, ethical, socio-economic and medico-legal issues arise which should be seriously taken into consideration. At the end of the day, vascular access creation is the lifeline of haemodialysis patients and the indication for surgery warrants patient-specific clinical judgement rather than 'group labelling'. | 2020-05-10 02:00:00+02:00 | pubmed | Arteriovenous Shunt, Surgical__adverse effects;Betacoronavirus__pathogenicity;Catheterization, Central Venous__adverse effects;Clinical Decision-Making;Coronavirus Infections__diagnosis;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Infectious Disease Transmission, Professional-to-Patient__prevention & control;Kidney Diseases__diagnosis;Occupational Exposure__adverse effects;Occupational Health;Pandemics__prevention & control;Patient Safety;Patient Selection;Pneumonia, Viral__diagnosis;Renal Dialysis__adverse effects;Risk Assessment;Risk Factors;Time-to-Treatment;Virulence;COVID-19;severe acute respiratory syndrome coronavirus 2 | George S Georgiadis;Christos Argyriou;Selcuk Baktiroglu;Miltos K Lazarides;Alexandros Mallios;Jan Hm Tordoir | Covid-19 vascular guidelines;arteriovenous fistula;catheters;dialysis;dialysis access;economics and health services;ethics and end-of-life issues;pre-dialysis patients | 2020-05-10 02:00:00+02:00 | 32390495 | FR;GR;TR;NL | Department of Vascular Surgery, 'Democritus' University of Thrace, University General Hospital of Evros, Alexandroupolis, Greece.;General Surgery Clinic, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.;Service de Chir Vasc, Institut Mutualiste Montsouris, Paris, France.;Department of Vascular Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. | 510 | |||||
| Journal Article | fr | [Diabetes and COVID-19 infection]. | https://www.ncbi.nlm.nih.gov/pubmed/32374541 | Based on the epidemiological data currently available, diabetes does not seem to be a risk factor for infection with SARS-CoV-2 but may be associated with a more severe course. Diabetes is extremely common in older patients with co-morbidities who are at risk of unfavorable outcomes. As with any other infection, poorly controlled pre-existing diabetes can promote secondary infections and lead to acute complications related to hyperglycemia, worsened itself by the infection. It is important to advise patients to have enough diabetic equipment and supplies at home, to make regular blood glucose self-tests, and to contact a caregiver immediately in case of glycemic imbalance or signs of infection. Antidiabetic therapy may need adjustments following usual sick day rules. Insulin therapy should be considered to treat any persistent hyperglycemia in patients hospitalized for an acute infection. | 2020-05-10 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Blood Glucose;Coronavirus Infections__complications;Diabetes Complications;Diabetes Mellitus__drug therapy;Humans;Hypoglycemic Agents__therapeutic use;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Christophe Kosinski;Anne Zanchi;Anne Wojtusciszyn | 2020-05-07 02:00:00+02:00 | 32374541 | FR;CH | Service d'Endocrinologie, Diabétologie et Métabolisme, CHUV, 1011 Lausanne.;Laboratoire de Thérapie Cellulaire du Diabète, IRMB, CHU Montpellier, 34295 Montpellier, France. | 512 | ||||||
| 10.2174/1871526520999200505174704 | Editorial | en | SARS-CoV-2 & Covid-19: Key-Roles of the 'Renin-Angiotensin' System / Vitamin D Impacting Drug and Vaccine Developments. | https://www.ncbi.nlm.nih.gov/pubmed/32370727 | 1871-5265 | 2020-05-10 02:00:00+02:00 | pubmed | Age Factors;Betacoronavirus__pathogenicity;Coronavirus Infections__drug therapy;Drug Development;Humans;Pandemics;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__drug therapy;Renin-Angiotensin System;Sex Factors;Vitamin D__metabolism;COVID-19;severe acute respiratory syndrome coronavirus 2 | Infectious Disorders - Drug Targets | Zhijian Cao;Yingliang Wu;Emmanuelle Faucon;Jean-Marc Sabatier | 2020-05-07 02:00:00+02:00 | 32370727 | FR;CN | State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, China.;EFFE, 252 Bd Grignan, 83000 Toulon, France.;Universite Aix-Marseille, Institut de Neuro-physiopathologie (INP), UMR 7051, Faculte de Pharmacie, 27 Bd Jean Moulin, 13385 Marseille Cedex, France. | 517 | ||||
| Letter;Comment | en | COVID-19 Digestive Symptoms Mimicking Internal Hernia Presentation After Roux-en-Y-Gastric Bypass; Comment on "Internal Hernia in the Times of COVID-19: to Laparoscope or Not to Laparoscope?" | https://www.ncbi.nlm.nih.gov/pubmed/32385664 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Gastric Bypass;Hernia, Abdominal;Humans;Laparoscopes;Obesity, Morbid__surgery;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Louis Betton;Deborah Benchetrit;Judith Aron-Wisnewsky;Jean-Michel Oppert;Adriana Torcivia;Jean-Christophe Vaillant;Laurent Genser | Bariatric;Bypass;CT;Coronavirus disease 2019 (COVID-19);Internal hernia;Obesity;SARS-CoV-2 | 2020-05-10 02:00:00+02:00 | 32385664 | FR | Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Hepato-Biliary and Pancreatic Surgery, Pitié-Salpêtrière University Hospital, Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Department of anaesthesia and intensive care,Pitié-Salpêtrière University Hospital, Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.;Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Nutrition Department, Pitié-Salpêtrière University Hospital, Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.;NutriOmics team, INSERM UMRS U1269, Sorbonne Universités, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Hepato-Biliary and Pancreatic Surgery, Pitié-Salpêtrière University Hospital, Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France. laurent.genser@aphp.fr.;Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France. laurent.genser@aphp.fr.;NutriOmics team, INSERM UMRS U1269, Sorbonne Universités, Paris, France. laurent.genser@aphp.fr. | 522 | ||||||
| 10.1016/j.autrev.2020.102567 | Journal Article;Review | en | Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. | https://www.ncbi.nlm.nih.gov/pubmed/32376392 | The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December 2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up extraordinary challenges. This unprecedented situation led to the inception of numerous fundamental research protocols and many clinical trials. It quickly became apparent that although COVID-19, in the vast majority of cases, was a benign disease, it could also develop a severe form with sometimes fatal outcomes. Cytokines are central to the pathophysiology of COVID-19; while some of them are beneficial (type-I interferon, interleukin-7), others appear detrimental (interleukin-1β, -6, and TNF-α) particularly in the context of the so-called cytokine storm. Yet another characteristic of the disease has emerged: concomitant immunodeficiency, notably involving impaired type-I interferon response, and lymphopenia. This review provides an overview of current knowledge on COVID-19 immunopathology. We discuss the defective type-I IFN response, the theoretical role of IL-7 to restore lymphocyte repertoire, as well as we mention the two patterns observed in severe COVID-19 (i.e. interleukin-1β-driven macrophage activation syndrome vs. interleukin-6-driven immune dysregulation). Next, reviewing current evidence drawn from clinical trials, we examine a number of cytokine and anti-cytokine therapies, including interleukin-1, -6, and TNF inhibitors, as well as less targeted therapies, such as corticosteroids, chloroquine, or JAK inhibitors. | 1568-9972 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__drug therapy;Cytokines__antagonists & inhibitors;Humans;Interferons__therapeutic use;Interleukin-1beta;Interleukin-6;Pandemics;Pneumonia, Viral__immunology;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Autoimmunity Reviews | Yvan Jamilloux;Thomas Henry;Alexandre Belot;Sébastien Viel;Maxime Fauter;Thomas El Jammal;Thierry Walzer;Bruno François;Pascal Sève | Anakinra;COVID-19;Cytokine storm;IL-1;IL-6;Sars-CoV2;Tocilizumab;Type-I interferon | 2020-05-04 02:00:00+02:00 | 32376392 | FR | Department of Internal Medicine, Lyon University Hospital, Lyon, France, Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard-Lyon 1, Lyon, France. Electronic address: yvan.jamilloux@chu-lyon.fr.;Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard-Lyon 1, Lyon, France.;Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard-Lyon 1, Lyon, France, Department of Pediatric rheumatology, nephrology, and dermatology, Lyon University Hospital, Lyon, France, National Referee Centre for Rheumatic and AutoImmune and Systemic diseases in childrEn (RAISE), Lyon, France.;Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard-Lyon 1, Lyon, France, Service d'Immunologie Biologique, Centre, Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France, National Referee Centre for Rheumatic and AutoImmune and Systemic diseases in childrEn (RAISE), Lyon, France.;Department of Internal Medicine, Lyon University Hospital, Lyon, France, Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard-Lyon 1, Lyon, France.;Department of Internal Medicine, Lyon University Hospital, Lyon, France.;Intensive care unit & Inserm CIC 1435 & Inserm UMR 1092, Dupuytren University Hospital, Limoges, France. | 527 | ||
| NIGMS NIH HHS | 10.1038/s41597-020-0477-8 | Journal Article | en | COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms. | https://www.ncbi.nlm.nih.gov/pubmed/32371892 | 2052-4463 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Computational Biology;Coronavirus Infections__immunology;Databases, Factual;Host Microbial Interactions;Host-Pathogen Interactions;Humans;International Cooperation;Models, Biological;Pandemics;Pneumonia, Viral__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Scientific Data | Marek Ostaszewski;Alexander Mazein;Marc E Gillespie;Inna Kuperstein;Anna Niarakis;Henning Hermjakob;Alexander R Pico;Egon L Willighagen;Chris T Evelo;Jan Hasenauer;Falk Schreiber;Andreas Dräger;Emek Demir;Olaf Wolkenhauer;Laura I Furlong;Emmanuel Barillot;Joaquin Dopazo;Aurelio Orta-Resendiz;Francesco Messina;Alfonso Valencia;Akira Funahashi;Hiroaki Kitano;Charles Auffray;Rudi Balling;Reinhard Schneider | 2020-05-05 02:00:00+02:00 | 32371892 | FR;CA;JP;GB;US;IT;AU;NL;ZA;ES;LU;DE | [{"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "P41 GM103504"}] | Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.;European Institute for Systems Biology and Medicine (EISBM), Vourles, France.;Ontario Institute for Cancer Research, Toronto, Canada.;College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.;Institut Curie, PSL Research University, Mines Paris Tech, Inserm, Paris, France.;Department of Biology, Univ. Évry, University of Paris-Saclay, Genopole, 91025, Évry, France.;European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, UK.;Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, United States.;Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands.;Maastricht Centre for Systems Biology, Maastricht University, Maastricht, The Netherlands.;Helmholtz Zentrum München, Institute of Computational Biology, Neuherberg, Germany.;Center for Mathematics, Technische Universität München, Garching, Germany.;Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany.;University of Konstanz, Department of Computer and Information Science, Konstanz, Germany.;Monash University, Faculty of Information Technology, Melbourne, Australia.;Computational Systems Biology of Infection and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tübingen, 72076, Tübingen, Germany.;Department of Computer Science, University of Tübingen, 72076, Tübingen, Germany.;German Center for Infection Research (DZIF), partner site, Tübingen, Germany.;Department of Molecular and Medical Genetics, School of Medicine, Oregon Health & Science University, Portland, USA.;Department of Systems Biology & Bioinformatics, University of Rostock, Rostock, Germany.;Stellenbosch Institute of Advanced Study (STIAS), Wallenberg Research Centre at Stellenbosch University, 7602, Stellenbosch, South Africa.;Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain.;Clinical Bioinformatics Area, Fundación Progreso y Salud. Hosp. Virgen del Rocío, Sevilla, Spain.;Bioinformatics in Rare Diseases. Centro de Investigación Biomédica en Red de Enfermedades Raras, Fundación Progreso y Salud, Hosp. Virgen del Rocío, Sevilla, Spain.;INB-ELIXIR-es, FPS, Hospital Virgen del Rocío, Sevilla, 42013, Spain.;Institute of Biomedicine of Seville (IBIS), Hospital Virgen del Rocio, 41013, Sevilla, Spain.;HIV, Inflammation and Persistence Unit, Virology Department, Institut Pasteur, Paris, France.;Bio Sorbonne Paris Cité, Université de Paris, Paris, France.;Dipartimento di Epidemiologia Ricerca Pre-Clinica e Diagnostica Avanzata, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy.;COVID 19 INMI Network Medicine for IDs Study Group, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy.;Barcelona Supercomputing Center (BSC), Barcelona, Spain.;Institucio Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain.;Department of Biosciences and Informatics, Keio University, Yokohama, Kanagawa, Japan.;The Systems Biology Institute, Shinagawa, Tokyo, Japan.;Okinawa Institute of Science and Technology Graduate University, Kunigami, Okinawa, Japan.;Sony Computer Science Laboratories, Inc., Tokyo, Japan.;Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg. reinhard.schneider@uni.lu. | 535 | ||
| 10.1038/s41577-020-0331-4 | Journal Article;Review | en | Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. | https://www.ncbi.nlm.nih.gov/pubmed/32376901 | The COVID-19 pandemic caused by infection with SARS-CoV-2 has led to more than 200,000 deaths worldwide. Several studies have now established that the hyperinflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. Macrophages are a population of innate immune cells that sense and respond to microbial threats by producing inflammatory molecules that eliminate pathogens and promote tissue repair. However, a dysregulated macrophage response can be damaging to the host, as is seen in the macrophage activation syndrome induced by severe infections, including in infections with the related virus SARS-CoV. Here we describe the potentially pathological roles of macrophages during SARS-CoV-2 infection and discuss ongoing and prospective therapeutic strategies to modulate macrophage activation in patients with COVID-19. | 1474-1733,1474-1741 | 2020-05-10 02:00:00+02:00 | pubmed | Animals;Betacoronavirus__immunology;Coronavirus Infections__complications;Humans;Inflammation__etiology;Macrophage Activation__drug effects;Macrophages__immunology;Monocytes__immunology;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nature Reviews Immunology | Miriam Merad;Jerome C Martin | 2020-05-06 02:00:00+02:00 | 32376901 | FR;US | Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.;Université de Nantes, Inserm, CHU Nantes, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, Nantes, France. jerome.martin@univ-nantes.fr.;CHU Nantes, Laboratoire d'Immunologie, Center for Immuno Monitoring Nantes-Atlantique (CIMNA), Nantes, France. jerome.martin@univ-nantes.fr. | 546 | |||
| Letter | en | Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. | https://www.ncbi.nlm.nih.gov/pubmed/32376597 | 2020-05-10 02:00:00+02:00 | pubmed | Achille Aouba;Aurelie Baldolli;Loïk Geffray;Renaud Verdon;Emmanuel Bergot;Nicolas Martin-Silva;Aurélien Justet | antirheumatic agents;biological therapy;cytokines;interleukin 1 receptor antagonist protein;therapeutics | 2020-05-06 02:00:00+02:00 | 32376597 | FR | Department of Internal Medicine and Clinical Immunology, CHU Caen, Caen, France achille.aouba@gmail.com.;Department of Infectious Diseases, CHU Caen, Caen, France.;Department of Internal Medicine and Clinical Immunology, CH Lisieux, Lisieux, France.;Department of Pulmonology, CHU Caen, Caen, France.;Department of Internal Medicine and Clinical Immunology, CHU Caen, Caen, France. | 548 | |||||||
| 10.1016/j.surg.2020.04.035 | Case Reports;Journal Article | en | Small bowel ischemia and SARS-CoV-2 infection: an underdiagnosed distinct clinical entity. | https://www.ncbi.nlm.nih.gov/pubmed/32473831 | 0039-6060 | 2020-05-10 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus;Coronavirus Infections__complications;Female;Humans;Intestinal Diseases__diagnostic imaging;Ischemia__diagnostic imaging;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Surgery | Mihaela Ignat;Guillaume Philouze;Lucie Aussenac-Belle;Vanina Faucher;Olivier Collange;Didier Mutter;Patrick Pessaux | 2020-05-04 02:00:00+02:00 | 32473831 | FR | Department of Digestive and Endocrine Surgery, University Hospital of Strasbourg, France, IRCAD/IHU: Institute of Image-guided Surgery, Strasbourg, France. Electronic address: danamihaela.ignat@chru-strasbourg.fr.;Department of Digestive and Endocrine Surgery, University Hospital of Strasbourg, France, IRCAD/IHU: Institute of Image-guided Surgery, Strasbourg, France.;Department of Pathology, University Hospital of Strasbourg, France.;Radiology Department, Nouvel Hôpital Civil, University Hospital of Strasbourg, France.;Anesthesia Department and Critical Care, Nouvel Hôpital Civil, University Hospital of Strasbourg, France. | 552 | ||||
| Letter | en | Urgent development of an anaesthesiology-based intensive care unit for critical COVID-19 infected patients. | https://www.ncbi.nlm.nih.gov/pubmed/32389563 | 2020-05-10 02:00:00+02:00 | pubmed | Anesthesiologists__statistics & numerical data;Anesthesiology__organization & administration;Bed Conversion;Bed Occupancy;Betacoronavirus;Coronavirus Infections__epidemiology;Critical Care__methods;France__epidemiology;Hospital Bed Capacity__statistics & numerical data;Hospitals, University__organization & administration;Humans;Intensive Care Units__organization & administration;Medical Staff, Hospital__statistics & numerical data;Nurse Anesthetists__statistics & numerical data;Nursing Staff, Hospital__statistics & numerical data;Pandemics;Patient Care Team;Patient Transfer;Pneumonia, Viral__epidemiology;Respiratory Therapy__methods;Resuscitation__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | Hakim Harkouk;Chantal Jacob;Dominique Fletcher | 2020-05-04 02:00:00+02:00 | 32389563 | FR | Service d'anesthésie, Hôpital Ambroise-Paré, Assistance Publique-Hôpitaux de Paris, 92100 Boulogne-Billancourt, France, Université Versailles Saint-Quentin, 78035, Ile-de-France, France, Université Paris-Saclay, 91190, Saint-Aubin, France, Centre d'évaluation et de traitement de la douleur, INSERM, U-987, Hôpital Ambroise-Paré, 92100 Boulogne-Billancourt, France. Electronic address: hakimharkouk@gmail.com.;Service d'anesthésie, Hôpital Ambroise-Paré, Assistance Publique-Hôpitaux de Paris, 92100 Boulogne-Billancourt, France.;Service d'anesthésie, Hôpital Ambroise-Paré, Assistance Publique-Hôpitaux de Paris, 92100 Boulogne-Billancourt, France, Université Versailles Saint-Quentin, 78035, Ile-de-France, France, Université Paris-Saclay, 91190, Saint-Aubin, France, Centre d'évaluation et de traitement de la douleur, INSERM, U-987, Hôpital Ambroise-Paré, 92100 Boulogne-Billancourt, France. | 568 | |||||||
| 10.1177/1179173x20924028 | Journal Article | en | Epidemiological Data From the COVID-19 Outbreak in Spain for the Promotion of Tobacco Smoking Cessation Policies. | https://www.ncbi.nlm.nih.gov/pubmed/32435132 | 1179-173X,1179-173X | 2020-05-10 02:00:00+02:00 | pubmed | Tobacco Use Insights | Javier Correa Vázquez;Diego Redolar-Ripoll | COVID-19;cessation policies;sex differences;smoking;tobacco | 2020-05-08 02:00:00+02:00 | 32435132 | FR;ES | Laboratoire NutriNeuro, Bordeaux Neurocampus, INRA 1286 University of Bordeaux, Bordeaux, France.;Cognitive NeuroLab, Faculty of Health Sciences, Universitat Oberta de Catalunya, Barcelona, Spain. | 594 | ||||
| 10.1016/j.jmii.2020.04.015 | Journal Article;Review | en | ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. | https://www.ncbi.nlm.nih.gov/pubmed/32414646 | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged in Chinese people in December 2019 and has currently spread worldwide causing the COVID-19 pandemic with more than 150,000 deaths. In order for a SARS-CoV like virus circulating in wild life for a very long time to infect the index case-patient, a number of conditions must be met, foremost among which is the encounter with humans and the presence in homo sapiens of a cellular receptor allowing the virus to bind. Recently it was shown that the SARS-CoV-2 spike protein, binds to the human angiotensin I converting enzyme 2 (ACE2). This molecule is a peptidase expressed at the surface of lung epithelial cells and other tissues, that regulates the renin-angiotensin-aldosterone system. Humans are not equal with respect to the expression levels of the cellular ACE2. Moreover, ACE2 polymorphisms were recently described in human populations. Here we review the most recent evidence that ACE2 expression and/or polymorphism could influence both the susceptibility of people to SARS-CoV-2 infection and the outcome of the COVID-19 disease. Further exploration of the relationship between the virus, the peptidase function of ACE2 and the levels of angiotensin II in SARS-CoV-2 infected patients should help to better understand the pathophysiology of the disease and the multi-organ failures observed in severe COVID-19 cases, particularly heart failure. | 1684-1182 | 2020-05-10 02:00:00+02:00 | pubmed | Amino Acid Sequence__genetics;Betacoronavirus__metabolism;Coronavirus Infections__pathology;Female;Genetic Predisposition to Disease__genetics;Heart Failure__virology;Humans;Male;Multiple Organ Failure__virology;Pandemics;Peptidyl-Dipeptidase A__genetics;Pneumonia, Viral__pathology;Polymorphism, Single Nucleotide__genetics;Spike Glycoprotein, Coronavirus__metabolism;Virus Attachment;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Microbiology, Immunology and Infection | Christian A Devaux;Jean-Marc Rolain;Didier Raoult | ACE2;COVID-19;Cardiac failure;Hypertension;SARS-CoV-2 | 2020-05-06 02:00:00+02:00 | 32414646 | FR | Aix-Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France, CNRS, Marseille, France, IHU-Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille, France. Electronic address: christian.devaux@mediterranee-infection.com.;Aix-Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France, IHU-Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille, France. | 600 | ||
| 10.12688/wellcomeopenres.15881.1 | Journal Article | en | Dynamic causal modelling of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32832701 | This technical report describes a dynamic causal model of the spread of coronavirus through a population. The model is based upon ensemble or population dynamics that generate outcomes, like new cases and deaths over time. The purpose of this model is to quantify the uncertainty that attends predictions of relevant outcomes. By assuming suitable conditional dependencies, one can model the effects of interventions (e.g., social distancing) and differences among populations (e.g., herd immunity) to predict what might happen in different circumstances. Technically, this model leverages state-of-the-art variational (Bayesian) model inversion and comparison procedures, originally developed to characterise the responses of neuronal ensembles to perturbations. Here, this modelling is applied to epidemiological populations-to illustrate the kind of inferences that are supported and how the model per se can be optimised given timeseries data. Although the purpose of this paper is to describe a modelling protocol, the results illustrate some interesting perspectives on the current pandemic; for example, the nonlinear effects of herd immunity that speak to a self-organised mitigation process. | 2398-502X | 2020-05-10 02:00:00+02:00 | pubmed | Wellcome Open Research | Karl J Friston;Thomas Parr;Peter Zeidman;Adeel Razi;Guillaume Flandin;Jean Daunizeau;Ollie J Hulme;Alexander J Billig;Vladimir Litvak;Rosalyn J Moran;Cathy J Price;Christian Lambert | Bayesian;compartmental models;coronavirus;dynamic causal modelling;epidemiology;variational | 2020-05-07 02:00:00+02:00 | 32832701 | FR;AU;GB;DK | Wellcome Centre for Human Neuroimaging, University College London, London, WC1N 3BG, UK.;Turner Institute for Brain and Mental Health & Monash Biomedical Imaging, Monash University, Clayton, VIC, 3800, Australia.;Institut du Cerveau et de la Moelle épinière, INSERM UMRS, Paris, 1127, France.;Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.;London Mathematical Laboratory, Hammersmith, London, UK.;Ear Institute, University College London, London, UK.;Centre for Neuroimaging Science, Department of Neuroimaging, IoPPN, King's College London, London, UK. | 606 | |||
| 10.1016/j.ijid.2020.05.001 | Comparative Study;Journal Article | en | Comparison of mortality associated with respiratory viral infections between December 2019 and March 2020 with that of the previous year in Southeastern France. | https://www.ncbi.nlm.nih.gov/pubmed/32389848 | Respiratory viruses are a major cause of mortality worldwide and in France, where they cause several thousands of deaths every year. University Hospital Institute-Méditerranée Infection performs real-time surveillance of all diagnoses of infections and associated deaths in public hospitals in Marseille, Southeastern France. This study compared mortality associated with diagnoses of respiratory viruses during the colder months of 2018-2019 and 2019-2020 (week 47-week 14). In 2018-2019, 73 patients (0.17% of 42,851 hospitalized patients) died after being diagnosed with a respiratory virus; 40 and 13 deaths occurred in patients diagnosed with influenza A virus and respiratory syncytial virus (RSV), respectively. In 2019-2020, 50 patients (0.10% of 49,043 patients hospitalized) died after being diagnosed with a common respiratory virus; seven and seven deaths occurred in patients diagnosed with influenza A virus and RSV, respectively. Additionally, 55 patients died after being diagnosed with SARS-CoV-2. The proportion of respiratory virus-associated deaths among hospitalized patients was thus significantly lower for common respiratory viruses in 2019-2020 than in 2018-2019 (102 versus 170 per 100,000 hospitalized patients; p = 0.003), primarily as a consequence of a decrease in influenza A virus (-83%) and RSV (-46%)-associated deaths. Overall, the proportion of respiratory virus-associated deaths among hospitalized patients was higher, but not significantly, in 2019-2020 than in 2018-2019 (214 versus 170 per 100,000 hospitalized patients; p = 0.08, Yates-corrected Chi-square test). These findings put into perspective the death burden of SARS-CoV-2 infections in this geographical area. | 1201-9712 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Child, Preschool;Coronavirus Infections__mortality;Female;France__epidemiology;Humans;Infant;Influenza A virus;Influenza, Human__epidemiology;Male;Middle Aged;Pandemics;Pneumonia, Viral__mortality;Respiratory Syncytial Virus Infections__epidemiology;Time Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Infectious Diseases | Audrey Giraud-Gatineau;Philippe Colson;Marie-Thérèse Jimeno;Christine Zandotti;Laetitia Ninove;Céline Boschi;Jean-Christophe Lagier;Bernard La Scola;Hervé Chaudet;Didier Raoult | France;Influenza virus;Mortality;Respiratory viruses;SARS-CoV-2 | 2020-05-07 02:00:00+02:00 | 32389848 | FR | IHU Méditerranée Infection, Marseille, France, Aix Marseille Univ, Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Service de Santé des Armées (SSA), Vecteurs - Infections Tropicales et Méditerranéennes (VITROME), Marseille, France, French Armed Forces Center for Epidemiology and Public Health (CESPA), Service de Santé des Armées (SSA), Marseille, France.;IHU Méditerranée Infection, Marseille, France, Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes Evolution Phylogeny and Infections (MEPHI), Marseille, France.;Service de l'Information Médicale, Hôpital de la Timone, Marseille, France.;IHU Méditerranée Infection, Marseille, France, Unité des Virus Emergents (UVE), Aix-Marseille University, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.;IHU Méditerranée Infection, Marseille, France, Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes Evolution Phylogeny and Infections (MEPHI), Marseille, France. Electronic address: didier.raoult@gmail.com. | 607 | ||
| 10.1016/s2213-8587(20)30157-1 | Comparative Study;Journal Article;Review | en | Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. | https://www.ncbi.nlm.nih.gov/pubmed/32386567 | The coronavirus disease 2019 pandemic is wreaking havoc on society, especially health-care systems, including disrupting bariatric and metabolic surgery. The current limitations on accessibility to non-urgent care undermine postoperative monitoring of patients who have undergone such operations. Furthermore, like most elective surgery, new bariatric and metabolic procedures are being postponed worldwide during the pandemic. When the outbreak abates, a backlog of people seeking these operations will exist. Hence, surgical candidates face prolonged delays of beneficial treatment. Because of the progressive nature of obesity and diabetes, delaying surgery increases risks for morbidity and mortality, thus requiring strategies to mitigate harm. The risk of harm, however, varies among patients, depending on the type and severity of their comorbidities. A triaging strategy is therefore needed. The traditional weight-centric patient-selection criteria do not favour cases based on actual clinical needs. In this Personal View, experts from the Diabetes Surgery Summit consensus conference series provide guidance for the management of patients while surgery is delayed and for postoperative surveillance. We also offer a strategy to prioritise bariatric and metabolic surgery candidates on the basis of the diseases that are most likely to be ameliorated postoperatively. Although our system will be particularly germane in the immediate future, it also provides a framework for long-term clinically meaningful prioritisation. | 2213-8587 | 2020-05-10 02:00:00+02:00 | pubmed | Bariatric Surgery__methods;Betacoronavirus;Coronavirus Infections__epidemiology;Disease Management;Humans;Obesity__epidemiology;Pandemics;Pneumonia, Viral__epidemiology;Postoperative Care__methods;Postoperative Complications__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Diabetes & Endocrinology | Francesco Rubino;Ricardo V Cohen;Geltrude Mingrone;Carel W le Roux;Jeffrey I Mechanick;David E Arterburn;Josep Vidal;George Alberti;Stephanie A Amiel;Rachel L Batterham;Stefan Bornstein;Ghassan Chamseddine;Stefano Del Prato;John B Dixon;Robert H Eckel;David Hopkins;Barbara M McGowan;An Pan;Ameet Patel;François Pattou;Philip R Schauer;Paul Z Zimmet;David E Cummings | 2020-05-07 02:00:00+02:00 | 32386567 | IE;FR;CN;GB;US;BR;IT;AU;ES;DE | Department of Diabetes, School of Life Course Sciences, King's College London, London, UK, Bariatric and Metabolic Surgery, King's College Hospital, London, UK. Electronic address: francesco.rubino@kcl.ac.uk.;Center for the treatment of Obesity and Diabetes, Oswaldo Cruz German Hospital, Sao Paulo, Brazil.;Department of Diabetes, School of Life Course Sciences, King's College London, London, UK, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, Università Cattolica del Sacro Cuore, Rome, Italy.;Diabetes Complications Research Centre, Conway Institute, University College of Dublin, Dublin, Ireland.;The Marie-Josee and Henry R Kravis Center for Clinical Cardiovascular Health at Mount Sinai Heart, New York, NY, USA, Divisions of Cardiology and Endocrinology, Diabetes, and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA, Department of Medicine, Division of General Internal Medicine, University of Washington, Seattle, WA, USA.;Endocrinology and Nutrition Department, Hospital Clinic Universitari, Barcelona, Spain, Institut d'Investigacions Biomèdiques August Pi Sunyer, Barcelona, Spain, Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain.;Department of Endocrinology and Metabolism, Imperial College, London, UK.;Department of Diabetes, School of Life Course Sciences, King's College London, London, UK.;Centre for Obesity Research, University College London, London, UK, University College London Hospitals Bariatric Centre for Weight Management and Metabolic Surgery, London, UK, National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK.;Paul Langerhans Institute Dresden, Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Faculty of Medicine, Technical University Dresden, Dresden, Germany.;Bariatric and Metabolic Surgery, King's College Hospital, London, UK.;Department of Clinical and Experimental Medicine, Section of Metabolic Diseases and Diabetes, University of Pisa, Pisa, Italy.;Iverson Health Innovation Research Institute, Swinburne University, Melbourne, VIC, Australia.;Division of Endocrinology, Metabolism and Diabetes and Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.;King's Health Partners' Institute of Diabetes, Endocrinology and Obesity, London, UK.;Institute of Diabetes, Endocrinology and Obesity, Guy's and St Thomas' National Health Service Foundation Trust, London, UK.;Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;European Genomic Institute for Diabetes, Lille, France, Translational Research for Diabetes, University of Lille, Inserm, Centre Hospitalier Regional Universitaire, Lille, France.;Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.;Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.;University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA, USA, Weight Management Program, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, WA, USA. | 608 | |||
| 10.12890/2020_001702 | Journal Article | en | Thrombocytopenia in the Course of COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32523922 | We report three cases of severe thrombocytopenia during COVID-19 infection associated with either cutaneous purpura or mucosal bleeding. The initial investigations ruled out other causes of thrombocytopenia. Two of the patients were treated with intravenous immunoglobulins and eltrombopag, while the third recovered spontaneously. A good clinical and biological response was achieved in all patients leading to hospital discharge. | 2020-05-10 02:00:00+02:00 | pubmed | Noel Lorenzo-Villalba;Abrar-Ahmad Zulfiqar;Marc Auburtin;Marie Helene Schuhmacher;Alain Meyer;Yasmine Maouche;Olivier Keller;Emmanuel Andres | COVID-19;eltrombopag;immune thrombocytopenia;immunoglobulins;thrombocytopenia | 2020-05-07 02:00:00+02:00 | 32523922 | FR | Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasboug, Strasbourg France.;Service de Médecine Interne, Centre Hospitalier d'Epinal, Epinal, France.;Service de Rhumatologie, Hôpitaux Universitaires de Strasboug, Strasbourg, France.;Service de Médecine Interne, Centre Hospitalier de Haguenau, Haguenau, France. | 609 | |||||
| 10.1016/j.therap.2020.05.002 | Journal Article | en | "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. | https://www.ncbi.nlm.nih.gov/pubmed/32418730 | COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny as they are known to foster cardiac adverse ADRs, notably QTc interval prolongation on the electrocardiogram and its arrhythmogenic consequences. | 0040-5957 | 2020-05-10 02:00:00+02:00 | pubmed | Therapies | Alexandre Gérard;Serena Romani;Audrey Fresse;Delphine Viard;Nadège Parassol;Aurélie Granvuillemin;Laurent Chouchana;Fanny Rocher;Milou-Daniel Drici | Arrhythmia;Azithromycin;COVID-19;Cardiac adverse effects;Hydroxychloroquine;Lopinavir;QTc prolongation | 2020-05-07 02:00:00+02:00 | 32418730 | FR | Pharmacovigilance, department of pharmacology, Pasteur hospital, Bât J4, 30, avenue de la Voie-Romaine, CS51069, 06001 Nice Cedex 01, France.;Centre régional de pharmacovigilance, 21079 Dijon, France.;Centre régional de pharmacovigilance Paris-Cochin, 75014 Paris, France.;Pharmacovigilance, department of pharmacology, Pasteur hospital, Bât J4, 30, avenue de la Voie-Romaine, CS51069, 06001 Nice Cedex 01, France. Electronic address: pharmacovigilance@chu-nice.fr. | 615 | |||
| 10.1016/j.ijid.2020.05.040 | Editorial | en | Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. | https://www.ncbi.nlm.nih.gov/pubmed/32425638 | As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. Currently, the ClinicalTrials.gov and the WHO Clinical Trials Registry Platform (WHO ICTRP) report a combined 28 trials exploring the potential of MSCs or their products for treatment of COVID-19. MSCs should also be trialed for treatment of other circulating WHO priority Blueprint pathogens such as MERS-CoV which causes upto 34% mortality rates. It's about time funding agencies invested more into development MSCs per se, and also for a range of other HDTs, in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 death rates and preventing long-term functional disability in those who survive disease. | 1201-9712 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Trials as Topic;Consensus;Coronavirus Infections__immunology;Humans;Mesenchymal Stem Cell Transplantation;Morbidity;Pandemics;Pneumonia, Viral__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Infectious Diseases | Alimuddin Zumla;Fu-Sheng Wang;Giuseppe Ippolito;Nicola Petrosillo;Chiara Agrati;Esam I Azhar;Chao Chang;Sherif A El-Kafrawy;Mohamed Osman;Laurence Zitvogel;Peter R Galle;Franco Locatelli;Ellen Gorman;Carlos Cordon-Cardo;Cecilia O'Kane;Danny McAuley;Markus Maeurer | 2020-05-17 02:00:00+02:00 | 32425638 | FR;SA;CN;PT;GB;US;IT;SD;DE | Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac.uk.;Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: fswang302@163.com.;National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.;National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: nicola.petrosillo@inmi.it.;National Institute for Infectious Diseases Lazzaro Spallanzani - IRCCS, Rome, Italy. Electronic address: Chiara.Agrati@inmi.it.;Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: eazhar@kau.edu.sa.;Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Electronic address: zhangch302@163.com.;Special Infectious Agents Unit, King Fahd Medical Research Center and Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: saelkfrawy@kau.edu.sa.;Emerging and Re-Emerging Diseases, University of Khartoum, Sudan and York Biomedical Research Institute, University of York, United Kingdom. Electronic address: mohamed.osman@york.ac.uk.;Gustave Roussy Cancer Center (GRCC), U1015 INSERM, University Paris Saclay Villejuif Cedex, France. Electronic address: laurence.zitvogel@orange.fr.;Medical Clinic, University Medical Center Mainz, Germany. Electronic address: Galle@uni-mainz.de.;Dept of Pediatric Hematology and Oncology, IRCCS Ospedale Bambino Gesu, and Sapienza, University of Rome, Italy. Electronic address: franco.locatelli@opbg.net.;Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom, Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: egorman03@qub.ac.uk.;Dept of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: carlos.cordon-cardo@mssm.edu.;Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom, Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: c.okane@qub.ac.uk.;Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom, Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom. Electronic address: d.f.mcauley@qub.ac.uk.;Medical Clinic, University Medical Center Mainz, Germany, Champalimaud Centre for the Unknown, Lisbon, Portugal. Electronic address: markus.maeurer@fundacaochampalimaud.pt. | 620 | |||
| Letter;Comment | en | MRI Evaluation of the Olfactory Clefts in Patients with SARS-CoV-2 Infection Revealed an Unexpected Mechanism for Olfactory Function Loss. | https://www.ncbi.nlm.nih.gov/pubmed/32425479 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Magnetic Resonance Imaging;Olfaction Disorders;Olfactory Bulb;Pandemics;Pneumonia, Viral;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Michael Eliezer;Charlotte Hautefort | 2020-05-16 02:00:00+02:00 | 32425479 | FR | Department of Neuroradiology, Lariboisière University Hospital, Paris, France. Electronic address: michael.eliezer@aphp.fr.;Department of Head and Neck Surgery, Lariboisière University Hospital, Paris, France. | 621 | |||||||
| Letter;Comment | en | Severe arterial thrombosis associated with Covid-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32425264 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Critical Illness;Humans;Incidence;Intensive Care Units;Pandemics;Pneumonia, Viral;Thrombosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Mahine Kashi;Aurélien Jacquin;Bassel Dakhil;Rym Zaimi;Emmanuel Mahé;Emilie Tella;Patrick Bagan | Arterial thrombosis;COVID-19;Floating aortic thrombus;Lower limb ischemia;SARS-CoV2 infection | 2020-05-16 02:00:00+02:00 | 32425264 | FR | Department of Vascular and Thoracic Surgery, Victor Dupouy Hospital, Argenteuil, France. Electronic address: mahine.kashidakhil@ch-argenteuil.fr.;Department of Vascular Medicine and Dermatology, Victor Dupouy Hospital, Argenteuil, France.;Department of Vascular and Thoracic Surgery, Victor Dupouy Hospital, Argenteuil, France. | 622 | ||||||
| 10.1016/j.waojou.2020.100126 | Journal Article;Review | en | COVID-19, asthma, and biological therapies: What we need to know. | https://www.ncbi.nlm.nih.gov/pubmed/32426090 | Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers. | 1939-4551 | 2020-05-17 02:00:00+02:00 | pubmed | World Allergy Organization Journal | Mário Morais-Almeida;Rita Aguiar;Bryan Martin;Ignacio J Ansotegui;Motohiro Ebisawa;L Karla Arruda;Marco Caminati;Giorgio Walter Canonica;Tara Carr;Geoffrey Chupp;Jonathan Corren;Ignacio Dávila;Hae-Sim Park;Nicola A Hanania;Lanny Rosenwasser;Mario Sánchez-Borges;J Christian Virchow;Anahí Yáñez;Jonathan A Bernstein;Luis Caraballo;Yoon-Seok Chang;Manana Chikhladze;Alessandro Fiocchi;Sandra N González-Diaz;Luciana Kase Tanno;Michael Levin;Jose António Ortega-Martell;Giovanni Passalacqua;David B Peden;Philip W Rouadi;James L Sublett;Gary W K Wong;Eugene R Bleecker | AAAAI, American Academy of Allergy, Asthma and Immunology;ACAAI, American College of Allergy, Asthma and Immunology;ACE2, Angiotensin-converting enzyme 2;ADCC, Antibody-Dependent Cell-mediated Cytotoxicity;AEs, Adverse events;Asthma;BTS, British Thoracic Society;Biologics;COVID-19;COVID-19, Coronavirus Disease 2019;DNA, Deoxyribonucleic acid;EBM, Evidence Based Medicine;ELF, European Lung Foundation;ERS, European Respiratory Society;FDA, Food and Drug Administration;GINA, Global Initiative for Asthma;GSK, Glaxo Smith Kline;ICS, inhaled corticosteroids;ICU, Intensive Care Unit;IL13, Interleukin 13;IL4, Interleukin 4;IL5, Interleukin 5;IL5Ra, Interleukin 5 alfa receptor;IL5r, Interleukin 5 receptor;IL6, Interleukin 6;IgE, Immunoglobulin E;NHLBI, National Heart, Lung, and Blood Institute;OCS, Oral corticosteroids;PDGFRA, Platelet-Derived Growth Factor Receptor A;PROSE study, Preventative Omalizumab or Step-up therapy for fall Exacerbations study;Pandemic;RCTs, Randomized Controlled Trials;SAEs, Serious Adverse Events;SARP, Severe Asthma Research Programme;SARS-CoV-2;SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2;SC, Subcutaneous;SIAAIC, Italian Society of Allergy, Asthma and Clinical Immunology;Severe;T2, Type 2 inflammation;TMPRSS2, Transmembrane Protease Serine 2 Enzyme;Treatment;USA, United States of America;mAb, Monoclonal antibody | 2020-05-16 02:00:00+02:00 | 32426090 | FR;AR;CO;GE;VE;PT;LB;JP;CN;US;HK;BR;IT;ZA;ES;MX;KR;DE | Allergy Centre, CUF Descobertas Hospital, Lisbon, Portugal.;The Ohio State University, Columbus, OH, USA.;Hospital Quironsalud Bizkaia, Bilbao-Erandio, Spain.;National Hospital Organization, Sagamihara National Hospital, Sagamihara, Kanagwa, Japan.;Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.;Department of Internal Medicine, University of Verona, Allergy Unit and Asthma Center, Verona University Hospital, Verona, Italy.;Personalized Medicine Asthma & Allergy Clinic, Humanitas University & Research Hospital IRCCS, Milano, Italy.;Asthma and Airway Disease Research Center, University of Arizona, Tucson, AZ, USA.;Division of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.;David Geffen School of Medicine, University of California at Los Angelas (UCLA), Los Angeles, CA, USA.;University Hospital, Faculty of Medicine, University of Salamanca, Salamanca, Spain.;Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Republic of Korea.;Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.;University of Missouri, Kansas City School of Medicine, USA.;Allergy and Clinical Immunology Department, Centro Médico Docente La Trinidad, Caracas, Venezuela.;Department of Pneumology/Intensive Care Medicine, Universitätsmedizin, Rostock, Germany.;INAER-Investigaciones en Alergia y Enfermedades Respiratorias, Buenos Aires, Argentina.;University of Cincinnati, College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati, OH, USA.;Institute for Immunological Research, University of Cartagena, Cartagena de Indias, Colombia.;Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.;Medical Faculty at Akaki Tsereteli State University, KuTaisi, Tskaltubo, Georgia.;Allergy Department, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.;Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico.;Division of Allergy, Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France.;Division Paediatric Allergology, University of Cape Town, Cape Town, South Africa.;School of Medicine, Autonomous University of Hidalgo State, Pachuca, Hidalgo, Mexico.;Allergy and Respiratory Diseases, IRCCS Policlinico San Martino, University of Genoa, Genoa, Italy.;Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon.;Pediatric Allergy & Immunology, University of Louisville School of Medicine, Louisville, KY, USA.;Department of Paediatrics, Chinese University of Hong Kong, Hong Kong.;Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona Health Sciences, Tucson, AZ, USA. | 624 | |||
| 10.1161/circulationaha.120.048360 | Journal Article | en | Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32418446 | Background: Cardiac injury and myocarditis have been described in adults with COVID-19. SARS-CoV-2 infection in children is typically minimally symptomatic. We report a series of febrile pediatric patients with acute heart failure potentially associated with SARS-CoV-2 infection and the multisystem inflammatory syndrome in children (MIS-C) as defined by the US Centers for Disease Control. Methods: Over a two-month period contemporary with the SARS-CoV-2 pandemic in France and Switzerland, we retrospectively collected clinical, biological, therapeutic, and early outcomes data in children who were admitted to pediatric intensive care units in 14 centers for cardiogenic shock, left ventricular dysfunction and severe inflammatory state. Results: Thirty-five children were identified and included in the study. Median age at admission was 10 years (range 2-16 years). Co-morbidities were present in 28% including asthma and overweight. Gastrointestinal symptoms were prominent. Left ventricular ejection fraction was <30% in one third; 80% required inotropic support with 28% treated with ECMO. Inflammation markers were suggestive of cytokine storm (interleukin 6 median 135 pg/mL) and macrophage activation (D-dimer median 5284 ng/mL). Mean brain natriuretic peptide was elevated (5743 pg/mL). Thirty-one/35 (88%) patients tested positive for SARS-CoV-2 infection by PCR of nasopharyngeal swab or serology. All patients received intravenous immune globulin, with adjunctive steroid therapy used in one third. Left ventricular function was restored in the 25/35 of those discharged from the intensive care unit. No patient died, and all patients treated with ECMO were successfully weaned. Conclusion: Children may experience an acute cardiac decompensation due to severe inflammatory state following SARS-CoV-2 infection (multisystem inflammatory syndrome in children - MIS-C). Treatment with immune globulin appears to be associated with recovery of left ventricular systolic function. | 0009-7322,1524-4539 | 2020-05-17 02:00:00+02:00 | pubmed | Circulation | Zahra Belhadjer;Mathilde Méot;Fanny Bajolle;Diala Khraiche;Antoine Legendre;Samya Abakka;Johanne Auriau;Marion Grimaud;Mehdi Oualha;Maurice Beghetti;Julie Wacker;Caroline Ovaert;Sebastien Hascoet;Maëlle Selegny;Sophie Malekzadeh-Milani;Alice Maltret;Gilles Bosser;Nathan Giroux;Laurent Bonnemains;Jeanne Bordet;Sylvie Di Filippo;Pierre Mauran;Sylvie Falcon-Eicher;Jean-Benoît Thambo;Bruno Lefort;Pamela Moceri;Lucile Houyel;Sylvain Renolleau;Damien Bonnet | COVID-19;SARS-CoV-2;myocardial stunning | 2020-05-17 02:00:00+02:00 | 32418446 | FR;CH | M3C-Necker Enfants Malades, AP-HP, Paris, France, Université de Paris, Paris, France.;M3C-Necker Enfants Malades, AP-HP, Paris, France.;Pediatric Cardiology Unit, University Hospital, Geneva, Switzerland.;Paediatric and Congenital Cardiology Department, M3C Regional CHD Centre, La Timone University Hospital, Marseille, France, INSERM UMR 1251, Marseille Medical Genetics, University of Aix-Marseille, Marseille, France.;M3C Marie-Lannelongue Hospital, Paediatric and Congenital Cardiac Surgery Department, Groupe Hospitalier Saint-Joseph, Paris Sud University, Plessis-Robinson, France.;Pediatric-Cardiology, Amiens-Picardie university hospital, Amiens, France.;CHRU de Nancy, Service de cardiologie congénitale et pédiatrique, Vandoeuvre-lès-Nancy, France.;Department of Cardiac Surgery, University of Strasbourg, Strasbourg, France.;Pediatric Cardiology and Congenital Heart Disease Department, Cardiovascular Louis-Pradel Hospital, Hospices Civils de Lyon, Lyon, France.;Department of paediatric and congenital cardiology, Centre de compétence M3C, American memorial hospital, CHU de Reims, Reims, France.;Dijon-Bourgogne, Dijon, France.;Bordeaux, Department of Pediatric Cardiology, Bordeaux-II University, Bordeaux, France.;Unité de Cardiologie Pédiatrique, Hôpital des Enfants Gatien de Clocheville, INSERM UMR 1069 et Université François Rabelais, Tours, France.;Department of Cardiology, Hôpital Pasteur, CHU de Nice, Nice, France. | 626 | |||
| 10.1016/j.accpm.2020.05.008 | Journal Article | en | Prioritisation of ICU treatments for critically ill patients in a COVID-19 pandemic with scarce resources. | https://www.ncbi.nlm.nih.gov/pubmed/32426441 | Relying on capacity increases and patient transfers to deal with the huge and continuous inflow of COVID-19 critically ill patients is a strategy limited by finite human and logistical resources. | 2352-5568 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Canada;Caregivers;Continuity of Patient Care__organization & administration;Coronavirus Infections__epidemiology;Critical Care__ethics;Critical Illness;France__epidemiology;Health Personnel;Health Priorities__ethics;Health Resources__supply & distribution;Health Services Accessibility__ethics;Humans;Intensive Care Units__organization & administration;Pandemics;Patient Transfer;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Refusal to Treat__ethics;Resource Allocation__ethics;Social Justice;Switzerland;Triage__ethics;COVID-19;severe acute respiratory syndrome coronavirus 2 | Anaesthesia Critical Care & Pain Medicine | Thomas Leclerc;Nicolas Donat;Alexis Donat;Pierre Pasquier;Nicolas Libert;Elodie Schaeffer;Erwan D'Aranda;Jean Cotte;Bruno Fontaine;Pierre-François Perrigault;Fabrice Michel;Laurent Muller;Eric Meaudre;Benoît Veber | COVID-19;Critical care;Ethics;Pandemic;Prioritisation;Triage | 2020-05-17 02:00:00+02:00 | 32426441 | FR | Percy military teaching hospital, Clamart, France, Val-de-Grâce military medical academy, Paris, France. Electronic address: thomas.leclerc@m4x.org.;Percy military teaching hospital, Clamart, France.;Legouest military teaching hospital & Mercy regional hospital, Metz, France.;Percy military teaching hospital, Clamart, France, Val-de-Grâce military medical academy, Paris, France.;R. Picqué military teaching hospital, Bordeaux, France.;Sainte Anne military teaching hospital, Toulon, France.;R. Picqué military teaching hospital, Bordeaux, France, Val-de-Grâce military medical academy, Paris, France.;Gui de Chauliac hospital & Montpellier University, Montpellier, France, Ethics committee, French society of anaesthesia and critical care (SFAR), Paris, France.;APHM, Aix Marseille Univ, UMR ADES n°7268, EFS, CNRS, Marseille, France, Ethics committee, French society of anaesthesia and critical care (SFAR), Paris, France.;CHU Nîmes Caremeau, Nîmes, France, Ethics committee, French society of anaesthesia and critical care (SFAR), Paris, France.;Sainte Anne military teaching hospital, Toulon, France, Val-de-Grâce military medical academy, Paris, France.;Charles Nicolle hospital & Rouen Normandie University, Rouen, France, Ethics committee, French society of anaesthesia and critical care (SFAR), Paris, France. | 627 | ||
| 10.1093/eurheartj/ehaa381 | Journal Article;Practice Guideline | en | EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32405641 | The coronavirus disease 2019 (COVID-19) pandemic poses an unprecedented challenge to healthcare worldwide. The infection can be life threatening and require intensive care treatment. The transmission of the disease poses a risk to both patients and healthcare workers. The number of patients requiring hospital admission and intensive care may overwhelm health systems and negatively affect standard care for patients presenting with conditions needing emergency interventions. This position statements aims to assist cardiologists in the invasive management of acute coronary syndrome (ACS) patients in the context of the COVID-19 pandemic. To that end, we assembled a panel of interventional cardiologists and acute cardiac care specialists appointed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and from the Acute Cardiovascular Care Association (ACVC) and included the experience from the first and worst affected areas in Europe. Modified diagnostic and treatment algorithms are proposed to adapt evidence-based protocols for this unprecedented challenge. Various clinical scenarios, as well as management algorithms for patients with a diagnosed or suspected COVID-19 infection, presenting with ST- and non-ST-segment elevation ACS are described. In addition, we address the need for re-organization of ACS networks, with redistribution of hub and spoke hospitals, as well as for in-hospital reorganization of emergency rooms and cardiac units, with examples coming from multiple European countries. Furthermore, we provide a guidance to reorganization of catheterization laboratories and, importantly, measures for protection of healthcare providers involved with invasive procedures. | 0195-668X,1522-9645 | 2020-05-17 02:00:00+02:00 | pubmed | Acute Coronary Syndrome__therapy;Cardiology__methods;Coronavirus Infections__epidemiology;Humans;Infection Control__methods;Non-ST Elevated Myocardial Infarction__therapy;Pandemics;Pneumonia, Viral__epidemiology;ST Elevation Myocardial Infarction__therapy;COVID-19 | European Heart Journal | Alaide Chieffo;Giulio G Stefanini;Susanna Price;Emanuele Barbato;Giuseppe Tarantini;Nicole Karam;Raul Moreno;Gill Louise Buchanan;Martine Gilard;Sigrun Halvorsen;Kurt Huber;Stefan James;Franz-Josef Neumann;Helge Möllmann;Marco Roffi;Guido Tavazzi;Josepa Mauri Ferré;Stephan Windecker;Dariusz Dudek;Andreas Baumbach | ACS;COVID-19;NSTEMI;PCI;STEMI | 2020-05-15 02:00:00+02:00 | 32405641 | FR;SE;NO;BO;GB;CH;US;IT;PL;ES;DE;AT | Interventional Cardiology Unit, IRCCS San Raffaele Hospital, Milan, Italy.;Humanitas Clinical and Research Hospital IRCCS, Rozzano, Milan, Italy.;Royal Brompton Hospital, London, UK.;Department of Advanced Biomedical Sciences University Federico II, Naples, Italy.;Interventional Cardiology Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy.;European Hospital Georges Pompidou (Cardiology Department) and University of Paris, Paris, France.;Cardiology Department, Hospital La Paz and IDIPAZ, Madrid, Spain.;Department of Cardiology, North Cumbria Integrated Care NHS Foundation Trust, Cumbria, UK.;Service de Cardiologie, Brest University Hospital, Brest, France.;Department of Cardiology, Oslo University Hospital Ulleval, and University of Oslo, Oslo, Norway.;3rdDepartment of Medicine, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, and Sigmund Freud University, Medical School, Vienna, Austria.;Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Sweden.;Division of Cardiology and Angiology II University Heart Centre Freiburg, Bad Krozingen, Germany.;Department of Cardiology St.-Johannes-Hospital Klinik für Innere Medizin I, Dortmund, Germany.;Division of Cardiology, University Hospitals, Geneva, Switzerland.;Department of clinical-surgical, diagnostic and pediatric sciences, Unit of anaesthesia and intensive care, Fondazione Policlinico San Matteo Hospital IRCCS, Pavia, Italy.;Hospital Universitari Germans Trias i Pujol, Badalona, Spain.;Department of Cardiology, Swiss Cardiovascular Center, University Hospital Bern, Bern, Switzerland.;Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland and Maria Cecilia Hospital GVM, Cotignola, Ravenna, Italy.;Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, Barts Heart Centre, London, UK and Yale University School of Medicine, New Haven, CT, USA. | 634 | ||
| 10.1093/alcalc/agaa045 | Journal Article | en | Is Alcohol in Hand Sanitizers Absorbed Through the Skin or Lungs? Implications for Disulfiram Treatment. | https://www.ncbi.nlm.nih.gov/pubmed/32400852 | In view of the increase in the use of ethanol-containing hand sanitizers throughout the world due to the current COVID-19 pandemic, we wished to review the possible risks to patients treated with disulfiram, following a case report in which an apparent DER (disulfiram-ethanol reaction) was attributed to the cutaneous absorption of alcohol from hand sanitizers as well as by inhalation of vapour. | 0735-0414,1464-3502 | 2020-05-17 02:00:00+02:00 | pubmed | Administration, Inhalation;Betacoronavirus;Breath Tests__methods;Coronavirus Infections__complications;Disulfiram__adverse effects;Ethanol__administration & dosage;Hand Sanitizers__administration & dosage;Humans;Pandemics;Pneumonia, Viral__complications;Skin Absorption__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Alcohol and Alcoholism | Colin Brewer;Emmanuel Streel | 2020-05-14 02:00:00+02:00 | 32400852 | FR;BE;GB | Retired Psychiatrist and addiction Physician, London, SE1, London, UK.;CHU Brugmann, Free University of Brussels, 1020, Brussels, Belgium. | 635 | |||
| 10.1186/s40634-020-00248-4 | Journal Article;Review | en | COVID-19 - ESSKA guidelines and recommendations for resuming elective surgery. | https://www.ncbi.nlm.nih.gov/pubmed/32405872 | The roadmap to elective surgery resumption after this COVID-19 pandemic should be progressive and cautious. The aim of this paper was to give recommendations and guidelines for resuming elective orthopedic surgery in the safest environment possible. Elective surgery should be performed in COVID-free facilities and hospital stay should be as short as possible. For matters of safety, patients considered first for surgery should be carefully selected according to COVID infection status/exposure, age, ASA physical status classification system / risk factors, socio-professional situation and surgical indication. A strategy for resuming elective surgery in four phases is proposed. Preoperative testing for COVID-19 infection is highly recommended. In any cases, COVID symptoms including fever and increased temperature should be constantly monitored until the day of surgery. Elective surgery should be postponed at the slightest suspicion of a COVID-19 infection. In case of surgery, adapted personal protective equipment in terms of gowns, gloves, masks and eye protection is highly recommended and described. | 2197-1153 | 2020-05-17 02:00:00+02:00 | pubmed | Journal of Experimental Orthopaedics | Caroline Mouton;Michael T Hirschmann;Matthieu Ollivier;Romain Seil;Jacques Menetrey | 2020-05-13 02:00:00+02:00 | 32405872 | FR;LU;CH | Sports Clinic, Centre Hospitalier de Luxembourg - Clinique d'Eich, 78, rue d' Eich, 1460, Luxembourg, Luxembourg.;Luxembourg Institute of Research in Orthopaedics, Sports Medicine and Science, Luxembourg, Luxembourg.;Department of Orthopaedic Surgery and Traumatology, Kantonsspital Baselland (Bruderholz, Liestal, Laufen), CH-4101, Bruderholz, Switzerland.;Department of Orthopedics and Traumatology, Aix Marseille Univ, APHM, CNRS, ISM, Sainte-Marguerite Hospital, Institute for Locomotion, Marseille, France.;Centre de Médecine du Sport et de l'Exercice (CMSE), Swiss Olympic Medical Center, Hirslanden Clinique La Colline, Chemin Thury 7A, CH-1206, Geneva, Switzerland. jacques.menetrey@hirslanden.ch.;Division of Orthopaedic Surgery, University Hospital of Geneva, Geneva, Switzerland. jacques.menetrey@hirslanden.ch. | 643 | ||||
| Letter | en | Managing ocular allergy in the time of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32402114 | 2020-05-17 02:00:00+02:00 | pubmed | Andrea Leonardi;Jean L Fauquert;Serge Doan;Luis Delgado;Nicolas Andant;Ludger Klimek;Banu Bozkurt | 2020-05-13 02:00:00+02:00 | 32402114 | FR;PT;IT;TR;DE | Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy.;Consultation Ophtalmologie et Allergie, CHU Montpied, Clermont-Ferrand, France.;Direction de l'Innovation et de la Recherche Clinique, CHU Montpied, Clermont-Ferrand, France.;Service d'Ophtalmologie, Hôpital Bichat and Fondation A. de Rothschild, Paris, France.;Basic and Clinical Immunology, Department of Pathology, Faculty of Medicine, Serviço de Imunoalergologia, Centro Hospitalar São João, EPE, University of Porto, Porto, Portugal.;Center for Rhinology and Allergology, Wiesbaden, Germany.;Department of Ophthalmology, Faculty of Medicine, Selcuk University, Konya, Turkey. | 653 | ||||||||
| 10.1016/j.encep.2020.05.005 | Journal Article | fr | [Appreciating COVID-19 as a child and adolescent psychiatrist on the move]. | https://www.ncbi.nlm.nih.gov/pubmed/32405083 | COVID-19 is a multi-organ disease due to an infection with the SARS-CoV2 virus. It has become a pandemic in early 2020. The disease appears less devastating in children and adolescents. However, stress, quarantine and eventually mourning have major impacts on development. It is difficult to describe what this pandemic implies for a child psychiatrist, other than by giving a first-hand account. I propose to go through the main ethical questions that have arisen; to describe how my hospital team has reorganized itself to meet the new demands and questions, in particular by opening a unit dedicated to people with autism and challenging behaviors affected by COVID-19; and to address, in a context of national discussion, how the discipline has sought to understand the conditions of a certain well-being during quarantine. Finally, I will try to conclude with more speculative reflections on re-opening. | 0013-7006 | 2020-05-17 02:00:00+02:00 | pubmed | Adolescent;Adolescent Behavior;Adolescent Psychiatry__ethics;Attitude of Health Personnel;Autistic Disorder__complications;Betacoronavirus;Child;Child Behavior;Child Psychiatry__ethics;Communicable Disease Control__methods;Coronavirus Infections__complications;Cross Infection__complications;Environmental Exposure;France;Health Services Accessibility;Hospital Restructuring;Hospital Units__organization & administration;Humans;Infection Control__methods;Mental Health Services__ethics;Olfaction Disorders__etiology;Pandemics__prevention & control;Patient Acceptance of Health Care;Patient Care Team;Patient Isolation__psychology;Play Therapy;Pneumonia, Viral__complications;Professional Practice__ethics;Protective Devices;Psychiatry;Risk Factors;Stress, Psychological__etiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | D Cohen | Adolescence;COVID-19;Childhood;Confinement;Déconfinement;Enfance;Quarantine;Re-opening | 2020-05-13 02:00:00+02:00 | 32405083 | FR | Service de psychiatrie de l'enfant et de l'adolescent, Sorbonne université, CNRS UMR 7222 « institut des systèmes intelligents et robotiques », AP-HP, Paris, France. Electronic address: david.cohen@aphp.fr. | 654 | ||
| 10.1080/15265161.2020.1764134 | Case Reports;Journal Article | en | Should Extremely Premature Babies Get Ventilators During the COVID-19 Crisis? | https://www.ncbi.nlm.nih.gov/pubmed/32400291 | In a crisis, societal needs take precedence over a patient's best interests. Triage guidelines, however, differ on whether limited resources should focus on maximizing lives or life-years. Choosing between these two approaches has implications for neonatology. Neonatal units have ventilators, some adaptable for adults. This raises the question of whether, in crisis conditions, guidelines for treating extremely premature babies should be altered to free-up ventilators. Some adults who need ventilators will have a survival rate higher than some extremely premature babies. But surviving babies will likely live longer, maximizing life-years. Empiric evidence demonstrates that these babies can derive significant survival benefits from ventilation when compared to adults. When "triaging" or choosing between patients, justice demands fair guidelines. Premature babies do not deserve special consideration; they deserve equal consideration. Solidarity is crucial but must consider needs specific to patient populations and avoid biases against people with disabilities and extremely premature babies. | 1526-5161,1536-0075 | 2020-05-17 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__therapy;Female;Humans;Infant, Extremely Premature;Infant, Newborn;Male;Pandemics__ethics;Pneumonia, Viral__therapy;Respiration, Artificial__ethics;Triage__ethics;COVID-19;severe acute respiratory syndrome coronavirus 2 | The American Journal of Bioethics | Marlyse F Haward;Annie Janvier;Gregory P Moore;Naomi Laventhal;Jessica T Fry;John Lantos | COVID-19;Health care delivery;ethics;justice;neonatology;rationing | 2020-05-13 02:00:00+02:00 | 32400291 | FR;CA;US;UNK | Albert Einstein College of Medicine.;Université de Montréal.;CHU Sainte-Justine.;Children's Hospital of Eastern Ontario.;University of Ottawa.;University of Michigan.;Ann & Robert H. Lurie Children's Hospital of Chicago.;Northwestern University Feinberg School of Medicine.;Children's Mercy Bioethics Center.;Children's Mercy Hospital. | 657 | ||
| Letter | en | Organising community primary care in the age of COVID-19: challenges in disadvantaged areas. | https://www.ncbi.nlm.nih.gov/pubmed/32411922 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;France__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Primary Health Care__organization & administration;Vulnerable Populations;COVID-19;severe acute respiratory syndrome coronavirus 2 | Chantal Julia;Yohan Saynac;Clémence Le Joubioux;Johann Cailhol;Pierre Lombrail;Olivier Bouchaud | 2020-05-13 02:00:00+02:00 | 32411922 | FR | Département de Santé Publique, Hôpitaux Paris-Seine-Saint-Denis (AP-HP), 93000 Bobigny, France, INSERM U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team, Epidemiology and Statistics Research Center-University of Paris, Université Sorbonne Paris Nord, Bobigny, France. Electronic address: c.julia@uren.smbh.univ-paris13.fr.;Département Universitaire de Médecine Générale, Unités de Formation et de Recherche de Santé Médecine et Biologie Humaine, Université Sorbonne Paris Nord, Bobigny, France.;Service de Maladies Infectieuses et Tropicales, Hôpitaux Paris-Seine-Saint-Denis (AP-HP), 93000 Bobigny, France.;Service de Maladies Infectieuses et Tropicales, Hôpitaux Paris-Seine-Saint-Denis (AP-HP), 93000 Bobigny, France, Laboratoire d'Educations et Pratiques en Santé EA 3412, Université Sorbonne Paris Nord, Bobigny, France.;Département de Santé Publique, Hôpitaux Paris-Seine-Saint-Denis (AP-HP), 93000 Bobigny, France, Laboratoire d'Educations et Pratiques en Santé EA 3412, Université Sorbonne Paris Nord, Bobigny, France. | 662 | |||||||
| 10.1016/j.neurol.2020.05.003 | Journal Article | en | §refers to: Camdessanche JP, Morel J,Pozzetto B, Paul S. COVID-19 may induce Guillain-Barré syndrome.COVID-19 and Guillain-Barré syndrome : response§. | https://www.ncbi.nlm.nih.gov/pubmed/32419708 | 0035-3787 | 2020-05-17 02:00:00+02:00 | pubmed | Revue Neurologique | Jean-Philippe Camdessanche;Jérôme Morel;Bruno Pozzetto;Stéphane Paul;Yannick Tholance;Elisabeth Botelho-Nevers | 2020-05-15 02:00:00+02:00 | 32419708 | FR | Department of Neurology, University Hospital of Saint-Etienne, France.;Department of Anesthesiology and Intensive Care Medicine, University Hospital of Saint-Etienne, France.;Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, France.;Department of Immunology, University Hospital of Saint-Etienne, France.;Laboratory of Biochemistry - University Hospital of Saint-Etienne, France. | 672 | |||||
| Letter | fr | [Care management and elective carcinological surgery place during the COVID-19 pandemic: A case report]. | https://www.ncbi.nlm.nih.gov/pubmed/32417400 | 2020-05-17 02:00:00+02:00 | pubmed | M Vermel;L Lecointre;É Faller;T Boisramé;C Akladios | 2020-05-14 02:00:00+02:00 | 32417400 | FR | Service de chirurgie gynécologique, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France. Electronic address: muriel.vermel@icloud.com.;Service de chirurgie gynécologique, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France. | 678 | ||||||||
| 10.1089/sur.2020.169 | Journal Article | en | COVID-19 in Post-Operative Patients: Imaging Findings. | https://www.ncbi.nlm.nih.gov/pubmed/32401630 | Background: Coronavirus 2019 (COVID-19) in the post-operative period is challenging. Its clinical manifestations may have similarities to other septic, thoracic, or gastrointestinal post-surgical complications. Additionally, the post-operative period may be a time of increased risk for severe manifestations of COVID-19. We sought to evaluate the frequency of COVID-19 in a cohort of patients who had recently had operations who were undergoing imaging for acute symptoms and the role of chest computed tomography (CT) in this setting. Patients and Methods: We included all patients who had chest CT for acute symptoms in the 15 days after a surgical procedure between March 1 and 31, 2020. Results: Of 46 patients with acute post-operative symptoms requiring chest imaging, eight (17%) were ultimately diagnosed with COVID-19. Among them, five (62%) required mechanical ventilation and two (25%) died. All had abnormal chest CT with typical findings of COVID-19 in 87%. Computed tomography provided an alternate diagnosis in 53% of patients who did not have COVID-19. The average time between a COVID-19-positive chest CT and the polymerase chain reaction (PCR) confirmation was 1.2 days (range, 0-4 days). Conclusion: COVID-19 is a serious post-operative condition associated with significant morbidity and mortality. Chest CT provides prompt diagnosis of COVID-19. In centers with a high prevalence of COVID-19, chest acquisition should be included in CT scans done for acute post-operative symptoms. | 1096-2964,1557-8674 | 2020-05-17 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus__isolation & purification;Coronavirus Infections__diagnosis;Female;Humans;Lung__diagnostic imaging;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;Postoperative Complications__diagnosis;Prevalence;Radiography, Thoracic;Reverse Transcriptase Polymerase Chain Reaction;Survival Analysis;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | Surgical Infections | Sebastien Moliere;Francis Veillon | COVID-19;complication;computed tomography;pneumonia;post-operative | 2020-05-13 02:00:00+02:00 | 32401630 | FR | Radiology Department, Hopital de Hautepierre, Strasbourg, France. | 688 | ||
| 10.1016/j.jogoh.2020.101787 | Editorial | en | Onco-gynecologic surgery in the COVID-19 era: Risks and precautions-A position paper from FRANCOGYN, SCGP, SFCO, and SFOG. | https://www.ncbi.nlm.nih.gov/pubmed/32407899 | 2468-7847 | 2020-05-17 02:00:00+02:00 | pubmed | Journal of Gynecology Obstetrics and Human Reproduction | Vincent Lavoué;Cherif Akladios;Laurence Gladieff;Jean-Marc Classe;Fabrice Lécuru;Pierre Collinet | 2020-05-11 02:00:00+02:00 | 32407899 | FR | Service de chirurgie gynécologique. CHU de Rennes. Hôpital Sud, 16 BD de Bulgarie, 35000 Rennes, France.;Service de chirurgie gynécologique, CHU de Strasbourg, Strasbourg, France.;Institut Claudius Regaud, IUCT-ONCOPOLE, Toulouse, France.;Service de chirurgie, Centre Renée Gauducheau, Nantes, France.;Service de chirurgie, Institut Curie, Paris, France.;Service de chirurgie gynécologique, CHRU Lille, France. | 695 | |||||
| 10.1016/j.jiph.2020.05.005 | Journal Article | en | Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed. | https://www.ncbi.nlm.nih.gov/pubmed/32451259 | Since the onset of the new coronavirus pandemic, the world is facing a public health emergency. Repositioning hydroxychloroquine (HQ) seems to be a promising option. Many emerging evidences have converged on the effectiveness of HQ in the treatment of Covid-19 infection. In a recent paper, Gautret et al. suggested that further works are needed to determine if HQ antiviral prophylaxis is useful, especially for healthcare workers. | 1876-0341 | 2020-05-17 02:00:00+02:00 | pubmed | Age Factors;Antiviral Agents__therapeutic use;Betacoronavirus;Chemoprevention;Coronavirus Infections__prevention & control;Health Personnel__statistics & numerical data;Humans;Hydroxychloroquine__therapeutic use;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Infection and Public Health | Rachid Tahiri Joutei Hassani;Ahmed Bennis | Antiviral prophylaxis;Chloroquine;Coronavirus;Healthcare workers | 2020-05-11 02:00:00+02:00 | 32451259 | FR;MA | Ambulatory Surgery Department, Avranches Granville Hospital, Granville, France. Electronic address: granville-tahiri@levisiologiste.com.;Cardiology Department, Jerada Clinic, Casablanca, Morocco. | 696 | ||
| Case Reports;Letter | en | Acute meningoencephalitis in a patient with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32414534 | 2020-05-17 02:00:00+02:00 | pubmed | Acute Disease;Aged;Anti-Bacterial Agents__therapeutic use;Antimalarials__therapeutic use;Azithromycin__therapeutic use;Betacoronavirus;Coronavirus Infections__complications;Drug Therapy, Combination;Humans;Hydroxychloroquine__therapeutic use;Male;Meningoencephalitis__etiology;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | H Chaumont;P Etienne;E Roze;C Couratier;P-M Roger;A Lannuzel | 2020-05-11 02:00:00+02:00 | 32414534 | FR;GP | Centre Hospitalier Universitaire de la Guadeloupe, Service de Neurologie, Pointe-à-Pitre/Abymes, France, Faculté de Médecine de l'université des Antilles, Pointe-à-Pitre, France, Faculté de Médecine de Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, U 1127, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France. Electronic address: hugo.chaumont@chu-guadeloupe.fr.;Centre Hospitalier Universitaire de la Guadeloupe, Unité d'Hospitalisation de Courte Durée, Pointe-à-Pitre/Abymes, France.;Faculté de Médecine de Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, U 1127, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France, AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Neurologie, Paris, France.;Centre Hospitalier Universitaire de la Guadeloupe, Service de Neurologie, Pointe-à-Pitre/Abymes, France.;Centre Hospitalier Universitaire de la Guadeloupe, Service d'Infectiologie, Pointe-à-Pitre/Abymes, France.;Centre Hospitalier Universitaire de la Guadeloupe, Service de Neurologie, Pointe-à-Pitre/Abymes, France, Faculté de Médecine de l'université des Antilles, Pointe-à-Pitre, France, Faculté de Médecine de Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, U 1127, CNRS, Unité Mixte de Recherche (UMR) 7225, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France, Centre d'investigation Clinique Antilles Guyane, Inserm CIC 1424, Pointe-à-Pitre, France. | 698 | |||||||
| 10.1016/j.jogoh.2020.101805 | Journal Article | en | Post-natal follow-up for women and neonates during the COVID-19 pandemic: French National Authority for Health recommendations. | https://www.ncbi.nlm.nih.gov/pubmed/32407898 | In the context of the stage 3 SARS-Cov-2 epidemic situation, it is necessary to put forward a method of rapid response for an HAS position statement in order to answer to the requests from the French Ministry of Solidarity and Health, healthcare professionals and/or health system users' associations, concerning post-natal follow-up for women and neonates during the COVID-19 pandemic. | 2468-7847 | 2020-05-17 02:00:00+02:00 | pubmed | Journal of Gynecology Obstetrics and Human Reproduction | Alexandre J Vivanti;Philippe Deruelle;Olivier Picone;Sophie Guillaume;Jean-Christophe Roze;Blandine Mulin;Fabienne Kochert;Isabelle De Beco;Sophie Mahut;Adrien Gantois;Chloé Barasinski;Karine Petitprez;Anne-Françoise Pauchet-Traversat;Alcyone Droy;Alexandra Benachi | 2020-05-11 02:00:00+02:00 | 32407898 | FR | Service de Gynécologie Obstétrique, Hôpital Antoine Béclère, AP-HP, Université Paris-Saclay, Clamart, France.;Collège National des Gynécologues Obstétriciens Français, France.;Service de Gynécologie-Obstétrique, Hôpital de Hautepierre, Faculté de Médecine de Strasbourg, Strasbourg, France.;Division of Obstetrics and Gynecology, "Louis Mourier" Hospital, Paris University, IAME INSERM U1137, APHP Paris, France, Groupe de Recherche sur les Infections pendant la Grossesse.;Collège National des Sages-Femmes de France, France.;Conseil National des Professionnels de Pédiatrie, France.;French Federation of Perinatal Health Networks, France.;French Association of Ambulatory Paediatrics, France.;College of General Medicine, France.;Université Clermont Auvergne, CNRS, CHU Clermont-Ferrand, SIGMA, INSTITUT PASCAL, F-63000 Clermont-Ferrand, France.;Guidelines Department, French National Authority for Health, Saint-Denis, France. | 701 | ||||
| Letter | en | Chloroquine and hydroxychloroquine during pregnancy: What do we know? | https://www.ncbi.nlm.nih.gov/pubmed/32418732 | 2020-05-17 02:00:00+02:00 | pubmed | Isabelle Lacroix;Justine Bénévent;Christine Damase-Michel | Chloroquine;Covid-19;Hydroxychloroquine;Pregnancy | 2020-05-11 02:00:00+02:00 | 32418732 | FR | Unité « Médicaments, grossesse et allaitement », service de pharmacologie médicale et clinique, CHU de Toulouse, faculté de médecine, Inserm 1027, 37, allées Jules-Guesde, 31000 Toulouse, France. Electronic address: isabelle.lacroix@univ-tlse3.fr.;Unité « Médicaments, grossesse et allaitement », service de pharmacologie médicale et clinique, CHU de Toulouse, faculté de médecine, Inserm 1027, 37, allées Jules-Guesde, 31000 Toulouse, France. | 707 | |||||||
| 10.1016/j.jogoh.2020.101785 | Editorial | en | Giving birth under lockdown during the COVID-19 epidemic. | https://www.ncbi.nlm.nih.gov/pubmed/32423532 | 2468-7847 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Depression, Postpartum__etiology;Female;Humans;Object Attachment;Pandemics;Parturition__psychology;Patient Discharge;Patient Isolation__psychology;Pneumonia, Viral__epidemiology;Pregnancy;Visitors to Patients;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Gynecology Obstetrics and Human Reproduction | S Viaux;P Maurice;D Cohen;J M Jouannic | COVID-19;Maternal isolation;Post-Partum depression;Psychological vulnerability | 2020-05-11 02:00:00+02:00 | 32423532 | FR | APHP.Sorbonne, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France.;Sorbonne Université, INSERM, UMRS 1142 LIMICS, Paris, France, APHP.Sorbonne, Fetal Medicine Department, Armand Trousseau Hospital, Paris, France.;APHP.Sorbonne, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France, Sorbonne Université, INSERM, UMRS 1142 LIMICS, Paris, France.;Sorbonne Université, INSERM, UMRS 1142 LIMICS, Paris, France, APHP.Sorbonne, Fetal Medicine Department, Armand Trousseau Hospital, Paris, France. Electronic address: jean-marie.jouannic@aphp.fr. | 709 | |||
| 10.1016/j.jcv.2020.104433 | Journal Article | en | Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories. | https://www.ncbi.nlm.nih.gov/pubmed/32405254 | With emergence of pandemic COVID-19, rapid and accurate diagnostic testing is essential. This study compared laboratory-developed tests (LDTs) used for the detection of SARS-CoV-2 in Canadian hospital and public health laboratories, and some commercially available real-time RT-PCR assays. Overall, analytical sensitivities were equivalent between LDTs and most commercially available methods. | 1386-6532 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Canada;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Humans;Laboratories;Limit of Detection;Pandemics;Pneumonia, Viral__diagnosis;Real-Time Polymerase Chain Reaction__methods;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Clinical Virology | Jason J LeBlanc;Jonathan B Gubbay;Yan Li;Robert Needle;Sandra Radons Arneson;Dionne Marcino;Hugues Charest;Guillaume Desnoyers;Kerry Dust;Ramzi Fattouh;Richard Garceau;Gregory German;Todd F Hatchette;Robert A Kozak;Mel Krajden;Theodore Kuschak;Amanda L S Lang;Paul Levett;Tony Mazzulli;Ryan McDonald;Samira Mubareka;Natalie Prystajecky;Candy Rutherford;Marek Smieja;Yang Yu;George Zahariadis;Nathan Zelyas;Nathalie Bastien | COVID-19;Coronavirus;Molecular;NAAT;PCR;SARS-CoV-2 | 2020-05-13 02:00:00+02:00 | 32405254 | FR;CA;GB;US | Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority (NSHA), Room 404B, MacKenzie Building, 5788 University Avenue, Halifax, Nova Scotia B3H 1V8, Canada, Departments of Pathology, Medicine, and Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada. Electronic address: jason.leblanc@nshealth.ca.;Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, Public Health Ontario Laboratories, Toronto, Ontario, Canada, Hospital for Sick Children, Toronto, Ontario, Canada.;National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba, Canada.;Public Health and Microbiology Laboratory, St. John's, Newfoundland, Canada.;Laboratoire De Santé Publique Du Québec/INSPQ, Sainte-Anne-de-Bellevue, Quebec, Canada.;Centre Hospitalier Universitaire Dr. Georges L. Dumont, Moncton, New-Brunswick, Canada.;Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada.;Department of Laboratory Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.;Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, Canada.;Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority (NSHA), Room 404B, MacKenzie Building, 5788 University Avenue, Halifax, Nova Scotia B3H 1V8, Canada, Departments of Pathology, Medicine, and Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.;Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, Sunnybrook Research Institute, Toronto, Ontario, Canada.;Public Health Laboratory, British Columbia Centre for Disease Control (BCCDC), Vancouver, British Columbia, Canada.;Roy Romanow Provincial Laboratory (RRPL), Saskatchewan Health Authority (SHA), Regina, Saskatchewan, Canada.;Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada.;St Joseph's Healthcare, Hamilton, Ontario, Canada.;Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority (NSHA), Room 404B, MacKenzie Building, 5788 University Avenue, Halifax, Nova Scotia B3H 1V8, Canada, Provincial Laboratory for Public Health (ProvLab), Calgary, Alberta, Canada. | 713 | ||
| 10.1016/j.jogoh.2020.101804 | Journal Article | en | Follow-up for pregnant women during the COVID-19 pandemic: French national authority for health recommendations. | https://www.ncbi.nlm.nih.gov/pubmed/32407897 | In the context of the stage 3 SARS-Cov-2 epidemic situation, it is necessary to put forward a method of rapid response for an HAS position statement in order to answer to the requests from the French Ministry of Solidarity and Health, healthcare professionals and/or health system users' associations concerning follow-up of pregnant women during the COVID-19 outbreak. | 2468-7847 | 2020-05-17 02:00:00+02:00 | pubmed | Journal of Gynecology Obstetrics and Human Reproduction | Alexandre J Vivanti;Philippe Deruelle;Olivier Picone;Sophie Guillaume;Jean-Christophe Roze;Blandine Mulin;Fabienne Kochert;Isabelle De Beco;Sophie Mahut;Adrien Gantois;Chloé Barasinski;Karine Petitprez;Anne-Françoise Pauchet-Traversat;Alcyone Droy;Alexandra Benachi | 2020-05-11 02:00:00+02:00 | 32407897 | FR | Service de Gynécologie Obstétrique, Hôpital Antoine Béclère, AP-HP, Université Paris-Saclay, 92140 Clamart, France.;Collège National des Gynécologues Obstétriciens Français, 75002 Paris, France.;Service de Gynécologie Obstétrique, Hôpital de Hautepierre, Faculté de Médecine de Strasbourg, 67000 Strasbourg, France.;Division of Obstetrics and Gynecology, "Louis Mourier" Hospital, Paris University, IAME INSERM U1137, APHP (Paris, France) GRIG (Groupe de Recherche sur les Infections pendant la Grossesse), 92700 Colombes.;Collège National des Sages-Femmes de France, 75015 Paris, France.;Conseil National des Professionnels de Pédiatrie, 75015 Paris, France.;French Federation of Perinatal Health Networks, 31000 Toulouse, France.;French Association of Ambulatory Paediatrics, 33400 Talence, France.;College of General Medicine, 75017 Paris 8, France.;Université Clermont Auvergne, CNRS, CHU Clermont-Ferrand, SIGMA, INSTITUT PASCAL, F63000 ClermontFerrand, France.;Guidelines Department, French National Authority for Health, 93200 Saint-Denis, France. | 728 | ||||
| ANR | 10.1007/s12015-020-09987-4 | Journal Article | en | Is COVID-19 a New Hematologic Disease? | https://www.ncbi.nlm.nih.gov/pubmed/32399806 | SARS-CoV-2 viruses are positive single-stranded RNA viruses, whose infection can be asymptomatic or lead to the coronavirus disease 2019 (Covid-19). Covid-19 is a respiratory infection with a significant impact on the hematopoietic system and hemostasis leading to several cardiovascular complications. Hematologic consequences of this new infection allowed medical community to start new treatment approaches concerning infection going from targeted anti-inflammatory drugs to anticoagulation or stem cell therapies. A better understanding of Covid-19 pathophysiology, in particular hematological disorders, will help to choose appropriate treatment strategies. | 2629-3269,2629-3277 | 2020-05-17 02:00:00+02:00 | pubmed | Stem Cell Reviews and Reports | Benjamin Debuc;David M Smadja | Coagulopathy;Covid-19;Cytokine;D-dimers;Inflammation;Lymphopenia;Mesenchymal stem cells;SARS-CoV-2;Stem cells;Thrombosis | 2020-05-12 02:00:00+02:00 | 32399806 | FR | [{"country": "", "agency": "ANR", "grantid": "SARCODO"}] | Université de Paris, Plastic Surgery Department, AP-HP, Georges Pompidou European Hospital, Paris, F-75015, France.;Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR-S 1140, Paris, F-75006, France. david.smadja@aphp.fr.;Hematology Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, 20 rue Leblanc, Paris, F-75015, France. david.smadja@aphp.fr. | 732 | |
| 10.1101/2020.05.15.098731 | Preprint | en | Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. | https://www.ncbi.nlm.nih.gov/pubmed/32511380 | The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase (RdRp) is a promising target with polymerase inhibitors successfully used for the treatment of several viral diseases. Here we show that Favipiravir exerts an antiviral effect as a nucleotide analogue through a combination of chain termination, slowed RNA synthesis and lethal mutagenesis. The SARS-CoV RdRp complex is at least 10-fold more active than any other viral RdRp known. It possesses both unusually high nucleotide incorporation rates and high-error rates allowing facile insertion of Favipiravir into viral RNA, provoking C-to-U and G-to-A transitions in the already low cytosine content SARS-CoV-2 genome. The coronavirus RdRp complex represents an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the treatment of COVID-19. | 2020-05-17 02:00:00+02:00 | pubmed | A Shannon;B Selisko;Ntt Le;J Huchting;F Touret;G Piorkowski;V Fattorini;F Ferron;E Decroly;C Meier;B Coutard;O Peersen;B Canard | 2020-05-15 02:00:00+02:00 | 32511380 | FR;US;DE | Architecture et Fonction des Macromolécules Biologiques, CNRS and Aix-Marseille Université, UMR 7257, Polytech Case 925, 13009 Marseille, France.;University of Hamburg, Faculty of Sciences, Department of Chemistry, Organic Chemistry, Martin-Luther-King-Platz 6, D-20146 Hamburg, Germany.;Unité des Virus Émergents (UVE: Aix-Marseille Univ - IRD 190 - Inserm 1207 - IHU Méditerranée Infection), Marseille, France.;Department of Biochemistry & Molecular Biology, Colorado State University, Fort Collins, CO 80523-1870, USA. | 736 | ||||||
| Journal Article;Comment | fr | [Covid-19: care protocols or research protocols?] | https://www.ncbi.nlm.nih.gov/pubmed/32452375 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Protocols;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Philippe Amiel;Hervé Chneiweiss;Christine Dosquet | 2020-05-15 02:00:00+02:00 | 32452375 | FR | CEEI (Comité d'évaluation éthique de l'Inserm/IRB), 101, rue de Tolbiac, 75013 Paris, France - UMR 1123 ECEVE Inserm, Université de Paris, 10, avenue de Verdun 75010 Paris, France.;Comité d'éthique de l'Inserm (CEI), 101, rue de Tolbiac, 75013 Paris, France - Neuroscience Paris Seine - IBPS, Équipe Plasticité gliale et tumeurs cérébrales, UMR8246 CNRS, U1130 Inserm, Sorbonne Université, Campus Pierre et Marie Curie, 7, quai Saint Bernard, 75005 Paris, France.;CEEI (Comité d'évaluation éthique de l'Inserm/IRB), 101, rue de Tolbiac, 75013 Paris, France. | 739 | |||||||
| 10.1111/head.13841 | Journal Article | en | Headaches During COVID-19: My Clinical Case and Review of the Literature. | https://www.ncbi.nlm.nih.gov/pubmed/32413158 | To analyze headaches related to COVID-19 based on personal case experience. | 0017-8748,1526-4610 | 2020-05-17 02:00:00+02:00 | pubmed | Headache: The Journal of Head and Face Pain | Robert Belvis | COVID-19;SARS-CoV-12;coronavirus;cytokine storm;headache | 2020-05-15 02:00:00+02:00 | 32413158 | FR;ES | Headache and Neuralgias Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. | 740 | |||
| Journal Article;Review | en | Clinical interventions for severe and critical COVID-19: what are the options. | https://www.ncbi.nlm.nih.gov/pubmed/32509205 | The coronavirus disease 2019 (COVID-19) has been ongoing outbreak and declared as a global public health emergency by the World Health Organization. Severe and critical COVID-19 has high fatality rate due to complications like acute respiratory distress syndrome, acute respiratory failure or multiple organ failure. So far, there have been mounting research on the epidemiological and clinical characteristics of COVID-19. However, the information regarding treatment of severe and critical COVID-19 is limited. The current study reviewed published evidence of clinical interventions of severe and critical COVID-19, aiming to provide an up-to-date reference for further clinical treatment. | 2020-05-17 02:00:00+02:00 | pubmed | Wei Yuan;Sheng Liu;Li Lu;Juan Feng;Xin He | COVID-19;SARS-CoV-2;intervention;severe pneumonia | 2020-05-15 02:00:00+02:00 | 32509205 | FR;CN | Department of Orthopedics, First Hospital of China Medical University Shenyang, China.;Department of Infectious Disease, First Hospital of China Medical University Shenyang, China.;Bordeaux Population Health Research Center, UMR U1219, INSERM, Université de Bordeaux Bordeaux, France.;Department of Neurology, Shengjing Hospital of China Medical University Shenyang, China. | 747 | ||||||
| 10.1016/j.scitotenv.2020.139542 | Journal Article | en | Amplified ozone pollution in cities during the COVID-19 lockdown. | https://www.ncbi.nlm.nih.gov/pubmed/32447070 | The effect of lockdown due to coronavirus disease (COVID-19) pandemic on air pollution in four Southern European cities (Nice, Rome, Valencia and Turin) and Wuhan (China) was quantified, with a focus on ozone (O3). Compared to the same period in 2017-2019, the daily O3 mean concentrations increased at urban stations by 24% in Nice, 14% in Rome, 27% in Turin, 2.4% in Valencia and 36% in Wuhan during the lockdown in 2020. This increase in O3 concentrations is mainly explained by an unprecedented reduction in NOx emissions leading to a lower O3 titration by NO. Strong reductions in NO2 mean concentrations were observed in all European cities, ~53% at urban stations, comparable to Wuhan (57%), and ~65% at traffic stations. NO declined even further, ~63% at urban stations and ~78% at traffic stations in Europe. Reductions in PM2.5 and PM10 at urban stations were overall much smaller both in magnitude and relative change in Europe (~8%) than in Wuhan (~42%). The PM reductions due to limiting transportation and fuel combustion in institutional and commercial buildings were partly offset by increases of PM emissions from the activities at home in some of the cities. The NOx concentrations during the lockdown were on average 49% lower than those at weekends of the previous years in all cities. The lockdown effect on O3 production was ~10% higher than the weekend effect in Southern Europe and 38% higher in Wuhan, while for PM the lockdown had the same effect as weekends in Southern Europe (~6% of difference). This study highlights the challenge of reducing the formation of secondary pollutants such as O3 even with strict measures to control primary pollutant emissions. These results are relevant for designing abatement policies of urban pollution. | 0048-9697 | 2020-05-24 02:00:00+02:00 | pubmed | Air Pollution__analysis;Betacoronavirus;China;Cities;Coronavirus Infections;Environmental Monitoring;Europe;Humans;Nitrogen Dioxide__analysis;Ozone__analysis;Pandemics;Particulate Matter__analysis;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Science of The Total Environment | Pierre Sicard;Alessandra De Marco;Evgenios Agathokleous;Zhaozhong Feng;Xiaobin Xu;Elena Paoletti;José Jaime Diéguez Rodriguez;Vicent Calatayud | Air quality;Coronavirus;Lockdown;Ozone;Risk assessment | 2020-05-20 02:00:00+02:00 | 32447070 | FR;IT;ES;CN | ARGANS, 260 route du Pin Montard, Biot, France.;Italian National Agency for New Technologies, Energy and the Environment, C.R. Casaccia, Italy. Electronic address: alessandra.demarco@enea.it.;Institute of Ecology, Key Laboratory of Agro-meteorology of Jiangsu Province, School of Applied Meteorology, Nanjing University of Information Science and Technology, Nanjing, China.;Institute of Ecology, Key Laboratory of Agro-meteorology of Jiangsu Province, School of Applied Meteorology, Nanjing University of Information Science and Technology, Nanjing, China. Electronic address: zhaozhong.feng@nuist.edu.cn.;State Key Laboratory of Severe Weather and Key Laboratory for Atmospheric Chemistry of China Meteorology Administration, Chinese Academy of Meteorological Sciences, Beijing, China.;Institute of Research on Terrestrial Ecosystems, National Research Council, Sesto Fiorentino, Italy.;Fundación CEAM, Parque Tecnológico, C/ Charles R. Darwin, 14, Paterna, Spain. | 751 | ||
| 10.1161/strokeaha.120.030373 | Journal Article | en | Mechanical Thrombectomy for Acute Ischemic Stroke Amid the COVID-19 Outbreak: Decreased Activity, and Increased Care Delays. | https://www.ncbi.nlm.nih.gov/pubmed/32432994 | The efficiency of prehospital care chain response and the adequacy of hospital resources are challenged amid the coronavirus disease 2019 (COVID-19) outbreak, with suspected consequences for patients with ischemic stroke eligible for mechanical thrombectomy (MT). | 0039-2499,1524-4628 | 2020-05-24 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Betacoronavirus;Brain Ischemia__epidemiology;Coronavirus Infections;Delivery of Health Care;Female;France__epidemiology;Hospitalization__statistics & numerical data;Humans;Male;Mechanical Thrombolysis__methods;Middle Aged;Pandemics;Patient Admission__statistics & numerical data;Pneumonia, Viral;Procedures and Techniques Utilization;Prospective Studies;Stroke__epidemiology;Time-to-Treatment__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | Stroke | Basile Kerleroux;Thibaut Fabacher;Nicolas Bricout;Martin Moïse;Benoit Testud;Sivadji Vingadassalom;Héloïse Ifergan;Kévin Janot;Arturo Consoli;Wagih Ben Hassen;Eimad Shotar;Julien Ognard;Guillaume Charbonnier;Vincent L'Allinec;Alexis Guédon;Federico Bolognini;Gaultier Marnat;Géraud Forestier;Aymeric Rouchaud;Raoul Pop;Nicolas Raynaud;François Zhu;Jonathan Cortese;Vanessa Chalumeau;Jérome Berge;Simon Escalard;Grégoire Boulouis | COVID-19;coronavirus;groin;hospitalization;thrombectomy | 2020-05-20 02:00:00+02:00 | 32432994 | FR;GB | Neuroradiology Department, CH Sainte-Anne, Paris, France (B.K., W.B.H., G.B.).;Public Health, CHRU Strasbourg, France (T.F.).;Interventional Neuroradiology Department, CHRU Lille, France (N.B., M.M.).;Interventional Neuroradiology Department, CHRU Marseille La Timone, France (B.T., S.V.).;Interventional Neuroradiology Department, CHRU Tours, France (H.I., K.J.).;Interventional Neuroradiology Department, CH Foch, France (A.C.).;Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France (E.S.).;Interventional Neuroradiology Department, CHRU Brest, France (J.O.).;Interventional Neuroradiology Department, CHRU Besançon, France (G.C.).;Radiology Department, CHU Angers, France (V.L.).;Department of Neuroradiology, Lariboisière Hospital, Paris, France (A.G.).;Interventional Neuroradiology Department, CHRU Colmar, France (F.B.).;Interventional Neuroradiology Department, CHRU Bordeaux, France (G.M., J.B.).;Interventional Neuroradiology Department, CHU Limoges, France (G.F., A.R.).;Interventional Neuroradiology Department, CHRU Strasbourg, France (R.P.).;Interventional Neuroradiology Department, CHRU Poitiers, France (N.R.).;Interventional Neuroradiology Department, CHRU Nancy, France (F.Z.).;Interventional Neuroradiology Department, Kremlin Bicêtre Hospital, Bicêtre, France (J.C., V.C.).;Interventional Neuroradiology Department, Fondation Rothschild, Paris, France (S.E.). | 752 | ||
| 10.1016/j.amp.2020.05.004 | English Abstract;Journal Article | fr | [Representations of the SARS-CoV-2 pandemic and confinement in a liberal psychiatric patient base in Paris]. | https://www.ncbi.nlm.nih.gov/pubmed/32836296 | A brief description of attitudes and representations of SARS-Cov-2 pandemic among patients in a psychiatric Parisian office. Collected data suggest that the confinement's measure has been accepted. However the end of confinement has been a time of increased anxiety for many. The representations of Covid-19 and the one of the other's body tended to be assimilated. Some perplexity over preventive measures has been observed. | 0003-4487 | 2020-05-24 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | F-R Ingold | Anthropology;Compliance;Confinement;Covid-19;Epidemiology;Representations | 2020-05-19 02:00:00+02:00 | 32836296 | FR | Cabinet médical, 55, rue des Archives, 75003 Paris, France. | 768 | |||
| Letter;Comment | en | Prothrombotic phenotype in COVID-19 severe patients. | https://www.ncbi.nlm.nih.gov/pubmed/32435823 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Incidence;Pandemics;Phenotype;Pneumonia, Viral;Pulmonary Embolism;COVID-19;severe acute respiratory syndrome coronavirus 2 | Julie Helms;François Severac;Hamid Merdji;Eduardo Anglés-Cano;Ferhat Meziani | 2020-05-20 02:00:00+02:00 | 32435823 | FR;US | Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, 1, place de l'Hôpital, 67091, Strasbourg cedex, France.;ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France.;Hôpitaux Universitaires de Strasbourg, Groupe Méthodes en Recherche Clinique (GMRC), Hôpital Civil, Strasbourg, France.;INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France.;Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR_S 1140, 75006, Paris, France.;Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, 1, place de l'Hôpital, 67091, Strasbourg cedex, France. Ferhat.Meziani@chru-strasbourg.fr.;INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France. Ferhat.Meziani@chru-strasbourg.fr. | 770 | |||||||
| Letter | en | Tricuspid Longitudinal Annular Displacement for the Assessment of Right Ventricular Systolic Dysfunction during Prone Positioning in Patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32561109 | 2020-05-24 02:00:00+02:00 | pubmed | Christophe Beyls;Yohann Bohbot;Pierre Huette;Osama Abou-Arab;Yazine Mahjoub | 2020-05-20 02:00:00+02:00 | 32561109 | FR | Department of Anaesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.;Department of Cardiology, Amiens University Hospital, Amiens, France. | 771 | ||||||||
| Letter | en | Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32445626 | 2020-05-24 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__complications;Female;Humans;Invasive Pulmonary Aspergillosis__epidemiology;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Prevalence;COVID-19;severe acute respiratory syndrome coronavirus 2 | Alexandre Alanio;Sarah Dellière;Sofiane Fodil;Stéphane Bretagne;Bruno Mégarbane | 2020-05-20 02:00:00+02:00 | 32445626 | FR | Laboratoire de Parasitologie-Mycologie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Paris, France, Université de Paris, Paris, France, Institut Pasteur, Centre National de la Recherche Scientifique, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, France. Electronic address: alexandre.alanio@pasteur.fr.;Laboratoire de Parasitologie-Mycologie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Paris, France, Université de Paris, Paris, France, Institut Pasteur, Centre National de la Recherche Scientifique, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, France.;Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Paris, France, Université de Paris, Paris, France.;Réanimation Médicale et Toxicologique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Paris, France, Université de Paris, Paris, France, Institut National de la Santé et de la Recherche Médicale, Paris, France. | 773 | |||||||
| 10.1007/s00134-020-06078-3 | Case Reports;Journal Article | en | SARS-CoV-2 pulmonary infection revealed by subcutaneous emphysema and pneumomediastinum. | https://www.ncbi.nlm.nih.gov/pubmed/32430514 | 0342-4642,1432-1238 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Laboratory Techniques;Coronavirus Infections__complications;Humans;Lung__diagnostic imaging;Male;Mediastinal Emphysema__diagnostic imaging;Middle Aged;Pandemics;Pneumonia, Viral__complications;Radiography, Thoracic;Subcutaneous Emphysema__diagnostic imaging;Tomography, X-Ray Computed;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Maxime Lacroix;Farouk Graiess;Laurence Monnier-Cholley;Lionel Arrivé | 2020-05-19 02:00:00+02:00 | 32430514 | FR | Hopital Saint-Antoine, Paris, France.;Hopital Saint-Antoine, Paris, France. laurence.monnier-cholley@aphp.fr. | 779 | ||||
| Letter;Comment | en | Cardiovascular phenotypes in ventilated patients with COVID-19 acute respiratory distress syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32423461 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Echocardiography;Humans;Pandemics;Phenotype;Pneumonia, Viral;Respiration, Artificial;Respiratory Distress Syndrome, Adult;Shock, Septic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bruno Evrard;Marine Goudelin;Noelie Montmagnon;Anne-Laure Fedou;Thomas Lafon;Philippe Vignon | Acute respiratory distress syndrome;COVID-19;Doppler;Echocardiography;Human;Influenza | 2020-05-18 02:00:00+02:00 | 32423461 | FR | Medical-Surgical Intensive Care Unit, Dupuytren Teaching Hospital, 87000, Limoges, France.;Inserm CIC 1435, Dupuytren Teaching Hospital, 87000, Limoges, France.;Emergency Department, Dupuytren Teaching Hospital, 87000, Limoges, France.;Faculty of Medicine, University of Limoges, 87000, Limoges, France.;Medical-Surgical Intensive Care Unit, Dupuytren Teaching Hospital, 87000, Limoges, France. philippe.vignon@unilim.fr.;Inserm CIC 1435, Dupuytren Teaching Hospital, 87000, Limoges, France. philippe.vignon@unilim.fr.;Faculty of Medicine, University of Limoges, 87000, Limoges, France. philippe.vignon@unilim.fr.;Inserm UMR 1092, Dupuytren Teaching Hospital, 87000, Limoges, France. philippe.vignon@unilim.fr.;Réanimation Polyvalente, CHU Dupuytren, 2 Avenue Martin Luther king, 87042, Limoges, France. philippe.vignon@unilim.fr. | 781 | ||||||
| NCATS NIH HHS | 10.1053/j.gastro.2020.05.032 | Journal Article | en | Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. | https://www.ncbi.nlm.nih.gov/pubmed/32425234 | The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown. We sought to characterize the clinical course of COVID-19 among patients with IBD and evaluate the association among demographics, clinical characteristics, and immunosuppressant treatments on COVID-19 outcomes. | 0016-5085 | 2020-05-24 02:00:00+02:00 | pubmed | Gastroenterology | Erica J Brenner;Ryan C Ungaro;Richard B Gearry;Gilaad G Kaplan;Michele Kissous-Hunt;James D Lewis;Siew C Ng;Jean-Francois Rahier;Walter Reinisch;Frank M Ruemmele;Flavio Steinwurz;Fox E Underwood;Xian Zhang;Jean-Frederic Colombel;Michael D Kappelman | COVID-19;Crohn’s Disease;Inflammatory Bowel Disease;Ulcerative Colitis | 2020-05-18 02:00:00+02:00 | 32425234 | FR;CA;NZ;CN;GB;US;HK;BR;BE;AT | [{"country": "United States", "agency": "NCATS NIH HHS", "grantid": "UL1 TR002489"}] | University of North Carolina Department of Pediatric Gastroenterology, Children's Hospital, Chapel Hill, North Carolina. Electronic address: Erica.Brenner@unchealth.unc.edu.;The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Ryan.ungaro@mssm.edu.;University of Otago Department of Medicine, Christchurch, New Zealand.;University of Calgary, Departments of Medicine and Community Health Sciences, Calgary, Alberta, Canada.;Mount Sinai Medical Center, New York, New York.;The University of Pennsylvania, Philadelphia, Pennsylvania.;Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, The People's Republic of China.;Department of Gastroenterology, Université catholique de Louvain, CHU UCL Namur 5530 Yvoir, Belgium.;Medical University of Vienna, Department Internal Medicine III, Division Gastroenterology & Hepatology, Vienna, Austria.;Université de Paris, France Assistance-Publique- Hôpitaux de Paris, Hôpital Necker Enfants Malades, Service de Gastroentérologie pédiatrique, Paris, France.;Hospital Israelita Albert Einstein, São Paulo, Brazil.;University of North Carolina, Department of Gastroenterology, Chapel Hill, North Carolina.;The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.;University of North Carolina Department of Pediatric Gastroenterology, Children's Hospital, Chapel Hill, North Carolina. | 794 | |
| 10.1016/j.endinu.2020.05.002 | Practice Guideline | en | Update of the hyperglycemia Gestational diagnosis during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32553745 | 2530-0164 | 2020-05-24 02:00:00+02:00 | pubmed | Endocrinología, Diabetes y Nutrición | Mercè Codina;Rosa Corcoy;María M Goya | 2020-05-19 02:00:00+02:00 | 32553745 | FR;ES;PS | Endocrinología, Hospital Son Espases, Palma de Mallorca, España.;Endocrinología, Hospital Santa Creu i Sant Pau, Barcelona, España.;Obstetricia, Hospital Universitari Vall d'Hebron, Barcelona, España. Electronic address: mariagoya@mac.com. | 804 | |||||
| Letter | en | Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32449091 | 2020-05-24 02:00:00+02:00 | pubmed | Sami Hraiech;Jérémy Bourenne;Khaldoun Kuteifan;Julie Helms;Julien Carvelli;Marc Gainnier;Ferhat Meziani;Laurent Papazian | 2020-05-24 02:00:00+02:00 | 32449091 | FR | Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, Hôpital Nord, 13015, Marseille, France. sami.hraiech@ap-hm.fr.;Faculté de médecine, Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, Marseille, 13005, France. sami.hraiech@ap-hm.fr.;Faculté de médecine, Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, Marseille, 13005, France.;Assistance Publique - Hôpitaux de Marseille, Hôpital Timone, Médecine Intensive Réanimation, 13005, Marseille, France.;Réanimation Médicale, GHR Mulhouse Sud Alsace, 68100, Mulhouse, France.;Service de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, Strasbourg, France.;Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, Hôpital Nord, 13015, Marseille, France. | 822 | ||||||||
| Letter | en | Specific organization for in-hospital belatacept infusion to avoid nosocomial transmission during the SARS-CoV-2 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32449188 | 2020-05-24 02:00:00+02:00 | pubmed | Nassim Kamar;Laure Esposito;Anne L Hebral;Joelle Guitard;Arnaud Del Bello | clinical research/practice;complication: infectious;immunosuppressant-fusion proteins and monoclonal antibodies: belatacept;immunosuppression/immune modulation;infectious disease | 2020-05-24 02:00:00+02:00 | 32449188 | FR | Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.;INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.;Université Paul Sabatier, Toulouse, France. | 823 | |||||||
| 10.1016/j.purol.2020.05.007 | Journal Article | en | COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. | https://www.ncbi.nlm.nih.gov/pubmed/32620366 | COVID-19 is the pandemic that hit the world starting December 2019. Recent studies and international statistics have shown an increased prevalence, morbidity as well as mortality of this disease in male patients compared to female patients. The aim of this brief communication is to describe the pathophysiology of this sex-discrepancy, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2 (ACE2), the Type II transmembrane Serine Protease (TMPRSS2), and the androgen receptor. This could help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy. | 1166-7087 | 2020-05-24 02:00:00+02:00 | pubmed | Progrès en Urologie | G Mjaess;A Karam;F Aoun;S Albisinni;T Roumeguère | Angiotensin-Converting Enzyme 2;COVID-19;Enzyme de conversion de l’angiotensine 2;Récepteur aux androgènes;Sérine protéase transmembranaire 2;Type II Transmembrane Serine Protease;androgen receptor | 2020-05-22 02:00:00+02:00 | 32620366 | FR;LB;BE | Urology Department, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium, Hotel-Dieu de France, University of Saint-Joseph, Beirut, Lebanon.;Hotel-Dieu de France, University of Saint-Joseph, Beirut, Lebanon.;Hotel-Dieu de France, University of Saint-Joseph, Beirut, Lebanon, Urology Department, Institut Jules-Bordet, Brussels, Belgium.;Urology Department, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.;Urology Department, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium, Urology Department, Institut Jules-Bordet, Brussels, Belgium. Electronic address: thierry.roumeguere@erasme.ulb.ac.be. | 831 | |||
| 10.1212/nxi.0000000000000777 | Case Reports;Journal Article | en | COVID-19-White matter and globus pallidum lesions: Demyelination or small-vessel vasculitis? | https://www.ncbi.nlm.nih.gov/pubmed/32444427 | 2332-7812 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnosis;Demyelinating Diseases__virology;Female;Globus Pallidus__virology;Humans;Middle Aged;Nervous System Malformations__virology;Pandemics;Pneumonia, Viral__diagnosis;Vasculitis__diagnosis;White Matter__pathology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Neurology - Neuroimmunology Neuroinflammation | Gilles Brun;Jean-François Hak;Stéphanie Coze;Elsa Kaphan;Julien Carvelli;Nadine Girard;Jan-Patrick Stellmann | 2020-05-22 02:00:00+02:00 | 32444427 | FR;GB | From the APHM (G.B., J.-F.H., S.C., N.G., J.-P.S.), Neuroradiology Department, La Timone University Hospital, APHM (E.K.), Department of Neurology, La Timone University Hospital, APHM (J.C.), Intensive Care Unit, La Timone University Hospital, Aix-Marseille University (N.G.), UMR CNRS 7339, and APHM (J.-P.S.), La Timone University Hospital, CEMEREM, Marseille, France. gilles.brun@ap-hm.fr.;From the APHM (G.B., J.-F.H., S.C., N.G., J.-P.S.), Neuroradiology Department, La Timone University Hospital, APHM (E.K.), Department of Neurology, La Timone University Hospital, APHM (J.C.), Intensive Care Unit, La Timone University Hospital, Aix-Marseille University (N.G.), UMR CNRS 7339, and APHM (J.-P.S.), La Timone University Hospital, CEMEREM, Marseille, France. | 836 | ||||
| 10.1007/s00431-020-03690-9 | Journal Article | en | The EPICENTRE (ESPNIC Covid pEdiatric Neonatal Registry) initiative: background and protocol for the international SARS-CoV-2 infections registry. | https://www.ncbi.nlm.nih.gov/pubmed/32440887 | The outbreak of SARS-CoV-2 is the worst healthcare emergency of this century, and its impact on pediatrics and neonatology is still largely unknown. The European Society for Pediatric and Neonatal Intensive Care (ESPNIC) launched the EPICENTRE (ESPNIC Covid pEdiatric Neonatal Registry) international, multicenter, and multidisciplinary initiative to study the epidemiology, clinical course, and outcomes of pediatric and neonatal SARS-CoV-2 infections. EPICENTRE background and aims are presented together with protocol details. EPICENTRE is open to centers all over the world, and this will allow to provide a pragmatic picture of the epidemic, with a particular attention to pediatric and neonatal critical care issues.Conclusions: EPICENTRE will allow researchers to clarify the epidemiology, clinical presentation, and outcomes of pediatric and neonatal SARS-CoV-2 infection, refining its clinical management and hopefully providing new insights for clinicians. What is Known: • COVID19 is the new disease caused by SARS-CoV-2 infection and is spreading around the globe. • Majority of data available about SARS-CoV-2 infections originates from adult patients. What is New: • EPICENTRE is the first international, multicenter, multidisciplinary, meta-data driven, hospital-based, online, prospective cohort registry dedicated to neonatal and pediatric SARS-CoV-2 infections. • EPICENTRE will allow to understand epidemiology and physiopathology of COVID19. | 0340-6199,1432-1076 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Child, Preschool;Clinical Protocols;Coronavirus Infections__diagnosis;Europe__epidemiology;Humans;Infant;Infant, Newborn;Pandemics;Pediatrics;Pneumonia, Viral__diagnosis;Prognosis;Public Health Surveillance__methods;Registries;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Pediatrics | Daniele De Luca;Lucilla Rava;Simon Nadel;Pierre Tissieres;Orsola Gawronski;Elisabeth Perkins;Giovanna Chidini;David G Tingay | Children;Coronavirus;Database;Neonate;Outbreak;Pandemic | 2020-05-22 02:00:00+02:00 | 32440887 | FR;GB;US;IT;AU | Division of Pediatrics and Neonatal Critical Care, Paris Saclay University Hospital-APHP & Paris Saclay University, Paris, France. dm.deluca@icloud.com.;Unit of Clinical Epidemiology, "Bambino Gesu" Children Hospital-IRCCS, Rome, Italy.;Paediatric Intensive Care Unit, Imperial College Healthcare NHS Trust, London, UK.;Division of Pediatric Critical Care, Paris Saclay University Hospital-APHP & Paris Saclay University, Paris, France.;Continuing Education and Nursing Research Unit, "Bambino Gesu" Children Hospital-IRCCS, Rome, Italy.;Neonatal Research, Murdoch Children's Research Institute, Melbourne, VIC, Australia.;Pediatric Intensive Care Unit, Department of Anesthesia, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. | 837 | ||
| 10.1111/1469-8676.12887 | Journal Article | en | Partying at times of crises and pandemics: solidarity, resilience and coping with the measures against COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32836967 | 0964-0282,1469-8676 | 2020-05-24 02:00:00+02:00 | pubmed | Social Anthropology | Panas Karampampas | 2020-05-22 02:00:00+02:00 | 32836967 | FR | Institut interdisciplinaire d'anthropologie du contemporain (IIAC) École des hautes études en sciences sociales (EHESS) 75006 Paris France. | 841 | |||||
| Journal Article;Comment | en | How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. | https://www.ncbi.nlm.nih.gov/pubmed/32441741 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Edetic Acid;Expert Testimony;Humans;Immunosuppression;Kidney Transplantation;Pandemics;Pneumonia, Viral;Transplant Recipients;COVID-19;severe acute respiratory syndrome coronavirus 2 | Umberto Maggiore;Daniel Abramowicz;Marta Crespo;Christophe Mariat;Geir Mjoen;Licia Peruzzi;Mehmet Sükrü Sever;Gabriel C Oniscu;Luuk Hilbrands;Bruno Watschinger | 2020-05-23 02:00:00+02:00 | 32441741 | FR;NO;GB;IT;TR;NL;ES;BE;AT | Dipartimento di Medicina e Chrurgia, Università d Parma, UO Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.;Department of Nephrology, Antwerp University Hospital, Antwerp University, Antwerp, Belgium.;Department of Nephrology, Hospital del Mar Barcelona, Barcelona, Spain.;Department of Nephrology, Dialysis, and Renal Transplantation, University North Hospital, Saint Etienne, France.;Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway.;Pediatric Nephrology Unit, Regina Margherita Children's Hospital, Turin, Italy.;Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.;Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.;Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.;Department of Nephrology, Medical University of Vienna, Vienna, Austria. | 850 | |||||||
| 10.1126/sciimmunol.abc6347 | Journal Article;Research Support, Non-U.S. Gov't | en | Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. | https://www.ncbi.nlm.nih.gov/pubmed/32430309 | Serological testing for SARS-CoV-2 has enormous potential to contribute to COVID-19 pandemic response efforts. However, the required performance characteristics of antibody tests will critically depend on the use case (individual-level vs. population-level). | 2470-9468 | 2020-05-24 02:00:00+02:00 | pubmed | Antibodies, Viral__analysis;Betacoronavirus__immunology;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Epidemiological Monitoring;Humans;Pandemics;Pneumonia, Viral__immunology;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Science Immunology | Juliet E Bryant;Andrew S Azman;Matthew J Ferrari;Benjamin F Arnold;Maciej F Boni;Yap Boum;Kyla Hayford;Francisco J Luquero;Michael J Mina;Isabel Rodriguez-Barraquer;Joseph T Wu;Djibril Wade;Guy Vernet;Daniel T Leung | 2020-05-21 02:00:00+02:00 | 32430309 | CF;FR;CN;SN;CH;US;CM;HK | Laboratory of Emerging Pathogens, Fondation Mérieux, Lyon, France.;Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.;Médecins Sans Frontières, Geneva, Switzerland.;Department Biology, Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA, USA.;Francis I Proctor Foundation, University of California San Francisco, CA, USA.;Epicentre, Yaounde, Cameroon.;Epicentre, Paris, France.;Departments of Epidemiology and of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA USA.;School of Medicine, University of California San Francisco, CA, USA.;WHO Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.;IRESSEF (Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation), Dakar, Senegal.;Institut Pasteur de Bangui, Bangui, Central African Republic.;Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, UT, USA daniel.leung@utah.edu. | 853 | |||
| 10.1093/jac/dkaa193 | Case Reports;Journal Article | en | COVID-19 infection also occurs in patients taking hydroxychloroquine. | https://www.ncbi.nlm.nih.gov/pubmed/32417904 | 0305-7453,1460-2091 | 2020-05-24 02:00:00+02:00 | pubmed | Arthritis, Rheumatoid__complications;Betacoronavirus;Coronavirus Infections__diagnosis;Female;Humans;Hydroxychloroquine__blood;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Antimicrobial Chemotherapy | M Lahouati;E Mériglier;L Martin;S Bouchet;A Desclaux;F Bonnet | 2020-05-18 02:00:00+02:00 | 32417904 | FR | CHU de Bordeaux, Hôpital Saint-André, Service de Médecine Interne et Maladies Infectieuses, F-33000 Bordeaux, France.;CHU de Bordeaux, Hôpital Saint-André, Service de Pharmacie Clinique, F-33000 Bordeaux, France.;CHU de Bordeaux, Hôpital Pellegrin, Service de Maladies Infectieuses et Tropicales, F-33000 Bordeaux, France.;CHU de Bordeaux, Hôpital Pellegrin, Service de Pharmacologie, F-33000 Bordeaux, France.;Université de Bordeaux, Bordeaux Population Health, INSERM U1219, F-33000 Bordeaux, France. | 861 | ||||
| 10.1371/journal.ppat.1008556 | Journal Article | en | Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32437478 | 1553-7374 | 2020-05-24 02:00:00+02:00 | pubmed | ABO Blood-Group System;Betacoronavirus;Coronavirus Infections__immunology;Glycosylation;Humans;Immunity, Innate;Pandemics;Peptidyl-Dipeptidase A;Pneumonia, Viral__immunology;Polysaccharides__immunology;Spike Glycoprotein, Coronavirus__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | PLOS Pathogens | Adrien Breiman;Nathalie Ruvën-Clouet;Jacques Le Pendu | 2020-05-21 02:00:00+02:00 | 32437478 | FR | Université de Nantes, Inserm, CRCINA, Nantes, France.;CHU de Nantes, Nantes, France.;Oniris, Ecole Nationale Vétérinaire, Agroalimentaire et de l'Alimentation, Nantes, France. | 864 | ||||
| Letter;Comment | en | Obesity is Associated with Severe Forms of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32314861 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Obesity;Pandemics;Pneumonia, Viral;Prevalence;Respiration, Artificial;SARS Virus;Severe Acute Respiratory Syndrome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cyrielle Caussy;Florent Wallet;Martine Laville;Emmanuel Disse | 2020-05-21 02:00:00+02:00 | 32314861 | FR | CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France.;Département Endocrinologie, Diabète et Nutrition, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.;Medical Intensive Care Unit, Hôpital Lyon-Sud, Lyon, France.;F CRIN/FORCE Network, Centre de Recherche en Nutrition Humaine Rhône-Alpes, Lyon, France. | 865 | |||||||
| 10.1002/hed.26279 | Journal Article | en | Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32437033 | To investigate olfactory dysfunction (OD) in patients with mild coronavirus disease 2019 (COVID-19) through patient-reported outcome questionnaires and objective psychophysical testing. | 1043-3074,1097-0347 | 2020-05-24 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections__complications;Female;Humans;Male;Middle Aged;Olfaction Disorders__diagnosis;Pandemics;Patient Reported Outcome Measures;Pneumonia, Viral__complications;Self Report;Surveys and Questionnaires;COVID-19;severe acute respiratory syndrome coronavirus 2 | Head & Neck | Jerome R Lechien;Pierre Cabaraux;Carlos M Chiesa-Estomba;Mohamad Khalife;Stéphane Hans;Christian Calvo-Henriquez;Delphine Martiny;Fabrice Journe;Leigh Sowerby;Sven Saussez | COVID-19;anosmia;coronavirus;evaluation;olfaction;olfactory;smell;taste | 2020-05-21 02:00:00+02:00 | 32437033 | FR;CA;GB;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Marseille, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Department of Neurology, CHU de Charleroi, Charleroi, Belgium.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Head and Neck Surgery, EpiCURA Hospital, Belgium.;Department of Otolaryngology-Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium.;Department of Dean, Faculté de Médecine et Pharmacie, Université de Mons (UMONS), Mons, Belgium.;Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada. | 869 | ||
| 10.1016/j.arbres.2020.05.018 | Case Reports | en | Tracheotomy in patients COVID-19: A necessary high risk procedure. Two center experience. | https://www.ncbi.nlm.nih.gov/pubmed/32586706 | 0300-2896 | 2020-05-31 02:00:00+02:00 | pubmed | Archivos de Bronconeumología | Elisabeth Martínez-Téllez;César Orús Dotú;Juan Carlos Trujillo-Reyes;Mauro Guarino;Esther Cladellas Gutiérrez;Georgina Planas Cánovas;Joaquim Ramón Cervelló;Alex Carvi Mallo;María Del Prado Venegas Pizarro;Xavier León Vintró;Josep Belda-Sanchis | 2020-05-31 02:00:00+02:00 | 32586706 | FR;ES | Servicio de Cirugía Torácica. Hospital de la Santa Creu i Sant Pau, Barcelona, España, Servicio de Cirugía Torácica. Hospital HM Delfos, Barcelona, España, Departamento de Cirugía, Facultad de Medicina, Universitat Autònoma de Barcelona (UAB), España. Electronic address: emartinezt@santpau.cat.;Servicio de Otorrinolaringología. Hospital de la Santa Creu i Sant Pau, Barcelona, España, Departamento de Cirugía, Facultad de Medicina, Universitat Autònoma de Barcelona (UAB), España.;Servicio de Cirugía Torácica. Hospital de la Santa Creu i Sant Pau, Barcelona, España, Servicio de Cirugía Torácica. Hospital HM Delfos, Barcelona, España, Departamento de Cirugía, Facultad de Medicina, Universitat Autònoma de Barcelona (UAB), España.;Servicio de Cirugía Torácica. Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Servicio de Medicina Intensiva. Hospital HM Delfos, Barcelona, España.;Servicio de Anestesiología, Reanimación y Clínica del Dolor. Hospital HM Delfos, Barcelona, España.;Servicio de Otorrinolaringología. Hospital de la Santa Creu i Sant Pau, Barcelona, España. | 874 | |||||
| 10.1007/s40620-020-00756-7 | Editorial | en | Nothing will ever be as before. Reflections on the COVID-19 epidemics by nephrologists in eleven countries. | https://www.ncbi.nlm.nih.gov/pubmed/32451809 | 1121-8428,1724-6059 | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Middle Aged;Nephrologists;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Nephrology | Giovanni Gambaro;Giorgina B Piccoli | 2020-05-27 02:00:00+02:00 | 32451809 | FR;IT | Nephrology, University of Verona, Verona, Italy.;Centre Hospitalier Le Mans, Le Mans, France. gbpiccoli@yahoo.it.;Dipartimento di Scienze Cliniche e Biologiche, University of Torino, Turin, Italy. gbpiccoli@yahoo.it. | 875 | ||||
| Letter;Comment | en | Impact of Potential Physiological Changes due to COVID-19 Home Confinement on Athlete Health Protection in Elite Sports: a Call for Awareness in Sports Programming. | https://www.ncbi.nlm.nih.gov/pubmed/32468329 | 2020-05-31 02:00:00+02:00 | pubmed | Athletes;Athletic Injuries;Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Sports;COVID-19;severe acute respiratory syndrome coronavirus 2 | F Sarto;F M Impellizzeri;J Spörri;S Porcelli;J Olmo;B Requena;L Suarez-Arrones;A Arundale;J Bilsborough;M Buchheit;J Clubb;A Coutts;D Nabhan;L Torres-Ronda;A Mendez-Villanueva;I Mujika;N A Maffiuletti;M V Franchi | Detraining;Elite athletes;Injury prevention;Injury risk;Skeletal muscle | 2020-05-30 02:00:00+02:00 | 32468329 | FR;CL;CH;US;GB;QA;IT;AU;ES | Department of Biomedical Sciences, Institute of Physiology, University of Padua, Padua, Italy.;Human Performance Research Centre, Faculty of Health, University of Technology Sydney, Sydney, Australia.;Sports Medical Research Group, Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.;Department of Molecular Medicine, University of Pavia, Pavia, Italy.;Sports Medicine Physician Team, Alpine Ski and Snowboard Team, Italian Winter Sports Federation, Milan, Italy.;Football Science Institute, Granada, Spain.;FC Basel 1983, Basel, Switzerland.;Brooklyn Nets, NBA, Brooklyn, NY, USA.;New England Patriots, NFL, Foxborough, MA, USA.;Myorobie Performance, Montvalezan, France.;Buffalo Bills, NFL, Buffalo, NY, USA.;US Olympic and Paralympic Committee, Colorado Springs, CO, USA.;Philadelphia 76ers, NBA, Philadelphia, PA, USA.;Qatar Football Association, Doha, Qatar.;Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country, Leioa, Basque Country, Spain.;Exercise Science Laboratory, School of Kinesiology, Faculty of Medicine, Universidad Finis Terrae, Santiago, Chile.;Human Performance Lab, Schulthess Clinic, Zurich, Switzerland.;Department of Biomedical Sciences, Institute of Physiology, University of Padua, Padua, Italy. martino.franchi@unipd.it. | 884 | ||||||
| Letter | en | Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. | https://www.ncbi.nlm.nih.gov/pubmed/32475831 | 2020-05-31 02:00:00+02:00 | pubmed | Lionel Carbillon;Amélie Benbara;Jeremy Boujenah | autoimmunity;epidemiology;hydroxychloroquine;immune complex diseases;lupus erythematosus, systemic | 2020-05-31 02:00:00+02:00 | 32475831 | FR | Obstetrics and Gynecology, Assistance Publique - Hopitaux de Paris, Bondy, France lionel.carbillon@aphp.fr.;Obstetrics and Gynecology, Sorbonne Paris Nord University, Bondy, France.;Obstetrics and Gynecology, Assistance Publique - Hopitaux de Paris, Bondy, France. | 889 | |||||||
| Case Reports;Letter | en | Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukaemia. | https://www.ncbi.nlm.nih.gov/pubmed/32369614 | 2020-05-31 02:00:00+02:00 | pubmed | Arterial Occlusive Diseases__blood;Betacoronavirus;Computed Tomography Angiography;Coronavirus Infections__blood;Fatal Outcome;Female;Hemorrhage__blood;Humans;Leukemia, Promyelocytic, Acute__blood;Middle Aged;Pandemics;Pneumonia, Viral__blood;Syndrome;Thrombosis__blood;COVID-19;severe acute respiratory syndrome coronavirus 2 | Mathieu Baldacini;Raoul Pop;Laurent Sattler;Laurent Mauvieux;Karin Bilger;Justine Gantzer;Francis Schneider;Remy Beaujeux;Célestine Simand;Raoul Herbrecht | 2020-05-26 02:00:00+02:00 | 32369614 | FR | Service de Médecine Intensive et Réanimation, University Hospitals of Strasbourg, Strasbourg, France.;Service de Neuroradiologie Interventionnelle, University Hospitals of Strasbourg, Strasbourg, France.;Laboratoire d'Hématologie, University Hospitals of Strasbourg, Strasbourg, France.;Département d'Oncologie et Hématologie, Institut de Cancérologie Strasbourg. Europe (ICANS), Strasbourg, France. | 892 | |||||||
| 10.1016/j.jbspin.2020.05.006 | Journal Article | en | Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32473418 | Rheumatologists must contend with COVID-19 pandemic in the management of their patients and many questions have been raised on the use of both anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARD). The French Society of Rheumatology (SFR) selected the most critical ones to the daily practice of a rheumatologist and a group of 10 experts from SFR and Club Rheumatism and Inflammation (CRI) boards proposed responses based on the current knowledge of May 2020. | 1297-319X | 2020-05-31 02:00:00+02:00 | pubmed | Joint Bone Spine | Christophe Richez;René-Marc Flipo;Francis Berenbaum;Alain Cantagrel;Pascal Claudepierre;Françoise Debiais;Philippe Dieudé;Philippe Goupille;Christian Roux;Thierry Schaeverbeke;Daniel Wendling;Thao Pham;Thierry Thomas | COVID-19;Health system;Inflammatory rheumatic diseases;Treatment | 2020-05-27 02:00:00+02:00 | 32473418 | FR | Centre Hospitalier Universitaire de Bordeaux, FHU ACRONIM, place Amélie-Raba-Léon, 33076 Bordeaux, France.;Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Lille, Hôpital Roger Salengro, rue du Professeur-Emile-Laine, 59037 Lille cedex, France.;Service de Rhumatologie, Centre Hospitalier Universitaire Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 755571 Paris cedex 12, France.;Service de Rhumatologie, Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France.;Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, 51 avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France.;Service de Rhumatologie, Centre Hospitalier Universitaire, 2, rue de la Milétrie, BP 577, 86021 Poitiers cedex, France.;Service de Rhumatologie, Groupe Hospitalier Universitaire Bichat-Claude Bernard, 46, rue Henri-Huchard, 75018 Paris, France.;Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Tours, Hôpital Trousseau, 37044 Tours cedex 9, France.;Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, 27, rue du Faubourg-Saint-Jacques, 75679 Paris cedex 14, France.;Service de Rhumatologie, Centre Hospitalier Universitaire Jean-Minjoz, 1, boulevard Fleming, 25030 Besançon cedex, France.;Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, 270, boulevard de Sainte-Marguerite, 13274 Marseille cedex 9, France.;Department of Rheumatology, Hôpital Nord, CHU Saint-Étienne, Inserm U1059, Université de Lyon-Université Jean-Monnet, Saint-Étienne, France. Electronic address: thierry.thomas@chuse.fr. | 895 | |||
| 10.3390/nu12061562 | Journal Article;Review | en | Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32471251 | The coronavirus-disease 2019 (COVID-19) was announced as a global pandemic by the World Health Organization. Challenges arise concerning how to optimally support the immune system in the general population, especially under self-confinement. An optimal immune response depends on an adequate diet and nutrition in order to keep infection at bay. For example, sufficient protein intake is crucial for optimal antibody production. Low micronutrient status, such as of vitamin A or zinc, has been associated with increased infection risk. Frequently, poor nutrient status is associated with inflammation and oxidative stress, which in turn can impact the immune system. Dietary constituents with especially high anti-inflammatory and antioxidant capacity include vitamin C, vitamin E, and phytochemicals such as carotenoids and polyphenols. Several of these can interact with transcription factors such as NF-kB and Nrf-2, related to anti-inflammatory and antioxidant effects, respectively. Vitamin D in particular may perturb viral cellular infection via interacting with cell entry receptors (angiotensin converting enzyme 2), ACE2. Dietary fiber, fermented by the gut microbiota into short-chain fatty acids, has also been shown to produce anti-inflammatory effects. In this review, we highlight the importance of an optimal status of relevant nutrients to effectively reduce inflammation and oxidative stress, thereby strengthening the immune system during the COVID-19 crisis. | 2072-6643 | 2020-05-31 02:00:00+02:00 | pubmed | Antioxidants;Betacoronavirus;Coronavirus Infections__immunology;Diet;Humans;Immune System__immunology;Inflammation__immunology;Nutrients__immunology;Nutritional Status__immunology;Oxidative Stress__immunology;Pandemics;Pneumonia, Viral__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nutrients | Mohammed Iddir;Alex Brito;Giulia Dingeo;Sofia Sosa Fernandez Del Campo;Hanen Samouda;Michael R La Frano;Torsten Bohn | coronavirus;cytokines;infection;innate immune system;macronutrients;nuclear factors;nutrient;protein intake;reactive oxygen species;trace elements;transcription factors | 2020-05-27 02:00:00+02:00 | 32471251 | FR;RU;LU;US | Nutrition and Health Research Group, Population Health Department, Luxembourg Institute of Health, 1A-B, rue Thomas Edison, L-1445 Strassen, Luxembourg.;Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology. I.M. Sechenov First Moscow Medical University, Trubetskay Str. 8, 119991 Moscow, Russia.;Independent Researcher, Val de Marne, 94999 Paris, France.;Department of Food Science and Nutrition, California Polytechnic State University, 1 Grand Avenue, San Luis Obispo, CA 93407, USA.;Center for Health Research, California Polytechnic State University, 1 Grand Avenue, San Luis Obispo, CA 93407, USA. | 900 | ||
| 10.1186/s13601-020-00323-0 | Journal Article;Review | en | Is diet partly responsible for differences in COVID-19 death rates between and within countries? | https://www.ncbi.nlm.nih.gov/pubmed/32499909 | Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely used in these countries may reduce angiotensin-converting enzyme activity or are anti-oxidants. Among the many possible areas of research, it might be important to understand diet and angiotensin-converting enzyme-2 (ACE2) levels in populations with different COVID-19 death rates since dietary interventions may be of great benefit. | 2045-7022 | 2020-05-31 02:00:00+02:00 | pubmed | Clinical and Translational Allergy | Jean Bousquet;Josep M Anto;Guido Iaccarino;Wienczyslawa Czarlewski;Tari Haahtela;Aram Anto;Cezmi A Akdis;Hubert Blain;G Walter Canonica;Victoria Cardona;Alvaro A Cruz;Maddalena Illario;Juan Carlos Ivancevich;Marek Jutel;Ludger Klimek;Piotr Kuna;Daniel Laune;Désirée Larenas-Linnemann;Joaquim Mullol;Nikos G Papadopoulos;Oliver Pfaar;Boleslaw Samolinski;Arunas Valiulis;Arzu Yorgancioglu;Torsten Zuberbier | Angiotensin-converting enzyme;Antioxidant;Coronavirus;Diet;Food | 2020-05-27 02:00:00+02:00 | 32499909 | FR;AR;LT;FI;GR;CH;GB;US;BR;IT;PL;TR;ES;MX;PS;DE | Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.;Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany.;MACVIA-France, Montpellier, France.;CHU Montpellier, 273 Avenue d'Occitanie, 34090 Montpellier, France.;Centre for Research in Environmental Epidemiology (CREAL), ISGlobAL, Barcelona, Spain.;IMIM (Hospital del Mar Research Institute), Barcelona, Spain.;Universitat Pompeu Fabra (UPF), Barcelona, Spain.;CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.;Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.;MASK-air, Montpellier, France.;Medical Consulting Czarlewski, Levallois, France.;Helsinki University, Helsinki, Finland.;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.;Department of Geriatrics, Montpellier University Hospital, Montpellier, France.;EA 2991, Euromov, University Montpellier, Montpellier, France.;Personalized Medicine Clinic Asthma & Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milan Italy.;Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL research network, Barcelona, Spain.;ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil.;WHO GARD Planning Group, Salvador, Brazil.;Division for Health Innovation, Campania Region, Naples, Italy.;Federico II University Hospital Naples (R&D and DISMET), Naples, Italy.;Clinica Santa Isabel, Servicio de Alergia e Immunologia, Buenos Aires, Argentina.;Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland.;Center for Rhinology and Allergology, Wiesbaden, Germany.;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Łódź, Poland.;KYomed INNOV, Montpellier, France.;Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.;Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.;Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.;Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital "P&A Kyriakou,", University of Athens, Athens, Greece.;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Marburg, Germany.;Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.;Institute of Clinical Medicine & Institute of Health Sciences, Vilnius University Faculty of Medicine, Vilnius, Lithuania.;Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey. | 905 | |||
| 10.1016/j.adro.2020.04.039 | Journal Article;Review | en | Radiation Therapy Department Reorganization during the Coronavirus Disease 2019 (COVID-19) Outbreak: Keys to Securing Staff and Patients During the First Weeks of the Crisis and Impact on Radiation Therapy Practice from a Single Institution Experience. | https://www.ncbi.nlm.nih.gov/pubmed/32775775 | During the first weeks of the coronavirus disease 2019 (COVID-19) outbreak in France, it was necessary to clearly define organizational priorities in the radiation therapy (RT) departments. In this report, we focus on the urgent measures taken to reduce risk for both our staff and patients by reducing the number of patients receiving treatment. | 2452-1094 | 2020-05-31 02:00:00+02:00 | pubmed | Advances in Radiation Oncology | Yazid Belkacemi;Gokoulakrichenane Loaganadane;Noémie Grellier;Gloria Fonteneau;Gaël Zaoui;Gabriele Coraggio;Asma Hadhri;Marie Adou;Jerôme Bendavid;Angela Boros;Sahar Ghith;Kamel Debbi;Pauline Cadot;Adeline Bak;Cindy Le Bret;Wissal Hassani;Mathilde Mahé;Marie-Laure Hervé;Laurianne Colson-Durand;Nhu Hanh To;Deng Feng Luo;Aziz Cherif | 2020-05-27 02:00:00+02:00 | 32775775 | FR | Assistance Publique Hopitaux de Paris (APHP), Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, Creteil, France.;Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM), U955 Team 21, and University Paris-Est Creteil (UPEC), Paris, France.;Association of Radiotherapy and Oncology of the Mediterranean Area (AROME), Paris, France.;TransAtlantic Radiation Oncology Network (TRONE), Paris, France. | 915 | ||||
| 10.2139/ssrn.3611280 | Preprint | en | The Heterogeneous Landscape and Early Evolution of Pathogen-Associated CpG Dinucleotides in SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32714120 | SARS-CoV-2 infection can lead to acute respiratory syndrome in patients, which can be due in part to dysregulated immune signalling. We analyze here the occurrences of CpG dinucleotides, which are putative pathogen-associated molecular patterns, along the viral sequence. Carrying out a comparative analysis with other ssRNA viruses and within the Coronaviridae family, we find the CpG content of SARS-CoV-2, while low compared to other betacoronaviruses, widely fluctuates along its primary sequence. While the CpG relative abundance and its associated CpG force parameter are low for the spike protein (S) and comparable to circulating seasonal coronaviruses such as HKU1, they are much greater and comparable to SARS and MERS for the 3'-end of the viral genome. In particular, the nucleocapsid protein (N), whose transcripts are relatively abundant in the cytoplasm of infected cells and present in the 3'UTRs of all subgenomic RNA, has high CpG content. We speculate this dual nature of CpG content can confer to SARS-CoV-2 high ability to both enter the host and trigger pattern recognition receptors (PRRs) in different contexts. We then investigate the evolution of synonymous mutations since the outbreak of the COVID-19 pandemic. Using a new application of selective forces on dinucleotides to estimate context driven mutational processes, we find that synonymous mutations seem driven both by the viral codon bias and by the high value of the CpG force in the N protein, leading to a loss in CpG content. Sequence motifs preceding these CpG-loss-associated loci match recently identified binding patterns of the Zinc Finger anti-viral Protein (ZAP) protein. Funding: This work was partially supported by the ANR19 Decrypted CE30-0021-01 grants. B.G. was supported by National Institutes of Health grants 7R01AI081848-04, 1R01CA240924-01, a Stand Up to Cancer - Lustgarten Foundation Convergence Dream Team Grant, and The Pershing Square Sohn Prize - Mark Foundation Fellow supported by funding from The Mark Foundation for Cancer Research. | 1556-5068 | 2020-05-31 02:00:00+02:00 | pubmed | SSRN Electronic Journal | Andrea Di Gioacchino;Petr Sulc;Anastassia V Komarova;Benjamin D Greenbaum;Rémi Monasson;Simona Cocco | CpG motifs;SARS-CoV-2;evolution of synonymous mutations;pathogen-associated molecular patterns (PAMPs);pattern recognition receptors (PRRs);ssRNA viruses;viral host mimicry | 2020-05-27 02:00:00+02:00 | 32714120 | FR;UNK | Laboratoire de Physique de l'École Normale Supérieure.;School of Molecular Sciences.;Institut Pasteur.;Memorial Sloan Kettering Cancer Center. | 917 | |||
| Letter;Comment | en | SARS-CoV-2 RT-PCR: at least 2 viral targets are needed. | https://www.ncbi.nlm.nih.gov/pubmed/32449639 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Negative Results;Pandemics;Pneumonia, Viral;Reverse Transcriptase Polymerase Chain Reaction;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eric Farfour;Emilie Jolly;Tiffany Pascreau;Marianne Asso-Bonnet;Laurence Mazaux;Marc Vasse | 2020-05-25 02:00:00+02:00 | 32449639 | FR | Service de biologie Clinique, Hôpital Foch, Suresnes, France. | 921 | |||||||
| 10.1136/annrheumdis-2020-217859 | Journal Article | en | Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli et al. | https://www.ncbi.nlm.nih.gov/pubmed/32451345 | 0003-4967,1468-2060 | 2020-05-31 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Alexis Mathian;Zahir Amoura | autoimmune diseases;hydroxychloroquine;lupus erythematosus, systemic | 2020-05-25 02:00:00+02:00 | 32451345 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@psl.aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 922 | ||||
| 10.4081/mrm.2020.672 | Journal Article | en | SARS-CoV-2 pandemic in Italy: ethical and organizational considerations. | https://www.ncbi.nlm.nih.gov/pubmed/32499910 | The current SARS-CoV-2 pandemic is still raging in Italy. The country is currently plagued by a huge burden of virusrelated cases and deaths. So far, the disease has highlighted a number of problems, some in common with other Countries and others peculiar to Italy which has suffered from a mortality rate higher than that observed in China and in most Countries in the world. The causes must be sought not only in the average age of the population (one of the oldest in the world), but also in the inconsistencies of the regional health systems (into which the National Health System is divided) and their delayed response, at least in some areas. Ethical issues emerged from the beginning, ranging from restrictions on freedom of movements and restrictions on personal privacy due to the lockdown, further to the dilemma for healthcare professionals to select people for ICU hospitalization in a shortage of beds in Intensive Care Unit (ICU). Organizational problems also emerged, although an official 2007 document from the Ministry of Health had planned not only what measures had to be taken during an epidemic caused by respiratory viruses, but also what had to be done in the inter-epidemic period (including the establishment of DPIs stocks and ventilators), vast areas of Italy were totally unprepared to cope with the disease, as a line of that document was not implemented. Since organizational problems can worsen (and even cause) ethical dilemmas, every effort should be made in the near future to prepare the health system to respond to a similar emergency in a joint, coherent, and homogeneous way across the Country, as planned in the 2007 document. In this perspective, Pulmonary Units and specialists can play a fundamental role in coping with the disease not only in hospitals, as intermediate care units, but also at a territorial level in an integrated network with GPs. | 2049-6958,1828-695X | 2020-05-31 02:00:00+02:00 | pubmed | Multidisciplinary Respiratory Medicine | Stefano Nardini;Claudio M Sanguinetti;Fernando De Benedetto;Claudio Baccarani;Mario Del Donno;Mario Polverino;Isabella Annesi-Maesano | ICU beds;SARS-CoV-2;ethical and organizational issues;intermediate respiratory care;mortality rate | 2020-05-25 02:00:00+02:00 | 32499910 | FR;IT | Italian Respiratory Society Research Centre, Milan, Italy.;Business Management, University of Verona, Italy.;Pneumology Unit, A.O.R.N. "San Pio" - P.O. "G. Rummo", Benevento, Italy.;Endoscopic Unit, Pulmonary Division, Hospital M. Scarlato, Scafati (SA), Italy.;INSERM and Epidemiology of Allergic and Respiratory Diseases Department, Sorbonne University, IPLESP, Paris, France. | 925 | |||
| Letter | en | Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32449789 | 2020-05-31 02:00:00+02:00 | pubmed | Van T Hoang;Thi L Dao;Philippe Gautret | 2020-05-25 02:00:00+02:00 | 32449789 | FR;VN | IRD, AP-HM, SSA, VITROME, Aix Marseille University, Marseille, France.;IHU-Méditerranée Infection, Marseille, France.;Thai Binh University of Medicine and Pharmacy, Thai Binh, Viet Nam. | 928 | ||||||||
| Letter | en | Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage. | https://www.ncbi.nlm.nih.gov/pubmed/32295896 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Equipment and Supplies;Humans;Nasopharynx__virology;Pandemics;Pneumonia, Viral__diagnosis;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Hélène Péré;Isabelle Podglajen;Maxime Wack;Edouard Flamarion;Tristan Mirault;Guillaume Goudot;Caroline Hauw-Berlemont;Laetitia Le;Eric Caudron;Sophie Carrabin;Julien Rodary;Tatiana Ribeyre;Laurent Bélec;David Veyer | COVID-19;RT-PCR;SARS-CoV-2;molecular diagnosis;nasal swab;nasopharyngeal swab | 2020-05-26 02:00:00+02:00 | 32295896 | FR | Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;INSERM U970, PARCC, Hôpital Européen Georges Pompidou, Faculté de Médecine, Université de Paris, Paris, France.;Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Faculté de Médecine Paris Descartes, Sorbonne Paris Cité, Université de Paris, Paris, France.;Département d'Informatique Médicale, Biostatistiques et Santé Publique, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Centre de Recherche des Cordeliers, INSERM, UMRS 1138, Université de Paris, Paris, France.;Département de Médecine Interne, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Départment de Médecine Vasculaire, HYPERVASC, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Service de Médecine Intensive-Réanimation, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Laboratoire de Chimie Analytique Pharmaceutique, EA7357, Université Paris Sud-Paris-Saclay, Châtenay-Malabry, France.;Départment de Pharmacie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France david.veyer@aphp.fr.;Unité de Génomique Fonctionnelle des Tumeurs Solides, Centre de Recherche des Cordeliers, INSERM, Université de Paris, Paris, France. | 936 | ||||||
| 10.1007/s11604-020-00988-4 | Journal Article | en | A retrospective study of the initial 25 COVID-19 patients in Luoyang, China. | https://www.ncbi.nlm.nih.gov/pubmed/32458125 | To summarize the chest CT imaging and clinical features of the initial COVID-19 patients and provide a clinical diagnostic method that is more effective and can be performed earlier. | 1867-1071,1867-108X | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Betacoronavirus__pathogenicity;China;Coronavirus Infections__complications;Cough__etiology;Fatigue__etiology;Female;Fever__etiology;Humans;Lung__diagnostic imaging;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Retrospective Studies;Tomography, X-Ray Computed__methods;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Japanese Journal of Radiology | Xiaopei Duan;Xinyu Guo;Jun Qiang | COVID-19 pneumonia;CT;SARS-CoV-2 | 2020-05-26 02:00:00+02:00 | 32458125 | FR;CN | Department of Radiology, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, 471003, China.;State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou, 511436, China.;Department of Radiology, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, 471003, China. 15838815301@163.com. | 939 | ||
| 10.1016/j.rssm.2020.100508 | Journal Article | en | The "Eye of the Hurricane" Paradox: An Unexpected and Unequal Rise of Well-Being During the Covid-19 Lockdown in France. | https://www.ncbi.nlm.nih.gov/pubmed/32834344 | Panel data covering the French population before and after the outbreak of the Covid-19 epidemic reveal that self-reported health and well-being have improved during the lockdown in comparison to previous years. We name this counterintuitive phenomenon the "eye of the hurricane" paradox: the large majority of individuals who are not infected by the virus may be seeing their current condition in a more positive light than they normally would. There are, however, divergences across social groups that reflect socioeconomic inequalities. In particular, blue-collar workers deviate from the prevailing trend as their level of self-reported health declines over the lockdown period, Parisian residents experience a sudden drop in their subjective well-being, and people working long hours at home exhibit higher levels of stress during the quarantine. | 0276-5624 | 2020-05-31 02:00:00+02:00 | pubmed | Research in Social Stratification and Mobility | Ettore Recchi;Emanuele Ferragina;Emily Helmeid;Stefan Pauly;Mirna Safi;Nicolas Sauger;Jen Schradie | Covid-19;Health;Inequality;Stress;Well-being | 2020-05-26 02:00:00+02:00 | 32834344 | FR;IT | Sciences Po, Observatoire sociologique du changement, CNRS, Paris, France.;MPC/EUI, Florence, Italy.;Sciences Po, Department of Economics, Paris, France.;Sciences Po, Center for European Studies and Comparative Politics (CEE) and Center for Socio-Political Data (CDSP), CNRS, Paris, France. | 945 | |||
| Letter;Comment | en | COVID-19 international neurological registries. | https://www.ncbi.nlm.nih.gov/pubmed/32470417 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Registries;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gustavo C Román;Jacques Reis;Peter S Spencer;Alain Buguet;Serefnur Öztürk;Mohammad Wasay | 2020-05-26 02:00:00+02:00 | 32470417 | FR;GB;US;TR;PK | Department of Neurology, Methodist Neurological Institute, Houston Methodist Hospital, Houston, TX 77030, USA, Weill Cornell Medical College, New York, NY, USA, Environmental Neurology Specialty Group, World Federation of Neurology, London, UK. Electronic address: gcroman@houstonmethodist.org.;Faculté de Médecine, Université de Strasbourg, Strasbourg, France, RISE Association, Oberhausbergen, France.;Department of Neurology, School of Medicine, Oregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, OR, USA.;Malaria Research Unit, Claude-Bernard Lyon-1 University, Villeurbanne, France, French Army Health Services, Paris, France.;Department of Neurology, Selcuk University Faculty of Medicine, Konya, Turkey, Turkish Neurological Society, Ankara, Turkey.;Medicine Department, Neurology Section, Aga Khan University, Karachi, Pakistan, Pakistan International Neuroscience Society, Karachi, Pakistan. | 946 | |||||||
| 10.1016/j.jemep.2020.100539 | English Abstract;Journal Article;Review | fr | [Ethical approach to the issue of confinement of the elderly in the context of the COVID-19 pandemic: Prevention of frailty versus risk of vulnerability]. | https://www.ncbi.nlm.nih.gov/pubmed/32835057 | COVID-19 pandemic particularly affects older people and exposes them to a higher risk of mortality. Containment, social distancing and isolation measures have been implemented to limit viral transmission. While there is a clear rationale for reducing the contagiousness of the infection through this means, the adverse consequences of this social isolation, especially for this heterogeneous, aged and frail people, are difficult to apprehend. In particular, the disruption of the usual support and care ecosystems at home or in institutions may paradoxically increase the frailty of these people and lead to adverse events we wanted to avoid. On the other hand, the risk of a decrease in the older person's empowerment regarding his or her own health and social life decisions requires particular vigilance to prevent the risk of societal ageism. Regarding this population in particular, a possible conflict of values between individual and collective protection on one hand and respect for autonomy and independence on the other hand could exist. This article proposes an ethical reflection on the issue of containment of frail ageing people, based on medical ethics principles, in order to open up positive approaches of vulnerability that guarantee respect for the dignity of the person and equity in care access. | 2352-5525 | 2020-05-31 02:00:00+02:00 | pubmed | Ethics, Medicine and Public Health | M Piccoli;T Tannou;I Hernandorena;S Koeberle | Ageism;COVID-19;Frailty;Geriatrics;Social isolation | 2020-05-27 02:00:00+02:00 | 32835057 | FR;CA | Département médico-universitaire de gériatrie, AP-HP, centre université de Paris, site Broca, 54-56, rue Pascal, 75013 Paris, France.;EA 4468 maladie d'Alzheimer, facteurs de risques, soins et accompagnement des patients et familles, université de Paris, 54-56, rue Pascal, 75013 Paris, France.;service de gériatrie, CHU, 25000 Besançon, France.;Équipe « éthique et progrès médical », CIC Inserm 1431, CHU de Besançon, 25000 France.;EA 481 Neurosciences intégratives et cliniques, université Franche Comté, 25000 Besançon, France.;Centre de recherche, institut universitaire gériatrique de Montréal, Montréal, Quebec, Canada. | 955 | |||
| 10.1016/j.jfo.2020.05.003 | English Abstract;Journal Article;Review | fr | [SARS-CoV-2, COVID-19 and the eye: An update on published data]. | https://www.ncbi.nlm.nih.gov/pubmed/32631687 | The COVID-19 pandemic has dramatically changed our daily lives as ophthalmologists. This general review firstly provides a better understanding of the virus responsible for the pandemic: the SARS-CoV-2, and the clinical manifestations of the COVID-19 disease. The second part is detailing the pathophysiology, clinical signs and challenges of ocular involvement, which seems rare and not functionally severe, but which may be a potential source of contamination. Finally, we discuss the preventive measures that need to be implemented in our daily practice to avoid any viral dissemination. | 0181-5512 | 2020-05-31 02:00:00+02:00 | pubmed | Journal Français d'Ophtalmologie | A Rousseau;J-R Fenolland;M Labetoulle | COVID-19;Conjonctivite;Conjunctivitis;Larmes;Ocular surface;SARS-CoV-2;Surface oculaire;Tears;Transmission | 2020-05-30 02:00:00+02:00 | 32631687 | FR | Service d'ophtalmologie, CHU Bicêtre, hôpital Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Le Kremlin-Bicêtre, France, Département immunologie des maladies virales, auto-immunes, bactériennes et hématologiques. UMR 1184, CEA, Fontenay-Aux-Roses, France. Electronic address: antoine.rousseau@aphp.fr.;Service d'ophtalmologie, hôpital d'instruction des Armées Bégin, Saint-Mandé, France.;Service d'ophtalmologie, CHU Bicêtre, hôpital Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Le Kremlin-Bicêtre, France, Département immunologie des maladies virales, auto-immunes, bactériennes et hématologiques. UMR 1184, CEA, Fontenay-Aux-Roses, France. | 959 | |||
| 10.1016/j.jogc.2020.05.007 | Journal Article | en | Health Care Team Training and Simulation-Based Education in Obstetrics During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32736852 | Health care team training and simulation-based education are important for preparing obstetrical services to meet the challenges of the COVID-19 pandemic. Priorities for training are identified in two key areas. First, the impact of infection prevention and control protocols on processes of care (e.g., appropriate and correct use of personal protective equipment, patient transport, preparation for emergency cesarean delivery with the potential for emergency intubation, management of simultaneous obstetric emergencies, delivery in alternate locations in the hospital, potential for increased decision-to-delivery intervals, and communication with patients). And second, the effects of COVID-19 pathophysiology on obstetrical patients (e.g., testing and diagnosis, best use of modified obstetric early warning systems, approach to maternal respiratory compromise, collaboration with critical care teams, and potential need for cardiopulmonary resuscitation). However, such training is more challenging during the COVID-19 pandemic because of the requirements for social distancing. This article outlines strategies (spatial, temporal, video-recording, video-conferencing, and virtual) to effectively engage in health care team training and simulation-based education while maintaining social distancing during the COVID-19 pandemic. | 1701-2163 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__diagnosis;Delivery, Obstetric__education;Emergency Treatment__methods;Female;Humans;Infection Control__methods;Interdisciplinary Placement__methods;Obstetrics__education;Pandemics__prevention & control;Patient Simulation;Pneumonia, Viral__diagnosis;Pregnancy;Pregnancy Complications, Infectious__diagnosis;Simulation Training__methods;Staff Development__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Obstetrics and Gynaecology Canada | Daniel J Kiely;Glenn D Posner;Andrée Sansregret | COVID-19;SARS-CoV-2;interprofessional education;obstetrics;patient simulation;simulation training | 2020-05-30 02:00:00+02:00 | 32736852 | FR;CA;UNK | Department of Obstetrics and Gynecology, Hôpital du Centre-de-la-Mauricie, Shawinigan, QC. Electronic address: danieljameskiely@gmail.com.;Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, ON.;Department of Obstetrics and Gynecology, CHU Ste-Justine, Université de Montréal, Montréal, QC. | 964 | ||
| Letter | en | Thrombocytopenia in pregnant patients with mild COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32673964 | 2020-05-31 02:00:00+02:00 | pubmed | A Le Gouez;A J Vivanti;D Benhamou;C Desconclois;F J Mercier | 2020-05-30 02:00:00+02:00 | 32673964 | FR | Department of Anesthesia and Critical Care Medicine, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Saclay, Clamart, France.;Department of Obstetrics and Gynecology, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Saclay, Clamart, France.;Department of Anesthesia and Critical Care Medicine, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Saclay, Le Kremlin-Bicêtre, France.;Biological Hematology, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Saclay, Clamart, France. | 966 | ||||||||
| Letter | en | Presenting symptoms of COVID-19 in children: a meta-analysis of published studies. | https://www.ncbi.nlm.nih.gov/pubmed/32534738 | 2020-05-31 02:00:00+02:00 | pubmed | Rita Assaker;Anne-Emmanuelle Colas;Florence Julien-Marsollier;Béatrice Bruneau;Lucile Marsac;Bruno Greff;Nathalie Tri;Charlotte Fait;Christopher Brasher;Souhayl Dahmani | COVID-19;clinical presentation;clinical signs;meta-analysis;paediatrics;symptoms | 2020-05-31 02:00:00+02:00 | 32534738 | FR;AU | Paris, France.;Melbourne, VIC, Australia.;Paris, France. Electronic address: souhayl.dahmani@aphp.fr. | 973 | |||||||
| 10.3855/jidc.12678 | Journal Article;Research Support, Non-U.S. Gov't | en | Epidemiological and clinical characteristics of COVID-19 patients in Nantong, China. | https://www.ncbi.nlm.nih.gov/pubmed/32525828 | COVID-19 is a newly emerging life-threatening respiratory disease caused by a newly identified coronavirus SARS-CoV-2. | 1972-2680 | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus;China__epidemiology;Coronavirus Infections__diagnostic imaging;Female;Humans;Male;Middle Aged;Pandemics__prevention & control;Pneumonia, Viral__diagnostic imaging;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Journal of Infection in Developing Countries | Renfei Lu;Jianru Qin;Yan Wu;Jian Wang;Shengyong Huang;Lijun Tian;Tao Zhang;Xiuming Wu;Songping Huang;Xia Jin;Chiyu Zhang | COVID-19;Nantong;SARS-CoV2;clinical characteristics;epidemiology;pneumonia;symptom | 2020-05-31 02:00:00+02:00 | 32525828 | FR;CN | Nantong Third Hospital Affiliated to Nantong University, Nantong, China. rainman78@163.com.;College of Life Sciences, Henan Normal University, Xinxiang, China. qinjr@ips.ac.cn.;Nantong Third Hospital Affiliated to Nantong University, Nantong, China. 496521231@qq.com.;Nantong Third Hospital Affiliated to Nantong University, Nantong, China. wjpossible@163.com.;Nantong Third Hospital Affiliated to Nantong University, Nantong, China. 297250334@qq.com.;Nantong Third Hospital Affiliated to Nantong University, Nantong, China. adam-120@163.com.;Nantong Third Hospital Affiliated to Nantong University, Nantong, China. 19931067@qq.com.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China. xmwu@ips.ac.cn.;Nantong Third Hospital Affiliated to Nantong University, Nantong, China. huangsp6116@126.com.;Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. jinxia@shphc.org.cn.;Pathogen Discovery and Evolution Unit, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China. zhangcy1999@ips.ac.cn. | 975 | ||
| Letter | en | Expression of angiotensin-converting enzyme 2 and proteases in COVID-19 patients: A potential role of cellular FURIN in the pathogenesis of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32512290 | Recently, a mini-review was published in the Medical Hypotheses journal by Usul Afsar entitled 2019-nCoV-SARS-CoV-2 (COVID-19) infection: Cruciality of Furin and relevance with cancer. Previous studies have pointed out that disruption of the proteolytic cleavage of proteins can promote infectious and non-infectious diseases. The last few weeks have been marked by an important revelation concerning the pathophysiology of SARS-CoV-2. This new coronavirus disease (COVID-19) is a highly contagious and transmissible acute respiratory infectious disorder. SARS-CoV-2 is composed of RNA-dependent RNA polymerase and structural proteins including Spike protein (S protein). Interestingly, the FURIN, one of the proproteins of the convertase family, plays a crucial role in the maturation of viral glycoproteins. In addition, many viruses including coronaviruses, exploit FURIN for the activation of their glycoproteins. Recent data indicate that SARS-CoV-2 enters human cells by binding to angiotensin-converting enzyme 2. Subsequently, the S protein is cleaved by transmembrane protease serine 2 with the help of FURIN which facilitates the entry of the virus into the cell after binding. Furthermore, it seems that FURIN is implicated in the pathogenesis of SARS-CoV-2 and potentially in the increased rates of human-to-human transmission. | 2020-05-31 02:00:00+02:00 | pubmed | Kinan Drak Alsibai | ACE2;COVID-19;Coronavirus;FURIN;Pathogenesis;Protease;SARS-CoV-2 | 2020-05-30 02:00:00+02:00 | 32512290 | FR | Department of Pathology, Cayenne Hospital Centre, F-97300 Cayenne, France, Biological Resource Centre (CRB Amazonie), Cayenne Hospital Centre, F-97300 Cayenne, France. Electronic address: kdrak.alsibai@doctor.com. | 976 | ||||||
| 10.1017/dmp.2020.174 | Journal Article | en | Coronavirus and Exceptional Health Situations: The First Disaster With Benefits on Air Pollution. | https://www.ncbi.nlm.nih.gov/pubmed/32468980 | 1935-7893,1938-744X | 2020-05-31 02:00:00+02:00 | pubmed | Disaster Medicine and Public Health Preparedness | Jean-Baptiste Bouillon-Minois;François-Xavier Lesage;Jeannot Schmidt;Frédéric Dutheil | COVID-19;air pollution;disasters;pandemics | 2020-05-29 02:00:00+02:00 | 32468980 | FR | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Emergency Medicine, F-63000Clermont-Ferrand, France.;University of Montpellier, Laboratory Epsylon EA, Dynamic of Human Abilities & Health Behaviors, CHU Montpellier, University Hospital of Montpellier, Occupational and Preventive Medicine, Montpellier, France.;Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Occupational and Environmental Medicine, WittyFit, F-63000Clermont-Ferrand, France. | 978 | ||||
| 10.3389/fpsyt.2020.00511 | Journal Article | en | Psychological Support System for Hospital Workers During the Covid-19 Outbreak: Rapid Design and Implementation of the Covid-Psy Hotline. | https://www.ncbi.nlm.nih.gov/pubmed/32670100 | The worldwide coronavirus outbreak has put hospital workers under extreme stress with possible mental health problems. In this context, we decided to rapidly design and implement a psychological support system for all hospital workers in Paris during the Covid-19 outbreak. | 1664-0640 | 2020-05-31 02:00:00+02:00 | pubmed | Frontiers in Psychiatry | Pierre A Geoffroy;Véronique Le Goanvic;Olivier Sabbagh;Charlotte Richoux;Aviv Weinstein;Geoffrey Dufayet;Michel Lejoyeux | healthcare workers;medical workers;mental health;psychiatry;psychological intervention;psychology | 2020-05-28 02:00:00+02:00 | 32670100 | FR;IL | Department of Psychiatry and Addictive Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), University Hospital Bichat, Paris, France.;Université de Paris, NeuroDiderot, Inserm, Paris, France.;Sector of Psychiatry, G.H.U. Paris et Neuroscience, Paris, France.;Ariel University, Ariel, Israël.;Université de Paris, Paris, France. | 987 | |||
| 10.1136/annrheumdis-2020-217875 | Journal Article | en | Response to: Correspondence regarding research letter to the editor by Mathian et al, 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour et al. | https://www.ncbi.nlm.nih.gov/pubmed/32471900 | 0003-4967,1468-2060 | 2020-05-31 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Alexis Mathian;Zahir Amoura | hydroxychloroquine;immune system diseases;lupus erythematosus, systemic;therapeutics | 2020-05-29 02:00:00+02:00 | 32471900 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 996 | ||||
| Journal Article;Research Support, Non-U.S. Gov't;Comment | en | Autoimmune and inflammatory diseases following COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32499548 | 2020-06-07 02:00:00+02:00 | pubmed | Autoimmune Diseases;Betacoronavirus;Cohort Studies;Coronavirus Infections;Humans;Inflammation;Italy;Pandemics;Pneumonia, Viral;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Caroline Galeotti;Jagadeesh Bayry | 2020-06-06 02:00:00+02:00 | 32499548 | FR | Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires Rares et des Amyloses, CHU de Bicêtre, le Kremlin Bicêtre, France.;Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France. jagadeesh.bayry@crc.jussieu.fr. | 1007 | |||||||
| 10.1007/s40264-020-00955-y | Journal Article | en | A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study. | https://www.ncbi.nlm.nih.gov/pubmed/32495148 | Hydroxychloroquine was recently promoted in patients infected with COVID-19 infection. A recent experimental study has suggested an increased toxicity of hydroxychloroquine in association with metformin in mice. | 0114-5916,1179-1942 | 2020-06-07 02:00:00+02:00 | pubmed | Adult;Adverse Drug Reaction Reporting Systems__statistics & numerical data;Betacoronavirus__isolation & purification;Coronavirus Infections__diagnosis;Drug Interactions;Drug Therapy, Combination__adverse effects;Female;Humans;Hydroxychloroquine__pharmacokinetics;Hypoglycemic Agents__pharmacokinetics;Male;Metformin__pharmacokinetics;Middle Aged;Pandemics;Pharmacovigilance;Pneumonia, Viral__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Drug Safety | Jean-Louis Montastruc;Pierre-Louis Toutain | 2020-06-05 02:00:00+02:00 | 32495148 | FR;GB | Service de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Faculté de Médecine, Centre Hospitalier Universitaire, 37 allées Jules-Guesde, 31000, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.;INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France.;The Royal Veterinary College, University of London, London, UK. | 1009 | |||
| 10.1038/s41575-020-0322-8 | Journal Article | en | The day after COVID-19 in IBD: how to go back to 'normal'. | https://www.ncbi.nlm.nih.gov/pubmed/32483356 | 1759-5045,1759-5053 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Global Health;Humans;Infection Control__organization & administration;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Inflammatory Bowel Diseases__therapy;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nature Reviews Gastroenterology & Hepatology | Silvio Danese;Bruce Sands;Siew C Ng;Laurent Peyrin-Biroulet | 2020-06-03 02:00:00+02:00 | 32483356 | FR;CN;US;HK;IT | IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center - IRCCS -, Rozzano, Italy. sdanese@hotmail.com.;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. sdanese@hotmail.com.;The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.;Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, Hong Kong.;Deparment of Gastroenterology, Nancy University Hospital, Vandoeuvre-les-Nancy, France.;Inserm U1256 NGERE, Lorraine University, Vandoeuvre-les-Nancy, France. | 1016 | ||||
| 10.1007/s11239-020-02163-y | Journal Article | en | Diagnosis of venous and arterial thromboembolic events in COVID-19 virus-infected patients. | https://www.ncbi.nlm.nih.gov/pubmed/32504449 | 0929-5305,1573-742X | 2020-06-07 02:00:00+02:00 | pubmed | Arterial Occlusive Diseases__blood;Betacoronavirus__pathogenicity;Biomarkers__blood;Clinical Laboratory Techniques;Coronavirus Infections__blood;Decision Support Techniques;Disseminated Intravascular Coagulation__blood;Female;Fibrin Fibrinogen Degradation Products__analysis;Fibrinogen__analysis;Host-Pathogen Interactions;Humans;International Normalized Ratio;Male;Middle Aged;Organ Dysfunction Scores;Pandemics;Platelet Count;Pneumonia, Viral__blood;Predictive Value of Tests;Prothrombin Time;Reproducibility of Results;Retrospective Studies;Thromboembolism__blood;Venous Thrombosis__blood;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Thrombosis and Thrombolysis | Anna Betoule;Camille Martinet;Guillaume Gasperini;Pauline Muller;Stéphane Foucher;Patrick Benner;Aurélien Renard | 2020-06-07 02:00:00+02:00 | 32504449 | FR | Service d'accueil des urgences, Hôpital D'instruction Des armées Sainte Anne, Toulon, France. anna.betoule@intradef.gouv.fr.;Service d'accueil des urgences, Hôpital D'instruction Des armées Sainte Anne, Toulon, France. | 1021 | ||||
| Letter | en | Detection of Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage Fluid of COVID-19 Patients: Is Perls Stain a Potential Indicator of Oxidative Alveolar Damage? | https://www.ncbi.nlm.nih.gov/pubmed/32506059 | 2020-06-07 02:00:00+02:00 | pubmed | Kinan Drak Alsibai | 2020-06-05 02:00:00+02:00 | 32506059 | FR | Department of Anatomic Pathology and Cytology, Cayenne Hospital Center, Cayenne, French Guiana, kdrak.alsibai@doctor.com. | 1026 | ||||||||
| 10.1126/sciadv.abc0764 | Editorial | en | Mobile phone data for informing public health actions across the COVID-19 pandemic life cycle. | https://www.ncbi.nlm.nih.gov/pubmed/32548274 | 2375-2548 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Cell Phone;Coronavirus Infections__epidemiology;Humans;Infection Control__methods;Interpersonal Relations;Movement;Pandemics;Pneumonia, Viral__epidemiology;Public Health;Travel;COVID-19;severe acute respiratory syndrome coronavirus 2 | Science Advances | Nuria Oliver;Bruno Lepri;Harald Sterly;Renaud Lambiotte;Sébastien Deletaille;Marco De Nadai;Emmanuel Letouzé;Albert Ali Salah;Richard Benjamins;Ciro Cattuto;Vittoria Colizza;Nicolas de Cordes;Samuel P Fraiberger;Till Koebe;Sune Lehmann;Juan Murillo;Alex Pentland;Phuong N Pham;Frédéric Pivetta;Jari Saramäki;Samuel V Scarpino;Michele Tizzoni;Stefaan Verhulst;Patrick Vinck | 2020-06-05 02:00:00+02:00 | 32548274 | FR;FI;GB;US;IT;NL;DK;ES;DE;BE;AT | ELLIS, the European Laboratory for Learning and Intelligent Systems, Alicante, Spain.;DataPop Alliance, New York, NY, USA.;Fondazione Bruno Kessler, Trento, Italy.;University of Vienna, Vienna, Austria.;University of Oxford, Oxford, UK.;The Alan Turing Institute, London, UK.;Rosa, Brussels, Belgium.;Open Algorithms (OPAL) collaborative project, New York, NY, USA.;Utrecht University, Utrecht, Netherlands.;Telefonica, Madrid, Spain.;odiseIA, Madrid, Spain.;University of Turin, Turin, Italy.;Orange Group, Paris, France.;INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.;Orange Group, France.;Dalberg Data Insights, Brussels, Belgium.;Freie University, Berlin, Germany.;Technical University of Denmark, Copenhagen, Denmark.;Banco Bilbao Vizcaya Argentaria, Madrid, Spain.;Massachusetts Institute of Technology, Cambridge, MA, USA.;Harvard University, Cambridge, MA, USA.;Dalberg Data Insights, Belgium.;Aalto University, Espoo, Finland.;Northeastern University, Boston, MA, USA.;The GovLab, New York University, New York, NY, USA. | 1028 | ||||
| Editorial;Comment | en | Easier access to mechanical ventilation worldwide: an urgent need for low income countries, especially in face of the growing COVID-19 crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32398301 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Feasibility Studies;Humans;Pandemics;Pneumonia, Viral;Respiration, Artificial;COVID-19;severe acute respiratory syndrome coronavirus 2 | Claude Guérin;Patrick Lévy | 2020-06-04 02:00:00+02:00 | 32398301 | FR | Intensive Care Unit-Réanimation Groupement Hospitalier Centre Edouard Herriot Hospital and Faculty of Medicine Lyon Est, University of Lyon, Lyon, France.;INSERM 955, Créteil, France.;Univ. Grenoble Alpes, Inserm, HP2 laboratory, Grenoble, France Patrick.levy@univ-grenoble-alpes.fr.;Grenoble Alpes University, Thorax and Vessels Dept, Physiology and Respiratory Section, Grenoble, France. | 1043 | |||||||
| 10.7326/m20-2854 | Journal Article | en | Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review. | https://www.ncbi.nlm.nih.gov/pubmed/32496919 | Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) will be critical for the public health response to the coronavirus disease 2019 pandemic. Many use cases are envisaged, including complementing molecular methods for diagnosis of active disease and estimating immunity for individuals. At the population level, carefully designed seroepidemiologic studies will aid in the characterization of transmission dynamics and refinement of disease burden estimates and will provide insight into the kinetics of humoral immunity. Yet, despite an explosion in the number and availability of serologic assays to test for antibodies against SARS-CoV-2, most have undergone minimal external validation to date. This hinders assay selection and implementation, as well as interpretation of study results. In addition, critical knowledge gaps remain regarding serologic correlates of protection from infection or disease, and the degree to which these assays cross-react with antibodies against related coronaviruses. This article discusses key use cases for SARS-CoV-2 antibody detection tests and their application to serologic studies, reviews currently available assays, highlights key areas of ongoing research, and proposes potential strategies for test implementation. | 0003-4819,1539-3704 | 2020-06-07 02:00:00+02:00 | pubmed | Annals of Internal Medicine | Matthew P Cheng;Cedric P Yansouni;Nicole E Basta;Michaël Desjardins;Sanjat Kanjilal;Katryn Paquette;Chelsea Caya;Makeda Semret;Caroline Quach;Michael Libman;Laura Mazzola;Jilian A Sacks;Sabine Dittrich;Jesse Papenburg | Antibodies;Antibody production;Blood plasma;COVID-19;Cross reactivity;Immunity;Proteins;SARS coronavirus;Specificity;Vaccines | 2020-06-04 02:00:00+02:00 | 32496919 | FR;CA;GB;CH;US | McGill University Health Centre and McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada (M.P.C.).;McGill University Health Centre, McGill Interdisciplinary Initiative in Infection and Immunity, and J.D. MacLean Centre for Tropical Diseases, McGill University, Montreal, Quebec, Canada (C.P.Y., M.S., M.L.).;School of Population and Global Health, McGill University, Montreal, Quebec, Canada (N.E.B.).;Brigham and Women's Hospital, Boston, Massachusetts, and Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada (M.D.).;Brigham and Women's Hospital and Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, Massachusetts (S.K.).;Montreal Children's Hospital, Montreal, Quebec, Canada (K.P.).;McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada (C.C.).;CHU Sainte-Justine, Université de Montréal, Montreal, Canada (C.Q.).;Foundation of Innovative New Diagnostics (FIND), Geneva, Switzerland (L.M., J.A.S.).;Foundation of Innovative New Diagnostics (FIND), Geneva, Switzerland, and Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom (S.D.).;McGill Interdisciplinary Initiative in Infection and Immunity, School of Population and Global Health, McGill University, and Montreal Children's Hospital, Montreal, Quebec, Canada (J.P.). | 1046 | |||
| 10.1016/j.banm.2020.04.015 | English Abstract;Journal Article | fr | [Pandemics: Lessons from the past]. | https://www.ncbi.nlm.nih.gov/pubmed/32834054 | Since Antiquity, pandemics periodically strike humanity. Plagues of Athens, galenic, justinianic, and medieval plagues provoked millions of deaths, and subsequent famines and socio-political changes. Smallpox was a scourge affecting the royal courts too. The influenza H1N1 of 1917 brought more deaths than the Great War. The decline of Europe benefited to the USA, dominant power during the XXth century. The present pandemic of coronavirus Covid-19 will have important economic consequences, some of then being unsuspected yet. | 0001-4079 | 2020-06-07 02:00:00+02:00 | pubmed | Bulletin de l'Académie Nationale de Médecine | J Battin | Public healthcare;epidemic;galenic plague;influenza;justinianic plague;measles;medieval black Death;pandemic;plague of Athens;smallpox | 2020-06-04 02:00:00+02:00 | 32834054 | FR | Académie nationale de médecine, 16, rue Bonaparte, 75006 Paris, France. | 1047 | |||
| Letter | en | COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases. | https://www.ncbi.nlm.nih.gov/pubmed/32503860 | 2020-06-07 02:00:00+02:00 | pubmed | Clementina López-Medina;Alejandro Escudero;Eduardo Collantes-Estevez | outcome and process assessment, health care;outcome assessment, health care;quality indicators, health care | 2020-06-05 02:00:00+02:00 | 32503860 | FR;ES;BG | Rheumatology Department, Reina Sofía University Hospital, Córdoba, Spain clementinalopezmedina@gmail.com.;GC05 group, Maimónides Institute for Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain.;Medicine Department, University of Córdoba, Córdoba, Spain.;Rheumatology Department, Cochin Hospital, Paris, France.;Rheumatology Department, Reina Sofía University Hospital, Córdoba, Spain. | 1049 | |||||||
| 10.1016/j.nmni.2020.100707 | Editorial | en | Remdesivir investigational trials in COVID-19: a critical reappraisal. | https://www.ncbi.nlm.nih.gov/pubmed/32837727 | During outbreak of emerging disease, the most important aim is to discover an effective drug to save life. Consequently, a lot of effort are generally made by the industry to promote clinical trials with new drugs. Here we review evidence of the 8 most recent reports including 3 randomized controlled trials on the clinical efficacy of remdesivir in treating COVID-19 patient. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention. | 2052-2975 | 2020-06-07 02:00:00+02:00 | pubmed | New Microbes and New Infections | P Brouqui;A Giraud-Gatineau;D Raoult | 2020-06-07 02:00:00+02:00 | 32837727 | FR | Aix Marseille Université,IRD, MEPHI, IHU-Méditerranée Infection,Marseille, France.;AP-HM, IHU-Méditerranée Infection,Marseille, France. | 1055 | ||||
| 10.1016/j.amjoto.2020.102605 | Journal Article | en | Olfactory and gustatory dysfunctions in COVID-19. First reports of Latin-American ethnic patients. | https://www.ncbi.nlm.nih.gov/pubmed/32531619 | 0196-0709 | 2020-06-07 02:00:00+02:00 | pubmed | American Journal of Otolaryngology | Carlos M Chiesa-Estomba;Jerome R Lechien;Patricia Portillo-Mazal;Federico Martínez;Jesús Cuauro-Sanchez;Christian Calvo-Henriquez;Sven Saussez | 2020-06-06 02:00:00+02:00 | 32531619 | FR;AR;VE;UY;ES;BE | Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Department of Otorhinolaryngology - Head & Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain. Electronic address: carlosmiguel.chiesaestomba@osakidetza.eus.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium, Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France, Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Department of Otolaryngology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.;Department of Otolaryngology, Hospital Masiel, Montevideo, Uruguay.;Department of Respiratory Diseases, Clínica Siatea, San Fernando de Apure, Venezuela.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Department of Otolaryngology, Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium, Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. | 1063 | |||||
| Letter | en | COVID-19 and Inflammatory Bowel Disease: Questions on Incidence, Severity, and Impact of Treatment? | https://www.ncbi.nlm.nih.gov/pubmed/32522559 | 2020-06-07 02:00:00+02:00 | pubmed | Benedicte Caron;Yves Arondel;Jean-Marie Reimund | 2020-06-06 02:00:00+02:00 | 32522559 | FR | Service d'Hépato-Gastroentérologie et d'Assistance Nutritive, Hôpitaux Universitaires de Strasbourg (HUS), Hôpital de Hautepierre, Strasbourg, France, INSERM U1113 IRFAC (Interface de Recherche, Fondamentale et Appliquée en Cancérologie), Université de Strasbourg, Faculté de Médecine, Strasbourg, France.;Service d'Hépato-gastro-entérologie et d'Endoscopie digestive, Centre Hospitalier de Haguenau, Haguenau, France.;Service d'Hépato-Gastroentérologie et d'Assistance Nutritive, HUS, Hôpital de Hautepierre, Strasbourg, France, INSERM U1113 IRFAC (Interface de Recherche, Fondamentale et Appliquée en Cancérologie), Université de Strasbourg, Faculté de Médecine, Strasbourg, France, Institut Hospitalo-Universitaire de Strasbourg, HUS, Strasbourg, France. | 1068 | ||||||||
| 10.1016/s0140-6736(20)31298-8 | Journal Article | en | The WHO we want. | https://www.ncbi.nlm.nih.gov/pubmed/32511944 | 0140-6736 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus Infections__epidemiology;Global Health;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Politics;United States;World Health Organization;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet | Olivier Nay;Marie-Paule Kieny;Lelio Marmora;Michel Kazatchkine | 2020-06-05 02:00:00+02:00 | 32511944 | FR;CH | University of Paris Panthéon-Sorbonne, Paris, France.;Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.;The Management Lab, Geneva, Switzerland.;Global Health Center, Graduate Institute for International Affairs and Development, 1211 Geneva, Switzerland. Electronic address: contact@michelkazatchkine.com. | 1070 | ||||
| 10.1126/sciadv.aaz5466 | Journal Article;Research Support, Non-U.S. Gov't | en | Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents. | https://www.ncbi.nlm.nih.gov/pubmed/32548259 | Uncontrolled inflammatory processes are at the root of numerous pathologies. Most recently, studies on confirmed COVID-19 cases have suggested that mortality might be due to virally induced hyperinflammation. Uncontrolled pro-inflammatory states are often driven by continuous positive feedback loops between pro-inflammatory signaling and oxidative stress, which cannot be resolved in a targeted manner. Here, we report on the development of multidrug nanoparticles for the mitigation of uncontrolled inflammation. The nanoparticles are made by conjugating squalene, a natural lipid, to adenosine, an endogenous immunomodulator, and then encapsulating α-tocopherol, as antioxidant. This resulted in high drug loading, biocompatible, multidrug nanoparticles. By exploiting the endothelial dysfunction at sites of acute inflammation, these multidrug nanoparticles delivered the therapeutic agents in a targeted manner, conferring survival advantage to treated animals in models of endotoxemia. Selectively delivering adenosine and antioxidants together could serve as a novel therapeutic approach for safe treatment of acute paradoxal inflammation. | 2375-2548 | 2020-06-07 02:00:00+02:00 | pubmed | Adenosine__administration & dosage;Animals;Antioxidants__administration & dosage;Betacoronavirus;Coronavirus Infections__drug therapy;Disease Models, Animal;Drug Delivery Systems__methods;Endotoxemia__chemically induced;Female;Immunologic Factors__administration & dosage;Lipopolysaccharides__pharmacology;Male;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Nanoparticles__administration & dosage;Pandemics;Pneumonia, Viral__drug therapy;Squalene__administration & dosage;Systemic Inflammatory Response Syndrome__chemically induced;Treatment Outcome;alpha-Tocopherol__administration & dosage;COVID-19;severe acute respiratory syndrome coronavirus 2 | Science Advances | Flavio Dormont;Romain Brusini;Catherine Cailleau;Franceline Reynaud;Arnaud Peramo;Amandine Gendron;Julie Mougin;Françoise Gaudin;Mariana Varna;Patrick Couvreur | 2020-06-05 02:00:00+02:00 | 32548259 | FR;BR | Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.;School of Pharmacy, Federal University of Rio de Janeiro, 21944-59 Rio de Janeiro, Brazil.;Plateforme d'Histologie Immunopathologie de Clamart (PHIC) Université Paris-Saclay, Inserm, CNRS, Institut Paris Saclay d'Innovation thérapeutique, 92296 Châtenay-Malabry, France.;Université Paris-Saclay, Inserm, Inflammation, Microbiome and Immunosurveillance, 92140 Clamart, France. | 1071 | |||
| 10.1016/j.oraloncology.2020.104844 | Journal Article;Review | en | Systematic review of international guidelines for tracheostomy in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32526655 | At this moment, the world lives under the SARS-CoV-2 outbreak pandemic. As Otolaryngologists - Head & Neck Surgeons, we need to perform and participate in examinations and procedures within the head and neck region and airway that carry a particularly high risk of exposure and infection because of aerosol and droplet contamination. One of those surgical procedures in demand at this moment is tracheostomy due the increasing ICU admissions. This review of international guidelines for tracheostomy in COVID-19 infected patients, aims to summarize in a systematic way the available recommendations: indications, timing, technique and safety measures for tracheostomy, from all over the world. | 1368-8375 | 2020-06-07 02:00:00+02:00 | pubmed | Oral Oncology | Carlos M Chiesa-Estomba;Jérome R Lechien;Christian Calvo-Henríquez;Nicolas Fakhry;Petros D Karkos;Shazia Peer;Jon A Sistiaga-Suarez;José A Gónzalez-García;Giovanni Cammaroto;Miguel Mayo-Yánez;Pablo Parente-Arias;Sven Saussez;Tareck Ayad | COVID-19;Guideline;Pandemic;SARS-CoV-2;Tracheostomy;Tracheotomy | 2020-06-05 02:00:00+02:00 | 32526655 | FR;CA;GR;IT;ZA;ES;BE | Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), France, Otorhinolaryngology - Head & Neck Surgery Department, Hospital Universitario Donostia, San Sebastian, Spain. Electronic address: carlosmiguel.chiesaestomba@osakidetza.eus.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), France, Department of Human Anatomy & Experimental Oncology, University of Mons, Mons, Belgium.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), France, Department of Otolaryngology - Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), France, Department of Otolaryngology - Head and Neck Surgery, Universitary Hospital of la Conception Marseille, France.;Department of Otolaryngology - Head and Neck Surgery, AHEPA University Hospital, Thessaloniki, Greece.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), France, Division of Otolaryngology, University of Cape Town, South Africa.;Otorhinolaryngology - Head & Neck Surgery Department, Hospital Universitario Donostia, San Sebastian, Spain.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), France.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), France, Department of Otolaryngology - Head & Neck Surgery, Morgagni Pierantoni Hospital, Forli, Italy.;Department of Otolaryngology - Hospital Complex of A Coruña, A Coruña, Spain.;Department of Otolaryngology - Head & Neck Surgery - Hospital Lucus Agusti, Lugo, Spain.;Task Force COVID-19 of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), France, Division of Otolaryngology - Head & Neck Surgery, Centre Hospitalier de l'Université de Montréal Montreal, Canada. | 1072 | |||
| 10.1186/s13054-020-03021-2 | Journal Article | en | Admission decisions to intensive care units in the context of the major COVID-19 outbreak: local guidance from the COVID-19 Paris-region area. | https://www.ncbi.nlm.nih.gov/pubmed/32503593 | SARS-CoV-2 has caused a global pandemic unprecedented in size, spread, severity, and mortality. The influx of patients with severe or life-threatening disease means that in some cases, the available medical resources are not sufficient to meet the needs of all patients. Hence, healthcare providers may be forced to make difficult choices about which patients should be referred to the ICU. This document is intended to provide conceptual support to all healthcare teams currently engaged in the frontline management of the COVID-19 pandemic. It aims to assist physicians in the decision-making process for ICU admission and to help them provide uninterrupted and high-quality care. | 1364-8535 | 2020-06-07 02:00:00+02:00 | pubmed | Clinical Decision-Making;Coronavirus Infections__epidemiology;Disease Outbreaks;Humans;Intensive Care Units;Pandemics;Paris__epidemiology;Patient Admission;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;COVID-19 | Critical Care | Élie Azoulay;Sadek Beloucif;Bertrand Guidet;Dominique Pateron;Benoît Vivien;Matthieu Le Dorze | Bereavement;Coronavirus;Decision-making;Mechanical ventilation;Triage | 2020-06-05 02:00:00+02:00 | 32503593 | FR | Médecine Intensive et Réanimation, APHP, Hôpital Saint-Louis, Paris University, 1 Avenue Claude Vellefaux, 75010, Paris, France. elie.azoulay@aphp.fr.;Médecine Intensive et Réanimation, APHP, Hôpital Saint-Louis, Paris University, 1 Avenue Claude Vellefaux, 75010, Paris, France.;Anesthesia and Critical Care Department, Avicenne Hospital, Paris, France.;Medecine Intensive et Réanimation Department, Saint-Antoine Hospital, Paris, France.;Emergency Department, Saint-Antoine Hospital, Paris, France.;Emergency Department, Neckers Hospital, Paris, France.;Anesthesia and Critical Care Department, Lariboisiere Hospital, Paris, France. | 1073 | ||
| Wellcome Trust | 10.1016/j.cels.2020.05.012 | Journal Article;Research Support, Non-U.S. Gov't | en | Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32619549 | The COVID-19 pandemic is an unprecedented global challenge, and point-of-care diagnostic classifiers are urgently required. Here, we present a platform for ultra-high-throughput serum and plasma proteomics that builds on ISO13485 standardization to facilitate simple implementation in regulated clinical laboratories. Our low-cost workflow handles up to 180 samples per day, enables high precision quantification, and reduces batch effects for large-scale and longitudinal studies. We use our platform on samples collected from a cohort of early hospitalized cases of the SARS-CoV-2 pandemic and identify 27 potential biomarkers that are differentially expressed depending on the WHO severity grade of COVID-19. They include complement factors, the coagulation system, inflammation modulators, and pro-inflammatory factors upstream and downstream of interleukin 6. All protocols and software for implementing our approach are freely available. In total, this work supports the development of routine proteomic assays to aid clinical decision making and generate hypotheses about potential COVID-19 therapeutic targets. | 2405-4712 | 2020-06-07 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Betacoronavirus__isolation & purification;Biomarkers__blood;Blood Proteins__analysis;Coronavirus Infections__blood;Female;Humans;Male;Middle Aged;Pandemics__classification;Pneumonia, Viral__blood;Proteomics__methods;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cell Systems | Christoph B Messner;Vadim Demichev;Daniel Wendisch;Laura Michalick;Matthew White;Anja Freiwald;Kathrin Textoris-Taube;Spyros I Vernardis;Anna-Sophia Egger;Marco Kreidl;Daniela Ludwig;Christiane Kilian;Federica Agostini;Aleksej Zelezniak;Charlotte Thibeault;Moritz Pfeiffer;Stefan Hippenstiel;Andreas Hocke;Christof von Kalle;Archie Campbell;Caroline Hayward;David J Porteous;Riccardo E Marioni;Claudia Langenberg;Kathryn S Lilley;Wolfgang M Kuebler;Michael Mülleder;Christian Drosten;Norbert Suttorp;Martin Witzenrath;Florian Kurth;Leif Erik Sander;Markus Ralser | COVID-19 infection;SWATH-MS;antiviral immune response;clinical classifiers;high-throughput proteomics;mass spectrometry | 2020-06-02 02:00:00+02:00 | 32619549 | FR;SE;GB;DE | [{"country": "United Kingdom", "agency": "Wellcome Trust"}] | The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, UK.;The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, UK, Department of Biochemistry, The University of Cambridge, Cambridge CB21GA, UK.;Charité Universitätsmedizin, Berlin, Department of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany.;Charité Universitätsmedizin, Institute of Physiology, 10117 Berlin, Germany.;Charité Universitätsmedizin, Core Facility - High-Throughput Mass Spectrometry, 10117 Berlin, Germany, Charité Universitätsmedizin, Department of Biochemistry, 10117 Berlin, Germany.;Charité Universitätsmedizin, Core Facility - High-Throughput Mass Spectrometry, 10117 Berlin, Germany.;Charité Universitätsmedizin, Department of Biochemistry, 10117 Berlin, Germany.;The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, UK, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg 412 96, Sweden.;Berlin Institute of Health (BIH) and Charité Universitätsmedizin, Clinical Study Center (CSC), 10117 Berlin, Germany.;Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK, Usher Institute, University of Edinburgh, Nine, Edinburgh Bioquarter, 9 Little France Road, Edinburgh EH16 4UX, UK.;MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.;Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.;The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, UK, MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK.;Department of Biochemistry, The University of Cambridge, Cambridge CB21GA, UK.;Charité Universitätsmedizin, Department of Virology, 10117 Berlin, Germany.;Charité Universitätsmedizin, Berlin, Department of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany, Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.;The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, UK, Charité Universitätsmedizin, Department of Biochemistry, 10117 Berlin, Germany. Electronic address: markus.ralser@charite.de. | 1088 |
| 10.1111/ene.14368 | Case Reports | en | SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with favorable outcome. | https://www.ncbi.nlm.nih.gov/pubmed/32478936 | The entire world has been experiencing the outbreak of a novel infectious agent known as severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), which is responsible for the coronavirus disease 19 (COVID-19)1 . Life-threatening complications described in SARS-CoV-2 infected patients include acute respiratory distress syndrome, acute kidney failure and cardiac injury2 . Nonetheless, only few neurological complications have been described so far3 . | 1351-5101,1468-1331 | 2020-06-07 02:00:00+02:00 | pubmed | European Journal of Neurology | Agustina M Lascano;Jean-Benoît Epiney;Matteo Coen;Jacques Serratrice;Raphaël Bernard-Valnet;Patrice H Lalive;Thierry Kuntzer;Annemarie Hübers | 2020-06-01 02:00:00+02:00 | 32478936 | FR;CH | Division of Neurology, Department of Clinical Neuroscience, Geneva University Hospitals and University of Geneva, Faculty of Medicine, Geneva, Switzerland.;Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Lausanne, Switzerland.;Service of Internal Medicine, Department of Medicine, Geneva University Hospitals and Unit of Development and Research in Medical Education (UDREM), University of Geneva, Faculty of Medicine, Geneva, Switzerland. | 1093 | ||||
| 10.1016/j.mehy.2020.109918 | Journal Article | en | COVID-19-related complications and decompression illness share main features.: Could the SARS-CoV2-related complications rely on blood foaming? | https://www.ncbi.nlm.nih.gov/pubmed/32512491 | A study by Saraiva et al. (2011) demonstrated the presence of Angiotensin II receptors on the erythrocyte membrane. This little-known information should be deemed as crucial as the SARS-CoV-2 relationships with oxygen saturation and the Renine Angiotensin System but it currently remains unexploited. The pulmonary and cardiovascular systems are involved in any typical complications of COVID-19 but numerous other unrelated symptoms may occur. To fill the gap, we shall first emphasize some similarities between the complications of this infectious disease and Decompression Illness (DCI), which involves bubble formation. We theorized that the Angiotensin II clearance by the red blood cells could trigger the release of its oxygen content in the bloodstream. The resulting foam would worsen the widespread endotheliitis, worsen the gas exchange, trigger the coagulation process, the inflammation process and the complement pathway as typically occurs in DCI. At the end, we propose a plausible mechanism. | 0306-9877 | 2020-06-07 02:00:00+02:00 | pubmed | Medical Hypotheses | Pierre A Denis | Angiotensin II;COVID-19;Decompression illness;Oxygen;Red blood cells;SARS-CoV | 2020-06-01 02:00:00+02:00 | 32512491 | FR | Occupational Medicine, Mutualité Sociale Agricole (M.S.A.), 12 rue de Paimpont 22025 Saint-Brieuc Cedex, France. Electronic address: pierredenisfr@yahoo.fr. | 1097 | |||
| Letter | en | Extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients: outcome and time-course of clinical and biological parameters. | https://www.ncbi.nlm.nih.gov/pubmed/32483742 | 2020-06-07 02:00:00+02:00 | pubmed | Pierre Huette;Christophe Beyls;Mathieu Guilbart;Alexandre Coquet;Pascal Berna;Guillaume Haye;Pierre-Alexandre Roger;Patricia Besserve;Michael Bernasinski;Hervé Dupont;Osama Abou-Arab;Yazine Mahjoub | 2020-06-01 02:00:00+02:00 | 32483742 | FR | Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France. huette.pierre@chu-amiens.fr.;Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France.;Department of Thoracic Surgery, Amiens University Hospital, Amiens, France. | 1099 | ||||||||
| 10.1016/j.adro.2020.04.034 | Journal Article | en | Brachytherapy Issues and Priorities in the Context of the Coronavirus Disease 2019 (COVID-19) Outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32775774 | 2452-1094 | 2020-06-07 02:00:00+02:00 | pubmed | Advances in Radiation Oncology | Cyrus Chargari;Supriya Chopra;Akila N Viswanathan;Eric Deutsch | 2020-06-02 02:00:00+02:00 | 32775774 | FR;IN;US | Department of Radiation Oncology, Gustave Roussy Comprehensive Cancer Center, Villejuif, France.;Faculté de Médecine, Université Paris Sud/Paris Saclay, Paris, France.;INSERM, U1030, Paris, France.;Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge, France.;Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Kharghar, Navi Mumbai, India.;Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland. | 1107 | |||||
| 10.1016/j.arcped.2020.05.010 | Journal Article;Observational Study | en | Severe and fatal forms of COVID-19 in children. | https://www.ncbi.nlm.nih.gov/pubmed/32518045 | The aim of this study was to describe severe forms of novel coronavirus disease 2019 in children, including patient characteristics, clinical, laboratory, and imaging findings, as well as the disease management and outcomes. | 0929-693X | 2020-06-07 02:00:00+02:00 | pubmed | Adolescent;Betacoronavirus__isolation & purification;Child;Child, Preschool;Clinical Laboratory Techniques;Comorbidity;Coronavirus Infections__diagnosis;Disease Progression;Female;Humans;Infant;Male;Pandemics;Paris__epidemiology;Pneumonia, Viral__diagnosis;Prognosis;Retrospective Studies;Risk Factors;Severity of Illness Index;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Archives de Pédiatrie | M Oualha;M Bendavid;L Berteloot;A Corsia;F Lesage;M Vedrenne;E Salvador;M Grimaud;J Chareyre;C de Marcellus;L Dupic;L de Saint Blanquat;C Heilbronner;D Drummond;M Castelle;R Berthaud;F Angoulvant;J Toubiana;Y Pinhas;P Frange;G Chéron;J Fourgeaud;F Moulin;S Renolleau | COVID-19;Coronavirus;SARS-Cov-2 | 2020-06-04 02:00:00+02:00 | 32518045 | FR | Pediatric Intensive Care Unit, Necker-Enfants-Malades University Hospital, APHP, Centre-Université de Paris, Paris, France. Electronic address: mehdi.oualha@aphp.fr.;Pediatric Intensive Care Unit, Necker-Enfants-Malades University Hospital, APHP, Centre-Université de Paris, Paris, France.;Pediatric Radiology Department, Necker-Enfants-Malades University Hospital, APHP, Centre-Université de Paris, Paris, France, INSERM U1163, Université Paris Descartes-Sorbonne Paris Cité, Institut Imagine, France.;Department of pediatric pneumology and allergology, Necker-Enfants-Malades University Hospital, APHP, Centre-Université de Paris, Paris, France, INSERM UMR 1138, Université de Paris, Paris, France.;Department of pediatric Immuno-hematology and rhumatology, Necker-Enfants Malades University Hospital, APHP, Centre-Université de Paris, Paris, France.;Department of Pediatric Nephrology, Necker-Enfants Malades University Hospital, APHP, Centre-Université de Paris, Paris, France.;Pediatric Emergency Department, Necker-Enfants-Malades University Hospital, APHP, Centre-Université de Paris, Paris, France, INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Université de Paris, Paris, France.;Department of General Paediatrics and Paediatric Infectious Diseases, Necker-Enfants-Malades University Hospital, APHP, Centre-Université de Paris, Paris, France.;Clinical microbiology laboratory, Necker-Enfants-Malades University Hospital, APHP, Centre-Université de Paris, Paris, France, EHU 7328 PACT, Imagine institute, Université de Paris, Paris, France.;Pediatric Emergency Department, Necker-Enfants-Malades University Hospital, APHP, Centre-Université de Paris, Paris, France.;Virology laboratory, Necker-Enfants-Malades University Hospital, APHP, Centre-Université de Paris, EHU 7328 PACT, Imagine Institute, University of Paris, Paris, France. | 1110 | ||
| 10.1186/s41182-020-00228-5 | Journal Article | en | The COVID-19 response must integrate people living with HIV needs in Sub-Saharan Africa: the case of Mali. | https://www.ncbi.nlm.nih.gov/pubmed/32514230 | The first COVID-19 cases in Mali were reported almost 1 month after the first case in the African continent. However, the outbreak continues to spread faster there than in other countries which, along with Mali, successfully tackled the 2014 Ebola outbreak in Africa. Given this context, specific actions targeting people living with HIV (PLWH) are needed to reinforce prevention. Community-based involvement is crucial to ensure continuity of care and treatment for PLWH. Furthermore, the health of frontline healthcare workers must take priority in any actions taken. The long-established trustful relationship between NGOs and PLWH in Mali is indispensable to disseminate key messages about COVID-19. | 1349-4147 | 2020-06-07 02:00:00+02:00 | pubmed | Tropical Medicine and Health | Luis Sagaon-Teyssier;Adam Yattassaye;Michel Bourrelly;Bintou Dembélé Keïta;Bruno Spire | COVID-19 prevention;HIV continuum of care;Mali;NGO implication;Public health | 2020-06-03 02:00:00+02:00 | 32514230 | FR;ML | Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France.;ARCAD Santé PLUS, Bamako, Mali. | 1119 | |||
| 10.1002/cyto.a.24040 | Journal Article | en | Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents. | https://www.ncbi.nlm.nih.gov/pubmed/32488957 | In response to the recent COVID-19 pandemic, many laboratories are involved in research supporting SARS-CoV-2 vaccine development and clinical trials. Flow cytometry laboratories will be responsible for a large part of this effort by sorting unfixed antigen-specific lymphocytes. Therefore, it is critical and timely that we have an understanding of risk assessment and established procedures of infectious cell sorting. Here we present procedures covering the biosafety aspects of sorting unfixed SARS-CoV-2-infected cells and other infectious agents of similar risk level. These procedures follow the ISAC Biosafety Committee guidelines and were recently approved by the National Institutes of Health Institutional Biosafety Committee for sorting SARS-CoV-2-infected cells. © 2020 International Society for Advancement of Cytometry. | 1552-4922,1552-4930 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Containment of Biohazards__methods;Coronavirus Infections__diagnosis;Flow Cytometry__methods;Humans;Laboratories__standards;Medical Laboratory Personnel__standards;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Risk Assessment;Specimen Handling__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cytometry Part A | Kristen M Reifel;Brandon K Swan;Evan R Jellison;David Ambrozak;Jan Baijer;Richard Nguyen;Simon Monard;Geoffrey Lyon;Benjamin Fontes;Stephen P Perfetto | COVID-19;ISAC Biosafety Committee;SARS-CoV-2 cell sorting procedure;biosafety and cell sorting;coronavirus;infectious cell sorting | 2020-06-03 02:00:00+02:00 | 32488957 | FR;AU;US | National Biodefense Analysis and Countermeasures Center, Frederick, Maryland, USA.;Department of Immunology, UConn Health, Farmington, Connecticut, USA.;Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.;CEA-DSV-IRCM, Fontenay-aux-Roses, France.;Walter and Eliza Hall Institute, Parkville, Victoria, Australia.;Yale University Flow Cytometry Facility, New Haven, Connecticut, USA.;Yale University Environmental Health and Safety Office, New Haven, Connecticut, USA. | 1125 | ||
| 10.1007/s13304-020-00822-6 | Journal Article | en | Resuming elective surgery in the time of COVID-19: a safe and comprehensive strategy. | https://www.ncbi.nlm.nih.gov/pubmed/32495280 | The 2019 novel corona virus and the disease it causes (COVID-19) is a public health crisis that has profoundly modified the way medical and surgical care is delivered. Countries around the globe had a variable initial response to the COVID-19 pandemic from imposing massive lock downs and quarantine to surrendering to herd immunity. However, healthcare bodies worldwide recognized early on that a triumph against COVID-19 could only be achieved by maintaining the infrastructure of healthcare systems and their capacity to accommodate a potentially overwhelming increase in critical patient care needs. Therefore, they reacted by restricting medical care to emergency cases and postponing elective surgical procedures in all disciplines. The priority was made for treatment of COVID-19 patients and emergency cases. Nevertheless, the battle against the COVID-19 pandemic is still ongoing. In the absence of vaccines or effective drug treatments, its timeline remains uncertain and it cannot be forecast how long healthcare systems will need to cope with it in managing inpatient and outpatient services. Accordingly, extreme measures and restriction may become a recipe for a disaster in the context of the potential adverse health implications imposed by delaying timely medical and surgical care. Therefore, restrictive measures should be substituted with a comprehensive surgical and medical care strategy. One that provides a safe balance between the prevention of COVID-19 and the delivery of essential surgical care. This article provides an overview on how to safely deliver essential surgical care in the time of COIVD-19. | 2038-131X,2038-3312 | 2020-06-07 02:00:00+02:00 | pubmed | Coronavirus Infections__prevention & control;Cross Infection__prevention & control;Elective Surgical Procedures__standards;Humans;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;COVID-19 | Updates in Surgery | Khaled Al-Omar;Sohail Bakkar;Laith Khasawneh;Gianluca Donatini;Paolo Miccoli | COVID-19;Elective surgery;Pandemic;SARS-CoV-2 | 2020-06-03 02:00:00+02:00 | 32495280 | FR;JO;IT | Department of Surgery, Faculty of Medicine, The Hashemite University, Zarqa, 13133, Jordan.;Department of Surgery, Faculty of Medicine, The Hashemite University, Zarqa, 13133, Jordan. sohail.bakkar@gmail.com.;Department of General and Endocrine Surgery, University of Poitiers, Poitiers, France.;Department of Surgical, Medical, Pathology, and Critical Care, the University of Pisa, 56124, Pisa, Italy. | 1127 | ||
| Letter | en | Does the newly observed inflammatory syndrome in children demonstrate a link between uncontrolled neutrophil extracellular traps formation and COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32492695 | 2020-06-07 02:00:00+02:00 | pubmed | Alain R Thierry | 2020-06-03 02:00:00+02:00 | 32492695 | FR | Research Institute of Cancerology of Montpellier, INSERM U1194, IRCM, ICM, Montpellier University, 34298, Montpellier, France. alain.thierry@inserm.fr. | 1128 | ||||||||
| Letter;Comment | en | Patient-Reported Outcome Questionnaires for the evaluation of olfactory and gustatory dysfunctions in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32494948 | 2020-06-07 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Humans;Pandemics;Patient Reported Outcome Measures;Pneumonia, Viral;Surveys and Questionnaires;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jerome R Lechien;Julien Hsieh;Maria Rosaria Barillari;Giovanni Cammaroto;Stephane Hans;Carlos M Chiesa-Estomba;Sven Saussez | Anosmia;COVID-19;Coronavirus;Hyposmia;Loss;Smell;Taste | 2020-06-03 02:00:00+02:00 | 32494948 | FR;CH;IT;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France. Jerome.Lechien@umons.ac.be.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium. Jerome.Lechien@umons.ac.be.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France. Jerome.Lechien@umons.ac.be.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. Jerome.Lechien@umons.ac.be.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France.;Rhinology-Olfactology Unit, Department of Otorhinolaryngology, Head and Neck Surgery, Geneva University Hospitals (HUG), Geneva, Switzerland.;Department of Mental and Physical Health and Preventive Medicine, University of L. Vanvitelli, Naples, Italy.;Department of Otolaryngology-Head and Neck Surgery, Morgagni Pierantoni Hospital, Forli, Italy.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. | 1131 | ||||||
| Letter | en | Chloroquine-Induced First-Episode Psychosis in a Patient Self-medicated for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32553277 | 2020-06-07 02:00:00+02:00 | pubmed | Marine Ambar Akkaoui;Michel Lejoyeux;Pierre A Geoffroy | 2020-06-02 02:00:00+02:00 | 32553277 | FR | Department of Psychiatry and Addictive Medicine, Hôpital Bichat-Claude-Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: marine.ambar@hotmail.com.;Department of Psychiatry and Addictive Medicine, Hôpital Bichat-Claude-Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France, Université de Paris, Paris, France.;Department of Psychiatry and Addictive Medicine, Hôpital Bichat-Claude-Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France, Joint Research Unit 1141, Université de Paris, NeuroDiderot, Inserm, F-75019. Paris, France. | 1134 | ||||||||
| 10.2807/1560-7917.es.2020.25.22.2001010 | Journal Article | en | SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32524957 | End of April 2020, French clinicians observed an increase in cases presenting with paediatric inflammatory multisystem syndrome (PIMS). Nationwide surveillance was set up and demonstrated temporospatial association with the coronavirus disease (COVID-19) epidemic for 156 reported cases as at 17 May: 108 were classified as confirmed (n = 79), probable (n = 16) or possible (n = 13) post-COVID-19 PIMS cases. A continuum of clinical features from Kawasaki-like disease to myocarditis was observed, requiring intensive care in 67% of cases. | 1560-7917 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Child, Preschool;Coronavirus__isolation & purification;Coronavirus Infections__complications;Disease Outbreaks;Female;France__epidemiology;Humans;Male;Pandemics;Pneumonia, Viral__complications;Systemic Inflammatory Response Syndrome__epidemiology;COVID-19;pediatric multisystem inflammatory disease, COVID-19 related;severe acute respiratory syndrome coronavirus 2 | Eurosurveillance | Alexandre Belot;Denise Antona;Sylvain Renolleau;Etienne Javouhey;Véronique Hentgen;François Angoulvant;Christophe Delacourt;Xavier Iriart;Caroline Ovaert;Brigitte Bader-Meunier;Isabelle Kone-Paut;Daniel Levy-Bruhl | COVID-19;Kawasaki disease;SARS-CoV2;children;inflammation;myocarditis;post-infectious disease | 2020-06-12 02:00:00+02:00 | 32524957 | FR | Filière de santé des maladies auto-immunes et auto-inflammatoires rares (FAI2R), Lyon, France.;Santé Publique France, Agence nationale de Santé publique, Saint-Maurice cedex, France.;Groupe francophone de réanimation et d'urgences pédiatriques (GFRUP), Paris, France.;Groupe de pathologies infectieuses pédiatriques (GPIP), Nice, France.;Société Française de Pédiatrie (SFP), Paris, France.;Société Française de Cardiologie, filiale de Cardiologie pédiatrique et congénitale (FCPC), Paris, France.;Société francophone dédiée à l'étude des maladies inflammatoires pédiatriques (SOFREMIP), Paris, France. | 1137 | ||
| 10.1007/s40261-020-00933-3 | Editorial | en | Azithromycin for COVID-19: More Than Just an Antimicrobial? | https://www.ncbi.nlm.nih.gov/pubmed/32533455 | 1173-2563,1179-1918 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Anti-Bacterial Agents__pharmacology;Anti-Inflammatory Agents__pharmacology;Antiviral Agents__pharmacology;Azithromycin__pharmacology;Child;Coronavirus Infections__drug therapy;Critical Care;Humans;Immunologic Factors__pharmacology;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment | Clinical Drug Investigation | Nathalie Bleyzac;Sylvain Goutelle;Laurent Bourguignon;Michel Tod | 2020-06-14 02:00:00+02:00 | 32533455 | FR | Service de Pharmacie, Hospices Civils de Lyon, Groupement Hospitalier Nord, Hôpital Pierre Garraud, 136 rue du Commandant Charcot, 69005, Lyon, France.;Service de Pharmacie, Hospices Civils de Lyon, Groupement Hospitalier Nord, Hôpital Pierre Garraud, 136 rue du Commandant Charcot, 69005, Lyon, France. sylvain.goutelle@chu-lyon.fr.;Univ Lyon, Université Lyon 1, ISPB, Faculté de Pharmacie de Lyon & UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, France. sylvain.goutelle@chu-lyon.fr.;Univ Lyon, Université Lyon 1, ISPB, Faculté de Pharmacie de Lyon & UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, France. | 1140 | ||||
| 10.5489/cuaj.6693 | Journal Article | en | Prioritization and management recommendations of pediatric urology conditions during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32525802 | 1920-1214,1911-6470 | 2020-06-14 02:00:00+02:00 | pubmed | Canadian Urological Association Journal | Daniel T Keefe;Mandy Rickard;Peter Anderson;Darius Bagli;Anne-Sophie Blais;Stéphane Bolduc;Luis H Braga;Natasha Brownrigg;Michael Chua;Sumit Dave;Joana Dos Santos;Luis Guerra;Allen H Hayashi;Mélise A Keays;Soojin Kim;Martin A Koyle;Linda C Lee;Armando J Lorenzo;Dawn MacLellan;Landan MacDonald;Andrew E MacNeily;Peter D Metcalfe;Katherine Moore;Rodrigo L P Romao;Peter Z T Wang | 2020-06-12 02:00:00+02:00 | 32525802 | FR;CA;GB;US | Division of Urology, The Hospital for Sick Children, Toronto, ON, Canada.;Division of Pediatric Urology, IWK Health Centre, Department of Urology, Dalhousie University, Halifax, NS, Canada.;Division d'Urologie, Département de Chirurgie, CHU de Québec, Quebec City, QC, Canada.;Department of Surgery/Urology, McMaster University, Hamilton, ON, Canada.;Department of Surgery, Division of Urology, Western University, London, ON, Canada.;Department of Surgery, Division of Pediatric Urology, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.;Division of Pediatric Surgery, Department of Surgery, Victoria General Hospital, Victoria, BC, Canada.;Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.;Department of Surgery, Division of Pediatric Surgery, University of Alberta, Stollery Children's Hospital, Edmonton, AB, Canada.;Division of Pediatric Surgery, IWK Health Centre, Department of Urology, Dalhousie University, Halifax, NS, Canada. | 1143 | |||||
| 10.1097/rlu.0000000000003152 | Case Reports;Journal Article | en | COVID-19 Pneumonia Mimicking Immunotherapy-Induced Pneumonitis on 18F-FDG PET/CT in a Patient Under Treatment With Nivolumab. | https://www.ncbi.nlm.nih.gov/pubmed/32520508 | Within a few months, coronavirus disease 2019 (COVID-19) has become a pandemic with more than 2 million patients infected and a high mortality rate. Early detection of COVID-19 in oncologic patients is crucial in order to rapidly apply isolation measures and avoid nosocomial spread. However, early diagnosis may be challenging, especially in cancer patients under treatment with immunotherapy as drug-induced pneumonitis can present similar clinical and radiological features. We describe the findings of a SARS-CoV-2 infection on PET/CT with F-FDG in a 51-year-old man with metastatic renal cell carcinoma under treatment with nivolumab. | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Carcinoma, Renal Cell__complications;Coronavirus Infections__complications;Diagnosis, Differential;Fluorodeoxyglucose F18;Humans;Immunotherapy__adverse effects;Kidney Neoplasms__complications;Male;Middle Aged;Nivolumab__adverse effects;Pandemics;Pneumonia__diagnostic imaging;Pneumonia, Viral__complications;Positron Emission Tomography Computed Tomography;COVID-19;severe acute respiratory syndrome coronavirus 2 | Carlos Artigas;Marc Lemort;Fabienne Mestrez;Thierry Gil;Patrick Flamen | 2020-06-11 02:00:00+02:00 | 32520508 | FR;BE;UNK | From the Departments of Nuclear Medicine.;Radiology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels.;Department of Nephrology-Dialysis, University Hospital (CHU) Ambroise Paré, Mons.;Department of Oncology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium. | 1145 | |||||
| 10.12998/wjcc.v8.i10.1756 | Journal Article;Review | en | French Spine Surgery Society guidelines for management of spinal surgeries during COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32518767 | Since the outbreak of coronavirus disease 2019 (COVID-19) in December 2019 in China, various measures have been adopted in order to attenuate the impact of the virus on the population. With regard to spine surgery, French physicians are devoted to take place in the national plan against COVID-19, the French Spine Surgery Society therefore decided to elaborate specific guidelines for management of spinal disorders during COVID-19 pandemic in order to prioritize management of patients. A three levels stratification was elaborated with Level I: Urgent surgical indications, Level II: Surgical indications associated to a potential loss of chance for the patient and Level III: Non-urgent surgical indications. We also report French experience in a COVID-19 cluster region illustrated by two clinical cases. We hope that the guidelines formulated by the French Spine Surgery Society and the experience of spine surgeons from a cluster region will be helpful in order optimizing the management of patients with urgent spinal conditions during the pandemic. | 2307-8960 | 2020-06-14 02:00:00+02:00 | pubmed | World Journal of Clinical Cases | Solène Prost;Yann Philippe Charles;Jérôme Allain;Jean-Luc Barat;Henri d'Astorg;Manuel Delhaye;Chistophe Eap;Fahed Zairi;Pierre Guigui;Brice Ilharreborde;Jean Meyblum;Jean-Charles Le Huec;Nicolas Lonjon;Guillaume Lot;Olivier Hamel;Guillaume Riouallon;Stéphane Litrico;Patrick Tropiano;Benjamin Blondel | COVID-19;Cluster region;Guidelines;Organization;Spine;Surgery | 2020-06-11 02:00:00+02:00 | 32518767 | FR | Aix-Marseille Université, APHM, CNRS, ISM, CHU Timone, Unité de Chirurgie Rachidienne, Marseille 13005, France.;Service de Chirurgie du Rachis, Hôpitaux Universitaires de Strasbourg, Strasbourg 67200, France.;Institut Parisien du dos, Paris 75005, France.;Service de Neurochirurgie, Hôpital privé Clairval - Ramsay santé, Marseille 13009, France.;Unité de Chirurgie du Rachis, Centre Orthopédique Santy, Lyon 69008, France.;Centre Francilien du dos, Versailles 78000, France.;CHU Reims, Hôpital Maison Blanche, Neurochirurgie, Reims 51100, France.;Hôpital Privé Le Bois Ramsay Santé, Lille 59000, France.;Hôpital Européen Georges-Pompidou HEGP, Paris 75015, France.;Service de Chirurgie Orthopédique Pédiatrique, CHU Robert Debré, AP-HP, Université de Paris, Paris 75019, France.;Service de Chirurgie Orthopédique, Groupe Hospitalier Paris Saint-Joseph, Paris 75014, France.;Polyclinique Bordeaux Nord Aquitaine, Bordeaux 33300, France.;Service de Neurochirurgie, Hôpital Gui de Chauliac, Montpellier 34090, France.;Hôpital - Fondation Rothschild, Service de Neurochirurgie, Paris 75019, France.;Clinique Des Cèdres Service de Neurochirurgie, Château D'Alliez, Cornebarrieu 31700, France.;Hôpital Paris Saint-Joseph, Paris 75014, France.;Unité de Chirurgie Rachidienne, Hôpital Pasteur 2, CHU de Nice, Nice 06001, France.;Aix-Marseille Université, APHM, CNRS, ISM, CHU Timone, Unité de Chirurgie Rachidienne, Marseille 13005, France. benjamin.blondel@ap-hm.fr. | 1146 | |||
| 10.1097/mej.0000000000000723 | Journal Article | en | COVID-19 epidemic in the Seine-Saint-Denis Department of Greater Paris: one month and three waves for a tsunami. | https://www.ncbi.nlm.nih.gov/pubmed/32516161 | Worldwide, the COVID-19 epidemic has put health systems to the test. The excess mortality is partly due to the influx of patients requiring hospitalization and intensive care. We propose that the chronology of epidemic spread gives a window of time in which hospitals can act to prevent reaching capacity. | 0969-9546 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Aged;Case-Control Studies;Communicable Disease Control__organization & administration;Coronavirus Infections__epidemiology;Critical Care__organization & administration;Delivery of Health Care__organization & administration;Disease Outbreaks__statistics & numerical data;Emergency Medical Services__organization & administration;Emergency Service, Hospital__statistics & numerical data;Female;France;Humans;Intensive Care Units__organization & administration;Male;Middle Aged;Organizational Innovation;Outcome Assessment, Health Care;Pandemics__statistics & numerical data;Paris;Pneumonia, Viral__epidemiology;Retrospective Studies;Risk Assessment;COVID-19 | European Journal of Emergency Medicine | Frédéric Lapostolle;Laurent Goix;Isabelle Vianu;Erick Chanzy;Carla De Stefano;Judith Gorlicki;Tomislav Petrovic;Frédéric Adnet | 2020-06-10 02:00:00+02:00 | 32516161 | FR | SAMU 93 - UF Recherche-Enseignement-Qualité Université Paris 13, Sorbonne Paris Cité, Inserm U942 Hôpital Avicenne, 125, rue de Stalingrad, 93009 Bobigny, France. | 1147 | |||
| 10.1016/j.jamda.2020.06.013 | Journal Article;Observational Study | en | Efficacy of a Test-Retest Strategy in Residents and Health Care Personnel of a Nursing Home Facing a COVID-19 Outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32674822 | To assess the American Testing Guidance for Nursing Homes (NHs)-updated May 19, 2020-with a new COVID-19 case. | 1525-8610 | 2020-06-14 02:00:00+02:00 | pubmed | Antibodies, Viral__analysis;Clinical Laboratory Techniques__methods;Contact Tracing__methods;Coronavirus Infections__diagnosis;DNA, Viral__analysis;Disease Outbreaks__prevention & control;Female;Health Personnel__statistics & numerical data;Humans;Infectious Disease Transmission, Vertical__prevention & control;Male;Nursing Homes__organization & administration;Occupational Health__statistics & numerical data;Outcome Assessment, Health Care;Pandemics;Patient Safety__statistics & numerical data;Pneumonia, Viral__diagnosis;Real-Time Polymerase Chain Reaction__methods;Skilled Nursing Facilities__organization & administration;United States__epidemiology;COVID-19;COVID-19 diagnostic testing | Journal of the American Medical Directors Association | Hubert Blain;Yves Rolland;Edouard Tuaillon;Nadia Giacosa;Mylène Albrand;Audrey Jaussent;Athanase Benetos;Stéphanie Miot;Jean Bousquet | COVID-19;antibodies against SARS-CoV-2;nursing home;rRT-PCR | 2020-06-11 02:00:00+02:00 | 32674822 | FR;DE | Department of Geriatrics, Montpellier University Hospital, Montpellier University, France. Electronic address: h-blain@chu-montpellier.fr.;Gérontopôle de Toulouse, INSERM 1027, Toulouse, France.;Department of Virology, Montpellier University Hospital, INSERM 1058, Montpellier University, France.;Department of Geriatrics, Montpellier University Hospital, Montpellier University, France.;Department of Medical Information, University Hospital of Montpellier, University of Montpellier, France.;Department of Geriatrics, CHRU de Nancy and Inserm DCAC, Université de Lorraine, Nancy, France.;Charité, Universitätsmedizin Berlin, Humboldt-Universität Berlin, Berlin, Germany, Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany, MACVIA-France, Montpellier, France. | 1165 | ||
| 10.1002/rth2.12358 | Journal Article | en | Emergence of institutional antithrombotic protocols for coronavirus 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32542211 | 2475-0379,2475-0379 | 2020-06-14 02:00:00+02:00 | pubmed | Research and Practice in Thrombosis and Haemostasis | Kevin P Cohoon;Guillaume Mahé;Alfonso J Tafur;Alex C Spyropoulos | COVID‐19;SARS‐CoV‐2;acute infectious disease;anticoagulant;antiplatelet;antithrombotic therapy;coronavirus;deep vein thrombosis;pulmonary embolism;pulmonary infection | 2020-06-12 02:00:00+02:00 | 32542211 | FR;US | Division of Cardiovascular Medicine Department of Medicine Froedtert and Medical College of Wisconsin Milwaukee Wisconsin USA.;CHU de Rennes, unité de médecine vasculaire Rennes France.;Inserm, CIC 1414 Univ Rennes, CHU Rennes Rennes France.;Pritzker School of Medicine at the University of Chicago Chicago Illinois USA.;Division of Vascular Medicine Department of Medicine NorthShore University HealthSystem Skokie Illinois USA.;Institute for Health Innovations and Outcomes Research Feinstein Institutes for Medical Research and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Manhasset New York USA. | 1181 | ||||
| 10.1136/annrheumdis-2020-217953 | Journal Article | en | Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al. | https://www.ncbi.nlm.nih.gov/pubmed/32527864 | 0003-4967,1468-2060 | 2020-06-14 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Latika Gupta;Durga Prasanna Misra;Vishwesh Agarwal;Suma Balan;Vikas Agarwal | arthritis;autoimmune diseases;dermatomyositis;lupus erythematosus;psoriatic;rheumatoid;systemic | 2020-06-11 02:00:00+02:00 | 32527864 | FR;IN | Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.;Mahatma Gandhi Mission's Medical College Kamothe, Navi Mumbai, India.;Department of Paediatric Rheumatology, Amrita Institute of Medical Sciences and Research Centre, Cochin, India.;Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India vikasagr@yahoo.com. | 1186 | ||||
| 10.1038/s41598-020-66368-0 | Journal Article | en | The 2020 coronavirus lockdown and seismic monitoring of anthropic activities in Northern Italy. | https://www.ncbi.nlm.nih.gov/pubmed/32523080 | In March/April 2020 the Italian government drastically reduced vehicle traffic and interrupted all non-essential industrial activities over the entire national territory. Italy thus became the first country in the world, with the exception of Hubei, to enact lockdown measures as a consequence of the COVID-19 outbreak and the need to contain it. Italy is also a seismically active area, and as such is monitored by a dense permanent network of seismic stations. We analyse continuous seismic data from many stations in northern and central Italy, and quantify the impact of the lockdown on seismic ambient noise, as a function of time and location. We find that the lockdown reduces ambient noise significantly in the 1-10 Hz frequency range; because natural sources of seismic noise are not affected by the lockdown, the seismic signature of anthropic noise can be characterised with unprecedented clarity, by simply comparing the signal recorded before and after the lockdown. Our results correlate well with independent evaluations of the impact of the lockdown (e.g., cell phone displacements), and we submit that ambient-noise seismology is a useful tool to monitor containment measures such as the coronavirus lockdowns. | 2045-2322 | 2020-06-14 02:00:00+02:00 | pubmed | Scientific Reports | Piero Poli;Jacopo Boaga;Irene Molinari;Valeria Cascone;Lapo Boschi | 2020-06-10 02:00:00+02:00 | 32523080 | FR;IT | ISTERRE, Université de Grenoble, Grenoble, France. piero.poli@univ-grenoble-alpes.fr.;Dipartimento di Geoscienze, Università degli Studi di Padova, Padova, Italy.;Istituto Nazionale di Geofisica e Vulcanologia, via Donato Creti 12, Bologna, Italy.;Sorbonne Université, CNRS, INSU, Institut des Sciences de la Terre de Paris, ISTeP UMR 7193, F-75005, Paris, France. | 1196 | ||||
| 10.1021/acsnano.0c03697 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32519842 | The COVID-19 outbreak has fueled a global demand for effective diagnosis and treatment as well as mitigation of the spread of infection, all through large-scale approaches such as specific alternative antiviral methods and classical disinfection protocols. Based on an abundance of engineered materials identifiable by their useful physicochemical properties through versatile chemical functionalization, nanotechnology offers a number of approaches to cope with this emergency. Here, through a multidisciplinary Perspective encompassing diverse fields such as virology, biology, medicine, engineering, chemistry, materials science, and computational science, we outline how nanotechnology-based strategies can support the fight against COVID-19, as well as infectious diseases in general, including future pandemics. Considering what we know so far about the life cycle of the virus, we envision key steps where nanotechnology could counter the disease. First, nanoparticles (NPs) can offer alternative methods to classical disinfection protocols used in healthcare settings, thanks to their intrinsic antipathogenic properties and/or their ability to inactivate viruses, bacteria, fungi, or yeasts either photothermally or via photocatalysis-induced reactive oxygen species (ROS) generation. Nanotechnology tools to inactivate SARS-CoV-2 in patients could also be explored. In this case, nanomaterials could be used to deliver drugs to the pulmonary system to inhibit interaction between angiotensin-converting enzyme 2 (ACE2) receptors and viral S protein. Moreover, the concept of "nanoimmunity by design" can help us to design materials for immune modulation, either stimulating or suppressing the immune response, which would find applications in the context of vaccine development for SARS-CoV-2 or in counteracting the cytokine storm, respectively. In addition to disease prevention and therapeutic potential, nanotechnology has important roles in diagnostics, with potential to support the development of simple, fast, and cost-effective nanotechnology-based assays to monitor the presence of SARS-CoV-2 and related biomarkers. In summary, nanotechnology is critical in counteracting COVID-19 and will be vital when preparing for future pandemics. | 1936-0851,1936-086X | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus__genetics;Biomimetics;Computer Simulation;Coronavirus Infections__genetics;Cytokines__antagonists & inhibitors;Disinfection;Drug Delivery Systems;Environmental Microbiology;Humans;Immunomodulation;Masks;Nanomedicine;Nanotechnology__methods;Pandemics__prevention & control;Personal Protective Equipment;Photochemotherapy;Pneumonia, Viral__immunology;Viral Vaccines__genetics;COVID-19;severe acute respiratory syndrome coronavirus 2 | ACS Nano | Carsten Weiss;Marie Carriere;Laura Fusco;Ilaria Capua;Jose Angel Regla-Nava;Matteo Pasquali;James A Scott;Flavia Vitale;Mehmet Altay Unal;Cecilia Mattevi;Davide Bedognetti;Arben Merkoçi;Ennio Tasciotti;Açelya Yilmazer;Yury Gogotsi;Francesco Stellacci;Lucia Gemma Delogu | 2020-06-10 02:00:00+02:00 | 32519842 | FR;CA;GB;US;CH;QA;IT;TR;ES;DE | Institute of Biological and Chemical Systems, Biological Information Processing, Karlsruhe Institute of Technology, Campus North, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany.;Univ. Grenoble Alpes, CEA, CNRS, IRIG, SyMMES-CIBEST, F-38000 Grenoble, France.;Department of Chemical and Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy.;Cancer Research Department, Sidra Medicine, Doha, Qatar.;One Health Center of Excellence, University of Florida, Gainesville, Florida 32611, United States.;Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, United States.;Department of Chemical & Biomolecular Engineering, Rice University, Houston, Texas 77251, United States.;Department of Chemistry, Rice University, Houston, Texas 77251, United States.;Department of Materials Science and Nanoengineering, Rice University, Houston, Texas 77251, United States.;Dalla Lana School of Public Health, University of Toronto, 223 College Street, M5T 1R4 Toronto, Ontario, Canada.;Department of Neurology, Bioengineering, Physical Medicine & Rehabilitation, Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.;Center for Neurotrauma, Neurodegeneration, and Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, United States.;Stem Cell Institute, Ankara University, Ankara, 06100 Turkey.;Department of Materials, Imperial College London, London SW7 2AZ, United Kingdom.;Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, 08193 Bellaterra, Spain.;ICREA - Institució Catalana de Recerca i Estudis Avançats, ES-08010 Barcelona, Spain.;Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States.;Department of Plastic Surgery, MD Anderson, Houston, Texas 77230, United States.;Department of Biomedical Engineering, Faculty of Engineering, Ankara University, Ankara, 06100 Turkey.;A.J. Drexel Nanomaterials Institute, and Materials Science and Engineering Department, Drexel University, Philadelphia, Pennsylvania 19104, United States.;Institute of Materials, Ecole Polytechnique Federale de Lausanne (EPFL), 1015 Lausanne, Switzerland.;Interfaculty Bioengineering Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.;Department of Biomedical Sciences, University of Padua, 35122 Padova, Italy. | 1201 | |||
| 10.1016/j.anorl.2020.06.002 | Journal Article | en | Percutaneous tracheostomy simulation training for ENT physicians in the treatment of COVID-19-positive patients. | https://www.ncbi.nlm.nih.gov/pubmed/32624392 | Tracheostomy in COVID-19-related severe acute respiratory syndrome is at high risk of viral dissemination. The percutaneous dilatation technique could reduce this risk, being performed at the bedside and minimising airway opening. In the COVID-19 context, however, with precarious respiratory status, it requires specific preparation. We designed a 3-hour training module, and here provide a step-by-step schedule, including video analysis, a demonstration of the kit, the recommended precautions related to COVID-19, and several simulation scenarios of increasing difficulty, using a high-tech mannequin. A low-tech procedural simulator was also developed for practicing the steps of the procedure. Our experience (3 sessions with 14 participants) highlighted the difficult points of the procedure in the COVID-19 context, and defined a checklist for clinical practice and an assessment grid. This type of simulation helps to prepare teams for a potentially delicate technical act. | 1879-7296 | 2020-06-14 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | V Favier;A Kimmoun;A Gatin;P Gallet | COVID-19;Checklist;Percutaneous dilatational tracheostomy;Simulation | 2020-06-10 02:00:00+02:00 | 32624392 | FR | Département d'ORL et chirurgie maxillofaciale, CHU de Montpellier, Montpellier, France, Aide à la décision médicale personnalisée, EA 2415, institut universitaire de recherche clinique, université de Montpellier, Montpellier, France.;Département de réanimation médicale, CHRU de Nancy, INSERM U1116, université de Lorraine, 54511, Vandœuvre-Lès-Nancy, Nancy, France.;Service des urgences pédiatriques, CHRU de Nancy, université de Lorraine, 54511, Vandœuvre-Lès-Nancy, Nancy, France, Centre universitaire d'enseignement par simulation, CUESim, hôpital virtuel de Lorraine HVL, université de Lorraine, Nancy, France.;Centre universitaire d'enseignement par simulation, CUESim, hôpital virtuel de Lorraine HVL, université de Lorraine, Nancy, France, Département d'ORL et chirurgie cervico-faciale, CHRU de Nancy, université de Lorraine, 54511, Vandœuvre-Lès-Nancy, Nancy, France. Electronic address: p.gallet@chru-nancy.fr. | 1205 | |||
| NINDS NIH HHS | 10.1101/2020.06.09.141101 | Preprint | en | SARS-CoV-2 nucleocapsid protein undergoes liquid-liquid phase separation stimulated by RNA and partitions into phases of human ribonucleoproteins. | https://www.ncbi.nlm.nih.gov/pubmed/32577653 | Tightly packed complexes of nucleocapsid protein and genomic RNA form the core of viruses and may assemble within viral factories, dynamic compartments formed within the host cells. Here, we examine the possibility that the multivalent RNA-binding nucleocapsid protein (N) from the severe acute respiratory syndrome coronavirus (SARS-CoV-2) compacts RNA via protein-RNA liquid-liquid phase separation (LLPS) and that N interactions with host RNA-binding proteins are mediated by phase separation. To this end, we created a construct expressing recombinant N fused to a N-terminal maltose binding protein tag which helps keep the oligomeric N soluble for purification. Using in vitro phase separation assays, we find that N is assembly-prone and phase separates avidly. Phase separation is modulated by addition of RNA and changes in pH and is disfavored at high concentrations of salt. Furthermore, N enters into in vitro phase separated condensates of full-length human hnRNPs (TDP-43, FUS, and hnRNPA2) and their low complexity domains (LCs). However, N partitioning into the LC of FUS, but not TDP-43 or hnRNPA2, requires cleavage of the solubilizing MBP fusion. Hence, LLPS may be an essential mechanism used for SARS-CoV-2 and other RNA viral genome packing and host protein co-opting, functions necessary for viral replication and hence infectivity. | 2020-06-14 02:00:00+02:00 | pubmed | Theodora Myrto Perdikari;Anastasia C Murthy;Veronica H Ryan;Scott Watters;Mandar T Naik;Nicolas L Fawzi | 2020-06-10 02:00:00+02:00 | 32577653 | FR;US | [{"country": "United States", "agency": "NINDS NIH HHS", "grantid": "F31 NS110301"}] | Center for Biomedical Engineering, Brown University, Providence, RI, USA.;Molecular Biology, Cell Biology & Biochemistry Graduate Program, Brown University, Providence, RI, USA.;Neuroscience Graduate Program, Brown University, Providence, RI, USA.;Department of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, RI, USA.;Robert J. and Nancy D. Carney Institute for Brain Science, Brown University, Providence, RI, USA. | 1206 | ||||
| 10.1016/j.encep.2020.06.001 | Editorial;Introductory Journal Article | fr | [French psychiatry and the novelty of the COVID-19 crisis]. | https://www.ncbi.nlm.nih.gov/pubmed/32620194 | 0013-7006 | 2020-06-14 02:00:00+02:00 | pubmed | Attitude;Betacoronavirus;Comorbidity;Coronavirus Infections__epidemiology;France;Humans;Mental Disorders__epidemiology;Mental Health Services__supply & distribution;Pandemics;Pneumonia, Viral__epidemiology;Psychiatry__trends;Social Change;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | M Masson;R Gaillard | 2020-06-11 02:00:00+02:00 | 32620194 | FR | Clinique du Château de Garches, Nightingale Hospitals-Paris, 11 bis, rue de la Porte-Jaune, 92380 Garches, France, Service hospitalo-universitaire, groupe hospito-universitaire, 1, rue Cabanis, 75014 Paris, France. Electronic address: m.masson@sinoue.com.;Service hospitalo-universitaire, groupe hospito-universitaire, 1, rue Cabanis, 75014 Paris, France, Institut Pasteur, unité perception et mémoire, 75015 Paris, France. | 1211 | ||||
| 10.1111/bjd.19163 | Journal Article | en | Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. | https://www.ncbi.nlm.nih.gov/pubmed/32348545 | The cutaneous manifestations of COVID-19 disease are poorly characterized. | 0007-0963,1365-2133 | 2020-06-14 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus__pathogenicity;Child;Consensus;Coronavirus Infections__complications;Dermatologists__statistics & numerical data;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Prognosis;Prospective Studies;Skin Diseases, Viral__classification;Spain__epidemiology;Surveys and Questionnaires__statistics & numerical data;Terminology as Topic;Time Factors;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | British Journal of Dermatology | C Galván Casas;A Català;G Carretero Hernández;P Rodríguez-Jiménez;D Fernández-Nieto;A Rodríguez-Villa Lario;I Navarro Fernández;R Ruiz-Villaverde;D Falkenhain-López;M Llamas Velasco;J García-Gavín;O Baniandrés;C González-Cruz;V Morillas-Lahuerta;X Cubiró;I Figueras Nart;G Selda-Enriquez;J Romaní;X Fustà-Novell;A Melian-Olivera;M Roncero Riesco;P Burgos-Blasco;J Sola Ortigosa;M Feito Rodriguez;I García-Doval | 2020-06-10 02:00:00+02:00 | 32348545 | FR;ES;BO;PS | Hospital Universitario de Móstoles, Madrid, Spain.;Hospital Plató, Barcelona, Spain.;Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.;Hospital Universitario de la Princesa, Madrid, Spain.;Hospital Universitario Ramón y Cajal, Madrid, Spain.;Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.;Hospital Universitario 'Marqués de Valdecilla', Santander, Spain.;Hospital Universitario Clínico San Cecilio, Granada, Spain.;Hospital Universitario 12 de Octubre, Madrid, Spain.;Gavín Dermatólogos, Vigo, Spain.;Hospital General Universitario Gregorio Marañón, Madrid, Spain.;Hospital Universitari Vall d'Hebron, Barcelona, Spain.;Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.;Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.;Consorci Sanitari Parc Taulí, Sabadell, Barcelona, Spain.;Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Barcelona, Spain.;Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.;Hospital General de Granollers, Barcelona, Spain.;Hospital Universitario La Paz, Madrid, Spain.;Research Unit, Fundación Piel Sana Academia Española de Dermatología y Venereología, Madrid, Spain. | 1213 | |||
| 10.1007/s00330-020-06977-5 | Journal Article | en | Acute pulmonary embolism in non-hospitalized COVID-19 patients referred to CTPA by emergency department. | https://www.ncbi.nlm.nih.gov/pubmed/32518989 | To evaluate the prevalence of acute pulmonary embolism (APE) in non-hospitalized COVID-19 patients referred to CT pulmonary angiography (CTPA) by the emergency department. | 0938-7994,1432-1084 | 2020-06-14 02:00:00+02:00 | pubmed | European Radiology | Alban Gervaise;Caroline Bouzad;Evelyne Peroux;Carole Helissey | CT angiography;Coronavirus;Pneumonia;Pulmonary embolism | 2020-06-09 02:00:00+02:00 | 32518989 | FR | Department of Radiology, Military Hospital Begin, 69 Avenue de Paris, 94163, Saint Mande Cedex, France. alban.gervaise@hotmail.fr.;Clinical Research Unit, Military Hospital Begin, Saint Mandé, France. alban.gervaise@hotmail.fr.;Department of Radiology, Military Hospital Begin, 69 Avenue de Paris, 94163, Saint Mande Cedex, France.;Clinical Research Unit, Military Hospital Begin, Saint Mandé, France. | 1214 | |||
| Letter;Observational Study | en | Patients with sickle cell disease and suspected COVID-19 in a paediatric intensive care unit. | https://www.ncbi.nlm.nih.gov/pubmed/32420608 | 2020-06-14 02:00:00+02:00 | pubmed | Adolescent;Anemia, Sickle Cell__diagnosis;Betacoronavirus;Child;Child, Preschool;Clinical Laboratory Techniques;Coronavirus Infections__diagnosis;Critical Care;Female;Humans;Intensive Care Units;Male;Pandemics;Pneumonia, Viral__diagnosis;Retrospective Studies;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Claire Heilbronner;Laureline Berteloot;Pierre Tremolieres;Laurent Dupic;Laure de Saint Blanquat;Fabrice Lesage;Marie-Hélène Odièvre;Charles de Marcellus;Jacques Fourgeaud;Marianne de Montalembert;Marion Grimaud;Florence Moulin;Sylvain Renolleau;Slimane Allali;Mehdi Oualha | COVID-19;acute chest syndrome;children;intensive care;sickle cell disease | 2020-06-08 02:00:00+02:00 | 32420608 | FR | Réanimation et Soins Continus Medico-chirurgicaux, Hôpital Necker-Enfants Malades, APHP Paris, Paris, France.;Service d'imagerie médicale pédiatrique, Hôpital Necker Enfants Malades, APHP Paris, Paris, France.;Unité d'hémaphérèse thérapeutique, Hôpital Necker-Enfants Malades, APHP Paris, Paris, France.;Pédiatrie générale, Centre de la drépanocytose, Hôpital Armand Trousseau, APHP, Université Paris, Paris, Sorbonne, France.;Laboratoire de Virologie, Hôpital Necker-Enfants Malades, Paris University, APHP Paris, Paris, France.;Pédiatrie générale et maladies infectieuses, Centre de référence de la drépanocytose, Hôpital Necker-Enfants Malades, APHP Paris, Paris, France. | 1217 | ||||||
| Letter;Comment | en | Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32453861 | 2020-06-14 02:00:00+02:00 | pubmed | Anemia, Hemolytic, Autoimmune;Betacoronavirus;Coronavirus Infections;Humans;Molecular Mimicry;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Francesca Angileri;Sébastien Légaré;Antonella Marino Gammazza;Everly Conway de Macario;Alberto J L Macario;Francesco Cappello | COVID-19;ankirin 1;autoantibodies;autoimmunity;molecular mimicry;severe acute respiratory syndrome coronavirus 2 | 2020-06-08 02:00:00+02:00 | 32453861 | FR;IT;US | Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Lyon, France.;Département d'Informatique de l'ÉNS, ÉNS, CNRS, Université PSL, Paris, France.;Centre de recherche Inria de Paris, Paris, France.;Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, Palermo, Italy.;Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore-Institute of Marine and Environmental Technology (IMET), Baltimore, MD, USA.;Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy. | 1219 | ||||||
| 10.1159/000509057 | Journal Article;Review | en | Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review. | https://www.ncbi.nlm.nih.gov/pubmed/32516795 | Even though respiratory viruses are one of the most common triggers for asthma exacerbations, not all of these viruses affect patients equally. There is no strong evidence supporting that patients with asthma have a higher risk of becoming seriously ill from coronavirus disease 2019 (CO-VID-19), although recent reports from the USA and the UK suggest that asthma is much more common in children and adults with mild to severe COVID-19 than has previously been reported in Asia and in Europe. As in previous severe acute respiratory syndrome (SARS) outbreaks, patients with asthma, especially children, appear to be less susceptible to the coronavirus with a low rate of asthma exacerbations. A different expression of viral receptors and T2 inflammation can be responsible for different outcomes. Future studies focused on asthma and on other allergic disorders are needed to provide a greater understanding of the impact of underlying asthma and allergic inflammation on COVID-19 susceptibility and disease severity. However, for the moment, it is crucial that asthmatic patients maintain their controller medication, from inhaled corticosteroids to biologics, without making any dose adjustments on their own or stopping the medication. New data are emerging daily, rapidly updating our understanding of this novel coronavirus. | 1018-2438,1423-0097 | 2020-06-14 02:00:00+02:00 | pubmed | International Archives of Allergy and Immunology | Mário Morais-Almeida;Helena Pité;Rita Aguiar;Ignacio Ansotegui;Jean Bousquet | Allergy;Asthma;COVID-19;Coronavirus disease 2019;Risk factors;T2 inflammation | 2020-06-09 02:00:00+02:00 | 32516795 | FR;ES;PT;DE | Allergy Center, CUF Descobertas and CUF Infante Santo Hospitals, Lisbon, Portugal.;Portuguese Association of Asthmatics (APA), Porto, Portugal.;CEDOC, Chronic Diseases Research Center, NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal.;Allergy Center, CUF Descobertas and CUF Infante Santo Hospitals, Lisbon, Portugal, aguiar2016@gmail.com.;Allergy Department, Hospital Quironsalud Bizkaia, Bizkaia, Spain.;Hospital Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.;Department of Dermatology and Allergy, Comprehensive Allergy Center, Berlin Institute of Health, Berlin, Germany.;MACVIA-France, Montpellier, France. | 1226 | |||
| 10.1212/wnl.0000000000010011 | Journal Article | en | Tapia syndrome at the time of the COVID-19 pandemic: Lower cranial neuropathy following prolonged intubation. | https://www.ncbi.nlm.nih.gov/pubmed/32518147 | 0028-3878,1526-632X | 2020-06-14 02:00:00+02:00 | pubmed | Neurology | Pierre Decavel;Carine Petit;Laurent Tatu | 2020-06-09 02:00:00+02:00 | 32518147 | FR | From the Department of Physical Medicine and Rehabilitation and Clinical Functional Exploration Laboratory of Movement (P.D.) and Department of Neurology (C.P.), CHRU, and Department of Neuromuscular Diseases and Department of Anatomy (L.T.), CHRU Besançon, University of Franche-Comté, France. pierre.decavel@univ-fcomte.fr.;From the Department of Physical Medicine and Rehabilitation and Clinical Functional Exploration Laboratory of Movement (P.D.) and Department of Neurology (C.P.), CHRU, and Department of Neuromuscular Diseases and Department of Anatomy (L.T.), CHRU Besançon, University of Franche-Comté, France. | 1229 | |||||
| 10.1007/s00134-020-06092-5 | Journal Article;Practice Guideline;Review | en | Managing ICU surge during the COVID-19 crisis: rapid guidelines. | https://www.ncbi.nlm.nih.gov/pubmed/32514598 | Given the rapidly changing nature of COVID-19, clinicians and policy makers require urgent review and summary of the literature, and synthesis of evidence-based guidelines to inform practice. The WHO advocates for rapid reviews in these circumstances. The purpose of this rapid guideline is to provide recommendations on the organizational management of intensive care units caring for patients with COVID-19 including: planning a crisis surge response; crisis surge response strategies; triage, supporting families, and staff. | 0342-4642,1432-1238 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Critical Care__standards;Equipment and Supplies, Hospital;Health Care Rationing__standards;Health Workforce;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Intensive Care Units__organization & administration;Pandemics;Personal Protective Equipment;Pneumonia, Viral__epidemiology;Respiration, Artificial__instrumentation;Triage;COVID-19;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Shadman Aziz;Yaseen M Arabi;Waleed Alhazzani;Laura Evans;Giuseppe Citerio;Katherine Fischkoff;Jorge Salluh;Geert Meyfroidt;Fayez Alshamsi;Simon Oczkowski;Elie Azoulay;Amy Price;Lisa Burry;Amy Dzierba;Andrew Benintende;Jill Morgan;Giacomo Grasselli;Andrew Rhodes;Morten H Møller;Larry Chu;Shelly Schwedhelm;John J Lowe;Du Bin;Michael D Christian | COVID-19;Critical care;Guideline;Pandemics;Surge capacity;Triage | 2020-06-08 02:00:00+02:00 | 32514598 | FR;CA;GE;SA;CN;GB;US;BR;IT;AE;DK;BE | London's Air Ambulance, Royal London Hospital, Barts NHS Health Trust, Whitechapel Rd, Whitechapel, London, E1 1FR, England, UK.;Intensive Care Department, Ministry of National Guard Health Affairs, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia.;Department of Medicine and Department of Health Research Methods, Evidence and Impact, Master University, Ontario, Canada.;Department of Pulmonary and Critical Care Medicine, University of Washington, Seattle, USA.;Università degli Studi di Milano - Bicocca, Milan, Italy.;Columbia University Medical Center, New York, USA.;Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, Brazil.;UZ Leuven, Louvain, Belgium.;Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Abu Dhabi, UAE.;Assistance publique - Hôpitaux de Paris, Paris, France.;Anaesthesia and Informatics Lab, Stanford University, Stanford, USA.;Sinai Health System, University of Toronto, Toronto, Canada.;New York-Presbyterian Hospital, Columbia University Irving Medical Center, New York, USA.;Emory University, Georgia, USA.;Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.;St Georges Hospitals NHS Foundation Trust, London, UK.;Department of Intensive Care, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.;Nebraska Medicine, Omaha, NE, USA.;Department of Environmental and Occupational Health, University of Nebraska Medical Center, Omaha, NE, USA.;Peking Union Medical College Hospital, Beijing, China.;London's Air Ambulance, Royal London Hospital, Barts NHS Health Trust, Whitechapel Rd, Whitechapel, London, E1 1FR, England, UK. michael.christian1@nhs.net. | 1234 | ||
| Letter | en | Solid organ transplant recipients during COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32515045 | 2020-06-14 02:00:00+02:00 | pubmed | Clémence Marcault;Sofiane Fodil;Thibault Dupont;Michael Darmon;Elie Azoulay | clinical research/practice;heart transplantation/cardiology;immune deficiency;immunosuppressant;immunosuppression/immune modulation;infection and infectious agents - viral;infectious disease | 2020-06-08 02:00:00+02:00 | 32515045 | FR | Hôpital Saint-Louis, Paris, France. | 1240 | |||||||
| 10.1093/ckj/sfaa109 | Journal Article | en | Coronavirus disease 2019: acute Fanconi syndrome precedes acute kidney injury. | https://www.ncbi.nlm.nih.gov/pubmed/32695327 | Recent data have shown that severe acute respiratory syndrome coronavirus 2 can infect renal proximal tubular cells via Angiotensin Converting Enzyme 2 (ACE2) . Our objective was to determine whether Fanconi syndrome is a frequent clinical feature in coronavirus disease 2019 (COVID-19) patients. | 2048-8505,2048-8513 | 2020-06-14 02:00:00+02:00 | pubmed | Clinical Kidney Journal | Raphaël Kormann;Audrey Jacquot;Asma Alla;Alice Corbel;Matthieu Koszutski;Paul Voirin;Matthieu Garcia Parrilla;Sybille Bevilacqua;Evelyne Schvoerer;Jean-Louis Gueant;Farès Namour;Bruno Levy;Luc Frimat;Abderrahim Oussalah | COVID-19;Fanconi syndrome;SARS-CoV-2;acute kidney injury;acute proximal tubule injury;hypophosphataemia | 2020-06-08 02:00:00+02:00 | 32695327 | FR | Department of Nephrology, University of Lorraine, CHRU-Nancy, Vandoeuvre, France.;Department of Intensive Care Medicine, University of Lorraine, CHRU-Nancy, Vandoeuvre, France.;Department of Infectious and Tropical Diseases, University of Lorraine, CHRU-Nancy, Vandoeuvre, France.;Department of Molecular Medicine, Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, University of Lorraine, CHRU-Nancy, Vandoeuvre, France.;Department of Microbiology, Division of Virology, University of Lorraine, CHRU-Nancy, Vandoeuvre, France.;INSERM UMRS 1256 NGERE (Nutrition Genetics Environmental Risk Exposure), University of Lorraine, Nancy, France.;INSERM U1116, University of Lorraine, Nancy, France.;INSERM CIC-EC CIE6, University of Lorraine, Nancy, France. | 1241 | |||
| Letter | en | Acute cholecystitis during COVID-19 pandemic: a multisocietary position statement. | https://www.ncbi.nlm.nih.gov/pubmed/32513287 | Following the spread of the infection from the new SARS-CoV2 coronavirus in March 2020, several surgical societies have released their recommendations to manage the implications of the COVID-19 pandemic for the daily clinical practice. The recommendations on emergency surgery have fueled a debate among surgeons on an international level.We maintain that laparoscopic cholecystectomy remains the treatment of choice for acute cholecystitis, even in the COVID-19 era. Moreover, since laparoscopic cholecystectomy is not more likely to spread the COVID-19 infection than open cholecystectomy, it must be organized in such a way as to be carried out safely even in the present situation, to guarantee the patient with the best outcomes that minimally invasive surgery has shown to have. | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Cholecystectomy__methods;Cholecystitis, Acute__surgery;Coronavirus Infections__complications;Humans;Infection Control__standards;Pandemics;Pneumonia, Viral__complications;Practice Guidelines as Topic;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Fabio Cesare Campanile;Mauro Podda;Alberto Arezzo;Emanuele Botteri;Alberto Sartori;Mario Guerrieri;Elisa Cassinotti;Irnerio Muttillo;Marcello Pisano;Riccardo Brachet Contul;Giancarlo D'Ambrosio;Diego Cuccurullo;Carlo Bergamini;Marco Ettore Allaix;Valerio Caracino;Wanda Luisa Petz;Marco Milone;Gianfranco Silecchia;Gabriele Anania;Antonino Agrusa;Salomone Di Saverio;Salvatore Casarano;Caterina Cicala;Piero Narilli;Sara Federici;Massimo Carlini;Alessandro Paganini;Paolo Pietro Bianchi;Adelona Salaj;Andrea Mazzari;Roberto Luca Meniconi;Alessandro Puzziello;Giovanni Terrosu;Belinda De Simone;Federico Coccolini;Fausto Catena;Ferdinando Agresta | Acute cholecystitis;COVID-19 pandemic;Emergency surgery;New coronavirus;Position statement | 2020-06-08 02:00:00+02:00 | 32513287 | FR;IT;US | Division of General Surgery, San Giovanni Decollato-Andosilla Hospital, Civita Castellana, ASL VT, Italy.;Department of Surgery, Azienda Ospedaliero-Universitaria di Cagliari, Policlinico Universitario di Monserrato "Duilio Casula" University of Cagliari, SS 554, Km 4,500, Monserrato, 09042, Cagliari, Italy. mauropodda@ymail.com.;Department of Surgical Sciences, University of Torino, Turin, Italy.;General Surgery, ASST Spedali Civili di Brescia, Montichiari, Italy.;Department of General Surgery, Ospedale di Montebelluna, Montebelluna, Italy.;Department of General Surgery, Università Politecnica delle Marche, Ancona, Italy.;Chirurgia Generale, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.;Department of General and Emergency Surgery, Ospedale San Filippo Neri, Roma, Italy.;Department of General Surgery, Ospedale San Marcellino di Muravera, Cagliari, Italy.;Department of General and Emergency Surgery, Ospedale Regionale Umberto Parini, Aosta, Italy.;Department of General Surgery, Surgical Specialties and Organ Transplantation, Rome, Italy.;Department of General Surgery, Ospedali dei Colli Monaldi Hospital, Naples, Italy.;Emergency Surgery Unit, Careggi Hospital, Florence, Italy.;2° General Surgery, Hospital "Spirito Santo", Pescara, Italy.;Department of Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.;Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.;Department of Medico-Surgical Sciences and Biotechnologies, University La Sapienza of Rome, Latina, Italy.;Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.;Department of General and Emergency Surgery, University of Palermo, Palermo, Italy.;Department of Surgery, University of Insubria, Varese, Italy.;Operating theatre, Pia Fondazione Panico Hospital, Tricase, Lecce, Italy.;Operating theatre, Fondazione Policlinico Gemelli IRCSS, Rome, Italy.;Division of General Surgery, Casa di Cura Nuova Itor, Rome, Italy.;Department of Surgery, Sant'Eugenio Hospital, Rome, Italy.;Department of Surgery "Paride Stefanini", La Sapienza University of Rome, Rome, Italy.;Department of General and Minimally Invasive Surgery, Misericordia Hospital, Grosseto, Italy.;Department of Mini-Invasive and General Surgery, Cristo Re Hospital, Rome, Italy.;Department of Surgery, San Camillo-Forlanini Hospital, Rome, Italy.;Department of General Surgery, Salerno University Hospital, Salerno, Italy.;Department of General Surgery, Clinica Chirurgica, University of Udine, Udine, Italy.;Department of Visceral Surgery, Centre Hospitalier Intercommunal Poissy/Saint-Germain-en-Laye, Poissy, France.;Emergency Surgery Unit and Trauma Center, Pisa University Hospital, Pisa, Italy.;Emergency and Trauma Surgery, Maggiore Hospital, Parma, Italy.;Department of General Surgery, Ospedale Civile, Adria, Italy. | 1245 | |||||
| Case Reports;Letter | en | Haemophagocytosis in bone marrow aspirates in patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32529634 | 2020-06-14 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Bone Marrow__pathology;Coronavirus Infections__complications;Female;Humans;Lymphohistiocytosis, Hemophagocytic__complications;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Agathe Debliquis;Inès Harzallah;Joy Y Mootien;Antoine Poidevin;Guylaine Labro;Amira Mejri;Mathilde Lamarque;Khaldoun Kuteifan;Bernard Drénou | COVID-19;bone marrow morph;haemophagocytic syndrome;infection | 2020-06-12 02:00:00+02:00 | 32529634 | FR | Département d'Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse, France.;Service de Réanimation médicale, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse, France. | 1246 | ||||||
| Letter | en | New-Onset Diabetes in Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32530585 | 2020-06-14 02:00:00+02:00 | pubmed | Francesco Rubino;Stephanie A Amiel;Paul Zimmet;George Alberti;Stefan Bornstein;Robert H Eckel;Geltrude Mingrone;Bernhard Boehm;Mark E Cooper;Zhonglin Chai;Stefano Del Prato;Linong Ji;David Hopkins;William H Herman;Kamlesh Khunti;Jean-Claude Mbanya;Eric Renard | 2020-06-12 02:00:00+02:00 | 32530585 | FR;SG;CN;GB;US;CM;IT;AU;DE | King's College London, London, United Kingdom francesco.rubino@kcl.ac.uk.;Monash University, Melbourne, VIC, Australia.;Imperial College London, London, United Kingdom.;Technical University of Dresden, Dresden, Germany.;University of Colorado Anschutz Medical Campus, Aurora, CO.;Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.;Nanyang Technological University, Singapore, Singapore.;University of Pisa, Pisa, Italy.;Peking University, Beijing, China.;King's Health Partners, London, United Kingdom.;University of Michigan, Ann Arbor, MI.;University of Leicester, Leicester, United Kingdom.;University of Yaounde 1, Yaounde, Cameroon.;University of Montpellier, Montpellier, France. | 1250 | ||||||||
| Letter | en | The need to adapt the rescue chain for out-of-hospital cardiac arrest during the COVID-19 pandemic: Experience from the Paris Fire Brigade Basic Life Support and Advanced Life Support teams. | https://www.ncbi.nlm.nih.gov/pubmed/32540262 | 2020-06-14 02:00:00+02:00 | pubmed | Advanced Cardiac Life Support__standards;Betacoronavirus;Coronavirus Infections__complications;Emergency Medical Services__standards;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Occupational Exposure__prevention & control;Out-of-Hospital Cardiac Arrest__therapy;Pandemics;Paris;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Daniel Jost;Clément Derkenne;Romain Kedzierewicz;Frédérique Briche;Benoit Frattini;Kilian Bertho;Bertrand Prunet;Daniel Jost;Frédéric Lemoine;Vincent Lanoë;Benoit Frattini;Clément Derkenne;Romain Kedzierewicz;Frédérique Briche;Romain Jouffroy;Sabine Lemoine;Xavier Lesaffre;Ludovic Delhaye;Laurent Prieux;Vivien Hong Tuan Ha;Julie Trichereau;Eric Gauyat;Olivier Stibbe;Stéphane Travers;Pascal Diegelmann;René Bihannic;Bertrand Prunet | 2020-06-12 02:00:00+02:00 | 32540262 | FR | Paris Fire Brigade, Emergency Medicine Department, 1 Place Jules Renard, 75017 Paris, France, Sudden Death Expertise Center, Paris, France. Electronic address: daniel.jost@pompiersparis.fr.;Paris Fire Brigade, Emergency Medicine Department, 1 Place Jules Renard, 75017 Paris, France.;Paris Fire Brigade, Emergency Medicine Department, 1 Place Jules Renard, 75017 Paris, France, French Military Health Service, Val de Grâce Military Academy, Paris, France. | 1253 | |||||||
| 10.1002/ana.25814 | Journal Article | en | Report on Electroencephalographic Findings in Critically Ill Patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32533727 | In March 2020, we treated a cohort of 26 critically ill hospitalized SARS-CoV-2-infected patients who underwent electroencephalography to assess unexplained altered mental status, loss of consciousness, or poor arousal and responsiveness. Of the 26 patients studied, 5 patients had electroencephalograms that showed periodic discharges consisting of high-amplitude frontal monomorphic delta waves with absence of epileptic activity. These findings may suggest central nervous system injury potentially related to COVID-19 in these patients. ANN NEUROL 2020. | 0364-5134,1531-8249 | 2020-06-14 02:00:00+02:00 | pubmed | Annals of Neurology | Hervé Vespignani;Damien Colas;Bruce S Lavin;Christine Soufflet;Louis Maillard;Valérie Pourcher;Olivier Paccoud;Samir Medjebar;Pierre-Yves Frouin | 2020-06-13 02:00:00+02:00 | 32533727 | FR;US | Lorraine University, Vandœuvre-lès-Nancy, France.;BioSerenity, Paris, France.;BioSerenity, Atlanta, GA.;Necker-Sainte Anne Hospital, Paris, France.;Pitié-Salpêtrière Hospital, Paris, France. | 1259 | ||||
| EMB's effort is supported in part by the National Heart Lung and Blood Institute | 10.1111/vox.12970 | Journal Article | en | Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries. | https://www.ncbi.nlm.nih.gov/pubmed/32533868 | COVID-19 convalescent plasma (CCP) has been used, predominantly in high-income countries (HICs) to treat COVID-19; available data suggest the safety and efficacy of use. We sought to develop guidance for procurement and use of CCP, particularly in low- and middle-income countries (LMICs) for which data are lacking. | 0042-9007,1423-0410 | 2020-06-14 02:00:00+02:00 | pubmed | Vox Sanguinis | Evan M Bloch;Ruchika Goel;Silvano Wendel;Thierry Burnouf;Arwa Z Al-Riyami;Ai Leen Ang;Vincenzo DeAngelis;Larry J Dumont;Kevin Land;Cheuk-Kwong Lee;Adaeze Oreh;Gopal Patidar;Steven L Spitalnik;Marion Vermeulen;Salwa Hindawi;Karin Van den Berg;Pierre Tiberghien;Hans Vrielink;Pampee Young;Dana Devine;Cynthia So-Osman | COVID-19;COVID-19 serotherapy;SARS-CoV-2;blood donors;blood transfusion | 2020-06-13 02:00:00+02:00 | 32533868 | FR;SG;OM;CA;SA;NG;CN;LB;GB;TW;US;HK;BR;IT;NL;ZA;IN | [{"country": "", "agency": "EMB's effort is supported in part by the National Heart Lung and Blood Institute", "grantid": "1K23HL151826-01"}] | Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.;Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and Mississippi Valley Regional Blood Center, Springfield, Illinois, USA.;Hospital Sirio Libanês, São Paulo, Brazil.;Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.;International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.;Department of Hematology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.;Blood Services Group, Health Sciences Authority, Singapore, Singapore.;Transfusion Medicine Dept, Udine University Hospital, Udine, Italy.;Vitalant Research Institute, Denver, CO, USA.;University of Colorado School of Medicine, Denver, CO, USA.;Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.;Vice President Clinical Services, Vitalant, Scottsdale, AZ, USA.;Department of Pathology, UT Health Science Center San Antonio, San Antonio, TX, USA.;Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China, China.;King's Park Rise, Kowloon, China.;National Blood Transfusion Service, Department of Hospital Services, Federal Ministry of Health, Abuja, Nigeria.;Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India.;Department of Pathology & Cell Biology, Columbia University, New York, NY, USA.;The South African National Blood Service, Johannesbur, South Africa.;Haematology & Transfusion Medicine, King Abdalaziz University, Jeddah, Saudi Arabia.;Etablissement Français du Sang, Paris, France.;Department Unit Transfusion Medicine, Sanquin Blood Supply Foundation, Amsterdam, NL, Netherlands.;American Red Cross, Washington, D.C, USA.;Canadian Blood Services, Vancouver, BC, Canada.;Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.;Department of Haematology, Erasmus Medical Center, Rotterdam, NL, Netherlands. | 1264 | |
| Letter | en | Digital tablets to improve quality of life of COVID-19 older inpatients during lockdown. | https://www.ncbi.nlm.nih.gov/pubmed/32535757 | 2020-06-14 02:00:00+02:00 | pubmed | Radjiv Goulabchand;Helene Boclé;Renaud Vignet;Albert Sotto;Paul Loubet | COVID-19;Digital tablets;End-of-life | 2020-06-13 02:00:00+02:00 | 32535757 | FR | Internal Medicine Department, CHU Nîmes Univ Montpellier, Place du Pr Debre, 30 029, Nîmes, France. radjiv.goulabchand@chu-nimes.fr.;Inserm U1183, Institute for Regenerative Medicine and Biotherapy, St Eloi Hospital, 80 avenue Augustin Fliche, Montpellier, France. radjiv.goulabchand@chu-nimes.fr.;Department of Infectious and Tropical Diseases, CHU Nîmes Univ Montpellier, Nîmes, France.;Inserm U1047, University of Montpellier, Nîmes, France.;Addictions Department, CHU Nîmes, Nîmes, France. | 1265 | |||||||
| 10.1016/j.cjca.2020.06.006 | Journal Article | en | Cardiac Rehabilitation During the COVID-19 Era: Guidance on Implementing Virtual Care. | https://www.ncbi.nlm.nih.gov/pubmed/32553606 | Cardiac rehabilitation programs across Canada have suspended in-person services as a result of large-scale physical distancing recommendations designed to flatten the COVID-19 pandemic curve. Virtual cardiac rehabilitation (VCR) offers an alternate mechanism of care delivery, capable of providing similar patient outcomes and safety profiles compared with centre-based programs. To minimize care gaps, all centres should consider developing and implementing a VCR program. The process of this rapid implementation, however, can be daunting. Centres should initially focus on the collation, utilization, and repurposing of existing resources, equipment, and technology. Once established, programs should then focus on ensuring that quality indicators are met and care processes are protocolized. This should be followed by the development of sustainable VCR solutions to account for care gaps that existed before COVID-19, and to improve cardiac rehabilitation delivery, moving forward. This article reviews the potential challenges and obstacles of this process and aims to provide pragmatic guidance to aid clinicians and administrators during this challenging time. | 0828-282X | 2020-06-14 02:00:00+02:00 | pubmed | Canadian Journal of Cardiology | Nathaniel Moulson;David Bewick;Tracy Selway;Jennifer Harris;Neville Suskin;Paul Oh;Thais Coutinho;Gurmeet Singh;Chi-Ming Chow;Brian Clarke;Simone Cowan;Christopher B Fordyce;Anne Fournier;Kenneth Gin;Anil Gupta;Sean Hardiman;Simon Jackson;Yoan Lamarche;Benny Lau;Jean-François Légaré;Howard Leong-Poi;Samer Mansour;Ariane Marelli;Ata Ur Rehman Quraishi;Idan Roifman;Marc Ruel;John Sapp;Gary Small;Ricky Turgeon;David A Wood;Shelley Zieroth;Sean Virani;Andrew D Krahn | 2020-06-14 02:00:00+02:00 | 32553606 | FR;CA;GB;US | Centre for Cardiovascular Innovation, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.;New Brunswick Heart Centre, Saint John, New Brunswick, Canada. Electronic address: bewickd@nbnet.nb.ca.;New Brunswick Heart Centre, Saint John, New Brunswick, Canada.;University of Ottawa Heart Institute, Ottawa, Ontario, Canada.;Western University, London, Ontario, Canada.;University Health Network, University of Toronto, Toronto, Ontario, Canada.;Mazankowski Alberta Hearth Institute, Departments of Critical Care Medicine and Surgery, Division of Cardiac Surgery, University of Alberta, Edmonton, Alberta, Canada.;Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.;Libin Cardiovascular Institute, Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada.;CHU Sainte-Justine, Université de Montréal, Montréal, Québec, Canada.;Trillium Health Partners, University of Toronto, Mississauga, Ontario, Canada.;Cardiac Services BC, Provincial Health Services Authority, Vancouver, British Columbia, Canada.;QEII Health Sciences Center, Division of Cardiology, Dalhousie University, Halifax, Nova Scotia, Canada.;Department of Surgery, Montréal Heart Institute, Université de Montréal, Montréal, Québec, Canada.;Department of Medicine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada.;McGill University Health Center, Department of Medicine, McGill University, Montréal, Québec, Canada.;Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.;University of Manitoba, Winnipeg, Manitoba, Canada. | 1266 | ||||
| 10.1186/s12967-020-02399-5 | Journal Article | en | Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey. | https://www.ncbi.nlm.nih.gov/pubmed/32513197 | On December 12th 2019, a new coronavirus (SARS-Cov2) emerged in Wuhan, China, sparking a pandemic of acute respiratory syndrome in humans (COVID-19). On the 24th of April 2020, the number of COVID-19 deaths in the world, according to the COVID-Case Tracker by Johns Hopkins University, was 195,313, and the number of COVID-19 confirmed cases was 2,783,512. The COVID-19 pandemic represents a massive impact on human health, causing sudden lifestyle changes, through social distancing and isolation at home, with social and economic consequences. Optimizing public health during this pandemic requires not only knowledge from the medical and biological sciences, but also of all human sciences related to lifestyle, social and behavioural studies, including dietary habits and lifestyle. | 1479-5876 | 2020-06-14 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus__physiology;Child;Coronavirus Infections__epidemiology;Diet, Mediterranean;Drinking;Emergencies;Feeding Behavior;Female;Guideline Adherence;Humans;Italy;Life Style;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Quarantine;Sleep;Smoking;Surveys and Questionnaires;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Translational Medicine | Laura Di Renzo;Paola Gualtieri;Francesca Pivari;Laura Soldati;Alda Attinà;Giulia Cinelli;Claudia Leggeri;Giovanna Caparello;Luigi Barrea;Francesco Scerbo;Ernesto Esposito;Antonino De Lorenzo | COVID-19;Coronavirus;Eating habits;Lifestyle;Mediterranean diet | 2020-06-08 02:00:00+02:00 | 32513197 | FR;IT | Section of Clinical Nutrition and Nutrigenomic, Department of Biomedicine and Prevention, University of Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.;Department of Health Sciences, University of Milan, Via A. Di Rudinì, 8, 20142, Milan, Italy. francesca.pivari@unimi.it.;Department of Health Sciences, University of Milan, Via A. Di Rudinì, 8, 20142, Milan, Italy.;School of Specialization in Food Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.;Predictive and Preventive Medicine Research Unit, "Bambino Gesù" Children Hospital IRCCS, 00165, Rome, Italy.;Dipartimento di Medicina Clinica e Chirurgia, Unit of Endocrinology, Federico II University Medical School of Naples, 80131, Naples, Italy.;Doctoral School in Public Health and Nursing, "Policlinico Tor Vergata" Foundation, Rome, Italy.;General Directorate for the Department of Human Policies, Basilicata Region, Italy. | 1270 | ||
| 10.1093/eurheartj/ehaa506 | Journal Article | en | Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic? | https://www.ncbi.nlm.nih.gov/pubmed/32556334 | 0195-668X,1522-9645 | 2020-06-21 02:00:00+02:00 | pubmed | Anti-Bacterial Agents;Antibodies, Monoclonal, Humanized__therapeutic use;Anticoagulants__therapeutic use;Antimalarials__therapeutic use;Antiviral Agents__therapeutic use;Azithromycin__therapeutic use;Betacoronavirus;Biomedical Research;Clinical Laboratory Techniques__standards;Coronavirus Infections__diagnosis;Data Accuracy;Device Approval;Diagnostic Test Approval;Drug Approval;Drug and Narcotic Control;European Union;Glucocorticoids__therapeutic use;Heparin__therapeutic use;Humans;Immunization, Passive__standards;Medical Device Legislation;Pandemics;Personal Protective Equipment__standards;Pneumonia, Viral__diagnosis;Ventilators, Mechanical__standards;COVID-19;COVID-19 diagnostic testing;COVID-19 drug treatment;COVID-19 serotherapy;severe acute respiratory syndrome coronavirus 2 | European Heart Journal | Alan G Fraser;Piotr Szymański;Elizabeth Macintyre;Martin Landray | 2020-06-20 02:00:00+02:00 | 32556334 | FR;PL;BE;GB | Department of Cardiology, University Hospital of Wales, Cardiff, UK.;Cardiovascular Imaging and Dynamics, Katholieke Universiteit Leuven Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.;Centre of Postgraduate Medical Education, MSWiA Central Clinical Hospital, ul. Woloska 137, 02-507 Warsaw, Poland.;Hématologie Biologique and INSERM UMR1151, Université de Paris (Descartes), Hôpital Necker Enfants Malades, 149 rue de Sèvres, Paris 75743, France.;Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK. | 1275 | ||||
| Journal Article;Comment | en | Helping Africa to breathe when COVID-19 strikes. | https://www.ncbi.nlm.nih.gov/pubmed/32552989 | 2020-06-21 02:00:00+02:00 | pubmed | Africa South of the Sahara;Betacoronavirus;Coronavirus Infections;Health Facilities;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | P M Fenton | 2020-06-20 02:00:00+02:00 | 32552989 | FR | Independent Consultant, Meyra, 47800, Agnac, France, <email></email>, Email: uam.paul@gmail.com. | 1284 | |||||||
| Journal Article;Comment | en | Preparing national tuberculosis control programmes for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32553013 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Tuberculosis__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | C Sandy;K C Takarinda;C Timire;H Mutunzi;M Dube;R A Dlodlo;A D Harries | 2020-06-20 02:00:00+02:00 | 32553013 | FR;ZW;GB;UNK | Ministry of Health and Child Care, AIDS and TB Department, Harare, Zimbabwe.;Ministry of Health and Child Care, AIDS and TB Department, Harare, Zimbabwe, International Union Against Tuberculosis and Lung Disease, Paris, France.;Directorate of Laboratory Services.;Directorate of Pharmacy Services, Ministry of Health and Child Care, Harare, Zimbabwe.;International Union Against Tuberculosis and Lung Disease, Paris, France.;International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK, <email></email>, Email: adharries@theunion.org. | 1286 | |||||||
| 10.1684/pnv.2020.0863 | Journal Article;Systematic Review | en | Symptoms of COVID-19 among older adults: systematic review of biomedical literature. | https://www.ncbi.nlm.nih.gov/pubmed/32554345 | The COVID-19 pandemic is particularly severe in older adults. Our objective was to identify, from international literature, the most common symptoms met in older adults infected with the SARS-CoV-2 virus. This systematic review of the literature was conducted using MEDLINE from December 1, 2019 to April 13, 2020. The analysis of methodological quality used a method dedicated to case series and case reports. Out of 260 articles initially identified, only two studies were finally included in the qualitative analysis. The mean age was relatively low, between 71 and 74 years on average. The symptoms of COVID-19 were as follows: fever, dry cough, dyspnea, asthenia, anorexia, chest tightness, diarrhea, and to a lesser extent myalgia, pharyngitis, nausea, dizziness, headache, abdominal pain and finally vomiting. Lymphopenia was found in the complete blood count. In conclusion, this systematic review of the international literature reveals a lack of data about the semiology of COVID-19 in older adults, especially in the frail oldest-old ones who commonly define the geriatric population. The national survey conducted by the French Society of Geriatrics and Gerontology will help fill this semiological gap. | 2020-06-21 02:00:00+02:00 | pubmed | Age Factors;Aged;Aged, 80 and over;Coronavirus Infections__diagnosis;Frail Elderly;Humans;Pandemics;Pneumonia, Viral__diagnosis;COVID-19 | Guillaume Sacco;Olivier Brière;Marine Asfar;Olivier Guérin;Gilles Berrut;Cédric Annweiler | COVID-19;SARS-Cov-2;older adults;semiology;symptomatology | 2020-06-20 02:00:00+02:00 | 32554345 | FR;CA;GB | Département de gériatrie et Centre Mémoire Ressources Recherche, Centre de recherche sur l'autonomie et la longévité, Centre hospitalier universitaire, Angers, France, UPRES EA 4638, Université d'Angers, Angers, France.;Département de gériatrie et Centre Mémoire Ressources Recherche, Centre de recherche sur l'autonomie et la longévité, Centre hospitalier universitaire, Angers, France.;Université Côte d'Azur, Centre hospitalier universitaire de Nice, Service de médecine gériatrique et thérapeutique, Nice, France, Université Côte d'Azur, CNRS UMR 7284/Inserm U108, Institute for Research on Cancer and Aging Nice (IRCAN), Faculté de médecine, Nice, France.;Pôle hospitalo-universitaire de gérontologie clinique, CHU de Nantes, France.;Département de gériatrie et Centre Mémoire Ressources Recherche, Centre de recherche sur l'autonomie et la longévité, Centre hospitalier universitaire, Angers, France, UPRES EA 4638, Université d'Angers, Angers, France, Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, ON, Canada. | 1292 | ||||
| Roche;national Research Agency (ANR) through the ANR-Flash calls for COVID-19;US Department of Energy | 10.1002/psp4.12543 | Journal Article | en | Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. | https://www.ncbi.nlm.nih.gov/pubmed/32558354 | We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory syndrome-coronavirus 2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than two logs, drug efficacy needs to be > 90% if treatment is administered after symptom onset; an efficacy of 60% could be sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current investigated drugs may be in a range of 6-87% efficacy. They may help control virus if administered very early, but may not have a major effect in severely ill patients. | 2163-8306,2163-8306 | 2020-06-21 02:00:00+02:00 | pubmed | CPT: Pharmacometrics & Systems Pharmacology | Antonio Gonçalves;Julie Bertrand;Ruian Ke;Emmanuelle Comets;Xavier de Lamballerie;Denis Malvy;Andrés Pizzorno;Olivier Terrier;Manuel Rosa Calatrava;France Mentré;Patrick Smith;Alan S Perelson;Jérémie Guedj | 2020-06-18 02:00:00+02:00 | 32558354 | FR;JE;MX;US | [{"country": "", "agency": "Roche", "grantid": "89233218CNA000001"}, {"country": "", "agency": "national Research Agency (ANR) through the ANR-Flash calls for COVID-19", "grantid": "ANR-20-COVI-0018"}, {"country": "", "agency": "US Department of Energy"}] | Université de Paris, IAME, INSERM, Paris, France.;Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA.;Institut Hospitalo-Universitaire Méditerranée Infection, UMR "Emergence des Pathologies Virales" (EPV: Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP), Marseille, France.;Inserm, UMR 1219, Université de Bordeaux, Bordeaux, France.;Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.;Certara, Integrated Drug Development, Princeton, New Jersey, USA. | 1295 | ||
| NCI NIH HHS;NCI NIH HHS | 10.1158/1078-0432.ccr-20-1657 | Journal Article;Research Support, Non-U.S. Gov't | en | Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. | https://www.ncbi.nlm.nih.gov/pubmed/32540850 | The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic. | 1078-0432,1557-3265 | 2020-06-21 02:00:00+02:00 | pubmed | Clinical Cancer Research | Michele Maio;Omid Hamid;James Larkin;Alessia Covre;Maresa Altomonte;Luana Calabrò;Santosh A Vardhana;Caroline Robert;Ramy Ibrahim;Andrea Anichini;Jedd D Wolchok;Anna Maria Di Giacomo | 2020-06-15 02:00:00+02:00 | 32540850 | FR;IT;GB;US | [{"country": "United States", "agency": "NCI NIH HHS", "grantid": "K08 CA237731"}, {"country": "United States", "agency": "NCI NIH HHS", "grantid": "P30 CA008748"}] | Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy. mmaiocro@gmail.com.;NIBIT Foundation Onlus, Genova, Italy.;The Angeles Clinic and Research Institute, Los Angeles, California.;The Royal Marsden Hospital, London, United Kingdom.;Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.;Toscana Life Sciences Foundation, Siena, Italy.;Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.;Department of Medicine, Gustave Roussy and Paris-Saclay University, Villejuif, France.;Parker Institute For Cancer Immunotherapy, San Francisco, California.;Human Tumor Immunobiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy. | 1296 | ||
| 10.1093/cid/ciaa791 | Journal Article | en | Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital. | https://www.ncbi.nlm.nih.gov/pubmed/32556143 | Data from non-randomized studies have suggested that hydroxychloroquine could be an effective therapeutic agent against Covid-19. | 1058-4838,1537-6591 | 2020-06-21 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Olivier Paccoud;Florence Tubach;Amandine Baptiste;Alexandre Bleibtreu;David Hajage;Gentiane Monsel;Gianpiero Tebano;David Boutolleau;Elise Klement;Nagisa Godefroy;Romain Palich;Oula Itani;Antoine Fayssal;Marc-Antoine Valantin;Roland Tubiana;Sonia Burrel;Vincent Calvez;Eric Caumes;Anne-Geneviève Marcelin;Valérie Pourcher | 2020-06-18 02:00:00+02:00 | 32556143 | FR | Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, 75013, Paris, France.;Sorbonne Université, INSERM UMR 1136, Département de Santé Publique, Unité de Recherche Clinique Pitié Salpêtrière - Charles Foix, Centre de Pharmaco-épidémiologie de l'AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, laboratoire de virologie, Paris, France.;Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France. | 1300 | ||||
| 10.1007/s00259-020-04920-w | Journal Article | en | Ventilation/perfusion SPECT/CT findings in different lung lesions associated with COVID-19: a case series. | https://www.ncbi.nlm.nih.gov/pubmed/32556400 | The aim of this series of cases is to show the aspects of ventilation/perfusion single-photon emission computed tomography combined with computed tomography (V/Q SPECT/CT) in patients hospitalized for COVID-19 pneumonia, with the worsening of respiratory symptoms raising the suspicion of a pulmonary embolism. Patients did not benefit from CT angiography for various reasons: a contraindication, unavailability of the CT angiography, or a low clinical probability for pulmonary embolism. | 1619-7070,1619-7089 | 2020-06-21 02:00:00+02:00 | pubmed | Adult;Aged;Blood Coagulation;Coronavirus Infections__diagnostic imaging;Disease Progression;Dyspnea__complications;Female;France;Hospitalization;Humans;Lung__diagnostic imaging;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnostic imaging;Probability;Pulmonary Embolism__diagnostic imaging;Retrospective Studies;Single Photon Emission Computed Tomography Computed Tomography;Ventilation-Perfusion Ratio;COVID-19 | European Journal of Nuclear Medicine and Molecular Imaging | Nina Cobes;Mohamed Guernou;David Lussato;Mathieu Queneau;Bernard Songy;Gérald Bonardel;Jean-François Grellier | COVID-19;Coagulopathy;Pulmonary embolism;V/Q SPECT | 2020-06-18 02:00:00+02:00 | 32556400 | FR | Imagerie Moléculaire et Fonctionnelle - Centre Cardiologique du Nord - Hôpital Delafontaine, Saint-Denis, France. nina.cobes@gmail.com.;Imagerie Moléculaire et Fonctionnelle - Centre Cardiologique du Nord - Hôpital Delafontaine, Saint-Denis, France. | 1302 | ||
| 10.2196/19787 | Journal Article | en | Wearable Activity Trackers for Monitoring Adherence to Home Confinement During the COVID-19 Pandemic Worldwide: Data Aggregation and Analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32501803 | In the context of home confinement during the coronavirus disease (COVID-19) pandemic, objective, real-time data are needed to assess populations' adherence to home confinement to adapt policies and control measures accordingly. | 1438-8871 | 2020-06-21 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections__epidemiology;Data Aggregation;Data Analysis;Europe;Female;Fitness Trackers;France;Humans;Locomotion;Male;Middle Aged;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Social Isolation;Spain;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Medical Internet Research | Jean Louis Pépin;Rosa Maria Bruno;Rui-Yi Yang;Vincent Vercamer;Paul Jouhaud;Pierre Escourrou;Pierre Boutouyrie | COVID-19;home confinement;lockdown;monitoring;pandemic;tracking;wearable activity trackers;wearables | 2020-06-19 02:00:00+02:00 | 32501803 | FR;US | HP2 (Hypoxia and Physio-Pathologies) Laboratory, Inserm (French National Institute of Health and Medical Research) U1042, University Grenoble Alpes, Grenoble, France.;EFCR (Cardiovascular and Respiratory Function) Laboratory, Grenoble Alpes University Hospital, Grenoble, France.;Inserm (French National Institute of Health and Medical Research) U970, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.;Université de Paris, Paris, France.;Withings, Issy les Moulineaux, France.;Hôpital Béclère, Assistance Publique Hôpitaux de Paris, Paris, France.;Université Paris Saclay, Paris, France. | 1304 | ||
| 10.1080/15548627.2020.1779531 | Journal Article | en | Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype? | https://www.ncbi.nlm.nih.gov/pubmed/32521191 | At a time when the world faces an emotional breakdown, crushing our dreams, if not, taking our lives, we realize that together we must fight the war against the COVID-19 outbreak even if almost the majority of the scientific community finds itself confined at home. Every day, we, scientists, listen to the latest news with its promises and announcements. Across the world, a surge of clinical trials trying to cure or slow down the coronavirus pandemic has been launched to bring hope instead of fear and despair. One first proposed clinical trial has drawn worldwide hype to the benefit of chloroquine (CQ), in the treatment of patients infected by the recently emerged deadly coronavirus (SARS-CoV-2). We should consider this information in light of the long-standing anti-inflammatory and anti-viral properties of CQ-related drugs. Yet, none of the articles promoting the use of CQ in the current pandemic evoked a possible molecular or cellular mechanism of action that could account for any efficacy. Here, given the interaction of viruses with macroautophagy (hereafter referred to as autophagy), a CQ-sensitive anti-viral safeguard pathway, we would like to discuss the pros, but also the cons concerning the current therapeutic options targeting this process. | 1554-8627,1554-8635 | 2020-06-21 02:00:00+02:00 | pubmed | Autophagy | Patrick Brest;Jonathan Benzaquen;Daniel J Klionsky;Paul Hofman;Baharia Mograbi | Anti-viral;COVID-19;hydroxychloroquine;immunology;infection;inflammation;lysophagy;microbiology;plaquenil;virophagy | 2020-06-19 02:00:00+02:00 | 32521191 | FR;US | Universitty Côte d'Azur, IRCAN, CNRS , INSERM, Centre Antoine Lacassagne, FHU-OncoAge , Nice, France.;Université Côte d'Azur, CHU De Nice, Department of Pulmonary Medicine and Oncology , Nice, France.;Department of Molecular, Cellular, and Developmental Biology, Life Sciences Institute, University of Michigan , Ann Arbor, MI, USA.;Université Côte d'Azur, CHU De Nice, Laboratory of Clinical and Experimental Pathology (LPCE) , Nice, France. | 1306 | |||
| 10.1051/medsci/2020115 | Historical Article;News | fr | [Scared to death? Retrospective at the time of COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32558642 | Mourir de peur ? Rétrospective au temps du COVID-19. | 0767-0974,1958-5381 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Cholera__history;Coronavirus Infections__psychology;Disease Transmission, Infectious__history;Fear__psychology;Government__history;History, 16th Century;History, 17th Century;History, 19th Century;History, Ancient;History, Medieval;Humans;Medicine in the Arts__history;Pandemics__history;Panic;Pneumonia, Viral__psychology;Stress, Psychological__psychology;COVID-19;severe acute respiratory syndrome coronavirus 2 | médecine/sciences | Anne-Marie Moulin | 2020-06-19 02:00:00+02:00 | 32558642 | FR | CNRS UMR SPHERE 7219 Université Paris 7, bâtiment Condorcet, 4 rue Elsa Morante, 75013 Paris, France. | 1307 | |||
| 10.1051/medsci/2020113 | Journal Article | fr | [Coronavirus, emerging viruses]. | https://www.ncbi.nlm.nih.gov/pubmed/32558641 | Coronavirus is a large family of viruses that infect mammals and birds. Coronaviruses are known to cross barrier species and infect new ones. In the past twenty years, we witnessed the emergence of three different coronaviruses, the latest one being the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for the COVID-19 (covid disease 19) pandemic. Coronaviruses are enveloped virus with a long positive sense RNA genome. Like all viruses, they hijack the cellular machinery to replicate and produce new virions. There is no approved vaccine or specific antiviral molecule against coronaviruses but with the urgency to treat COVID-19, several candidate therapies are currently investigated. | 0767-0974,1958-5381 | 2020-06-21 02:00:00+02:00 | pubmed | Animals;Betacoronavirus__classification;Coronavirus Infections__drug therapy;Epidemics;Humans;Middle East Respiratory Syndrome Coronavirus;Pandemics;Pneumonia, Viral__epidemiology;SARS Virus;Severe Acute Respiratory Syndrome__epidemiology;Viral Structural Proteins__chemistry;Virus Physiological Phenomena;Zoonoses__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | médecine/sciences | Dylan Juckel;Jean Dubuisson;Sandrine Belouzard | 2020-06-19 02:00:00+02:00 | 32558641 | FR | Virologie moléculaire et cellulaire des coronavirus, Centre d'infection et d'immunité de Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHRU, 59000 Lille, France. | 1316 | |||
| 10.1016/j.mito.2020.06.008 | Journal Article;Review | en | Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. | https://www.ncbi.nlm.nih.gov/pubmed/32574708 | The COVID-19 pandemic caused by the coronavirus (SARS-CoV-2) has taken the world by surprise into a major crisis of overwhelming morbidity and mortality. This highly infectious disease is associated with respiratory failure unusual in other coronavirus infections. Mounting evidence link the accelerated progression of the disease in COVID-19 patients to the hyper-inflammatory state termed as the "cytokine storm" involving major systemic perturbations. These include iron dysregulation manifested as hyperferritinemia associated with disease severity. Iron dysregulation induces reactive oxygen species (ROS) production and promotes oxidative stress. The mitochondria are the hub of cellular oxidative homeostasis. In addition, the mitochondria may circulate "cell-free" in non-nucleated platelets, in extracellular vesicles and mitochondrial DNA is found in the extracellular space. The heightened inflammatory/oxidative state may lead to mitochondrial dysfunction leading to platelet damage and apoptosis. The interaction of dysfunctional platelets with coagulation cascades aggravates clotting events and thrombus formation. Furthermore, mitochondrial oxidative stress may contribute to microbiota dysbiosis, altering coagulation pathways and fueling the inflammatory/oxidative response leading to the vicious cycle of events. Here, we discuss various cellular and systemic incidents caused by SARS-CoV-2 that may critically impact intra and extracellular mitochondrial function, and contribute to the progression and severity of the disease. It is crucial to understand how these key modulators impact COVID-19 pathogenesis in the quest to identify novel therapeutic targets that may reduce fatal outcomes of the disease. | 1567-7249 | 2020-06-21 02:00:00+02:00 | pubmed | Mitochondrion | Jumana Saleh;Carole Peyssonnaux;Keshav K Singh;Marvin Edeas | Extracellular mitochondria;Hyper-inflammation;Hypercoagulability;Iron;Microbiota;Oxidative stress;Platelet mitochondria | 2020-06-20 02:00:00+02:00 | 32574708 | FR;OM;GB;US | College of Medicine, Sultan Qaboos University, Oman.;Université de Paris, INSERM U1016, Institut Cochin, CNRS UMR8104, Faculté de médecine Cochin-Port Royal, Paris, France, Laboratory of Excellence GR-Ex, Paris, France.;Integrated Center for Aging Research, Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.;Université de Paris, INSERM U1016, Institut Cochin, CNRS UMR8104, Faculté de médecine Cochin-Port Royal, Paris, France, Laboratory of Excellence GR-Ex, Paris, France. Electronic address: marvin.edeas@inserm.fr. | 1317 | |||
| 10.1016/j.jaip.2020.06.001 | Journal Article | en | Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden. | https://www.ncbi.nlm.nih.gov/pubmed/32561497 | It is unclear whether asthma may affect susceptibility or severity of coronavirus disease 2019 (COVID-19) in children and how pediatric asthma services worldwide have responded to the pandemic. | 2213-2198 | 2020-06-21 02:00:00+02:00 | pubmed | The Journal of Allergy and Clinical Immunology: In Practice | Nikolaos G Papadopoulos;Adnan Custovic;Antoine Deschildre;Alexander G Mathioudakis;Wanda Phipatanakul;Gary Wong;Paraskevi Xepapadaki;Ioana Agache;Leonard Bacharier;Matteo Bonini;Jose A Castro-Rodriguez;Zhimin Chen;Timothy Craig;Francine M Ducharme;Zeinab Awad El-Sayed;Wojciech Feleszko;Alessandro Fiocci;Luis Garcia-Marcos;James E Gern;Anne Goh;René Maximiliano Gómez;Eckard H Hamelmann;Gunilla Hedlin;Elham M Hossny;Tuomas Jartti;Omer Kalayci;Alan Kaplan;Jon Konradsen;Piotr Kuna;Susanne Lau;Peter Le Souef;Robert F Lemanske;Mika J Mäkelä;Mário Morais-Almeida;Clare Murray;Karthik Nagaraju;Leyla Namazova-Baranova;Antonio Nieto Garcia;Osman M Yusuf;Paulo M C Pitrez;Petr Pohunek;Cesar Fireth Pozo Beltrán;Graham C Roberts;Arunas Valiulis;Heather J Zar | Adherence;Asthma;COVID-19;Children;Control;SARS-CoV2;Virus | 2020-06-17 02:00:00+02:00 | 32561497 | LT;CA;PT;BR;CZ;AR;CL;MX;FR;RU;CN;GR;GB;US;HK;RO;IT;PL;EG;DE;SE;FI;BO;AU;TR;ZA;ES;IN | Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: ngpallergy@gmail.com.;Department of Paediatrics, Imperial College London, London, United Kingdom.;Pediatric Pulmonology and Allergy Department, Hôpital Jeanne de Flandre, Lille, France.;Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom, North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.;Children's Hospital Boston, Pediatric Allergy and Immunology, Boston, Mass.;Department of Pediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.;Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.;Allergy & Clinical Immunology, Transylvania University, Brasov, Romania.;Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University, St Louis, Mo.;Department of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, National Heart and Lung Institute (NHLI), Imperial College London, London, United Kingdom.;Division of Pediatrics, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.;Pulmonology Department, Children's Hospital Zhejiang University School of Medicine, Zhejiang, China.;Department of Allergy and Immunology, Penn State University, State College, Pa.;Department of Pediatrics, University of Montréal, Department of Social and Preventive Medicine, University of Montréal, Montréal, QC, Canada.;Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt.;Department of Pediatric Respiratory Diseases and Allergy, The Medical University of Warsaw, Warsaw, Poland.;Allergy Department, Bambino Gesù Children's Hospital, Rome, Italy.;Pediatric Respiratory and Allergy Units, "Virgen de la Arrixaca" Children's University Clinical Hospital, University of Murcia, Murcia, Spain, Institute for Biomedical Research of Murcia, IMIB-Arrixaca, & Network of Asthma and Adverse and Allergic Reactions (ARADyAL), Murcia, Spain.;Department of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis.;Department of Internal Medicine, Rush Medical College, Chicago, Ill.;Research & Education, Ayre Foundation, Salta, Argentina, Allergy & Asthma Department, Alas Medical Institute, Salta, Argentina.;Children's Center Bethel, EvKB, University Bielefeld, Bielefeld, Germany.;Paediatric Allergy, Centre for Allergy Research, Karolinska Institutet, Solna, Sweden.;Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.;Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey.;Family Physician Airways Group of Canada, Edmonton, AB, Canada.;Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.;Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland.;Charité Universitätsmedizin Berlin, Pediatric Pulmonology, Immunology and Intensive Care Medicine, Berlin, Germany.;School of Paediatrics & Child Health, Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, Crawley, WA, Australia.;Departments of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis.;Department of Allergy, Helsinki University Central Hospital, Helsinki, Finland.;Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.;Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom.;VN Allergy & Asthma Research Centre, Chennai, Tamilnadu, India.;Pediatric Department, Pirogov Russian National Research Medical University, the Ministry of Health, Moscow, Russia.;Pediatric Pulmonology & Allergy Unit, Children's Hospital la Fe, Valencia, Spain.;Allergy and Respiratory Research Group, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom.;Pediatric Pulmonology Division, Hospital Moinhos de Vento, Porto Alegre, Brazil.;Pediatric Pulmonology, Pediatric Department, 2nd Faculty of Medicine, Charles University, Prague, University Hospital Motol, Prague, Czech Republic.;Teaching and Research Department and Paediatric Allergy Department, Hospital with Specialties Juan María de Salvatierra, La Paz, Baja California Sur México, La Paz, Mexico, Allergy & Immunology Department, Hospital Infantil de Medico Federico Gomez, Mexico City, Mexico.;Paediatric Allergy and Respiratory Medicine within Medicine at the University of Southampton, Southampton, United Kingdom.;Clinic of Children's Diseases, Institute of Clinical Medicine, Medical Faculty of Vilnius University, Vilnius, Lithuania.;Department of Pediatrics & Child Health, MRC Unit on Child & Adolescent Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa. | 1329 | |||
| Letter | en | Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia. | https://www.ncbi.nlm.nih.gov/pubmed/32557555 | 2020-06-21 02:00:00+02:00 | pubmed | Julien Favresse;Christine Eucher;Marc Elsen;Carlos Graux;Paul Goebels;Kim Laffineur;Jean-Baptiste Nicolas;Jean-Michel Dogné;Jonathan Douxfils | COVID-19;SARS-CoV-2;kinetics;serology;symptom onset | 2020-06-17 02:00:00+02:00 | 32557555 | FR;BE;GB | Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.;Department of Pharmacy, Namur Research Institute for LIfes Sciences, University of Namur, Namur, Belgium.;Department of Hematology, CHU UCL Namur, Yvoir, Belgium.;Department of Laboratory Medicine, Saint Nikolaus Hospital, Eupen, Belgium.;Department of Internal Medicine, Clinique St-Luc Bouge, Namur, Belgium.;Qualiblood sa, Namur, Belgium. | 1330 | |||||||
| Letter | en | Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study. | https://www.ncbi.nlm.nih.gov/pubmed/32776849 | 2020-06-21 02:00:00+02:00 | pubmed | Paul Masi;Guillaume Hékimian;Manon Lejeune;Juliette Chommeloux;Cyrielle Desnos;Marc Pineton De Chambrun;Isabelle Martin-Toutain;Ania Nieszkowska;Guillaume Lebreton;Nicolas Bréchot;Matthieu Schmidt;Charles Edouard Luyt;Alain Combes;Corinne Frere | COVID-19;respiratory distress syndrome, adult;systemic inflammatory response syndrome | 2020-06-17 02:00:00+02:00 | 32776849 | FR | Medical Intensive Care Unit (P.M., G.H., J.C., C.D., M.P.D.C., A.N., N.B., M.S., C.E.L., A.C.), Department of Hematology (M.L., I.M.-T., C.F.), and Cardiothoracic Surgery Department (G.L.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, France. Sorbonne Université, INSERM UMRS_1166, Institute of Cardiometabolism and Nutrition, Paris, France (G.H., G.L., M.S., C.E.L., A.C., C.F.). | 1335 | |||||||
| Letter | en | Impact of home confinement during the COVID-19 pandemic on medication use and disease activity in spondyloarthritis patients. | https://www.ncbi.nlm.nih.gov/pubmed/32779880 | Home confinement, imposed as part of the social distancing measures in the fight against the coronavirus disease 2019 (COVID-19), poses several problems for patients with spondyloarthritis (SpA), including the lack of physical activity, psychological factors, and the confusion related to the prescriptions of NSAIDs. We investigated the impact of confinement on the medication intake and disease activity in SpA patients in a questionnaire-based survey. | 2020-06-21 02:00:00+02:00 | pubmed | C H Roux;O Brocq;F Gerald;C Pradier;L Bailly | 2020-06-17 02:00:00+02:00 | 32779880 | FR;MC | Rheumatology Department, University Hospital Centre Nice, Cote d'Azur University, Nice, France.;Laboratory LAMHESS, Cote d'Azur University, Nice, France.;Rheumatology Department, CHPG Monaco, Monaco, Monaco.;Department of Public Health, University Hospital Centre Nice, Cote d'Azur University, Nice, France. | 1338 | |||||||
| 10.1055/a-1201-9618 | Journal Article | en | Impact of the COVID-19 pandemic on gastrointestinal endoscopy activity in France. | https://www.ncbi.nlm.nih.gov/pubmed/32557489 | The SARS-CoV-2 pandemic has majorly affected medical activity around the world. We sought to measure the impact of the COVID-19 pandemic on gastrointestinal (GI) endoscopy activity in France. | 0013-726X,1438-8812 | 2020-06-21 02:00:00+02:00 | pubmed | Endoscopy | Arthur Belle;Maximilien Barret;David Bernardini;Anne-Laure Tarrerias;Erwan Bories;Vianna Costil;Bernard Denis;Rodica Gincul;David Karsenti;Stephane Koch;Arthur Laquiere;Thierry Lecomte;Vincent Quentin;Gabriel Rahmi;Michel Robaszkiewicz;Eric Vaillant;Geoffroy Vanbiervliet;Ariane Vienne;Franck Dumeiran;Olivier Gronier;Stanislas Chaussade | 2020-06-17 02:00:00+02:00 | 32557489 | FR | Gastroenterology and Digestive Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;University of Paris, Paris, France.;Gastroenterology Department, La Casamance Private Hospital, Aubagne, France.;Gastroenterology Department, Hôpital Foch, Suresnes, Île-de-France, France.;Gastroenterology Department, Hôpital Privé de Provence, Aix En Provence, France.;Gastroenterology Department, Pôle Santé des 4 Temps, Puteaux, France.;Médecine A, Hôpital Pasteur, Colmar, France.;Service de Gastroentérologie, Hôpital Edouard Herriot, Lyon, France.;Digestive Endoscopy Unit, Clinique de Paris-Bercy, Charenton-le-Pont, France.;Gastroenterology Department, CHU Besançon, Besançon, France.;Gastroenterology Department, Hôpital St Joseph, Marseille, France.;Department of Hepatogastroenterology and Digestive Oncology, Trousseau University Hospital, Tours, France.;Digestive Endoscopy Unit, Hôpital St Brieuc, St Brieuc, France.;Gastroenterology and Digestive Endoscopy, Georges Pompidou European Hospital, Paris, France.;Department of Gastrointestinal Endoscopy, CHRU de Brest, Brest, France.;Department of Gastroenterology, Centre médical du Nord, Lille, France.;Digestive Endoscopy, Hôpital de L'Archet 2, Nice, France.;Department of Gastroenterology, Hôpital privé d'Anthony, Anthony, France.;Gastroenterology Department, Société française d'endoscopie digestive, Limoges, France.;Department of Gastroenterology and Hepatology, Clinique Sainte Barbe, Strasbourg, France. | 1339 | ||||
| Agence Nationale de la Recherche | 10.1111/jth.14968 | Journal Article | en | Curative anticoagulation prevents endothelial lesion in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32558198 | Coronavirus disease-2019 (COVID-19) has been associated with cardiovascular complications and coagulation disorders. | 1538-7933,1538-7836 | 2020-06-21 02:00:00+02:00 | pubmed | Journal of Thrombosis and Haemostasis | Lina Khider;Nicolas Gendron;Guillaume Goudot;Richard Chocron;Caroline Hauw-Berlemont;Charles Cheng;Nadia Rivet;Helene Pere;Ariel Roffe;Sébastien Clerc;David Lebeaux;Benjamin Debuc;David Veyer;Bastien Rance;Pascale Gaussem;Sébastien Bertil;Cécile Badoual;Philippe Juvin;Benjamin Planquette;Emmanuel Messas;Olivier Sanchez;Jean-Sébastien Hulot;Jean-Luc Diehl;Tristan Mirault;David M Smadja | COVID-19;D-dimers;SARS-CoV-2;circulating endothelial cells;coagulopathy | 2020-06-18 02:00:00+02:00 | 32558198 | FR | [{"country": "", "agency": "Agence Nationale de la Recherche", "grantid": "SARCODO"}] | Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.;Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France.;Hematology Department and Biosurgical Research Lab (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, Paris, France.;PARCC, INSERM, Université de Paris, Paris, France.;Emergency Department, AP-HP, Georges Pompidou European Hospital, Paris, France.;Intensive Care Unit, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.;Virology Department, AP-HP, Georges Pompidou European Hospital, Paris, France.;Respiratory Medicine Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.;Infectious Disease Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.;Plastic Surgery Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.;Centre de Recherche des Cordeliers, Functional Genomics of Solid Tumors, INSERM, Université de Paris, Paris, France.;Department of Medical Informatics, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.;Hematology Department, AH-HP, Georges Pompidou European Hospital, Paris, France.;Pathology Department and PRB (Plateforme de ressources biologiques), AP-HP, Georges Pompidou European Hospital, Paris, France.;Emergency Department, AP-HP, Georges Pompidou European Hospital, Université de Paris, Paris, France.;Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, Paris, France.;Clinical Center of Investigation, AP-HP, Georges Pompidou European Hospital, Paris, France.;Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, Paris, France. | 1343 | |
| 10.3174/ajnr.a6651 | Case Reports;Journal Article | en | COVID-19 Neurologic Complication with CNS Vasculitis-Like Pattern. | https://www.ncbi.nlm.nih.gov/pubmed/32554425 | Coronavirus disease 2019 (COVID-19) is a viral infection caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), which spreads rapidly from person to person and manifests in most symptomatic patients as a respiratory illness, similar to prior SARS viruses. Neurologic manifestations of COVID-19 are uncommon; those so far reported include encephalopathy, stroke from large-vessel occlusion, and polyneuropathy. We report a unique neurologic complication of COVID-19 in a patient who had extensive cerebral small-vessel ischemic lesions resembling cerebral vasculitis in a characteristic combined imaging pattern of ischemia, hemorrhage, and punctuate postcontrast enhancement. Also, a characteristic lower extremity skin rash was present in our patient. Our observation lends support to the increasingly suspected mechanism of "endotheliitis" associated with this novel coronavirus. | 0195-6108,1936-959X | 2020-06-21 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__complications;Humans;Magnetic Resonance Imaging;Male;Multimodal Imaging;Pandemics;Pneumonia, Viral__complications;Tomography, X-Ray Computed;Vasculitis, Central Nervous System__diagnostic imaging;COVID-19;severe acute respiratory syndrome coronavirus 2 | American Journal of Neuroradiology | R Hanafi;P-A Roger;B Perin;G Kuchcinski;N Deleval;F Dallery;D Michel;L Hacein-Bey;J-P Pruvo;O Outteryck;J-M Constans | 2020-06-18 02:00:00+02:00 | 32554425 | FR;US | From the Department of Neuroradiology (R.H., G.K., J.-P.P., O.O.), University Hospital of Lille, Hôpital Roger Salengro, Lille, France riyad.hanafi@chru-lille.fr.;Departments of Interventional Radiology (R.H.), Cardiothoracic, Vascular and Respiratory Intensive Care (P.-A.R.), Neurology and Neurophysiology (B.P.), and Neuroradiology (N.D., F.D., D.M., J.-M.C.), University Hospital of Amiens, Amiens, France.;From the Department of Neuroradiology (R.H., G.K., J.-P.P., O.O.), University Hospital of Lille, Hôpital Roger Salengro, Lille, France.;Departments of Neuroradiology and Radiology (L.H.-B.), University of California Davis School of Medicine, Sacramento, California. | 1346 | |||
| 10.1016/j.frl.2020.101647 | Journal Article | en | How the cryptocurrency market has performed during COVID 19? A multifractal analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32837367 | Cryptocurrency markets are complex systems based on speculation. Where investors interact using strategies that generate some biases responsible for endogenous instabilities. This paper investigated the herding biases by quantifying the self-similarity intensity of cryptocurrency returns' during the COVID-19 pandemic. The main purpose of this work was to study the level of cryptocurrency efficiency through multifractal analysis before and after the coronavirus pandemic. The empirical results proved that COVID-19 has a positive impact on the cryptocurrency market efficiency. | 1544-6123 | 2020-06-21 02:00:00+02:00 | pubmed | Finance Research Letters | Emna Mnif;Anis Jarboui;Khaireddine Mouakhar | COVID-19;Cryptocurrency;Efficiency index;Generalised Hurst exponent;Herding behaviour | 2020-06-18 02:00:00+02:00 | 32837367 | FR;TN | Department of Finance, Sfax University, Box 1169, France.;Nice University - Sfax University- 10448, F-60007 Box 1424, France.;EM Normandie, Métis Lab. 76600 Le Havre, France. | 1347 | |||
| Letter;Comment | en | Acute cardiovascular diseases may be less likely to be considered because of the COVID-19 pandemic-our duty is first to alert, then to analyse more deeply: Response to a letter entitled "Severity of cardiovascular diseases during the COVID-19 pandemic" from T. Imamura. | https://www.ncbi.nlm.nih.gov/pubmed/32616390 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Cardiovascular Diseases;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Fabien Huet;Cyril Prieur;Guillaume Schurtz;Edouard Gerbaud;Stéphane Manzo-Silberman;Gerald Vanzetto;Meyer Elbaz;Victoria Tea;Grégoire Mercier;Benoît Lattuca;Claire Duflos;François Roubille | Acute cardiac care;Acute coronary syndrome;COVID-19;Heart failure;Insuffisance cardiaque;Intensive care unit;Soins aigus cardiaque;Syndrome coronarien aigu;Unité de soins intensifs | 2020-06-18 02:00:00+02:00 | 32616390 | FR | Department of Cardiology, Hôpital Universitaire de Montpellier, 34295 Montpellier, France, PhyMedExp, Université de Montpellier, INSERM U1046, CNRS UMR 9214, 34295 Montpellier, France.;Department of Cardiology, Hôpital Cardiologique Louis-Pradel, 69500 Bron, France.;Department of Cardiology, Institut Coeur Poumons, Hôpital Cardiologique, 59000 Lille, France.;Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut-Lévêque, 33604 Pessac, France, Bordeaux Cardio-Thoracic Research Centre, U1045, Bordeaux University, Hôpital Xavier-Arnozan, 33600 Pessac, France.;Department of Cardiology, Hôpital Lariboisiere, 75010 Paris, France.;Department of Cardiology, Hôpital de Grenoble, 38700 La Tronche, France.;Department of Cardiology, Hôpital Rangueil, 31400 Toulouse, France.;Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Européen Georges-Pompidou, 75015 Paris, France.;CEPEL, Université de Montpellier, CNRS, 34090 Montpellier, France, Medico-Economic Research Unit, CHU de Montpellier, Université de Montpellier, 34295 Montpellier, France.;Department of Cardiology, CHU de Nîmes, 30029 Nîmes, France.;CEPEL, Université de Montpellier, CNRS, 34090 Montpellier, France, Clinical Research and Epidemiology Unit, CHU de Montpellier, Université de Montpellier, 34295 Montpellier, France.;Department of Cardiology, Hôpital Universitaire de Montpellier, 34295 Montpellier, France, PhyMedExp, Université de Montpellier, INSERM U1046, CNRS UMR 9214, 34295 Montpellier, France. Electronic address: francois.roubille@gmail.com. | 1349 | ||||||
| 10.1093/ehjci/jeaa169 | Journal Article | en | CMR and serology to diagnose COVID-19 infection with primary cardiac involvement. | https://www.ncbi.nlm.nih.gov/pubmed/32556106 | 2047-2404,2047-2412 | 2020-06-21 02:00:00+02:00 | pubmed | European Heart Journal - Cardiovascular Imaging | Pierre Gravinay;Nahema Issa;David Girard;Fabrice Camou;Hubert Cochet | 2020-06-17 02:00:00+02:00 | 32556106 | FR | Cardiac Intensive Care Unit, Hôpital St André, CHU Bordeaux, Bordeaux, France.;Intensive Care and Infectious Disease Unit, CHU Bordeaux, Bordeaux, France.;Medical Biology Laboratory, Groupe Hospitalier Sud Gironde, Langon, France.;Department of Cardiovascular Imaging, CHU Bordeaux, Pessac, France.;IHU Liryc, CHU/Univ. Bordeaux/Inserm1045, Pessac, France. | 1355 | |||||
| 10.1186/s13613-020-00702-7 | Journal Article;Review | en | Ethical dilemmas due to the Covid-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32556826 | The devastating pandemic that has stricken the worldwide population induced an unprecedented influx of patients in ICUs, raising ethical concerns not only surrounding triage and withdrawal of life support decisions, but also regarding family visits and quality of end-of-life support. These ingredients are liable to shake up our ethical principles, sharpen our ethical dilemmas, and lead to situations of major caregiver sufferings. Proposals have been made to rationalize triage policies in conjunction with ethical justifications. However, whatever the angle of approach, imbalance between utilitarian and individual ethics leads to unsolvable discomforts that caregivers will need to overcome. With this in mind, we aimed to point out some critical ethical choices with which ICU caregivers have been confronted during the Covid-19 pandemic and to underline their limits. The formalized strategies integrating the relevant tools of ethical reflection were disseminated without deviating from usual practices, leaving to intensivists the ultimate choice of decision. | 2110-5820 | 2020-06-21 02:00:00+02:00 | pubmed | Annals of Intensive Care | René Robert;Nancy Kentish-Barnes;Alexandre Boyer;Alexandra Laurent;Elie Azoulay;Jean Reignier | Burnout;Covid-19;End-of-life;Ethics;Family-centered care;ICU;Pandemic;Triage;Withdrawal of life support | 2020-06-17 02:00:00+02:00 | 32556826 | FR | Université de Poitiers, Poitiers, France. rene.robert@chu-poitiers.fr.;Inserm CIC 1402, Axe Alive, Poitiers, France. rene.robert@chu-poitiers.fr.;Service de Médecine Intensive Réanimation, CHU Poitiers, Poitiers, France. rene.robert@chu-poitiers.fr.;Service de Réanimation Médicale, APHP, CHU Saint-Louis, Paris, France.;Groupe de Recherche Famiréa, Paris, France.;Université de Bordeaux, Bordeaux, France.;Service de Médecine Intensive Réanimation, CHU Bordeaux, Bordeaux, France.;Laboratoire psy-DREPI, Université de Bourgogne Franche-Comté, 7458, Dijon, France.;Service de Réanimation Chirurgicale, Dijon, France.;Université de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, CHU de Nantes, Nantes, France. | 1364 | |||
| 10.1016/j.jcv.2020.104511 | Comparative Study;Evaluation Study;Journal Article;Research Support, Non-U.S. Gov't | en | Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). | https://www.ncbi.nlm.nih.gov/pubmed/32593133 | The emergence of new SARS-CoV-2 has promoted the development of new serological tests that could be complementary to RT-PCR. Nevertheless, the assessment of clinical performances of available tests is urgently required as their use has just been initiated for diagnose. | 1386-6532 | 2020-06-21 02:00:00+02:00 | pubmed | Aged;Antibodies, Viral__blood;Automation, Laboratory__methods;Betacoronavirus__immunology;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Female;Humans;Immunoassay__methods;Immunoglobulin A__blood;Immunoglobulin G__blood;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnosis;Retrospective Studies;Sensitivity and Specificity;Serologic Tests__methods;Time Factors;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Clinical Virology | Thomas Nicol;Caroline Lefeuvre;Orianne Serri;Adeline Pivert;Françoise Joubaud;Vincent Dubée;Achille Kouatchet;Alexandra Ducancelle;Françoise Lunel-Fabiani;Hélène Le Guillou-Guillemette | Automated immunoassays;COVID-19;Lateral flow immunoassay;Performance;SARS-CoV-2 | 2020-06-15 02:00:00+02:00 | 32593133 | FR | Virology Department, Angers University Hospital, Angers, France.;Virology Department, Angers University Hospital, Angers, France, HIFIH Laboratory EA 3859, LUNAM, Angers, France.;Department of Biochemistry and Genetics, Angers University Hospital, Angers, France.;Infectious Diseases and Tropical Medicine, University Hospital of Angers, Angers, France, Equipe ATIP AVENIR, CRCINA, INSERM, University of Nantes and Angers.;Medical Intensive Care Department, University Hospital of Angers, Angers, France.;Virology Department, Angers University Hospital, Angers, France, HIFIH Laboratory EA 3859, LUNAM, Angers, France. Electronic address: heleguillou@chu-angers.fr. | 1371 | ||
| Letter | en | To fight SARS-CoV-2: putting your guns down. | https://www.ncbi.nlm.nih.gov/pubmed/32542509 | 2020-06-21 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Firearms__statistics & numerical data;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;United States__epidemiology;COVID-19 | Frédéric Dutheil;Julien S Baker;Valentin Navel | 2020-06-15 02:00:00+02:00 | 32542509 | FR;HK | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, F-63000, Clermont-Ferrand, France. fdutheil@chu-clermontferrand.fr.;Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong.;Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, F-63000, Clermont-Ferrand, France. | 1376 | |||||||
| 10.3390/v12060646 | Journal Article;Research Support, Non-U.S. Gov't | en | A Putative Role of de-Mono-ADP-Ribosylation of STAT1 by the SARS-CoV-2 Nsp3 Protein in the Cytokine Storm Syndrome of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32549200 | As more cases of COVID-19 are studied and treated worldwide, it had become apparent that the lethal and most severe cases of pneumonia are due to an out-of-control inflammatory response to the SARS-CoV-2 virus. I explored the putative causes of this specific feature through a detailed genomic comparison with the closest SARS-CoV-2 relatives isolated from bats, as well as previous coronavirus strains responsible for the previous epidemics (SARS-CoV and MERS-CoV). The high variability region of the nsp3 protein was confirmed to exhibit the most variations between closest strains. It was then studied in the context of physiological and molecular data available in the literature. A number of convergent findings suggest de-mono-ADP-ribosylation (de-MARylation) of STAT1 by the SARS-CoV-2 nsp3 as a putative cause of the cytokine storm observed in the most severe cases of COVID-19. This may suggest new therapeutic approaches and help in designing assays to predict the virulence of naturally circulating SARS-like animal coronaviruses. | 1999-4915 | 2020-06-21 02:00:00+02:00 | pubmed | ADP-Ribosylation__physiology;Amino Acid Sequence__genetics;Betacoronavirus__genetics;Coronavirus Infections__pathology;Cytokine Release Syndrome__pathology;Humans;Inflammation__pathology;Middle East Respiratory Syndrome Coronavirus__genetics;Pandemics;Peptidyl-Dipeptidase A__biosynthesis;Pneumonia, Viral__pathology;SARS Virus__genetics;STAT1 Transcription Factor__metabolism;Sequence Homology;Viral Nonstructural Proteins__genetics;COVID-19;severe acute respiratory syndrome coronavirus 2 | Viruses | Jean-Michel Claverie | ACE2;PARP14;de-MARylation;inflammation;interferon-stimulated gene | 2020-06-15 02:00:00+02:00 | 32549200 | FR | Structural & Genomic Information Laboratory (IGS, UMR 7256), Mediterranean Institute of Microbiology (FR3479), Aix-Marseille University and CNRS, 13288 Marseille, France. | 1377 | ||
| 10.1684/mrh.2020.0465 | Journal Article | en | The COVID-19 pandemic: is there a role for magnesium? Hypotheses and perspectives. | https://www.ncbi.nlm.nih.gov/pubmed/32554340 | More and more studies are accumulating about COVID-19. Some aspects of the pathogenesis of the disease recall events occurring in Mg deficiency, such as a drop of T cells, increased plasma concentration of inflammatory cytokines, and endothelial dysfunction. We hypothesize that a low Mg status, which is rather common, might foment the transition from mild to critical clinical manifestations of the disease. Epidemiological, clinical, and fundamental research is needed to clarify the potential role of Mg deficiency in COVID-19. | 2020-06-21 02:00:00+02:00 | pubmed | Stefano Iotti;Federica Wolf;André Mazur;Jeanette A Maier | COVID-19;inflammation;magnesium;pandemic | 2020-06-15 02:00:00+02:00 | 32554340 | FR;IT | University of Bologna, Department of Pharmacy and Biotechnology, BolognaItaly.;Università Cattolica del Sacro Cuore-Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Medicina e Chirurgia Traslazionale, RomaItaly.;Université Clermont Auvergne, INRAE, unité de nutrition humaine (UNH), Clermont-FerrandFrance.;Università di Milano, Department of Biomedical and Clinical Sciences L. Sacco, MilanItaly. | 1378 | |||||
| 10.3389/fpubh.2020.00284 | Journal Article | en | Ethical Criteria for the Admission and Management of Patients in the ICU Under Conditions of Limited Medical Resources: A Shared International Proposal in View of the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32612972 | 2296-2565 | 2020-06-21 02:00:00+02:00 | pubmed | Frontiers in Public Health | Vittoradolfo Tambone;Donald Boudreau;Massimo Ciccozzi;Karen Sanders;Laura Leondina Campanozzi;Jane Wathuta;Luciano Violante;Roberto Cauda;Carlo Petrini;Antonio Abbate;Rossana Alloni;Josepmaria Argemi;Josep Argemí Renom;Anna De Benedictis;France Galerneau;Emilio García-Sánchez;Giampaolo Ghilardi;Janet Palmer Hafler;Magdalena Linden;Alfredo Marcos;Andrea Onetti Muda;Marco Pandolfi;Thierry Pelaccia;Mario Picozzi;Ruben Oscar Revello;Giovanna Ricci;Robert Rohrbaugh;Patrizio Rossi;Ascanio Sirignano;Antonio Gioacchino Spagnolo;Trevor Stammers;Lourdes Velázquez;Evandro Agazzi;Mark Mercurio | COVID-19;Intensive Care Unit;common good;disaster medicine;ethical triage criteria | 2020-06-16 02:00:00+02:00 | 32612972 | SE;FR;AR;CA;KE;GB;US;IT;ES;MX | Institute of Philosophy of Scientific and Technological Practice (FAST), Campus Bio-Medico University of Rome, Rome, Italy.;Department of Medicine, Institute of Health Sciences Education, McGill University, Montreal, QC, Canada.;Research Unit of Medical Statistic and Molecular Epidemiology, Campus Bio-Medico University of Rome, Rome, Italy.;Department of Business, Law and Society, St Mary's University, London, United Kingdom.;Institute for Family Studies & Ethics, Strathmore University, Nairobi, Kenya.;Fondazione Leonardo, Civiltà delle Macchine, Rome, Italy.;Section of Infection Diseases, Department of Healthcare Surveillance and Bioethics, Catholic University of Sacred Heart, Rome, Italy.;Bioethics Unit, Italian National Institute of Health, Rome, Italy.;Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, United States.;Hospital Clinical Direction, Campus Bio-Medico University of Rome, Rome, Italy.;Division of Medicine, Gastroenterology and Hepatology Department, University of Pittsburgh, Pittsburgh, PA, United States.;Department of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain.;Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, United States.;Department of Political Sciences, Ethics and Sociology, University CEU Cardenal Herrera, Valencia, Spain.;Teaching and Learning Center, Yale University School of Medicine, New Haven, CT, United States.;Department of Medicine, Solna, Karolinska Institutet, Center for Molecular Medicine, Stockholm, Sweden.;Department of Philosophy, Universidad de Valladolid, Valladolid, Spain.;Department of Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.;Prehospital Emergency Medical Service (SAMU 67), Strasbourg University Hospital, Strasbourg, France.;Center for Clinical Ethics, Insubria University, Varese, Italy.;Instituto de Bioética de la Facultad de Ciencias Médica, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina.;School of Law, University of Camerino, Macerata, Italy.;Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.;Central Medical Department, National Institute for Insurance against Accidents at Work (INAIL), Rome, Italy.;School of Medicine, Catholic University of Sacred Heart, Rome, Italy.;Centre for Bioethics and Emerging Technologies, Institute of Theology, St Mary's University, London, United Kingdom.;Interdisciplinary Bioethics Center, Universidad Panamericana, Mexico City, Mexico.;Program for Biomedical Ethics, Yale University School of Medicine, New Haven, CT, United States. | 1380 | ||||
| 10.1016/j.jaccas.2020.06.011 | Case Reports | en | Acute Cor Pulmonale in COVID-19-Related ARDS: Improvement With Almitrine Infusion. | https://www.ncbi.nlm.nih.gov/pubmed/32835274 | Coronavirus disease-19 (COVID-19)-related severe acute respiratory distress syndrome can lead to acute cor pulmonale. We report a case of acute cor pulmonale secondary to severe COVID-19 acute respiratory distress syndrome diagnosed with transesophageal echocardiography. Almitrine infusion allowed rapid enhancement of right ventricular function as well as improvement in oxygenation. (Level of Difficulty: Intermediate.). | 2666-0849 | 2020-06-21 02:00:00+02:00 | pubmed | JACC: Case Reports | Pierre Huette;Christophe Beyls;Mathieu Guilbart;Guillaume Haye;Fatim-Zahra Najid;Benjamin Mestan;Pierre-Alexandre Roger;Hervé Dupont;Osama Abou-Arab;Yazine Mahjoub | ACE2, angiotensin-converting enzyme 2;ACP, acute cor pulmonale;ARDS;ARDS, acute respiratory distress syndrome;CI, cardiac index;COVID-19;COVID-19, coronavirus disease-19;CT, computed tomography;Fio2, fraction of inspired oxygen;Pao2, partial pressure of oxygen;RV, right ventricle;RVSWI, right ventricular stroke work index;SARS-CoV-2;SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2;TEE, transesophageal echocardiography;acute cor pulmonale;almitrine | 2020-06-16 02:00:00+02:00 | 32835274 | FR | Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France. | 1382 | |||
| Letter | en | Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32564417 | 2020-06-21 02:00:00+02:00 | pubmed | A-C Fougerousse;M Perrussel;P-A Bécherel;E Begon;V Pallure;I Zaraa;G Chaby;J Parier;M Kemula;L Mery-Bossard;C Poreaux;C Taieb;F Maccari;Z Reguiai | 2020-06-21 02:00:00+02:00 | 32564417 | FR | Dermatology Department, Military Teaching Hospital Bégin, Saint Mandé, France.;Private Practice Auray, Dermatology Department, University Hospital Rennes, Rennes, France.;Dermatology Department, Private Hospital, Antony, France.;Dermatology Department, Centre Hospitalier Pontoise, Pontoise, France.;Dermatology Department, Perpignan Hospital, Perpignan, France.;Dermatology Department, Saint-Joseph Hospital, Paris, France.;Dermatology Department, University Hospital, Amiens, France.;Private Practice, La Varenne Saint Hilaire, France.;Dermatology Department, Saint Louis Hospital, Paris, France.;Private Practice, Paris, France.;Dermatology Department, Tarnier Hospital, Paris, France.;Dermatology Department, Centre Hospitalier Intercommunal Poissy-Saint Germain en Laye, Poissy, France.;Private Practice, Nancy, Pasteur Clinic, Essey-les-Nancy, France.;Emma Clinic, Fontenay sous Bois, France.;Dermatology Department, Courlancy Polyclinic, Reims-Bezannes, France. | 1383 | ||||||||
| Letter;Comment | en | Clinical presentation of Covid-19 in health care workers from a French University Hospital. | https://www.ncbi.nlm.nih.gov/pubmed/32579992 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Health Personnel;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Aude Jary;Philippe Flandre;Agnès Chabouis;Séverine Nguyen;Stéphane Marot;Sonia Burrel;David Boutolleau;Vincent Calvez;Anne-Geneviève Marcelin;Martine Louet | 2020-06-21 02:00:00+02:00 | 32579992 | FR | Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France. Electronic address: aude.jary@aphp.fr.;INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Paris, France.;AP-HP, Hôpital Pitié-Salpêtrière, Service de Santé au Travail, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, France. | 1384 | |||||||
| Letter | en | Clinical feedback from experience with COVID-19: Specific considerations for extracorporeal membrane oxygenation. | https://www.ncbi.nlm.nih.gov/pubmed/32579990 | 2020-06-21 02:00:00+02:00 | pubmed | Antonio Fiore;Quentin de Roux;Nejla Daami;Simon Clariot;Thierry Folliguet;Fabio Silvio Taccone;Nicolas Mongardon | Acute respiratory distress syndrome (ARDS);Covid-19;Extracorporeal Membrane Oxygenation (ECMO);Pneumonia;Sars-CoV-2 | 2020-06-21 02:00:00+02:00 | 32579990 | FR;BE | Service de chirurgie cardiaque, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France. Electronic address: antonio.fiore@aphp.fr.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France.;Service de chirurgie cardiaque, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France, Université Paris Est Creteil, Faculté de Santé, F-94010 Créteil, France.;Department of Intensive Care, Clinique Universitaire de Bruxelles (CUB) Erasme, Université Libre de Bruxelles, Bruxelles, Belgium.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France, Université Paris Est Creteil, Faculté de Santé, F-94010 Créteil, France, U955-IMRB, Equipe 03 "Pharmacologie et Technologies pour les Maladies Cardiovasculaires (PROTECT)", Inserm, Univ Paris Est Creteil (UPEC), Ecole Nationale Vétérinaire d'Alfort (EnVA), F-94700 Maisons-Alfort, France, AfterROSC research group, F-75014 Paris, France. | 1385 | |||||||
| Letter | en | The SARS-Cov-2 Pandemic: A Good Time for Stem Cell Transplantation? | https://www.ncbi.nlm.nih.gov/pubmed/32561337 | 2020-06-21 02:00:00+02:00 | pubmed | Frédéric Dutheil;Julien S Baker;Valentin Navel | 2020-06-16 02:00:00+02:00 | 32561337 | FR;HK | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, F-63000 Clermont-Ferrand, France. Electronic address: fdutheil@chu-clermontferrand.fr.;Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong.;Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, F-63000 Clermont-Ferrand, France. | 1402 | ||||||||
| 10.1093/cid/ciaa762 | Journal Article | en | Bacterial Pneumonia in COVID-19 critically ill patients: a case series. | https://www.ncbi.nlm.nih.gov/pubmed/32544219 | 1058-4838,1537-6591 | 2020-06-21 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Emmanuel Dudoignon;François Caméléna;Benjamin Deniau;Adrien Habay;Maxime Coutrot;Quentin Ressaire;Benoit Plaud;Béatrice Berçot;François Dépret | 2020-06-16 02:00:00+02:00 | 32544219 | FR | Department of Anaesthesiology, Critical Care Medicine and Burn unit, AP-HP Nord, Saint Louis and Lariboisière University Hospitals, Paris, France.;INSERM UMR-S942, Institut National de la Santé et de la Recherche Médicale (INSERM), Lariboisière hospital and INI-CRCT network.;Paris University, F-75475, Paris, France.;Department of Microbiology, Saint-Louis-Lariboisière Hospital Group, AP-HP Nord, Paris, France.;University of Paris, INSERM 1137, IAME, Paris, France. | 1403 | |||||
| 10.2337/dc20-1192 | Journal Article | en | Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. | https://www.ncbi.nlm.nih.gov/pubmed/32546593 | Evidence relating to the impact of COVID-19 in people with diabetes (PWD) is limited but continuing to emerge. PWD appear to be at increased risk of more severe COVID-19 infection, though evidence quantifying the risk is highly uncertain. The extent to which clinical and demographic factors moderate this relationship is unclear, though signals are emerging that link higher BMI and higher HbA1c to worse outcomes in PWD with COVID-19. As well as posing direct immediate risks to PWD, COVID-19 also risks contributing to worse diabetes outcomes due to disruptions caused by the pandemic, including stress and changes to routine care, diet, and physical activity. Countries have used various strategies to support PWD during this pandemic. There is a high potential for COVID-19 to exacerbate existing health disparities, and research and practice guidelines need to take this into account. Evidence on the management of long-term conditions during national emergencies suggests various ways to mitigate the risks presented by these events. | 0149-5992,1935-5548 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Diabetes Mellitus;Disasters;Emergencies;Humans;Pandemics;Pneumonia, Viral__epidemiology;Risk Management;COVID-19;severe acute respiratory syndrome coronavirus 2 | Diabetes Care | Jamie Hartmann-Boyce;Elizabeth Morris;Clare Goyder;Jade Kinton;James Perring;David Nunan;Kamal Mahtani;John B Buse;Stefano Del Prato;Linong Ji;Ronan Roussel;Kamlesh Khunti | 2020-06-16 02:00:00+02:00 | 32546593 | FR;CN;GB;US;IT | Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, U.K. jamie.hartmann-boyce@phc.ox.ac.uk.;Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, U.K.;Medical Sciences Division, University of Oxford, Oxford, U.K.;Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, U.K.;University of North Carolina School of Medicine, Chapel Hill, NC.;Department of Clinical and Experimental Medicine, Section of Metabolic Diseases and Diabetes, University of Pisa, Pisa, Italy.;Peking University Diabetes Center, Peking University People's Hospital, China.;Federation de Diabetologie, Bichat Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.;UFR de Médecine, Université de Paris, Paris, France.;Diabetes Research Centre, University of Leicester, Leicester, U.K. | 1404 | |||
| 10.1016/j.ijrobp.2020.05.012 | Journal Article | en | Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. | https://www.ncbi.nlm.nih.gov/pubmed/32589990 | The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. | 0360-3016 | 2020-06-28 02:00:00+02:00 | pubmed | Consensus;Coronavirus Infections__epidemiology;Humans;Lung Neoplasms__radiotherapy;Medical Oncology;Pandemics;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Risk Management;Societies, Medical;Triage;COVID-19 | International Journal of Radiation Oncology*Biology*Physics | Matthias Guckenberger;Claus Belka;Andrea Bezjak;Jeffrey Bradley;Megan E Daly;Dirk DeRuysscher;Rafal Dziadziuszko;Corinne Faivre-Finn;Michael Flentje;Elizabeth Gore;Kristin A Higgins;Puneeth Iyengar;Brian D Kavanagh;Sameera Kumar;Cecile Le Pechoux;Yolande Lievens;Karin Lindberg;Fiona McDonald;Sara Ramella;Ramesh Rengan;Umberto Ricardi;Andreas Rimner;George B Rodrigues;Steven E Schild;Suresh Senan;Charles B Simone;Ben J Slotman;Martin Stuschke;Greg Videtic;Joachim Widder;Sue S Yom;David Palma | 2020-06-27 02:00:00+02:00 | 32589990 | FR;SE;CA;GB;CH;US;AT;PL;IT;NL;BE;DE | Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland. Electronic address: Matthias.Guckenberger@usz.ch.;Department of Radiation Oncology, LMU Klinikum, LMU Munich, Germany.;Department of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Canada.;Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.;Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, USA.;Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center(+), GROW Research Institute, The Netherlands.;Dept. of Oncology and Radiotherapy, Medical University of Gdansk, Poland.;Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.;Department of Radiation Oncology, University Hospital Würzburg, JMU Würzburg, Germany.;Department of Radiation Oncology, Medical College of Wisconsin and Zablocki VAMC, Milwaukee, USA.;Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, USA.;Department of Radiation Oncology, University of Colorado, Aurora, USA.;Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.;Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Department of Radiation Oncology, Ghent University Hospital and Ghent University, Belgium.;Department of Head, Neck, Lung and Skin Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.;Royal Marsden Hospital, London, UK.;Radiation Oncology, Campus Bio-Medico University of Rome, Italy.;Department of Radiation Oncology, University of Washington School of Medicine, Seattle, USA.;Department of Oncology, University of Turin, Italy.;Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.;Division of Radiation Oncology, Western University, London, Canada.;Department of Radiation Oncology, Mayo Clinic, Phoenix, USA.;Department of Radiation Oncology, Amsterdam UMC, The Netherlands.;Department of Radiation Oncology, New York Proton Center and Memorial Sloan Kettering Cancer Center, USA.;Department of Radiotherapy, University Duisburg-Essen, Germany.;Department of Radiation Oncology, Cleveland Clinic Lerner College of Medicine of Case Western University, USA.;Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.;Department of Radiation Oncology, University of California San Francisco, USA. | 1407 | |||
| Letter;Comment | en | Clozapine and COVID-19: The authors respond. | https://www.ncbi.nlm.nih.gov/pubmed/32584530 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Clozapine;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Dan Siskind;William G Honer;Scott Clark;Christoph U Correll;Alkomiet Hasan;Oliver Howes;John M Kane;Deanna L Kelly;Robert Laitman;Jimmy Lee;James H MacCabe;Nick Myles;Jimmi Nielsen;Peter F Schulte;David Taylor;Helene Verdoux;Amanda Wheeler;Oliver Freudenreich | 2020-06-26 02:00:00+02:00 | 32584530 | FR;SG;CA;GB;US;AU;NL;DK;DE | From the Metro South Addiction and Mental Health Service, Brisbane, Australia (Siskind), the University of Queensland, School of Clinical Medicine, Brisbane, Australia (Siskind, Myles), the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Honer), the University of Adelaide, School of Medicine, Adelaide, Australia (Clark, Kane), the The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA (Correll, Kane), the Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA (Correll), the Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany (Correll), the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Augsburg, Augsburg, Germany (Hasan), the Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK (Howes), the MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK (Howes, MacCabe), the Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK (Howes), the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA (Kelly), the Bronx Westchester Medical Group, New York, USA (Laitman), the North Region & Department of Psychosis, Institute of Mental Health, Singapore (Lee), the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Lee), the Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark (Nielsen), the Mental Health Service Noord-Holland-Noord, Alkmaar, The Netherlands (Schulte), the South London and Maudsley NHS Foundation Trust, Pharmacy Department, Maudsley Hospital, London, UK (Taylor), the University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France (Verdoux), the Menzies Health Institute Queensland, Griffith University, Brisbane, Australia (Wheeler), the MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA (Freudenreich), and the Harvard Medical School, Boston, Massachusetts, USA (Freudenreich). | 1410 | |||||||
| Letter;Comment | en | Will the COVID-19 pandemic decrease the FatMax? | https://www.ncbi.nlm.nih.gov/pubmed/32574528 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Exercise Test;Humans;Menstrual Cycle;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Frédéric Dutheil;Yolande Esquirol;Valentin Navel | COVID-19;SARS-CoV-2 pandemic;quarantine;sedentary activities | 2020-06-24 02:00:00+02:00 | 32574528 | FR | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, Clermont-Ferrand, France.;Université Paul Sabatier Toulouse 3, INSERM UMR-1027, University Hospital of Toulouse, CHU Toulouse, Occupational and Preventive Medicine, Toulouse, France.;Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, Clermont-Ferrand, France. | 1415 | ||||||
| 10.4997/jrcpe.2020.204 | Editorial | en | COVID-19: An initial view from the Scottish critical care frontline. | https://www.ncbi.nlm.nih.gov/pubmed/32568276 | 1478-2715,2042-8189 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Clinical Protocols;Coronavirus Infections__epidemiology;Critical Care__organization & administration;Critical Care Outcomes;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Scotland;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of the Royal College of Physicians of Edinburgh | Gillian Fleming;Gregor McNeill | 2020-06-23 02:00:00+02:00 | 32568276 | FR;GB | Royal Infirmary of Edinburgh, UK.;Department of Critical Care, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK Email: gregor.mcneill@nhs.net. | 1418 | ||||
| 10.3892/ijmm.2020.4659 | Journal Article;Review | en | Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). | https://www.ncbi.nlm.nih.gov/pubmed/32588061 | The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a novel β coronavirus that is the etiological agent of the pandemic coronavirus disease 2019 (COVID‑19) that at the time of writing (June 16, 2020) has infected almost 6 million people with some 450,000 deaths. These numbers are still rising daily. Most (some 80%) cases of COVID‑19 infection are asymptomatic, a substantial number of cases (15%) require hospitalization and an additional fraction of patients (5%) need recovery in intensive care units. Mortality for COVID‑19 infection appears to occur globally between 0.1 and 0.5% of infected patients although the frequency of lethality is significantly augmented in the elderly and in patients with other comorbidities. The development of acute respiratory distress syndrome and episodes of thromboembolism that may lead to disseminated intravascular coagulation (DIC) represent the primary causes of lethality during COVID‑19 infection. Increasing evidence suggests that thrombotic diathesis is due to multiple derangements of the coagulation system including marked elevation of D‑dimer that correlate negatively with survival. We propose here that the thromboembolic events and eventually the development of DIC provoked by SARS‑CoV‑2 infection may represent a secondary anti‑phospholipid antibody syndrome (APS). We will apply both Baconian inductivism and Cartesian deductivism to prove that secondary APS is likely responsible for coagulopathy during the course of COVID‑19 infection. Diagnostic and therapeutic implications of this are also discussed. | 1107-3756,1791-244X | 2020-06-28 02:00:00+02:00 | pubmed | Antiphospholipid Syndrome__immunology;Antiviral Agents__therapeutic use;Betacoronavirus;Blood Coagulation__physiology;Coronavirus Infections__drug therapy;Disseminated Intravascular Coagulation__immunology;Fibrin Fibrinogen Degradation Products__metabolism;Humans;Pandemics;Phospholipids__immunology;Pneumonia, Viral__drug therapy;Thromboembolism__immunology;Thrombosis__pathology;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Molecular Medicine | Eugenio Cavalli;Alessia Bramanti;Rosella Ciurleo;Andrey I Tchorbanov;Antonio Giordano;Paolo Fagone;Cristina Belizna;Placido Bramanti;Yehuda Shoenfeld;Ferdinando Nicoletti | 2020-06-25 02:00:00+02:00 | 32588061 | FR;IL;US;BG;IT | Department of Biomedical and Biotechnological Sciences, University of Catania, I-95123 Catania, Italy.;IRCCS Centro Neurolesi 'Bonino‑Pulejo', I-98124 Messina, Italy.;Laboratory of Experimental Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.;Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.;Vascular and Coagulation Department, University Hospital Angers, 49000 Angers, France.;Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Tel‑Aviv University, Ramat Gan 5265601, Israel. | 1421 | |||
| 10.1016/j.jogoh.2020.101841 | Editorial | en | Impact of the outbreak of SARS-CoV-2 infection on urgent gynecological care. | https://www.ncbi.nlm.nih.gov/pubmed/32590109 | 2468-7847 | 2020-06-28 02:00:00+02:00 | pubmed | Journal of Gynecology Obstetrics and Human Reproduction | Yoann Athiel;Marie-Sophie Civadier;Dominique Luton;Pierre-François Ceccaldi;Antoine Bourret;Jeremy Sroussi;Laurent Mandelbrot;Yves Ville;Jacky Nizard;Olivier Sibony;Emile Darai;Pierre Delorme;Hervé Fernandez;Gwen Le Begat;Mélody Nublat;Alexandra Benachi;Xavier Deffieux | COVID-19;Gynecologic emergency;Gynecology;Outbreak;SARS-CoV-2 | 2020-06-23 02:00:00+02:00 | 32590109 | FR | Department of Obstetrics and Gynaecology, Hôpital Antoine Béclère, 157 rue de la porte de Trivaux, 92140 Clamart, APHP, France.;Medical Informatics Unit, Hôpital Antoine Béclère, 157 rue de la porte de Trivaux, 92140 Clamart, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Bichat - Claude Bernard, 46 rue Henri Huchard, 75018 Paris, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Beaujon, 100 boulevard du Général Leclerc, 92110 Clichy, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Cochin Port-Royal, 123 Boulevard de Port-Royal, 74014 Paris, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Lariboisière, 2 rue Ambroisé Paré, 75010 Paris, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Louis Mourier, 178 rue des renouillers, 92700 Colombes, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Necker, 149 Rue de Sèvres, 75015 Pairs, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Pitié-Salpétrière, 47-83 Boulevard de l'Hôpital, 75013 Paris, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Robert-Debré, 48 Boulevard Sérurier, 75019 Paris, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Trousseau, 26 Avenue du Dr Arnold Netter, 75012 Paris, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, APHP, France.;Hospital Group Finance Department, APHP, France.;Department of Obstetrics and Gynaecology, Hôpital Antoine Béclère, 157 rue de la porte de Trivaux, 92140 Clamart, APHP, France. Electronic address: xavier.deffieux@aphp.fr. | 1424 | ||||
| Letter | en | Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity. | https://www.ncbi.nlm.nih.gov/pubmed/32583231 | 2020-06-28 02:00:00+02:00 | pubmed | Adolescent;Adult;Age Factors;Aged;Betacoronavirus;Child;Child, Preschool;Coronavirus Infections__complications;Female;Humans;Immunity, Cellular__physiology;Infant;Infant, Newborn;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Severity of Illness Index;T-Lymphocytes__physiology;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Francesco Nicoli;Maria Teresa Solis-Soto;Deepak Paudel;Peggy Marconi;Riccardo Gavioli;Victor Appay;Antonella Caputo | 2020-06-24 02:00:00+02:00 | 32583231 | FR;CL;JP;NP;IT | Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Via Fossato di Mortara 64/B, 44121, Ferrara, Italy. nclfnc1@unife.it.;Universidad de O'Higgins, Rancagua, Chile.;Nepal Public Health Association, Kathmandu, Nepal.;Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Via Fossato di Mortara 64/B, 44121, Ferrara, Italy.;Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.;Kumamoto University, International Research Center for Medical Sciences (IRCMS), Kumamoto, Japan. | 1436 | |||||||
| Letter | en | Neurological, Cognitive, and Behavioral Disorders during COVID-19: The Nitric Oxide Track. | https://www.ncbi.nlm.nih.gov/pubmed/32583434 | 2020-06-28 02:00:00+02:00 | pubmed | Cédric Annweiler;Alexis Bourgeais;Emmanuelle Faucon;Zhijian Cao;Yingliang Wu;Jean-Marc Sabatier | 2020-06-24 02:00:00+02:00 | 32583434 | FR;CN;CA;GB | Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France.;UPRES EA 4638, University of Angers, Angers, France.;Department of Medical Biophysics, Schulich School of Medicine and Dentistry, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.;EFFE, Toulon, France.;State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, China.;Hubei Province Engineering and Technology Research, Center for Fluorinated Pharmaceuticals, Wuhan University, Wuhan, China.;Institute of NeuroPhysiopathology, UMR 7051, Aix-Marseille University, Marseille, France. | 1437 | ||||||||
| 10.3389/fneur.2020.00664 | Journal Article | en | Chronic Neurology in COVID-19 Era: Clinical Considerations and Recommendations From the REPROGRAM Consortium. | https://www.ncbi.nlm.nih.gov/pubmed/32695066 | With the rapid pace and scale of the emerging coronavirus 2019 (COVID-19) pandemic, a growing body of evidence has shown a strong association of COVID-19 with pre- and post- neurological complications. This has necessitated the need to incorporate targeted neurological care for this subgroup of patients which warrants further reorganization of services, healthcare workforce, and ongoing management of chronic neurological cases. The social distancing and the shutdown imposed by several nations in the midst of COVID-19 have severely impacted the ongoing care, access and support of patients with chronic neurological conditions such as Multiple Sclerosis, Epilepsy, Neuromuscular Disorders, Migraine, Dementia, and Parkinson disease. There is a pressing need for governing bodies including national and international professional associations, health ministries and health institutions to harmonize policies, guidelines, and recommendations relating to the management of chronic neurological conditions. These harmonized guidelines should ensure patient continuity across the spectrum of hospital and community care including the well-being, safety, and mental health of the patients, their care partners and the health professionals involved. This article provides an in-depth analysis of the impact of COVID-19 on chronic neurological conditions and specific recommendations to minimize the potential harm to those at high risk. | 1664-2295 | 2020-06-28 02:00:00+02:00 | pubmed | Frontiers in Neurology | Sonu Bhaskar;Sian Bradley;Simon Israeli-Korn;Bindu Menon;Vijay Kumar Chattu;Pravin Thomas;Jasvinder Chawla;Rajeev Kumar;Paolo Prandi;Daniel Ray;Sailaja Golla;Nirmal Surya;Harvey Yang;Sandra Martinez;Mihriban Heval Ozgen;John Codrington;Eva María Jiménez González;Mandana Toosi;Nithya Hariya Mohan;Koravangattu Valsraj Menon;Abderrahmane Chahidi;Susana Mederer Hengstl | chronic neurological disease;coronavirus disease 2019 (COVID-19);guidelines;healthcare services;neurodegenerative disorders;pandemics;protocols;recommendations | 2020-06-24 02:00:00+02:00 | 32695066 | IL;SR;FR;CA;UNK;GB;US;QA;BR;IT;AU;NL;MA;ES;IN | Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†.;Department of Neurology and Neurophysiology, Liverpool Hospital, Sydney, NSW, Australia.;Neurovascular Imaging Laboratory & NSW Brain Clot Bank, Ingham Institute for Applied Medical Research and South West Sydney Clinical School, The University of New South Wales, UNSW Medicine, Sydney, NSW, Australia.;The University of New South Wales, UNSW Medicine, Sydney, NSW, Australia.;Department of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan and Sackler School of Medicine, Movement Disorders Institute, Tel Aviv University, Tel Aviv-Yafo, Israel.;Department of Neurology, Apollo Hospitals, Nellore, India.;Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.;Department of Neurology, University Hospitals NHS Foundation Trust, Birmingham, United Kingdom.;Department of Neurology, Loyola University Medical Center & Hines VA Hospital, Chicago, IL, United States.;Department of Psychiatry, Hamad Medical Center, Qatar & Australian National University, Canberra, ACT, Australia.;Department of Neurology, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy.;Farr Institute of Health Informatics, University College London (UCL) & NHS Foundation Trust, Birmingham, United Kingdom.;Texas Institute for Neurological Disorders, Dallas, TX, United States.;Department of Neurology, Bombay Hospital & Medical Research Centre, and Epilepsy Foundation India, Mumbai, India.;Department of Neurology, Academic Hospital Paramaribo & Anton de Kom Universiteit van Suriname Faculteit der Medische Wetenschappen, Paramaribo, Suriname.;Department of Neurology, Hospital da Restauração, Recife, Brazil.;Department of Psychiatry, Parnassia Psychiatric Institute, The Hague, Netherlands.;Curium-Leiden University Medical Centre, Oegstgeest, Netherlands.;Department of Laboratory Medicine, Academic Hospital Paramaribo and Anton de Kom Universiteit van Suriname Faculteit der Medische Wetenschappen, Paramaribo, Suriname.;Department of Forensic Psychology, Forensic Psychology and Forensic Sciences Institute, Ministry of Justice, Granada, Spain.;LodeStone Center for Behavioral Health and Eastern Illinois University, Chicago, IL, United States.;Chengalpattu Medical College and Hospital, Chengalpattu, India.;Department of Psychiatry, South London and Maudsley NHS Foundation Trust, Kings Health Partners, London, United Kingdom.;ED 268, DR 178, Sorbonne Nouvelle University, Paris, France.;Moroccan Society of Neurophysiology, Marrakech, Morocco.;Morocco and Basic and Clinical Neurosciences Research Laboratory, University Medical School of Marrakech, Marrakech, Morocco.;Department of Neurology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain. | 1443 | |||
| 10.2196/19630 | Journal Article | en | Global changes and factors of increase in caloric/salty food, screen, and substance use, during the early COVID-19 containment phase in France: a general population online survey. | https://www.ncbi.nlm.nih.gov/pubmed/32589149 | The international outbreak of the COVID-19 pandemic has led many countries to enforce drastic containment measures. It has been suggested that this abrupt lockdown of populations would foster addiction-related habits, such as caloric/salty (C/S) food intake, screen use, and substance use. However, no data has supported this assumption until now. | 2369-2960 | 2020-06-28 02:00:00+02:00 | pubmed | JMIR Public Health and Surveillance | Benjamin Rolland;Frédéric Haesebaert;Elodie Zante;Amine Benyamina;Julie Haesebaert;Nicolas Franck | 2020-06-25 02:00:00+02:00 | 32589149 | FR | ch vinatier, Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier, Bâtiment 502, BRON, FR.;APHP Paul Brousse Hospital, Paris, FR.;CHU Lyon, Lyon, FR. | 1445 | ||||
| Letter | en | Guillain-Barré syndrome in the COVID-19 era: another occasional cluster? | https://www.ncbi.nlm.nih.gov/pubmed/32577868 | 2020-06-28 02:00:00+02:00 | pubmed | Laurent Tatu;Sandra Nono;Simone Grácio;Serdar Koçer | 2020-06-23 02:00:00+02:00 | 32577868 | FR;CH | Department of Neuromuscular Diseases, CHRU Besançon, University of Franche-Comté, 3 boulevard Fleming, 25000, Besançon, France. laurent.tatu@univ-fcomte.fr.;Department of Anatomy, University of Franche-Comté, Besançon, France. laurent.tatu@univ-fcomte.fr.;Department of Neurology, CHRU Besançon, Besançon, France.;Department of Rehabilitation, Hôpital du Jura, Porrentruy, Switzerland. | 1450 | ||||||||
| 10.1140/epjp/s13360-020-00526-1 | Journal Article | en | Common trends in the epidemic of Covid-19 disease. | https://www.ncbi.nlm.nih.gov/pubmed/32834912 | The discovery of SARS-CoV-2, the responsible virus for the Covid-19 epidemic, has sparked a global health concern with many countries affected. Developing models that can interpret the epidemic and give common trend parameters are useful for prediction purposes by other countries that are at an earlier phase of the epidemic; it is also useful for future planning against viral respiratory diseases. One model is developed to interpret the fast-growth phase of the epidemic and another model for an interpretation of the entire data set. Both models agree reasonably with the data. It is shown by the first model that during the fast phase, the number of new infected cases depends on the total number of cases by a power-law relation with a scaling exponent equal to 0.82. The second model gives a duplication time in the range 1-3 days early in the start of the epidemic, and another parameter (α = 0.1-0.5) that deviates the progress of the epidemic from an exponential growth. Our models may be used for data interpretation and for guiding predictions regarding this disease, e.g., the onset of the maximum in the number of new cases. | 2190-5444 | 2020-06-28 02:00:00+02:00 | pubmed | The European Physical Journal Plus | Milad Radiom;Jean-François Berret | 2020-06-22 02:00:00+02:00 | 32834912 | FR | Matière et systèmes complexes, CNRS, Université de Paris, 75013 Paris, France. | 1451 | ||||
| 10.1111/den.13777 | Journal Article;Review | en | Recommendations for the Operation of Endoscopy Centers in the setting of the COVID-19 pandemic - World Endoscopy Organization guidance document. | https://www.ncbi.nlm.nih.gov/pubmed/32569438 | Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) is the etiologic agent causing the disease Corona Virus Disease 19 (COVID-19), resulting in a worldwide pandemic. Non-emergent endoscopy services have been disrupted as incidence and hospitalizations were rising. It is anticipated that the peak incidence may be leveling off in many parts of the world, but there is a concern for resurgence of the virus activity. Thus, it is important for endoscopy units to have plans in place during peak times of the epidemic and when resuming endoscopic services as the pandemic wanes. The global endoscopy community is faced with the challenge of providing care during this time. The WEO-COVID guidance task force has provided this resource document based on the current evidence and consensus opinion. These World Endoscopy Organization (WEO) recommendations are meant to guide endoscopists worldwide, should be interpreted in light of specific clinical conditions and resource availability and may not apply in all situations. This guidance document does not supersede the need to check for all local regulations and legislations. | 0915-5635,1443-1661 | 2020-06-28 02:00:00+02:00 | pubmed | Digestive Endoscopy | Nalini M Guda;Fabian Emura;Duvvur Nageshwar Reddy;Jean-Fracois Rey;Dong-Wan Seo;Tibor Gyokeres;Hisao Tajiri;Douglas Faigel | COVID-19;PPE and pandemic;SARS-CoV 2;best practices;clinical practice guideline;corona virus;endoscopy | 2020-06-22 02:00:00+02:00 | 32569438 | FR;CO;JP;US;HU;IN;KR | Aurora St.Luke's Medical Center, Milwaukee and GI Associates, Milwaukee, USA.;Advanced Endoscopy, EmuraCenter Latinoamérica, Bogotá, Colombia.;Gastroenterology Division, Universidad de La Sabana, Chia, Colombia.;Asian Institute of Gatroenterology, Hyderabad, India.;Department of Hepato-Gastroenterology, Institut Arnault Tzanck, Saint-Laurent-du-Var, France.;Department of Gastroenterology, Asan Medical Center University of Ulsan Medical College, Seoul, Korea.;Department of Gastroenterology, Medical Centre, Hungarian Defence Forces, Budapest, Hungary.;Department of Innovative Interventional Endoscopy Research, The Jikei University School of Medicine, Tokyo, Japan.;Department of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, USA. | 1453 | |||
| 10.1515/cclm-2020-0612 | Journal Article | en | Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient. | https://www.ncbi.nlm.nih.gov/pubmed/32573468 | Objectives A method based on liquid chromatography coupled to triple quadrupole mass spectrometry detection using 50 µL of plasma was developed and fully validated for quantification of remdesivir and its active metabolites GS-441524. Methods A simple protein precipitation was carried out using 75 µL of methanol containing the internal standard (IS) remdesivir-13C6 and 5 µL ZnSO4 1 M. After separation on Kinetex® 2.6 µm Polar C18 100A LC column (100 × 2.1 mm i.d.), both compounds were detected by a mass spectrometer with electrospray ionization in positive mode. The ion transitions used were m/z 603.3 → m/z 200.0 and m/z 229.0 for remdesivir, m/z 292.2 → m/z 173.1 and m/z 147.1 for GS-441524 and m/z 609.3 → m/z 206.0 for remdesivir-13C6. Results Calibration curves were linear in the 1-5000 μg/L range for remdesivir and 5-2500 for GS-441524, with limit of detection set at 0.5 and 2 μg/L and limit of quantification at 1 and 5 μg/L, respectively. Precisions evaluated at 2.5, 400 and 4000 μg/L for remdesivir and 12.5, 125, 2000 μg/L for GS-441524 were lower than 14.7% and accuracy was in the [89.6-110.2%] range. A slight matrix effect was observed, compensated by IS. Higher stability of remdesivir and metabolite was observed on NaF-plasma. After 200 mg IV single administration, remdesivir concentration decrease rapidly with a half-life less than 1 h while GS-441524 appeared rapidly and decreased slowly until H24 with a half-life around 12 h. Conclusions This method would be useful for therapeutic drug monitoring of these compounds in Covid-19 pandemic. | 1437-4331,1434-6621 | 2020-06-28 02:00:00+02:00 | pubmed | Clinical Chemistry and Laboratory Medicine (CCLM) | Jean-Claude Alvarez;Pierre Moine;Isabelle Etting;Djillali Annane;Islam Amine Larabi | Covid-19;GS-441524;LC–MS/MS;remdesivir | 2020-06-22 02:00:00+02:00 | 32573468 | FR | Laboratoire de Pharmacologie-Toxicologie, Université de Versailles Saint-Quentin en Yvelines, Inserm U-1173, Hôpital Raymond Poincaré, AP-HP, 104, Boulevard R. Poincaré, 92380, Garches, France.;Intensive Care Unit, Paris-Saclay University (Versailles Saint-Quentin-en-Yvelines), Inserm U-1173, Raymond Poincaré Hospital, AP-HP, Garches, France.;Department of Pharmacology and Toxicology, Paris-Saclay University (Versailles Saint-Quentin-en-Yvelines), Inserm U-1173, Raymond Poincaré Hospital, AP-HP, Garches, France. | 1458 | |||
| 10.1016/j.anorl.2020.06.014 | Journal Article | en | Telemedicine for ENT: Effect on quality of care during Covid-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32624390 | To assess the benefit of telemedicine consultation during the Covid-19 pandemic. | 1879-7296 | 2020-06-28 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | M Fieux;S Duret;N Bawazeer;L Denoix;S Zaouche;S Tringali | Covid-19;Otolaryngology;Satisfaction;Telehealth;Telemedicine | 2020-06-22 02:00:00+02:00 | 32624390 | FR;SA | Service d'Otologie et d'Otoneurologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université de Lyon, Université Claude Bernard Lyon 1, 69495, Pierre-Bénite, France. Electronic address: maxime.fieux@chu-lyon.fr.;Service d'Otologie et d'Otoneurologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université de Lyon, Université Claude Bernard Lyon 1, 69495, Pierre-Bénite, France.;Service d'Otorhinolaryngologie et Chirurgie Cervico-Faciale, Umm Al Qura University, Mecca, Saudi Arabia. | 1461 | |||
| Wellcome Trust | 10.1016/j.biologicals.2020.06.005 | Journal Article | en | SARS-CoV-2: Virology, epidemiology, immunology and vaccine development. | https://www.ncbi.nlm.nih.gov/pubmed/32600951 | This first International Alliance for Biological Standardization Covid-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries, to discuss the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2. | 1045-1056 | 2020-06-28 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Basic Reproduction Number;Betacoronavirus;Congresses as Topic;Coronavirus Infections__epidemiology;Drug Design;Female;Global Health;Humans;International Cooperation;Internet;Male;Middle Aged;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Reference Standards;Seasons;Telecommunications;Viral Vaccines;Virology__trends;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Biologicals | Marc Baay;Bruno Lina;Arnaud Fontanet;Arnaud Marchant;Melanie Saville;Philippe Sabot;Philippe Duclos;Joris Vandeputte;Pieter Neels | Epidemiology;Immunology;SARS-CoV-2;Vaccine development;Virology | 2020-06-23 02:00:00+02:00 | 32600951 | FR;BE;GB;CH | [{"country": "United Kingdom", "agency": "Wellcome Trust"}] | P95 Epidemiology & Pharmacovigilance, Leuven, Belgium. Electronic address: marc.baay@p-95.com.;University Claude Bernard Lyon, VirPath Research Laboratory, Lyon, France. Electronic address: bruno.lina@univ-lyon1.fr.;Department of Global Health, Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France. Electronic address: arnaud.fontanet@pasteur.fr.;Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: arnaud.marchant@ulb.be.;Vaccine R&D, CEPI Vaccines, London, UK. Electronic address: melanie.saville@cepi.net.;International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: philippe.sabot@iabs.org.;ADVAC, University of Geneva, Geneva, Switzerland. Electronic address: Philippe.Duclos@unige.ch.;International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: joris.vandeputte@iabs.org.;International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: Pieter.neels@vaccine-advice.be. | 1467 |
| Letter | en | COVID-19, impact on myeloma patients. | https://www.ncbi.nlm.nih.gov/pubmed/32577846 | 2020-06-28 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Belgium__epidemiology;Betacoronavirus;Coronavirus Infections__diagnosis;Female;Humans;Male;Middle Aged;Multiple Myeloma__diagnosis;Pandemics;Pneumonia, Viral__diagnosis;Surveys and Questionnaires;COVID-19;severe acute respiratory syndrome coronavirus 2 | Inès Dufour;Juliette Raedemaeker;Fabio Andreozzi;Géraldine Verstraete;Sarah Bailly;Michel Delforge;Pauline Storms;Caroline Jacquy;Ann Van de Velde;Philippe Mineur;Marie Lejeune;Deborah Bauwens;Florence Van Obbergh;Alain Kentos;Jasmine Nguyen;Karel Fostier;Anne De Weweire;Nathalie Meuleman;Marie-Christiane Vekemans | 2020-06-23 02:00:00+02:00 | 32577846 | FR;BE;GB | Department of Hematology, Cliniques universitaires Saint-Luc, UCL, 1200, Brussels, Belgium.;University Hospital Leuven, Leuven, Belgium.;Centre Hospitalier Ambroise Paré, Mons, Belgium.;University Hospital Antwerpen, Antwerp, Belgium.;Grand Hôpital de Charleroi, Charleroi, Belgium.;Centre Hospitalier Universitaire de Liège, Liège, Belgium.;Clinique Saint-Jean, Brussels, Belgium.;Hôpital de Jolimont, Haine-Saint-Paul, Belgium.;Centre Hospitalier Régional de Namur, Namur, Belgium.;University Hospital Brussels, Brussels, Belgium.;Centre Hospitalier EpiCURA, Mons, Belgium.;Institut Jules Bordet, Brussels, Belgium.;Department of Hematology, Cliniques universitaires Saint-Luc, UCL, 1200, Brussels, Belgium. Marie-christiane.vekemans@uclouvain.be. | 1468 | |||||||
| 10.1016/j.therap.2020.06.006 | Journal Article | en | Addictovigilance contribution during COVID-19 epidemic and lockdown in France. | https://www.ncbi.nlm.nih.gov/pubmed/32660776 | Addictovigilance is a safety monitoring targeted at substances with potential for abuse and dependence. This vigilance was involved during the period of COVID-19 epidemic due to the significant changes in access to drugs and psychological disruption caused by the pandemic and lockdown. This article aims to present the different steps implemented by the French Addictovigilance network in collaboration with the French Health authorities from March to May 2020, including monitoring of potential harmful events, and scientific communication. The first events were identified through the continuity of the networking between the French addictovigilance centres and their partners: community pharmacies, general practitioners, specialized structures and emergency wards. As soon as the lockdown began, first cases of overdoses (lethal or not) were reported with opioids, mainly with methadone, and other opioids (heroin, oxycodone, tramadol or antitussive codeine). Lockdown-related noteworthy events consisted in clinical cases or other relevant information for which lockdown clearly played an important role: among the many substances identified at least once, pregabalin, benzodiazepines, cannabis, cocaine and nitrous oxide were the most significant in terms of prevalence, seriousness or particularly specific to the lockdown context. Despite significant decrease in the activity and travel limited to vital needs, community pharmacies continued to identify falsified prescriptions in this period, highlighting an increase in suspicious requests for pregabalin, codeine and tramadol. In parallel, the French addictovigilance network continued its communications efforts in the period, issuing a newsletter on tramadol, a press release on methadone and naloxone, and participating in the COVID-19 frequently asked questions (FAQs) of the French Society of Pharmacology and Therapeutic website (https://sfpt-fr.org/covid19). COVID-19 epidemic has been an important challenge for addictovigilance, and has proved that this monitoring is highly essential for alerting health professionals and health authorities to points of vigilance in the field of psychoactive substances. | 0040-5957 | 2020-06-28 02:00:00+02:00 | pubmed | Therapies | Maryse Lapeyre-Mestre;Alexandra Boucher;Amélie Daveluy;Valérie Gibaja;Emilie Jouanjus;Michel Mallaret;Helene Peyrière;Joëlle Micallef | Abuse;Addiction;Addictovigilance;COVID-19;Cocaine;Lockdown;Methadone;Nitrous oxide;Pregabalin;Psychoactive substances | 2020-06-23 02:00:00+02:00 | 32660776 | FR | CEIP-A Toulouse, 31000 Toulouse, France. Electronic address: maryse.lapeyre-mestre@univ-tlse3.fr.;CEIP-A Lyon, 69424 Lyon, France.;CEIP-A Bordeaux, 33076 Bordeaux, France.;CEIP-A Nancy, 54035 Nancy, France.;CEIP-A Toulouse, 31000 Toulouse, France.;CEIP-A Grenoble, 38043 Grenoble, France.;CEIP-A Montpellier, 34295 Montpellier, France.;CEIP-A Marseille, 13385 Marseille, France. | 1472 | |||
| Letter | en | Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. | https://www.ncbi.nlm.nih.gov/pubmed/32589293 | 2020-06-28 02:00:00+02:00 | pubmed | S Matar;B Oulès;P Sohier;O Chosidow;M Beylot-Barry;N Dupin;S Aractingi | 2020-06-26 02:00:00+02:00 | 32589293 | FR | Department of Dermatology, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre Cochin-Hôtel Dieu-Broca, Paris, France.;Faculté de Médecine Paris Centre Santé, University of Paris, Paris, France.;Cutaneous Biology Lab, INSERM U1016, UMR8104, Institut Cochin, Paris, France.;Department of Pathology, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre Cochin-Hôtel Dieu-Broca, Paris, France.;Department of Dermatology, Hôpital Henri Mondor, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Research Group Dynamyc, EA7380, Faculté de Médecine, Université Paris-Est Créteil, Ecole nationale vétérinaire d'Alfort, USC ANSES, Créteil, France.;Department of Dermatology, CHU Bordeaux, Bordeaux, France.;Bordeaux Research in Translational Oncology, INSERM U1053, Bordeaux, France. | 1486 | ||||||||
| 10.1002/cpt.1968 | Journal Article | en | QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32588427 | Association between Hydroxychloroquine (HCQ) and Azithromycin (AZT) is under evaluation for patients with lower respiratory tract infection (LRTI) caused by the Severe Acute Respiratory Syndrome (SARS-CoV-2). Both drugs have a known torsadogenic potential, but sparse data are available concerning QT prolongation induced by this association. Our objective was to assess for COVID-19 LRTI variations of QT interval under HCQ/AZT in patients hospitalized, and to compare manual versus automated QT measurements. Before therapy initiation, a baseline 12 lead-ECG was electronically sent to our cardiology department for automated and manual QT analysis (Bazett and Fridericia's correction), repeated 2 days after initiation. According to our institutional protocol (Pasteur University Hospital), HCQ/AZT was initiated only if baseline QTc ≤ 480ms and potassium level> 4.0 mmol/L. From March 24th to April 20th 2020, 73 patients were included (mean age 62 ± 14 years, male 67%). Two patients out of 73 (2.7%) were not eligible for drug initiation (QTc ≥ 500 ms). Baseline average automated QTc was 415 ± 29 ms and lengthened to 438 ± 40 ms after 48 hours of combined therapy. The treatment had to be stopped because of significant QTc prolongation in two out of 71 patients (2.8%). No drug-induced life-threatening arrhythmia, nor death was observed. Automated QTc measurements revealed accurate in comparison with manual QTc measurements. In this specific population of inpatients with COVID-19 LRTI, HCQ/AZT could not be initiated or had to be interrupted in less than 6% of the cases. | 0009-9236,1532-6535 | 2020-06-28 02:00:00+02:00 | pubmed | Clinical Pharmacology & Therapeutics | Sok-Sithikun Bun;Philippe Taghji;Johan Courjon;Fabien Squara;Didier Scarlatti;Guillaume Theodore;Delphine Baudouy;Benjamin Sartre;Mohamed Labbaoui;Jean Dellamonica;Denis Doyen;Charles-Hugo Marquette;Jacques Levraut;Vincent Esnault;Sok-Siya Bun;Emile Ferrari | 2020-06-26 02:00:00+02:00 | 32588427 | FR | Cardiology Department, Pasteur University Hospital, Nice, France.;Cardiology Department, Clinique la Casamance, Aubagne, France.;Infectious Diseases Department, Archet University Hospital, Nice, France.;Medical Intensive Care Unit, Archet University Hospital, Nice, France.;Department of Respiratory Medicine, Pasteur University Hospital, Nice, France.;Department of Emergency Medicine, Pasteur University Hospital, Nice, France.;Nephrology Department, Pasteur University Hospital, Nice, France.;Pharmacy Faculty, CNRS, IRD, IMBE, Aix Marseille University, Marseille, France.;Pharmacy Department, CHU Nord, APHM, Marseille, France. | 1487 | ||||
| 10.1093/tropej/fmaa032 | Journal Article | en | Infant Case of Co-infection with SARS-CoV-2 and Citrobacter koseri Urinary Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32594151 | Since 2019 coronavirus disease (COVID-19) is highly contagious with a high mortality rate. France has taken strict infection control measures. According to the report by the Center for Disease Control and Prevention, children are less affected with COVID-19 and seem to have less severe disease than adults. We reported the first confirmed infant case of co-infection with SARS-CoV-2 and Citrobacter koseri urinary infection in 6-week-old child admitted on 25 March 2020 with mild symptoms in the Pediatric COVID Unit of Amiens University Hospital, France. | 0142-6338,1465-3664 | 2020-06-28 02:00:00+02:00 | pubmed | Journal of Tropical Pediatrics | Hyppolite K Tchidjou;Bernard Romeo | 2020-06-28 02:00:00+02:00 | 32594151 | FR | Pediatric Emergency Services Department, Amiens University Hospital, 80000 Amiens, France. | 1509 | ||||
| 10.1016/j.anorl.2020.06.016 | Journal Article | en | Percutaneous dilatational tracheostomy for saturating influx of COVID-19 patients: Experience of military ENT physicians deployed in Mulhouse, France. | https://www.ncbi.nlm.nih.gov/pubmed/32631724 | The main objective was to demonstrate the feasibility of percutaneous tracheostomy performed under difficult conditions by military ENT physicians during their deployment in the military intensive care field hospital of the French Military Medical Service in Mulhouse to confront the exceptional COVID-19 pandemic. The secondary objective was to assess reliability and safety for patient and caregivers, with a risk of iatrogenic viral contamination. | 1879-7296 | 2020-06-28 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | J-B Morvan;D Rivière;M Danguy des Déserts;G Bonfort;Q Mathais;P Pasquier | COVID-19;ENT physician;Military;Percutaneous tracheostomy;SARS-CoV-2 | 2020-06-28 02:00:00+02:00 | 32631724 | FR | Service d'ORL et de Chirurgie Cervico-Faciale, Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France, Elément Militaire de Réanimation du Service de Santé des Armées EMRSSA, Mulhouse, France. Electronic address: jbmorvan@hotmail.com.;Service d'ORL et de Chirurgie Cervico-Faciale, Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France, Elément Militaire de Réanimation du Service de Santé des Armées EMRSSA, Mulhouse, France.;Elément Militaire de Réanimation du Service de Santé des Armées EMRSSA, Mulhouse, France, Service d'Anesthésie-Réanimation, Hôpital d'Instruction des Armées Clermont Tonnerre, Brest, France.;Elément Militaire de Réanimation du Service de Santé des Armées EMRSSA, Mulhouse, France, Service d'ORL et de Chirurgie Cervico-Faciale, Hôpital d'Instruction des Armées Legouest, Metz, France.;Elément Militaire de Réanimation du Service de Santé des Armées EMRSSA, Mulhouse, France, Service d'Anesthésie-Réanimation, Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France.;Elément Militaire de Réanimation du Service de Santé des Armées EMRSSA, Mulhouse, France, Service d'Anesthésie-Réanimation, Hôpital d'Instruction des Armées Percy, Clamart, France, École du Val-de-Grâce, Paris, France. | 1512 | |||
| 10.1016/j.neucli.2020.06.001 | Journal Article | en | Electroencephalogram (EEG) in COVID-19: A systematic retrospective study. | https://www.ncbi.nlm.nih.gov/pubmed/32653111 | Although rare, neurological manifestations in SARS-CoV-2 infection are increasingly being reported. We conducted a retrospective systematic study to describe the electroencephalography (EEG) characteristics in this disease, looking for specific patterns. | 0987-7053 | 2020-06-28 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Arousal__physiology;Betacoronavirus__isolation & purification;Brain Waves__physiology;Cardiovascular Diseases__complications;Comorbidity;Confusion__etiology;Coronavirus Infections__complications;Deep Sedation;Delayed Emergence from Anesthesia__etiology;Dementia__complications;Electroencephalography;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Polymerase Chain Reaction;Respiratory Distress Syndrome, Adult__etiology;Retrospective Studies;COVID-19;severe acute respiratory syndrome coronavirus 2 | Neurophysiologie Clinique | Ana-Maria Petrescu;Delphine Taussig;Viviane Bouilleret | Brain;COVID 19;Electroencephalogram;Encephalitis;Encephalopathy;Intensive care unit | 2020-06-25 02:00:00+02:00 | 32653111 | FR | Université Paris Saclay-APHP, Unité de Neurophysiologie Clinique et d'Epileptologie (UNCE), Le Kremlin-Bicêtre, France.;Université Paris Saclay-APHP, Unité de Neurophysiologie Clinique et d'Epileptologie (UNCE), Le Kremlin-Bicêtre, France. Electronic address: delphine.taussig@aphp.fr.;Université Paris Saclay-APHP, Unité de Neurophysiologie Clinique et d'Epileptologie (UNCE), Le Kremlin-Bicêtre, France, UMR BIOMAPS- CNRS, Université Paris Saclay, Inserm, CEA, 91401 Orsay, France. | 1525 | ||
| Letter | en | Proteinuria in Covid-19 pregnant women: Preeclampsia or severe infection? | https://www.ncbi.nlm.nih.gov/pubmed/32654789 | 2020-07-05 02:00:00+02:00 | pubmed | Matthieu Dap;Olivier Morel | 2020-07-03 02:00:00+02:00 | 32654789 | FR | Obstetric and Fetal Medicine Unit, CHRU of Nancy, 10, avenue du Dr Heydenreich, 54000, Nancy, France. Electronic address: m.dap@chru-nancy.fr.;Obstetric and Fetal Medicine Unit, CHRU of Nancy, 10, avenue du Dr Heydenreich, 54000, Nancy, France. | 1532 | ||||||||
| 10.1016/j.medin.2020.06.010 | Journal Article | en | Pneumomediastinum in critically ill adult with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32736894 | 0210-5691 | 2020-07-05 02:00:00+02:00 | pubmed | Medicina Intensiva | N Collercandy;A Guillon | 2020-07-04 02:00:00+02:00 | 32736894 | FR | CHU de Tours, service de médecine intensive réanimation, université de Tours, Tours, France. Electronic address: nived.collercandy@yahoo.fr.;CHU de Tours, service de médecine intensive réanimation, université de Tours, Tours, France, INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), Université de Tours, France. Electronic address: antoine.guillon@univ-tours.fr. | 1538 | |||||
| 10.1016/j.ijantimicag.2020.106077 | Journal Article | en | Corticosteroid therapy for patients with COVID-19 pneumonia: a before-after study. | https://www.ncbi.nlm.nih.gov/pubmed/32634602 | Anti-inflammatory drugs such as corticosteroids may beneficially modulate the host inflammatory response to coronavirus disease 2019 (COVID-19) pneumonia. The aim of this study was to evaluate the impact of addition of corticosteroids to the hospital protocol for treatment of suspected or confirmed COVID-19 pneumonia on rates of death or intensive care unit (ICU) admission. A before-after study was performed to evaluate the effect of addition of corticosteroids to our institution's COVID-19 treatment protocol on hospital mortality. A total of 257 patients with a COVID-19 diagnosis were included in this study between 3 March 2020 and 14 April 2020. As corticosteroids were widely used after 27 March 2020, two periods were considered for the purposes of this study: the 'before' period from 3-20 March 2020 (n = 85); and the 'after' period from 26 March-14 April 2020 (n = 172). The 'after' period was associated with a lower risk of death [adjusted hazard ratio (aHR) = 0.47, 95% confidence interval (CI) 0.23-0.97; P = 0.04] and a lower risk of ICU admission or of death before ICU admission (aHR = 0.37, 95% CI 0.21-0.64; P = 0.0005) by multivariate analysis adjusted for age, National Early Warning score and institutionalisation status. In conclusion, addition of corticosteroids to our institution's COVID-19 treatment protocol was associated with a significant reduction in hospital mortality in the 'after' period. | 0924-8579 | 2020-07-05 02:00:00+02:00 | pubmed | Adrenal Cortex Hormones__therapeutic use;Aged;Aged, 80 and over;Betacoronavirus__isolation & purification;Coronavirus Infections__drug therapy;Female;Hospital Mortality;Humans;Male;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Firouzé Bani-Sadr;Maxime Hentzien;Madeline Pascard;Yohan N'Guyen;Amélie Servettaz;Laurent Andreoletti;Lukshe Kanagaratnam;Damien Jolly | COVID-19;COVID-19 pneumonia;Corticosteroid;SARS-CoV-2 | 2020-07-04 02:00:00+02:00 | 32634602 | FR | Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Reims University Hospital, Reims, France. Electronic address: fbanisadr@chu-reims.fr.;Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Reims University Hospital, Reims, France.;Department of Research and Public Health, Reims University Hospital, Reims, France.;Department of Virology, Reims University Hospital, Reims, France. | 1540 | ||
| Letter | en | A first case of Mild Encephalitis with Reversible Splenial Lesion(MERS) as a presenting feature of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32682536 | 2020-07-05 02:00:00+02:00 | pubmed | S El Aoud;D Sorial;A Selmaoui;I Menif;M Lazard;M Si Hocine;L Thomas | 2020-07-04 02:00:00+02:00 | 32682536 | FR | Department of Internal Medicine, Saint-Camille Hospital, 94360 Bry-Sur-Marne, France. Electronic address: elaoudsahar@gmail.com.;Department of Internal Medicine, Saint-Camille Hospital, 94360 Bry-Sur-Marne, France.;Department of Radiology, Saint-Camille Hospital, 94360 Bry-Sur-Marne, France. | 1543 | ||||||||
| Letter | en | ICU outcomes of COVID-19 critically ill patients: An international comparative study. | https://www.ncbi.nlm.nih.gov/pubmed/32654909 | 2020-07-05 02:00:00+02:00 | pubmed | Ashraf Nadeem;Fadi Hamed;Khaled Saleh;Baraa Abduljawad;Jihad Mallat | 2020-07-03 02:00:00+02:00 | 32654909 | FR;US;AE | Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.;Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, Normandy University, UNICAEN, ED 497, Caen, France. Electronic address: mallatjihad@gmail.com. | 1545 | ||||||||
| 10.4269/ajtmh.20-0597 | Journal Article;Observational Study;Research Support, Non-U.S. Gov't | en | Detection of Pulmonary Embolism in Returning Travelers with Hypoxemic Pneumonia due to COVID-19 in Reunion Island. | https://www.ncbi.nlm.nih.gov/pubmed/32618261 | The aim of this study was to evaluate the occurrence of pulmonary embolism in returning travelers with hypoxemic pneumonia due to COVID-19. All returning travelers to Reunion Island with hypoxemic pneumonia due to COVID-19 underwent computed tomography pulmonary angiography (CTPA) and were included in the cohort. Thirty-five patients were returning travelers with hypoxemic pneumonia due to COVID-19 and had recently returned from one of the countries most affected by the COVID-19 outbreak (mainly from France and Comoros archipelago). Five patients (14.3%) were found to have pulmonary embolism and two (5.9%) were incidentally found to have deep vein thrombosis on CTPA. Patients with pulmonary embolism or deep vein thrombosis had higher D-dimer levels than those without pulmonary embolism or deep vein thrombosis (P = 0.04). Returning travelers with hypoxemic pneumonia due to COVID-19 should be systematically screened for pulmonary embolism. | 0002-9637,1476-1645 | 2020-07-05 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Angiography;Betacoronavirus;Comoros;Coronavirus Infections__complications;Female;Fibrin Fibrinogen Degradation Products__analysis;France;Humans;Hypoxia__virology;Lung__diagnostic imaging;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Pulmonary Embolism__diagnostic imaging;Reunion;Tomography, X-Ray Computed;Travel;Venous Thrombosis__diagnostic imaging;COVID-19;severe acute respiratory syndrome coronavirus 2 | The American Journal of Tropical Medicine and Hygiene | Kevin Larsen;Nathalie Coolen-Allou;Laurie Masse;Alexandre Angelino;Jérôme Allyn;Lea Bruneau;Adrien Maillot;Marie Lagrange-Xelot;Thierry Vitry;Michel André;Jean Yves Travers;Emilie Foch;Nicolas Allou | 2020-07-01 02:00:00+02:00 | 32618261 | FR | Pneumologie, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, Saint Denis, France.;Radiologie, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, Saint Denis, France.;Réanimation Polyvalente, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, Saint Denis, France.;Department of Public Health and Research Support, Methodological Support and Biostatistics Unit, University Hospital, Saint Denis, France.;INSERM CIC 1410 Clinical and Epidemiology, University Hospital, Saint Denis, France.;Service des Maladies Infectieuses, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, Saint Denis, France. | 1549 | |||
| Letter | en | Dramatic reduction of psychiatric emergency consultations during lockdown linked to COVID-19 in Paris and suburbs. | https://www.ncbi.nlm.nih.gov/pubmed/32609417 | 2020-07-05 02:00:00+02:00 | pubmed | Baptiste Pignon;Raphaël Gourevitch;Sarah Tebeka;Caroline Dubertret;Hélène Cardot;Valérie Dauriac-Le Masson;Anne-Kristelle Trebalag;David Barruel;Liova Yon;François Hemery;Marie Loric;Corentin Rabu;Antoine Pelissolo;Marion Leboyer;Franck Schürhoff;Alexandra Pham-Scottez | 2020-07-01 02:00:00+02:00 | 32609417 | FR | AP-HP, Department of Psychiatry and Addictology, Mondor University Hospital, DMU IMPACT, Créteil, France.;Translational Neuro-Psychiatry Laboratory, INSERM U955, Créteil, France.;FondaMental Foundation, Créteil, France.;Paris-Est Créteil University (UPEC), Medical School, Créteil, France.;CPOA, Sainte-Anne Hospital, Paris Psychiatry & Neurosciences University Hospital, Paris, France.;Department of Psychiatry, AP-HP, Louis Mourier Hospital, Colombes, France.;INSERM U1266, Paris, France.;Paris University, Paris, France.;Department of Medical Information, Paris Psychiatry & Neurosciences University Hospital, Paris, France.;AP-HP, Department of Medical Information, Mondor University Hospital, Créteil, France. | 1552 | ||||||||
| Letter | en | How should data on airborne transmission of SARS-CoV-2 change occupational health guidelines? | https://www.ncbi.nlm.nih.gov/pubmed/32606018 | 2020-07-05 02:00:00+02:00 | pubmed | Jean François Gehanno;Vincent Bonneterre;Pascal Andujar;Jean-Claude Pairon;Christophe Paris;Audrey Petit;Catherine Verdun-Esquer;Alexis Descatha;Quentin V Durand-Moreau;Patrick Brochard | health and safety;investigation of outbreaks of illness;occupational health practice;public health;respiratory | 2020-06-30 02:00:00+02:00 | 32606018 | FR;CA | Department of occupational Medicine, Rouen University Hospital, Rouen, France.;Laboratoire d'informatique médicale et d'ingénierie des connaissances en e-santé, LIMICS, Sorbonne Université, Inserm, université Paris 13, Paris, France.;TIMC Research Laboratory, Grenoble Alpes University, La Tronche cedex, France.;Occupational & Environmental Diseases Centre, Grenoble cedex 09, France.;U955, Equipe 4, INSERM, Creteil, France.;Service de Pneumologie et de Pathologie Professionnelle, Centre Hospitalier Intercommunal de Créteil, Creteil, France.;Faculte de Sante, Université Paris-Est Creteil, Créteil, France.;Service de pathologie professionnelle et de l'environnement, CHU Rennes, Rennes, France.;UMR_S1085 Ester team, UNIV Angers, CHU Angers, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Angers, France.;Department of Occupational Health, University Hospital of Angers, Angers, France.;CHU de Bordeaux, Bordeaux, France.;UMR_S1085 Ester team, UNIV Angers, CHU Angers, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Angers, France Alexis.Descatha@inserm.fr.;CAPTV CDC, CHU Angers Pôle A Vasculaire, Angers, France.;Division of Preventive Medicine, University of Alberta, Edmonton, Alberta, Canada.;Université Bordeaux, Bordeaux, France. | 1556 | |||||||
| 10.1080/17843286.2020.1787659 | Journal Article | en | Lessons from the Belgian experience with regulatory control during the COVID-19 pandemic for the implementation of the European IVD regulation 2017/746. | https://www.ncbi.nlm.nih.gov/pubmed/32615912 | 1784-3286,2295-3337 | 2020-07-05 02:00:00+02:00 | pubmed | Acta Clinica Belgica | Pieter Vermeersch;Frédéric Cotton;Dieter De Smet;Geert Martens;Matthijs Oyaert;Etienne Cavalier | 2020-07-02 02:00:00+02:00 | 32615912 | FR;BE;US | Department of Laboratory Medicine, University Hospitals Leuven , Leuven, Belgium.;Department of Clinical Chemistry, LHUB-ULB , Brussels, Belgium.;AZ Delta Medical Laboratories, AZ Delta General Hospital , Roeselare, Belgium.;Department of Laboratory Medicine, Clinical Chemistry, Ghent University Hospital , Ghent, Belgium.;Department of Clinical Chemistry, University of Liège , CHU de Liège, Liège, Belgium, etienne.cavalier@chu.ulg.ac.be. | 1567 | |||||
| Instituto de Salud Carlos III | Clinical Trial Protocol;Letter | en | Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial. | https://www.ncbi.nlm.nih.gov/pubmed/32616063 | The primary objectives of the study are: 1. To assess the effect of hydroxychloroquine (HCQ) in reducing SARS-CoV-2 viral shedding by PCR in infected pregnant women with mild symptoms. 2. To assess the efficacy of HCQ to prevent SARS-CoV-2 infection in pregnant women in contact with an infected or suspected case. 3. To evaluate the effect of HCQ in preventing the development of the COVID-19 disease in asymptomatic SARS-CoV-2-infected pregnant women. The secondary objectives are: 1. To determine the effect of HCQ on the clinical course and duration of the COVID-19 disease in SARS-CoV-2-infected pregnant women. 2. To determine the impact of HCQ on the risk of hospitalization and mortality of SARS-CoV-2-infected pregnant women. 3. To assess the safety and tolerability of HCQ in pregnant women. 4. To describe the clinical presentation of SARS-CoV-2 infection during pregnancy. 5. To describe the effects of maternal SARS-CoV-2 infection on pregnancy and perinatal outcomes by treatment group. 6. To determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2. | 2020-07-05 02:00:00+02:00 | pubmed | Antiviral Agents__administration & dosage;Betacoronavirus__drug effects;Chemoprevention;Coronavirus Infections__diagnosis;Double-Blind Method;Drug Administration Schedule;Female;Host-Pathogen Interactions;Humans;Hydroxychloroquine__administration & dosage;Multicenter Studies as Topic;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Pregnancy;Pregnancy Complications, Infectious__diagnosis;Protective Factors;Randomized Controlled Trials as Topic;Risk Assessment;Risk Factors;Severity of Illness Index;Spain;Time Factors;Treatment Outcome;Virus Shedding__drug effects;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Raquel González;Laura García-Otero;Clara Pons-Duran;Elena Marbán-Castro;Anna Goncé;Elisa Llurba;Maria Del Mar Gil;Miguel Ángel Rodríguez-Zambrano;Haily Chen;Máximo Ramírez;Azucena Bardají;Clara Menendez | COVID-19;Hydroxychloroquine;Pregnant;Protocol;Randomised controlled trial;Women | 2020-07-02 02:00:00+02:00 | 32616063 | FR;ES;MZ | [{"country": "", "agency": "Instituto de Salud Carlos III", "grantid": "COV20/00286"}] | ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain. raquel.gonzalez@isglobal.org.;Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. raquel.gonzalez@isglobal.org.;Manhiça Health Research Center (CISM), Manhiça, Mozambique. raquel.gonzalez@isglobal.org.;ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.;Manhiça Health Research Center (CISM), Manhiça, Mozambique.;Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.;BCNATAL | Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Clínic de Barcelona, Barcelona, Spain.;Obstetrics and Gynecology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Obstetrics and Gynecology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain.;School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.;HM Puerta del Sur, Móstoles, Madrid, Spain. | 1573 | |||
| 10.1016/j.ejvs.2020.06.020 | Editorial | en | Teleproctoring in Vascular Surgery to Defy COVID-19 Travel Restrictions. | https://www.ncbi.nlm.nih.gov/pubmed/32718826 | 1078-5884 | 2020-07-05 02:00:00+02:00 | pubmed | European Journal of Vascular and Endovascular Surgery | Andrej Isaak;Alexandros Mallios;Lorenz Gürke;Thomas Wolff | 2020-07-03 02:00:00+02:00 | 32718826 | FR;CH | Vascular and Endovascular Surgery Aarau-Basel, Aarau Cantonal Hospital, Aarau, Switzerland, Vascular and Endovascular Surgery Aarau-Basel, University Hospital Basel, Basel, Switzerland. Electronic address: andrej.isaak@ksa.ch.;Vascular Surgery, Institut Mutualiste Montsouris, Paris, France.;Vascular and Endovascular Surgery Aarau-Basel, Aarau Cantonal Hospital, Aarau, Switzerland, Vascular and Endovascular Surgery Aarau-Basel, University Hospital Basel, Basel, Switzerland.;Vascular and Endovascular Surgery Aarau-Basel, University Hospital Basel, Basel, Switzerland. | 1581 | |||||
| Letter | en | Patients with COVID-19 present with low plasma citrulline concentrations that associate with systemic inflammation and gastrointestinal symptoms. | https://www.ncbi.nlm.nih.gov/pubmed/32646736 | 2020-07-05 02:00:00+02:00 | pubmed | Mathieu Uzzan;Damien Soudan;Katell Peoc'h;Emmanuel Weiss;Olivier Corcos;Xavier Treton | 2020-07-03 02:00:00+02:00 | 32646736 | FR | Gastroenterology department, Beaujon Hospital, APHP, Clichy, France. Electronic address: mathieu.uzzan@aphp.fr.;Gastroenterology department, Beaujon Hospital, APHP, Clichy, France.;Biochemistry department, Beaujon Hospital, APHP, Clichy, France, CRI, INSERM UMRs 1149 and University of Paris, Paris, France.;Intensive care unit, Beaujon Hospital, APHP, Clichy, France.;Gastroenterology department, Beaujon Hospital, APHP, Clichy, France, CRI, INSERM UMRs 1149 and University of Paris, Paris, France. | 1583 | ||||||||
| Journal Article;Review | en | BSGIE survey on COVID-19 and gastrointestinal endoscopy in Belgium : results and recommendations. | https://www.ncbi.nlm.nih.gov/pubmed/32603061 | With the first wave of the COVID-19 pandemic declining, activities in the gastrointestinal clinic are being recommenced after a period of stringent measures. Since a second COVID-19 wave is not entirely ruled out health care professionals might remain faced with the need to perform endoscopic procedures in patients with a confirmed positive or unknown COVID-19 status. With this report we aim to provide a practical relevant overview of preparation and protective measures for gastroenterologists based on the currently available guidelines and our local experience and results of a national Belgian survey, to guarantee a fast recall of an adequate infection prevention if COVID-19 reoccurs. | 2020-07-05 02:00:00+02:00 | pubmed | Belgium;Betacoronavirus;Coronavirus Infections__epidemiology;Disease Transmission, Infectious__prevention & control;Endoscopy, Gastrointestinal;Gastroenterologists;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Pandemics__prevention & control;Personal Protective Equipment;Pneumonia, Viral__epidemiology;Surveys and Questionnaires;COVID-19;severe acute respiratory syndrome coronavirus 2 | P Sinonquel;M Aerts;A Badaoui;R Bisschops;D Blero;I Demedts;P Deprez;P Dewint;P Eisendrath;P Hindryckx;A Lemmers;Ph Roelandt;C Snauwaert;E Toussaint;T Moreels | Belgium;Covid-19;endoscopy;personal protective equipment (PPE) | 2020-07-01 02:00:00+02:00 | 32603061 | FR;BE;UNK | Universitair Ziekenhuis Gasthuisberg, Leuven.;Universitair Ziekenhuis Brussel, Brussels.;Centre Hospitalier Universitaire de Namur, Namur.;Hôpital Erasme, Brussels.;Cliniques Universitaires Saint-Luc, Brussels.;Algemeen Ziekenhuis Maria-Middelares, Ghent.;Universitair Ziekenhuis Antwerpen, Antwerp.;Centre Hospitalier Universitaire Saint-Pierre, Brussels.;Universitair Ziekenhuis Gent, Ghent.;Algemeen Ziekenhuis Sint-Jan, Bruges.;Centre Hospitalier Universitaire de Charleroi, Charleroi. | 1594 | |||||
| Journal Article | fr | https://www.ncbi.nlm.nih.gov/pubmed/32608593 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;France;Humans;Pandemics;Pneumonia, Viral;Science;COVID-19;severe acute respiratory syndrome coronavirus 2 | Kenza Bakhta;Laëtitia Atlani-Duault;Daniel Benamouzing;Lila Bouadma;Franck Chauvin;Pierre-Louis Druais;Jean-François Delfraissy | 2020-07-02 02:00:00+02:00 | 32608593 | FR | Assistant coordinator of the French Scientific Council, 66 rue de Bellechasse, 75007 Paris, France.;WHO Collaborative Center for Research on Health and Humanitarian Policies & Practices, CEPED UMR 196, University of Paris, IRD, INSERM, 15 rue de l'École de Médecine, 75006 Paris, France, et Fondation Maison des Sciences de l'Homme, 54 Boulevard Raspail, 75006 Paris, France.;Sciences Po, Centre de sociologie des organisations, CNRS, 3 rue Michel-Ange, 75016 Paris, France.;Medical and Infectious Diseases Intensive Care Unit, Bichat-Claude Bernard University Hospital, Assistance Publique-Hôpitaux de Paris, 46 rue Henri Huchard, 75018 Paris, France, et Infections Antimicrobials Modelling Evolution (IAME-UMR1137), University of Paris, INSERM, 15 rue de l'École de Médecine, 75006 Paris, France.;French High Council of Public Health, 14 avenue Duquesne, 75007 Paris, France, et Institut PRESAGE, Jean Monnet University - Saint-Etienne University Hospital, 6 rue Basse des Rives, 42100 Saint-Etienne, France.;Haute Autorité de Santé, 5 avenue du Stade de France, 93210 Saint-Denis, France.;National Ethical consultative Commitee for Life Sciences and Health, Paris, 66 rue de Bellechasse, 75007 Paris, France. | 1602 | ||||||||
| 10.1080/22221751.2020.1791737 | Journal Article | en | Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines. | https://www.ncbi.nlm.nih.gov/pubmed/32619390 | Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and is continuing to spread rapidly around the globe. No effective vaccine is currently available to prevent COVID-19, and intense efforts are being invested worldwide into vaccine development. In this context, all technology platforms must overcome several challenges resulting from the use of an incompletely characterized new virus. These include finding the right conditions for virus amplification for the development of vaccines based on inactivated or attenuated whole viral particles. Here, we describe a shotgun tandem mass spectrometry workflow, the data produced can be used to guide optimization of the conditions for viral amplification. In parallel, we analysed the changes occurring in the host cell proteome following SARS-CoV-2 infection to glean information on the biological processes modulated by the virus that could be further explored as potential drug targets to deal with the pandemic. | 2222-1751 | 2020-07-05 02:00:00+02:00 | pubmed | Animals;Antigens, Viral__biosynthesis;Betacoronavirus__immunology;Chlorocebus aethiops;Proteomics__methods;Tandem Mass Spectrometry;Vero Cells;Viral Vaccines__immunology;Virion__immunology;severe acute respiratory syndrome coronavirus 2 | Emerging Microbes & Infections | Lucia Grenga;Fabrice Gallais;Olivier Pible;Jean-Charles Gaillard;Duarte Gouveia;Hélène Batina;Niza Bazaline;Sylvie Ruat;Karen Culotta;Guylaine Miotello;Stéphanie Debroas;Marie-Anne Roncato;Gérard Steinmetz;Charlotte Foissard;Anne Desplan;Béatrice Alpha-Bazin;Christine Almunia;Fabienne Gas;Laurent Bellanger;Jean Armengaud | COVID-19;SARS-CoV-2;host response;infection kinetics;mass spectrometry;proteomics;vaccine;viral protein detection | 2020-07-04 02:00:00+02:00 | 32619390 | FR | Département Médicaments et Technologies pour la Santé (DMTS), Université Paris Saclay, CEA, INRAE, SPI Bagnols-sur-Cèze, France. | 1603 | ||
| 10.1007/s00125-020-05207-3 | Journal Article;Published Erratum | en | Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. | https://www.ncbi.nlm.nih.gov/pubmed/32617649 | The authors regret a mistake in Table 1. | 0012-186X,1432-0428 | 2020-07-05 02:00:00+02:00 | pubmed | Diabetologia | Bertrand Cariou;Samy Hadjadj;Matthieu Wargny;Matthieu Pichelin;Abdallah Al-Salameh;Ingrid Allix;Coralie Amadou;Gwénaëlle Arnault;Florence Baudoux;Bernard Bauduceau;Sophie Borot;Muriel Bourgeon-Ghittori;Olivier Bourron;David Boutoille;France Cazenave-Roblot;Claude Chaumeil;Emmanuel Cosson;Sandrine Coudol;Patrice Darmon;Emmanuel Disse;Amélie Ducet-Boiffard;Bénédicte Gaborit;Michael Joubert;Véronique Kerlan;Bruno Laviolle;Lucien Marchand;Laurent Meyer;Louis Potier;Gaëtan Prevost;Jean-Pierre Riveline;René Robert;Pierre-Jean Saulnier;Ariane Sultan;Jean-François Thébaut;Charles Thivolet;Blandine Tramunt;Camille Vatier;Ronan Roussel;Jean-François Gautier;Pierre Gourdy | 2020-07-04 02:00:00+02:00 | 32617649 | FR | Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France. bertrand.cariou@univ-nantes.fr.;Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France. samy.hadjadj@univ-nantes.fr.;Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France.;CIC-EC 1413, Clinique des Données, CHU Nantes, Nantes, France.;Département d'Endocrinologie, Diabétologie et Nutrition, CHU Amiens, PeriToxUMR_I 01, Université de Picardie, Amiens, France.;Département d'Endocrinologie, Diabétologie, Nutrition, CHU de Angers, Angers, France.;Département de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil Essonne, France.;Département d'Endocrinologie, Diabétologie et Maladies Métaboliques, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Clinique d'Endocrinologique Marc-Linquette, Hôpital ClaudeHuriez, CHRU de Lille, Lille, France.;Département de Diabétologie, H.I.A. Begin, Saint Mandé, France.;Fondation Francophone pour la Recherche sur le Diabète (FFRD), Paris, France.;Département d'Endocrinologie, Diabétologie et Nutrition, CHU de Besançon, Besançon, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Assistance Publique Hôpitaux de Paris, Université Paris Saclay, Hôpital Antoine Béclère, Clamart, Hôpital Bicêtre, Le Kremlin Bicêtre, France.;Sorbonne Université, Assistance Publique Hôpitaux de Paris, Département de Diabétologie, CHU La Pitié Salpêtrière-Charles Foix, Inserm, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06, Institute of Cardiometabolism and Nutrition ICAN, Paris, France.;Département des Maladies Infectieuses et Tropicales, CHU Nantes, Nantes, France.;Département des Maladies Infectieuses et Tropicales, CHU de Poitiers, INSERM U1070, Poitiers, France.;Société de Pathologie Infectieuse de langue Française (SPILF), Paris, France.;Fédération Française des Diabétiques (FFD), Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, Université Paris 13, Sorbonne Paris Cité, Département d'Endocrinologie, Diabétologie et Nutrition, CRNH-IdF, CINFO, Bobigny, France.;Université Paris 13, Sorbonne Paris Cité, UMR U557 Inserm / U11125 INRAE / CNAM / Université Paris13, Unité de Recherche Epidémiologique Nutritionnelle, Bobigny, France.;Département d'Endocrinologie et de Diabétologie, Hôpital de la Conception, Assistance Publique Hôpitaux de Marseille, Marseille, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Hospices Civils de Lyon, CarMeN Laboratory, Inserm 1060, Lyon, France, Université Claude Bernard Lyon 1, Lyon, France.;Département d'Endocrinologie et de Diabétologie, Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France.;Département d'Endocrinologie et de Diabétologie, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Marseille, France.;Département de Diabétologie, CHU de Caen, Caen, France.;Département d'Endocrinologie, CHU de Brest, EA 3878 GETBO, Brest, France.;Université de Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France.;Département d'Endocrinologie et de Diabétologie, Centre Hospitalier St. Joseph - St. Luc, Lyon, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Centre de Recherche des Cordeliers, Inserm, U-1138, Université de Paris, Paris, France.;Département d'Endocrinologie, Diabétologie et Maladies Métaboliques, CHU de Rouen, Université de Rouen, Rouen, France.;Département Diabète et Endocrinologie, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France.;Paris Diderot-Paris VII Université, Paris, France.;Inserm UMRS 1138, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France.;Université de Poitiers, CIC Inserm 1402, Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique CIC 1402, Université de Poitiers, Inserm, CHU de Poitiers, Poitiers, France.;Département d'Endocrinologie, Diabète, Nutrition et CIC Inserm 1411, CHU de Montpellier, Montpellier, France.;Centre du Diabète DIAB-eCARE, Hospices Civils de Lyon et Laboratoire CarMeN, Inserm, INRA, INSA, Université Claude Bernard Lyon 1, Lyon, France.;Société Francophone du Diabète (SFD), Paris, France.;Département d'Endocrinologie, Diabétologie et Nutrition, CHU Toulouse, Institut des Maladies Métaboliques et Cardiovasculaires, UMR1048 Inserm/UPS, Université de Toulouse, Toulouse, France.;Assistance Publique Hôpitaux de Paris, Saint-Antoine Hospital, Reference Center of Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Department of Endocrinology, Paris, France.;Sorbonne University, Inserm UMRS 938, Saint-Antoine Research Center, Paris, France. | 1607 | ||||
| 10.1016/j.psychres.2020.113264 | Journal Article;Review | en | Adolescent psychiatric disorders during the COVID-19 pandemic and lockdown. | https://www.ncbi.nlm.nih.gov/pubmed/32622172 | The aim of this paper was to review the literature on adolescent psychiatric disorders related to the COVID-19 pandemic and lockdown. Stressful life events, extended home confinement, brutal grief, intrafamilial violence, overuse of the Internet and social media are factors that could influence the mental health of adolescents during this period. The COVID-19 pandemic could result in increased psychiatric disorders such as Post-Traumatic Stress, Depressive, and Anxiety Disorders, as well as grief-related symptoms. Adolescents with psychiatric disorders are at risk of a break or change in their care and management; they may experience increased symptoms. The COVID-19 pandemic and lockdown may have a negative impact on the mental health of adolescents, although there is still no data on the long term impact of this crisis. Adolescents' individual, familial, and social vulnerability, as well as individual and familial coping abilities, are factors related to adolescent mental health in times of crisis. Adolescents are often vulnerable and require careful consideration by caregivers and healthcare system adaptations to allow for mental health support despite the lockdown. Research on adolescent psychiatric disorders in times of pandemics is necessary, as such a global situation could be prolonged or repeated. | 0165-1781 | 2020-07-05 02:00:00+02:00 | pubmed | Psychiatry Research | Sélim Benjamin Guessoum;Jonathan Lachal;Rahmeth Radjack;Emilie Carretier;Sevan Minassian;Laelia Benoit;Marie Rose Moro | Adolescent;Covid-19;Depression;Mental disorder;Pandemic;Post-traumatic stress disorder | 2020-06-29 02:00:00+02:00 | 32622172 | FR | Greater Paris University Hospital, University Hospital Cochin, Maison des Adolescents - Youth Department, F-75014 Paris, France, University of Paris, PCPP, F-92100 Boulogne-Billancourt, France, University Paris-Saclay, UVSQ, Inserm, CESP, Team DevPsy, F-94807, Villejuif, France. Electronic address: selim.guessoum@gmail.com.;Greater Paris University Hospital, University Hospital Cochin, Maison des Adolescents - Youth Department, F-75014 Paris, France, University of Paris, PCPP, F-92100 Boulogne-Billancourt, France, University Paris-Saclay, UVSQ, Inserm, CESP, Team DevPsy, F-94807, Villejuif, France.;Greater Paris University Hospital, University Hospital Cochin, Maison des Adolescents - Youth Department, F-75014 Paris, France, University Paris-Saclay, UVSQ, Inserm, CESP, Team DevPsy, F-94807, Villejuif, France.;Greater Paris University Hospital, University Hospital Cochin, Maison des Adolescents - Youth Department, F-75014 Paris, France. | 1608 | |||
| Letter | en | Clomipramine Could Be Useful in Preventing Neurological Complications of SARS-CoV-2 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32601885 | 2020-07-05 02:00:00+02:00 | pubmed | B Nobile;M Durand;E Olié;S Guillaume;J P Molès;E Haffen;P Courtet | 2020-06-29 02:00:00+02:00 | 32601885 | FR | Department of Emergency Psychiatry and Acute Care, CHU Montpellier, Montpellier, France. benedicte.nobile@gmail.com.;PSNREC, INSERM, CHU de Montpellier, University Montpellier, Montpellier, France. benedicte.nobile@gmail.com.;Pathogenesis and control of chronic infection, INSERM, EFS, CHU Montpellier, Montpellier, University of Montpellier, Montpellier, France.;Department of Emergency Psychiatry and Acute Care, CHU Montpellier, Montpellier, France.;PSNREC, INSERM, CHU de Montpellier, University Montpellier, Montpellier, France.;FondaMental Foundation, Créteil, France.;Service de Psychiatrie de l'Adulte, CIC-1431 INSERM, CHU de Besançon, Laboratoire de Neurosciences, Université de Franche-Comté, UBFC, Besançon, France. | 1611 | ||||||||
| 10.1016/j.transproceed.2020.06.024 | Journal Article | en | Bilateral Acute Cardioembolic Limb Ischemia After Coronavirus Disease 2019 Pneumonia in a Lung Transplant Recipient: A Case Report. | https://www.ncbi.nlm.nih.gov/pubmed/32713821 | Very few cases of lung transplant patients affected by coronavirus disease 2019 (COVID-19) have been reported to date. A 31-year-old patient who underwent bilateral lung transplantation for cystic fibrosis in 2012 was admitted for severe acute lower limb pain. He had a confirmed exposure to COVID-19 and a 3-week history of upper respiratory tract infection. Whole-body computed tomography (CT) angiography revealed an occlusion of the 2 common femoral arteries. CT angiography detected an intracardiac thrombus in the left ventricle. Chest CT angiography showed ground-glass opacities consistent with COVID-19. A bilateral femoral surgical embolectomy using Fogarty catheter was successfully performed. Specific reverse transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 performed on an extracted thrombus was negative, but IgM antibodies specific for COVID-19 were detected. Cardiac magnetic resonance imaging demonstrated a subendocardial and almost transmural late gadolinium enhancement in the mid and distal inferolateral and inferior wall segments, consistent with a nonrecent myocardial infarction and an apical centimetric thrombus adjacent to the lesion. Thrombophilia laboratory tests found the presence of a positive lupus anticoagulant. Treatment with low-molecular-weight heparin and aspirin was prescribed. On day 13, the patient was discharged from the hospital. This case underlines the need to be vigilant with respect to the thrombotic complications of COVID-19 and raises the issue of thrombosis prevention in COVID-19 patients. | 0041-1345 | 2020-07-05 02:00:00+02:00 | pubmed | Transplantation Proceedings | Benjamin Renaud-Picard;Floriane Gallais;Mickael Ohana;Floriane Zeyons;Benjamin Kretz;Jocelyn Andre;Laurent Sattler;Sandrine Hirschi;Romain Kessler | 2020-06-30 02:00:00+02:00 | 32713821 | FR | Pneumology Unit, Strasbourg Lung Transplant Program, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. Electronic address: benjaminrenaud@free.fr.;Laboratory of Virology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Department of Radiology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Department of Cardiology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Vascular and Endovascular Surgery, Hôpitaux Civils de Colmar, Colmar, France.;Anesthesiology and Intensive Care Unit, Hôpitaux Civils de Colmar, Colmar, France.;Laboratory of Hematology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Pneumology Unit, Strasbourg Lung Transplant Program, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. | 1614 | ||||
| Letter | en | Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia. | https://www.ncbi.nlm.nih.gov/pubmed/32809882 | 2020-07-12 02:00:00+02:00 | pubmed | Christophe Beyls;Nicolas Martin;Alexis Hermida;Osama Abou-Arab;Yazine Mahjoub | COVID-19;bradycardia;critical illness;humans;lopinavir;ritonavir | 2020-07-09 02:00:00+02:00 | 32809882 | FR | Department of Anesthesiology and Critical Care Medicine (C.B., O.A.-A., Y.M.), Amiens University Hospital, France.;Department of Rythmology (N.M., A.H.), Amiens University Hospital, France. | 1617 | |||||||
| 10.1016/j.pratan.2020.07.009 | Editorial | fr | [COVID-19 a few months after the beginning of the first pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32837206 | 1279-7960 | 2020-07-12 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Francis Bonnet | 2020-07-09 02:00:00+02:00 | 32837206 | FR | Services d'anesthésie réanimation, Saint-Antoine Tenon, DMU DREAM, hôpitaux Sorbonne université, 75020 Paris, France. | 1618 | |||||
| 10.1021/acs.bioconjchem.0c00287 | Journal Article;Research Support, Non-U.S. Gov't | en | The Potential of Various Nanotechnologies for Coronavirus Diagnosis/Treatment Highlighted through a Literature Analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32639742 | With the current COVID-19 outbreak, it has become essential to develop efficient methods for the treatment and detection of this virus. Among the new approaches that could be tested, that relying on nanotechnology finds one of its main grounds in the similarity between nanoparticle (NP) and coronavirus (COV) sizes, which promotes NP-COV interactions. Since COVID-19 is very recent, most studies in this field have focused on other types of coronavirus than COVID-19, such as those involved in MERS or SARS diseases. Although their number is limited, they have led to promising results on various COV using a wide range of different types of nanosystems, e.g., nanoparticles, quantum dos, or nanoassemblies of polymers/proteins. Additional efforts deserve to be spent in this field to consolidate these findings. Here, I first summarize the different nanotechnology-based methods used for COV detection, i.e., optical, electrical, or PCR ones, whose sensitivity was improved by the presence of nanoparticles. Furthermore, I present vaccination methods, which comprise nanoparticles used either as adjuvants or as active principles. They often yield a better-controlled immune response, possibly due to an improved antigen presentation/processing than in non-nanoformulated vaccines. Certain antiviral approaches also took advantage of nanoparticle uses, leading to specific mechanisms such as the blocking of virus replication at the cellular level or the reduction of a COV induced apoptotic cellular death. | 1043-1802,1520-4812 | 2020-07-12 02:00:00+02:00 | pubmed | Bioconjugate Chemistry | Edouard Alphandéry | 2020-07-08 02:00:00+02:00 | 32639742 | FR;CH | Paris Sorbonne Université, Muséum National d'Histoire Naturelle, UMR CNRS 7590, IRD, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, 75005, Paris, France.;Nanobacterie SARL, 36 Boulevard Flandrin, 75116, Paris, France.;Institute of Anatomy, UZH University of Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland. | 1640 | ||||
| 10.1016/j.jogoh.2020.101859 | Journal Article | en | Technics to put on and remove personal protective equipment before surgical or obstetrical procedure in suspected or infected COVID-19 patients (with video). | https://www.ncbi.nlm.nih.gov/pubmed/32652303 | Coronavirus pandemic is widely changing our professional daily practice and preventive measures must be taken and taught. Before any planned gynaecological or obstetric surgery, specific technics to put on and safely remove personal protective equipment should be implemented in order to avoid any contamination for both patients and healthcare workers. | 2468-7847 | 2020-07-12 02:00:00+02:00 | pubmed | Journal of Gynecology Obstetrics and Human Reproduction | Erdogan Nohuz;Anthony Atallah;Emanuele Cerruto;Manon Curtis;Oriane Bernigaud;Dominique Chassard;Pascal Fascia;Lionel Bouvet;Gautier Chene | Coronavirus;Covid-19;Personal protective equipment;Surgical clothes | 2020-07-08 02:00:00+02:00 | 32652303 | FR;CA | Department of Gynecology and Obstetrics, Hôpital Femme Mère Enfant, HFME, 59 boulevard Pinel, Hospices civils de Lyon, 69000 Lyon, France.;Department of Anesthesy, Hôpital Femme Mère Enfant, HFME, 59 boulevard Pinel, Hospices civils de Lyon, 69000 Lyon, France.;CPIAS Auvergne Rhône Alpes (Center for Prévention of Healthcare Associated Infections), Hôpital Henry Gabrielle, Hospices Civils de Lyon, 20 route de Vourles, 69230 Saint Genis Laval, France.;Department of Gynecology and Obstetrics, Hôpital Femme Mère Enfant, HFME, 59 boulevard Pinel, Hospices civils de Lyon, 69000 Lyon, France, Université Claude Bernard Lyon 1, EMR 3738, 69000 Lyon, France. Electronic address: chenegautier@yahoo.fr. | 1643 | |||
| 10.1165/rcmb.2020-0188tr | Journal Article | en | Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept. | https://www.ncbi.nlm.nih.gov/pubmed/32640172 | Poly(ADP-ribose) polymerase 1 (PARP1), the major isoform of a family of ADP-ribosylating enzymes, has been implicated in the regulation of various biological processes including DNA repair, gene transcription and cell death. The concept that PARP1 becomes activated in acute lung injury (ALI), and pharmacological inhibition or genetic deletion of this enzyme can provide therapeutic benefits has emerged over 20 years ago. The current article provides an overview of the cellular mechanisms involved in the pathogenetic roles of PARP1 in ALI, and overviews the preclinical data supporting the efficacy of PARP inhibitors. In recent years, several ultrapotent PARP inhibitors have been approved for clinical use (for the therapy of various oncological diseases): these newly-approved PARP inhibitors were recently reported to show efficacy in animal models of ALI. These observations offer the possibility of therapeutic repurposing of these inhibitors for patients with ALI. The current article lays out a potential roadmap for such repurposing efforts. In addition, the article also overviews the scientific basis of potentially applying PARP inhibitors for the experimental therapy of viral ALI, such as COVID-19-associated ARDS. | 1044-1549,1535-4989 | 2020-07-12 02:00:00+02:00 | pubmed | American Journal of Respiratory Cell and Molecular Biology | Csaba Szabo;Vanessa Martins;Lucas Liaudet | 2020-07-08 02:00:00+02:00 | 32640172 | FR;CH | University of Fribourg, 27211, Fribourg, Switzerland, csaba.szabo@unifr.ch.;University of Fribourg, 27211, Fribourg, Switzerland.;Centre Hospitalier Universitaire Vaudois, 30635, Adult Intensive Care Medicine, Lausanne, Switzerland. | 1651 | ||||
| 10.1161/strokeaha.120.031208 | Journal Article | en | Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry. | https://www.ncbi.nlm.nih.gov/pubmed/32787707 | Recent case-series of small size implied a pathophysiological association between coronavirus disease 2019 (COVID-19) and severe large-vessel acute ischemic stroke. Given that severe strokes are typically associated with poor prognosis and can be very efficiently treated with recanalization techniques, confirmation of this putative association is urgently warranted in a large representative patient cohort to alert stroke clinicians, and inform pre- and in-hospital acute stroke patient pathways. We pooled all consecutive patients hospitalized with laboratory-confirmed COVID-19 and acute ischemic stroke in 28 sites from 16 countries. To assess whether stroke severity and outcomes (assessed at discharge or at the latest assessment for those patients still hospitalized) in patients with acute ischemic stroke are different between patients with COVID-19 and non-COVID-19, we performed 1:1 propensity score matching analyses of our COVID-19 patients with non-COVID-19 patients registered in the Acute Stroke Registry and Analysis of Lausanne Registry between 2003 and 2019. Between January 27, 2020, and May 19, 2020, 174 patients (median age 71.2 years; 37.9% females) with COVID-19 and acute ischemic stroke were hospitalized (median of 12 patients per site). The median National Institutes of Health Stroke Scale was 10 (interquartile range [IQR], 4-18). In the 1:1 matched sample of 336 patients with COVID-19 and non-COVID-19, the median National Institutes of Health Stroke Scale was higher in patients with COVID-19 (10 [IQR, 4-18] versus 6 [IQR, 3-14]), P=0.03; (odds ratio, 1.69 [95% CI, 1.08-2.65] for higher National Institutes of Health Stroke Scale score). There were 48 (27.6%) deaths, of which 22 were attributed to COVID-19 and 26 to stroke. Among 96 survivors with available information about disability status, 49 (51%) had severe disability at discharge. In the propensity score-matched population (n=330), patients with COVID-19 had higher risk for severe disability (median mRS 4 [IQR, 2-6] versus 2 [IQR, 1-4], P<0.001) and death (odds ratio, 4.3 [95% CI, 2.22-8.30]) compared with patients without COVID-19. Our findings suggest that COVID-19 associated ischemic strokes are more severe with worse functional outcome and higher mortality than non-COVID-19 ischemic strokes. | 0039-2499,1524-4628 | 2020-07-12 02:00:00+02:00 | pubmed | Stroke | George Ntaios;Patrik Michel;Georgios Georgiopoulos;Yutao Guo;Wencheng Li;Jing Xiong;Patricia Calleja;Fernando Ostos;Guillermo González-Ortega;Blanca Fuentes;María Alonso de Leciñana;Exuperio Díez-Tejedor;Sebastian García-Madrona;Jaime Masjuan;Alicia DeFelipe;Guillaume Turc;Bruno Gonçalves;Valerie Domigo;Gheorghe-Andrei Dan;Roxana Vezeteu;Hanne Christensen;Louisa Marguerite Christensen;Per Meden;Lejla Hajdarevic;Angela Rodriguez-Lopez;Fernando Díaz-Otero;Andrés García-Pastor;Antonio Gil-Nuñez;Errikos Maslias;Davide Strambo;David J Werring;Arvind Chandratheva;Laura Benjamin;Robert Simister;Richard Perry;Rahma Beyrouti;Pascal Jabbour;Ahmad Sweid;Stavropoula Tjoumakaris;Elisa Cuadrado-Godia;Ana Rodríguez Campello;Jaume Roquer;Tiago Moreira;Michael V Mazya;Fabio Bandini;Karl Matz;Helle K Iversen;Alejandra González-Duarte;Cristina Tiu;Julia Ferrari;Milan R Vosko;Helmut J F Salzer;Bernd Lamprecht;Martin W Dünser;Carlo W Cereda;Ángel Basilio Corredor Quintero;Eleni Korompoki;Eduardo Soriano-Navarro;Luis Enrique Soto-Ramírez;Paulo F Castañeda-Méndez;Daniela Bay-Sansores;Antonio Arauz;Vanessa Cano-Nigenda;Espen Saxhaug Kristoffersen;Marjaana Tiainen;Daniel Strbian;Jukka Putaala;Gregory Y H Lip | COVID-19;coronavirus;prognosis;propensity score;survivors | 2020-07-09 02:00:00+02:00 | 32787707 | FR;SE;NO;CO;UNK;FI;CN;GR;BO;GB;CH;RO;US;BR;IT;AT;ES;MX;DK;DE | Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece (G.N.).;Stroke Center, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital, Switzerland (P.M., E.M., D. Strambo).;School of Biomedical Engineering and Imaging Sciences, King's College, London, United Kingdom (G.G.).;Department of Cardiology, Chinese PLA General Hospital, Beijing, China (Y.G.).;Department of Urology (W.L.), Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, China.;Department of Nephrology (J.X.), Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, China.;Department of Neurology and Stroke Center, Doce de Octubre University Hospital, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain (P.C., F.O., G.G.-O.).;Department of Neurology and Stroke Center, La Paz University Hospital, IdiPAZ Health Research Institute, Madrid, Spain (B.F., M.A.d.L., E.D.-T.).;Department of Neurology and Stroke Centre, Ramón y Cajal University Hospital, IRYCIS Health Research Institute, Madrid, Spain (S.G.-M., J.M., A.D.).;Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, and FHU Neurovasc, France (G.T., B.G., V.D.).;Intensive Care Unit, Paulo Niemeyer State Brain Institute, Rio de Janeiro, Brazil (B.G.).;Colentina University Hospital, Medicine Faculty, University of Medicine "Carol Davila"-Bucharest, Romania (G.-A.D., R.V.).;Bispebjerg Hospital & University of Copenhagen, Denmark (H.C., L.M.C., P.M., L.H.).;Vascular Neurology Section - Stroke Center, Hospital General Universitario Gregorio Marañón, Madrid, Spain (A.R.L., F.D.O., A.G.P., A.G.-N.).;Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, London, United Kingdom (D.J.W., A.C., L.B., R.S., R.P., R.B.).;Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA (P.J., A.S., S.T.).;Stroke Unit, Department of Neurology, Hospital del Mar (E.C.-G., A.R.C., J.R.).;Neurovascular Research Group, IMIM-Hospital del Mar (Institut Hospital del Mar d'Investigacions Mèdiques), Universitat Autònoma de Barcelona/DCEXS-Universitat Pompeu Fabra, Barcelona, Spain (E.C.-G., A.R.C., J.R.).;Department of Clinical Neuroscience (T.M., M.V.M.), Karolinska Institutet, Stockholm, Sweden.;Department of Neurology (T.M., M.V.M.), Karolinska Institutet, Stockholm, Sweden.;Department of Neurology, San Paolo Hospital, Savona, Italy (F.B.).;Landesklinikum Mödling, Neurologische Abteilung und Donau-Universität Krems, Zentrum für Vaskuläre Prävention, Krems, Austria (K.M.).;Stroke Centre Rigshospitalet, Department of Neurology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark (H.K.I.).;Department of Neurology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, a COVID Center, Mexico City (A.G.-D.).;Carol Davila University of Medicine and Pharmacy, Bucharest, Romania (C.T.).;University Emergency Hospital, Bucharest, Romania (C.T.).;Department of Neurology, Krankenhaus Barmherzige Brüder, Vienna, Austria (J.F.).;Department of Neurology 2 (M.R.V.), Kepler University Hospital, Linz, Austria.;Department of Pulmonary Medicine (H.J.F.S., B.L.), Kepler University Hospital, Linz, Austria.;Department of Anesthesiology and Intensive Care Medicine, Johannes Kepler University, Linz, Austria (M.W.D.).;Stroke Center EOC, Neurocenter of Southern Switzerland, Lugano (C.W.C.).;Department of Neurology, Hospital Departamental Universitario del Quindío San Juan de DiosArmenia, Colombia (Á.B.C.Q.).;Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Greece (E.K.).;Internal Medicine, Fundación Clínica Médica Sur, Mexico City (E.S.-N., L.E.S.-R., P.F.C.-M., D.B.-S.).;Stroke Clinic, Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Mexico City (A.A., V.C.-N.).;Department of Neurology, Akershus University Hospital, Norway (E.S.K.).;Department of General Practice, HELSAM, University of Oslo (E.S.K.).;Department of Neurology, Helsinki University Hospital, Finland (M.T., D. Strbian, J.P.).;Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, United Kingdom (G.Y.H.L.).;Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.). | 1656 | |||
| 10.1007/s11920-020-01166-z | Journal Article;Review | en | The Psychological Impact of Epidemic and Pandemic Outbreaks on Healthcare Workers: Rapid Review of the Evidence. | https://www.ncbi.nlm.nih.gov/pubmed/32651717 | We aim to provide quantitative evidence on the psychological impact of epidemic/pandemic outbreaks (i.e., SARS, MERS, COVID-19, ebola, and influenza A) on healthcare workers (HCWs). | 1523-3812,1535-1645 | 2020-07-12 02:00:00+02:00 | pubmed | Anxiety__etiology;Betacoronavirus;Child;Coronavirus Infections__epidemiology;Depression__etiology;Disease Outbreaks;Female;Health Personnel__psychology;Hemorrhagic Fever, Ebola__epidemiology;Humans;Influenza, Human__epidemiology;Male;Mental Health;Pandemics;Pneumonia, Viral__epidemiology;Psychological Distress;Sleep Initiation and Maintenance Disorders__etiology;Stress, Psychological__etiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Current Psychiatry Reports | Emanuele Preti;Valentina Di Mattei;Gaia Perego;Federica Ferrari;Martina Mazzetti;Paola Taranto;Rossella Di Pierro;Fabio Madeddu;Raffaella Calati | COVID-19;Epidemic;Healthcare workers;Mental health;Pandemic;Psychological distress | 2020-07-10 02:00:00+02:00 | 32651717 | FR;IT | Department of Psychology, University of Milan-Bicocca, Piazza dell'Ateneo Nuovo, 1, 20126, Milan, Italy. emanuele.preti@unimib.it.;Centro per lo studio e la terapia dei disturbi della personalità (C.R.E.S.T.), Milan, Italy. emanuele.preti@unimib.it.;School of Psychology, Vita-Salute San Raffaele University, Via Olgettina, 58, 20132, Milan, Italy.;Clinical and Health Psychology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.;Department of Psychology, University of Milan-Bicocca, Piazza dell'Ateneo Nuovo, 1, 20126, Milan, Italy.;Centro per lo studio e la terapia dei disturbi della personalità (C.R.E.S.T.), Milan, Italy.;Department of Adult Psychiatry, Nîmes University Hospital, 4 Rue du Professeur Robert Debré, 30029, Nimes, France. | 1670 | ||
| 10.1016/j.pratan.2020.07.003 | English Abstract;Journal Article;Review | fr | [Cardiac complications in critically ill COVID-19 patients]. | https://www.ncbi.nlm.nih.gov/pubmed/32837211 | The World Health Organization declared the SARS-CoV-2 infection causing severe acute respiratory distress a global pandemic in March 2020. While respiratory features are commonly at the forefront of the disease, cardiovascular complications have been observed and associated with a poorer prognosis. The ACE2 enzyme intrinsically involved in the physiology of cardiac function and in the development of hypertension and diabetes has been identified as a functional receptor for SARS-CoV-2. It is difficult to highlight the precise mechanisms of cardiac damage because of its possible multiple implications, through direct damage from SARS-CoV-2 responsible for viral myocarditis or indirect damage from the state of exacerbated systemic inflammation associated with hypoxaemia. The treatments of the disease may also induce adverse effects such as an increase in QT segment duration. Measurements of cardiac biomarkers are required if myocardial damage is suspected and are part of a panel of arguments confronted with clinical features, ultrasonic monitoring and electrocardiogram. As the cardiac disorders increase post-hospital morbidity, risk stratification with cardiac MRI and prolonged follow-up are required. | 1279-7960 | 2020-07-12 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Jessica Tran Van Nho;Emmanuel Pardo | COVID-19 pandemic;Cardiac complication;Myocardial damage;Myocarditis;SARS-CoV-2 | 2020-07-10 02:00:00+02:00 | 32837211 | FR | Service d'anesthésie-réanimation, hôpital Saint-Antoine, AP-HP, Paris, France.;Sorbonne universités, UPMC université Paris 06, Paris, France. | 1672 | |||
| Letter | en | Limiting positive end-expiratory pressure to protect renal function in SARS-CoV-2 critically ill patients. | https://www.ncbi.nlm.nih.gov/pubmed/32683213 | 2020-07-12 02:00:00+02:00 | pubmed | Alexandra Beurton;Luc Haudebourg;Noémie Simon-Tillaux;Alexandre Demoule;Martin Dres | 2020-07-10 02:00:00+02:00 | 32683213 | FR | Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France, AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), F-75013 Paris, France.;AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), F-75013 Paris, France.;APHP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Biostatistique Santé Publique et Information Médicale, F-75013 Paris, France.;Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France, AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine intensive - Réanimation (Département "R3S"), F-75013 Paris, France. Electronic address: martin.dres@aphp.fr. | 1674 | ||||||||
| Letter | en | Adrenomedullin in COVID-19 induced endotheliitis. | https://www.ncbi.nlm.nih.gov/pubmed/32646523 | 2020-07-12 02:00:00+02:00 | pubmed | Adrenomedullin__therapeutic use;Coronavirus Infections__complications;Endothelium__virology;Humans;Inflammation__virology;Pandemics;Pneumonia, Viral__complications;COVID-19;COVID-19 drug treatment | Darius Cameron Wilson;Joerg C Schefold;Jaume Baldirà;Thibaud Spinetti;Kordo Saeed;Gunnar Elke | 2020-07-09 02:00:00+02:00 | 32646523 | FR;GB;CH;ES;PS;DE | Shock, Organ Dysfunction and Resuscitation Research Group, Vall d'Hebron Institut of Research, Barcelona, Spain. Dwilso52@caledonian.ac.uk.;Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.;Intensive Care Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;University Hospital Southampton NHS Foundation Trust, Southampton, UK.;Department of Anaesthesiology and Intensive Care Medicine, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3 Haus R3, 24105, Kiel, Germany. | 1685 | |||||||
| 10.1007/s00592-020-01570-0 | Journal Article | en | Type 1 diabetes onset triggered by COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32653960 | 0940-5429,1432-5233 | 2020-07-12 02:00:00+02:00 | pubmed | Acta Diabetologica | Lucien Marchand;Matthieu Pecquet;Cédric Luyton | 2020-07-11 02:00:00+02:00 | 32653960 | FR | Department of Endocrinology and Diabetes, Centre Hospitalier Saint Joseph Saint Luc, Quai Claude Bernard, 69007, Lyon, France. lmarchand@ch-stjoseph-stluc-lyon.fr.;Department of Biology, Centre Hospitalier Saint Joseph Saint Luc, Lyon, France.;Department of Endocrinology and Diabetes, Centre Hospitalier Saint Joseph Saint Luc, Quai Claude Bernard, 69007, Lyon, France. | 1694 | |||||
| Letter | en | Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? | https://www.ncbi.nlm.nih.gov/pubmed/32631836 | 2020-07-12 02:00:00+02:00 | pubmed | Margherita Giannini;Mickael Ohana;Benoit Nespola;Giovanni Zanframundo;Bernard Geny;Alain Meyer | 2020-07-06 02:00:00+02:00 | 32631836 | FR;IT | Physiology and Functional Explorations Department, University Hospitals of Strasbourg, Strasbourg Cedex, France.;Radiology Department, Nouvel Hôpital Civil, University Hospitals of Strasbourg, Strasbourg Cedex, France.;Laboratory of Immunology, Nouvel Hôpital Civil, University Hospitals of Strasbourg, Strasbourg Cedex, France.;Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.;Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy.;Physiology and Functional Explorations Department, University Hospitals of Strasbourg, Strasbourg, France.;Federation of Translational Medicine of Strasbourg, Strasbourg University, Strasbourg Cedex, France.;Rheumatology Department, National Centre for Rare Systemic Autoimmune Diseases, University Hospitals of Strasbourg, Strasbourg, France. | 1695 | ||||||||
| 10.1080/14767058.2020.1786811 | Journal Article | en | Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state. | https://www.ncbi.nlm.nih.gov/pubmed/32627622 | For last months, humanity has faced a formidable unknown enemy, which is presented as a new coronavirus infection. Despite the fact that the causative agents of new diseases appear at a certain frequency and that the virus SARS-CoV-2 has certain common properties with its predecessors, at the moment we are dealing with a new unknown pathogenesis of the development of severe complications in patients with risk factors. A final understanding of pathological process mechanisms is the goal of the scientific community. Summarizing research data from different countries, it became obvious that in severe cases of viral infection, we are dealing with a combination of the systemic inflammatory response syndrome, disseminated intravascular coagulation and thrombotic microangiopathy (TMA). Thrombotic microangiopathy is represented by a group of different conditions in which thrombocytopenia, hemolytic anemia, and multiple organ failure occur. The article reflects the main types of TMA, pathogenesis and principles of therapy. The main participants in the process are described in detail, including the von Willebrand factor and ADAMTS-13. Based on the knowledge available, as well as new data obtained from patients with COVID-19, we proposed possible models for the implementation of conditions such as sepsis, TMA, and DIC in patients with severe new coronavirus infection. Through a deeper understanding of pathogenesis, it will be possible to develop more effective diagnosis and therapy. | 1476-7058,1476-4954 | 2020-07-12 02:00:00+02:00 | pubmed | The Journal of Maternal-Fetal & Neonatal Medicine | A D Makatsariya;E V Slukhanchuk;V O Bitsadze;J K H Khizroeva;M V Tretyakova;V I Tsibizova;I Elalamy;J-C Gris;E Grandone;N A Makatsariya;T Mashkova | COVID-19 and coagulopathy;DIC-syndrome;complement system activation;prothrombotic state in pregnancy;thrombotic microangiopathy and COVID-19 | 2020-07-06 02:00:00+02:00 | 32627622 | FR;IT;RU | Obstetrics and Gynecology, The First I.M. Sechenov Moscow State Medical University, (Sechenov University), Moscow, Russia.;Head of Gynecology Unit, Petrovsky National Research Center of Surgery, Moscow, Russia.;Gynecology Department, «Medical Center» LLC, Moscow, Russia.;Almazov National Medical Research Centre, Saint Petersburg, Health Ministry of Russian Federation, Saint Petersburg, Russia.;Director of Hematology Department of Thrombosis Center, Medicine Sorbonne University, Paris, France.;University Montpellier, Montpellier, France.;Hemostasis and Thrombosis Unit, Fondazione I.R.C.C.S. "Casa Sollievo della Sofferenza", Puglia, Italy. | 1698 | |||
| 10.1016/j.banm.2020.07.003 | Journal Article | fr | [Covid-19 epidemic phases: Criteria, challenges and issues for the future]. | https://www.ncbi.nlm.nih.gov/pubmed/32836262 | 0001-4079 | 2020-07-12 02:00:00+02:00 | pubmed | Bulletin de l'Académie Nationale de Médecine | A Migus;P Netter;C Boitard;B Clement;J-F Allilaire;R Ardaillou;P Berche;B Charpentier;P Debre;F Galibert;B Nordlinger | 2020-07-09 02:00:00+02:00 | 32836262 | FR | Académie nationale de médecine, 16, rue Bonaparte, 75006 Paris, France. | 1705 | |||||
| 10.1016/j.comppsych.2020.152191 | Journal Article | en | Stress and anxiety among university students in France during Covid-19 mandatory confinement. | https://www.ncbi.nlm.nih.gov/pubmed/32688023 | While necessary from a public health standpoint, Covid-19 confinement strategies are often contrary to evidence-based therapies used to treat mental disorders. University students may be particularly vulnerable to mental health problems, but recent studies have indicated only a negligible impact of confinement strategies. French respondents to a World Mental Health survey of university students completed questions concerning Covid-19 confinement. The sample experienced increased anxiety as well as moderate to severe stress during confinement. Respondents who did not relocate to live with parents were disproportionately affected. Knowledge of confinement effects may be used to reduce its negative impact in vulnerable populations. | 0010-440X | 2020-07-12 02:00:00+02:00 | pubmed | Comprehensive Psychiatry | Mathilde M Husky;Viviane Kovess-Masfety;Joel D Swendsen | Confinement;Covid-19;Stress | 2020-07-12 02:00:00+02:00 | 32688023 | FR | Université de Bordeaux, Laboratoire de Psychologie EA4139, Bordeaux, France. Electronic address: mathilde.husky@u-bordeaux.fr.;Université de Paris EA 4057, Sorbonne Paris Cite, Paris, France.;EPHE PSL Research University, University of Bordeaux CNRS UMR 5287, Institut Universitaire de France, France. | 1708 | |||
| 10.1111/tbed.13724 | Journal Article | en | First expert elicitation of knowledge on drivers of emergence of the COVID-19 in pets. | https://www.ncbi.nlm.nih.gov/pubmed/32654387 | Infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) induces the coronavirus infectious disease 19 (COVID-19). Its pandemic form in human population and its probable animal origin, along with recent case reports in pets, make drivers of emergence crucial in domestic carnivore pets, especially cats, dogs and ferrets. Few data are available in these species; we first listed forty-six possible drivers of emergence of COVID-19 in pets, regrouped in eight domains (i.e. pathogen/disease characteristics, spatial-temporal distance of outbreaks, ability to monitor, disease treatment and control, characteristics of pets, changes in climate conditions, wildlife interface, human activity, and economic and trade activities). Secondly, we developed a scoring system per driver, then elicited scientific experts (N = 33) to: (a) allocate a score to each driver, (b) weight the drivers scores within each domain and (c) weight the different domains between them. Thirdly, an overall weighted score per driver was calculated; drivers were ranked in decreasing order. Fourthly, a regression tree analysis was used to group drivers with comparable likelihood to play a role in the emergence of COVID-19 in pets. Finally, the robustness of the expert elicitation was verified. Five drivers were ranked with the highest probability to play a key role in the emergence of COVID-19 in pets: availability and quality of diagnostic tools, human density close to pets, ability of preventive/control measures to avoid the disease introduction or spread in a country (except treatment, vaccination and reservoir(s) control), current species specificity of the disease-causing agent and current knowledge on the pathogen. As scientific knowledge on the topic is scarce and still uncertain, expert elicitation of knowledge, in addition with clustering and sensitivity analyses, is of prime importance to prioritize future studies, starting from the top five drivers. The present methodology is applicable to other emerging pet diseases. | 1865-1674,1865-1682 | 2020-07-12 02:00:00+02:00 | pubmed | Transboundary and Emerging Diseases | Claude Saegerman;Juana Bianchini;Véronique Renault;Nadia Haddad;Marie-France Humblet | COVID-19;SARS-CoV-2;carnivores;clustering analysis;drivers;expert elicitation;pets;sensitivity analysis | 2020-07-11 02:00:00+02:00 | 32654387 | FR;BE | Fundamental and Applied Research for Animal and Health (FARAH) Center, University of Liège, Liège, Belgium.;Member of the Risk Assessment Group Covid-19 Animals, Brussels, Belgium.;UMR BIPAR, Ecole nationale vétérinaire d'Alfort, Anses, INRAE, Université Paris-Est, Maisons-Alfort, France.;Department for Occupational Protection and Hygiene, Unit Biosafety, Biosecurity and Environmental Licences, University of Liege, Liege, Belgium. | 1719 | |||
| 10.3390/ijerph17145173 | Journal Article | en | Demographic and Comorbidities Data Description of Population in Mexico with SARS-CoV-2 Infected Patients(COVID19): An Online Tool Analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32709027 | The Word Health Organization (WHO) declared in March 2020 that we are facing a pandemic designated as COVID-19, which is the acronym of coronavirus disease 2019, caused by a new virus know as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In Mexico, the first cases of COVID-19, was reported by the Secretary of Health on 28 February 2020. More than sixteen thousand cases and more than fifteen thousand deaths have been reported in Mexico, and it continues to rise; therefore, this article proposes two online visualization tools (a web platform) that allow the analysis of demographic data and comorbidities of the Mexican population. The objective of these tools is to provide graphic information, fast and updated, based on dataset obtained directly from National Governments Health Secretary (Secretaría de Salud, SSA) which is daily refreshed with the information related to SARS-CoV-2. To allow a dynamical update and friendly interface, and approach with R-project, a well-known Open Source language and environment for statistical computing and Shiny package, were implemented. The dataset is loaded automatically from the latest version released by the federal government of Mexico. Users can choose to study particular groups determined by gender, entity, type of result (positive, negative, pending outcome) and comorbidity. The image results are plots that can be instantly interpreted and supported by the text summary. This tool, in addition to being a consultation for the general public, is useful in Public Health to facilitate the visualization of the data, allowing its timely interpretation due to the changing nature of COVID-19, it can even be used for decision-making by leaders, for the benefit of the health of the community. | 1660-4601 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Comorbidity;Coronavirus Infections__complications;Demography;Humans;Internet;Mexico__epidemiology;Pandemics;Pneumonia, Viral__complications;Public Health;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Environmental Research and Public Health | Carlos E Galván-Tejada;Laura A Zanella-Calzada;Karen E Villagrana-Bañuelos;Arturo Moreno-Báez;Huizilopoztli Luna-García;Jose María Celaya-Padilla;Jorge Issac Galván-Tejada;Hamurabi Gamboa-Rosales | COVID-19;comorbidity analysis;demographic analysis;web interface development | 2020-07-17 02:00:00+02:00 | 32709027 | FR;MX | Unidad Académica de Ingeniería Eléctrica, Universidad Autónoma de Zacatecas, Jardín Juarez 147, Centro, Zacatecas 98000, Zac, Mexico.;LORIA (INRIA, CNRS, Université de Lorraine), Campus Scientifique BP 239, 54506 Nancy, France. | 1722 | ||
| 10.1007/s12185-020-02943-5 | Journal Article | en | Immune thrombocytopenia in a patient with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32677007 | This case report describes immune thrombocytopenic purpura in a 41-year-old man hospitalized in the intensive-care unit for COVID-19, 13 days after the onset of COVID-19 symptoms with respiratory failure at admission. Acute respiratory distress syndrome was treated with, among other drugs, low-molecular-weight heparin. On day 8, his platelet count began descending rapidly. On day 10, heparin treatment was replaced by danaparoid sodium, but by day 13, the continued low platelet count made a diagnosis of heparin-induced thrombocytopenia unlikely. Normocytic nonregenerative anemia gradually developed. On day 13, a bone marrow aspiration showed numerous megakaryocytes and a few signs of hemophagocytosis. Corticosteroids were introduced on day 14, and platelets began rising after 3 days and then fell again on day 19. Intravenous immunoglobulin (IV Ig) was then administered. Two days later, the platelet count returned to normal. The immune cause was confirmed by ruling out the differential diagnoses and the excellent and rapid response to intravenous immunoglobulins. Finally, the patient's respiratory state improved. He was discharged to a respiratory rehabilitation unit on day 38. Our case suggests that an immunological cause should be considered in patients with thrombocytopenia during COVID-19. | 0925-5710,1865-3774 | 2020-07-19 02:00:00+02:00 | pubmed | International Journal of Hematology | Emilie Deruelle;Omar Ben Hadj Salem;Sonnthida Sep Hieng;Claire Pichereau;Hervé Outin;Matthieu Jamme | 2020-07-16 02:00:00+02:00 | 32677007 | FR | Intensive Care Unit, Poissy Saint Germain Hospital, 9-10 rue du champ Gaillard, 78300, Poissy, France.;Laboratory of Hematology, Poissy Saint Germain Hospital, 9-10 rue du champ Gaillard, 78300, Poissy, France.;Intensive Care Unit, Poissy Saint Germain Hospital, 9-10 rue du champ Gaillard, 78300, Poissy, France. Matthieu.Jamme@ght-yvelinesnord.fr.;INSERM U-1018, CESP, Team 5 (EpReC, Renal and Cardiovascular Epidemiology), UVSQ, Villejuif, France. Matthieu.Jamme@ght-yvelinesnord.fr. | 1724 | ||||
| World Health Organization | 10.3390/tropicalmed5030118 | Journal Article | en | Investing in Operational Research Capacity Building for Front-Line Health Workers Strengthens Countries' Resilience to Tackling the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32708821 | (1) Introduction. The Structured Operational Research and Training IniTiative (SORT IT) supports countries to build operational research capacity for improving public health. We assessed whether health workers trained through SORT IT were (1) contributing to the COVID-19 pandemic response and if so, (2) map where and how they were applying their SORT IT skills. (2) Methods. An online questionnaire survey of SORT IT alumni trained between 2009 and 2019. (3) Results. Of 895 SORT IT alumni from 93 countries, 652 (73%) responded to the survey and 417 were contributing to the COVID-19 response in 72 countries. Of those contributing, 307 (74%) were applying their SORT IT skills to tackle the pandemic in 60 countries and six continents including Africa, Asia, Europe, South Pacific and North/South America. Skills were applied to all the pillars of the emergency response with the highest proportions of alumni applying their skills in data generation/analysis/reporting (56%), situation analysis (55%) and surveillance (41%). Skills were also being used to mitigate the health system effects of COVID-19 on other diseases (27%) and in conducting research (26%). (4) Conclusion. Investing in people and in research training ahead of public health emergencies generates downstream dividends by strengthening health system resilience for tackling pandemics. It also strengthens human resources for health and the integration of research within health systems. | 2414-6366 | 2020-07-19 02:00:00+02:00 | pubmed | Tropical Medicine and Infectious Disease | Rony Zachariah;Selma Dar Berger;Pruthu Thekkur;Mohammed Khogali;Karapet Davtyan;Ajay M V Kumar;Srinath Satyanarayana;Francis Moses;Garry Aslanyan;Abraham Aseffa;Anthony D Harries;John C Reeder | COVID-19;SORT IT;health systems;operational research;pandemics;training | 2020-07-16 02:00:00+02:00 | 32708821 | FR;SL;CH;GB;IN;DK | [{"country": "International", "agency": "World Health Organization", "grantid": "001"}] | UNICEF, UNDP, World Bank, WHO Special Programme for Research and Training in Tropical Disease (TDR), 1211 Geneva, Switzerland.;Center for Operational Research, International Union against Tuberculosis and Lung Disease (The Union), 75006 Paris, France.;Center for Operational Research, The Union South-East Asia (USEA), New Delhi 110016, India.;Country Health Policies and Systems, World Health Organization Regional Office for Europe, 2100 Copenhagen, Denmark.;Community Medicine, Yenepoya Medical College (Deemed to Be University), Yenepoya, Mangalore 575018, India.;Reproductive Health and Family Planning Program, Ministry of Health and Sanitation, Freetown 23222, Sierra Leone.;London School of Hygiene and Tropical Medicine, Keppel Street, London WC1 7HT, UK. | 1735 | |
| 10.1007/s00264-020-04729-0 | Journal Article | en | Were protective procedures against SARS-CoV-2 effective in an orthopaedic and trauma centre during the lockdown period? A retrospective study. | https://www.ncbi.nlm.nih.gov/pubmed/32676776 | The SARS-CoV-2 epidemic started in December 2019 in Wuhan. The lockdown was declared on March 16, 2020 in France. Our centre had to adapt daily practices to continue to take care of bone and soft tissue tumours and emergencies. Through this study, we wanted to assess the various procedures implemented during the lockdown period between March 17 and May 10. | 0341-2695,1432-5195 | 2020-07-19 02:00:00+02:00 | pubmed | International Orthopaedics | Pierre-Alban Bouche;Barthelemy Valteau;Valerie Dumaine;Elena Lang;Karine Michel;Luc Eyrolle;Guillaume Auberger;Philippe Anract;Moussa Hamadouche | Bone tumor;COVID-19;Orthopedic department;Traumatology | 2020-07-16 02:00:00+02:00 | 32676776 | FR | Orthopaedic Department, Cochin University Hospital, APHP, Paris, Paris Descartes University, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. pierrealban309@gmail.com.;Orthopaedic Department, Cochin University Hospital, APHP, Paris, Paris Descartes University, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France.;Anesthesic Department, Cochin University Hospital, APHP, Paris, Paris Descartes University, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. | 1739 | |||
| 10.1007/s00405-020-06200-7 | Journal Article | en | Transmission of droplet-conveyed infectious agents such as SARS-CoV-2 by speech and vocal exercises during speech therapy: preliminary experiment concerning airflow velocity. | https://www.ncbi.nlm.nih.gov/pubmed/32676677 | Infectious agents, such as SARS-CoV-2, can be carried by droplets expelled during breathing. The spatial dissemination of droplets varies according to their initial velocity. After a short literature review, our goal was to determine the velocity of the exhaled air during vocal exercises. | 0937-4477,1434-4726 | 2020-07-19 02:00:00+02:00 | pubmed | European Archives of Oto-Rhino-Laryngology | Antoine Giovanni;Thomas Radulesco;Gilles Bouchet;Alexia Mattei;Joana Révis;Estelle Bogdanski;Justin Michel | COVID-19;Pulmonary ventilation;Speech therapy;Voice | 2020-07-16 02:00:00+02:00 | 32676677 | FR | Aix Marseille Univ, CNRS, LPL, Aix-en-Provence, France. antoine.giovanni@ap-hm.fr.;ENT-HNS Department, Aix Marseille Univ, La Conception University Hospital, Marseille, France. antoine.giovanni@ap-hm.fr.;Service ORL, CHU Conception, 147 boulevard Baille, 13385, Marseille Cedex 5, France. antoine.giovanni@ap-hm.fr.;ENT-HNS Department, Aix Marseille Univ, La Conception University Hospital, Marseille, France.;Aix Marseille Univ, CNRS, IUSTI, Marseille, France.;Aix Marseille Univ, CNRS, LPL, Aix-en-Provence, France. | 1745 | |||
| Letter | en | Potential factors linked to high COVID-19 death rates in British minority ethnic groups. | https://www.ncbi.nlm.nih.gov/pubmed/32687806 | 2020-07-19 02:00:00+02:00 | pubmed | Marion Cook | 2020-07-17 02:00:00+02:00 | 32687806 | FR | Échenevex, France. Electronic address: marion.cook@wanadoo.fr. | 1746 | ||||||||
| 10.1002/lary.28993 | Journal Article | en | Clinical and Radiological Evaluations of COVID-19 Patients With Anosmia: Preliminary Report. | https://www.ncbi.nlm.nih.gov/pubmed/32678494 | To investigate clinical and radiological features of olfactory clefts of patients with mild coronavirus disease 2019 (COVID-19). | 0023-852X,1531-4995 | 2020-07-19 02:00:00+02:00 | pubmed | The Laryngoscope | Jerome R Lechien;Justin Michel;Thomas Radulesco;Carlos M Chiesa-Estomba;Luigi A Vaira;Giacomo De Riu;Leigh Sowerby;Claire Hopkins;Sven Saussez | COVID-19;anosmia;computed tomography scan;coronavirus;evaluation;imaging;olfaction;olfactory;smell;taste | 2020-07-17 02:00:00+02:00 | 32678494 | FR;CA;GB;IT;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Marseille, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Oto-Rhino-Laryngology-Head and Neck Surgery, Aix Marseille University, APHM, IUSTI, La Conception University Hospital, Marseille, France.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Maxillofacial Surgery Unit, University Hospital of Sassari, Sassari, Italy.;Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.;Department of Otolaryngology, King's College, London, United Kingdom. | 1757 | |||
| Letter | en | Venous thromboembolism in non-critically ill patients with COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32707275 | 2020-07-19 02:00:00+02:00 | pubmed | Antonin Trimaille;Anaïs Curtiaud;Benjamin Marchandot;Kensuke Matsushita;Chisato Sato;Ian Leonard-Lorant;Laurent Sattler;Lelia Grunebaum;Mickaël Ohana;Jean-Jacques Von Hunolstein;Emmanuel Andres;Bernard Goichot;François Danion;Charlotte Kaeuffer;Vincent Poindron;Patrick Ohlmann;Laurence Jesel;Olivier Morel | Acute pulmonary embolism;COVID-19;Deep vein thrombosis;SARS-CoV-2;Venous thromboembolism | 2020-07-17 02:00:00+02:00 | 32707275 | FR;US | Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France, INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, Strasbourg, France.;Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.;Radiology Department, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.;Department Laboratory Haematology, Center for Thrombosis and Haemostasis, Nouvel Hôpital Civil Strasbourg University Hospital, Strasbourg, France.;Department of Internal Medicine, Médicale B, Strasbourg University Hospital, Strasbourg, France.;Department of Internal Medicine, Diabetes and Metabolic Disorders, Strasbourg University Hospital, Strasbourg, France.;Department of Infectious Disease, Strasbourg University Hospital, Strasbourg, France.;National Referral Center for Systemic Autoimmune Diseases, Clinical Immunology Department, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.;Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France, INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, Strasbourg, France. Electronic address: olivier.morel@chru-strasbourg.fr. | 1765 | |||||||
| Letter | en | Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32672895 | 2020-07-19 02:00:00+02:00 | pubmed | Anna Faura;Susana Rives;Álvaro Lassaletta;Elena Sebastián;Luis Madero;Jorge Huerta;Marina García-Morín;Antonio Pérez Martínez;Luisa Sisinni;Itziar Astigarraga;Pablo Velasco;Luis Gros;Lucas Moreno;Ana Carboné;Carmen Rodríguez-Vigil;Susana Riesco;María Del Carmen Mendoza;Elena García Macias;Maria Trabazo;Montse Torrent;Isabel Badell;José Luis Fuster;Nerea Dominguez-Pinilla;Antonio Juan Ribelles;Vanesa Pérez-Alonso;Manuel Fernández Sanmartín;Marta Baragaño;Maite Gorostegui;Sara Perez-Jaume;Ana Fernández-Teijeiro;Andrés Morales La Madrid;José Luis Dapena | 2020-07-16 02:00:00+02:00 | 32672895 | FR;ES;BO;PS | Pediatric Oncology and Hematology Department, Hospital Sant Joan de Deu, Barcelona, Spain.;Pediatric Hematology-Oncology Department, Hospital Universitario Niño Jesús, Madrid, Spain.;Pediatric Hematology-Oncology Department, Hospital Materno-Infantil Gregorio Marañón, Madrid, Spain.;Pediatric Hemato-Oncology Department, Hospital Universitario La Paz, Madrid, Spain.;Department of Pediatrics, BioCruces Bizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country UPV/EHU, Barakaldo, Spain.;Pediatric Oncology and Hematology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.;Pediatric Hemato-Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.;Pediatric Hemato-Oncology Department, Hospital Clínico Universitario, Salamanca, Spain.;Pediatric Hemato-Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain.;Pediatric Oncology and Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Pediatric Oncology and Hematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.;Pediatric Oncology and Hematology Department, Hospital Virgen de la Salud, Toledo, Spain.;Pediatric Oncology and Hematology Unit, Hospital Universitario La Fe, La Valencia, Valencia, Spain.;Pediatric Oncology and Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.;Pediatric Oncology and Hematology Department, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.;Pediatric Oncology and Hematology Department, Hospital Universitario Quiron Salud, Madrid, Spain.;Pediatric Oncology Unit, Hospitales Universitarios Virgen Macarena y Virgen del Rocio, Sevilla, Spain.;Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain. | 1771 | ||||||||
| 10.1016/j.eururo.2020.07.007 | Editorial | en | Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future. | https://www.ncbi.nlm.nih.gov/pubmed/32703638 | 0302-2838 | 2020-07-19 02:00:00+02:00 | pubmed | European Urology | Roman Sosnowski;Hubert Kamecki;Steven Joniau;Jochen Walz;Zachary Klaassen;Joan Palou | 2020-07-14 02:00:00+02:00 | 32703638 | FR;GE;US;PL;ES;BE | Department of Urogenital Cancer, Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Warsaw, Poland. Electronic address: Sosnowski@pib-nio.pl.;Department of Urogenital Cancer, Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Warsaw, Poland.;Department of Urology, University Hospitals Leuven, Leuven, Belgium.;Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.;Department of Surgery, Division of Urology, Augusta University - Medical College of Georgia, Augusta, GA, USA.;Oncology Urology Unit, Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain. | 1774 | |||||
| 10.1093/eurheartj/ehaa500 | Journal Article | en | Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. | https://www.ncbi.nlm.nih.gov/pubmed/32656565 | While pulmonary embolism (PE) appears to be a major issue in COVID-19, data remain sparse. We aimed to describe the risk factors and baseline characteristics of patients with PE in a cohort of COVID-19 patients. | 0195-668X,1522-9645 | 2020-07-19 02:00:00+02:00 | pubmed | European Heart Journal | Charles Fauvel;Orianne Weizman;Antonin Trimaille;Delphine Mika;Thibaut Pommier;Nathalie Pace;Amine Douair;Eva Barbin;Antoine Fraix;Océane Bouchot;Othmane Benmansour;Guillaume Godeau;Yasmine Mecheri;Romane Lebourdon;Cédric Yvorel;Michael Massin;Tiphaine Leblon;Chaima Chabbi;Erwan Cugney;Léa Benabou;Matthieu Aubry;Camille Chan;Ines Boufoula;Clement Barnaud;Léa Bothorel;Baptiste Duceau;Willy Sutter;Victor Waldmann;Guillaume Bonnet;Ariel Cohen;Théo Pezel | COVID-19;Computed tomography angiography;Intensive care unit;Pulmonary embolism;Risk factors | 2020-07-13 02:00:00+02:00 | 32656565 | FR | Rouen University Hospital, FHU REMOD-VHF, F-76000 Rouen, France.;Centre Hospitalier Régional Universitaire de Nancy, 54511 Vandoeuvre-Les-Nancy, France.;Université de Paris, PARCC, INSERM, 75015 Paris, France.;Nouvel Hôpital Civil, Centre Hospitalier Régional Universitaire de Strasbourg, 67000 Strasbourg, France.;Université Paris-Saclay, Inserm, UMR-S 1180, 92296 Chatenay-Malabry, France.;Centre hospitalier Universitaire de Dijon, 21000 Dijon, France.;Centre Hospitalier Annecy Genevois, 74370 Epagny Metz-Tessy, France.;Centre Hospitalier Régionnal de Orléans, 45100 Orléans, France.;Institut Cardiovasculaire Paris Sud, 91300 Massy, France.;Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux, France.;Centre Hospitalier Universitaire de Saint-Etienne, 42270 Saint-Priest-en-Jarez, France.;Centre Hospitalier Universitaire de Lille, Université Catholique de Lille, 59000 Lille, France.;Hospices Civils de Lyon, Centre Hospitalier Universitaire, 69003 Lyon, France.;Hôpital Européen Georges Pompidou, Université de Paris, 75015 Paris, France.;Saint Antoine Hospital, 75012 Paris, France.;Lariboisiere hospital, APHP, University of Paris, 75010 Paris, France. | 1776 | |||
| Letter | en | Early bacterial co-infection in ARDS related to COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32661615 | 2020-07-19 02:00:00+02:00 | pubmed | Louis Kreitmann;Céline Monard;Olivier Dauwalder;Marie Simon;Laurent Argaud | 2020-07-13 02:00:00+02:00 | 32661615 | FR | Médecine Intensive-Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69437, Lyon Cedex 03, France.;Département d'Anesthésie-Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.;Institut des Agents Infectieux, Centre de Biologie et Pathologie Nord, Hospices Civils de Lyon, Lyon, France.;Médecine Intensive-Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69437, Lyon Cedex 03, France. laurent.argaud@chu-lyon.fr. | 1778 | ||||||||
| 10.1016/j.psychres.2020.113294 | Journal Article | en | High depression and anxiety in people with Alzheimer's disease living in retirement homes during the covid-19 crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32763552 | To cope with Covid-19 and limits its spread among residents, retirement homes have prohibited physical contact between residents and families and friend and, in some cases, even between residents or between residents and caregivers. We investigated the effects of measures against Covid-19 on the mental health of participants with Alzheimer's disease (AD) who live in retirement homes in France. We instructed on-site caregivers to assess depression and anxiety in participants with mild AD who live in retirement homes. Fifty-eight participants consented to participate in the study. The participants rated their depression and anxiety during and before the Covid-19 crisis. Participants reported higher depression (p = .005) and anxiety (p = .004) during than before the Covid-19 crisis. These increases can be attributed to the isolation of the residents and/or to the drastic changes in their daily life and care they receive. While, in their effort to prevent infections, retirement homes are forced to physically separate residents from the outside world and to drastically reduce residents' activities, these decisions are likely to come at a cost to residents with AD and their mental health. | 0165-1781 | 2020-07-19 02:00:00+02:00 | pubmed | Psychiatry Research | Mohamad El Haj;Emin Altintas;Guillaume Chapelet;Dimitrios Kapogiannis;Karim Gallouj | Alzheimer's disease;Anxiety;Coronavirus;Covid-19;Depression;Mental health | 2020-07-13 02:00:00+02:00 | 32763552 | FR;US | Nantes Université, Univ Angers, Laboratoire de Psychologie des Pays de la Loire (LPPL - EA 4638), F-44000 Nantes, France, Unité de Gériatrie, Centre Hospitalier de Tourcoing, Tourcoing, France, Institut Universitaire de France, Paris, France. Electronic address: mohamad.elhaj@univ-nantes.fr.;Unité de Gériatrie, Centre Hospitalier de Tourcoing, Tourcoing, France, Laboratoire PSITEC - Psychologie: Interactions Temps Émotions Cognition, Université Lille Nord de France - 59000 Lille - France.;Department of Geriatric Medicine, Angers University Hospital, Angers, France, CHU Nantes, Inserm CIC04, Département de Neurologie, Centre Mémoire de Ressources et Recherche, Nantes, France.;Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA.;Unité de Gériatrie, Centre Hospitalier de Tourcoing, Tourcoing, France. | 1790 | |||
| 10.1016/j.jcrc.2020.07.013 | Journal Article | en | Extracorporeal membrane oxygenation for refractory COVID-19 acute respiratory distress syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32731100 | 0883-9441 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Critical Care | C Le Breton;S Besset;S Freita-Ramos;M Amouretti;P A Billiet;M Dao;L M Dumont;L Federici;B Gaborieau;D Longrois;P Postel-Vinay;C Vuillard;N Zucman;G Lebreton;A Combes;D Dreyfuss;J D Ricard;D Roux | Acute respiratory distress syndrome;COVID-19;Extracorporeal membrane oxygenation | 2020-07-16 02:00:00+02:00 | 32731100 | FR;US | Médecine Intensive-Réanimation, AP-HP, Hôpital Louis Mourier, F92700 Colombes, France.;Médecine Intensive-Réanimation, AP-HP, Hôpital Louis Mourier, F92700 Colombes, France, Common and Rare Kidney Diseases, French National Institute of Health and Medical Research, INSERM UMR_S 1155, Sorbonne Université, Paris, France.;Médecine Intensive-Réanimation, AP-HP, Hôpital Louis Mourier, F92700 Colombes, France, Université de Paris, Paris Nord Medical School, F-75018 Paris, France.;Médecine Intensive-Réanimation, AP-HP, Hôpital Louis Mourier, F92700 Colombes, France, IAME, INSERM UMR1137, Université de Paris, F-75018 Paris, France.;Université de Paris, Paris Nord Medical School, F-75018 Paris, France, Département d'Anesthésie, AP-HP, Hôpital Louis Mourier, F92700 Colombes, France.;Cardio-Thoracic Surgery Department, AP-HP, Pitié-Salpétrière Hospital, Paris, France.;Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, F-75013 Paris, France, Service de médecine intensive-réanimation, Institut de Cardiologie, APHP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France.;Médecine Intensive-Réanimation, AP-HP, Hôpital Louis Mourier, F92700 Colombes, France, Common and Rare Kidney Diseases, French National Institute of Health and Medical Research, INSERM UMR_S 1155, Sorbonne Université, Paris, France, Université de Paris, Paris Nord Medical School, F-75018 Paris, France.;Médecine Intensive-Réanimation, AP-HP, Hôpital Louis Mourier, F92700 Colombes, France, Université de Paris, Paris Nord Medical School, F-75018 Paris, France, IAME, INSERM UMR1137, Université de Paris, F-75018 Paris, France.;Médecine Intensive-Réanimation, AP-HP, Hôpital Louis Mourier, F92700 Colombes, France, Université de Paris, Paris Nord Medical School, F-75018 Paris, France, IAME, INSERM UMR1137, Université de Paris, F-75018 Paris, France. Electronic address: damien.roux@aphp.fr. | 1796 | ||||
| Letter | en | Prediction of outcome of nasal high flow use during COVID-19-related acute hypoxemic respiratory failure. | https://www.ncbi.nlm.nih.gov/pubmed/32671470 | 2020-07-19 02:00:00+02:00 | pubmed | Noémie Zucman;Jimmy Mullaert;Damien Roux;Oriol Roca;Jean-Damien Ricard | 2020-07-15 02:00:00+02:00 | 32671470 | FR;PS;ES | Assistance Publique-Hôpitaux de Paris, DMU ESPRIT, Médecine Intensive Réanimation, Medico-Surgical ICU, Louis Mourier Hospital, 92700, Colombes, France.;Assistance Publique-Hôpitaux de Paris, Department of Epidemiology, Biostatistics and Clinical Research, Hôpital Bichat, 75018, Paris, France.;Université de Paris, IAME, INSERM, UMR 1137, Paris, France.;Critical Care Department, Vall D'Hebron University Hospital, Vall D'Hebron Research Institute, 08035, Barcelona, Spain.;Assistance Publique-Hôpitaux de Paris, DMU ESPRIT, Médecine Intensive Réanimation, Medico-Surgical ICU, Louis Mourier Hospital, 92700, Colombes, France. jean-damien.ricard@aphp.fr. | 1799 | ||||||||
| 10.1002/ccd.29114 | Journal Article | en | Changes in characteristics and management among patients with ST-elevation myocardial infarction due to COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32667726 | To assess changes in characteristics and management among ST-elevation myocardial infarction (STEMI) patients with coronavirus disease (COVID-19) who underwent primary percutaneous coronary intervention. | 1522-1946,1522-726X | 2020-07-19 02:00:00+02:00 | pubmed | Catheterization and Cardiovascular Interventions | Batric Popovic;Jeanne Varlot;Pierre Adrien Metzdorf;Hélène Jeulin;François Goehringer;Edoardo Camenzind | Acute myocardial infarction/STEMI;Coronary Artery Disease;Percutaneous Coronary Intervention | 2020-07-15 02:00:00+02:00 | 32667726 | FR | Département de Cardiologie, CHU Nancy, Nancy, France.;Laboratoire de Virologie, Service de Microbiologique, Nancy, France.;Service de Maladies Infectieuses et Tropicales, CHU de Nancy, Bâtiment Philippe Canton, Nancy, France. | 1802 | |||
| 10.1016/j.jconrel.2020.07.007 | Journal Article | en | Delivering the power of nanomedicine to patients today. | https://www.ncbi.nlm.nih.gov/pubmed/32681950 | The situation of the COVID-19 pandemic reminds us that we permanently need high-value flexible solutions to urgent clinical needs including simplified diagnostic technologies suitable for use in the field and for delivering targeted therapeutics. From our perspective nanotechnology is revealed as a vital resource for this, as a generic platform of technical solutions to tackle complex medical challenges. It is towards this perspective and focusing on nanomedicine that we take issue with Prof Park's recent editorial published in the Journal of Controlled Release. Prof. Park argued that in the last 15 years nanomedicine failed to deliver the promised innovative clinical solutions to the patients (Park, K. The beginning of the end of the nanomedicine hype. Journal of Controlled Release, 2019; 305, 221-222 [1]. We, the ETPN (European Technology Platform on Nanomedicine) [2], respectfully disagree. In fact, the more than 50 formulations currently in the market, and the recent approval of 3 key nanomedicine products (e. g. Onpattro, Hensify and Vyxeos), have demonstrated that the nanomedicine field is concretely able to design products that overcome critical barriers in conventional medicine in a unique manner, but also to deliver within the cells new drug-free therapeutic effects by using pure physical modes of action, and therefore make a difference in patients lives. Furthermore, the >400 nanomedicine formulations currently in clinical trials are expecting to bring novel clinical solutions (e.g. platforms for nucleic acid delivery), alone or in combination with other key enabling technologies to the market, including biotechnologies, microfluidics, advanced materials, biomaterials, smart systems, photonics, robotics, textiles, Big Data and ICT (information & communication technologies) more generally. However, we agree with Prof. Park that " it is time to examine the sources of difficulty in clinical translation of nanomedicine and move forward ". But for reaching this goal, the investments to support clinical translation of promising nanomedicine formulations should increase, not decrease. As recently encouraged by EMA in its roadmap to 2025, we should create more unity through a common knowledge hub linking academia, industry, healthcare providers and hopefully policy makers to reduce the current fragmentation of the standardization and regulatory body landscape. We should also promote a strategy of cross-technology innovation, support nanomedicine development as a high value and low-cost solution to answer unmet medical needs and help the most promising innovative projects of the field to get better and faster to the clinic. This global vision is the one that the ETPN chose to encourage for the last fifteen years. All actions should be taken with a clear clinical view in mind, " without any fanfare", to focus "on what matters in real life", which is the patient and his/her quality of life. This ETPN overview of achievements in nanomedicine serves to reinforce our drive towards further expanding and growing the maturity of nanomedicine for global healthcare, accelerating the pace of transformation of its great potential into tangible medical breakthroughs. | 0168-3659 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Controlled Release | Matthieu Germain;Fanny Caputo;Su Metcalfe;Giovanni Tosi;Kathleen Spring;Andreas K O Åslund;Agnes Pottier;Raymond Schiffelers;Alexandre Ceccaldi;Ruth Schmid | Clinical translation;Healthtech;Nanomedicine;Nanotechnology;Regulatory;Standardization | 2020-07-15 02:00:00+02:00 | 32681950 | FR;NO;GB;IT;NL;DE | Curadigm SAS, 60 rue de wattignies, 75012 Paris, France. Electronic address: matthieu.germain@curadigm.com.;Department of Biotechnology and Nanomedicine, SINTEF Industry, 7465 Trondheim, Norway.;LIFNano Therapeutics, 10 Fendon Road, University of Cambridge Clinical School, Cambridge CB1 7RT, UK.;Nanotech Lab, Te.Far.T.I., Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41124 Modena, Italy.;Gesellschaft fuer Bioanalytik Muenster e.V., Mendelstrasse 17, 48151 Muenster, Germany.;ETPN association, 64-66 rue des archives, 75003 Paris, France.;Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, 3584, CX, Utrecht, the Netherlands. | 1808 | |||
| 10.3390/jcm9072227 | Journal Article | en | Epidemiology and Clinical Presentation of Children Hospitalized with SARS-CoV-2 Infection in Suburbs of Paris. | https://www.ncbi.nlm.nih.gov/pubmed/32674306 | Understanding the clinical presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and prognosis in children is a major issue. Children often present mild symptoms, and some severe forms require paediatric intensive care, with in some cases a fatal prognosis. Our aim was to identify the epidemiological characteristics, clinical presentation, and prognosis of children with coronavirus disease 2019 (Covid-19) hospitalized in Paris suburb hospitals. In this prospective, observational, multicentre study, we included children hospitalized in paediatric departments of Paris suburb hospitals from 23 March 2020 to 10 May 2020, during the national lockdown in France with confirmed SARS-CoV-2 infection (positive RNA test on a nasopharyngeal swab) or highly suspected infection (clinical, biological, and/or radiological data features suggestive for SARS-CoV-2 infection). A total of 192 children were included for confirmed (n = 157) or highly suspected (n = 35) SARS-CoV-2 infection. The median age was one year old (interquartile range 0.125-11) with a sex ratio 1.3:1. Fever was recorded in 147 (76.6%) children and considered poorly tolerated in 29 (15.1%). The symptoms ranged from rhinorrhoea (34.4%) and gastrointestinal (35.5%) to respiratory distress (25%). Only 10 (5.2%) children had anosmia and five (2.6%) had chest pain. An underlying condition was identified in almost 30% of the children in our study. Overall, 24 (12.5%) children were admitted to paediatric intensive care units, 12 required mechanical ventilation, and three died. For children in Paris suburbs, most cases of Covid-19 showed mild or moderate clinical expression. However, one-eighth of children were admitted to paediatric intensive care units and three died. | 2077-0383 | 2020-07-19 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Louise Gaborieau;Celine Delestrain;Philippe Bensaid;Audrey Vizeneux;Philippe Blanc;Aurélie Garraffo;Emilie Georget;Arnaud Chalvon;Nathalie Garrec;Yacine Laoudi;Emmanuelle Varon;Sébastien Rouget;Alexandre Pupin;Khaled Abdel Aal;David Toulorge;Sarah Ducrocq;Catherine Barrey;Letitia Pantalone;Blandine Robert;Lydie Joly-Sanchez;Caroline Thach;Caroline Masserot-Lureau;Jamilé Chahine;Veronica Risso Garcia-Roudaut;Jonathan Rozental;Sylvie Nathanson;Mohamed Khaled;Alexis Mandelcwajg;Nadia Demayer;Stéphanie Muller;Mustapha Mazerghane;Ralph Epaud;Béatrice Pellegrino;Fouad Madhi | SARS-Co2 infection;clinical presentation;hospitalized children | 2020-07-14 02:00:00+02:00 | 32674306 | FR | Service de Pédiatrie Générale, Centre Hospitalier Intercommunal de Créteil, 94000 Créteil, France.;UPMC, Sorbonne Université, 75006 Paris, France.;INSERM, U955, Team GEIC2O, 94000 Créteil, France.;INSERM, IMRB, Univ Paris Est Creteil, F-94010 Creteil, France.;Centre des Maladies Respiratoires Rares (RESPIRARE®), 94000 Créteil, France.;Service de Pédiatrie Générale, Centre Hospitalier Argenteuil, 95107 Argenteuil, France.;Service de Pédiatrie Générale, Centre Hospitalier Intercommunal Poissy Saint-Germain en Laye, 78300 Poissy, France.;Service de Pédiatrie Générale, Centre Hospitalier Intercommunal Villeneuve Saint Georges, 94190 Villeneuve Saint George, France.;Site de Marne-la-Vallée, Service de Pédiatrie Générale, Grand Hôpital de L'Est Francilien, 77600 Jossigny, France.;Service de Pédiatrie Générale, Centre Hospitalier Intercommunal Robert Ballanger, 93600 Aulnay-sous-Bois, France.;Laboratoire de Microbiologie, Centre Hospitalier Intercommunal de Créteil, 94000 Créteil, France.;Centre National de Référence des Pneumocoques, Centre Hospitalier Intercommunal Créteil, 94000 Créteil, France.;Service de Pédiatrie Générale, Centre Hospitalier Sud Francilien, 91100 Corbeil-Essonnes, France.;Service de Pédiatrie Générale, Centre Hospitalier Gonesse, 95500 Gonesse, France.;Site Longjumeau, Service de Pédiatrie Générale, Groupe Hospitalier Nord Essonne, 91160 Longjumeau, France.;Service de Pédiatrie Générale, Hôpital Saint Camille, 94360 Bry-sur-Marne, France.;Service de Pédiatrie Générale, Centre Hospitalier René Dubos, 95300 Pontoise, France.;Service de Pédiatrie Générale, Centre Hospitalier de Melun, 77000 Melun, France.;Site Meaux, Service de Pédiatrie Générale, Grand Hôpital de L'Est Francilien, 77100 Meaux, France.;Service de Pédiatrie Générale, Hôpital Simone Veil, 95600 Eaubonne, France.;Service de Pédiatrie Générale, Centre Hospitalier Fontainebleau, 77300 Fontainebleau, France.;Service de Pédiatrie Générale, Hôpital Franco-Britannique, 92300 Levallois-Perret, France.;Service de Pédiatrie Générale, Centre Hospitalier de Versailles, 78150 Le Chesnay, France.;Service de Pédiatrie Générale, Groupe Hospitalier Intercommunal Le Raincy Montfermeil, 93370 Montfermeil, France.;Service de Pédiatrie Générale, Centre Hospitalier de Saint-Denis, 93200 Saint-Denis, France.;Service de Pédiatrie Générale, Centre Hospitalier Arpajon, 91294 Arpajon, France.;Service de Pédiatrie Générale, Centre Hospitalier de Rambouillet, 78120 Rambouillet, France.;Service de Pédiatrie Générale, Centre Hospitalier André Grégoire, 93100 Montreuil, France.;Service de Pédiatrie Générale, Centre Hospitalier François Quesnay, 78200 Mantes-la-Jolie, France.;IMRB-GRC GEMINI, Univ Paris Est Creteil, 94000 Créteil, France. | 1814 | |||
| 10.1177/1352458520941485 | Journal Article | en | COVID-19 in people with multiple sclerosis: A global data sharing initiative. | https://www.ncbi.nlm.nih.gov/pubmed/32662757 | We need high-quality data to assess the determinants for COVID-19 severity in people with MS (PwMS). Several studies have recently emerged but there is great benefit in aligning data collection efforts at a global scale. | 1352-4585,1477-0970 | 2020-07-19 02:00:00+02:00 | pubmed | Multiple Sclerosis Journal | Liesbet M Peeters;Tina Parciak;Clare Walton;Lotte Geys;Yves Moreau;Edward De Brouwer;Daniele Raimondi;Ashkan Pirmani;Tomas Kalincik;Gilles Edan;Steve Simpson-Yap;Luc De Raedt;Yann Dauxais;Clément Gautrais;Paulo R Rodrigues;Landon McKenna;Nikola Lazovski;Jan Hillert;Lars Forsberg;Tim Spelman;Robert McBurney;Hollie Schmidt;Arnfin Bergmann;Stefan Braune;Alexander Stahmann;Rodden Middleton;Amber Salter;Bruce F Bebo;Juan I Rojas;Anneke van der Walt;Helmut Butzkueven;Ingrid van der Mei;Rumen Ivanov;Kerstin Hellwig;Guilherme Sciascia do Olival;Jeffrey A Cohen;Wim Van Hecke;Ruth Dobson;Melinda Magyari;Doralina Guimarães Brum;Ricardo Alonso;Richard Nicholas;Johana Bauer;Anibal Chertcoff;Jérôme de Sèze;Céline Louapre;Giancarlo Comi;Nick Rijke | COVID-19;Multiple sclerosis;coronavirus 2;data collection;humans;pandemics;registries | 2020-07-14 02:00:00+02:00 | 32662757 | FR;SE;AR;GB;US;BG;BR;IT;AU;DK;ES;BE;DE | Biomedical Research Institute and Data Science Institute, Hasselt University, Diepenbeek, Belgium.;Department of Medical Informatics, University Medical Center Göttingen, Göttingen, Germany.;MS International Federation, London, UK.;ESAT-STADIUS, KU Leuven, Leuven, Belgium.;Biomedical Research Institute and Data Science Institute, Hasselt University, Diepenbeek, Belgium/ESAT-STADIUS, KU Leuven, Leuven, Belgium.;Clinical Outcomes Research (CORe) Unit, The University of Melbourne, Melbourne, VIC, Australia/Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia.;Department of Neurology, CHU Pontchaillou, Rennes, France.;Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Melbourne, VIC, Australia/Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.;Department of Computer Science and Leuven.AI, KU Leuven, Leuven, Belgium.;QMENTA, Barcelona, Spain.;Department of Clinical Neuroscience, Swedish MS Registry, Stockholm, Sweden.;iConquerMS People-Powered Research Network, Accelerated Cure Project for MS, Waltham, MA, USA.;NeuroTransData Study Group, NeuroTransData, Neuburg, Germany.;MS Forschungs- und Projektentwicklungs-gGmbH, Hannover, Germany.;UK MS Register, Swansea, UK.;COViMS, St Louis, USA/ Division of Biostatistics, Washington University in St. Louis, St. Louis, MO, USA.;COViMS, USA/National Multiple Sclerosis Society, Portland, OR, USA.;Neurology Department, Hospital Universitario de CEMIC, Buenos Aires, Argentina/RELACOEM, Buenos Aires, Argentina.;MSBase Registry, Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.;The Australian MS Longitudinal Study (AMSLS), Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.;Bulgarian SmartMS COVID-19 Dataset, Sofia, Bulgaria.;LEOSS, Department of Neurology, Katholisches Klinikum Bochum, Bochum, Germany.;Brazilian Multiple Sclerosis Association (ABEM), São Paulo, Brazil.;Cleveland Clinic MS COVID-19 Registry, Mellen MS Center, Cleveland Clinic, Cleveland, OH, USA.;Icometrix - Icompanion, Leuven, Belgium.;OptimiseMS, Preventive Neurology Unit, Queen Mary University of London, London, UK.;The Danish Multiple Sclerosis Registry, Department of Neurology, University Hospital Rigshospitalet, Glostrup, Denmark.;Universidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatu/REDONE - Brazilian Registry of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders, São Paulo, Brazil.;RELACOEM, Buenos Aires, Argentina/Multiple Sclerosis University Center, Ramos Mejia Hospital - EMA, Buenos Aires, Argentina.;UK MS Register, Swansea, UK/Imperial College London, London, UK/Swansea University, Swansea, UK.;Mental Health Area, EMA, Buenos Aires, Argentina.;MS and Demyelinating Diseases, Hospital Británico de Buenos Aires - EMA, Buenos Aires, Argentina.;Department of Neurology, Strasbourg University Hospital, Strasbourg, France/ COVISEP, France.;COVISEP, France/Institut du Cerveau ICM, APHP - Hôpital Pitié Salpêtrière, Sorbonne University, Paris, France.;Institute of Experimental Neurology, Ospedale San Raffaele, Milan, Italy. | 1815 | |||
| 10.4037/aacnacc2020802 | Journal Article | en | COVID-19: An Immunopathologic Assault. | https://www.ncbi.nlm.nih.gov/pubmed/32668462 | When caring for patients with coronavirus disease 2019 (COVID-19), clinicians have noticed some unusual clinical presentations not observed before, such as profound hypoxia and severe hypotension. Scientists are probing the evidence to explain these issues and many other unanswered questions. Severe acute respiratory syndrome associated with coronavirus 2 presents an unchartered acute and critical care dilemma. Some of the theories and proposed interventions that will improve outcomes for these critically ill patients are explored in this article. Various testing procedures for COVID-19 are described so valid results can be obtained. Clinical presentations are discussed but continue to evolve as the pandemic ravages our society. The psychological impact of this devastation is also addressed from multiple perspectives. The health care provider is faced with an unprecedented, harrowing situation that has become an internal war that also must be confronted. Professional dedication has provided a formidable response to this destructive virus. | 1559-7768,1559-7776 | 2020-07-19 02:00:00+02:00 | pubmed | AACN Advanced Critical Care | Nancy Munro;Kristine Anne Scordo;Misty M Richmond | COVID-19;SARS-CoV-2;coronavirus;cytokine release syndrome | 2020-07-15 02:00:00+02:00 | 32668462 | FR;US | Nancy Munro is Acute Care Nurse Practitioner, Critical Care Medicine Department, National Institutes of Health, 10 Center Dr, Bldg 10-CRC Room 3-3677, Bethesda, MD 20892 (munronl@cc.nih.gov).;Kristine Anne Scordo is Acute Care Nurse Practitioner, Infectious Diseases, TriHealth, Cincinnati, Ohio.;Misty M. Richmond is Assistant Professor, Wright State University College of Nursing and Health, Dayton, Ohio. | 1816 | |||
| Letter | en | Vulnerability of sickle cell disease persons to the COVID-19 in sub-Saharan Africa. | https://www.ncbi.nlm.nih.gov/pubmed/32657260 | 2020-07-19 02:00:00+02:00 | pubmed | Africa South of the Sahara__epidemiology;Anemia, Sickle Cell__complications;Bacterial Infections__complications;Betacoronavirus__isolation & purification;Blood Transfusion;Coronavirus Infections__complications;Humans;Pandemics;Pneumonia, Viral__complications;Prognosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Serge Tonen-Wolyec;Roland Marini Djang'eing'a;Paul Kambale-Kombi;Charles Kayembe Tshilumba;Laurent Bélec;Salomon Batina-Agasa | 2020-07-14 02:00:00+02:00 | 32657260 | FR;CD;BE;GA | Ecole Doctorale Régionale D'Afrique Centrale en Infectiologie Tropicale, Franceville, Gabon.;Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic of the Congo.;Faculty of Medicine, University of Liège, Liège, Belgium.;Faculty of Medicine, University of Paris Descartes, Paris, France. | 1820 | |||||||
| 10.1007/s00264-020-04728-1 | Journal Article | en | Post-COVID-19 return to elective orthopaedic surgery-is rescheduling just a reboot process? Which timing for tests? Is chest CT scan still useful? Safety of the first hundred elective cases? How to explain the "new normality health organization" to patients? | https://www.ncbi.nlm.nih.gov/pubmed/32683461 | The long incubation period and asymptomatic spread of COVID-19 present considerable challenges for health care institutions when patients return to elective surgery. | 0341-2695,1432-5195 | 2020-07-19 02:00:00+02:00 | pubmed | International Orthopaedics | Jacques Hernigou;Jérome Valcarenghi;Adonis Safar;Mohamed Amine Ferchichi;Esfandiar Chahidi;Harold Jennart;Philippe Hernigou | Chest CT scan;Elective surgery;Ethics;Fracture;Hip arthroplasty;Post-COVID-19;Psychological burden;Surgery cancellation | 2020-07-19 02:00:00+02:00 | 32683461 | FR;BE | Orthopedic Department, EpiCURA Baudour Hornu Hospital, Mons, Belgium.;Orthopedic Department, Tivoli hospital, La Louvière, Belgium.;Orthopedic Department, Clinique Geoffroy Saint Hilaire, 75005, Paris, France. philippe.hernigou@wanadoo.fr.;Hospital Henri Mondor, University Paris, Paris, France. philippe.hernigou@wanadoo.fr. | 1825 | |||
| Letter | en | SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32686042 | 2020-07-19 02:00:00+02:00 | pubmed | M Mateu-Salat;E Urgell;A Chico | 2020-07-19 02:00:00+02:00 | 32686042 | FR;ES | Endocrinology and Nutrition Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. m.mateu7@gmail.com.;Biochemistry Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.;Endocrinology and Nutrition Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.;Universitat Autònoma de Barcelona, Barcelona, Spain.;CIBER-BBN, Madrid, Spain. | 1826 | ||||||||
| 10.1186/s13054-020-03159-z | Journal Article;Review | en | Nutrition of the COVID-19 patient in the intensive care unit (ICU): a practical guidance. | https://www.ncbi.nlm.nih.gov/pubmed/32684170 | Five to 10% of the coronavirus SARS-CoV-2-infected patients, i.e., with new coronavirus disease 2019 (COVID-19), are presenting with an acute respiratory distress syndrome (ARDS) requiring urgent respiratory and hemodynamic support in the intensive care unit (ICU). However, nutrition is an important element of care. The nutritional assessment and the early nutritional care management of COVID-19 patients must be integrated into the overall therapeutic strategy. The international recommendations on nutrition in the ICU should be followed. Some specific issues about the nutrition of the COVID-19 patients in the ICU should be emphasized. We propose a flow chart and ten key issues for optimizing the nutrition management of COVID-19 patients in the ICU. | 1364-8535 | 2020-07-19 02:00:00+02:00 | pubmed | Coronavirus Infections__therapy;Humans;Intensive Care Units;Nutrition Assessment;Nutrition Therapy;Pandemics;Pneumonia, Viral__therapy;Practice Guidelines as Topic;Randomized Controlled Trials as Topic;COVID-19 | Critical Care | Ronan Thibault;Philippe Seguin;Fabienne Tamion;Claude Pichard;Pierre Singer | Critical illness;Energy target;Enteral nutrition;Malnutrition;Protein target;SARS-Cov2 virus;Supplemental parenteral nutrition | 2020-07-19 02:00:00+02:00 | 32684170 | FR;CH;IL | Unité de Nutrition, CHU Rennes, 2, rue Henri Le Guilloux, 35000, Rennes, France. ronan.thibault@chu-rennes.fr.;INRAE, INSERM, Nutrition Métabolismes et Cancer, NuMeCan, Univ Rennes, Rennes, France. ronan.thibault@chu-rennes.fr.;INRAE, INSERM, Nutrition Métabolismes et Cancer, NuMeCan, Univ Rennes, Rennes, France.;Service de Réanimation chirurgicale, CHU Rennes, Rennes, France.;Service de Réanimation Médicale, Normandie Univ, UNIROUEN, U1096, CHU de Rouen, F 76000, Rouen, France.;Unité de Nutrition, Hôpitaux universitaires de Genève, Geneva, Switzerland.;Department of General Intensive Care and Institute for Nutrition Research, Rabin Medical Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. | 1827 | ||
| 10.1016/j.bbmt.2020.07.021 | Practice Guideline | en | Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. | https://www.ncbi.nlm.nih.gov/pubmed/32717432 | The current COVID-19 pandemic, caused by SARS-CoV-2, has impacted many facets of hematopoietic cell transplantation (HCT) in both developed and developing countries. Realizing the challenges as a result of this pandemic affecting the daily practice of the HCT centers and the recognition of the variability in practice worldwide, the Worldwide Network for Blood and Marrow Transplantation (WBMT) and the Center for International Blood and Marrow Transplant Research's (CIBMTR) Health Services and International Studies Committee have jointly produced an expert opinion statement as a general guide to deal with certain aspects of HCT, including diagnostics for SARS-CoV-2 in HCT recipient, pre- and post-HCT management, donor issues, medical tourism, and facilities management. During these crucial times, which may last for months or years, the HCT community must reorganize to proceed with transplantation activity in those patients who urgently require it, albeit with extreme caution. This shared knowledge may be of value to the HCT community in the absence of high-quality evidence-based medicine. © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. | 1083-8791 | 2020-07-26 02:00:00+02:00 | pubmed | Biology of Blood and Marrow Transplantation | Ghada Algwaiz;Mahmoud Aljurf;Mickey Koh;Mary M Horowitz;Per Ljungman;Daniel Weisdorf;Wael Saber;Yoshihisa Kodera;Jeff Szer;Dunia Jawdat;William A Wood;Ruta Brazauskas;Leslie Lehmann;Marcelo C Pasquini;Adriana Seber;Pei Hua Lu;Yoshiko Atsuta;Marcie Riches;Miguel-Angel Perales;Nina Worel;Shinichiro Okamoto;Alok Srivastava;Roy F Chemaly;Catherine Cordonnier;Christopher E Dandoy;John R Wingard;Mohamed A Kharfan-Dabaja;Mehdi Hamadani;Navneet S Majhail;Alpana A Waghmare;Nelson Chao;Nicolaus Kröger;Bronwen Shaw;Mohamad Mohty;Dietger Niederwieser;Hildegard Greinix;Shahrukh K Hashmi | COVID-19;Pandemic;Stem cells;Transplantation | 2020-07-24 02:00:00+02:00 | 32717432 | SE;SG;FR;SA;CN;JP;GB;US;BR;AU;DE;IN;AT | Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.;Department of Adult Hematology and Stem Cell Transplant, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia. Electronic address: maljurf@kfshrc.edu.sa.;Department of Haematology. St George's Hospital and Medical School, London, United Kingdom, Cell Therapy Facility, Blood Services Group, Health Sciences Authority, Singapore.;Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.;Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden, Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.;Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.;Center for Hematopoietic Stem Cell Transplantation, Aichi Medical University Hospital, Nagakute, Japan.;Clinical Haematology at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.;Cord Blood Bank, King Abdullah International Medical Research Center, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.;Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.;Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.;Department of Pediatric Hematology-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.;Department of Medicine, Universidade Federal de Sao Paulo Escola Paulista de Medicina: Sao Paulo, Brazil.;Hematology and Oncology Department, Hebei Yanda Ludaopei Hospital, Langfang, China.;Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, Weill Cornell Medical College, New York, New York.;Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.;Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.;Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India.;Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.;Hematology Department, Henri Mondor Hospital and University Paris-Est Créteil, Créteil, France.;Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio.;Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, Florida.;Division of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.;Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio.;Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Washington and Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.;Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.;Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.;Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRS 938, Paris, France.;Division of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany.;Division of Hematology, Medical University of Graz, Graz, Austria.;Department of Adult Hematology and Stem Cell Transplant, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. | 1834 | |||
| 10.2967/jnumed.120.249292 | Journal Article | en | Autoimmune encephalitis concomitant with SARS-CoV-2 infection: insight from 18F-FDG PET imaging and neuronal autoantibodies. | https://www.ncbi.nlm.nih.gov/pubmed/32709734 | We report the case of a 72-years-old man with concomitant autoimmune encephalitis and SARS-CoV-2 infection. Methods: Review of clinical examination, CT, PET, MRI imaging, and autoantibodies testing. Results: The patient presented subacute cerebellar syndrome and myoclonus several days after general infectious symptoms. The oropharyngeal swab test was positive for SARS-CoV-2. Brain MRI was normal. CSF testing showed normal cell counts, negative RT-qPCR and no oligoclonal banding. Brain 18F-FDG-PET showed diffuse cortical hypometabolism, associated with putaminal and cerebellum hypermetabolism, compatible with encephalitis, and especially cerebellitis. The immunological study revealed high titers of IgG autoantibodies in serum and CSF directed against the nuclei of Purkinje cells, striatal and hippocampal neurons. Search for neoplasia including whole-body 18F-FDG-PET and CT scans was negative. Treatment with steroids allowed a rapid improvement of symptoms. Conclusion: This clinical case brings arguments on the possible relationship between SARS-CoV-2 infection and autoimmune encephalitis, and on the interest of 18F-FDG-PET in such context. | 0161-5505,2159-662X | 2020-07-26 02:00:00+02:00 | pubmed | Journal of Nuclear Medicine | Stephan Grimaldi;Stanislas Lagarde;Jean-Robert Harle;Joseph Boucraut;Eric Guedj | 18F-FDG PET;Infectious Disease;Neurology;PET;PET/CT;SARS-CoV-2;autoantibodies;encephalitis;infection | 2020-07-24 02:00:00+02:00 | 32709734 | FR | Aix Marseille Univ, France.;CHU Timone, France. | 1836 | |||
| 10.1093/cid/ciaa1041 | Journal Article | en | Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. | https://www.ncbi.nlm.nih.gov/pubmed/32706859 | We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe COVID-19 using data from a phase 3 remdesivir trial and a retrospective cohort of patients with severe COVID-19 treated with standard-of-care. | 1058-4838,1537-6591 | 2020-07-26 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Susan A Olender;Katherine K Perez;Alan S Go;Bindu Balani;Eboni G Price-Haywood;Nirav S Shah;Su Wang;Theresa L Walunas;Shobha Swaminathan;Jihad Slim;BumSik Chin;Stéphane De Wit;Shamim M Ali;Alex Soriano Viladomiu;Philip Robinson;Robert L Gottlieb;Tak Yin Owen Tsang;I-Heng Lee;Richard H Haubrich;Anand P Chokkalingam;Lanjia Lin;Lijie Zhong;B Nebiyou Bekele;Robertino Mera-Giler;Joel Gallant;Lindsey E Smith;Anu O Osinusi;Diana M Brainard;Hao Hu;Chloé Phulpin;Holly Edgar;Helena Diaz-Cuervo;Jose I Bernardino | SARS-CoV-2;antiviral treatment;remdesivir;severe COVID-19 | 2020-07-24 02:00:00+02:00 | 32706859 | FR;JE;KE;BO;GB;US;HK;KR;ES;BE | Division of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York, USA.;Houston Methodist, Houston, TX, USA.;Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.;Hackensack University Medical Center, Hackensack, USA.;Ochsner Health System and Ochsner Clinical School, New Orleans, USA.;NorthShore University HealthSystem, Evanston, USA.;Saint Barnabas Medical Center, RWJBarnabas Medical Group, Livingston, USA.;Northwestern University Feinberg School of Medicine, Chicago, USA.;Rutgers New Jersey Medical School, Newark, USA.;Prime Healthcare Services, St Michael's LLC, Newark, USA.;National Medical Center, Seoul, South Korea.;NEAT ID Foundation, CHU Saint Pierre, Brussels, Belgium.;NEAT ID Foundation, Chelsea and Westminster Hospital, London, UK, and School of Medicine, Moi University, Eldoret, Kenya.;Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.;Hoag Memorial Hospital Presbyterian, Newport Beach, USA.;Baylor University Medical Center Dallas, Dallas, USA, and Baylor Scott and White Health, Dallas, USA.;Princess Margaret Hospital, Kwai Chung, Hong Kong.;Gilead Sciences, Foster City, USA.;Gilead Sciences, Causeway Bay, Hong Kong.;Gilead Sciences, Stockley Park, Uxbridge, UK.;Gilead Sciences, Madrid, Spain.;Hospital La Paz, IdiPAZ, Madrid, Spain. | 1841 | |||
| 10.1002/ehf2.12871 | Editorial | en | COVID-19 pandemic: no increase of takotsubo syndrome occurrence despite high-stress conditions. | https://www.ncbi.nlm.nih.gov/pubmed/32705813 | 2055-5822,2055-5822 | 2020-07-26 02:00:00+02:00 | pubmed | ESC Heart Failure | Clement Delmas;Frédéric Bouisset;Olivier Lairez | 2020-07-23 02:00:00+02:00 | 32705813 | FR | Intensive Cardiac Care Unit, Rangueil University Hospital, Toulouse, France.;Department of Cardiology, Rangueil University Hospital, Toulouse, France.;Cardiac Imaging Center, Rangueil University Hospital, Toulouse, France. | 1844 | |||||
| 10.3390/ijerph17155328 | Journal Article | en | On the True Number of COVID-19 Infections: Effect of Sensitivity, Specificity and Number of Tests on Prevalence Ratio Estimation. | https://www.ncbi.nlm.nih.gov/pubmed/32722110 | In this paper, a formula for estimating the prevalence ratio of a disease in a population that is tested with imperfect tests is given. The formula is in terms of the fraction of positive test results and test parameters, i.e., probability of true positives (sensitivity) and the probability of true negatives (specificity). The motivation of this work arises in the context of the COVID-19 pandemic in which estimating the number of infected individuals depends on the sensitivity and specificity of the tests. In this context, it is shown that approximating the prevalence ratio by the ratio between the number of positive tests and the total number of tested individuals leads to dramatically high estimation errors, and thus, unadapted public health policies. The relevance of estimating the prevalence ratio using the formula presented in this work is that precision increases with the number of tests. Two conclusions are drawn from this work. First, in order to ensure that a reliable estimation is achieved with a finite number of tests, testing campaigns must be implemented with tests for which the sum of the sensitivity and the specificity is sufficiently different than one. Second, the key parameter for reducing the estimation error is the number of tests. For a large number of tests, as long as the sum of the sensitivity and specificity is different than one, the exact values of these parameters have very little impact on the estimation error. | 1660-4601 | 2020-07-26 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Prevalence;Probability;Sensitivity and Specificity;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Environmental Research and Public Health | Eitan Altman;Izza Mounir;Fatim-Zahra Najid;Samir M Perlaza | Covid-19;SARS-CoV-2;cross-sectional studies;false positive and false negative probabilities;molecular, serological and medical imaging diagnostics;number of infections;policy-making and testing campaigns;prevalence ratio;sensitivity and specificity | 2020-07-24 02:00:00+02:00 | 32722110 | FR | Centre de Recherche de Sophia Antipolis-Mediterranee, 06902 Valbonne, France.;Laboratoire Informatique d'Avignon, Campus Jean-Henri Fabre, Avignon Universite, 84 911 Avignon, France.;Laboratory of Information, Network and Communication Sciences, Avignon Universite, 75013 Paris, France.;Centre Hospitalier Universitaire de Nice, School of Medicine, Université Côte D'Azur, 06000 Nice, France.;Centre Hospitalier Universitaire Amiens Picardie, School of Medicine, Université de Picardie Jules Verne, 80054 Amiens, France. | 1846 | ||
| Letter | en | Preparing for COVID-19: The experiences of a long-term care facility in Taiwan. | https://www.ncbi.nlm.nih.gov/pubmed/32691923 | 2020-07-26 02:00:00+02:00 | pubmed | Age Factors;Aged;Betacoronavirus__isolation & purification;Change Management;Civil Defense__methods;Comorbidity;Coronavirus Infections__epidemiology;Government Regulation;Homes for the Aged__statistics & numerical data;Humans;Long-Term Care__methods;Nursing Homes__statistics & numerical data;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Policy Making;Taiwan__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cheng-Ren Chen;Hui-Chun Huang;Hsiu-Chen Huang;Wei Chen | COVID-19;healthcare professional;long-term care facility;nursing care;prevention | 2020-07-22 02:00:00+02:00 | 32691923 | FR;TW | Department of Community Health, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.;Pau-Kan Long-term Care Facility, Chiayi, Taiwan.;Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan. | 1850 | ||||||
| Journal Article;Multicenter Study;Observational Study | en | Clinical findings, risk factors, and final outcome in patients diagnosed with pulmonary thromboembolism and COVID-19 in hospital emergency departments. | https://www.ncbi.nlm.nih.gov/pubmed/32692002 | To analyze clinical, laboratory, and radiologic findings and final health outcomes in patients with pulmonary embolism and coronavirus disease 2019 (COVID-19). To compare them to findings and outcomes in patients with pulmonary embolism without COVID-19. | 2020-07-26 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Comorbidity;Computed Tomography Angiography__statistics & numerical data;Coronavirus Infections__blood;Emergency Service, Hospital__statistics & numerical data;Female;Hospital Mortality;Humans;Intensive Care Units;Intubation, Intratracheal;Length of Stay;Male;Odds Ratio;Pandemics;Pneumonia, Viral__blood;Pulmonary Embolism__blood;Retrospective Studies;Risk Factors;Spain__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Sònia Jiménez Hernández;Laura Lozano Polo;Guillem Suñen Cuquerella;Bárbara Peña Pardo;Begoña Espinosa;Carlos Cardozo;Alfons Aguirre Tejedo;Pere Llorens Soriano;Òscar Miró | COVID-19;Embolia de pulmón;Hospital emergency department;Pulmonary embolism;Servicio de urgencias | 2020-07-22 02:00:00+02:00 | 32692002 | FR;ES | Area de Urgencias, Hospital Clínic. Grupo UPyP, Área 1, IDIBAPS, Barcelona, España.;Servicio de Urgencias, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Servicio de Medicina Interna, Hospital del Mar, Barcelona, España.;Servicio de Urgencias, Hospital General de Alicante, Universidad Miguel Hernández, Elche, Alicante, España.;Servicio de Urgencias, Hospital del Mar, Barcelona, España. | 1852 | |||||
| Letter;Comment | en | Management of diabetes in patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32707108 | 2020-07-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Diabetes Mellitus;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean-Daniel Lalau;Abdallah Al-Salameh | 2020-07-25 02:00:00+02:00 | 32707108 | FR | Department of Endocrinology-Diabetology-Nutrition, Amiens University Hospital, Amiens, France. Electronic address: lalau.jean-daniel@chu-amiens.fr.;Department of Endocrinology-Diabetology-Nutrition, Amiens University Hospital, Amiens, France. | 1854 | |||||||
| 10.1007/s00259-020-04968-8 | Journal Article | en | COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome. | https://www.ncbi.nlm.nih.gov/pubmed/32712702 | [18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19. | 1619-7070,1619-7089 | 2020-07-26 02:00:00+02:00 | pubmed | European Journal of Nuclear Medicine and Molecular Imaging | Matthieu Dietz;Gilles Chironi;Yann-Erick Claessens;Ryan Lukas Farhad;Isabelle Rouquette;Benjamin Serrano;Valérie Nataf;Florent Hugonnet;Benoît Paulmier;Frédéric Berthier;Olivia Keita-Perse;Francesco Giammarile;Christophe Perrin;Marc Faraggi | COVID-19;FDG PET/CT;Inflammation | 2020-07-25 02:00:00+02:00 | 32712702 | FR;MC;AT | Nuclear Medicine Department, Centre Hospitalier Princesse Grace, 1 Avenue Pasteur, 98000, Monaco, Monaco.;Check-up Unit, Centre Hospitalier Princesse Grace, Monaco, Monaco.;Department of Emergency Medicine, Centre Hospitalier Princesse Grace, Monaco, Monaco.;Pulmonary Department, Centre Hospitalier Princesse Grace, Monaco, Monaco.;Department of Intensive Care Medicine, Centre Hospitalier Princesse Grace, Monaco, Monaco.;Medical Physics Department, Centre Hospitalier Princesse Grace, Monaco, Monaco.;Department of Biostatistics, Centre Hospitalier Princesse Grace, Monaco, Monaco.;Infection disease Department, Centre Hospitalier Princesse Grace, Monaco, Monaco.;Division of Human Health, International Atomic Energy Agency, Vienna, Austria.;Centre Leon Berard, Lyon, France.;Nuclear Medicine Department, Centre Hospitalier Princesse Grace, 1 Avenue Pasteur, 98000, Monaco, Monaco. marc.faraggi@chpg.mc. | 1855 | |||
| Letter | en | The association between screen time and mental health during COVID-19: A cross sectional study. | https://www.ncbi.nlm.nih.gov/pubmed/32738551 | 2020-07-26 02:00:00+02:00 | pubmed | Lee Smith;Louis Jacob;Mike Trott;Anita Yakkundi;Laurie Butler;Yvonne Barnett;Nicola C Armstrong;Daragh McDermott;Felipe Schuch;Jacob Meyer;Rubén López-Bueno;Guillermo F López Sánchez;Declan Bradley;Mark A Tully | 2020-07-25 02:00:00+02:00 | 32738551 | FR;IE;GB;US;BR;ES | The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK, CB1 1PT. Electronic address: lee.smith@anglia.ac.uk.;Faculty of Medicine University of Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le- Bretonneux, France Research and Development Unit Parc Sanitari Sant Joan de Déu, CIBERSAM Dr. Antoni Pujadas 42, Sant Boi de Llobregat, 08830, Barcelona, Spain.;The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK, CB1 1PT.;Northern Ireland Public Health Research Network and the School of Health Sciences, Ulster University, Northern Ireland.;Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, UK, CB1 1PT.;Health and Social Care Research & Development Division, Public Health Agency, Northern Ireland.;School of Psychology and Sport, Anglia Ruskin University, Cambridge, UK, CB1 1PT.;Department of Sports Methods and Techniques, Federal University of Santa, Maria, Brazil.;Department of Kinesiology, Iowa State University, Ames, IA, USA.;Department of Physical Medicine and Nursing, University of Zaragoza, Zaragoza, Spain.;Faculty of Sport Sciences, University of Murcia, Murcia, Spain.;Centre for Public Health, Queens University Belfast, Belfast, UK.;Institute of Mental Health Sciences School of Health Sciences, Ulster University, Newtownabbey, UK. | 1856 | ||||||||
| 10.1002/jmv.26354 | Journal Article | en | A structural equation model to examine the clinical features of mild-to-moderate COVID-19: A multicenter Italian study. | https://www.ncbi.nlm.nih.gov/pubmed/32710639 | The purpose of this study was to evaluate the clinical features of mild-to-moderate coronavirus disease 2019 (COVID-19) in a sample of Italian patients and to investigate the occurrence of smell and taste disorders. Infected individuals with suspected (clinical diagnosis) or laboratory-confirmed COVID-19 infection were recruited. Patients completed a survey-based questionnaire with the aim of assessing their epidemiological and clinical characteristics, general otorhinolaryngological symptoms, and smell and taste disorders. A total of 294 patients with mild-to-moderate COVID-19 completed the survey (147 females). The most prevalent general symptoms included fever, myalgia, cough, and headache. A total of 70.4% and 59.2% of patients reported smell and taste disorders, respectively. A significant association between the two above-mentioned disorders was found (rs: 0.412; P < .001). Smell disorders occurred before the other symptoms in 11.6% of patients and was not significantly associated with nasal obstruction or rhinorrhea. Interestingly, our statistical analysis did not show any significant difference, either for general symptoms or otorhinolaryngological features, between the clinical diagnosis group and the laboratory-confirmed diagnosis (polymerase chain reaction) group. The structural equation model confirmed significant standardized paths (P < .05) between general symptoms, comorbidities, and general otorhinolaryngological complaints in the absence of a significant correlation between these elements and smell and taste alterations. The prevalence of smell and taste disorders in mild-to-moderate Italian COVID-19 patients is significant both in suspected and laboratory-confirmed cases and reveals a strong correlation between these clinical signs regardless of the presence of general or otorhinolaryngological symptoms, such as nasal obstruction or rhinorrhea. | 0146-6615,1096-9071 | 2020-07-26 02:00:00+02:00 | pubmed | Journal of Medical Virology | Maria Rosaria Barillari;Luca Bastiani;Jerome R Lechien;Giuditta Mannelli;Gabriele Molteni;Giovanna Cantarella;Nicola Coppola;Giuseppe Costa;Eleonora M C Trecca;Calogero Grillo;Ignazio La Mantia;Carlos M Chiesa-Estomba;Claudio Vicini;Sven Saussez;Andrea Nacci;Giovanni Cammaroto | COVID-19;ENT;SARS-CoV-2;anosmia;coronavirus;smell and taste;structural equation model | 2020-07-25 02:00:00+02:00 | 32710639 | FR;US;IT;ES;BE | Department of Mental and Physical Health and Preventive Medicine, "L. Vanvitelli" University, Naples, Italy.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies, Paris, France.;CNR Institute of Clinical Physiology, Pisa, Italy.;Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines, Paris Saclay University, Paris, France.;Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.;Otorhinolaryngology Unit, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University Hospital AOUI Borgo Trento, University of Verona, Verona, Italy.;Department of Clinical Sciences and Community Health, Milan University, Milan University, Milan, Italy.;Department of Otolaryngology, Fondazione IRCCS Ca' Granda Policlinico Hospital, Milan, Italy.;Department of Otolaryngology-Head and Neck Surgery, University Hospital of Foggia, Foggia, Italy.;Department of Medical Sciences, Surgical and Advanced Technologies 'G.F. Ingrassia', University of Catania, Catania, Italy.;Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Unit of Otolaryngology, University of Ferrara, Ferrara, Italy.;Head-Neck and Oral Surgery Unit, Department of Head-Neck Surgery, Otolaryngology, Morgagni Pierantoni Hospital, Azienda USL Della Romagna, Forlì, Italy.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.;ENT Audiology Phoniatric Unit, University of Pisa, Pisa, Italy. | 1860 | |||
| Letter | en | A crisis of ethics in the ethics of crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32718864 | 2020-07-26 02:00:00+02:00 | pubmed | A Zarzavadjian Le Bian;C Tresallet;E Martinod | COVID-19;Ethics;Pandemia;Surgery | 2020-07-24 02:00:00+02:00 | 32718864 | FR | Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University hospital of Seine Saint-Denis, Digestive, Bariatric and Endocrine Surgery Department, Sorbonne Paris Nord University, 93000 Bobigny, France. Electronic address: alban.lebian@aphp.fr.;Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University hospital of Seine Saint-Denis, Digestive, Bariatric and Endocrine Surgery Department, Sorbonne Paris Nord University, 93000 Bobigny, France.;Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University Hospital of Seine Saint-Denis, Thoracic and Vascular Surgery Department, Sorbonne Paris Nord University, 93000 Bobigny, France. | 1863 | |||||||
| Evaluation Study;Letter | en | Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. | https://www.ncbi.nlm.nih.gov/pubmed/32404480 | 2020-07-26 02:00:00+02:00 | pubmed | Antigens, Viral__analysis;Betacoronavirus__isolation & purification;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Humans;Immunoassay__methods;Nasopharynx__virology;Pandemics;Pneumonia, Viral__diagnosis;Point-of-Care Testing;Sensitivity and Specificity;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Sidonie Lambert-Niclot;Alexis Cuffel;Samuel Le Pape;Christelle Vauloup-Fellous;Laurence Morand-Joubert;Anne-Marie Roque-Afonso;Jérôme Le Goff;Constance Delaugerre | SARS-CoV-2;antigen;rapid diagnostic test | 2020-07-23 02:00:00+02:00 | 32404480 | FR | INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France sidonie.lambert@aphp.fr.;Hôpital Saint-Antoine, Laboratoire de Virologie, Paris, France.;Hôpital Saint Louis, Laboratoire de Virologie, Paris, France.;Service de Virologie, Hôpital Paul-Brousse, INSERM U 1193, Université Paris-Saclay Villejuif, APHP Paris-Saclay, France.;INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France.;Université de Paris, INSERM U976, Team Insight, Paris, France.;INSERM U944, Université de Paris, Paris, France. | 1864 | ||||||
| 10.3390/jcm9072315 | Journal Article | en | The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. | https://www.ncbi.nlm.nih.gov/pubmed/32708205 | The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. Since the RAAS can induce and modulate pro-inflammatory responses, it could play a key role in the pathophysiology of Covid-19. Thus, we aimed to determine the levels of plasma renin and aldosterone as indicators of RAAS activation in a series of consecutively admitted patients for Covid-19 in our clinic. | 2077-0383 | 2020-07-26 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Orianne Villard;David Morquin;Nicolas Molinari;Isabelle Raingeard;Nicolas Nagot;Jean-Paul Cristol;Boris Jung;Camille Roubille;Vincent Foulongne;Pierre Fesler;Sylvain Lamure;Patrice Taourel;Amadou Konate;Alexandre Thibault Jacques Maria;Alain Makinson;Ivan Bertchansky;Romaric Larcher;Kada Klouche;Vincent Le Moing;Eric Renard;Philippe Guilpain | Covid-19;endocrine;inflammation;renin angiotensin aldosterone system;severity | 2020-07-21 02:00:00+02:00 | 32708205 | FR | Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, France.;Department of Endocrinology, Diabetes, Nutrition, and INSERM 1411 Clinical Investigation Centre, Montpellier University Hospital, INSERM, 34000 Montpellier, France.;Institute of Functional Genomics, CNRS, INSERM, University of Montpellier, 34000 Montpellier, France.;Department of Infectious and Tropical Diseases, Montpellier University Hospital, 34000 Montpellier, France.;IMAG, CNRS, University of Montpellier, Montpellier University Hospital, 34000 Montpellier, France.;Laboratory of Biochemistry, Montpellier University Hospital, 34000 Montpellier, France.;Department of Intensive Care Medicine, Montpellier University Hospital, 34000 Montpellier, France.;PhyMedExp, Université de Montpellier, INSERM, CNRS, 34000 Montpellier, France.;Laboratory of Virology, Montpellier University Hospital, 34000 Montpellier, France.;Department of Radiology, Montpellier University Hospital, 34000 Montpellier, France.;Department of Internal Medicine-Multi-Organ Diseases, Local Referral Center for Auto-Immune Diseases, Montpellier University Hospital, 34000 Montpellier, France.;Department of Internal Medicine-'DIAGORA Unit', Montpellier University Hospital, 34000 Montpellier, France.;IRMB, INSERM U1183, Montpellier University Hospital, 34000 Montpellier, France. | 1872 | |||
| 10.1016/s1877-1203(20)30001-x | Journal Article | fr | [Can we talk about asthma in the midst of a COVID-19 epidemic?] | https://www.ncbi.nlm.nih.gov/pubmed/32834882 | 1877-1203 | 2020-07-26 02:00:00+02:00 | pubmed | Revue des Maladies Respiratoires Actualités | C Taillé | 2020-07-21 02:00:00+02:00 | 32834882 | FR | Service de Pneumologie et Centre de Référence constitutif des maladies pulmonaires rares, Hôpital Bichat, Paris, France. | 1876 | |||||
| 10.1097/mat.0000000000001258 | Journal Article | en | A simple approach for gas blender on extracorporeal membrane oxygenation in resource shortage context. | https://www.ncbi.nlm.nih.gov/pubmed/32740128 | With the massive influx of patients during COVID-19 pandemic into ICU, resources have quickly been stretched to the limit, including ExtraCorporeal Membrane Oxygenation (ECMO). Gas blender attached to ECMO is used to allow precise adjustment of characteristics of fresh gas flow, i.e. blood oxygen delivery and carbon dioxide removal. In order to cope with the gas blender shortage, we describe a back-up system set up in our French tertiary referral ECMO center using air and oxygen flowmeters. A Table has been created to facilitate medical prescription but also nurse monitoring. This extraordinary situation forces physicians to adapt medical devices and that could be useful in future viral pandemics. | 1058-2916 | 2020-07-26 02:00:00+02:00 | pubmed | ASAIO Journal | Quentin de Roux;Mathilde Delage;Minh Pierre LÊ;Thomas Vincent;Nicolas Mongardon | 2020-07-23 02:00:00+02:00 | 32740128 | FR | Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France.;Service de chirurgie cardiaque, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France.;Univ Paris Est Créteil, Faculté de Santé, F-94010 Créteil, France.;U955-IMRB, Equipe 03 'Pharmacologie et Technologies pour les Maladies Cardiovasculaires (PROTECT)', Inserm, Univ Paris Est Créteil (UPEC), Ecole Nationale Vétérinaire d'Alfort (EnVA), F-94700 Maisons-Alfort, France.;AfterROSC research group, F-75014 Paris, France. | 1895 | ||||
| 10.1002/jmv.26333 | Journal Article | en | Transmission route and introduction of pandemic SARS-CoV-2 between China, Italy, and Spain. | https://www.ncbi.nlm.nih.gov/pubmed/32697346 | We present a phylodynamic and phylogeographic analysis of this new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in this report. A tree of maximum credibility was constructed using the 72 entire genome sequences of this virus, from the three countries (China, Italy, and Spain) available as of 26 March 2020 on the GISAID reference frame. To schematize the current SARS-CoV-2 migration scenario between and within the three countries chosen, using the multitype bearth-death model implemented in BEAST2. Bayesian phylogeographic reconstruction shows that SARS-CoV-2 has a rate of evolution of 2.11 × 10-3 per sites per year (95% highest posterior density: 1.56 × 10-3 to 3.89 × 10-3 ), and a geographic origin in Shanghai, where time until the most recent common ancestor (tMRCA) emerged, according to the analysis of the molecular clock, around 13 November 2019. While for Italy and Spain, there are two tMRCA for each country, which agree with the assumption of several introductions for these countries. That explains also this very short period of subepidermal circulation before the recent events. A total of 8 (median) migration events occurred during this short period, the largest proportion of which (6 events [75%]) occurred from Shanghai (China) to Spain and from Italy to Spain. Such events are marked by speeds of migration that are comparatively lower as compared with that from Shanghai to Italy. Shanghai's R0 and Italy's are closer to each other, though Spain's is slightly higher. All these results allow us to conclude the need for an automatic system of mixed, molecular and classical epidemiological surveillance, which could play a role in this global surveillance of public health and decision-making. | 0146-6615,1096-9071 | 2020-07-26 02:00:00+02:00 | pubmed | Journal of Medical Virology | Benazi Nabil;Bounab Sabrina;Bounab Abdelhakim | SARS-CoV-2;migration rate;multitype bearth-death;number of introductions | 2020-07-22 02:00:00+02:00 | 32697346 | FR;DZ | Institut PASTEUR Algérie, Algiers, Algeria.;Faculty of Sciences, University of M'sila, M'sila, Algeria.;Department of Pharmacy, Faculty of Medicine, University of Algiers, Algiers, Algeria. | 1901 | |||
| 10.1021/acsnano.0c04117 | Journal Article | en | Hard Nanomaterials in Time of Viral Pandemics. | https://www.ncbi.nlm.nih.gov/pubmed/32667191 | The SARS-Cov-2 pandemic has spread worldwide during 2020, setting up an uncertain start of this decade. The measures to contain infection taken by many governments have been extremely severe by imposing home lockdown and industrial production shutdown, making this the biggest crisis since the second world war. Additionally, the continuous colonization of wild natural lands may touch unknown virus reservoirs, causing the spread of epidemics. Apart from SARS-Cov-2, the recent history has seen the spread of several viral pandemics such as H2N2 and H3N3 flu, HIV, and SARS, while MERS and Ebola viruses are considered still in a prepandemic phase. Hard nanomaterials (HNMs) have been recently used as antimicrobial agents, potentially being next-generation drugs to fight viral infections. HNMs can block infection at early (disinfection, entrance inhibition) and middle (inside the host cells) stages and are also able to mitigate the immune response. This review is focused on the application of HNMs as antiviral agents. In particular, mechanisms of actions, biological outputs, and limitations for each HNM will be systematically presented and analyzed from a material chemistry point-of-view. The antiviral activity will be discussed in the context of the different pandemic viruses. We acknowledge that HNM antiviral research is still at its early stage, however, we believe that this field will rapidly blossom in the next period. | 1936-0851,1936-086X | 2020-07-26 02:00:00+02:00 | pubmed | ACS Nano | Giacomo Reina;Shiyuan Peng;Lucas Jacquemin;Andrés Felipe Andrade;Alberto Bianco | antiviral;biomaterials;immune system;nanoparticles;phototherapy;surface chemistry;vaccine;virucidal | 2020-07-22 02:00:00+02:00 | 32667191 | FR | CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France. | 1910 | |||
| 10.1192/bjb.2020.63 | Journal Article | en | The recruitment legacy of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32718374 | 2056-4694,2056-4708 | 2020-08-02 02:00:00+02:00 | pubmed | BJPsych Bulletin | Rajaei K Sharma;Bhupinder Sharma;Harriet L Ogle | 2020-07-29 02:00:00+02:00 | 32718374 | FR;GB | Medical Student, University of Exeter, UK, email: rajaei.sharma@nhs.net.;Consultant, Royal Marsden Hospital, UK NICE Expert Advisor Centre for Guidelines Development, UK.;Medical Student, University of Exeter, UK. | 1914 | |||||
| Letter | en | Pandemic chain of survival: Gathering strength to revive our societies. | https://www.ncbi.nlm.nih.gov/pubmed/32745633 | 2020-08-02 02:00:00+02:00 | pubmed | Clément Buléon;Rebecca D Minehart;Emmanuel Bergot;Albert Chan;Marc-Olivier Fischer | COVID-19;Chain of Survival;Pandemic | 2020-07-31 02:00:00+02:00 | 32745633 | FR;US;HK | CHU de Caen, Caen F-14000, France, Université Caen Normandie, Medical School, Caen F-14000, France. Electronic address: clement.buleon@wanadoo.fr.;Massachusetts General Hospital, Boston, MA, USA, Harvard Medical School, Boston, MA, USA.;CHU de Caen, Caen F-14000, France, Université Caen Normandie, Medical School, Caen F-14000, France.;Prince of Wales Hospital, Shatin, Hong Kong. | 1915 | |||||||
| ANR project DATAREDUX;EU H2020 grant MOOD;EU H2020 grant RECOVER;ANR project EVALCOVID-19;ANR project SPHINX | 10.1186/s12916-020-01698-4 | Journal Article;Research Support, Non-U.S. Gov't | en | Impact of lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. | https://www.ncbi.nlm.nih.gov/pubmed/32727547 | More than half of the global population is under strict forms of social distancing. Estimating the expected impact of lockdown and exit strategies is critical to inform decision makers on the management of the COVID-19 health crisis. | 1741-7015 | 2020-08-02 02:00:00+02:00 | pubmed | Betacoronavirus;Communicable Disease Control__methods;Coronavirus Infections__epidemiology;France;Hospitalization__statistics & numerical data;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Social Isolation;COVID-19;severe acute respiratory syndrome coronavirus 2 | BMC Medicine | Laura Di Domenico;Giulia Pullano;Chiara E Sabbatini;Pierre-Yves Boëlle;Vittoria Colizza | COVID-19;Exit strategies;Lockdown;Mathematical modeling;Non-pharmaceutical interventions;Reproductive number;Social distancing | 2020-07-30 02:00:00+02:00 | 32727547 | FR | [{"country": "International", "agency": "ANR project DATAREDUX", "grantid": "ANR-19-CE46-0008-03"}, {"country": "International", "agency": "EU H2020 grant MOOD", "grantid": "H2020-874850"}, {"country": "International", "agency": "EU H2020 grant RECOVER", "grantid": "H2020- 101003589"}, {"country": "International", "agency": "ANR project EVALCOVID-19", "grantid": "ANR-20-COVI-0007"}, {"country": "International", "agency": "ANR project SPHINX", "grantid": "ANR-17-CE36-0008-05"}] | INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.;Sociology and Economics of Networks and Services lab at Orange Experience Design Lab (SENSE/XDLab) Chatillion, Paris, France.;INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France. vittoria.colizza@inserm.fr. | 1920 |
| Letter | en | SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department. | https://www.ncbi.nlm.nih.gov/pubmed/32739490 | 2020-08-02 02:00:00+02:00 | pubmed | Marta Cancella de Abreu;Christophe Choquet;Héloise Petit;Donia Bouzid;Florence Damond;Stephane Marot;Valentine Marie Ferre;Sonia Burrel;David Boutolleau;Nadhira Houdou-Fidouh;Anne-Geneviève Marcelin;Diane Descamps;Pierre Hausfater | 2020-07-30 02:00:00+02:00 | 32739490 | FR | Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France. Electronic address: martabfca@gmail.com.;Emergency Department, Hôpital Pitié-Salpêtrière, 7-83 Boulevard de l'Hôpital, 75013 Paris, France. | 1927 | ||||||||
| APHM | 10.1007/s00259-020-04973-x | Journal Article | en | 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? | https://www.ncbi.nlm.nih.gov/pubmed/32728799 | Several brain complications of SARS-CoV-2 infection have been reported. It has been moreover speculated that this neurotropism could potentially cause a delayed outbreak of neuropsychiatric and neurodegenerative diseases of neuroinflammatory origin. A propagation mechanism has been proposed across the cribriform plate of the ethmoid bone, from the nose to the olfactory epithelium, and possibly afterward to other limbic structures, and deeper parts of the brain including the brainstem. | 1619-7070,1619-7089 | 2020-08-02 02:00:00+02:00 | pubmed | European Journal of Nuclear Medicine and Molecular Imaging | E Guedj;M Million;P Dudouet;H Tissot-Dupont;F Bregeon;S Cammilleri;D Raoult | 18F-FDG-PET;Anosmia;Brainstem;COVID-19;Functional disorders;Limbic system;SARS-CoV-2 | 2020-07-30 02:00:00+02:00 | 32728799 | FR | [{"country": "", "agency": "APHM", "grantid": "PHRC régional"}] | Nuclear Medicine Department, Aix Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, 264 rue Saint Pierre, 13005, Marseille, France. eric.guedj@ap-hm.fr.;IHU-Méditerranée Infection, Marseille, France.;Aix Marseille University, IRD, APHM, MEPHI, Marseille, France.;APHM, Marseille, France.;Service des Explorations Fonctionnelles Respiratoires, Pôle Cardio-Vasculaire et Thoracique, CHU Nord, APHM, Marseille, France.;Nuclear Medicine Department, Aix Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, 264 rue Saint Pierre, 13005, Marseille, France. | 1929 | |
| Letter;Comment | en | COVID-19 in Italy: passing through bitter waters. | https://www.ncbi.nlm.nih.gov/pubmed/32444413 | 2020-08-02 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Italy;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Lorenzo Guglielmetti;Sheila Chiesi | 2020-07-30 02:00:00+02:00 | 32444413 | FR;IT | Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy lorenzo.guglielmetti@aphp.fr.;APHP, Sorbonne Université, Site Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.;Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 2, Paris, France.;'Spedali Civili' Hospital of Brescia, Brescia, Italy. | 1932 | |||||||
| Letter | en | Blood Myeloperoxidase-DNA, a biomarker of early response to SARS-CoV-2 infection? | https://www.ncbi.nlm.nih.gov/pubmed/32743884 | Convergent arguments suggest that innate immunity related to neutrophils, and in particular neutrophil extracellular traps (NETs), could play a key role in response to SARS-CoV-2 infection. | 2020-08-02 02:00:00+02:00 | pubmed | Jean-Louis Guéant;Julien Fromonot;Rosa-Maria Guéant-Rodriguez;Patrick Lacolley;Régis Guieu;Véronique Regnault | COVID-19;Neutrophil Extra-cellular Traps (NETs);innate immunity;myeloperoxidase;neutrophils | 2020-08-02 02:00:00+02:00 | 32743884 | FR | Department INSERM UMR_S1256, Nutrition-Genetics-Environmental Risk Exposure University of Lorraine, Nancy, France.;Center for CardioVascular and Nutrition Research, INSERM, INRA and Aix-Marseille University, Marseille, France.;Department INSERM, UMR_S1116 Défaillance cardiovasculaire aiguë et chronique, University of Lorraine, Nancy, France. | 1943 | ||||||
| 10.1002/art.41469 | Journal Article | en | Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32741139 | Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. We conducted a systematic review and meta-analysis to describe the current evidence. | 2326-5191,2326-5205 | 2020-08-02 02:00:00+02:00 | pubmed | Arthritis & Rheumatology | Michael Putman;Yu Pei Eugenia Chock;Herman Tam;Alfred H J Kim;Sebastian E Sattui;Francis Berenbaum;Maria I Danila;Peter Korsten;Catalina Sanchez-Alvarez;Jeffrey A Sparks;Laura C Coates;Candace Palmerlee;Andrea Peirce;Arundathi Jayatilleke;Sindhu R Johnson;Adam Kilian;Jean Liew;Larry J Prokop;M Hassan Murad;Rebecca Grainger;Zachary S Wallace;Alí Duarte-García | Antirheumatic medications;COVID-19;SARS-CoV-2;coronavirus | 2020-08-02 02:00:00+02:00 | 32741139 | FR;IE;CA;NZ;GB;US;DE | Northwestern Medicine, Division of Rheumatology, Chicago, IL, USA.;Section of Rheumatology, Yale School of Medicine, New Haven, CT, USA.;Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada.;Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.;Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA.;Department of Rheumatology, Sorbonne Université, INSERM CRSA, AP-HP Hopital Saint Antoine, Paris, France.;University of Alabama at Birmingham, Birmingham, AL, USA.;Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.;Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.;Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.;Patient Research Partner and Nuffield, Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.;Patient Research Partner and Orthopedic Manual Therapist, Private Practice, Berkeley, CA, United Kingdom of Great Britain and Northern Ireland.;Patient Research Partner, USA, Oxford.;Division of Rheumatology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.;Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institute of health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.;Division of Rheumatology, Department of Internal Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.;Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA.;Library Public Services, Mayo Clinic, Rochester, MN, USA.;Evidence-Based Practice Center, Mayo Clinic, Rochester, MN, USA.;Department of Medicine, University of Otago, Wellington, New Zealand.;Clinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.;Division of Rheumatology and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. | 1944 | |||
| 10.1016/j.jcv.2020.104569 | Journal Article | en | Comparison of different serological assays for SARS-CoV-2 in real life. | https://www.ncbi.nlm.nih.gov/pubmed/32769023 | The emergence of the global SARS-CoV-2 pandemic required the rapid and large-scale deployment of PCR and serological tests in different formats. | 1386-6532 | 2020-08-02 02:00:00+02:00 | pubmed | Journal of Clinical Virology | Etienne Brochot;Baptiste Demey;Lynda Handala;Catherine François;Gilles Duverlie;Sandrine Castelain | COVID-19;Performance assays;SARS-CoV-2;Serological assays | 2020-08-02 02:00:00+02:00 | 32769023 | FR | Department of Virology, Amiens University Medical Center, Amiens, France, Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France. Electronic address: etienne.brochot@u-picardie.fr.;Department of Virology, Amiens University Medical Center, Amiens, France, Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France. | 1945 | |||
| 10.1016/j.envres.2020.110001 | Journal Article | en | Potential link between compromised air quality and transmission of the novel corona virus (SARS-CoV-2) in affected areas. | https://www.ncbi.nlm.nih.gov/pubmed/32750327 | The emergence of a novel human corona virus disease (COVID-19) has been declared as a pandemic by the World Health Organization. One of the mechanisms of airborne transmission of the severe acute respiratory syndrome - corona virus (SARS-CoV-2) amid humans is through direct ejection of droplets via sneezing, coughing and vocalizing. Nevertheless, there are ample evidences of the persistence of infectious viruses on inanimate surfaces for several hours to a few days. Through a critical review of the current literature and a preliminary analysis of the link between SARS-CoV-2 transmission and air pollution in the affected regions, we offer a perspective that polluted environment could enhance the transmission rate of such deadly viruses under moderate-to-high humidity conditions. The aqueous atmospheric aerosols offer a conducive surface for adsorption/absorption of organic molecules and viruses onto them, facilitating a pathway for higher rate of transmission under favourable environmental conditions. This mechanism partially explains the role of polluted air besides the exacerbation of chronic respiratory diseases in the rapid transmission of the virus amongst the public. Hence, it is stressed that more ambitious policies towards a cleaner environment are required globally to nip in the bud what could be the seeds of a fatal outbreak such as COVID-19. | 0013-9351 | 2020-08-02 02:00:00+02:00 | pubmed | Environmental Research | M G Manoj;M K Satheesh Kumar;K T Valsaraj;C Sivan;Soumya K Vijayan | Adsorption;Air pollution;Corona virus;Meteorological parameters;Pandemic | 2020-08-01 02:00:00+02:00 | 32750327 | FR;IN;US | Advanced Centre for Atmospheric Radar Research, Cochin University of Science and Technology, Cochin, 682022, India. Electronic address: mgatmos@gmail.com.;Department of Atomic and Molecular Physics, Manipal Academy of Higher Education, Manipal, India.;Cain Department of Chemical Engineering, Louisiana State University, LA, 70803, USA.;Advanced Centre for Atmospheric Radar Research, Cochin University of Science and Technology, Cochin, 682022, India.;College of Pharmaceutical Sciences, Govt. Medical College, Kannur, India. | 1950 | |||
| 10.1007/s11695-020-04883-9 | Journal Article | en | The First Modified Delphi Consensus Statement for Resuming Bariatric and Metabolic Surgery in the COVID-19 Times. | https://www.ncbi.nlm.nih.gov/pubmed/32740826 | The purpose of this study was to achieve consensus amongst a global panel of expert bariatric surgeons on various aspects of resuming Bariatric and Metabolic Surgery (BMS) during the Coronavirus Disease-2019 (COVID-19) pandemic. A modified Delphi consensus-building protocol was used to build consensus amongst 44 globally recognised bariatric surgeons. The experts were asked to either agree or disagree with 111 statements they collectively proposed over two separate rounds. An agreement amongst ≥ 70.0% of experts was construed as consensus as per the predetermined methodology. We present here 38 of our key recommendations. This first global consensus statement on the resumption of BMS can provide a framework for multidisciplinary BMS teams planning to resume local services as well as guide future research in this area. | 0960-8923,1708-0428 | 2020-08-02 02:00:00+02:00 | pubmed | Obesity Surgery | Sjaak Pouwels;Islam Omar;Sandeep Aggarwal;Ali Aminian;Luigi Angrisani;Jose María Balibrea;Mohit Bhandari;L Ulas Biter;Robin P Blackstone;Miguel A Carbajo;Catalin A Copaescu;Jerome Dargent;Mohamed Hayssam Elfawal;Mathias A Fobi;Jan-Willem Greve;Eric J Hazebroek;Miguel F Herrera;Jacques M Himpens;Farah A Hussain;Radwan Kassir;David Kerrigan;Manish Khaitan;Lilian Kow;Jon Kristinsson;Marina Kurian;Rami Edward Lutfi;Rachel L Moore;Patrick Noel;Mahir M Ozmen;Jaime Ponce;Gerhard Prager;Sanjay Purkayastha;Juan Pujol Rafols;Almino C Ramos;Rui J S Ribeiro;Nasser Sakran;Paulina Salminen;Asim Shabbir;Scott A Shikora;Rishi Singhal;Peter K Small;Craig J Taylor;Antonio J Torres;Carlos Vaz;Yury Yashkov;Kamal Mahawar | Bariatric surgery;COVID-19;Obesity surgery;Resuming elective surgery | 2020-08-01 02:00:00+02:00 | 32740826 | IL;PT;BR;AE;NL;MX;BE;FR;RU;GB;US;RO;IT;AT;SG;NO;FI;LB;AU;TR;ES;IN | Department of Intensive Care Medicine, Elisabeth Tweesteden Hospital, Tilburg, The Netherlands.;Bariatric Unit, South Tyneside and Sunderland NHS Trust, Sunderland, SR4 7TP, UK.;All India Institute of Medical Sciences (AIIMS), New Delhi, India.;Cleveland Clinic, Cleveland, OH, USA.;Public Health Department - Federico II School of Medicine, University of Naples, Naples, Italy.;Hospital Clínic de Barcelona, Barcelona, Spain.;Mohak Bariatric and Robotic Surgery Center Indore, Indore, India.;Franciscus Gasthuis Rotterdam, Rotterdam, The Netherlands.;University of Arizona, Tucson, AZ, USA.;Center of Excellence for the Study and Treatment of the Obesity and Diabetes, Valladolid, Spain.;Ponderas Academic Hospital, Bucharest, Romania.;Polyclinique Lyon Nord, Rillieux-la-Pape, France.;Makassed General Hospital, Beirut, Lebanon.;Zuyerland Medical Center, University of Maastricht, Maastricht, The Netherlands.;Rijnstate Hospital Arnhem, Arnhem, Netherlands.;Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico.;CHIREC Delta Hospital, Auderghem, Belgium.;Oregon Health & Science University, Portland, OR, USA.;Department of Bariatric Surgery, CHU Félix Guyon, Saint Denis, La Réunion, France.;Phoenix Health, Chester, UK.;KD Hospital, Ahmedabad, India.;Flinders University, Adelaide, South Australia, Australia.;Oslo University Hospital, Oslo, Norway.;New York University School of Medicine, New York, NY, USA.;University of Illinois, Chicago, IL, USA.;Private Practice, New York, NY, USA.;Bouchard Private Hospital, Elsan, Marseille, France.;Mediclinic Parkview, Dubai, United Arab Emirates.;Istinye University, Istanbul, Turkey.;CHI Memorial Hospital, Chattanooga, TN, USA.;Medical University of Vienna, Wien, Austria.;Imperial College (On Behalf of the PanSurg Collaborative), London, UK.;Clínica Mi Tres Torres, Barcelona, Spain.;Gastro Obeso Center, Sao Paulo, Brazil.;CLISA-Lusiadas, Amadora, Portugal.;Emek Medical Center, Afula, Israel.;Turku University Hospital, Turku, Finland.;Satasairaala Central Hospital, Pori, Finland.;National University Hospital, Singapore, Singapore.;Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.;Birmingham Heartlands Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.;Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK.;Concord Repatriation General Hospital, Sydney, Australia.;Hospital Clinico San Carlos, Universidad Complutense Madrid, IdISSC, Madrid, Spain.;Hospital CUF Tejo, Lisbon, Portugal.;CELT-clinic, Moscow, Russia.;Bariatric Unit, South Tyneside and Sunderland NHS Trust, Sunderland, SR4 7TP, UK. kmahawar@gmail.com.;Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK. kmahawar@gmail.com. | 1951 | |||
| 10.1016/j.jhin.2020.07.032 | Journal Article | en | Stockpiled N95 respirator/surgical mask release beyond manufacturer-designated shelf-life: a French experience. | https://www.ncbi.nlm.nih.gov/pubmed/32745593 | To reduce the shortage of N95 respirators and surgical masks during the COVID-19 pandemic, stockpiled equipment beyond its expiry date could be released. | 0195-6701 | 2020-08-02 02:00:00+02:00 | pubmed | Journal of Hospital Infection | D Brun;C Curti;T Mekideche;A Benech;I Hounliasso;E Lamy;C Castera;P Rathelot;P Vanelle | COVID-19;N95 respirators;Quality control;Surgical masks | 2020-07-31 02:00:00+02:00 | 32745593 | FR | Service Central de La Qualité et de L'Information Pharmaceutiques (SCQIP), Pharmacy Department, AP-HM, Marseille, France, Aix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Equipe de Pharmaco-Chimie Radicalaire, Marseille, France.;Service Central de La Qualité et de L'Information Pharmaceutiques (SCQIP), Pharmacy Department, AP-HM, Marseille, France, Aix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Equipe de Pharmaco-Chimie Radicalaire, Marseille, France. Electronic address: christophe.curti@univ-amu.fr.;Service Central de La Qualité et de L'Information Pharmaceutiques (SCQIP), Pharmacy Department, AP-HM, Marseille, France.;Service Central de La Qualité et de L'Information Pharmaceutiques (SCQIP), Pharmacy Department, AP-HM, Marseille, France, Aix-Marseille Université, UMR 7287 CNRS, Institut des Sciences Du Mouvement ISM, Faculté des Sciences Du Sport, Marseille, France. | 1958 | |||
| 10.1136/jclinpath-2020-206957 | Journal Article | en | Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. | https://www.ncbi.nlm.nih.gov/pubmed/32737190 | Lung cancer predictive biomarker testing is essential to select advanced-stage patients for targeted treatments and should be carried out without delays even during health emergencies, such as the coronavirus (COVID-19) outbreak. | 0021-9746,1472-4146 | 2020-08-02 02:00:00+02:00 | pubmed | Journal of Clinical Pathology | Umberto Malapelle;Pasquale Pisapia;Antonino Iaccarino;Massimo Barberis;Claudio Bellevicine;Hans Brunnström;Dario de Biase;Giovanna De Maglio;Kajsa Ericson Lindquist;Matteo Fassan;Gabriella Fontanini;Elisa Gruppioni;Paul Hofman;Sabine Merkelbach-Bruse;Miguel A Molina Vila;Anaïs Pujals;Ida Rapa;Luisella Righi;Rafael Rosell;Oliver Schildgen;Verena Schildgen;Fernando C Schmitt;Giovanni Tallini;Sara Vander Borght;Elena Vigliar;Marco Volante;Svenja Wagener-Ryczek;Birgit Weynand;Giancarlo Troncone | biomarkers;lung neoplasms;molecular;molecular biology;pathology;tumour | 2020-07-31 02:00:00+02:00 | 32737190 | FR;SE;PT;IT;ES;BE;DE | Department of Public Health, University of Naples Federico II, Naples, Italy.;Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.;Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.;Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.;Department of Pathology, University Hospital of Udine, Udine, Italy.;Surgical Pathology Unit, Department of Medicine, University of Padua, Padua, Italy.;Department of Surgical, Medical, and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.;Department of Pathology, University of Bologna Medical Center, Bologna, Italy.;Pathology, INSERM, Nice, France.;Institute of Pathology, University of Cologne, Cologne, Germany.;Laboratory of Oncology, Pangaea Oncology, Barcelona, Spain.;Department of Pathology, CHU Henri Mondor, Creteil, France.;Pathology Unit, Department of Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy.;Pathology Unit, Department of Oncology, University of Turin, Turin, Italy.;Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital Badalona, Barcelona, Spain.;Institute of Pathology, Hospital of the Private University Witten/Herdecke, Cologne, Germany.;Pathology, IPATIMUP and Medical Faculty of Porto, Porto, Portugal.;Department of Pathology, University Hospitals Leuven, Leuven, Belgium.;Department of Public Health, University of Naples Federico II, Naples, Italy giancarlo.troncone@unina.it. | 1961 | |||
| Letter | en | COVID-19 and role of pharmacist in correctional facilities. | https://www.ncbi.nlm.nih.gov/pubmed/32800459 | 2020-08-02 02:00:00+02:00 | pubmed | Qui Thanh Hoai Ta;Muhammad Faisal Nadeem;Nazish Matti;Shagufta Parveen;Muhammad Jawad | 2020-07-31 02:00:00+02:00 | 32800459 | FR;PK;VN | Institute of Research and Development, Duy Tan University, Danang, 550000, Viet Nam. Electronic address: tathoaiqui@duytan.edu.vn.;The University of Strasbourg, Alsace, France, University of Veterinary and Animal Sciences, Lahore, Pakistan. Electronic address: faisal.nadeem@uvas.edu.pk.;Department of pharmacy, Quaid-i-Azam University, Islamabad, Pakistan. Electronic address: nazish341@yahoo.com.;Institute of agricultural science, University of the Punjab, Lahore, Pakistan. Electronic address: shagufta06@yahoo.com.;Ziauddin University, Karachi, Pakistan. Electronic address: rph.jawad.zu@gmail.com. | 1962 | ||||||||
| UHK | 10.3390/vaccines8030423 | Journal Article | en | Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach. | https://www.ncbi.nlm.nih.gov/pubmed/32731461 | The present study aimed to work out a peptide-based multi-epitope vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We predicted different B-cell and T-cell epitopes by using the Immune Epitopes Database (IEDB). Homology modeling of the construct was done using SWISS-MODEL and then docked with different toll-like-receptors (TLR4, TLR7, and TLR8) using PatchDock, HADDOCK, and FireDock, respectively. From the overlapped epitopes, we designed five vaccine constructs C1-C5. Based on antigenicity, allergenicity, solubility, different physiochemical properties, and molecular docking scores, we selected the vaccine construct 1 (C1) for further processing. Docking of C1 with TLR4, TLR7, and TLR8 showed striking interactions with global binding energy of -43.48, -65.88, and -60.24 Kcal/mol, respectively. The docked complex was further simulated, which revealed that both molecules remain stable with minimum RMSF. Activation of TLRs induces downstream pathways to produce pro-inflammatory cytokines against viruses and immune system simulation shows enhanced antibody production after the booster dose. In conclusion, C1 was the best vaccine candidate among all designed constructs to elicit an immune response SARS-CoV-2 and combat the coronavirus disease (COVID-19). | 2076-393X | 2020-08-02 02:00:00+02:00 | pubmed | Vaccines | Noor Rahman;Fawad Ali;Zarrin Basharat;Muhammad Shehroz;Muhammad Kazim Khan;Philippe Jeandet;Eugenie Nepovimova;Kamil Kuca;Haroon Khan | allergenicity;antigenicity;coronavirus;multi-epitopes;pneumonia;vaccine | 2020-07-28 02:00:00+02:00 | 32731461 | CZ;FR;PK | [{"country": "", "agency": "UHK", "grantid": "faculty of science VT209-2021"}] | H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan.;Department of Biochemistry, Hazara University, Mansehra 21120, Pakistan.;Jamil-ur-Rahman Center for Genome Research, PCMD, ICCBS, University of Karachi, Karachi 75270, Pakistan.;Department of Biotechnology, Virtual University of Pakistan, Lahore 54000, Pakistan.;Centre for Applied Molecular Biology, University of the Punjab, Lahore 53700, Pakistan.;Faculty of Sciences, University of Reims Champagne-Ardenne, CEDEX 2, 51687 Reims, France.;Department of Chemistry, Faculty of Science, University of Hradec Kralove, 50005 Hradec Kralove, Czech Republic.;Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan. | 1971 | |
| Letter;Comment | en | Inhibiting IL-6 in COVID-19: we are not sure. | https://www.ncbi.nlm.nih.gov/pubmed/32718345 | 2020-08-02 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Interleukin-6;Pandemics;Pneumonia, Viral__epidemiology;Respiratory Distress Syndrome, Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Patrick M Honore;Leonel Barreto Gutierrez;Luc Kugener;Sebastien Redant;Rachid Attou;Andrea Gallerani;David De Bels | 2020-07-27 02:00:00+02:00 | 32718345 | FR;BE | ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. Patrick.Honore@CHU-Brugmann.be.;Centre Hospitalier Universitaire Brugmann, Brussels, Belgium.;ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. | 1974 | |||||||
| 10.1016/j.radonc.2020.04.019 | Journal Article | en | Reprint of: Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. | https://www.ncbi.nlm.nih.gov/pubmed/32730830 | Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff. | 0167-8140 | 2020-08-02 02:00:00+02:00 | pubmed | Radiotherapy and Oncology | David J Thomson;David Palma;Matthias Guckenberger;Panagiotis Balermpas;Jonathan J Beitler;Pierre Blanchard;David Brizel;Wilfred Budach;Jimmy Caudell;June Corry;Renzo Corvo;Mererid Evans;Adam S Garden;Jordi Giralt;Vincent Gregoire;Paul M Harari;Kevin Harrington;Ying J Hitchcock;Jorgen Johansen;Johannes Kaanders;Shlomo Koyfman;J A Langendijk;Quynh-Thu Le;Nancy Lee;Danielle Margalit;Michelle Mierzwa;Sandro Porceddu;Yoke Lim Soong;Ying Sun;Juliette Thariat;John Waldron;Sue S Yom | 2020-07-27 02:00:00+02:00 | 32730830 | FR;SG;CA;GE;CN;GB;US;CH;IT;AU;NL;ES;DK;PS;DE | Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, and the Division of Cancer Sciences, The University of Manchester, UK.;Division of Radiation Oncology, Western University, London, Canada.;Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.;Department of Radiation Oncology, Emory University, Atlanta, Georgia.;Department of Radiation Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Radiation Oncology, Duke Cancer Institute, Durham, North Carolina.;Department of Radiation Oncology, University Hospital Düsseldorf, Germany.;Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida.;Department Radiation Oncology Genesiscare, St Vincent's Hospital, Melbourne, Australia.;Department of Radiation Oncology, Ospedale Policlinico San Martino and University, Genoa, Italy.;Department of Clinical Oncology, Velindre University NHS Trust, Cardiff, Wales, UK.;Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.;Department of Radiation Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.;Department of Radiation Oncology, Centre Leon Berard, Lyon, France.;Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.;Division of Radiotherapy and Imaging, Institute for Cancer Research, London, UK.;Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah.;Department of Oncology, Odense University Hospital, Department of Oncology, Denmark.;Department of Radiation Oncology, Radboudumc, Nijmegen, The Netherlands.;Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio.;Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.;Department of Radiation Oncology, Stanford University, Palo Alto, California.;Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.;Department of Radiation Oncology, Dana-Farber/Brigham & Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.;Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.;Department of Radiation Oncology, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia.;Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.;Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, PR China.;Department of Radiation Oncology, Centre François Baclesse, University of Normandy, Caen, France.;Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.;Department of Radiation Oncology, University of California San Francisco, San Francisco, California. Electronic address: sue.yom@ucsf.edu. | 1975 | ||||
| 10.3390/ijerph17155404 | Journal Article | en | A Systems Approach to Assess Transport and Diffusion of Hazardous Airborne Particles in a Large Surgical Suite: Potential Impacts on Viral Airborne Transmission. | https://www.ncbi.nlm.nih.gov/pubmed/32727142 | Airborne transmission of viruses, such as the coronavirus 2 (SARS-CoV-2), in hospital systems are under debate: it has been shown that transmission of SARS-CoV-2 virus goes beyond droplet dynamics that is limited to 1 to 2 m, but it is unclear if the airborne viral load is significant enough to ensure transmission of the disease. Surgical smoke can act as a carrier for tissue particles, viruses, and bacteria. To quantify airborne transmission from a physical point of view, we consider surgical smoke produced by thermal destruction of tissue during the use of electrosurgical instruments as a marker of airborne particle diffusion-transportation. Surgical smoke plumes are also known to be dangerous for human health, especially to surgical staff who receive long-term exposure over the years. There are limited quantified metrics reported on long-term effects of surgical smoke on staff's health. The purpose of this paper is to provide a mathematical framework and experimental protocol to assess the transport and diffusion of hazardous airborne particles in every large operating room suite. Measurements from a network of air quality sensors gathered during a clinical study provide validation for the main part of the model. Overall, the model estimates staff exposure to airborne contamination from surgical smoke and biological material. To address the clinical implication over a long period of time, the systems approach is built upon previous work on multi-scale modeling of surgical flow in a large operating room suite and takes into account human behavior factors. | 1660-4601 | 2020-08-02 02:00:00+02:00 | pubmed | Air Microbiology;Air Movements;Air Pollution;Betacoronavirus;Coronavirus Infections__transmission;Diffusion;Humans;Hydrodynamics;Models, Theoretical;Operating Rooms;Pandemics;Particulate Matter;Pneumonia, Viral__transmission;Smoke__analysis;Systems Analysis;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Environmental Research and Public Health | Marc Garbey;Guillaume Joerger;Shannon Furr | COVID-19;airborne virus;indoor air quality;multi-scale model;particle transport;surgical smoke;surgical suite | 2020-07-27 02:00:00+02:00 | 32727142 | FR;US | ORintelligence, Houston, TX 77021, USA.;LaSIE, UMR CNRS 7356, University of la Rochelle, 17000 La Rochelle, France.;GEPROVAS, 67000 Strasbourg, France. | 1979 | ||
| 10.1017/s0950268820001685 | Journal Article | en | Geographical variation in case fatality rate and doubling time during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32713371 | Case fatality rate (CFR) and doubling time are important characteristics of any epidemic. For coronavirus disease 2019 (COVID-19), wide variations in the CFR and doubling time have been noted among various countries. Early in the epidemic, CFR calculations involving all patients as denominator do not account for the hospitalised patients who are ill and will die in the future. Hence, we calculated cumulative CFR (cCFR) using only patients whose final clinical outcomes were known at a certain time point. We also estimated the daily average doubling time. Calculating CFR using this method leads to temporal stability in the fatality rates, the cCFR stabilises at different values for different countries. The possible reasons for this are an improved outcome rate by the end of the epidemic and a wider testing strategy. The United States, France, Turkey and China had high cCFR at the start due to low outcome rate. By 22 April, Germany, China and South Korea had a low cCFR. China and South Korea controlled the epidemic and achieved high doubling times. The doubling time in Russia did not cross 10 days during the study period. | 0950-2688,1469-4409 | 2020-08-02 02:00:00+02:00 | pubmed | Age Factors;China__epidemiology;Coronavirus Infections__mortality;Europe__epidemiology;Humans;India__epidemiology;Iran__epidemiology;Pandemics__prevention & control;Pneumonia, Viral__mortality;Republic of Korea__epidemiology;Time Factors;United States__epidemiology;COVID-19 | Epidemiology and Infection | A Mazumder;M Arora;M S Sra;A Gupta;P Behera;M Gupta;M Agarwal;A Rao;S S Mohanta;G G Parameswaran;A Lohiya;H D Shewade | Coronavirus;epidemiology;public health | 2020-07-27 02:00:00+02:00 | 32713371 | FR;IN | All India Institute of Medical Sciences (AIIMS), New Delhi, India.;All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.;Indian Institute of Science Education and Research (IISER), Pune, India.;Super Specialty Cancer Institute and Hospital, Lucknow, Uttar Pradesh, India.;International Union Against Tuberculosis and Lung Disease (The Union), Paris, France.;The Union South-East Asia Office, New Delhi, India. | 1981 | ||
| 10.1111/apa.15495 | Journal Article;Review | en | Review of guidelines and recommendations from 17 countries highlights the challenges that clinicians face caring for neonates born to mothers with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32716579 | This review examined how applicable national and regional clinical practice guidelines and recommendations for managing neonates born to mothers with COVID-19 mothers were to the evolving pandemic. | 0803-5253,1651-2227 | 2020-08-02 02:00:00+02:00 | pubmed | Acta Paediatrica | Kee Thai Yeo;Ju Lee Oei;Daniele De Luca;Georg M Schmölzer;Robert Guaran;Pamela Palasanthiran;Kishore Kumar;Giuseppe Buonocore;Jeanie Cheong;Louise S Owen;Satoshi Kusuda;Jennifer James;Gina Lim;Ankur Sharma;Sabita Uthaya;Christopher Gale;Elizabeth Whittaker;Cheryl Battersby;Neena Modi;Mikael Norman;Lars Naver;Eric Giannoni;Yenge Diambomba;Prakeshkumar S Shah;Luigi Gagliardi;Michael Harrison;Shakti Pillay;Abdullah Alburaey;Yuan Yuan;Huayan Zhang | COVID-19;neonate;perinatal care;practice guidelines;transmission | 2020-07-27 02:00:00+02:00 | 32716579 | FR;SG;SE;CA;SA;CN;JP;GB;US;CH;IT;AU;ZA;IN;KR | KK Women's & Children's Hospital, Singapore, Singapore.;Duke-NUS Medical School, Singapore, Singapore.;School of Women's and Children's Health, University of New South Wales, Australia.;Royal Hospital for Women, Randwick, NSW, Australia.;Division of Pediatrics and Neonatal Critical Care, "A. Béclère" Medical Center, Paris Saclay University Hospitals, APHP, Paris, France.;Physiopathology and Therapeutic Innovation Unit-INSERM U999, South Paris-Saclay, Paris, France.;University of Alberta, Edmonton, AB, Canada.;NSW Perinatal Services Network, Sydney, NSW, Australia.;Sydney Children's Hospital Network, Randwick, NSW, Australia.;Cloudnine Hospitals, Bangalore, India.;Azienda Ospedaliera Universitaria Senese, Siena, Italy.;Clinical Sciences, Murdoch Children's Research Institute, Parkville, VIC, Australia.;Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC, Australia.;Royal Women's Hospital, Melbourne, VIC, Australia.;Kyorin University, Tokyo, Japan.;Children's Hospital of Philadelphia, Philadelphia, PA, USA.;Ulsan University Hospital, Ulsan, South Korea.;Imperial College London and Chelsea and Westminster NHS Foundation Trust, London, UK.;Imperial College Healthcare NHS Trust, London, UK.;Imperial College London, London, UK.;Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.;Department Mother-Woman-Child, Clinic of Neonatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.;Mount Sinai Hospital, Toronto, ON, Canada.;Ospedale Versilia, Lido di Camaiore, AUSL Toscana Nord Ovest, Pisa, Italy.;University of Cape Town, Cape Town, South Africa.;Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia.;Guangzhou Women and Children's Medical Center, Guangzhou, China.;University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. | 1982 | |||
| 10.1007/s00423-020-01948-2 | Journal Article | en | Acute abdomen in patients with SARS-CoV-2 infection or co-infection. | https://www.ncbi.nlm.nih.gov/pubmed/32720012 | Patients with an acute abdomen require emergency surgery. SARS-CoV-2 infection can affect multiple organ systems, including the digestive tract. Little is known about the consequences of COVID-19 infection in emergency surgical patients. | 1435-2443,1435-2451 | 2020-08-02 02:00:00+02:00 | pubmed | Langenbeck's Archives of Surgery | Barbara Seeliger;Guillaume Philouze;Zineb Cherkaoui;Emanuele Felli;Didier Mutter;Patrick Pessaux | Abdominal surgery;Acute abdomen;COVID-19;Laparoscopy;Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | 2020-07-27 02:00:00+02:00 | 32720012 | FR | IHU-Strasbourg, Institute of Image-Guided Surgery, Strasbourg, France.;Department of Visceral and Digestive Surgery, Nouvel Hopital Civil, Hôpitaux Universitaires de Strasbourg, 1 Place de l'Hôpital, 67091, Strasbourg Cedex, France.;INSERM U1110, Institut de Recherche Sur Maladies Virales et Hépatiques, Strasbourg, France.;IHU-Strasbourg, Institute of Image-Guided Surgery, Strasbourg, France. patrick.pessaux@chru-strasbourg.fr.;Department of Visceral and Digestive Surgery, Nouvel Hopital Civil, Hôpitaux Universitaires de Strasbourg, 1 Place de l'Hôpital, 67091, Strasbourg Cedex, France. patrick.pessaux@chru-strasbourg.fr.;INSERM U1110, Institut de Recherche Sur Maladies Virales et Hépatiques, Strasbourg, France. patrick.pessaux@chru-strasbourg.fr. | 1985 | |||
| 10.1016/j.avsg.2020.07.013 | Case Reports | en | Femoral arterial thrombosis in a young adult following non-severe COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32736027 | Few cases of arterial thromboembolisms have been reported after 2019 coronavirus disease (COVID-19), in case of severe infection or elderly patients. We report a case of femoral arterial thrombosis in a young patient following non-severe infection. | 0890-5096 | 2020-08-02 02:00:00+02:00 | pubmed | Annals of Vascular Surgery | Florian Veyre;Corinne Poulain-Veyre;Aurélie Esparcieux;Nicolas Monsarrat;Abdellah Aouifi;Joel Lapeze;Philippe Chatelard | 2020-07-28 02:00:00+02:00 | 32736027 | FR;US | Université Claude-Bernard Lyon 1, Domaine Rockefeller, Lyon, France.;Médecine Vasculaire, Vienne, France.;Service de Médecine Interne et Maladies Infectieuses, Infirmerie Protestante de Lyon, Caluire et Cuire, France.;Service de Cardiologie, Infirmerie Protestante de Lyon, Caluire et Cuire, France.;Service de Réanimation, Infirmerie Protestante de Lyon, Caluire et Cuire, France.;Service de Chirurgie Cardiaque et Vasculaire, Infirmerie Protestante de Lyon, Caluire et Cuire, France.;Service de Chirurgie Cardiaque et Vasculaire, Infirmerie Protestante de Lyon, Caluire et Cuire, France. Electronic address: ph.chatelard@wanadoo.fr. | 1986 | ||||
| 10.3390/jcm9082392 | Journal Article | en | Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32726951 | (1) Background: The use of corticosteroids in critical coronavirus infections, including severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome (MERS), or Coronavirus disease 2019 (COVID-19), has been controversial. However, a meta-analysis on the efficacy of steroids in treating these coronavirus infections is lacking. (2) Purpose: We assessed a methodological criticism on the quality of previous published meta-analyses and the risk of misleading conclusions with important therapeutic consequences. We also examined the evidence of the efficacy of corticosteroids in reducing mortality in SARS, MERS and COVID-19. (3) Methods: PubMed, MEDLINE, Embase, and Web of Science were used to identify studies published until 25 April 2020, that reported associations between steroid use and mortality in treating SARS/MERS/COVID-19. Two investigators screened and extracted data independently. Searches were restricted to studies on humans, and articles that did not report the exact number of patients in each group or data on mortality were excluded. We calculated odds ratios (ORs) or hazard ratios (HRs) under the fixed- and random-effect model. (4) Results: Eight articles (4051 patients) were eligible for inclusion. Among these selected studies, 3416 patients were diagnosed with SARS, 360 patients with MERS, and 275 with COVID-19; 60.3% patients were administered steroids. The meta-analyses including all studies showed no differences overall in terms of mortality (OR 1.152, 95% CI 0.631-2.101 in the random effects model, p = 0.645). However, this conclusion might be biased, because, in some studies, the patients in the steroid group had more severe symptoms than those in the control group. In contrast, when the meta-analysis was performed restricting only to studies that used appropriate adjustment (e.g., time, disease severity), there was a significant difference between the two groups (HR 0.378, 95% CI 0.221-0.646 in the random effects model, p < 0.0001). Although there was no difference in mortality when steroids were used in severe cases, there was a difference among the group with more underlying diseases (OR 3.133, 95% CI 1.670-5.877, p < 0.001). (5) Conclusions: To our knowledge, this study is the first comprehensive systematic review and meta-analysis providing the most accurate evidence on the effect of steroids in coronavirus infections. If not contraindicated, and in the absence of side effects, the use of steroids should be considered in coronavirus infection including COVID-19. | 2077-0383 | 2020-08-02 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Keum Hwa Lee;Sojung Yoon;Gwang Hun Jeong;Jong Yeob Kim;Young Joo Han;Sung Hwi Hong;Seohyun Ryu;Jae Seok Kim;Jun Young Lee;Jae Won Yang;Jinhee Lee;Marco Solmi;Ai Koyanagi;Elena Dragioti;Louis Jacob;Joaquim Radua;Lee Smith;Hans Oh;Kalthoum Tizaoui;Sarah Cargnin;Salvatore Terrazzino;Ramy Abou Ghayda;Andreas Kronbichler;Jae Il Shin | Middle East respiratory syndrome (MERS);coronavirus;coronavirus disease 2019 (COVID-19);corticosteroids;severe acute respiratory syndrome (SARS) | 2020-07-27 02:00:00+02:00 | 32726951 | SE;FR;TN;GB;US;IT;ES;KR;AT | Department of Pediatrics, Yonsei University College of Medicine, Seoul 03722, Korea.;Yonsei University College of Medicine, Seoul 03722, Korea.;College of Medicine, Gyeongsang National University, Jinju 52727, Korea.;Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon 51353, Korea.;Department of Global Health and Population, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.;Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.;Department of Psychiatry, Yonsei University Wonju College of Medicine, Wonju 26426, Korea.;Department of Neuroscience, University of Padova, 35121 Padova, Italy.;Research and development unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Dr. Antoni Pujadas, 42, Sant Boi de Llobregat, 08830 Barcelona, Spain.;ICREA, Pg. Lluis Companys 23, 08010 Barcelona, Spain.;Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring Sciences, Linkoping University, SE-581 85 Linkoping, Sweden.;Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-le-Bretonneux, France.;Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.;Mental Health Research Networking Center (CIBERSAM), 08036 Barcelona, Spain.;Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.;Centre for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, 11330 Stockholm, Sweden.;The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge CB1 1PT, UK.;School of Social Work, University of Southern California, Los Angeles, CA 90015, USA.;Department of Basic Sciences, Division of Histology and Immunology, Faculty of Medicine Tunis, Tunis El Manar University, Tunis 1068, Tunisia.;Department of Pharmaceutical Sciences and Interdepartmental Research Center of Pharmacogenetics and Pharmacogenomics (CRIFF), University of Piemonte Orientale, 28100 Novara, Italy.;Division of Urology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.;Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020 Innsbruck, Austria. | 1988 | |||
| 10.1007/s00134-020-06186-0 | Journal Article | en | Comparative study of lung ultrasound and chest computed tomography scan in the assessment of severity of confirmed COVID-19 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32728966 | The relationship between lung ultrasound (LUS) and chest computed tomography (CT) scans in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia is not clearly defined. The primary objective of our study was to assess the performance of LUS in determining severity of SARS-CoV-2 pneumonia compared with chest CT scan. Secondary objectives were to test the association between LUS score and location of the patient, use of mechanical ventilation, and the pulse oximetry (SpO2)/fractional inspired oxygen (FiO2) ratio. | 0342-4642,1432-1238 | 2020-08-02 02:00:00+02:00 | pubmed | Intensive Care Medicine | Laurent Zieleskiewicz;Thibaut Markarian;Alexandre Lopez;Chloé Taguet;Neyla Mohammedi;Mohamed Boucekine;Karine Baumstarck;Guillaume Besch;Gautier Mathon;Gary Duclos;Lionel Bouvet;Pierre Michelet;Bernard Allaouchiche;Kathia Chaumoître;Mathieu Di Bisceglie;Marc Leone | Chest computed tomography;Diagnostic accuracy;Lung ultrasound;SARS-CoV-2 | 2020-07-29 02:00:00+02:00 | 32728966 | FR | Department of Anesthesiology and Intensive Care Medicine, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, 13015, Marseille, France. laurent.zieleskiewicz@ap-hm.fr.;Center for Cardiovascular and Nutrition Research (C2VN), INRA, Aix Marseille Université, INSERM, 13005, Marseille, France. laurent.zieleskiewicz@ap-hm.fr.;Department of Emergency Medicine, Timone University Hospital, Marseille, France.;Department of Anesthesiology and Intensive Care Medicine, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, 13015, Marseille, France.;Centre D'Etudes Et de Recherches Sur Les Services de Santé Et Qualité, Faculté de Médecine, Aix-Marseille Université, 13005, Marseille, France.;Department of Anesthesiology and Intensive Care MedicineUniversity Hospital of Besancon,, University of Franche-Comte, 2. EA3920, Besancon, France.;Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Service de Réanimation, 69310, Pierre-Bénite, France.;Service Anesthésie Réanimation, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France.;Lyon1, Université Claude Bernard, Villeurbanne, France.;VetAgro Sup, Pulmonary and Cardiovascular Aggresion in Sepsis, UPSP 2016.A101, Université de Lyon, Campus Vétérinaire de Lyon, 69280, Marcy l'Étoile, France.;Assistance Publique Hôpitaux de Marseille, Hôpital Nord, Aix Marseille University, Service d'Imagerie Médicale, 13015, Marseille, France. | 1996 | |||
| 10.1093/ecco-jcc/jjaa160 | Journal Article | en | Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce. | https://www.ncbi.nlm.nih.gov/pubmed/32722754 | Our knowledge on COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as Inflammatory Bowel Disease (IBD). In this paper, we compiled the existing evidence on the impact of COVID-19 in IBD patients and provide guidance and on the most appropriate care to adopt during the pandemic. Our review highlighted that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management shall be carefully adapted: i) in SARS-CoV-2 positive IBD patients, medical treatments should be re-evaluated (with particular focus on corticosteroids) always with the purpose of treating active disease and maintaining remission; ii) non-urgent surgeries and endoscopic procedures should be postponed for all patients; iii) online consultancy should be implemented; and iv) hospitalization and surgery should be limited to life threatening situations. | 1873-9946,1876-4479 | 2020-08-02 02:00:00+02:00 | pubmed | Journal of Crohn's and Colitis | F Magro;J-F Rahier;C Abeu;E MacMahon;A Hart;C J van der Woude;H Gordon;M Adamina;N Viget;S Vavricka;T Kucharzik;S Leone;B Siegmund;S Danese;L Peyrin-Biroulet | 2020-07-29 02:00:00+02:00 | 32722754 | FR;PT;GB;CH;IT;NL;BE;DE | Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal, Department of Gastroenterology, Centro Hospitalar de São João, Porto, Portugal,Department of Clinical Pharmacology Centro Hospitalar de São João, Porto, Portugal.;CHU UCL Namur, Université catholique de Louvain, service de Hépato-gastroentérologie, Yvoir, Belgium.;Infectious Diseases Service, Centro Hospitalar Universitário São João, Porto, Portugal. Instituto de Inovação e Investigação em Saúde (I3s), Faculty of Medicine, Department of Medicine, University of Porto, Portugal.;Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, U.K.;IBD Unit, St Mark's Hospital, London, UK.;Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlnads.;Department of Gastroenterology Royal London Hospital, Barts Health NHS Trust, London, England. Centre for Immunobiology, The Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, England.;Department of Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland.;Department of Infectious Diseases, Tourcoing Hospital, Tourcoing.;Center for Gastroenterology and Hepatology, Zürich, Switzerland.;Lüneburg Hospital, University of Hamburg, Department of Gastroenterology, Lüneburg, Germany.;EFCCA, European Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium.;Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany.;Division of Gastroenterology, IBD Center, Humanitas University, Rozzano, Milan, Italy.;Department of Gastroenterology Nancy University Hospital, Vandoeuvre-Les-Nancy, France.;Inserm NGERE U1256, Lorraine University, Vandoeuvre-Les-Nancy, France. | 1997 | ||||
| 10.3390/v12080855 | Journal Article;Research Support, Non-U.S. Gov't | en | Wide Diversity of Coronaviruses in Frugivorous and Insectivorous Bat Species: A Pilot Study in Guinea, West Africa. | https://www.ncbi.nlm.nih.gov/pubmed/32764506 | Zoonoses can constitute a threat for public health that can have a global importance, as seen with the current COVID-19 pandemic of severe acute respiratory syndrome coronavirus (SARS-CoV2). Bats have been recognized as an important reservoir of zoonotic coronaviruses (CoVs). In West Africa, where there is a high diversity of bat species, little is known on the circulation of CoVs in these hosts, especially at the interface with human populations. In this study, in Guinea, we tested a total of 319 bats belonging to 14 genera and six families of insectivorous and frugivorous bats across the country, for the presence of coronaviruses. We found CoVs in 35 (11%) of the tested bats-in three insectivorous bat species and five fruit bat species that were mostly captured close to human habitat. Positivity rates varied from 5.7% to 100%, depending on bat species. A wide diversity of alpha and beta coronaviruses was found across the country, including three sequences belonging to SarbeCoVs and MerbeCoVs subgenera known to harbor highly pathogenic human coronaviruses. Our findings suggest that CoVs are widely spread in West Africa and their circulation should be assessed to evaluate the risk of exposure of potential zoonotic CoVs to humans. | 1999-4915 | 2020-08-09 02:00:00+02:00 | pubmed | Viruses | Audrey Lacroix;Nicole Vidal;Alpha K Keita;Guillaume Thaurignac;Amandine Esteban;Hélène De Nys;Ramadan Diallo;Abdoulaye Toure;Souana Goumou;Abdoul Karim Soumah;Moriba Povogui;Joel Koivogui;Jean-Louis Monemou;Raisa Raulino;Antoine Nkuba;Vincent Foulongne;Eric Delaporte;Ahidjo Ayouba;Martine Peeters | Africa;Guinea;bat;coronavirus;virus diversity | 2020-08-05 02:00:00+02:00 | 32764506 | FR;CD;ZW;GN | TransVIHMI, Institut de Recherche pour le Développement, University of Montpellier, INSERM, 34394 Montpellier, France.;Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG), Université Gamal Abder Nasser de Conakry, Conakry BP6629, Guinea.;ASTRE, CIRAD, INRA, University of Montpellier, 34398 Montpellier, France.;CIRAD, UMR ASTRE, Harare, Zimbabwe.;Laboratoire Central de Diagnostic Vétérinaire, Ministère de l'Elevage et des Productions Animales, Conakry BP3982, Guinea.;Institut National de Sante Publique (INSP), Conakry BP6623, Guinea.;Institut National de Recherche Biomédicale and Service de Microbiologie, Cliniques Universitaires de Kinshasa, Gombe, Kinshasa P.O. Box 1197, Democratic Republic of the Congo.;Département de bacteriologie-virologie, CHU de Montpellier, 34295 Montpellier, France. | 2012 | |||
| 10.1136/annrheumdis-2020-218176 | Journal Article | en | Response to: 'Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo et al. | https://www.ncbi.nlm.nih.gov/pubmed/32759253 | 0003-4967,1468-2060 | 2020-08-09 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Alexis Mathian;Zahir Amoura | autoimmune diseases;hydroxychloroquine;lupus erythematosus;systemic | 2020-08-05 02:00:00+02:00 | 32759253 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 2022 | ||||
| 10.1136/annrheumdis-2020-218614 | Journal Article | en | Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al' by Pino et al. | https://www.ncbi.nlm.nih.gov/pubmed/32759261 | 0003-4967,1468-2060 | 2020-08-09 02:00:00+02:00 | pubmed | Annals of the Rheumatic Diseases | Naim Ouldali;Marie Pouletty;Johanna Lokmer;Cherine Benzouid;Constance Beyler;Anna Deho;Ulrich Meinzer;Albert Faye;Isabelle Melki | immune system diseases;inflammation;therapeutics | 2020-08-05 02:00:00+02:00 | 32759261 | FR | General Paediatrics, Department of Infectious Disease and Internal Medicine, Robert Debré University Hospital, AP-HP, Paris, France, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France.;Université de Paris, UFR de Médecine Paris Nord, Paris, France.;INSERM UMR 1123, ECEVE, Paris, France.;Cardiopaediatric Unit, Robert Debré University Hospital, AP-HP, Paris, France.;Paediatric Intensive Care Unit, Robert Debré University Hospital, AP-HP, Paris, France.;Center for Research on Inflammation, INSERM, UMR1149, Paris, France.;Biology and Genetics of Bacterial Cell Wall Unit, Pasteur Institute, Paris, France.;General Paediatrics, Department of Infectious Disease and Internal Medicine, Robert Debré University Hospital, AP-HP, Paris, France, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France isabelle.melki@aphp.fr.;Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris, France.;Paediatric Hematology-Immunology and Rheumatology Department, Necker-Enfants-Malades University Hospital, AP-HP, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France. | 2025 | ||||
| Letter | en | Seroprevalence and presentation of SARS-CoV-2 in pregnancy. | https://www.ncbi.nlm.nih.gov/pubmed/32771084 | 2020-08-09 02:00:00+02:00 | pubmed | Francesca Crovetto;Fàtima Crispi;Elisa Llurba;Francesc Figueras;María Dolores Gómez-Roig;Eduard Gratacós | 2020-08-06 02:00:00+02:00 | 32771084 | FR;ES | Department of Maternal-Fetal Medicine, BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, Universitat de Barcelona, Barcelona 08950, Spain, Institut de Recerca Sant Joan de Deu, Barcelona, Spain, Center for Biomedical Network Research on Rare Diseases, Instituto de Salud Carlos III, Barcelona, Spain.;Department of Maternal-Fetal Medicine, BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, Universitat de Barcelona, Barcelona 08950, Spain, Institut de Recerca August Pi Sunyer, Barcelona, Spain, Center for Biomedical Network Research on Rare Diseases, Instituto de Salud Carlos III, Barcelona, Spain.;Maternal and Child Health and Development Network, Instituto de Salud Carlos III, Barcelona, Spain, Department of Obstetrics and Gynaecology, Hospital Sant Pau, Barcelona, Spain.;Department of Maternal-Fetal Medicine, BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, Universitat de Barcelona, Barcelona 08950, Spain, Institut de Recerca Sant Joan de Deu, Barcelona, Spain, Maternal and Child Health and Development Network, Instituto de Salud Carlos III, Barcelona, Spain.;Department of Maternal-Fetal Medicine, BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, Universitat de Barcelona, Barcelona 08950, Spain, Institut de Recerca August Pi Sunyer, Barcelona, Spain, Center for Biomedical Network Research on Rare Diseases, Instituto de Salud Carlos III, Barcelona, Spain. Electronic address: egratacos@sjdhospitalbarcelona.org. | 2026 | ||||||||
| 10.1534/g3.120.401554 | Journal Article | en | A Comprehensive, Flexible Collection of SARS-CoV-2 Coding Regions. | https://www.ncbi.nlm.nih.gov/pubmed/32763951 | The world is facing a global pandemic of COVID-19 caused by the SARS-CoV-2 coronavirus. Here we describe a collection of codon-optimized coding sequences for SARS-CoV-2 cloned into Gateway-compatible entry vectors, which enable rapid transfer into a variety of expression and tagging vectors. The collection is freely available. We hope that widespread availability of this SARS-CoV-2 resource will enable many subsequent molecular studies to better understand the viral life cycle and how to block it. | 2160-1836 | 2020-08-09 02:00:00+02:00 | pubmed | G3&#58; Genes|Genomes|Genetics | Dae-Kyum Kim;Jennifer J Knapp;Da Kuang;Aditya Chawla;Patricia Cassonnet;Hunsang Lee;Dayag Sheykhkarimli;Payman Samavarchi-Tehrani;Hala Abdouni;Ashyad Rayhan;Roujia Li;Oxana Pogoutse;Étienne Coyaud;Sylvie van der Werf;Caroline Demeret;Anne-Claude Gingras;Mikko Taipale;Brian Raught;Yves Jacob;Frederick P Roth | Gateway-compatible;SARS-CoV-2;TEV (tobacco etch virus) sequence;coding sequence collection | 2020-08-06 02:00:00+02:00 | 32763951 | FR;CA;UNK | University of Toronto, Sinai Health System.;Institut Pasteur, Centre National de la Recherche Scientifique, Université de Paris.;University of Toronto.;Sinai Health System.;Université de Paris.;University of Toronto, Canadian Institute for Advanced Research.;Institut Pasteur, Centre National de la Recherche Scientifique, Université de Paris yves.jacob@pasteur.fr. | 2036 | |||
| 10.1002/mco2.12 | Journal Article;Review | en | Regulatory T cells: A potential weapon to combat COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32838397 | Since the end of December 2019, a novel coronavirus SARS-CoV-2 began to spread, an infection disease termed COVID-19. The virus has spread throughout the world in a short period of time, resulting in a pandemic. The number of reported cases in global reached 5 695 596 including 352 460 deaths, as of May 27, 2020. Due to the lack of effective treatment options for COVID-19, various strategies are being tested. Recently, pathologic studies conducted by two teams in China revealed immunopathologic abnormalities in lung tissue. These results have implications for immunotherapy that could offer a novel therapy strategy for combating lethal viral pneumonia. This review discusses the clinical and pathological features of COVID-19, the roles of immune cells in pathological processes, and the possible avenues for induction of immunosuppressive T regulatory cells attenuating lung inflammation due to viral infection. It is our hope that these proposals may both be helpful in understanding the novel features of SARS-CoV-2 pneumonia as well as providing new immunological strategies for treating the severe sequelae of disease manifestations seen in people infected with SARS-CoV-2. | 2688-2663,2688-2663 | 2020-08-09 02:00:00+02:00 | pubmed | MedComm | Yu Liu;Guangying Qi;Joseph A Bellanti;René Moser;Bernhard Ryffel;Song Guo Zheng | 2019 novel coronavirus;SRAS‐CoV‐2;Tregs;pathology;pneumonia | 2020-08-06 02:00:00+02:00 | 32838397 | FR;CN;CH;US | Department of Clinical Immunology Sun Yat-sen University Third Affiliated Hospital Guangzhou P. R. China.;Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation Guilin Medical University Guilin P. R. China.;Department of Pediatrics and Microbiology-Immunology Georgetown University Medical Center Washington District of Columbia.;Institute for Biopharmaceutical Research Matzingen Switzerland.;Experimental and Molecular Immunology and Neurogenetics (INEM) UMR 7355 INEM CNRS-University of Orleans Orleans France.;Department of Internal Medicine Ohio State University College of Medicine and Wexner Medical Center, Medical Center Columbus Ohio. | 2042 | |||
| 10.1136/bmjmilitary-2020-001520 | Journal Article | en | Critical COVID-19 patient evacuation on an amphibious assault ship: feasibility and safety. A case series. | https://www.ncbi.nlm.nih.gov/pubmed/32764134 | An amphibious assault ship was deployed on 22 March in Corsica to carry out medical evacuation of 12 critical patients infected with COVID-19. The ship has on-board hospital capacity and is the first time that an amphibious assault ship is engaged in this particular condition. The aim is to evaluate the feasibility and safety of prolonged medical evacuation of critical patients with COVID-19. | 2633-3767,2633-3775 | 2020-08-09 02:00:00+02:00 | pubmed | BMJ Military Health | Cédric Nguyen;A Montcriol;F Janvier;P-J Cungi;P Esnault;Q Mathais;C Vallet;S Boussen;P-Y Cordier;L Serpin;L Papazian;J Bordes | health & safety;intensive & critical care;public health;quality in health care;respiratory infections | 2020-08-06 02:00:00+02:00 | 32764134 | FR | Anesthesiology and Intensive Care, HIA Sainte Anne, Toulon Armees, France ced040@hotmail.fr.;Anesthesiology and Intensive Care, HIA Sainte Anne, Toulon Armees, France.;French Navy, Toulon, France.;APHM, Marseille, Provence-Alpes-Côte d'Azur, France.;Anesthesiology and Intensive Care, HIA LAVERAN, Marseille, France.;Emergency, Hospital Centre Ajaccio, Ajaccio, France. | 2044 | |||
| 10.1371/journal.pntd.0008476 | Case Reports;Journal Article | en | Co-infection of dengue and COVID-19: A case report. | https://www.ncbi.nlm.nih.gov/pubmed/32745101 | 1935-2735 | 2020-08-09 02:00:00+02:00 | pubmed | Adolescent;Coinfection__diagnosis;Coronavirus Infections__diagnosis;Dengue__diagnosis;Exanthema__pathology;Humans;Male;Pandemics;Pneumonia, Viral__diagnosis;Reunion;COVID-19 | PLOS Neglected Tropical Diseases | Morgane Verduyn;Nathalie Allou;Virgile Gazaille;Michel Andre;Tannvir Desroche;Marie-Christine Jaffar;Nicolas Traversier;Cecile Levin;Marie Lagrange-Xelot;Marie-Pierre Moiton;Stella Hoang | 2020-08-03 02:00:00+02:00 | 32745101 | FR | Department of Respiratory Medicine, University Hospital Centre of Réunion, Saint-Denis, France.;Department of Dermatology, University Hospital Centre of Réunion, Saint-Denis, France.;Department of Microbiology, University Hospital Centre of Réunion, Saint-Denis, France.;Department of Infectious Diseases, University Hospital Centre of Réunion, Saint-Pierre, France. | 2053 | ||||
| 10.1016/j.enfi.2020.07.001 | Editorial | en | What has happened to care during the COVID-19 pandemic? | https://www.ncbi.nlm.nih.gov/pubmed/32739041 | 1130-2399 | 2020-08-09 02:00:00+02:00 | pubmed | Coronavirus Infections__therapy;Critical Care__standards;Critical Care Nursing__standards;Humans;Pandemics;Pneumonia, Viral__therapy;Spain;COVID-19 | Enfermería Intensiva | J I Torres-González;S Arias-Rivera;T Velasco-Sanz;Dávila A Mateos;Pascual B Planas;I Zaragoza-García;M Raurell-Torredà | 2020-08-03 02:00:00+02:00 | 32739041 | FR;ES;PS;UNK | Oficina Regional de Coordinación de Trasplantes. Servicio Madrileño de Salud. En nombre del Grupo de Trabajo ECMO de la Sociedad Española de Enfermería Intensiva y Unidades Coronarias (SEEIUC).;Hospital Universitario de Getafe. En nombre del Grupo de Trabajo Analgesia, Sedación, Delirio y Contenciones (ASCyD) de SEEIUC.;Hospital Clínico San Carlos. En nombre del Grupo de Trabajo Bioética de SEEIUC.;Hospital Universitari Sant Pau i Santa Creu. En nombre del Grupo de Trabajo Terapias Extracorpóreas de SEEIUC.;Hospital Universitari Vall Hebrón. En nombre del Grupo de Trabajo Rehabilitación Precoz de SEEIUC.;Facultad de Enfermería, Fisioterapia y Podología de la Universidad Complutense de Madrid. En nombre del GT Grupo de Trabajo de Simulación de SEEIUC.;Escuela de Enfermería de la Universidad de Barcelona. Presidenta SEEIUC. Electronic address: mraurell@ub.edu. | 2061 | ||||
| 10.26355/eurrev_202007_22293 | Journal Article | en | SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential. | https://www.ncbi.nlm.nih.gov/pubmed/32744716 | The coronavirus SARS-CoV-2 at the origin of COVID-19 shares more than 70% genetic similarity with SARS-CoV-1 that was at the origin of 2003 SARS. Infection-associated symptoms are very similar between SARS and COVID-19 diseases and are the same as community-acquired pneumonia symptoms. Antibiotics were empirically given to SARS patients in the early stages of the pathology whereas a different strategy has been decided in the management of COVID-19 pandemic with a worldwide shutdown. The cytokine storm, both identified in SARS and COVID-19 severe cases, is generated through inflammasome activation, which opens therapeutic perspectives to counteract the pathogenic inflammation. As corticoids have numerous side effects that limit their use, focusing on anti-inflammasome agents could represent a safer alternative for patients with severe COVID-19. | 2020-08-09 02:00:00+02:00 | pubmed | Adrenal Cortex Hormones__therapeutic use;Anti-Bacterial Agents__therapeutic use;Betacoronavirus__isolation & purification;Coronavirus Infections__drug therapy;Humans;Inflammasomes__chemistry;Pandemics;Pneumonia, Viral__drug therapy;Purinergic P2X Receptor Antagonists__therapeutic use;Receptors, Purinergic P2X7__chemistry;SARS Virus__isolation & purification;Severe Acute Respiratory Syndrome__drug therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | P Rat;E Olivier;M Dutot | 2020-08-04 02:00:00+02:00 | 32744716 | FR | UMR CNRS 8038 CiTCoM, Chimie Toxicologie Analytique et Cellulaire, Université de Paris, Faculté de Pharmacie, Paris, France. melody.dutot@yslab.fr. | 2063 | |||||
| 10.3390/children7080087 | Case Reports | en | Neonatal COVID-19 Pneumonia: Report of the First Case in a Preterm Neonate in Mayotte, an Overseas Department of France. | https://www.ncbi.nlm.nih.gov/pubmed/32756337 | We report the first case of COVID-19 pneumonia in a preterm neonate in Mayotte, an overseas department of France. The newborn developed an acute respiratory distress by 14 days of life with bilateral ground glass opacities on a chest CT scan and a 6-week-long stay in the neonatal intensive care unit (NICU). This case report emphasizes the need for a cautious and close follow-up period for asymptomatic neonates born to mothers with COVID-19 infection. Vertical transmission cannot be excluded in this case. | 2227-9067 | 2020-08-09 02:00:00+02:00 | pubmed | Children | Soumeth Abasse;Laila Essabar;Tereza Costin;Voninavoko Mahisatra;Mohamed Kaci;Axelle Braconnier;Roger Serhal;Louis Collet;Abdallah Fayssoil | COVID-19;length of stay;pneumonia;preterm neonate;vertical transmission | 2020-08-03 02:00:00+02:00 | 32756337 | FR;YT | Mayotte Hospital, Mayotte Island, 97600 Mamoudzou, France.;Raymond Poincaré Hospital, APHP, 92380 Garches, France. | 2064 | |||
| 10.1007/s10640-020-00464-7 | Journal Article | en | Green Stimulus in a Post-pandemic Recovery: the Role of Skills for a Resilient Recovery. | https://www.ncbi.nlm.nih.gov/pubmed/32836847 | As nations struggle to restart their economy after COVID-19 lockdowns, calls to include green investments in a pandemic-related stimulus are growing. Yet little research provides evidence of the effectiveness of a green stimulus. We begin by summarizing recent research on the effectiveness of the green portion of the 2009 American Recovery and Reinvestment Act on employment growth. Green investments are most effective in communities whose workers have the appropriate "green" skills. We then provide new evidence on the skills requirements of both green and brown occupations, as well as from occupations at risk of job losses due to COVID-19, to illustrate which workers are most likely to benefit from a pandemic-related green stimulus. We find similarities between some energy sector workers and green jobs, but a poor match between green jobs and occupations at risk due to COVID-19. Finally, we provide suggestive evidence on the potential for job training programs to help ease the transition to a green economy. | 0924-6460,1573-1502 | 2020-08-09 02:00:00+02:00 | pubmed | Environmental and Resource Economics | Ziqiao Chen;Giovanni Marin;David Popp;Francesco Vona | American Recovery and Reinvestment Act;Distributional impacts;Green stimulus;Green subsides;Heterogeneous effect | 2020-08-04 02:00:00+02:00 | 32836847 | FR;IT;GB;US | Syracuse University, New York, USA.;University of Urbino Carlo Bo, Urbino, Italy.;SEEDS, Urbino, Italy.;NBER, Cambridge, USA.;OFCE Sciences-Po, Paris, France.;SKEMA Business School, Université Côte d'Azur, Valbonne, France.;CMCC, Ca' Foscari, Venice, Italy. | 2074 | |||
| 10.1016/j.jhepr.2020.100169 | Journal Article;Review | en | Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32835190 | During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. While some healthcare systems are returning to a more normal routine, many countries and healthcare systems have been, or still are, overwhelmed by the pandemic, which is significantly impacting on the care of these patients. In addition, many studies have been published focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence the clinical course of COVID-19. While many aspects remain poorly understood, it has become increasingly evident that pre-existing liver diseases and liver injury during the disease course must be kept in mind when caring for patients with COVID-19. This review should serve as an update on the previous position paper, summarising the evidence for liver disease involvement during COVID-19 and providing recommendations on how to return to routine care wherever possible. | 2589-5559 | 2020-08-09 02:00:00+02:00 | pubmed | JHEP Reports | Tobias Boettler;Thomas Marjot;Philip N Newsome;Mario U Mondelli;Mojca Maticic;Elisa Cordero;Rajiv Jalan;Richard Moreau;Markus Cornberg;Thomas Berg | ACE2, angiotensin-converting enzyme 2;ACLF, acute-on-chronic liver failure;COVID-19;COVID-19, coronavirus disease 2019;Cancer;Cirrhosis;ERC, endoscopic retrograde cholangiography;HCC, hepatocellular carcinoma;IL-6, interleukin-6;LT, liver transplant;Liver;MELD, model for end-stage liver disease;NAFLD;NAFLD, non-alcoholic fatty liver disease;NASH, non-alcoholic steatohepatitis;OGD, oesophagogastroduodenoscopy;SARS-CoV-2, severe acute respiratory syndrome coronavirus 2;Telemedicine;Transplantation;ULN, upper limit of normal | 2020-08-04 02:00:00+02:00 | 32835190 | FR;SI;GB;IT;ES;DE | Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.;Oxford Liver Unit, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, University of Oxford, UK.;National Institute for Health Research, Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.;Centre for Liver & Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.;Division of Infectious Diseases and Immunology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.;Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Slovenia.;Faculty of Medicine, University of Ljubljana, Slovenia.;Department of Medicine, University of Seville, Clinical Unit of Infectious Diseases University Hospital Virgen del Rocio, Institute of Biomedicine, Sevilla, CSIC, Spain.;Liver Failure Group, Institute for Liver and Digestive Health, University College London, London, UK.;Inserm, Université de Paris, U1149, Centre de Recherche sur l'Inflammation (CRI), UMRS1149, Paris, France.;Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France.;Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;Centre for Individualised Infection Medicine (CIIM), Hannover, Germany.;Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany. | 2078 | |||
| 10.1007/s12192-020-01148-3 | Journal Article | en | Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32754823 | Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), the cause of COVID-19 disease, has the potential to elicit autoimmunity because mimicry of human molecular chaperones by viral proteins. We compared viral proteins with human molecular chaperones, many of which are heat shock proteins, to determine if they share amino acid-sequence segments with immunogenic-antigenic potential, which can elicit cross-reactive antibodies and effector immune cells with the capacity to damage-destroy human cells by a mechanism of autoimmunity. We identified the chaperones that can putatively participate in molecular mimicry phenomena after SARS-CoV-2 infection, focusing on those for which endothelial cell plasma-cell membrane localization has already been demonstrated. We also postulate that post-translational modifications, induced by physical (shear) and chemical (metabolic) stress caused respectively by the risk factors hypertension and diabetes, might have a role in determining plasma-cell membrane localization and, in turn, autoimmune-induced endothelial damage. | 1355-8145,1466-1268 | 2020-08-09 02:00:00+02:00 | pubmed | Cell Stress and Chaperones | Antonella Marino Gammazza;Sébastien Légaré;Giosuè Lo Bosco;Alberto Fucarino;Francesca Angileri;Everly Conway de Macario;Alberto Jl Macario;Francesco Cappello | Autoimmunity;COVID-19;Endothelialitis;Molecular chaperones;Molecular mimicry;Severe acute respiratory syndrome coronavirus 2 | 2020-08-04 02:00:00+02:00 | 32754823 | FR;IT;US | Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, Palermo, Italy.;Département d'Informatique de l'ÉNS, ÉNS, CNRS, Université PSL, Paris, France.;Centre de Recherche Inria de Paris, Paris, France.;Department of Mathematics and Computer Science, University of Palermo, Palermo, Italy.;Centre Léon Bérard, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.;Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore-Institute of Marine and Environmental Technology (IMET), Baltimore, MD, 21202, USA.;Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy.;Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, Palermo, Italy. francesco.cappello@unipa.it.;Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy. francesco.cappello@unipa.it. | 2079 | |||
| 10.1007/s00405-020-06267-2 | Journal Article | en | Psychophysical evaluation of chemosensory functions 5 weeks after olfactory loss due to COVID-19: a prospective cohort study on 72 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32754871 | To evaluate the evolution of chemosensation via extended psychophysical testing in patients who suffered from sudden chemosensory loss due to coronavirus disease 2019 (COVID-19). Additionally, this study sought to determine whether odor threshold testing provided additional information on olfactory loss due to COVID-19 compared to the more common odor identification testing. | 0937-4477,1434-4726 | 2020-08-09 02:00:00+02:00 | pubmed | European Archives of Oto-Rhino-Laryngology | Serge-Daniel Le Bon;Nathalie Pisarski;Justine Verbeke;Léa Prunier;Gaëtan Cavelier;Marie-Paule Thill;Alexandra Rodriguez;Didier Dequanter;Jérôme R Lechien;Olivier Le Bon;Thomas Hummel;Mihaela Horoi | COVID-19;Chemosensory loss;Psychophysical test;SARS-CoV-2 | 2020-08-04 02:00:00+02:00 | 32754871 | FR;BE;DE | Department of Otorhinolaryngology, CHU Saint-Pierre, 129 Boulevard de Waterloo, 1000, Brussels, Belgium. sergelebon@gmail.com.;Department of Otorhinolaryngology, CHU Saint-Pierre, 129 Boulevard de Waterloo, 1000, Brussels, Belgium.;Department of Psychiatry and Laboratory of Psychiatric Research (ULB 266), Cliniques universitaires de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium.;Smell and Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Dresden, Germany. | 2080 | |||
| 10.1093/cvr/cvaa230 | Journal Article | en | Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. | https://www.ncbi.nlm.nih.gov/pubmed/32750108 | The COVID-19 pandemic is an unprecedented healthcare emergency causing mortality and illness across the world. Although primarily affecting the lungs, the SARS-CoV-2 virus also affects the cardiovascular system. In addition to cardiac effects, e.g. myocarditis, arrhythmias, and myocardial damage, the vasculature is affected in COVID-19, both directly by the SARS-CoV-2 virus, and indirectly as a result of a systemic inflammatory cytokine storm. This includes the role of the vascular endothelium in the recruitment of inflammatory leucocytes where they contribute to tissue damage and cytokine release, which are key drivers of acute respiratory distress syndrome (ARDS), in disseminated intravascular coagulation, and cardiovascular complications in COVID-19. There is also evidence linking endothelial cells (ECs) to SARS-CoV-2 infection including: (i) the expression and function of its receptor angiotensin-converting enzyme 2 (ACE2) in the vasculature; (ii) the prevalence of a Kawasaki disease-like syndrome (vasculitis) in COVID-19; and (iii) evidence of EC infection with SARS-CoV-2 in patients with fatal COVID-19. Here, the Working Group on Atherosclerosis and Vascular Biology together with the Council of Basic Cardiovascular Science of the European Society of Cardiology provide a Position Statement on the importance of the endothelium in the underlying pathophysiology behind the clinical presentation in COVID-19 and identify key questions for future research to address. We propose that endothelial biomarkers and tests of function (e.g. flow-mediated dilatation) should be evaluated for their usefulness in the risk stratification of COVID-19 patients. A better understanding of the effects of SARS-CoV-2 on endothelial biology in both the micro- and macrovasculature is required, and endothelial function testing should be considered in the follow-up of convalescent COVID-19 patients for early detection of long-term cardiovascular complications. | 0008-6363,1755-3245 | 2020-08-09 02:00:00+02:00 | pubmed | Cardiovascular Research | Paul C Evans;G Ed Rainger;Justin C Mason;Tomasz J Guzik;Elena Osto;Zania Stamataki;Desley Neil;Imo E Hoefer;Maria Fragiadaki;Johannes Waltenberger;Christian Weber;Marie-Luce Bochaton-Piallat;Magnus Bäck | 2020-08-04 02:00:00+02:00 | 32750108 | FR;SE;CH;GB;PL;NL;DE | Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK and Insigneo Institute for In Silico Medicine, Sheffield, UK.;Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Vascular Science, National Heart and Lung Institute, Imperial College London and Rheumatology Department, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.;Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK and Department of Medicine, Jagiellonian University Collegium Medicum, Cracow, Poland.;University and University Hospital Zurich, Institute of Clinical Chemistry and University Heart Center, Zurich, Switzerland, Swiss Federal Institute of Technology, Laboratory of Translational Nutrition Biology, Zurich, Switzerland.;Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Central Diagnostic Laboratory, University Medical Centre Utrecht, The Netherlands.;Department of Cardiovascular Medicine, Medical Faculty, University of Münster, Münster, Germany and SRH Central Hospital Suhl, Suhl, Germany.;Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximillian-Universität (LMU) München and German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany, Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.;Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Center for Molecular Medicine and Department of Cardiology, Karolinska University Hospital, Solna, Stockholm, Sweden and INSERM U1116, Université de Lorraine, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre les Nancy, France. | 2081 | ||||
| 10.1016/j.amcp.2020.08.001 | Editorial | fr | [The heart and COVID-19: A first update]. | https://www.ncbi.nlm.nih.gov/pubmed/32837204 | 1261-694X | 2020-08-09 02:00:00+02:00 | pubmed | Archives des Maladies du Coeur et des Vaisseaux - Pratique | R Isnard | 2020-08-07 02:00:00+02:00 | 32837204 | FR | DMU ARCHIMEDE, département de cardiologie, Sorbonne université, hôpital de la Pitié-Salpêtrière, AP-HP, 47, boulevard de l'Hôpital, 75013 Paris, France. | 2088 | |||||
| 10.1016/j.ejrad.2020.109209 | Journal Article | en | COVID-19 pneumonia: Diagnostic and prognostic role of CT based on a retrospective analysis of 214 consecutive patients from Paris, France. | https://www.ncbi.nlm.nih.gov/pubmed/32810701 | To evaluate the diagnostic and prognostic performance of CT in patients referred for COVID19 suspicion to a French university hospital, depending on symptoms and date of onset. | 0720-048X | 2020-08-09 02:00:00+02:00 | pubmed | European Journal of Radiology | Enora Guillo;Ines Bedmar Gomez;Severine Dangeard;Souhail Bennani;Ines Saab;Mickael Tordjman;Lea Jilet;Guillaume Chassagnon;Marie-Pierre Revel | COVID;Diagnostic tests;Multidetector computed tomography;Prognosis;Routine | 2020-08-08 02:00:00+02:00 | 32810701 | FR | Department of Radiology, Cochin Hospital, AP-HP. Centre, 75014, Paris, France.;Department of Radiology, Cochin Hospital, AP-HP. Centre, 75014, Paris, France, Université de Paris, Descartes-Paris 5, 75006, Paris, France.;Unité de Recherche Clinique Centre d'Investigation Clinique, Paris Descartes Necker/Cochin, Hôpital Tarnier, 75014, Paris, France.;Department of Radiology, Cochin Hospital, AP-HP. Centre, 75014, Paris, France, Université de Paris, Descartes-Paris 5, 75006, Paris, France. Electronic address: marie-pierre.revel@aphp.fr. | 2094 | |||
| 10.1093/cid/ciaa1172 | Journal Article | en | Alveolar SARS-CoV-2 viral load is tightly correlated with severity in COVID-19 ARDS. | https://www.ncbi.nlm.nih.gov/pubmed/32770223 | 1058-4838,1537-6591 | 2020-08-09 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Mathieu Blot;Marine Jacquier;Catherine Manoha;Lionel Piroth;Pierre-Emmanuel Charles | 2020-08-08 02:00:00+02:00 | 32770223 | FR | Infectious Diseases Department, Dijon Bourgogne University Hospital, Univ. Bourgogne Franche-Comté, LNC UMR1231, F-21000, Dijon, France , INSERM, LNC UMR 1231, F-21000, Dijon, France , FCS Bourgogne-Franche Comté, LipSTIC LabEx, F-21000, Dijon, France.;Department of Intensive Care, Dijon Bourgogne University Hospital, Univ. Bourgogne Franche-Comté, LNC UMR1231, F-21000, Dijon, France , INSERM, LNC UMR 1231, F-21000, Dijon, France , FCS Bourgogne-Franche Comté, LipSTIC LabEx, F-21000, Dijon, France.;Laboratory of virology, Dijon Bourgogne University Hospital, Dijon, France. | 2096 | |||||
| 10.1016/j.accpm.2020.08.001 | Journal Article | en | Haemodynamic Monitoring and Management in COVID-19 Intensive Care Patients: An International Survey. | https://www.ncbi.nlm.nih.gov/pubmed/32781167 | To survey haemodynamic monitoring and management practices in ICU patients with the coronavirus disease 2019 (COVID-19). | 2352-5568 | 2020-08-09 02:00:00+02:00 | pubmed | Anaesthesia Critical Care & Pain Medicine | Frédéric Michard;Manu Lng Malbrain;Greg S Martin;Thierry Fumeaux;Suzana Lobo;Filipe Gonzalez;Vitor Pinho-Oliveira;Jean-Michel Constantin | COVID-19;acute circulatory failure;echocardiography;haemodynamics;shock | 2020-08-08 02:00:00+02:00 | 32781167 | FR;PT;CH;US;BR;BE | MiCo, Denens, Switzerland. Electronic address: frederic.michard@bluewin.ch.;Intensive Care Unit, University Hospital Brussel, Jette, Belgium & Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.;Emory University and Grady Memorial Hospital, Atlanta, USA.;Intensive Care Unit, Nyon hospital, Nyon, Switzerland.;Intensive Care Division, Hospital de Base - FAMERP, Sao Jose do Rio Preto, SP, Brazil.;Intensive Care Department, Hospital Garcia de Orta, Almada, Portugal.;Department of Anesthesia, Hospital CUF Viseu, Viseu, Portugal.;Department of Anesthesia & Critical Care, La Pitié Salpetriere Hospital, University Paris-Sorbonne, Paris, France. | 2097 | |||
| 10.1007/s41742-020-00276-z | Journal Article;Review | en | Role of Damage-Associated Molecular Patterns in Light of Modern Environmental Research: A Tautological Approach. | https://www.ncbi.nlm.nih.gov/pubmed/32837525 | Two prominent models emerged as a result of intense interdisciplinary discussions on the environmental health paradigm, called the "exposome" concept and the "adverse outcome pathway" (AOP) concept that links a molecular initiating event to the adverse outcome via key events. Here, evidence is discussed, suggesting that environmental stress/injury-induced damage-associated molecular patterns (DAMPs) may operate as an essential integrating element of both environmental health research paradigms. DAMP-promoted controlled/uncontrolled innate/adaptive immune responses reflect the key events of the AOP concept. The whole process starting from exposure to a distinct environmental stress/injury-associated with the presence/emission of DAMPs-up to the manifestation of a disease may be regarded as an exposome. Clinical examples of such a scenario are briefly sketched, in particular, a model in relation to the emerging COVID-19 pandemic, where the interaction of noninfectious environmental factors (e.g., particulate matter) and infectious factors (SARS CoV-2) may promote SARS case fatality via superimposition of both exogenous and endogenous DAMPs. | 1735-6865,2008-2304 | 2020-08-09 02:00:00+02:00 | pubmed | International Journal of Environmental Research | Walter Gottlieb Land | Adverse outcome pathway;COVID-19;DAMPs;Exposome;Innate immunity | 2020-08-09 02:00:00+02:00 | 32837525 | FR;DE | German Academy for Transplantation Medicine, Munich, Germany.;Molecular ImmunoRheumatology, Laboratory of Excellence Transplantex, Faculty of Medicine, INSERM UMR_S1109, University of Strasbourg, Strasbourg, France. | 2100 | |||
| Letter | en | Response to Letter: "Reply to 'High frequency of Antiphospholipid Antibodies in Critically-ill COVID19 patients: a Link with Hypercoagulability?'". | https://www.ncbi.nlm.nih.gov/pubmed/32772406 | We read with great interest the comment by Suarez-Perez et al. on our article.[1] We share their concerns regarding the need for a cautious interpretation of antiphospholipid antibodies (aPLA) positivity in patients with coronary virus disease 2019 (COVID-19). Herein, we would like to add further insights in the discussion. | 2020-08-09 02:00:00+02:00 | pubmed | Marc Pineton de Chambrun;Corinne Frere;Makoto Miyara;Zahir Amoura;Isabelle Martin-Toutain;Alexis Mathian;Guillaume Hekimian;Alain Combes | COVID-19;SARS-CoV-2;antiphospholipid antibody;thrombosis | 2020-08-09 02:00:00+02:00 | 32772406 | FR | Sorbonne Université, INSERM, Institute of Cardiometabolism and Nutrition (ICAN), UMRS_1166-ICAN, F-75013, PARIS, France.;Service de Médecine Intensive-réanimation, Institut de Cardiologie, Assistance Publique Hôpitaux de Paris (APHP), Hôpital La Pitié- Salpêtrière, F-75013, PARIS, France.;Service de Médecine Interne 2, Centre de Référence de Maladie Rare Lupus Systémique et Syndrome des Anticorps Antiphospholipides, Institut E3M, APHP, Hôpital La Pitié- Salpêtrière, F-75013, PARIS, France.;Service d'Hématologie Biologique, APHP, Hôpital La Pitié-Salpêtrière, F-75013, PARIS, France.;Laboratoire d'Immunochimie, APHP, Hôpital La Pitié-Salpêtrière, F-75013, PARIS, France. | 2103 | ||||||
| 10.1093/jac/dkaa326 | Journal Article | en | Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey. | https://www.ncbi.nlm.nih.gov/pubmed/32766706 | Antibiotics may be indicated in patients with COVID-19 due to suspected or confirmed bacterial superinfection. | 0305-7453,1460-2091 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Antimicrobial Chemotherapy | Bojana Beović;May Doušak;João Ferreira-Coimbra;Kristina Nadrah;Francesca Rubulotta;Mirko Belliato;Joana Berger-Estilita;Folusakin Ayoade;Jordi Rello;Hakan Erdem | 2020-08-07 02:00:00+02:00 | 32766706 | FR;SI;PT;GB;CH;US;IT;TR;ES;PS | University Medical Centre Ljubljana, Ljubljana, Slovenia.;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;Faculty of Social Sciences, University of Ljubljana, Ljubljana, Slovenia.;Department of Internal Medicine, Centro Hospitalar Universitário do Porto, Porto, Portugal.;Department of Intensive Care Medicine, Charing Cross Hospital, Imperial College NHS Trust, London, UK.;UOC Anestesia e Rianimazone 1, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.;Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.;Division of Infectious Diseases, Department of Medicine, University of Miami, Miami, FL, USA.;Department of Anaesthesia Critical Care Emergency and Pain Medicine, University Hospital of Nimes, Montpellier University, Nimes, France.;CIBERES, Vall d'Hebron Institut of Research, Barcelona, Spain.;Centro Biomedico de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.;ID-IRI, Ankara, Turkey. | 2106 | ||||
| 10.1016/s2665-9913(20)30273-3 | Journal Article | en | Anakinra for severe forms of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32838320 | 2665-9913 | 2020-08-09 02:00:00+02:00 | pubmed | The Lancet Rheumatology | Naim Akhtar Khan | 2020-08-07 02:00:00+02:00 | 32838320 | FR | INSERM U1231 UB/AroSup, Physiologie de la Nutrition & Toxicologie, Université de Bourgogne-Franche Comté, Dijon 21000, France. | 2108 | |||||
| 10.1016/j.cgh.2020.08.003 | Journal Article;Review | en | Systematic review on IBD patients with COVID-19: it is time to take stock. | https://www.ncbi.nlm.nih.gov/pubmed/32777550 | Clinical characteristics' data of patients with inflammatory bowel diseases (IBD) with COVID-19 are scarce. Aim of our systematic review was to investigate symptoms and diagnostic-therapeutic management of IBD patients with COVID-19. | 1542-3565 | 2020-08-09 02:00:00+02:00 | pubmed | Clinical Gastroenterology and Hepatology | Ferdinando D'Amico;Silvio Danese;Laurent Peyrin-Biroulet | COVID-19;Crohn’s disease;SARS-CoV-2;inflammatory bowel disease;ulcerative colitis | 2020-08-07 02:00:00+02:00 | 32777550 | FR;IT | Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy, Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy, IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center - IRCCS, Rozzano Milan, Italy.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com. | 2113 | |||
| 10.1093/ecco-jcc/jjaa138 | Journal Article | en | Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32766822 | 1873-9946,1876-4479 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Crohn's and Colitis | Walter Reinisch;Silvio Danese;Laurent Peyrin-Biroulet;Edward V Loftus | 2020-08-07 02:00:00+02:00 | 32766822 | FR;IT;US;AT | Department of Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.;Inflammatory Bowel Disease Center, Humanitas University, IRCCS Humanitas Research Hospital, Milano, Italy.;Inserm NGERE U1256 and Department of Gastroenterology, Nancy University Hospital, Lorraine University, France.;Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. | 2122 | |||||
| Letter | en | Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains. | https://www.ncbi.nlm.nih.gov/pubmed/32790069 | We read with great interest the report of Le Cleach et al discussing chilblains as a manifestation of COVID-19 pandemic. They reported 311 patients with acral lesions occurring during the COVID-19 lockdown in France. The most frequent clinical presentation of these acral lesions was typical chilblains. Among the 150 patients with RT-PCR testing and/or serology, only 10 had confirmed COVID-19. They concluded that there is no evidence of SARS-CoV-2 infection in the large majority of patients with acral lesions. They hypothesized that the situation could be due to the media stating that chilblains were caused by SARS-CoV-2 infection and leading to a higher rate of consultation or the lockdown leading to more inactivity and long periods at home barefoot on a cold floor1 . | 2020-08-16 02:00:00+02:00 | pubmed | G Battesti;V Descamps | 2020-08-13 02:00:00+02:00 | 32790069 | FR | Departments of Pathology, Bichat Hospital AP-HP, 46 rue Henri Huchard, 75018, Paris.;Departments of Dermatology, Bichat Hospital AP-HP, 46 rue Henri Huchard, 75018, Paris. | 2130 | |||||||
| Letter | en | Kidney transplantation during the COVID-19 pandemic: Potential long-term consequences of an early post-transplant infection. | https://www.ncbi.nlm.nih.gov/pubmed/32790932 | Recently, Akalin et al.1 reported a 28% mortality among kidney-transplant patients infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Two of the 10 patients who died had been transplanted within the previous 5 weeks. During the coronavirus disease (COVID)-19 outbreak, kidney transplant programs were suspended in several countries2 . Although the pandemic is still ongoing, the stop of lockdown has prompted several transplant centers to restart kidney transplantation programs. It is recommended to consider that donors and recipients are screened for SARS-CoV-2 before transplantation by means of nuclear acid tests with or without chest CT scans. | 2020-08-16 02:00:00+02:00 | pubmed | Arnaud Del Bello;Olivier Marion;Federico Sallusto;Audrey Delas;Laure Esposito;Nicolas Doumerc;Nassim Kamar | COVID-19;living-donor kidney transplantation;nosocomial transmission;organ transplantation;safety | 2020-08-13 02:00:00+02:00 | 32790932 | FR | Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.;INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.;Université Paul Sabatier, Toulouse, France.;Department of Surgery and Kidney Transplantation, CHU Rangueil, Toulouse, France.;Department of Pathology, Institut Universitaire du Cancer, Toulouse, France. | 2131 | ||||||
| Wellcome Trust;Cancer Research UK;Medical Research Council | 10.1242/jcs.249607 | Journal Article;Review;Research Support, Non-U.S. Gov't | en | Science during lockdown - from virtual seminars to sustainable online communities. | https://www.ncbi.nlm.nih.gov/pubmed/32801132 | The COVID-19 pandemic has disrupted traditional modes of scientific communication. In-person conferences and seminars have been cancelled and most scientists around the world have been confined to their homes. Although challenging, this situation has presented an opportunity to adopt new ways to communicate science and build scientific relationships within a digital environment, thereby reducing the environmental impact and increasing the inclusivity of scientific events. As a group of researchers who have recently created online seminar series for our respective research communities, we have come together to share our experiences and insights. Only a few weeks into this process, and often learning 'on the job', we have collectively encountered different problems and solutions. Here, we share our advice on formats and tools, security concerns, spreading the word to your community and creating a diverse, inclusive and collegial space online. We hope our experience will help others launch their own online initiatives, helping to shape the future of scientific communication as we move past the current crisis. | 0021-9533,1477-9137 | 2020-08-16 02:00:00+02:00 | pubmed | Journal of Cell Science | Francesca Bottanelli;Bruno Cadot;Felix Campelo;Scott Curran;Patricia M Davidson;Gautam Dey;Ishier Raote;Anne Straube;Matthew P Swaffer | 2020-08-14 02:00:00+02:00 | 32801132 | FR;GB;US;ES;DE | [{"country": "United Kingdom", "agency": "Wellcome Trust"}, {"country": "United Kingdom", "agency": "Cancer Research UK"}, {"country": "United Kingdom", "agency": "Medical Research Council"}] | Institute of Chemistry and Biochemistry, Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Thielallee 63, Berlin 14195, Germany.;Institut de Myologie, INSERM UMR974, Sorbonne Université, Paris 75013, France.;ICFO-Institut de Ciencies Fotoniques, The Barcelona Institute of Science and Technology, Barcelona 08860, Spain.;The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK.;MRC Lab for Molecular Cell Biology, UCL, Gower Street, London WC1E 6BT, UK g.dey@ucl.ac.uk.;Centre for Genonmic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr Aiguader 88, Barcelona 08003, Spain.;Universitat Pompeu Fabra (UPF), Barcelona 08003, Spain.;Centre for Mechanochemical Cell Biology & Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.;Department of Biology, Stanford University, Stanford CA 94305, USA. | 2139 | ||
| 10.1371/journal.pntd.0008426 | Journal Article | en | Simultaneous dengue and COVID-19 epidemics: Difficult days ahead? | https://www.ncbi.nlm.nih.gov/pubmed/32797035 | 1935-2735 | 2020-08-16 02:00:00+02:00 | pubmed | PLOS Neglected Tropical Diseases | Mathieu Nacher;Maylis Douine;Mélanie Gaillet;Claude Flamand;Dominique Rousset;Cyril Rousseau;Chedli Mahdaoui;Stanley Carroll;Audrey Valdes;Nathalie Passard;Gabriel Carles;Félix Djossou;Magalie Demar;Loïc Epelboin | 2020-08-14 02:00:00+02:00 | 32797035 | FR | Centre d'Investigation Clinique Antilles Guyane, CIC INSERM 1424, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana.;DFR Santé, Université de Guyane, Cayenne, French Guiana.;Centres Délocalisés de Prévention et de Soins, Centre Hospitalier de Cayenne, Cayenne, French Guiana.;Unité d'épidémiologie, Institut Pasteur de la Guyane, Cayenne, French Guiana.;Centre National de Référence Arbovirus et virus respiratoires, Institut Pasteur de la Guyane, Cayenne, French Guiana.;Santé Publique France, CIRE Antilles Guyane, Cayenne, French Guiana.;Maison de Garde, Centre Hospitalier de Cayenne, Cayenne, French Guiana.;Réseau de médecins sentinelles, Cayenne, French Guiana.;Hygiène, Centre Hospitalier de Cayenne, Cayenne, French Guiana.;CPIAS, Centre Hospitalier de Cayenne, Cayenne, French Guiana.;Service d'obstétrique, centre hospitalier de l'Ouest Guyanais, French Guiana.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier de Cayenne, Cayenne, French Guiana.;Laboratoire, Centre Hospitalier de Cayenne, Cayenne, French Guiana.;TBIP, Université de Guyane, Cayenne, French Guiana. | 2142 | |||||
| 10.3390/biology9080226 | Journal Article | en | Inverted Covariate Effects for First versus Mutated Second Wave Covid-19: High Temperature Spread Biased for Young. | https://www.ncbi.nlm.nih.gov/pubmed/32823981 | (1) Background: Here, we characterize COVID-19's waves, following a study presenting negative associations between first wave COVID-19 spread parameters and temperature. (2) Methods: Visual examinations of daily increases in confirmed COVID-19 cases in 124 countries, determined first and second waves in 28 countries. (3) Results: The first wave spread rate increases with country mean elevation, median population age, time since wave onset, and decreases with temperature. Spread rates decrease above 1000 m, indicating high ultraviolet lights (UVs) decrease the spread rate. The second wave associations are the opposite, i.e., spread increases with temperature and young age, and decreases with time since wave onset. The earliest second waves started 5-7 April at mutagenic high elevations (Armenia, Algeria). The second waves also occurred at the warm-to-cold season transition (Argentina, Chile). Second vs. first wave spread decreases in most (77%) countries. In countries with late first wave onset, spread rates better fit second than first wave-temperature patterns. In countries with ageing populations (for example, Japan, Sweden, and Ukraine), second waves only adapted to spread at higher temperatures, not to infect the young. (4) Conclusions: First wave viruses evolved towards lower spread. Second wave mutant COVID-19 strain(s) adapted to higher temperature, infecting younger ages and replacing (also in cold conditions) first wave COVID-19 strains. Counterintuitively, low spread strains replace high spread strains, rendering prognostics and extrapolations uncertain. | 2079-7737 | 2020-08-16 02:00:00+02:00 | pubmed | Biology | Hervé Seligmann;Siham Iggui;Mustapha Rachdi;Nicolas Vuillerme;Jacques Demongeot | COVID-19;adaptation for low pathogenicity;exponential slope;random drift;regression | 2020-08-14 02:00:00+02:00 | 32823981 | FR;IL | Laboratory AGEIS EA 7407, Team Tools for e-Gnosis Medical & Labcom CNRS/UGA/OrangeLabs Telecom4Health, Faculty of Medicine, University Grenoble Alpes (UGA), 38700 La Tronche, France.;The National Natural History Collections, The Hebrew University of Jerusalem, Jerusalem 91404, Israel. | 2145 | |||
| 10.1016/j.ijid.2020.08.032 | Journal Article | en | Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. | https://www.ncbi.nlm.nih.gov/pubmed/32805422 | At the end of November 2019, a novel coronavirus responsible for respiratory tract infections (COVID-19) emerged in China. Despite drastic containment measures, this virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread in Asia and Europe. The pandemic is ongoing with particular hotspot in Southern Europe and America. Many studies predicted a similar epidemic in Africa as that currently seen in Europe and the United States of America. However, reported data do not confirm these predictions. One of the hypotheses that could explain the later emergence and spread of COVID-19 pandemic in African countries is the use of antimalarial drugs to treat malaria, and more particularly artemisinin-based combination therapy (ACT). | 1201-9712 | 2020-08-16 02:00:00+02:00 | pubmed | International Journal of Infectious Diseases | Mathieu Gendrot;Isabelle Duflot;Manon Boxberger;Océane Delandre;Priscilla Jardot;Marion Le Bideau;Julien Andreani;Isabelle Fonta;Joel Mosnier;Clara Rolland;Sébastien Hutter;Bernard La Scola;Bruno Pradines | Antimalarial drug;Antiviral;COVID-19;Malaria;SARS-CoV-2;in vitro | 2020-08-14 02:00:00+02:00 | 32805422 | FR | Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France, Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France.;IHU Méditerranée Infection, Marseille, France, Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.;Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France, Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France, Centre National de Référence du Paludisme, Marseille, France.;Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France.;Unité Parasitologie et Entomologie, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France, Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France, IHU Méditerranée Infection, Marseille, France, Centre National de Référence du Paludisme, Marseille, France. Electronic address: bruno.pradines@gmail.com. | 2149 | |||
| 10.1016/j.clon.2020.08.003 | Editorial | en | Personal View: Low-Dose Lung Radiotherapy Should be Evaluated as a Treatment for Severe COVID-19 Lung Disease. | https://www.ncbi.nlm.nih.gov/pubmed/32829986 | 0936-6555 | 2020-08-16 02:00:00+02:00 | pubmed | Clinical Oncology | D Hadjiyiannakis;D Dimitroyannis;L Eastlake;C Peedell;L Tripathi;R Simcock;A Vyas;E Deutsch;A J Chalmers | 2020-08-14 02:00:00+02:00 | 32829986 | FR;AU;GB;US | Lancashire Teaching Hospitals, NHS Foundation Trust, Preston, UK, NIHR Lancashire Clinical Research Facility, Preston, UK.;Edward Hines Jr, VA Hospital, Hines, Illinois, USA.;University Hospitals Plymouth NHS Trust, Plymouth, UK. Electronic address: leonie.eastlake@nhs.net.;James Cook University Hospital, Middlesbrough, UK.;Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.;Lancashire Teaching Hospitals, NHS Foundation Trust, Preston, UK.;Radiation Oncology Department, Gustave Roussy Cancer Campus, Université Paris, Villejuif, France.;Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. | 2150 | |||||
| 10.1016/j.techfore.2020.120261 | Journal Article | en | On the Efficiency of Foreign Exchange Markets in times of the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32836478 | We employ multifractal detrended fluctuation analysis (MF-DFA) to provide a first look at the efficiency of forex markets during the initial period of the ongoing coronavirus disease 2019 (COVID-19), which has disrupted the global financial markets. We use high-frequency (5-min interval) data of six major currencies traded in forex markets during the period October 1, 2019 to 31 March 31, 2020. Before applying MF-DFA, we examine the inner dynamics of multifractality through seasonal and trend decompositions using loess. Overall, the results confirm the presence of multifractality in forex markets, which demonstrates, in particular, (i) a decline in the efficiency of forex markets during the COVID-19 outbreak and (ii) heterogeneous effects on the strength of multifractality of exchange rate returns under investigation. The largest effect is observed for the Australian dollar, which shows the highest (lowest) efficiency before (during) the COVID-19 pandemic, assessed in terms of low (high) multifractality. The Canadian dollar and the Swiss Franc exhibit the highest efficiency during the COVID-19 outbreak. Our findings may help policymakers shape a comprehensive response to improve forex market efficiency during such a black swan event. | 0040-1625 | 2020-08-16 02:00:00+02:00 | pubmed | Technological Forecasting and Social Change | Faheem Aslam;Saqib Aziz;Duc K Nguyen;Khurrum S Mughal;Maaz Khan | COVID-19 pandemic;MF-DFA;efficiency;forex market;high frequency | 2020-08-15 02:00:00+02:00 | 32836478 | FR;VN;PK | COMSATS University, 45550, Islamabad, Pakistan.;Rennes School of Business, Rennes, France.;IPAG Business School, Paris, France.;International School, Vietnam National University, Hanoi, Vietnam.;State Bank of Pakistan, Karachi, Pakistan. | 2151 | |||
| 10.5603/cj.a2020.0101 | Journal Article | en | Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality. | https://www.ncbi.nlm.nih.gov/pubmed/32789839 | Coronavirus disease 2019 (COVID-19) is rapidly spreading globally. As of July 3, 2020, the number of confirmed cases has been nearly 11 million with 521,000 fatalities. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is accountable for COVID-19. Newly diagnosed and worsening cardiovascular disease are common complications in COVID-19 patients, including acute cardiac injury, hypertension, arrhythmia, myocardial infarction, heart failure and sudden cardiac arrest. The mechanisms contributing to cardiac disease burden include hypoxemia, inflammatory factor storm, dysfunctional angiotensin converting enzyme 2 (ACE2), and drug-induced cardiac toxicity. Notably, the macrophages expressing ACE2 as direct host cells of SARS-CoV-2 secrete chemokine and inflammatory cytokines, as well as a decrease in cellular immune responses to SARS-CoV-2 infection due to elevated exhaustion levels and dysfunctional diversity of T cells, that may be accountable for the "hyperinflammation and cytokine storm syndrome" and subsequently acute cardiac injury and deteriorating cardiovascular disease in COVID-19 patients. However, no targeted medication or vaccines for COVID-19 are yet available. The management of cardiovascular disease in patients with COVID-19 include general supportive treatment, circulatory support, other symptomatic treatment, psychological assistance as well as online consultation. Further work should be concentrated on better understanding the pathogenesis of COVID-19 and accelerating the development of drugs and vaccines to reduce the cardiac disease burden and promote the management of COVID-19 patients, especially those with a severe disease course and cardiovascular complications. | 1898-018X,1897-5593 | 2020-08-16 02:00:00+02:00 | pubmed | Cardiology Journal | Guoliang Li;Ardan M Saguner;Jiaqi An;Yuye Ning;John D Day;Ligang Ding;Xavier Waintraub;Jie Wang | COVID-19;angiotensin converting enzyme 2;cardiovascular complications;endotheliitis;inflammatory factor storm;online consultation | 2020-08-13 02:00:00+02:00 | 32789839 | FR;CN;CH;US | Department of Cardiovascular Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. liguoliang_med@163.com.;Atrial Fibrillation Centre, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. liguoliang_med@163.com.;Cardiology Institute, Rhythmology Unit, Hôpital Universitaire La Pitié-Salpêtrière, Paris, France. liguoliang_med@163.com.;Department of Cardiology, University Heart Center Zurich, Switzerland.;Atrial Fibrillation Centre, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.;Stroke Centre and Department of Neurology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.;Department of Neurology, Massachusetts General Hospital, Boston, United States.;Department of Cardiovascular Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.;Intermountain Medical Center Heart Institute, United States.;Department of Cardiovascular Medicine, Clinical EP Lab & Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.;Cardiology Institute, Rhythmology Unit, Hôpital Universitaire La Pitié-Salpêtrière, Paris, France.;Department of Hematology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. | 2154 | |||
| 10.1111/dth.14170 | Journal Article | en | Maculopapular eruptions associated to COVID-19: a subanalysis of the COVID-Piel study. | https://www.ncbi.nlm.nih.gov/pubmed/32779280 | A previous study has defined the maculopapular subtype of manifestations of COVID-19. | 1396-0296,1529-8019 | 2020-08-16 02:00:00+02:00 | pubmed | Dermatologic Therapy | Alba Català;Cristina Galván-Casas;Gregorio Carretero-Hernández;Pedro Rodríguez-Jiménez;Daniel Fernández-Nieto;Ana Rodríguez-Villa;Íñigo Navarro-Fernández;Ricardo Ruiz-Villaverde;Daniel Falkenhain-López;Mar Llamas-Velasco;Lucía Carnero-Gonzalez;Juan García-Gavin;Ofelia Baniandrés;Carlos González-Cruz;Víctor Morillas-Lahuerta;Xavier Cubiró;Ignasi Figueras;Gerald Selda-Enriquez;Xavier Fustà-Novell;Mónica Roncero-Riesco;Patrícia Burgos-Blasco;Jorge Romaní;Joaquim Solà-Ortigosa;Ignacio García-Doval | COVID-19;Coronavirus;Cutaneous Manifestations;Skin | 2020-08-10 02:00:00+02:00 | 32779280 | FR;ES;PS | Hospital Plató, Barcelona, Spain.;Hospital Universitario de Móstoles, Madrid, Spain.;Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.;Hospital Universitario de la Princesa, Madrid, Spain.;Hospital Universitario Ramón y Cajal, Madrid, Spain.;Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.;Hospital Universitario "Marqués de Valdecilla", Santander, Spain.;Hospital Universitario Clínico San Cecilio, Granada, Spain.;Hospital Universitario 12 de Octubre, Madrid, Spain.;HUA Santiago, Vitoria-Gasteiz, Spain.;Gavín Dermatólogos, Vigo, Spain.;Hospital General Universitario Gregorio Marañón, Madrid, Spain.;Hospital Universitari Vall d'Hebron, Barcelona, Spain.;Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.;Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.;Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.;Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Barcelona, Spain.;Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.;Consorci Sanitari Parc Taulí, Sabadell, Barcelona, Spain.;Hospital General de Granollers, Barcelona, Spain.;Research Unit, Fundación Piel Sana Academia Española de Dermatología y Venereología, Madrid, Spain. | 2160 | |||
| 10.1016/j.ypmed.2020.106236 | Journal Article;Review | en | Universal masking during COVID-19 pandemic: Can textile engineering help public health? Narrative review of the evidence. | https://www.ncbi.nlm.nih.gov/pubmed/32795645 | The Coronavirus Disease-2019 (COVID-19) pandemic caused by the virus SARS-CoV-2 is spreading very quickly around the world. In less than 7 months since it became known to the international community, the virus has infected 18 million in more than 180 countries and killing more than 700,000 people. Person-to-person transmission through infected respiratory droplets from patients with symptoms and asymptomatic carriers is the main mode of spread in the community. There is currently no standard agreed upon drug to treat the disease and the prospect of having a safe and efficacious vaccine might be years away. Thus, public health interventions such as social distancing and hand washing have been introduced and has, to some extent, slowed the progression of the pandemic. Universal masking as a public health intervention is currently mandatory in a vast majority of countries around the world. To avoid personal protective equipment (PPE) shortage crisis for medical staff and other frontline workers, health authorities are recommending the use cloth masks. Although in theory, cloth masks can be helpful to limit the spread of the COVID-19, serious consideration should be given to the choice of textile, the number of layers of cloth used, pre-treatment of the material with water repellent material and other compounds that can enhance the filtration efficiency of the masks without compromising their breathability. This review uses concepts of textile engineering and the theoretical principles of filtration to make suggestions and recommendations to improve the quality and safety of cloth masks for the general public. | 0091-7435 | 2020-08-16 02:00:00+02:00 | pubmed | Preventive Medicine | Sanjay Beesoon;Nemeshwaree Behary;Anne Perwuelz | COVID-19;Electrostatic filtration;Fabric pore size;Face masks;Filtration efficiency;Mechanical filtration;Prevention;Public health;Respiratory droplets | 2020-08-11 02:00:00+02:00 | 32795645 | FR;CA;US | Surgery Strategic Clinical Network, Alberta Health Services, Canada, Division of Community Engagement, Faculty of Medicine and Dentistry, University of Alberta, Canada. Electronic address: beesoon@ualberta.ca.;Ecole Nationale Supérieure des Arts et Industries Textiles (ENSAIT), GEMTEX Laboratory, 2 allée Louise et Victor Champier BP 30329, 59056 Roubaix, France, Université de Lille, Nord de France, F-59000 Lille, France. | 2169 | |||
| 10.1093/occmed/kqaa147 | Journal Article | en | Studying smoking benefit in farmer's lung to understand Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32779722 | 0962-7480,1471-8405 | 2020-08-16 02:00:00+02:00 | pubmed | Occupational Medicine | Anne-Pauline Bellanger;Gabriel Reboux | 2020-08-11 02:00:00+02:00 | 32779722 | FR | Parasitology-Mycology Department, University Hospital, Besançon, France.;Chrono-Environment Research Team UMR/CNRS-6249, University of Bourgogne Franche-Comté, Besançon, France. | 2172 | |||||
| 10.1007/s00431-020-03773-7 | Editorial | en | COVID-19 surveillance for all newborns at the NICU; conditio sine qua non? | https://www.ncbi.nlm.nih.gov/pubmed/32785859 | 0340-6199,1432-1076 | 2020-08-16 02:00:00+02:00 | pubmed | European Journal of Pediatrics | J Peter de Winter;Daniele De Luca;David G Tingay | 2020-08-12 02:00:00+02:00 | 32785859 | AU;FR;BE;NL | Department of Pediatrics, Spaarne Gasthuis, Hoofddorp/Haarlem, The Netherlands. ejp@spaarnegasthuis.nl.;Department of Development and Regeneration, KU Leuven, Leuven, Belgium. ejp@spaarnegasthuis.nl.;Division of Pediatrics and Neonatal Critical Care, "A. Beclere" medical center, Paris Saclay University Hospitals, Paris, France.;Physiopathology and Therapeutic Innovation Unit, INSERM U999, Paris Saclay University, Paris, France.;Neonatal Research, Murdoch Children's Research Institute, Melbourne, VIC, Australia.;Department of Neonatology, Royal Children's Hospital, Melbourne, VIC, Australia.;Department of Pediatrics, University of Melbourne, Melbourne, VIC, Australia. | 2178 | |||||
| 10.1016/j.jcv.2020.104588 | Journal Article | en | Thermal inactivation and nucleic acid amplification-based testing for SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32829140 | 1386-6532 | 2020-08-16 02:00:00+02:00 | pubmed | Journal of Clinical Virology | Hélène Péré;Isabelle Podglajen;Jean-Louis Baillard;Ralph-Sydney Mboumba Bouassa;David Veyer;Laurent Bélec | 2020-08-12 02:00:00+02:00 | 32829140 | FR | Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, INSERM U970, PARCC, Hôpital Européen Georges Pompidou, Faculté de Médecine, Centre Université de Paris, Paris, France, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Université of Paris, Sorbonne Paris Cité, Paris, France.;Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Université of Paris, Sorbonne Paris Cité, Paris, France.;Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Université of Paris, Sorbonne Paris Cité, Paris, France. Electronic address: laurent.belec@aphp.fr. | 2180 | |||||
| Walloon Region of Belgium | 10.1186/s13054-020-03218-5 | Journal Article;Research Support, Non-U.S. Gov't | en | Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32787909 | Post-mortem studies can provide important information for understanding new diseases and small autopsy case series have already reported different findings in COVID-19 patients. | 1364-8535 | 2020-08-16 02:00:00+02:00 | pubmed | Aged;Autopsy;Betacoronavirus__isolation & purification;Brain__virology;Colon__virology;Coronavirus Infections__therapy;Female;Heart__virology;Humans;Kidney__virology;Liver__virology;Lung__virology;Male;Middle Aged;Pandemics;Pneumonia, Viral__therapy;Reverse Transcriptase Polymerase Chain Reaction;Spleen__virology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Critical Care | Myriam Remmelink;Ricardo De Mendonça;Nicky D'Haene;Sarah De Clercq;Camille Verocq;Laetitia Lebrun;Philomène Lavis;Marie-Lucie Racu;Anne-Laure Trépant;Calliope Maris;Sandrine Rorive;Jean-Christophe Goffard;Olivier De Witte;Lorenzo Peluso;Jean-Louis Vincent;Christine Decaestecker;Fabio Silvio Taccone;Isabelle Salmon | Autopsy;COVID-19;Immunohistochemistry;RT-PCR;SARS-CoV-2 | 2020-08-12 02:00:00+02:00 | 32787909 | FR;BE | [{"country": "International", "agency": "Walloon Region of Belgium", "grantid": "411132-957270"}] | Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium.;Centre Universitaire inter Régional d'expertise en Anatomie Pathologique Hospitalière (CurePath, CHIREC, CHU Tivoli, ULB), Rue de Borfilet 12A, 6040, Jumet, Belgium.;Immunodeficiency Treatment Unit, Erasme Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium.;Department of Neurosurgery, Erasme Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium.;Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium.;Laboratory of Image Synthesis and Analysis (LISA), Université Libre de Bruxelles (ULB), CPI 165/57, Avenue Franklin Roosevelt 50, 1050, Brussels, Belgium.;DIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), CPI 305/1, Rue Adrienne Bolland, 8, 6041, Gosselies, Belgium.;Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium. Isabelle.Salmon@erasme.ulb.ac.be.;Centre Universitaire inter Régional d'expertise en Anatomie Pathologique Hospitalière (CurePath, CHIREC, CHU Tivoli, ULB), Rue de Borfilet 12A, 6040, Jumet, Belgium. Isabelle.Salmon@erasme.ulb.ac.be.;DIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), CPI 305/1, Rue Adrienne Bolland, 8, 6041, Gosselies, Belgium. Isabelle.Salmon@erasme.ulb.ac.be. | 2183 |
| 10.1016/j.pnpbp.2020.110070 | Journal Article;Review | en | Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review. | https://www.ncbi.nlm.nih.gov/pubmed/32800868 | In the context of the COVID-19 worldwide pandemic, an up-to-date review of current challenges in addictions is necessary. While large scale disasters may have an impact on substance use and addictions, the use of some substances is also likely to modify the risk of COVID-19 infection or course. Many countries have imposed lockdowns. Whether this quarantine or the end of lockdown measures will have an impact on substance use is discussed. The aim of this review is to gather knowledge for clinicians and to guide public health policies during/after lockdown. | 0278-5846 | 2020-08-16 02:00:00+02:00 | pubmed | Progress in Neuro-Psychopharmacology and Biological Psychiatry | Jasmina Mallet;Caroline Dubertret;Yann Le Strat | Addictions;Alcohol;COVID-19;Lockdown;Opioids;SARS-CoV2;Tobacco | 2020-08-12 02:00:00+02:00 | 32800868 | FR | AP-HP, Department of Psychiatry, Louis Mourier Hospital, Université de Paris, Faculté de Médecine, Colombes, France, Institute of Psychiatry and Neurosciences of Paris (IPNP, Inserm U1266), 102 rue de la Santé, 75014 Paris, France. Electronic address: Jasmina.mallet@aphp.fr.;AP-HP, Department of Psychiatry, Louis Mourier Hospital, Université de Paris, Faculté de Médecine, Colombes, France, Institute of Psychiatry and Neurosciences of Paris (IPNP, Inserm U1266), 102 rue de la Santé, 75014 Paris, France. | 2185 | |||
| 10.1007/s00134-020-06202-3 | Journal Article | en | Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset. | https://www.ncbi.nlm.nih.gov/pubmed/32780165 | Coronavirus disease 2019 (COVID-19) is creating an unprecedented healthcare crisis. Understanding the determinants of mortality is crucial to optimise intensive care unit (ICU) resource use and to identify targets for improving survival. | 0342-4642,1432-1238 | 2020-08-16 02:00:00+02:00 | pubmed | Intensive Care Medicine | Elie Azoulay;Muriel Fartoukh;Michael Darmon;Guillaume Géri;Guillaume Voiriot;Thibault Dupont;Lara Zafrani;Lola Girodias;Vincent Labbé;Martin Dres;Alexandra Beurton;Antoine Vieillard-Baron;Alexandre Demoule | Acute kidney injury;Acute respiratory distress syndrome;Coronavirus;Viral infection | 2020-08-11 02:00:00+02:00 | 32780165 | FR | Service de Médecine Intensive et Réanimation, Hôpital Saint-Louis, APHP, Paris, France. elie.azoulay@aphp.fr.;Université de Paris, Paris, France. elie.azoulay@aphp.fr.;Université de Paris, Paris, France.;Service de Médecine Intensive et Réanimation, Hôpital Tenon, APHP, Paris, France.;Service de Médecine Intensive et Réanimation, Hôpital Saint-Louis, APHP, Paris, France.;Service de Médecine Intensive et Réanimation, Hôpital Ambroise Paré, APHP, Paris, France.;Service de Médecine Intensive et Réanimation, Hôpital Pitié-Salpêtrière, APHP, Paris, France. | 2189 | |||
| 10.1371/journal.pone.0236465 | Journal Article;Research Support, Non-U.S. Gov't | en | Time and Covid-19 stress in the lockdown situation: Time free, «Dying» of boredom and sadness. | https://www.ncbi.nlm.nih.gov/pubmed/32776990 | A lockdown of people has been used as an efficient public health measure to fight against the exponential spread of the coronavirus disease (Covid-19) and allows the health system to manage the number of patients. The aim of this study (clinicaltrials.gov NCT00430818) was to evaluate the impact of both perceived stress aroused by Covid-19 and of emotions triggered by the lockdown situation on the individual experience of time. A large sample of the French population responded to a survey on their experience of the passage of time during the lockdown compared to before the lockdown. The perceived stress resulting from Covid-19 and stress at work and home were also assessed, as were the emotions felt. The results showed that people have experienced a slowing down of time during the lockdown. This time experience was not explained by the levels of perceived stress or anxiety, although these were considerable, but rather by the increase in boredom and sadness felt in the lockdown situation. The increased anger and fear of death only explained a small part of variance in the time judgment. The conscious experience of time therefore reflected the psychological difficulties experienced during lockdown and was not related to their perceived level of stress or anxiety. | 1932-6203 | 2020-08-16 02:00:00+02:00 | pubmed | PLOS ONE | Sylvie Droit-Volet;Sandrine Gil;Natalia Martinelli;Nicolas Andant;Maélys Clinchamps;Lénise Parreira;Karine Rouffiac;Michael Dambrun;Pascal Huguet;Benoît Dubuis;Bruno Pereira;Jean-Baptiste Bouillon;Frédéric Dutheil | 2020-08-10 02:00:00+02:00 | 32776990 | FR;CH | Université Clermont Auvergne, CNRS, LAPSCO, Clermont-Ferrand, France.;Université de Poitiers, CNRS, UMR 7295, Poitiers, France.;University Hospital of Clermont Ferrand, CHU Clermont-Ferrand, Clinical Research and Innovation Direction - Biostatistics, Clermont-Ferrand, France.;University Hospital of Clermont Ferrand, CHU Clermont-Ferrand, Occupational and Environmental Medicine, Clermont-Ferrand, France.;Université de Genève, UNIGE, Fondation INARTIS, Genève, Switzerland.;Université Clermont Auvergne, CNRS, LAPSCO, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Emergency Medicine, Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, LAPSCO, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Occupational and Environmental Medicine, WittyFit, Clermont-Ferrand, France. | 2200 | ||||
| 10.1097/ccm.0000000000004585 | Journal Article | en | Core Outcomes Set for Trials in People With Coronavirus Disease 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32804792 | The outcomes reported in trials in coronavirus disease 2019 are extremely heterogeneous and of uncertain patient relevance, limiting their applicability for clinical decision-making. The aim of this workshop was to establish a core outcomes set for trials in people with suspected or confirmed coronavirus disease 2019. | 0090-3493 | 2020-08-23 02:00:00+02:00 | pubmed | Critical Care Medicine | Allison Tong;Julian H Elliott;Luciano Cesar Azevedo;Amanda Baumgart;Andrew Bersten;Lilia Cervantes;Derek P Chew;Yeoungjee Cho;Tess Cooper;Sally Crowe;Ivor S Douglas;Nicole Evangelidis;Ella Flemyng;Elyssa Hannan;Peter Horby;Martin Howell;Jaehee Lee;Emma Liu;Eduardo Lorca;Deena Lynch;John C Marshall;Andrea Matus Gonzalez;Anne McKenzie;Karine E Manera;Charlie McLeod;Sangeeta Mehta;Mervyn Mer;Andrew Conway Morris;Saad Nseir;Pedro Povoa;Mark Reid;Yasser Sakr;Ning Shen;Alan R Smyth;Tom Snelling;Giovanni Fm Strippoli;Armando Teixeira-Pinto;Antoni Torres;Tari Turner;Andrea K Viecelli;Steve Webb;Paula R Williamson;Laila Woc-Colburn;Junhua Zhang;Jonathan C Craig | 2020-08-17 02:00:00+02:00 | 32804792 | FR;CA;CL;PT;CN;GB;US;BR;IT;AU;ZA;DK;ES;KR;DE | Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.;Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia.;Cochrane Australia, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.;Department of Critical Care Medicine, Hospital Sirio-Libanes, São Paulo, Brazil.;College of Medicine and Public Health, Flinders University, Adelaide, Australia.;Department of Medicine, Denver Health, Denver, CO.;Faculty of Medicine, University of Queensland at Princess Alexandra Hospital, Brisbane, Qld, Australia.;Crowe Associates Ltd, Oxon, United Kingdom.;Department of Medicine, Pulmonary Sciences and Critical Care, Denver Health and University of Colorado Anschutz, School of Medicine Denver, Aurora, CO.;Department of Editorial and Methods, Cochrane, London, United Kingdom.;Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.;Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.;Department of Internal Medicine, Faculty of Medicine, University of Chile, Santiago, Chile.;Jonze Society, Brisbane, Qld, Australia.;Department of Surgery, University of Toronto, Toronto, ON, Canada.;Telethon Kids Institute, Perth, WA, Australia.;Department of Infectious Diseases, Perth Children's Hospital, Perth, WA, Australia.;Department of Medicine and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.;Department of Medicine, Divisions of Critical Care and Pulmonology, Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.;Department of Medicine, University of Cambridge, Cambridge, United Kingdom.;Critical Care Centre, CHU Lille, and Lille University, F-59000 Lille, France.;Nova Medical School, CHRC, New University of Lisbon, Polyvalent Intensive Care Unit, Sao Francisco Xavier Hospital, CHLO, Lisbon, Portugal.;Center for Clinical Epidemiology and Research Unit of Clinical Epidemiology, OUH Odense University Hospital, Odense, Denmark.;Department of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany.;Department of Respiratory Medicine, Peking University Third Hospital, Beijing, China.;Evidence Based Child Health Group, University of Nottingham, Nottingham, United Kingdom.;Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.;Department of Pulmonology Hospital Clinic. University of Barcelona, CIBERES, IDIBAPS, Barcelona, Spain.;Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.;Section of Infectious Diseases Department of Medicine, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX.;Evidence-based Medicine center, Tianjin University of Traditional Chinese Medicine, Tianjin, China. | 2201 | ||||
| 10.1016/j.jgar.2020.08.001 | Journal Article | en | A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island. | https://www.ncbi.nlm.nih.gov/pubmed/32828896 | 2213-7165 | 2020-08-23 02:00:00+02:00 | pubmed | Journal of Global Antimicrobial Resistance | Arthur Dubernet;Kevin Larsen;Laurie Masse;Jérôme Allyn;Emilie Foch;Lea Bruneau;Adrien Maillot;Marie Lagrange-Xelot;Vincent Thomas;Marie-Christine Jaffar-Bandjee;Loraine Gauzere;Loic Raffray;Karine Borsu;Servane Dibernardo;Stéphane Renaud;Michel André;Diane Moreau;Julien Jabot;Nathalie Coolen-Allou;Nicolas Allou | COVID-19;SARS-CoV-2;azithromycin;corticosteroids;hydroxychloroquine | 2020-08-20 02:00:00+02:00 | 32828896 | FR | Pneumologie, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: arthurdubernet@yahoo.fr.;Pneumologie, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: kevin.larsen0511@gmail.com.;Pneumologie, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: laurie.masse@chu-reunion.fr.;Réanimation polyvalente, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France, Département d'Informatique Clinique, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: jerome.allyn@chu-reunion.fr.;Pneumologie, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: emilie.foch@chu-reunion.fr.;INSERM CIC 1410 Clinical and Epidemiology, University Hospital, Saint Pierre, Reunion Island, France, Department of Public health and research support, Methodological Support and Biostatistics Unit, University Hospital, Saint Denis, Reunion Island, France. Electronic address: lea.bruneau@chu-reunion.fr.;Department of Public health and research support, Methodological Support and Biostatistics Unit, University Hospital, Saint Denis, Reunion Island, France. Electronic address: adrien.maillot@chu-reunion.fr.;Service des Maladies Infectieuses, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: marie.lagrange-xelot@chu-reunion.fr.;Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: vincent.thomas@chu-reunion.fr.;Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: marie-christine.jaffarbandjee@chu-reunion.fr.;Médecine Interne, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: loraine.gauzere@chu-reunion.fr.;Médecine Interne, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: loic.raffray@chu-reunion.fr.;Médecine Polyvalente, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: karine.borsu@chu-reunion.fr.;Médecine Polyvalente, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: servane.dibernardo@chu-reunion.fr.;Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: stephane.renaud@chu-reunion.fr.;Pneumologie, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: michel.andre@chu-reunion.fr.;Pneumologie, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: diane.moreau@chu-reunion.fr.;Réanimation polyvalente, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: julien.jabot@chu-reunio.fr.;Pneumologie, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: nathalie.allou@chu-reunion.fr.;Réanimation polyvalente, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France, Département d'Informatique Clinique, Centre Hospitalier Universitaire Felix Guyon Allée des Topazes, 97405 Saint Denis, France. Electronic address: nicolas.allou@hotmail.fr. | 2210 | ||||
| 10.1055/a-1170-8426 | Journal Article | ge | [Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)]. | https://www.ncbi.nlm.nih.gov/pubmed/32823368 | 0935-8943,1438-8685 | 2020-08-23 02:00:00+02:00 | pubmed | Laryngo-Rhino-Otologie | O Pfaar;L Klimek;M Worm;K-C Bergmann;T Bieber;R Buhl;J Buters;U Darsow;T Keil;J Kleine-Tebbe;S Lau;M Maurer;H Merk;R Mösges;J Saloga;P Staubach;P Stute;K Rabe;U Rabe;C Vogelmeier;T Biedermann;K Jung;W Schlenter;J Ring;A Chaker;W Wehrmann;S Becker;N Mülleneisen;K Nemat;W Czech;H Wrede;R Brehler;T Fuchs;P-V Tomazic;W Aberer;A Fink-Wagner;F Horak;S Wöhrl;V Niederberger-Leppin;I Pali-Schöll;W Pohl;R Roller-Wirnsberger;O Spranger;R Valenta;M Akdis;C Akdis;K Hoffmann-Sommergruber;M Jutel;P Matricardi;F Spertini;N Khaltaev;J-P Michel;L Nicod;P Schmid-Grendelmeier;E Hamelmann;T Jakob;T Werfel;M Wagenmann;C Taube;M Gerstlauer;C Vogelberg;J Bousquet;T Zuberbier | 2020-08-21 02:00:00+02:00 | 32823368 | FR;UNK;CH;DE;BE;AT | Sektion Rhinologie und Allergologie, Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Gießen und Marburg, Philipps-Universität Marburg.;Zentrum für Rhinologie und Allergologie, Wiesbaden.;Comprehensive Allergy Centre Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin.;Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Bonn.;III. Medizinische Klinik und Poliklinik Hämatologie, Internistische Onkologie und Pneumologie, Universitätsmedizin Mainz.;Zentrum Allergie und Umwelt (ZAUM), Technische Universität und Helmholtz-Zentrum München.;Klinik und Poliklinik für Dermatologie und Allergologie der Technischen Universität München.;Institut für klinische Epidemiologie und Biometrie, Julius-Maximilian-Universität, Würzburg.;Allergie- und Asthma-Zentrum Westend, Berlin.;Klinik für Pädiatrie m. S. Pneumologie, Immunologie und Intensivmedizin, Charité-Universitätsmedizin Berlin.;Dermatologische Allergologie, Allergie-Centrum Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin.;Abteilung Dermatologie & Allergologie, RWTH Aachen Universität.;Medizinische Fakultät der Universität zu Köln.;CRI - Clinical Research International Ltd., Hamburg.;ClinCompetence Cologne GmbH, Köln.;Hautklinik, Universitätsmedizin, Johannes-Gutenberg-Universität, Mainz.;Europäische Vereinigung für Vitalität und Aktives Altern, Leipzig.;Abteilung für Pneumologie, LungenClinic Grosshansdorf.;Klinik für Allergologie, Johanniter-Krankenhaus im Fläming Treuenbrietzen GmbH, Treuenbrietzen.;Klinik für Innere Medizin Schwerpunkt Pneumologie, Philipps-Universität Marburg.;Einheit für Klinische Allergologie (EKA), Helmholtz-Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Neuherberg.;Praxis für Dermatologie, Immunologie und Allergologie, Erfurt.;Ärzteverband Deutscher Allergologen, Dreieich.;Haut- und Laserzentrum an der Oper, München.;Academia, München.;HNO-Klinik des Klinikums rechts der Isar, Technische Universität München.;Zentrum Allergie und Umwelt, München (ZAUM), Helmholtz-Zentrum München.;Praxis für Dermatologie und Allergologie, Münster.;Klinik für Hals-, Nasen- und Ohrenheilkunde, Universität Tübingen.;Asthma und Allergiezentrum Leverkusen.;Universitäts AllergieCentrum (UAC), Universitätsklinikum Carl Gustav Carus, Dresden.;Praxis für Kinderpneumologie/Allergologie am Kinderzentrum Dresden (Kid), Dresden.;Praxis für Dermatologie, Allergologie, Phlebologie, Villingen-Schwenningen.;HNO- und Allergiezentrum Herford.;Klinik für Allergologie, Berufsdermatologie und Umweltmedizin, Universitätsklinikum Münster.;Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum, Georg-August-Universität, Göttingen.;Klinische Abteilung für Allgemeine HNO, Medizinische Universität Graz, Österreich.;Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Graz, Österreich.;Global Allergy and Airways Patient Platform GAAPP, Wien, Österreich.;Praxis für Hals-, Nasen- und Ohrenkrankheiten, Wien, Österreich.;Floridsdorfer Allergiezentrum, Wien, Österreich.;Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Medizinische Universität Wien, Österreich.;Institut für Komparative Medizin, Interdisziplinäres Messerli Forschungsinstitut, Veterinärmedizinische Universität Wien und Medizinische Universität Wien, Österreich.;Institut für Pathophysiologie und Allergieforschung, Medizinische Universität Wien, Österreich.;Abteilung für Atmungs- und Lungenkrankheiten, Krankenhaus Hietzing, Wien, Österreich.;Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Österreich.;Institut für Pathophysiologie, Medizinische Universität Wien, Österreich.;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Schweiz.;Department of Clinical Immunology, Medizinische Universität Breslau, Polen.;Charité-Universitätsmedizin Berlin.;Division of Allergy and Immunology, Centre Hospitalier Universitaire Vaudois, Lausanne, Schweiz.;GARD Chairman, Genf, Schweiz.;Department of Rehabilitation and Geriatrics, University of Geneva, Genf, Schweiz.;Clinique Cecil, Hirslanden-Gruppe, Lausanne, Schweiz.;Abteilung Pneumologie, Centre hospitalier universitaire vaudois, Lausanne, Schweiz.;Allergiestation, Dermatologische Klinik, Universitätsspital Zürich, Schweiz.;Kinderzentrum Bethel, Evangelisches Klinikum Bethel, Universitätsmedizin OWL der Universität Bielefeld.;Klinik für Dermatologie, Allergologie, Universitätsklinikum Gießen, UKGM, Justus-Liebig-Universität Gießen.;Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover.;HNO-Klinik, Universitätsklinikum Düsseldorf.;Klinik für Pneumologie, Ruhrlandklinik, Universitätsmedizin Essen.;Abteilung für Kinderpneumologie und Allergologie, Medizinische Universität Augsburg.;Fachbereich Kinderpneumologie und Allergologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden.;MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, Frankreich.;INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif.;Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, Frankreich.;Euforea, Brussels, Belgien.;Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin.;Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin. | 2220 | |||||
| 10.2105/ajph.2020.305886 | Editorial | en | ENOUGH: COVID-19, Structural Racism, Police Brutality, Plutocracy, Climate Change-and Time for Health Justice, Democratic Governance, and an Equitable, Sustainable Future. | https://www.ncbi.nlm.nih.gov/pubmed/32816556 | COVID-19 starkly reveals how structural injustice cuts short the lives of people subjected to systemic racism and economic deprivation.2-4 It is not, however, the only crisis at hand. (Am J Public Health. Published online ahead of print August 20, 2020: e1-e4. doi:10.2105/AJPH.2020.305886). | 0090-0036,1541-0048 | 2020-08-23 02:00:00+02:00 | pubmed | American Journal of Public Health | Nancy Krieger | 2020-08-20 02:00:00+02:00 | 32816556 | FR;US | Nancy Krieger is professor of social epidemiology and American Cancer Society clinical research professor in the Department of Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA. | 2224 | ||||
| 10.1371/journal.pone.0237901 | Journal Article | en | Spatial and temporal regularization to estimate COVID-19 reproduction number R(t): Promoting piecewise smoothness via convex optimization. | https://www.ncbi.nlm.nih.gov/pubmed/32817697 | Among the different indicators that quantify the spread of an epidemic such as the on-going COVID-19, stands first the reproduction number which measures how many people can be contaminated by an infected person. In order to permit the monitoring of the evolution of this number, a new estimation procedure is proposed here, assuming a well-accepted model for current incidence data, based on past observations. The novelty of the proposed approach is twofold: 1) the estimation of the reproduction number is achieved by convex optimization within a proximal-based inverse problem formulation, with constraints aimed at promoting piecewise smoothness; 2) the approach is developed in a multivariate setting, allowing for the simultaneous handling of multiple time series attached to different geographical regions, together with a spatial (graph-based) regularization of their evolutions in time. The effectiveness of the approach is first supported by simulations, and two main applications to real COVID-19 data are then discussed. The first one refers to the comparative evolution of the reproduction number for a number of countries, while the second one focuses on French departments and their joint analysis, leading to dynamic maps revealing the temporal co-evolution of their reproduction numbers. | 1932-6203 | 2020-08-23 02:00:00+02:00 | pubmed | PLOS ONE | Patrice Abry;Nelly Pustelnik;Stéphane Roux;Pablo Jensen;Patrick Flandrin;Rémi Gribonval;Charles-Gérard Lucas;Éric Guichard;Pierre Borgnat;Nicolas Garnier | 2020-08-20 02:00:00+02:00 | 32817697 | FR | Université de Lyon, ENS de Lyon, CNRS, Laboratoire de Physique, Lyon, France.;Université de Lyon, ENS de Lyon, CNRS, Inst. Systèmes Complexes, Lyon, France.;Univ Lyon, Inria, CNRS, ENS de Lyon, UCB Lyon 1, LIP UMR 5668, Lyon, France.;Université de Lyon, ENS de Lyon, CNRS, Laboratoire Triangle, Lyon, France. | 2225 | ||||
| Letter | en | Possible role of ABCB1 in lysosomal accumulation of azithromycin in COVID-19 therapy. | https://www.ncbi.nlm.nih.gov/pubmed/32804426 | The antiviral use of azithromycin in COVID-19 was recently reported by Damle et al. Its combination with hydroxychloroquine did not aim at preventing bacterial super-infection as often believed, but at benefiting from their common lysosomotropic properties which buffer the acidic conditions (pH 4-5) of the endolysosomal lumen where SARS-CoV-2 transits following its ACE-2 receptor-mediated endocytosis. These two powerful cationic and amphiphilic drugs increase up to neutrality the intravesicular pH causing disorders in lysosomal functions such as enzyme inhibitions involved in the virus replication cycle. We recently hypothesized that the ATP-binding cassette ABCB1 (P-glycoprotein) could be involved in this reported synergistic effect. | 2020-08-23 02:00:00+02:00 | pubmed | Jean-Michel Scherrmann | 2020-08-17 02:00:00+02:00 | 32804426 | FR | Faculty of Pharmacy, University of Paris, Inserm, UMRS-1144, Paris, France. | 2229 | |||||||
| Conseil Régional de l'île de La Réunion | 10.1186/s12967-020-02480-z | Journal Article;Review;Research Support, Non-U.S. Gov't | en | The current landscape of coronavirus-host protein-protein interactions. | https://www.ncbi.nlm.nih.gov/pubmed/32811513 | In less than 20 years, three deadly coronaviruses, SARS-CoV, MERS-CoV and SARS-CoV-2, have emerged in human population causing hundreds to hundreds of thousands of deaths. Other coronaviruses are causing epizootic representing a significant threat for both domestic and wild animals. Members of this viral family have the longest genome of all RNA viruses, and express up to 29 proteins establishing complex interactions with the host proteome. Deciphering these interactions is essential to identify cellular pathways hijacked by these viruses to replicate and escape innate immunity. Virus-host interactions also provide key information to select targets for antiviral drug development. Here, we have manually curated the literature to assemble a unique dataset of 1311 coronavirus-host protein-protein interactions. Functional enrichment and network-based analyses showed coronavirus connections to RNA processing and translation, DNA damage and pathogen sensing, interferon production, and metabolic pathways. In particular, this global analysis pinpointed overlooked interactions with translation modulators (GIGYF2-EIF4E2), components of the nuclear pore, proteins involved in mitochondria homeostasis (PHB, PHB2, STOML2), and methylation pathways (MAT2A/B). Finally, interactome data provided a rational for the antiviral activity of some drugs inhibiting coronaviruses replication. Altogether, this work describing the current landscape of coronavirus-host interactions provides valuable hints for understanding the pathophysiology of coronavirus infections and developing effective antiviral therapies. | 1479-5876 | 2020-08-23 02:00:00+02:00 | pubmed | Journal of Translational Medicine | Laure Perrin-Cocon;Olivier Diaz;Clémence Jacquemin;Valentine Barthel;Eva Ogire;Christophe Ramière;Patrice André;Vincent Lotteau;Pierre-Olivier Vidalain | Coronavirus;Interactome;Protein–protein interactions;SARS-CoV-2;Virus-host interactions | 2020-08-18 02:00:00+02:00 | 32811513 | FR | [{"country": "International", "agency": "Conseil Régional de l'île de La Réunion", "grantid": "DIRED 20181189"}] | CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007, Lyon, France.;UMR Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, CNRS, 9192 INSERM U1187, IRD 249, Plateforme de Recherche CYROI, Sainte Clotilde La Réunion, France.;Laboratoire de Virologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007, Lyon, France. vincent.lotteau@inserm.fr.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007, Lyon, France. pierre-olivier.vidalain@inserm.fr. | 2242 | |
| 10.3390/ijms21165932 | Journal Article;Review | en | Deciphering SARS-CoV-2 Virologic and Immunologic Features. | https://www.ncbi.nlm.nih.gov/pubmed/32824753 | Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 and its associated pathology, COVID-19, have been of particular concerns these last months due to the worldwide burden they represent. The number of cases requiring intensive care being the critical point in this epidemic, a better understanding of the pathophysiology leading to these severe cases is urgently needed. Tissue lesions can be caused by the pathogen or can be driven by an overwhelmed immune response. Focusing on SARS-CoV-2, we and others have observed that this virus can trigger indeed an immune response that can be dysregulated in severe patients and leading to further injury to multiple organs. The purpose of the review is to bring to light the current knowledge about SARS-CoV-2 virologic and immunologic features. Thus, we address virus biology, life cycle, tropism for many organs and how ultimately it will affect several host biological and physiological functions, notably the immune response. Given that therapeutic avenues are now highly warranted, we also discuss the immunotherapies available to manage the infection and the clinical outcomes. | 1422-0067 | 2020-08-23 02:00:00+02:00 | pubmed | International Journal of Molecular Sciences | Grégorie Lebeau;Damien Vagner;Étienne Frumence;Franck Ah-Pine;Xavier Guillot;Estelle Nobécourt;Loïc Raffray;Philippe Gasque | COVID-19;SARS-CoV-2;immunopathology;immunotherapy;virus biology | 2020-08-18 02:00:00+02:00 | 32824753 | FR | Unité de Recherche Études Pharmaco-Immunologiques, Centre Hospitalier Universitaire La Réunion Site Félix Guyon, CS11021, 97400 Saint Denis de La Réunion, France.;Laboratoire de Biologie, Secteur Laboratoire d'immunologie Clinique et Expérimentale de la Zone de l'océan Indien (LICE-OI), Centre Hospitalier Universitaire La Réunion Site Félix Guyon, CS11021, 97400 Saint Denis de La Réunion, France.;Unité Mixte de Recherche Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Platform CYROI, 2 rue Maxime Rivière, 97491 Sainte Clotilde, La Réunion, France.;Service d'anatomo-Pathologie, Centre Hospitalier Universitaire Sud Réunion, 97410 Saint Pierre, France.;Service de Rhumatologie, Centre Hospitalier Universitaire La Réunion Site Félix Guyon, CS11021, 97400 Saint Denis de La Réunion, France.;Service d'endocrinologie Diabétologie, Centre Hospitalier Universitaire Sud Réunion, 97410 Saint Pierre, France.;Université de Formation et de Recherche Santé, Université de la Réunion, 97400 Saint-Denis, France.;Service de Médecine Interne, Centre Hospitalier Universitaire La Réunion Site Félix Guyon, CS11021, 97400 Saint Denis de La Réunion, France. | 2243 | |||
| 10.1007/s00259-020-04999-1 | Journal Article | en | CT abnormalities evocative of lung infection are associated with lower 18F-FDG uptake in confirmed COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32808079 | CT signs that are evocative of lung COVID-19 infections have been extensively described, whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19 18F-FDG-PET signs in patients that were (i) suspected to have a lung infection based on 18F-FDG-PET/CT recorded during the COVID-19 outbreak and (ii) whose COVID-19 diagnosis was definitely established or excluded by appropriate viral testing. | 1619-7070,1619-7089 | 2020-08-23 02:00:00+02:00 | pubmed | European Journal of Nuclear Medicine and Molecular Imaging | Achraf Bahloul;Caroline Boursier;Hélène Jeulin;Laëtitia Imbert;Damien Mandry;Gilles Karcher;Pierre-Yves Marie;Antoine Verger | 18F-FDG-PET;COVID-19;CT;Lung infection;Serological tests | 2020-08-18 02:00:00+02:00 | 32808079 | FR | Lorraine University, Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, F-54000, Nancy, France.;Lorraine University, Department of Virology, CHRU Nancy, F-54000, Nancy, France.;Lorraine University, IADI, INSERM U1254, F-54000, Nancy, France.;Lorraine University, Department of Radiology, Brabois, CHRU Nancy, F-54000, Nancy, France.;Lorraine University, DCAC, INSERM U1116, F-54000, Nancy, France.;Lorraine University, Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, F-54000, Nancy, France. a.verger@chru-nancy.fr.;Lorraine University, IADI, INSERM U1254, F-54000, Nancy, France. a.verger@chru-nancy.fr. | 2255 | |||
| Letter | en | Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. | https://www.ncbi.nlm.nih.gov/pubmed/32831155 | Primary objective: To estimate the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization. Secondary objectives: To examine whether the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization varies between subgroups related to treatment characteristics, disease severity at the time of randomization, patient characteristics, or risk of bias. To examine the effect of corticosteroids compared with usual care or placebo on serious adverse events. | 2020-08-30 02:00:00+02:00 | pubmed | Jonathan A C Sterne;Janet Diaz;Jesús Villar;Srinivas Murthy;Arthur S Slutsky;Anders Perner;Peter Jüni;Derek C Angus;Djillali Annane;Luciano Cesar Pontes Azevedo;Bin Du;Pierre-Francois Dequin;Anthony C Gordon;Cameron Green;Julian P T Higgins;Peter Horby;Martin J Landray;Giuseppe Lapadula;Amelie Le Gouge;Marie Leclerc;Jelena Savović;Bruno Tomazini;Balasubramanian Venkatesh;Steve Webb;John C Marshall | COVID-19;Corticosteroid;Dexamethasone;Hydrocortisone;Meta-analysis;Methylprednisolone;Mortality;Randomised controlled trial;Systematic Review | 2020-08-24 02:00:00+02:00 | 32831155 | FR;CA;NZ;CN;CH;GB;US;BR;IT;AU;ES;DK | Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. jonathan.sterne@bristol.ac.uk.;NIHR Bristol Biomedical Research Centre, Bristol, UK. jonathan.sterne@bristol.ac.uk.;Clinical Unit, Health Emergencies Programme, World Health Organization, Geneva, Switzerland.;Research Unit, Hospital Universitario Dr. Negrin Las Palmas de Gran Canaria, Las Palmas, Spain.;CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.;Department of Pediatrics, University of British Columbia, Vancouver, Canada.;Applied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Department of Medicine, University of Toronto, Toronto, Canada.;Department of Intensive Care, Rigshospitalet, Copenhagen, Denmark.;Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.;Department of Intensive Care, Raymond Poincaré Hospital (APHP), School of Medicine Simone Veil, University Paris Saclay -UVSQ, Paris, France.;Critical Care and Emergency Medicine, Hospital Sirio Libanês, São Paulo, Brazil.;Peking Union Medical College Hospital, Beijing, China.;Médecine Intensive - Réanimation, INSERM CIC1415, CHRU de Tours, Tours, France.;CRICS-TriGGERSep network, Centre d'Etude des Pathologies Respiratoires, Université de Tours, Tours, France.;Division of Anaesthetics, Pain Medicine & Intensive Care, Imperial College London, London, UK.;Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.;Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.;NIHR Bristol Biomedical Research Centre, Bristol, UK.;NIHR Applied Research Collaboration (ARC) West, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.;Nuffield Department of Medicine, University of Oxford, Oxford, UK.;Nuffield Department of Population Health, University of Oxford, Oxford, UK.;MRC Population Health Research Unit, University of Oxford, Oxford, UK.;NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.;Division of Infectious Diseases, San Gerardo Hospital, ASST Monza, Monza, Italy.;CIC INSERM 1415 - CHRU de Tours, Hôpital Bretonneau, Tours, France.;Délégation à la Recherche Clinique et à l'Innovation, CHRU de Tours, Tours, France.;George Institute for Global Health, University of New South Wales, Sydney, Australia.;Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada. | 2260 | ||||||
| Letter | en | Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. | https://www.ncbi.nlm.nih.gov/pubmed/32009228 | 2020-01-26 01:00:00+01:00 | pubmed | Alphacoronavirus__genetics;Betacoronavirus__genetics;Binding Sites;China__epidemiology;Coronavirus Infections__epidemiology;Disease Outbreaks;Genetic Variation;Humans;Middle East Respiratory Syndrome Coronavirus__genetics;Models, Chemical;Models, Theoretical;Peptidyl-Dipeptidase A__physiology;Phylogeny;Pneumonia, Viral__epidemiology;Protein Conformation;SARS Virus__genetics;Spike Glycoprotein, Coronavirus__genetics;COVID-19;severe acute respiratory syndrome coronavirus 2 | Xintian Xu;Ping Chen;Jingfang Wang;Jiannan Feng;Hui Zhou;Xuan Li;Wu Zhong;Pei Hao | 2020-01-21 01:00:00+01:00 | 32009228 | FR;CN | Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai, 200031, China.;Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Chinese Academy of Sciences, Shanghai, 200032, China.;The Joint Program in Infection and Immunity: Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China.;Key Laboratory of Systems Biomedicine, Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200240, China.;National Engineering Research Center for the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.;Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Chinese Academy of Sciences, Shanghai, 200032, China. lixuan@sippe.ac.cn.;National Engineering Research Center for the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. zhongwu@bmi.ac.cn.;Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai, 200031, China. phao@ips.ac.cn.;The Joint Program in Infection and Immunity: Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. phao@ips.ac.cn.;The Joint Program in Infection and Immunity: Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China. phao@ips.ac.cn. | 1 | |||||||
| 10.2807/1560-7917.es.2020.25.3.2000045 | Journal Article | en | Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. | https://www.ncbi.nlm.nih.gov/pubmed/31992387 | The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. | 1560-7917 | 2020-02-02 01:00:00+01:00 | pubmed | Clinical Laboratory Techniques__methods;Coronavirus__classification;Coronavirus Infections__diagnosis;Disease Outbreaks;Humans;RNA, Viral__analysis;Real-Time Polymerase Chain Reaction__methods;Sensitivity and Specificity;COVID-19 diagnostic testing | Eurosurveillance | Victor M Corman;Olfert Landt;Marco Kaiser;Richard Molenkamp;Adam Meijer;Daniel Kw Chu;Tobias Bleicker;Sebastian Brünink;Julia Schneider;Marie Luisa Schmidt;Daphne Gjc Mulders;Bart L Haagmans;Bas van der Veer;Sharon van den Brink;Lisa Wijsman;Gabriel Goderski;Jean-Louis Romette;Joanna Ellis;Maria Zambon;Malik Peiris;Herman Goossens;Chantal Reusken;Marion Pg Koopmans;Christian Drosten | 2019-nCoV;RT-PCR;Wuhan;diagnostics;laboratory;novel coronavirus;outbreak;testing | 2020-01-30 01:00:00+01:00 | 31992387 | FR;CN;GB;HK;NL;BE;DE | Charité - Universitätsmedizin Berlin Institute of Virology, Berlin, Germany and German Centre for Infection Research (DZIF), Berlin, Germany.;Tib-Molbiol, Berlin, Germany.;GenExpress GmbH, Berlin, Germany.;Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands.;National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.;University of Hong Kong, Hong Kong, China.;Universite d Aix-Marseille, Marseille, France.;Public Health England, London, United Kingdom.;Department of Medical Microbiology, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium. | 2 | ||
| 10.1016/s2542-5196(20)30035-8 | Journal Article | en | 2019-nCoV in context: lessons learned? | https://www.ncbi.nlm.nih.gov/pubmed/32035507 | 2542-5196 | 2020-02-09 01:00:00+01:00 | pubmed | Animals;Animals, Wild;Betacoronavirus__genetics;Civil Defense;Commerce;Coronavirus Infections__economics;Global Health__economics;Humans;Pandemics__economics;Pneumonia, Viral__economics;Public Health;Risk;Severe Acute Respiratory Syndrome__epidemiology;Zoonoses__prevention & control;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Planetary Health | Richard A Kock;William B Karesh;Francisco Veas;Thirumalaisamy P Velavan;David Simons;Leonard E G Mboera;Osman Dar;Liã Bárbara Arruda;Alimuddin Zumla | 2020-02-07 01:00:00+01:00 | 32035507 | FR;VN;GB;US;TZ;DE | Department of Pathobiology and Population Science, Royal Veterinary College, North Mymms, Hatfield, AL9 7TA, UK. Electronic address: Rkock@rvc.ac.uk.;EcoHealth Alliance, New York, NY, USA.;IRD, UMR5569, Faculty of Pharmacy, Montpellier University, Montpellier, France.;Institute of Tropical Medicine, Universitätsklinikum Tübingen, Tübingen, Germany, Vietnamese-German Center for Medical Research (VG-CARE), Hanoi, Vietnam, Faculty of Medicine, Duy Tan University, Da Nang, Vietnam.;Department of Pathobiology and Population Science, Royal Veterinary College, North Mymms, Hatfield, AL9 7TA, UK.;SACIDS Foundation for One Health, Sokoine University of Agriculture, Chuo Kikuu, Morogoro, Tanzania.;Chatham House Centre on Global Health Security, Royal Institute of International Affairs, London, UK.;Division of Infection and Immunity, University College London, and UCL Hospitals NIHR Biomedical Research Centre London, London, UK. | 3 | ||||
| 10.1101/2020.01.28.20019299 | Preprint | en | Risk for Transportation of 2019 Novel Coronavirus (COVID-19) from Wuhan to Cities in China. | https://www.ncbi.nlm.nih.gov/pubmed/32511457 | On January 23, 2020, China quarantined Wuhan to contain an emerging coronavirus (COVID-19). We estimated the probability of transportation of COVID-19 from Wuhan to 369 cities in China before the quarantine. The expected risk is >50% in 130 (95% CI 89-190) cities and >99% in the 4 largest metropolitan areas of China. | 2020-02-23 01:00:00+01:00 | pubmed | Zhanwei Du;Lin Wang;Simon Cauchemez;Xiaoke Xu;Xianwen Wang;Benjamin J Cowling;Lauren Ancel Meyers | Wuhan;coronavirus;epidemiology;importation | 2020-02-17 01:00:00+01:00 | 32511457 | FR;CN;US;HK;MX | The University of Texas at Austin, Austin, Texas 78712, The United States of America.;nstitut Pasteur, 28 rue du Dr Roux, Paris 75015, France.;Dalian Minzu University, Dalian 116600, China.;Dalian University of Technology, Dalian 116024, China.;The University of Hong Kong, Sassoon Rd 7, Hong Kong SAR, China.;Santa Fe Institute, Santa Fe, New Mexico, The United States of America. | 9 | |||||
| 10.1016/j.ijantimicag.2020.105937 | Editorial | en | COVID-19 Therapeutic and Prevention. | https://www.ncbi.nlm.nih.gov/pubmed/32151714 | 0924-8579 | 2020-03-08 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__prevention & control;Humans;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Antimicrobial Agents | Didier Raoult;Po-Ren Hsueh;Stefania Stefani;Jean-Marc Rolain | 2020-03-07 01:00:00+01:00 | 32151714 | FR;IT;TW | MEФI, IRD, Aix Marseille Univ, AP-HM, Marseille, France, IHU-Méditerranée Infection, Marseille, France. Electronic address: didier.raoult@gmail.com.;Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.;University of Catania, Department of Biomedical and Biotechnological Sciences, Biological Tower, Third floor -Est Tower, Catania, Italy.;MEФI, IRD, Aix Marseille Univ, AP-HM, Marseille, France, IHU-Méditerranée Infection, Marseille, France. | 21 | ||||
| Letter;Comment | en | Managing neonates with respiratory failure due to SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32151320 | 2020-03-08 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Disease Outbreaks;Humans;Infant, Newborn;Intensive Care Units, Neonatal;Pneumonia, Viral;Respiratory Insufficiency;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Daniele De Luca | 2020-03-06 01:00:00+01:00 | 32151320 | FR | Division of Pediatrics and Neonatal Critical Care, "A Béclère" Medical Center, Paris Saclay University Hospitals, Assistance Publique-Hopitaux de Paris, Paris, France, Therapeutic Innovation Unit, U999, Paris Saclay University, Paris, France. Electronic address: dm.deluca@icloud.com. | 23 | |||||||
| 10.1101/2020.03.02.20026708 | Preprint | en | The effect of human mobility and control measures on the COVID-19 epidemic in China. | https://www.ncbi.nlm.nih.gov/pubmed/32511452 | The ongoing COVID-19 outbreak has expanded rapidly throughout China. Major behavioral, clinical, and state interventions are underway currently to mitigate the epidemic and prevent the persistence of the virus in human populations in China and worldwide. It remains unclear how these unprecedented interventions, including travel restrictions, have affected COVID-19 spread in China. We use real-time mobility data from Wuhan and detailed case data including travel history to elucidate the role of case importation on transmission in cities across China and ascertain the impact of control measures. Early on, the spatial distribution of COVID-19 cases in China was well explained by human mobility data. Following the implementation of control measures, this correlation dropped and growth rates became negative in most locations, although shifts in the demographics of reported cases are still indicative of local chains of transmission outside Wuhan. This study shows that the drastic control measures implemented in China have substantially mitigated the spread of COVID-19. | 2020-03-08 01:00:00+01:00 | pubmed | Moritz U G Kraemer;Chia-Hung Yang;Bernardo Gutierrez;Chieh-Hsi Wu;Brennan Klein;David M Pigott;Louis du Plessis;Nuno R Faria;Ruoran Li;William P Hanage;John S Brownstein;Maylis Layan;Alessandro Vespignani;Huaiyu Tian;Christopher Dye;Simon Cauchemez;Oliver G Pybus;Samuel V Scarpino | 2020-03-06 01:00:00+01:00 | 32511452 | FR;CN;GB;US;EC | Department of Zoology, University of Oxford, United Kingdom.;Harvard Medical School, Harvard University, Boston, United States.;Boston Children's Hospital, Boston, United States.;Network Science Institute, Northeastern University, Boston, United States.;School of Biological and Environmental Sciences, Universidad San Francisco de Quito USFQ, Quito, Ecuador.;Mathematical Sciences, University of Southampton, Southampton, United Kingdom.;Institute for Health Metrics and Evaluation, Department of Health Metrics, University of Washington, Seattle, United States.;Harvard T.H. Chan School of Public Health, Boston, United States.;Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France.;State Key Laboratory of Remote Sensing Science, College of Global Change and Earth System Science, Beijing Normal University, Beijing, China. | 24 | ||||||
| Letter | en | COVID 19: Will the 2020 Hajj pilgrimage and Tokyo Olympic Games be cancelled? | https://www.ncbi.nlm.nih.gov/pubmed/32171882 | 2020-03-15 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Crowding;Humans;Islam;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Saudi Arabia;Sports;Tokyo;Travel;COVID-19;severe acute respiratory syndrome coronavirus 2 | Philippe Gautret;Jaffar A Al-Tawfiq;Van Thuan Hoang | 2020-03-11 01:00:00+01:00 | 32171882 | FR;VN;US;SA | Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France, IHU-Méditerranée Infection, Marseille, France. Electronic address: philippe.gautret@ap-hm.fr.;Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.;Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France, IHU-Méditerranée Infection, Marseille, France, Thai Binh University of Medicine and Pharmacy, Thai Binh, Viet Nam. | 35 | |||||||
| Editorial;Comment | fr | [The novel coronavirus Covid-19: What are the ophthalmic risks?] | https://www.ncbi.nlm.nih.gov/pubmed/32165057 | 2020-03-15 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | R Tahiri Joutei Hassani;O Sandali | 2020-03-09 01:00:00+01:00 | 32165057 | FR | Service de chirurgie ambulatoire, centre hospitalier d'Avranches Granville, 849, rue des Menneries, 50400 Granville, France. Electronic address: tjhr78@hotmail.com.;Service de chirurgie ambulatoire, clinique Guillaume-de-Varye, Bourges, France. | 37 | |||||||
| Letter | en | Real estimates of mortality following COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32171390 | 2020-03-15 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Data Interpretation, Statistical;Global Health__statistics & numerical data;Humans;Pandemics;Pneumonia, Viral__epidemiology;World Health Organization;COVID-19;severe acute respiratory syndrome coronavirus 2 | David Baud;Xiaolong Qi;Karin Nielsen-Saines;Didier Musso;Léo Pomar;Guillaume Favre | 2020-03-12 01:00:00+01:00 | 32171390 | FR;CN;CH;US | Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: david.baud@chuv.ch.;CHESS Center, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.;Division of Pediatric Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.;Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique-Hôpitaux de Marseille, Service de Santé des Armées, Vecteurs-Infections Tropicales et Méditerranéennes (VITROME), Institut Hospitalo-Universitaire-Méditerranée Infection, Marseille, France, Laboratoire Eurofins-Labazur Guyane, French Guiana, France.;Materno-fetal and Obstetrics Research Unit, Department Woman-Mother-Child, Lausanne University Hospital, 1011 Lausanne, Switzerland. | 38 | |||||||
| 10.1016/s2213-2600(20)30121-1 | Journal Article;Review | en | Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. | https://www.ncbi.nlm.nih.gov/pubmed/32203711 | WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality. | 2213-2600 | 2020-03-22 01:00:00+01:00 | pubmed | Betacoronavirus__isolation & purification;Communicable Diseases, Emerging__epidemiology;Coronavirus Infections__epidemiology;Extracorporeal Membrane Oxygenation__methods;Humans;Pandemics;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Respiratory Distress Syndrome, Adult__therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Respiratory Medicine | Kollengode Ramanathan;David Antognini;Alain Combes;Matthew Paden;Bishoy Zakhary;Mark Ogino;Graeme MacLaren;Daniel Brodie;Kiran Shekar | 2020-03-20 01:00:00+01:00 | 32203711 | FR;SG;AU;US | Cardiothoracic Intensive Care Unit, National University Hospital, National University of Singapore, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Bond University, Robina, QLD, Australia.;University of Queensland, Brisbane, QLD, Australia.;Institute of Cardiometabolism and Nutrition, University of Paris, Paris, France, Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.;Department of Pediatrics, Emory University, Atlanta, GA, USA.;Division of Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA.;Department of Paediatrics, Division of Neonatology, Nemours Alfred I duPont Hospital for Children, Wilmington, DE, USA, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.;Cardiothoracic Intensive Care Unit, National University Hospital, National University of Singapore, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Paediatric Intensive Care Unit, The Royal Children's Hospital, University of Melbourne, Melbourne, VIC, Australia.;Columbia University College of Physicians and Surgeons, New York, NY, USA, Centre for Acute Respiratory Failure, New York-Presbyterian Hospital, New York, NY, USA.;Bond University, Robina, QLD, Australia, University of Queensland, Brisbane, QLD, Australia, Adult Intensive Care Services, The Prince Charles Hospital, Metro North Hospital and Health Service, Brisbane, QLD, Australia, Critical Care Research Group, Centre of Research Excellence for Advanced Cardio-respiratory Therapies Improving OrgaN Support, Brisbane, QLD, Australia. Electronic address: kiran.shekar@health.qld.gov.au. | 47 | |||
| 10.1016/j.gofs.2020.03.014 | Journal Article | fr | [SARS-CoV-2 infection during pregnancy. Information and proposal of management care. CNGOF]. | https://www.ncbi.nlm.nih.gov/pubmed/32199996 | A new coronavirus (SARS-CoV-2) highlighted at the end of 2019 in China is spreading across all continents. Most often at the origin of a mild infectious syndrome, associating mild symptoms (fever, cough, myalgia, headache and possible digestive disorders) to different degrees, SARS-Covid-2 can cause serious pulmonary pathologies and sometimes death. Data on the consequences during pregnancy are limited. The first Chinese data published seem to show that the symptoms in pregnant women are the same as those of the general population. There are no cases of intrauterine maternal-fetal transmission, but cases of newborns infected early suggest that there could be vertical perpartum or neonatal transmission. Induced prematurity and cases of respiratory distress in newborns of infected mothers have been described. Pregnancy is known as a period at higher risk for the consequences of respiratory infections, as for influenza, so it seems important to screen for Covid-19 in the presence of symptoms and to monitor closely pregnant women. In this context of the SARS-Covid-2 epidemic, the societies of gynecology-obstetrics, infectious diseases and neonatalogy have proposed a French protocol for the management of possible and proven cases of SARS-Covid-2 in pregnant women. These proposals may evolve on a daily basis with the advancement of the epidemic and knowledge in pregnant women. Subsequently, an in-depth analysis of cases in pregnant women will be necessary in order to improve knowledge on the subject. | 2468-7189 | 2020-03-22 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnosis;Female;Guidelines as Topic;Humans;Infant, Newborn;Infectious Disease Transmission, Vertical__prevention & control;Obstetrics__standards;Pandemics;Pneumonia, Viral__diagnosis;Pregnancy;Pregnancy Complications, Infectious__diagnosis;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gynécologie Obstétrique Fertilité & Sénologie | V Peyronnet;J Sibiude;P Deruelle;C Huissoud;X Lescure;J-C Lucet;L Mandelbrot;I Nisand;C Vayssière;Y Yazpandanah;D Luton;O Picone | COVID-19;Coronavirus SARS-CoV-2;Covid-19;Grossesse;Maternal-fetal transmission;Newborn;Nouveau-né;Pregnancy;Transmission materno-fœtale | 2020-03-19 01:00:00+01:00 | 32199996 | FR | Service de gynécologie-obstétrique Colombes, Assistance publique-Hôpitaux de Paris, hôpital Louis-Mourier, université de Paris, 92700 Colombes, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France.;Service de gynécologie-obstétrique Colombes, Assistance publique-Hôpitaux de Paris, hôpital Louis-Mourier, université de Paris, 92700 Colombes, France, Inserm IAME-U1137, 75000 Paris, France, Groupe de recherche sur les infections pendant la grossesse (GRIG), 75000 Paris, France, CNGOF, 91, boulevard de Sébastopol, 75002 Paris, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France.;CNGOF, 91, boulevard de Sébastopol, 75002 Paris, France, Service de gynécologie obstétrique, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France.;University Lyon, University Claude-Bernard Lyon 1, 69100 Villeurbanne, France, Hospices civils de Lyon, hôpital de la Croix-Rousse, 69004 Lyon, France, Inserm U846, stem cell and brain research institute, 18, avenue Doyen-Lepine, 69500 Bron, France, CNGOF, 91, boulevard de Sébastopol, 75002 Paris, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France.;Inserm IAME-U1137, 75000 Paris, France, Service de maladies infectieuses et tropicales, hôpital Bichat Claude-Bernard, université de Paris, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France.;Inserm IAME-U1137, 75000 Paris, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France.;CNGOF, 91, boulevard de Sébastopol, 75002 Paris, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France.;Hôpital Paule-de-Viguier, CHU de Toulouse, 31000 Toulouse, France, Équipe SPHERE, Inserm UMR1027, université Toulouse III, 31000 Toulouse, France, CNGOF, 91, boulevard de Sébastopol, 75002 Paris, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France.;Service de gynécologie obstétrique, maternité Aline-de-Crepy, FHU Prematurity INSERM U1016, hôpital Bichat APHP, université de Paris, Institut Imagine, 75018 Paris, France, CNGOF, 91, boulevard de Sébastopol, 75002 Paris, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France.;Service de gynécologie-obstétrique Colombes, Assistance publique-Hôpitaux de Paris, hôpital Louis-Mourier, université de Paris, 92700 Colombes, France, Inserm IAME-U1137, 75000 Paris, France, Groupe de recherche sur les infections pendant la grossesse (GRIG), 75000 Paris, France, CNGOF, 91, boulevard de Sébastopol, 75002 Paris, France, Infection Control Unit, Bichat University Hospital, Assistance publique-Hôpitaux de Paris, université de Paris, 75018 Paris, France. Electronic address: olivier.picone@aphp.fr. | 49 | ||
| Letter | en | Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino acid deletion in nsp2 (Asp268del). | https://www.ncbi.nlm.nih.gov/pubmed/32234449 | 2020-03-29 01:00:00+01:00 | pubmed | Amino Acid Sequence__genetics;Base Sequence;Betacoronavirus__genetics;Coronavirus Infections__epidemiology;France__epidemiology;Genome, Viral__genetics;Humans;Pandemics;Pneumonia, Viral__epidemiology;Sequence Analysis, RNA;Sequence Deletion__genetics;Viral Load;Viral Nonstructural Proteins__genetics;COVID-19;severe acute respiratory syndrome coronavirus 2 | A Bal;G Destras;A Gaymard;M Bouscambert-Duchamp;M Valette;V Escuret;E Frobert;G Billaud;S Trouillet-Assant;V Cheynet;K Brengel-Pesce;F Morfin;B Lina;L Josset | 2020-03-28 01:00:00+01:00 | 32234449 | FR | Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France, Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France, Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.;Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France, Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France.;Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France, Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France.;Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France, Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.;Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.;Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Lyon, France, Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de La Croix-Rousse, Hospices Civils de Lyon, Lyon, France, Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France. Electronic address: laurence.josset@chu-lyon.fr. | 58 | |||||||
| Letter;Comment | en | Considering the challenge of the Covid-19 pandemic, is there a need to adapt the guidelines for basic life support resuscitation? | https://www.ncbi.nlm.nih.gov/pubmed/32234368 | 2020-03-29 01:00:00+01:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Resuscitation;COVID-19;severe acute respiratory syndrome coronavirus 2 | Dominique Savary;François Morin;Marc Fadel;Pierre Metton;J C Richard;Alexis Descatha | 2020-03-28 01:00:00+01:00 | 32234368 | FR | Département de Médecine d'Urgence, Centre Hospitalier Universitaire d'Angers, Université de Santé d'Angers, 4 rue Larrey, 49933 Angers Cedex 9, France, UNIV Angers, CHU Angers, Univ Rennes, Inserm, EHESP, Irset, Institut de recherche en santé, environnement et travail - UMR_S1085, CAPTV CDC, F-49000 Angers, France. Electronic address: dsavary74@gmail.com.;Département de Médecine d'Urgence, Centre Hospitalier Universitaire d'Angers, Université de Santé d'Angers, 4 rue Larrey, 49933 Angers Cedex 9, France.;Occupational Health Unit, Poincaré University Hospital, AP-HP (Paris Hospital) UVSQ, Garches, France.;Réseau Nord Alpin des Urgences, CH-Annecy Genevois 1 avenue de l'hôpital, 74270 Pringy Annecy, France.;Réanimation Médicale, Centre Hospitalier Universitaire d'Angers, Université de Santé d'Angers, 4 rue Larrey, 49933 Angers Cedex 9, France.;UNIV Angers, CHU Angers, Univ Rennes, Inserm, EHESP, Irset, Institut de recherche en santé, environnement et travail - UMR_S1085, CAPTV CDC, F-49000 Angers, France. | 61 | |||||||
| 10.3390/ijms21072272 | Journal Article | en | Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients? | https://www.ncbi.nlm.nih.gov/pubmed/32218340 | The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen Candida albicans in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 °C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available. | 1422-0067 | 2020-03-29 01:00:00+01:00 | pubmed | Animals;Betacoronavirus__immunology;Coronavirus Infections__immunology;Humans;Immune System;Immunization, Passive;Immunoglobulins, Intravenous__isolation & purification;Mice;Pandemics;Periodicals as Topic;Pneumonia, Viral__immunology;COVID-19;COVID-19 serotherapy;severe acute respiratory syndrome coronavirus 2 | International Journal of Molecular Sciences | Samir Jawhara | IVIg;coronavirus;immunotherapy;nCoV-2019;virus | 2020-03-25 01:00:00+01:00 | 32218340 | FR | CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, INSERM U1285, F-59000 Lille, France.;University of Lille, F-59000 Lille, France. | 62 | ||
| 10.1016/j.gofs.2020.03.017 | Journal Article | fr | [Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF]. | https://www.ncbi.nlm.nih.gov/pubmed/32222433 | Recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. | 2468-7189 | 2020-03-29 01:00:00+01:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Cytoreduction Surgical Procedures;Female;France;Genital Neoplasms, Female__complications;Gynecologic Surgical Procedures__adverse effects;Humans;Minimally Invasive Surgical Procedures;Pandemics;Pneumonia, Viral__complications;Practice Guidelines as Topic;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gynécologie Obstétrique Fertilité & Sénologie | C Akladios;H Azais;M Ballester;S Bendifallah;P-A Bolze;N Bourdel;A Bricou;G Canlorbe;X Carcopino;P Chauvet;P Collinet;C Coutant;Y Dabi;L Dion;T Gauthier;O Graesslin;C Huchon;M Koskas;F Kridelka;V Lavoue;L Lecointre;M Mezzadri;C Mimoun;L Ouldamer;E Raimond;C Touboul | COVID-19;Cancer gynécologique;Guideline;Gynaecological cancer;Management;Prise en charge;Recommandation | 2020-03-25 01:00:00+01:00 | 32222433 | FR;BE | Service de gynécologie, CHU de Hautepierre, 67000 Strasbourg, France.;Service de gynécologie, hôpital la Pitié-Salpêtrière, 75013 Paris, France.;Service de gynécologie, Dioconessess Croix Saint Simon, 75012 Paris, France.;Service de gynécologie obstétrique, hôpital Tenon, 75020 Paris, France.;Service de gynécologie obstétrique, CHU Lyon Sud, 69000 Lyon, France.;Service de gynécologie obstétrique, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.;Service de gyécologie, La Timone, 13000 Marseille, France.;Service de gynécologie, hôpital Jeanne de Flandres, 59000 Lille, France.;Centre de lutte contre le cancer, 21000 Dijon, France.;Service de gynécologie, CHU hôpital Sud, 16, boulevard de Bulgarie, 35000 Rennes, France.;Service de gynécologie obstétrique, CHU, 87000 Limoges, France.;Service de gynécologie obstétrique, CHU, 51000 Reims, France.;Service de gynécologie obstétrique, CHI Poissy, 78300 Poissy, France.;Service de gynécologie obstétrique, hôpital Bichat, 75018 Paris, France.;Service de chirurgie oncologique, CHU, Liège, Belgique.;Service de gynécologie, CHU hôpital Sud, 16, boulevard de Bulgarie, 35000 Rennes, France. Electronic address: Vincent.lavoue@gmail.com.;Service de gynécologie, hôpital Lariboisière, 75010 Paris, France.;Service de gynécologie, CHU Tours, 37000 Tours, France. | 64 | ||
| Journal Article;Comment | en | The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32220659 | 2020-03-29 01:00:00+01:00 | pubmed | Betacoronavirus;China;Coronavirus Infections;Humans;Neoplasms;Pandemics;Pneumonia, Viral;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Benoit You;Alain Ravaud;Anne Canivet;Gérard Ganem;Philippe Giraud;Rosine Guimbaud;Laure Kaluzinski;Ivan Krakowski;Didier Mayeur;Thomas Grellety;Jean-Pierre Lotz | 2020-03-25 01:00:00+01:00 | 32220659 | FR | Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon, Centre d'Investigation des Thérapeutiques en Oncologie et Hématologie de lyon, Université Claude Bernard Lyon 1, Lyon 69495, France. Electronic address: benoit.you@chu-lyon.fr.;Medical Oncology, Bordeaux University Hospital, Bordeaux, France.;Service d'hygiene, Centre de Lutte Contre le Cancer François Baclesse, Caen, France.;Clinique Victor Hugo-Centre Jean Bernard, Le Mans, France.;Radiotherapy Department, Hôpital Européen Georges Pompidou, Sociéré Francaise de Radiothérapie Oncologique, France.;Oncologie Médicale Digestive, CHU de Toulouse, Toulouse, France.;Centre Hospitalier Public du Cotentin, Cherbourg-en-Cotentin, France.;Centre de Lutte Contre le Cancer Institut Bergonié, Bordeaux, Association Francophone pour les Soins Oncologiques de Support (AFSOS), France.;Oncologie médicale, Centre Georges Francois Leclerc, Dijon, AFSOS, France.;Centre hospitalier de la Côte Basque, Service D'Oncologie Médicale, Bayonne, France.;Tenon Hospital, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris, France. | 67 | |||||||
| 10.1136/bjsports-2020-102306 | Editorial | en | Football cannot restart soon during the COVID-19 emergency! A critical perspective from the Italian experience and a call for action. | https://www.ncbi.nlm.nih.gov/pubmed/32209554 | 0306-3674,1473-0480 | 2020-03-29 01:00:00+01:00 | pubmed | British Journal of Sports Medicine | Alessandro Corsini;Gian Nicola Bisciotti;Cristiano Eirale;Piero Volpi | football;health;illness;training;virus | 2020-03-24 01:00:00+01:00 | 32209554 | QA;FR;IT | FC Internazionale Milano, Milano, Italy sirconi@gmail.com.;Aspetar Orthopaedic and Sports Medicine Hospital, Doha, Qatar.;Paris Saint Germain Football Club, Paris, France.;FC Internazionale Milano, Milano, Italy.;Knee Orthopaedics and Sport Traumatology, Humanitas Research Hospital, Rozzano, Milano, Italy. | 69 | ||||
| 10.1093/cid/ciaa171 | Journal Article | en | The first locally acquired novel case of 2019-nCoV infection in a healthcare worker in the Paris area. | https://www.ncbi.nlm.nih.gov/pubmed/32211789 | 1058-4838,1537-6591 | 2020-03-29 01:00:00+01:00 | pubmed | Clinical Infectious Diseases | Elise Klement;Nagisa Godefroy;Sonia Burrel;Dimitri Kornblum;Gentiane Monsel;Alexandre Bleibtreu;Anne-Geneviève Marcelin;Vincent Calvez;Eric Caumes;David Boutolleau;Valérie Pourcher | 2020-03-25 01:00:00+01:00 | 32211789 | FR | Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies infectieuses et Tropicales, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, laboratoire de virologie, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France. | 71 | |||||
| 10.1016/j.jemep.2020.100510 | Editorial | fr | [Covid-19 and some ethical issues in France]. | https://www.ncbi.nlm.nih.gov/pubmed/32292810 | 2352-5525 | 2020-04-05 02:00:00+02:00 | pubmed | Ethics, Medicine and Public Health | P Charlier | 2020-04-04 02:00:00+02:00 | 32292810 | FR | Laboratoire Anthropologie, Archéologie, Biologie (LAAB), Université Paris-Saclay (UVSQ), 2, avenue de la source de la Bièvre, 78180 Montigny-Le-Bretonneux, France. | 76 | |||||
| 10.1016/j.onehlt.2020.100131 | Editorial | en | Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32292817 | Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of people with close contact with patients with positive COVID19 rtPCR, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at doses matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/ day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people. | 2352-7714 | 2020-04-05 02:00:00+02:00 | pubmed | One Health | Stephane Picot;Aileen Marty;Anne-Lise Bienvenu;Lucille H Blumberg;Jean Dupouy-Camet;Pierre Carnevale;Shigeyuki Kano;Malcolm K Jones;Cláudio Tadeu Daniel-Ribeiro;Santiago Mas-Coma | COVID19;Chloroquine;Coronavirus, malaria, antiviral;Hydroxychloroquine;Immunomodulation;SARS-CoV2;Systemic lupus erythematosus | 2020-04-04 02:00:00+02:00 | 32292817 | FR;JP;US;BR;AU;ZA;ES | Malaria Research Unit, ICBMS, UMR 5246, CNRS, INSA, CPE University Lyon, 69100 Villeurbanne, France.;Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon, 69004 Lyon, France.;Translational Medicine, HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development, Miami, FL, United States.;Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, 69004 Lyon, France.;Division of Public Health Surveillance and Response, National Institute for Communicable Diseases, 2131 Johannesburg, South Africa.;Faculté de Médecine Paris Descartes, Académie Vétérinaire de France, Paris, France.;Institute of Research for Development (former), Montpellier Centre, BP 64501, 34394 Montpellier, France.;Department of Tropical Medicine and Malaria, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.;School of Veterinary Science, The University of Queensland, Brisbane, QLD, Australia.;Laboratório de Pesquisa em Malária, Instituto Oswaldo Cruz & Centro de Pesquisa de Diagnóstico e Treinamento, Fiocruz. Av. Brasil 4365. CEP 21.040-360, Rio de Janeiro, Brazil.;Departamento de Parasitología, Facultad de Farmacia, Universidad de Valencia, 46100, Valencia, Spain. | 83 | |||
| FIC NIH HHS;NIAID NIH HHS;FIC NIH HHS | 10.1093/cid/ciaa353 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't | en | The Late Arrival of Coronavirus Disease 2019 (COVID-19) in Africa: Mitigating Pan-continental Spread. | https://www.ncbi.nlm.nih.gov/pubmed/32227121 | The novel coronavirus disease 2019 (COVID-19) has rapidly spread to all 7 continents. Due to yet unknown reasons, the African continent has remained relatively unaffected. We discuss the importance of mitigating pan-continental spread in light of the fragile healthcare systems. | 1058-4838,1537-6591 | 2020-04-05 02:00:00+02:00 | pubmed | Adult;Africa__epidemiology;Betacoronavirus;Coronavirus Infections__epidemiology;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;World Health Organization;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Infectious Diseases | Jean Nachega;Moussa Seydi;Alimuddin Zumla | Africa;COVID-19;SARS-Cov-2;pandemic | 2020-04-01 02:00:00+02:00 | 32227121 | FR;SN;GB;US;ZA | [{"country": "United States", "agency": "FIC NIH HHS", "grantid": "R25 TW011217"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U01 AI069521"}, {"country": "United States", "agency": "FIC NIH HHS", "grantid": "D43 TW010937"}] | Department of Medicine and Center for Infectious Diseases, Stellenbosch University, Cape Town, South Africa.;Department of Epidemiology and Center for Global Health, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.;Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.;Service de Maladies Infectieuses et Tropicale, Centre Hospitalier Universitaire de Fann, Université Cheikh Anta Diop, Dakar, Senegal.;Department of Infection, Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, United Kingdom.;National Institute for Health Research Biomedical Research Centre, University College London Hospitals, London, United Kingdom. | 86 |
| 10.1002/uog.22029 | Consensus Development Conference;Journal Article | en | ISUOG Consensus Statement on organization of routine and specialist obstetric ultrasound services in context of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32233049 | 0960-7692,1469-0705 | 2020-04-05 02:00:00+02:00 | pubmed | Appointments and Schedules;Coronavirus Infections__diagnosis;Delivery of Health Care__methods;Female;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Infectious Disease Transmission, Professional-to-Patient__prevention & control;Masks;Mass Screening;Obstetrics;Pandemics__prevention & control;Patient Isolation;Pneumonia, Viral__diagnosis;Point-of-Care Testing;Pregnancy;Quarantine;Telemedicine;Triage__methods;Ultrasonography, Prenatal__methods;COVID-19 | Ultrasound in Obstetrics & Gynecology | R S Abu-Rustum;R Akolekar;A Sotiriadis;L J Salomon;F Da Silva Costa;Q Wu;T Frusca;C M Bilardo;F Prefumo;L C Poon | 2020-04-02 02:00:00+02:00 | 32233049 | FR;CN;GR;GB;US;HK;BR;IT;AU;NL | Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL, USA.;Fetal Medicine Unit, Medway NHS Foundation Trust, Gillingham, UK.;Institute of Medical Sciences, Canterbury Christ Church University, Kent, UK.;Second Department of Obstetrics and Gynecology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.;Obstétrique et Plateforme LUMIERE, Hôpital Necker-Enfants Malades (AP-HP) et Université de Paris, Paris, France.;Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.;Department of Obstetrics and Gynaecology, Monash University, Meulbourne, Australia.;Department of Ultrasound, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, P.R. China.;Obstetrics and Gynecology Unit, University of Parma, Parma, Italy.;Department of Obstetrics, Gynaecology and Fetal Medicine, AmsterdamUmc, Location VUmc, Amsterdam, The Netherlands.;Department of Clinical and Experimental Sciences, University of Brescia, Italy.;Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR. | 87 | ||||
| 10.1016/j.hrthm.2020.03.024 | Journal Article | en | SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. | https://www.ncbi.nlm.nih.gov/pubmed/32244059 | Ever since the first case was reported at the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and the associated lung disease "coronavirus disease 2019" (COVID-19) has become a serious threat to public health globally in short time. At this point in time, there is no proven effective therapy. The interactions with concomitant disease are largely unknown, and that may be particularly pertinent to inherited arrhythmia syndrome. An arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk of cardiac arrhythmias, either secondary to acquired conditions or comorbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to proarrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances, and use of antiviral drugs. Here, we describe the potential COVID-19-associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic. | 1547-5271 | 2020-04-05 02:00:00+02:00 | pubmed | Heart Rhythm | Cheng-I Wu;Pieter G Postema;Elena Arbelo;Elijah R Behr;Connie R Bezzina;Carlo Napolitano;Tomas Robyns;Vincent Probst;Eric Schulze-Bahr;Carol Ann Remme;Arthur A M Wilde | Brugada syndrome;COVID-19;Catecholaminergic polymorphic ventricular tachycardia;Long QT syndrome;SARS-CoV-2;Short QT syndrome | 2020-03-31 02:00:00+02:00 | 32244059 | FR;GB;TW;IT;NL;ES;BE;DE | Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, The Netherlands, European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart), Heart Rhythm Center, Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Electronic address: c.wu@amsterdamumc.nl.;Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, The Netherlands, European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart).;Arrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.;European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart), Cardiology Clinical Academic Group, St George's University of London and St George's University Hospitals NHS Foundation Trust, London, United Kingdom.;European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart), Molecular Cardiology and Medicine Division, Istituti Clinici Scientifici Maugeri, IRCCS, Pavia, Italy.;European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart), Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart), l'Institut du thorax, Service de Cardiologie du CHU de Nantes, Hopital Nord, Nantes Cedex, France.;European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart), Institute for Genetics of Heart Diseases (IfGH), Division of Cardiovascular Medicine, University Hospital Münster, Münster, Germany.;Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, The Netherlands, European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart). Electronic address: a.a.wilde@amsterdamumc.nl. | 106 | |||
| World Health Organization | Letter | en | Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. | https://www.ncbi.nlm.nih.gov/pubmed/32233040 | 2020-04-05 02:00:00+02:00 | pubmed | Jean Bousquet;Cezmi Akdis;Marek Jutel;Claus Bachert;Ludger Klimek;Ioana Agache;Ignacio J Ansotegui;Anna Bedbrook;Sinthia Bosnic-Anticevich;Giorgio W Canonica;Tomas Chivato;Alvaro A Cruz;Wienia Czarlewski;Stefano Del Giacco;Hui Du;Joao A Fonseca;Yadong Gao;Tari Haahtela;Karin Hoffmann-Sommergruber;Juan C Ivancevich;Nikolai Khaltaev;Edward F Knol;Piotr Kuna;Desiree Larenas-Linnemann;Joaquim Mullol;Robert Naclerio;Ken Ohta;Y Okamoto;Liam O'Mahony;Gabrielle L Onorato;Nikos G Papadopoulos;Oliver Pfaar;Boleslaw Samolinski;Jürgen Schwarze;Sanna Toppila-Salmi;Maria Teresa Ventura;Arunas Valiulis;Arzu Yorgancioglu;Torsten Zuberbier | 2020-03-31 02:00:00+02:00 | 32233040 | LT;PT;JP;BR;AR;NL;MX;BE;FR;CN;GR;CH;RO;US;GB;PL;IT;AT;DE;IE;FI;AU;TR;ES | [{"country": "International", "agency": "World Health Organization", "grantid": "001"}] | Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.;University Hospital Montpellier, France.;MACVIA-France, Montpellier, France.;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.;Department of Clinical Immunology, Wrocław Medical University, ALL-MED Medical Research Institute, Wroclaw, Poland.;Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium.;Center for Rhinology and Allergology, Wiesbaden, Germany.;Transylvania University Brasov, Brasov, Romania.;Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain.;Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia.;Personalized Medicine Clinic Asthma & Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milan, Italy.;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.;School of Medicine, University CEU San Pablo, Madrid, Spain.;3ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil.;Medical Consulting Czarlewski, Levallois, and MASK-air, Montpellier, France.;Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital "Duilio Casula", University of Cagliari, Cagliari, Italy.;Department of Respiratory Medicine, Wuhan Children's Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, Hubei, China.;Center for research in health technologies and information systems- CINTESIS, Universidade do Porto, Porto, Portugal.;Allergy Unit, Instituto CUF Porto e Hospital CUF Porto, Porto, Portugal.;Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.;Faculdade de Medicina da Universidade do Porto, Porto, Portugal.;Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.;Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.;Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.;Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.;GARD Chairman, Geneva, Switzerland.;Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.;Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland.;Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.;Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain.;Johns Hopkins School of Medicine, Baltimore, Maryland, USA.;National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.;Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.;Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.;Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.;Allergy Dpt, Pediatric Clinic, University of Athens, Athens, Greece.;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany.;Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Poland.;Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, United Kingdom.;University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy.;Vilnius University, Faculty of Medicine, Institute of Clinical Medicine &, Institute of Health Sciences, Vilnius, Lithuania.;European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.;Celal Bayar University, Department of Pulmonology, Manisa, Turkey.;Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Uniersität zu Berlin, Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, member of GA2LEN, Berlin, Germany. | 112 | ||||||
| 10.4088/jcp.20com13361 | Journal Article | en | A Viewpoint From Paris on the COVID-19 Pandemic: A Necessary Turn to Telepsychiatry. | https://www.ncbi.nlm.nih.gov/pubmed/32237302 | 1555-2101 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Communication;Coronavirus Infections__epidemiology;Humans;Inpatients;Interprofessional Relations;Mental Disorders__therapy;Pandemics;Paris;Pneumonia, Viral__epidemiology;Practice Patterns, Physicians'__trends;Psychiatric Department, Hospital;Psychiatry__trends;Telemedicine__trends;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Journal of Clinical Psychiatry | Emmanuelle Corruble | 2020-03-31 02:00:00+02:00 | 32237302 | FR | Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin-Bicêtre, 94270, France. emmanuelle.corruble@aphp.fr.;Psychiatry Department, Mood Center, Bicêtre Hospital, GH Paris Saclay-Assistance Publique-Hôpitaux de Paris, France;INSERM CESP MOODS team, Bicêtre Hospital, Paris Saclay University, Le Kremin-Bicêtre, France | 114 | ||||
| 10.1016/j.jogoh.2020.101729 | Practice Guideline | en | Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF. | https://www.ncbi.nlm.nih.gov/pubmed/32247066 | In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. | 2468-7847 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Chemotherapy, Adjuvant;Coronavirus Infections__complications;Endometrial Neoplasms__pathology;Female;France;Genital Neoplasms, Female__complications;Gynecology;Humans;Interdisciplinary Communication;Obstetrics;Ovarian Neoplasms__drug therapy;Pandemics__prevention & control;Pneumonia, Viral__complications;Receptors, Lymphocyte Homing;Risk;Societies, Medical;Trophoblastic Neoplasms__drug therapy;Uterine Cervical Neoplasms__therapy;Vaginal Neoplasms__therapy;Vulvar Neoplasms__surgery;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Gynecology Obstetrics and Human Reproduction | Cherif Akladios;Henri Azais;Marcos Ballester;Sofiane Bendifallah;Pierre-Adrien Bolze;Nicolas Bourdel;Alexandre Bricou;Geoffroy Canlorbe;Xavier Carcopino;Pauline Chauvet;Pierre Collinet;Charles Coutant;Yohann Dabi;Ludivine Dion;Tristan Gauthier;Olivier Graesslin;Cyrille Huchon;Martin Koskas;Frederic Kridelka;Vincent Lavoue;Lise Lecointre;Matthieu Mezzadri;Camille Mimoun;Lobna Ouldamer;Emilie Raimond;Cyril Touboul | COVID-19;Guideline;Gynaecological cancer;Management | 2020-04-01 02:00:00+02:00 | 32247066 | FR;BE | Service de gynécologie, CHU de Hautepierre, 67000 Strasbourg, France.;Service de gynécologie, Hopital la Pitié Salpetriee, 75013 Paris, France.;Service de gynécologie, Dioconessess Croix Saint Simon, 75012 Paris, France.;Service de gynécologie obstétrique, HôpitalTenon, 75020 Paris, France.;Service de gynécologie Obstétrique, CHU Lyon Sud, 69000 Lyon, France.;Service de gynécologie obstétrique, Chu Clermont Ferrand, 63000 Clermont Ferrand, France.;Service de gyécologie, La Timone, 13000 Marseille, France.;Service de gynécologie, Hôpital Jeanne de Flandres, 59 000 Lille, France.;Centre de Lutte Contre le Cancer, 21 000 Dijon, France.;Service de gynécologie, CHU Hôpital Sud, 35000 Rennes, France.;Service de gynécologie obstétrique, CHU, 87000 Limoges, France.;Service de gynécologie obstétrique, CHU 51000 Reims, France.;Service de gynécologie obstétrique, CHI Poissy, 78300 Poissy, France.;Service de gynécologie obstétrique, Hopital Bichat, 75018 Paris, France.;Service de chirurgie oncologique, CHU, Liege, Belgique, France.;Service de gynécologie, CHU Hôpital Sud, 35000 Rennes, France. Electronic address: Vincent.lavoue@gmail.com.;Service de gynécologie, Hôpital Lariboisière, 75010 Paris, France.;Service de gynécologie, CHU Tours, 37000 Tours, France. | 116 | ||
| 10.2196/18810 | Journal Article | en | Global Telemedicine Implementation and Integration Within Health Systems to Fight the COVID-19 Pandemic: A Call to Action. | https://www.ncbi.nlm.nih.gov/pubmed/32238336 | On March 11, 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) outbreak as a pandemic, with over 720,000 cases reported in more than 203 countries as of 31 March. The response strategy included early diagnosis, patient isolation, symptomatic monitoring of contacts as well as suspected and confirmed cases, and public health quarantine. In this context, telemedicine, particularly video consultations, has been promoted and scaled up to reduce the risk of transmission, especially in the United Kingdom and the United States of America. Based on a literature review, the first conceptual framework for telemedicine implementation during outbreaks was published in 2015. An updated framework for telemedicine in the COVID-19 pandemic has been defined. This framework could be applied at a large scale to improve the national public health response. Most countries, however, lack a regulatory framework to authorize, integrate, and reimburse telemedicine services, including in emergency and outbreak situations. In this context, Italy does not include telemedicine in the essential levels of care granted to all citizens within the National Health Service, while France authorized, reimbursed, and actively promoted the use of telemedicine. Several challenges remain for the global use and integration of telemedicine into the public health response to COVID-19 and future outbreaks. All stakeholders are encouraged to address the challenges and collaborate to promote the safe and evidence-based use of telemedicine during the current pandemic and future outbreaks. For countries without integrated telemedicine in their national health care system, the COVID-19 pandemic is a call to adopt the necessary regulatory frameworks for supporting wide adoption of telemedicine. | 2369-2960 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections__epidemiology;Disease Outbreaks;Humans;Pandemics;Pneumonia, Viral__epidemiology;Population Surveillance;Public Health;Telemedicine;COVID-19;severe acute respiratory syndrome coronavirus 2 | JMIR Public Health and Surveillance | Robin Ohannessian;Tu Anh Duong;Anna Odone | COVID-19;SARS-CoV-2;coronavirus;digital health;digital medicine;outbreak;pandemic;public health;surveillance;telehealth;telemedicine | 2020-04-02 02:00:00+02:00 | 32238336 | FR;IT | Télémédecine 360, TLM360, Paris, France.;Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.;Chaire Avenir Sante numérique, équipe 8 IMRB, Inserm, Créteil, France.;School of Public Health, Faculty of Medicine, University Vita-Salute San Raffaele, Milan, Italy.;Clinical Epidemiology and HTA, IRCCS San Raffaele Scientific Institute, Milan, Italy.;Digital Health Section, European Public Health Association, Milan, Italy. | 118 | ||
| Letter | en | A New Symptom of COVID-19: Loss of Taste and Smell. | https://www.ncbi.nlm.nih.gov/pubmed/32237199 | 2020-04-05 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Female;Humans;Olfaction Disorders__virology;Pandemics;Pneumonia, Viral__complications;Smell;Taste;Taste Disorders__virology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean-François Gautier;Yann Ravussin | 2020-04-01 02:00:00+02:00 | 32237199 | FR;CH | Department of Diabetes and Endocrinology, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France.;INSERM UMRS 1138, Centre de Recherches des Cordeliers, Paris, France.;Department of Endocrinology, Metabolism & Cardiovascular System, Faculty of Science & Medicine, University of Fribourg, Fribourg, Switzerland. | 128 | |||||||
| 10.1016/j.recesp.2020.04.001 | Case Reports | sp | [Fulminant myocarditis due to COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32292228 | 0300-8932 | 2020-04-12 02:00:00+02:00 | pubmed | Revista Española de Cardiología | Ángela Irabien-Ortiz;José Carreras-Mora;Alessandro Sionis;Julia Pàmies;José Montiel;Manel Tauron | 2020-04-10 02:00:00+02:00 | 32292228 | FR;ES | Servicio de Cirugía Cardiovascular, Hospital de la Santa Creu i Sant Pau, Barcelona, España.;Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. | 133 | |||||
| Gilead Sciences | 10.1056/nejmoa2007016 | Journal Article;Research Support, Non-U.S. Gov't | en | Compassionate Use of Remdesivir for Patients with Severe Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32275812 | Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. | 0028-4793,1533-4406 | 2020-04-12 02:00:00+02:00 | pubmed | Adenosine Monophosphate__adverse effects;Administration, Intravenous;Adult;Aged;Aged, 80 and over;Alanine__adverse effects;Antiviral Agents__adverse effects;Betacoronavirus;Canada;Compassionate Use Trials;Coronavirus Infections__drug therapy;Europe;Female;Humans;Japan;Male;Middle Aged;Pandemics;Pneumonia, Viral__drug therapy;Respiration, Artificial;United States;Young Adult;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | New England Journal of Medicine | Jonathan Grein;Norio Ohmagari;Daniel Shin;George Diaz;Erika Asperges;Antonella Castagna;Torsten Feldt;Gary Green;Margaret L Green;François-Xavier Lescure;Emanuele Nicastri;Rentaro Oda;Kikuo Yo;Eugenia Quiros-Roldan;Alex Studemeister;John Redinski;Seema Ahmed;Jorge Bernett;Daniel Chelliah;Danny Chen;Shingo Chihara;Stuart H Cohen;Jennifer Cunningham;Antonella D'Arminio Monforte;Saad Ismail;Hideaki Kato;Giuseppe Lapadula;Erwan L'Her;Toshitaka Maeno;Sumit Majumder;Marco Massari;Marta Mora-Rillo;Yoshikazu Mutoh;Duc Nguyen;Ewa Verweij;Alexander Zoufaly;Anu O Osinusi;Adam DeZure;Yang Zhao;Lijie Zhong;Anand Chokkalingam;Emon Elboudwarej;Laura Telep;Leighann Timbs;Ilana Henne;Scott Sellers;Huyen Cao;Susanna K Tan;Lucinda Winterbourne;Polly Desai;Robertino Mera;Anuj Gaggar;Robert P Myers;Diana M Brainard;Richard Childs;Timothy Flanigan | 2020-04-10 02:00:00+02:00 | 32275812 | FR;CA;JP;BO;US;AT;IT;NL;ES;DE | [{"country": "International", "agency": "Gilead Sciences", "grantid": "N/A"}] | From Cedars-Sinai Medical Center, Los Angeles (J.G.), El Camino Hospital, Mountain View (D.S., D. Chelliah), Sutter Santa Rosa Regional Hospital, Santa Rosa (G.G.), Regional Medical Center (A.S., J.R.) and Good Samaritan Hospital (S.M.), San Jose, John Muir Health, Walnut Creek (J.B.), UC Davis Health, Sacramento (S.H.C.), NorthBay Medical Center, Fairfield (S.I.), and Gilead Sciences, Foster City (A.O.O., A.D., Y.Z., L.Z., A. Chokkalingam, E.E., L. Telep, L. Timbs, I.H., S.S., H.C., S.K.T., L.W., P.D., R.M., A.G., R.P.M., D.M.B.) - all in California, the National Center for Global Health and Medicine, Tokyo (N.O.), Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu City (R.O.), Hiratsuka City Hospital, Hiratsuka (K.Y.), Yokohama City University Hospital, Yokohama (H.K.), Gunma University Hospital, Gunma (T.M.), and Tosei General Hospital, Seto (Y.M.) - all in Japan, Providence Regional Medical Center Everett, Everett (G.D.), and University of Washington Medical Center-Northwest (M.L.G.) and Virginia Mason Medical Center (S. Chihara), Seattle - all in Washington, Fondazione IRCCS Policlinico San Matteo, Pavia (E.A.), IRCCS, San Raffaele Scientific Institute (A. Castagna) and Azienda Socio Sanitaria Territoriale Spedali (ASST) Santi Paolo e Carlo, Department of Health Services, University of Milan (A.D.M.), Milan, National Institute for Infectious Diseases, IRCCS, L. Spallanzani, Rome (E.N.), Università degli Study of Brescia, ASST Civili di Brescia, Brescia (E.Q.-R.), San Gerardo Hospital, ASST Monza, University of Milan-Bicocca, Monza (G.L.), and Azienda Unite Sanitarie Locali-IRCCS, Reggio Emilia (M.M.) - all in Italy, Universitätsklinikum Düsseldorf, Düsseldorf, Germany (T. Feldt), Université de Paris, Infection, Antimicrobiens, Modélisation, Evolution (IAME), INSERM, and Assistance Publique-Hôpitaux de Paris, Department of Infectious Diseases, Bichat Hospital, Paris (F.-X.L.), Centre Hospitalier Régional et Universitaire de Brest-La Cavale Blanche, Brest (E.L.), and Division of Infectious Diseases and Tropical Medicine, University Hospital of Bordeaux, Bordeaux (D.N.) - all in France, St. Alexius Medical Center, Hoffman Estates, IL (S.A.), Mackenzie Health, Richmond Hill, ON, Canada (D. Chen), Columbia University Irving Medical Center, New York (J.C.), Hospital Universitario La Paz-Carlos III, Instituto de Investigación Hospital Universitario La Paz, Madrid (M.M.-R.), Bernhoven Hospital, Uden, the Netherlands (E.V.), Kaiser Franz Josef Hospital, Vienna (A.Z.), the U.S. Public Health Service Commissioned Corps, Washington, DC (R.C.), and Miriam Hospital, Providence, RI (T. Flanigan). | 134 | |
| Letter;Comment | en | Regional air pollution persistence links to COVID-19 infection zoning. | https://www.ncbi.nlm.nih.gov/pubmed/32283151 | 2020-04-12 02:00:00+02:00 | pubmed | Air Pollution;Beijing;Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Antonio Frontera;Claire Martin;Kostantinos Vlachos;Giovanni Sgubin | 2020-04-10 02:00:00+02:00 | 32283151 | FR;IT;GB | IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.;Royal Papworth Hospital NHS Foundation Trust, Papworth Rd, Trumpington, Cambridge CB2 0AY, UK.;Hôpital Haut Leveque, 1 avenue Magellan, Bordeaux, France, LIRYC institute, Pessac 33600, France.;Department of Climatology, Environnements et Paléoenvironnements Océaniques et Continentaux, University of Bordeaux, Bordeaux, France. | 135 | |||||||
| Case Reports;Letter | en | Tracheal trauma after difficult airway management in morbidly obese patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32334809 | 2020-04-12 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__complications;Female;Humans;Hypoxia__diagnostic imaging;Intubation, Intratracheal__adverse effects;Male;Mediastinal Emphysema__diagnostic imaging;Middle Aged;Obesity, Morbid__complications;Pandemics;Pneumonia, Viral__complications;Tomography, X-Ray Computed;Trachea__diagnostic imaging;COVID-19;severe acute respiratory syndrome coronavirus 2 | Osama Abou-Arab;Pierre Huette;Pascal Berna;Yazine Mahjoub | ARDS;COVID-19;ECMO;airway management;obesity;pneumomediastinum;tracheal perforation | 2020-04-11 02:00:00+02:00 | 32334809 | FR | Amiens, France. Electronic address: osama.abouarab@gmail.com.;Amiens, France. | 137 | ||||||
| 10.1016/j.anorl.2020.04.008 | Practice Guideline | en | French consensus on management of head and neck cancer surgery during COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32303485 | In the context of the current pandemic, there is a need for specific advice concerning treatment of patients with Head and Neck cancers. The rule is to limit as much as possible the number of patients in order to reduce the risks of contamination by the SARS-Cov-2 virus for both patients and the caregivers, who are particularly exposed in ENT. The aim is to minimize the risk of loss of opportunity for patients and to anticipate the increased number of cancer patients to be treated at the end of the pandemic, taking into account the degree of urgency, the difficulty of the surgery, the risk of contaminating the caregivers (tracheotomy) and the local situation (whether or not the hospital and intensive care departments are overstretched). | 1879-7296 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Consensus;Coronavirus Infections__diagnosis;France__epidemiology;Head and Neck Neoplasms__surgery;Humans;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Squamous Cell Carcinoma of Head and Neck__surgery;Surgical Oncology__methods;Tracheostomy__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Annals of Otorhinolaryngology, Head and Neck Diseases | N Fakhry;P Schultz;S Morinière;I Breuskin;A Bozec;S Vergez;L de Garbory;D Hartl;S Temam;E Lescanne;V Couloigner;B Barry | COVID;COVID-19;ENT;Head and neck cancer;SARS-Cov-2 | 2020-04-11 02:00:00+02:00 | 32303485 | FR | Department of otorhinolaryngology, head and neck surgery, centre hospitalier universitaire (CHU) la Conception, Aix Marseille université, Assistance publique-Hôpitaux de Marseille, Marseille, France. Electronic address: nicolas.fakhry@ap-hm.fr.;Department of otorhinolaryngology, head and neck surgery, CHU, Strasbourg, France.;Department of otorhinolaryngology, head and neck surgery, CHU, Tours, France.;Department of otorhinolaryngology, head and neck surgery, institut Gustave-Roussy, Villejuif, France.;Department of otorhinolaryngology, head and neck surgery, centre Antoine-Lacassagne, Institut universitaire de la face et du cou, Nice, France.;Department of otorhinolaryngology, head and neck surgery, CHU de Toulouse/Oncopôle, Toulouse, France.;Department of otorhinolaryngology, head and neck surgery, CHU, Bordeaux, France.;Department of otorhinolaryngology, head and neck surgery, université Paris-Descartes, Assistance publique-Hôpitaux de Paris, Paris, France.;Department of otorhinolaryngology, head and neck surgery, hôpital Xavier Bichat-Claude Bernard, CHU Paris Nord-Val de Seine, Assistance publique-Hôpitaux de Paris, Paris, France. | 138 | ||
| 10.1007/s40264-020-00933-4 | Editorial | en | Chloroquine for COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32266694 | 0114-5916,1179-1942 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus__drug effects;Chloroquine__therapeutic use;Coronavirus Infections__drug therapy;Humans;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Drug Safety | Nicholas Moore | 2020-04-09 02:00:00+02:00 | 32266694 | FR | Bordeaux PharmacoEpi, INSERM CIC1401, Bordeaux, France. nicholas.moore@u-bordeaux.fr. | 141 | ||||
| 10.1002/uog.22047 | Consensus Development Conference;Journal Article | en | ISUOG Consensus Statement on rationalization of gynecological ultrasound services in context of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32267984 | 0960-7692,1469-0705 | 2020-04-12 02:00:00+02:00 | pubmed | Abscess__diagnostic imaging;Coronavirus Infections__prevention & control;Delivery of Health Care__methods;Female;Genital Diseases, Female__diagnostic imaging;Genital Neoplasms, Female__diagnostic imaging;Gynecology;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Infectious Disease Transmission, Professional-to-Patient__prevention & control;Ovarian Cysts__diagnostic imaging;Ovarian Diseases__diagnostic imaging;Ovarian Hyperstimulation Syndrome__diagnostic imaging;Pandemics__prevention & control;Pelvic Inflammatory Disease__diagnostic imaging;Pneumonia, Viral__prevention & control;Rupture, Spontaneous__diagnostic imaging;Torsion Abnormality__diagnostic imaging;Triage__methods;Ultrasonography__methods;Uterine Hemorrhage__diagnostic imaging;COVID-19 | Ultrasound in Obstetrics & Gynecology | T Bourne;M Leonardi;C Kyriacou;M Al-Memar;C Landolfo;D Cibula;G Condous;U Metzger;D Fischerova;D Timmerman;T van den Bosch | 2020-04-09 02:00:00+02:00 | 32267984 | FR;GB;US;IT;AU;CZ;BE | Early pregnancy and Acute Gynaecology Unit, Department of Obstetrics and Gynaecology, Queen Charlotte's and Chelsea Hospital, Imperial College, London, UK.;Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium.;KU Leuven, Department of Development and Regeneration, Leuven, Belgium.;Acute Gynecology, Early Pregnancy & Advanced Endoscopic Surgery Unit, Sydney Medical School Nepean, University of Sydney Nepean Hospital, Penrith, Sydney, Australia.;Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Rome, Italy.;Gynaecological Oncology Centre, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.;Centre d'Échographie de l'Odéon, Paris, France. | 144 | ||||
| 10.1007/s40257-020-00514-2 | Journal Article | en | Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32277351 | Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has spread rapidly worldwide and has been shown to have a wide spectrum of severity. COVID-19 has become a public health emergency of relevant international concern, and it was declared a pandemic by the World Health Organization on 11 March, 2020. SARS-CoV-2 infection in severe cases involves the host response as an important contributor to the disease process and tissue damage, mainly due to dysregulated and excessive innate immune responses. The primary immune response leads to viral clearance in the majority of cases. However, in a subgroup of patients, the secondary immune response may be exaggerated, leading to inflammatory-induced lung injury and other complications including pneumonitis, acute respiratory distress syndrome, respiratory failure, shock, organ failure, and potentially death. Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, are therapeutically managed with biologic and non-biologic immunosuppressive and immunomodulatory drugs. The outbreak of COVID-19 affects the management of these chronic conditions, not only for those who are already receiving treatment but also for those who are about to start a new treatment to control their disease. In this article, the management of cutaneous immune-mediated diseases during the COVID-19 pandemic is discussed. | 1175-0561,1179-1888 | 2020-04-12 02:00:00+02:00 | pubmed | Contraindications, Drug;Coronavirus Infections__immunology;Dermatitis, Atopic__drug therapy;Hidradenitis Suppurativa__drug therapy;Humans;Immunomodulation;Immunosuppressive Agents__therapeutic use;Pandemics;Pneumonia, Viral__immunology;Psoriasis__drug therapy;Skin Diseases__drug therapy;COVID-19 | American Journal of Clinical Dermatology | Tiago Torres;Luis Puig | 2020-04-12 02:00:00+02:00 | 32277351 | FR;PT;ES | Department of Dermatology, Centro Hospitalar Universitário Do Porto, Porto, Portugal. torres.tiago@outlook.com.;Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal. torres.tiago@outlook.com.;Department of Dermatology, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. | 148 | |||
| 10.1093/cid/ciaa424 | Journal Article | en | Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32277759 | On 7 February 2020, French Health authorities were informed of a confirmed case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an Englishman infected in Singapore who had recently stayed in a chalet in the French Alps. We conducted an investigation to identify secondary cases and interrupt transmission. | 1058-4838,1537-6591 | 2020-04-12 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Betacoronavirus__isolation & purification;Cluster Analysis;Coronavirus Infections__virology;Female;France;Humans;Middle Aged;Pandemics;Pneumonia, Viral__virology;Retrospective Studies;Serologic Tests__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Infectious Diseases | Kostas Danis;Olivier Epaulard;Thomas Bénet;Alexandre Gaymard;Séphora Campoy;Elisabeth Botelho-Nevers;Maude Bouscambert-Duchamp;Guillaume Spaccaferri;Florence Ader;Alexandra Mailles;Zoubida Boudalaa;Violaine Tolsma;Julien Berra;Sophie Vaux;Emmanuel Forestier;Caroline Landelle;Erica Fougere;Alexandra Thabuis;Philippe Berthelot;Raphael Veil;Daniel Levy-Bruhl;Christian Chidiac;Bruno Lina;Bruno Coignard;Christine Saura | COVID-19;SARS-CoV-2;cluster;coronavirus;infection | 2020-04-12 02:00:00+02:00 | 32277759 | FR | French National Public Health Agency, Department of Infectious Diseases, Saint-Maurice, France.;Infectious Diseases Department, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Fédération d'infectiologie multidisciplinaire de l'Arc Alpin, Université Grenoble Alpes, Grenoble, France.;Unité Mixte de Recherche 5075 (UMR 5075), Institut de biologie structurale, Grenoble, France.;French National Public Health Agency, Auvergne-Rhône-Alpes Regional Office, Lyon, France.;Department of Virology, Infective Agents Institute, National Reference Center for Respiratory Viruses North Hospital Network, Lyon, France.;Regional Health Agency of Auvergne Rhône Alpes, Lyon, France.;Infectious Diseases Department, University Hospital of Saint-Etienne, Lyon, France.;Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, St-Etienne, France.;Infectious and Tropical Disease Department, Croix-Rousse Hospital, University Hospital of Lyon, Lyon, France.;Infectious Diseases Unit, Centre Hospitalier Annecy Genevois, Annecy, France.;Infectious Disease Department, Centre Hospitalier Metropole Savoie, Chambery, France.;Service d'Hygiène Hospitalière et de Gestion des Risques, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques, Applications, Grenoble, Unité Mixte de Recherche 5525 (TIMC-IMAG UMR5525), CNRS, Université Grenoble Alpes, Grenoble, France.;Public Health Emergency Operations Center, French Ministry of Health, Paris, France.;Maladies Infectieuses et Tropicales, Université Claude Bernard Lyon 1 (UCBL1), Unité de formation et de recherche (UFR) Lyon Sud-Charles Mérieux, Lyon, France. | 149 | ||
| 10.5114/biolsport.2020.94348 | Journal Article;Review | en | Medical recommendations for home-confined footballers' training during the COVID-19 pandemic: from evidence to practical application. | https://www.ncbi.nlm.nih.gov/pubmed/32508388 | In early 2020, the world is facing a global emergency called COVID-19. Many professional footballers around the world are home confined. The maintenance of physical capacity is a fundamental requirement for the athlete, so the training sessions must be adapted to this unique situation. Specific recommendations must be followed concerning the type of training, its intensity, the precautions that have to be followed to avoid the possibility of contagion, and the restrictions in accordance with the presence of any symptoms. This article analyses the available scientific evidence in order to recommend a practical approach. | 0860-021X | 2020-04-12 02:00:00+02:00 | pubmed | Biology of Sport | Cristiano Eirale;Giannicola Bisciotti;Alessandro Corsini;Christophe Baudot;Gerard Saillant;Hakim Chalabi | Coronavirus;Football;Illness;Soccer;Training | 2020-04-10 02:00:00+02:00 | 32508388 | QA;FR;IT | Paris Saint Germain FC, France.;Aspetar Sports and Orthopedics Hospital- Doha, Qatar.;Internazionale Milano FC, Italy. | 153 | |||
| 10.1016/j.canrad.2020.04.001 | Journal Article;Review | fr | [Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context]. | https://www.ncbi.nlm.nih.gov/pubmed/32307313 | Overall treatment time is an important factor of local recurrence and indirectly of distant evolution, namely in case of protracted treatments. The current pandemic impacts on the duration of radiotherapy if patients under treatments and synchronously suffering from COVID-19. The models used to compensate the total dose in case of temporary treatment interruption are well known but it is of importance in that pandemic context to update and homogenize clinical practice in order to improve local control without increasing normal tissue complications. | 1278-3218 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Breast Neoplasms__radiotherapy;Carcinoma, Non-Small-Cell Lung__radiotherapy;Cell Proliferation;Coronavirus Infections__epidemiology;Female;Humans;Lung Neoplasms__radiotherapy;Male;Neoplasms__pathology;Pandemics;Pneumonia, Viral__epidemiology;Prostatic Neoplasms__radiotherapy;Radiobiology__methods;Radiotherapy Dosage;Time Factors;Uterine Cervical Neoplasms__radiotherapy;Withholding Treatment;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cancer/Radiothérapie | D Azria;C Hennequin;P Giraud | Compensation;Dose totale;Radiotherapy;Radiothérapie;Total dose;Treatment duration;Étalement | 2020-04-10 02:00:00+02:00 | 32307313 | FR | IRCM, Institut de recherche en cancérologie de Montpellier (U1194), 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France, Inserm, U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France, Université de Montpellier, centre de recherche U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 05, France, Fédération universitaire d'oncologie radiothérapie, ICM, institut régional du cancer de Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05, France. Electronic address: david.azria@icm.unicancer.fr.;Service de cancérologie-radiothérapie, AP-HP, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France.;Service d'oncologie radiothérapie, AP-HP, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France, Université de Paris, 20, rue Leblanc, 75015 Paris, France. | 158 | ||
| 10.1001/jamaoto.2020.0832 | Journal Article | en | Sudden and Complete Olfactory Loss Function as a Possible Symptom of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32267483 | 2168-6181 | 2020-04-12 02:00:00+02:00 | pubmed | JAMA Otolaryngology–Head & Neck Surgery | Michael Eliezer;Charlotte Hautefort;Anne-Laure Hamel;Benjamin Verillaud;Philippe Herman;Emmanuel Houdart;Corinne Eloit | 2020-04-08 02:00:00+02:00 | 32267483 | FR | Department of Neuroradiology, Lariboisière University Hospital, Paris, France.;Department of Head and Neck Surgery, Lariboisière University Hospital, Paris, France. | 172 | |||||
| Letter | en | The French response to COVID-19: intrinsic difficulties at the interface of science, public health, and policy. | https://www.ncbi.nlm.nih.gov/pubmed/32275857 | 2020-04-12 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;France__epidemiology;Health Policy;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Public Health;Science;COVID-19 | Jean-Paul Moatti | 2020-04-08 02:00:00+02:00 | 32275857 | FR | Aix-Marseille University, Marseille, France. Electronic address: jean-paul.moatti@ird.fr. | 176 | |||||||
| Letter | en | What Does COVID-19 Mean for the Pathology-Urology Interaction? | https://www.ncbi.nlm.nih.gov/pubmed/32273180 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Diagnostic Techniques, Urological;Humans;Interprofessional Relations;Pandemics;Pneumonia, Viral__complications;Urologic Diseases__complications;Urology__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eva Compérat | 2020-04-07 02:00:00+02:00 | 32273180 | FR | Department of Pathology, Hôpital Tenon, Sorbonne University, Paris, France. Electronic address: evacomperat@gmail.com. | 181 | |||||||
| Editorial;Comment | fr | [Urgent digestive surgery, a collateral victim of the Covid-19 crisis?] | https://www.ncbi.nlm.nih.gov/pubmed/32292533 | 2020-04-12 02:00:00+02:00 | pubmed | K Slim;J Veziant | Appendicitis;Cholecystitis;Covid-19 epidemic;Emergency;Surgery | 2020-04-06 02:00:00+02:00 | 32292533 | FR | Service de chirurgie digestive, CHU Clermont-Ferrand, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand, France.;Groupe francophone de réhabilitation améliorée après chirurgie (GRACE), allée du Riboulet, 63110 Beaumont France. | 187 | |||||||
| 10.1016/j.jchirv.2020.04.005 | Journal Article | fr | [Re: "Strategy for the practice of digestive and oncological surgery during the COVID-19 epidemic"]. | https://www.ncbi.nlm.nih.gov/pubmed/32292531 | 1878-786X | 2020-04-12 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | P Pessaux | 2020-04-09 02:00:00+02:00 | 32292531 | FR | Unité de chirurgie hépato-biliaire et pancréatique, service de chirurgie digestive et endocrinienne, nouvel hôpital civil, université de Strasbourg, 1, place de l'Hôpital, 67100 Strasbourg, France. | 188 | |||||
| 10.1186/s13017-020-00304-5 | Journal Article | en | COVID-19 the showdown for mass casualty preparedness and management: the Cassandra Syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32272957 | Since December 2019, the world is potentially facing one of the most difficult infectious situations of the last decades. COVID-19 epidemic warrants consideration as a mass casualty incident (MCI) of the highest nature. An optimal MCI/disaster management should consider all four phases of the so-called disaster cycle: mitigation, planning, response, and recovery. COVID-19 outbreak has demonstrated the worldwide unpreparedness to face a global MCI.This present paper thus represents a call for action to solicitate governments and the Global Community to actively start effective plans to promote and improve MCI management preparedness in general, and with an obvious current focus on COVID-19. | 1749-7922 | 2020-04-12 02:00:00+02:00 | pubmed | Civil Defense__standards;Coronavirus Infections;Delivery of Health Care__standards;Disaster Planning__standards;Global Health;Human Rights__standards;Humans;Mass Casualty Incidents__classification;Pandemics;Pneumonia, Viral;Risk Assessment;COVID-19 | World Journal of Emergency Surgery | Federico Coccolini;Massimo Sartelli;Yoram Kluger;Emmanouil Pikoulis;Evika Karamagioli;Ernest E Moore;Walter L Biffl;Andrew Peitzman;Andreas Hecker;Mircea Chirica;Dimitrios Damaskos;Carlos Ordonez;Felipe Vega;Gustavo P Fraga;Massimo Chiarugi;Salomone Di Saverio;Andrew W Kirkpatrick;Fikri Abu-Zidan;Alain Chicom Mefire;Ari Leppaniemi;Vladimir Khokha;Boris Sakakushev;Rodolfo Catena;Raul Coimbra;Luca Ansaloni;Davide Corbella;Fausto Catena | COVID-19;Coronavirus;Criticalities;Epidemia;Management;Mass casualties;Pademia;Resource;WSES | 2020-04-09 02:00:00+02:00 | 32272957 | IL;FR;CO;CA;FI;GR;GB;US;CM;BR;IT;BG;BY;AE;MX;DE | General, Emergency and Trauma Surgery Department, Pisa University Hospital, Via Paradisia 1, 56100, Pisa, Italy. federico.coccolini@gmail.com.;General and Emergency Surgery, Macerata Hospital, Macerata, Italy.;Division of General Surgery, Rambam Health Care Campus, Haifa, Israel.;3rd Department of Surgery, Attiko Hospital, MSc "Global Health-Disaster Medicine", National and Kapodistrian University of Athens (NKUA), Athens, Greece.;MSc "Global Health-Disaster Medicine" School of Medicine, National and Kapodistrian University of Athens (NKUA), Athens, Greece.;Ernest E Moore Shock Trauma Center, Denver Health, Denver, CO, USA.;Trauma Surgery Department, Scripps Memorial Hospital, La Jolla, San Diego, CA, USA.;Surgery Department, University of Pittsburgh, Pittsburgh, PA, USA.;Deparment of General & Thoracic Surgery, University Hospital of Giessen, Giessen, Germany.;Chirurgie Digestive, CHUGA-CHU Grenoble Alpes, Grenoble, France.;General and Emergency Surgery, NHS Lothian, Edinburgh, UK.;Division of Trauma and Acute Care Surgery, Fundación Valle del Lili, Cali, Colombia.;Department of Surgery, Hospital Angeles Lomas, Mexico, Mexico.;Division of Trauma Surgery, School of Medical Sciences (SMS), University of Campinas (Unicamp), Campinas, Brazil.;General, Emergency and Trauma Surgery Department, Pisa University Hospital, Via Paradisia 1, 56100, Pisa, Italy.;General and Trauma Surgery, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.;Department of General Surgery, University of Insubria, University Hospital of Varese, ASST Sette Laghi, Laghi, Regione Lombardia, Italy.;General, Acute Care, Abdominal Wall Reconstruction, and Trauma Surgery, Foothills Medical Centre, Calgary, Alberta, Canada.;Department of Surgery, College of Medicine and Health Sciences, UAE University, Al-Ain, United Arab Emirates.;Department of Surgery and Obstetrics and Gynecology, University of Buea, Buea, Cameroon.;General Surgery Department, Meihlati Hospital, Helsinki, Finland.;General Surgery Department, Mozir City Hospital, Mozir, Belarus.;General Surgery Department, Medical University, University Hospital St George, Plovdiv, Bulgaria.;Emergency and Trauma Surgery, Maggiore Hospital, Parma, Italy.;Riverside University Health System, CECORC Research Center, and Loma Linda University, Loma Linda, USA.;General, Emergency and Trauma Surgery Department, Bufalini Hospital, Cesena, Italy.;Neuro ICU, Papa Giovanni XXIII Hospital, Bergamo, Italy. | 193 | ||
| 10.1016/j.radonc.2020.04.001 | Journal Article;Practice Guideline | en | Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. | https://www.ncbi.nlm.nih.gov/pubmed/32342863 | The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. | 0167-8140 | 2020-04-12 02:00:00+02:00 | pubmed | Betacoronavirus;Consensus;Coronavirus Infections__prevention & control;Delphi Technique;Europe;Humans;Lung Neoplasms__radiotherapy;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Radiation Oncology__methods;Societies, Medical;United States;COVID-19;severe acute respiratory syndrome coronavirus 2 | Radiotherapy and Oncology | Matthias Guckenberger;Claus Belka;Andrea Bezjak;Jeffrey Bradley;Megan E Daly;Dirk DeRuysscher;Rafal Dziadziuszko;Corinne Faivre-Finn;Michael Flentje;Elizabeth Gore;Kristin A Higgins;Puneeth Iyengar;Brian D Kavanagh;Sameera Kumar;Cecile Le Pechoux;Yolande Lievens;Karin Lindberg;Fiona McDonald;Sara Ramella;Ramesh Rengan;Umberto Ricardi;Andreas Rimner;George B Rodrigues;Steven E Schild;Suresh Senan;Charles B Simone;Ben J Slotman;Martin Stuschke;Greg Videtic;Joachim Widder;Sue S Yom;David Palma | COVID-19;Lung cancer;Non-small cell lung cancer;Pandemic;Radiotherapy;Small cell lung cancer | 2020-04-06 02:00:00+02:00 | 32342863 | FR;SE;CA;GB;CH;US;AT;PL;IT;NL;BE;DE | Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland. Electronic address: Matthias.Guckenberger@usz.ch.;Department of Radiation Oncology, LMU Klinikum, LMU Munich, Germany.;Department of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Canada.;Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.;Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, USA.;Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center(+), GROW Research Institute, The Netherlands.;Dept. of Oncology and Radiotherapy, Medical University of Gdansk, Poland.;Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.;Department of Radiation Oncology, University Hospital Würzburg, JMU Würzburg, Germany.;Department of Radiation Oncology, Medical College of Wisconsin and Zablocki VAMC, Milwaukee, USA.;Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, USA.;Department of Radiation Oncology, University of Colorado, Aurora, USA.;Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.;Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Department of Radiation Oncology, Ghent University Hospital and Ghent University, Belgium.;Department of Head, Neck, Lung and Skin Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.;Royal Marsden Hospital, London, UK.;Radiation Oncology, Campus Bio-Medico University of Rome, Italy.;Department of Radiation Oncology, University of Washington School of Medicine, Seattle, USA.;Department of Oncology, University of Turin, Italy.;Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.;Division of Radiation Oncology, Western University, London, Canada.;Department of Radiation Oncology, Mayo Clinic, Phoenix, USA.;Department of Radiation Oncology, Amsterdam UMC, The Netherlands.;Department of Radiation Oncology, New York Proton Center and Memorial Sloan Kettering Cancer Center, USA.;Department of Radiotherapy, University Duisburg-Essen, Germany.;Department of Radiation Oncology, Cleveland Clinic Lerner College of Medicine of Case Western University, USA.;Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.;Department of Radiation Oncology, University of California San Francisco, USA. | 194 | ||
| 10.1093/ecco-jcc/jjaa077 | Journal Article | en | Will COVID-19 infection be less severe in ulcerative colitis than in Crohn's patients due to a lower rate of smokers? | https://www.ncbi.nlm.nih.gov/pubmed/32303741 | 1873-9946,1876-4479 | 2020-04-19 02:00:00+02:00 | pubmed | Journal of Crohn's and Colitis | Carina Peyrin-Biroulet;Ferdinando D'Amico;Laurent Peyrin-Biroulet | 2020-04-18 02:00:00+02:00 | 32303741 | FR;IT | Department of Pneumology, Nancy University Hospital, Vandoeuvre-les-Nancy.;Department of Biomedical Sciences, Humanitas University, Milan, Italy.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France. | 204 | |||||
| Letter | en | A model for a ventilator-weaning and early rehabilitation unit to deal with post-ICU impairments following severe COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32315800 | 2020-04-19 02:00:00+02:00 | pubmed | Aged;Anxiety__etiology;Betacoronavirus;Coronavirus Infections__epidemiology;Critical Care;Delirium__etiology;Female;France__epidemiology;Hospital Design and Construction;Hospital Units__organization & administration;Hospitals, University__organization & administration;Humans;Hypoalbuminemia__etiology;Length of Stay;Male;Middle Aged;Muscle Weakness__etiology;Pandemics;Paresis__etiology;Patient Care Team;Patient Isolation;Patients' Rooms;Pneumonia, Viral__epidemiology;Respiration, Artificial;Stress Disorders, Post-Traumatic__etiology;Ventilator Weaning__methods;Ventilators, Mechanical__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jonathan Levy;Antoine Léotard;Christine Lawrence;Julie Paquereau;Djamel Bensmail;Djillali Annane;Vincent Delord;Frédéric Lofaso;Simon Bessis;Hélène Prigent | 2020-04-18 02:00:00+02:00 | 32315800 | FR | Ventilator weaning unit-AP-HP, Hôpital Raymond-Poincaré, Garches, France, Department of Physical and Rehabilitation Medicine-AP-HP, Hôpital Raymond-Poincaré, Garches, France, UFR des Sciences de la Santé Simone-Veil, Université de Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France. Electronic address: jonathan.levy2@aphp.fr.;Ventilator weaning unit-AP-HP, Hôpital Raymond-Poincaré, Garches, France, Department of Physiology-AP-HP, Hôpital Raymond-Poincaré, Garches, France, UFR des Sciences de la Santé Simone-Veil, Université de Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France.;Microbiology laboratory-AP-HP, Hôpital Raymond-Poincaré, Garches, France.;Ventilator weaning unit-AP-HP, Hôpital Raymond-Poincaré, Garches, France, Department of Physical and Rehabilitation Medicine-AP-HP, Hôpital Raymond-Poincaré, Garches, France.;Department of Physical and Rehabilitation Medicine-AP-HP, Hôpital Raymond-Poincaré, Garches, France, UFR des Sciences de la Santé Simone-Veil, Université de Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France.;Intensive Care Unit-AP-HP, Hôpital Raymond-Poincaré, Garches, France, UFR des Sciences de la Santé Simone-Veil, Université de Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France.;Ventilator weaning unit-AP-HP, Hôpital Raymond-Poincaré, Garches, France, Department of Physiology-AP-HP, Hôpital Raymond-Poincaré, Garches, France, SOS Oxygène, Nice, France.;Infectious diseases unit-AP-HP, Hôpital Raymond-Poincaré, Garches, France, UFR des Sciences de la Santé Simone-Veil, Université de Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France. | 207 | |||||||
| Letter | en | Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA. | https://www.ncbi.nlm.nih.gov/pubmed/32307609 | 2020-04-19 02:00:00+02:00 | pubmed | Marion Ferreira;Timothee Blin;Nived Collercandy;Piotr Szychowiak;Pierre-François Dequin;Youenn Jouan;Antoine Guillon | 2020-04-19 02:00:00+02:00 | 32307609 | FR | CHRU de Tours, Service de Médecine Intensive-Réanimation, CHRU Bretonneau, INSERM U1100, Centre d'Etude des Pathologies Respiratoires, Université de Tours, 2 Bd Tonnellé, 37044, Tours, France.;CHRU de Tours, Service de Pneumologie, INSERM U1100, Centre d'Etude des Pathologies Respiratoires, Université de Tours, 2 Bd Tonnellé, 37044, Tours, France.;CHRU de Tours, Service de Médecine Intensive-Réanimation, CHRU Bretonneau, INSERM U1100, Centre d'Etude des Pathologies Respiratoires, Université de Tours, 2 Bd Tonnellé, 37044, Tours, France. antoine.guillon@univ-tours.fr. | 209 | ||||||||
| 10.1007/s40271-020-00421-y | Editorial | en | Our Most Powerful Weapon to Fight COVID-19: Patient Involvement. | https://www.ncbi.nlm.nih.gov/pubmed/32301034 | 1178-1653,1178-1661 | 2020-04-19 02:00:00+02:00 | pubmed | Coronavirus Infections__prevention & control;Humans;Pandemics__prevention & control;Patient Participation;Pneumonia, Viral__prevention & control;COVID-19 | The Patient - Patient-Centered Outcomes Research | Peter J Pitts | 2020-04-18 02:00:00+02:00 | 32301034 | FR;US | University of Paris, Paris, France. ppitts@cmpi.org.;Center for Medicine in the Public Interest, New York, NY, USA. ppitts@cmpi.org. | 214 | ||||
| 10.1503/jpn.200061 | Journal Article | en | Consensus statement on the use of clozapine during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32297722 | 1180-4882 | 2020-04-19 02:00:00+02:00 | pubmed | Antipsychotic Agents__adverse effects;Betacoronavirus;Clinical Laboratory Techniques;Clozapine__adverse effects;Consensus;Coronavirus Infections__blood;Humans;Neutropenia__chemically induced;Pandemics;Pneumonia, Viral__blood;Schizophrenia__blood;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Psychiatry and Neuroscience | Dan Siskind;William G Honer;Scott Clark;Christoph U Correll;Alkomiet Hasan;Oliver Howes;John M Kane;Deanna L Kelly;Robert Laitman;Jimmy Lee;James H MacCabe;Nick Myles;Jimmi Nielsen;Peter F Schulte;David Taylor;Helene Verdoux;Amanda Wheeler;Oliver Freudenreich | 2020-04-17 02:00:00+02:00 | 32297722 | FR;SG;CA;GB;US;AU;NL;DK;DE | From the Metro South Addiction and Mental Health Service, Brisbane, Australia (Siskind), the University of Queensland, School of Clinical Medicine, Brisbane, Australia (Siskind, Myles), the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Honer), the University of Adelaide, School of Medicine, Adelaide, Australia (Clark, Kane), the The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA (Correll, Kane), the Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA (Correll), Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany (Correll), the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Augsburg, Augsburg, Germany (Hassan), the Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK (Howes, MacCabe), the MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK (Howes), the Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK (Howes), the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA (Kelly), the Bronx Westchester Medical Group, New York, NY, USA (Laitman), the North Region & Department of Psychosis, Institute of Mental Health, Singapore (Lee), the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Lee), the Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen (Nielsen), the Mental Health Service Noord-Holland-Noord, Alkmaar, The Netherlands (Schulte), the South London and Maudsley NHS Foundation Trust, Pharmacy Department, Maudsley Hospital, London, UK (Taylor), the University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France (Verdoux), the Menzies Health Institute Queensland, Griffith University, Brisbane, Australia (Wheeler), the MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA (Freudenreich), and the Harvard Medical School, Boston, MA, USA (Freudenreich). | 217 | ||||
| 10.14309/ajg.0000000000000663 | Journal Article | en | Clinical Research and Trials-A "Nonessential" Victim of the COVID-19 Pandemic? | https://www.ncbi.nlm.nih.gov/pubmed/32287137 | 0002-9270 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Clinical Trials as Topic__organization & administration;Coronavirus Infections__epidemiology;Disease Transmission, Infectious__prevention & control;Gastroenterology__methods;Humans;Infection Control__methods;Pandemics__prevention & control;Patient Care Management__methods;Pneumonia, Viral__epidemiology;Research Subjects;COVID-19;severe acute respiratory syndrome coronavirus 2 | American Journal of Gastroenterology | Laurent Peyrin-Biroulet;Ashwin N Ananthakrishnan | 2020-04-15 02:00:00+02:00 | 32287137 | FR;US | Department of Hepato-Gastroenterology, University Hospital of Nancy-Brabois, Inserm U1256 NGERE, Lorraine University, Vandoeuvre-lès-Nancy, France.;Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. | 222 | ||||
| Letter;Comment | en | Good IgA Bad IgG in SARS-CoV-2 Infection? | https://www.ncbi.nlm.nih.gov/pubmed/32280952 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Immunoglobulin A;Immunoglobulin G;Pandemics;Pneumonia, Viral;Severe Acute Respiratory Syndrome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Marie C Béné;Marcelo de Carvalho Bittencourt;Marion Eveillard;Yannick Le Bris | 2020-04-14 02:00:00+02:00 | 32280952 | FR | Hematology Biology, Nantes University Hospital & CRCINA, Nantes, France.;Immunology Laboratory, Nancy University Hospital & IMOPA UMR7365, Nancy, France. | 224 | |||||||
| NIAMS NIH HHS;NIAMS NIH HHS;NIAMS NIH HHS;NIAMS NIH HHS;NIAMS NIH HHS;NIAMS NIH HHS | Journal Article;Review;Comment | en | Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist. | https://www.ncbi.nlm.nih.gov/pubmed/32295786 | 2020-04-19 02:00:00+02:00 | pubmed | Azithromycin;Betacoronavirus;Coronavirus Infections;Humans;Hydroxychloroquine;Pandemics;Pneumonia, Viral;Rheumatologists;COVID-19;severe acute respiratory syndrome coronavirus 2 | Elizabeth R Graef;Jean W Liew;Michael S Putman;Julia F Simard;Emily Sirotich;Francis Berenbaum;Alí Duarte-García;Rebecca Grainger;Carly Harrison;Maximilian F Konig;Peter Korsten;Laurie Proulx;Dawn P Richards;Philip C Robinson;Sebastian E Sattui;Manuel Francisco Ugarte-Gil;Kristen J Young;Alfred Hj Kim;Jeffrey A Sparks | antirheumatic agents;health services research;hydroxychloroquine | 2020-04-15 02:00:00+02:00 | 32295786 | FR;IL;SE;CA;NZ;US;AU;PE;DE | [{"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "L30 AR072421"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "P30 AR073752"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "T32 AR048522"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "K23 AR069688"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "L30 AR066953"}, {"country": "United States", "agency": "NIAMS NIH HHS", "grantid": "R03 AR075886"}] | Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.;Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, United States.;Department of Medicine, Division of Rheumatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.;Health Research & Policy, Division of Epidemiology and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California, USA.;Department of Medicine, Clinical Epidemiology Unit, Sweden.;McMaster University, Hamilton, Ontario, Canada.;Department of Rheumatology, Sorbonne Université, Paris, France.;Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.;Malaghan Institute of Medical Research, Wellington, New Zealand.;LupusChat, New York, New York, USA.;Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.;Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.;Canadian Arthritis Patient Alliance, Ottawa, Ontario, Canada.;Princess Alexandra Hospital, Diamantina Institute, University of Queensland, Brisbane, Queensland, Australia.;Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA.;Universidad Cientifica del Sur, Lima, Peru.;University of Texas Southwestern Medical School, Dallas, Texas, USA.;Division of Rheumatology, Department of Medicine, Washington University School of Medicine in St. Louis, Saint Louis, Missouri, USA jsparks@bwh.harvard.edu akim@wustl.edu.;Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA jsparks@bwh.harvard.edu akim@wustl.edu. | 232 | ||||
| Letter | en | Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32304632 | 2020-04-19 02:00:00+02:00 | pubmed | François Bénézit;Paul Le Turnier;Charles Declerck;Cécile Paillé;Matthieu Revest;Vincent Dubée;Pierre Tattevin | 2020-04-15 02:00:00+02:00 | 32304632 | FR | Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.;Infectious Diseases and Tropical Medicine, Hotel Dieu, University Hospital of Nantes, France.;Infectious Diseases and Tropical Medicine, University Hospital of Angers, France.;Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France. Electronic address: pierre.tattevin@chu-rennes.fr. | 235 | ||||||||
| 10.1016/j.onehlt.2020.100133 | Editorial | en | The risk of SARS-CoV-2 transmission to pets and other wild and domestic animals strongly mandates a one-health strategy to control the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32363229 | 2352-7714 | 2020-04-19 02:00:00+02:00 | pubmed | One Health | Eric M Leroy;Meriadeg Ar Gouilh;Jeanne Brugère-Picoux | Animal;Bat;COVID-19;Cat;Coronavirus;Dog;Farm animals;Pet;SARS-CoV-2;Wild animals | 2020-04-13 02:00:00+02:00 | 32363229 | FR | Research Director, UMR MIVEGEC IRD-CNRS-UM, Institute for sustainable Development (IRD), 911, Avenue Agropolis, 34394 Montpellier, France.;GRAM 2.0, Caen University, Rouen University, Esplanade de la Paix, 14000 Caen, France.;Alfort National Veterinary School, 20 rue Edmond Nocard, 94700 Maisons-Alfort, France. | 258 | ||||
| Letter;Comment | en | Clinical characteristics of older patients: The experience of a geriatric short-stay unit dedicated to patients with COVID-19 in France. | https://www.ncbi.nlm.nih.gov/pubmed/32305489 | 2020-04-19 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections;France;Humans;Length of Stay;Middle Aged;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Lidvine Godaert;Emeline Proye;David Demoustier-Tampere;Pecory Souleymane Coulibaly;Fanny Hequet;Moustapha Dramé | 2020-04-17 02:00:00+02:00 | 32305489 | FR;MQ | General Hospital of Valenciennes, Short-stay Unit, Department of geriatrics, Valenciennes, France. Electronic address: lidvinegodaert@me.com.;General Hospital of Valenciennes, Short-stay Unit, Department of geriatrics, Valenciennes, France.;University Hospitals of Martinique, Department of Clinical Research and Innovation, Fortde-France, Martinique France. | 262 | |||||||
| 10.1016/j.jaut.2020.102468 | Journal Article;Review | en | The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32317220 | The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has posed the world at a pandemic risk. Coronavirus-19 disease (COVID-19) is an infectious disease caused by SARS-CoV-2, which causes pneumonia, requires intensive care unit hospitalization in about 10% of cases and can lead to a fatal outcome. Several efforts are currently made to find a treatment for COVID-19 patients. So far, several anti-viral and immunosuppressive or immunomodulating drugs have demonstrated some efficacy on COVID-19 both in vitro and in animal models as well as in cases series. In COVID-19 patients a pro-inflammatory status with high levels of interleukin (IL)-1B, IL-1 receptor (R)A and tumor necrosis factor (TNF)-α has been demonstrated. Moreover, high levels of IL-6 and TNF-α have been observed in patients requiring intensive-care-unit hospitalization. This provided rationale for the use of anti-rheumatic drugs as potential treatments for this severe viral infection. Other agents, such as hydroxychloroquine and chloroquine might have a direct anti-viral effect. The anti-viral aspect of immunosuppressants towards a variety of viruses has been known since long time and it is herein discussed in the view of searching for a potential treatment for SARS-CoV-2 infection. | 0896-8411 | 2020-04-19 02:00:00+02:00 | pubmed | Antibodies, Monoclonal, Humanized__therapeutic use;Antirheumatic Agents__therapeutic use;Antiviral Agents__therapeutic use;Betacoronavirus__drug effects;Chloroquine__therapeutic use;Coronavirus Infections__drug therapy;Cytokines__antagonists & inhibitors;Humans;Hydroxychloroquine__therapeutic use;Immunomodulation__drug effects;Immunosuppressive Agents__therapeutic use;Pandemics;Pneumonia, Viral__drug therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Autoimmunity | Carlo Perricone;Paola Triggianese;Elena Bartoloni;Giacomo Cafaro;Angelo F Bonifacio;Roberto Bursi;Roberto Perricone;Roberto Gerli | Autoimmunity;Biologics;COVID-19;Coronavirus;DMARDs;IL-6;Immunosuppressant. IL-1;Infection;Rheumatic;SARS-CoV-2;tDMARDs | 2020-04-17 02:00:00+02:00 | 32317220 | FR;IT | Rheumatology, Department of Medicine, University of Perugia, Piazzale Giorgio Menghini, 1, 06129, Perugia, Italy.;Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.;Rheumatology, Department of Medicine, University of Perugia, Piazzale Giorgio Menghini, 1, 06129, Perugia, Italy. Electronic address: roberto.gerli@unipg.it. | 271 | ||
| 10.5152/eurjrheum.2020.20061 | Journal Article | en | Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists. | https://www.ncbi.nlm.nih.gov/pubmed/32352361 | 2147-9720,2148-4279 | 2020-04-19 02:00:00+02:00 | pubmed | European Journal of Rheumatology | Hèctor Corominas;Ivan Castellví;Pere Domingo;Jordi Casademont | 2020-04-17 02:00:00+02:00 | 32352361 | FR;ES | Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.;Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.;Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain. | 274 | |||||
| 10.1016/j.revmed.2020.04.004 | Journal Article;Review | fr | [COVID-19: Clinical, biological and radiological characteristics in adults, infants and pregnant women. An up-to-date review at the heart of the pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32334862 | The spread of the new coronavirus SARS-CoV-2, discovered in China in January 2020, led to a pandemic as early as March 2020, forcing every health care system in the affected countries to adapt quickly. In order to better address this major health crisis, which has given rise to numerous scientific publications, we have synthesized the main original clinical studies to facilitate the day-to-day management of patients with COVID-19. We detail the early signs and progression of the disease as well as the different clinical forms, including extra-pulmonary, as known at the beginning of this pandemic. We focus on clinical, biological and CT markers predictive of severity or mortality. Finally, we discuss the impact of SARS-CoV-2 infection in populations suspected to be at high risk of severe forms. | 0248-8663 | 2020-04-19 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Child;Coronavirus Infections__diagnostic imaging;Female;Humans;Male;Pandemics;Pneumonia, Viral__diagnostic imaging;Pregnancy;Radiography__methods;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | La Revue de Médecine Interne | L Plaçais;Q Richier | COVID-19;Clinical;Clinique;Epidemiology;Nouveau coronavirus;Novel coronavirus;SARS-CoV-2;Épidémiologie | 2020-04-17 02:00:00+02:00 | 32334862 | FR | Médecine interne, Sorbonne Université, 15-21, rue de l'École-de-médecine, 75006 Paris, France.;Médecine interne, Université de Paris, 12, rue de l'École-de-médecine, 75006 Paris, France. Electronic address: quentin.richier@hotmail.fr. | 277 | ||
| 10.1016/s2352-4642(20)30110-3 | Journal Article | en | ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. | https://www.ncbi.nlm.nih.gov/pubmed/32311314 | 2352-4642 | 2020-04-19 02:00:00+02:00 | pubmed | Attention Deficit Disorder with Hyperactivity__therapy;Child;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;COVID-19 | The Lancet Child & Adolescent Health | Samuele Cortese;Philip Asherson;Edmund Sonuga-Barke;Tobias Banaschewski;Daniel Brandeis;Jan Buitelaar;David Coghill;David Daley;Marina Danckaerts;Ralf W Dittmann;Manfred Doepfner;Maite Ferrin;Chris Hollis;Martin Holtmann;Eric Konofal;Michel Lecendreux;Paramala Santosh;Aribert Rothenberger;César Soutullo;Hans-Christoph Steinhausen;Eric Taylor;Saskia Van der Oord;Ian Wong;Alessandro Zuddas;Emily Simonoff | 2020-04-17 02:00:00+02:00 | 32311314 | FR;BE;CH;GB;US;IT;AU;NL;DK;DE | Center for Innovation in Mental Health, University of Southampton and Solent NHS Trust, Southampton SO17 1BJ, UK, New York University Child Study Center, New York, NY, USA, Division of Psychiatry and Applied Psychology, School of Medicine and National Institute for Health Research MindTech Mental Health MedTech Cooperative and Centre for ADHD and Neurodevelopmental Disorders Across the Lifespan, Institute of Mental Health, University of Nottingham, UK. Electronic address: samuele.cortese@soton.ac.uk.;Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.;Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK, Department of Child & Adolescent Psychiatry, Aarhus University, Aarhus, Denmark.;Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.;Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry, Zurich, Switzerland, Neuroscience Center Zurich, University of Zurich, Zurich, Switzerland, Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland, ETH Zurich, Zurich, Switzerland.;Radboud University Medical Center, Nijmegen, Netherlands.;Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia, Murdoch Children's Research Institute, Melbourne, VIC, Australia, Royal Children's Hospital, Melbourne, Melbourne, VIC, Australia.;Division of Psychiatry and Applied Psychology, School of Medicine and National Institute for Health Research MindTech Mental Health MedTech Cooperative and Centre for ADHD and Neurodevelopmental Disorders Across the Lifespan, Institute of Mental Health, University of Nottingham, UK.;Research Group of Developmental Psychiatry, Center for Developmental Psychiatry, KU Leuven, Leuven, Belgium, Department of Child and Adolescent Psychiatry, University Psychiatry Hospitals-KU Leuven, Leuven, Belgium.;Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Faculty of Medicine, and University Hospital Cologne, University of Cologne, Cologne, Germany.;Haringey Children and Adolescent Mental Health Service, National Health Service, London, UK, ReCognition Health, London, UK.;LWL-University Hospital for Child and Adolescent Psychiatry, Ruhr-University Bochum, Hamm, Germany.;Service de Physiologie Pédiatrique, Centre Pédiatrique des Pathologies Du Sommeil, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris, France.;Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.;Klinik für Kinder und Jugendpsychiatrie/Psychotherapie, Universitätsmedizin, Georg-August Universität Göttingen, Göttingen, Germany.;Louis A Fallace Department of Psychiatry and Behavioral Science, University of Texas, Houston, TX, USA.;Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry, Zurich, Switzerland, Clinical Psychology and Epidemiology, Institute of Psychology, University of Basel, Basel, Switzerland, Department of Child and Adolescent Mental Health, University of Southern Denmark, Odense, Denmark, Child and Adolescent Mental Health Centre, Capital Region Psychiatry, Copenhagen, Denmark.;Clinical Psychology, KU Leuven, Leuven, Belgium, Developmental Psychology, University of Amsterdam, Amsterdam, Netherlands.;School of Pharmacy, University College London, London, UK.;Department of Biomedical Sciences, University of Cagliari & Antonio Cao Paediatric Hospital, G Brotzu Hospital Trust, Cagliari, Italy. | 280 | ||||
| 10.1016/j.jviscsurg.2020.04.010 | Journal Article;Review | en | Risks of viral contamination in healthcare professionals during laparoscopy in the Covid-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32340900 | The Covid-19 pandemic has markedly changed our practices. This article analyses the risks of contamination among healthcare professionals (HCPs) during laparoscopic surgery on patients with Covid-19. Harmful effects of aerosols from a pneumoperitoneum, with the virus present, have not yet been quantified. Measures for the protection of HCPs are an extrapolation of those taken during other epidemics. They must still be mandatory to minimise the risk of viral contamination. Protection measures include personal protection equipment for HCPs, adaptation of surgical technique (method for obtaining pneumoperitoneum, filters, preferred intracorporeal anastomosis, precautions during the exsufflation of the pneumoperitoneum), and organisation of the operating room. | 1878-7886 | 2020-04-19 02:00:00+02:00 | pubmed | Coronavirus Infections__prevention & control;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Intraoperative Period;Laparoscopy;Occupational Diseases__prevention & control;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Practice Guidelines as Topic;Risk Assessment;COVID-19 | Journal of Visceral Surgery | J Veziant;N Bourdel;K Slim | Laparoscopy;SARS-CoV-2;Viral contamination;Virus | 2020-04-17 02:00:00+02:00 | 32340900 | FR | Digestive surgery department, University Hospital of Clermont-Ferrand, 63003 Clermont-Ferrand, France.;Gynaecology Department, University Hospital of Clermont-Ferrand, 63003 Clermont-Ferrand, France.;Digestive surgery department, University Hospital of Clermont-Ferrand, 63003 Clermont-Ferrand, France. Electronic address: kslim@chu-clermontferrand.fr. | 286 | ||
| Letter;Comment | en | Resource-sparing urgent endoscopies by a mobile on-call team in the Paris area during the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32305344 | 2020-04-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Endoscopy;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Marine Camus;Aymeric Becq;Benedicte Jaïs;Xavier Dray | 2020-04-16 02:00:00+02:00 | 32305344 | FR | Endoscopy Department, Saint Antoine Hospital, Paris, France, Sorbonne University, Paris, France.;Endoscopy Unit, Beaujon Hospital, Clichy, France.;Saint Antoine Hospital, Paris, France.;Endoscopy Unit, Saint Antoine Hospital, Paris, France, Sorbonne University, Paris, France. | 288 | |||||||
| 10.1016/j.biochi.2020.04.008 | Journal Article | en | Renin-angiotensin system at the heart of COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32305506 | Significant aspects of COVID-19 pandemic remain obscure. Angiotensin converting enzyme 2 (ACE2), a component of the renin-angiotensin system, whose expression dominates on lung alveolar epithelial cells, is the human cell receptor of SARS-CoV-2, the causative agent of COVID-19. We strongly encourage the concept that thorough considerations of receptor-ligand interactions should be kept at the heart of scientific debate on infection. In this idea, the whole renin-angiotensin system has to be evaluated. We hypothesize that factors related to ethnicity, environment, behaviors, associated illness, and medications involving this complex system are probably responsible for situations regarded as anomalous from both an epidemiological and a clinical point of view, but, taken together, such factors may explain most of the aspects of current outbreak. We decided to use the analogy of a play and speculate about the possible impact in this tragedy of 1) air pollution via the interference of nitrogen dioxide on ACE2 expression; 2) the dual role of nicotine; 3) the hypothetical involvement of ACE2 polymorphisms, the relationships of which with ethnic factors and susceptibility to cardiovascular disease seems intriguing; 4) the impact on the severity of infection of hypertension and related medications acting on the renin/angiotensin system, and, finally, 5) the possible helpful role of chloroquine, thanks to its capacity of modifying ACE2 affinity to the viral spike protein by altering glycosylation. This hypothesis paper is an urgent call for the development of research programs that aim at questioning whether the putative protagonists of this tragedy are real-life actors in COVID-19. | 0300-9084 | 2020-04-19 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Cardiovascular Diseases__complications;Coronavirus Infections__complications;Female;Humans;Hypertension__complications;Male;Middle Aged;Pandemics;Peptidyl-Dipeptidase A__genetics;Pneumonia, Viral__complications;Renin-Angiotensin System__physiology;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Biochimie | Marco Alifano;Pietro Alifano;Patricia Forgez;Antonio Iannelli | ACE2;COVID-19;Mechanisms | 2020-04-16 02:00:00+02:00 | 32305506 | FR;IT | Thoracic Surgery Department, Cochin Hospital, APHP Centre, University of Paris, France, INSERM U1138 Team «Cancer, Immune Control, and Escape», Cordeliers Research Center, University of Paris, France. Electronic address: marco.alifano@aphp.fr.;Chair of Microbiology, Department of Biological and Environmental Sciences and Technologies, Salento University, Lecce, Italy.;Inserm UMR-S 1124 T3S, Eq 5 CELLULAR HOMEOSTASIS, CANCER and THERAPY, University of Paris, Campus Saint Germain, Paris, France.;Digestive Disease Department, Archet 2 Hospital, Nice University Hospital, University of Nice Côte d'Azur, Nice, France, Inserm, U1065, Team 8 "Hepatic Complications of Obesity", University Nice Côte d'Azur, France. | 289 | ||
| 10.1016/j.jhin.2020.04.036 | Journal Article | en | What face mask for what use in the context of COVID-19 pandemic? The French guidelines. | https://www.ncbi.nlm.nih.gov/pubmed/32348833 | In the context of the COVID-19 pandemic, wearing a face mask has become usual and ubiquitous, in both hospitals and community. However, the general public is consuming surgical or filtering face piece (FFP) masks irrespective of their specificity, leading to global supply shortage for the most exposed persons, which are healthcare workers. This underlines the urgent need to clarify the indications of the different categories of mask, in order to rationalize their use. The study herein specifies the French position for the rational use of respiratory protective equipment for healthcare workers. | 0195-6701 | 2020-04-26 02:00:00+02:00 | pubmed | Journal of Hospital Infection | Didier Lepelletier;Bruno Grandbastien;Sara Romano-Bertrand;Serge Aho;Christian Chidiac;Jean-François Géhanno;Franck Chauvin | COVID-19 pandemic;N95 mask;filtering face piece (FFP) mask;respiratory protective equipment;surgical mask | 2020-04-26 02:00:00+02:00 | 32348833 | FR;CH | French Society for Hospital Hygiene, France, Bacteriology and Hospital Hygiene Department, Nantes University Hospital, Nantes, FR-44000, High Council for Public Health, French Ministry of Health. Electronic address: didier.lepelletier@chu-nantes.fr.;French Society for Hospital Hygiene, France, Infection Prevention and Control Team, Preventive medicine Department, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, CH-1011.;French Society for Hospital Hygiene, France, HydroSciences Montpellier, IRD, CNRS, Montpellier University, Montpellier, France, Hospital, Hygiene and Infection Control Team, University Hospital of Montpellier, Montpellier, FR-34000.;French Society for Hospital Hygiene, France, Epidemiology and Hospital Hygiene Department, Dijon University Hospital, Dijon, FR-21079.;High Council for Public Health, French Ministry of Health, Infectious and Tropical Diseases Department, Lyon University Hospital Hospices Civils de Lyon, Lyon FR-69000.;High Council for Public Health, French Ministry of Health, Department of Occupational Medicine, Rouen University Hospital, Rouen, FR-76000.;High Council for Public Health, French Ministry of Health, Public Health Department, St-Etienne University Hospital, St-Etienne, FR-42000. | 292 | |||
| 10.1016/j.wneu.2020.04.155 | Journal Article;Review | en | Patients with Coronavirus 2019 (COVID-19) and Surgery: Guidelines and Checklist Proposal. | https://www.ncbi.nlm.nih.gov/pubmed/32344143 | The management of patients with novel coronavirus 2019 (COVID-19) represents a new challenge for medical and surgical teams. Each operating room in the world should be prepared thoughtfully, and the development of a protocol and patient route seems mandatory. An adequate degree of protection must be used. We propose recommendations to help different professionals in the establishment of protocols for the management of patients with COVID-19. We also offer a checklist that could be used in the operating room. | 1878-8750 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Checklist__methods;Coronavirus Infections__prevention & control;Health Personnel__standards;Humans;Infection Control__methods;Operating Rooms__standards;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Practice Guidelines as Topic__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | World Neurosurgery | Michael Grelat;Benjamin Pommier;Sylvain Portet;Aymeric Amelot;Cédric Barrey;Henri-Arthur Leroy;Rachid Madkouri | COVID-19;Checklist;Health care workers;Operating room;Surgery | 2020-04-25 02:00:00+02:00 | 32344143 | FR | Department of Neurosurgery, Dijon University Hospital, Dijon, France. Electronic address: michael.grelat@gmail.com.;Department of Neurosurgery, Saint-Etienne University Hospital, Saint Etienne, France.;Department of Neurosurgery, Lyon University Hospital, Lyon, France.;Department of Neurosurgery, Tours University Hospital, Tours, France.;Department of Neurosurgery, Lille University Hospital, Lille, France.;Department of Neurosurgery, Dijon University Hospital, Dijon, France. | 295 | ||
| Letter;Comment | en | Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32236983 | 2020-04-26 02:00:00+02:00 | pubmed | Adaptive Immunity;Anti-Infective Agents;Betacoronavirus;Bronchiolitis;Coronavirus Infections;Cystic Fibrosis;Haemophilus Infections;Humans;Immune System;Macrolides;Pandemics;Pneumonia, Viral;COVID-19;Diffuse panbronchiolitis;severe acute respiratory syndrome coronavirus 2 | Pedram Ahmadpoor;Lionel Rostaing | 2020-04-25 02:00:00+02:00 | 32236983 | FR;IR | Service de Néphrologie, CHU Carémeau Nîmes, Nimes, France.;Labafi Nejad Hospital, Shahid Beheshti Medical University, Tehran, Iran.;Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble-Alpes, Grenoble, France.;Université Grenoble-Alpes, Grenoble, France. | 298 | |||||||
| NIAID NIH HHS | Editorial;Comment | en | COVID-19: First Do No Harm. | https://www.ncbi.nlm.nih.gov/pubmed/32311297 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Retrospective Studies;COVID-19;severe acute respiratory syndrome coronavirus 2 | Grant W Waterer;Jordi Rello;Richard G Wunderink | 2020-04-21 02:00:00+02:00 | 32311297 | FR;US;AU;ES;PS | [{"country": "United States", "agency": "NIAID NIH HHS", "grantid": "U19 AI135964"}] | School of MedicineUniversity of Western AustraliaCrawley, Western Australia, Australia.;Northwestern University Feinberg School of MedicineChicago, Illinois.;Centro de Investigación Biomedica en Red (CIBERES)Instituto de Salud Carlos IIIMadrid, España.;Vall d'Hebron Institute of Research (VHIR)Barcelona, Spainand.;CHU NîmesUniversité Montpellier-NîmesNîmes, France. | 306 | |||||
| 10.2807/1560-7917.es.2020.25.15.2000448 | Journal Article | en | Potential lethal outbreak of coronavirus disease (COVID-19) among the elderly in retirement homes and long-term facilities, France, March 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32317051 | Motivated by the potential devastating effect of a COVID-19 outbreak in retirement homes and long-term facilities for dependent elderly, we present the impact of worst-case scenarios in French institutions using a specific age structure and case-age fatality ratios. The death toll could equal the yearly death toll caused by seasonal influenza in those older than 65 years or could largely exceed that, depending on the final attack rate and proportion of infected institutions. | 1560-7917 | 2020-04-26 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Comorbidity;Coronavirus Infections__epidemiology;Disease Outbreaks;France__epidemiology;Homes for the Aged;Humans;Long-Term Care;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Residential Facilities;COVID-19 | Eurosurveillance | Jean-François Etard;Philippe Vanhems;Laëtitia Atlani-Duault;René Ecochard | COVID-19;elderly;long-term care facilities | 2020-04-23 02:00:00+02:00 | 32317051 | FR | EpiGreen, Paris, France.;TransVIHMI, Institut de Recherche pour le Développement (IRD), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Montpellier, Montpellier, France.;Laboratoire des Pathogènes Emergents, Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Lyon, France.;Hospices Civils de Lyon, Service d'Hygiène Hospitalière, Epidémiologie, Infectiovigilance et Prévention, Lyon, France.;Fondation Maison des Sciences de l'Homme (FMSH), Paris, France.;Centre Population et Développement (CEPED), Institut de Recherche pour le Développement (IRD), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, Paris, France.;Université de Lyon, Lyon, France.;Hospices Civils de Lyon, Service de Biostatistique-Bioinformatique, Lyon, France.;Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique Santé, Pierre-Bénite, France. | 310 | ||
| 10.1016/j.jbspin.2020.03.010 | Editorial | en | Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. | https://www.ncbi.nlm.nih.gov/pubmed/32321633 | 1297-319X | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Chronic Disease;Coronavirus Infections__complications;Delivery of Health Care__organization & administration;Humans;Infection Control__methods;Pandemics;Pneumonia, Viral__complications;Rheumatic Diseases__complications;Risk Factors;Telemedicine__trends;COVID-19;severe acute respiratory syndrome coronavirus 2 | Joint Bone Spine | Christophe Richez;Estibaliz Lazaro;Maël Lemoine;Marie-Elise Truchetet;Thierry Schaeverbeke | COVID-19;Health system;Inflammatory rheumatic diseases;Treatment | 2020-04-24 02:00:00+02:00 | 32321633 | FR | Université de Bordeaux, CNRS-UMR 5164 Immuno ConcEpT, 146 rue Léo Saignat, 33076 Bordeaux, France, Centre Hospitalier Universitaire de Bordeaux, FHU ACRONIM, Place Amélie Raba Léon, 33076 Bordeaux, France. Electronic address: christophe.richez@u-bordeaux.fr.;Université de Bordeaux, CNRS-UMR 5164 Immuno ConcEpT, 146 rue Léo Saignat, 33076 Bordeaux, France, Centre Hospitalier Universitaire de Bordeaux, FHU ACRONIM, Place Amélie Raba Léon, 33076 Bordeaux, France.;Université de Bordeaux, CNRS-UMR 5164 Immuno ConcEpT, 146 rue Léo Saignat, 33076 Bordeaux, France. | 313 | |||
| 10.1016/j.jcf.2020.04.012 | Journal Article | en | A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. | https://www.ncbi.nlm.nih.gov/pubmed/32376098 | Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis. | 1569-1993 | 2020-04-26 02:00:00+02:00 | pubmed | Adolescent;Adult;Australia;Betacoronavirus;Canada;Coronavirus Infections__complications;Cystic Fibrosis__complications;Europe;Female;Humans;Male;Middle Aged;New Zealand;Pandemics;Pneumonia, Viral__complications;Symptom Assessment;United States;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Cystic Fibrosis | Rebecca Cosgriff;Susannah Ahern;Scott C Bell;Keith Brownlee;Pierre-Régis Burgel;Cass Byrnes;Harriet Corvol;Stephanie Y Cheng;Alexander Elbert;Albert Faro;Christopher H Goss;Vincent Gulmans;Bruce C Marshall;Edward McKone;Peter G Middleton;Rasa Ruseckaite;Anne L Stephenson;Siobhán B Carr | Coronavirus;Cystic fibrosis;SARS-CoV-2 | 2020-04-25 02:00:00+02:00 | 32376098 | FR;IE;CA;NZ;GB;US;AU;NL | Cystic Fibrosis Trust, London, UK. Electronic address: rebecca.cosgriff@cysticfibrosis.org.uk.;Monash University, Melbourne, Australia.;The Prince Charles Hospital, Brisbane, Australia.;Cystic Fibrosis Trust, London, UK.;Université de Paris, Inserm U1016, Institut Cochin and Cochin Hospital, Assistance Publique Hôpitaux de Paris (APHP).;University of Auckland, Auckland, New Zealand.;Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Assistance Publique Hôpitaux de Paris (APHP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Paris, France.;Cystic Fibrosis Canada, Toronto, Canada.;Cystic Fibrosis Foundation, Bethesda, US.;University of Washington, Seattle, US.;Dutch CF Foundation NCFS, Baarn, Netherlands.;St Vincent's University Hospital, Dublin, Ireland.;Westmead Hospital, Sydney, Australia.;Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Assistance Publique Hôpitaux de Paris (APHP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Paris, France, Toronto Adult Cystic Fibrosis Centre, St. Michael's Hospital, Toronto, Canada.;Royal Brompton Hospital and Imperial College London, UK. | 315 | ||
| Letter | en | COVID-19: home poisoning throughout the containment period. | https://www.ncbi.nlm.nih.gov/pubmed/32339480 | 2020-04-26 02:00:00+02:00 | pubmed | Accidents, Home__statistics & numerical data;Coronavirus Infections__epidemiology;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Poisoning__epidemiology;Quarantine;COVID-19 | Gael Le Roux;Sandra Sinno-Tellier;Alexis Descatha | 2020-04-25 02:00:00+02:00 | 32339480 | FR | Poison Control Center, Academic Hospital CHU Angers, Angers, France.;French Agency for Food, Environmental and Occupational Health and Safety, Maisons-Alfort, France.;Poison Control Center, Academic Hospital CHU Angers, Angers, France, University of Angers, Centre Hospitalier Universitaire d'Angers, Université de Rennes, INSERM, École des hautes études en santé publique, Institut de recherche en santé, environnement et travail UMR_S 1085, F49000 Angers, France. Electronic address: alexis.descatha@inserm.fr. | 316 | |||||||
| Letter | en | Predictive factors of poor outcomes in the COVID-19 epidemic: Consider the inflammatory response. | https://www.ncbi.nlm.nih.gov/pubmed/32339596 | 2020-04-26 02:00:00+02:00 | pubmed | J Razanamahery;L Malinowski;S Humbert;A S Brunel;Q Lepiller;C Chirouze;K Bouiller | 2020-04-24 02:00:00+02:00 | 32339596 | FR | Internal Medicine Department, Besançon University Hospital, Besançon, France.;Infectious and tropical disease Department, Besançon University Hospital, Besançon, France.;Laboratory of virology, Besançon University Hospital, Besançon, France.;Infectious and tropical disease Department, Besançon University Hospital, Besançon, France, UMR CNRS 6249, chrono environnement, University of Bourgogne Franche-Comté, Besançon, France.;Internal Medicine Department, Besançon University Hospital, Besançon, France, UMR CNRS 6249, chrono environnement, University of Bourgogne Franche-Comté, Besançon, France. Electronic address: kbouiller@chu-besancon.fr. | 317 | ||||||||
| Letter;Comment | en | Coping with the COVID-19 crisis in Sub-Saharan Africa: let us not leave older people behind! | https://www.ncbi.nlm.nih.gov/pubmed/32323250 | 2020-04-26 02:00:00+02:00 | pubmed | Moustapha Dramé;Lidvine Godaert;Kuate Tegueu Callixte;Fiona Ecarnot;Nadine Simo-Tabue;Maturin Tabue Teguo | COVID-19;Older people;Sub-Saharan Africa | 2020-04-22 02:00:00+02:00 | 32323250 | FR;MQ;CM;GP | Faculty of Medicine, University of the French West Indies, Fort-de-France, Martinique. moustapha.drame@chu-martinique.fr.;Department of Clinical Research and Innovation, University Hospitals of Martinique, Pierre Zobda-Quitman Hospital, CS 90632, 97261, Fort-de-France, Martinique. moustapha.drame@chu-martinique.fr.;Department of Geriatrics, General Hospital of Valenciennes, Valenciennes, France.;Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.;Department of Cardiology, University Hospital Besancon and EA3920, University of Franche-Comté, Besancon, France.;Department of Geriatrics, University Hospitals of Guadeloupe, Pointe-à-Pitre, Guadeloupe.;LAMIA Research Team, University of the French West Indies, Pointe-à-Pitre, Guadeloupe.;U1219 INSERM, University of Bordeaux, Bordeaux, France. | 318 | |||||||
| 10.1016/j.anorl.2020.04.012 | Practice Guideline | en | COVID-19 and ENT Surgery. | https://www.ncbi.nlm.nih.gov/pubmed/32362564 | In Otorhinolaryngology - Head and Neck Surgery, clinical examination and invasive procedures on the respiratory tract and on airway-connected cavities, such as paranasal sinuses and the middle ear, expose people to direct transmission of SARS-CoV-2 by inhalation or ocular projection of contaminated droplets, and to indirect transmission by contact with contaminated hands, objects or surfaces. Estimating an R0 of COVID-19 at around 3 justified postponing non-urgent face-to-face consultations and expanding the use of teleconsultation in order to limit the risks of SARS-CoV-2 infection of patients or health workers and comply with the lockdown. The health authority recommends cancellation of all medical or surgical activities, which are not urgent as long as this does not involve a loss of chance for the patient. The purpose of this cancellation is to significantly increase critical care capacity, prioritise the reception of patients with COVID-19, prioritise the allocation of staff and provision of the equipment necessary for their medical or surgical management, and contribute to the smooth running of downstream critical care within their establishment. Another goal is to reduce the risks of patient contamination within healthcare facilities. This document provides guidance on how to proceed with and adapt ENT surgery in the current pandemic context, as well as on the management of postponed operations. This best practice advice must of course be adapted in each region according to the development of the epidemic and pre-existing arrangements. Their local application can only be decided within the framework of collaboration between the ENT teams, the operational hygiene units and all the other specialties concerned. | 1879-7296 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;France__epidemiology;Head and Neck Neoplasms__pathology;Humans;Infection Control__methods;Otolaryngology__methods;Otorhinolaryngologic Surgical Procedures__methods;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Annals of Otorhinolaryngology, Head and Neck Diseases | V Couloigner;S Schmerber;R Nicollas;A Coste;B Barry;M Makeieff;P Boudard;E Bequignon;N Morel;E Lescanne | COVID-19;Droplet-based transmission;Infectious disease;Personal protective equipment (PPE);SARS-CoV-2 | 2020-04-23 02:00:00+02:00 | 32362564 | FR | Paediatric ENT Department, Necker-Enfants Malades University Hospital, AP-HP, Paris, France.;Department of Otorhinolaryngology, Head and Neck Surgery, Grenoble University Hospital, Grenoble, France.;Paediatric ENT Department, Marseille University Hospital, AP-HM, Marseille, France.;Department of Otorhinolaryngology, Head and Neck Surgery, Henri-Mondor University Hospitals, AP-HP, Tassigny, France, Department of Otorhinolaryngology, Head and Neck Surgery, Créteil Intercommunal University Hospital, AP-HP, Créteil, France.;Department of Otorhinolaryngology, Head and Neck Surgery, Bichat University Hospital, AP-HP, Paris, France.;Department of Otorhinolaryngology, Head and Neck Surgery, Reims University Hospital, Reims, France.;ENT clinic, Bordeaux, France.;ENT clinic, Échirolles, France.;Department of Otorhinolaryngology, Head and Neck Surgery, Tours University Hospital, Tours, France. Electronic address: lescanne@univ-tours.fr. | 329 | ||
| 10.1016/j.mehy.2020.109785 | Journal Article | en | Oxytocin as a potential defence against Covid-19? | https://www.ncbi.nlm.nih.gov/pubmed/32344303 | 0306-9877 | 2020-04-26 02:00:00+02:00 | pubmed | Medical Hypotheses | Amélie Soumier;Angela Sirigu | 2020-04-23 02:00:00+02:00 | 32344303 | FR | Institute of Cognitive Science Marc Jeannerod, UMR 5229, CNRS, University Claude Bernard LyonI, Bron, France. | 331 | |||||
| 10.1007/s00330-020-06865-y | Journal Article | en | COVID-19 patients and the radiology department - advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). | https://www.ncbi.nlm.nih.gov/pubmed/32314058 | This document from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI) aims to present the main imaging features, and the role of CT scan in the early diagnosis of COVID-19, describing, in particular, the typical findings which make it possible to identify the disease and distinguish it from bacterial causes of infection, and to define which category of patients may benefit from CT imaging. The precautions that must be taken when performing scans to protect radiologists and technologists from infection will be described. The organisational measures that can be taken within radiology departments in order to cope with the influx of patients, while continuing to manage other emergency and time-sensitive activity (e.g. oncology, other infectious diseases etc.), will be discussed. KEY POINTS: • Bilateral ground glass opacities are typical CT manifestations of COVID-19. • Crazy paving and organising pneumonia pattern are seen at a later stage. • Extensive consolidation is associated with a poor prognosis. | 0938-7994,1432-1084 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__diagnostic imaging;Emergency Service, Hospital;Europe;Humans;Pandemics;Pneumonia, Viral__diagnostic imaging;Radiography, Thoracic;Radiology Department, Hospital;Societies, Medical;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Radiology | Marie-Pierre Revel;Anagha P Parkar;Helmut Prosch;Mario Silva;Nicola Sverzellati;Fergus Gleeson;Adrian Brady | Coronavirus infections;Pneumonia;Tomography, X-ray computed | 2020-04-20 02:00:00+02:00 | 32314058 | FR;SE;NO;IE;GB;IT;AT | Department of Radiology, Cochin Hospital, Université de Paris, 75006, Paris, France. marie-pierre.revel@aphp.fr.;Department of Radiology, Haraldsplass Deaconess Hospital, Bergen, Norway.;Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway.;Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.;Radiology, Department of Medicine and Surgery, University of Parma, Parma, Italy.;Department of Oncology, University of Oxford, Oxford, UK.;Department Radiology, Mercy University Hospital, Cork, Ireland. adrianbrady@me.com. | 341 | ||
| Letter | en | Plea for multitargeted interventions for severe COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32325035 | 2020-04-26 02:00:00+02:00 | pubmed | Benjamin Jean Gaborit;Jean-François Bergmann;Cristina Mussini;Jose Ramon Arribas;Georg Behrens;Sharon Walmsley;Anton Pozniak;François Raffi | 2020-04-20 02:00:00+02:00 | 32325035 | FR;CA;BO;GB;IT;ES;DE | Department of Infectious Diseases, Hotel-Dieu Hospital and INSERM CIC 1413, Nantes University Hospital, Nantes 44093, France.;Internal Medicine Department, Lariboisière Hospital, Paris, France.;Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.;Infectious Diseases Unit, Internal Medicine Service, Hospital La Paz, IdiPAZ, Madrid, Spain.;Department for Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany.;Toronto General Hospital Research Institute, Toronto, ON, Canada.;Chelsea and Westminster Hospital NHS Foundation Trust and London School of Hygiene & Tropical Medicine, London, UK.;Department of Infectious Diseases, Hotel-Dieu Hospital and INSERM CIC 1413, Nantes University Hospital, Nantes 44093, France. Electronic address: francois.raffi@wanadoo.fr. | 342 | ||||||||
| 10.1016/s2468-2667(20)30092-x | Journal Article | en | Can a virus undermine human rights? | https://www.ncbi.nlm.nih.gov/pubmed/32325013 | 2468-2667 | 2020-04-26 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Human Rights;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;COVID-19 | The Lancet Public Health | Olivier Nay | 2020-04-21 02:00:00+02:00 | 32325013 | FR | University of Paris 1 Pantheon-Sorbonne, Paris 75005, France. Electronic address: onay@univ-paris1.fr. | 344 | ||||
| Letter | en | Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. | https://www.ncbi.nlm.nih.gov/pubmed/32332072 | 2020-04-26 02:00:00+02:00 | pubmed | Adult;Aged;Coronavirus Infections__complications;Female;Humans;Hydroxychloroquine__administration & dosage;Lupus Erythematosus, Systemic__complications;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;COVID-19 | Alexis Mathian;Matthieu Mahevas;Julien Rohmer;Mathilde Roumier;Fleur Cohen-Aubart;Blanca Amador-Borrero;Audrey Barrelet;Cecile Chauvet;Thibaud Chazal;Michel Delahousse;Mathilde Devaux;Romain Euvrard;Jehane Fadlallah;Nans Florens;Julien Haroche;Miguel Hié;Laurent Juillard;Raphael Lhote;Thibault Maillet;Gaelle Richard-Colmant;Jean Baptiste Palluy;Micheline Pha;Laurent Perard;Philippe Remy;Etienne Rivière;Damien Sène;Pascal Sève;Capucine Morélot-Panzini;Jean-François Viallard;Jean-Simon Virot;Neila Benameur;Noël Zahr;Hans Yssel;Bertrand Godeau;Zahir Amoura | hydroxychloroquine;lupus erythematosus, systemic;lupus nephritis | 2020-04-24 02:00:00+02:00 | 32332072 | FR | Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.;Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Service de Médecine Interne, Paris, France.;Service de Médecine Interne, Hôpital Foch, Suresnes, France.;Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.;Université de Paris (Paris-Diderot), Assistance Publique-Hôpitaux de Paris, Département de Médecine Interne et d'Immunologie Clinique Hôpital Lariboisière, Paris, France.;Service de Maladies Infectieuses et Tropicales, Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée, Jossigny, France.;Service de Néphrologie, Hôpital Saint-Joseph-Saint-Luc, Lyon, France.;Service de Néphrologie, Hôpital Foch, Suresnes, France.;Service de Médecine Interne, CHI Poissy Saint Germain, Poissy, France.;Service de réanimation polyvalente, Centre Hospitalier Fleyriat, Bourg-en-Bresse, France.;Université Lyon 1, Hospices Civils de Lyon, Hôpital Edouard Herriot, CarMeN - UMR INSERM U.1060, Service de néphrologie, hypertension, hémodialyse et explorations fonctionnelles rénales, Lyon, France.;Sorbonne Université, UPMC, Institut Pierre Louis d'Epidémiologie et de Santé Public (IPLESP), UMRS 1136, Epidémiologie des Pathologies Allergique et Respiratoire (EPAR), Faculté de médecine de Saint Antoine, Paris, France.;Service de Médecine Interne - Unité 11, Centre Hospitalier de Mâcon, Groupe Hospitalier Bourgogne Méridionale, Macon, France.;Service de Médecine Interne, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France.;Service de Médecine interne, Hôpital Saint-Joseph-Saint-Luc, Lyon, France.;Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Service de Néphrologie, Paris, France.;Internal Medicine Department, Hôpital Haut-Lévêque, Bordeaux University Hospital, Avenue de Magellan, Pessac, France.;Sorbonne Université, INSERM, UMRS1158, AP-HP, Groupe Hospitalier Universitaire APHP Sorbonne Université, site Pitié-Salpêtrière, Service de Pneumologie et Réanimation Médicale (Département R3S), Paris, France.;Service de service de Néphrologie/Dialyse, Centre Hospitalier de Mâcon, Groupe Hospitalier Bourgogne Méridionale, Macon, France.;Service De La Pharmacie, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Paris, France.;Service De Pharmacologie, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Paris, France.;Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France. | 363 | ||||||
| 10.1016/s0140-6736(20)30912-0 | Case Reports;Journal Article | en | Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. | https://www.ncbi.nlm.nih.gov/pubmed/32334650 | 0140-6736 | 2020-04-26 02:00:00+02:00 | pubmed | Aged;Chemokines, CXC;Clinical Laboratory Techniques;Coronary Angiography;Coronavirus Infections__complications;Electrocardiography;Humans;Italy;Male;Myocarditis__diagnostic imaging;Pandemics;Platelet Aggregation Inhibitors__therapeutic use;Pneumonia, Viral__complications;Respiratory Distress Syndrome, Adult__etiology;Tomography, X-Ray Computed;Troponin I__blood;Ventricular Function, Left;COVID-19;COVID-19 diagnostic testing | The Lancet | Denis Doyen;Pamela Moceri;Dorothée Ducreux;Jean Dellamonica | 2020-04-23 02:00:00+02:00 | 32334650 | FR;US | Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nice, Nice, France, UR2CA, Unité de Recherche Clinique Côte d'Azur, Université Côte d'Azur, Nice, France. Electronic address: doyen.d@chu-nice.fr.;UR2CA, Unité de Recherche Clinique Côte d'Azur, Université Côte d'Azur, Nice, France, Cardiology Department, Centre Hospitalier, Universitaire de Nice, Nice, France.;Department of Radiology, Université Côte d'Azur, Centre Hospitalier, Universitaire de Nice, Nice, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nice, Nice, France, UR2CA, Unité de Recherche Clinique Côte d'Azur, Université Côte d'Azur, Nice, France. | 370 | ||||
| 10.1007/s00417-020-04703-x | Journal Article;Review | en | Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32328757 | There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection. | 0721-832X,1435-702X | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__prevention & control;Disinfection;Humans;Intravitreal Injections;Ophthalmology__organization & administration;Pandemics__prevention & control;Personal Protective Equipment;Pneumonia, Viral__prevention & control;Retinal Diseases__drug therapy;Vascular Endothelial Growth Factor A__antagonists & inhibitors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Graefe's Archive for Clinical and Experimental Ophthalmology | Jean-François Korobelnik;Anat Loewenstein;Bora Eldem;Antonia M Joussen;Adrian Koh;George N Lambrou;Paolo Lanzetta;Xiaoxin Li;Monica Lövestam-Adrian;Rafael Navarro;Annabelle A Okada;Ian Pearce;Francisco J Rodríguez;David T Wong;Lihteh Wu | COVID-19;Coronavirus;Ophthalmology;Recommendations;Retinal disease;Vision Academy | 2020-04-23 02:00:00+02:00 | 32328757 | CR;FR;SG;IL;SE;CO;CA;CN;JP;CH;GB;IT;TR;ES;DE | Service d'ophtalmologie, CHU Bordeaux, Bordeaux, France. jean-francois.korobelnik@chu-bordeaux.fr.;Inserm, Bordeaux Population Health Research Center, team LEHA, Université de Bordeaux, UMR 1219, F-33000, Bordeaux, France. jean-francois.korobelnik@chu-bordeaux.fr.;Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;Department of Ophthalmology, Hacettepe University, Ankara, Turkey.;Charité - University Medicine Berlin, Berlin, Germany.;Eye and Retina Surgeons, Camden Medical Centre, Singapore, Singapore.;Global Medical Affairs Ophthalmology, Bayer, Basel, Switzerland.;Department of Medicine - Ophthalmology, University of Udine, Udine, Italy.;Department of Ophthalmology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Ospedale Santa Maria della Misericordia, Udine, Italy.;Istituto Europeo di Microchirurgia Oculare, IEMO, Udine, Italy.;Eye Center and Eye Institute, Peking University People's Hospital, Beijing, China.;Department of Ophthalmology, Lund University Hospital, Lund, Sweden.;Instituto Microcirugia Ocular, Barcelona, Spain.;Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.;Royal Liverpool University Hospital, Liverpool, UK.;Fundación Oftalmologia Nacional, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.;Unity Health Toronto - St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.;Macula, Vitreous and Retina Associates of Costa Rica, San José, Costa Rica. | 374 | ||
| Editorial;Comment | en | COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors. | https://www.ncbi.nlm.nih.gov/pubmed/32344292 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;China;Coronavirus Infections;Humans;Lung Neoplasms;Pandemics;Pneumonia, Viral;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Receptor Protein-Tyrosine Kinases;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | Alessandro Leonetti;Francesco Facchinetti;Teresa Zielli;Elena Brianti;Marcello Tiseo | 2020-04-23 02:00:00+02:00 | 32344292 | FR;IT | Medical Oncology Unit, University Hospital of Parma, Parma, Italy, Department of Medicine and Surgery, University of Parma, Parma, Italy.;Université Paris-Saclay, Institut Gustave Roussy, Inserm, Biomarqueurs Prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France, Internal Medicine, Fidenza Hospital, Local Health Authority, Parma, Italy. Electronic address: Francesco.Facchinetti@gustaveroussy.fr.;Medical Oncology Unit, University Hospital of Parma, Parma, Italy.;Internal Medicine, Fidenza Hospital, Local Health Authority, Parma, Italy. | 375 | |||||||
| 10.1016/j.bulcan.2020.04.001 | Practice Guideline | fr | [COVID 19 and cancer: What are the consequences of the cancer care reorganization?] | https://www.ncbi.nlm.nih.gov/pubmed/32359766 | 0007-4551 | 2020-04-26 02:00:00+02:00 | pubmed | Betacoronavirus;China__epidemiology;Coronavirus Infections__complications;France__epidemiology;Humans;Incidence;Medical Oncology__organization & administration;Neoplasms__complications;Pandemics__prevention & control;Pneumonia, Viral__complications;Risk Factors;Societies, Medical__standards;Surgical Oncology__organization & administration;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bulletin du Cancer | Mehdi El Amrani;Stéphanie Truant;Anthony Turpin | 2020-04-23 02:00:00+02:00 | 32359766 | FR | CHRU de Lille, département de chirurgie digestive et transplantation, Lille, France, Université de Lille, Lille, France. Electronic address: mehdi_elamrani@hotmail.fr.;CHRU de Lille, département de chirurgie digestive et transplantation, Lille, France, Université de Lille, Lille, France.;CHRU de Lille, département d'oncologie médicale, Lille, France, Université de Lille, Lille, France. | 376 | ||||
| 10.1016/j.adro.2020.04.010 | Journal Article | en | Practice Considerations for Proton Beam Radiation Therapy of Uveal Melanoma During the Coronavirus Disease Pandemic: Particle Therapy Co-Operative Group Ocular Experience. | https://www.ncbi.nlm.nih.gov/pubmed/32337386 | Uveal melanoma (UM) is a rare but life-threatening cancer of the eye. In light of the coronavirus disease (COVID-19) pandemic, hospitals and proton eye therapy facilities must analyze several factors to ensure appropriate treatment protocols for patients and provider teams. Practice considerations to limit COVID-19 transmission in the proton ocular treatment setting for UM are necessary. The Particle Therapy Co-Operative Group is the largest international community of particle/proton therapy providers. Participating experts have current or former affiliation with the member institutions of the Particle Therapy Co-Operative Group Ocular subcommittee with long-standing high-volume proton ocular programs. The practices reviewed in this document must be taken in conjunction with local hospital procedures, multidisciplinary recommendations, and regional/national guidelines, as each community may have its unique needs, supplies, and protocols. Importantly, as the pandemic evolves, so will the strategies and recommendations. Given the unique circumstances for UM patients, along with indications of potential ophthalmologic transmission as a result of health care providers working in close proximity to patients and intrinsic infectious risk from eyelashes, tears, and hair, practice strategies may be adapted to reduce the risk of viral transmission. Certainly, providers and health care systems will continue to examine and provide as safe and effective care as possible for patients in the current environment. | 2452-1094 | 2020-04-26 02:00:00+02:00 | pubmed | Advances in Radiation Oncology | Kavita K Mishra;Armin Afshar;Juliette Thariat;Helen A Shih;Jessica E Scholey;Inder K Daftari;Andrzej Kacperek;Alessia Pica;Jan Hrbacek;Remi Dendale;Alejandro Mazal;Jens Heufelder;Devron H Char;Wolfgang A G Sauerwein;Damien C Weber;Bertil E Damato | 2020-04-23 02:00:00+02:00 | 32337386 | FR;CH;GB;US;ES;DE | Ocular Tumor Proton Therapy Program, Department of Radiation Oncology, University of California San Francisco, San Francisco, California.;Department of Ophthalmology, University of California San Francisco, San Francisco, California.;Department of Radiation Oncology, Centre François Baclesse, Normandie Universite, Caen, France.;F.H. Burr Proton Therapy Center, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.;National Proton Therapy Centre, Clatterbridge Cancer Centre, Wirral, United Kingdom.;Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.;Institut Curie Proton Therapy Center, Orsay, France.;Centro de Protonterapia Quironsalud, Madrid, Spain.;BerlinProtonen am HZB, Charité-Universitätsmedizin Berlin, Berlin, Germany.;The Tumori Foundation, San Francisco, California.;Department of Radiation Oncology, University Hospital Essen, Essen, Germany.;Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom. | 379 | ||||
| 10.1111/1471-0528.16270 | Journal Article | en | How should we treat pregnant women infected with SARS-CoV-2? | https://www.ncbi.nlm.nih.gov/pubmed/32324956 | 1470-0328,1471-0528 | 2020-04-26 02:00:00+02:00 | pubmed | BJOG: An International Journal of Obstetrics & Gynaecology | V Faure-Bardon;L J Salomon;M Leruez-Ville;Y Ville | 2020-04-23 02:00:00+02:00 | 32324956 | FR | EA 73-28, Paris Descartes University, Sorbonne Paris Cité, Paris, France.;Maternity, AP-HP, Hospital Necker-E.M., Paris, France.;Virology Laboratory, AP-HP, Hospital Necker-E.M., Paris, France. | 386 | |||||
| 10.1148/radiol.2020201561 | Journal Article | en | Acute Pulmonary Embolism in Patients with COVID-19 at CT Angiography and Relationship to d-Dimer Levels. | https://www.ncbi.nlm.nih.gov/pubmed/32324102 | Online supplemental material is available for this article. | 0033-8419,1527-1315 | 2020-04-26 02:00:00+02:00 | pubmed | Radiology | Ian Léonard-Lorant;Xavier Delabranche;François Séverac;Julie Helms;Coralie Pauzet;Olivier Collange;Francis Schneider;Aissam Labani;Pascal Bilbault;Sébastien Molière;Pierre Leyendecker;Catherine Roy;Mickaël Ohana | 2020-04-23 02:00:00+02:00 | 32324102 | FR | From the Hôpitaux Universitaires de Strasbourg, Service de Radiologie, Nouvel Hôpital Civil, 1 place de l'Hôpital, 67000, Strasbourg, France (I.L.L., A.L., P.L., C.R., M.O.), Hôpitaux Universitaires de Strasbourg, Service de Réanimation Polyvalente, Nouvel Hôpital Civil, Strasbourg, France (X.D., C.P., O.C.), Hôpitaux universitaires de Strasbourg, Groupe Méthodes en Recherche Clinique (GMRC), Hôpital Civil, Strasbourg, France (F. Séverac), Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive et Réanimation, Nouvel Hôpital Civil, Strasbourg, France (J.H.), ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France (J.H.), Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive-Réanimation, Hôpital de Hautepierre I, Strasbourg, France (F. Schneider), Hôpitaux Universitaires de Strasbourg, Service d'Accueil des Urgences, Nouvel Hôpital Civil, Strasbourg, France (P.B.), and Hôpitaux Universitaires de Strasbourg, Service de Radiologie, Hôpital de Hautepierre I, Strasbourg, France (S.M.). | 388 | ||||
| 10.1016/j.autrev.2020.102569 | Journal Article;Review | en | Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. | https://www.ncbi.nlm.nih.gov/pubmed/32376394 | Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called "cytokine storm". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19. | 1568-9972 | 2020-05-03 02:00:00+02:00 | pubmed | Angiotensin-Converting Enzyme Inhibitors__therapeutic use;Anticoagulants__therapeutic use;Antimalarials__therapeutic use;Antiviral Agents;Betacoronavirus;Coronavirus Infections__therapy;Cytokines__antagonists & inhibitors;Glucocorticoids__therapeutic use;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors__therapeutic use;Immunoglobulins, Intravenous__therapeutic use;Immunomodulation;Janus Kinases__antagonists & inhibitors;Pandemics;Pneumonia, Viral__therapy;Risk Factors;COVID-19;severe acute respiratory syndrome coronavirus 2 | Autoimmunity Reviews | Jaume Alijotas-Reig;Enrique Esteve-Valverde;Cristina Belizna;Albert Selva-O'Callaghan;Josep Pardos-Gea;Angela Quintana;Arsene Mekinian;Ariadna Anunciacion-Llunell;Francesc Miró-Mur | Acute respiratory distress syndrome;COVID-19;Cytokine storm;Immunosuppressive;SARS-CoV-2;Treatment | 2020-05-03 02:00:00+02:00 | 32376394 | FR;ES;PS | Systemic Autoimmune Diseases Unit, Department of Internal Medicine-1, Vall d'Hebron University Hospital, Barcelona, Spain, Systemic Autoimmune Research Unit, Vall d'Hebron Reseacrh Institute, Spain, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: jalijotas@vhebron.net.;Department of Internal Medicine, Althaia Network Health, Manresa, Barcelona, Spain, Universitat Central de Catalunya, Spain.;Vascular and Coagulation Department, University Hospital Angers, Angers, France, UMR CNRS 6015, Angers, France, INSERM U1083, Angers, France.;Systemic Autoimmune Diseases Unit, Department of Internal Medicine-1, Vall d'Hebron University Hospital, Barcelona, Spain, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.;Systemic Autoimmune Diseases Unit, Department of Internal Medicine-1, Vall d'Hebron University Hospital, Barcelona, Spain, Universitat Autònoma de Barcelona, Barcelona, Spain.;Systemic Autoimmune Research Unit, Vall d'Hebron Research Institute, Barcelona, Spain.;Service de Médecine Interne, Centre de référence AO Bradykiniques et compétence Maladies Auto-immunes FAI2R, Hôpital Saint Antoine Hôpitaux Universitaires de l'Est Parisien, Professeur des Universités-Praticien Hospitalier Sorbonne Université, France. | 392 | ||
| 10.1177/1747493020923234 | Consensus Development Conference;Journal Article | en | Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel. | https://www.ncbi.nlm.nih.gov/pubmed/32362244 | On 11 March 2020, World Health Organization (WHO) declared the COVID-19 infection a pandemic. The risk of ischemic stroke may be higher in patients with COVID-19 infection similar to those with other respiratory tract infections. We present a comprehensive set of practice implications in a single document for clinicians caring for adult patients with acute ischemic stroke with confirmed or suspected COVID-19 infection. | 1747-4930,1747-4949 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Brain Ischemia__diagnosis;Cerebral Angiography;Comorbidity;Computed Tomography Angiography;Coronavirus Infections__blood;Disease Management;Health Personnel;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Magnetic Resonance Angiography;Magnetic Resonance Imaging;Pandemics;Patient Isolators;Perfusion Imaging;Pneumonia, Viral__blood;Risk;Stroke__diagnosis;Thrombophilia__blood;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Stroke | Adnan I Qureshi;Foad Abd-Allah;Fahmi Al-Senani;Emrah Aytac;Afshin Borhani-Haghighi;Alfonso Ciccone;Camilo R Gomez;Erdem Gurkas;Chung Y Hsu;Vishal Jani;Liqun Jiao;Adam Kobayashi;Jun Lee;Jahanzeb Liaqat;Mikael Mazighi;Rajsrinivas Parthasarathy;Thorsten Steiner;M Fareed K Suri;Kazunori Toyoda;Marc Ribo;Fernando Gongora-Rivera;Jamary Oliveira-Filho;Guven Uzun;Yongjun Wang | COVID-19;Coronavirus;acute stroke;ischemic stroke;mechanical thrombectomy;thrombolysis | 2020-05-03 02:00:00+02:00 | 32362244 | FR;MX;SA;CN;PS;JP;US;TW;BR;IT;PL;IR;EG;TR;ES;IN;KR;PK;DE | Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USA.;Department of Neurology, Kasralainy school of Medicine, Cairo University, Cairo, Egypt.;Neurology Department, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia.;Department of Neurology, University of FIRAT, Elazig Turkey.;Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.;Department of Neurosciences, Hospital Carlo Poma, ASST di Mantova, Mantua, Italy.;Department of Neurology, University of Missouri, MO, USA.;Stroke Center, Department of Neurology, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey.;Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan.;Department of Neurology, Creighton University Medical Center/CHI Health, Omaha, NE, USA.;Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.;Department of Neurology and Interventional Stroke Treatment Centre, Kazimierz Pulaski University of Technology and Humanities, Radom, Poland.;Department of Neurology, Yeungnam University School of Medicine, Daegu, Korea.;Pakistan Emirates Military Hospital (J.L.), Rawalpindi, Pakistan.;Department of Interventional Neuroradiology, Rothschild Foundation Hospital, University of Paris, Laboratory of Vascular Translational Sciences, Paris, France.;Stroke & Neurointervention Artemis Hospitals, Gurugram, India.;Department of Neurology, Klinikum Frankfurt Höchst, Frankfurt and Heidelberg University Hospital, Heidelberg, Germany.;St Cloud Hospital, St Cloud, MN, USA.;Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.;Department of Neurology, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Spain.;Servicio de Neurología, Hospital Universitario José Eleuterio González de la Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México, Instituto de Neurología y Neurocirugía, Hospital Zambrano Hellion, Tecnológico de Monterrey, San Pedro, Nuevo León, México.;Department of Biomorphology, Federal University of Bahia, Salvador, Brazil.;Beverly Hills Pain Institute and Neurology, Beverly Hills, CA, USA.;Tiantan Comprehensive Stroke Center, Beijing Tiantan Hospital, Capital Medical University Beijing, China. | 393 | ||
| 10.3390/biology9050094 | Journal Article | en | Temperature Decreases Spread Parameters of the New Covid-19 Case Dynamics. | https://www.ncbi.nlm.nih.gov/pubmed/32375234 | (1) Background: The virulence of coronavirus diseases due to viruses like SARS-CoV or MERS-CoV decreases in humid and hot weather. The putative temperature dependence of infectivity by the new coronavirus SARS-CoV-2 or covid-19 has a high predictive medical interest. (2) Methods: External temperature and new covid-19 cases in 21 countries and in the French administrative regions were collected from public data. Associations between epidemiological parameters of the new case dynamics and temperature were examined using an ARIMA model. (3) Results: We show that, in the first stages of the epidemic, the velocity of contagion decreases with country- or region-wise temperature. (4) Conclusions: Results indicate that high temperatures diminish initial contagion rates, but seasonal temperature effects at later stages of the epidemy remain questionable. Confinement policies and other eviction rules should account for climatological heterogeneities, in order to adapt the public health decisions to possible geographic or seasonal gradients. | 2079-7737 | 2020-05-03 02:00:00+02:00 | pubmed | Biology | Jacques Demongeot;Yannis Flet-Berliac;Hervé Seligmann | covid-19;heat inhibition;temperature sensitivity;weather-dependent virulence | 2020-05-03 02:00:00+02:00 | 32375234 | FR;IL | Laboratory AGEIS EA 7407, Team Tools for e-Gnosis Medical & Labcom CNRS/UGA/OrangeLabs Telecom4Health, Faculty of Medicine, Université Grenoble Alpes, F-38700 La Tronche, France.;Laboratory CRIStAL, UMR 9189, CNRS, Université de Lille, Campus Scientifique, Avenue Henri Poincaré, F-59655 Villeneuve d'Ascq, France.;The National Natural History Collections, The Hebrew University of Jerusalem, 91404 Jerusalem, Israel. | 395 | |||
| Letter;Comment | en | Integration of telemedicine into the public health response to COVID-19 must include dentists. | https://www.ncbi.nlm.nih.gov/pubmed/32320488 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Dentists;Humans;Pandemics;Pneumonia, Viral;Public Health;Telemedicine;COVID-19;severe acute respiratory syndrome coronavirus 2 | D Maret;O A Peters;F Vaysse;E Vigarios | 2020-05-02 02:00:00+02:00 | 32320488 | FR;AU;US | Faculté de Chirurgie Dentaire, Centre Hospitalier Universitaire, Université Paul Sabatier, Toulouse, France.;Laboratoire Anthropologie Moléculaire et Imagerie de Synthèse, Université Paul Sabatier, Toulouse, France.;Department of Endodontics, Arthur A Dugoni School of Dentistry, University of the Pacific, San Francisco, CA, USA.;School of Dentistry, University of Queensland, Brisbane, Australia.;Département de Pneumologie, Faculté de Chirurgie Dentaire, Centre Hospitalier Universitaire, Université Paul Sabatier, Toulouse, France.;Oral Medicine Department, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France. | 396 | |||||||
| 10.1093/ndt/gfaa113 | Journal Article | en | The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much? | https://www.ncbi.nlm.nih.gov/pubmed/32358609 | 0931-0509,1460-2385 | 2020-05-03 02:00:00+02:00 | pubmed | Nephrology Dialysis Transplantation | Marie Essig;Morgan Matt;Ziad Massy | 2020-05-03 02:00:00+02:00 | 32358609 | FR | APHP University Paris Saclay, Ambroise Paré Hospital, Division of Nephrology, Boulogne Billancourt, France.;INSERM U-1018, Team 5, Centre de recherche en épidémiologie et santé des populations, Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Paris-Sud University, and Paris Saclay University, Villejuif, France.;APHP University Paris Saclay, Raymond Poincaré Hospital, Division of Infectious disease, Garches, France. | 402 | |||||
| 10.1016/j.gofs.2020.04.006 | Editorial | fr | [COVID-19, a brutal blow…]. | https://www.ncbi.nlm.nih.gov/pubmed/32354561 | 2468-7189 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Female;Global Health;Humans;Pandemics;Pneumonia, Viral__epidemiology;Pregnancy;Pregnant Women;COVID-19;severe acute respiratory syndrome coronavirus 2 | Gynécologie Obstétrique Fertilité & Sénologie | P Deruelle;F De Marcillac | Complications;Covid_19;Grossesse;Neonate;Nouveau-né;Pregnancy;SARS-COV2 | 2020-05-02 02:00:00+02:00 | 32354561 | FR | Pôle de gynécologie, obstétrique et fertilité, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France. Electronic address: pderuelle@unistra.fr.;Pôle de gynécologie, obstétrique et fertilité, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France. | 403 | |||
| 10.1093/ehjqcco/qcaa034 | Journal Article | en | Where have the ST-segment elevation myocardial infarctions gone during COVID-19 lockdown? | https://www.ncbi.nlm.nih.gov/pubmed/32348457 | 2058-5225,2058-1742 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Emergency Service, Hospital__statistics & numerical data;Facilities and Services Utilization;France__epidemiology;Hospitalization__statistics & numerical data;Humans;Pandemics;Pneumonia, Viral__epidemiology;Registries;ST Elevation Myocardial Infarction__therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Heart Journal - Quality of Care and Clinical Outcomes | Gregoire Rangé;Radwan Hakim;Pascal Motreff | 2020-04-30 02:00:00+02:00 | 32348457 | FR | Cardiology Department, les Hôpitaux de Chartres, 4 rue Claude Bernard, 28630, Le Coudray, France.;Cardiology Department, Centre Hospitalo-Universitaire de Clermont-Ferrand, 58 Rue Montalembert, 63000, Clermont-Ferrand, France. | 405 | ||||
| 10.1097/mej.0000000000000717 | Journal Article;Review | en | Collateral damage of the COVID-19 outbreak: expression of concern. | https://www.ncbi.nlm.nih.gov/pubmed/32345850 | 0969-9546 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Communicable Disease Control__organization & administration;Coronavirus Infections__epidemiology;Delivery of Health Care__organization & administration;Disease Outbreaks__prevention & control;Emergency Service, Hospital__organization & administration;Female;Humans;Male;Pandemics__statistics & numerical data;Pneumonia, Viral__epidemiology;Public Health;Risk Assessment;Safety Management;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Journal of Emergency Medicine | Anne-Laure Feral-Pierssens;Pierre-Géraud Claret;Tahar Chouihed | 2020-04-30 02:00:00+02:00 | 32345850 | FR;CA;UNK | IMProving Emergency Care Federation (IMPEC).;Emergency Department, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Paris.;CR CSIS, Département des Sciences de la Santé Communautaire, Sherbrooke University, Longueuil, Québec, Canada.;Emergency Department, Nîmes University Hostpial Nîmes.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques- 1433, and Inserm U1116 CHRU Nancy.;Emergency Department, University Hospital of Nancy, Vandoeuvre les Nancy, France. | 406 | ||||
| 10.1007/s00268-020-05546-7 | Editorial | en | We Asked the Experts: How Do We Maintain Surgical Quality Standards for Enhanced Recovery Programs After Cancer Surgery During the COVID-19 Outbreak? | https://www.ncbi.nlm.nih.gov/pubmed/32335691 | 0364-2313,1432-2323 | 2020-05-03 02:00:00+02:00 | pubmed | World Journal of Surgery | Alexandre Doussot;Bruno Heyd;Zaher Lakkis | 2020-04-27 02:00:00+02:00 | 32335691 | FR | Department of Digestive Surgical Oncology - Liver Transplantation Unit, University Hospital of Besançon, 2, Boulevard Alexander Fleming, 25000, Besançon, France. adoussot@chu-besancon.fr.;Department of Digestive Surgical Oncology - Liver Transplantation Unit, University Hospital of Besançon, 2, Boulevard Alexander Fleming, 25000, Besançon, France. | 410 | |||||
| Letter | en | Protective Device during Airway Management in Patients with Coronavirus Disease 2019 (COVID-19). | https://www.ncbi.nlm.nih.gov/pubmed/32358250 | 2020-05-03 02:00:00+02:00 | pubmed | Airway Management__methods;Betacoronavirus;Coronavirus Infections__prevention & control;Equipment Design;Humans;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Protective Devices;COVID-19;severe acute respiratory syndrome coronavirus 2 | Farid Chakib Rahmoune;Mohamed Mehdi Ben Yahia;Ridha Hajjej;Solene Pic;Kais Chatti | 2020-05-03 02:00:00+02:00 | 32358250 | FR | CH Robert Bisson, Lisieux, France. fc.rahmoune@ch-lisieux.fr. | 414 | |||||||
| Letter | en | Conception and deployment of a 30-bed field military intensive care hospital in Eastern France during the 2020 COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32360981 | 2020-05-03 02:00:00+02:00 | pubmed | Aged;Anesthesia, General__statistics & numerical data;Bed Conversion;Betacoronavirus;Coronavirus Infections__complications;Critical Care__organization & administration;Emergency Medical Dispatch__organization & administration;Female;France__epidemiology;Hospital Bed Capacity, under 100;Hospital Shared Services__organization & administration;Hospitals, General__organization & administration;Hospitals, Military__organization & administration;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Intensive Care Units__organization & administration;Intubation, Intratracheal__statistics & numerical data;Length of Stay__statistics & numerical data;Male;Middle Aged;Mobile Health Units__organization & administration;Occupational Diseases__prevention & control;Pandemics__prevention & control;Patient Admission__statistics & numerical data;Patient Transfer__methods;Personal Protective Equipment;Pneumonia, Viral__complications;Procedures and Techniques Utilization;Respiration, Artificial__statistics & numerical data;Respiratory Distress Syndrome, Adult__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Marc Danguy des Déserts;Quentin Mathais;Antoine Luft;Jacques Escarment;Pierre Pasquier | COVID-19;Field hospital;Military | 2020-04-29 02:00:00+02:00 | 32360981 | FR | Élément militaire de réanimation du service de santé des armées, Mulhouse, France, Hôpital d'instruction des armées Clermont Tonnerre, Brest, France. Electronic address: marc.danguy@gmail.com.;Élément militaire de réanimation du service de santé des armées, Mulhouse, France, Hôpital d'instruction des armées Sainte-Anne, Toulon, France. Electronic address: quentin.mathais@orange.fr.;Élément militaire de réanimation du service de santé des armées, Mulhouse, France, État major opérationnel du service de santé des armées, Paris, France. Electronic address: antoine.luft@protonmail.com.;Élément militaire de réanimation du service de santé des armées, Mulhouse, France, École du Val-de-Grâce, Paris, France. Electronic address: jescarment@gmail.com.;Élément militaire de réanimation du service de santé des armées, Mulhouse, France, École du Val-de-Grâce, Paris, France, Hôpital d'instruction des armées Percy, Clamart, France. Electronic address: pasquier9606@me.com. | 421 | ||||||
| Letter | en | The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France. | https://www.ncbi.nlm.nih.gov/pubmed/32360497 | A new virus, SARS-CoV-2, has spread world-wide since December 2019, probably affecting millions of people and killing thousands. Failure to anticipate the spread of the virus now seriously threatens many health systems. We have designed a model for predicting the evolution of the SARS-CoV-2 epidemic in France, which is based on seroprevalence and makes it possible to anticipate the deconfinement strategy. | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;France__epidemiology;Humans;Infection Control__methods;Models, Statistical;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Seroepidemiologic Studies;COVID-19;severe acute respiratory syndrome coronavirus 2 | Chloé Dimeglio;Jean-Michel Loubes;Benjamin Deporte;Martine Dubois;Justine Latour;Jean-Michel Mansuy;Jacques Izopet | SARS-CoV-2;deconfinement;seroprevalence;statistical model | 2020-04-29 02:00:00+02:00 | 32360497 | FR | UMR Inserm, U1043, UMR CNRS, U5282, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse 31300, France, CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300 France. Electronic address: dimeglio.c@chu-toulouse.fr.;Université de Toulouse, Institut de Mathématiques de Toulouse, Toulouse 31400, France.;UMR Inserm, U1043, UMR CNRS, U5282, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse 31300, France, CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300 France.;CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300 France. | 422 | |||||
| Letter | en | Will participation restrictions related to the COVID-19 lockdown boost inclusivity? | https://www.ncbi.nlm.nih.gov/pubmed/32360290 | 2020-05-03 02:00:00+02:00 | pubmed | Adaptation, Psychological;Betacoronavirus;Coronavirus Infections__prevention & control;Disabled Persons__psychology;Empathy;Humans;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Quarantine__psychology;Resilience, Psychological;Social Distance;Social Isolation__psychology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Eleonore Bayen;François Stefanescu;Hélène Robert;Agnès Weil-Chounlamountry;Marie Villain;Clémentine Gouriou;Sofia Gueorguieva;Christine Picq;Pascale Bruguière;Pascale Pradat-Diehl | 2020-04-29 02:00:00+02:00 | 32360290 | FR;US | Department of Physical and Rehabilitation Medicine, Pitié-Salpêtrière hospital, Assistance Publique des Hôpitaux de Paris, and GRC 24 Sorbonne Université, Paris, France, Laboratoire d'Imagerie Biomédicale (LIB), Sorbonne Université, Paris, France, Global Brain Health Institute, Memory and Aging Center, University of California, San Francisco, USA. Electronic address: eleonore.bayen@gbhi.org.;Department of Physical and Rehabilitation Medicine, Pitié-Salpêtrière hospital, Assistance Publique des Hôpitaux de Paris, and GRC 24 Sorbonne Université, Paris, France.;Department of Physical and Rehabilitation Medicine, Pitié-Salpêtrière hospital, Assistance Publique des Hôpitaux de Paris, and GRC 24 Sorbonne Université, Paris, France, Laboratoire d'Imagerie Biomédicale (LIB), Sorbonne Université, Paris, France. | 429 | |||||||
| 10.23736/s0390-5616.20.04963-2 | Journal Article | en | Impact of COVID-19 pandemic on subarachnoid hemorrhage. | https://www.ncbi.nlm.nih.gov/pubmed/32347681 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Coronavirus Infections__complications;Humans;Pandemics;Pneumonia, Viral__complications;Subarachnoid Hemorrhage__etiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Anne L Bernat;Lorenzo Giammattei;Rosaria Abbritti;Sebastien Froelich | 2020-04-29 02:00:00+02:00 | 32347681 | FR | Department of Neurosurgery, Lariboisière Hospital, Paris, France.;Department of Neurosurgery, Lariboisière Hospital, Paris, France - lore1985nch@gmail.com.;Diderot University, Paris, France. | 434 | ||||||
| 10.1016/j.jfo.2020.04.010 | Journal Article;Practice Guideline | fr | [Eye protection in intensive care (French Ophthalmology Society-National Council of Professionals in Ophthalmology) during COVID-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32386903 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Anti-Infective Agents, Local__administration & dosage;Bandages;Betacoronavirus;Blinking;Coronavirus Infections__epidemiology;Critical Care;Eye Infections, Viral__prevention & control;Eyelids;Humans;Ophthalmology;Pandemics__prevention & control;Patient Positioning__methods;Pneumonia, Viral__epidemiology;Protective Agents__administration & dosage;Societies, Medical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | 2020-04-30 02:00:00+02:00 | 32386903 | FR | 17, VLA d'Alésia, 75014, Paris, France. | 436 | |||||
| 10.1101/2020.04.23.20076885 | Preprint | en | Facing the COVID-19 epidemic in NYC: a stochastic agent-based model of various intervention strategies. | https://www.ncbi.nlm.nih.gov/pubmed/32511467 | Global spread of coronavirus disease 2019 (COVID-19) has created an unprecedented infectious disease crisis worldwide. Despite uncertainties about COVID-19, model-based forecasting of competing mitigation measures on its course is urgently needed to inform mitigation policy. We used a stochastic agent-based microsimulation model of the COVID-19 epidemic in New York City and evaluated the potential impact of quarantine duration (from 4 to 16 weeks), quarantine lifting type (1-step lifting for all individuals versus a 2-step lifting according to age), post-quarantine screening, and use of a hypothetical effective treatment against COVID-19 on the disease's cumulative incidence and mortality, and on ICU-bed occupancy. The source code of the model has been deposited in a public source code repository (GitHub®). The model calibrated well and variation of model parameter values had little impact on outcome estimates. While quarantine is efficient to contain the viral spread, it is unlikely to prevent a rebound of the epidemic once lifted. We projected that lifting quarantine in a single step for the full population would be unlikely to substantially lower the cumulative mortality, regardless of quarantine duration. By contrast, a two-step quarantine lifting according to age was associated with a substantially lower cumulative mortality and incidence, up to 71% and 23%, respectively, as well as lower ICU-bed occupancy. Although post-quarantine screening was associated with diminished epidemic rebound, this strategy may not prevent ICUs from being overcrowded. It may even become deleterious after a 2-step quarantine lifting according to age if the herd immunity effect does not had sufficient time to become established in the younger population when the quarantine is lifted for the older population. An effective treatment against COVID-19 would considerably reduce the consequences of the epidemic, even more so if ICU capacity is not exceeded. | 2020-05-03 02:00:00+02:00 | pubmed | Nicolas Hoertel;Martin Blachier;Carlos Blanco;Mark Olfson;Marc Massetti;Frédéric Limosin;Henri Leleu | COVID-19;ICU-bed occupancy;New York;SARS-CoV-2;United States;incidence;lifting;mortality;quarantine;screening;treatment | 2020-04-28 02:00:00+02:00 | 32511467 | FR;US | AP-HP.Centre, Paris University, Paris, France.;INSERM U1266, Paris, France.;Division of Biostatistics, Modeling and Health Economics, Public Health Expertise, Paris, France.;National Institute on Drug Abuse, Bethesda, MD, 20892, USA.;Columbia University/New York State Psychiatric Institute, 1051 Riverside Drive, Unit 69, New York, NY, 10032, USA. | 441 | |||||
| 10.1111/1462-2920.15025 | Journal Article | en | Cytosine drives evolution of SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32291894 | 1462-2912,1462-2920 | 2020-05-03 02:00:00+02:00 | pubmed | Environmental Microbiology | Antoine Danchin;Philippe Marlière | 2020-04-27 02:00:00+02:00 | 32291894 | FR | Kodikos Labs, 24 rue Jean Baldassini, 69007 Lyon/Institut Cochin, 75013 Paris, France.;TESSSI, The European Syndicate of Synthetic Scientists and Industrialists, 81 rue Réaumur, 75002, Paris, France. | 443 | |||||
| Case Reports;Letter | en | Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum. | https://www.ncbi.nlm.nih.gov/pubmed/32362357 | 2020-05-03 02:00:00+02:00 | pubmed | Antibodies, Monoclonal, Humanized__therapeutic use;Betacoronavirus;Coronavirus Infections__diagnosis;Female;Fingolimod Hydrochloride__therapeutic use;Humans;Immunosuppressive Agents__therapeutic use;Middle Aged;Multiple Sclerosis, Chronic Progressive__diagnostic imaging;Multiple Sclerosis, Relapsing-Remitting__drug therapy;Natalizumab__therapeutic use;Pandemics;Pneumonia, Viral__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | C Louapre;E Maillart;T Roux;V Pourcher;G Bussone;C Lubetzki;C Papeix | 2020-04-27 02:00:00+02:00 | 32362357 | FR | Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France, Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France. Electronic address: celine.louapre@aphp.fr.;Institut du cerveau, ICM, Sorbonne université, hôpital de la Pitié-Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France, Département de neurologie, hôpital Pitié-Salpetrière, AP-HP, Paris, France.;Service de maladies infectieuses et tropicales, hôpitaux universitaires Pitié-Salpêtrière Charles-Foix, Assistance publique-Hôpitaux de Paris, 75013, Paris, France, INSERM 1136, institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, 75013, Paris, France.;Département de médecine interne, hôpital Antoine-Béclère, AP-HP, Clamart, France. | 449 | |||||||
| 10.1016/j.eururo.2020.04.056 | Journal Article;Multicenter Study | en | European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. | https://www.ncbi.nlm.nih.gov/pubmed/32376137 | The coronavirus disease 2019 (COVID-19) pandemic is unlike anything seen before by modern science-based medicine. Health systems across the world are struggling to manage it. Added to this struggle are the effects of social confinement and isolation. This brings into question whether the latest guidelines are relevant in this crisis. We aim to support urologists in this difficult situation by providing tools that can facilitate decision making, and to minimise the impact and risks for both patients and health professionals delivering urological care, whenever possible. We hope that the revised recommendations will assist urologist surgeons across the globe to guide the management of urological conditions during the current COVID-19 pandemic. | 0302-2838 | 2020-05-03 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__complications;Disease Management;Europe;Humans;Pandemics;Pneumonia, Viral__complications;Practice Guidelines as Topic;Societies, Medical;Urologic Diseases__complications;Urology__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Urology | Maria J Ribal;Philip Cornford;Alberto Briganti;Thomas Knoll;Stavros Gravas;Marek Babjuk;Christopher Harding;Alberto Breda;Axel Bex;Jens J Rassweiler;Ali S Gözen;Giovannalberto Pini;Evangelos Liatsikos;Gianluca Giannarini;Alex Mottrie;Ramnath Subramaniam;Nikolaos Sofikitis;Bernardo M C Rocco;Li-Ping Xie;J Alfred Witjes;Nicolas Mottet;Börje Ljungberg;Morgan Rouprêt;Maria P Laguna;Andrea Salonia;Gernot Bonkat;Bertil F M Blok;Christian Türk;Christian Radmayr;Noam D Kitrey;Daniel S Engeler;Nicolaas Lumen;Oliver W Hakenberg;Nick Watkin;Rizwan Hamid;Jonathon Olsburgh;Julie Darraugh;Robert Shepherd;Emma-Jane Smith;Christopher R Chapple;Arnulf Stenzl;Hendrik Van Poppel;Manfred Wirth;Jens Sønksen;James N'Dow | Coronavirus disease 2019;European Association of Urology;Guidelines;Guidelines Office;Pandemic;Section Offices | 2020-04-27 02:00:00+02:00 | 32376137 | FR;SE;IL;CN;GR;GB;US;AT;CH;IT;NL;TR;DK;CZ;ES;BE;DE | Uro-Oncology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain. Electronic address: m.ribal@uroweb.org.;Liverpool University Hospitals Foundation NHS Trust, Liverpool, UK.;Department of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.;Department of Urology, Sindelfingen-Böblingen Medical Centre, University of Tübingen, Sindelfingen, Germany.;Department of Urology, University Hospital of Larissa, Larissa, Greece.;Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic, Department of Urology, Medical University of Vienna, Vienna, Austria.;Urology Department, Freeman Hospital, Newcastle-upon-Tyne, UK.;Oncology Urology Unit, Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.;The Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London, UK, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Department of Urology, SLK Kliniken Heilbronn, University of Heidelberg, Heilbronn, Germany.;Department of Urology, Ospedale San Raffaele-Turro, Milan, Italy.;Urology Department, University of Patras, Patras, Greece.;Urology Unit, Academic Medical Centre Hospital "Santa Maria della Misericordia", Udine, Italy.;Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium, ORSI Academy, Melle, Belgium.;Department of Paediatric Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.;Department of Urology, Medical School, University of Ioannina, University Campus, Ioannina, Greece.;Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.;Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.;Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.;Department of Urology, University Hospital, St. Etienne, France.;Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.;Urology, Sorbonne University, GRC 5 Predictive onco-uro, AP-HP, Pitie-Salpetriere Hospital, Paris, France.;Department of Urology Medipol Mega, Istanbul Medipol University, Istanbul, Turkey, Amsterdam UMC, Amsterdam, The Netherlands.;Alta Uro AG, Merian Iselin Klinik, Center of Biomechanics and Calorimetry, University Basel, Basel, Switzerland.;Department of Urology, Erasmus MC, Rotterdam, The Netherlands.;Department of Urology, Hospital of the Sisters of Charity, Vienna, Austria, Urologische Praxis mit Steinzentrum, Vienna, Austria.;Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.;Department of Urology, Sheba Medical Centre, Tel-Hashomer, Israel.;Department of Urology, Cantonal Hospital St Gallen, Switzerland.;Department of Urology, Ghent University Hospital, Ghent, Belgium.;Klinik und Poliklinik für Urologie, Universitätsmedizin Rostock, Rostock, Germany.;NHS Foundation Trust, St. George's University Hospitals, London, UK.;Department of Female, Functional and Restorative Urology, University College London Hospitals NHS Foundation Trust, London, UK.;Department of Urology and Transplant, Guy's & St Thomas' NHS Trust Hospitals, London, UK.;European Association of Urology Guidelines Office, Arnhem, The Netherlands.;Department of Urology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.;Department of Urology, University Hospital Tuebingen, Tuebingen, Germany.;Department of Urology, University Hospitals Leuven, Leuven, Belgium.;Department of Urology, Medical Faculty Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.;Department of Urology, Herlev and Gentofte University Hospital, Herlev, Denmark, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.;Academic Urology Unit, University of Aberdeen, Aberdeen, UK. | 453 | ||
| 10.1016/j.jchirv.2020.04.013 | English Abstract;Journal Article;Review | fr | [What do surgeons need to know about the digestive disorders and paraclinical abnormalities induced by COVID-19?] | https://www.ncbi.nlm.nih.gov/pubmed/32341722 | The symptoms associated with COVID-19 are mainly characterized by a triad composed of fever, dry cough and dyspnea. However, digestive symptoms have also been reportedAt first considered as infrequent, they in fact seem to affect more than half of patients. The symptoms are mainly manifested by anorexia, diarrhea, nausea and/or vomiting and abdominal pain. Even though prognosis is associated with lung injury, digestive symptoms seem significantly more frequent in patients presenting with severe COVID-19 infection. Digestive forms, which may be isolated or which can precede pulmonary symptoms, have indeed been reported, with diarrhea as a leading clinical sign. The main biological abnormalities that can suggest COVID-19 infection at an early stage are lymphopenia, elevated CRP and heightened ASAT transaminases. Thoraco-abdominal scan seems useful as a means of on the one hand ruling out digestive pathology unrelated to coronavirus and on the other hand searching for pulmonary images suggestive of COVID-19 infection. No data exist on the interest of digestive endoscopy in cases of persistent digestive symptoms. Moreover, the endoscopists may themselves be at significant risk of contamination. Fecal-oral transmission of the infection is possible, especially insofar as viral shedding in stools seems frequent and of longer duration than at the ENT level, including in patients with negative throat swab and without digestive symptoms. In some doubtful cases, virologic assessment of stool samples can yield definitive diagnosis. In the event of prolonged viral shedding in stools, a patient's persistent contagiousness is conceivable but not conclusively established. Upcoming serology should enable identification of the patients having been infected by the COVID-19 epidemic, particularly among previously undetected pauci-symptomatic members of a health care staff. Resumption of medico-surgical activity should be guided by dedicated strategy preceding deconfinement. | 1878-786X | 2020-05-03 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | J-M Gornet;M L Tran Minh;F Leleu;D Hassid | COVID-19;Diarrhea;Digestive disorders | 2020-04-27 02:00:00+02:00 | 32341722 | FR | Université de Paris, Service de Gastroenterologie, AP-HP Hôpital Saint Louis, 1, avenue Claude Vellefaux, Paris, France.;Université de Paris, Service de Radiologie, AP-HP Hôpital Saint Louis, Paris, France. | 461 | |||
| 10.1001/jamadermatol.2020.1704 | Journal Article | en | Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32352486 | 2168-6068 | 2020-05-03 02:00:00+02:00 | pubmed | JAMA Dermatology | Adrien Sanchez;Pierre Sohier;Sarah Benghanem;Anne-Sophie L'Honneur;Flore Rozenberg;Nicolas Dupin;Bethsabée Garel | 2020-04-30 02:00:00+02:00 | 32352486 | FR | Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Division of Dermatology and Venereology, AP-HP Centre-Université de Paris, Paris, France.;Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Division of Pathology, AP-HP Centre-Université de Paris, Paris, France.;Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Division of Intensive Care, AP-HP Centre-Université de Paris, France.;Laboratory of Virology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, AP-HP Centre-Université de Paris, Paris, France. | 468 | |||||
| 10.1002/ppul.24800 | Journal Article | en | Brief report: International perspectives on the pediatric COVID-19 experience. | https://www.ncbi.nlm.nih.gov/pubmed/32356583 | The 2019 novel coronavirus (SARS-CoV-2) is endangering human health worldwide; scarcity of published pediatric cases and current literature and the absence of evidence-based guidelines necessitate international sharing of experience and personal communication. On 31 March 2020 the International Committee of the American Thoracic Society Pediatrics Assembly recorded an online podcast, during which pediatric pulmonologists worldwide shared their experience on the novel coronavirus disease (COVID-19) in children. The aim was to share personal experience in organizing pediatric care in different health care settings globally, protecting health care workers, and isolation practices. This manuscript summarizes the common themes of the podcast which centered around three main topics: more benign clinical disease and progression in pediatric cases compared to adults, a strong need for strategies to protect health care workers, and social or economic disparities as a barrier to successful pandemic control. | 8755-6863,1099-0496 | 2020-05-03 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Child;Chronic Disease;Communicable Disease Control__methods;Coronavirus Infections__complications;Disease Progression;Global Health;Healthcare Disparities;Hospitalization;Hospitals, Pediatric__organization & administration;Humans;Internationality;Occupational Health;Pandemics;Pediatrics__methods;Pneumonia, Viral__complications;Pulmonary Medicine;Quarantine;Respiration Disorders__complications;United States;Webcasts as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Pediatric Pulmonology | Ozge Yilmaz;Laura Gochicoa-Rangel;Hannah Blau;Ralph Epaud;Larry C Lands;Enrico Lombardi;Paul E Moore;Renato T Stein;Gary W K Wong;Heather J Zar | COVID-19;disparity;pandemic;pediatric pulmonology | 2020-05-01 02:00:00+02:00 | 32356583 | FR;IL;CA;PT;CN;US;HK;BR;IT;TR;ZA;MX | Department of Pediatric Allergy and Pulmonology, Medical Faculty, Celal Bayar University, Manisa, Turkey.;Department of Pulmonary Physiology, National Institute of Respiratory Diseases, Mexico City, Mexico.;Pulmonary Institute at Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;Department of Pediatrics, CHI Créteil, Service de Pédiatrie, INSERM U955 (IMRB), équipe GEIC2O, UPEC, Créteil, France.;Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada.;Pediatric Pulmonary Unit, Meyer Children's Hospital, Florence, Italy.;Department of Pediatrics, Monroe Carell Jr. Children's Hospital, Vanderbilt University Medical Center, Nashville, Tennessee.;Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.;Department of Pediatrics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong.;Department of Paediatrics and Child Health, SA MRC Unit on Child and Adolescent Health, Red Cross Children's Hospital, University of Cape Town, Cape Town, South Africa. | 472 | ||
| 10.1016/j.jfo.2020.04.018 | Journal Article;Practice Guideline | fr | [Pediatric ophthalmology consultations during COVID-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32423579 | 0181-5512 | 2020-05-03 02:00:00+02:00 | pubmed | Amblyopia__diagnosis;Betacoronavirus;Child;Child, Preschool;Coronavirus Infections__epidemiology;Emergencies;Eye Infections__therapy;Humans;Infant;Ophthalmology__methods;Pandemics;Pneumonia, Viral__epidemiology;Strabismus__etiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal Français d'Ophtalmologie | C Speeg-Schatz | 2020-05-01 02:00:00+02:00 | 32423579 | FR | Service ophtalmologie, 1, place de L'Hôpital, 67000 Strasbourg, France. Electronic address: Claude.Speeg@chru-strasbourg.fr. | 473 | ||||
| 10.1016/j.cmi.2020.04.024 | Journal Article | en | COVID-19: don't neglect antimicrobial stewardship principles! | https://www.ncbi.nlm.nih.gov/pubmed/32360446 | 1198-743X | 2020-05-03 02:00:00+02:00 | pubmed | Anti-Bacterial Agents__therapeutic use;Antimicrobial Stewardship__methods;Bacteria__classification;Betacoronavirus;Coronavirus Infections__drug therapy;Critical Care__methods;Humans;Pandemics;Pneumonia, Viral__drug therapy;Primary Prevention__methods;Superinfection__drug therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Microbiology and Infection | B D Huttner;G Catho;J R Pano-Pardo;C Pulcini;J Schouten | 2020-04-30 02:00:00+02:00 | 32360446 | FR;ES;NL;CH | Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Electronic address: benedikt.huttner@hcuge.ch.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Division of Infectious Diseases, Hospital Clínico Universitario, IIS Aragón, Zaragoza, Spain.;Université de Lorraine, APEMAC, équipe MICS, F-54000, Nancy, France, Université de Lorraine, CHRU-Nancy, Infectious Diseases Department, F-54000 Nancy, France.;Radboud Center for Infectious Diseases, Intensive Care Department, Nijmegen, the Netherlands. | 499 | ||||
| Letter;Comment | en | Putting some context to the aerosolization debate around SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32360356 | 2020-05-03 02:00:00+02:00 | pubmed | Aerosols;Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | A Peters;P Parneix;J Otter;D Pittet | 2020-04-30 02:00:00+02:00 | 32360356 | GB;FR;CH | Infection Control Programme, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.;Nouvelle Aquitaine Healthcare-Associated Infection Control Centre, Bordeaux University Hospital, Bordeaux, France.;Imperial College London, London, UK.;Infection Control Programme, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland. Electronic address: didier.pittet@hcuge.ch. | 500 | |||||||
| 10.14336/ad.2020.0506 | Journal Article | en | Whole-lung Low Dose Irradiation for SARS-Cov2 Induced Pneumonia in the Geriatric Population: An Old Effective Treatment for a New Disease? Recommendation of the International Geriatric Radiotherapy Group. | https://www.ncbi.nlm.nih.gov/pubmed/32489696 | A cytokine storm induced by SARS-Cov2 may produce pneumonitis which may be fatal for older patients with underlying lung disease. Hyper-elevation of Interleukin1 (IL-1), Tumor necrosis factor-1alfa (TNF-1 alfa), and Interleukin 6 (IL-6) produced by inflammatory macrophage M1 may damage the lung alveoli leading to severe pneumonitis, decreased oxygenation, and potential death despite artificial ventilation. Older patients may not be suitable candidates for pharmaceutical intervention targeting IL-1/6 blockade or artificial ventilation. Low dose total lung (LDTL) irradiation at a single dose of 50 cGy may stop this cytokine cascade, thus preventing, and/or reversing normal organs damage. This therapy has been proven in the past to be effective against pneumonitis of diverse etiology and could be used to prevent death of older infected patients. Thus, LDRT radiotherapy may be a cost-effective treatment for this frail patient population whom radiation -induced malignancy is not a concern because of their advanced age. This hypothesis should be tested in future prospective trials. | 2152-5250 | 2020-05-10 02:00:00+02:00 | pubmed | Aging and disease | Pedro C Lara;Nam P Nguyen;David Macias-Verde;Javier Burgos-Burgos;Meritxell Arenas;Alice Zamagni;Vincent Vinh-Hung;Brigitta G Baumert;Micaela Motta;Arthur Sun Myint;Marta Bonet;Tiberiu Popescu;Te Vuong;Gokula Kumar Appalanaido;Lurdes Trigo;Ulf Karlsson;Juliette Thariat | LDRT;SARS-Cov 2;elderly;inflammation;treatment | 2020-05-09 02:00:00+02:00 | 32489696 | FR;MQ;MY;CA;PT;CH;US;GB;RO;IT;ES | 1Department of Radiation Oncology, Hospital Universitario San Roque, Fernando Pessoa Canarias Las Palmas University, Las Palmas, Spain.;2Department of Radiation Oncology, Howard University, Washington D.C., USA.;3Department of Radiation Oncology, Sant Joan de Reus University, University Rovira I Virgili, Tarragona, Spain.;4Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.;5Department of Radiation Oncology, University Hospital of Martinique, Martinique, France.;6Institute of Radiation Oncology, Cantonal Hospital Graubuenden, Chur, Switzerland.;7Department of Radiation Oncology, ASST Papa Giovanni XXIII, Bergamo, Italy.;8Department of Radiation Oncology, Clatterbridge Cancer Center, Liverpool, United Kingdom.;9Department of Radiation Oncology, Arnau de Vilanova University Hospital, Lleida, Spain.;10Department of Radiation Oncology, Prof. Dr. Ion Chricuta Oncology Institute, Cluj-Napoca, Romania.;11Department Of Radiation Oncology, McGill University, Montreal, Canada.;12Department of Radiation Oncology, Penang Adventist Hospital, Penang, Malaysia.;13Department of Radiation Oncology, Instituto Portuges de Oncologia Porto Francisco Gentil E.P.E, Porto, Portugal.;14Department of Radiation Oncology, International Geriatric Group, Washington D.C., USA.;15Department of Radiation Oncology, Baclesse Cancer Center, Caen, France. | 504 | |||
| 10.4103/idoj.idoj_231_20 | Journal Article | en | Dermoscopy Practice during COVID-19 Pandemic: Recommendations by SIG Dermoscopy (IADVL Academy). | https://www.ncbi.nlm.nih.gov/pubmed/32695690 | 2020-05-10 02:00:00+02:00 | pubmed | Deepak Jakhar;Yasmeen J Bhat;Manas Chatterjee;Vinay Keshavmurthy;Balachandra S Ankad;Abhijeet K Jha;Puravoor Jayasree;Sushrut Save;Samipa S Mukherjee;Hita Mehta;Satish Udare;Savitha Beergouder | 2020-05-10 02:00:00+02:00 | 32695690 | FR;IN | Department of Dermatology, North Delhi Municipal Corporation Medical College and Hindu Rao Hospital, New Delhi, India.;Department of Dermatology, Venereology and Leprosy, GMC, Jammu and Kashmir, India.;Department of Dermatology, Command Hospital (Eastern Command), Kolkata, West Bengal, India.;Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Department of Dermatology, S Nijaligappa Medical College, Bengaluru, Karnataka, India.;Department of Skin and VD, Patna Medical College, Patna, Bihar, India.;Medical Trust Hospital, Cochin, Kerala, Mumbai, India.;Dr. Save's Clinic, Mumbai, India.;Consultant Pediatric Dermatologist and Dermatologist, Department of Dermatology, Cloudine Hospitals, Bengaluru, Karnataka, India.;Department of Dermatology, Government Medical College, Bhavnagar, Gujrat, India.;Dr Udare Skin Clinic, Navi Mumbai, Maharashtra, India.;Consultant Dermatologist, Anagha Skin Care Clinic, Bagalkot, Karnataka, India. | 505 | |||||||
| Letter;Comment | en | When nuclear medicine radiological protection meets biological COVID-19 protection. | https://www.ncbi.nlm.nih.gov/pubmed/32388613 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Humans;Nuclear Medicine;Pandemics;Pneumonia, Viral;Radiation Protection;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jonathan Vigne;Nicolas Aide;Damien Peyronnet;Catherine Nganoa;Denis Agostini;Pierre Barbey | 2020-05-09 02:00:00+02:00 | 32388613 | FR | Department of Nuclear Medicine, CHU de Caen Normandie, Normandie University, UNICAEN, F-14000, Caen, France. vigne-jo@chu-caen.fr.;Department of Pharmacy, CHU de Caen Normandie, Normandie University, UNICAEN, F-14000, Caen, France. vigne-jo@chu-caen.fr.;Normandie Univ, UNICAEN, Institut National de la Santé et de la Recherche Médicale, PhIND, Institut Blood and Brain @ Caen-Normandie, Centre Cyceron, F-14000, Caen, France. vigne-jo@chu-caen.fr.;Department of Nuclear Medicine, CHU de Caen Normandie, Normandie University, UNICAEN, F-14000, Caen, France.;Normandie University, UNICAEN, INSERM ANTICIPE, F-14000, Caen, France.;Department of Pharmacy, CHU de Caen Normandie, Normandie University, UNICAEN, F-14000, Caen, France.;IMOGERE Laboratory, Normandie University, UNICAEN, F-14000, Caen, France. | 508 | |||||||
| 10.1530/eje-20-0352 | Journal Article | en | ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32380475 | Clinical evaluation should guide those needing immediate investigation. Strict adherence to COVID-19 protection measures is necessary. Alternative ways of consultations (telephone, video) should be used. Early discussion with regional/national experts about investigation and management of potential and existing patients is strongly encouraged. Patients with moderate or severe clinical features need urgent investigation and management. Patients with active Cushing's syndrome, especially when severe, are immunocompromised and vigorous adherence to the principles of social isolation is recommended. In patients with mild features or in whom a diagnosis is less likely, clinical re-evaluation should be repeated at 3 and 6 months or deferred until the prevalence of SARS-CoV-2 has significantly decreased; however, those individuals should be encouraged to maintain social distancing. Diagnostic pathways may need to be very different from usual recommendations in order to reduce possible exposure to SARS-CoV-2. When extensive differential diagnostic testing and/or surgery is not feasible, it should be deferred and medical treatment should be initiated. Transsphenoidal pituitary surgery should be delayed during high SARS-CoV-2 viral prevalence. Medical management rather than surgery will be the used for most patients, since the short- to mid-term prognosis depends in most cases on hypercortisolism rather than its cause; it should be initiated promptly to minimize the risk of infection in these immunosuppressed patients. The risk/benefit ratio of these recommendations will need re-evaluation every 2-3 months from April 2020 in each country (and possibly local areas) and will depend on the local health care structure and phase of pandemic. | 0804-4643,1479-683X | 2020-05-10 02:00:00+02:00 | pubmed | 14-alpha Demethylase Inhibitors__therapeutic use;ACTH-Secreting Pituitary Adenoma__complications;Adenoma__complications;Coronavirus Infections__prevention & control;Cushing Syndrome__diagnosis;Disease Management;Enzyme Inhibitors__therapeutic use;Glucocorticoids__therapeutic use;Humans;Hydrocortisone__blood;Immunocompromised Host;Infection Control__methods;Ketoconazole__therapeutic use;Metyrapone__therapeutic use;Neurosurgical Procedures__methods;Pandemics__prevention & control;Patient Education as Topic;Pneumonia, Viral__prevention & control;Practice Guidelines as Topic;Severity of Illness Index;Telemedicine;Time Factors;COVID-19 | European Journal of Endocrinology | John Newell-Price;Lynnette K Nieman;Martin Reincke;Antoine Tabarin | 2020-05-08 02:00:00+02:00 | 32380475 | FR;GB;US;DE | Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK.;The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, Maryland, USA.;Department of Medicine IV, Klinikum University of Munich, Munich, Germany.;Service d'Endocrinologie - Diabète et Nutrition, CHU de Bordeaux, Bordeaux, France. | 514 | |||
| 10.1136/bmjgh-2020-002655 | Journal Article | en | Governance of the Covid-19 response: a call for more inclusive and transparent decision-making. | https://www.ncbi.nlm.nih.gov/pubmed/32371570 | 2059-7908 | 2020-05-10 02:00:00+02:00 | pubmed | Advisory Committees;Coronavirus Infections__epidemiology;Decision Making;Global Health;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;COVID-19 | BMJ Global Health | Dheepa Rajan;Kira Koch;Katja Rohrer;Csongor Bajnoczki;Anna Socha;Maike Voss;Marjolaine Nicod;Valery Ridde;Justin Koonin | health policy;health systems;public health | 2020-05-07 02:00:00+02:00 | 32371570 | FR;AU;CH;DE | UHC2030 Partnership and Health Systems Governance Collaborative, World Health Organization, Geneva, Switzerland rajand@who.int.;UHC2030 Partnership and Health Systems Governance Collaborative, World Health Organization, Geneva, Switzerland.;UHC2030 Partnership, Geneva, Switzerland.;German Institute for International and Security Affairs (SWP), Berlin, Germany.;CEPED, Institute for Research on Sustainable Development, IRD-Université de Paris, ERL INSERM SAGESUD, Paris, France.;AIDS Council of New South Wales (ACON), Surry Hills, New South Wales, Australia. | 519 | |||
| Editorial;Comment | en | Lessons learned from chest CT in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32362428 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Diagnosis, Differential;Pandemics;Pneumonia, Viral;Tomography, X-Ray Computed;COVID-19;severe acute respiratory syndrome coronavirus 2 | P Soyer | 2020-05-05 02:00:00+02:00 | 32362428 | FR | Department of radiology, hôpital Cochin, AP-HP, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France, Université de Paris, Descartes-Paris 5, 75006 Paris, France. Electronic address: philippe.soyer@aphp.fr. | 520 | |||||||
| Editorial;Comment | en | COVID-19 and ischemic stroke: Should we systematically look for lupus anticoagulant and antiphospholipid antibodies? | https://www.ncbi.nlm.nih.gov/pubmed/32409176 | 2020-05-10 02:00:00+02:00 | pubmed | Antibodies, Antiphospholipid;Betacoronavirus;Brain Ischemia;Coronavirus Infections;Humans;Lupus Coagulation Inhibitor;Pandemics;Pneumonia, Viral;Stroke;COVID-19;severe acute respiratory syndrome coronavirus 2 | M Aubignat;O Godefroy | 2020-05-08 02:00:00+02:00 | 32409176 | FR | Department of neurology, University Hospital of Amiens, 1, rond-point du professeur Christian-Cabrol, 80054 Amiens, France. Electronic address: aubignat.mickael@chu-amiens.fr.;Department of neurology, University Hospital of Amiens, 1, rond-point du professeur Christian-Cabrol, 80054 Amiens, France. | 523 | |||||||
| Letter | en | COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms? | https://www.ncbi.nlm.nih.gov/pubmed/32383827 | 2020-05-10 02:00:00+02:00 | pubmed | Adolescent;Anemia, Sickle Cell__complications;Betacoronavirus;Child;Child, Preschool;Coronavirus Infections__epidemiology;Female;France;Hematology;Hematopoietic Stem Cell Transplantation;Humans;Immunocompromised Host;Intensive Care Units;Leukemia, B-Cell__complications;Male;Medical Oncology;Pandemics;Pediatrics;Pneumonia, Viral__epidemiology;Risk Factors;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nicolas André;Jérémie Rouger-Gaudichon;Benoît Brethon;Aurélie Phulpin;Éric Thébault;Sophie Pertuisel;Virginie Gandemer | 2020-05-08 02:00:00+02:00 | 32383827 | FR | Pediatric Hematology and Oncology Department, Hôpital pour enfant de La Timone, AP-HM, Marseille, France.;Pediatric Oncology and Hematology Department, University Hospital of Caen (CHU de Caen Normandie), Caen, 14000, France.;Department of Pediatric Hematology, Robert Debre Hospital, APHP, Paris, France.;Pediatric Oncology and Hematology Department, University Hospital of Nancy (CHRU Nancy), Nancy, France.;Department of Oncology for Child and Adolescent, Gustave Roussy, Villejuif, France.;Department of Paediatric Hemato-oncology, University Hospital of Rennes, Rennes, France. | 524 | |||||||
| 10.1016/j.canrad.2020.04.005 | Practice Guideline | fr | [Practical guidelines for the radiotherapy for patients presented with haematological malignancies in the epidemic COVID-19 situation: International Lymphoma Radiation Oncology Group recommendations]. | https://www.ncbi.nlm.nih.gov/pubmed/32402596 | 1278-3218 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Hematologic Neoplasms__radiotherapy;Hodgkin Disease__radiotherapy;Humans;Lymphoma__radiotherapy;Organs at Risk__radiation effects;Pandemics;Pneumonia, Viral__epidemiology;Radiation Dose Hypofractionation;Radiation Oncology__standards;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cancer/Radiothérapie | Y Kirova | COVID-19;Haematological malignancies;Hémopathies malignes;Radiotherapy;Radiothérapie | 2020-05-04 02:00:00+02:00 | 32402596 | FR | Département de radiothérapie-oncologie, institut Curie, 25, rue d'Ulm, 75005 Paris, France. Electronic address: youlia.kirova@curie.fr. | 528 | |||
| Letter | en | Covid-19 pandemic containment: following the example of military submariners. | https://www.ncbi.nlm.nih.gov/pubmed/32371541 | 2020-05-10 02:00:00+02:00 | pubmed | Jean-Baptiste Bouillon-Minois;M Trousselard;F Dutheil | depression & mood disorders;occupational & industrial medicine;preventive medicine;primary care;sleep medicine | 2020-05-04 02:00:00+02:00 | 32371541 | FR | CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, Emergency Medicine, Clermont Auvergne University, Clermont-Ferrand, France jbb.bouillon@gmail.com.;French Armed Forces Biomedical Research Institute-IRBA, Neurophysiology of Stress, Neuroscience and Operational Constraint Department, IRBA, Bretigny-sur-Orge, Île-de-France, France.;CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, Occupational and Environmental Medicine, WittyFit, Clermont Auvergne University, Clermont-Ferrand, Auvergne-Rhône-Alpes, France. | 529 | |||||||
| 10.1101/2020.04.30.20086264 | Preprint | en | Lockdown exit strategies and risk of a second epidemic peak: a stochastic agent-based model of SARS-CoV-2 epidemic in France. | https://www.ncbi.nlm.nih.gov/pubmed/32511469 | Most European countries have responded to the COVID-19 threat by nationwide implementation of barrier measures and lockdown. However, assuming that population immunity will build up through the epidemic, it is likely to rebound once these measures are relaxed, possibly leading to a second or multiple repeated lockdowns. In this report, we present results of epidemiological modelling that has helped inform policy making in France. We used a stochastic agent-based microsimulation model of the COVID-19 epidemic in France, and examined the potential impact of post-quarantine measures, including social distancing, mask-wearing, and shielding of the population the most vulnerable to severe COVID-19 infection, on the disease's cumulative incidence and mortality, and on ICU-bed occupancy. The model calibrated well and variation of model parameter values had little impact on outcome estimates. While quarantine is effective in containing the viral spread, it would be unlikely to prevent a rebound of the epidemic once lifted, regardless of its duration. Both social distancing and mask-wearing, although effective in slowing the epidemic and in reducing mortality, would also be ineffective in ultimately preventing the overwhelming of ICUs and a second lockdown. However, these measures coupled with shielding of vulnerable people would be associated with better outcomes, including lower cumulative incidence, mortality, and maintaining an adequate number of ICU beds to prevent a second lockdown. Benefits would nonetheless be markedly reduced if these measures were not applied by most people or not maintained for a sufficiently long period, as herd immunity progressively establishes in the less vulnerable population. | 2020-05-10 02:00:00+02:00 | pubmed | Nicolas Hoertel;Martin Blachier;Carlos Blanco;Mark Olfson;Marc Massetti;Marina Sánchez Rico;Frédéric Limosin;Henri Leleu | ABM;COVID-19;France;ICU-bed occupancy;SARS-CoV-2;incidence;lifting;lockdown;mortality;quarantine | 2020-05-05 02:00:00+02:00 | 32511469 | FR;ES;US | AP-HP.Centre, Paris University, Paris, France.;INSERM U1266, Paris, France.;Division of Biostatistics, Modeling and Health Economics, Public Health Expertise, Paris, France.;National Institute on Drug Abuse, Bethesda, MD, 20892, USA.;Columbia University, 1051 Riverside Drive, Unit 69, New York, NY, 10032, USA.;Universidad Complutense de Madrid, Campus de Somosaguas, Pozuelo de Alarcon, Spain. | 537 | |||||
| National Institute of Allergy and Infectious Diseases;National Institute of Allergy and Infectious Diseases;NIAID NIH HHS;NIGMS NIH HHS;Pew Charitable Trusts;Burroughs Wellcome Fund;NIDA NIH HHS;Howard Hughes Medical Institute | 10.3390/v12050513 | Journal Article;Research Support, N.I.H., Intramural;Research Support, Non-U.S. Gov't | en | Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. | https://www.ncbi.nlm.nih.gov/pubmed/32384820 | SARS-CoV-2 enters cells using its Spike protein, which is also the main target of neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated viral infection are important for studying immunity. Because SARS-CoV-2 is a biosafety-level-3 virus, one way to simplify such assays is to pseudotype biosafety-level-2 viral particles with Spike. Such pseudotyping has now been described for single-cycle lentiviral, retroviral, and vesicular stomatitis virus (VSV) particles, but the reagents and protocols are not widely available. Here, we detailed how to effectively pseudotype lentiviral particles with SARS-CoV-2 Spike and infect 293T cells engineered to express the SARS-CoV-2 receptor, ACE2. We also made all the key experimental reagents available in the BEI Resources repository of ATCC and the NIH. Furthermore, we demonstrated how these pseudotyped lentiviral particles could be used to measure the neutralizing activity of human sera or plasma against SARS-CoV-2 in convenient luciferase-based assays, thereby providing a valuable complement to ELISA-based methods that measure antibody binding rather than neutralization. | 1999-4915 | 2020-05-10 02:00:00+02:00 | pubmed | Antibodies, Neutralizing__immunology;Antibodies, Viral__blood;Containment of Biohazards;HEK293 Cells;Humans;Lentivirus;Neutralization Tests__methods;Peptidyl-Dipeptidase A__metabolism;Plasma__immunology;Spike Glycoprotein, Coronavirus__analysis | Viruses | Katharine H D Crawford;Rachel Eguia;Adam S Dingens;Andrea N Loes;Keara D Malone;Caitlin R Wolf;Helen Y Chu;M Alejandra Tortorici;David Veesler;Michael Murphy;Deleah Pettie;Neil P King;Alejandro B Balazs;Jesse D Bloom | 293T-ACE2;ACE2;ALAYT;COVID-19;SARS-CoV-2;Spike;coronavirus;cytoplasmic tail;lentiviral pseudotype;luciferase;neutralization assay | 2020-05-06 02:00:00+02:00 | 32384820 | FR;GB;US | [{"country": "International", "agency": "National Institute of Allergy and Infectious Diseases", "grantid": "R01AI141707"}, {"country": "International", "agency": "National Institute of Allergy and Infectious Diseases", "grantid": "F30AI149928"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "HHSN272201700059C"}, {"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "R01GM120553"}, {"country": "International", "agency": "Pew Charitable Trusts", "grantid": "Pew Biomedical Scholars Award"}, {"country": "International", "agency": "Burroughs Wellcome Fund", "grantid": "Investigators in the Pathogenesis of Infectious Disease Award"}, {"country": "United States", "agency": "NIDA NIH HHS", "grantid": "DP2DA040254"}, {"country": "United States", "agency": "Howard Hughes Medical Institute", "grantid": "Investigator Research Budget"}] | Division of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.;Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.;Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA.;Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.;Department of Biochemistry, University of Washington, Seattle, WA 98109, USA.;Institute Pasteur & CNRS UMR 3569, Unité de Virologie Structurale, 75015 Paris, France.;Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.;The Ragon Institute of Massachusetts General Hospital, the Massachusetts Institute Technology, and Harvard University, Cambridge, MA 02139, USA.;Howard Hughes Medical Institute, Seattle, WA 98103, USA. | 539 |
| 10.1016/j.ajoc.2020.100735 | Case Reports | en | Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32377594 | To describe the multiplicity of ocular manifestations of COVID-19 patients, we report a case of pseudomembranous and hemorrhagic conjunctivitis related with SARS-CoV-2 pneumonia in a patient of intensive care unit (ICU). | 2451-9936 | 2020-05-10 02:00:00+02:00 | pubmed | American Journal of Ophthalmology Case Reports | Valentin Navel;Frédéric Chiambaretta;Frédéric Dutheil | COVID-19;Conjunctivitis;External ocular infections;Intensive care unit;Pandemic;SARS-CoV-2 | 2020-05-06 02:00:00+02:00 | 32377594 | FR | Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, F-63000, Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, F-63000, Clermont-Ferrand, France. | 540 | |||
| Letter;Review | en | COVID-19 in pediatric patients: What the prehospital teams need to know. | https://www.ncbi.nlm.nih.gov/pubmed/32402434 | 2020-05-10 02:00:00+02:00 | pubmed | Adolescent;Betacoronavirus__isolation & purification;Child;Child, Preschool;Clinical Laboratory Techniques;Coronavirus Infections__complications;Emergency Medical Services__methods;Humans;Infant;Infant, Newborn;Pandemics;Pneumonia, Viral__complications;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Sabine Lemoine;Jean-Louis Chabernaud;Stephane Travers;Bertrand Prunet | 2020-05-06 02:00:00+02:00 | 32402434 | FR | Paris Fire Brigade Medical Emergency Department, 1, place Jules-Renard, 75017 Paris, France. Electronic address: sabine.lemoine@pompiersparis.fr.;Délégation aux relations internationales, université Paris-Saclay, hôpital Antoine-Béclère, groupe hospitalo-universitaire (GHU), AP-HP, 157, rue Porte-de-Trivaux, 92140 Clamart, France.;Paris Fire Brigade Medical Emergency Department, 1, place Jules-Renard, 75017 Paris, France. | 541 | |||||||
| Letter | en | We must not forget the most disadvantaged people facing the COVID-19 crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32480325 | 2020-05-10 02:00:00+02:00 | pubmed | J M Mansuy;J Izopet | 2020-05-06 02:00:00+02:00 | 32480325 | FR | Virology Department, Toulouse University Hospital, France. Electronic address: mansuy.jm@chu-toulouse.fr.;Virology Department, Toulouse University Hospital, France, INSERM UMR1043 Center for Pathophysiology of Toulouse Purpan, France, Toulouse III University Paul Sabatier, Toulouse, France. | 543 | ||||||||
| 10.1016/j.canrad.2020.04.004 | Practice Guideline | fr | [Breast radiation therapy during COVID-19 outbreak: Practical advice]. | https://www.ncbi.nlm.nih.gov/pubmed/32389580 | 1278-3218 | 2020-05-10 02:00:00+02:00 | pubmed | Adult;Age Factors;Aged;Aged, 80 and over;Betacoronavirus;Breast Neoplasms__radiotherapy;Carcinoma, Ductal, Breast__radiotherapy;Coronavirus Infections__epidemiology;Dose Fractionation, Radiation;Female;Humans;Middle Aged;Pandemics;Patient Positioning;Pneumonia, Viral__epidemiology;Radiation Oncology__organization & administration;Respiration;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cancer/Radiothérapie | P Loap;Y Kirova;S Takanen;G Créhange;A Fourquet | 2020-05-04 02:00:00+02:00 | 32389580 | FR | Département de radiothérapie-oncologie, institut Curie, 25, rue d'Ulm, 75005 Paris, France. Electronic address: pierre.loap@gmail.com.;Département de radiothérapie-oncologie, institut Curie, 25, rue d'Ulm, 75005 Paris, France. | 550 | ||||
| 10.15698/mic2020.05.715 | Journal Article | en | Digesting the crisis: autophagy and coronaviruses. | https://www.ncbi.nlm.nih.gov/pubmed/32391393 | Autophagy is a catabolic pathway with multifaceted roles in cellular homeostasis. This process is also involved in the antiviral response at multiple levels, including the direct elimination of intruding viruses (virophagy), the presentation of viral antigens, the fitness of immune cells, and the inhibition of excessive inflammatory reactions. In line with its central role in immunity, viruses have evolved mechanisms to interfere with or to evade the autophagic process, and in some cases, even to harness autophagy or constituents of the autophagic machinery for their replication. Given the devastating consequences of the current COVID-19 pandemic, the question arises whether manipulating autophagy might be an expedient approach to fight the novel coronavirus SARS-CoV-2. In this piece, we provide a short overview of the evidence linking autophagy to coronaviruses and discuss whether such links may provide actionable targets for therapeutic interventions. | 2311-2638 | 2020-05-10 02:00:00+02:00 | pubmed | Microbial Cell | Didac Carmona-Gutierrez;Maria A Bauer;Andreas Zimmermann;Katharina Kainz;Sebastian J Hofer;Guido Kroemer;Frank Madeo | COVID-19;MERS;SARS;SARS-CoV-2;coronavirus;immunity;inflammation;virophagy | 2020-05-04 02:00:00+02:00 | 32391393 | FR;CN;SE;AT | Institute for Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria.;BioHealth Graz, Graz, Austria.;Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.;Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.;Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.;Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.;Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.;BioTechMed Graz, Graz, Austria. | 558 | |||
| 10.1007/s00134-020-06058-7 | Case Reports;Journal Article | en | "No dose" lung ultrasound correlation with "low dose" CT scan for early diagnosis of SARS-CoV-2 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32367166 | 0342-4642,1432-1238 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Disease Progression;Early Diagnosis;Humans;Intensive Care Units;Lung__diagnostic imaging;Male;Middle Aged;Pandemics;Pneumonia, Viral__diagnostic imaging;Tomography, X-Ray Computed;Ultrasonography;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Gary Duclos;Alexandre Lopez;Marc Leone;Laurent Zieleskiewicz | 2020-05-04 02:00:00+02:00 | 32367166 | FR | Service d'Anesthésie et de Réanimation, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Aix Marseille Université, Chemin des Bourrely, 13015, Marseille, France. gary.duclos@ap-hm.fr.;Service d'Anesthésie et de Réanimation, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Aix Marseille Université, Chemin des Bourrely, 13015, Marseille, France.;C2VN, Service d'Anesthésie et de Réanimation, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Aix Marseille Université, Marseille, France. | 560 | ||||
| Letter;Comment | en | COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept. | https://www.ncbi.nlm.nih.gov/pubmed/32418867 | 2020-05-10 02:00:00+02:00 | pubmed | Anticoagulants;Betacoronavirus;Coronavirus Infections;Humans;Inflammation;Pandemics;Pneumonia, Viral;Thrombosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jean-Christophe Gris;Antonia Perez-Martin;Isabelle Quéré;Albert Sotto | 2020-05-04 02:00:00+02:00 | 32418867 | FR;RU | Department of haematology, university Montpellier, CHU Nîmes, Nîmes, France, UPRES EA 2992, Montpellier university, Nîmes, France, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation. Electronic address: jean.christophe.gris@chu-nimes.fr.;Department of vascular medicine, university Montpellier, CHU Nîmes, Nîmes, France.;Department of vascular medicine, university Montpellier, CHU Montpellier, Montpellier, France.;Department of infectious and tropical diseases, university Montpellier, CHU Nîmes, Nîmes, France. | 562 | |||||||
| 10.15252/emmm.202012463 | Editorial | en | COVID-19, chronicle of an expected pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32259394 | What is COVID-19? What are the causes, parameters, and effects of this disease? What are the short- and long-term prospects? Philippe Sansonetti, Infectious disease specialist and Chief Editor of EMBO Molecular Medicine, explains why the fate of the epidemic is in our hands. | 1757-4676,1757-4684 | 2020-05-10 02:00:00+02:00 | pubmed | Animals;Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Zoonoses;COVID-19;severe acute respiratory syndrome coronavirus 2 | EMBO Molecular Medicine | Philippe J Sansonetti | 2020-05-04 02:00:00+02:00 | 32259394 | FR | Chaire de Microbiologie et Maladies Infectieuses, Collège de France, Paris, France.;Institut Pasteur, Paris Cedex 15, France. | 564 | |||
| 10.1016/j.jviscsurg.2020.04.019 | Editorial;Introductory Journal Article | en | A special edition of the Journal of Visceral Surgery on COVID-19: What problems, dangers and solutions have been identified? | https://www.ncbi.nlm.nih.gov/pubmed/32402794 | 1878-7886 | 2020-05-10 02:00:00+02:00 | pubmed | Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19 | Journal of Visceral Surgery | M Pocard | 2020-05-04 02:00:00+02:00 | 32402794 | FR | UMR 1275 CAP Paris-Tech, université de Paris, 75010 Paris, France, Service de chirurgie digestive et cancérologique, hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France. Electronic address: marc.pocard@aphp.fr. | 567 | ||||
| 10.1007/s00134-020-06062-x | Journal Article;Multicenter Study | en | High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. | https://www.ncbi.nlm.nih.gov/pubmed/32367170 | Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection. | 0342-4642,1432-1238 | 2020-05-10 02:00:00+02:00 | pubmed | Aged;Anticoagulants__therapeutic use;Betacoronavirus__pathogenicity;Coronavirus Infections__mortality;Critical Illness;Female;Fibrin Fibrinogen Degradation Products__analysis;France__epidemiology;Humans;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral__mortality;Propensity Score;Prospective Studies;Pulmonary Embolism__complications;Severe Acute Respiratory Syndrome__complications;Thrombosis__etiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Intensive Care Medicine | Julie Helms;Charles Tacquard;François Severac;Ian Leonard-Lorant;Mickaël Ohana;Xavier Delabranche;Hamid Merdji;Raphaël Clere-Jehl;Malika Schenck;Florence Fagot Gandet;Samira Fafi-Kremer;Vincent Castelain;Francis Schneider;Lélia Grunebaum;Eduardo Anglés-Cano;Laurent Sattler;Paul-Michel Mertes;Ferhat Meziani | ARDS;COVID-19;Coagulopathy;Lupus anticoagulant;Thrombosis | 2020-05-04 02:00:00+02:00 | 32367170 | FR;US | Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, 1, Place de l'Hôpital, 67091, Strasbourg Cedex, France.;ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France.;Service d'Anesthésie-Réanimation, Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, Strasbourg, France.;Groupe Méthodes en Recherche Clinique (GMRC), Hôpital Civil, Hôpitaux universitaires de Strasbourg, Strasbourg, France.;Radiology Department, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.;UMR 1260, Regenerative Nanomedicine (RNM), FMTS, INSERM (French National Institute of Health and Medical Research), Strasbourg, France.;Service de Médecine Intensive Réanimation, Hautepierre, Hôpitaux universitaires de Strasbourg, Strasbourg, France.;Laboratoire de Virologie Médicale, Hôpitaux universitaires de Strasbourg, Strasbourg, France.;Laboratoire de d'Hématologie, Hautepierre, Hôpitaux universitaires de Strasbourg, Strasbourg, France.;Innovative Therapies in Haemostasis, INSERM UMR_S 1140, Université de Paris, 75006, Paris, France.;Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, 1, Place de l'Hôpital, 67091, Strasbourg Cedex, France. Ferhat.Meziani@chru-strasbourg.fr.;UMR 1260, Regenerative Nanomedicine (RNM), FMTS, INSERM (French National Institute of Health and Medical Research), Strasbourg, France. Ferhat.Meziani@chru-strasbourg.fr. | 569 | ||
| 10.3389/fmed.2020.00225 | Journal Article | en | Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. | https://www.ncbi.nlm.nih.gov/pubmed/32574326 | Introduction: COVID-19 Ag Respi-Strip, an immunochromatographic (ICT) assay for the rapid detection of SARS-CoV-2 antigen on nasopharyngeal specimen, has been developed to identify positive COVID-19 patients allowing prompt clinical and quarantine decisions. In this original research article, we describe the conception, the analytical and clinical performances as well as the risk management of implementing the COVID-19 Ag Respi-Strip in a diagnostic decision algorithm. Materials and Methods: Development of the COVID-19 Ag Respi-Strip resulted in a ready-to-use ICT assay based on a membrane technology with colloidal gold nanoparticles using monoclonal antibodies directed against the SARS-CoV and SARS-CoV-2 highly conserved nucleoprotein antigen. Four hundred observations were recorded for the analytical performance study and thirty tests were analyzed for the cross-reactivity study. The clinical performance study was performed in a retrospective multi-centric evaluation on aliquots of 328 nasopharyngeal samples. COVID-19 Ag Respi-Strip results were compared with qRT-PCR as golden standard for COVID-19 diagnostics. Results: In the analytical performance study, the reproducibility showed a between-observer disagreement of 1.7%, a robustness of 98%, an overall satisfying user friendliness and no cross-reactivity with other virus-infected nasopharyngeal samples. In the clinical performance study performed in three different clinical laboratories during the ascendant phase of the epidemiological curve, we found an overall sensitivity and specificity of 57.6 and 99.5%, respectively with an accuracy of 82.6%. The cut-off of the ICT was found at CT <22. User-friendliness analysis and risk management assessment through Ishikawa diagram demonstrate that COVID-19 Ag Respi-Strip may be implemented in clinical laboratories according to biosafety recommendations. Conclusion: The COVID-19 Ag Respi-Strip represents a promising rapid SARS-CoV-2 antigen assay for the first-line diagnosis of COVID-19 in 15 min at the peak of the pandemic. Its role in the proposed diagnostic algorithm is complementary to the currently-used molecular techniques. | 2296-858X | 2020-05-10 02:00:00+02:00 | pubmed | Frontiers in Medicine | Pascal Mertens;Nathalie De Vos;Delphine Martiny;Christian Jassoy;Ali Mirazimi;Lize Cuypers;Sigi Van den Wijngaert;Vanessa Monteil;Pierrette Melin;Karolien Stoffels;Nicolas Yin;Davide Mileto;Sabrina Delaunoy;Henri Magein;Katrien Lagrou;Justine Bouzet;Gabriela Serrano;Magali Wautier;Thierry Leclipteux;Marc Van Ranst;Olivier Vandenberg | COVID-19;SARS-CoV-2;antigen;diagnostic;immunochromatographic test | 2020-05-08 02:00:00+02:00 | 32574326 | FR;SE;GB;IT;BE;DE | Coris BioConcept, Gembloux, Belgium.;Department of Clinical Chemistry, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium.;Department of Microbiology, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium.;Medical Faculty and University Clinics, Institute for Virology, University of Leipzig, Leipzig, Germany.;Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.;Clinical Department of Laboratory Medicine and National Reference Center for Respiratory Pathogens, UZ Leuven, Leuven, Belgium.;Department of Clinical Microbiology, Centre Hospitalier Universitaire Sart-Tilman, Université de Liège, Liège, Belgium.;Laboratory of Clinical Microbiology, Virology and Bioemergency, ASST Fatebene fratelli Sacco, Luigi Sacco Hospital, Milan, Italy.;Innovation and Business Development Unit, LHUB-ULB, Université Libre de Bruxelles, Brussels, Belgium.;Division of Infection and Immunity, Faculty of Medical Sciences, University College London, London, United Kingdom. | 587 | |||
| 10.1016/j.encep.2020.05.002 | Journal Article | fr | [Mental health care in French correctional facilities during the Covid-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32475693 | The impact of the Covid-19 pandemic on the 11 million people currently incarcerated worldwide is the subject of many concerns. Prisons and jails are filled with people suffering from many preexisting medical conditions increasing the risk of complications. Detainees' access to medical services is already limited and overcrowding poses a threat of massive contagion. Beyond the health impact of the crisis, the tightening of prison conditions worries. On March 16, 2020, in France, the lockdown measures have been accompanied by specific provisions for prisons: all facilities have suspended visitations, group activities and external interventions. Over 10,000 prisoners have been released to reduce the prison population and the risk of virus propagation. These adjustments had major consequences on the healthcare system in French prisons. The objectives of this article are to describe the reorganization of the three levels of psychiatric care for inmates in France in the context of Covid-19 pandemic and to have a look at the impact of lockdown measures and early releases on mental health of prisoners. | 0013-7006 | 2020-05-10 02:00:00+02:00 | pubmed | Adult;Ambulatory Care__organization & administration;Betacoronavirus;Coronavirus Infections__prevention & control;Delivery of Health Care;Female;France__epidemiology;Health Care Surveys;Health Services Accessibility;Hospital Units__organization & administration;Humans;Infection Control__methods;Male;Mental Disorders__epidemiology;Mental Health Services__organization & administration;Pandemics__prevention & control;Patient Isolation;Pneumonia, Viral__prevention & control;Prisoners__psychology;Prisons;Psychiatric Department, Hospital__organization & administration;Quarantine;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | T Fovet;C Lancelevée;M Eck;T Scouflaire;E Bécache;D Dandelot;P Giravalli;A Guillard;P Horrach;M Lacambre;T Lefebvre;A-H Moncany;D Touitou;M David;P Thomas | Confinement;Coronavirus;Covid-19;Epidemic;Lockdown;Milieu pénitentiaire;Pandemic;Pandémie;Prison;Psychiatrie;Psychiatry;SARS-CoV-2;SARS-Cov-2;Épidémie | 2020-05-08 02:00:00+02:00 | 32475693 | FR | CHU de Lille, Pôle de psychiatrie, 59000 Lille, France, Université Lille, Inserm, U1172 - Lille Neuroscience & Cognition - Équipe Plasticity & Subjectivity, 59000 Lille, France. Electronic address: thomas.fovet@chru-lille.fr.;Fédération de recherches en psychiatrie et santé mentale des Hauts-de-France (F2RSM Psy), Saint-André-Lez-Lille, France.;CHU de Lille, Pôle de psychiatrie, 59000 Lille, France.;UHSA Simone-Veil, Pôle de Santé Mentale des Détenus et de Psychiatrie Légale, centre hospitalier le Vinatier, Bron, France.;UHSA, pôle psychiatrie médicolégale, centre hospitalier Cadillac, Cadillac, France.;Pôle 11 : psychiatrie médecine addictologie en détention, médecine légale, UMR ADES AMU, AP-HM, Marseille, France.;Pôle de psychiatrie en milieu pénitentiaire, EPSM Georges-Daumezon, Loiret, France.;Département santé mentale-justice, pôle SMPR, CPN Nancy Laxou, centre hospitalier Lorquin, Lorquin, France.;CHU de Montpellier, Montpellier, France.;UHSA de Rennes, pôle de psychiatrie en milieu pénitentiaire, Centre hospitalier Guillaume Regnier, Rennes, France.;Pôle de psychiatrie et conduites addictives en milieu pénitentiaire, centre hospitalier Marchant, Toulouse, France.;UHSA Paul-Verlaine, groupe hospitalier Paul-Guiraud, 94800 Villejuif, France.;Association des secteurs de psychiatrie en milieu pénitentiaire et de la fédération française de psychiatrie et co-référent de l'atelier « psychiatrie en milieu pénitentiaire » du Comité de pilotage de la psychiatrie, France.;CHU de Lille, Pôle de psychiatrie, 59000 Lille, France, Université Lille, Inserm, U1172 - Lille Neuroscience & Cognition - Équipe Plasticity & Subjectivity, 59000 Lille, France. | 590 | ||
| 10.2196/19007 | Journal Article | en | Impact of Home Quarantine on Physical Activity Among Older Adults Living at Home During the COVID-19 Pandemic: Qualitative Interview Study. | https://www.ncbi.nlm.nih.gov/pubmed/32356777 | Older adults and those with pre-existing medical conditions are at risk of death from severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). In this period of quarantine, one of the reasons for going out is physical activity. This issue is important, as the impact of a sedentary lifestyle might be lower for children and young adults, but is far more severe for older adults. Although older adults need to stay at home because they have a higher risk of coronavirus disease (COVID-19), they need to avoid a sedentary lifestyle. Physical activity is important for older adults, especially to maintain their level of independence, mental health, and well-being. Maintaining mobility in old age is necessary, as it may predict loss of independence in older adults. | 2561-7605 | 2020-05-10 02:00:00+02:00 | pubmed | JMIR Aging | Luc Goethals;Nathalie Barth;Jessica Guyot;David Hupin;Thomas Celarier;Bienvenu Bongue | COVID-19;older adults;physical activity;social marketing | 2020-05-07 02:00:00+02:00 | 32356777 | FR | Autonomic Nervous System Research Laboratory, University of Jean Monnet, Saint-Etienne, France.;Chaire Santé des Ainés, University of Jean Monnet, Saint-Etienne, France.;Gerontopole Auvergne-Rhône-Alpes, Saint-Etienne, France.;Clinical physiology and Exercise Department, University Hospital of Saint-Etienne, Saint-Etienne, France.;Department of Clinical Gerontology, University Hospital of Saint-Etienne, Saint-Etienne, France.;Support and Education Technic Centre of Health Examination Centres (CETAF), Saint-Etienne, France. | 596 | |||
| Deutsche Forschungsgemeinschaft (German Research Foundation);Deutsche Forschungsgemeinschaft (German Research Foundation) | 10.1038/s41380-020-0758-9 | Editorial;Research Support, Non-U.S. Gov't | en | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. | https://www.ncbi.nlm.nih.gov/pubmed/32382135 | 1359-4184,1476-5578 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__immunology;Humans;Neurosecretory Systems;Pandemics;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__immunology;Stem Cells;Stress, Psychological;COVID-19;severe acute respiratory syndrome coronavirus 2 | Molecular Psychiatry | Charlotte Steenblock;Vladimir Todorov;Waldemar Kanczkowski;Graeme Eisenhofer;Andreas Schedl;Ma-Li Wong;Julio Licinio;Michael Bauer;Allan H Young;Raul R Gainetdinov;Stefan R Bornstein | 2020-05-07 02:00:00+02:00 | 32382135 | FR;RU;GB;US;DE | [{"country": "International", "agency": "Deutsche Forschungsgemeinschaft (German Research Foundation)", "grantid": "314061271, TRR 205/1"}, {"country": "International", "agency": "Deutsche Forschungsgemeinschaft (German Research Foundation)", "grantid": "288034826, IRTG 2251"}] | Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. charlotte.steenblock@uniklinikum-dresden.de.;Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.;Institute of Clinical Chemistry, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.;Université Côte d'Azur, INSERM, CNRS, iBV, Nice, France.;State University of New York, Upstate Medical University, Syracuse, NY, USA.;Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany.;Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.;Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia.;St. Petersburg State University Hospital, St. Petersburg State University, St. Petersburg, Russia.;Diabetes and Nutritional Sciences Division, King's College London, London, UK. | 612 | ||
| Horizon 2020 | Letter | en | ICU capacity management during the COVID-19 pandemic using a process simulation. | https://www.ncbi.nlm.nih.gov/pubmed/32383060 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus;Computer Simulation;Coronavirus Infections__epidemiology;Hospital Bed Capacity;Humans;Intensive Care Units__organization & administration;Models, Statistical;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Andres Alban;Stephen E Chick;Dave A Dongelmans;Alexander P J Vlaar;Danielle Sent | 2020-05-07 02:00:00+02:00 | 32383060 | FR;NL | [{"country": "", "agency": "Horizon 2020", "grantid": "Marie Skłodowska-Curie grant No 676129"}] | Technology and Operations Management Area, INSEAD, Fontainebleau, France.;Technology and Operations Management Area, INSEAD, Fontainebleau, France. stephen.chick@insead.edu.;Healthcare Management Initiative, INSEAD, Fontainebleau, France. stephen.chick@insead.edu.;Department of Intensive Care Medicine, Amsterdam UMC (Location AMC), University of Amsterdam, Amsterdam, The Netherlands.;Department of Medical Informatics, Amsterdam Public Health Research Institute, Amsterdam UMC (Location AMC), University of Amsterdam, Amsterdam, The Netherlands. | 613 | |||||
| NIAID NIH HHS | 10.1007/s12630-020-01684-7 | Clinical Trial Protocol;Journal Article;Multicenter Study;Randomized Controlled Trial | en | Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. | https://www.ncbi.nlm.nih.gov/pubmed/32383125 | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 causing the coronavirus disease (COVID-19) pandemic. Currently, there is a lack of evidence-based therapies to prevent COVID-19 following exposure to the virus, or to prevent worsening of symptoms following confirmed infection. We describe the design of a clinical trial of hydroxychloroquine for post-exposure prophylaxis (PEP) and pre-emptive therapy (PET) for COVID-19. | 0832-610X,1496-8975 | 2020-05-10 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__prevention & control;Double-Blind Method;Humans;Hydroxychloroquine__administration & dosage;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Post-Exposure Prophylaxis__methods;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Sylvain A Lother;Mahsa Abassi;Alyssa Agostinis;Ananta S Bangdiwala;Matthew P Cheng;Glen Drobot;Nicole Engen;Kathy H Hullsiek;Lauren E Kelly;Todd C Lee;Sarah M Lofgren;Lauren J MacKenzie;Nicole Marten;Emily G McDonald;Elizabeth C Okafor;Katelyn A Pastick;Matthew F Pullen;Radha Rajasingham;Ilan Schwartz;Caleb P Skipper;Alexis F Turgeon;Ryan Zarychanski;David R Boulware | COVID-19;Hydroxychloroquine;SARS-CoV-2;clinical trials;coronavirus;healthcare worker;post-exposure prophylaxis;pre-emptive therapy | 2020-05-07 02:00:00+02:00 | 32383125 | FR;IE;CA;US | [{"country": "United States", "agency": "NIAID NIH HHS", "grantid": "K23 AI138851"}] | Department of Internal Medicine, Section of Critical Care, University of Manitoba, Winnipeg, MB, Canada. slother@manitoba-physicians.ca.;Section of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. slother@manitoba-physicians.ca.;Department of Medicine, University of Minnesota, Minneapolis, MN, USA.;Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.;School of Medicine, Trinity College Dublin, Dublin, Ireland.;Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.;Divisions of Infectious Diseases & Medical Microbiology, McGill University Health Centre, Montreal, QC, Canada.;McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, QC, Canada.;Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.;Department of Pediatrics and Child Health, Department of Pharmacology, University of Manitoba, Winnipeg, MB, Canada.;Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, QC, Canada.;Section of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.;Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada.;Critical Care Research, St-Boniface Hospital, Winnipeg, MB, Canada.;CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit Trauma - Emergency - Critical Care Medicine, Université Laval, Quebec, QC, Canada.;Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Université Laval, Quebec, QC, Canada.;Department of Internal Medicine, Section of Critical Care, University of Manitoba, Winnipeg, MB, Canada.;Department of Internal Medicine, Section of Hematology and Oncology, University of Manitoba, Winnipeg, MB, Canada.;Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada. | 618 |
| 10.1016/j.resmer.2020.100760 | Editorial | en | Bronchoscopy use in the COVID-19 era. | https://www.ncbi.nlm.nih.gov/pubmed/32474396 | 2590-0412 | 2020-05-10 02:00:00+02:00 | pubmed | Respiratory Medicine and Research | J-M Vergnon;V Trosini-Desert;C Fournier;S Lachkar;H Dutau;N Guibert;B Escarguel;M Froudarakis | 2020-05-07 02:00:00+02:00 | 32474396 | FR | Department of chest diseases and thoracic oncology, North Hospital, university hospital of Saint-Étienne, Saint-Étienne, France.;Service de pneumologie, médecine Intensive et réanimation, département R3S, groupe hospitalier universitaire AP-HP-Sorbonne-Université site Pitié-Salpêtrière, AP-HP, Paris, France.;Pôle Cœur Poumon, clinique de pneumologie, CHU de Lille, 59000 Lille, France.;Thoracic Oncology and Respiratory Intensive Care & CIC-CRB 1404, Department of Pulmonology, Rouen University Hospital, 76000 Rouen, France.;Thoracic Endoscopy Unit, North University Hospital, AP-HM, Marseille, France.;Thoracic Endoscopy Unit, Larrey University Hospital, Toulouse, France.;Interventional Pulmonology Unit, Hôpital Saint-Joseph, Marseille, France. | 619 | |||||
| Letter;Comment | en | Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32358817 | 2020-05-17 02:00:00+02:00 | pubmed | Acute Chest Syndrome;Antibodies, Monoclonal, Humanized;Betacoronavirus;Child;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Marie-Hélène Odièvre;Charles de Marcellus;Hubert Ducou Le Pointe;Slimane Allali;Anne-Sophie Romain;Jenny Youn;Jessica Taytard;Nadia Nathan;Harriet Corvol | 2020-05-16 02:00:00+02:00 | 32358817 | FR | Department of General Pediatrics, Center for Sickle Cell Disease, Trousseau Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.;Pediatric Intensive Care Unit, Necker-Enfants-Malades Hospital, AP-HP, Université de Paris, Paris, France.;Imaging Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France.;Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker-Enfants-Malades Hospital, AP-HP, Université de Paris, Paris, France.;Pediatric Pulmonology Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France. | 623 | |||||||
| Letter | en | [Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence]. | https://www.ncbi.nlm.nih.gov/pubmed/32425245 | 2020-05-17 02:00:00+02:00 | pubmed | Antiviral Agents__adverse effects;Betacoronavirus;Coronavirus Infections__drug therapy;Evidence-Based Medicine;Humans;Hydroxychloroquine__adverse effects;Pandemics;Patient Safety;Pneumonia, Viral__drug therapy;Practice Guidelines as Topic;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Ernesto Cairoli;Gerard Espinosa | 2020-05-16 02:00:00+02:00 | 32425245 | FR;UY;ES | Unidad de Enfermedades Autoinmunes Sistémicas, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Laboratorio de Inmunorregulación e Inflamación, Institut Pasteur de Montevideo, Montevideo, Uruguay. Electronic address: ecairoli@hc.edu.uy.;Servicio de Enfermedades Autoinmunes, Institut d'Investigacions August Pi i Sunyer, Universitat de Barcelona, Hospital Clinic, Barcelona, España. | 625 | |||||||
| 10.1007/s00467-020-04584-6 | Journal Article;Research Support, Non-U.S. Gov't | en | Rapid response in the COVID-19 pandemic: a Delphi study from the European Pediatric Dialysis Working Group. | https://www.ncbi.nlm.nih.gov/pubmed/32418146 | COVID-19 was declared a global health emergency. Since children are less than 1% of reported cases, there is limited information to develop evidence-based practice recommendations. The objective of this study was to rapidly gather expert knowledge and experience to guide the care of children with chronic kidney disease during the COVID-19 pandemic. | 0931-041X,1432-198X | 2020-05-17 02:00:00+02:00 | pubmed | Adolescent;Child;Child, Preschool;Coronavirus Infections__complications;Delphi Technique;Europe;Evidence-Based Medicine;Humans;Infant;Infection Control;Pandemics__prevention & control;Pneumonia, Viral__complications;Renal Dialysis;Renal Insufficiency, Chronic__complications;COVID-19 | Pediatric Nephrology | Fabian Eibensteiner;Valentin Ritschl;Gema Ariceta;Augustina Jankauskiene;Günter Klaus;Fabio Paglialonga;Alberto Edefonti;Bruno Ranchin;Claus Peter Schmitt;Rukshana Shroff;Constantinos J Stefanidis;Johan Vande Walle;Enrico Verrina;Karel Vondrak;Aleksandra Zurowska;Tanja Stamm;Christoph Aufricht | COVID-19;Delphi;Dialysis;Pandemic;Transplantation | 2020-05-17 02:00:00+02:00 | 32418146 | LT;FR;GR;GB;AT;US;IT;PL;CZ;ES;BE;PS;DE | Division of Pediatric Nephrology and Gastroenterology, Comprehensive Center for Pediatrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.;Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.;Department of Pediatric Nephrology, University Hospital Vall d' Hebron, Barcelona, Spain.;Pediatric Center, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.;Department of Pediatric Nephrology, KfH Children's Kidney Center, Marburg, Germany.;Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.;Department of Pediatric Nephrology, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France.;Pediatric Nephrology, Center for Child and Adolescent Medicine, Heidelberg, Germany.;Renal Unit, UCL Great Ormond Street Hospital for Children NHS Foundation Trust, and Institute of Child Health, London, UK.;Department of Pediatric Nephrology, Mitera Children's Hospital, Athens, Greece.;Department of Pediatric Nephrology, Utoped, Universitair Ziekenhuis Gent, Ghent, Belgium.;Dialysis Unit, Department of Pediatrics, IRCCS Giannina Gaslini, Genoa, Italy.;Department of Pediatric Nephrology, University Hospital Motol, Prague, Czech Republic.;Department of Pediatric Nephrology, Medical University of Gdansk, Gdansk, Poland.;Division of Pediatric Nephrology and Gastroenterology, Comprehensive Center for Pediatrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. christoph.aufricht@meduniwien.ac.at. | 630 | ||
| Agence Nationale de Sécurité du Médicament et des Produits de Santé | 10.1111/fcp.12564 | Journal Article | en | Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32394481 | On March 16, 2020, the French Society of Pharmacology and Therapeutics put online a national Question and Answer (Q&A) website, https://sfpt-fr.org/covid19 on the proper use of drugs during the COVID-19 pandemic. The working group 'Drugs and COVID-19' was composed of a scientific council, an editorial team, and experts in the field. The first questions were posted online during the first evening of home-confinement in France, March 17, 2020. Six weeks later, 140 Q&As have been posted. Questions on the controversial use of hydroxychloroquine and to a lesser extent concerning azithromycin have been the most consulted Q&As. Q&As have been consulted 226 014 times in 41 days. This large visibility was obtained through an early communication on Twitter, Facebook, traditional print, and web media. In addition, an early communication through the French Ministry of Health and the French National Agency for Medicines and Health Products Safety ANSM had a large impact in terms of daily number of views. There is a pressing need to sustain a public drug information service combining the expertise of scholarly pharmacology societies, pharmacovigilance network, and the Ministry of Health to quickly provide understandable, clear, expert answers to the general population's concerns regarding COVID-19 and drug use and to counter fake news. | 0767-3981,1472-8206 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus__drug effects;Consumer Health Information__methods;Coronavirus Infections__drug therapy;Drug Information Services__organization & administration;France;Humans;Pandemics;Pneumonia, Viral__drug therapy;Public Health__methods;Social Networking;Societies, Pharmaceutical;COVID-19;severe acute respiratory syndrome coronavirus 2 | Fundamental & Clinical Pharmacology | Louis Larrouquere;Manon Gabin;Emmanuelle Poingt;Amelle Mouffak;Alex Hlavaty;Marion Lepelley;Charles Khouri;Alexandre Bellier;Joachim Alexandre;Pierrick Bedouch;Laurent Bertoletti;Regis Bordet;Béatrice Bouhanick;Annie-Pierre Jonville-Bera;Silvy Laporte;Claire Le Jeunne;Louis Letinier;Joëlle Micallef;Florian Naudet;Matthieu Roustit;Mathieu Molimard;Vincent Richard;Jean-Luc Cracowski | COVID-19;pharmacology;public drug information;public health | 2020-05-13 02:00:00+02:00 | 32394481 | FR | [{"country": "", "agency": "Agence Nationale de Sécurité du Médicament et des Produits de Santé"}] | Univ. Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France.;Univ. Caen Normandie, CHU Caen Normandie, Caen, France.;Univ. Saint Etienne, CHU Saint Etienne, Saint Etienne, France.;Univ. Lille, CHU Lille, Lille, France.;Univ. Toulouse, CHU Toulouse, Toulouse, France.;Univ. Tours, CHU Tours, Tours, France.;Univ. Paris, APHP, Paris, France.;Univ. Bordeaux, CHU Bordeaux, Bordeaux, France.;Aix-Marseille Université, Hôpitaux Universitaires de Marseille - APHM, Marseille, France.;Univ. Rennes, CHU Rennes, Rennes, France.;Univ. Rouen, CHU Rouen, Rouen, France. | 638 |
| 10.1016/j.anorl.2020.05.005 | Journal Article | en | SARS-CoV-2 infection may mask another infection. | https://www.ncbi.nlm.nih.gov/pubmed/32426076 | 1879-7296 | 2020-05-17 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | A Leon;C Debry;M Renaud | 2020-05-16 02:00:00+02:00 | 32426076 | FR | Service d'Oto-Rhino-Laryngologie et de Chirurgie Maxillo-Faciale, Hôpitaux Universitaires de Strasbourg, France. | 640 | |||||
| 10.1093/cid/ciaa600 | Journal Article | en | COVID-19: The New Caledonia experience. | https://www.ncbi.nlm.nih.gov/pubmed/32415955 | New Caledonia is a French associated territory in the South Pacific Ocean. While COVID-19 is expanding over the world, we seem to be well preserved with a total of 18 documented cases. We report the measures implemented on our island that probably helped containing an epidemic spread. | 1058-4838,1537-6591 | 2020-05-17 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Jad Kerbaj;Cecile Cazorla;Thierry De Greslan;Mathieu Serie;Ann-Claire Gourinat;Benoit Marot | COVID-19;New Caledonia;SARS-CoV-2;containment;epidemic;quarantine | 2020-05-16 02:00:00+02:00 | 32415955 | FR | Infectious Diseases Department, Centre Hospitalier Territorial Gaston Bourret, Noumea, New Caledonia.;Head of Medical Staff, Centre Hospitalier Territorial Gaston Bourret , Noumea, New Caledonia.;Intensive Care Unit, Centre Hospitalier Territorial Gaston Bourret , Noumea, New Caledonia.;Microbiology Laboratory, Centre Hospitalier Territorial Gaston Bourret , Noumea, New Caledonia. | 642 | |||
| 10.1016/j.accpm.2020.05.006 | Journal Article;Review | en | Anaesthesia and intensive care in obstetrics during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32405520 | 2352-5568 | 2020-05-17 02:00:00+02:00 | pubmed | Analgesia, Obstetrical__methods;Anesthesia, Obstetrical__adverse effects;Betacoronavirus;Cesarean Section;Coronavirus Infections__prevention & control;Critical Care__methods;Cross Infection__prevention & control;Delivery, Obstetric__methods;Diagnostic Tests, Routine;Disease Transmission, Infectious__prevention & control;Doulas;Female;Fetal Monitoring;Health Personnel__education;Humans;Infant, Newborn;Infection Control__methods;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Infectious Disease Transmission, Vertical__prevention & control;Labor, Induced;Occupational Diseases__prevention & control;Pandemics__prevention & control;Patient Care Team;Personal Protective Equipment;Pneumonia, Viral__prevention & control;Pregnancy;Pregnancy Complications, Infectious__epidemiology;Pregnancy, High-Risk;Prenatal Care__methods;Respiratory Distress Syndrome, Adult__epidemiology;Telemedicine;Thrombophilia__drug therapy;COVID-19;severe acute respiratory syndrome coronavirus 2 | Anaesthesia Critical Care & Pain Medicine | Estelle Morau;Lionel Bouvet;Hawa Keita;Florence Vial;Marie Pierre Bonnet;Martine Bonnin;Agnès Le Gouez;Dominique Chassard;Frédéric J Mercier;Dan Benhamou | Anaesthesia;Analgesia;COVID-19;Maternal morbidity;Obstetric;Pregnancy;SARS-CoV-2 | 2020-05-13 02:00:00+02:00 | 32405520 | FR | Department of Anaesthesia Intensive Care and Perioperative Medicine, CHU Nîmes, 4, rue du Professeur-Rober-Debré, 30029 Nîmes, France. Electronic address: Estelle.morau@chu-nimes.fr.;Service d'Anesthésie-Réanimation, Groupement Hospitalier Est, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Lyon, France.;Assistance publique des Hôpitaux Paris, hôpital Necker-Enfants-Malades, service d'anesthésie-réanimation, AP-HP, Centre - Université de Paris, Paris, France, Unité de Recherche EA 7323 Pharmacologie et Evaluation des Thérapeutiques Chez l'Enfant et la Femme Enceinte, Université de Paris, Paris, France.;Department of Anaesthesia and Critical Care Medicine CHRU Nancy, Nancy, France.;Department of Anaesthesiology and Critical Care, Armand Trousseau Hospital, DMU DREAM, Assistance publique des Hôpitaux de Paris, Paris, France, Université de Paris, Centre for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France, Obstetrical Perinatal and Paediatric Epidemiology Research Team, EPOPé, INSERM, INRA, Paris, France.;Department of Anaesthesia and Critical Care Medicine, Pôle Anesthésie-Réanimation-Estaing, Clermont-Ferrand, France.;Department of Anaesthesia and Critical Care Medicine, Antoine Béclère Hospital, AP-HP, Université Paris-Saclay, Clamart, France.;Service d'Anesthésie Réanimation Médecine Péri Opératoire, AP-HP, Université Paris Saclay, Hôpital Bicêtre, 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre Cedex, France. | 647 | |||
| 10.1080/20016689.2020.1758390 | Journal Article | en | Commentary on "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial" by Gautret et al. | https://www.ncbi.nlm.nih.gov/pubmed/32537099 | The results of a clinical trial comparing hydroxychloroquine with or without azithromycin to the standard of care for the treatment of COVID-19 were recently published by Philippe Gautret et al. This study provides outstanding results for the combination of hydroxychloroquine and azithromycin over the standard of care, but the evidence was deemed insufficiently robust to warrant a public health decision to widen the use of hydroxychloroquine for the treatment of COVID-19. We provide a scientific critical review of the Gautret et al. publication, put the results in the context of the current knowledge, provide an evaluation of the validity of the results (from a methodologic perspective), and discuss public health implications. The study has a number of limitations, including small sample size, lack of comparability between patients in active treatment and control arms, lack of blinding, use of interim analyses without controlling for the risk of type 1 error, use of analysis in the per-protocol population instead of the intention-to-treat population, and inconsistencies between the study protocol and article. However, none of these observations is of a nature to reverse the conclusions. The study brings useful knowledge consistent with available evidence and clinical practice from China and South Korea, which could have prompted quicker policy decision-making. | 2001-6689 | 2020-05-17 02:00:00+02:00 | pubmed | Journal of Market Access & Health Policy | Mondher Toumi;Samuel Aballea | COVID 19;Coronavirus;azithromycin;decision-making;hydroxychloroquine;public health | 2020-05-13 02:00:00+02:00 | 32537099 | FR | Department of Public Health Research, Unit EA 3279, Aix Marseille University, Marseille, France.;Creativ-Ceutical, Paris, France. | 651 | |||
| 10.1016/j.ijantimicag.2020.106020 | Journal Article | en | Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. | https://www.ncbi.nlm.nih.gov/pubmed/32405156 | The emergence of SARS-coronavirus-2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19). Hydroxychloroquine (CLQ-OH)/azithromycin (ATM) combination therapy is currently being tested for the treatment of COVID-19, with promising results. However, the molecular mechanism of action of this combination is not yet established. Using molecular dynamics (MD) simulations, this study shows that the drugs act in synergy to prevent any close contact between the virus and the plasma membrane of host cells. Unexpected molecular similarity is shown between ATM and the sugar moiety of GM1, a lipid raft ganglioside acting as a host attachment cofactor for respiratory viruses. Due to this mimicry, ATM interacts with the ganglioside-binding domain of SARS-CoV-2 spike protein. This binding site shared by ATM and GM1 displays a conserved amino acid triad Q-134/F-135/N-137 located at the tip of the spike protein. CLQ-OH molecules are shown to saturate virus attachment sites on gangliosides in the vicinity of the primary coronavirus receptor, angiotensin-converting enzyme-2 (ACE-2). Taken together, these data show that ATM is directed against the virus, whereas CLQ-OH is directed against cellular attachment cofactors. We conclude that both drugs act as competitive inhibitors of SARS-CoV-2 attachment to the host-cell membrane. This is consistent with a synergistic antiviral mechanism at the plasma membrane level, where therapeutic intervention is likely to be most efficient. This molecular mechanism may explain the beneficial effects of CLQ-OH/ATM combination therapy in patients with COVID-19. Incidentally, the data also indicate that the conserved Q-134/F-135/N-137 triad could be considered as a target for vaccine strategies. | 0924-8579 | 2020-05-17 02:00:00+02:00 | pubmed | International Journal of Antimicrobial Agents | Jacques Fantini;Henri Chahinian;Nouara Yahi | ACE-2, angiotensin-converting enzyme-2;ATM, azithromycin;Azithromycin;CLQ, chloroquine;CLQ-OH, hydroxychloroquine;COVID-19, coronavirus disease 19;Chloroquine;Coronavirus;Ganglioside;NTD, N-terminal domain;Pandemic;RBD, receptor binding domain;SARS-CoV, severe acute respiratory syndrome coronavirus;SARS-CoV-2;SARS-CoV-2, SARS-coronavirus-2 | 2020-05-13 02:00:00+02:00 | 32405156 | FR | INSERM UMR_S 1072, 13015 Marseille, France.;Aix-Marseille Université, 13015 Marseille, France. | 658 | |||
| 10.1089/cmb.2020.0193 | Journal Article | en | Conserved High Free Energy Sites in Human Coronavirus Spike Glycoprotein Backbones. | https://www.ncbi.nlm.nih.gov/pubmed/32401043 | Methods previously developed by the author are applied to uncover several sites of interest in the spike glycoproteins of all known human coronaviruses (hCoVs), including SARS-CoV-2 that causes COVID-19. The sites comprise three-dimensional neighborhoods of peptides characterized by four key properties: (1) they pinpoint regions of high free energy in the backbone whose obstruction might interrupt function; (2) by their very definition, they occur rarely in the universe of all gene-encoded proteins that could obviate host response to compounds designed for their interference; (3) they are common to all known hCoV spikes, possibly retaining activity in light of inevitable viral mutation; and (4) they are exposed in the molecular surface of the glycoprotein. These peptides in SARS-CoV-2 are given by the triples of residues (131, 117, 134), (203, 227, 228), and (1058, 730, 731) in its spike. | 1557-8666 | 2020-05-17 02:00:00+02:00 | pubmed | Journal of Computational Biology | Robert C Penner | COVID-19;SARS-CoV-2;conserved high free energy sites;coronavirus;spike glycoprotein backbones | 2020-05-13 02:00:00+02:00 | 32401043 | FR;US | Institut des Hautes Études Scientifiques, Bures-sur-Yvette, France.;Mathematics Department, University of California at Los Angeles, Los Angeles, California, USA. | 663 | |||
| Letter | en | Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients. | https://www.ncbi.nlm.nih.gov/pubmed/32410112 | 2020-05-17 02:00:00+02:00 | pubmed | Souheil Zayet;Timothee Klopfenstein;Julien Mercier;N'dri Juliette Kadiane-Oussou;Ludovic Lan Cheong Wah;Pierre-Yves Royer;Lynda Toko;Vincent Gendrin | 2020-05-14 02:00:00+02:00 | 32410112 | FR | Department of Infectious Diseases, Nord Franche-Comte Hospital, 90400, Trévenans, France. souhail.zayet@gmail.com.;Department of Infectious Diseases, Nord Franche-Comte Hospital, 90400, Trévenans, France. | 665 | ||||||||
| 10.1007/s11739-020-02356-6 | Journal Article | en | Bronchoalveolar lavage findings in severe COVID-19 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32415560 | 1828-0447,1970-9366 | 2020-05-17 02:00:00+02:00 | pubmed | Internal and Emergency Medicine | Guillaume Voiriot;Anne Fajac;Julien Lopinto;Vincent Labbé;Muriel Fartoukh | 2020-05-15 02:00:00+02:00 | 32415560 | FR | Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de médecine intensive réanimation, Hôpital Tenon, 4 rue de la Chine, 75020, Paris, France. guillaume.voiriot@aphp.fr.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service d'anatomie et cytologie pathologiques, Hôpital Tenon, Paris, France.;Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de médecine intensive réanimation, Hôpital Tenon, 4 rue de la Chine, 75020, Paris, France. | 670 | |||||
| Letter | en | Balancing risks and benefits in inflammatory bowel disease patients during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32422207 | 2020-05-17 02:00:00+02:00 | pubmed | Paulo Gustavo Kotze;Laurent Peyrin-Biroulet;Silvio Danese | 2020-05-15 02:00:00+02:00 | 32422207 | FR;BR;IT | IBD outpatient clinics, Colorectal Surgery Unit, Catholic University of Paraná (PUCPR), Curitiba, Brazil. Electronic address: pgkotze@hotmail.com.;IBD Unit, Nancy hospital, Nancy, France.;IBD Unit, Humanitas Research Hospital, Milan, Italy. | 671 | ||||||||
| 10.1016/j.bbih.2020.100081 | Journal Article;Review | en | How to detect and track chronic neurologic sequelae of COVID-19? Use of auditory brainstem responses and neuroimaging for long-term patient follow-up. | https://www.ncbi.nlm.nih.gov/pubmed/32427134 | This review intends to provide an overview of the current knowledge on neurologic sequelae of COVID-19 and their possible etiology, and, based on available data, proposes possible improvements in current medical care procedures. We conducted a thorough review of the scientific literature on neurologic manifestations of COVID-19, the neuroinvasive propensity of known coronaviruses (CoV) and their possible effects on brain structural and functional integrity. It appears that around one third of COVID-19 patients admitted to intensive care units (ICU) for respiratory difficulties exhibit neurologic symptoms. This may be due to progressive brain damage and dysfunction triggered by severe hypoxia and hypoxemia, heightened inflammation and SARS-CoV-2 dissemination into brain parenchyma, as suggested by current reports and analyses of previous CoV outbreaks. Viral invasion of the brain may particularly target and alter brainstem and thalamic functions and, consequently, result in sensorimotor dysfunctions and psychiatric disorders. Moreover, data collected from other structurally homologous CoV suggest that SARS-CoV-2 infection may lead to brain cell degeneration and demyelination similar to multiple sclerosis (MS). Hence, current evidence warrants further evaluation and long-term follow-up of possible neurologic sequelae in COVID-19 patients. It may be particularly relevant to evaluate brainstem integrity in recovered patients, as it is suspected that this cerebral area may particularly be dysfunctional following SARS-CoV-2 infection. Because CoV infection can potentially lead to chronic neuroinflammation and progressive demyelination, neuroimaging features and signs of MS may also be evaluated in the long term in recovered COVID-19 patients. | 2666-3546 | 2020-05-17 02:00:00+02:00 | pubmed | Brain, Behavior, & Immunity - Health | Michael Ogier;Guillaume Andéol;Emmanuel Sagui;Gregory Dal Bo | Auditory brainstem responses;Brainstem dysfunction;COVID-19;Cytokine storm;Microglia priming;Multiple sclerosis;Neuroimaging;Neuroinflammatory mechanisms;Neurologic sequelae;SARS-CoV-2 | 2020-05-15 02:00:00+02:00 | 32427134 | FR | French Armed Forces Biomedical Research Institute, 1 place Valérie André, 91220, Brétigny sur Orge, France.;European Hospital of Marseille, 6 rue Désirée Clary, 13003, Marseille, France. | 675 | |||
| 10.1016/j.jsxm.2020.05.001 | Journal Article | en | Challenges in the Practice of Sexual Medicine in the Time of COVID-19 in the United Kingdom. | https://www.ncbi.nlm.nih.gov/pubmed/32411271 | On 23rd March 2020, the UK government released self-isolation/social distancing guidance to reduce the risk of transmission of SARS-CoV-2. The influence such guidance has on sexual activity is not known. | 1743-6095 | 2020-05-17 02:00:00+02:00 | pubmed | Adult;Betacoronavirus__pathogenicity;Coronavirus Infections__epidemiology;Female;Health Surveys;Humans;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Sexual Behavior;Sexual Health;Sexual Partners__psychology;Social Isolation;United Kingdom__epidemiology;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Journal of Sexual Medicine | Louis Jacob;Lee Smith;Laurie Butler;Yvonne Barnett;Igor Grabovac;Daragh McDermott;Nicola Armstrong;Anita Yakkundi;Mark A Tully | COVID-19;SARS-CoV-2;Self-isolation;Sexual activity;UK | 2020-05-14 02:00:00+02:00 | 32411271 | FR;IE;GB;AT | Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le- Bretonneux, France.;The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK. Electronic address: Lee.smith@anglia.ac.uk.;Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, UK.;Anglia Ruskin University, Cambridge, UK.;Department of Social and Preventive Medicine, Centre for Public Health, Medical University of Vienna, Vienna, Austria.;School of Psychology and Sport Science, Anglia Ruskin University, Cambridge, UK.;HSC R&D Division, Public Health Agency (Northern Ireland), Belfast, UK.;Northern Ireland Public Health Research Network, School of Health Sciences, Ulster University, Newtownabbey, UK.;Institute of Mental Health Sciences, School of Health Sciences, Ulster University, Newtownabbey, UK. | 680 | ||
| 10.1111/bjh.16730 | Case Reports;Journal Article | en | SARS-CoV-2: a new aetiology for atypical lymphocytes. | https://www.ncbi.nlm.nih.gov/pubmed/32311762 | 0007-1048,1365-2141 | 2020-05-17 02:00:00+02:00 | pubmed | Aged;Betacoronavirus__immunology;Coronavirus Infections__immunology;Cytoplasm__immunology;Female;Humans;Lymphocytes__immunology;Pandemics;Pneumonia, Viral__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | British Journal of Haematology | Delphine Gérard;Sylvain Henry;Benoît Thomas | 2020-05-14 02:00:00+02:00 | 32311762 | FR | Service d'hématologie Biologique, Université de Lorraine, CHRU de Nancy, Nancy, France.;Laboratoire de Biologie Médicale, Hôpitaux Privés de Metz, Metz, France. | 682 | ||||
| Letter;Comment | en | Corticosteroid use in selected patients with severe acute respiratory distress syndrome related to COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32417314 | 2020-05-17 02:00:00+02:00 | pubmed | Adrenal Cortex Hormones;Betacoronavirus;Coronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Respiratory Distress Syndrome, Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Suzanne Goursaud;Richard Descamps;Cédric Daubin;Damien du Cheyron;Xavier Valette | Acute respiratory distress syndrome;COVID-19;Corticosteroids | 2020-05-14 02:00:00+02:00 | 32417314 | FR | Department of Medical Intensive Care, CHU de Caen Normandie, 14000 Caen, France. Electronic address: goursaud-s@chu-caen.fr.;Department of Medical Intensive Care, CHU de Caen Normandie, 14000 Caen, France. | 683 | ||||||
| Letter;Comment | en | Just a little bit more patience…. | https://www.ncbi.nlm.nih.gov/pubmed/32405519 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections__drug therapy;Humans;Pandemics;Pneumonia, Viral;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Philippe Montravers;Christian de Tymowski;Maksud Assadi;Sonia Yung;Elie Kantor | Antiviral therapy;COVID-19;Clinical trials | 2020-05-13 02:00:00+02:00 | 32405519 | FR | Département d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, DMU PARABOL, HUPNVS, AP-HP, Paris, France, Université de Paris, Paris, France, Inserm UMR 1152, Université de Paris, Paris, France. Electronic address: philippe.montravers@aphp.fr.;Département d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, DMU PARABOL, HUPNVS, AP-HP, Paris, France, Université de Paris, Paris, France, Inserm UMR 1149, Université de Paris, Paris, France.;Département d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, DMU PARABOL, HUPNVS, AP-HP, Paris, France, Université de Paris, Paris, France.;Département d'Anesthésie-Réanimation, CHU Bichat-Claude Bernard, DMU PARABOL, HUPNVS, AP-HP, Paris, France. | 686 | ||||||
| 10.1126/science.abc3517 | Journal Article;Research Support, Non-U.S. Gov't | en | Estimating the burden of SARS-CoV-2 in France. | https://www.ncbi.nlm.nih.gov/pubmed/32404476 | France has been heavily affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and went into lockdown on 17 March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find that 2.9% of infected individuals are hospitalized and 0.5% of those infected die (95% credible interval: 0.3 to 0.9%), ranging from 0.001% in those under 20 years of age to 8.3% in those 80 years of age or older. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 2.90 to 0.67 (77% reduction). By 11 May 2020, when interventions are scheduled to be eased, we project that 3.5 million people (range: 2.1 million to 6.0 million), or 5.3% of the population (range: 3.3 to 9.3%), will have been infected. Population immunity appears to be insufficient to avoid a second wave if all control measures are released at the end of the lockdown. | 0036-8075,1095-9203 | 2020-05-17 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Coronavirus Infections__epidemiology;Cost of Illness;Critical Care;Female;France__epidemiology;Hospitalization__statistics & numerical data;Humans;Immunity;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Quarantine;SARS Virus;Young Adult;COVID-19 | Science | Henrik Salje;Cécile Tran Kiem;Noémie Lefrancq;Noémie Courtejoie;Paolo Bosetti;Juliette Paireau;Alessio Andronico;Nathanaël Hozé;Jehanne Richet;Claire-Lise Dubost;Yann Le Strat;Justin Lessler;Daniel Levy-Bruhl;Arnaud Fontanet;Lulla Opatowski;Pierre-Yves Boelle;Simon Cauchemez | 2020-05-13 02:00:00+02:00 | 32404476 | FR;GB;US | Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France.;Department of Genetics, University of Cambridge, Cambridge, UK.;Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.;Collège Doctoral, Sorbonne Université, Paris, France.;DREES, Ministère des Solidarités et de la Santé, Paris, France.;Santé Publique France, French National Public Health Agency, Saint-Maurice, France.;Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.;PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France.;Epidemiology and Modelling of Antibiotic Evasion Unit, Institut Pasteur, Paris, France.;Anti-infective Evasion and Pharmacoepidemiology Team, CESP, Université Paris-Saclay, UVSQ, INSERM U1018, Montigny-le-Bretonneux, France.;Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, Paris, France.;Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France. simon.cauchemez@pasteur.fr. | 687 | |||
| Letter;Comment | en | Re: Toward a consensus view in the management of acute facial injuries during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32418761 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Consensus;Coronavirus Infections;Facial Injuries;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | H Bertin;C Koudougou;F Marion;P Corre;R Deransy | 2020-05-11 02:00:00+02:00 | 32418761 | FR | Service de Chirurgie Maxillo-faciale et Stomatologie, CHU de Nantes, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France, Laboratoire des Sarcomes Osseux et Remodelage des Tissus Calcifiés (PhyOs, UMR 1238), Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes cedex, France. Electronic address: helios.bertin@chu-nantes.fr.;Chirurgie Maxillo-faciale et Stomatologie, Hôpital Privé du Confluent, 2-4 rue Eric Tabarly, 44277 Nantes cedex 2, France. Electronic address: dr.koudougou@groupeconfluent.fr.;Chirurgie Maxillo-faciale et Stomatologie, Clinique Bretéché, 3 rue de la Beraudière, 44000 Nantes, France. Electronic address: dr.marionfrancois@gmail.com.;Service de Chirurgie Maxillo-faciale et Stomatologie, CHU de Nantes, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France, Laboratoire D'Ingénierie Ostéo-Articulaire et Dentaire (LIOAD), Faculté de Chirurgie Dentaire, 1 Place Alexis Ricordeau, 44042 Nantes, France. Electronic address: pierre.corre@chu-nantes.fr.;Service D'anesthésie et Réanimation, CHU de Nantes, 1 Place Alexis Ricordeau, 44093 Nantes Cedex 1, France. Electronic address: romain.deransy@chu-nantes.fr. | 694 | |||||||
| 10.1016/j.resmer.2020.100764 | Editorial | en | Chronic obstructive pulmonary disease and the COVID-19 pandemic: Reciprocal challenges. | https://www.ncbi.nlm.nih.gov/pubmed/32498023 | 2590-0412 | 2020-05-17 02:00:00+02:00 | pubmed | Respiratory Medicine and Research | G Deslée;M Zysman;P-R Burgel;T Perez;L Boyer;J Gonzalez;N Roche | COPD;COVID-19;Infection | 2020-05-11 02:00:00+02:00 | 32498023 | FR | Service de Pneumologie, inserm U1250, CHU Reims, Université Reims Champagne Ardenne, Reims, France.;Service des Maladies Respiratoires, CHU Bordeaux, Univ-Bordeaux, Centre de Recherche cardio-thoracique de Bordeaux, U1045, CIC 1401, Pessac, France.;Service de Pneumologie, AP-HP Paris, Institut Cochin, inserm U1016, Université de Paris, Paris, France.;Service de Pneumologie, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, Lille, France.;Département de physiologie-explorations fonctionnelles, AP-HP Hôpital Henri-Mondor, Inserm U955, Créteil, France.;Sorbonne Université, inserm, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, AP-HP, Groupe Hospitalier Universitaire AP-HP-Sorbonne Université, site Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Paris, France. | 703 | ||||
| 10.1016/j.accpm.2020.05.003 | Journal Article;Review | en | Coagulation changes and thromboembolic risk in COVID-19 obstetric patients. | https://www.ncbi.nlm.nih.gov/pubmed/32437961 | 2352-5568 | 2020-05-17 02:00:00+02:00 | pubmed | Anticoagulants__therapeutic use;Autoantibodies__blood;Betacoronavirus__isolation & purification;Blood Proteins__analysis;Cerebrovascular Disorders__etiology;Contraindications, Drug;Coronavirus Infections__blood;Cytokine Release Syndrome__blood;Disseminated Intravascular Coagulation__drug therapy;Endothelial Cells__virology;Female;Heparin, Low-Molecular-Weight__administration & dosage;Humans;Pandemics;Partial Thromboplastin Time;Plasma;Pneumonia, Viral__blood;Postpartum Hemorrhage__drug therapy;Pregnancy;Pregnancy Complications, Hematologic__drug therapy;Pregnancy Complications, Infectious__blood;Puerperal Disorders__blood;Thromboembolism__etiology;Thrombophilia__drug therapy;Tranexamic Acid__adverse effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Anaesthesia Critical Care & Pain Medicine | Dan Benhamou;Hawa Keita;Anne Sophie Ducloy-Bouthors | Coagulation;Fibrinolysis;Haemorrhage;Hypercoagulability;Pregnancy;Regional anaesthesia | 2020-05-11 02:00:00+02:00 | 32437961 | FR | Service d'Anesthésie Réanimation Médecine Péri Opératoire, AP-HP, Université Paris Saclay, Hôpital Bicêtre, 78, rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France. Electronic address: dan.benhamou@aphp.fr.;Assistance publique des Hôpitaux Paris, hôpital Necker-Enfants-Malades, service d'anesthésie-réanimation, AP-HP, Centre-Université de Paris, Paris, France, Unité de Recherche EA 7323 Pharmacologie et Evaluation des Thérapeutiques Chez l'Enfant et la Femme Enceinte, Université de Paris, Paris, France.;Anaesthesia Intensive care unit, Jeanne de Flandre Women Hospital, Academic hospital, 59037 Lille, France, University Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, 59000 Lille, France. | 706 | |||
| Letter | en | Thinking Beyond the Box: Preparing for the End of COVID-19 Outbreak in a Vascular Surgery Department. | https://www.ncbi.nlm.nih.gov/pubmed/32437917 | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;Pandemics;Pneumonia, Viral__epidemiology;Surgery Department, Hospital__organization & administration;Vascular Surgical Procedures__statistics & numerical data;COVID-19;severe acute respiratory syndrome coronavirus 2 | Calin Gheorghe Precup;Marine Bordet;Patrick Lermusiaux;Antoine Millon;Nellie Della Schiava | 2020-05-11 02:00:00+02:00 | 32437917 | FR | Service de chirurgie vasculaire et endovasculaire, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France. Electronic address: calin-gheorghe.precup@chu-lyon.fr.;Service de chirurgie vasculaire et endovasculaire, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France, Université Claude Bernard Lyon 1, Lyon, France.;Service de chirurgie vasculaire et endovasculaire, Etablissement Edouard Herriot, Hospices Civils de Lyon, Lyon, France. | 710 | |||||||
| 10.1016/j.ejrad.2020.109075 | Journal Article | en | Chest-X-ray is a mainstay for follow-up in critically ill patients with covid-19 induced pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32405142 | 0720-048X | 2020-05-17 02:00:00+02:00 | pubmed | European Journal of Radiology | Olivier de Barry;Ilan Obadia;Mostafa El Hajjam;Robert-Yves Carlier | 2020-05-13 02:00:00+02:00 | 32405142 | FR | DMU Smart Imaging, Medical Imaging Department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay, Ambroise Paré Teaching Hospital, 92100 Boulogne-Billancourt, France, DMU Smart Imaging, Medical Imaging Department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay, Raymond Poincaré Teaching Hospital, 92380 Garches, France. Electronic address: olivier.debarry@aphp.fr.;DMU Smart Imaging, Medical Imaging Department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay, Ambroise Paré Teaching Hospital, 92100 Boulogne-Billancourt, France. Electronic address: Ilan.obadia@aphp.fr.;DMU Smart Imaging, Medical Imaging Department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay, Ambroise Paré Teaching Hospital, 92100 Boulogne-Billancourt, France. Electronic address: mostafa.elhajjam@aphp.fr.;DMU Smart Imaging, Medical Imaging Department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay, Ambroise Paré Teaching Hospital, 92100 Boulogne-Billancourt, France, DMU Smart Imaging, Medical Imaging Department. Assistance Publique-Hôpitaux de Paris, GH Université Paris-Saclay, Raymond Poincaré Teaching Hospital, 92380 Garches, France, UMR 1179 End-icap, Université Versailles Saint-Quentin-en-Yvelines/Paris-Saclay, France. Electronic address: Robert.carlier@aphp.fr. | 714 | |||||
| Letter | en | COVID-19 and assisted reproductive technology services: repercussions for patients and proposal for individualized clinical management. | https://www.ncbi.nlm.nih.gov/pubmed/32404170 | The prolonged lockdown of health services providing high-complexity fertility treatments -as currently recommended by many reproductive medicine entities- is detrimental for society as a whole, and infertility patients in particular. Globally, approximately 0.3% of all infants born every year are conceived using assisted reproductive technology (ART) treatments. By contrast, the total number of COVID-19 deaths reported so far represents approximately 1.0% of the total deaths expected to occur worldwide over the first three months of the current year. It seems, therefore, that the number of infants expected to be conceived and born -but who will not be so due to the lockdown of infertility services- might be as significant as the total number of deaths attributed to the COVID-19 pandemic. We herein propose remedies that include a prognostic-stratification of more vulnerable infertility cases in order to plan a progressive restart of worldwide fertility treatments. At a time when preventing complications and limiting burdens for national health systems represent relevant issues, our viewpoint might help competent authorities and health care providers to identify patients who should be prioritized for the continuation of fertility care in a safe environment. | 2020-05-17 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections;Female;Fertilization in Vitro;Humans;Infertility, Female__therapy;Pandemics;Pneumonia, Viral;Pregnancy;Reproductive Health Services__organization & administration;Reproductive Techniques, Assisted;Sperm Injections, Intracytoplasmic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Carlo Alviggi;Sandro C Esteves;Raoul Orvieto;Alessandro Conforti;Antonio La Marca;Robert Fischer;Claus Y Andersen;Klaus Bühler;Sesh K Sunkara;Nikolaos P Polyzos;Ida Strina;Luigi Carbone;Fabiola C Bento;Daniela Galliano;Hakan Yarali;Lan N Vuong;Michael Grynberg;Panagiotis Drakopoulos;Pedro Xavier;Joaquin Llacer;Fernando Neuspiller;Marcos Horton;Matheus Roque;Evangelos Papanikolaou;Manish Banker;Michael H Dahan;Shu Foong;Herman Tournaye;Christophe Blockeel;Alberto Vaiarelli;Peter Humaidan;Filippo M Ubaldi | Assisted reproductive technology;COVID-19;In vitro fertilization;Infertility;Intracytoplasmic sperm injection;Poseidon criteria;Viewpoint | 2020-05-13 02:00:00+02:00 | 32404170 | IL;FR;BE;AR;CA;PT;GR;GB;VN;BR;IT;TR;ES;IN;DK;DE | Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico II, Via Sergio Pansini 5, 80131, Naples, Italy. alviggi@unina.it.;ANDROFERT, Andrology and Human Reproduction Clinic, Av. Dr. Heitor Penteado, 1463, Campinas, SP, 13075-460, Brazil. s.esteves@androfert.com.br.;Department of Surgery (Division of Urology), University of Campinas (UNICAMP), Campinas, Brazil. s.esteves@androfert.com.br.;Faculty of Health, Aarhus University, Aarhus, Denmark. s.esteves@androfert.com.br.;Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel.;The Tarnesby-Tarnowski Chair for Family Planning and Fertility Regulation, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.;Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico II, Via Sergio Pansini 5, 80131, Naples, Italy.;Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.;Fertility Center Hamburg, Hamburg, Germany.;Laboratory of Reproductive Biology, University Hospital of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark.;Center for Gynecology, Endocrinology and Reproductive Medicine, and Stuttgart, Ulm, Germany.;Scientific-Clinical Centre for Endometriosis of the University Hospitals of Saarland, Saarbrücken, Germany.;Department of Women's Health, Faculty of Life Sciences, King's College London, London, UK.;Dexeus University Hospital, Barcelona, Spain.;ANDROFERT, Andrology and Human Reproduction Clinic, Av. Dr. Heitor Penteado, 1463, Campinas, SP, 13075-460, Brazil.;Instituto Valenciano de Infertilidad (IVI), Rome, Italy.;Anatolia IVF, Ankara, Turkey.;Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.;IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.;Service de Médecine de la Reproduction et Préservation de la Fertilité, Hôpital Antoine Béclère, Clamart, France, Université Paris Saclay, Saint-Aubin, France.;Center for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.;Department of Obstetrics and Gynecology, Medical School, University of Crete, 71110, Heraklion, Crete, Greece.;Unit of Reproductive Medicine, Department of Gynecology and Obstetrics, Hospital Center São João, Porto, Portugal.;Instituto Bernabeu, Alicante, Spain.;Instituto Valenciano de Infertilidad (IVI), Buenos Aires, Argentina.;Pregna Medicina Reprodutiva, Buenos Aires, Argentina.;MaterPrime, São Paulo, Brazil.;Assisting Nature, Centre of Assisted Reproduction and Genetics, Thessaloniki, Greece.;3rd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.;Nova IVF Fertility, Ahmedabad, India.;Department of Obstetrics and Gynecology, McGill University, Montreal, Canada.;Department of Obstetrics & Gynecology, University of Calgary, Calgary, Canada.;Regional Fertility Program, Calgary, Canada.;Fertility Clinic Skive, Skive Regional Hospital, Skive, Denmark.;Faculty of Health, Aarhus University, Aarhus, Denmark.;GENERA, Center for Reproductive Medicine, Rome, Italy. | 716 | |||||
| 10.1038/s41423-020-0454-3 | Journal Article | en | Is aberrant CD8+ T cell activation by hypertension associated with cardiac injury in severe cases of COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32398804 | 1672-7681,2042-0226 | 2020-05-17 02:00:00+02:00 | pubmed | Animals;CD8-Positive T-Lymphocytes__immunology;Cardiovascular Diseases__complications;Comorbidity;Coronavirus Infections__complications;Humans;Hypertension__complications;Mice;Pandemics;Pneumonia, Viral__complications;Receptor, Angiotensin, Type 2__metabolism;COVID-19 | Cellular & Molecular Immunology | Chao Zhang;Fu-Sheng Wang;Jean-Sébastien Silvestre;Fernando Arenzana-Seisdedos;Hong Tang | 2020-05-12 02:00:00+02:00 | 32398804 | FR;CN | Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.;Inserm UMRS 970, Paris Centre de Recherche Cardiovasculaire (PARCC), 75737 Paris cedex 15, Cedex, France.;CAS Key Laboratory of Molecular Virology and Immunology, COVID-19 Response Team, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.;CAS Key Laboratory of Molecular Virology and Immunology, COVID-19 Response Team, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China. htang@ips.ac.cn. | 719 | ||||
| 10.1016/j.obmed.2020.100255 | Journal Article | en | COVID-19: How the quarantine could lead to the depreobesity. | https://www.ncbi.nlm.nih.gov/pubmed/32427138 | In this paper, we will introduce coronavirus (COVID-19) and how it spreads around the globe. We will also present the term of quarantine and associated with it requirement of locking down at home in some countries. We will study how frustration related to quarantine relates to several psychological problems including depression. This environment pushes people to consume high sugar foods that increase obesity. In conclusion, countries should be prepared for the upcoming epidemic (depreobesity). | 2451-8476 | 2020-05-17 02:00:00+02:00 | pubmed | Obesity Medicine | Mohamed Mediouni;Riadh Madiouni;Karolina Elżbieta Kaczor-Urbanowicz | COVID‐19;Depreobesity;Depression;Obesity;Quarantine | 2020-05-15 02:00:00+02:00 | 32427138 | FR;CA;US | 1420 Rue Laterrière, Sherbrooke, QC J1K 2R2, Canada.;University of Paris-Est, Créteil, Vitry sur Seine, France.;Center for Oral and Head/Neck Oncology Research, UCLA Section of Oral Biology, Division of Oral Biology & Medicine, Center for the Health Sciences, UCLA School of Dentistry, University of California at Los Angeles, USA, 10833 Le Conte Ave, Box 951668, Los Angeles, CA, 90095-1668, USA.;UCLA Institute for Quantitative and Computational Biosciences, University of California at Los Angeles, 611 Charles E. Young Drive Boyer Hall 570, Box 951570, Los Angeles, CA, 90095-1606, USA. | 721 | |||
| 10.1016/j.encep.2020.05.006 | Clinical Trial, Phase III;Journal Article;Multicenter Study;Randomized Controlled Trial | en | Repurposing chlorpromazine to treat COVID-19: The reCoVery study. | https://www.ncbi.nlm.nih.gov/pubmed/32425222 | The ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals. In Sainte-Anne Hospital (GHU PARIS Psychiatrie & Neuroscience, Paris, France) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff. This observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection, since several of these psychotropic drugs have documented antiviral properties. Chlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis. Recentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity. | 0013-7006 | 2020-05-17 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Anxiety__complications;Betacoronavirus__pathogenicity;Blood-Brain Barrier__drug effects;Chlorpromazine__therapeutic use;Clathrin-Coated Vesicles__drug effects;Coronavirus Infections__complications;Disease Progression;Drug Repositioning;Dyspnea__drug therapy;Endocytosis__drug effects;France__epidemiology;Humans;Length of Stay;Mortality;Pandemics;Patient Outcome Assessment;Pilot Projects;Pneumonia, Viral__complications;Recovery of Function;Single-Blind Method;Time-to-Treatment;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | M Plaze;D Attali;A-C Petit;M Blatzer;E Simon-Loriere;F Vinckier;A Cachia;F Chrétien;R Gaillard | COVID-19;Chlorpromazine;Clinical trial;Essai clinique;Repositionnement de molécules;Repurposing of molecules;SARS-CoV-2 | 2020-05-16 02:00:00+02:00 | 32425222 | FR | GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France, Université de Paris, Paris, France. Electronic address: m.plaze@ghu-paris.fr.;GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France, Université de Paris, Paris, France, Physics for Medicine Paris, Inserm, ESPCI Paris, CNRS, PSL Research University, Univ Paris Diderot, Sorbonne Paris Cite, Paris, France.;GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France, Institut Pasteur, Experimental Neuropathology Unit, Paris, France.;Institut Pasteur, Experimental Neuropathology Unit, Paris, France.;Institut Pasteur, G5 Evolutionary Genomics of RNA Viruses, Paris, France.;GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France, Université de Paris, Paris, France.;Université de Paris, Institut de Psychiatrie et Neurosciences de Paris, INSERM, Paris, France, Université de Paris, Laboratoire de Psychologie du développement et de l'Éducation de l'Enfant, CNRS, Paris, France.;Institut Pasteur, Experimental Neuropathology Unit, Paris, France, GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service de Neuropathologie, Paris, France.;GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France, Université de Paris, Paris, France, Institut Pasteur, Experimental Neuropathology Unit, Paris, France. | 734 | ||
| 10.1016/j.amp.2020.05.003 | English Abstract;Journal Article | fr | [Crisis psychopathology: Chronicle of ordinary tensions in an extraordinary health situation. Phase1: Anxious reorganization]. | https://www.ncbi.nlm.nih.gov/pubmed/32836299 | Humanity is facing a global pandemic at the start of 2020. The health systems of each country are reorganizing to cope with an influx of patients. This crisis reorganization is the source of psychological tension that can lead to symptomatic manifestations in many caregivers. This situation is similar in many points to that encountered by soldiers on external operations (loss of usual bearings, feeling of threat, focusing of attention on the crisis, deterioration of living conditions with limitation of the possibility of taking breaks). The aim of this work is to describe at the hospital level the changes in the professional and personal environment linked to the crisis likely to cause stress and then to describe the clinical manifestations observed both on an individual and collective level. | 0003-4487 | 2020-05-24 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Thomas Gilles | Adaptation;Covid-19;Crisis;Psychopathology;Stress | 2020-05-20 02:00:00+02:00 | 32836299 | FR | Service de psychiatrie de l'HIA Robert-Picqué, 351, route de Toulouse, 33140 Villenave-d'Ornon, France. | 753 | |||
| Letter | en | Did Whatsapp® reveal a new cutaneous COVID-19 manifestation? | https://www.ncbi.nlm.nih.gov/pubmed/32330322 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__complications;Europe;Humans;Mobile Applications;Pandemics;Pneumonia, Viral__complications;Skin Diseases__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | T A Duong;C Velter;M Rybojad;C Comte;M Bagot;L Sulimovic;J D Bouaziz | 2020-05-19 02:00:00+02:00 | 32330322 | FR | Dermatology Department, Henri Mondor Hospital, Créteil, France.;Chaire Avenir Santé numérique, Equipe 8 IMRB U955, INSERM, Université Paris Est Créteil, Créteil, France.;Dermatology Department, Paris University, Saint-Louis Hospital, Paris, France.;INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Université de Paris, Paris, France.;President of the SNDV (syndicat national des dermatologues vénéréologues)/on behalf of SNDV Corona group, Paris, France. | 757 | |||||||
| Letter;Comment | en | Immunotherapies for COVID-19: Restoring the immunity could be the priority. | https://www.ncbi.nlm.nih.gov/pubmed/32499129 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Immunotherapy;Pandemics;Pneumonia, Viral;Sepsis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Bernard Allaouchiche | 2020-05-20 02:00:00+02:00 | 32499129 | FR | Service de Réanimation, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, 69310 Pierre-Bénite, France, Université Claude Bernard Lyon1, France, Université de Lyon, VetAgro Sup, Campus Vétérinaire de Lyon, UPSP 2016.A101, Pulmonary and Cardiovascular Aggression in Sepsis, 69280 Marcy l'Étoile, France. Electronic address: bernard.allaouchiche@gmail.com. | 767 | |||||||
| 10.1016/j.annemergmed.2020.05.022 | Journal Article | en | Accuracy of Emergency Department Clinical Findings for Diagnosis of Coronavirus Disease 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32563600 | We seek to describe the medical history and clinical findings of patients attending the emergency department (ED) with suspected coronavirus disease 2019 (COVID-19) and estimate the diagnostic accuracy of patients' characteristics for predicting COVID-19. | 0196-0644 | 2020-05-24 02:00:00+02:00 | pubmed | Annals of Emergency Medicine | Olivier Peyrony;Carole Marbeuf-Gueye;Vy Truong;Marion Giroud;Clémentine Rivière;Khalil Khenissi;Léa Legay;Marie Simonetta;Arben Elezi;Alessandra Principe;Pierre Taboulet;Carl Ogereau;Mathieu Tourdjman;Sami Ellouze;Jean-Paul Fontaine | 2020-05-21 02:00:00+02:00 | 32563600 | FR | Emergency Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: o.peyrony@hotmail.fr.;Emergency Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Santé Publique France, Paris, France, Emergency Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. | 775 | ||||
| Letter;Comment | en | Rescue fibrinolysis in suspected massive pulmonary embolism during SARS-CoV-2 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32445784 | 2020-05-24 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Fibrinolysis;Fibrinolytic Agents;Humans;Pandemics;Pneumonia, Viral;Pulmonary Embolism;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | André Ly;Claire Alessandri;Elena Skripkina;Arnaud Meffert;Simon Clariot;Quentin de Roux;Olivier Langeron;Nicolas Mongardon | 2020-05-20 02:00:00+02:00 | 32445784 | FR | Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France, Univ Paris Est Creteil, Faculté de Santé, F-94010 Créteil, France.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France, U955-IMRB, Equipe 03 "Pharmacologie et Technologies pour les Maladies Cardiovasculaires (PROTECT)", Inserm, Univ Paris Est Creteil (UPEC), Ecole Nationale Vétérinaire d'Alfort (EnVA), F-94700 Maisons-Alfort, France.;Service d'anesthésie-réanimation chirurgicale, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France, Univ Paris Est Creteil, Faculté de Santé, F-94010 Créteil, France, U955-IMRB, Equipe 03 "Pharmacologie et Technologies pour les Maladies Cardiovasculaires (PROTECT)", Inserm, Univ Paris Est Creteil (UPEC), Ecole Nationale Vétérinaire d'Alfort (EnVA), F-94700 Maisons-Alfort, France, AfterROSC Research Group, F-75014 Paris, France. Electronic address: nicolas.mongardon@aphp.fr. | 776 | |||||||
| 10.3390/cancers12051287 | Journal Article | en | Older Cancer Patients during the COVID-19 Epidemic: Practice Proposal of the International Geriatric Radiotherapy Group. | https://www.ncbi.nlm.nih.gov/pubmed/32438703 | The coronavirus disease 19 (COVID-19) pandemic is unprecedented as it reached all countries in the world within a record short period of time. Even though COVID-19 infection may be just severe in any adults, older adults (65-year-old or older) may experience a higher mortality rate. Among those affected, cancer patients may have a worse outcome compared to the general population because of their depressed immune status. As the health resources of most countries are limited, clinicians may face painful decisions about which patients to save if they require artificial ventilation. Cancer patients, especially the older ones, may be denied supportive care because of their shorter life expectancy. Thus, special considerations should be taken to prevent infection of older cancer patients and to provide them with adequate social support during their cancer treatment. The following proposal was reached: (1) Education of health care providers about the special needs of older cancer patients and their risks of infection. (2) Special consideration such as surgical masks and separate scheduling should be made to protect them from being infected. (3) Social services such as patient navigators should be provided to ensure adequate medical supply, food, and daily transportation to cancer centers. (4) Close monitoring through phone calls, telecommunication to ensure social distancing and psychological support from patient family to prevent anxiety and depression. (5) Shorter course of radiotherapy by use of hypofractionation where possible to decrease the needs for daily transportation and exposure to infection. (6) Enrollment of older cancer patients in clinical trials for potential antiviral medications if infection does occur. (7) Home health care telemedicine may be an effective strategy for older cancer patients with COVID-19 infection to avoid hospital admission when health care resources become restricted. (8) For selected patients, immunotherapy and targeted therapy may become the systemic therapy of choice for older cancer patients and need to be tested in clinical trials. | 2072-6694 | 2020-05-24 02:00:00+02:00 | pubmed | Cancers | Nam P Nguyen;Vincent Vinh-Hung;Brigitta Baumert;Alice Zamagni;Meritxell Arenas;Micaela Motta;Pedro Carlos Lara;Arthur Sun Myint;Marta Bonet;Tiberiu Popescu;Te Vuong;Gokula Kumar Appalanaido;Lurdes Trigo;Ulf Karlsson;Juliette Thariat | cancer patients;corona virus 19;epidemic;older;treatment | 2020-05-19 02:00:00+02:00 | 32438703 | FR;MY;CA;ES;PT;CH;US;GB;RO;IT;MQ | Department of Radiation Oncology, Howard University, Washington, DC 20060, USA.;Department of Radiation Oncology, University Hospital of Martinique, 97200 Fort-de-France, France.;Institute of Radiation Oncology, Cantonal Hospital Graubuenden, 7000 Chur, Switzerland.;Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy.;Department of Radiation Oncology, Sant Joan de Reus University, University Rovira I Virgili, 43201 Tarragona, Spain.;Department of Radiation Oncology, Hospital Papa Giovanni XXIII, 24127 Bergamo, Italy.;Department of Radiation Oncology, Fernando Pessoa Canarias Las Palmas University, 35001 Las Palmas, Spain.;Department of Radiation Oncology, Clatterbridge Cancer Center, Liverpool CH63 4JY, UK.;Department of Radiation Oncology, Arnau de Vilanova University Hospital, 25198 Lleida, Spain.;Department of Radiation Oncology, Prof. Dr. Ion Chricuta Oncology Institute, 400015 Cluj-Napoca, Romania.;Department of Radiation Oncology, McGill University, Jewish General Hospital, Montreal, QC H3T1E2, Canada.;Department of Radiation Oncology, AMDI, Universiti Sains Malaysia, Penang 13200, Malaysia.;Department of Radiation Oncology, Instituto Portugues de Oncologia do Porto Francisco Martins Porto E.P.E, 4200-072 Porto, Portugal.;Department of Radiation Oncology, International Geriatric Group, Washington, DC 20001, USA.;Department of Radiation Oncology, Baclesse Cancer Center, 14000 Caen, France. | 778 | |||
| 10.1055/a-1175-4169 | Journal Article | en | EASAPS/ESPRAS Considerations in getting back to work in Plastic Surgery with the COVID-19 Pandemic - A European point of view. | https://www.ncbi.nlm.nih.gov/pubmed/32422664 | The aim of this paper is to summarize the results of a consensus process and a European webinar of the two societies, European Association of Societies of Aesthetic Surgery (EASAPS) and the European Society of Plastic, Reconstructive and Aesthetic Societies (ESPRAS) on what is considered safe practice based on the scientific knowledge we have today. This review of the current situations gives considerations which have to be taken into account when getting back to work in plastic surgery with COVID-19 in Europe. At all times, one should be familiar the local and regional infection rates in the community, with particular emphasis on the emergence of second and third waves of the pandemic. Due to the fast-evolving nature of the COVID-19 pandemic the recommendations aim to be rather considerations than fixed guidelines and might need to be revised in near future. | 0722-1819,1439-3980 | 2020-05-24 02:00:00+02:00 | pubmed | Handchirurgie · Mikrochirurgie · Plastische Chirurgie | Ivar van Heijningen;Konstantin Frank;Francisco Almeida;Urs Bösch;Nicola Bradic;Horacio Costa;Cenk Demirdover;Mark Henley;Lars Peter Kamolz;Michel Rouif;Stephan Spendel;Katharina Russe-Wilflingseder;Birgit Stark;Riccardo E Giunta;Jose Carlos Parreira;Rado Zic | 2020-05-18 02:00:00+02:00 | 32422664 | FR;SE;PT;CH;US;HR;GB;AT;TR;BE;DE | Duinbergen Clinic and AZ Zeno, Knokke Heist, Belgium.;Department for Hand, Plastic and Aesthetic Surgery, Ludwig-Maximilian University Munich, Germany.;Infection Prevention and control unit, Centro Hospitalar de São João, Alameda Prof. Hernâni Monteiro, Porto, Portugal.;MEON Clinic Luzern, Switzerland.;Department of Cardiovascular Anesthesiology and Cardiac Intensive Medicine, University Hospital Dubrava, Zagreb, Croatia.;Plastic Reconstructive Craniomaxilofacial Hand and Microsurgical Unit, Gaia Hospital Center and Aveiro University, Portugal.;Department of Plastic, Reconstructive and Aesthetic Surgery of Dokuz Eylul University, Izmir, Turkey.;Department of Plastic and Reconstructive Surgery, Nottingham University Hospitals, United Kingdom.;Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.;Private Practice, Tours, France.;Private Practice, Innsbruck, Austria.;Kliniken för Rekonstruktiv Plastikkirurgi Karolinska Institute, Stockholm, Sweden.;Department of Plastic Surgery, Hospital Garcia de Orta, Almada , Portugal And Private Practice, Portugal.;University Hospital Dubrava Department of Plastic Reconstructive and Aesthetic Surgery, School of Medicine University of Zagreb. | 783 | ||||
| 10.1016/j.scispo.2020.05.001 | Editorial | fr | [Physical activity during the Covid-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32454558 | 0765-1597 | 2020-05-24 02:00:00+02:00 | pubmed | Science & Sports | J-F Kaux;M Francaux | 2020-05-18 02:00:00+02:00 | 32454558 | FR;BE | Service de Médecine Physique, Réadaptation et Traumatologie du Sport, SportS, Centre Médical d'Excellence de la FIFA, Centre de Recherche du CIO, Centre de Médecine du Sport de la FIMS, CHU et Université de Liège, avenue de l'Hôpital, B35, 4000 Liège, Belgique.;Institut des Neurosciences, UCLouvain, Place Pierre de Coubertin 1, Louvain-la-Neuve, Belgique. | 790 | |||||
| 10.1016/j.amp.2020.05.001 | English Abstract;Journal Article | fr | [COVID-19 victims: To be or not to be ?] | https://www.ncbi.nlm.nih.gov/pubmed/32836298 | As part of this work, we propose to understand the global epidemic of COVID-19 coronavirus, as a sociobiological phenomenon. To carry out our reflection, we will base ourselves on a psychological listening experience (in a psychoanalytic orientation) conducted during the Nice attacks in 2016, and continued today, during the current pandemic context. More specifically, we will look at the signifier "victim", including all that it involves as questions about the subject. Our proposal will be to consider the victim status as a crossing. During this one, it is important that the suffering of the subjects is listened to, recognised, judged and compensated. In order for this to happen, everyone can find his own way of giving an answer to the reality of the virus, as it has imposed itself on us; but we will also see that one of the possible conclusions of this crossing consists in going through various forms of sublimation. | 0003-4487 | 2020-05-24 02:00:00+02:00 | pubmed | Annales Médico-psychologiques, revue psychiatrique | Virginie Jacob Alby | Attacks;Pandemic of COVID-19;Psychopathology;Sublimation;Victim | 2020-05-19 02:00:00+02:00 | 32836298 | FR | Maitre de conférences, HDR, en psychopathologie clinique, UCO Bretagne Nord, France.;Laboratoire RPPsy (EA 4050) « Recherches en psychopathologie, nouveaux symptômes et lien social », Université de Rennes 2, Rennes, France. | 796 | |||
| 10.1002/ajh.25829 | Journal Article;Systematic Review | en | Hematological findings and complications of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32282949 | COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID-19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted. | 0361-8609,1096-8652 | 2020-05-24 02:00:00+02:00 | pubmed | Anticoagulants__therapeutic use;Betacoronavirus;Biomarkers;Blood Coagulation Tests;Blood Donors__supply & distribution;C-Reactive Protein__analysis;Clinical Laboratory Techniques;Coronavirus Infections__blood;Cytokine Release Syndrome__blood;Cytokines__blood;Disseminated Intravascular Coagulation__blood;Early Diagnosis;Ferritins__blood;Fibrin Fibrinogen Degradation Products__analysis;Humans;Lymphopenia__etiology;Meta-Analysis as Topic;Pandemics;Pneumonia, Viral__blood;Risk;Thrombophilia__blood;Venous Thromboembolism__blood;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | American Journal of Hematology | Evangelos Terpos;Ioannis Ntanasis-Stathopoulos;Ismail Elalamy;Efstathios Kastritis;Theodoros N Sergentanis;Marianna Politou;Theodora Psaltopoulou;Grigoris Gerotziafas;Meletios A Dimopoulos | 2020-05-23 02:00:00+02:00 | 32282949 | FR;RU;GR | Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.;Hematology and Thrombosis Center, Tenon University Hospital, Sorbonne University, INSERM U938, Sorbonne University, Paris, France.;Department of Obstetrics and Gynaecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia.;Hematology Laboratory-Blood Bank, Aretaieio Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.;Research Group "Cancer, Haemostasis and Angiogenesis," INSERM U938, Centre de Recherche Saint-Antoine, Institut Universitaire de Cancérologie, Faculty of Medicine, Sorbonne University, Paris, France. | 816 | |||
| 10.1016/j.cmi.2020.05.019 | Journal Article;Review;Systematic Review | en | Review of trials currently testing treatment and prevention of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32454187 | As COVID-19 cases continue to rise globally, evidence from large randomized controlled trials is still lacking. Currently, numerous trials testing potential treatment and preventative options are being undertaken all over the world. | 1198-743X | 2020-05-24 02:00:00+02:00 | pubmed | Antiviral Agents__pharmacology;Betacoronavirus__drug effects;Cell- and Tissue-Based Therapy__methods;Clinical Trials as Topic;Coronavirus Infections__therapy;Humans;Pandemics;Pneumonia, Viral__therapy;Randomized Controlled Trials as Topic;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Microbiology and Infection | P C Fragkou;D Belhadi;N Peiffer-Smadja;C D Moschopoulos;F-X Lescure;H Janocha;E Karofylakis;Y Yazdanpanah;F Mentré;C Skevaki;C Laouénan;S Tsiodras | Anti-inflammatory;Antivirals;COVID-19;Clinical trials;Immunomodulators;Novel coronavirus;Pneumonia;Prevention;SARS-CoV-2;Treatment | 2020-05-23 02:00:00+02:00 | 32454187 | FR;GR;CH;DE | 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV), Switzerland. Electronic address: evita.fragou@gmail.com.;Université de Paris, IAME, INSERM, F-75018 Paris, France, Département d'Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat - Claude-Bernard, AP-HP, 75018 Paris, France.;Université de Paris, IAME, INSERM, F-75018 Paris, France, Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France.;4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.;Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL) Marburg, Germany.;European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV), Switzerland, Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL) Marburg, Germany.;4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV), Switzerland. | 819 | ||
| Letter | en | SARS-CoV-2 related liver impairment - perception may not be the reality. | https://www.ncbi.nlm.nih.gov/pubmed/32454042 | 2020-05-24 02:00:00+02:00 | pubmed | Cyriac Abby Philips;Rizwan Ahamed;Philip Augustine | 2020-05-23 02:00:00+02:00 | 32454042 | FR;IN | The Liver Unit and Monarch, Cochin Gastroenterology Group, Ernakulam Medical Center Hospital, Kochi, Kerala, India. Electronic address: abbyphilips@gmail.com.;The Liver Unit and Monarch, Cochin Gastroenterology Group, Ernakulam Medical Center Hospital, Kochi, Kerala, India. | 820 | ||||||||
| 10.1016/j.nedt.2020.104479 | Journal Article | en | Increasing global awareness of timely COVID-19 healthcare guidelines through FPV training tutorials: Portable public health crises teaching method. | https://www.ncbi.nlm.nih.gov/pubmed/32473497 | The current COVID-19 pandemic has prompted a timely response from the healthcare system train a large and diverse group of healthcare workers/responders swiftly. | 0260-6917 | 2020-05-24 02:00:00+02:00 | pubmed | Nurse Education Today | Maxime Ros;Lorenz S Neuwirth | COVID-19;Educational technology;Health personnel;Interactive tutorial;Mobile applications;Public health informatics;Video recording | 2020-05-21 02:00:00+02:00 | 32473497 | FR;US | REVINAX, Cap Omega, Montpellier, France, Education Sciences School - LIRDEF, Montpellier University, Montpellier, France. Electronic address: maxime.ros@revinax.net.;Psychology Department, SUNY, Old Westbury, NY, USA, SUNY Neuroscience Research Institute (NRI), SUNY, Old Westbury, NY, USA. | 825 | |||
| 10.1093/ckj/sfaa088 | Journal Article | en | Indirect effects of severe acute respiratory syndrome coronavirus 2 on the kidney in coronavirus disease patients. | https://www.ncbi.nlm.nih.gov/pubmed/32695325 | Among patients hospitalized for novel coronavirus disease (COVID-19), between 10 and 14% develop an acute kidney injury and around half display marked proteinuria and haematuria. Post-mortem analyses of COVID-19 kidney tissue suggest that renal tubular cells and podocytes are affected. Here we report two cases of collapsing glomerulopathy and tubulointerstitial lesions in living COVID-19 patients. Despite our use of sensitive reverse transcription polymerase chain reaction techniques in this study, we failed to detect the virus in blood, urine and kidney tissues. Our observations suggest that these kidney lesions are probably not due to direct infection of the kidney by severe acute respiratory syndrome coronavirus 2. | 2048-8505,2048-8513 | 2020-05-24 02:00:00+02:00 | pubmed | Clinical Kidney Journal | Aymeric Couturier;Sophie Ferlicot;Kévin Chevalier;Matthieu Guillet;Marie Essig;Stéphane Jauréguiberry;Rocco Collarino;Mathilde Dargelos;Alice Michaut;Guillaume Geri;Anne-Marie Roque-Afonso;Mohamad Zaidan;Ziad A Massy | APOL1;COVID-19;SARS-CoV-2;collapsing glomerulopathy;kidney disease | 2020-05-22 02:00:00+02:00 | 32695325 | FR | Service de Néphrologie et Dialyse, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Universitaire Ambroise Paré, Boulogne Billancourt, France.;INSERM U1018, Equipe 5, CESP (Centre de Recherche en Épidémiologie et Santé des Populations), Université Paris Saclay et Université Versailles Saint Quentin en Yvelines), Villejuif, France.;Service d'Anatomie Pathologique, Assistance Publique-Hôpitaux de Paris (APHP) Université Paris Saclay, Hôpital Universitaire Bicêtre, Kremlin Bicêtre, France.;Service de Maladies Infectieuses et Médecine Tropicales, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Universitaire Bicêtre, Kremlin Bicêtre, France.;Service de Néphrologie, Dialyse et Transplantation, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Universitaire Bicêtre, Kremlin Bicêtre, France.;Université Paris Saclay, Villejuif, France.;Service de MIR, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Universitaire Ambroise Paré, Boulogne Billancourt, France.;Service de Virologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Universitaire Paul Brousse, Villejuif, France. | 828 | |||
| 10.1212/wnl.0000000000009850 | Case Reports;Journal Article | en | Bilateral transient olfactory bulb edema during COVID-19-related anosmia. | https://www.ncbi.nlm.nih.gov/pubmed/32444492 | 0028-3878,1526-632X | 2020-05-24 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Brain Edema__diagnostic imaging;Coronavirus Infections__complications;Dysgeusia__etiology;Humans;Magnetic Resonance Imaging;Male;Olfaction Disorders__etiology;Olfactory Bulb__diagnostic imaging;Pandemics;Pneumonia, Viral__complications;COVID-19;severe acute respiratory syndrome coronavirus 2 | Neurology | Thomas Laurendon;Thomas Radulesco;Justine Mugnier;Mélanie Gérault;Christophe Chagnaud;Ahmed-Ali El Ahmadi;Arthur Varoquaux | 2020-05-22 02:00:00+02:00 | 32444492 | FR;GB;US | From the Departments of Medical Imaging (T.L., J.M., C.C., A.-A.E.A., A.V.) and ENT Surgery (T.R.), Conception University Hospital, and Center for Magnetic Resonance in Biology and Medicine (C.C., A.V.), UMR 7339, La Timone University Hospital, Aix-Marseille University, France, and Department of Earth, Atmospheric and Planetary Sciences (M.G.), Massachusetts Institute of Technology, Cambridge.;From the Departments of Medical Imaging (T.L., J.M., C.C., A.-A.E.A., A.V.) and ENT Surgery (T.R.), Conception University Hospital, and Center for Magnetic Resonance in Biology and Medicine (C.C., A.V.), UMR 7339, La Timone University Hospital, Aix-Marseille University, France, and Department of Earth, Atmospheric and Planetary Sciences (M.G.), Massachusetts Institute of Technology, Cambridge. arthur.varoquaux@ap-hm.fr Arthur@Varoquaux.com. | 829 | ||||
| 10.1093/chemse/bjaa034 | Journal Article | en | Relationship between odor intensity estimates and COVID-19 prevalence prediction in a Swedish population. | https://www.ncbi.nlm.nih.gov/pubmed/32441744 | In response to the COVID-19 pandemic, countries have implemented various strategies to reduce and slow the spread of the disease in the general population. For countries that have implemented restrictions on its population in a step-wise manner, monitoring of COVID-19 prevalence is of importance to guide decision on when to impose new, or when to abolish old, restrictions. We are here determining whether measures of odor intensity in a large sample can serve as one such measure. Online measures of how intense common household odors are perceived and symptoms of COVID-19 were collected from 2440 Swedes. Average odor intensity ratings were then compared to predicted COVID-19 population prevalence over time in the Swedish population and were found to closely track each other (r=-0.83). Moreover, we found that there was a large difference in rated intensity between individuals with and without COVID-19 symptoms and number of symptoms was related to odor intensity ratings. Finally, we found that individuals progressing from reporting no symptoms to subsequently reporting COVID-19 symptoms demonstrated a large drop in olfactory performance. These data suggest that measures of odor intensity, if obtained in a large and representative sample, can be used as an indicator of COVID-19 disease in the general population. Importantly, this simple measure could easily be implemented in countries without widespread access to COVID-19 testing or implemented as a fast early response before wide-spread testing can be facilitated. | 0379-864X,1464-3553 | 2020-05-24 02:00:00+02:00 | pubmed | Chemical Senses | Behzad Iravani;Artin Arshamian;Aharon Ravia;Eva Mishor;Kobi Snitz;Sagit Shushan;Yehudah Roth;Ofer Perl;Danielle Honigstein;Reut Weissgross;Shiri Karagach;Gernot Ernst;Masako Okamoto;Zachary Mainen;Erminio Monteleone;Caterina Dinnella;Sara Spinelli;Franklin Mariño-Sánchez;Camille Ferdenzi;Monique Smeets;Kazushige Touhara;Moustafa Bensafi;Thomas Hummel;Noam Sobel;Johan N Lundström | COVID-19;Coronavirus;anosmia;olfactory dysfunction;population prevalence | 2020-05-22 02:00:00+02:00 | 32441744 | SE;IL;NO;FR;PT;JP;US;IT;NL;ES;DE | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.;Department of Psychology, Stockholm University, Stockholm, Sweden.;Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel.;Department of Otolaryngology-Head and Neck Surgery, Edith Wolfson Medical Center, Holon, Israel.;Vestre Viken, Kongsberg hospital and Psychological institute, University in Oslo, Norway.;Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Japan.;Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal.;Department of Agriculture, Food, Environment and Forestry, University of Florence, Italy.;Rhinology and Skull Base Surgery Unit. Otorhinolaryngology Department. Ramón y Cajal University Hospital. Madrid, Spain.;Lyon Neuroscience Research Center, CNRS - INSERM - University Claude Bernard of Lyon.;Faculty of Social and Behavioral Sciences, Utrecht University, Utrecht, the Netherlands.;Smell and Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Dresden, Germany.;Monell Chemical Senses Center, Philadelphia, Pennsylvania. | 830 | |||
| 10.3389/fneur.2020.00516 | Journal Article | en | Medical and Paramedical Care of Patients With Cerebellar Ataxia During the COVID-19 Outbreak: Seven Practical Recommendations of the COVID 19 Cerebellum Task Force. | https://www.ncbi.nlm.nih.gov/pubmed/32574247 | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the cause of the current pandemic coronavirus disease 2019 (COVID-19), primarily targets the respiratory system. Some patients also experience neurological signs and symptoms ranging from anosmia, ageusia, headache, nausea, and vomiting to confusion, encephalitis, and stroke. Approximately 36% of those with severe COVID-19 experience neurological complications. The virus may enter the central nervous system through the olfactory nerve in the nasal cavity and damage neurons in the brainstem nuclei involved in the regulation of respiration. Patients with cerebellar ataxia (CA) are particularly vulnerable to severe outcome if they contract COVID-19 because of the complexity of their disease, the presence of comorbidities, and their use of immunosuppressive therapies. Most CA patients burdened by progressive neurologic deficits have substantially impaired mobility and other essential functions, for which they rely heavily on ambulatory services, including rehabilitation and psychosocial care. Cessation of these interventions because of isolation restrictions places the CA patient population at risk of further deterioration. This international panel of ataxia experts provides recommendations for neurologists caring for patients with CA, emphasizing a pro-active approach designed to maintain their autonomy and well-being: continue long-term medications, promote rehabilitation efforts, utilize the technology of virtual visits for regular contact with healthcare providers, and pay attention to emotional and psychosocial health. Neurologists should play an active role in decision-making in those CA cases requiring escalation to intensive care and resuscitation. Multi-disciplinary collaboration between care teams is always important, and never more so than in the context of the current pandemic. | 1664-2295 | 2020-05-24 02:00:00+02:00 | pubmed | Frontiers in Neurology | Mario Manto;Nicolas Dupre;Marios Hadjivassiliou;Elan D Louis;Hiroshi Mitoma;Marco Molinari;Aasef G Shaikh;Bing-Wen Soong;Michael Strupp;Frank Van Overwalle;Jeremy D Schmahmann | COVID-19;SARS-CoV-2;ataxia;cerebellum;therapies | 2020-05-22 02:00:00+02:00 | 32574247 | FR;CA;JP;GB;US;TW;IT;BE;DE | CHU-Charleroi and Service des Neurosciences, University of Mons, Mons, Belgium.;Department of Medicine, Faculty of Medicine, Université Laval & Neuroscience Axis, CHU de Québec-Université Laval, Quebec City, QC, Canada.;Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom.;Department of Neurology and Neurotherapeutics, University of Texas Southwestern, Dallas, TX, United States.;Department of Medical Education, Tokyo Medical University, Tokyo, Japan.;IRCCS Fondazione S. Lucia, Rome, Italy.;Department of Neurology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland VA Medical Center, Cleveland, OH, United States.;Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan.;Department of Neurology, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.;Department of Neurology, Taipei Veterans General Hospital, and Brain Research Center, National Yang-Ming University, Taipei, Taiwan.;Department of Neurology, Ludwig Maximilians University, Munich, Germany.;Brain, Body and Cognition Lab, Faculty of Psychology, Vrije Universiteit Brussel, Brussels, Belgium.;Ataxia Center, Cognitive Behavioral Neurology Unit, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. | 839 | |||
| 10.1021/acs.jpclett.0c00571 | Journal Article | en | Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks. | https://www.ncbi.nlm.nih.gov/pubmed/32392072 | The pandemic outbreak of a new coronavirus (CoV), SARS-CoV-2, has captured the world's attention, demonstrating that CoVs represent a continuous global threat. As this is a highly contagious virus, it is imperative to understand RNA-dependent-RNA-polymerase (RdRp), the key component in virus replication. Although the SARS-CoV-2 genome shares 80% sequence identity with severe acute respiratory syndrome SARS-CoV, their RdRps and nucleotidyl-transferases (NiRAN) share 98.1% and 93.2% identity, respectively. Sequence alignment of six coronaviruses demonstrated higher identity among their RdRps (60.9%-98.1%) and lower identity among their Spike proteins (27%-77%). Thus, a 3D structural model of RdRp, NiRAN, non-structural protein 7 (nsp7), and nsp8 of SARS-CoV-2 was generated by modeling starting from the SARS counterpart structures. Furthermore, we demonstrate the binding poses of three viral RdRp inhibitors (Galidesivir, Favipiravir, and Penciclovir), which were recently reported to have clinical significance for SARS-CoV-2. The network of interactions established by these drug molecules affirms their efficacy to inhibit viral RNA replication and provides an insight into their structure-based rational optimization for SARS-CoV-2 inhibition. | 1948-7185,1948-7185 | 2020-05-24 02:00:00+02:00 | pubmed | Adenine__analogs & derivatives;Amides__chemistry;Antiviral Agents__chemistry;Betacoronavirus__enzymology;Binding Sites;Coronavirus Infections__epidemiology;Humans;Molecular Docking Simulation;Nucleotidyltransferases__chemistry;Pandemics;Pneumonia, Viral__epidemiology;Protein Structure, Tertiary;Pyrazines__chemistry;Pyrrolidines__chemistry;RNA Replicase__chemistry;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Journal of Physical Chemistry Letters | Wen-Fa Zhang;Preyesh Stephen;Jean-François Thériault;Ruixuan Wang;Sheng-Xiang Lin | 2020-05-22 02:00:00+02:00 | 32392072 | FR;CA | Axe Molecular Endocrinology and Nephrology, CHU Research Center and Laval University, Québec City, Québec G1 V 4G2, Canada.;Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario K7L 3N6, Canada. | 840 | |||
| 10.1007/s10308-020-00577-0 | Journal Article | en | Governmental responses to COVID-19 and its economic impact: a brief Euro-Asian comparison. | https://www.ncbi.nlm.nih.gov/pubmed/32837470 | 1610-2932,1612-1031 | 2020-05-24 02:00:00+02:00 | pubmed | Asia Europe Journal | Frauke Austermann;Wei Shen;Assen Slim | 2020-05-22 02:00:00+02:00 | 32837470 | FR;AU | EU Asia Institute of ESSCA School of Management, Angers, France.;Deakin University, Melbourne, Australia.;ESSCA School of Management, Paris, France.;INALCO, Paris, France. | 845 | |||||
| 10.1016/j.jinf.2020.05.031 | Journal Article | en | Severe air pollution links to higher mortality in COVID-19 patients: The "double-hit" hypothesis. | https://www.ncbi.nlm.nih.gov/pubmed/32447007 | In areas of SARS-CoV-2 outbreak worldwide mean air pollutants concentrations vastly exceed the maximum limits. Chronic exposure to air pollutants have been associated with lung ACE-2 over-expression which is known to be the main receptor for SARS-CoV-2. The aim of this study was to analyse the relationship between air pollutants concentration (PM 2.5 and NO2) and COVID-19 outbreak, in terms of transmission, number of patients, severity of presentation and number of deaths. | 0163-4453 | 2020-05-24 02:00:00+02:00 | pubmed | Air Pollutants__adverse effects;Air Pollution__adverse effects;Betacoronavirus;Coronavirus Infections__epidemiology;Disease Outbreaks__statistics & numerical data;Hospitalization__statistics & numerical data;Humans;Intensive Care Units__statistics & numerical data;Italy__epidemiology;Nitrogen Dioxide__adverse effects;Pandemics;Particulate Matter__adverse effects;Pneumonia, Viral__epidemiology;Risk Factors;Severity of Illness Index;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Infection | Antonio Frontera;Lorenzo Cianfanelli;Konstantinos Vlachos;Giovanni Landoni;George Cremona | 2020-05-21 02:00:00+02:00 | 32447007 | FR;IT | IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy. Electronic address: frontera.antonio@hsr.it.;IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy. Electronic address: cianfanelli.lorenzo@hsr.it.;University of Bordeaux, France.;IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy, Vita-Salute San Raffaele University of Milan, Italy. Electronic address: landoni.giovanni@hsr.it.;IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy. Electronic address: cremona.george@hsr.it. | 846 | |||
| 10.1002/pds.5029 | Journal Article;Review | en | Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32369865 | The coronavirus disease 2019 (COVID-19) pandemic has triggered several hypotheses regarding use of specific medicines and risk of infection as well as prognosis. Under these unique circumstances, rapid answers require quick engagement in data collection and analyses; however, appropriate design and conduct of pharmacoepidemiologic studies are needed to generate valid and reliable evidence. In this paper, endorsed by the International Society for Pharmacoepidemiology, we provide methodological considerations for the conduct of pharmacoepidemiological studies in relation to the pandemic across eight domains: (1) timeliness of evidence, including the need to prioritise some questions over others in the acute phase of the pandemic; (2) the need to align observational and interventional research on efficacy; (3) the specific challenges related to "real-time epidemiology" during an ongoing pandemic; (4) what design to use to answer a specific question; (5) considerations on the definition of exposures; (6) what covariates to collect; (7) considerations on the definition of outcomes; and (8) the need for transparent reporting. | 1053-8569,1099-1557 | 2020-05-24 02:00:00+02:00 | pubmed | Pharmacoepidemiology and Drug Safety | Anton Pottegård;Xavier Kurz;Nicholas Moore;Christian F Christiansen;Olaf Klungel | COVID-19;bias;methodology;pharmacoepidemiology | 2020-05-21 02:00:00+02:00 | 32369865 | FR;DK;NL | Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.;Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands.;Bordeaux PharmacoEpi, University of Bordeaux, Bordeaux, France.;Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.;Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands. | 867 | |||
| 10.1016/j.encep.2020.05.010 | Journal Article;Review | fr | [Panic and pandemic: Review of the literature on the links between panic disorder and the SARS-CoV-2 epidemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32507556 | Although the "panic" word has been abundantly linked to the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic in the press, in the scientific literature very few studies have considered whether the current epidemic could predispose to the onset or the aggravation of panic attacks or panic disorder. Indeed, most studies thus far have focused on the risk of increase and aggravation of other psychiatric disorders as a consequence of the SARS-CoV-2 epidemic, such as obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and generalized anxiety disorder (GAD). Yet, risk of onset or aggravation of panic disorder, especially the subtype with prominent respiratory symptoms, which is characterized by a fear response conditioning to interoceptive sensations (e.g., respiratory), and hypervigilance to these interoceptive signals, could be expected in the current situation. Indeed, respiratory symptoms, such as coughs and dyspnea, are among the most commonly associated with the SARS-CoV-2 (59-82% and 31-55%, respectively), and respiratory symptoms are associated with a poor illness prognosis. Hence given that some etiological and maintenance factors associated with panic disorder - i.e., fear conditioning to abnormal breathing patterns attributable or not to the COVID-19 (coronavirus disease 2019), as well as hypervigilance towards breathing abnormalities - are supposedly more prevalent, one could expect an increased risk of panic disorder onset or aggravation following the COVID-19 epidemic in people who were affected by the virus, but also those who were not. In people with the comorbidity (i.e., panic disorder or panic attacks and the COVID-19), it is particularly important to be aware of the risk of hypokalemia in specific at-risk situations or prescriptions. For instance, in the case of salbutamol prescription, which might be overly used in patients with anxiety disorders and COVID-19, or in patients presenting with diarrhea and vomiting. Hypokalemia is associated with an increased risk of torsade de pointe, thus caution is required when prescribing specific psychotropic drugs, such as the antidepressants citalopram and escitalopram, which are first-line treatments for panic disorder, but also hydroxyzine, aiming at anxiety reduction. The results reviewed here highlight the importance of considering and further investigating the impact of the current pandemic on the diagnosis and treatment of panic disorder (alone or comorbid with the COVID-19). | 0013-7006 | 2020-05-24 02:00:00+02:00 | pubmed | Anxiety__etiology;Anxiety Disorders__drug therapy;Betacoronavirus;Catastrophization;Comorbidity;Coronavirus Infections__epidemiology;Dyspnea__etiology;Female;Humans;Hypokalemia__etiology;Male;Pandemics;Panic Disorder__drug therapy;Pneumonia, Viral__epidemiology;Psychotropic Drugs__adverse effects;Renin-Angiotensin System__physiology;Respiration__drug effects;Stress, Psychological__etiology;Terminology as Topic;Torsades de Pointes__chemically induced;COVID-19;severe acute respiratory syndrome coronavirus 2 | L'Encéphale | H Javelot;L Weiner | Attaque de panique;COVID-19;Panic attack;Panic disorder;SARS-Cov-2;Trouble panique | 2020-05-21 02:00:00+02:00 | 32507556 | FR | Établissement Public de Santé Alsace Nord (EPSAN), Brumath, France, Laboratoire de toxicologie et pharmacologie neurocardiovasculaire, université de Strasbourg, Strasbourg, France. Electronic address: herve.javelot@ch-epsan.fr.;Clinique de psychiatrie, CHU de Strasbourg, Strasbourg, France, Laboratoire de psychologie des cognitions, université de Strasbourg, Strasbourg, France. | 868 | ||
| 10.3390/jcm9061651 | Journal Article;Review | en | COVID-19 Related Coagulopathy: A Distinct Entity? | https://www.ncbi.nlm.nih.gov/pubmed/32486469 | The coronavirus disease 2019 (COVID-19) pandemic has impacted healthcare communities across the globe on an unprecedented scale. Patients have had diverse clinical outcomes, but those developing COVID-19-related coagulopathy have shown a disproportionately worse outcome. This narrative review summarizes current evidence regarding the epidemiology, clinical features, known and presumed pathophysiology-based models, and treatment guidance regarding COVID-19 coagulopathy. | 2077-0383 | 2020-05-31 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Benjamin Marchandot;Laurent Sattler;Laurence Jesel;Kensuke Matsushita;Valerie Schini-Kerth;Lelia Grunebaum;Olivier Morel | COVID-19;antiphospholipid antibodies;coronavirus disease 2019;endothelium;hemostasis;microparticles;thrombosis | 2020-05-31 02:00:00+02:00 | 32486469 | FR | Université de Strasbourg, Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, 67000 Strasbourg, France.;Université de Strasbourg, Pôle de Biologie, Département d'Hémostase, Centre Hospitalier Universitaire, 67000 Strasbourg, France.;UMR INSERM 1260, Regenerative Nanomedicine, Faculté de Pharmacie, Université de Strasbourg, 67400 Illkirch, France. | 872 | |||
| Journal Article;Comment | en | Commentary: Gamifying teleconsultation during COVID-19 lockdown. | https://www.ncbi.nlm.nih.gov/pubmed/32461417 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Electronic Health Records;Humans;India;Pandemics;Patient Care;Pneumonia, Viral;Remote Consultation;COVID-19;severe acute respiratory syndrome coronavirus 2 | John D Akkara;Anju Kuriakose | 2020-05-29 02:00:00+02:00 | 32461417 | FR;IN | Department of Ophthalmology, Little Flower Hospital and Research Centre, Angamaly, Cataract and Glaucoma Services, Westend Eye Hospital, Cochin, Kerala, India.;Department of Retina, Aravind Eye Hospital, Chennai, Tamil Nadu, India. | 880 | |||||||
| 10.1093/cid/ciaa688 | Journal Article | en | Household COVID-19 Prevalence. | https://www.ncbi.nlm.nih.gov/pubmed/32474601 | 1058-4838,1537-6591 | 2020-05-31 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Emmanuel Mandonnet;Jean-Michel Molina | 2020-05-31 02:00:00+02:00 | 32474601 | FR | Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France.;Paris University, Paris, France.;Frontlab, ICM, INSERM U1127, Paris, France.;Department of Infectious Diseases, Saint-Louis Hospital, Paris, France.;INSERM UMR-S-941, Paris, France. | 887 | |||||
| 10.1007/s10067-020-05200-6 | Journal Article | en | Switching to teleconsultation for rheumatology in the wake of the COVID-19 pandemic: feasibility and patient response in India. | https://www.ncbi.nlm.nih.gov/pubmed/32474883 | The emergent COVID-19 pandemic dictates an urgent switch to teleconsultation. India has high patient to rheumatologist ratio, and patients have limited concepts about telemedicine. Thus, we attempted to find the feasibility and acceptance of patients in switching to teleconsultation. The CARE rheumatology clinic at Kerala, India, caters to average 170 (range: 140-240) patients per day. Patients with prefixed appointments had two-level screening for eligibility for teleconsultation. Those eligible were given the option for teleconsultation on the widely available WhatsApp app. Of those who completed teleconsultations, 100 were chosen at random to provide feedback. In the first 7 days, out of 1469 appointments, 975 were found eligible for teleconsultation. Of these, 723 (74%) opted for it. The average footfall in the clinic was reduced to 67 (range 29-117). The proportion of patients accepting teleconsultations increased with time. Amongst the 100 respondents, median satisfaction was 9 (IQR 8-10) and recommendation for continuing was 9.5 (IQR 8-10) on a 0-10 scale. Multivariate analysis showed the recommendation score was dependent on beliefs about social distancing, perceptions about clinical examination, and the satisfaction score of the first teleconsultation. Age, sex, availability of personal video conferencing app or of vehicles did not independently influence this score. Without teleconsultation facilities, three-fourths of the respondents would have stopped drugs or self-medicated. The switch was feasible and accepted by patients. It enabled quick reduction in the number of persons travelling to the centre. Not making the switch could have deprived approximately three-quarters of these patients of proper medical care. Key Points • Patient to rheumatologist ratios in India is heavily skewed and awareness about telemedicine is limited. • Switch to telemedicine was feasible and allowed a decrease in the number of people attending the clinic. • Not switching could have lead to disruption of care or self-medication in a majority of patients. | 0770-3198,1434-9949 | 2020-05-31 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections__epidemiology;Delivery of Health Care;Feasibility Studies;Female;Humans;India__epidemiology;Male;Middle Aged;Multivariate Analysis;Pandemics;Patient Acceptance of Health Care;Patient Satisfaction;Pneumonia, Viral__epidemiology;Remote Consultation__methods;Rheumatology__methods;Telemedicine;Videoconferencing;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Rheumatology | Padmanabha Shenoy;Sakir Ahmed;Aby Paul;Teny Grace Skaria;Joel Joby;Bazil Alias | COVID-19;Social distancing;Telemedicine;Telerheumatology;Video consultation | 2020-05-30 02:00:00+02:00 | 32474883 | FR;IN | Centre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Cochin, India. drdpshenoy@gmail.com.;Department of Clinical Immunology & Rheumatology, Kalinga Institute of Medical Sciences (KIMS), KIIT University, Bhubaneswar, 751024, India.;Centre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Cochin, India. | 888 | ||
| Letter | en | Mobile phones: A forgotten source of SARS-CoV-2 transmission. | https://www.ncbi.nlm.nih.gov/pubmed/32464293 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Cell Phone;Coronavirus Infections__transmission;Humans;Pandemics;Pneumonia, Viral__transmission;COVID-19;severe acute respiratory syndrome coronavirus 2 | Tony Ibrahim;Ali N Chamseddine;Maria Baz | 2020-05-26 02:00:00+02:00 | 32464293 | FR | International Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: tony.ibrahim@gustaveroussy.fr.;International Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Tumor Biology Department, Gustave Roussy Cancer Campus, Villejuif, France. | 890 | |||||||
| 10.1080/17441692.2020.1771396 | Journal Article | en | Unmet healthcare needs among migrants without medical insurance in Montreal, Canada. | https://www.ncbi.nlm.nih.gov/pubmed/32459571 | While access to healthcare for permanent residents in Canada is well known, this is not the case for migrants without healthcare coverage. This is the first large-scale study that examines the unmet healthcare needs of migrants without healthcare coverage in Montreal. 806 participants were recruited: 436 in the community and 370 at the NGO clinic. Proportions of individuals reporting unmet healthcare needs were similar (68.4% vs. 69.8%). The main reason invoked for these unmet needs was lacking money (80.6%). Situations of not working or studying, not having had enough food in the past 12 months, not having a medical prescription to get medication and having had a workplace injury were all significantly associated with higher odds of having unmet healthcare needs. Unmet healthcare needs were more frequent among migrants without healthcare coverage than among recent immigrants or the citizens with health healthcare coverage (69%, 26%, 16%). Canada must take measures to enable these individuals to have access to healthcare according to their needs in order to reduce the risk of worsening their health status, something that may have an impact on the healthcare system and population health. The Government of Quebec announced that all individuals without any healthcare coverage will have access to COVID-19 related health care. We hope that this right, the application of which is not yet obvious, can continue after the pandemic for all health care. | 1744-1692,1744-1706 | 2020-05-31 02:00:00+02:00 | pubmed | Global Public Health | Valéry Ridde;Joséphine Aho;Elhadji Malick Ndao;Magalie Benoit;Jill Hanley;Solène Lagrange;Amandine Fillol;Marie-France Raynault;Patrick Cloos | Canada;Quebec;Universal health coverage;access to care;medical insurance;migrants;undocumented;unmet healthcare needs | 2020-05-27 02:00:00+02:00 | 32459571 | FR;SN;CA | IRD (French Institute For Research on sustainable Development), CEPED (IRD-Université de Paris), ERL INSERM SAGESUD, Dakar, Senegal.;University of Montreal School of Public Health, Montreal, Canada.;School of Social Work, McGill University, Quebec, Canada.;Centre de recherche Léa Roback sur les inégalités sociales de santé de Montréal, University of Montreal, Montréal, Canada.;Centre de recherche en santé publique, Montréal, Canada. | 904 | |||
| 10.1016/j.ypmed.2020.106150 | Journal Article | en | Prevention is life- and cost-saving. | https://www.ncbi.nlm.nih.gov/pubmed/32473263 | 0091-7435 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__economics;Cost Savings;Cost-Benefit Analysis;Humans;Pandemics__economics;Pneumonia, Viral__economics;Quality-Adjusted Life Years;COVID-19;severe acute respiratory syndrome coronavirus 2 | Preventive Medicine | Iacopo Baussano;Rengaswamy Sankaranarayanan;Elisabete Weiderpass | Cancer;Covid-19;Prevention | 2020-05-27 02:00:00+02:00 | 32473263 | FR;IN | International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. Electronic address: baussanoi@iarc.fr.;RTI International India, 6th Floor, Pullman Commercial Tower, Aero City, 110037 New Delhi, India.;International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. Electronic address: WeiderpassE@iarc.fr. | 910 | |||
| 10.1016/j.anorl.2020.05.013 | Journal Article | en | Keys for analysis of diagnostic and serologic tests for CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32473864 | Based on a review of the medical literature, the authors document the key points regarding the tests available in France to screen for and diagnose of CoV-2 infestation. | 1879-7296 | 2020-05-31 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | O Laccourreye;R Cohen;V Couloigner | COVID-19;SARS-CoV-2;Screening;Tests | 2020-05-27 02:00:00+02:00 | 32473864 | FR | Service d'Otorhinolaryngologie, Université Paris-Centre, Hôpital Européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France. Electronic address: ollivier.laccourreye@aphp.fr.;Service de Pédiatrie, Université Paris-Est, Centre Hospitalier Intercommunal, 40, avenue de Verdun, 94000 Créteil, France.;Service d'Otorhinolaryngologie, Université Paris-Centre, Hôpital Necker-Enfants malades, AP-HP, 149, rue de Sèvres, 75015 Paris, France. | 913 | |||
| Letter | en | Contribution of certified registered nurse anaesthetists to the management of the COVID-19 pandemic health crisis. | https://www.ncbi.nlm.nih.gov/pubmed/32536514 | 2020-05-31 02:00:00+02:00 | pubmed | Amina Ouersighni;Daniel Aiham Ghazali | 2020-05-26 02:00:00+02:00 | 32536514 | FR | Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Universitaire Paris Nord Val de Seine, EMS of Beaujon Academic Hospital, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Universitaire Paris Nord Val de Seine, Emergency Department of Bichat Academic Hospital, Paris, France, Infection Antimicrobials Modelling Evolution (IAME) research Center, UMR 1137 - INSERM, University of Paris Diderot, Paris, France. Electronic address: danielaiham.ghazali@aphp.fr. | 918 | ||||||||
| 10.1007/s00264-020-04619-5 | Journal Article;Observational Study | en | Staying home during "COVID-19" decreased fractures, but trauma did not quarantine in one hundred and twelve adults and twenty eight children and the "tsunami of recommendations" could not lockdown twelve elective operations. | https://www.ncbi.nlm.nih.gov/pubmed/32451655 | The current pandemic caused by COVID-19 is the biggest challenge for national health systems for a century. While most medical resources are allocated to treat COVID-19 patients, fractures still need to be treated, as some patients with non-deferrable pathologies. The aim of this paper is to report the early experience of an integrated team of orthopaedic surgeons during this period. | 0341-2695,1432-5195 | 2020-05-31 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus;Child;Child, Preschool;Coronavirus Infections;Elective Surgical Procedures;Emergency Service, Hospital;Female;Fractures, Bone__epidemiology;Humans;Infant;Length of Stay;Male;Middle Aged;Pandemics;Pneumonia, Viral;Quarantine;Retrospective Studies;Wounds and Injuries__epidemiology;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Orthopaedics | Jacques Hernigou;Xavier Morel;Antoine Callewier;Olivier Bath;Philippe Hernigou | Adult trauma;COVID-19;Children fractures;Dislocation;Fracture;Lockdown;Paediatrics;Quarantine;Recommendation;Sprain | 2020-05-25 02:00:00+02:00 | 32451655 | FR;BE | EpiCURA Hospital, Orthopedic Department, Baudour, Hornu, Belgium.;Hospital Henri Mondor, University of Paris-Est, Creteil, France. philippe.hernigou@wanadoo.fr. | 920 | ||
| Letter;Comment | en | Rethinking the role of the school after COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32464100 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Health Literacy;Humans;Pandemics;Pneumonia, Viral;COVID-19;severe acute respiratory syndrome coronavirus 2 | Annamaria Colao;Prisco Piscitelli;Manuela Pulimeno;Salvatore Colazzo;Alessandro Miani;Stefania Giannini | 2020-05-25 02:00:00+02:00 | 32464100 | FR;IT | UN Educational, Scientific and Cultural Organisation (UNESCO) Chair on Health Education and Sustainable Development, Federico II University, Naples 80131, Italy.;UN Educational, Scientific and Cultural Organisation (UNESCO) Chair on Health Education and Sustainable Development, Federico II University, Naples 80131, Italy, Italian Society of Environmental Medicine, Milan, Italy. Electronic address: piscitelli@unescochairnapoli.it.;UN Educational, Scientific and Cultural Organisation (UNESCO) Chair on Health Education and Sustainable Development, Federico II University, Naples 80131, Italy, Human Relations Sciences, University of Bari Aldo Moro, Bari, Italy.;UN Educational, Scientific and Cultural Organisation (UNESCO) Chair on Health Education and Sustainable Development, Federico II University, Naples 80131, Italy, Department of History, Society, and Human Studies, University of Salento, Lecce, Italy.;UN Educational, Scientific and Cultural Organisation (UNESCO) Chair on Health Education and Sustainable Development, Federico II University, Naples 80131, Italy, Italian Society of Environmental Medicine, Milan, Italy.;UNESCO Assistant Director General for Education, Paris, France. | 926 | |||||||
| 10.1016/j.lungcan.2020.05.029 | Journal Article;Review | en | Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32585497 | COVID-19 has spread around the planet, sending billions of people into lockdown as health services struggle to cope. Meanwhile in Asia, where the disease began, the spread continues, in China it seems for now to have passed its peak. Italy, Spain, France, UK, and the US have been the countries more affected in terms of deaths. The coronavirus is more dangerous to the elderly and those with certain pre-existing medical conditions which is precisely the profile of lung cancer patients. Essential cancer services should be delivered but all steps should be taken to protect patients and the health workforce from infection with COVID-19. This presents a major challenge to radiotherapy (RT) departments worldwide. An international panel with expertise in the management of lung cancer in high-volume comprehensive centres has come together to share its experience on COVID-19 preparedness to deliver optimal care in such exceptional circumstances. A comprehensive systematic review of the literature through a PubMed search was undertaken. Twelve recommendations including, among others, the consideration of shorter courses, delays, and the omission of RT for lung cancer are proposed by the panel. In summary, we recommend the screening of every single person accessing the treatment room, the consideration of hypofractionation and to delay postoperative RT for non-small cell lung cancer, to avoid twice-daily treatments and delay or deliver prophylactic cranial irradiation during radio(chemo)therapy for limited-stage small cell lung cancer, review image guided RT images for suspicious image findings, and the use of single-fraction RT for the palliative treatment of stage IV lung cancer patients. Given that lung cancer is one of the most common and severe pathologies in radiation oncology departments, the following recommendations require particularly urgent consideration. The decision-making paths strongly depend on locally available resources, and a tailored approach should be used to attend lung cancer patients during this pandemic. | 0169-5002 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Carcinoma, Non-Small-Cell Lung__complications;China__epidemiology;Coronavirus Infections__complications;Disease Outbreaks;Dose Fractionation, Radiation;France__epidemiology;Humans;Italy__epidemiology;Palliative Care__methods;Pandemics;Pneumonia, Viral__complications;Small Cell Lung Carcinoma__complications;Spain__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Lung Cancer | Zhongxing Liao;Eleonor Rivin Del Campo;Ahmed Salem;Qingsong Pang;Hui Liu;Jose Luis Lopez Guerra | COVID-19;Lung cancer;Outbreak;Pandemic;Radiation therapy | 2020-05-26 02:00:00+02:00 | 32585497 | FR;CN;GB;US;ES | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: zliao@mdanderson.org.;Department of Radiation Oncology, Tenon University Hospital, Sorbonne University, 4 Rue de la Chine, 75020 Paris, France.;Division of Cancer Sciences, University of Manchester, United Kingdom, Department of Clinical Oncology, The Christie Hospital NHS Trust, Manchester, United Kingdom.;Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.;Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.;Department of Radiation Oncology, University Hospital Virgen del Rocío, Avda. Manuel Siurot s/n, 41013 Seville, Spain, Instituto de Biomedicina de Sevilla, Universidad de Sevilla-CSIC-Hospital Universitario V. del Rocío, Avda. Manuel Siurot s/n, 41013 Seville, Spain. Electronic address: chanodetriana@yahoo.es. | 937 | ||
| Letter | en | Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children. | https://www.ncbi.nlm.nih.gov/pubmed/32455505 | 2020-05-31 02:00:00+02:00 | pubmed | P Labé;A Ly;C Sin;M Nasser;E Chapelon-Fromont;P Ben Saïd;E Mahé | 2020-05-26 02:00:00+02:00 | 32455505 | FR | Pediatric Department, Hôpital Victor Dupouy, Argenteuil, France.;Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France. | 938 | ||||||||
| Letter | en | Implementation of Medical and Scientific Cooperation in the Caribbean Using Blockchain Technology in Coronavirus (Covid-19) Pandemics. | https://www.ncbi.nlm.nih.gov/pubmed/32458071 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Blockchain;Capacity Building__organization & administration;Caribbean Region__epidemiology;Communicable Disease Control__organization & administration;Cooperative Behavior;Coronavirus Infections__epidemiology;Health Resources__organization & administration;Humans;Information Dissemination;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Dabor Resiere;Dajour Resiere;Hatem Kallel | 2020-05-26 02:00:00+02:00 | 32458071 | FR;MQ;US | Department of Intensive Care Unit, University Hospital of Martinique, CS 90632, 97261, Fort-de-France, Martinique. dabor.resiere@chu-martinique.fr.;Morehouse College, Atlanta, GA, USA.;Department of Intensive Care Unit, Cayenne General Hospital, Av des flamboyant, Cayenne, French Guiana. | 944 | |||||||
| 10.1007/s00384-020-03622-x | Journal Article;Multicenter Study | en | From high volume to "zero" proctology: Italian experience in the COVID era. | https://www.ncbi.nlm.nih.gov/pubmed/32468103 | The coronavirus disease 2019 (COVID-19) pandemic hit Italy early and strongly, challenging the whole health care system. Proctological patients and surgeons are experiencing a previously unseen change in care with unknown repercussion. Here we discuss the proctological experience of 4 Italian hospitals during the COVID-19 pandemic. | 0179-1958,1432-1262 | 2020-05-31 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Elective Surgical Procedures__methods;Female;Humans;Infection Control__methods;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Italy;Male;Occupational Health__statistics & numerical data;Outcome Assessment, Health Care;Pandemics__prevention & control;Patient Safety__statistics & numerical data;Pneumonia, Viral__epidemiology;Proctectomy__methods;Risk Assessment;Telemedicine__statistics & numerical data;COVID-19 | International Journal of Colorectal Disease | Domenico Mascagni;Chiara Eberspacher;Pietro Mascagni;Alberto Arezzo;Francesco Selvaggi;Alessandro Sturiale;Giovanni Milito;Gabriele Naldini | Covid-19;Pandemic;Proctology;Telemedicine | 2020-05-29 02:00:00+02:00 | 32468103 | FR;IT | Department of Surgical Sciences, Policlinico Umberto I, "Sapienza" University of Rome, Viale Regina Elena 324, 00100, Rome, Italy. dmascagni@tiscali.it.;Department of Surgical Sciences, Policlinico Umberto I, "Sapienza" University of Rome, Viale Regina Elena 324, 00100, Rome, Italy.;IHU Strasbourg - Institute of Image-Guided Surgery, Strasbourg, France.;Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.;Department of Surgical Sciences, University of Turin, Turin, Italy.;Colorectal Surgery, Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy.;Proctological and Perineal Surgical Unit, Universitary Hospital of Pisa, Pisa, Italy.;Tor Vergata University, Rome, Italy. | 951 | ||
| 10.1016/j.jgar.2020.05.006 | Journal Article | en | Vitamin D deficiency and the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32474141 | 2213-7165 | 2020-05-31 02:00:00+02:00 | pubmed | Journal of Global Antimicrobial Resistance | Patrick Zemb;Peter Bergman;Carlos A Camargo;Etienne Cavalier;Catherine Cormier;Marie Courbebaisse;Bruce Hollis;Fabrice Joulia;Salvatore Minisola;Stefan Pilz;Pawel Pludowski;François Schmitt;Mihnea Zdrenghea;Jean-Claude Souberbielle | Covid-19;Vitamin D;coronavirus;respiratory infections | 2020-05-29 02:00:00+02:00 | 32474141 | FR;SE;RO;US;IT;PL;BE;AT | Gynecology Department, Centre hospitalier de Lorient, Lorient, France. Electronic address: patrick.zemb@orange.fr.;Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.;Department of Clinical Chemistry, University of Liège, CHU de Liège, Liège, Belgium.;Department of Rheumatology, Cochin Hospital, AP-HP, Paris, France.;Department of Physiology, Georges Pompidou European Hospital, AP-HP, Paris, France.;Medical University of South Carolina, Charleston, SC, USA.;Center of Research in Cardiovascular and Nutrition (C2VN), Aix-Marseille University & INSERM 1260, France.;Department of Clinical, Internal, Anaesthesiologic and Cardiovascular Sciences, 'Sapienza', Rome University, Viale del Policlinico 155, Rome, 00161 Italy.;Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.;Department of Biochemistry, Radioimmunology and Experimental Medicine, The Children's Memorial Health Institute, Warsaw, Poland.;Department of Laboratory Medicine, Centre hospitalier de Lorient, Lorient, France.;Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.;Department of Physiology, Necker-Enfants malades hospital, AP-HP, Paris, France. | 952 | ||||
| 10.1016/s2665-9913(20)30164-8 | Journal Article | en | Anakinra for severe forms of COVID-19: a cohort study. | https://www.ncbi.nlm.nih.gov/pubmed/32835245 | Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress among patients with COVID-19. We aimed to assess the off-label use of anakinra in patients who were admitted to hospital for severe forms of COVID-19 with symptoms indicative of worsening respiratory function. | 2665-9913 | 2020-05-31 02:00:00+02:00 | pubmed | The Lancet Rheumatology | Thomas Huet;Hélène Beaussier;Olivier Voisin;Stéphane Jouveshomme;Gaëlle Dauriat;Isabelle Lazareth;Emmanuelle Sacco;Jean-Marc Naccache;Yvonnick Bézie;Sophie Laplanche;Alice Le Berre;Jérôme Le Pavec;Sergio Salmeron;Joseph Emmerich;Jean-Jacques Mourad;Gilles Chatellier;Gilles Hayem | 2020-05-29 02:00:00+02:00 | 32835245 | FR | Rheumatology Department, Hôpital Paris Saint-Joseph, Paris, France.;Clinical Research Centre, Hôpital Paris Saint-Joseph, Paris, France.;Internal Medicine Department, Hôpital Paris Saint-Joseph, Paris, France.;Pulmonology Department, Hôpital Paris Saint-Joseph, Paris, France.;Division of Lung Transplantation and Thoracic Surgery, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Vascular Medicine Department, Hôpital Paris Saint-Joseph, Paris, France.;Pharmacy Department, Hôpital Paris Saint-Joseph, Paris, France.;Biochemistry and Microbiology Department, Hôpital Paris Saint-Joseph, Paris, France.;Radiology Department, Hôpital Paris Saint-Joseph, Paris, France.;Université de Paris, INSERM 1153-CRESS, Paris, France.;Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Université de Paris, CIC 14-18 INSERM, Paris, France. | 953 | ||||
| Journal Article;Comment | en | Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure". | https://www.ncbi.nlm.nih.gov/pubmed/32471831 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Heart Failure;Humans;Pandemics;Pneumonia, Viral;Renin-Angiotensin System;COVID-19;severe acute respiratory syndrome coronavirus 2 | David S Fedson;Steven M Opal;Ole Martin Rordam | COVID-19;angiotensin converting enzyme inhibitors;angiotensin receptor blockers;neprilysin inhibitors;statins | 2020-05-29 02:00:00+02:00 | 32471831 | FR;NO;US | 57, chemin du Lavoir, Sergy Haut, France davidsfedson@gmail.com.;Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA.;Fyordgata 59, Trondheim, Norway. | 957 | ||||||
| 10.1016/j.jemep.2020.100538 | English Abstract;Journal Article;Review | fr | [From the intimate to the collective, multi-traumas are in process: Let's dare to prevent rather than cure, let's dare an ethical policy]. | https://www.ncbi.nlm.nih.gov/pubmed/32835056 | The COVID-19 epidemic, its mortality, the uncertainties that persist on its origin, its evolution, the period of confinement and its consequences lead to situations of anxiety and even anguish to the point of trauma for some people. While these are naturally legitimate, this does not mean that they should not be taken seriously, and benefit from appropriate care as soon as they have a significant impact on the lives of individuals, knowing that prevention remains the best form of care. | 2352-5525 | 2020-05-31 02:00:00+02:00 | pubmed | Ethics, Medicine and Public Health | M Baranes | COVID-19;PTSD;Prevention;Screening | 2020-05-29 02:00:00+02:00 | 32835056 | FR | Hôpital universitaire Pitié-Salpêtrière, service d'oncologie radiothérapie, 83, boulevard de l'Hôpital, 75013 Paris, France. | 962 | |||
| 10.1016/j.jpp.2020.05.001 | Editorial | fr | [Back to school and COVID-19: It is urgent to control our fears and move forward for the good of children]. | https://www.ncbi.nlm.nih.gov/pubmed/32508483 | 0987-7983 | 2020-05-31 02:00:00+02:00 | pubmed | Journal de Pédiatrie et de Puériculture | C Delacourt;C Gras-Le Guen;E Gonzales | 2020-05-30 02:00:00+02:00 | 32508483 | FR | Société française de pédiatrie, 149, rue de Sèvres, 75015 Paris, France. | 967 | |||||
| 10.1093/cid/ciaa682 | Journal Article | en | A Conceptual Discussion about R0 of SARS-COV-2 in Healthcare Settings. | https://www.ncbi.nlm.nih.gov/pubmed/32473007 | To date, no specific estimate of R0 for SARS-CoV-2 is available for healthcare settings. Using inter-individual contact data, we highlight that R0 estimates from the community cannot translate directly to healthcare settings, with pre-pandemic R0 values ranging 1.3-7.7 in three illustrative healthcare institutions. This has implications for nosocomial Covid-19 control. | 1058-4838,1537-6591 | 2020-05-31 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Laura Temime;Marie-Paule Gustin;Audrey Duval;Niccolò Buetti;Pascal Crépey;Didier Guillemot;Rodolphe Thiébaut;Philippe Vanhems;Jean-Ralph Zahar;David R M Smith;Lulla Opatowski | COVID-19;basic reproduction number;hospital;modelling;transmission | 2020-05-30 02:00:00+02:00 | 32473007 | FR | MESuRS laboratory, Conservatoire national des arts et métiers, Paris, France, PACRI Unit, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France.;Institute of Pharmaceutic and Biological Sciences, University Claude Bernard Lyon 1, Villeurbanne, France, Emerging Pathogens Laboratory-Fondation Mérieux, International Center for Infectiology Research (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Lyon, France.;Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France, Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion unit, Paris, France.;INSERM IAME, U1137, Team DesCID, Paris, France.;UPRES-EA 7449 REPERES « Recherche en Pharmaco-Epidémiologie et Recours aux Soins » - EHESP - Université de Rennes, Rennes, France.;Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France, Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion unit, Paris, France, AP-HP Paris Saclay, Public Health, Medical Information, Clinical research, Le Kremlin-Bicêtre, France.;INSERM U1219 Bordeaux Population Health, Université de Bordeaux, Bordeaux, France, INRIA SISTM team, Talence, France, Vaccine Research Institute, Créteil, France.;Emerging Pathogens Laboratory-Fondation Mérieux, International Center for Infectiology Research (CIRI), Inserm U1111, CNRS UMR5308, ENS de Lyon, Lyon, France, Service d'Hygiène, Epidémiologie et Prévention, Hospices Civils de Lyon, F-69437, Lyon, France , Inserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France.;IAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France, Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du Risque Infectieux, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, France.;Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France, Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion unit, Paris, France, MESuRS laboratory, Conservatoire national des arts et métiers, Paris, France. | 969 | |||
| Fondation Francophone pour la Recherche sur le Diabète;Air Liquide;Sociéte Francophone du Diabète | 10.1007/s00125-020-05180-x | Journal Article;Multicenter Study;Research Support, Non-U.S. Gov't | en | Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. | https://www.ncbi.nlm.nih.gov/pubmed/32472191 | Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown. | 0012-186X,1432-0428 | 2020-05-31 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Coronavirus Infections__complications;Diabetes Mellitus, Type 2__metabolism;Female;Glycated Hemoglobin A__metabolism;Humans;Hypertension__pathology;Inpatients__statistics & numerical data;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Prognosis;Respiration, Artificial__statistics & numerical data;Risk Factors;COVID-19 | Diabetologia | Bertrand Cariou;Samy Hadjadj;Matthieu Wargny;Matthieu Pichelin;Abdallah Al-Salameh;Ingrid Allix;Coralie Amadou;Gwénaëlle Arnault;Florence Baudoux;Bernard Bauduceau;Sophie Borot;Muriel Bourgeon-Ghittori;Olivier Bourron;David Boutoille;France Cazenave-Roblot;Claude Chaumeil;Emmanuel Cosson;Sandrine Coudol;Patrice Darmon;Emmanuel Disse;Amélie Ducet-Boiffard;Bénédicte Gaborit;Michael Joubert;Véronique Kerlan;Bruno Laviolle;Lucien Marchand;Laurent Meyer;Louis Potier;Gaëtan Prevost;Jean-Pierre Riveline;René Robert;Pierre-Jean Saulnier;Ariane Sultan;Jean-François Thébaut;Charles Thivolet;Blandine Tramunt;Camille Vatier;Ronan Roussel;Jean-François Gautier;Pierre Gourdy | BMI;COVID-19;Death;Diabetes;HbA1c;Hypertension;Mechanical ventilation | 2020-05-29 02:00:00+02:00 | 32472191 | FR | [{"country": "International", "agency": "Fondation Francophone pour la Recherche sur le Diabète", "grantid": "CORONADO Initiative Emergency Grant"}, {"country": "International", "agency": "Air Liquide", "grantid": "CORONADO Initiative Emergency grant"}, {"country": "International", "agency": "Sociéte Francophone du Diabète", "grantid": "CORONADO Initiative Emergency Grant"}] | Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France. bertrand.cariou@univ-nantes.fr.;Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France. samy.hadjadj@univ-nantes.fr.;Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France.;CIC-EC 1413, Clinique des Données, CHU Nantes, Nantes, France.;Département d'Endocrinologie, Diabétologie et Nutrition, CHU Amiens, PeriToxUMR_I 01, Université de Picardie, Amiens, France.;Département d'Endocrinologie, Diabétologie, Nutrition, CHU de Angers, Angers, France.;Département de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil Essonne, France.;Département d'Endocrinologie, Diabétologie et Maladies Métaboliques, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Clinique d'Endocrinologique Marc-Linquette, Hôpital Claude-Huriez, CHRU de Lille, Lille, France.;Département de Diabétologie, H.I.A. Begin, Saint Mandé, France.;Fondation Francophone pour la Recherche sur le Diabète (FFRD), Paris, France.;Département d'Endocrinologie, Diabétologie et Nutrition, CHU de Besançon, Besançon, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Assistance Publique Hôpitaux de Paris, Université Paris Saclay, Hôpital Antoine Béclère, Clamart, Hôpital Bicêtre, Le Kremlin Bicêtre, France.;Sorbonne Université, Assistance Publique Hôpitaux de Paris, Département de Diabétologie, CHU La Pitié Salpêtrière-Charles Foix, Inserm, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06, Institute of Cardiometabolism and Nutrition ICAN, Paris, France.;Département des Maladies Infectieuses et Tropicales, CHU Nantes, Nantes, France.;Département des Maladies Infectieuses et Tropicales, CHU de Poitiers, INSERM U1070, Poitiers, France.;Société de Pathologie Infectieuse de langue Française (SPILF), Paris, France.;Fédération Française des Diabétiques (FFD), Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, Université Paris 13, Sorbonne Paris Cité, Département d'Endocrinologie, Diabétologie et Nutrition, CRNH-IdF, CINFO, Bobigny, France.;Université Paris 13, Sorbonne Paris Cité, UMR U557 Inserm / U11125 INRAE / CNAM / Université Paris13, Unité de Recherche Epidémiologique Nutritionnelle, Bobigny, France.;Département d'Endocrinologie et de Diabétologie, Hôpital de la Conception, Assistance Publique Hôpitaux de Marseille, Marseille, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Hospices Civils de Lyon, CarMeN Laboratory, Inserm 1060, Lyon, France, Université Claude Bernard Lyon 1, Lyon, France.;Département d'Endocrinologie et de Diabétologie, Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France.;Département d'Endocrinologie et de Diabétologie, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Marseille, France.;Département de Diabétologie, CHU de Caen, Caen, France.;Département d'Endocrinologie, CHU de Brest, EA 3878 GETBO, Brest, France.;Université de Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, France.;Département d'Endocrinologie et de Diabétologie, Centre Hospitalier St. Joseph - St. Luc, Lyon, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Centre de Recherche des Cordeliers, Inserm, U-1138, Université de Paris, Paris, France.;Département d'Endocrinologie, Diabétologie et Maladies Métaboliques, CHU de Rouen, Université de Rouen, Rouen, France.;Département Diabète et Endocrinologie, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France.;Paris Diderot-Paris VII Université, Paris, France.;Inserm UMRS 1138, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France.;Université de Poitiers, CIC Inserm 1402, Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique CIC 1402, Université de Poitiers, Inserm, CHU de Poitiers, Poitiers, France.;Département d'Endocrinologie, Diabète, Nutrition et CIC Inserm 1411, CHU de Montpellier, Montpellier, France.;Centre du Diabète DIAB-eCARE, Hospices Civils de Lyon et Laboratoire CarMeN, Inserm, INRA, INSA, Université Claude Bernard Lyon 1, Lyon, France.;Société Francophone du Diabète (SFD), Paris, France.;Département d'Endocrinologie, Diabétologie et Nutrition, CHU Toulouse, Institut des Maladies Métaboliques et Cardiovasculaires, UMR1048 Inserm/UPS, Université de Toulouse, Toulouse, France.;Assistance Publique Hôpitaux de Paris, Saint-Antoine Hospital, Reference Center of Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Department of Endocrinology, Paris, France.;Sorbonne University, Inserm UMRS 938, Saint-Antoine Research Center, Paris, France. | 979 |
| 10.1016/s2468-2667(20)30117-1 | Journal Article;Observational Study;Research Support, Non-U.S. Gov't | en | Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study. | https://www.ncbi.nlm.nih.gov/pubmed/32473113 | Although mortality due to COVID-19 is, for the most part, robustly tracked, its indirect effect at the population level through lockdown, lifestyle changes, and reorganisation of health-care systems has not been evaluated. We aimed to assess the incidence and outcomes of out-of-hospital cardiac arrest (OHCA) in an urban region during the pandemic, compared with non-pandemic periods. | 2468-2667 | 2020-05-31 02:00:00+02:00 | pubmed | Aged;Coronavirus Infections__epidemiology;Female;Humans;Male;Out-of-Hospital Cardiac Arrest__epidemiology;Pandemics;Paris__epidemiology;Pneumonia, Viral__epidemiology;COVID-19 | The Lancet Public Health | Eloi Marijon;Nicole Karam;Daniel Jost;David Perrot;Benoit Frattini;Clément Derkenne;Ardalan Sharifzadehgan;Victor Waldmann;Frankie Beganton;Kumar Narayanan;Antoine Lafont;Wulfran Bougouin;Xavier Jouven | 2020-05-27 02:00:00+02:00 | 32473113 | FR | Université de Paris, Centre de Recherche Cardiovasculaire de Paris, INSERM, Paris, France, Paris-Sudden Death Expertise Center, Paris, France, European Georges Pompidou Hospital, Cardiology Department, Paris, France. Electronic address: eloi_marijon@yahoo.fr.;Université de Paris, Centre de Recherche Cardiovasculaire de Paris, INSERM, Paris, France, Paris-Sudden Death Expertise Center, Paris, France, European Georges Pompidou Hospital, Cardiology Department, Paris, France.;Paris-Sudden Death Expertise Center, Paris, France, Paris Fire Brigade, Paris, France.;Université de Paris, Centre de Recherche Cardiovasculaire de Paris, INSERM, Paris, France, Paris-Sudden Death Expertise Center, Paris, France.;Paris Fire Brigade, Paris, France.;Paris-Sudden Death Expertise Center, Paris, France.;Université de Paris, Centre de Recherche Cardiovasculaire de Paris, INSERM, Paris, France, Paris-Sudden Death Expertise Center, Paris, France, Jacques Cartier Hospital, Intensive Care Unit, Massy, France. | 980 | |||
| 10.1016/j.clnu.2020.05.023 | Journal Article | en | Considerations for the management of home parenteral nutrition during the SARS-CoV-2 pandemic: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN. | https://www.ncbi.nlm.nih.gov/pubmed/32487434 | The management of patients with chronic intestinal failure requiring home parenteral nutrition has been and will continue to be impaired during the SARS-CoV-2 pandemic. Multidisciplinary intestinal failure teams may have to adapt their clinical approaches to home care, outpatient care as well as hospital admission and discharge in order to keep this vulnerable group of patients as safe and well as possible during the unprecedented challenges that countries are facing during the pandemic. Equally, it is important that expert advice from intestinal failure teams is available when home parenteral nutrition (HPN)-dependent patients require admission with SARS-CoV-2 infection. The Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of the European Society for Clinical Nutrition and Metabolism (ESPEN) has developed a position paper to outline areas for intestinal failure teams to consider when managing patients with chronic intestinal failure during the SARS-CoV-2 pandemic. | 0261-5614 | 2020-05-31 02:00:00+02:00 | pubmed | Betacoronavirus;Chronic Disease;Coronavirus Infections__complications;Hospitalization;Humans;Intestinal Diseases__complications;Pandemics;Parenteral Nutrition, Home;Pneumonia, Viral__complications;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | Clinical Nutrition | Simon Lal;Andre Van Gossum;Francisca Joly;Federico Bozzetti;Cristina Cuerda;Georg Lamprecht;Manpreet S Mundi;Michael Staun;Kinga Szczepanek;Geert Wanten;Carolyn Wheatley;Loris Pironi | Chronic intestinal failure;Coronavirus;Home parenteral nutrition | 2020-05-28 02:00:00+02:00 | 32487434 | FR;UNK;GB;US;IT;PL;NL;DK;ES;BE;DE | Intestinal Failure Unit, Salford Royal Foundation Trust and University of Manchester, Manchester, Stott Lane, Salford, M6 8HD, UK. Electronic address: simon.lal@srft.nhs.uk.;Medico-Surgical Department of Gastroenterology, Hˆopital Erasme, Free University of Brussels, Belgium.;Centre for Intestinal Failure, Department of Gastroenterology and Nutritional Support, Hˆopital Beaujon, Clichy, France.;Faculty of Medicine, University of Milan, Milan, Italy.;Nutrition Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain.;Division of Gastroenterology and Endocrinology, University Medical Center Rostock, Germany.;Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.;Rigshospitalet, Department of Gastroenterology, Copenhagen, Denmark.;General and Oncology Surgery Unit, Stanley Dudrick's Memorial Hospital, Skawina, Poland.;Intestinal Failure Unit, Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.;Expert Patient.;Clinical Nutrition and Metabolism Unit and Center for Chronic Intestinal Failure, Department of Digestive System, St. Orsola-Malpighi University Hospital, Bologna, Italy. | 982 | ||
| 10.1016/j.diabet.2020.05.009 | Journal Article | en | Towards individualised and optimalised positioning of non-ventilated COVID-19 patients: Putting the affected parts of the lung(s) on top? | https://www.ncbi.nlm.nih.gov/pubmed/32473964 | The outbreak of COVID-19 led to an unprecedented inflow of hospitalised patients with severe acute respiratory syndrome (SARS), requiring high-flow non-invasive oxygenation, if not invasive mechanical ventilation. While the best option in terms of non-invasive systems of oxygen delivery is still a matter of debate, it also remains unclear as to whether or not the optimal in-bed positioning of patients might also help to improve their oxygen saturation levels. On the basis of three representative cases, it is possible to propose the following hypotheses: (i) how patients are positioned has a strong influence on their oxygen saturation levels; (ii) saturation-optimalised positions are patient-specific; (iii) prone positions require ergonomic devices; and (iv) saturation-optimalised positions should aim to place the most affected part(s) of the lung(s) on top. Considered together, these hypotheses have led us to recommend that COVID-19 patients should undergo a specific assessment at admission to determine their saturation-optimalised in-bed position. However, further studies are still needed to assess the benefits of such a strategy on clinical outcomes. | 1262-3636 | 2020-05-31 02:00:00+02:00 | pubmed | Diabetes & Metabolism | S Froelich;E Mandonnet;J-B Julla;C Touchard;M Laloi-Michelin;J-P Kevorkian;J-F Gautier | Body positioning;COVID-19;Oxygen saturation | 2020-05-28 02:00:00+02:00 | 32473964 | FR | Department of Neurosurgery, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France.;Department of Diabetes and Endocrinology, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France.;Department of Anaesthesiology and Critical Care, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, INSERM 1138, Paris, France.;Department of Diabetes and Endocrinology, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France. Electronic address: jean-francois.gautier@aphp.fr. | 992 | |||
| 10.1186/s13058-020-01293-8 | Journal Article | en | COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. | https://www.ncbi.nlm.nih.gov/pubmed/32460829 | Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). | 1465-542X | 2020-05-31 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Breast Neoplasms__complications;Cause of Death;Coronavirus Infections__complications;Female;France__epidemiology;Hospitalization;Humans;Lung__diagnostic imaging;Middle Aged;Pandemics;Pneumonia, Viral__complications;Prognosis;RNA, Viral__blood;Risk Factors;Tomography, X-Ray Computed;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Breast Cancer Research | Perrine Vuagnat;Maxime Frelaut;Toulsie Ramtohul;Clémence Basse;Sarah Diakite;Aurélien Noret;Audrey Bellesoeur;Vincent Servois;Delphine Hequet;Enora Laas;Youlia Kirova;Luc Cabel;Jean-Yves Pierga;Laurence Bozec;Xavier Paoletti;Paul Cottu;François-Clément Bidard | Breast cancer;COVID-19;Outcome;SARS-CoV-2;Survival | 2020-05-28 02:00:00+02:00 | 32460829 | FR | UVSQ, Université Paris-Saclay, Saint Cloud, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Medical Oncology, Institut Curie, Saint Cloud, France.;Department of Drug Development and Innovation, Institut Curie, Paris, France.;Department of Radiology, Institut Curie, Paris, France.;Department of Surgical Oncology, Institut Curie, Paris, France.;Department of Radiation Oncology, Institut Curie, Paris, France.;Université de Paris, Paris, France.;INSERM U900 STAMPM Team, Saint Cloud, France.;UVSQ, Université Paris-Saclay, Saint Cloud, France. fcbidard@curie.fr.;Department of Medical Oncology, Institut Curie, Paris, France. fcbidard@curie.fr.;Department of Medical Oncology, Institut Curie, Saint Cloud, France. fcbidard@curie.fr. | 997 | ||
| 10.7759/cureus.8333 | Case Reports | en | Managing Acute Portal Hypertensive Gastropathy Bleed During the Time of COVID-19 Pandemic: Novelty or Necessity? | https://www.ncbi.nlm.nih.gov/pubmed/32489751 | Acute bleeding from portal hypertensive gastropathy (PHG) is an extremely rare event in the natural history of cirrhosis. The treatment recommendations include portal pressure reduction strategies including pharmacotherapy with vasoactive agents and beta-blockers and interventional strategies such as transjugular intrahepatic portosystemic shunt placement. In this report, we present the case of a patient with cirrhosis in whom acute PHG-related bleed was managed with endoscopic band ligation, a therapeutic modality which has not been described in current literature. Our decision to re-purpose a technique for variceal bleeding stems from the fact that during the ongoing COVID-19 pandemic, the technical assistance, resource availability, and sourcing of materials that were required for us to follow recommended management guidelines for acute PHG-related bleed was severely affected due to imposed lockdown between districts and states. | 2168-8184 | 2020-05-31 02:00:00+02:00 | pubmed | Cureus | Cyriac A Philips;Sandeep Kumbar;Rizwan Ahamed;Philip Augustine | banding;cirrhosis;coronavirus;covid;endoscopy;evl;gi bleeding;phg | 2020-05-28 02:00:00+02:00 | 32489751 | FR;UNK | Gastroenterology, Cochin Gastroenterology Group, Kochi, IND.;Gastroenterology, Ernakulam Medical Center, Kochi, IND. | 1003 | |||
| 10.1038/s41591-020-0948-7 | Journal Article;Published Erratum | en | Author Correction: Caring for patients with cancer in the COVID-19 era. | https://www.ncbi.nlm.nih.gov/pubmed/32494062 | An amendment to this paper has been published and can be accessed via a link at the top of the paper. | 1078-8956,1546-170X | 2020-06-07 02:00:00+02:00 | pubmed | Nature Medicine | Joris van de Haar;Louisa R Hoes;Charlotte E Coles;Kenneth Seamon;Stefan Fröhling;Dirk Jäger;Franco Valenza;Filippo de Braud;Luigi De Petris;Jonas Bergh;Ingemar Ernberg;Benjamin Besse;Fabrice Barlesi;Elena Garralda;Alejandro Piris-Giménez;Michael Baumann;Giovanni Apolone;Jean Charles Soria;Josep Tabernero;Carlos Caldas;Emile E Voest | 2020-06-05 02:00:00+02:00 | 32494062 | SE;FR;GB;IT;NL;ES;PS;DE | Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Cancer Research UK Cambridge Cancer Center, Cambridge, UK.;German Cancer Consortium, Heidelberg, Germany.;Division of Translational Medical Oncology, National Center for Tumor Diseases Heidelberg and German Cancer Research Center, Heidelberg, Germany.;Department of Medical Oncology, National Center for Tumor Diseases Heidelberg and Heidelberg University Hospital, Heidelberg, Germany.;Università Statale di Milano, Milan, Italy.;Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.;Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.;Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.;Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.;Gustave Roussy Cancer Campus, Villejuif, France.;Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.;Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.;German Cancer Research Center, Heidelberg, Germany.;Cancer Research UK Cambridge Cancer Center, Cambridge, UK. carlos.caldas@cruk.cam.ac.uk.;Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Center, University of Cambridge, Cambridge, UK. carlos.caldas@cruk.cam.ac.uk.;Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.;Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl. | 1012 | ||||
| 10.1016/j.jviscsurg.2020.06.005 | Practice Guideline | en | SOFFCO-MM guidelines for the resumption of bariatric and metabolic surgery during and after the Covid-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32600823 | Bariatric/metabolic surgery was paused during the Covid-19 pandemic. The impact of social confinement and the interruption of this surgery on the population with obesity has been underestimated, with weight gain and worsened comorbidities. Some candidates for this surgery are exposed to a high risk of mortality linked to the pandemic. Obesity and diabetes are two major risk factors for severe forms of Covid-19. The only currently effective treatment for obesity is metabolic surgery, which confers prompt, lasting benefits. It is thus necessary to resume such surgery. To ensure that this resumption is both gradual and well-founded, we have devised a priority ranking plan. The flow charts we propose will help centres to identify priority patients according to a benefit/risk assessment. Diabetes holds a central place in the decision tree. Resumption patterns will vary from one centre to another according to human, physical and medical resources, and will need adjustment as the epidemic unfolds. Specific informed consent will be required. Screening of patients with obesity should be considered, based on available knowledge. If Covid-19 is suspected, surgery must be postponed. Emphasis must be placed on infection control measures to protect patients and healthcare professionals. Confinement is strongly advocated for patients for the first month post-operatively. Patient follow-up should preferably be by teleconsultation. | 1878-7886 | 2020-06-07 02:00:00+02:00 | pubmed | Journal of Visceral Surgery | R Kassir;L Rebibo;L Genser;A Sterkers;M-C Blanchet;F Pattou;S Msika | Bariatric surgery;Covid-19;Guidelines;Obesity;Pandemic | 2020-06-05 02:00:00+02:00 | 32600823 | FR | Service de chirurgie digestive et bariatrique, hôpital Felix-Guyon, CHU de la Réunion, La Réunion, France.;Service de chirurgie digestive œsogastrique et bariatique, hôpital Bichat - Claude-Bernard, Paris, France, Inserm UMR 1149, université de Paris, 75018 Paris, France.;Service de chirurgie digestive hépato-bilio-pancréatique et transplantation hépatique, hôpital universitaire, Sorbonne université, Assistance publique-Hôpitaux de Paris, Pitié-Salpêtrière, Paris, France.;Service de chirurgie digestive et hépatobiliaire, centre hospitalier Privé Saint-Grégoire, Saint-Grégoire, France.;Centre Lyonnais de chirurgie digestive, CSO Sauvegarde Lyon, Lyon, France.;Service de chirurgie générale et endocrinienne, CHU de Lille, Lille, France, Inserm, Lille Pasteur Institute, EGID, U1190, université Lille, CHU Lille, Lille, France.;Service de chirurgie digestive œsogastrique et bariatique, hôpital Bichat - Claude-Bernard, Paris, France, Inserm UMR 1149, université de Paris, 75018 Paris, France. Electronic address: simon.msika@aphp.fr. | 1023 | |||
| 10.1016/j.radonc.2020.05.043 | Editorial | en | Post-lockdown management of oncological priorities and postponed radiation therapy following the COVID-19 pandemic: Experience of the Institut Curie. | https://www.ncbi.nlm.nih.gov/pubmed/32512077 | 0167-8140 | 2020-06-07 02:00:00+02:00 | pubmed | Radiotherapy and Oncology | Arnaud Beddok;Valentin Calugaru;Mathieu Minsat;Rémi Dendale;Aurélien De Oliveira;Émilie Costa;Farid Goudjil;Rezart Belshi;Noelle Pierrat;Christophe Rochas;Anne Catherine Gravigny;Lucas Soisick;Hélène Colella Fleury;Gilles Créhange | COVID-19 pandemic;Crisis intervention;Data visualization;Radiotherapy;SARS-CoV-2 infection | 2020-06-05 02:00:00+02:00 | 32512077 | FR | Department of Radiation Oncology, Institut Curie, Paris, Saint Cloud, France. Electronic address: arnaud.beddok@curie.fr.;Department of Radiation Oncology, Institut Curie, Paris, Saint Cloud, France. | 1029 | ||||
| 10.1016/j.anorl.2020.06.001 | Journal Article | en | How to perform a nasopharyngeal swab in adults and children in the COVID-19 era. | https://www.ncbi.nlm.nih.gov/pubmed/32646750 | The nasopharyngeal swab is currently the main testing method used to diagnose COVID-19. The principle is to collect respiratory cells infected by the virus and to use the RT-PCR (Reverse Transcription - Polymerase Chain Reaction) technique to detect the RNA of the virus. The false negative rate is high, about 30%, which can mainly be explained by an incorrect execution of the technique may increase the false negative rate and decrease the test's sensitivity. The aim of this note is to help healthcare providers to perform this test correctly in adults and children. | 1879-7296 | 2020-06-07 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | S Pondaven-Letourmy;F Alvin;Y Boumghit;F Simon | COVID-19;Diagnosis;Nasopharyngeal swab;RT-PCR;SARS-CoV-2 | 2020-06-05 02:00:00+02:00 | 32646750 | FR | Department of Otorhinolaryngology, Head and Neck Surgery, Tours University Hospital, Tours, France. Electronic address: soizik.pondaven-letourmy@univ-tours.fr.;Department of pediatric otolaryngology, Head and Neck Surgery, Hôpital Necker-Enfants Malades, AP-HP, Centre - Université de Paris, Paris, France.;Department of Otorhinolaryngology, Head and Neck Surgery, Tours University Hospital, Tours, France. | 1033 | |||
| 10.1111/all.14407 | Journal Article | en | Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement. | https://www.ncbi.nlm.nih.gov/pubmed/32500526 | The outbreak of the SARS-CoV-2-induced Coronavirus Disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant numberof the patients are on treatment with biologicals and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a "cytokine storm" and associated organ damage characterized by an exaggerated release of proinflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19 with studies focusing on severe allergic phenotypes lacking. At present, non-infected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management is demanded. | 0105-4538,1398-9995 | 2020-06-07 02:00:00+02:00 | pubmed | Allergy | Alessandra Vultaggio;Ioana Agache;Cezmi A Akdis;Mubeccel Akdis;Sevim Bavbek;Apostolos Bossios;Jean Bousquet;Onur Boyman;Adam M Chaker;Susan Chan;Alexia Chatzipetrou;Wojciech Feleszko;Davide Firinu;Marek Jutel;Paula Kauppi;Ludger Klimek;Antonios Kolios;Akash Kothari;Marek L Kowalski;Andrea Matucci;Oscar Palomares;Oliver Pfaar;Barbara Rogala;Eva Untersmayr;Thomas Eiwegger | 2020-06-05 02:00:00+02:00 | 32500526 | SE;FR;IL;CA;FI;GR;CH;RO;GB;US;AT;IT;PL;TR;ES;DE | Immunoallergology Unit, Careggi University Hospital, Florence, Italy.;Transylvania University, Brasov, Romania.;Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich, Davos, Switzerland.;Ankara University, School of Medicine, Department of Chest Disease, Division of Immunology and Allergy, Ankara, Turkey.;Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Huddinge and Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.;Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden.;Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and , Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Charité, Berlin, Germany.;MACVIA-France, Montpellier, and CHU Monpellier, Montpellier, France.;Department of Immunology, University Hospital Zurich, Zurich, Switzerland.;Faculty of Medicine, University of Zurich, Zurich, Switzerland.;Technical University of Munich, TUM School of Medicine, Klinikumrechts der Isar, Department of Otolaryngology and Center for Allergy and Environment, Munich, Germany.;Guy's and St, Thomas' NHS Foundation Trust, Westminster Bridge Road, London, United KingdomKing's, College LondonSchool of Life Course Sciences & School of Immunology & Microbial Sciences, King's Health Partners, London, United Kingdom.;Allergy Unit 2, nd Department of Dermatology and Venereology, National University of Athens, Medical School, University General Hospital 'ATTIKON", Athens, Greece.;Department of Pediatric Allergy and Pneumology, Medical University of Warsaw, Warsaw, Poland.;Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.;Department of Clinical Immunology, Wroclaw Medical University, ALL-MED Medical Research Institute, Wrocław, Poland, Wroclaw, Poland.;Department of Allergy, Inflammation Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland.;Centre for Rhinology and Allergy, Wiesbaden, Germany.;Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.;Translational Medicine Program, Peter Gilgan Centre for Research and Learning, Hospital for Sick Children, Toronto, Ontario, Canada.;Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.;Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain.;Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.;Department of Internal Diseases, Allergology & Clinical Immunology Medical, University of Silesia, Katowice, Poland.;Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.;Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Departments of Paediatrics and Immunology, University of Toronto, Toronto, ON, Canada.;Department of Immunology, University of Toronto, Toronto, ON, Canada. | 1035 | ||||
| NIGMS NIH HHS | 10.3389/fphar.2020.00870 | Journal Article | en | Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32581816 | There is an urgent need for new therapeutic strategies to contain the spread of the novel coronavirus disease 2019 (COVID-19) and to curtail its most severe complications. Severely ill patients experience pathologic manifestations of acute respiratory distress syndrome (ARDS), and clinical reports demonstrate striking neutrophilia, elevated levels of multiple cytokines, and an exaggerated inflammatory response in fatal COVID-19. Mechanical respirator devices are the most widely applied therapy for ARDS in COVID-19, yet mechanical ventilation achieves strikingly poor survival. Many patients, who recover, experience impaired cognition or physical disability. In this review, we argue the need to develop therapies aimed at inhibiting neutrophil recruitment, activation, degranulation, and neutrophil extracellular trap (NET) release. Moreover, we suggest that currently available pharmacologic approaches should be tested as treatments for ARDS in COVID-19. In our view, targeting host-mediated immunopathology holds promise to alleviate progressive pathologic complications of ARDS and reduce morbidities and mortalities in severely ill patients with COVID-19. | 1663-9812 | 2020-06-07 02:00:00+02:00 | pubmed | Frontiers in Pharmacology | Teluguakula Narasaraju;Benjamin M Tang;Martin Herrmann;Sylviane Muller;Vincent T K Chow;Marko Radic | COVID-19;SARS-CoV-2;acute respiratory distress syndrome;neutrophil extracellular traps;neutrophilia;neutrophils;pathogenesis;therapeutics | 2020-06-05 02:00:00+02:00 | 32581816 | FR;SG;US;AU;DE | [{"country": "United States", "agency": "NIGMS NIH HHS", "grantid": "P20 GM103648"}] | College of Veterinary Medicine, Oklahoma State University, Stillwater, OK, United States.;Department of Intensive Care Medicine, Nepean Hospital, Sydney, NSW, Australia.;Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.;CNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France.;Laboratory of Excellence Medalis, Institut de science et d'ingénierie supramoléculaire, and University of Strasbourg Institute for Advanced Study (USIAS), Strasbourg, France.;Department of Microbiology and Immunology, Infectious Diseases Program, School of Medicine, National University of Singapore, National University Health System, Singapore, Singapore.;Department of Microbiology, Immunology and Biochemistry, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States. | 1038 | |
| 10.1016/j.jogoh.2020.101826 | Journal Article | en | A snapshot of the Covid-19 pandemic among pregnant women in France. | https://www.ncbi.nlm.nih.gov/pubmed/32505805 | To describe the course over time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in French women from the beginning of the pandemic until mid-April, the risk profile of women with respiratory complications, and short-term pregnancy outcomes. | 2468-7847 | 2020-06-07 02:00:00+02:00 | pubmed | Journal of Gynecology Obstetrics and Human Reproduction | Gilles Kayem;Edouard Lecarpentier;Philippe Deruelle;Florence Bretelle;Elie Azria;Julie Blanc;Caroline Bohec;Marie Bornes;Pierre-François Ceccaldi;Yasmine Chalet;Céline Chauleur;Anne-Gael Cordier;Raoul Desbrière;Muriel Doret;Michel Dreyfus;Marine Driessen;Marion Fermaut;Denis Gallot;Charles Garabédian;Cyril Huissoud;Dominique Luton;Olivier Morel;Franck Perrotin;Olivier Picone;Patrick Rozenberg;Loïc Sentilhes;Jeremy Sroussi;Christophe Vayssière;Eric Verspyck;Alexandre J Vivanti;Norbert Winer;Vivien Alessandrini;Thomas Schmitz | COVID 19;Lockdown;Respiratory complications;Risk factors | 2020-06-04 02:00:00+02:00 | 32505805 | FR | Assistance Publique-Hôpitaux de Paris, 75004, Paris, France. Electronic address: gkayem@gmail.com.;Centre Hospitalier Intercommunal de Créteil, 94000, Créteil, France.;Centre Hospitalo-Universitaire de Strasbourg, 67000, Strasbourg, France.;Assistance Publique-Hôpitaux de Marseille, 13000, Marseille, France.;Groupe Hospitalier Saint-Joseph, 75014, Paris, France.;Centre Hospitalier de Pau, 64000, Pau, France.;Assistance Publique-Hôpitaux de Paris, 75004, Paris, France.;Centre Hospitalo-Universitaire de Saint-Etienne, 42000, Saint-Etienne, France.;Hôpital Saint-Joseph, 13000, Marseille, France.;Hospices Civiles de Lyon, 69000, Lyon, France.;Centre Hospitalo-Universitaire de Caen, 14000, Caen, France.;Centre Hospitalo-Universitaire Clermont-Ferrand, 63000, Clermont-Ferrand, France.;Centre Hospitalier Régional Universitaire de Lille, 59000, Lille, France.;Maternité Régionale de Nancy, 54000, Nancy, France.;Centre Hospitalier Régional Universitaire de Tours, 37000, Tours, France.;Centre Hospitalier Intercommunal de Poissy, 78300, Poissy, France.;Centre Hospitalo-Universitaire de Bordeaux, 33000, Bordeaux, France.;Centre Hospitalo-Universitaire de Toulouse, 31000, Toulouse, France.;Centre Hospitalo-Universitaire de Rouen, 76000, Rouen, France.;Centre Hospitalo-Universitaire de Nantes, 44000, Nantes, France. | 1042 | |||
| Letter | en | Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32333823 | 2020-06-07 02:00:00+02:00 | pubmed | Adrenal Cortex Hormones__therapeutic use;Autoimmune Diseases__complications;Betacoronavirus__isolation & purification;Blister__complications;Coronavirus Infections__complications;Humans;Immunologic Factors__therapeutic use;Pandemics;Pneumonia, Viral__complications;Practice Guidelines as Topic;COVID-19;severe acute respiratory syndrome coronavirus 2 | M Kasperkiewicz;E Schmidt;J A Fairley;P Joly;A S Payne;M L Yale;D Zillikens;D T Woodley | 2020-06-04 02:00:00+02:00 | 32333823 | FR;US;DE | Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.;Department of Dermatology, University of Lübeck, Lübeck, Germany.;Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.;Department of Dermatology, University of Iowa, Iowa City, IA, USA.;Department of Dermatology, Rouen University Hospital, Rouen, France.;Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.;International Pemphigus and Pemphigoid Foundation, Sacramento, CA, USA. | 1045 | |||||||
| 10.1016/j.jchirv.2020.05.002 | English Abstract;Journal Article | fr | [SOFFCO-MM guidelines for the resumption of bariatric and metabolic surgery during and after the Covid-19 pandemic]. | https://www.ncbi.nlm.nih.gov/pubmed/32834886 | Bariatric/metabolic surgery was paused during the Covid-19 pandemic. The impact of social confinement and the interruption of this surgery on the population with obesity has been underestimated, with weight gain and worsened comorbidities. Some candidates for this surgery are exposed to a high risk of mortality linked to the pandemic. Obesity and diabetes are two major risk factors for severe forms of Covid-19. The only currently effective treatment for obesity is metabolic surgery, which confers prompt, lasting benefits. It is thus necessary to resume such surgery. To ensure that this resumption is both gradual and well-founded, we have devised a priority ranking plan. The flow charts we propose will help centres to identify priority patients according to a benefit/risk assessment. Diabetes holds a central place in the decision tree. Resumption patterns will vary from one centre to another according to human, physical and medical resources, and will need adjustment as the epidemic unfolds. Specific informed consent will be required. Screening of patients with obesity should be considered, based on available knowledge. If Covid-19 is suspected, surgery must be postponed. Emphasis must be placed on infection control measures to protect patients and healthcare professionals. Confinement is strongly advocated for patients for the first month post-operatively. Patient follow-up should preferably be by teleconsultation. | 1878-786X | 2020-06-07 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | R Kassir;L Rebibo;L Genser;A Sterkers;M-C Blanchet;F Pattou;S Msika | Bariatric surgery;Covid-19;Guidelines;Obesity;Pandemic | 2020-06-05 02:00:00+02:00 | 32834886 | FR | Service de chirurgie digestive et bariatrique, hôpital Felix-Guyon, CHU de la Réunion, La Réunion, France.;Service de chirurgie digestive œsogastrique et bariatique, hôpital Bichat - Claude-Bernard, Paris, France.;Inserm UMR 1149, université de Paris, 75018 Paris, France.;Service de chirurgie digestive hépato-bilio-pancréatique et transplantation hépatique, hôpital universitaire, Sorbonne université, Assistance publique-Hôpitaux de Paris, Pitié-Salpêtrière, Paris, France.;Service de chirurgie digestive et hépatobiliaire, centre hospitalier Privé Saint-Grégoire, Saint-Grégoire, France.;Centre Lyonnais de chirurgie digestive, CSO Sauvegarde Lyon, Lyon, France.;Service de chirurgie générale et endocrinienne, CHU de Lille, Lille, France.;Inserm, Lille Pasteur Institute, EGID, U1190, université Lille, CHU Lille, Lille, France. | 1048 | |||
| Letter | en | Histology of skin lesions establishes that the vesicular rash associated with COVID-19 is not 'varicella-like'. | https://www.ncbi.nlm.nih.gov/pubmed/32500642 | 2020-06-07 02:00:00+02:00 | pubmed | A Mahé;E Birckel;C Merklen;P Lefèbvre;C Hannedouche;M Jost;L Droy-Dupré | 2020-06-05 02:00:00+02:00 | 32500642 | FR | Hôpital Pasteur, Colmar, France. | 1050 | ||||||||
| 10.5802/crbiol.8 | News | en | A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. | https://www.ncbi.nlm.nih.gov/pubmed/32720486 | SARS-CoV-2 epidemics raises a considerable issue of public health at the planetary scale. There is a pressing urgency to find treatments based upon currently available scientific knowledge. Therefore, we tentatively propose a hypothesis which hopefully might ultimately help save lives. Based on the current scientific literature and on new epidemiological data which reveal that current smoking status appears to be a protective factor against the infection by SARS-CoV-2 [1], we hypothesize that the nicotinic acetylcholine receptor (nAChR) plays a key role in the pathophysiology of Covid-19 infection and might represent a target for the prevention and control of Covid-19 infection. | 2020-06-07 02:00:00+02:00 | pubmed | Coronavirus Infections__physiopathology;Humans;Nicotine__therapeutic use;Nicotinic Agonists__therapeutic use;Pandemics__prevention & control;Pneumonia, Viral__physiopathology;Receptors, Nicotinic;Smoking;Transdermal Patch;COVID-19 | Comptes Rendus. Biologies | Jean-Pierre Changeux;Zahir Amoura;Felix A Rey;Makoto Miyara | Covid-19;clinical trials of nicotine patches;nicotinic receptors;smoking | 2020-06-05 02:00:00+02:00 | 32720486 | FR | Institut Pasteur CNRS UMR 3571 Department of Neuroscience and Collège de France, Paris France.;Sorbonne Université, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris).;Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Service de Médecine Interne 2, Maladies auto-immune et systémiques Institut E3M.;Institut Pasteur, Structural Virology Unit, Department of Virology, CNRS UMR 3569, Institut Pasteur Paris France.;Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Département d'Immunologie, Paris, France. | 1051 | |||
| 10.1016/j.ejca.2020.05.028 | Comparative Study;Journal Article;Research Support, Non-U.S. Gov't | en | High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. | https://www.ncbi.nlm.nih.gov/pubmed/32540204 | Cancer patients presenting with COVID-19 have a high risk of death. In this work, predictive factors for survival in cancer patients with suspected SARS-COV-2 infection were investigated. | 0959-8049 | 2020-06-07 02:00:00+02:00 | pubmed | Age Factors;Betacoronavirus__genetics;Clinical Laboratory Techniques__statistics & numerical data;Coronavirus Infections__complications;Female;Follow-Up Studies;Humans;Karnofsky Performance Status__statistics & numerical data;Male;Middle Aged;Mortality;Neoplasm Recurrence, Local__complications;Neoplasms__complications;Pandemics;Pneumonia, Viral__complications;RNA, Viral__isolation & purification;Retrospective Studies;Reverse Transcriptase Polymerase Chain Reaction__statistics & numerical data;Risk Factors;Sex Factors;Survival Analysis;Time Factors;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | European Journal of Cancer | Souad Assaad;Virginie Avrillon;Marie-Line Fournier;Benedicte Mastroianni;Bruno Russias;Aurélie Swalduz;Philippe Cassier;Lauriane Eberst;Marie-Pierre Steineur;Marianne Kazes;Maurice Perol;Anne-Sophie Michallet;Philippe Rey;Anne-Sophie Erena-Penet;Astrid Morel;Mehdi Brahmi;Armelle Dufresne;Olivier Tredan;Gisèle Chvetzoff;Jérome Fayette;Christelle de la Fouchardiere;Isabelle Ray-Coquard;Thomas Bachelot;Pierre Saintigny;Mayeul Tabutin;Aurélien Dupré;Emmanuelle Nicolas-Virelizier;Amine Belhabri;Pierre-Eric Roux;Christine Fuhrmann;Franck Pilleul;Alexandre Basle;Amine Bouhamama;Christelle Galvez;Andrée-Laure Herr;Julien Gautier;Sylvie Chabaud;Philippe Zrounba;David Perol;Jean-Yves Blay | COVID-19;Cancer patients;RT-PCR;Risk factors;SARS-COV-2;Survival | 2020-06-07 02:00:00+02:00 | 32540204 | FR | Centre Léon Bérard, 28 Rue Laënnec, 69373, Lyon Cedex 08, France, Université Claude Bernard Lyon I, France, Unicancer, Paris, France.;Centre Léon Bérard, 28 Rue Laënnec, 69373, Lyon Cedex 08, France, Université Claude Bernard Lyon I, France, Unicancer, Paris, France. Electronic address: jean-yves.blay@lyon.unicancer.fr. | 1052 | ||
| Letter | en | How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection? | https://www.ncbi.nlm.nih.gov/pubmed/32522666 | Statistical surveys of COVID-19 patients indicate, against all common logic, that people who smoke are less prone to the infection and/or exhibit less severe respiratory symptoms than non-smokers. This suggests that nicotine may have some preventive or modulatory effect on the inflammatory response in the lungs. Because it is known that the response to, and resolution of the SARS-CoV-2 infection depends mainly on the lung macrophages, we discuss the recent scientific findings, which may explain why and how nicotine may modulate lung macrophage response during COVID-19 infection. | 2020-06-07 02:00:00+02:00 | pubmed | Administration, Inhalation;Anti-Inflammatory Agents__administration & dosage;Betacoronavirus__drug effects;Coronavirus Infections__diagnosis;Cytokine Release Syndrome__diagnosis;Cytokines__immunology;Host-Pathogen Interactions;Humans;Lung__drug effects;Macrophages__drug effects;Nicotine__administration & dosage;Nicotinic Agonists__administration & dosage;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Protective Factors;Receptors, Nicotinic__drug effects;Risk Factors;Severity of Illness Index;Smokers;alpha7 Nicotinic Acetylcholine Receptor__agonists;COVID-19;severe acute respiratory syndrome coronavirus 2 | Malgorzata Kloc;Rafik M Ghobrial;Jacek Z Kubiak | Acute respiratory distress syndrome - ARDS;COVID-19;Cytokine storm;Cytokines;Inflammation;Lungs;Macrophages;Nicotine;SARS-CoV-2;α4/α7 Nicotinic Ach receptors - nAChRs | 2020-06-06 02:00:00+02:00 | 32522666 | FR;PL;US | The Houston Methodist Research Institute, Houston, Texas 77030, USA, The Houston Methodist Hospital, Department of Surgery, Houston, Texas, USA, The University of Texas, M.D. Anderson Cancer Center, Department of Genetics, Houston Texas, USA. Electronic address: mkloc@houstonmethodist.org.;The Houston Methodist Research Institute, Houston, Texas 77030, USA, The Houston Methodist Hospital, Department of Surgery, Houston, Texas, USA.;Laboratory of Regenerative Medicine and Cell Biology, Military Institute of Hygiene and Epidemiology (WIHE), Warsaw, Poland, UnivRennes, UMR 6290, CNRS, Institute of Genetics and Development of Rennes, Cell Cycle Group, Faculty of Medicine, Rennes, France. Electronic address: jacek.kubiak@univ-rennes1.fr. | 1062 | |||||
| 10.1016/j.chest.2020.05.573 | Journal Article | en | Efficacy of Almitrine in the Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32512007 | 0012-3692 | 2020-06-07 02:00:00+02:00 | pubmed | Chest | Romain Barthélémy;Pierre-Louis Blot;Ambre Tiepolo;Arthur Le Gall;Claire Mayeur;Samuel Gaugain;Louis Morisson;Etienne Gayat;Alexandre Mebazaa;Benjamin Glenn Chousterman | 2020-06-06 02:00:00+02:00 | 32512007 | FR | Department of Anesthesia and Critical Care, Hôpital Lariboisière, DMU Parabol, APHP Nord, Université de Paris, Paris, France, Inserm UMR-S942, Mascot, Université de Paris, Paris, France. Electronic address: romain.barthelemy@aphp.fr.;Department of Anesthesia and Critical Care, Hôpital Lariboisière, DMU Parabol, APHP Nord, Université de Paris, Paris, France.;Department of Anesthesia and Critical Care, Hôpital Lariboisière, DMU Parabol, APHP Nord, Université de Paris, Paris, France, Inserm UMR-S942, Mascot, Université de Paris, Paris, France.;Department of Anesthesia and Critical Care, Hôpital Lariboisière, DMU Parabol, APHP Nord, Université de Paris, Paris, France, MΞDISIM, Inria Paris-Saclay-LMS, Ecole Polytechnique, Palaiseau, France.;Department of Anesthesia and Critical Care, Hôpital Lariboisière, DMU Parabol, APHP Nord, Université de Paris, Paris, France, Department of Applied Mathematics, Université de Paris, Paris, France. | 1064 | |||||
| 10.1186/s13054-020-03014-1 | Editorial | en | Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure? | https://www.ncbi.nlm.nih.gov/pubmed/32487139 | 1364-8535 | 2020-06-07 02:00:00+02:00 | pubmed | Acute Disease;Coronavirus Infections__drug therapy;Cyclosporine__therapeutic use;Humans;Pandemics;Pneumonia, Viral__drug therapy;Respiratory Insufficiency__drug therapy;Treatment Outcome;COVID-19 | Critical Care | Martin Cour;Michel Ovize;Laurent Argaud | 2020-06-02 02:00:00+02:00 | 32487139 | FR | Hospices Civils de Lyon, Service de Médecine Intensive-Réanimation, Hôpital Edouard Herriot, 5, place d'Arsonval, 69437, Lyon Cedex 03, France.;INSERM UMR1060 (CarMeN), Université de Lyon, Lyon, France.;Hospices Civils de Lyon, Centre d'Investigation Clinique de Lyon, Université de Lyon, Lyon, France.;Hospices Civils de Lyon, Service de Médecine Intensive-Réanimation, Hôpital Edouard Herriot, 5, place d'Arsonval, 69437, Lyon Cedex 03, France. laurent.argaud@chu-lyon.fr.;INSERM UMR1060 (CarMeN), Université de Lyon, Lyon, France. laurent.argaud@chu-lyon.fr. | 1082 | ||||
| 10.1016/j.jaad.2020.05.145 | Journal Article | en | Chilblain-like acral lesions during the COVID-19 pandemic ("COVID toes"): Histologic, immunofluorescence, and immunohistochemical study of 17 cases. | https://www.ncbi.nlm.nih.gov/pubmed/32502585 | During the coronavirus disease 2019 pandemic, several acral chilblain-like lesions were observed in young patients with suspected, but mostly unconfirmed, infection with severe acute respiratory syndrome coronavirus 2. The histopathologic aspect of these lesions is as yet poorly known. | 0190-9622 | 2020-06-07 02:00:00+02:00 | pubmed | Journal of the American Academy of Dermatology | Jean Kanitakis;Cécile Lesort;Marie Danset;Denis Jullien | COVID-19;SARS-CoV-2;chilblains;dermatopathology;direct immunofluorescence;eosinophils;immunohistochemistry | 2020-06-02 02:00:00+02:00 | 32502585 | FR | Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France, Department of Anatomic Pathology, Lyon Sud Hospital Center, Pierre Bénite, France. Electronic address: jean.kanitakis@univ-lyon1.fr.;Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France. | 1084 | |||
| Letter;Research Support, Non-U.S. Gov't;Validation Study | en | Validating QT-Interval Measurement Using the Apple Watch ECG to Enable Remote Monitoring During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32478565 | 2020-06-07 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Coronavirus Infections__diagnosis;Electrocardiography, Ambulatory__methods;Female;Humans;Long QT Syndrome__diagnosis;Male;Middle Aged;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Remote Sensing Technology__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Marc Strik;Théo Caillol;F Daniel Ramirez;Saer Abu-Alrub;Hugo Marchand;Nicolas Welte;Philippe Ritter;Michel Haïssaguerre;Sylvain Ploux;Pierre Bordachar | ambulatory electrocardiography;cardiac arrhythmias;cardiology;electrocardiography;long QT syndrome;remote consultation;telemedicine | 2020-06-01 02:00:00+02:00 | 32478565 | FR | Bordeaux University Hospital (CHU), Cardio-Thoracic Unit, Pessac, France (M.S., T.C., F.D.R., S.A.-A., H.M., N.W., P.R., M.H., S.P., P.B.).;IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Pessac-Bordeaux, France (M.S., S.A.-A., P.R., M.H., S.P., P.B.). | 1102 | ||||||
| Journal Article | en | COVID-19: Armageddon before Light? | https://www.ncbi.nlm.nih.gov/pubmed/32549877 | 2020-06-07 02:00:00+02:00 | pubmed | Damien Gruson;Gabriel Ko;David Luu | COVID-19;coronavirus;laboratory;outbreak;testing | 2020-06-02 02:00:00+02:00 | 32549877 | FR;BE;US | Department of Clinical Biochemistry, St-Luc University Clinics and Catholic University of Louvain, Brussels, Belgium.;Research Unit for Endocrinology, Diabetes and Nutrition, Institute of Experimental and Clinical Research, St-Luc University Clinics and Catholic University of Louvain, Brussels, Belgium.;GKo and Co Consulting, Paris, France.;The Heart Fund, Paris, France.;Absolutys, New York, USA. | 1109 | |||||||
| Letter;Comment | en | Does type of immunosupression influence the course of Covid-19 infection? | https://www.ncbi.nlm.nih.gov/pubmed/32504741 | Coronavirus disease 19 (Covid-19) is a new emerging virus responsible for pandemic and death. High blood pressure, diabetes, obesity have been described as poor prognosis factors. Few data have been reported in patient with immunocompromised status (solid tumor, hematological malignancy, rheumatoid conditions or organ transplant). We evaluated the characteristics of patients, including the outcome, with immunodepression hospitalized in Besancon University hospital (East of France). We wanted to identify if a type of immunosupression influences the course of Covid-19. In a cohort of 80 patients with immunosupression (42 solid tumors, 20 hematological malignancy and 18 non neoplastic immunosupression), poor outcomes (Intensive care unit hospitalization and or deaths) was frequent (38%) and tended to be more frequent in patients with hematological malignancy. | 2020-06-07 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Child;Coronavirus Infections__epidemiology;France;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | J Razanamahery;T Soumagne;S Humbert;A S Brunel;Q Lepiller;E Daguindau;L Mansi;C Chirouze;K Bouiller | Covid-19;cancer;immunosupression;poor outcomes | 2020-06-03 02:00:00+02:00 | 32504741 | FR | Internal Medicine Department, Besancon University Hospital, Besancon, France. Electronic address: jrazanamahery@chu-besancon.fr.;Intensive Care Unit Department, Besancon University Hospital, Besancon, France.;Internal Medicine Department, Besancon University Hospital, Besancon, France.;Infectious and tropical disease Department, Besancon University Hospital, Besancon, France.;Laboratory of virology, Besancon University Hospital, Besancon, France.;Department of Hematology, Besancon University Hospital, Besancon, France.;Oncology Department, Besancon University Hospital, Besancon, France, UMR 1098, Interaction Hôte-Greffon-Tumeurs/Ingénierie Cellulaire et Génique.;Infectious and tropical disease Department, Besancon University Hospital, Besancon, France, UMR CNRS 6249, Chrono environnement, University of Bourgogne Franche-Comté. | 1116 | |||||
| Letter | en | Severe pulmonary embolism in COVID-19 patients: a call for increased awareness. | https://www.ncbi.nlm.nih.gov/pubmed/32487231 | 2020-06-07 02:00:00+02:00 | pubmed | Adult;Aged;Coronavirus Infections__epidemiology;Female;Humans;Intensive Care Units;Male;Middle Aged;Pandemics;Paris__epidemiology;Pneumonia, Viral__epidemiology;Pulmonary Embolism__epidemiology;Retrospective Studies;Severity of Illness Index;COVID-19 | Guillaume Hékimian;Guillaume Lebreton;Nicolas Bréchot;Charles-Edouard Luyt;Matthieu Schmidt;Alain Combes | 2020-06-02 02:00:00+02:00 | 32487231 | FR | Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, F-75013, Paris, France. guillaume.hekimian@aphp.fr.;Service de médecine intensive-réanimation, Institut de Cardiologie, APHP Hôpital Pitié-Salpêtrière, F-75013, Paris, France. guillaume.hekimian@aphp.fr.;Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, F-75013, Paris, France.;Service de chirurgie thoracique et cardio-vasculaire, Institut de Cardiologie, APHP Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Service de médecine intensive-réanimation, Institut de Cardiologie, APHP Hôpital Pitié-Salpêtrière, F-75013, Paris, France. | 1133 | |||||||
| Letter | en | SARS-CoV-2 Does Not Spread Through Extracorporeal Membrane Oxygenation or Dialysis Membranes. | https://www.ncbi.nlm.nih.gov/pubmed/32525400 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__transmission;Extracorporeal Membrane Oxygenation;Humans;Membranes, Artificial;Pandemics;Pneumonia, Viral__transmission;Renal Dialysis;COVID-19;severe acute respiratory syndrome coronavirus 2 | Martin Dres;Sonia Burrel;David Boutolleau;Guillaume Voiriot;Alexandre Demoule;Alain Combes;Guillaume Lebreton;Matthieu Schmidt | 2020-06-12 02:00:00+02:00 | 32525400 | FR | UMR_S 1158 Neurophysiologie respiratoire expérimentale et cliniqueParis, France.;AP-HP Sorbonne UniversitéParis, France.;INSERM UMR_S 1136Paris, Franceand.;UMRS_1166-ICAN Institute of Cardiometabolism and NutritionParis, France. | 1136 | |||||||
| 10.1093/jac/dkaa223 | Journal Article | en | Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32514563 | 0305-7453,1460-2091 | 2020-06-14 02:00:00+02:00 | pubmed | Journal of Antimicrobial Chemotherapy | Nathan Peiffer-Smadja;François-Xavier Lescure;Erwan Sallard;Philippe Ravaud;Bruno Vegreville;Jean-David Zeitoun | 2020-06-10 02:00:00+02:00 | 32514563 | FR;GB | Université de Paris, IAME, INSERM, F-75018 Paris, France.;National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.;Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018 Paris, France.;École normale supérieure de Paris, 45 rue d'Ulm, 75005 Paris, France.;U1153, Epidemiology and Biostatistics Sorbonne, Paris Cite Research Center (CRESS), Methods of therapeutic evaluation of chronic diseases team (METHODS), INSERM, Université Paris Descartes, Paris, Île-de-France, France.;Inato, Paris, France. | 1149 | |||||
| 10.1016/j.dss.2020.113342 | Journal Article | en | How do agribusinesses thrive through complexity? The pivotal role of e-commerce capability and business agility. | https://www.ncbi.nlm.nih.gov/pubmed/32834263 | The recent COVID-19 pandemic has clearly shown how agricultural foods and e-commerce initiatives are critical for many organizations, regions, and countries worldwide. Despite this vital importance, prior IS research on the business value of IT has not paid enough attention to the potential specificities of the agribusinesses. This study examines the impact of e-commerce capability on business agility in agribusinesses. Using a sample of Chinese agriculture firms, we find that: 1) The e-commerce capability of agribusinesses enables two types of business agility: market capitalizing agility and operational adjustment agility, and 2) while environmental complexity positively moderates the effects of e-commerce capability on the market capitalizing agility and operational adjustment agility, environmental dynamism does not. This study contributes to the IS research on the business value of IT by providing an eloquent theoretical explanation and empirical evidence on how e-commerce capability help agricultural firms to thrive through complexity by enabling market capitalizing agility (strategic focus) and operational adjustment agility (operational focus). | 0167-9236 | 2020-06-14 02:00:00+02:00 | pubmed | Decision Support Systems | Jiabao Lin;Lei Li;Xin Robert Luo;Jose Benitez | Agribusinesses;Business agility;Business value of IT;Complexity;E-commerce capability;IT-enabled organizational capabilities perspective | 2020-06-11 02:00:00+02:00 | 32834263 | FR;CN;MX;US | College of Economics and Management, South China Agricultural University, Guangzhou, China.;Anderson School of Management, University of New Mexico, Albuquerque, NM, USA.;Department of Supply Chain Management and Information Systems, Rennes School of Business, Rennes, France. | 1158 | |||
| 10.1037/tra0000798 | Journal Article | en | Prolonged grief related to COVID-19 deaths: Do we have to fear a steep rise in traumatic and disenfranchised griefs? | https://www.ncbi.nlm.nih.gov/pubmed/32525367 | The circumstances of coronavirus disease (COVID-19)-related deaths embed multiple traumatic characteristics, alongside several external factors that can disenfranchise individual grief. In this context, severe forms of traumatic distress, guilt, somatization, regret, anger, and unspecific symptoms not yet included in prolonged grief disorder (PGD) criteria could emerge. This article (a) analyzes factors related to bereavement in the context of the COVID-19 pandemic; (b) proposes avenues for meaning-making practices to facilitate individual and collective mourning process; and (c) invites clinicians to pay attention to the traumatic characteristics of COVID-19-related deaths adopting a holistic approach of PGD clinical manifestations, as well as in evaluation and treatment of cases. (PsycInfo Database Record (c) 2020 APA, all rights reserved). | 1942-969X,1942-9681 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Coronavirus Infections__mortality;Disenfranchised Grief;Grief;Humans;Pandemics;Pneumonia, Viral__mortality;Psychological Trauma__psychology;COVID-19 | Psychological Trauma: Theory, Research, Practice, and Policy | Cyrille Kossigan Kokou-Kpolou;Manuel Fernández-Alcántara;Jude Mary Cénat | 2020-06-11 02:00:00+02:00 | 32525367 | FR;CA;ES | Department of Psychology, University of Picardy Jules Verne.;Department of Health Psychology, University of Alicante.;School of Psychology, University of Ottawa. | 1159 | |||
| Letter;Research Support, Non-U.S. Gov't | en | Molecular mimicry may explain multi-organ damage in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32535095 | 2020-06-14 02:00:00+02:00 | pubmed | Autoimmune Diseases__immunology;Betacoronavirus__chemistry;Coronavirus Infections__immunology;Cross Reactions;Epitopes__chemistry;Humans;Models, Immunological;Molecular Mimicry__immunology;Pandemics;Pneumonia, Viral__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Francesca Angileri;Sébastien Legare;Antonella Marino Gammazza;Everly Conway de Macario;Alberto Jl Macario;Francesco Cappello | Anosmia;Kawasaki vasculitis;Leukopenia;Molecular mimicry;OR7D4;PARP9;SLC12A6;Severe acute respiratory syndrome coronavirus 2;Vascular damage | 2020-06-11 02:00:00+02:00 | 32535095 | FR;IT;US | Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.;Département d'Informatique de l'ÉNS, ÉNS, CNRS, Université PSL, Paris, France, Centre de recherche Inria de Paris, Paris, France.;University of Palermo, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Palermo, Italy.;Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore-Institute of Marine and Environmental Technology (IMET), Baltimore, MD 21202, USA.;Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore-Institute of Marine and Environmental Technology (IMET), Baltimore, MD 21202, USA, Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy.;University of Palermo, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Palermo, Italy, Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy. Electronic address: francesco.cappello@unipa.it. | 1164 | ||||||
| Letter | en | COVID-19 encephalopathy: detection of antibodies against SARS-CoV-2 in CSF. | https://www.ncbi.nlm.nih.gov/pubmed/32529577 | 2020-06-14 02:00:00+02:00 | pubmed | Daniela Andriuta;Pierre-Alexandre Roger;William Thibault;Bénédicte Toublanc;Chloe Sauzay;Sandrine Castelain;Olivier Godefroy;Etienne Brochot | 2020-06-11 02:00:00+02:00 | 32529577 | FR | Department of Neurology and Laboratoire de Neurosciences Fonctionnelles et Pathologies (UR UPJV 4559), Amiens University Medical Center and Jules Verne University of Picardy, 80054, Amiens, France. andriuta.daniela@chu-amiens.fr.;Department of Respiratory Intensive Care Unit and Lung Diseases, Amiens University Medical Center and Jules Verne University of Piacardy, Amiens, France.;Department of Neurology and Laboratoire de Neurosciences Fonctionnelles et Pathologies (UR UPJV 4559), Amiens University Medical Center and Jules Verne University of Picardy, 80054, Amiens, France.;Department of Pneumology, Amiens University Medical Center and INSERM U1088, Jules Verne University of Picardy, Amiens, France.;Department of Biochemistry, Amiens University Medical Center, Amiens, France.;CHIMERE Unit, EA7516, Jules Verne University of Picardie, Amiens, France.;Department of Virology, Amiens University Medical Center, Amiens, France.;AGIR Reaserch Unit ER4294, Jules Verne University of Picardie, Amiens, France. | 1166 | ||||||||
| 10.1021/acs.est.0c02777 | News | en | Existence of SARS-CoV-2 in Wastewater: Implications for Its Environmental Transmission in Developing Communities. | https://www.ncbi.nlm.nih.gov/pubmed/32525667 | 0013-936X,1520-5851 | 2020-06-14 02:00:00+02:00 | pubmed | Environmental Science & Technology | Muhammad Usman;Muhammad Farooq;Khalil Hanna | 2020-06-11 02:00:00+02:00 | 32525667 | FR;OM;PK | PEIE Research Chair for the Development of Industrial Estates and Free Zones, Center for Environmental Studies and Research, Sultan Qaboos University, Al-Khoud 123, Muscat, Oman.;Department of Clinical Sciences, College of Veterinary and Animal Sciences, Jhang, University of Veterinary and Animal Sciences, Lahore, Pakistan.;Univ Rennes, Ecole Nationale Supérieure de Chimie de Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes) - UMR 6226, F-35000, Rennes, France.;Institut Universitaire de France (IUF), MESRI, 1 rue Descartes, 75231 Paris, France. | 1169 | |||||
| 10.1016/j.diii.2020.06.001 | Journal Article;Review | en | Chest CT in COVID-19 pneumonia: A review of current knowledge. | https://www.ncbi.nlm.nih.gov/pubmed/32571748 | The current COVID-19 pandemic has highlighted the essential role of chest computed tomography (CT) examination in patient triage in the emergency departments, allowing them to be referred to "COVID" or "non-COVID" wards. Initial chest CT examination must be performed without intravenous administration of iodinated contrast material, but contrast material administration is required when pulmonary embolism is suspected, which seems to be frequent in severe forms of the disease. Typical CT features consist of bilateral ground-glass opacities with peripheral, posterior and basal predominance. Lung disease extent on CT correlates with clinical severity. Artificial intelligence could assist radiologists for diagnosis and prognosis evaluation. | 2211-5684 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Aged;Artificial Intelligence;Betacoronavirus;Child;Contrast Media;Coronavirus Infections__complications;Female;Hospital Units__classification;Hospitalization;Humans;Lung__diagnostic imaging;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Pregnancy;Pulmonary Embolism__diagnostic imaging;Radiography, Thoracic__methods;Severity of Illness Index;Tomography, X-Ray Computed;Triage;COVID-19;severe acute respiratory syndrome coronavirus 2 | Diagnostic and Interventional Imaging | C Jalaber;T Lapotre;T Morcet-Delattre;F Ribet;S Jouneau;M Lederlin | COVID-19;Pulmonary embolism;Severe acute respiratory syndrome coronavirus 2;Tomography;X-ray computed | 2020-06-11 02:00:00+02:00 | 32571748 | FR | CHU Saint-Étienne, Department of Radiology, 42270 Saint-Priest-en-Jarez, France.;CHU de Rennes, Department of Radiology, 35033 Rennes, France.;CHU de Rennes, Department of Respiratory Medicine, 35033 Rennes, France.;CHU de Rennes, Department of Radiology, 35033 Rennes, France, LTSI, INSERM, UMR 1099, Université de Rennes, 35000 Rennes, France. Electronic address: mathieu.lederlin@chu-rennes.fr. | 1170 | ||
| 10.1038/s41575-020-0319-3 | Journal Article;Review | en | SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. | https://www.ncbi.nlm.nih.gov/pubmed/32528139 | The current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has required a complete change in the management of patients with inflammatory bowel disease (IBD) who need to undergo endoscopic procedures. Several preventive measures must be taken to avoid the spread of infection among health-care professionals and patients with IBD, including the use of personal protective equipment, greater attention to endoscopic room hygiene and rescheduling of non-urgent procedures. This Perspective aims to provide a guide based on the Italian and French experience to better face the difficulties encountered by endoscopists during this global health emergency. In particular, recommendations regarding the use of personal protective equipment to prevent COVID-19 transmission, both for patients and health-care professionals, are proposed and different scenarios in endoscopic IBD management are evaluated to suggest when endoscopy could be rescheduled and replaced by alternative biomarkers. | 1759-5045,1759-5053 | 2020-06-14 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Decision Making;Endoscopy, Gastrointestinal;France__epidemiology;Humans;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Inflammatory Bowel Diseases__diagnosis;Italy__epidemiology;Pandemics__prevention & control;Patient Selection;Personal Protective Equipment;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nature Reviews Gastroenterology & Hepatology | Federica Furfaro;Lucine Vuitton;Gionata Fiorino;Stephane Koch;Mariangela Allocca;Daniela Gilardi;Alessandra Zilli;Ferdinando D'Amico;Simona Radice;Jean-Baptiste Chevaux;Marion Schaefer;Stanislas Chaussade;Silvio Danese;Laurent Peyrin-Biroulet | 2020-06-11 02:00:00+02:00 | 32528139 | FR;IT | IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.;Department of Gastroenterology, Besançon University Hospital, Bourgogne-Franche-Comté University, Besançon, France.;Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Gastroenterology, Paris Cochin University Hospital APHP, Paris 5 University, Besançon, France.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France. peyrinbiroulet@gmail.com. | 1171 | |||
| 10.1208/s12248-020-00465-w | Journal Article | en | Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. | https://www.ncbi.nlm.nih.gov/pubmed/32533263 | The co-administration of hydroxychloroquine with azithromycin is proposed in COVID-19 therapy. We hypothesize a new mechanism supporting the synergistic interaction between these drugs. Azithromycin is a substrate of ABCB1 (P-glycoprotein) which is localized in endosomes and lysosomes with a polarized substrate transport from the cell cytosol into the vesicle interior. SARS-CoV-2 and drugs meet in these acidic organelles and both basic drugs, which are potent lysosomotropic compounds, will become protonated and trapped within these vesicles. Consequently, their intra-vesicular concentrations can attain low micromolar effective cytotoxic concentrations on SARS-CoV-2 while concomitantly increase the intra-vesicular pH up to around neutrality. This last effect inhibits lysosomal enzyme activities responsible in virus entry and replication cycle. Based on these considerations, we hypothesize that ABCB1 could be a possible enhancer by confining azithromycin more extensively than expected when the trapping is solely dependent on the passive diffusion. This additional mechanism may therefore explain the synergistic effect when azithromycin is added to hydroxychloroquine, leading to apparently more rapid virus clearance and better clinical benefit, when compared to monotherapy with hydroxychloroquine alone. | 1550-7416 | 2020-06-14 02:00:00+02:00 | pubmed | ATP Binding Cassette Transporter, Subfamily B__agonists;Anti-Infective Agents__pharmacology;Azithromycin__pharmacology;Coronavirus Infections__drug therapy;Drug Synergism;Drug Therapy, Combination;Humans;Hydroxychloroquine__pharmacology;Pandemics;Pneumonia, Viral__drug therapy;COVID-19 | The AAPS Journal | J M Scherrmann | ABCB1;COVID-19;azithromycin;hydroxychloroquine;lysosomes | 2020-06-12 02:00:00+02:00 | 32533263 | FR | Faculty of Pharmacy, University of Paris, Inserm UMRS-1144, Paris, France. jean-michel.scherrmann@inserm.fr.;Laboratoire de Pharmacocinétique, Faculté de Pharmacie, 4, avenue de l'Observatoire, 75006, Paris, France. jean-michel.scherrmann@inserm.fr. | 1176 | ||
| 10.1016/j.jri.2020.103168 | Journal Article;Review | en | COVID-19 and immunomodulation treatment for women with reproductive failures. | https://www.ncbi.nlm.nih.gov/pubmed/32603991 | COVID-19 pandemic is affecting various areas of health care, including human reproduction. Many women with reproductive failures, during the peri-implantation period and pregnancy, are on the immunotherapy using immune modulators and immunosuppressant due to underlying autoimmune diseases, cellular immune dysfunction, and rheumatic conditions. Many questions have been raised for women with immunotherapy during the COVID-19 pandemic, including infection susceptibility, how to manage women with an increased risk of and active COVID-19 infection. SARS-CoV-2 is a novel virus, and not enough information exists. Yet, we aim to review the data from previous coronavirus outbreaks and current COVID-19 and provide interim guidelines for immunotherapy in women with reproductive failures. | 0165-0378 | 2020-06-14 02:00:00+02:00 | pubmed | Journal of Reproductive Immunology | Joanne Kwak-Kim;Kuniaki Ota;Nayoung Sung;Changsheng Huang;Lujain Alsubki;Sungki Lee;Jae Won Han;Aera Han;Xiuhua Yang;Wael Saab;Youssef Derbala;Wen-Juan Wang;Qiaohua He;Aihua Liao;Toshifumi Takahashi;Marcelo Borges Cavalcante;Ricardo Barini;Shihua Bao;Atsushi Fukui;Nathalie Lédée;Carolyn Coulam | COVID-19;Immunotherapy;Pregnancy;Reproductive failure;SARS-CoV-2 | 2020-06-12 02:00:00+02:00 | 32603991 | FR;SA;CN;JP;GB;US;BR;KR | Reproductive Medicine and Immunology, Obstetrics and Gynecology, Clinical Sciences Department, Center for Cancer Cell Biology, Immunology and Infection, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 830 West End Court, Vernon Hills, IL, 60061, USA. Electronic address: Joanne.KwakKim@rosalindfranklin.edu.;Fukushima Medical Center for Children and Women, Fukushima Medical University, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan.;Reproductive Medicine and Immunology, Obstetrics and Gynecology, Clinical Sciences Department, Center for Cancer Cell Biology, Immunology and Infection, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 830 West End Court, Vernon Hills, IL, 60061, USA.;Reproductive Medicine and Immunology, Obstetrics and Gynecology, Clinical Sciences Department, Center for Cancer Cell Biology, Immunology and Infection, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 830 West End Court, Vernon Hills, IL, 60061, USA, Traditional Chinese Medicine Department of Rheumatism, Huazhong University of Science and Technology Union Shenzhen Hospital, China.;Reproductive Medicine and Immunology, Obstetrics and Gynecology, Clinical Sciences Department, Center for Cancer Cell Biology, Immunology and Infection, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 830 West End Court, Vernon Hills, IL, 60061, USA, Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Riyadh. Saudi Arabia.;Department of Obstetrics and Gynecology, Myuonggok Medical Research Center, Konyang University College of Medicine, Daejeon, South Korea.;Department of Obstetrics and Gynecology, MizMedi Hospital, Seoul, South Korea.;Department of Obstetrics, The First Hospital of China Medical University, Shenyang, China.;The Centre for Reproductive & Genetic Health, 230-232 Great Portland St, Fitzrovia, London W1W 5QS, UK.;Obstetrics and Gynecology, Beaumont Hospital, Dearborn, Grosse Pointe, MI, USA.;Reproduction Medical Center, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, China.;Department of Reproductive Medicine Center, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital of Henan University, Zhengzhou, Henan, 450003, China.;Institute of Reproductive Health, Center for Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.;Department of Obstetrics and Gynecology, Fortaleza University (UNIFOR), Fortaleza, CE, Brazil, CONCEPTUS - Reproductive Medicine, Fortaleza, CE, Brazil.;Department of Obstetrics and Gynecology, Campinas University (UNICAMP), Campinas, SP, Brazil.;Department of Reproductive Immunology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, 201204, China.;Department of Obstetrics and Gynecology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.;MatriceLAB Innove, Pépinière Paris Santé Cochin, Hôpital Cochin, 29 rue du faubourg St Jacques, 75014 Paris, France, Centre d'assistance médicale à la procréation, Hôpital des Bluets, 4 rue Lasson, 75012, Paris, France.;Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, 60064, IL, USA. | 1180 | |||
| 10.1136/annrheumdis-2020-217960 | Journal Article;Multicenter Study | en | Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. | https://www.ncbi.nlm.nih.gov/pubmed/32527868 | Current data suggest that COVID-19 is less frequent in children, with a milder course. However, over the past weeks, an increase in the number of children presenting to hospitals in the greater Paris region with a phenotype resembling Kawasaki disease (KD) has led to an alert by the French national health authorities. | 0003-4967,1468-2060 | 2020-06-14 02:00:00+02:00 | pubmed | Adolescent;Betacoronavirus;Child;Child, Preschool;Cohort Studies;Coronavirus Infections__diagnosis;Diagnosis, Differential;Female;Humans;Male;Mucocutaneous Lymph Node Syndrome__diagnosis;Pandemics;Paris__epidemiology;Pneumonia, Viral__diagnosis;Systemic Inflammatory Response Syndrome__diagnosis;COVID-19;pediatric multisystem inflammatory disease, COVID-19 related;severe acute respiratory syndrome coronavirus 2 | Annals of the Rheumatic Diseases | Marie Pouletty;Charlotte Borocco;Naim Ouldali;Marion Caseris;Romain Basmaci;Noémie Lachaume;Philippe Bensaid;Samia Pichard;Hanane Kouider;Guillaume Morelle;Irina Craiu;Corinne Pondarre;Anna Deho;Arielle Maroni;Mehdi Oualha;Zahir Amoura;Julien Haroche;Juliette Chommeloux;Fanny Bajolle;Constance Beyler;Stéphane Bonacorsi;Guislaine Carcelain;Isabelle Koné-Paut;Brigitte Bader-Meunier;Albert Faye;Ulrich Meinzer;Caroline Galeotti;Isabelle Melki | cytokines;inflammation;outcome and process assessment, health care | 2020-06-11 02:00:00+02:00 | 32527868 | FR | General Paediatrics, Department of Infectious Disease and Internal Medicine, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France, Robert Debré University Hospital, AP-HP, Paris, France.;Université de Paris, UFR de Médecine Paris Nord, 75010 Paris, France.;Department of Pediatric Rheumatology Reference centre for Autoinflammatory diseases and amyloidosis (CEREMAIA), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France.;Université Paris Sud-Saclay, UVSQ, 94276 Le Kremlin-Bicêtre, France.;INSERM UMR 1123, ECEVE, Paris, France.;Department of Microbiology, Robert Debré University Hospital,AP-HP, Paris, France.;Departments of General Paediatrics and Paediatric Emergency, Louis-Mourier Hospital, AP-HP, Colombes, France.;Infection-Antimicrobials-Modelling-Evolution IAME, INSERM, UMR-1137, Université de Paris, 75018, Paris, France.;Department of General Paediatrics, Victor Dupouy Hospital, Argenteuil, France.;Department of General Paediatrics, René Dubos, Pontoise Hospital, Pontoise, France.;Department of General Paediatrics, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France.;Paediatric emergency Department, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France.;Sickle cell disease referal center, INSERM U955, Centre hospitalier Intercommunal de Créteil, Paris XII University, Créteil, France.;Paediatric Intensive Care Unit, Robert Debré University Hospital, AP-HP, Paris, France.;Paediatric Intensive Care Unit, Necker-Enfants-Malades University Hospital, AP-HP, Paris, France.;Inserm UMR-S 1135, Sorbonne Université, Paris, France.;Department of Immunology and Infectious disease (CIMI-Paris), Pitié-Salpêtrière Hospital, AP-HP, Paris, France.;Medical Intensive Care Unit, Institut de Cardiologie, AP-HP, Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France.;Cardiopaediatric Unit, M3-C, Necker-Enfants-Malades University Hospital, AP-HP, Paris, France.;Cardiopaediatric Unit, Robert Debré University Hospital, AP-HP, Paris, France.;Department of Immunology, Robert Debré University Hospital, AP-HP, Paris, France.;Paediatric Hematology-Immunology and Rheumatology Department, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France, Necker-Enfants-Malades University Hospital, AP-HP, Paris, France.;Laboratory of Immunogenetics of paediatric autoimmune diseases, INSERM UMR 1163, Paris, France.;Center for Research on Inflammation, INSERM, UMR1149, Paris, France.;Biology and Genetics of Bacterial Cell Wall Unit, Pasteur Institute, Paris, France.;General Paediatrics, Department of Infectious Disease and Internal Medicine, Reference centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France, Robert Debré University Hospital, AP-HP, Paris, France isabelle.melki@aphp.fr.;Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, Paris, France. | 1183 | ||
| 10.1148/radiol.2020202288 | Journal Article | en | Cardiac MRI of Children with Multisystem Inflammatory Syndrome (MIS-C) Associated with COVID-19: Case Series. | https://www.ncbi.nlm.nih.gov/pubmed/32515676 | This case series examines cardiac MRI findings in four children and adolescents admitted to intensive care in April 2020 for multisystem inflammatory syndrome and Kawasaki disease-like features related to COVID-19. Acute myocarditis occurred less than 1 week after onset of fever and gastrointestinal symptoms. Physical examination showed rash and cheilitis/conjunctivitis. All patients recovered after intravenous immunoglobulin therapy. SARS-CoV-2 RT-PCR was negative on nasopharyngeal, stool, and respiratory samples and was positive on serology. Cardiac MRI showed diffuse myocardial edema on T2-STIR sequences and native-T1 mapping, with no evidence of late gadolinium enhancement suggestive of replacement fibrosis or focal necrosis. These findings favor post-infectious myocarditis in children and adolescents with COVID-19. | 0033-8419,1527-1315 | 2020-06-14 02:00:00+02:00 | pubmed | Radiology | Eléonore Blondiaux;Pauline Parisot;Alban Redheuil;Lucile Tzaroukian;Yaël Levy;Chiara Sileo;Aurélie Schnuriger;Mathie Lorrot;Romain Guedj;Hubert Ducou le Pointe | 2020-06-09 02:00:00+02:00 | 32515676 | FR | From the Department of imaging, Hôpital Trousseau - Assistance Publique-Hôpitaux Parisiens (AP-HP), Sorbonne Université, Paris, France (E.B., C.S., H.D.L.P.), Laboratoire d'Imagerie Biomédicale, Sorbonne Université, INSERM, CNRS, Paris, France (E.B., A.R.), Pediatric cardiovascular Unit, Hôpital Trousseau - Assistance Publique-Hôpitaux Parisiens (AP-HP), Sorbonne Université, Paris, France (P.P., A.R.), Department of Cardiovascular and Thoracic Imaging and Interventional Radiology, Institute of Cardiology, Hôpital Pitié-Salpêtrière - Assistance Publique-Hôpitaux Parisiens (AP-HP) Sorbonne Université, Paris, France (A.R.), Neonatal and Pediatric Intensive Care Unit, Hôpital Trousseau - Assistance Publique-Hôpitaux Parisiens (AP-HP), Sorbonne Université, Paris, France (L.T., Y.L.), Laboratoire INSERM U955- PHYDES-IMRB - Stratégies pharmacologiques et thérapeutiques de l'ischémie myocardique et l'insuffisance coronaire- Ecole Vétérinaire, Maisons-Alfort (Y.L.), Laboratoire de virologie, Hôpital Trousseau - Assistance Publique-Hôpitaux Parisiens (AP-HP), Sorbonne Université, Paris, France (A.S.), Department of Pediatrics, Hôpital Trousseau - Assistance Publique-Hôpitaux Parisiens (AP-HP), Sorbonne Université, Paris, France (M.L.), Pediatric Emergency Department, Hôpital Trousseau - Assistance Publique-Hôpitaux Parisiens (AP-HP), Sorbonne Université, Paris, France (R.G.). | 1187 | ||||
| 10.1093/ecco-jcc/jjaa119 | Journal Article | en | Clinical trials for inflammatory bowel disease: a global guidance during COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32520311 | The severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]-causing coronavirus disease [COVID]-19 pandemic poses major challenges for patients with inflammatory bowel disease to be recruited and maintained in clinical trials. However, clinical trials offer patients who have failed multiple drugs access to study medications with alternative mode of action and the potential for relief from inflammation-mediated symptoms. Therefore, the continuation of clinical trials in IBD during the COVID-19 pandemic is important both for participants and the community of IBD patients, due to the dire need of an expanded therapeutic armamentarium. As the safety of patients in clinical trials is the leading principle, we are providing ten specific rules to guide patients and principal investigators safely through the challenging time. | 1873-9946,1876-4479 | 2020-06-14 02:00:00+02:00 | pubmed | Journal of Crohn's and Colitis | Walter Reinisch;Silvio Danese;Laurent Peyrin-Biroulet;Edward V Loftus | 2020-06-10 02:00:00+02:00 | 32520311 | FR;IT;US;AT | Department of Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.;Inflammatory Bowel Disease Center, Humanitas University, IRCCS Humanitas Research Hospital, Milano, Italy.;Inserm NGERE U1256 and Department of Gastroenterology, Nancy University Hospital, Lorraine University, France.;Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, U.S.A. | 1194 | ||||
| Letter | en | COVID-19 in Nursing Homes: The Problematic Management of Residents Without Positive COVID-19 RT-PCR. | https://www.ncbi.nlm.nih.gov/pubmed/32610807 | 2020-06-14 02:00:00+02:00 | pubmed | Frédéric Bloch | 2020-06-10 02:00:00+02:00 | 32610807 | FR | Department of Geriatric Medicine, University Hospital of Amiens-Picardie, Amiens, France.;Laboratory of Functional Neurosciences (EA 4559), University of Picardie Jules Verne, Amiens, France. | 1195 | ||||||||
| 10.1016/j.diii.2020.05.011 | Journal Article | en | Incidental diagnosis of Covid-19 pneumonia on chest computed tomography. | https://www.ncbi.nlm.nih.gov/pubmed/32571747 | The purpose of this study was to determine the prevalence and imaging characteristics of incidentally diagnosed COVID-19 pneumonia on computed tomography (CT). | 2211-5684 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Aged, 80 and over;Asymptomatic Diseases;Betacoronavirus;Coronavirus Infections__complications;Fatigue__diagnosis;Female;Humans;Incidental Findings;Male;Middle Aged;Multidetector Computed Tomography;Pandemics;Paris__epidemiology;Pneumonia, Viral__complications;Radiography, Thoracic;Retrospective Studies;Reverse Transcriptase Polymerase Chain Reaction;COVID-19;severe acute respiratory syndrome coronavirus 2 | Diagnostic and Interventional Imaging | S Neveu;I Saab;S Dangeard;S Bennani;M Tordjman;G Chassagnon;M-P Revel | COVID-19 pneumonia;Computed tomography;Incidental findings;Multidetector | 2020-06-10 02:00:00+02:00 | 32571747 | FR | Department of Radiology, Hopital Cochin, AP-HP centre, 75014 Paris, France.;Department of Radiology, Hopital Cochin, AP-HP centre, 75014 Paris, France, Université de Paris, Descartes-Paris 5, 75006 Paris, France.;Department of Radiology, Hopital Cochin, AP-HP centre, 75014 Paris, France, Université de Paris, Descartes-Paris 5, 75006 Paris, France. Electronic address: marie-pierre.revel@aphp.fr. | 1197 | ||
| 10.1111/anae.15175 | Journal Article | en | The association of lung ultrasound images with COVID-19 infection in an emergency room cohort. | https://www.ncbi.nlm.nih.gov/pubmed/32520406 | Lung ultrasound could facilitate the triage of patients with suspected COVID-19 infection admitted to the emergency room. We developed a predictive model for COVID-19 diagnosis based on lung ultrasound and clinical features. We used ultrasound to image the lung bilaterally at two anterior sites, one and two hands below each clavicle, and a posterolateral site that was the posterior transverse continuation from the lower anterior site. We studied 100 patients, 31 of whom had a COVID-19 positive reverse transcriptase polymerase chain reaction. A positive test was independently associated with: quick sequential organ failure assessment score ≥1; ≥3 B-lines at the upper site; consolidation and thickened pleura at the lower site; and thickened pleura line at the posterolateral site. The model discrimination was an area (95%CI) under the receiver operating characteristic curve of 0.82 (0.75-0.90). The characteristics (95%CI) of the model's diagnostic threshold, applied to the population from which it was derived, were: sensitivity, 97% (83-100%); specificity, 62% (50-74%); positive predictive value, 54% (41-98%); and negative predictive value, 98% (88-99%). This model may facilitate triage of patients with suspected COVID-19 infection admitted to the emergency room. | 0003-2409,1365-2044 | 2020-06-14 02:00:00+02:00 | pubmed | Anaesthesia | S Bar;A Lecourtois;M Diouf;E Goldberg;C Bourbon;E Arnaud;L Domisse;H Dupont;P Gosset | COVID-19;lung ultrasound;triage | 2020-06-10 02:00:00+02:00 | 32520406 | FR | Anaesthesiology and Critical Care Department, Amiens University Hospital, Amiens, France.;Emergency Medicine Department, Amiens University Hospital, Amiens, France.;Amiens University Hospital, Amiens, France. | 1203 | |||
| 10.1016/j.resmer.2020.100774 | Editorial | en | Covid-19: Adapting the geriatric organisations to respond to the pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32563967 | 2590-0412 | 2020-06-14 02:00:00+02:00 | pubmed | Respiratory Medicine and Research | T Celarier;L Lafaie;L Goethals;N Barth;B Gramont;E Ojardias;B Bongue | Coronavirus disease;Covid-19;Elderly;SARS-CoV-2 | 2020-06-11 02:00:00+02:00 | 32563967 | FR | Department of Clinical Gerontology, University Hospital of Saint-Etienne, Saint-Etienne, France, Gérontopôle Auvergne Rhône-Alpes, Saint-Etienne, France, Chaire santé des Aînés, université Jean-Monnet, Saint-Etienne, France. Electronic address: thomas.celarier@chu-st-etienne.fr.;Department of Clinical Gerontology, University Hospital of Saint-Etienne, Saint-Etienne, France.;Chaire santé des Aînés, université Jean-Monnet, Saint-Etienne, France, SNA EPIS Laboratory EA 4607, université Jean-Monnet, Saint-Etienne, France.;Gérontopôle Auvergne Rhône-Alpes, Saint-Etienne, France, Chaire santé des Aînés, université Jean-Monnet, Saint-Etienne, France, SNA EPIS Laboratory EA 4607, université Jean-Monnet, Saint-Etienne, France.;Chaire santé des Aînés, université Jean-Monnet, Saint-Etienne, France, Support and Education Technic Centre of Health Examination Centres (CETAF), Saint-Etienne, France, SNA EPIS Laboratory EA 4607, université Jean-Monnet, Saint-Etienne, France. | 1212 | ||||
| 10.1177/1945892420930954 | Journal Article;Multicenter Study | en | Prevalence and Recovery From Olfactory and Gustatory Dysfunctions in Covid-19 Infection: A Prospective Multicenter Study. | https://www.ncbi.nlm.nih.gov/pubmed/32527141 | Covid-19 is defined by an association of multiple symptoms, including frequently reported olfactory and gustatory disorders. | 1945-8924,1945-8932 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Aged;Aged, 80 and over;Betacoronavirus;Coronavirus Infections__complications;Female;Follow-Up Studies;France__epidemiology;Humans;Male;Middle Aged;Olfaction Disorders__etiology;Olfactory Perception__physiology;Pandemics;Pneumonia, Viral__complications;Prevalence;Prospective Studies;Recovery of Function;Taste Disorders__epidemiology;Taste Perception__physiology;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | American Journal of Rhinology & Allergy | Eléonore Chary;Florent Carsuzaa;Jean-Paul Trijolet;Anne-Laure Capitaine;Mariam Roncato-Saberan;Kevin Fouet;France Cazenave-Roblot;Mélanie Catroux;Caroline Allix-Beguec;Xavier Dufour | Ageusia;Anosmia;Covid-19;Gustatory disorders;Olfactory disorders;Recovery;SARS-CoV-2 | 2020-06-12 02:00:00+02:00 | 32527141 | FR | ORL-Head and Neck Surgery, University Hospital of Poitiers, Poitiers, France.;ORL-Head and Neck Surgery, Saint Louis Hospital, La Rochelle, France.;Infectious Diseases, Saint Louis Hospital, La Rochelle, France.;Infectious Diseases, University Hospital of Poitiers, Poitiers, France.;Clinical Research Department, Saint Louis Hospital, La Rochelle, France. | 1216 | ||
| Letter | en | Covid-19 in pregnant women: General data from a French National Survey. | https://www.ncbi.nlm.nih.gov/pubmed/32540156 | 2020-06-14 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Cesarean Section;Coronavirus Infections__therapy;Female;Humans;Infant, Newborn;Pandemics;Pneumonia, Viral__therapy;Pregnancy;Pregnancy Complications, Infectious__therapy;Pregnant Women;Surveys and Questionnaires;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jonathan Cohen;Olivier Vignaux;François Jacquemard | 2020-06-09 02:00:00+02:00 | 32540156 | FR | Mother and Infant Health Department, Hôpital Américain de Paris, 92200 Neuilly, France. Electronic address: drcohenjonathan@gmail.com.;Department of Medical Imaging and Nuclear Medicine, Hôpital Américain de Paris, 92200 Neuilly, France.;Mother and Infant Health Department, Hôpital Américain de Paris, 92200 Neuilly, France. | 1228 | |||||||
| Letter | en | Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study. | https://www.ncbi.nlm.nih.gov/pubmed/32514594 | 2020-06-14 02:00:00+02:00 | pubmed | Benoit Painvin;Pauline Guillot;Marie-Clémence Verdier;Arnaud Gacouin;Adel Maamar | 2020-06-08 02:00:00+02:00 | 32514594 | FR | Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France. benoit.painvin@chu-rennes.fr.;Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Laboratoire de Pharmacologie Biologique, Centre Hospitalier Universitaire Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France. | 1236 | ||||||||
| Letter | en | Letter from France. | https://www.ncbi.nlm.nih.gov/pubmed/32515049 | 2020-06-14 02:00:00+02:00 | pubmed | Jérémy Charriot;Laurie Pahus;Pascal Chanez;Nicolas Nagot;Arnaud Bourdin | COVID-19;droplet;tuberculosis | 2020-06-08 02:00:00+02:00 | 32515049 | FR | Université de Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France.;Clinique des bronches allergies et sommeil, Aix Marseille Univ, APHM, Marseille, France.;Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France.;Aix Marseille Univ, INSERM U1263, INRA 1260 (C2VN), Marseille, France.;Pathogenesis and Control of Chronic Infections, Inserm, Etablissement Français du Sang, CHU Montpellier, University of Montpellier, Montpellier, France. | 1239 | |||||||
| 10.1002/adts.202000074 | Journal Article | en | Investigation of Plasmonic Detection of Human Respiratory Virus. | https://www.ncbi.nlm.nih.gov/pubmed/32838127 | The COVID-19 virus has been recently identified as a new species of virus that can cause severe infections such as pneumonia. The sudden outbreak of this disease is being considered a pandemic. Given all this, it is essential to develop smart biosensors that can detect pathogens with minimum time delay. Surface plasmon resonance (SPR) biosensors make use of refractive index (RI) changes as the sensing parameter. In this work, based on actual data taken from previous experimental works done on plasmonic detection of viruses, a detailed simulation of the SPR scheme that can be used to detect the COVID-19 virus is performed and the results are extrapolated from earlier schemes to predict some outcomes of this SPR model. The results indicate that the conventional Kretschmann configuration can have a limit of detection (LOD) of 2E-05 in terms of RI change and an average sensitivity of 122.4 degRIU-1 at a wavelength of 780 nm. | 2513-0390,2513-0390 | 2020-06-14 02:00:00+02:00 | pubmed | Advanced Theory and Simulations | Chandreyee Manas Das;Yan Guo;Lixing Kang;Ho-Pui Ho;Ken-Tye Yong | COVID‐19;graphenes;kretschmann layout;plasmonic bio‐sensing;simulations | 2020-06-08 02:00:00+02:00 | 32838127 | FR;SG;CN;HK | CINTRA CNRS/NTU/THALES, UMI 3288 Research Techno Plaza 50 Nanyang Drive, Border X Block Singapore 637553 Singapore.;School of Electrical and Electronic Engineering Nanyang Technological University 50 Nanyang Avenue Singapore 639798 Singapore.;School of Automation Hangzhou Dianzi University Hangzhou Zhejiang 310018 China.;Department of Biomedical Engineering The Chinese University of Hong Kong New Territories Hong Kong SAR 999077 China. | 1244 | |||
| 10.1016/s1470-2045(20)30314-4 | Journal Article;Multicenter Study;Observational Study | en | COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. | https://www.ncbi.nlm.nih.gov/pubmed/32539942 | Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies. | 1470-2045 | 2020-06-14 02:00:00+02:00 | pubmed | Aged;Betacoronavirus;Cause of Death;Coronavirus Infections__epidemiology;Cross-Sectional Studies;Female;Hospitalization__statistics & numerical data;Humans;Longitudinal Studies;Male;Middle Aged;Pandemics;Pneumonia, Viral__epidemiology;Registries__statistics & numerical data;Risk Factors;Thoracic Neoplasms__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | The Lancet Oncology | Marina Chiara Garassino;Jennifer G Whisenant;Li-Ching Huang;Annalisa Trama;Valter Torri;Francesco Agustoni;Javier Baena;Giuseppe Banna;Rossana Berardi;Anna Cecilia Bettini;Emilio Bria;Matteo Brighenti;Jacques Cadranel;Alessandro De Toma;Claudio Chini;Alessio Cortellini;Enriqueta Felip;Giovanna Finocchiaro;Pilar Garrido;Carlo Genova;Raffaele Giusti;Vanesa Gregorc;Francesco Grossi;Federica Grosso;Salvatore Intagliata;Nicla La Verde;Stephen V Liu;Julien Mazieres;Edoardo Mercadante;Olivier Michielin;Gabriele Minuti;Denis Moro-Sibilot;Giulia Pasello;Antonio Passaro;Vieri Scotti;Piergiorgio Solli;Elisa Stroppa;Marcello Tiseo;Giuseppe Viscardi;Luca Voltolini;Yi-Long Wu;Silvia Zai;Vera Pancaldi;Anne-Marie Dingemans;Jan Van Meerbeeck;Fabrice Barlesi;Heather Wakelee;Solange Peters;Leora Horn | 2020-06-12 02:00:00+02:00 | 32539942 | FR;CN;GB;US;CH;IT;NL;ES;BE;PS | Thoracic Unit, Medical Oncology Department, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: marina.garassino@istitutotumori.mi.it.;Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Evaluative Epidemiology, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Laboratory of Clinical Research Methodology, Oncology Department, "Mario Negri" Institute of Pharmacological Researches-IRCCS, Milan, Italy.;Medical Oncology Department, Fondazione IRCCS Policlinico "San Matteo", Pavia, Italy.;Medical Oncology Department, Thoracic Cancer and Early Drug Development Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.;Department of Oncology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.;Medical Oncology Department, AOU Ospedali Riuniti di Ancona, Università Politecnica delle Marche, Ancona, Italy.;Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.;Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.;Medical Oncology Department, ASST Cremona, Cremona, Italy.;Hopital Tenon, Paris, France.;Thoracic Unit, Medical Oncology Department, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Oncology Unit, ASST dei Sette Laghi, Varese, Italy.;Department of Biotechnology and Applied Clinical Science, University of L'Aquila, L'Aquila, Italy.;Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.;IRYCIS, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain.;IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Medical Oncology Unit, Sant'Andrea Hospital, Rome, Italy.;Department of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.;Medical Oncology Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.;Mesothelioma Unit, Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.;Medical Oncology Department, ASST Spedali Civili di Brescia, Brescia, Italy.;Medical Oncology Department, ASST Fatebenefratelli Sacco, Milan, Italy.;Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.;CHU, Institut universitaire du cancer, Toulouse, France.;Thoracic Surgery Unit, Experimental Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.;Oncology Department, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland.;Department of Oncology and Hematology, AUSL della Romagna, Ravenna, Italy.;Service Hospitalier Universitaire Pneumologie Physiologie, CHU Grenoble-Alpes, Grenoble, France.;Istituto Oncologico Veneto IRCCS, Padova, Italy.;European Institute of Oncology, European Institute of Oncology IRCCS, Milan, Italy.;Radiotherapy Unit V Scotti, Thoracic Surgery Unit L Voltolini, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.;Thoracic Surgery, Policlinico S Orsola, Alma Mater Studiorum University, Bologna, Italy.;Medical Oncology Unit, Ospedale "Guglielmo da Saliceto", Piacenza, Italy.;Department of Medicine and Surgery, University of Parma, University Hospital of Parma, Parma, Italy.;Guangdong Lung Cancer Department, Guangdong General Hospital, Guangzhou, China.;Medical Oncology Department, Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.;Centre de Recherche en Cancérologie de Toulouse, Toulouse, France.;Department of Pulmonology, Erasmus University Medical Center, Rotterdam, University Maastricht, Maastricht, Netherlands.;Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital, Edegem, Belgium.;Gustave Roussy Institute, Villejuif, Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.;Stanford Cancer Institute, Stanford University, Stanford, CA, USA.;Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA. | 1249 | |||
| 10.1016/j.jaccas.2020.06.012 | Case Reports | en | Feasibility of Prone Position Coronary Angiography in a Patient With COVID-19 Pneumonia and Refractory Hypoxemia. | https://www.ncbi.nlm.nih.gov/pubmed/32835272 | A 57-year-old woman hospitalized for a COVID-19 (coronavirus disease-2019)-related refractory acute respiratory distress syndrome developed a few days later anteroseptal ST-segment elevation with acute systolic dysfunction. Coronary angiography was performed with the patient in prone (face down) position, owing to the necessity to maintain a reasonable oxygen saturation during the examination. (Level of Difficulty: Intermediate.). | 2666-0849 | 2020-06-14 02:00:00+02:00 | pubmed | JACC: Case Reports | Andrea Mangiameli;Ines Bendib;Anne-Sophie Martin;Keyvan Razazi;Emmanuel Teiger;Romain Gallet | ARDS, acute respiratory distress syndrome;COVID-19;COVID-19, coronavirus disease-2019;SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2;coronary angiography;heart failure | 2020-06-13 02:00:00+02:00 | 32835272 | FR | Department of Cardiology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Creteil, France.;Intensive Care Unit, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Creteil, France. | 1261 | |||
| Letter | en | The organisation of a French emergency department in a coronavirus hotspot. | https://www.ncbi.nlm.nih.gov/pubmed/32544434 | 2020-06-14 02:00:00+02:00 | pubmed | Mathieu Oberlin;Pierrick Le Borgne;Martin Behr;Sabrina Kepka;Pascal Bilbault | COVID-19 outbreak;Disaster medicine;Emergency department | 2020-06-13 02:00:00+02:00 | 32544434 | FR | Emergency Department, University Hospitals of Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France. Electronic address: Mathieu.oberlin@outlook.fr.;Emergency Department, University Hospitals of Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France, Unité inserm UMR 1260, Regenerative NanoMedicine (RNM), Fédération de Médecine Translationnelle (FMTS), Faculté de Médecine - Université de Strasbourg, 4, rue Kirschleger, 67085 Strasbourg Cedex, France. Electronic address: pierrick_med@yahoo.fr.;Emergency Department, University Hospitals of Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France.;Emergency Department, University Hospitals of Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France, Unité inserm UMR 1260, Regenerative NanoMedicine (RNM), Fédération de Médecine Translationnelle (FMTS), Faculté de Médecine - Université de Strasbourg, 4, rue Kirschleger, 67085 Strasbourg Cedex, France. | 1272 | |||||||
| Letter | en | Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19-related Acute Respiratory Distress Syndrome: Worth the Effort? | https://www.ncbi.nlm.nih.gov/pubmed/32543208 | 2020-06-21 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus;Coronavirus Infections__complications;Critical Care;Extracorporeal Membrane Oxygenation;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Respiratory Distress Syndrome, Adult__mortality;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Pierre-Emmanuel Falcoz;Alexandra Monnier;Marc Puyraveau;Stephanie Perrier;Pierre-Olivier Ludes;Anne Olland;Paul-Michel Mertes;Francis Schneider;Julie Helms;Ferhat Meziani | 2020-06-17 02:00:00+02:00 | 32543208 | FR | Strasbourg University HospitalStrasbourg, France.;uMETh-INSERM CIC 431Besançon, France.;Besançon University HospitalBesançon, Franceand.;University of StrasbourgStrasbourg, France. | 1274 | |||||||
| 10.1684/vir.2020.0830 | Journal Article | en | A scenario to safely ease the covid-19 lockdown while allowing economic recovery. | https://www.ncbi.nlm.nih.gov/pubmed/32540828 | If they work as expected, the strict containment measures enforced to stop the French Covid-19 epidemic will leave a large proportion of the population "naive" about the SARS-CoV-2 virus. In these conditions, how can we prevent the epidemic from rebounding, at a time when this restrictive policy will soon become untenable economically and socially? Based on the figures, now well known, of the lethality of covid-19 according to age classes, I suggest that a gradual release of the containment be instituted, which will keep retirees in isolation (the 65+ age class), whose risk is maximal and the impact on economic production the lowest. This scenario might be applicable to most European countries that enforce mandatory retirement ages for most of workers. | 2020-06-21 02:00:00+02:00 | pubmed | Jean-Michel Claverie | Covid-19;age-dependent lethality;economic recovery;lockdown termination | 2020-06-17 02:00:00+02:00 | 32540828 | FR;US | PU-PH émérite, Aix-Marseille Université/APHM Information génomique & structurale (UMR7256), Institut de Microbiologie de la Méditerranée (FR 3479) Membre du CA de la Société Française de Virologie au 30 mars 2020. | 1278 | |||||
| 10.1016/j.revmed.2020.05.004 | Editorial | fr | [Preventing Covid-19 after lockdown: For a rapid comeback to "life before"]. | https://www.ncbi.nlm.nih.gov/pubmed/32540118 | 0248-8663 | 2020-06-21 02:00:00+02:00 | pubmed | Activities of Daily Living;Betacoronavirus;Catastrophization;Coronavirus Infections__diagnosis;Humans;Masks;Pandemics__prevention & control;Pneumonia, Viral__diagnosis;Social Isolation__psychology;Symptom Assessment;COVID-19;severe acute respiratory syndrome coronavirus 2 | La Revue de Médecine Interne | T Hanslik;A Flahault | Covid-19;Hand hygiene;Lavage des mains;Mask;Masques | 2020-06-17 02:00:00+02:00 | 32540118 | FR;CH | UFR Simone Veil - santé, Université de Versailles Saint Quentin-Université Paris Saclay, France, Service de Médecine Interne, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris (APHP), Boulogne Billancourt, France, Réseau Sentinelles, Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France. Electronic address: thomas.hanslik@aphp.fr.;Institut de santé globale, Faculté de médecine, Université de Genève, Suisse, Service de Médecine Tropicale et Humanitaire, Hôpitaux Universitaires de Genève, Suisse, Swiss School of Public Health, Zürich, Suisse. | 1279 | |||
| 10.1684/pnv.2020.0872 | Editorial;Introductory Journal Article | en | File "COVID-19 in the elderly". | https://www.ncbi.nlm.nih.gov/pubmed/32554341 | 2020-06-21 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Coronavirus Infections__therapy;France;Humans;Pandemics;Pneumonia, Viral__therapy;Risk Factors;COVID-19 | Gilles Berrut | 2020-06-20 02:00:00+02:00 | 32554341 | FR | Rédacteur en chef - Gériatrie Chef du pôle de Gérontologie clinique du CHU de Nantes, France Vice doyen à la formation continue santé de l'université de Nantes, France Président fondateur du Gérontopôle des Pays de la Loire, France Président du comité d'orientation de l'espace régional d'éthique des Pays de la Loire, France. | 1285 | ||||||
| Letter | en | Impact of COVID-19 on tuberculosis services in India. | https://www.ncbi.nlm.nih.gov/pubmed/32553014 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Delivery of Health Care__organization & administration;Humans;India__epidemiology;Pandemics;Pneumonia, Viral__epidemiology;Tuberculosis__diagnosis;COVID-19;severe acute respiratory syndrome coronavirus 2 | A Gupta;R Singla;J A Caminero;N Singla;P Mrigpuri;A Mohan | 2020-06-20 02:00:00+02:00 | 32553014 | FR;IN;ES | Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi.;Department of Pneumology, Dr Negrín University Hospital of Gran Canaria, Barranco de la Ballena, Las Palmas de Gran Canaria, Spain, MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease, Paris, France.;Department of Epidemiology, National Institute of Tuberculosis and Respiratory Diseases, New Delhi.;Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi.;Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India, <email></email>, Email: drrupaksingla@yahoo.com. | 1287 | |||||||
| NCATS NIH HHS;NIAID NIH HHS | 10.1038/s41577-020-0373-7 | Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't;Review | en | Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? | https://www.ncbi.nlm.nih.gov/pubmed/32555547 | 1474-1733,1474-1741 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus__immunology;Coronavirus Infections__immunology;Genetic Diseases, Inborn__immunology;Humans;Immunity__immunology;Pandemics;Pneumonia, Viral__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nature Reviews Immunology | Shen-Ying Zhang;Qian Zhang;Jean-Laurent Casanova;Helen C Su | 2020-06-20 02:00:00+02:00 | 32555547 | FR;US | [{"country": "United States", "agency": "NCATS NIH HHS", "grantid": "UL1 TR001866"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI088364"}] | St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA. shzh289@rockefeller.edu.;Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France. shzh289@rockefeller.edu.;University of Paris, Imagine Institute, Paris, France. shzh289@rockefeller.edu.;St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA. qzhang02@rockefeller.edu.;Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France. qzhang02@rockefeller.edu.;University of Paris, Imagine Institute, Paris, France. qzhang02@rockefeller.edu.;St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA. casanova@rockefeller.edu.;Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France. casanova@rockefeller.edu.;University of Paris, Imagine Institute, Paris, France. casanova@rockefeller.edu.;Howard Hughes Medical Institute, New York, NY, USA. casanova@rockefeller.edu.;Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, AP-HP, Paris, France. casanova@rockefeller.edu.;Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. | 1290 | ||
| 10.1684/pnv.2020.0871 | Journal Article | en | Geriatric units at the beginning of the 2020 COVID-19 epidemic in France. | https://www.ncbi.nlm.nih.gov/pubmed/32554344 | The COVID-19 epidemic that started in November in China became a national epidemic from March 16, 2020 with the declaration of population containment in order to reduce the spread of the virus in France. From March 17 to March 27, 2020, the monitoring unit of the French society of geriatrics and gerontology decided to conduct a survey to analyze the implementation of the mobilization of geriatric units, given that this epidemic had shown that it resulted in excess mortality mainly among the elderly. The survey was able to bring together the response of 34 services, nine of which were located in a high epidemic cluster zone. Dedicated acute geriatric units for patients infected with COVID-19 were present in eight facilities, only outside the cluster zones. Nine geriatric follow-up and rehabilitation services were dedicated, an additional telemedicine activity concerned 35% of the facilities, and family listening and tablet communication facilities concerned 36% of the facilities. This survey is a snapshot of an initial moment in the epidemic. It provides an opportunity to describe the context in which this epidemic occurred in terms of geriatric policy, and to assess the responsiveness and inventiveness of these services in meeting the needs of the elderly. | 2020-06-21 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Coronavirus Infections__epidemiology;Female;France__epidemiology;Geriatrics;Health Services Needs and Demand;Hospital Units__statistics & numerical data;Humans;Male;Pandemics;Pneumonia, Viral__epidemiology;Surveys and Questionnaires;Telemedicine;COVID-19 | Gilles Berrut;Laure de Decker;Jean-Pierre Aquino;Sabiha Ahmine;Nathalie Amalberti;Cyprien Arlaud;Astrid Aubry;Philippe Beau;Harold Behara;Fanny Bernard;Frederic Bloch;Sylvie Bonin-Guillaume;Anne-Sophie Boureau;Astrid Chaffringeon;Bernard Chaudier;Claire Collins;Axelle Courau;Tristan Cudennec;Matthieu Debray;Bertrand Fougère;Déborah Gaudeau;Dominique Huvent-Grelle;Marie Laurent;Barbara Mizzi;Karin Maley;Hassan Mecheri;Camille Merlhès;Braham Merouani;Marc Nicolini;Eric Pautas;Bruno Pellerano;Emilie Piet;Catherine Rascle;Agnes Rouaud;Dominique Somme;Gaetan Gavazzi;Nathalie Salles;Olivier Guérin | COVID-19;elderly subject;epidemic;geriatrics;hospital | 2020-06-20 02:00:00+02:00 | 32554344 | FR | Pôle Hospitalo-Universitaire de Gérontologie Clinique, CHU Nantes, Nantes, France, Membre de la cellule de veille de la Société Française de Gériatrie et Gérontologie, France.;Pôle Hospitalo-Universitaire de Gérontologie Clinique, CHU Nantes, Nantes, France.;Délégué national de la Société Française de Gériatrie et Gérontologie, France.;SSR hôpital gériatrique Pierre Garraud - Hcl Lyon, France.;CH intercommunal Toulon-La Seyne-sur-Mer, France.;Service de médecine gériatrique, Hôpital Claude Dejean, Villeneuve-de-Berg, France.;CH Aix-en-Provence, France.;Equipe mobile de gériatrie Haut-Vaucluse, CH Vaison, Vaison-la-Romaine, France.;Service de Médecine Polyvalente Post Urgence, CH Saint Joseph, Marseille, France.;Service de médecine interne et gériatrie, Hôpital Nord, Marseille, France.;Service de Gériatrie, Pôle Autonomie Hôpital Nord, Amiens, France.;Service de médecine interne gériatrie, Marseille, France.;SSR La Palmola, Oletta, France.;Service de Médecine Interne et Tropicale, Hôpital d'Instruction des Armées Laveran, Marseille, France.;Pôle universitaire Inter-établissement de Psychiatrie de la personne Âgée et de l'Adulte, Centre Hospitalier Esquirol, Limoges, France.;Hôpital de Fourvière, Lyon, France.;Service de Médecine Gériatrique. Hôpital Paré, Boulogne-Billancourt, France.;Pôle de Gériatrie, CH Annecy Genevois, Pringy, France.;Service de Gériatrie, CHU Tours, France.;Équipe mobile de gériatrie, CH Apt, France.;Service De Long Séjour Bateliers, Lille, France.;Hôpitaux Universitaires Henri Mondor, Créteil, France.;Service de Médecine interne gériatrie, Hôpital Sainte Marguerite, Marseille, France.;Unité gériatrie aiguë, Groupe Hospitalier Diaconesses-Croix-Saint-Simon, Paris, France.;SSR hôpital Saint Loup, Agde, France.;CH de Chalons-en-Champagne, France.;Court Séjour de Gériatrie, CH de Pithiviers, France.;Ehpad, Bormes-les-Mimosas, France.;Service de Gériatrie aiguë polyvalente, GH AP-HP Sorbonne Université, site Charles Foix, Ivry-sur-Seine, France.;SSL, Clinique Pagerie, Allauch, France.;Service de maladies infectieuses. CH Annecy Genevois, France.;Ehpad Orpea La Talaudière, France.;Pole de Gériarie, CHU Rennes, France.;CHU de Grenoble-Alpes, Président du Collège National des Enseignants de Gériatrie, France.;CHU de Bordeaux, Présidente du conseil scientifique de la Société Française de Gériatrie et Gérontologie, France.;CHU de Nice, Président de la Société Française de Gériatrie et Gérontologie, France. | 1291 | ||||
| 10.1093/cid/ciaa792 | Journal Article | en | National French survey of COVID-19 symptoms in people aged 70 and over. | https://www.ncbi.nlm.nih.gov/pubmed/32556328 | The objective of this national French survey was to determine the COVID-19 semiology in seniors(n=353; mean,84.7±7.0y). 57.8% of patients exhibited ≤3symptoms, including thermal dysregulation(83.6%), cough(58.9%), asthenia(52.7%), polypnea(39.9%), gastrointestinal signs(24.4%). Patients≥80y exhibited falls(P=0.002) and asthenia(P=0.002). Patients with neurocognitive disorders exhibited delirium(P<0.001) and altered consciousness(P=0.001). Clinical peculiarities of COVID-19 were reported in seniors. | 1058-4838,1537-6591 | 2020-06-21 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Cédric Annweiler;Guillaume Sacco;Nathalie Salles;Jean-Pierre Aquino;Jennifer Gautier;Gilles Berrut;Olivier Guérin;Gaetan Gavazzi | 2020-06-18 02:00:00+02:00 | 32556328 | FR;CA;GB | Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France.;UPRES EA 4638, Université d'Angers, Angers, France.;Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, ON, Canada.;Department of Clinical Gerontology, University Hospital, Bordeaux, France.;Délégation générale de la Société Française de Gériatrie et Gérontologie (SFGG).;Pôle hospitalo-universitaire de gérontologie clinique, CHU de Nantes, France.;Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Service de Médecine Gériatrique et Thérapeutique, Nice.;Université Côte d'Azur, CNRS UMR 7284/INSERM U108, Institute for Research on Cancer and Aging Nice (IRCAN), Faculté de médecine, Nice, France.;Service Gériatrie Clinique, Centre Hospitalo-Universitaire Grenoble-Alpes, Saint-Martin-d'Hères, France. | 1297 | ||||
| Letter | en | Re. Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared pragmatic protocol. | https://www.ncbi.nlm.nih.gov/pubmed/32739226 | 2020-06-21 02:00:00+02:00 | pubmed | Marie-Astrid Piquet;Benoit Dupont | 2020-06-19 02:00:00+02:00 | 32739226 | FR | Hepatology Gastroenterology Nutrition Department, Caen Normandie University Hospital, France. | 1312 | ||||||||
| 10.1051/medsci/2020106 | News | fr | [SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32558640 | 0767-0974,1958-5381 | 2020-06-21 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Betacoronavirus__enzymology;Coronavirus Infections__drug therapy;HIV Protease Inhibitors__therapeutic use;Humans;Pandemics__prevention & control;Peptide Hydrolases__physiology;Pneumonia, Viral__drug therapy;Protease Inhibitors__therapeutic use;Virus Replication;COVID-19;severe acute respiratory syndrome coronavirus 2 | médecine/sciences | Annie Ladoux;Stéphane Azoulay;Christian Dani | 2020-06-19 02:00:00+02:00 | 32558640 | FR | Université Côte d'Azur, Institut de biologie Valrose, Faculté de médecine, 28 avenue Valombrose, 06107 Nice, France.;Université Côte d'Azur, Institut de chimie de Nice, Faculté des sciences, 28 avenue Valrose, 06108 Nice, France. | 1314 | ||||
| 10.1016/j.acvd.2020.05.001 | Editorial | en | The potential sudden shift in clinical research and epidemiology of cardiovascular diseases, caused by COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32586675 | 1875-2136 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus__pathogenicity;Biomedical Research__trends;Cardiovascular Diseases__diagnosis;Coronavirus Infections__diagnosis;Epidemiologic Methods;Host Microbial Interactions;Humans;Pandemics;Pneumonia, Viral__diagnosis;Prognosis;Research Design__trends;Risk Assessment;Risk Factors;Virulence;COVID-19;severe acute respiratory syndrome coronavirus 2 | Archives of Cardiovascular Diseases | Théo Pezel;Joao A C Lima | COVID-19;Cardiovascular diseases;Cardiovascular imaging;Clinical research;Epidemiology;Imagerie cardiovasculaire;Maladies cardiovasculaires;Recherche clinique;Épidémiologie | 2020-06-19 02:00:00+02:00 | 32586675 | FR;US | Cardiology Division, Department of Medicine, Johns Hopkins University, 600 North Wolfe Street, 21287-0409 Baltimore, MD, USA, Department of Cardiology, Lariboisière Hospital, AP-HP, Inserm UMRS 942, University of Paris, 75010 Paris, France.;Cardiology Division, Department of Medicine, Johns Hopkins University, 600 North Wolfe Street, 21287-0409 Baltimore, MD, USA. Electronic address: jlima@jhmi.edu. | 1315 | |||
| 10.1016/j.ces.2020.115918 | Journal Article | en | Analogies between SARS-CoV-2 infection dynamics and batch chemical reactor behavior. | https://www.ncbi.nlm.nih.gov/pubmed/32834062 | The pandemic infection of SARS-CoV-2 presents analogies with the behavior of chemical reactors. Susceptible population (A), active infected population (B), recovered cases (C) and deaths (D) can be assumed to be molecules of chemical compounds and their dynamics seem well aligned with those of composition and conversions in chemical syntheses. Thanks to these analogies, it is possible to generate pandemic predictive models based on chemical and physical considerations and regress their kinetic parameters, either globally or locally, to predict the peak time, entity and end of the infection with certain reliability. These predictions can strongly support the emergency plans decision making process. The model predictions have been validated with data from Chinese provinces that already underwent complete infection dynamics. For all the other countries, the evolution is re-regressed and re-predicted every day, updating a pandemic prediction database on Politecnico di Milano's webpage based on the real-time available data. | 0009-2509 | 2020-06-21 02:00:00+02:00 | pubmed | Chemical Engineering Science | F Manenti;A Galeazzi;F Bisotti;K Prifti;A Dell'Angelo;A Di Pretoro;C Ariatti | Batch chemical reactor;Infection dynamics;Non-linear regression;Pandemic mathematical model;Predictive model;SARS-CoV-2 | 2020-06-20 02:00:00+02:00 | 32834062 | FR;IT | Politecnico di Milano, Dipartimento di Chimica, Materiali e Ingegneria Chimica "Giulio Natta", Center for Sustainable Process Engineering Research (SuPER), Piazza Leonardo da Vinci 32, 20133 Milano, Italy.;Laboratoire de Génie Chimique, Université de Toulouse, CNRS/INP/UPS, Toulouse, France. | 1322 | |||
| 10.1016/j.accpm.2020.06.006 | Journal Article | en | Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32565254 | The pathophysiology of acute kidney injury (AKI) in COVID-19 patients is still poorly understood. SARS-CoV-2 has been suggested to modulate the renin-angiotensin-aldosterone system (RAAS). In this series of COVID-19 critically ill patients, we report evidence of activation of the RAAS in COVID-19 patients with AKI. | 2352-5568 | 2020-06-21 02:00:00+02:00 | pubmed | Anaesthesia Critical Care & Pain Medicine | Emmanuel Dudoignon;Nabila Moreno;Benjamin Deniau;Maxime Coutrot;Romain Longer;Quentin Amiot;Alexandre Mebazaa;Romain Pirracchio;François Depret;Matthieu Legrand | COVID-19;Renin-angiotensin-aldosterone system | 2020-06-18 02:00:00+02:00 | 32565254 | FR;US | Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Department of Anaesthesiology and Critical Care and Burn Unit, Paris, France, University of Paris, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Department of Biochemistry, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Department of Anaesthesiology and Critical Care and Burn Unit, Paris, France, Inserm UMR-S 942, Mascot, Lariboisière Hospital, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Department of Anaesthesiology and Critical Care and Burn Unit, Paris, France.;Department of Anesthesiology and Peri-operative Medicine and Critical Care Medicine, University of California, San Francisco, California.;Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Department of Anaesthesiology and Critical Care and Burn Unit, Paris, France, University of Paris, Paris, France, Department of Anesthesiology and Peri-operative Medicine and Critical Care Medicine, University of California, San Francisco, California. Electronic address: matthieu.m.legrand@gmail.com. | 1323 | |||
| Letter | en | Negative SARS-CoV-2 PCR in patients with chilblain-like lesions. | https://www.ncbi.nlm.nih.gov/pubmed/32563281 | 2020-06-21 02:00:00+02:00 | pubmed | Thomas Hubiche;Florence Le Duff;Christine Chiaverini;Valérie Giordanengo;Thierry Passeron | 2020-06-18 02:00:00+02:00 | 32563281 | FR | Department of Dermatology, Université Côte d'Azur, Nice 06200, France.;Department of Pathology, Université Côte d'Azur, Nice 06200, France, Department of Virology, Université Côte d'Azur, Nice 06200, France.;Department of Dermatology, Université Côte d'Azur, Nice 06200, France, Department of Virology, Université Côte d'Azur, Nice 06200, France, Centre Hospitalier Universitaire de Nice, and INSERM U1065, Université Côte d'Azur, Nice 06200, France. Electronic address: passeron@unice.fr. | 1326 | ||||||||
| Letter | en | COVID-19 Epidemic: Regional Organization Centered on Nursing Homes. | https://www.ncbi.nlm.nih.gov/pubmed/32557563 | 2020-06-21 02:00:00+02:00 | pubmed | Cécilia Cofais;David Veillard;Céline Farges;Marion Baldeyrou;Pascal Jarno;Dominique Somme;Aline Corvol | 2020-06-17 02:00:00+02:00 | 32557563 | FR | Service de Gériatrie. Centre Hospitalier Universitaire de Rennes, Rennes, France.;Structure Régionale d'Appui, CAPPs Bretagne, Rennes, France.;Service des Urgences, SAMU, SMUR. Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Maladies Infectieuses et réanimation médicale. Centre Hospitalier Universitaire de Rennes, Rennes, France.;UFR Médecine, Université de Rennes 1, Rennes, France.;UMR 6051, ARENES, CNRS/IEP, Rennes, France. | 1327 | ||||||||
| 10.1111/ene.14407 | Journal Article | en | The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32558002 | Although the main clinical features of COVID-19 infection are pulmonary, several associated neurological signs, symptoms and diseases are emerging. The incidence and characteristics of neurological complications are unclear. For this reason, the European Academy of Neurology (EAN) core COVID-19 Task Force initiated a survey on neurological symptoms observed in patients with COVID-19 infection. | 1351-5101,1468-1331 | 2020-06-21 02:00:00+02:00 | pubmed | European Journal of Neurology | E Moro;A Priori;E Beghi;R Helbok;L Campiglio;C L Bassetti;E Bianchi;L F Maia;S Ozturk;F Cavallieri;M Zedde;J Sellner;D Bereczki;M Rakusa;G Di Liberto;A Sauerbier;A Pisani;A Macerollo;R Soffietti;P Taba;M Crean;A Twardzik;C Oreja-Guevara;B Bodini;T M Jenkins;T J von Oertzen | COVID-19;coronavirus;neurological;survey | 2020-06-17 02:00:00+02:00 | 32558002 | FR;SI;PT;CH;GB;IT;EE;TR;ES;DE;HU;AT | Division of Neurology, CHU of Grenoble, Grenoble Alpes University, Grenoble Institute of Neurosciences, Grenoble, France.;Department of Neurology, Division of Neurology, 'Aldo Ravelli' Research Center, University of Milan and ASST Santi Paolo e Carlo, Milan, Italy.;Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.;Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.;Department of Neurology, University of Bern, Inselspital, Bern, Switzerland.;Department of Neurology, Centro Hospitalar Universitário do Porto, Porto, Portugal.;Department of Neurology, Faculty of Medicine, Selcuk University, Konya, Turkey.;Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Italy.;Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.;Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.;Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.;Department of Neurology, Semmelweis University, Budapest, Hungary.;Department of Neurology, University Medical Centre Maribor, Maribor, Slovenia.;Department of Pathology and Immunology, Geneva Faculty of Medicine, Geneva, Switzerland.;Department of Neurology, University Hospital Cologne, Cologne, Germany.;National Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.;Neurology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.;Walton Centre NHS Foundation Trust, Liverpool, UK.;School of Psychology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.;Department of Neuroscience, Division of Neuro-Oncology, University of Turin, Turin, Italy.;Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Estonia.;European Academy of Neurology, Head Office, Vienna, Austria.;Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain.;Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain.;IdISSC, Madrid, Spain.;Department of Neurology, Sorbonne University, Saint-Antoine Hospital, APHP, Paris, France.;Sheffield Institute for Translational Neuroscience, University of Sheffield, and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.;Department of Neurology 1, Kepler Universitätklinikum, Linz, Austria. | 1331 | |||
| 10.1016/j.ejphar.2020.173288 | Journal Article | en | Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? | https://www.ncbi.nlm.nih.gov/pubmed/32561291 | In December 2019, many pneumonia cases with unidentified sources appeared in Wuhan, Hubei, China, with clinical symptoms like viral pneumonia. Deep sequencing analysis of samples from lower respiratory tract revealed a novel coronavirus, called 2019 novel coronavirus (2019-nCoV). Currently there is a rapid global spread. World Health Organization declare the disease a pandemic condition. The pathologic source of this disease was a new RNA virus from Coronaviridae family, which was named COVID-19. SARS-CoV-2 entry starts with the binding of the spike glycoprotein expressed on the viral envelope to ACE2 on the alveolar surface followed by clathrin-dependent endocytosis of the SARS-CoV-2 and ACE2 complex. SARS-CoV-2 enters the cells through endocytosis process, which is possibly facilitated, via a pH dependent endosomal cysteine protease cathepsins. Once inside the cells, SARS-CoV-2 exploits the endogenous transcriptional machinery of alveolar cells to replicate and spread through the entire lung. Endosomal acidic pH for SARS-CoV-2 processing and internalization is critical. After entering the cells, it possibly activates or hijack many intracellular pathways in favor of its replication. In the current opinion article, we will explain the possible involvement of unfolded protein response as a cellular stress response to the SARS-CoV-2 infection. | 0014-2999 | 2020-06-21 02:00:00+02:00 | pubmed | Alveolar Epithelial Cells__cytology;Betacoronavirus__metabolism;Clathrin-Coated Vesicles__drug effects;Coronavirus Infections__drug therapy;Endocytosis__drug effects;Endoplasmic Reticulum__drug effects;Endosomes__drug effects;Humans;Ionophores__pharmacology;Pandemics;Peptidyl-Dipeptidase A__metabolism;Pneumonia, Viral__drug therapy;Unfolded Protein Response__drug effects;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | European Journal of Pharmacology | Antoni Sureda;Javad Alizadeh;Seyed Fazel Nabavi;Ioana Berindan-Neagoe;Cosmin Andrei Cismaru;Philippe Jeandet;Marek J Łos;Emilio Clementi;Seyed Mohammad Nabavi;Saeid Ghavami | Endoplasmic reticulum;IRE1;PERK;Spliced XBP1;Unfolded protein response | 2020-06-17 02:00:00+02:00 | 32561291 | FR;CA;RO;US;PL;IT;IR;ES | Research Group in Community Nutrition and Oxidative Stress, University of Balearic Islands, Health Research Institute of Balearic Islands (IdISBa), and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122, Palma, Balearic Islands, Spain.;Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.;Division of Translational Medicine, Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran, Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.;Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania, The Center for Advanced Medicine - Medfuture- "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania, The Department for Functional Genomics and Experimental Pathology, The Oncology Institute, "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania.;Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania, Department of Functional Sciences, Immunology and Allergology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.;Research Unit, Induced Resistance and Plant Bioprotection, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences, University of Reims Champagne-Ardenne, PO Box 1039, 51687, Reims Cedex 2, France.;Department of Pathology, Pomeranian Medical University, Szczecin, Poland. Electronic address: mjelos@gmail.com.;Department of Biomedical and Clinical Sciences, "Luigi Sacco" (DIBIC), Università Degli Studi di Milano, 20157, Milano, Italy.;Division of Translational Medicine, Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran, Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: Nabavi208@gmail.com.;Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada, Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada, Faculty of Medicine, Katowice School of Technology, Katowice, Poland. Electronic address: saeid.ghavami@umanitoba.ca. | 1336 | ||
| 10.1016/j.diabet.2020.06.003 | Editorial | en | SGLT2 inhibition during the COVID-19 epidemic: Friend or foe? | https://www.ncbi.nlm.nih.gov/pubmed/32562762 | 1262-3636 | 2020-06-21 02:00:00+02:00 | pubmed | Diabetes & Metabolism | A J Scheen | Adipose tissue;COVID-19;Inflammation;Ketoacidosis;SGLT2 inhibitor | 2020-06-17 02:00:00+02:00 | 32562762 | FR;BE | Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège, Belgium, Clinical Pharmacology Unit, CHU Liège, Center for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be. | 1337 | ||||
| Letter;Comment | en | French West Indies castaway children as a result of the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32488896 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Child;Coronavirus Infections;Disease Outbreaks;Humans;Pandemics;Pneumonia, Viral;Triage;West Indies;COVID-19;severe acute respiratory syndrome coronavirus 2 | Jérôme Rambaud;Olivier Flechelles | 2020-06-18 02:00:00+02:00 | 32488896 | FR;MQ | Pediatric and Neonatal Intensive Care Unit, Armand-Trousseau Hospital, Sorbonne University, Paris, France.;Pediatric and Neonatal Intensive Care Unit, Chu Fort de France, Martinique, France. | 1342 | |||||||
| 10.1016/j.ajem.2020.06.027 | Case Reports | en | Priapism in a patient with coronavirus disease 2019 (COVID-19): A case report. | https://www.ncbi.nlm.nih.gov/pubmed/32732087 | Thromboembolic complications related to SARS-CoV-2 have been extensively reported. They include deep vein thrombosis, pulmonary embolism, ischemic stroke, and acute coronary syndrome. Penile thrombosis has not been reported as a thrombotic complication of SARS-CoV-2 infection with hypercoagulability. Here we describe a case of priapism as a thromboembolic complication in a patient with COVID-19 who recovered from acute respiratory distress syndrome (ARDS). We discuss the underlying pathophysiological mechanisms mainly related to an hypercoagulability state. Emergency management consisted on an intracavernosal injection of the sympathomimetic agent ethylephrine and cavernosal blood aspiration. The patient experienced no recurrences under thromboprophylaxis by enoxaparin 40 mg twice daily. | 0735-6757 | 2020-06-21 02:00:00+02:00 | pubmed | The American Journal of Emergency Medicine | Myriam Lamamri;Ala Chebbi;Jordan Mamane;Sofia Abbad;Milena Munuzzolini;Florence Sarfati;Stéphane Legriel | 2020-06-18 02:00:00+02:00 | 32732087 | FR | Intensive Care department, Centre Hospitalier de Versailles - Site André Mignot, Le Chesnay, France.;Urology department, Paris Saint-Joseph Hospital, Paris, France.;Urology department, Centre Hospitalier de Versailles - Site André Mignot, Le Chesnay, France.;Intensive Care department, Centre Hospitalier de Versailles - Site André Mignot, Le Chesnay, France, University Paris-Saclay, UVSQ, INSERM, CESP, Team "PsyDev", Villejuif, France. Electronic address: slegriel@ch-versailles.fr. | 1344 | ||||
| 10.1016/j.jormas.2020.06.008 | Case Reports | en | Facial pressure ulcers in COVID-19 patients undergoing prone positioning: How to prevent an underestimated epidemic? | https://www.ncbi.nlm.nih.gov/pubmed/32565264 | Prone positioning is an adjuvant therapy used to treat COVID-19 pneumonia complicated by acute respiratory distress syndrome. However, prolonged pressure on facial skin at the level of the bony structures may be responsible for facial pressure ulcers. In the context of severe COVID-19 pneumonia, we hypothesized that hypoxemia, microvascular injury and thrombosis can increase the risk of pressure ulcers. We described two cases in order to emphasize the risk of facial pressure ulcers as a result of prone positioning, so as to discuss their physiopathology and highlight the importance of appropriate preventive measures. | 2468-7855 | 2020-06-21 02:00:00+02:00 | pubmed | Journal of Stomatology, Oral and Maxillofacial Surgery | A Perrillat;J-M Foletti;A-S Lacagne;L Guyot;N Graillon | COVID-19;Facial;Pressure ulcers;Prone positioning | 2020-06-18 02:00:00+02:00 | 32565264 | FR | Department of oral and maxillofacial surgery, CHU Conception, AP-HM, 147, boulevard Baille, 13005 Marseille, France.;Department of oral and maxillofacial surgery, CHU Conception, AP-HM, 147, boulevard Baille, 13005 Marseille, France, IFSTTAR, LBA UMR_T24, Aix-Marseille university, boulevard Pierre-Dramard, 13916 Marseille, France.;Department of oral and maxillofacial surgery, CHU Conception, AP-HM, 147, boulevard Baille, 13005 Marseille, France, CNRS, EFS, ADES, Aix-Marseille university, boulevard Pierre-Dramard, 13344 Marseille, France.;Department of oral and maxillofacial surgery, CHU Conception, AP-HM, 147, boulevard Baille, 13005 Marseille, France, IFSTTAR, LBA UMR_T24, Aix-Marseille university, boulevard Pierre-Dramard, 13916 Marseille, France. Electronic address: nicolas.graillon@ap-hm.fr. | 1348 | |||
| 10.1016/j.jvoice.2020.06.015 | Editorial | en | The Challenge of Virtual Voice Therapy During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32660845 | 0892-1997 | 2020-06-21 02:00:00+02:00 | pubmed | Journal of Voice | Giovanna Cantarella;Maria Rosaria Barillari;Jerome R Lechien;Lorenzo Pignataro | 2020-06-18 02:00:00+02:00 | 32660845 | FR;IT;US | Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, Department of Otolaryngology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.;Division of Phoniatrics and Audiology, Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.;Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France. Electronic address: Jerome.Lechien@umons.ac.be. | 1352 | |||||
| 10.1016/s2213-2600(20)30266-6 | Journal Article;Research Support, Non-U.S. Gov't | en | Delivering evidence-based critical care for mechanically ventilated patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32559420 | 2213-2600 | 2020-06-21 02:00:00+02:00 | pubmed | The Lancet Respiratory Medicine | Jorge I F Salluh;Fernando Ramos;Jean Daniel Chiche | 2020-06-16 02:00:00+02:00 | 32559420 | FR;BR | Department of Critical Care and Postgraduate Program in Translational Medicine, D'Or Institute for Research and Education, Rio de Janeiro, CEP 22281-100, Brazil, Programa de Pós-Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: jorgesalluh@gmail.com.;Intensive Care Department, Hospital BP Mirante, São Paulo, Brazil, Anesthesiology, Pain and Intensive Care Department, Federal University of São Paulo-UNIFESP, São Paulo, Brazil.;Medical Intensive Care Unit, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France. | 1363 | |||||
| 10.1016/j.jiph.2020.06.014 | Case Reports | en | What if the worst consequences of COVID-19 concerned non-COVID patients? | https://www.ncbi.nlm.nih.gov/pubmed/32576501 | We highlight in this short article the side-effects of COVID-19 pandemic on the management of non-COVID patients, with potential detrimental and irreversible complications. We thus propose adjusted strategies to deal with both COVID and non-COVID patients. | 1876-0341 | 2020-06-21 02:00:00+02:00 | pubmed | Journal of Infection and Public Health | Radjiv Goulabchand;Pierre-Géraud Claret;Benoit Lattuca | COVID-19;Pandemic;Public health system | 2020-06-15 02:00:00+02:00 | 32576501 | FR | Internal Medicine Department, Nîmes University Hospital, Montpellier University, Nîmes, France. Electronic address: radjiv.goulabchand@chu-nimes.fr.;Department of Anaesthesia, Intensive Care, Pain and Emergency, Nîmes University Hospital, Montpellier University, Nîmes, France.;Cardiology Department, Nîmes University Hospital, Montpellier University, Nîmes, France. | 1369 | |||
| 10.1016/j.jamda.2020.06.018 | Journal Article;Multicenter Study | en | The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. | https://www.ncbi.nlm.nih.gov/pubmed/32674818 | Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors ("statins") have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19-infected older adults residing in nursing homes. | 1525-8610 | 2020-06-21 02:00:00+02:00 | pubmed | Aged;Aged, 80 and over;Angiotensin Receptor Antagonists__administration & dosage;Angiotensin-Converting Enzyme Inhibitors__administration & dosage;Belgium__epidemiology;Cause of Death;Cohort Studies;Coronavirus Infections__drug therapy;Female;Geriatric Assessment;Homes for the Aged__statistics & numerical data;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors__administration & dosage;Logistic Models;Male;Nursing Homes__statistics & numerical data;Odds Ratio;Pandemics__statistics & numerical data;Pneumonia, Viral__drug therapy;Retrospective Studies;Risk Assessment;Severity of Illness Index;Survival Rate;Treatment Outcome;COVID-19 | Journal of the American Medical Directors Association | Anton De Spiegeleer;Antoon Bronselaer;James T Teo;Geert Byttebier;Guy De Tré;Luc Belmans;Richard Dobson;Evelien Wynendaele;Christophe Van De Wiele;Filip Vandaele;Diemer Van Dijck;Dan Bean;David Fedson;Bart De Spiegeleer | Angiotensin-converting enzyme inhibitors;COVID-19;angiotensin II receptor blockers;nursing home residents;statins | 2020-06-15 02:00:00+02:00 | 32674818 | FR;BE;GB | Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium, Department of Geriatrics, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium, Unit for Molecular Immunology and Inflammation, VIB-Center for Inflammation Research, Ghent, Belgium.;DDCM Laboratory, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Ghent, Belgium.;Department of Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.;Bioconstat BV, Ghent, Belgium.;Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium.;Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.;Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.;Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent, Belgium.;VZW Zorg-Saam Zusters Kindsheid Jesu, Ghent, Belgium.;Corilus Health IT Center, Ghent, Belgium.;57, chemin du Lavoir, Sergy Haut, France.;Drug Quality and Registration Group, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. Electronic address: bart.despiegeleer@ugent.be. | 1372 | ||
| 10.1016/j.euf.2020.06.006 | Journal Article | en | Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines. | https://www.ncbi.nlm.nih.gov/pubmed/32571743 | Determining whether members follow guidelines, including guidelines prepared to help direct practice management during the coronavirus disease 2019 (COVID-19) pandemic, is an important goal for medical associations. | 2405-4569 | 2020-06-21 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Guideline Adherence__statistics & numerical data;Humans;Pandemics;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Practice Patterns, Physicians';Societies, Medical;Surveys and Questionnaires;Triage;Urogenital Neoplasms__pathology;Urologic Diseases__surgery;Urologic Surgical Procedures__methods;Urologists;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Urology Focus | Stavros Gravas;Georges Fournier;Mototsugu Oya;Duncan Summerton;Roberto Mario Scarpa;Piotr Chlosta;Ioannis Gkialas;Li-Ping Xie;Nur Rasyid;Damien Bolton;Reynaldo Gomez;Laurence Klotz;Sanjay Kulkarni;Simon Tanguay;Jean de la Rosette | COVID-19;Coronavirus;Guidelines;Pandemic;Practice management;Severe acute respiratory syndrome coronavirus 2;Urology | 2020-06-15 02:00:00+02:00 | 32571743 | FR;ID;CA;CN;GR;JP;GB;CL;IT;PL;AU;TR;IN;DE | Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. Electronic address: sgravas2002@yahoo.com.;Department of Urology, Hopital de la Cavale Blanche, University of Brest, Brest, France.;Department of Urology, Keio University School of Medicine, Tokyo, Japan.;Department of Urology, University Hospitals of Leicester NHS Trust, Leicester, UK.;Department of Urology, Università Campus Biomedico, Rome, Italy.;Department of Urology, Jagiellonian University-Medical College, Krakow, Poland.;Department of Urology, Anticancer Hospital of Athens "Agios Savvas", Athens, Greece.;Department of Urology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.;Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.;Department of Urology, Austin Health, Heidelberg, VIC, Australia.;Universidad Andres Bello, Hospital del Trabajador, Santiago, Chile.;Division of Urology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;Kulkarni Reconstructive Urology Center, Pune, India.;Department of Surgery, Division of Urology, McGill University, Montreal, QC, Canada.;Department of Urology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey. | 1379 | ||
| Letter | en | Anti-cardiolipin IgG autoantibodies are an independent risk factor of COVID-19 severity. | https://www.ncbi.nlm.nih.gov/pubmed/32564467 | A growing body of evidence indicates that patients with cardiovascular complications are at a higher risk for developing severe Coronavirus Disease 2019 (COVID-19) (1). In addition, the high incidence of thromboembolic events suggests an important role of COVID-19-induced coagulopathy (2). Antiphospholipid autoantibodies (aPL), that are essential markers for antiphospholipid syndrome, are considered as a cardiovascular risk factor. | 2020-06-21 02:00:00+02:00 | pubmed | Daniel Bertin;Alexandre Brodovitch;Abdou Beziane;Sylvia Hug;Afaf Bouamri;Jean Louis Mege;Nathalie Bardin | 2020-06-21 02:00:00+02:00 | 32564467 | FR | Service d'Immunologie, Pôle de Biologie, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.;Aix-Marseille Université, CNRS, INP UMR 7051, 13916, Marseille, France.;Aix-Marseille Université, IRD, MEPHI, IHU-Méditerranée Infection, Marseille, France.;Aix Marseille Université, C2VN, INSERM UMR_S 1263, Marseille, France. | 1387 | |||||||
| 10.1177/0194599820934376 | Journal Article | en | Olfactory and Gustatory Dysfunction as an Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study. | https://www.ncbi.nlm.nih.gov/pubmed/32539586 | To evaluate the prevalence and characteristics of olfactory or gustatory dysfunction in coronavirus disease 2019 (COVID-19) patients. | 0194-5998,1097-6817 | 2020-06-21 02:00:00+02:00 | pubmed | Otolaryngology–Head and Neck Surgery | Chenghao Qiu;Chong Cui;Charlotte Hautefort;Antje Haehner;Jun Zhao;Qi Yao;Hui Zeng;Eric J Nisenbaum;Li Liu;Yu Zhao;Di Zhang;Corinna G Levine;Ivette Cejas;Qi Dai;Mei Zeng;Philippe Herman;Clement Jourdaine;Katja de With;Julia Draf;Bing Chen;Dushyantha T Jayaweera;James C Denneny;Roy Casiano;Hongmeng Yu;Adrien A Eshraghi;Thomas Hummel;Xuezhong Liu;Yilai Shu;Hongzhou Lu | COVID-19;COVID-19 screening;SARS-CoV-2;anosmia;dysgeusia;gustatory dysfunction;olfactory dysfunction | 2020-06-16 02:00:00+02:00 | 32539586 | FR;CN;US;DE | Center of Stomatology, Shanghai Public Health Clinical Center, Shanghai, China.;ENT Institute and Otorhinolaryngology Department of the Affiliated Eye and ENT Hospital, State Key Laboratory of Medical Neurobiology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.;NHC Key Laboratory of Hearing Medicine, Fudan University, Shanghai, China.;Department of Head and Neck Surgery, Hopital Lariboisiere, University of Paris, Paris, France.;Smell and Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Dresden, Germany.;Center of Pediatrics, Shanghai Public Health Clinical Center, Shanghai, China.;Department of Otorhinolaryngology, Chinese and Western Medicine Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Department of Cardiovascularology, The Third People's Hospital of Shenzhen, Shenzhen, China.;Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA.;Department of Infectious Diseases, Shanghai Public Health Clinical Center, Shanghai, China.;Department of Otolaryngology, The Third People's Hospital of Shenzhen, Shenzhen, China.;Department of Infectious Diseases, Children's Hospital of Fudan University, Shanghai, China.;Division of Infectious Diseases, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, Germany.;Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.;American Academy of Otolaryngology-Head and Neck Surgery, Alexandria, Virginia, USA. | 1398 | |||
| 10.1016/j.micinf.2020.05.016 | Journal Article | en | Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. | https://www.ncbi.nlm.nih.gov/pubmed/32561409 | Clinical descriptions about influenza-like illnesses (ILI) in COVID-19 seem non-specific. We aimed to compare the clinical features of COVID-19 and influenza. We retrospectively investigated the clinical features and outcomes of confirmed cases of COVID-19 and influenza in Nord Franche-Comté Hospital between February 26th and March 14th 2020. We used SARS-CoV-2 RT-PCR and influenza virus A/B RT-PCR in respiratory samples to confirm the diagnosis. We included 124 patients. The mean age was 59 (±19 [19-98]) years with 69% female. 70 patients with COVID-19 and 54 patients with influenza A/B. Regarding age, sex and comorbidities, no differences were found between the two groups except a lower Charlson index in COVID-19 group (2 [±2.5] vs 3 [±2.4],p = 0.003). Anosmia (53% vs 17%,p < 0.001), dysgeusia (49% vs 20%,p = 0.001), diarrhea (40% vs 20%,p = 0.021), frontal headache (26% vs 9%,p = 0.021) and bilateral cracklings sounds (24% vs 9%,p = 0.034) were statistically more frequent in COVID-19. Sputum production (52% vs 29%,p = 0.010), dyspnea (59% vs 34%,p = 0.007), sore throat (44% vs 20%,p = 0.006), conjunctival hyperhemia (30% vs 4%,p < 0.001), tearing (24% vs 6%,p = 0.004), vomiting (22% vs 3%,p = 0.001) and rhonchi sounds (17% vs 1%,p = 0.002) were more frequent with influenza infection. We described several clinical differences which can help the clinicians during the co-circulation of influenza and SARS-CoV-2. | 1286-4579 | 2020-06-21 02:00:00+02:00 | pubmed | Microbes and Infection | Souheil Zayet;N'dri Juliette Kadiane-Oussou;Quentin Lepiller;Hajer Zahra;Pierre-Yves Royer;Lynda Toko;Vincent Gendrin;Timothée Klopfenstein | COVID- 19;Clinical feature;Influenza;Influenza-like-illness;SARS-CoV-2 | 2020-06-16 02:00:00+02:00 | 32561409 | FR | Infectious Disease Department, Nord Franche-Comté Hospital, France. Electronic address: souhail.zayet@gmail.com.;Infectious Disease Department, Nord Franche-Comté Hospital, France.;Virology Department, Centre-Hospitalier Universitaire de Besançon, France.;Diabetology Department Nord Franche-Comté Hospital, France.;Infectious Disease Department, Nord Franche-Comté Hospital, France. Electronic address: timothee.klopfenstein@hnfc.fr. | 1400 | |||
| Editorial;Comment | fr | [Pragmatic proposals of respiratory follow-up for patients with SARS-CoV-2 infection established in record time for all healthcare practioners]. | https://www.ncbi.nlm.nih.gov/pubmed/32564800 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Follow-Up Studies;Humans;Language;Pandemics;Pneumonia, Viral;Pulmonary Medicine;SARS Virus;COVID-19;severe acute respiratory syndrome coronavirus 2 | C Raherison | 2020-06-23 02:00:00+02:00 | 32564800 | FR | Service des maladies respiratoires, CHU de Bordeaux & université de Bordeaux, U1219 Epicene, Bordeaux, France. Electronic address: Presidente-splf@splf.org. | 1405 | |||||||
| 10.1016/s2665-9913(20)30178-8 | Journal Article | en | Anakinra for patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32835235 | 2665-9913 | 2020-06-28 02:00:00+02:00 | pubmed | The Lancet Rheumatology | Nicolas Martin-Silva;Hubert de Boysson;Achille Aouba | 2020-06-25 02:00:00+02:00 | 32835235 | FR | Department of Internal Medicine and Clinical Immunology, CHU et Université de Caen Normandie, Caen 14000, France. | 1406 | |||||
| 10.1136/esmoopen-2020-000820 | Journal Article | en | ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. | https://www.ncbi.nlm.nih.gov/pubmed/32581069 | The COVID-19 pandemic, characterised by a fast and global spread during the first months of 2020, has prompted the development of a structured set of recommendations for cancer care management, to maintain the highest possible standards. Within this framework, it is crucial to ensure no disruption to essential oncological services and guarantee the optimal care.This is a structured proposal for the management of lung cancer, comprising three levels of priorities, namely: tier 1 (high priority), tier 2 (medium priority) and tier 3 (low priority)-defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and Magnitude of Clinical Benefit Scale.The manuscript emphasises the impact of the COVID-19 pandemic on lung cancer care and reconsiders all steps from diagnosis, staging and treatment.These recommendations should, therefore, serve as guidance for prioritising the different aspects of cancer care to mitigate the possible negative impact of the COVID-19 pandemic on the management of our patients.As the situation is rapidly evolving, practical actions are required to guarantee the best patients' treatment while protecting and respecting their rights, safety and well-being. In this environment, cancer practitioners have great responsibilities: provide timely, appropriate, compassionate and justified cancer care, while protecting themselves and their patients from being infected with COVID-19. In case of shortages, resources must be distributed fairly. Consequently, the following recommendations can be applied with significant nuances, depending on the time and location for their use, considering variable constraints imposed to the health systems. An exceptional flexibility is required from cancer caregivers. | 2059-7029 | 2020-06-28 02:00:00+02:00 | pubmed | Ambulatory Care;Betacoronavirus;Carcinoma, Non-Small-Cell Lung__pathology;Chemoradiotherapy;Coronavirus Infections__epidemiology;Delivery of Health Care__methods;Humans;Lung Neoplasms__pathology;Medical Oncology;Neoplasm Staging;Pandemics;Pneumonectomy;Pneumonia, Viral__epidemiology;Practice Guidelines as Topic;Radiation Oncology;Radiosurgery;Small Cell Lung Carcinoma__pathology;Surgical Oncology;Telemedicine;Time-to-Treatment;Tomography, X-Ray Computed;Triage;COVID-19;severe acute respiratory syndrome coronavirus 2 | ESMO Open | Antonio Passaro;Alfredo Addeo;Christophe Von Garnier;Fiona Blackhall;David Planchard;Enriqueta Felip;Rafal Dziadziuszko;Filippo de Marinis;Martin Reck;Hasna Bouchaab;Solange Peters | COVID19;SARS-CoV-2;lung cancer | 2020-06-26 02:00:00+02:00 | 32581069 | FR;GB;CH;IT;PL;ES;PS;DE | Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy Antonio.Passaro@ieo.it.;University Hospital of Geneva Department of Oncology, Geneva, Switzerland.;Department of Pulmonary Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.;Division of Cancer Sciences, University of Manchester & The Christie NHS Foundation Trust, Manchester, UK.;Department of Medical Oncology, Thoracic Unit, Gustave Roussy, Villejuif, France.;Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Department of Oncology and Radiotherapy, Gdanski Uniwersytet Medyczny, Gdansk, Poland.;Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.;LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.;Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. | 1409 | ||
| Letter;Comment | en | Do pregnant women have protective immunity against COVID-19? | https://www.ncbi.nlm.nih.gov/pubmed/32583553 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Female;Humans;Pandemics;Pneumonia, Viral__epidemiology;Pregnancy;Pregnant Women;COVID-19;severe acute respiratory syndrome coronavirus 2 | Hanane Bouchghoul;Solene Vigoureux | 2020-06-24 02:00:00+02:00 | 32583553 | FR | Department of Gynaecology and Obstetrics, AP-HP, GHU-Sud, University Paris-Sud Saclay, Hospital Bicêtre, Le Kremlin Bicêtre, France.;CESP Centre for Research in Epidemiology and Population Health, Gender, Inserm U1018, UVSQ, University of Paris-Saclay, University of Paris-Sud, Villejuif, France. | 1432 | |||||||
| 10.1016/j.vaccine.2020.06.056 | Journal Article | en | Logistical challenges for potential SARS-CoV-2 vaccine and a call to research institutions, developers and manufacturers. | https://www.ncbi.nlm.nih.gov/pubmed/32600910 | 0264-410X | 2020-06-28 02:00:00+02:00 | pubmed | Biomedical Research__organization & administration;Coronavirus Infections__prevention & control;Drug Industry__organization & administration;Humans;International Cooperation;Pandemics__prevention & control;Pneumonia, Viral__prevention & control;Viral Vaccines__supply & distribution;World Health Organization__organization & administration;COVID-19 | Vaccine | Umit H Kartoglu;Kelly L Moore;John S Lloyd | SARS-CoV-2;VVM;Vaccine logistics;Vaccine target profile;Vaccine vial monitor | 2020-06-23 02:00:00+02:00 | 32600910 | FR;CH;US | Extensio et Progressio, 1A Chemin du Pre-d'Orsat, 1245 Collonge-Bellerive, Switzerland. Electronic address: umit@kartoglu.ch.;Immunization Action Coalition, Saint-Paul, MN, United States, Vanderbilt School of Medicine, TN, United States. Electronic address: Kelly.moore@immunize.org.;Independent consultant, Tournus, France. Electronic address: john.lloyd1945@gmail.com. | 1434 | |||
| 10.1016/j.diabres.2020.108275 | Journal Article | en | COVID-19 and type 1 diabetes: Challenges and actions. | https://www.ncbi.nlm.nih.gov/pubmed/32590008 | 0168-8227 | 2020-06-28 02:00:00+02:00 | pubmed | Diabetes Research and Clinical Practice | Emma L Klatman;Stéphane Besançon;Silver Bahendeka;Mary Mayige;Graham D Ogle | COVID 19;Diabetes;Insulin;Supply chain;Type 1 diabetes | 2020-06-24 02:00:00+02:00 | 32590008 | TZ;FR;UG;AU | Life for a Child Program, Diabetes NSW & ACT, Glebe, NSW, Australia. Electronic address: emma@lifeforachild.org.;ONG Santé Diabète, 17 Avenue Malherbe, 38100 Grenoble, France.;Mother Kevin Post Graduate Medical School, Uganda Martyrs University, Kampala, Uganda.;National Institute for Medical Research, Dar es Salaam, Tanzania.;Life for a Child Program, Diabetes NSW & ACT, Glebe, NSW, Australia. | 1439 | ||||
| 10.1016/j.ajogmf.2020.100159 | Journal Article;Review | en | Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32838264 | Treatment of coronavirus disease 2019 is mostly symptomatic, but a wide range of medications are under investigation against severe acute respiratory syndrome coronavirus 2. Although pregnant women are excluded from clinical trials, they will inevitably receive therapies whenever they seem effective in nonpregnant patients and even under compassionate use. | 2589-9333 | 2020-06-28 02:00:00+02:00 | pubmed | American Journal of Obstetrics & Gynecology MFM | Margaux Louchet;Jeanne Sibiude;Gilles Peytavin;Olivier Picone;Jean-Marc Tréluyer;Laurent Mandelbrot | coronavirus disease 2019;placenta;pregnancy;severe acute respiratory syndrome coronavirus 2 | 2020-06-22 02:00:00+02:00 | 32838264 | FR | Assistance Publique-Hôpitaux de Paris, Service de Gynécologie-Obstétrique, Hôpital Louis Mourier, Colombes, France.;Inserm Infection, Antimicrobials, Modelling, Evolution U1137, Paris, France.;Université de Paris, Paris, France.;Fédération Hospitalo-Universitaire PREMA, Paris, France.;Assistance Publique-Hôpitaux de Paris, Service de Pharmacologie-Toxicologie, Hôpital Bichat, Paris, France, and Assistance Publique-Hôpitaux de Paris, URC/CIC Cochin-Necker, Paris, France. | 1456 | |||
| 10.1111/inr.12604 | Journal Article | en | COVID-19 pandemic in France: health emergency experiences from the field. | https://www.ncbi.nlm.nih.gov/pubmed/32567057 | This paper describes the situation regarding COVID-19 emergency in France as of early May 2020, the main policies to fight this virus, and the roles and responsibilities of nurses regarding their work at this time, as well as the challenges facing the profession. | 0020-8132,1466-7657 | 2020-06-28 02:00:00+02:00 | pubmed | International Nursing Review | P Chamboredon;C Roman;S Colson | COVID-19;France;Health Emergency;Health Policy;Nursing Nursing Policy;Pandemics Primary Care Nursing;Public Health;Roles and Responsibilities | 2020-06-22 02:00:00+02:00 | 32567057 | FR | French National Council Order of Nurses, Paris, France.;Faculty of Medical and Paramedical Sciences, Nursing School, Aix-Marseille Université, Marseille, France.;Hôpital Saint-Joseph, Marseille, France. | 1459 | |||
| 10.1016/j.anorl.2020.06.013 | Journal Article | en | Impact of the SARS-CoV-2 epidemic on private ENT consulting practice during the first month of lockdown in Réunion Island in 2020. | https://www.ncbi.nlm.nih.gov/pubmed/32712116 | To analyze the impact of the first month of lockdown related to the 2020 SARS-Cov-2 epidemic on the consulting activity of private ENT physicians in Réunion Island. | 1879-7296 | 2020-06-28 02:00:00+02:00 | pubmed | European Annals of Otorhinolaryngology, Head and Neck Diseases | F Rubin;J-F Vellin;J Berkaoui;W Al Assaf;A Pennica;B Girard;P Hoarau;P Pescatori;M Dupre;S Bensoussan;P Vurpillot;N Challut;O Laccourreye | Covid-19;ENT;France;Réunion Island;SARS-CoV-2 | 2020-06-23 02:00:00+02:00 | 32712116 | FR | Clinique St-Vincent, 8, rue de Paris, CS 71027, Saint-Denis Cedex 97404, La Réunion, France. Electronic address: dr.frubin@orlsaintdenis.fr.;Clinique St-Vincent, 8, rue de Paris, CS 71027, Saint-Denis Cedex 97404, La Réunion, France.;Clinique des Orchidées, 30, avenue Lénine, 97420 Le Port, La Réunion, France.;Clinique Durieux, 100, rue de France, 97430 Le Tampon, La Réunion, France.;Cabinet ORL, 135 N1C, 97450 Saint-Louis, La Réunion, France.;Cabinet ORL, 43, rue du Maréchal-Leclerc, 97400 Saint-Denis, La Réunion, France.;Université Paris Centre, Service ORL HEGP, AP-HP, 20-40, rue Leblanc, 75015 Paris, France. | 1466 | |||
| 10.1016/j.tmaid.2020.101791 | Journal Article | en | Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. | https://www.ncbi.nlm.nih.gov/pubmed/32593867 | In our institute in Marseille, France, we initiated early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with hydroxychloroquine and azithromycin (HCQ-AZ) was proposed for the positive cases. | 1477-8939 | 2020-06-28 02:00:00+02:00 | pubmed | Travel Medicine and Infectious Disease | Jean-Christophe Lagier;Matthieu Million;Philippe Gautret;Philippe Colson;Sébastien Cortaredona;Audrey Giraud-Gatineau;Stéphane Honoré;Jean-Yves Gaubert;Pierre-Edouard Fournier;Hervé Tissot-Dupont;Eric Chabrière;Andreas Stein;Jean-Claude Deharo;Florence Fenollar;Jean-Marc Rolain;Yolande Obadia;Alexis Jacquier;Bernard La Scola;Philippe Brouqui;Michel Drancourt;Philippe Parola;Didier Raoult | Azithromycin;COVID-19;Hydroxychloroquine;SARS-CoV-2 | 2020-06-25 02:00:00+02:00 | 32593867 | FR | IHU-Méditerranée Infection, Marseille, France, Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille University, IRD, AP-HM, SSA, VITROME, Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille University, IRD, AP-HM, SSA, VITROME, Marseille, France, Centre d'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille, France, AP-HM, Marseille, France.;Aix Marseille University, Laboratoire de Pharmacie Clinique, Marseille, France, AP-HM, Hôpital Timone, Service Pharmacie, Marseille, France.;Department of Radiology and Cardiovascular Imaging, Aix Marseille Univ, LIIE, Marseille, France.;IHU-Méditerranée Infection, Marseille, France.;AP-HM, Aix Marseille University, Hôpital Timone, Cardiologie, Rythmologie, Marseille, France.;Department of Radiology and Cardiovascular Imaging, Aix-Marseille Univ., UMR 7339, CNRS, CRMBM-CEMEREM (Centre de Résonance Magnétique Biologique et Médicale-Centre d'Exploration Métaboliques Par Résonance Magnétique), Marseille, France.;IHU-Méditerranée Infection, Marseille, France, Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France. Electronic address: didier.raoult@gmail.com. | 1478 | |||
| 10.1111/apa.15455 | Journal Article | en | Promoting attachment between parents and neonates despite the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32588911 | Social distancing is the only option available during the COVID-19 pandemic until a vaccine is developed. However, this is having a major impact on human relationships and bonding between parents and neonates is a major concern. Separation during this health emergency could have lifelong consequences for offspring and there are even greater concerns if newborn infants are sick or vulnerable and need intensive care. We look at how bonding can be safely supported and maintained without risking infecting neonates, by comparing the international guidelines and proposing safe actions within those frameworks. | 0803-5253,1651-2227 | 2020-06-28 02:00:00+02:00 | pubmed | Acta Paediatrica | Charlotte Tscherning;Jacques Sizun;Pierre Kuhn | COVID-19;bonding;guidelines;pandemic;separation | 2020-06-26 02:00:00+02:00 | 32588911 | QA;FR;US | Division of Neonatology, Sidra Medicine, Weill-Cornell Medical College, Doha, Qatar.;Center of Physiopathology Toulouse-Purpan (CPTP), Inserm, CNRS, University of Toulouse, Toulouse, France.;CHU Brest, Service de Néonatalogie et Réanimation Pédiatrique, Brest, France.;CHU Toulouse, Service de Néonatalogie, Toulouse, France.;Service de Médecine et de Réanimation du Nouveau-né, Hôpital Hautepierre, Strasbourg, France.;Institut des Neurosciences Cellulaires et Intégratives, CNRS UPR 3212, Strasbourg, France. | 1482 | |||
| Letter | en | Recent outbreak of chilblain-like lesions is not directly related to SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32589294 | 2020-06-28 02:00:00+02:00 | pubmed | J Rouanet;E Lang;F Beltzung;B Evrard;C Henquell;I Joulie;M D'Incan | 2020-06-26 02:00:00+02:00 | 32589294 | FR | Department of Dermatology, CHU, Université Clermont Auvergne, Clermont-Ferrand, France.;Department of Pathology, CHU, Université Clermont Auvergne, Clermont-Ferrand, France.;Department of Immunology, CHU, Université Clermont Auvergne, Clermont-Ferrand, France.;Department of Virology, CHU, 3IHP, Université Clermont Auvergne, Clermont-Ferrand, France. | 1483 | ||||||||
| 10.1111/epi.16612 | Journal Article | en | Orbitofrontal involvement in a neuroCOVID-19 patient. | https://www.ncbi.nlm.nih.gov/pubmed/32589794 | Neurological manifestations of coronavirus disease 19 (COVID-19) such as encephalitis and seizures have been reported increasingly, but our understanding of COVID-19-related brain injury is still limited. Herein we describe prefrontal involvement in a patient with COVID-19 who presented prior anosmia, raising the question of a potential trans-olfactory bulb brain invasion. | 0013-9580,1528-1167 | 2020-06-28 02:00:00+02:00 | pubmed | Epilepsia | Loïc Le Guennec;Julia Devianne;Laurence Jalin;Albert Cao;Damien Galanaud;Vincent Navarro;David Boutolleau;Benjamin Rohaut;Nicolas Weiss;Sophie Demeret | 2020-06-26 02:00:00+02:00 | 32589794 | FR;US | Neurology Department, Neurological Intensive Care Unit, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.;Sorbonne Université, Paris, France.;Brain Institute Paris, ICM (Inserm, CNRS, Sorbonne Université), Paris, France.;Neurosurgical Intensive Care Unit, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.;Neuroradiology Department, Hôpital Pitié-Salpêtrière, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.;Neurology and Neurophysiology Department, Hôpital Pitié-Salpêtrière, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.;Virology Department, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, Paris, France.;Department of Neurology, Columbia University, New York, New York. | 1485 | ||||
| 10.1097/ccm.0000000000004504 | Journal Article | en | Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans. | https://www.ncbi.nlm.nih.gov/pubmed/32618700 | The main objective of the study was to determine the prevalence of venous thromboembolism events in patients infected with severe acute respiratory syndrome coronavirus 2 requiring venovenous extracorporeal membrane oxygenation. The secondary objective was to compare venous thromboembolism events and coagulation variables in patients requiring venovenous extracorporeal membrane oxygenation according to the pathogen. | 0090-3493 | 2020-06-28 02:00:00+02:00 | pubmed | Critical Care Medicine | Gabriel Parzy;Florence Daviet;Basile Puech;Aude Sylvestre;Christophe Guervilly;Alizée Porto;Sami Hraiech;Kathia Chaumoitre;Laurent Papazian;Jean-Marie Forel | 2020-06-26 02:00:00+02:00 | 32618700 | FR | 1Médecine Intensive Réanimation Détresses Respiratoires et Infection Sévères, AP-HM, CHU Nord, Marseille, France. 2CEReSS - Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France. 3Service d'Imagerie Médicale, AP-HM, CHU Nord, Marseille, France. 4Département de Chirurgie Cardiaque, AP-HM, CHU Timone, Marseille, France. | 1489 | ||||
| 10.1016/j.drudis.2020.06.022 | Editorial | en | Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders. | https://www.ncbi.nlm.nih.gov/pubmed/32593662 | 1359-6446 | 2020-06-28 02:00:00+02:00 | pubmed | Drug Discovery Today | Bruno O Villoutreix;Philippe H Beaune;Ryad Tamouza;Rajagopal Krishnamoorthy;Marion Leboyer | 2020-06-25 02:00:00+02:00 | 32593662 | FR | Univ. Lille, INSERM, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, F-59000 Lille, France, Université de Paris, NeuroDiderot, INSERM, hôpital Robert-Debré, F-75019 Paris, France. Electronic address: bruno.villoutreix@inserm.fr.;INSERM U1138 Centre de recherche des Cordeliers 75006 Paris, Service de Biochimie et Pôle Biologie Produits de Santé, Hôpital Européen Georges Pompidou, APHP, and Université de Paris, Paris, France. Electronic address: philippe.beaune@parisdescartes.fr.;Université Paris Est Créteil, INSERM U955, IMRB, Laboratoire Neuro-psychiatrie translationnelle, AP-HP, Département Medico-Universitaire de Psychiatrie et d'Addictologie (DMU ADAPT), Hôpital Henri Mondor, Fondation FondaMental, F-94010 Créteil, France.;Université Paris Est Créteil, INSERM U955, IMRB, Laboratoire Neuro-psychiatrie translationnelle, AP-HP, Département Medico-Universitaire de Psychiatrie et d'Addictologie (DMU ADAPT), Hôpital Henri Mondor, Fondation FondaMental, F-94010 Créteil, France. Electronic address: marion.leboyer@inserm.fr. | 1490 | |||||
| H2020 Research Infrastructures;H2020 Fast Track to Innovation;H2020 European Institute of Innovation and Technology;Agence Nationale de la Recherche;Institut National de la Santé et de la Recherche Médicale | 10.3390/v12060686 | Comparative Study;Evaluation Study;Journal Article;Research Support, Non-U.S. Gov't | en | Development and Evaluation of a duo SARS-CoV-2 RT-qPCR Assay Combining Two Assays Approved by the World Health Organization Targeting the Envelope and the RNA-Dependant RNA Polymerase (RdRp) Coding Regions. | https://www.ncbi.nlm.nih.gov/pubmed/32630601 | The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide has highlighted the importance of reliable and rapid diagnostic testing to prevent and control virus circulation. Dozens of monoplex in-house RT-qPCR assays are already available; however, the development of dual-target assays is suited to avoid false-negative results caused by polymorphisms or point mutations, that can compromise the accuracy of diagnostic and screening tests. In this study, two mono-target assays recommended by WHO (E-Sarbeco (enveloppe gene, Charite University, Berlin, Germany) and RdRp-IP4 (RdRp, Institut Pasteur, Paris, France)) were selected and combined in a unique robust test; the resulting duo SARS-CoV-2 RT-qPCR assay was compared to the two parental monoplex tests. The duo SARS-CoV-2 assay performed equally, or better, in terms of sensitivity, specificity, linearity and signal intensity. We demonstrated that combining two single systems into a dual-target assay (with or without an MS2-based internal control) did not impair performances, providing a potent tool adapted for routine molecular diagnosis in clinical microbiology laboratories. | 1999-4915 | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus__genetics;Coronavirus Infections__diagnosis;Humans;Pandemics;Pneumonia, Viral__diagnosis;RNA Replicase__genetics;RNA, Viral__analysis;Real-Time Polymerase Chain Reaction__methods;Sensitivity and Specificity;Viral Envelope Proteins__genetics;Viral Nonstructural Proteins__genetics;World Health Organization;COVID-19;severe acute respiratory syndrome coronavirus 2 | Viruses | Laura Pezzi;Remi N Charrel;Laetitia Ninove;Antoine Nougairede;Gregory Molle;Bruno Coutard;Guillaume Durand;Isabelle Leparc-Goffart;Xavier de Lamballerie;Laurence Thirion | COVID-19;TaqMan;coronavirus;diagnosis;diagnostics;emerging;molecular;outbreak;preparedness;real-time PCR;respiratory;response | 2020-06-25 02:00:00+02:00 | 32630601 | FR | [{"country": "International", "agency": "H2020 Research Infrastructures", "grantid": "871029"}, {"country": "International", "agency": "H2020 Fast Track to Innovation", "grantid": "101003544"}, {"country": "International", "agency": "H2020 European Institute of Innovation and Technology", "grantid": "823666"}, {"country": "International", "agency": "Agence Nationale de la Recherche", "grantid": "PREPMedVet"}, {"country": "International", "agency": "Institut National de la Santé et de la Recherche Médicale", "grantid": "Reacting"}] | UR7310, Laboratoire de Virologie, Université de Corse-Inserm, 20250 Corte, France.;Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), 13005 Marseille, France.;Institut de Recherche Biomédicale des Armées, National Reference Laboratory for Arboviruses, 13005 Marseille, France. | 1491 |
| 10.1212/nxi.0000000000000825 | Journal Article;Observational Study | en | Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? | https://www.ncbi.nlm.nih.gov/pubmed/32587103 | To evaluate disease activity in patients with relapsing-remitting MS (RRMS) receiving rituximab with an extended dosing interval. | 2332-7812 | 2020-06-28 02:00:00+02:00 | pubmed | Adult;Betacoronavirus;Coronavirus Infections__diagnosis;Drug Administration Schedule;Female;Humans;Immunologic Factors__administration & dosage;Male;Middle Aged;Multiple Sclerosis, Relapsing-Remitting__diagnosis;Pandemics;Pneumonia, Viral__diagnosis;Prospective Studies;Rituximab__administration & dosage;COVID-19;severe acute respiratory syndrome coronavirus 2 | Neurology - Neuroimmunology Neuroinflammation | Adil Maarouf;Audrey Rico;Clemence Boutiere;Marine Perriguey;Sarah Demortiere;Jean Pelletier;Bertrand Audoin | multiple sclerosis | 2020-06-25 02:00:00+02:00 | 32587103 | FR | From the Service de Neurologie, Pôle de Neurosciences Cliniques, APHM, Hôpital de la Timone, Aix Marseille Univ, France.;From the Service de Neurologie, Pôle de Neurosciences Cliniques, APHM, Hôpital de la Timone, Aix Marseille Univ, France. bertrand.audoin@ap-hm.fr. | 1497 | ||
| 10.1016/j.cmi.2020.06.019 | Journal Article;Review | en | Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. | https://www.ncbi.nlm.nih.gov/pubmed/32593741 | To face the current COVID-19 pandemic, diagnostic tools are essential. It is recommended to use real-time RT-PCR for RNA viruses in order (a) to perform a rapid and accurate diagnostic, (b) to guide patient care and management and (c) to guide epidemiological strategies. Further studies are warranted to define the role of serological diagnosis and a possible correlation between serological response and prognosis. | 1198-743X | 2020-06-28 02:00:00+02:00 | pubmed | Clinical Microbiology and Infection | G Caruana;A Croxatto;A T Coste;O Opota;F Lamoth;K Jaton;G Greub | COVID-19;Coronavirus;Molecular diagnostic testing;Reverse transcriptase polymerase chain reaction;SARS-COV-2;Serology | 2020-06-25 02:00:00+02:00 | 32593741 | FR;CH | Institut de Microbiologie, Département de médecine de laboratoire et pathologie (DMLP), Centre Hospitalier Universitaire Vaudois and Université de Lausanne, Lausanne, Switzerland.;Institut de Microbiologie, Département de médecine de laboratoire et pathologie (DMLP), Centre Hospitalier Universitaire Vaudois and Université de Lausanne, Lausanne, Switzerland, Service de Maladies Infectieuses, Département de médecine, Centre Hospitalier Universitaire Vaudois and Université de Lausanne, Lausanne, Switzerland.;Institut de Microbiologie, Département de médecine de laboratoire et pathologie (DMLP), Centre Hospitalier Universitaire Vaudois and Université de Lausanne, Lausanne, Switzerland, Service de Maladies Infectieuses, Département de médecine, Centre Hospitalier Universitaire Vaudois and Université de Lausanne, Lausanne, Switzerland. Electronic address: gilbert.greub@chuv.ch. | 1499 | |||
| 10.1001/jamaneurol.2020.2581 | Journal Article | en | Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. | https://www.ncbi.nlm.nih.gov/pubmed/32589189 | Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities. | 2168-6149 | 2020-06-28 02:00:00+02:00 | pubmed | JAMA Neurology | Céline Louapre;Nicolas Collongues;Bruno Stankoff;Claire Giannesini;Caroline Papeix;Caroline Bensa;Romain Deschamps;Alain Créange;Abir Wahab;Jean Pelletier;Olivier Heinzlef;Pierre Labauge;Laurent Guilloton;Guido Ahle;Mathilde Goudot;Kevin Bigaut;David-Axel Laplaud;Sandra Vukusic;Catherine Lubetzki;Jérôme De Sèze | 2020-06-26 02:00:00+02:00 | 32589189 | FR | Institut du Cerveau et de la Moelle Épinière, Assistance Publique des Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Clinical Investigation Center Neuroscience, Paris, France.;Service de Neurologie, Clinical Investigation Center Institut National de la Santé et de la Recherche Médicale 1434, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Hôpital St Antoine, Assistance Publique des Hôpitaux de Paris, Paris, France.;Département de Neurologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.;Service de Neurologie, Centre de Ressources et de Compétences-Sclérose en Plaques, Assistance Publique des Hôpitaux de Paris, Groupe Hospitalier Henri Mondor, Université Paris-Est Créteil, Créteil, France.;Service de Neurologie, Pôle de Neurosciences Cliniques, Assistance Publique-Hôpitaux de Marseille, Hôpital de la Timone, Aix Marseille Université, Marseille, France.;Département de Neurologie, Centre Hospitalier de Poissy, St Germain, France.;Département de Neurologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Association des Neurologues Libéraux de Langue Française, Bergerac, France.;Département de Neurologie, Hôpitaux Civils de Colmar, Colmar, France.;Service de Neurologie, Groupe Hospitalier de la Region de Mulhouse, Mulhouse, France.;Centre de Recherche en Transplantation et Immunologie-Institut National de la Santé et de la Recherche Médicale U1064, Service Neurologie, Clinical Investigation Center 1413, Centre Hospitalier Universitaire Nantes, Nantes, France.;Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon/Bron, France. | 1503 | ||||
| 10.1136/jech-2020-214839 | Journal Article;Review | en | Prevention in COVID-19 time: from failure to future. | https://www.ncbi.nlm.nih.gov/pubmed/32595136 | The COVID-19 pandemic has developed as a consequence of sheer prevention failures, leading in many countries to a sizeable number of deaths and over-saturation of intensive care units. This triggered the imposition of generalisd quarantine ('lockdown') of variable stringency in different countries: with the decrease of the epidemic, the lockdown is now gradually relaxed and replaced by tight tracing and isolation of new cases and their contacts. Prevention, however, remains not a constant priority, as the objective may be avoidance of saturation of intensive care beds or more generally of healthcare facilities rather than the minimisation of the disease incidence. This combined with the fact that notwithstanding repeated warnings in past years the epidemic occurred as a surprise denotes a way of thinking in which prevention is an important option but not a guiding principle of choice and action within the health system. To modify this way of thinking and place prevention at the core of the system, non-negligible changes are required: they may become possible in light of emerging hazards like new viruses and climate change, huge economic costs of failed prevention and initial changes in the health system already induced by the COVID-19 epidemic. | 2020-06-28 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus;Coronavirus Infections__epidemiology;Forecasting;Humans;Immunity, Herd;Pandemics__prevention & control;Pneumonia, Viral__epidemiology;Quarantine;COVID-19;severe acute respiratory syndrome coronavirus 2 | Rodolfo Saracci | Covid-19;Emerging hazards;Health system;Lockdown;Prevention;Prevention failure | 2020-06-28 02:00:00+02:00 | 32595136 | FR | Former President, International Epidemiological Association, Lyon, France saracci@hotmail.com. | 1508 | ||||
| Letter | en | Beta-thalassemia may protect against COVID 19. | https://www.ncbi.nlm.nih.gov/pubmed/32615501 | 2020-06-28 02:00:00+02:00 | pubmed | Emmanuel Drouin | 2020-06-28 02:00:00+02:00 | 32615501 | FR | Centre Supérieur de la Renaissance, 59 rue Néricault Destouches, 37013 Tours, France. Electronic address: emmanuel.drouin2@wanadoo.fr. | 1510 | ||||||||
| Letter | en | COVID-19 and outbreak of chilblains: are they related? | https://www.ncbi.nlm.nih.gov/pubmed/32594575 | 2020-06-28 02:00:00+02:00 | pubmed | C Lesort;J Kanitakis;A Villani;E Ducroux;P Bouschon;K Fattouh;B Bensaid;M Danset;D Jullien | 2020-06-27 02:00:00+02:00 | 32594575 | FR | Dermatology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Université Claude Bernard Lyon I, Lyon, France. | 1516 | ||||||||
| 10.1007/s00586-020-06517-1 | Journal Article;Multicenter Study | en | The short-term impact of COVID-19 pandemic on spine surgeons: a cross-sectional global study. | https://www.ncbi.nlm.nih.gov/pubmed/32591880 | The outbreak of COVID-19 erupted in December 2019 in Wuhan, China. In a few weeks, it progressed rapidly into a global pandemic which resulted in an overwhelming burden on health care systems, medical resources and staff. Spine surgeons as health care providers are no exception. In this study, we try to highlight the impact of the crisis on spine surgeons in terms of knowledge, attitude, practice and socioeconomic burden. | 0940-6719,1432-0932 | 2020-06-28 02:00:00+02:00 | pubmed | Adult;Aged;Attitude of Health Personnel;Betacoronavirus;Clinical Competence__statistics & numerical data;Coronavirus Infections__economics;Cost of Illness;Cross-Sectional Studies;Female;Global Health;Humans;Male;Middle Aged;Occupational Stress__economics;Orthopedic Surgeons__economics;Pandemics__economics;Pneumonia, Viral__economics;Practice Patterns, Physicians'__statistics & numerical data;Surveys and Questionnaires;COVID-19;severe acute respiratory syndrome coronavirus 2 | European Spine Journal | Mohamed Fawzy Khattab;Tareq M A Kannan;Ahmed Morsi;Qussay Al-Sabbagh;Fadi Hadidi;Mohammed Qussay Al-Sabbagh;Muzahem M Taha;Anouar Bourghli;Ibrahim Obeid | COVID-19;Economy;Mitigation;Quarantine;Spine surgeons | 2020-06-26 02:00:00+02:00 | 32591880 | FR;SA;JO;IQ;EG | Orthopedic Surgery Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.;Spine Unit, Jordan University Hospital, University of Jordan, Amman, Jordan.;School of Medicine, University of Jordan, Amman, Jordan.;Orthopaedic Surgery Department, Kirkuk University, Kirkuk, Iraq.;Orthopedic and Spine Surgery Department, Kingdom Hospital, Riyadh, Saudi Arabia.;Spine Surgery Unit, Elsan Group Jean Villar Private Hospital, Bruges-Bordeaux, France. ibrahim.obeid@gmail.com. | 1523 | ||
| Letter | en | Letter to the editor on the outcomes in fracture patients infected with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32605785 | 2020-06-28 02:00:00+02:00 | pubmed | Maroun Rizkallah;Elias Melhem;Mansour Sadeqi;Jean Meyblum;Pomme Jouffroy;Guillaume Riouallon | 2020-06-25 02:00:00+02:00 | 32605785 | FR;LB | Orthopedic Surgery Department, Groupe Hospitalier Paris Saint Joseph, Paris, France., Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon. Electronic address: maroun.rizkallah@gmail.com.;Orthopedic Surgery Department, Groupe Hospitalier Paris Saint Joseph, Paris, France. | 1528 | ||||||||
| 10.1016/j.etiqe.2020.06.003 | English Abstract;Journal Article | fr | [What are the ethical issues raised by the COVID 19 epidemic?] | https://www.ncbi.nlm.nih.gov/pubmed/32837544 | The COVID-19 epidemic has highlighted or revealed real ethical issues, revealing the limits of knowledge, the limits of life, the limits of our health care system, the limits of our society. Questioning these limits and therefore these ethical issues can be interesting to advance our health system and our society. In this article, we have chosen to address a few ethical questions concerning more particularly the function of care, the relationship to death, the relationship to uncertainty, questions more related to containment measures than to COVID itself and finally a more political questioning on what this epidemic reveals about the fragility of our societies and our economies. We arbitrarily set aside, given the constrained format of the article, some extremely important issues such as research ethics issues, issues related to the notion of patient selection or triage, issues related to the ethics of managing the shortage, and finally issues related to the tracing of contacts or patients. | 1765-4629 | 2020-06-28 02:00:00+02:00 | pubmed | Éthique & Santé | R Aubry | COVID-19;Ethics and politics | 2020-06-25 02:00:00+02:00 | 32837544 | FR | Hôpital Jean-Minjoz, boulevard Fleming, 25030 Besançon cedex, France. | 1529 | |||
| 10.1016/j.ijinfomgt.2020.102178 | Journal Article | en | Contact tracing apps and values dilemmas: A privacy paradox in a neo-liberal world. | https://www.ncbi.nlm.nih.gov/pubmed/32836636 | Contact tracing apps are presented as a solution, if not the solution, to curb pandemics in the Covid-19 crisis. In France, despite heated public institutional debate on privacy related issues, the app was presented by government as an essential benefit for protecting health and lives, thus avoiding both politicians and citizens to feel morally responsible and looking guilty, and as essential to recover our freedom to move. However we argue that, while detection of cases have still not been reported after 10 days and one million app downloads - a situation comparable to Australia who launched its app a month before -, the adoption of the app generates important risks to our informational privacy, surveillance and habituation to security policies. It also may create discrimination, distrust and generate other health problems such as addiction and others as 5G technology continues to be deployed without prior impact studies. Finally the smartphone app against covid epidemics appears as an extreme case of the privacy paradox where the government plays on the immediate benefits and downplays long-term concerns while inducing a technology of self. Contact tracing apps may become an emblematic case for digital transformation and value changes in the western world. | 0268-4012 | 2020-07-05 02:00:00+02:00 | pubmed | International Journal of Information Management | Frantz Rowe | Contact tracing apps;Freedom of movement;Health;Privacy paradox;Technology of the self | 2020-06-30 02:00:00+02:00 | 32836636 | FR | University of Nantes, LEMNA and SKEMA Businesss School, Nantes, France. | 1531 | |||
| 10.1007/s00247-020-04749-3 | Journal Article;Practice Guideline | en | Management strategies for children with COVID-19: ESPR practical recommendations. | https://www.ncbi.nlm.nih.gov/pubmed/32621013 | During the outbreak of the COVID-19 pandemic, guidelines have been issued by international, national and local authorities to address management and the need for preparedness. Children with COVID-19 differ from adults in that they are less often and less severely affected. Additional precautions required in the management of children address their increased radiosensitivity, need for accompanying carers, and methods for dealing with children in a mixed adult-paediatric institution. In this guidance document, our aim is to define a pragmatic strategy for imaging children with an emphasis on proven or suspected COVID-19 cases. Children suspected of COVID-19 should not be imaged routinely. Imaging should be performed only when expected to alter patient management, depending on symptoms, preexisting conditions and clinical evolution. In order to prevent disease transmission, it is important to manage the inpatient caseload effectively by triaging children and carers outside the hospital, re-scheduling nonurgent elective procedures and managing symptomatic children and carers as COVID-19 positive until proven otherwise. Within the imaging department one should consider conducting portable examinations with COVID-19 machines or arranging dedicated COVID-19 paediatric imaging sessions and performing routine nasopharyngeal swab testing before imaging under general anaesthesia. Finally, regular personal hygiene, appropriate usage of personal protective equipment, awareness of which procedures are considered aerosol generating and information on how to best disinfect imaging machinery after examinations should be highlighted to all staff members. | 0301-0449,1432-1998 | 2020-07-05 02:00:00+02:00 | pubmed | Adolescent;Betacoronavirus;Child;Child, Preschool;Coronavirus Infections__prevention & control;Diagnostic Imaging__methods;Humans;Infant;Infection Control__methods;Pandemics__prevention & control;Pediatrics__methods;Pneumonia, Viral__prevention & control;COVID-19;severe acute respiratory syndrome coronavirus 2 | Pediatric Radiology | Maria Raissaki;Susan C Shelmerdine;Maria Beatrice Damasio;Seema Toso;Ola Kvist;Jovan Lovrenski;Franz Wolfgang Hirsch;Süreyya Burcu Görkem;Anne Paterson;Owen J Arthurs;Andrea Rossi;Joost van Schuppen;Philippe Petit;Maria I Argyropoulou;Amaka C Offiah;Karen Rosendahl;Pablo Caro-Domínguez | COVID-19;Children;Coronavirus;Imaging protocol;Management;Radiology | 2020-07-03 02:00:00+02:00 | 32621013 | SE;FR;NO;GR;CH;GB;IT;TR;NL;RS;ES;DE | Department of Radiology, University Hospital of Heraklion, University of Crete, Crete, Greece.;Department of Clinical Radiology, Great Ormond Street Hospital for Children, London, WC1N 3JH, UK. susan.shelmerdine@gosh.nhs.uk.;UCL Great Ormond Street Institute of Child Health, Great Ormond Street Hospital for Children, London, UK. susan.shelmerdine@gosh.nhs.uk.;NIHR Great Ormond Street Biomedical Research Centre, London, UK. susan.shelmerdine@gosh.nhs.uk.;U.O.C. Radiologia, Istituto Giannina Gaslini, Genoa, Italy.;Department of Diagnostics, Geneva Children's Hospitals, Geneva, Switzerland.;Department of Pediatric Radiology, Karolinska University Hospital, Stockholm, Sweden.;Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.;Institute for Children and Adolescent Health Care of Vojvodina, Novi Sad, Serbia.;Department of Pediatric Radiology, University of Leipzig, Leipzig, Germany.;Paediatric Radiology Department, Erciyes University School of Medicine, Children's Hospital, Kayseri, Turkey.;Department of Radiology, Royal Belfast Hospital for Sick Children, Belfast, UK.;Department of Clinical Radiology, Great Ormond Street Hospital for Children, London, WC1N 3JH, UK.;UCL Great Ormond Street Institute of Child Health, Great Ormond Street Hospital for Children, London, UK.;NIHR Great Ormond Street Biomedical Research Centre, London, UK.;Neuroradiology Unit, Istituto Giannina Gaslini, Genoa, Italy.;Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.;Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.;Service d'imagerie pédiatrique et prénatale, Aix Marseille University, Hôpital de La Timone-Enfants, Marseille, France.;Department of Clinical Radiology and Imaging, Medical School, University Hospital of Ioannina, Ioannina, Greece.;Academic Unit of Child Health, University of Sheffield, Sheffield, UK.;Department of Radiology, Sheffield Children's NHS Foundation Trust, Sheffield, UK.;Department of Radiology, University Hospital of North Norway, Tromsø, Norway.;Department of Clinical Medicine, UiT the Arctic University of Norway, Tromsø, Norway.;Unidad de Radiología Pediátrica, Servicio de Radiodiagnóstico, Hospital Universitario Virgen del Rocío, Sevilla, Spain. | 1535 | ||
| 10.1016/j.bbi.2020.06.032 | Journal Article | en | Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. | https://www.ncbi.nlm.nih.gov/pubmed/32629042 | Anosmia is one of the most prevalent symptoms of SARS-CoV-2 infection during the COVID-19 pandemic. However, the cellular mechanism behind the sudden loss of smell has not yet been investigated. The initial step of odour detection takes place in the pseudostratified olfactory epithelium (OE) mainly composed of olfactory sensory neurons surrounded by supporting cells known as sustentacular cells. The olfactory neurons project their axons to the olfactory bulb in the central nervous system offering a potential pathway for pathogens to enter the central nervous system by bypassing the blood brain barrier. In the present study, we explored the impact of SARS-CoV-2 infection on the olfactory system in golden Syrian hamsters. We observed massive damage of the OE as early as 2 days post nasal instillation of SARS-CoV-2, resulting in a major loss of cilia necessary for odour detection. These damages were associated with infection of a large proportion of sustentacular cells but not of olfactory neurons, and we did not detect any presence of the virus in the olfactory bulbs. We observed massive infiltration of immune cells in the OE and lamina propria of infected animals, which may contribute to the desquamation of the OE. The OE was partially restored 14 days post infection. Anosmia observed in COVID-19 patient is therefore likely to be linked to a massive and fast desquamation of the OE following sustentacular cells infection with SARS-CoV-2 and subsequent recruitment of immune cells in the OE and lamina propria. | 0889-1591 | 2020-07-05 02:00:00+02:00 | pubmed | Brain, Behavior, and Immunity | Bertrand Bryche;Audrey St Albin;Severine Murri;Sandra Lacôte;Coralie Pulido;Meriadeg Ar Gouilh;Sandrine Lesellier;Alexandre Servat;Marine Wasniewski;Evelyne Picard-Meyer;Elodie Monchatre-Leroy;Romain Volmer;Olivier Rampin;Ronan Le Goffic;Philippe Marianneau;Nicolas Meunier | Central nervous system;Nasal cavity;Olfaction;Respiratory virus;SARS | 2020-07-03 02:00:00+02:00 | 32629042 | FR | Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France.;Laboratoire de Lyon, ANSES, Unité virologie, Lyon, France.;Laboratoire de Lyon, ANSES, Plateforme d'expérimentation animale, Lyon, France.;Groupe de Recherche sur l'Adaptation Microbienne, UNICAEN-UNIROUEN, Université de Caen Normandie, 14 000 Caen, France, Service de Virologie, CHU de Caen, Caen, France.;Laboratoire rage et faune sauvage, ANSES, Malzéville, France.;Université de Toulouse, ENVT, INRA, UMR 1225, Toulouse, France.;Université Paris Saclay, INRAE, AgroParisTech, PNCA, 78350 Jouy-en-Josas, France.;Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France. Electronic address: nicolas.meunier@inrae.fr. | 1536 | |||
| 10.1080/14767058.2020.1786055 | Journal Article | en | Vertical transmission risk of SARS-CoV-2 infection in the third trimester: a systematic scoping review. | https://www.ncbi.nlm.nih.gov/pubmed/32611247 | Background: Studies on COVID-19 infection in pregnancy thus far have largely focused on characterizing maternal and neonatal clinical characteristics. However, another evolving focus is assessing and mitigating the risk of vertical transmission amongst COVID-19-positive mothers. The objective of this review was to summarize the current evidence on the vertical transmission potential of COVID-19 infection in the third trimester and its effects on the neonate.Methods: OVID MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trial (CENTRAL) were searched from January 2020 to May 2020, with continuous surveillance.Results: 18 studies met the inclusion criteria, consisting of 157 mothers and 160 neonates. The mean age of the pregnant patients was 30.8 years and the mean gestational period was 37 weeks and 1 d. Currently, there is currently no conclusive evidence to suggest that vertical transmission of SARS-CoV-2 occurs. Amongst 81 (69%) neonates who were tested for SARS-CoV-2, 5 (6%) had a positive result. However, amongst these 5 neonates, the earliest test was performed at 16 h after birth, and only 1 neonate was positive when they were later re-tested. However, this neonate initially tested negative at birth, suggesting that the SARS-CoV-2 infection was likely hospital-acquired rather than vertically transmitted. 13 (8%) neonates had complications or symptoms.Conclusions: The findings of this rapid descriptive review based on early clinical evidence suggest that vertical transmission of SARS-CoV-2 from mother to neonate/newborn did not occur. Future studies are needed to determine the optimal management of neonates born to COVID-19-positive mothers. | 1476-7058,1476-4954 | 2020-07-05 02:00:00+02:00 | pubmed | The Journal of Maternal-Fetal & Neonatal Medicine | Priya Thomas;Paul Elias Alexander;Usman Ahmed;Erica Elderhorst;Hussein El-Khechen;Manoj J Mammen;Victoria Borg Debono;Zuleika Aponte Torres;Komal Aryal;Eva Brocard;Begoña Sagastuy;Waleed Alhazzani | Covid-19;maternal;neonatal;sars-cov-2;vertical transmission | 2020-07-01 02:00:00+02:00 | 32611247 | FR;BB;CA;CL;US | Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.;GUIDE Research Methods Group, McMaster University, Hamilton, Canada.;Department of Medical Sciences, McMaster University, Hamilton, Canada.;McMaster Midwifery Research Centre, McMaster University, Hamilton, Canada.;Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA.;Department of Anesthesia, Faculty of Health Sciences, McMaster University, Hamilton, Canada.;Independent Epidemiology Consultant, Santiago de Chile, Chile.;Ecole des Hautes Etudes en Santé Publique (EHESP), Saint Denis, France.;Consultant, Pan American Health Organization, Bridgetown, Barbados.;Department of Medicine, McMaster University, Hamilton, Canada. | 1546 | |||
| 10.1161/strokeaha.120.030794 | Journal Article;Multicenter Study;Observational Study | en | Acute Stroke Management During the COVID-19 Pandemic: Does Confinement Impact Eligibility for Endovascular Therapy? | https://www.ncbi.nlm.nih.gov/pubmed/32716828 | During the coronavirus disease 2019 (COVID-19) pandemic, the World Health Organization recommended measures to mitigate the outbreak such as social distancing and confinement. Since these measures have been put in place, anecdotal reports describe a decrease in the number of endovascular therapy (EVT) treatments for acute ischemic stroke due to large vessel occlusion. The purpose of our study was to determine the effect on EVT for patients with acute ischemic stroke during the COVID-19 confinement. In this retrospective, observational study, data were collected from November 1, 2019, to April 15, 2020, at 17 stroke centers in countries where confinement measures have been in place since March 2020 for the COVID-19 pandemic (Switzerland, Italy, France, Spain, Portugal, Germany, Canada, and United States). This study included 1600 patients treated by EVT for acute ischemic stroke. Date of EVT and symptom onset-to-groin puncture time were collected. Mean number of EVTs performed per hospital per 2-week interval and mean stroke onset-to-groin puncture time were calculated before confinement measures and after confinement measures. Distributions (non-normal) between the 2 groups (before COVID-19 confinement versus after COVID-19 confinement) were compared using 2-sample Wilcoxon rank-sum test. The results show a significant decrease in mean number of EVTs performed per hospital per 2-week interval between before COVID-19 confinement (9.0 [95% CI, 7.8-10.1]) and after COVID-19 confinement (6.1 [95% CI, 4.5-7.7]), (P<0.001). In addition, there is a significant increase in mean stroke onset-to-groin puncture time (P<0.001), between before COVID-19 confinement (300.3 minutes [95% CI, 285.3-315.4]) and after COVID-19 confinement (354.5 minutes [95% CI, 316.2-392.7]). Our preliminary analysis indicates a 32% reduction in EVT procedures and an estimated 54-minute increase in symptom onset-to-groin puncture time after confinement measures for COVID-19 pandemic were put into place. | 0039-2499,1524-4628 | 2020-07-05 02:00:00+02:00 | pubmed | Brain Ischemia__therapy;Coronavirus Infections;Disease Management;Eligibility Determination;Endovascular Procedures__statistics & numerical data;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral;Quarantine;Retrospective Studies;Spain;Stroke__therapy;Time-to-Treatment;Treatment Outcome;COVID-19 | Stroke | Steven D Hajdu;Valerie Pittet;Francesco Puccinelli;Wagih Ben Hassen;Malek Ben Maacha;Raphaël Blanc;Sandra Bracco;Gabriel Broocks;Bruno Bartolini;Tommaso Casseri;Frederic Clarençon;Olivier Naggara;François Eugène;Jean-Christophe Ferré;Alexis Guédon;Emmanuel Houdart;Timo Krings;Pierre Lehmann;Nicola Limbucci;Paolo Machi;Juan Macho;Nicolo Mandruzzato;Sergio Nappini;Marie Teresa Nawka;Patrick Nicholson;João Pedro Marto;Vitor Pereira;Manuel A Correia;Teresa Pinho-E-Melo;João Nuno Ramos;Eytan Raz;Patrícia Ferreira;João Reis;Maksim Shapiro;Eimad Shotar;Noel van Horn;Michel Piotin;Guillaume Saliou | COVID-19;goal;groin;pandemic;standard of care | 2020-07-01 02:00:00+02:00 | 32716828 | FR;CA;PT;GB;CH;US;IT;ES;DE | Department of Interventional and Diagnostic Radiology, Lausanne University Hospital, Switzerland (S.D.H., F.P., B.B., G.S.).;Center for Primary Care and Public Health, University of Lausanne, Switzerland (V.P.).;Department of Neuroradiology, Sainte Anne Hospital, Paris, France (W.B.H., O.N.).;Interventional Neuroradiology, Fondation Rothschild Hospital, Paris, France (M.B.M., R.B., M.P.).;Unit of Neuroimaging and Neurointervention, University Hospital of Siena, Italy (S.B., T.C.).;Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany (G.B., M.T.N., N.v.H.).;Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France (F.C., E.S.).;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, Rennes, France (F.E., J.-C.F.).;Department of Neuroradiology, Lariboisière Hospital, Paris, France (A.G., E.H.).;Division of Neuroradiology, Joint Department of Medical Imaging, Toronto Western Hospital, Canada (T.K., P.N., V.P.).;Department of Neuroradiology, Marseille Hospital, France (P.L.).;Department of Interventional Neuroradiology, Careggi University Hospital, Florence, Italy (N.L., S.N.).;Service of diagnostic and interventional neuroradiology, Geneva University Hospital, Switzerland (P.M., N.M.).;Radiology Department, Hospital Clinic, Barcelona, Spain (J.M.).;Departments of Neurology and Neuroradiology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal (J.P.M., J.N.R.).;Departments of Neurology and Neuroradiology, Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal (M.A.C., T.P.-e.-M.).;NYU Langone Health, New York (E.R., M.S.).;Stroke Unit and Department of Neuroradiology, Hospital São José, Centro Hospitalar Lisboa Central, Lisbon, Portugal (P.F., J.R.). | 1548 | ||
| Letter | en | Characteristics of critically ill patients infected with COVID-19 in Abu Dhabi, United Arab Emirates. | https://www.ncbi.nlm.nih.gov/pubmed/32660852 | 2020-07-05 02:00:00+02:00 | pubmed | Khaled Abdallah;Fadi Hamed;Nadeem Rahman;Shameen Salam;Jihad Mallat | 2020-07-01 02:00:00+02:00 | 32660852 | FR;US;AE | Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.;Critical Care Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, Normandy University, UNICAEN, ED 497, Caen, France. Electronic address: mallatjihad@gmail.com. | 1551 | ||||||||
| 10.12890/2020_001822 | Journal Article | en | Rapid Radiological Worsening and Cytokine Storm Syndrome in COVID-19 Pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32665942 | In June 2020, a large randomised controlled clinical trial in the UK found that dexamethasone was effective in reducing the number of deaths in patients with severe coronavirus disease 2019 (COVID-19). | 2020-07-05 02:00:00+02:00 | pubmed | Yvon Ruch;Charlotte Kaeuffer;Aurélien Guffroy;Nicolas Lefebvre;Yves Hansmann;François Danion | COVID-19;computed tomography;coronavirus;corticosteroids;cytokine storm syndrome | 2020-07-02 02:00:00+02:00 | 32665942 | FR | Department of Infectious Diseases, Strasbourg University Hospital, Strasbourg, France.;Department of Clinical Immunology and Internal Medicine, Strasbourg University Hospital, Strasbourg, France. | 1569 | |||||
| 10.3389/fonc.2020.01267 | Journal Article | en | Screening Strategies for COVID-19 in Patients With Hematologic Malignancies. | https://www.ncbi.nlm.nih.gov/pubmed/32719749 | COVID-19 has been declared a pandemic by the world health organization. Patients with cancer, and particularly hematologic malignancies may be at higher risk for severe complications due to their malignancy, immune dysregulation, therapy, and associated comorbidities. The oncology community has been proactive in issuing practice guidelines to help optimize management, and limit infection risk and complications from SARS-COV-2. Although hematologic malignancies account for only 10% of all cancers, their management is particularly complex, especially in the time of COVID-19. Screening or early detection of COVID-19 are central for preventative/mitigation strategy, which is the best current strategy in our battle against COVID-19. Herein, we provide an overview of COVID-19 screening strategies and highlight the unique aspects of treating patients with hematologic malignancies. | 2234-943X | 2020-07-05 02:00:00+02:00 | pubmed | Frontiers in Oncology | Tarek Assi;Bachar Samra;Laurent Dercle;Elie Rassy;Joseph Kattan;Marwan Ghosn;Roch Houot;Samy Ammari | COVID-19;CT scan;coronavirus;hematologic malignancies;hematology;polymerase chain reaction;screening | 2020-07-03 02:00:00+02:00 | 32719749 | FR;LB;US | Department of Hematology and Medical Oncology, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.;Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.;Radiology Department, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, United States.;Department of Hematology, CHU de Rennes, Université de Rennes, Rennes, France.;Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.;Radiology Department, Gustave Roussy Cancer Campus, Villejuif, France.;BIOMAPS, UMR1281, INSERM.CEA.CNRS, Université Paris-Saclay, Paris, France. | 1576 | |||
| 10.3389/fimmu.2020.01662 | Systematic Review | en | Cell-Mediated Immune Responses to COVID-19 Infection. | https://www.ncbi.nlm.nih.gov/pubmed/32719687 | An unprecedented outbreak of pneumonia caused by a novel coronavirus (CoV), subsequently termed COVID-19 by the World Health Organization, emerged in Wuhan City (China) in December 2019. Despite rigorous containment and quarantine efforts, the incidence of COVID-19 continues to expand, causing explosive outbreaks in more than 160 countries with waves of morbidity and fatality, leading to significant public health problems. In the past 20 years, two additional epidemics caused by CoVs have occurred: severe acute respiratory syndrome-CoV, which has caused a large-scale epidemic in China and 24 other countries; and respiratory syndrome-CoV of the Middle East in Saudi Arabia, which continues to cause sporadic cases. All of these viruses affect the lower respiratory tract and manifest as pneumonia in humans, but the novel SARS-Cov-2 appears to be more contagious and has spread more rapidly worldwide. This mini-review focuses on the cellular immune response to COVID-19 in human subjects, compared to other clinically relevant coronaviruses to evaluate its role in the control of infection and pathogenesis and accelerate the development of a preventive vaccine or immune therapies. | 1664-3224 | 2020-07-05 02:00:00+02:00 | pubmed | Betacoronavirus__immunology;Coronavirus Infections__epidemiology;Epidemics;Humans;Immunity, Cellular;Immunotherapy;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Frontiers in Immunology | Amélie Guihot;Elena Litvinova;Brigitte Autran;Patrice Debré;Vincent Vieillard | COVID-19;SARS - CoV-2;adaptive immunity;coronavirus;innate immunity | 2020-07-03 02:00:00+02:00 | 32719687 | FR | Sorbonne Université, Inserm U1135, CNRS ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Département d'Immunologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. | 1580 | ||
| Letter | en | Covid-19: Breaking bad news with social distancing in pediatric oncology. | https://www.ncbi.nlm.nih.gov/pubmed/32618416 | 2020-07-05 02:00:00+02:00 | pubmed | Nicolas André | 2020-07-03 02:00:00+02:00 | 32618416 | FR | Department of Pediatric Hematology and Oncology, AP-HM, Aix Marseille University, Marseille, France.;Marseille Early Phases Cancer Trials Center CLIP, AP-HM, Aix Marseille University, Marseille, France.;Metronomics Global Health Initiative, Marseille, France. | 1582 | ||||||||
| Astellas;Novartis;Institut Georges Lopez;Sandoz;Paul Brousse Hospital | 10.1111/tri.13680 | Journal Article | en | Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry. | https://www.ncbi.nlm.nih.gov/pubmed/32609908 | There are scarce data on the impact of COVID-19 pandemic on liver transplantation (LT) in Europe. The aim of this study was to obtain a preliminary data on incidence, management, and outcome of COVID-19 in liver transplant recipients and candidates in Europe. An Internet-based survey was sent to the centers affiliated with European Liver Transplant Registry (ELTR). One hundred nine out of 149 (73%) of ELTR centers located in 28 European countries (93%) responded. Ninety-four (86%) of the centers tested all donors, and 75 (69%) centers tested all LT recipients for SARS-CoV-2. Seventy-three (67%) centers selected recipients for LT in the COVID-19 pandemic, whereas 33% did not. Eighty-eight centers reported COVID-19 infection in 57 LT candidates and in 272 LT recipients. Overall crude incidence of COVID-19 among LT candidates and recipients was estimated 1.05% (range 0.5-20%) and 0.34% (range 0.1-4.8%), respectively, and it was significantly higher among candidates (P < 0.001). Crude rate of death was 18% (10/57) among candidates and 15% (36/244) among recipients. This first large-scale European snapshot study clearly shows that both LT candidates and recipients are at a high risk for COVID-19. These results plead for an early and pro-active screening of COVID-19 symptoms in these populations. | 0934-0874,1432-2277 | 2020-07-05 02:00:00+02:00 | pubmed | Transplant International | Wojciech G Polak;Constantino Fondevila;Vincent Karam;Rene Adam;Ulrich Baumann;Giacomo Germani;Silvio Nadalin;Pavel Taimr;Christian Toso;Roberto I Troisi;Krzysztof Zieniewicz;Luca S Belli;Christophe Duvoux | COVID-19;SARS-CoV-2;liver recipient;liver transplantation;mortality;survey | 2020-07-01 02:00:00+02:00 | 32609908 | FR;GB;CH;IT;PL;NL;CZ;ES;DE | [{"country": "", "agency": "Astellas"}, {"country": "", "agency": "Novartis"}, {"country": "", "agency": "Institut Georges Lopez"}, {"country": "", "agency": "Sandoz"}, {"country": "", "agency": "Paul Brousse Hospital"}] | Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.;Liver Transplant Unit, Department of General and Digestive Surgery, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.;Department of European Liver Transplant Registry, Centre Hépatobiliaire, Hôpital Universitaire, Paul Brousse, Villejuif, France.;Department of Hepatobiliary Surgery, Cancer and Transplantation, AP-HP Hôpital Universitaire Paul Brousse, Villejuif, France.;Division of Paediatric Gastroenterology and Hepatology, Department of Paediatric Kidney-, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.;Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.;Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.;Department of General, Visceral and Transplant Surgery, Tuebingen University Hospital, Tuebingen, Germany.;Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.;Division of Abdominal Surgery, Department of Surgery, Geneva University Hospitals, Geneva, Switzerland.;Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.;Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.;Division of Hepatology and Gastroenterology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.;Medical Liver Transplant Unit and Liver Department, Henri Mondor Hospital AP-HP, Paris Est University, Créteil, France. | 1590 | |
| Letter | en | Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32619736 | 2020-07-05 02:00:00+02:00 | pubmed | C Poignon;M Blaize;C Vezinet;A Lampros;A Monsel;A Fekkar | 2020-06-30 02:00:00+02:00 | 32619736 | FR | AP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Service de Parasitologie Mycologie, Paris, France.;AP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Multidisciplinary Intensive Care Unit, Department of Anesthesiology and Critical Care, Paris, France.;AP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Multidisciplinary Intensive Care Unit, Department of Anesthesiology and Critical Care, Paris, France, Sorbonne Université, INSERM, UMR-S 959, Immunology Immunopathology Immunotherapy (I3), Paris, France, AP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), France.;AP-HP, Groupe Hospitalier La Pitié-Salpêtrière, Service de Parasitologie Mycologie, Paris, France, Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, France. Electronic address: arnaud.fekkar@aphp.fr. | 1597 | ||||||||
| 10.1097/ccm.0000000000004503 | Journal Article | en | A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2. | https://www.ncbi.nlm.nih.gov/pubmed/32618691 | 0090-3493 | 2020-07-05 02:00:00+02:00 | pubmed | Critical Care Medicine | Fabrice Petitjeans;Jean-Yves Martinez;Marc Danguy des Déserts;Sandrine Leroy;Luc Quintin;Jacques Escarment | 2020-06-29 02:00:00+02:00 | 32618691 | FR | Critical Care, Hôpital d'Instruction des Armées Desgenettes, Lyon, France, and Élément Militaire de Réanimation, Centre Hospitalier, Mulhouse, and Epismart, Paris, France. | 1599 | |||||
| Letter | en | COVID-19: a prison-breaker? | https://www.ncbi.nlm.nih.gov/pubmed/32602043 | 2020-07-05 02:00:00+02:00 | pubmed | Frédéric Dutheil;Jean-Baptiste Bouillon-Minois;Maëlys Clinchamps | 2020-06-29 02:00:00+02:00 | 32602043 | FR | Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, F-63000, Clermont-Ferrand, France.;University Hospital of Clermont-Ferrand, Emergency Medicine, F-63000, Clermont-Ferrand, France.;Preventive and Occupational Medicine, University Hospital of Clermont-Ferrand, F-63000, Clermont-Ferrand, France. mclinchamps@chu-clermontferrand.fr.;Occupational and Environmental Medicine, University Hospital of Clermont-Ferrand (CHU), 58 rue Montalembert, 63000, Clermont-Ferrand, France. mclinchamps@chu-clermontferrand.fr. | 1605 | ||||||||
| Letter | en | Clinical performance of a rapid test compared to a microplate test to detect total anti SARS-CoV-2 antibodies directed to the spike protein. | https://www.ncbi.nlm.nih.gov/pubmed/32771904 | 2020-07-05 02:00:00+02:00 | pubmed | Florence Abravanel;Marcel Miédouge;Sabine Chapuy-Regaud;Jean-Michel Mansuy;Jacques Izopet | 2020-06-29 02:00:00+02:00 | 32771904 | FR | UMR Inserm, U1043, UMR CNRS, U5282, Centre De Physiopathologie De Toulouse Purpan (CPTP), Toulouse 31300, France, CHU Toulouse, Hôpital Purpan, Laboratoire De Virologie, Centre National De Référence Du Virus De l'Hépatite E, 31300 France. Electronic address: Abravanel.f@ch-toulouse.fr.;CHU Toulouse, Hôpital Purpan, Laboratoire De Virologie, Centre National De Référence Du Virus De l'Hépatite E, 31300 France.;UMR Inserm, U1043, UMR CNRS, U5282, Centre De Physiopathologie De Toulouse Purpan (CPTP), Toulouse 31300, France, CHU Toulouse, Hôpital Purpan, Laboratoire De Virologie, Centre National De Référence Du Virus De l'Hépatite E, 31300 France. | 1609 | ||||||||
| 10.1111/fcp.12586 | Journal Article;Review | en | Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. | https://www.ncbi.nlm.nih.gov/pubmed/32603486 | Patients with COVID-19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions. Here, we analyzed the potential or proven risk of the co-administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID-19. Practical recommendations are offered, where possible. | 0767-3981,1472-8206 | 2020-07-05 02:00:00+02:00 | pubmed | Fundamental & Clinical Pharmacology | Florian Lemaitre;Caroline Solas;Matthieu Grégoire;Laurence Lagarce;Laure Elens;Elisabeth Polard;Béatrice Saint-Salvi;Agnès Sommet;Michel Tod;Chantal Barin-Le Guellec | adverse events;hydroxychloroquine;lopinavir;pharmacodynamics;pharmacokinetics;therapeutic drug monitoring | 2020-06-30 02:00:00+02:00 | 32603486 | FR;BE;GB | Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, F-35000, France.;INSERM, Centre d'Investigation Clinique, CIC 1414, Rennes, F-35000, France.;Aix-Marseille University, APHM, UMR "Emergence des Pathologies Virales" Inserm 1207 IRD 190, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, 13005, France.;Clinical Pharmacology Department, CHU Nantes, Nantes Cedex 1, Nantes, 44093, France.;UMR INSERM 1235, The Enteric Nervous System in Gut and Brain Disorders, University of Nantes, Nantes Cedex 1, Nantes, 44093, France.;Service de Pharmacologie-Toxicologie et Pharmacovigilance, Centre Hospitalo-Universitaire d'Angers, Angers, 49100, France.;Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics (PMGK), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCL), Louvain, Belgique.;Louvain Center for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), Louvain, Belgique.;Medical Interactions Unit, Agence National de Sécurité du Médicaments et des produits de santé, Saint-Denis, 93200, France.;Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, INSERM UMR 1027, CIC 1426, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, 31000, France.;Pharmacy, Croix-Rousse Hospital, Lyon, 69005, France.;ISPB, University Lyon 1, Lyon, 69005, France.;Laboratoire de Biochimie et de Biologie Moléculaire, CHU de Tours, Tours, F37044, France.;Université de Tours, Tours, F-37044, France.;INSERM, IPPRITT, U1248, Limoges, F-87000, France. | 1613 | |||
| Letter | en | Heart retransplantation following COVID-19 illness in a heart transplant recipient. | https://www.ncbi.nlm.nih.gov/pubmed/32718694 | 2020-07-12 02:00:00+02:00 | pubmed | Jerome Soquet;Natacha Rousse;Mouhamed Moussa;Celine Goeminne;Delphine Deblauwe;Fanny Vuotto;François Pontana;Arnaud Lionet;Romain Dubois;Emmanuel Robin;Andre Vincentelli | 2020-07-07 02:00:00+02:00 | 32718694 | FR | Univ. Lille, CHU Lille, Department of Cardiac Surgery, F-59000 Lille, France.;Univ Lille, CHU Lille, Department of Anesthesia and Intensive Care, F-59000 Lille, France.;Univ Lille, CHU Lille, Department of Infectious Diseases, F-59000 Lille, France.;Univ Lille, CHU Lille, Department of Cardiovascular Imaging, F-59000 Lille, France.;Univ Lille, CHU Lille, Department of Nephrology, F-59000 Lille, France.;Univ Lille, CHU Lille, Department of Pathology, F-59000 Lille, France.;Univ. Lille, CHU Lille, Department of Cardiac Surgery, F-59000 Lille, France. Electronic address: andre.vincentelli@chru-lille.fr. | 1620 | ||||||||
| NHLBI NIH HHS | 10.1136/jim-2020-001391 | Journal Article | en | Peer mentoring for professional and personal growth in academic medicine. | https://www.ncbi.nlm.nih.gov/pubmed/32641352 | Mentorship is a critical component of career development, particularly in academic medicine. Peer mentorship, which does not adhere to traditional hierarchies, is perhaps more accessible for underrepresented groups, including women and minorities. In this article, we review various models of peer mentorship, highlighting their respective advantages and disadvantages. Structured peer mentorship groups exist in different settings, such as those created under the auspices of formal career development programs, part of training grant programs, or through professional societies. Social media has further enabled the establishment of informal peer mentorship through participatory online groups, blogs, and forums that provide platforms for peer-to-peer advice and support. Such groups can evolve rapidly to address changing conditions, as demonstrated by physician listserv and Facebook groups related to the COVID-19 pandemic. Peer mentorship can also be found among colleagues brought together through a common location, interest, or goal, and typically these relationships are informal and fluid. Finally, we highlight here our experience with intentional formation of a small peer mentoring group that provides structure and a safe space for professional and social-emotional growth and support. In order to maximize impact and functionality, this model of peer mentorship requires commitment among peers and a more formalized process than many other peer mentoring models, accounting for group dynamics and the unique needs of members. When done successfully, the depth of these mentoring relationships can produce myriad benefits for individuals with careers in academic medicine including, but not limited to, those from underrepresented backgrounds. | 1081-5589,1708-8267 | 2020-07-12 02:00:00+02:00 | pubmed | Career Choice;Coronavirus Infections;Female;Humans;Inservice Training;Interprofessional Relations;Male;Mentoring;Mentors;Minority Groups;Occupational Exposure;Pandemics;Peer Group;Physicians;Physicians, Women;Pneumonia, Viral;Social Media;Social Support;Societies, Medical;United States;Universities;COVID-19 | Journal of Investigative Medicine | Melanie Cree-Green;Anne-Marie Carreau;Shanlee M Davis;Brigitte I Frohnert;Jill L Kaar;Nina S Ma;Natalie J Nokoff;Jane E B Reusch;Stacey L Simon;Kristen J Nadeau | academic medical centers;biomedical research;education, medical;interprofessional relations | 2020-07-07 02:00:00+02:00 | 32641352 | FR;CA;US | [{"country": "United States", "agency": "NHLBI NIH HHS", "grantid": "K24 HL145076"}] | Pediatric Endocrinology, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado, USA Melanie.Green@childrenscolorado.org.;Center for Women's Health Research, University of Colorado Denver -Anschutz Medical Campus, Aurora, Colorado, USA.;Endocrinology, CHU de Québec-Université Laval, Quebec, Québec, Canada.;Pediatric Endocrinology, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado, USA.;Pediatric Endocrinology, Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Denver, Colorado, USA.;Endocrinology, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado, USA.;Endocrinology, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado, USA.;Pediatric Pulmonology, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado, USA. | 1623 |
| 10.1016/j.neuron.2020.05.026 | Journal Article | en | Golden Anniversary of the Nicotinic Receptor. | https://www.ncbi.nlm.nih.gov/pubmed/32645305 | The high-resolution structure of the nicotinic acetylcholine receptor from Torpedo electric tissue in association with the snake toxin α-bungarotoxin (Rahman et al., 2020) is presented 50 years after its identification as the first neurotransmitter receptor and ligand-gated ion channel. | 0896-6273 | 2020-07-12 02:00:00+02:00 | pubmed | Neuron | Jean-Pierre Changeux | 2020-07-10 02:00:00+02:00 | 32645305 | FR | Department of Neuroscience, CNRS UMR 3571 Institut Pasteur & Collège de France, 75005 Paris, France. Electronic address: changeux@noos.fr. | 1633 | ||||
| Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung | Letter | en | Serum antibody response in critically ill patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32642784 | 2020-07-12 02:00:00+02:00 | pubmed | Alban Longchamp;Justine Longchamp;Antony Croxatto;Gilbert Greub;Bienvenido Sanchez;Julie Delaloye | 2020-07-08 02:00:00+02:00 | 32642784 | FR;CH | [{"country": "", "agency": "Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung", "grantid": "PZ00P3-185927"}] | Department of Intensive Care Medicine, Centre Hospitalier du Valais Romand de l'Hôpital du Valais, (Site de Sion) Avenue du Grand-Champsec 80, 1951, Sion, Switzerland.;Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.;Department of Vascular Surgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.;Department of Laboratory Medicine and Pathology, Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Department of Intensive Care Medicine, Centre Hospitalier du Valais Romand de l'Hôpital du Valais, (Site de Sion) Avenue du Grand-Champsec 80, 1951, Sion, Switzerland. bienvenido.sanchez@hopitalvs.ch.;Department of Intensive Care Medicine, Centre Hospitalier du Valais Romand de l'Hôpital du Valais, (Site de Sion) Avenue du Grand-Champsec 80, 1951, Sion, Switzerland. Julie.Delaloye@hopitalvs.ch. | 1637 | ||||||
| 10.1007/s00701-020-04482-8 | Journal Article | en | A snapshot of European neurosurgery December 2019 vs. March 2020: just before and during the Covid-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32642834 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or Covid-19), which began as an epidemic in China and spread globally as a pandemic, has necessitated resource management to meet emergency needs of Covid-19 patients and other emergent cases. We have conducted a survey to analyze caseload and measures to adapt indications for a perception of crisis. | 0001-6268,0942-0940 | 2020-07-12 02:00:00+02:00 | pubmed | Acta Neurochirurgica | T Mathiesen;M Arraez;T Asser;N Balak;S Barazi;C Bernucci;C Bolger;M L D Broekman;A K Demetriades;Z Feldman;M M Fontanella;N Foroglou;J Lafuente;A D Maier;B Meyer;M Niemelä;P H Roche;F Sala;N Samprón;U Sandvik;K Schaller;C Thome;M Thys;M Tisell;P Vajkoczy;M Visocchi | Covid-19;Epidemic;Europe;Healthcare management;Neurosurgery;Pandemic;SARS-CoV-2 | 2020-07-08 02:00:00+02:00 | 32642834 | SE;IE;IL;FR;BE;FI;GR;GB;US;CH;AT;IT;TR;NL;ES;EE;DK;DE | Department of Neurosurgery, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Tiit.illimar.mathiesen@regionh.dk.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Tiit.illimar.mathiesen@regionh.dk.;Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Tiit.illimar.mathiesen@regionh.dk.;Department of Neurosurgery, Carlos Haya University Hospital,, University of Malaga, Malaga, Spain.;University of Tartu, Tartu, Estonia.;Department of Neurosurgery, Istanbul Medeniyet University, Göztepe Education and Research Hospital, Istanbul, Turkey.;King's College Hospital, London, UK.;Department of Neuroscience and Surgery of the Nervous System, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.;National Centre for Neurosurgery, Beaumont Hospital, Dublin, Ireland.;Departments of Neurosurgery, Haaglanden Medical Center and Leiden University Medical Center, Leiden University, Leiden, Zuid-Holland, the Netherlands.;Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.;Department of Neurosurgery, Western General Hospital, Edinburgh, UK.;Department of Neurosurgery, Sheba Medical Center, Ramat Gan, Israel.;Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Spedali Civili di Brescia, Brescia, Italy.;Department of Neurosurgery, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.;Neurosurgery, Hospital Del Mar, Barcelona, Spain.;Department of Neurosurgery, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.;Department of Neurosurgery, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.;Helsinki University and Helsinki University Hospital, Helsinki, Finland.;Department of Neurosurgery, Hôpital Nord, Assistance Publique - Hôpitaux de Marseille, Aix Marseille Université, Marseille, France.;Section of Neurosurgery, Department of Neurosciences, Biomedicine and Movement Sciences, University Hospital, Verona, Italy.;Servicio de Neurocirugía, Hospital Universitario Donostia, San Sebastián, Spain.;Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.;Department of Neurosurgery, Karolinska University Hospital, Solna, Sweden.;Department of Neurosurgery, Geneva University Medical Center & Faculty of Medicine, Geneva, Switzerland.;Department of Neurosurgery, Medical University Innsbruck, Innsbruck, Austria.;Neurosciences Department, Grand Hopital de Charleroi, Charleroi, Belgium.;Department of Neurosurgery, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Göteborg, Sweden.;Department of Neurosurgery, Charite Universitätsmedizin Berlin, Berlin, Germany.;Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy. | 1638 | |||
| Letter | en | Update on asthma prevalence in severe COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32639631 | 2020-07-12 02:00:00+02:00 | pubmed | Mário Morais-Almeida;Miguel T Barbosa;Cláudia S Sousa;Rita Aguiar;Jean Bousquet | 2020-07-08 02:00:00+02:00 | 32639631 | FR;PT;DE | Allergy Centre, CUF Descobertas Hospital, Lisbon, Portugal.;Portuguese Association of Asthmatics (APA), Porto, Portugal.;Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.;Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany.;MACVIA-France, Montpellier, France. | 1641 | ||||||||
| 10.1016/j.biochi.2020.07.001 | Journal Article | en | High prevalence for obesity in severe COVID-19: Possible links and perspectives towards patient stratification. | https://www.ncbi.nlm.nih.gov/pubmed/32649962 | It is becoming obvious that in addition to aging and various hearth pathologies, excess of body weight, especially obesity is a major risk factor for severity of COVID-19 infection. Intriguingly the receptor for SARS-CoV-2 is ACE2, a member of the angiotensin receptor family that has a relatively large tissue distribution. This observation likely explains the multitude of symptoms that have been described from human patients. The adipose tissue also expresses ACE2, suggesting that adipocytes are potentially infected by SARS-CoV-2. Here we discuss some of the potential contribution of the adipose tissue to the severity of the infection and propose some aspects of obese patients metabolic phenotyping to help stratification of individuals with high risk of severe disease. | 0300-9084 | 2020-07-12 02:00:00+02:00 | pubmed | Biochimie | Isabelle Dugail;Ez-Zoubir Amri;Nicolas Vitale | 2020-07-08 02:00:00+02:00 | 32649962 | FR | UMRS 1269 INSERM/Sorbonne University, Nutriomics, Faculté de médecine Pitié-Salpêtrière, F-75013, Paris, France, Member of the scientific council of the Groupe d'Etude et de Recherche en Lipidomique (GERLI), France.;Université Côte d'Azur, CNRS, Inserm, iBV, Nice, France, Member of the scientific council of the Groupe d'Etude et de Recherche en Lipidomique (GERLI), France.;Centre National de la Recherche Scientifique, Université de Strasbourg, Institut des Neurosciences Cellulaires et Intégratives, F-67000, Strasbourg, France, Member of the scientific council of the Groupe d'Etude et de Recherche en Lipidomique (GERLI), France. Electronic address: vitalen@unistra.fr. | 1642 | ||||
| 10.1016/j.revmed.2020.06.017 | English Abstract;Journal Article | fr | [Nasopharyngeal carriage of SARS-CoV-2 among health personnel with symptoms suggestive of COVID-19 in a University Hospital in the Paris suburbs]. | https://www.ncbi.nlm.nih.gov/pubmed/32680715 | A consultation dedicated to symptomatic health professionals was opened at the beginning of the COVID-19 epidemic in order to meet the specific needs of this population. The objective of this work was to estimate the frequency of SARS-Cov-2 nasopharyngeal carriage in symptomatic healthcare workers suspected of having COVID-19 and to determine the factors associated with this carriage. | 0248-8663 | 2020-07-12 02:00:00+02:00 | pubmed | La Revue de Médecine Interne | S Greffe;F Espinasse;C Duran;S Labrune;M Sirol;B Mantalvan;M C Gramer;C Babulle;G Do Rosario;Q Vauvillier;A Huet;A Van der Heidjen;J Tysebaert;L F Kramarz;J-P Rabes;G Pellissier;T Chinet;F Moreau;E Rouveix | COVID-19;Clinical symptoms;Healthcare workers;Personnels de santé;RT-PCR screening;SARS-CoV-2;Symptômes cliniques;Test RT-PCR | 2020-07-08 02:00:00+02:00 | 32680715 | FR | Service de médecine interne, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France.;Equipe opérationnelle d'hygiène, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France.;Service de pneumologie, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France.;Service de radiologie, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France.;Service de rhumatologie, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France.;UFR Simone Veil-Santé, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris-Saclay, 2 avenue de la Source de la Bièvre, 78180 Montigny-Le-Bretonneux, France.;Service de direction, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France.;UFR Simone Veil-Santé, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris-Saclay, 2 avenue de la Source de la Bièvre, 78180 Montigny-Le-Bretonneux, France, Service de biochimie et Génétique Moléculaire, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France.;GERES, UFR de Médecine Bichat, 16 rue Henri Huchard, 75018 Paris, France.;Service de pneumologie, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France, UFR Simone Veil-Santé, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris-Saclay, 2 avenue de la Source de la Bièvre, 78180 Montigny-Le-Bretonneux, France.;Service de biochimie et Génétique Moléculaire, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France.;Service de médecine interne, CHU Ambroise Paré, GH Paris Saclay, Assistance Publique Hôpitaux de Paris (APHP), France, UFR Simone Veil-Santé, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris-Saclay, 2 avenue de la Source de la Bièvre, 78180 Montigny-Le-Bretonneux, France, GERES, UFR de Médecine Bichat, 16 rue Henri Huchard, 75018 Paris, France. Electronic address: elisabeth.rouveix@aphp.fr. | 1644 | |||
| 10.1002/per.2281 | Journal Article | en | Psychological and Behavioural Responses to Coronavirus Disease 2019: The Role of Personality. | https://www.ncbi.nlm.nih.gov/pubmed/32836766 | This study examined the associations between personality traits and psychological and behavioural responses to the coronavirus disease 2019 (COVID-19) pandemic. Personality was assessed in January/February 2020 when the public was not aware of the spread of coronavirus in the USA. Participants were reassessed in late March 2020 with four sets of questions about the pandemic: concerns, precautions, preparatory behaviours, and duration estimates. The sample consisted of N = 2066 participants (mean age = 51.42; range = 18-98; 48.5% women). Regression models were used to analyse the data with age, gender, education, race, and ethnicity as covariates. Consistent with the preregistered hypotheses, higher neuroticism was related to more concerns and longer duration estimates related to COVID-19, higher extraversion was related to shorter duration estimates, and higher conscientiousness was associated with more precautions. In contrast to the preregistered hypotheses, higher neuroticism was associated with fewer precautions and unrelated to preparatory behaviours. Age moderated several trait-response associations, suggesting that some of the responses were associated more strongly in older adults, a group at risk for complications of COVID-19. For example, older adults high in conscientiousness prepared more. The present findings provide insights into how personality predicts concerns and behaviours related to the COVID-19 pandemic. © 2020 European Association of Personality Psychology. | 0890-2070,1099-0984 | 2020-07-12 02:00:00+02:00 | pubmed | European Journal of Personality | Damaris Aschwanden;Jason E Strickhouser;Amanda A Sesker;Ji Hyun Lee;Martina Luchetti;Yannick Stephan;Angelina R Sutin;Antonio Terracciano | COVID‐19;behavioural responses;conscientiousness;neuroticism;personality traits | 2020-07-08 02:00:00+02:00 | 32836766 | FR;US | Department of Geriatrics, College of Medicine Florida State University FL USA.;Department of Behavioral Sciences and Social Medicine, College of Medicine Florida State University FL USA.;Euromov University of Montpellier Montpellier France. | 1646 | |||
| Wellcome Trust | 10.7554/elife.58631 | Journal Article;Research Support, Non-U.S. Gov't | en | Concentration-dependent mortality of chloroquine in overdose. | https://www.ncbi.nlm.nih.gov/pubmed/32639233 | Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment. Although generally safe they are potentially lethal in overdose. In-vitro data suggest that high concentrations and thus high doses are needed for COVID-19 infections, but as yet there is no convincing evidence of clinical efficacy. Bayesian regression models were fitted to survival outcomes and electrocardiograph QRS durations from 302 prospectively studied French patients who had taken intentional chloroquine overdoses, of whom 33 died (11%), and 16 healthy volunteers who took 620 mg base chloroquine single doses. Whole blood concentrations of 13.5 µmol/L (95% credible interval 10.1-17.7) were associated with 1% mortality. Prolongation of ventricular depolarization is concentration-dependent with a QRS duration >150 msec independently highly predictive of mortality in chloroquine self-poisoning. Pharmacokinetic modeling predicts that most high dose regimens trialled in COVID-19 are unlikely to cause serious cardiovascular toxicity. | 2050-084X | 2020-07-12 02:00:00+02:00 | pubmed | Adult;Antimalarials__administration & dosage;Biotransformation;Chloroquine__administration & dosage;Coronavirus Infections__drug therapy;Dose-Response Relationship, Drug;Drug Overdose__mortality;Drug Repositioning;Electrocardiography;Female;Heart Diseases__chemically induced;Humans;Hydroxychloroquine__administration & dosage;Long QT Syndrome__chemically induced;Malaria__drug therapy;Male;Pandemics;Pneumonia, Viral__drug therapy;Randomized Controlled Trials as Topic__statistics & numerical data;Risk Assessment;Suicide;Suicide, Attempted;COVID-19;COVID-19 drug treatment | eLife | James A Watson;Joel Tarning;Richard M Hoglund;Frederic J Baud;Bruno Megarbane;Jean-Luc Clemessy;Nicholas J White | bayesian;chloroquine;human;human biology;medicine;overdose;pharmacodynamics;pharmacokinetics | 2020-07-08 02:00:00+02:00 | 32639233 | FR;GB;TH | [{"country": "United Kingdom", "agency": "Wellcome Trust", "grantid": "Principal Research Fellowship 093956/Z/10/C"}] | Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.;Assistance Publique - Hôpitaux de Paris, Paris, France.;Université de Paris, Paris, France.;Université de Paris, INSERM UMRS-11 44, Paris, France.;Reanimation Medicale et Toxicologique, Hopital Lariboisiere, Paris, France.;Clinique du Sport, Paris, France. | 1653 |
| Letter;Comment | en | Transpulmonary pressure in SARS-CoV-2-associated acute respiratory distress syndrome: a single-center observational study. | https://www.ncbi.nlm.nih.gov/pubmed/32646456 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Respiratory Distress Syndrome, Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Severin Ramin;Jonathan Charbit;Geoffrey Dagod;Mehdi Girard;Samir Jaber;Xavier Capdevila | 2020-07-09 02:00:00+02:00 | 32646456 | FR | Anesthesiology and Intensive Care, Anesthesia and Critical Care Department A, Lapeyronie Teaching Hospital, Montpellier Cedex 5, France. severin.ramin@gmail.com.;Département d'Anesthésie Réanimation Lapeyronie, Hôpital Lapeyronie, 371 Avenue du Doyen G. Giraud, 34090, Montpellier, France. severin.ramin@gmail.com.;Anesthesiology and Intensive Care, Anesthesia and Critical Care Department A, Lapeyronie Teaching Hospital, Montpellier Cedex 5, France.;Département d'Anesthésie Réanimation Lapeyronie, Hôpital Lapeyronie, 371 Avenue du Doyen G. Giraud, 34090, Montpellier, France.;Anesthesiology and Intensive Care, Anesthesia and Critical Care Department B, Saint Eloi Teaching Hospital, PhyMedExp, University of Montpellier, INSERM U1046, CNRS, UMR 9214, 80 Avenue Augustin Fliche, 34295, Montpellier Cedex 5, France.;Département d'Anesthésie Réanimation Saint-Eloi, Hôpital Saint-Eloi, 80 Avenue Augustin Fliche, 34090, Montpellier, France. | 1657 | |||||||
| Letter | en | Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. | https://www.ncbi.nlm.nih.gov/pubmed/32457198 | 2020-07-12 02:00:00+02:00 | pubmed | Adult;Aged;Antitubercular Agents__therapeutic use;Antiviral Agents__therapeutic use;Azithromycin__therapeutic use;Betacoronavirus;Clinical Laboratory Techniques;Cohort Studies;Coinfection;Coronavirus Infections__complications;Drug Combinations;Emigrants and Immigrants;Female;Humans;Hydroxychloroquine__therapeutic use;Lopinavir__therapeutic use;Lung__diagnostic imaging;Male;Middle Aged;Mortality;Pandemics;Pneumonia, Viral__complications;Ritonavir__therapeutic use;Tomography, X-Ray Computed;Tuberculosis__complications;Tuberculosis, Pulmonary__complications;COVID-19;COVID-19 diagnostic testing;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Marina Tadolini;Luigi Ruffo Codecasa;José-María García-García;François-Xavier Blanc;Sergey Borisov;Jan-Willem Alffenaar;Claire Andréjak;Pierre Bachez;Pierre-Alexandre Bart;Evgeny Belilovski;José Cardoso-Landivar;Rosella Centis;Lia D'Ambrosio;María- Luiza De Souza-Galvão;Angel Dominguez-Castellano;Samir Dourmane;Mathilde Fréchet Jachym;Antoine Froissart;Vania Giacomet;Delia Goletti;Soazic Grard;Gina Gualano;Armine Izadifar;Damien Le Du;Margarita Marín Royo;Jesica Mazza-Stalder;Ilaria Motta;Catherine Wei Min Ong;Fabrizio Palmieri;Frédéric Rivière;Teresa Rodrigo;Denise Rossato Silva;Adrián Sánchez-Montalvá;Matteo Saporiti;Paolo Scarpellini;Frédéric Schlemmer;Antonio Spanevello;Elena Sumarokova;Eva Tabernero;Paul Anantharajah Tambyah;Simon Tiberi;Alessandro Torre;Dina Visca;Miguel Zabaleta Murguiondo;Giovanni Sotgiu;Giovanni Battista Migliori | 2020-07-09 02:00:00+02:00 | 32457198 | FR;SG;RU;UNK;PT;CH;GB;BR;IT;AU;ES;BE;PS | Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.;Co-first authors.;TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy.;Tuberculosis Research Programme (PII-TB), SEPAR, Barcelona, Spain.;Centre Hospitalier Universitaire, Nantes, France.;Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation.;The University of Sydney, Sydney Pharmacy School, Sydney, Australia.;Westmead Hospital, Sydney, Australia.;Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.;Service de Pneumologie CHU AMIENS PICARDIE, France AND UR Université de Picardie Jules Verne, Amiens, France.;Service de Pneumologie, Clinique Saint Luc, Bouge, Belgium.;Dept of Internal Medicine, Lausanne University, Lausanne, Switzerland.;Servicio Neumología, Vall D´Hebron University Hospital, Barcelona, Spain.;Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.;Public Health Consulting Group, Lugano, Switzerland.;Servicio de Enfermedades Infecciosas y Microbiología, Hospital Virgen Macarena, Sevilla, Spain.;Service de Pneumologie, Groupe hospitalier sud île de France (GHSIF), Melun, France.;Centre Hospitalier de Bligny, Briis Sous Forges, France.;Service de Médecine interne, CHI de Créteil, Créteil, France.;Pediatric Infectious Diseases Unit, Dept of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, Italy.;Translational Research Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy.;Centre de Lutte Antituberculeuse (CLAT 38), Grenoble, France.;Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy.;Hôpital Européen de Paris La Roseraie, Aubervilliers, France.;Servicio Neumología, Hospital General Universitario de Castellón, Castelló, Spain.;Pulmonary Division, Lausanne University Hospital CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Dipartimento di Scienze Mediche, Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italia.;Dept of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.;Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore.;Hôpital d'Instruction des Armées (HIA) Percy, Clamart, France.;Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS, Porto Alegre, Brazil.;Infectious Diseases Dept, International Health and Tuberculosis Unit, Vall d'Hebron University Hospital, Barcelona, Spain.;Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.;Grupo de Estudio de Infecciones por Micobacterias (GEIM), Spanish Society of Infectious Diseases (SEIMC), Spain.;Unit of Infectious Diseases, Università Vita e Salute, San Raffaele Hospital, Milan, Italy.;Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France.;Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy.;Dept of Medicine and Surgery, Respiratory Diseases, University of Insubria, Tradate, Italy.;Servicio Neumología, Hospital de Cruces, Bilbao, Spain.;Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.;Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.;Dept of Infectious Diseases, University of Milan, L. Sacco Hospital, Milan, Italy.;Servicio Neumología Hospital Universitario Marqués de Valdecilla, Santander, Spain.;Clinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.;Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy giovannibattista.migliori@icsmaugeri.it. | 1664 | |||||||
| Letter;Comment | en | More on Covid-19 in Immune-Mediated Inflammatory Diseases. | https://www.ncbi.nlm.nih.gov/pubmed/32649069 | 2020-07-12 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__epidemiology;Humans;New York;Pandemics;Pneumonia, Viral__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Laurent Peyrin-Biroulet;Silvio Danese | 2020-07-10 02:00:00+02:00 | 32649069 | FR;IT | Centre Hospitalier Régional Universitaire de Nancy, Nancy, France peyrinbiroulet@gmail.com.;Humanitas Clinical and Research Center IRCCS, Milan, Italy. | 1666 | |||||||
| 10.1016/j.pratan.2020.07.008 | English Abstract;Journal Article;Review | fr | [Neurological complications of COVID-19]. | https://www.ncbi.nlm.nih.gov/pubmed/32837213 | Neurological manifestations are likely to be more frequent and complex during COVID-19 than originally anticipated. | 1279-7960 | 2020-07-12 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Hugo Flis-Richard;Franck Verdonk | COVID-19;SARS-CoV-2 | 2020-07-10 02:00:00+02:00 | 32837213 | FR | Service d'anesthésie-réanimation, hôpital Saint-Antoine, Sorbonne université, AP-HP, Paris, France. | 1667 | |||
| 10.1016/j.pratan.2020.07.001 | English Abstract;Journal Article;Review | fr | [COVID-19, an atypical acute respiratory distress syndrome]. | https://www.ncbi.nlm.nih.gov/pubmed/32837209 | SARS-coV2 infection may induce a severe pneumonia that may lead to an acute respiratory distress syndrome. Hypoxaemia is the key symptom of the disease but other features are different such as pulmonary compliance that is most of the time initially normal. The mechanisms of the pulmonary damage are not completely understood. A new ventilation strategy has been set up to prevent ventilator induced lung injury (VILI). | 1279-7960 | 2020-07-12 02:00:00+02:00 | pubmed | Le Praticien en Anesthésie Réanimation | Jo-Anna Tirolien;Marc Garnier | Acute respiratory distress syndrome;COVID-19;Protective ventilation;SARS-coV2 | 2020-07-10 02:00:00+02:00 | 32837209 | FR | Service d'anesthésie réanimation, hôpital Saint-Antoine, hôpitaux Sorbonne Université, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France. | 1668 | |||
| 10.3389/fcell.2020.00616 | Journal Article;Review | en | nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. | https://www.ncbi.nlm.nih.gov/pubmed/32754599 | In December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related epidemic was first observed in Wuhan, China. In 2020, owing to the highly infectious and deadly nature of the virus, this widespread novel coronavirus disease 2019 (nCOVID-19) became a worldwide pandemic. Studies have revealed that various environmental factors including temperature, humidity, and air pollution may also affect the transmission pattern of COVID-19. Unfortunately, still, there is no specific drug that has been validated in large-scale studies to treat patients with confirmed nCOVID-19. However, remdesivir, an inhibitor of RNA-dependent RNA polymerase (RdRp), has appeared as an auspicious antiviral drug. Currently, a large-scale study on remdesivir (i.e., 200 mg on first day, then 100 mg once/day) is ongoing to evaluate its clinical efficacy to treat nCOVID-19. Good antiviral activity against SARS-CoV-2 was not observed with the use of lopinavir/ritonavir (LPV/r). Nonetheless, the combination of umifenovir and LPV/r was found to have better antiviral activity. Furthermore, a combination of hydroxychloroquine (i.e., 200 mg 3 times/day) and azithromycin (i.e., 500 mg on first day, then 250 mg/day from day 2-5) also exhibited good activity. Currently, there are also ongoing studies to evaluate the efficacy of teicoplanin and monoclonal and polyclonal antibodies against SARS-CoV-2. Thus, in this article, we have analyzed the genetic diversity and molecular pathogenesis of nCOVID-19. We also present possible therapeutic options for nCOVID-19 patients. | 2296-634X | 2020-07-12 02:00:00+02:00 | pubmed | Frontiers in Cell and Developmental Biology | Md Tanvir Kabir;Md Sahab Uddin;Md Farhad Hossain;Jawaher A Abdulhakim;Md Asraful Alam;Ghulam Md Ashraf;Simona G Bungau;May N Bin-Jumah;Mohamed M Abdel-Daim;Lotfi Aleya | RdRp inhibitors;SARS-CoV-2;corticosteroids;eculizumab;favipiravir;immunomodulators;nCOVID-19;remdesivir | 2020-07-10 02:00:00+02:00 | 32754599 | FR;SA;CN;RO;BD;EG;KR | Department of Pharmacy, Brac University, Dhaka, Bangladesh.;Department of Pharmacy, Southeast University, Dhaka, Bangladesh.;Pharmakon Neuroscience Research Network, Dhaka, Bangladesh.;Department of Physical Therapy, Graduate School of Inje University, Gimhae, South Korea.;Department of Medical Laboratory, Faculty of Applied Medical Sciences, Taibah University, Yanbu, Saudi Arabia.;School of Chemical Engineering, Zhengzhou University, Zhengzhou, China.;King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.;Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.;Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.;Department of Biology, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.;Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.;Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.;Chrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University, Besançon, France. | 1675 | |||
| 10.3389/fpubh.2020.00367 | Journal Article | en | Evidence That Higher Temperatures Are Associated With a Marginally Lower Incidence of COVID-19 Cases. | https://www.ncbi.nlm.nih.gov/pubmed/32754568 | Seasonal variations in COVID-19 incidence have been suggested as a potentially important factor in the future trajectory of the pandemic. Using global line-list data on COVID-19 cases reported until 17th of March 2020 and global gridded weather data, we assessed the effects of air temperature and relative humidity on the daily incidence of confirmed COVID-19 local cases at the subnational level (first-level administrative divisions). After adjusting for surveillance capacity and time since first imported case, average temperature had a statistically significant, negative association with COVID-19 incidence for temperatures of -15°C and above. However, temperature only explained a relatively modest amount of the total variation in COVID-19 cases. The effect of relative humidity was not statistically significant. These results suggest that warmer weather may modestly reduce the rate of spread of COVID-19, but anticipation of a substantial decline in transmission due to temperature alone with onset of summer in the northern hemisphere, or in tropical regions, is not warranted by these findings. | 2296-2565 | 2020-07-12 02:00:00+02:00 | pubmed | Frontiers in Public Health | Anne Meyer;Rohan Sadler;Céline Faverjon;Angus Robert Cameron;Melanie Bannister-Tyrrell | COVID-19;SARS-CoV-2;coronavirus;humidity;pandemic;temperature | 2020-07-10 02:00:00+02:00 | 32754568 | FR;AU;US | Ausvet Europe, Lyon, France.;Ausvet, Fremantle, WA, Australia. | 1681 | |||
| 10.1016/j.accpm.2020.07.007 | Journal Article | en | How to resume elective surgery in light of COVID-19 post-pandemic propofol shortage: The common concern of anaesthesists and surgeons. | https://www.ncbi.nlm.nih.gov/pubmed/32753363 | 2352-5568 | 2020-07-12 02:00:00+02:00 | pubmed | Anaesthesia Critical Care & Pain Medicine | Hélène Charbonneau;Ségolène Mrozek;Benjamin Pradere;Jean-Nicolas Cornu;Vincent Misrai | COVID-19;Drugs shortage;Propofol;Regional Anaesthesia;Surgery | 2020-07-09 02:00:00+02:00 | 32753363 | FR | Department of Anaesthesia and Critical care, Clinique Pasteur, 31300 Toulouse, France. Electronic address: hcharbonneau@clinique-pasteur.com.;Department of Anaesthesia and Critical care, University Hospital of Toulouse, Toulouse, France.;Department of Urology, University Hospital of Tours, Tours, France.;Department of Urology, University Hospital of Rouen, Rouen, France.;Department of Urology, Clinique Pasteur, 31300 Toulouse, France. | 1686 | ||||
| 10.1016/j.antiviral.2020.104866 | Journal Article;Review | en | Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32659293 | In the context of the COVID-19 pandemic, several drugs have been repurposed as potential candidates for the treatment of COVID-19 infection. While preliminary choices were essentially based on in vitro potency, clinical translation into effective therapies may be challenging due to unfavorable in vivo pharmacokinetic properties at the doses chosen for this new indication of COVID-19 infection. However, available pharmacokinetic and pharmacokinetic-pharmacodynamic studies suffer from severe limitations leading to unreliable conclusions, especially in term of dosing optimization. In this paper we propose to highlight these limitations and to identify some of the major requirements that need to be addressed in designing PK and PK-PD studies in this era of COVID. A special attention should be paid to pre-analytical and analytical requirements and to the proper collection of covariates affecting dose-exposure relationships (co-medications, use of specific organ support techniques and other clinical and para-clinical data). We also promote the development of population PK and PK-PD models specifically dedicated to COVID-19 patients since those previously developed for other diseases (SEL, malaria, HIV) and clinical situations (steady-state, non-ICU patients) are not representative of severe patients. Therefore, implementation of well-designed PK and PD studies targeted to COVID-19 patients is urgently needed. For that purpose we call for multi-institutional collaborative work and involvement of clinical pharmacologists in multidisciplinary research consortia. | 0166-3542 | 2020-07-12 02:00:00+02:00 | pubmed | Antiviral Research | Nicolas Venisse;Gilles Peytavin;Stephane Bouchet;Marie-Claude Gagnieu;Rodolphe Garraffo;Romain Guilhaumou;Caroline Solas | COVID-19;PK-PD;Pharmacodynamics;Pharmacokinetics | 2020-07-10 02:00:00+02:00 | 32659293 | FR | INSERM CIC1402, University Hospital of Poitiers, University of Poitiers, 86021, Poitiers Cedex, France, Biology-Pharmacy-Public Health Department, University Hospital of Poitiers, 2 Rue de La Milétrie, 86021, Poitiers Cedex, France. Electronic address: Nicolas.venisse@chu-poitiers.fr.;AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department and IAME, INSERM, UMRS1137, Université de Paris, 75018, Paris, 7 France.;Laboratoire de Pharmaco-Toxicologie, Service de Pharmacologie Médicale, CHU De Bordeaux, INSERM U1219, F-33076, Bordeaux Cedex, France.;Hospices Civils de Lyon, GHS-Centre de Biologie Sud, Pierre Bénite, Lyon, France.;Pharmacologie et Toxicologie Médicales, CHU et Faculté de Médecine de Nice, Université Côte D'Azur, Nice, France.;Service de Pharmacologie Clinique et Pharmacovigilance, APHM, Institut de Neurosciences des Systèmes, Inserm UMR 1106, Université D'Aix-Marseille, 13005, Marseille, France.;Aix-Marseille Univ, APHM, Unité des Virus Emergents (UVE) IRD 190, INSERM 1207, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, 13005, Marseille, France. Electronic address: Caroline.SOLAS@ap-hm.fr. | 1691 | |||
| Letter | en | Covid-19 related IgA vasculitis. | https://www.ncbi.nlm.nih.gov/pubmed/32633104 | IgA vasculitis is a systemic small-vessel vasculitis which may be triggered by different microorganisms. IgA vasculitis cases have been reported in patients with immune-mediated inflammatory disorders treated with TNF inhibitors. Here we report the case of a young Crohn's disease patient in clinical remission under adalimumab admitted for an IgA vasculitis, with an extended ileitis, and a positive PCR testing for Covid-19. Serum IgA levels were markedly increased and serology for Covid-19 was weakly positive for IgA. Even if we cannot prove the causality of Covid-19, it is remarkable to note that this case of IgA vasculitis was associated with high IgA levels in the serum and the Covid-19 serology was positive only for IgA. | 2020-07-12 02:00:00+02:00 | pubmed | Matthieu Allez;Blandine Denis;Jean-David Bouaziz;Maxime Battistella;Anne-Marie Zagdanski;Jules Bayart;Ingrid Lazaridou;Caroline Gatey;Evangeline Pillebout;Marie-Laure Chaix Baudier;Constance Delaugerre;Jean-Michel Molina;Jérôme Le Goff | 2020-07-06 02:00:00+02:00 | 32633104 | FR | Department of Gastroenterology, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France.;Department of infectious diseases, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France.;Department of Dermatology, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France.;Department of Pathology, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France.;Department of Radiology, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France.;Department of Nephrology, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France.;Department of Virology, Hôpital Saint-Louis, APHP, Université de Paris, Paris, France. | 1703 | |||||||
| 10.1007/s00246-020-02411-1 | Journal Article;Review | en | Telehealth for Pediatric Cardiology Practitioners in the Time of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32656626 | Due to the COVID-19 pandemic, there has been an increased interest in telehealth as a means of providing care for children by a pediatric cardiologist. In this article, we provide an overview of telehealth utilization as an extension of current pediatric cardiology practices and provide some insight into the rapid shift made to quickly implement these telehealth services into our everyday practices due to COVID-19 personal distancing requirements. Our panel will review helpful tips into the selection of appropriate patient populations and specific cardiac diagnoses for telehealth that put patient and family safety concerns first. Numerous practical considerations in conducting a telehealth visit must be taken into account to ensure optimal use of this technology. The use of adapted staffing and billing models and expanded means of remote monitoring will aid in the incorporation of telehealth into more widespread pediatric cardiology practice. Future directions to sustain this platform include the refinement of telehealth care strategies, defining best practices, including telehealth in the fellowship curriculum and continuing advocacy for technology. | 0172-0643,1432-1971 | 2020-07-12 02:00:00+02:00 | pubmed | Pediatric Cardiology | Devyani Chowdhury;Kyle D Hope;Lindsay C Arthur;Sharon M Weinberger;Christina Ronai;Jonathan N Johnson;Christopher S Snyder | Pediatric cardiology;Remote monitoring;Telehealth;Telemedicine | 2020-07-12 02:00:00+02:00 | 32656626 | FR;GB;US | Cardiology Care for Children, 1834 Oregon Pike, Ste 20, Lancaster, PA, 17601, USA. dchowdhury@cardiologylancaster.com.;Lille Frank Abercrombie Section of Cardiology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.;Division of Pediatric Cardiology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.;Nemours Cardiac Center, Nemours AI DuPont Children's Hospital, Wilmington, DE, USA.;Division of Pediatric Cardiology, Department of Pediatrics, Oregon Health & Sciences University, Portland, OR, USA.;Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic Children's Center, Rochester, MN, USA.;The Congenital Heart Collaborative, Case Western Reserve University School of Medicine, Cleveland, OH, USA. | 1707 | |||
| 10.3390/jcm9072198 | Editorial | en | Medicine 4.0: New Technologies as Tools for a Society 5.0. | https://www.ncbi.nlm.nih.gov/pubmed/32664634 | Are new technologies in the medicine sector a driver to support the development of a society 5.0? Innovation pushes the artisan to become smart and lean, customer-oriented but within a standardized environment of production, maintaining and ensuring the quality of the product. An artisan is a user and innovator, as an essential part of the industrial chain. In the healthcare sector, the doctor is the industrial artisan, and medicine can be considered as an example of a smart tool, strongly tailored, that embeds the innovation of materials, nano-devices, and smart technology (e.g., sensors and controllers). But how much of society is ready to host smart technology "on board", becoming "on life", constantly connected with remote controls that allow us to monitor, gather data, and, in any case, act, with preventive healthcare solutions? After a short overview of the medicine sector, a preliminary, tentative link between technological innovation and the healthcare sector allows us to adopt several outlooks on how to change research, always more transdisciplinary, combining science with social science in order to remain human-centered. | 2077-0383 | 2020-07-12 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Giuseppe Ioppolo;Franck Vazquez;Michael G Hennerici;Emmanuel Andrès | Covid-19;emerging technology;medicine 4.0;society 5.0 | 2020-07-12 02:00:00+02:00 | 32664634 | FR;IT;CH;DE | Department of Economics, University of study of Messina, Via dei Verdi, 75, 98122 Messina, Italy.;MDPI AG, St. Alban-Anlage 66, CH-4052 Basel, Switzerland.;Department of Neurology, Medical Faculty Mannheim, University Hospital Mannheim-University Heidelberg, D-68167 Mannheim, Germany.;Pôle M.I.R.N.E.D. et Service du Service de Médecine Interne, Diabète et Maladies Métaboliques Hôpitaux Universitaires de Strasbourg, Faculté de Médecine-Université de Strasbourg, 1 porte de l'Hôpital, 67000 Strasbourg, France. | 1709 | |||
| 10.1053/j.ajkd.2020.06.009 | Case Reports | en | COVID-19-Related Collapsing Glomerulopathy in a Kidney Transplant Recipient. | https://www.ncbi.nlm.nih.gov/pubmed/32668317 | We report a case of a kidney transplant recipient who presented with acute kidney injury and nephrotic-range proteinuria in a context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Kidney biopsy revealed collapsing glomerulopathy. Droplet-based digital polymerase chain reaction did not detect the presence of SARS-CoV-2 RNA in the biopsy fragment, and the virus was barely detectable in plasma at the time of the biopsy. SARS-CoV-2 RNAemia peaked several days later, followed by a seroconversion despite the absence of circulating CD19-positive lymphocytes at admission due to rituximab-based treatment of antibody-mediated rejection 3 months earlier. Genotyping for the 2 risk alleles of the apolipoprotein L1 (APOL1) gene revealed that the donor carried the low-risk G0/G2 genotype. This case illustrates that coronavirus disease 2019 infection may promote a collapsing glomerulopathy in kidney allografts with a low-risk APOL1 genotype in the absence of detectable SARS-CoV-2 RNA in the kidney and that podocyte injury may precede SARS-CoV-2 RNAemia. | 0272-6386 | 2020-07-12 02:00:00+02:00 | pubmed | American Journal of Kidney Diseases | Hélène Lazareth;Hélène Péré;Yannick Binois;Melchior Chabannes;Juliet Schurder;Thomas Bruneau;Alexandre Karras;Eric Thervet;Marion Rabant;David Veyer;Nicolas Pallet | Kidney transplantation;acute kidney injury (AKI);allograft biopsy;case report;collapsing glomerulopathy;coronavirus 2019 (COVID-19);severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | 2020-07-12 02:00:00+02:00 | 32668317 | FR | Service de Néphrologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: helene.lazareth@aphp.fr.;Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, INSERM U970, PARCC, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Hôpital Européen Georges Pompidou, Faculté de Médecine Centre Université de Paris, Université, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Service de Néphrologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Service de Néphrologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Hôpital Européen Georges Pompidou, Faculté de Médecine Centre Université de Paris, Université, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Personalized Medicine Pharmacogenomics, therapeutic optimization, eDIAG plateform, laboratory, équipe labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, Paris, France.;Service d'Anatomopathologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.;Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Unité de Génomique Fonctionnelle des Tumeurs Solides, Centre de Recherche des Cordeliers, INSERM, Université Paris, Paris, France.;Service de Néphrologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Hôpital Européen Georges Pompidou, Faculté de Médecine Centre Université de Paris, Université, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, Service de Biochimie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France. | 1710 | |||
| 10.1007/s10140-020-01817-x | Journal Article | en | Radiographic and chest CT imaging presentation and follow-up of COVID-19 pneumonia: a multicenter experience from an endemic area. | https://www.ncbi.nlm.nih.gov/pubmed/32653961 | COVID-19 has infected more than 2 million people in the world in less than 5 months outbreak. Chest imaging is recommended for triage of suspected cases of COVID-19 with moderate-severe clinical features and high pre-test probability of disease, and may help for patient follow-up and to identify patients at higher risk of disease worsening. This pictorial essay illustrates typical and uncommon imaging findings of COVID-19 pneumonia and the role of imaging for patient management. | 1070-3004,1438-1435 | 2020-07-12 02:00:00+02:00 | pubmed | Emergency Radiology | Federica Vernuccio;Dario Giambelluca;Roberto Cannella;Francesco Paolo Lombardo;Fabio Panzuto;Massimo Midiri;Paolo Cabassa | CT;Coronavirus disease 2019 (COVID-19);Coronavirus infections;Pulmonary embolism;SARS-CoV-2 | 2020-07-11 02:00:00+02:00 | 32653961 | FR;IT | Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University Hospital of Palermo, Via del Vespro 129, 90127, Palermo, Italy. federica.vernuccio@unipa.it.;University Paris Diderot, Sorbonne Paris Cité, Paris, France. federica.vernuccio@unipa.it.;I.R.C.C.S. Centro Neurolesi Bonino Pulejo, Contrada Casazza, SS113, 98124, Messina, Italy. federica.vernuccio@unipa.it.;Section of Radiology - BiND, University Hospital "Paolo Giaccone", Via del Vespro 129, 90127, Palermo, Italy. federica.vernuccio@unipa.it.;Department of Radiology, ASST Franciacorta, Azienda Ospedaliera M. Mellini, Viale Mazzini 4, 25032, Chiari, BS, Italy.;Section of Radiology - BiND, University Hospital "Paolo Giaccone", Via del Vespro 129, 90127, Palermo, Italy.;Department of Radiology, ASST Valtellina ed Alto Lario Ospedale "E. Morelli", Via Zubiani 33, 23035, Sondalo, SO, Italy.;Department of Radiology, ASST Lariana Ospedale "S. Anna", Via Ravona, 20, 22042, San Fermo della Battaglia, CO, Italy. | 1716 | |||
| 10.1007/s00134-020-06170-8 | Journal Article | en | Pulmonary immune responses against SARS-CoV-2 infection: harmful or not? | https://www.ncbi.nlm.nih.gov/pubmed/32681297 | 0342-4642,1432-1238 | 2020-07-19 02:00:00+02:00 | pubmed | Intensive Care Medicine | A Guillon;P S Hiemstra;M Si-Tahar | 2020-07-17 02:00:00+02:00 | 32681297 | FR;NL | Intensive Care Unit, Tours University Hospital, 2 Bd Tonnellé, 37044, Tours Cedex 9, France. antoine.guillon@univ-tours.fr.;University of Tours, Tours, France. antoine.guillon@univ-tours.fr.;Research Center for Respiratory Diseases, INSERM U1100, Tours, France. antoine.guillon@univ-tours.fr.;Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.;University of Tours, Tours, France.;Research Center for Respiratory Diseases, INSERM U1100, Tours, France. | 1758 | |||||
| 10.1159/000509650 | Journal Article;Review | en | The Day after Tomorrow: How Should We Address Health System Organization to Treat Cancer Patients after the Peak of the COVID-19 Epidemic? | https://www.ncbi.nlm.nih.gov/pubmed/32683373 | On March 11, 2020, the WHO director general declared COVID-19 a pandemic. This pandemic evolves in successive phases, i.e., phase 1 (the start phase), phase 2 ("the storm"), and phase 3 (the recession). To date, oncology and surgery groups have only given instructions for addressing phases 1 and 2. To prevent excess cancer mortality, health care systems (HCS) need to be restructured. Our aim is to detail the specificities of each epidemic phase and discuss several methods of organization to optimize cancer patient flow during the COVID-19 pandemic, particularly during phase 3. Hospitals must be reorganized in order to create a cancer hub that is free of infection, allowing for the safe treatment of patients. Hospital structures are different, but all allow for the creation of virus-free areas. Screening programs are critical and need to be applied to all people entering the virus-free zone, including health care workers. Some reorganization proposals are internal to a hospital, while others require interhospital collaboration. The heterogeneity and complexity of HCS will make interhospital management difficult. The ministry of health has an important role in managing the cancer crisis. Cancer management should be declared a priority. Oncological and surgical societies must coordinate their efforts to facilitate this prioritization. The anticipation of oncological management during phase 3 of the pandemic is necessary because it requires a complete readjustment of HCS. This adaptation should allow for the continuation of cancer care to prevent excess cancer mortality, as the virus will still be present for a currently undetermined period of time. | 0030-2414,1423-0232 | 2020-07-19 02:00:00+02:00 | pubmed | Oncology | Jean-Jacques Tuech;Alice Gangloff;Frederic Di Fiore;Ahmed Benyoucef;Pierre Michel;Lilian Schwarz | COVID-19 outbreak;Cancer;Health care systems;Oncology;Pandemic | 2020-07-17 02:00:00+02:00 | 32683373 | FR | Department of Digestive Surgery, Rouen University Hospital, Rouen, France, jean-jacques.tuech@chu-rouen.fr.;UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie University, Rouen, France, jean-jacques.tuech@chu-rouen.fr.;Department of Digestive Oncology, Rouen University Hospital, Rouen, France.;UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie University, Rouen, France.;Radiotherapy Department, Centre de Lutte Contre le Cancer Henri-Bequerel, Rouen, France.;Department of Digestive Surgery, Rouen University Hospital, Rouen, France. | 1761 | |||
| 10.1097/j.pbj.0000000000000073 | Editorial | en | Fast and slow health crises of Homo urbanicus: loss of resilience in communicable diseases, like COVID-19, and non-communicable diseases. | https://www.ncbi.nlm.nih.gov/pubmed/32734013 | 2444-8664 | 2020-07-19 02:00:00+02:00 | pubmed | Porto Biomedical Journal | Tari Haahtela;Josep M Anto;Jean Bousquet | 2020-07-17 02:00:00+02:00 | 32734013 | FI;ES;FR;DE | Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.;ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.;Charité. Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.;University hospital, Montpellier, France. | 1763 | |||||
| Letter | en | COVID-19 and macular edema: a necessarily blindness? | https://www.ncbi.nlm.nih.gov/pubmed/32666248 | 2020-07-19 02:00:00+02:00 | pubmed | Valentin Navel;Julien S Baker;Frédéric Dutheil | 2020-07-14 02:00:00+02:00 | 32666248 | FR;HK | Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, F-63000, Clermont-Ferrand, France. valentin.navel@hotmail.fr.;Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong.;Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, Witty Fit, F-63000, Clermont-Ferrand, France. | 1781 | ||||||||
| 10.1126/science.abc6027 | Journal Article;Research Support, Non-U.S. Gov't | en | Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32661059 | Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression that suggest diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A distinct phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), which was associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor nuclear factor-κB and characterized by increased tumor necrosis factor-α and interleukin-6 production and signaling. These data suggest that type I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches. | 0036-8075,1095-9203 | 2020-07-19 02:00:00+02:00 | pubmed | Adult;Aged;Betacoronavirus__immunology;Coronavirus Infections__immunology;Critical Illness;Cross-Sectional Studies;Female;Gene Expression Profiling;Humans;Immunity, Innate;Inflammation;Interferon alpha-2__metabolism;Interferon-alpha__metabolism;Interferon-beta__metabolism;Interleukin-6__metabolism;Male;Middle Aged;NF-kappa B__metabolism;Pandemics;Pneumonia, Viral__immunology;Signal Transduction;T-Lymphocyte Subsets__immunology;Tumor Necrosis Factor-alpha__metabolism;Viral Load;COVID-19;severe acute respiratory syndrome coronavirus 2 | Science | Jérôme Hadjadj;Nader Yatim;Laura Barnabei;Aurélien Corneau;Jeremy Boussier;Nikaïa Smith;Hélène Péré;Bruno Charbit;Vincent Bondet;Camille Chenevier-Gobeaux;Paul Breillat;Nicolas Carlier;Rémy Gauzit;Caroline Morbieu;Frédéric Pène;Nathalie Marin;Nicolas Roche;Tali-Anne Szwebel;Sarah H Merkling;Jean-Marc Treluyer;David Veyer;Luc Mouthon;Catherine Blanc;Pierre-Louis Tharaux;Flore Rozenberg;Alain Fischer;Darragh Duffy;Frédéric Rieux-Laucat;Solen Kernéis;Benjamin Terrier | 2020-07-13 02:00:00+02:00 | 32661059 | FR | Université de Paris, Imagine Institute Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR 1163, F-75015 Paris, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP-CUP, Hôpital Cochin, F-75014 Paris, France.;Institut Pasteur, Laboratory of Dendritic Cell Immunobiology, INSERM U1223, Department of Immunology, F-75015 Paris, France.;Sorbonne Université, UMS037, PASS, Plateforme de cytométrie de la Pitié-Salpêtrière CyPS, F-75013 Paris, France.;Université de Paris, INSERM, U970, PARCC, F-75015 Paris, France.;Service de Microbiologie, AP-HP, APHP-CUP, Hôpital Européen Georges Pompidou, F-75015 Paris, France.;Institut Pasteur, Cytometry and Biomarkers UTechS, CRT, F-75015 Paris, France.;Department of Automated Diagnostic Biology, Hôpital Cochin, APHP, APHP-CUP, F-75014 Paris, France.;Department of Pulmonology, Hôpital Cochin, AP-HP, APHP-CUP, F-75014 Paris, France.;Equipe Mobile d'Infectiologie, Hôpital Cochin, AP-HP, APHP-CUP, F-75014 Paris, France.;Université de Paris, Institut Cochin, INSERM U1016, CNRS UMR8104, F-75006 Paris, France.;Service de Médecine Intensive et Réanimation, Hôpital Cochin, AP-HP, APHP-CUP, F-75014 Paris, France.;Institut Pasteur, Insect-Virus Interactions Unit, UMR 2000, CNRS, Paris, France.;Université de Paris, Pharmacologie et Evaluation des Thérapeutiques Chez l'Enfant et la Femme Enceinte EA7323, F-75006 Paris, France.;Recherche Clinique et Pharmacologie, AP-HP, APHP-CUP, Hôpitaux Cochin Necker, F-75014 Paris, France.;Université de Paris and Sorbonne Université, INSERM, Centre de Recherche des Cordeliers, Functional Genomics of Solid Tumors (FunGeST), F-75006 Paris, France.;Service de Virologie, Hôpital Cochin, AP-HP, APHP-CUP, F-75014 Paris, France.;Department of Paediatric Immuno-Haematology and Rheumatology, AP-HP, APHP.CUP, Hôpital Necker, F-75015 Paris, France.;Collège de France, Paris, France.;Université de Paris, INSERM, IAME, F-75006 Paris, France.;Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), F-75015 Paris, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP-CUP, Hôpital Cochin, F-75014 Paris, France. benjamin.terrier@aphp.fr. | 1782 | |||
| Letter | en | SARS-CoV-2 RT-PCR and Chest CT, two complementary approaches for COVID-19 diagnosis. | https://www.ncbi.nlm.nih.gov/pubmed/32661878 | 2020-07-19 02:00:00+02:00 | pubmed | Eric Farfour;François Mellot;Philippe Lesprit;Marc Vasse | COVID-19;Chest CT;Infection prevention and control (IPC);RT-PCR;SARS-CoV-2 | 2020-07-13 02:00:00+02:00 | 32661878 | FR | Service de Biologie Clinique, Hôpital Foch, 40 rue Worth, 92 150, Suresnes, France. ericf6598@yahoo.fr.;Service d'Imagerie Médicale, Hôpital Foch, 40 rue Worth, 92 150, Suresnes, France.;Service de Biologie Clinique, Hôpital Foch, 40 rue Worth, 92 150, Suresnes, France. | 1783 | |||||||
| Letter | fr | [Spontaneous pneumomediastinum: A rare complication of COVID-19?] | https://www.ncbi.nlm.nih.gov/pubmed/32675006 | 2020-07-19 02:00:00+02:00 | pubmed | M Underner;G Peiffer;J Perriot;N Jaafari | 2020-07-13 02:00:00+02:00 | 32675006 | FR | Unité de recherche clinique, centre hospitalier Henri-Laborit, université de Poitiers, 86021 Poitiers, France. Electronic address: mike.underner@orange.fr.;Service de pneumologie, CHR Metz-Thionville, 57038 Metz, France.;Dispensaire Emile-Roux, centre de tabacologie, 63100 Clermont-Ferrand, France.;Unité de recherche clinique, centre hospitalier Henri-Laborit, université de Poitiers, 86021 Poitiers, France. | 1786 | ||||||||
| 10.12688/wellcomeopenres.16123.1 | Journal Article | en | The social underpinnings of mental distress in the time of COVID-19 - time for urgent action. | https://www.ncbi.nlm.nih.gov/pubmed/32802967 | We argue that predictions of a 'tsunami' of mental health problems as a consequence of the pandemic of coronavirus disease 2019 (COVID-19) and the lockdown are overstated; feelings of anxiety and sadness are entirely normal reactions to difficult circumstances, not symptoms of poor mental health. Some people will need specialised mental health support, especially those already leading tough lives; we need immediate reversal of years of underfunding of community mental health services. However, the disproportionate effects of COVID-19 on the most disadvantaged, especially BAME people placed at risk by their social and economic conditions, were entirely predictable. Mental health is best ensured by urgently rebuilding the social and economic supports stripped away over the last decade. Governments must pump funds into local authorities to rebuild community services, peer support, mutual aid and local community and voluntary sector organisations. Health care organisations must tackle racism and discrimination to ensure genuine equal access to universal health care. Government must replace highly conditional benefit systems by something like a universal basic income. All economic and social policies must be subjected to a legally binding mental health audit. This may sound unfeasibly expensive, but the social and economic costs, not to mention the costs in personal and community suffering, though often invisible, are far greater. | 2398-502X | 2020-07-19 02:00:00+02:00 | pubmed | Wellcome Open Research | Nikolas Rose;Nick Manning;Richard Bentall;Kamaldeep Bhui;Rochelle Burgess;Sarah Carr;Flora Cornish;Delan Devakumar;Jennifer B Dowd;Stefan Ecks;Alison Faulkner;Alex Ruck Keene;James Kirkbride;Martin Knapp;Anne M Lovell;Paul Martin;Joanna Moncrieff;Hester Parr;Martyn Pickersgill;Genevra Richardson;Sally Sheard | BAME;Mental distress;benefit system reform;social disadvantage;universal basic income | 2020-07-13 02:00:00+02:00 | 32802967 | FR;GB;US | Centre for Society and Mental Health, King's College London, London, WC2B 4BG, UK.;Department of Psychology,, University of Sheffield, Sheffield, S1 2LT, UK.;Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK.;Institute for Global Health, University College, London, WC1N 1EH, UK.;Institute for Mental Health, University of Birmingham, UK, Birmingham, B15 2TT, UK.;Methodology Institute, London School of Economics and Political Science, London, WC2A 2AE, UK.;Leverhulme Centre for Demographic Science, University of Oxford, Oxford, OX1 1JD, UK.;Department of Anthropology, University of Edinburgh, Edinburgh, EH8 9LD, UK.;Survivor Researcher and Trainer, Independent Researcher, London, UK.;39 Essex Chambers, 81 Chancery Lane, London, WC2A 1DD, UK.;Department of Psychiatry, University College, London, WC1N 1EH, UK.;Care Policy and Evaluation Centre, London School of Economics and Political Science, London, WC2A 2AE, UK.;CERMES3, Ecole des Hautes Etudes en Sciences Sociales, Paris, 75006, France.;Department of Sociology, University of Sheffield, Sheffield, S10 2TN, UK.;Department of Geography, University of Glasgow, Glasgow, G12 8QQ, UK.;Usher Institute, University of Edinburgh, Edinburgh, EH8 9LD, UK.;School of Law, King's College London, London, WC2R 2LS, UK.;Department of Public Health, Policy and Systems, University of Liverpool, Liverpool, L69 3GB, UK. | 1788 | |||
| Letter;Research Support, Non-U.S. Gov't | en | Tackling cervical cancer in Europe amidst the COVID-19 pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32673570 | 2020-07-19 02:00:00+02:00 | pubmed | Coronavirus Infections__epidemiology;Europe__epidemiology;Female;Humans;Pandemics;Pneumonia, Viral__epidemiology;Uterine Cervical Neoplasms__epidemiology;COVID-19 | Marc Arbyn;Laia Bruni;Daniel Kelly;Partha Basu;Mario Poljak;Murat Gultekin;Christine Bergeron;David Ritchie;Elisabete Weiderpass | 2020-07-13 02:00:00+02:00 | 32673570 | FR;SI;GB;TR;ES;BE | Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels B1050, Belgium. Electronic address: marc.arbyn@sciensano.be.;Consortium for Biomedical Research in Cancer Epidemiology Research Program, Catalan Institute of Oncology - IDIBELL, Barcelona, Spain.;Royal College of Nursing, School of Healthcare Sciences, University of Cardiff, Cardiff, UK.;International Agency for Research on Cancer, Lyon, France.;Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;Hacettepe University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Ankara, Turkey.;Laboratoire Cerba, Cergy Pontoise France, Paris, France.;Association of European Cancer Leagues, Brussels, Belgium. | 1789 | |||||||
| Letter;Research Support, Non-U.S. Gov't | en | Prone positioning under VV-ECMO in SARS-CoV-2-induced acute respiratory distress syndrome. | https://www.ncbi.nlm.nih.gov/pubmed/32665007 | 2020-07-19 02:00:00+02:00 | pubmed | Aged;Coronavirus Infections__complications;Extracorporeal Membrane Oxygenation__methods;Female;Humans;Male;Middle Aged;Pandemics;Pneumonia, Viral__complications;Prone Position;Respiratory Distress Syndrome, Adult__therapy;Retrospective Studies;Treatment Outcome;COVID-19 | Bruno Garcia;Nicolas Cousin;Claire Bourel;Mercé Jourdain;Julien Poissy;Thibault Duburcq | COVID-19;ECMO;Prone positioning;Refractory hypoxemia | 2020-07-14 02:00:00+02:00 | 32665007 | FR | CHU Lille, Pôle de réanimation, F-59000, Lille, France.;Univ. Lille, Inserm Pasteur Lille, Inserm U1190 EGID, F-59000, Lille, France.;Univ. Lille, Inserm U1285, CNRS, UMR 8576 - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000, Lille, France.;CHU Lille, Pôle de réanimation, F-59000, Lille, France. thibault.duburcq@chru-lille.fr. | 1794 | ||||||
| Letter | en | A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir. | https://www.ncbi.nlm.nih.gov/pubmed/32759053 | 2020-07-19 02:00:00+02:00 | pubmed | H Joumaa;L Regard;N Carlier;G Chassagnon;E Alabadan;E Canouï;A L'honneur;F Rozenberg;P-R Burgel;N Roche | COVID-19;Human immunodeficiency virus;Lopinavir;Pneumonia;Pulmonary embolism | 2020-07-15 02:00:00+02:00 | 32759053 | FR | Service de pneumologie, hôpital Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.;Service de pneumologie, hôpital Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France, Université de Paris, institut Cochin, Inserm U1016, 24, rue du Faubourg-Saint-Jacques, 75014 Paris, France.;Université de Paris, institut Cochin, Inserm U1016, 24, rue du Faubourg-Saint-Jacques, 75014 Paris, France, Service de Radiologie, hôpital Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.;Équipe mobile d'infectiologie, centre université de Paris, site Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.;Service de virologie, hôpital Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.;Service de pneumologie, hôpital Cochin, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France, Université de Paris, institut Cochin, Inserm U1016, 24, rue du Faubourg-Saint-Jacques, 75014 Paris, France. Electronic address: nicolas.roche@aphp.fr. | 1797 | |||||||
| 10.1016/j.ejmech.2020.112653 | Journal Article | en | Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses. | https://www.ncbi.nlm.nih.gov/pubmed/32693294 | Flavaglines are cyclopenta[b]benzofurans found in plants of the genus Aglaia, several species of which are used in traditional Chinese medicine. These compounds target the initiation factor of translation eIF4A and the scaffold proteins prohibitins-1 and 2 (PHB1/2) to exert various pharmacological activities, including antiviral effects against several types of viruses, including coronaviruses. This review is focused on the antiviral effects of flavaglines and their therapeutic potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). | 0223-5234 | 2020-07-19 02:00:00+02:00 | pubmed | European Journal of Medicinal Chemistry | Canan G Nebigil;Christiane Moog;Stéphan Vagner;Nadia Benkirane-Jessel;Duncan R Smith;Laurent Désaubry | COVID-19;Chikungunya virus;Coronavirus;Ebola virus;Natural products;Picornaviruses;Prohibitin;SARS-CoV-2;Zika virus;eIF4A | 2020-07-15 02:00:00+02:00 | 32693294 | FR;TH | INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France.;INSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, Strasbourg, France.;Institut Curie, PSL Research University, CNRS UMR 3348, INSERM U1278, Orsay, France, Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3348, INSERM U1278, Orsay, France.;INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France, Université de Strasbourg, Faculté de Chirurgie Dentaire, Hôpitaux Universitaires de Strasbourg, 8 Rue de Ste Elisabeth, 67000, Strasbourg, France.;Institute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand.;INSERM U 1260, Regenerative Nanomedicine (RNM), FMTS, 11 Rue Humann, 67000, Strasbourg, France. Electronic address: desaubry@unistra.fr. | 1801 | |||
| 10.1080/10428194.2020.1791854 | Journal Article | en | Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. | https://www.ncbi.nlm.nih.gov/pubmed/32667230 | The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COVID-19 era, where decreases in blood donations have stressed the blood supply. In March 2018, using a modified Delphi method, we convened a panel of 13 expert MDS clinicians for three iterative rounds to discuss a minimum safe Hb for this population. While the panel was unable to reach the pre-set consensus of 75% for a specific Hb threshold, there was 100% consensus that it be no greater than 7.5 g/dL. Our data suggest that, given no end-organ effects of anemia, patients with MDS can safely forgo transfusions with a Hb of 7.5 g/dL or higher. | 1042-8194,1029-2403 | 2020-07-19 02:00:00+02:00 | pubmed | Leukemia & Lymphoma | Anna M Tanasijevic;Anna Revette;Heidi D Klepin;Amer Zeidan;Danielle Townsley;Courtney D DiNardo;Marie Sebert;Amy E DeZern;Richard M Stone;Emily S Magnavita;Richard Chen;Mikkael A Sekeres;Gregory A Abel | Myelodysplastic syndromes;hemoglobin threshold;transfusion | 2020-07-15 02:00:00+02:00 | 32667230 | FR;US | Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.;Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.;Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA.;Oncology at MedImmune/AstraZeneca, Gaithersburg, MD, USA.;Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Service de Hematologie Seniors, Hospital Saint Louis, Universit Paris 7, Paris, France.;Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA.;Department of Medical Oncology, Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA.;Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA. | 1804 | |||
| Clinical Trial Protocol;Comparative Study;Letter;Multicenter Study | en | The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. | https://www.ncbi.nlm.nih.gov/pubmed/32665040 | To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 infection. | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus;Coronavirus Infections__drug therapy;Drug Therapy, Combination;Hospitalization;Humans;Hydroxychloroquine__administration & dosage;Lopinavir__administration & dosage;Pandemics;Pneumonia, Viral__drug therapy;Randomized Controlled Trials as Topic;Ritonavir__administration & dosage;Standard of Care;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | Justin T Denholm;Joshua Davis;David Paterson;Jason Roberts;Susan Morpeth;Thomas Snelling;Dominica Zentner;Megan Rees;Matthew O'Sullivan;David Price;Asha Bowen;Steven Y C Tong | COVID-19;Randomised controlled trial;hydroxychloroquine;lopinavir;protocol;ritonavir | 2020-07-14 02:00:00+02:00 | 32665040 | FR;NZ;AU | Victorian Infectious Diseases Service, The Royal Melbourne Hospital, and Doherty Department University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne, Victoria, Australia. justin.denholm@mh.org.au.;Menzies School of Health Research, Charles Darwin University, Darwin, Australia.;Department of Infectious Diseases, John Hunter Hospital, Newcastle, NSW, Australia.;University of Queensland Centre for Clinical Research, Faculty of Medicine & Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, Australia.;Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.;Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.;Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France.;Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.;School of Public Health, University of Sydney, Sydney, New South Wales, Australia.;Department of Cardiology, The Royal Melbourne Hospital and Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Department of Respiratory Medicine, The Royal Melbourne Hospital and Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, New South Wales, Australia.;University of Sydney, Sydney, New South Wales, Australia.;Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, The University of Melbourne, Melbourne, Victoria, Australia.;Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at the Peter Doherty Institute for Infection & Immunity, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Victoria, Australia.;Telehealth Kids Institute, Perth, West Australia, Australia.;Victorian Infectious Diseases Service, The Royal Melbourne Hospital, and Doherty Department University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne, Victoria, Australia. | 1813 | |||||
| Letter;Multicenter Study;Observational Study | en | Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study. | https://www.ncbi.nlm.nih.gov/pubmed/32684169 | 2020-07-19 02:00:00+02:00 | pubmed | Aged;Coronavirus Infections__complications;Female;Humans;Male;Middle Aged;Neuromuscular Blocking Agents__therapeutic use;Pandemics;Pneumonia, Viral__complications;Prospective Studies;Respiratory Distress Syndrome, Adult__drug therapy;Treatment Outcome;COVID-19 | Romain Courcelle;Stéphane Gaudry;Nicolas Serck;Gauthier Blonz;Jean-Baptiste Lascarrou;David Grimaldi | 2020-07-19 02:00:00+02:00 | 32684169 | FR;BE | Unité de soins intensifs, Centres Hospitaliers de Jolimont, La Louvière, Belgium.;Réanimation médico-chirurgicale CHU Avicenne, Université Sorbonne Paris Nord, Bobigny, France.;Unité de soins intensifs, Clinique Saint Pierre, Ottignies, Belgium.;Medecine Intensive Reanimation, District Hospital Center, Boulevard Stephane Moreau, 85000, La Roche Sur Yon, France.;Medecine Intensive Reanimation, CHU Nantes, 30 Boulevard Jean Monnet, 44093, Nantes Cedex 9, France.;Soins Intensifs, Hôpital Erasme, ULB, Route de Lennik 808, 1070, Bruxelles, Belgium. david.grimaldi@erasme.ulb.ac.be. | 1817 | |||||||
| Fonds National de la Recherche Luxembourg;Fonds National de la Recherche Luxembourg;Fonds National de la Recherche Luxembourg;Fonds National de la Recherche Luxembourg;Fonds National de la Recherche Luxembourg;Fonds National de la Recherche Luxembourg;European Cooperation in Science and Technology;European Cooperation in Science and Technology | 10.3390/ijms21145094 | Journal Article;Review | en | The COVID-19 Pandemic: Does Our Early Life Environment, Life Trajectory and Socioeconomic Status Determine Disease Susceptibility and Severity? | https://www.ncbi.nlm.nih.gov/pubmed/32707661 | A poor socioeconomic environment and social adversity are fundamental determinants of human life span, well-being and health. Previous influenza pandemics showed that socioeconomic factors may determine both disease detection rates and overall outcomes, and preliminary data from the ongoing coronavirus disease (COVID-19) pandemic suggests that this is still true. Over the past years it has become clear that early-life adversity (ELA) plays a critical role biasing the immune system towards a pro-inflammatory and senescent phenotype many years later. Cytotoxic T-lymphocytes (CTL) appear to be particularly sensitive to the early life social environment. As we understand more about the immune response to SARS-CoV-2 it appears that a functional CTL (CD8+) response is required to clear the infection and COVID-19 severity is increased as the CD8+ response becomes somehow diminished or exhausted. This raises the hypothesis that the ELA-induced pro-inflammatory and senescent phenotype may play a role in determining the clinical course of COVID-19, and the convergence of ELA-induced senescence and COVID-19 induced exhaustion represents the worst-case scenario with the least effective T-cell response. If the correct data is collected, it may be possible to separate the early life elements that have made people particularly vulnerable to COVID-19 many years later. This will, naturally, then help us identify those that are most at risk from developing the severest forms of COVID-19. In order to do this, we need to recognize socioeconomic and early-life factors as genuine medically and clinically relevant data that urgently need to be collected. Finally, many biological samples have been collected in the ongoing studies. The mechanisms linking the early life environment with a defined later-life phenotype are starting to be elucidated, and perhaps hold the key to understanding inequalities and differences in the severity of COVID-19. | 1422-0067 | 2020-07-19 02:00:00+02:00 | pubmed | Betacoronavirus__immunology;CD8-Positive T-Lymphocytes__immunology;Coronavirus Infections__drug therapy;Disease Susceptibility__immunology;Healthcare Disparities;Humans;Pandemics;Pneumonia, Viral__drug therapy;Risk Factors;Social Class;Socioeconomic Factors;Stress, Psychological__immunology;COVID-19;severe acute respiratory syndrome coronavirus 2 | International Journal of Molecular Sciences | Cyrielle Holuka;Myriam P Merz;Sara B Fernandes;Eleftheria G Charalambous;Snehaa V Seal;Nathalie Grova;Jonathan D Turner | COVID-19;SARS-CoV-2;early life adversity;health inequalities;immune exhaustion;immunosenescence;psychosocial stress;socioeconomic status | 2020-07-19 02:00:00+02:00 | 32707661 | FR;LU | [{"country": "", "agency": "Fonds National de la Recherche Luxembourg", "grantid": "C12/BM/3985792 \"EpiPath\""}, {"country": "", "agency": "Fonds National de la Recherche Luxembourg", "grantid": "C19/SC/13650569 \"ALAC\""}, {"country": "", "agency": "Fonds National de la Recherche Luxembourg", "grantid": "C16/BM/11342695 \"MetCOEPs\""}, {"country": "", "agency": "Fonds National de la Recherche Luxembourg", "grantid": "INTER/ANR/16/11568350 \"MADAM\""}, {"country": "", "agency": "Fonds National de la Recherche Luxembourg", "grantid": "PRIDE/11012546/NEXTIMMUNE"}, {"country": "", "agency": "Fonds National de la Recherche Luxembourg", "grantid": "PRIDE17/11823097/MicrOH"}, {"country": "", "agency": "European Cooperation in Science and Technology", "grantid": "CA18211"}, {"country": "", "agency": "European Cooperation in Science and Technology", "grantid": "CA16120"}] | Immune Endocrine Epigenetics Research Group, Department of Infection and Immunity, Luxembourg Institute of Health, L-4345 Esch-sur-Alzette, Luxembourg.;Calbinotox, Faculty of Science and Technology, Lorraine University, 54506 Nancy, France. | 1822 |
| 10.3390/nu12072152 | Journal Article | en | Psychological Aspects and Eating Habits during COVID-19 Home Confinement: Results of EHLC-COVID-19 Italian Online Survey. | https://www.ncbi.nlm.nih.gov/pubmed/32707724 | The COVID-19 pandemic has had a huge impact on the population with consequences on lifestyles. The aim of the study was to analyse the relationship between eating habits, mental and emotional mood. A survey was conducted online during social isolation, from 24 April to 18 May 2020, among the Italian population. A total of 602 interviewees were included in the data analysis. A high percentage of respondents experienced a depressed mood, anxious feelings, hypochondria and insomnia (61.3%, 70.4%, 46.2% and 52.2%). Almost half of the respondents felt anxious due to the fact of their eating habits, consumed comfort food and were inclined to increase food intake to feel better. Age was inversely related to dietary control (OR = 0.971, p = 0.005). Females were more anxious and disposed to comfort food than males (p < 0.001; p < 0.001). A strength of our study was represented by the fact that the survey was conducted quickly during the most critical period of the Italian epidemic lockdown. As the COVID-19 pandemic is still ongoing, our data need to be confirmed and investigated in the future with larger population studies. | 2072-6643 | 2020-07-19 02:00:00+02:00 | pubmed | Adolescent;Adult;Affect;Age Factors;Aged;Anxiety__epidemiology;Betacoronavirus;Coronavirus Infections__epidemiology;Feeding Behavior__psychology;Female;Humans;Hypochondriasis__epidemiology;Internet;Italy__epidemiology;Life Style;Male;Middle Aged;Pandemics__statistics & numerical data;Pneumonia, Viral__epidemiology;Sex Factors;Social Isolation__psychology;Surveys and Questionnaires;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | Nutrients | Laura Di Renzo;Paola Gualtieri;Giulia Cinelli;Giulia Bigioni;Laura Soldati;Alda Attinà;Francesca Fabiola Bianco;Giovanna Caparello;Vanessa Camodeca;Elena Carrano;Simona Ferraro;Silvia Giannattasio;Claudia Leggeri;Tiziana Rampello;Laura Lo Presti;Maria Grazia Tarsitano;Antonino De Lorenzo | COVID-19;SarsCoV2;eating behaviours;emotional eating;lifestyle;lockdown;psychological effects | 2020-07-19 02:00:00+02:00 | 32707724 | FR;IT | Section of Clinical Nutrition and Nutrigenomic, Department of Biomedicine and Prevention, University of Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.;School of Specialization in Food Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.;Predictive and Preventive Medicine Research Unit, Bambino Gesù Children's Hospital IRCCS, 00165 Rome, Italy.;Department of Physic, University of Rome Sapienza, P.zza Aldo Moro 5, 00185 Rome, Italy.;Department of Health Sciences, University of Milan, Via A. Di Rudinì, 8, 20142 Milan, Italy.;Unitelma Sapienza, University of Rome Sapienza, Via Regina Elena, 295, 00161 Rome, Italy.;Department of Experimental Medicine, University of Rome Sapienza, Rome 00161, Italy. | 1828 | ||
| NIAID NIH HHS;NIAID NIH HHS;NIAID NIH HHS | 10.1128/jcm.00926-20 | Evaluation Study;Journal Article;Multicenter Study | en | Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test. | https://www.ncbi.nlm.nih.gov/pubmed/32366669 | Nucleic acid amplification tests (NAATs) are the primary means of identifying acute infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Accurate and fast test results may permit more efficient use of protective and isolation resources and allow rapid therapeutic interventions. We evaluated the analytical and clinical performance characteristics of the Xpert Xpress SARS-CoV-2 (Xpert) test, a rapid, automated molecular test for SARS-CoV-2. Analytical sensitivity and specificity/interference were assessed with infectious SARS-CoV-2; other infectious coronavirus species, including SARS-CoV; and 85 nasopharyngeal swab specimens positive for other respiratory viruses, including endemic human coronaviruses (hCoVs). Clinical performance was assessed using 483 remnant upper- and lower-respiratory-tract specimens previously analyzed by standard-of-care (SOC) NAATs. The limit of detection of the Xpert test was 0.01 PFU/ml. Other hCoVs, including Middle East respiratory syndrome coronavirus, were not detected by the Xpert test. SARS-CoV, a closely related species in the subgenus Sarbecovirus, was detected by a broad-range target (E) but was distinguished from SARS-CoV-2 (SARS-CoV-2-specific N2 target). Compared to SOC NAATs, the positive agreement of the Xpert test was 219/220 (99.5%), and the negative agreement was 250/261 (95.8%). A third tie-breaker NAAT resolved all but three of the discordant results in favor the Xpert test. The Xpert test provided sensitive and accurate detection of SARS-CoV-2 in a variety of upper- and lower-respiratory-tract specimens. The high sensitivity and short time to results of approximately 45 min may impact patient management. | 0095-1137,1098-660X | 2020-07-26 02:00:00+02:00 | pubmed | Adolescent;Adult;Aged;Aged, 80 and over;Automation, Laboratory__methods;Betacoronavirus__genetics;Child;Child, Preschool;Clinical Laboratory Techniques__methods;Coronavirus Infections__diagnosis;Female;Humans;Infant;Infant, Newborn;Male;Middle Aged;Molecular Diagnostic Techniques__methods;Nasopharynx__virology;Pandemics;Pneumonia, Viral__diagnosis;Sensitivity and Specificity;Young Adult;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Journal of Clinical Microbiology | Michael J Loeffelholz;David Alland;Susan M Butler-Wu;Utsav Pandey;Carlo Frederico Perno;Alice Nava;Karen C Carroll;Heba Mostafa;Emma Davies;Ashley McEwan;Jennifer L Rakeman;Randal C Fowler;Jean-Michel Pawlotsky;Slim Fourati;Sukalyani Banik;Padmapriya P Banada;Shobha Swaminathan;Soumitesh Chakravorty;Robert W Kwiatkowski;Victor C Chu;JoAnn Kop;Rajiv Gaur;Mandy L Y Sin;Duy Nguyen;Simranjit Singh;Na Zhang;David H Persing | COVID-19;RT-PCR;SARS-CoV-2;Xpert | 2020-07-23 02:00:00+02:00 | 32366669 | FR;JE;GB;US;IT | [{"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI098713"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI131617"}, {"country": "United States", "agency": "NIAID NIH HHS", "grantid": "R01 AI148437"}] | Cepheid, Sunnyvale, California, USA Michael.loeffelholz@cepheid.com.;Center for Emerging Pathogens, Department of Medicine, Rutgers-New Jersey Medical School, Newark New Jersey, USA.;Keck School of Medicine of USC, Department of Pathology, Los Angeles, California, USA.;Children's Hospital Los Angeles, Los Angeles, California, USA.;Niguarda Hospital, Ospedale Niguarda Ca' Granda, Milan, Italy.;The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.;Department of Virology, Manchester University NHS Foundation Trust, Manchester, United Kingdom.;NYC Public Health Laboratory, Department of Health and Mental Hygiene, New York, New York, USA.;Bacteriology-Virology, Henri Mondor Hospital, Creteil, France.;Cepheid, Sunnyvale, California, USA. | 1839 |
| 10.1016/j.cmi.2020.07.032 | Journal Article | en | Evolution of viral quasispecies during SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32717416 | Studies are needed to better understand the genomic evolution of the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to describe genomic diversity of SARS-CoV-2 by next-generation sequencing (NGS) in a patient with longitudinal follow-up for SARS-CoV-2 infection. | 1198-743X | 2020-07-26 02:00:00+02:00 | pubmed | Clinical Microbiology and Infection | Aude Jary;Valentin Leducq;Isabelle Malet;Stéphane Marot;Elise Klement-Frutos;Elisa Teyssou;Cathia Soulié;Basma Abdi;Marc Wirden;Valérie Pourcher;Eric Caumes;Vincent Calvez;Sonia Burrel;Anne-Geneviève Marcelin;David Boutolleau | Infection follow-up;Minority variants;NGS;Quasispecies;SARS-CoV-2 | 2020-07-24 02:00:00+02:00 | 32717416 | FR | Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France. Electronic address: aude.jary@aphp.fr.;Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Maladie Infectieuses et Tropicales, Paris, France. | 1847 | |||
| 10.1093/jac/dkaa261 | Journal Article | en | Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. | https://www.ncbi.nlm.nih.gov/pubmed/32688374 | The combination lopinavir/ritonavir is recommended to treat HIV-infected patients at the dose regimen of 400/100 mg q12h, oral route. The usual lopinavir trough plasma concentrations are 3000-8000 ng/mL. A trend towards a 28 day mortality reduction was observed in COVID-19-infected patients treated with lopinavir/ritonavir. | 0305-7453,1460-2091 | 2020-07-26 02:00:00+02:00 | pubmed | Journal of Antimicrobial Chemotherapy | Minh Patrick Lê;Pierre Jaquet;Juliette Patrier;Paul-Henri Wicky;Quentin Le Hingrat;Marc Veyrier;Juliette Kauv;Romain Sonneville;Benoit Visseaux;Cédric Laouénan;Lila Bouadma;Diane Descamps;Etienne de Montmollin;Gilles Peytavin;Jean-François Timsit | 2020-07-21 02:00:00+02:00 | 32688374 | FR | AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.;INSERM, UMRS-1144, Université de Paris, 75006 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Medical and Infectious Diseases ICU (MI2), 75018 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Virology Department, 75018 Paris, France.;IAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Pharmacy Department, 75018 Paris, France.;AP-HP, Bichat Claude Bernard Hospital, Department of Epidemiology, Biostatistics and Clinical Research, CIC-EC 1425, 75018 Paris, France. | 1849 | ||||
| 10.1016/j.cgh.2020.07.050 | Journal Article | en | Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. | https://www.ncbi.nlm.nih.gov/pubmed/32721580 | Remdesivir is a nucleotide analog prodrug with antiviral activity against a broad spectrum of human coronavirus in cell cultures and mouse models including severe acute respiratory syndrome-associated coronavirus 2. Recently, the Food and Drug Agency (FDA) and the European Medicines Agency (EMA) recommended remdesivir for the treatment of patients hospitalized with severe coronavirus disease 2019 (COVID-19) infection.1,2 In the remdesivir clinical development program, some cases have raised concerns regarding potential hepatobiliary disorders associated with remdesivir, including in healthy volunteers and patients with COVID-19.3 In cohort studies of patients hospitalized for severe COVID-19 who were treated with compassionate-use remdesivir, elevated hepatic enzymes were the most frequent adverse drug reaction reported.4,5 In the first randomized, double-blind, placebo-controlled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19 (n = 237), a higher proportion of remdesivir recipients than placebo recipients had dosing prematurely stopped by the investigators because of adverse events including aminotransferase or bilirubin increases (3 versus 0).6 Although there is no signal from the available data of severe hepatotoxicity or drug-induced liver injury in clinical trials, the number of patients exposed to remdesivir was too limited. Therefore, there is an urgent need to investigate the hepatic safety profile associated with remdesivir in COVID-19 patients. | 1542-3565 | 2020-07-26 02:00:00+02:00 | pubmed | Clinical Gastroenterology and Hepatology | François Montastruc;Samuel Thuriot;Geneviève Durrieu | 2020-07-25 02:00:00+02:00 | 32721580 | FR | Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), Faculty of Medicine, Toulouse, France, INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France. Electronic address: francois.montastruc@univ-tlse3.fr.;Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), Faculty of Medicine, Toulouse, France.;Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), Faculty of Medicine, Toulouse, France, INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, Toulouse, France. | 1859 | ||||
| 10.1097/sla.0000000000004265 | Journal Article | en | Prone Positioning for Severe Acute Respiratory Distress Syndrome in COVID-19 Patients by a Dedicated Team: A Safe and Pragmatic Reallocation of Medical and Surgical Work Force in Response to the Outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32740251 | The aim of this study was to define whether rapidly reallocating health care workers not experienced with PP for performing PP in ICU is feasible and safe. | 0003-4932 | 2020-07-26 02:00:00+02:00 | pubmed | Annals of Surgery | Alexandre Doussot;Floriane Ciceron;Emilie Cerutti;Lucie Salomon du Mont;Laurent Thines;Gilles Capellier;Jean-Baptiste Pretalli;Philippe Evrard;Lucie Vettoretti;Patrick Garbuio;Anne-Sophie Brunel;Sebastien Pili-Floury;Zaher Lakkis | 2020-07-24 02:00:00+02:00 | 32740251 | FR | Department of Digestive Surgical Oncology - Liver Transplant Unit, University Hospital of Besançon, Besançon, France.;Department of Anesthesiology and Intensive Care, University Hospital of Besançon, Besancon, France.;CESIUS, University Simulation Center for Health, University of Franche-Comté, Besançon, France.;Department of Urology and Renal Transplantation, University Hospital of Besançon, Besançon, France.;Department of Vascular and Endovascular Surgery, University Hospital of Besançon, Besançon, France.;Department of Neurosurgery, University Hospital of Besançon, Besançon, France.;Medical Intensive Care Unit, University Hospital of Besançon, Besançon, France.;Clinical Methodology Center (CIC 1431 INSERM), University Hospital of Besançon, Besançon, France.;Department of Orthopedic and Traumatology Surgery, Plastic and Reconstruction Surgery, University Hospital of Besançon, Besançon, France.;Department of Infectious and Tropical Disease, University Hospital of Besançon, Besançon, France. | 1865 | ||||
| 10.1016/j.ebiom.2020.102890 | Journal Article | en | Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. | https://www.ncbi.nlm.nih.gov/pubmed/32707445 | The novel coronavirus (SARS-CoV-2) shares approximately 80% whole genome sequence identity and 66% spike (S) protein identity with that of SARS-CoV. The cross-neutralization between these viruses is currently not well-defined. | 2352-3964 | 2020-07-26 02:00:00+02:00 | pubmed | EBioMedicine | Ren Yang;Jiaming Lan;Baoying Huang;Ruhan A;Mingqing Lu;Wen Wang;Wenling Wang;Wenhui Li;Yao Deng;Gary Wong;Wenjie Tan | ACE2;COVID-19;CoV;Cross-neutralization;SARS-CoV-2 | 2020-07-21 02:00:00+02:00 | 32707445 | FR;CN;CA | NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China.;CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.;National Institute of Biological Sciences, Beijing 102206, China.;NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China. Electronic address: dengyao31@163.com.;CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China, Department of Microbiology-Infectiology and Immunology, Laval University, Quebec City G1V 4G2, Canada. Electronic address: garyckwong@ips.ac.cn.;NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China. Electronic address: tanwj28@163.com. | 1875 | |||
| 10.1038/s41431-020-0696-7 | Journal Article | en | COVID-19 and Down's syndrome: are we heading for a disaster? | https://www.ncbi.nlm.nih.gov/pubmed/32686759 | 1018-4813,1476-5438 | 2020-07-26 02:00:00+02:00 | pubmed | European Journal of Human Genetics | Rodolphe Dard;Nathalie Janel;François Vialard | 2020-07-20 02:00:00+02:00 | 32686759 | FR | Genetics Department, CHI Poissy St Germain-en-Laye, F-78300, Poissy, France. Rodolphe.dard@ght-yvelinesnord.fr.;Université Paris-Saclay, UVSQ, INRAE, ENVA, BREED, 78350, Jouy-en-Josas, France. Rodolphe.dard@ght-yvelinesnord.fr.;Université de Paris, BFA, UMR 8251, CNRS, F-75213, Paris, France. Rodolphe.dard@ght-yvelinesnord.fr.;Université de Paris, BFA, UMR 8251, CNRS, F-75213, Paris, France.;Genetics Department, CHI Poissy St Germain-en-Laye, F-78300, Poissy, France.;Université Paris-Saclay, UVSQ, INRAE, ENVA, BREED, 78350, Jouy-en-Josas, France. | 1881 | |||||
| 10.1186/s12933-020-01089-2 | Journal Article;Review | en | Issues for the management of people with diabetes and COVID-19 in ICU. | https://www.ncbi.nlm.nih.gov/pubmed/32690029 | In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act. | 1475-2840 | 2020-07-26 02:00:00+02:00 | pubmed | Antihypertensive Agents__therapeutic use;Betacoronavirus__pathogenicity;Biomarkers__blood;Blood Glucose__drug effects;Coronavirus Infections__diagnosis;Diabetes Mellitus__blood;Dyslipidemias__drug therapy;Host-Pathogen Interactions;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors__therapeutic use;Hypertension__drug therapy;Hypoglycemic Agents__adverse effects;Intensive Care Units;Pandemics;Pneumonia, Viral__diagnosis;Risk Assessment;Risk Factors;Treatment Outcome;COVID-19;severe acute respiratory syndrome coronavirus 2 | Cardiovascular Diabetology | Antonio Ceriello;Eberhard Standl;Doina Catrinoiu;Baruch Itzhak;Nebojsa M Lalic;Dario Rahelic;Oliver Schnell;Jan Škrha;Paul Valensi | COVID-19;Cardiovascular complications;Diabetes, Intensive Care Unit | 2020-07-20 02:00:00+02:00 | 32690029 | IL;FR;RO;HR;IT;RS;CZ;DE | IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan, Italy. antonio.ceriello@hotmail.it.;Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.;Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.;Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.;Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.;Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.;University of Zagreb School of Medicine, Zagreb, Croatia.;University of Osijek School of Medicine, Osijek, Croatia.;Department of Internal Medicine 3, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.;Unit of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, APHP, Paris Nord University, Sorbonne Paris Cité, CINFO, CRNH-IdF, Bondy, France. | 1883 | ||
| 10.1093/aje/kwaa155 | Journal Article | en | Commentary: Comment on "Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis". | https://www.ncbi.nlm.nih.gov/pubmed/32685969 | A major error is found in the article: Early Outpatient Treatment of Symptomatic, High_Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis, by Harvey Risch, which highlights how the work by Prof. Raoult should be read and considered. | 0002-9262,1476-6256 | 2020-07-26 02:00:00+02:00 | pubmed | American Journal of Epidemiology | Vincent Fleury | 2020-07-20 02:00:00+02:00 | 32685969 | FR | Laboratoire Matière et Systèmes Complexes Université de Paris CNRS UMR 7057 10 rue Alice Domont et Léonie Duquet Paris 75013 France. | 1886 | ||||
| 10.1183/13993003.01704-2020 | Editorial | en | A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals. | https://www.ncbi.nlm.nih.gov/pubmed/32586874 | 0903-1936,1399-3003 | 2020-07-26 02:00:00+02:00 | pubmed | Asthma__complications;Coronavirus Infections__complications;Humans;Pandemics__prevention & control;Pneumonia, Viral__complications;Pulmonary Disease, Chronic Obstructive__complications;COVID-19 | European Respiratory Journal | Teresa To;Giovanni Viegi;Alvaro Cruz;Luis Taborda-Barata;Innes Asher;Digambar Behera;Kazi Bennoor;Louis-Philippe Boulet;Jean Bousquet;Paulo Camargos;Claudia Conceiçao;Sandra Gonzalez Diaz;Asma El-Sony;Marina Erhola;Mina Gaga;David Halpin;Letitia Harding;Tamaz Maghlakelidze;Mohammad Reza Masjedi;Yousser Mohammad;Elizabete Nunes;Bernard Pigearias;Talant Sooronbaev;Rafael Stelmach;Ioanna Tsiligianni;Le Thi Tuyet Lan;Arunas Valiulis;Chen Wang;Sian Williams;Arzu Yorgancioglu | 2020-07-23 02:00:00+02:00 | 32586874 | CA;NZ;PT;KG;BR;GE;VN;SD;MX;FR;CN;GR;GB;US;IT;IR;SY;FI;MZ;BD;TR;LT;IN | The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada teresa.to@sickkids.ca.;CNR Institutes of Clinical Physiology, Pisa, and Biomedical Research and Innovation, Palermo, Italy.;ProAR Foundation and Federal University of Bahia, Salvador, Brazil.;Dept of Allergy and Clinical Immunology, Cova da Beira University Hospital Centre, Covilhã, Portugal.;Dept of Paediatrics and Child Health, University of Auckland, Auckland, New Zealand.;OSD, All India Institutes of Medical Sciences (AIIMS), Raebareli, India.;Dept of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.;Québec heart and Lung Institute, Laval University, Québec, QC, Canada.;MACVIA-France, Fondation Partenariale FMC VIA-LR, CHRU Arnaud de Villeneuve, Montpellier, France.;Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte, Brazil.;Instituto de Higiene e Medicina Tropical, Institute of Tropical Medicine and Hygiene, NOVA University of Lisbon, Lisbon, Portugal.;Hospital Universitario y Facultad de Medicina, Monterrey Nuevo Leon, Mexico.;Public Health Epidemiological Laboratory [Epi Lab] for Research and Development, Khartoum, Sudan.;Division of Health and Social Service, Finnish Institute for Health and Welfare, Helsinki, Finland.;7th Respiratory Medicine Dept, Asthma Cen, Athens Chest Hospital, Athens, Greece.;University of Exeter Medical School, College of Medicine and Health, Exeter, UK.;Asthma and Respiratory Foundation, Wellington, New Zealand.;Ivane Javakhishvili Tbilisi State University, Pulmonology Dept, Chapidze Emergency Cardiology Center, Tbilisi, Georgia.;Shahid Beheshti University of Medical Sciences, Tehran, Iran.;National Center for Research inn Chronic Respiratory Diseases, Tishreen University, School of Medicine, Latakia, Syria.;Pulmonology Dept, Maputo Central Hospital, Maputo, Mozambique.;Espace Francophone de Pneumologie, La Maison du poumon, Paris, France.;Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan.;ProAR Foundation and Heart Institute (InCor) Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.;International Primary Care Respiratory Group, Dept of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.;Respiratory Care Center, University Medical Center, Ho Chi Minh City, Vietnam.;Clinic of Children's Diseases, Institute of Clinical Medicine, and Dept of Public Health, Institute of Health Sciences, Vilnius University, Vilnius, Lithuania.;Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.;International Primary Care Respiratory Group, London, UK.;Dept of Pulmonology, Medical Faculty, Celal Bayar University, Manisa, Turkey. | 1893 | ||||
| 10.1016/j.amjmed.2020.06.025 | Case Reports | en | Multisystem Inflammatory Syndrome With Particular Cutaneous Lesions Related to COVID-19 in a Young Adult. | https://www.ncbi.nlm.nih.gov/pubmed/32712145 | 0002-9343 | 2020-07-26 02:00:00+02:00 | pubmed | The American Journal of Medicine | Parna Moghadam;Laurent Blum;Btissem Ahouach;Aguila Radjou;Céleste Lambert;Agnès Scanvic;Pascale Martres;Véronique Decalf;Edouard Bégon;Claude Bachmeyer | 2020-07-23 02:00:00+02:00 | 32712145 | FR;UNK | Unité de dermatologie, Hôpital René Dubos.;Service de réanimation, Hôpital René Dubos.;Unité d'infectiologie, Hôpital René Dubos.;Laboratoire de microbiologie, Hôpital René Dubos.;Service de cardiologie, Hôpital René Dubos, Pontoise, France.;Service de médecine interne, Hôpital Tenon (AP-HP), Paris, France. Electronic address: claude.bachmeyer@tnn.aphp.fr. | 1894 | |||||
| 10.1016/j.diabres.2020.108343 | Journal Article | en | The COVID19 Pandemic - Perspectives from People Living with Diabetes. | https://www.ncbi.nlm.nih.gov/pubmed/32711002 | During theunprecedented times of the COVID 19 pandemic,the livesof people with diabetes have been severely impacted. This article discusses the extent of this impact presenting the obstacles and challenges from the perspective of the patient,including specifics of practical day-to-day diabetes self-management routines. Since the COVID19 outbreak, certain psychosocial factors have been amplifieddue tothe manner in whichmainstream media and policy makers have carelessly emphasized the vulnerability of people with diabetes. The authors discuss the increased importance of support networksdue to people living in isolation and quarantine. Anewlayer of complexity has been added to the already difficult task of managing one's diabetes and ithasincreasedanxiety and stress levels. Guidelines and tips for people living with diabetes are discussed based on theauthors' personalexperiences as well as those ofthe diabetes associations they work with. | 0168-8227 | 2020-07-26 02:00:00+02:00 | pubmed | Diabetes Research and Clinical Practice | Rose Kyle Jacques;Scibilia Renza | 2020-07-22 02:00:00+02:00 | 32711002 | AU;FR;BE | International Diabetes Federation, Brussels, Belgium, INSEAD Healthcare, Institut Européen d'Administration des Affaires, Fontainebleau, France.;Diabetes Australia, Melbourne, Australia. | 1898 | ||||
| 10.1016/j.clim.2020.108545 | Journal Article;Review | en | Micronutrients as immunomodulatory tools for COVID-19 management. | https://www.ncbi.nlm.nih.gov/pubmed/32710937 | COVID-19 rapidly turned to a global pandemic posing lethal threats to overwhelming health care capabilities, despite its relatively low mortality rate. The clinical respiratory symptoms include dry cough, fever, anosmia, breathing difficulties, and subsequent respiratory failure. No known cure is available for COVID-19. Apart from the anti-viral strategy, the supports of immune effectors and modulation of immunosuppressive mechanisms is the rationale immunomodulation approach in COVID-19 management. Diet and nutrition are essential for healthy immunity. However, a group of micronutrients plays a dominant role in immunomodulation. The deficiency of most nutrients increases the individual susceptibility to virus infection with a tendency for severe clinical presentation. Despite a shred of evidence, the supplementation of a single nutrient is not promising in the general population. Individuals at high-risk for specific nutrient deficiencies likely benefit from supplementation. The individual dietary and nutritional status assessments are critical for determining the comprehensive actions in COVID-19. | 1521-6616 | 2020-07-26 02:00:00+02:00 | pubmed | Clinical Immunology | Amin Gasmi;Torsak Tippairote;Pavan Kumar Mujawdiya;Massimiliano Peana;Alain Menzel;Maryam Dadar;Asma Gasmi Benahmed;Geir Bjørklund | COVID-19;Immunomodulation;Nutrients;SARs-CoV-2;Trace elements;Vitamins | 2020-07-22 02:00:00+02:00 | 32710937 | FR;NO;TH;IT;IR;IN | Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée, Villeurbanne, France.;Philosophy Program in Nutrition, Faculty of Medicine, Ramathibodi Hospital and Institute of Nutrition, Mahidol University, Bangkok, Thailand, Nutritional and Environmental Medicine Department, BBH Hospital, Bangkok, Thailand.;Birla Institute of Technology and Science -Pilani, Hyderabad, India.;Department of Chemistry and Pharmacy, University of Sassari, Italy.;Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.;Académie Internationale de Médecine Dentaire Intégrative, Paris, France.;Council for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway. Electronic address: bjorklund@conem.org. | 1900 | |||
| Letter | en | Lung scintigraphy for pulmonary embolism diagnosis during the COVID-19 pandemic: does the benefit-risk ratio really justify omitting the ventilation study? | https://www.ncbi.nlm.nih.gov/pubmed/32700057 | 2020-07-26 02:00:00+02:00 | pubmed | Pierre-Yves Le Roux;Grégoire Le Gal;Pierre-Yves Salaun | 2020-07-22 02:00:00+02:00 | 32700057 | FR;CA | Service de médecine nucléaire, CHRU de Brest, EA3878 (GETBO), Université de Brest, CHRU Morvan, Médecine nucléaire, 2 avenue Foch, 29609, Brest Cedex, France. pierre-yves.leroux@chu-brest.fr.;Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.;Service de médecine nucléaire, CHRU de Brest, EA3878 (GETBO), Université de Brest, CHRU Morvan, Médecine nucléaire, 2 avenue Foch, 29609, Brest Cedex, France. | 1902 | ||||||||
| Letter | en | The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32513798 | 2020-07-26 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Azithromycin__therapeutic use;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Deception;Drug Combinations;France;Humans;Hydroxychloroquine__therapeutic use;Lopinavir__therapeutic use;Pandemics;Pneumonia, Viral__drug therapy;Ritonavir__therapeutic use;Scholarly Communication;COVID-19;COVID-19 drug treatment;severe acute respiratory syndrome coronavirus 2 | François Danion;Yvon Ruch;Marion Fourtage;Charlotte Kaeuffer;Valentin Greigert;Nicolas Lefebvre;Joris Muller;Thierry Nai;Yves Hansmann | COVID-19;consumption;hydroxychloroquine;lopinavir–ritonavir;treatment | 2020-07-22 02:00:00+02:00 | 32513798 | FR | CHU de Strasbourg, Service de Maladies Infectieuses et Tropicales, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France francois.danion@chru-strasbourg.fr.;CHU de Strasbourg, Service de Maladies Infectieuses et Tropicales, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France.;CHU de Strasbourg, Service Pharmacie-Stérilisation, Strasbourg, France.;CHU de Strasbourg, Service de Médecine Interne, NHC, Strasbourg, France.;CHU de Strasbourg, Service de Santé Publique, Strasbourg, France. | 1906 | ||||||
| 10.1007/s42399-020-00423-9 | Journal Article;Review | en | The Multifaceted Engagement of the Dermatologist in the Covid-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32838174 | Dermatologists worldwide are engaged in the struggle against Covid-19. They limited their daily activity to priority cases, intending to reduce the exposure of patients in the waiting room. Teledermatology was recommended as an efficient alternative to assure patients' needs and safety. At the same time, dermatologists had to manage the skin injuries of frontline healthcare workers; to characterize the cutaneous manifestations of Covid-19; to assess the optimal treatment of patients with skin diseases, especially those taking immunomodulating and immunosuppressant molecules; and finally to promote balanced precautions in healthy persons. | 2523-8973 | 2020-07-26 02:00:00+02:00 | pubmed | SN Comprehensive Clinical Medicine | Boutros Soutou;Roland Tomb | Covid-19;Cutaneous manifestations;Dermatitis;Teledermatology | 2020-07-22 02:00:00+02:00 | 32838174 | FR;LB | Dermatology Department, School of Medicine, Université Saint-Joseph, Beirut, Lebanon.;Hôtel-Dieu de France Hospital, Achrafieh, Bvd Alfred Naccache, Beirut, 16-6830 Lebanon. | 1907 | |||
| 10.1093/cid/ciaa1044 | Journal Article | en | Systematic SARS-CoV-2 screening at hospital admission in children:a French prospective multicenter study. | https://www.ncbi.nlm.nih.gov/pubmed/32710743 | To assess the relevance of systematic SARS-CoV-2 screening of all children admitted to hospital, we conducted a prospective multicenter study including 438 consecutive hospitalized children. A symptom-based SARS-CoV-2 testing strategy failed to identify 45% (95%CI [24; 68]) of hospitalized children infected by SARS-CoV-2. To limit intra-hospital transmission, a systematic screening of children admitted to hospital should be considered. | 1058-4838,1537-6591 | 2020-07-26 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Julie Poline;Jean Gaschignard;Claire Leblanc;Fouad Madhi;Elsa Foucaud;Elodie Nattes;Albert Faye;Stéphane Bonacorsi;Patricia Mariani;Emmanuelle Varon;Mounira Smati-Lafarge;Marion Caseris;Romain Basmaci;Noémie Lachaume;Naïm Ouldali | 2020-07-25 02:00:00+02:00 | 32710743 | FR | Department of General Pediatrics, Pediatric Infectious Disease and Internal Medicine, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Université de Paris, INSERM, Center for Research on Inflammation, INSERM UMR, Paris, France.;Université de Paris, Infection, Antimicrobiens, Modélisation, Evolution (IAME), INSERM UMR, Paris, France.;Université de Paris, UFR de Médecine Paris Nord, Paris, France.;Department of General Pediatrics, Centre Hospitalier Intercommunal de Créteil, Créteil, France.;Department of Microbiology, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of General Pediatrics, Jean Verdier University Hospital, Assistance Publique-Hôpitaux de Paris, Bondy, France.;Université de Paris, INSERM UMR, ECEVE, Paris, France.;Department of microbiology, Centre Hospitalier Intercommunal de Créteil, Créteil, France.;National reference center for pneumococci, Créteil, France.;Service de Pédiatrie-Urgences, AP-HP, Hôpital Louis-Mourier, Colombes, France.;ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France. | 1911 | ||||
| 10.1083/jcb.202006005 | Journal Article;Research Support, Non-U.S. Gov't;Review | en | Role of the early secretory pathway in SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32725137 | Similar to other RNA viruses, SARS-CoV-2 must (1) enter a target/host cell, (2) reprogram it to ensure its replication, (3) exit the host cell, and (4) repeat this cycle for exponential growth. During the exit step, the virus hijacks the sophisticated machineries that host cells employ to correctly fold, assemble, and transport proteins along the exocytic pathway. Therefore, secretory pathway-mediated assemblage and excretion of infective particles represent appealing targets to reduce the efficacy of virus biogenesis, if not to block it completely. Here, we analyze and discuss the contribution of the molecular machines operating in the early secretory pathway in the biogenesis of SARS-CoV-2 and their relevance for potential antiviral targeting. The fact that these molecular machines are conserved throughout evolution, together with the redundancy and tissue specificity of their components, provides opportunities in the search for unique proteins essential for SARS-CoV-2 biology that could also be targeted with therapeutic objectives. Finally, we provide an overview of recent evidence implicating proteins of the early secretory pathway as potential antiviral targets with effective therapeutic applications. | 0021-9525,1540-8140 | 2020-08-02 02:00:00+02:00 | pubmed | Antiviral Agents__therapeutic use;Betacoronavirus__drug effects;Coronavirus Infections__drug therapy;Humans;Pandemics;Pneumonia, Viral__drug therapy;Secretory Pathway__drug effects;Virus Replication__drug effects;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Cell Biology | Daria Sicari;Aristotelis Chatziioannou;Theodoros Koutsandreas;Roberto Sitia;Eric Chevet | 2020-07-30 02:00:00+02:00 | 32725137 | FR;IT;GR | Inserm U1242, Université de Rennes, Rennes, France.;Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France.;Università Vita-Salute San Raffaele, Milan, Italy.;e-NIOS Applications PC, Kallithea-Athens, Greece.;Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. | 1912 | |||
| 10.1093/pubmed/fdaa112 | Journal Article | en | NICE public health guidance update. | https://www.ncbi.nlm.nih.gov/pubmed/32735011 | This article highlights recent guidance from the National Institute for Health and Care Excellence (NICE). It highlights the organization's response to the COVID-19 pandemic and then provides a spotlight on workplace health in the context of long-term sickness absence and capability to work. It discusses some of the actions that need to be taken by a range of stakeholders in order to implement NICE guidance in this area and aid employees in ensuring good workplace health. The NICE guidance on workplace health, discussed in this article, predates the current pandemic. Comment is made specifically on fitness for work assessments, where the COVID-19 pandemic has posed a range of unique clinical challenges. | 1741-3842,1741-3850 | 2020-08-02 02:00:00+02:00 | pubmed | Journal Of Public Health | Fizzah Ali;Mark Gabbay;Nick Baillie | 2020-07-30 02:00:00+02:00 | 32735011 | FR;GB | NICE, London SW1A 2BU, UK.;University of Liverpool, Liverpool L69 3BX, UK.;Leadership and Engagement, NICE, London SW1A 2BU, UK. | 1922 | ||||
| 10.1097/hs9.0000000000000433 | Journal Article;Review | en | Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. | https://www.ncbi.nlm.nih.gov/pubmed/32803133 | In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others. | 2572-9241 | 2020-08-02 02:00:00+02:00 | pubmed | HemaSphere | Dipti Talaulikar;Ranjana H Advani;Andrew R Branagan;Christian Buske;Meletios A Dimopoulos;Shirley D'Sa;Maria J Kersten;Veronique Leblond;Monique C Minnema;Roger G Owen;Maria Lia Palomba;Alessandra Tedeschi;Judith Trotman;Marzia Varettoni;Josephine M Vos;Steven P Treon;Efstathios Kastritis;Jorge J Castillo | 2020-07-30 02:00:00+02:00 | 32803133 | FR;GR;GB;US;IT;AU;NL;DE | Department of Hematology, Canberra Hospital and College of Health and Medicine, Australian National University, Canberra, Australia.;Department of Medicine, Stanford University Medical Center, Stanford, California, USA.;Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.;Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany.;Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.;Waldenström Clinic, Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.;Department of Hematology, Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), University of Amsterdam, Amsterdam, The Netherlands.;Service of Clinical Hematology, Pitié-Salpêtrière Hospital, APHP, Sorbonne University, Paris, France.;Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.;Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.;Lymphoma Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA.;Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.;Department of Haematology, Concord Hospital, Department of Medicine, University of Sydney, Sydney, Australia.;Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.;Department of Hematology and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam UMC, location AMC, Amsterdam, The Netherlands.;Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. | 1928 | ||||
| 10.1111/acem.14096 | Journal Article | en | Association between Pulmonary Embolism and COVID-19 in ED patients Undergoing CTPA: the PEPCOV international retrospective study. | https://www.ncbi.nlm.nih.gov/pubmed/32734624 | There have been reports of pro-coagulant activity in patients with COVID-19. Whether there is an association between pulmonary embolism (PE) and COVID-19 in the emergency department (ED) is unknown. The aim of this study was to assess whether COVID-19 is associated with PE in ED patients that underwent a CTPA? | 1069-6563,1553-2712 | 2020-08-02 02:00:00+02:00 | pubmed | Academic Emergency Medicine | Yonathan Freund;Marie Drogrey;Òscar Miró;Alessio Marra;Anne-Laure Féral-Pierssens;Andrea Penaloza;Barbara A Lara Hernandez;Sebastien Beaune;Judith Gorlicki;Prabakar Vattinada Ayar;Jennifer Truchot;Barbara Pena;Alfons Aguirre;Florent Fémy;Nicolas Javaud;Anthony Chauvin;Tahar Chouihed;Emmanuel Montassier;Pierre-Géraud Claret;Céline Occelli;Mélanie Roussel;Fabien Brigant;Sami Ellouze;Pierrick Le Borgne;Said Laribi;Tabassome Simon;Olivier Lucidarme;Marine Cachanado;Ben Bloom | 2020-07-30 02:00:00+02:00 | 32734624 | FR;CA;CL;GB;US;IT;ES;BE | Sorbonne Université, Paris, France.;Emergency department, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris (APHP), APHP.SU, Paris, France.;Emergency Departement, Hospital Clínic, Barcelona, Catalonia, Spain.;Emergency Department, Centro EAS - Emergenza Alta Specializzazione, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.;Charles Lemoyne - Saguenay Lac Saint-Jean research center on health innovations (CR CSIS), Sherbrooke University, Longueuil, Québec, Canada.;Emergency Department, european Georges Pompidou hospital, APHP, Paris, France.;Service des Urgences, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Neuve, Belgium.;Emergency Medicine Section. Pontificia, Universidad Católica de Chile, Santiago, Chile.;Emergency department, Hôpital Ambroise-Paré, APHP, Boulogne, inserm UMR 1144, université Paris Centre, Paris, France.;Emergency Department, SAMU 93, Avicenne University Hospital, APHP.HUPSSD, Bobigny, France. Inserm UMR-S 942, Sorbonne Paris Nord University, Bobigny, France.;Emergency Department, University Hospital of Beaujon, APHP, Clichy, France,UMR-S 942, INSERM, MASCOT, Paris , University, Paris, France.;Emergency Department, Cochin Hospital, Hôpitaux Universitaire Paris Centre, APHP, Paris, France.;Emergency Department, Hospital General Universitario de Alicante, Alicante, Spain.;Emergency Department, Hospital del Mar, Barcelona, Catalonia, Spain.;Emergency department, Georges Pompidou European Hospital, APHP, Université de Paris, Paris, France. Toxicology and Chemical Risks Department, French Armed Forces Biomedical Institute, Bretigny-Sur-Orges, France.;Emergency Department, Louis Mourier Hospital, University of Paris, APHP.North, Paris, France.;Emergency Department, Hopital Lariboisière, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine, Université de Paris, Paris, France.;Université de Lorraine, Emergency Department, University Hospital of Nancy, Centre d'Investigations Cliniques- 1433, and Inserm UMR_S 1116, F-CRIN INI-CRCT, Nancy, France.;Department of Emergency Medicine, CHU Nantes, 44000-Nantes, France, MiHAR Laboratory, Université de Nantes, 44000, Nantes, France.;Department of Anesthesia Resuscitation Pain Emergency Medicine, Nîmes University Hospital, France.;Emergency Department, CHU Pasteur 2, Nice, France , University Nice Côte d'Azur, France.;Emergency Department, Rouen University Hospital, F-76000, Rouen, France.;Emergency department, Hôpital Saint-Antoine, APHP.SU, Paris, France.;Emergency department, Hôpital Saint-Louis, APHP, Paris, France.;Emergency Department, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France and INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative NanoMedicine (RNM), Fédération de Médecine Translationnelle (FMTS), University of Strasbourg, Strasbourg, France.;Emergency Medicine Department,School of Medicine and CHU Tours, Tours University, France.;Clinical research plateform(URC-CRC-CRB), AP-HP Hôpital Saint-Antoine, Paris, France.;APHP-Sorbonne Universités, Pitié salpêtrière hospital, Radiology department and UPMC Univ Paris 06, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, F-75013, Paris, France.;Emergency Department, Royal London Hospital, Barts Health NHS Trust, London, UK. | 1936 | ||||
| 10.1016/j.jcv.2020.104571 | Journal Article | en | Evaluation of the Quotient® MosaiQ™ COVID-19 antibody microarray for the detection of IgG and IgM antibodies to SARS-CoV-2 virus in humans. | https://www.ncbi.nlm.nih.gov/pubmed/32750664 | The MosaiQ® COVID-19 Antibody test fulfills the minimal requirements for serological testing according to the French regulation. | 1386-6532 | 2020-08-02 02:00:00+02:00 | pubmed | Journal of Clinical Virology | Christophe Martinaud;Carine Hejl;Alexandre Igert;Christine Bigaillon;Céline Bonnet;Audrey Mérens;Audrey Wolf;Vincent Foissaud;Isabelle Leparc-Goffart | COVID-19;SARS-CoV-2;Serology | 2020-07-31 02:00:00+02:00 | 32750664 | FR | Blood Donation Screening Laboratory, French Military Blood Institute, Clamart, France. Electronic address: christophe.martinaud@intradef.gouv.fr.;Laboratoire de Biologie Médicale, Military Medical Center Percy, Clamart, France.;Institut de Recherche Biomédicales des Armées, Brétigny, France.;Laboratoire de Biologie Médicale, Military Medical Center Bégin, Saint-Mandé, France.;Laboratoire de Biologie Médicale, Military Medical Center Laveran, Marseille, France.;Unité de Virologie, Institut de Recherche Biomédicales des Armées, Marseille, France. | 1938 | |||
| Letter | en | Treatment Impact on COVID-19 evolution in hemodialysis patients. | https://www.ncbi.nlm.nih.gov/pubmed/32750459 | 2020-08-02 02:00:00+02:00 | pubmed | Sylvain Chawki;Albert Buchard;Hamza Sakhi;Karim Dardim;Karim El Sakhawi;Mokhtar Chawki;Henri Boulanger;Tomek Kofman;Djamal Dahmane;Philippe Rieu;David Attaf;Salima Ahriz-Saksi;Frederic Besson;Remy Boula;Ali Hafi;Afshin Massoumi;Ali Zineddine Diddaoui;Luc Fromentin;Patrick Michaut;Rachida Nebbad;Jean-François Desassis;Laurence Nicolet;Abderrahmane Ghazali;Julie Sohier-Attias;Larbi Lamriben;Arezki Adem;Emmanuel Dupuis;Mohamad-Khair Rifard;Dominique Joly;Khalil El Karoui;Philippe Attias | ACE Inhibitors;COVID-19;SARS-CoV-2;angiotensin;hemodialysis | 2020-08-01 02:00:00+02:00 | 32750459 | FR;GB | INSERM Unité U944, Paris, France.;BIOS Health, Cambridge, UK.;AP-HP, Hôpital henri Mondor, Department of Nephrology, INSERM Unité U955, Créteil, France.;ALURAD, ISLE, France.;Clinique Claude Bernard, Department of Nephrology and Dialysis, Ermont, France.;Clinique de l'Estrée, Department of Nephrology and Dialysis, Stains, France.;ANDRA, Paris, France.;Hôpital Privé Nord Parisien, Department of Nephrology and Dialysis, Sarcelles, France.;FRESENIUS, Paris, France.;Clinique Lambert, Dialysis, La Garenne-Colombes, France.;Clinique Internationale du Parc Monceau, Nephrology and Dialysis, Paris, France.;Centre d'autodialyse le Figuier, Drancy France.;Centre Edouard Rist, Nephrology and Dialysis, Paris, France.;Groupe Hospitalier Public Sud de l'Oise, Dialysis, Creil, France.;Centre de Néphrologie SIRTA, Argenteuil, France.;Clinique les Martinets, Dialysis, Rueil Malmaison, France.;American Hospital of Paris, Nephrology and Dialysis, Neuilly-sur- Seine, France.;Centre Hospitalier des Quatre Villes, Nephrology and dialysis, Saint Cloud, France.;AP-HP, Hôpital Necker-Enfants Malades, Department of Adult Nephrology, Paris, France.;AP-HP, Hôpital henri Mondor, Department of Nephrology, INSERM Unité U955, Créteil, France. Electronic address: khalil.el-karoui@inserm.fr.;Hôpital Privé Nord Parisien, Department of Nephrology and Dialysis, Sarcelles, France. Electronic address: attias.philippe@gmail.com. | 1946 | |||||||
| 10.1016/j.humpath.2020.07.023 | Journal Article;Review | en | A review of the main histopathological findings in the Coronavirus Disease 2019 (COVID-19). | https://www.ncbi.nlm.nih.gov/pubmed/32750378 | Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has been declared by the WHO as an emerging public health problem of global importance and classified as a pandemic. SARS-CoV-2 infection can result in diverse, multi-organ pathology, the most significant being in the lungs (diffuse alveolar damage in its different phases, microthrombi, bronchopneumonia, necrotizing bronchiolitis, viral pneumonia), heart (lymphocytic myocarditis), kidney (acute tubular injury), central nervous system (microthrombi, ischemic necrosis, acute hemorrhagic infarction, congestion, and vascular edema), lymph nodes (hemophagocytosis and histiocytosis), bone marrow (hemophagocytosis) and vasculature (deep vein thrombosis). An understanding of the spectrum and frequency of histologic findings in COVID-19 disease is essential for gaining a better understanding of disease pathophysiology and its ongoing impact on public health. To this end, we conducted a systematic meta-analysis of histopathologic observations to date and review the reported findings. | 0046-8177 | 2020-08-02 02:00:00+02:00 | pubmed | Human Pathology | Walter O Vasquez-Bonilla;Roberto Orozco;Víctor Argueta;Manuel Sierra;Lysien I Zambrano;Fausto Muñoz-Lara;Dennis Salomón López-Molina;Kovy Arteaga-Livias;Zachary Grimes;Clare Bryce;Alberto Paniz-Mondolfi;Alfonso J Rodríguez-Morales | Autopsy;COVID-19;Histopathology;Pathology;SARS-CoV-2 | 2020-08-01 02:00:00+02:00 | 32750378 | FR;HN;GT;CO;VE;US;PE | Department of Pathology, Hospital General San Juan de Dios, Guatemala City, Guatemala, Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19), Pereira, Risaralda, Colombia.;Department of Pathology, Hospital General San Juan de Dios, Guatemala City, Guatemala.;Central American Technological University, Tegucigalpa, Honduras.;Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19), Pereira, Risaralda, Colombia, Department of Morphological Sciences, School of Medical, Sciences, Universidad Nacional Autónoma de Honduras (UNAH), Tegucigalpa, Honduras.;Department of Internal Medicine, Hospital Escuela, Tegucigalpa, Honduras, Department of Internal Medicine, School of Medical, Sciences, Universidad Nacional Autónoma de Honduras (UNAH), Tegucigalpa, Honduras.;Institute Pasteur, Paris, France, Health Biology: Microbiology and Immunology, Faculté de Sciences, Université de Montpellier, France.;Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19), Pereira, Risaralda, Colombia, Facultad de Medicina, Universidad Nacional Hermilio Valdizán, Huánuco, Peru, Master of Clinical Epidemiology and Biostatistics, Universidad Científica Del Sur, Lima, Peru.;Icahn School of Medicine at Mount Sinai, New York, USA.;Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19), Pereira, Risaralda, Colombia, Icahn School of Medicine at Mount Sinai, New York, USA, Laboratorio de Señalización Celular y Bioquímica de Parásitos, Instituto de Estudios Avanzados (IDEA), Caracas, Caracas, Venezuela, Academia Nacional de Medicina, Caracas, Venezuela, Instituto de Investigaciones Biomedicas IDB / Incubadora Venezolana de La Ciencia, Cabudare, Edo. Lara, Venezuela.;Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19), Pereira, Risaralda, Colombia, Master of Clinical Epidemiology and Biostatistics, Universidad Científica Del Sur, Lima, Peru, Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Risaralda, Colombia, Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de Las Americas, Pereira, Risaralda, Colombia. Electronic address: arodriguezm@utp.edu.co. | 1949 | |||
| 10.1007/s00520-020-05658-9 | Journal Article | en | COVID-19 management in a cancer center: the ICU storm. | https://www.ncbi.nlm.nih.gov/pubmed/32734394 | A novel coronavirus, SARS-CoV-2, was first reported as a respiratory illness in December 2019 in Wuhan, China. Since then, the World Health Organization (WHO) Emergency Committee declared a global health. COVID-19 has now spread worldwide and is responsible of more than 472,216 persons, out of 9,100,090 officially diagnosed worldwide since 23 of June. In the context of cancer patients, COVID-19 has a severe impact, regarding pulmonary infection but also cancer treatments in this fragile and immunocompromised population, and ICU admission for cancer patients in the context of COVID-19 requires ethical and clinical consideration. In our cancer center, intensivists, oncologists, pharmacists, and hospital administrators had to prepare for a substantial increase in critical care bed capacity (from 10 ICU beds, 6 medical intensive care beds, and 12 surgical intensive care beds, bed capacity was increased to 28 medical intensive care beds with ventilating capacity) and to adapt infrastructure (i.e., ICU beds), supplies (i.e., drugs, ventilators, protective materials), and staff (i.e., nurses and medical staff). Overall, thirty-three COVID-19 patients were admitted in our ICU, 17 cancer-free and 16 with cancer, and 23 required mechanical ventilation, resulting in 4 deaths (of them two patients with cancer). We report here management of a dedicated intensive care unit of a cancer center during the COVID-19 infection pandemic, considering resource allocation and redistribution of healthcare workers. | 0941-4355,1433-7339 | 2020-08-02 02:00:00+02:00 | pubmed | Supportive Care in Cancer | Alice Boilève;Annabelle Stoclin;Fabrice Barlesi;Florent Varin;Stéphanie Suria;André Rieutord;François Blot;Florence Netzer;Florian Scotté | COVID-19;Cancer;Coronavirus;Intensive care unit;Management;Pandemic | 2020-07-31 02:00:00+02:00 | 32734394 | FR | Medical Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France. alice.boileve@gmail.com.;Intensive Care Unit, Gustave Roussy Cancer Campus, Villejuif, France.;Interdisciplinary Cancer Course Department (DIOPP), Gustave Roussy Cancer Campus, Villejuif, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.;Department of Anesthesia, Gustave Roussy Cancer Campus, Villejuif, France.;Pharmacy Department, Gustave Roussy Cancer Campus, Villejuif, France. | 1953 | |||
| 10.1016/j.ebiom.2020.102915 | Journal Article | en | Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. | https://www.ncbi.nlm.nih.gov/pubmed/32747185 | The serologic response of individuals with mild forms of SARS-CoV-2 infection is poorly characterized. | 2352-3964 | 2020-08-02 02:00:00+02:00 | pubmed | EBioMedicine | Samira Fafi-Kremer;Timothée Bruel;Yoann Madec;Rebecca Grant;Laura Tondeur;Ludivine Grzelak;Isabelle Staropoli;François Anna;Philippe Souque;Sandrine Fernandes-Pellerin;Nathalie Jolly;Charlotte Renaudat;Marie-Noëlle Ungeheuer;Catherine Schmidt-Mutter;Nicolas Collongues;Alexandre Bolle;Aurélie Velay;Nicolas Lefebvre;Marie Mielcarek;Nicolas Meyer;David Rey;Pierre Charneau;Bruno Hoen;Jérôme De Seze;Olivier Schwartz;Arnaud Fontanet | Antibodies;Mild covid-19;Neutralization;Serology;sars-cov-2 | 2020-07-31 02:00:00+02:00 | 32747185 | FR;UNK | CHU de Strasbourg, Laboratoire de virologie, F-67091 Strasbourg, France, Université de Strasbourg, INSERM, IRM UMR_S 1109, Strasbourg, France. Electronic address: samira.fafi-kremer@chru-strasbourg.fr.;Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France, CNRS UMR 3569, Paris, France, Vaccine Research Institute, Creteil, France. Electronic address: timothee.bruel@pasteur.fr.;Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.;Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France, CNRS UMR 3569, Paris, France, Vaccine Research Institute, Creteil, France, Université de Paris, Sorbonne Paris Cité, Paris, France.;Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France, CNRS UMR 3569, Paris, France, Vaccine Research Institute, Creteil, France.;Pasteur-TheraVectys joined unit.;Molecular Virology & Vaccinology Unit, Department of Virology, Institut Pasteur, Paris, France.;Center for Translational Science, Institut Pasteur, Paris, France.;Center for Translational Science, Institut Pasteur, Paris, France, Clinical Investigation & Access to BioResources Platform, Institut Pasteur, Paris, France.;Centre d'investigation Clinique INSERM 1434, CHU Strasbourg, France.;Centre d'investigation Clinique INSERM 1434, CHU Strasbourg, France, CHU de Strasbourg, Service de Neurologie, F-67091 Strasbourg, France.;CHU de Strasbourg, Laboratoire de virologie, F-67091 Strasbourg, France, Université de Strasbourg, INSERM, IRM UMR_S 1109, Strasbourg, France.;CHU de Strasbourg, Service des infectieuses et tropicales, F-67091 Strasbourg, France.;CHU de Strasbourg, Service de santé Publique, GMRC, F-67091 Strasbourg, France.;CHU de Strasbourg, Service de santé Publique, GMRC, F-67091 Strasbourg, France, Université de Strasbourg, CNRS, iCUBE UMR 7357, Strasbourg, France.;CHU de Strasbourg, Pôle SMO, le Trait d'Union, F-67091 Strasbourg, France.;Pasteur-TheraVectys joined unit, Molecular Virology & Vaccinology Unit, Department of Virology, Institut Pasteur, Paris, France.;Direction de la recherche médicale, Institut Pasteur, Paris, France.;Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France, Conservatoire National des Arts et Métiers, PACRI Unit, Paris, France. | 1954 | |||
| 10.1016/j.ejphar.2020.173450 | Journal Article | en | Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32739174 | Virus onslaughts continue to spread fear and cause rampage across the world every now and then. The twenty first century is yet again witnessing a gross global pandemic, Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Globally no vaccines or drug specific to COVID-19 is available. Corona viruses have been in mutual relationship with humans and other hosts over many decades though aggressive zoonotic strains have caused havoc. Zoonotic emergent corona viruses prior to SARS-COV-2 included severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), with the former leading to aggressive infectious spread and the later with high mortality rate. Although they emerged in the early period of the twenty first century, resilient biomedical and expertise in pharmaceutical domain could not appropriate any proprietary therapeutics. Studies envisaged towards curtailing their spread employed different stages of the virus life cycle with all zoonotic coronaviruses (CoVs) sharing genomic and structural similarities. Hence the strategies against SARS-CoV and MERS-CoV could prove effective against the recent outbreak of SAR-CoV-2. The review unravels key events involved in the lifecycle of SARS-CoV-2 while highlighting the possible avenues of therapy. The review also holds the scope in better understanding a broad-spectrum antivirals, monoclonal antibodies and small molecule inhibitors against viral glycoproteins, host cell receptor, viral mRNA synthesis, RNA-dependent RNA polymerase (RdRp) and viral proteases in order to design and develop antiviral drugs for SARS-CoV-2. | 0014-2999 | 2020-08-02 02:00:00+02:00 | pubmed | European Journal of Pharmacology | Gayathri Krishna;Vinod Soman Pillai;Mohanan Valiya Veettil | Antiviral targets;Antivirals;COVID-19;SARS-CoV-2;Therapeutics | 2020-07-31 02:00:00+02:00 | 32739174 | FR;IN | Virology Laboratory, Department of Biotechnology, Cochin University of Science and Technology, Cochin, 682022, Kerala, India.;Virology Laboratory, Department of Biotechnology, Cochin University of Science and Technology, Cochin, 682022, Kerala, India. Electronic address: mohanwiwi@gmail.com. | 1963 | |||
| 10.1093/fampra/cmaa069 | Journal Article | en | Is a COVID-19 prediction model based on symptom tracking through an app applicable in primary care? | https://www.ncbi.nlm.nih.gov/pubmed/32719842 | 1460-2229 | 2020-08-02 02:00:00+02:00 | pubmed | Family Practice | Dagmar M Haller;Paul Sebo;Benoit Tudrej;Hubert Maisonneuve | 2020-07-28 02:00:00+02:00 | 32719842 | FR;CH | Primary Care Unit, Faculty of Medicine, University of Geneva, Geneva, Switzerland.;University College of General Medicine, University Claude Bernard Lyon 1, Lyon, France.;Mermoz Primary Health Centre, Lyon, France. | 1967 | |||||
| 10.1186/s13054-020-03172-2 | Journal Article | en | Provision of ECPR during COVID-19: evidence, equity, and ethical dilemmas. | https://www.ncbi.nlm.nih.gov/pubmed/32718340 | The use of extracorporeal cardiopulmonary resuscitation (ECPR) to restore circulation during cardiac arrest is a time-critical, resource-intensive intervention of unproven efficacy. The current COVID-19 pandemic has brought additional complexity and significant barriers to the ongoing provision and implementation of ECPR services. The logistics of patient selection, expedient cannulation, healthcare worker safety, and post-resuscitation care must be weighed against the ethical considerations of providing an intervention of contentious benefit at a time when critical care resources are being overwhelmed by pandemic demand. | 1364-8535 | 2020-08-02 02:00:00+02:00 | pubmed | Bioethical Issues;Cardiopulmonary Resuscitation__methods;Coronavirus Infections__epidemiology;Evidence-Based Practice;Extracorporeal Membrane Oxygenation;Health Equity;Heart Arrest__therapy;Humans;Pandemics;Pneumonia, Viral__epidemiology;COVID-19 | Critical Care | Elliott Worku;Denzil Gill;Daniel Brodie;Roberto Lorusso;Alain Combes;Kiran Shekar | 2020-07-27 02:00:00+02:00 | 32718340 | FR;AU;NL;US | Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia. Elliott.worku@health.qld.gov.au.;University of Queensland, Brisbane, Queensland, Australia. Elliott.worku@health.qld.gov.au.;Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia.;Center for Acute Respiratory Failure, New York-Presbyterian Hospital, New York, USA.;Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, New York, USA.;Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.;Institute of Cardiometabolism and Nutrition, Sorbonne Universités, UPMC Univ Paris 06, 75651, Paris Cedex 13, France.;Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, 75651, Paris Cedex 13, France.;University of Queensland, Brisbane, Queensland, Australia.;Bond University, Gold Coast, Queensland, Australia.;Critical Care Research Group and Centre of Research Excellence for Advanced Cardio-respiratory Therapies Improving OrgaN Support (ACTIONS), Brisbane, Australia. | 1972 | |||
| 10.1016/j.ejca.2020.07.009 | Journal Article | en | Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management? | https://www.ncbi.nlm.nih.gov/pubmed/32805640 | The outbreak of the Coronavirus disease (COVID-19) pandemic has deeply challenged healthcare systems and care of patients with cancer. Phase 1 studies are among the most complicated clinical trials and require thorough patient selection, as well as intensive patient monitoring. In this perspective, we discuss the key factors that should be considered for the conduct of phase 1 trials and management of COVID-19-positive patients with cancer enrolled in such trials. We notably present the risks and challenges raised by COVID-19-infected phase 1 patients, in terms of safety, toxicity causality assessment, drug efficacy evaluation and clinical research priorities. We finally propose some guidelines for the conduct of phase 1 trials and management of COVID-19-infected patients in a pandemic time. | 0959-8049 | 2020-08-02 02:00:00+02:00 | pubmed | European Journal of Cancer | Sophie Postel-Vinay;Christophe Massard;Jean-Charles Soria | COVID-19;Drug development;Phase 1;SARS-Cov-2 | 2020-07-27 02:00:00+02:00 | 32805640 | FR | Drug Development Department, DITEP, Gustave Roussy, Villejuif, France, Université Paris Saclay, Université Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre, France, ATIP-Avenir Group, Inserm Unit U981, Gustave Roussy, Villejuif, France. Electronic address: m.t.m.reinders@umcutrecht.nl.;Drug Development Department, DITEP, Gustave Roussy, Villejuif, France, Université Paris Saclay, Université Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre, France. | 1976 | |||
| GINOP;statutory funding | 10.1038/s41598-020-69351-x | Journal Article;Research Support, Non-U.S. Gov't | en | A negative covariation between toxoplasmosis and CoVID-19 with alternative interpretations. | https://www.ncbi.nlm.nih.gov/pubmed/32719490 | Coronaviruses may exert severely negative effects on the mortality and morbidity of birds and mammals including humans and domestic animals. Most recently CoVID-19 has killed about half million people (27th of June, 2020). Susceptibility to this disease appears to differ markedly across different societies but the factors underlying this variability are not known. Given that prevalence of toxoplasmosis in human societies may serve as a proxy for hygiene, and it also exerts both direct and immune-mediated antiviral effects, we hypothesize a negative covariation between toxoplasmosis and measures of the CoVID-19 pandemic across countries. We obtained aged-adjusted toxoplasmosis prevalence of pregnant women from the literature. Since the differences in the CoVID-19 morbidity and mortality may depend on the different timing of the epidemics in each country, we applied the date of first documented CoVID-19 in each country as a proxy of susceptibility, with a statistical control for population size effects. Using these two indices, we show a highly significant negative co-variation between the two pandemics across 86 countries. Then, considering that the wealth of nations often co-varies with the prevalence of diseases, we introduced GDP per capita into our model. The prevalence of toxoplasmosis co-varies negatively, while the date of first CoVID-19 co-varies positively with GDP per capita across countries. Further, to control for the strong spatial autocorrelation among countries, we carried out a Spatial Structure Analyses of the relationships between the date of first CoVID-19, prevalence of toxoplasmosis, and GDP per capita. Results of this analysis did not confirm a direct causal relationship between toxoplasmosis and susceptibility to the CoVID-19 pandemics. As far as an analysis of observational data let us to suggest, it appears that the interaction between CoVID-19 and toxoplasmosis is mediated by GDP per capita and spatial effects. This prompts the question whether the formerly known covariations of CoVID-19 and BCG vaccination or air pollution might have also emerged as spurious indirect effects. | 2045-2322 | 2020-08-02 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Coronavirus Infections__epidemiology;Disease Susceptibility__economics;Humans;Linear Models;Pandemics;Pneumonia, Viral__epidemiology;Prevalence;Toxoplasmosis__epidemiology;COVID-19;severe acute respiratory syndrome coronavirus 2 | Scientific Reports | Łukasz Jankowiak;Lajos Rozsa;Piotr Tryjanowski;Anders Pape Møller | 2020-07-27 02:00:00+02:00 | 32719490 | FR;PL;HU;CN | [{"country": "International", "agency": "GINOP", "grantid": "GINOP-2.3.2-15-2016-00057"}, {"country": "International", "agency": "statutory funding", "grantid": "FVS PULS 506-511-05"}] | Institute of Biology, University of Szczecin, Wąska 13, 71-415, Szczecin, Poland. jankowiakl@gmail.com.;GINOP Evolutionary Systems Research Group, Institute of Evolution, Centre for Ecological Research, Klebelsberg 3, Budapest, 8237, Hungary.;Institute of Zoology, Poznan University of Life Sciences, Wojska Polskiego 71C, Poznan, 60-625, Poland.;Ministry of Education Key Laboratory for Biodiversity Science and Ecological Engineering, College of Life Sciences, Beijing Normal University, Beijing, 100875, China.;Ecologie Systématique Evolution, Université Paris-Sud, CNRS, AgroParisTech, Université Paris-Saclay, 91405, Orsay Cedex, France. | 1978 | |
| 10.1097/cce.0000000000000173 | Journal Article | en | Preparedness and Reorganization of Care for Coronavirus Disease 2019 Patients in a Swiss ICU: Characteristics and Outcomes of 129 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32766566 | In many countries, large numbers of critically ill patients with coronavirus disease 2019 are admitted to the ICUs within a short period of time, overwhelming usual care capacities. Preparedness and reorganization ahead of the wave to increase ICU surge capacity may be associated with favorable outcome. The purpose of this study was to report our experience in terms of ICU organization and anticipation, as well as reporting patient characteristics, treatment, and outcomes. | 2639-8028 | 2020-08-02 02:00:00+02:00 | pubmed | Critical Care Explorations | Steve Primmaz;Christophe Le Terrier;Noémie Suh;François Ventura;Filippo Boroli;Karim Bendjelid;Sara Cereghetti;Raphaël Giraud;Claudia Heidegger;Deborah Pugin;Nils Siegenthaler;Didier Tassaux;Jean-Clément Cabrol;Nathan Dolet;Christoph Ellenberger;Gleicy Keli Barcelos;Marc-Joseph Licker;Georges Savoldelli;Eduardo Schiffer;Angèle Gayet-Ageron;Laurent Kaiser;Martin R Tramèr;Jérôme Pugin | acute respiratory distress syndrome;coronavirus disease 2019;intensive care unit;mortality;severe acute respiratory syndrome coronavirus 2;surge capacity | 2020-07-29 02:00:00+02:00 | 32766566 | FR;CH | Division of Intensive Care, Geneva University Hospitals and the University of Geneva Faculty of Medicine, Geneva, Switzerland.;Division of Anesthesiology, Geneva University Hospitals and the University of Geneva Faculty of Medicine, Geneva, Switzerland.;Department of Research, University Hospital of Caen, Caen, France.;Department of Pediatric Surgery, University Hospital of Caen, Caen, France.;Clinical Trial Unit, Division of Clinical Epidemiology, Geneva University Hospitals and the University of Geneva Faculty of Medicine, Geneva, Switzerland.;Division of Infectious Diseases, Geneva University Hospitals and the University of Geneva Faculty of Medicine, Geneva, Switzerland. | 1998 | |||
| Letter | en | COVID-19 and skin cancer management: French nation-wide questionnaire survey from real-life practice. | https://www.ncbi.nlm.nih.gov/pubmed/32723105 | 2020-08-02 02:00:00+02:00 | pubmed | Charlée Nardin;Eve Puzenat;Sophie Dalac;Eve Maubec;François Aubin | COVID-19;Sars-CoV-2;immunotherapy;melanoma;skin cancer | 2020-07-29 02:00:00+02:00 | 32723105 | FR | Dermatology Department, Hospital Minjoz, Besancon, France.;Inserm 1098, University of Bourgogne-Franche Comté, Besançon, France.;Dermatology Department, Hospital Le Bocage, Dijon, France.;Dermatology Department, Hospital Avicenne, Paris, France.;Groupe de Cancérologie Cutanée from the French Society of Dermatology (SFD), France. | 1999 | |||||||
| 10.1186/s42234-020-00051-7 | Journal Article | en | Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19? | https://www.ncbi.nlm.nih.gov/pubmed/32743022 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), at the origin of the worldwide COVID-19 pandemic, is characterized by a dramatic cytokine storm in some critical patients with COVID-19. This storm is due to the release of high levels of pro-inflammatory cytokines such as interleukin (IL)-1 β, IL-6, tumor necrosis factor (TNF), and chemokines by respiratory epithelial and dendritic cells, and macrophages. We hypothesize that this cytokine storm and the worsening of patients' health status can be dampened or even prevented by specifically targeting the vagal-driven cholinergic anti-inflammatory pathway (CAP). The CAP is a concept that involves an anti-inflammatory effect of vagal efferents by the release of acetylcholine (ACh). Nicotinic acetylcholine receptor alpha7 subunit (α7nAChRs) is required for ACh inhibition of macrophage-TNF release and cytokine modulation. Hence, targeting the α7nAChRs through vagus nerve stimulation (VNS) could be of interest in the management of patients with SARS-CoV-2 infection. Indeed, through the wide innervation of the organism by the vagus nerve, especially the lungs and gastrointestinal tract, VNS appears as a serious candidate for a few side effect treatment that could dampen or prevent the cytokine storm observed in COVID-19 patients with severe symptoms. Finally, a continuous vagal tone monitoring in patients with COVID-19 could be used as a predictive marker of COVID-19 illness course but also as a predictive marker of response to COVID-19 treatment such as VNS or others. | 2332-8886 | 2020-08-02 02:00:00+02:00 | pubmed | Bioelectronic Medicine | Bruno Bonaz;Valérie Sinniger;Sonia Pellissier | COVID-19;Cholinergic anti-inflammatory pathway;SARS-CoV-2;Vagus nerve;Vagus nerve stimulation;α7 nicotinic acetylcholine receptor | 2020-07-29 02:00:00+02:00 | 32743022 | FR | Division of Hepato-Gastroenterology, Grenoble University Hospital, 38000 Grenoble, France.;Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institute Neurosciences, 38000 Grenoble, France.;Univ. Grenoble Alpes, Univ. Savoie Mont Blanc and LIP/PC2S, 38000 Grenoble, France. | 2001 | |||
| 10.1038/s41423-020-0516-6 | Journal Article | en | Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient. | https://www.ncbi.nlm.nih.gov/pubmed/32728202 | 1672-7681,2042-0226 | 2020-08-02 02:00:00+02:00 | pubmed | Cellular & Molecular Immunology | Guillaume Monneret;Donatien de Marignan;Rémy Coudereau;Céline Bernet;Florence Ader;Emilie Frobert;Morgane Gossez;Sébastien Viel;Fabienne Venet;Florent Wallet | 2020-07-29 02:00:00+02:00 | 32728202 | FR | Hospices Civils de Lyon, Immunology Laboratory, Edouard Herriot Hospital, Lyon, France. guillaume.monneret@chu-lyon.fr.;Hospices Civils de Lyon, Lyon-Sud University Hospital, Medical Intensive Care Unit, Lyon, France.;Hospices Civils de Lyon, Immunology Laboratory, Edouard Herriot Hospital, Lyon, France.;Hospices Civils de Lyon, Department of infectious Diseases, North University Hospital, Lyon, France.;International Center of Research in Infectiology (CIRI), INSERM U1111, CNRS-UMR 5308, ENS Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France.;Hospices Civils de Lyon, Department of Virology, Infective Agents Institute, North University Hospital, Lyon, France.;Hospices Civils de Lyon, Lyon-Sud University Hospital, Immunology Laboratory, 69495, Pierre Bénite, France. | 2004 | |||||
| 10.1016/j.jchirv.2020.06.003 | Journal Article | fr | [A crisis of ethics in the ethics of crisis]. | https://www.ncbi.nlm.nih.gov/pubmed/32834889 | 1878-786X | 2020-08-02 02:00:00+02:00 | pubmed | Journal de Chirurgie Viscérale | A Zarzavadjian Le Bian;C Tresallet;E Martinod | COVID-19;Ethics;Pandemia;Surgery | 2020-07-29 02:00:00+02:00 | 32834889 | FR | Service de chirurgie digestive, bariatrique et endocrinienne, hôpital Avicenne, hôpitaux universitaires Seine Saint-Denis, université Sorbonne Paris Nord, Assistance publique-Hôpitaux de Paris, 125, rue de Stalingrad, 93000 Bobigny, France.;Service de chirurgie thoracique et vasculaire, hôpital Avicenne, hôpitaux universitaires Seine Saint-Denis, université Sorbonne Paris Nord, Assistance publique-Hôpitaux de Paris, 93000 Bobigny, France. | 2006 | ||||
| 10.1371/journal.pone.0236918 | Journal Article | en | Knowledge, attitude, and perceptions towards the 2019 Coronavirus Pandemic: A bi-national survey in Africa. | https://www.ncbi.nlm.nih.gov/pubmed/32726340 | The current Coronavirus (COVID-19) pandemic has impacted and changed lives on a global scale since its emergence and spread from China in late 2019. It has caused millions of infections, and thousands of deaths worldwide. However, the control of this pandemic still remains unachievable in many African countries including Egypt and Nigeria, despite the application of some strict preventive and control measures. Therefore, this study assessed the knowledge, attitude, and perceptions of Egyptians and Nigerians towards the COVID-19 pandemic. This study was designed as a cross-sectional community-based questionnaire survey in both countries. Participants' demography, knowledge, attitude, and perceptions towards the COVID-19 outbreak were obtained using a convenience sampling technique. Data collected were subjected to descriptive statistics and logistic regression analysis. A total of 1437 respondents were included in this preliminary report. The mean knowledge score was 14.7±2.3. The majority of the respondents (61.6%) had a satisfactory knowledge of the disease. Age (18-39 years), education (College/bachelors), and background of respondents were factors influencing knowledge levels. The attitude of most respondents (68.9%) towards instituted preventive measures was satisfactory with an average attitude score of 6.9 ± 1.2. The majority of the respondents (96%) practiced self-isolation and social-distancing but only 36% follow all health recommendations. The perception of most respondents (62.1%) on the global efforts at controlling the virus and preventing further spread was satisfactory with an average score of 10.9 ± 2.7. Only 22% of the respondents were satisfied with their country's handling of the pandemic. An apprehensive understanding of the current status in Africa through studies like KAP is crucial to avoid Africa being the next epicenter of the pandemic. For the populace to follow standard infection prevention and control measures adequately, governments need to gain the trust of citizens by strengthening the health systems and improving surveillance activities in detecting cases, to offer the optimum health services to their communities. | 1932-6203 | 2020-08-02 02:00:00+02:00 | pubmed | Adolescent;Adult;Attitude to Health;Betacoronavirus;Coronavirus Infections__epidemiology;Cross-Sectional Studies;Egypt__epidemiology;Female;Humans;Knowledge;Male;Middle Aged;Nigeria__epidemiology;Pandemics;Perception;Pneumonia, Viral__epidemiology;Surveys and Questionnaires;Young Adult;COVID-19;severe acute respiratory syndrome coronavirus 2 | PLOS ONE | Elnadi Hager;Ismail A Odetokun;Obasanjo Bolarinwa;Ahmed Zainab;Ochulor Okechukwu;Ahmad I Al-Mustapha | 2020-07-29 02:00:00+02:00 | 32726340 | FR;FI;NG;ZA;EG | Infectiologie et Santé Publique, Institut National de la Recherche Agronomique, Nouzilly, France.;Department of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine, University of Ilorin, Kwara State, Nigeria.;School of Nursing & Public Health Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.;Department of Veterinary Microbiology, Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt.;Department of Global Health, Unit of Functional Genetics of Infectious Diseases, Institute Pasteur, Paris, France.;Department of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.;Department of Veterinary Services, Kwara State Ministry of Agriculture and Rural Development, Ilorin, Nigeria.;Department of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria. | 2007 | |||
| 10.1002/art.41458 | Editorial | en | Synergy between cytokines and risk factors in the cytokine storm of Covid-19: protection from the chronic use of cytokine inhibitors? | https://www.ncbi.nlm.nih.gov/pubmed/32725790 | The severity of SARS-COV2 results from an abnormal immune response with massive local and systemic inflammation, referred to as a cytokine storm [1, 2]. A key question is why patients with obesity or diabetes are at such high risk for severe disease while patients treated with cytokine inhibitors are evidently not [3]? | 2326-5191,2326-5205 | 2020-08-02 02:00:00+02:00 | pubmed | Arthritis & Rheumatology | Pierre Miossec | 2020-07-28 02:00:00+02:00 | 32725790 | FR | Immunogenomics and Inflammation Unit, EA, 4130, Departments of Immunology and Rheumatology, University of Lyon, Lyon, France. | 2008 | ||||
| 10.1051/medsci/2020124 | English Abstract;Journal Article | fr | [A race against the clock: creation of SARS-Cov-2 in the laboratory, a month after its emergence!] | https://www.ncbi.nlm.nih.gov/pubmed/32755538 | SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2, which emerged in China at the end of 2019, is responsible for a global health crisis resulting in the confinement of more than 3 billion people worldwide and the sharp decline of the world economy. In this context, a race against the clock is launched in order to develop a treatment to stop the pandemic as soon as possible. A study published in Nature by the Volker Thiel team reports the development of reverse genetics for SARS-CoV-2 allowing them to recreate the virus in just a few weeks. The perspectives of this work are very interesting since it will allow the genetic manipulation of the virus and thus the development of precious tools which will be useful to fight the infection. Even though this approach represents a technological leap that will improve our knowledge of the virus, it also carries the germ of possible misuse and the creation of the virus for malicious purposes. The advantages and disadvantages of recreating SARS-CoV-2 in this pandemic period are discussed in this mini-synthesis. | 0767-0974,1958-5381 | 2020-08-09 02:00:00+02:00 | pubmed | médecine/sciences | Frédéric Iseni;Jean-Nicolas Tournier | 2020-08-05 02:00:00+02:00 | 32755538 | FR | Institut de recherche biomédicale des armées, Unité de virologie, Département Microbiologie et maladies infectieuses, 1 place général Valérie André, 91220 Brétigny-sur-Orge, France.;Institut de recherche biomédicale des armées, Unité Biothérapies anti-infectieuses et immunité, Département Microbiologie et maladies infectieuses, Brétigny-sur-Orge, France - Institut Pasteur, unité génomique virale et vaccination, CNRS UMR 3569, Paris, France - École du Val-de-Grâce, Paris, France. | 2009 | ||||
| 10.1186/s13054-020-03194-w | Journal Article | en | International variation in the management of severe COVID-19 patients. | https://www.ncbi.nlm.nih.gov/pubmed/32758266 | There is little evidence to support the management of severe COVID-19 patients. | 1364-8535 | 2020-08-09 02:00:00+02:00 | pubmed | Adult;Coronavirus Infections__therapy;Critical Care;Health Care Surveys;Humans;Internationality;Pandemics;Pneumonia, Viral__therapy;Practice Patterns, Physicians'__statistics & numerical data;Severity of Illness Index;COVID-19 | Critical Care | Elie Azoulay;Jan de Waele;Ricard Ferrer;Thomas Staudinger;Marta Borkowska;Pedro Povoa;Katerina Iliopoulou;Antonio Artigas;Stefan J Schaller;Manu Shankar-Hari;Mariangela Pellegrini;Michael Darmon;Jozef Kesecioglu;Maurizio Cecconi | Acute respiratory distress syndrome;Coronavirus;Remdesivir;Viral infection | 2020-08-05 02:00:00+02:00 | 32758266 | FR;SE;PT;GR;GB;IT;NL;ES;DE;BE;PS;AT | Médecine Intensive et Réanimation, Department of the St-Louis Hospital, APHP, Hôpital Saint-Louis, Paris University, 1 avenue Claude Vellefaux, 75010, Paris, France. elie.azoulay@aphp.fr.;Department of Critical Care Medicine, Ghent University Hospital, 9000, Gent, Netherlands.;Shock, Organ Dysfunction, and Resuscitation Research Group (SODIR), Instituto de Investigación de Vall d'Hebron, Barcelona, Spain.;Departmento de Medicina Intensiva, Hospital Universitario de Vall d́Hebron, Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias, Barcelona, Spain.;Department of Medicine I, Intensive Care Unit, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.;NOVA Medical School, CHRC, New University of Lisbon, Unidade de Cuidados Intensivos Polivalente, Hospital de São Francisco Xavier, CHLO, Estrada Do Forte Do Alto Do Duque, 1449-005, Lisbon, Portugal.;Hellenic Army, ICU Nurse Manager General Military Hospital, Athens, Greece.;Critical Care Center, Sabadell Hospital, University Institute Parc Taulí, Autonomous University of Barcelona, Ciberes, Barcelona, Spain.;Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Anesthesiology and Surgical Intensive Care, Berlin, Germany.;School of Immunology and Microbial Science, Kings College London. Guy's and St Thomas' NHS Foundation Trust, ICU Support Offices, St Thomas' Hospital, London, UK.;Department of Surgical Sciences and Central Intensive Care Unit, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.;Department of Anesthesia, Operation, and Intensive Care, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.;Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.;Médecine Intensive et Réanimation, Department of the St-Louis Hospital, APHP, Hôpital Saint-Louis, Paris University, 1 avenue Claude Vellefaux, 75010, Paris, France.;Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care and Emergency Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.;Humanitas Clinical and Research Center, Humanitas University, Milan, Italy. | 2011 | ||
| 10.1164/rccm.202005-1582le | Journal Article | en | High Respiratory Drive and Excessive Respiratory Efforts Predict Relapse of Respiratory Failure in Critically Ill Patients with COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32755309 | 1073-449X,1535-4970 | 2020-08-09 02:00:00+02:00 | pubmed | American Journal of Respiratory and Critical Care Medicine | Pierre Esnault;Michael Cardinale;Sami Hraiech;Philippe Goutorbe;Karine Baumstrack;Eloi Prud'homme;Julien Bordes;Jean-Marie Forel;Eric Meaudre;Laurent Papazian;Christophe Guervilly | SARS-CoV-2, COVID-19, ARDS, P0.1, ΔPocc, P-SILI. | 2020-08-05 02:00:00+02:00 | 32755309 | FR | HIA Sainte Anne, 54899, ICU, Toulon Armees, France, pierre.esnault@gmail.com.;HIA Sainte Anne, 54899, Intensive care unit, Toulon Armees, France.;Aix-Marseille Univ, APHM, URMITE UMR CNRS 7278, Hôpital Nord, Réanimation des Détresses Respiratoires et Infections Sévères, Marseille, France.;Assistance Publique Hopitaux de Marseille, 36900, Centre d'Etudes et de Recherches sur les Services de Santé et Qualité, Faculté de Médecine, Aix-Marseille Université, Marseille, 13005, France, Marseille, France.;Medical Intensive Care Unit, North Hospital, APHM, Marseille, France.;HIA Sainte Anne, 54899, Anesthesia Departement, Toulon Armees, France.;Hôpitaux de Marseille, Hôpital NordAnd Aix-Marseille Université, Réanimation des Détresses Respiratoires et des Infections Sévères, Marseille, France.;HIA Sainte Anne, 54899, ICU, Toulon Armees, France.;Ecole du Val-de-Grace, 89677, Paris, France.;CEReSS - Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France. | 2021 | ||||
| 10.1051/medsci/2020122 | English Abstract;Journal Article | fr | [Neurological damage linked to coronaviruses : SARS-CoV-2 and other human coronaviruses]. | https://www.ncbi.nlm.nih.gov/pubmed/32755537 | The recent emergence of a new coronavirus, SARS-CoV-2, responsible for COVID-19, is a new warning of the risk to public health represented by viral zoonoses and in particular by coronaviruses. Mainly described as being able to infect the upper and lower respiratory tract, coronaviruses can also infect the central and peripheral nervous systems as many other respiratory viruses, such as influenza or respiratory syncytial virus. Viral infections of the nervous system are a major public health concern as they can cause devastating illnesses up to death, especially when they occur in the elderly, who are more susceptible to these infections. Knowledge concerning the pathophysiology of recently emerging coronaviruses (MERS-CoV, SARS-CoV and SARS-CoV-2) and how they reach the central nervous system are very sketchy and the work in progress aims in particular to better understand their biology and the mechanisms associated with neurological damage. In this review we will discuss the current state of knowledge on the neurotropism of human coronaviruses and the associated mechanisms by developing in particular the latest data concerning SARS-CoV-2. | 0767-0974,1958-5381 | 2020-08-09 02:00:00+02:00 | pubmed | médecine/sciences | Sara Salinas;Yannick Simonin | 2020-08-05 02:00:00+02:00 | 32755537 | FR | Pathogenèse et contrôle des infections chroniques (PCCI), UMR 1058, université de Montpellier, Inserm, EFS, 60 rue de Navacelles, 34000 Montpellier, France. | 2028 | ||||
| 10.1016/j.ekir.2020.07.035 | Journal Article | en | Acute kidney injury associated with lopinavir/ritonavir combined therapy in patients with Covid-19. | https://www.ncbi.nlm.nih.gov/pubmed/32838087 | 2468-0249 | 2020-08-09 02:00:00+02:00 | pubmed | Kidney International Reports | Yannick Binois;Hafsah Hachad;Joe-Elie Salem;Julien Charpentier;Bénédicte Lebrun-Vignes;Frédéric Pène;Alain Cariou;Jean-Daniel Chiche;Jean-Paul Mira;Lee S Nguyen | 2020-08-06 02:00:00+02:00 | 32838087 | FR | AP.HP.Centre, Cochin university hospital, Intensive Care Medicine department.;AP.HP.Sorbonne, Pitie-Salpetriere university hospital, INSERM, Clinical Investigations Center Paris-Est.;Univ Paris Est Créteil, EpiDermE, F-94010 Créteil, France.;CMC Ambroise Paré, Research and Innovation (RICAP). | 2031 | |||||
| 10.1016/j.jaccas.2020.07.047 | Journal Article | en | Takotsubo syndrome associated with Covid 19: and the interTAK diagnosis score? | https://www.ncbi.nlm.nih.gov/pubmed/32838334 | 2666-0849 | 2020-08-09 02:00:00+02:00 | pubmed | JACC: Case Reports | P A Reper;F Oguz;J Henrie;G Horlait | 2020-08-06 02:00:00+02:00 | 32838334 | FR;BE;GB | Critical Care, CHU UCL Namur, Yvoir, Belgium. | 2035 | |||||
| 10.1093/jamia/ocaa183 | Journal Article | en | Health Informatics Support for Outbreak Management: how to respond without an Electronic Health Record? | https://www.ncbi.nlm.nih.gov/pubmed/32761100 | 1067-5027,1527-974X | 2020-08-09 02:00:00+02:00 | pubmed | Journal of the American Medical Informatics Association | Emmanuelle Sylvestre;René-Michel Thuny;Elsa Cecilia-Joseph;Papa Gueye;Cyrille Chabartier;Yannick Brouste;Hossein Mehdaoui;Fatiha Najioullah;Sandrine Pierre-François;Sylvie Abel;André Cabié;Moustapha Dramé | COVID-19;Electronic Health Record;Health informatics;digital divide;pandemic | 2020-08-06 02:00:00+02:00 | 32761100 | FR;MQ | INSERM, U1099, Rennes, F-35000, France.;Université de Rennes 1, LTSI, Rennes, F-35000, France.;CHU de Martinique, Department of Infectious Diseases, Martinique, F-97200, France.;CHU de Martinique, Centre de Données Cliniques, Martinique, F-97200, France.;CHU de Martinique, Information Technology Department, Martinique, F-97200, France.;CHU de Martinique, SAMU de Martinique, Martinique, F-97200, France.;CHU de Martinique, Intensive Care Unit, Martinique, F-97200, France.;CHU de Martinique, Department of Emergency Medicine, Martinique, F-97200, France.;CHU de Martinique, Virology Laboratory, Martinique, F-97200, France.;INSERM, EA 4537, Martinique, F-97200, France.;CHU de Martinique, INSERM, CIC-1424, Martinique, F-97200, France.;CHU de Martinique, Department of Clinical Research and Innovation, Martinique, F-97200, France. | 2037 | ||||
| Letter | en | Environmental samples: a valuable military help for COVID-19 lockdown exit strategy. | https://www.ncbi.nlm.nih.gov/pubmed/32764135 | 2020-08-09 02:00:00+02:00 | pubmed | Nicolas Cazes;A Lacoste;P Augier | infectious diseases;public health;virology | 2020-08-06 02:00:00+02:00 | 32764135 | FR;US | Emergency Medical Service, Bataillon de Marins-Pompiers de Marseille, Marseille, France md.ncazes@gmail.com.;CBRN Laboratory, Bataillon de Marins-Pompiers de Marseille, Marseille, France.;General staff, Bataillon de Marins-Pompiers de Marseille, Marseille, France. | 2039 | |||||||
| 10.3390/jcm9082543 | Journal Article | en | Clinical and Imaging Characteristics in Patients with SARS-CoV-2 Infection and Acute Intracranial Hemorrhage. | https://www.ncbi.nlm.nih.gov/pubmed/32781623 | Intracranial hemorrhage has been observed in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19), but the clinical, imaging, and pathophysiological features of intracranial bleeding during COVID-19 infection remain poorly characterized. This study describes clinical and imaging characteristics of patients with COVID-19 infection who presented with intracranial bleeding in a European multicenter cohort. | 2077-0383 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Jawed Nawabi;Andrea Morotti;Moritz Wildgruber;Gregoire Boulouis;Hermann Kraehling;Frieder Schlunk;Elif Can;Helge Kniep;Götz Thomalla;Marios Psychogios;Bernd Hamm;Jens Fiehler;Uta Hanning;Peter Sporns | COVID-19;SARS-CoV-2;imaging characteristics;intracranial hemorrhage | 2020-08-06 02:00:00+02:00 | 32781623 | FR;IT;CH;DE | Department of Radiology (CCM), Charité-Universitätsmedizin Berlin, Campus Mitte, Humboldt-Universität zu Berlin, Freie Universität Berlin, 14195 Berlin, Germany.;Neurology Unit, ASST Valcamonica, Esine, 25040 Brescia, Italy.;Klinik und Poliklinik für Radiologie, Klinikum der Universität (LMU), 81377 Munich, Germany.;Pediatric Radiology Department, Necker Enfants Malades & GHU Paris, Sainte-Anne Hospital, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, Université de Paris, 75015 Paris, France.;Department of Radiology, University Hospital Muenster, 48149 Muenster, Germany.;Department of Neuroradiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 14195 Berlin, Germany.;Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg Eppendorf, 20251 Hamburg, Germany.;Department of Neurology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.;Department of Neuroradiology, Clinic for Radiology and Nuclear Medicine, University Hospital Basel, 4031 Basel, Switzerland. | 2043 | |||
| Letter | en | Patterns of Gustatory Recovery in Patients Affected by the COVID-19 Outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32748131 | 2020-08-09 02:00:00+02:00 | pubmed | Carlos M Chiesa-Estomba;Jerome R Lechien;Maria R Barillari;Sven Saussez | 2020-08-03 02:00:00+02:00 | 32748131 | FR;IT;BE;ES | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France. chiesaestomba86@gmail.com.;Department of Otorhinolaryngology-Head and Neck Surgery, Osakidetza, Hospital Universitario Donostia, San Sebastian, 20014, Spain. chiesaestomba86@gmail.com.;Biodonostia Health Research Institute, San Sebastian, 20014, Spain. chiesaestomba86@gmail.com.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), 7000, Mons, Belgium.;Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, 92150, France.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, 1000, Belgium.;Department of Mental and Physical Health and Preventive Medicine, "L. Vanvitelli" University, 80138, Naples, Italy.;Department of Head and Neck Surgery, EpiCURA Hospital, Hornu, 7331, Belgium. | 2054 | ||||||||
| 10.1001/jamanetworkopen.2020.17533 | Journal Article | en | Coronavirus Disease 2019 Outcomes in French Nursing Homes That Implemented Staff Confinement With Residents. | https://www.ncbi.nlm.nih.gov/pubmed/32789517 | Coronavirus disease 2019 (COVID-19) is a major threat to nursing homes. During the COVID-19 pandemic wave that hit France in March and April 2020, staff members of some French nursing homes decided to confine themselves with their residents on a voluntary basis to reduce the risk of entry of the severe acute respiratory syndrome coronavirus 2 into the facility. | 2574-3805 | 2020-08-09 02:00:00+02:00 | pubmed | JAMA Network Open | Joël Belmin;Nathavy Um-Din;Cristiano Donadio;Maurizio Magri;Quoc Duy Nghiem;Bruno Oquendo;Sylvie Pariel;Carmelo Lafuente-Lafuente | 2020-08-03 02:00:00+02:00 | 32789517 | FR | Service Universitaire de Gériatrie, Hôpital Charles Foix, Groupe Hospitalier APHP Sorbonne Université, Ivry-sur-Seine, France.;Faculté de Médecine Sorbonne Médecine, Paris, France. | 2056 | ||||
| 10.1136/archdischild-2020-319963 | Journal Article;Review | en | Reopening schools during the COVID-19 pandemic: governments must balance the uncertainty and risks of reopening schools against the clear harms associated with prolonged closure. | https://www.ncbi.nlm.nih.gov/pubmed/32747375 | 0003-9888,1468-2044 | 2020-08-09 02:00:00+02:00 | pubmed | Archives of Disease in Childhood | Russell M Viner;Christopher Bonell;Lesley Drake;Didier Jourdan;Nicolette Davies;Valentina Baltag;John Jerrim;Jenny Proimos;Ara Darzi | Adolescent Health;Epidemiology;Psychology | 2020-08-03 02:00:00+02:00 | 32747375 | AU;FR;CH;GB | Population, Policy and Practice Research Programme, University College London Institute of Child Health, London, UK r.viner@ucl.ac.uk.;Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.;Partnership for Child Development, Imperial College London, London, UK.;Faculty of Education, Université Blaise-Pascal, Clermont-Ferrand, Auvergne-Rhône-Alpes, France.;Institute of Global Health Innovation, Imperial College London, London, UK.;Child and Adolescent Health, WHO, Geneve, Switzerland.;UCL Institute of Education, University College London Institute of Education, London, UK.;Centre for Adolescent Health, The Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia. | 2057 | ||||
| 10.1097/prs.0000000000007120 | Case Reports;Journal Article | en | Failure of Free Flaps in Head and Neck Oncology Surgery in COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32740633 | 0032-1052 | 2020-08-09 02:00:00+02:00 | pubmed | Betacoronavirus__isolation & purification;Clinical Laboratory Techniques__standards;Coronavirus Infections__complications;Female;Free Tissue Flaps__adverse effects;Gingival Neoplasms__complications;Graft Rejection__etiology;Humans;Infection Control__standards;Infectious Disease Transmission, Patient-to-Professional__prevention & control;Middle Aged;Pandemics;Pneumonia, Viral__complications;Squamous Cell Carcinoma of Head and Neck__complications;Surgeons__standards;Treatment Failure;COVID-19;COVID-19 diagnostic testing;severe acute respiratory syndrome coronavirus 2 | Plastic & Reconstructive Surgery | Nadia Benmoussa;Quitterie de Kerangal;Nicolas Leymarie;Ingrid Breuskin;Tiffany Rigal;Heba Alkhashnam;Alexandre Tendron | 2020-08-03 02:00:00+02:00 | 32740633 | FR | Department of Head and Neck Oncology Department of Plastic Surgery Department of Head and Neck Oncology Department of Plastic Surgery Department of Head and Neck Oncology, Gustave Roussy Institute, Paris-Saclay University, Villejuif, France. | 2060 | ||||
| 10.1007/s00247-020-04747-5 | Journal Article | en | Thoracic imaging of coronavirus disease 2019 (COVID-19) in children: a series of 91 cases. | https://www.ncbi.nlm.nih.gov/pubmed/32749530 | Pulmonary infection with SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus 2; COVID-19) has rapidly spread worldwide to become a global pandemic. | 0301-0449,1432-1998 | 2020-08-09 02:00:00+02:00 | pubmed | Pediatric Radiology | Pablo Caro-Dominguez;Susan Cheng Shelmerdine;Seema Toso;Aurelio Secinaro;Paolo Toma;Maria Beatrice Damasio;María Navallas;Lucia Riaza-Martin;David Gomez-Pastrana;Maryam Ghadimi Mahani;Sarah M Desoky;Carlos F Ugas Charcape;Judith Almanza-Aranda;Maria Elena Ucar;Jovan Lovrenski;Sureyya Burcu Gorkem;Efthymia Alexopoulou;Pierluigi Ciet;Joost van Schuppen;Hubert Ducou le Pointe;Hyun Woo Goo;Christian J Kellenberger;Maria Raissaki;Catherine M Owens;Franz Wolfgang Hirsch;Rick R van Rijn | COVID-19;Children;Computed tomography;Coronavirus;Imaging;Lower respiratory tract infection;Pneumonitis;Radiography | 2020-08-04 02:00:00+02:00 | 32749530 | FR;AR;MX;GR;CH;GB;US;QA;IT;TR;NL;RS;ES;PE;KR;PS;DE | Unidad de Radiologia Pediatrica, Servicio de Radiologia, Hospital Universitario Virgen del Rocio, Avenida Manuel Siurot s/n, CP 41013, Sevilla, Spain. pablocaro82@hotmail.com.;Department of Clinical Radiology, Great Ormond Street Hospital for Children, NHS Trust, London, UK.;UCL Great Ormond Street Institute of Child Health, London, UK.;Department of Diagnostics, Pediatric Radiology, Geneva Children's Hospitals, Geneva, Switzerland.;Department of Imaging, IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy.;U.O.C. Radiologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy.;Radiología Pediátrica, Servicio de Radiología, Hospital Universitario 12 de Octubre, Madrid, Spain.;Radiología Pediátrica, Servicio de Radiología, Hospital Universitario Vall d'Hebron, Barcelona, Spain.;Neumología Pediátrica, Servicio de Pediatría, Hospital Universitario Jerez de la Frontera, Cádiz, Spain.;Section of Pediatric Radiology, C. S. Mott Children's Hospital, Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA.;Department of Medical Imaging, University of Arizona College of Medicine, Tucson, AZ, USA.;Department of Imaging, Instituto Nacional de Salud del Niño San Borja, Lima, Peru.;Imaging Department, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico.;Radiologia Pediatrica, Sor Maria Ludovica Children's Hospital, La Plata, Argentina.;Faculty of Medicine Novi Sad, University of Novi Sad, Institute for Children and Adolescents Health Care of Vojvodina, Novi Sad, Serbia.;Paediatric Radiology Section, Children's Hospital Department of Radiology, Kayseri, Turkey.;Paediatric Radiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.;Department of Radiology and Nuclear Medicine, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, The Netherlands.;Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.;Imaging Department, Trousseau Hospital, AP-HP, Sorbonne University, Paris, France.;Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.;Diagnostic Imaging, University Children's Hospital Zurich, Zurich, Switzerland.;Department of Radiology, University Hospital of Heraklion, University of Crete, Crete, Greece.;Department of Clinical Radiology, Sidra Medicine, Doha, Qatar.;Paediatric Radiology, University Hospital of Leipzig, Leipzig, Germany. | 2071 | |||
| 10.1007/s13238-020-00768-w | Journal Article | en | Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. | https://www.ncbi.nlm.nih.gov/pubmed/32754890 | Emerging and re-emerging RNA viruses occasionally cause epidemics and pandemics worldwide, such as the on-going outbreak of the novel coronavirus SARS-CoV-2. Herein, we identified two potent inhibitors of human DHODH, S312 and S416, with favorable drug-likeness and pharmacokinetic profiles, which all showed broad-spectrum antiviral effects against various RNA viruses, including influenza A virus, Zika virus, Ebola virus, and particularly against SARS-CoV-2. Notably, S416 is reported to be the most potent inhibitor so far with an EC50 of 17 nmol/L and an SI value of 10,505.88 in infected cells. Our results are the first to validate that DHODH is an attractive host target through high antiviral efficacy in vivo and low virus replication in DHODH knock-out cells. This work demonstrates that both S312/S416 and old drugs (Leflunomide/Teriflunomide) with dual actions of antiviral and immuno-regulation may have clinical potentials to cure SARS-CoV-2 or other RNA viruses circulating worldwide, no matter such viruses are mutated or not. | 1674-800X,1674-8018 | 2020-08-09 02:00:00+02:00 | pubmed | Protein & Cell | Rui Xiong;Leike Zhang;Shiliang Li;Yuan Sun;Minyi Ding;Yong Wang;Yongliang Zhao;Yan Wu;Weijuan Shang;Xiaming Jiang;Jiwei Shan;Zihao Shen;Yi Tong;Liuxin Xu;Yu Chen;Yingle Liu;Gang Zou;Dimitri Lavillete;Zhenjiang Zhao;Rui Wang;Lili Zhu;Gengfu Xiao;Ke Lan;Honglin Li;Ke Xu | DHODH inhibitors;SARS-CoV-2;de novo pyrimidine biosynthesis;immuno-regulation;influenza viruses;virus replication | 2020-08-04 02:00:00+02:00 | 32754890 | FR;CN | Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.;State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.;State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430072, China.;CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.;Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China. hlli@ecust.edu.cn.;State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430072, China. xuke03@whu.edu.cn.;CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. xuke03@whu.edu.cn. | 2084 | |||
| 10.1016/j.hansur.2020.07.001 | Journal Article | en | Hand injuries treated at a hand emergency center during the COVID-19 lockdown. | https://www.ncbi.nlm.nih.gov/pubmed/32777488 | The recent coronavirus outbreak has tested the adaptability, cooperation and organizational capabilities of our healthcare systems. Restrictions were implemented in several countries to reduce virus transmission whilst emergency departments (ED) were overwhelmed and there was shortage of healthcare providers. Given this situation and the consequences of hand injuries, we studied the epidemiology of hand injuries in an accredited FESSH emergency center during the lockdown in France (March 17 to May 10, 2020) due to the coronavirus outbreak. During this period, 1947 patients consulted for a hand injury. We found high percentages of men (63%), open wounds (70%), domestic accidents (88%) and surgical treatment being required (76%). There was a significant decrease in admissions and consultations relative to the same period in 2019. This reference data can help healthcare systems prepare for future outbreaks and similar restrictions. | 2468-1229 | 2020-08-09 02:00:00+02:00 | pubmed | Hand Surgery and Rehabilitation | I Régas;P Bellemère;B Lamon;Y Bouju;F-A Lecoq;C Chaves | Covid-19;Emergency;Epidemiology;Epidémiologie;Hand trauma;Plaies;SOS-mains;Urgences;Wounds | 2020-08-07 02:00:00+02:00 | 32777488 | FR | Institut de la Main Nantes Atlantique, Boulevard Charles-Gautier, 44800 Saint Herblain, France.;Institut de la Main Nantes Atlantique, Boulevard Charles-Gautier, 44800 Saint Herblain, France. Electronic address: med@cchaves.com. | 2091 | |||
| Letter | en | Intracranial Hemorrhage related to brain vascular disease and COVID-19 containment: where are the patients? | https://www.ncbi.nlm.nih.gov/pubmed/32781087 | 2020-08-09 02:00:00+02:00 | pubmed | Anne-Laure Bernat;Thomas Gaberel;Lorenzo Giammattei;Frédérik Rault;Clément Gakuba;Elsa Magro;Charles Peltier;Thomas Graillon;Bertrand Baussart;Kevin Premat;Frédéric Clarençon;Aurélien Nouet;Vittorio Civelli;Sébastien Froelich | 2020-08-08 02:00:00+02:00 | 32781087 | FR | Neurosurgical Department, Lariboisière University Hospital, Paris, France, Universités de Paris, Paris, France. Electronic address: annelaure.bernat@aphp.fr.;Neurosurgical Department, University Hospital, Caen, France.;Neurosurgical Department, Lariboisière University Hospital, Paris, France, Universités de Paris, Paris, France.;Anesthesiology Department, University Hospital, Caen, France.;Neurosurgical Department, University Hospital, Brest, UMR 1101 LaTIM, UBO, France.;Neurosurgical Department, APHM La Timone Hospital, Marseille, France.;Neurosurgical Department, Foch Hospital, Suresnes, France.;Interventional Neuroradiology Department, La Pitié-Salpêtrière Hospital, Paris, France, Universités de Paris, Paris, France.;Neurosurgical Department, La Pitié-Salpêtrière Hospital, Paris, France, Universités de Paris, Paris, France.;Interventional Neuroradiology Department, Lariboisière Hospital, Paris, France, Universités de Paris, Paris, France. | 2098 | ||||||||
| Letter | en | Response to Re: COVID-19, sweat, tears… and myopia? | https://www.ncbi.nlm.nih.gov/pubmed/32776346 | 2020-08-09 02:00:00+02:00 | pubmed | Valentin Navel;Frédéric Chiambaretta;Frédéric Dutheil | 2020-08-09 02:00:00+02:00 | 32776346 | FR | Translational Approach to Epithelial Injury and Repair, CNRS, INSERM, GReD, Université Clermont Auvergne, Clermont-Ferrand, France.;Ophthalmology, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.;Physiological and Psychosocial Stress, LaPSCo, CNRS, Université Clermont Auvergne, Clermont-Ferrand, France.;Preventive and Occupational Medicine, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Witty Fit, Clermont-Ferrand, France. | 2101 | ||||||||
| 10.1016/j.amcp.2020.08.002 | Journal Article;Review | fr | [Infection with SARS-CoV-2]. | https://www.ncbi.nlm.nih.gov/pubmed/32837205 | 1261-694X | 2020-08-09 02:00:00+02:00 | pubmed | Archives des Maladies du Coeur et des Vaisseaux - Pratique | E Caumes | 2020-08-07 02:00:00+02:00 | 32837205 | FR | Département des maladies infectieuses et tropicales, Sorbonne Université, hôpitaux universitaires Pitié-Salpêtrière Charles-Foix, 47, boulevard de l'Hôpital, 75013 Paris, France.;Inserm, Sorbonne Université, institut Pierre-Louis d'épidémiologie et de santé publique, 56, boulevard Vincent-Auriol, 75646 Paris, France. | 2105 | |||||
| 10.1186/s13613-020-00722-3 | Journal Article | en | Symptoms of burnout in intensive care unit specialists facing the COVID-19 outbreak. | https://www.ncbi.nlm.nih.gov/pubmed/32770449 | The COVID-19 pandemic has resulted in an unprecedented healthcare crisis with a high prevalence of psychological distress in healthcare providers. We sought to document the prevalence of burnout syndrome amongst intensivists facing the COVID-19 outbreak. | 2110-5820 | 2020-08-09 02:00:00+02:00 | pubmed | Annals of Intensive Care | Elie Azoulay;Jan De Waele;Ricard Ferrer;Thomas Staudinger;Marta Borkowska;Pedro Povoa;Katerina Iliopoulou;Antonio Artigas;Stefan J Schaller;Manu Shankar Hari;Mariangela Pellegrini;Michael Darmon;Jozef Kesecioglu;Maurizio Cecconi | Acute respiratory distress syndrome;Coronavirus;Depersonalization;Exhaustion;Pneumonia;Well-being | 2020-08-08 02:00:00+02:00 | 32770449 | FR;SE;PT;GR;GB;IT;NL;ES;DE;BE;PS;AT | Médecine Intensive et Réanimation, PHP, Hôpital Saint-Louis, Paris University, Paris, France. elie.azoulay@aphp.fr.;Department of Critical Care Medicine, Ghent University Hospital, 9000, Gent, The Netherlands.;Shock, Organ Dysfunction, and Resuscitation Research Group (SODIR), Instituto de Investigación de Vall d'Hebron, Barcelona, Spain.;Departmento de Medicina Intensiva, Hospital Universitario de Vall d́Hebron, Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias, Barcelona, Spain.;Department of Medicine I, Intensive Care Unit, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.;NOVA Medical School, CHRC, New University of Lisbon, Lisbon, Portugal.;Unidade de Cuidados Intensivos Polivalente, Hospital de São Francisco Xavier, CHLO, Estrada Do Forte Do Alto Do Duque, 1449-005, Lisbon, Portugal.;Hellenic Army, ICU Nurse Manager General Military Hospital, Athens, Greece.;Critical Care Center, Sabadell Hospital, University Institute Parc Taulí, Autonomous University of Barcelona, Ciberes, Barcelona, Spain.;Department of Anesthesiology and Intensive Care, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.;School of Immunology and Microbial Science, Kings College London, London, UK.;Guy's and St Thomas' NHS Foundation Trust, ICU Support Offices, St Thomas' Hospital, London, UK.;Department of Surgical Sciences and Central Intensive Care Unit, Department of Anesthesia, Operation, and Intensive Care and Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.;Médecine Intensive et Réanimation, PHP, Hôpital Saint-Louis, Paris University, Paris, France.;Department of Intensive Care Medicine, Division of Anesthesiology, Intensive Care and Emergency Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.;Humanitas Clinical and Research Center, Humanitas University, Milan, Italy. | 2107 | |||
| 10.1093/jac/dkaa327 | Journal Article | en | Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. | https://www.ncbi.nlm.nih.gov/pubmed/32766679 | 0305-7453,1460-2091 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Antimicrobial Chemotherapy | Bruno Mégarbane;Jean-Michel Scherrmann | 2020-08-07 02:00:00+02:00 | 32766679 | FR | Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology APHP, University of Paris, INSERM UMRS-1144, Paris, France.;Faculty of Pharmacy, University of Paris, INSERM UMRS-1144, Paris, France. | 2111 | |||||
| Letter | en | Homeless people hospitalized with COVID-19 in Brussels. | https://www.ncbi.nlm.nih.gov/pubmed/32777362 | 2020-08-09 02:00:00+02:00 | pubmed | Loïc Schrooyen;Marc Delforge;Faustine Lebout;Thibaut Vanbaelen;Amaryl Lecompte;Nicolas Dauby | COVID-19;SARS-CoV-2;homeless;hospitalization;incidence;mortality | 2020-08-07 02:00:00+02:00 | 32777362 | FR;BE | Department of Infectious Diseases, CHU Saint-Pierre, Brussels. Electronic address: loic.schrooyen@ulb.ac.be.;Department of Infectious Diseases, CHU Saint-Pierre, Brussels.;Department of Infectious Diseases, CHU Saint-Pierre, Brussels, Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Environmental Health Research Centre, Public Health School, Université Libre de Bruxelles (ULB), Brussels, Belgium. | 2114 | |||||||
| 10.1021/acs.jmedchem.0c00776 | Journal Article | en | Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS? | https://www.ncbi.nlm.nih.gov/pubmed/32692176 | Cathepsin C (CatC) is a cysteine dipeptidyl aminopeptidase that activates most of tissue-degrading elastase-related serine proteases. Thus, CatC appears as a potential therapeutic target to impair protease-driven tissue degradation in chronic inflammatory and autoimmune diseases. A depletion of proinflammatory elastase-related proteases in neutrophils is observed in patients with CatC deficiency (Papillon-Lefèvre syndrome). To address and counterbalance unwanted effects of elastase-related proteases, chemical inhibitors of CatC are being evaluated in preclinical and clinical trials. Neutrophils may contribute to the diffuse alveolar inflammation seen in acute respiratory distress syndrome (ARDS) which is currently a growing challenge for intensive care units due to the outbreak of the COVID-19 pandemic. Elimination of elastase-related neutrophil proteases may reduce the progression of lung injury in these patients. Pharmacological CatC inhibition could be a potential therapeutic strategy to prevent the irreversible pulmonary failure threatening the life of COVID-19 patients. | 0022-2623,1520-4804 | 2020-08-09 02:00:00+02:00 | pubmed | Journal of Medicinal Chemistry | Brice Korkmaz;Adam Lesner;Sylvain Marchand-Adam;Celia Moss;Dieter E Jenne | 2020-08-07 02:00:00+02:00 | 32692176 | FR;PL;GB;DE | INSERM UMR-1100, Centre d'Etude des Pathologies Respiratoires and Université de Tours, 37032 Tours, France.;Faculty of Chemistry, University of Gdansk, 80-398 Gdansk, Poland.;Service de Pneumologie, CHRU de Tours, 37032 Tours, France.;Birmingham Children's Hospital and University of Birmingham, B4 6NH Birmingham, U.K.;Comprehensive Pneumology Center, Institute of Lung Biology and Disease, German Center for Lung Research (DZL), Munich and Max-Planck Institute of Neurobiology, 82152 Planegg-Martinsried, Germany. | 2125 | ||||
| 10.1186/s13049-020-00775-0 | Journal Article | en | Impact of two-level filtering on emergency medical communication center triage during the COVID-19 pandemic: an uncontrolled before-after study. | https://www.ncbi.nlm.nih.gov/pubmed/32799911 | Rapid access to emergency medical communication centers (EMCCs) is pivotal to address potentially life-threatening conditions. Maintaining public access to EMCCs without delay is crucial in case of disease outbreak despite the significant increased activity and the difficulties to mobilize extra staff resources. The aim of our study was to assess the impact of two-level filtering on EMCC performance during the COVID-19 outbreak. | 1757-7241 | 2020-08-16 02:00:00+02:00 | pubmed | Betacoronavirus;Communication;Controlled Before-After Studies;Coronavirus Infections__epidemiology;Emergencies;Emergency Medical Service Communication Systems__organization & administration;Emergency Medical Services__methods;Humans;Pandemics;Pneumonia, Viral__epidemiology;Prospective Studies;Telephone;Triage__methods;COVID-19;severe acute respiratory syndrome coronavirus 2 | Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine | Y Penverne;B Leclere;J Labady;F Berthier;J Jenvrin;F Javaudin;E Montassier | Accessibility;Emergency medical communication center;System;Triage | 2020-08-14 02:00:00+02:00 | 32799911 | FR | Samu 44, Department of Emergency Medicine, University Hospital of Nantes, Nantes, France. yann.penverne@chu-nantes.fr.;Department of Medical Evaluation and Epidemiology, Nantes University Hospital, Nantes, France.;MiHAR lab, University of Nantes, Nantes, France.;Samu 44, Department of Emergency Medicine, University Hospital of Nantes, Nantes, France. | 2127 | ||
| 10.1016/j.bbih.2020.100127 | Journal Article;Review | en | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Glial Cells: insights and perspectives. | https://www.ncbi.nlm.nih.gov/pubmed/32838339 | In December 2019, a pneumonia outbreak was reported in Wuhan, Hubei province, China. Since then, the World Health Organization declared a public health emergency of international concern due to a growing number of deaths around the globe, as well as unparalleled economic and sociodemographic consequences. The disease called coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel form of human coronavirus. Although coronavirus infections have been associated with neurological manifestations such as febrile seizures, convulsions, change in mental status, and encephalitis, less is known about the impact of SARS-CoV-2 in the brain. Recently, emerging evidence suggests that SARS-CoV-2 is associated with neurological alterations in COVID-19 patients with severe clinical manifestations. The molecular and cellular mechanisms involved in this process, as well as the neurotropic and neuroinvasive properties of SARS-CoV-2, are still poorly understood. Glial cells, such as astrocytes and microglia, play pivotal roles in the brain response to neuroinflammatory insults and neurodegenerative diseases. Further, accumulating evidence has shown that those cells are targets of several neurotropic viruses that severely impact their function. Glial cell dysfunctions have been associated with several neuroinflammatory diseases, suggesting that SARS-CoV-2 likely has a primary effect on these cells in addition to a secondary effect from neuronal damage. Here, we provide an overview of these data and discuss the possible implications of glial cells as targets of SARS-CoV-2. Considering the roles of microglia and astrocytes in brain inflammatory responses, we shed light on glial cells as possible drivers and potential targets of therapeutic strategies against neurological manifestations in patients with COVID-19. The main goal of this review is to highlight the need to consider glial involvement in the progression of COVID-19 and potentially include astrocytes and microglia as mediators of SARS-CoV-2-induced neurological damage. | 2666-3546 | 2020-08-16 02:00:00+02:00 | pubmed | Brain, Behavior, & Immunity - Health | Gabriele Vargas;Luiz Henrique Medeiros Geraldo;Natália Salomão;Marciano Vianna Paes;Flavia Regina Souza Lima;Flávia Carvalho Alcantara Gomes | COVID-19;SARS-CoV-2;astrocyte;coronavirus;glial cells;microglia;neuroinflammation | 2020-08-13 02:00:00+02:00 | 32838339 | FR;BR | Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil.;Paris Cardiovascular Research Center (PARCC - INSERM U970), Université de Paris, Paris, France.;Laboratório Interdisciplinar de Pesquisas Médicas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brasil. | 2128 | |||
| Letter | en | Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains: reply from authors. | https://www.ncbi.nlm.nih.gov/pubmed/32790922 | With great interest, we read Battesti and Descamps comment on our recently published study in this journal. Their comment is based on their findings that histological and immunostaining of skin biopsy of 7 cases of "epidemic chilblains" with negative SARS-CoV-2 RT-PCR and repeated serology was similar to those of a historical series of 11 cases of chilblains lupus notably for high expression of CD123 and MxA a type-I interferon (IFN-I)-induced protein in both groups1 . | 2020-08-16 02:00:00+02:00 | pubmed | L Le Cleach;S Fourati;E Sbidian;M Beylot-Barry | 2020-08-13 02:00:00+02:00 | 32790922 | FR | Departments of Dermatology, Virology Hôpital Henri Mondor, Créteil, France.;Virology Hôpital Henri Mondor, Créteil, France.;Department of Dermatology, University Hospital Bordeaux, Bordeaux, France. | 2129 | |||||||
| Letter | en | Letter to the Editor: Influence of Altitude on the Prevalence and Case Fatality Rate of COVID-19 in Peru. | https://www.ncbi.nlm.nih.gov/pubmed/32803989 | 2020-08-16 02:00:00+02:00 | pubmed | Claudio Intimayta-Escalante;Daniel Rojas-Bolivar;Ivan Hancco | 2020-08-14 02:00:00+02:00 | 32803989 | FR;PE | Sociedad Científica de San Fernando, Lima, Peru.;Universidad Nacional Mayor de San Marcos, Lima, Peru.;Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales (CITBM), Callao, Peru.;Laboratoire de Hypoxie et Physiopathologie (HP2), Université Grenoble Alpes, Grenoble, France. | 2141 | ||||||||
| 10.1371/journal.pone.0237300 | Journal Article | en | Structural insight into the role of novel SARS-CoV-2 E protein: A potential target for vaccine development and other therapeutic strategies. | https://www.ncbi.nlm.nih.gov/pubmed/32785274 | The outbreak of COVID-19 across the world has posed unprecedented and global challenges on multiple fronts. Most of the vaccine and drug development has focused on the spike proteins and viral RNA-polymerases and main protease for viral replication. Using the bioinformatics and structural modelling approach, we modelled the structure of the envelope (E)-protein of novel SARS-CoV-2. The E-protein of this virus shares sequence similarity with that of SARS- CoV-1, and is highly conserved in the N-terminus regions. Incidentally, compared to spike proteins, E proteins demonstrate lower disparity and mutability among the isolated sequences. Using homology modelling, we found that the most favorable structure could function as a gated ion channel conducting H+ ions. Combining pocket estimation and docking with water, we determined that GLU 8 and ASN 15 in the N-terminal region were in close proximity to form H-bonds which was further validated by insertion of the E protein in an ERGIC-mimic membrane. Additionally, two distinct "core" structures were visible, the hydrophobic core and the central core, which may regulate the opening/closing of the channel. We propose this as a mechanism of viral ion channeling activity which plays a critical role in viral infection and pathogenesis. In addition, it provides a structural basis and additional avenues for vaccine development and generating therapeutic interventions against the virus. | 1932-6203 | 2020-08-16 02:00:00+02:00 | pubmed | PLOS ONE | Manish Sarkar;Soham Saha | 2020-08-12 02:00:00+02:00 | 32785274 | FR;IN | Department of Biochemistry, Bose Institute, Kolkata, India.;Laboratory for Perception and Memory, Institut Pasteur, Paris, France.;Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR-3571), Paris, France. | 2156 | ||||
| European Union's Horizon 2020 research and innovation programme;SCORE project H2020 SC1-PHE-Coronavirus194 2020;Fondation pour la Recherche Médicale;Inserm | 10.1002/rmv.2143 | Journal Article;Review | en | Drugs against SARS-CoV-2: What do we know about their mode of action? | https://www.ncbi.nlm.nih.gov/pubmed/32779326 | The health emergency caused by the recent Covid-19 pandemic highlights the need to identify effective treatments against the virus causing this disease (SARS-CoV-2). The first clinical trials have been testing repurposed drugs that show promising anti-SARS-CoV-2 effects in cultured cells. Although more than 2400 clinical trials are already under way, the actual number of tested compounds is still limited to approximately 20, alone or in combination. In addition, knowledge on their mode of action (MoA) is currently insufficient. Their first results reveal some inconsistencies and contradictory results and suggest that cohort size and quality of the control arm are two key issues for obtaining rigorous and conclusive results. Moreover, the observed discrepancies might also result from differences in the clinical inclusion criteria, including the possibility of early treatment that may be essential for therapy efficacy in patients with Covid-19. Importantly, efforts should also be made to test new compounds with a documented MoA against SARS-CoV-2 in clinical trials. Successful treatment will probably be based on multitherapies with antiviral compounds that target different steps of the virus life cycle. Moreover, a multidisciplinary approach that combines artificial intelligence, compound docking, and robust in vitro and in vivo assays will accelerate the development of new antiviral molecules. Finally, large retrospective studies on hospitalized patients are needed to evaluate the different treatments with robust statistical tools and to identify the best treatment for each Covid-19 stage. This review describes different candidate antiviral strategies for Covid-19, by focusing on their mechanism of action. | 1052-9276,1099-1654 | 2020-08-16 02:00:00+02:00 | pubmed | Reviews in Medical Virology | Coralie Valle;Baptiste Martin;Franck Touret;Ashleigh Shannon;Bruno Canard;Jean-Claude Guillemot;Bruno Coutard;Etienne Decroly | 2020-08-11 02:00:00+02:00 | 32779326 | FR | [{"country": "", "agency": "European Union's Horizon 2020 research and innovation programme", "grantid": "101003627"}, {"country": "", "agency": "SCORE project H2020 SC1-PHE-Coronavirus194 2020", "grantid": "101003627"}, {"country": "", "agency": "Fondation pour la Recherche Médicale"}, {"country": "", "agency": "Inserm"}] | Laboratoire AFMB, Aix Marseille Université, CNRS, UMR 7257, Marseille, France.;Beyond Humanity, Lyon, France.;Unité des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France. | 2174 | ||
| 10.1186/s12874-020-01082-z | Journal Article;Research Support, Non-U.S. Gov't | en | Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach. | https://www.ncbi.nlm.nih.gov/pubmed/32781984 | The clinical progress of patients hospitalized due to COVID-19 is often associated with severe pneumonia which may require intensive care, invasive ventilation, or extracorporeal membrane oxygenation (ECMO). The length of intensive care and the duration of these supportive therapies are clinically relevant outcomes. From the statistical perspective, these quantities are challenging to estimate due to episodes being time-dependent and potentially multiple, as well as being determined by the competing, terminal events of discharge alive and death. | 1471-2288 | 2020-08-16 02:00:00+02:00 | pubmed | BMC Medical Research Methodology | Derek Hazard;Klaus Kaier;Maja von Cube;Marlon Grodd;Lars Bugiera;Jerome Lambert;Martin Wolkewitz | Competing risks;Length of stay;Mechanical ventilation;Multistate model;SARS-CoV-2 | 2020-08-11 02:00:00+02:00 | 32781984 | FR;DE | Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Stefan-Meier-Str. 26, 79104, Freiburg, Germany. hazard@imbi.uni-freiburg.de.;Freiburg Center for Data Analysis and Modeling- University of Freiburg, Ernst-Zermelo-Str. 1, 79104, Freiburg, Germany. hazard@imbi.uni-freiburg.de.;Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Stefan-Meier-Str. 26, 79104, Freiburg, Germany.;Freiburg Center for Data Analysis and Modeling- University of Freiburg, Ernst-Zermelo-Str. 1, 79104, Freiburg, Germany.;INSERM U1153 CRESS, Epidemiology and Clinical Statistics for Tumor, Respiratory, and Resuscitation Assessments (ECSTRRA) Team, Hôpital Saint Louis, 1 av Claude Vellefaux, 75010, Paris, France. | 2175 | |||
| 10.1111/ctr.14063 | Journal Article | en | Pediatric transplantation in Europe during the COVID-19 pandemic: early impact on activity and healthcare. | https://www.ncbi.nlm.nih.gov/pubmed/32786120 | The current pandemic SARS-CoV-2 virus has required an unusual allocation of resources that can negatively impact of chronically ill patients and high-complexity procedures. Across the European reference network on pediatric transplantation (ERN-TransplantChild) we conducted a survey to investigate the impact of the COVID-19 outbreak on pediatric transplant activity and healthcare practices in both solid organ transplantation (SOT) and hematopoietic stem cell (HSCT) transplantation. The replies of 30 professionals from 18 centers in Europe were collected. Twelve of 18 centers (67%) showed a reduction in their usual transplant activity. Additionally, outpatient visits have been modified, restricted to selected ones and to the use of telemedicine tools has increased. Additionally, a total of 14 COVID-19 pediatric transplanted patients were identified at the time of the survey, including eight transplant recipients and six candidates for transplantation. Only two moderate-severe cases were reported, both in HSCT setting. These survey results demonstrate the limitations in healthcare resources for pediatric transplantation patients during early stages of this pandemic. COVID-19 disease is a major worldwide challenge for the field of pediatric transplantation, where there will be a need for systematic data collection, encouraging regular discussions to address the long-term consequences for pediatric transplantation candidates, recipients and their families. | 0902-0063,1399-0012 | 2020-08-16 02:00:00+02:00 | pubmed | Clinical Transplantation | Daniele Doná;Juan Torres Canizales;Elisa Benetti;Mara Cananzi;Federica De Corti;Elisabetta Calore;Loreto Hierro;Esther Ramos Boluda;Marta Melgosa Hijosa;Luis Garcia Guereta;Antonio Pérez-Martínez;Maribel Barrios;Patricia Costa Reis;Ana Teixeira;Maria Francelina Lopes;Piotr Kaliciński;Sophie Branchereau;Olivia Boyer;Dominque Debray;Marco Sciveres;Lars Wennberg;Björn Fischler;Peter Barany;Alastair Baker;Ulrich Baumann;Nicolaus Schwerk;Emanuele Nicastro;Manila Candusso;Jacek Toporski;Etienne Sokal;Xavier Stephenne;Caroline Lindemans;Marius Miglinas;Jelena Rascon;Paloma Jara | COVID-19;SARS-CoV-2;children;coronavirus disease 2019;hematopoietic stem cell transplantation;pediatric transplantation;post-transplant management;solid organ transplantation;young and adolescents | 2020-08-12 02:00:00+02:00 | 32786120 | FR;SE;BE;LT;PT;BO;GB;IT;PL;NL;ES;DK;DE | Pediatric Infectious diseases, Department of Women's and Children's Health, University Hospital of Padova, Italy.;La Paz Institute of Biomedical Research, IdiPAZ, La Paz University Hospital, Madrid, Spain.;Pediatric Nephrology, Dialysis and Transplant Unit, Department of Women's and Children's Health, University Hospital of Padova, Italy.;Pediatric Gastroenterology, Digestive Endoscopy, Hepatology and Care of the Child with Liver Transplantation, Department of Women's and Children's Health, University Hospital of Padova, Italy.;Pediatric Surgery, Department of Women's and Children's Health, University Hospital of Padova, Italy.;Pediatric Hematology, Oncology and Stem Cell Transplant Division, Department of Women's and Children's Health, University Hospital of Padova, Italy.;Pediatric Hepatology Department, La Paz University Hospital, Madrid, Spain.;Pediatric Gastroenterology Intestinal Rehabilitation Unit, La Paz University Hospital, Madrid, Spain.;Pediatric Nephrology Deparment, La Paz University Hospital, Madrid, Spain.;Pediatric Cardiology Department, La Paz University Hospital, Madrid, Spain.;Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain.;Pediatric Pneumology Department, La Paz University Hospital, Madrid, Spain.;Pediatric Nephrology and Kidney Transplantation Unit, Pediatrics Department, Hospital de Santa Maria, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.;Department of Pediatric Nephrology, Pediatric Service, Centro Materno Infantil do Norte, Centro Hospitalar do Porto, Porto, Portugal.;Department of Pediatric Surgery, Centro Hospitalar e Universitário de Coimbra, Portugal.;Department of Pediatric Surgery and Organ Transplantation, Children's Memorial Health Institute, Warsaw, Poland.;Pediatric Surgery Department, Hospital du Kremlin Bicêtre, France.;Service of Pediatric Nephrology, Hôpital Necker-Enfants Malades, AP-HP, Université de Paris Descartes, Paris, France.;Pediatric Hepatology Unit, reference center for Biliary Atresia and Genetic cholestasis, Hôpital Necker-Enfants Malades, AP-HP, Université Paris Centre, Paris, France.;Pediatric Hepatology and Liver Transplantation, ISMETT UPMC Palermo, Palermo, Italy.;Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden.;Department of Pediatric Hepatology, Karolinska University Hospital, CLINTEC, Karolinska Institutet, Stockholm, Sweden.;Department of Pediatric Nephrology, Karolinska University Hospital, Stockholm, Sweden.;Pediatric Liver, Gastrointestinal and Nutrition Centre, King's College London School of Medicine at King's College Hospital, Denmark Hill, London, UK.;Division of Pediatric Gastroenterology and Hepatology, Children's Hospital, Hannover Medical School, Hannover, Germany.;Clinic for Pediatric Pneumology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany.;Centre for Pediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Bergamo, Italy.;Department of Hepatology and Gastroenterology, Bambino Gesù Children Hospital, Rome, Italy.;Section of Pediatric Oncology/Hematology, Department of Pediatrics, Skåne University Hospital, Lund, Sweden.;Laboratoire d'Hépatologie Pédiatrique et Thérapie Cellulaire, Unité PEDI, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Service de gastroentérologie et hépatologie pédiatrique, Département de Pédiatrie, Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Pediatric Blood and Marrow Transplantation Program, Prinsesmaxima centrum, Utrecht, Netherlands.;Faculty of Medicine, Nephrology Center, Vilnius University, Vilnius, Lithuania.;Centre for Pediatric Oncology and Haematology, Children's Hospital, Vilnius University Hospital, Vilnius, Lithuania. | 2176 | |||
| 10.3949/ccjm.87a.ccc057 | Journal Article | en | Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 3: The role of GM-CSF. | https://www.ncbi.nlm.nih.gov/pubmed/32753517 | Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been used experimentally in patients with acute respiratory distress syndrome. Recombinant GM-CSF administered by direct inhalation is currently being studied in a cohort of patients with advanced COVID-19. | 0891-1150,1939-2869 | 2020-08-16 02:00:00+02:00 | pubmed | Cleveland Clinic Journal of Medicine | Leonard H Calabrese;Tiphaine Lenfant;Cassandra Calabrese | 2020-08-12 02:00:00+02:00 | 32753517 | FR;US | Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, Cleveland Clinic calabrl@ccf.org.;Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute Department of Infectious Disease, Cleveland Clinic, Assistance Publique des Hôpitaux de Paris, Université de Paris, Hôpital européen Georges Pompidou, Service de médecine interne, Paris, France.;Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, and Department of Infectious Disease, Cleveland Clinic. | 2179 | ||||
| 10.1002/alz.12143 | Journal Article | en | Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. | https://www.ncbi.nlm.nih.gov/pubmed/32789951 | We have provided an overview on the profound impact of COVID-19 upon older people with Alzheimer's disease and other dementias and the challenges encountered in our management of dementia in different health-care settings, including hospital, out-patient, care homes, and the community during the COVID-19 pandemic. We have also proposed a conceptual framework and practical suggestions for health-care providers in tackling these challenges, which can also apply to the care of older people in general, with or without other neurological diseases, such as stroke or parkinsonism. We believe this review will provide strategic directions and set standards for health-care leaders in dementia, including governmental bodies around the world in coordinating emergency response plans for protecting and caring for older people with dementia amid the COIVD-19 outbreak, which is likely to continue at varying severity in different regions around the world in the medium term. | 1552-5260,1552-5279 | 2020-08-16 02:00:00+02:00 | pubmed | Alzheimer's & Dementia | Vincent C T Mok;Sarah Pendlebury;Adrian Wong;Suvarna Alladi;Lisa Au;Philip M Bath;Geert Jan Biessels;Christopher Chen;Charlotte Cordonnier;Martin Dichgans;Jacqueline Dominguez;Philip B Gorelick;SangYun Kim;Timothy Kwok;Steven M Greenberg;Jianping Jia;Rajesh Kalaria;Miia Kivipelto;Kandiah Naegandran;Linda C W Lam;Bonnie Yin Ka Lam;Allen T C Lee;Hugh S Markus;John O'Brien;Ming-Chyi Pai;Leonardo Pantoni;Perminder Sachdev;Ingmar Skoog;Eric E Smith;Velandai Srikanth;Guk-Hee Suh;Joanna Wardlaw;Ho Ko;Sandra E Black;Philip Scheltens | Alzheimer's disease;COVID-19;dementia;older people | 2020-08-12 02:00:00+02:00 | 32789951 | FR;SG;SE;CA;FI;CN;GB;US;HK;TW;IT;AU;NL;PH;IN;KR;DE | Department of Medicine and Therapeutics, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, New Territories, Shatin, Hong Kong SAR, China.;Gerald Choa Neuroscience Centre, Margaret K. L. Cheung Research Centre for Management of Parkinsonism, Therese Pei Fong Chow Research Centre for Prevention of Dementia, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.;Li Ka Shing Institute of Health Sciences, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.;NIHR Oxford Biomedical Research Centre, The Joint Research Office, Oxford, UK.;Departments of Acute General Medicine and Geratology, John Radcliffe Hospital, Oxford, UK.;Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.;Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, India.;Stroke Trials Unit, Division of Clinical Neuroscience, School of Medicine, The University of Nottingham, Nottingham, UK.;Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.;Department of Pharmacology, Memory Aging and Cognition Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.;Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France.;Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.;German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.;Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.;Memory Center, International Institute for Neurosciences, St. Luke's Medical Center, Manila, Philippines.;The Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.;Division of Cerebrovascular Disease and Neurocritical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.;Department of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.;Department of Neurology, Seoul National University College of Medicine, Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seoul, South Korea.;Division of Geriatrics, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.;Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.;Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.;Translational and Clinical Research Institute, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK.;Karolinska Institutet, Dept NVS, Division of Clinical Geriatrics, Center for Alzheimer Research and Karolinska University Hospital, Theme Aging, Stockholm, Sweden.;Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.;Ageing and Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, UK.;Department of Neurology, National Neuroscience Institute, Singapore.;Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, New Territories, Shatin, Hong Kong SAR, China.;Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.;Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.;Division of Behavioral Neurology, Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.;Stroke and Dementia Lab, "Luigi Sacco" Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.;Neuropsychiatric Institute, School of Psychiatry, The University of New South Wales, Sydney, Australia.;Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.;Division of Neurology, Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.;Department of Geriatric Medicine Peninsula Health, Peninsula Clinical School, Monash University, Clayton, Victoria, Australia.;Department of Psychiatry, Hallym University College of Medicine, Seoul, South Korea.;Centre for Clinical Brain Sciences, Edinburgh Imaging and UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.;Department of Medicine (Neurology), Canadian Partnership for Stroke Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.;Alzheimer Center Amsterdam, University Medical Centers, Amsterdam, the Netherlands. | 2181 | |||
| 10.1007/s10047-020-01203-x | Journal Article | en | Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports. | https://www.ncbi.nlm.nih.gov/pubmed/32789604 | Veno-venous (VV) extracorporeal membrane oxygenation (ECMO) is increasingly used in Coronavirus disease-19 (COVID-19) patients with the most severe forms of acute respiratory distress syndrome (ARDS). Its use is associated with a significant hemostatic challenge, especially in COVID- 19 patients who have been demonstrated to otherwise present a COVID-19-associated coagulopathy. The systematic use of unfractionated heparin therapy to prevent circuit thrombosis is warranted during ECMO support. The clinical presentation and management of heparin-induced thrombocytopenia, which is a rare but life-threatening complication of heparin therapy, has not been described in those patients yet. We report herein two cases of laboratory-confirmed HIT in COVID-19 patients with severe ARDS admitted to our intensive care unit for VV-ECMO support and the successful use of argatroban as an alternative therapy. We also provide a brief literature review of best evidence for managing such patients. The diagnosis and management of HIT is particularly challenging in COVID-19 patients receiving ECMO support. An increased awareness is warranted in those patients who already present a procoagulant state leading to higher rates of thrombotic events which can confuse the issues. Argatroban seems to be an appropriate and safe therapeutic option in COVID-19 patients with HIT while on VV-ECMO. | 1434-7229,1619-0904 | 2020-08-16 02:00:00+02:00 | pubmed | Journal of Artificial Organs | Frank Bidar;Guillaume Hékimian;Isabelle Martin-Toutain;Guillaume Lebreton;Alain Combes;Corinne Frère | Argatroban;COVID-19;Extracorporeal membrane oxygenation;Heparin-induced thrombocytopenia | 2020-08-12 02:00:00+02:00 | 32789604 | FR | Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, F-75013, Paris, France. frankbidar@gmail.com.;Service de médecine Intensive-réanimation, Institut de Cardiologie, APHP Hôpital Pitié-Salpêtrière, 75013, Paris, France. frankbidar@gmail.com.;Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, F-75013, Paris, France.;Service de médecine Intensive-réanimation, Institut de Cardiologie, APHP Hôpital Pitié-Salpêtrière, 75013, Paris, France.;Service D'hématologie Biologique, APHP Hôpital Pitié-Salpêtrière, 75013, Paris, France.;Service de Chirurgie Thoracique Et Cardio-Vasculaire, Institut de Cardiologie, APHP Hôpital Pitié-Salpêtrière, 75013, Paris, France. | 2184 | |||
| Letter | en | Movement disorders as a new neurological clinical picture in severe SARS-CoV-2 infection. | https://www.ncbi.nlm.nih.gov/pubmed/32786131 | New forms of neurological complications of severe SARS-CoV-2 infection have been described, mainly including encephalopathy, agitation and confusion.1 Only one publication reveals the emergence of de novo myoclonus in three patients,2 with most publications reporting the aggravation of pre-existing abnormal movements disorders. Here, we identified and characterized in depth clinically a new type of delayed onset movement disorders in five patients who were admitted to the AP-HP intensive care unit (ICU) units for severe SARS-CoV-2 infection. All patients underwent intubation and mechanical ventilation. | 2020-08-16 02:00:00+02:00 | pubmed | Paulina Cunha;Bastien Herlin;Kosta Vassilev;Aurelie Kas;Stephane Lehericy;Yulia Worbe;Emmanuelle Apartis;Marie Vidailhet;Sophie Dupont | SARS-CoV-2 infection;movement disorders;neurological complications | 2020-08-12 02:00:00+02:00 | 32786131 | FR | Rehabilitation Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.;Nuclear medicine Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.;Université Paris Sorbonne, Paris, France.;Institute of brain and spinal cord, Paris, France.;Neuroradiology Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.;Neurophysiology Unit, Saint Antoine Hospital, AP-HP, Paris, France.;Movement disorders Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.;Epilepsy Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris, France. | 2187 | ||||||
| 10.1016/j.etiqe.2020.07.001 | English Abstract;Journal Article | fr | [Freedom in retirement home, facing confinement]. | https://www.ncbi.nlm.nih.gov/pubmed/32837548 | The COVID-19 pandemic has limited the freedom of any citizen, further increased constraint for people in EHPAD - the most widespread type of French Residential care for senior citizens with a high level of dependency, often very aged, suffering multiple pathologies and sometimes psycho-behavioral disorders. "Golden" containment rule was 24/7 confinement in their room, with the very restrictive framework - up to NO visiting by relatives - and very often with a total absence of consent as for screening sample decisions. We can then question the fundamentals of such restriction of freedom, which is a constitutional right for everybody, including for residents in EHPAD, especially non-compliance with self-determination and consent. The principal objective has been a collective interest, before the individual right and the benefit for the patient itself. Nothing would have been justifying to create a possible risk to other residents, generated by another resident's behavior or one of his relatives. But these safety measures were taken despite the underlying risk of deteriorating individual situations through social and emotional isolation, and thus to further reduce autonomy capacities. "Luckily" the know-how and creative spirit of EHPAD professionals limited the consequences of this restriction of freedom. Hard lessons should be learned from share experiences if such a context were to occur again. But above all arises the question of the place of these dependent people in our society. It is essential to think collectively about these living spaces including protocols that should reflect people's choice and on-location adapted to be more open to the outside/foreigners visits. Spaces shall be adapted to their vulnerability, designed to reduce isolation, to repeat such extreme restrictive measures in the event if it shall occur. Of course, rigorous confinement rules allowed to limit deaths linked to the COVID infection, but at the risk of dying in loneliness and grief. | 1765-4629 | 2020-08-16 02:00:00+02:00 | pubmed | Éthique & Santé | M Ladiesse;T Léonard;B Birmelé | Autonomy;Consent;Elderly;Freedom of movement;Pandemia | 2020-08-16 02:00:00+02:00 | 32837548 | FR | Espace de réflexion éthique région Centre Val-de-Loire, CHU Tours, 2, boulevard Tonnellé, 37044 Tours, France.;CMRR, Consultation intersectorielle de gérontopsychiatrie, CHU Tours, 37044 Tours, France. | 2191 | |||
| 10.1016/j.tig.2020.08.003 | Journal Article | en | Host Polymorphisms May Impact SARS-CoV-2 Infectivity. | https://www.ncbi.nlm.nih.gov/pubmed/32828550 | Based on a broad public database compilation, we support the hypothesis that germinal polymorphisms may regulate the expression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular target itself and proteases controlling the process of its shedding or, conversely, its internalization. Consequently, a genetic influence on individual susceptibility to coronavirus disease 2019 (COVID-19) infection is strongly suspected. | 0168-9525 | 2020-08-16 02:00:00+02:00 | pubmed | Trends in Genetics | Patrick Brest;Sadal Refae;Baharia Mograbi;Paul Hofman;Gerard Milano | SNP;coronavirus;genetic variation;infection;pharmacogenetics | 2020-08-10 02:00:00+02:00 | 32828550 | FR;IT;SA | Université Côte d'Azur, Centre Antoine Lacassagne, CNRS, Inserm, IRCAN, FHU-OncoAge, Nice, F-06189, France.;Université Côte d'Azur, Centre Antoine Lacassagne, EA7497, Nice, F-06100 France, Ministry of National Guard - Health Affairs (NGHA), Al Madinah Kingdom of Saudi Arabia, Riyadh 11426, Saudi Arabia.;Université Côte d'Azur, Centre Antoine Lacassagne, CNRS, Inserm, IRCAN, FHU-OncoAge, Nice, F-06189, France, Université Côte d'Azur, CHU-Nice, Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Hospital-Integrated Biobank (BB-0033-00025), Nice, F-06001, France.;Université Côte d'Azur, Centre Antoine Lacassagne, EA7497, Nice, F-06100 France. Electronic address: gerard.milano@nice.unicancer.fr. | 2192 | |||
| 10.2196/19611 | Journal Article | en | Assessment of the Impact of Media Coverage on COVID-19-Related Google Trends Data: Infodemiology Study. | https://www.ncbi.nlm.nih.gov/pubmed/32530816 | The influence of media coverage on web-based searches may hinder the role of Google Trends (GT) in monitoring coronavirus disease (COVID-19). | 1438-8871 | 2020-08-16 02:00:00+02:00 | pubmed | Betacoronavirus;Communication;Communications Media;Coronavirus Infections;Humans;Pandemics;Pneumonia, Viral;Search Engine;COVID-19;severe acute respiratory syndrome coronavirus 2 | Journal of Medical Internet Research | Bernardo Sousa-Pinto;Aram Anto;Wienia Czarlewski;Josep M Anto;João Almeida Fonseca;Jean Bousquet | COVID-19;Google Trends;coronavirus;infodemic;infodemiology;media;media coverage;monitoring;pandemic;symptom;trend | 2020-08-10 02:00:00+02:00 | 32530816 | FR;PT;ES;DE | Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.;Center for Health Technology and Services Research, University of Porto, Porto, Portugal.;MASK-air, Montpellier, France.;Medical Consulting Czarlewski, Levallois, France.;Centre for Research in Environmental Epidemiology, Barcelona Institute for Global Health, Barcelona, Spain.;Universitat Pompeu Fabra, Barcelona, Spain.;CIBER Epidemiología y Salud Pública, Barcelona, Spain.;Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.;Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany.;MACVIA-France, Montpellier, France. | 2195 | ||
| 10.1007/s12105-020-01212-5 | Journal Article;Review | en | ACE2 & TMPRSS2 Expressions in Head & Neck Tissues: A Systematic Review. | https://www.ncbi.nlm.nih.gov/pubmed/32816230 | To review the data regarding the expression of angiotensin converting enzyme-2 (ACE2) and transmembrane protease serine-2 (TMPRSS2) in head and neck tissue. Scopus, Cochrane Library, Medrxiv, Google Scholar and PubMED/MEDLINE were searched by four independent investigators for studies investigating ACE2 or TMPRSS2 expressions in head and neck tissues. The following outcomes were considered: sample origin (animal versus human); detection method; anatomical location and cell types. PRISMA checklist and modified population, intervention, comparison, outcome, timing and setting (PICOTS) framework were used to perform the review. Of the 24 identified studies, 17 met our inclusion criteria. Thirteen studies were conducted during the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. ACE2 and TMPRSS2 were expressed in oral, pharyngeal, sinusonasal human mucosa. The following cell types expressed ACE2: basal, apical, goblet, minor salivary, and endothelial cells. TMPRSS2 was found in goblet and apical respiratory cells. ACE2 and TMPRSS2 were found in the olfactory region, especially in sustentacular non-neural and neural stem cells. Animal studies suggested that ACE2 expression may vary regarding age. There was an important heterogeneity between studies in the methods used to detect ACE2 and TMPRSS2, leading to a potential identification bias. The SARS-CoV-2 receptors, ACE2 and TMPRSS2, are both expressed in many head and neck tissues, enabling the viral entry into the host organism. | 1936-0568 | 2020-08-23 02:00:00+02:00 | pubmed | Head and Neck Pathology | Jerome R Lechien;Thomas Radulesco;Christian Calvo-Henriquez;Carlos M Chiesa-Estomba;Stéphane Hans;Maria R Barillari;Giovanni Cammaroto;Géraldine Descamps;Julien Hsieh;Luigi Vaira;Giacomo De Riu;Leigh Sowerby;Isabelle Gengler;Justin Michel;Sven Saussez | ACE2;COVID;Coronavirus;Head Neck;SARS-CoV-2;TMPRSS2 | 2020-08-20 02:00:00+02:00 | 32816230 | FR;CA;CH;GB;US;IT;ES;BE | COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France. jerome.lechien@umons.ac.be.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium. jerome.lechien@umons.ac.be.;Department of Otolaryngology-Head & Neck Surgery, School of Medicine, Foch Hospital, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France. jerome.lechien@umons.ac.be.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. jerome.lechien@umons.ac.be.;COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France.;Department of Oto-Rhino-Laryngology Head and Neck Surgery, La Conception University Hospital, Aix Marseille Univ, APHM, IUSTI, Marseille, France.;Department of Otolaryngology-Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain.;Department of Otorhinolaryngology-Head & Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.;Department of Otolaryngology-Head & Neck Surgery, School of Medicine, Foch Hospital, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.;Department of Mental and Physical Health and Preventive Medicine, University of L. Vanvitelli, Naples, Italy.;Department of Otolaryngology-Head & Neck Surgery, Morgagni Pierantoni Hospital, Forli, Italy.;Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.;Rhinology-Olfactology Unit, Department of Otorhinolaryngology, Head and Neck Surgery, Geneva University Hospitals (HUG), Geneva, Switzerland.;Maxillofacial Surgery Unit, University Hospital of Sassari, Sassari, Italy.;Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, ON, Canada.;Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati Medical Center, Cincinnati, OH, USA.;Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium. | 2203 | |||
| Fondation francophone Recherche Diabète (FFRD);Fonds dotation du CHU de Nantes;Société Francophone du Diabète | Letter | en | Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jüni P et al [letter]. | https://www.ncbi.nlm.nih.gov/pubmed/32816095 | 2020-08-23 02:00:00+02:00 | pubmed | Bertrand Cariou;Samy Hadjadj;Matthieu Wargny;Matthieu Pichelin;Abdallah Al-Salameh;Ingrid Allix;Coralie Amadou;Gwénaëlle Arnault;Florence Baudoux;Bernard Bauduceau;Sophie Borot;Muriel Bourgeon-Ghittori;Olivier Bourron;David Boutoille;France Cazenave-Roblot;Claude Chaumeil;Emmanuel Cosson;Sandrine Coudol;Patrice Darmon;Emmanuel Disse;Amélie Ducet-Boiffard;Bénédicte Gaborit;Michael Joubert;Véronique Kerlan;Bruno Laviolle;Lucien Marchand;Laurent Meyer;Louis Potier;Gaëtan Prevost;Jean-Pierre Riveline;René Robert;Pierre-Jean Saulnier;Ariane Sultan;Jean-François Thébaut;Charles Thivolet;Blandine Tramunt;Camille Vatier;Ronan Roussel;Jean-François Gautier;Pierre Gourdy | Blood glucose;COVID-19;Diabetes;Mortality;Prognosis | 2020-08-20 02:00:00+02:00 | 32816095 | FR | [{"country": "", "agency": "Fondation francophone Recherche Diabète (FFRD)", "grantid": "CORONADO"}, {"country": "", "agency": "Fonds dotation du CHU de Nantes", "grantid": "CORONADO"}, {"country": "", "agency": "Société Francophone du Diabète", "grantid": "CORONADO"}] | Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France.;Département d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France. samy.hadjadj@univ-nantes.fr.;CIC-EC 1413, Clinique des Données, CHU Nantes, Nantes, France.;Département d'Endocrinologie, Diabétologie et Nutrition, CHU Amiens, PeriToxUMR_I 01, Université de Picardie, Amiens, France.;Département d'Endocrinologie, Diabétologie, Nutrition, CHU de Angers, Angers, France.;Département de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil Essonne, France.;Département d'Endocrinologie, Diabétologie et Maladies Métaboliques, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Clinique d'Endocrinologique Marc-Linquette, Hôpital Claude-Huriez, CHRU de Lille, Lille, France.;Département de Diabétologie, H.I.A. Begin, Saint Mandé, France.;Fondation Francophone pour la Recherche sur le Diabète (FFRD), Paris, France.;Département d'Endocrinologie, Diabétologie et Nutrition, CHU de Besançon, Besançon, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Assistance Publique Hôpitaux de Paris, Université Paris Saclay, Hôpital Antoine Béclère, Clamart, Hôpital Bicêtre, Le Kremlin Bicêtre, France.;Sorbonne Université, Assistance Publique Hôpitaux de Paris, Département de Diabétologie, CHU La Pitié Salpêtrière-Charles Foix, Inserm, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06, Institute of Cardiometabolism and Nutrition ICAN, Paris, France.;Département des Maladies Infectieuses et Tropicales, CHU Nantes, Nantes, France.;Département des Maladies Infectieuses et Tropicales, CHU de Poitiers, INSERM U1070, Poitiers, France.;Société de Pathologie Infectieuse de langue Française (SPILF), Paris, France.;Fédération Française des Diabétiques (FFD), Paris, France.;Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, Université Paris 13, Sorbonne Paris Cité, Département d'Endocrinologie, Diabétologie et Nutrition, CRNH-IdF, CINFO, Bobigny, France.;Université Paris 13, Sorbonne Paris Cité, UMR U557 Inserm / U11125 INRAE / CNAM / Université Paris13, Unité de Recherche Epidémiologique Nutritionnelle, Bobigny, France.;Département d'Endocrinologie et de Diabétologie, Hôpital de la Conception, Assistance Publique Hôpitaux de Marseille, Marseille, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Hospices Civils de Lyon, CarMeN Laboratory, Inserm 1060, Lyon, France, Université Claude Bernard Lyon 1, Lyon, France.;Département d'Endocrinologie et de Diabétologie, Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France.;Département d'Endocrinologie et de Diabétologie, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Marseille, France.;Département de Diabétologie, CHU de Caen, Caen, France.;Département d'Endocrinologie, CHU de Brest, EA 3878 GETBO, Brest, France.;CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Université de Rennes, Rennes, France.;Département d'Endocrinologie et de Diabétologie, Centre Hospitalier St. Joseph - St. Luc, Lyon, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Département d'Endocrinologie, Diabétologie et Nutrition, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Centre de Recherche des Cordeliers, Inserm, Université de Paris, U-1138, Paris, France.;Département d'Endocrinologie, Diabétologie et Maladies Métaboliques, CHU de Rouen, Université de Rouen, Rouen, France.;Département Diabète et Endocrinologie, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France.;Paris Diderot-Paris VII Université, Paris, France.;Inserm UMRS 1138, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France.;Université de Poitiers, CIC Inserm 1402, Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique CIC 1402, Université de Poitiers, Inserm, CHU de Poitiers, Poitiers, France.;Département d'Endocrinologie, Diabète, Nutrition et CIC Inserm 1411, CHU de Montpellier, Montpellier, France.;Centre du Diabète DIAB-eCARE, Hospices Civils de Lyon et Laboratoire CarMeN, Inserm, INRA, INSA, Université Claude Bernard Lyon 1, Lyon, France.;Société Francophone du Diabète (SFD), Paris, France.;Département d'Endocrinologie, Diabétologie et Nutrition, CHU Toulouse, Institut des Maladies Métaboliques et Cardiovasculaires, UMR1048 Inserm/UPS, Université de Toulouse, Toulouse, France.;Assistance Publique Hôpitaux de Paris, Saint-Antoine Hospital, Reference Center of Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Department of Endocrinology, Paris, France.;Inserm UMRS 938, Saint-Antoine Research Center, Sorbonne University, Paris, France. | 2205 | |||||
| 10.3390/jcm9092697 | Journal Article | en | Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. | https://www.ncbi.nlm.nih.gov/pubmed/32825383 | Technological progress, including virtual clinics, web or smartphone-based applications, and assessment of fecal calprotectin (FC) at home has favored the implementation of treat to target strategies for patients with inflammatory bowel diseases (IBD). Although these innovations are promising and have been associated with a significant reduction in health costs, their application in clinical practice is limited. Here, we summarize the most recent literature on virtual clinics and available FC home tests. In addition, we report the experience of IBD patients monitored through the IBDoc® test at the Nancy University Hospital, focusing on usability testing and patient's satisfaction. This pilot experience shows that a virtual calprotectin clinic doubles adherence rate to FC in IBD patients. This finding is especially clinically relevant in the post-coronavirus disease 2019 (COVID-19) pandemic era, with an increasing use of e-health. | 2077-0383 | 2020-08-23 02:00:00+02:00 | pubmed | Journal of Clinical Medicine | Ferdinando D'Amico;Patrick Netter;Cedric Baumann;Muriel Veltin;Camille Zallot;Isabelle Aimone-Gastin;Silvio Danese;Laurent Peyrin-Biroulet | IBDoc®;fecal calprotectin home test;inflammatory bowel disease;virtual clinic | 2020-08-20 02:00:00+02:00 | 32825383 | FR;IT | Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy.;Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, 54500 Vandoeuvre-lès-Nancy, France.;Ingénierie Moléculaire et Ingénierie Articulaire (IMoPA), UMR-7365 CNRS, Faculté de Médecine, University of Lorraine and University Hospital of Nancy, 54000 Nancy, France.;Clinical Research Support Facility, Methodological and Statistical Unit, University Hospital of Nancy, 54000 Nancy, France.;Department of Biochemistry-Molecular Biology-Nutrition, Nancy University Hospital, 54000 Nancy, France.;Inserm UMR_S1256 N-GERE, Nutrition-Genetics-Environmental Risk Exposure, University Hospital of Nancy, University of Lorraine, 54500 Vandoeuvre-lès-Nancy, France.;IBD center, Department of Gastroenterology, Humanitas Clinical and Research Center-IRCCS, Rozzano, 20089 Milan, Italy. | 2209 | |||
| 10.1016/j.meegid.2020.104506 | Journal Article | en | The first months of COVID-19 in Madagascar. | https://www.ncbi.nlm.nih.gov/pubmed/32828939 | Using the officially published data and aware of the uncertain source and insufficient number of samples, we present a first and (for the moment) unique attempt to study the first two months spread of the pandemic COVID-19 in Madagascar. The approach has been tested by predicting the number of contaminated persons for the next week after fitting the inputs data collected within 7 or 15 days using standard least χ2-fit method. Encouraged by this first test, we study systematically during 67 days, 1-2 weeks new data and predict the contaminated persons for the coming week. We find that the first month data are well described by a linear or quadratic polynomial with an increase of about (4-5) infected persons per day. Pursuing the analysis, one note that data until 46 days favours a cubic polynomial behaviour which signals an eventual near future stronger growth as confirmed by the new data on the 48th day. We complete the analysis until 67 days and find that the data until 77 days confirm the cubic polynomial behaviour which is a remarkable feature of the pandemic spread in Madagascar. We expect that these results will be useful for some new model buildings. A comparison with some other SI-like models predictions is done. These results for infected persons may also be interpreted as the lowest values of the real cases due to the insufficient number of samples (about 12,907 for 27 million habitants on 05/06/20). The data analysis of the absolute number of cured persons until 67 days shows an approximate linear behaviour with about 3 cured persons per day. However, the number of percentage number of cured persons decreases above 42-46 days indicating the limits of the hospital equipment and care to face the 2nd phase of the pandemic for the 67th first days. Some comments on the social, economical and political impacts of COVID-19 and confinement for Madagascar and, in general, for Worldwide are shortly discussed. | 1567-1348 | 2020-08-23 02:00:00+02:00 | pubmed | Infection, Genetics and Evolution | Stephan Narison | Confinement;Covid-19;Infectious disease;Pandemic;Virus spread | 2020-08-20 02:00:00+02:00 | 32828939 | FR;MG | Laboratoire Particules et Univers de Montpellier, CNRS-IN2P3, Case 070, Place Eugène Bataillon, 34095 Montpellier, France, iHEPMAD Research Institute, University of Ankatso, Antananarivo 101, Madagascar. Electronic address: snarison@yahoo.fr. | 2211 | |||
| 10.1038/s41385-020-00340-z | Journal Article;Review | en | Animal and translational models of SARS-CoV-2 infection and COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32820248 | COVID-19 is causing a major once-in-a-century global pandemic. The scientific and clinical community is in a race to define and develop effective preventions and treatments. The major features of disease are described but clinical trials have been hampered by competing interests, small scale, lack of defined patient cohorts and defined readouts. What is needed now is head-to-head comparison of existing drugs, testing of safety including in the background of predisposing chronic diseases, and the development of new and targeted preventions and treatments. This is most efficiently achieved using representative animal models of primary infection including in the background of chronic disease with validation of findings in primary human cells and tissues. We explore and discuss the diverse animal, cell and tissue models that are being used and developed and collectively recapitulate many critical aspects of disease manifestation in humans to develop and test new preventions and treatments. | 1933-0219,1935-3456 | 2020-08-23 02:00:00+02:00 | pubmed | Mucosal Immunology | M D Johansen;A Irving;X Montagutelli;M D Tate;I Rudloff;M F Nold;N G Hansbro;R Y Kim;C Donovan;G Liu;A Faiz;K R Short;J G Lyons;G W McCaughan;M D Gorrell;A Cole;C Moreno;D Couteur;D Hesselson;J Triccas;G G Neely;J R Gamble;S J Simpson;B M Saunders;B G Oliver;W J Britton;P A Wark;C A Nold-Petry;P M Hansbro | 2020-08-20 02:00:00+02:00 | 32820248 | FR;CN;AU;GB | Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, Sydney, Australia.;Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, ZJU International Campus, Haining, China.;Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.;Department of Genomes and Genetics, Institut Pasteur, Paris, France.;Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia.;Department of Molecular and Translational Sciences, Monash University, Clayton, VIC, Australia.;Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, 3168, Australia.;Department of Paediatrics, Monash University, Clayton, VIC, 3168, Australia.;Monash Newborn, Monash Children's Hospital, Clayton, VIC, Australia.;Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and University of Newcastle, Newcastle, NSW, Australia.;School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Australia.;Centenary Institute and Dermatology, The University of Sydney and Cancer Services, Royal Prince Alfred Hospital, Sydney, NSW, Australia.;Centenary Institute and Faculty of Medicine and Health, University of Sydney, Sydney, Australia.;Dr. John and Anne Chong Lab for Functional Genomics, Charles Perkins Centre, Centenary Institute, and School of Life and Environmental Sciences, University of Sydney, Sydney, NSW, Australia.;Charles Perkins Centre and School of Life and Environmental Sciences, University of Sydney, and Faculty of Medicine and Health, Concord Clinical School, ANZAC Research Institute and Centre for Education and Research on Ageing, Sydney, Australia.;Discipline of Infectious Diseases and Immunology, Central Clinical School, Faculty of Medicine and Health and the Charles Perkins Centre, The University of Sydney, Camperdown, Sydney, Australia.;Woolcock Institute of Medical Research, Sydney, Australia.;Centenary Institute, The University of Sydney and Department of Clinical Immunology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.;Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, Sydney, Australia. Philip.Hansbro@uts.edu.au.;Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and University of Newcastle, Newcastle, NSW, Australia. Philip.Hansbro@uts.edu.au. | 2212 | ||||
| 10.1093/ije/dyaa134 | Journal Article | en | Risk factors for positive and negative COVID-19 tests: a cautious and in-depth analysis of UK biobank data. | https://www.ncbi.nlm.nih.gov/pubmed/32814959 | The recent COVID-19 outbreak has generated an unprecedented public health crisis, with millions of infections and hundreds of thousands of deaths worldwide. Using hospital-based or mortality data, several COVID-19 risk factors have been identified, but these may be confounded or biased. | 0300-5771,1464-3685 | 2020-08-23 02:00:00+02:00 | pubmed | International Journal Of Epidemiology | Marc Chadeau-Hyam;Barbara Bodinier;Joshua Elliott;Matthew D Whitaker;Ioanna Tzoulaki;Roel Vermeulen;Michelle Kelly-Irving;Cyrille Delpierre;Paul Elliott | COVID-19;SARS-CoV-2;UK Biobank;infection;prospective cohort;test data | 2020-08-20 02:00:00+02:00 | 32814959 | FR;GR;GB;NL | Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.;MRC Centre for Environment and Health, Imperial College, London, UK.;Royal Surrey County Hospital, Guildford, Surrey, UK.;Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece.;Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.;UMR LEASP, Université de Toulouse III, UPS, Inserm, Toulouse, France. | 2215 | |||
| Wellcome Trust (Wellcome);National Institute for Academic Anaesthesia (NIAA) | 10.1038/s41591-020-1038-6 | Journal Article | en | A dynamic COVID-19 immune signature includes associations with poor prognosis. | https://www.ncbi.nlm.nih.gov/pubmed/32807934 | Improved understanding and management of COVID-19, a potentially life-threatening disease, could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward this end, we have identified a core peripheral blood immune signature across 63 hospital-treated patients with COVID-19 who were otherwise highly heterogeneous. The signature includes discrete changes in B and myelomonocytic cell composition, profoundly altered T cell phenotypes, selective cytokine/chemokine upregulation and SARS-CoV-2-specific antibodies. Some signature traits identify links with other settings of immunoprotection and immunopathology; others, including basophil and plasmacytoid dendritic cell depletion, correlate strongly with disease severity; while a third set of traits, including a triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent clinical progression. Hence, contingent upon independent validation in other COVID-19 cohorts, individual traits within this signature may collectively and individually guide treatment options; offer insights into COVID-19 pathogenesis; and aid early, risk-based patient stratification that is particularly beneficial in phasic diseases such as COVID-19. | 1078-8956,1546-170X | 2020-08-23 02:00:00+02:00 | pubmed | Nature Medicine | Adam G Laing;Anna Lorenc;Irene Del Molino Del Barrio;Abhishek Das;Matthew Fish;Leticia Monin;Miguel Muñoz-Ruiz;Duncan R McKenzie;Thomas S Hayday;Isaac Francos-Quijorna;Shraddha Kamdar;Magdalene Joseph;Daniel Davies;Richard Davis;Aislinn Jennings;Iva Zlatareva;Pierre Vantourout;Yin Wu;Vasiliki Sofra;Florencia Cano;Maria Greco;Efstathios Theodoridis;Joshua Freedman;Sarah Gee;Julie Nuo En Chan;Sarah Ryan;Eva Bugallo-Blanco;Pärt Peterson;Kai Kisand;Liis Haljasmägi;Loubna Chadli;Philippe Moingeon;Lauren Martinez;Blair Merrick;Karen Bisnauthsing;Kate Brooks;Mohammad A A Ibrahim;Jeremy Mason;Federico Lopez Gomez;Kola Babalola;Sultan Abdul-Jawad;John Cason;Christine Mant;Jeffrey Seow;Carl Graham;Katie J Doores;Francesca Di Rosa;Jonathan Edgeworth;Manu Shankar-Hari;Adrian C Hayday | 2020-08-17 02:00:00+02:00 | 32807934 | FR;EE;GB;IT | [{"country": "", "agency": "Wellcome Trust (Wellcome)", "grantid": "106292/Z/4/Z"}, {"country": "", "agency": "National Institute for Academic Anaesthesia (NIAA)", "grantid": "WKR0-2018-0047"}] | Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.;UCL Cancer Institute, University College London, London, UK.;London School of Hygiene & Tropical Medicine, London, UK.;Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.;The Francis Crick Institute, London, UK.;Regeneration Group, Wolfson Centre for Age-Related Diseases, IoPPN, King's College London, London, UK.;Department of Plastic and Reconstructive Surgery, Royal Free NHS Foundation Trust, London, UK.;Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.;Department of Inflammation Biology, King's College London, London, UK.;Molecular Pathology Research Group, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.;Center for Therapeutic Innovation in Immuno-inflammation, Servier, France.;Infectious Diseases Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.;Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.;Immunological Medicine, Kings College Hospital NHS Foundation Trust, London, UK.;The European Bioinformatics Institute (EMBL-EBI) Wellcome Genome Campus, Hinxton, UK.;Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.;Infectious Diseases Biobank, Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.;Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), Rome, Italy.;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK. manu.shankar-hari@kcl.ac.uk.;Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK. manu.shankar-hari@kcl.ac.uk.;Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK. adrian.hayday@kcl.ac.uk.;The Francis Crick Institute, London, UK. adrian.hayday@kcl.ac.uk. | 2216 | ||
| 10.1001/jama.2020.16349 | Journal Article | en | Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. | https://www.ncbi.nlm.nih.gov/pubmed/32821939 | Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown. | 0098-7484 | 2020-08-23 02:00:00+02:00 | pubmed | JAMA | Christoph D Spinner;Robert L Gottlieb;Gerard J Criner;José Ramón Arribas López;Anna Maria Cattelan;Alex Soriano Viladomiu;Onyema Ogbuagu;Prashant Malhotra;Kathleen M Mullane;Antonella Castagna;Louis Yi Ann Chai;Meta Roestenberg;Owen Tak Yin Tsang;Enos Bernasconi;Paul Le Turnier;Shan-Chwen Chang;Devi SenGupta;Robert H Hyland;Anu O Osinusi;Huyen Cao;Christiana Blair;Hongyuan Wang;Anuj Gaggar;Diana M Brainard;Mark J McPhail;Sanjay Bhagani;Mi Young Ahn;Arun J Sanyal;Gregory Huhn;Francisco M Marty | 2020-08-21 02:00:00+02:00 | 32821939 | FR;SG;CN;BO;GB;US;HK;CH;TW;IT;NL;ES;KR;DE | Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Munich, Germany.;Baylor University Medical Center, Dallas, Texas.;Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.;Instituto de Investigación Hospital Universitario La Paz, Madrid, Spain.;Azienda Ospedaliera di Padova, Padova, Italy.;Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain.;Yale School of Medicine, New Haven, Connecticut.;North Shore University Hospital, Manhasset, New York.;University of Chicago, Chicago, Illinois.;IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.;National University Health System, Singapore.;Leiden University Medical Center, Leiden, the Netherlands.;Princess Margaret Hospital, Hong Kong, China.;Ente Ospedaliero Cantonale, Bellinzona, Switzerland.;University of Nantes, Nantes, France.;National Taiwan University Hospital, Taipei, Taiwan.;Gilead Sciences, Foster City, California.;King's College, London, England.;Royal Free Hospital, London, England.;Seoul Medical Center, Seoul, South Korea.;Virginia Commonwealth University, Richmond.;Cook County Health, Chicago, Illinois.;Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. | 2219 | ||||
| 10.1093/cid/ciaa1223 | Journal Article | en | BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden. | https://www.ncbi.nlm.nih.gov/pubmed/32829400 | The Bacille Calmette-Guérin (BCG) tuberculosis vaccine has immunity benefits against respiratory infections. Accordingly, it has been hypothesized to have a protective effect against COVID-19. Recent research found that countries with universal BCG childhood vaccination policies tend to be less affected by the COVID-19 pandemic. However, such ecological studies are biased by numerous confounders. Instead, this paper takes advantage of a rare nationwide natural experiment that took place in Sweden in 1975, where discontinuation of newborns BCG vaccination led to a dramatic fall of the BCG coverage rate, thus allowing us to estimate the BCG's effect without the biases associated with cross-country comparisons. | 1058-4838,1537-6591 | 2020-08-23 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | Clément de Chaisemartin;Luc de Chaisemartin | BCG;Covid-19;Regression discontinuity | 2020-08-23 02:00:00+02:00 | 32829400 | FR;US | Department of Economics, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.;Immunology Department, APHP.Nord-Université de Paris, Bichat Hospital, Paris, France.;Université Paris-Saclay, Inserm, "Inflammation, microbiome, immunosurveillance", Châtenay-Malabry, France. | 2223 | |||
| 10.1177/1740774520943846 | Journal Article | en | Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. | https://www.ncbi.nlm.nih.gov/pubmed/32815416 | Mortality from COVID-19 is high among hospitalized patients and effective therapeutics are lacking. Hypercoagulability, thrombosis and hyperinflammation occur in COVID-19 and may contribute to severe complications. Therapeutic anticoagulation may improve clinical outcomes through anti-thrombotic, anti-inflammatory and anti-viral mechanisms. Our primary objective is to evaluate whether therapeutic-dose anticoagulation with low-molecular-weight heparin or unfractionated heparin prevents mechanical ventilation and/or death in patients hospitalized with COVID-19 compared to usual care. | 1740-7745,1740-7753 | 2020-08-23 02:00:00+02:00 | pubmed | Clinical Trials | Brett L Houston;Patrick R Lawler;Ewan C Goligher;Michael E Farkouh;Charlotte Bradbury;Marc Carrier;Vlad Dzavik;Dean A Fergusson;Robert A Fowler;Jean-Phillippe Galanaud;Peter L Gross;Emily G McDonald;Mansoor Husain;Susan R Kahn;Anand Kumar;John Marshall;Srinivas Murthy;Arthur S Slutsky;Alexis F Turgeon;Scott M Berry;Robert S Rosenson;Jorge Escobedo;Jose C Nicolau;Lindsay Bond;Bridget-Anne Kirwan;Sophie de Brouwer;Ryan Zarychanski | COVID-19;Heparin;adaptive clinical trial;protocol;thrombosis | 2020-08-20 02:00:00+02:00 | 32815416 | FR;CA;GB;US;CH;BR;MX | Max Rady Faculty of Health Sciences, Max Rady College of Medicine, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.;Peter Munk Cardiac Centre, University Health Network and University of Toronto, Toronto, ON, Canada.;Toronto General Hospital Research Institute, Toronto, ON, Canada.;Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.;Department of Medicine, Division of Respirology, University Health Network, Toronto, ON, Canada.;Faculty of Health Sciences, University of Bristol, Bristol, UK.;Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.;Department of Medicine, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada.;Thrombosis and Atherosclerosis Research Institute, Department of Medicine, McMaster University & Hamilton Health Sciences, Hamilton, ON, Canada.;Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.;Center for Clinical Epidemiology, Jewish General Hospital/Lady Davis Institute, Division of Internal Medicine, Department of Medicine, McGill University, Montreal, QC, Canada.;Department of Surgery, St Michael's Hospital and the University of Toronto, Toronto, ON, Canada.;The University of British Columbia, Vancouver, BC, Canada.;Keenan Research Centre at the Li Ka Shing Knowledge Institute, St. Michael's Hospital and Departments of Medicine, Surgery, and Biomedical Engineering, University of Toronto, Toronto, ON, Canada.;Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.;CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Trauma-Emergency-Critical Care Medicine, Université Laval, Québec, QC, Canada.;Berry Consultants, LLC, Austin, TX, USA.;The Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josee and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Medical Research Unit on Clinical Epidemiology, Mexican Social Security Institute, Mexico City, Mexico.;Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.;Ozmosis Research Inc., Toronto, ON, Canada.;Department of Clinical Research, SOCAR Research SA, Nyon, Switzerland.;Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, London, England.;Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada. | 2226 | |||
| 10.1002/dmrr.3396 | Journal Article | en | Fast-track pathway for diabetic foot ulceration during COVID-19 crisis: a document from International Diabetic Foot Care Group and D-Foot International. | https://www.ncbi.nlm.nih.gov/pubmed/32804425 | 1520-7552,1520-7560 | 2020-08-23 02:00:00+02:00 | pubmed | Diabetes/Metabolism Research and Reviews | Marco Meloni;Benjamin Bouillet;Raju Ahluwalia;Claas Lüdemann;Juan Pedro Sánchez-Ríos;Elisabetta Iacopi;Jose Luis Lazaro Martinez | COVID-19;diabetes;diabetic foot ulceration;fast-track;limb salvage | 2020-08-17 02:00:00+02:00 | 32804425 | FR;GB;IT;ES;DE | Diabetic Foot Center, University of Tor Vergata, Rome, Italy.;Endocrinology Department, University Hospital Center, Dijon, France.;Department of Trauma and Ortophaedic Department, King ́s College Hospital, London, UK.;Franziskus Krankenhaus Berlin, Berlin, Germany.;Diabetic Foot Unit, Vascular Surgery Department, Hospital Fundación Alcorcón, Madrid, Spain.;Diabetic Foot Section, University of Pisa, Ospedale di Cisanello, Pisa, Italy.;Diabetic foot Unit, Universidad Complutense de Madrid, Spain. | 2232 | ||||
| 10.1093/cid/ciaa1196 | Journal Article | en | Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value. | https://www.ncbi.nlm.nih.gov/pubmed/32803231 | Coronavirus disease 2019 (COVID-19) is a global public health problem that has already caused more than 662,000 deaths worldwide. Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients present other severe damage such as cardiovascular, renal and liver injury or/and multiple organ failure, suggesting a spread of the SARS-CoV-2 in blood. Recent ultrasensitive polymerase chain reaction (PCR) technology now allows absolute quantification of nucleic acids in plasma. We herein intended to use the droplet-based digital PCR technology to obtain sensitive detection and precise quantification of plasma SARS-CoV-2 viral load (SARS-CoV-2 RNAaemia) in hospitalized COVID-19 patients. | 1058-4838,1537-6591 | 2020-08-23 02:00:00+02:00 | pubmed | Clinical Infectious Diseases | David Veyer;Solen Kernéis;Geoffroy Poulet;Maxime Wack;Nicolas Robillard;Valérie Taly;Anne-Sophie L'Honneur;Flore Rozenberg;Pierre Laurent-Puig;Laurent Bélec;Jérôme Hadjadj;Benjamin Terrier;Hélène Péré | 2020-08-17 02:00:00+02:00 | 32803231 | FR | Assistance Publique Hôpitaux de Paris-Centre (AP-HP.Centre), Service de Microbiologie (Unité de virologie), Hôpital Européen Georges Pompidou, Paris, France.;Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Functional Genomics of Solid Tumors laboratory, équipe labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, Paris, France.;Equipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, F-75014 Paris, France.;Université de Paris, INSERM, IAME, F-75006 Paris, France.;Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), F-75015 Paris, France.;Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Personalized Medicine Pharmacogenomics, therapeutic optimization, eDIAG plateform, laboratory, équipe labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, Paris, France.;Eurofins-Biomnis, Lyon.;Département d'Informatique Médicale, Biostatistiques et Santé Publique, Hôpital Européen Georges Pompidou, AP-HP CUP, Paris, France.;Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Information sciences to support medicine Paris, France.;Assistance Publique Hôpitaux de Paris-Centre (AP-HP.Centre), Service de Virologie, Hôpital Cochin, Paris, France.;Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, AP-HP CUP, Paris, France.;Assistance Publique Hôpitaux de Paris-Centre (AP-HP.Centre), Service de Biochimie, Hôpital Européen Georges Pompidou, Paris, France.;Imagine Institute, laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR 1163.;PARCC, Université de Paris, INSERM U970, Paris, France. | 2234 | ||||
| 10.1016/s2665-9913(20)30282-4 | Journal Article | en | Tocilizumab for severe COVID-19 pneumonia. | https://www.ncbi.nlm.nih.gov/pubmed/32838324 | 2665-9913 | 2020-08-23 02:00:00+02:00 | pubmed | The Lancet Rheumatology | Jean-Jacques Mourad;Philippe Azria | 2020-08-17 02:00:00+02:00 | 32838324 | FR | Department of Internal Medicine, Groupe Hospitalier Paris Saint-Joseph, Paris 75014, France. | 2235 | |||||
| Letter | en | Psychoactive compounds as multifactorial protection factors against COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32812114 | 2020-08-23 02:00:00+02:00 | pubmed | Hervé Javelot;Luisa Weiner;Julien Petrignet;Guillaume Meyer;Jeanne Briet;Wissam El-Hage;Coraline Hingray | 2020-08-18 02:00:00+02:00 | 32812114 | FR | Établissement Public de Santé Alsace Nord, Brumath, France. herve.javelot@ch-epsan.fr.;Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France. herve.javelot@ch-epsan.fr.;Clinique de Psychiatrie, CHU de Strasbourg, Strasbourg, France.;Laboratoire de Psychologie des Cognitions, Université de Strasbourg, Strasbourg, France.;Laboratoire Synthèse et Isolement de Molécules BioActives (SIMBA, EA 7502), , Faculté des Sciences et Techniques, Université de Tours, Tours, France.;Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France.;Service Pharmacie, CHU de de Strasbourg, Strasbourg, France.;Service Pharmacie, Centre Hospitalier de Montceau, Montceau-les-Mines, France.;UMR 1253, iBrain, Université de Tours, CHRU de Tours, INSERM, Tours, France.;Centre Expert Dépression Résistante, Fondation FondaMental, Tours, France.;Pôle Hospitalo-Universitaire de Psychiatrie d'Adultes du Grand Nancy, Centre Psychothérapique de Nancy, Laxou, France.;Département de Neurologie, CHU de Nancy, Nancy, France. | 2237 | ||||||||
| 10.1002/sctm.20-0239 | Journal Article | en | Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19. | https://www.ncbi.nlm.nih.gov/pubmed/32808462 | Sepsis is defined as life-threatening organ dysfunction caused by a deregulated immune host response to infection. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted this multifactorial and complex syndrome. The absence of specific treatment neither against SARS-CoV-2 nor against acute respiratory distress syndrome (ARDS), the most serious stage of this infection, has emphasized the need to find alternative treatments. Several therapeutics are currently tested and among them, mesenchymal stromal cells. These cells, already used in preclinical models of ARDS, sepsis, and septic shock and also in few clinical trials appear well-tolerated, promising, but many questions remain unanswered. | 2020-08-23 02:00:00+02:00 | pubmed | Caroline Laroye;Sébastien Gibot;Céline Huselstein;Danièle Bensoussan | COVID-19;Wharton's Jelly;acute respiratory distress syndrome;mesenchymal stromal/stem cells;sepsis | 2020-08-18 02:00:00+02:00 | 32808462 | FR | Unité de Thérapie Cellulaire et banque de Tissus, Université de Lorraine, CHRU de Nancy, Nancy, France.;CNRS, IMoPA, Université de Lorraine, Nancy, France.;Inserm, DCAC, Université de Lorraine, Nancy, France.;CHRU de Nancy, Service de Réanimation Médicale, Université de Lorraine, Nancy, France. | 2238 | |||||
| 10.1002/jmv.26446 | Journal Article | en | Behavioural manipulation - key to the successful global spread of the new Coronavirus SARS-Cov-2? | https://www.ncbi.nlm.nih.gov/pubmed/32813286 | Human- SARS-CoV-2 interaction can have an array of various outcomes - it could be mortal, morbid or merely carrying minor health consequences. The very rapid global spread has raised the issue whether there are further multi-dimensional consequences of SARS-CoV-2 infection on human behaviour, the key of its transmission. During the coronavirus crisis, odd, abnormal, and irresponsible behaviour has been reported in COVID-19 individuals, particularly in super-spreaders, i.e. persons with a high viral load, thus constituting also super-emitters. Indeed, cases of infected persons ignoring self-confinement orders, intentionally disregarding physical distancing and multiplying social interactions, or even deliberately sneezing, spitting or coughing were reported. While it is known that some other viruses such as rabies and even influenza do change human behaviour, this remains unclear for SARS-CoV-2. In this perspective, we highlight the possibility that COVID-19 is facilitated by altered human social behaviour that benefits SARS-CoV-2 transmission, through showcasing similar virus-induced changed behaviour by other pathogens and relating this to reports from the grey literature. This article is protected by copyright. All rights reserved. | 2020-08-23 02:00:00+02:00 | pubmed | Jaouad Bouayed;Torsten Bohn | Abnormal behaviour;Brain-immune axis;CNS-changes;COVID-19;Obligate parasites;Social interactions | 2020-08-19 02:00:00+02:00 | 32813286 | FR;LU | LCOMS/Neurotoxicologie Alimentaire et Bioactivité, Université de Lorraine, 57000, Metz, France.;Luxembourg Institute of Health (LIH), Department of Population Health (DOPH), Nutrition and Health Research Group, 1 A-B, rue Thomas Edison, L-1445, Strassen, Luxembourg. | 2241 | |||||
| 10.1093/infdis/jiaa528 | Journal Article | en | Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19. | https://www.ncbi.nlm.nih.gov/pubmed/32812049 | Beside the commonly described pulmonary expression of the coronavirus disease 2019 (COVID-19), major vascular events have been reported. The objective of this study was to investigate whether increased levels of circulating endothelial cells (CEC) might be associated with severe forms of COVID-19. Ninety-nine patients with COVID-19 were enrolled in this retrospective study. Patients in the intensive care units (ICU) had significantly higher CEC counts than non-ICU patients and the extent of endothelial injury was correlated with putative markers of disease severity and inflammatory cytokines. Altogether, these data provide in vivo evidence that endothelial injury is a key feature of COVID-19. | 0022-1899,1537-6613 | 2020-08-23 02:00:00+02:00 | pubmed | The Journal of Infectious Diseases | Christophe Guervilly;Stephane Burtey;Florence Sabatier;Raphaël Cauchois;Guillaume Lano;Evelyne Abdili;Florence Daviet;Laurent Arnaud;Philippe Brunet;Sami Hraiech;Noémie Jourde-Chiche;Marie Koubi;Romaric Lacroix;Léa Pietri;Yaël Berda;Thomas Robert;Clara Degioanni;Mélanie Velier;Laurent Papazian;Gilles Kaplanski;Françoise Dignat-George | COVID-19;Circulating endothelial cells;endothelial injury | 2020-08-19 02:00:00+02:00 | 32812049 | FR | Medical Intensive Care Unit, North Hospital, APHM, Chemin des Bourrely, Marseille, France.;CEReSS, Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France.;Department of Nephrology and Renal Transplantation, La Conception, APHM, Marseille, France.;Aix Marseille Univ, INSERM 1263, INRAE, C2VN, Marseille, France.;Laboratory of hematology and vascular biology, La Conception Hospital, APHM, Marseille, France.;Cell Therapy Unit, INSERM CBT1409, La Conception Hospital, APHM, Marseille, France.;Department of Internal Medicine and Clinical Immunology, La Conception Hospital, APHM, Marseille, France.;Department of Nutrition, Metabolic Diseases, Endocrinology, La Conception Hospital, Marseille. | 2245 | |||
| 10.1007/s00330-020-07154-4 | Journal Article | en | Chest CT for rapid triage of patients in multiple emergency departments during COVID-19 epidemic: experience report from a large French university hospital. | https://www.ncbi.nlm.nih.gov/pubmed/32813105 | To assess the diagnostic performances of chest CT for triage of patients in multiple emergency departments during COVID-19 epidemic, in comparison with reverse transcription polymerase chain reaction (RT-PCR) test. | 0938-7994,1432-1084 | 2020-08-23 02:00:00+02:00 | pubmed | European Radiology | Victoria Ducray;Anna Sesilia Vlachomitrou;Maude Bouscambert-Duchamp;Salim Si-Mohamed;Sylvain Gouttard;Adeline Mansuy;Florian Wickert;Alain Sigal;Alexandre Gaymard;François Talbot;Catherine Michel;Thomas Perpoint;Jean-Baptiste Pialat;Olivier Rouviere;Laurent Milot;François Cotton;Philippe Douek;Muriel Rabilloud;Loic Boussel | Coronavirus;Diagnostic imaging;Emergency medicine;Sensitivity and specificity;Tomography, X-ray | 2020-08-19 02:00:00+02:00 | 32813105 | FR | Department of Radiology, Hospices Civils de Lyon, Lyon, France.;PHILIPS France, 33, rue de Verdun, CS 60 055, 92156, Suresnes Cedex, France.;Laboratoire de Virologie, Institut des Agents Infectieux de Lyon, Centre National de Référence des virus respiratoires France Sud, Centre de Biologie et de Pathologie Nord, Hospices Civils de Lyon, F-69317, Lyon, France.;Université de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372, Lyon, France.;Department of Radiology, Hospices Civils de Lyon, Lyon, France. salim.si-mohamed@chu-lyon.fr.;Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, F-69621, Lyon, France. salim.si-mohamed@chu-lyon.fr.;Department of cardiothoracic and vascular imaging, CHU cardiologique Louis Pradel, 59 Boulevard Pinel, 69500, Bron, France. salim.si-mohamed@chu-lyon.fr.;Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, F-69621, Lyon, France.;Department of Emergency, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.;Department of Information Technology, Hospices Civils de Lyon, Lyon, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Croix-Rousse, Hospices Civils de Lyon, Lyon, France.;LabTAU INSERM U1032, Lyon, France.;Service de Biostatistique et Bioinformatique des HCL, Laboratoire Biostatistique Santé, UMR 5558, 69424, Lyon, France. | 2250 | |||
| 10.1161/strokeaha.120.031011 | Journal Article | en | Early Brain Imaging Shows Increased Severity of Acute Ischemic Strokes With Large Vessel Occlusion in COVID-19 Patients. | https://www.ncbi.nlm.nih.gov/pubmed/32813602 | Reports are emerging regarding the association of acute ischemic strokes with large vessel occlusion and coronavirus disease 2019 (COVID-19). While a higher severity of these patients could be expected from the addition of both respiratory and neurological injury, COVID-19 patients with strokes can present with mild or none respiratory symptoms. We aimed to compare anterior circulation large vessel occlusion strokes severity between patients with and without COVID-19. | 0039-2499,1524-4628 | 2020-08-23 02:00:00+02:00 | pubmed | Stroke | Simon Escalard;Vanessa Chalumeau;Clément Escalard;Hocine Redjem;François Delvoye;Solène Hébert;Stanislas Smajda;Gabriele Ciccio;Jean-Philippe Desilles;Mikael Mazighi;Raphael Blanc;Benjamin Maïer;Michel Piotin | brain;coronavirus;ischemia;prognosis;stroke | 2020-08-19 02:00:00+02:00 | 32813602 | FR | Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France (S.E., H.R., F.D., S.H., S.S., G.C., J.-P.D., M.M., R.B., B.M., M.P.).;Department of Interventional Neuroradiology, CHU Bicêtre, France (V.C.).;Department of Radiology, Centre Hospitalier Universitaire de Caen, France (C.E.). | 2252 | |||